FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Arias, MA
   Loxley, A
   Eatmon, C
   Van Roey, G
   Fairhurst, D
   Mitchnick, M
   Dash, P
   Cole, T
   Wegmann, F
   Sattentau, Q
   Shattock, R
AF Arias, Mauricio A.
   Loxley, Andrew
   Eatmon, Christy
   Van Roey, Griet
   Fairhurst, David
   Mitchnick, Mark
   Dash, Philip
   Cole, Tom
   Wegmann, Frank
   Sattentau, Quentin
   Shattock, Robin
TI Carnauba wax nanoparticles enhance strong systemic and mucosal cellular
   and humoral immune responses to HIV-gp140 antigen
SO VACCINE
LA English
DT Article
DE HIV; gp140 antigen; Nanoparticles; Mucosal immunity; Vaccines
ID HUMAN DENDRITIC CELLS; ANIONIC PLG MICROPARTICLES; NASAL IMMUNIZATION;
   BIODEGRADABLE NANOPARTICLES; NEUTRALIZING ANTIBODIES; VACCINE; VIRUS;
   INDUCTION; ADJUVANT; DELIVERY
AB Induction of humoral responses to HIV at mucosal compartments without inflammation is important for vaccine design. We developed charged wax nanoparticles that efficiently adsorb protein antigens and are internalized by DC in the absence of inflammation. HIV-gp140-adsorbed nanoparticles induced stronger in vitro T-cell proliferation responses than antigen alone. Such responses were greatly enhanced when antigen was co-adsorbed with TLR ligands. Immunogenicity studies in mice showed that intradermal vaccination with HIV-gp140 antigen-adsorbed nanoparticles induced high levels of specific IgG. Importantly, intranasal immunization with HIV-gp140-adsorbed nanoparticles greatly enhanced serum and vaginal IgG and IgA responses. Our results show that HIV-gp140-carrying wax nanoparticles can induce strong cellular/humoral immune responses without inflammation and may be of potential use as effective mucosal adjuvants for HIV vaccine candidates. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Arias, Mauricio A.; Van Roey, Griet; Dash, Philip; Cole, Tom; Shattock, Robin] St Georges Univ London, Div Clin Sci, London SW17 0RE, England.
   [Loxley, Andrew; Eatmon, Christy; Fairhurst, David; Mitchnick, Mark] Particle Sci Inc, Bethlehem, PA 18017 USA.
   [Wegmann, Frank; Sattentau, Quentin] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
RP Arias, MA (reprint author), St Georges Univ London, Div Clin Sci, London SW17 0RE, England.
EM marias@sgul.ac.uk; shattock@sgul.ac.uk
OI Dash, Phil/0000-0002-6029-4560
FU Bill & Melinda Gates Foundation; Wellcome Trust under the Grand
   Challenges in Global Health Initiative; Fondation Dormeur; Polymun
   Scientific GmbH; European Union; Particle Science Inc
FX This work was funded by a grant to SGUL by the Bill & Melinda Gates
   Foundation and the Wellcome Trust, under the Grand Challenges in Global
   Health Initiative.; We are indebted to the Fondation Dormeur for funding
   of equipment used in the course of this study. We thank Professors Ralf
   Wagner and Hans Wolf, University of Regensburg and GENEART AG for the
   CN54-expressing plasmid. We thank Simon Jeffs, Sueli Vieira and Saba
   Hussein for work on gp140 cloning and expression. CN54-gp140 used in
   this study was produced under contract by Polymun Scientific GmbH. Griet
   Van Roey is supported by a EUROPRISE studentship funded by the European
   Union.; Particle Science Inc has IP rights and economical interests in
   carnauba wax based nanoparticles mentioned in this article.
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Asahi Y, 2002, J IMMUNOL, V168, P2930, DOI 10.4049/jimmunol.168.6.2930                                                     
   Barnetta SW, 2008, AIDS, V22, P339, DOI 10.1097/QAD.0b013e3282f3ca57
   Bekeredjian-Ding I, 2009, IMMUNOLOGY, V128, P311, DOI 10.1111/j.1365-2567.2009.03173.x
   Biancotto A, 2007, BLOOD, V109, P4272, DOI 10.1182/blood-2006-11-055764
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Bradac J, 2009, IDRUGS, V12, P435
   Bradney CP, 2002, J VIROL, V76, P517, DOI 10.1128/JVI.76.2.517-524.2002
   Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935                                                       
   Buonaguro L, 2005, J VIROL, V79, P7059, DOI 10.1128/JVI.79.11.7059-7067.2005
   Caputo A, 2009, VACCINE, V27, P3605, DOI 10.1016/j.vaccine.2009.03.047
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Chesko J, 2005, J PHARM SCI-US, V94, P2510, DOI 10.1002/jps.20472
   Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4                                                   
   Davis IC, 1997, SPRINGER SEMIN IMMUN, V18, P421, DOI 10.1007/BF00824051                                                              
   Do TQ, 2008, J IMMUNOL, V181, P4177, DOI 10.4049/jimmunol.181.6.4177                                                     
   Fujimura Y, 2000, VIRCHOWS ARCH, V436, P560, DOI 10.1007/s004289900177                                                           
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   Harandi AM, 2010, VACCINE, V28, P2363, DOI 10.1016/j.vaccine.2009.12.084
   Henderson RA, 1997, J IMMUNOL, V159, P635
   Hirano T, 2006, IMMUNOL LETT, V107, P131, DOI 10.1016/j.imlet.2006.08.005
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Kempf M, 2003, J DRUG TARGET, V11, P11, DOI 10.1080/1061186031000072978
   Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087
   Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17                                                       
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Shattock RJ, 2008, PLOS MED, V5, P537, DOI 10.1371/journal.pmed.0050081
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 2004, EXPERT OPIN BIOL TH, V4, P483, DOI 10.1517/14712598.4.4.483
   Singh M, 2004, J PHARM SCI-US, V93, P273, DOI 10.1002/jps.10538
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   Su L, 2000, J VIROL, V74, P11367, DOI 10.1128/JVI.74.23.11367-11376.2000                                              
   Tobio M, 1999, PHARMACEUT RES, V16, P682, DOI 10.1023/A:1018820507379
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Vila A, 2005, INT J PHARMACEUT, V292, P43, DOI 10.1016/j.ijpharm.2004.09.002
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Westwood A, 2005, VACCINE, V23, P3857, DOI 10.1016/j.vaccine.2004.11.079
   Wischke C, 2006, J CONTROL RELEASE, V114, P359, DOI 10.1016/j.jconrel.2006.06.020
   [Anonymous], 2003, DRUGS R D, V4, P249
NR 52
TC 15
Z9 15
U1 5
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 1
PY 2011
VL 29
IS 6
BP 1258
EP 1269
DI 10.1016/j.vaccine.2010.11.084
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 721FU
UT WOS:000287339800022
PM 21145913
OA gold
DA 2018-01-05
ER

PT J
AU Gao, B
   Fu, WG
   Dong, ZH
   Fang, ZD
   Liu, ZJ
   Si, Y
   Zhang, XM
   Wang, YQ
AF Gao Bin
   Fu Wei-guo
   Dong Zhi-hui
   Fang Zheng-dong
   Liu Zhen-jie
   Si Yi
   Zhang Xiang-man
   Wang Yu-qi
TI Functional endothelial cells derived from embryonic stem cells labeled
   with HIV transactivator peptide-conjugated superparamagnetic
   nanoparticles
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE embryonic stem cells; endothelial cells; cell differentiation;
   ferumoxides
ID IN-VIVO; T-CELLS; TRACKING; VITRO; DIFFERENTIATION; TRANSPLANTATION;
   MATURATION; DELIVERY; CULTURE; MODEL
AB Background The development of regenerative therapies using derivatives of embryonic stem (ES) cells would be facilitated by a non-invasive method to monitor transplanted cells in vivo, for example, magnetic resonance imaging of cells labeled with superparamagnetic iron oxide (SPIO) nanoparticles. Although ES cells have been labeled with SPIO particles, the potential adverse effects of the label have not been fully examined. The objective of this study was to determine whether SPIO labeling affects murine ES cell viability, proliferation, or ability to differentiate into functional endothelial cells (ECs).
   Methods Cross-linked iron oxide (CLIO, an SPIO) was conjugated with human immunodeficiency virus transactivator of transcription (HIV-Tat) peptides, and murine ES cells were labeled with either CLIO-Tat, CLIO, or HIV-Tat. After labeling, ES cells were cultured for 4 days and Flk-1(+) ES cells identified and sorted by immunocytochemistry and fluorescence activated cell sorting (FACS). Flk-1(+) cells were replated on fibronectin-coated dishes, and ECs were obtained by culturing these for 4 weeks in endothelial cell growth medium supplemented with vascular endothelial growth factor (VEGF). ES cell viability was determined using trypan blue exclusion, and the proportion of SPIO+ cells was evaluated using Prussian blue staining and transmission electron microscopy. After differentiation, the behavior and phenotype of ECs were analyzed by reverse transcription-polymerase chain reaction, flow cytometry, immunocytochemistry, Dil-labeled acetylated low-density lipoprotein (AcLDL) uptake, and Matrigel tube formation assay.
   Results CLIO-Tat was a highly effective label for ES cells, with >96% of cells incorporating the particles, and it did not alter the viability of the labeled cells. ECs derived from CLIO-Tat(+) ES cells were very similar to murine aortic ECs in their morphology, expression of endothelial cell markers, ability to form vascular-like channels, and scavenging of AcLDL from the culture medium.
   Conclusions CLIO-Tat is a highly effective label for ES cells and does not adversely affect cell viability, differentiation, or behavior. CLIO-Tat could be a useful marker for the non-invasive monitoring of transplanted stem cells. Chin Med J 2011;124(2):298-303
C1 [Gao Bin; Fu Wei-guo; Dong Zhi-hui; Fang Zheng-dong; Si Yi; Zhang Xiang-man; Wang Yu-qi] Fudan Univ, Zhongshan Hosp, Dept Vasc Surg, Shanghai 200032, Peoples R China.
   [Liu Zhen-jie] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China.
RP Fu, WG (reprint author), Fudan Univ, Zhongshan Hosp, Dept Vasc Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM fu.weiguo@zs-hospital.sh.cn
FU National Natural Science Foundation of China [30571821]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 30571821).
CR Baker M, 2008, NATURE, V452, P263, DOI 10.1038/452263a
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Cho SW, 2007, CIRCULATION, V116, P2409, DOI 10.1161/CIRCULATIONAHA.106.687038
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Farrell E, 2008, BIOCHEM BIOPH RES CO, V369, P1076, DOI 10.1016/j.bbrc.2008.02.159
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Hirashima M, 1999, BLOOD, V93, P1253
   Hoehn M, 2007, J PHYSIOL-LONDON, V584, P25, DOI 10.1113/jphysiol.2007.139451
   Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P469, DOI 10.1006/bbrc.2001.4790
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaufman DS, 2004, BLOOD, V103, P1325, DOI 10.1182/blood-2003-03-0799
   Kostura L, 2004, NMR BIOMED, V17, P513, DOI 10.1002/nbm.925
   Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li Z, 2007, CIRCULATION, V116, pI46, DOI 10.1161/CIRCULATIONAHA.106.680561
   Li ZJ, 2009, J CELL BIOCHEM, V106, P194, DOI 10.1002/jcb.22003
   McCloskey KE, 2003, ENDOTHELIUM-J ENDOTH, V10, P329, DOI 10.1080/10623320390272325
   Nishikawa S, 1998, DEVELOPMENT, V125, P1747
   Nishikawa SI, 2007, NAT REV MOL CELL BIO, V8, P502, DOI 10.1038/nrm2189
   Rosenthal N, 2003, NEW ENGL J MED, V349, P267, DOI 10.1056/NEJMra020849
   Schoepf U, 1998, BIOTECHNIQUES, V24, P642
   Schoepf U., 1998, BIOTECHNIQUES, V24, P648
   Vittet D, 1996, BLOOD, V88, P3424
   YEH TC, 1993, MAGNET RESON MED, V30, P617, DOI 10.1002/mrm.1910300513
   YEH TC, 1995, MAGNET RESON MED, V33, P200, DOI 10.1002/mrm.1910330209
NR 25
TC 2
Z9 2
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD JAN 20
PY 2011
VL 124
IS 2
BP 298
EP 303
DI 10.3760/cma.j.issn.0366-6999.2011.02.027
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 714DI
UT WOS:000286787300029
PM 21362384
DA 2018-01-05
ER

PT J
AU Clouser, CL
   Holtz, CM
   Mullett, M
   Crankshaw, DL
   Briggs, JE
   Chauhan, J
   VanHoutan, IM
   Patterson, SE
   Mansky, LM
AF Clouser, Christine L.
   Holtz, Colleen M.
   Mullett, Mary
   Crankshaw, Duane L.
   Briggs, Jacquie E.
   Chauhan, Jay
   VanHoutan, Ilze Matise
   Patterson, Steven E.
   Mansky, Louis M.
TI Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of
   Gemcitabine
SO PLOS ONE
LA English
DT Article
ID RETROVIRUS-INDUCED IMMUNODEFICIENCY; RIBONUCLEOTIDE REDUCTASE
   INHIBITORS; DEFECTIVE VIRUS; SYNDROME MAIDS; BONE-MARROW; MURINE AIDS;
   CELL-LINES; MICE; DISEASE; INDUCTION
AB Replication of retroviral and host genomes requires ribonucleotide reductase to convert rNTPs to dNTPs, which are then used as substrates for DNA synthesis. Inhibition of ribonucleotide reductase by hydroxyurea (HU) has been previously used to treat cancers as well as HIV. However, the use of HU as an antiretroviral is limited by its associated toxicities such as myelosuppression and hepatotoxicity. In this study, we examined the ribonucleotide reductase inhibitor, gemcitabine, both in cell culture and in C57Bl/6 mice infected with LP-BM5 murine leukemia virus (LP-BM5 MuLV, a murine AIDS model). Gemcitabine decreased infectivity of MuLV in cell culture with an EC50 in the low nanomolar range with no detectable cytotoxicity. Similarly, gemcitabine significantly decreased disease progression in mice infected with LP-BM5. Specifically, gemcitabine treatment decreased spleen size, plasma IgM, and provirus levels compared to LP-BM5 MuLV infected, untreated mice. Gemcitabine efficacy was observed at doses as low as 1 mg/kg/day in the absence of toxicity. Higher doses of gemcitabine (3 mg/kg/day and higher) were associated with toxicity as determined by a loss in body mass. In summary, our findings demonstrate that gemcitabine has antiretroviral activity ex vivo and in vivo in the LP-BM5 MuLV model. These observations together with a recent ex vivo study with HIV-1[1], suggest that gemcitabine has broad antiretroviral activity and could be particularly useful in vivo when used in combination drug therapy.
C1 [Clouser, Christine L.; Holtz, Colleen M.; Patterson, Steven E.; Mansky, Louis M.] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA.
   [Holtz, Colleen M.; Mansky, Louis M.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, MinnCResT Program, Minneapolis, MN 55455 USA.
   [Chauhan, Jay; Patterson, Steven E.; Mansky, Louis M.] Univ Minnesota, Ctr Drug Design, Minneapolis, MN USA.
   [Mansky, Louis M.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.
   [VanHoutan, Ilze Matise] Univ Minnesota, Masonic Canc Ctr Comparat Pathol Shared Resource, Minneapolis, MN USA.
   [Mullett, Mary; Crankshaw, Duane L.; Briggs, Jacquie E.] VA Med Ctr, Dept Food Sci & Nutr, Minneapolis, MN USA.
RP Clouser, CL (reprint author), Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA.
EM mansky@umn.edu
FU Academic Health Center; NIH [GM56615, T32 CA009138, T32 DE07288]
FX Supported from a Center for Drug Design Funding Agreement, an Academic
   Health Center Translational Research Grant, and NIH grants GM56615, T32
   CA009138 (Cancer Biology Training Grant, to C. L. C.) and T32 DE07288
   (MinnCResT Program, to C. M. H.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487
   BEBENEK K, 1992, J BIOL CHEM, V267, P3589
   Bender DM, 2009, J MED CHEM, V52, P6958, DOI 10.1021/jm901181h
   Casabianca A, 2004, J CLIN MICROBIOL, V42, P4361, DOI 10.1128/JCM.42.9.4361-4364.2004
   CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862                                                         
   CHATTOPADHYAY SK, 1991, J VIROL, V65, P4232
   Clouser CL, 2010, J VIROL, V84, P9301, DOI 10.1128/JVI.01006-10
   Dias ASP, 2006, CURR HIV RES, V4, P431
   HARRINGTON RD, 1993, J VIROL, V67
   HARTLEY JW, 1989, J VIROL, V63, P1223
   HEINEMANN V, 1990, MOL PHARMACOL, V38, P567
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   Lori F, 1999, ANTIVIR THER, V4, P101
   Mayhew C, 1997, CELL MOL BIOL, V43, P1019
   Mayhew CN, 2002, ANTIVIR RES, V56, P167, DOI 10.1016/S0166-3542(02)00108-0
   MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001
   MORSE HC, 1994, SYMP SOC GEN MICROBI, V51, P265
   MOSIER DE, 1987, J EXP MED, V165, P1737, DOI 10.1084/jem.165.6.1737                                                          
   NOZAKI A, 2010, ARCH VIROL, V45, P66
   OHNOTA H, 1990, ANTIMICROB AGENTS CH, V34, P605, DOI 10.1128/AAC.34.4.605                                                            
   PATTENGALE PK, 1982, AM J PATHOL, V107, P362
   Pear WS, 1998, BLOOD, V92, P3780
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Rossi L, 2002, J ANTIMICROB CHEMOTH, V50, P639, DOI 10.1093/jac/dkf205
   Sakamoto H, 2006, J GASTROENTEROL, V41, P70, DOI 10.1007/s00535-005-1724-7
   SIMARD C, 1995, VIROLOGY, V206, P555, DOI 10.1016/S0042-6822(95)80072-7
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828
   YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623
NR 30
TC 11
Z9 11
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2011
VL 6
IS 1
AR e15840
DI 10.1371/journal.pone.0015840
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 710MS
UT WOS:000286516500013
PM 21264291
OA gold
DA 2018-01-05
ER

PT S
AU Domingo-Espin, J
   Unzueta, U
   Saccardo, P
   Rodriguez-Carmono, E
   Corchero, JL
   Vazquez, E
   Ferrer-Miralles, N
AF Domingo-Espin, Joan
   Unzueta, Ugutz
   Saccardo, Paolo
   Rodriguez-Carmono, Escarlata
   Luis Corchero, Jose
   Vazquez, Esther
   Ferrer-Miralles, Neus
BE Villaverde, A
TI Engineered Biological Entities for Drug Delivery and Gene Therapy:
   Protein Nanoparticles
SO NANOPARTICLES IN TRANSLATIONAL SCIENCE AND MEDICINE
SE Progress in Molecular Biology and Translational Science
LA English
DT Review; Book Chapter
ID VIRUS-LIKE PARTICLES; BLOOD-BRAIN-BARRIER; CELL-PENETRATING PEPTIDES;
   NUCLEAR-LOCALIZATION SIGNAL; SEROVAR TYPHIMURIUM LT2; IN-VIVO DELIVERY;
   B-12-DEPENDENT 1,2-PROPANEDIOL DEGRADATION; POLYOMAVIRUS JC VIRUS; HIV-1
   TAT PROTEIN; CYANOBACTERIUM SYNECHOCOCCUS PCC7942
AB The development of genetic engineering techniques has speeded up the growth of the biotechnological industry, resulting in a significant increase in the number of recombinant protein products on the market. The deep knowledge of protein function, structure, biological interactions, and the possibility to design new polypeptides with desired biological activities have been the main factors involved in the increase of intensive research and preclinical and clinical approaches. Consequently, new biological entities with added value for innovative medicines such as increased stability, improved targeting, and reduced toxicity, among others have been obtained. Proteins are complex nanoparticles with sizes ranging from a few nanometers to a few hundred nanometers when complex supramolecular interactions occur, as for example, in viral capsids. However, even though protein production is a delicate process that imposes the use of sophisticated analytical methods and negative secondary effects have been detected in some cases as immune and inflammatory reactions, the great potential of biodegradable and tunable protein nanoparticles indicates that protein-based biotechnological products are expected to increase in the years to come.
C1 [Domingo-Espin, Joan; Unzueta, Ugutz; Saccardo, Paolo; Rodriguez-Carmono, Escarlata; Luis Corchero, Jose; Vazquez, Esther; Ferrer-Miralles, Neus] Univ Autonoma Barcelona, Inst Biotechnol & Biomed, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
   [Domingo-Espin, Joan; Unzueta, Ugutz; Saccardo, Paolo; Rodriguez-Carmono, Escarlata; Luis Corchero, Jose; Vazquez, Esther; Ferrer-Miralles, Neus] CIBER BBN, Barcelona, Spain.
RP Domingo-Espin, J (reprint author), Univ Autonoma Barcelona, Inst Biotechnol & Biomed, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
RI Saccardo, Paolo/C-2503-2017; Corchero, Jose/G-8413-2016; Unzueta,
   Ugutz/C-2521-2017; Ferrer-Miralles, Neus/G-7934-2016
OI Saccardo, Paolo/0000-0002-3092-1404; Corchero, Jose/0000-0002-6109-144X;
   Unzueta, Ugutz/0000-0001-5119-2266; Ferrer-Miralles,
   Neus/0000-0003-2981-3913; Vazquez, Esther/0000-0003-1052-0424;
   Domingo-Espin, Joan/0000-0001-8149-0803
CR Adamina M, 2011, EXPERT OPIN DRUG MET, V7, P201, DOI 10.1517/17425255.2011.543674
   Adjei AA, 2001, CANCER, V93, P1062
   Aina OH, 2007, MOL PHARM, V4, P631, DOI 10.1021/mp700073y
   Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Alcala P, 2001, BIOCHEM BIOPH RES CO, V285, P201, DOI 10.1006/bbrc.2001.5157
   Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Amexis G, 2006, J INFECT DIS, V194, P790, DOI 10.1086/506361
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Andreasson K, 2009, INT J CANCER, V124, P150, DOI 10.1002/ijc.23920
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Aris A, 2000, BIOCHEM BIOPH RES CO, V278, P455, DOI 10.1006/bbrc.2000.3824
   Aris A, 2004, TRENDS BIOTECHNOL, V22, P371, DOI 10.1016/j.tibtech.2004.05.004
   Aris A, 2003, BIOCHEM BIOPH RES CO, V304, P625, DOI 10.1016/S0006-291X(03)00644-2
   Asokan A, 2010, NAT BIOTECHNOL, V28, P79, DOI 10.1038/nbt.1599
   Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208
   Baleja JD, 1997, J BIOMOL NMR, V10, P397, DOI 10.1023/A:1018332327565
   Balestrieri ML, 2007, EUR J CANCER, V43, P1242, DOI 10.1016/j.ejca.2007.02.006
   Balhorn R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-227
   Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8                                                   
   Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200
   Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
   Bian J, 2007, CIRC RES, V100, P1626, DOI 10.1161/01.RES.0000269778.75877.68
   Bidwell GL, 2007, BIOCHEM PHARMACOL, V73, P620, DOI 10.1016/j.bcp.2006.10.028
   BIRCH JR, 1994, BIOLOGICALS, V22, P127, DOI 10.1006/biol.1994.1019
   Boado RJ, 2008, BIOTECHNOL BIOENG, V100, P387, DOI 10.1002/bit.21764
   Boado RJ, 2008, BIOTECHNOL BIOENG, V99, P475, DOI 10.1002/bit.21602
   Boado RJ, 2007, BIOTECHNOL BIOENG, V97, P1376, DOI 10.1002/bit.21369
   Boado RJ, 2007, BIOTECHNOL BIOENG, V96, P381, DOI 10.1002/bit.21120
   Bobik TA, 1999, J BACTERIOL, V181, P5967
   Bothner B, 2005, VIROLOGY, V334, P17, DOI 10.1016/j.virol.2005.01.017
   Box M, 2003, J DRUG TARGET, V11, P333, DOI 10.1080/1061186310001634667
   Brandenburg B, 2005, HEPATOLOGY, V42, P1300, DOI 10.1002/hep.20950
   Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120
   Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Bucci M, 2000, NAT MED, V6, P1362
   Buonaguro FM, 2009, EXPERT REV VACCINES, V8, P1379, DOI [10.1586/erv.09.81, 10.1586/ERV.09.81]
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   Carrio MM, 2003, FEBS LETT, V537, P215, DOI 10.1016/S0014-5793(03)00126-1
   Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI11849
   Chan CK, 2002, IMMUNOL CELL BIOL, V80, P119, DOI 10.1046/j.1440-1711.2002.01061.x
   Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366
   Chen LS, 2010, GENE THER, V17, P1033, DOI 10.1038/gt.2010.50
   Chen LA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/10/105708
   CHEN P, 1994, J BACTERIOL, V176, P5474
   Cheong WS, 2009, ANTIVIR RES, V81, P113, DOI 10.1016/j.antiviral.2008.10.003
   Chou MI, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-51
   Clark B, 2001, J GEN VIROL, V82, P2791, DOI 10.1099/0022-1317-82-11-2791                                                    
   Collins L, 2004, J GENE MED, V6, P185, DOI 10.1002/jgm.482
   Collins L, 2003, J NEUROSCI METH, V125, P113, DOI 10.1016/S0165-0270(03)00042-6
   Cornuz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002547
   Cortes-Perez NG, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/317545
   Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935
   Cot SSW, 2008, J BACTERIOL, V190, P936, DOI 10.1128/JB.01283-07
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511                                                          
   Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82
   Dalmau M, 2008, BIOTECHNOL BIOENG, V101, P654, DOI 10.1002/bit.21988
   Dalmau M, 2009, BIOMACROMOLECULES, V10, P3199, DOI 10.1021/bm900674v
   DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048                                                           
   Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006
   Datta K, 2001, CANCER RES, V61, P1768
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Desai N, 2009, TRANSL ONCOL, V2, P59, DOI 10.1593/tlo.09109
   Desai NP, 2008, ANTI-CANCER DRUG, V19, P899, DOI 10.1097/CAD.0b013e32830f9046
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dietz Gunnar P. H., 2007, V399, P181, DOI 10.1007/978-1-59745-504-6_13
   Diez-Gil C, 2010, BIOMATERIALS, V31, P5805, DOI 10.1016/j.biomaterials.2010.04.008
   Dijkgraaf I, 2007, EUR J NUCL MED MOL I, V34, P267, DOI 10.1007/s00259-006-0180-9
   Dokland T, 1999, CELL MOL LIFE SCI, V56, P580, DOI 10.1007/s000180050455
   Domingo-Espin J, 2011, NANOMEDICINE-UK, V6, P1047, DOI [10.2217/nnm.11.28, 10.2217/NNM.11.28]
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Eriksson J, 2010, METHODS MOL BIOL, V673, P223, DOI 10.1007/978-1-60761-842-3_14
   Fabre JW, 2006, CURR GENE THER, V6, P459, DOI 10.2174/156652306777934865
   Fan CG, 2010, P NATL ACAD SCI USA, V107, P7509, DOI 10.1073/pnas.0913199107
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrer-Miralles N, 2008, TRENDS BIOTECHNOL, V26, P267, DOI 10.1016/j.tibtech.2008.02.003
   Fischer N, 1997, J BIOL CHEM, V272, P3999, DOI 10.1074/jbc.272.7.3999                                                          
   Fischlechner M, 2007, ANGEW CHEM INT EDIT, V46, P3184, DOI 10.1002/anie.200603445
   Flenniken ML, 2003, NANO LETT, V3, P1573, DOI 10.1021/nl034786l
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Floudas CA, 2006, CHEM ENG SCI, V61, P966, DOI 10.1016/j.ces.2005.04.009
   Fominaya J, 1998, GENE THER, V5, P521, DOI 10.1038/sj.gt.3300614
   Fominaya J, 1996, J BIOL CHEM, V271, P10560, DOI 10.1074/jbc.271.18.10560                                                        
   Frankel AE, 2002, CURR PROTEIN PEPT SC, V3, P399, DOI 10.2174/1389203023380567                                                        
   Freyschmidt EJ, 2004, ANTIVIR THER, V9, P479
   Fukunaga-Kalabis M, 2007, J INVEST DERMATOL, V127, P2497, DOI 10.1038/sj.jid.5701050
   Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028
   Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002
   Garcia-Fruitos E, 2009, ADV MATER, V21, P4249, DOI 10.1002/adma.200900283
   Georgens C, 2005, CURR PHARM BIOTECHNO, V6, P49
   Gervais A, 2003, GLYCOBIOLOGY, V13, P179, DOI 10.1093/glycob/cwg020
   GHARAKHANIAN E, 1987, VIROLOGY, V157, P440, DOI 10.1016/0042-6822(87)90286-8
   Gleiter S, 2003, BIOL CHEM, V384, P247, DOI 10.1515/BC.2003.028
   Gleiter S, 2001, PROTEIN SCI, V10, P434, DOI 10.1110/ps.31101
   Glover DJ, 2009, FASEB J, V23, P2996, DOI 10.1096/fj.09-131425
   Goldmann C, 1999, J VIROL, V73, P4465
   Goldmann C, 2000, J VIROL METHODS, V90, P85, DOI 10.1016/S0166-0934(00)00226-3
   Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105                                                
   Gottschalk S, 1996, GENE THER, V3, P448
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Grinberg O, 2007, ULTRASON SONOCHEM, V14, P661, DOI 10.1016/j.ultsonch.2006.11.004
   Hammonds J, 2007, VACCINE, V25, P8036, DOI 10.1016/j.vaccine.2007.09.016
   Harada H, 2002, CANCER RES, V62, P2013
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Hart SL, 1999, CURR OPIN MOL THER, V1, P197
   Havemann GD, 2002, J BACTERIOL, V184, P1253, DOI 10.1128/JB.184.5
   Havemann GD, 2003, J BACTERIOL, V185, P5086, DOI 10.1128/JB.185.17.5086-5095.2003
   Herbst-Kralovetz M, 2010, EXPERT REV VACCINES, V9, P299, DOI 10.1586/ERV.09.163
   Houk BE, 2001, PHARMACEUT RES, V18, P67, DOI 10.1023/A:1011078711008                                                         
   Hu PS, 2003, CANCER RES, V63, P5046
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Ikonomou L, 2003, APPL MICROBIOL BIOT, V62, P1, DOI 10.1007/s00253-003-1223-9
   Ishiwata A, 2009, J GENE MED, V11, P1020, DOI 10.1002/jgm.1391
   Istrate C, 2008, VACCINE, V26, P4594, DOI 10.1016/j.vaccine.2008.05.089
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jeong JH, 2005, J CONTROL RELEASE, V107, P562, DOI 10.1016/j.jconrel.2005.07.010
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Johnson JE, 2000, CURR OPIN STRUC BIOL, V10, P229, DOI 10.1016/S0959-440X(00)00073-7                                                   
   Joung I, 2005, BIOCHEM BIOPH RES CO, V328, P1182, DOI 10.1016/j.bbrc.2005.01.080
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kaufmann AM, 2001, INT J CANCER, V92, P285, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1181>3.0.CO;2-Q
   Kaufmann AM, 2007, INT J CANCER, V121, P2794, DOI 10.1002/ijc.23022
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397
   Kessler T, 2005, CLIN CANCER RES, V11, P6317, DOI 10.1158/1078-0432.CCR-05-0389
   Kichler A, 2007, J MOL MED, V85, P191, DOI 10.1007/s00109-006-0119-4
   KIEFER P, 1994, EMBO J, V13, P4126
   Kim ES, 2010, BIOCHEM BIOPH RES CO, V392, P9, DOI 10.1016/j.bbrc.2009.12.135
   Kim J, 2005, GENE THER, V12, P1581, DOI 10.1038/sj.gt.3302575
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kimchi-Sarfaty C, 2005, HUM GENE THER, V16, P1110, DOI 10.1089/hum.2005.16.1110
   KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605
   Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664
   Kofoid E, 1999, J BACTERIOL, V181, P5317
   Kopecek J, 2003, EUR J PHARM SCI, V20, P1, DOI 10.1016/S0928-0987(03)00164-7
   Kost TA, 2002, TRENDS BIOTECHNOL, V20, P173, DOI 10.1016/S0167-7799(01)01911-4
   Krauzewicz N, 2000, GENE THER, V7, P2122, DOI 10.1038/sj.gt.3301322
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Lawatscheck R, 2007, VIRAL IMMUNOL, V20, P453, DOI 10.1089/vim.2007.0023
   Leal NA, 2003, ARCH MICROBIOL, V180, P353, DOI 10.1007/s00203-003-0601-0
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Leckband D, 2000, ANNU REV BIOPH BIOM, V29, P1, DOI 10.1146/annurev.biophys.29.1.1                                                  
   Lee CD, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-69
   Lee LA, 2006, NANOMED-NANOTECHNOL, V2, P137, DOI 10.1016/j.nano.2006.07.009
   Lenz P, 2001, J IMMUNOL, V166, P5346, DOI 10.4049/jimmunol.166.9.5346                                                     
   Leonchiks A, 2002, FEBS LETT, V522, P93, DOI 10.1016/S0014-5793(02)02897-1
   Li SD, 2006, GENE THER, V13, P1313, DOI 10.1038/sj.gt.3302838
   Li TC, 2005, J VIROL, V79, P12999, DOI 10.1128/JVI.79.20.12999-13006.2005
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Liang XY, 2008, CHEM BIOL DRUG DES, V72, P97, DOI 10.1111/j.1747-0285.2008.00681.x
   Liew MWO, 2010, J BIOTECHNOL, V150, P224, DOI 10.1016/j.jbiotec.2010.08.010
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Liu S, 2008, J BIOL CHEM, V283, P529, DOI 10.1074/jbc.M707419200
   Liu X, 2003, CANCER GENE THER, V10, P529, DOI 10.1038/sj.cgt.7700596
   Long BM, 2007, J BIOL CHEM, V282, P29323, DOI 10.1074/jbc.M703896200
   Ludtke JJ, 1999, J CELL SCI, V112, P2033
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295
   Lutz S, 2004, CURR OPIN BIOTECH, V15, P291, DOI 10.1016/j.copbio.2004.05.004
   LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451                                                            
   Mamot C, 2005, CANCER RES, V65, P11631, DOI 10.1158/0008-5472.CAN-05-1093
   Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014
   Mannisto M, 2002, J CONTROL RELEASE, V83, P169, DOI 10.1016/S0168-3659(02)00178-5
   Maranga Luis, 2002, Adv Biochem Eng Biotechnol, V74, P183
   Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Martinez-Fong D, 1999, MOL BRAIN RES, V69, P249, DOI 10.1016/S0169-328X(99)00114-X
   Martinez-Moreno M, 2003, FEBS LETT, V544, P262, DOI 10.1016/S0014-5793(03)00516-7
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Masuda T, 2005, FEBS LETT, V579, P2143, DOI 10.1016/j.febslet.2005.02.071
   Mateu MG, 2011, PROTEIN ENG DES SEL, V24, P53, DOI 10.1093/protein/gzq069
   May T, 2002, J VIROL METHODS, V105, P147, DOI 10.1016/S0166-0934(02)00099-X
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   McKay T, 2002, MOL THER, V5, P447, DOI 10.1006/mthe.2002.0540
   McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i
   McKenzie DL, 1999, J PEPT RES, V54, P311, DOI 10.1034/j.1399-3011.1999.00104.x                                                
   MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0                                                    
   Menon BB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003570
   Meyer EE, 2006, P NATL ACAD SCI USA, V103, P15739, DOI 10.1073/pnas.0606422103
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Midoux Patrick, 2002, Somatic Cell and Molecular Genetics, V27, P27, DOI 10.1023/A:1022931923153
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Muratori C, 2010, METHODS MOL BIOL, V614, P111, DOI 10.1007/978-1-60761-533-0_7
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Neu U, 2009, VIROLOGY, V384, P389, DOI 10.1016/j.virol.2008.12.021
   Neylon C, 2004, NUCLEIC ACIDS RES, V32, P1448, DOI 10.1093/nar/gkh315
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   Ogasawara Y, 2006, IN VIVO, V20, P319
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   OSTERMAN JV, 1970, P NATL ACAD SCI USA, V67, P37, DOI 10.1073/pnas.67.1.37
   Otten LG, 2005, BIOMOL ENG, V22, P1, DOI 10.1016/j.bioeng.2005.02.002
   Ou WC, 1999, J GEN VIROL, V80, P39, DOI 10.1099/0022-1317-80-1-39                                                       
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Pardridge WM, 2010, J DRUG TARGET, V18, P157, DOI 10.3109/10611860903548354
   PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8713, DOI 10.1021/bi00489a030
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031
   Parker AL, 2005, J GENE MED, V7, P1545, DOI 10.1002/jgm.809
   Parsons JB, 2010, MOL CELL, V38, P305, DOI 10.1016/j.molcel.2010.04.008
   Pattenden LK, 2005, TRENDS BIOTECHNOL, V23, P523, DOI 10.1016/j.tibtech.2005.07.011
   Pease LF, 2009, BIOTECHNOL BIOENG, V102, P845, DOI 10.1002/bit.22085
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Peluffo H, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-35
   Penrod JT, 2006, J BACTERIOL, V188, P2865, DOI 10.1128/JB.188.8.2865-2874.2006
   PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086
   Petry H, 2003, CURR OPIN MOL THER, V5, P524
   Pichon C, 2001, ADV DRUG DELIVER REV, V53, P75, DOI 10.1016/S0169-409X(01)00221-6
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101                                                       
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784
   PRICE GD, 1993, J BACTERIOL, V175, P2871
   Pumpens P, 2002, INTERVIROLOGY, V45, P24, DOI 10.1159/000050084                                                               
   Pushko P, 2010, VACCINE, V28, P4771, DOI 10.1016/j.vaccine.2010.04.093
   Qu QM, 2004, J BIOL CHEM, V279, P27735, DOI 10.1074/jbc.M310827200
   Raja KS, 2003, BIOMACROMOLECULES, V4, P472, DOI 10.1021/bm025740+
   Raja SM, 2011, CANCER BIOL THER, V11, P263, DOI 10.4161/cbt.11.2.13959
   Ramqvist T, 2009, IMMUNOTHERAPY, V1, P303, DOI 10.2217/1750-743X.1.2.303
   Ramqvist T, 2007, EXPERT OPIN BIOL TH, V7, P997, DOI 10.1517/14712598.7.7.997
   Ramsey JD, 2010, J CONTROL RELEASE, V144, P39, DOI 10.1016/j.jconrel.2010.01.031
   Reiter Manfred, 1994, Current Opinion in Biotechnology, V5, P175, DOI 10.1016/S0958-1669(05)80032-1
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501
   Rivkin I, 2010, BIOMATERIALS, V31, P7106, DOI 10.1016/j.biomaterials.2010.05.067
   ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T
   Rodriguez-Carmona E, 2010, TRENDS MICROBIOL, V18, P423, DOI 10.1016/j.tim.2010.06.007
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   RONDON MR, 1995, J BACTERIOL, V177, P7119, DOI 10.1128/jb.177.24.7119-7124.1995                                                
   RONDON MR, 1995, J BACTERIOL, V177, P5434, DOI 10.1128/jb.177.19.5434-5439.1995                                                
   Roy P, 2008, HUM VACCINES, V4, P5, DOI 10.4161/hv.4.1.5559                                                             
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Said Hassane F, 2010, CELL MOL LIFE SCI, V67, P715
   Sampson EM, 2008, J BACTERIOL, V190, P2966, DOI 10.1128/JB.01925-07
   Sanchez-Rodriguez S. P., 2010, CURRENT CHEM BIOL, V4, P231
   Santi L, 2008, VACCINE, V26, P1846, DOI 10.1016/j.vaccine.2008.01.053
   Santi L, 2006, METHODS, V40, P66, DOI 10.1016/j.ymeth.2006.05.020
   Sasnauskas K, 1999, BIOL CHEM, V380, P381, DOI 10.1515/BC.1999.050
   Sasnauskas K, 2002, INTERVIROLOGY, V45, P308, DOI 10.1159/000067922
   Sato Y, 2000, FASEB J, V14, P2108, DOI 10.1096/fj.99-1052com
   Schaffer DV, 2008, ANNU REV BIOMED ENG, V10, P169, DOI 10.1146/annurev.bioeng.10.061807.160514
   Scheerlinck JPY, 2008, DRUG DISCOV TODAY, V13, P882, DOI 10.1016/j.drudis.2008.06.016
   Schmid EF, 2005, DRUG DISCOV TODAY, V10, P1031, DOI 10.1016/S1359-6446(05)03524-5
   Schmidt FR, 2004, APPL MICROBIOL BIOT, V65, P363, DOI 10.1007/s00253-004-1656-9
   Schneider H, 1998, FEBS LETT, V429, P269, DOI 10.1016/S0014-5793(98)00612-7
   Schneider HJ, 2009, ANGEW CHEM INT EDIT, V48, P3924, DOI 10.1002/anie.200802947
   SCHREIBER V, 1992, EMBO J, V11, P3263
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Seebeck FP, 2006, J AM CHEM SOC, V128, P4516, DOI 10.1021/ja058363s
   Sen G.S., 2005, BIOCONJUGATE CHEM, V16, P1572
   Seow Y, 2009, MOL THER, V17, P767, DOI 10.1038/mt.2009.41
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Sharipo A, 2001, FEBS LETT, V499, P137, DOI 10.1016/S0014-5793(01)02542-X
   Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   SHIVELY JM, 1973, SCIENCE, V182, P584, DOI 10.1126/science.182.4112.584                                                    
   SHIVELY JM, 1970, J BACTERIOL, V101, P618
   Shun TY, 2011, J BIOMOL SCREEN, V16, P1, DOI 10.1177/1087057110389039
   Singh P, 2006, DRUG DEVELOP RES, V67, P23, DOI 10.1002/ddr.20064
   Singh P, 2009, TUMOR TARGETING USIN, P123
   Singh Pratik, 2006, J Nanobiotechnology, V4, P2, DOI 10.1186/1477-3155-4-2
   SLILATY SN, 1983, SCIENCE, V220, P725, DOI 10.1126/science.6301016
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Sorensen HP, 2005, J BIOTECHNOL, V115, P113, DOI 10.1016/j.jbiotec.2004.08.004
   Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484                                                           
   Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139
   STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0
   Stubenrauch K, 2001, BIOCHEM J, V356, P867, DOI 10.1042/0264-6021:3560867
   SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002
   Subramanian A, 1999, NAT BIOTECHNOL, V17, P873
   Sun YL, 2009, VIROLOGY, V383, P12, DOI 10.1016/j.virol.2008.09.020
   Sutter M, 2008, NAT STRUCT MOL BIOL, V15, P939, DOI 10.1038/nsmb.1473
   Takamura S, 2004, GENE THER, V11, P628, DOI 10.1038/sj.gt.3302193
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Tanaka S, 2008, SCIENCE, V319, P1083, DOI 10.1126/science.1151458
   Tanaka S, 2010, SCIENCE, V327, P81, DOI 10.1126/science.1179513
   Tiera MJ, 2006, CURR GENE THER, V6, P59, DOI 10.2174/156652306775515510                                                      
   Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022
   Tsumoto K, 2003, BIOPHYS CHEM, V106, P23, DOI 10.1016/S0301-4622(03)00138-8
   Tu RS, 2004, ADV DRUG DELIVER REV, V56, P1537, DOI 10.1016/j.addr.2003.10.047
   Uherek C, 1998, J BIOL CHEM, V273, P8835, DOI 10.1074/jbc.273.15.8835
   Vaccaro L, 2005, BIOPHYS J, V88, P25, DOI 10.1529/biophysj.104.044537
   Vaysse L, 2004, J BIOL CHEM, V279, P5555, DOI 10.1074/jbc.M311894200
   Vazquez E, 2010, NANOMEDICINE-UK, V5, P259, DOI 10.2217/NNM.09.98
   Vazquez E, 2009, CURR PHARM DESIGN, V15, P893, DOI 10.2174/138161209787582084                                                      
   Vazquez E, 2008, DRUG DISCOV TODAY, V13, P1067, DOI 10.1016/j.drudis.2008.08.008
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Voronkova T, 2007, VIRUS GENES, V34, P303, DOI 10.1007/s11262-006-0028-1
   Vuorela P, 2004, CURR MED CHEM, V11, P1375, DOI 10.2174/0929867043365116                                                        
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Walsh STR, 1999, P NATL ACAD SCI USA, V96, P5486, DOI 10.1073/pnas.96.10.5486
   Wang Wei, 1999, International Journal of Pharmaceutics (Amsterdam), V185, P129, DOI 10.1016/S0378-5173(99)00152-0
   Wang X, 2007, J NEUROSCI RES, V85, P3567, DOI 10.1002/jnr.21440
   Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221
   Warfield KL, 2003, P NATL ACAD SCI USA, V100, P15889, DOI 10.1073/pnas.2237038100
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   White SJ, 2001, HYPERTENSION, V37, P449, DOI 10.1161/01.HYP.37.2.449                                                         
   Wilke M, 1996, GENE THER, V3, P1133
   Windram OP, 2008, ARCH VIROL, V153, P585, DOI 10.1007/s00705-007-0025-2
   Wolschek MF, 2002, HEPATOLOGY, V36, P1106, DOI 10.1053/jhep.2002.36372
   Wu Ying-Ta, 2004, Current Drug Delivery, V1, P119, DOI 10.2174/1567201043479939
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xiang JH, 2002, J MED VIROL, V68, P537, DOI 10.1002/jmv.10237
   Xu YF, 2006, ARCH VIROL, V151, P2133, DOI 10.1007/s00705-006-0798-8
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
   Yeates TO, 2010, ANNU REV BIOPHYS, V39, P185, DOI 10.1146/annurev.biophys.093008.131418
   Yin Y, 2008, VACCINE, V26, P5814, DOI 10.1016/j.vaccine.2008.08.031
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
   YU JW, 1992, PLANT PHYSIOL, V100, P794, DOI 10.1104/pp.100.2.794                                                            
   Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91                                                            
   Zeng JM, 2004, J GENE MED, V6, P1247, DOI 10.1002/jgm.610
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Zhang XF, 2006, J MOL BIOL, V362, P753, DOI 10.1016/j.jmb.2006.07.037
   Zhao HY, 2010, EXPERT OPIN DRUG DIS, V5, P123, DOI 10.1517/17460440903584874
   Zhao XJ, 2006, CHEM SOC REV, V35, P1105, DOI 10.1039/b511336a
NR 332
TC 8
Z9 8
U1 0
U2 32
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1877-1173
BN 978-0-12-416020-0
J9 PROG MOL BIOL TRANSL
JI Prog. Molec. Biol. Transl. Sci.
PY 2011
VL 104
BP 247
EP 298
DI 10.1016/B978-0-12-416020-0.00006-1
PG 52
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BYL90
UT WOS:000299296000006
PM 22093221
DA 2018-01-05
ER

PT S
AU Zhang, XL
   Yang, Q
AF Zhang Xiaoling
   Yang Qiao
BE Zeng, DH
TI Using Single-walled Carbon Nanotubes as Solid-phase Extraction Adsorbent
   for the Sensitive Determination of Amino Acid Neurotransmitters in Human
   Cerebrospinal Fluids
SO MICRO NANO DEVICES, STRUCTURE AND COMPUTING SYSTEMS
SE Advanced Materials Research
LA English
DT Proceedings Paper
CT International Conference on Micro Nano Devices, Structure and Computing
   Systems
CY NOV 06-07, 2010
CL Int Sci & Engn Ctr, Singapore, SINGAPORE
SP Int Sci & Engn Ctr, Natl Univ Singapore, Shanzhen Univ
HO Int Sci & Engn Ctr
DE Single-walled carbon nanotubes; Solid-phase extraction; Amino acid
   neurotransmitters; HPLC; Human cerebrospinal fluids
ID INDUCED FLUORESCENCE DETECTION; GAS-CHROMATOGRAPHY; MICROEXTRACTION
AB Carbon nanotubes are a kind of new carbon-based nanomaterials, which have drawn great attention in many application fields including the biomarker analysis in biomedical and clinical research. In the present study, the feasibility of single-walled carbon nanotubes (SWCNTs) as solid-phase extraction (SPE) adsorbent for the determination of amino acid neurotransmitters (AANs) (glutamic, dopamine and gamma-amino-n-butyric acid) in human cerebrospinal fluids (CSFs) was investigated. Various parameters affecting SPE efficiency including the eluent and its volume, adsorbent amount and sample volume were systematically studied. The acquired calibration curves were linear (r(2) > 0.999) over the concentration range 10 to 500 ng per injection. By using SWCNTs as the SPE adsorbent, the detection limit of 12.9-42.5 fmol (at S/N of 3) were achieved with the preconcentration efficiency of more than 500-folds. The feasibility of the proposed method was validated by successfully applied to the measurements of ANNs in human CSFs sampled from healthy subjects and the patients with human immunodeficiency virus (HIV) infection, malignant melanoma and hypertension. This original application represents a powerful tool to study the kinetics of ANNs release by neuronal cells during neurotransmission, as well as for the understanding of the pathobiological and therapeutic basis of these remarkable molecular for diverse diseases.
C1 [Zhang Xiaoling; Yang Qiao] Chinese Acad Fishery Sci, E China Sea Fisheries Res Inst, Shanghai 200090, Peoples R China.
RP Yang, Q (reprint author), Chinese Acad Fishery Sci, E China Sea Fisheries Res Inst, Shanghai 200090, Peoples R China.
EM nyyqxl@126.com; qyang@mail.whu.edu.cn
CR Capriotti AL, 2010, J CHROMATOGR A, V1217, P2521, DOI 10.1016/j.chroma.2010.01.030
   Forrester MT, 2009, FREE RADICAL BIO MED, V46, P119, DOI 10.1016/j.freeradbiomed.2008.09.034
   Huestis MA, 1999, J CHROMATOGR B, V733, P247, DOI 10.1016/S0378-4347(99)00246-7
   Li QL, 2010, J CHROMATOGR A, V1217, P2191, DOI 10.1016/j.chroma.2010.02.009
   Liska I, 2000, J CHROMATOGR A, V885, P3, DOI 10.1016/S0021-9673(99)01144-9
   Nikolaus S, 2010, REV NEUROSCIENCE, V21, P119
   Perry M, 2009, ANAL CHIM ACTA, V653, P1, DOI 10.1016/j.aca.2009.08.038
   Rastkari N, 2009, J CHROMATOGR B, V877, P1568, DOI 10.1016/j.jchromb.2009.04.002
   SCHNEIDER U, 2008, J CHEM SOC, V424, P63
   van Leeuwen SPJ, 2007, J CHROMATOGR A, V1153, P172, DOI 10.1016/j.chroma.2007.02.069
   Wu F, 2010, TALANTA, V82, P1038, DOI 10.1016/j.talanta.2010.06.016
   Yang Q, 2008, J CHROMATOGR A, V1201, P120, DOI 10.1016/j.chroma.2008.06.001
   Yang Q, 2007, ANAL CHIM ACTA, V589, P231, DOI 10.1016/j.aca.2007.03.005
   Zhang XL, 2008, J CHROMATOGR B, V861, P136, DOI 10.1016/j.jchromb.2007.11.031
NR 14
TC 0
Z9 0
U1 0
U2 9
PU TRANS TECH PUBLICATIONS LTD
PI STAFA-ZURICH
PA LAUBLSRUTISTR 24, CH-8717 STAFA-ZURICH, SWITZERLAND
SN 1022-6680
BN 978-3-03785-009-1
J9 ADV MATER RES-SWITZ
PY 2011
VL 159
BP 622
EP 627
DI 10.4028/www.scientific.net/AMR.159.622
PG 6
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Engineering; Science & Technology - Other Topics; Materials Science
GA BVA31
UT WOS:000290888500113
DA 2018-01-05
ER

PT J
AU Ellis, JS
   Thompson, M
AF Ellis, Jonathan S.
   Thompson, Michael
TI Conformational states of nucleic acid-peptide complexes monitored by
   acoustic wave propagation and molecular dynamics simulation
SO CHEMICAL SCIENCE
LA English
DT Article
ID QUARTZ-CRYSTAL MICROBALANCE; SURFACE-PLASMON RESONANCE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; SLIP BOUNDARY-CONDITION; SOLID-LIQUID
   INTERFACE; TAT-DERIVED PEPTIDES; HIV-1 TAR; KELVIN NANOPROBE; PROTEIN;
   RNA
AB Material properties, interfacial slip, and conformational changes are modelled for the immobilisation of HIV-1 TAR RNA and subsequent binding of tat peptide fragments to the surface of a transverse-shear mode acoustic wave device. The modelling is based on previously-reported experimental results [N. Tassew, Ph.D. Thesis, 2003, University of Toronto, Toronto, Canada] and follows on from a previous modelling paper [J. S. Ellis and M. Thompson, Langmuir, 2010, 26, 11558]. A three-layer shear acoustic model is used to represent the system, where the layers describe the biomolecular monolayers and the contacting bulk buffer solution. Each layer is described by geometric, viscoelastic, and interfacial parameters, which are numerically fit to experimental values using a two-parameter minimisation algorithm. The neutravidin and TAR are described as distinct viscoelastic monolayers. Binding of tat peptide fragment to the TAR monolayer is modelled using a complex slip parameter and a change in length, corresponding to a straightening of the molecule. Molecular dynamics ( MD) simulations of the TAR-tat fragment system are performed to corroborate the modelling results. Starting structures are computed by molecular docking, and MD simulations of TAR complexed with various length tat fragments are described. The simulations are in general agreement with the modelling results and literature values from similar molecular dynamics experiments. A new parameter is introduced to describe biomolecule-solvent affinity, and is compared to interfacial coupling values obtained from modelling. This research demonstrates that acoustic wave devices can be used to detect conformational shifts in surface-attached biomolecules, provided molecular details about such shifts are known.
C1 [Ellis, Jonathan S.; Thompson, Michael] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [Thompson, Michael] Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada.
RP Thompson, M (reprint author), Univ Toronto, Inst Biomat & Biomed Engn, 164 Coll St, Toronto, ON, Canada.
EM mikethom@chem.utoronto.ca
FU Natural Sciences and Engineering Research Council of Canada; NATO;
   Ontario Graduate Scholarship (OGS); Victoria Noakes Ontario Graduate
   Scholarship in Science and Technology (OGSST)
FX The authors are grateful for support of this work from the Natural
   Sciences and Engineering Research Council of Canada and a NATO Science
   for Peace Grant. JSE would like to thank the Ontario Graduate
   Scholarship (OGS) and the Victoria Noakes Ontario Graduate Scholarship
   in Science and Technology (OGSST) Programs for financial support. The
   authors wish to express their appreciation to Professors Gordon Hayward
   (University of Guelph), Glen McHale (The Nottingham Trent University),
   and Michael Urbakh (Tel-Aviv University), and Drs. David Stone
   (University of Toronto) and Nardos Tassew (Toronto Western Hospital) for
   much very helpful discussion.
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Aboulela G, 1996, NUCLEIC ACIDS RES, V24, P4598
   Barrat JL, 1999, PHYS REV LETT, V82, P4671, DOI 10.1103/PhysRevLett.82.4671
   Baudry J, 2001, LANGMUIR, V17, P5232, DOI 10.1021/la0009994
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bonaccurso E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.076103
   Bonaccurso E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144501
   Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012
   Braunhut SJ, 2005, ASSAY DRUG DEV TECHN, V3, P77, DOI 10.1089/adt.2005.3.77
   Cavic BA, 1999, ANALYST, V124, P1405, DOI 10.1039/a903236c
   Cheran LE, 2007, ANALYST, V132, P242, DOI 10.1039/b615476j
   Cheran LE, 2005, ANALYST, V130, P1569, DOI 10.1039/b509724j
   Cheran LE, 2004, ANALYST, V129, P161, DOI 10.1039/b314058j
   CHO JHJ, 2004, PHYS REV LETT, V92
   CIEPLAK M, 1994, SCIENCE, V265, P1209, DOI 10.1126/science.265.5176.1209
   Cottin-Bizonne C, 2002, EUR PHYS J E, V9, P47, DOI [10.1140/epje/i2001-10112-9, 10.1140/epje/i2002-10112-9]
   Craig VSJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.054504
   Daikhin L, 2000, ELECTROCHIM ACTA, V45, P3615, DOI 10.1016/S0013-4686(00)00444-8                                                   
   DeLano W.L, 2007, MACPYMOL PYMOL BASED
   Du BY, 2004, LANGMUIR, V20, P10617, DOI 10.1021/la0483515
   DUNCANHEWITT WC, 1992, ANAL CHEM, V64, P94, DOI 10.1021/ac00025a017                                                             
   Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369
   Eaton J.W., 2002, GNU OCTAVE MANUAL
   EATON JW, 2007, OCTAVE
   EBERSOLE RC, 1990, J AM CHEM SOC, V112, P3239, DOI 10.1021/ja00164a070
   EGGERS F, 1987, J PHYS E SCI INSTRUM, V20, P523, DOI 10.1088/0022-3735/20/5/011
   EISENHABER F, 1995, J COMPUT CHEM, V16, P273, DOI 10.1002/jcc.540160303
   Ellis JS, 2010, LANGMUIR, V26, P11558, DOI 10.1021/la100798c
   Ellis JS, 2004, PHYS CHEM CHEM PHYS, V6, P4928, DOI 10.1039/b409342a
   Ellis JS, 2004, CHEM COMMUN, P1310, DOI 10.1039/b402822h
   Ellis JS, 2003, J APPL PHYS, V94, P7856, DOI 10.1063/1.1627949
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   FERRANTE F, 1994, J APPL PHYS, V76, P3448, DOI 10.1063/1.357475                                                                
   Furtado LM, 1999, ANAL CHEM, V71, P1167, DOI 10.1021/ac980880o
   GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9
   Granick S, 2003, NAT MATER, V2, P221, DOI 10.1038/nmat854                                                                 
   Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084
   Gwenin CD, 2007, SENSOR ACTUAT B-CHEM, V126, P499, DOI 10.1016/j.snb.2007.03.037
   Hayward GL, 1998, J APPL PHYS, V83, P2194, DOI 10.1063/1.366956
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Huo H, 2007, ACS SYM SER, V963, P312
   JOHANNSMANN D, 1992, PHYS REV B, V46, P7808, DOI 10.1103/PhysRevB.46.7808
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Krim J, 1998, MRS BULL, V23, P20
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   Lu F, 2004, J PHYS D APPL PHYS, V37, P898, DOI 10.1088/0022-3727/37/6/014
   Lubarsky GV, 2007, BIOSENS BIOELECTRON, V22, P1275, DOI 10.1016/j.bios.2006.05.024
   Lucklum R, 1997, FARADAY DISCUSS, V107, P123, DOI 10.1039/a703127k
   Mahoney MW, 2000, J CHEM PHYS, V112, P8910, DOI 10.1063/1.481505
   Marx KA, 2001, BIOSENS BIOELECTRON, V16, P773, DOI 10.1016/S0956-5663(01)00219-6
   McHale G, 2004, J APPL PHYS, V95, P373, DOI 10.1063/1.1630373
   McHale G, 2000, J APPL PHYS, V88, P7304, DOI 10.1063/1.1326855
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805                                                           
   More J. J., 1980, USER GUIDE MINPACK 1
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mu YG, 2006, BIOPHYS J, V90, P391, DOI 10.1529/biophysj.105.069559
   Neto C, 2003, EUR PHYS J E, V12, pS71, DOI 10.1140/epjed/e2003-01-018-0
   Nifosi R, 2000, NUCLEIC ACIDS RES, V28, P4944, DOI 10.1093/nar/28.24.4944
   OLIVIER S, 2007, P 8 IEEE INT WORKSH
   Peh WYX, 2007, BIOPHYS J, V92, P4415, DOI 10.1529/biophysj.106.099382
   Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2
   Perez A, 2004, NUCLEIC ACIDS RES, V32, P6144, DOI 10.1093/nar/gkh954
   Pit R, 1999, TRIBOL LETT, V7, P147, DOI 10.1023/A:1019161101812                                                         
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   REED CE, 1990, J APPL PHYS, V68, P1993, DOI 10.1063/1.346548
   Righetti PG, 2001, ELECTROPHORESIS, V22, P2359, DOI 10.1002/1522-2683(200107)22:12<2359::AID-ELPS2359>3.0.CO;2-8
   ROBERT K, 2004, J MOL RECOGNIT, V17, P151
   Rodahl M, 1996, SENSOR ACTUAT A-PHYS, V54, P448, DOI 10.1016/S0924-4247(97)80002-7
   Salomaki M, 2004, LANGMUIR, V20, P7794, DOI 10.1021/la049107g
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Scheuring S, 2001, SINGLE MOL, V2, P59
   Smith ED, 1996, PHYS REV B, V54, P8252, DOI 10.1103/PhysRevB.54.8252
   Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938
   Stengel G, 2005, ANAL CHEM, V77, P3709, DOI 10.1021/ac048302x
   Su XD, 2005, BIOSENS BIOELECTRON, V21, P719, DOI 10.1016/j.bios.2005.01.006
   Su XD, 2004, SENSOR ACTUAT B-CHEM, V100, P309, DOI 10.1016/j.snb.2004.01.020
   TESSIER L, 1994, SENSOR ACTUAT B-CHEM, V19, P698, DOI 10.1016/0925-4005(93)01134-P                                                    
   Tretheway DC, 2004, PHYS FLUIDS, V16, P1509, DOI 10.1063/1.1669400
   Tsortos A, 2008, BIOPHYS J, V94, P2706, DOI 10.1529/biophysj.107.119271
   VANGUNSTEREN WF, 1995, COMPUT PHYS COMMUN, V91, P305, DOI 10.1016/0010-4655(95)00055-K
   Wang XM, 2008, ANALYST, V133, P85, DOI 10.1039/b714210b
   WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015                                                             
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Willmott GR, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.066306
   YANG MS, 1993, LANGMUIR, V9, P802, DOI 10.1021/la00027a033                                                             
   ZACHARIAS M, 1995, P NATL ACAD SCI USA, V92, P6052, DOI 10.1073/pnas.92.13.6052
   Zhang J, 2002, BIOPHYS CHEM, V99, P31, DOI 10.1016/S0301-4622(02)00109-6                                                   
   Zhu YX, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.106102
NR 91
TC 5
Z9 5
U1 0
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
J9 CHEM SCI
JI Chem. Sci.
PY 2011
VL 2
IS 2
BP 237
EP 255
DI 10.1039/c0sc00423e
PG 19
WC Chemistry, Multidisciplinary
SC Chemistry
GA 707YO
UT WOS:000286327600008
DA 2018-01-05
ER

PT J
AU Masek, J
   Bartheldyova, E
   Korvasova, Z
   Skrabalova, M
   Koudelka, S
   Kulich, P
   Kratochvilova, I
   Miller, AD
   Ledvina, M
   Raska, M
   Turanek, J
AF Masek, Josef
   Bartheldyova, Eliska
   Korvasova, Zina
   Skrabalova, Michaela
   Koudelka, Stepan
   Kulich, Pavel
   Kratochvilova, Irena
   Miller, Andrew D.
   Ledvina, Miroslav
   Raska, Milan
   Turanek, Jaroslav
TI Immobilization of histidine-tagged proteins on monodisperse
   metallochelation liposomes: Preparation and study of their structure
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Liposome; Proteoliposome; Detergent removal method; Recombinant protein;
   Metallochelation; Atomic force microscopy (AFM); Transmission electron
   microscopy (TEM); Dynamic light scattering (DLS); Confocal microscopy
ID EXTRUSION PROCEDURE; DETERGENT REMOVAL; DELIVERY; RESPONSES; VESICLES;
   ANTIGEN
AB Liposomes represent a biocompatible platform for the construction of self-assembling proteoliposomes using nickel or zinc metallochelation. Potential applications of such structures consist in the development of new biocompatible vaccination nanoparticles and drug delivery nanoparticle systems. Here, we describe the design and construction of a flow-through ultrafiltration cell suitable for the preparation of monodisperse liposomes enabled for metallochelation and, hence, the formation of proteoliposomes. The linkage of the cell with a fast protein liquid chromatography system facilitates automation of the procedure, which fits the criteria for upscaling. Proof-of-concept experiments are performed using a mixture of egg phosphatidyl choline and nickel-chelating lipid DOGS-NTA-Ni (1,2-dioleoyl-sn-glycero-3-{[N(5-amino-1-carboxypentyl)iminodiacetic acid]succinyl}(nickel salt)) to formulate proteoliposomes with proteins attached by metallochelation, including histidine (His)-tagged recombinant green fluorescent protein and rgp120 (derived from HIV-1 Env). These model proteoliposomes are characterized by gel permeation chromatography and by dynamic light scattering. Transmission electron microscopy and immunogold staining are used to characterize surface-bound proteins, revealing the tendency of rgp120 to form microdomains on liposome surfaces. These microdomains possess a two-dimensional crystal-like structure that is seen more precisely by atomic force microscopy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Masek, Josef; Bartheldyova, Eliska; Korvasova, Zina; Skrabalova, Michaela; Koudelka, Stepan; Kulich, Pavel; Turanek, Jaroslav] Vet Res Inst, Dept Pharmacol Toxicol & Immunotherapy, CS-62132 Brno, Czech Republic.
   [Kratochvilova, Irena] Acad Sci Czech Republic, Inst Phys, Prague 18221, Czech Republic.
   [Miller, Andrew D.] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Genet Genet Therapies Ctr, Dept Chem, London SW7 2AZ, England.
   [Ledvina, Miroslav] Acad Sci Czech Republic, Inst Organ Chem & Biochem, CR-16610 Prague, Czech Republic.
   [Raska, Milan] Palacky Univ, Fac Med & Dent, Dept Immunol, CR-77147 Olomouc, Czech Republic.
RP Turanek, J (reprint author), Vet Res Inst, Dept Pharmacol Toxicol & Immunotherapy, CS-62132 Brno, Czech Republic.
EM turanek@vri.cz
RI Kratochvilova, Irena/G-5571-2014; Raska, Milan/E-9813-2013; Masek,
   Josef/B-3734-2015
OI Masek, Josef/0000-0001-6788-8487; Raska, Milan/0000-0002-8572-7246
FU Academy of Sciences of the Czech Republic [KAN200520703,
   32-KAN200100801]; Ministry of Education, Youth, and Sports of the Czech
   Republic [MSM6198959223]; GACR [P305/10/1951]; MZE [0002716202]
FX This work was supported by the following: grant GACR P305/10/1951 to
   J.T.; grant MZE 0002716202 to J.T.; grants from the Academy of Sciences
   of the Czech Republic (projects KAN200520703 and 32-KAN200100801) to
   J.T., I.K, and M.L., and from the Ministry of Education, Youth, and
   Sports of the Czech Republic (MSM6198959223) to M.R. The authors thank
   Jan Masek for the preparation of schematic drawings.
CR Altin JG, 2006, METHODS, V40, P39, DOI 10.1016/j.ymeth.2006.05.027
   Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1                                                   
   DUBOBIE J, 2003, VACCINE, V21, P605
   Gregoriadis G, 1995, TRENDS BIOTECHNOL, V13, P527, DOI 10.1016/S0167-7799(00)89017-4
   Leng J, 2002, EUROPHYS LETT, V59, P311, DOI 10.1209/epl/i2002-00243-1                                                       
   Malliaros J, 2004, VACCINE, V22, P3968, DOI 10.1016/j.vaccine.2004.03.054
   MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0
   Peschka R, 1998, INT J PHARMACEUT, V162, P177, DOI 10.1016/S0378-5173(97)00424-9                                                   
   Raska M, 2008, VACCINE, V26, P1541, DOI 10.1016/j.vaccine.2008.01.035
   Rigaud JL, 2003, METHOD ENZYMOL, V372, P65
   Ruger R, 2006, J DRUG TARGET, V14, P576, DOI 10.1080/10611860600864018
   Schubert R, 2003, METHOD ENZYMOL, V367, P46
   Small D. M., 1971, BILE ACIDS CHEMISTRY, V1, P249
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
   TERRY BR, 1995, BIOCHEM BIOPH RES CO, V217, P21, DOI 10.1006/bbrc.1995.2740
   TURANEK J, 1994, ANAL BIOCHEM, V218, P352, DOI 10.1006/abio.1994.1191
   van Broekhoven CL, 2004, CANCER RES, V64, P4357, DOI 10.1158/0008-5472.CAN-04-0138
   Walter A, 2000, BBA-BIOMEMBRANES, V1508, P20, DOI 10.1016/S0304-4157(00)00005-8
   ZUMBUEHL O, 1981, BIOCHIM BIOPHYS ACTA, V640, P252, DOI 10.1016/0005-2736(81)90550-2
NR 19
TC 13
Z9 13
U1 5
U2 52
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JAN 1
PY 2011
VL 408
IS 1
BP 95
EP 104
DI 10.1016/j.ab.2010.08.023
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 676CB
UT WOS:000283886600013
PM 20732292
DA 2018-01-05
ER

PT J
AU Faure-Perraud, A
   Metifiot, M
   Reigadas, S
   Recordon-Pinson, P
   Parissi, V
   Ventura, M
   Andreola, ML
AF Faure-Perraud, Aurelie
   Metifiot, Mathieu
   Reigadas, Sandrine
   Recordon-Pinson, Patricia
   Parissi, Vincent
   Ventura, Michel
   Andreola, Marie-Line
TI The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo
   by interfering with viral entry, reverse transcription and integration
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AFFINITY RNA LIGANDS; IN-VITRO; DNA
   APTAMERS; POTENT INHIBITOR; INFECTED-CELLS; TYPE-1; EVOLUTION;
   RALTEGRAVIR; SELECTION
AB Background: We have previously identified the guanine-rich oligonucleotide (ODN) 93del as a potent inhibitor in vitro of HIV-1 integrase. Moreover, low nanomolar concentrations of ODN 93del have been shown to inhibit HIV-1 replication in infected cells.
   Methods: To investigate the ex vivo mechanism of ODN 93del inhibition, we analysed its antiviral effects on the early steps of HIV-1 replication such as viral entry, reverse transcription and integration using quantitative PCR.
   Results: In addition to the effect on viral entry previously described for other guanine-quadruplex ODNs, transfection experiments showed that ODN 93del severely affects the proviral integration step independently of the effect on viral entry. Moreover, incubation of viral particles with ODN 93del revealed a potential microbicide activity of the aptamer.
   Conclusions: Our data point to an original multimodal inhibition of HIV-1 replication by ODN 93del, strongly suggesting that targets of guanine-quartet-forming ODNs involve entry as well as other intracellular early steps of HIV-1 replication.
C1 [Faure-Perraud, Aurelie; Metifiot, Mathieu; Parissi, Vincent; Ventura, Michel; Andreola, Marie-Line] Univ Bordeaux 2, CNRS, UMR 5234, F-33076 Bordeaux, France.
   [Faure-Perraud, Aurelie; Metifiot, Mathieu; Reigadas, Sandrine; Recordon-Pinson, Patricia; Parissi, Vincent; Ventura, Michel; Andreola, Marie-Line] Inst Federatif Rech Pathol Infect & Canc, Bordeaux, France.
   [Reigadas, Sandrine; Recordon-Pinson, Patricia] Univ Bordeaux 2, CHU Bordeaux, Lab Virol UPRES EA 2968, F-33076 Bordeaux, France.
RP Andreola, ML (reprint author), Univ Bordeaux 2, CNRS, UMR 5234, F-33076 Bordeaux, France.
EM marie-line.andreola@reger.u-bordeaux2.fr
FU French National Research Agency against AIDS (ANRS); Centre National de
   la Recherche Scientifique (CNRS); University Victor Segalen (Bordeaux
   2); ANRS; Ministry of Education and Research
FX This work was supported by the French National Research Agency against
   AIDS (ANRS), by the Centre National de la Recherche Scientifique (CNRS)
   and the University Victor Segalen (Bordeaux 2). AP-F gratefully
   acknowledges a PhD fellowship from the ANRS and MM a PhD fellowship from
   the Ministry of Education and Research. We thank Professor R Cooke
   (English Department, University Bordeaux 2) for his editorial assistance
   and S Litvak for careful reading of the manuscript and fruitful
   discussions.
CR ALLEN P, 1995, VIROLOGY, V209, P327, DOI 10.1006/viro.1995.1264
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Brody E N, 2000, J Biotechnol, V74, P5
   Brussel A, 2003, AIDS, V17, P645, DOI 10.1097/01.aids.0000050866.71999.a4
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   D'Andrea G, 2008, CURR CLIN PHARMACOL, V3, P20, DOI 10.2174/157488408783329913
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   DeStefano JJ, 2008, OLIGONUCLEOTIDES, V18, P133, DOI 10.1089/oli.2008.0103
   DeStefano JJ, 2006, NUCLEIC ACIDS RES, V34, P130, DOI 10.1093/nar/gkj426
   DOLLE V, 1995, J MED CHEM, V38, P4679, DOI 10.1021/jm00023a007
   Emery S, 2009, LANCET, V374, P764, DOI 10.1016/S0140-6736(09)61392-1
   Este JA, 1998, MOL PHARMACOL, V53, P340
   Gold L, 1997, P NATL ACAD SCI USA, V94, P59, DOI 10.1073/pnas.94.1.59
   Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002
   Kensch O, 2000, J BIOL CHEM, V275, P18271, DOI 10.1074/jbc.M001309200                                                          
   Marozzi A, 1998, J BIOTECHNOL, V61, P117, DOI 10.1016/S0168-1656(98)00017-0
   Metifiot M, 2005, BIOCHIMIE, V87, P911, DOI 10.1016/j.biochi.2005.03.013
   Metifiot M, 2007, OLIGONUCLEOTIDES, V17, P151, DOI 10.1089/oli.2006.0061
   Miller MD, 1997, J VIROL, V71, P5382
   Neidle S, 2009, CURR OPIN STRUC BIOL, V19, P239, DOI 10.1016/j.sbi.2009.04.001
   OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426                                                          
   Patel DJ, 2007, NUCLEIC ACIDS RES, V35, P7429, DOI 10.1093/nar/gkm711
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Pileur F, 2003, NUCLEIC ACIDS RES, V31, P5776, DOI 10.1093/nar/gkg748
   Reigadas S, 2010, J ANTIMICROB CHEMOTH, V65, P434, DOI 10.1093/jac/dkp473
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   Stolk LML, 2004, PHARM WORLD SCI, V26, P133, DOI 10.1023/B:PHAR.0000026815.44214.83                                              
   Tan JH, 2008, MINI-REV MED CHEM, V8, P1163, DOI 10.2174/138955708785909880                                                      
   TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2                                                    
   Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522
   Wu YT, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-61
   Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004
NR 40
TC 11
Z9 11
U1 1
U2 8
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2011
VL 16
IS 3
BP 383
EP 394
DI 10.3851/IMP1756
PG 12
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 813OA
UT WOS:000294375600012
PM 21555821
DA 2018-01-05
ER

PT J
AU Gonzalez-Nilo, F
   Perez-Acle, T
   Guinez-Molinos, S
   Geraldo, DA
   Sandoval, C
   Yevenes, A
   Santos, LS
   Laurie, VF
   Mendoza, H
   Cachau, RE
AF Gonzalez-Nilo, Fernando
   Perez-Acle, Tomas
   Guinez-Molinos, Sergio
   Geraldo, Daniela A.
   Sandoval, Claudia
   Yevenes, Alejandro
   Santos, Leonardo S.
   Felipe Laurie, V.
   Mendoza, Hegaly
   Cachau, Raul E.
TI Nanoinformatics: an emerging area of information technology at the
   intersection of bioinformatics, computational chemistry and
   nanobiotechnology
SO BIOLOGICAL RESEARCH
LA English
DT Article
DE Bioinformatics; molecular simulation; nanobiotechnology;
   nanoinformatics; nanomedicine
ID MOLECULAR-DYNAMICS SIMULATIONS; HIV-1 REVERSE-TRANSCRIPTASE; HR-LIKE
   RESPONSE; STRUCTURAL GENOMICS; FORCE-FIELDS; PENICILLIUM-PURPUROGENUM;
   CARBON NANOTUBES; PROTEIN; INHIBITORS; DELIVERY
AB After the progress made during the genomics era, bioinformatics was tasked with supporting the flow of information generated by nanobiotechnology efforts. This challenge requires adapting classical bioinformatic and computational chemistry tools to store, standardize, analyze, and visualize nanobiotechnological information. Thus, old and new bioinformatic and computational chemistry tools have been merged into a new sub-discipline: nanoinformatics. This review takes a second look at the development of this new and exciting area as seen from the perspective of the evolution of nanobiotechnology applied to the life sciences. The knowledge obtained at the nano-scale level implies answers to new questions and the development of new concepts in different fields. The rapid convergence of technologies around nanobiotechnologies has spun off collaborative networks and web platforms created for sharing and discussing the knowledge generated in nanobiotechnology. The implementation of new database schemes suitable for storage, processing and integrating physical, chemical, and biological properties of nanoparticles will be a key element in achieving the promises in this convergent field. In this work, we will review some applications of nanobiotechnology to life sciences in generating new requirements for diverse scientific fields, such as bioinformatics and computational chemistry.
C1 [Gonzalez-Nilo, Fernando] Univ Talca, Ctr Bioinformat & Mol Simulat, 2 Norte 685,Casilla 721, Talca, Chile.
   [Perez-Acle, Tomas] Univ Chile, Fac Ciencias Fis & Matemat, CMM, Computat Biol Lab DLab, Santiago, Chile.
   [Cachau, Raul E.] NCI, ABCC ISP, Sci Applicat Int Corp, Frederick Inc, Frederick, MD 21702 USA.
RP Gonzalez-Nilo, F (reprint author), Univ Talca, Ctr Bioinformat & Mol Simulat, 2 Norte 685,Casilla 721, Talca, Chile.
EM dgonzalez@utalca.cl
RI Perez-Acle, Tomas/F-7176-2012; Laurie, V. Felipe/C-4041-2012; Santos,
   Leonardo/A-7953-2008; Gonzalez Nilo, Fernando Danilo/M-5368-2017
OI Perez-Acle, Tomas/0000-0002-3769-390X; Santos,
   Leonardo/0000-0003-0908-0134; Gonzalez Nilo, Fernando
   Danilo/0000-0001-6857-3575; Yevenes, Alejandro/0000-0003-3799-1509;
   Laurie, Felipe/0000-0003-4465-2337
FU ACTION-GRID project; PBCT Anillo Cientifico [ACT/24]; Fondecyt [3100037,
   1100882]; Instituto Milenio Centro Interdisciplinario de Neurociencias
   de Valparaiso (CINV); National Cancer Institute, National Institutes of
   Health [N01-CO-12400, HHSN261200800001E]
FX This review was supported in part by ACTION-GRID project, PBCT Anillo
   Cientifico ACT/24, Fondecyt Project 3100037 and 1100882, and Instituto
   Milenio Centro Interdisciplinario de Neurociencias de Valparaiso (CINV).
   We thank Fabian Avila (UTalca) and Raul Araya-Secchi (UChile) for their
   great support to this initiative.r This work was funded in part with
   funds from the National Cancer Institute, National Institutes of Health,
   under contracts No. N01-CO-12400 and HHSN261200800001E. The content of
   this publication does not necessarily reflect the views or policies IF
   the Department of Health and Human Services, nor does mention of trade
   names, commercial products, or organizations imply endorsement by the
   U.S. government.
CR Arayne MS, 2007, PAK J PHARM SCI, V20, P340
   Archakov AI, 2007, MOL BIOSYST, V3, P336, DOI 10.1039/b618285b
   ARTIGAS RA, 2008, J CLIN ENDOCRINOL ME
   Artigas RA, 2008, J CLIN ENDOCR METAB, V93, P3097, DOI 10.1210/jc.2008-0048
   Belting M, 2009, MOL BIOTECHNOL, V43, P89, DOI 10.1007/s12033-009-9185-5
   BEWICK S, 2009, WILEY INTERDISCIPLIN, V1
   Bianco Alberto, 2004, Expert Opin Drug Deliv, V1, P57, DOI 10.1517/17425247.1.1.57
   Carvajal CA, 2003, J CLIN ENDOCR METAB, V88, P2501, DOI 10.1210/jc.2002-021909
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   CHOTHIA C, 1986, SCIENCE, V233, P755, DOI 10.1126/science.3090684                                                         
   CHOTHIA C, 1986, EMBO J, V5, P823
   Cieplak M, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2939247
   Colombres M, 2008, J COMPUT AID MOL DES, V22, P19, DOI 10.1007/s10822-007-9149-4
   Daggett V, 2001, Methods Mol Biol, V168, P215
   de la Calle G, 2008, ST HEAL T, V136, P163
   de la Calle G, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-320
   Diekmann S., 2002, REV MOL BIOTECHNOLOG, V90, P157, DOI 10.1016/S1389-0352(01)00074-5
   DREXLER KE, 1992, SCIENCE, V255, P268, DOI 10.1126/science.255.5042.268-b
   Ehrenfeld N, 2008, J GEN VIROL, V89, P809, DOI 10.1099/vir.0.83355-0
   ERICKSON B, 2009, CHEM ENG, V87, P42
   Eyzaguirre J, 2004, FASEB J, V18, pC146
   FAN D, 2009, J COLLOID INTERFACE
   Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011
   Fermeglia M, 2009, COMPUT CHEM ENG, V33, P1701, DOI 10.1016/j.compchemeng.2009.04.006
   Freddolino PL, 2006, STRUCTURE, V14, P437, DOI 10.1016/j.str.2005.11.014
   Freitas RA, 2005, DM-DIS MON, V51, P325, DOI 10.1016/j.disamonth.2005.08.003
   Frisch M. J., 2004, GAUSSIAN
   Gao H., 2001, EUROPEAN WHITE BOOK, P144
   GARCIAREMESAL M, 2007, LOGICAL SCHEMA ACQUI, P259
   GATES T, 2004, COMPUTATIONAL MAT MO, V2, P1872
   Gates TS, 2005, COMPOS SCI TECHNOL, V65, P2416, DOI 10.1016/j.compscitech.2005.06.009
   Gogonea V, 2001, CURR OPIN STRUC BIOL, V11, P217, DOI 10.1016/S0959-440X(00)00193-7
   Gonzalez A, 2008, BIOORGAN MED CHEM, V16, P4378, DOI 10.1016/j.bmc.2008.02.070
   GONZALEZIBANEZ A, 2009, BIOPHYS J, V96, P49
   GONZALEZNILO D, 2008, 5 RIB RED IB BIOINF
   Gordon N, 2003, NANOMEDICINE TAXONOM
   Haddish-Berhane N, 2007, INT J NANOMED, V2, P315
   IGLESIA DDL, 2009, NANOINFORMATICS NEW
   Barria MI, 2009, NUCLEIC ACIDS RES, V37, P957, DOI 10.1093/nar/gkn1022
   Inestrosa Nibaldo C., 2005, Current Alzheimer Research, V2, P301, DOI 10.2174/1567205054367928
   Ironi L, 2003, COMPUT CHEM ENG, V27, P803, DOI 10.1016/S0098-1354(02)00266-1
   KANG W, 2009, SMALL
   Khurana E, 2006, J PHYS CHEM B, V110, P18965, DOI 10.1021/jp057471y
   Lagos CF, 2008, CHEM BIOL DRUG DES, V72, P360, DOI 10.1111/j.1747-0285.2008.00716.x
   LEE H, 2009, PHYSICA B
   Lee SY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/49/495101
   LEE W, 2009, J COLLOID INTERFACE
   Lizama C, 2009, J CELL PHYSIOL, V221, P296, DOI 10.1002/jcp.21868
   Lu DY, 2006, PHYS BIOL, V3, pS40, DOI 10.1088/1478-3975/3/1/S05
   Lundstrom K, 2007, J CELL MOL MED, V11, P224, DOI 10.1111/j.1582-4934.2007.00028.x
   MacKerell AD, 2001, BIOPOLYMERS, V56, P257
   Martin W, 2008, J PHYS CHEM B, V112, P16076, DOI 10.1021/jp8040567
   MAUGER B, 2007, BUILDING DATA GRID A, P312
   McGuffin LJ, 2002, PROTEINS, V48, P44, DOI 10.1002/prot.10129
   Milanesi L, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-I1
   MOHAN YM, 2009, J COLLOID INTERFACE
   *NAN, 2005, FUND SUPP INT NAN CO
   NEWKOME G, 2007, POLYMER
   Patra M, 2004, J COMPUT CHEM, V25, P678, DOI 10.1002/jcc.10417
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Prasad K, 2010, J COLLOID INTERF SCI, V342, P68, DOI 10.1016/j.jcis.2009.10.003
   Price DJ, 2002, J COMPUT CHEM, V23, P1045, DOI 10.1002/jcc.10083
   RICKMAN J, 2003, COMPUTATIONAL MAT RE
   RODRIGUEZ A, 2008, NBIC NANO BIO INFO C
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306
   Sali A, 2007, STRUCTURE, V15, P1341, DOI 10.1016/i.str.2007.10.009
   Sanchez R, 2000, METH MOL B, V143, P97
   SELIM W, 2009, PROG POLYM SCI, V34
   Shapiro Bruce A., 2008, V474, P93, DOI 10.1007/978-1-59745-480-3_7
   Sibeko B, 2009, BIOMED MATER, V4, DOI 10.1088/1748-6041/4/1/015014
   Sommerfeld D, 2009, FUTURE GENER COMP SY, V25, P337, DOI 10.1016/j.future.2008.05.010
   Staggers N, 2008, NURS OUTLOOK, V56, P268, DOI 10.1016/j.outlook.2008.06.004
   Stange C, 2008, J MOL GRAPH MODEL, V26, P850, DOI 10.1016/j.jmgm.2007.05.006
   Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703
   Strobel P, 2004, FREE RADICAL BIO MED, V36, pS151
   Talbi EG, 2008, GRID COMPUTING FOR BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, P1
   Thierry Benjamin, 2009, Current Drug Delivery, V6, P391
   Tischler ND, 2005, J GEN VIROL, V86, P2937, DOI 10.1099/vir.0.81083-0
   Tomalia DA, 2005, MATER TODAY, V8, P34, DOI 10.1016/S1369-7021(05)00746-7
   Vasquez D, 2007, J CHIL CHEM SOC, V52, P1281, DOI 10.4067/S0717-97072007000400002
   Zimmerli U, 2008, BIOPHYS J, V94, P2546, DOI 10.1529/biophysj.106.102467
   Zweigenbaum P, 2007, BRIEF BIOINFORM, V8, P358, DOI 10.1093/bib/bbm045
   ICON EHS DATABASE
   DATABASE NANOPARTICL
NR 85
TC 9
Z9 10
U1 0
U2 18
PU SOC BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0716-9760
EI 0717-6287
J9 BIOL RES
JI Biol. Res.
PY 2011
VL 44
IS 1
BP 43
EP 51
DI 10.4067/S0716-97602011000100006                                         
          
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 750JF
UT WOS:000289541700006
PM 21720680
OA gold
DA 2018-01-05
ER

PT J
AU Numata, M
   Shinkai, S
AF Numata, Munenori
   Shinkai, Seiji
TI 'Supramolecular wrapping chemistry' by helix-forming polysaccharides: a
   powerful strategy for generating diverse polymeric nano-architectures
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID WALLED CARBON NANOTUBES; ONE-DIMENSIONAL HOST; CIRCULARLY-POLARIZED
   ELECTROLUMINESCENCE; SCHIZOPHYLLUM-COMMUNE POLYSACCHARIDE; TARGETED
   ANTISENSE CARRIER; BORON-NITRIDE NANOTUBES; SINGLE-STRANDED RNA;
   ANTI-HIV ACTIVITY; CONJUGATED POLYMERS; BETA-1,3-GLUCAN POLYSACCHARIDES
AB We have exploited novel supramolecular wrapping techniques by helix-forming polysaccharides, beta-1,3-glucans, which have strong tendency to form regular helical structures on versatile nanomaterials in an induced-fit manner. This approach is totally different from that using the conventional interpolymer interactions seen in both natural and synthetic polymeric architectures, and therefore has potential to create novel polymeric architectures with diverse and unexpected functionalities. The wrapping by beta-1,3-glucans enforces the entrapped guest polymer to adopt helical or twisted conformations through the convergent interpolymer interactions. On the contrary, the wrapping by chemically modified semi-artificial beta-1,3-glucans can bestow the divergent self-assembling abilities on the entrapped guest polymer to create hierarchical polymeric architectures, where the polymer/beta-1,3-glucan composite acts as a huge one-dimensional building block. Based on the established wrapping strategy, we have further extended the wrapping techniques toward the creation of three-dimensional polymeric architectures, in which the polymer/beta-1,3-glucan composite behaves as a sort of amphiphilic block copolymers. The present wrapping system would open several paths to accelerate the development of the polymeric supramolecular assembly systems, giving the strong stimuli to the frontier of polysaccharide-based functional chemistry.
C1 [Shinkai, Seiji] Inst Syst Informat Technol & Nanotechnol ISIT, Nishi Ku, Fukuoka 8190385, Japan.
   [Numata, Munenori] Kyoto Prefectural Univ, Grad Sch Life & Environm Sci, Sakyo Ku, Kyoto 6068522, Japan.
   [Shinkai, Seiji] Sojo Univ, Dept Nanosci, Fac Engn, Kumamoto 8600082, Japan.
RP Shinkai, S (reprint author), Inst Syst Informat Technol & Nanotechnol ISIT, Nishi Ku, 203-1 Motooka, Fukuoka 8190385, Japan.
EM shinkai_center@mail.cstm.kyushu-u.ac.jp
FU Japan Science and Technology Agency; MEXT; Mitsubishi Chemical
   Corporation; Technology Foundation; Kansai Research Foundation for
   Technology Promotion; Tokuyama Science Foundation; Iketani Science
   Technology Foundation; Sumitomo Foundation
FX The present works were performed in cooperation with many project
   members; Mr. T. Matsumoto, Ms. M. Umeda, Dr T. Hasegawa, Dr C. Li, Dr
   A.-H. Bae, Mr. T. Fujisawa, Dr S. Haraguchi, Dr S. Tamesue, Dr M. Ikeda
   and Dr K. Sugikawa. The authors express their gratitude for all the
   members. The authors thank Mitusi Sugar Co., Japan, for providing the
   schizophyllan samples. This work was supported by the SORST of the Japan
   Science and Technology Agency. This work was partially supported by the
   MEXT, Grant-in-Aid for Scientific Research on Innovative Areas
   'Emergence in Chemistry'. M. N. thanks Mitsubishi Chemical Corporation
   Fund, Izumi Science and Technology Foundation, Kansai Research
   Foundation for Technology Promotion, Tokuyama Science Foundation,
   Iketani Science Technology Foundation and Sumitomo Foundation for
   partial financial supports.
CR ATKINS EDT, 1968, NATURE, V220, P784, DOI 10.1038/220784a0
   Boerakker MJ, 2002, ANGEW CHEM INT EDIT, V41, P4239, DOI 10.1002/1521-3773(20021115)41:22<4239::AID-ANIE4239>3.0.CO;2-E                  
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3
   Brunsveld L, 2001, CHEM REV, V101, P4071, DOI 10.1021/cr990125q
   Caruso MM, 2009, CHEM REV, V109, P5755, DOI 10.1021/cr9001353
   Cathcart H, 2008, J AM CHEM SOC, V130, P12734, DOI 10.1021/ja803273s
   Chen SH, 1999, NATURE, V397, P506, DOI 10.1038/17343                                                                   
   CHEN Y, 2009, CHEM COMMUN, P4196
   Chichak KS, 2005, SMALL, V1, P452, DOI 10.1002/smll.200400070
   De Greef TFA, 2009, CHEM REV, V109, P5687, DOI 10.1021/cr900181u
   DEMLEITNER S, 1992, CARBOHYD RES, V226, P239, DOI 10.1016/0008-6215(92)84071-Y
   Didenko VV, 2005, NANO LETT, V5, P1563, DOI 10.1021/nl050840h
   Ding K, 2007, ANGEW CHEM INT EDIT, V46, P1172, DOI 10.1002/anie.200603064
   Escudero C, 2006, ANGEW CHEM INT EDIT, V45, P8032, DOI 10.1002/anie.200603182
   Ewert KK, 2006, J AM CHEM SOC, V128, P3998, DOI 10.1021/ja055907h
   FIKRI F, 2007, CHEM COMMUN, P1358
   FORSTER GS, 2002, ANGEW CHEM INT EDIT, V41, P688
   Frampton MJ, 2008, CHEM COMMUN, P2797, DOI 10.1039/b803335h
   Frampton MJ, 2007, ANGEW CHEM INT EDIT, V46, P1028, DOI 10.1002/anie.200601780
   FRANCISCO T, 2007, CHEM COMMUN, P1130
   FUJIKI M, 1994, J AM CHEM SOC, V116, P6017, DOI 10.1021/ja00092a082                                                             
   Gao Y, 1999, MACROMOLECULES, V32, P8319, DOI 10.1021/ma990782k                                                               
   Gigliotti B, 2006, NANO LETT, V6, P159, DOI 10.1021/nl0518775
   Goto H, 2005, ANGEW CHEM INT EDIT, V44, P4322, DOI 10.1002/anie.200462859
   Goto H, 2002, J AM CHEM SOC, V124, P7943, DOI 10.1021/ja025900p
   Goto H, 2007, MACROMOLECULES, V40, P1377, DOI 10.1021/ma062296k
   Hannink JM, 2001, ANGEW CHEM INT EDIT, V40, P4732, DOI 10.1002/1521-3773(20011217)40:24<4732::AID-ANIE4732>3.0.CO;2-P                  
   Haraguchi S, 2005, ORG LETT, V7, P5605, DOI 10.1021/ol052170s
   Haraguchi S., 2009, CHEM LETT, P254
   HASAGAWA T, 2004, CHEM COMMUN, P382
   Hasegawa T, 2006, CARBOHYD RES, V341, P35, DOI 10.1016/j.carres.2005.10.009
   Hasegawa T, 2005, ORG BIOMOL CHEM, V3, P4321, DOI 10.1039/b510646j
   Hasegawa T, 2005, CHEM LETT, V34, P40, DOI 10.1246/cl.2005.40
   Hasegawa T, 2005, BIOORG MED CHEM LETT, V15, P327, DOI 10.1016/j.bmcl.2004.10.071
   Hasegawa T, 2004, ORG BIOMOL CHEM, V2, P3091, DOI 10.1039/b412124b
   Hasegawa T, 2004, CHEM COMMUN, P2150, DOI 10.1039/b407409b
   Hill DJ, 2001, CHEM REV, V101, P3893, DOI 10.1021/cr990120t
   Hofmeier H, 2005, CHEM COMMUN, P2423, DOI 10.1039/b419171d
   Hosomizu K, 2008, J PHYS CHEM B, V112, P16517, DOI 10.1021/jp807991k
   Ichino Y, 2001, J PHYS CHEM B, V105, P4111, DOI 10.1021/jp002503x                                                               
   IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0                                                                
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Ikai T, 2009, CHEM REV, V109, P6077, DOI 10.1021/cr8005558
   Ikeda A, 2006, ORG LETT, V8, P5489, DOI 10.1021/ol062187q
   Ikeda M, 2007, ORG BIOMOL CHEM, V5, P2219, DOI 10.1039/b705997c
   Ikeda M, 2007, J AM CHEM SOC, V129, P3979, DOI 10.1021/ja0684343
   Ikeda M, 2006, ANGEW CHEM INT EDIT, V45, P6491, DOI 10.1002/anie.200602134
   Ikkala O, 1999, ADV MATER, V11, P1206, DOI 10.1002/(SICI)1521-4095(199910)11:14<1206::AID-ADMA1206>3.0.CO;2-U              
   Kadokawa J, 2001, CHEM COMMUN, P449, DOI 10.1039/b008180i                                                                
   Kang YJ, 2009, CURR APPL PHYS, V9, pS7, DOI 10.1016/j.cap.2008.08.028
   Katsuraya K, 1999, CARBOHYD RES, V315, P234, DOI 10.1016/S0008-6215(98)00315-2
   Kida T, 2007, CHEM COMMUN, P1559, DOI 10.1039/b616231b
   Kim OK, 2003, J AM CHEM SOC, V125, P4426, DOI 10.1021/ja029233b
   Kimura T, 2000, CHEM LETT, P1242, DOI 10.1246/cl.2000.1242
   Klok HA, 2000, MACROMOLECULES, V33, P7819, DOI 10.1021/ma0009606
   Koumoto K, 2004, CARBOHYD RES, V339, P161, DOI 10.1016/j.carres.2003.09.022
   Kubo Y, 2006, ANGEW CHEM INT EDIT, V45, P1548, DOI 10.1002/anie.200503128
   Kumaki J, 2007, ANGEW CHEM INT EDIT, V46, P5348, DOI 10.1002/anie.200700455
   LangeveldVoss BMW, 1996, J AM CHEM SOC, V118, P4908, DOI 10.1021/ja9600643                                                               
   Li C, 2005, CHEM LETT, V34, P1532, DOI 10.1246/cl.2005.1532
   Li C, 2005, J AM CHEM SOC, V127, P4548, DOI 10.1021/ja050168q
   Lii CY, 2003, CARBOHYD POLYM, V51, P93, DOI 10.1016/S0144-8617(02)00122-4                                                   
   Liu YZ, 2010, J PHYS CHEM B, V114, P5783, DOI 10.1021/jp9110772
   LU FL, 1986, J AM CHEM SOC, V108, P8311, DOI 10.1021/ja00286a057                                                             
   Meskers SCJ, 2000, ADV MATER, V12, P589, DOI 10.1002/(SICI)1521-4095(200004)12:8<589::AID-ADMA589>3.3.CO;2-3
   Morikawa M, 2005, CHEM-EUR J, V11, P1574, DOI 10.1002/chem.200400751
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Naito M, 2008, J AM CHEM SOC, V130, P16697, DOI 10.1021/ja806109z
   Nakashima H, 2001, J AM CHEM SOC, V123, P1963, DOI 10.1021/ja000869h
   Nakashima N, 2003, CHEM LETT, V32, P456, DOI 10.1246/cl.2003.456
   Numata M, 2005, J AM CHEM SOC, V127, P5875, DOI 10.1021/ja044168m
   Numata M, 2004, ORG LETT, V6, P4447, DOI 10.1021/ol0483448
   Numata M, 2004, CHEM LETT, V33, P232, DOI 10.1246/cl.2004.232                                                             
   Numata M, 2003, BIOORG CHEM, V31, P163, DOI 10.1016/S0045-2068(03)00020-8
   Numata M, 2008, CHEM-EUR J, V14, P2398, DOI 10.1002/chem.200701205
   Numata M, 2007, SUPRAMOL CHEM, V19, P107, DOI 10.1080/10610270600982508
   Numata M, 2009, CHEM-EUR J, V15, P12338, DOI 10.1002/chem.200901783
   Numata M, 2008, ADV POLYM SCI, V220, P65, DOI 10.1007/12_2008_145
   Oda M, 2000, ADV MATER, V12, P362, DOI 10.1002/(SICI)1521-4095(200003)12:5<362::AID-ADMA362>3.0.CO;2-P                 
   Okumura H, 2003, MACROMOLECULES, V36, P6422, DOI 10.1021/ma030164a
   Peeters E, 1997, J AM CHEM SOC, V119, P9909, DOI 10.1021/ja971912c                                                               
   Peng WQ, 2004, J AM CHEM SOC, V126, P13822, DOI 10.1021/ja046235i
   Percec V, 1998, NATURE, V391, P161, DOI 10.1038/34384
   POUGET JP, 1992, SYNTHETIC MET, V51, P95, DOI 10.1016/0379-6779(92)90258-K
   Purrello R, 1998, J PHYS CHEM B, V102, P8852, DOI 10.1021/jp9828686                                                               
   Qian H, 2008, NANO LETT, V8, P2706, DOI 10.1021/nl801038t
   Reynhout IC, 2009, ACCOUNTS CHEM RES, V42, P681, DOI 10.1021/ar800143a
   Rosen BM, 2009, CHEM REV, V109, P6275, DOI 10.1021/cr900157q
   Sakurai K, 2005, CHEM COMMUN, P4383, DOI 10.1039/b506673p
   Sakurai K, 2000, J AM CHEM SOC, V122, P4520, DOI 10.1021/ja0000145                                                               
   Sanji T, 2005, ANGEW CHEM INT EDIT, V44, P7301, DOI 10.1002/anie.200502073
   Sanji T, 2005, CHEM LETT, V34, P1144, DOI 10.1246/cl.2005.1144
   Sano M, 2001, SCIENCE, V293, P1299, DOI 10.1126/science.1061050                                                         
   SATO T, 1981, CARBOHYD RES, V95, P195, DOI 10.1016/S0008-6215(00)85576-7                                                   
   Satrijo A, 2006, J AM CHEM SOC, V128, P9030, DOI 10.1021/ja063027c
   Schatz C, 2009, ANGEW CHEM INT EDIT, V48, P2572, DOI 10.1002/anie.200805895
   Schwab AD, 2003, J PHYS CHEM B, V107, P11339, DOI 10.1021/jp035569b
   Sijbesma RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/science.278.5343.1601
   STAFSTROM S, 1987, PHYS REV LETT, V59, P1464, DOI 10.1103/PhysRevLett.59.1464
   Star A, 2004, ORG LETT, V6, P2089, DOI 10.1021/ol0495826
   Star A, 2002, ANGEW CHEM INT EDIT, V41, P2508, DOI 10.1002/1521-3773(20020715)41:14<2508::AID-ANIE2508>3.0.CO;2-A                  
   Star A, 2001, ANGEW CHEM INT EDIT, V40, P1721, DOI 10.1002/1521-3773(20010504)40:9<1721::AID-ANIE17210>3.0.CO;2-F                  
   STOKKE BT, 1991, MACROMOLECULES, V24, P6349, DOI 10.1021/ma00023a046                                                             
   Sugikawa K, 2011, ORG BIOMOL CHEM, V9, P146, DOI 10.1039/c0ob00407c
   Sugikawa K, 2008, LANGMUIR, V24, P13270, DOI 10.1021/la802211q
   Tamesue S, 2008, CHEM COMMUN, P4478, DOI 10.1039/b808599d
   Tang BZ, 1999, MACROMOLECULES, V32, P2569, DOI 10.1021/ma981825k                                                               
   van Dongen SFM, 2009, CHEM REV, V109, P6212, DOI 10.1021/cr900072y
   Velonia K, 2002, J AM CHEM SOC, V124, P4224, DOI 10.1021/ja017809b
   Vriezema DM, 2005, CHEM REV, V105, P1445, DOI 10.1021/cr0300688
   YANAKI T, 1980, MACROMOLECULES, V13, P1462, DOI 10.1021/ma60078a019                                                             
   YANAKI T, 1983, BIOPHYS CHEM, V17, P337, DOI 10.1016/0301-4622(83)80018-0
   YANG L, 2004, NAT MATER, V3, P614
   Yashima E, 2009, CHEM REV, V109, P6102, DOI 10.1021/cr900162q
   Yoo PJ, 2006, NAT MATER, V5, P234, DOI 10.1038/nmat1596
   YOSHIDA T, 1995, CARBOHYD RES, V276, P425, DOI 10.1016/0008-6215(95)00186-W
   Yuan WZ, 2006, MACROMOLECULES, V39, P8011, DOI 10.1021/ma061856c
   Zahn S, 2002, ANGEW CHEM INT EDIT, V41, P4225, DOI 10.1002/1521-3773(20021115)41:22<4225::AID-ANIE4225>3.0.CO;2-3
   Zhang F, 2008, MACROMOLECULES, V41, P4519, DOI 10.1021/ma800514a
   Zhao W, 2006, CHEM COMMUN, P3582, DOI 10.1039/b606518j
   Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877
   Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911
   Zhi CY, 2006, J PHYS CHEM B, V110, P1525, DOI 10.1021/jp054941f
   Zhi CY, 2005, J AM CHEM SOC, V127, P15996, DOI 10.1021/ja053917c
   Zorbas V, 2004, J AM CHEM SOC, V126, P7222, DOI 10.1021/ja049202b
NR 125
TC 57
Z9 58
U1 1
U2 61
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2011
VL 47
IS 7
BP 1961
EP 1975
DI 10.1039/c0cc03133j
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA 713VX
UT WOS:000286766600003
PM 21246150
DA 2018-01-05
ER

PT J
AU Biswas, P
   Cella, LN
   Kang, SH
   Mulchandani, A
   Yates, MV
   Chen, W
AF Biswas, Payal
   Cella, Lakshmi N.
   Kang, Seung Hyun
   Mulchandani, Ashok
   Yates, Marylynn V.
   Chen, Wilfred
TI A quantum-dot based protein module for in vivo monitoring of protease
   activity through fluorescence resonance energy transfer
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MATRIX METALLOPROTEINASES;
   ELASTIN-PROTEIN; HIV-1 PROTEASE; INHIBITORS; RESISTANCE; PEPTIDES;
   DELIVERY; TARGETS; CANCER
AB Here, we present a new generation of nanoscale probes for in vivo monitoring of protease activity by fluorescence resonance energy transfer (FRET). The approach is based on a genetically programmable protein module carrying a fluorescently labeled, protease-specific sequence that can self-assemble onto quantum dots. The protein module was used for real-time detection of human immunodeficiency virus type-1 protease (HIV-1 Pr) activity as well as quantitative assessment of inhibitor efficiency.
C1 [Cella, Lakshmi N.; Chen, Wilfred] Univ Delaware, Dept Chem Engn, Newark, DE 19716 USA.
   [Biswas, Payal; Kang, Seung Hyun; Mulchandani, Ashok] Univ Calif Riverside, Dept Chem & Environm Engn, Riverside, CA 92521 USA.
   [Cella, Lakshmi N.] Univ Calif Riverside, Cell Mol & Dev Biol Grad Program, Riverside, CA 92521 USA.
   [Yates, Marylynn V.] Univ Calif Riverside, Dept Environm Sci, Riverside, CA 92521 USA.
RP Chen, W (reprint author), Univ Delaware, Dept Chem Engn, Newark, DE 19716 USA.
EM wilfred@udel.edu
RI Mulchandani, Ashok/B-9692-2016; Chen, Wilfred/H-4335-2013
OI Mulchandani, Ashok/0000-0002-2831-4154; 
FU NSF [CBET0755775]
FX This work was supported by a grant from NSF (CBET0755775). The plasmid
   pNL4-3.HSA.R<SUP>-</SUP>E<SUP>-</SUP> was obtained from Dr Nathaniel
   Landau.
CR Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
   Blum G, 2005, NAT CHEM BIOL, V1, P203, DOI 10.1038/nchembo728
   Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775
   BRYD CM, 2006, DRUG DEVELOP RES, V67, P501
   Cheng TJ, 2004, ANTIMICROB AGENTS CH, V48, P2437, DOI 10.1128/AAC.48.7.2437-2447.2004
   Cihlar T, 2006, J MOL BIOL, V363, P635, DOI 10.1016/j.jmb.2006.07.073
   Concha NO, 2002, CURR MED CHEM, V9, P713, DOI 10.2174/0929867023370761                                                        
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   Delehanty JB, 2009, EXPERT OPIN DRUG DEL, V6, P1091, DOI 10.1517/17425240903167934
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   HE JL, 1995, J VIROL, V69, P6705
   Hilton BJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010940
   Hwang YC, 2006, APPL ENVIRON MICROB, V72, P3710, DOI 10.1128/AEM.72.5.3710-3715.2006
   Kim JY, 2005, ANAL CHEM, V77, P2318, DOI 10.1021/ac0484326
   Kolli M, 2009, J VIROL, V83, P11027, DOI 10.1128/JVI.00628-09
   Kostal J, 2001, MACROMOLECULES, V34, P2257, DOI 10.1021/ma001973m
   Lao UL, 2006, J AM CHEM SOC, V128, P14756, DOI 10.1021/ja065343x
   Lee JC, 2005, ASSAY DRUG DEV TECHN, V3, P385, DOI 10.1089/adt.2005.3.385
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Massodi I, 2005, J CONTROL RELEASE, V108, P396, DOI 10.1016/j.jcornel.2005.08.007
   Medintz IL, 2006, NAT MATER, V5, P581, DOI 10.1038/nmat1676
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   Neurath H, 1999, P NATL ACAD SCI USA, V96, P10962, DOI 10.1073/pnas.96.20.10962                                                        
   Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614
   Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t                                                               
   Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799
   Zhang B, 2004, BIOCHEM BIOPH RES CO, V323, P674, DOI 10.1016/j.bbrc.2004.08.143
NR 29
TC 27
Z9 27
U1 0
U2 39
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2011
VL 47
IS 18
BP 5259
EP 5261
DI 10.1039/c1cc10648a
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 752KH
UT WOS:000289689600043
PM 21445447
DA 2018-01-05
ER

PT J
AU Wang, X
   Matei, E
   Deng, LQ
   Ramstrom, O
   Gronenborn, AM
   Yan, MD
AF Wang, Xin
   Matei, Elena
   Deng, Lingquan
   Ramstroem, Olof
   Gronenborn, Angela M.
   Yan, Mingdi
TI Multivalent glyconanoparticles with enhanced affinity to the anti-viral
   lectin Cyanovirin-N
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID HIV-INACTIVATING PROTEIN; GOLD NANOPARTICLES; LIGAND PRESENTATION;
   BINDING; GP120; GLYCOPROTEINS; RECOGNITION; MAN(8)
AB Low-mannose (LM) structures were coupled to gold nanoparticles (Au NPs) to amplify the affinity of LMs with Cyanovirin-N (CV-N) lectins and to study the structures of CV-N variants CVNQ50C and CVNMutDB.
C1 [Wang, Xin; Yan, Mingdi] Portland State Univ, Dept Chem, Portland, OR 97207 USA.
   [Matei, Elena; Gronenborn, Angela M.] Univ Pittsburgh, Dept Biol Struct, Sch Med, Pittsburgh, PA 15260 USA.
   [Deng, Lingquan; Ramstroem, Olof] KTH Royal Inst Technol, Dept Chem, S-10044 Stockholm, Sweden.
RP Wang, X (reprint author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.
EM ramstrom@kth.se; amg100@pitt.edu; yanm@pdx.edu
RI Wang, Xin/A-4751-2012
OI Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health [R01GM080295, 2R15GM066279, R01GM080642];
   China Scholarship Council
FX This work was supported by National Institutes of Health Grants
   R01GM080295 and 2R15GM066279 (to M.Y.) and R01GM080642 (to A. M. G.). L.
   D. thanks the China Scholarship Council for a special scholarship award.
CR Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   CHOI SK, 2004, SYNTHETIC MULTIVALEN, P53
   Dam TK, 2010, GLYCOBIOLOGY, V20, P270, DOI 10.1093/glycob/cwp186
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Jayaraman N, 2009, CHEM SOC REV, V38, P3463, DOI 10.1039/b815961k
   LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001                                                             
   Lim Y, 2007, ORG BIOMOL CHEM, V5, P401, DOI 10.1039/b615744k
   Lin CC, 2002, J AM CHEM SOC, V124, P3508, DOI 10.1021/ja0200903
   Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g                                                               
   Liu LH, 2010, ACCOUNTS CHEM RES, V43, P1434, DOI 10.1021/ar100066t
   Liu YA, 2009, BIOPOLYMERS, V92, P194, DOI 10.1002/bip.21173
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Matei E, 2008, STRUCTURE, V16, P1183, DOI 10.1016/j.str.2008.05.011
   Nolting B, 2003, LANGMUIR, V19, P6465, DOI 10.1021/la034414s
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   Shenhar R, 2003, ACCOUNTS CHEM RES, V36, P549, DOI 10.1021/ar020083j
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   Wang X, 2010, ANAL CHEM, V82, P9082, DOI 10.1021/ac102114z
   Wang X, 2010, ADV MATER, V22, P1946, DOI 10.1002/adma.200903908
   Wang X, 2009, J MATER CHEM, V19, P8944, DOI 10.1039/b917900c
   Wang X, 2009, EXP BIOL MED, V234, P1128, DOI 10.3181/0904-MR-134
NR 28
TC 34
Z9 34
U1 0
U2 23
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2011
VL 47
IS 30
BP 8620
EP 8622
DI 10.1039/c1cc12981c
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 795PT
UT WOS:000292986800042
PM 21720651
OA green_accepted
DA 2018-01-05
ER

PT J
AU Collie, GW
   Parkinson, GN
AF Collie, Gavin W.
   Parkinson, Gary N.
TI The application of DNA and RNA G-quadruplexes to therapeutic medicines
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID REPEAT-CONTAINING RNA; C-MYC PROMOTER; ELECTROSPRAY MASS-SPECTROMETRY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAMOLECULAR G-QUADRUPLEX;
   LOCKED-NUCLEIC-ACID; SINGLE-STRANDED-DNA; HUMAN TELOMERIC RNA; I-MOTIF
   STRUCTURES; THROMBIN BINDING APTAMER
AB The intriguing structural diversity in folded topologies available to guanine-rich nucleic acid repeat sequences have made four-stranded G-quadruplex structures the focus of both basic and applied research, from cancer biology and novel therapeutics through to nanoelectronics. Distributed widely in the human genome as targets for regulating gene expression and chromosomal maintenance, they offer unique avenues for future cancer drug development. In particular, the recent advances in chemical and structural biology have enabled the construction of bespoke selective DNA based aptamers to be used as novel therapeutic agents and access to detailed structural models for structure based drug discovery. In this critical review, we will explore the important underlying characteristics of G-quadruplexes that make them functional, stable, and predictable nanoscaffolds. We will review the current structural database of folding topologies, molecular interfaces and novel interaction surfaces, with a consideration to their future exploitation in drug discovery, molecular biology, supermolecular assembly and aptamer design. In recent years the number of potential applications for G-quadruplex motifs has rapidly grown, so in this review we aim to explore the many future challenges and highlight where possible successes may lie. We will highlight the similarities and differences between DNA and RNA folded G-quadruplexes in terms of stability, distribution, and exploitability as small molecule targets. Finally, we will provide a detailed review of basic G-quadruplex geometry, experimental tools used, and a critical evaluation of the application of high-resolution structural biology and its ability to provide meaningful and valid models for future applications (255 references).
C1 [Collie, Gavin W.; Parkinson, Gary N.] Univ London, Sch Pharm, CRUK Biomol Struct Grp, London WC1N 1AX, England.
RP Parkinson, GN (reprint author), Univ London, Sch Pharm, CRUK Biomol Struct Grp, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM gary.parkinson@pharmacy.ac.uk
OI Collie, Gavin/0000-0002-0406-922X
CR Alberti P, 2006, ORG BIOMOL CHEM, V4, P3383, DOI 10.1039/b605739j
   Amato Jussara, 2008, Nucleic Acids Symp Ser (Oxf), P165, DOI 10.1093/nass/nrn084
   Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Arora A, 2008, RNA, V14, P1290, DOI 10.1261/rna.1001708
   Arora A, 2009, J PHYS CHEM B, V113, P10515, DOI 10.1021/jp810638n
   Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182
   Baker ES, 2006, INT J MASS SPECTROM, V253, P225, DOI 10.1016/j.ijms.2006.03.016
   Baker ES, 2006, J AM CHEM SOC, V128, P2641, DOI 10.1021/ja0564968
   Balkwill GD, 2009, BIOCHEMISTRY-US, V48, P11487, DOI 10.1021/bi901420k
   Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Beaudoin JD, 2010, NUCLEIC ACIDS RES, V38, P7022, DOI 10.1093/nar/gkq557
   Bensaid M, 2009, NUCLEIC ACIDS RES, V37, P1269, DOI 10.1093/nar/gkn1058
   Benz A, 2011, CHEMBIOCHEM, V12, P1422, DOI 10.1002/cbic.201100094
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Bonifacio L, 2008, INT J MOL SCI, V9, P422, DOI 10.3390/ijms9030422                                                             
   Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200
   Brooks TA, 2010, FEBS J, V277, P3459, DOI 10.1111/j.1742-4658.2010.07759.x
   Bugaut A, 2010, ORG BIOMOL CHEM, V8, P2771, DOI 10.1039/c002418j
   Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910
   Caceres C, 2004, NUCLEIC ACIDS RES, V32, P1097, DOI 10.1093/nar/gkh269
   Campbell NH, 2008, J AM CHEM SOC, V130, P6722, DOI 10.1021/ja8016973
   Campbell NH, 2007, METHODS, V43, P252, DOI 10.1016/j.ymeth.2007.08.005
   Campbell NH, 2011, ORG BIOMOL CHEM, V9, P1328, DOI 10.1039/c0ob00886a
   Campbell NH, 2009, BIOCHEMISTRY-US, V48, P1675, DOI 10.1021/bi802233v
   Casagrande V, 2009, J MASS SPECTROM, V44, P530, DOI 10.1002/jms.1529
   Caslini C, 2009, MOL CELL BIOL, V29, P4519, DOI 10.1128/MCB.00195-09
   Castets M, 2005, HUM MOL GENET, V14, P835, DOI 10.1093/hmg/ddi077
   Chan DSH, 2011, BIOCHIMIE, V93, P1055, DOI 10.1016/j.biochi.2011.02.013
   Choi EW, 2010, NUCLEIC ACIDS RES, V38, P1623, DOI 10.1093/nar/gkp1088
   CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709
   Ciesielski A., 2010, ANGEW CHEM INT EDIT, V49, P1895
   Ciesielski A, 2010, CHEM COMMUN, V46, P4493, DOI 10.1039/c0cc00443j
   Clark GR, 2003, J AM CHEM SOC, V125, P4066, DOI 10.1021/ja0297988
   Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286
   Cogoi S, 2009, J MED CHEM, V52, P564, DOI 10.1021/jm800874t
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Collie G, 2009, CHEM COMMUN, P7482, DOI 10.1039/b901889a
   Collie GW, 2011, J AM CHEM SOC, V133, P2721, DOI 10.1021/ja109767y
   Collie GW, 2010, NUCLEIC ACIDS RES, V38, P5569, DOI 10.1093/nar/gkq259
   Collie GW, 2010, J AM CHEM SOC, V132, P9328, DOI 10.1021/ja100345z
   Cosconati S, 2010, J AM CHEM SOC, V132, P6425, DOI 10.1021/ja1003872
   Creze C, 2007, ACTA CRYSTALLOGR D, V63, P682, DOI 10.1107/S0907444907013315
   da Silva MW, 2009, ANGEW CHEM INT EDIT, V48, P9167, DOI 10.1002/anie.200902454
   Dai JX, 2007, NUCLEIC ACIDS RES, V35, P2440, DOI 10.1093/nar/gkm009
   Dai JX, 2006, NUCLEIC ACIDS RES, V34, P5133, DOI 10.1093/nar/gkl610
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9
   Dash J, 2008, CHEM COMMUN, P3055, DOI 10.1039/b806042h
   Dash J, 2011, CHEM-EUR J, V17, P4571, DOI 10.1002/chem.201003157
   Webba Da Silva M, 2007, CHEM-EUR J, V13, P9738
   Davis JT, 2007, CHEM SOC REV, V36, P296, DOI 10.1039/b600282j
   De Armond R, 2005, BIOCHEMISTRY-US, V44, P16341, DOI 10.1021/bi051618u
   De Cian A, 2008, CHEMBIOCHEM, V9, P2730, DOI 10.1002/cbic.200800330
   De Cian A, 2008, BIOCHIMIE, V90, P131, DOI 10.1016/j.biochi.2007.07.011
   De Cian A, 2007, METHODS, V42, P183, DOI 10.1016/j.ymeth.2006.10.004
   de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   De Cian A., 2008, NUCL ACIDS S SER, V52, P7
   Deng JP, 2001, P NATL ACAD SCI USA, V98, P13665, DOI 10.1073/pnas.241374798
   Deng Z, 2009, MOL CELL, V35, P403, DOI 10.1016/j.molcel.2009.06.025
   Didiot MC, 2008, NUCLEIC ACIDS RES, V36, P4902, DOI 10.1093/nar/gkn472
   Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304
   Du Y., 2010, ANALYST, V136, P493
   Eddy J, 2006, NUCLEIC ACIDS RES, V34, P3887, DOI 10.1093/nar/gkl529
   Eddy J, 2009, MOL CARCINOGEN, V48, P319, DOI 10.1002/mc.20496
   Elcock AH, 2010, CURR OPIN STRUC BIOL, V20, P196, DOI 10.1016/j.sbi.2010.01.008
   Fernando H, 2006, BIOCHEMISTRY-US, V45, P7854, DOI 10.1021/bi0601510
   FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692                                                        
   Gabelica V, 2007, J AM CHEM SOC, V129, P895, DOI 10.1021/ja065989p
   Garbett NC, 2010, METHODS MOL BIOL, V608, P97, DOI 10.1007/978-1-59745-363-9_7
   Gatto B, 2009, CURR MED CHEM, V16, P1248, DOI 10.2174/092986709787846640                                                      
   Ge BX, 2010, ANGEW CHEM INT EDIT, V49, P9965, DOI 10.1002/anie.201004946
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Gomez D, 2010, NUCLEIC ACIDS RES, V38, P7187, DOI 10.1093/nar/gkq563
   Gonzalez-Rodriguez D, 2010, J AM CHEM SOC, V132, P4710, DOI 10.1021/ja908537k
   Gray RD, 2010, METHODS MOL BIOL, V608, P121, DOI 10.1007/978-1-59745-363-9_8
   Gray RD, 2010, BIOCHEMISTRY-US, V49, P179, DOI 10.1021/bi901357r
   Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3                                                   
   Gros J, 2008, CHEMBIOCHEM, V9, P2075, DOI 10.1002/cbic.200800300
   Gros J, 2007, NUCLEIC ACIDS RES, V35, P3064, DOI 10.1093/nar/gkm111
   Gros Julien, 2005, Nucleic Acids Symp Ser (Oxf), P61
   Gunaratnam M, 2009, J MED CHEM, V52, P3774, DOI 10.1021/jm900424a
   Guo K, 2007, J AM CHEM SOC, V129, P10220, DOI 10.1021/ja072185g
   Haider S, 2002, J MOL BIOL, V320, P189, DOI 10.1016/S0022-2836(02)00428-X
   Haider SM, 2003, J MOL BIOL, V326, P117, DOI 10.1016/S0022-2836(02)01354-2
   Halder K, 2009, NUCLEIC ACIDS RES, V37, P6811, DOI 10.1093/nar/gkp696
   Hampel SM, 2010, BIOORG MED CHEM LETT, V20, P6459, DOI 10.1016/j.bmcl.2010.09.066
   Hansel R., 2011, NUCL ACIDS RES
   Hazel P, 2006, J AM CHEM SOC, V128, P5480, DOI 10.1021/ja058577+
   Heddi B., 2011, J AM CHEM SOC
   Henn A, 2008, CHEMBIOCHEM, V9, P2722, DOI 10.1002/cbic.200800271
   Horsburgh BC, 1996, CELL, V86, P949, DOI 10.1016/S0092-8674(00)80170-1
   Horvath MP, 2001, J MOL BIOL, V310, P367, DOI 10.1006/jmbi.2001.4766
   Hounsou C, 2007, CHEMMEDCHEM, V2, P655, DOI 10.1002/cmdc.200600286
   Huang YC, 2008, J AM CHEM SOC, V130, P8023, DOI 10.1021/ja8011066
   Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609
   Huppert JL, 2007, NUCLEIC ACIDS RES, V35, P406, DOI 10.1093/nar/gkl1057
   Huppert JL, 2008, NUCLEIC ACIDS RES, V36, P6260, DOI 10.1093/nar/gkn511
   Jin KS, 2009, J PHYS CHEM B, V113, P1852, DOI 10.1021/jp808186z
   Jing NJ, 2006, MOL CANCER THER, V5, P279, DOI 10.1158/1535-7163.MCT-05-0302
   Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y
   Joachimi A, 2009, BIOORGAN MED CHEM, V17, P6811, DOI 10.1016/j.bmc.2009.08.043
   Juskowiak Bernard, 2006, V335, P311
   KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0
   Karimata Hisae, 2007, Nucleic Acids Symp Ser (Oxf), P251
   Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kimura Takashi, 2009, Nucleic Acids Symp Ser (Oxf), P239, DOI 10.1093/nass/nrp120
   Kimura T, 2007, TETRAHEDRON, V63, P3585, DOI 10.1016/j.tet.2006.08.108
   Kumari S, 2007, NAT CHEM BIOL, V3, P218, DOI 10.1038/nchembio864
   Kumari S, 2008, BIOCHEMISTRY-US, V47, P12664, DOI 10.1021/bi8010797
   Kuryavyi V, 2010, NUCLEIC ACIDS RES, V38, P6757, DOI 10.1093/nar/gkq558
   Kuzmine I, 2001, NUCLEIC ACIDS RES, V29, P2601, DOI 10.1093/nar/29.12.2601
   Lacroix L, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1199
   Lane AN, 2008, NUCLEIC ACIDS RES, V36, P5482, DOI 10.1093/nar/gkn517
   LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494
   Lee JY, 2008, BIOCHEMISTRY-US, V47, P3389, DOI 10.1021/bi702013d
   Lee MPH, 2007, J AM CHEM SOC, V129, P10106, DOI 10.1021/ja0740869
   Lena S, 2009, CHEM-EUR J, V15, P7792, DOI 10.1002/chem.200802506
   Levesque D, 2007, BIOCHEM J, V403, P129, DOI 10.1042/BJ20061216
   Li J, 2005, NUCLEIC ACIDS RES, V33, P4649, DOI 10.1093/nar/gki782
   Li MH, 2011, J MOL MODEL, V17, P515, DOI 10.1007/s00894-010-0746-0
   Li T, 2009, CHEM-EUR J, V15, P1036, DOI 10.1002/chem.200801282
   Lim KW, 2010, J AM CHEM SOC, V132, P12331, DOI 10.1021/ja101252n
   Lombardo CM, 2010, CHEM COMMUN, V46, P9116, DOI 10.1039/c0cc02917c
   Lombardo C. M., 2010, CHEM COMMUN CAMBRIDG
   de Silanes IL, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1032
   Luke B, 2008, MOL CELL, V32, P465, DOI 10.1016/j.molcel.2008.10.019
   Ma H, 2010, CHEM-ASIAN J, V5, P114, DOI 10.1002/asia.200900270
   MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696                                                            
   Martadinata H, 2009, J AM CHEM SOC, V131, P2570, DOI 10.1021/ja806592z
   Martino L, 2006, NUCLEIC ACIDS RES, V34, P6653, DOI 10.1093/nar/gkl915
   Mashima T, 2009, NUCLEIC ACIDS RES, V37, P6249, DOI 10.1093/nar/gkp647
   Masiero S, 2010, ORG BIOMOL CHEM, V8, P2683, DOI 10.1039/c003428b
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   McLuckie KIE, 2011, J AM CHEM SOC, V133, P2658, DOI 10.1021/ja109474c
   Melko M, 2010, BIOCHIMIE, V92, P919, DOI 10.1016/j.biochi.2010.05.018
   Mergny J. L., 2009, CURR PROTOC NUCL ACI
   Michalowski D, 2008, NUCLEIC ACIDS RES, V36, P7124, DOI 10.1093/nar/gkn891
   Miller MC, 2010, J AM CHEM SOC, V132, P17105, DOI 10.1021/ja105259m
   Mizuta R, 2003, J BIOL CHEM, V278, P4431, DOI 10.1074/jbc.M209262200
   Monchaud D, 2008, BIOCHIMIE, V90, P1207, DOI 10.1016/j.biochi.2008.02.019
   Monchaud D, 2008, ORG BIOMOL CHEM, V6, P627, DOI 10.1039/b714772b
   Morris MJ, 2009, BIOCHEMISTRY-US, V48, P5313, DOI 10.1021/bi900498z
   MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622
   Muller S, 2010, NAT CHEM, V2, P1095, DOI 10.1038/NCHEM.842
   Mullen MA, 2010, NUCLEIC ACIDS RES, V38, P8149, DOI 10.1093/nar/gkq804
   Murakami K, 2008, PRION, V2, P73, DOI 10.4161/pri.2.2.7024                                                            
   Nallagatla SR, 2009, J COMB CHEM, V11, P364, DOI 10.1021/cc800178m
   Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P936, DOI 10.1093/nar/gkq824
   Nandakumar J, 2010, P NATL ACAD SCI USA, V107, P651, DOI 10.1073/pnas.0911099107
   Neaves KJ, 2009, NUCLEIC ACIDS RES, V37, P6269, DOI 10.1093/nar/gkp679
   Nielsen JT, 2009, ANGEW CHEM INT EDIT, V48, P3099, DOI 10.1002/anie.200806244
   Nielsen JT, 2006, NUCLEIC ACIDS RES, V34, P2006, DOI 10.1093/nar/gkl144
   Norseen J, 2009, J VIROL, V83, P10336, DOI 10.1128/JVI.00747-09
   Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991
   Olsen CM, 2010, METHODS MOL BIOL, V608, P147, DOI 10.1007/978-1-59745-363-9_10
   Ou TM, 2008, CHEMMEDCHEM, V3, P690, DOI 10.1002/cmdc.200700300
   Padmanabhan K, 1996, ACTA CRYSTALLOGR D, V52, P272, DOI 10.1107/S0907444995013977
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Pagano B, 2008, BIOPHYS J, V94, P562, DOI 10.1529/biophysj.107.117382
   Palumbo SL, 2008, NUCLEIC ACIDS RES, V36, P1755, DOI 10.1093/nar/gkm1069
   Palumbo SL, 2009, J AM CHEM SOC, V131, P10878, DOI 10.1021/ja902281d
   Pan B, 2006, P NATL ACAD SCI USA, V103, P3130, DOI 10.1073/pnas.0507730103
   Pan BC, 2006, J MOL BIOL, V363, P451, DOI 10.1016/j.jmb.2006.08.022
   Pan BC, 2003, STRUCTURE, V11, P1423, DOI 10.1016/j.str.2003.09.017
   Pan BC, 2003, STRUCTURE, V11, P825, DOI 10.1016/S0969-2126(03)00108-4
   Pan BC, 2003, STRUCTURE, V11, P815, DOI 10.1016/S0969-2126(03)00107-2
   Paramasivan S, 2007, METHODS, V43, P324, DOI 10.1016/j.ymeth.2007.02.009
   Parkinson GN, 2008, J MOL BIOL, V381, P1145, DOI 10.1016/j.jmb.2008.06.022
   Parkinson GN, 2007, BIOCHEMISTRY-US, V46, P2390, DOI 10.1021/bi062244n
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Pasternak A., 2010, NUCLEIC ACIDS RES, V39, P1155
   Pedersen E. B., 2010, NUCLEIC ACIDS RES, V39, P2470
   Peng D, 2010, BIOORGAN MED CHEM, V18, P8235, DOI 10.1016/j.bmc.2010.10.021
   Phan AT, 2005, NAT CHEM BIOL, V1, P167, DOI 10.1038/nchembio723
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Phatak P, 2007, BRIT J CANCER, V96, P1223, DOI 10.1038/sj.bjc.6603691
   Phillips K, 1997, J MOL BIOL, V273, P171, DOI 10.1006/jmbi.1997.1292
   Pradhan D, 2011, CHEM-EUR J, V17, P2405, DOI 10.1002/chem.201001961
   Qi JY, 2007, BIOCHEMISTRY-US, V46, P7599, DOI 10.1021/bi602392u
   Qin Y, 2007, NUCLEIC ACIDS RES, V35, P7698, DOI 10.1093/nar/gkm538
   Randall A, 2009, J BIOL CHEM, V284, P13980, DOI 10.1074/jbc.M900631200
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Rangan A, 2001, J BIOL CHEM, V276, P4640, DOI 10.1074/jbc.M005962200
   Rankin S, 2005, J AM CHEM SOC, V127, P10584, DOI 10.1021/ja050823u                                                               
   Raviv SM, 2008, J THROMB HAEMOST, V6, P1764, DOI 10.1111/j.1538-7836.2008.03106.x
   Redon S, 2010, NUCLEIC ACIDS RES, V38, P5797, DOI 10.1093/nar/gkq296
   Rosu F, 2002, RAPID COMMUN MASS SP, V16, P1729, DOI 10.1002/rcm.778
   Rosu F, 2010, NUCLEIC ACIDS RES, V38, P5217, DOI 10.1093/nar/gkq208
   Rzuczek SG, 2010, J MED CHEM, V53, P3632, DOI 10.1021/jm1000612
   Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461
   Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b
   Sexton AN, 2011, MOL CELL BIOL, V31, P736, DOI 10.1128/MCB.01033-10
   Shahid R, 2010, BIOCHEMISTRY-US, V49, P8300, DOI 10.1021/bi100957h
   Shen W, 2009, J BIOL CHEM, V284, P33883, DOI 10.1074/jbc.M109.055368
   Sheng J, 2010, CHEM BIODIVERS, V7, P753, DOI 10.1002/cbdv.200900200
   Shieh YA, 2010, ACS NANO, V4, P1433, DOI 10.1021/nn901374b
   Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q
   Shirude PS, 2008, CHEM COMMUN, P2007, DOI 10.1039/b801465e
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Simonsson T, 2000, BIOCHEM BIOPH RES CO, V278, P158, DOI 10.1006/bbrc.2000.3783
   Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167
   Smargiasso N, 2008, J AM CHEM SOC, V130, P10208, DOI 10.1021/ja801535e
   Smargiasso N, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-362
   Sotoya H, 2004, NUCLEIC ACIDS RES, V32, P5113, DOI 10.1093/nar/gkh849
   Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723
   Sparapani S, 2010, J AM CHEM SOC, V132, P12263, DOI 10.1021/ja1003944
   Stegle O, 2009, BIOINFORMATICS, V25, pI374, DOI 10.1093/bioinformatics/btp210
   Sun D., 2010, NUCLEIC ACIDS RES, V39, P1256
   Sun D, 2008, MOL CANCER THER, V7, P880, DOI 10.1158/1535-7163.MCT-07-2119
   Sun D, 2009, J MED CHEM, V52, P2863, DOI 10.1021/jm900055s
   Sun DY, 2005, NUCLEIC ACIDS RES, V33, P6070, DOI 10.1093/nar/gki917
   Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z
   SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393
   Tauchi T, 2006, ONCOGENE, V25, P5719, DOI 10.1038/sj.onc.1209577
   Teller C, 2010, CURR OPIN BIOTECH, V21, P376, DOI 10.1016/j.copbio.2010.06.001
   Teller C, 2009, ANAL CHEM, V81, P9114, DOI 10.1021/ac901773b
   Temime-Smaali N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006919
   Todd AK, 2005, NUCLEIC ACIDS RES, V33, P2901, DOI 10.1093/nar/gki553
   Todd A. K., 2011, NUCL ACIDS RES
   Wang XD, 2010, J MED CHEM, V53, P4390, DOI 10.1021/jm100445e
   WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668
   Wanrooij PH, 2010, P NATL ACAD SCI USA, V107, P16072, DOI 10.1073/pnas.1006026107
   Weerasinghe P, 2008, PROSTATE, V68, P1430, DOI 10.1002/pros.20807
   Westmark CJ, 2007, PLOS BIOL, V5, P629, DOI 10.1371/journal.pbio.0050052
   Wieland M, 2007, CHEM BIOL, V14, P757, DOI 10.1016/j.chembiol.2007.06.005
   Wong HM, 2010, J NUCL ACIDS, DOI [10.4061/2010/564946, DOI 10.4061/2010/564946]
   WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029
   Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801                                                          
   Xiao JF, 2009, J SEP SCI, V32, P1654, DOI 10.1002/jssc.200900060
   Xu LA, 2011, CHEM COMMUN, V47, P3517, DOI 10.1039/c0cc05242f
   Xu Y, 2006, NUCLEIC ACIDS RES, V34, P949, DOI 10.1093/nar/gkj485
   Xu Y, 2008, J AM CHEM SOC, V130, P11179, DOI 10.1021/ja8031532
   Xu Y, 2011, CHEM SOC REV, V40, P2719, DOI 10.1039/c0cs00134a
   Xu Y, 2010, P NATL ACAD SCI USA, V107, P14579, DOI 10.1073/pnas.1001177107
   Xu Y, 2010, J AM CHEM SOC, V132, P7231, DOI 10.1021/ja909708a
   Xu Yan, 2008, Nucleic Acids Symp Ser (Oxf), P175, DOI 10.1093/nass/nrn089
   Xu Y, 2009, ANGEW CHEM INT EDIT, V48, P3281, DOI 10.1002/anie.200806306
   Xu Yan, 2008, Nucleic Acids Symp Ser (Oxf), P169, DOI 10.1093/nass/nrn086
   Xue Y, 2007, J AM CHEM SOC, V129, P11185, DOI 10.1021/ja0730462
   Yuan YL, 2011, BIOSENS BIOELECTRON, V26, P4236, DOI 10.1016/j.bios.2011.03.038
   Zaitseva M, 2010, BIOPHYS CHEM, V146, P1, DOI 10.1016/j.bpc.2009.09.011
   Zhang DH, 2010, BIOCHEMISTRY-US, V49, P4554, DOI 10.1021/bi1002822
   Zhang N, 2005, J AM CHEM SOC, V127, P17277, DOI 10.1021/ja0543090
   Zhou HX, 2008, ANNU REV BIOPHYS, V37, P375, DOI 10.1146/annurev.biophys.37.032807.125817
NR 254
TC 267
Z9 274
U1 25
U2 240
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2011
VL 40
IS 12
BP 5867
EP 5892
DI 10.1039/c1cs15067g
PG 26
WC Chemistry, Multidisciplinary
SC Chemistry
GA 847PX
UT WOS:000296986000021
PM 21789296
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Shukla, RK
   Tiwari, A
AF Shukla, Raj Kumar
   Tiwari, Akanksha
TI Carbohydrate Molecules: An Expanding Horizon in Drug Delivery and
   Biomedicine
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE carbohydrate molecules; cell specific delivery; targeted drug delivery;
   immunology; vaccines
ID TARGETED DELIVERY; ALGINATE MICROSPHERES; VACCINE CANDIDATE; IN-VITRO;
   DC-SIGN; NANOPARTICLES; CANCER; CELLS; HIV-1; MACROPHAGES
AB This review presents successful applications of carbohydrate molecules in drug delivery, vaccine development, cancer, HIV and various other diseases based on advances in glycobiology and glycochemistry. Carbohydrate-mediated delivery could be site specific/cell specific. Carbohydrate-based delivery system has been successfully utilized for the delivery of macromolecular drugs, antigen, and potential therapeutic drug candidates. Lectin, the high affinity carbohydrate-binding nonimmune glycoproteins has specific and noncovalent binding sites for defined carbohydrates. Endogenous surface lectins of cancer cells participate in the regulation of tumor cell growth. The oligosaccharides constitute potential recognition sites for carbohydrate-mediated interactions between cells and drug carriers bearing suitable site directing molecules. The recognition of carbohydrate immunodeterminants has created great attention in the development of carbohydrate-based vaccines. Peptide mimotopes provide a strategy to augment human immunodeficiency virus 1 (HIV-1) specific carbohydrate reactive immune responses. Experimental cancer and HIV vaccines are being developed in attempts to overcome weak immunological responses to carbohydrate-rich surface antigens using carriers, adjuvants, and novel carbohydrate antigen constructs. Current carbohydrate-based vaccines are used for prostate cancer, typhus, pneumonia, and meningitis; vaccines for malaria, anthrax, and leishmaniasis are under development. This article discusses the current research involved in the role of carbohydrate molecules in targeted controlled drug delivery, immunology, and vaccine development.
C1 [Shukla, Raj Kumar] Sun Pharma Ind Ltd, Sun Pharma Adv Res Ctr, Baroda 390020, Gujarat, India.
   [Tiwari, Akanksha] Parul Trust, Baroda Coll Pharm, Dept Pharmaceut, Baroda 391760, Gujarat, India.
RP Shukla, RK (reprint author), Sun Pharma Ind Ltd, Sun Pharma Adv Res Ctr, Baroda 390020, Gujarat, India.
EM rajrgpv@gmail.com
CR Abdel-Motal UM, 2007, J VIROL, V81, P9131, DOI 10.1128/JVI.00647-07
   Ahmadi F, 2011, DRUG DELIV, V18, P122, DOI 10.3109/10717544.2010.520352
   Aich U, 2010, GLYCOCONJUGATE J, V27, P445, DOI 10.1007/s10719-010-9292-3
   Asgeirsdottir SA, 2008, AM J PHYSIOL-RENAL, V294, P554
   AYELET D, 2010, ISR J CHEM, V50, P204
   Baldwin AD, 2010, BIOPOLYMERS, V94, P128, DOI 10.1002/bip.21334
   Balzarini J, 2010, ANTIMICROB AGENTS CH, V54, P1425, DOI 10.1128/AAC.01347-09
   BARBARA L, 2010, EUR J PHARM BIOPHARM, V75, P381
   Bertolotti A, 2009, IN VIVO, V23, P929
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Bisht S, 2009, WIRES NANOMED NANOBI, V1, P415, DOI [10.1002/wnan.43, 10.1002/wnan.043]
   Boontheekul T, 2005, BIOMATERIALS, V26, P2455, DOI 10.1016/j.biomaterials.2004.06.044
   Borsig L, 2010, PROG MOL BIOL TRANSL, V93, P335, DOI 10.1016/S1877-1173(10)93014-7
   Burton RA, 2010, NAT CHEM BIOL, V6, P724, DOI [10.1038/nchembio.439, 10.1038/NCHEMBIO.439]
   Cao SL, 2009, INT J PHARM, V365, P109, DOI 10.1016/j.ijpharm.2008.08.042
   Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001                                                      
   Coutinho DF, 2010, BIOMATERIALS, V31, P7494, DOI 10.1016/j.biomaterials.2010.06.035
   Cox AD, 2010, GLYCOCONJUGATE J, V27, P643, DOI 10.1007/s10719-010-9309-y
   De Clercq E, 2006, NAT REV DRUG DISCOV, V5, P1015, DOI 10.1038/nrd2175
   Dev RK, 2011, INT J PHARMACEUT, V411, P142, DOI 10.1016/j.ijpharm.2011.03.057
   Dhanaraju MD, 2011, DRUG DELIV, V18, P198, DOI 10.3109/10717544.2010.528069
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P17107, DOI 10.1073/pnas.1002717107
   Du YZ, 2010, ACS NANO, V4, P6894, DOI 10.1021/nn100927t
   Dube D, 2010, DRUG DEV IND PHARM, V36, P547, DOI 10.3109/03639040903325560
   Dukic-Ott A, 2009, EUR J PHARM BIOPHARM, V71, P38, DOI 10.1016/j.ejpb.2008.08.005
   EDUARDO P, 2004, ADV DRUG DELIV REV, V13, P311
   Elgart A, 2010, BIOMACROMOLECULES, V11, P1972, DOI 10.1021/bm100298r
   Eniola AO, 2005, BIOMATERIALS, V26, P7136, DOI 10.1016/j.biomaterials.2005.05.005
   Eniola AO, 2005, BIOMATERIALS, V26, P661, DOI 10.1016/j.biomaterials.2004.03.003
   Galonic DP, 2007, NATURE, V446, P1000, DOI 10.1038/nature05813
   Garnier P, 2010, J DRUG TARGET, V18, P794, DOI 10.3109/1061186X.2010.529909
   Ghazarian H, 2011, ACTA HISTOCHEM, V113, P236, DOI 10.1016/j.acthis.2010.02.004
   GIANNI C, 2008, MED ENG PHYS, V30, P848
   Giovagnoli S, 2010, PHARM RES-DORD, V27, P285, DOI 10.1007/s11095-009-0017-x
   Greupink R, 2005, J HEPATOL, V43, P884, DOI 10.1016/j.jhep.2005.04.014
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778
   Gupta H, 2010, J DRUG TARGET, V18, P499, DOI 10.3109/10611860903508788
   Hecht ML, 2009, CURR OPIN CHEM BIOL, V13, P354, DOI 10.1016/j.cbpa.2009.05.127
   Hoorelbeke B, 2010, ANTIMICROB AGENTS CH, V54, P3287, DOI 10.1128/AAC.00254-10
   Houston Todd A., 2007, Current Drug Delivery, V4, P264, DOI 10.2174/156720107782151278
   Huskens D, 2010, J BIOL CHEM, V285, P24845, DOI 10.1074/jbc.M110.128546
   Ingale S, 2007, NAT CHEM BIOL, V3, P663, DOI 10.1038/nchembio.2007.25
   Itoh K, 2007, INT J PHARM, V335, P90, DOI 10.1016/j.ijpharm.2006.10.042
   Izydorczyk M, 2005, FOOD CARBOHYDRATES: CHEMISTY, PHYSICAL PROPERTIES, AND APPLICATIONS, P263
   Jain AK, 2008, EUR J PHARM BIOPHARM, V69, P426, DOI 10.1016/j.ejpb.2007.12.001
   Jain SK, 2008, EXPERT OPIN DRUG DEL, V5, P483, DOI [10.1517/17425240802078950, 10.1517/17425247.5.5.483 ]
   Jeong YI, 2011, ARCH PHARM RES, V34, P159, DOI 10.1007/s12272-011-0119-y
   Kamat M, 2010, BIOCONJUGATE CHEM, V21, P2128, DOI 10.1021/bc100354m
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953
   Kim SS, 2010, MOL THER, V18, P993, DOI 10.1038/mt.2010.27
   KNUF M, 2008, ISPPD JUN 8 12 REYKJ
   Kubler-Kielb J, 2008, VACCINE, V26, P3587, DOI 10.1016/j.vaccine.2008.04.079
   Kurtenkov O, 2005, EXP ONCOL, V27, P136
   Leathers TD, 2003, APPL MICROBIOL BIOT, V62, P468, DOI 10.1007/s00253-003-1386-4
   Li YR, 2011, MOL IMMUNOL, V48, P670, DOI 10.1016/j.molimm.2010.11.011
   Lim HT, 2010, INT J PHARMACEUT, V397, P225, DOI 10.1016/j.ijpharm.2010.07.013
   Lin AH, 2009, DRUG DEV IND PHARM, V35, P1348, DOI 10.3109/03639040902939197
   Liu B, 2009, AUTOPHAGY, V5, P253, DOI 10.4161/auto.5.2.7561                                                           
   Liu J, 2011, DRUG DELIV, V18, P181, DOI 10.3109/10717544.2010.520355
   Liu XY, 2006, ACS CHEM BIOL, V1, P161, DOI 10.1021/cb600086b
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   Matsui M, 2010, CANCER SCI, V101, P1670, DOI 10.1111/j.1349-7006.2010.01587.x
   MOTAL UMA, 2010, VACCINE, V28, P1758
   Naessens M, 2005, J CHEM TECHNOL BIOT, V80, P845, DOI 10.1002/jctb.1322
   Nahar M, 2009, PHARM RES-DORD, V26, P2588, DOI 10.1007/s11095-009-9973-4
   Naikwade SR, 2009, DRUG DEV IND PHARM, V35, P417, DOI 10.1080/03639040802422104 
   NEIMERT AT, 2008, ALLERGY, V63, P518
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/NMAT2784, 10.1038/nmat2784]
   Oddo L, 2010, ACTA BIOMATER, V6, P3657, DOI 10.1016/j.actbio.2010.03.013
   Oppenheimer SB, 2008, ACTA HISTOCHEM, V110, P6, DOI 10.1016/j.acthis.2007.08.003
   Parajo Y, 2010, DRUG DELIV, V17, P596, DOI 10.3109/10717544.2010.509357
   Paul A, 2011, IMMUNOL LETT, V136, P55, DOI 10.1016/j.imlet.2010.12.004
   Phalipon A, 2009, J IMMUNOL, V182, P2241, DOI 10.4049/jimmunol.0803141
   Raiber EA, 2010, ACS CHEM BIOL, V5, P461, DOI 10.1021/cb100008p
   Rastogi R, 2007, INT J PHARM, V334, P71, DOI 10.1016/j.ijpharm.2006.10.024
   RENE R, 2004, DRUG DISCOV TODAY, V1, P327
   Robbins JB, 2009, P NATL ACAD SCI USA, V106, P7974, DOI 10.1073/pnas.0900891106
   Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598
   Robinson MA, 2004, P NATL ACAD SCI USA, V101, P14527, DOI 10.1073/pnas.0303574101
   Rojo J., 2007, Anti-Infective Agents in Medicinal Chemistry, V6, P151
   Russell D, 2009, CARBOHYD RES, V344, P1508, DOI 10.1016/j.carres.2009.06.033
   SANDRA K, 2009, ACS SYM SER, V1017, P13
   Santos E, 2010, ADV EXP MED BIOL, V670, P5
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Seeberger PH, 2007, NATURE, V446, P1046, DOI 10.1038/nature05819
   Shamay Y, 2009, BIOMATERIALS, V30, P6460, DOI 10.1016/j.biomaterials.2009.08.013
   SHIWALI T, 2009, CARBOHYD POLYM, V76, P513
   Singh A, 2010, DRUG DELIV, V17, P426, DOI 10.3109/10717541003777530
   Svensson A, 2005, BIOMATERIALS, V26, P419, DOI 10.1016/j.biomaterials.2004.02.049
   Tiwari A, 2010, J BIOMAT SCI-POLYM E, V21, P937, DOI 10.1163/156856209X452278
   Vliegenthart JFG, 2006, FEBS LETT, V580, P2945, DOI 10.1016/j.febslet.2006.03.053
   Wang Q, 2002, CHEM MATER, V14, P3232, DOI 10.1021/cm0200137
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wang SY, 2011, BIOCHEM BIOPH RES CO, V406, P497, DOI 10.1016/j.bbrc.2011.02.049
   WHO, 2002, WEEKLY EPIDEMIOLOGIC, V77, P329
   Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005
   Yamasaki T, 2011, J GASTROENTEROL, V46, P359, DOI 10.1007/s00535-010-0306-5
   Yan F, 2005, BIOCONJUGATE CHEM, V16, P90, DOI 10.1021/bc049805c
   Yang F, 2011, ACS CHEM BIOL, V6, P252, DOI 10.1021/cb100287q
   Yi HM, 2005, BIOMACROMOLECULES, V6, P2881, DOI 10.1021/bm0504101
   Yoshihara S, 2005, FEBS LETT, V579, P2722, DOI 10.1016/j.febslet.2005.03.079
   Yu WY, 2010, PHARM RES-DORDR, V27, P1584, DOI 10.1007/s11095-010-0149-z
   Zhang HL, 2010, MED RES REV, V30, P270, DOI 10.1002/med.20171
NR 105
TC 21
Z9 22
U1 4
U2 53
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0743-4863
EI 2162-660X
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2011
VL 28
IS 3
BP 255
EP 292
PG 38
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 782KW
UT WOS:000292008700002
PM 21663577
DA 2018-01-05
ER

PT J
AU Li, HM
   Nelson, CE
   Evans, BC
   Duvall, CL
AF Li, Hongmei
   Nelson, Chris E.
   Evans, Brian C.
   Duvall, Craig L.
TI Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Biomacromolecular drug; apoptosis; intracellular delivery; RNA
   interference; siRNA; peptide drug; endosome escape; delivery barriers
ID SMALL INTERFERING RNA; CELL-PENETRATING PEPTIDES; NF-KAPPA-B; BCL-2
   FAMILY-MEMBERS; ERBIUM-YAG LASER; POLO-LIKE KINASE; CHEMOTHERAPY-INDUCED
   APOPTOSIS; PROTEIN TRANSDUCTION DOMAINS; HUMAN IMMUNODEFICIENCY VIRUS;
   REVERSING DRUG-RESISTANCE
AB The recent elucidation of molecular regulators of apoptosis and their roles in cellular oncogenesis has motivated the development of biomacromolecular anticancer therapeutics that can activate intracellular apoptotic signaling pathways. Pharmaceutical scientists have employed a variety of classes of biologics toward this goal, including antisense oligodeoxynucleotides, small interfering RNA, proteins, antibodies, and peptides. However, stability in the in vivo environment, tumor-specific biodistribution, cell internalization, and localization to the intracellular microenvironment where the targeted molecule is localized pose significant challenges that limit the ability to directly apply intracellular-acting, pro-apoptotic biologics for therapeutic use. Thus, approaches to improve the pharmaceutical properties of therapeutic biomacromolecules are of great significance and have included chemically modifying the bioactive molecule itself or formulation with auxiliary compounds. Recently, promising advances in delivery of pro-apoptotic biomacromolecular agents have been made using tools such as peptide "stapling", cell penetrating peptides, fusogenic peptides, liposomes, nanoparticles, smart polymers, and synergistic combinations of these components. This review will discuss the molecular mediators of cellular apoptosis, the respective mechanisms by which these mediators are dysregulated in cellular oncogenesis, the history and development of both nucleic-acid and amino-acid based drugs, and techniques to achieve intracellular delivery of these biologics. Finally, recent applications where proapoptotic functionality has been achieved through delivery of intracellular-acting biomacromolecular drugs will be highlighted.
C1 [Li, Hongmei; Nelson, Chris E.; Evans, Brian C.; Duvall, Craig L.] Vanderbilt Univ, Dept Biomed Engn, VU Stn, Nashville, TN 37235 USA.
RP Duvall, CL (reprint author), PMB 351631,2301 Vanderbilt Pl, Nashville, TN 37235 USA.
EM craig.duvall@vanderbilt.edu
FU NIH [F32CA134152]
FX C. L. D. would like to acknowledge NIH F32CA134152 for funding support
   and Patrick Stayton, Allan Hoffman, Oliver Press, Anthony Convertine,
   Danielle Benoit, and Corinna Palanca-Wessels for constructive
   conversations on this research area.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Aigner A, 2006, J BIOTECHNOL, V124, P12, DOI 10.1016/j.jbiotec.2005.12.003
   Aigner A, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/71659
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Alshamsan A, 2010, BIOMATERIALS, V31, P1420, DOI 10.1016/j.biomaterials.2009.11.003
   Altieri DC, 2010, BIOCHEM J, V430, P199, DOI 10.1042/BJ20100814
   Amarzguioui M, 2006, CLIN CANCER RES, V12, P4055, DOI 10.1158/1078-0432.CCR-05-2482
   Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361
   Amundson SA, 2000, CANCER RES, V60, P6101
   An J, 2005, INT J CANCER, V117, P531, DOI 10.1002/ijc.21093
   Anderson DG, 2005, MOL THER, V11, P426, DOI 10.1016/j.ymthe.2004.11.015
   ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126
   Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130
   ARAUJO H, 1993, J BIOL CHEM, V268, P5911
   Asakura T, 1999, BRIT J CANCER, V80, P711, DOI 10.1038/sj.bjc.6690414
   Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926                                                                 
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305                                                   
   Awasthi YC, 2007, CURR DRUG METAB, V8, P315, DOI 10.2174/138920007780655414                                                      
   Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s
   Banga AK, 1998, TRENDS BIOTECHNOL, V16, P408, DOI 10.1016/S0167-7799(98)01238-4
   Banoczi Z, 2010, BIOCONJUGATE CHEM, V21, P1948, DOI 10.1021/bc100028z
   Bartlett DW, 2008, BIOTECHNOL BIOENG, V99, P975, DOI 10.1002/bit.21668
   Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483
   Behr JP, 1996, M S-MED SCI, V12, P56
   Belting M, 2005, ADV DRUG DELIVER REV, V57, P505, DOI 10.1016/j.addr.2004.10.004
   Benoit DSW, 2010, MOL PHARMACEUT, V7, P442, DOI 10.1021/mp9002255
   Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542
   BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618                                                          
   Berg K, 2005, CLIN CANCER RES, V11, P8476, DOI 10.1158/1078-0432.CCR-05.1245
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110                                                                
   Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2
   Beyerle A, 2010, TOXICOL APPL PHARM, V242, P146, DOI 10.1016/j.taap.2009.10.001
   Biliran H, 2007, CLIN CANCER RES, V13, P2811, DOI 10.1158/1078-0432.CCR-06-1844
   Bitler BG, 2010, RECENT PAT ANTI-CANC, V5, P99, DOI 10.2174/157489210790936252                                                      
   Blackwell HE, 1998, ANGEW CHEM INT EDIT, V37, P3281, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.3.CO;2-M
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225                                                                
   Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x                                                       
   BORDEN KA, 1987, MACROMOLECULES, V20, P454, DOI 10.1021/ma00168a046                                                             
   Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1
   Boussif O, 1996, GENE THER, V3, P1074
   Brunel FM, 2005, CHEM COMMUN, P2552, DOI 10.1039/b419015g
   Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Burke RS, 2008, BIOCONJUGATE CHEM, V19, P693, DOI 10.1021/bc700388u
   Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894
   Cahill K, 2010, IET SYST BIOL, V4, P367, DOI 10.1049/iet-syb.2010.0007
   Cai Y, 2007, CANCER BIOL THER, V6, P1794, DOI 10.4161/cbt.6.11.4860                                                           
   Calcabrini A, 2000, HISTOCHEM J, V32, P599, DOI 10.1023/A:1026732405381                                                         
   CAO N, 2010, BIOMATERIALS
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860                                                   
   Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416
   Chen CP, 2006, BIOCONJUGATE CHEM, V17, P1057, DOI 10.1021/bc060028l
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chen YC, 2010, J INVEST DERMATOL, V130, P2790, DOI 10.1038/jid.2010.222
   Chen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136
   Chen YC, 2010, J BIOL CHEM, V285, P22639, DOI 10.1074/jbc.M110.125906
   Chen YC, 2010, MOL THER, V18, P828, DOI 10.1038/mt.2009.291
   Chen YC, 2009, MOL PHARMACEUT, V6, P696, DOI 10.1021/mp800136v
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   CHOREV M, 1979, FED PROC, V38, P363
   Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3
   Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   Cohen GM, 1997, BIOCHEM J, V326, P1
   Convertine AJ, 2010, BIOMACROMOLECULES, V11, P2904, DOI 10.1021/bm100652w
   Convertine AJ, 2009, J CONTROL RELEASE, V133, P221, DOI 10.1016/j.jconrel.2008.10.004
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6
   CREUSAT G, BIOCONJUG CHEM, V21, P994
   Crnkovic-Mertens I, 2003, ONCOGENE, V22, P8330, DOI 10.1038/sj.onc.1206973
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010
   Dasgupta A, 2010, BIOCHEM BIOPH RES CO, V400, P53, DOI 10.1016/j.bbrc.2010.08.001
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380
   Degim IT, 2007, CURR PHARM DESIGN, V13, P99
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239                                                            
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Dharap SS, 2003, PHARMACEUT RES, V20, P889, DOI 10.1023/A:1023839319950
   Dimitrov Dimiter S., 2009, V525, P1, DOI 10.1007/978-1-59745-554-1_1
   Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222
   Duvall CL, 2010, MOL PHARMACEUT, V7, P468, DOI 10.1021/mp9002267
   Efremov RG, 1999, FEBS LETT, V462, P205, DOI 10.1016/S0014-5793(99)01505-7
   El-Sayed A, 2008, J BIOL CHEM, V283, P23450, DOI 10.1074/jbc.M709387200
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301                                                              
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3                                                   
   Ellerby HM, 1999, NAT MED, V5, P1032
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Fang JY, 2004, BRIT J DERMATOL, V151, P132, DOI 10.1111/j.1365-2133.2004.06051.x
   FELBER AE, 2010, J CONTROLLED RELEASE
   Finnegan NM, 2001, BRIT J CANCER, V85, P115, DOI 10.1054/bjoc.2001.1850
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Flynn CR, 2010, J PHARM SCI-US, V99, P3100, DOI 10.1002/jps.22087
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951
   FOSTER S, BIOCONJUG CHEM
   Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, PHARM RES, V24, P2040, DOI 10.1007/s11095-007-9338-9
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Futaki S, 2005, J GENE MED, V7, P1450, DOI 10.1002/jgm.796
   Futami Takashi, 2002, Nucleic Acids Res Suppl, P251
   Fyrberg A, 2010, CYTOTECHNOLOGY, V62, P497, DOI 10.1007/s10616-010-9309-6
   Gao J, 2010, BIOMATERIALS, V31, P2655, DOI 10.1016/j.biomaterials.2009.11.112
   Gascoyne RD, 1997, BLOOD, V90, P244
   GERVASONI JE, 1991, CANCER RES, V51, P4955
   GHADIRI MR, 1990, J AM CHEM SOC, V112, P1630, DOI 10.1021/ja00160a054
   Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043
   Gomme PT, 2005, DRUG DISCOV TODAY, V10, P267, DOI 10.1016/S1359-6446(04)03333-1
   Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227                                                          
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6
   GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9                                                    
   Hammond SM, 2000, NATURE, V404, P293
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9                                                   
   Hao JS, 2009, EXP EYE RES, V89, P934, DOI 10.1016/j.exer.2009.08.001
   Harada Y, 2000, CANCER GENE THER, V7, P27, DOI 10.1038/sj.cgt.7700079
   HARDING CV, 1992, EUR J IMMUNOL, V22, P1865, DOI 10.1002/eji.1830220728                                                          
   Hatakeyama H, 2009, J CONTROL RELEASE, V139, P127, DOI 10.1016/j.jconrel.2009.06.008
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henchey LK, 2008, CURR OPIN CHEM BIOL, V12, P692, DOI 10.1016/j.cbpa.2008.08.019
   Henry SM, 2006, BIOMACROMOLECULES, V7, P2407, DOI 10.1021/bm060143z
   Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298
   HOLM T, 2010, BIOCHIM BIOPHYS ACTA
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Hua J, 2010, CANCER LETT, V292, P41, DOI 10.1016/j.canlet.2009.11.007
   Huang HA, 2011, LAB CHIP, V11, P163, DOI [10.1039/c0lc00195c, 10.1039/c01c00195c]
   Huang Shao, 2007, Sheng Li Ke Xue Jin Zhan, V38, P301
   Huang Z, 2009, GENE THER, V16, P1271, DOI 10.1038/gt.2009.76
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   JANS DA, 1994, FASEB J, V8, P841
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677
   Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785
   KARI B, 1986, DIABETES, V35, P217, DOI 10.2337/diabetes.35.2.217
   Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33                                                             
   Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100
   Kigasawa K, 2010, INT J PHARMACEUT, V383, P157, DOI 10.1016/j.ijpharm.2009.08.036
   Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Ko YT, 2009, MOL PHARMACEUT, V6, P971, DOI 10.1021/mp900006h
   KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T
   Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643                                                
   Kong WH, 2009, J CONTROL RELEASE, V138, P141, DOI 10.1016/j.jconrel.2009.04.034
   Kritzer JA, 2010, NAT CHEM BIOL, V6, P566, DOI 10.1038/nchembio.407
   Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001                                                
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   Kumar M, 2010, CANCER RES, V70, P7553, DOI 10.1158/0008-5472.CAN-10-2070
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   Kyriakides TR, 2002, J CONTROL RELEASE, V78, P295, DOI 10.1016/S0168-3659(01)00504-1
   Lackey CA, 1999, BIOCONJUGATE CHEM, V10, P401, DOI 10.1021/bc980109k                                                               
   Lackey CA, 2002, BIOCONJUGATE CHEM, V13, P996, DOI 10.1021/bc010053l
   Langkjaer L, 1998, J CONTROL RELEASE, V51, P47, DOI 10.1016/S0168-3659(97)00155-7                                                   
   Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491
   Lee WR, 2008, J CONTROL RELEASE, V128, P200, DOI 10.1016/j.jconrel.2008.03.003
   Lee WR, 2009, HUM GENE THER, V20, P580, DOI 10.1089/hum.2008.156
   Lee WR, 2001, J CONTROL RELEASE, V75, P155, DOI 10.1016/S0168-3659(01)00391-1
   Lehne Gustav, 2000, Current Drug Targets, V1, P85, DOI 10.2174/1389450003349443
   Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658
   LI B, 2010, ANTICANCER DRUGS
   Li N, 2009, AM J PHYSIOL-CELL PH, V296, pC267, DOI 10.1152/ajpcell.00390.2008
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Li SD, 2009, BBA-BIOMEMBRANES, V1788, P2259, DOI 10.1016/j.bbamem.2009.06.022
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1                                                   
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2
   Link KH, 1998, SEMIN SURG ONCOL, V14, P189, DOI 10.1002/(SICI)1098-2388(199804/05)14:3<189::AID-SSU2>3.0.CO;2-4
   Link KH, 1997, INT J PANCREATOL, V21, P71
   Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101
   Liu JL, 2010, CHINESE MED J-PEKING, V123, P2901, DOI 10.3760/cma.j.issn.0366-6999.2010.20.028
   Liu XX, 2009, CHEMMEDCHEM, V4, P1302, DOI 10.1002/cmdc.200900076
   Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006
   Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100
   Liu YQ, 2009, MOL THER, V17, P269, DOI 10.1038/mt.2008.266
   Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122
   Lopes LB, 2008, EUR J PHARM BIOPHARM, V68, P441, DOI 10.1016/j.ejpb.2007.09.019
   Lopes LB, 2009, BIOCHEM BIOPH RES CO, V382, P535, DOI 10.1016/j.bbrc.2009.03.056
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   Lu W, 2010, CANCER RES, V70, P3177, DOI 10.1158/0008-5472.CAN-09-3379
   LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Malek A, 2009, TOXICOL APPL PHARM, V236, P97, DOI 10.1016/j.taap.2009.01.014
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   McDermott U, 2005, CANCER RES, V65, P8951, DOI 10.1158/008-5472.CAN-05-0961
   McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5
   Mendonca LS, 2010, BIOCONJUGATE CHEM, V21, P157, DOI 10.1021/bc9004365
   Mesner P W Jr, 1997, Adv Pharmacol, V41, P461, DOI 10.1016/S1054-3589(08)61069-8
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Mitragotri S, 2000, BIOTECHNOL PROGR, V16, P488, DOI 10.1021/bp000024+
   Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032
   Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543
   MONSIGNY M, 1994, ADV DRUG DELIVER REV, V14, P1, DOI 10.1016/0169-409X(94)90003-5
   MORI A, 1987, PAVLOVIAN J BIOL SCI, V22, P85
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0
   Mudhakir D, 2008, J CONTROL RELEASE, V125, P164, DOI 10.1016/j.jconrel.2007.10.020
   Murthy N, 2003, BIOCONJUGATE CHEM, V14, P412, DOI 10.1021/bc020056d
   Murthy N, 2003, J CONTROL RELEASE, V89, P365, DOI 10.1016/S0168-3659(03)00099-3
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Naeye B, 2010, EUR J PHARM SCI, V40, P342, DOI 10.1016/j.ejps.2010.04.010
   Nam HY, 2010, BIOMATERIALS, V31, P8081, DOI 10.1016/j.biomaterials.2010.07.025
   NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279
   Niidome T, 1999, BIOCONJUGATE CHEM, V10, P773, DOI 10.1021/bc990012d
   Nishikawa M, 2010, MOL THER, V18, P421, DOI 10.1038/mt.2009.203
   Noh SM, 2011, BIOMATERIALS, V32, P849, DOI 10.1016/j.biomaterials.2010.09.027
   O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Opanasopit P, 2002, CRIT REV THER DRUG, V19, P191
   OSAPAY G, 1992, J AM CHEM SOC, V114, P6966, DOI 10.1021/ja00044a003
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pack DW, 2000, BIOTECHNOL BIOENG, V67, P217, DOI 10.1002/(SICI)1097-0290(20000120)67:2<217::AID-BIT11>3.0.CO;2-Q
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002                                                              
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Pichon C, 2001, ADV DRUG DELIVER REV, V53, P75, DOI 10.1016/S0169-409X(01)00221-6
   Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757                                                        
   Pirollo KF, 2006, HUM GENE THER, V17, P117, DOI 10.1089/hum.2006.17.117
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Pliquett EF, 2000, BIOELECTROCHEMISTRY, V51, P41
   Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887
   Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017
   POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8
   Pro B, 2008, BRIT J HAEMATOL, V143, P355, DOI 10.1111/j.1365-2141.2008.07353.x
   Prost AC, 1998, INT J ONCOL, V13, P871
   Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127
   Puhlmann U, 2005, J PHARMACOL EXP THER, V312, P346, DOI 10.1124/jpet.104.071571
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   RAAB R, 2005, AM J CLIN ONCOL-CANC, V33, P61
   Raagel H, 2010, BBA-BIOMEMBRANES, V1798, P2240, DOI 10.1016/j.bbamem.2010.02.013
   Raemdonck K, 2010, J CONTROL RELEASE, V145, P281, DOI 10.1016/j.jconrel.2010.04.012
   REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61                                                    
   Reichert JM, 2007, NAT REV DRUG DISCOV, V6, P349, DOI 10.1038/nrd2241
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   RHEE K, 1995, CANCER RES, V55, P4188
   Richardson Alan, 2008, Curr Mol Pharmacol, V1, P244
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rols MP, 1998, NAT BIOTECHNOL, V16, P168, DOI 10.1038/nbt0298-168                                                             
   Rumpold H, 2007, BIOCHEM BIOPH RES CO, V361, P549, DOI 10.1016/j.bbrc.2007.07.049
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269
   Sasi N, 2009, MOL CANCER THER, V8, P1421, DOI 10.1158/1535-7163.MCT-08-0895
   Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983
   Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Selbo PK, 2000, BBA-GEN SUBJECTS, V1475, P307, DOI 10.1016/S0304-4165(00)00082-9
   Shamay Y, 2011, BIOMATERIALS, V32, P1377, DOI 10.1016/j.biomaterials.2010.10.029
   Shangary S, 2004, MOL CANCER THER, V3, P1343
   Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h
   Shen DW, 2000, J CELL PHYSIOL, V183, P108, DOI 10.1002/(SICI)1097-4652(200004)183:1<108::AID-JCP13>3.3.CO;2-W
   Shen DW, 1998, CANCER RES, V58, P268
   Sheridan C, 2010, NAT BIOTECHNOL, V28, P992, DOI 10.1038/nbt1010-992c
   Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880
   Singhal SS, 2010, INT J CANCER, V126, P1327, DOI 10.1002/ijc.24767
   Singhal SS, 2009, CANCER RES, V69, P4244, DOI 10.1158/0008-5472.CAN-08-3521
   Singhal SS, 2009, BIOCHEM PHARMACOL, V77, P1074, DOI 10.1016/j.bcp.2008.11.013
   Singhal SS, 2006, FEBS LETT, V580, P2258, DOI 10.1016/j.febslet.2006.03.038
   Singhal SS, 2006, CANCER RES, V66, P2354, DOI 10.1158/0008-5472.CAN-05-3534
   Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song WJ, 2010, SMALL, V6, P239, DOI 10.1002/smll.200901513
   Spankuch-Schmitt B, 2002, J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863                                                         
   Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200
   Sternberg CN, 2009, ANN ONCOL, V20, P1264, DOI 10.1093/annonc/mdn784
   Stewart ML, 2010, NAT CHEM BIOL, V6, P595, DOI [10.1038/NCHEMBIO.391, 10.1038/nchembio.391]
   STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0
   Suzuki E, 2010, INT J ONCOL, V36, P1299, DOI 10.3892/ijo_00000615
   TAKAKUWA O, 2010, CANC CHEMOTHER PHARM
   Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682
   Takeshita F, 2006, CANCER SCI, V97, P689, DOI 10.1111/j.1349-7006.2006.00234.x
   Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102
   Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446                                                          
   Taylor JW, 2002, BIOPOLYMERS, V66, P49, DOI 10.1002/bip.10203
   THOMAS JL, 1994, BIOPHYS J, V67, P1101, DOI 10.1016/S0006-3495(94)80575-2                                                   
   THOMAS JL, 1992, ACCOUNTS CHEM RES, V25, P336, DOI 10.1021/ar00020a003                                                             
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312                                                   
   Tokatlian T, 2010, WIRES NANOMED NANOBI, V2, P305, DOI 10.1002/wnan.81
   Top D, 2005, EMBO J, V24, P2980, DOI 10.1038/sj.emboj.7600767
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Tracey L, 2005, J PATHOL, V206, P123, DOI 10.1002/path.1768
   Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200
   Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836
   Turk MJ, 2002, BBA-BIOMEMBRANES, V1559, P56, DOI 10.1016/S0005-2736(01)00441-2
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Turunen MP, 1999, GENE THER, V6, P6, DOI 10.1038/sj.gt.3300800                                                           
   van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027
   van Rossenberg SMW, 2002, J BIOL CHEM, V277, P45803, DOI 10.1074/jbc.M203510200
   Vandenbroucke RE, 2008, J GENE MED, V10, P783, DOI 10.1002/jgm.1202
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   VARKOUHI AK, 2010, EUR J PHARM BIOPHARM
   Vatsyayan R, 2010, BIOCHEM PHARMACOL, V79, P1699, DOI 10.1016/j.bcp.2010.01.016
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Villares GJ, 2008, CANCER RES, V68, P9078, DOI 10.1158/0008-5472.CAN-08-2397
   VOGL DT, 2008, NUCL ACID THERAPIES
   von Bueren AO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-10
   Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840
   Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191
   WANG CY, 1984, BIOCHEMISTRY-US, V23, P4409, DOI 10.1021/bi00314a026
   Wang CY, 1999, MOL CELL BIOL, V19, P5923
   Wang LF, 2009, CANCER INVEST, V27, P774, DOI 10.1080/07357900802427935
   Wang XL, 2009, J CONTROL RELEASE, V134, P207, DOI 10.1016/j.jconrel.2008.11.010
   Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975
   Ward B, 2009, J PEPT SCI, V15, P668, DOI 10.1002/psc.1168
   Warenius HM, 1996, INT J CANCER, V67, P224, DOI 10.1002/(SICI)1097-0215(19960717)67:2<224::AID-IJC13>3.3.CO;2-5
   Wartenberg M, 2001, J BIOL CHEM, V276, P17420, DOI 10.1074/jbc.M100141200                                                          
   Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812                                                      
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653
   Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289
   Wilson TR, 2009, CURR CANCER DRUG TAR, V9, P307, DOI 10.2174/156800909788166547                                                      
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xu L, 2011, J PHARM SCI-US, V100, P38, DOI 10.1002/jps.22243
   Xu YM, 2004, J IMMUNOL, V173, P61, DOI 10.4049/jimmunol.173.1.61                                                       
   Yadav S, 2009, CANCER CHEMOTH PHARM, V63, P711, DOI 10.1007/s00280-008-0790-y
   Yamada Y, 2007, MITOCHONDRION, V7, P63, DOI 10.1016/j.mito.2006.12.003
   Yan XD, 2005, J LIPOSOME RES, V15, P109, DOI 10.1081/LPR-200064971
   Yang Ding Cheng, 2002, Expert Opin Ther Targets, V6, P375, DOI 10.1517/14728222.6.3.375
   Yang LL, 2003, CANCER RES, V63, P831
   Yezhelyev MV, 2008, J AM CHEM SOC, V130, P9006, DOI 10.1021/ja800086u
   Yin James Q, 2003, J Exp Ther Oncol, V3, P194, DOI 10.1046/j.1359-4117.2003.01092.x
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Yu HH, 2010, BBA-BIOMEMBRANES, V1798, P2249, DOI 10.1016/j.bbamem.2010.02.003
   Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x
   Zamora-Avila DE, 2009, CANCER GENE THER, V16, P892, DOI 10.1038/cgt.2009.35
   Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5
   Zhang Y, 2010, INT J PHARMACEUT, V390, P198, DOI 10.1016/j.ijpharm.2010.01.035
   Zhang YC, 2006, BREAST CANCER RES TR, V96, P267, DOI 10.1007/s10549-005-9080-0
   Zhao PQ, 2010, PHARM RES-DORDR, V27, P1914, DOI 10.1007/s11095-010-0196-5
   Zhao Y, 2010, J NANOSCI NANOTECHNO, V10, P5137, DOI 10.1166/jnn.2010.2396
   Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382                                                            
NR 349
TC 16
Z9 16
U1 1
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JAN
PY 2011
VL 17
IS 3
BP 293
EP 319
DI 10.2174/138161211795049642                                              
          
PG 27
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 768OW
UT WOS:000290945500010
PM 21348831
OA green_accepted
DA 2018-01-05
ER

PT J
AU Khalil, NM
   Carraro, E
   Cotica, LF
   Mainardes, RM
AF Khalil, Najeh Maissar
   Carraro, Emerson
   Cotica, Luiz Fernando
   Mainardes, Rubiana Mara
TI Potential of polymeric nanoparticles in AIDS treatment and prevention
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE AIDS; antiretroviral drugs; polymeric nanoparticles; targeting
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD-BRAIN-BARRIER; REVERSE-TRANSCRIPTASE
   INHIBITORS; DRUG-DELIVERY SYSTEMS; ANTI-HIV DRUGS; SOLID LIPID
   NANOPARTICLES; PEG BLEND NANOPARTICLES; IN-VITRO; ANTIRETROVIRAL
   THERAPY; PLA NANOPARTICLES
AB Importance of the field: Acquired immunodeficiency syndrome ( AIDS) remains one of the greatest challenges in public health. The AIDS virus is now responsible for > 2.5 million new infections worldwide each year. Despite significant advances in understanding the mechanism of viral infection and identifying effective treatment approaches, the search for optimum treatment strategies for AIDS remains a major challenge. Recent advances in the field of drug delivery have provided evidence that engineered nanosystems may contribute to the enhancement of current antiretroviral therapy.
   Areas covered in this review: This review describes the potential of polymeric nanoparticle-based drug delivery systems in the future treatment of AIDS. Polymeric nanoparticles have been developed to improve physicochemical drug characteristics (by increasing drug solubility and stability), to achieve sustained drug release profile, to provide targeting to the cellular and anatomic human immunodeficiency virus (HIV) latent reservoirs and to be applied as an adjuvant in anti-HIV vaccine formulations.
   What the reader will gain: The insight that will be gained is knowledge about the progress in the development of polymeric nanoparticle-based drug delivery systems for antiretroviral drugs as alternative for AIDS treatment and prevention.
   Take home message: The advances in the field of targeted drug delivery can result in more efficient strategies for AIDS treatment and prevention.
C1 [Khalil, Najeh Maissar; Carraro, Emerson; Mainardes, Rubiana Mara] Univ Estadual, Ctr Oeste UNICENTRO, Dept Farm, BR-85040080 Guarapuava, PR, Brazil.
   [Cotica, Luiz Fernando] Univ Estadual Maringa UEM, Dept Fis, BR-87020900 Maringa, PR, Brazil.
RP Mainardes, RM (reprint author), Univ Estadual, Ctr Oeste UNICENTRO, Dept Farm, Rua Simeao Camargo Varela de Sa 03, BR-85040080 Guarapuava, PR, Brazil.
EM rubianamainardes@pq.cnpq.br
RI Cotica, Luiz/C-7239-2013
OI Carraro, Emerson/0000-0001-5420-2300; Mainardes,
   Rubiana/0000-0002-4442-2075
CR AIDS E, 2010, SEPTEMBER, V2009, P29
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Aquaro S, 2002, J MED VIROL, V68, P479, DOI 10.1002/jmv.10245
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bagnarelli P, 1996, J VIROL, V70, P7603
   BARTLETT JG, 2004, 2004 MED MANAGEMENT, P99
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Betbeder D, 2000, PHARM RES-DORDR, V17, P743, DOI 10.1023/A:1007594602449
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5                                                   
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Chen XQ, 1998, J ALZHEIMERS DIS, V1, P35, DOI DOI 10.1080/10942919809524563
   Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Copland MJ, 2005, IMMUNOL CELL BIOL, V83, P97, DOI 10.1111/j.1440-1711.2005.01315.x
   Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   Croxtall JD, 2009, DRUGS, V69, P1059, DOI 10.2165/00003495-200969080-00007
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E., 2007, INT J ANTIMICROB AG, V33, P307
   DECLERCQ E, 2010, ANTIVIRAL D IN PRESS
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Dennison SR, 2007, BIOCHEM BIOPH RES CO, V363, P178, DOI 10.1016/j.bbrc.2007.08.162
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   FATTAL E, 2002, NANOPARTICLES DRUG D, P10
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Fundaro C, 2002, AIDS, V16, P299, DOI 10.1097/00002030-200201250-00025                                                
   Fung HB, 2004, CLIN THER, V26, P352, DOI 10.1016/S0149-2918(04)90032-X
   Gallichan WS, 1996, J EXP MED, V184, P1879, DOI 10.1084/jem.184.5.1879
   Garaci E, 1999, P NATL ACAD SCI USA, V96, P14013, DOI 10.1073/pnas.96.24.14013
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x
   Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292
   Grant I, 2008, INT REV PSYCHIATR, V20, P33, DOI 10.1080/09540260701877894
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Hanson LR, 2007, J NEUROIMMUNE PHARM, V2, P81, DOI 10.1007/s11481-006-9039-x
   Haubrich RH, 2009, AIDS, V23, P1109, DOI 10.1097/QAD.0b013e32832b4377
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   Hel Z, 2006, TRENDS IMMUNOL, V27, P274, DOI 10.1016/j.it.2006.04.007
   Herlitz LC, 2010, KIDNEY INT, V78, P1171, DOI 10.1038/ki.2010.318
   Hillaireau H, 2006, INT J PHARM, V324, P37, DOI 10.1016/j.ijpharm.2006.07.006
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310
   Hoffart V, 2006, J CONTROL RELEASE, V113, P38, DOI 10.1016/j.jconrel.2006.03.020
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   KANG YS, 1994, DRUG METAB DISPOS, V22, P99
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kawashima Y, 2001, ADV DRUG DELIVER REV, V47, P1, DOI 10.1016/S0169-409X(00)00117-4
   Khalil Najeh Maissar, 2009, Current Drug Delivery, V6, P261
   KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903
   Koziara JM, 2006, J NANOSCI NANOTECHNO, V6, P2712, DOI 10.1166/jnn.2006.441
   Kreuter J, 2005, INT CONGR SER, V1277, P85, DOI 10.1016/j.ics.2005.02.014
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   KREUTER J, 1994, NANOPARTICLES, P10
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   LARGENT BL, 1984, J BIOL CHEM, V259, P1764
   Letendre Scott L, 2010, Top HIV Med, V18, P45
   Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001
   LEVY J, 2007, HIV PATH AIDS 3 ED, pNIL1
   LEWIS DH, 1990, BIODEGRADABLE POLYM, P45
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lieberman-Blum SS, 2008, CLIN THER, V30, P1228, DOI 10.1016/j.clinthera.2008.07.008
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   Locher CP, 2003, IMMUNOL LETT, V90, P67, DOI 10.1016/j.imlet.2003.02.001
   Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mainardes RM, 2010, INT J PHARMACEUT, V395, P266, DOI 10.1016/j.ijpharm.2010.05.020
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675
   MCGANN KA, 1994, J INFECT DIS, V169, P746, DOI 10.1093/infdis/169.4.746                                                        
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Ndegwa S, 2007, ISSUES EMERG HLTH TE, V110, P1
   O'Hagan DT, 1998, ADV DRUG DELIVER REV, V32, P225, DOI 10.1016/S0169-409X(98)00012-X                                                   
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   OPPENHEIM RC, 1981, INT J PHARM, V8, P217, DOI 10.1016/0378-5173(81)90100-9
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001                                                
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Plosker GL, 1999, DRUGS, V58, P1165, DOI 10.2165/00003495-199958060-00011
   Pozniak A, 2008, INT J CLIN PRACT, V62, P1285, DOI 10.1111/j.1742-1241.2008.01817.x
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Ross TM, 2004, J NEUROIMMUNOL, V151, P66, DOI 10.1016/j.jneuroim.2004.02.011
   *RXLIST INC, RXLIST INT DRUG IND
   Sabin CA, 2008, LANCET, V371, P1417
   Saksena Nitin K., 2003, Current Drug Targets - Infectious Disorders, V3, P179, DOI 10.2174/1568005033481187
   Saupe A, 2006, EXPERT OPIN DRUG DEL, V3, P345, DOI 10.1517/17425247.3.3.345
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Schinkel AH, 2001, ADV EXP MED BIOL, V500, P365
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   SHAO J, 1997, J DRUG DELIV TARGET, V1998, P43
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   SHIN SU, 1995, P NATL ACAD SCI USA, V92, P2820, DOI 10.1073/pnas.92.7.2820
   SIMON JK, 2006, IMMUNOPOTENTIATORS M
   Smith CJ, 2008, AIDS, V22, P47, DOI 10.1097/QAD.0b013e3282f03094                                                    
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Staszewski S, 1999, AIDS, V13, P367, DOI 10.1097/00002030-199902250-00009                                                
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   STOLNIK S, 1995, ADV DRUG DELIVER REV, V16, P195, DOI 10.1016/0169-409X(95)00025-3                                                    
   Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74                                                           
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029
   THORNE RG, 1995, BRAIN RES, V692, P278, DOI 10.1016/0006-8993(95)00637-6
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Ubrich N, 2005, INT J PHARMACEUT, V288, P169, DOI 10.1016/j.ijpharm.2004.09.019
   VANCTWOUT AB, 1994, J CLIN INVEST, V94, P2060
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9                                                   
   VOGEL FR, 1995, VACCINE DESIGN SUBUN
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   WONG HL, 2010, ADV DRUG DELIV REV, V18, P503
   Yang Z, 2005, J PHARM SCI-US, V94, P1577, DOI 10.1002/jps.20334
   Zhang QZ, 2006, J DRUG TARGET, V14, P281, DOI 10.1080/10611860600721051
NR 151
TC 16
Z9 16
U1 1
U2 17
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JAN
PY 2011
VL 8
IS 1
BP 95
EP 112
DI 10.1517/17425247.2011.543673
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 697XP
UT WOS:000285553400006
PM 21143001
DA 2018-01-05
ER

PT J
AU Armstead, AL
   Li, BY
AF Armstead, Andrea L.
   Li, Bingyun
TI Nanomedicine as an emerging approach against intracellular pathogens
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE intracellular pathogen; infection; nanomedicine; nanoparticle; drug
   delivery
ID HEPATITIS-C VIRUS; RESPIRATORY SYNCYTIAL VIRUS; TARGETED DRUG-DELIVERY;
   STAPHYLOCOCCUS-AUREUS; BIODEGRADABLE NANOPARTICLES;
   ENDOPLASMIC-RETICULUM; SALMONELLA-TYPHIMURIUM; PEPTIDE NANOPARTICLES;
   SILICA NANOPARTICLES; PLGA NANOPARTICLES
AB Diseases such as tuberculosis, hepatitis, and HIV/AIDS are caused by intracellular pathogens and are a major burden to the global medical community. Conventional treatments for these diseases typically consist of long-term therapy with a combination of drugs, which may lead to side effects and contribute to low patient compliance. The pathogens reside within intracellular compartments of the cell, which provide additional barriers to effective treatment. Therefore, there is a need for improved and more effective therapies for such intracellular-diseases. This review will summarize, for the first time, the intracellular compartments in which pathogens can reside and discuss how nanomedicine has the potential to improve intracellular disease therapy by offering properties such as targeting, sustained drug release, and drug delivery to the pathogen's intracellular location. The characteristics of nanomedicine may prove advantageous in developing improved or alternative therapies for intracellular diseases.
C1 [Armstead, Andrea L.; Li, Bingyun] W Virginia Univ, Sch Med, Dept Orthoped, Biomat Bioengn & Nanotechnol Lab, Morgantown, WV 26506 USA.
   [Armstead, Andrea L.; Li, Bingyun] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA.
   [Armstead, Andrea L.; Li, Bingyun] WVNano Initiat, Morgantown, WV USA.
RP Li, BY (reprint author), W Virginia Univ, Sch Med, Dept Orthoped, Biomat Bioengn & Nanotechnol Lab, Morgantown, WV 26506 USA.
EM bli@hsc.wvu.edu
FU National Science Foundation [1003907]; National Institutes of Health
   [HL091456]; WVNano
FX The authors acknowledge financial support from the National Science
   Foundation (No 1003907), the National Institutes of Health (No
   HL091456), and WVNano.
CR Ahmad S, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/814943
   AKHTAR J, 2009, FEBS J, V276, P7728
   Al-Khodor S, 2010, CELL MICROBIOL, V12, P1604, DOI 10.1111/j.1462-5822.2010.01494.x
   Allhoff F, 2009, AM J BIOETHICS, V9, P3, DOI 10.1080/15265160902985027
   Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436                                                        
   Aspler A, 2008, INT J TUBERC LUNG D, V12, P928
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605
   Balland O, 1996, J ANTIMICROB CHEMOTH, V37, P105, DOI 10.1093/jac/37.1.105
   Balloy V, 2009, MICROBES INFECT, V11, P919, DOI 10.1016/j.micinf.2009.07.002
   Blanco-Prieto MJ, 2002, INT J PHARM, V242, P203, DOI 10.1016/S0378-5173(02)00158-8
   Briones E, 2008, J CONTROL RELEASE, V125, P210, DOI 10.1016/j.jconrel.2007.10.027
   BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232
   BUCKI R, 2010, ARCH IMMUNOL THER EX, V85, P15
   CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531
   CASTELLO G, 2010, CLIN IMMUNOL, V130, P237
   *CDCP, 2010, SIGNS SYMPT TB DIS
   *CDCP, 2010, TYPH FEV GEN INF
   *CDCP, 2010, TUB GEN INF
   Celli J, 2003, J EXP MED, V198, P545, DOI 10.1084/jem.20030088
   Chatterjee K, 2010, J GENET, V89, P109, DOI 10.1007/s12041-010-0003-4                                                       
   Chiang CY, 2010, INT J TUBERC LUNG D, V14, P672
   Cho WM, 2007, BIOORG MED CHEM LETT, V17, P5772, DOI 10.1016/j.bmcl.2007.08.056
   Clercq ED, 2010, J MED CHEM, V53, P1438
   CLOUTIER MJ, 1995, AM J PHARM EDUC, V59, P167
   Collins CA, 2010, TRENDS CELL BIOL, V20, P205, DOI 10.1016/j.tcb.2010.01.002
   Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1
   DORSOGNA MR, 2009, PLOS ONE, V4, P8165
   Durr UHN, 2006, BBA-BIOMEMBRANES, V1758, P1408, DOI 10.1016/j.bbamem.2006.03.030
   EBY DM, 2008, BIOMACROMOLECULES, V9, P2481
   Ellington JK, 2003, J BONE JOINT SURG BR, V85B, P918, DOI 10.1302/0301-620X.85B6.13509
   Empey KM, 2010, CLIN INFECT DIS, V50, P1258, DOI 10.1086/651603
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Ferrati S, 2010, NANOSCALE, V2, P1512, DOI 10.1039/c0nr00227e
   Finch R, 2002, CLIN MICROBIOL INFEC, V8, P21, DOI 10.1046/j.1469-0691.8.s.3.3.x                                                   
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Franco MP, 2007, LANCET INFECT DIS, V7, P775, DOI 10.1016/S1473-3099(07)70286-4
   Freitas RA, 2005, NANOMED-NANOTECHNOL, V1, P2, DOI 10.1016/j.nano.2004.11.003
   Gamazo Carlos, 2006, Current Drug Delivery, V3, P359, DOI 10.2174/156720106778559038
   Garner P, 2007, B WORLD HEALTH ORGAN, V85, P404, DOI 10.2471/BLT.06.035568
   Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005
   Gaspar MM, 2008, CURR TOP MED CHEM, V8, P579, DOI 10.2174/156802608783955629                                                      
   Gomez MA, 2010, VIRULENCE, V1, P314, DOI 10.4161/viru.1.4.12194
   Goossens H, 2009, CLIN MICROBIOL INFEC, V15, P12, DOI 10.1111/j.1469-0691.2009.02725.x
   Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]
   Gu F, 2008, P NATL ACAD SCI USA, V105, P2586, DOI 10.1073/pnas.0711714105
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Guzman CA, 2006, VACCINE, V24, P3804, DOI 10.1016/j.vaccine.2005.07.111
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hawkey PM, 2009, J ANTIMICROB CHEMOTH, V64, P3, DOI 10.1093/jac/dkp256
   Heuer D, 2009, NATURE, V457, P731, DOI 10.1038/nature07578
   Hu CMJ, 2010, MOL PHARMACEUT, V7, P914, DOI 10.1021/mp900316a
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026
   Izquierdo-Barba I, 2009, BIOMATERIALS, V30, P5729, DOI 10.1016/j.biomaterials.2009.07.003
   Jevon M, 1999, INFECT IMMUN, V67, P2677
   Joralemon MJ, 2010, CHEM COMMUN, V46, P1377, DOI 10.1039/b920570p
   Juliano RL, 2009, WIRES NANOMED NANOBI, V1, P324, DOI 10.1002/wnan.4
   Jung SH, 2009, EUR J PHARM SCI, V37, P313, DOI 10.1016/j.ejps.2009.02.021
   Kamat M, 2010, BIOCONJUGATE CHEM, V21, P2128, DOI 10.1021/bc100354m
   Kaufmann SHE, 2010, IMMUNITY, V33, P567, DOI 10.1016/j.immuni.2010.09.015
   Kohane DS, 2006, J BIOMED MATER RES A, V77A, P351, DOI 10.1002/jbm.a.30654
   Kumar D, 2011, MICROBES INFECT, V13, P121, DOI 10.1016/j.micinf.2010.10.009
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lahiri A, 2010, MICROBES INFECT, V12, P809, DOI 10.1016/j.micinf.2010.05.010
   Lalloo Umesh G, 2010, Curr HIV/AIDS Rep, V7, P143, DOI 10.1007/s11904-010-0054-4
   Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   LAWLOR C, 2010, TUBERCULOSIS, V91, P93
   Lecaroz C, 2006, J ANTIMICROB CHEMOTH, V58, P549, DOI 10.1093/jac/dkl257
   Lecaroz C, 2006, J MICROENCAPSUL, V23, P782, DOI 10.1080/02652040600946886
   Lee H, 2010, MOL PHARMACEUT, V7, P1195, DOI 10.1021/mp100038h
   Leszczynska K, 2010, APMIS, V118, P830, DOI 10.1111/j.1600-0463.2010.02667.x
   Lin PL, 2010, J IMMUNOL, V185, P15, DOI 10.4049/jimmunol.0903856
   Liu LH, 2009, NAT NANOTECHNOL, V4, P457, DOI [10.1038/nnano.2009.153, 10.1038/NNANO.2009.153]
   LOBUE PS, 2010, INT J TUBERC LUNG D, V14, P1126
   Lopez-Martinez R, 2010, CLIN DERMATOL, V28, P178, DOI 10.1016/j.clindermatol.2009.12.014
   Lorenz S, 2010, MACROMOL BIOSCI, V10, P1034, DOI 10.1002/mabi.201000099
   Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI [10.1586/erm.09.15, 10.1586/ERM.09.15]
   Margeridon-Thermet S, 2010, VIRUSES-BASEL, V2, P2696, DOI 10.3390/v2122696
   Martins M, 2009, INT J TUBERC LUNG D, V13, P569
   Misra R, 2010, EUR J PHARM SCI, V39, P152, DOI 10.1016/j.ejps.2009.11.010
   Mkandawire M, 2009, J BIOPHOTONICS, V2, P596, DOI 10.1002/jbio.200910002
   Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017
   Murday JS, 2009, NANOMED-NANOTECHNOL, V5, P251, DOI 10.1016/j.nano.2009.06.001
   Murthy N, 2003, BIOCONJUGATE CHEM, V14, P412, DOI 10.1021/bc020056d
   Nguyen HM, 2009, J ANTIMICROB CHEMOTH, V65, P24
   NOBS L, 2007, J PHARM SCI, V90, P1980
   Onoshita T, 2010, COLLOID SURFACE B, V76, P151, DOI 10.1016/j.colsurfb.2009.10.036
   Panos Ines, 2008, Curr Drug Discov Technol, V5, P333, DOI 10.2174/157016308786733528
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Panyam J, 2004, MOL PHARMACEUT, V1, P77, DOI 10.1021/mp034002c
   PARK JH, 2009, ADV DRUG DELIVERY RE, V62, P28
   Passarella RJ, 2010, CANCER RES, V70, P4550, DOI 10.1158/0008-5472.CAN-10-0339
   Pissuwan D, 2010, TRENDS BIOTECHNOL, V28, P207, DOI 10.1016/j.tibtech.2009.12.004
   Qaddoumi MG, 2004, PHARM RES, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76                                              
   Reis CP, 2006, J MICROENCAPSUL, V23, P245, DOI 10.1080/02652040500286086
   Roop RM, 2004, MOL MICROBIOL, V52, P621, DOI 10.1111/j.1365-2958.2004.04017.x
   Rosenholm JM, 2009, NANO LETT, V9, P3308, DOI 10.1021/nl901589y
   Roy CR, 2006, NAT REV IMMUNOL, V6, P136, DOI 10.1038/nri1775
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Sadanand Saheli, 2010, Yale Journal of Biology and Medicine, V83, P185
   Sajeesh S, 2006, INT J PHARM, V325, P147, DOI 10.1016/j.ijpharm.2006.06.019
   Sandegren L, 2009, NAT REV MICROBIOL, V7, P578, DOI 10.1038/nrmicro2174
   SARAOGI GK, 2009, INT J PHARMACEUT, V385, P143
   Schiffelers R, 2001, J ANTIMICROB CHEMOTH, V48, P333, DOI 10.1093/jac/48.3.333
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Seale-Goldsmith MM, 2009, WIRES NANOMED NANOBI, V1, P553, DOI 10.1002/wnan.49
   Seleem MN, 2009, ANTIMICROB AGENTS CH, V53, P4270, DOI 10.1128/AAC.00815-09
   Sendi P, 2009, TRENDS MICROBIOL, V17, P54, DOI 10.1016/j.tim.2008.11.004
   Sharma SD, 2010, INDIAN J MED RES, V131, P17
   Sinai AP, 1997, J CELL SCI, V110, P2117
   Sinha B, 2010, INT J MED MICROBIOL, V300, P170, DOI 10.1016/j.ijmm.2009.08.019
   Stavru F, 2011, P NATL ACAD SCI USA, V108, P3612, DOI 10.1073/pnas.1100126108
   Thaver D, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1865
   THEIROT JA, 1995, ANNU REV CELL DEV BI, V11, P213
   Tilney LG, 2001, J CELL SCI, V114, P4637
   Trebichavsky I, 2010, FOLIA MICROBIOL, V55, P295, DOI 10.1007/s12223-010-0044-3
   Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003
   Vazquez E, 2010, BIOMATERIALS, V31, P9333, DOI 10.1016/j.biomaterials.2010.08.065
   Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
   Wan XJ, 2010, LANGMUIR, V26, P15574, DOI 10.1021/la102148x
   Wang GH, 2004, INT J PHARM, V273, P203, DOI 10.1016/j.ijpharm.2004.01.010
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   Waters L, 2007, INT J CLIN PRACT, V61, P983, DOI 10.1111/j.1742-1241.2007.01383.x
   Watson KG, 2010, CELL MICROBIOL, V12, P1389, DOI 10.1111/j.1462-5822.2010.01511.x
   Welliver RC, 2010, CURR OPIN PHARMACOL, V10, P289, DOI 10.1016/j.coph.2010.04.013
   World Health Organization, 2009, GLOB SUMM AIDS EP 20
   Wilson SS, 2009, EXPERT REV ANTI-INFE, V7, P559, DOI 10.1586/ERI.09.34
   Wohl David Alain, 2010, Curr HIV/AIDS Rep, V7, P77, DOI 10.1007/s11904-010-0040-x
   Woodford N, 2009, J INFECTION, V59, pS4, DOI 10.1016/S0163-4453(09)60003-7
   Xiao RZ, 2010, INT J NANOMED, V5, P1057, DOI [10.2147/IJN.S14912, 10.2147/ijn.S14912]
   Yan Y, 2010, ACS NANO, V4, P2928, DOI 10.1021/nn100173h
   Yu CI, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/548280
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhang XL, 2008, CELL MOL IMMUNOL, V5, P91, DOI 10.1038/cmi.2008.11
   Zolopa AR, 2010, ANTIVIR RES, V85, P241, DOI 10.1016/j.antiviral.2009.10.018
NR 139
TC 42
Z9 43
U1 0
U2 20
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2011
VL 6
BP 3281
EP 3293
DI 10.2147/IJN.S27285
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 863LK
UT WOS:000298165300001
PM 22228996
OA gold
DA 2018-01-05
ER

PT J
AU Balkundi, S
   Nowacek, AS
   Veerubhotla, RS
   Chen, H
   Martinez-Skinner, A
   Roy, U
   Mosley, RL
   Kanmogne, G
   Liu, XM
   Kabanov, AV
   Bronich, T
   McMillan, J
   Gendelman, HE
AF Balkundi, Shantanu
   Nowacek, Ari S.
   Veerubhotla, Ram S.
   Chen, Han
   Martinez-Skinner, Andrea
   Roy, Upal
   Mosley, R. Lee
   Kanmogne, Georgette
   Liu, Xinming
   Kabanov, Alexander V.
   Bronich, Tatiana
   McMillan, JoEllyn
   Gendelman, Howard E.
TI Comparative manufacture and cell-based delivery of antiretroviral
   nanoformulations
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE human immunodeficiency virus type one; nanotoxicology; monocyte-derived
   macrophage; nanoformulated antiretroviral therapy; manufacturing
   techniques
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY; HIV-INFECTION; VIROLOGICAL
   RESPONSE; PLGA NANOPARTICLES; THERAPY; RELEASE; NANOSUSPENSIONS;
   REPLICATION; MACROPHAGES
AB Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were manufactured by wet milling, homogenization or sonication with a variety of excipients. The chemical, biological, immune, virological, and toxicological properties of these formulations were compared using an established monocyte-derived macrophage scoring indicator system. Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated differences amongst preparation methods. Interestingly, for drug cell targeting and antiretroviral responses the most significant difference among the particles was the drug itself. We posit that the choice of drug and formulation composition may ultimately affect clinical utility.
C1 [Balkundi, Shantanu; Nowacek, Ari S.; Veerubhotla, Ram S.; Martinez-Skinner, Andrea; Roy, Upal; Mosley, R. Lee; Kanmogne, Georgette; Liu, Xinming; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Chen, Han] Univ Nebraska, Ctr Biotechnol, Lincoln, NE USA.
   [Mosley, R. Lee; Liu, Xinming; Kabanov, Alexander V.; Bronich, Tatiana; Gendelman, Howard E.] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE 68198 USA.
   [Liu, Xinming; Kabanov, Alexander V.; Bronich, Tatiana] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Roy, Upal/0000-0002-0325-567X
FU National Institutes of Health [1P01 DA028555, 2R01 NS034239, 2R37
   NS36126, P01 NS31492, P20RR 15635, P01MH64570, 5P20 RR021937, P01
   NS43985]; Baxter Healthcare
FX The work was supported by the National Institutes of Health grants 1P01
   DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635,
   P01MH64570, 5P20 RR021937 (AVK), and P01 NS43985 (HEG) and from a
   research grant from Baxter Healthcare. The authors thank Alec Anderson,
   Landon Ehlers, Yudong Li, and Nathan Smith for their expert technical
   assistance. The authors would also like to thank Dr You Zhou of the
   University of Nebraska-Lincoln electron microscopy core facility for
   supplying the scanning electron microscopy images.
CR Alos L, 2005, MODERN PATHOL, V18, P127, DOI 10.1038/modpathol.3800267
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bressani R. F., 2010, NANOTOXICOLOGY, V5, P592
   Corrias Francesco, 2011, Recent Pat Drug Deliv Formul, V5, P201
   Deeks ED, 2010, DRUGS, V70, P2315, DOI 10.2165/11203800-000000000-00000
   Delaugerre C, 2005, J MED VIROL, V77, P345, DOI 10.1002/jmv.20462
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duval X, 2004, HIV MED, V5, P307, DOI 10.1111/j.1468-1293.2004.00226.x                                                
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Haas DW, 2004, AIDS, V18, P2391
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99
   Kadiu I, 2011, NANOMEDICINE, V6, P25
   KALTER DC, 1991, J IMMUNOL, V146, P298
   Mainardes RM, 2005, INT J PHARM, V290, P137, DOI 10.1016/j.ijpharm.2004.11.027
   Martins S, 2008, CURR MED CHEM, V15, P1083, DOI 10.2174/092986708784221467                                                      
   Murray JL, 2005, J VIROL, V79, P11742, DOI 10.1128/JVI.79.18.11742-11751.2005
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Nakarani Mahendra, 2010, Sci Pharm, V78, P345, DOI 10.3797/scipharm.0908-12
   Niwa T, 2011, INT J PHARMACEUT, V405, P218, DOI 10.1016/j.ijpharm.2010.12.013
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1
   Shegokar R, 2011, NANOMED-NANOTECHNOL, V7, P333, DOI 10.1016/j.nano.2010.10.012
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Swindells S, 2006, JAMA-J AM MED ASSOC, V296, P806, DOI 10.1001/jama.296.7.806                                                          
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Takatsuka T, 2009, CHEM PHARM BULL, V57, P1061, DOI 10.1248/cpb.57.1061                                                             
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x
NR 39
TC 28
Z9 28
U1 1
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2011
VL 6
BP 3393
EP 3404
DI 10.2147/IJN.S27830
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 877FR
UT WOS:000299163200001
PM 22267924
OA gold
DA 2018-01-05
ER

PT J
AU Khawaja, AM
AF Khawaja, Ayaz Mahmood
TI The legacy of nanotechnology: Revolution and prospects in neurosurgery
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Review
DE Nanotechnology; Neurosurgery; Alzheimer's disease; HIV; Glioblastoma
   multiforme; Encephalopathy; Nanoparticles; Brain; Brain implants;
   Fullerenes; Nanowires; Thermotherapy; Photodynamic therapy; Quantum dots
ID BLOOD-BRAIN-BARRIER; IRON-OXIDE NANOPARTICLES; LOW-DENSITY-LIPOPROTEIN;
   NINCDS-ADRDA CRITERIA; DRUG-DELIVERY VEHICLE; GLIOBLASTOMA-MULTIFORME;
   ALZHEIMERS-DISEASE; NEUROPROTECTIVE AGENTS; PARTICLE-SIZE; IN-VIVO
AB Nanotechnology has been an ever-growing field since the discovery of carbon fullerenes, and is being assimilated progressively into a variety of other disciplines including medical science. The association with neurosurgery had initially been less well characterized compared to other organ systems, but has recently offered promising future potential for a wide range of utilities including new therapeutic options for Glioblastoma Multiforme, neurprotection against oxidative stress, nerve nanorepair, nanodiagnosis of Alzheimer's disease, nanoimaging with nanoparticles and quantum dots, nanomanipulation of CNS with surgical nanobots, and nanoneuromodulation with nanofibres & nanowires. This article examines such potentials as well as others, of the utility of nanotechnology in Neurosurgery. (C) 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
C1 [Khawaja, Ayaz Mahmood] King Edward Med Univ, Mayo Hosp, Lahore, Pakistan.
RP Khawaja, AM (reprint author), House 43-B,Block B-3,Gulberg 3, Lahore, Pakistan.
EM dr.ayazmk@yahoo.com
CR Albayrak B, 2004, ACTA NEUROCHIR, V146, P543, DOI 10.1007/s00701-004-0229-0
   Anderson P, 2008, SURGERY, V143, P723
   Artemov D, 2003, MAGNET RESON MED, V49, P403, DOI 10.1002/mrm.10406
   Azzazy HME, 2006, CLIN CHEM, V52, P1238, DOI 10.1373/clinchem.2006.066654
   Baek SK, 2011, J NEURO-ONCOL, V104, P439, DOI 10.1007/s11060-010-0511-3
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bennett KM, 2008, MAGN RESON MED, V60, P564, DOI 10.1002/mrm.21684
   Beric A, 2001, STEREOT FUNCT NEUROS, V77, P73, DOI 10.1159/000064600
   BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573                                                              
   Chang WC, 2008, NEUROL RES, V30, P1053, DOI 10.1179/174313208X362532
   Chung SW, 2005, SMALL, V1, P64, DOI 10.1002/smll.200400005
   Ciofani G, 2009, NANOSCALE RES LETT, V4, P113, DOI 10.1007/s11671-008-9210-9
   De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   DOUGLAS SJ, 1984, J COLLOID INTERF SCI, V101, P149, DOI 10.1016/0021-9797(84)90015-8                                                    
   Drexler E., 2004, B SCI TECHNOL SOC, V24, P21, DOI DOI 10.1177/0270467604263113
   Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Ecker JL, 1997, OBSTET GYNECOL, V89, P643, DOI 10.1016/S0029-7844(97)00007-0                                                   
   Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103
   Evers S, 2004, AIDS RES HUM RETROV, V20, P483, DOI 10.1089/088922204323087723
   Fujita M, 2007, J CONTROL RELEASE, V122, P356, DOI 10.1016/j.jconrel.2007.05.032
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   Gray F, 2001, CLIN NEUROPATHOL, V20, P146
   Gunaseelan S, 2009, ADV DRUG DELIVERY RE
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Husain SR, 2003, J NEURO-ONCOL, V65, P37, DOI 10.1023/A:1026242432647                                                         
   Jackson H, 2007, NEUROSURGERY, V60, P524, DOI 10.1227/01.NEU.0000255334.95532.DD
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F
   KIMBLE DP, 1986, BRAIN RES, V363, P358, DOI 10.1016/0006-8993(86)91023-1
   Kircher MF, 2003, CANCER RES, V63, P8122
   Kirson ED, 2000, J NEUROSCI METH, V98, P119, DOI 10.1016/S0165-0270(00)00194-1
   Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5
   Kong G, 2000, CANCER RES, V60, P4440
   Krex D, 2007, BRAIN, V130, P2596, DOI 10.1093/brain/awm204
   Kupsch A, 1999, J MOL MED-JMM, V77, P178, DOI 10.1007/s001090050332
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190                                                      
   Lacroix M, 2001, J NEUROSURGERY PEDIA, V95
   Lawson HC, 2007, J NEURO-ONCOL, V83, P61, DOI 10.1007/s11060-006-9303-1
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481                                                           
   Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008-5472.CAN-06-2354
   Maier-Hauff K, 2007, J NEURO-ONCOL, V81, P53, DOI 10.1007/s11060-006-9195-0
   Matsumoto I, 2010, INTERACT CARDIOV TH, V10, P498, DOI 10.1510/icvts.2009.227744
   McConathy WJ, 2008, ANTI-CANCER DRUG, V19, P183, DOI 10.1097/CAD.0b013e3282f1da86
   McKenzie JL, 2004, BIOMATERIALS, V25, P1309, DOI 10.1016/j.biomaterials.2003.08.006
   Neuwelt EA, 2004, NEUROPATH APPL NEURO, V30, P456, DOI 10.1111/j.1365-2990.2004.00557.x
   Nikanjam M, 2007, INT J PHARM, V328, P86, DOI 10.1016/j.ijpharm.2006.07.046
   Nikanjarn M, 2007, J CONTROL RELEASE, V124, P163, DOI 10.1016/j.jconrel.2007.09.007
   OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624                                                              
   Orringer DA, 2009, CLIN PHARMACOL THER, V85, P531, DOI 10.1038/clpt.2008.296
   Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P5, DOI 10.1016/S1359-6446(01)02082-7                                                   
   PARDRIDGE WM, 1995, ADV DRUG DELIVER REV, V15, P5, DOI 10.1016/0169-409X(95)00003-P
   Reddy GR, 2006, CLIN CANCER RES, V12, P6677, DOI 10.1158/1078-0432.CCR-06-0946
   Reza V, 2009, OPHTHALMOLOGY, V116, P585
   Roberts A, 2005, INT J SURG, V3, P243
   Sacktor NC, 2000, J NEUROVIROL, V6, P84, DOI 10.3109/13550280009006385                                                       
   Saini Rajiv, 2010, Surg Neurol Int, V1, P57, DOI 10.4103/2152-7806.69384
   Santos SICO, 2010, OPT EXPRESS, V18, P364, DOI 10.1364/OE.18.000364
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Serkova NJ, 2010, RADIOLOGY, V255, P517, DOI 10.1148/radiol.09091134
   Shao TT, 2009, J OCUL PHARMACOL TH, V25, P499, DOI 10.1089/jop.2009.0042
   Shultz MD, 2010, J AM CHEM SOC, V132, P4980, DOI 10.1021/ja9093617
   Silva GA, 2004, SURG NEUROL, V61, P216, DOI 10.1016/j.surneu.2003.09.036
   Smith JS, 2005, J NEUROSURG, V103, P428, DOI 10.3171/jns.2005.103.3.0428
   Sretavan DW, 2005, NEUROSURGERY, V57, P635, DOI 10.1227/01.NEU.0000175545.57795.ac
   Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384
   Takasawa K, 1997, J PHARMACOL EXP THER, V281, P369
   Tamai I, 2000, J PHARM SCI, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D
   Taniguchi N., 1974, P INT C PROD ENG 2
   Varma AR, 1999, J NEUROL NEUROSUR PS, V66, P184, DOI 10.1136/jnnp.66.2.184                                                           
   Veiseh O, 2005, NANO LETT, V5, P1003, DOI 10.1021/nl0502569
   Wang K, 2003, INVEST OPHTH VIS SCI, V44, pU702
   Yanase M, 1998, JPN J CANCER RES, V89, P463, DOI 10.1111/j.1349-7006.1998.tb00586.x                                              
   Yanik MF, 2004, NATURE, V432, P822, DOI 10.1038/432822a
   YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531                                                         
NR 79
TC 8
Z9 8
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PY 2011
VL 9
IS 8
BP 608
EP 614
DI 10.1016/j.ijsu.2011.10.002
PG 7
WC Surgery
SC Surgery
GA 890TJ
UT WOS:000300167800006
PM 22027280
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, JA
   Fu, Y
   Li, G
   Zhao, RY
   Lakowicz, JR
AF Zhang, Jian
   Fu, Yi
   Li, Ge
   Zhao, Richard Y.
   Lakowicz, Joseph R.
TI Detection of CXCR4 receptors on cell surface using a fluorescent metal
   nanoshell
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE chemokine receptor 4 (CXCR4); anti-CXCR4 monoclonal antibody (mAb);
   T-lymphocytic CEM-SS cell; metal nanoshell; Ru(bpy)(3)(2+) complex;
   fluorescence cell image; single molecule count
ID LABELED SILVER NANOSHELL; CD4(+) CELLS; CANCER; PROBE; NANOSTRUCTURES;
   NANOPARTICLES; EMISSION; PARTICLE; BIOLOGY; HIV-1
AB Fluorescence cell imaging can be used for disease diagnosis and cellular signal transduction. Using a metal nanoshell as molecular imaging agent, we develop a cellular model system to detect CXCR4 chemokine receptor on T-lymphatic cell surface. These metal nanoshells are observed to express enhanced emission intensity and shortened lifetimes due to the near-field interactions. They are covalently bound with anti-CXCR4 monoclonal antibodies for immunoreactions with the target sites of the CXCR4 receptors on the CEM-SS cells. The fluorescence intensity and lifetime cell images are recorded with a time-resolved confocal microscopy. As expected, the emission signals from the metal nanoshells are clearly isolated from the cellular autofluorescence due to strong intensities and distinctive lifetimes. The number of emission spots on the single cell image is estimated by direct count to the emission signals. Analyzing a pool of cell images, a maximal count number is obtained in a range of 200 +/- 50. Because there is an average of similar to 6000 binding sites on the cell surface, we estimate that one emission spot from the metal nanoshell may represent similar to 30 CXCR5 receptors. In addition, the CXCR4 receptors are estimated to distribute on similar to 70% area of the cell surface. (C) 2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3528623]
C1 [Zhang, Jian; Fu, Yi; Lakowicz, Joseph R.] Univ Maryland, Sch Med, Ctr Fluorescence Spect, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
   [Li, Ge; Zhao, Richard Y.] Univ Maryland, Sch Med, Div Mol Pathol, Dept Pathol, Baltimore, MD 21201 USA.
   [Zhao, Richard Y.] Univ Maryland, Sch Med, Dept Microbiol Immunol, Baltimore, MD 21201 USA.
   [Zhao, Richard Y.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
RP Zhang, JA (reprint author), Univ Maryland, Sch Med, Ctr Fluorescence Spect, Dept Biochem & Mol Biol, 725 W Lombard St, Baltimore, MD 21201 USA.
EM jian@cfs.biomet.umaryland.edu
FU NIH [EB009509, HG-002655, HG005090, EB006521, CA134386]
FX The authors thank the NIH AIDS Research and Reference Reagent Program
   for providing the anti-CXCR4 mAbs. This research was supported in part
   by grants from NIH (EB009509, HG-002655, HG005090, EB006521, and
   CA134386).
CR Agrawal L, 2004, J VIROL, V78, P2277, DOI 10.1128/JVI.78.5.2277-2287.2004
   Bacon K, 2002, J INTERF CYTOK RES, V22, P1067
   Baleux F, 2009, NAT CHEM BIOL, V5, P743, DOI 10.1038/nchembio.207
   Bardhan R, 2009, ACS NANO, V3, P744, DOI 10.1021/nn900001q
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Enderlein J, 2002, APPL PHYS LETT, V80, P315, DOI 10.1063/1.1434314
   Fang XH, 2010, ACCOUNTS CHEM RES, V43, P48, DOI 10.1021/ar900101s
   Grivel JC, 1999, NAT MED, V5, P344, DOI 10.1038/6565                                                                    
   Hao E, 2004, J PHYS CHEM B, V108, P1224, DOI 10.1021/jp036301n
   Huang XY, 1996, ANAL CHEM, V68, P4119, DOI 10.1021/ac960587t
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Kamat PV, 2002, J PHYS CHEM B, V106, P7729, DOI 10.1021/jp0209289
   Lakowicz JR, 2001, ANAL BIOCHEM, V298, P1, DOI 10.1006/abio.2001.5377
   Lakowicz JR, 2005, ANAL BIOCHEM, V337, P171, DOI 10.1016/j.ab.2004.11.026
   LAKOWICZ JR, 2006, PRINCIPLES FLUORESCE, pCH8, DOI DOI 10.1007/978-0-387-46312-4
   Lassiter JB, 2009, NANO LETT, V9, P4326, DOI 10.1021/nl9025665
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Levine B, 2006, J CLIN INVEST, V116, P2078, DOI 10.1172/JCI29447
   Licha K, 2000, PHOTOCHEM PHOTOBIOL, V72, P392, DOI 10.1562/0031-8655(2000)072<0392:HCDACA>2.0.CO;2
   Mahmood U, 2003, MOL CANCER THER, V2, P489
   Nakanishi J, 2001, ANAL CHEM, V73, P2920, DOI 10.1021/ac001528p
   Ntziachristos V, 2001, BREAST CANCER RES, V3, P41, DOI 10.1186/bcr269
   Olson TY, 2008, J PHYS CHEM C, V112, P6319, DOI 10.1021/jp7116714
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Tchou I, 2001, J LEUKOCYTE BIOL, V70, P313
   Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933                                                                    
   YUAN F, 1995, CANCER RES, V55, P3752
   Zhang J, 2006, J PHYS CHEM B, V110, P8986, DOI 10.1021/jp057032z
   Zhang J, 2008, NANO LETT, V8, P1179, DOI 10.1021/nl080093z
   Zhang JA, 2007, J PHYS CHEM C, V111, P1955, DOI 10.1021/jp063996u
   Zhang J, 2010, ANAL CHEM, V82, P4464, DOI 10.1021/ac100241f
   Zhang J, 2009, J PHYS CHEM C, V113, P19404, DOI 10.1021/jp906742q
   Zhang J, 2009, ANAL CHEM, V81, P883, DOI 10.1021/ac801932m
NR 35
TC 7
Z9 7
U1 1
U2 10
PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JAN
PY 2011
VL 16
IS 1
AR 016011
DI 10.1117/1.3528623
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 725HW
UT WOS:000287636800029
PM 21280917
OA gold
DA 2018-01-05
ER

PT J
AU Dodiya, SS
   Chavhan, SS
   Sawant, KK
   Korde, AG
AF Dodiya, Shamsunder S.
   Chavhan, Sandip S.
   Sawant, Krutika K.
   Korde, Aruna G.
TI Solid lipid nanoparticles and nanosuspension formulation of Saquinavir:
   preparation, characterization, pharmacokinetics and biodistribution
   studies
SO JOURNAL OF MICROENCAPSULATION
LA English
DT Article
DE bioavailability; saturation solubility; solid-state studies; particle
   size
ID ORAL BIOAVAILABILITY; RATIONAL DESIGN; HIV PROTEINASE; DRUG-DELIVERY;
   INHIBITORS; STABILITY; INFECTION; TRANSPORT; IMPROVE; RATS
AB Solid lipid nanoparticles (SLNs) and nanosuspensions (NSs) have shown great promise for improving bioavailability of poorly water-soluble drugs. This study was aimed to develop SLNs and NS of Saquinavir (SQ) for improvement in bioavailability. These formulations were characterized and their pharmacokinetics and biodistribution in mice were evaluated. Saquinavir-loaded SLNs (SQSLNs) showed particle size 215 +/- 9nm and entrapment efficiency 79.24 +/- 1.53%, while solid-state studies (differential scanning calorimetry and X-ray diffraction) indicated entrapment of the drug in SLNs. Saquinavir NS (SNS) showed particle size 344 +/- 16nm with fourfold increase in saturation solubility and its solid-state studies showed reduction in crystallinity. Pharmacokinetics and biodistribution studies of orally administered SQSLN and SNS in mice exhibited higher plasma level concentration compared to saquinavir microsuspension (SMS). The relative bioavailabilities for SNS and SQSLN were 37.39% and 66.53%, respectively, compared to 18.87% bioavailability obtained after administration of SMS, indicating suitability of nanoparticulate formulations for improving bioavailability.
C1 [Dodiya, Shamsunder S.; Chavhan, Sandip S.; Sawant, Krutika K.] Maharaja Sayajirao Univ Baroda, Drug Delivery Lab, TIFAC Ctr Relevance & Excellence NDDS, Dept Pharm,Fac Technol & Engn, Vadodara 390002, Gujarat, India.
   [Korde, Aruna G.] Bhabha Atom Res Ctr, Radiopharmaceut Div, Bombay 400085, Maharashtra, India.
RP Sawant, KK (reprint author), Maharaja Sayajirao Univ Baroda, Dept Pharm, Vadodara 390001, Gujarat, India.
EM dr_krutikasawant@rediffmail.com
FU Indian Council for Medical research (ICMR), New Delhi
FX The authors thank Dr Meera Venkatesh, Head, Radiopharmaceutical
   Division, Bhabha Atomic Research Centre, Mumbai for providing the
   facilities to carry out the radiolabelling studies. Mr Shamsunder Dodiya
   thanks Indian Council for Medical research (ICMR), New Delhi, for
   providing Senior Research Fellowship.
CR Agueros M, 2010, J CONTROL RELEASE, V145, P2, DOI 10.1016/j.jconrel.2010.03.012
   Arulsudar N, 2003, J DRUG TARGET, V11, P187, DOI 10.1080/10611860310001615415
   Briesen H., 2000, AIDS REV, V2, P31
   Cavalli R, 1998, PHARMAZIE, V53, P392
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S
   DUPRE J, 1995, DIABETES, V44, P626, DOI 10.2337/diabetes.44.6.626
   Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5
   GRANT DJW, 1995, PHYSICAL CHARACTERIZ, P322
   Hu LD, 2004, J PHARM PHARMACOL, V56, P1527, DOI 10.1211/0022357044959
   Irache G, 1998, ADV DRUG DELIV REV, V34, P191
   JANI P, 1989, J PHARM PHARMACOL, V41, P809, DOI 10.1111/j.2042-7158.1989.tb06377.x                                              
   KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Lai F., 2006, AAPS PHARMSCITECH, V7, pE1
   Li YQ, 2006, PHARM RES, V23, P1877, DOI 10.1007/s11095-006-9033-2
   MAINCENT P, 1992, PHARMACEUT RES, V9, P1534, DOI 10.1023/A:1015895804597
   Manjunath K, 2005, J CONTROL RELEASE, V107, P215, DOI 10.1016/j.jconrel.2005.06.006
   Mathot F, 2006, J CONTROL RELEASE, V111, P47, DOI 10.1016/j.conrel.2005.11.012
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   OTSUKA M, 1986, J PHARM SCI, V75, P506, DOI 10.1002/jps.2600750517                                                          
   Palla BJ, 2002, J COLLOID INTERF SCI, V256, P143, DOI 10.1006/jcis.2002.8648
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Harivardhan R. L., 2005, AAPS PHARMSCITECH, V6, P158
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   Sawant Krutika K, 2008, Recent Pat Drug Deliv Formul, V2, P120, DOI 10.2174/187221108784534081
   Shin SC, 2000, INT J PHARM, V209, P37, DOI 10.1016/S0378-5173(00)00542-1                                                   
   Sigfridsson K, 2007, EUR J PHARM BIOPHARM, V67, P540, DOI 10.1016/j.ejpb.2007.02.008
   Smith A, 2010, INT J PHARMACEUT, V389, P207, DOI 10.1016/j.ijpharm.2010.01.012
   Su YM, 2004, DRUG METAB REV, V36, P377, DOI 10.1081/DMR-120037570
   Taburet AM, 2003, CLIN PHARMACOKINET, V42, P1179, DOI 10.2165/00003088-200342140-00001                                                
   Tsai YM, 2011, FOOD CHEM, V127, P918, DOI 10.1016/j.foodchem.2011.01.059
   Venkataraju M. P., 2008, CURRENT DRUG THERAPY, V3, P70
   Vivek K, 2007, AAPS PHARMSCITECH, V8, pE1
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   WU MS, 1981, BIOCHIM BIOPHYS ACTA, V674, P19, DOI 10.1016/0304-4165(81)90342-1                                                    
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
NR 39
TC 22
Z9 22
U1 1
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0265-2048
J9 J MICROENCAPSUL
JI J. Microencapsul.
PY 2011
VL 28
IS 6
BP 515
EP 527
DI 10.3109/02652048.2011.590612
PG 13
WC Chemistry, Applied; Engineering, Chemical; Pharmacology & Pharmacy
SC Chemistry; Engineering; Pharmacology & Pharmacy
GA 805QS
UT WOS:000293744700007
PM 21728760
DA 2018-01-05
ER

PT J
AU Kumar, A
   Boruah, BM
   Liang, XJ
AF Kumar, Anil
   Boruah, Bhargavi Mazinder
   Liang, Xing-Jie
TI Gold Nanoparticles: Promising Nanomaterials for the Diagnosis of Cancer
   and HIV/AIDS
SO JOURNAL OF NANOMATERIALS
LA English
DT Review
ID SURFACE-PLASMON RESONANCE; POLY(BETA-AMINO ESTER) NANOPARTICLES;
   MOLECULARLY IMPRINTED POLYMER; ENHANCED RAMAN-SCATTERING; TUMOR-TARGETED
   DELIVERY; PH-SENSITIVE SYSTEM; IN-VIVO; OPTICAL-PROPERTIES; CONTRAST
   AGENTS; LUNG-CANCER
AB Gold nanoparticles (AuNPs) are currently playing a significant role for human welfare in the field of clinical diagnosis as well as several biomedical applications. More and more research shows that AuNPs-based technologies are becoming promising approaches in cancer research and AIDS treatment. In this paper, we have focused mainly on the exploitation of unique and characteristic properties of AuNPs such as surface plasmon resonance (SPR), surface enhance Raman scattering (SERS), magnetic properties (MRI), and fluorescence behavior shown upon conjugation with biological and biocompatible ligands. These properties find wide prevalence in biodiagnostics like plasmon-based labeling and imaging, enzyme-linked immunosorbant assay (ELISA), and electrochemical-based methods that can pave the way for developing novel techniques towards diagnosis and therapy of cancer and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS).
C1 [Kumar, Anil; Liang, Xing-Jie] Chinese Acad Sci, Natl Ctr Nanosci & Nanotechnol, CAS Key Lab Biomed Effects Nanoparticles & Nanosa, Beijing 100190, Peoples R China.
   [Boruah, Bhargavi Mazinder] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
RP Liang, XJ (reprint author), Chinese Acad Sci, Natl Ctr Nanosci & Nanotechnol, CAS Key Lab Biomed Effects Nanoparticles & Nanosa, Beijing 100190, Peoples R China.
EM liangxj@nanoctr.cn
FU Chinese Natural Science Foundation [30970784]; National Key Basic
   Research Program of China [2009CB930200]; Chinese Academy of Sciences
   (CAS) [07165111ZX]
FX This work was supported in part by Chinese Natural Science Foundation
   project (no. 30970784), National Key Basic Research Program of China
   (2009CB930200), Chinese Academy of Sciences (CAS) "Hundred Talents
   Program" (07165111ZX), and CAS Knowledge Innovation Program.
CR Agarwal A., 2007, J APPL PHYS, V102
   Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927
   Alric C, 2008, GOLD BULL, V41, P90, DOI 10.1007/BF03216586                                                              
   Alric C, 2008, J AM CHEM SOC, V130, P5908, DOI 10.1021/ja078176p
   *AM CANC SOC RES, 2010, CANC FACT FIG HLTH P
   Ambrosi A, 2010, ANAL CHEM, V82, P1151, DOI 10.1021/ac902492c
   Baptista P, 2008, ANAL BIOANAL CHEM, V391, P943, DOI 10.1007/s00216-007-1768-z
   BAUDHUIN P, 1989, COLLOIDAL GOLD PRINC, V2, P1
   Bich C, 2008, ANAL BIOCHEM, V375, P35, DOI 10.1016/j.ab.2007.11.016
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a
   Chah S, 2005, CHEM BIOL, V12, P323, DOI 10.1016/j.chembiol.2005.01.013
   Chen HX, 2010, SENSOR ACTUAT B-CHEM, V147, P548, DOI 10.1016/j.snb.2010.03.033
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Cheow LF, 2010, ANAL CHEM, V82, P3383, DOI 10.1021/ac9024335
   Cho SJ, 2006, NANOTECHNOLOGY, V17, P640, DOI 10.1088/0957-4484/17/3/004
   Choi YE, 2010, SENSORS-BASEL, V10, P428, DOI 10.3390/s100100428
   Chon H, 2009, ANAL CHEM, V81, P3029, DOI 10.1021/ac802722c
   CUI DX, 2008, CHEMISTRY, V3, P2010
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Darbha GK, 2008, CHEM-EUR J, V14, P3896, DOI 10.1002/chem.200701850
   Devalapally H, 2007, CANCER CHEMOTH PHARM, V59, P477, DOI 10.1007/s00280-006-0287-5
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Durr NJ, 2007, NANO LETT, V7, P941, DOI 10.1021/nl062962v
   Eck W, 2008, ACS NANO, V2, P2263, DOI 10.1021/nn800429d
   Eghtedari M, 2009, NANO LETT, V9, P287, DOI 10.1021/nl802915q
   El-Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e
   Endo M, 2010, J AM CHEM SOC, V132, P1592, DOI 10.1021/ja907649w
   Englebienne P, 2003, SPECTROSC-INT J, V17, P255, DOI 10.1155/2003/372913                                                             
   Englebienne P, 2000, IMMUNE RECEPTOR ASSA
   Fang ZC, 2009, ACS NANO, V3, P3207, DOI 10.1021/nn900733d
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ginger DS, 2004, ANGEW CHEM INT EDIT, V43, P30, DOI 10.1002/anie.200300608
   Hahn MA, 2011, ANAL BIOANAL CHEM, V399, P3, DOI 10.1007/s00216-010-4207-5
   Hall WP, 2011, J PHYS CHEM C, V115, P1410, DOI 10.1021/jp106912p
   He F, 2009, TALANTA, V77, P1009, DOI 10.1016/j.talanta.2008.07.063
   He H, 2008, ANAL CHEM, V80, P5951, DOI 10.1021/ac8005796
   Ho JAA, 2010, ANAL CHEM, V82, P5944, DOI 10.1021/ac1001959
   Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h                                                                
   Huang HZ, 2008, SENSOR ACTUAT B-CHEM, V131, P417, DOI 10.1016/j.snb.2007.11.050
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c
   Iwasaki Y, 2001, ANAL CHEM, V73, P1595, DOI 10.1021/ac0012851
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jin RC, 2003, NATURE, V425, P487, DOI 10.1038/nature02020
   Johne B, 1998, MOL BIOTECHNOL, V9, P65, DOI 10.1007/BF02752698
   Jordan CE, 1997, ANAL CHEM, V69, P4939, DOI 10.1021/ac9709763                                                               
   Kaganer E, 1999, LANGMUIR, V15, P3920, DOI 10.1021/la981147v                                                               
   Kah JCY, 2007, INT J NANOMED, V2, P785
   Kang JH, 2010, BIOSENS BIOELECTRON, V25, P1869, DOI 10.1016/j.bios.2009.12.022
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kenseth JR, 2001, LANGMUIR, V17, P4105, DOI 10.1021/la0100744
   Kneipp K, 2006, ACCOUNTS CHEM RES, V39, P443, DOI 10.1021/ar050107x
   Kugimiya A, 2001, BIOSENS BIOELECTRON, V16, P1059, DOI 10.1016/S0956-5663(01)00227-5                                                   
   Kumagai M, 2010, MACROMOL RAPID COMM, V31, P1521, DOI 10.1002/marc.201000341
   Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g
   Lee H, 2009, ADV FUNCT MATER, V19, P1884, DOI 10.1002/adfm.200801838
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Lee KS, 2005, J PHYS CHEM B, V109, P20331, DOI 10.1021/jp054385p
   Lee K, 2011, ACS NANO, V5, P2109, DOI 10.1021/nn1030862
   Lee SB, 2007, NANOMEDICINE-UK, V2, P647, DOI 10.2217/17435889.2.5.647
   Lee S, 2008, ANGEW CHEM INT EDIT, V47, P2804, DOI 10.1002/anie.200705240
   Li X, 2009, COLLOID SURFACE A, V332, P172, DOI 10.1016/j.colsurfa.2008.09.009
   Liang XJ, 2008, CURR DRUG METAB, V9, P697, DOI 10.2174/138920008786049230
   LIN AWH, 2005, J BIOMEDICAL OPTICS, V10
   Link S, 2005, J PHYS CHEM B, V109, P10531, DOI 10.1021/jp058091f
   Link S, 1999, J PHYS CHEM B, V103, P3073, DOI 10.1021/jp990183f
   Liu MZ, 2002, NANO LETT, V2, P863, DOI 10.1021/nl025626x
   Losurdo M, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.155451
   Lu WT, 2010, ACS NANO, V4, P1739, DOI 10.1021/nn901742q
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Coto-Garcia AM, 2011, ANAL BIOANAL CHEM, V399, P29, DOI 10.1007/s00216-010-4330-3
   Matsui J, 2005, ANAL CHEM, V77, P4282, DOI 10.1021/ac050227i
   Matsumoto K, 2005, TALANTA, V68, P305, DOI 10.1016/j.talanta.2005.08.054
   Mayilo S, 2009, NANO LETT, V9, P4558, DOI 10.1021/nl903178n
   Medina MB, 1997, J AGR FOOD CHEM, V45, P389, DOI 10.1021/jf960014h
   Medley CD, 2008, ANAL CHEM, V80, P1067, DOI 10.1021/ac702037y
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Moriggi L, 2009, J AM CHEM SOC, V131, P10828, DOI 10.1021/ja904094t
   Mullett WM, 2000, METHODS, V22, P77, DOI 10.1006/meth.2000.1039
   Nasiruzzaman S. M., 2010, B KOREAN CHEM SOC, V31, P1177
   Nelson BP, 2001, ANAL CHEM, V73, P1, DOI 10.1021/ac0010431
   Nishimura S, 2002, ANAL SCI, V18, P267, DOI 10.2116/analsci.18.267                                                          
   Njoki PN, 2007, J PHYS CHEM C, V111, P14664, DOI 10.1021/jp074902z
   Pellequer Y, 2009, NANOTHERAPEUTICS: DRUG DELIVERY CONCEPTS IN NANOSCIENCE, P93
   Peng G, 2009, NAT NANOTECHNOL, V4, P669, DOI 10.1038/nnano.2009.235
   Perez-Juste J, 2005, COORDIN CHEM REV, V249, P1870, DOI 10.1016/j.ccr.2005.01.030
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Rahman M, 2005, GYNECOL ONCOL, V99, pS112, DOI 10.1016/j.ygyno.2005.07.053
   Ray PC, 2007, PLASMONICS, V2, P173, DOI 10.1007/s11468-007-9036-9
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Sau TK, 2004, J AM CHEM SOC, V126, P8648, DOI 10.1021/ja047846d
   Sha MY, 2007, NANOMEDICINE-UK, V2, P725, DOI 10.2217/17435889.2.5.725
   Shankaran DR, 2007, J PHYS D APPL PHYS, V40, P7187, DOI 10.1088/0022-3727/40/23/S02
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Shi XG, 2007, SMALL, V3, P1245, DOI 10.1002/smll.200700054
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Soppimath KS, 2008, BIOMEDICAL NANOSTRUCTURES, P409
   Sosa IO, 2003, J PHYS CHEM B, V107, P6269, DOI 10.1021/jp0274076
   Spisak S, 2009, CURR MED CHEM, V16, P2806, DOI 10.2174/092986709788803141                                                      
   Sun IC, 2009, CHEM-EUR J, V15, P13341, DOI 10.1002/chem.200902344
   Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229
   Tang JF, 2009, DIAGN MICR INFEC DIS, V65, P372, DOI 10.1016/j.diagmicrobio.2009.07.017
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Thiel AJ, 1997, ANAL CHEM, V69, P4948, DOI 10.1021/ac9708001                                                               
   Tong L, 2009, PHOTOCHEM PHOTOBIOL, V85, P21, DOI 10.1111/j.1751-1097.2008.00507.x
   Towne V, 2004, ABSTR PAP AM CHEM S, V228, pU201
   Viator JA, 2010, J BIOMED NANOTECHNOL, V6, P187, DOI 10.1166/jbn.2010.1105
   Wadu-Mesthrige K, 1999, LANGMUIR, V15, P8580, DOI 10.1021/la991196n                                                               
   Wallnofer EA, 2011, INT J CLIN PHARM TH, V49, P73, DOI 10.5414/CPP49073
   Wang L. J., 2009, ACTA BIOPHYSICA SINI, V25, P168
   Wang X, 2011, CANCER RES, V71, P1526, DOI 10.1158/0008-5472.CAN-10-3069
   Wegner GJ, 2002, ANAL CHEM, V74, P5161, DOI 10.1021/ac025922u
   Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872
   Wilcoxon J, 2009, J PHYS CHEM B, V113, P2647, DOI 10.1021/jp806930t
   Wolf LK, 2007, J AM CHEM SOC, V129, P10503, DOI 10.1021/ja072401l
   Yang WC, 2010, LAB CHIP, V10, P2527, DOI 10.1039/c005288d
   You CC, 2007, NAT NANOTECHNOL, V2, P318, DOI 10.1038/nnano.2007.99
   Zhang C, 2002, ANAL CHEM, V74, P96, DOI 10.1021/ac.0103468
   Zhao W, 2008, CHEMBIOCHEM, V9, P2363, DOI 10.1002/cbic.200800282
   Zhou F, 2011, LANGMUIR, V27, P2155, DOI 10.1021/la1049937
   GOLD GOOD GOLD NANOT
NR 125
TC 20
Z9 20
U1 5
U2 91
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-4110
J9 J NANOMATER
JI J. Nanomater.
PY 2011
AR 202187
DI 10.1155/2011/202187
PG 17
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 866YQ
UT WOS:000298422500001
OA gold
DA 2018-01-05
ER

PT J
AU Wang, SP
   Tan, M
   Zhong, ZF
   Chen, MW
   Wang, YT
AF Wang, Shengpeng
   Tan, Miao
   Zhong, Zhangfeng
   Chen, Meiwan
   Wang, Yitao
TI Nanotechnologies for Curcumin: An Ancient Puzzler Meets Modern Solutions
SO JOURNAL OF NANOMATERIALS
LA English
DT Review
ID DRUG-DELIVERY SYSTEM; SOLID LIPID NANOPARTICLES; PROSTATE-CANCER CELLS;
   IN-VITRO; ORAL BIOAVAILABILITY; BETA-CYCLODEXTRIN; CELLULAR UPTAKE;
   FORMULATION; DISPERSION; MICELLES
AB Curcumin, a low-molecular-weight natural polyphenol mainly found in the plant Curcuma longa (turmeric), is widely used as a food colorant and as a potential protective agent against several chronic diseases including cancer, HIV-infection, neurological, cardiovascular, and skin diseases. Moreover, evidences from long-term use process and preclinical trials have demonstrated low toxicity of curcumin, even at relatively high doses. However, it has been well known that the application of curcumin was limited owing to its water insolubility, instability, and poor bioavailability. For decades, many attempts have been made to compensate for these disadvantages, with the development of improved delivery platforms as the feasible approaches. The past ten years witnessed the encouraging progress in the use of nanoscale drug delivery systems on curcumin such as loading curcumin into liposomes or nanoparticles, forming self-microemulsifying drug delivery systems (SMEDDS), cyclodextrin inclusions, and solid dispersions, as well as the latest reported technologies such as nadodisks and nanotubes. This paper summarizes the recent works on the design and development of nanoscale delivery systems of curcumin, with the goal of harnessing the true difficulties of thismultifunctional agent in the clinical arena.
C1 [Wang, Shengpeng; Tan, Miao; Zhong, Zhangfeng; Chen, Meiwan; Wang, Yitao] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa 999078, Macau, Peoples R China.
RP Chen, MW (reprint author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Av Padre Tomas Pereira SJ, Taipa 999078, Macau, Peoples R China.
EM chenmeiwan81@163.com; pktwhkmo@163.com
RI Wang, Yitao/O-5184-2016
FU University of Macau [MYRG 208 (Y1-L4)-ICMS11-WYT]
FX This study was supported by the Research Fund of the University of Macau
   (MYRG 208 (Y1-L4)-ICMS11-WYT).
CR Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Anand P, 2010, BIOCHEM PHARMACOL, V79, P330, DOI 10.1016/j.bcp.2009.09.003
   Anitha A, 2011, CARBOHYD POLYM, V83, P452, DOI 10.1016/j.carbpol.2010.08.008
   Barik A, 2007, EUR J MED CHEM, V42, P431, DOI 10.1016/j.ejmech.2006.11.012
   Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Bisht Savita, 2009, Curr Drug Discov Technol, V6, P192
   Caiju X., 2005, PHARM CLIN CHINESE M, V21, P36
   Carrier RL, 2007, J CONTROL RELEASE, V123, P78, DOI 10.1016/j.jconrel.2007.07.018
   Chen C, 2009, INT J PHARM, V366, P133, DOI 10.1016/j.ijpharm.2008.09.009
   CHIOU WL, 1971, J PHARM SCI-US, V60, P1281, DOI 10.1002/jps.2600600902                                                          
   Cortes J, 2010, EJC SUPPL, V8, P1, DOI 10.1016/S1359-6349(10)70002-1                                                   
   Cui J, 2009, INT J PHARM, V371, P148, DOI 10.1016/j.ijpharm.2008.12.009
   Das RK, 2010, NANOMED-NANOTECHNOL, V6, P153, DOI 10.1016/j.nano.2009.05.009
   Del Valle EMM, 2004, PROCESS BIOCHEM, V39, P1033, DOI 10.1016/S0032-9592(03)00258-9
   Ghosh M., 2010, NANOMEDICINE, V7, P162
   Gupta N. K., 2010, ARCH DERMATOLOGICAL, V303, P89
   Gupta V, 2009, INT J NANOMED, V4, P115
   [宏伟 HONG Wei], 2008, [中国中药杂志, China Journal of Chinese Materia Medica], V33, P889
   HUANG XW, 2008, CHINESE PHARMACOL B, V24, P1525
   Huh KM, 2005, J CONTROL RELEASE, V101, P59, DOI 10.1016/j.jconrel.2004.07.003
   Iwunze MO, 2004, J MOL LIQ, V111, P161, DOI 10.1016/j.molliq.2003.12.013
   JI L, 2009, BIOMEDICAL CHROMATOG, V23, P1201
   Jurenka JS, 2009, ALTERN MED REV, V14, P141
   Kakkar Vandita, 2011, Mol Nutr Food Res, V55, P495, DOI 10.1002/mnfr.201000310
   Kim TH, 2011, INT J PHARMACEUT, V403, P285, DOI 10.1016/j.ijpharm.2010.10.041
   Kunwar A, 2006, BBA-GEN SUBJECTS, V1760, P1513, DOI 10.1016/j.bbagen.2006.06.012
   Kwon GS, 1996, ADV DRUG DELIVER REV, V21, P107, DOI 10.1016/S0169-409X(96)00401-2
   Laza-Knoerr AL, 2010, J DRUG TARGET, V18, P645, DOI 10.3109/10611861003622552
   Leung MHM, 2008, LANGMUIR, V24, P5672, DOI 10.1021/la800780w
   Li DC, 2009, J CONTROL RELEASE, V138, P103, DOI 10.1016/j.jconrel.2009.05.008
   Li R, 2011, FOOD CHEM, V126, P1890, DOI 10.1016/j.foodchem.2010.12.014
   Liang Y., 2009, J TIANJIN U TECHNOLO, V25, P75
   Li-Chao Z., 2008, CHINESE J PHARM, V39, P905
   Lin CC, 2009, FOOD CHEM, V116, P923, DOI 10.1016/j.foodchem.2009.03.052
   Liu CH, 2011, COLLOID SURFACE B, V82, P63, DOI 10.1016/j.colsurfb.2010.08.018
   Ma ZS, 2008, J BIOMED MATER RES A, V86A, P300, DOI 10.1002/jbm.a.31584
   Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   Manju S, 2011, COLLOID SURFACE B, V82, P588, DOI 10.1016/j.colsurfb.2010.10.021
   Mei L., 2010, J FUJIAN MED U, V44, P178
   Mourtas S, 2011, BIOMATERIALS, V32, P1635, DOI 10.1016/j.biomaterials.2010.10.027
   Mukerjee A, 2009, ANTICANCER RES, V29, P3867
   Mulik R, 2009, EUR J PHARM SCI, V37, P395, DOI 10.1016/j.ejps.2009.03.009
   Mulik RS, 2010, INT J PHARMACEUT, V398, P190, DOI 10.1016/j.ijpharm.2010.07.021
   Onoue S, 2010, J PHARM SCI-US, V99, P1871, DOI 10.1002/jps.21964
   Paradkar A, 2004, INT J PHARM, V271, P281, DOI 10.1016/j.ijpharm.2003.11.014
   Paramera EI, 2011, FOOD CHEM, V125, P913, DOI 10.1016/j.foodchem.2010.09.071
   Pardeike J, 2009, INT J PHARM, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003
   Sahu A, 2008, ACTA BIOMATER, V4, P1752, DOI 10.1016/j.actbio.2008.04.021
   Setthacheewakul S, 2010, EUR J PHARM BIOPHARM, V76, P475, DOI 10.1016/j.ejpb.2010.07.011
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Song ZM, 2011, J COLLOID INTERF SCI, V354, P116, DOI 10.1016/j.jcis.2010.10.024
   Srivastava R. M., 2010, INT IMMUNOPHARMACOL, V11, P331
   Tang HD, 2010, BIOMATERIALS, V31, P7139, DOI 10.1016/j.biomaterials.2010.06.007
   Tayyem RR, 2006, NUTR CANCER, V55, P126, DOI 10.1207/s15327914nc5502_2
   Terreno E, 2008, CHEM BIODIVERS, V5, P1901, DOI 10.1002/cbdv.200890178
   Thangapazham RL, 2008, INT J ONCOL, V32, P1119
   Tiyaboonchai W, 2007, INT J PHARM, V337, P299, DOI 10.1016/j.ijpharm.2006.12.043
   Tran LD, 2010, COLLOID SURF A, V371, P104
   Wang D, 2008, CLIN CANCER RES, V14, P6228, DOI 10.1158/1078-0432.CCR-07-5177
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   Wang XY, 2008, FOOD CHEM, V108, P419, DOI 10.1016/j.foodchem.2007.10.086
   Wang Y, 2009, INT J FOOD MICROBIOL, V136, P71, DOI 10.1016/j.ijfoodmicro.2009.09.001
   Wu WT, 2011, BIOMATERIALS, V32, P598, DOI 10.1016/j.biomaterials.2010.08.112
   Xiang L., 2008, CHINESE J PHARM, V39, P194
   Xiao-Hui Z., 2010, CHINESE J EXPT TRADI, V16, P107
   Xiu-Wang H., 2008, CHINESE J HOSP PHARM, V28, P1819
   Yadav VR, 2010, BIOCHEM PHARMACOL, V80, P1021, DOI 10.1016/j.bcp.2010.06.022
   Yallapu MM, 2010, J COLLOID INTERF SCI, V351, P19, DOI 10.1016/j.jcis.2010.05.022
   Yallapu MM, 2010, COLLOID SURFACE B, V79, P113, DOI 10.1016/j.colsurfb.2010.03.039
   Yang KY, 2007, J CHROMATOGR B, V853, P183, DOI 10.1016/j.jchromb.2007.03.010
   Yang Y, 2009, J MATER SCI-MATER M, V20, P301, DOI 10.1007/s10856-008-3577-0
   Yin YM, 2009, J CONTROL RELEASE, V140, P86, DOI 10.1016/j.jconrel.2009.08.015
   Yu HL, 2010, FOOD CHEM, V119, P669, DOI 10.1016/j.foodchem.2009.07.018
   Yue Y., 2010, ASIA PACIFIC TRADITI, V6, P8
   Zhang P, 2008, INT J PHARM, V355, P269, DOI 10.1016/j.ijpharm.2007.12.026
   Zheng L, 2009, SENSOR ACTUAT B-CHEM, V135, P650, DOI 10.1016/j.snb.2008.09.035
   Zhu RR, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/5/055702
NR 81
TC 10
Z9 10
U1 2
U2 36
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-4110
J9 J NANOMATER
JI J. Nanomater.
PY 2011
AR 723178
DI 10.1155/2011/723178
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 845GN
UT WOS:000296811100001
OA gold
DA 2018-01-05
ER

PT J
AU Palacio, J
   Orozco, VH
   Lopez, BL
AF Palacio, Juliana
   Orozco, Victor H.
   Lopez, Betty L.
TI Effect of the Molecular Weight on the Physicochemical Properties of
   Poly(lactic acid) Nanoparticles and on the Amount of Ovalbumin
   Adsorption
SO JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY
LA English
DT Article
DE poly(lactic acid); nanoparticles; ovalbumin; adsorption
ID LOADED POLYMERIC NANOPARTICLES; L-LACTIC ACID; POLY(L-LACTIC ACID);
   DRUG-DELIVERY; SOLVENT DISPLACEMENT; PLA NANOPARTICLES; BIODEGRADABLE
   NANOPARTICLES; DIRECT POLYCONDENSATION; HIV-1 P24; NANOPRECIPITATION
AB Poly(lactic acid) (PLA) nanoparticles were prepared to be used as potential platform for vaccine systems. Commercial high molecular weight PLA (PLA(HMW)) with M(w) 1.5 x 10(5) and low molecular weight poly(lactic acid) (PLA(LMW)) with M(w) 9.3 x 10(3) were obtained by direct polycondensation from D, L lactic acid and used to prepare nanoparticles by solvent displacement method. The effect of the molecular weight on the physicochemical properties of the polymers, on the nanoparticles dispersions and the amount of ovalbumin (OVA) adsorption was studied. The PLA(HMW) and PLA(LMW) were characterized by Fourier transformed infrared spectroscopy (FTIR), thermogravimetrical analysis (TGA), modulated temperature differential scanning calorimetry (MTDSC) and gel permeation chromatography (GPC). The particle size distribution and zeta-potential of the obtained dispersions were measured by dynamic light scattering (DLS) and electroacoustic spectroscopy, respectively. The ovalbumin adsorption on nanoparticles was evaluated by the Bradford method. PLA(LMW) dispersion showed lower.-potential values and larger sizes compared to PLA(HMW) dispersion. A minor OVA adsorption was achieved for PLA(LMW).
C1 [Palacio, Juliana; Orozco, Victor H.; Lopez, Betty L.] Univ Antioquia, Medellin, Antioquia, Colombia.
RP Palacio, J (reprint author), Univ Antioquia, Calle 62,52-59,Torre 1 Lab 310, Medellin, Antioquia, Colombia.
EM juli.pb@gmail.com
FU Colciencias [1115-452-21346, 439-2008]
FX The authors wish to thank Colciencias for the financial support to the
   project code 1115-452-21346, corresponding to the No. 439-2008.
CR Achmad F, 2009, CHEM ENG J, V151, P342, DOI 10.1016/j.cej.2009.04.014
   Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Anal AK, 2008, COLLOID SURFACE B, V64, P104, DOI 10.1016/j.colsurfb.2008.01.010
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bajpai AK, 2008, PROG POLYM SCI, V33, P1088, DOI 10.1016/j.progpolymsci.2008.07.005
   Belbella A, 1996, INT J PHARM, V129, P95, DOI 10.1016/0378-5173(95)04258-X
   Bilati U, 2005, EUR J PHARM SCI, V24, P67, DOI 10.1016/j.ejps.2004.09.011                                                      
   Blanco MD, 1997, EUR J PHARM BIOPHARM, V43, P287, DOI 10.1016/S0939-6411(97)00056-8
   Chen GX, 2006, EUR POLYM J, V42, P468, DOI 10.1016/j.eurpolymj.2005.07.022
   Coates J., 2006, ENCY ANAL CHEM
   D'Aubeterre A, 2005, INT COMMUN HEAT MASS, V32, P677, DOI 10.1016/j.icheatmasstransfer.2004.06.012
   des Rieux A., 2006, J CONTROL RELEASE, V116, P1, DOI DOI 10.1016/J.JC0NREL.2006.08.013
   Di Lorenzo ML, 2005, EUR POLYM J, V41, P569, DOI 10.1016/j.eurpolymj.2004.10.020
   Espuelas S., 2009, GAZ MED BAHIA, V79, P134
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Galindo-Rodriguez S, 2004, PHARM RES, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be
   Garlotta D, 2001, J POLYM ENVIRON, V9, P63, DOI 10.1023/A:1020200822435
   Gupta AP, 2007, EUR POLYM J, V43, P4053, DOI 10.1016/j.eurpolymj.2007.06.045
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Harshe YM, 2007, MACROMOL REACT ENG, V1, P611, DOI 10.1002/mren.200700019
   Harush-Frenkel O, 2010, TOXICOL APPL PHARM, V246, P83, DOI 10.1016/j.taap.2010.04.011
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Huntington JA, 2001, J CHROMATOGR B, V756, P189, DOI 10.1016/S0378-4347(01)00108-6                                                   
   Hyon SH, 1997, BIOMATERIALS, V18, P1503, DOI 10.1016/S0142-9612(97)00076-8
   Jain AK, 2009, J CONTROL RELEASE, V136, P161, DOI 10.1016/j.jconrel.2009.02.010
   Kim KW, 2002, MACROMOL CHEM PHYSIC, V203, P2245, DOI 10.1002/1521-3935(200211)203:15<2245::AID-MACP2245>3.0.CO;2-3                   
   KOHN FE, 1984, J APPL POLYM SCI, V29, P4265, DOI 10.1002/app.1984.070291255                                                      
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Langer K, 2000, EUR J PHARM BIOPHARM, V49, P303, DOI 10.1016/S0939-6411(00)00068-0
   Legrand P, 2007, INT J PHARM, V344, P33, DOI 10.1016/j.ijpbarm.2007.05.054
   Mehta RC, 1996, J CONTROL RELEASE, V41, P249, DOI 10.1016/0168-3659(96)01332-6                                                    
   Mohanraj VJ, 2007, TROP J PHARM RES, V5, P561, DOI DOI 10.4314/TJPR.V5I1.14634
   Moon SI, 2000, J POLYM SCI POL CHEM, V38, P1673, DOI 10.1002/(SICI)1099-0518(20000501)38:9<1673::AID-POLA33>3.0.CO;2-T               
   Mosqueira VCF, 2000, J PHARM SCI, V89, P614, DOI 10.1002/(SICI)1520-6017(200005)89:5<614::AID-JPS7>3.3.CO;2-Z
   Narayanan S, 2010, NANOTECHNOLOGY, V21, P1
   NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x                                              
   Ogier J, 2009, FUTURE MED CHEM, V1, P693, DOI [10.4155/fmc.09.48, 10.4155/FMC.09.48]
   Orozco VH, 2007, MACROMOL SYMP, V258, P45, DOI 10.1002/masy.200751206
   Orozco VH, 2010, POLYMER, V51, P4127, DOI 10.1016/j.polymer.2010.06.060
   Park K, 2011, REACT FUNCT POLYM, V71, P280, DOI 10.1016/j.reactfunctpolym.2010.10.002
   PLAPIED L, 2011, CURR OPIN COLLOID IN
   PRIETO MJB, 1994, INT J PHARM, V111, P137
   Quintanar-Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571                                                       
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Ribeiro HS, 2008, FOOD HYDROCOLLOID, V22, P12, DOI 10.1016/j.foodhyd.2007.04.009
   Sameni J., 2009, IND EL APPL ISIEA 20, P700
   Shaver MP, 2010, BIOMACROMOLECULES, V11, P3673, DOI 10.1021/bm101140d
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   STERNLING CV, 1959, AICHE J, V5, P514, DOI 10.1002/aic.690050421                                                           
   THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P433, DOI 10.1071/BI9780433                                                               
   Xiong LZ, 2010, POLYM-PLAST TECHNOL, V49, P1201, DOI 10.1080/03602559.2010.496412
   Xu F, 2009, INT J PHARMACEUT, V377, P199, DOI 10.1016/j.ijpharm.2009.05.015
   Yang HC, 2009, MICROCHEM J, V92, P87, DOI 10.1016/j.microc.2009.02.001
   Zambaux MF, 1998, J CONTROL RELEASE, V50, P31, DOI 10.1016/S0168-3659(97)00106-5                                                   
   Zambaux MF, 1999, J CONTROL RELEASE, V60, P179, DOI 10.1016/S0168-3659(99)00073-5                                                   
NR 56
TC 10
Z9 10
U1 1
U2 10
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0103-5053
J9 J BRAZIL CHEM SOC
JI J. Braz. Chem. Soc.
PY 2011
VL 22
IS 12
BP 2304
EP 2311
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 875AG
UT WOS:000299000600009
DA 2018-01-05
ER

PT J
AU Sowinski, S
   Alakoskela, JM
   Jolly, C
   Davis, DM
AF Sowinski, Stefanie
   Alakoskela, Juha-Matti
   Jolly, Clare
   Davis, Daniel M.
TI Optimized methods for imaging membrane nanotubes between T cells and
   trafficking of HIV-1
SO METHODS
LA English
DT Review
DE Membrane nanotubes; Laser scanning confocal microscopy; Live cell
   imaging; Gag-GFP; Filopodia; Cytoplasmic bridges
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VIROLOGICAL SYNAPSE FORMATION; TUNNELING
   NANOTUBES; IMMUNOLOGICAL SYNAPSE; INFECTIOUS SYNAPSE; DENDRITIC CELLS;
   IMMUNE SYNAPSE; TARGET-CELLS; CUTTING EDGE; SPREAD
AB A wide variety of cell types, including immune cells, have been observed to frequently interact via transient, long-distance membrane connections [1-17] However, considerable heterogeneity in their structure, mode of formation and functional properties has emerged, suggesting the existence of distinct subclasses [18-21]. Open-ended tunneling nanotubes allow for the trafficking of cytoplasmic material, e.g. endocytic vesicles, or the transmission of calcium signals [1,8]. Closed-ended membrane nanotubes do not seamlessly connect the cytoplasm between two interacting cells and a junction exists within the nanotube or where the nanotube meets a cell body [4,5,7]. Recent live cell imaging suggested that membrane nanotubes between T cells could present a novel route for HIV-1 transmission [7,22]. Here, we describe detailed protocols for observing membrane nanotubes and HIV-1 trafficking by live cell fluorescence microscopy. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Sowinski, Stefanie] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
   [Alakoskela, Juha-Matti; Davis, Daniel M.] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England.
   [Jolly, Clare] UCL, Wohl Vir Ctr, London W1T 4JF, England.
   [Jolly, Clare] UCL, MRC UCL Ctr Med Mol Virol, London W1T 4JF, England.
RP Sowinski, S (reprint author), Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.
EM stefanie.sowinski@gladstone.ucsf.edu
RI Jolly, Clare/A-4501-2013
OI Jolly, Clare/0000-0002-4603-2281; Alakoskela,
   Juha-Matti/0000-0002-7358-038X; Davis, Daniel/0000-0002-9182-291X
FU Wellcome Trust
FX The authors thank Bjorn Onfelt, Marco Purbhoo, Anne Chauveau and Otto
   Berninghausen for helping develop the methods discussed here. This work
   was funded by a Wellcome Trust PhD studentship to S.S.
CR ARKWRIGHT PD, 2009, CELL RES, P72
   Arrighi JF, 2004, J EXP MED, V200, P1279, DOI 10.1084/jem.20041356
   Bousso P, 2008, NAT REV IMMUNOL, V8, P675, DOI 10.1038/nri2379
   Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Davis DM, 2009, NAT REV IMMUNOL, V9, P543, DOI 10.1038/nri2602
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Eriksson M, 1999, J EXP MED, V190, P1005, DOI 10.1084/jem.190.7.1005                                                          
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Gurke S, 2008, EXP CELL RES, V314, P3669, DOI 10.1016/j.yexcr.2008.08.022
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X
   Jolly C, 2007, J VIROL, V81, P13916, DOI 10.1128/JVI.01585-07
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jolly C, 2007, J VIROL, V81, P5547, DOI 10.1128/JVI.01469-06
   Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Oddos S, 2008, BIOPHYS J, V95, pL66, DOI 10.1529/biophysj.108.143198
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Otegui MS, 2005, TRENDS CELL BIOL, V15, P404, DOI 10.1016/j.tcb.2005.06.003
   Pontes B, 2008, EUR BIOPHYS J BIOPHY, V37, P121, DOI 10.1007/s00249-007-0184-9
   Roda-Navarro P, 2004, J IMMUNOL, V173, P3640, DOI 10.4049/jimmunol.173.6.3640                                                     
   Roda-Navarro P, 2006, P NATL ACAD SCI USA, V103, P11258, DOI 10.1073/pnas.0600721103
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.embroj.7601509
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5                                                   
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Yu HJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000134
NR 45
TC 23
Z9 24
U1 2
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD JAN
PY 2011
VL 53
IS 1
BP 27
EP 33
DI 10.1016/j.ymeth.2010.04.002
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 713AS
UT WOS:000286708000005
PM 20382227
DA 2018-01-05
ER

PT J
AU Ulasov, AV
   Khramtsov, YV
   Trusov, GA
   Rosenkranz, AA
   Sverdlov, ED
   Sobolev, AS
AF Ulasov, Alexey V.
   Khramtsov, Yuri V.
   Trusov, Georgiy A.
   Rosenkranz, Andrey A.
   Sverdlov, Eugene D.
   Sobolev, Alexander S.
TI Properties of PEI-based Polyplex Nanoparticles That Correlate With Their
   Transfection Efficacy
SO MOLECULAR THERAPY
LA English
DT Article
ID HIV-1 TAT PROTEIN; GENE DELIVERY-SYSTEM; PLASMID DNA; POLY(ETHYLENE
   IMINE); TRANSDUCTION DOMAIN; IN-VIVO; CELLS; UNPACKING; COMPLEXES;
   THERAPY
AB We have evaluated the key properties of the polyethylenimine (PEI)-polyethylene glycol (PEG)-TAT peptide polyplex nanoparticles including their behavior in cells and compared them with the transfection efficacy (TE) using 11 different cell lines. We found statistically significant positive correlation between TE and the share of 50-75 nm fraction in the whole mixture of nanoparticles estimated with atomic force microscopy. Variations in PEG/PEI and N/P ratios (PEI nitrogen to DNA phosphate ratio) enabled us to find their optimal combinations, which resulted in up to 100% TE for several cell lines. Surfaces of the TE dependence of both PEG/PEI and N/P turned out to be similar in appearance for all investigated cell lines, while maximum TEs were different. We investigated subcellular transport kinetics and unpacking of the polyplex nanoparticles labeled with quantum dots (plasmid DNA) and AlexaFluor647 (block-copolymer part) using Forster Resonance Energy Transfer approach. The results demonstrated clear and statistically significant positive correlation of TE with the cellular uptake rate of the nanoparticles and negative correlation with the rate constant of their unpacking within endo/lysosomal compartments in the living cells.
C1 [Ulasov, Alexey V.; Khramtsov, Yuri V.; Trusov, Georgiy A.; Rosenkranz, Andrey A.; Sobolev, Alexander S.] Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, Moscow 119334, Russia.
   [Trusov, Georgiy A.; Rosenkranz, Andrey A.; Sobolev, Alexander S.] Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow, Russia.
   [Sverdlov, Eugene D.] Russian Acad Sci, Inst Mol Genet, Oncogenom Grp, Moscow 119334, Russia.
   [Sverdlov, Eugene D.] Russian Acad Sci, Shemiakin Ovchinnikov Inst Bioorgan Chem, Dept Genom & Postgenom Technol, Moscow 119334, Russia.
RP Sobolev, AS (reprint author), Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, 34-5 Vavilov St, Moscow 119334, Russia.
EM sobolev@igb.ac.ru
RI Rosenkranz, Andrey/J-3514-2015; Sobolev, Alexander/P-6302-2015
OI Rosenkranz, Andrey/0000-0001-9941-6118; Sobolev,
   Alexander/0000-0001-8315-7764
FU RF State [02.522.11.2005, 02.512.12.2027, 2z-405/09]; RFBR
   [10-04-01037-a]
FX Experiments were carried out with the use of the equipment from the
   Center of collective usage of the unique instrumentation of the
   Institute of Gene Biology. We are thankful to Drs I. Korobko (Institute
   of Gene Biology, Moscow, Russia) and A. Buzdin (Shemiakin-Ovchinnikov
   Institute of Bioorganic Chemistry, Moscow, Russia) for provided
   plasmids, M. Durymanov (Institute of Gene Biology, Moscow, Russia) for
   help with transfection experiments, and Prof. D. Tremethick and Dr. T.
   Soboleva (Australian National University, Canberra, Australia) for
   critical reading of the manuscript. This work was supported by RF State
   contracts no. 02.522.11.2005 and no. 02.512.12.2027 (grant no.
   2z-405/09) as well as by RFBR grant no. 10-04-01037-a.
CR ABDELMALEK ZA, 1987, CANCER RES, V47, P3141
   Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005
   *AM BIOSC PROT, 2001, LAB PROT CYDYE N HYD, P4
   *ATCC, PROD DESCR ATCC CCL
   *ATCC, PROD DESCR ATCC HTB
   CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X
   Chen HH, 2008, MOL THER, V16, P324, DOI 10.1038/sj.mt.6300392
   Cho CW, 2001, CANCER LETT, V162, P75, DOI 10.1016/S0304-3835(00)00629-7
   DUNN WA, 1980, J BIOL CHEM, V255, P5971
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Gong XW, 2007, TALANTA, V71, P381, DOI 10.1016/j.talanta.2006.04.010
   Grigsby CL, 2010, J R SOC INTERFACE, V7, pS67, DOI 10.1098/rsif.2009.0260
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   He CX, 2010, INT J PHARMACEUT, V386, P232, DOI 10.1016/j.ijpharm.2009.11.006
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Ho YP, 2006, J CONTROL RELEASE, V116, P83, DOI 10.1016/j.jconrel.2006.09.005
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Iida T, 2007, J CONTROL RELEASE, V118, P364, DOI 10.1016/j.jconrel.2006.12.027
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Kremer TM, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-16
   Kunath K, 2002, PHARMACEUT RES, V19, P810, DOI 10.1023/A:1016152831963
   Merdan T, 2003, BIOCONJUGATE CHEM, V14, P989, DOI 10.1021/bc0340767
   Merdan T, 2005, BIOCONJUGATE CHEM, V16, P785, DOI 10.1021/bc049743q
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Nakamura T, 2006, BIOL PHARM BULL, V29, P1290, DOI 10.1248/bpb.29.1290
   Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773
   Ogris M, 2003, J CONTROL RELEASE, V91, P173, DOI 10.1016/S0168-3659(03)00230-X
   Periasamy A., 2005, MOL IMAGING FRET MIC
   PERRINE TD, 1967, J POLYM SCI A1, V5, P1993, DOI 10.1002/pol.1967.150050816
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   *PROT MOL PROB INC, 2009, WHEAT GERM AGGL CONJ, P4
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Schaffer DV, 1998, J BIOL CHEM, V273, P28004, DOI 10.1074/jbc.273.43.28004
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Smrekar B, 2003, GENE THER, V10, P1079, DOI 10.1038/sj.gt.3301965
   Vaidyanathan G, 2006, NAT PROTOC, V1, P707, DOI 10.1038/nprot.2006.99
   Wiethoff C M, 2001, Methods Mol Med, V65, P349, DOI 10.1385/1-59259-139-6:349
NR 37
TC 37
Z9 37
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JAN
PY 2011
VL 19
IS 1
BP 103
EP 112
DI 10.1038/mt.2010.233
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 702BI
UT WOS:000285869200014
PM 21045811
OA gold
DA 2018-01-05
ER

PT J
AU Niu, YH
   Jones, A
   Wu, HF
   Varani, G
   Cai, JF
AF Niu, Youhong
   Jones, Alisha Jonesy
   Wu, Haifan
   Varani, Gabriele
   Cai, Jianfeng
TI gamma-AApeptides bind to RNA by mimicking RNA-binding proteins
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID HIV-1 TAR RNA; BETA-HAIRPIN PEPTIDOMIMETICS; IMMUNODEFICIENCY-VIRUS;
   SMALL-MOLECULE; HIGH-AFFINITY; RECOGNITION; PEPTIDE; LIGANDS; DESIGN;
   PNA
AB The interactions between proteins and RNAs are of vital importance for many cellular processes, including transcription and processing of RNA, translation, and viral infections. Here we report an gamma-AApeptide that can mimic HIV-1 Tat protein and bind to TAR RNAs of HIV and BIV with nanomolar affinity, comparable to that of the RNA-binding fragment of Tat (amino acids 49-58). The interaction is resistant to the presence of a large excess of tRNA. With resistance to proteolytic hydrolysis and limitless potential for diversification, gamma-AApeptides may emerge as a new class of peptidomimetics to modulate RNA-protein interactions.
C1 [Jones, Alisha Jonesy; Varani, Gabriele] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Niu, Youhong; Wu, Haifan; Cai, Jianfeng] Univ S Florida, Dept Chem, Tampa, FL 33620 USA.
   [Varani, Gabriele] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
RP Varani, G (reprint author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.
EM varani@chem.washington.edu; jianfengcai@usf.edu
RI Wu, Haifan/F-8818-2014; Wu, Haifan/O-1935-2013
OI Wu, Haifan/0000-0002-2050-9950; Wu, Haifan/0000-0002-2050-9950
FU USF; NIH-NIAID
FX This work is supported by USF start-up fund to JC and by a grant from
   NIH-NIAID to GV.
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   Al-Hashimi HM, 2005, CHEMBIOCHEM, V6, P1506, DOI 10.1002/cbic.200500002
   Athanassiou Z, 2004, J AM CHEM SOC, V126, P6906, DOI 10.1021/ja0497680
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Bardaro MF, 2009, NUCLEIC ACIDS RES, V37, P1529, DOI 10.1093/nar/gkn1074
   Davidson A., 2010, NUCLEIC ACIDS RES, V39, P248
   Davidson A, 2009, P NATL ACAD SCI USA, V106, P11931, DOI 10.1073/pnas.0900629106
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   Debaene F, 2004, TETRAHEDRON, V60, P8677, DOI 10.1016/j.tet.2004.05.107
   Debaene F, 2007, TETRAHEDRON, V63, P6577, DOI 10.1016/j.tet.2007.03.033
   Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991                                                          
   Gelman MA, 2003, ORG LETT, V5, P3563, DOI 10.1021/ol034977v
   Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Hu YG, 2011, BIOORG MED CHEM LETT, V21, P1469, DOI 10.1016/j.bmcl.2011.01.005
   Huang W, 2010, J AM CHEM SOC, V132, P17643, DOI 10.1021/ja1051439
   Huq I, 1997, NAT STRUCT BIOL, V4, P881, DOI 10.1038/nsb1197-881
   Lalonde MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002038
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Moehle K, 2007, ANGEW CHEM INT EDIT, V46, P9101, DOI 10.1002/anie.200702801
   Nathans R, 2008, NAT BIOTECHNOL, V26, P1187, DOI 10.1038/nbt.1496
   Niu YH, 2011, NEW J CHEM, V35, P542, DOI 10.1039/c0nj00943a
   Rapireddy S, 2007, J AM CHEM SOC, V129, P15596, DOI 10.1021/ja074886j
   Tamilarasu N, 1999, J AM CHEM SOC, V121, P1597, DOI 10.1021/ja983822t                                                               
   Wang XL, 1997, J AM CHEM SOC, V119, P6444, DOI 10.1021/ja963895h                                                               
NR 25
TC 33
Z9 33
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2011
VL 9
IS 19
BP 6604
EP 6609
DI 10.1039/c1ob05738c
PG 6
WC Chemistry, Organic
SC Chemistry
GA 818AL
UT WOS:000294720600024
PM 21826330
OA green_accepted
DA 2018-01-05
ER

PT S
AU Maswadi, S
   Glickman, RD
   Elliot, R
   Barsalou, N
AF Maswadi, Saher
   Glickman, Randolph D.
   Elliot, Rowe
   Barsalou, Norman
BE Oraevsky, AA
   Wang, LV
TI NANO-LISA FOR IN VITRO DIAGNOSTIC APPLICATIONS
SO PHOTONS PLUS ULTRASOUND: IMAGING AND SENSING 2011
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Photons Plus Ultrasound - Imaging and Sensing
CY JAN 23-25, 2011
CL San Francisco, CA
SP SPIE
DE NanoLISA; pathogenic detection; HLTV; HIV; Hep-B; optoacoustic
   spectroscopy; gold; in vitro diagnostic; nanoparticles; probe beam
   deflection technique; ultrasound optical sensor
ID COVALENT MICROSPHERE IMMUNOASSAY; BACILLUS-ANTHRACIS; ANTIBODIES;
   MICROSCOPY; ANTIGEN; ASSAY; SIZE
AB We previously reported the detection of bacterial antigen with immunoaffinity reactions using laser optoacoustic spectroscopy and antibody-coupled gold nanorods (Ab-NR) as a contrast agent specifically targeted to the antigen of interest. The Nano-LISA (Nanoparticle Linked Immunosorbent Assay) method has been adapted to detect three very common blood-borne viral infectious agents, i.e. human T-lymphotropic virus (HTLV), human immunodeficiency virus (HIV) and hepatitis-B (Hep-B). These agents were used in a model test panel to illustrate the performance of the Nano-LISA technique. A working laboratory prototype of a Nano-LISA microplate reader-sensor was assembled and tested against the panel containing specific antigens of each of the infectious viral agents. Optoacoustic (OA) responses generated by the samples were detected using the probe beam deflection technique, an all-optical, non-contact technique. A LabView graphical user interface was developed for control of the instrument and real-time display of the test results. The detection limit of Nano-LISA is at least 1 ng/ml of viral antigen, and can reach 10 pg/ml, depending on the binding affinity of the specific detection antibody used to synthesize the Ab-NR. The method has sufficient specificity, i.e. the detection reagents do not cross-react with non-complementary antigens. Thus, the OA microplate reader, incorporating NanoLISA, has adequate detection sensitivity and specificity for use in clinical in vitro diagnostic testing.
C1 [Maswadi, Saher; Glickman, Randolph D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
   [Elliot, Rowe; Barsalou, Norman] Naval Med Res Unit San Antonio, Ft Sam Houston, TX 78234 USA.
RP Maswadi, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
EM maswadi@uthscsa.edu
FU Office of Naval Research [N00014-08-1-0193]; National Science Foundation
   Partnerships for Research and Education in Materials (PREM) in
   collaboration with Northwestern University MRSEC [DMR-0934218]
FX This research was supported by grant N00014-08-1-0193 from the Office of
   Naval Research (to RDG), as well as by the National Science Foundation
   Partnerships for Research and Education in Materials (PREM) Grant No.
   DMR-0934218 in collaboration with Northwestern University MRSEC.
CR Biagini RE, 2004, CLIN DIAGN LAB IMMUN, V11, P50, DOI 10.1128/CDLI.11.1.50-55.2004
   Biagini RE, 2004, OCCUP ENVIRON MED, V61, P703, DOI 10.1136/oem.2003.008565
   Conjusteau A., 2009, P SPIE, V7177
   Hoffmaster AR, 2002, EMERG INFECT DIS, V8, P1178, DOI 10.3201/eid0810.020393                                                          
   Link S, 2000, J PHYS CHEM B, V104, P6152, DOI 10.1021/jp000679t
   Luna VA, 2003, J CLIN MICROBIOL, V41, P1252, DOI 10.1128/JCM.41.3.1252-1255.2003
   Martin S, 2004, MOL BIOL CELL, V15, P2449, DOI 10.1091/mbc.E04-01-0045
   Maswadi S.M., 2008, P SPIE, V6856
   Maswadi S.M., 2009, P SPIE, V7177
   MURPHY RM, 1988, BIOPHYS J, V54, P45, DOI 10.1016/S0006-3495(88)82929-1                                                   
   PINI R, 1995, APPL PHYS B-LASERS O, V61, P505, DOI 10.1007/BF01081281
   Pluckthun A, 2010, NATURE, V467, P537, DOI 10.1038/467537a
   SULLIVAN B, 1984, J ACOUST SOC AM, V75, P437, DOI 10.1121/1.390467
NR 13
TC 0
Z9 0
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-8436-9
J9 PROC SPIE
PY 2011
VL 7899
AR 78991O
DI 10.1117/12.874922
PG 10
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BXY67
UT WOS:000297633500049
DA 2018-01-05
ER

PT J
AU Mateu, MG
AF Mateu, Mauricio G.
TI Virus engineering: functionalization and stabilization
SO PROTEIN ENGINEERING DESIGN & SELECTION
LA English
DT Review
DE nanotechnology; nanoparticle; protein engineering; thermal and
   mechanical stability; virus capsid
ID MOUTH-DISEASE VIRUS; PARVOVIRUS MINUTE VIRUS; CHLOROTIC MOTTLE VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; SITE-DIRECTED MUTAGENESIS;
   TOBACCO-MOSAIC-VIRUS; AMINO-ACID-RESIDUES; ADENOASSOCIATED VIRUS;
   GENE-THERAPY; CAPSID PROTEIN
AB Chemically and/or genetically engineered viruses, viral capsids and viral-like particles carry the promise of important and diverse applications in biomedicine, biotechnology and nanotechnology. Potential uses include new vaccines, vectors for gene therapy and targeted drug delivery, contrast agents for molecular imaging and building blocks for the construction of nanostructured materials and electronic nanodevices. For many of the contemplated applications, the improvement of the physical stability of viral particles may be critical to adequately meet the demanding physicochemical conditions they may encounter during production, storage and/or medical or industrial use. The first part of this review attempts to provide an updated general overview of the fast-moving, interdisciplinary virus engineering field; the second part focuses specifically on the modification of the physical stability of viral particles by protein engineering, an emerging subject that has not been reviewed before.
C1 Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, E-28049 Madrid, Spain.
RP Mateu, MG (reprint author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa CSIC UAM, E-28049 Madrid, Spain.
EM mgarcia@cbm.uam.es
OI G. Mateu, Mauricio/0000-0002-2915-1529
FU Ministerio de Ciencia e Innovacion [BIO2009-10092]; Comunidad Autonoma
   de Madrid [S-2009/MAT/1467]; FIPSE [36557/06]; Fundacion Ramon Areces
FX Work in the author's laboratory is supported by grants from Ministerio
   de Ciencia e Innovacion (BIO2009-10092), Comunidad Autonoma de Madrid
   (S-2009/MAT/1467) and FIPSE (36557/06), and by an institutional grant
   from Fundacion Ramon Areces.
CR Abedin MJ, 2009, J AM CHEM SOC, V131, P4346, DOI 10.1021/ja8079862
   ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0
   Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3                                                   
   Allen M, 2005, MAGN RESON MED, V54, P807, DOI 10.1002/mrm.20614
   Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2                                                   
   ANDERSON EA, 2006, NANO LETT, V6, P1161
   Arora PS, 2004, CHEM BIOL, V11, P418, DOI 10.1016/j.chembiol.2004.04.003
   Ashcroft AE, 2005, J NANOSCI NANOTECHNO, V5, P2034, DOI 10.1166/jnn.2005.507
   Asokan A, 2008, GENE THER, V15, P1618, DOI 10.1038/gt.2008.127
   Asokan A, 2010, NAT BIOTECHNOL, V28, P79, DOI 10.1038/nbt.1599
   Bar H, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-37
   Belnap DM, 2000, J VIROL, V74, P1342, DOI 10.1128/JVI.74.3.1342-1354.2000
   BENITO A, 1995, BIO-TECHNOL, V13, P801, DOI 10.1038/nbt0895-801
   Blum AS, 2007, IEEE T NANOBIOSCI, V6, P270, DOI 10.1109/TNB.2007.908978
   Blum AS, 2005, SMALL, V1, P702, DOI 10.1002/smll.200500021
   BRANNIGAN JA, 2002, NAT REV MOL CELL BIO, V3, P965
   CALDEIRA JC, 2007, J NANOBIOTECHNOL, V26, P5
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Carrasco C, 2009, P NATL ACAD SCI USA, V106, P5475, DOI 10.1073/pnas.0810095106
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   Carreira A, 2004, J BIOL CHEM, V279, P6517, DOI 10.1074/jbc.M307662200
   Casjens SR, 1997, STRUCTURAL BIOL VIRU, P3
   Chiu W, 1997, STRUCTURAL BIOL VIRU
   Chow M, 1997, STRUCTURAL BIOL VIRU, P157
   Cormode DP, 2010, ADV DRUG DELIVER REV, V62, P329, DOI 10.1016/j.addr.2009.11.005
   Cotmore SF, 2007, ADV VIRUS RES, V70, P183, DOI 10.1016/S0065-3527(07)70005-2
   Croyle MA, 2001, GENE THER, V8, P1281, DOI 10.1038/sj.gt.3301527
   CULVER JN, 1995, VIROLOGY, V206, P724, DOI 10.1016/S0042-6822(95)80096-4
   CURRY S, 1995, J VIROL, V69, P430
   Dalmau M, 2009, NANO LETT, V9, P160, DOI 10.1021/nl8027069
   DEBAGGE P, 2008, HISTOCHEM CELL BIOL, V130, P845
   del Alamo M, 2005, J MOL BIOL, V345, P893, DOI 10.1016/j.jmb.2004.10.086
   DOMINGO E, 2006, CURRENT TOPICS MICRO, V289
   Donath E, 2009, NAT NANOTECHNOL, V4, P215, DOI 10.1038/nnano.2009.64
   Douglas CC, 2004, BIOCHEMISTRY-US, V43, P10435, DOI 10.1021/bi049359g
   Douglas T, 2006, SCIENCE, V312, P873, DOI 10.1126/science.1123223
   Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211
   Douglas T, 2002, ADV MATER, V14, P415, DOI 10.1002/1521-4095(20020318)14:6<415::AID-ADMA415>3.0.CO;2-W                     
   Douglas T, 1999, ADV MATER, V11, P679, DOI 10.1002/(SICI)1521-4095(199906)11:8<679::AID-ADMA679>3.0.CO;2-J                 
   Ellard FM, 1999, J GEN VIROL, V80, P1911, DOI 10.1099/0022-1317-80-8-1911                                                     
   Everts M, 2006, NANO LETT, V6, P587, DOI 10.1021/nl0500555
   Ferreira E, 2009, VACCINE, V27, P5332, DOI 10.1016/j.vaccine.2009.06.099
   FILMAN DJ, 1989, EMBO J, V8, P1567
   Fischlechner M, 2007, ANGEW CHEM INT EDIT, V46, P3184, DOI 10.1002/anie.200603445
   Flenniken ML, 2009, CURR TOP MICROBIOL, V327, P71
   Forrer P, 1999, CURR OPIN STRUC BIOL, V9, P514, DOI 10.1016/S0959-440X(99)80073-6                                                   
   Fox JM, 1997, VIROLOGY, V227, P229, DOI 10.1006/viro.1996.8292
   Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002
   Gillitzer E, 2002, CHEM COMMUN, P2390, DOI 10.1039/b207853h
   Golmohammadi R, 1996, STRUCTURE, V4, P543, DOI 10.1016/S0969-2126(96)00060-3
   Hegde NR, 2009, VACCINE, V27, P2199, DOI 10.1016/j.vaccine.2009.01.032
   Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658
   Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123
   Hogle JM, 2002, ANNU REV MICROBIOL, V56, P677, DOI 10.1146/annurev.micro.56.012302.160757
   Hooker JM, 2004, J AM CHEM SOC, V126, P3718, DOI 10.1021/ja031790q
   Huang Y, 2005, NANO LETT, V5, P1429, DOI 10.1021/nl050795d
   HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466
   Inoue T, 2008, J BIOTECHNOL, V134, P181, DOI 10.1016/j.jbiotec.2007.12.006
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014
   Johnson HR, 2007, BIOTECHNOL BIOENG, V97, P224, DOI 10.1002/bit.21245
   Johnson JE, 2003, ADV PROTEIN CHEM, V64, P197
   Johnson JE, 2010, CURR OPIN STRUC BIOL, V20, P210, DOI 10.1016/j.sbi.2010.01.004
   Kehoe JW, 2005, CHEM REV, V105, P4056, DOI 10.1021/cr000261r
   Kissmann J, 2008, HUM VACCINES, V4, P350, DOI 10.4161/hv.4.5.5863                                                             
   Kissmann J, 2008, J PHARM SCI-US, V97, P4208, DOI 10.1002/jps.21315
   Knez M, 2006, NAT NANOTECHNOL, V1, P22, DOI 10.1038/nnano.2006.73
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Kontou M, 2005, J VIROL, V79, P10931, DOI 10.1128/JVI.79.17.10931-10943.2005
   Kriplani U, 2005, CURR OPIN BIOTECH, V16, P470, DOI 10.1016/j.copbio.2005.07.001
   LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9                                                   
   LEATHERBARROW RJ, 1986, PROTEIN ENG, V1, P7, DOI 10.1093/protein/1.1.7
   Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054
   Leisola M, 2007, APPL MICROBIOL BIOT, V75, P1225, DOI 10.1007/s00253-007-0964-2
   Levin AM, 2006, MOL BIOSYST, V2, P49, DOI 10.1039/b511782h
   Lewis JD, 2006, NAT MED, V12, P354, DOI 10.1038/nm1368
   Li ML, 1998, J VIROL, V72, P2160
   Liepold L, 2007, MAGN RESON MED, V58, P871, DOI 10.1002/mrm.21307
   Liepold LO, 2005, PHYS BIOL, V2, pS166, DOI 10.1088/1478-3975/2/4/S11
   Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1028/JVI.76.14.7049-7059.2002
   Maheshri N, 2006, NAT BIOTECHNOL, V24, P198, DOI 10.1038/nbt1182
   Manayani DJ, 2007, PLOS PATHOG, V3, P1422, DOI 10.1371/journal.ppat.0030142
   Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014
   Manchester Marianne, 2009, Curr Top Microbiol Immunol, V327, pv
   Mani B, 2006, J VIROL, V80, P1015, DOI 10.1128/JVI.80.2.1015-1024.2006
   Mao CB, 2004, SCIENCE, V303, P213, DOI 10.1126/science.1092740
   Mao CB, 2003, P NATL ACAD SCI USA, V100, P6946, DOI 10.1073/pnas.0832310100
   Mao CB, 2009, ANGEW CHEM INT EDIT, V48, P6790, DOI 10.1002/anie.200900231
   Maroto B, 2004, J VIROL, V78, P10685, DOI 10.1128/jvi.78.19.10685-10694.2004
   Martin-Acebes MA, 2010, J VIROL, V84, P2902, DOI 10.1128/JVI.02311-09
   Mateo R, 2003, J BIOL CHEM, V278, P41019, DOI 10.1074/jbc.M304990200
   Mateo R, 2007, J GEN VIROL, V88, P859, DOI 10.1099/vir.0.82521-0
   Mateo R, 2008, J VIROL, V82, P12232, DOI 10.1128/JVI.01553-08
   Mateu MG, 2009, FEBS J, V276, P6098, DOI 10.1111/j.1742-4658.2009.07313.x
   MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U
   Merzlyak A, 2009, NANO LETT, V9, P846, DOI 10.1021/nl8036728
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856
   Muratori C, 2010, METHODS MOL BIOL, V614, P111, DOI 10.1007/978-1-60761-533-0_7
   Nam KT, 2008, P NATL ACAD SCI USA, V105, P17227, DOI 10.1073/pnas.0711620105
   Nam KT, 2006, SCIENCE, V312, P885, DOI 10.1126/science.1122716
   Odegard A, 2010, CURR TOP MICROBIOL, V343, P1, DOI 10.1007/82_2010_35
   Palucha A, 2005, PROG NUCLEIC ACID RE, V80, P135, DOI 10.1016/S0079-6603(05)80004-2
   Park JS, 2009, NAT NANOTECHNOL, V4, P259, DOI [10.1038/nnano.2009.38, 10.1038/NNANO.2009.38]
   Paschke M, 2006, APPL MICROBIOL BIOT, V70, P2, DOI 10.1007/s00253-005-0270-9
   Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100
   Perabo L, 2006, J GENE MED, V8, P155, DOI 10.1002/jgm.849
   Powell SK, 2000, NAT BIOTECHNOL, V18, P1279, DOI 10.1038/82391                                                                   
   Raja KS, 2003, BIOMACROMOLECULES, V4, P472, DOI 10.1021/bm025740+
   Reguera J, 2005, J BIOL CHEM, V280, P17969, DOI 10.1074/jbc.M500867200
   Reguera J, 2004, P NATL ACAD SCI USA, V101, P2724, DOI 10.1073/pnas.0307748101
   Ren Y, 2007, BIOCONJUGATE CHEM, V18, P836, DOI 10.1021/bc060361p
   Ren YP, 2006, J GEN VIROL, V87, P2749, DOI 10.1099/vir.0.81944-0
   Riolobos L, 2006, J MOL BIOL, V357, P1026, DOI 10.1016/j.jmb.2006.01.019
   Roos WH, 2009, ADV MATER, V21, P1187, DOI 10.1002/adma.200801709
   Roos WH, 2009, P NATL ACAD SCI USA, V106, P9673, DOI 10.1073/pnas.0901514106
   Ross PD, 2005, EMBO J, V24, P1352, DOI 10.1038/sj.emboj.7600613
   Ross PE, 2006, SCI AM, V295, P52, DOI 10.1038/scientificamerican1006-52                                               
   ROSSMANN MG, 1997, STRUCTURAL BIOL VIRU, P105
   Roy P, 2008, HUM VACCINES, V4, P5, DOI 10.4161/hv.4.1.5559                                                             
   Saini V, 2008, SMALL, V4, P262, DOI 10.1002/smll.200700403
   Saini V, 2006, NANOMED-NANOTECHNOL, V2, P200, DOI 10.1016/j.nano.2006.07.002
   Schaffer DV, 2008, ANNU REV BIOMED ENG, V10, P169, DOI 10.1146/annurev.bioeng.10.061807.160514
   SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028
   Singh P, 2006, DRUG DEVELOP RES, V67, P23, DOI 10.1002/ddr.20064
   Singh Pratik, 2006, J Nanobiotechnology, V4, P2, DOI 10.1186/1477-3155-4-2
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Smothers JF, 2002, SCIENCE, V298, P621, DOI 10.1126/science.298.5593.621                                                    
   Smyth MS, 2002, J CLIN PATHOL-MOL PA, V55, P214
   Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132
   Soto CM, 2006, J AM CHEM SOC, V128, P5184, DOI 10.1021/ja058574x
   Speir JA, 2006, J VIROL, V80, P3582, DOI 10.1128/JVI.80.7.3582-3591.2006
   SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6
   STEINMETZ NF, 2009, CURR TOP MICROBIOL I, V327, P323
   Steinmetz NF, 2007, ORG BIOMOL CHEM, V5, P2891, DOI 10.1039/b708175h
   Strable E, 2009, CURR TOP MICROBIOL, V327, P1
   TSAO T, 1991, SCIENCE, V251, P1456
   Tseng RJ, 2006, NAT NANOTECHNOL, V1, P72, DOI 10.1038/nnano.2006.55
   Tsuboi M, 2005, BIOCHEMISTRY-US, V44, P4861, DOI 10.1021/bi0479306
   TWOMEY T, 1995, VIROLOGY, V206, P69, DOI 10.1016/S0042-6822(95)80020-4
   Uchida M, 2007, ADV MATER, V19, P1025, DOI 10.1002/adma.200601168
   Uetrecht C, 2008, P NATL ACAD SCI USA, V105, P9216, DOI 10.1073/pnas.0800406105
   VALLE N, 2005, PARVOVIRUSES, P157
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Vu HN, 2008, MOL THER, V16, P308, DOI 10.1038/sj.mt.6300350
   Wang Q, 2003, J AM CHEM SOC, V125, P3192, DOI 10.1021/ja021381e
   Wang Q, 2002, ANGEW CHEM INT EDIT, V41, P459
   WINTER G, 1982, NATURE, V299, P756, DOI 10.1038/299756a0
   Wittrup KD, 1999, TRENDS BIOTECHNOL, V17, P423, DOI 10.1016/S0167-7799(99)01349-9                                                   
   Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000
   Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009
   Young M, 2008, ANNU REV PHYTOPATHOL, V46, P361, DOI 10.1146/annurev.phyto.032508.131939
   Yu DW, 2005, FEBS J, V272, P3651, DOI 10.1111/j.1742-4658.2005.04790.x
   Zaiss AK, 2008, GENE THER, V15, P808, DOI 10.1038/gt.2008.54
   ZHOU SL, 1992, J VIROL, V66, P5393
NR 157
TC 53
Z9 53
U1 1
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-0126
J9 PROTEIN ENG DES SEL
JI Protein Eng. Des. Sel.
PD JAN-FEB
PY 2011
VL 24
IS 1-2
SI SI
BP 53
EP 63
DI 10.1093/protein/gzq069
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 696CV
UT WOS:000285420400009
PM 20923881
OA gold
DA 2018-01-05
ER

PT J
AU Roux, C
   Bhatt, F
   Foret, J
   de Courcy, B
   Gresh, N
   Piquemal, JP
   Jeffery, CJ
   Salmon, L
AF Roux, Celine
   Bhatt, Forum
   Foret, Johanna
   de Courcy, Benoit
   Gresh, Nohad
   Piquemal, Jean-Philip
   Jeffery, Constance J.
   Salmon, Laurent
TI The reaction mechanism of type I phosphomannose isomerases: New
   information from inhibition and polarizable molecular mechanics studies
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE competitive inhibitor; hydroxamic acid; metalloenzyme; aldose-ketose
   isomerase; computational studies
ID INTERMOLECULAR INTERACTION ENERGIES; D-MANNOSE PYROPHOSPHORYLASE; HIV-1
   NUCLEOCAPSID PROTEIN; MEDIATED HYDRIDE SHIFT; METALLO-BETA-LACTAMASE;
   D-XYLOSE ISOMERASE; PHOSPHOGLUCOSE ISOMERASE; CANDIDA-ALBICANS;
   CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE
AB Type I phosphomannose isomerases (PMIs) are zinc-dependent metalloenzymes involved in the reversible isomerization of D-mannose 6-phosphate (M6P) and D-fructose 6-phosphate (F6P). 5-Phospho-D-arabinonohydroxamic acid (5PAH), an inhibitor endowed with nanomolar affinity for yeast (Type I) and Pseudomonas aeruginosa (Type II) PMIs (Roux et al., Biochemistry 2004; 43: 2926-2934), strongly inhibits human (Type I) PMI (for which we report an improved expression and purification procedure), as well as Escherichia coli (Type I) PMI. Its K(i) value of 41 nM for human PMI is the lowest value ever reported for an inhibitor of PMI. 5-Phospho-D-arabinonhydrazide, a neutral analogue of the reaction intermediate 1,2-cis-enediol, is about 15 times less efficient at inhibiting both enzymes, in accord with the anionic nature of the postulated high-energy reaction intermediate. Using the polarizable molecular mechanics, sum of interactions between fragments ab initio computed (SIBFA) procedure, computed structures of the complexes between Candida albicans (Type I) PMI and the cyclic substrate beta-D-mannopyranose 6-phosphate (beta-M6P) and between the enzyme and the high-energy intermediate analogue inhibitor 5PAH are reported. Their analysis allows us to identify clearly the nature of each individual active site amino acid and to formulate a hypothesis for the overall mechanism of the reaction catalyzed by Type I PMIs, that is, the ring-opening and isomerization steps, respectively. Following enzyme-catalyzed ring-opening of beta-M6P by zinc-coordinated water and Gln111 ligands, Lys136 is identified as the probable catalytic base involved in proton transfer between the two carbon atoms C1 and C2 of the substrate D-mannose 6-phosphate. Proteins 2011; 79: 203-220. (C) 2010 Wiley-Liss, Inc.
C1 [Roux, Celine; Foret, Johanna; Salmon, Laurent] Univ Paris 11, ICMMO, Lab Chim Bioorgan & Bioinorgan, UMR 8182, F-91405 Orsay, France.
   [Roux, Celine; Foret, Johanna; Salmon, Laurent] CNRS, UMR 8182, Lab Chim Bioorgan & Bioinorgan, ICMMO, F-91405 Orsay, France.
   [Bhatt, Forum; Jeffery, Constance J.] Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA.
   [de Courcy, Benoit; Piquemal, Jean-Philip] Univ Paris 06, UMR 7616, Chim Theor Lab, F-75252 Paris 05, France.
   [de Courcy, Benoit; Piquemal, Jean-Philip] CNRS, UMR 7616, Chim Theor Lab, F-75252 Paris 05, France.
   [de Courcy, Benoit; Gresh, Nohad] Univ Paris 05, CNRS, UMR 8601, Chim & Biochim Pharmacol & Toxicol Lab, F-75006 Paris, France.
RP Salmon, L (reprint author), Univ Paris 11, ICMMO, Lab Chim Bioorgan & Bioinorgan, UMR 8182, Batiment 420,15 Rue Georges Clemenceau, F-91405 Orsay, France.
EM laurent.salmon@u-psud.fr
RI Piquemal, Jean-Philip/B-9901-2009
OI Piquemal, Jean-Philip/0000-0001-6615-9426; Jeffery,
   Constance/0000-0002-2147-3638
FU GENCI (CINES/IDRIS) [2009075009]; Centre de Ressources Informatiques de
   Haute Normandie (CRIHAN, Rouen, France); CNRS (France); Ligue Nationale
   contre le Cancer (comite Ile-de-France, France); American Heart
   Association
FX Grant sponsor: GENCI (CINES/IDRIS) (SIBFA Computations); Grant number:
   2009075009; Grant sponsors: Centre de Ressources Informatiques de Haute
   Normandie (CRIHAN, Rouen, France) (SIBFA Computations), CNRS (France),
   Ligue Nationale contre le Cancer (comite Ile-de-France, France),
   American Heart Association
CR *ACC SOFTW INC, 2005, DS VIS
   *ADV CHEM DEV LABS, 2009, ACD CHEMSK VERS 12 0
   ALLEN KN, 1994, BIOCHEMISTRY-US, V33, P1481, DOI 10.1021/bi00172a026
   ALLEN KN, 1994, BIOCHEMISTRY-US, V33, P1488, DOI 10.1021/bi00172a027
   ALLEN KN, 1995, BIOCHEMISTRY-US, V34, P3742, DOI 10.1021/bi00011a032
   Antony J, 2005, J COMPUT CHEM, V26, P1131, DOI 10.1002/jcc.20245
   Antony J, 2002, J COMPUT CHEM, V23, P1281, DOI 10.1002/jcc.10111
   Bas DC, 2008, PROTEINS, V73, P765, DOI 10.1002/prot.22102
   BENTLEY R, 1972, ANNU REV BIOCHEM, V41, P953, DOI 10.1146/annurev.bi.41.070172.004513                                             
   Berrisford JM, 2006, J MOL BIOL, V358, P1353, DOI 10.1016/j.jmb.2006.03.015
   Cantor SM, 1940, J AM CHEM SOC, V62, P2113, DOI 10.1021/ja01865a056                                                             
   CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272
   CLAVERIE P, 1978, J PHYS CHEM-US, V82, P405, DOI 10.1021/j100493a008                                                             
   Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6                                                   
   COULIN F, 1993, BIOCHEMISTRY-US, V32, P14139, DOI 10.1021/bi00214a010
   CUFF ME, 2005, STRUCTURE PUTATIVE M, DOI DOI 10.2210/PDB1ZX5/PDB
   DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002
   de Courcy B, 2010, J CHEM THEORY COMPUT, V6, P1048, DOI 10.1021/ct100089s
   de Courcy B, 2010, J AM CHEM SOC, V132, P3312, DOI 10.1021/ja9059156
   Fenn TD, 2004, BIOCHEMISTRY-US, V43, P6464, DOI 10.1021/bi049812o
   Foret J, 2009, BIOORGAN MED CHEM, V17, P7100, DOI 10.1016/j.bmc.2009.09.005
   Garami A, 2001, J BIOL CHEM, V276, P6566, DOI 10.1074/jbc.M009226200
   Garmer DR, 1998, PROTEINS, V31, P42
   *GIMP TEAM, 2001, GNU IM MAN PROGR VER
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   GRACY RW, 1968, J BIOL CHEM, V243, P4109
   GRACY RW, 1968, J BIOL CHEM, V243, P3161
   GRACY RW, 1968, J BIOL CHEM, V243, P5410
   Gresh N, 2005, J COMPUT CHEM, V26, P1113, DOI 10.1002/jcc.20244
   Gresh N, 1999, J PHYS CHEM B, V103, P11415, DOI 10.1021/jp9921351                                                               
   Gresh N, 2004, J COMPUT CHEM, V25, P160, DOI 10.1002/jcc.10312
   Gresh N, 2003, J PHYS CHEM B, V107, P8669, DOI 10.1021/jp022659s
   Gresh N, 2003, J PHYS CHEM B, V107, P4862, DOI 10.1021/jp022527z
   Gresh N, 1997, BIOPOLYMERS, V41, P145, DOI 10.1002/(SICI)1097-0282(199702)41:2<145::AID-BIP3>3.3.CO;2-#
   Gresh N, 2007, J CHEM THEORY COMPUT, V3, P1960, DOI 10.1021/ct700134r
   Hardre R, 1999, CARBOHYD RES, V318, P110, DOI 10.1016/S0008-6215(99)00100-7
   Hardre R, 1998, BIOORG MED CHEM LETT, V8, P3435, DOI 10.1016/S0960-894X(98)00621-0
   Jenkins LMM, 2007, J AM CHEM SOC, V129, P11067, DOI 10.1021/ja071254o
   Jensen SO, 1998, BBA-PROTEIN STRUCT M, V1382, P5, DOI 10.1016/S0167-4838(97)00122-2                                                   
   KIM Y, 2004, CRYSTAL STRUCTURE AN, DOI DOI 10.2210/PDB1QWR/PDB
   Korndorfer IP, 2000, J MOL BIOL, V300, P917, DOI 10.1006/jmbi.2000.3896
   Lee JH, 2005, PROTEIN SCI, V14, P727, DOI 10.1110/ps.041070205
   Lee JH, 2001, BIOCHEMISTRY-US, V40, P7799, DOI 10.1021/bi002916o
   Li H, 2005, ACTA CRYSTALLOGR E, V61, pM761, DOI 10.1107/S1600536805009098
   MALAISSELAGAE F, 1989, BIOCHIM BIOPHYS ACTA, V998, P118, DOI 10.1016/0167-4838(89)90262-8
   MAPLE JR, 1988, P NATL ACAD SCI USA, V85, P5350, DOI 10.1073/pnas.85.15.5350                                                         
   MILES JS, 1984, GENE, V32, P41, DOI 10.1016/0378-1119(84)90030-1
   Noltmann EA, 1966, METHOD ENZYMOL, V9, P557
   NOLTMANN EA, 1972, ENZYMES, V3, P271
   PATSKOVSKY Y, 2007, CRYSTAL STRUCTURE MA, DOI DOI 10.2210/PDB2QH5/PDB
   Patterson JH, 2003, BIOCHEM J, V372, P77, DOI 10.1042/BJ20021700
   PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991                                                 
   *PERS VIS RAYTR, 2004, PERS VIS RAYTR VERS
   Piquemal JP, 2007, J PHYS CHEM A, V111, P8170, DOI 10.1021/jp072687g
   Piquemal JP, 2007, J CHEM THEORY COMPUT, V3, P824, DOI 10.1021/ct7000182
   Piquemal JP, 2003, J PHYS CHEM A, V107, P10353, DOI 10.1021/jp035748t
   Pitkanen JP, 2004, J BIOL CHEM, V279, P55737, DOI 10.1074/jbc.M410619200
   PROUDFOOT AEI, 1994, EUR J BIOCHEM, V219, P415, DOI 10.1111/j.1432-1033.1994.tb19954.x
   PROUDFOOT AEI, 1994, J PROTEIN CHEM, V13, P619, DOI 10.1007/BF01890460
   Roos AK, 2005, J BIOL CHEM, V280, P6416, DOI 10.1074/jbc.M412018200
   ROSE IA, 1961, J BIOL CHEM, V236, P3086
   ROSE IA, 1973, J BIOL CHEM, V248, P2232
   Roux C, 2004, BIOCHEMISTRY-US, V43, P2926, DOI 10.1021/bi035688h
   Roux C, 2007, J COMPUT CHEM, V28, P938, DOI 10.1002/jcc.20586
   Sagurthi SR, 2009, ACTA CRYSTALLOGR D, V65, P724, DOI 10.1107/S0907444909013328
   Salmon L, 2001, CARBOHYD RES, V335, P195, DOI 10.1016/S0008-6215(01)00210-5                                                   
   SHINABARGER D, 1991, J BIOL CHEM, V266, P2080
   SMITH DJ, 1995, YEAST, V11, P301, DOI 10.1002/yea.320110402
   SMITH DJ, 1994, MOL CELL BIOL, V14, P6030, DOI 10.1128/MCB.14.9.6030                                                           
   Smith JJ, 1997, EUR J BIOCHEM, V244, P325, DOI 10.1111/j.1432-1033.1997.00325.x
   Solomons JTG, 2004, J MOL BIOL, V342, P847, DOI 10.1016/j.jmb.2004.07.085
   Swan MK, 2004, BIOCHEMISTRY-US, V43, P14088, DOI 10.1021/bi048608y
   Swan MK, 2004, J BIOL CHEM, V279, P39838, DOI 10.1074/jbc.M406855200
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   TOPPER YJ, 1957, J BIOL CHEM, V225, P419
   VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1
   WELLS TNC, 1993, BIOCHEMISTRY-US, V32, P1294, DOI 10.1021/bi00056a014
   WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P5777, DOI 10.1021/bi00185a015
   WHITLOW M, 1991, PROTEINS, V9, P153, DOI 10.1002/prot.340090302
   Wills EA, 2001, MOL MICROBIOL, V40, P610, DOI 10.1046/j.1365-2958.2001.02401.x
   Wu BY, 2002, FEBS LETT, V519, P87, DOI 10.1016/S0014-5793(02)02717-5                                                   
   Xiao JF, 2006, J MOL GRAPH MODEL, V25, P289, DOI 10.1016/j.jmgm.2006.01.001
NR 83
TC 15
Z9 15
U1 0
U2 15
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD JAN
PY 2011
VL 79
IS 1
BP 203
EP 220
DI 10.1002/prot.22873
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 702HB
UT WOS:000285884100016
PM 21058398
DA 2018-01-05
ER

PT J
AU Smoak, EM
   Fath, KR
   Barnaby, SN
   Grant, VC
   Banerjee, IA
AF Smoak, Evan M.
   Fath, Karl R.
   Barnaby, Stacey N.
   Grant, Valerie C.
   Banerjee, Ipsita A.
TI pH tunable self-assembly of chicoric acid and their biocompatibility
   studies
SO SUPRAMOLECULAR CHEMISTRY
LA English
DT Article
DE self-assembly; chicoric acid; gold nanoparticles; biocompatibility
ID METAL NANOPARTICLES; BUILDING-BLOCKS; HIV-1 INTEGRASE; CAPPING AGENT;
   QUANTUM DOTS; PEPTIDE; AU; DELIVERY; GOLD; NANOSTRUCTURES
AB We report for the first time, the pH tunable self-assembly of chicoric acid, an HIV-I integrase inhibitor, which displayed a remarkable tendency to self-assemble at room temperature into varying nano- and microstructures. Furthermore, those assemblies were then functionalised with gold (Au) nanoparticles. We then investigated the biocompatibility of the materials by conducting in vitro cell attachment and cytotoxicity studies using normal rat kidney cells. The studies revealed that the biomaterials were non-toxic and biocompatible, and showed considerable adhesion to the cells. These results suggest that the assemblies could potentially be used for a variety of applications, such as carriers for targeted drug delivery as well as optoelectronics and sensors. Furthermore, the formation of highly organised nano- and microstructures of medicinally significant phytohormones such as chicoric acid is of particular interest as it might help in further understanding the supramolecular assembly mechanism of higher organised biological structures for the development of building blocks for various device fabrications.
C1 [Smoak, Evan M.; Barnaby, Stacey N.; Grant, Valerie C.; Banerjee, Ipsita A.] Fordham Univ, Dept Chem, Bronx, NY 10458 USA.
   [Fath, Karl R.] CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA.
   [Fath, Karl R.] Grad Ctr, Flushing, NY 11367 USA.
RP Banerjee, IA (reprint author), Fordham Univ, Dept Chem, 441 E Fordham Rd, Bronx, NY 10458 USA.
EM banerjee@fordham.edu
OI Fath, Karl/0000-0002-6766-2530
FU Trinity Charitable Fund; Fordham University; Undergraduate
   Research/Mentoring Education initiative at Queens College; PSC-CUNY
FX The authors thank Dr Patrick Brock of the Queens College, CUNY,
   Department of Geology for the use of the scanning electron microscope.
   E. S. thanks the Trinity Charitable Fund Award for financial support. K.
   F. thanks Omid Khalpari and Rivka Lederman for their assistance with
   ultrastructural analysis. This work was conducted in part using
   instruments in the Queens College Core Facility for Imaging, Cell and
   Molecular Biology. These studies were funded by grants from the Fordham
   University Faculty Research Program (I. B.), PSC-CUNY (K. F.), and the
   Undergraduate Research/Mentoring Education initiative at Queens College
   (K.F.).
CR Banerjee IA, 2003, NANO LETT, V3, P283, DOI 10.1021/nl034038w
   Banerjee IA, 2004, NANO LETT, V4, P2437, DOI 10.1021/nl0484503
   Basit H, 2008, CHEM-EUR J, V14, P6534, DOI 10.1002/chem.200800374
   Bhat S, 2006, CHEM MATER, V18, P4224, DOI 10.1021/cm0607684
   Bhattacharya S, 2006, ANGEW CHEM INT EDIT, V45, P2934, DOI 10.1002/anie.200504461
   Bose PP, 2007, ORG LETT, V9, P2489, DOI 10.1021/ol0708471
   Bose PP, 2006, CHEM COMMUN, P3196, DOI 10.1039/b606371c
   Coates IA, 2010, J MATER CHEM, V20, P6696, DOI 10.1039/c0jm01166e
   Cos P, 2004, J NAT PROD, V67, P284, DOI 10.1021/np034016p
   Cui H, 2009, NANO LETT, V9, P945, DOI 10.1021/nl802813f
   Di Santo R, 2008, J MED CHEM, V51, P4744, DOI 10.1021/jm8001422
   Dong J, 2001, APPL SPECTROSC, V55, P1603, DOI 10.1366/0003702011954161                                                        
   Drummond CJ, 1999, CURR OPIN COLLOID IN, V4, P449, DOI 10.1016/S1359-0294(00)00020-0                                                   
   Du D, 2007, SENSOR ACTUAT B-CHEM, V127, P317, DOI 10.1016/j.snb.2007.04.023
   Fameau AL, 2010, J COLLOID INTERF SCI, V341, P38, DOI 10.1016/j.jcis.2009.09.034
   Fowles CC, 2010, COLLOID SURFACE B, V78, P250, DOI 10.1016/j.colsurfb.2010.03.010
   Gao XY, 2005, ADV MATER, V17, P2037, DOI 10.1002/adma.200401849
   Gazit E, 2007, CHEM SOC REV, V36, P1263, DOI 10.1039/b605536m
   Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s                                                               
   Huang CH, 2006, TETRAHEDRON, V62, P2050, DOI 10.1016/j.tet.2005.09.150
   Huang PH, 2006, J ORGANOMET CHEM, V691, P975, DOI 10.1016/j.jorganchem.2005.10.046
   Huo Q, 2007, COLLOID SURFACE B, V59, P1, DOI 10.1016/j.colsurfb.2007.04.019
   Jayawarna V, 2006, ADV MATER, V18, P611, DOI 10.1002/adma.200501522
   Jin YG, 2010, INT J PHARMACEUT, V386, P268, DOI 10.1016/j.ijpharm.2009.11.018
   Jokerst JV, 2009, BIOSENS BIOELECTRON, V24, P3622, DOI 10.1016/j.bios.2009.05.026
   Kato T., 1996, SUPRAMOL SCI, V3, P53
   Kim B, 2004, LANGMUIR, V20, P8239, DOI 10.1021/la049424n
   Kimura M, 2004, ADV MATER, V16, P335, DOI 10.1002/adma.200305804
   Kinge SS, 2007, LANGMUIR, V23, P8772, DOI 10.1021/la700514u
   Kogiso M, 1998, LANGMUIR, V14, P4978, DOI 10.1021/la9802419                                                               
   Lee J, 2009, FOOD CHEM, V115, P650, DOI 10.1016/j.foodchem.2008.12.075
   Li HY, 2009, MATER TODAY, V12, P24, DOI 10.1016/S1369-7021(09)70157-9
   Li LL, 2008, CHEM MATER, V20, P5977, DOI 10.1021/cm800293y
   Lin ZQ, 1999, SCI CHINA SER E, V42, P44, DOI 10.1007/BF02917057                                                              
   Liu TB, 2003, J AM CHEM SOC, V125, P312, DOI 10.1021/ja028933d
   Long YQ, 2004, J MED CHEM, V47, P2561, DOI 10.1021/jm030559k
   Mandal S, 2005, CURR APPL PHYS, V5, P118, DOI 10.1016/j.cap.2004.06.006
   Mantion A, 2008, SOFT MATTER, V4, P606, DOI 10.1039/b712826f
   Maura R., 2002, CHEM MATER, V14, P3047
   Miao XR, 2010, APPL SURF SCI, V256, P4647, DOI 10.1016/j.apsusc.2010.02.065
   Niemeyer C.M., 2000, CURR OPIN CHEM BIOL, V4, P600
   Onoda M, 1999, SYNTHETIC MET, V102, P1253, DOI 10.1016/S0379-6779(98)01454-4
   Pallavicini P, 2009, COORDIN CHEM REV, V253, P2226, DOI 10.1016/j.ccr.2008.11.010
   Pan M, 2003, SENSOR ACTUAT A-PHYS, V108, P258, DOI 10.1016/j.sna.2003.08.009
   Pereira GG, 2004, CURR APPL PHYS, V4, P255, DOI 10.1016/j.cap.2003.11.022
   Ray S, 2006, CHEM COMMUN, P2816, DOI 10.1039/b605498f
   Robinson WE, 1996, MOL PHARMACOL, V50, P846
   Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X                                                   
   SCHEPARTZ A, 1989, J AM CHEM SOC, V111, P5976, DOI 10.1021/ja00197a088                                                             
   SEMBDNER G, 1976, PLANTA, V132, P249, DOI 10.1007/BF00399724
   Silhar P, 2010, J AM CHEM SOC, V132, P2868, DOI 10.1021/ja910761y
   Smoak EM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/2/025603
   Stefan IC, 2002, LANGMUIR, V18, P6976, DOI 10.1021/la025722d
   Su JM, 2007, POLYMER, V48, P7598, DOI 10.1016/j.polymer.2007.11.007
   Tabaei SR, 2009, J STRUCT BIOL, V168, P200, DOI 10.1016/j.jsb.2009.07.008
   Tallury Padmavathy, 2010, Adv Drug Deliv Rev, V62, P424, DOI 10.1016/j.addr.2009.11.014
   Taylor D.M., 1995, SUPRAMOL SCI, V2, P75
   Thakkar KN, 2010, NANOMED-NANOTECHNOL, V6, P257, DOI 10.1016/j.nano.2009.07.002
   Thurman E. M., 1985, ORGANIC GEOCHEMISTRY
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   van Herrikhuyzen J, 2007, ANGEW CHEM INT EDIT, V46, P1825, DOI 10.1002/anie.200604225
   Vemula PK, 2009, BIOMATERIALS, V30, P383, DOI 10.1016/j.biomaterials.2008.09.045
   Viney C, 2004, CURR OPIN SOLID ST M, V8, P95, DOI 10.1016/j.cossms.2004.04.001
   Wei DW, 2009, CARBOHYD RES, V344, P2375, DOI 10.1016/j.carres.2009.09.001
   WEILER EW, 1981, PLANTA, V152, P159, DOI 10.1007/BF00391188
   Wu ZQ, 2005, TETRAHEDRON LETT, V46, P8067, DOI 10.1016/j.tetlet.2005.06.173
   Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q                                                               
   Xu CY, 2007, POLYM BULL, V58, P53, DOI 10.1007/s00289-006-0597-0
   Yan DY, 2004, SCIENCE, V303, P65, DOI 10.1126/science.1090763
   Yan XH, 2008, CHEM MATER, V20, P1522, DOI 10.1021/cm702931b
   Yang YL, 2009, NANO TODAY, V4, P193, DOI 10.1016/j.nantod.2009.02.009
   Yap FL, 2007, BIOSENS BIOELECTRON, V22, P775, DOI 10.1016/j.bios.2006.03.016
   Zhang SG, 2002, BIOTECHNOL ADV, V20, P321, DOI 10.1016/S0734-9750(02)00026-5                                                   
NR 73
TC 0
Z9 0
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-0278
EI 1029-0478
J9 SUPRAMOL CHEM
JI Supramol. Chem.
PY 2011
VL 23
IS 10
BP 678
EP 688
DI 10.1080/10610278.2011.601309
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 882KY
UT WOS:000299563700002
DA 2018-01-05
ER

PT J
AU Zhu, AZ
   Zhan, WQ
   Liang, ZX
   Yoon, Y
   Yang, H
   Grossniklaus, HE
   Xu, JG
   Rojas, M
   Lockwood, M
   Snyder, JP
   Liotta, DC
   Shim, H
AF Zhu, Aizhi
   Zhan, Weiqiang
   Liang, Zhongxing
   Yoon, Younghyoun
   Yang, Hua
   Grossniklaus, Hans E.
   Xu, Jianguo
   Rojas, Mauricio
   Lockwood, Mark
   Snyder, James P.
   Liotta, Dennis C.
   Shim, Hyunsuk
TI Dipyrimidine Amines: A Novel Class of Chemokine Receptor. Type 4
   Antagonists with High Specificity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER METASTASIS; CXCR4 ANTAGONISTS; OCULAR MELANOMA; HIV-1
   ENTRY; CELLS; CORECEPTOR; MIGRATION; TUMOR; MODEL; AXIS
AB The C-X-C chemokine receptor type 4 (CXCR4)/stromal cell derived factor-1 (SDF-1 or CXCL12) interaction and the resulting cell signaling cascade play a key role in metastasis and inflammation. On the basis of the previously published CXCR4 antagonist 5 (WZ811), a series of novel nonpeptidic anti-CXCR4 small molecules have been designed and synthesized to improve potency. Following a structure-activity profile around 5, more advanced compounds in the N,N'-(1, 4-phenylenebis-(methylene)) dipyrimidin-2-amines series were discovered and shown to possess higher CXCR4 binding potential and specificity than 5. Compound 26 (508MCl) is the lead compound and exhibits sub-nanomolar potency in three in vitro assays including competitive binding, Matrigel invasion and Ga(i) cyclic adenosine monophosphate (cAMP) modulation signaling. Furthermore, compound 26 displays promising effects by interfering with CXCR4 function in three mouse models: paw inflammation, Matrigel plug angiogenesis, and uveal melanoma micrometastasis. These data demonstrate that dipyrimidine amines are unique CXCR4 antagonists with high potency and specificity.
C1 [Zhan, Weiqiang; Lockwood, Mark; Snyder, James P.; Liotta, Dennis C.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA.
   [Shim, Hyunsuk] Emory Univ, Dept Radiol, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Yang, Hua; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Xu, Jianguo; Rojas, Mauricio] Emory Univ, Dept Med, Div Pulm, Atlanta, GA 30322 USA.
RP Snyder, JP (reprint author), Emory Univ, Dept Chem, 1521 Dickey Dr, Atlanta, GA 30322 USA.
EM jsnyder@emory.edu; dliotta@emory.edu; hshim@emory.edu
FU Georgia Cancer Coalition; NCI [R01 CA 109366]; NIH [R01 CA126447]
FX This study was supported by Distinguished Cancer Scientist Development
   Fund of Georgia Cancer Coalition, and NCI R01 CA 109366 (H.S.) and NIH
   R01 CA126447 (H.E.G.). We are grateful to Jessica Paulishen for careful
   reading of the manuscript and helpful remarks.
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x                                                               
   Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X
   Chavance M, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-37
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   Dithmar S, 2000, MELANOMA RES, V10, P2, DOI 10.1097/00008390-200010010-00001
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8
   Fujii N, 2001, Curr Opin Investig Drugs, V2, P1198
   Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/eoid.12.2.185.21405
   Gao C, 2007, TRANSPLANT P, V39, P268, DOI 10.1016/j.transproceed.2006.10.020
   Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0
   Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847
   Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5
   Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102
   Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x
   Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Liang ZX, 2005, CANCER RES, V65, P967
   Mori T, 2004, MOL CANCER THER, V3, P29
   Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595
   Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3
   Oonuma T, 2003, J VET MED SCI, V65, P1069, DOI 10.1292/jvms.65.1069
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Pyo RT, 2006, J MOL CELL CARDIOL, V41, P834, DOI 10.1016/j.yjmcc.2006.08.008
   Richard CL, 2008, PPAR RES, DOI 10.1155/2008/769413
   Sanchez X, 1997, J BIOL CHEM, V272, P27529, DOI 10.1074/jbc.272.44.27529
   Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200
   Xu JG, 2007, AM J RESP CELL MOL, V37, P291, DOI 10.1165/rcmb.2006-01870C
   Yang H, 2006, CURR EYE RES, V31, P557, DOI 10.1080/02713680600718962
   Yang JY, 2008, CANCER LETT, V269, P46, DOI 10.1016/j.canlet.2008.04.016
   Yoon Y, 2007, CANCER RES, V67, P7518, DOI 10.1158/0008-5472.CAN-06-2263
   Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369                                                             
   Zhan WQ, 2007, J MED CHEM, V50, P5655, DOI 10.1021/jm070679i
   ZHU A, 2010, SNM 57 ANN M SALT LA
NR 39
TC 29
Z9 29
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 23
PY 2010
VL 53
IS 24
BP 8556
EP 8568
DI 10.1021/jm100786g
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 693ZQ
UT WOS:000285264300010
PM 21105715
OA green_accepted
DA 2018-01-05
ER

PT J
AU Braz, VA
   Barkley, MD
   Jockusch, RA
   Wintrode, PL
AF Braz, Valerie A.
   Barkley, Mary D.
   Jockusch, Rebecca A.
   Wintrode, Patrick L.
TI Efavirenz Binding Site in HIV-1 Reverse Transcriptase Monomers
SO BIOCHEMISTRY
LA English
DT Article
ID EXCHANGE MASS-SPECTROMETRY; POL POLYPROTEIN PRECURSOR; STRUCTURAL BASIS;
   NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; HYDROGEN-EXCHANGE;
   ELECTROSPRAY-IONIZATION; CONFORMATIONAL-CHANGES; P66/P51 HETERODIMER;
   CRYSTAL-STRUCTURE
AB Efavirenz (EFV) is a potent nonnucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of AIDS. NNRTIs bind in a hydrophobic pocket located in the p66 subunit of reverse transcriptase (RT), which is not present in crystal structures of RT without an inhibitor. Recent studies showed that monomeric forms of the p66 and p51 subunits bind efavirenz with micromolar affinity. The effect of efavirenz on the solution conformations of p66 and p51 monomers was studied by hydrogen-deuterium exchange mass spectrometry (HXMS) and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). HXMS data reveal that five peptides, four of which contain efavirenz contact residues seen in the crystal structure of the RT EFV complex, exhibit a reduced level of exchange in monomer EFV complexes. Moreover, peptide 232-246 undergoes slow cooperative unfolding-refolding in the bound monomers, but at a rate much slower than that observed in the p66 subunit of the RT heterodimer [Seckler, J. M., Howard, K. J., Barkley, M. D., and Wintrode, P. L. (2009) Biochemistry 48, 7646-7655]. These results suggest that the efavirenz binding site on p66 and p51 monomers is similar to the NNRTI binding pocket in the p66 subunit of RT. Nanoelectrospray ionization FT-ICR mass spectra indicate that the intact monomers each have (at least) two different conformations. In the presence of efavirenz, the mass spectra change significantly and suggest that p51 adopts a single, more compact conformation, whereas p66 undergoes facile, electrospray-induced cleavage. The population shift is consistent with a selected-fit binding mechanism.
C1 [Braz, Valerie A.; Barkley, Mary D.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Barkley, Mary D.; Wintrode, Patrick L.] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
   [Jockusch, Rebecca A.] Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada.
RP Barkley, MD (reprint author), Case Western Reserve Univ, Dept Chem, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM mdb4@case.edu; patrick.wintrode@case.edu
RI Barkley, Mary/C-6973-2011
FU National Institutes of Health [GM071267]
FX This work was supported by National Institutes of Health Grant GM071267.
CR BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003
   Benesch JLP, 2007, CHEM REV, V107, P3544, DOI 10.1021/cr068289b
   Braz VA, 2010, BIOCHEMISTRY-US, V49, P601, DOI 10.1021/bi901579y
   Braz VA, 2009, ANAL BIOCHEM, V388, P170, DOI 10.1016/j.ab.2009.02.019
   Chen ML, 2007, ANAL CHEM, V79, P2031, DOI 10.1021/ac061743r
   CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074
   COFFIN JM, 1997, RETROVIRUSES
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Engen JR, 1997, BIOCHEMISTRY-US, V36, P14384, DOI 10.1021/bi971635m
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   Figueiredo A, 2006, PLOS PATHOG, V2, P1051, DOI 10.1371/journal.ppat.0020119
   Geitmann M, 2006, J MED CHEM, V49, P2367, DOI 10.1021/jm0504048
   Grobler JA, 2007, J BIOL CHEM, V282, P8005, DOI 10.1074/jbc.M608274200
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Ignatov ME, 2005, BIOCHEMISTRY-US, V44, P5346, DOI 10.1021/bi048000p
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Kaltashov IA, 2005, WI S MAS SP, P1
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Konermann L, 1997, BIOCHEMISTRY-US, V36, P12296, DOI 10.1021/bi971266u
   Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7
   LEGRICE SFJ, 1991, EMBO J, V10, P3905
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   RESTLE T, 1990, J BIOL CHEM, V265, P8986
   Seckler JM, 2009, BIOCHEMISTRY-US, V48, P7646, DOI 10.1021/bi900790x
   SECKLER JM, 2010, BIOPHYS J IN PRESS
   Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777
   Sluis-Cremer N, 2004, INT J BIOCHEM CELL B, V36, P1836, DOI 10.1016/j.biocel.2004.02.020
   Sluis-Cremer N, 2000, BIOCHEMISTRY-US, V39, P1427, DOI 10.1021/bi991682+                                                               
   Sluis-Cremer N, 2008, VIRUS RES, V134, P147, DOI 10.1016/j.virusres.2008.01.002
   Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327
   Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Tachedjian G, 2005, PROTEINS, V60, P5, DOI 10.1002/prot.20480
   Tachedjian G, 2005, FEBS LETT, V579, P379, DOI 10.1016/j.febslet.2004.11.099
   Tachedjian G, 2003, J MOL BIOL, V326, P381, DOI 10.1016/S0022-2836(02)01433-X
   Tachedjian G, 2001, P NATL ACAD SCI USA, V98, P7188, DOI 10.1073/pnas.121055998
   Tsutsui Y, 2006, BIOCHEMISTRY-US, V45, P6561, DOI 10.1021/bi060431f
   Van Berkel GJ, 2001, J AM SOC MASS SPECTR, V12, P853
   Venezia CF, 2009, BIOCHEMISTRY-US, V48, P9084, DOI 10.1021/bi9010495
   Venezia CF, 2006, BIOCHEMISTRY-US, V45, P2779, DOI 10.1021/bi051915z
   VERONESE FD, 1986, SCIENCE, V231, P1289
   Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   Weikl TR, 2009, PROTEINS, V75, P104, DOI 10.1002/prot.22223
   Weis DD, 2006, J AM SOC MASS SPECTR, V17, P1498, DOI 10.1016/j.jasms.2006.05.014
   ZHANG Z, MAGTRAN MAGIC TRANSF
   ZHANG Z, 1993, PROTEIN SCI, V2, P779
   Zheng XH, 2010, BIOCHEMISTRY-US, V49, P2821, DOI 10.1021/bi902116z
   Zheng XH, 2009, ANTIVIR RES, V84, P205, DOI 10.1016/j.antiviral.2009.07.021
NR 51
TC 9
Z9 9
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD DEC 14
PY 2010
VL 49
IS 49
BP 10565
EP 10573
DI 10.1021/bi101480z
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 690BL
UT WOS:000284975000022
PM 21090588
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tian, XT
   Qin, BJ
   Wu, ZY
   Wang, XF
   Lu, H
   Morris-Natschke, SL
   Chen, CH
   Jiang, SB
   Lee, KH
   Xie, L
AF Tian, Xingtao
   Qin, Bingjie
   Wu, Zhiyuan
   Wang, Xiaofeng
   Lu, Hong
   Morris-Natschke, Susan L.
   Chen, Chin Ho
   Jiang, Shibo
   Lee, Kuo-Hsiung
   Xie, Lan
TI Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines
   as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIVIRAL ACTIVITY; ETRAVIRINE TMC125;
   ENTRY INHIBITORS; RILPIVIRINE; DERIVATIVES; RESISTANCE; INFECTION;
   COMPLEXES; MK-4965
AB On the basis of the structures and activities of our previously identified non-nucleoside reverse transcriptase inhibitors (NNRTIs), we designed and synthesized two sets of derivatives, diarylpyridines (A) and diarylanilines (B), and tested their anti-HIV-1 activity against infection by HIV-1 NL4-3 and IIIB in TZM-bl and MT-2 cells, respectively. The results showed that most compounds exhibited potent anti-HIV-1 activity with low nanomolar EC(50) values, and some of them, such as 13m, 14c, and 14e, displayed high potency with subnanomolar EC(50) values, which were more potent than etravirine (TMC125, 1) in the same assays. Notably, these compounds were also highly effective against infection by multi-RTI-resistant strains, suggesting a high potential to further develop these compounds as a novel class of NNRTIs with improved antiviral efficacy and resistance profile.
C1 [Tian, Xingtao; Qin, Bingjie; Wu, Zhiyuan; Wang, Xiaofeng; Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Lu, Hong; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [Chen, Chin Ho] Duke Univ, Med Ctr, Surg Oncol Res Facil, Durham, NC 27710 USA.
   [Morris-Natschke, Susan L.; Lee, Kuo-Hsiung] Univ N Carolina, Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA.
   [Lee, Kuo-Hsiung] China Med Univ & Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.
RP Xie, L (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM lanxieshi@yahoo.com
RI Jiang, Shibo/L-4500-2014; Xie, Lan /A-4533-2012
FU Natural Science Foundation of China (NSFC) [30930106, 20472114,
   7052057]; Beijing municipal government; U.S. NIH [AI46221, AI65310,
   AI33066]
FX This investigation was supported by grants 30930106, 20472114, and
   7052057 from the Natural Science Foundation of China (NSFC) and Beijing
   municipal government, respectively, awarded to L. Xie, and U.S. NIH
   grants awarded to S. Jiang (AI46221), C. H. Chen (AI65310), and K. H.
   Lee (AI33066).
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4680.2004
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Dang Z, 2009, J MED CHEM, V52, P7887, DOI 10.1021/jm9004253
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Lai MT, 2009, ANTIMICROB AGENTS CH, V53, P2424, DOI 10.1128/AAC.01559-08
   Lansdon EB, 2010, J MED CHEM, V53, P4295, DOI 10.1021/jm1002233
   Minuto Joshua J, 2008, Futur HIV Ther, V2, P525, DOI 10.2217/17469600.2.6.525
   Mordant C, 2007, EUR J MED CHEM, V42, P567, DOI 10.1016/j.ejmech.2006.11.014
   Obiol-Pardo C, 2007, J CHEM INF MODEL, V47, P134, DOI 10.1021/ci600412z
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   REDEMANN CT, 1949, ORG SYNTH, V29, P8
   Ripamonti D, 2008, CURR OPIN INVEST DR, V9, P899
   Rossotti Roberto, 2009, HIV Therapy, V3, P63, DOI 10.2217/17584310.3.1.63
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   TIAN XT, 2009, BIOORG MED CHEM LETT, V19, P3482
   Tucker TJ, 2008, J MED CHEM, V51, P6503, DOI 10.1021/jm800856c
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
NR 23
TC 35
Z9 41
U1 2
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 9
PY 2010
VL 53
IS 23
BP 8287
EP 8297
DI 10.1021/jm100738d
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 686YO
UT WOS:000284738400008
PM 21049929
OA green_accepted
DA 2018-01-05
ER

PT J
AU Emani, PS
   Olsen, GL
   Echodu, DC
   Varani, G
   Drobny, GP
AF Emani, Prashant S.
   Olsen, Gregory L.
   Echodu, Dorothy C.
   Varani, Gabriele
   Drobny, Gary P.
TI Slow Exchange Model of Nonrigid Rotational Motion in RNA for Combined
   Solid-State and Solution NMR Studies
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID TAR RNA; HYDRODYNAMIC PROPERTIES; TRANSPORT-PROPERTIES;
   NEUTRON-DIFFRACTION; MOLECULAR-DYNAMICS; BROWNIAN-MOTION; RELAXATION;
   RECOGNITION; COMPLEX; DNA
AB Functional RNA molecules are conformationally dynamic and sample a multitude of dynamic modes over a wide range of frequencies Thus, a comprehensive description of RNA dynamics requires the inclusion of a broad range of motions across multiple dynamic rates which must be derived from multiple spectroscopies Here we describe a slow conformational exchange theoretical approach to combining the description of local motions in RNA that occur in the nanosecond to microsecond window and are detected by solid-state NMR with nonrigid rotational motion of the HIV-1 transactivation response element (TAR) RNA in solution as observed by solution NMR This theoretical model unifies the experimental results generated by solution and solid-state NMR and provides a comprehensive view of the dynamics of HIV-1 TAR RNA, a well-known paradigm of an RNA where function requires extensive conformational rearrangements This methodology provides a quantitative atomic level view of the amplitudes and rates of the local and collective displacements of the TAR RNA molecule and provides directly motional parameters for the conformational capture hypothesis of this classical RNA-ligand interaction
C1 [Olsen, Gregory L.; Echodu, Dorothy C.; Varani, Gabriele; Drobny, Gary P.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Emani, Prashant S.] Univ Washington, Dept Phys, Seattle, WA 98195 USA.
   [Varani, Gabriele] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
RP Drobny, GP (reprint author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.
RI Olsen, Greg/B-7525-2008
OI Olsen, Greg/0000-0001-6039-8434
FU NSF [MCB-0642253]; NIH [RO1-EB03152]
FX This work was supported by grants from the NSF (MCB-0642253) and NIH
   (RO1-EB03152) to G PD and G V We are grateful to Michael Bardaro for
   providing the TAR relaxation data and their error analysis and to Kari
   Pederson for help with the editing of the manuscript
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Abragam A., 1961, PRINCIPLES NUCL MAGN
   Al-Hashimi HM, 2007, BIOPOLYMERS, V86, P345, DOI 10.1002/bip.20754
   ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1                                                            
   Aragon SR, 2009, MACROMOLECULES, V42, P6290, DOI 10.1021/ma900453c
   ARAGON SR, 2006, MOL COLLOIDAL ELECTR, V134
   Bardaro MF, 2009, NUCLEIC ACIDS RES, V37, P1529, DOI 10.1093/nar/gkn1074
   Brodsky AS, 1997, J MOL BIOL, V267, P624, DOI 10.1006/jmbi.1996.0879
   Carrasco B, 1999, BIOPHYS J, V76, P3044, DOI 10.1016/S0006-3495(99)77457-6                                                   
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   DELATORRE JG, 1977, BIOPOLYMERS, V16, P1747, DOI DOI 10.1002/BIP.1977.360160811
   Dethoff EA, 2008, BIOPHYS J, V95, P3906, DOI 10.1529/biophysj.108.140285
   Duchardt E, 2005, J BIOMOL NMR, V32, P295, DOI 10.1007/s10858-005-0659-x
   Echodu D, 2008, J PHYS CHEM B, V112, P13934, DOI 10.1021/jp801723x
   FAVRO LD, 1960, PHYS REV, V119, P53, DOI 10.1103/PhysRev.119.53                                                          
   Fernandes MX, 2002, NUCLEIC ACIDS RES, V30, P1782, DOI 10.1093/nar/30.8.1782
   FREY MN, 1973, J CHEM PHYS, V59, P915, DOI 10.1063/1.1680114                                                               
   Hansen AL, 2007, J AM CHEM SOC, V129, P16072, DOI 10.1021/ja0757982
   Hennig M, 2000, NUCLEIC ACIDS RES, V28, P1585, DOI 10.1093/nar/28.7.1585
   Koplin J, 2005, STRUCTURE, V13, P1255, DOI 10.1016/j.str.2005.05.015
   Lange OF, 2008, SCIENCE, V320, P1471, DOI 10.1126/science.1157092
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041
   MILLERO FJ, 1971, J CHEM ENG DATA, V16, P85, DOI 10.1021/je60048a006                                                             
   Olsen GL, 2008, J AM CHEM SOC, V130, P2896, DOI 10.1021/ja0778803
   Olsen GL, 2010, J AM CHEM SOC, V132, P303, DOI 10.1021/ja907515s
   Olsen GL, 2009, J BIOMOL NMR, V45, P133, DOI 10.1007/s10858-009-9355-6
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   SCHURR JM, 1994, J MAGN RESON SER A, V106, P1, DOI 10.1006/jmra.1994.1001                                                          
   Shajani Z, 2005, J MOL BIOL, V349, P699, DOI 10.1016/j.jmb.2005.04.012
   Shajani Z, 2007, BIOPOLYMERS, V86, P348, DOI 10.1002/bip.20650
   Shajani Z, 2006, TRENDS BIOCHEM SCI, V31, P421, DOI 10.1016/j.tibs.2006.06.002
   Tugarinov V, 2001, J AM CHEM SOC, V123, P3055, DOI 10.1021/ja003803v
   WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390                                                               
   Wong V, 2009, P NATL ACAD SCI USA, V106, P11016, DOI 10.1073/pnas.0809994106
   YAMAKAWA H, 1970, J CHEM PHYS, V53, P436, DOI 10.1063/1.1673799                                                               
   Ying JF, 2006, J AM CHEM SOC, V128, P11443, DOI 10.1021/ja061984g
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2008, NAT METHODS, V5, P243, DOI 10.1038/NMETH.1180
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
   Zhang Q, 2009, RNA, V15, P1941, DOI 10.1261/rna.1806909
NR 43
TC 8
Z9 8
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD DEC 9
PY 2010
VL 114
IS 48
BP 15991
EP 16002
DI 10.1021/jp107193z
PG 12
WC Chemistry, Physical
SC Chemistry
GA 686YR
UT WOS:000284738800032
PM 21067190
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jen, CH
   Leary, JA
AF Jen, Connie H.
   Leary, Julie A.
TI A competitive binding study of chemokine, sulfated receptor, and
   glycosaminoglycan interactions by nano-electrospray ionization mass
   spectrometry
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE C-C motif chemokine 7 (CCL7); C-C chemokine receptor type 2 (CCR2);
   Arixtra; Glycosaminoglycan (GAG); Tyrosine sulfation; nano-Electrospray
   ionization (nano-ESI); Mass spectrometry (MS); Association constant
   (K(a)); Noncovalent complex
ID MONOCYTE CHEMOTACTIC PROTEIN-1; VANCOMYCIN GROUP ANTIBIOTICS; TYROSINE
   SULFATION; CC-CHEMOKINE; LIGAND-BINDING; HIV-1 ENTRY; NONCOVALENT
   COMPLEXES; AMINO-TERMINUS; GAS-PHASE; IN-VIVO
AB Chemokines are secreted proteins that play roles in inducing chemotaxis, extravasation, and activation of leukocytes associated with inflammatory or homeostatic processes. Tyrosine sulfation of the chemokine receptor has been shown to be important for binding and signaling. We have applied a mass spectrometry method to measure the contribution of this posttranslational modification to binding of its ligand chemokine. Using nano-electrospray time-of-flight mass spectrometry (nano-ESI TOF MS), we determined the association constants of C-C motif chemokine 7 (CCL7) with C-C chemokine receptor type 2 (CCR2), monosulfated CCR2, and disulfated CCR2 peptides to be 1.1 x 10(4) M(-1), 3.9 x 10(4) M(-1), and 4.0 x 10(5) M(-1), respectively. To our knowledge, this is the first reported association constant measurement between a protein and sulfated peptide using MS. Furthermore, nano-ESI MS was used to characterize noncovalent binding interactions among CCL7, Arixtra (a pentasaccharide glycosaminoglycan [GAG] analog), and disulfated CCR2 peptide. A lack of observable ternary complex formation prompted investigation of competitive binding. Results of this study suggest that CCR2 competes partially with GAG for CCL7 binding and that disulfated CCR2 peptide has a higher binding affinity than Arixtra, which correlates with data from association constant measurements for CCL7-disulfated CCR2 and CCL7-Arixtra. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Jen, Connie H.; Leary, Julie A.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
RP Leary, JA (reprint author), Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
EM jaleary@ucdavis.edu
FU National Institutes of Health (NIH) [HD056022, GM47356]
FX This work was supported in part by National Institutes of Health (NIH)
   grants HD056022 and GM47356.
CR Ali S, 2005, J IMMUNOL, V175, P1257, DOI 10.4049/jimmunol.175.2.1257                                                     
   Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529
   Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661                                                         
   Benkestock K, 2004, J MASS SPECTROM, V39, P1059, DOI 10.1002/jms.685
   Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06
   Duma L, 2007, J MOL BIOL, V365, P1063, DOI 10.1016/j.jmb.2006.10.040
   Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200
   Gabelica V, 2002, RAPID COMMUN MASS SP, V16, P1723, DOI 10.1002/rcm.776
   Gao QY, 1996, J MASS SPECTROM, V31, P31
   Gutierrez J, 2004, J BIOL CHEM, V279, P14726, DOI 10.1074/jbc.M309689200
   Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747
   Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m
   HSIEH FYL, 1995, ANAL BIOCHEM, V229, P20, DOI 10.1006/abio.1995.1373
   Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239
   Jorgensen TJD, 1998, ANAL CHEM, V70, P4427, DOI 10.1021/ac980563h                                                               
   Karas M, 2000, FRESEN J ANAL CHEM, V366, P669, DOI 10.1007/s002160051561                                                           
   Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d                                                               
   Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200
   Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   LIM HK, 1995, J MASS SPECTROM, V30, P708, DOI 10.1002/jms.1190300509                                                          
   Loo JA, 1997, J AM SOC MASS SPECTR, V8, P234, DOI 10.1016/S1044-0305(96)00238-3                                                   
   Loo JA, 1997, MASS SPECTROM REV, V16, P1
   Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200
   Parish CR, 2006, NAT REV IMMUNOL, V6, P633, DOI 10.1038/nri1918
   Peschke M, 2004, J AM SOC MASS SPECTR, V15, P1424, DOI [10.1016/j.jasms.2004.05.005, 10.1016/j.asms.2004.05.005]
   Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295                                                     
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x                                                               
   Salek M, 2004, ANAL CHEM, V76, P5136, DOI 10.1021/ac0400414
   SannesLowery KA, 1997, ANAL CHEM, V69, P5130, DOI 10.1021/ac970745w
   Schenauer MR, 2009, INT J MASS SPECTROM, V287, P70, DOI 10.1016/j.ijms.2009.02.023
   Seibert C, 2008, BIOCHEMISTRY-US, V47, P11251, DOI 10.1021/bi800965m
   Simpson LS, 2009, CHEM BIOL, V16, P153, DOI 10.1016/j.chembiol.2008.12.007
   Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052
   Wang WJ, 2003, ANAL CHEM, V75, P4945, DOI 10.1021/ac0343001
   Wang WJ, 2003, METHOD ENZYMOL, V362, P376
   Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519                                                               
   Wu QY, 1997, J AM CHEM SOC, V119, P1157, DOI 10.1021/ja9630250                                                               
   Yu GL, 2000, THROMB RES, V100, P549, DOI 10.1016/S0049-3848(00)00368-6
   Yu YH, 2006, J AM SOC MASS SPECTR, V17, P524, DOI 10.1016/j.jasms.2005.12.008
   Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200
NR 46
TC 11
Z9 11
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD DEC 1
PY 2010
VL 407
IS 1
BP 134
EP 140
DI 10.1016/j.ab.2010.08.005
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 658OY
UT WOS:000282500500016
PM 20696123
OA green_accepted
DA 2018-01-05
ER

PT J
AU Whaley, KJ
   Hanes, J
   Shattock, R
   Cone, RA
   Friend, DR
AF Whaley, Kevin J.
   Hanes, Justin
   Shattock, Robin
   Cone, Richard A.
   Friend, David R.
TI Novel Approaches to Vaginal Delivery and Safety of Microbicides:
   Biopharmaceuticals, Nanoparticles, and Vaccines
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Microbicides; Biopharmaceuticals; Nanoparticles; Vaccine; Vaginal
   immunity; Safety
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; HUMAN MUCUS BARRIER;
   GENITAL HERPES; MONOCLONAL-ANTIBODIES; CHLAMYDIA-TRACHOMATIS; HIV
   TRANSMISSION; PROTECTS MICE; MOUSE MODEL; IN-VIVO
AB The HIV-1 epidemic remains unchecked despite existing technology; vaccines and microbicides in development may help reverse the epidemic. Reverse transcriptase inhibitors (RTIs) formulated in gels tenofovir (TFV) and IVRs (dapivirine) are under clinical development. While TFV or similar products may prove successful for HIV-1, alternatives to RTIs may provide additional benefits, e.g., broader STI prevention. Biopharmaceutical agents under development as microbicides include cyanovirin, RANTES analogues, commensals, and Mabs. Cost of manufacturing biopharmaceuticals has been reduced and they can be formulated into tablets, films, and IVRs for vaginal delivery. Nanotechnology offers a novel approach to formulate microbicides potentially leading to uniform epithelial delivery. Delivery through vaginal mucus may be possible by controlling nanoparticle size and surface characteristics. Combining prevention modalities may be the most effective means of preventing STI transmission, importantly, codelivery of microbicides and vaccines has demonstrated. Finally, the safety of microbicide preparations and excipients commonly used can be assessed using a mouse/HSV-2 susceptibility model. Screening of new microbicide candidates and formulation excipients may avoid past issues of enhancing HIV-1 transmission. This article forms part of a special supplement covering several presentations on novel microbicide formulations from the symposium on "Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Friend, David R.] CONRAD, Eastern Virginia Med Sch, Arlington, VA 22209 USA.
   [Whaley, Kevin J.] Mapp Biopharmaceut Inc, San Diego, CA 92121 USA.
   [Hanes, Justin] Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21212 USA.
   [Hanes, Justin] Hopkins Univ, Inst NanoBiotechnol, Baltimore, MD 21212 USA.
   [Shattock, Robin] St Georges Univ London, Ctr Infect, Div Cellular & Mol Med, London SW1 0RE, England.
   [Cone, Richard A.] Johns Hopkins Univ, Mucosal Protect Lab, Dept Biophys, Baltimore, MD 21218 USA.
RP Friend, DR (reprint author), CONRAD, Eastern Virginia Med Sch, Arlington, VA 22209 USA.
EM dfriend@conard.org
CR Achilles SL, 2002, SEX TRANSM DIS, V29, P655, DOI 10.1097/00007435-200211000-00007
   Adriaens E, 2008, SEX TRANSM DIS, V35, P512, DOI 10.1097/OLQ.0b013e3181644669
   Anderson DJ, 2010, J INFECT DIS, V202, P333, DOI 10.1086/653620
   Anderson DJ, 2010, AIDS, V24, P163, DOI 10.1097/QAD.0b013e32833424c8
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Bourne N, 2003, CLIN MICROBIOL INFEC, V9, P816, DOI 10.1046/j.1469-0691.2003.00659.x                                                
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   Cates W, 2010, CONTRACEPTION, V81, P460, DOI 10.1016/j.contraception.2010.01.002
   Cerini F, 2008, JAIDS-J ACQ IMM DEF, V49, P472, DOI 10.1097/QAI.0b013e31818c953f
   Cherpelis S, 2001, J VIROL, V75, P1547, DOI 10.1128/JVI.75.3.1547-1550.2001                                                 
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157
   Doncel GF, 2010, ANTIVIR RES, V88, pS10, DOI 10.1016/j.antiviral.2010.09.018
   Food and Drug Administration, 2004, CHALL OPP CRIT PATH
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005
   Fuchs EJ, 2007, J INFECT DIS, V195, P703, DOI 10.1086/511279
   Gaertner H., 2008, P NATL ACAD SCI USA, V205, P17706
   Galen BT, 2007, J INFECT DIS, V195, P1332, DOI 10.1086/513279
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103
   Hiatt A, 2006, P NATL ACAD SCI USA, V103, P14645, DOI 10.1073/pnas.0607089103
   Hladik F, 2010, ANTIVIR RES, V88, pS3, DOI 10.1016/j.antiviral.2010.09.011
   Holt BY, 2006, J WOMENS HEALTH, V15, P281, DOI 10.1089/jwh.2006.15.281                                                         
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang Z, 2010, BIOTECHNOL BIOENG, V106, P9, DOI 10.1002/bit.22652
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Lian Y, 2005, J VIROL, V79, P13338, DOI 10.1128/JVI.79.21.13338-13349.2005
   Liu Y., 2010, TRENDS MICR FORM WOR
   Maguire RA, 2001, SEX TRANSM DIS, V28, P259, DOI 10.1097/00007435-200105000-00003
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   McGowan I, 2006, BIOLOGICALS, V34, P241, DOI 10.1016/j.biologicals.2006.08.002
   Morris G., 2010, MICR 2010 PITTSB PA, P229
   Morrow KM, 2010, ANTIVIR RES, V88, pS40, DOI 10.1016/j.antiviral.2010.09.008
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   [PATH Coalition Advancing Multipurpose Innovations (CAMI)], 2010, SAV LIV MULT TECHN T
   Phillips DM, 1998, CONTRACEPTION, V57, P341, DOI 10.1016/S0010-7824(98)00040-7                                                   
   RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133
   Saltzman W.M., 1995, BIOPHYS J, V55, P508
   Schlievert PM, 2008, ANTIMICROB AGENTS CH, V52, P4448, DOI 10.1128/AAC.00989-08
   Secchi M, 2009, PROTEIN EXPRES PURIF, V68, P34, DOI 10.1016/j.pep.2009.06.018
   Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468
   Simons-Rudolph A., 2008, MICROBICIDE Q, V6, P1
   Srivastava IK, 2002, J VIROL, V76, P2835, DOI 10.1128/JVI.76.6.2835-2847.2002
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Tuyama ACG, 2006, J INFECT DIS, V194, P795, DOI 10.1086/506948
   Veazey RS, 2009, J INFECT DIS, V199, P1525, DOI 10.1086/598685
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   WHALEY KJ, 1993, J INFECT DIS, V168, P1009, DOI 10.1093/infdis/168.4.1009                                                       
   Whaley K.J., 2004, MICROBICIDE Q, V2, P11
   Yu RR, 2009, J MED PRIMATOL, V38, P125, DOI 10.1111/j.1600-0684.2008.00316.x
   Zeitlin L, 1997, CONTRACEPTION, V56, P329, DOI 10.1016/S0010-7824(97)00154-6                                                   
   Zeitlin L, 2009, P NATL ACAD SCI USA, V106, P6029, DOI 10.1073/pnas.0902239106
NR 60
TC 53
Z9 54
U1 1
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD DEC
PY 2010
VL 88
SU 1
BP S55
EP S66
DI 10.1016/j.antiviral.2010.09.006
PG 12
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 699JP
UT WOS:000285660000008
PM 21109069
DA 2018-01-05
ER

PT J
AU Thomas, A
   Lins, L
   Divita, G
   Brasseur, R
AF Thomas, Annick
   Lins, Laurence
   Divita, Gilles
   Brasseur, Robert
TI Realistic modeling approaches of structure-function properties of CPPs
   in non-covalent complexes
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Review
DE CPPs; Cargo; Peptide disorder; Arginine; Tryptophan; Complex;
   Nanoparticle; Molecular modeling
ID CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAIN; MAMMALIAN-CELLS;
   IN-VIVO; MOLECULAR-MECHANISMS; BINDING MECHANISM; SIRNA DELIVERY; TAT
   PEPTIDE; HIV-1 TAT; TRANSLOCATION
AB Transfers of cargoes into cells by means of carrier peptides are multi-steps biological phenomenon the mechanisms of which are unclear. We here discuss bases of realistic in silica molecular modeling approaches of the formation of non-covalent complexes considering CPPs and cargo diversities. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Thomas, Annick; Lins, Laurence; Brasseur, Robert] ULg, Gembloux AgroBiotech, CBMN, B-5030 Gembloux, Belgium.
   [Divita, Gilles] CNRS, FRE 2593, CRBM, F-34293 Montpellier, France.
RP Thomas, A (reprint author), ULg, Gembloux AgroBiotech, CBMN, 2 Passage Deportes, B-5030 Gembloux, Belgium.
EM athomas@ulg.ac.be
OI Lins, Laurence/0000-0001-7772-6748
CR Alexandrescu AT, 2003, PROTEIN SCI, V12, P2132, DOI 10.1110/ps.03164403
   BRASSEUR R, 1995, J MOL GRAPHICS, V13, P312, DOI 10.1016/0263-7855(95)00052-6
   BRASSEUR R, 1991, J BIOL CHEM, V266, P16120
   Brasseur R, 1988, Virus Genes, V1, P325
   BRASSEUR R, 2000, MOL DESCRIPTION BIOL, V1
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Deshayes S, 2008, BBA-BIOMEMBRANES, V1778, P1197, DOI 10.1016/j.bbamem.2008.01.027
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   ELANDALOUSSI H, 2005, J CONTROL RELEASE, V110, P189
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Epand RF, 2006, BIOCHEMISTRY-US, V45, P6105, DOI 10.1021/bi060245+
   Etchebest C, 2005, PROTEINS, V59, P810, DOI 10.1002/prot.20458
   Fotin-Mleczek M, 2005, CURR PHARM DESIGN, V11, P3613, DOI 10.2174/138161205774580778                                                      
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Glick M, 2000, PROTEINS, V38, P273, DOI 10.1002/(SICI)1097-0134(20000215)38:3<273::AID-PROT4>3.3.CO;2-9
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   KONATE K, 2010, INSIGHT CEL IN PRESS
   Lazaridis T, 2002, CURR ORG CHEM, V6, P1319, DOI 10.2174/1385272023373491                                                        
   LEACH JR, 1996, MOL MODELLING PRINCI, P171
   Lins L, 2006, BIOPHYS J, V90, P470, DOI 10.1529/biophysj.105.068213
   Lins L, 2003, PROTEIN SCI, V12, P1406, DOI 10.1110/ps.0304803
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   MENDOZAESPINOSA A, 2008, BIOCHEM BIOPH RES CO, V365, P8
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Munoz-Morris MA, 2007, BIOCHEM BIOPH RES CO, V355, P877, DOI 10.1016/j.bbrc.2007.02.046
   Oehlke J, 2005, J MOL RECOGNIT, V18, P50, DOI 10.1002/jmr.691
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Sakai N, 2003, J AM CHEM SOC, V125, P14348, DOI 10.1021/ja0376011
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Thomas A, 2006, PROTEINS, V65, P889, DOI 10.1002/prot.21151
   Thomas A, 2006, CURR PROTEIN PEPT SC, V7, P523, DOI 10.2174/138920306779025594
   Thomas A, 2010, BBA-PROTEINS PROTEOM, V1804, P1265, DOI 10.1016/j.bbapap.2010.02.008
   Uversky VN, 2008, ANNU REV BIOPHYS, V37, P215, DOI 10.1146/annurev.biophys.37.032807.125924
   VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Yesylevskyy S, 2009, BIOPHYS J, V97, P40, DOI 10.1016/j.bpj.2009.03.059
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
NR 52
TC 10
Z9 10
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD DEC
PY 2010
VL 1798
IS 12
SI SI
BP 2217
EP 2222
DI 10.1016/j.bbamem.2010.02.020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 682HV
UT WOS:000284392900006
PM 20188064
OA gold
DA 2018-01-05
ER

PT J
AU Vazquez, E
   Cubarsi, R
   Unzueta, U
   Roldan, M
   Domingo-Espin, J
   Ferrer-Miralles, N
   Villaverde, A
AF Vazquez, Esther
   Cubarsi, Rafael
   Unzueta, Ugutz
   Roldan, Monica
   Domingo-Espin, Joan
   Ferrer-Miralles, Neus
   Villaverde, Antonio
TI Internalization and kinetics of nuclear migration of protein-only,
   arginine-rich nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Nanoparticle; Genetic engineering; Protein; Biocompatibility; Drug
   delivery
ID NONVIRAL GENE-THERAPY; INTRACELLULAR TRAFFICKING; HEPARAN-SULFATE; HIV-1
   TAT; TRANSDUCTION DOMAIN; ARTIFICIAL VIRUSES; ESCHERICHIA-COLI;
   MAMMALIAN-CELLS; PLASMID DNA; IN-VIVO
AB Understanding the intracellular trafficking of nanoparticles internalized by mammalian cells is a critical issue in nanomedicine, intimately linked to therapeutic applications but also to toxicity concerns. While the uptake mechanisms of carbon nanotubes and polymeric particles have been investigated fairly extensively, there are few studies on the migration and fate of protein-only nanoparticles other than natural viruses. Interestingly, protein nanoparticles are emerging as tools in personalized medicines because of their biocompatibility and functional tuneability, and are particularly promising for gene therapy and also conventional drug delivery. Here, we have investigated the uptake and kinetics of intracellular migration of protein nanoparticles built up by a chimerical multifunctional protein, and functionalized by a pleiotropic, membrane-active (R9) terminal peptide. Interestingly, protein nanoparticles are first localized in endosomes, but an early endosomal escape allows them to reach and accumulate in the nucleus (but not in the cytoplasm), with a migration speed of 0.0044 +/- 0.0003 mu m/s, ten-fold higher than that expected for passive diffusion. Interestingly, the plasmatic, instead of the nuclear membrane is the main cellular barrier in the nuclear way of R9-assisted protein-only nanoparticles. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Vazquez, Esther; Unzueta, Ugutz; Domingo-Espin, Joan; Ferrer-Miralles, Neus; Villaverde, Antonio] Univ Autonoma Barcelona, Inst Biotechnol & Biomed, E-08193 Barcelona, Spain.
   [Vazquez, Esther; Unzueta, Ugutz; Domingo-Espin, Joan; Ferrer-Miralles, Neus; Villaverde, Antonio] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
   [Vazquez, Esther; Cubarsi, Rafael; Unzueta, Ugutz; Domingo-Espin, Joan; Ferrer-Miralles, Neus; Villaverde, Antonio] CIBER BBN, Barcelona 08193, Spain.
   [Cubarsi, Rafael] Univ Politecn Cataluna, Dept Matemat Aplicada 4, ES-08034 Barcelona, Spain.
   [Roldan, Monica] Univ Autonoma Barcelona, Servei Microscopia, E-08193 Barcelona, Spain.
RP Villaverde, A (reprint author), Univ Autonoma Barcelona, Inst Biotechnol & Biomed, E-08193 Barcelona, Spain.
EM prof.a.villaverde@gmail.com
RI Unzueta, Ugutz/C-2521-2017; Ferrer-Miralles, Neus/G-7934-2016
OI Unzueta, Ugutz/0000-0001-5119-2266; Ferrer-Miralles,
   Neus/0000-0003-2981-3913; Vazquez, Esther/0000-0003-1052-0424;
   Villaverde, Antonio/0000-0002-2615-4521; Domingo-Espin,
   Joan/0000-0001-8149-0803
FU MICINN [BIO2007-61194, ACI2009-0919]; FISS [PS0900165]; AGAUR
   [2009SGR-108]; CIBER de Bioingenieria, Biomateriales y Nanomedicina; VI
   National RDi Plan; Iniciativa Ingenio; Consolider Program; CIBER
   Actions; Instituto de Salud Carlos III; European Regional Development
   Fund
FX We are indebted to the Cell Culture Unit of the Servei de Cultius
   Cel.lulars, Produccio d'Anticossos i Citometria (SCAC), and to the
   Servei de Microscopia, both at the UAB. We also appreciate the financial
   support received for the design and production of artificial viruses for
   gene therapy to AV and EV from MICINN (BIO2007-61194 and ACI2009-0919),
   FISS (PS0900165), AGAUR (2009SGR-108) and CIBER de Bioingenieria,
   Biomateriales y Nanomedicina (specially through the IMAFEN and PROGLIO
   intramural projects 2008-2011), an initiative funded by the VI National
   R&D&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program,
   CIBER Actions and financed by the Instituto de Salud Carlos III with
   assistance from the European Regional Development Fund. AV has been
   distinguished with an ICREA ACADEMIA award.
CR Aaron J, 2009, NANO LETT, V9, P3612, DOI 10.1021/nl9018275
   Aris A, 2004, TRENDS BIOTECHNOL, V22, P371, DOI 10.1016/j.tibtech.2004.05.004
   Balestrieri ML, 2007, EUR J CANCER, V43, P1242, DOI 10.1016/j.ejca.2007.02.006
   Barua S, 2010, BIOMATERIALS, V31, P5894, DOI 10.1016/j.biomaterials.2010.04.007
   Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   Bergen JM, 2008, J GENE MED, V10, P187, DOI 10.1002/jgm.1137
   Brown KC, 2010, CURR PHARM DESIGN, V16, P1040, DOI 10.2174/138161210790963788                                                      
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Douglas KL, 2008, BIOTECHNOL PROGR, V24, P871, DOI 10.1021/bp070319o
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Feliu JX, 1998, BIOTECHNOL BIOENG, V58, P536, DOI 10.1002/(SICI)1097-0290(19980605)58:5<536::AID-BIT10>3.0.CO;2-9
   Ferrari M, 2010, TRENDS BIOTECHNOL, V28, P181, DOI 10.1016/j.tibtech.2009.12.007
   Ferrer-Miralles N, 2008, TRENDS BIOTECHNOL, V26, P267, DOI 10.1016/j.tibtech.2008.02.003
   Fink TL, 2006, GENE THER, V13, P1048, DOI 10.1038/sj.gt.3302761
   Garcia-Fruitos E, 2007, J MOL BIOL, V374, P195, DOI 10.1016/j.jmb.2007.09.004
   Hakansson S, 2001, PROTEIN SCI, V10, P2138, DOI 10.1110/ps.23401                                                                
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Karve S, 2009, BIOMATERIALS, V30, P6055, DOI 10.1016/j.biomaterials.2009.07.038
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lamm MH, 2010, METHODS MOL BIOL, V625, P135, DOI 10.1007/978-1-60761-579-8_12
   Li PC, 2008, BIOMATERIALS, V29, P3617, DOI 10.1016/j.biomaterials.2008.05.020
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Masuda T, 2009, BIOMATERIALS, V30, P4806, DOI 10.1016/j.biomaterials.2009.05.036
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Ng CP, 2009, BIOMATERIALS, V30, P951, DOI 10.1016/j.biomaterials.2008.10.059
   Peng L, 2009, BIOMATERIALS, V30, P5825, DOI 10.1016/j.biomaterials.2009.07.005
   Perumal OP, 2008, BIOMATERIALS, V29, P3469, DOI 10.1016/j.biomaterials.2008.04.038
   Pouton CW, 2007, ADV DRUG DELIVER REV, V59, P698, DOI 10.1016/j.addr.2007.06.010
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Saccardo P, 2009, BIOTECHNOL ADV, V27, P432, DOI 10.1016/j.biotechadv.2009.03.004
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   SERDA RE, 2010, BIOCH BIOPHYS A 0521
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Uchida M, 2007, ADV MATER, V19, P1025, DOI 10.1002/adma.200601168
   Vasir JK, 2008, BIOMATERIALS, V29, P4244, DOI 10.1016/j.biomaterials.2008.07.020
   Vazquez E, 2010, NANOMEDICINE-UK, V5, P259, DOI 10.2217/NNM.09.98
   Vazquez E, 2009, CURR PHARM DESIGN, V15, P893, DOI 10.2174/138161209787582084                                                      
   Vazquez E, 2008, DRUG DISCOV TODAY, V13, P1067, DOI 10.1016/j.drudis.2008.08.008
   Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 43
TC 18
Z9 18
U1 2
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2010
VL 31
IS 35
BP 9333
EP 9339
DI 10.1016/j.biomaterials.2010.08.065
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 682HZ
UT WOS:000284393300020
PM 20869766
DA 2018-01-05
ER

PT J
AU Lamers, SL
   Fogel, GB
   Huysentruyt, LC
   McGrath, MS
AF Lamers, Susanna L.
   Fogel, Gary B.
   Huysentruyt, Leanne C.
   McGrath, Michael S.
TI HIV-1 Nef Protein Visits B-Cells via Macrophage Nanotubes: A Mechanism
   for AIDS-Related Lymphoma Pathogenesis?
SO CURRENT HIV RESEARCH
LA English
DT Article
DE HIV-1; AIDS-related lymphoma; macrophages; HIV-1 nef protein
ID HIV-1-INFECTED CELLS; SUPPRESSOR-CELLS; MYRISTOYLATION; ASSOCIATION;
   MEMBRANE; POLARIZATION; PROGRESSION; EXPRESSION; MONOCYTES; INFECTION
AB This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1). The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes. Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered. ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation. In this letter we discuss several studies that link HIV-infected macrophages and specific forms of the nef protein to the development of ARL. The conduits discovered by Xu et al. [1] may lead to a better understanding of how HIV infection results in lymphomagenesis.
C1 [McGrath, Michael S.] Univ Calif San Francisco, Dept Lab Med, Posit Hlth Program, San Francisco, CA 94110 USA.
   [Lamers, Susanna L.] NYU, Polytech Inst, Brooklyn, NY USA.
   [Lamers, Susanna L.] BioInfoExperts, Thibodaux, LA USA.
   [Fogel, Gary B.] Nat Select Inc, San Diego, CA USA.
   [McGrath, Michael S.] W Coast AIDS & Canc Specimen Resource, San Francisco, CA USA.
RP McGrath, MS (reprint author), Univ Calif San Francisco, Dept Lab Med, Posit Hlth Program, San Francisco, CA 94110 USA.
EM MMcGrath@php.ucsf.edu
FU NIH [U01 CA066529, U19 MH081835]
FX The project was funded by NIH grants U01 CA066529 and U19 MH081835.
CR Bentham M, 2006, J GEN VIROL, V87, P563, DOI 10.1099/vir.0.81200-0
   Carl S, 2001, J VIROL, V75, P3657, DOI 10.1128/JVI.75.8.3657-3665.2001
   Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673
   Chaudhry A, 2009, J IMMUNOL, V183, P2415, DOI 10.4049/jimmunol.0804014
   Choi HJ, 2004, J BIOL CHEM, V279, P51688, DOI 10.1074/jbc.M410068200
   Coates K, 1997, RES VIROLOGY, V148, P68, DOI 10.1016/S0923-2516(97)81917-6
   Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x
   Giese SI, 2006, VIROLOGY, V355, P175, DOI 10.1016/j.virol.2006.07.003
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   Huysentruyt LC, 2009, J LEUKOCYTE BIOL, V87, P627
   KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003
   KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011
   LAMERS S, 2010, INT AIDS C 2010 VIEN
   LAMERS S, 2010, 12 INT C MAL AIDS OT
   Lamers SL, 2008, IEEE ACM T COMPUT BI, V5, P291, DOI 10.1109/TCBB.2007.1074
   Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3
   Lehmann MH, 2006, EXP CELL RES, V312, P3659, DOI 10.1016/j.yexcr.2006.08.008
   Mantovani A, 2009, HUM IMMUNOL, V70, P325, DOI 10.1016/j.humimm.2009.02.008
   MCGRATH MS, 1997, CLIN REV ALLERG IMMU, V14, P359
   Moir S, 2010, IMMUNOL CELL BIOL, V88, P1, DOI 10.1038/icb.2009.82
   NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605
   Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998
   Rudnicka D, 2009, NAT IMMUNOL, V10, P933, DOI 10.1038/ni0909-933
   Salemi M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008153
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   SWINGLER S, 1999, NAT MED, V5, P985
   Swingler S, 2008, CELL HOST MICROBE, V4, P63, DOI 10.1016/j.chom.2008.05.015
   Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Yeung ML, 2009, NUCLEIC ACIDS RES, V37, P6575, DOI 10.1093/nar/gkp707
NR 30
TC 11
Z9 11
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD DEC
PY 2010
VL 8
IS 8
BP 638
EP 640
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 720TN
UT WOS:000287305000009
PM 21067513
DA 2018-01-05
ER

PT J
AU Parpia, ZA
   Elghanian, R
   Nabatiyan, A
   Hardie, DR
   Kelso, DM
AF Parpia, Zaheer A.
   Elghanian, Robert
   Nabatiyan, Arman
   Hardie, Diana R.
   Kelso, David M.
TI p24 Antigen Rapid Test for Diagnosis of Acute Pediatric HIV Infection
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE carbon nanoparticles; HIV p24 assay; heat shock immune disruption;
   infant HIV; lateral flow diagnostic
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HEAT-DENATURED PLASMA; ANTIRETROVIRAL
   THERAPY; VIRAL-RNA; DISEASE PROGRESSION; ASSAY; INFANTS; AIDS
AB Currently, the majority of HIV-infected infants are found within limited-resource settings, where inadequate screening for HIV due to the lack of access to simple and affordable point-of-care tests impedes implementation of antiretroviral therapy. Here we report development of a low-cost dipstick p24 antigen assay using a visual readout format that can facilitate the diagnosis of HIV for infants in resource-poor conditions. A heat shock methodology was developed to optimize disruption of immune complexes present in the plasma of infected infants. The analytical sensitivity of the assay using recombinant p24 antigen is 50 pg/mL (2 pM) with whole virus detection as low as 42.5k RNA copies per milliliter plasma. In a blinded study comprising 51 archived infant samples from the Women and Infants Transmission Study, our assay demonstrated an overall sensitivity and specificity of 90% and 100%, respectively. In field evaluations of 389 fresh samples from South African infants, a sensitivity of 95% and specificity of 99% was achieved. The assay is simple to perform, requires minimal plasma volume (25 mu L), and yields a result in less than 40 minutes making it ideal for implementation in resource-limited settings.
C1 [Parpia, Zaheer A.; Elghanian, Robert; Nabatiyan, Arman; Kelso, David M.] Northwestern Univ, Dept Biomed Engn, Ctr Innovat Global Hlth Technol, Evanston, IL 60208 USA.
   [Hardie, Diana R.] Groote Schuur Hosp, Virol Lab, Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa.
   [Hardie, Diana R.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
RP Nabatiyan, A (reprint author), Northwestern Univ, Dept Biomed Engn, Ctr Innovat Global Hlth Technol, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM arman@northwestern.edu
RI Kelso, David/B-7619-2009; Kelso, David/F-5622-2013
FU Bill and Melinda Gates Foundation Grand Challenges in Global Health
   [37774]
FX This work was funded by the Bill and Melinda Gates Foundation Grand
   Challenges in Global Health, grant #37774. Monoclonal antibodies mAb108
   and mAb115B and recombinant p24 antigen were generously provided by Dr.
   John Hackett (Abbott Diagnostics, Abbott Park, IL).
CR Aledort Julia E, 2006, Nature, V444 Suppl 1, P19, DOI 10.1038/nature05443
   Boni J, 1997, AIDS, V11, pF47, DOI 10.1097/00002030-199706000-00001
   Brinkhof MWG, 2006, JAIDS-J ACQ IMM DEF, V41, P557, DOI 10.1097/01.qai.0000209824.77784.2c
   Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2
   Fiscus SA, 2007, J CLIN MICROBIOL, V45, P2274, DOI 10.1128/JCM.00813-07
   George E, 2007, J CLIN MICROBIOL, V45, P3416, DOI 10.1128/JCM.01314-07
   JACKSON JB, 1993, J CLIN MICROBIOL, V31, P3123
   Khamadi S, 2008, J TROP PEDIATRICS, V54, P370, DOI 10.1093/tropej/fmn036
   Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366
   Ly TD, 2004, J VIROL METHODS, V122, P185, DOI 10.1016/j.jviromet.2004.08.018
   Nabatiyan A, 2010, JAIDS-J ACQ IMM DEF, V53, P55, DOI 10.1097/QAI.0b013e3181c4b9d5
   PALAMOUNTAIN K, 2009, UGANDA HIV DIAGNOSTI
   PALAMOUNTAIN K, 2010, ZAMBIA HIV DIAGNOSTI
   Schupbach J, 2006, J MED VIROL, V78, P1003, DOI 10.1002/jmv.20655
   Schupbach J, 2003, INT ARCH ALLERGY IMM, V132, P196, DOI 10.1159/000074552
   Schupbach J, 2001, J MED VIROL, V65, P225, DOI 10.1002/jmv.2024
   Schupbach J, 2000, INT J ANTIMICROB AG, V16, P441, DOI 10.1016/S0924-8579(00)00272-7
   Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   *WHO U, 2008, UN ACC SCAL PRIOR HI
NR 20
TC 28
Z9 28
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2010
VL 55
IS 4
BP 413
EP 419
DI 10.1097/QAI.0b013e3181f1afbc
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 675RR
UT WOS:000283849100004
PM 20811289
OA gold
DA 2018-01-05
ER

PT J
AU Liu, BR
   Huang, YW
   Chiang, HJ
   Lee, HJ
AF Liu, Betty R.
   Huang, Yue-Wern
   Chiang, Huey-Jenn
   Lee, Han-Jung
TI Cell-Penetrating Peptide-Functionalized Quantum Dots for Intracellular
   Delivery
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE Arginine-Rich; Cell-Penetrating Peptide; Cellular Internalization;
   Protein Transduction Domain; Quantum Dot
ID ARGININE-RICH PEPTIDES; NONCOVALENT PROTEIN TRANSDUCTION; HUMAN
   IMMUNODEFICIENCY VIRUS; LIVING CELLS; IN-VIVO; PLANT-CELLS;
   PLASMA-MEMBRANE; FUSOGENIC PEPTIDE; TAT PROTEIN; INTERNALIZATION
AB Quantum dots (QDs) are luminescent semiconductor nanocrystals that are widely used as fluorescent probes in biomedical applications, including cellular imaging and tumor tracking. Cell-penetrating peptides (CPPs), also called protein transduction domains (PTDs), are short basic peptides that permeate cell membranes and are able to deliver a variety of macromolecule cargoes, such as DNAs, RNAs, proteins, and nanomaterials. Here we review strategies to couple QDs to CPPs, by either covalent linkages or noncovalent interactions, to provide a tool to study intracellular delivery. This facilitated transport of QDs by CPPs into cells is both simple and efficient. Accordingly, CPP-QD nanoparticles are likely to be of broad utility in biological research and advance the development of medical and pharmaceutical therapeutics.
C1 [Huang, Yue-Wern] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
   [Liu, Betty R.; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
   [Liu, Betty R.; Chiang, Huey-Jenn] Natl Dong Hwa Univ, Inst Biotechnol, Hualien 97401, Taiwan.
RP Huang, YW (reprint author), Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
FU National Institute of Biomedical Imaging and Bioengineering
   [R15EB009530]; National Science Council of Taiwan [NSC
   97-2621-B-259-003-MY3]
FX We are grateful to Dr. Robert S. Aronstam from the Department of
   Biological Sciences, Missouri University of Science and Technology, for
   editing of the manuscript. This work was supported by Award Number
   R15EB009530 from the National Institute of Biomedical Imaging and
   Bioengineering (to Yue-Wern Huang) and the National Science Council (NSC
   97-2621-B-259-003-MY3) of Taiwan (to Han-Jung Lee).
CR Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Anikeeva PO, 2009, NANO LETT, V9, P2532, DOI 10.1021/nl9002969
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Delehanty JB, 2009, EXPERT OPIN DRUG DEL, V6, P1091, DOI 10.1517/17425240903167934
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Hess GT, 2007, BBA-MOL CELL RES, V1773, P1583, DOI 10.1016/j.bbamcr.2007.07.009
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Iga AM, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/76087
   Jablonski AE, 2009, J PHYS CHEM B, V113, P405, DOI 10.1021/jp809956w
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016
   Kobayashi S, 2009, BIOCONJUGATE CHEM, V20, P953, DOI 10.1021/bc800530v
   Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006
   Lagerholm B Christoffer, 2007, Methods Mol Biol, V374, P105
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l
   Lam KM, 2009, J NANOSCI NANOTECHNO, V9, P2337, DOI 10.1166/jnn.2009.SE30
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Lei Y, 2009, J NANOSCI NANOTECHNO, V9, P5726, DOI 10.1166/jnn.2009.1258
   LI JF, 2010, ANTICANCER RES
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   LIU BR, 2010, J NANOSCI N IN PRESS
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Manokaran S, 2008, J BIOMED NANOTECHNOL, V4, P491, DOI 10.1166/jbn.2008.009
   Medintz IL, 2008, BIOCONJUGATE CHEM, V19, P1785, DOI 10.1021/bc800089r
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   MORK H, 2009, LANGMUIR, V25, P1645
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   Neundorf Ines, 2009, Pharmaceuticals (Basel), V2, P49
   Nitin N, 2009, ANN BIOMED ENG, V37, P2018, DOI 10.1007/s10439-009-9768-0
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Ozkan M, 2004, DRUG DISCOV TODAY, V9, P1065, DOI 10.1016/S1359-6446(04)03291-X
   Parungo CP, 2005, J THORAC CARDIOV SUR, V129, P844, DOI 10.1016/j.jtcvs.2004.08.001
   Pathak S, 2009, J NANOSCI NANOTECHNO, V9, P5047, DOI 10.1166/jnn.2009.GR08
   Reuter M, 2009, BIOPHYS CHEM, V144, P27, DOI 10.1016/j.bpc.2009.06.002
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Sapsford KE, 2007, J PHYS CHEM C, V111, P11528, DOI 10.1021/jp073550t
   SCHMIDT N, 2010, FEBS LETT IN PRESS
   Soltesz EG, 2006, ANN SURG ONCOL, V13, P386, DOI 10.1245/ASO.2006.04.025
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Takayama K, 2009, J CONTROL RELEASE, V138, P128, DOI 10.1016/j.jconrel.2009.05.019
   Takayama K, 2009, BIOCONJUGATE CHEM, V20, P249, DOI 10.1021/bc800327f
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Toita S, 2008, J NANOSCI NANOTECHNO, V8, P2279, DOI 10.1166/jnn.2008.240
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   Zhang K, 2008, BIOCONJUGATE CHEM, V19, P1880, DOI 10.1021/bc800160b
   Zhang LW, 2009, TOXICOL SCI, V110, P138, DOI 10.1093/toxsci/kfp087
   Zhou M, 2007, BIOPOLYMERS, V88, P325, DOI 10.1002/bip.20655
NR 84
TC 44
Z9 44
U1 0
U2 32
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD DEC
PY 2010
VL 10
IS 12
BP 7897
EP 7905
DI 10.1166/jnn.2010.3012
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 672XQ
UT WOS:000283621400003
PM 21121277
OA green_accepted
DA 2018-01-05
ER

PT J
AU Nowacek, AS
   McMillan, J
   Miller, R
   Anderson, A
   Rabinow, B
   Gendelman, HE
AF Nowacek, Ari S.
   McMillan, JoEllyn
   Miller, Reagan
   Anderson, Alec
   Rabinow, Barrett
   Gendelman, Howard E.
TI Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and
   Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for
   NeuroAIDS Therapeutics
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE antiretroviral therapy; nanoparticles; macrophages; drug delivery; HIV;
   nanomedicine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR THERAPY; HIV-INFECTION;
   BRONCHOALVEOLAR MACROPHAGES; NERVOUS-SYSTEM; NAIVE PATIENTS; HUMAN LUNG;
   ATAZANAVIR; RITONAVIR; EXPRESSION
AB We posit that improvements in pharmacokinetics and biodistributions of antiretroviral therapies (ART) for human immunodeficiency virus type one-infected people can be achieved through nanoformulationed drug delivery systems. To this end, we manufactured nanoparticles of atazanavir, efavirenz, and ritonavir (termed nanoART) and treated human monocyte-derived macrophages (MDM) in combination therapies to assess antiretroviral responses. This resulted in improved drug uptake, release, and antiretroviral efficacy over monotherapy. MDM rapidly, within minutes, ingested nanoART combinations, at equal or similar rates, as individual formulations. Combination nanoART ingested by MDM facilitated individual drug release from 15 to >20 days. These findings are noteworthy as a nanoART cell-mediated drug delivery provides a means to deliver therapeutics to viral sanctuaries, such as the central nervous system during progressive human immunodeficiency virus type one infection. The work brings us yet another step closer to realizing the utility of nanoART for virus-infected people.
C1 [Nowacek, Ari S.; McMillan, JoEllyn; Anderson, Alec; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Miller, Reagan; Rabinow, Barrett] Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 600 S 42nd St, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU National Institutes of Health [2R01 NS034239, 2R37 NS36126, P01 NS31492,
   P20RR 15635, P01MH64570, P01 NS43985]; Baxter Healthcare
FX The work was supported by the National Institutes of Health grants 2R01
   NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635, P01MH64570, and P01
   NS43985 (to H.E.G.) and from a research grant from Baxter Healthcare.
CR Anttila S, 1997, AM J RESP CELL MOL, V16, P242, DOI 10.1165/ajrcmb.16.3.9070608                                                     
   Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bruce RD, 2006, CLIN INFECT DIS, V43, pS216, DOI 10.1086/508186                                                                  
   Bruce RD, 2006, JAIDS-J ACQ IMM DEF, V41, P563, DOI 10.1097/01.qai.0000219769.89679.ec
   Danel C, 2009, J INFECT DIS, V199, P66, DOI 10.1086/595298
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502
   Feldt T, 2005, EUR J MED RES, V10, P7
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Garvie PA, 2009, J ADOLESCENT HEALTH, V44, P124, DOI 10.1016/j.jadohealth.2008.05.006
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gianotti N, 2007, NEW MICROBIOL, V30, P79
   Gisslen M, 2006, SCAND J INFECT DIS, V38, P86, DOI 10.1080/00365540500388834
   Gray F, 2001, CLIN NEUROPATHOL, V20, P146
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Hesse LM, 2001, DRUG METAB DISPOS, V29, P100
   Horberg M, 2008, HIV CLIN TRIALS, V9, P367, DOI 10.1310/hct0906-367
   Hukkanen J, 2002, CRIT REV TOXICOL, V32, P391, DOI 10.1080/20024091064273
   Hukkanen J, 1997, MOL CARCINOGEN, V20, P224, DOI 10.1002/(SICI)1098-2744(199710)20:2<224::AID-MC9>3.0.CO;2-M
   Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   KALTER DC, 1991, J IMMUNOL, V146, P3396
   Kraft-Terry SD, 2009, NEURON, V64, P133, DOI 10.1016/j.neuron.2009.09.042
   KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Mascolini Mark, 2008, Antivir Ther, V13, P1097
   Meade CS, 2009, AIDS PATIENT CARE ST, V23, P259, DOI 10.1089/apc.2008.0210
   Metzner KJ, 2009, CLIN INFECT DIS, V48, P239, DOI 10.1086/595703
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P541, DOI [10.2217/nnm.09.37, 10.2217/NNM.09.37]
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7
   Piipari R, 2000, INT J CANCER, V86, P610, DOI 10.1002/(SICI)1097-0215(20000601)86:5<610::AID-IJC2>3.0.CO;2-M
   Raunio H, 1999, EXP TOXICOL PATHOL, V51, P412, DOI 10.1016/S0940-2993(99)80031-1                                                   
   Royal SW, 2009, AIDS CARE, V21, P448, DOI 10.1080/09540120802270250
   Valcour V, 2006, CLIN INFECT DIS, V42, P1449, DOI 10.1086/503565
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Xu LH, 2009, CURR OPIN INVEST DR, V10, P775
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   ZOLOPA AR, 2009, ANTIVIR RES, V85, P241
NR 47
TC 44
Z9 44
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD DEC
PY 2010
VL 5
IS 4
BP 592
EP 601
DI 10.1007/s11481-010-9198-7
PG 10
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 686YX
UT WOS:000284739500013
PM 20237859
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mastro, MA
   Hardy, AW
   Boasso, A
   Shearer, GM
   Eddy, CR
   Kub, FJ
AF Mastro, Michael A.
   Hardy, Andrew W.
   Boasso, Adriano
   Shearer, Gene M.
   Eddy, Charles R., Jr.
   Kub, Francis J.
TI Non-toxic inhibition of HIV-1 replication with silver-copper
   nanoparticles
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE HIV; Nanoparticles; Silver; Copper
ID GP120; CELLS; SULFADIAZINE; APOPTOSIS; SIZE
AB Cu and Ag-Cu mixed alloy nanoparticles displayed significant inhibition to HIV-1 replication with limited toxicity to human cells at relatively low concentrations of metal. A previous study (Elechiguerra et al. in J Nanobiotechnol 3:6-16, 2005) suggested a size-specific Ag nanoparticle can be tailored to block or damage the glycoprotein (gp) 120/gp41 spike or, more specifically, the invariant epitope at the gp120 binding site. Two different protocols were employed to test whether nanoparticles block entry of HIV-1, and in both instances the nanoparticles acted at some point other than initial binding. This work shows that Ag, Cu, and Ag-Cu mixed alloy metals display a chemically dependent inactivation of the target virus.
C1 [Mastro, Michael A.; Eddy, Charles R., Jr.; Kub, Francis J.] USN, Res Lab, Div Elect Sci & Technol, Washington, DC 20375 USA.
   [Hardy, Andrew W.] Vitae Pharmaceut, Ft Washington, PA USA.
   [Boasso, Adriano; Shearer, Gene M.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20910 USA.
RP Mastro, MA (reprint author), USN, Res Lab, Div Elect Sci & Technol, Code 6882,4555 Overlook Ave SW, Washington, DC 20375 USA.
EM michael.mastro@nrl.navy.mil
OI Boasso, Adriano/0000-0001-9673-6319
FU Office of Naval Research
FX This research was supported by the Office of Naval Research.
CR BECKER RO, 1978, J BONE JOINT SURG AM, V60, P871, DOI 10.2106/00004623-197860070-00001                                                
   Borkow G, 2004, FASEB J, V18, P1728, DOI 10.1096/fj.04-2029fje
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHANG TW, 1975, J INFECT DIS, V132, P79, DOI 10.1093/infdis/132.1.79                                                         
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Coyle B, 2003, BIOMETALS, V16, P321, DOI 10.1023/A:1020695923788
   Davies RL, 1997, CATAL TODAY, V36, P107, DOI 10.1016/S0920-5861(96)00203-9                                                   
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Herbeuval JP, 2006, P NATL ACAD SCI USA, V103, P7000, DOI 10.1073/pnas.0600363103
   Herbeuval JP, 2005, BLOOD, V106, P3524, DOI 10.1182/blood-2005-03-1243
   Herbeuval JP, 2005, P NATL ACAD SCI USA, V102, P13974, DOI 10.1073/pnas.0505251102
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Jiang H., 2005, P INT S ADV PACK MAT, P173, DOI DOI 10.1109/ISAPM.2005.1432072
   Kurihara K, 2005, NANOTECHNOLOGY, V16, P1565, DOI 10.1088/0957-4484/16/9/026
   Mastro MA, 2008, J CERAM PROCESS RES, V9, P1
   MITUN NI, 1983, PHARM CHEM J, V17, P351
   Munch J, 2007, CELL, V129, P263, DOI 10.1016/j.cell.2007.02.042
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   THURMAN RB, 1989, CRC CRIT R ENVIRON, V18, P295, DOI DOI 10.1080/10643388909388351
   TOKUMARU T, 1974, RES COMMUN CHEM PATH, V8, P151
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yang L, 2003, MICROELECTRON ENG, V66, P192, DOI 10.1016/S0167-9317(03)00046-7
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
NR 24
TC 5
Z9 5
U1 0
U2 6
PU SPRINGER BIRKHAUSER
PI NEW YORK
PA 233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA
SN 1054-2523
EI 1554-8120
J9 MED CHEM RES
JI Med. Chem. Res.
PD DEC
PY 2010
VL 19
IS 9
BP 1074
EP 1081
DI 10.1007/s00044-009-9253-1
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 682VV
UT WOS:000284432000006
DA 2018-01-05
ER

PT J
AU De Clercq, E
AF De Clercq, Erik
TI Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100,
   Mozobil (TM)) and potential of other CXCR4 antagonists as stem cell
   mobilizers
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Proceedings Paper
CT Meeting of the Clinical Pharmacology Section of the
   British-Pharmacological-Society
CY DEC 15-17, 2009
CL London, ENGLAND
SP British Pharmacol Soc, Clin Pharmacol Sect
DE Granulocyte colony-stimulating factor (G-CSF); AMD300; Plerixafor;
   Mozobil (TM); CD34(+) cells; SDF-1 (CXCL12); CXCR4; HIV; Non-Hodgkin's
   lymphoma (NHL); Multiple myeloma (MM); Hematopoietic stem cells
ID HEMATOPOIETIC PROGENITOR CELLS; NON-HODGKINS-LYMPHOMA; PLUS G-CSF;
   CHEMOKINE RECEPTOR ANTAGONISTS; MULTIPLE-MYELOMA PATIENTS;
   SMALL-MOLECULE; BONE-MARROW; RAPID MOBILIZATION; ENTRY INHIBITORS;
   TRANSPLANTATION
AB AMD3100 was originally discovered as an anti-HIV agent effective in inhibiting the replication of HIV in vitro at nanomolar concentrations. We found it to be a potent and selective antagonist of CXCR4, the receptor for the chemokine SDF-1 (now called CXCL12). AMD3100 was then developed, and marketed, as a stem cell mobilizer, and renamed plerixafor (Mozobil (TM)). The path to the discovery of Mozobil (TM) as a stem cell mobilizer was described in Biochem. Pharmacol. 77: 1655-1664 (2009). Here I review the recent advances that have consolidated the role of plerixafor in mobilizing hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) from the bone marrow into the blood circulation. Plerixafor acts synergistically with granulocyte colony-stimulating factor (G-CSF), and its usefulness has been proven particularly for the mobilization of HSCs and HPCs for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). Plerixafor also has great potential for the treatment of hematological malignancies other than NHL and MM, and non-hematological malignancies, and, eventually, several other diseases depending on the CXCL12-CXCR4 interaction. Various AMD3100 analogs have been described (i.e. AMD11070, AMD3465, KRH-3955, T-140, and 4F-benzoyl-TN14003), primarily as potential anti-HIV agents. They are all strong CXCR4 antagonists. Their role in stem cell mobilization remains to be assessed. (C) 2010 Elsevier Inc. All rights reserved.
C1 Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP De Clercq, E (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM erik.declercq@rega.kuleuven.be
CR Abraham M, 2009, LEUKEMIA, V23, P1378, DOI 10.1038/leu.2009.56
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668
   BENSINGER W, 2009, BONE MARROW TRANSPL, V43, P188
   Bonig H, 2009, EXP HEMATOL, V37, P402, DOI 10.1016/j.exphem.2008.10.017
   Bridger GJ, 2010, J MED CHEM, V53, P1250, DOI 10.1021/jm901530b
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Burger JA, 2009, EXPERT OPIN INV DRUG, V18, P481, DOI [10.1517/13543780902804249 , 10.1517/13543780902804249]
   Burroughs L, 2005, BLOOD, V106, P4002, DOI 10.1182/blood-2005-05-1937
   Calandra G, 2008, BONE MARROW TRANSPL, V41, P331, DOI 10.1038/sj.bmt.1705908
   Cashen A, 2008, BIOL BLOOD MARROW TR, V14, P1253, DOI 10.1016/j.bbmt.2008.08.011
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   De Clercq E, 2009, BIOCHEM PHARMACOL, V77, P1655, DOI 10.1016/j.bcp.2008.12.014
   Devine SM, 2008, BLOOD, V112, P990, DOI 10.1182/blood-2007-12-130179
   Dillmann F, 2009, LEUKEMIA LYMPHOMA, V50, P1676, DOI [10.3109/10428190903150847, 10.1080/10428190903150847]
   DIPERSIO JF, 2009, NAT REV DRUG DISCOV, V6, P105
   DiPersio JF, 2009, J CLIN ONCOL, V27, P4767, DOI 10.1200/JCO.2008.20.7209
   DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946
   Donahue RE, 2009, BLOOD, V114, P2530, DOI 10.1182/blood-2009-04-214403
   Dugan MJ, 2010, BONE MARROW TRANSPL, V45, P39, DOI 10.1038/bmt.2009.119
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Flomenberg N, 2005, BLOOD, V106, P1867, DOI 10.1182/blood-2005-02-0468
   Fowler CJ, 2009, BONE MARROW TRANSPL, V43, P909, DOI 10.1038/bmt.2008.409
   Fricker SP, 2008, EXPERT OPIN INV DRUG, V17, P1749, DOI [10.1517/13543780802447958, 10.1517/13543784.17.11.1749 ]
   Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010
   Fukuda S, 2007, BLOOD, V110, P860, DOI 10.1182/blood-2006-06-031401
   Gerlach LO, 2003, BIOCHEMISTRY-US, V42, P710, DOI 10.1021/bi0264770
   Giralt S, 2009, LEUKEMIA, V23, P1904, DOI 10.1038/leu.2009.127
   Greinix HT, 2009, TRANSFUS APHER SCI, V41, P67, DOI 10.1016/j.transci.2009.05.015
   Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5
   Holtan SG, 2007, CLIN LYMPHOMA MYELOM, V7, P315, DOI 10.3816/CLM.2007.n.009                                                          
   Ichiyama K, 2003, P NATL ACAD SCI USA, V100, P4185, DOI 10.1073/pnas.0630420100
   Jacobson O, 2009, BIOORGAN MED CHEM, V17, P1486, DOI 10.1016/j.bmc.2009.01.014
   Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389
   Kawaguchi A, 2009, BLOOD, V114, P2961, DOI 10.1182/blood-2008-11-189308
   Kazmierski WM, 2007, ANNU REP MED CHEM, V42, P301, DOI 10.1016/S0065-7743(07)42019-X
   Khan A, 2009, J AM CHEM SOC, V131, P3416, DOI 10.1021/ja807921k
   Kurtova AV, 2009, BLOOD, V113, P4604, DOI 10.1182/blood-2008-10-185827
   Lack NA, 2005, CLIN PHARMACOL THER, V77, P427, DOI 10.1016/j.clpt.2004.12.268
   Lee HJ, 2009, INT J ONCOL, V34, P473, DOI 10.3892/ijo_00000172
   Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Liles WC, 2005, TRANSFUSION, V45, P295, DOI 10.1111/j.1537-2995.2005.04222.x                                                
   Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663
   MOYLE G, 2007, 14 C RETR OPP INF LO
   Moyle G, 2009, CLIN INFECT DIS, V48, P798, DOI 10.1086/597097
   Murakami T, 2009, ANTIMICROB AGENTS CH, V53, P2940, DOI 10.1128/AAC.01727-08
   Nervi B, 2006, J CELL BIOCHEM, V99, P690, DOI 10.1002/jcb.21043
   Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123
   Pelus LM, 2008, LEUKEMIA, V22, P466, DOI 10.1038/sj.leu.2405021
   Pepinsky RB, 2005, J PHARMACOL EXP THER, V312, P742, DOI 10.1124/jpet.104.075648
   Perseghin P, 2009, TRANSFUS APHER SCI, V41, P33, DOI 10.1016/j.transci.2009.05.011
   Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017
   Pusic I, 2008, BIOL BLOOD MARROW TR, V14, P1045, DOI 10.1016/j.bbmt.2008.07.004
   Ramirez P, 2009, BLOOD, V114, P1340, DOI 10.1182/blood-2008-10-184721
   Rettig MP, 2009, METHOD ENZYMOL, V460, P57, DOI 10.1016/S0076-6879(09)05203-3
   RETTIG MP, 2008, BLOOD, V112, pA367
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   SAAG M, 2007, 14 C RETR OPP INF LO
   SCHOLS D, 2003, 10 C RETR OPP INF BO
   Shepherd RM, 2006, BLOOD, V108, P3662, DOI 10.1182/blood-2006-06-030577
   Stewart DA, 2009, BIOL BLOOD MARROW TR, V15, P39, DOI 10.1016/j.bbmt.2008.10.018
   Stiff P, 2009, BIOL BLOOD MARROW TR, V15, P249, DOI 10.1016/j.bbmt.2008.11.028
   Stone ND, 2007, ANTIMICROB AGENTS CH, V51, P2351, DOI 10.1128/AAC.00013-07
   Tamamura H, 2006, ORG BIOMOL CHEM, V4, P2354, DOI 10.1039/b603818b
   Traynor K, 2009, AM J HEALTH-SYST PH, V66, P112, DOI 10.2146/news090006
   Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200
   Tricot G, 2010, BONE MARROW TRANSPL, V45, P63, DOI 10.1038/bmt.2009.130
   Uy GL, 2008, EXPERT OPIN BIOL TH, V8, P1797, DOI [10.1517/14712598.8.11.1797 , 10.1517/14712590802397142]
   Vose JM, 2009, LEUKEMIA LYMPHOMA, V50, P1412, DOI 10.1080/10428190903096701
   Wagstaff AJ, 2009, DRUGS, V69, P319, DOI 10.2165/00003495-200969030-00007
   Wong RSY, 2008, MOL PHARMACOL, V74, P1485, DOI 10.1124/mol.108.049775
NR 72
TC 60
Z9 63
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD DEC
PY 2010
VL 128
IS 3
BP 509
EP 518
DI 10.1016/j.pharmthera.2010.08.009
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 686UO
UT WOS:000284721900008
PM 20826182
DA 2018-01-05
ER

PT J
AU Rai, VK
   Singh, S
   Singh, P
   Yadav, LDS
AF Rai, Vijai K.
   Singh, Santosh
   Singh, Pankaj
   Yadav, Lal Dhar S.
TI Carbohydrate Building Blocks in the Ugi Three-Component Coupling
   Reaction: Convenient Annulation of Iminosugars on Imidazoles
SO SYNTHESIS-STUTTGART
LA English
DT Article
DE heterocycles; carbohydrates; cyclizations; multicomponent reactions;
   catalysis; Ugi reaction
ID RING TRANSFORMATIONS; PYRIMIDINES; DERIVATIVES; ALDEHYDES; PYRIDINES;
   CLAY; HIV
AB An unprecedented version of the Ugi three-component coupling reaction is reported in which isocyanides react with unprotected aldoses as biorenewable aldehyde components and acyclic amidines as amine components. The reaction proceeds through [4 + 1] cycloaddition of a conjugated imine intermediate with the isocyanide followed by dehydrative ring transformation of the resulting 4-amino-5-(polyhydroxyalkyl)imidazole to afford imino sugar-annulated imidazoles in excellent yields (86-95%). The procedure is performed in one pot in the presence of a nanoclay (K-10) catalyst, and can be expeditiously effected under solvent-free microwave-irradiation conditions.
C1 [Rai, Vijai K.; Singh, Santosh; Singh, Pankaj; Yadav, Lal Dhar S.] Univ Allahabad, Dept Chem, Green Synth Lab, Allahabad 211002, Uttar Pradesh, India.
   [Rai, Vijai K.] Shri Mata Vaishno Devi Univ, Sch Biotechnol, Katra 182320, Jammu & Kashmir, India.
RP Yadav, LDS (reprint author), Univ Allahabad, Dept Chem, Green Synth Lab, Allahabad 211002, Uttar Pradesh, India.
EM ldsyadav@hotmail.com
FU CSIR, New Delhi
FX We sincerely thank the CSIR, New Delhi, for financial support. V. K. R.
   is grateful to the CSIR, New Delhi, for the award of a Research
   Associateship. We are also thankful to SAIF, Punjab University,
   Chandigarh, for providing microanalyses and spectra.
CR Adib M, 2007, TETRAHEDRON LETT, V48, P7263, DOI 10.1016/j.tetlet.2007.08.049
   ALMIRANTE L, 1965, J MED CHEM, V8, P305, DOI 10.1021/jm00327a007
   Asano N, 2003, GLYCOBIOLOGY, V13, p93R, DOI 10.1093/glycob/cwg090
   Elbein A. D., 1999, COMPREHENSIVE NATURA, V3, P129
   FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6
   Gross P. E., 1995, CLIN CANCER RES, V1, P935
   Horii S., 1991, DIABETES, V40, P825
   HORII S, 1987, DRUGS FUTURE, V12, P1157
   HORII S, 1986, DRUGS FUTURE, V11, P1039
   Ireland SM, 2003, TETRAHEDRON LETT, V44, P4369, DOI 10.1016/S0040-4039(03)00941-9
   LANGER SZ, 1990, ADV BIOCHEM PSYCHOPH, V46, P61
   Nash R.J., 1996, ALKALOIDS CHEM BIOL, V11, P345
   Nishimura Y., 1995, STUD NAT PROD CHEM, V16, P75
   Parchinsky VZ, 2006, TETRAHEDRON LETT, V47, P947, DOI 10.1016/j.tetlet.2005.11.152
   Shaabani A, 2006, TETRAHEDRON LETT, V47, P3031, DOI 10.1016/j.tetlet.2006.03.011
   Stevens C. V., 2004, RENEWABLE BIORESOURC
   TAYLOR DL, 1991, AIDS, V5, P693, DOI 10.1097/00002030-199106000-00008
   Varma RS, 1999, TETRAHEDRON LETT, V40, P7665, DOI 10.1016/S0040-4039(99)01585-3                                                   
   Yadav LDS, 2008, TETRAHEDRON, V64, P4246, DOI 10.1016/j.tet.2008.02.084
   Yadav LDS, 2008, TETRAHEDRON LETT, V49, P2377, DOI 10.1016/j.tetlet.2008.02.067
   Yadav LDS, 2007, TETRAHEDRON LETT, V48, P4899, DOI 10.1016/j.tetlet.2007.05.057
   Yadav LDS, 2009, CARBOHYD RES, V344, P2329, DOI 10.1016/j.carres.2009.06.017
   Yadav LDS, 2008, SYNLETT, P2257, DOI 10.1055/s-2008-1078277
   Yadav LDS, 2008, SYNLETT, P529, DOI 10.1055/s-2008-1042760
NR 24
TC 18
Z9 18
U1 0
U2 10
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0039-7881
J9 SYNTHESIS-STUTTGART
JI Synthesis
PD DEC
PY 2010
IS 23
BP 4051
EP 4056
DI 10.1055/s-0030-1258252
PG 6
WC Chemistry, Organic
SC Chemistry
GA 684FN
UT WOS:000284535900018
DA 2018-01-05
ER

PT J
AU Jain, A
   Yan, WL
   Miller, KR
   O'Carra, R
   Woodward, JG
   Mumper, RJ
AF Jain, Anekant
   Yan, Weili
   Miller, Keith R.
   O'Carra, Ronan
   Woodward, Jerold G.
   Mumper, Russell J.
TI Tresyl-based conjugation of protein antigen to lipid nanoparticles
   increases antigen immunogenicity
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Ovalbumin; Nanoparticles; Covalent conjugation; Vaccine; HIV protein
ID IMMUNE-RESPONSES; DENDRITIC CELLS; COATED NANOPARTICLES; VACCINE
   DELIVERY; ADJUVANT; HIV-1; LIPOSOMES; TYPE-1; SYSTEMS; CARRIER
AB The present studies were aimed at investigating the engineering of NPs with protein-conjugated-surfactant at their surface. In order to increase the immunogenicity of a protein antigen, Brij 78 was functionalized by tresyl chloride and then further reacted with the primary amine of the model proteins ovalbumin (OVA) or horseradish peroxide (HRP). The reaction yielded Brij 78-OVA and Brij 78-HRP conjugates which were then used directly to form NP-OVA or NP-HRP using a one-step warm oil-in-water microemulsion precursor method with emulsifying wax as the oil phase, and Brij 78 and the Brij 78-OVA or Brij 78-HRP conjugate as surfactants. Similarly, Brij 700 was conjugated to HIV p24 antigen to yield Brij 700-p24 conjugate. The utility of these NPs for enhancing the immune responses to protein-based vaccines was evaluated in vivo using ovalbumin (OVA) as model protein and p24 as a relevant HIV antigen. In separate in vivo studies, female BALB/c mice were immunized by subcutaneous (s.c.) injection with NP-OVA and NP-p24 formulations along with several control formulations. These results suggested that with multiple antigens, covalent attachment of the antigen to the NP significantly enhanced antigen-specific immune responses. This facile covalent conjugation and incorporation method may be utilized to further incorporate other protein antigens, even multiple antigens, into an enhanced vaccine delivery system. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Jain, Anekant; Mumper, Russell J.] Univ N Carolina, Div Mol Pharmaceut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27514 USA.
   [Jain, Anekant; Mumper, Russell J.] Univ N Carolina, Ctr Nanotechnol Drug Delivery, UNC Eshelman Sch Pharm, Chapel Hill, NC 27514 USA.
   [Yan, Weili] Auburn Univ, Harrison Sch Pharm, Dept Pharmacal Sci, Auburn, AL 36849 USA.
   [Miller, Keith R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA.
   [O'Carra, Ronan] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   [Woodward, Jerold G.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
RP Mumper, RJ (reprint author), Univ N Carolina, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, UNC Eshelman Sch Pharm, 1044 Genet Med Bldg,CB 7362, Chapel Hill, NC 27599 USA.
EM mumper@email.unc.edu
FU NIH-NIAID [AI058842]
FX This research was funded by NIH-NIAID AI058842 to RJM and JGW.
CR Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   ALLISON AC, 1974, NATURE, V252, P252, DOI 10.1038/252252a0
   ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5                                                    
   Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289
   BOLLINGER JRR, 1992, J INFECT DIS, V165, P913
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2005, CANCER IMMUNOL IMMUN, V54, P1180, DOI 10.1007/s00262-005-0685-2
   Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                                   
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   Dominguez AL, 2010, VACCINE, V28, P1383, DOI 10.1016/j.vaccine.2009.10.153
   Elamanchili P, 2007, J IMMUNOTHER, V30, P378, DOI 10.1097/CJI.0b013e31802cf3e3
   Gabutti G, 2005, J INT MED RES, V33, P406, DOI 10.1177/147323000503300406                                                      
   Guinn BA, 2007, MOL THER, V15, P1065, DOI 10.1038/sj.mt.6300138
   Guler ML, 1997, J IMMUNOL, V159, P1767
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   Hagmann M, 2000, SCIENCE, V290, P80, DOI 10.1126/science.290.5489.80                                                     
   Koziara JM, 2005, PHARM RES, V22, P1821, DOI 10.1007/s11095-005-7547-7
   LEWIS MA, 1990, ECOTOX ENVIRON SAFE, V20, P123, DOI 10.1016/0147-6513(90)90052-7
   Marechal V, 1998, J VIROL, V72, P2208
   NILSSON K, 1984, METHOD ENZYMOL, V104, P56
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Patel JD, 2007, J BIOMED NANOTECHNOL, V3, P97, DOI 10.1166/jbn.2007.007
   Patel JD, 2007, PHARM RES, V24, P343, DOI 10.1007/s11095-006-9154-7
   Pichichero ME, 2008, HUM VACCINES, V4, P262, DOI 10.4161/hv.4.4.5742                                                             
   Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091
   Sloat BR, 2010, INT J PHARMACEUT, V393, P197, DOI 10.1016/j.ijpharm.2010.04.003
   Sloat BR, 2010, J CONTROL RELEASE, V141, P93, DOI 10.1016/j.jconrel.2009.08.023
   Steenpass T, 2006, BBA-BIOMEMBRANES, V1758, P20, DOI 10.1016/j.bbamen.2005.12.010
   Tang C, 2003, J MOL BIOL, V327, P1013, DOI 10.1016/S0022-2836(03)00289-4
   VANDENBERG, 2010, J CONTROL RELEASE, V141, P234
   Yan WL, 2008, J CONTROL RELEASE, V130, P22, DOI 10.1016/j.jconrel.2008.05.005
   Yan W, 2007, POLYM REV, V47, P329, DOI 10.1080/15583720701455020
   Yoshikawa T, 2008, VACCINE, V26, P1303, DOI 10.1016/j.vaccine.2007.12.037
NR 38
TC 9
Z9 10
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 30
PY 2010
VL 401
IS 1-2
BP 87
EP 92
DI 10.1016/j.ijpharm.2010.09.003
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 693KJ
UT WOS:000285222700013
PM 20837122
OA green_accepted
DA 2018-01-05
ER

PT J
AU Van Prooyen, N
   Gold, H
   Andresen, V
   Schwartz, O
   Jones, K
   Ruscetti, F
   Lockett, S
   Gudla, P
   Venzon, D
   Franchini, G
AF Van Prooyen, Nancy
   Gold, Heather
   Andresen, Vibeke
   Schwartz, Owen
   Jones, Kathryn
   Ruscetti, Frank
   Lockett, Stephen
   Gudla, Prabhakar
   Venzon, David
   Franchini, Genoveffa
TI Human T-cell leukemia virus type 1 p8 protein increases cellular
   conduits and virus transmission
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE human leukemia retrovirus; orf-I
ID RECEPTOR SIGNAL-TRANSDUCTION; TROPICAL SPASTIC PARAPARESIS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOTROPIC-VIRUS; P12(I) PROTEIN;
   IMMUNOLOGICAL SYNAPSE; TUNNELING NANOTUBULES; VIROLOGICAL-SYNAPSE;
   MEMBRANE NANOTUBES; ANIMAL-CELLS
AB The human T-cell leukemia virus type 1 (HTLV-1) is the cause of adult T-cell leukemia/lymphoma as well as tropical spastic paraparesis/HTLV-1-associated myelopathy. HTLV-1 is transmitted to T cells through the virological synapse and by extracellular viral assemblies. Here, we uncovered an additional mechanism of virus transmission that is regulated by the HTLV-1-encoded p8 protein. We found that the p8 protein, known to anergize T cells, is also able to increase T-cell contact through lymphocyte function-associated antigen-1 clustering. In addition, p8 augments the number and length of cellular conduits among T cells and is transferred to neighboring T cells through these conduits. p8, by establishing a T-cell network, enhances the envelope-dependent transmission of HTLV-1. Thus, the ability of p8 to simultaneously anergize and cluster T cells, together with its induction of cellular conduits, secures virus propagation while avoiding the host's immune surveillance. This work identifies p8 as a viral target for the development of therapeutic strategies that may limit the expansion of infected cells in HTLV-1 carriers and decrease HTLV-1-associated morbidity.
C1 [Van Prooyen, Nancy; Gold, Heather; Andresen, Vibeke; Franchini, Genoveffa] NCI, Anim Models Retroviral Vaccine Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA.
   [Van Prooyen, Nancy] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   [Schwartz, Owen] NIAID, NIH, Bethesda, MD 20892 USA.
   [Jones, Kathryn] NCI, Basic Res Program, Sci Applicat Int Corp Frederick, Frederick, MD 21702 USA.
   [Ruscetti, Frank] NCI, Expt Immunol Lab, Frederick, MD 21702 USA.
   [Lockett, Stephen] NCI, Opt Microscopy & Anal Lab, Frederick, MD 21702 USA.
   [Gudla, Prabhakar] NCI, Image Anal Lab, Res Tech Program, Sci Applicat Int Corp Frederick, Frederick, MD 21702 USA.
   [Venzon, David] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA.
RP Franchini, G (reprint author), NCI, Anim Models Retroviral Vaccine Sect, Vaccine Branch, NIH, Bethesda, MD 20892 USA.
EM franchig@mail.nih.gov
FU National Institutes of Health [HHSN261200800001E]; National Cancer
   Institute [HHSN261200800001E]; Center for Cancer Research; Howard Hughes
   Medical Institute
FX We are dedicating this work to the memory of the late Dr. David Derse,
   as his very generous contribution of reagents greatly helped. We thank
   Drs. T. Misteli and Dustin Edwards for critical reading of the
   manuscript, Teresa Habina for editorial assistance, and Graham Myers for
   assistance in some of the experiments. We are grateful to Dr. K.
   Nagashima for transmission electron microscopy and to T. Karpova and J.
   McNally for help with the confocal microscopy. This work was supported
   by the Intramural Research Program of the National Institutes of Health,
   National Cancer Institute, Center for Cancer Research, and federal funds
   from the National Cancer Institute, National Institutes of Health, under
   Contract HHSN261200800001E. N.V.P. is a Gilliam graduate fellow of the
   Howard Hughes Medical Institute.
CR Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002
   ALI A, 1993, CLIN EXP IMMUNOL, V94, P32
   ASTIERGIN T, 1995, J VIROL METHODS, V51, P19, DOI 10.1016/0166-0934(94)00097-Z
   Banerjee P, 2007, J VIROL, V81, P9707, DOI 10.1128/JVI.00887-07
   Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850
   Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065
   BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501
   Cho NH, 2004, J EXP MED, V200, P681, DOI 10.1084/jem.20040924
   CIMINALE V, 1995, VIROLOGY, V209, P445, DOI 10.1006/viro.1995.1277
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001
   Fenard D, 2005, J IMMUNOL, V175, P6050, DOI 10.4049/jimmunol.175.9.6050                                                     
   Fukumoto R, 2007, J VIROL, V81, P9088, DOI 10.1128/JVI.02703-06
   Fukumoto R, 2009, BLOOD, V113, P3726, DOI 10.1182/blood-2008-04-146928
   GALLO RC, 1986, SCI AM, V255, P88, DOI 10.1038/scientificamerican1286-88                                               
   Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   GESSAIN A, 1985, LANCET, V2, P407
   GONDA MA, 1976, J NATL CANCER I, V56, P245, DOI 10.1093/jnci/56.2.245                                                           
   Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0                                                   
   Heidecker G, 2004, J VIROL, V78, P6636, DOI 10.1128/JVI.78.12.6636-6648.2004
   Hope TJ, 2007, NAT CELL BIOL, V9, P243, DOI 10.1039/ncb0307-243
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001                                                
   Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745
   Kim SJ, 2006, J IMMUNOL, V176, P5463, DOI 10.4049/jimmunol.176.9.5463                                                     
   KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813
   MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104                                                          
   Mazurov D, 2006, VIROLOGY, V346, P194, DOI 10.1016/j.virol.2005.10.033
   Mulloy JC, 1996, J VIROL, V70, P3599
   Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858                                                        
   Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200
   Nejmeddine M, 2009, BLOOD, V114, P1016, DOI 10.1182/blood-2008-03-136770
   Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984
   Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823
   Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415                                                         
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Taylor JM, 2009, J VIROL, V83, P11467, DOI 10.1128/JVI.00952-09
   Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016
   Valeri VW, 2010, BLOOD, V116, P3809, DOI 10.1182/blood-2010-05-284141
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   YARCHOAN R, 1986, J CLIN INVEST, V77, P1466, DOI 10.1172/JCI112459                                                               
NR 47
TC 49
Z9 49
U1 1
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 30
PY 2010
VL 107
IS 48
BP 20738
EP 20743
DI 10.1073/pnas.1009635107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 687ET
UT WOS:000284762400031
PM 21076035
OA gold
DA 2018-01-05
ER

PT J
AU Jahnichen, S
   Blanchetot, C
   Maussang, D
   Gonzalez-Pajuelo, M
   Chow, KY
   Bosch, L
   De Vrieze, S
   Serruys, B
   Ulrichts, H
   Vandevelde, W
   Saunders, M
   De Haard, HJ
   Schols, D
   Leurs, R
   Vanlandschoot, P
   Verrips, T
   Smit, MJ
AF Jahnichen, Sven
   Blanchetot, Christophe
   Maussang, David
   Gonzalez-Pajuelo, Maria
   Chow, Ken Y.
   Bosch, Leontien
   De Vrieze, Sindi
   Serruys, Benedikte
   Ulrichts, Hans
   Vandevelde, Wesly
   Saunders, Michael
   De Haard, Hans J.
   Schols, Dominique
   Leurs, Rob
   Vanlandschoot, Peter
   Verrips, Theo
   Smit, Martine J.
TI CXCR4 nanobodies (VHH-based single variable domains) potently inhibit
   chemotaxis and HIV-1 replication and mobilize stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE nanobody; CXCR4 antagonist; chemotaxis; HIV; stem cell mobilization
ID PROTEIN-COUPLED RECEPTORS; IMMUNODEFICIENCY-VIRUS TYPE-1; HEAVY-CHAIN
   ANTIBODIES; CHEMOKINE RECEPTOR; ANTI-CXCR4 ANTIBODIES; CONSTITUTIVE
   ACTIVITY; MONOCLONAL-ANTIBODY; DRUG TARGETS; AMD3100; CORECEPTOR
AB The important family of G protein-coupled receptors has so far not been targeted very successfully with conventional monoclonal antibodies. Here we report the isolation and characterization of functional VHH-based immunoglobulin single variable domains (or nanobodies) against the chemokine receptor CXCR4. Two highly selective monovalent nanobodies, 238D2 and 238D4, were obtained using a time-efficient whole cell immunization, phage display, and counterselection method. The highly selective VHH-based immunoglobulin single variable domains competitively inhibited the CXCR4-mediated signaling and antagonized the chemoattractant effect of the CXCR4 ligand CXCL12. Epitope mapping showed that the two nanobodies bind to distinct but partially overlapping sites in the extracellular loops. Short peptide linkage of 238D2 with 238D4 resulted in significantly increased affinity for CXCR4 and picomolar activity in antichemotactic assays. Interestingly, the monovalent nanobodies behaved as neutral antagonists, whereas the biparatopic nanobodies acted as inverse agonists at the constitutively active CXCR4-N3.35A. The CXCR4 nanobodies displayed strong antiretroviral activity against T cell-tropic and dual-tropic HIV-1 strains. Moreover, the biparatopic nanobody effectively mobilized CD34-positive stem cells in cynomolgus monkeys. Thus, the nanobody platform may be highly effective at generating extremely potent and selective G protein-coupled receptor modulators.
C1 [Gonzalez-Pajuelo, Maria; De Vrieze, Sindi; Serruys, Benedikte; Ulrichts, Hans; Vandevelde, Wesly; Saunders, Michael; De Haard, Hans J.; Vanlandschoot, Peter] Ablynx, B-9052 Ghent, Belgium.
   [Jahnichen, Sven; Maussang, David; Chow, Ken Y.; Leurs, Rob; Smit, Martine J.] Vrije Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, Fac Sci, NL-1081 HV Amsterdam, Netherlands.
   [Blanchetot, Christophe; Verrips, Theo] Univ Utrecht, Dept Cellular Architecture & Dynam, NL-3584 CH Utrecht, Netherlands.
   [Schols, Dominique] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Vanlandschoot, P (reprint author), Ablynx, B-9052 Ghent, Belgium.
EM peter.vanlandschoot@ablynx.com; mj.smit@few.vu.nl
RI Schols, Dominique/S-9057-2017
OI Schols, Dominique/0000-0003-3256-5850
FU Ablynx; Flemish government [IWT70050]; Fonds voor Wetenschappelijk
   Onderzoek [G-485-08]; Centers of Excellence of Katholieke Universiteit
   Leuven [EF/05/015]
FX We thank Claesand and Rebecca Provinciael for excellent technical
   assistance with the anti-HIV experiments. We also thank Guus van Dongen
   and Dennis Verzijl for the technical feedback on labeling and handling
   procedures of nanobodies. This work was funded by Ablynx and supported
   by Institute for the Promotion of Innovation by Science and Technology
   in Flanders Grant IWT70050 from the Flemish government, "Fonds voor
   Wetenschappelijk Onderzoek" Grant G-485-08, and Centers of Excellence of
   Katholieke Universiteit Leuven Grant EF/05/015.
CR Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200
   Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957-8967.2001                                                
   Beider K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005125
   Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200                                                          
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Carnec X, 2005, J VIROL, V79, P1930, DOI 10.1128/JVI.79.3.1930-1933.2005
   Cashen AF, 2009, DRUG TODAY, V45, P497, DOI 10.1358/dot.2009.45.7.1395292
   Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717
   Coppieters K, 2006, ARTHRITIS RHEUM-US, V54, P1856, DOI 10.1002/art.21827
   Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061
   Dalrymple MB, 2008, PHARMACOL THERAPEUT, V118, P359, DOI 10.1016/j.pharmthera.2008.03.004
   De Clercq E, 2009, BIOCHEM PHARMACOL, V77, P1655, DOI 10.1016/j.bcp.2008.12.014
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   DiPersio JF, 2009, J CLIN ONCOL, V27, P4767, DOI 10.1200/JCO.2008.20.7209
   DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Flomenberg N, 2005, BLOOD, V106, P1867, DOI 10.1182/blood-2005-02-0468
   Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499                                                      
   Gupta A, 2008, COMB CHEM HIGH T SCR, V11, P463, DOI 10.2174/138620708784911465
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Harmsen MM, 2007, VET MICROBIOL, V120, P193, DOI 10.1016/j.vetmic.2006.10.029
   Henderson KA, 2007, STRUCTURE, V15, P1452, DOI 10.1016/j.str.2007.09.011
   Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef
   Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007
   Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev
   Kofuku Y, 2009, J BIOL CHEM, V284, P35240, DOI 10.1074/jbc.M109.024851
   Lagane B, 2008, BLOOD, V112, P34, DOI 10.1182/blood-2007-07-102103
   Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512
   Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618
   Liang XY, 2008, CHEM BIOL DRUG DES, V72, P97, DOI 10.1111/j.1747-0285.2008.00681.x
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686                                                     
   McKnight A, 1997, J VIROL, V71, P1692
   Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Ottaiano A, 2005, CANCER IMMUNOL IMMUN, V54, P781, DOI 10.1007/s00262-004-0636-3
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Paes C, 2009, J AM CHEM SOC, V131, P6952, DOI 10.1021/ja900186n
   Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4
   Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200
   Strizki JM, 1997, J VIROL, V71, P5678
   Vaday GG, 2004, CLIN CANCER RES, V10, P5630, DOI 10.1158/1078-0432.CCR-03-0633
   Van Bockstaele F, 2009, CURR OPIN INVEST DR, V10, P1212
   Wang JH, 2006, MOL CANCER THER, V5, P2474, DOI 10.1158/1535-7163.MCT-05-0261
   Wong RSY, 2008, MOL PHARMACOL, V74, P1485, DOI 10.1124/mol.108.049775
   Xu C, 2007, J IMMUNOL, V179, P2408, DOI 10.4049/jimmunol.179.4.2408                                                     
   Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034
   Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200
   Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200
NR 50
TC 76
Z9 80
U1 3
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 23
PY 2010
VL 107
IS 47
BP 20565
EP 20570
DI 10.1073/pnas.1012865107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 684DT
UT WOS:000284529000076
PM 21059953
OA gold
DA 2018-01-05
ER

PT J
AU Chang, R
   Lee, J
AF Chang, Rakwoo
   Lee, Junun
TI Dynamics of C-60 Molecules in Biological Membranes: Computer Simulation
   Studies
SO BULLETIN OF THE KOREAN CHEMICAL SOCIETY
LA English
DT Article
DE Fullerene; Carbon nanoparticle; DMPC membrane; Molecular dynamics
   simulation
ID CARBON NANOTUBE MATERIAL; HIV-1 PROTEASE; FULLERENE DERIVATIVES;
   PULMONARY TOXICITY; PROTON TRANSPORT; LIPID-BILAYER; FORCE-FIELD; WATER;
   MACROMOLECULES; TRANSLOCATION
AB We have performed molecular dynamics simulations of atomistic models of C-60 molecules and DMPC bilayer membranes to study the static and dynamic effects of carbon nanoparticles on biological membranes All four C-60-membrane systems were investigated representing dilute and concentrated solutions of C-60 residing either inside or outside the membrane The concentrated C-60 molecules in water phase start forming an aggregated cluster Due to its heavy mass, the cluster tends to adhere on the surface of the bilayer membrane, hindering both translational and rotational diffusion of individual C-60 On the other hand, once C-60 molecules accumulate inside the membrane, they are well dispersed in the central region of the bilayer membrane Because of the homogeneous dispersion of C-60 inside the membrane, each leaflet is pushed away from the center, making the bilayer membrane thicker This thickening of the membrane provides more room for both translational and rotational motions of C-60 inside the membrane compared to that in the water region As a result, the dynamics of C-60 inside the membrane becomes faster with increasing its concentration
C1 [Chang, Rakwoo; Lee, Junun] Kwangwoon Univ, Dept Chem, Seoul 139701, South Korea.
RP Chang, R (reprint author), Kwangwoon Univ, Dept Chem, Seoul 139701, South Korea.
FU Korean Government (MOEHRD) [KRF-2007-331-C00132]; Korea Institute of
   Science and Technology Information [KSC-2009-S01-0015]; Kwangwoon
   Research Fund
FX This work was supported by the Korea Research Foundation Grand funded by
   the Korean Government (MOEHRD, Basic Research Promotion Fund)
   (KRF-2007-331-C00132), Korea Institute of Science and Technology
   Information (KSC-2009-S01-0015), and Kwangwoon Research Fund (2010)
CR ADELMANN P, 1994, EFFECTS FULLERENES A
   Ajayan PM, 1999, P NATL ACAD SCI USA, V96, P14199, DOI 10.1073/pnas.96.25.14199                                                        
   Arnall A.H., 2003, FUTURE TECHNOLOGIES
   Ball P, 2001, NATURE, V414, P142, DOI 10.1038/35102721
   Bedrov D, 2008, J PHYS CHEM B, V112, P2078, DOI 10.1021/jp075149c
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Chang R, 2006, J PHYS CHEM B, V110, P5073, DOI 10.1021/jp0565148
   Chang R, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1931651
   Choe S, 2008, BIOPHYS J, V95, P4102, DOI 10.1529/biophysj.107.123976
   Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875
   de Jonge N, 2004, PHILOS T R SOC A, V362, P2239, DOI 10.1098/rsta.2004.1438
   Degiorgi L, 1998, ADV PHYS, V47, P207, DOI 10.1080/000187398243555                                                         
   Dresselhaus MS, 2004, MRS BULL, V29, P237, DOI 10.1557/mrs2004.74                                                              
   Endo M, 2004, PHILOS T ROY SOC A, V362, P2223, DOI 10.1098/rsta.2004.1437
   Florian J, 2005, P NATL ACAD SCI USA, V102, P6819, DOI 10.1073/pnas.0408173102
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gao HJ, 2004, ANNU REV MATER RES, V34, P123, DOI 10.1146/annurev.matsci.34.040203.120402
   Huczko A, 1999, FULLERENE SCI TECHN, V7, P935, DOI 10.1080/10641229909351390                                                       
   Huczko A, 2001, FULLERENE SCI TECHN, V9, P251, DOI 10.1081/FST-100102973                                                           
   JOHNSON RD, 1992, SCIENCE, V255, P1235, DOI 10.1126/science.255.5049.1235                                                   
   JOHNSON RD, 1992, ACCOUNTS CHEM RES, V25, P169, DOI 10.1021/ar00015a011
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kohl P, 2000, PHILOS T R SOC A, V358, P579, DOI 10.1098/rsta.2000.0547                                                          
   Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243
   Li LW, 2007, J PHYS CHEM B, V111, P4067, DOI 10.1021/jp064982r
   Li LW, 2006, J PHYS CHEM B, V110, P10509, DOI 10.1021/jp060718m
   Lin Y, 2004, J MATER CHEM, V14, P527, DOI 10.1039/b314481j
   Maynard AD, 2004, J TOXICOL ENV HEAL A, V67, P87, DOI 10.1080/15287390490253688
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   MERLO DF, 2004, OCCUP ENVIRON MED, P61
   Moraitakis G, 2003, REP PROG PHYS, V66, P383, DOI 10.1088/0034-4885/66/3/203
   Noon WH, 2002, P NATL ACAD SCI USA, V99, P6466, DOI 10.1073/pnas.022532599
   Prato M, 1997, J MATER CHEM, V7, P1097, DOI 10.1039/a700080d                                                                
   Prato M, 1999, TOP CURR CHEM, V199, P173
   Qiao R, 2007, NANO LETT, V7, P614, DOI 10.1021/nl062515f
   Redondo A, 2004, ANNU REV MATER RES, V34, P279, DOI 10.1146/annurev.matsci.34.070503.123908
   ROUX B, 1995, COMPUT PHYS COMMUN, V91, P275, DOI 10.1016/0010-4655(95)00053-I
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Saiz L, 2002, BIOSCIENCE REP, V22, P151, DOI 10.1023/A:1020130420869
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Schlick T, 1997, ANNU REV BIOPH BIOM, V26, P181, DOI 10.1146/annurev.biophys.26.1.181
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/15287390390231566
   Smith W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4                                                   
   Smondyrev AM, 1999, J COMPUT CHEM, V20, P531, DOI 10.1002/(SICI)1096-987X(19990415)20:5<531::AID-JCC5>3.0.CO;2-3                  
   Smondyrev AM, 2002, BIOPHYS J, V82, P1460, DOI 10.1016/S0006-3495(02)75500-8                                                   
   Smondyrev AM, 1999, J CHEM PHYS, V110, P3981, DOI 10.1063/1.478278
   Srinivas G, 2004, NANOTECHNOLOGY, V15, P1289, DOI 10.1088/0957-4484/15/9/030
   Subramoney S, 1998, ADV MATER, V10, P1157, DOI 10.1002/(SICI)1521-4095(199810)10:15<1157::AID-ADMA1157>3.0.CO;2-N
   TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8
   Uragoda CG, 1997, OCCUP MED-OXFORD, V47, P269, DOI 10.1093/occmed/47.5.269
   Voth GA, 2003, FRONT BIOSCI-LANDMRK, V8, pS1384, DOI 10.2741/1213                                                                    
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Warshel A, 2005, P NATL ACAD SCI USA, V102, P1813, DOI 10.1073/pnas.0409788102
   Wong-Ekkabut J, 2008, NAT NANOTECHNOL, V3, P363, DOI 10.1038/nnano.2008.130
   Xie YH, 2005, MATER LETT, V59, P971, DOI 10.1016/j.matlet.2004.10.079
   Yeh IC, 2004, P NATL ACAD SCI USA, V101, P12177, DOI 10.1073/pnas.0402699101
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 58
TC 12
Z9 12
U1 0
U2 11
PU KOREAN CHEMICAL SOC
PI SEOUL
PA 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 0253-2964
J9 B KOREAN CHEM SOC
JI Bull. Korean Chem. Soc.
PD NOV 20
PY 2010
VL 31
IS 11
BP 3195
EP 3200
DI 10.5012/bkcs.2010.31.11.3195
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 687QX
UT WOS:000284794100026
OA gold
DA 2018-01-05
ER

PT J
AU Trylska, J
AF Trylska, Joanna
TI Coarse-grained models to study dynamics of nanoscale biomolecules and
   their applications to the ribosome
SO JOURNAL OF PHYSICS-CONDENSED MATTER
LA English
DT Review
ID ELASTIC NETWORK MODEL; KNOWLEDGE-BASED POTENTIALS; AMINO-ACID-SEQUENCE;
   MOLECULAR-DYNAMICS; HIV-1 PROTEASE; LOW-RESOLUTION; EXIT TUNNEL;
   COMPUTER-SIMULATION; NOBEL LECTURE; FORCE-FIELD
AB Biopolymers are of dynamic nature and undergo functional motions spanning a large spectrum of timescales. To study the internal dynamics of nano-sized molecular complexes that exceed hundred thousands of atoms with atomic detail is computationally inefficient. Therefore, to achieve both the spatial and temporal scales of biological interest coarse-grained models of macromolecules are often used. By uniting groups of atoms into single interacting centers one decreases the resolution of the system and gets rid of the irrelevant degrees of freedom. This simplification, even though it requires parameterization, makes the studies of biomolecular dynamics computationally tractable and allows us to reach beyond the microsecond time frame. Here, I review the coarse-grained models of macromolecules composed of proteins and nucleic acids. I give examples of one-bead models that were developed to investigate the internal dynamics and focus on their applications to the ribosome-the nanoscale protein synthesis machine.
C1 Univ Warsaw, Interdisciplinary Ctr Math & Computat Modelling, PL-02106 Warsaw, Poland.
RP Trylska, J (reprint author), Univ Warsaw, Interdisciplinary Ctr Math & Computat Modelling, Pawinskiego 5A, PL-02106 Warsaw, Poland.
EM joanna@icm.edu.pl
FU ICM, U Warsaw [BST1450/2009, BST1550/2010, G31-4]; Polish Ministry of
   Science and Higher Education [N N301 245236]; Foundation for Polish
   Science [TEAM/2009-3/8]; European Regional Development Fund
FX The author acknowledges support from ICM, U Warsaw (BST1450/2009,
   BST1550/2010 and G31-4), Polish Ministry of Science and Higher Education
   (N N301 245236), and Foundation for Polish Science (Focus program and
   Team project (TEAM/2009-3/8) co-financed by European Regional
   Development Fund operated within Innovative Economy Operational
   Programme). JT would like to thank Filip Leonarski for preparing figure
   2.
CR ABE H, 1981, BIOPOLYMERS, V20, P1013, DOI 10.1002/bip.1981.360200512
   Adcock SA, 2004, J COMPUT CHEM, V25, P16, DOI 10.1002/jcc.10314
   Alexandrov V, 2005, PROTEIN SCI, V14, P633, DOI 10.1110/ps.04882105
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X                                                   
   Bahar I, 2005, CURR OPIN STRUC BIOL, V15, P586, DOI 10.1016/j.sbi.2005.08.007
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   Bahar I, 2010, ANNU REV BIOPHYS, V39, P23, DOI 10.1146/annurev.biophys.093008.131258
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Bhushan S, 2010, NAT STRUCT MOL BIOL, V17, P313, DOI 10.1038/nsmb.1756
   Borovinskaya MA, 2008, RNA, V14, P1590, DOI 10.1261/rna.1076908
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Cecconi F, 2001, PROTEINS, V43, P365, DOI 10.1002/prot.1049.abs
   Chacon P, 2003, J MOL BIOL, V326, P485, DOI 10.1016/S0022-2836(02)01426-2
   Chang CE, 2006, BIOPHYS J, V90, P3880, DOI 10.1529/biophysj.105.074575
   Christen M, 2008, J COMPUT CHEM, V29, P157, DOI 10.1002/jcc.20725
   Chu JW, 2007, BIOPHYS J, V93, P3860, DOI 10.1529/biophysj.107.112060
   Clementi C, 2008, CURR OPIN STRUC BIOL, V18, P10, DOI 10.1016/j.sbi.2007.10.005
   Cui QZ, 2006, MULTISCALE MODEL SIM, V5, P1248, DOI 10.1137/05064850X
   Das P, 2005, P NATL ACAD SCI USA, V102, P10141, DOI 10.1073/pnas.0409471102
   Ding F, 2008, RNA, V14, P1164, DOI 10.1261/rna.894608
   Doruker P, 2003, PROTEINS, V53, P174, DOI 10.1002/prot.10486
   Doruker P, 2002, J COMPUT CHEM, V23, P119, DOI 10.1002/jcc.1160
   Drukker K, 2001, J CHEM PHYS, V114, P579, DOI 10.1063/1.1329137
   Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104
   Elber R, 2005, CURR OPIN STRUC BIOL, V15, P151, DOI 10.1016/j.sbi.2005.02.004
   Elcock AH, 2006, PLOS COMPUT BIOL, V2, P824, DOI 10.1371/journal.pcbi.0020098
   Erman B, 2006, BIOPHYS J, V91, P3589, DOI 10.1529/biophysj.106.090803
   Eyal E, 2006, BIOINFORMATICS, V22, P2619, DOI 10.1093/bioinformatics./btl.448
   Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597
   GONTHEORETICAL S, 1983, Annu Rev Biophys Bio, V12, P183
   Gorecki A, 2009, J COMPUT CHEM, V30, P2364, DOI 10.1002/jcc.21223
   GUMBART J, 2010, STRUCTURE, V17, P1453
   Haliloglu T, 1997, PHYS REV LETT, V79, P3090, DOI 10.1103/PhysRevLett.79.3090
   HAMACHER K, 2006, PLOS COMPUT BIOL, V2
   Hansmann UHE, 1996, CHEM PHYS LETT, V259, P321, DOI 10.1016/0009-2614(96)00761-0
   Heath AP, 2007, PROTEINS, V68, P646, DOI 10.1002/prot.21371
   HELD WA, 1973, BIOCHEMISTRY-US, V12, P3273, DOI 10.1021/bi00741a020
   Hills RD, 2009, INT J MOL SCI, V10, P889, DOI 10.3390/ijms10030889
   Hinsen K, 2005, BIOPHYS J, V88, P818, DOI 10.1529/biophysj.104.050716
   Hinsen K, 1998, PROTEINS, V33, P417, DOI 10.1002/(SICI)1097-0134(19981115)33:3<417::AID-PROT10>3.0.CO;2-8
   Hinsen K, 1999, J CHEM PHYS, V111, P10766, DOI 10.1063/1.480441
   Hinsen K, 2008, BIOINFORMATICS, V24, P521, DOI 10.1093/bioinformatics/btm625
   Hoang TX, 2000, J CHEM PHYS, V112, P6851, DOI 10.1063/1.481261
   Hollup S.M., 2005, BMC BIOINFORMATICS, V6, P1
   Izvekov S, 2005, J PHYS CHEM B, V109, P2469, DOI 10.1021/jp044629q
   Jernigan RL, 1996, CURR OPIN STRUC BIOL, V6, P195, DOI 10.1016/S0959-440X(96)80075-3
   Jonikas MA, 2009, RNA, V15, P189, DOI 10.1261/rna.1270809
   Kantarci-Carsibasi N, 2008, BIOPHYS J, V95, P5862, DOI 10.1529/biophysj.107.128447
   KIMM K, 2002, BIOPHYS J, V83, P1620
   KIMM KLI, 2003, J BIOMOL STRUCT DYN, V21, P395
   Kirmizialtin S, 2004, J CHEM PHYS, V121, P10268, DOI 10.1063/1.1807832
   Kolinski A, 2004, ACTA BIOCHIM POL, V51, P349
   Kondrashov DA, 2006, BIOPHYS J, V91, P2760, DOI 10.1529/biophysj.106.085894
   Kurkcuoglu O, 2004, POLYMER, V45, P649, DOI 10.1016/j.polymer.2003.10.071
   Kurkcuoglu O, 2009, BIOPHYS J, V97, P1178, DOI 10.1016/j.bpj.2009.06.009
   Kurkcuoglu O, 2009, PROTEINS, V75, P837, DOI 10.1002/prot.22292
   Kurkcuoglu O, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/4/046005
   Laing C, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/28/283101
   Lattanzi G, 2004, COMP MATER SCI, V30, P163, DOI 10.1016/j.commatsci.2004.01.024
   Leach A.R., 2001, MOL MODELLING PRINCI
   LESYNG B, 1988, ACTA CRYSTALLOGR B, V44, P193, DOI 10.1107/S0108768187011170
   LEVITT M, 1975, NATURE, V253, P694, DOI 10.1038/253694a0
   Liljas A, 2004, STRUCTURAL ASPECTS P
   Limbach HJ, 2006, COMPUT PHYS COMMUN, V174, P704, DOI 10.1016/j.cpc.2005.10.005
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Liwo A, 2005, P NATL ACAD SCI USA, V102, P2362, DOI 10.1073/pnas.0408885102
   Lu MY, 2005, BIOPHYS J, V89, P2395, DOI 10.1529/biophysj.105.065904
   LUJL, 2005, Nat Struct Mol Biol, V12, P1123
   Lyman E, 2008, BIOPHYS J, V95, P4183, DOI 10.1529/biophysj.108.139733
   LYUBARTSEV AP, 1995, PHYS REV E, V52, P3730, DOI 10.1103/PhysRevE.52.3730
   Maciejczyk M, 2010, J COMPUT CHEM, V31, P1644, DOI 10.1002/jcc.21448
   MALHOTRA A, 1994, BIOPHYS J, V66, P1777, DOI 10.1016/S0006-3495(94)80972-5                                                   
   Maragakis P, 2005, J MOL BIOL, V352, P807, DOI 10.1016/j.jmb.2005.07.031
   Maupetit J, 2006, NUCLEIC ACIDS RES, V34, pW147, DOI 10.1093/nar/gkl289
   MCCAMMON JA, 1980, BIOPOLYMERS, V19, P2033, DOI 10.1002/bip.1980.360191108
   McGreevy RL, 1988, MOL SIMULAT, V1, P359, DOI 10.1080/08927028808080958
   Micheletti C, 2004, PROTEINS, V55, P635, DOI 10.1002/prot.20049
   Ming D, 2002, P NATL ACAD SCI USA, V99, P8620, DOI 10.1073/pnas.082148899
   Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x
   Moritsugu K, 2007, BIOPHYS J, V93, P3460, DOI 10.1529/biophysj.107.111898
   Mueller-Plathe F., 2002, CHEMPHYSCHEM, V3, P754
   Mullinax JW, 2010, J PHYS CHEM C, V114, P5661, DOI 10.1021/jp9073976
   Mullinax JW, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.198104
   Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9                                                   
   Neri M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.218102
   Nymeyer H, 2004, METHOD ENZYMOL, V383, P119
   Pasquali S, 2010, J PHYS CHEM B, V114, P11957, DOI 10.1021/jp102497y
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Ramakrishnan V, 2010, ANGEW CHEM INT EDIT, V49, P4355, DOI 10.1002/anie.201001436
   Reith D, 2003, J COMPUT CHEM, V24, P1624, DOI 10.1002/jcc.10307
   Sanbonmatsu KY, 2005, P NATL ACAD SCI USA, V102, P15854, DOI 10.1073/pnas.0503456102
   Savelyev A, 2009, BIOPHYS J, V96, P4044, DOI 10.1016/j.bpj.2009.02.067
   SCHLICK T, 2006, MOL MODELLING SIMULA
   SCHMEING TM, 2009, NATURE, V46, P1234
   Schroder GF, 2007, STRUCTURE, V15, P1630, DOI 10.1016/j.str.2007.09.021
   SENT Z, 2006, J Chem Theory Comput, V2, P696
   Sherwood P, 2008, CURR OPIN STRUC BIOL, V18, P630, DOI 10.1016/j.sbi.2008.07.003
   SIPPL MJ, 1995, CURR OPIN STRUC BIOL, V5, P229, DOI 10.1016/0959-440X(95)80081-6
   Smith W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4                                                   
   Song G, 2006, PROTEINS, V63, P197, DOI 10.1002/prot.208365
   Stagg SM, 2003, J MOL BIOL, V328, P49, DOI 10.1016/S0022-2836(03)00174-8
   Steitz TA, 2010, ANGEW CHEM INT EDIT, V49, P4381, DOI 10.1002/anie.201000708
   STRAUB JE, 1991, J CHEM PHYS, V94, P6737, DOI 10.1063/1.460250
   Suhre K, 2004, NUCLEIC ACIDS RES, V32, pW610, DOI 10.1093/nar/gkh368
   Sulkowska JI, 2008, BIOPHYS J, V95, P3174, DOI 10.1529/biophysj.107.127233
   TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445
   Tama F, 2000, PROTEINS, V41, P1
   Tama F, 2004, J STRUCT BIOL, V147, P315, DOI 10.1016/j.jsb.2004.03.002
   Tama F, 2003, P NATL ACAD SCI USA, V100, P9319, DOI 10.1073/pnas.1632476100
   Tama F, 2002, J MOL BIOL, V321, P297, DOI 10.1016/S0022-2836(02)00627-7
   Tama F, 2002, J MOL BIOL, V318, P733, DOI 10.1016/S0022-2836(02)00135-3
   Tama F, 2006, ANNU REV BIOPH BIOM, V35, P115, DOI 10.1146/annurev.biophys.35.040405.102010
   TANR KZ, 2006, J Chem Theory Comput, V2, P529
   Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905                                                     
   Tozzini V, 2006, J CHEM THEORY COMPUT, V2, P667, DOI 10.1021/ct050294k
   Tozzini V, 2005, CHEM PHYS LETT, V413, P123, DOI 10.1016/j.cplett.2005.07.075
   Tozzini V, 2005, CURR OPIN STRUC BIOL, V15, P144, DOI 10.1016/j.sbi.2005.02.005
   Tozzini V, 2007, J STRUCT BIOL, V157, P606, DOI 10.1016/j.jsb.2006.08.005
   Trabuco LG, 2010, STRUCTURE, V18, P627, DOI 10.1016/j.str.2010.02.011
   Trovato F, 2008, J PHYS CHEM B, V112, P13197, DOI 10.1021/jp807085d
   Trylska J, 2005, BIOPHYS J, V89, P1455, DOI 10.1529/biophysj.104.058495
   Trylska J, 2005, J AM CHEM SOC, V127, P11125, DOI 10.1021/ja052639e
   Trylska J, 2004, BIOPOLYMERS, V74, P423, DOI 10.1002/bip.20093
   Trylska J, 2007, BIOPHYS J, V92, P4179, DOI 10.1529/biophysj.106.100560
   Trylska J, 2009, Q REV BIOPHYS, V42, P301, DOI 10.1017/S0033583510000028
   UEDA Y, 1978, BIOPOLYMERS, V17, P1531, DOI 10.1002/bip.1978.360170612
   VERKHIVKER G, 1992, J CHEM PHYS, V97, P7838, DOI 10.1063/1.463456
   Voltz K, 2008, J COMPUT CHEM, V29, P1429, DOI 10.1002/jcc.20902
   Voss NR, 2006, J MOL BIOL, V360, P893, DOI 10.1016/j.jmb.2006.05.023
   Wang YM, 2004, J STRUCT BIOL, V147, P302, DOI 10.1016/j.jsb.2004.01.005
   Wang YM, 2005, BIOPHYS J, V89, P3399, DOI 10.1529/biophysj.105.064840
   Williamson JR, 2008, CURR OPIN STRUC BIOL, V18, P299, DOI 10.1016/j.sbi.2008.05.001
   Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2
   YANA M, 2008, J Chem Theory Comput, V4, P1757
   Yang LW, 2008, BIOINFORM BIOL INSIG, V2, P25
   Yang L, 2009, P NATL ACAD SCI USA, V106, P12347, DOI 10.1073/pnas.0902159106
   Yap EH, 2008, PROTEINS, V70, P626, DOI 10.1002/prot.21515
   Yonath A, 2010, ANGEW CHEM INT EDIT, V49, P4340, DOI 10.1002/anie.201001297
   Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089
   Ziv G, 2005, P NATL ACAD SCI USA, V102, P18956, DOI 10.1073/pnas.0508234102
   J MOL BIOL, V298, P937
NR 143
TC 30
Z9 30
U1 0
U2 17
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0953-8984
J9 J PHYS-CONDENS MAT
JI J. Phys.-Condes. Matter
PD NOV 17
PY 2010
VL 22
IS 45
AR 453101
DI 10.1088/0953-8984/22/45/453101
PG 13
WC Physics, Condensed Matter
SC Physics
GA 673HZ
UT WOS:000283651400002
PM 21339588
DA 2018-01-05
ER

PT J
AU Ali, A
   Reddy, GSKK
   Nalam, MNL
   Anjum, SG
   Cao, H
   Schiffer, CA
   Rana, TM
AF Ali, Akbar
   Reddy, G. S. Kiran Kumar
   Nalam, Madhavi N. L.
   Anjum, Saima Ghafoor
   Cao, Hong
   Schiffer, Celia A.
   Rana, Tariq M.
TI Structure-Based Design, Synthesis, and Structure-Activity Relationship
   Studies of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidinones
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTED PATIENTS; DRUG-RESISTANCE;
   DISCOVERY; SUBSTRATE; THERAPY; TMC114; MODEL; SUSCEPTIBILITY; TIPRANAVIR
AB A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar antiviral potency against patient-derived viruses from HIV-1 clades A, B, and C, and most retained potency against drug-resistant viruses. Further optimization of these compounds using structure-based design may lead to the development of novel protease inhibitors with improved activity against drug-resistant strains of HIV-1.
C1 [Ali, Akbar; Reddy, G. S. Kiran Kumar; Nalam, Madhavi N. L.; Anjum, Saima Ghafoor; Cao, Hong; Schiffer, Celia A.; Rana, Tariq M.] Univ Massachusetts, Dept Biochem & Mol Pharmacol, Sch Med, Worcester, MA 01605 USA.
   [Ali, Akbar; Reddy, G. S. Kiran Kumar; Anjum, Saima Ghafoor; Cao, Hong; Rana, Tariq M.] Univ Massachusetts, Chem Biol Program, Sch Med, Worcester, MA 01605 USA.
RP Schiffer, CA (reprint author), Univ Massachusetts, Dept Biochem & Mol Pharmacol, Sch Med, Worcester, MA 01605 USA.
EM Celia.Schiffer@umassmed.edu; trana@sanfordburnham.org
FU National Institutes of General Medical Sciences of the NIH
   [PO1-GM066524]
FX We thank Kaneka USA for generous gifts of chiral epoxides, Ellen A.
   Nalivaika for providing the wild-type and MDR HIV-1 proteases, the AIDS
   Research and Reference Reagent Program (NIAD, NIH) for reference
   protease inhibitors, Monogram Biosciences for antiviral testing, and
   members of the Rana and Schiffer laboratories for helpful discussions.
   This work was supported in part by a grant from the National Institutes
   of General Medical Sciences of the NIH (Grant. PO1-GM066524).
CR ALI A, 2007, NAT M AM CHEM SOC
   Ali A, 2006, J MED CHEM, V49, P7342, DOI 10.1021/jm060666p
   Altman MD, 2008, J AM CHEM SOC, V130, P6099, DOI 10.1021/ja076558p
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
   Baxter JD, 2006, J VIROL, V80, P10794, DOI 10.1128/JVI.00712-06
   Bissantz C, 2010, J MED CHEM, V53, P5061, DOI 10.1021/jm100112j
   Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556
   CLAVEL F, 2004, J MED */* IV ENGL J, V350, P1023
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   de Meyer S, 2008, AIDS RES HUM RETROV, V24, P379, DOI 10.1089/aid.2007.0173
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Freire E, 2008, DRUG DISCOV TODAY, V13, P869, DOI 10.1016/j.drudis.2008.07.005
   GRECO WR, 1979, J BIOL CHEM, V254, P2104
   Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450                                                          
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654
   King NM, 2002, PROTEIN SCI, V11, P418, DOI 10.1110/ps.25502
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P2773, DOI 10.1073/pnas.88.7.2773
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Minor W., 1993, XDISPLAYF
   Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Nalam MNL, 2010, J VIROL, V84, P5368, DOI 10.1128/JVI.02531-09
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Reddy GSKK, 2007, J MED CHEM, V50, P4316, DOI 10.1021/jm070284z
   SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718
   Shafer RW, 2008, AIDS REV, V10, P67
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tickle I.J., 1999, IUCR99 COMPUTING SCH
   *UNAIDS, 2008, JOINT UN PROGR HIV A
   Youle M, 2007, J ANTIMICROB CHEMOTH, V60, P1195, DOI 10.1093/jac/dkm364
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   1998, J MED CHEM, V41, P3467
NR 42
TC 31
Z9 33
U1 2
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 11
PY 2010
VL 53
IS 21
BP 7699
EP 7708
DI 10.1021/jm1008743
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 673ZP
UT WOS:000283703000018
PM 20958050
OA green_accepted
DA 2018-01-05
ER

PT J
AU Umashankara, M
   McFadden, K
   Zentner, I
   Schon, A
   Rajagopal, S
   Tuzer, F
   Kuriakose, SA
   Contarino, M
   LaLonde, J
   Freire, E
   Chaiken, I
AF Umashankara, Muddegowda
   McFadden, Karyn
   Zentner, Isaac
   Schoen, Arne
   Rajagopal, Srivats
   Tuzer, Ferit
   Kuriakose, Syna A.
   Contarino, Mark
   LaLonde, Judith
   Freire, Ernesto
   Chaiken, Irwin
TI The Active Core in a Triazole Peptide Dual-Site Antagonist of HIV-1
   gp120
SO CHEMMEDCHEM
LA English
DT Article
DE click chemistry; entry inhibitors; HIV-1; peptide triazoles; surface
   plasmon resonance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; ENTRY INHIBITOR;
   FUSION INHIBITORS; AIDS PATIENTS; HTLV-III; CD4; RECEPTOR; TYPE-1;
   BINDING
AB In an effort to identify broadly active inhibitors of HIV-1 entry into host cells, we previously reported a family of dodecamer triazole-peptide conjugates with nanomolar affinity for the viral surface protein gp120. This peptide class exhibits potent antiviral activity and the capacity to simultaneously inhibit interaction of the viral envelope protein with both CD4 and co-receptor. In this investigation, we minimized the structural complexity of the lead triazole inhibitor HNG-156 (peptide 1) to explore the limits of the pharmacophore that enables dual antagonism and to improve opportunities for peptidomimetic design. Truncations of both carboxy-and amino-terminal residues from the parent 12-residue peptide 1 were found to have minimal effects on both affinity and antiviral activity. In contrast, the central triazole(Pro)-Trp cluster at residues 6 and 7 with ferrocenyl-triazole(Pro) (Ftp) was found to be critical for bioactivity. Amino-terminal residues distal to the central triazole(Pro)-Trp sequence tolerated decreasing degrees of side chain variation upon approaching the central cluster. A peptide fragment containing residues 3-7 (Asn-Asn-Ile-Ftp-Trp) exhibited substantial direct binding affinity, antiviral potency, dual receptor site antagonism, and induction of gp120 structuring, all properties that define the functional signature of the parent compound 1. This active core contains a stereochemically specific hydrophobic triazole(Pro)-Trp cluster, with a short N-terminal peptide extension providing groups for potential main chain and side chain hydrogen bonding. The results of this work argue that the pharmacophore for dual antagonism is structurally limited, thereby enhancing the potential to develop minimized peptidomimetic HIV-1 entry inhibitors that simultaneously suppress binding of envelope protein to both of its host cell receptors. The results also argue that the target epitope on gp120 is relatively small, pointing to a localized allosteric inhibition site in the HIV-1 envelope that could be targeted for small-molecule inhibitor discovery.
C1 [Umashankara, Muddegowda; McFadden, Karyn; Zentner, Isaac; Rajagopal, Srivats; Tuzer, Ferit; Kuriakose, Syna A.; Contarino, Mark; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   [LaLonde, Judith] Bryn Mawr Coll, Dept Chem, Bryn Mawr, PA 19010 USA.
RP Umashankara, M (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
EM ichaiken@drexelmed.edu
FU National Institutes of Health [P01 GM 56550, R21 AI071965, GM 57144];
   International Partnership for Microbicides/USAID; National Science
   Foundation [MCB 0641252]
FX This research was supported by National Institutes of Health grants P01
   GM 56550 and R21 AI071965, as well as a grant from the International
   Partnership for Microbicides/USAID. E.F. also acknowledges support from
   the National Institutes of Health GM 57144 and the National Science
   Foundation MCB 0641252.
CR ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290                                                         
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Ferrer M, 1999, J VIROL, V73, P5795
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Gopi H, 2008, J MED CHEM, V51, P2638, DOI 10.1021/jm070814r
   Gopi H, 2009, J MOL RECOGNIT, V22, P169, DOI 10.1002/jmr.892
   Gopi HN, 2006, CHEMMEDCHEM, V1, P54, DOI 10.1002/cmdc.200500037
   Haim H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000360
   He YX, 2008, P NATL ACAD SCI USA, V105, P16332, DOI 10.1073/pnas.0807335105
   HELSETH E, 1991, J VIROL, V65, P2119
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244
   Leavitt SA, 2004, CURR PROTEIN PEPT SC, V5, P1
   Liu D, 2007, J VIROL, V81, P11489, DOI 10.1128/JVI.02845-06
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013
   Madani N, 2008, STRUCTURE, V16, P1689, DOI 10.1016/j.str.2008.09.005
   Neffe AT, 2004, ANGEW CHEM INT EDIT, V43, P2937, DOI 10.1002/anie.200353271
   Neffe A. T., 2004, ANGEW CHEM, V116, P2997
   Neffe AT, 2007, J MED CHEM, V50, P3482, DOI 10.1021/jm070206b
   Neffe AT, 2006, ORG BIOMOL CHEM, V4, P3259, DOI 10.1039/b605380g
   ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774                                                         
   SATTENTAU QJ, 1993, J VIROL, V67, P7383
   Schon A, 2006, BIOCHEMISTRY-US, V45, P10973, DOI 10.1021/bi061193r
   Shino T, 2006, BIOCHEMISTRY-US, V45, P1106, DOI 10.1021/bi0518038
   Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0
   *UNAIDS, 2009, AIDS EP UPD
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
NR 37
TC 22
Z9 22
U1 0
U2 9
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD NOV 8
PY 2010
VL 5
IS 11
SI SI
BP 1871
EP 1879
DI 10.1002/cmdc.201000222
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 684WI
UT WOS:000284585500010
PM 20677318
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dix, AV
   Fischer, L
   Sarrazin, S
   Redgate, CPH
   Esko, JD
   Tor, Y
AF Dix, Andrew V.
   Fischer, Lucile
   Sarrazin, Stephane
   Redgate, Christopher P. H.
   Esko, Jeffrey D.
   Tor, Yitzhak
TI Cooperative, Heparan Sulfate-Dependent Cellular Uptake of Dimeric
   Guanidinoglycosides
SO CHEMBIOCHEM
LA English
DT Article
DE cellular uptake; cooperative effects; heparan sulfate; molecular
   recognition; molecular transporters
ID ARGININE-RICH PEPTIDES; CONTAINING MOLECULAR TRANSPORTERS;
   INTERNALIZATION MECHANISMS; PROTEIN TRANSDUCTION; TAT PEPTIDE; HIV-1
   TAT; PENETRATING PEPTIDES; DELIVERY; CELLS; PROTEOGLYCANS
AB Oligoarginine and guanidinium-rich molecular transporters have been shown to facilitate the intracellular delivery of a diverse range of biologically relevant cargos. Several such transporters have been suggested to interact with cell-surface heparan sulfate proteoglycans as part of their cell-entry pathway. Unlike for other guanidinium-rich transporters, the cellular uptake of guanidinoglycosides at nanomolar concentrations is exclusively heparan sulfate dependent. As distinct cells differ in their expression levels and/or the composition of cell-surface heparan sulfate proteoglycans, one might be able to exploit such differences to selectively target certain cell types. To systematically investigate the nature of their cell-surface interactions, monomeric and dimeric guanidinoglycosides were synthesized by using neomycin, paromomycin, and tobramycin as scaffolds. These transporters differ in the number and 3D arrangement of their guanidinium groups. Their cellular uptake was measured by flow cytometry in wild-type and mutant Chinese hamster ovary cells after the corresponding fluorescent streptavidin-phycoerythrin-Cy5 conjugates had been generated. All derivatives showed negligible uptake in mutant cells lacking heparan sulfate. Decreasing the number of guanidinium groups diminished uptake, but the three dimensional arrangement of these groups was less important for cellular delivery. Whereas conjugates prepared with the monomeric carriers showed significantly reduced uptake in mutant cells expressing heparan sulfate chains with altered patterns of sulfation, conjugates prepared with the dimeric guanidinoglycosides could overcome this deficiency and maintain high levels of uptake in such deficient cells. This finding suggests that cellular uptake depends on the valency of the transporter and both the content and arrangement of the sulfate groups on the cell-surface receptors. Competition studies with chemically desulfated or carboxy-reduced heparin derivatives corroborated these observations. Taken together, these findings show that increasing the valency of the transporters retains heparan sulfate specificity and provides reagents that could distinguish different cell types based on the specific composition of their cell-surface heparan sulfate proteoglycans.
C1 [Dix, Andrew V.; Fischer, Lucile; Redgate, Christopher P. H.; Esko, Jeffrey D.; Tor, Yitzhak] Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA.
   [Dix, Andrew V.; Fischer, Lucile; Redgate, Christopher P. H.; Tor, Yitzhak] Univ Calif San Diego, Dept Biochem, La Jolla, CA 92093 USA.
RP Esko, JD (reprint author), Univ Calif San Diego, Dept Chem, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM jesko@ucsd.edu; ytor@ucsd.edu
FU National Institutes of Health [GM 077471]; National Science Foundation
   [CHE-0741968]; Fulbright Program
FX We thank the National Institutes of Health for their generous support
   (GM 077471), the National Science Foundation (instrumentation grant
   CHE-0741968), the Fulbright Program for a fellowship (L.F.), the
   Foundation pour la Recherche Medicale (S.S), and Yun Xie for her
   assistance with preparation of the manuscript.
CR Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172
   Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711                                                        
   Baker TJ, 2000, J ORG CHEM, V65, P9054, DOI 10.1021/jo001142e
   BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081                                                               
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Blount KF, 2006, CHEMBIOCHEM, V7, P1612, DOI 10.1002/cbic.200600109
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597
   Chung SK, 2008, INT J PHARM, V354, P16, DOI 10.1016/j.ijpharm.2007.08.016
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Cooley CB, 2009, J AM CHEM SOC, V131, P16401, DOI 10.1021/ja907363k
   Dietz GPH, 2010, CURR PHARM BIOTECHNO, V11, P167, DOI 10.2174/138920110790909731                                                      
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Elson-Schwab L, 2007, J BIOL CHEM, V282, P13585, DOI 10.1074/jbc.M700463200
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Hassane FS, 2009, BIOCONJUGATE CHEM, V20, P1523, DOI 10.1021/bc900075p
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Lambert S, 2009, BLOOD, V113, P5176, DOI 10.1182/blood-2008-04-150342
   Lawrence R, 2008, J BIOL CHEM, V283, P33674, DOI 10.1074/jbc.M804288200
   Lentacker I, 2010, MOL THER, V18, P101, DOI 10.1038/mt.2009.160
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267                                                          
   Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135
   Luedtke NW, 2000, J AM CHEM SOC, V122, P12035, DOI 10.1021/ja002421m
   Maiti KK, 2007, ANGEW CHEM INT EDIT, V46, P5880, DOI 10.1002/anie.200701346
   Maiti KK, 2007, CHEM-EUR J, V13, P762, DOI 10.1002/chem.200600898
   Maiti K.K., 2007, ANGEW CHEM, V119, P5984
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   MIAO HQ, 1995, J CELL BIOCHEM, V57, P173, DOI 10.1002/jcb.240570202
   Michael K, 1999, BIOORGAN MED CHEM, V7, P1361, DOI 10.1016/S0968-0896(99)00071-1                                                   
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Potocky TB, 2007, CHEMBIOCHEM, V8, P917, DOI 10.1002/cbic.200600563
   Prochiantz A, 2005, ADV DRUG DELIVER REV, V57, P491, DOI 10.1016/j.addr.2004.11.002                                                      
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Sakai N, 2005, CHEMBIOCHEM, V6, P114, DOI 10.1002/cbic.200400256
   Sarrazin S, 2010, MOL THER, V18, P1268, DOI 10.1038/mt.2010.78
   Sorensen HP, 2008, J BIOL CHEM, V283, P31920, DOI 10.1074/jbc.M804113200
   Steinmetz NF, 2010, NANO LETT, V10, P305, DOI 10.1021/nl9035753
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Ugarkar BG, 2003, J MED CHEM, V46, P4750, DOI 10.1021/jm030230z
   Varki A., 2009, ESSENTIALS GLYCOBIOL
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Wang NX, 2007, SYNTHESIS-STUTTGART, P1154, DOI 10.1055/s-2007-965993
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Wu W., 2009, ANGEW CHEM, V121, P9657
   Wu W, 2009, ANGEW CHEM INT EDIT, V48, P9493, DOI 10.1002/anie.200902426
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 57
TC 22
Z9 22
U1 1
U2 26
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1439-4227
J9 CHEMBIOCHEM
JI ChemBioChem
PD NOV 2
PY 2010
VL 11
IS 16
BP 2302
EP 2310
DI 10.1002/cbic.201000399
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 678DF
UT WOS:000284050800013
PM 20931643
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kanzer, J
   Hupfeld, S
   Vasskog, T
   Tho, I
   Holig, P
   Magerlein, M
   Fricker, G
   Brandl, M
AF Kanzer, Johanna
   Hupfeld, Stefan
   Vasskog, Terje
   Tho, Ingunn
   Hoelig, Peter
   Maegerlein, Markus
   Fricker, Gert
   Brandl, Martin
TI In situ formation of nanoparticles upon dispersion of melt extrudate
   formulations in aqueous medium assessed by asymmetrical flow field-flow
   fractionation
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Solid dispersion; Melt extrudate; Asymmetrical flow field-flow
   fractionation; Nanoparticle; Particle size
ID IMMUNODEFICIENCY-VIRUS PROTEASE; SOLID DISPERSIONS; IONIC-STRENGTH;
   DRUG-RELEASE; SOLUBILITY; EXTRUSION; LIPOSOMES; MECHANISM
AB In recent years melt extrudates (e.g Meltrex (R)) have proven to be a promising formulation tool for poorly water-soluble and poorly bioavailable drugs. During the hot-melt extrusion process solid dispersions are formed For several of these formulations improved bioavailabilities have been reported. the mechanism behind, however is still not very well understood The aim of this study was to investigate whether solid dispersions prepared by melt extrusion upon dispersion in aqueous medium form particles and/or supramolecular assemblies The formulation investigated here contained the human immunodeficiency virus (HIV) protease inhibitors lopinavir and ritonavir, polyvinylpyrrolidone-vinyl acetate copolymer (Kollidon (R) VA64), sorbitan monolaurate (Span (R) 20) and hydrophilic fumed silica (Aerosil (R) 200) The aqueous dispersions originating from both, API-containing and placebo formulation were investigated using photon correlation spectroscopy (PCS) and asymmetrical flow field-flow fractionation (AsFIFFF) with subsequent online multi-angle light-scattering (MALS) particle size analysis The content of both APIs in the AsFIFFF-fractions was quantified using high performance liquid chromatography-mass spectrometry
   PCS indicated sub-micron particles. AsFIFFF revealed the co-existence of up to three different types of colloidal to nanoparticulate assemblies in the aqueous dispersions Even though a complete resolution of the composition of the sub-fractions could not be achieved, the following types could be clearly distinguished The first fraction eluting from AsFIFFF, appears to be colloidal polymer Only marginal amounts of the APIs were found associated with the polymer Secondly. API-rich nanoparticles eluted Thirdly, nanoparticulate assemblies assigned to sorbitan monolaurate and/or hydrophilic fumed silica were identified A limited amount of drug was found associated with this fraction Using AsFIFFF-MALS the size of particles in fractions could be determined.
   From this experience AsFIFFF is regarded as promising technique for investigation of particles/structures originating during dispersion of melt extrudates in aqueous medium in terms of size and type of nanoparticles and their API-content. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Brandl, Martin] Univ So Denmark, Dept Chem & Phys, DK-5230 Odense M, Denmark.
   [Kanzer, Johanna; Hupfeld, Stefan; Tho, Ingunn; Brandl, Martin] Univ Tromso, Dept Pharm, Drug Transport & Delivery Grp, N-9037 Tromso, Norway.
   [Kanzer, Johanna; Fricker, Gert] Univ Heidelberg, Inst Pharm & Mol Biotechnol, Dept Pharmaceut Technol & Biopharm, D-69120 Heidelberg, Germany.
   [Vasskog, Terje] Univ Tromso, Inst Pharnacy, Res Grp Nat Prod & Med Chem, N-9037 Tromso, Norway.
   [Hoelig, Peter; Maegerlein, Markus] Abbott GmbH & Co KG, SOLIQS, D-67061 Ludwigshafen, Germany.
RP Brandl, M (reprint author), Univ So Denmark, Dept Chem & Phys, Campusvej 55, DK-5230 Odense M, Denmark.
RI Tho, Ingunn/A-9755-2015
OI Tho, Ingunn/0000-0003-4241-4183; Brandl, Martin/0000-0003-3561-5016
FU SOLIQS, Abbott GmbH and Co. KG, Ludwigshafen, Germany
FX This study was supported by SOLIQS, Abbott GmbH and Co. KG,
   Ludwigshafen, Germany. We would like to thank Dr. Ulrich Westedt, Dr
   Bernd Liepold and Dr. Joerg Rosenberg for their contribution to
   discussions.
CR Albers J, 2009, EUR J PHARM BIOPHARM, V71, P387, DOI 10.1016/j.ejpb.2008.10.002
   Andersson M, 2003, ANAL CHEM, V75, P4279, DOI 10.1021/ac030128+
   BARTHEL H, 1995, COLLOID SURFACE A, V101, P217, DOI 10.1016/0927-7757(95)03179-H                                                    
   Breitenbach J, 2002, EUR J PHARM BIOPHARM, V54, P107, DOI 10.1016/S0939-6411(02)00061-9
   BUHLER V, 2005, POLYVINYLPYRROLIDONE, P179
   CHIOU WL, 1971, J PHARM SCI-US, V60, P1281, DOI 10.1002/jps.2600600902                                                          
   Craig DQM, 2002, INT J PHARM, V231, P131, DOI 10.1016/S0378-5173(01)00891-2
   Fraunhofer W, 2004, EUR J PHARM BIOPHARM, V58, P369, DOI 10.1016/j.ejpb.2004.03.034
   GIDDINGS JC, 1993, SCIENCE, V260, P1456, DOI 10.1126/science.8502990                                                         
   Hupfeld S, 2010, CHEM PHYS LIPIDS, V163, P141, DOI 10.1016/j.chemphyslip.2009.10.009
   Hupfeld S, 2009, J SEP SCI, V32, P1465, DOI 10.1002/jssc.200800626
   Karavas E, 2007, EUR J PHARM BIOPHARM, V66, P334, DOI 10.1016/j.ejpb.2006.11.020
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654
   Klein CE, 2007, JAIDS-J ACQ IMM DEF, V44, P401, DOI 10.1097/QAI.0b013e31803133c5
   Law D, 2004, J PHARM SCI-US, V93, P563, DOI 10.1002/jps.10566
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Lin SYD, 2005, J AGR FOOD CHEM, V53, P5018, DOI 10.1021/jf0481305
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   LITZEN A, 1991, J CHROMATOGR, V548, P393, DOI 10.1016/S0021-9673(01)88622-2                                                   
   Miller DA, 2008, ADV DRUG FORMULATION, P451
   Moon MH, 1998, J CHROMATOGR A, V813, P91, DOI 10.1016/S0021-9673(98)00325-2
   Owen S.C., 2006, HDB PHARM EXIPIENTS, P188
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   THO I, 2010, EUR J PHARM SCI, DOI DOI 10.1016/4.E4PS.2010.02.003
NR 24
TC 27
Z9 28
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD NOV 2
PY 2010
VL 53
IS 3
BP 359
EP 365
DI 10.1016/j.jpba.2010.04.012
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 632PD
UT WOS:000280435800019
PM 20447794
DA 2018-01-05
ER

PT J
AU Mercorelli, B
   Oreste, P
   Sinigalia, E
   Muratore, G
   Lembo, D
   Palu, G
   Loregian, A
AF Mercorelli, Beatrice
   Oreste, Pasqua
   Sinigalia, Elisa
   Muratore, Giulia
   Lembo, David
   Palu, Giorgio
   Loregian, Arianna
TI Sulfated Derivatives of Escherichia coli K5 Capsular Polysaccharide Are
   Potent Inhibitors of Human Cytomegalovirus
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID GLYCOPROTEIN-B; IN-VITRO; INFECTION; HEPARIN; ANTAGONIST; POLYMERASE;
   RESISTANCE; BINDING; HIV
AB To date, there are few drugs licensed for the treatment of human cytomegalovirus (HCMV) infections, most of which target the viral DNA polymerase and suffer from many drawbacks. Thus, there is still a strong need for new anti-HCMV compounds with novel mechanisms of action. In this study, we investigated the anti-HCMV activity of chemically sulfated derivatives of Escherichia coli K5 capsular polysaccharide. These compounds are structurally related to cellular heparan sulfate and have been previously shown to be effective against some enveloped and nonenveloped viruses. We demonstrated that two derivatives, i.e., K5-N, OS(H) and K5-N, OS(L), are able to prevent cell infection by different strains of HCMV at concentrations in the nanomolar range while having no significant cytotoxicity. Studies performed to elucidate the mechanism of action of their anti-HCMV activity revealed that these compounds do not interact with either the host cell or the viral particle but need a virus-cell interaction to exert antiviral effects. Furthermore, these K5 derivatives were able to inhibit the attachment step of HCMV infection, as well as the viral cell-to-cell spread. Since the mode of inhibition of these compounds appears to differ from that of the available anti-HCMV drugs, sulfated K5 derivatives could represent the basis for the development of a novel class of potent anti-HCMV compounds. Interestingly, our studies highlight that small variations of the K5 derivatives structure can modulate the selectivity and potency of their activities against different viruses, including viruses belonging to the same family.
C1 [Mercorelli, Beatrice; Sinigalia, Elisa; Muratore, Giulia; Palu, Giorgio; Loregian, Arianna] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy.
   [Oreste, Pasqua] Glycores 2000 Srl, Milan, Italy.
   [Lembo, David] Univ Turin, Dept Clin & Biol Sci, Turin, Italy.
RP Loregian, A (reprint author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via Gabelli 63, I-35121 Padua, Italy.
EM arianna.loregian@unipd.it
FU MURST [CPDA074945, 20085FF4J4]; Regione Piemonte (Ricerca Finalizzata);
   Regione Veneto
FX This study was supported by MURST EX60%, Progetto di Ricerca di Ateneo
   2007 (grant CPDA074945), and PRIN 2008 (grant 20085FF4J4) to A.L; by
   Regione Veneto to G.P.; and by Regione Piemonte (Ricerca Finalizzata
   2008-bis) to D.L.
CR Britt W, 2008, CURR TOP MICROBIOL, V325, P417
   CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3
   CASU B, 1975, CARBOHYD RES, V39, P168, DOI 10.1016/S0008-6215(00)82654-3
   CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637
   Compton T, 2004, TRENDS CELL BIOL, V14, P5, DOI 10.1016/j.tcb.2003.10.009
   Ghosh T, 2009, GLYCOBIOLOGY, V19, P2, DOI 10.1093/glycob/cwn092
   Gordon M, 1997, J MED, V28, P108
   Harden EA, 2009, ANTIVIR RES, V83, P282, DOI 10.1016/j.antiviral.2009.06.007
   HARENBERG J, 1983, J CHROMATOGR, V261, P287, DOI 10.1016/S0021-9673(01)87952-8
   Hayashi K, 2008, J PHARMACOL SCI, V106, P369, DOI 10.1254/jphs.FP0071679
   Jones TR, 2004, J VIROL, V78, P1289, DOI 10.1128/JVI.78.3.1289-1300.2004
   KARI B, 1992, J VIROL, V66, P1761
   Kern E. R, 1999, HDB ANIMAL MODELS IN, P927
   Klibanov OM, 2009, CURR OPIN INVEST DR, V10, P845
   Kuritzkes DR, 2009, CURR OPIN HIV AIDS, V4, P82, DOI 10.1097/COH.0b013e328322402e
   Leali D, 2001, J BIOL CHEM, V276, P37900
   Lembo D, 2008, ANTIMICROB AGENTS CH, V52, P1374, DOI 10.1128/AAC.01467-07
   Lischka P, 2008, CURR OPIN PHARMACOL, V8, P541, DOI 10.1016/j.coph.2008.07.002
   Loregian A, 2006, CHEM BIOL, V13, P191, DOI 10.1016/j.chembiol.2005.12.002
   LOREGIAN A, ANTIMICROB AGENTS CH, V54, P1930
   LUGANINI A, ANTIVIR RES, V85, P532
   Mocarski ES, 2007, FIELDS VIROLOGY, P2701
   Pinna D, 2008, ANTIMICROB AGENTS CH, V52, P3078, DOI 10.1128/AAC.00359-08
   Rusnati M, 2005, CURR PHARM DESIGN, V11, P2489, DOI 10.2174/1381612054367553
   Rusnati M, 2009, PHARMACOL THERAPEUT, V123, P310, DOI 10.1016/j.pharmthera.2009.05.001
   Schmidtke M, 2003, VIROLOGY, V311, P134, DOI 10.1016/S0042-6822(03)00166-1
   Shogan B, 2006, J VIROL, V80, P4740, DOI 10.1128/JVI.80.10.4740-4747.2006
   Stinski MF, 2008, CURR TOP MICROBIOL, V325, P133
   SULLIVAN V, 1993, ANTIMICROB AGENTS CH, V37, P19, DOI 10.1128/AAC.37.1.19                                                             
   SULLIVAN V, 1992, NATURE, V359, P85, DOI 10.1038/359085a0                                                                
   SULLIVAN V, 1991, J INFECT DIS, V164, P781, DOI 10.1093/infdis/164.4.781                                                        
   Vicenzi E, 2003, AIDS, V17, P177, DOI 10.1097/01.aids.0000042949.95433.74
NR 32
TC 11
Z9 11
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2010
VL 54
IS 11
BP 4561
EP 4567
DI 10.1128/AAC.00721-10
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 679IL
UT WOS:000284155000007
PM 20713657
OA gold
DA 2018-01-05
ER

PT J
AU Pion, M
   Serramia, MJ
   Diaz, L
   Bryszewska, M
   Gallart, T
   Garcia, F
   Gomez, R
   de la Mata, FJ
   Munoz-Fernandez, MA
AF Pion, Marjorie
   Serramia, Maria J.
   Diaz, Laura
   Bryszewska, Maria
   Gallart, Teresa
   Garcia, Felipe
   Gomez, Rafael
   de la Mata, Francisco J.
   Munoz-Fernandez, Maria A.
TI Phenotype and functional analysis of human monocytes-derived dendritic
   cells loaded with a carbosilane dendrimer
SO BIOMATERIALS
LA English
DT Article
DE Dendritic cells; Carbosilane dendrimer 2 G-NN16; Immunomodulation;
   Nanoparticle; Peptide
ID MELANOMA PATIENTS; HIV-1 INFECTION; IMMUNOTHERAPY; VACCINE; CANCER;
   MATURATION; TOLERANCE; MIGRATION; RESPONSES
AB Dendritic cells (DCs) play a major role in development of cell-mediated immunotherapy due to their unique role in linking innate and adaptive immunities. In spite of improvement in this area, strategies employing ex vivo generated DCs have shown limited efficacy in clinical trials. Dendrimers have been proposed as new carriers for drug delivery in aim to ameliorate DCs antigen loading that is a pivotal point in DCs approaches. In this study, we have investigated the phenotypic and functional characteristics of human monocytes-derived dendritic cells after HIV-derived peptides uptake in vitro. We have found that iDCs and mDCs were able to capture efficiently water soluble carbosilane (CBS) dendrimer 2 G-NN16 and did not induce changes in maturation markers levels at the DCs surface. Therefore, CBS 2 G-NN16-loaded mDCs migrated as efficiently as unloaded DCs towards CCL19 or CCL21. Furthermore, DCs viability, activation of allogenic naive CD4 + T cells by mDCs and secretion of cytokines were not significantly changed by 2 G-NN16 loading. Summing up, our data indicate that CBS 2 G-NN16 has no negative effects on the pivotal properties of DCs in vitro. It should therefore be feasible to further develop this antigen loading strategy for clinical use in immunotherapy against viral infections. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Pion, Marjorie; Serramia, Maria J.; Diaz, Laura; Munoz-Fernandez, Maria A.] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Bryszewska, Maria] Univ Lodz, Katedra Biofiz Ogolnej, PL-90237 Lodz, Poland.
   [Gallart, Teresa; Garcia, Felipe] Hosp Clin Barcelona, Serv Inmunol, E-08036 Barcelona, Spain.
   [Gomez, Rafael; de la Mata, Francisco J.] Univ Alcala De Henares, Dept Quim Inorgan, Alcala De Henares 28801, Spain.
   [Pion, Marjorie; Serramia, Maria J.; Diaz, Laura; Gomez, Rafael; de la Mata, Francisco J.; Munoz-Fernandez, Maria A.] Inst Salud Carlos III, CIBER BBN, Madrid 28029, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@salud.madrid.org
RI De la Mata, F. Javier/K-1649-2014; Pion, Marjorie/D-8139-2012; Gomez
   Ramirez, Rafael/K-1216-2014; Garcia, Felipe/F-4242-2014
OI De la Mata, F. Javier/0000-0003-0418-3935; Pion,
   Marjorie/0000-0002-6406-747X; Gomez Ramirez, Rafael/0000-0001-6448-2414;
   Garcia, Felipe/0000-0001-7658-5832; Munoz-Fernandez/0000-0002-0813-4500;
   Bryszewska, Maria/0000-0003-4676-3743; Pion,
   Marjorie/0000-0003-1828-4745
FU Fundacion para la Investigacion y Prevencion del SIDA en Espana, FIPSE
   [240800/09]; Red Tematica de Investigacion Cooperativa Sanitaria ISCIII
   (RETIC) [RD06/0006/0035]; MNT-ERA NET [NAN2007-31198-E,
   NAN2007-31135-E]; EuroNanoMed [PS09102669]; Fondos de Investigacion
   Sanitaria (FIS) [PI09/02029, PI08222]; Fundacion Caja Navarra, Comunidad
   Autonoma de Madrid [S-SAL-0159-2006]; COST Action [TD0802]; Fondo de
   Investigacion Sanitaria [PS09/01297]
FX We acknowledge the Spanish HIV BioBank for the generous gifts of human
   peripheral blood mononuclear cells (PBMCs). This work was supported by
   grants from Fundacion para la Investigacion y Prevencion del SIDA en
   Espana, FIPSE (240800/09), Red Tematica de Investigacion Cooperativa
   Sanitaria ISCIII (RETIC RD06/0006/0035), MNT-ERA NET 2007
   (NAN2007-31198-E), EuroNanoMed 2009 (DENPEPTHIV, PS09102669), Fondos de
   Investigacion Sanitaria (FIS PI09/02029), Fundacion Caja Navarra,
   Comunidad Autonoma de Madrid (S-SAL-0159-2006) and COST Action (TD0802)
   to MAMF. Authors from the Universidad de Alcala were supported by
   MNT-ERA NET 2007 (NAN2007-31135-E), EuroNanoMed 2009 (DEN-PEPTHIV,
   PS09102669), and Fondos de Investigacion Sanitaria (PI08222) Authors
   from the RIS HIV-Vaccine group were supported by Fondo de Investigacion
   Sanitaria (PS09/01297).
CR Baker James R Jr, 2009, Hematology Am Soc Hematol Educ Program, P708, DOI 10.1182/asheducation-2009.1.708
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Buelens C, 1997, EUR J IMMUNOL, V27, P756, DOI 10.1002/eji.1830270326                                                          
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Connolly NC, 2007, CURR OPIN MOL THER, V9, P353
   Cools N, 2007, J LEUKOCYTE BIOL, V82, P1365, DOI 10.1189/jlb.0307166
   de Vries IJM, 2003, CANCER RES, V63, P12
   de Vries IJM, 2003, CLIN CANCER RES, V9, P5091
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9
   Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52
   Jonuleit H, 2001, INT J CANCER, V93, P243, DOI 10.1002/ijc.1323                                                                
   Kalinski P, 2009, FUTURE ONCOL, V5, P379, DOI [10.2217/fon.09.6, 10.2217/FON.09.6]
   Kameyama S, 2007, BIOPOLYMERS, V88, P98, DOI 10.1002/bip.20689
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001                                                          
   Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403
   Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2002-11-0017
   Scherer E, 2008, CLIN EXP IMMUNOL, V154, P6, DOI 10.1111/j.1365-2249.2008.03750.x
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698                                                          
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Waeckerle-Men Y, 2004, J IMMUNOL METHODS, V287, P109, DOI 10.1016/j.jim.2004.01.010
   Wang JQ, 2010, CURR DRUG METAB, V11, P129, DOI 10.2174/138920010791110827                                                      
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
NR 32
TC 32
Z9 32
U1 2
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2010
VL 31
IS 33
BP 8749
EP 8758
DI 10.1016/j.biomaterials.2010.07.093
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 676LK
UT WOS:000283912700027
PM 20832111
DA 2018-01-05
ER

PT J
AU Wang, SQ
   Xu, F
   Demirci, U
AF Wang, ShuQi
   Xu, Feng
   Demirci, Utkan
TI Advances in developing HIV-1 viral load assays for resource-limited
   settings
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review
DE HIV-1; Viral load; Resource-limited settings; Point-of-care
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE ACTIVITY;
   ANTIRETROVIRAL TREATMENT FAILURE; SEQUENCE-BASED AMPLIFICATION;
   NUCLEIC-ACID AMPLIFICATION; POLYMERASE-CHAIN-REACTION; DISSOCIATED P24
   ANTIGEN; SIGNAL-AMPLIFICATION; RNA 3.0; MULTICENTER EVALUATION
AB Commercial HIV-1 RNA viral load assays have been routinely used in developed countries to monitor antiretroviral treatment (ART). However, these assays require expensive equipment and reagents, well-trained operators, and established laboratory infrastructure. These requirements restrict their use in resource-limited settings where people are most afflicted with the HIV-1 epidemic. Inexpensive alternatives such as the Ultrasensitive p24 assay, the reverse transcriptase (RT) assay and in-house reverse transcription quantitative polymerase chain reaction (RT-qPCR) have been developed. However, they are still time-consuming, technologically complex and inappropriate for decentralized laboratories as point-of-care (POC) tests. Recent advances in microfluidics and nanotechnology offer new strategies to develop low-cost, rapid, robust and simple HIV-1 viral load monitoring systems. We review state-of-the-art technologies used for HIV-1 viral load monitoring in both developed and developing settings. Emerging approaches based on microfluidics and nanotechnology, which have potential to be integrated into POC HIV-1 viral load assays, are also discussed. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Demirci, Utkan] Harvard MIT Hlth Sci & Technol, Demirci Bioacoust MEMS Med BAMM Lab, Cambridge, MA 02139 USA.
   [Wang, ShuQi; Xu, Feng; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Dept Med,Ctr Biomed Engn, Demirci Bioacoust MEMS Med BAMM Lab,Med Sch, Boston, MA 02115 USA.
RP Demirci, U (reprint author), Harvard MIT Hlth Sci & Technol, Demirci Bioacoust MEMS Med BAMM Lab, 65 Landsdowne St, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu
RI Wang, Shuqi/F-2861-2011; Xu, Feng/C-7430-2011; Xu, Feng/H-4468-2011
OI Xu, Feng/0000-0003-4351-0222
FU NIH [R01AI081534, R21AI087107]; Center for Integration of Medicine and
   Innovative Technology (CIMIT)
FX We acknowledge support from the MIT Deshpande Center, W.H. Coulter
   Foundation Young Investigator Award. We also acknowledge support from
   NIH (R01AI081534) and NIH (R21AI087107). This work was supported by the
   Center for Integration of Medicine and Innovative Technology (CIMIT)
   under U.S. Army Medical Research Acquisition Activity Cooperative
   Agreement.
CR *ABB, 2007, ABB REALTIME HIV 1 P
   Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Bhattacharyya A, 2007, BIOMED MICRODEVICES, V9, P245, DOI 10.1007/s10544-006-9026-2
   Bonard D, 2003, JAIDS-J ACQ IMM DEF, V34, P267, DOI 10.1097/00126334-200311010-00002
   Boni J, 1997, AIDS, V11, pF47, DOI 10.1097/00002030-199706000-00001
   Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073
   Cassol S, 1997, J CLIN MICROBIOL, V35, P2795
   Chang Denison, 2006, Expert Rev Anti Infect Ther, V4, P565, DOI 10.1586/14787210.4.4.565
   CHANTRY CJ, 1995, PEDIATR INFECT DIS J, V14, P382, DOI 10.1097/00006454-199505000-00009
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2009, LAB CHIP, V9, P1357, DOI 10.1039/b818813k
   Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979
   COMPTON J, 1991, NATURE, V350, P91, DOI 10.1038/350091a0
   de Mendoza C, 2005, J VIROL METHODS, V127, P54, DOI 10.1016/j.jviromet.2005.03.013
   de Mendoza C, 2009, FUTURE VIROL, V4, P423, DOI 10.2217/FVL.09.24
   Deiman B, 2002, MOL BIOTECHNOL, V20, P163, DOI 10.1385/MB:20:2:163
   Drosten C, 2006, CLIN CHEM, V52, P1258, DOI 10.1373/clinchem.2006.066498
   Easley CJ, 2006, P NATL ACAD SCI USA, V103, P19272, DOI 10.1073/pnas.0604663103
   Elbeik T, 2002, J ACQ IMMUN DEF SYND, V29, P330
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Fiscus SA, 2007, J CLIN MICROBIOL, V45, P2274, DOI 10.1128/JCM.00813-07
   Galli R, 2005, J CLIN VIROL, V34, P245, DOI 10.1016/j.jcv.2004.12.012
   Ginocchio CC, 2003, J CLIN MICROBIOL, V41, P164, DOI 10.1128/JCM.41.1.164-173.2003
   Gleaves CA, 2002, J CLIN VIROL, V25, P205, DOI 10.1016/S1386-6532(02)00011-2
   Gonzalez A, 2007, BIOMED MICRODEVICES, V9, P261, DOI 10.1007/s10544-006-9030-6
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Harries AD, 2010, LANCET INFECT DIS, V10, P60, DOI 10.1016/S1473-3099(09)70321-4
   Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005
   Johannessen A, 2009, CLIN INFECT DIS, V49, P976, DOI 10.1086/605502
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kolari K, 2008, SENSOR ACTUAT B-CHEM, V128, P442, DOI 10.1016/j.snb.2007.06.034
   Kuritzkes DR, 2007, J INFECT DIS, V195, P1169, DOI 10.1086/512619
   Labbett W, 2009, J CLIN MICROBIOL, V47, P3266, DOI 10.1128/JCM.00715-09
   Lee BS, 2009, LAB CHIP, V9, P1548, DOI 10.1039/b820321k
   Lee HH, 2010, J INFECT DIS, V201, pS65, DOI 10.1086/650385
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Lee SH, 2008, LAB CHIP, V8, P2121, DOI 10.1039/b811131f
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   LIEGLER TJ, 2009, NUCL ACID BASED HIV
   Liu WT, 2005, LAB CHIP, V5, P1327, DOI 10.1039/b509086e
   Lombart JP, 2005, AIDS, V19, P1273, DOI 10.1097/01.aids.0000180098.58017.48
   Malmsten A, 2003, J MED VIROL, V71, P347, DOI 10.1002/jmv.10492
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Martinez AW, 2008, LAB CHIP, V8, P2146, DOI 10.1039/b811135a
   Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   Michael NL, 1999, J CLIN MICROBIOL, V37, P2557
   Mine M, 2009, J VIROL METHODS, V159, P93, DOI 10.1016/j.jviromet.2009.03.008
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Murphy DG, 2000, J CLIN MICROBIOL, V38, P4034
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703                                                     
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Pascual A, 2002, J CLIN MICROBIOL, V40, P2472, DOI 10.1128/JCM.40.7.2472-2475.2002
   Prado JG, 2004, J CLIN MICROBIOL, V42, P1620, DOI 10.1128/JCM.42.4.1620-1625.2004
   *ROCH, 2007, COBAS AMPLIPREP COBA
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Rouet F, 2001, AIDS, V15, P1849, DOI 10.1097/00002030-200109280-00015
   Rouet F, 2008, EXPERT REV MOL DIAGN, V8, P635, DOI 10.1586/14737159.8.5.635
   Rouet F, 2007, EXPERT REV MOL DIAGN, V7, P703, DOI 10.1586/14737159.7.6.703
   Rouet F, 2007, JAIDS-J ACQ IMM DEF, V45, P380, DOI 10.1097/QAI.0b013e3180640cf5
   Ruelle J, 2009, J CLIN VIROL, V44, P297, DOI 10.1016/j.jcv.2009.01.004
   Schumacher W, 2007, J CLIN VIROL, V38, P304, DOI 10.1016/j.jcv.2006.12.022
   Schupbach J, 1996, AIDS, V10, P1085
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005
   Swanson P, 2007, J VIROL METHODS, V141, P49, DOI 10.1016/j.jviromet.2006.11.026
   TANG N, 2007, J VIROL METH
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tang W, 2010, J INFECT DIS, V201, pS46, DOI 10.1086/650388
   TANRIVERDI C, 2010, J INFECT DIS S1, V201, pS52
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737
   UNAIDS, 2008, REP GLOB AIDS EP
   Usdin M, 2010, J INFECT DIS, V201, pS73, DOI 10.1086/650384
   van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x
   Vekemans M, 2007, AIDS, V21, P1205, DOI 10.1097/QAD.0b013e3281c617e8
   WANG S, 2010, P SPIE INT SOC OPT E
   World Health Organization, 2009, SCAL PRIOR HIV AIDS
   WHO, 2006, UN ACC 2010
   WHO, 2006, ANT THER HIV INF AD
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yao J, 2005, J VIROL METHODS, V129, P40, DOI 10.1016/j.jviromet.2005.04.017
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Zhang CS, 2007, NUCLEIC ACIDS RES, V35, P4223, DOI 10.1093/nar/gkm389
   Zhao WA, 2008, LAB CHIP, V8, P1988, DOI 10.1039/b814043j
NR 91
TC 96
Z9 100
U1 0
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD NOV-DEC
PY 2010
VL 28
IS 6
BP 770
EP 781
DI 10.1016/j.biotechadv.2010.06.004
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 671RH
UT WOS:000283526500012
PM 20600784
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gan, N
   Luo, NX
   Li, TH
   Zheng, L
   Ni, MJ
AF Gan Ning
   Luo Nai-Xin
   Li Tian-Hua
   Zheng Lei
   Ni Min-Jun
TI A Non-enzyme Amperometric Immunosensor for Rapid Determination of Human
   Immunodeficiency Virus p24 Based on Magnetism Controlled Carbon
   Nanotubes Modified Printed Electrode
SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
LA Chinese
DT Article
DE N,N '-Bis (2-hydroxy-methylene)-o-phenylenediamine copper; Screen
   printed carbon electrode; Gold magnetic particles/carbon nanotube
   composite particles; Human immunocleficency virus capsid protein 24;
   Magnetic non-enzyme immunosensor
ID ELECTROCHEMICAL IMMUNOSENSOR; CARCINOEMBRYONIC ANTIGEN; NANOPARTICLES;
   PEROXIDASE
AB A magnetism controlled and non-enzyme amperometric immunosensor was fabricated for the determination of human immunodeficiency virus p24 (HIV p24). First, Fe(3)O(4)/Au composite nanoparticles (GMP) were modified on multiwalled carbon nanotubes (MWNTs-GMP). Then, antibody of p24(anti p24) was coated on it to prepare MWNTs-GMP/anti p24 biomarker. Finally, the marker was absorbed on the surface of N,N'-Bis (2-hydroxy-methylene)-o-phenylenediamine copper (CuRb) modified screen-printed carbon electrodes (SPCEs) through external magnetic field in which CuRb can be employed as an electron transfer mediator and catalyst for detection of H(2)O(2). After the immunosensor is incubated with p24 sample at room temperature for 15 min, the electron transfer access of CuRb to H(2)O(2) is partly inhibited, which leads to a linear decrease of the catalytic efficiency to H(2)O(2) at 300 mV in pH 7.0 PBS. Under optimal conditions, the linear range of p24 is from 0.6 to 160 mu g/L and the detection limit is 0.32 mu g/L at 3 times noise. The immunosensor was employed to determine p24 in acquired immure deficiency syndrome (AIDs) patients' serum samples and the results were consistent to the tradition ELISA method which was suitable for screen determination of trace p24 in serums of AIDs' patients.
C1 [Gan Ning; Luo Nai-Xin; Li Tian-Hua] Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Zheng Lei] Nanfang Med Hosp, Guangzhou 410003, Guangdong, Peoples R China.
   [Ni Min-Jun] Ningbo Entry Exit Inspect & Quarantine Bur, Ctr Tech, Ningbo 315200, Zhejiang, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn
CR China State Bureau of Technical Supervision, 2004, NAT AIDS TEST SPEC, P1
   DEBRA RR, 1990, CHEM REV, V90, P867
   Gan N, 2008, CHINESE J ANAL CHEM, V36, P1167, DOI 10.1016/S1872-2040(08)60064-X                                                   
   Gao HL, 2008, CHINESE J ANAL CHEM, V36, P1614, DOI 10.1016/S1872-2040(09)60008-6                                                   
   HE XL, 2008, BIOCH BIOPHYS METHOD, P823
   Kagan K., 2007, CHEM COMMUN, V43, P3829
   Li SX, 2004, ACTA CHIM SINICA, V62, P567
   Min LG, 2008, ACTA CHIM SINICA, V66, P1676
   Perez-Filgueira DM, 2004, J VIROL METHODS, V121, P201, DOI 10.1016/j.viromet.2004.06.022
   Priscila V.C., 2005, PEPTIDES, V26, P243
   Stewart TGB, 2008, ANAL BIOCHEM, V382, P9
   WANG XX, 2009, CHINESE SCI BULL, V54, P430
   Wu J, 2006, BIOSENS BIOELECTRON, V22, P102, DOI 10.1016/j.bios.2005.12.008
   Xu Q, 2006, BIOSENS BIOELECTRON, V22, P768, DOI 10.1016/j.bios.2006.02.010
   Yu Y, 2009, MICRO NANO LETT, V4, P27, DOI 10.1049/mnl:20080054
NR 15
TC 20
Z9 20
U1 2
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0253-3820
J9 CHINESE J ANAL CHEM
JI Chin. J. Anal. Chem.
PD NOV
PY 2010
VL 38
IS 11
BP 1556
EP 1562
DI 10.3724/SP.J.1096.2010.01556
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 694GP
UT WOS:000285283300005
DA 2018-01-05
ER

PT J
AU Cattaneo, AG
   Gornati, R
   Sabbioni, E
   Chiriva-Internati, M
   Cobos, E
   Jenkins, MR
   Bernardini, G
AF Cattaneo, Anna Giulia
   Gornati, Rosalba
   Sabbioni, Enrico
   Chiriva-Internati, Maurizio
   Cobos, Everardo
   Jenkins, Marjorie R.
   Bernardini, Giovanni
TI Nanotechnology and human health: risks and benefits
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Review
DE nanomedicine; nanotoxicology; cancer; nanodrugs; carriers;
   nanoinformatics; pharmacokinetics
ID SOLID LIPID NANOPARTICLES; PEGYLATED LIPOSOMAL DOXORUBICIN; WALLED
   CARBON NANOTUBES; POLYMERIC NANOGEL FORMULATIONS; SUPERPARAMAGNETIC
   IRON-OXIDE; PROSTATE-CANCER PATIENTS; DRUG-DELIVERY SYSTEM; HIV-1 PR
   INHIBITORS; AMPHOTERICIN-B; IN-VIVO
AB Nanotechnology is expected to be promising in many fields of medical applications, mainly in cancer treatment. While a large number of very attractive exploitations open up for the clinics, regulatory agencies are very careful in admitting new nanomaterials for human use because of their potential toxicity. The very active research on new nanomaterials that are potentially useful in medicine has not been counterbalanced by an adequate knowledge of their pharmacokinetics and toxicity. The different nanocarriers used to transport and release the active molecules to the target tissues should be treated as additives, with potential side effects of themselves or by virtue of their dissolution or aggregation inside the body. Only recently has a systematic classification of nanomaterials been proposed, posing the basis for dedicated modeling at the nanoscale level. The use of in silico methods, such as nano-QSAR and PSAR, while highly desirable to expedite and rationalize the following stages of toxicological research, are not an alternative, but an introduction to mandatory experimental work. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Cattaneo, Anna Giulia; Gornati, Rosalba; Bernardini, Giovanni] Univ Insubria, Dept Biotechnol & Mol Sci, Varese, Italy.
   [Gornati, Rosalba; Bernardini, Giovanni] Univ Insubria, Milan, Italy.
   [Gornati, Rosalba; Bernardini, Giovanni] Politecn Milan, Interuniv Ctr, Prot Factory, I-20133 Milan, Italy.
   [Sabbioni, Enrico] Univ G dAnnunzio, Aging Res Ctr, Chieti, Italy.
   [Chiriva-Internati, Maurizio; Cobos, Everardo] Texas Tech Univ, Hlth Sci Ctr, Div Hematol & Oncol, Lubbock, TX 79430 USA.
   [Sabbioni, Enrico] Veneto Nanotech Scpa, ECSIN European Ctr Sustainable Impact Nanotechnol, Rovigo, Italy.
   [Jenkins, Marjorie R.] Texas Tech Univ, Hlth Sci Ctr, Dept Obstet & Gynecol, Lubbock, TX 79430 USA.
   [Jenkins, Marjorie R.] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA.
RP Bernardini, G (reprint author), Univ Insubria, Dept Biotechnol & Mol Sci, Varese, Italy.
EM giovanni.bernardini@uninsubria.it
OI Cattaneo, Anna Giulia/0000-0001-5685-3684
CR Ali MM, 2009, MOL PHARMACEUT, V6, P1409, DOI 10.1021/mp900040u
   Angst MS, 2006, CLIN PHARMACOKINET, V45, P1153, DOI 10.2165/00003088-200645120-00002                                                
   Antonelli A, 2008, J NANOSCI NANOTECHNO, V8, P2270, DOI 10.1166/jnn.2008.190
   Aoshima H, 2009, J TOXICOL SCI, V34, P555, DOI 10.2131/jts.34.555                                                              
   Azeem A, 2009, J DRUG TARGET, V17, P671, DOI 10.3109/10611860903079454
   Bakeine GJ, 2009, MICROELECTRON ENG, V86, P1468, DOI 10.1016/j.mee.2008.12.059
   Baker GL, 2008, TOXICOL SCI, V101, P122, DOI 10.1093/toxsci/kfm243
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   Barentsz JO, 2007, EUR J RADIOL, V63, P369, DOI 10.1016/j.ejrad.2007.06.025
   Bartlett DW, 2008, BIOTECHNOL BIOENG, V99, P975, DOI 10.1002/bit.21668
   Batist G, 2001, BREAST, V10, P16, DOI 10.1016/S0960-9776(01)80003-5
   Bellmann Romuald, 2009, Clin Adv Hematol Oncol, V7, P1
   Bello D, 2009, NANOTOXICOLOGY, V3, P249, DOI 10.1080/17435390902989270
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65                                                        
   Bleyer WA, 1999, CLIN CANCER RES, V5, P3349
   Boddy AV, 2005, CLIN CANCER RES, V11, P7834, DOI 10.1158/1078-0432.CCR-05-0803
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Boyen HG, 2002, SCIENCE, V297, P1533, DOI 10.1126/science.1076248                                                         
   Cattaneo AG, 2009, ISJ-INVERT SURVIV J, V6, P78
   Chen J, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/6/065004
   Chen LC, 2007, NUCL MED BIOL, V34, P415, DOI 10.1016/j.nucmedbio.2007.02.003
   Chen X, 2008, TOXICOL LETT, V176, P1, DOI 10.1016/j.toxlet.2007.10.004
   Chiesa S, 2009, STUD HEALTH TECHNOL, V150, P757, DOI 10.3233/978-1-60750-044-5-757
   DAVIDSON RN, 1994, Q J MED, V87, P75
   de la Calle G, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-320
   de la Iglesia D, 2009, STUD HEALTH TECHNOL, V150, P987, DOI 10.3233/978-1-60750-044-5-987
   Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584
   Di Gioacchino M., 2009, NANOTOXICITY, P519
   Djordjevic A, 2006, J BUON, V11, P391
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Durdagi S, 2009, J CHEM INF MODEL, V49, P1139, DOI 10.1021/ci900047s
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006                                               
   Fetterly GJ, 2008, CLIN CANCER RES, V14, P5856, DOI 10.1158/1078-0432.CCR-08-1046
   Fong J, 2006, INT J NANOMED, V1, P441, DOI 10.2147/nano.2006.1.4.441
   Fort A, 2008, CELL TRANSPLANT, V17, P997, DOI 10.3727/096368908786991498                                                      
   Freitas R A, 1999, NANOMEDICINE, V1
   Fukunishi H, 2008, J CHEM INF MODEL, V48, P575, DOI 10.1021/ci7003384
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002                                                
   Ganta C, 2008, J NANOSCI NANOTECHNO, V8, P2334, DOI 10.1166/jnn.2008.294
   Gardner ER, 2008, CLIN CANCER RES, V14, P4200, DOI 10.1158/1078-0432.CCR-07-4592
   Garg G, 2007, BIOL PHARM BULL, V30, P350, DOI 10.1248/bpb.30.350
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Goh ASW, 2007, INT J RADIAT ONCOL, V67, P786, DOI 10.1016/j.ijrobp.2006.09.011
   Gornati R, 2009, NANOTOXICITY IN VIVO, P279
   Gravante G, 2009, ANN PLAS SURG, V63, P201, DOI 10.1097/SAP.0b013e3181893825
   Green AE, 2006, INT J NANOMED, V1, P229
   Grinstaff MW, 2007, BIOMATERIALS, V28, P5205, DOI 10.1016/j.biomaterials.2007.08.041
   Hay R J, 1994, J Infect, V28 Suppl 1, P35, DOI 10.1016/S0163-4453(94)95956-0
   HE Q, 2009, SMALL, V23, P2722
   Hilder TA, 2008, J COMPUT THEOR NANOS, V5, P2153, DOI 10.1166/jctn.2008.1112
   Hong R, 2005, CHEM MATER, V17, P4617, DOI 10.1021/cm0507819
   Ibrahim NK, 2002, CLIN CANCER RES, V8, P1038
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Isaacson CW, 2009, ENVIRON SCI TECHNOL, V43, P6463, DOI 10.1021/es900692e
   Ito Y, 1998, NANOTECHNOLOGY, V9, P200, DOI 10.1088/0957-4484/9/3/009
   Jain J, 2009, MOL PHARMACEUT, V6, P1388, DOI 10.1021/mp900056g
   Jehn CF, 2008, ANTICANCER RES, V28, P3961
   Jimenez IR, 2008, NUCL MED COMMUN, V29, P166, DOI 10.1097/MNM.0b013e3282f258d9                                                    
   Johnson RR, 2009, J PHYS CHEM B, V113, P11589, DOI 10.1021/jp901999a
   Joshi MD, 2009, EUR J PHARM BIOPHARM, V71, P161, DOI 10.1016/j.ejpb.2008.09.003
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI [10.1517/17425247.5.9.1039 , 10.1517/17425240802358246]
   Kasermann F, 1997, ANTIVIR RES, V34, P65, DOI 10.1016/S0166-3542(96)01207-7
   KERN J, 2008, ARTIF INTELL MED, V16, P156
   Khan MK, 2008, NANOMED-NANOTECHNOL, V4, P57, DOI 10.1016/j.nano.2007.11.005
   Kim BS, 2005, NANO LETT, V5, P1987, DOI 10.1021/nl0513939
   Kim H, 2009, PHARM RES-DORD, V26, P329, DOI 10.1007/s11095-008-9745-6
   Kim SC, 2001, J CONTROL RELEASE, V72, P191, DOI 10.1016/S0168-3659(01)00275-9                                                   
   Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655
   Klajnert B, 2001, ACTA BIOCHIM POL, V48, P199
   Kompella U B, 2007, Arch Soc Esp Oftalmol, V82, P667
   Kostoff RN, 2007, J NANOPART RES, V9, P701, DOI 10.1007/s11051-007-9224-8
   KREUTER J, 1978, PHARM ACTA HELV, V53, P33
   Krol S, 2006, NANO LETT, V6, P1933, DOI 10.1021/nl061049r
   Lansdown Alan B G, 2006, Curr Probl Dermatol, V33, P17
   Leary SP, 2006, NEUROSURGERY, V58, P1009, DOI 10.1227/01.NEU.0000217016.79256.16
   Lee HY, 2010, J NANOPART RES, V12, P1567, DOI 10.1007/s11051-009-9666-2
   Lee TJ, 2009, ANN BIOMED ENG, V37, P2064, DOI 10.1007/s10439-009-9723-0
   Leonov AP, 2008, ACS NANO, V2, P2481, DOI 10.1021/nn800466c
   Li L, 2009, MOL BIOSYST, V5, P1361, DOI 10.1039/b903428e
   Li X, 2009, J NANOPART RES, V11, P529, DOI 10.1007/s11051-008-9491-z
   Lim WT, 2009, ANN ONCOL, V21, P382, DOI [10.1093/annonc/mdp315, DOI 10.1093/ANNONC/MDP315]
   Lin CC, 2009, BIOMACROMOLECULES, V10, P2460, DOI 10.1021/bm900420f
   Lin YL, 2000, VIROLOGY, V275, P258, DOI 10.1006/viro.2000.0490
   Liu ZL, 2004, J MAGN MAGN MATER, V283, P258, DOI 10.1016/j.jmmm.2004.05.031
   Low SCS, 2006, ANN ACAD MED SINGAP, V35, P851
   Lu AH, 2004, J AM CHEM SOC, V126, P8616, DOI 10.1021/ja0486521
   Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
   Ma DH, 2001, APPL RADIAT ISOTOPES, V55, P463, DOI 10.1016/S0969-8043(01)00048-3                                                   
   Manandhar KD, 2008, J ANTIMICROB CHEMOTH, V62, P376, DOI 10.1093/jac/dkn189
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Margolis J, 2007, CLIN CARDIOL, V30, P165, DOI 10.1002/clc.20066
   Martin-Sanchez F, 2008, LECT NOTES ARTIF INT, V5178, P66, DOI 10.1007/978-3-540-85565-1_9
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   McCarthy J. R., 2009, NANOMEDICINE, V4, P639
   McDevitt MR, 2000, CANCER RES, V60, P6095
   McDevitt MR, 2001, SCIENCE, V294, P1537, DOI 10.1126/science.1064126
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Miederer M, 2004, J NUCL MED, V45, P129
   Mitchell LA, 2007, TOXICOL SCI, V100, P203, DOI 10.1093/toxsci/kfm196
   Mody VV, 2009, ADV DRUG DELIVER REV, V61, P795, DOI 10.1016/j.addr.2009.04.020
   Moen MD, 2009, DRUGS, V69, P361, DOI 10.2165/00003495-200969030-00010
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   Muthu MS, 2010, NANOMEDICINE-UK, V5, P169, DOI 10.2217/NNM.09.107
   Nasterlack M, 2008, INT ARCH OCC ENV HEA, V81, P721, DOI 10.1007/s00420-007-0245-5
   Nohynek GJ, 2008, SKIN PHARMACOL PHYS, V21, P136, DOI 10.1159/000131078
   Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021
   Oberdorster Gunter, 2005, Part Fibre Toxicol, V2, P8, DOI 10.1186/1743-8977-2-8
   OLIVER IN, 2008, THER CLIN RISK MANAG, V4, P501
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Pardeike J, 2009, INT J PHARM, V366, P170, DOI 10.1016/j.ijpharm.2008.10.003
   Park EJ, 2010, TOXICOL APPL PHARM, V244, P226, DOI 10.1016/j.taap.2009.12.036
   Partha R, 2009, INT J NANOMED, V4, P261
   Patel MM, 2009, CNS DRUGS, V23, P35, DOI 10.2165/0023210-200923010-00003
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Porter AL, 2008, J NANOPART RES, V10, P715, DOI 10.1007/s11051-007-9266-y
   Porter DW, 2010, TOXICOLOGY, V269, P136, DOI 10.1016/j.tox.2009.10.017
   Prokop A, 2001, ANN NY ACAD SCI, V944, P472
   Puzyn T, 2009, SMALL, V5, P2494, DOI 10.1002/smll.200900179
   Qi SJ, 2007, CHEMBIOCHEM, V8, P1115, DOI 10.1002/cbic.200700119
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rakesh L, 2008, NANOMEDICINE-UK, V3, P719, DOI 10.2217/17435889.3.5.719
   Ravaioli A, 2009, J CHEMOTHERAPY, V21, P86, DOI 10.1179/joc.2009.21.1.86                                                        
   Rawat M, 2008, YAKUGAKU ZASSHI, V128, P269, DOI 10.1248/yakushi.128.269
   Robinson RF, 1999, J CLIN PHARM THER, V24, P249, DOI 10.1046/j.1365-2710.1999.00220.x
   Rosiak JM, 2007, EURASIAN CHEMTECH J, V9, P9
   Rosiak J. M., 2007, EURASIAN CHEMTECH J, V9, P165
   Salonen J, 2008, J PHARM SCI-US, V97, P632, DOI 10.1002/jps.20999
   Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269
   Sargent LM, 2009, ENVIRON MOL MUTAGEN, V50, P708, DOI 10.1002/em.20529
   Sayes CM, 2007, NANO LETT, V7, P2399, DOI 10.1021/nl0710710
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Schmid G, 2008, CHEM SOC REV, V37, P1909, DOI 10.1039/b713631p
   Singer JW, 2005, J CONTROL RELEASE, V109, P120, DOI 10.1016/j.jconrel.2005.09.033
   Singh R, 2008, FASEB J, V22, P3389, DOI 10.1096/fj.08-103275
   Singh R, 2008, ACS NANO, V2, P1040, DOI 10.1021/nn8000565
   Singh R, 2009, TRENDS BIOTECHNOL, V27, P220, DOI 10.1016/j.tibtech.2009.01.003
   Sobal NS, 2002, NANO LETT, V2, P621, DOI 10.1021/nl025533f
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   Sosnovik DE, 2007, CIRCULATION, V115, P2076, DOI 10.1161/CIRCULATIONAHA.106.658930
   Spohn P, 2009, ENVIRON POLLUT, V157, P1134, DOI 10.1016/j.envpol.2008.08.013
   Steinmetz NF, 2009, CURR TOP MICROBIOL, V327, P23
   Stinchcombe TE, 2007, NANOMEDICINE-UK, V2, P415, DOI 10.2217/17435889.2.4.415
   Sumer B, 2008, NANOMEDICINE-UK, V3, P137, DOI 10.2217/17435889.3.2.137
   Suresh G, 2007, AAPS PHARMSCITECH, V8, pE162, DOI [10.1208/pt081024, DOI 10.1208/PT081024]
   Tanaka T, 2009, BIOMED MICRODEVICES, V11, P49, DOI 10.1007/s10544-008-9209-0
   Tang TY, 2009, J AM COLL CARDIOL, V53, P2039, DOI 10.1016/j.jacc.2009.03.018
   Tasciotti E, 2008, NAT NANOTECHNOL, V3, P151, DOI 10.1038/nnano.2008.34
   Thoeny HC, 2009, EUR UROL, V55, P761, DOI 10.1016/j.eururo.2008.12.034
   Ting G, 2009, ANTICANCER RES, V29, P4107
   Tomalia DA, 2010, SOFT MATTER, V6, P456, DOI 10.1039/b917370f
   Tomalia DA, 2009, J NANOPART RES, V11, P1251, DOI 10.1007/s11051-009-9632-z
   Totsuka Y, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-23
   Uchino H, 2005, BRIT J CANCER, V93, P678, DOI 10.1038/sj.bjc.6602772
   Uner M, 2007, INT J NANOMED, V2, P289
   Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003
   Villiers CL, 2010, J NANOPART RES, V12, P55, DOI 10.1007/s11051-009-9692-0
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Vinogradov SV, 2006, PHARM RES, V23, P920, DOI 10.1007/s11095-006-9788-5
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381
   Walker NJ, 2009, TOXICOL SCI, V110, P251, DOI 10.1093/toxsci/kfp106
   Wang HZ, 2005, ADV MATER, V17, P2506, DOI 10.1002/adma.200500503
   Whitehead MA, 2008, TISSUE ENG PT A, V14, P195, DOI 10.1089/ten.a.2006.0370
   Wickline SA, 2006, ARTERIOSCL THROM VAS, V26, P435, DOI 10.1161/01.ATV.0000201069.47550.8b
   *WIK, WIK NAN PORT
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Xu JY, 2009, J APPL TOXICOL, V29, P578, DOI 10.1002/jat.1442
   Zhang K, 2005, CLIN CANCER RES, V11, P7532, DOI 10.1158/1078-0432.CCR-05-0400
   CCN TR
NR 175
TC 59
Z9 64
U1 3
U2 95
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0260-437X
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD NOV
PY 2010
VL 30
IS 8
BP 730
EP 744
DI 10.1002/jat.1609
PG 15
WC Toxicology
SC Toxicology
GA 693LN
UT WOS:000285225700002
PM 21117037
DA 2018-01-05
ER

PT J
AU Ma, HL
   Liang, XJ
AF Ma HuiLi
   Liang Xing-Jie
TI Fullerenes as unique nanopharmaceuticals for disease treatment
SO SCIENCE CHINA-CHEMISTRY
LA English
DT Review
DE fullerene; nanoparticle; nanomedicine; clinical application; biological
   effect
ID ANTI-HIV PROPERTIES; IN-VIVO; MOLECULAR-DYNAMICS; ANTIMYCOBACTERIAL
   ACTIVITY; AMINO-ACID; DERIVATIVES; INHIBITION; C-60; NANOPARTICLES;
   C-60(OH)(24)
AB As unique nanoparticles, fullerenes have attracted much attention due to their unparalleled physical, chemical and biological properties. Various functionalized fullerenes with -OH, -NH2, -COOH, and peptide modifications were developed. It summarized the biological activities of fullerenes derivatives in cancer therapy with high efficiency and low toxicity, as reactive oxygen species scavenger and lipid peroxidation inhibitor, to inhibit human immunodeficiency virus and to suppress bacteria and microbial at low concentration. In addition, the mechanism for fullerene to enter cells and biodistribution of fullerene in vivo was also discussed. This research focuses on the current understanding of fullerenes-based nanomaterials in the potential clinical application as well as biological mechanism of fullerenes and its derivatives in disease therapy.
C1 [Ma HuiLi; Liang Xing-Jie] Chinese Acad Sci, Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
RP Liang, XJ (reprint author), Chinese Acad Sci, Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
EM liangxj@nanoctr.cn
FU National Natural Science Foundation of China [30970784]; National Key
   Basic Research Program of China [2009CB930200]; Chinese Academy of
   Sciences [07I65111ZX]; China-Finland Bilateral Nanotechnology
   Collaboration [2008DFA01510]
FX We thank the National Natural Science Foundation of China (30970784),
   National Key Basic Research Program of China (2009CB930200), Chinese
   Academy of Sciences "Hundred Talents Program" (07I65111ZX), and
   China-Finland Bilateral Nanotechnology Collaboration (2008DFA01510) for
   financial supports.
CR Bedrov D, 2008, J PHYS CHEM B, V112, P2078, DOI 10.1021/jp075149c
   Bogdanovic V, 2008, J RADIAT RES, V49, P321, DOI 10.1269/jrr.07092
   Bolskar RD, 2003, J AM CHEM SOC, V125, P5471, DOI 10.1021/ja03400984
   Bosi S, 2000, BIOORG MED CHEM LETT, V10, P1043, DOI 10.1016/S0960-894X(00)00159-1
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Chaudhuri P, 2010, ACS NANO, V4, P574, DOI 10.1021/nn901465h
   Chaudhuri P, 2009, ACS NANO, V3, P2505, DOI 10.1021/nn900318y
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Cho M, 2009, ENVIRON SCI TECHNOL, V43, P7410, DOI 10.1021/es901262z
   Corona-Morales AA, 2003, J NEUROSCI RES, V71, P121, DOI 10.1002/jnr.10456
   Daroczi B, 2006, CLIN CANCER RES, V12, P7086, DOI 10.1158/1078-0432.CCR-06-0514
   Ding YY, 2007, J RARE EARTH, V25, P310
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   GEISOW M, 1980, NATURE, V288, P434, DOI 10.1038/288434a0
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   GOLDSTEIN IL, 1979, NATURE, V279, P679
   Huang ST, 2008, BIOORGAN MED CHEM, V16, P8619, DOI 10.1016/j.bmc.2008.08.004
   Injac R, 2009, PHARMACOL REP, V61, P335, DOI 10.1016/S1734-1140(09)70041-6                                                   
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Kumar A, 2009, CHEM BIOL DRUG DES, V73, P553, DOI 10.1111/j.1747-0285.2009.00804.x
   Kumar A, 2009, EUR J MED CHEM, V44, P2178, DOI 10.1016/j.ejmech.2008.10.036
   Lao F, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/22/225103
   Lee VS, 2007, J MOL GRAPH MODEL, V26, P558, DOI 10.1016/j.jmgm.2007.03.013
   Li W, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/14/145102
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   Liu Y, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/41/415102
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Lyon DY, 2008, NANO LETT, V8, P1539, DOI 10.1021/nl0726398
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005
   Markovic Z, 2007, BIOMATERIALS, V28, P5437, DOI 10.1016/j.biomaterials.2007.09.002
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mashino T, 2003, BIOORGAN MED CHEM, V11, P1433, DOI 10.1016/S0968-0896(02)00610-7
   Meng H, 2010, ACS NANO, V4, P2773, DOI 10.1021/nn100448z
   Mirkov SM, 2004, NITRIC OXIDE-BIOL CH, V11, P201, DOI 10.1016/j.niox.2004.08.003
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Okumura M, 2002, ACAD RADIOL, V9, pS495, DOI 10.1016/S1076-6332(03)80274-X                                                   
   Pantarotto D, 2002, J AM CHEM SOC, V124, P12543, DOI 10.1021/ja027603q
   Partha R, 2008, ACS NANO, V2, P1950, DOI 10.1021/nn800422k
   Pastorin G, 2006, ORG BIOMOL CHEM, V4, P2556, DOI 10.1039/b604361e
   Pellarini F, 2001, ORG LETT, V3, P1845, DOI 10.1021/ol015934m
   Qiao R, 2007, NANO LETT, V7, P614, DOI 10.1021/nl062515f
   Qu L, 2006, J ALLOY COMPD, V408, P400, DOI 10.1016/j.jallcom.2004.12.101
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665                                                      
   Satoh M, 2006, J PHARMACOL SCI, V100, P513, DOI 10.1254/jphs.CPJ06002X
   Sayes CM, 2005, BIOMATERIALS, V26, P7587, DOI 10.1016/j.biomaterials.2005.05.027
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Tabata Y, 1997, JPN J CANCER RES, V88, P1108, DOI 10.1111/j.1349-7006.1997.tb00336.x                                              
   THOU GQ, 2009, J NANOSCI N IN PRESS
   Trajkovic S, 2007, COLLOID SURFACE B, V58, P39, DOI 10.1016/j.colsurfb.2007.01.005
   Tsao N, 2002, J ANTIMICROB CHEMOTH, V49, P641, DOI 10.1093/jac/49.4.641
   Tsao N, 2001, ANTIMICROB AGENTS CH, V45, P1788, DOI 10.1128/AAC.45.6.1788-1793.2001                                                 
   Tsao N, 1999, ANTIMICROB AGENTS CH, V43, P2273
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   WANG Y, 2010, CURR DRUG METAB, V11, P207
   Xing GM, 2008, J PHYS CHEM B, V112, P6288, DOI 10.1021/jp8012706
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   Yang JH, 2007, ORG BIOMOL CHEM, V5, P260, DOI 10.1039/b614298b
   Yin JJ, 2008, MOL PHARMACOL, V74, P1132, DOI 10.1124/mol.108.048348
   Yin JJ, 2009, BIOMATERIALS, V30, P611, DOI 10.1016/j.biomaterials.2008.09.061
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zarubaev VV, 2007, PHOTODIAGN PHOTODYN, V4, P31, DOI 10.1016/j.pdpdt.2006.08.003
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 64
TC 16
Z9 16
U1 2
U2 23
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7291
J9 SCI CHINA CHEM
JI Sci. China-Chem.
PD NOV
PY 2010
VL 53
IS 11
BP 2233
EP 2240
DI 10.1007/s11426-010-4118-5
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 678LZ
UT WOS:000284078200004
DA 2018-01-05
ER

PT J
AU Lares, MR
   Rossi, JJ
   Ouellet, DL
AF Lares, Monica R.
   Rossi, John J.
   Ouellet, Dominique L.
TI RNAi and small interfering RNAs in human disease therapeutic
   applications
SO TRENDS IN BIOTECHNOLOGY
LA English
DT Review
ID APTAMER-SIRNA CHIMERAS; SHORT HAIRPIN RNAS; HIV-1 INFECTION;
   GENE-THERAPY; IN-VIVO; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; RATIONAL
   DESIGN; VIRAL VECTORS; DELIVERY
AB Small interfering RNAs (siRNAs) have been shown to effectively downregulate gene expression in human cells, giving them potential to eradicate disease. Prospects for clinical applications are discussed in this review, along with an overview of recent history and our current understanding of siRNAs used for therapeutic application in human diseases, such as cancer and viral infections. Over recent years, progress has been made in lipids, ligands, nanoparticles, polymers and viral vectors as delivery agents and for gene-based expression of siRNA to enhance the efficacy and specificity of these methods while at the same time reducing toxicity. It has become apparent that given the recent advances in chemistry and delivery, RNAi will soon prove to be an important and widely used therapeutic modality.
C1 [Lares, Monica R.; Rossi, John J.; Ouellet, Dominique L.] City Hope Natl Med Ctr, Beckman Inst, Dept Mol & Cellular Biol, Duarte, CA 91010 USA.
RP Rossi, JJ (reprint author), City Hope Natl Med Ctr, Beckman Inst, Dept Mol & Cellular Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM jrossi@coh.org
FU NIH
FX We apologize for not being all-inclusive with our reference list owing
   to space limitations. This work is supported by NIH grants to J.J.R.
CR Aagaard L, 2008, GENE THER, V15, P1536, DOI 10.1038/gt.2008.147
   Azuma K, 2010, BIOCHEM BIOPH RES CO, V391, P1075, DOI 10.1016/j.bbrc.2009.12.024
   BAOLIANG G, 2009, ANAT REC HOBOKEN, V292, P633
   Barichievy S, 2007, OLIGONUCLEOTIDES, V17, P419, DOI 10.1089/oli.2007.0095
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bauer M, 2009, GENE THER, V16, P142, DOI 10.1038/gt.2008.123
   Beer S, 2010, MOL THER, V18, P161, DOI 10.1038/mt.2009.222
   Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   Chang CI, 2009, MOL CELLS, V27, P689, DOI 10.1007/s10059-009-0093-0
   Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   DiGiusto DL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000931
   Ehsani A, 2010, MOL THER, V18, P796, DOI 10.1038/mt.2009.321
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301                                                              
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Escors D, 2010, ARCH IMMUNOL THER EX, V58, P107, DOI 10.1007/s00005-010-0063-4
   Feigner P.L., 1989, NATURE, V337, P387
   Frank-Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105
   Gantier MP, 2010, MOL THER, V18, P785, DOI 10.1038/mt.2010.4
   Giering JC, 2008, MOL THER, V16, P1630, DOI 10.1038/mt.2008.144
   Gijsbers R, 2010, MOL THER, V18, P552, DOI 10.1038/mt.2010.36
   Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   HOSHANG U, 2008, CURR HIV AIDS REP, V5, P40
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   Kamata M, 2010, HUM GENE THER, V21, P1555, DOI 10.1089/hum.2010.050
   Keates AC, 2007, PHARMACOGENOMICS, V8, P867, DOI 10.2217/14622416.8.7.867
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Kim S.H., 2008, MOL PHARM, V6, P718
   Kim SM, 2010, ANTIVIR RES, V87, P307, DOI 10.1016/j.antiviral.2010.06.004
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Laursen MB, 2010, MOL BIOSYST, V6, P862, DOI 10.1039/b918869j
   Leng QX, 2007, DRUG NEWS PERSPECT, V20, P77, DOI 10.1358/dnp.2007.20.2.1083026
   Li MJ, 2005, MOL THER, V12, P900, DOI 10.1016/j.ymthe.2005.07.524
   Liu YP, 2008, NUCLEIC ACIDS RES, V36, P2811, DOI 10.1093/nar/gkn109
   Liu YP, 2007, NUCLEIC ACIDS RES, V35, P5683, DOI 10.1093/nar/gkm596
   Liu YP, 2009, MOL THER, V17, P1712, DOI 10.1038/mt.2009.176
   Lu XB, 2004, J VIROL, V78, P7079, DOI 10.1128/JVI.78.13.7079-7088.2004
   MacDiarmid JA, 2009, NAT BIOTECHNOL, V27, P643, DOI 10.1038/nbt.1547
   Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161
   McCarthy Edward F, 2006, Iowa Orthop J, V26, P154
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Michelfelder S, 2009, ADV GENET, V67, P29, DOI 10.1016/S0065-2660(09)67002-4
   Miyoshi H, 1998, J VIROL, V72, P8150
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Moses J, 2010, RNA, V16, P430, DOI 10.1261/rna.1808510
   Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80
   Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005
   Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148
   Pastor F, 2010, NATURE, V465, P227, DOI 10.1038/nature08999
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887
   Puerta-Fernandez E, 2005, AIDS, V19, P863, DOI 10.1097/01.aids.0000171399.77500.e0
   Saayman S, 2010, NUCLEIC ACIDS RES, V38, P6652, DOI 10.1093/nar/gkq460
   Saetrom P, 2004, BIOINFORMATICS, V20, P3055, DOI 10.1093/bioinformatics/bth364
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Schopman NCT, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-52
   Shukla S, 2010, CHEMMEDCHEM, V5, P328, DOI 10.1002/cmdc.200900444
   Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052
   Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Sonoke S, 2008, CANCER RES, V68, P8843, DOI 10.1158/0008-5472.CAN-08-0127
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   STEIN CA, 2010, NUCLEIC ACIDS RES, V38, pNIL34
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Unwalla HJ, 2006, J VIROL, V80, P1863, DOI 10.1128/JVI.80.4.1863-1873.2006
   VANCLENDRIESSCH.T, 2002, BLOOD, V100, P813
   von Eije KJ, 2008, J VIROL, V82, P2895, DOI 10.1128/JVI.02035-07
   Weinberg MS, 2007, NUCLEIC ACIDS RES, V35, P7303, DOI 10.1093/nar/gkm847
   Weinberg MS, 2006, RNA, V12, P256, DOI 10.1261/rna.2235106
   Wu Y, 2010, INT J NANOMED, V5, P129
   Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558
   Yang N, 2008, CANCER BIOL THER, V7, P147
   Zhang J, 2007, MOL BIOTECHNOL, V37, P225, DOI 10.1007/s12033-007-9000-0                                                       
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
NR 78
TC 149
Z9 170
U1 2
U2 46
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0167-7799
J9 TRENDS BIOTECHNOL
JI Trends Biotechnol.
PD NOV
PY 2010
VL 28
IS 11
BP 570
EP 579
DI 10.1016/j.tibtech.2010.07.009
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 673ZS
UT WOS:000283703300005
PM 20833440
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kim, PS
   Read, SW
AF Kim, Peter S.
   Read, Sarah W.
TI Nanotechnology and HIV: potential applications for treatment and
   prevention
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID VAGINAL SHIV TRANSMISSION; PLACEBO-CONTROLLED TRIAL; ANTIRETROVIRAL
   THERAPY; NASAL IMMUNIZATION; DRUG-DELIVERY; DOUBLE-BLIND; SPL7013 GEL;
   VIRAL LOAD; IN-VITRO; VACCINE
AB HIV/AIDS is a global pandemic and is the leading infectious cause of death among adults. Although antiretroviral (ARV) therapy has dramatically improved the quality of life and increased the life expectancy of those infected with HIV, life-long suppressive treatment is required and a cure for HIV infection remains elusive; frequency of dosing and drug toxicity as well as the development of viral resistance pose additional limitations. Furthermore, preventative measures such as a vaccine or microbicide are urgently needed to curb the rate of new infections. The capabilities inherent to nanotechnology hold much potential for impact in the field of HIV treatment and prevention. This article reviews the potential for the multidisciplinary field of nanotechnology to advance the fields of HIV treatment and prevention. (C) 2010 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2010 2 693-702
C1 [Kim, Peter S.; Read, Sarah W.] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA.
RP Read, SW (reprint author), NIAID, Div AIDS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM readsa@niaid.nih.gov
CR Adamson CS, 2010, ANTIVIR RES, V85, P119, DOI 10.1016/j.antiviral.2009.09.009
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akita H, 2009, BIOMATERIALS, V30, P2940, DOI 10.1016/j.biomaterials.2009.02.009
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Atmar RL, 2006, CLIN INFECT DIS, V43, P1135, DOI 10.1086/508174
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Brave A, 2007, VACCINE, V25, P6882, DOI 10.1016/j.vaccine.2007.07.012
   Calarota SA, 2007, VACCINE, V25, P3070, DOI 10.1016/j.vaccine.2007.01.024
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   CHISEMBELE M, 2010, 17 C RETR OPP INF SA
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109                                                        
   Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828
   Dolin R, 2008, AIDS THERAPY
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Durando P, 2010, EXPERT OPIN BIOL TH, V10, P639, DOI 10.1517/14712591003724662
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   FRIEND DR, 2009, PHARM DEV TECHNOL, pE1
   Friis-Moller N, 2003, AIDS, V17, P1179, DOI [10.1097/00002030-200305230-00010, 10.1097/01.aids.0000060358.78202.c1]
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Karim SSA, 2010, 18 INT AIDS C VIENN
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lamprecht A, 2009, NANOTHERAPEUTICS: DRUG DELIVERY CONCEPTS IN NANOSCIENCE, P1
   LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001
   Langer R, 1998, NATURE, V392, P5
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Leung L, 2004, AIDS, V18, P991, DOI 10.1097/01.aids.0000111468.61782.5b
   Lori F, 2007, CURR MED CHEM, V14, P1911
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70
   Mitchell DK, 2002, PEDIATR INFECT DIS J, V21, P133, DOI 10.1097/00006454-200202000-00009
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Ray S, 2010, MINI-REV MED CHEM, V10, P147, DOI 10.2174/138955710791185145                                                      
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Schwartz JL, 2008, SEX TRANSM DIS, V35, P414, DOI 10.1097/OLQ.0b013e318162c4d8
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Singh SK, 2006, VACCINE, V24, P4161, DOI 10.1016/j.vaccine.2006.02.047
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084
   TRONO D, SCIENCE, V329, P174
   *UN WHO, AIDS EP UPD 2009
   VANDAMM, 2002, LANCET, V360, P971
   VANDAMM, 2008, NEW ENGL J MED, V359, P463
   VANTKLOOSTE, 2010, ANTIMICROB AGENTS CH, V54, P2042
   Villalonga-Barber C, 2008, CURR TOP MED CHEM, V8, P1294, DOI 10.2174/156802608785849012
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Warnke D, 2007, J CLIN PHARMACOL, V47, P1570, DOI 10.1177/0091270007308034
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
NR 72
TC 20
Z9 20
U1 2
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD NOV-DEC
PY 2010
VL 2
IS 6
BP 693
EP 702
DI 10.1002/wnan.118
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 669YU
UT WOS:000283387000009
PM 20860050
DA 2018-01-05
ER

PT J
AU Ofek, G
   Guenaga, FJ
   Schief, WR
   Skinner, J
   Baker, D
   Wyatt, R
   Kwong, PD
AF Ofek, Gilad
   Guenaga, F. Javier
   Schief, William R.
   Skinner, Jeff
   Baker, David
   Wyatt, Richard
   Kwong, Peter D.
TI Elicitation of structure-specific antibodies by epitope scaffolds
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE computational design; epitope transplantation; structural mimicry
ID COMPLEMENTARITY-DETERMINING REGION; VIRUS TYPE-1 HIV-1;
   CRYSTAL-STRUCTURES; NEUTRALIZING ANTIBODIES; ECTODOMAIN REGION;
   RIBONUCLEASE-S; HEAVY-CHAIN; GP41; PROTEIN; MEMBRANE
AB Elicitation of antibodies against targets that are immunorecessive, cryptic, or transient in their native context has been a challenge for vaccine design. Here we demonstrate the elicitation of structure-specific antibodies against the HIV-1 gp41 epitope of the broadly neutralizing antibody 2F5. This conformationally flexible region of gp41 assumes mostly helical conformations but adopts a kinked, extended structure when bound by antibody 2F5. Computational techniques were employed to transplant the 2F5 epitope into select acceptor scaffolds. The resultant "2F5-epitope scaffolds" possessed nanomolar affinity for antibody 2F5 and a range of epitope flexibilities and antigenic specificities. Crystallographic characterization of the epitope scaffold with highest affinity and antigenic discrimination confirmed good to near perfect attainment of the target conformation for the gp41 molecular graft in free and 2F5-bound states, respectively. Animals immunized with 2F5-epitope scaffolds showed levels of graft-specific immune responses that correlated with graft flexibility (p < 0.04), while antibody responses against the graft-as dissected residue-by-residue with alanine substitutions-resembled more closely those of 2F5 than sera elicited with flexible or cyclized peptides, a resemblance heightened by heterologous prime-boost. Lastly, crystal structures of a gp41 peptide in complex with monoclonal antibodies elicited by the 2F5-epitope scaffolds revealed that the elicited antibodies induce gp41 to assume its 2F5-recognized shape. Epitope scaffolds thus provide a means to elicit antibodies that recognize a predetermined target shape and sequence, even if that shape is transient in nature, and a means by which to dissect factors influencing such elicitation.
C1 [Ofek, Gilad; Guenaga, F. Javier; Wyatt, Richard; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Schief, William R.; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Skinner, Jeff] NIAID, Bioinformat & Computat Biosci Branch, Off Cyber Infrastruct & Computat Biol, NIH, Bethesda, MD 20892 USA.
RP Kwong, PD (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM pdkwong@nih.gov
RI Baker, David/K-8941-2012
OI Baker, David/0000-0001-7896-6217; Skinner, Jeff/0000-0001-5697-0442
FU National Institutes of Health; International AIDS Vaccine Initiative and
   its Neutralizing Antibody Consortium; U.S. Department of Energy, Basic
   Energy Sciences, Office of Science
FX We thank B.K. Chakrabarti and G.J. Nabel for sera generated from placing
   the 2F5 epitope into the flexible V3 loop of gp120; Y. Geng and V.
   Savich (ProSci) for assistance for monoclonal antibody elicitation; H.
   Katinger for antibody 2F5; J.R. Mascola and K. McKee for neutralization
   analysis; G.J. Nabel, J.R. Mascola, L. Shapiro, I. Wilson, and members
   of the Structural Bioinformatics and Biology Sections, Vaccine Research
   Center, for discussions and comments on the manuscript; J. Stuckey for
   assistance with figures; and GlaxoSmithKline for AS01B adjuvant. Support
   for this work was provided by the Intramural Research Program of the
   National Institutes of Health and by the International AIDS Vaccine
   Initiative and its Neutralizing Antibody Consortium. Use of SER-CAT at
   the Advanced Photon Source was supported by the U.S. Department of
   Energy, Basic Energy Sciences, Office of Science.
CR Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0
   Arnold GF, 2009, J VIROL, V83, P5087, DOI 10.1128/JVI.00184-09
   Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y
   Buzon V, 2010, PLOS PATHOG, V6
   Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7
   Chakrabarti BK, 2005, VACCINE, V23, P3434, DOI 10.1016/j.vaccine.2005.01.099
   Das R, 2008, ANNU REV BIOCHEM, V77, P363, DOI 10.1146/annurev.biochem.77.062906.171838
   Fernandez-Carneado J, 2000, BIOPOLYMERS, V55, P451, DOI 10.1002/1097-0282(2000)55:6<451::AID-BIP1020>3.0.CO;2-1                         
   Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8
   Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Julien JP, 2010, J VIROL, V84, P4136, DOI 10.1128/JVI.02357-09
   Julien JP, 2008, J MOL BIOL, V384, P377, DOI 10.1016/j.jmb.2008.09.024
   Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4                                                   
   Kohno M, 1996, J BIOCHEM-TOKYO, V120, P505
   Liang XP, 1999, VACCINE, V17, P2862, DOI 10.1016/S0264-410X(99)00125-5
   Liu J, 2009, BIOCHEMISTRY-US, V48, P2915, DOI 10.1021/bi802303b
   Lowther WT, 1999, BIOCHEMISTRY-US, V38, P7678, DOI 10.1021/bi990684r
   Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3
   MUSTER T, 1994, J VIROL, V68, P4031
   NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331                                                            
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Ofek G, 2010, J VIROL, V84, P2955, DOI 10.1128/JVI.02257-09
   Ortiz AR, 2002, PROTEIN SCI, V11, P2606, DOI 10.1110/ps.0215902
   Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324                                                            
   THOMSON J, 1994, BIOCHEMISTRY-US, V33, P8587, DOI 10.1021/bi00194a025
   VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019
   VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404
   Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0
   Zhang HT, 2004, J VIROL, V78, P8342, DOI 10.1128/jvi.78.15.8342-8348.2004
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2004, J VIROL, V78, P3155, DOI 10.1128/JVI.78.6.3155-3161.2004
NR 41
TC 176
Z9 178
U1 0
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 19
PY 2010
VL 107
IS 42
BP 17880
EP 17887
DI 10.1073/pnas.1004728107
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 667HV
UT WOS:000283184800010
PM 20876137
OA gold
DA 2018-01-05
ER

PT J
AU Teeparuksapun, K
   Hedstrom, M
   Wong, EY
   Tang, SX
   Hewlett, IK
   Mattiasson, B
AF Teeparuksapun, Kosin
   Hedstrom, Martin
   Wong, Eric Y.
   Tang, Shixing
   Hewlett, Indira K.
   Mattiasson, Bo
TI Ultrasensitive Detection of HIV-1 p24 Antigen Using Nanofunctionalized
   Surfaces in a Capacitive Immunosensor
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID BIOSENSOR; PREVENTION; ELECTRODES; CAMEROON; TYPE-1; TESTS
AB The HIV-1 capsid protein, p24 antigen, is of considerable diagnostic interest because following HIV exposure it is detectable several days earlier than host-generated HIV antibodies (which are the target of almost all current tests used in the field) and can be used to design very sensitive assays without the need for PCR. Here, we present an ultrasensitive capacitive immunosensor that is capable of detecting subattogram per milliliter concentrations of p24 antigen, which to our knowledge is the lowest level of detection ever reported. Dilution studies using p24-spiked human plasma samples indicate that the immunosensor is robust against the interfering effects of a complex biological matrix. Moreover, the capacitive immunosensor assay is rapid (<20 min), label-free, and generates data in real-time, with a portable format in development. Additional optimization of the capture agents and/or surface chemistries may further improve performance, highlighting the potential of this platform to serve as a diagnostic tool for early detection of HIV in field settings.
C1 [Teeparuksapun, Kosin; Hedstrom, Martin; Mattiasson, Bo] Lund Univ, Dept Biotechnol, SE-22100 Lund, Sweden.
   [Wong, Eric Y.; Tang, Shixing; Hewlett, Indira K.] US FDA, Mol Virol Lab, Div Emerging & Transfus Transmitted Dis, Off Blood Res & Review,Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
RP Mattiasson, B (reprint author), Lund Univ, Dept Biotechnol, POB 124, SE-22100 Lund, Sweden.
EM Bo.Mattiasson@biotek.lu.se
CR Aghokeng AF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007702
   Allain JP, 2005, EXPERT REV MOL DIAGN, V5, P31, DOI 10.1586/14737159.5.1.31
   Brown KR, 2000, CHEM MATER, V12, P306, DOI 10.1021/cm980065p                                                               
   BUCK RP, 1994, PURE APPL CHEM, V66, P2527, DOI 10.1351/pac199466122527                                                         
   Busch Michael P., 1997, American Journal of Medicine, V102, P117, DOI 10.1016/S0002-9343(97)00077-6
   Busch MP, 1997, AM J MED, V102, P125
   Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828
   GAO ZQ, 1991, ELECTROCHIM ACTA, V36, P147, DOI 10.1016/0013-4686(91)85193-B                                                    
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Labib M, 2010, ANAL CHIM ACTA, V659, P194, DOI 10.1016/j.aca.2009.11.028
   Lee S, 2007, AIDS RES HUM RETROV, V23, P1262, DOI 10.1089/aid.2006.0301
   Limbut W, 2007, ANAL BIOANAL CHEM, V389, P517, DOI 10.1007/s00216-007-1443-4
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Loyprasert S, 2010, BIOSENS BIOELECTRON, V25, P1977, DOI 10.1016/j.bios.2010.01.020
   MOHAMMAD AM, 2008, COLLOID SURF A, P78
   Murphy G, 2008, EUROSURVEILLANCE, V13, P4
   Pandori MW, 2009, J CLIN MICROBIOL, V47, P2639, DOI 10.1128/JCM.00119-09
   Plate DK, 2007, AIDS RES HUM RETROV, V23, P1491, DOI 10.1089/aid.2007.0020
   R Development Core Team, 2006, R LANG ENV STAT COMP
   Schupbach Jorg, 2002, AIDS Reviews, V4, P83
   Stevens W, 2008, Open AIDS J, V2, P17, DOI 10.2174/1874613600802010017
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, CLIN VACCINE IMMUNOL, V17, P1244, DOI 10.1128/CVI.00066-10
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tehe A, 2006, J CLIN VIROL, V37, P199, DOI 10.1016/j.jcv.2006.08.005
   Wong Eric Y., 2010, HIV Therapy, V4, P399, DOI 10.2217/HIV.10.29
   Xu SY, 2004, BIOSENS BIOELECTRON, V19, P1117, DOI 10.1016/j.bios.2003.09.007
NR 28
TC 37
Z9 37
U1 1
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 15
PY 2010
VL 82
IS 20
BP 8406
EP 8411
DI 10.1021/ac102144a
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 663BX
UT WOS:000282859100009
PM 20873850
DA 2018-01-05
ER

PT J
AU Wadhwa, S
   Jain, A
   Mumper, RJ
AF Wadhwa, S.
   Jain, A.
   Mumper, R. J.
TI Lipid Nanocapsules with Surface Accessible Nickel are Effective Antigen
   Delivery Systems for Histidine-Tagged HIV Gag p41 Protein Antigen
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2010
CY SEP 28-OCT 01, 2010
CL Atlanta, GA
C1 [Wadhwa, S.; Jain, A.; Mumper, R. J.] Univ N Carolina, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2010
VL 26
IS 10
BP A127
EP A127
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 665OC
UT WOS:000283044200325
DA 2018-01-05
ER

PT J
AU Le, GA
   Vandegraaff, N
   Rhodes, DI
   Jones, ED
   Coates, JAV
   Thienthong, N
   Winfield, LJ
   Lu, L
   Li, XM
   Yu, CJ
   Feng, XA
   Deadman, JJ
AF Le, Giang
   Vandegraaff, Nick
   Rhodes, David I.
   Jones, Eric D.
   Coates, Jonathan A. V.
   Thienthong, Neeranat
   Winfield, Lisa J.
   Lu, Long
   Li, Xinming
   Yu, Changjiang
   Feng, Xiao
   Deadman, John J.
TI Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2:
   Azoles: Effective metal chelators
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Integrase; Inhibitor; Metal chelator; Synthesis
ID AMIDE BOND ISOSTERE; ANTIVIRAL ACTIVITY; RALTEGRAVIR; DISCOVERY; POTENT
AB Synthesis of a diverse set of azoles and their utilizations as an amide isostere in the design of HIV integrase inhibitors is described. The Letter identified thiazole, oxazole, and imidazole as the most promising heterocycles. Initial SAR studies indicated that these novel series of integrase inhibitors are amenable to lead optimization. Several compounds with low nanomolar inhibitory potency are reported. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Le, Giang; Vandegraaff, Nick; Rhodes, David I.; Jones, Eric D.; Coates, Jonathan A. V.; Thienthong, Neeranat; Winfield, Lisa J.; Deadman, John J.] Avexa Ltd, Richmond, Vic 3121, Australia.
   [Lu, Long; Li, Xinming; Yu, Changjiang; Feng, Xiao] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China.
RP Deadman, JJ (reprint author), Avexa Ltd, 576 Swan St, Richmond, Vic 3121, Australia.
EM jjdeadman@bigpond.com
RI Le, Giang/I-3178-2016
OI Le, Giang/0000-0002-2591-9190
CR Boros EE, 2009, J MED CHEM, V52, P2754, DOI 10.1021/jm801404b
   Chang TLY, 2003, J VIROL, V77, P6777, DOI 10.1128/JVI.77.12.6777-6784.2003
   Cohen F, 2010, BIOORG MED CHEM LETT, V20, P2229, DOI 10.1016/j.bmcl.2010.02.021
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   JOHNS AB, 2009, BIOORG MED CHEM LETT, V19, P1802
   Jones ED, 2010, BIOORG MED CHEM LETT, V20, P5913, DOI 10.1016/j.bmcl.2010.07.079
   Le GA, 2010, BIOORG MED CHEM LETT, V20, P5013, DOI 10.1016/j.bmcl.2010.07.041
   Melamed JY, 2008, BIOORG MED CHEM LETT, V18, P5307, DOI 10.1016/j.bmcl.2008.08.038
   Ovenden SPB, 2004, PHYTOCHEMISTRY, V65, P3255, DOI 10.1016/j.phytochem.2004.10.006
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   THOMPSON SK, 1994, J MED CHEM, V37, P3100, DOI 10.1021/jm00045a015
   THOMPSON SK, 1994, BIOORG MED CHEM LETT, V4, P2441, DOI 10.1016/S0960-894X(01)80406-6
   Vandegraaff Nick, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000257
NR 13
TC 26
Z9 27
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 1
PY 2010
VL 20
IS 19
BP 5909
EP 5912
DI 10.1016/j.bmcl.2010.07.081
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 648ZY
UT WOS:000281735600067
PM 20727753
DA 2018-01-05
ER

PT J
AU Smolarek, D
   Hattab, C
   Hassanzadeh-Ghassabeh, G
   Cochet, S
   Gutierrez, C
   de Brevern, AG
   Udomsangpetch, R
   Picot, J
   Grodecka, M
   Wasniowska, K
   Muyldermans, S
   Colin, Y
   Le Van Kim, C
   Czerwinski, M
   Bertrand, O
AF Smolarek, Dorota
   Hattab, Claude
   Hassanzadeh-Ghassabeh, Gholamreza
   Cochet, Sylvie
   Gutierrez, Carlos
   de Brevern, Alexandre G.
   Udomsangpetch, Rachanee
   Picot, Julien
   Grodecka, Magdalena
   Wasniowska, Kazimiera
   Muyldermans, Serge
   Colin, Yves
   Le Van Kim, Caroline
   Czerwinski, Marcin
   Bertrand, Olivier
TI A recombinant dromedary antibody fragment (VHH or nanobody) directed
   against human Duffy antigen receptor for chemokines
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Duffy antigen receptor for chemokines; VHH; Atypical chemokine receptor;
   Plasmodium vivax; Immunoaffinity; Cancer; Inflammation; HIV
ID HEAVY-CHAIN ANTIBODIES; PLASMODIUM-VIVAX; BINDING-PROTEIN; NEGATIVE
   INDIVIDUALS; DISEASE PROGRESSION; MONOCLONAL-ANTIBODY;
   AFRICAN-AMERICANS; HIV-1 ACQUISITION; MALARIA PARASITE; MOLECULAR-BASIS
AB Fy blood group antigens are carried by the Duffy antigen receptor for chemokines (DARC), a red cells receptor for Plasmodium vivax broadly implicated in human health and diseases. Recombinant VHHs, or nanobodies, the smallest intact antigen binding fragment derivative from the heavy chain-only antibodies present in camelids, were prepared from a dromedary immunized against DARC N-terminal extracellular domain and selected for DARC binding. A described VHH, CA52, does recognize native DARC on cells. It inhibits P. vivax invasion of erythrocytes and displaces interleukin-8 bound to DARC. The targeted epitope overlaps the well-defined DARC Fy6 epitope. K (D) of CA52-DARC equilibrium is sub-nanomolar, hence ideal to develop diagnostic or therapeutic compounds. Immunocapture by immobilized CA52 yielded highly purified DARC from engineered K562 cells. This first report on a VHH with specificity for a red blood cell protein exemplifies VHHs' potentialities to target, to purify, and to modulate the function of cellular markers.
C1 [Smolarek, Dorota; Hattab, Claude; Cochet, Sylvie; de Brevern, Alexandre G.; Picot, Julien; Colin, Yves; Le Van Kim, Caroline; Bertrand, Olivier] INSERM, UMR S 665, F-75015 Paris, France.
   [Smolarek, Dorota; Grodecka, Magdalena; Wasniowska, Kazimiera; Czerwinski, Marcin] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Smolarek, Dorota; Hattab, Claude; Cochet, Sylvie; de Brevern, Alexandre G.; Picot, Julien; Colin, Yves; Le Van Kim, Caroline; Bertrand, Olivier] Inst Natl Transfus Sanguine, F-75015 Paris, France.
   [Smolarek, Dorota; Hattab, Claude; Cochet, Sylvie; de Brevern, Alexandre G.; Picot, Julien; Colin, Yves; Le Van Kim, Caroline; Bertrand, Olivier] Univ Paris 07, F-75013 Paris, France.
   [Hassanzadeh-Ghassabeh, Gholamreza; Muyldermans, Serge] Vrije Univ Brussel, Lab Cellular & Mol Immunol, B-1050 Brussels, Belgium.
   [Hassanzadeh-Ghassabeh, Gholamreza; Muyldermans, Serge] VIB, Dept Mol & Cellular Interact, Brussels, Belgium.
   [Gutierrez, Carlos] Univ Las Palmas, Fac Vet, Dept Anim Med & Surg, Las Palmas Gran Canaria, Spain.
   [Udomsangpetch, Rachanee] Mahidol Univ, Fac Sci, Dept Pathobiol, Bangkok 10400, Thailand.
RP Bertrand, O (reprint author), INSERM, UMR S 665, F-75015 Paris, France.
EM olivier-s.bertrand@inserm.fr
RI Muyldermans, Serge/C-6418-2016; colin, yves/O-1910-2017; de Brevern,
   Alexandre/B-4788-2009; Gutierrez, Carlos/E-2989-2012; Cochet,
   sylvie/I-2721-2015
OI Muyldermans, Serge/0000-0002-3678-3575; colin, yves/0000-0001-5196-4254;
   de Brevern, Alexandre/0000-0001-7112-5626; Gutierrez,
   Carlos/0000-0003-0764-7408; le van kim, caroline/0000-0002-3251-1310
FU Flemish government; Ministry of Science and Higher Education of Poland
   [N N302 118835]; Polonium Partenariat Hubert Curien grant; French
   Embassy in Warsaw
FX The deepest gratitude is due to Inge Mestdagh and Jan van Gompel for
   their generous help and their patient teaching during library
   construction and screening. D. S. was supported by scholarship from
   French Embassy in Warsaw and from the Flemish government. The project
   was supported by grant no. N N302 118835 from the Ministry of Science
   and Higher Education of Poland and in part by a Polonium Partenariat
   Hubert Curien grant. Authors thank Dr. Bach Nga Pham and Eliane Vera at
   CNRGS for making available phenotyped human blood, Dr. Christophe
   Tournamille for the recombinant K562 cells, and Prof. Donald Engelman
   for the plasmid used for some of the E. coli protein productions.
CR Abderrazek Rahma Ben, 2009, Biochem J, V424, P263, DOI 10.1042/BJ20090697
   Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389                                                          
   Baral TN, 2006, NAT MED, V12, P580, DOI 10.1038/nm1395
   Beck Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008297
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Blackburn PE, 2004, BIOCHEM J, V379, P263, DOI 10.1042/BJ20031266
   Cavasini CE, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-167
   Chakera A, 2008, MOL PHARMACOL, V73, P1362, DOI 10.1124/mol.107.040915
   CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793
   Chelikani P, 2006, PROTEIN SCI, V15, P1433, DOI 10.1110/ps.062080006
   Choe H, 2005, MOL MICROBIOL, V55, P1413, DOI 10.1111/j.1365-2958.2004.04478.x
   Comerford Iain, 2005, Immunology Letters, V96, P163, DOI 10.1016/j.imlet.2004.08.018
   Conrath K, 2009, PROTEIN SCI, V18, P619, DOI 10.1002/pro.69
   Czerwinski M, 2007, BIOCHEM BIOPH RES CO, V356, P816, DOI 10.1016/j.bbrc.2007.03.054
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075
   Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870
   FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159                                                            
   FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028
   Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459
   Gardner L, 2006, ARTHRITIS RHEUM, V54, P2022, DOI 10.1002/art.21909
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8                                                    
   Graham GJ, 2009, EUR J IMMUNOL, V39, P342, DOI 10.1002/eji.200838858
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Grisshammer R, 2009, METHOD ENZYMOL, V463, P631, DOI 10.1016/S0076-6879(09)63036-6
   Grodecka M, 2010, ACTA BIOCHIM POL, V57, P49
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Handel TM, 2010, TRENDS PARASITOL, V26, P329, DOI 10.1016/j.pt.2010.03.010
   Hans D, 2005, MOL MICROBIOL, V55, P1423, DOI 10.1111/j.1365-2958.2005.04484.x
   He WJ, 2008, CELL HOST MICROBE, V4, P52, DOI 10.1016/j.chom.2008.06.002
   Horne KC, 2009, CELL HOST MICROBE, V5, P415, DOI 10.1016/j.chom.2009.04.013
   Horuk R, 1996, J LEUKOCYTE BIOL, V59, P29
   HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250                                                         
   IWAMOTO S, 1995, BLOOD, V85, P622
   Johnson Z, 2005, TRENDS IMMUNOL, V26, P268, DOI 10.1016/j.it.2005.03.001
   Julg B, 2009, CELL HOST MICROBE, V5, P413, DOI 10.1016/j.chom.2009.04.009
   Kasehagen LJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000336
   King CL, 2008, P NATL ACAD SCI USA, V105, P8363, DOI 10.1073/pnas.0800371105
   Kulkarni H, 2009, BLOOD, V114, P2783, DOI 10.1182/blood-2009-04-215186
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351
   Lentsch AB, 2002, FASEB J, V16, P1093, DOI 10.1096/fj.02-0066hyp
   Albuquerque SRL, 2010, PARASITOL RES, V106, P1049, DOI 10.1007/s00436-010-1745-x
   Mariette N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-219
   Menard D, 2010, P NATL ACAD SCI USA, V107, P5967, DOI 10.1073/pnas.0912496107
   MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602
   Mouro-Chanteloup I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008921
   Murdoch C, 2000, BLOOD, V95, P3032
   Muyldermans S, 2009, VET IMMUNOL IMMUNOP, V128, P178, DOI 10.1016/j.vetimm.2008.10.299
   Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921                                                          
   NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776
   PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311                                                          
   Pogo AO, 2000, SEMIN HEMATOL, V37, P122
   Pruenster M, 2006, BIOCHEM SOC T, V34, P1005, DOI 10.1042/BST0341005                                                              
   Rios M, 2000, BRIT J HAEMATOL, V108, P448
   Rosenberg R, 2007, TRENDS PARASITOL, V23, P193, DOI 10.1016/j.pt.2007.02.009
   Rot A, 2005, CYTOKINE GROWTH F R, V16, P687, DOI 10.1016/j.cytogfr.2005.05.011
   Rot A, 2009, METHOD ENZYMOL, V461, P191, DOI 10.1016/S0076-6879(09)05409-3
   Saerens D, 2005, ANAL CHEM, V77, P7547, DOI 10.1021/ac051092j
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Segerer S, 2000, KIDNEY INT, V58, P1546, DOI 10.1046/j.1523-1755.2000.00316.x                                                
   SHIBUYA N, 1987, J BIOL CHEM, V262, P1596
   Singh SK, 2006, NATURE, V439, P741, DOI 10.1038/nature04443
   Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016
   STUDIER FW, 1990, METHOD ENZYMOL, V185, P60
   SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348                                                        
   Tereshko V, 2008, PROTEIN SCI, V17, P1175, DOI 10.1110/ps.034892.108
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tournamille C, 2005, MOL BIOCHEM PARASIT, V144, P100, DOI 10.1016/j.molbiopara.2005.04.016
   Tournamille C, 2003, BRIT J HAEMATOL, V122, P1014, DOI 10.1046/j.1365-2141.2003.04533.x
   Tournamille C, 1998, BLOOD, V92, P2147
   TOURNAMILLE C, 1995, HUM GENET, V95, P407, DOI 10.1007/BF00208965                                                              
   TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224
   Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050
   Walley NM, 2009, CELL HOST MICROBE, V5, P408, DOI 10.1016/j.chom.2009.04.011
   Wang J, 2006, ONCOGENE, V25, P7201, DOI 10.1038/sj.onc.1209703
   Wasniowska K, 2002, TRANSFUSION MED, V12, P205, DOI 10.1046/j.1365-3148.2002.00373.x                                                
   Wells TNC, 2006, TRENDS PHARMACOL SCI, V27, P41, DOI 10.1016/j.tips.2005.11.001
   Winkler CA, 2009, CELL HOST MICROBE, V5, P411, DOI 10.1016/j.chom.2009.04.010
   Zarbock A, 2010, AM J PHYSIOL-LUNG C, V298, pL462, DOI 10.1152/ajplung.00224.2009
NR 80
TC 20
Z9 20
U1 1
U2 14
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD OCT
PY 2010
VL 67
IS 19
BP 3371
EP 3387
DI 10.1007/s00018-010-0387-6
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 648CN
UT WOS:000281668100012
PM 20458517
OA green_accepted
DA 2018-01-05
ER

PT J
AU Destache, CJ
   Belgum, T
   Goede, M
   Shibata, A
   Belshan, MA
AF Destache, Christopher J.
   Belgum, Todd
   Goede, Michael
   Shibata, Annemarie
   Belshan, Michael A.
TI Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles
   in mice
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE HIV-1; ritonavir; lopinavir; efavirenz; PLGA
ID REVERSE-TRANSCRIPTASE INHIBITOR; VIRUS-INFECTED PATIENTS; PROTEASE
   INHIBITOR; DRUG-DELIVERY; IN-VITRO; HIV-1; COMBINATION; THERAPY;
   MACROPHAGES; RESERVOIRS
AB Free ritonavir, lopinavir and efavirenz injected intraperitoneally were compared with antiretroviral (AR) nanoparticles (NPs).
   This is a prospective study in BALB/c mice comparing the pharmacokinetics of free drugs with AR NPs. All animals received free drugs or AR NPs (20 mg/kg) in PBS. In vitro replication assays were used for determination of the anti-HIV efficacy of NP formulations. At specific times (free drugs 0.08, 0.125, 0.25, 0.33, 1, 2 and 3 days; AR NPs 0.125, 0.33, 1, 2, 4, 7, 14, 21, 28, 35 and 42 days) mice were euthanized and serum and organs were harvested for determination of AR concentrations by HPLC. Single treatment of monocyte-derived macrophages (MDMs) infected with HIV-1(ada) compared AR NPs (0.005-0.05 mg/mL) with free efavirenz or lopinavir/ritonavir (0.01-0.1 mg/mL), blank NPs and controls. Results are presented as means +/- SEM.
   Serum free AR drug concentrations peaked 4 h post-injection (ritonavir 3.9 +/- 3.05, lopinavir 3.4 +/- 2.5 and efavirenz 1.8 +/- 0.63 mu g/mL) and were eliminated by 72 h. Poly(dl-lactide-co-glycolide) NP animals had detectable ritonavir, lopinavir and efavirenz concentrations in all tissues for 28 days. Treatment of MDMs with AR NPs resulted in sustained inhibition of HIV-1(ada) replication.
   AR drug concentrations from NPs are sustained for 28 days in vivo and anti-HIV inhibition was comparable to that of free drugs in vitro and could be a sustained treatment for delivery of AR drugs.
C1 [Destache, Christopher J.; Belgum, Todd; Goede, Michael] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Shibata, Annemarie] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Belshan, Michael A.] Creighton Univ, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Destache, Christopher/0000-0001-7923-3939
FU National Institute of Allergy and Infectious Diseases
   [1R15AI076039-01A1]; National Center for Research Resources
   [G20RR024001]
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (grant number 1R15AI076039-01A1 to C. J. D.). The
   Animal Facility has been supported by G20RR024001 from the National
   Center for Research Resources.
CR Allavena C, 2005, JAIDS-J ACQ IMM DEF, V39, P300, DOI 10.1097/01.qai.0000165914.42827.bb
   Anabwani G, 2005, NUTRITION, V21, P96, DOI 10.1016/j.nut.2004.09.013
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Calmy A, 2007, HIV MED, V8, P171, DOI 10.1111/j.1468-1293.2007.00448.x                                                
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   CROWE SM, 1992, CLIN IMMUNOL IMMUNOP, V65, P143, DOI 10.1016/0090-1229(92)90217-C
   CROWE SM, 1990, AIDS RES HUM RETROV, V6, P1031
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Di Mascio M, 2009, ANTIMICROB AGENTS CH, V53, P4086, DOI 10.1128/AAC.00419-09
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dybul M, 2000, J INFECT DIS, V181, P1273, DOI 10.1086/315407
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Plot P., 2001, NATURE, V410, P968
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Weller DR, 2007, J CHROMATOGR B, V848, P369, DOI 10.1016/j.jchromb.2006.10.022
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 26
TC 37
Z9 38
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD OCT
PY 2010
VL 65
IS 10
BP 2183
EP 2187
DI 10.1093/jac/dkq318
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 654NK
UT WOS:000282174800021
PM 20729545
OA gold
DA 2018-01-05
ER

PT J
AU Numata, M
AF Numata, Munenori
TI Creation of unique supramolecular nanoarchitectures utilizing natural
   polysaccharide as a one-dimensional host
SO JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY
LA English
DT Review
DE Polysaccharide; Helical polymer; Inclusion complex; Self-assemble;
   Nanomaterials
ID WALLED CARBON NANOTUBES; SCHIZOPHYLLUM-COMMUNE POLYSACCHARIDE; TARGETED
   ANTISENSE CARRIER; SINGLE-STRANDED RNA; ANTI-HIV ACTIVITY; CONJUGATED
   POLYMERS; HELICAL SUPERSTRUCTURE; INCLUSION COMPLEX; DILUTE-SOLUTION;
   DYE ASSEMBLIES
AB We recently revealed that beta-1,3-glucans act as unique natural nanotubes, which can accept functional polymers and molecular assemblies in an induced-fit manner. A variety of individual conjugated polymers or molecular assemblies can be incorporated into the one-dimensional hollow constructed by the helical superstructure of beta-1,3-glucans to create water-soluble one-dimensional nanocomposites. The advantageous point of the present hosting system is that the selective modification of beta-1,3-glucans leads to the creation of various functional one-dimensional nanocomposites in a supramolecular manner. Furthermore, the composites with functional surfaces can act as one-dimensional building blocks toward further hierarchical self-assembles, leading to the creation of two- or three-dimensional nanoarchitectures, which are applicable for fundamental nanomaterials.
C1 Kyoto Prefectural Univ, Dept Biomol Chem, Grad Sch Life & Environm Sci, Sakyo Ku, Kyoto 6068522, Japan.
RP Numata, M (reprint author), Kyoto Prefectural Univ, Dept Biomol Chem, Grad Sch Life & Environm Sci, Sakyo Ku, 1-5 Nakaragi Chou, Kyoto 6068522, Japan.
EM numata@kpu.ac.jp
FU Committee of Host-Guest and Supramolecular Chemistry Society, Japan
FX The author thanks the committee of Host-Guest and Supramolecular
   Chemistry Society, Japan for awarding the "HGCS Japan Award of
   Excellence 2009". Most of the present works were done in Kyushu
   University as JST SORST Project led by Prof. Seiji Shinkai working from
   2002 to 2007. First of all, the author thanks Prof. Seiji Shinkai for
   leading him throughout the project. The author also thanks Prof. Kazuo
   Sakurai (The University of Kitakyushu) and Takeshi Nagasaki (Osaka City
   University) for productive discussion executing the research, and Prof
   Kenji Kaneko for TEM observations. The present works were performed in
   cooperation with many project members; Mr. Takahiro Matsumoto, Ms.
   Mariko Umeda, Dr. Teruaki Hasegawa, Dr. Chun Li, Ms. Ah Hhun Bae, Mr.
   Tomohisa Fujisawa, Mr. Shu-ichi Haraguchi, Mr. Shingo Tamesue, Dr.
   Masato Ikeda, and Mr. Kouta Sugikawa. The author expresses his gratitude
   for all the members. The author also gratefully acknowledges Mitusi
   Sugar Co., Japan, for providing the schizophyllan samples.
CR Aoki K, 2000, J AM CHEM SOC, V122, P10997, DOI 10.1021/ja001790f
   ATKINS EDT, 1968, NATURE, V220, P784, DOI 10.1038/220784a0
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3
   Buey J, 2000, ANGEW CHEM INT EDIT, V39, P608, DOI 10.1002/(SICI)1521-3773(20000204)39:3<608::AID-ANIE608>3.0.CO;2-W               
   Choi LS, 1998, MACROMOLECULES, V31, P9406, DOI 10.1021/ma981151d                                                               
   DEMLEITNER S, 1992, CARBOHYD RES, V226, P239, DOI 10.1016/0008-6215(92)84071-Y
   DiCesare N, 2002, LANGMUIR, V18, P7785, DOI 10.1021/la0264926
   Dieckmann GR, 2003, J AM CHEM SOC, V125, P1770, DOI 10.1021/ja029084x
   Endo M, 2006, CHEM-EUR J, V12, P3735, DOI 10.1002/chem.200501309
   Escudero C, 2006, ANGEW CHEM INT EDIT, V45, P8032, DOI 10.1002/anie.200603182
   Ewert KK, 2006, J AM CHEM SOC, V128, P3998, DOI 10.1021/ja055907h
   Fan CH, 2002, J AM CHEM SOC, V124, P5642, DOI 10.1021/ja025899u
   Frampton MJ, 2007, ANGEW CHEM INT EDIT, V46, P1028, DOI 10.1002/anie.200601780
   FUJIKI M, 1994, J AM CHEM SOC, V116, P6017, DOI 10.1021/ja00092a082                                                             
   Gao Y, 1999, MACROMOLECULES, V32, P8319, DOI 10.1021/ma990782k                                                               
   Garoff RA, 2002, LANGMUIR, V18, P6330, DOI 10.1021/la025742f
   Gattuso G, 1997, ANGEW CHEM INT EDIT, V36, P1451, DOI 10.1002/anie.199714511                                                          
   Goto H, 2002, CHEM-EUR J, V8, P4027, DOI 10.1002/1521-3765(20020902)8:17<4027::AID-CHEM4027>3.0.CO;2-Q
   Hannah KC, 2004, ACCOUNTS CHEM RES, V37, P845, DOI 10.1021/ar030257c
   HARADA A, 1993, NATURE, V364, P516, DOI 10.1038/364516a0                                                                
   Harada A, 2001, ACCOUNTS CHEM RES, V34, P456, DOI 10.1021/ar000174l
   Harada A, 1997, ADV POLYM SCI, V133, P141
   Haraguchi S, 2005, ORG LETT, V7, P5605, DOI 10.1021/ol052170s
   HASAGAWA T, 2004, CHEM COMMUN, P382
   Hasegawa T, 2006, CHEM LETT, V35, P82, DOI 10.1246/cl.2006.82
   Hasegawa T, 2006, CARBOHYD RES, V341, P35, DOI 10.1016/j.carres.2005.10.009
   Hasegawa T, 2005, CHEM LETT, V34, P1118, DOI 10.1246/cl.2005.1118
   Hasegawa T, 2005, BIOORG MED CHEM LETT, V15, P327, DOI 10.1016/j.bmcl.2004.10.071
   Hasegawa T, 2004, ORG BIOMOL CHEM, V2, P3091, DOI 10.1039/b412124b
   Hasegawa T, 2004, CHEM COMMUN, P2150, DOI 10.1039/b407409b
   Hecht S, 2001, ANGEW CHEM INT EDIT, V40, P74, DOI 10.1002/1521-3773(20010105)40:1<74::AID-ANIE74>3.0.CO;2-C
   Heuer WB, 1998, CHEM COMMUN, P2649, DOI 10.1039/a808359b                                                                
   Hosomizu K, 2008, J PHYS CHEM B, V112, P16517, DOI 10.1021/jp807991k
   Ichino Y, 2001, J PHYS CHEM B, V105, P4111, DOI 10.1021/jp002503x                                                               
   IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0                                                                
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Ikeda M, 2007, CHEM-ASIAN J, V2, P1290, DOI 10.1002/asia.200700150
   Ikeda M, 2007, ORG BIOMOL CHEM, V5, P2219, DOI 10.1039/b705997c
   Ikeda M, 2007, J AM CHEM SOC, V129, P3979, DOI 10.1021/ja0684343
   Ikeda M, 2006, ANGEW CHEM INT EDIT, V45, P6491, DOI 10.1002/anie.200602134
   IMMEL S, 2000, STARCH, V52
   Jones RM, 2001, P NATL ACAD SCI USA, V98, P14769, DOI 10.1073/pnas.251555298
   Kadokawa J, 2001, CHEM COMMUN, P449, DOI 10.1039/b008180i                                                                
   Kashida H, 2004, ANGEW CHEM INT EDIT, V43, P6522, DOI 10.1002/anie.200460870
   Kashida H, 2006, CHEM COMMUN, P2768, DOI 10.1039/b604776a
   Katsuraya K, 1999, CARBOHYD RES, V315, P234, DOI 10.1016/S0008-6215(98)00315-2
   KATSURAYA K, 1994, CARBOHYD RES, V260, P51, DOI 10.1016/0008-6215(94)80021-9                                                    
   Kida T, 2007, CHEM COMMUN, P1559, DOI 10.1039/b616231b
   Kim J, 2000, ANGEW CHEM INT EDIT, V39, P3868, DOI 10.1002/1521-3773(20001103)39:21<3868::AID-ANIE3868>3.0.CO;2-2                  
   Kim OK, 2006, J AM CHEM SOC, V128, P510, DOI 10.1021/ja0533141
   Kim OK, 2003, J AM CHEM SOC, V125, P4426, DOI 10.1021/ja029233b
   KIM OK, 1994, LANGMUIR, V10, P2842, DOI 10.1021/la00020a055                                                             
   Kimura T, 2000, CHEM LETT, P1242, DOI 10.1246/cl.2000.1242
   Kool ET, 2002, ACCOUNTS CHEM RES, V35, P936, DOI 10.1021/ar000183u                                                               
   Koti ASR, 2003, CHEM MATER, V15, P369, DOI 10.1021/cm025664h
   Koumoto K, 2004, CARBOHYD RES, V339, P161, DOI 10.1016/j.carres.2003.09.022
   Kubo Y, 2006, ANGEW CHEM INT EDIT, V45, P1548, DOI 10.1002/anie.200503128
   Kumaraswamy S, 2004, P NATL ACAD SCI USA, V101, P7511, DOI 10.1073/pnas.0402367101
   LangeveldVoss BMW, 1996, J AM CHEM SOC, V118, P4908, DOI 10.1021/ja9600643                                                               
   Li C, 2005, ANGEW CHEM INT EDIT, V44, P6371, DOI 10.1002/anie.200501823
   LI G, 1994, SCIENCE, V264, P249, DOI 10.1126/science.264.5156.249
   LU FL, 1986, J AM CHEM SOC, V108, P8311, DOI 10.1021/ja00286a057                                                             
   Martin RE, 1999, ANGEW CHEM INT EDIT, V38, P1350, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1350::AID-ANIE1350>3.0.CO;2-6            
   Michels JJ, 2003, CHEM-EUR J, V9, P6167, DOI 10.1002/chem.200305245                                                          
   Morikawa M, 2005, J AM CHEM SOC, V127, P1358, DOI 10.1021/ja043844h
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Nakagawa M, 2005, ADV MATER, V17, P200, DOI 10.1002/adma.200400520
   Nakashima H, 2001, J AM CHEM SOC, V123, P1963, DOI 10.1021/ja000869h
   Nakashima N, 2003, CHEM LETT, V32, P456, DOI 10.1246/cl.2003.456
   Nepogodiev SA, 1998, CHEM REV, V98, P1959, DOI 10.1021/cr970049w                                                               
   Numata M, 2005, J AM CHEM SOC, V127, P5875, DOI 10.1021/ja044168m
   Numata M, 2004, ORG LETT, V6, P4447, DOI 10.1021/ol0483448
   Numata M, 2004, CHEM LETT, V33, P232, DOI 10.1246/cl.2004.232                                                             
   Numata M, 2003, BIOORG CHEM, V31, P163, DOI 10.1016/S0045-2068(03)00020-8
   Numata M, 2008, CHEM-EUR J, V14, P2398, DOI 10.1002/chem.200701205
   Numata M, 2007, SUPRAMOL CHEM, V19, P107, DOI 10.1080/10610270600982508
   Numata M, 2006, ORG LETT, V8, P5533, DOI 10.1021/ol062229a
   Onouchi H, 2006, ANGEW CHEM INT EDIT, V45, P2381, DOI 10.1002/anie.200504162
   Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r
   PARINS LJ, 2001, P NATL ACAD SCI USA, V98, P10042
   Peng WQ, 2004, J AM CHEM SOC, V126, P13822, DOI 10.1021/ja046235i
   Pinto MR, 2004, P NATL ACAD SCI USA, V101, P7505, DOI 10.1073/pnas.0402280101
   Pistolis G, 1996, J PHYS CHEM-US, V100, P15562, DOI 10.1021/jp9613403                                                               
   POUGET JP, 1992, SYNTHETIC MET, V51, P95, DOI 10.1016/0379-6779(92)90258-K
   Purrello R, 1998, J PHYS CHEM B, V102, P8852, DOI 10.1021/jp9828686                                                               
   Rao V. S. R., 1998, CONFORMATION CARBOHY
   Raymo FM, 1999, CHEM REV, V99, P1643, DOI 10.1021/cr970081q                                                               
   Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o                                                               
   Renikuntla BR, 2005, LANGMUIR, V21, P5362, DOI 10.1021/la0500651
   Sakurai K, 2005, CHEM COMMUN, P4383, DOI 10.1039/b506673p
   Sakurai K, 2000, J AM CHEM SOC, V122, P4520, DOI 10.1021/ja0000145                                                               
   Sanji T, 2005, ANGEW CHEM INT EDIT, V44, P7301, DOI 10.1002/anie.200502073
   Sanji T, 2005, CHEM LETT, V34, P1144, DOI 10.1246/cl.2005.1144
   Sano M, 2001, SCIENCE, V293, P1299, DOI 10.1126/science.1061050                                                         
   SATO T, 1981, CARBOHYD RES, V95, P195, DOI 10.1016/S0008-6215(00)85576-7                                                   
   SATO T, 1983, MACROMOLECULES, V16, P185, DOI 10.1021/ma00236a006                                                             
   Sato T, 1999, J AM CHEM SOC, V121, P10658, DOI 10.1021/ja9922983                                                               
   Sauvage JP, 2002, NEW J CHEM, V26, P1287, DOI 10.1039/b201853p
   Schwab AD, 2003, J PHYS CHEM B, V107, P11339, DOI 10.1021/jp035569b
   STAFSTROM S, 1987, PHYS REV LETT, V59, P1464, DOI 10.1103/PhysRevLett.59.1464
   Star A, 2002, ANGEW CHEM INT EDIT, V41, P2508, DOI 10.1002/1521-3773(20020715)41:14<2508::AID-ANIE2508>3.0.CO;2-A                  
   STOKKE BT, 1991, MACROMOLECULES, V24, P6349, DOI 10.1021/ma00023a046                                                             
   SUGIKAWA K, HIERARCHICAL P UNPUB
   Takahashi T, 2002, CHEM LETT, P690, DOI 10.1246/cl.2002.690                                                             
   Tan CY, 2004, J AM CHEM SOC, V126, P13685, DOI 10.1021/ja046856b
   Wang MM, 2000, J AM CHEM SOC, V122, P9977, DOI 10.1021/ja002184n
   Wenz G, 2006, CHEM REV, V106, P782, DOI 10.1021/cr970027+
   Wosnick JH, 2005, J AM CHEM SOC, V127, P3400, DOI 10.1021/ja043134b
   Wurthner F, 2003, ANGEW CHEM INT EDIT, V42, P3247, DOI 10.1002/anie.200351414
   YANAKI T, 1980, MACROMOLECULES, V13, P1462, DOI 10.1021/ma60078a019                                                             
   YANAKI T, 1983, BIOPHYS CHEM, V17, P337, DOI 10.1016/0301-4622(83)80018-0
   Yao S, 2004, J AM CHEM SOC, V126, P8336, DOI 10.1021/ja0496367
   YOSHIDA T, 1995, CARBOHYD RES, V276, P425, DOI 10.1016/0008-6215(95)00186-W
   ZAHN S, 2002, ANGEW CHEM INT EDIT, V41, P4226
   Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877
   Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911
   Zorbas V, 2004, J AM CHEM SOC, V126, P7222, DOI 10.1021/ja049202b
NR 117
TC 7
Z9 7
U1 0
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-3127
EI 1573-1111
J9 J INCL PHENOM MACRO
JI J. Incl. Phenom. Macrocycl. Chem.
PD OCT
PY 2010
VL 68
IS 1-2
BP 25
EP 47
DI 10.1007/s10847-010-9754-z
PG 23
WC Chemistry, Multidisciplinary
SC Chemistry
GA 648OC
UT WOS:000281702800002
DA 2018-01-05
ER

PT J
AU Liu, BR
   Li, JF
   Lu, SW
   Lee, HJ
   Huang, YW
   Shannon, KB
   Aronstam, RS
AF Liu, Betty R.
   Li, Jheng-Fong
   Lu, Shu-Wan
   Lee, Han-Jung
   Huang, Yue-Wern
   Shannon, Katie B.
   Aronstam, Robert S.
TI Cellular Internalization of Quantum Dots Noncovalently Conjugated with
   Arginine-Rich Cell-Penetrating Peptides
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Cell-Penetrating Peptide (CPP); Cellular Internalization; Polyarginine;
   Protein Transduction Domain (PTD); Quantum Dot (QD)
ID INTRACELLULAR DELIVERY PEPTIDES; HUMAN IMMUNODEFICIENCY VIRUS;
   TAT-FUSION PROTEINS; LIVING CELLS; PLANT-CELLS; CATIONIC PEPTIDE;
   PLASMA-MEMBRANE; STEM-CELLS; MACROPINOCYTOSIS; TRANSDUCTION
AB Protein transduction domains comprised of basic amino acid-rich peptides, can efficiently deliver covalently fused macromolecules into cells. Quantum dots (QDs) are luminescent semiconductor nanocrystals that are finding increasing application in biological imaging. Previous studies showed that protein transduction domains mediate the internalization of covalently attached QDs. In this study, we demonstrate that arginine-rich intracellular delivery peptides (cell-penetrating peptides; CPPs), analogs of naturally-occuring protein transduction domains, deliver noncovalently associated QDs into living cells; CPPs dramatically increase the rate and efficiency of cellular uptake of QD probes. The optimal molecular ratio between arginine-rich CPPs and OD cargoes for cellular internalization is approximately 60:1. Upon entry into cells, the QDs are concentrated in the perinuclear region. There is no cytotoxicity following transport of QDs present at concentrations up to 200 nM. The mechanism for arginine-rich CPP/QD complexes to traverse cell membrane appears to involve a combination of internalization pathways. These results provide insight into the mechanism of arginine-rich CPP delivery of noncovalently attached cargoes, and may provide a powerful tool for imaging in vivo.
C1 [Liu, Betty R.; Li, Jheng-Fong; Lu, Shu-Wan; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
   [Liu, Betty R.; Li, Jheng-Fong; Lu, Shu-Wan; Lee, Han-Jung] Natl Dong Hwa Univ, Inst Biotechnol, Hualien 97401, Taiwan.
   [Huang, Yue-Wern; Shannon, Katie B.; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Sci Biol, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
OI Shannon, Katie/0000-0002-8493-6505
FU National Institute of Biomedical Imaging and Bioengineering
   [R15EB009530]; National Science Council of Taiwan [NSC
   97-2621-B-259-003-MY3]
FX We thank Yi Xu and members of our laboratories for technical assistance.
   This work was supported by Award Number R15EB009530 from the National
   Institute of Biomedical Imaging and Bioengineering (to Y. W. H.) and the
   National Science Council (NSC 97-2621-B-259-003-MY3) of Taiwan (to H. J.
   L.).
CR BOOT JH, 1995, CELL STRUCT FUNCT, V20, P233, DOI 10.1247/csf.20.233                                                              
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chakraborty SK, 2007, NANO LETT, V7, P2618, DOI 10.1021/nl0709930
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Crombez L, 2008, CURR PHARM DESIGN, V14, P3656, DOI 10.2174/138161208786898842
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   DOWDY SF, 2005, EXPERT OPIN DRUG DEL, V2, P43
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   EQUCHI A, 2001, J BIOL CHEM, V276, P26204
   FERVARI A, 2003, MOL THER, V8, P284
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hammond TG, 1998, J MEMBRANE BIOL, V162, P157, DOI 10.1007/s002329900353                                                           
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Hess GT, 2007, BBA-MOL CELL RES, V1773, P1583, DOI 10.1016/j.bbamcr.2007.07.009
   Holzer AK, 2006, CANCER RES, V66, P10944, DOI 10.1158/0008-5472.CAN-06-1710
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Iga AM, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/76087
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Lin S, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-67
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472
   Medintz IL, 2008, BIOCONJUGATE CHEM, V19, P1785, DOI 10.1021/bc800089r
   Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nishimura S, 2008, J BIOL CHEM, V283, P11752, DOI 10.1074/jbc.M708849200
   Poon GMK, 2007, BIOCHEM SOC T, V35, P788, DOI 10.1042/BST0350788                                                              
   Pouniotis DS, 2006, IMMUNOLOGY, V117, P329, DOI 10.1111/j.1365-2567.2005.02304.x
   Robinson LJ, 1997, J CELL SCI, V110, P2079
   Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961                                                            
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399                                                        
   SCHNITZER JE, 1995, AM J PHYSIOL, V268, P48
   Shurety W, 1996, J CELL SCI, V109, P2927
   SPURCK TP, 1986, PROTOPLASMA, V131, P47, DOI 10.1007/BF01281686                                                              
   Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160                                                         
   Subtil A, 1997, J CELL SCI, V110, P2441
   Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775
   SUDHAKARAN PR, 1982, J BIOSCIENCE, V4, P413, DOI 10.1007/BF02704633                                                              
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Weijer CJ, 2003, SCIENCE, V300, P96, DOI 10.1126/science.1082830
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   Zhang LW, 2009, TOXICOL SCI, V110, P138, DOI 10.1093/toxsci/kfp087
NR 77
TC 48
Z9 48
U1 4
U2 29
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2010
VL 10
IS 10
BP 6534
EP 6543
DI 10.1166/jnn.2010.2637
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 631QA
UT WOS:000280361400038
PM 21137758
OA green_accepted
DA 2018-01-05
ER

PT J
AU Guo, Q
   Du, T
   Yang, H
   Liu, B
   Bao, CC
   He, R
   Cui, DX
AF Guo, Qin
   Du, Tong
   Yang, Hao
   Liu, Bin
   Bao, Chenchen
   He, Rong
   Cui, Daxiang
TI Preparation of HIV-1 Env Protein and Establishment of Ultrasensitive
   Detection Method of HIV-1 gp41 Antibody
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE HIV-1-Env Protein; Rapid Translation System; Quantum Dots; Fluorescent
   Immunoassay
ID SEMICONDUCTOR QUANTUM DOTS; NANOPARTICLE THIN-FILMS; IN-VITRO; CDTE;
   IDENTIFICATION; ANTIGEN; PHOTOLUMINESCENCE; NANOCRYSTALS; CANCER; ASSAY
AB Preparation of HIV-1 Env protein and development of ultrasensitive detection method of HIV-1 gp41 antibody are challengeable tasks for early diagnosis of patients with HIV virus. The env gene fragments were obtained from the plasmid with HIV-1 env by PCR, and were cloned into T vector, and then were sequenced. The linear env gene fragments were prepared by Rapid Translation System (RTS) Linear Template Kit, the Env proteins were obtained by RTS Kit, and were purified by magnetic bead method. The Env protein's bioactivity was identified by Western Blotting. The prepared Env proteins were labeled with CdTe quantum dots (QDs), and the goat anti-HIV-1 gp41 IgG antibodies were detected by CdTe QDs-labeled Env proteins, the fluorescent signals were recorded by photoluminescent spectroscopy. Results show that the prepared Env proteins own bioactivity, the CdTe ODs-labeled Env proteins can combine with anti-HIV-1 gp41 IgG antibodies, and formed the Env-gp41-CdTe QDs complex, the fluorescent intensity of final products were negatively associated with the concentration of anti-HIV-1 gp41 IgG antibodies in sample, the limitation of detection is 100 pg/mL. In conclusion, HIV-1 Env proteins with bioactivity were successfully prepared by RTS, established CdTe QDs labeled Env proteins-based fluorescent immunoassay can successfully detect HIV-1 gp41 IgG antibodies, which has great potential in early diagnosis of HIV.
C1 [Guo, Qin; Du, Tong; Yang, Hao; Liu, Bin; Bao, Chenchen; He, Rong; Cui, Daxiang] Shanghai Jiao Tong Univ, Dept Bionano Sci & Engn, Natl Key Lab Nano Micro Fabricat Technol, Key Lab Thin Film & Micro fabricat,Minist Educ,In, Shanghai 200240, Peoples R China.
RP Cui, DX (reprint author), Shanghai Jiao Tong Univ, Dept Bionano Sci & Engn, Natl Key Lab Nano Micro Fabricat Technol, Key Lab Thin Film & Micro fabricat,Minist Educ,In, Shanghai 200240, Peoples R China.
RI He, Rong/P-3151-2015
FU Shanghai Nano Project [0275nm024]; China National 973 Project
   [2010CB933900]; China National 863 Project [2007AA022004]; National
   Natural Scientific Fund [20471599, 30672147]; China Infective Disease
   Project [2009ZX10004-311]
FX This study was supported by Shanghai Nano Project (0275nm024), China
   National 973 Project (No. 2010CB933900), China National 863 Project
   (No.2007AA022004), National Natural Scientific Fund (No.20471599 and
   No.30672147), as well as China Infective Disease Project
   (2009ZX10004-311). Here we would like to extend the appreciation to
   Professor Shao Yiming and Professor Liu Yin from STD/AIDS Control and
   Prevention Center of China Control and Prevention Center, who kindly
   offered the vector with HIV-1 env gene for us and instructed our
   experiment.
CR Ao LM, 2006, ANAL CHEM, V78, P1104, DOI 10.1021/ac051323m
   Azzazy HME, 2007, CLIN BIOCHEM, V40, P917, DOI 10.1016/j.clinbiochem.2007.018
   Bao J, 2007, FEBS LETT, V581, P2737, DOI 10.1016/j.febslet.2007.05.029
   BARANOVA SV, 2009, J BIOCHIMIE, V91, P1081
   BROLIDEN PA, 1991, IMMUNOLOGY, V73, P371
   Cai LF, 2009, ANTIMICROB AGENTS CH, V53, P2444, DOI 10.1128/AAC.00150-09
   CHAN WC, 1998, SCIENCE, V281, P1930
   CHEN SS, 1996, INTERVIROLOGY, V38, P242
   Cheng KH, 2008, J NANOSCI NANOTECHNO, V8, P1170, DOI 10.1166/jnn.2008.309
   Cui DX, 2008, ANAL CHEM, V80, P7996, DOI 10.1021/ac800992m
   Cui DX, 2004, CANCER EPIDEM BIOMAR, V13, P1136
   Dunn S, 2008, J NANOSCI NANOTECHNO, V8, P2544, DOI 10.1166/jnn.2008.122
   Gardner HC, 2008, J NANOSCI NANOTECHNO, V8, P2578, DOI 10.1166/jnn.2008.400
   Ghosh S, 2008, J NANOSCI NANOTECHNO, V8, P5952, DOI 10.1166/jnn.2008.323
   Gill R, 2008, ANGEW CHEM INT EDIT, V47, P7602, DOI 10.1002/anie.200800169
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Han YD, 2006, BIOTECHNOL PROGR, V22, P1084, DOI 10.1021/bp0504445
   He R, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/31/315601
   Hoshino A, 2005, MICROBIOL IMMUNOL, V49, P461, DOI 10.1111/j.1348-0421.2005.tb03750.x                                              
   Jeong H, 2001, SCIENCE, V293, P2221, DOI 10.1126/science.1063182
   Kim S, 2009, J NANOSCI NANOTECHNO, V9, P7061, DOI 10.1166/jnn.2009.1595
   KNOPP D, 2009, J ANAL CHIM ACTA, V647, P14
   LAPERCHE S, 2000, TRANSFUS CLIN BIO S1, V7, P18
   Li XQ, 2003, SCIENCE, V301, P809, DOI 10.1126/science.1083800
   Li ZB, 2007, J NANOSCI NANOTECHNO, V7, P2567, DOI 10.1166/jnn.2007.628
   Madhi SA, 2005, PEDIATR INFECT DIS J, V24, P410, DOI 10.1097/01.inf.0000160942.84169.14
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Sachithanandham J, 2009, INDIAN J MED MICROBI, V27, P210, DOI 10.4103/0255-0857.53202
   SEIJFFERS DE, 2001, FASEB J, V15, P2112
   SHREESH S, 2003, J MED VIROL, V71, P167
   Su JF, 2008, J NANOSCI NANOTECHNO, V8, P1174, DOI 10.1166/jnn.2008.317
   Sun HZ, 2009, J NANOSCI NANOTECHNO, V9, P7374, DOI 10.1166/jnn.2009.1746
   Tan TLR, 1997, J IMMUNOL METHODS, V205, P201, DOI 10.1016/S0022-1759(97)00086-0
   Tholouli E, 2008, J PATHOL, V216, P275, DOI 10.1002/path.2421
   THOMPSON IR, 2009, AIDS RES THERAPY, V6, P1
   Wang C, 2008, J NANOSCI NANOTECHNO, V8, P4408, DOI 10.1166/jnn.2008.269
   Wang Y, 2008, J NANOSCI NANOTECHNO, V8, P1068, DOI 10.1166/jnn.2008.303
   WU FX, 2008, J NANOSCI NANOTECHNO, V8, P6532
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xie HY, 2005, J NANOSCI NANOTECHNO, V5, P880, DOI 10.1166/jnn.2005.119
   Yezhelyev MV, 2006, LANCET ONCOL, V7, P657, DOI 10.1016/S1470-2045(06)70793-8
   Yin DG, 2008, J IMMUNOASS IMMUNOCH, V29, P257, DOI 10.1080/15321810802119075
   Zhang J, 2008, J NANOSCI NANOTECHNO, V8, P1155, DOI 10.1166/jnn.2008.316
   ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411
NR 44
TC 2
Z9 2
U1 1
U2 9
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2010
VL 10
IS 10
BP 6618
EP 6623
DI 10.1166/jnn.2010.2550
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 631QA
UT WOS:000280361400051
PM 21137771
DA 2018-01-05
ER

PT J
AU Eugenin, EA
   Gaskill, P
   Hazleton, J
   Berman, JW
AF Eugenin, Eliseo A.
   Gaskill, Peter
   Hazleton, Joy
   Berman, Joan W.
TI Tunneling nanotubes (TNT), a novel communication system in the
   pathogenesis of HIV/AIDS
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
CT 10th International Symposium on NeuroVirology
CY OCT 12-16, 2010
CL Milan, ITALY
C1 [Eugenin, Eliseo A.; Gaskill, Peter; Hazleton, Joy; Berman, Joan W.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
   [Berman, Joan W.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2010
VL 16
SU 1
BP 31
EP 32
PG 2
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 670GS
UT WOS:000283409800069
DA 2018-01-05
ER

PT J
AU Reynolds, JL
   Mahajan, SD
   Aalinkeel, R
   Nair, BB
   Sykes, DE
   Law, R
   Prasad, PN
   Schwartz, SA
AF Reynolds, Jessica L.
   Mahajan, Supriya D.
   Aalinkeel, Ravikumar
   Nair, Bindukumar B.
   Sykes, Donald E.
   Law, Roy
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Targeted Nanoparticles for Gene Silencing: HIV-1 and Drugs of Abuse
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
CT 10th International Symposium on NeuroVirology
CY OCT 12-16, 2010
CL Milan, ITALY
C1 [Reynolds, Jessica L.; Mahajan, Supriya D.; Aalinkeel, Ravikumar; Nair, Bindukumar B.; Sykes, Donald E.; Law, Roy; Prasad, Paras N.; Schwartz, Stanley A.] SUNY Buffalo, Buffalo, NY 14260 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD OCT
PY 2010
VL 16
SU 1
BP 70
EP 71
PG 2
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 670GS
UT WOS:000283409800153
DA 2018-01-05
ER

PT J
AU Wang, F
   Zhou, L
   Zhou, JH
   Gu, XT
   Feng, YY
AF Wang, Fang
   Zhou, Lin
   Zhou, Jiahong
   Gu, Xiaotian
   Feng, Yuying
TI Characterization of anticancer hypocrellin A encapsulated with silica
   nanoparticles
SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
LA English
DT Article
DE Hypocrellin; Silica nanoparticle; Differential scanning calorimetry;
   Thermogravimetry
ID PHOTODYNAMIC THERAPY; MYOGLOBIN; WATER
AB Hypocrellins, natural photosensitizers including hypocrellin A (HA) and hypocrellin B (HB), have been used as a traditional Chinese herbal medicine to cure various skin diseases. Hypocrellins have excellent antiviral activity, which can inhibit the growth of human immunodeficiency virus. They also exhibit significant light-induced antitumor property. In this article, thermal analysis technologies (e.g., differential scanning calorimetry and thermogravimetry) are employed to characterize whether the photosensitive hypocrellin A could be encapsulated with silica nanoparticle (SN) material or not, and evaluate the stability of inclusion complex. The results show that the inclusion complex exhibits improved performance in both stability and hydrophilicity than natural hypocrellin A. Fluorescence spectrophotometry studies have also been performed to verify the thermal analysis results. The results suggest that the thermal analysis technology could be used as an effective and rapid tool to characterize the encapsulation properties of the novel anticancer HA-SN complex.
C1 [Wang, Fang; Zhou, Lin; Zhou, Jiahong; Gu, Xiaotian; Feng, Yuying] Nanjing Normal Univ, Anal & Testing Ctr, Nanjing 210097, Jiangsu, Peoples R China.
   [Wang, Fang; Zhou, Jiahong; Gu, Xiaotian; Feng, Yuying] Nanjing Normal Univ, Jiangsu Testing Serv Ctr Biomed Mat, Nanjing 210097, Jiangsu, Peoples R China.
   [Zhou, Lin] China Pharmaceut Univ, Complex Presect CMM, Nanjing 210038, Jiangsu, Peoples R China.
RP Wang, F (reprint author), Nanjing Normal Univ, Anal & Testing Ctr, Nanjing 210097, Jiangsu, Peoples R China.
EM wangfang@njnu.edu.cn
FU Natural Science Foundation of China [20603018]; Natural Science
   Foundation of Jiangsu Province of China [BM2007132]
FX This research was supported by the grants received from the Natural
   Science Foundation of China (No. 20603018), and the Natural Science
   Foundation of Jiangsu Province of China (No. BM2007132)
CR *ASTM, E79481 ASTM
   *ASTM, E91483 ASTM
   Bellavia G, 2009, J THERM ANAL CALORIM, V95, P699, DOI 10.1007/s10973-008-9490-4                                                       
   DIWU ZJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P609
   Falk H., 1999, ANGEW CHEM INT EDIT, V38, P3116
   Gabelica Z, 2009, J THERM ANAL CALORIM, V95, P445, DOI 10.1007/s10973-008-9256-z
   Giancola C, 2008, J THERM ANAL CALORIM, V91, P79, DOI 10.1007/s10973-007-8436-6
   Rodriguez JGI, 2007, J THERM ANAL CALORIM, V87, P45, DOI 10.1007/s10973-006-7805-x
   Khvedelidze M, 2010, J THERM ANAL CALORIM, V99, P337, DOI 10.1007/s10973-009-0137-x
   Lee-Sullivan P, 2005, J THERM ANAL CALORIM, V81, P169, DOI 10.1007/s10973-005-0763-x
   Lopez C, 2009, J THERM ANAL CALORIM, V98, P29, DOI 10.1007/s10973-009-0183-4
   Markovska IG, 2007, J THERM ANAL CALORIM, V89, P809, DOI 10.1007/s10973-007-8294-2
   Miller GG, 1997, PHOTOCHEM PHOTOBIOL, V65, P714, DOI 10.1111/j.1751-1097.1997.tb01915.x
   Pentak D, 2008, J THERM ANAL CALORIM, V93, P471, DOI 10.1007/s10973-007-8653-z
   ROY I, 2003, J AM CHEM SOC, V125, P7861
   Sestak J, 2007, J THERM ANAL CALORIM, V88, P411, DOI 10.1007/s10973-006-8232-8
   WENDLANDT WW, 1985, THERMAL ANAL
   Yan F, 2003, PHOTOCHEM PHOTOBIOL, V78, P587, DOI 10.1562/0031-8655(2003)078<0587:TEOMIS>2.0.CO;2
   Yavlovich A, 2009, J THERM ANAL CALORIM, V98, P97, DOI 10.1007/s10973-009-0228-8
   YUYING F, 2005, CHIN J APPL CHEM, V22, P895
   ZHONGMIN L, 1997, GEN ANAL MEASUREMENT
   Zhou JH, 2007, SPECTROSC-INT J, V21, P235, DOI 10.1155/2007/503537                                                             
   Zhou JH, 2006, SPECTROSC-INT J, V20, P269, DOI 10.1155/2006/152816                                                             
   Zhou JH, 2005, J PHYS CHEM B, V109, P19529, DOI 10.1021/jp0522563
NR 24
TC 7
Z9 8
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-6150
J9 J THERM ANAL CALORIM
JI J. Therm. Anal. Calorim.
PD OCT
PY 2010
VL 102
IS 1
BP 69
EP 74
DI 10.1007/s10973-009-0630-2
PG 6
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 648PD
UT WOS:000281705500012
DA 2018-01-05
ER

PT J
AU Ganta, S
   Deshpande, D
   Korde, A
   Amiji, M
AF Ganta, Srinivas
   Deshpande, Dipti
   Korde, Anisha
   Amiji, Mansoor
TI A review of multifunctional nanoemulsion systems to overcome oral and
   CNS drug delivery barriers
SO MOLECULAR MEMBRANE BIOLOGY
LA English
DT Review
DE Oral; blood-brain barrier; P-glycoprotein; cytochrome P450;
   nanotechnology; multifunctional nanoemulsions
ID BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE PROTEINS; NUCLEOSIDE
   TRANSPORTER FAMILY; ANTI-HIV DRUGS; P-GLYCOPROTEIN; TIGHT JUNCTION;
   CHOROID-PLEXUS; IN-VITRO; EFFLUX TRANSPORTERS; TUMOR-CELLS
AB The oral and central nervous systems (CNS) present a unique set of barriers to the delivery of important diagnostic and therapeutic agents. Extensive research over the past few years has enabled a better understanding of these physical and biological barriers based on tight cellular junctions and expression of active transporters and metabolizing enzymes at the luminal surfaces of the gastrointestinal (GI) tract and the blood-brain barrier (BBB). This review focuses on the recent understanding of transport across the GI tract and BBB and the development of nanotechnology-based delivery strategies that can enhance bioavailability of drugs. Multifunctional lipid nanosystems, such as oil-in-water nanoemulsions, that integrate enhancement in permeability, tissue and cell targeting, imaging, and therapeutic functions are especially promising. Based on strategic choice of edible oils, surfactants and additional surface modifiers, and different types of payloads, rationale design of multifunctional nanoemulsions can serve as a safe and effective delivery vehicle across oral and CNS barriers.
C1 [Ganta, Srinivas; Deshpande, Dipti; Korde, Anisha; Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Amiji, M (reprint author), Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, 110 Mugar Life Sci Bldg, Boston, MA 02115 USA.
EM m.amiji@neu.edu
RI Amiji, Mansoor/A-4365-2014
OI Amiji, Mansoor/0000-0001-6170-881X
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Abbott NJ, 2005, CELL MOL NEUROBIOL, V25, P5, DOI 10.1007/s10571-004-1374-y
   Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x                                                
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2
   Bali V, 2010, J DRUG TARGET, V18, P506, DOI 10.3109/10611860903548362
   Barchet TM, 2009, EXPERT OPIN DRUG DEL, V6, P211, DOI 10.1517/17425240902758188
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Begley DJ, 2003, PROG DRUG RES, V61, P39
   Benet LZ, 2004, INT J PHARM, V277, P3, DOI 10.1016/j.ijpharm.2002.12.002
   Brasnjevic I, 2009, PROG NEUROBIOL, V87, P212, DOI 10.1016/j.pneurobio.2008.12.002
   Buggins TR, 2007, ADV DRUG DELIVER REV, V59, P1482, DOI 10.1016/j.addr.2007.08.017
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   CORNFORD EM, 1985, MOL PHYSIOL, V7, P219
   Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054
   Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122
   Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005
   Deli MA, 2009, BBA-BIOMEMBRANES, V1788, P892, DOI 10.1016/j.bbamem.2008.09.016
   Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X                                                   
   Edmond J, 2001, J MOL NEUROSCI, V16, P181, DOI 10.1385/JMN:16:2-3:181
   Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479
   Eyal S, 2009, PHARMACOL THERAPEUT, V123, P80, DOI 10.1016/j.pharmthera.2009.03.017
   Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Florence Alexander T, 2005, Drug Discov Today Technol, V2, P75, DOI 10.1016/j.ddtec.2005.05.019
   Fricker G, 2004, PHARMACOLOGY, V70, P169, DOI 10.1159/000075545
   GANTA S, 2008, PERMEABILITY ASSESSM
   Ganta S, 2008, INT J PHARM, V360, P115, DOI 10.1016/j.ijpharm.2008.04.027
   Ganta S, 2008, J BIOMED NANOTECHNOL, V4, P165, DOI 10.1166/jbn.2008.014
   Ganta S, 2010, J PHARM SCI-US, V99, P4630, DOI 10.1002/jps.22157
   Ganta S, 2010, J DRUG TARGET, V18, P125, DOI 10.3109/10611860903244199
   Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j
   Gindy ME, 2009, EXPERT OPIN DRUG DEL, V6, P865, DOI 10.1517/17425240902932908
   Goldberg M, 2003, NAT REV DRUG DISCOV, V2, P289, DOI 10.1038/nrd1067
   Golden PL, 2003, J PHARM SCI-US, V92, P1739, DOI 10.1002/jps.10424
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y
   Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y
   Hawkins BT, 2008, CURR TOP DEV BIOL, V80, P277, DOI 10.1016/S0070-2153(07)80007-X
   Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y
   HOCHMAN J, 1994, J CONTROL RELEASE, V29, P253, DOI 10.1016/0168-3659(94)90072-8                                                    
   Hubensack M, 2008, J CANCER RES CLIN, V134, P597, DOI 10.1007/s00432-007-0323-9
   Jabr-Milane LS, 2008, CANCER TREAT REV, V34, P592, DOI 10.1016/j.ctrv.2008.04.003
   Jeffrey P, 2010, NEUROBIOL DIS, V37, P33, DOI 10.1016/j.nbd.2009.07.033
   Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9
   Kim KY, 2007, NANOMED-NANOTECHNOL, V3, P103, DOI 10.1016/j.nano.2006.12.002
   Koning GA, 2007, ANTI-CANCER AGENT ME, V7, P425
   Kusuhara H., 2005, NEURORX, V2, P73, DOI 10.1007/BF03206644
   La Guardia M, 2005, PANMINERVA MED, V47, P245
   Lennernas H, 2005, J PHARM PHARMACOL, V57, P273, DOI 10.1211/022357055263
   Levchenko TS, 2002, INT J PHARM, V240, P95, DOI 10.1016/S0378-5173(02)00129-1
   Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006
   Loscher W, 2005, NEURORX, V2, P86, DOI 10.1007/BF03206645
   Luurtsema G, 2004, MOL IMAGING BIOL, V6, P306, DOI 10.1016/j.mibio.2004.06.008
   Madhusudhan B, 2007, J DRUG TARGET, V15, P154, DOI 10.1080/10611860601141150
   Malingre MM, 2001, INVEST NEW DRUG, V19, P155, DOI 10.1023/A:1010635000879                                                         
   Minuesa G, 2008, J PHARMACOL EXP THER, V324, P558, DOI 10.1124/jpet.107.131482
   Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947
   Nies AT, 2007, CANCER LETT, V254, P11, DOI 10.1016/j.canlet.2006.12.023
   Nishioka Y, 2001, ADV DRUG DELIVER REV, V47, P55, DOI 10.1016/S0169-409X(00)00121-6
   Oyewumi MO, 2003, BIOCONJUGATE CHEM, V14, P404, DOI 10.1021/bc0340013
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Pardridge WM, 1999, J NEUROVIROL, V5, P556, DOI 10.3109/13550289909021285
   Pardridge WM, 2002, NAT REV DRUG DISCOV, V1, P131, DOI 10.1038/nrd725
   Patlolla RR, 2008, J DRUG TARGET, V16, P269, DOI [10.1080/10611860801945400, 10.1080/10611860801945400 ]
   Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x
   Potschka H, 2010, PHARMACOL THERAPEUT, V125, P118, DOI 10.1016/j.pharmthera.2009.10.004
   Rajagopal A, 2003, MOL BIOL CELL, V14, P3389, DOI 10.1091/mbc.E02-11-0704
   Redzic ZB, 2005, J NEUROCHEM, V94, P1420, DOI 10.1111/j.1471-4159.2005.03312.x
   Salama NN, 2006, ADV DRUG DELIVER REV, V58, P15, DOI 10.1016/j.addr.2006.01.003
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007
   Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x
   Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9                                                   
   Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031
   Soontornmalai A, 2006, NEUROSCIENCE, V138, P159, DOI 10.1016/j.neuroscience.2005.11.011
   Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89
   Straubinger RM, 2004, ANTICANCER RES, V24, P397
   Taogoshi T, 2005, J PHARM PHARMACOL, V57, P61, DOI 10.1211/0022357055173
   Thummel KE, 1997, ADV DRUG DELIVER REV, V27, P99, DOI 10.1016/S0169-409X(97)00039-2
   TIWARI S, 2006, J NANOSCI NANOTECHNO, V9, P3215
   TIWARI S, 2007, NANOTECHNOLOGY CANC
   Tiwari S, 2006, J BIOMED NANOTECHNOL, V2, P217, DOI 10.1166/jbn.2006.038
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4
   van Asperen J, 1998, CLIN CANCER RES, V4, P2293
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wickline SA, 2003, CIRCULATION, V107, P1092, DOI 10.1161/01.CIR.0000059651.17045.77
   Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8                                                   
   Wolburg H, 2001, NEUROSCI LETT, V307, P77, DOI 10.1016/S0304-3940(01)01927-9
   Yang XB, 2000, BIOSCIENCE, V50, P476, DOI 10.1641/0006-3568(2000)050[0476:AMAGT]2.0.CO;2                                  
   Zhang WX, 2007, DRUG METAB DISPOS, V35, P110, DOI 10.1124/dmd.106.011072
   Zhang YC, 2001, CLIN PHARMACOKINET, V40, P159, DOI 10.2165/00003088-200140030-00002
NR 98
TC 32
Z9 32
U1 2
U2 33
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0968-7688
J9 MOL MEMBR BIOL
JI Mol. Membr. Biol.
PD OCT
PY 2010
VL 27
IS 7
BP 260
EP 273
DI 10.3109/09687688.2010.497971
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 672NE
UT WOS:000283591200005
PM 20929336
DA 2018-01-05
ER

PT J
AU Simons, K
   Gerl, MJ
AF Simons, Kai
   Gerl, Mathias J.
TI Revitalizing membrane rafts: new tools and insights
SO NATURE REVIEWS MOLECULAR CELL BIOLOGY
LA English
DT Review
ID T-CELL-RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS;
   SINGLE-MOLECULE TRACKING; HUMAN-IMMUNODEFICIENCY-VIRUS; SHOTGUN
   MASS-SPECTROMETRY; PLASMA-MEMBRANE; LIPID RAFTS; PHASE-SEPARATION;
   EPITHELIAL-CELLS; FLUORESCENCE CORRELATION
AB Ten years ago, we wrote a Review on lipid rafts and signalling in the launch issue of Nature Reviews Molecular Cell Biology. At the time, this field was suffering from ambiguous methodology and imprecise nomenclature. Now, new techniques are deepening our insight into the dynamics of membrane organization. Here, we discuss how the field has matured and present an evolving model in which membranes are occupied by fluctuating nanoscale assemblies of sphingolipids, cholesterol and proteins that can be stabilized into platforms that are important in signalling, viral infection and membrane trafficking.
C1 [Simons, Kai; Gerl, Mathias J.] Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany.
RP Simons, K (reprint author), Max Planck Inst Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.
EM simons@mpi-cbg.de; gerl@mpi-cbg.de
OI Simons, Kai/0000-0002-9231-9996
FU EU [LSHB-CT2007-037, 740]; DFG [Schwerpunktprogramm 1175]; BMBF
   [0313,827, 03FO1212]
FX We thank H. He for critically reading the manuscript and the members of
   the K. S. laboratory for input, especially D. Lingwood and I. Levental.
   Work in the K. S. laboratory was supported by the EUFP6 PRISM grant
   LSHB-CT2007-037,740, DFG Schwerpunktprogramm 1175, the BMBF BioChance
   Plus grant 0313,827 and the BMBF ForMaT grant 03FO1212.
CR Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Andrews NL, 2008, NAT CELL BIOL, V10, P955, DOI 10.1038/ncb1755
   Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043                                                           
   Baumgart T, 2007, P NATL ACAD SCI USA, V104, P3165, DOI 10.1073/pnas.0611357104
   Bhagatji P, 2009, J CELL BIOL, V186, P615, DOI 10.1083/jcb.200903102
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182
   Castillon GA, 2009, TRAFFIC, V10, P186, DOI 10.1111/j.1600-0854.2008.00857.x
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Chen Y, 2009, J CELL SCI, V122, P3966, DOI 10.1242/jcs.049346
   Collins MD, 2008, P NATL ACAD SCI USA, V105, P124, DOI 10.1073/pnas.0702970105
   Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005
   Davis MM, 2007, ANNU REV IMMUNOL, V25, P681, DOI 10.1146/annurev.immunol.24.021605.090600
   Day CA, 2009, BBA-BIOMEMBRANES, V1788, P245, DOI 10.1016/j.bbamem.2008.10.024
   Dennis EA, 2009, P NATL ACAD SCI USA, V106, P2089, DOI 10.1073/pnas.0812636106
   Devaux PF, 2004, TRAFFIC, V5, P241, DOI 10.1111/j.1600-0854.2004.0170.x
   Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0                                                   
   Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009
   Dunne PD, 2009, BIOPHYS J, V97, pL5, DOI 10.1016/j.bpj.2009.05.046
   Dupuy AD, 2008, P NATL ACAD SCI USA, V105, P2848, DOI 10.1073/pnas.0712379105
   Eggeling C, 2009, NATURE, V457, P1159, DOI 10.1038/nature07596
   Ejsing CS, 2006, ANAL CHEM, V78, P6202, DOI 10.1021/ac060545x
   Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106
   Elson EL, 2010, ANNU REV BIOPHYS, V39, P207, DOI 10.1146/annurev.biophys.093008.131238
   Ewers H, 2010, NAT CELL BIOL, V12, P11, DOI 10.1038/ncb1999
   Feigenson GW, 2006, NAT CHEM BIOL, V2, P560, DOI 10.1038/nchembio1106-560
   Fujita M, 2006, MOL BIOL CELL, V17, P834, DOI 10.1091/mbc.E05-05-0443
   Fujita M, 2006, MOL BIOL CELL, V17, P5253, DOI 10.1091/mbc.E06-08-0715
   Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103
   Goswami D, 2008, CELL, V135, P1085, DOI 10.1016/j.cell.2008.11.032
   Grassme H, 2007, PROG LIPID RES, V46, P161, DOI 10.1016/j.plipres.2007.03.002
   Gupta N, 2006, NAT IMMUNOL, V7, P625, DOI 10.1038/ni1337
   Hammond AT, 2005, P NATL ACAD SCI USA, V102, P6320, DOI 10.1073/pnas.0405654102
   Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925
   HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297                                                           
   He HT, 2008, EMBO REP, V9, P525, DOI 10.1038/embor.2008.78
   Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395
   Honerkamp-Smith AR, 2009, BBA-BIOMEMBRANES, V1788, P53, DOI 10.1016/j.bbamem.2008.09.010
   Huang J, 2010, NATURE, V464, P932, DOI 10.1038/nature08944
   Huppa JB, 2010, NATURE, V463, P963, DOI 10.1038/nature08746
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7
   James JR, 2007, P NATL ACAD SCI USA, V104, P17662, DOI 10.1073/pnas.0700411104
   Johnson SA, 2010, BBA-BIOMEMBRANES, V1798, P1427, DOI 10.1016/j.bbamem.2010.03.009
   Johnston LJ, 2007, LANGMUIR, V23, P5886, DOI 10.1021/la070108t
   JORGENSEN K, 1995, BIOPHYS J, V69, P942, DOI 10.1016/S0006-3495(95)79968-4                                                   
   Kahya N, 2006, MOL MEMBR BIOL, V23, P29, DOI 10.1080/09687860500489099
   Kaiser HJ, 2009, P NATL ACAD SCI USA, V106, P16645, DOI 10.1073/pnas.0908987106
   Kaizuka Y, 2007, P NATL ACAD SCI USA, V104, P20296, DOI 10.1073/pnas.0710258105
   Kaizuka Y, 2009, J CELL BIOL, V185, P521, DOI 10.1083/jcb.200809136
   Kajiwara K, 2008, MOL BIOL CELL, V19, P2069, DOI 10.1091/mbc.E07-08-0740
   Kalvodova L, 2009, J VIROL, V83, P7996, DOI 10.1128/JVI.00635-09
   Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170
   Kenworthy AK, 2008, EMBO REP, V9, P531, DOI 10.1038/embor.2008.92
   Kholodenko BN, 2010, NAT REV MOL CELL BIO, V11, P414, DOI 10.1038/nrm2901
   Klemm RW, 2009, J CELL BIOL, V185, P601, DOI 10.1083/jcb.200901145
   Klose C, 2010, J BIOL CHEM, V285, P30224, DOI 10.1074/jbc.M110.123554
   Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x
   Lagerholm BC, 2005, ANNU REV PHYS CHEM, V56, P309, DOI 10.1146/annurev.physchem.56.092503.141211
   Lasserre R, 2008, NAT CHEM BIOL, V4, P538, DOI 10.1038/nchembio.103
   Lenne PF, 2006, EMBO J, V25, P3245, DOI 10.1038/sj.emboj.7601214
   Levental I, 2009, BIOCHEM J, V424, P163, DOI 10.1042/BJ20091283
   Lichtenberg D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/j.tibs.2005.06.004
   Lillemeier BF, 2010, NAT IMMUNOL, V11, P90, DOI 10.1038/ni.1832
   Lillemeier BF, 2006, P NATL ACAD SCI USA, V103, P18992, DOI 10.1073/pnas.0609009103
   Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n                                                               
   Lingwood D, 2008, P NATL ACAD SCI USA, V105, P10005, DOI 10.1073/pnas.0804374105
   Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Lorizate M, 2009, J BIOL CHEM, V284, P22238, DOI 10.1074/jbc.M109.029256
   McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259
   Meder D, 2006, P NATL ACAD SCI USA, V103, P329, DOI 10.1073/pnas.0509885103
   Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626
   Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103
   Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Niemela PS, 2010, J AM CHEM SOC, V132, P7574, DOI 10.1021/ja101481b
   Nika K, 2010, IMMUNITY, V32, P766, DOI 10.1016/j.immuni.2010.05.011
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Pinaud F, 2009, TRAFFIC, V10, P691, DOI 10.1111/j.1600-0854.2009.00902.x
   Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2                    
   Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997
   Proszynski TJ, 2005, P NATL ACAD SCI USA, V102, P17981, DOI 10.1073/pnas.0509107102
   Reynwar BJ, 2007, NATURE, V447, P461, DOI 10.1038/nature05840
   Romer W, 2007, NATURE, V450, P670, DOI 10.1038/nature05996
   Romer W, 2010, CELL, V140, P540, DOI 10.1016/j.cell.2010.01.010
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Saad JS, 2006, P NATL ACAD SCI USA, V103, P11364, DOI 10.1073/pnas.0602818103
   Sahl SJ, 2010, P NATL ACAD SCI USA, V107, P6829, DOI 10.1073/pnas.0912894107
   Sandvig K, 2004, INT J MED MICROBIOL, V293, P483, DOI 10.1078/1438-4221-00294                                                         
   Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038
   SCHERMELLEH L, J CELL BIOL, V190, P165
   Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596
   Seminario MC, 2008, IMMUNOL REV, V221, P90, DOI 10.1111/j.1600-065X.2008.00593.x
   Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9                                                   
   SHARPE HJ, CELL, V142, P158
   Shaw AS, 2006, NAT IMMUNOL, V7, P1139, DOI 10.1038/ni1405
   Shevchenko A, 2010, NAT REV MOL CELL BIO, V11, P593, DOI 10.1038/nrm2934
   Shroff H, 2008, NAT METHODS, V5, P417, DOI 10.1038/NMETH.1202
   Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803                                        
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001
   Simons M, 2007, CURR OPIN NEUROBIOL, V17, P533, DOI 10.1016/j.conb.2007.08.003
   SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720
   STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635
   Suzuki KGN, 2007, J CELL BIOL, V177, P731, DOI 10.1083/jcb.200609175                                                           
   Suzuki KGN, 2007, J CELL BIOL, V177, P717, DOI 10.1083/jcb.200609174
   Tong J, 2008, BIOPHYS J, V94, P125, DOI 10.1529/biophysj.107.110536
   VANDERMERWE, 2010, NAT IMMUNOL, V11, P51
   VANMEE, 2008, NAT REV MOL CELL BIO, V9, P112
   VANZANTEN, 2010, BBA-BIOMEMBRANES, V1798, P777
   Veatch SL, 2008, ACS CHEM BIOL, V3, P287, DOI 10.1021/cb800012x
   Veatch SL, 2007, P NATL ACAD SCI USA, V104, P17650, DOI 10.1073/pnas.0703513104
   Viola A, 2007, NAT REV IMMUNOL, V7, P889, DOI 10.1038/nri2193
   Vyas N, 2008, CELL, V133, P1214, DOI 10.1016/j.cell.2008.05.026
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   Wassall SR, 2009, BBA-BIOMEMBRANES, V1788, P24, DOI 10.1016/j.bbamem.2008.10.011
   Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200
   Wawrezinieck L, 2005, BIOPHYS J, V89, P4029, DOI 10.1529/biophysj.105.067959
   Wenger J, 2007, BIOPHYS J, V92, P913, DOI 10.1529/biophysj.106.096586
   Windschiegl B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006238
   Zech T, 2009, EMBO J, V28, P466, DOI 10.1038/emboj.2009.6
   Zhong LY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005945
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
NR 125
TC 665
Z9 671
U1 10
U2 244
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-0072
J9 NAT REV MOL CELL BIO
JI Nat. Rev. Mol. Cell Biol.
PD OCT
PY 2010
VL 11
IS 10
BP 688
EP 699
DI 10.1038/nrm2977
PG 12
WC Cell Biology
SC Cell Biology
GA 654FB
UT WOS:000282152800012
PM 20861879
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Syed, MA
   Pervaiz, S
AF Syed, Muhammad Ali
   Pervaiz, Saima
TI Advances in Aptamers
SO OLIGONUCLEOTIDES
LA English
DT Review
ID FUNCTIONALIZED GOLD NANOPARTICLES; HIV-1 REVERSE-TRANSCRIPTASE; MOUSE
   PRION PROTEIN; RNA APTAMER; MICROARRAY TECHNOLOGY; SIRNA CHIMERAS; DNA
   APTAMERS; CELL-SELEX; APTASENSORS; BIOSENSORS
AB Aptamers are nucleic acid sequences synthesized through in vitro selection and amplification technique, possessing a broader range of applications in therapeutics, biosensing, diagnostics, and research. Aptamers offer a number of advantages over their antibodies counterpart, one of them is their ability to undergo chemical derivatization to increase their life in the body fluids and bioavailability in animals. Although aptamers were discovered in 1990s, they have become one of the most widely investigated molecules, with a huge number of publications in the last decade. This article presents an overview of the advancements that have been made in aptamers. We mainly focused on articles published since 2005.
C1 [Syed, Muhammad Ali] Comsats Inst Informat Technol, Dept Biosci, Islamabad 44000, Pakistan.
   [Pervaiz, Saima] Pir Mehr Ali Shah Arid Agr Univ, Dept Zool, Rawalpindi, Pakistan.
RP Syed, MA (reprint author), Comsats Inst Informat Technol, Dept Biosci, Chak Shehzad Campus,Pk Rd, Islamabad 44000, Pakistan.
EM mirwah2000@yahoo.de
CR Bouchard PR, 2010, ANNU REV PHARMACOL, V50, P237, DOI 10.1146/annurev.pharmtox.010909.105547
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   Burmeister PE, 2006, OLIGONUCLEOTIDES, V16, P337, DOI 10.1089/oli.2006.16.337
   Cao C, 2007, BIOSENS BIOELECTRON, V22, P1874, DOI 10.1016/j.bios.2006.07.021
   Cao XX, 2009, NUCLEIC ACIDS RES, V37, P4621, DOI 10.1093/nar/gkp489
   Cao ZH, 2009, ANGEW CHEM INT EDIT, V48, P6494, DOI 10.1002/anie.200901452
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Chen F, 2007, BIOCHEM BIOPH RES CO, V357, P743, DOI 10.1016/j.bbrc.2007.04.007
   Chen XL, 2009, ANAL CHEM, V81, P7009, DOI 10.1021/ac9011073
   Cho EJ, 2006, ANAL CHIM ACTA, V564, P82, DOI 10.1016/j.aca.2005.12.038
   Chou SH, 2005, TRENDS BIOCHEM SCI, V30, P231, DOI 10.1016/j.tibs.2005.03.004
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Collett JR, 2005, METHODS, V37, P4, DOI 10.1016/j.ymeth.2005.05.009
   DAPIEVE C, 2008, BREAST CANCER RES, V10, pS1
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Dausse E, 2009, CURR OPIN PHARMACOL, V9, P602, DOI 10.1016/j.coph.2009.07.006
   Degefa TH, 2009, ELECTROCHIM ACTA, V54, P6788, DOI 10.1016/j.electacta.2009.06.082
   DeStefano JJ, 2008, OLIGONUCLEOTIDES, V18, P133, DOI 10.1089/oli.2008.0103
   Dey AK, 2005, RNA, V11, P873, DOI 10.1261/rna.7205405
   Dobrovolsky AB, 2009, B EXP BIOL MED+, V148, P33, DOI 10.1007/s10517-009-0627-7
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Fischer N, 2007, CURR OPIN CHEM BIOL, V11, P316, DOI 10.1016/j.cbpa.2007.05.017
   Frauendorf C, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng034
   Gilch S, 2009, CELL MOL LIFE SCI, V66, P2445, DOI 10.1007/s00018-009-0031-5
   Gopinath SCB, 2006, J GEN VIROL, V87, P479, DOI 10.1099/vir.0.81508-0
   Gopinath SCB, 2008, THROMB RES, V122, P838, DOI 10.1016/j.thromres.2007.10.022
   Guo KT, 2008, INT J MOL SCI, V9, P668, DOI 10.3390/ijms9040668
   Hall DA, 2007, MECH AGEING DEV, V128, P161, DOI 10.1016/j.mad.2006.11.021
   Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916
   Hasegawa H, 2008, SENSORS-BASEL, V8, P1090, DOI 10.3390/s8021090                                                                
   Held DM, 2006, J BIOL CHEM, V281, P25712, DOI 10.1074/jbc.M604460200
   Huang YF, 2009, J NANOPART RES, V11, P775, DOI 10.1007/s11051-008-9424-x
   Huang YF, 2008, ANAL CHEM, V80, P567, DOI 10.1021/ac702322j
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Javier DJ, 2008, BIOCONJUGATE CHEM, V19, P1309, DOI 10.1021/bc8001248
   Joshi R, 2009, MOL CELL PROBE, V23, P20, DOI 10.1016/j.mcp.2008.10.006
   Lam BJ, 2009, NAT BIOTECHNOL, V27, P288, DOI 10.1038/nbt.1528
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   LEE JF, 2004, NUCLEIC ACIDS RES, V32, pD99
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Leva S, 2002, CHEM BIOL, V9, P351, DOI 10.1016/S1074-5521(02)00111-4
   Li HH, 2008, CHINESE CHEM LETT, V19, P1108, DOI 10.1016/j.cclet.2008.06.010
   Li N, 2008, NUCLEIC ACIDS RES, V36, P6739, DOI 10.1093/nar/gkn775
   Li Y, 2006, NUCLEIC ACIDS RES, V34, P6416, DOI 10.1093/nar/gkl738
   Lim YC, 2009, COMM COM INF SC, V51, P118, DOI 10.1007/978-3-642-04962-0_14
   Lupold SE, 2002, CANCER RES, V62, P4029
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4
   Mashima T, 2009, NUCLEIC ACIDS RES, V37, P6249, DOI 10.1093/nar/gkp647
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365
   Mercey R, 2006, ARCH VIROL, V151, P2197, DOI 10.1007/s00705-006-0790-3
   Missailidis S, 2005, J IMMUNOL METHODS, V296, P45, DOI 10.1016/j/jim.2004.10.011
   Mok W, 2008, SENSORS-BASEL, V8, P7050, DOI 10.3390/s8117050
   Nirnjee SM, 2005, TRENDS CARDIOVAS MED, V15, P41
   Nitsche A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-48
   Ogasawara D, 2007, PRION, V1, P248, DOI 10.4161/pri.1.4.5803                                                            
   Oney S, 2009, NAT MED, V15, P1224, DOI 10.1038/nm.1990
   Pendergrast P Shannon, 2005, J Biomol Tech, V16, P224
   Phillips JA, 2008, ANAL CHIM ACTA, V621, P101, DOI 10.1016/j.aca.2008.05.031
   PIEVE CD, 2009, BIOCONJUG CHEM, V21, P169
   PROSKE D, 2010, CHEM BIOCH, V3, P17
   Pultar J, 2009, BIOSENS BIOELECTRON, V24, P1456, DOI 10.1016/j.bios.2008.08.052
   Radko SP, 2007, BIOCHEM MOSC-SUPPL S, V1, P198, DOI 10.1134/S1990750807030043
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   Sassolas A, 2009, ELECTROANAL, V21, P1237, DOI 10.1002/elan.200804554
   Sekiya S, 2006, J BIOCHEM, V139, P383, DOI 10.1093/jb.mvj046
   Semizarov D, 2004, NUCLEIC ACIDS RES, V32, P3836, DOI 10.1093/nar/gkh714
   Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Strehlitz B, 2008, SENSORS-BASEL, V8, P4296, DOI 10.3390/s8074296
   Tang ZW, 2009, CLIN CHEM, V55, P813, DOI 10.1373/clinchem.2008.113514
   Thiel KW, 2009, OLIGONUCLEOTIDES, V19, P209, DOI 10.1089/oli.2009.0199
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Torres-Chavolla E, 2009, BIOSENS BIOELECTRON, V24, P3175, DOI 10.1016/j.bios.2008.11.010
   Ulrich H, 2009, CYTOM PART A, V75A, P727, DOI 10.1002/cyto.a.20766
   Vallian S, 2007, RES PHARM SCI, V2, P59
   VOLLER A, 1978, J CLIN PATHOL, V31, P507, DOI 10.1136/jcp.31.6.507
   Wang Da-peng, 2009, Zhongguo Yaolixue Tongbao, V25, P124
   Wei F, 2009, ANAL BIOANAL CHEM, V393, P1943, DOI 10.1007/s00216-009-2687-y
   Willner I, 2007, ANGEW CHEM INT EDIT, V46, P6408, DOI 10.1002/anie.200604524
   Xu H, 2009, ANAL CHEM, V81, P669, DOI 10.1021/ac8020592
   Xu Y, 2009, ELECTROANAL, V21, P1251, DOI 10.1002/elan.200804561
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou Jiehua, 2010, Silence, V1, P4, DOI 10.1186/1758-907X-1-4
NR 85
TC 53
Z9 60
U1 6
U2 45
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1545-4576
EI 1557-8526
J9 OLIGONUCLEOTIDES
JI Oligonucleotides
PD OCT
PY 2010
VL 20
IS 5
BP 215
EP 224
DI 10.1089/oli.2010.0234
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 671GU
UT WOS:000283489700001
PM 20677985
DA 2018-01-05
ER

PT J
AU Pandey, KK
   Bera, S
   Vora, AC
   Grandgenett, DP
AF Pandey, Krishan K.
   Bera, Sibes
   Vora, Ajaykumar C.
   Grandgenett, Duane P.
TI Physical Trapping of HIV-1 Synaptic Complex by Different Structural
   Classes of Integrase Strand Transfer Inhibitors
SO BIOCHEMISTRY
LA English
DT Article
ID VIRUS TYPE-1 INTEGRASE; CONCERTED INTEGRATION; IN-VITRO; ANTIRETROVIRAL
   ACTIVITY; FLEXIBLE LOOP; RALTEGRAVIR; RESISTANT; DNA; INFECTION; BINDING
AB Raltegravir is an FDA approved inhibitor directed against human immunodeficiency virus type 1 (HIV-1) integrase (IN). in this study, we investigated the mechanisms associated with multiple strand transfer inhibitors capable of inhibiting concerted integration by HIV-1 IN. The results show raltegravir, elvitegravir, MK-2048, RDS 1997, and RDS 2197 all appear to encompass a common inhibitory mechanism by modifying IN viral DNA interactions. These structurally different inhibitors bind to and inactivate the synaptic complex, an intermediate in the concerted integration pathway in vitro. The inhibitors physically trap the synaptic complex, thereby preventing target DNA binding and thus concerted integration. The efficiency of a particular inhibitor to trap the synaptic complex observed on native agarose gels correlated with its potency for inhibiting the concerted integration reaction, defined by IC50 values for each inhibitor. At low nanomolar concentrations (<50 nM), raltegravir displayed a time-dependent inhibition of concerted integration, a property associated with slow-binding inhibitors. Studies of raltegravir-resistant IN mutants N155H and Q148H without inhibitors demonstrated that their capacity to assemble the synaptic complex and promote concerted integration was similar to their reported virus replication capacities. The concerted integration activity of Q148H showed a higher cross-resistance to raltegravir than observed with N155H, providing evidence as to why the Q148H pathway with secondary mutations is the predominant pathway upon prolonged treatment. Notably, MK-2048 is equally potent against wild-type IN and raltegravir-resistant IN mutant N155H, suggesting this inhibitor may bind similarly within their drug-binding pockets.
C1 [Pandey, Krishan K.; Bera, Sibes; Vora, Ajaykumar C.; Grandgenett, Duane P.] St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63104 USA.
RP Pandey, KK (reprint author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 1100 S Grand Blvd, St Louis, MO 63104 USA.
EM pandeykk@slu.edu
OI Pandey, Krishan/0000-0002-3973-9844
FU National Institute of Allergy and Infectious Diseases [R21AI081629];
   Saint Louis University
FX This work was supported in part. by National Institute of Allergy and
   Infectious Diseases Grant R21AI081629 and by Saint Louis University.
CR Bera S, 2009, J MOL BIOL, V389, P183, DOI 10.1016/j.jmb.2009.04.007
   Ceccherini-Silberstein F, 2009, AIDS REV, V11, P17
   Chen HM, 1999, J BIOL CHEM, V274, P17358, DOI 10.1074/jbc.274.24.17358
   Chen X, 2008, J MOL BIOL, V380, P504, DOI 10.1016/j.jmb.2008.04.054
   Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   COPELAND RA, 2005, EVALUATION ENZYME IN, P141
   Delelis O, 2010, ANTIMICROB AGENTS CH, V54, P491, DOI 10.1128/AAC.01075-09
   Delelis O, 2009, NUCLEIC ACIDS RES, V37, P1193, DOI 10.1093/nar/gkn1050
   DI SANTO R, 2006, J MED CHEM, V49, P1939
   DI SANTO R, 2008, J MED CHEM, V51, P4744
   Dicker IB, 2008, J BIOL CHEM, V283, P23599, DOI 10.1074/jbc.M804213200
   Engelman A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000046
   Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241
   Fransen S, 2009, J VIROL, V83, P11440, DOI 10.1128/JVI.01168-09
   Fransen S, 2009, ANTIMICROB AGENTS CH, V53, P4522, DOI 10.1128/AAC.00651-09
   Garvey EP, 2009, BIOCHEMISTRY-US, V48, P1644, DOI 10.1021/bi802141y
   Goethals O, 2008, J VIROL, V82, P10366, DOI 10.1128/JVI.00470-08
   Goffinet C, 2009, J VIROL, V83, P7706, DOI 10.1128/JVI.00683-09
   GRANDGENETT DP, 1993, J VIROL, V67, P2628
   Grandgenett DP, 2009, METHODS, V47, P229, DOI 10.1016/j.ymeth.2008.11.002
   GROBLER JA, 2009, 10 INT WORKSH CLIN P
   Hare S, 2009, VIRUSES-BASEL, V1, P780, DOI 10.3390/v1030780
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Johnson AA, 2006, J BIOL CHEM, V281, P461, DOI 10.1074/jbc.M511348200
   Kessl JJ, 2009, VIRUSES-BASEL, V1, P713, DOI 10.3390/v1030713
   Langley DR, 2008, BIOCHEMISTRY-US, V47, P13481, DOI 10.1021/bi801372d
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005
   Li M, 2009, METHODS, V47, P237, DOI 10.1016/j.ymeth.2009.02.001
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Marinello J, 2008, BIOCHEMISTRY-US, V47, P9345, DOI 10.1021/bi800791q
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   MCCOLL DJ, 2007, 16 INT DRUG RES WORK, pS11
   Metifiot M, 2010, BIOCHEMISTRY-US, V49, P3715, DOI 10.1021/bi100130f
   Mouscadet JF, 2009, J MOL RECOGNIT, V22, P480, DOI 10.1002/jmr.970
   MOUSCADET JF, 2010, DRUG RESIST IN PRESS
   Pandey KK, 2007, J VIROL, V81, P12189, DOI 10.1128/JVI.02863-06
   Pandey KK, 2007, J VIROL, V81, P3969, DOI 10.1128/JVI.02322-06
   Pandey Krishan K, 2008, Retrovirology (Auckl), V2, P11
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Pommier Yves, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P421
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002
   Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004
   VACCA J, 2007, 4 INT AIDS SOC IAS C
   WAI J, 2007, 14 C RETR OPP INF 25
   Wirden M, 2009, J ANTIMICROB CHEMOTH, V64, P1087, DOI 10.1093/jac/dkp310
   Witmer M, 2009, METHODS, V47, P277, DOI 10.1016/j.ymeth.2009.02.025
   Zahm JA, 2008, ANTIMICROB AGENTS CH, V52, P3358, DOI 10.1128/AAC.00271-08
NR 56
TC 15
Z9 15
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD SEP 28
PY 2010
VL 49
IS 38
BP 8376
EP 8387
DI 10.1021/bi100514s
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 650YT
UT WOS:000281891500015
PM 20799722
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhang, JA
   Fu, Y
   Li, G
   Nowaczyk, K
   Zhao, RY
   Lakowicz, JR
AF Zhang, Jian
   Fu, Yi
   Li, Ge
   Nowaczyk, Kazimierz
   Zhao, Richard Y.
   Lakowicz, Joseph R.
TI Direct observation to chemokine receptor 5 on T-lymphocyte cell surface
   using fluorescent metal nanoprobes
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Chemokine receptor 5 (CCR5); Monoclonal antibody (mAb); Alexa Fluor 680;
   mAb-metal complex; T-lymphocytic PM1 cell; Fluorescence cell image
ID SINGLE-MOLECULE; BREAST-CANCER; HIV-1; CCR5; PARTICLE; IMPACT
AB Chemokine receptor 5 (CCR5) is a cell surface protein required for HIV-1 infection. It is important to detect the amount and observe the spatial distribution of the CCR5 receptors on the cell surfaces. In this report, we describes the metal nanoparticles which were specially designed as molecular fluorescent probes for imaging of CCR5 receptors on the T-lymphocytic PM1 cell surfaces. These CCR5 monoclonal antibodies (mAbs) metal complexes were prepared by labeling mAbs with Alexa Fluor 680 followed by covalent binding the labeled mAbs on the 20 nm silver nanoparticles. Compared with the labeled mAbs without metal, the mAb-metal complexes were found to display enhanced emission intensity and shortened lifetime due to interactions between fluorophores and metal. The mAb-metal complexes were incubated with the PM1 cell lines. The confocal fluorescent intensity and lifetime cell images were recorded on single cells. It was observed that the mAb-metal complexes could be clearly distinguished from the cellular autofluorescence. By analyzing a pool of cell images, we observed that most CCR5 receptors appeared as clusters on the cell surfaces. The fluorophore-metal complexes developed in this report are generally useful for detection of cell surface receptors and provide a new class of probe to study the interaction between the CCR5 receptors with viral gp120 during HIV infections. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Zhang, Jian; Fu, Yi; Nowaczyk, Kazimierz; Lakowicz, Joseph R.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, Baltimore, MD 21201 USA.
   [Li, Ge; Zhao, Richard Y.] Univ Maryland, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21201 USA.
   [Zhao, Richard Y.] Univ Maryland, Sch Med, Dept Microbiol Immunol, Baltimore, MD 21201 USA.
   [Zhao, Richard Y.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
RP Zhang, JA (reprint author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, 725 W Lombard St, Baltimore, MD 21201 USA.
EM jian@cfs.bioment.umaryland.edu; rzhao@som.umaryland.edu
RI Nowaczyk, Kazimierz/J-8446-2013
FU NIH [EB009509, HG-002655, HG005090, EB006521, CA134386]
FX This research was supported by grants from NIH (EB009509, HG-002655,
   HG005090, EB006521, and CA134386).
CR BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001                                                             
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Hao E, 2004, J PHYS CHEM B, V108, P1224, DOI 10.1021/jp036301n
   Hawrysz DJ, 2000, NEOPLASIA, V2, P388, DOI 10.1038/sj.neo.7900118                                                          
   Heredia A, 2007, AIDS, V21, P1317, DOI 10.1097/QAD.0b013e32815278ea
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   JACQUES R, 2001, AIDS, V15, P1627
   Lakowicz JR, 2001, ANAL BIOCHEM, V298, P1, DOI 10.1006/abio.2001.5377
   Lakowicz JR, 2005, ANAL BIOCHEM, V337, P171, DOI 10.1016/j.ab.2004.11.026
   Lakowicz JR, 2006, PRINCIPLES FLUORESCE
   Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   Michalet X, 2006, CHEM REV, V106, P1785, DOI 10.1021/cr0404343
   Ntziachristos V, 2001, BREAST CANCER RES, V3, P41, DOI 10.1186/bcr269
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Smiley RD, 2006, CHEM REV, V106, P3080, DOI 10.1021/cr0502955
   Sokolov K, 1998, ANAL CHEM, V70, P3898, DOI 10.1021/ac9712310
   Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664
   Thompson DAD, 2002, J VIROL, V76, P3059, DOI 10.1128/JVI.76.6.3059-3064.2002
   VANDIJK, 2005, ACCOUNTS CHEM RES, V38, P594
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933                                                                    
   Zhang J, 2004, J PHYS CHEM B, V108, P12210, DOI 10.1021/jp037772c
   Zhang J, 2008, NANO LETT, V8, P1179, DOI 10.1021/nl080093z
   Zhang J, 2008, J PHYS CHEM C, V112, P18, DOI 10.1021/jp074938r
   Zhang J, 2009, ANAL CHEM, V81, P883, DOI 10.1021/ac801932m
NR 25
TC 7
Z9 8
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 10
PY 2010
VL 400
IS 1
BP 111
EP 116
DI 10.1016/j.bbrc.2010.08.020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 654EI
UT WOS:000282150900019
PM 20705055
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ristic, N
   Chin, MPS
AF Ristic, Natalia
   Chin, Mario P. S.
TI Mutations in matrix and SP1 repair the packaging specificity of a Human
   Immunodeficiency Virus Type 1 mutant by reducing the association of Gag
   with spliced viral RNA
SO RETROVIROLOGY
LA English
DT Article
ID DIMERIZATION INITIATION SITE; HIV-1 GENOMIC RNA; NUCLEOCAPSID PROTEIN;
   STEM-LOOP; IN-VITRO; REVERSE TRANSCRIPTION; INTERSUBTYPE RECOMBINATION;
   SECONDARY STRUCTURE; BINDING-SITES; CELLULAR RNAS
AB Background: The viral genome of HIV-1 contains several secondary structures that are important for regulating viral replication. The stem-loop 1 (SL1) sequence in the 5' untranslated region directs HIV-1 genomic RNA dimerization and packaging into the virion. Without SL1, HIV-1 cannot replicate in human T cell lines. The replication restriction phenotype in the SL1 deletion mutant appears to be multifactorial, with defects in viral RNA dimerization and packaging in producer cells as well as in reverse transcription of the viral RNA in infected cells. In this study, we sought to characterize SL1 mutant replication restrictions and provide insights into the underlying mechanisms of compensation in revertants.
   Results: HIV-1 lacking SL1 (NL Delta SL1) did not replicate in PM-1 cells until two independent non-synonymous mutations emerged: G913A in the matrix domain (E42K) on day 18 postinfection and C1907T in the SP1 domain (P10L) on day 11 postinfection. NL Delta SL1 revertants carrying either compensatory mutation showed enhanced infectivity in PM-1 cells. The SL1 revertants produced significantly more infectious particles per nanogram of p24 than did NL Delta SL1. The SL1 deletion mutant packaged less HIV-1 genomic RNA and more cellular RNA, particularly signal recognition particle RNA, in the virion than the wild-type. NL Delta SL1 also packaged 3- to 4-fold more spliced HIV mRNA into the virion, potentially interfering with infectious virus production. In contrast, both revertants encapsidated 2.5- to 5-fold less of these HIV-1 mRNA species. Quantitative RT-PCR analysis of RNA cross-linked with Gag in formaldehyde-fixed cells demonstrated that the compensatory mutations reduced the association between Gag and spliced HIV-1 RNA, thereby effectively preventing these RNAs from being packaged into the virion. The reduction of spliced viral RNA in the virion may have a major role in facilitating infectious virus production, thus restoring the infectivity of NL Delta SL1.
   Conclusions: HIV-1 evolved to overcome a deletion in SL1 and restored infectivity by acquiring compensatory mutations in the N-terminal matrix or SP1 domain of Gag. These data shed light on the functions of the N-terminal matrix and SP1 domains and suggest that both regions may have a role in Gag interactions with spliced viral RNA.
C1 [Ristic, Natalia; Chin, Mario P. S.] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA.
RP Chin, MPS (reprint author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 1230 York Ave, New York, NY 10021 USA.
EM mchin@adarc.org
FU Aaron Diamond AIDS Research Center; National Institutes of Health
   [DA026293]
FX We thank David Ho, Cecilia Cheng-Mayer and Paul Bieniasz for helpful
   discussion and critique of this work. We thank Wendy Chen for
   preparation of Figures. This work was supported by internal funds of
   Aaron Diamond AIDS Research Center and National Institutes of Health
   grant DA026293.
CR ADACHI A, 1986, J VIROL, V59, P284
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Berkhout B, 1996, J VIROL, V70, P6723
   Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684
   Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177
   Chen JB, 2009, P NATL ACAD SCI USA, V106, P13535, DOI 10.1073/pnas.0906822106
   Chin MPS, 2008, J MOL BIOL, V377, P1324, DOI 10.1016/j.jmb.2008.02.003
   Chin MPS, 2007, VIROLOGY, V363, P437, DOI 10.1016/j.virol.2007.01.034
   Chin MPS, 2005, P NATL ACAD SCI USA, V102, P9002, DOI 10.1073/pnas.0502522102
   CLEVER J, 1995, J VIROL, V69, P2101
   Clever JL, 2000, J VIROL, V74, P541, DOI 10.1128/JVI.74.1.541-546.2000                                                   
   Clever JL, 1997, J VIROL, V71, P3407
   Clever JL, 1996, J VIROL, V70, P5902
   Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   FU W, 1994, J VIROL, V68, P5013
   Hill MK, 2003, J VIROL, V77, P8329, DOI 10.1128/JVI.77.15.8329-8335.2003
   Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585
   Houzet L, 2007, NUCLEIC ACIDS RES, V35, P2695, DOI 10.1093/nar/gkm153
   Huthoff H, 2004, J VIROL, V78, P4907, DOI 10.1128/JVI.78.9.4907-4913.2004
   JIANG M, 1992, BIOCHEM BIOPH RES CO, V185, P1005, DOI 10.1016/0006-291X(92)91727-8                                                    
   Jones KL, 2008, NUCLEIC ACIDS RES, V36, P1578, DOI 10.1093/nar/gkm1149
   KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964
   Kaye JF, 1998, J VIROL, V72, P5877
   Kieken F, 2006, NUCLEIC ACIDS RES, V34, P343, DOI 10.1093/nar/gkj427
   King SR, 2008, J VIROL, V82, P2376, DOI 10.1128/JVI.02100-07
   L'Hernault A, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-90
   Lanchy JM, 2007, J VIROL, V81, P3285, DOI 10.1128/JVI.02025-06
   LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035
   Laughrea M, 1997, J VIROL, V71, P3397
   Liang C, 1999, J VIROL, V73, P7014
   Liang C, 1998, J VIROL, V72, P6629
   LUSSO P, 1995, J VIROL, V69, P3712
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700                                                          
   McBride MS, 1997, J VIROL, V71, P2050
   McBride MS, 1996, J VIROL, V70, P2963
   Moore MD, 2007, J VIROL, V81, P4002, DOI 10.1128/JVI.02589-06
   Moore MD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000627
   Moore MD, 2009, AIDS REV, V11, P91
   Muriaux D, 2003, FRONT BIOSCI, V8, pD135, DOI 10.2741/950
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686                                                        
   MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209                                                         
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X                                                   
   Onafuwa-Nuga AA, 2006, RNA, V12, P542, DOI 10.1261/rna.2306306
   Paillart JC, 1996, J VIROL, V70, P8348
   PURCELL DFJ, 1993, J VIROL, V67, P6365
   Rulli SJ, 2007, J VIROL, V81, P6623, DOI 10.1128/JVI.02833-06
   Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003
   SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219
   Shen N, 2000, J VIROL, V74, P5729, DOI 10.1128/JVI.74.12.5729-5735.2000
   Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Song R, 2008, BIOCHEMISTRY-US, V47, P3283, DOI 10.1021/bi7023173
   Song R, 2007, J MOL BIOL, V371, P1084, DOI 10.1016/j.jmb.2007.06.010
   Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361                                                              
   Tian CJ, 2007, NUCLEIC ACIDS RES, V35, P7288, DOI 10.1093/nar/gkm816
   Wilkinson KA, 2008, PLOS BIOL, V6, pe96, DOI DOI 10.1371/J0URNAL.PBI0.0060096
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 62
TC 5
Z9 5
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 8
PY 2010
VL 7
AR 73
DI 10.1186/1742-4690-7-73
PG 12
WC Virology
SC Virology
GA 659KL
UT WOS:000282565300002
PM 20825656
OA gold
DA 2018-01-05
ER

PT J
AU McCalla, SE
   Tripathi, A
AF McCalla, Stephanie E.
   Tripathi, Anubhav
TI Quantifying Transcription of Clinically Relevant Immobilized DNA within
   a Continuous Flow Microfluidic Reactor
SO LANGMUIR
LA English
DT Article
ID T7 RNA-POLYMERASE; IN-VITRO TRANSCRIPTION; LINEAR AMPLIFICATION; HIV-1
   RNA; SAMPLES; PLASMA; HYBRIDIZATION; QUANTITATION; INITIATION; DIFFUSION
AB Flow-through reactors are commonly used to control and optimize reagent delivery and product removal. Although recent research suggests that transcription reactions using picogram quantities of cDNA produce RNA efficiently in a flow-through microreactor, there has not been a detailed study on the mass transport and reagent dependence of microfluidic transcription reactions. We present a novel microreactor that contains H5 influenza cDNA immobilized directly onto the reactor walls to study the kinetics and reagent dependence of in vitro transcription reactions on a microfluidic platform. Enzyme and the rNTP substrate continuously flow over the cDNA and create RNA, which flows to a downstream collection well. Using nanogram quantities of cDNA, we found that enzyme limiting conditions caused by the concentration of cDNA in a small-volume microreactor channel may be partially overcome as the enzyme binds and concentrates near the channel wall. Kinetics confirm this phenomenon and show that the timescale for enzyme binding can be approximated by t(f) = cDNA/Q[E]. Surprisingly, on-chip transcription reactions have a strong dependence on the rNTP concentration from 5 to 9 mM despite a low consumption rate of rNTP molecules that is largely independent of the flow rate. Faster flow rates decrease the time it takes to fill DNA promoter sites with enzyme while additionally refreshing rNTP and MgCl(2) to allow for a greater consumption of rNTP. These two effects cause reactions with higher concentrations of cDNA in the reactor channel to have a greater dependence on the flow rate. At high flow rates (> 0.37 nL/s), the reaction rate begins to drop, likely because of the release and escape of enzyme molecules from the cDNA layer. This critical flow rate can be predicted by a new modified Peclet number, Pe(m) = L(c)V/D, where Le is the full length of the tightly packed cDNA molecules, V is the velocity at the DNA/fluid interface, and D is the diffusivity of the enzyme molecule. Together, these insights can inspire reactor designs for a variety of applications.
C1 [McCalla, Stephanie E.; Tripathi, Anubhav] Brown Univ, Sch Engn & Med Sci, Biomed Engn Program, Providence, RI 02912 USA.
RP Tripathi, A (reprint author), Brown Univ, Sch Engn & Med Sci, Biomed Engn Program, Providence, RI 02912 USA.
OI zaraat, javad/0000-0001-5341-7481
FU National Science Foundation [BES-0555874]; National Health Institute
   [1R21 A1073808-01 A1]
FX Authors acknowledge the financial support of the National Science
   Foundation (Grant No. BES-0555874) and the National Health Institute
   (Grant No. 1R21 A1073808-01 A1).
CR Batada NN, 2004, P NATL ACAD SCI USA, V101, P17361, DOI 10.1073/pnas.0408168101
   BOWEN WJ, 1964, ARCH BIOCHEM BIOPHYS, V107, P30, DOI 10.1016/0003-9861(64)90265-6                                                    
   Davis RH, 1999, J BIOTECHNOL, V71, P25, DOI 10.1016/S0168-1656(99)00013-9
   DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009                                                             
   Dimov IK, 2008, LAB CHIP, V8, P2071, DOI 10.1039/b812515e
   Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0                                                    
   Furuberg L, 2008, MICROSYST TECHNOL, V14, P673, DOI 10.1007/s00542-007-0515-x
   Gilbert I, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp193
   GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874
   Gulliksen A, 2005, LAB CHIP, V5, P416, DOI 10.1039/b415525d
   Holmberg A, 2005, ELECTROPHORESIS, V26, P501, DOI 10.1002/elps.200410070
   HUANG SC, 1994, ANAL BIOCHEM, V222, P441, DOI 10.1006/abio.1994.1514
   Hunter SM, 2008, J BIOCHEM BIOPH METH, V70, P1048, DOI 10.1016/j.jprot.2007.11.011
   Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467
   Kerby MB, 2006, ANAL CHEM, V78, P8273, DOI 10.1021/ac061189l
   Kern JA, 1999, BIOTECHNOL PROGR, V15, P174, DOI 10.1021/bp990008g
   Kern JA, 1997, BIOTECHNOL PROGR, V13, P747, DOI 10.1021/bp970094p
   Kim JH, 2007, NUCLEIC ACIDS RES, V35, P3848, DOI 10.1093/nar/gkm332
   Kralj JG, 2009, LAB CHIP, V9, P917, DOI 10.1039/b811714d
   Kuzmine I, 2001, J MOL BIOL, V305, P559, DOI 10.1006/jmbi.2000.4316
   Madou M.J., 2002, FUNDAMENTALS MICROFA
   Marcus JS, 2006, ANAL CHEM, V78, P3084, DOI 10.1021/ac0519460
   MCCALLA SE, 2009, LANGMUIR, V25, P283
   Moll PR, 2004, ANAL BIOCHEM, V334, P164, DOI 10.1016/j.ab.2004.07.013
   Peterson AW, 2001, NUCLEIC ACIDS RES, V29, P5163, DOI 10.1093/nar/29.24.5163                                                          
   Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104
   Shearstone JR, 2006, GENOMICS, V88, P111, DOI 10.1016/j.ygeno.2006.03.004
   Sousa R, 2003, PROG NUCLEIC ACID RE, V73, P1, DOI 10.1016/S0079-6603(03)01001-8
   SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0                                                                
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Stirewalt DL, 2004, GENOMICS, V83, P321, DOI 10.1016/j.ygeno.2003.08.008
   Katz D. F., 2004, TRANSPORT PHENOMENA
   VANDAMME AM, 1995, J VIROL METHODS, V52, P121, DOI 10.1016/0166-0934(94)00151-6
   VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663                                                          
   YOBAS L, 2005, SENSORS 2005 IEEE, DOI DOI 10.1109/ICSENS.2005.1597634
   ZAAIJER HL, 1995, J VIROL METHODS, V52, P175, DOI 10.1016/0166-0934(94)00160-I
   Zhong JF, 2008, LAB CHIP, V8, P68, DOI 10.1039/b712116d
NR 37
TC 2
Z9 2
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD SEP 7
PY 2010
VL 26
IS 17
BP 14372
EP 14379
DI 10.1021/la101826x
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 644DX
UT WOS:000281354000090
PM 20695456
DA 2018-01-05
ER

PT J
AU Le, GA
   Vandegraaff, N
   Rhodes, DI
   Jones, ED
   Coates, JAV
   Lu, L
   Li, XM
   Yu, CJ
   Feng, X
   Deadman, JJ
AF Le, Giang
   Vandegraaff, Nick
   Rhodes, David I.
   Jones, Eric D.
   Coates, Jonathan A. V.
   Lu, Long
   Li, Xinming
   Yu, Changjiang
   Feng, Xiao
   Deadman, John J.
TI Discovery of potent HIV integrase inhibitors active against raltegravir
   resistant viruses
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Integrase; Inhibitor; Synthesis; HIV; QHGS; NHEQ; Mutant virus
ID ARYL HALIDES; COMPLEXES
AB A series of novel HIV integrase inhibitors active against rategravir resistant strains are reported. Initial SAR studies revealed that activities against wild-type virus were successfully maintained at single digit nanomolar level with a wide range of substitutions. However, inclusion of nitrogen-based cyclic substitutions was crucial for achieving potency against mutant viruses. Several compounds with excellent activities against wild-type virus as well as against the viruses with the mutations Q148H/G140S or N155H/E92Q were reported. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Le, Giang; Vandegraaff, Nick; Rhodes, David I.; Jones, Eric D.; Coates, Jonathan A. V.; Deadman, John J.] Avexa Ltd, Richmond, Vic 3121, Australia.
   [Lu, Long; Li, Xinming; Yu, Changjiang; Feng, Xiao] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China.
RP Deadman, JJ (reprint author), Avexa Ltd, 576 Swan St, Richmond, Vic 3121, Australia.
EM jjdeadman@hotmail.com
RI Le, Giang/I-3178-2016
OI Le, Giang/0000-0002-2591-9190
CR Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979                                                                   
   Ceccherini-Silberstein F, 2009, AIDS REV, V11, P17
   Chang TLY, 2003, J VIROL, V77, P6777, DOI 10.1128/JVI.77.12.6777-6784.2003
   Charpentier C, 2010, AIDS, V24, P867, DOI 10.1097/QAD.0b013e3283367796
   Engelman A, 2009, METHODS, V47, P283, DOI 10.1016/j.ymeth.2009.02.005
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hatano H, 2010, JAIDS-J ACQ IMM DEF, V54, P389, DOI 10.1097/QAI.0b013e3181c42ea4
   JONES E, J BIOORG ME IN PRESS
   Kassahun K, 2007, DRUG METAB DISPOS, V35, P1657, DOI 10.1124/dmd.107.016196
   LE G, BIOORG MED IN PRESS
   Ovenden SPB, 2004, PHYTOCHEMISTRY, V65, P3255, DOI 10.1016/j.phytochem.2004.10.006
   Reigadas S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010311
   Ren W, 2010, J ORG CHEM, V75, P3017, DOI 10.1021/jo1002592
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Sunderland CJ, 2001, INORG CHEM, V40, P6746, DOI 10.1021/ic010313a
   Vandegraaff Nick, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000257
   Wu XY, 2005, J ORG CHEM, V70, P3094, DOI 10.1021/jo050080v
   Yin JJ, 2002, J AM CHEM SOC, V124, P6043, DOI 10.1021/ja012610k
NR 18
TC 14
Z9 14
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2010
VL 20
IS 17
BP 5013
EP 5018
DI 10.1016/j.bmcl.2010.07.041
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 642UT
UT WOS:000281247000007
PM 20685117
DA 2018-01-05
ER

PT J
AU Gamaley, SG
   Bateneva, AV
   Sysoeva, GM
   Danilenko, ED
   Lebedev, LR
   Masycheva, VI
AF Gamaley, S. G.
   Bateneva, A. V.
   Sysoeva, G. M.
   Danilenko, E. D.
   Lebedev, L. R.
   Masycheva, V. I.
TI Pharmacokinetics and Antitumor Effects of the Drug Containing TNF-alpha
   in Nanoparticles
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE tumor necrosis factor-alpha; double-strand RNA; nanoparticle;
   pharmacokinetics; Ehrlich carcinoma
ID TUMOR-NECROSIS-FACTOR; VACCINE; HIV-1
AB Antitumor activity of TNF-alpha incorporated in nanoparticles (VLP-TNF-alpha) and dynamics of its accumulation and elimination from the blood and tumor tissue were studied in ICR mice. The VLP-TNF-alpha preparation exhibited higher antitumor activity compared to free TNF-alpha, presumably due to longer circulation of the cytokine in the blood and its more intensive accumulation by tumor tissue.
C1 [Gamaley, S. G.; Bateneva, A. V.; Sysoeva, G. M.; Danilenko, E. D.; Lebedev, L. R.; Masycheva, V. I.] Vector Ctr Virol & Biotechnol, Inst Med Biotechnol, Berdsk, Novosibirsk Reg, Russia.
RP Gamaley, SG (reprint author), Vector Ctr Virol & Biotechnol, Inst Med Biotechnol, Berdsk, Novosibirsk Reg, Russia.
EM gamalei58@mail.ru
RI Danilenko, Elena/A-7083-2014
FU Federal Targeted Program for Science and Technology [02.513.11.3372]
FX The study was supported by the Federal Targeted Program for Science and
   Technology (State Contract No. 02.513.11.3372, November 26, 2007).
CR Bazhan SI, 2004, VACCINE, V22, P1672, DOI 10.1016/j.vaccine.2003.09.048
   IMOTO H, 1992, CANCER RES, V52, P4396
   Karpenko LI, 2007, DOKL BIOCHEM BIOPHYS, V413, P65, DOI 10.1134/S160767290702007X
   Kedar E, 1997, J IMMUNOTHER, V20, P180, DOI 10.1097/00002371-199705000-00003
   Krippner-Heidenreich A, 2008, J IMMUNOL, V180, P8176, DOI 10.4049/jimmunol.180.12.8176                                                    
   LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52                                                        
   LODATO RF, 1995, J IMMUNOTHER, V17, P19, DOI 10.1097/00002371-199501000-00003
   Masycheva V I, 1998, Vestn Ross Akad Med Nauk, P13
   Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001
   2144958
   2158303
NR 11
TC 0
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4888
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD SEP
PY 2010
VL 149
IS 3
BP 320
EP 323
DI 10.1007/s10517-010-0937-9                                               
          
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 641YH
UT WOS:000281168400013
PM 21246092
DA 2018-01-05
ER

PT J
AU Moretton, MA
   Glisoni, RJ
   Chiappetta, DA
   Sosnik, A
AF Moretton, Marcela A.
   Glisoni, Romina J.
   Chiappetta, Diego A.
   Sosnik, Alejandro
TI Molecular implications in the nanoencapsulation of the anti-tuberculosis
   drug rifampicin within flower-like polymeric micelles
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Microwave-Assisted Polymer Synthesis (MAPS);
   Poly(epsilon-caprolactone)-b-poly(ethylene
   glycol)-poly(epsilon-caprolactone) block copolymers; Flower-like
   polymeric micelles; Tuberculosis; Rifampicin encapsulation
ID BLOCK-COPOLYMER MICELLES; IN-VITRO; TUBERCULOSIS; STABILITY; DELIVERY;
   COMBINATION; POLOXAMINE; RELEASE; BIOAVAILABILITY; PACLITAXEL
AB Tuberculosis (TB) is the second most deadly infectious disease behind the Human Immunodeficiency Virus (HIV). An effective pharmacotherapy has been available for more than 5 decades. However, the length of the treatment and the pill burden result in low patient compliance and adherence to the regimens. Nanotechnologies can overcome these basic technological drawbacks. The present work explored the molecular implications governing the encapsulation and water solubilization of RIF within Flower-like micelles of poly(epsilon-caprolactone)-b-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) block copolymers. Ten derivatives of different molecular weight and hydrophobic/hydrophilic caprolactone/ethylene oxide ratio (CL/EO) were synthesized by a fast and high-yield Microwave-Assisted Polymer Synthesis (MAPS) technique; CL/EO values are determined by taking the ratios of the number of repeating units in the PCL and the PEG segments. The aggregation behavior of the copolymers was thoroughly investigated by means of surface tension (critical micellar concentration), dynamic light scattering (size, size distribution and zeta potential) and transmission electron microscopy (morphology). In general, the greater the central PEG segment, the larger the micelles formed. The physical stability was intimately associated with the molecular weight and the composition. Then, the encapsulation of RIF in the different copolymer families was evaluated, and the physical stability of the drug-loaded aggregates characterized. The micellar size appears as the most crucial property, this phenomenon being primarily controlled by the molecular weight of the PEG central block. Having expressed this, sufficiently high CL/EO ratios (and long PCL segments) are also demanded to attain stable micellar systems with cores that are large enough to host the bulky RIF molecule. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Moretton, Marcela A.; Glisoni, Romina J.; Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1113 Buenos Aires, DF, Argentina.
   [Moretton, Marcela A.; Glisoni, Romina J.; Chiappetta, Diego A.; Sosnik, Alejandro] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
FU CONICET
FX RJG and MAM thank Ph.D. scholarships of the CONICET. DAC and AS are
   members of the CONICET. The authors thank Dr. L. Diaz and Dr. G. Copello
   (Faculty of Pharmacy and Biochemistry, University of Buenos Aires) and
   Dr. G. Abraham (INTEMA, National University of Mar del Plata, Argentina)
   for GC and GPC analysis, respectively.
CR Agrawal S, 2004, INT J PHARM, V287, P97, DOI 10.1016/j.ijpharm.2004.09.005
   Becker C, 2009, J PHARM SCI-US, V98, P2252, DOI 10.1002/jps.21624
   Brewer TF, 2005, ARCH MED RES, V36, P617, DOI 10.1016/j.arcmed.2005.06.002
   Changsan N, 2009, J DRUG TARGET, V17, P751, DOI 10.3109/10611860903079462
   Chiappetta DA, 2008, EUR J PHARM BIOPHARM, V69, P535, DOI 10.1016/j.ejpb.2007.11.021
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   [Anonymous], 2000, EUR PHARM S, P298
   Dong JF, 2004, THERMOCHIM ACTA, V417, P201, DOI 10.1016/j.tca.2003.08.030
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   Ferreira D.A., 2004, BRAZ J PHARM SCI, V40, P43
   Forrest ML, 2008, PHARM RES, V25, P194, DOI 10.1007/s11095-007-9451-9
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Gallo G.G., 1976, ANAL PROFILES DRUG S, P467
   Gaucher G, 2005, J CONTROL RELEASE, V109, P169, DOI 10.1016/j.jconrel.2005.09.034
   Gohel MC, 2007, AAPS PHARMSCITECH, V8
   Golden MP, 2005, AM FAM PHYSICIAN, V72, P1761
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   GOTELLI G, 2009, ARCHIPOL 2009 5 ARG
   Hu Y, 2006, J NANOSCI NANOTECHNO, V6, P3032, DOI 10.1166/jnn.2006.432
   *INT UN TUB LUNG D, TUB
   Jain S. K., 2008, MICROBE, V3, P285
   KABANOV AV, 1995, MACROMOLECULES, V28, P2303, DOI 10.1021/ma00111a026                                                             
   Kappe CO, 2004, ANGEW CHEM INT EDIT, V43, P6250, DOI 10.1002/anie.200400655
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Letchford K, 2008, J PHARM SCI-US, V97, P1179, DOI 10.1002/jps.21037
   Letchford K, 2009, EUR J PHARM BIOPHARM, V71, P196, DOI 10.1016/j.ejpb.2008.08.003
   Lin WJ, 2003, PHARMACEUT RES, V20, P668, DOI 10.1023/A:1023215320026                                                         
   Liu JB, 2007, EUR J PHARM BIOPHARM, V65, P309, DOI 10.1016/j.ejpb.2006.11.010
   MAGGI N, 1968, J MED CHEM, V11, P936, DOI 10.1021/jm00311a004
   Mariappan TT, 2003, INT J TUBERC LUNG D, V7, P797
   MARIAPPAN TT, 2006, CLIN RES REGUL AFF, V23, P1, DOI DOI 10.1080/10601330500533990
   Mehta SK, 2005, COLLOID POLYM SCI, V283, P532, DOI 10.1007/s00396-004-1181-5
   MORETTON MA, 2009, BIOOMAT 2009 1 WORKS
   Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857
   Piao LH, 2003, POLYMER, V44, P2025, DOI 10.1016/S0032-3861(03)00087-9
   Rao BP, 2006, ARS PHARM, V47, P37
   Richter A, 2010, EUR J PHARM BIOPHARM, V75, P80, DOI 10.1016/j.ejpb.2010.02.010
   Rivers EC, 2008, DRUG DISCOV TODAY, V13, P1090, DOI 10.1016/j.drudis.2008.09.004
   Rote A. R., 1997, Indian Journal of Pharmaceutical Sciences, V59, P119
   Sanchez-Soto PJ, 2002, J THERM ANAL CALORIM, V67, P189, DOI 10.1023/A:1013758518721                                                         
   Schwach G, 1999, INT J BIOL MACROMOL, V25, P283, DOI 10.1016/S0141-8130(99)00043-4
   Shishoo CJ, 1999, INT J PHARM, V190, P109, DOI 10.1016/S0378-5173(99)00286-0
   Shishoo CJ, 2001, INT J PHARM, V228, P53, DOI 10.1016/S0378-5173(01)00831-6
   Singh Saranjit, 2000, Pharmacy and Pharmacology Communications, V6, P405
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003
   Sosnik A, 2003, POLYMER, V44, P7033, DOI 10.1016/j.polymer.2003.09.012
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   SOSNIK A, 2010, ADV DRUG DEL REV, V62, P365
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P547, DOI 10.1016/j.addr.2009.11.023
   WHO declares tuberculosis a global emergency, 1993, SOZ PRAVENTIVMED, V38, P251, DOI DOI 10.1007/BF01624546
   World Health Organization, 2003, TREATM TUB GUID NAT
   Yang Y, 2009, BIOMACROMOLECULES, V10, P2310, DOI 10.1021/bm900497z
   Zaru M, 2007, EUR J PHARM BIOPHARM, V67, P655, DOI 10.1016/j.ejpb.2007.04.005
   Zhao Y, 2001, J PHYS CHEM B, V105, P848, DOI 10.1021/jp003001m
NR 56
TC 47
Z9 47
U1 4
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD SEP 1
PY 2010
VL 79
IS 2
BP 467
EP 479
DI 10.1016/j.colsurfb.2010.05.016
PG 13
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 627FE
UT WOS:000280024100023
PM 20627665
DA 2018-01-05
ER

PT J
AU Chiappetta, DA
   Alvarez-Lorenzo, C
   Rey-Rico, A
   Taboada, P
   Concheiro, A
   Sosnik, A
AF Chiappetta, Diego A.
   Alvarez-Lorenzo, Carmen
   Rey-Rico, Ana
   Taboada, Pablo
   Concheiro, Angel
   Sosnik, Alejandro
TI N-alkylation of poloxamines modulates micellar assembly and
   encapsulation and release of the antiretroviral efavirenz
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Polymeric micelles; Pristine and N-alkylated poloxamines self-assembly;
   HIV/AIDS; Efavirenz encapsulation; Drug release
ID TETRONIC BLOCK-COPOLYMERS; LIGHT-SCATTERING; AQUEOUS-SOLUTION;
   ETHYLENE-OXIDE; PROPYLENE-OXIDE; ASSOCIATION BEHAVIOR; COLORIMETRIC
   ASSAY; POLYMERIC MICELLES; SURFACE-ACTIVITY; HIV-INFECTION
AB Poloxamines (X-shaped poly(ethylene oxide)-poly(propylene oxide) (PEO-PPO) diblocks connected to a central ethylenediamine group) were N-methylated and N-allylated with the aim of widening their versatility as drug nanocarriers. The self-aggregation properties of various derivatives, covering a wide range of molecular weights and EO/PO ratios, were thoroughly investigated. The cytocompatibility of different modified poloxamines was compared to that of the pristine counterparts by MTT and LDH assays. The most hydrophilic varieties were highly cytocompatible even at concentrations of 5%. Toward the optimization of the oral pharmacotherapy of the Human Immunodeficiency Virus (HIV) infection in pediatric patients, the encapsulation and in vitro delivery of efavirenz (EFV), a lipophilic first-line antiretroviral drug, were evaluated. Pristine and N-alkylated poloxamines behaved as highly efficient EFV solubilizers enhancing the aqueous solubility of the drug between 166 and 7426-times. EFV promotes self-micellization of poloxamines; their tiny structural modification (i.e., just one methyl- or allyl-group) being able to regulate drug/micellar core interaction. Despite the physical stability of the micelles against dilution in physiological mimicking fluids, the N-alkylated derivatives were slightly more prone to disassembly promoting EFV release from the micellar reservoir. For all the derivatives evaluated, the in vitro release fitted zero-order kinetics and was sustained for at least 24 h. These findings point out N-alkylated poloxamines as promising nanocarriers for oral or parenteral drug delivery. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Natl Sci Res Council, CONICET, Buenos Aires, DF, Argentina.
   [Alvarez-Lorenzo, Carmen; Rey-Rico, Ana; Concheiro, Angel] Univ Santiago Compostela, Dept Farm & Tecnol Farmaceut, Santiago De Compostela, Spain.
   [Taboada, Pablo] Univ Santiago Compostela, Dept Fis Mat Condensada, Santiago De Compostela, Spain.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Junin St,6th Floor,CP1113, Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
RI Rey Rico, Ana/K-5951-2014; Alvarez-Lorenzo, Carmen/J-8101-2014; Taboada,
   Pablo/C-3000-2015; Concheiro, Angel/J-8109-2014
OI Rey Rico, Ana/0000-0003-1682-498X; Alvarez-Lorenzo,
   Carmen/0000-0002-8546-7085; Taboada, Pablo/0000-0002-2903-7857;
   Concheiro, Angel/0000-0003-0507-049X
FU Agencia Espanola de Cooperacion Internacional para el Desarrollo (AECID)
   [A/016343/08]
FX This work was financed by Agencia Espanola de Cooperacion Internacional
   para el Desarrollo (AECID Grant A/016343/08, MAE, Spain). The authors
   express their gratitude to A. Santovena (Universidad de La Laguna,
   Spain) for help with GPC analysis and to BASF Corporation (Verena
   Geiselhart) for providing poloxamine samples.
CR Al-Hanbali O, 2007, ANAL BIOCHEM, V361, P287, DOI 10.1016/j.ab.2006.11.028
   ALEXANDRIDIS P, 1994, LANGMUIR, V10, P2604, DOI 10.1021/la00020a019                                                             
   Altinok H, 1999, COLLOID SURFACE B, V16, P73, DOI 10.1016/S0927-7765(99)00062-4                                                   
   Altinok H, 1997, LANGMUIR, V13, P5837, DOI 10.1021/la970586b                                                               
   Alvarez-Lorenzo C, 2007, EUR J PHARM BIOPHARM, V66, P244, DOI 10.1016/j.ejpb.2006.10.010
   Bae YH, 2008, J CONTROL RELEASE, V131, P2, DOI 10.1016/j.jconrel.2008.06.015
   Bahal SM, 2003, PHARM DEV TECHNOL, V8, P111, DOI 10.1081/PDT-120017518
   Barbosa S, 2007, J PHYS CHEM B, V111, P10920, DOI 10.1021/jp073481i
   BEATTIE WH, 1960, J PHYS CHEM-US, V64, P696, DOI 10.1021/j100834a516                                                             
   Brown E., 2007, ANTIRETROVIRAL THERA, P419
   CASASSA EF, 1989, POLYM HDB, P485
   Cavet ME, 2009, CONTACT LENS ANTERIO, V32, P171, DOI 10.1016/j.clae.2009.05.002
   Chaibundit C, 2007, LANGMUIR, V23, P9229, DOI 10.1021/la701157j
   Chiappetta DA, 2010, CURR HIV RES, V8, P23
   Chiappetta D. A., 2010, POLYM AGING STABILIZ
   Chiappetta DA, 2008, EUR J PHARM BIOPHARM, V69, P535, DOI 10.1016/j.ejpb.2007.11.021
   Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001                                                
   DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9
   Dong JF, 2004, COLLOID SURFACE A, V246, P91, DOI 10.1016/j.colsurfa.2004.07.006
   Dong JF, 2004, THERMOCHIM ACTA, V417, P201, DOI 10.1016/j.tca.2003.08.030
   Dong JF, 2003, COLLOID SURFACE A, V212, P9, DOI 10.1016/S0927-7757(02)00295-9                                                   
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   GULARI E, 1979, BIOPOLYMERS, V18, P2943, DOI 10.1002/bip.1979.360181204
   He W, 2009, CHEM PHARM BULL, V57, P122, DOI 10.1248/cpb.57.122                                                              
   Huglin M. B., 1972, LIGHT SCATTERING POL, P165
   Imayasu M, 2008, EYE CONTACT LENS, V34, P50, DOI 10.1097/ICL.0b013e318073cbdb
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   Kairuz TE, 2007, CURR DRUG SAF, V2, P89
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   MUNCH MR, 1989, POLYM COMMUN, V30, P324
   Nunn T, 2005, BRIT J CLIN PHARMACO, V59, P674, DOI 10.1111/j.1365-2125.2005.02410.x
   Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6
   PERCUS JK, 1958, PHYS REV, V110, P1, DOI 10.1103/PhysRev.110.1                                                           
   PROVENCHER SW, 1979, MAKROMOL CHEM, V180, P201
   Riess G, 2003, PROG POLYM SCI, V28, P1107, DOI 10.1016/S0079-6700(03)00015-7
   Sosnik A, 2005, TISSUE ENG, V11, P1807, DOI 10.1089/ten.2005.11.1807                                                        
   Sosnik A, 2006, BIOMACROMOLECULES, V7, P331, DOI 10.1021/bm050693h
   Sosnik A, 2005, J BIOMED MATER RES A, V75A, P295, DOI 10.1002/jbm.a.30419
   Sosnik A, 2005, BIOMATERIALS, V26, P7425, DOI 10.1016/j.biomaterials.2005.05.086
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   Sosnik A, 2008, J BIOMED MATER RES A, V86A, P339, DOI 10.1002/jbm.a.31594
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Standing JF, 2005, INT J PHARM, V300, P56, DOI 10.1016/j.ijpharm.2005.05.006
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273
   VRIJ A, 1978, J CHEM PHYS, V69, P1742, DOI 10.1063/1.436750
   WANG L, 2008, BIOCONJ CHEM, V19, P28
   *WHO, WHO MAK MED CHILD SI
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   XU RL, 1991, MACROMOLECULES, V24, P87, DOI 10.1021/ma00001a014                                                             
   ZHOU ZK, 1988, J COLLOID INTERF SCI, V126, P171, DOI 10.1016/0021-9797(88)90111-7                                                    
NR 52
TC 51
Z9 52
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2010
VL 76
IS 1
BP 24
EP 37
DI 10.1016/j.ejpb.2010.05.007
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 650YY
UT WOS:000281892000004
PM 20493946
DA 2018-01-05
ER

PT J
AU Tzur, S
   Rosset, S
   Shemer, R
   Yudkovsky, G
   Selig, S
   Tarekegn, A
   Bekele, E
   Bradman, N
   Wasser, WG
   Behar, DM
   Skorecki, K
AF Tzur, Shay
   Rosset, Saharon
   Shemer, Revital
   Yudkovsky, Guennady
   Selig, Sara
   Tarekegn, Ayele
   Bekele, Endashaw
   Bradman, Neil
   Wasser, Walter G.
   Behar, Doron M.
   Skorecki, Karl
TI Missense mutations in the APOL1 gene are highly associated with end
   stage kidney disease risk previously attributed to the MYH9 gene
SO HUMAN GENETICS
LA English
DT Article
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; LIPID-BINDING PROTEIN; AUTOPHAGIC
   CELL-DEATH; APOLIPOPROTEIN-L GENE; AFRICAN-AMERICANS; RENAL-DISEASE;
   NEPHROPATHY; ANCESTRY; SPECTRUM; REGIONS
AB MYH9 has been proposed as a major genetic risk locus for a spectrum of nondiabetic end stage kidney disease (ESKD). We use recently released sequences from the 1000 Genomes Project to identify two western African-specific missense mutations (S342G and I384M) in the neighboring APOL1 gene, and demonstrate that these are more strongly associated with ESKD than previously reported MYH9 variants. The APOL1 gene product, apolipoprotein L-1, has been studied for its roles in trypanosomal lysis, autophagic cell death, lipid metabolism, as well as vascular and other biological activities. We also show that the distribution of these newly identified APOL1 risk variants in African populations is consistent with the pattern of African ancestry ESKD risk previously attributed to MYH9.
   Mapping by admixture linkage disequilibrium (MALD) localized an interval on chromosome 22, in a region that includes the MYH9 gene, which was shown to contain African ancestry risk variants associated with certain forms of ESKD (Kao et al. 2008; Kopp et al. 2008). MYH9 encodes nonmuscle myosin heavy chain IIa, a major cytoskeletal nanomotor protein expressed in many cell types, including podocyte cells of the renal glomerulus. Moreover, 39 different coding region mutations in MYH9 have been identified in patients with a group of rare syndromes, collectively termed the Giant Platelet Syndromes, with clear autosomal dominant inheritance, and various clinical manifestations, sometimes also including glomerular pathology and chronic kidney disease (Kopp 2010; Sekine et al. 2010). Accordingly, MYH9 was further explored in these studies as the leading candidate gene responsible for the MALD signal. Dense mapping of MYH9 identified individual single nucleotide polymorphisms (SNPs) and sets of such SNPs grouped as haplotypes that were found to be highly associated with a large and important group of ESKD risk phenotypes, which as a consequence were designated as MYH9-associated nephropathies (Bostrom and Freedman 2010). These included HIV-associated nephropathy (HIVAN), primary nonmonogenic forms of focal segmental glomerulosclerosis, and hypertension affiliated chronic kidney disease not attributed to other etiologies (Bostrom and Freedman 2010). The MYH9 SNP and haplotype associations observed with these forms of ESKD yielded the largest odds ratios (OR) reported to date for the association of common variants with common disease risk (Winkler et al. 2010). Two specific MYH9 variants (rs5750250 of S-haplotype and rs11912763 of F-haplotype) were designated as most strongly predictive on the basis of Receiver Operating Characteristic analysis (Nelson et al. 2010). These MYH9 association studies were then also extended to earlier stage and related kidney disease phenotypes and to population groups with varying degrees of recent African ancestry admixture (Behar et al. 2010; Freedman et al. 2009a, b; Nelson et al. 2010), and led to the expectation of finding a functional African ancestry causative variant within MYH9. However, despite intensive efforts including re-sequencing of the MYH9 gene no suggested functional mutation has been identified (Nelson et al. 2010; Winkler et al. 2010). This led us to re-examine the interval surrounding MYH9 and to the detection of novel missense mutations with predicted functional effects in the neighboring APOL1 gene, which are significantly more associated with ESKD than all previously reported SNPs in MYH9.
C1 [Tzur, Shay; Shemer, Revital; Yudkovsky, Guennady; Selig, Sara; Skorecki, Karl] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.
   [Tzur, Shay; Shemer, Revital; Yudkovsky, Guennady; Selig, Sara; Skorecki, Karl] Technion Israel Inst Technol, Res Inst, IL-31096 Haifa, Israel.
   [Rosset, Saharon] Tel Aviv Univ, Dept Stat & Operat Res, IL-69978 Tel Aviv, Israel.
   [Selig, Sara; Behar, Doron M.; Skorecki, Karl] Mol Med Lab, IL-31096 Haifa, Israel.
   [Tarekegn, Ayele; Bradman, Neil] UCL, Ctr Genet Anthropol, Res Dept Genet Evolut & Environm, London WC1E 6BT, England.
   [Tarekegn, Ayele; Bekele, Endashaw] Univ Addis Ababa, Dept Biol, Addis Ababa 1176, Ethiopia.
   [Wasser, Walter G.] Hadassah Med Ctr, IL-91120 Jerusalem, Israel.
   [Behar, Doron M.] Univ Tartu, Dept Evolutionary Biol, Estonian Bioctr, EE-51010 Tartu, Estonia.
RP Skorecki, K (reprint author), 8 Ha Aliyah St, IL-31096 Haifa, Israel.
EM skorecki@tx.technion.ac.il
FU Canadian Technion Society; American Technion Society; Israel Science
   Foundation [890015, 1227/09]; Legacy Heritage Fund; European Research
   Commission [MIRG-CT-2007-208019]; European Commission,
   Directorate-General for Research [205419]
FX We thank Steve Smith, Susan Kirby, Rhian Gwilliam, Daniella Magen and
   Liat Linde for excellent technical assistance. This study was supported
   by the Canadian and American Technion Societies (Eshagian Estate Fund,
   Dr. Sidney Kremer Kidney Disease Research Fund), the Israel Science
   Foundation (890015), and Legacy Heritage Fund to KS and by the European
   Research Commission (MIRG-CT-2007-208019) and the Israel Science
   Foundation (1227/09) to SR. DMB thanks the European Commission,
   Directorate-General for Research for FP7 Ecogene grant 205419.
CR Bedoya G, 2006, P NATL ACAD SCI USA, V103, P7234, DOI 10.1073/pnas.0508716103
   Behar DM, 2006, AM J KIDNEY DIS, V47, P88, DOI 10.1053/j.ajkd.2005.09.023
   Behar DM, 2010, HUM MOL GENET, V19, P1816, DOI 10.1093/hmg/ddq040
   Bostrom MA, 2010, CLIN J AM SOC NEPHRO, V5, P1107, DOI 10.2215/CJN.08721209
   Candiano G, 2001, J AM SOC NEPHROL, V12, P143
   Duchateau PN, 2001, J LIPID RES, V42, P620
   Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576                                                        
   Freedman BI, 2009, NEPHROL DIAL TRANSPL, V24, P3366, DOI 10.1093/ndt/gfp316
   Freedman BI, 2009, KIDNEY INT, V75, P736, DOI 10.1038/ki.2008.701
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492
   Kao WHL, 2008, NAT GENET, V40, P1185, DOI 10.1038/ng.232
   Kopp JB, 2008, NAT GENET, V40, P1175, DOI 10.1038/ng.226
   Kopp JB, 2010, KIDNEY INT, V78, P130, DOI 10.1038/ki.2010.82
   Lecordier L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000685
   Monajemi H, 2002, GENOMICS, V79, P539, DOI 10.1006/geno.2002.6729
   Nelson GW, 2010, HUM MOL GENET, V19, P1805, DOI 10.1093/hmg/ddq039
   Sekine T, 2010, KIDNEY INT, V78, P207, DOI 10.1038/ki.2010.21
   Smith EE, 2009, GENOME RES, V19, P850, DOI 10.1101/gr.085647.108
   Stephan W, 2006, GENETICS, V172, P2647, DOI 10.1534/genetics.105.050179
   TAKEMURA T, 1993, KIDNEY INT, V43, P918, DOI 10.1038/ki.1993.129
   Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461
   Vanhollebeke B, 2006, CELL MOL LIFE SCI, V63, P1937, DOI 10.1007/s00018-006-6091-x
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Winkler CA, 2010, SEMIN NEPHROL, V30, P111, DOI 10.1016/j.semnephrol.2010.01.003
   Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066                                                               
NR 26
TC 249
Z9 255
U1 4
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD SEP
PY 2010
VL 128
IS 3
BP 345
EP 350
DI 10.1007/s00439-010-0861-0
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 638UP
UT WOS:000280922800010
PM 20635188
OA gold
DA 2018-01-05
ER

PT J
AU Cheng, YA
   Li, DC
   Ji, BH
   Shi, XH
   Gao, HJ
AF Cheng, Yuan
   Li, Dechang
   Ji, Baohua
   Shi, Xinghua
   Gao, Huajian
TI Structure-based design of carbon nanotubes as HIV-1 protease inhibitors:
   Atomistic and coarse-grained simulations
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE HIV-1 protease; Carbon nanotubes; Molecular dynamics; Atomistic model;
   Coarse-grained model
ID MOLECULAR-DYNAMICS SIMULATIONS; FULLERENE DERIVATIVES;
   CONFORMATIONAL-CHANGES; DIELECTRIC MEDIUM; FREE-ENERGIES; BINDING;
   MODEL; DOCKING; ELECTROSTATICS; C-60-FULLERENE
AB Nanoparticles such as fullerenes and carbon nanotubes have been extensively studied for biomedical applications. In this paper, we report the design of carbon nanotubes as HIV-1 protease inhibitors. Docking and molecular dynamics calculations are performed using an atomistic model to explore the optimal interaction structure and free energy between the nanotube and HIV-1 protease. A coarse-grained model is then developed based on the atomistic model, allowing us to investigate the dynamic behaviors of the protease in the bound and unbound states. The dynamic process reveals that the carbon nanotube is able to bind to the active site of the protease and prevent the active flaps from opening up, thus blocking the function of the protease. This process is strongly influenced by the size of the nanotube. The binding of carbon nanotubes to an alternative binding site other than the active site is also explored. Therefore, carbon nanotube-based inhibitors have great potential for application as HIV-1 protease inhibitors. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Cheng, Yuan] Inst High Performance Comp, Singapore 138632, Singapore.
   [Li, Dechang] Tsinghua Univ, Dept Engn Mech, Sch Aerospace, Beijing 100084, Peoples R China.
   [Ji, Baohua] Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
   [Shi, Xinghua; Gao, Huajian] Brown Univ, Div Engn, Providence, RI 02912 USA.
RP Cheng, YA (reprint author), Inst High Performance Comp, 1 Fusionopolis Way,16-16 Connexis, Singapore 138632, Singapore.
EM chengy@ihpc.a-star.edu.sg
RI Li, Dechang/D-2766-2009; Gao, Huajian/F-9360-2010; Shi,
   Xinghua/F-9378-2010; Cheng, Yuan/E-9259-2014; Ji, Baohua/B-6713-2008
OI Li, Dechang/0000-0002-9528-6851; Shi, Xinghua/0000-0001-5012-3453;
   Cheng, Yuan/0000-0003-0061-3934; Ji, Baohua/0000-0002-0092-6562
FU A<SUP>*</SUP>Star; National Natural Science Foundation of China
   [10628205, 10732050, 10872115]
FX This work reported was supported by the A<SUP>star</SUP>Star Visiting
   Investigator Program "Size Effects in Small Scale Materials" hosted at
   the Institute of High Performance Computing in Singapore. We gratefully
   acknowledge the contributions of Dr. Chun Lu and Prof. Yongwei Zhang,
   who provided helpful management and discussions during the course of the
   work. Y.C. wishes to thank Dr. Bing Zhang from Research Centre of
   Excellent in Mechanobiology, National University of Singapore for
   helpful discussions. B.J. would like to acknowledge the support by the
   National Natural Science Foundation of China through Grant Nos.
   10628205, 10732050, and 10872115.
CR Aruksakunwong O, 2007, CURR COMPUT-AID DRUG, V3, P201, DOI 10.2174/157340907781695431                                                      
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   CASE DA, 2004, AMBER 8
   Chang CEA, 2007, CHEM BIOL DRUG DES, V69, P5, DOI 10.1111/j.1747-0285.2007.00464.x
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n                                                               
   HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K
   Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   Lepsik M, 2004, PROTEINS, V57, P279, DOI 10.1002/prot.20192
   Lexa KW, 2009, PROTEINS, V74, P872, DOI 10.1002/prot.22195
   Li DC, 2010, J PHYS CHEM B, V114, P3060, DOI 10.1021/jp1005549
   Li DC, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3148022
   Mashino T, 2001, FULLERENE SCI TECHN, V9, P191, DOI 10.1081/FST-100102966                                                           
   MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412                                                           
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006
   Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.0.CO;2-Y
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   Spackova N, 2003, J AM CHEM SOC, V125, P1759, DOI 10.1021/ja025660d
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   STEINMETZ FN, 2009, J AM CHEM SOC, V131, P17093
   Tozzini V, 2005, CHEM PHYS LETT, V413, P123, DOI 10.1016/j.cplett.2005.07.075
   Tozzini V, 2007, J STRUCT BIOL, V157, P606, DOI 10.1016/j.jsb.2006.08.005
   Tsui V, 2001, BIOPOLYMERS, V56, P275
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Wang W, 2001, P NATL ACAD SCI USA, V98, P14937, DOI 10.1073/pnas.251265598
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A                  
   Wittayanarakul K, 2007, J COMPUT CHEM, V29, P673, DOI DOI 10.1002/JCC.20821
   Wolff DJ, 2002, ARCH BIOCHEM BIOPHYS, V399, P130, DOI 10.1006/abbi.2002.2766
   Zacharias M, 2003, PROTEIN SCI, V12, P1271, DOI 10.1110/ps.0239303
   Zhang B, 2006, J COMPUT AID MOL DES, V20, P395, DOI 10.1007/s10822-006-9081-z
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 40
TC 29
Z9 29
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD SEP
PY 2010
VL 29
IS 2
BP 171
EP 177
DI 10.1016/j.jmgm.2010.05.009
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA 660ER
UT WOS:000282623300007
PM 20580296
DA 2018-01-05
ER

PT J
AU Radhakrishnan, A
   Yeo, D
   Brown, G
   Myaing, MZ
   Iyer, LR
   Fleck, R
   Tan, BH
   Aitken, J
   Sanmun, D
   Tang, K
   Yarwood, A
   Brink, J
   Sugrue, RJ
AF Radhakrishnan, Anuradha
   Yeo, Dawn
   Brown, Gaie
   Myaing, Myint Zu
   Iyer, Laxmi Ravi
   Fleck, Roland
   Tan, Boon-Huan
   Aitken, Jim
   Sanmun, Duangmanee
   Tang, Kai
   Yarwood, Andy
   Brink, Jacob
   Sugrue, Richard J.
TI Protein Analysis of Purified Respiratory Syncytial Virus Particles
   Reveals an Important Role for Heat Shock Protein 90 in Virus Particle
   Assembly
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID ACTIN-BASED MOTILITY; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED-CELLS;
   N-WASP; RNA REPLICATION; ARP2/3 COMPLEX; VACCINIA VIRUS; MOLECULAR
   CHAPERONE; POLYMERASE COMPLEX; PROTEOMIC ANALYSIS
AB In this study, we used imaging and proteomics to identify the presence of virus-associated cellular proteins that may play a role in respiratory syncytial virus (RSV) maturation. Fluorescence microscopy of virus-infected cells revealed the presence of virus-induced cytoplasmic inclusion bodies and mature virus particles, the latter appearing as virus filaments. In situ electron tomography suggested that the virus filaments were complex structures that were able to package multiple copies of the virus genome. The virus particles were purified, and the protein content was analyzed by one-dimensional nano-LC MS/MS. In addition to all the major virus structural proteins, 25 cellular proteins were also detected, including proteins associated with the cortical actin network, energy pathways, and heat shock proteins (HSP70, HSC70, and HSP90). Representative actin-associated proteins, HSC70, and HSP90 were selected for further biological validation. The presence of beta-actin, filamin-1, cofilin-1, HSC70, and HSP90 in the virus preparation was confirmed by immunoblotting using relevant antibodies. Immunofluorescence microscopy of infected cells stained with antibodies against relevant virus and cellular proteins confirmed the presence of these cellular proteins in the virus filaments and inclusion bodies. The relevance of HSP90 to virus infection was examined using the specific inhibitors 17-N-Allylamino-17-demethoxygeldanamycin. Although virus protein expression was largely unaffected by these drugs, we noted that the formation of virus particles was inhibited, and virus transmission was impaired, suggesting an important role for HSP90 in virus maturation. This study highlights the utility of proteomics in facilitating both our understanding of the role that cellular proteins play during RSV maturation and, by extrapolation, the identification of new potential targets for antiviral therapy. Molecular & Cellular Proteomics 9:1829-1848, 2010.
C1 [Radhakrishnan, Anuradha; Yeo, Dawn; Myaing, Myint Zu; Iyer, Laxmi Ravi; Sugrue, Richard J.] Nanyang Technol Univ, Sch Biol Sci, Div Mol & Cell Biol, Singapore 637551, Singapore.
   [Sanmun, Duangmanee; Tang, Kai] Nanyang Technol Univ, Sch Biol Sci, Div Chem Biol & Biotechnol, Singapore 637551, Singapore.
   [Brown, Gaie; Aitken, Jim] MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland.
   [Fleck, Roland] Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
   [Tan, Boon-Huan] Def Sci Org, Natl Labs, Detect & Diagnost Lab, Singapore 117510, Singapore.
   [Yarwood, Andy] JEOL UK Ltd, Welwyn Garden City AL7 1LT, Herts, England.
   [Brink, Jacob] JEOL USA Inc, Peabody, MA 01960 USA.
RP Sugrue, RJ (reprint author), Nanyang Technol Univ, Sch Biol Sci, Div Mol & Cell Biol, 60 Nanyang Dr, Singapore 637551, Singapore.
EM rjsugrue@ntu.edu.sg
RI Tang, Kai/A-2194-2011
FU Medical Research Council (UK); Defense Science Technology Agency
   Singapore; Singapore-Massachusetts Institute of Technology Alliance for
   Research and Technology
FX This work was supported by the Medical Research Council (UK), Defense
   Science Technology Agency Singapore, and Singapore-Massachusetts
   Institute of Technology Alliance for Research and Technology.
CR Arcaro A, 2007, CELL SIGNAL, V19, P1081, DOI 10.1016/j.cellsig.2006.12.003
   Arslanagic E, 1996, ACTA VIROL, V40, P209
   BACHI T, 1973, J VIROL, V12, P1173
   Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2                                                   
   Beckers CML, 2010, THROMB HAEMOSTASIS, V103, P40, DOI 10.1160/TH09-06-0403
   Bermingham A, 1999, P NATL ACAD SCI USA, V96, P11259, DOI 10.1073/pnas.96.20.11259
   Brasier AR, 2004, J VIROL, V78, P11461, DOI 10.1128/JVI.78.21.1146-11476.2004
   Brodsky JL, 2006, CURR TOP MED CHEM, V6, P1215, DOI 10.2174/156802606777811997                                                      
   Brown G, 2005, VIROLOGY, V338, P69, DOI 10.1016/j.virol.2005.05.004
   Brown G, 2004, VIROLOGY, V327, P175, DOI 10.1016/j.virol.2004.06.038
   Brown G, 2002, J GEN VIROL, V83, P1841, DOI 10.1099/0022-1317-83-8-1841                                                     
   Brown G, 2002, J GEN VIROL, V83, P611, DOI 10.1099/vir.0.18074-0
   Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e
   Burke E, 2000, J VIROL, V74, P669, DOI 10.1128/JVI.74.2.669-675.2000
   Burke E, 1998, VIROLOGY, V252, P137, DOI 10.1006/viro.1998.9471
   Calistri A, 2009, REV MED VIROL, V19, P31, DOI 10.1002/rmv.588
   Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332
   Carromeu C, 2007, ARCH VIROL, V152, P2259, DOI 10.1007/s00705-007-1048-4
   Chadda R, 2007, TRAFFIC, V8, P702, DOI 10.1111/j.1600-0854.2007.00565.x
   Chang KW, 2006, HEPATOL RES, V36, P33, DOI 10.1016/j.hepres.2006.05.003
   Chen B, 2005, GENOMICS, V86, P627, DOI 10.1016/j.ygeno.2005.08.012
   Collins PL, 1996, P NATL ACAD SCI USA, V93, P81, DOI 10.1073/pnas.93.1.81
   COLLINS PL, 1992, J GEN VIROL, V73, P849, DOI 10.1099/0022-1317-73-4-849
   Connor JH, 2007, VIROLOGY, V362, P109, DOI 10.1016/j.virol.2006.12.026
   CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0                                                                
   Denzer K, 2000, J CELL SCI, V113, P3365
   Dohner K, 2005, CURR TOP MICROBIOL, V285, P67
   Fearns R, 1999, J VIROL, V73, P5852
   FERNIE BF, 1980, VIROLOGY, V106, P141, DOI 10.1016/0042-6822(80)90229-9
   Frangakis AS, 2001, J STRUCT BIOL, V135, P239, DOI 10.1006/jsbi.2001.4406
   Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860                                                                   
   GARCIA J, 1993, VIROLOGY, V195, P243, DOI 10.1006/viro.1993.1366
   Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103
   Ghildyal R, 2002, J GEN VIROL, V83, P753, DOI 10.1099/0022-1317-83-4-753                                                      
   GIUFFRE RM, 1982, J VIROL, V42, P963
   Gower TL, 2005, J VIROL, V79, P5326, DOI 10.1128/JVI.79.9.5326-5336.2005
   Gower TL, 2001, ANTIMICROB AGENTS CH, V45, P1231, DOI 10.1128/AAC.45.4.1231-1237.2001
   GROSFELD H, 1995, J VIROL, V69, P5677
   Han CL, 2008, MOL CELL PROTEOMICS, V7, P1983, DOI 10.1074/mcp.M800068-MCP200
   Hardy RW, 1998, J VIROL, V72, P520
   Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X
   HENNESSEY ES, 1993, BIOCHEM J, V291, P657, DOI 10.1042/bj2910657                                                               
   Jeffree CE, 2003, VIROLOGY, V306, P254, DOI 10.1016/S0042-6822(02)00016-8
   Jeffree CE, 2007, VIROLOGY, V369, P309, DOI 10.1016/j.virol.2007.08.007
   Jiang W, 2005, CURR OPIN STRUC BIOL, V15, P571, DOI 10.1016/j.sbi.2005.08.004
   Kallewaard NL, 2005, VIROLOGY, V331, P73, DOI 10.1016/j.virol.2004.10.010
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   LEVINE S, 1987, J GEN VIROL, V68, P2521, DOI 10.1099/0022-1317-68-9-2521                                                     
   Lillemeier BF, 2006, P NATL ACAD SCI USA, V103, P18992, DOI 10.1073/pnas.0609009103
   Liu P, 2008, J BIOL CHEM, V283, P23169, DOI 10.1074/jbc.M802729200
   Loney C, 2009, J VIROL, V83, P8191, DOI 10.1128/JVI.00693-09
   Lu XN, 2005, MOL CELL PROTEOMICS, V4, P1948, DOI 10.1074/mcp.M500138-MCP200
   Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739                                                          
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Mastronarde D.N., 2003, MICROSC MICROANAL, V9, P1182
   Mayer MP, 2005, REV PHYSIOL BIOCH P, V153, P1, DOI 10.1007/s10254-004-0025-5
   McCurdy LH, 2003, J VIROL, V77, P1747, DOI 10.1128/JVI.77.3.1747-1756.2003
   McDonald TP, 2004, VIROLOGY, V330, P147, DOI 10.1016/j.virol.2004.09.034
   Momose F, 2002, J BIOL CHEM, V277, P45306, DOI 10.1074/jbc.M206822200
   Moreau V, 2000, NAT CELL BIOL, V2, P441
   Naito T, 2007, J VIROL, V81, P1339, DOI 10.1128/JVI.01917-06
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   NORRBY E, 1970, J VIROL, V6, P237
   Ogino T, 2001, BIOCHEM BIOPH RES CO, V285, P447, DOI 10.1006/bbrc.2001.5160
   Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200                                                          
   PARHAM DM, 1993, AM J CLIN PATHOL, V99, P588
   Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586
   Park SJ, 2007, GENES CELLS, V12, P611, DOI 10.1111/j.1365-2443.2007.01081.x
   PARRY JE, 1979, J GEN VIROL, V44, P479, DOI 10.1099/0022-1317-44-2-479
   Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640
   Rixon HWML, 2004, J GEN VIROL, V85, P1153, DOI 10.1099/vir.0.19769-0
   ROBERTS SR, 1995, J VIROL, V69, P2667
   Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1                                                   
   Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200
   Saifuddin M, 1997, J GEN VIROL, V78, P1907, DOI 10.1099/0022-1317-78-8-1907                                                     
   Santangelo P, 2006, J VIROL, V80, P682, DOI 10.1128/JVI.80.2.682-688.2006
   Santangelo PJ, 2007, NUCLEIC ACIDS RES, V35, P3602, DOI 10.1093/nar/gkm246
   Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6                                                   
   SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4
   Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000
   Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817
   Shaw ML, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000085
   Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007
   Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325                                                            
   Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307
   Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082
   Sugrue Richard J., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000081
   Sugrue RJ, 2001, J GEN VIROL, V82, P1375, DOI 10.1099/0022-1317-82-6-1375                                                     
   Thomas KW, 2002, J BIOL CHEM, V277, P492, DOI 10.1074/jbc.M108107200
   TYRRELL DLJ, 1978, J GEN VIROL, V39, P219, DOI 10.1099/0022-1317-39-2-219                                                      
   UEBA O, 1978, ACTA MED OKAYAMA, V32, P265
   Ulloa L, 1998, VIRUS RES, V53, P13, DOI 10.1016/S0168-1702(97)00121-4
   Verkhivker GM, 2009, CURR TOP MED CHEM, V9, P1369, DOI 10.2174/156802609789895700                                                      
   Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080
   Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200
   Yeo DSY, 2009, VIROLOGY, V386, P168, DOI 10.1016/j.virol.2008.12.017
   YU QZ, 1995, J VIROL, V69, P2412
   Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002
NR 99
TC 54
Z9 55
U1 0
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD SEP
PY 2010
VL 9
IS 9
BP 1829
EP 1848
DI 10.1074/mcp.M110.001651
PG 20
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 646SE
UT WOS:000281562100004
PM 20530633
OA gold
DA 2018-01-05
ER

PT J
AU Fournier-Wirth, C
   Jaffrezic-Renault, N
   Coste, J
AF Fournier-Wirth, Chantal
   Jaffrezic-Renault, Nicole
   Coste, Joliette
TI Detection of blood-transmissible agents: can screening be miniaturized?
SO TRANSFUSION
LA English
DT Review
ID BIO-BARCODE ASSAY; EMERGING INFECTIOUS-DISEASES;
   POLYMERASE-CHAIN-REACTION; GOLD NANOPARTICLE PROBES; BAR CODE ASSAY;
   PROTEIN MICROARRAYS; DNA DETECTION; MOLECULAR DIAGNOSTICS; MICROFLUIDIC
   DEVICES; OPTICAL BIOSENSORS
AB Transfusion safety relating to blood-transmissible agents is a major public health concern, particularly when faced with the continuing emergence of new infectious agents. These include new viruses appearing alongside other known reemerging viruses (West Nile virus, Chikungunya) as well as new strains of bacteria and parasites (Plasmodium falciparum, Trypanosoma cruzi) and finally pathologic prion protein (variant Creutzfeldt-Jakob disease). Genomic mutations of known viruses (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) can also be at the origin of variants susceptible to escaping detection by diagnostic tests. New technologies that would allow the simultaneous detection of several blood-transmissible agents are now needed for the development and improvement of screening strategies. DNA microarrays have been developed for use in immunohematology laboratories for blood group genotyping. Their application in the detection of infectious agents, however, has been hindered by additional technological hurdles. For instance, the variability among and within genomes of interest complicate target amplification and multiplex analysis. Advances in biosensor technologies based on alternative detection strategies have offered new perspectives on pathogen detection; however, whether they are adaptable to diagnostic applications testing biologic fluids is under debate. Elsewhere, current nanotechnologies now offer new tools to improve the sample preparation, target capture, and detection steps. Second-generation devices combining micro- and nanotechnologies have brought us one step closer to the potential development of innovative and multiplexed approaches applicable to the screening of blood for transmissible agents.
C1 [Fournier-Wirth, Chantal] Etab Francais Sang Pyrenees Mediterranee, Lab R&D Agents Transmissibles Transfus R&D ATT, F-34094 Montpellier 5, France.
   Univ Lyon 1, Sci Analyt Lab, F-69622 Villeurbanne, France.
RP Fournier-Wirth, C (reprint author), Etab Francais Sang Pyrenees Mediterranee, Lab R&D Agents Transmissibles Transfus R&D ATT, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.
EM chantal.fournier@efs.sante.fr
CR Agrawal A, 2005, J VIROL, V79, P8625, DOI 10.1128/JVI.79.13.8625-8628.2005                                                
   Allain JP, 2009, BIOLOGICALS, V37, P71, DOI 10.1016/j.biologicals.2009.01.002
   Alter HJ, 2007, SEMIN HEMATOL, V44, P32, DOI 10.1053/j.seminhematol.2006.09.016
   Arya H, 2005, BIOCHEM BIOPH RES CO, V329, P1173, DOI 10.1016/j.bbrc.2005.02.043
   Avent ND, 2007, TRANSFUS CLIN BIOL, V14, P10, DOI 10.1016/j.tracli.2007.04.011
   Aytur T, 2006, J IMMUNOL METHODS, V314, P21, DOI 10.1016/j.jim.2006.05.006
   Azzazy HME, 2006, CLIN CHEM, V52, P1238, DOI 10.1373/clinchem.2006.066654
   Bally M, 2009, NANOMEDICINE-UK, V4, P447, DOI [10.2217/nnm.09.16, 10.2217/NNM.09.16]
   Beiboer SHW, 2005, TRANSFUSION, V45, P667, DOI 10.1111/j.1537-2995.2005.04319.x
   Bres JC, 2005, BIOMED MICRODEVICES, V7, P137, DOI 10.1007/s10544-005-1593-0
   Brooks BD, 2008, ANAL BIOCHEM, V382, P60, DOI 10.1016/j.ab.2008.07.009
   Busch M, 2009, BIOLOGICALS, V37, P78, DOI 10.1016/j.biologicals.2009.01.007
   Campbell CJ, 2006, ANAL CHEM, V78, P1930, DOI 10.1021/ac051651m
   Candotti D, 2007, DEV BIOLOGICALS, V127, P71
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chen L, 2007, LAB CHIP, V7, P1413, DOI 10.1039/b708362a
   Cheng MMC, 2006, CURR OPIN CHEM BIOL, V10, P11, DOI 10.1016/j.cbpa.2006.01.006
   Compston LI, 2008, J VIROL METHODS, V151, P47, DOI 10.1016/j.jviromet.2008.03.023
   Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x
   COSTE J, 2006, TRANSFUSION MED LOOK, P24
   Csako G, 2006, CLIN CHIM ACTA, V363, P6, DOI 10.1016/j.ccn.2005.07.009
   Denomme GA, 2005, TRANSFUSION, V45, P660, DOI 10.1111/j.1537-2995.2005.04365.x
   Dodd RY, 2007, DEV BIOLOGICALS, V127, P237
   Dodd RY, 2003, NEW ENGL J MED, V349, P1205, DOI 10.1056/NEJMp038138
   Dong J, 2008, J MOL DIAGN, V10, P185, DOI 10.2353/jmoldx.2008.070063
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023
   Ecker DJ, 2008, NAT REV MICROBIOL, V6, P553, DOI 10.1038/nrmicro1918
   Elsholz B, 2009, BIOSENS BIOELECTRON, V24, P1737, DOI 10.1016/j.bios.2008.09.003
   Fan XD, 2008, ANAL CHIM ACTA, V620, P8, DOI 10.1016/j.aca.2008.05.022
   Ferguson BS, 2009, ANAL CHEM, V81, P6503, DOI 10.1021/ac900923e
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Fishbein I, 2009, NATURE, V461, P890, DOI 10.1038/461890a
   Fortina P, 2005, TRENDS BIOTECHNOL, V23, P168, DOI 10.1016/j.tibtech.2005.02.007
   FOURNIERWIRTH C, 2007, ADV TRANSFUSION SAFE, V4, P61
   Fuentes M, 2006, BIOSENS BIOELECTRON, V21, P1574, DOI 10.1016/j.bios.2005.07.017
   Gaster RS, 2009, NAT MED, V15, P1327, DOI 10.1038/nm.2032
   Goluch ED, 2006, LAB CHIP, V6, P1293, DOI 10.1039/b606294f
   Grinev A, 2008, J VIROL METHODS, V154, P27, DOI 10.1016/j.jviromet.2008.09.015
   Gupta S, 2007, ANAL CHEM, V79, P3810, DOI 10.1021/ac062341m
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Hashmi G, 2005, TRANSFUSION, V45, P680, DOI 10.1111/j.1537-2995.2005.04362.x
   He MX, 2008, J VIROL METHODS, V151, P126, DOI 10.1016/j.jviromet.2008.03.005
   Henares TG, 2008, ANAL CHIM ACTA, V611, P17, DOI 10.1016/j.aca.2008.01.064
   Hill HD, 2007, ANAL CHEM, V79, P9218, DOI 10.1021/ac701626y
   Hillyer CD, 2008, TRANSFUS MED REV, V22, P117, DOI 10.1016/j.tmrv.2007.12.002
   HNAIEN M, 2008, ELECTROCHEM COMMS, P1152
   HOUMMADY M, 2006, TRANSFUSION MED LOOK, P45
   Hsia CC, 2007, BIOCHEM BIOPH RES CO, V356, P1017, DOI 10.1016/j.bbrc.2007.03.087
   Hultschig C, 2006, CURR OPIN CHEM BIOL, V10, P4, DOI 10.1016/j.cbpa.2005.12.011
   Ivnitski D, 1999, BIOSENS BIOELECTRON, V14, P599, DOI 10.1016/S0956-5663(99)00039-1
   Jaffrezic-Renault N, 2007, SENSORS-BASEL, V7, P589, DOI 10.3390/s7040589                                                                
   Jain KK, 2008, MED PRIN PRACT, V17, P89, DOI 10.1159/000112961
   Jain KK, 2007, CLIN CHEM, V53, P2002, DOI 10.1373/clinchem.2007.090795
   Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014
   Johnson CJ, 2008, PROTEOMICS, V8, P715, DOI 10.1002/pmic.200700665
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Kleinman SH, 2009, TRANSFUSION, V49, P2454, DOI 10.1111/j.1537-2995.2009.02322.x
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   Kreutzberger J, 2006, APPL MICROBIOL BIOT, V70, P383, DOI 10.1007/s00253-006-0312-y
   Kuhr WG, 2000, NAT BIOTECHNOL, V18, P1042, DOI 10.1038/80229
   Kuswandi B, 2007, ANAL CHIM ACTA, V601, P141, DOI 10.1016/j.aca.2007.08.046
   Lazcka O, 2007, BIOSENS BIOELECTRON, V22, P1205, DOI 10.1016/j.bios.2006.06.036
   Le Nel A, 2008, LAB CHIP, V8, P294, DOI 10.1039/b715238h
   Lee YF, 2009, BIOSENS BIOELECTRON, V25, P745, DOI 10.1016/j.bios.2009.08.020
   Lien KY, 2007, LAB CHIP, V7, P868, DOI 10.1039/b700516d
   Lin FYH, 2005, CLIN DIAGN LAB IMMUN, V12, P418, DOI 10.1128/CDLI.12.3.418-425.2005
   Liu GD, 2007, TALANTA, V74, P308, DOI 10.1016/j.talanta.2007.10.014
   Liu GD, 2007, ANAL CHEM, V79, P7644, DOI 10.1021/ac070691i
   Liu HH, 2006, J BIOCHEM MOL BIOL, V39, P247
   Loy A, 2006, CLIN CHIM ACTA, V363, P106, DOI 10.1016/j.cccn.2005.05.041
   Maalouf R, 2008, MICROCHIM ACTA, V163, P157, DOI 10.1007/s00604-008-0008-3
   Maalouf R, 2007, ANAL CHEM, V79, P4879, DOI 10.1021/ac070085n
   MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037
   Marquette CA, 2006, BIOSENS BIOELECTRON, V21, P1424, DOI 10.1016/j.bios.2004.09.037
   Medini D, 2008, NAT REV MICROBIOL, V6, P419, DOI 10.1038/nrmicro1901
   Merkoci A, 2007, FEBS J, V274, P310, DOI 10.1111/j.1742-4658.2006.05603.x
   Meyer MHF, 2007, J MICROBIOL METH, V68, P218, DOI 10.1016/j.mimet.2006.08.004
   Mezzasoma L, 2002, CLIN CHEM, V48, P121
   Molina S, 2008, PROTEOM CLIN APPL, V2, P751, DOI 10.1002/prca.200800020
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Nam JM, 2002, J AM CHEM SOC, V124, P3820, DOI 10.1021/ja0178766
   Nam JM, 2007, NAT PROTOC, V2, P1438, DOI 10.1038/nprot.2007.201
   Oh M, 2005, NATURE, V438, P651, DOI 10.1038/nature04191
   Osterfeld SJ, 2008, P NATL ACAD SCI USA, V105, P20637, DOI 10.1073/pnas.0810822105
   Pejcic B, 2006, ANALYST, V131, P1079, DOI 10.1039/b603402k
   Peters RPH, 2004, LANCET INFECT DIS, V4, P751, DOI 10.1016/S1473-3099(04)01205-8                                                   
   Petrik J, 2001, VOX SANG, V80, P1, DOI 10.1046/j.1423-0410.2001.00010.x                                                
   Petrik J, 2006, TRANSFUSION MED, V16, P233, DOI 10.1111/j.1365-3148.2006.00673.x
   Petrik J, 2007, TRANSFUS APHER SCI, V36, P201, DOI 10.1016/j.transci.2007.01.003
   Reid ME, 2003, TRANSFUSION, V43, P1748, DOI 10.1111/j.0041-1132.2003.00597.x
   Rios M, 2009, ISBT SCI SERIES, V4, P87, DOI 10.1111/j.1751-2824.2009.01216.x                                                
   Robb JS, 2006, TRANSFUSION MED, V16, P119, DOI 10.1111/j.1365-3148.2005.00628.x
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.108952
   Scheller FW, 2001, CURR OPIN BIOTECH, V12, P35, DOI 10.1016/S0958-1669(00)00169-5                                                   
   Schrenzel J, 2007, INT J ANTIMICROB AG, V30, pS2, DOI 10.1016/j.ijantimicag.2007.06.030
   Schweitzer B, 2002, CURR OPIN BIOTECH, V13, P14, DOI 10.1016/S0958-1669(02)00278-1
   Sheridan C, 2005, NAT BIOTECHNOL, V23, P3, DOI 10.1038/nbt0105-3
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Storhoff JJ, 2004, BIOSENS BIOELECTRON, V19, P875, DOI 10.1016/j.bios.2003.08.014
   Storhoff JJ, 2004, NAT BIOTECHNOL, V22, P883, DOI 10.1038/nbt977
   Tamanaha CR, 2008, BIOSENS BIOELECTRON, V24, P1, DOI 10.1016/j.bios.2008.02.009
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Teles FRR, 2008, TALANTA, V77, P606, DOI 10.1016/j.talanta.2008.07.024
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   Tomioka K, 2005, J MOL DIAGN, V7, P486, DOI 10.1016/S1525-1578(10)60579-X
   Uttamchandani M, 2009, TRENDS BIOTECHNOL, V27, P53, DOI 10.1016/j.tibtech.2008.09.004
   van der Schoot CE, 2009, VOX SANG, V96, P167, DOI 10.1111/j.1423-0410.2008.01131.x
   Velasco-Garcia MN, 2009, SEMIN CELL DEV BIOL, V20, P27, DOI 10.1016/j.semcdb.2009.01.013
   Wan ZX, 2005, J BIOCHEM MOL BIOL, V38, P399
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Wang L, 2006, NANOMEDICINE-UK, V1, P413, DOI 10.2217/17435889.1.4.413
   Wang RH, 2009, TALANTA, V79, P159, DOI 10.1016/j.talanta.2009.03.017
   Wiesinger-Mayr H, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-78
   Xu XL, 2009, TALANTA, V80, P8, DOI 10.1016/j.talanta.2009.06.039
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Zuo BL, 2004, ANAL CHEM, V76, P3536, DOI 10.1021/ac035367b                                                               
NR 122
TC 12
Z9 12
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2010
VL 50
IS 9
BP 2032
EP 2045
DI 10.1111/j.1537-2995.2010.02678.x
PG 14
WC Hematology
SC Hematology
GA 646OZ
UT WOS:000281553200025
PM 20546202
DA 2018-01-05
ER

PT J
AU Smith, RA
   Gottlieb, GS
   Miller, AD
AF Smith, Robert A.
   Gottlieb, Geoffrey S.
   Miller, A. Dusty
TI Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors
SO RETROVIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 REVERSE-TRANSCRIPTASE;
   CHRONIC-FATIGUE-SYNDROME; PROSTATE CARCINOMA-CELLS; NUCLEOSIDE ANALOGS;
   INFECTIOUS RETROVIRUS; GAMMARETROVIRUS XMRV; DRUG SUSCEPTIBILITY; CANCER
   PATIENTS; GENE-TRANSFER
AB Background: XMRV (xenotropic murine leukemia virus-related virus) is the first known example of an exogenous gammaretrovirus that can infect humans. A limited number of reports suggest that XMRV is intrinsically resistant to many of the antiretroviral drugs used to treat HIV-1 infection, but is sensitive to a small subset of these inhibitors. In the present study, we used a novel marker transfer assay to directly compare the antiviral drug sensitivities of XMRV and HIV-1 under identical conditions in the same host cell type.
   Results: We extend the findings of previous studies by showing that, in addition to AZT and tenofovir, XMRV and HIV-1 are equally sensitive to AZddA (3'-azido-2', 3'-dideoxyadenosine), AZddG (3'-azido-2', 3'-dideoxyguanosine) and adefovir. These results indicate that specific 3'-azido or acyclic nucleoside analog inhibitors of HIV-1 reverse transcriptase (RT) also block XMRV infection with comparable efficacy in vitro. Our data confirm that XMRV is highly resistant to the non-nucleoside RT inhibitors nevirapine and efavirenz and to inhibitors of HIV-1 protease. In addition, we show that the integrase inhibitors raltegravir and elvitegravir are active against XMRV, with EC(50) values in the nanomolar range.
   Conclusions: Our analysis demonstrates that XMRV exhibits a distinct pattern of nucleoside analog susceptibility that correlates with the structure of the pseudosugar moiety and that XMRV is sensitive to a broader range of antiretroviral drugs than has previously been reported. We suggest that the divergent drug sensitivity profiles of XMRV and HIV-1 are partially explained by specific amino acid differences in their respective protease, RT and integrase sequences. Our data provide a basis for choosing specific antiretroviral drugs for clinical studies in XMRV-infected patients.
C1 [Smith, Robert A.; Miller, A. Dusty] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Gottlieb, Geoffrey S.] Univ Washington, Dept Med, Seattle, WA USA.
   [Miller, A. Dusty] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98104 USA.
RP Smith, RA (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
EM smithra@u.washington.edu
OI Miller, Dusty/0000-0002-3736-3660; Gottlieb,
   Geoffrey/0000-0002-5749-481X
FU University of Washington Center for AIDS Research (UW-CFAR) [P30
   AI27757]; UWCFAR Computational Core; Public Health Service [R01
   AI060466, P30 DK056465];  [R37 AI47734]
FX We thank Robert Silverman (Cleveland Clinic) for providing the plasmid
   encoding the full-length infectious clone of XMRVVP62 (pVP62). This work
   was supported by a New Investigator Award to RAS from the University of
   Washington Center for AIDS Research (UW-CFAR; P30 AI27757), the UWCFAR
   Computational Core, and Public Health Service grants R01 AI060466 to GSG
   and P30 DK056465 to ADM. We thank Jim Mullins (UW) for additional
   support (R37 AI47734) and both Jim Mullins and John Mittler (UW) for
   helpful discussions and critical review of the manuscript.
CR ADACHI A, 1986, J VIROL, V59, P284
   Arnold RS, 2010, UROLOGY, V75, P755, DOI 10.1016/j.urology.2010.01.038
   Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385
   Beck-Engeser GB, 2009, P NATL ACAD SCI USA, V106, P20865, DOI 10.1073/pnas.0908074106
   Blikstad V, 2008, CELL MOL LIFE SCI, V65, P3348, DOI 10.1007/s00018-008-8495-2
   Boyer PL, 2001, J VIROL, V75, P6321, DOI 10.1128/JVI.75.14.6321-6328.2001
   Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277
   COFFIN JM, 1997, RETROVIRUSES
   Cote ML, 2008, VIRUS RES, V134, P186, DOI 10.1016/j.virusres.2008.01.001
   D'Arcy F, 2008, EUR UROL SUPPL, V7, P271, DOI 10.1016/S1569-9056(08)60798-8
   Dong B, 2007, P NATL ACAD SCI USA, V104, P1655, DOI 10.1073/pnas.0610291104
   Erlwein O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008519
   Feher A, 2006, J GEN VIROL, V87, P1321, DOI 10.1099/vir.0.81382-0
   Fischera N, 2008, J CLIN VIROL, V43, P277, DOI 10.1016/j.jcv.2008.04.016
   Groom HCT, 2010, P NATL ACAD SCI USA, V107, P5166, DOI 10.1073/pnas.0913650107
   Groom HCT, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-10
   Hachiya A, 2001, ANTIMICROB AGENTS CH, V45, P495, DOI 10.1128/AAC.45.2.495-501.2001
   Halvas EK, 2000, J VIROL, V74, P6669, DOI 10.1128/JVI.74.14.6669-6674.2000
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda D, 2009, ANNU REV PHARMACOL, V49, P377, DOI 10.1146/annurev.pharmtox.011008.145553
   Hohn O, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-92
   Hong SH, 2009, J VIROL, V83, P6995, DOI 10.1128/JVI.00268-09
   HUANG P, 1990, J BIOL CHEM, V265, P11914
   Johnson Victoria A, 2009, Top HIV Med, V17, P138
   Jones GS, 2009, ANTIMICROB AGENTS CH, V53, P1194, DOI 10.1128/AAC.00984-08
   Kim S, 2008, J VIROL, V82, P9964, DOI 10.1128/JVI.01299-08
   Knouf EC, 2009, J VIROL, V83, P7353, DOI 10.1128/JVI.00546-09
   LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436                                                            
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   Metzger MJ, 2010, J VIROL, V84, P1874, DOI 10.1128/JVI.01941-09
   Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9
   Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471
   MILLER AD, 1989, BIOTECHNIQUES, V7, P980
   MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895                                                            
   Miller AD, 1996, J VIROL, V70, P1804
   Miller A. D., 1989, BIOTECHNIQUES, V7, P984
   Miller A. D., 1989, BIOTECHNIQUES, V7, P989
   MOUSCADET JF, 2010, DRUG RESIST UPDAT
   OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1
   Paprotka T, 2010, J VIROL, V84, P5719, DOI 10.1128/JVI.00134-10
   Parikh UM, 2005, ANTIMICROB AGENTS CH, V49, P1139, DOI 10.1128/AAC.49.3.1139-1144.2005
   PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   POCH O, 1989, EMBO J, V8, P3867
   Powell SK, 1999, J VIROL, V73, P8813
   RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   Rodriguez JJ, 2010, J VIROL, V84, P2556, DOI 10.1128/JVI.01969-09
   Rosenblum LL, 2001, ANTIVIR CHEM CHEMOTH, V12, P91, DOI 10.1177/095632020101200202                                                      
   Sakuma R, 2010, VIROLOGY, V397, P1, DOI 10.1016/j.virol.2009.11.013
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875                                                            
   Schlaberg R, 2009, P NATL ACAD SCI USA, V106, P16351, DOI 10.1073/pnas.0906922106
   Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Singh IR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009948
   Sluis-Cremer N, 2009, ANTIMICROB AGENTS CH, V53, P3715, DOI 10.1128/AAC.00392-09
   Smith RA, 2004, J BIOL CHEM, V279, P26726, DOI 10.1074/jbc.M314038200
   Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403
   Stanford University HIV Drug Resistance Database, STANF U HIV DRUG RES
   STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972                                                          
   Stieler K, 2010, VIROLOGY, V399, P23, DOI 10.1016/j.virol.2009.12.028
   STRAIR RK, 1991, J VIROL, V65, P6339
   Suruga Y, 1998, J ACQ IMMUN DEF SYND, V18, P316, DOI 10.1097/00042560-199808010-00002                                                
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   van Kuppeveld FJ, 2010, BMJ-BRIT MED J, V340, pe1018
   Winters MA, 2001, ANTIMICROB AGENTS CH, V45, P2276, DOI 10.1128/AAC.45.8.2276-2279.2001
   EMBOSS PAIRWISE ALIG
   IMAGE J SOFTWARE
NR 69
TC 29
Z9 29
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 31
PY 2010
VL 7
AR 70
DI 10.1186/1742-4690-7-70
PG 12
WC Virology
SC Virology
GA 659KJ
UT WOS:000282565100001
PM 20807431
OA gold
DA 2018-01-05
ER

PT J
AU Kanazawa, T
   Takashima, Y
   Tamura, T
   Tsuchiya, M
   Shibata, Y
   Udagawa, H
   Okada, H
AF Kanazawa, Takanori
   Takashima, Yuuki
   Tamura, Toshiaki
   Tsuchiya, Miki
   Shibata, Yasunori
   Udagawa, Haruhide
   Okada, Hiroaki
TI Local gene expression and immune responses of vaginal DNA vaccination
   using a needle-free injector
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Vaginal DNA vaccine; Needle-free injector; Cellular immunity; Local
   humoral immunity
ID COATED NANOPARTICLES; JET-INJECTORS; IMMUNIZATION; PLASMID; CELLS; MICE
AB The vaginal mucosa is the most common site of initiation of virus infections that are transmitted through heterosexual intercourse, including HIV and papillomavirus. Thus, in order to prevent or treat these infections, strong vaginal immunity is required as the first line of defense In this study, to establish a less invasive, safe, convenient and effective immunization method, we examined the local (skin and vagina) gene transfection efficiency of a non-needle jet injector for daily insulin injection In the skin experiment, the needle-free injector resulted in a marked Increase in marker gene expression, compared to the conventional needle-syringe injection. In addition, intradermal DNA vaccination using the needle-free injector dramatically induced IFN-gamma and antibody systemic responses in mice Furthermore, we investigated the applicability of the needle-free injector as a vaginal vaccination tool in rabbits. Vaginal gene expression using the needle-free injector was significantly greater than that using needle-syringe injection Moreover, intravaginal vaccination by the needle-free injector promoted vaginal IgA secretion and IFN-gamma mRNA expression in the blood lymphocytes, to a degree significantly higher than that by needle-syringe injection In conclusion, local vaginal DNA vaccination using a needle-free jet injector is a promising approach for the prevention and treatment of mucosal infectious diseases (C) 2010 Elsevier B.V. All rights reserved
C1 [Kanazawa, Takanori; Takashima, Yuuki; Tamura, Toshiaki; Tsuchiya, Miki; Shibata, Yasunori; Okada, Hiroaki] Tokyo Univ Pharm & Life Sci, Lab Pharmaceut & Drug Delivery, Dept Pharmaceut Sci, Sch Pharm, Tokyo 1920392, Japan.
   [Udagawa, Haruhide] Shimadzu Co Ltd, Med Syst Div, Nakagyo Ku, Kyoto 6048511, Japan.
RP Okada, H (reprint author), Tokyo Univ Pharm & Life Sci, Lab Pharmaceut & Drug Delivery, Dept Pharmaceut Sci, Sch Pharm, 1432-1 Horinouchi, Tokyo 1920392, Japan.
FU Promotion and Mutual Aid Corporation for Private Schools of Japan
FX We thank Professor Michael J. Beuan (Howard Hughes Medical Institute of
   Washington University) for kindly supplying the pAc-neo-OVA. We also
   thank Ms. Ayumi Yago, Ms. Motoko Yonehara, Mr Yoshihiro Imai, Mr
   Yoshitaka Yokoi and Mr. Tomohiro Tsuchiya (School of Pharmacy, Tokyo
   University of Pharmacy and Life Sciences) for excellent technical
   assistance. This study was supported in part by a grant from the
   Promotion and Mutual Aid Corporation for Private Schools of Japan.
CR Anwer K, 1999, PHARMACEUT RES, V16, P889, DOI 10.1023/A:1018834305079
   Aquiar J.C., 2002, VACCINE, V20, P275
   Belyakov IM, 2007, J IMMUNOL, V178, P7211, DOI 10.4049/jimmunol.178.11.7211                                                    
   Cui ZR, 2003, J BIOTECHNOL, V102, P105, DOI 10.1016/S0168-1656(03)00029-4
   DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   Haensler J, 1999, VACCINE, V17, P628, DOI 10.1016/S0264-410X(98)00242-4                                                   
   Hamajima K, 2002, CLIN IMMUNOL, V102, P12, DOI 10.1006/clim.2001.5141
   Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0
   Jain SL, 1996, VACCINE, V14, P42, DOI 10.1016/0264-410X(95)00158-W
   Kanazawa T, 2008, INT J PHARM, V360, P164, DOI 10.1016/j.ijpharm.2008.04.038
   Kanazawa T, 2009, J PHARM PHARMACOL, V61, P1457, DOI 10.1211/jpp/61.11.0004
   MCGHEE JR, 1993, INFECT AGENT DIS, V2, P55
   Mumper RJ, 2003, METHODS, V31, P255, DOI 10.1016/S1046-2023(03)00138-5
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   Ren Shuxun, 2002, BMC Biotechnol, V2, P10, DOI 10.1186/1472-6750-2-10
   Wassen L, 1996, SCAND J IMMUNOL, V44, P408, DOI 10.1046/j.1365-3083.1996.d01-320.x                                              
   Yang LS, 2008, VACCINE, V26, P4451, DOI 10.1016/j.vaccine.2008.06.075
NR 18
TC 11
Z9 12
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD AUG 30
PY 2010
VL 396
IS 1-2
BP 11
EP 16
DI 10.1016/j.ijpharm.2010.05.040
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 638YH
UT WOS:000280936000002
PM 20621704
DA 2018-01-05
ER

PT J
AU Tyssen, D
   Henderson, SA
   Johnson, A
   Sterjovski, J
   Moore, K
   La, J
   Zanin, M
   Sonza, S
   Karellas, P
   Giannis, MP
   Krippner, G
   Wesselingh, S
   McCarthy, T
   Gorry, PR
   Ramsland, PA
   Cone, R
   Paull, JRA
   Lewis, GR
   Tachedjian, G
AF Tyssen, David
   Henderson, Scott A.
   Johnson, Adam
   Sterjovski, Jasminka
   Moore, Katie
   La, Jennifer
   Zanin, Mark
   Sonza, Secondo
   Karellas, Peter
   Giannis, Michael P.
   Krippner, Guy
   Wesselingh, Steve
   McCarthy, Tom
   Gorry, Paul R.
   Ramsland, Paul A.
   Cone, Richard
   Paull, Jeremy R. A.
   Lewis, Gareth R.
   Tachedjian, Gilda
TI Structure Activity Relationship of Dendrimer Microbicides with Dual
   Action Antiviral Activity
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; RANDOMIZED
   CONTROLLED-TRIAL; CANDIDATE TOPICAL MICROBICIDES; HIV-INFECTION;
   CELLULOSE SULFATE; SPL7013 GEL; IN-VIVO; VAGINAL MICROBICIDES;
   MACROPHAGE TROPISM
AB Background: Topical microbicides, used by women to prevent the transmission of HIV and other sexually transmitted infections are urgently required. Dendrimers are highly branched nanoparticles being developed as microbicides. However, the anti-HIV and HSV structure-activity relationship of dendrimers comprising benzyhydryl amide cores and lysine branches, and a comprehensive analysis of their broad-spectrum anti-HIV activity and mechanism of action have not been published.
   Methods and Findings: Dendrimers with optimized activity against HIV-1 and HSV-2 were identified with respect to the number of lysine branches (generations) and surface groups. Antiviral activity was determined in cell culture assays. Time-of-addition assays were performed to determine dendrimer mechanism of action. In vivo toxicity and HSV-2 inhibitory activity were evaluated in the mouse HSV-2 susceptibility model. Surface groups imparting the most potent inhibitory activity against HIV-1 and HSV-2 were naphthalene disulfonic acid (DNAA) and 3,5-disulfobenzoic acid exhibiting the greatest anionic charge and hydrophobicity of the seven surface groups tested. Their anti-HIV-1 activity did not appreciably increase beyond a second-generation dendrimer while dendrimers larger than two generations were required for potent anti-HSV-2 activity. Second (SPL7115) and fourth generation (SPL7013) DNAA dendrimers demonstrated broad-spectrum anti-HIV activity. However, SPL7013 was more active against HSV and blocking HIV-1 envelope mediated cell-to-cell fusion. SPL7013 and SPL7115 inhibited viral entry with similar potency against CXCR4-(X4) and CCR5-using (R5) HIV-1 strains. SPL7013 was not toxic and provided at least 12 h protection against HSV-2 in the mouse vagina.
   Conclusions: Dendrimers can be engineered with optimized potency against HIV and HSV representing a unique platform for the controlled synthesis of chemically defined multivalent agents as viral entry inhibitors. SPL7013 is formulated as VivaGel (R) and is currently in clinical development to provide protection against HIV and HSV. SPL7013 could also be combined with other microbicides.
C1 [Tyssen, David; Johnson, Adam; Sterjovski, Jasminka; Moore, Katie; La, Jennifer; Zanin, Mark; Sonza, Secondo; Wesselingh, Steve; Gorry, Paul R.; Ramsland, Paul A.; Tachedjian, Gilda] Burnet Inst, Ctr Virol, Melbourne, Vic, Australia.
   [Tyssen, David; Johnson, Adam; Sterjovski, Jasminka; Moore, Katie; La, Jennifer; Zanin, Mark; Sonza, Secondo; Wesselingh, Steve; Gorry, Paul R.; Ramsland, Paul A.; Tachedjian, Gilda] Burnet Inst, Ctr Immunol, Melbourne, Vic, Australia.
   [Henderson, Scott A.; Karellas, Peter; Giannis, Michael P.; Krippner, Guy; McCarthy, Tom; Paull, Jeremy R. A.; Lewis, Gareth R.] Starpharma Pty Ltd, Melbourne, Vic, Australia.
   [Wesselingh, Steve] Monash Univ, Fac Nursing & Hlth Sci, Clayton, Vic, Australia.
   [La, Jennifer] Monash Univ, Fac Pharm & Pharmaceut Sci, Parkville, Vic, Australia.
   [Sonza, Secondo; Tachedjian, Gilda] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia.
   [Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
   [Gorry, Paul R.; Tachedjian, Gilda] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia.
   [Ramsland, Paul A.] Univ Melbourne, Dept Surg Austin Hlth, Heidelberg, Vic, Australia.
   [Ramsland, Paul A.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
   [Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD USA.
RP Tyssen, D (reprint author), Burnet Inst, Ctr Virol, Melbourne, Vic, Australia.
EM gildat@burnet.edu.au
OI Tachedjian, Gilda/0000-0002-7733-7037; Ramsland,
   Paul/0000-0002-2107-2738; Sterjovski, Jasminka/0000-0002-2471-3000
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services
   [HHSN266200500042C, U19 AI060598]; NIAD, NIH [N01-AI-05420,
   N01-AI-25478]; National Health and Medical Research Council of Australia
   (NHMRC) [543105, 365209]; Australian Centre for HIV and Hepatitis
   Virology Research [ACH2]
FX This study was supported by US Federal funds from the National Institute
   of Allergy and Infectious Diseases, National Institutes of Health,
   Department of Health and Human Services under Contract No.
   HHSN266200500042C and Grant No. U19 AI060598 awarded to Starpharma Pty
   Ltd. Southern Research Institute evaluation of dendrimer activity was
   supported by US funds NIAD, NIH contracts N01-AI-05420 (Principal
   Investigator: Dr Luke Pallansch) and N01-AI-25478 (Principal
   Investigator: Mr Roger Ptak), under the direction of Dr Steven Turk,
   Project Officer, NIAID, Division of AIDS. G. T. was supported by the
   National Health and Medical Research Council of Australia (NHMRC) Senior
   Research Fellowship 543105 and funding from the Australian Centre for
   HIV and Hepatitis Virology Research (ACH2). P. A. R. was supported by
   the NHMRC R. Douglas Wright Career Development Award 365209. The authors
   gratefully acknowledge the contribution to this work of the Victorian
   Operational Infrastructure Support Program received by the Burnet
   Institute. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   results and conclusions of this report are those of the authors and do
   not necessarily represent the views of NIH.
CR Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424                                                                  
   ADACHI A, 1986, J VIROL, V59, P284
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   BINDER D, 1987, J MED CHEM, V30, P678, DOI 10.1021/jm00387a017
   BIRCH CJ, 1992, J INFECT DIS, V166, P108, DOI 10.1093/infdis/166.1.108                                                        
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Boyd BJ, 2006, MOL PHARMACEUT, V3, P614, DOI 10.1021/mp060032e
   Brown JM, 2007, AIDS, V21, P1515, DOI 10.1097/QAD.0b013e3282004929
   Butler DM, 2010, SCI TRANSL MED, V2
   Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6
   CHISEMBELE M, 2010, 17 C RET OPP INF SAN
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Etemad-Moghadam B, 2000, J VIROL, V74, P4433, DOI 10.1128/JVI.74.9.4433-4440.2000
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   Galen BT, 2007, J INFECT DIS, V195, P1332, DOI 10.1086/513279
   Gao F, 1996, J VIROL, V70, P1651
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gorry PR, 2001, J VIROL, V75, P10073, DOI 10.1128/JVI.75.21.10073-10089.2001
   Gray L, 2005, VIROLOGY, V337, P384, DOI 10.1016/j.virol.2005.04.034
   Hantson Anke, 2005, Antiviral Chemistry & Chemotherapy, V16, P253
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Kaminskas LM, 2007, MOL PHARMACEUT, V4, P949, DOI 10.1021/mp070047s
   KARIM QA, 2010, SCIENCE         0719
   Abdool Karim S, 2009, 16 C RETR OPP INF MO
   Ketas TJ, 2007, VIROLOGY, V364, P281, DOI 10.1016/j.virol.2007.02.022
   Lacey CJN, 2006, AIDS, V20, P1027, DOI 10.1097/01.aids.0000222075.83490.ca                                             
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McElrath MJ, 2010, ANTIMICROB AGENTS CH, V54, P763, DOI 10.1128/AAC.00891-09
   Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PRICE CF, 2010, SPL7013 GEL VIVAGEL
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Roberts BP, 2009, MACROMOLECULES, V42, P2775, DOI 10.1021/ma802154e
   Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Sonza S, 1996, J VIROL, V70, P3863
   Sonza S, 2009, ANTIMICROB AGENTS CH, V53, P3565, DOI 10.1128/AAC.00102-09
   Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x
   Springer CJ, 1995, J MED CHEM, V38, P5051, DOI 10.1021/jm00026a013
   Sterjovski J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-89
   Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043
   AIDS Epidemic, 2007, JOINT UN PROGR HIV A
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Wawer MJ, 2009, LANCET, V374, P229, DOI 10.1016/S0140-6736(09)60998-3
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weller S, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003255
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   WYATT R, 1995, J VIROL, V69, P5723
   Yap SH, 2007, PLOS MED, V4, P1887, DOI 10.1371/journal.pmed.0040335
   Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002
   MATHEWS BR, 2002, Patent No. 02079299
NR 70
TC 78
Z9 78
U1 2
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2010
VL 5
IS 8
AR e12309
DI 10.1371/journal.pone.0012309
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 641TV
UT WOS:000281153500004
PM 20808791
OA gold
DA 2018-01-05
ER

PT J
AU Paskaleva, EE
   Xue, J
   Lee, DYW
   Shekhtman, A
   Canki, M
AF Paskaleva, Elena E.
   Xue, Jing
   Lee, David Y-W.
   Shekhtman, Alexander
   Canki, Mario
TI Palmitic Acid Analogs Exhibit Nanomolar Binding Affinity for the HIV-1
   CD4 Receptor and Nanomolar Inhibition of gp120-to-CD4 Fusion
SO PLOS ONE
LA English
DT Article
ID PROTEINS; DOCKING
AB Background: We recently reported that palmitic acid (PA) is a novel and efficient CD4 fusion inhibitor to HIV-1 entry and infection. In the present report, based on in silico modeling of the novel CD4 pocket that binds PA, we describe discovery of highly potent PA analogs with increased CD4 receptor binding affinities (K(d)) and gp120-to-CD4 inhibition constants (K(i)). The PA analogs were selected to satisfy Lipinski's rule of drug-likeness, increased solubility, and to avoid potential cytotoxicity.
   Principal Findings: PA analog 2-bromopalmitate (2-BP) was most efficacious with K(d) similar to 74 nM and K(i) similar to 122 nM, ascorbyl palmitate (6-AP) exhibited slightly higher K(d) similar to 140 nM and K(i) similar to 354 nM, and sucrose palmitate (SP) was least efficacious binding to CD4 with K(d) similar to 364 nM and inhibiting gp120-to-CD4 binding with K(i) similar to 1486 nM. Importantly, PA and its analogs specifically bound to the CD4 receptor with the one to one stoichiometry.
   Significance: Considering observed differences between K(i) and K(d) values indicates clear and rational direction for improving inhibition efficacy to HIV-1 entry and infection. Taken together this report introduces a novel class of natural small molecules fusion inhibitors with nanomolar efficacy of CD4 receptor binding and inhibition of HIV-1 entry.
C1 [Paskaleva, Elena E.; Canki, Mario] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA.
   [Xue, Jing; Shekhtman, Alexander] SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   [Lee, David Y-W.] Harvard Univ, Sch Med, McLean Hosp, Mailman Res Ctr, Belmont, MA 02178 USA.
RP Paskaleva, EE (reprint author), Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA.
EM cankim@mail.amc.edu
OI Shekhtman, Alexander/0000-0003-2649-2675
FU NIH [AT003371]; American Diabetes Association [1-06-CD-23, 1R01GM085006]
FX This work was supported by NIH grant number AT003371 to MC and American
   Diabetes Association Career Development Award number 1-06-CD-23 and
   1R01GM085006 to AS. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295
   Bhal SK, 2007, MOL PHARM, V4, P556, DOI 10.1021/mp0700209
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Dong SL, 2008, J PHYS CHEM B, V112, P9371, DOI 10.1021/jp801216e
   Eftink MR, 1997, METHOD ENZYMOL, V278, P221
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Goodsell D.S, 2009, CSH PROTOC
   Hetenyi C, 2006, FEBS LETT, V580, P1447, DOI 10.1016/j.febslet.2006.01.074
   LEE DY, 2009, AIDS RES HUM RETROV, V12, P1231
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Morris G. M., 2008, CURR PROTOC BIOINFOR, P8, DOI DOI 10.1002/0471250953.BI0814S24
   Paskaleva Elena E, 2006, AIDS Res Ther, V3, P15, DOI 10.1186/1742-6405-3-15
   Paskaleva EE, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-8
   Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0                                                   
   Resh M. D., 2006, SCI STKE, V2006, pre14, DOI DOI 10.1126/STKE.3592006RE14
NR 15
TC 9
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2010
VL 5
IS 8
AR e12168
DI 10.1371/journal.pone.0012168
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 638AP
UT WOS:000280862200022
PM 20730055
OA gold
DA 2018-01-05
ER

PT J
AU Gregas, MK
   Scaffidi, JP
   Lauly, B
   Vo-Dinh, T
AF Gregas, Molly K.
   Scaffidi, Jonathan P.
   Lauly, Benoit
   Vo-Dinh, Tuan
TI Surface-Enhanced Raman Scattering Detection and Tracking of Nanoprobes:
   Enhanced Uptake and Nuclear Targeting in Single Cells
SO APPLIED SPECTROSCOPY
LA English
DT Article
DE Surface-enhanced Raman scattering; SERS; Biosensing; Nanoparticles;
   Cellular uptake
ID GOLD NANOPARTICLES; IN-VIVO; SILVER NANORODS; CANCER-THERAPY;
   BREAST-CANCER; LIVING CELLS; SERS; PEPTIDE; SPECTROSCOPY; DIAGNOSTICS
AB We describe the development and application of a co-functionalized nanoprobe and biodelivery platform combining a nuclear targeting peptide (NTP) for improved cellular uptake and intracellular targeting with p-mercaptobenzoic acid (pMBA) as a surface-enhanced Raman scattering (SERS) reporter for tracking and imaging. The nuclear targeting peptide, an HIV-1 protein-derived TAT sequence, has been previously shown to aid entry of cargo through the cell membrane via normal cellular processes, and furthermore, to localize small cargo to the nucleus of the cell. Previous work in our lab has verified cell uptake and distribution of the nanoprobes in clinically relevant mouse and human cell lines. In this work, two-dimensional SERS mapping was used to track the spatial and temporal progress of nanoparticle uptake in PC-3 human prostate cells and to characterize localization at various time points, demonstrating the potential for an intracellularly targeted multiplexed nanobiosensing system with excellent sensitivity and specificity. Silver nanoparticles co-functionalized with the TAT peptide showed greatly enhanced cellular uptake over the control nanoparticles lacking the targeting moiety. The ability to detect and monitor nanoprobe trafficking using SERS spectroscopy offers an improved alternative over previous tracking and detection methods such as light microscopy and fluorescence methods. The development of multifunctional nanoconstructs for intracellular delivery has potential clinical applications in early detection and selective treatment of disease in affected cells. Other applications include use in basic research aimed at understanding the inner workings of living cells and how they respond to chemical and biological stimuli.
C1 [Gregas, Molly K.; Scaffidi, Jonathan P.; Lauly, Benoit; Vo-Dinh, Tuan] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Vo-Dinh, Tuan] Duke Univ, Dept Chem, Durham, NC 27708 USA.
   [Gregas, Molly K.; Scaffidi, Jonathan P.; Lauly, Benoit; Vo-Dinh, Tuan] Duke Univ, Fitzpatrick Inst Photon, Durham, NC 27708 USA.
RP Vo-Dinh, T (reprint author), Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
EM tuan.vodinh@duke.edu
FU National Institutes of Health [R01 EB006201, R01 ES014774]
FX The authors thank Dr. Guy Griffin for insightful discussions. This work
   was sponsored by the National Institutes of Health (Grants R01 EB006201
   and R01 ES014774).
CR ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   Allain LR, 2002, ANAL CHIM ACTA, V469, P149, DOI 10.1016/S0003-2670(01)01537-9                                                   
   Auffan M, 2009, NAT NANOTECHNOL, V4, P634, DOI 10.1038/nnano.2009.242
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Brown RJC, 2008, J RAMAN SPECTROSC, V39, P1313, DOI 10.1002/jrs.2030
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cuenca AG, 2006, CANCER, V107, P459, DOI 10.1002/cncr.22035
   Cui Y, 2007, J RAMAN SPECTROSC, V38, P896, DOI 10.1002/jrs.1742
   Culha M, 2003, ANAL CHEM, V75, P6196, DOI 10.1021/ac0346003
   Dong Y, 2007, INT J PHARM, V342, P208, DOI 10.1016/j.ijpharm.2007.04.031
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   Gomez-Hens A, 2008, TRAC-TREND ANAL CHEM, V27, P394, DOI 10.1016/j.trac.2008.03.006
   GREGAS MK, 2007, ADV ENV CHEM BIOL SE, V5
   Gu FX, 2007, NANO TODAY, V2, P14, DOI 10.1016/S1748-0132(07)70083-X                                                   
   Gu X, 2006, MATER CHEM PHYS, V96, P217, DOI 10.1016/j.matchemphys.2005.07.006
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Hering K, 2008, ANAL BIOANAL CHEM, V390, P113, DOI 10.1007/s00216-007-1667-3
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Jana NR, 2001, CHEM COMMUN, P617, DOI 10.1039/b100521i                                                                
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V1, P84
   Jennings GK, 1997, J AM CHEM SOC, V119, P5208, DOI 10.1021/ja962973y                                                               
   Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541
   KERKER M, 1984, ACCOUNTS CHEM RES, V17, P271, DOI 10.1021/ar00104a002                                                             
   Khoury CG, 2008, J PHYS CHEM C, V112, P18849, DOI 10.1021/jp8054747
   Kim K, 2008, BIOTECHNOL LETT, V30, P1331, DOI 10.1007/s10529-008-9695-4
   Kneipp J, 2007, NANO LETT, V7, P2819, DOI 10.1021/nl071418z
   Kneipp J, 2006, NANO LETT, V6, P2225, DOI 10.1021/nl061517x
   Kneipp K, 1998, APPL SPECTROSC, V52, P1493, DOI 10.1366/0003702981943059                                                        
   Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667
   Kneipp K, 2002, APPL SPECTROSC, V56, P150, DOI 10.1366/0003702021954557
   Leopold N, 2003, J PHYS CHEM B, V107, P5723, DOI 10.1021/jp027460u
   Li H., 2006, NANOBIOTECHNOLOGY, V2, P17
   Li JY, 2007, CHEMMEDCHEM, V2, P374, DOI [10.1002/cmdc.200600264, 10.1002/cdmc.200600264]
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Michota A, 2003, J RAMAN SPECTROSC, V34, P21, DOI 10.1002/jrs.928
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Roeske JC, 2007, TECHNOL CANCER RES T, V6, P395, DOI 10.1177/153303460700600504                                                      
   Scaffidi JP, 2009, ANAL BIOANAL CHEM, V393, P1135, DOI 10.1007/s00216-008-2521-y
   Kumar PS, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/01/015606
   Stiles PL, 2008, ANNU REV ANAL CHEM, V1, P601, DOI 10.1146/annurev.anchem.1.031207.112814
   Sun L, 2007, ANAL CHEM, V79, P3981, DOI 10.1021/ac070078z
   Talley CE, 2004, ANAL CHEM, V76, P7064, DOI 10.1021/ac049093j
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   Willets KA, 2009, ANAL BIOANAL CHEM, V394, P85, DOI 10.1007/s00216-009-2682-3
   Yamamoto N, 2002, COLLOID SURFACE B, V25, P157, DOI 10.1016/S0927-7765(01)00306-X                                                   
   Yen HJ, 2009, SMALL, V5, P1553, DOI 10.1002/smll.200900126
   Yezhelyev MV, 2006, LANCET ONCOL, V7, P657, DOI 10.1016/S1470-2045(06)70793-8
   Yih TC, 2005, NANOMED-NANOTECHNOL, V1, P191, DOI 10.1016/j.nano.2005.04.001
   Yu DB, 2004, J AM CHEM SOC, V126, P13200, DOI 10.1021/ja046037r
   Zahr AS, 2006, LANGMUIR, V22, P8178, DOI 10.1021/la060951b
   Zhang RY, 2006, NANOTECHNOLOGY, V17, P3622, DOI 10.1088/0957-4484/17/14/043
   Zhang ZP, 2008, PHARM RES-DORDR, V25, P1925, DOI 10.1007/s11095-008-9611-6
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 58
TC 26
Z9 27
U1 9
U2 57
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003-7028
EI 1943-3530
J9 APPL SPECTROSC
JI Appl. Spectrosc.
PD AUG
PY 2010
VL 64
IS 8
BP 858
EP 866
DI 10.1366/000370210792081037                                              
          
PG 9
WC Instruments & Instrumentation; Spectroscopy
SC Instruments & Instrumentation; Spectroscopy
GA 638KR
UT WOS:000280894300003
PM 20719048
DA 2018-01-05
ER

PT J
AU Kim, J
   Shirasawa, T
   Miyamoto, Y
AF Kim, Juewon
   Shirasawa, Takuji
   Miyamoto, Yusei
TI The effect of TAT conjugated platinum nanoparticles on lifespan in a
   nematode Caenorhabditis elegans model
SO BIOMATERIALS
LA English
DT Article
DE Nano particle; Platinum; Biomimetic material; Metal surface treatment;
   Surface modification; Drug delivery
ID FUNCTIONALIZED GOLD NANOPARTICLES; TARGETED DRUG-DELIVERY; SUPEROXIDE;
   PROTEIN; NANOTECHNOLOGY; TRANSDUCTION; CHEMISTRY; EXTENSION; MOLECULE;
   PLATFORM
AB We have shown that platinum nanoparticle species (nano-Pt) is a superoxide dismutase/catalase mimetic that scavenges superoxide and hydrogen peroxide. In Caenorhabditis elegans, nano-Pt functions as an effective antioxidant that induces an extension in lifespan and strong resistance against excessive oxidative stress. Our study with C. elegans was the first trial to use nano-Pt as a bio-active substance. However, a high concentration of nano-Pt was required for these survival effects, probably due to limited membrane permeability. Here, we show that the conjugation of nano-Pt with an HIV-1 TAT fusion protein C-terminally linked to a peptide with high affinity for platinum improves internalization, eliciting a similar level of antioxidant effects at one hundredth the concentration of unconjugated nano-Pt. This approach is a potential method to facilitate translocation of bio-active nanoparticles into living organisms and could be a model assay for estimate the effects of antioxidant in living organism. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Miyamoto, Yusei] Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Chiba 2778562, Japan.
   [Shirasawa, Takuji] Juntendo Univ, Dept Aging Control, Grad Sch Med, Tokyo 1130033, Japan.
RP Miyamoto, Y (reprint author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Biosci Bldg 402,5-1-5 Kashiwanoha, Chiba 2778562, Japan.
EM yusei74@k.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology
FX This work was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology (YM).
CR Bergen JM, 2006, MACROMOL BIOSCI, V6, P506, DOI 10.1002/mabi.200600075
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009
   Buetler TM, 2004, NEWS PHYSIOL SCI, V19, P120, DOI 10.1152/nips.01514.2003
   Cao ZX, 2007, ANAL LETT, V40, P2116, DOI 10.1080/00032710701566909
   Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Gami MS, 2006, AGING CELL, V5, P31, DOI 10.1111/j.1474-9726.2005.00188.x
   Glomm WR, 2005, J DISPER SCI TECHNOL, V26, P389, DOI 10.1081/DIS-200052457
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hampton MB, 1998, BLOOD, V92, P3007
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298                                                         
   Houthoofd K, 2005, AGING CELL, V4, P87, DOI 10.1111/j.1474-9728.2005.00150.x
   Kajita M, 2007, FREE RADICAL RES, V41, P615, DOI 10.1080/10715760601169679
   Kim J, 2008, MECH AGEING DEV, V129, P322, DOI 10.1016/j.mad.2008.02.011
   MANNWEILER K, 1982, J MICROSC-OXFORD, V126, P145, DOI 10.1111/j.1365-2818.1982.tb00363.x                                              
   Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   Paciotti GF, 2006, DRUG DEVELOP RES, V67, P47, DOI 10.1002/ddr.20066
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Sarikaya M, 2003, NAT MATER, V2, P577, DOI 10.1038/nmat964
   SCHMID G, 1989, ANGEW CHEM INT EDIT, V28, P778, DOI 10.1002/anie.198907781                                                          
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Templeton AC, 1999, LANGMUIR, V15, P66, DOI 10.1021/la9808420                                                               
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289                                                        
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
NR 27
TC 40
Z9 40
U1 1
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2010
VL 31
IS 22
BP 5849
EP 5854
DI 10.1016/j.biomaterials.2010.03.077
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 614XK
UT WOS:000279092900015
PM 20434216
DA 2018-01-05
ER

PT J
AU Su, DS
   Lim, JJ
   Tinney, E
   Tucker, TJ
   Saggar, S
   Sisko, JT
   Wan, BL
   Young, MB
   Anderson, KD
   Rudd, D
   Munshi, V
   Bahnck, C
   Felock, PJ
   Lu, MQ
   Lai, MT
   Touch, S
   Moyer, G
   DiStefano, DJ
   Flynn, JA
   Liang, YX
   Sanchez, R
   Perlow-Poehnelt, R
   Miller, M
   Vacca, JP
   Williams, TM
   Anthony, NJ
AF Su, Dai-Shi
   Lim, John J.
   Tinney, Elizabeth
   Tucker, Thomas J.
   Saggar, Sandeep
   Sisko, John T.
   Wan, Bang-Lin
   Young, Mary Beth
   Anderson, Kenneth D.
   Rudd, Deanne
   Munshi, Vandna
   Bahnck, Carolyn
   Felock, Peter J.
   Lu, Meiquing
   Lai, Ming-Tain
   Touch, Sinoeun
   Moyer, Gregory
   DiStefano, Daniel J.
   Flynn, Jessica A.
   Liang, Yuexia
   Sanchez, Rosa
   Perlow-Poehnelt, Rebecca
   Miller, Mike
   Vacca, Joe P.
   Williams, Theresa M.
   Anthony, Neville J.
TI Biaryl ethers as potent allosteric inhibitors of reverse transcriptase
   and its key mutant viruses: Aryl substituted pyrazole as a surrogate for
   the pyrazolopyridine motif
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Non-nucleoside reverse transcriptase inhibitors (NNRTI);
   Structural-activity relationship (SAR); Mutant virus; Aryl substituted
   pyrazoles; Surrogate for pyrazolopyridine
ID DESIGN
AB Biaryl ethers were recently reported as potent NNRTIs. Herein, we disclose a detailed effort to modify the previously reported compound 1. We have designed and synthesized a series of novel pyrazole derivatives as a surrogate for pyrazolopyridine motif that were potent inhibitors of HIV-1 RT with nanomolar intrinsic activity on the WT and key mutant enzymes and potent antiviral activity in infected cells. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Su, Dai-Shi; Lim, John J.; Tinney, Elizabeth; Tucker, Thomas J.; Saggar, Sandeep; Sisko, John T.; Wan, Bang-Lin; Young, Mary Beth; Anderson, Kenneth D.; Rudd, Deanne; Perlow-Poehnelt, Rebecca; Vacca, Joe P.; Williams, Theresa M.; Anthony, Neville J.] Merck Res Lab, Dept Med Chem & Struct Biol, West Point, PA 19486 USA.
RP Su, DS (reprint author), GlaxoSmithKline Inc, 1250S Collegeville Rd,UP1205, Collegeville, PA 19426 USA.
EM Dai-Shi.X.Su@gsk.com
CR Elworthy TR, 2008, BIOORG MED CHEM LETT, V18, P6344, DOI 10.1016/j.bmcl.2008.10.090
   Su DS, 2009, J MED CHEM, V52, P7163, DOI 10.1021/jm901230r
   Sweeney ZK, 2008, J MED CHEM, V51, P7449, DOI 10.1021/jm800527x
   Tucker TJ, 2008, J MED CHEM, V51, P6503, DOI 10.1021/jm800856c
   Tucker TJ, 2008, BIOORG MED CHEM LETT, V18, P2959, DOI 10.1016/j.bmcl.2008.03.064
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Saggar S., 2007, U.S. Patent, Patent No. [2,007,021,442, 2007021442]
NR 7
TC 13
Z9 13
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2010
VL 20
IS 15
BP 4328
EP 4332
DI 10.1016/j.bmcl.2010.06.083
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 625BK
UT WOS:000279866300006
PM 20609585
DA 2018-01-05
ER

PT J
AU Yin, DG
   Liu, BH
   Zhang, L
   Xie, CJ
   Zhang, L
AF Yin Dong-Guang
   Liu Bin-Hu
   Zhang Li
   Xie Chun-Juan
   Zhang Le
TI Preparation of Fluorescent Nanoparticle Ru(bpy)(3)/SiO2 and Its
   Application in Protein Microarray for Human Immunodeficiency Virus p24
   Detection
SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
LA Chinese
DT Article
DE Fluorescent nanoparticles; Tris(2,2 '-bipyridyll)ruthenium; p24 Antigen;
   Protein microarray chip
ID SILICA NANOPARTICLES; ASSAY
AB A core-shell type of tris(2,2'-bipyridyl)ruthenium(Ru(hpy)(3))-doped silica fluorescent nanoparticles with amino groups on the surface was developed by a water-in-oil microemulsion method. The characterizations by transmission electron microscopy (TEM), UV-Visible spectra and fluorescent spectra show that the nanoparticles are amino groups functioned (385 nmol amino groups per milligram nanoparticles), spherical, monodisperse, and uniform in size with the diameters being (70 +/- 6) nm. Due to a lot of Ru(bpy)(3) molecules encapsulated in the silica matrix that also severs to protect Ru(bpy)(3) dye from photodamaging oxidation, the nanoparticles are extremely bright, photo stable and chemical stable. The fluorescent intensity of the pure Ru(bpy)(3) was decreased approximately 56% after 90 min of continuous excitation with 100 W of Xenon lamp, whereas the fluorescent intensity of the nanoparticles was only decreased 8%. When the nanoparticles were continuously ultrasonic 60 min in aqueous solution, their fluorescent intensity was only decreased approximately 0.05%. The nanoparticles were conjugated with streptavidin and applied in protein microarray for detection of HIV p24. Results show that fluorescence intensity and p24 concentration present a good positive correlation. The analytical sensitivity is 3.1 mu g/L. These results demonstrate the potential to apply the nanoparticles in ultrasensitive protein microarray and fluorescent immunoassay systems.
C1 [Yin Dong-Guang; Liu Bin-Hu; Zhang Li; Xie Chun-Juan; Zhang Le] Shanghai Univ, Coll Environm & Chem Engn, Shanghai 200444, Peoples R China.
RP Yin, DG (reprint author), Shanghai Univ, Coll Environm & Chem Engn, Shanghai 200444, Peoples R China.
EM ydg@shu.edu.cn
CR Burgess STG, 2008, ANAL BIOCHEM, V382, P9, DOI 10.1016/j.ab.2008.07.017
   Henry AC, 2000, ANAL CHEM, V72, P5331, DOI 10.1021/ac000685l
   Jesse V.J., 2009, BIOSENS BIOELECTRON, V24, P3622
   LI QS, 2009, IMMUNOLOGY, V183, P1975
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Pang JT, 2006, CHINESE J ANAL CHEM, V34, P884
   PETRA P, 2002, J PROTEOME RES, V1, P227
   RAHUL PB, 2004, LANGMUIR, V20, P8336
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Tan MQ, 2004, CHEM MATER, V16, P2494, DOI 10.1021/cm030305n
   Wang H, 2008, CHINESE J ANAL CHEM, V36, P1531
   Weber B, 2002, J CLIN MICROBIOL, V40, P1938, DOI 10.1128/JCM.40.6.1938-1946.2002
   Wu JQ, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-83
   Zhang H, 2007, CHEM MATER, V19, P5875, DOI 10.1021/cm070900f
   ZHOU MQ, 2005, J INSTRU ANAL, V24, P133
NR 15
TC 8
Z9 10
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0253-3820
J9 CHINESE J ANAL CHEM
JI Chin. J. Anal. Chem.
PD AUG
PY 2010
VL 38
IS 8
BP 1095
EP 1099
DI 10.3724/SP.J.1096.2010.01095
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 646HN
UT WOS:000281530100003
DA 2018-01-05
ER

PT J
AU Tang, SX
   Zhao, JQ
   Wang, AF
   Viswanath, R
   Harma, H
   Little, RF
   Yarchoan, R
   Stramer, SL
   Nyambi, PN
   Lee, S
   Wood, O
   Wong, EY
   Wang, X
   Hewlett, IK
AF Tang, Shixing
   Zhao, Jiangqin
   Wang, Aifeng
   Viswanath, Ragupathy
   Harma, Harri
   Little, Richard F.
   Yarchoan, Robert
   Stramer, Susan L.
   Nyambi, Phillipe N.
   Lee, Sherwin
   Wood, Owen
   Wong, Eric Y.
   Wang, Xue
   Hewlett, Indira K.
TI Characterization of Immune Responses to Capsid Protein p24 of Human
   Immunodeficiency Virus Type 1 and Implications for Detection
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; HIV-1 P24; SIGNAL AMPLIFICATION; GENETIC
   DIVERSITY; CORE PROTEIN; ANTIGEN; INFECTION; ASSAY; IMMUNOASSAYS;
   EPITOPES
AB To further refine our current nanoparticle-based HIV-1 p24 antigen assay, we investigated immune responses to p24 to identify diagnostically significant immune dominant epitopes (IDEs) in HIV-infected human sera, to address cross-reactivity of anti-p24 antibodies to different subtypes, and to identify new biomarkers that distinguish acute from chronic HIV infection for more accurate incidence estimation. We identified two major linear epitope regions, located in the CypA binding loop and adjacent helices and at the end of the C-terminal domain. Most sera (86%) from acutely HIV-1-infected individuals reacted with multiple peptides, while 60% and 30% of AIDS patient samples reacted with multiple and single peptides, respectively. In contrast, 46% and 43% of chronically HIV-1-infected individuals reacted with one and none of the peptides, respectively, and only 11% reacted with multiple p24 peptides, indicating a progression of immune responses from polyclone-like during acute infection to monoclone-like or a nonresponse to linear epitopes during chronic infection. Anti-p24 antibodies (subtype B) show broad cross-reactivity to different HIV-1 subtypes, and the synergistic action of different combinations of anti-HIV antibodies improves capture and detection of divergent HIV-1 subtypes. Our results indicate that the modified peptide immunoassay is sensitive and specific for the rapid identification of HIV-1 p24 IDEs and for investigation of immune responses to p24 during natural HIV-1 infection. The data provide the foundation for development and refinement of new assays for improved p24 antigen testing as future tools for rapid and accurate diagnosis as part of early intervention strategies and estimations of incidence.
C1 [Tang, Shixing; Zhao, Jiangqin; Wang, Aifeng; Viswanath, Ragupathy; Lee, Sherwin; Wood, Owen; Wong, Eric Y.; Wang, Xue; Hewlett, Indira K.] US FDA, Mol Virol Lab, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
   [Harma, Harri] Univ Turku, Biophys Lab, FIN-20520 Turku, Finland.
   [Little, Richard F.; Yarchoan, Robert] NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA.
   [Stramer, Susan L.] Amer Red Cross, Biomed Serv Sci Support Off, Gaithersburg, MD 20877 USA.
   [Nyambi, Phillipe N.] NYU, Sch Med, New York, NY 10010 USA.
RP Tang, SX (reprint author), US FDA, Mol Virol Lab, Ctr Biol Evaluat & Res, Bldg 29B,Room 4NN16,8800 Rockville Pike, Bethesda, MD 20892 USA.
EM shixing.tang@fda.hhs.gov; indira.hewlett@fda.hhs.gov
FU National Heart, Lung and Blood Institute (NHLBI); National Institute of
   Allergy and Infectious Diseases (NIAID), NIH; National Cancer Institute
   (NCI), NIH
FX This study was funded by an interagency agreement with the National
   Heart, Lung and Blood Institute (NHLBI) and the National Institute of
   Allergy and Infectious Diseases (NIAID), NIH, and was supported in part
   by the Intramural Research Program of the National Cancer Institute
   (NCI), NIH.
CR ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804
   Barletta J, 2009, J VIROL METHODS, V157, P122, DOI 10.1016/j.jviromet.2008.12.013
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X                                                    
   DEWOLF F, 1988, J INFECT DIS, V158, P615
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   GALLINA A, 1990, J MED VIROL, V32, P164, DOI 10.1002/jmv.1890320307                                                          
   Gaudy C, 2004, J CLIN MICROBIOL, V42, P2847, DOI 10.1128/JCM.42.6.2847-2849.2004
   GRAHAM S, 1992, AIDS RES HUM RETROV, V8, P1781, DOI 10.1089/aid.1992.8.1781                                                         
   HAAHEIM LR, 1991, SCAND J IMMUNOL, V34, P341, DOI 10.1111/j.1365-3083.1991.tb01555.x
   Harma H, 2001, CLIN CHEM, V47, P561
   JANVIER B, 1990, J VIROL, V64, P4258
   JANVIER B, 1991, J CLIN MICROBIOL, V29, P488
   Kwon JA, 2006, J VIROL METHODS, V133, P20, DOI 10.1016/j.jviromet.2005.10.013
   LANGEDIJK JPM, 1990, J GEN VIROL, V71, P2609, DOI 10.1099/0022-1317-71-11-2609
   Lee S, 2006, J VIROL METHODS, V137, P287, DOI 10.1016/j.jviromet.2006.07.001
   Li JW, 2009, ANAL BIOANAL CHEM, V394, P489, DOI 10.1007/s00216-009-2712-1
   Liu GJ, 2005, CELL MOL IMMUNOL, V2, P289
   Ly TD, 2004, J VIROL METHODS, V122, P185, DOI 10.1016/j.jviromet.2004.08.018
   Machuca A, 2007, JAIDS-J ACQ IMM DEF, V45, P361, DOI 10.1097/QAI.0b013e318053754c
   McCutchan FE, 2000, AIDS, V14, pS31
   MULLER S, 1993, SCAND J IMMUNOL, V38, P327, DOI 10.1111/j.1365-3083.1993.tb01734.x
   NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21                                                         
   Peeters M., 2000, AIDS S, V14, P129
   PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x
   Schupbach J, 2006, J MED VIROL, V78, P1003, DOI 10.1002/jmv.20655
   Schupbach J, 1996, AIDS, V10, P1085
   SPENCE RP, 1989, J GEN VIROL, V70, P2843, DOI 10.1099/0022-1317-70-11-2843                                                    
   Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2009, CHIM OGGI, V27, P50
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tang SX, 2009, CLIN VACCINE IMMUNOL, V16, P408, DOI 10.1128/CVI.00412-08
   TERSMETTE M, 1989, VIROLOGY, V171, P149, DOI 10.1016/0042-6822(89)90521-7                                                    
   Vogt VM, 1999, J VIROL, V73, P7050
   Zhang X, 2006, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2005/01/003
NR 38
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2010
VL 17
IS 8
BP 1244
EP 1251
DI 10.1128/CVI.00066-10
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 633XG
UT WOS:000280539900012
PM 20534793
OA gold
DA 2018-01-05
ER

PT J
AU Mahajan, S
   Prashant, CK
   Koul, V
   Choudhary, V
   Dinda, AK
AF Mahajan, Shveta
   Prashant, C. K.
   Koul, Veena
   Choudhary, Veena
   Dinda, Amit K.
TI Receptor Specific Macrophage Targeting by Mannose-Conjugated Gelatin
   Nanoparticles- An In Vitro and In Vivo Study
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Macrophage targeting; gelatin nanoparticles; mannosylation;
   biocompatibility; in vitro uptake; biodistribution
ID SALMONELLA-TYPHIMURIUM; DRUG-DELIVERY; MICROSPHERES; LIPOSOMES; LUNG;
   PHAGOCYTOSIS; TUBERCULOSIS; NANOSPHERES; EXPRESSION; APOPTOSIS
AB Macrophage targeting therapies are a promising approach to treat various intracellular infections like AIDS, tuberculosis and leprosy. The present paper demonstrates the design and development of mannosylated nanoparticles of biopolymeric origin. Spherical and smooth gelatin nanoparticles in the size range of 100-200 nm with a narrow polydispersity index (<0.1) were synthesized and characterized by TEM, AFM and XPS for their morphology and mannosylation. Cell uptake studies by spectrofluorimetry in J774 macrophage cell-line demonstrate two-fold greater internalisation of mannosylated gelatin nanoparticles (MGNP) through macrophage mannose-receptor, than unconjugated nanoparticles (GNP); enhanced uptake of MGNP in J774 macrophages was confirmed by laser confocal microscopy. Evaluation of cellular toxicity by MTT assay reveals close to 100% cell viability confirming biocompatibility. In addition, neither MGNP nor GNP caused ROS (reactive oxidative species) generation in J774 cells. Biodistribution studies in murine model showed significant uptake of MGNP by reticuloendothelial system as early as 15 min after intravenous administration (spleen 0.99 +/- 0.14 percent injected dose/100 mg tissue; liver, 1.04 +/- 0.11 percent dose/100 mg). The anti-HIV drug stavudine was loaded to 38.2% entrapment efficiency in MGNP and showed 77.5% release in 96 h.
   Thus, these mannosylated nanoparticles appear to be a very useful carrier system for receptor-specific drug delivery in treatment of macrophage-mediated intracellular infections.
C1 [Mahajan, Shveta; Choudhary, Veena] Indian Inst Technol Delhi, Ctr Polymer Sci & Engn, New Delhi 110016, India.
   [Prashant, C. K.; Dinda, Amit K.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
   [Koul, Veena] Indian Inst Technol Delhi, Ctr Biomed Engn, New Delhi 110016, India.
RP Choudhary, V (reprint author), Indian Inst Technol Delhi, Ctr Polymer Sci & Engn, New Delhi 110016, India.
EM veenach@hotmail.com; amit_dinda@yahoo.com
FU Department of Biotechnology, Government of India; Council for Scientific
   and Industrial Research, India
FX The research work has been funded by Department of Biotechnology,
   Government of India. SM is grateful to the Council for Scientific and
   Industrial Research, India for Senior Research Fellowship.
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6                                                   
   Balland O, 1996, J ANTIMICROB CHEMOTH, V37, P105, DOI 10.1093/jac/37.1.105
   BRAIN JD, 1980, ENVIRON HEALTH PERSP, V35, P21, DOI 10.2307/3428970
   Broz P, 2007, TRENDS CARDIOVAS MED, V17, P190, DOI 10.1016/j.tcm.2007.05.002
   Chanwong S, 2007, TUBERCULOSIS, V87, P130, DOI 10.1016/j.tube.2006.06.001
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Coester CJ, 2000, J MICROENCAPSUL, V17, P187
   Espuelas MS, 2002, J DRUG TARGET, V10, P593, DOI 10.1080/1061186021000060738
   Fraser IP, 1998, SEMIN IMMUNOL, V10, P363, DOI 10.1006/smim.1998.0141                                                          
   GORDON S, 1989, Advanced Drug Delivery Reviews, V4, P27, DOI 10.1016/0169-409X(89)90036-7
   HAENSLER J, 1988, BIOCHIM BIOPHYS ACTA, V946, P95, DOI 10.1016/0005-2736(88)90461-0                                                    
   Jung EM, 2005, CARCINOGENESIS, V26, P1905, DOI 10.1093/carcin/bgi167
   Kaul G, 2002, PHARMACEUT RES, V19, P1061, DOI 10.1023/A:1016486910719                                                         
   Kima PE, 2007, INT J PARASITOL, V37, P1087, DOI 10.1016/j.ijpara.2007.04.007
   Li JK, 1997, J PHARM SCI, V86, P891, DOI 10.1021/js970084i                                                               
   LIPSCOMB MF, 1997, LUNG MACROPHAGES DEN
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   Mladenovska K, 2002, INT J PHARM, V242, P247, DOI 10.1016/S0378-5173(02)00167-9
   Narang Deepak, 2004, BMC Pharmacology, V4, P29, DOI 10.1186/1471-2210-4-29
   Park KH, 2005, J BIOSCI BIOENG, V99, P285, DOI 10.1263/jbb.99.285                                                              
   SEHGAL D, 1994, ANAL BIOCHEM, V218, P87, DOI 10.1006/abio.1994.1144                                                          
   SENO S, 1975, Cell Structure and Function, V1, P119
   STAHL P, 1982, J CELL BIOL, V93, P49, DOI 10.1083/jcb.93.1.49
   STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V
   Tabata Y, 1999, J BIOMAT SCI-POLYM E, V10, P79, DOI 10.1163/156856299X00298
   TABATA Y, 1993, J CONTROL RELEASE, V27, P79
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   TABATA Y, 1989, PHARMACEUT RES, V6, P422, DOI 10.1023/A:1015991617704
   Tomoda K, 2007, COLLOID SURFACE B, V55, P115, DOI 10.1016/j.colsurfb.2006.11.030
   Truong-Le VL, 1998, HUM GENE THER, V9, P1709, DOI 10.1089/hum.1998.9.12-1709                                                      
   VLADOIANU IR, 1990, MICROB PATHOGENESIS, V8, P83, DOI 10.1016/0882-4010(90)90072-X
   Werneck-Barroso E, 2000, RESP MED, V94, P64, DOI 10.1053/rmed.1999.0669                                                          
   Wijagkanalan W, 2008, J CONTROL RELEASE, V125, P121, DOI 10.1016/j.jconrel.2007.10.011
   Wine Y, 2007, BIOTECHNOL BIOENG, V98, P711, DOI 10.1002/bit.21459
   Yeeprae W, 2006, J CONTROL RELEASE, V114, P193, DOI 10.1016/j.jconrel.2006.04.010
   Zhao Jinshun, 2009, Journal of Nanobiotechnology, V7, P2, DOI 10.1186/1477-3155-7-2
NR 37
TC 9
Z9 9
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
J9 CURR NANOSCI
JI Curr. Nanosci.
PD AUG
PY 2010
VL 6
IS 4
BP 413
EP 421
DI 10.2174/157341310791658928                                              
          
PG 9
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 633MJ
UT WOS:000280506800013
DA 2018-01-05
ER

PT J
AU Uchman, M
   Cigler, P
   Gruner, B
   Prochazka, K
   Matejicek, P
AF Uchman, Mariusz
   Cigler, Petr
   Gruner, Bohumir
   Prochazka, Karel
   Matejicek, Pavel
TI Micelle-like nanoparticles of block copolymer poly(ethylene
   oxide)-block-poly(methacrylic acid) incorporating fluorescently
   substituted metallacarboranes designed as HIV protease inhibitor
   interaction probes
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE AFM; Dicarbollide anions; Drug delivery; Fluorometry; Light scattering;
   Micelles; Nanoparticles; Metallacarboranes; Polymeric composites
ID METAL-COMPOUNDS; DRUG-DELIVERY; OXIDE); AGGREGATION; BEHAVIOR; ANIONS;
   WATER
AB We prepared nanoparticles differing in morphology from double-hydrophilic block copolymer poly(ethylene oxide)-block-poly(methacrylic acid), PEO-PMA, and two types of fluorescein-[3-cobalt(III) bis(1,2-dicarbollide)] conjugates, GB176 and GB179, in alkaline buffer. GB176 molecule consists of fluorescein attached to the metallacarborane anion. In GB179 molecule, the fluorescein moiety connects two metallacarborane anions. The self-assembly is based on the unusual interaction of metallacarborane clusters with PEO blocks which form insoluble micellar cores. The GB176 containing nanoparticles are loose and irregular, while the GB179 ones are rigid and spherical. The structure of nanoparticles depends to some extent on a procedure of preparation. The micelles were studied by static and dynamic light scattering, fluorometry and atomic force microscopy. Since the metallacarborane conjugates act as potent inhibitors of HIV protease, the presented system is important from the point of view of drug delivery. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Uchman, Mariusz; Prochazka, Karel; Matejicek, Pavel] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12840 2, Czech Republic.
   [Cigler, Petr] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Gilead Sci & IOCB Res Ctr, Vvi, CR-16610 Prague 6, Czech Republic.
   [Gruner, Bohumir] Acad Sci Czech Republic, Inst Inorgan Chem, Vvi, Area Res Inst 1001, Husinec Rez 25068, Czech Republic.
RP Matejicek, P (reprint author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Hlavova 2030, Prague 12840 2, Czech Republic.
EM matej@lynette.natur.cuni.cz
RI Uchman, Mariusz/B-2302-2009; Matejicek, Pavel/M-6582-2017; Cigler,
   Petr/B-1142-2012; Gruner, Bohumir/G-5181-2014; Prochazka,
   Karel/C-3012-2014
OI Matejicek, Pavel/0000-0001-5482-3465; Gruner,
   Bohumir/0000-0002-2595-9125; Prochazka, Karel/0000-0003-2144-5378
FU Grant Agency of the Academy of Sciences of the Czech Republic
   [IAAX00320901]; Ministry of Education of the Czech Republic [MSM
   0021620857, AV0Z40320502]; Marie Curie Research and Training Network
   [505 027]
FX Authors would like to acknowledge the financial support of the Grant
   Agency of the Academy of Sciences of the Czech Republic (IAAX00320901).
   The authors were supported by long term Research Plans of the Ministry
   of Education of the Czech Republic MSM 0021620857, AV0Z40320502 and
   partly by Research Center LC 523. MU and KP acknowledge the financial
   support by the Marie Curie Research and Training Network (Grant No. 505
   027, POLY-AMPHI). Dr. Milena Spirkova is gratefully acknowledged for
   fruitful discussions on (not only) AFM technique in MBS, Prague, Czech
   Republic. The authors thank Dr. Jiri Zednik for assistance with NMR
   experiments, Prof. Jan Konvalinka for HIV protease inhibition data and
   Dr. Jana Humpolickova for fluorescence lifetime imaging (FLIM) and
   fluorescence correlation spectroscopy (FCS) data that have not been
   included to the manuscript.
CR Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bronich TK, 2005, J AM CHEM SOC, V127, P8236, DOI 10.1021/ja043042m
   Bronstein LH, 1999, LANGMUIR, V15, P6256, DOI 10.1021/la990146f                                                               
   Bronstein LM, 1998, INORG CHIM ACTA, V280, P348, DOI 10.1016/S0020-1693(98)00208-4                                                   
   Chevrot G, 2006, J PHYS CHEM B, V110, P9488, DOI 10.1021/jp060930q
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   Colfen H, 2001, MACROMOL RAPID COMM, V22, P219, DOI 10.1002/1521-3927(20010201)22:4<219::AID-MARC219>3.0.CO;2-G
   Forster S, 1999, J PHYS CHEM B, V103, P6657, DOI 10.1021/jp990076l
   Gatsouli KA, 2007, J PHYS CHEM C, V111, P15201, DOI 10.1021/jp071681o
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   Hao E, 2007, CHEM-EUR J, V13, P9035, DOI 10.1002/chem.200700752
   Harada A, 2006, PROG POLYM SCI, V31, P949, DOI 10.1016/j.progpolymsci.2006.09.004
   Juhasz M, 2004, ANGEW CHEM INT EDIT, V43, P5352, DOI 10.1002/anie.200460005
   Kawaguchi S, 1996, MACROMOLECULES, V29, P4465, DOI 10.1021/ma950726t                                                               
   KHATTAR R, 1990, INORG CHEM, V29, P2191, DOI 10.1021/ic00337a002                                                             
   King WJ, 2009, SOFT MATTER, V5, P2399, DOI 10.1039/b819060g
   KONVALINKA J, 2009, COMMUNICATION   0419
   Kozisek M, 2008, J MED CHEM, V51, P4839, DOI 10.1021/jm8002334
   Kubat P, 2007, J PHYS CHEM B, V111, P4539, DOI 10.1021/jp066494p
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lesnikowski ZJ, 2007, COLLECT CZECH CHEM C, V72, P1646, DOI 10.1135/cccc20071646
   Matejicek P, 2006, LANGMUIR, V22, P575, DOI 10.1021/la052201s
   Matejicek P, 2008, LANGMUIR, V24, P2625, DOI 10.1021/la702852e
   Matejicek P, 2009, MACROMOLECULES, V42, P4829, DOI 10.1021/ma900484y
   Planas JG, 2005, J AM CHEM SOC, V127, P15976, DOI 10.1021/ja055210w
   Planas JG, 2007, CHEM-EUR J, V13, P2493, DOI 10.1002/chem.200601297
   Plesek J, 2002, POLYHEDRON, V21, P975
   Rak J, 2008, CHEM LISTY, V102, P209
   Reed CA, 1998, ACCOUNTS CHEM RES, V31, P133, DOI 10.1021/ar970230r                                                               
   Rezacova P, 2009, J MED CHEM, V52, P7132, DOI 10.1021/jm9011388
   Rodriguez-Hernandez J, 2005, PROG POLYM SCI, V30, P691, DOI 10.1016/j.progpolymsci.2005.04.002
   Sedlak M, 1998, MACROMOL CHEM PHYSIC, V199, P247, DOI 10.1002/macp.1998.021990211
   Sivaev IB, 2009, EUR J INORG CHEM, P1433, DOI 10.1002/ejic.200900003
   Sjoback R., 1995, SPECTROCHIM ACTA A, V51, pL7
   Uchman M, 2010, LANGMUIR, V26, P6268, DOI 10.1021/la904047k
NR 35
TC 14
Z9 14
U1 4
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD AUG 1
PY 2010
VL 348
IS 1
BP 129
EP 136
DI 10.1016/j.jcis.2010.04.037
PG 8
WC Chemistry, Physical
SC Chemistry
GA 612SY
UT WOS:000278924600016
PM 20447643
DA 2018-01-05
ER

PT J
AU Sosnik, A
AF Sosnik, Alejandro
TI Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a
   dual scientific and ethical challenge and a still pending agenda
SO NANOMEDICINE
LA English
DT Editorial Material
DE cost-viable liquid formulations; efavirenz; ethical affordability;
   neglected diseases; pediatric HIV; scalable liquid formulations
ID ANTIRETROVIRAL DRUGS; EFAVIRENZ; CHILDREN; PHARMACOKINETICS;
   FORMULATION; INFECTION
C1 [Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, Buenos Aires, DF, Argentina.
   [Sosnik, Alejandro] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Janin St,6th Floor,CP1113, Buenos Aires, DF, Argentina.
EM olesosnik@gmail.com
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   *AVERT ORG, 2010, AIDS ORPH
   Barrueco N, 2005, Farm Hosp, V29, P367
   Chiappetta DA, 2010, CURR HIV RES, V8, P23
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001                                                
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Dionisio D, 2007, CURR HIV RES, V5, P155, DOI 10.2174/157016207780077075
   Fabbiani M, 2009, J ANTIMICROB CHEMOTH, V64, P109, DOI 10.1093/jac/dkp132
   Gao JZ, 2007, J PHARM SCI-US, V96, P2970, DOI 10.1002/jps.20962
   Kairuz TE, 2007, CURR DRUG SAF, V2, P89
   Matic S, 2006, HIV AIDS EUROPE MOVI
   Nunn T, 2005, BRIT J CLIN PHARMACO, V59, P674, DOI 10.1111/j.1365-2125.2005.02410.x
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
   Sellers RS, 2005, DRUG CHEM TOXICOL, V28, P423, DOI 10.1080/01480540500262839
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Standing JF, 2005, INT J PHARM, V300, P56, DOI 10.1016/j.ijpharm.2005.05.006
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273
   *US PEPFAR, PED TREATM CAR
   van Luin M, 2009, JAIDS-J ACQ IMM DEF, V52, P240, DOI 10.1097/QAI.0b013e3181b061e6
   *WHO, AIDS EP UPD 2007
   *WHO, WHO MAK MED CHILD SI
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
NR 24
TC 12
Z9 12
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD AUG
PY 2010
VL 5
IS 6
BP 833
EP 837
DI 10.2217/NNM.10.64
PG 5
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 655QP
UT WOS:000282264800001
PM 20735219
DA 2018-01-05
ER

PT J
AU Dubey, V
   Mishra, D
   Nahar, M
   Jain, V
   Jain, NK
AF Dubey, Vaibhav
   Mishra, Dinesh
   Nahar, Manoj
   Jain, Vikas
   Jain, Narendra Kumar
TI Enhanced transdermal delivery of an anti-HIV agent via ethanolic
   liposomes
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Ethanolic liposomes; Indinavir; Percutaneous permeation; Ethosomes
ID MOLECULAR WEIGHT SOLUTES; HUMAN-SKIN; INFRARED-SPECTROSCOPY; PROTEASE
   INHIBITORS; IN-VIVO; PERMEATION; ETHOSOMES; VESICLES; SEPARATION;
   STABILITY
AB Indinavir, as a protease inhibitor with a short biological half life, variable pH-dependent oral absorption, and extensive first-pass metabolism, presents a challenge with respect to its oral administration. The current work aims to formulate and characterize indinavir-bearing ethanolic liposomes (ethosomes), and to investigate their enhanced transdermal delivery potential. The prepared ethanolic liposomes were characterized to be spherical, unilamellar structures having low polydispersity, nanometric size range, and improved entrapment efficiency over other delivery formulations. Permeation studies of indinavir across human cadaver skin resulted in enhanced transdermal flux from ethanolic liposomes that was significantly (P < 0.05) greater than that with ethanolic drug solution, conventional liposomes, or plain drug solution. Additionally, the ethanolic liposomes showed the shortest lag time for indinavir, thus presenting a suitable approach for transdermal delivery of this protease inhibitor.
   From the Clinical Editor: This study characterizes indinavir bearing ethanolic liposomes (ethosomes), and investigate their enhanced transdermal delivery potential, demonstrating a potentially a suitable approach for transdermal delivery of this protease inhibitor for HIV treatment, which typically has been associated with limited bioavailability via the oral route. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Dubey, Vaibhav; Mishra, Dinesh; Nahar, Manoj; Jain, Vikas; Jain, Narendra Kumar] Dr Hari Singh Gour Vishwavidyalaya, Pharmaceut Res Lab, Dept Pharmaceut Sci, Sagar, Madhya Pradesh, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Pharmaceut Res Lab, Dept Pharmaceut Sci, Sagar, Madhya Pradesh, India.
EM jnarendr@yahoo.co.in
OI JAIN, VIKAS/0000-0001-5863-3159
FU Council of Scientific and Industrial Research (CSIR), New Delhi
FX The authors are thankful to Council of Scientific and Industrial
   Research (CSIR), New Delhi for providing financial assistance in the
   form of a Senior Research Fellowship to V. Dubey.
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Barry AL, 1995, BIOCHEMISTRY-US, V33, P8082
   Celia C, 2009, COLLOID SURFACE B, V72, P155, DOI 10.1016/j.colsurfb.2009.03.007
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Dayan N, 2000, BIOMATERIALS, V21, P1879, DOI 10.1016/S0142-9612(00)00063-6
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dubey V, 2006, BIOMATERIALS, V27, P3491, DOI 10.1016/j.biomaterials.2006.01.060
   Dubey V, 2007, EXPERT OPIN DRUG DEL, V4, P579, DOI 10.1517/17425247.4.6.579
   Dubey V, 2007, J CONTROL RELEASE, V123, P148, DOI 10.1016/j.jconrel.2007.08.005
   Dubey V, 2007, EUR J PHARM BIOPHARM, V67, P398, DOI 10.1016/j.ejpb.2007.03.007
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   Harrison JE, 1996, J CONTROL RELEASE, V41, P283, DOI 10.1016/0168-3659(96)01348-X
   Honeywell-Nguyen PL, 2002, BBA-GEN SUBJECTS, V1573, P130
   JACOBS M, 1988, J PHARM PHARMACOL, V40, P829, DOI 10.1111/j.2042-7158.1988.tb06283.x                                              
   KADIR R, 1987, J PHARM SCI, V76, P774, DOI 10.1002/jps.2600761004
   Komatsu H, 1996, BBA-BIOMEMBRANES, V1283, P73, DOI 10.1016/0005-2736(96)00082-X
   Lasic D, 1998, PHARM DOSAGE FORMS D, V3, P43
   Lodzki M, 2003, J CONTROL RELEASE, V93, P377, DOI 10.1016/j.jconrel.2003.09.001
   Lopez-Pinto JM, 2000, INT J PHARMACEUT, V298, P1
   Magnusson BM, 1997, INT J PHARM, V157, P113, DOI 10.1016/S0378-5173(97)00235-4
   Mishra D, 2008, EUR J PHARM SCI, V33, P424, DOI 10.1016/j.ejps.2008.01.015
   Panchagnula R, 2001, INT J PHARM, V219, P95, DOI 10.1016/S0378-5173(01)00634-2                                                   
   Paolino D, 2005, J CONTROL RELEASE, V106, P99, DOI 10.1016/j.jconrel.2005.04.007
   Schiffman SS, 1999, NUTRITION, V15, P767, DOI 10.1016/S0899-9007(99)00152-5
   Singh P, 2008, J PHARMACEUT BIOMED, V47, P248, DOI 10.1016/j.jpba.2008.01.001
   SORENSEN EN, 1977, ANAL BIOCHEM, V82, P376, DOI 10.1016/0003-2697(77)90175-0
   TOTEVA MM, 2007, J PHARM SCI, V97, P3810
   Touitou E, 2000, J CONTROL RELEASE, V65, P403, DOI 10.1016/S0168-3659(99)00222-9
   Verma DD, 2003, INT J PHARM, V258, P141, DOI 10.1016/S0378-5173(03)00183-2
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Williams GC, 1999, ADV DRUG DELIVER REV, V39, P211, DOI 10.1016/S0169-409X(99)00027-7                                                   
NR 32
TC 39
Z9 43
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD AUG
PY 2010
VL 6
IS 4
BP 590
EP 596
DI 10.1016/j.nano.2010.01.002
PG 7
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 634TP
UT WOS:000280608700014
PM 20093197
DA 2018-01-05
ER

PT J
AU Tozzini, V
AF Tozzini, Valentina
TI Minimalist models for proteins: a comparative analysis
SO QUARTERLY REVIEWS OF BIOPHYSICS
LA English
DT Review
ID ELASTIC NETWORK MODELS; COARSE-GRAINED MODELS; MOLECULAR-DYNAMICS
   SIMULATIONS; FORCE-FIELD; GLOBULAR-PROTEINS; HIV-1 PROTEASE; ATOMISTIC
   SIMULATIONS; BIOMOLECULAR SYSTEMS; RESIDUE POTENTIALS; HYDROGEN-BONDS
AB The last decade has witnessed a renewed interest in the coarse-grained (CG) models for biopolymers, also stimulated by the needs of modern molecular biology, dealing with nano- to micro-sized bio-molecular systems and larger than microsecond timescale. This combination of size and timescale is, in fact, hard to access by atomic-based simulations. Coarse graining the system is a route to be followed to overcome these limits, but the ways of practically implementing it are many and different, making the landscape of CG models very vast and complex.
   In this paper, the CG models are reviewed and their features, applications and performances compared. This analysis, restricted to proteins, focuses on the minimalist models, namely those reducing at minimum the number of degrees of freedom without losing the possibility of explicitly describing the secondary structures. This class includes models using a single or a few interacting centers (beads) for each amino acid.
   From this analysis several issues emerge. The difficulty in building these models resides in the need for combining transferability/predictive power with the capability of accurately reproducing the structures. It is shown that these aspects could be optimized by accurately choosing the force field (FF) terms and functional forms, and combining different parameterization procedures. In addition, in spite of the variety of the minimalist models, regularities can be found in the parameters values and in FF terms. These are outlined and schematically presented with the aid of a generic phase diagram of the polypeptide in the parameter space and, hopefully, could serve as guidelines for the development of minimalist models incorporating the maximum possible level of predictive power and structural accuracy.
C1 CNR, Scuola Normale Super, Ist Nanosci, NEST, I-56127 Pisa, Italy.
RP Tozzini, V (reprint author), CNR, Scuola Normale Super, Ist Nanosci, NEST, Piazza San Silvestro 12, I-56127 Pisa, Italy.
EM tozzini@nest.sns.it
RI Tozzini, Valentina/E-8206-2011
OI Tozzini, Valentina/0000-0002-7586-5039
CR Alemani D, 2010, J CHEM THEORY COMPUT, V6, P315, DOI 10.1021/ct900457z
   ARCANGELI C, CRINKLE VIRUS UNPUB
   ARORA N, 1996, J COMPUT CHEM, V18, P1246
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X                                                   
   Ayton GS, 2007, CURR OPIN STRUC BIOL, V17, P192, DOI 10.1016/j.sbi.2007.03.004
   Bahar I, 1997, J MOL BIOL, V266, P195, DOI 10.1006/jmbi.1996.0758
   Bahar I, 1997, PROTEINS, V29, P292, DOI 10.1002/(SICI)1097-0134(199711)29:3<292::AID-PROT4>3.0.CO;2-D
   Banachowicz E, 2000, BIOPHYS J, V78, P70, DOI 10.1016/S0006-3495(00)76573-8                                                   
   BAY Y, 1994, PROTEINS, V18, P262
   Betancourt MR, 1999, PROTEIN SCI, V8, P361
   Buck PM, 2009, PROTEINS, V76, P331, DOI 10.1002/prot.22348
   CASCELLA M, 2008, CURR OPIN STRUC BIOL, V18, P630
   Chang CEA, 2007, CHEM BIOL DRUG DES, V69, P5, DOI 10.1111/j.1747-0285.2007.00464.x
   Chennubhotla C, 2005, PHYS BIOL, V2, pS173, DOI [10.1088/1478-3975/2/4/S12, 10.1088/1475-3975/2/4/S12]
   CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343                                             
   Chu JW, 2007, BIOPHYS J, V93, P3860, DOI 10.1529/biophysj.107.112060
   Clementi C, 2000, J MOL BIOL, V298, P937, DOI 10.1006/jmbi.2000.3693
   Das A, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3173812
   Das P, 2005, P NATL ACAD SCI USA, V102, P10141, DOI 10.1073/pnas.0409471102
   Demirel MC, 2005, J BIOMOL STRUCT DYN, V22, P381, DOI 10.1080/07391102.2005.10507010                                                  
   Di Fenza A, 2009, PROTEINS, V76, P946, DOI 10.1002/prot.22399
   ERCOLESSI F, 1994, EUROPHYS LETT, V26, P583, DOI 10.1209/0295-5075/26/8/005
   Friedel M, 2004, J CHEM PHYS, V120, P5809, DOI 10.1063/1.1649934
   Friedel M, 2003, J CHEM PHYS, V118, P8106, DOI 10.1063/1.1564048
   GO N, 1976, MACROMOLECULES, V9, P535, DOI 10.1021/ma60052a001
   Ha-Duong T, 2010, J CHEM THEORY COMPUT, V6, P761, DOI 10.1021/ct900408s
   Hamacher K, 2006, J CHEM THEORY COMPUT, V2, P873, DOI 10.1021/ct050247s
   HONEYCUTT JD, 1990, P NATL ACAD SCI USA, V87, P3526, DOI 10.1073/pnas.87.9.3526
   Izvekov S, 2006, J CHEM THEORY COMPUT, V2, P637, DOI 10.1021/ct050300c
   Izvekov S, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2038787
   Izvekov S, 2004, J CHEM PHYS, V120, P10896, DOI 10.1063/1.1739396
   Jang HB, 2004, BIOPHYS J, V86, P31, DOI 10.1016/S0006-3495(04)74081-3                                                   
   Jeong JI, 2006, J MOL GRAPH MODEL, V24, P296, DOI 10.1016/j.jmgm.2005.09.006
   Kaya H, 2003, J MOL BIOL, V326, P911, DOI 10.1016/S0022-2836(02)01434-1
   Keskin O, 1998, PROTEIN SCI, V7, P2578, DOI 10.1002/pro.5560071211                                                          
   Klimov DK, 1998, FOLD DES, V3, P481, DOI 10.1016/S1359-0278(98)00065-0
   Klimov DK, 2000, P NATL ACAD SCI USA, V97, P2544, DOI 10.1073/pnas.97.6.2544                                                          
   Koga N, 2001, J MOL BIOL, V313, P171, DOI 10.1006/jmbi.2001.5037
   Korkut A, 2009, P NATL ACAD SCI USA, V106, P15667, DOI 10.1073/pnas.0907674106
   LEVITT M, 1975, NATURE, V253, P694, DOI 10.1038/253694a0
   LEVITT M, 1976, BIRD, V104, P59
   Liwo A, 1997, J COMPUT CHEM, V18, P874, DOI 10.1002/(SICI)1096-987X(199705)18:7<874::AID-JCC2>3.0.CO;2-O
   LIWO A, 1997, COMOM CHEM, V18, P849
   LU P, 2007, J PHYS CHEM B, V111, P11566
   Lyman E, 2008, BIOPHYS J, V95, P4183, DOI 10.1529/biophysj.108.139733
   Majek P, 2009, PROTEINS, V76, P822, DOI 10.1002/prot.22388
   Maragakis P, 2005, J MOL BIOL, V352, P807, DOI 10.1016/j.jmb.2005.07.031
   Mathews C.K., 2000, BIOCHEMISTRY
   Matysiak S, 2006, J MOL BIOL, V363, P297, DOI 10.1016/j.jmb.2006.07.088
   MCCAMMON JA, 1980, FIOPOIYMERTT, V19, P2033
   Miyazawa S, 1996, J MOL BIOL, V256, P623, DOI 10.1006/jmbi.1996.0114
   Monticelli L., 2008, CHEM THEMY COMPD, V4, P819
   Mukherjee A, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1940058
   Mukherjee A, 2003, J CHEM PHYS, V118, P4733, DOI 10.1063/1.1542599
   Nakagawa N, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.041916
   Noid WG, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2938857
   Noid WG, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2938860
   Nymeyer H, 1998, P NATL ACAD SCI USA, V95, P5921, DOI 10.1073/pnas.95.11.5921
   Okur A, 2003, J COMPUT CHEM, V24, P21, DOI 10.1002/jcc.10184
   Ono S, 2000, J COMPUT CHEM, V21, P748, DOI 10.1002/(SICI)1096-987X(20000715)21:9<748::AID-JCC4>3.0.CO;2-2                  
   Reith D, 2003, J COMPUT CHEM, V24, P1624, DOI 10.1002/jcc.10307
   RUSSEL DD, 2009, CURR OPIN CELL BIOL, V21, P1
   Sherwood P, 2008, CURR OPIN STRUC BIOL, V18, P630, DOI 10.1016/j.sbi.2008.07.003
   SHI Q, 2006, PHY CHEM, V110, P15045
   Silverstein KAT, 1998, J AM CHEM SOC, V120, P3166, DOI 10.1021/ja973029k                                                               
   SOHEILIFARD R, 2011, PHYS BIOL, V5
   Sorensen JM, 2002, PROTEINS, V46, P368, DOI 10.1002/prot.1174
   SORENSON JM, 2002, PROTEIN ENG, V9, P35
   TAMA F, 2005, ANNU REV BIOPH BIOM, V35, P115
   Thorpe IF, 2008, J PHYS CHEM B, V112, P13079, DOI 10.1021/jp8015968
   Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905                                                     
   Tozzini V, 2006, J CHEM THEORY COMPUT, V2, P667, DOI 10.1021/ct050294k
   Tozzini V, 2005, CHEM PHYS LETT, V413, P123, DOI 10.1016/j.cplett.2005.07.075
   Tozzini V, 2005, CURR OPIN STRUC BIOL, V15, P144, DOI 10.1016/j.sbi.2005.02.005
   TOZZINI V, 2008, COARSE GRAINING COND, P285
   TOZZINI V, PHASE DIAGRAM UNPUB
   TOZZINI V, 2007, STAID BIS, V157, P606
   Tozzini V, 2010, ACCOUNTS CHEM RES, V43, P220, DOI 10.1021/ar9001476
   TROVATO F, COARSE GRAINED UNPUB
   Trylska J, 2005, BIOPHYS J, V89, P1455, DOI 10.1529/biophysj.104.058495
   Trylska J, 2007, BIOPHYS J, V92, P4179, DOI 10.1529/biophysj.106.100560
   VanAalten DMF, 1997, J COMPUT CHEM, V18, P169
   Voet D, 2005, BIOCHEMISTRY
   Voltz K, 2008, J COMPUT CHEM, V29, P1429, DOI 10.1002/jcc.20902
   Wang YT, 2009, PHYS CHEM CHEM PHYS, V11, P2002, DOI 10.1039/b819182d
   Wu YH, 2007, PROTEIN SCI, V16, P1449, DOI 10.1110/ps.072796107
   Yap EH, 2008, PROTEINS, V70, P626, DOI 10.1002/prot.21515
   Zacharias M, 2003, PROTEIN SCI, V12, P1271, DOI 10.1110/ps.0239303
   Zhou HY, 2002, PROTEIN SCI, V11, P2714, DOI 10.1110/ps.0217002
   Zhou J, 2007, BIOPHYS J, V92, P4289, DOI 10.1529/biophysj.106.094425
   2004, PROTEINS, V57, P725
NR 91
TC 64
Z9 64
U1 0
U2 49
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-5835
J9 Q REV BIOPHYS
JI Q. Rev. Biophys.
PD AUG
PY 2010
VL 43
IS 3
BP 333
EP 371
DI 10.1017/S0033583510000132
PG 39
WC Biophysics
SC Biophysics
GA 675HP
UT WOS:000283818800002
PM 20707940
DA 2018-01-05
ER

PT J
AU Himeno, A
   Akagi, T
   Uto, T
   Wang, X
   Baba, M
   Ibuki, K
   Matsuyama, M
   Horiike, M
   Igarashi, T
   Miura, T
   Akashi, M
AF Himeno, Ai
   Akagi, Takami
   Uto, Tomofumi
   Wang, Xin
   Baba, Masanori
   Ibuki, Kentaro
   Matsuyama, Megumi
   Horiike, Mariko
   Igarashi, Tatsuhiko
   Miura, Tomoyuki
   Akashi, Mitsuru
TI Evaluation of the immune response and protective effects of rhesus
   macaques vaccinated with biodegradable nanoparticles carrying gp120 of
   human immunodeficiency virus
SO VACCINE
LA English
DT Article
DE HIV vaccine; Biodegradable nanoparticles; Adjuvant
ID POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES; HUMAN MONOCLONAL-ANTIBODIES;
   HIV-1/SIV CHIMERIC VIRUS; AMPHIPHILIC GAMMA-PGA; T-CELL RESPONSES;
   DENDRITIC CELLS; ANTIGEN-DELIVERY; INTRANASAL IMMUNIZATION;
   NONHUMAN-PRIMATES; TUMOR-VACCINE
AB We previously reported that biodegradable amphiphilic poly(gamma-glutamic acid) nanoparticles (NPs) carrying the recombinant gp120 env protein of the human immunodeficiency virus type 1 (HIV-1) were efficiently taken up by dendritic cells, and induced strong CDR(+) T cell responses against the gp120 in mice. To evaluate gp120-carrying NPs (gp120-NPs) as a vaccine candidate for HIV-1 infection, we vaccinated rhesus macaques with these gp120-NPs and examined the immune response and protective efficacy against a challenge inoculation of simian and human immunodeficiency chimeric virus (SHIV). We found that gp120-NP vaccination induced stronger responses for both gp120-specific cellular and humoral immunity than gp120-alone vaccination. After the challenge inoculation with SHIV, however, the peak value of viral RNA in the peripheral blood was higher in the vaccinated groups, especially the gp120-NP vaccinated group, than naive control group. Higher value of viral load was also maintained in gp120-NP vaccinated group. Furthermore, CD4(+) T cells from the peripheral blood decreased more in the vaccinated groups than the control group. Thus, induced immune responses against gp120 enclosed in NPs were not effective for protection but, conversely enhanced the infection, although the gp120-NP5 showed a stronger induction of immune responses against the vaccinated antigen in rhesus macaques. These results support the importance of determining immune correlate of protective immunity for vaccine development against HIV-1 infection. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Himeno, Ai; Ibuki, Kentaro; Matsuyama, Megumi; Horiike, Mariko; Igarashi, Tatsuhiko; Miura, Tomoyuki] Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Lab Primate Model,Sakyo Ku, Kyoto 6068507, Japan.
   [Akagi, Takami; Akashi, Mitsuru] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   [Akagi, Takami; Uto, Tomofumi; Wang, Xin; Baba, Masanori; Miura, Tomoyuki; Akashi, Mitsuru] Japan Sci & Technol Agcy JST, Core Res Evolut Sci & Technol CREST, Saitama 3320012, Japan.
   [Uto, Tomofumi; Wang, Xin; Baba, Masanori] Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
RP Miura, T (reprint author), Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Lab Primate Model,Sakyo Ku, 53 Shogoinkawaramachi, Kyoto 6068507, Japan.
EM tmiura@virus.kyoto-u.ac.jp; akashi@chem.eng.osaka-u.ac.jp
RI Baba, Masanori/G-3867-2011
FU Japan Science and Technology Agency (JST)
FX This work was supported by CREST from the Japan Science and Technology
   Agency (JST).
CR Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2006, BIOMACROMOLECULES, V7, P297, DOI 10.1021/bm050657i
   Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akagi T, 2007, POLYMER, V48, P6729, DOI 10.1016/j.polymer.2007.08.038
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   Barnetta SW, 2008, AIDS, V22, P339, DOI 10.1097/QAD.0b013e3282f3ca57
   BOGERS WM, 2000, AIDS S, V14, P141
   BORROW P, 1994, J VIROL, V68, P6103
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Earl PL, 2001, J VIROL, V75, P645, DOI 10.1128/JVI.75.2.645-653.2001
   Egan MA, 2004, VACCINE, V22, P3774, DOI 10.1016/j.vaccine.2004.03.011
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120
   Imaoka K, 1998, J IMMUNOL, V161, P5952
   Joag SV, 1996, J VIROL, V70, P3189
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kim H, 2009, MACROMOL BIOSCI, V9, P842, DOI 10.1002/mabi.200800367
   Koopman G, 2007, J MED VIROL, V79, P474, DOI [10.1002/jmv.20860, 10.1002/jmw.20860]
   Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matano T, 1998, J VIROL, V72, P164
   Matsuo K, 2007, BIOCHEM BIOPH RES CO, V362, P1069, DOI 10.1016/j.bbrc.2007.08.112
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   MOOIJ P, 1998, AIDS, V12, P15
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   OHAGAN DT, 2002, AIDS, V16, P115
   OKAMOTO M, 2009, VACCINE, V27, P5896
   Okamoto S, 2008, VACCINE, V26, P589, DOI 10.1016/j.vaccine.2007.11.067
   Okamoto S, 2007, VACCINE, V25, P8270, DOI 10.1016/j.vaccine.2007.09.051
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001                                                
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Pomerantz RJ, 2003, NAT MED, V9, P867, DOI 10.1038/nm0703-867
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183                                                         
   TAKEDA A, 1992, J CLIN INVEST, V89, P1952, DOI 10.1172/JCI115802                                                               
   Tsukamoto T, 2009, J VIROL, V83, P9339, DOI 10.1128/JVI.01120-09
   Uto T, 2009, BIOCHEM BIOPH RES CO, V379, P600, DOI 10.1016/j.bbrc.2008.12.122
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Uto T, 2009, IMMUNOL LETT, V125, P46, DOI 10.1016/j.imlet.2009.05.008
   Verschoor EJ, 1999, J VIROL, V73, P3292
   Waeckerle-Men Y, 2005, ADV DRUG DELIVER REV, V57, P475, DOI 10.1016/j.addr.2004.09.007
   WANG X, 2007, MINI-REV ORG CHEM, V4, P281
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Yoshikawa T, 2008, VACCINE, V26, P1303, DOI 10.1016/j.vaccine.2007.12.037
   Yoshikawa T, 2008, BIOCHEM BIOPH RES CO, V366, P408, DOI 10.1016/j.bbre.2007.11.153
   Yoshino N, 2004, J IMMUNOL, V173, P6850, DOI 10.4049/jimmunol.173.11.6850                                                    
   Zhao Z, 1996, J PHARM SCI-US, V85, P1261, DOI 10.1021/js9602812
NR 59
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 19
PY 2010
VL 28
IS 32
BP 5377
EP 5385
DI 10.1016/j.vaccine.2010.04.110
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 639QF
UT WOS:000280988600033
PM 20472029
DA 2018-01-05
ER

PT J
AU Wang, QA
   Li, YF
   Song, CJ
   Qian, KD
   Chen, CH
   Lee, KH
   Chang, JB
AF Wang, Qiang
   Li, Yanfeng
   Song, Chuanjun
   Qian, Keduo
   Chen, Chin-Ho
   Lee, Kuo-Hsiung
   Chang, Junbiao
TI Synthesis and anti-HIV activity of 2 '-deoxy-2 '-fluoro-4 '-C-ethynyl
   nucleoside analogs
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE 2 '-Deoxy-2 '-fluoro-4 '-C-ethynyl nucleosides; Anti-HIV activity
ID REVERSE-TRANSCRIPTASE; ANTIVIRAL AGENT; AIDS;
   3'-AZIDO-3'-DEOXYTHYMIDINE; REPLICATION; INHIBITORS; DISCOVERY; DESIGN;
   DRUGS
AB Based on the favorable antiviral profiles of 4'-substituted nucleosides, novel 1-(2'-deoxy-2'-fluoro-4'-C-ethynyl-beta-D-arabinofuranosyl)-uracil (1a), -thymine (1b), and -cytosine ( 2) analogs were synthesized. Compounds 1b and 2 exhibited potent anti-HIV-1 activity with IC50 values of 86 and 1.34 nM, respectively, without significant cytotoxicity. Compound 2 was 35-fold more potent than AZT against wild-type virus, and also retained nanomolar antiviral activity against resistant strains, NL4-3 (K101E) and RTMDR. Thus, 2 merits further development as a novel NRTI drug. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Qian, Keduo; Lee, Kuo-Hsiung] Univ N Carolina, Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA.
   [Wang, Qiang; Li, Yanfeng; Song, Chuanjun; Chang, Junbiao] Zhengzhou Univ, Dept Chem, Zhengzhou, Peoples R China.
   [Chen, Chin-Ho] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
RP Lee, KH (reprint author), Univ N Carolina, Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA.
EM khlee@unc.edu; changjunbiao@zzu.edu.cn
RI chang, junbiao/P-1095-2014
OI chang, junbiao/0000-0001-6236-1256
FU National Natural Science Foundation of China [20672030]; Outstanding
   Young Scholarship of NSFC [30825043]; National Institute of Allergies
   and Infectious Diseases [AI-33066]
FX J. Chang thanks the National Natural Science Foundation of China
   (#20672030) and the Outstanding Young Scholarship of NSFC (#30825043)
   for financial support. The research was also partially supported by
   Grant AI-33066 from the National Institute of Allergies and Infectious
   Diseases awarded to K.H. Lee.
CR Aquaro S, 2006, J LEUKOCYTE BIOL, V80, P1103, DOI 10.1189/jlb.0606376
   CARMICHAEL J, 1987, CANCER RES, V47, P943
   Chu JC, 2004, CHINESE CHEM LETT, V15, P785
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   DECLERCQ E, 1987, ANTICANCER RES, V7, P1023
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   Dong CH, 2004, CHINESE J ORG CHEM, V24, P1099
   DONG CH, 2004, GAODENG XUEXIAO HUAX, V25, P2054
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   HERTEL LW, 1988, J ORG CHEM, V53, P2406, DOI 10.1021/jo00246a002
   MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015                                                             
   Meadows DC, 2006, CHEMMEDCHEM, V1, P16, DOI 10.1002/cmdc.200500026
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   NICOLAS J, 2008, TETRAHEDRON, V64, P4444
   Ohrui Hiroshi, 2001, Current Drug Targets - Infectious Disorders, V1, P1, DOI 10.2174/1568005013343218
   Qian KD, 2009, J MED CHEM, V52, P3248, DOI 10.1021/jm900136j
   SARIN PS, 1988, ANNU REV PHARMACOL, V28, P411
   SCHARER OD, 1995, J AM CHEM SOC, V117, P10781, DOI 10.1021/ja00148a036                                                             
   Smith DB, 2007, BIOORG MED CHEM LETT, V17, P2570, DOI 10.1016/j.bmcl.2007.02.004
   Stevens M, 2006, MED RES REV, V26, P595, DOI 10.1002/med.20081
   Sugimoto I, 1999, BIOORG MED CHEM LETT, V9, P385, DOI 10.1016/S0960-894X(99)00010-4                                                   
   WATANABE KA, 1979, J MED CHEM, V22, P21, DOI 10.1021/jm00187a005
   YARCHOAN R, 1986, LANCET, V1, P575
NR 24
TC 13
Z9 14
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 15
PY 2010
VL 20
IS 14
BP 4053
EP 4056
DI 10.1016/j.bmcl.2010.05.090
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 617CQ
UT WOS:000279258800012
PM 20542430
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ramana, LN
   Sethuraman, S
   Ranga, U
   Krishnan, UM
AF Ramana, Lakshmi N.
   Sethuraman, Swaminathan
   Ranga, Udaykumar
   Krishnan, Uma M.
TI Development of a liposomal nanodelivery system for nevirapine
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
ID SOLID LIPID NANOPARTICLES; DRUG-DELIVERY SYSTEM; REVERSE-TRANSCRIPTASE;
   PROTEASE INHIBITOR; IN-VITRO; HIV; TRANSPORT; RELEASE; PHARMACOKINETICS;
   ENCAPSULATION
AB Background: The treatment of AIDS remains a serious challenge owing to high genetic variation of Human Immunodeficiency Virus type 1 ( HIV-1). The use of different antiretroviral drugs (ARV) is significantly limited by severe side-effects that further compromise the quality of life of the AIDS patient. In the present study, we have evaluated a liposome system for the delivery of nevirapine, a hydrophobic non-nucleoside reverse transcriptase inhibitor. Liposomes were prepared from egg phospholipids using thin film hydration. The parameters of the process were optimized to obtain spherical liposomes below 200 nm with a narrow polydispersity. The encapsulation efficiency of the liposomes was optimized at different ratios of egg phospholipid to cholesterol as well as drug to total lipid. The data demonstrate that encapsulation efficiency of 78.14% and 76.25% were obtained at egg phospholipid to cholesterol ratio of 9: 1 and drug to lipid ratio of 1: 5, respectively. We further observed that the size of the liposomes and the encapsulation efficiency of the drug increased concomitantly with the increasing ratio of drug and lipid and that maximum stability was observed at the physiological pH. Thermal analysis of the drug encapsulated liposomes indicated the formation of a homogenous drug-lipid system. The magnitude of drug release from the liposomes was examined under different experimental conditions including in phosphate buffered saline (PBS), Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum or in the presence of an external stimulus such as low frequency ultrasound. Within the first 20 minutes 40, 60 and 100% of the drug was released when placed in PBS, DMEM or when ultrasound was applied, respectively. We propose that nevirapine-loaded liposomal formulations reported here could improve targeted delivery of the anti-retroviral drugs to select compartments and cells and alleviate systemic toxic side effects as a consequence.
C1 [Ramana, Lakshmi N.; Sethuraman, Swaminathan; Krishnan, Uma M.] SASTRA Univ, Sch Chem & Biotechnol, Ctr Nanotechnol & Adv Biomat CeNTAB, Thanjavur 613401, India.
   [Ranga, Udaykumar] Jawaharlal Nehru Ctr Adv Sci Res, Mol Virol Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.
RP Krishnan, UM (reprint author), SASTRA Univ, Sch Chem & Biotechnol, Ctr Nanotechnol & Adv Biomat CeNTAB, Thanjavur 613401, India.
EM umakrishnan@sastra.edu
FU SASTRA University
FX The authors wish to record their gratitude to Nano Mission Council,
   Department of Science and Technology and Prof. T. R. Rajagopalan R& D
   Grant, SASTRA University, for financial support.
CR Al-Ayed MS, 2006, INDIAN J BIOCHEM BIO, V43, P186
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   ATYABI F, 2005, ACTA PHARM, V59, P133
   Baert L, 2008, INT J PHARM, V355, P38, DOI 10.1016/j.ijpharm.2008.01.029
   Benghuzzi H, 2000, Biomed Sci Instrum, V36, P343
   Betageri GV, 2001, DRUG DEV IND PHARM, V27, P129, DOI 10.1081/DDC-100000479
   BHATIA VK, 2009, BIOPHYS J, V96, pA570
   Bordi F, 2002, COLLOID SURFACE B, V26, P341, DOI 10.1016/S0927-7765(02)00018-8                                                   
   Casals E, 2003, CHEM PHYS LIPIDS, V125, P139, DOI 10.1016/S0009-3084(03)00086-0
   Chan YH, 2004, INT J FOOD SCI TECH, V39, P985, DOI 10.1111/j.1365-2621.2004.00867.x
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chen RX, 2005, J VIROL, V79, P12045, DOI 10.1128/JVI.79.18.12045-12057.2005
   Coderch L, 2000, J CONTROL RELEASE, V68, P85, DOI 10.1016/S0168-3659(00)00240-6
   Currier Judith S, 2005, Top HIV Med, V13, P16
   de Requena DG, 2002, AIDS, V16, P290, DOI 10.1097/00002030-200201250-00020
   DELANEY M, 2006, RETROVIROLOGY, V3, P56
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   EERDENBURGH BV, 2007, INT J PHARMACEUT, V338, P298
   Ferrari M, 2005, CURR OPIN CHEM BIOL, V9, P343, DOI 10.1016/j.cbpa.2005.06.001
   Fiala Milan, 2004, Cardiovasc Toxicol, V4, P327, DOI 10.1385/CT:4:4:327
   Govender S, 2005, INT J PHARM, V306, P24, DOI 10.1016/j.ijpharm.2005.07.026
   Griffin BT, 2006, J PHARM PHARMACOL, V58, P917, DOI 10.1211/jpp.58.7.0006
   Hofstede HJM, 2003, NETH J MED, V61, P393
   Jin SX, 2005, PHARMAZIE, V60, P840
   Katrin K, 1995, INT J PHARMACEUT, V125, P231
   KAUR A, 2008, NANOMEDICINE, V4, P41
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kontorinis Nickolas, 2003, AIDS Reviews, V5, P36
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lin JH, 1999, ADV DRUG DELIVER REV, V39, P33, DOI 10.1016/S0169-409X(99)00018-6                                                   
   Maga G, 2000, ANTIMICROB AGENTS CH, V44, P1186, DOI 10.1128/AAC.44.5.1186-1194.2000
   Maheswari KU, 2000, BBA-BIOMEMBRANES, V1463, P230, DOI 10.1016/S0005-2736(99)00189-3
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   Mickova A, 2008, ACTA VET BRNO, V77, P285, DOI 10.2754/avb200877020285
   PETIT F, 2005, TRENDS PHARMACOL SCI, V26, P2558
   Pevzner A, 2008, ADV FUNCT MATER, V18, P242, DOI 10.1002/adfm.200700726
   Pilon AA, 2002, ANTIMICROB AGENTS CH, V46, P2687, DOI 10.1128/AAC.46.8.2687-2691.2002
   Ruckenstein E, 1996, LANGMUIR, V12, P4134, DOI 10.1021/la960193x                                                               
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   SUBHEET J, 2006, CURR DRUG DELIV, V3, P157
   Trif M, 2008, MICRON, V39, P1042, DOI 10.1016/j.micron.2008.01.008
   Tronchet JMJ, 2003, CURR TOP MED CHEM, V3, P1496, DOI 10.2174/1568026033451754                                                        
   Uhumwangho M. U., 2005, Journal of Medicine and Biomedical Research, V4, P9
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Xu QG, 2007, BIOMATERIALS, V28, P2687, DOI 10.1016/j.biomaterials.2007.02.007
NR 50
TC 53
Z9 53
U1 1
U2 22
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD JUL 13
PY 2010
VL 17
AR 57
DI 10.1186/1423-0127-17-57
PG 9
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 656LH
UT WOS:000282336100001
PM 20624325
OA gold
DA 2018-01-05
ER

PT J
AU Liu, Y
   Bae, SW
   Wang, K
   Hong, JI
   Zhu, Z
   Tan, WH
   Pappas, D
AF Liu, Yan
   Bae, Se Won
   Wang, Kelong
   Hong, Jong-In
   Zhu, Zhi
   Tan, Weihong
   Pappas, Dimitri
TI The effects of flow type on aptamer capture in differential mobility
   cytometry cell separations
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Differential mobility cytometry; Aptamer; Cell separation; Cell capture
   time
ID HIV-INFECTED SUBJECTS; CANCER-CELLS; MICROFLUIDIC DEVICE; CONJUGATED
   NANOPARTICLES; AFFINITY-CHROMATOGRAPHY; MICROPALLET ARRAYS; SINGLE;
   DIELECTROPHORESIS; CONTAMINATION; COLLECTION
AB In this work, differential mobility cytometry (DMC) was used to monitor cell separation based on aptamer recognition for target cells. In this device, open-tubular capillaries coated with Sgc8 aptamers were used as affinity chromatography columns for separation. After cells were injected into the columns, oscillating flow was generated to allow for long-term cell adhesion studies. This process was monitored by optical microscopy, and differential imaging was used to analyze the cells as they adhered to the affinity surface. We investigated the capture time, capture efficiency, purity of target and control cells, as well as the reusability of the affinity columns. Capture time for both CCRF-CEM cells and Jurkat T cells was 0.4 +/- 0.2 s, which demonstrated the high separation affinity between aptamers and target cells. The capture efficiency for CCRF-CEM cells was 95% and purity was 99% in a cell mixture. With the advantage of both high cell capture efficiency and purity. DMC combined with aptamer-based separation emerges as a powerful tool for rare cell enrichment. In addition, aptamer-based DMC channels were found to be more robust than antibody based channels with respect to reuse of the separation device. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Liu, Yan; Wang, Kelong; Pappas, Dimitri] Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.
   [Bae, Se Won; Hong, Jong-In] Seoul Natl Univ, Dept Chem, Seoul 151, South Korea.
   [Bae, Se Won; Hong, Jong-In; Zhu, Zhi; Tan, Weihong] Univ Florida, Dept Chem, Ctr Res Bio Nano Interface, Gainesville, FL 32611 USA.
   [Bae, Se Won; Hong, Jong-In; Zhu, Zhi; Tan, Weihong] Univ Florida, Dept Physiol & Funct Gen, Shands Canc Ctr, UF Genet Inst, Gainesville, FL 32611 USA.
   [Bae, Se Won; Hong, Jong-In; Zhu, Zhi; Tan, Weihong] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA.
RP Pappas, D (reprint author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.
EM d.pappas@ttu.edu
RI Zhu, Zhi/D-3721-2011; Bae, Se Won/H-7550-2012; Tan, Weihong/A-5412-2008;
   Wang, Kelong/F-8445-2012; Pappas, Dimitri/F-7912-2013
OI Zhu, Zhi/0000-0002-3287-4920; Bae, Se Won/0000-0003-1926-5466; Tan,
   Weihong/0000-0002-8066-1524; Pappas, Dimitri/0000-0002-5725-4816
FU Robert A. Welch Foundation [D-1667]
FX D.P. was supported in part by a grant from the Robert A. Welch
   Foundation (Grant D-1667).
CR Busscher HJ, 2006, CLIN MICROBIOL REV, V19, P127, DOI 10.1128/CMR.19.1.127-141.2006
   CHEN H, 2008, CHEMMEDCHEM, V6, P991
   Chen XL, 2008, J BIOMED NANOTECHNOL, V4, P400, DOI 10.1166/jbn.2008.002
   CHEN Y, 2009, CHEM-EUR J, P5327
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Dainiak MB, 2006, J CHROMATOGR A, V1123, P145, DOI 10.1016/j.chroma.2006.05.089
   Dainiak MB, 2005, BIOTECHNOL PROGR, V21, P644, DOI 10.1021/bp049615g
   Delehanty JB, 2002, ANAL CHEM, V74, P5681, DOI 10.1021/ac025631l
   Hashimoto M, 2009, BIOSENS BIOELECTRON, V24, P2892, DOI 10.1016/j.bios.2009.02.025
   Herr JK, 2006, ANAL CHEM, V78, P2918, DOI 10.1021/ac052015r
   HERTZ CM, 1985, BIOTECHNOL BIOENG, V27, P603, DOI 10.1002/bit.260270509
   Higuchi A, 2006, J BIOMED MATER RES A, V78A, P491, DOI 10.1002/jbm.a.30729
   Hu XY, 2005, P NATL ACAD SCI USA, V102, P15757, DOI 10.1073/pnas.0507719102
   Irimia D, 2004, ANAL CHEM, V76, P6137, DOI 10.1021/ac0497508
   Kumar A, 2005, J MOL RECOGNIT, V18, P84, DOI 10.1002/jmr.693
   Lantz AW, 2007, ANAL CHEM, V79, P1720, DOI 10.1021/ac061770h
   MEINDERS JM, 1992, J MICROBIOL METH, V16, P119, DOI 10.1016/0167-7012(92)90031-X
   NORTON JC, 1997, P AM ASS CANC RES AN, P504
   PAPPAS D, 2010, PRACTICAL CELL ANAL, P279
   Pappas D, 2007, ANAL CHIM ACTA, V601, P26, DOI 10.1016/j.aca.2007.08.033
   Phillips JA, 2008, ANAL CHIM ACTA, V621, P101, DOI 10.1016/j.aca.2008.05.031
   Phillips JA, 2009, ANAL CHEM, V81, P1033, DOI 10.1021/ac802092j
   Reif RD, 2009, ANAL BIOANAL CHEM, V395, P2411, DOI 10.1007/s00216-009-3154-5
   Reif R.D., 2009, ANAL BIOANAL CHEM, V295, P787
   Rodriguez MA, 2006, ANAL CHEM, V78, P4759, DOI 10.1021/ac051936z
   Salazar GT, 2007, ANAL CHEM, V79, P682, DOI 10.1021/ac0615706
   Sekine K, 2006, J IMMUNOL METHODS, V313, P96, DOI 10.1016/j.jim.2006.03.017
   Sethu P, 2004, ANAL CHEM, V76, P6247, DOI 10.1021/ac049429p
   Shadpour H, 2009, CYTOM PART A, V75A, P121, DOI 10.1002/cyto.a.20672
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Sharma PK, 2005, APPL ENVIRON MICROB, V71, P3668, DOI 10.1128/AEM.71.7.3668-3673.2005
   Smith JE, 2007, ANAL CHEM, V79, P3075, DOI 10.1021/ac062151b
   Vahey MD, 2008, ANAL CHEM, V80, P3135, DOI 10.1021/ac7020568
   Wang K, 2008, ANAL CHEM, V80, P2118, DOI 10.1021/ac702553w
   Wang K, 2007, ANAL CHIM ACTA, V601, P1, DOI 10.1016/j.aca.2007.08.029
   Wang KL, 2009, ANAL CHEM, V81, P3334, DOI 10.1021/ac900277y
   Wang L, 2007, LAB CHIP, V7, P1114, DOI 10.1039/b705386j
   Yang SY, 2006, MEAS SCI TECHNOL, V17, P2001, DOI 10.1088/0957-0233/17/7/045
NR 39
TC 9
Z9 10
U1 0
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD JUL 12
PY 2010
VL 673
IS 1
BP 95
EP 100
DI 10.1016/j.aca.2010.05.017
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 628PP
UT WOS:000280133000011
PM 20630183
DA 2018-01-05
ER

PT J
AU Vercruysse, T
   Pardon, E
   Vanstreels, E
   Steyaert, J
   Daelemans, D
AF Vercruysse, Thomas
   Pardon, Els
   Vanstreels, Els
   Steyaert, Jan
   Daelemans, Dirk
TI An Intrabody Based on a Llama Single-domain Antibody Targeting the
   N-terminal alpha-Helical Multimerization Domain of HIV-1 Rev Prevents
   Viral Production
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID VIRUS TYPE-1 REPLICATION; NUCLEAR EXPORT SIGNAL; PFIZER MONKEY VIRUS;
   MESSENGER-RNA; IN-VIVO; GENE-EXPRESSION; FUNCTIONAL-ANALYSIS; STRUCTURAL
   MODEL; TRANS-ACTIVATOR; PROTEIN
AB The human immunodeficiency virus, type 1 (HIV-1)-encoded Rev protein is essential for the expression of late viral mRNAs. Rev forms a large organized multimeric protein-protein complex on the Rev response element of these viral mRNA species and transports them from the nucleus to the cytoplasm, exploiting the CRM1-mediated cellular machinery. Here we report the selection of a nanobody, derived from a llama heavy-chain only antibody, that efficiently blocks the assembly of Rev multimers. The nanobody inhibits HIV-1 replication in cells and specifically suppresses the Rev-dependent expression of partially spliced and unspliced HIV-1 RNA. In HIV-susceptible cells, this nanobody thus has potential as an effective anti-HIV agent using genetic immunization strategies. Its binding site was mapped to Rev residues Lys-20 and Tyr-23 located in the N-terminal alpha-helical multimerization domain. In the presence of this nanobody, we observed an accumulation of dimeric Rev species, supporting a head-to-head/tail-to-tail molecular model for Rev assembly. The results indicate that the oligomeric assembly of Rev follows an ordered stepwise process and identify a new epitope within Rev that could guide strategies for the development of novel HIV inhibitors.
C1 [Vercruysse, Thomas; Vanstreels, Els; Daelemans, Dirk] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Pardon, Els; Steyaert, Jan] Vrije Univ Brussel VIB, Struct Biol Brussels Lab, B-1050 Brussels, Belgium.
   [Pardon, Els; Steyaert, Jan] Vrije Univ Brussel VIB, Dept Mol & Cell Interact, B-1050 Brussels, Belgium.
RP Daelemans, D (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM dirk.daelemans@rega.kuleuven.be
RI Daelemans, Dirk/P-7923-2017; Steyaert, Jan/H-4662-2011
OI Daelemans, Dirk/0000-0001-7092-1153; Steyaert, Jan/0000-0002-3825-874X
FU Fonds voor Weteschappelijk Onderzoek-Vlaanderen [1.5.104.07,
   1.5.165.10]; Belgian Government [I.A.P. P6/19]; K.U. Leuven
   Impulsfinanciering
FX This work was supported by "Fonds voor Weteschappelijk
   Onderzoek-Vlaanderen" Grants 1.5.104.07 and 1.5.165.10, the Belgian
   Government under the framework of the Interuniversity Attraction Poles
   (I.A.P. P6/19), the "Instituut voor de Aanmoediging van Innovatie door
   Wetenschap en Technologie," and the "K.U. Leuven Impulsfinanciering."
CR AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031
   Bayer TS, 2005, RNA, V11, P1848, DOI 10.1261/rna.2167605
   BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870
   Blanco FJ, 2001, J MOL BIOL, V313, P845, DOI 10.1006/jmbi.2001.5067
   BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256
   COCHRANE AW, 1990, J VIROL, V64, P881
   Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001
   Costes SV, 2004, BIOPHYS J, V86, P3993, DOI 10.1529/biophysi.103.038422
   Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005
   Daelemans D, 2004, J BIOL CHEM, V279, P50167, DOI 10.1074/jbc.M407713200
   Daelemans D, 2002, P NATL ACAD SCI USA, V99, P14440, DOI 10.1073/pnas.212285299
   DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0
   Daugherty MD, 2008, MOL CELL, V31, P824, DOI 10.1016/j.molcel.2008.07.016
   DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093
   DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075
   Fang JH, 2004, VIROLOGY, V330, P471, DOI 10.1016/j.virol.2004.09.039
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.001
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0
   Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2
   Fukuda M, 1997, NATURE, V390, P308
   Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4
   GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P343, DOI 10.1089/aid.1994.10.343
   HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304
   HOPE TJ, 1990, J VIROL, V64, P5360
   Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6
   KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436                                                          
   KIM SY, 1989, J VIROL, V63, P3708
   Kubota S, 1998, ONCOGENE, V16, P1851, DOI 10.1038/sj.onc.1201738
   LAM AY, 2008, J STRUCT BIOL, V166, P8
   MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9                                                    
   MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488
   McNally JG, 2008, METHOD CELL BIOL, V85, P329, DOI 10.1016/S0091-679X(08)85014-5
   MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538
   Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Pasternak AO, 2008, J CLIN MICROBIOL, V46, P2206, DOI 10.1128/JCM.00055-08
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   POMERANTZ RJ, 1992, J VIROL, V66, P1809
   Pond SJK, 2009, P NATL ACAD SCI USA, V106, P1404, DOI 10.1073/pnas.0807388106
   Smith CA, 2000, MOL CELL, V6, P1067, DOI 10.1016/S1097-2765(00)00105-2
   SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   Thomas SL, 1998, J VIROL, V72, P2935
   TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758
   Van Neck T, 2008, BIOORGAN MED CHEM, V16, P9487, DOI 10.1016/j.bmc.2008.09.051
   Watts NR, 1998, J STRUCT BIOL, V121, P41, DOI 10.1006/jsbi.1998.3964
   Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X                                                   
   Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029                                                      
   ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944
NR 56
TC 36
Z9 39
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 9
PY 2010
VL 285
IS 28
BP 21768
EP 21780
DI 10.1074/jbc.M110.112490
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 620RD
UT WOS:000279516100062
PM 20406803
OA gold
DA 2018-01-05
ER

PT J
AU Ciobanasu, C
   Siebrasse, JP
   Kubitscheck, U
AF Ciobanasu, Corina
   Siebrasse, Jan Peter
   Kubitscheck, Ulrich
TI Cell-Penetrating HIV1 TAT Peptides Can Generate Pores in Model Membranes
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID SINGLE-PARTICLE TRACKING; INTRACELLULAR DELIVERY; PROTEIN TRANSDUCTION;
   LIPID-MEMBRANES; FUSION PROTEINS; PLASMA-MEMBRANE; MECHANISM; DYNAMICS;
   BINDING; MACROPINOCYTOSIS
AB Cell-penetrating peptides like the cationic human immunodeficiency virus-1 trans-acting activator of transcription (TAT) peptide have the capability to traverse cell membranes and to deliver large molecular cargoes into the cellular interior. We used optical sectioning and state-of-the-art single-molecule microscopy to examine the passive membrane permeation of fluorescently labeled TAT peptides across the membranes of giant unilamellar vesicles (GUVs). In GUVs formed by phosphatidylcholine and cholesterol only, no translocation of TAT up to a concentration of 2 mu M into the GUVs could be observed. At the same peptide concentration, but with 40 mol % of anionic phosphatidylserine in the membrane, rapid translocation of TAT peptides across the bilayers was detected. Efficient translocation of TAT peptides was observed across GUVs containing 20 mol % of phosphatidylethanolamine, which is known to induce a negative curvature into membranes. We discovered that TAT peptides are not only capable of penetrating membranes directly in a passive manner, but they were also able to form physical pores with sizes in the nanometer range, which could be passed by small dye tracer molecules. Lipid topology and anionic charge of the lipid bilayer are decisive parameters for pore formation.
C1 [Ciobanasu, Corina; Siebrasse, Jan Peter; Kubitscheck, Ulrich] Univ Bonn, Inst Phys & Theoret Chem, D-5300 Bonn, Germany.
RP Kubitscheck, U (reprint author), Univ Bonn, Inst Phys & Theoret Chem, Wegelerstr 12, D-5300 Bonn, Germany.
EM u.kubitscheck@uni-bonn.de
RI Ciobanasu, Corina/O-4117-2014
OI Ciobanasu, Corina/0000-0003-1107-8738; Kubitscheck,
   Ulrich/0000-0003-3750-5355
FU European Commission [MCRTN-33439]; German Research Foundation [SFB 624]
FX This work was supported by the European Commission under the 6th
   Framework Programme through the Marie-Curie Action BIOCONTROL (contract
   MCRTN-33439) and the German Research Foundation through the
   Collaborative Research Center SFB 624 Templates-Functional Chemical
   Matrices.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   ALBERTS B, 2002, MOL BIOL CELL
   Ambroggio EE, 2005, BIOPHYS J, V89, P1874, DOI 10.1529/biophysj.105.066589
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   BIMER R, 2001, MOL BIOL CELL, V12, P997
   BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7
   Chaudhary A, 2009, BIOTECHNOL BIOENG, V104, P1075, DOI 10.1002/bit.22500
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   Crank J, 1975, MATH DIFFUSION
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   DIMITROV DS, 1988, BIOELECTROCH BIOENER, V19, P323, DOI 10.1016/0302-4598(88)80013-8
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   HAUSER H, 2005, STRUCTURE BIOL MEMBR
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kearns DB, 2001, J BACTERIOL, V183, P763, DOI 10.1128/JB.183.2.763-767.2001
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Kues T, 2001, P NATL ACAD SCI USA, V98, P12021, DOI 10.1073/pnas.211250098                                                          
   Leekumjorn S, 2006, BIOPHYS J, V90, P3951, DOI 10.1529/biophysj.105.076596
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Menger FM, 1998, CURR OPIN CHEM BIOL, V2, P726, DOI 10.1016/S1367-5931(98)80110-5
   Mishra A, 2008, ANGEW CHEM INT EDIT, V47, P2986, DOI 10.1002/anie.200704444
   Murcia Michael J., 2007, V400, P277
   Opekarova M, 2002, BBA-BIOMEMBRANES, V1564, P9, DOI 10.1016/S0005-2736(02)00455-8
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   PERSKY B, 1990, ANAT REC, V228, P15, DOI 10.1002/ar.1092280104
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373                                                
   Scherfeld D, 2003, BIOPHYS J, V85, P3758, DOI 10.1016/S0006-3495(03)74791-2
   SCHMIDT T, 1995, J PHYS CHEM-US, V99, P17662, DOI 10.1021/j100049a030                                                             
   Schutz GJ, 2000, MOL MEMBR BIOL, V17, P17, DOI 10.1080/096876800294452                                                         
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Siebrasse JP, 2007, ANAL BIOANAL CHEM, V387, P41, DOI 10.1007/s00216-006-0763-0
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Tiriveedhi V, 2007, BIOCHEMISTRY-US, V46, P3888, DOI 10.1021/bi602527t
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   Willumeit R, 2005, BBA-BIOMEMBRANES, V1669, P125, DOI 10.1016/j.bbamem.2005.01.011
   Yao Y, 2006, J CHROMATOGR A, V1126, P107, DOI 10.1016/j.chroma.2006.06.057
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Ziegler A, 2008, BIOPHYS J, V94, P2142, DOI 10.1529/biophysj.107.113472
NR 49
TC 46
Z9 47
U1 0
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JUL 7
PY 2010
VL 99
IS 1
BP 153
EP 162
DI 10.1016/j.bpj.2010.03.065
PG 10
WC Biophysics
SC Biophysics
GA 623EL
UT WOS:000279720800022
PM 20655843
OA gold
DA 2018-01-05
ER

PT J
AU Smith, AB
   Wang, WY
   Charnley, AK
   Carroll, PJ
   Kenesky, CS
   Hirschmann, R
AF Smith, Amos B., III
   Wang, Wenyong
   Charnley, Adam K.
   Carroll, Patrick J.
   Kenesky, Craig S.
   Hirschmann, Ralph
TI Design, Synthesis, and Structural Analysis of D,L-Mixed
   Polypyrrolinones. 1. From Nonpeptide Peptidomimetics to Nanotubes
SO ORGANIC LETTERS
LA English
DT Article
ID MOLECULAR-FORCE FIELD; HELICAL SECONDARY STRUCTURE; HIV-1 PROTEASE
   INHIBITORS; CRYSTAL-STRUCTURE; BETA-PEPTIDES; CONFORMATIONAL ENERGIES;
   BIOLOGICAL EVALUATION; FOLDAMERS; MMFF94; GEOMETRIES
AB To expand the potential conformational space available to the polypyrroline structural motif, an open chain, D,L-alternating hexapyrrolinone was designed and synthesized. Structural studies, including solution NMR and X-ray crystallographic analysis, revealed that the hexapyrrolinone adopts a turn conformation both in solution and in the solid state, with aggregation in solution and a nanotube-like quaternary structure in the crystal.
C1 [Smith, Amos B., III; Wang, Wenyong; Charnley, Adam K.; Carroll, Patrick J.; Kenesky, Craig S.; Hirschmann, Ralph] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
RP Smith, AB (reprint author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
EM smithab@sas.upenn.edu
FU NIH [AI-42010]; Bristol-Myers Squibb; University of Pennsylvania
FX Support was provided by the NIH through Grant AI-42010. Additional
   support was provided by Graduate Fellowships from Bristol-Myers Squibb
   and the University of Pennsylvania to A.K.C. We thank Dr. G. Furst at
   University of Pennsylvania for assistance obtaining and analyzing the 2D
   NMR spectra. We also thank Samuel H. Gellman, the Ralph Hirschmann
   Professor of Chemistry at the University of Wisconsin, for insightful
   discussion,
CR Angelo NG, 2005, J AM CHEM SOC, V127, P17134, DOI 10.1021/ja056406z
   Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l                                                               
   CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035                                                             
   CHIANG CC, 1982, INT J PEPT PROT RES, V20, P133
   Clark TD, 1998, J AM CHEM SOC, V120, P8949, DOI 10.1021/ja981485i                                                               
   DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029
   DESANTIS P, 1974, MACROMOLECULES, V7, P52, DOI 10.1021/ma60037a011                                                             
   Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r                                                               
   GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0
   GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931                                                          
   Goodman CM, 2007, NAT CHEM BIOL, V3, P252, DOI 10.1038/nchembio876
   GUZMAN MC, 1995, THESIS U PENNSYLVANI
   Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.3.CO;2-K
   Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X
   Halgren TA, 1996, J COMPUT CHEM, V17, P553
   Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:6<587::AID-JCC4>3.0.CO;2-P
   Halgren T. A., 1996, J COMPUT CHEM, V17, P587
   Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s                                                               
   Heeht S., 2007, FOLDAMERS STRUCTURE
   Hill DJ, 2001, CHEM REV, V101, P3893, DOI 10.1021/cr990120t
   Horne WS, 2008, ACCOUNTS CHEM RES, V41, P1399, DOI 10.1021/ar800009n
   KARLE IL, 1975, ACTA CRYSTALLOGR B, V31, P555, DOI 10.1107/S0567740875003226
   Lee KH, 2000, J AM CHEM SOC, V122, P8370, DOI 10.1021/ja000994t
   NUTT RF, 1983, INT J PEPT PROT RES, V21, P66
   NUTT RF, 1987, SOMATOSTATIN, P83
   PAVONE V, 1989, BIOPOLYMERS, V28, P215, DOI 10.1002/bip.360280123                                                           
   SAVIANO M, 1994, J INCLUS PHENOM MOL, V18, P27, DOI 10.1007/BF00706936                                                              
   Seebach D, 2006, BIOPOLYMERS, V84, P23, DOI 10.1002/bip.20391
   Seebach D, 1997, CHEM COMMUN, P2015, DOI 10.1039/a704933a                                                                
   Seebach D, 1996, HELV CHIM ACTA, V79, P913, DOI 10.1002/hlca.19960790402                                                        
   Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802                                                        
   Smith AB, 2000, J AM CHEM SOC, V122, P11037, DOI 10.1021/ja002964w
   Smith AB, 2006, BIOORG MED CHEM LETT, V16, P859, DOI 10.1016/j.bmcl.2005.11.011
   Smith AB, 2005, ORG LETT, V7, P399, DOI 10.1021/ol0476974
   Smith AB, 2003, J MED CHEM, V46, P1831, DOI 10.1021/jm0204587
   Smith AB, 2000, ORG LETT, V2, P3809, DOI 10.1021/ol000254p
   SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093
   SMITH AB, 1993, TETRAHEDRON LETT, V34, P63, DOI 10.1016/S0040-4039(00)60058-8
   SMITH AB, 1995, BIOPOLYMERS, V37, P29, DOI 10.1002/bip.360370106
   SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017
   Smith AB, 1999, BIOORGAN MED CHEM, V7, P9, DOI 10.1016/S0968-0896(98)00234-X                                                   
   Stigers KD, 1999, CURR OPIN CHEM BIOL, V3, P714, DOI 10.1016/S1367-5931(99)00030-7                                                   
   SUN XC, 1994, HELV CHIM ACTA, V77, P1520, DOI 10.1002/hlca.19940770607                                                        
   TOMASIC L, 1987, HELV CHIM ACTA, V70, P1012, DOI 10.1002/hlca.19870700413
   VEBER DF, 1992, PEPTIDES CHEM BIOL, P3
   Xi N, 1998, J AM CHEM SOC, V120, P80, DOI 10.1021/ja9729903                                                               
NR 48
TC 5
Z9 5
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
J9 ORG LETT
JI Org. Lett.
PD JUL 2
PY 2010
VL 12
IS 13
BP 2990
EP 2993
DI 10.1021/ol101007n
PG 4
WC Chemistry, Organic
SC Chemistry
GA 614OR
UT WOS:000279070100026
PM 20518540
OA green_accepted
DA 2018-01-05
ER

PT J
AU Smith, AB
   Xiong, H
   Charnley, AK
   Brenner, M
   Mesaros, EF
   Kenesky, CS
   Di Costanzo, L
   Christianson, DW
   Hirschmann, R
AF Smith, Amos B., III
   Xiong, Hui
   Charnley, Adam K.
   Brenner, Meinrad
   Mesaros, Eugen F.
   Kenesky, Craig S.
   Di Costanzo, Luigi
   Christianson, David W.
   Hirschmann, Ralph
TI Design, Synthesis, and Structural Analysis of D,L-Mixed
   Polypyrrolinones. 2. Macrocyclic Hexapyrrolinones
SO ORGANIC LETTERS
LA English
DT Article
ID ASSEMBLING ORGANIC NANOTUBES; HIV-1 PROTEASE INHIBITORS; BIOLOGICAL
   EVALUATION; PEPTIDE NANOTUBES; CRYSTAL-STRUCTURE; BETA-STRAND;
   AMINO-ACIDS; CONFORMATION; ALKYLATION
AB The design, synthesis, and structural analysis of two macrocyclic D,L-alternating hexapyrrolinones have been achieved. These cyclic peptide mimics adopt a flat, hexagonal conformation, stabilized by intramolecular hydrogen bonding between adjacent pyrrolinone rings. Extensive NMR studies and X-ray analysis reveal, respectively, that the macrocyclic hexapyrrolinones aggregate in solution and in the solid state form staggered stacked nanotube-like assemblies.
C1 [Smith, Amos B., III; Xiong, Hui; Charnley, Adam K.; Brenner, Meinrad; Mesaros, Eugen F.; Kenesky, Craig S.; Di Costanzo, Luigi; Christianson, David W.; Hirschmann, Ralph] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
RP Smith, AB (reprint author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
EM smithab@sas.upenn.edu
OI Di Costanzo, Luigi/0000-0002-4795-2573
FU NIH [Al-42010, GM-49758]; Department of Defense [PC-030136]; Swiss
   National Science Foundation; Bristol-Myers Squibb; University of
   Pennsylvania
FX Support was provided by the NIH through Grants AI-42010 and GM-49758.
   Additional support was provided by Postdoctoral Fellowships from the
   Department of Defense (PC-030136) to E.F.M., from the Swiss National
   Science Foundation to MB., and Graduate Fellowships from Bristol-Myers
   Squibb and the University of Pennsylvania to A.K.C. We thank the
   Advanced Light Source (Berkeley, CA) for access to synchrotron beamline
   5.0.2. We also thank Samuel H. Gellman, the Ralph Hirschmann Professor
   of Chemistry at the University of Wisconsin, for insightful discussion.
CR Bong DT, 2001, ANGEW CHEM INT EDIT, V40, P988, DOI 10.1002/1521-3773(20010316)40:6<988::AID-ANIE9880>3.3.CO;2-E
   CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035                                                             
   Clark TD, 1998, J AM CHEM SOC, V120, P8949, DOI 10.1021/ja981485i                                                               
   Fischer L, 2009, ANGEW CHEM INT EDIT, V48, P1625, DOI 10.1002/anie.200804019
   GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0
   GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931                                                          
   Haque TS, 1996, J AM CHEM SOC, V118, P6975, DOI 10.1021/ja960429j                                                               
   KARADY S, 1984, TETRAHEDRON LETT, V25, P4337, DOI 10.1016/S0040-4039(01)81432-5                                                   
   KARLE IL, 1975, ACTA CRYSTALLOGR B, V31, P555, DOI 10.1107/S0567740875003226
   Lee KH, 2000, J AM CHEM SOC, V122, P8370, DOI 10.1021/ja000994t
   LIPSHUTZ BH, 1982, SYNTHETIC COMMUN, V12, P267, DOI 10.1080/00397918209409233                                                       
   Paquette LA, 1996, J AM CHEM SOC, V118, P11990, DOI 10.1021/ja962799d                                                               
   Scanlon S, 2008, NANO TODAY, V3, P22, DOI 10.1016/S1748-0132(08)70041-0                                                   
   SEEBACH D, 1985, HELV CHIM ACTA, V68, P1243, DOI 10.1002/hlca.19850680521
   Smith AB, 2000, J AM CHEM SOC, V122, P11037, DOI 10.1021/ja002964w
   Smith AB, 2006, BIOORG MED CHEM LETT, V16, P859, DOI 10.1016/j.bmcl.2005.11.011
   Smith AB, 2005, ORG LETT, V7, P399, DOI 10.1021/ol0476974
   Smith AB, 2003, J MED CHEM, V46, P1831, DOI 10.1021/jm0204587
   Smith AB, 2000, ORG LETT, V2, P3809, DOI 10.1021/ol000254p
   SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093
   SMITH AB, 1993, TETRAHEDRON LETT, V34, P63, DOI 10.1016/S0040-4039(00)60058-8
   SMITH AB, 1995, BIOPOLYMERS, V37, P29, DOI 10.1002/bip.360370106
   SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017
   SUN XC, 1994, HELV CHIM ACTA, V77, P1520, DOI 10.1002/hlca.19940770607                                                        
   TOMASIC L, 1987, HELV CHIM ACTA, V70, P1012, DOI 10.1002/hlca.19870700413
   WALKUP RD, 1987, SYNTHESIS-STUTTGART, P607
NR 26
TC 4
Z9 4
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
J9 ORG LETT
JI Org. Lett.
PD JUL 2
PY 2010
VL 12
IS 13
BP 2994
EP 2997
DI 10.1021/ol101008y
PG 4
WC Chemistry, Organic
SC Chemistry
GA 614OR
UT WOS:000279070100027
PM 20518572
OA green_accepted
DA 2018-01-05
ER

PT J
AU Liang, YH
   He, QQ
   Zeng, ZS
   Liu, ZQ
   Feng, XQ
   Chen, FE
   Balzarini, J
   Pannecouque, C
   De Clercq, E
AF Liang, Yong-Hong
   He, Qiu-Qin
   Zeng, Zhao-Sen
   Liu, Zhi-Qian
   Feng, Xiao-Qing
   Chen, Fen-Er
   Balzarini, Jan
   Pannecouque, Christophe
   De Clercq, Erik
TI Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues
   as non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1; Reverse transcriptase; NNRTIs; DAPY
ID DIARYLPYRIMIDINE ANALOGS; COLORIMETRIC ASSAY; ANTIVIRAL ACTIVITY; MUTANT
   STRAINS; WILD-TYPE
AB Nine newly 6-cynao-2-naphthyl substituted diarylpyrimidines (DAPY) were synthesized as non-nucleoside reverse transcriptase inhibitors on the basis of our previous work. The antiviral and cytotoxicity evaluation indicated that these compounds displayed strong activity against wild-type HIV-1 at nanomolar concentrations with selectivity index SI greater than 23 779. The most active compounds 3c and 3e exhibited activity against the double mutant (103N+181C) strains at an EC(50) of 0.16 and 0.15 mu M, and were more activity than that of efavirenz. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Liang, Yong-Hong; He, Qiu-Qin; Zeng, Zhao-Sen; Liu, Zhi-Qian; Feng, Xiao-Qing; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [Balzarini, Jan; Pannecouque, Christophe; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Chen, FE (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM rfchen@fudan.edu.cn
FU National Natural Science Foundation of China [20872018, 30672536];
   Science and Technology Commission of Shanghai Municipality [09431902800]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 20872018 and 30672536) and the Science and
   Technology Commission of Shanghai Municipality (No. 09431902800).
CR Appendino G, 2005, J MED CHEM, V48, P4663, DOI 10.1021/jm050139q
   Feng XQ, 2009, CHEMMEDCHEM, V4, P219, DOI 10.1002/cmdc.200800334
   FRAUZEN H, 1921, J PRAKT CHEM, V103, P369
   Fries K, 1930, LIEBIGS ANN CHEM, V484, P245
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Haubrich R, 2008, NAT REV DRUG DISCOV, V7, P287, DOI 10.1038/nrd2563
   Liang YH, 2009, CHEMMEDCHEM, V4, P1537, DOI 10.1002/cmdc.200900212
   Liang YH, 2009, EUR J MED CHEM, V44, P625, DOI 10.1016/j.ejmech.2008.03.021
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Mordant C, 2007, EUR J MED CHEM, V42, P567, DOI 10.1016/j.ejmech.2006.11.014
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
NR 13
TC 18
Z9 21
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUL 1
PY 2010
VL 18
IS 13
BP 4601
EP 4605
DI 10.1016/j.bmc.2010.05.036
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 613VN
UT WOS:000279011000001
PM 20570527
DA 2018-01-05
ER

PT J
AU Mahajan, SD
   Roy, I
   Xu, GX
   Yong, KT
   Ding, H
   Aalinkeel, R
   Reynolds, JL
   Sykes, DE
   Nair, BB
   Lin, EY
   Prasad, PN
   Schwartz, SA
AF Mahajan, Supriya D.
   Roy, Indrajit
   Xu, GaiXia
   Yong, Ken-Tye
   Ding, Hong
   Aalinkeel, Ravikumar
   Reynolds, Jessica L.
   Sykes, Donald E.
   Nair, Bindukumar B.
   Lin, Elaine Y.
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Enhancing the Delivery of Anti Retroviral Drug "Saquinavir" Across the
   Blood Brain Barrier Using Nanoparticles
SO CURRENT HIV RESEARCH
LA English
DT Article
DE HIV-1; antiretroviral drugs; saquinavir; protease inhibitor; quantum
   rods (QR); blood brain barrier; transferrin receptor; multimodal
   nanoparticles and bioconjugation
ID HIV-1 ENCEPHALITIS; TARGETED PROBES; QUANTUM DOTS; CELLS; RNA; MODEL;
   PCR
AB Antiretroviral drugs are ineffective at treating viral infection in the brain because they cannot freely diffuse across the blood-brain barrier (BBB). Therefore, HIV-1 viral replication persists in the central nervous system (CNS) and continues to augment the neuropathogenesis process. Nanotechnology can play a pivotal role in HIV-1 therapeutics as it can increase drug solubility, enhance systemic bioavailability, and at the same time offer multifunctionality. Moreover, following conjugation with transferrin (Tf), these drug-loaded nanoformulations can permeate across biological barriers such as the blood brain barrier (BBB) via a receptor mediated transport mechanism. In the current study, we have stably incorporated the antiviral drug, Saquinavir, within Tf-conjugated quantum rods (QRs), which are novel nanoparticles with unique optical properties. We have evaluated the transversing ability of the QR-Tf-Saquinavir nanoformulation across an in vitro model of BBB. In addition, we have analyzed the subsequent antiviral efficacy of this targeted nanoformulation in HIV-1 infected peripheral blood mononuclear cells (PBMCs), which are cultured on the basolateral end of the in vitro BBB model. Our results show a significant uptake of QR-Tf-Saquinavir by brain microvascular endothelial cells (BMVECs), which constitute the BBB. In addition, we observed a significant enhancement in the transversing capability of QR-Tf-Saquinavir across the BBB, along with a marked decrease in HIV-1 viral replication in the PBMCs. These observations indicate that drug-loaded nanoparticles can deliver therapeutics across the BBB. These results highlight the potential of this nanoformulation in the treatment of Neuro-AIDS and other neurological disorders.
C1 [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Reynolds, Jessica L.; Sykes, Donald E.; Nair, Bindukumar B.; Lin, Elaine Y.; Schwartz, Stanley A.] SUNY Buffalo, Buffalo Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY 14203 USA.
   [Roy, Indrajit; Xu, GaiXia; Ding, Hong; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore.
RP Mahajan, SD (reprint author), SUNY Buffalo, Buffalo Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, 310 Multi Res Bldg,100 High St, Buffalo, NY 14203 USA.
EM smahajan@buffalo.edu
RI Ding, Hong/C-2322-2011
OI Ding, Hong/0000-0003-0376-0008
FU National Institute of Health [1RO1AI08556901A, RO1CA119397,
   K01DA024577]; Pfizer Inc [GA 400IN3]; John R. Oishei and Kaleida Health
   Foundations
FX Saquinavir was obtained through the AIDS Research and Reference Reagent
   Program, Division of AIDS, NIAID, NIH. This study was supported by
   grants from the National Institute of Health ARRA Grant #
   1RO1AI08556901A, RO1CA119397, K01DA024577, Pfizer Inc (Grant # GA
   400IN3) the John R. Oishei and Kaleida Health Foundations.
CR Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   De Luca A, 2002, NEUROLOGY, V59, P342, DOI 10.1212/WNL.59.3.342                                                            
   Dragsted UB, 2003, J INFECT DIS, V188, P635, DOI 10.1086/377288
   Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   Letendre Scott L, 2009, Top HIV Med, V17, P46
   Mahajan SD, 2008, J CLIN IMMUNOL, V28, P528, DOI 10.1007/s10875-008-9208-1
   Meyer TPH, 2005, J IMMUNOL METHODS, V307, P150, DOI 10.1016/j.jim.2005.10.004
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Pathak S, 2006, J NEUROSCI, V26, P1893, DOI 10.1523/JNEUROSCI.3847-05.2006
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Prasad P. N., 2004, NANOPHOTONICS
   Prasad P. N., 2003, INTRO BIOPHOTONICS
   Qian J, 2007, J PHYS CHEM B, V111, P6969, DOI 10.1021/jp070620n
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11
   Schroeder U, 1998, J PHARM SCI, V87, P1305, DOI 10.1021/js980084y
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u
   Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m
NR 26
TC 45
Z9 48
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD JUL
PY 2010
VL 8
IS 5
BP 396
EP 404
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 599JX
UT WOS:000277909200006
PM 20426757
DA 2018-01-05
ER

PT J
AU Fan, X
   Zhang, HS
   Chen, L
   Long, YQ
AF Fan, Xing
   Zhang, Hu-Shan
   Chen, Li
   Long, Ya-Qiu
TI Efficient synthesis and identification of novel propane-1,3-diamino
   bridged CCR5 antagonists with variation on the basic center carrier
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE CCR5 antagonist; Propane-1,3-diamine; Convergent synthesis;
   (S)-beta-amino-beta-arylpropanal; 4-Amino-4-methylpiperidine; Basic
   center carrier
ID SMALL-MOLECULE CCR5; BETA-AMINO; REDUCTIVE AMINATION; HIV-1 INHIBITORS;
   DISCOVERY; RECEPTOR; POTENT; DERIVATIVES; HETEROCYCLES; EPIBATIDINE
AB By employing pharmacophore-based design and the privileged fragments reassembly, a series of piperidine-/tropane-/piperazine-bridged CCR5 antagonists were designed and synthesized via an efficient convergent synthesis strategy, with focus on the optimal choice of the basic center carrier structure. Significantly, the 4-amino-4-methylpiperidine bridged 1-acyl-1,3-propanediamine compounds were identified as a new class of nanomolar CCR5 antagonists, providing an efficient approach and novel scaffolds for further development of potent CCR5 inhibitors. (C) 2010 Elsevier Masson SAS. All rights reserved.
C1 [Fan, Xing; Zhang, Hu-Shan; Long, Ya-Qiu] CAS, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Chen, Li] Shanghai TargetDrug Co Ltd, Shanghai 200233, Peoples R China.
RP Long, YQ (reprint author), CAS, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
EM yqlong@mail.shcnc.ac.cn
FU National Natural Science Foundation of China [30672528]; Science and
   Technology Commission of Shanghai Municipality [07QH14018, 08JC1422200];
   National Science and Technology Major Project [2009ZX09301-001]
FX National Natural Science Foundation of China (30672528), Science and
   Technology Commission of Shanghai Municipality (07QH14018, 08JC1422200)
   and National Science and Technology Major Project (2009ZX09301-001) are
   greatly appreciated for the financial supports.
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x                                                               
   Allegretti M, 2001, TETRAHEDRON LETT, V42, P4257, DOI 10.1016/S0040-4039(01)00663-3
   Ando K, 1997, J ORG CHEM, V62, P1934, DOI 10.1021/jo970057c                                                               
   Barber CG, 2009, BIOORG MED CHEM LETT, V19, P1499, DOI 10.1016/j.bmcl.2009.01.008
   Berdini V, 2002, TETRAHEDRON, V58, P5669, DOI 10.1016/S0040-4020(02)00530-6                                                   
   Blackburn C, 2006, BIOORG MED CHEM LETT, V16, P2621, DOI 10.1016/j.bmcl.2006.02.044
   Boto A, 2005, EUR J ORG CHEM, P673, DOI 10.1002/ejoc.200400698
   Cascieri MA, 2000, CURR OPIN CHEM BIOL, V4, P420, DOI 10.1016/S1367-5931(00)00113-7
   Coleman PJ, 2000, TETRAHEDRON LETT, V41, P5803, DOI 10.1016/S0040-4039(00)00965-5
   DAVIES SG, 1993, J CHEM SOC CHEM COMM, P1153, DOI 10.1039/c39930001153
   DAVIES SG, 1991, TETRAHEDRON-ASYMMETR, V2, P183, DOI 10.1016/S0957-4166(00)82354-X
   Davies S. G, 1994, J CHEM SOC P1, V9, P1141
   ERICKSON KL, 1971, J ORG CHEM, V36, P1024, DOI 10.1021/jo00807a002                                                             
   Huang ZZ, 2002, J ORG CHEM, V67, P3096, DOI 10.1021/jo025586h
   Imamura S, 2006, J MED CHEM, V49, P2784, DOI 10.1021/jm051034q
   Jiang XH, 2004, BIOORG MED CHEM LETT, V14, P3675, DOI 10.1016/j.bmcl.2004.05.014
   Kazmierski W, 2003, BIOORGAN MED CHEM, V11, P2663, DOI 10.1016/S0968-0868(03)00161-5
   Kim D, 2005, BIOORG MED CHEM LETT, V15, P2129, DOI 10.1016/j.bmcl.2005.02.030
   Leonard JT, 2006, CURR MED CHEM, V13, P911, DOI 10.2174/092986706776361030
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Luca C., 2006, CURR MED CHEM, V13, P65
   Maeda K, 2006, J BIOL CHEM, V281, P12688, DOI 10.1074/jbc.M.512688200
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   MORAGUES J, 1980, FARMACO-ED SCI, V35, P951
   Nishikawa M, 2005, ANTIMICROB AGENTS CH, V49, P4708, DOI 10.1128/AAC.49.11.4708-4715.2005
   Olivo HF, 1999, J ORG CHEM, V64, P4966, DOI 10.1021/jo990097b                                                               
   Palani A, 2006, J MED CHEM, V49, P2851, DOI 10.1021/jm0600009x
   Price DA, 2005, SYNLETT, P1133, DOI 10.1055/s-2005-865208
   Schols D, 2006, ANTIVIR RES, V71, P216, DOI 10.1016/j.antiviral.2006.04.009
   Schwarz MK, 2002, NAT REV DRUG DISCOV, V1, P347, DOI 10.1038/nrd795
   Seibert C, 2006, VIROLOGY, V349, P41, DOI 10.1016/j.virol.2006.01.018
   Tagat JR, 2004, J MED CHEM, V47, P2405, DOI 10.1021/jm0304515
   Wood A, 2005, PROGR MED CHEM, V43, P239, DOI 10.1016/S0079-6468(05)43007-6
   WUTS PGM, 1988, J ORG CHEM, V53, P5989, DOI 10.1021/jo00261a001                                                             
   Xu R, 1996, TETRAHEDRON LETT, V37, P1463, DOI 10.1016/0040-4039(96)00042-1                                                    
   Xu Y, 2004, BIOORGAN MED CHEM, V12, P6193, DOI 10.1016/j.bmc.2004.08.045
   Yang JW, 2008, NATURE, V452, P453, DOI 10.1038/nature06740
NR 37
TC 11
Z9 12
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUL
PY 2010
VL 45
IS 7
BP 2827
EP 2840
DI 10.1016/j.ejmech.2010.03.003
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 609AF
UT WOS:000278626400016
PM 20347189
DA 2018-01-05
ER

PT J
AU Chawla, P
   Chawla, V
   Maheshwari, R
   Saraf, SA
   Saraf, SK
AF Chawla, Pooja
   Chawla, Viney
   Maheshwari, Radhika
   Saraf, Shubhini A.
   Saraf, Shailendra. K.
TI Fullerenes: From Carbon to Nanomedicine
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Anti HIV; antioxidant; antiapoptotic; enzyme inhibition; nanomedicines;
   neuroprotective
ID ANTI-HIV PROPERTIES; IN-VITRO; FUNCTIONALIZED FULLERENES; PHOTODYNAMIC
   THERAPY; LIPID-PEROXIDATION; AZOMETHINE YLIDES; HYDROGEN-PEROXIDE;
   DELIVERY-SYSTEMS; C-60 FULLERENE; AMINO-ACID
AB Fullerenes, the third carbon allotrope, have emerged as agents which could revolutionize the treatment of many diseases. Fullerenes possess different biological applications like neuroprotective agents, antioxidants, anti-HIV activity, enzyme inhibition, antiapoptotic activity and the list is ever increasing. Moreover, they are being utilized as drug carrier systems and also for many non-biological applications like superconductors, catalysis and so on. Their size has made them promising agents for nanotechnology. This article aims at outlining the chemistry, properties and non-biological applications of fullerenes and their evolution to biological applications, thereby traversing their evolution from simple carbon allotropes to present day nano-medicinal agents.
C1 [Chawla, Viney; Saraf, Shailendra. K.] No India Engn Coll, Fac Pharm, Lucknow 227105, Uttar Pradesh, India.
   [Chawla, Pooja; Maheshwari, Radhika; Saraf, Shubhini A.] Babu Banarasi Das Natl Inst Technol & Management, Fac Pharm, Lucknow 227105, Uttar Pradesh, India.
RP Saraf, SK (reprint author), No India Engn Coll, Fac Pharm, Dr Akhilesh Das Nagar,Sector 1,Faizabad Rd, Lucknow 227105, Uttar Pradesh, India.
EM dirpharmniec@gmail.com
OI Saraf, Shubhini/0000-0002-4180-0931; saraf, shailendra
   k./0000-0002-0569-1213
CR Akasaka T, 2008, J PHYS CHEM A, V112, P1294, DOI 10.1021/jp7097747
   Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   An YZ, 1996, TETRAHEDRON, V52, P5179, DOI 10.1016/0040-4020(96)00123-8
   Bianco A, 2001, J PEPT SCI, V7, P208, DOI 10.1002/psc.313                                                                 
   BIRKETT PR, 1992, NATURE, V357, P479, DOI 10.1038/357479a0                                                                
   Bisaglia M, 2000, J NEUROCHEM, V74, P1197
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   BOUTORINE AS, 1994, ANGEW CHEM INT EDIT, V33, P2462
   Brettreich M, 1998, TETRAHEDRON LETT, V39, P2731, DOI 10.1016/S0040-4039(98)00491-2                                                   
   Chen BX, 1998, P NATL ACAD SCI USA, V95, P10809, DOI 10.1073/pnas.95.18.10809                                                        
   CHEN HS, 1992, J PHYS CHEM-US, V96, P1016, DOI 10.1021/j100182a003                                                             
   Chen Y, 1998, J POLYM SCI POL PHYS, V36, P2653, DOI 10.1002/(SICI)1099-0488(199810)36:14<2653::AID-POLB18>3.0.CO;2-A                
   CHEUH SC, 1999, TRANSPL P, V31, P1976
   Chien CT, 2001, J AM SOC NEPHROL, V12, P973
   Da Ros T, 1999, CHEM COMMUN, P663
   Da Ros T, 2001, CROAT CHEM ACTA, V74, P743
   DaRos T, 1996, J ORG CHEM, V61, P9070, DOI 10.1021/jo961522t                                                               
   Del Carlo M, 2002, ARTHRITIS RHEUM, V46, P394, DOI 10.1002/art.10056
   Dugan LL, 2001, PARKINSONISM RELAT D, V7, P243, DOI 10.1016/S1353-8020(00)00064-X                                                   
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Dugan LL, 1996, NEUROBIOL DIS, V3, P129, DOI 10.1006/nbdi.1996.0013
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0                                                                
   EHRHARDT GJ, 2000, NUCL RAD CHEM APPROA, P174
   FLEMING RM, 1991, NATURE, V352, P787, DOI 10.1038/352787a0
   Foldvari M, 2008, NANOMED-NANOTECHNOL, V4, P173, DOI 10.1016/j.nano.2008.04.002
   Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006-291X(02)00445-X
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gayathri SS, 2007, CHEM PHYS LETT, V433, P317, DOI 10.1016/j.cplett.2006.11.055
   GEVAERT M, 1992, J CHEM SOC CHEM COMM, P1470, DOI 10.1039/c39920001470                                                            
   Goldshleger NF, 2001, FULLERENE SCI TECHN, V9, P255, DOI 10.1081/FST-100104493                                                           
   Gonzalez KA, 2002, BIOORGAN MED CHEM, V10, P1991, DOI 10.1016/S0968-0896(02)00049-4                                                   
   Halford B, 2006, CHEM ENG NEWS, V84, P47, DOI 10.1021/cen-v084n013.p047                                                       
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x
   HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0                                                                
   Hsu SC, 1998, BLOOD, V91, P2658
   Huang ST, 2008, BIOORG MED CHEM LETT, V18, P99, DOI 10.1016/j.bmcl.2007.11.004
   Huang YL, 1998, EUR J BIOCHEM, V254, P38, DOI 10.1046/j.1432-1327.1998.2540038.x                                              
   HUMMELEN JC, 1995, J AM CHEM SOC, V117, P7003, DOI 10.1021/ja00131a024                                                             
   Hunter DJ, 2005, J RHEUMATOL, V32, P2192
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Illescas B, 2002, TETRAHEDRON LETT, V43, P4133, DOI 10.1016/S0040-4039(02)00762-1
   Injac R, 2008, BIOMATERIALS, V29, P3451, DOI 10.1016/j.biomaterials.2008.04.048
   Injac R, 2009, BIOMATERIALS, V30, P1184, DOI 10.1016/j.biomaterials.2008.10.060
   Isobe H, 2001, CHEM LETT, P1214
   Isobe H, 2006, MOL PHARMACEUT, V3, P124, DOI 10.1021/mp050068r
   Iwamoto Y, 2006, CHEM COMMUN, P4805, DOI 10.1039/b614305
   Iwashita A, 2007, ANGEW CHEM INT EDIT, V46, P3513, DOI 10.1002/anie.200700062
   Iwata N, 1998, FULLERENE SCI TECHN, V6, P213, DOI 10.1080/10641229809350196                                                       
   JEUSEN W, 1996, BIOORGAN MED CHEM, V4, P767
   Jia JF, 2008, J AM CHEM SOC, V130, P3985, DOI 10.1021/ja0781590
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kato H, 2001, BIOORG MED CHEM LETT, V11, P2935, DOI 10.1016/S0960-894X(01)00583-2                                                   
   KAWATA S, 1992, CHEM LETT, P1659, DOI 10.1246/cl.1992.1659
   Kepman AV, 2006, J FLUORINE CHEM, V127, P832, DOI 10.1016/j.jfluchem.2006.02.019
   Kim JE, 2003, BIOCHEM BIOPH RES CO, V303, P576, DOI 10.1016/S0006-291X(03)00393-0
   Kostarelos K, 2003, ADV COLLOID INTERFAC, V106, P147, DOI 10.1016/S0001-8686(03)00109-X
   Kotelnikova RA, 2003, J NANOPART RES, V5, P561, DOI 10.1023/B:NAN0.0000006070.61144.93
   KROTO HW, 1991, CHEM REV, V91, P1213, DOI 10.1021/cr00006a005                                                             
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   KRUSIC PJ, 1991, SCIENCE, V254, P1183, DOI 10.1126/science.254.5035.1183                                                   
   Kurz B, 2005, ANN ANAT, V187, P473, DOI 10.1016/j.aanat.2005.07.003
   Kurz B, 2004, ARTHRITIS RHEUM, V50, P123, DOI 10.1002/art.11438
   Lai HS, 2000, WORLD J SURG, V24, P450, DOI 10.1007/s002689910071                                                           
   Lai YL, 2003, LIFE SCI, V72, P1271, DOI 10.1016/S0024-3205(02)02374-3
   Lee YT, 2000, P SOC EXP BIOL MED, V224, P69, DOI 10.1046/j.1525-1373.2000.22403.x                                                
   Lin AMY, 2002, NEUROSCI RES, V43, P317, DOI 10.1016/S0168-0102(02)00056-1
   Liu FL, 2009, CHEM PHYS LETT, V471, P116, DOI 10.1016/j.cplett.2009.02.032
   Liu J, 2007, J CONTROL RELEASE, V117, P104, DOI 10.1016/j.jconrel.2006.10.008
   LIU Y, 1998, APPL CATAL A-GEN, V67, pL1
   Loeser RF, 2002, ARTHRITIS RHEUM, V46, P2349, DOI 10.1002/art.10496
   MAGGINI M, 1993, J AM CHEM SOC, V115, P9798, DOI 10.1021/ja00074a056                                                             
   MANOLIS M, 2007, J ORG CHEM, V72, P6526
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mashino T, 1999, BIOORG MED CHEM LETT, V9, P2959, DOI 10.1016/S0960-894X(99)00515-6
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mashino T, 2003, BIOORGAN MED CHEM, V11, P1433, DOI 10.1016/S0968-0896(02)00610-7
   MATSUBARA Y, 1995, J ORG CHEM, V60, P5372, DOI 10.1021/jo00122a004                                                             
   Matsuo Y, 2006, ORG SYNTH, V83, P80, DOI 10.15227/orgsyn.083.0080
   Miura K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.055509
   Miura K, 2005, E-J SURF SCI NANOTEC, V3, P21, DOI 10.1380/ejssnt.2005.21
   Mori T, 2007, TOXICOLOGY, V236, P149, DOI 10.1016/j.tox.2007.03.027
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Nakamura E, 2003, ACCOUNTS CHEM RES, V36, P807, DOI 10.1021/ar030027y
   Nakamura Y, 2004, ORG LETT, V6, P2797, DOI 10.1021/ol048952n
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Pellarini F, 2001, ORG LETT, V3, P1845, DOI 10.1021/ol015934m
   Podolski IY, 2007, J NANOSCI NANOTECHNO, V7, P1479, DOI 10.1166/jnn.2007.330
   Podolski IY, 2004, FULLER NANOTUB CAR N, V12, P421, DOI 10.1081/FST-120027201
   Rezayat SM, 2009, EUR J MED CHEM, V44, P1554, DOI 10.1016/j.ejmech.2008.07.030
   Rouff R.S., 1993, J PHYS CHEM-US, V97, P3379
   Rouse JG, 2007, NANO LETT, V7, P155, DOI 10.1021/nl062464m
   Rubin Y, 1996, NATO ADV SCI I E-APP, V316, P295
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665                                                      
   Ryman-Rasmussen JP, 2006, TOXICOL SCI, V91, P159, DOI 10.1093/toxsci/kfj122
   SAUNDERS M, 1994, J AM CHEM SOC, V116, P2193, DOI 10.1021/ja00084a089                                                             
   Sayes CM, 2005, BIOMATERIALS, V26, P7587, DOI 10.1016/j.biomaterials.2005.05.027
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Schick G, 1996, CHEM-EUR J, V2, P935, DOI 10.1002/chem.19960020807                                                        
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   SCHUSTER DI, 2000, P ELECTROCHEM SOC, V11, P267
   SCRIVENS WA, 1992, J AM CHEM SOC, V114, P7917, DOI 10.1021/ja00046a051                                                             
   Sibley SP, 1997, SPECTROCHIM ACTA A, V53, P679, DOI 10.1016/S1386-1425(96)01843-4                                                   
   SINGH MS, 2005, ADV ORGANIC CHEM REA
   SIVARAMAN N, 1992, J ORG CHEM, V57, P6077, DOI 10.1021/jo00048a056                                                             
   SMALLEY RE, AB INITIO THEORETICA
   Tagmatarchis N., 2001, Mini-Reviews in Medicinal Chemistry, V1, P339, DOI 10.2174/1389557013406693
   TAYLOR R, 1990, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39900001423                                                            
   TAYLOR R, 1993, NATURE, V363, P685, DOI 10.1038/363685a0                                                                
   TAYLOR R, 1991, NATURE, V351, P277, DOI 10.1038/351277a0                                                                
   Taylor R., 1995, CHEM FULLERENES
   Thrash TP, 1999, CHEM PHYS LETT, V308, P329, DOI 10.1016/S0009-2614(99)00581-3
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Tsai MC, 1997, J PHARM PHARMACOL, V49, P438, DOI 10.1111/j.2042-7158.1997.tb06821.x                                              
   Tsao N, 2001, ANTIMICROB AGENTS CH, V45, P1788, DOI 10.1128/AAC.45.6.1788-1793.2001                                                 
   TSUCHIYA T, 1995, BIOCHEM BIOPH RES CO, V206, P885, DOI 10.1006/bbrc.1995.1126
   Tykhomyrov AA, 2008, TOXICOLOGY, V246, P158, DOI 10.1016/j.tox.2008.01.005
   Ueng TH, 1997, TOXICOL LETT, V93, P29, DOI 10.1016/S0378-4274(97)00071-4
   Vogelson C T, 2001, MOD DRUG DISCOV, V4, P49
   Wang IC, 1999, J MED CHEM, V42, P4614, DOI 10.1021/jm990144s
   WHARTON T, 2000, RECENT ADV CHEM PHYS, V9, P258
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1043, DOI 10.1016/0960-894X(96)00164-3
   Wilson L. J., 1999, Electrochemical Society Interface, V8, P24
   Wilson SR, 2000, FULLERENES CHEM PHYS, P437
   Wolff DJ, 2000, ARCH BIOCHEM BIOPHYS, V378, P216, DOI 10.1006/abbi.2000.1843
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   Yamakoshi Y, 2003, J AM CHEM SOC, V125, P12803, DOI 10.1021/ja0355574
   YOULE RJ, 2005, NATURE REV MOL CELL, V127, P12508
   Yudoh K, 2005, ARTHRITIS RES THER, V7, pR904, DOI 10.1186/ar1765
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zhou ZG, 2009, NANOMED-NANOTECHNOL, V5, P202, DOI 10.1016/j.nano.2008.09.005
NR 134
TC 30
Z9 30
U1 0
U2 45
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD JUL
PY 2010
VL 10
IS 8
BP 662
EP 677
DI 10.2174/138955710791572497                                              
          
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 628PZ
UT WOS:000280134000001
PM 20236059
DA 2018-01-05
ER

PT J
AU Kwon, EJ
   Liong, S
   Pun, SH
AF Kwon, Ester J.
   Liong, Sylvie
   Pun, Suzie H.
TI A Truncated HGP Peptide Sequence That Retains Endosomolytic Activity and
   Improves Gene Delivery Efficiencies
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Gene delivery; peptide; polyethylenimine
ID INTRACELLULAR TRAFFICKING; PLASMID DNA; POLYETHYLENIMINE; PROTEIN;
   CELLS; TRANSFECTION; POLYPLEXES; VECTORS; CULTURE
AB HGP is a 24-amino acid peptide derived from HIV gp41 that increases vesicular escape when incorporated into gene delivery vehicles. The typical yield of HGP from solid phase peptide synthesis is low due to its length and hydrophobicity. The goal of this work was to investigate truncated sequences that maintained activity in order to improve the ease and yield of synthesis. A shortened, 15-amino acid sequence retained comparable lytic activity and the ability to interact with lipids when compared to the full length peptide. A scrambled peptide showed poor lytic activity, confirming that the activity of these endosomal escape peptides is sequence specific. Peptides were covalently attached to polyethylenimine (PEI) and used to condense plasmid DNA to form nanoparliculate carriers. When delivery efficiencies of PEI peptide conjugates were compared in vitro, PEI modified with the truncated HGP sequence increased transgene expression over unmodified PEI and full length HGP.
C1 [Kwon, Ester J.; Liong, Sylvie; Pun, Suzie H.] Univ Washington, Ctr Bioengn, Seattle, WA 98195 USA.
RP Pun, SH (reprint author), Univ Washington, Ctr Bioengn, Box 355061,1705 NE Pacific St, Seattle, WA 98195 USA.
EM spun@u.washington.edu
OI Kwon, Ester/0000-0002-6335-9681
FU National Science Foundation [CBET 0448547]; National Institutes of
   Health [R01NS064404, 5F31NS064805]
FX The authors would like to acknowledge Dr. Niels H. Andersen, Irene Shu,
   and D. Victoria Williams for their help with circular dichroism. This
   work was supported by grants from the National Science Foundation (CBET
   0448547) and the National Institutes of Health (R01NS064404). E.J.K was
   supported by the National Institutes of Health (5F31NS064805).
CR Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005
   BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43
   Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BRAND L, 1962, BIOCHEMISTRY-US, V1, P423, DOI 10.1021/bi00909a009
   Chan W. C., 2000, FMOC SOLID PHASE PEP, pxxiv
   Costin JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-123
   DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Kwon EJ, 2008, J CONTROL RELEASE, V132, P230, DOI 10.1016/j.jconrel.2008.06.012
   Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   Park IK, 2007, J GENE MED, V9, P691, DOI 10.1002/jgm.1062
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121
   SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
NR 20
TC 24
Z9 24
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL-AUG
PY 2010
VL 7
IS 4
BP 1260
EP 1265
DI 10.1021/mp1000668
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 632SM
UT WOS:000280448100034
PM 20476763
OA green_accepted
DA 2018-01-05
ER

PT J
AU De Haes, W
   De Koker, S
   Pollard, C
   Atkinson, D
   Vlieghe, E
   Hoste, J
   Rejman, J
   De Smedt, S
   Grooten, J
   Vanham, G
   Van Gulck, E
AF De Haes, Winni
   De Koker, Stefaan
   Pollard, Charlotte
   Atkinson, Derek
   Vlieghe, Erika
   Hoste, Jessy
   Rejman, Joanna
   De Smedt, Stefaan
   Grooten, Johan
   Vanham, Guido
   Van Gulck, Ellen
TI Polyelectrolyte Capsules-containing HIV-1 p24 and Poly I:C Modulate
   Dendritic Cells to Stimulate HIV-1-specific Immune Responses
SO MOLECULAR THERAPY
LA English
DT Article
ID CD8(+) T-CELLS; COATED PLGA MICROPARTICLES; IN-VITRO;
   CROSS-PRESENTATION; AUTOLOGOUS HIV-1; ANTIGEN DELIVERY; INFECTION;
   NANOPARTICLES; MICROCAPSULES; THERAPY
AB Polyelectrolyte microcapsules (MCs) are potent protein delivery vehicles which can be tailored with ligands to stimulate maturation of dendritic cells (DCs). We investigated the immune stimulatory capacity of monocyte-derived DC (Mo-DC) loaded with these MCs, containing p24 antigen from human immunodeficiency virus type 1 (HIV-1) alone [p24-containing MC (MCp24)] or with the Toll-like receptor ligand 3 (TLR3) ligand poly I: C (MCp24pIC) as a maturation factor. MO-DC, loaded with MCp24pIC, upregulated CCR7, CD80, CD83, and CD86 and produced high amounts of interleukin-12 (IL-12) cytokine, to a similar extent as MCp24 in the presence of an optimized cytokine cocktail. MO-DC from HIV-infected patients under highly active antiretroviral therapy (HAART) exposed to MCp24 together with cytokine cocktail or to MCp24pIC expanded autologous p24-specific CD4(+) and CD8(+) T-cell responses as measured by interferon-gamma (IFN-gamma) and IL-2 cytokine production and secretion. In vivo relevance was shown by immunizing C57BL/6 mice with MCp24pIC, which induced both humoral and cellular p24-specific immune responses. Together these data provide a proof of principle that both antigen and DC maturation signal can be delivered as a complex with polyelectrolyte capsules to stimulate virus-specific T cells both in vitro and in vivo. Polyelectrolyte MCs could be useful for in vivo immunization in HIV-1 and other infections.
C1 [De Haes, Winni; Pollard, Charlotte; Atkinson, Derek; Vanham, Guido; Van Gulck, Ellen] Inst Trop Med Antwerp, Dept Microbiol, Virol Unit, B-2000 Antwerp, Belgium.
   [De Koker, Stefaan; Pollard, Charlotte; Grooten, Johan] Univ Ghent, Dept Biol Mol, Lab Mol Immunol, B-9000 Ghent, Belgium.
   [Vlieghe, Erika; Hoste, Jessy] Inst Trop Med Antwerp, Dept Clin Sci, Unit HIV STD, B-2000 Antwerp, Belgium.
   [Rejman, Joanna; De Smedt, Stefaan] Univ Ghent, Dept Pharmaceut, Lab Gen Biochem & Phys Pharm, B-9000 Ghent, Belgium.
   [Vanham, Guido] Univ Antwerp, Dept Pharmaceut Vet & Biomed Sci, B-2020 Antwerp, Belgium.
   [Vanham, Guido] Free Univ Brussels, Dept Med & Pharmacol, Antwerp, Belgium.
RP De Haes, W (reprint author), Inst Trop Med Antwerp, Dept Microbiol, Virol Unit, Natl Str 155, B-2000 Antwerp, Belgium.
EM wdehaes@itg.be
OI Atkinson, Derek/0000-0001-6097-3670; De Smedt,
   Stefaan/0000-0002-8653-2598
FU FWO (Fund for Scientific Research Flanders) [G.0226.10]; SOFI-B; IUAP
   (Inter-University Attraction Poles of the Belgian Government) [P6/41]
FX We thank the HIV<SUP>+</SUP> persons for donating their blood and the
   personnel of the AIDS reference clinic (ARC) and laboratory (ARL) of our
   institute for the recruitment of the patients and collecting the
   samples. We are grateful to the NIH AIDS Research and Reference Reagent
   Program for providing the peptides. We also thank Bernard Verrier and
   Severine Munier for providing p24 used in the in vivo studies and for
   their scientific advice and discussion. We acknowledge the skillful help
   of Bruno De Geest (Laboratory of Pharmaceutical Technology, Ghent
   University, Belgium) for the preparation of the microcapsules. This work
   was supported by grants from IUAP (Inter-University Attraction Poles,
   P6/41 of the Belgian Government), FWO (Fund for Scientific Research
   Flanders, project number G.0226.10), and SOFI-B (Secondary Research
   Funding ITM). W.D.H. is a predoctoral fellow of the Institute for
   Science and Technology (IWT), Flanders. The work was performed at the
   Institute of Tropical Medicine (Antwerp, Belgium). The authors declared
   no conflict of interest.
CR Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Blander JM, 2007, TRENDS IMMUNOL, V28, P19, DOI 10.1016/j.it.2006.11.001
   Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596
   Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111                                                   
   Chassin D, 1999, EUR J IMMUNOL, V29, P196, DOI 10.1002/(SICI)1521-4141(199901)29:01<196::AID-IMMU196>3.3.CO;2-W
   De Koker S, 2007, ADV FUNCT MATER, V17, P3754, DOI 10.1002/adfm.200700416
   De Koker S, 2010, J IMMUNOL, V184, P203, DOI 10.4049/jimmunol.0803591
   De Koker S, 2009, ANGEW CHEM INT EDIT, V48, P8485, DOI 10.1002/anie.200903769
   DEROSE R, 2008, ADV MATER, V20, P1
   Donath E, 1998, ANGEW CHEM INT EDIT, V37, P2202
   Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fan Z, 2001, J VIROL, V75, P4413, DOI 10.1128/JVI.75.9.4413-4419.2001
   Fischer S, 2007, BIOMATERIALS, V28, P994, DOI 10.1016/j.biomaterials.2006.10.034
   Fischer S, 2009, J DRUG TARGET, V17, P652, DOI 10.1080/10611860903119656
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035
   Heit A, 2007, EUR J IMMUNOL, V37, P2063, DOI 10.1002/eji.200737169
   Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323
   Ide F, 2006, J MED VIROL, V78, P711, DOI 10.1002/jmv.20612
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551
   Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320                                                     
   Lu W, 2001, J VIROL, V75, P8949, DOI 10.1128/JVI.75.19.8949-8956.2001
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Malyala P, 2009, ADV DRUG DELIVER REV, V61, P218, DOI 10.1016/j.addr.2008.12.009
   Men Y, 1999, VACCINE, V17, P1047, DOI 10.1016/S0264-410X(98)00321-1
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Pomerantz RJ, 2003, NAT MED, V9, P867, DOI 10.1038/nm0703-867
   Ponsaerts P, 2002, LEUKEMIA, V16, P1324, DOI 10.1038/sj.leu.2402511
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105
   UNAIDS and WHO, 2007, AIDS EP UPD
   Van Gulck ER, 2008, J VIROL, V82, P3561, DOI 10.1128/JVI.02080-07
   Van Gulck ERA, 2006, BLOOD, V107, P1818, DOI 10.1182/blood-2005-01-0339
   Volodkin DV, 2004, BIOMACROMOLECULES, V5, P1962, DOI 10.1021/bm049669e
   Volodkin DV, 2004, LANGMUIR, V20, P3398, DOI 10.1021/la036177z
   Waeckerle-Men Y, 2005, ADV DRUG DELIVER REV, V57, P475, DOI 10.1016/j.addr.2004.09.007
   Waeckerle-Men Y, 2004, J IMMUNOL METHODS, V287, P109, DOI 10.1016/j.jim.2004.01.010
   Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102
   Wischke C, 2009, INT J PHARMACEUT, V365, P61, DOI 10.1016/j.ijpharm.2008.08.039
NR 44
TC 15
Z9 15
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUL
PY 2010
VL 18
IS 7
BP 1408
EP 1416
DI 10.1038/mt.2010.82
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 619AP
UT WOS:000279398900020
PM 20461059
OA gold
DA 2018-01-05
ER

PT J
AU Marton, S
   Reyes-Darias, JA
   Sanchez-Luque, FJ
   Romero-Lopez, C
   Berzal-Herranz, A
AF Marton, Soledad
   Reyes-Darias, Jose A.
   Sanchez-Luque, Francisco J.
   Romero-Lopez, Cristina
   Berzal-Herranz, Alfredo
TI In Vitro and Ex Vivo Selection Procedures for Identifying Potentially
   Therapeutic DNA and RNA Molecules
SO MOLECULES
LA English
DT Review
DE in vitro selection; SELEX; aptamer; ribozyme; therapeutic nucleic acids
ID HEPATITIS-C-VIRUS; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS;
   GROWTH-FACTOR-B; VON-WILLEBRAND-FACTOR; LOCKED NUCLEIC-ACIDS; NICOTINIC
   ACETYLCHOLINE-RECEPTOR; TETRAD-FORMING OLIGONUCLEOTIDES; OCULAR
   VASCULAR-DISEASE; PLGA-PEG NANOPARTICLES
AB It was only relatively recently discovered that nucleic acids participate in a variety of biological functions, besides the storage and transmission of genetic information. Quite apart from the nucleotide sequence, it is now clear that the structure of a nucleic acid plays an essential role in its functionality, enabling catalysis and specific binding reactions. In vitro selection and evolution strategies have been extremely useful in the analysis of functional RNA and DNA molecules, helping to expand our knowledge of their functional repertoire and to identify and optimize DNA and RNA molecules with potential therapeutic and diagnostic applications. The great progress made in this field has prompted the development of ex vivo methods for selecting functional nucleic acids in the cellular environment. This review summarizes the most important and most recent applications of in vitro and ex vivo selection strategies aimed at exploring the therapeutic potential of nucleic acids.
C1 [Marton, Soledad; Reyes-Darias, Jose A.; Sanchez-Luque, Francisco J.; Romero-Lopez, Cristina; Berzal-Herranz, Alfredo] CSIC, Inst Parasitol & Biomed Lopez Neyra, PT Ciencias Salud, Granada 18100, Spain.
RP Berzal-Herranz, A (reprint author), CSIC, Inst Parasitol & Biomed Lopez Neyra, PT Ciencias Salud, Av Conocimiento S-N, Granada 18100, Spain.
EM smarton@ipb.csic.es; joanreda@hotmail.com; kiko@ipb.csic.es;
   cristina_romero@ipb.csic.es; aberzalh@ipb.csic.es
RI Berzal-Herranz, Alfredo/K-8614-2014; Sanchez-Luque,
   Francisco/B-5682-2017
OI Berzal-Herranz, Alfredo/0000-0003-3722-7973; Sanchez-Luque,
   Francisco/0000-0003-1138-6124
FU Spanish Ministry of Science and Innovation [BFU2009-08137]; Junta de
   Andalucia [CTS-5077]; E.U.
FX The work of Berzal-Herranz's group is funded by grant BFU2009-08137 from
   the Spanish Ministry of Science and Innovation, grant CTS-5077 from the
   Junta de Andalucia, and by FEDER funds from the E.U.
CR Aldaz-Carroll L, 2002, BIOCHEMISTRY-US, V41, P5883, DOI 10.1021/bi0121508
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Barfod A, 2009, PARASITOL RES, V105, P1557, DOI 10.1007/s00436-009-1583-x
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Becker RC, 2010, THROMB HAEMOSTASIS, V103, P586, DOI 10.1160/TH09-10-0716
   Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164
   Bellecave P, 2008, ANTIMICROB AGENTS CH, V52, P2097, DOI 10.1128/AAC.01227-07
   BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129                                                             
   BerzalHerranz A, 1996, J HEPATOL, V25, P1002, DOI 10.1016/S0168-8278(96)80312-6
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Blake CM, 2009, OLIGONUCLEOTIDES, V19, P117, DOI 10.1089/oli.2008.0177
   BLANN A, 1993, BRIT J BIOMED SCI, V50, P125
   Bless NM, 1997, CURR BIOL, V7, P877, DOI 10.1016/S0960-9822(06)00376-9
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Bondensgaard K, 2000, CHEM-EUR J, V6, P2687, DOI 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.3.CO;2-L
   Boucard D, 2006, BIOCHEMISTRY-US, V45, P1518, DOI 10.1021/bi051187f
   Breaker RR, 1997, CHEM REV, V97, P371, DOI 10.1021/cr960008k                                                               
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   BURKE JM, 1993, FASEB J, V7, P106
   Buskirk AR, 2003, CHEM BIOL, V10, P533, DOI 10.1016/S1074-5521(03)00109-1
   Buskirk AR, 2004, CHEM BIOL, V11, P1157, DOI 10.1016/j.chembiol.2004.05.017
   Cassiday LA, 2003, P NATL ACAD SCI USA, V100, P3930, DOI 10.1073/pnas.0736013100
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Chan MY, 2008, J THROMB HAEMOST, V6, P789, DOI 10.1111/j.1538-7836.2008.02932.x
   Chan MY, 2008, CIRCULATION, V117, P2865, DOI 10.1161/CIRCULATIONAHA.107.745687
   Charlton J, 1997, BIOCHEMISTRY-US, V36, P3018, DOI 10.1021/bi962669h
   Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100
   Chen X, 2007, CHEM BIODIVERS, V4, P633, DOI 10.1002/cbdv.200790055
   Chen X, 2009, RNA, V15, P2035, DOI 10.1261/rna.1635209
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Dausse Eric, 2005, V288, P391
   Dausse E, 2009, CURR OPIN PHARMACOL, V9, P602, DOI 10.1016/j.coph.2009.07.006
   DEANDA A, 1994, ANN THORAC SURG, V58, P344, DOI 10.1016/0003-4975(94)92206-3                                                    
   DEGOLS G, 1992, ANN NY ACAD SCI, V660, P331, DOI 10.1111/j.1749-6632.1992.tb21104.x                                              
   Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105
   Diener JL, 2009, J THROMB HAEMOST, V7, P1155, DOI 10.1111/j.1538-7836.2009.03459.x
   Doherty EA, 2000, ANNU REV BIOCHEM, V69, P597, DOI 10.1146/annurev.biochem.69.1.597
   Dollins CM, 2008, CHEM BIOL, V15, P675, DOI 10.1016/j.chembiol.2008.05.016
   DORING G, 1994, AM J RESP CRIT CARE, V150, pS114
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Dyke CK, 2006, CIRCULATION, V114, P2490, DOI 10.1161/CIRUCLATIONAHA.106.668434
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Fan SA, 2008, WORLD J GASTROENTERO, V14, P6360, DOI 10.3748/wjg.14.6360
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
   Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7
   Gevertz J, 2005, RNA, V11, P853, DOI 10.1261/rna.7271405
   Giangrande PH, 2007, P NATL ACAD SCI USA, V104, P12988, DOI 10.1073/pnas.0704754104
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Gissot A, 2008, ORG BIOMOL CHEM, V6, P1324, DOI 10.1039/b719280k
   Gopinath SCB, 2006, J BIOCHEM, V139, P837, DOI 10.1093/jb/mvj095
   GOUNNI AS, 1994, NATURE, V367, P183
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0
   GRIFFIN LC, 1993, BLOOD, V81, P3271
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   HELDIN CH, 1992, EMBO J, V11, P4251
   Helmling S, 2004, P NATL ACAD SCI USA, V101, P13174, DOI 10.1073/pnas.0404175101
   Hess GP, 2000, P NATL ACAD SCI USA, V97, P13895, DOI 10.1073/pnas.240459497
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Huang Z, 2007, BIOCHEMISTRY-US, V46, P12648, DOI 10.1021/bi701036p
   Huang Z, 2009, NUCLEIC ACIDS RES, V37, P4022, DOI 10.1093/nar/gkp284
   HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X                                                    
   IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Isaka Y, 2007, CURR OPIN MOL THER, V9, P132
   Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386
   Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079
   JAIN RK, 1987, CANCER RES, V47, P3039
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Jarosch F, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl463
   Jian Y, 2009, ONCOGENE, V28, P4201, DOI 10.1038/onc.2009.275
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kanamori H, 2009, VIROLOGY, V388, P91, DOI 10.1016/j.virol.2009.02.032
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kikuchi K, 2005, NUCLEIC ACIDS RES, V33, P683, DOI 10.1093/nar/gki215
   Kikuchi K, 2003, J BIOCHEM, V133, P263, DOI 10.1093/jb/mvg036
   Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V386, P118, DOI 10.1016/j.bbrc.2009.05.135
   Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112
   Kolb Gaelle, 2006, RNA Biol, V3, P150
   Konno K., 2008, NUCL ACIDS S SER, V52, P493
   Kumar R, 1998, BIOORG MED CHEM LETT, V8, P2219, DOI 10.1016/S0960-894X(98)00366-7                                                   
   Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x                                                               
   Lee KS, 2008, EUR RESPIR J, V31, P523, DOI 10.1183/09031936.00125007
   LINDNER V, 1995, CIRC RES, V76, P951
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Lupold SE, 2002, CANCER RES, V62, P4029
   Madsen JB, 2010, BIOCHEMISTRY-US, V49, P4103, DOI 10.1021/bi100066j
   MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365
   Mi J, 2008, MOL THER, V16, P66, DOI 10.1038/sj.mt.6300320
   Mi J, 2006, NUCLEIC ACIDS RES, V34, P3577, DOI 10.1093/nar/gkl482
   MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217                                                           
   Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894                                                              
   Naimuddin M, 2007, J MOL RECOGNIT, V20, P58, DOI 10.1002/jmr.812
   NEVINS JR, 1992, SCIENCE, V258, P424
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nieuwlandt D, 2000, Curr Issues Mol Biol, V2, P9
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Nolte A, 1996, NAT BIOTECHNOL, V14, P1116, DOI 10.1038/nbt0996-1116
   Nomura Y, 2007, J AM CHEM SOC, V129, P13814, DOI 10.1021/ja076298b                                                               
   Ostendorf T, 2002, J AM SOC NEPHROL, V13
   Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909
   Pan WH, 2008, BIOTECHNIQUES, V44, P351, DOI 10.2144/000112689
   Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6                
   Pietras K, 2001, CANCER RES, V61, P2929
   Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C
   Reyes-Darias JA, 2008, CURR HIV RES, V6, P500, DOI 10.2174/157016208786501454
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Romero-Lopez C, 2007, BIOTECHNOL BIOTEC EQ, V21, P272, DOI 10.1080/13102818.2007.10817461                                                  
   Romero-Lopez C, 2007, CELL MOL LIFE SCI, V64, P2994, DOI 10.1007/s00018-007-7345-y
   Romero-Lopez C, 2005, BIOL CHEM, V386, P183, DOI 10.1515/BC.2005.023
   Romero-Lopez C, 2009, J GEN VIROL, V90, P1659, DOI 10.1099/vir.0.008821-0
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   Rusconi CP, 2000, THROMB HAEMOSTASIS, V84, P841
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262                                                          
   Santulli-Marotto S, 2003, CANCER RES, V63, P7483
   Sarraf-Yazdi S, 2008, J SURG RES, V146, P16, DOI 10.1016/j.jss.2007.04.028
   Sawa Y, 1997, CIRCULATION, V96, P280
   Sawa Y, 1997, CIRCULATION, V96
   Schubert S, 2004, J MOL BIOL, V339, P355, DOI 10.1016/j.jmb.2004.03.064
   Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0893
   Shukla Dhananjay, 2007, Indian Journal of Ophthalmology, V55, P427
   SINGH Y, 2010, CHEM SOC REV
   Sivaprakasam K, 2010, J MEMBRANE BIOL, V233, P1, DOI 10.1007/s00232-009-9215-z
   SMITH D, 1995, CHEM BIOL, V2, P741, DOI 10.1016/1074-5521(95)90102-7                                                    
   Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723
   Sriram B, 2000, BIOCHEM J, V352, P667, DOI 10.1042/0264-6021:3520667
   SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N
   SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0
   Thiel KW, 2009, OLIGONUCLEOTIDES, V19, P209, DOI 10.1089/oli.2009.0199
   Tomita T, 2000, RHEUMATOLOGY, V39, P749, DOI 10.1093/rheumatology/39.7.749
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ueno T, 2001, J THORAC CARDIOV SUR, V122, P720, DOI 10.1067/mtc.2001.115917
   Ulrich H, 1998, P NATL ACAD SCI USA, V95, P14051, DOI 10.1073/pnas.95.24.14051                                                        
   Unwalla HJ, 2008, MOL THER, V16, P1113, DOI 10.1038/mt.2008.54
   Vater A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng130
   Veedu RN, 2008, J AM CHEM SOC, V130, P8124, DOI 10.1021/ja801389n
   Veedu RN, 2007, NUCLEOS NUCLEOT NUCL, V26, P1207, DOI 10.1080/15257770701527844
   Veedu RN, 2010, CHEM BIODIVERS, V7, P536, DOI 10.1002/cbdv.200900343
   Veedu RN, 2009, ORG BIOMOL CHEM, V7, P1404, DOI 10.1039/b819946a
   Vento MT, 2008, MOL CANCER THER, V7, P3381, DOI 10.1158/1535-7163.MCT-08-0580
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Wang YX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009726
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
   White RR, 2008, ANGIOGENESIS, V11, P395, DOI 10.1007/s10456-008-9122-4
   White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   Wieland M, 2010, CHEM BIOL, V17, P236, DOI 10.1016/j.chembiol.2010.02.012
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399
   Wu LH, 1999, NUCLEIC ACIDS RES, V27, P1512, DOI 10.1093/nar/27.6.1512
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Wurster SE, 2008, RNA, V14, P1037, DOI 10.1261/rna.878908
   Wurster SE, 2009, NUCLEIC ACIDS RES, V37, P6214, DOI 10.1093/nar/gkp670
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
NR 174
TC 14
Z9 14
U1 0
U2 18
PU MDPI AG
PI BASEL
PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2010
VL 15
IS 7
BP 4610
EP 4638
DI 10.3390/molecules15074610
PG 29
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 631IV
UT WOS:000280340900009
PM 20657381
OA gold
DA 2018-01-05
ER

PT J
AU Gan, N
   Hou, JG
   Hu, FT
   Zheng, L
   Ni, MJ
   Cao, YT
AF Gan, Ning
   Hou, Jianguo
   Hu, Futao
   Zheng, Lei
   Ni, Minjun
   Cao, Yuting
TI An Amperometric Immunosensor Based on a Polyelectrolyte/Gold Magnetic
   Nanoparticle Supramolecular Assembly-Modified Electrode for the
   Determination of HIV p24 in Serum
SO MOLECULES
LA English
DT Article
DE electrochemical biosensor; polyelectrolyte/gold magentic nanoparticle;
   immunosensor; HIV p24
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CARCINOEMBRYONIC ANTIGEN; GOLD
   NANOPARTICLES; ELECTROCHEMICAL BIOSENSORS; MULTICENTER EVALUATION;
   SCREENING ASSAY; IMMUNOASSAY; REDUCTION
AB A novel supramolecular amperometric immunosensor for the determination of Human Immunodeficiency Virus antigen p24 (HIV p24) was built up using the electrostatic layer-by-layer self-assembly technique upon a gold electrode with HIV p24 antibody (anti-p24) being immobilized on polyelectrolyte/gold nanoparticle multilayer films. The multilayer films were composed of poly(L-lysine) (pLys) and mercaptosuccinic acid (MSA) stabilized Fe(3)O(4)(core)/gold(shell) nano particles (GMPs). The immunosensor preparation steps were monitored by X-ray fluorescence spectrometry (XRFS), scanning electron microscopy (SEM) and transmission electron microscopy (TEM). In pH 6.5 PBS, after the immunosensor was incubated with HIV p24 solution at 25 degrees C for 5 min, the electron transfer access of FeCN is partially inhibited, which leads to a linear decrease of peak current. In addition, the performance of the immunosensor was studied in detail. It offers high-sensitivity for the detection of p24 and has good correlation for the detection of p24 in the range of 0.1 to 100.0 ng/mL with a detection limit of 0.05 ng/mL estimated at a signalto- noise ratio of 3. The proposed immunosensor was used to analyze p24 in human serum specimens and the results showed the developed immunosensor provides a promising alternative approach for detecting p24 in the early diagnosis of AIDS patients.
C1 [Gan, Ning; Hou, Jianguo; Hu, Futao; Cao, Yuting] Ningbo Univ, State Key Lab Base Novel Funct Mat & Preparat Sci, Fac Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.
   [Zheng, Lei; Ni, Minjun] So Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, State Key Lab Base Novel Funct Mat & Preparat Sci, Fac Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn; nfyyzl@163.com
FU National Natural Science Foundation of China [20805024]; Zhejiang
   Provincial Natural Science Foundation [Y106725, Y4080023]
FX The authors appreciate the support of the National Natural Science
   Foundation of China (grant no. 20805024) and Zhejiang Provincial Natural
   Science Foundation (Y106725 & Y4080023).
CR ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560
   Ban ZH, 2005, J MATER CHEM, V15, P4660, DOI 10.1039/b504304b
   Baron R, 2007, CHEM COMMUN, P323, DOI 10.1039/b610721b
   Chai R, 2008, TALANTA, V74, P1330, DOI 10.1016/j.talanta.2007.08.046
   Constantine CA, 2003, J AM CHEM SOC, V125, P1805, DOI 10.1021/ja028691h
   Guo SJ, 2007, ANAL CHIM ACTA, V598, P181, DOI 10.1016/j.aca.2007.07.054
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Gurtler L, 1998, J VIROL METHODS, V75, P27, DOI 10.1016/S0166-0934(98)00094-9
   He XL, 2008, J BIOCHEM BIOPH METH, V70, P823, DOI 10.1016/j.jbbm.2007.06.002
   Kim JH, 2009, J CERAM PROCESS RES, V10, P770
   Li XL, 2006, J BIOTECHNOL, V123, P356, DOI 10.1016/j.jbiotec.2005.11.023
   MARIANA C, 2005, J PHYS CHEM B, V109, P21808
   Sickinger E, 2004, J CLIN MICROBIOL, V42, P21, DOI 10.1128/JCM.42.1.21-29.2004
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Thevenot DR, 2001, BIOSENS BIOELECTRON, V16, P121, DOI 10.1016/S0956-5663(01)00115-4                                                   
   Wang J, 2005, ANALYST, V130, P421, DOI 10.1039/b414248a
   Wang SF, 2008, BIOSENS BIOELECTRON, V23, P1781, DOI 10.1016/j.bios.2008.02.014
   Wang YY, 2007, J ENVIRON SCI-CHINA, V19, P776, DOI 10.1016/S1001-0742(07)60130-2
   Weber B, 2002, J CLIN MICROBIOL, V40, P1938, DOI 10.1128/JCM.40.6.1938-1946.2002
   Wu J, 2006, BIOSENS BIOELECTRON, V22, P102, DOI 10.1016/j.bios.2005.12.008
   Wu L, 2007, BIOSENS BIOELECTRON, V23, P479, DOI 10.1016/j.bios.2007.06.009
   Wu Y, 2009, BIOSENS BIOELECTRON, V24, P1389, DOI 10.1016/j.bios.2008.07.075
   ZHANG K, 2002, BRIT MED J, V324, P332
NR 23
TC 21
Z9 21
U1 1
U2 44
PU MDPI AG
PI BASEL
PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2010
VL 15
IS 7
BP 5053
EP 5065
DI 10.3390/molecules15075053
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 631IV
UT WOS:000280340900036
PM 20657408
OA gold
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Novel liquid formulation developed to deliver nanomedicine treatment for
   HIV/AIDS
SO NANOMEDICINE
LA English
DT News Item
CR Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
NR 1
TC 0
Z9 0
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUL
PY 2010
VL 5
IS 5
BP 684
EP 684
PG 1
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 632UM
UT WOS:000280454400003
DA 2018-01-05
ER

PT J
AU Dobrowsky, TM
   Daniels, BR
   Siliciano, RF
   Sun, SX
   Wirtz, D
AF Dobrowsky, Terrence M.
   Daniels, Brian R.
   Siliciano, Robert F.
   Sun, Sean X.
   Wirtz, Denis
TI Organization of Cellular Receptors into a Nanoscale Junction during
   HIV-1 Adhesion
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN;
   MEMBRANE-FUSION; 6-HELIX BUNDLE; CD4 RECEPTOR; LIPID RAFTS; CELLS;
   DYNAMICS; CCR5; REPLICATION
AB The fusion of the human immunodeficiency virus type 1 (HIV-1) with its host cell is the target for new antiretroviral therapies. Viral particles interact with the flexible plasma membrane via viral surface protein gp120 which binds its primary cellular receptor CD4 and subsequently the coreceptor CCR5. However, whether and how these receptors become organized at the adhesive junction between cell and virion are unknown. Here, stochastic modeling predicts that, regarding binding to gp120, cellular receptors CD4 and CCR5 form an organized, ring-like, nanoscale structure beneath the virion, which locally deforms the plasma membrane. This organized adhesive junction between cell and virion, which we name the viral junction, is reminiscent of the well-characterized immunological synapse, albeit at much smaller length scales. The formation of an organized viral junction under multiple physiopathologically relevant conditions may represent a novel intermediate step in productive infection.
C1 [Dobrowsky, Terrence M.; Daniels, Brian R.; Sun, Sean X.; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Siliciano, Robert F.] Johns Hopkins Sch Med, Howard Hughes Med Inst, Baltimore, MD USA.
   [Siliciano, Robert F.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
   [Sun, Sean X.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA.
   [Sun, Sean X.; Wirtz, Denis] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD 21218 USA.
RP Dobrowsky, TM (reprint author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
EM wirtz@jhu.edu
RI Daniels, Brian/A-8133-2010; Wirtz, Denis/A-3257-2010; Sun,
   Sean/C-6755-2009
OI Sun, Sean/0000-0002-9077-7088
FU US National Institutes of Health [R01GM084204, U54CA143868]
FX This work was supported by US National Institutes of Health grants
   R01GM084204 and U54CA143868. The funder had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Atilgan E, 2006, BIOPHYS J, V90, P65, DOI 10.1529/biophysj.105.071480
   Baker AM, 2007, J BIOL CHEM, V282, P35163, DOI 10.1074/jbc.M705617200
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   CANHAM PB, 1970, J THEOR BIOL, V26, P61, DOI 10.1016/S0022-5193(70)80032-7
   Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/vir.0.18313-0
   DeGottardi MQ, 2008, J VIROL, V82, P321, DOI 10.1128/JVI.01094-07
   Dobrowsky TM, 2008, J VIROL, V82, P7022, DOI 10.1128/JVI.00053-08
   Dustin ML, 2008, IMMUNOL REV, V221, P77, DOI 10.1111/j.1600-065X.2008.00589.x
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094                                                     
   Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596
   Gilbert C, 2005, VIRAL IMMUNOL, V18, P474, DOI 10.1089/vim.2005.18.474                                                         
   Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453
   Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221
   HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693
   Hummer G, 2001, P NATL ACAD SCI USA, V98, P3658, DOI 10.1073/pnas.071034098
   Jimenez-Baranda S, 2007, NAT CELL BIOL, V9, P838, DOI 10.1038/ncb1610
   Kozak SL, 1997, J VIROL, V71, P873
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0                                                                
   Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Liu SQ, 2003, J MOL MODEL, V9, P329, DOI 10.1007/s00894-003-0154-9
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   MURPHY FA, 1995, VIRUS TAXONOMY CLASS
   NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9                                                   
   Nokta MA, 2001, AIDS, V15, P161, DOI 10.1097/00002030-200101260-00004
   Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   Platt EJ, 1998, J VIROL, V72, P2855
   Saff EB, 1997, MATH INTELL, V19, P5, DOI 10.1007/BF03024331                                                              
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Sun SX, 2008, METHOD CELL BIOL, V89, P601, DOI 10.1016/S0091-679X(08)00623-7
   Sun SX, 2006, BIOPHYS J, V90, pL10, DOI 10.1529/biophysj.105.074203
   Trister AD, 2008, BIOPHYS J, V95, P40, DOI 10.1529/biophysj.107.118430
   Wang HY, 2003, J THEOR BIOL, V221, P491, DOI 10.1006/jtbi.2003.3200
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yoder A, 2008, CELL, V134, P782, DOI 10.1016/j.cell.2008.06.036
   Yuste E, 2004, J VIROL, V78, P6775, DOI 10.1128/JVI.78.13.6775-6785.2004
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 40
TC 11
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-734X
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD JUL
PY 2010
VL 6
IS 7
AR e1000855
DI 10.1371/journal.pcbi.1000855
PG 14
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 633TG
UT WOS:000280528300024
PM 20657663
OA gold
DA 2018-01-05
ER

PT J
AU Lee, KN
   Bae, SY
   Jo, M
   Park, J
   Jung, M
   Han, BD
   Lee, C
   Yoon, S
   Kim, S
AF Lee, K. N.
   Bae, S. Y.
   Jo, M.
   Park, J.
   Jung, M.
   Han, B. D.
   Lee, C.
   Yoon, S.
   Kim, S.
TI A NOVEL DIAGNOSTIC METHOD FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) 1 USING
   NANOPOROUS SOL-GEL BASED PROTEIN MICROARRAY
SO VOX SANGUINIS
LA English
DT Meeting Abstract
C1 [Lee, K. N.; Bae, S. Y.; Lee, C.; Yoon, S.] Univ Korea Hosp, Seoul, South Korea.
   [Jo, M.; Park, J.; Jung, M.; Han, B. D.] PCL Inc, Seoul, South Korea.
   [Kim, S.] Dongguk Univ Biomed Engn, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2010
VL 99
SU 1
BP 302
EP 302
PG 1
WC Hematology
SC Hematology
GA 625DE
UT WOS:000279872501356
DA 2018-01-05
ER

PT J
AU Sadeghian, F
   Goosen, H
   Bossche, A
   van Keulen, F
AF Sadeghian, Flamed
   Goosen, Hans
   Bossche, Andre
   van Keulen, Fred
TI Application of electrostatic pull-in instability on sensing adsorbate
   stiffness in nanomechanical resonators
SO THIN SOLID FILMS
LA English
DT Article
DE Decoupling mass and stiffness; Nanocantilever; Mass sensing; Adsorption;
   Surface stress; Nanomechanical resonator
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYSTEMS
AB Recent theoretical and experimental research showed that the response of micro/nanocantilevers to detect materials is not always simply related to extra mass. Stiffness of adsorbates and surface stress-induced changes in the stiffness, arising from adsorption, can produce frequency shifts that are several times greater in magnitude than those induced by mass loading. Consequently, the calculated adsorbed mass does not fully represent the real adsorbed mass, making the measurements qualitative. Therefore, a proper method for measuring the stiffness of adsorbed layers has to be combined with resonance frequency measurement to quantitatively analyze changes in both the mass and the stiffness. This letter presents the theory for application of electrostatic pull-in instability for measuring the stiffness of adsorbates at the surface of cantilever resonators. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Sadeghian, Flamed; Goosen, Hans; van Keulen, Fred] Delft Univ Technol, SOCM Grp, Dept Precis & Microsyst Engn, NL-2600 AA Delft, Netherlands.
   [Sadeghian, Flamed; Bossche, Andre] Delft Univ Technol, Elect Instrumentat Lab, Dept Microelect, NL-2600 AA Delft, Netherlands.
RP Sadeghian, F (reprint author), Delft Univ Technol, SOCM Grp, Dept Precis & Microsyst Engn, NL-2600 AA Delft, Netherlands.
RI Goosen, Johannes/J-8419-2012
OI Goosen, Johannes/0000-0001-5709-1845
FU Dutch national research program on micro technology, MicroNed [IV-C-2]
FX This work was financially supported by the Dutch national research
   program on micro technology, MicroNed (Project code: IV-C-2).
CR Craighead H, 2007, NAT NANOTECHNOL, V2, P18, DOI 10.1038/nnano.2006.181
   Hu YC, 2004, SENSOR ACTUAT A-PHYS, V112, P155, DOI 10.1016/j.sna.2003.12.012
   Hwang KS, 2009, ANNU REV ANAL CHEM, V2, P77, DOI 10.1146/annurev-anchem-060908-155232
   Ilic B, 2001, J VAC SCI TECHNOL B, V19, P2825, DOI 10.1116/1.1421572
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Lee D, 2009, J APPL PHYS, V106, DOI 10.1063/1.3177326
   Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004
   Osterberg PM, 1997, J MICROELECTROMECH S, V6, P107, DOI 10.1109/84.585788
   Pamidighantam S, 2002, J MICROMECH MICROENG, V12, P458, DOI 10.1088/0960-1317/12/4/319
   Ramos D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/03/035503
   Ramos D, 2006, J APPL PHYS, V100, DOI 10.1063/1.2370507
   Sadeghian H, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3148774
   Sadeghian H, 2007, J MICROELECTROMECH S, V16, P1334, DOI 10.1109/JMEMS.2007.909237
   Tamayo J, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2388925
NR 14
TC 12
Z9 12
U1 0
U2 4
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD JUN 30
PY 2010
VL 518
IS 17
BP 5018
EP 5021
DI 10.1016/j.tsf.2010.03.036
PG 4
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 621HH
UT WOS:000279566100046
DA 2018-01-05
ER

PT J
AU Harrison, RS
   Shepherd, NE
   Hoang, HN
   Ruiz-Gomez, G
   Hill, TA
   Driver, RW
   Desai, VS
   Young, PR
   Abbenante, G
   Fairlie, DP
AF Harrison, Rosemary S.
   Shepherd, Nicholas E.
   Hoang, Huy N.
   Ruiz-Gomez, Gloria
   Hill, Timothy A.
   Driver, Russell W.
   Desai, Vishal S.
   Young, Paul R.
   Abbenante, Giovanni
   Fairlie, David P.
TI Downsizing human, bacterial, and viral proteins to short water-stable
   alpha helices that maintain biological potency
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE helix; inhibitor; structure; mimetic; anti-infective
ID COMPETENCE-STIMULATING PEPTIDE; 6-HELIX BUNDLE FORMATION; SYNCYTIAL
   VIRUS FUSION; NMR-SPECTROSCOPY; HEPTAD-REPEATS; INHIBITORS; REV;
   RECOGNITION; SPECIFICITY; MIMETICS
AB Recombinant proteins are important therapeutics due to potent, highly specific, and nontoxic actions in vivo. However, they are expensive medicines to manufacture, chemically unstable, and difficult to administer with low patient uptake and compliance. Small molecule drugs are cheaper and more bioavailable, but less target-specific in vivo and often have associated side effects. Here we combine some advantages of proteins and small molecules by taking short amino acid sequences that confer potency and selectivity to proteins, and fixing them as small constrained molecules that are chemically and structurally stable and easy to make. Proteins often use short alpha-helices of just 1-4 helical turns (4-15 amino acids) to interact with biological targets, but peptides this short usually have negligible alpha-helicity in water. Here we show that short peptides, corresponding to helical epitopes from viral, bacterial, or human proteins, can be strategically fixed in highly alpha-helical structures in water. These helix-constrained compounds have similar biological potencies as proteins that bear the same helical sequences. Examples are (i) a picomolar inhibitor of Respiratory Syncytial Virus F protein mediated fusion with host cells, (ii) a nano-molar inhibitor of RNA binding to the transporter protein HIV-Rev, (iii) a submicromolar inhibitor of Streptococcus pneumoniae growth induced by quorum sensing pheromone Competence Stimulating Peptide, and (iv) a picomolar agonist of the GPCR pain receptor opioid receptor like receptor ORL-1. This approach can be generally applicable to downsizing helical regions of proteins with broad applications to biology and medicine.
C1 [Harrison, Rosemary S.; Shepherd, Nicholas E.; Hoang, Huy N.; Ruiz-Gomez, Gloria; Hill, Timothy A.; Driver, Russell W.; Abbenante, Giovanni; Fairlie, David P.] Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld 4072, Australia.
   [Desai, Vishal S.; Young, Paul R.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
RP Fairlie, DP (reprint author), Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld 4072, Australia.
EM d.fairlie@imb.uq.edu.au
RI Shepherd, Nicholas/H-6781-2016; Fairlie, David/F-8865-2014; Hoang,
   Huy/I-6357-2015; Young, Paul/A-6176-2010; Hill, Timothy/C-9670-2017
OI Shepherd, Nicholas/0000-0001-6234-4456; Hoang, Huy/0000-0002-7124-6097;
   Young, Paul/0000-0002-2040-5190; Hill, Timothy/0000-0001-9727-9930;
   Fairlie, David/0000-0002-7856-8566
FU Australian Research Council (ARC) [FF0668733, DP0210330, DP0770936];
   National Health Medical Research Council [511194]; Ministerio de
   Educacion y Ciencia (MEC); Fundacion Espanola para la Ciencia y la
   Tecnologia (FECYT) (Spain)
FX We thank Renee Beyer for fluorescent Rev peptide and Stephen Kidd for S.
   pneumoniae. We thank the Australian Research Council (ARC) for Grants
   FF0668733, DP0210330, and DP0770936; and the National Health Medical
   Research Council for Grant 511194. D. P. F. is supported by an ARC
   Federation Fellowship, and G. R.-G. by a postdoctoral fellowship from
   Ministerio de Educacion y Ciencia (MEC) and Fundacion Espanola para la
   Ciencia y la Tecnologia (FECYT) (Spain).
CR *ACC INC, 2002, INSIGHT2
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   BRUNGER AT, 1992, XPLOR 3 851
   Cabezas E, 1999, J AM CHEM SOC, V121, P3862, DOI 10.1021/ja983212t                                                               
   Chapman RN, 2004, J AM CHEM SOC, V126, P12252, DOI 10.1021/ja0466659
   CHOU PY, 1973, J MOL BIOL, V74, P263, DOI 10.1016/0022-2836(73)90372-0
   Davis JM, 2007, CHEM SOC REV, V36, P326, DOI 10.1039/b608043j
   Debnath AK, 2006, CURR OPIN INVEST DR, V7, P118
   DOIG AJ, 2001, BIOCH SOC S, V68, P95
   Driver RW, 2009, ORG LETT, V11, P3092, DOI 10.1021/ol901181b
   Johnsborg O, 2006, J BACTERIOL, V188, P1744, DOI 10.1128/JB.188.5.1744-1749.2006
   Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405                                                          
   Luedtke NW, 2003, BIOPOLYMERS, V70, P103, DOI 10.1002/bip.10428
   MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0
   Mills NL, 2007, J BIOMOL SCREEN, V12, P946, DOI 10.1177/108705710730612
   Morton CJ, 2003, VIROLOGY, V311, P275, DOI 10.1016/S0042-6822(03)00115-6
   Oggioni MR, 2004, ANTIMICROB AGENTS CH, V48, P4725, DOI 10.1128/AAC.48.12.4725-4732.2004
   Okada K, 2000, BIOCHEM BIOPH RES CO, V278, P493, DOI 10.1006/bbrc.2000.3822
   ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415
   Pal L, 2003, J MOL BIOL, V326, P273, DOI 10.1016/S0022-2836(02)01338-4
   Roymans D, 2010, P NATL ACAD SCI USA, V107, P308, DOI 10.1073/pnas.0910108106
   SCANLON MJ, 1995, BIOCHEMISTRY-US, V34, P8242, DOI 10.1021/bi00026a005
   SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523
   Seebach D, 2006, BIOPOLYMERS, V84, P23, DOI 10.1002/bip.20391
   Shepherd NE, 2004, ANGEW CHEM INT EDIT, V43, P2687, DOI 10.1002/anie.200352659
   SHEPHERD NE, 2005, J AM CHEM SOC, V127, P1974
   Shepherd NE, 2006, J AM CHEM SOC, V128, P13284, DOI 10.1021/ja064058a
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   Taylor JW, 2002, BIOPOLYMERS, V66, P49, DOI 10.1002/bip.10203
   Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191
   Wallimann P, 2003, J AM CHEM SOC, V125, P1203, DOI 10.1021/ja0275360
   Wang EX, 2003, BIOCHEM BIOPH RES CO, V302, P469, DOI 10.1016/S0006-291X(03)00197-9
   Wang JW, 2003, PROTEIN ENG, V16, P799, DOI 10.1093/protein/gzg101
   Wider G, 2006, J AM CHEM SOC, V128, P2571, DOI 10.1021/ja055336t
NR 34
TC 89
Z9 90
U1 2
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 29
PY 2010
VL 107
IS 26
BP 11686
EP 11691
DI 10.1073/pnas.1002498107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 618DT
UT WOS:000279332300009
PM 20543141
OA gold
DA 2018-01-05
ER

PT J
AU Mehla, R
   Bivalkar-Mehla, S
   Zhang, RN
   Handy, I
   Albrecht, H
   Giri, S
   Nagarkatti, P
   Nagarkatti, M
   Chauhan, A
AF Mehla, Rajeev
   Bivalkar-Mehla, Shalmali
   Zhang, Ruonan
   Handy, Indhira
   Albrecht, Helmut
   Giri, Shailendra
   Nagarkatti, Prakash
   Nagarkatti, Mitzi
   Chauhan, Ashok
TI Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling
   but Inhibits Acute Infection in a Receptor Independent Manner
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   SUBEROYLANILIDE HYDROXAMIC ACID; T-CELL LYMPHOMA; KINASE-C-ZETA;
   NF-KAPPA-B; VALPROIC ACID; IN-VIVO; BUGULA-NERITINA; UP-REGULATION
AB HIV's ability to establish long-lived latent infection is mainly due to transcriptional silencing in resting memory T lymphocytes and other non dividing cells including monocytes. Despite an undetectable viral load in patients treated with potent antiretrovirals, current therapy is unable to purge the virus from these latent reservoirs. In order to broaden the inhibitory range and effectiveness of current antiretrovirals, the potential of bryostatin was investigated as an HIV inhibitor and latent activator. Bryostatin revealed antiviral activity against R5- and X4-tropic viruses in receptor independent and partly via transient decrease in CD4/CXCR4 expression. Further, bryostatin at low nanomolar concentrations robustly reactivated latent viral infection in monocytic and lymphocytic cells via activation of Protein Kinase C (PKC) -alpha and -delta, because PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect. Bryostatin specifically modulated novel PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated the viral reactivation effect. Above all, bryostatin was non-toxic in vitro and was unable to provoke T-cell activation. The dual role of bryostatin on HIV life cycle may be a beneficial adjunct to the treatment of HIV especially by purging latent virus from different cellular reservoirs such as brain and lymphoid organs.
C1 [Mehla, Rajeev; Bivalkar-Mehla, Shalmali; Zhang, Ruonan; Handy, Indhira; Nagarkatti, Prakash; Nagarkatti, Mitzi; Chauhan, Ashok] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
   [Albrecht, Helmut] Univ S Carolina, Sch Med, Dept Med, Columbia, SC 29208 USA.
   [Giri, Shailendra] Mayo Clin, Dept Expt Pathol, Rochester, MN USA.
RP Mehla, R (reprint author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA.
EM Ashok.Chauhan@uscmed.sc.edu
RI Albrecht, Helmut/D-5319-2011
FU National Institutes of Health [RO1 NS 050064, PO1AT003961]
FX The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. This work was
   supported with federal funds from National Institutes of Health grant
   RO1 NS 050064 (AC) and PO1AT003961 (PN and MN).
CR Archin NM, 2009, AIDS RES HUM RETROV, V25, P207, DOI 10.1089/aid.2008.0191
   Archin NM, 2008, AIDS, V22, P1131, DOI 10.1097/QAD.0b013e3282fd6df4
   ASIEDU C, 1995, CANCER RES, V55, P3716
   Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06
   Banda N K, 1999, Biol Blood Marrow Transplant, V5, P162, DOI 10.1053/bbmt.1999.v5.pm10392962
   Bedoya LM, 2009, BIOCHEM PHARMACOL, V77, P965, DOI 10.1016/j.bcp.2008.11.025
   BOTO WMO, 1991, CELL REGUL, V2, P95
   Brown A, 2006, J LEUKOCYTE BIOL, V80, P1127, DOI 10.1189/jlb.0206126
   Camargo JF, 2009, J INFECT DIS, V199, P1872, DOI 10.1086/598858
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200
   Chauhan A, 2007, FASEB J, V21, P777, DOI 10.1096/fj.06-7051com
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   Das SR, 2005, INDIAN J MED RES, V121, P315
   Davidson SK, 2001, APPL ENVIRON MICROB, V67, P4531, DOI 10.1128/AEM.67.10.4531-4537.2001
   Do Y, 2004, CANCER RES, V64, P6756, DOI 10.1158/0008-5472.CAN-03-4002
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Edelstein LC, 2009, AIDS RES HUM RETROV, V25, P883, DOI 10.1089/aid.2008.0294
   ESA AH, 1990, INT J IMMUNOPHARMACO, V12, P481, DOI 10.1016/0192-0561(90)90110-9                                                    
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   Folgueira L, 1996, J VIROL, V70, P223
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   He X, 2008, CANCER RES, V68, P8678, DOI 10.1158/0008-5472.CAN-08-0294
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807
   Jones J, 2005, VIROLOGY, V331, P106, DOI 10.1016/j.virol.2004.10.013
   Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006
   Kutsch O, 2002, J VIROL, V76, P8776, DOI 10.1128/JVI.76.17.8776-8786.2002
   Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114
   Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006
   Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5
   Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101
   Lewinski MK, 2005, ADV GENET, V55, P147, DOI 10.1016/S0065-2660(05)55005-3
   LINT CV, 1996, EMBO J, V15, P1112
   Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839                                                            
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   MANN DL, 1990, J IMMUNOL, V144, P2152
   Margolis David M., 2006, Infectious Disorders - Drug Targets, V6, P369, DOI 10.2174/187152606779025824
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Martelli AM, 2003, HISTOL HISTOPATHOL, V18, P1301, DOI 10.14670/HH-18.1301
   MATTHES E, 1990, ANTIVIR RES, V13, P273, DOI 10.1016/0166-3542(90)90012-V                                                    
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191
   NELSON TJ, 2008, TRENDS BIOCHEM SCI, V34, P136
   Nishino Y, 2004, CARDIOVASC RES, V61, P610, DOI 10.1016/j.cardiores.2003.10.022
   Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105
   PETTIT GR, 1984, J AM CHEM SOC, V106, P6768, DOI 10.1021/ja00334a050
   Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000
   REUSE S, 2009, PLOS, V4, P1
   Sagot-Lerolle N, 2008, AIDS, V22, P1125, DOI 10.1097/QAD.0b013e3282fd6ddc
   SAJAN MP, 2009, AM J PHYSIOL-ENDOC M, DOI DOI 10.1152/AJPENDO.00392
   Scripture-Adams DD, 2002, J VIROL, V76, P13077, DOI 10.1128/JVI.76.24.13077-13082.2002
   Siliciano JD, 2007, J INFECT DIS, V195, P833, DOI 10.1086/511823
   Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199                                                          
   STANLEY SK, 1992, J IMMUNOL, V149, P689
   Steel A, 2006, AIDS, V20, P1681, DOI 10.1097/01.aids.0000238421.36313.fa                                             
   Sundstrom JB, 2007, BLOOD, V109, P5293, DOI 10.1182/blood-2006-11-058438
   THEOPHILUS SV, 2008, VIROLOGY, V381, P1
   Thiebot H, 2001, J VIROL, V75, P11594, DOI 10.1128/JVI.75.23.11594-11602.2001                                              
   Wang FX, 2005, J CLIN INVEST, V115, P128, DOI 10.1172/JCI200522574
   Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200
   Wolf D, 2008, VIROLOGY, V370, P45, DOI 10.1016/j.virol.2007.08.015
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Yang HC, 2009, J CLIN INVEST, V119, P3473, DOI 10.1172/JCI39199
   Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002
NR 69
TC 108
Z9 111
U1 4
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2010
VL 5
IS 6
AR e11160
DI 10.1371/journal.pone.0011160
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 612GZ
UT WOS:000278886100021
PM 20585398
OA gold
DA 2018-01-05
ER

PT J
AU Weber, C
   Drogoz, A
   David, L
   Domard, A
   Charles, MH
   Verrier, B
   Delair, T
AF Weber, Caroline
   Drogoz, Alexandre
   David, Laurent
   Domard, Alain
   Charles, Marie-Helene
   Verrier, Bernard
   Delair, Thierry
TI Polysaccharide-based vaccine delivery systems: Macromolecular assembly,
   interactions with antigen presenting cells, and in vivo immunomonitoring
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE chitosan; vaccine delivery; particles; polyelectrolyte complexes; HIV
ID SPHERICAL POLYELECTROLYTE BRUSHES; DENDRITIC CELLS; CHITOSAN
   NANOPARTICLES; AQUEOUS-SOLUTION; COMPLEX-FORMATION; IMMUNE-RESPONSES;
   DRUG-DELIVERY; GENE DELIVERY; MICROPARTICLES; MICROSPHERES
AB Using a strategy of macromolecular assembly, a colloidal vaccine delivery system was obtained from chitosan and dextran sulfate and loaded with an antigenic protein (p24, the capsid protein of HIV-1). The colloidal polyelectrolyte complexes (PECs) were obtained by charge neutralization of the polyanion and polycation at a charge ratio (n(+)/n(-)) of 2 (CHDS). The conditions of assembly were tuned to maintain the colloidal properties of the carrier in high salt environment. The relative molar masses of the two polyions and the degree of acetylation (DA) of chitosan were essential parameters to achieve this goal, and this could be related to the nanometric scale organization of the colloids observed by Small Angle X-rays Scattering experiments. The binding of p24 to the colloidal carrier was achieved and the release of the antigen was investigated. Antigen presenting cells [dendritic cells (DCs)], obtained from monocytes, could internalize the colloids. Immature DCs (iDCs) were not matured by the colloidal PECs either loaded or not loaded with p24, as proved by Fluorescent Activated Cell Sorting (FACS) analysis. Despite this lack of in vitro interaction, a specific immune response was observed in mice with a high production of antibodies, after subcutaneous injection. The analysis of the interleukin production shows that both the cellular and the Immoral responses were stimulated. This work brings a physico-chemical insight on polysaccharide-based antigen delivery systems and opens up new perspectives for their use as vaccine carriers. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res 93A: 1322-1334, 2010
C1 [Drogoz, Alexandre; David, Laurent; Domard, Alain; Delair, Thierry] Univ Lyon 1, Lab Mat Polymeres & Biomat, CNRS, UMR Ingn Mat Polymeres 5223, F-69622 Villeurbanne, France.
   [Weber, Caroline; Verrier, Bernard] Inst Biol & Chim Prot, F-69367 Lyon 07, France.
   [Charles, Marie-Helene] BioMerieux, F-69280 Marcy Letoile, France.
RP Delair, T (reprint author), Univ Lyon 1, Lab Mat Polymeres & Biomat, CNRS, UMR Ingn Mat Polymeres 5223, Domaine Sci Doua, F-69622 Villeurbanne, France.
EM Thierry.Delair@univ-lyon1.fr
RI Delair, Thierry/E-7896-2012; d2am, beamline/I-6445-2015
FU NanoBiosaccharide and MunanoVac European Programs; Europrise NOB
FX This work was partially supported by the NanoBiosaccharide and MunanoVac
   European Programs and the Europrise NOB. The authors thank, Jean-Michel
   Lucas for SEC data, le Rochas for Small angle X-ray Scattering,
   Christine Servet (IFR 128, BioSciences) and Marie-Madeleine
   Fiers-Didelot for help in DC cell culture and fruitful discussions.
CR Allard L, 2002, BIOTECHNOL BIOENG, V80, P341, DOI 10.1002/bit.10390
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Babensee JE, 2005, J BIOMED MATER RES A, V74A, P503, DOI 10.1002/jbm.a.30429
   Berthold A, 1996, J CONTROL RELEASE, V39, P17, DOI 10.1016/0168-3659(95)00129-8                                                    
   Buchhammer HM, 2003, COLLOID SURFACE A, V218, P151, DOI 10.1016/S0927-7757(02)00582-4
   Caruso F, 2000, LANGMUIR, V16, P9595, DOI 10.1021/la000942h
   Chen WB, 2005, J BIOMED MATER RES A, V75A, P128, DOI 10.1002/jbm.a.30393
   Chen Y, 2003, LETT PEPT SCI, V10, P621, DOI 10.1007/BF02442596                                                              
   CHEYNET V, 1993, PROTEIN EXPRES PURIF, V4, P367, DOI 10.1006/prep.1993.1048                                                          
   COOMBES AGA, 1994, BIOMATERIALS, V15, P673, DOI 10.1016/0142-9612(94)90165-1
   Dautzenberg H, 1997, MACROMOLECULES, V30, P7810, DOI 10.1021/ma970803f                                                               
   Douglas KL, 2005, J BIOMAT SCI-POLYM E, V16, P43, DOI 10.1163/1568562052843339
   Dragan ES, 2004, J POLYM SCI POL CHEM, V42, P5244, DOI 10.1002/pola.20388
   Drogoz A, 2008, BIOMACROMOLECULES, V9, P583, DOI 10.1021/bm701154h
   Drogoz A, 2007, LANGMUIR, V23, P10950, DOI 10.1021/la7008545
   Du J, 2005, BIOPOLYMERS, V78, P1, DOI 10.1002/bip.20119                                                               
   Dumitriu S, 1997, BIOTECHNOL PROGR, V13, P539, DOI 10.1021/bp970059i
   Etrych T, 2005, EUR J PHARM SCI, V25, P281, DOI 10.1016/j.ejps.2005.03.005
   Fischer S, 2007, BIOMATERIALS, V28, P994, DOI 10.1016/j.biomaterials.2006.10.034
   Gu HW, 2003, CHEM COMMUN, P1966, DOI 10.1039/b305421g
   HIRAI A, 1991, POLYM BULL, V26, P87, DOI 10.1007/BF00299352                                                              
   Ichikawa S, 2005, BIOSCI BIOTECH BIOCH, V69, P1637, DOI 10.1271/bbb.69.1637
   Jilek S, 2004, PHARM RES, V21, P1240, DOI 10.1023/B:PHAM.0000033012.16152.5d                                              
   KABANOV VA, 1984, PURE APPL CHEM, V56, P343, DOI 10.1351/pac198456030343                                                         
   Kabanov VA, 2004, J PHYS CHEM B, V108, P1485, DOI 10.1021/jp035821f
   Kabanov V.A., 1984, MACROMOL CHEM S, V6, P259
   Kim MH, 2004, J APPL CRYSTALLOGR, V37, P643, DOI 10.1107/S0021889804013196
   KISSEL T, 2006, J PHARM SCI, V95, P1035
   Koping-Hoggard M, 2005, EXPERT REV VACCINES, V4, P185, DOI 10.1586/14760584.4.2.185
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Lamarque G, 2005, BIOMACROMOLECULES, V6, P131, DOI 10.1021/bm0496357
   Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92                                                     
   Lin YH, 2005, BIOMACROMOLECULES, V6, P1104, DOI 10.1021/bm049312a
   MARCINKIEWICZ J, 1991, Archivum Immunologiae et Therapiae Experimentalis, V39, P127
   Montembault A, 2005, BIOMACROMOLECULES, V6, P653, DOI 10.1021/bm049593m
   Nagamoto T, 2004, PHARM RES, V21, P671, DOI 10.1023/B:PHAM.0000022414.17183.58
   Ozbas-Turan S, 2002, J PHARM SCI, V91, P1245, DOI 10.1002/jps.10122
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Read RC, 2005, VACCINE, V23, P4367, DOI 10.1016/j.vaccine.2005.04.021
   Sarmento B, 2006, COLLOID SURFACE B, V53, P193, DOI 10.1016/j.colsurfb.2006.09.012
   Sarmento B, 2006, CARBOHYD POLYM, V66, P1, DOI 10.1016/j.carbpol.2006.02.008
   Schatz C, 2004, LANGMUIR, V20, P7766, DOI 10.1021/la049460m
   Schatz C, 2004, BIOMACROMOLECULES, V5, P1882, DOI 10.1021/bm049786
   Schatz C, 2003, BIOMACROMOLECULES, V4, P641, DOI 10.1021/bm025724c
   Seferian PG, 2000, VACCINE, V19, P661, DOI 10.1016/S0264-410X(00)00248-6
   Shi XW, 2006, J APPL POLYM SCI, V100, P4614, DOI 10.1002/app.23021
   Vachoud L, 1997, CARBOHYD RES, V302, P169, DOI 10.1016/S0008-6215(97)00126-2
   van der Lubben IM, 2001, EUR J PHARM SCI, V14, P201, DOI 10.1016/S0928-0987(01)00172-5                                                   
   Van der Lubben IM, 2001, J DRUG TARGET, V9, P39, DOI 10.3109/10611860108995631                                                       
   Vila A, 2004, EUR J PHARM BIOPHARM, V57, P123, DOI 10.1016/j.ejpb.2003.09.006
   Waeckerle-Men Y, 2004, J IMMUNOL METHODS, V287, P109, DOI 10.1016/j.jim.2004.01.010
   Wischke C, 2006, J CONTROL RELEASE, V114, P359, DOI 10.1016/j.jconrel.2006.06.020
   Wittemann A, 2005, J AM CHEM SOC, V127, P9688, DOI 10.1021/ja0513234
   Wittemann A, 2003, PHYS CHEM CHEM PHYS, V5, P1671, DOI 10.1039/b300607g
   Xu YM, 2003, INT J PHARM, V250, P215, DOI 10.1016/S0378-5173(02)00548-3
   Yoshida M, 2004, J BIOMED MATER RES A, V71A, P45, DOI 10.1002/jbm.a.30131
   Yoshida M, 2006, J BIOMAT SCI-POLYM E, V17, P893, DOI 10.1163/156856206777996844                                                      
   Yu SY, 2006, LANGMUIR, V22, P2754, DOI 10.1021/la053158b
   Zaharoff DA, 2007, VACCINE, V25, P2085, DOI 10.1016/j.vaccine.2006.11.034
NR 59
TC 20
Z9 20
U1 2
U2 21
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUN 15
PY 2010
VL 93A
IS 4
BP 1322
EP 1334
DI 10.1002/jbm.a.32605
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 594GG
UT WOS:000277523600012
PM 19859973
DA 2018-01-05
ER

PT J
AU Matoba, N
   Husk, AS
   Barnett, BW
   Pickel, MM
   Arntzen, CJ
   Montefiori, DC
   Takahashi, A
   Tanno, K
   Omura, S
   Cao, HY
   Mooney, JP
   Hanson, CV
   Tanaka, H
AF Matoba, Nobuyuki
   Husk, Adam S.
   Barnett, Brian W.
   Pickel, Michelle M.
   Arntzen, Charles J.
   Montefiori, David C.
   Takahashi, Atsushi
   Tanno, Kazunobu
   Omura, Satoshi
   Cao, Huyen
   Mooney, Jason P.
   Hanson, Carl V.
   Tanaka, Haruo
TI HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of
   Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic
   Activity
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; N-LINKED GLYCOSYLATION; CYANOVIRIN-N;
   ENVELOPE GLYCOPROTEIN; SYNCYTIUM FORMATION; ANTIBODY 2G12; INFECTION;
   GP120; MICROBICIDES; TRANSMISSION
AB The development of a topical microbicide blocking the sexual transmission of HIV-1 is urgently needed to control the global HIV/AIDS pandemic. The actinomycete-derived lectin actinohivin (AH) is highly specific to a cluster of high-mannose-type glycans uniquely found on the viral envelope (Env). Here, we evaluated AH's candidacy toward a microbicide in terms of in vitro anti-HIV-1 activity, potential side effects, and recombinant producibility. Two validated assay systems based on human peripheral blood mononuclear cell (hPBMC) infection with primary isolates and TZM-bl cell infection with Env-pseudotyped viruses were employed to characterize AH's anti-HIV-1 activity. In hPMBCs, AH exhibited nanomolar neutralizing activity against primary viruses with diverse cellular tropisms, but did not cause mitogenicity or cytotoxicity that are often associated with other anti-HIV lectins. In the TZM-bl-based assay, AH showed broad anti-HIV-1 activity against clinically-relevant, mucosally transmitting strains of clades B and C. By contrast, clade A viruses showed strong resistance to AH. Correlation analysis suggested that HIV-19s AH susceptibility is significantly linked to the N-glycans at the Env C2 and V4 regions. For recombinant (r)AH expression, we evaluated a tobacco mosaic virus-based system in Nicotiana benthamiana plants as a means to facilitate molecular engineering and cost-effective mass production. Biochemical analysis and an Env-mediated syncytium formation assay demonstrated high-level expression of functional rAH within six days. Taken together, our study revealed AH's cross-clade anti-HIV-1 activity, apparent lack of side effects common to lectins, and robust producibility using plant biotechnology. These findings justify further efforts to develop rAH toward a candidate HIV-1 microbicide.
C1 [Matoba, Nobuyuki; Husk, Adam S.; Barnett, Brian W.] Owensboro Canc Res Program, Owensboro, KY USA.
   [Matoba, Nobuyuki] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
   [Matoba, Nobuyuki] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
   [Pickel, Michelle M.; Arntzen, Charles J.] Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, Tempe, AZ USA.
   [Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [Takahashi, Atsushi] Iwaki Meisei Univ, Fac Pharm, Fukushima, Japan.
   [Takahashi, Atsushi; Tanaka, Haruo] Iwaki Meisei Univ, Coll Sci & Engn, Fukushima, Japan.
   [Tanno, Kazunobu; Tanaka, Haruo] KIIM Pharmaceut Labs Inc, Fukushima, Japan.
   [Omura, Satoshi] Kitasato Univ, Kitasato Inst Lifesci, Tokyo, Japan.
   [Cao, Huyen; Mooney, Jason P.; Hanson, Carl V.] Calif Dept Publ Hlth, Richmond, CA USA.
RP Matoba, N (reprint author), Owensboro Canc Res Program, Owensboro, KY USA.
EM n.matoba@louisville.edu
OI Mooney, Jason/0000-0002-2824-124X
FU Owensboro Cancer Research Program startup funds; Telemedicine and
   Advanced Technology Research Center (TATRC) [W81XWH-09-2-0022];
   University of Louisville School of Medicine; National Institutes of
   Health [AI30034]
FX The work was supported in part by Owensboro Cancer Research Program
   startup funds (as part of a contract that was awarded and administered
   by the United States Army Medical Research and Materiel Command
   (USAMRMC) and the Telemedicine and Advanced Technology Research Center
   (TATRC), under contract number: W81XWH-09-2-0022 and a grant from the
   University of Louisville School of Medicine (to NM), and a National
   Institutes of Health Grant AI30034 (to DCM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alouf JE, 2003, INT J MED MICROBIOL, V292, P429, DOI 10.1078/1438-4221-00232
   Bachrach E, 2005, VIROLOGY, V332, P418, DOI 10.1016/j.virol.2004.11.031
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2006, J VIROL, V80, P8411, DOI 10.1128/JVI.00369-06
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0
   Buonaguro L, 2007, J VIROL, V81, P10209, DOI 10.1128/JVI.00872-07
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chiba H, 2004, BIOCHEM BIOPH RES CO, V316, P203, DOI 10.1016/j.bbrc.2004.02.036
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   Chiba H, 2001, J ANTIBIOT, V54, P818, DOI 10.7164/antibiotics.54.818                                                      
   Cutalo JM, 2004, J AM SOC MASS SPECTR, V15, P1545, DOI 10.1016/j.jasms.2004.07.008
   DSOUZA MP, 1995, AIDS, V9, P867, DOI 10.1097/00002030-199508000-00006
   Elrefaei M, 2004, J IMMUNOL, V173, P2184, DOI 10.4049/jimmunol.173.3.2184                                                     
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x
   Garg Anita B, 2009, Antivir Chem Chemother, V19, P143
   Gavrovic-Jankulovic M, 2008, INT J BIOCHEM CELL B, V40, P929, DOI 10.1016/j.biocel.2007.10.033
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Huskens D, 2008, INT J BIOCHEM CELL B, V40, P2802, DOI 10.1016/j.biocel.2008.05.023
   Inokoshi J, 2001, BIOCHEM BIOPH RES CO, V281, P1261, DOI 10.1006/bbrc.2001.4496
   The Joint United Nations Programme on HIV/AIDS, 2009, AIDS EP UPD
   Keller MJ, 2009, SEX TRANSM DIS, V36, pS92, DOI 10.1097/OLQ.0b013e318199417d
   Lederman MM, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-116
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Liedtke S, 1997, GLYCOCONJUGATE J, V14, P785, DOI 10.1023/A:1018577619036
   Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003
   Ma JKC, 2005, TRENDS PLANT SCI, V10, P580, DOI 10.1016/j.tplants.2005.10.009
   Marillonnet S, 2005, NAT BIOTECHNOL, V23, P718, DOI 10.1038/nbt1094
   Marillonnet S, 2004, P NATL ACAD SCI USA, V101, P6852, DOI 10.1073/pnas.0400149101
   Mascola JR, 1996, AIDS RES HUM RETROV, V12, P1319, DOI 10.1089/aid.1996.12.1319
   MATOBA N, METHODS MOL IN PRESS
   Matoba N, 2009, PLANT BIOTECHNOL J, V7, P129, DOI 10.1111/j.1467-7652.2008.00381.x
   McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   OKEEFE BR, 2009, P NATL ACAD SCI US
   Paranjpe S, 2002, AIDS RES HUM RETROV, V18, P1271, DOI 10.1089/088922202320886316
   Peters PJ, 2006, J VIROL, V80, P6324, DOI 10.1128/JVI.02328-05
   Polonis VR, 2008, VIROLOGY, V375, P315, DOI 10.1016/j.virol.2008.02.007
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Sharon N., 2004, GLYCOBIOLOGY, V14, P53, DOI DOI 10.1093/GLYC0B/CWH122
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   SWANSON MD, 2010, J BIOL CHEM
   Takahashi A, 2005, ARCH BIOCHEM BIOPHYS, V437, P233, DOI 10.1016/j.abb.2005.03.017
   Tanaka H, 2009, P NATL ACAD SCI USA, V106, P15633, DOI 10.1073/pnas.0907572106
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Wang CY, 1999, P NATL ACAD SCI USA, V96, P10367, DOI 10.1073/pnas.96.18.10367                                                        
   Willey RL, 1996, J VIROL, V70, P6431
   Yuste E, 2004, J VIROL, V78, P6775, DOI 10.1128/JVI.78.13.6775-6785.2004
   Zeitlin L, 2009, P NATL ACAD SCI USA, V106, P6029, DOI 10.1073/pnas.0902239106
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m
NR 58
TC 20
Z9 22
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 15
PY 2010
VL 5
IS 6
AR e11143
DI 10.1371/journal.pone.0011143
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 610YF
UT WOS:000278775900027
PM 20559567
OA gold
DA 2018-01-05
ER

PT J
AU das Neves, J
   Sarmento, B
   Amiji, MM
   Bahia, MF
AF das Neves, Jose
   Sarmento, Bruno
   Amiji, Mansoor M.
   Bahia, Maria Fernanda
TI Development and validation of a rapid reversed-phase HPLC method for the
   determination of the non-nucleoside reverse transcriptase inhibitor
   dapivirine from polymeric nanoparticles
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Dapivirine; HIV-1; Antiretroviral; Microbicides; RP-HPLC;
   Poly(lactic-co-glycolic acid); Nanoparticles
ID INTRAVAGINAL RING; GEL FORMULATION; TMC120; HIV-1; MICROBICIDES;
   DELIVERY
AB The objective of this work was to develop and validate a rapid reversed-phase (RP) high-performance liquid chromatography (HPLC) method for the in vitro pharmaceutical characterization of dapivirine-loaded polymeric nanoparticles. Chromatographic runs were performed on a RP C18 column with a mobile phase comprising acetonitrile-0.5% (w/v) triethanolamine solution in isocratic mode (80:20, v/v) at a flow rate of 1 ml/min. Dapivirine was detected at a wavelength of 290 nm. The method was shown to be specific, linear in the range of 1-50 mu g/ml (R(2) =0.9998), precise at the intra-day and inter-day levels as reflected by the relative standard deviation values (less than 0.85%), accurate (recovery rate of 100.17 +/- 0.35%), and robust to changes in the mobile phase and column brand. The detection and quantitation limits were 0.08 and 0.24 mu g/ml, respectively. The method was successfully used to determine the loading capacity and association efficiency of dapivirine in poly(lactic-co-glycolic acid)-based nanoparticles and its in vitro release. (C) 2010 Elsevier B.V. All rights reserved.
C1 [das Neves, Jose; Sarmento, Bruno; Bahia, Maria Fernanda] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, P-4050047 Oporto, Portugal.
   [Sarmento, Bruno] Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, Hlth Sci Res Ctr, Gandra, Portugal.
   [Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
RP das Neves, J (reprint author), Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Anibal Cunha 164, P-4050047 Oporto, Portugal.
EM j.dasneves@gmail.com
RI Amiji, Mansoor/A-4365-2014; Sarmento, Bruno/J-6265-2013; das Neves,
   Jose/J-8369-2013
OI Amiji, Mansoor/0000-0001-6170-881X; Sarmento, Bruno/0000-0001-5763-7553;
   das Neves, Jose/0000-0002-2317-2759
FU Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BD/43393/2008]
FX Jose das Neves is supported by Fundacao para a Ciencia e a Tecnologia,
   Portugal (grant SFRH/BD/43393/2008). The authors are grateful to
   Inovapotek, Pharmaceutical Research and Development, Lda. (Porto,
   Portugal) for technical HPLC hardware assistance.
CR BUGADA DC, 1985, J APPL POLYM SCI, V30, P4137, DOI 10.1002/app.1985.070301015                                                      
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   FAHEEM A, 2009, P 16 C RETR OPP INF
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   International Conference on Harmonization H.T.G., 2005, Q2R1 ICH
   Jespers VA, 2007, JAIDS-J ACQ IMM DEF, V44, P154, DOI 10.1097/QAI.0b013e31802bb35f
   LAUS G, 2001, J CHEM SOC PERK T, V6, P864
   LoBrutto R., 2007, HPLC PHARM SCI, P455
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   McNair H., 2007, HPLC METHOD DEV PHAR, V8, P459
   Nuttall JP, 2008, ANTIMICROB AGENTS CH, V52, P909, DOI 10.1128/AAC.00330-07
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Shabir GA, 2003, J CHROMATOGR A, V987, P57, DOI 10.1016/S0021-9673(02)01536-4                                                   
   Shabir GA, 2007, J LIQ CHROMATOGR R T, V30, P311, DOI 10.1080/10826070601084753
   Sonnergaard JM, 2006, INT J PHARM, V321, P12, DOI 10.1016/j.ijpharm.2006.06.001
   *TEKN MED SEA, TECHN DAT
   Terrazas-Aranda Katty, 2007, Antiviral Chemistry & Chemotherapy, V18, P141
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 22
TC 22
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD JUN 5
PY 2010
VL 52
IS 2
BP 167
EP 172
DI 10.1016/j.jpba.2010.01.007
PG 6
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 561LV
UT WOS:000274979700001
PM 20117900
DA 2018-01-05
ER

PT J
AU Bhatt, AP
   Bhende, PM
   Sin, SH
   Roy, D
   Dittmer, DP
   Damania, B
AF Bhatt, Aadra P.
   Bhende, Prasanna M.
   Sin, Sang-Hoon
   Roy, Debasmita
   Dittmer, Dirk P.
   Damania, Blossom
TI Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine
   proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
SO BLOOD
LA English
DT Article
ID SARCOMA-ASSOCIATED HERPESVIRUS; PROTEIN-COUPLED RECEPTOR; PRIMARY
   EFFUSION LYMPHOMA; PPAR-GAMMA LIGANDS; K1 PROTEIN; IN-VIVO;
   ENDOTHELIAL-CELLS; KINASE-B; PHOSPHORYLATION; EXPRESSION
AB Primary effusion lymphoma (PEL) constitutes a subset of non-Hodgkin lymphoma whose incidence is highly increased in the context of HIV infection. Kaposisarcoma-associated herpesvirus is the causative agent of PEL. The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a critical role in cell proliferation and survival, and this pathway is dysregulated in many different cancers, including PEL, which display activated PI3K, Akt, and mammalian target of rapamycin (mTOR) kinases. PELs rely heavily on PI3K/Akt/mTOR signaling, are dependent on autocrine and paracrine growth factors, and also have a poor prognosis with reported median survival times of less than 6 months. We compared different compounds that inhibit the PI3K/Akt/mTOR pathway in PEL. Although compounds that modulated activity of only a single pathway member inhibited PEL proliferation, the use of a novel compound, NVP-BEZ235, that dually inhibits both PI3K and mTOR kinases was significantly more efficacious in culture and in a PEL xenograft tumor model. NVP-BEZ235 was effective at low nanomolar concentrations and has oral bioavailability. We also report a novel mechanism for NVP-BEZ235 involving the suppression of multiple autocrine and paracrine growth factors required for lymphoma survival. Our data have broad applicability for the treatment of cytokine-dependent tumors with PI3K/mTOR dual inhibitors. (Blood. 2010; 115(22): 4455-4463)
C1 [Bhatt, Aadra P.; Bhende, Prasanna M.; Sin, Sang-Hoon; Roy, Debasmita; Dittmer, Dirk P.; Damania, Blossom] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Bhatt, Aadra P.; Bhende, Prasanna M.; Sin, Sang-Hoon; Roy, Debasmita; Dittmer, Dirk P.; Damania, Blossom] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
RP Damania, B (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.
EM damania@med.unc.edu
FU National Institutes of Health [CA096500, DE018304]; University Cancer
   Research Fund; University of Pennsylvania [P30-AI045008]; Leukemia &
   Lymphoma Society [6021]; AIDS malignancy consortium [CA121947]; Cancer
   Cell Biology [T32CA071341]
FX B. D. is a Leukemia & Lymphoma Society Scholar, American Heart
   Association established investigator, and a Burroughs Wellcome Fund
   Investigator in Infectious Disease. This work was supported by the
   National Institutes of Health (grant CA096500), University Cancer
   Research Fund and University of Pennsylvania (CFAR pilot project grant
   P30-AI045008; B. D.), as well as the Leukemia & Lymphoma Society (6021),
   the AIDS malignancy consortium (CA121947), and the National Institutes
   of Health (CA DE018304; D. P. D.). A. P. B. was supported by Cancer Cell
   Biology (training grant T32CA071341).
CR Aoki Y, 2000, BLOOD, V96, P1599
   Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2
   Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020
   Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084
   Boulanger E, 2009, HAEMATOL-HEMATOL J, V94, P1170, DOI 10.3324/haematol.2009.007260
   Capello D, 2000, LEUKEMIA, V14, P285, DOI 10.1038/sj.leu.2401666                                                          
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318                                                   
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0                                                                
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   delPeso L, 1997, SCIENCE, V278, P687
   Drexler HG, 1999, LEUKEMIA, V13, P634, DOI 10.1038/sj.leu.2401371
   Faraway J. J., 2006, EXTENDING LINEAR MOD
   Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200
   Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200
   Girnun GD, 2007, CANCER CELL, V11, P395, DOI 10.1016/j.ccr.2007.02.025
   Han SW, 2006, MOL CANCER THER, V5, P430, DOI 10.1158/1535-7163.MCT-05-0347
   Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jones D, 2000, BLOOD, V95, P627
   Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15
   Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Montaner S, 2001, CANCER RES, V61, P2641
   Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200
   Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176
   Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634
   Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06
   Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/01.cad.0000054974.31252.f7
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385
   Sgadari C, 1997, BLOOD, V89, P2635
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Sin SH, 2007, BLOOD, V109, P2165, DOI 10.1182/blood-2006-06-028092
   Sodhi A, 2000, CANCER RES, V60, P4873
   Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101
   Sodhi A, 2006, CANCER CELL, V10, P133, DOI 10.1016/j.ccr.2006.05.026
   Teichmann M, 2005, J PATHOL, V206, P68, DOI 10.1002/path.1745
   Tjin EPM, 2006, BLOOD, V107, P760, DOI 10.1182/blood-2005-05-1929
   Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004
   Tomlinson CC, 2008, J VIROL, V82, P6514, DOI 10.1128/JVI.02637-07
   Wang L, 2006, CANCER RES, V66, P3658, DOI 10.1158/0008-5472.CAN-05-3680
   Wang L, 2004, CANCER RES, V64, P2774, DOI 10.1158/0008-5472.CAN-03-3653
   Wang L, 2008, CANCER RES, V68, P4640, DOI 10.1158/0008-5472.CAN-07-5988
   Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI200112864
NR 49
TC 81
Z9 83
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 3
PY 2010
VL 115
IS 22
BP 4455
EP 4463
DI 10.1182/blood-2009-10-251082
PG 9
WC Hematology
SC Hematology
GA 605UN
UT WOS:000278372600023
PM 20299510
OA gold
DA 2018-01-05
ER

PT J
AU Yadav, R
   Dwivedi, S
   Kumar, S
   Chaudhury, A
AF Yadav, Rakesh
   Dwivedi, Sadhana
   Kumar, Sandeep
   Chaudhury, Ashok
TI Trends and Perspectives of Biosensors for Food and Environmental
   Virology
SO FOOD AND ENVIRONMENTAL VIROLOGY
LA English
DT Review
DE Biosensors; Nanotechnology; Food virology; Microsystems; Noroviruses
ID HEPATITIS-C VIRUS; SURFACE-PLASMON RESONANCE; CRYSTAL MICROBALANCE
   IMMUNOSENSOR; DNA ELECTROCHEMICAL BIOSENSOR;
   HUMAN-IMMUNODEFICIENCY-VIRUS; OPTICAL-FIBER IMMUNOSENSOR;
   ESCHERICHIA-COLI O157-H7; DEPENDENT RNA-POLYMERASE; APTAMER-BASED
   BIOSENSORS; NUCLEIC-ACID
AB Food and environmental virology has become a very important and interesting area of research because of food safety and public health concerns. During the last few decades, increasing foodborne diseases and environmental generated illnesses are considered to be highly challenging issues. Biosensor technology holds great promise for the healthcare market, and the security sector. Similar to clinical diagnostic tools, biosensors are being developed for the rapid, reliable, yet inexpensive identification and enumeration of pathogenic viruses which are adulterating environment, food and feed commodities. In this modern era, bio-and nano-technologies play a pivotal role in virological diagnostics of food industry, environmental and veterinary samples. This review covers the recent advances and future prospects of nanotechnology-based bioanalytical microsystems for food and environmental virology.
C1 [Yadav, Rakesh; Dwivedi, Sadhana; Chaudhury, Ashok] Guru Jambheshwar Univ Sci & Technol, Dept Bio & Nano Technol, Hisar 125001, Haryana, India.
   [Kumar, Sandeep] ICAR Res Complex, Div Biochem, Directorate Rapeseed Mustard Res, Bharatpur 321303, Rajasthan, India.
RP Yadav, R (reprint author), Guru Jambheshwar Univ Sci & Technol, Dept Bio & Nano Technol, Hisar 125001, Haryana, India.
EM ry.yadav01@gmail.com
OI chaudhury, ashok/0000-0002-0383-1497
FU Department of Biotechnology and Department of Science and Technology,
   Govt. of India
FX Authors thank Dr. Suchitra Banerjee for critical reading, valuable
   comments and suggestions on an earlier version of this manuscript. We
   regret all those researchers of this broad and dynamic field whose
   contribution unavoidably cannot be reviewed herein due to scope and
   relevance constraint. We are grateful to Department of Biotechnology and
   Department of Science and Technology, Govt. of India for their financial
   assistance regarding academic and research programs.
CR Abad-Valle P, 2005, BIOSENS BIOELECTRON, V20, P2251, DOI 10.1016/j.bios.2004.10.019
   Baek MG, 2000, BIOCONJUGATE CHEM, V11, P777, DOI 10.1021/bc000026f
   Baert L, 2008, INT J FOOD MICROBIOL, V123, P101, DOI 10.1016/j.ijfoodmicro.2007.12.020
   Baeumner AJ, 2002, ANAL CHEM, V74, P1442, DOI 10.1021/ac015675e
   BEARDS GM, 1988, EUR J CLIN MICROBIOL, V7, P11, DOI 10.1007/BF01962164
   BEARDS GM, 1984, J CLIN MICROBIOL, V19, P248
   Bellecave P, 2003, OLIGONUCLEOTIDES, V13, P455, DOI 10.1089/154545703322860771                                                      
   Biroccio A, 2002, J VIROL, V76, P3688, DOI 10.1128/JVI.76.8.3688-3696.2002
   CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021
   Chen X, 1998, BIOSENS BIOELECTRON, V13, P451, DOI 10.1016/S0956-5663(97)00095-X                                                   
   Cho EJ, 2009, ANNU REV ANAL CHEM, V2, P241, DOI 10.1146/annurev.anchem.1.031207.112851
   Cho SY, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni174
   Cliver DO, 2009, FOOD ENVIRON VIROL, V1, P3, DOI 10.1007/s12560-008-9005-2
   Collings AF, 1997, REP PROG PHYS, V60, P1397, DOI 10.1088/0034-4885/60/11/005
   Cooper MA, 2001, NAT BIOTECHNOL, V19, P833, DOI 10.1038/nbt0901-833
   Culha M, 2003, ANAL CHEM, V75, P6196, DOI 10.1021/ac0346003
   de Cal IW, 2007, CLIN MICROBIOL INFEC, V13, P341, DOI 10.1111/j.1469-0691.2006.01594.x
   Dhawan MD, 2002, ANAL BIOANAL CHEM, V374, P421, DOI 10.1007/s00216-002-1489-2
   Donaldson KA, 2004, BIOSENS BIOELECTRON, V20, P322, DOI 10.1016/j.bios.2004.01.029
   Edvardsson M, 2005, ANAL CHEM, V77, P4918, DOI 10.1021/ac050116j
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Erdem A, 1999, ELECTROANAL, V11, P586
   Eun AJC, 2002, J VIROL METHODS, V99, P71, DOI 10.1016/S0166-0934(01)00382-2                                                   
   Fischer TK, 2004, REV MED VIROL, V14, P71, DOI 10.1002/rmv.411
   Fukushima H, 2007, APPL ENVIRON MICROB, V73, P92, DOI 10.1128/AEM.01772-06
   Gabrieli R, 2009, FOOD ENVIRON VIROL, V1, P92, DOI 10.1007/s12560-009-9014-9
   Gore MR, 2003, ANAL CHEM, V75, P6586, DOI 10.1021/ac034918v
   Grant SA, 2006, SENS LETT, V4, P246, DOI 10.1166/sl.2006.027
   Guix S, 2005, LETT APPL MICROBIOL, V41, P103, DOI 10.1111/j.1472-765X.2005.01759.x
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Holthoff EL, 2007, ACCOUNTS CHEM RES, V40, P756, DOI 10.1021/ar700087t
   Huang JG, 2006, BIOSENS BIOELECTRON, V22, P519, DOI 10.1016/j.bios.2006.07.030
   Ionescu RE, 2007, ANAL CHEM, V79, P8662, DOI 10.1021/ac0707129
   JACKSON BJ, 1993, J RAPID METH AUT MIC, V2, P39
   James W, 2007, J GEN VIROL, V88, P351, DOI 10.1099/vir.0.82442-0
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jaykus LA, 2003, ASM NEWS, V69, P341
   Kelso E, 2000, ELECTROANAL, V12, P490, DOI 10.1002/(SICI)1521-4109(200005)12:7<490::AID-ELAN490>3.0.CO;2-Y
   Kim D, 2008, J MICROBIOL, V46, P436, DOI 10.1007/s12275-008-0131-1
   Koenig Bernd, 1994, Analytical Chemistry, V66, P341, DOI 10.1021/ac00075a005
   Konry T, 2005, ANAL CHEM, V77, P1771, DOI 10.1021/ac048569w
   Krishnan R, 1996, ELECTROANAL, V8, P1131, DOI 10.1002/elan.1140081211
   Panda SK, 2007, REV MED VIROL, V17, P151, DOI 10.1002/rmv.522
   Kwakye S, 2006, BIOSENS BIOELECTRON, V21, P2217, DOI 10.1016/j.bios.2005.11.017
   Larsson K, 1999, ANALUSIS, V27, P617, DOI 10.1051/analusis:1999270617                                                     
   Leclerc M, 1999, ADV MATER, V11, P1491, DOI 10.1002/(SICI)1521-4095(199912)11:18<1491::AID-ADMA1491>3.0.CO;2-O
   Lee S, 2007, BIOCHEM BIOPH RES CO, V358, P47, DOI 10.1016/j.bbrc.2007.04.057
   Liao JC, 2006, J CLIN MICROBIOL, V44, P561, DOI 10.1128/JCM.44.2.561-570.2006
   Liu AH, 2004, ANAL CHEM, V76, P2975, DOI 10.1021/ac0303970                                                               
   Marshall JA, 2006, CLIN LAB, V52, P571
   Mattison K, 2009, FOOD ENVIRON VIROL, V1, P107, DOI 10.1007/s12560-009-9017-6
   Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502                                                          
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Mok W, 2008, SENSORS-BASEL, V8, P7050, DOI 10.3390/s8117050
   Niemeyer C. M., 2004, NANOBIOTECHNOLOGY CO
   Patel DJ, 2000, REV MOL BIOTECHNOL, V74, P39
   Petrosova A, 2007, SENSOR ACTUAT B-CHEM, V122, P578, DOI 10.1016/j.snb.2006.07.005
   PIUNNO PAE, 1995, ANAL CHEM, V67, P2635, DOI 10.1021/ac00111a022
   Prentice N, 2006, J RAPID METH AUT MIC, V14, P299, DOI 10.1111/j.1745-4581.2006.00069.x
   Qi C, 2006, BIOMED MICRODEVICES, V8, P247, DOI 10.1007/s10544-006-8305-2
   REICHERT A, 1995, J AM CHEM SOC, V117, P829, DOI 10.1021/ja00107a032
   Teles FRR, 2007, SENSORS-BASEL, V7, P2510, DOI 10.3390/s7112510
   Rowe-Taitt CA, 2000, BIOSENS BIOELECTRON, V14, P785, DOI 10.1016/S0956-5663(99)00052-4
   RYAN KJ, 2004, SHERRIS MED MICROBIO, P247
   Sabzi RE, 2008, J IRAN CHEM SOC, V5, P476, DOI 10.1007/BF03246005                                                              
   Sato T, 1996, BBA-BIOMEMBRANES, V1285, P14, DOI 10.1016/S0005-2736(96)00138-1                                                   
   Schofield DJ, 2000, J VIROL, V74, P5548, DOI 10.1128/JVI.74.12.5548-5555.2000
   Schofield DJ, 1996, J VIROL METHODS, V62, P33, DOI 10.1016/0166-0934(96)02086-1                                                    
   SCHOTTER J, 2004, THESIS U BIELEFELD G
   SMITH TF, 1993, INFECT DIS CLIN N AM, V7, P183
   Sobarzo A, 2007, J VIROL METHODS, V146, P327, DOI 10.1016/j.jviromet.2007.07.017
   Song LN, 2006, ANAL CHEM, V78, P1023, DOI 10.1021/ac051417w
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Su CC, 2003, ANAL CHIM ACTA, V479, P117, DOI 10.1016/S0003-2670(02)01529-5
   Su SX, 2008, BIOMACROMOLECULES, V9, P935, DOI 10.1021/bm7013608
   Su SX, 2007, LANGMUIR, V23, P1300, DOI 10.1021/la060961c
   Susmel S, 2000, ENZYME MICROB TECH, V27, P639, DOI 10.1016/S0141-0229(00)00196-4
   Tudorache M, 2007, ANAL BIOANAL CHEM, V388, P565, DOI 10.1007/s00216-007-1293-0
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Turner APF, 2000, SCIENCE, V290, P1315, DOI 10.1126/science.290.5495.1315
   Uttenthaler E, 2001, BIOSENS BIOELECTRON, V16, P735, DOI 10.1016/S0956-5663(01)00220-2
   Uttenthaler E, 1998, BIOSENS BIOELECTRON, V13, P1279, DOI 10.1016/S0956-5663(98)00089-X
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Warren BR, 2006, J RAPID METH AUT MIC, V14, P309, DOI 10.1111/j.1745-4581.2006.00060.x
   Wu SJL, 2001, J CLIN MICROBIOL, V39, P2794, DOI 10.1128/JCM.39.8.2794-2798.2001
   Wu VCH, 2004, J RAPID METH AUT MIC, V12, P57, DOI 10.1111/j.1745-4581.2004.tb00047.x                                              
   Xie H, 2004, ANAL CHEM, V76, P1611, DOI 10.1021/ac0350965
   Xu J, 2007, ANAL BIOANAL CHEM, V389, P1193, DOI 10.1007/s00216-007-1525-3
   Yu JS, 2006, J VIROL METHODS, V137, P219, DOI 10.1016/j.jviromet.2006.06.014
   Zaytseva NV, 2005, LAB CHIP, V5, P805, DOI 10.1039/b503856a
   Zaytseva NV, 2004, ANAL BIOANAL CHEM, V380, P46, DOI 10.1007/s00216-004-2724-9
   Zhou XD, 2002, J PHARMACEUT BIOMED, V27, P341, DOI 10.1016/S0731-7085(01)00538-6                                                   
   Zuo BL, 2004, ANAL CHEM, V76, P3536, DOI 10.1021/ac035367b                                                               
NR 94
TC 15
Z9 15
U1 0
U2 60
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1867-0334
EI 1867-0342
J9 FOOD ENVIRON VIROL
JI Food Environ. Virol.
PD JUN
PY 2010
VL 2
IS 2
BP 53
EP 63
DI 10.1007/s12560-010-9034-5
PG 11
WC Environmental Sciences; Microbiology; Virology
SC Environmental Sciences & Ecology; Microbiology; Virology
GA 618KB
UT WOS:000279350500001
DA 2018-01-05
ER

PT J
AU Ramsey, JD
   Vu, HN
   Pack, DW
AF Ramsey, Joshua D.
   Vu, Halong N.
   Pack, Daniel W.
TI A top-down approach for construction of hybrid polymer-virus gene
   delivery vectors
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Gene delivery; Polyethylenimine; Polylysine; Murine leukemia virus;
   Hybrid vectors
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADENOASSOCIATED VIRUS; DIRECTED EVOLUTION;
   IN-VIVO; THERAPY; CELLS; POLYETHYLENIMINE; GLYCOPROTEIN; TRANSFECTION;
   RETROVIRUS
AB Safe and efficient delivery of therapeutic nucleic acids remains the primary hurdle for human gene therapy. While many researchers have attempted to re-engineer viruses to be suited for gene delivery, others have sought to develop non-viral alternatives. We have developed a complementary approach in which viral and synthetic components are combined to form hybrid nanoparticulate vectors. In particular, we complexed non-infectious retrovirus-like particles lacking a viral envelope protein, from Moloney murine leukemia virus (M-VLP) or human immunodeficiency virus (H-VLP), with poly-L-lysine (PLL) or polyethylenimine (PEI) over a range of polymer/VLP ratios. At appropriate stoichiometry (75-250 mu g polymer/10(6) VLP), the polymers replace the function of the viral envelope protein and interact with the target cell membrane, initiate cellular uptake and facilitate escape from endocytic vesicles. The viral particle, once in the cytosol, efficiently completes its normal infection process including integration of viral genes with the host genome as demonstrated by long-term (at least 5 weeks) transgene expression. In addition, hybrid vectors comprising H-VLP were shown to be capable of infecting non-dividing cells. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ramsey, Joshua D.; Vu, Halong N.; Pack, Daniel W.] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
RP Pack, DW (reprint author), Univ Illinois, Dept Chem & Biomol Engn, Box C-3,600 S Mathews Ave, Urbana, IL 61801 USA.
EM dpack@illinois.edu
FU National Science Foundation [CBET 06-02636]
FX We thank Sandy McMasters at the SCS Cell Media Facility for her advice
   and assistance with the cell lines used in this study and Lou Ann Miller
   at the UIUC Center for Microscopic Imaging for her assistance with the
   transmission electron microscopy. We are grateful for the financial
   support of the National Science Foundation (CBET 06-02636).
CR Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947                                                      
   Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104
   Anderson WF, 2002, HUM GENE THER, V13, P1261, DOI 10.1089/104303402760128496                                                      
   BASHFORD CL, 1986, J BIOL CHEM, V261, P9300
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0
   BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580                                                         
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033
   Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   COFFIN JM, 1996, FIELDS VIROLOGY, P1767
   DeLong R, 1997, J PHARM SCI, V86, P762, DOI 10.1021/js960409f                                                               
   Doody AM, 2006, J CONTROL RELEASE, V116, P227, DOI 10.1016/j.jcornel.2006.07.019
   GAD AE, 1982, BIOCHIM BIOPHYS ACTA, V690, P124, DOI 10.1016/0005-2736(82)90246-2
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hedley SJ, 2006, GENE THER, V13, P88, DOI 10.1038/sj.gt.3302603
   Jung Y, 2007, J CONTROL RELEASE, V123, P164, DOI 10.1016/j.jconrel.2007.08.002
   Koerber JT, 2009, MOL THER, V17, P2088, DOI 10.1038/mt.2009.184
   Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110
   LEWIS PF, 1994, J VIROL, V68, P510
   Li SD, 2007, J CONTROL RELEASE, V123, P181, DOI 10.1016/j.jconrel.2007.09.004
   Maheshri N, 2006, NAT BIOTECHNOL, V24, P198, DOI 10.1038/nbt1182
   MARTELLO F, 2008, J CONTROL RELEASE, V132, P10
   MCGRATH M, 1978, J VIROL, V25, P923
   Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Powell SK, 2000, NAT BIOTECHNOL, V18, P1279, DOI 10.1038/82391                                                                   
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132
   van Beusechem VW, 2000, GENE THER, V7, P1940, DOI 10.1038/sj.gt.3301323
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Vu HN, 2008, MOL THER, V16, P308, DOI 10.1038/sj.mt.6300350
   Yu JH, 2005, ADV BIOCHEM ENG BIOT, V99, P147, DOI 10.1007/10_006
   Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5
   Zuhorn IS, 2007, EUR BIOPHYS J BIOPHY, V36, P349, DOI 10.1007/s00249-006-0092-4
   GENE THERAPY CLIN TR
NR 35
TC 24
Z9 24
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 21
PY 2010
VL 144
IS 1
BP 39
EP 45
DI 10.1016/j.jconrel.2010.01.031
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 608IQ
UT WOS:000278577500007
PM 20117154
DA 2018-01-05
ER

PT J
AU Miller, JF
   Gudmundsson, KS
   Richardson, LD
   Jenkinson, S
   Spaltenstein, A
   Thomson, M
   Wheelan, P
AF Miller, John F.
   Gudmundsson, Kristjan S.
   Richardson, Leah D'Aurora
   Jenkinson, Stephen
   Spaltenstein, Andrew
   Thomson, Michael
   Wheelan, Pat
TI Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent
   anti-HIV activity
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CXCR4; Isoquinoline; Tetrahydroquinoline; AMD070; HIV; Antiviral
ID ENTRY INHIBITORS; THERAPY; CORECEPTOR; TYPE-1
AB Using AMD070 as a starting point for structural modification, a novel series of isoquinoline CXCR4 antagonists was developed. A structure-activity scan of alternate lower heterocycles led to the 3-isoquinolinyl moiety as an attractive replacement for benzimidazole. Side chain optimization in the isoquinoline series led to a number of compounds with low nanomolar anti-HIV activities and promising rat PK properties. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Miller, John F.; Gudmundsson, Kristjan S.; Richardson, Leah D'Aurora; Spaltenstein, Andrew] GlaxoSmithKline Res & Dev Ltd, Dept Med Chem, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Thomson, Michael] GlaxoSmithKline Res & Dev Ltd, Dept Virol, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Wheelan, Pat] GlaxoSmithKline Res & Dev Ltd, Dept DMPK, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Jenkinson, Stephen] GlaxoSmithKline Res & Dev Ltd, Dept Biochem & Analyt Pharmacol, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
RP Miller, JF (reprint author), GlaxoSmithKline Res & Dev Ltd, Dept Med Chem, Infect Dis Ctr Excellence Drug Discovery, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM john.6.miller@gsk.com
CR Agrawal L, 2006, CURR PHARM DESIGN, V12, P2031, DOI 10.2174/138161206777442100
   Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941
   Grande F, 2008, CURR PHARM DESIGN, V14, P385
   Gudmundsson KS, 2009, BIOORG MED CHEM LETT, V19, P6399, DOI 10.1016/j.bmcl.2009.09.056
   Gudmundsson KS, 2009, BIOORG MED CHEM LETT, V19, P5048, DOI 10.1016/j.bmcl.2009.07.037
   Hatse S, 2001, MOL PHARMACOL, V60, P164
   Kazmierski WM, 2007, ANNU REP MED CHEM, V42, P301, DOI 10.1016/S0065-7743(07)42019-X
   Kelly TR, 2002, J ORG CHEM, V67, P2197, DOI 10.1021/jo016250v
   Kuritzkes DR, 2009, CURR OPIN HIV AIDS, V4, P82, DOI 10.1097/COH.0b013e328322402e
   Mosley CA, 2009, EXPERT OPIN THER PAT, V19, P23, DOI 10.1517/13543770802553483
   Moyle G, 2009, CLIN INFECT DIS, V48, P798, DOI 10.1086/597097
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354
   BRIDGER G, 2004, Patent No. 2004020992
   GUDMUNDSSON K, 2006, Patent No. 2006020415
   BRIDGER G, 2004, Patent No. 20040019058
   BRIDGER GJ, 2003, Patent No. 2003055876
NR 17
TC 20
Z9 20
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 15
PY 2010
VL 20
IS 10
BP 3026
EP 3030
DI 10.1016/j.bmcl.2010.03.118
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 590RY
UT WOS:000277246300003
PM 20443225
DA 2018-01-05
ER

PT J
AU Rose, T
   Pillet, AH
   Lavergne, V
   Tamarit, B
   Lenormand, P
   Rousselle, JC
   Namane, A
   Theze, J
AF Rose, Thierry
   Pillet, Anne-Helene
   Lavergne, Vincent
   Tamarit, Blanche
   Lenormand, Pascal
   Rousselle, Jean-Claude
   Namane, Abdelkader
   Theze, Jacques
TI Interleukin-7 Compartmentalizes Its Receptor Signaling Complex to
   Initiate CD4 T Lymphocyte Response
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID THYMIC STROMAL LYMPHOPOIETIN; HIV-INFECTED PATIENTS; PLASMA-MEMBRANE;
   CELL HOMEOSTASIS; ERM PROTEINS; IL-7; CYTOSKELETON; CLONING; EZRIN;
   ACTIVATION
AB Interleukin (IL)-7 is a central cytokine that controls homeostasis of the CD4 T lymphocyte pool. Here we show on human primary cells that IL-7 binds to preassembled receptors made up of proprietary chain IL-7R alpha and the common chain gamma c shared with IL-2, -4, -9, -15, and -21 receptors. Upon IL-7 binding, both chains are driven in cholesterol-and sphingomyelin-rich rafts where associated signaling proteins Jak1, Jak3, STAT1, -3, and -5 are found to be phosphorylated. Meanwhile the IL-7 center dot IL-7R complex interacts with the cytoskeleton that halts its diffusion as measured by single molecule fluorescence autocorrelated spectroscopy monitored by microimaging. Comparative immunoprecipitations of IL-7R alpha signaling complex from non-stimulated and IL-7-stimulated cells confirmed recruitment of proteins such as STATs, but many others were also identified by mass spectrometry from two-dimensional gels. Among recruited proteins, two-thirds are involved in cytoskeleton and raft formation. Thus, early events leading to IL-7 signal transduction involve its receptor compartmentalization into membrane nanodomains and cytoskeleton recruitment.
C1 [Lenormand, Pascal; Rousselle, Jean-Claude; Namane, Abdelkader] Plate Forme Prote, F-75724 Paris 15, France.
   [Theze, Jacques] Inst Pasteur, Unite Immunogenet Cellulaire, Dept Infect & Epidemiol, Dept Immunol, F-75724 Paris 15, France.
EM rose@pasteur.fr
RI Namane, Abdelkader/O-1857-2013
OI Namane, Abdelkader/0000-0001-7180-7619; ROSE,
   Thierry/0000-0001-8863-0207
FU Institut Pasteur
FX This work was supported in part by the Institut Pasteur.
CR Alves NL, 2008, J IMMUNOL, V180, P5201, DOI 10.4049/jimmunol.180.8.5201                                                     
   ANDREOLI C, 1994, J CELL SCI, V107, P2509
   Bacia K, 2007, NAT PROTOC, V2, P2842, DOI 10.1038/nprot.2007.410
   Bolotin E, 1999, BONE MARROW TRANSPL, V23, P783, DOI 10.1038/sj.bmt.1701655                                                          
   Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882
   Brikos C, 2007, MOL CELL PROTEOMICS, V6, P1551, DOI 10.1074/mcp.M600455-MCP200
   Chichili GR, 2009, CELL MOL LIFE SCI, V66, P2319, DOI 10.1007/s00018-009-0022-6
   Colle JH, 2007, AIDS, V21, P101, DOI 10.1097/QAD.0b013e3280115b6a
   Colle JH, 2006, CLIN EXP IMMUNOL, V143, P398, DOI 10.1111/j.1365-2249.2006.03022.x
   Eckenberg R, 2000, J EXP MED, V191, P529, DOI 10.1084/jem.191.3.529
   Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.jbbamcr.2006.06.013
   Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571                                                    
   Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2
   GARY R, 1995, MOL BIOL CELL, V6, P1061
   Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0
   GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C
   GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302
   Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37
   Jiang Q, 2004, MOL CELL BIOL, V24, P6501, DOI 10.1128/MCB.24.14.6501-6513.2004
   Khaled AR, 2002, IMMUNITY, V17, P561, DOI 10.1016/S1074-7613(02)00450-8
   Lasserre R, 2008, NAT CHEM BIOL, V4, P538, DOI 10.1038/nchembio.103
   Lee SK, 2005, IMMUNOL REV, V208, P169, DOI 10.1111/j.0105-2896.2005.00339.x
   Lenne PF, 2006, EMBO J, V25, P3245, DOI 10.1038/sj.emboj.7601214
   Leonard WJ, 1999, COLD SPRING HARB SYM, V64, P417, DOI 10.1101/sqb.1999.64.417
   Lopez-Perez M, 2006, INT J BIOCHEM CELL B, V38, P1716, DOI 10.1016/j.biocel.2006.04.001
   Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727
   Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5
   McElroy CA, 2009, STRUCTURE, V17, P54, DOI 10.1016/j.str.2008.10.019
   Napolitano LA, 2001, NAT MED, V7, P73
   NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1
   Palmer MJ, 2008, CELL MOL IMMUNOL, V5, P79, DOI 10.1038/cmi.2008.10
   Pandey A, 2000, NAT IMMUNOL, V1, P59
   Park JH, 2004, IMMUNITY, V21, P289, DOI 10.1016/j.immuni.2004.07.016
   Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659
   Pillet AH, 2008, EUR CYTOKINE NETW, V19, P49, DOI 10.1684/ecn.2008.0120
   Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580
   Rose T, 2003, J BIOL CHEM, V278, P22868, DOI 10.1074/jbc.M301757200
   Rose T, 2009, J IMMUNOL, V182, P7389, DOI 10.4049/jimmunol.0900190
   Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681
   Stroud Robert M, 2004, Sci STKE, V2004, pre7, DOI 10.1126/stke.2312004re7
   Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371
   THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178
   Zoubiane GS, 2004, J CELL SCI, V117, P271, DOI 10.1242/jcs.00855
NR 43
TC 22
Z9 24
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 14
PY 2010
VL 285
IS 20
BP 14898
EP 14908
DI 10.1074/jbc.M110.104232
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 592SB
UT WOS:000277399000011
PM 20167604
OA gold
DA 2018-01-05
ER

PT J
AU Dev, A
   Binulal, NS
   Anitha, A
   Nair, SV
   Furuike, T
   Tamura, H
   Jayakumar, R
AF Dev, Ashish
   Binulal, N. S.
   Anitha, A.
   Nair, S. V.
   Furuike, T.
   Tamura, H.
   Jayakumar, R.
TI Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV
   drug delivery applications
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Poly(lactic acid); Chitosan; Lamivudine drug; Emulsion; Nanoparticles;
   Controlled drug delivery
ID SOLVENT EVAPORATION TECHNIQUE; CHITOSAN; DEGRADATION; MICROSPHERES;
   SCAFFOLDS; BEHAVIOR; THERAPY; RELEASE; TABLETS
AB Poly(lactic acid) (PLA)/chitosan (CS) nanoparticles were prepared by emulsion method for anti-HIV drug delivery applications. The prepared PLA/CS nanoparticles were characterized using DLS, SEM, and FTIR. The hydrophilic antiretroviral drug Lamivudine was loaded into PLA/CS nanoparticles. The encapsulation efficiency and in-vitro drug release behaviour of drug loaded PLA/CS nanoparticles were studied using UV spectrophotometer. In addition, the cytotoxicity of the PLA/CS nanoparticles using MTT assay was also studied. The in-vitro drug release studies showed that drug release rate was lower in the acidic pH when compared to alkaline pH. This may due to repulsion between H ions and cationic groups present in the polymeric nanoparticles. Drug release rate was found to be higher in the 6% drug loaded formulation when compared to 6% drug loaded formulation. These results indicated that the PLA/CS nanoparticles are a promising carrier system for controlled delivery of anti-HIV drugs. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Dev, Ashish; Binulal, N. S.; Anitha, A.; Nair, S. V.; Jayakumar, R.] Amrita Vishwa Vidhyapeetham Univ, Amrita Ctr Nanosci & Mol Med, Amrita Inst Med Sci, Cochin 682041, Kerala, India.
   [Dev, Ashish; Binulal, N. S.; Anitha, A.; Nair, S. V.; Jayakumar, R.] Amrita Vishwa Vidhyapeetham Univ, Res Ctr, Cochin 682041, Kerala, India.
   [Furuike, T.; Tamura, H.] Kansai Univ, Fac Chem Mat & Bioengn, Osaka 5648680, Japan.
   [Furuike, T.; Tamura, H.] Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan.
RP Jayakumar, R (reprint author), Amrita Vishwa Vidhyapeetham Univ, Amrita Ctr Nanosci & Mol Med, Amrita Inst Med Sci, Cochin 682041, Kerala, India.
EM rjayakumar@aims.amrita.edu
RI Sudheesh Kumar, Anitha/I-3739-2016
OI Sudheesh Kumar, Anitha/0000-0003-0964-741X
FU Department of Biotechnology (DBT), Govt. of India; Nanomission,
   Department of Science and Technology, India
FX The authors are thankful to Department of Biotechnology (DBT), Govt. of
   India, for their financial support for this work under the Nanoscience
   and Nanotechnology Initiative Program. This work was also partially
   supported by Nanomission, Department of Science and Technology, India
   under the Nanoinitiative Program monitored by Prof. C.N.R. Rao.
CR Agnihotri SA, 2004, J CONTROL RELEASE, V96, P245, DOI 10.1016/j.jconrel.2004.01.025
   Anderson KS, 2002, BBA-MOL BASIS DIS, V1587, P296, DOI 10.1016/S0925-4439(02)00092-3
   Bajaj A., 2006, PHARMA TIMES, V38, P12
   BERGSMA JE, 1995, BIOMATERIALS, V16, P25, DOI 10.1016/0142-9612(95)91092-D
   Caroline MP, 1997, DRUGS, V53, P7
   CHEN YW, 1992, CONCEPT SYSTEM DESIG
   CLERCQ ED, 2002, BIOCHIM BIOPHYS ACTA, V158, P257
   Dutta J., 2005, ASIAN CHITIN J, V1, P79
   Fernandes C, 2006, J PHARMACEUT BIOMED, V42, P601, DOI 10.1016/j.jpba.2006.05.009
   Gonzalez MF, 1999, J APPL POLYM SCI, V71, P1223, DOI 10.1002/(SICI)1097-4628(19990222)71:8<1223::AID-APP2>3.0.CO;2-I                 
   Inez MV, 2003, VACCINE, V21, P13
   Jayakumar R, 2007, INT J BIOL MACROMOL, V40, P175, DOI 10.1016/j.ijbiomac.2006.06.021
   Jayakumar R, 2007, DRUG DELIV, V14, P9, DOI 10.1080/10717540600739872
   Jayakumar R, 2005, CARBOHYD POLYM, V62, P142, DOI 10.1016/j.carbpol.2005.07.017
   Jayakumar R, 2010, BIOTECHNOL ADV, V28, P142, DOI 10.1016/j.biotechadv.2009.11.001
   Jayakumar R, 2010, CARBOHYD POLYM, V79, P1, DOI 10.1016/j.carbpol.2009.08.026
   Jozwiakowski MJ, 1996, J PHARM SCI, V85, P193, DOI 10.1021/js9501728
   Kao JH, 2000, J HEPATOL, V33, P998, DOI 10.1016/S0168-8278(00)80135-X
   KHOR E, 2001, CHITIN FULFILLING BI
   Kim K, 2003, BIOMATERIALS, V24, P4977, DOI 10.1016/S0142-9612(03)00407-1
   Lathia JD, 2004, ULTRASONICS, V42, P763, DOI 10.1016/j.ultras.2003.12.018
   Ma ZW, 2003, J BIOMED MATER RES B, V67B, P610, DOI 10.1002/jbm.b.10049
   Muzzarelli R.A.A., 1977, CHITIN, P1
   ODonnell PB, 1997, ADV DRUG DELIVER REV, V28, P25, DOI 10.1016/S0169-409X(97)00049-5                                                   
   Park SJ, 2004, J COLLOID INTERF SCI, V271, P336, DOI 10.1016/j.jcis.2003.08.067
   Prabaharan M, 2005, DRUG DELIV, V12, P41, DOI 10.1080/10717540590889781
   Prabaharan M, 2009, BIOMATERIALS, V30, P3009, DOI 10.1016/j.biomaterials.2009.02.011
   Proikakis CS, 2006, EUR POLYM J, V42, P3269, DOI 10.1016/j.eurpolymj.2006.08.023
   Roberts G. A. F., 1992, CHITIN CHEM
   Shin ILG, 1998, J CONTROL RELEASE, V51, P1
   Suh H, 2001, BIOMATERIALS, V22, P219, DOI 10.1016/S0142-9612(00)00177-0
   YZDANIAN M, 1999, J PHARM SCI, V88, P950
   Zhao Y, 2004, MACROMOL BIOSCI, V4, P901, DOI 10.1002/mabi.200400072
NR 33
TC 84
Z9 90
U1 4
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD MAY 5
PY 2010
VL 80
IS 3
BP 833
EP 838
DI 10.1016/j.carbpol.2009.12.040
PG 6
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 587JM
UT WOS:000276987800029
DA 2018-01-05
ER

PT J
AU Tang, YL
   Achyuthan, KE
   Whitten, DG
AF Tang, Yanli
   Achyuthan, Komandoor E.
   Whitten, David G.
TI Label-free and Real-Time Sequence Specific DNA Detection Based on
   Supramolecular Self-assembly
SO LANGMUIR
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CATIONIC CONJUGATED POLYMERS; NUCLEIC-ACID
   PROBES; ELECTROCHEMICAL BIOSENSOR; CIRCULAR-DICHROISM; HYBRIDIZATION;
   IMMOBILIZATION; NANOPARTICLES; RECOGNITION; SELECTIVITY
AB A new label-free, optical method was developed to detect sequence-specific DNA based on supramolecular self-assembly. A cationic phenylene ethynylene oligomer with two pairs of positively charged side chains (OPE-2) can form a J-dimer or J-aggregate with negatively charged DNA by a combination of electrostatic and hydrophobic interactions. At mu M concentrations of dsDNA (number of bases in ssDNA ranges from 8 to 32), the optimum supramolecular self-assembly occurs between OPE-2 and dsDNA and is characterized by a new absorption peak emerging, at 418 am and an increase in fluorescence intensity (about 4.5-fold for dsDNA(1)). In contrast, the self-assembled complexes between OPE-2 and ssDNA are less readily formed under the same conditions. Interestingly, the induced circular dichroism (CD) signal for OPE-2/ssDNA is quite strong, likely owing to the self-assembly onto ssDNA simultaneously templating helix formation. In contrast, the induced CD signal for OPE-2/dsDNA is weak, likely because the dsDNA is in a double helix conformation, and OPE-2 associated with the dsDNA should be outside of the helix. In fact, there is a steady decrease in the induced CD signal for ssDNA with the addition of equimolar complementary ssDNA over time that allows the monitoring of DNA hybridization in real time. Introduction of mismatched bases into the target DNA sequence prevents the full hybridization between ssDNA and the target DNA. For these cases, the decrease in the induced CD signals occurs more slowly and to a lesser extent, as sonic of the unhybridized portions may remain in helical association with OPE-2. In view of these observed signal changes, sequence specific DNA and single nucleotide mismatch can be detected in a very simple and sensitive manner without any modification of the DNA.
C1 [Tang, Yanli; Whitten, David G.] Univ New Mexico, Ctr Biomed Engn, Albuquerque, NM 87131 USA.
   [Tang, Yanli; Whitten, David G.] Univ New Mexico, Dept Chem & Nucl Engn, Albuquerque, NM 87131 USA.
   [Achyuthan, Komandoor E.] Sandia Natl Labs, Biosensors & Nanomat Dept, Albuquerque, NM 87185 USA.
RP Whitten, DG (reprint author), Univ New Mexico, Ctr Biomed Engn, Albuquerque, NM 87131 USA.
RI Tang, Yanli/F-9636-2015
FU Defense Threat Reduction Agency Joint Science and Technology Office
   (DTRA-JSTO) [MIPR9-FO89XR052-0, AA07CBT008, MIPR9FO89XR076,
   HDTRA1-07-BRCWMD]
FX We thank the Defense Threat Reduction Agency Joint Science and
   Technology Office (DTRA-JSTO) for funding these investigations through
   Project No. MIPR9-FO89XR052-0, Contract AA07CBT008 (DGW), Project No.
   MIPR9FO89XR076, Contract AA07CBT008(KEA), and through Grant No.
   HDTRA1-07-BRCWMD.
CR Alfonta L, 2001, ANAL CHEM, V73, P91, DOI 10.1021/ac00819v
   Boman FC, 2009, J AM CHEM SOC, V131, P844, DOI 10.1021/ja808007b
   Caruso F, 1997, ANAL CHEM, V69, P2043, DOI 10.1021/ac961220r
   Duan XR, 2007, J AM CHEM SOC, V129, P4154, DOI 10.1021/ja070452c
   Feng XL, 2008, LANGMUIR, V24, P12138, DOI 10.1021/la802932t
   Ganguly A, 2009, J MATER CHEM, V19, P928, DOI 10.1039/b816556d
   Gaylord BS, 2002, P NATL ACAD SCI USA, V99, P10954, DOI 10.1073/pnas.162375999
   He F, 2006, J AM CHEM SOC, V128, P6764, DOI 10.1021/ja058075w
   He F, 2005, J AM CHEM SOC, V127, P12343, DOI 10.1021/ja051507i
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Ho HA, 2002, ANGEW CHEM INT EDIT, V41, P1548, DOI 10.1002/1521-3773(20020503)41:9<1548::AID-ANIE1548>3.0.CO;2-I                   
   Katz E, 2005, J AM CHEM SOC, V127, P9191, DOI 10.1021/ja0517771
   Kim OK, 2006, J AM CHEM SOC, V128, P510, DOI 10.1021/ja0533141
   Komurian-Pradel F, 2001, J VIROL METHODS, V95, P111, DOI 10.1016/S0166-0934(01)00300-7
   Kushon SA, 2002, LANGMUIR, V18, P7245, DOI 10.1021/la026211u
   Li K, 2009, ANAL CHEM, V81, P4099, DOI 10.1021/ac9003985
   Liu B, 2004, CHEM MATER, V16, P4467, DOI 10.1021/cm049587x
   Liu Y, 2009, CHEM COMMUN, P665, DOI 10.1039/b819526a
   Marrazza G, 2000, CLIN CHEM, V46, P31
   Martin SR, 2008, METHOD CELL BIOL, V84, P263, DOI 10.1016/S009l-679X(07)84010-6
   Martinez MT, 2009, NANO LETT, V9, P530, DOI 10.1021/nl8025604
   NUNES JA, 1993, ANAL CHEM, V65, P2990, DOI 10.1021/ac00069a009
   PALECEK E, 2002, CRIT REV ANAL CHEM, P32
   Pu KY, 2009, ADV FUNCT MATER, V19, P1371, DOI 10.1002/adfm.200801653
   Rant U, 2007, P NATL ACAD SCI USA, V104, P17364, DOI 10.1073/pnas.0703974104
   Raymond FR, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-10
   Ren XS, 2009, LANGMUIR, V25, P43, DOI 10.1021/la803430g
   SEVALL JS, 1993, CLIN CHEM, V39, P433
   SOUTHERN E, 1999, NAT GENET, P21
   Steichen M, 2009, LANGMUIR, V25, P4162, DOI 10.1021/la802834a
   Stender H, 2002, J MICROBIOL METH, V48, P1, DOI 10.1016/S0167-7012(01)00340-2                                                   
   Tang YL, 2009, J PHOTOCH PHOTOBIO A, V207, P4, DOI 10.1016/j.jphotochem.2009.03.006
   Tang YL, 2009, LANGMUIR, V25, P21, DOI 10.1021/la803111b
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Tercero N, 2009, J AM CHEM SOC, V131, P4953, DOI 10.1021/ja810051q
   Thelwell N, 2000, NUCLEIC ACIDS RES, V28, P3752, DOI 10.1093/nar/28.19.3752
   Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557                                                    
   Wang H, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf061                                                              
   Wang J, 2003, LANGMUIR, V19, P989, DOI 10.1021/la026697e
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   WANG J, 2002, ELECTROANALYTICAL ME, P27
   WANG L, 1999, COMMENTS MOD PHYS C, V1, P117
   Wang S, 2004, J AM CHEM SOC, V126, P5446, DOI 10.1021/ja035550m
   Wang YS, 2007, ANAL CHEM, V79, P7214, DOI 10.1021/ac0712594
   Zari N, 2009, ANAL LETT, V42, P519, DOI 10.1080/00032710802421897
NR 45
TC 11
Z9 11
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAY 4
PY 2010
VL 26
IS 9
BP 6832
EP 6837
DI 10.1021/la904008v
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 587DV
UT WOS:000276969700111
PM 20030336
DA 2018-01-05
ER

PT J
AU Schlosser, K
   Li, YF
AF Schlosser, Kenny
   Li, Yingfu
TI A Versatile Endoribonuclease Mimic Made of DNA: Characteristics and
   Applications of the 8-17 RNA-Cleaving DNAzyme
SO CHEMBIOCHEM
LA English
DT Review
DE 8-17; catalysis; deoxyribozymes; DNAzymes; enzymes
ID IN-VITRO SELECTION; SYNTHESIZE BRANCHED RNA; CATALYTIC BEACON SENSOR;
   DELTA VIRUS RIBOZYME; HIV-1 TAR RNA; GOLD NANOPARTICLES; NUCLEIC-ACIDS;
   LOGIC GATES; TRANSCRIBED RNA; BASE CATALYSIS
AB Enzymes play a crucial role in all living organisms by accelerating the rates of a myriad of biochemical reactions that are necessary to sustain life. Although the vast majority of known enzymes are made of protein, in recent years it has become increasingly apparent that other molecular formats, like nucleic acids, can also serve in this capacity. DNAzymes (also known as deoxyribozymes) are synthetic enzymes made of short, single strands of deoxyribonucleic acid. These DNA-based enzymes offer the prospect of significant commercial utility, because they are exceptionally stable and can be produced very easily and inexpensively. The study of one particular DNAzyme, known as "8-17", has enhanced our understanding of DNAzyme-mediated catalysis. Moreover, the function of 8-17 has been regarded with special importance because it can catalyze sequence-specific cleavage of RNA, a reaction that has broad implications in biotechnology and biomedical fields. In this review, we explore the creation, characterization, and application of the 8-17 RNA-cleaving DNAzyme.
C1 [Schlosser, Kenny; Li, Yingfu] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada.
   [Schlosser, Kenny; Li, Yingfu] McMaster Univ, Dept Chem & Chem Biol, Hamilton, ON L8N 3Z5, Canada.
RP Li, YF (reprint author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM liying@mcmaster.ca
FU Natural Sciences and Engineering Research Council of Canada; Canadian
   Institutes of Health Research [200903MOP199965]
FX This work was supported by the Natural Sciences and Engineering Research
   Council of Canada (NSERC; Scholarships to K.S. and Discovery Grant to
   Y.L.) and the Canadian Institutes of Health Research (CIHR;
   200903MOP199965). Y.L. is a Canada Research Chair.
CR Achenbach JC, 2005, ANAL CHIM ACTA, V534, P41, DOI 10.1016/j.aca.2004.03.080
   Baum DA, 2008, CELL MOL LIFE SCI, V65, P2156, DOI 10.1007/s00018-008-8029-y
   Beale G, 2003, J DRUG TARGET, V11, P449, DOI 10.1080/1061186042000207039
   Bonaccio M, 2004, NUCLEIC ACIDS RES, V32, P916, DOI 10.1093/nar/gkh250
   Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0
   Breaker RR, 2003, RNA, V9, P949, DOI 10.1261/rna.5670703
   BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4
   Brown AK, 2003, BIOCHEMISTRY-US, V42, P7152, DOI 10.1021/bi027332w
   Bruesehoff PJ, 2002, COMB CHEM HIGH T SCR, V5, P327
   Buchhaupt M, 2007, ANAL BIOCHEM, V361, P102, DOI 10.1016/j.ab.2006.11.001
   Carrigan MA, 2004, BIOCHEMISTRY-US, V43, P11446, DOI 10.1021/bi049898l
   Chakraborti S, 2003, BIOMACROMOLECULES, V4, P568, DOI 10.1021/bm025698i
   Chakraborti S, 2003, MOL THER, V7, P817, DOI 10.1016/S1525-0016(03)00096-0
   Chandra M, 2008, J AM CHEM SOC, V130, P2936, DOI 10.1021/ja7111965
   Chandra M, 2009, NAT CHEM BIOL, V5, P718, DOI 10.1038/nchembio.201
   Chang IH, 2005, ENVIRON SCI TECHNOL, V39, P3756, DOI 10.1021/es040505f
   Chiuman W, 2007, NUCLEIC ACIDS RES, V35, P401, DOI 10.1093/nar/gkl1056
   Coppins RL, 2005, BIOCHEMISTRY-US, V44, P13439, DOI 10.1021/bi0507229
   Coppins RL, 2004, J AM CHEM SOC, V126, P16426, DOI 10.1021/ja045817x
   COWAN JA, 1993, J INORG BIOCHEM, V49, P171, DOI 10.1016/0162-0134(93)80002-Q
   Cruz RPG, 2004, CHEM BIOL, V11, P57, DOI 10.1016/j.chembiol.2003.12.012
   Dalavoy TS, 2008, LAB CHIP, V8, P786, DOI 10.1039/b718624j
   Das SR, 2005, NAT CHEM BIOL, V1, P45, DOI 10.1038/nchembio703
   Dass CR, 2008, MOL CANCER THER, V7, P243, DOI 10.1158/1535-7163.MCT-07-0510
   Donini S, 2007, J BIOL CHEM, V282, P35510, DOI 10.1074/jbc.M706993200
   Emilsson GM, 2003, RNA, V9, P907, DOI 10.1261/rna.5680603
   Faulhammer D, 1997, J MOL BIOL, V269, P188, DOI 10.1006/jmbi.1997.1036
   Faulhammer D, 1996, ANGEW CHEM INT EDIT, V35, P2837, DOI 10.1002/anie.199628371                                                          
   Feldman AR, 2001, J MOL BIOL, V313, P283, DOI 10.1006/jmbi.2001.5058
   Ferrari D, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf111                                                              
   FerreDAmare AR, 1996, NUCLEIC ACIDS RES, V24, P977, DOI 10.1093/nar/24.5.977
   Flynn-Charlebois A, 2003, J AM CHEM SOC, V125, P5346, DOI 10.1021/ja0340331
   Flynn-Charlebois A, 2003, J AM CHEM SOC, V125, P2444, DOI 10.1021/ja028774y
   Geyer CR, 1997, CHEM BIOL, V4, P579, DOI 10.1016/S1074-5521(97)90244-1
   Hollenstein M., 2008, ANGEW CHEM, V120, P4418
   Hollenstein M, 2008, ANGEW CHEM INT EDIT, V47, P4346, DOI 10.1002/anie.200800960
   Hollenstein M, 2009, NUCLEIC ACIDS RES, V37, P1638, DOI 10.1093/nar/gkn1070
   Khan A, 2004, J DRUG TARGET, V12, P393, DOI 10.1080/10611860400003858
   Kim HK, 2008, CHEM-EUR J, V14, P8696, DOI 10.1002/chem.200701789
   Kim HK, 2007, NAT CHEM BIOL, V3, P763, DOI 10.1038/nchembio.2007.45
   Kim HK, 2007, J AM CHEM SOC, V129, P6896, DOI 10.1021/ja0712625
   Kuhns ST, 2003, J MOL EVOL, V56, P711, DOI 10.1007/s00239-002-2445-7
   Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074
   Lapham J, 1996, RNA, V2, P289
   Lederman H, 2006, BIOCHEMISTRY-US, V45, P1194, DOI 10.1021/bi051871u
   Lee NK, 2007, J AM CHEM SOC, V129, P15526, DOI 10.1021/ja0725145
   Lermer L, 2002, J AM CHEM SOC, V124, P9960, DOI 10.1021/ja0205075
   Leung EKY, 2007, CHEM BIOL, V14, P41, DOI 10.1016/j.chembiol.2006.11.006
   Li J, 2000, J AM CHEM SOC, V122, P10466, DOI 10.1021/ja0021316
   Li J, 2000, NUCLEIC ACIDS RES, V28, P481, DOI 10.1093/nar/28.2.481
   Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p                                                               
   Liu J, 2005, J AM CHEM SOC, V127, P12677, DOI 10.1021/ja053567u
   Liu J, 2007, CHEM COMMUN, P4872, DOI 10.1039/b712421j
   Liu JW, 2006, ORG BIOMOL CHEM, V4, P3435, DOI 10.1039/b605799c
   Liu J, 2007, ANGEW CHEM INT EDIT, V46, P7587, DOI 10.1002/anie.200702006
   Liu J, 2007, J AM CHEM SOC, V129, P9838, DOI 10.1021/ja0717358
   Liu JW, 2007, P NATL ACAD SCI USA, V104, P2056, DOI 10.1073/pnas.0607875104
   Liu JW, 2003, J AM CHEM SOC, V125, P6642, DOI 10.1021/ja034775u
   Liu JW, 2004, ANAL CHEM, V76, P1627, DOI 10.1021/ac0351769
   Liu JW, 2004, J AM CHEM SOC, V126, P12298, DOI 10.1021/ja046628h
   Liu JW, 2005, ANGEW CHEM INT EDIT, V44, P7290, DOI 10.1002/anie.200501815
   Liu JW, 2002, J AM CHEM SOC, V124, P15208, DOI 10.1021/ja027647z
   Liu JW, 2003, ANAL CHEM, V75, P6666, DOI 10.1021/AC034924r
   Liu Y, 2004, J MOL BIOL, V341, P887, DOI 10.1016/j.jmb.2004.06.060
   LIU Y, 2009, J MOL BIOL, V395, P234
   Liu Y, 2008, J MOL BIOL, V381, P845, DOI 10.1016/j.jmb.2008.06.036
   Macdonald J, 2006, NANO LETT, V6, P2598, DOI 10.1021/nl0620864
   Mazumdar D, 2009, J AM CHEM SOC, V131, P5506, DOI 10.1021/ja8082939
   Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8                                                   
   Nagraj N, 2009, CHEM COMMUN, P4103, DOI 10.1039/b903059j
   Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493
   Nelson KE, 2005, J MOL EVOL, V61, P216, DOI 10.1007/s00239-004-0374-3
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   Ota N, 1998, NUCLEIC ACIDS RES, V26, P3385, DOI 10.1093/nar/26.14.3385                                                          
   Pei R, 2006, J AM CHEM SOC, V128, P12693, DOI 10.1021/ja058394n
   Peracchi A, 2005, J MOL BIOL, V352, P783, DOI 10.1016/j.jmb.2005.07.059
   Peracchi A, 2000, J BIOL CHEM, V275, P11693, DOI 10.1074/jbc.275.16.11693
   Perrin DM, 2001, J AM CHEM SOC, V123, P1556, DOI 10.1021/ja003290s
   Purtha WE, 2005, J AM CHEM SOC, V127, P13124, DOI 10.1021/ja0533702
   Reyes-Gutierrez P, 2009, OLIGONUCLEOTIDES, V19, P233, DOI 10.1089/oli.2009.0193
   Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027                                                         
   Sando S, 2003, J AM CHEM SOC, V125, P15720, DOI 10.1021/ja0386492
   Sando S, 2005, ORG BIOMOL CHEM, V3, P1002, DOI 10.1039/b418078j                                                                
   Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221
   Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262                                                          
   Schlosser K, 2006, NUCLEIC ACIDS RES, V34, P2445, DOI 10.1093/nar/gkl276
   Schlosser K, 2004, BIOCHEMISTRY-US, V43, P9695, DOI 10.1021/bi049757j
   Schlosser K, 2008, NUCLEIC ACIDS RES, V36, P4768, DOI 10.1093/nar/gkn396
   Schlosser K, 2008, NUCLEIC ACIDS RES, V36, P1472, DOI 10.1093/nar/gkm1175
   Schlosser K, 2007, NAT CHEM BIOL, V3, P753, DOI 10.1038/nchembio1207-753
   Schlosser K, 2009, CHEM BIOL, V16, P311, DOI 10.1016/j.chembiol.2009.01.008
   Schlosser K, 2009, NUCLEIC ACIDS RES, V37, P413, DOI 10.1093/nar/gkn930
   Shaikh KA, 2005, P NATL ACAD SCI USA, V102, P9745, DOI 10.1073/pnas.0504082102
   Shen L, 2008, ANAL CHEM, V80, P6323, DOI 10.1021/ac800601y
   Shyr MHS, 2008, J AM CHEM SOC, V130, P8234, DOI 10.1021/ja711026r
   Silverman SK, 2008, CHEM COMMUN, P3467, DOI 10.1039/b807292m
   Silverman SK, 2009, ACCOUNTS CHEM RES, V42, P1521, DOI 10.1021/ar900052y
   Silverman SK, 2005, NUCLEIC ACIDS RES, V33, P6151, DOI 10.1093/nar/gki930
   Sohail M., 2003, NUCLEIC ACIDS RES, V31, P38
   Stojanovic MN, 2008, PROG NUCLEIC ACID RE, V82, P199, DOI 10.1016/S0079-6603(08)00006-8
   Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v
   Stojanovic MN, 2005, J AM CHEM SOC, V127, P6914, DOI 10.1021/ja0430003a
   Stojanovic MN, 2003, J AM CHEM SOC, V125, P6673, DOI 10.1021/ja0296632
   Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862
   Swearingen CB, 2005, ANAL CHEM, V77, P442, DOI 10.1021/ac0401016
   Wang DY, 2002, J MOL BIOL, V318, P33, DOI 10.1016/S0022-2836(02)00046-3
   Wang DY, 2002, NUCLEIC ACIDS RES, V30, P1735, DOI 10.1093/nar/30.8.1735
   Wang H, 2009, J AM CHEM SOC, V131, P8221, DOI 10.1021/ja901132y
   Wang YM, 2005, BIOCHEMISTRY-US, V44, P3017, DOI 10.1021/bi0478291
   Wang YM, 2003, BIOCHEMISTRY-US, V42, P15252, DOI 10.1021/bi0355847
   Wang YM, 2003, J AM CHEM SOC, V125, P6880, DOI 10.1021/ja035150z
   Wang ZD, 2008, ADV MATER, V20, P3263, DOI 10.1002/adma.200703181
   Wei H, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/9/095501
   Wernette DP, 2007, LANGMUIR, V23, P9513, DOI 10.1021/la701303k
   Wernette DP, 2006, ANALYST, V131, P41, DOI 10.1039/b510071b
   Wilson TJ, 2006, RNA, V12, P980, DOI 10.1261/rna.11706
   Xiang Y, 2009, J AM CHEM SOC, V131, P15352, DOI 10.1021/ja905854a
   Xiao Y, 2007, J AM CHEM SOC, V129, P262, DOI 10.1021/ja067278x
   Yim TJ, 2005, J AM CHEM SOC, V127, P12200, DOI 10.1021/ja0541581
   Zhao WA, 2008, SMALL, V4, P810, DOI 10.1002/smll.200700757
   Zhu X, 2009, CHEM COMMUN, P6050, DOI 10.1039/b911191c
NR 121
TC 63
Z9 63
U1 9
U2 59
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1439-4227
J9 CHEMBIOCHEM
JI ChemBioChem
PD MAY 3
PY 2010
VL 11
IS 7
BP 866
EP 879
DI 10.1002/cbic.200900786
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 596ZO
UT WOS:000277725000002
PM 20213779
DA 2018-01-05
ER

PT J
AU van 't Klooster, G
   Hoeben, E
   Borghys, H
   Looszova, A
   Bouche, MP
   van Velsen, F
   Baert, L
AF Van 't Klooster, Gerben
   Hoeben, Eva
   Borghys, Herman
   Looszova, Adriana
   Bouche, Marie-Paule
   van Velsen, Frans
   Baert, Lieven
TI Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension
   as a Long-Acting Injectable Antiretroviral Formulation
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITOR; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1
   SUBTYPE-C; VIROLOGICAL RESPONSE; ANTIVIRAL ACTIVITY; DRUG-RESISTANCE;
   THERAPY; NEVIRAPINE; ADHERENCE; INFECTION
AB The next-generation human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) was administered in rats and dogs as single intramuscular (IM) or subcutaneous (SC) injections, formulated as a 200-nm nanosuspension. The plasma pharmacokinetics, injection site concentrations, disposition to lymphoid tissues, and tolerability were evaluated in support of its potential use as a once-monthly antiretroviral agent in humans. Rilpivirine plasma concentration-time profiles showed sustained and dose-proportional release over 2 months in rats and over 6 months in dogs. The absolute bioavailability approached 100%, indicating a complete release from the depot, in spite of rilpivirine concentrations still being high at the injection site(s) 3 months after administration in dogs. For both species, IM administration was associated with higher initial peak plasma concentrations and a more rapid washout than SC administration, which resulted in a stable plasma-concentration profile over at least 6 weeks in dogs. The rilpivirine concentrations in the lymph nodes draining the IM injection site exceeded the plasma concentrations by over 100-fold 1 month after administration, while the concentrations in the lymphoid tissues decreased to 3- to 6-fold the plasma concentrations beyond 3 months. These observations suggest uptake of nanoparticles by macrophages, which generates secondary depots in these lymph nodes. Both SC and IM injections were generally well tolerated and safe, with observations of a transient inflammatory response at the injection site. The findings support clinical investigations of rilpivirine nanosuspension as a long-acting formulation to improve adherence during antiretroviral therapy and for preexposure prophylaxis.
C1 [Van 't Klooster, Gerben; van Velsen, Frans; Baert, Lieven] Tibotec BVBA, B-2800 Mechelen, Belgium.
   [Hoeben, Eva; Borghys, Herman; Looszova, Adriana; Bouche, Marie-Paule] Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium.
RP Baert, L (reprint author), Tibotec BVBA, Gen Wittelaan L11B 3, B-2800 Mechelen, Belgium.
EM lbaert@its.jnj.com
CR Arasteh K, 2009, ANTIVIR THER, V14, P713
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Burger DM, 2004, J PEDIATR-US, V145, P403, DOI 10.1016/j.jpeds.2004.04.048
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   *DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1
   DRAPER BH, 2006, COCHRANE DB SYST REV, V3
   Duong M, 2005, ANN PHARMACOTHER, V39, P603, DOI 10.1345/aph.1E563
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   Garvey L, 2009, EXPERT OPIN INV DRUG, V18, P1035, DOI 10.1517/13543780903055056
   Gatti G, 2002, HIV Med, V3, P125, DOI 10.1046/j.1468-1293.2002.00108.x
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Harrison TS, 2004, CNS DRUGS, V18, P113
   Hirschel B, 2007, LANCET, V370, P3, DOI 10.1016/S0140-6736(07)61022-8                                                   
   Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305
   Lee EJ, 2005, J INFECT DIS, V192, P1260, DOI 10.1086/444424
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y
   Miller V, 1998, ANTIMICROB AGENTS CH, V42, P3123
   Mordant C, 2007, EUR J MED CHEM, V42, P567, DOI 10.1016/j.ejmech.2006.11.014
   Morris L, 2003, AIDS, V17, P1698, DOI 10.1097/01.aids.0000076295.76477.6c
   Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341                                                              
   Pauwels R, 2006, ANTIVIR RES, V71, P77, DOI 10.1016/j.antiviral.2006.05.007
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rathbun RC, 2005, CLIN THER, V27, P199, DOI 10.1016/j.clinthera.2005.02.010
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   Sorbera LA, 2007, DRUG FUTURE, V32, P1046, DOI 10.1358/dof.2007.032.12.1159663
   Sorensen VB, 2000, MICROVASC RES, V59, P301
   Torti C, 2005, CLIN INFECT DIS, V40, P1828, DOI 10.1086/429917
   Van Gyseghem E, 2008, EUR J PHARM BIOPHARM, V70, P853, DOI 10.1016/j.ejpb.2008.06.030
   van't Klooster G., 2008, 15 C RETR OPP INF BO
   Verloes R., 2008, 17 INT AIDS C MEX CI
   World Health Organization, 2006, TAK STOCK HIV CHILDR
   Wu HL, 2006, J PHARMACOKINET PHAR, V33, P399, DOI 10.1007/s10928-006-9006-4
NR 32
TC 62
Z9 62
U1 0
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2010
VL 54
IS 5
BP 2042
EP 2050
DI 10.1128/AAC.01529-09
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 585DK
UT WOS:000276804300049
PM 20160045
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, S
   Alexander, L
   Wang, T
   Agler, M
   Zhou, NN
   Fang, H
   Kadow, J
   Clapham, P
   Lin, PF
AF Zhang, Sharon
   Alexander, Louis
   Wang, Tao
   Agler, Michele
   Zhou, Nannon
   Fang, Hua
   Kadow, John
   Clapham, Paul
   Lin, Pin-Fang
TI Protection against HIV-envelope-induced neuronal cell destruction by HIV
   attachment inhibitors
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; AIDS PATIENTS; GP120-INDUCED APOPTOSIS;
   CONFORMATIONAL-CHANGES; VIRUS; BRAIN; ENTRY; MACROPHAGES; INFECTION;
   DEMENTIA
AB We demonstrate that HIV attachment inhibitors (AIs) prevent HIV envelope-induced destruction of two neuronal cell lines (SH-SY5Y and BE(2)-M17) at low nanomolar concentrations. The fusion inhibitor enfuvirtide and the CCR5 inhibitors UK427,857 and TAK779 do not display protection activity, suggesting the involvement of Env/cell interaction site(s) distinct from the sites involved in the viral entry process. We surmise that by inducing conformation changes in the envelope, AIs likely obstruct novel interactions with a neuronal cell factor(s) required for induction of apoptosis. This antiretroviral class may therefore have the potential to inhibit HIV-induced neuron damage, thereby curtailing the increasing incidence of HIV-associated cognitive impairment.
C1 [Zhang, Sharon; Alexander, Louis; Zhou, Nannon; Lin, Pin-Fang] Bristol Myers Squibb Co, Dept Virol, Wallingford, CT 06492 USA.
   [Wang, Tao; Kadow, John] Bristol Myers Squibb Co, Antiviral Chem, Wallingford, CT 06492 USA.
   [Agler, Michele; Fang, Hua] Bristol Myers Squibb Co, Lead Discovery, Wallingford, CT 06492 USA.
   [Clapham, Paul] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.
   [Clapham, Paul] Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Ctr AIDS Res, Worcester, MA 01605 USA.
RP Alexander, L (reprint author), Bristol Myers Squibb Co, Dept Virol, 5 Res Pkwy, Wallingford, CT 06492 USA.
EM louis.alexander@bms.com
FU NIMH NIH HHS [R01 MH064408]
CR Alexander L, 2009, ANTIMICROB AGENTS CH, V53, P4726, DOI 10.1128/AAC.00494-09
   Alirezaei M, 2007, J NEUROSCI, V27, P11047, DOI 10.1523/JNEUROSCI.2733-07.2007
   An SF, 1999, J NEUROPATH EXP NEUR, V58, P1156, DOI 10.1097/00005072-199911000-00005                                                
   Bardi G, 2006, J NEUROVIROL, V12, P211, DOI 10.1080/13550280600848373
   BREW BJ, 2009, J NEUROIMMU IN PRESS
   Dunfee RL, 2007, VIROLOGY, V367, P222, DOI 10.1016/j.virol.2007.05.029
   Everall IP, 2002, MOL CELL NEUROSCI, V21, P493, DOI 10.1006/mcne.2002.1196
   Granter SR, 1996, AM J CLIN PATHOL, V105, P364
   Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8                                                   
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903
   Lim JY, 2008, J NEUROSCI RES, V86, P2168, DOI 10.1002/jnr.21669
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Marra CM, 1999, SEMIN NEUROL, V19, P177, DOI 10.1055/s-2008-1040835
   McQuaid S, 1998, ACTA NEUROPATHOL, V96, P637, DOI 10.1007/s004010050945                                                           
   Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109
   Nath A, 2008, INT REV PSYCHIATR, V20, P25, DOI 10.1080/09540260701861930
   Peng FW, 2008, J NEUROVIROL, V14, P62, DOI 10.1080/13550280701809084
   Peters PJ, 2004, J VIROL, V78, P6915, DOI 10.1128/JVI.78.13.6915-6926.2004
   Price RW, 2008, J INFECT DIS, V197, pS294, DOI 10.1086/533419
   Rossio JL, 1998, J VIROL, V72, P7992
   Si ZH, 2004, P NATL ACAD SCI USA, V101, P5036, DOI 10.1073/pnas.0307953101
   Tait JF, 2008, J NUCL MED, V49, P1573, DOI 10.2967/jnumed.108.052803
   Thomas S, 2009, INT J NEUROSCI, V119, P157, DOI 10.1080/00207450802335537
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
NR 25
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PD MAY
PY 2010
VL 155
IS 5
BP 777
EP 781
DI 10.1007/s00705-010-0644-x
PG 5
WC Virology
SC Virology
GA 589PP
UT WOS:000277164900018
PM 20300783
DA 2018-01-05
ER

PT J
AU Smith, CAM
   de la Fuente, J
   Pelaz, B
   Furlani, EP
   Mullin, M
   Berry, CC
AF Smith, Carol-Anne M.
   de la Fuente, Jesus
   Pelaz, Beatriz
   Furlani, Edward P.
   Mullin, Margaret
   Berry, Catherine C.
TI The effect of static magnetic fields and tat peptides on cellular and
   nuclear uptake of magnetic nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Nanoparticles; Fibroblast; Tat peptide; Magnetism; Endocytosis;
   Microarray
ID HUMAN IMMUNODEFICIENCY VIRUS; PENETRATING PEPTIDES; IN-VITRO; GOLD
   NANOPARTICLES; GENE-EXPRESSION; DRUG-DELIVERY; CELLS; PROTEIN;
   MECHANISM; VIVO
AB Magnetic nanoparticles are widely used in bioapplications such as imaging (MRI), targeted delivery (drugs/genes) and cell transfection (magnetofection). Historically, the impermeable nature of both the plasma and nuclear membranes hinder potential. Researchers combat this by developing techniques to enhance cellular and nuclear uptake. Two current popular methods are using external magnetic fields to remotely control particle direction or functionalising the nanoparticles with a cell penetrating peptide (e.g. tat); both of which facilitate cell entry. This paper compares the success of both methods in terms of nanoparticle uptake, analysing the type of magnetic forces the particles experience, and determines gross cell response in terms of morphology and structure and changes at the gene level via microarray analysis. Results indicated that both methods enhanced uptake via a caveolin dependent manner, with tat peptide being the more efficient and achieving nuclear uptake. On comparison to control cells, many groups of gene changes were observed in response to the particles. Importantly, the magnetic field also caused many change in gene expression, regardless of the nanoparticles, and appeared to cause F-actin alignment in the cells. Results suggest that static fields should be modelled and analysed prior to application in culture as cells clearly respond appropriately. Furthermore, the use of cell penetrating peptides may prove more beneficial in terms of enhancing uptake and maintaining cell homeostasis than a magnetic field. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Smith, Carol-Anne M.; Berry, Catherine C.] Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
   [de la Fuente, Jesus; Pelaz, Beatriz] Aragon Inst Nanosci, Zaragoza, Spain.
   [Furlani, Edward P.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Mullin, Margaret] Univ Glasgow, Integrated Microscopy Facil, Glasgow G12 8QQ, Lanark, Scotland.
RP Berry, CC (reprint author), Univ Glasgow, Ctr Cell Engn, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
EM catherine.berry@bio.gla.ac.uk
RI Pelaz, Beatriz/I-7703-2015
OI Pelaz, Beatriz/0000-0002-4626-4576
FU Royal Society
FX The authors wish to thank The Royal Society for funding this work
   through their fellowship scheme.
CR Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x                                               
   Aspalter M, 2009, J NEUROSCI METH, V176, P96, DOI 10.1016/j.jneumeth.2008.08.035
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Berry CC, 2003, J PHYS D, V36, P198, DOI DOI 10.1088/0022-3727/36/13/203
   Bhattarai SR, 2008, J VIROL METHODS, V147, P213, DOI 10.1016/j.jviromet.2007.08.028
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Coletti D, 2007, CYTOM PART A, V71A, P846, DOI 10.1002/cyto.a.20447
   da Costa SR, 2003, ADV DRUG DELIVER REV, V55, P1359, DOI 10.1016/j.addr.2003.07.011
   Dalby MJ, 2003, EXP CELL RES, V284, P274, DOI 10.1016/S0014-4827(02)00053-8
   DALBY MJ, 2005, EUR CELLS MATER, V9, P8
   de la Fuente JM, 2006, LANGMUIR, V22, P3286, DOI 10.1021/la053029v
   DELAFUENTE JM, 2005, J BIOCONJUG CHEM, V16, P1176
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dini L, 2005, MICRON, V36, P195, DOI 10.1016/j.micron.2004.12.009
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Euguchi Y, 2003, NEUROSCI LETT, V351, P130
   Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Furlani EP, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.061914
   Furlani EP, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.061919
   Furlani EP, 2006, J APPL PHYS, V99, DOI 10.1063/1.2164531
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Harush-Frenkel O, 2008, CRIT REV THER DRUG, V25, P485, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i6.10                                    
   HIGASHI T, 1993, BLOOD, V82, P1328
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hirose H, 2003, IN VITRO CELL DEV-AN, V39, P348
   Kamei K, 2009, BIOMATERIALS, V30, P1809, DOI 10.1016/j.biomaterials.2008.12.015
   Kim JA, 2009, BIOMED MICRODEVICES, V11, P287, DOI 10.1007/s10544-008-9235-y
   KOTANI H, 2002, J BONE MINER RES, V171, P814
   Loubery S, 2008, TRAFFIC, V9, P492, DOI 10.1111/j.1600-0854.2008.00704.x
   Luhmann T, 2008, BIOCONJUGATE CHEM, V19, P1907, DOI 10.1021/bc800206r
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Masotti A., 2008, COLLOID SURFACE B, V68, P136
   Miyakoshi J, 2005, PROG BIOPHYS MOL BIO, V87, P213, DOI 10.1016/j.pbiomolbio.2004.08.008
   MURAYAMA M, 1965, NATURE, V206, P420, DOI 10.1038/206420a0
   Pacini S, 2003, CANCER DETECT PREV, V27, P327, DOI 10.1016/S0361-090X(03)00124-7
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Sajja Hari Krishna, 2009, Curr Drug Discov Technol, V6, P43
   Sakamoto N, 2008, J GASTROEN HEPATOL, V23, P1437, DOI 10.1111/j.1440-1746.2007.05076.x
   Scarberry KE, 2008, J AM CHEM SOC, V130, P10258, DOI 10.1021/ja801969b
   Shi WD, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.061914
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Wang LY, 2005, J PHYS CHEM B, V109, P21593, DOI 10.1021/jp0543429
   Zhang K, 2008, BIOCONJUGATE CHEM, V19, P1880, DOI 10.1021/bc800160b
   Zhang Y, 2008, CURR OPIN BIOTECH, V19, P506, DOI 10.1016/j.copbio.2008.07.005
NR 49
TC 50
Z9 52
U1 5
U2 45
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2010
VL 31
IS 15
BP 4392
EP 4400
DI 10.1016/j.biomaterials.2010.01.096
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 586SH
UT WOS:000276932600017
PM 20189242
DA 2018-01-05
ER

PT J
AU Di Gianvincenzo, P
   Marradi, M
   Martinez-Avila, OM
   Bedoya, LM
   Alcami, J
   Penades, S
AF Di Gianvincenzo, Paolo
   Marradi, Marco
   Maria Martinez-Avila, Olga
   Miguel Bedoya, Luis
   Alcami, Jose
   Penades, Soledad
TI Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Sulfated gold nanoparticles; gp120 interaction; Surface plasmon
   resonance; HIV neutralization assays; Anti-HIV systems
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DC-SIGN; INFECTION; INHIBITION; GP120;
   POLYANIONS; BINDING; SYSTEMS; CELLS
AB Gold nanoparticles coated with multiple copies of an amphiphilic sulfate-ended ligand are able to bind the HIV envelope glycoprotein gp120 as measured by surface plasmon resonance (SPR) and inhibit in vitro the HIV infection of T-cells at nanomolar concentrations. A 50% density of sulfated ligands on similar to 2 nm nanoparticles (the other ligands being inert glucose derivatives) is enough to achieve high anti-HIV activities. This result opens up the possibility of tailoring both sulfated ligands and other anti-HIV molecules on the same gold cluster, thus contributing to the development of non-cocktail based multifunctional anti-HIV systems. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Di Gianvincenzo, Paolo; Marradi, Marco; Maria Martinez-Avila, Olga; Penades, Soledad] CIBER BBN, Lab GlycoNanotechnol, CIC BiomaGUNE, E-20009 San Sebastian, Spain.
   [Miguel Bedoya, Luis; Alcami, Jose] Inst Salud Carlos III, AIDS Immunopathol Unit, Natl Ctr Microbiol, Madrid, Spain.
RP Penades, S (reprint author), CIBER BBN, Lab GlycoNanotechnol, CIC BiomaGUNE, P Miramon 182, E-20009 San Sebastian, Spain.
EM spenades@cicbiomagune.es
RI biomaGUNE, CIC/J-9136-2014; Marradi, Marco/H-7247-2012; BEDOYA DEL OLMO,
   LUIS MIGUEL/I-5500-2016
OI biomaGUNE, CIC/0000-0001-7690-0660; BEDOYA DEL OLMO, LUIS
   MIGUEL/0000-0001-6249-6847
FU MICINN [CTQ2008-04638]; EU [LSHP-CT-2003-503558]; Red de Investigacion
   en SIDA [RIS ISCIII-RETIC RD06/0006]; Network of Excellence EUROPRISE;
   Fondo de Investigacion Sanitaria FIS [PI080752]; EC; AVIP and NGIN
   consortia; Bill and Melinda Gates GHRC; EMPRO; MICINN
FX This work was supported by MICINN (NANBIOMED grant CTQ2008-04638), EU
   (EMPRO grant LSHP-CT-2003-503558), Red de Investigacion en SIDA: RIS
   ISCIII-RETIC RD06/0006, Network of Excellence EUROPRISE and Fondo de
   Investigacion Sanitaria FIS: PI080752. Recombinant gp120 from HIV-1 CN54
   clone (repository reference ARP683) was obtained from the Programme EVA
   Centre for AIDS Reagents, NIBSC, UK, supported by the EC FP6/7 Europrise
   Network of Excellence, AVIP and NGIN consortia and the Bill and Melinda
   Gates GHRC-CAVD Project and was donated by Prof. Ian Jones (Reading
   University, UK). P. D. G and O.M.M.-A. thank EMPRO and MICINN,
   respectively, for financial support.
CR Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762                                                         
   De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46
   Gantlett KE, 2007, ANTIVIR RES, V75, P188, DOI 10.1016/j.antiviral.2007.03.004
   Garcia-Perez J, 2007, J MED VIROL, V79, P127, DOI 10.1002/jmv.20770
   GUO L, 1994, ANTIMICROB AGENTS CH, V38, P2483, DOI 10.1128/AAC.38.10.2483                                                          
   Kim J, 2009, CHEM SOC REV, V38, P372, DOI 10.1039/b709883a
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601                                                      
NR 22
TC 43
Z9 44
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2010
VL 20
IS 9
BP 2718
EP 2721
DI 10.1016/j.bmcl.2010.03.079
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 585HT
UT WOS:000276816600004
PM 20382017
DA 2018-01-05
ER

PT J
AU Caron, J
   Reddy, LH
   Lepetre-Mouelhi, S
   Wack, S
   Clayette, P
   Rogez-Kreuz, C
   Yousfi, R
   Couvreur, P
   Desmaele, D
AF Caron, Joachim
   Reddy, L. Harivardhan
   Lepetre-Mouelhi, Sinda
   Wack, Severine
   Clayette, Pascal
   Rogez-Kreuz, Christine
   Yousfi, Rahima
   Couvreur, Patrick
   Desmaele, Didier
TI Squalenoyl nucleoside monophosphate nanoassemblies: New prodrug strategy
   for the delivery of nucleotide analogues
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Nucleotides; Prodrug; Nanoassemblies; Antiviral agents; Antitumor agents
ID ANTICANCER NANOMEDICINE; BIOLOGICAL EVALUATION; GEMCITABINE; INHIBITOR;
   PHOSPHATE
AB 4-(N)-1,1',2-Trisnor-squalenoyldideoxycytidine monophosphate (SQddC-MP) and 4-(N)-1,1',2-trisnorsqualenoylgemcitabine monophosphate (SQdFdC-MP) were synthesized using phosphoramidite chemistry. These amphiphilic molecules self-assembled to about hundred nanometers size nanoassemblies in aqueous medium. Nanoassemblies of SQddC-MP displayed significant anti-HIV activity whereas SQdFdC-MP nanoassemblies displayed promising anticancer activity on leukemia cells. These results suggested that squalene conjugate of negatively charged nucleotide analogues efficiently penetrated within cells. Thus, we propose a new prodrug strategy for improved delivery of nucleoside analogues to ameliorate their biological efficacy. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Caron, Joachim; Lepetre-Mouelhi, Sinda; Desmaele, Didier] Univ Paris Sud, Fac Pharm, UMR CNRS 8076, F-92296 Chatenay Malabry, France.
   [Reddy, L. Harivardhan; Wack, Severine; Couvreur, Patrick] Univ Paris Sud, Fac Pharm, UMR CNRS 8612, F-92296 Chatenay Malabry, France.
   [Clayette, Pascal; Rogez-Kreuz, Christine; Yousfi, Rahima] CEA, SPI BIO, Lab Neurovirol, F-92265 Fontenay Aux Roses, France.
RP Desmaele, D (reprint author), Univ Paris Sud, Fac Pharm, UMR CNRS 8076, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.
EM didier.desmaele@u-psud.fr
RI Lepetre-Mouelhi, Sinda/J-7176-2012; COUVREUR, Patrick/G-4844-2011
OI COUVREUR, Patrick/0000-0001-7961-5443
FU European Research Council [FP7/2007-2013]; Agence Nationale de la
   Recherche [249835anf]; Ministere de la Recherche et de la Technologie;
   CNRS
FX The research leading to these results has received funding from the
   European Research Council under the European Community's Seventh
   Framework Programme FP7/2007-2013 Grant Agreement no. 249835anf from
   Agence Nationale de la Recherche Grant SYLIANU. The financial supports
   of the Ministere de la Recherche et de la Technologie (fellowship to
   J.C.) and from CNRS (Grant Ingenieur de valorisation to L. H. R) are
   acknowledged. The authors thank Mrs. Ludivine Houel Renault for
   recording transmission electron micrographs, Dr. Estelle Morvan for 2D
   NMR spectral analyses, Karen Storck and Vincent Huyot for their
   technical assistance for anti-HIV assays.
CR Alexander RL, 2003, J MED CHEM, V46, P4205, DOI 10.1021/jm020571x
   Ali SM, 2005, BIOORG MED CHEM LETT, V15, P2571, DOI 10.1016/j.bmcl.2005.03.046
   Ariza ME, 2005, DRUG DES REV ONLINE, V2, P373
   BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4
   Bekkara-Aounallah F, 2008, ADV FUNCT MATER, V18, P3715, DOI 10.1002/adfm.200800705
   Bialy L, 2004, CHEM-EUR J, V10, P2759, DOI 10.1002/chem.200305543                                                          
   CERUTI M, 1987, EUR J MED CHEM, V22, P199, DOI 10.1016/0223-5234(87)90050-X                                                    
   Couvreur P, 2008, SMALL, V4, P247, DOI 10.1002/smll.200700731
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   el Kouni MH, 2002, CURR PHARM DESIGN, V8, P581, DOI 10.2174/1381612024607171                                                        
   Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X
   Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114
   Huang YH, 2003, BIOORG CHEM, V31, P136, DOI 10.1016/S0045-2068(02)00525-4
   JONES JJ, 1995, ANTIVIR RES, V27, P1
   Kennedy KJ, 2001, BIOORG MED CHEM LETT, V11, P95, DOI 10.1016/S0960-894X(00)00608-9
   LICHTENSTEIN J, 1960, J BIOL CHEM, V235, P457
   Reddy LH, 2008, DRUG METAB DISPOS, V36, P1570, DOI 10.1124/dmd.108.020735
   Reddy LH, 2008, J NANOPART RES, V10, P887, DOI 10.1007/s11051-007-9322-7
   Reddy LH, 2008, J PHARMACOL EXP THER, V325, P484, DOI 10.1124/jpet.107.133751
   Reddy LH, 2007, J CONTROL RELEASE, V124, P20, DOI 10.1016/j.jeonrel.2007.08.018
   Schultz C, 2003, BIOORGAN MED CHEM, V11, P885, DOI 10.1016/S0968-0896(02)00552-7                                                   
   SMITH M, 1962, J AM CHEM SOC, V84, P430, DOI 10.1021/ja00862a023                                                             
   VANTAMELEN EE, 1962, TETRAHEDRON LETT, P121
   Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z                          
   Watanabe Y, 1997, TETRAHEDRON LETT, V38, P7407, DOI 10.1016/S0040-4039(97)85781-4
   Williams D. M., 2004, ORGANOPHOSPHORUS REA, P237
   Zhong MH, 2008, J ORG CHEM, V73, P603, DOI 10.1021/jo702070m
NR 27
TC 20
Z9 21
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2010
VL 20
IS 9
BP 2761
EP 2764
DI 10.1016/j.bmcl.2010.03.070
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 585HT
UT WOS:000276816600013
PM 20363623
DA 2018-01-05
ER

PT J
AU Yamaguchi, S
   Tatsumi, T
   Takehara, T
   Sasakawa, A
   Yamamoto, M
   Kohga, K
   Miyagi, T
   Kanto, T
   Hiramastu, N
   Akagi, T
   Akashi, M
   Hayashi, N
AF Yamaguchi, Shinjiro
   Tatsumi, Tomohide
   Takehara, Tetsuo
   Sasakawa, Akira
   Yamamoto, Masashi
   Kohga, Keisuke
   Miyagi, Takuya
   Kanto, Tatsuya
   Hiramastu, Naoki
   Akagi, Takami
   Akashi, Mitsuru
   Hayashi, Norio
TI EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid)
   nanoparticles elicits an anti-tumor effect against mouse liver tumor
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE Peptide vaccine; EphA2-derived peptide; Acquired immunity; Liver tumor
ID RECEPTOR TYROSINE KINASE; INACTIVATED HIV-1-CAPTURING NANOSPHERES;
   CELL-BASED VACCINES; LUNG-CANCER; BIODEGRADABLE NANOPARTICLES; MUCOSAL
   IMMUNIZATION; CURATIVE RESECTION; ANTIBODY-RESPONSE; FREUND ADJUVANT;
   DENDRITIC CELLS
AB The prognosis of liver cancer remains poor, but recent advances in nanotechnology offer promising possibilities for cancer treatment. Novel adjuvant, amphiphilic nanoparticles (NPs) composed of l-phenylalanine (Phe)-conjugated poly(gamma-glutamic acid) (gamma-PGA-Phe NPs) having excellent capacity for carrying peptides, were found to have the potential for use as a peptide vaccine against tumor models overexpressing artificial antigens, such as ovalbumin (OVA). However, the anti-tumor potential of gamma-PGA-Phe NPs vaccines using much less immunogenic tumor-associated antigen (TAA)-derived peptide needs to be clarified. In this study, we evaluated the effectiveness of immunization with EphA2, recently identified TAA, derived peptide-immobilized gamma-PGA-Phe NPs (Eph-NPs) against mouse liver tumor of MC38 cells (EphA2-positive colon cancer cells). Immunization of normal mice with Eph-NPs resulted in generation of EphA2-specific type-1 CD8+ T cells. Immunization with Eph-NPs tended to provide a degree of anti-MC38 liver tumor protection more than that observed for immunization with the mixture of EphA2-derived peptide and complete Freund's adjuvant (Eph + CFA). Neither Eph-NPs nor Eph + CFA vaccines inhibited tumor growth of BL6, EphA2-negative melanoma cells. Splenocytes isolated from MC38-bearing mice treated with Eph-NPs showed strong and specific cytotoxic activity against MC38 cells. Immunization with Eph + CFA induced liver damage as evidenced by elevation of serum alanine aminotransferase, while Eph-NPs vaccination did not exhibit any toxic damage to the liver. These results demonstrated that immunization with Eph-NPs displayed anti-tumor effects against liver tumor by generating acquired immunity equivalent to the toxic adjuvant CFA, suggesting that safe gamma-PGA-Phe NPs could be applied clinically for the vaccine treatment of liver cancer.
C1 [Yamaguchi, Shinjiro; Tatsumi, Tomohide; Takehara, Tetsuo; Sasakawa, Akira; Yamamoto, Masashi; Kohga, Keisuke; Miyagi, Takuya; Kanto, Tatsuya; Hiramastu, Naoki; Hayashi, Norio] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan.
   [Akagi, Takami; Akashi, Mitsuru] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   [Yamaguchi, Shinjiro; Tatsumi, Tomohide; Takehara, Tetsuo; Sasakawa, Akira; Yamamoto, Masashi; Akagi, Takami; Akashi, Mitsuru; Hayashi, Norio] Japan Sci & Technol Agcy, Tokyo, Japan.
RP Tatsumi, T (reprint author), Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM tatsumit@gh.med.osaka-u.ac.jp
FU Evolutional Science and Technology (CREST); Japan Science and Technology
   Agency (JST)
FX This work was supported by a Grant-in-Aid from Core Research for
   Evolutional Science and Technology (CREST) from Japan Science and
   Technology Agency (JST).
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   AMYX HL, 1987, J AM VET MED ASSOC, V191, P1287
   Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075
   Bottomley A, 2008, EUR J CANCER, V44, P2178, DOI 10.1016/j.ejca.2008.06.036
   Brannan JM, 2009, CLIN CANCER RES, V15, P4423, DOI 10.1158/1078-0432.CCR-09-0473
   BRODERSON JR, 1989, LAB ANIM SCI, V39, P400
   D'Amico TA, 2001, ANN THORAC SURG, V72, P1144, DOI 10.1016/S0003-4975(01)02979-4
   DeRisi J, 1996, NAT GENET, V14, P457
   Dhodapkar MV, 2000, CLIN CANCER RES, V6, P4831
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Doherty DG, 2000, IMMUNOL REV, V174, P5, DOI 10.1034/j.1600-0528.2002.017416.x
   Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247
   Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F
   GEORGE AP, 2005, TOXICOL PATHOL, V33, P52
   Gilewski TA, 2007, CLIN CANCER RES, V13, P2977, DOI 10.1158/1078-0432.CCR-06-2189
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Khatri K, 2008, INT J PHARM, V354, P235, DOI 10.1016/j.ijpharm.2007.11.027
   Lu M, 2003, CANCER RES, V63, P3425
   MALCOLM AW, 1981, SURG GYNECOL OBSTET, V152, P131
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Mocellin S, 2004, GASTROENTEROLOGY, V127, P1821, DOI 10.1053/j.gastro.2004.07.012
   Obst M, 2004, BIOMACROMOLECULES, V5, P1166, DOI 10.1021/bm049949u
   OLSON RM, 1980, CANCER, V45, P2969, DOI 10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>3.0.CO;2-7
   Perales MA, 2008, MOL THER, V16, P2022, DOI 10.1038/mt.2008.196
   Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5
   Shih IL, 2001, BIORESOURCE TECHNOL, V79, P207, DOI 10.1016/S0960-8524(01)00074-8
   Sung MH, 2005, CHEM REC, V5, P352, DOI 10.1002/tcr.20061
   Tatsumi T, 2002, CANCER RES, V62, P5853
   TOTH LA, 1989, LAB ANIM SCI, V39, P122
   Uto T, 2009, BIOCHEM BIOPH RES CO, V379, P600, DOI 10.1016/j.bbrc.2008.12.122
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104
   Wang F, 1999, CLIN CANCER RES, V5, P2756
   Yamaguchi S, 2008, CANCER IMMUNOL IMMUN, V57, P1861, DOI 10.1007/s00262-008-0514-5
   Yamaguchi S, 2007, CANCER, V110, P1469, DOI 10.1002/cncr.22958
   Yoshikawa T, 2008, VACCINE, V26, P1303, DOI 10.1016/j.vaccine.2007.12.037
   Yoshikawa T, 2008, BIOCHEM BIOPH RES CO, V366, P408, DOI 10.1016/j.bbre.2007.11.153
   Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629
   Zelinski DP, 2001, CANCER RES, V61, P2301
NR 45
TC 23
Z9 29
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD MAY
PY 2010
VL 59
IS 5
BP 759
EP 767
DI 10.1007/s00262-009-0796-2
PG 9
WC Oncology; Immunology
SC Oncology; Immunology
GA 563OJ
UT WOS:000275141900012
PM 19943047
DA 2018-01-05
ER

PT J
AU Parikh, N
   Venishetty, VK
   Sistla, R
AF Parikh, Nirali
   Venishetty, Vinay Kumar
   Sistla, Ramakrishna
TI Simultaneous Determination of Ketoconazole, Ritonavir and Lopinavir in
   Solid Lipid Nanoparticles by RP-LC
SO CHROMATOGRAPHIA
LA English
DT Article
DE Column liquid chromatography; Solid lipid nanoparticles; Ketoconazole,
   ritonavir and lopinavir
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; HIV-PROTEASE INHIBITORS; TANDEM
   MASS-SPECTROMETRY; HUMAN-IMMUNODEFICIENCY-VIRUS; SIMULTANEOUS
   QUANTITATIVE-DETERMINATION; BLOOD MONONUCLEAR-CELLS; HUMAN PLASMA;
   CEREBROSPINAL-FLUID; INFECTED PATIENTS; P-GLYCOPROTEIN
AB Lopinavir (LPV), ritonavir (RTV) and ketoconazole (KTZ) loaded solid lipid nanoparticles (SLN) were formulated based on reported drug-drug interaction among these three drugs. In order to study the drug-drug interactions and to optimize the formulation, the in vitro release data of these three drugs from the formulation is necessary. Hence, there is a need to develop a simple, accurate and a rapid RP-LC method for the simultaneous determination of KTZ, RTV and LPV. The present method was developed using Kromasil C18 column (250 mm x 4.5 mm, 5 mu m) with mobile phase consisting of acetonitrile: 0.2% triethylamine pH adjusted to 6.5 (60:40 v/v) at a flow rate of 1 mL min(-1). Chromatographic separation was monitored at 210 nm. Retention times of KTZ, RTV and LPV were 6.24, 8.05 and 9.23 min respectively. The method was linear over range of 0.5-10 mu g mL(-1). This method was successfully applied for the determination of KTZ, RTV and LPV in SLN.
C1 [Parikh, Nirali; Venishetty, Vinay Kumar; Sistla, Ramakrishna] Indian Inst Chem Technol, Div Pharmacol, Hyderabad 500007, Andhra Pradesh, India.
   [Parikh, Nirali] Natl Inst Pharmaceut Educ & Res, Hyderabad, Andhra Pradesh, India.
RP Sistla, R (reprint author), Indian Inst Chem Technol, Div Pharmacol, Hyderabad 500007, Andhra Pradesh, India.
EM sistla@iict.res.in
FU CSIR, New Delhi
FX The authors are grateful to Dr. J.S. Yadav, Director, IICT, Hyderabad,
   India for extending the facilities to carry out the work. One of the
   authors, Vinay Kumar would like to thank CSIR, New Delhi for awarding
   Senior Research Fellowship.
CR Akeb F, 2002, J IMMUNOL METHODS, V263, P1, DOI 10.1016/S0022-1759(02)00026-1
   Albengres E, 1998, DRUG SAFETY, V18, P83, DOI 10.2165/00002018-199818020-00001                                                
   Albert V, 2004, J PHARMACEUT BIOMED, V36, P835, DOI 10.1016/j.jpba.2004.08.013
   Azoulay S, 2004, J IMMUNOL METHODS, V295, P37, DOI 10.1016/j.jim.2004.08.016
   Back D, 2002, AIDS, V16, pS5, DOI 10.1097/00002030-200203001-00002
   BERTZ R, 1998, CLIN PHARMACOL THER, V63, P228
   Chi JD, 2002, J PHARMACEUT BIOMED, V30, P675, DOI 10.1016/S0731-7085(02)00357-6
   Colombo S, 2005, J CHROMATOGR B, V819, P259, DOI 10.1016/j.jchromb.2005.02.010
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004                                                
   DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303                                                     
   Dickinson L, 2005, J CHROMATOGR B, V829, P82, DOI 10.1016/j.jchromb.2005.09.032
   DiFrancesco R, 2007, J PHARMACEUT BIOMED, V44, P1139, DOI 10.1016/j.jpba.2007.05.020
   Fin B, 2002, J PHARM BIOMED ANAL, V30, P935
   Frappier S, 1998, J CHROMATOGR B, V714, P384, DOI 10.1016/S0378-4347(98)00220-5
   Frerichs VA, 2003, J CHROMATOGR B, V787, P393, DOI 10.1016/S1570-0232(02)01002-4
   Gehrig AK, 2007, RAPID COMMUN MASS SP, V21, P2704, DOI 10.1002/rcm.3138
   Granda BW, 1998, J PHARMACOL TOXICOL, V40, P235, DOI 10.1016/S1056-8719(99)00013-1                                                   
   Grub S, 2001, EUR J CLIN PHARMACOL, V57, P115, DOI 10.1007/s002280100277
   Hoetelmans RMW, 1998, J CHROMATOGR B, V705, P119, DOI 10.1016/S0378-4347(97)00500-8
   Horacio N., 2008, IPC USP 7 ANN SCI M
   Hugen PWH, 1999, J CHROMATOGR B, V727, P139, DOI 10.1016/S0378-4347(99)00079-1
   Janoly A, 2002, J CHROMATOGR B, V780, P155, DOI 10.1016/S1570-0232(02)00465-8
   Justesen US, 2003, J CHROMATOGR B, V783, P491, DOI 10.1016/S1570-0232(02)00728-6
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   Khaliq Y, 2000, CLIN PHARMACOL THER, V68, P637, DOI 10.1067/mcp.2000.112363
   Langmann P, 1999, J CHROMATOGR B, V735, P41, DOI 10.1016/S0378-4347(99)00388-6
   MANISH Y, 2009, J PHARM BIOMED ANAL, V49, P1115
   Marsh KC, 1997, J CHROMATOGR B, V704, P307, DOI 10.1016/S0378-4347(97)00454-4
   MARTA B, 2003, AIDS RES HUM RETROV, V19, P941
   Martin TM, 2006, AIDS, V20, P1085, DOI 10.1097/01.aids.0000222091.59658.6d                                             
   Marzolini C, 2002, J CHROMATOGR B, V774, P127, DOI 10.1016/S1570-0232(02)00169-1                                                   
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Notari S, 2006, J CHROMATOGR B, V833, P109, DOI 10.1016/j.jchromb.2006.02.010
   OWEN A, 2002, AIDS, V8, P11
   Ray J, 2002, J CHROMATOGR B, V775, P225, DOI 10.1016/S1570-0232(02)00295-7                                                   
   RITA CEE, 2008, RAPID COMMUN MASS SP, V22, P657
   Rouzes A, 2004, J CHROMATOGR B, V813, P209, DOI 10.1016/j.jchromb.2004.09.041
   Salphati L, 1998, PHARMACOLOGY, V56, P308, DOI 10.1159/000028214                                                               
   Sarasa-Nacenta M, 2001, J CHROMATOGR B, V757, P325, DOI 10.1016/S0378-4347(01)00172-4
   Temghare GA, 2009, E-J CHEM, V6, P223, DOI 10.1155/2009/709478                                                             
   Usami Y, 2003, CHEM PHARM BULL, V51, P715
   van Heeswijk RPG, 1998, J CHROMATOGR B, V719, P159, DOI 10.1016/S0378-4347(98)00392-2                                                   
   Verbesselt R, 2007, J CHROMATOGR B, V845, P51, DOI 10.1016/j.jchromb.2006.07.068
   von Hentig N, 2007, DRUG TODAY, V43, P221, DOI 10.1358/dot.2006.43.4.1050793
   Wang EJ, 2002, ANTIMICROB AGENTS CH, V46, P160, DOI 10.1128/AAC.46.1.160-165.2002
   Yamada H, 2001, J CHROMATOGR B, V755, P85, DOI 10.1016/S0378-4347(00)00617-4
   1999, INT C ANT AG CHEM, V39, P24
NR 48
TC 0
Z9 0
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0009-5893
J9 CHROMATOGRAPHIA
JI Chromatographia
PD MAY
PY 2010
VL 71
IS 9-10
BP 941
EP 946
DI 10.1365/s10337-010-1551-8
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 595FF
UT WOS:000277595400028
DA 2018-01-05
ER

PT J
AU Wang, YJ
   McKenna, PM
   Hrin, R
   Felock, P
   Lu, M
   Jones, KG
   Coburn, CA
   Grobler, JA
   Hazuda, DJ
   Miller, MD
   Lai, MT
AF Wang, Ying-Jie
   McKenna, Philip M.
   Hrin, Renee
   Felock, Peter
   Lu, Meiqing
   Jones, Kristen G.
   Coburn, Craig A.
   Grobler, Jay A.
   Hazuda, Dania J.
   Miller, Michael D.
   Lai, Ming-Tain
TI Assessment of the susceptibility of mutant HIV-1 to antiviral agents
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Phenotypic assay; Resistance selection; HIV-1; Protease inhibitor;
   Susceptibility
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO SELECTION; REVERSE-TRANSCRIPTASE
   INHIBITOR; HIGH GENETIC BARRIER; HIV-1-INFECTED PATIENTS; DRUG
   SUSCEPTIBILITY; RETROVIRAL VECTORS; PHENOTYPIC ASSAY; MAGNETIC FORCE;
   RESISTANCE
AB Traditional phenotypic assays used to assess the susceptibility of mutant human immunodeficiency virus type-1 (HIV-1) obtained from infected patients or from resistance selection to antiviral agents in cell culture are rather tedious and time consuming. To improve the efficiency of this process, a novel method was developed in which mutant viruses are captured with magnetic nano-beads and used to infect gag-GFP reporter cells to evaluate the extent of resistance conferred by the mutant viruses against antiviral agents. The optimal timing for measuring the inhibitory potencies of antiviral agents was found to be day 3 post-infection for integrase strand transfer inhibitors and protease inhibitors and day 4 for non-nucleoside reverse transcriptase inhibitors. Comparable EC(50) values were obtained when bead-captured breakthrough virus from in vitro resistance selection experiments and its matched site-directed mutagenesis virus were tested side by side in this assay. This assay protocol was also employed to evaluate the inhibitor susceptibility of breakthrough viruses collected from resistance selections that were conducted in the presence of increasing concentrations of an HIV-1 protease inhibitor. Taken together, these findings suggest that a rapid, sensitive, non-invasive, and homogeneous phenotypic assay has been developed for assessing the antiviral agent susceptibility of mutant viruses that emerge from in vitro resistance selection studies. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Wang, Ying-Jie; McKenna, Philip M.; Hrin, Renee; Felock, Peter; Lu, Meiqing; Jones, Kristen G.; Coburn, Craig A.; Grobler, Jay A.; Hazuda, Dania J.; Miller, Michael D.; Lai, Ming-Tain] Merck Res Labs, Dept Antiviral Res, West Point, PA 19486 USA.
RP Lai, MT (reprint author), Merck Res Labs, Dept Antiviral Res, West Point, PA 19486 USA.
EM mingtain_lai@merck.com
CR BABA M, 2007, ANTIMICROB AGENTS CH, V51, P707, DOI DOI 10.1128/AAC.01079-06
   Brussel A, 2004, J VIROL, V78, P11263, DOI 10.1128/JVI.78.20.11263-11271.2004
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033
   Dandache S, 2008, J MED VIROL, V80, P2053, DOI 10.1002/jmv.21329
   de Mendoza Carmen, 2002, HIV Clin Trials, V3, P304
   Delelis O, 2009, NUCLEIC ACIDS RES, V37, P1193, DOI 10.1093/nar/gkn1050
   GAO Q, 1992, J VIROL, V66, P12
   GAO Q, 1994, ARCH VIROL, V136, P111, DOI 10.1007/BF01538821                                                              
   Gehringer H, 2003, J VIROL METHODS, V109, P143, DOI 10.1016/S0166-0934(03)00065-X
   Haim H, 2005, J VIROL, V79, P622, DOI 10.1128/JVI.79.1.622-625.2005
   Hazen RJ, 2005, ANTIMICROB AGENTS CH, V49, P4465, DOI 10.1128/AAC.49.11.4465-4473.2005
   Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269
   Higashikawa F, 2001, VIROLOGY, V280, P124, DOI 10.1006/viro.2000.0743
   Kadota S, 2005, J VIROL METHODS, V128, P61, DOI 10.1016/j.jviromet.2005.04.003
   KELLAM P, 1995, J VIROL, V69, P669
   KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23                                                             
   Lai MT, 2009, ANTIMICROB AGENTS CH, V53, P2424, DOI 10.1128/AAC.01559-08
   LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0
   Malet I, 2009, J ANTIMICROB CHEMOTH, V63, P795, DOI 10.1093/jac/dkp014
   Nijhuis M, 2007, PLOS MED, V4, P152, DOI 10.1371/journal.pmed.0040036
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Papandreou MJ, 1996, FEBS LETT, V379, P171, DOI 10.1016/0014-5793(95)01505-1
   PARTALEDIS JA, 1995, J VIROL, V69, P5228
   Perelson AS, 1997, AIDS, V11, pS17
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/eobt.3.5.745.21225
   Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082
   Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22
   Tremblay Cecile L, 2008, Ther Clin Risk Manag, V4, P759
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548
NR 31
TC 7
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD MAY
PY 2010
VL 165
IS 2
BP 230
EP 237
DI 10.1016/j.jviromet.2010.02.002
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 597NC
UT WOS:000277763700015
PM 20153375
DA 2018-01-05
ER

PT J
AU Nalam, MNL
   Ali, A
   Altman, MD
   Reddy, GSKK
   Chellappan, S
   Kairys, V
   Ozen, A
   Cao, H
   Gilson, MK
   Tidor, B
   Rana, TM
   Schiffer, CA
AF Nalam, Madhavi N. L.
   Ali, Akbar
   Altman, Michael D.
   Reddy, G. S. Kiran Kumar
   Chellappan, Sripriya
   Kairys, Visvaldas
   Ozen, Aysegul
   Cao, Hong
   Gilson, Michael K.
   Tidor, Bruce
   Rana, Tariq M.
   Schiffer, Celia A.
TI Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of
   Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug
   Resistance
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS PROTEASE; ORALLY BIOAVAILABLE INHIBITOR; POTENT
   INHIBITOR; TMC114; DISCOVERY; VARIANTS
AB Drug resistance mutations in HIV-1 protease selectively alter inhibitor binding without significantly affecting substrate recognition and cleavage. This alteration in molecular recognition led us to develop the substrate-envelope hypothesis which predicts that HIV-1 protease inhibitors that fit within the overlapping consensus volume of the substrates are less likely to be susceptible to drug-resistant mutations, as a mutation impacting such inhibitors would simultaneously impact the processing of substrates. To evaluate this hypothesis, over 130 HIV-1 protease inhibitors were designed and synthesized using three different approaches with and without substrate-envelope constraints. A subset of 16 representative inhibitors with binding affinities to wild-type protease ranging from 58 nM to 0.8 pM was chosen for crystallographic analysis. The inhibitor-protease complexes revealed that tightly binding inhibitors (at the picomolar level of affinity) appear to "lock" into the protease active site by forming hydrogen bonds to particular active-site residues. Both this hydrogen bonding pattern and subtle variations in protein-ligand van der Waals interactions distinguish nanomolar from picomolar inhibitors. In general, inhibitors that fit within the substrate envelope, regardless of whether they are picomolar or nanomolar, have flatter profiles with respect to drug-resistant protease variants than inhibitors that protrude beyond the substrate envelope; this provides a strong rationale for incorporating substrate-envelope constraints into structure-based design strategies to develop new HIV-1 protease inhibitors.
C1 [Ali, Akbar; Reddy, G. S. Kiran Kumar; Cao, Hong; Rana, Tariq M.; Schiffer, Celia A.] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, Worcester, MA 01605 USA.
   [Altman, Michael D.] MIT, Dept Chem, Cambridge, MA 02139 USA.
   [Chellappan, Sripriya; Kairys, Visvaldas; Gilson, Michael K.] Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.
   [Ozen, Aysegul] Bogazici Univ, Polymer Res Ctr, TR-34342 Istanbul, Turkey.
   [Ozen, Aysegul] Bogazici Univ, Dept Chem Engn, TR-34342 Istanbul, Turkey.
   [Tidor, Bruce] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Tidor, Bruce] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
RP Schiffer, CA (reprint author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, 364 Plantat St, Worcester, MA 01605 USA.
EM Celia.Schiffer@umassmed.edu
RI Kairys, Visvaldas/K-9893-2013
OI Kairys, Visvaldas/0000-0002-5427-0175; Ozen, Aysegul/0000-0002-6240-1948
FU National Institute of General Medical Sciences, National Institutes of
   Health [P01GM66524]; Fundacao para a Ciencia e a Tecnologia (Portugal)
   [SFRH/BPD/41787/2007]
FX This work was made possible by a grant from the National Institute of
   General Medical Sciences, National Institutes of Health (P01GM66524).
   V.K. thanks Fundacao para a Ciencia e a Tecnologia (Portugal) for grant
   SFRH/BPD/41787/2007.
CR Ali A, 2006, J MED CHEM, V49, P7342, DOI 10.1021/jm060666p
   Altman MD, 2008, J AM CHEM SOC, V130, P6099, DOI 10.1021/ja076558p
   Chellappan S, 2007, CHEM BIOL DRUG DES, V69, P298, DOI 10.1111/j.1747-0285.2007.00514.x
   Chellappan S, 2007, PROTEINS, V68, P561, DOI 10.1002/prot.21431
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   Hoffman NG, 2003, VIROLOGY, V314, P536, DOI 10.1016/S0042-6822(03)00484-7
   Joint United Nations Programme against HIV/AIDS, 2008, 2008 REP GLOB AIDS E
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   King NM, 2004, CHEM BIOL, V11, P1333, DOI 10.1016/j.chembiol.2004.08.010
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Nalam MNL, 2008, CURR OPIN HIV AIDS, V3, P642, DOI 10.1097/COH.0b013e3283136cee
   Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000                                                 
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Turner SR, 1998, J MED CHEM, V41, P3467, DOI 10.1021/jm9802158
   Wu TD, 2003, J VIROL, V77, P4836, DOI 10.1128/JVI.77.8.4836-4847.2003
NR 27
TC 52
Z9 53
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2010
VL 84
IS 10
BP 5368
EP 5378
DI 10.1128/JVI.02531-09
PG 11
WC Virology
SC Virology
GA 591QW
UT WOS:000277318600049
PM 20237088
OA gold
DA 2018-01-05
ER

PT J
AU Cesarini, S
   Spallarossa, A
   Ranise, A
   Schenone, S
   La Colla, P
   Collu, G
   Sanna, G
   Loddo, R
AF Cesarini, Sara
   Spallarossa, Andrea
   Ranise, Angelo
   Schenone, Silvia
   La Colla, Paolo
   Collu, Gabriella
   Sanna, Giuseppina
   Loddo, Roberta
TI (Hetero)aroyl esters of 2-(N-phthalimido)ethanol and analogues: parallel
   synthesis, anti-HIV-1 activity and cytotoxicity
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Anti-HIV-1 activity; Cytotoxicity; Parallel synthesis; Esters
ID REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS TYPE-1;
   ANTI-HIV CHEMOTHERAPY; NONNUCLEOSIDE INHIBITORS;
   PHENETHYLTHIAZOLYLTHIOUREA DERIVATIVES; RT INHIBITORS; RESISTANCE;
   DESIGN; NNRTIS; THERAPY
AB The structural simplification of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) O-(2-phthalimidoethyl)-N-(hetero)aroyl-N-arylthiocarbamates led us to design (hetero)aroyl esters of 2-(N-phthalimido)ethanol as a potential new class of anti-HIV-1 agents. The setup of a solution-phase parallel synthesis method allowed the rapid preparation of a high number of analogues. In cell-based assays, 20 of 34 esters showed anti-HIV-1 activity ranging from nanomolar to micromolar concentrations. The most potent esters had only a minor effect or were ineffective in enzyme assay against HIV-1 reverse transcriptase. Variations on the O-(2-phthalimidoethyl) moiety led to compounds devoid of antiretroviral activity, but cytotoxic, in particular those bearing the 4-chloro-3-nitrobenzoyl moiety. The most cytotoxic compound displayed a CC(50) value of 1.6 mu M.
C1 [Cesarini, Sara; Spallarossa, Andrea; Ranise, Angelo; Schenone, Silvia] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   [La Colla, Paolo; Collu, Gabriella; Sanna, Giuseppina; Loddo, Roberta] Univ Cagliari, Dipartimento Sci & Tecnol Biomed, I-09042 Cagliari, Italy.
RP Cesarini, S (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto XV 3, I-16132 Genoa, Italy.
EM sara.cesarini@unige.it
RI Loddo, Roberta/B-9038-2011; La Colla , Paolo /B-8587-2011
OI Sanna, Giuseppina/0000-0002-3999-4263
FU MURST (Cofinanziamento Nazionale); CNR (Rome); Ministero Italiano della
   Salute - Istituto Superiore di Sanita [40D.46]
FX This work was supported by MURST (Cofinanziamento Nazionale), CNR (Rome)
   and Ministero Italiano della Salute - Istituto Superiore di Sanita
   (grant no. 40D.46). Fondazione Carige is gratefully acknowledged for
   financially supporting S.C. The authors thank Mr. O. Gagliardo for the
   microanalyses, Mr. F. Tuberoni, Dr. M. Anzaldi, Dr. R. Raggio, and Dr.
   C. Rossi, for the IR and NMR spectra.
CR Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420                                                        
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 2001, FARMACO, V56, P3, DOI 10.1016/S0014-827X(01)01007-2                                                   
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   LEIGHBROWN AJ, 2003, J INFECT DIS, V187, P683
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   MIZUCH KG, 1957, ZH OBSHCH KHIM+, V27, P189
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pedersen OS, 1999, ANTIVIR CHEM CHEMOTH, V10, P285, DOI 10.1177/095632029901000601                                                      
   Pedersen OS, 2000, SYNTHESIS-STUTTGART, P479
   Ranise A, 2005, J MED CHEM, V48, P3858, DOI 10.1021/jm049252r
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7
   Silverman R. B., 2004, ORGANIC CHEM DRUG DE, P17
   SOVA M, 2006, J BIOL CHEM, V275, P5633
   Spallarossa A, 2009, EUR J MED CHEM, V44, P1650, DOI 10.1016/j.ejmech.2008.09.024
   Spallarossa A, 2009, EUR J MED CHEM, V44, P2190, DOI 10.1016/j.ejmech.2008.10.032
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   THOMAS G, 2000, MED CHEM, P40
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
NR 29
TC 3
Z9 3
U1 0
U2 2
PU BIRKHAUSER BOSTON INC
PI CAMBRIDGE
PA 675 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA
SN 1054-2523
J9 MED CHEM RES
JI Med. Chem. Res.
PD MAY
PY 2010
VL 19
IS 4
BP 311
EP 336
DI 10.1007/s00044-009-9192-x
PG 26
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 581DV
UT WOS:000276502600001
DA 2018-01-05
ER

PT J
AU Bitler, A
   Lev, N
   Fridmann-Sirkis, Y
   Blank, L
   Cohen, SR
   Shai, Y
AF Bitler, Arkady
   Lev, Naama
   Fridmann-Sirkis, Yael
   Blank, Lior
   Cohen, Sidney R.
   Shai, Yechiel
TI Kinetics of interaction of HIV fusion protein (gp41) with lipid
   membranes studied by real-time AFM imaging
SO ULTRAMICROSCOPY
LA English
DT Article; Proceedings Paper
CT 11th International Scanning Probe Microscopy Conference (ISPM)
CY JUN 17-19, 2009
CL Madrid, SPAIN
DE AFM; Fusion peptide; gp41; Membrane destruction; Kinetics
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ATOMIC-FORCE MICROSCOPY; TERMINAL HEPTAD
   REPEAT; ENVELOPE GLYCOPROTEIN; PHOSPHATIDYLCHOLINE BILAYERS; ACTIVE
   CONFORMATION; PEPTIDE; ECTODOMAIN; MODEL; REGIONS
AB One of the most important steps in the process of viral infection is a fusion between cell membrane and virus, which is mediated by the viral envelope glycoprotein. The study of activity of the glycoprotein in the post-fusion state is important for understanding the progression of infection. Here we present a first real-time kinetic study of the activity of gp41 (the viral envelope glycoprotein of human immunodeficiency virus-HIV) and its two mutants in the post-fusion state with nanometer resolution by atomic force microscopy (AFM). Tracking the changes in the phosphatidylcholine (PC) and phosphatidylcholine-phosphatidylserine (PC:PS) membrane integrity over one hour by a set of AFM images revealed differences in the interaction of the three types of protein with zwitterionic and negatively charged membranes. A quantitative analysis of the slow kinetics of hole formation in the negatively charged lipid bilayer is presented. Specifically, analysis of the rate of roughness change for the three types of proteins suggests that they exhibit different types of kinetic behavior. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Bitler, Arkady; Lev, Naama; Fridmann-Sirkis, Yael; Blank, Lior; Shai, Yechiel] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
RP Bitler, A (reprint author), Weizmann Inst Sci, Dept Biol Chem, POB 26, IL-76100 Rehovot, Israel.
EM arkady.bitler@weizmann.ac.il
RI Blank, Lior/M-3885-2017; Cohen, Sidney/J-7153-2012; Blank,
   Lior/E-5945-2013
OI Blank, Lior/0000-0002-8753-0113; Cohen, Sidney/0000-0003-4255-3351; 
CR Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2
   Douglas NW, 1997, J MOL BIOL, V273, P122, DOI 10.1006/jmbi.1997.1277
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   El Kirat K, 2005, LANGMUIR, V21, P3116, DOI 10.1021/la047640q
   El Kirat K, 2008, BBA-BIOMEMBRANES, V1778, P276, DOI 10.1016/j.bbamem.2007.09.029
   El Kirat K, 2006, BIOCHEMISTRY-US, V45, P9336, DOI 10.1021/bi060317x
   Engel A, 2000, NAT STRUCT BIOL, V7, P715, DOI 10.1038/78929
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Gamsjaeger R, 2005, BIOCHEM J, V389, P665, DOI 10.1042/BJ20050156                                                              
   Giocondi MC, 2001, LANGMUIR, V17, P1653, DOI 10.1021/la0012135
   Jena B.P., 2002, METHODS CELL BIOL
   Kiely JD, 1997, J VAC SCI TECHNOL B, V15, P1483, DOI 10.1116/1.589480
   Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004
   Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091
   KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244
   Lev N, 2007, J MOL BIOL, V374, P220, DOI 10.1016/j.jmb.2007.09.008
   Lev N, 2009, BIOCHEMISTRY-US, V48, P3166, DOI 10.1021/bi802243j
   Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573
   Milhiet PE, 2002, EMBO REP, V3, P485, DOI 10.1093/embo-reports/kvf096
   Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Munoz-Barroso I, 1999, J VIROL, V73, P6089
   Pascual R, 2005, BIOCHEMISTRY-US, V44, P14275, DOI 10.1021/bi050928
   Pascual R, 2005, J VIROL, V79, P5142, DOI 10.1128/JVI.79.8.5142-5152.2005
   Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i
   Puntheeranurak T, 2005, ULTRAMICROSCOPY, V105, P115, DOI 10.1016/j.ultramic.2005.06.026
   Rinia HA, 1999, BIOPHYS J, V77, P1683, DOI 10.1016/S0006-3495(99)77015-3
   Rinia HA, 2002, BIOCHEMISTRY-US, V41, P2814, DOI 10.1021/bi011796x
   Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322
   Salzwedel K, 1999, J VIROL, V73, P2469
   Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000
   VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223
   Vie V, 1998, LANGMUIR, V14, P4574, DOI 10.1021/la980203p                                                               
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706                                                         
   Wexler-Cohen Y, 2005, BIOCHEMISTRY-US, V44, P5853, DOI 10.1021/bi047666g
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
NR 39
TC 8
Z9 8
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3991
J9 ULTRAMICROSCOPY
JI Ultramicroscopy
PD MAY
PY 2010
VL 110
IS 6
BP 694
EP 700
DI 10.1016/j.ultramic.2010.02.034
PG 7
WC Microscopy
SC Microscopy
GA 620EX
UT WOS:000279482900024
PM 20399563
DA 2018-01-05
ER

PT J
AU Hurtig, J
   Chiu, DT
   Onfelt, B
AF Hurtig, Johan
   Chiu, Daniel T.
   Onfelt, Bjorn
TI Intercellular nanotubes: insights from imaging studies and beyond
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID TUBULOVESICULAR EXTENSIONS CYTONEMES; CELL-CELL COMMUNICATION; TUNNELING
   NANOTUBES; MEMBRANE NANOTUBES; VESICLE NETWORKS; IMMUNE CELLS;
   FLUORESCENCE MICROSCOPY; ELASTIC PROPERTIES; SURFACE PROTEINS; LIPID
   NANOTUBES
AB Cell-cell communication is critical to the development, maintenance, and function of multicellular organisms. Classical mechanisms for intercellular communication include secretion of molecules into the extracellular space and transport of small molecules through gap junctions. Recent reports suggest that cells also can communicate over long distances via a network of transient intercellular nanotubes. Such nanotubes have been shown to mediate intercellular transfer of organelles as well as membrane components and cytoplasmic molecules. Moreover, intercellular nanotubes have been observed in vivo and have been shown to enhance the transmission of pathogens such as human immunodeficiency virus (HIV)-1 and prions in vitro. These studies indicate that intercellular nanotubes may play a role both in normal physiology and in disease. (C) 2010 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2010 2 260-276
C1 [Hurtig, Johan; Chiu, Daniel T.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Onfelt, Bjorn] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, SE-17177 Stockholm, Sweden.
   [Onfelt, Bjorn] Royal Inst Technol, Dept Appl Phys, Div Cell Phys, SE-10691 Stockholm, Sweden.
RP Chiu, DT (reprint author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.
EM chiu@u.washington.edu; bjorn.onfelt@ki.se
RI Hurtig, Johan/C-2634-2009
OI Hurtig, Johan/0000-0003-0167-5416
FU Knut & Alice Wallenberg Foundation; National Institutes of Health;
   National Science Foundation; Swedish Foundation; Swedish Research
   Council
FX This work was supported by a fellowship from the Knut & Alice Wallenberg
   Foundation (to J. Hurtig), by the National Institutes of Health and the
   National Science Foundation (to D. T. Chiu), and from Swedish Foundation
   for Strategic Research and Swedish Research Council (to B. Onfelt).
CR BARZIV R, 1994, PHYS REV LETT, V73, P1392, DOI 10.1103/PhysRevLett.73.1392
   Bauer B, 2006, LANGMUIR, V22, P9329, DOI 10.1021/la060828k
   Belting M, 2008, J CELL BIOL, V183, P1187, DOI 10.1083/jcb.200810038
   BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526
   Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065
   Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Chiu DT, 2009, ACCOUNTS CHEM RES, V42, P649, DOI 10.1021/ar8002464
   Chiu DT, 2001, PROC SPIE, V4255, P1, DOI 10.1117/12.455417
   Chizmadzhev YA, 1999, BIOPHYS J, V76, P2951, DOI 10.1016/S0006-3495(99)77450-3                                                   
   Cuvelier D, 2005, BIOPHYS J, V88, P2714, DOI 10.1529/biophysj.104.056473
   Cuvelier D, 2005, EUROPHYS LETT, V71, P1015, DOI 10.1209/epl/i2005-10173-4
   Dalby MJ, 2004, CELL BIOL INT, V28, P229, DOI 10.1016/j.cellbi.2003.12.004
   Dass C, 2007, FUNDAMENTALS CONT MA
   Davidson M, 2003, J AM CHEM SOC, V125, P374, DOI 10.1021/ja027699o
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Davis DM, 2007, NAT REV IMMUNOL, V7, P238, DOI 10.1038/nri2020
   Derenyi I, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.238101
   Dommersnes PG, 2005, EUROPHYS LETT, V70, P271, DOI 10.1209/epl/i2004-10477-9
   Edgar JS, 2006, ANAL CHEM, V78, P6948, DOI 10.1021/ac0613131
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   EVANS E, 1994, CHEM PHYS LIPIDS, V73, P39, DOI 10.1016/0009-3084(94)90173-2
   EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003
   Galkina SI, 2001, EXP CELL RES, V266, P222, DOI 10.1006/excr.2001.5227
   Galkina SI, 2005, EXP CELL RES, V304, P620, DOI 10.1016/j.yexcr.2004.12.005
   Galkina SI, 2009, FEMS IMMUNOL MED MIC, V56, P162, DOI 10.1111/j.1574-695X.2009.00560.x
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   Gimsa U, 2007, MOL MEMBR BIOL, V24, P243, DOI 10.1080/09687860601141730
   Gorak-Stolinska P, 2002, CELL IMMUNOL, V219, P98, DOI 10.1016/S0008-8749(02)00598-1
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   GUPTON SL, 2007, SCI STKE, pRE5, DOI DOI 10.1126/STKE.4002007RE5
   Gurke S, 2008, HISTOCHEM CELL BIOL, V129, P539, DOI 10.1007/s00418-008-0412-0
   Gurke S, 2008, EXP CELL RES, V314, P3669, DOI 10.1016/j.yexcr.2008.08.022
   HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hodneland E, 2006, CYTOM PART A, V69A, P961, DOI 10.1002/cyto.a.20302
   Hurtig J, 2004, LANGMUIR, V20, P5637, DOI 10.1021/la0498051
   Hurtig J, 2008, SOFT MATTER, V4, P1515, DOI 10.1039/b800333e
   Hurtig J, 2006, ANAL CHEM, V78, P5281, DOI 10.1021/ac060229i
   Iglic A, 2003, PHYS LETT A, V310, P493, DOI 10.1016/S0375-9601(03)00449-3
   Iglic A, 2006, J THEOR BIOL, V240, P368, DOI 10.1016/j.jtbi.2005.09.020
   Jeffries GDM, 2007, NANO LETT, V7, P415, DOI 10.1021/nl0626784
   Jesorka A, 2008, ANNU REV ANAL CHEM, V1, P801, DOI 10.1146/annurev.anchem.1.031207.112747
   Jones S, 2008, NAT REV MICROBIOL, V6, P175, DOI 10.1038/nrmicro1866
   Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4
   Karlsson A, 2001, NATURE, V409, P150, DOI 10.1038/35051656                                                                
   Karlsson M, 2004, ANNU REV PHYS CHEM, V55, P613, DOI 10.1146/annurev.physchem.55.091602.094319
   Karlsson M, 2002, P NATL ACAD SCI USA, V99, P11573, DOI 10.1073/pnas.172183699
   Karlsson M, 2001, LANGMUIR, V17, P6754, DOI 10.1021/la0108611
   Karlsson R, 2003, J PHYS CHEM B, V107, P11201, DOI 10.1021/jp0345021
   Karlsson R, 2002, LANGMUIR, V18, P4186, DOI 10.1021/la025533v
   Klar TA, 2000, P NATL ACAD SCI USA, V97, P8206, DOI 10.1073/pnas.97.15.8206                                                         
   Koster G, 2003, P NATL ACAD SCI USA, V100, P15583, DOI 10.1073/pnas.2531786100
   Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Lichtman JW, 2005, NAT METHODS, V2, P910, DOI 10.1038/NMETH817
   LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0
   Lizana L, 2008, P NATL ACAD SCI USA, V105, P4099, DOI 10.1073/pnas.0709932105
   Lizana L, 2007, J PHYS CHEM B, V111, P6214, DOI 10.1021/jp068313p
   Lobovkina T, 2008, SOFT MATTER, V4, P467, DOI 10.1039/b715771a
   Lobovkina T, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.188105
   Lorenz RM, 2007, ANAL CHEM, V79, P224, DOI 10.1021/ac061586w
   Magalhaes AC, 2005, J NEUROSCI, V25, P5207, DOI 10.1523/JNEUROSCI.0653-05.2005
   Magin TM, 2007, EXP CELL RES, V313, P2021, DOI 10.1016/j.yexcr.2007.03.005
   Markstrom M, 2007, SOFT MATTER, V3, P587, DOI 10.1039/b610351k
   Markstrom M, 2008, LANGMUIR, V24, P5166, DOI 10.1021/la7035967
   Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406
   McCann FE, 2007, J IMMUNOL, V178, P3418, DOI 10.4049/jimmunol.178.6.3418                                                     
   McClay DR, 1999, EXP CELL RES, V253, P296, DOI 10.1006/excr.1999.4723                                                          
   MILLER J, 1995, DEVELOPMENT, V121, P2501
   Niu XL, 2009, J CELL SCI, V122, P600, DOI 10.1242/jcs.031427
   Obermajer N, 2009, CELL MOL LIFE SCI, V66, P1126, DOI 10.1007/s00018-009-8829-8
   Onfelt B, 2004, BIOCHEM SOC T, V32, P676
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545                                                
   Pontes B, 2008, EUR BIOPHYS J BIOPHY, V37, P121, DOI 10.1007/s00249-007-0184-9
   Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0                                                   
   Raucher D, 1999, BIOPHYS J, V77, P1992, DOI 10.1016/S0006-3495(99)77040-2                                                   
   Rechavi O, 2009, FEBS LETT, V583, P1792, DOI 10.1016/j.febslet.2009.03.014
   Roux A, 2002, P NATL ACAD SCI USA, V99, P5394, DOI 10.1073/pnas.082107299
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Salas-Vidal E, 2004, DEV BIOL, V265, P75, DOI 10.1016/j.ydbio.2003.09.012
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Schiro PG, 2007, ELECTROPHORESIS, V28, P2430, DOI 10.1002/elps.200600730
   Shelby JP, 2005, PHOTOCHEM PHOTOBIOL, V81, P994, DOI 10.1562/2005-02-02-RA-431R1.1
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sott K, 2006, NANO LETT, V6, P209, DOI 10.1021/nl052078p
   Sott K, 2003, LANGMUIR, V19, P3904, DOI 10.1021/la026947r
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5                                                   
   TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597
   TOKARZ M, 2007, LANGMUIR, V23, P7651
   Tsafrir I, 2001, PHYS REV LETT, V86, P1138, DOI 10.1103/PhysRevLett.86.1138
   Upadhyaya A, 2004, BIOPHYS J, V86, P2923, DOI 10.1016/S0006-3495(04)74343-X                                                   
   Vanherberghen B, 2004, P NATL ACAD SCI USA, V101, P16873, DOI 10.1073/pnas.0406240101
   Veranic P, 2008, BIOPHYS J, V95, P4416, DOI 10.1529/biophysj.108.131375
   Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582-4934.2004.tb00328.x                                              
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Westphal V, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.143903
   Williams GS, 2007, TRAFFIC, V8, P1190, DOI 10.1111/j.1600-0854.2007.00603.x
   WOLPERT L, 1961, EXP CELL RES, V25, P374, DOI 10.1016/0014-4827(61)90287-7
   Wood W, 2002, INT J BIOCHEM CELL B, V34, P726, DOI 10.1016/S1357-2725(01)00172-8                                                   
   KEGG KYOTO ENCY GENE
NR 106
TC 36
Z9 37
U1 0
U2 25
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD MAY-JUN
PY 2010
VL 2
IS 3
BP 260
EP 276
DI 10.1002/wnan.80
PG 17
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 590JN
UT WOS:000277221800005
PM 20166114
OA green_accepted
DA 2018-01-05
ER

PT J
AU Matei, E
   Zheng, A
   Furey, W
   Rose, J
   Aiken, C
   Gronenborn, AM
AF Matei, Elena
   Zheng, Andrew
   Furey, William
   Rose, Jeremy
   Aiken, Christopher
   Gronenborn, Angela M.
TI Anti-HIV Activity of Defective Cyanovirin-N Mutants Is Restored by
   Dimerization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN GP120;
   DOMAIN-SWAPPED DIMER; INACTIVATING PROTEIN; ANTIVIRAL ACTIVITY;
   BINDING-SITE; CONTAINS 2; X-RAY; NMR; 2G12
AB Cyanovirin-N (CV-N) is a two-domain, cyanobacterial protein that inhibits human immunodeficiency virus (HIV) at nano-molar concentrations by binding to high mannose sugars on the HIV envelope glycoprotein gp120. The wild type protein can exist as a monomer or a domain-swapped dimer with the monomer and dimer containing two or four sugar binding sites, respectively, one on each domain. Here we demonstrate that monomeric, single binding site mutants are completely inactive and that a single site, whether located on domain A or B, is insufficient to impart the antiviral activity. Linking inactive, monomeric proteins in a head-to-head fashion by an intermolecular disulfide bond or by creating an exclusively domain-swapped dimer via a hinge residue deletion restored antiviral activity to levels similar to that of wild type CV-N. These findings demonstrate unequivocally that multisite binding by CV-N type lectins is necessary for viral inhibition.
C1 [Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [Furey, William] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.
   [Furey, William] Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA.
   [Zheng, Andrew] Duke Univ, Dept Chem, Durham, NC 27708 USA.
   [Rose, Jeremy; Aiken, Christopher] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
RP Gronenborn, AM (reprint author), Univ Pittsburgh, Sch Med, Dept Biol Struct, 3501 5th Ave,BST3-Rm 1050, Pittsburgh, PA 15260 USA.
EM amg100@pitt.edu
OI Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health [RO1GM080642]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant RO1GM080642 (to A. M. G.).
CR Barrientos LG, 2006, PROTEIN ENG DES SEL, V19, P525, DOI 10.1093/protein/gzl040
   Barrientos LG, 2004, J INFECT DIS, V189, P1440, DOI 10.1086/382658
   Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Barrientos LG, 2002, BIOCHEM BIOPH RES CO, V298, P598, DOI 10.1016/S0006-291X(02)02489-0                                                   
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Botos I, 2002, BIOCHEM BIOPH RES CO, V294, P184, DOI 10.1016/S0006-291X(02)00455-2
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   Chen B, 2005, STRUCTURE, V13, P197, DOI 10.1016/j.str.2004.12.004
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Esser MT, 1999, J VIROL, V73, P4360
   FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515                                                       
   Fromme R, 2007, BIOCHEMISTRY-US, V46, P9199, DOI 10.1021/bi700666m
   Grey MJ, 2003, J AM CHEM SOC, V125, P14324, DOI 10.1021/ja0367389
   GRZESIEK S, 1993, J BIOMOL NMR, V3, P487
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0                                                                
   Johnson Bruce A, 2004, Methods Mol Biol, V278, P313
   Kiessling L. L., 2008, GLYCOSCIENCE, P2483, DOI DOI 10.1007/978-3-540-30429-6_64
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Matei E, 2008, STRUCTURE, V16, P1183, DOI 10.1016/j.str.2008.05.011
   McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   PATTERSON GML, 1993, J PHYCOL, V29, P125, DOI 10.1111/j.1529-8817.1993.tb00290.x
   Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X                                                       
   Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Trkola A, 1996, J VIROL, V70, P1100
   Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301                                             
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Yang RF, 2007, J VIROL, V81, P3749, DOI 10.1128/JVI.02634-06
NR 41
TC 23
Z9 25
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 23
PY 2010
VL 285
IS 17
BP 13057
EP 13065
DI 10.1074/jbc.M109.094938
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 584XO
UT WOS:000276787800063
PM 20147291
OA gold
DA 2018-01-05
ER

PT J
AU Smith, A
   Giunta, B
   Bickford, PC
   Fountain, M
   Tan, J
   Shytle, RD
AF Smith, Adam
   Giunta, Brian
   Bickford, Paula C.
   Fountain, Michael
   Tan, Jun
   Shytle, R. Douglas
TI Nanolipidic particles improve the bioavailability and alpha-secretase
   inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment
   of Alzheimer's disease
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoparticle; EGCG; Bioavailability; Alzheimer's disease;
   Pharmacokinetics
ID GREEN TEA CATECHINS; AMYLOID PRECURSOR PROTEIN; SOLID LIPID
   NANOPARTICLES; CACO-2 MONOLAYER MODEL; HEALTHY-VOLUNTEERS;
   DRUG-DELIVERY; ORAL BIOAVAILABILITY; MASS-SPECTROMETRY; POLYMER
   MICELLES; MOUSE PLASMA
AB Prevention of amyloidogenic processing of amyloid precursor protein with the use of natural phyto-chemicals capable of enhancing a-secretase activity may be a therapeutic approach for treatment of neurodegenerative diseases including Alzheimer's disease (AD) and HIV-associated dementia (HAD). We have recently shown promising preclinical results with the use of green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG) in mouse models of both diseases, however the translation into clinical use has been problematic primarily as a result of poor bioavailability and inefficient delivery to the central nervous system (CNS). While the antioxidant properties of EGCG are well known, we have shown that it is able to promote non-amyloidogenic processing of amyloid precursor protein (APP) by upregulating a-secretase, thus preventing brain beta amyloid plaque formation, a hallmark of AD pathology and common finding in HIV infection. In this preliminary study, we investigated the ability of one preformulation method to improve the oral bioavailability of EGCG. We found that forming nanolipidic EGCG particles improves the neuronal (SweAPP N2a cells) alpha-secretase enhancing ability in vitro by up to 91% (P<001) and it's oral bioavailability in vivo by more than two-fold over free EGCG. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Tan, Jun; Shytle, R. Douglas] Univ S Florida, Silver Child Dev Ctr, Dept Psychiat & Behav Med, Tampa, FL 33612 USA.
   [Smith, Adam; Bickford, Paula C.; Tan, Jun; Shytle, R. Douglas] Univ S Florida, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA.
   [Smith, Adam; Giunta, Brian; Tan, Jun] Univ S Florida, Neuroimmunol Lab, Dept Psychiat & Behav Med, Tampa, FL 33612 USA.
   [Smith, Adam; Giunta, Brian; Tan, Jun; Shytle, R. Douglas] Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, Tampa, FL 33612 USA.
   [Fountain, Michael] Univ S Florida, Coll Business, Ctr Entrepreneurship, Tampa, FL 33612 USA.
   [Fountain, Michael] Univ S Florida, Coll Engn, Dept Ind & Management Syst Engn, Tampa, FL 33612 USA.
   [Bickford, Paula C.] Vet Adm Hosp, Res Serv, Tampa, FL 33612 USA.
RP Tan, J (reprint author), Univ S Florida, Silver Child Dev Ctr, Dept Psychiat & Behav Med, 12901 Bruce B Downs Blvd,MDC 102, Tampa, FL 33612 USA.
EM jtan@health.usf.edu; dshytle@health.usf.edu
RI Tan, Jun/I-5339-2012; Giunta, Brian/H-3817-2011; Smith,
   Adam/J-8246-2012; Shytle, Roland/J-4249-2012; Bickford,
   Paula/J-5970-2012
OI Smith, Adam/0000-0001-9724-173X; Bickford, Paula/0000-0001-9657-7725
FU NIMH K08 Clinical Scientist Career Development Award [5K08MH082642-02];
   SBIR [R43AT004871]; NCAAM (JT); NIA (RDS) [R21AG031037]
FX B.G. is supported by an NIMH K08 Clinical Scientist Career Development
   Award (5K08MH082642-02) (K08). This work was also supported by an SBIR
   grant (R43AT004871) from the NCAAM (JT) and an R21 grant (R21AG031037)
   from the NIA (RDS).
CR Alisky JM, 2007, MED HYPOTHESES, V69, P1140, DOI 10.1016/j.mehy.2007.02.030
   Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001                                                
   Bailey AR, 2008, INT J CLIN EXP MED, V1, P338
   BANO G, 1991, EUR J CLIN PHARMACOL, V41, P615, DOI 10.1007/BF00314996
   Bontha S, 2006, J CONTROL RELEASE, V114, P163, DOI 10.1016/j.jconrel.2006.06.015
   Burns A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b75
   Cai Y, 2002, DRUG METAB DISPOS, V30, P1246, DOI 10.1124/dmd.30.11.1246
   Chan KY, 2007, J PHARM PHARMACOL, V59, P395, DOI 10.1211/jpp.59.3.0009
   Chow HHS, 2001, CANCER EPIDEM BIOMAR, V10, P53
   Feng WY, 2006, CURR DRUG METAB, V7, P755
   Frezard F, 2008, INT J PHARM, V347, P102, DOI 10.1016/j.ijpharm.2007.06.029
   Ghafouri M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-28
   Giunta B, 2006, BRAIN RES, V1123, P216, DOI 10.1016/j.brainres.2066.09.057
   Giunta B, 2008, INT J CLIN EXP PATHO, V1, P260
   He WL, 2007, INT J PHARM, V334, P173, DOI 10.1016/j.ijpharm.2006.10.025
   Henning SM, 2008, J NUTR, V138, P1529
   Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026
   Italia JL, 2008, J BIOMED NANOTECHNOL, V4, P304, DOI 10.1166/jbn.2008.341
   Khajuria A, 2002, PHYTOMEDICINE, V9, P224, DOI 10.1078/0944-7113-00114
   Kim JO, 2009, J CONTROL RELEASE, V138, P197, DOI 10.1016/j.jconrel.2009.04.019
   Kumar VV, 2007, INT J PHARM, V335, P167, DOI 10.1016/j.ijpharm.2006.11.004
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   Lambert JD, 2004, J NUTR, V134, P1948
   Lambert JD, 2003, J NUTR, V133, P4172
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P2111, DOI 10.1124/dmd.106.011460
   Lin LC, 2007, J AGR FOOD CHEM, V55, P1517, DOI 10.1021/jf062816a
   Liu J, 2006, CURR PHARM DESIGN, V12, P4685, DOI 10.2174/138161206779026263                                                      
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Meeuwsen EJ, 2009, J NUTR HEALTH AGING, V13, P242, DOI 10.1007/s12603-009-0066-1                                                       
   Obregon DF, 2006, J BIOL CHEM, V281, P16419, DOI 10.1074/jbc.M600617200
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027
   Pattanaik S, 2006, PHYTOTHER RES, V20, P683, DOI 10.1002/ptr.1937
   Rao SVR, 2008, INT J PHARM, V362, P16, DOI 10.1016/j.ijpharm.2008.05.015
   Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005
   Rezai-Zadeh K, 2009, J CELL MOL MED, V13, P574, DOI 10.1111/j.1582-4934.2008.00344.x
   SAKAMOTO A, 1993, BRAIN RES, V629, P171, DOI 10.1016/0006-8993(93)90499-D
   Siddiqui IA, 2009, CANCER RES, V69, P1712, DOI 10.1158/0008-5472.CAN-08-3978
   Sparidans RW, 2007, J CHROMATOGR B, V855, P200, DOI 10.1016/j.jchromb.2007.05.008
   Tarkowski E, 2003, BRAIN RES BULL, V61, P255, DOI 10.1016/S0361-9230(03)00088-1
   Tian Y, 2007, J CONTROL RELEASE, V121, P137, DOI 10.1016/j.jconrel.2007.05.010
   Ullmann U, 2004, INT J VITAM NUTR RES, V74, P269, DOI 10.1024/0300-9831.74.4.269
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205                                                      
   Wang M, 2007, J CHROMATOGR B, V856, P318, DOI 10.1016/j.jchromb.2007.06.037
   Wang YW, 2004, J CHROMATOGR B, V808, P215, DOI 10.1016/j.jchromb.2004.05.006
   Wang Z, 2000, J MASS SPECTROM, V35, P71, DOI 10.1002/(SICI)1096-9888(200001)35:1<71::AID-JMS915>3.0.CO;2-5
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Wojtera M, 2005, FOLIA NEUROPATHOL, V43, P311
   Yokoyama M, 1998, J CONTROL RELEASE, V50, P79, DOI 10.1016/S0168-3659(97)00115-6
   Zhang L, 2004, INT J PHARM, V287, P1, DOI 10.1016/j.ijpharm.2004.08.020
   Zutshi R K, 1985, J Assoc Physicians India, V33, P223
NR 50
TC 87
Z9 92
U1 3
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD APR 15
PY 2010
VL 389
IS 1-2
BP 207
EP 212
DI 10.1016/j.ijpharm.2010.01.012
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 577JO
UT WOS:000276219200024
PM 20083179
DA 2018-01-05
ER

PT J
AU Tang, SX
   Hewlett, I
AF Tang, Shixing
   Hewlett, Indira
TI Nanoparticle-Based Immunoassays for Sensitive and Early Detection of
   HIV-1 Capsid (p24) Antigen
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TIME-RESOLVED FLUORESCENCE;
   PROSTATE-SPECIFIC ANTIGEN; ULTRASENSITIVE DETECTION; ASSAY; PROTEINS;
   PLASMA; INFECTION; DIAGNOSIS; PCR
AB We evaluated the feasibility of using nanoparticle (NP)-based assays for improving detection sensitivity of human immunodeficiency virus type 1 (HIV-1) p24 antigen. One assay that was evaluated is a gold NP-based biobarcode amplification (BCA) assay, which can detect HIV-1 p24 antigen at levels as low as 0.1 pg/mL. The lower limit of detection for an enzyme-linked immunosorbent assay (ELISA) is 10-15 pg/mL. These results demonstrate that the HIV-1 p24 BCA assay offers 100-150-fold enhancement in the detection limit over the traditional colorimetric ELISA. Furthermore, the BCA assay detected HIV-1 infection 3 days earlier than did ELISA in samples from patients who had experienced seroconversion. The other assay that we tested is the europium NP-based immunoassay, which uses europium NPs to replace gold NPs in the BCA assay to further simplify the detection method and decrease the incubation time. For detection of HIV-1 p24, the lower limit of detection for the europium NP-based immunoassay was 0.5 pg/mL. These results indicate that the universal labeling technology based on NPs and its application may provide a rapid and sensitive testing platform for clinical diagnosis and laboratory research.
C1 [Tang, Shixing; Hewlett, Indira] US FDA, Mol Virol Lab, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.
RP Hewlett, I (reprint author), US FDA, Mol Virol Lab, Ctr Biol Evaluat & Res, Bldg 29B,Rm 4NN16,8800 Rockville Pike, Bethesda, MD 20892 USA.
EM Indira.hewlett@fda.hhs.gov
FU Office of Science and Health Coordination; Food and Drug Administration;
   National Heart, Lung and Blood Institute; National Institute of Allergy
   and Infectious Diseases; National Institutes of Health
FX Office of Science and Health Coordination, Food and Drug Administration;
   National Heart, Lung and Blood Institute and National Institute of
   Allergy and Infectious Diseases, National Institutes of Health.
CR Bao YP, 2006, ANAL CHEM, V78, P2055, DOI 10.1021/ac051798d
   Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Harma H, 2000, LUMINESCENCE, V15, P351, DOI 10.1002/1522-7243(200011/12)15:6<351::AID-BIO624>3.0.CO;2-3
   Harma H, 2001, CLIN CHEM, V47, P561
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   SCHUPBACH J, 1994, J INFECT DIS, V170, P318, DOI 10.1093/infdis/170.2.318                                                        
   Schupbach J, 1996, AIDS, V10, P1085
   Simon JHM, 1997, J VIROL, V71, P5259
   Soukka T, 2001, ANAL CHEM, V73, P2254, DOI 10.1021/ac001287i
   Storhoff JJ, 2004, BIOSENS BIOELECTRON, V19, P875, DOI 10.1016/j.bios.2003.08.014
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2009, CLIN VACCINE IMMUNOL, V16, P408, DOI 10.1128/CVI.00412-08
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481
   Zhang HQ, 2007, ANALYST, V132, P724, DOI 10.1039/b704256f
NR 21
TC 64
Z9 67
U1 3
U2 40
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 15
PY 2010
VL 201
SU 1
BP S59
EP S64
DI 10.1086/650386
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 568AK
UT WOS:000275493500009
PM 20225948
OA gold
DA 2018-01-05
ER

PT J
AU Hu, GD
   Chen, JZ
   Shi, SH
   Yi, CH
   Zhang, SL
   Zhang, QG
AF Hu Guodong
   Chen Jianzhong
   Shi Shuhua
   Yi Changhong
   Zhang Shaolong
   Zhang Qinggang
TI Molecular Dynamics Study of the Effects of V82A and L90M on PR-IDV
   Complex
SO ACTA CHIMICA SINICA
LA Chinese
DT Article
DE HIV-1 protease; mutation; molecular dynamics simulation
ID FREE-ENERGY CALCULATION; MIGRATION INHIBITORY FACTOR; BOUND HIV-1
   PROTEASES; BINDING FREE-ENERGIES; DRUG-RESISTANCE; ACCURATE PREDICTION;
   FORCE-FIELD; WILD-TYPE; SIMULATIONS; INSIGHTS
AB In order to elucidate the influences of V82A and L90M mutations on the HIV-1 protease (PR) and the indinavir (IDV) complex, molecular dynamics simulations have been successfully carried out for 5.5 nanoseconds. The binding free energies calculated by an MM-PBSA method are in agreement with the experimental ones. The analysis of the detailed interaction energies shows that the changes of entropic contribution in V82A and L90M complex are larger than changes of enthalpic contribution compared with the wild complex. Detailed binding free energies of the IDV and individual protein residue show that the wild, V82A and L90M complexes have a similar binding mode, and the binding free energies mainly come from six groups around A28/A28', I50/I50' and I84/I84'. The mode between wild and IDV was analyzed in detail, the little changes of V82A were also compared with L90M. The changes of V82A mutation are caused by the steric hindrance, and those of L90M are by the stronger interaction between D25 and L90 compared with the wild. It was expected that this work could provide some helpful insights into the nature of mutational influences and aid design of better inhibitors in the future.
C1 [Hu Guodong; Chen Jianzhong; Shi Shuhua; Yi Changhong; Zhang Shaolong; Zhang Qinggang] Shandong Normal Univ, Coll Phys & Elect, Jinan 250014, Peoples R China.
RP Hu, GD (reprint author), Shandong Normal Univ, Coll Phys & Elect, Jinan 250014, Peoples R China.
EM zhangqg@sdnu.edu.cn
CR Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen XF, 2004, J MOL MODEL, V10, P373, DOI 10.1007/s00894-004-0205-x
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201
   Duan LL, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2770720
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Frish M. J., 2003, GAUSSIAN 03 REV B 05
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Hong L, 2000, PROTEIN SCI, V9, P1898, DOI 10.1110/ps.9.10.1898                                                            
   Hou TJ, 2007, J MED CHEM, V50, P1177, DOI 10.1021/jm0609162
   Hou TJ, 2009, PROTEINS, V74, P837, DOI 10.1002/prot.22192
   Hu GD, 2010, EUR J MED CHEM, V45, P227, DOI 10.1016/j.ejmech.2009.09.048
   Hu GD, 2009, ACTA CHIM SINICA, V67, P1019
   Hu JP, 2006, ACTA CHIM SINICA, V64, P2079
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Lu YP, 2006, J AM CHEM SOC, V128, P11830, DOI 10.1021/ja058042g
   Mahalingam B, 2004, EUR J BIOCHEM, V271, P1516, DOI 10.1111/j.1432-1033.2004.04060.x
   Ode H, 2006, J AM CHEM SOC, V128, P7887, DOI 10.1021/ja060682b
   Pearlman DA, 2005, J MED CHEM, V48, P7796, DOI 10.1021/jm050306m
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Sa-Filho Dercy J, 2003, J Clin Virol, V28, P186, DOI 10.1016/S1386-6532(03)00007-6
   Sadiq SK, 2008, J CHEM INF MODEL, V48, P1909, DOI 10.1021/ci8000937
   Shi SH, 2009, ACTA CHIM SINICA, V67, P2791
   Stoica I, 2008, J AM CHEM SOC, V130, P2639, DOI 10.1021/ja0779250
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, CURR COMPUT-AID DRUG, V2, P287, DOI 10.2174/157340906778226454                                                      
   Wang W, 2001, P NATL ACAD SCI USA, V98, P14937, DOI 10.1073/pnas.251265598
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A                  
   Wittayanarakul K, 2008, J COMPUT CHEM, V29, P673, DOI 10.1002/jcc.20821
   Wu EL, 2008, CHEM-EUR J, V14, P8704, DOI 10.1002/chem.200800277
   Wu EL, 2009, J THEOR COMPUT CHEM, V8, P551, DOI 10.1142/S0219633609004903
   Wu EL, 2009, J PHYS CHEM B, V113, P2477, DOI 10.1021/jp808182y
   Xu Y, 2006, PROTEINS, V64, P1058, DOI 10.1002/prot.21044
   Zhuang SL, 2006, J MOL STRUC-THEOCHEM, V763, P97, DOI 10.1016/j.theochem.2006.01.031
   Zhuang SL, 2005, J MED CHEM, V48, P7208, DOI 10.1021/jm050562z
NR 37
TC 3
Z9 3
U1 0
U2 8
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 0567-7351
J9 ACTA CHIM SINICA
JI Acta Chim. Sin.
PD APR 14
PY 2010
VL 68
IS 7
BP 603
EP 610
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 592YU
UT WOS:000277418700002
DA 2018-01-05
ER

PT J
AU Brunel, F
   Veron, L
   David, L
   Domard, A
   Verrier, B
   Delair, T
AF Brunel, Fabrice
   Veron, Laurent
   David, Laurent
   Domard, Alain
   Verrier, Bernard
   Delair, Thierry
TI Self-Assemblies on Chitosan Nanohydrogels
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE chitosan; hydrogel; nanoparticles; sorption; surface-biomolecule
   interactions
ID MOLECULAR-WEIGHT MANIPULATION; PLA NANOPARTICLES; DELIVERY-SYSTEM;
   IMMUNE-RESPONSES; VACCINE DELIVERY; AQUEOUS-SOLUTION; LATEX-PARTICLES;
   NITROUS-ACID; P24 PROTEIN; HIV-1 P24
AB Nanohydrogels of pure chitosan, containing neither potentially toxic solvent nor chemical cross-linker, were obtained by an ammonia-induced physical gelation of a reverse emulsion of a chitosan solution in a triglyceride mixture as an organic phase. The resulting colloids were obtained with a controlled size distribution and displayed a positive surface charge. Assemblies with various macromolecules were investigated as a first step toward new nano-carriers for bioactive molecules. Chondroitin sulfate formed polyelectrolyte complexes with the positively charged surface of the nanogels, leading to negative chitosan-based colloidal hydrogels with preservation of the original average size of the dispersion. The mode of assembly of HIV-1 p24 protein with these colloids relied on multiple interactions between the protein and the hydrogels, irrespective of their surface charges. Anyhow, the amounts of loaded protein remained limited, suggesting a surface association. The assembly of an immunoglobulin (IgG) was markedly different from p24. No association was detected with the positive colloidal hydrogels whereas a very high loading capacity could be obtained with the negative ones. So, this work reports that fully biodegradable sub micrometric physical hydrogels could be obtained from naturally occurring polymers. These gels could cargo a variety of biomolecules making them versatile carriers with many potential applications in Life Sciences.
C1 [Brunel, Fabrice; David, Laurent; Domard, Alain; Delair, Thierry] Univ Lyon 1, CNRS, UMR Ingn Mat Polymeres 5223, Lab Mat Polymeres & Biomat, F-69622 Villeurbanne, France.
   [Brunel, Fabrice; Veron, Laurent] BioMerieux, Marcy Ietoile, France.
   [Verrier, Bernard] Univ Lyon, CNRS, UMR 5086, IBCP, F-69367 Lyon 07, France.
RP Delair, T (reprint author), Univ Lyon 1, CNRS, UMR Ingn Mat Polymeres 5223, Lab Mat Polymeres & Biomat, Bat ISTIL,15 Bd A Latarjet, F-69622 Villeurbanne, France.
EM thierry.delair@univ-lyon.fr
RI Delair, Thierry/E-7896-2012; d2am, beamline/I-6445-2015
FU bioMerieux; EU; Munanovac; NanoBioSaccharide
FX We thank Charlotte Primard, Severine Murrier, Caroline Weber, and B. V.
   for gift of the proteins. Stephane Trombotto and J. M. Lucas for their
   assistance. Beatrice Burdin and the members of the Centre Technologique
   des Microstructures for help in TEM. We would also like to thank
   bioMerieux for financial support. Additional funding was provided by the
   EU via Europrize (NoE), Munanovac (Strep), and the NanoBioSaccharide
   European project.
CR ALLAN GG, 1995, CARBOHYD RES, V277, P273, DOI 10.1016/0008-6215(95)00208-B
   ALLAN GG, 1995, CARBOHYD RES, V277, P257, DOI 10.1016/0008-6215(95)00207-A
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   BAGCHI P, 1981, J COLLOID INTERF SCI, V83, P460, DOI 10.1016/0021-9797(81)90342-8
   Borges O, 2005, INT J PHARM, V299, P155, DOI 10.1016/j.ijpharm.2005.04.037
   Brunel F, 2008, LANGMUIR, V24, P11370, DOI 10.1021/la801917a
   Brunel F, 2009, LANGMUIR, V25, P8935, DOI 10.1021/la9002753
   Bulte JWM, 2008, FUND BIOMED TECHNOL, V3, P1
   DEBAILLOU N, 1985, COLLOID SURFACE, V16, P271, DOI 10.1016/0166-6622(85)80258-4                                                    
   DROGOZ A, 2007, COMPLEXES POLYELECTR
   DROGOZ A, 2007, BIOMACROMOLECULES, V23, P10959
   Drogoz A, 2007, LANGMUIR, V23, P10950, DOI 10.1021/la7008545
   Duracher D, 2000, LANGMUIR, V16, P9002, DOI 10.1021/la0004045
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   HIRANO S, 1989, AGR BIOL CHEM TOKYO, V53, P3065, DOI 10.1080/00021369.1989.10869777                                                  
   HIRANO S, 1988, POLYM ENG SCI, V59, P897
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Kabanov VA, 2004, J PHYS CHEM B, V108, P1485, DOI 10.1021/jp035821f
   Kim TH, 2006, MOL CANCER THER, V5, P1723, DOI 10.1158/1535-7163.MCT-06-0540
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   LIFENG Q, 2007, EUR J CANCER, V43, P184
   Liu WG, 2002, J CONTROL RELEASE, V83, P1
   MAO HQ, 1993, ANAL BIOCHEM, V211, P240
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X                                                   
   Moon JS, 2007, APPL MICROBIOL BIOT, V75, P989, DOI 10.1007/s00253-007-0898-8
   Mulloy B, 2000, J BIOTECHNOL, V77, P123, DOI 10.1016/S0168-1656(99)00211-4                                                   
   MUMPER RJ, 1995, P INT S CONTROL REL, V22, P179
   Nagamoto T, 2004, PHARM RES, V21, P671, DOI 10.1023/B:PHAM.0000022414.17183.58
   ROSENFELDT S, 2004, PHYS REV, V70
   Schatz C, 2003, LANGMUIR, V19, P9896, DOI 10.1021/la034410n
   Schatz C, 2003, BIOMACROMOLECULES, V4, P641, DOI 10.1021/bm025724c
   Seferian PG, 2000, VACCINE, V19, P661, DOI 10.1016/S0264-410X(00)00248-6
   Sogias IA, 2008, BIOMACROMOLECULES, V9, P1837, DOI 10.1021/bm800276d
   Taniguchi T, 2003, COLLOID SURFACE B, V29, P53, DOI 10.1016/S0927-7765(02)00176-5                                                   
   Tokumitsu H, 1999, CHEM PHARM BULL, V47, P838
   USAMI Y, 1994, J VET MED SCI, V56, P761, DOI 10.1292/jvms.56.761                                                             
   Vachoud L, 1997, CARBOHYD RES, V302, P169, DOI 10.1016/S0008-6215(97)00126-2
   van der Lubben IM, 2003, VACCINE, V21, P1400, DOI 10.1016/S0264-410X(02)00686-2
   Van der Lubben IM, 2001, J DRUG TARGET, V9, P39, DOI 10.3109/10611860108995631                                                       
   VandeVord PJ, 2002, J BIOMED MATER RES, V59, P585, DOI 10.1002/jbm.1270
   Wittemann A, 2003, PHYS CHEM CHEM PHYS, V5, P1671, DOI 10.1039/b300607g
   Zaharoff DA, 2007, VACCINE, V25, P2085, DOI 10.1016/j.vaccine.2006.11.034
NR 44
TC 12
Z9 12
U1 1
U2 45
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1616-5187
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD APR 8
PY 2010
VL 10
IS 4
BP 424
EP 432
DI 10.1002/mabi.200900356
PG 9
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA 584SL
UT WOS:000276772900011
PM 20166229
DA 2018-01-05
ER

PT J
AU Balzarini, J
   Francois, KO
   Van Laethem, K
   Hoorelbeke, B
   Renders, M
   Auwerx, J
   Liekens, S
   Oki, T
   Igarashi, Y
   Schols, D
AF Balzarini, Jan
   Francois, Katrien O.
   Van Laethem, Kristel
   Hoorelbeke, Bart
   Renders, Marleen
   Auwerx, Joeri
   Liekens, Sandra
   Oki, Toshikazu
   Igarashi, Yasuhiro
   Schols, Dominique
TI Pradimicin S, a Highly Soluble Nonpeptidic Small-Size
   Carbohydrate-Binding Antibiotic, Is an Anti-HIV Drug Lead for both
   Microbicidal and Systemic Use
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DC-SIGN; ANTIFUNGAL ANTIBIOTICS; ENVELOPE
   GLYCOPROTEIN; GLYCOSYLATION SITES; D-MANNOPYRANOSIDE; GLYCAN DELETIONS;
   T-LYMPHOCYTES; PLANT-LECTINS; GP120
AB Pradimicin S (PRM-S) is a highly water-soluble, negatively charged derivative of the antibiotic pradimicin A (PRM-A) in which the terminal xylose moiety has been replaced by 3-sulfated glucose. PRM-S does not prevent human immunodeficiency virus (HIV) adsorption on CD4(+) T cells, but it blocks virus entry into its target cells. It inhibits a wide variety of HIV-1 laboratory strains and clinical isolates, HIV-2, and simian immunodeficiency virus (SIV) in various cell culture systems (50% and 90% effective concentrations [EC(50)s and EC(90)s] invariably in the lower micromolar range). PRM-S inhibits syncytium formation between persistently HIV-1- and SIV-infected cells and uninfected CD4(+) T lymphocytes, and prevents dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-mediated HIV-1 and SIV capture and subsequent virus transmission to CD4(+) T cells. Surface plasmon resonance (SPR) studies revealed that PRM-S strongly binds to gp120 in a Ca(2+)-dependent manner at an affinity constant (K(D)) in the higher nanomolar range. Its anti-HIV activity and HIV-1 gp120-binding properties can be dose-dependently reversed in the presence of an (alpha-1,2) mannose trimer. Dose-escalating exposure of HIV-1- infected cells to PRM-S eventually led to the isolation of mutant virus strains that had various deleted N-glycosylation sites in the envelope gp120 with a strong preference for the deletion of the high-mannose-type glycans. Genotypic resistance development occurred slowly, and significant phenotypic resistance occurred only after the sequential appearance of up to six mutations in gp120, pointing to a high genetic barrier of PRM-S. The antibiotic is nontoxic against a variety of cell lines, is not mitogenic, and does not induce cytokines and chemokines in peripheral blood mononuclear cells as determined by the Bio-Plex human cytokine 27-plex assay. It proved stable at high temperature and low pH. Therefore, PRM-S may qualify as a potential anti-HIV drug candidate for further (pre) clinical studies, including its microbicidal use.
C1 [Balzarini, Jan; Francois, Katrien O.; Van Laethem, Kristel; Hoorelbeke, Bart; Renders, Marleen; Auwerx, Joeri; Liekens, Sandra; Schols, Dominique] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Oki, Toshikazu; Igarashi, Yasuhiro] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama 9390398, Japan.
RP Balzarini, J (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.be
RI Renders, Marleen/L-2603-2015; Schols, Dominique/S-9057-2017; Van
   Laethem, Kristel/R-6282-2016
OI Renders, Marleen/0000-0002-4099-9045; Schols,
   Dominique/0000-0003-3256-5850; Van Laethem, Kristel/0000-0001-6036-2271
FU EMPRO [503558]; European Commission [242135]; Fonds voor
   Wetenschappelijk Onderzoek (FWO) [G-485-08]; Centers of Excellence of
   the Katholieke Universiteit at Leuven [EF/05/015]; Fondation Dormeur
FX This work was supported by the EMPRO no. 503558 of the 6th Frame Work
   Programme and CHAARM no. 242135 of the 7th Frame Work Programme of the
   European Commission, the Fonds voor Wetenschappelijk Onderzoek (FWO)
   Krediet nr. G-485-08, the Centers of Excellence of the Katholieke
   Universiteit at Leuven ( Krediet nr. EF/05/015), and the Fondation
   Dormeur.
CR Auwerx J, 2008, VIROLOGY, V382, P10, DOI 10.1016/j.virol.2008.09.010
   Balzarini J, 2006, ANTIVIR RES, V71, P237, DOI 10.1016/j.antiviral.2006.02.004
   Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155
   Balzarini J, 2007, J VIROL, V81, P362, DOI 10.1128/JVI.01404-06
   Balzarini J, 2006, J VIROL, V80, P8411, DOI 10.1128/JVI.00369-06
   CHANG T, 2004, AIDS RES, V6, P1161
   de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003
   de Witte L, 2007, NAT MED, V13, P367, DOI 10.1038/nm1541
   DRICKAMER K, 2006, NAT STRUCT MOL BIOL, V12, P830
   Ezekowitz RA, 2003, J INFECT DIS, V187, pS335, DOI 10.1086/374746                                                                  
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   HOSHINO H, 1989, J ANTIBIOT, V42, P344, DOI 10.7164/antibiotics.42.344                                                      
   Hu M, 1999, SPECTROCHIM ACTA A, V55, P2547, DOI 10.1016/S1386-1425(99)00106-7                                                   
   Huskens D, 2008, INT J BIOCHEM CELL B, V40, P2802, DOI 10.1016/j.biocel.2008.05.023
   Huskens D, 2007, VIROLOGY, V360, P294, DOI 10.1016/j.virol.2006.10.027
   KONDO S, 1992, DRUG EXP CLIN RES, V18, P217
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Liu YA, 2009, BIOPOLYMERS, V92, P194, DOI 10.1002/bip.21173
   OKI T, 1988, J ANTIBIOT, V41, P1701, DOI 10.7164/antibiotics.41.1701                                                     
   Pollielta M, 2008, VIROLOGY, V370, P382, DOI 10.1016/j.virol.2007.08.033
   SAITOH K, 1993, J ANTIBIOT, V46, P406, DOI 10.7164/antibiotics.46.406                                                      
   SAITOH K, 1993, J ANTIBIOT, V46, P580, DOI 10.7164/antibiotics.46.580                                                      
   TANABETOCHIKURA A, 1990, VIROLOGY, V176, P467, DOI 10.1016/0042-6822(90)90016-K
   UEKI T, 1993, J ANTIBIOT, V46, P465, DOI 10.7164/antibiotics.46.465                                                      
   UEKI T, 1993, J ANTIBIOT, V46, P455, DOI 10.7164/antibiotics.46.455                                                      
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Van Laethem K, 2005, J VIROL METHODS, V123, P25, DOI 10.1016/j.jviromet.2004.09.003
   Van Damme E. J., 1998, HDB PLANT LECTINS PR
NR 33
TC 35
Z9 36
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 2010
VL 54
IS 4
BP 1425
EP 1435
DI 10.1128/AAC.01347-09
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 570HG
UT WOS:000275662700005
PM 20047920
OA gold
DA 2018-01-05
ER

PT J
AU Makarov, E
   Gerson, T
   Senanayake, T
   Poluektova, L
   Vinogradov, S
AF Makarov, Edward
   Gerson, Trevor
   Senanayake, Thulani
   Poluektova, Larisa
   Vinogradov, Serguei
TI Efficient Suppression of Human Immunodeficiency Virus in Macrophages by
   Nano-NRTIs
SO ANTIVIRAL RESEARCH
LA English
DT Meeting Abstract
CT 23rd International Conference on Antiviral Research
CY APR 25-28, 2010
CL San Francisco, CA
SP Int Soc Antiviral Res
C1 [Makarov, Edward; Gerson, Trevor; Senanayake, Thulani; Poluektova, Larisa; Vinogradov, Serguei] Univ Nebraska Med Ctr, Omaha, NE USA.
OI Poluektova, Larisa/0000-0001-7339-8732
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD APR
PY 2010
VL 86
IS 1
MA 78
BP A38
EP A39
DI 10.1016/j.antivira1.2010.02.388
PG 2
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 598CH
UT WOS:000277809600058
DA 2018-01-05
ER

PT J
AU Miller, JF
   Turner, EM
   Gudmundsson, KS
   Jenkinson, S
   Spaltenstein, A
   Thomson, M
   Wheelan, P
AF Miller, John F.
   Turner, Elizabeth M.
   Gudmundsson, Kristjan S.
   Jenkinson, Stephen
   Spaltenstein, Andrew
   Thomson, Michael
   Wheelan, Pat
TI Novel N-substituted benzimidazole CXCR4 antagonists as potential
   anti-HIV agents
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CXCR4; Benzimidazole; Tetrahydroquinoline; HIV; Antiviral
ID IMMUNODEFICIENCY-VIRUS-INFECTION; ENTRY INHIBITORS; THERAPY; TYPE-1
AB The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar anti-HIV activity. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Miller, John F.; Turner, Elizabeth M.; Gudmundsson, Kristjan S.; Spaltenstein, Andrew] GlaxoSmithKline Res & Dev Ltd, Infect Dis Ctr Excellence Drug Discovery, Dept Med Chem, Res Triangle Pk, NC 27709 USA.
   [Thomson, Michael] GlaxoSmithKline Res & Dev Ltd, Infect Dis Ctr Excellence Drug Discovery, Dept Virol, Res Triangle Pk, NC 27709 USA.
   [Wheelan, Pat] GlaxoSmithKline Res & Dev Ltd, Infect Dis Ctr Excellence Drug Discovery, Dept DMPK, Res Triangle Pk, NC 27709 USA.
   [Jenkinson, Stephen] GlaxoSmithKline Res & Dev Ltd, Infect Dis Ctr Excellence Drug Discovery, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA.
RP Miller, JF (reprint author), GlaxoSmithKline Res & Dev Ltd, Infect Dis Ctr Excellence Drug Discovery, Dept Med Chem, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM john.6.miller@gsk.com
CR CARLOFEDERICO P, 2008, J MED VIROL, V80, P565
   Chirch LM, 2009, EXPERT OPIN PHARMACO, V10, P1203, DOI [10.1517/14656560902911488 , 10.1517/14656560902911488]
   Detels R, 2001, AIDS, V15, P347, DOI 10.1097/00002030-200102160-00008
   Grande F, 2008, CURR PHARM DESIGN, V14, P385
   Gudmundsson KS, 2009, BIOORG MED CHEM LETT, V19, P6399, DOI 10.1016/j.bmcl.2009.09.056
   Gudmundsson KS, 2009, BIOORG MED CHEM LETT, V19, P5048, DOI 10.1016/j.bmcl.2009.07.037
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef
   Kazmierski WM, 2007, ANNU REP MED CHEM, V42, P301, DOI 10.1016/S0065-7743(07)42019-X
   Kelly TR, 2002, J ORG CHEM, V67, P2197, DOI 10.1021/jo016250v
   Kuritzkes DR, 2009, CURR OPIN HIV AIDS, V4, P82, DOI 10.1097/COH.0b013e328322402e
   Mallewa JE, 2008, J ANTIMICROB CHEMOTH, V62, P648, DOI 10.1093/jac/dkn251
   Mosley CA, 2009, EXPERT OPIN THER PAT, V19, P23, DOI 10.1517/13543770802553483
   Moyle G, 2009, CLIN INFECT DIS, V48, P798, DOI 10.1086/597097
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354
   Shaheen F, 2004, CURR OPIN INFECT DIS, V17, P7, DOI 10.1097/01.qco.0000113643.29255.5c
   Vandekerckhove L, 2009, J ANTIMICROB CHEMOTH, V63, P1087, DOI 10.1093/jac/dkp113
   GUDMUNDSSON K, 2006, Patent No. 2006020415
NR 20
TC 42
Z9 42
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2010
VL 20
IS 7
BP 2125
EP 2128
DI 10.1016/j.bmcl.2010.02.053
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 572CZ
UT WOS:000275805900014
PM 20207537
DA 2018-01-05
ER

PT J
AU Zhang, HS
   Feng, DZ
   Chen, L
   Long, YQ
AF Zhang, Hu-Shan
   Feng, Dong-Zhi
   Chen, Li
   Long, Ya-Qiu
TI Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing
   CCR5 antagonists via functionality inversion approach
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CCR5 antagonist; HIV-1 entry inhibitor; Functionality inversion;
   Bioisostere; Butanamide; Tropane; 2-Methyl-3H-imidazo[4,5-b]pyridine;
   3H-[1,2,3]Triazolo[4,5-b]pyridine
ID MOLECULAR-INTERACTIONS; POTENT; INHIBITORS; INFECTION; MARAVIROC; ENTRY;
   AGENT
AB By using functionality inversion approach, we identified a new scaffold containing (S)-alpha-phenyl-gamma-amino butanamide as CCR5 antagonists derived from the 1,3-propanediamine carboxamide pharmacophore protocol. The (2S)-2-phenyl-4-(8-aza-bicyclo[3.2.1]octan-8-yl)-butanamide derivatives display significantly high potency to antagonize CCR5 receptor with nanomolar IC50 values. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Zhang, Hu-Shan; Feng, Dong-Zhi; Long, Ya-Qiu] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China.
   [Chen, Li] Shanghai TargetDrug Co Ltd, Shanghai 200233, Peoples R China.
RP Long, YQ (reprint author), Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.
EM yqlong@mail.shcnc.ac.cn
FU National Natural Science Foundation of China [30672528]; Science and
   Technology Commission of Shanghai Municipality [07QH14018, 08JC1422200];
   National Science & Technology Major [2009ZX09301-001]
FX National Natural Science Foundation of China (30672528), Science and
   Technology Commission of Shanghai Municipality 07QH14018, 08JC1422200)
   and National Science & Technology Major Project (2009ZX09301-001) are
   greatly appreciated for the financial supports.
CR Allegretti M, 2001, TETRAHEDRON LETT, V42, P4257, DOI 10.1016/S0040-4039(01)00663-3
   Cascieri MA, 2000, CURR OPIN CHEM BIOL, V4, P420, DOI 10.1016/S1367-5931(00)00113-7
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   EVANS DA, 1981, J AM CHEM SOC, V103, P3099, DOI 10.1021/ja00401a031                                                             
   Evans DA, 1999, J ORG CHEM, V64, P6411, DOI 10.1021/jo990756k                                                               
   Imamura S, 2006, J MED CHEM, V49, P2784, DOI 10.1021/jm051034q
   Kazmierski WM, 2008, J MED CHEM, V51, P6538, DOI 10.1021/jm800598a
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Kuritzkes D, 2008, NAT REV DRUG DISCOV, V7, P15, DOI 10.1038/nrd2490
   Lewin AH, 1998, J MED CHEM, V41, P988, DOI 10.1021/jm9707129
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Ma DW, 2007, CHEMMEDCHEM, V2, P187, DOI 10.1002/cmdc.200600182
   Maeda K, 2006, J BIOL CHEM, V281, P12688, DOI 10.1074/jbc.M.512688200
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   MEHTA LK, 1993, J CHEM SOC P1, V11, P1261, DOI DOI 10.1039/P19930001261
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Palani A, 2006, J MED CHEM, V49, P2851, DOI 10.1021/jm0600009x
   Sayana S, 2009, EXPERT REV ANTI-INFE, V7, P9, DOI 10.1586/14787210.7.1.9
   *UNAIDS, 2008, REP UNAIDS
   Wood A, 2005, PROGR MED CHEM, V43, P239, DOI 10.1016/S0079-6468(05)43007-6
   ZHANG HS, EUR J MED C IN PRESS
NR 21
TC 4
Z9 4
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2010
VL 20
IS 7
BP 2219
EP 2223
DI 10.1016/j.bmcl.2010.02.023
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 572CZ
UT WOS:000275805900036
PM 20207141
DA 2018-01-05
ER

PT J
AU Chiappetta, DA
   Hocht, C
   Sosnik, A
AF Chiappetta, Diego A.
   Hocht, Christian
   Sosnik, Alejandro
TI A Highly Concentrated and Taste-Improved Aqueous Formulation of
   Efavirenz for a More Appropriate Pediatric Management of the Anti-HIV
   Therapy
SO CURRENT HIV RESEARCH
LA English
DT Article
DE Efavirenz liquid formulation; Pediatric HIV; Taste masking test;
   Physicochemical stability; in vitro drug delivery
ID ANTIRETROVIRAL DRUGS; INFECTED CHILDREN; IN-VITRO; PHARMACOKINETICS;
   MICELLES; DELIVERY; BEHAVIOR; MASKING
AB Pediatric HIV is scarce in developed countries; 90% of pediatric HIV patients are in developing countries. In contrast, children represent 15% of the new infections in poor countries. Approximately 90% of the HIV-positive children do not have access to antiretrovirals (ARVs). Without treatment, 50% of the patients die before the 2 years of age. Efavirenz (EFV, aqueous solubility similar to 4 mu g/mL, 40-45% bioavailability), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is a first-choice pediatric ARV. To assure therapeutic plasma concentrations, the low oral bioavailability demands the administration of relatively high EFV doses. Aqueous EFV irritates the oral mucosa, causing a Burning Mouth Syndrome (BMS). A triglyceride-based liquid formulation of EFV (30 mg/mL) is not commercially available worldwide, making the appropiate dose adjustment and the swallowing difficult. More importantly, clinical trials indicated that the oral bioavailability of this oily solution is lower than that of the solid one. Moreover, a relatively high inter-subject variability has been found. The present work reports the development and full characterization of a concentrated (20 mg/mL, 2%) and taste-masked aqueous formulation of EFV for a more appropriate management of the pediatric anti-HIV therapy. Formulations displayed high physicochemical stability over time under regular storage conditions. Release assays in vitro showed a burst effect (2 h) and zero-order kinetics later on (between 2 and 24 h), compatible with the oral administration route and release. Finally, taste tests performed by adult healthy volunteers indicated that the unique combination of flavors and sweeteners employed (i) reduced the intensity of the BMS and (ii) shortened its duration significantly. Overall results indicate that the cost-effective and scalable nanotechnological strategy proposed could enable the more covenient and compliant administration of lower EFV doses. Due to a better pharmacokinetic profile, this would result in similar plasma levels than higher doses administered in solid or triglyceride-soluble form. In this context, some reduction of the treatment cost can be envisioned. This could improve the access of less affluent pediatric patients to medication in poor countries.
C1 [Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1053 Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Hocht, Christian] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, RA-1053 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Junin St,6th Floor,Buenos Aires CP1113, RA-1053 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
FU University of Buenos Aires [UBACyT-B424]; CONICET
FX Authors thank the University of Buenos Aires for partial financial
   support (Grant UBACyT-B424) and the CONICET. DAC and AS are members of
   the National Science Research Council (CONICET).
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   ALVAREZLORENZO C, 2010, HYDROGELS P IN PRESS
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Bahal SM, 2003, PHARM DEV TECHNOL, V8, P111, DOI 10.1081/PDT-120017518
   BARRUECO N, 2005, HOSP PHARM, V29, P367
   BECKERS EJ, 1988, GUT, V29, P1725, DOI 10.1136/gut.29.12.1725                                                          
   Borras-Blasco J, 2006, ANN PHARMACOTHER, V40, P1471, DOI 10.1345/aph.1H036
   Brichard B, 2009, EUR J PEDIATR, V168, P387, DOI 10.1007/s00431-008-0914-8
   Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X
   Brown E., 2007, ANTIRETROVIRAL THERA, P419
   Bunupuradah Torsak, 2006, AIDS Res Ther, V3, P30, DOI 10.1186/1742-6405-3-30
   CHIAPPETTA DA, N ALKYLATION P UNPUB
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chiappetta DA, 2009, AAPS PHARMSCITECH, V10, P1, DOI 10.1208/s12249-008-9168-z
   Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001                                                
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Ribeiro JAD, 2007, J PHARMACEUT BIOMED, V43, P298, DOI 10.1016/j.jpba.2006.06.010
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Fabbiani M, 2009, J ANTIMICROB CHEMOTH, V64, P109, DOI 10.1093/jac/dkp132
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399
   Gao JZ, 2007, J PHARM SCI-US, V96, P2970, DOI 10.1002/jps.20962
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   HAN M, 2008, J PHARM SCI, V98, P2626
   He W, 2009, CHEM PHARM BULL, V57, P122, DOI 10.1248/cpb.57.122                                                              
   Kairuz TE, 2007, CURR DRUG SAF, V2, P89
   KUMAR A, 2003, ADVERSE DRUG REACT, V222, P851
   Marcellin F, 2008, TROP MED INT HEALTH, V13, P1470, DOI 10.1111/j.1365-3156.2008.02170.x
   MEADWAY J, 2001, HELPING CHILDREN TAK
   Nunn T, 2005, BRIT J CLIN PHARMACO, V59, P674, DOI 10.1111/j.1365-2125.2005.02410.x
   Rabel SR, 2001, AAPS PHARMSCI, V3
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   SCHIFFMAN SS, 2004, BRAIN RES B, V35, P189
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Shown I, 2008, SUPRAMOL CHEM, V20, P573, DOI 10.1080/10610270701500084
   SMART T, 2005, CHILDREN HIV ARE BEI
   Sohi H, 2004, DRUG DEV IND PHARM, V30, P429, DOI 10.1081/DDC-120037477
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   SOSNIK A, 2009, P090102571 INPI
   SOSNIK A, 2008, J CONTROL RELEASE, V138, P2
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Standing JF, 2005, INT J PHARM, V300, P56, DOI 10.1016/j.ijpharm.2005.05.006
   Starr SE, 2002, PEDIATR INFECT DIS J, V21, P659, DOI 10.1097/01.inf.0000020966.06388.92
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273
   UNAIDS/WHO, AIDS EP
   *US PEPFAR, PED TREATM CAR
   van Luin M, 2009, JAIDS-J ACQ IMM DEF, V52, P240, DOI 10.1097/QAI.0b013e3181b061e6
   *WHO, AIDS EP UPD 2007
   *WHO, WHO MAK MED CHILD SI
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   [Anonymous], 1991, Avicel CE-15, Microcrystalline cellulose and guar gum. For superior sensory characteristics in chewable tablets, Patent No. 4983394
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
NR 55
TC 19
Z9 19
U1 2
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD APR
PY 2010
VL 8
IS 3
BP 223
EP 231
DI 10.2174/157016210791111142                                              
          
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 589DF
UT WOS:000277125000007
PM 20158456
DA 2018-01-05
ER

PT J
AU Sivin, I
   Istvan, B
AF Sivin, Irving
   Istvan Batar
TI State-of-the-art of non-hormonal methods of contraception: III.
   Intrauterine devices
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Review
ID PELVIC-INFLAMMATORY-DISEASE; ECTOPIC PREGNANCY; TUBAL INFERTILITY;
   CLINICAL-PERFORMANCE; COMPARATIVE TRIAL; REPEAT ABORTION; SPERM
   TRANSPORT; UTERINE CAVITY; CERVICAL-MUCUS; COPPER IUDS
AB Since the 1959 revival of the IUD, non-hormonal devices have become the most widely used of all reversible contraceptives. Pregnancy rates of copper-releasing IUDs in current use range from approximately 0.5 to 1.5 per hundred continuing users in the first year, with somewhat lower annual pregnancy rates thereafter. Evidence-based research has been systematically conducted and translated into guidelines for eligibility criteria and problem management. Recent device research, beyond the T, Multiload and frameless devices has centred on improved designs such as U ,Y and Slimline shapes, or enhanced copper release, the latter through electrochemical effects or nanotechnology applications. Other IUD research foci concern devices that decrease bleeding and pain by releasing non-steroidal anti-inflammatory drugs. Yet other research lines indicate noncontraceptive benefits of copper intrauterine devices in protecting against endometrial cancer, and favourable risk-benefit analyses of IUD use by women at risk of or post HIV infection. IUD mechanisms of action and the relation of IUDs to pelvic infection and ectopic pregnancy are briefly reviewed. For our literature search we used Medline, Popline and Cochrane Library data bases, Google search, our personal files, and the references contained in articles in our files.</.
C1 [Sivin, Irving] Populat Council, New York, NY 10065 USA.
   [Istvan Batar] Univ Debrecen, Family Planning Ctr, Dept Obstet & Gynaecol, H-4012 Debrecen, Hungary.
RP Sivin, I (reprint author), Populat Council, 1230 York Ave, New York, NY 10065 USA.
EM sivin@popcbr.rockefeller.edu
CR ALVAREZ F, 1988, FERTIL STERIL, V49, P768
   Amy JJ, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2895
   ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0                                                    
   AREF I, 1983, CONTRACEPT DELIV SYS, V4, P203
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bakken IJ, 2006, HUM REPROD, V21, P3132, DOI 10.1093/humrep/del289
   BATAR I, 1995, BRIT J FAM PLAN, V20, P137
   Batar I, 2006, EUR J CONTRACEP REPR, V11, P262, DOI 10.1080/136251880600907966
   BEERTHUIZEN RJCM, 1982, EUR J OBSTET GYN R B, V13, P31, DOI 10.1016/0028-2243(82)90035-1
   Beining RM, 2008, ANN EPIDEMIOL, V18, P492, DOI 10.1016/j.annepidem.2007.11.011
   BERAL V, 1975, BRIT J OBSTET GYNAEC, V82, P775, DOI 10.1111/j.1471-0528.1975.tb00572.x                                              
   CHE Y, 2007, J REPROD CONTRACEPT, V18, P72
   Cheng L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001324.pub3
   CRAMER DW, 1985, NEW ENGL J MED, V312, P941, DOI 10.1056/NEJM198504113121502
   DALING JR, 1985, NEW ENGL J MED, V312, P937, DOI 10.1056/NEJM198504113121501                                                     
   DATEY S, 1995, CONTRACEPTION, V51, P155, DOI 10.1016/0010-7824(95)00012-Y
   Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776                                                       
   ELBADRAWI HH, 1980, CONTRACEPT DELIV SYS, V1, P303
   FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M
   FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W                                                    
   Goodman S, 2008, CONTRACEPTION, V78, P143, DOI 10.1016/j.contraception.2008.03.003
   GRAFENBERG E, 1930, P 3 WORLD LEAG SEX R, P166
   GRAFENBERG E, 1931, PRACTICE CONTRACEPTI, P33
   GRAY RH, 1985, INTRAUTERINE CONTRAC, P354
   Grimes D, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD01777.PUB2
   GRIMES D, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003036
   Grimes DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006034.pub2
   HAGENFELDT K, 1972, CONTRACEPTION, V6, P37, DOI 10.1016/S0010-7824(72)80004-0
   HARLAP S, 1991, PREVENTING PREGNANCY
   Haugan T, 2007, CONTRACEPTION, V75, P171, DOI 10.1016/j.contraception.2006.09.005
   Heikinheimo O, 2008, CONTRACEPTION, V78, P149, DOI 10.1016/j.contraception.2008.03.013
   Heikinheimo O, 2009, HUM REPROD UPDATE, V15, P165, DOI 10.1093/humupd/dmn049
   Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024                                                
   Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438                                                            
   Hubacher D, 2007, CONTRACEPTION, V75, pS8, DOI 10.1016/j.contraception.2006.12.005
   ISHIHAMA A, 1959, Yokohama Med Bull, V10, P89
   JAIN AK, 1975, CONTRACEPTION, V11, P243, DOI 10.1016/0010-7824(75)90033-5                                                    
   JONSSON B, 1991, CONTRACEPTION, V43, P447, DOI 10.1016/0010-7824(91)90135-3                                                    
   Kapp N, 2009, CONTRACEPTION, V80, P327, DOI 10.1016/j.contraception.2009.03.024
   KOCH UJ, 1980, ACTA EUR FERTIL, V2, P33
   Kulier R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005347.pub3
   LEE NC, 1988, OBSTET GYNECOL, V72, P1
   LEE NC, 1983, OBSTET GYNECOL, V62, P1
   LEHFELDT H, 1970, AM J OBSTET GYNECOL, V108, P1005, DOI 10.1016/0002-9378(70)90443-6                                                    
   Li J, 2007, CONTRACEPTION, V76, P233, DOI 10.1016/j.contraception.2007.04.010
   Mansour D, 2007, CONTRACEPTION, V75, pS144, DOI 10.1016/j.contraception.2006.12.021
   MEIRIK O, 1981, ACTA OBSTET GYN SCAN, V60, P545, DOI 10.3109/00016348109155483                                                       
   Meirik O, 2007, CONTRACEPTION, V75, pS41, DOI 10.1016/j.contraception.2006.12.017
   MISHELL DR, 1966, AM J OBSTET GYNECOL, V96, P119, DOI 10.1016/S0002-9378(16)34650-6                                                   
   Moreau C, 2007, HUM REPROD, V22, P2422, DOI 10.1093/humrep/dem184
   NI FX, 2001, CHIN J FAM PLANN, V9, P308
   OBRIEN PA, 2005, COCHRANE DB SYST REV, V1
   OPPENHEIMER W, 1959, AM J OBSTET GYNECOL, V78, P446, DOI 10.1016/0002-9378(59)90203-0                                                    
   Ortiz ME, 2007, CONTRACEPTION, V75, pS16, DOI 10.1016/j.contraception.2007.01.020
   ORTIZ ME, 1987, CONTRACEPTION, V36, P37, DOI 10.1016/0010-7824(87)90060-6
   ORY HW, 1981, OBSTET GYNECOL, V57, P137
   Ota T, 1934, Jpn J Obstet Gynecol, V17, P210
   OZALP SS, WHO REPROD HLTH LIB
   Pakarinen P, 2003, CONTRACEPTION, V68, P31, DOI 10.1016/S0010-7824(03)104-5
   Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0                                                   
   Roblero L, 1996, REPROD FERT DEVELOP, V8, P871, DOI 10.1071/RD9960871
   ROSENFIELD AG, 1974, AM J OBSTET GYNECOL, V118, P1104, DOI 10.1016/0002-9378(74)90690-5                                                    
   Rowe PJ, 1997, CONTRACEPTION, V56, P341
   SAGIROGLU N, 1971, INT J FERTIL, V16, P1
   SALEM R, 2006, POPULATION REPORTS B, V7
   SEGAL SJ, 1985, FERTIL STERIL, V44, P214
   SETTLAGE DS, 1973, FERTIL STERIL, V24, P655
   SIVIN I, 1991, OBSTET GYNECOL, V78, P291
   SIVIN I, 1971, STUD FAMILY PLANN, V2, P248, DOI 10.2307/1965080
   SIVIN I, 1987, CONTRACEPTION, V35, P245, DOI 10.1016/0010-7824(87)90026-6
   SIVIN I, 1989, STUD FAMILY PLANN, V20, P355, DOI 10.2307/1966438
   SIVIN I, 1991, CONTRACEPTION, V44, P481, DOI 10.1016/0010-7824(91)90150-E
   SIVIN I, 1979, STUD FAMILY PLANN, V10, P263, DOI 10.2307/1965507                                                                 
   Sivin I, 2007, CONTRACEPTION, V75, pS70, DOI 10.1016/j.contraception.2007.01.016
   SKJELDESTAD F, 1988, Advances in Contraceptive Delivery Systems, V4, P179, DOI 10.1007/BF01849435
   Skouby S O, 1976, Ugeskr Laeger, V138, P339
   Stringer EM, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.031
   Thiery M, 1997, Eur J Contracept Reprod Health Care, V2, P15
   TIETZE C, 1970, STUD FAMILY PLANN, P1
   TREDWAY DR, 1975, AM J OBSTET GYNECOL, V123, P734, DOI 10.1016/0002-9378(75)90497-4                                                    
   TRUSSELL J, 1995, AM J PUBLIC HEALTH, V85, P494, DOI 10.2105/AJPH.85.4.494
   ULLMANN G, 1972, CONTRACEPTION, V6, P71, DOI 10.1016/S0010-7824(72)80007-6                                                   
   *UN DEP EC SOC AFF, WORLD CONTR US 2007
   VESSEY M, 1976, Journal of Biosocial Science, V8, P373
   WHO, 1985, CLIN REPROD FERTIL, V3, P131
   *WHO, 2000, WHO CLASS TUM PATH G, P190
   *WHO DEP REPR HLTH, 2005, SEL PRACT REC CONTR
   WILCOX AJ, 1985, FERTIL STERIL, V44, P366
   WILDEMEERSCH D, 1988, Advances in Contraceptive Delivery Systems, V4, P197, DOI 10.1007/BF01849438
   WILSON JC, 1989, AM J OBSTET GYNECOL, V160, P391, DOI 10.1016/0002-9378(89)90455-9                                                    
   Xia XP, 2007, CONTRACEPTION, V76, P326, DOI 10.1016/j.contraception.2007.06.006
   Xiao BL, 2007, CONTRACEPTION, V75, pS31, DOI 10.1016/j.contraception.2006.12.007
   Yu J, 2008, CONTRACEPTION, V78, P319, DOI 10.1016/j.contraception.2008.05.008
NR 93
TC 24
Z9 26
U1 0
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD APR
PY 2010
VL 15
IS 2
BP 96
EP 112
DI 10.3109/13625180903519885
PG 17
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA 569GO
UT WOS:000275584800004
PM 20230337
DA 2018-01-05
ER

PT J
AU Fu, Y
   Kao, WJ
AF Fu, Yao
   Kao, Weiyuan John
TI Drug release kinetics and transport mechanisms of non-degradable and
   degradable polymeric delivery systems
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
ID ETHYLENE-VINYL ACETATE; POTENTIAL BIOMEDICAL APPLICATIONS; IN-VITRO;
   POLY(ETHYLENE GLYCOL); PLGA NANOPARTICLES; MATHEMATICAL-MODEL; ERODIBLE
   TABLETS; COPOLYMER MATRIX; HIV MICROBICIDE; POLYURETHANE
AB Areas covered in this review: The structure and function information of selected non-degradable and degradable polymers have been collected and summarized from literature published after the 1990s. The release kinetics of selected drug compounds from various material systems is discussed in case studies. Recent progress in the mathematical models based on different transport mechanisms is highlighted.
   What the reader will gain: This article aims to provide an overview of structure-function relationships of selected non-degradable and degradable polymers as drug delivery matrices.
   Take home message: Understanding the structure-function relationship of the material system is key to the successful design of a delivery system for a particular application. Moreover, developing complex polymeric matrices requires more robust mathematical models to elucidate the solute transport mechanisms.
C1 [Fu, Yao; Kao, Weiyuan John] Univ Wisconsin, Sch Pharm, Dept Surg, Madison, WI 53705 USA.
   [Kao, Weiyuan John] Univ Wisconsin, Coll Engn, Dept Biomed Engn, Madison, WI 53705 USA.
   [Kao, Weiyuan John] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53705 USA.
RP Kao, WJ (reprint author), Univ Wisconsin, Sch Pharm, Dept Surg, 777 Highland Ave, Madison, WI 53705 USA.
EM wjkao@pharmacy.wisc.edu
FU NIH [R01-EB006613]
FX This paper was funded by NIH grant R01-EB006613.
CR Aimetti AA, 2009, BIOMATERIALS, V30, P6048, DOI 10.1016/j.biomaterials.2009.07.043
   Alfrey T., 1966, J POLYM SCI        C, V12, P249, DOI DOI 10.1002/P0LC.5070120119
   Arnold RR, 2008, J BIOMED MATER RES B, V86B, P506, DOI 10.1002/jbm.b.31049
   Artifin D.Y., 2006, ADV DRUG DELIV REV, V58, P1274
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Biondi M, 2008, ADV DRUG DELIVER REV, V60, P229, DOI 10.1016/j.addr.2007.08.038
   Bonacucina G, 2009, INT J PHARMACEUT, V377, P153, DOI 10.1016/j.ijpharm.2009.04.043
   BRANNONPEPPAS L, 1995, INT J PHARM, V116, P1, DOI 10.1016/0378-5173(94)00324-X
   Burmania JA, 2003, BIOMATERIALS, V24, P3921, DOI 10.1016/S0142-9612(03)00270-9
   Caracciolo PC, 2009, J MATER SCI-MATER M, V20, P145, DOI 10.1007/s10856-008-3561-8
   Cassano R, 2009, EUR J PHARM BIOPHARM, V72, P232, DOI 10.1016/j.ejpb.2008.10.003
   Chang CP, 2005, COLLOID SURFACE B, V44, P187, DOI 10.1016/j.colsurfb.2005.06.013
   Charlier A, 2000, INT J PHARM, V200, P115, DOI 10.1016/S0378-5173(00)00356-2
   Chen XM, 2009, DRUG DEV IND PHARM, V35, P704, DOI 10.1080/03639040802512235
   Cho CW, 2005, INT J PHARM, V299, P127, DOI 10.1016/j.ijpharm.2005.05.001
   de Queiroz AAA, 2006, ACTA BIOMATER, V2, P641, DOI 10.1016/j.actbio.2006.05.010
   Donelli G, 2006, J APPL MICROBIOL, V100, P615, DOI 10.1111/j.1365-2672.2005.02801.x
   Dorati R, 2007, POLYM DEGRAD STABIL, V92, P1660, DOI 10.1016/j.polymdegradstab.2007.06.020
   Ebewele RO, 2000, POLYM SCI TECHNOLOGY
   Zugasti ME, 2009, DRUG DEV IND PHARM, V35, P1264, DOI 10.1080/03639040902882306
   Ferrero C, 2010, J CONTROL RELEASE, V141, P223, DOI 10.1016/j.jconrel.2009.09.011
   FU JC, 1978, J BIOMED MATER RES, V12, P249, DOI 10.1002/jbm.820120302                                                           
   Fu Y, 2009, PHARM RES-DORD, V26, P2115, DOI 10.1007/s11095-009-9923-1
   Fung LK, 1997, ADV DRUG DELIVER REV, V26, P209, DOI 10.1016/S0169-409X(97)00036-7                                                   
   Aparicio Gallego E, 2005, REV ENFERM, V28, P49
   Grassi Mario, 2005, Current Drug Delivery, V2, P97, DOI 10.2174/1567201052772906
   GRIZZI I, 1995, BIOMATERIALS, V16, P305, DOI 10.1016/0142-9612(95)93258-F
   Grzybowski J, 1999, INT J PHARM, V184, P179, DOI 10.1016/S0378-5173(99)00064-2                                                   
   HELLER J, 1980, BIOMATERIALS, V1, P51, DOI 10.1016/0142-9612(80)90060-5                                                    
   HELLER J, 1978, J APPL POLYM SCI, V22, P1191
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hopfenberg HB, 1976, ACS SYM SER, V33, P26
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168-3659(01)00248-6
   JU RTC, 1995, J PHARM SCI, V84, P1464, DOI 10.1002/jps.2600841214
   Kakizawa Y, 2010, J CONTROL RELEASE, V142, P8, DOI 10.1016/j.jconrel.2009.09.024
   Kamalesh S, 2000, J BIOMED MATER RES, V52, P467, DOI 10.1002/1097-4636(20001205)52:3<467::AID-JBM4>3.0.CO;2-6
   Kang E, 2009, MOL PHARMACEUT, V6, P1110, DOI 10.1021/mp8002623
   Karasulu HY, 2000, EUR J PHARM BIOPHARM, V49, P177, DOI 10.1016/S0939-6411(99)00082-X
   Karlsson S., 1995, DEGRADABLE POLYM PRI
   KATZ JL, 2004, ENCY BIOMATERIALS BI
   Katzhendler I, 1997, J PHARM SCI, V86, P110, DOI 10.1021/js9600538                                                               
   KELM J, 2007, ANTIMICROB AGENTS CH, V50, P332
   Kim BS, 2009, MOL PHARMACEUT, V6, P353, DOI 10.1021/mp800087t
   Kim J, 2006, INT J PHARM, V315, P134, DOI 10.1016/j.ijpharm.2006.03.019
   Kim S, 2009, EUR J PHARM BIOPHARM, V71, P420, DOI 10.1016/j.ejpb.2008.09.021
   KLEINBECK KR, 2008, J BURN CARE RES, V3, P37
   Klose D, 2008, INT J PHARMACEUT, V354, P95, DOI 10.1016/j.ijpharm.2007.10.030
   Koutsopoulos S, 2009, P NATL ACAD SCI USA, V106, P4623, DOI 10.1073/pnas.0807506106
   Kranz H, 2007, INT J PHARM, V332, P107, DOI 10.1016/j.ijpharm.2006.09.033
   LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494
   Lao LL, 2008, EUR J PHARM BIOPHARM, V70, P796, DOI 10.1016/j.ejpb.2008.05.024
   Lewis DH, 1990, BIODEGRADABLE POLYM
   LI B, 2009, BIOMATERIALS, V30, P6789
   Li B, 2009, BIOMATERIALS, V30, P3486, DOI 10.1016/j.biomaterials.2009.03.008
   Li YP, 2001, J CONTROL RELEASE, V71, P203, DOI 10.1016/S0168-3659(01)00218-8
   Li ZBA, 2009, J BIOMAT SCI-POLYM E, V20, P1179, DOI 10.1163/156856209X452944
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   LIN SB, 1985, COLLOID POLYM SCI, V263, P128, DOI 10.1007/BF01412787                                                              
   Liu WH, 2005, J CONTROL RELEASE, V107, P417, DOI 10.1016/j.jconrel.2005.03.025
   Maeda H, 2003, INT J PHARM, V261, P9, DOI 10.1016/S0378-5173(03)00293-X
   Malcolm RK, 2004, J CONTROL RELEASE, V97, P313, DOI 10.1016/j.jconrel.2004.03.029
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   Manoharan C, 2009, J PHARM SCI-US, V98, P4237, DOI 10.1002/jps.21741
   MEISTER BJ, 1989, MACROMOLECULES, V22, P3611, DOI 10.1021/ma00199a019                                                             
   Miller-Chou BA, 2003, PROG POLYM SCI, V28, P1223, DOI 10.1016/S0079-6700(03)00045-5
   Modesti G, 2009, MACROMOLECULES, V42, P4681, DOI 10.1021/ma900614j
   Narasimhan B, 2001, ADV DRUG DELIVER REV, V48, P195, DOI 10.1016/S0169-409X(01)00117-X                                                   
   Narasimhan B, 1997, J PHARM SCI, V86, P297, DOI 10.1021/js960372z
   Park ES, 1998, J CONTROL RELEASE, V52, P179, DOI 10.1016/S0168-3659(97)00223-X
   PARK K, 1993, BIODEGRADABLE HYDROG, P191
   Park K., 1993, BIODEGRADABLE HYDROG, P189
   Patil RD, 2000, COMPUT THEOR POLYM S, V10, P189, DOI 10.1016/S1089-3156(99)00079-3
   PEPPAS NA, 1989, INT J PHARM, V57, P169, DOI 10.1016/0378-5173(89)90306-2
   Pillai O, 2001, CURR OPIN CHEM BIOL, V5, P447, DOI 10.1016/S1367-5931(00)00227-1                                                   
   Riggs PD, 1999, J CONTROL RELEASE, V61, P165, DOI 10.1016/S0168-3659(99)00116-9
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Rothstein SN, 2009, BIOMATERIALS, V30, P1657, DOI 10.1016/j.biomaterials.2008.12.002
   Sahana DK, 2008, J PHARM SCI-US, V97, P1530, DOI 10.1002/jps.21158
   Schierholz JM, 1997, BIOMATERIALS, V18, P839, DOI 10.1016/S0142-9612(96)00199-8
   Serra L, 2006, BIOMATERIALS, V27, P5440, DOI 10.1016/j.biomaterials.2006.06.011
   Shah PN, 2009, POLYMER, V50, P2281, DOI 10.1016/j.polymer.2009.02.048
   Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169-409X(01)00116-8                                                   
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P137
   Simmons A, 2008, BIOMATERIALS, V29, P2987, DOI 10.1016/j.biomaterials.2008.04.007
   Singh L, 2004, BIOMATERIALS, V25, P2611, DOI 10.1016/j.biomaterials.2003.09.040
   Tallury P, 2007, DENT MATER, V23, P404, DOI 10.1016/j.dental.2006.02.011
   Tang RP, 2009, BIOMACROMOLECULES, V10, P722, DOI 10.1021/bm9000475
   Wang XT, 2006, BIOMATERIALS, V27, P5588, DOI 10.1016/j.biomaterials.2006.07.016
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
   Yilgor E, 2002, POLYMER, V43, P6561, DOI 10.1016/S0032-3861(02)00566-9
   Zheng J, 2009, ACTA BIOMATER, V5, P1499, DOI 10.1016/j.actbio.2009.01.017
   Zimmermann I, 2005, EUR J PHARM BIOPHARM, V59, P217, DOI 10.1016/j.ejpb.2004.07.006
NR 93
TC 224
Z9 226
U1 15
U2 97
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD APR
PY 2010
VL 7
IS 4
BP 429
EP 444
DI 10.1517/17425241003602259
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 573EL
UT WOS:000275891100002
PM 20331353
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Li, MH
   Zhou, YH
   Luo, Q
   Li, ZS
AF Li, Ming-Hui
   Zhou, Yi-Han
   Luo, Quan
   Li, Ze-Sheng
TI The 3D structures of G-Quadruplexes of HIV-1 integrase inhibitors:
   molecular dynamics simulations in aqueous solution and in the gas phase
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE Guadruplex; Molecular dynamic simulation; Molecular modeling; Principal
   components analysis; Stability
ID IONIZATION MASS-SPECTROMETRY; DOUBLE-STRANDED OLIGODEOXYNUCLEOTIDES;
   HUMAN TELOMERIC SEQUENCE; MINOR-GROOVE BINDERS; NONCOVALENT COMPLEXES;
   PRINCIPAL-COMPONENTS; CIRCULAR-DICHROISM; QUARTET STRUCTURES; DNA
   QUADRUPLEXES; PROTEIN DYNAMICS
AB The unimolecular G-quadruplex structures of d(GGGTGGGTGGGTGGGT) (G1) and d(GTGGTGGG TGGGTGGGT) (G2) are known as the potent nanomolar HIV-1 integrase inhibitors, thus investigating the 3D structures of the two sequences is significant for structure-based rational anti-HIV drug design. In this research, based on the experimental data of circular dichroism (CD) spectropolarimetry and electrospray ionization mass spectrometry (ESI-MS), the initial models of G1 and G2 were constructed by molecular modeling method. The modeling structures of G1 and G2 are intramolecular parallel-stranded quadruplex conformation with three guanine tetrads. Particularly, the structure of G2 possesses a T loop residue between the first and the second G residues that are the component of two adjacent same-stranded G-tetrad planes. This structure proposed by us has a very novel geometry and is different from all reported G-quadruplexes. The extended (35 ns) molecular dynamic (MD) simulations for the models indicate that the G-quadruplexes maintain their structures very well in aqueous solution whether the existence of K(+) or NH(4)(+) in the central channel. Furthermore, we perform 500 ns MD simulations for the models in the gas phase. The results show that all the ion-G-quadruplex complexes are maintained during the whole simulations, despite the large magnitude of phosphate-phosphate repulsions. The gas phase MD simulations provide a good explanation to ESI-MS experiments. Our 3D structures for G1 and G2 will assist in understanding geometric formalism of G-quadruplex folding and may be helpful as a platform for rational anti-HIV drug design.
C1 [Li, Ming-Hui; Zhou, Yi-Han; Luo, Quan; Li, Ze-Sheng] Jilin Univ, Inst Theoret Chem, State Key Lab Theoret & Computat Chem, Changchun 130023, Peoples R China.
RP Li, ZS (reprint author), Jilin Univ, Inst Theoret Chem, State Key Lab Theoret & Computat Chem, Changchun 130023, Peoples R China.
EM zeshengli@hit.edu.cn
RI Li, Minghui/M-9209-2014; Li, Minghui/E-4339-2016
OI Li, Minghui/0000-0002-2056-1249; 
FU National Science Foundation of China [20333050, 20673044]; PCSIRT
   [IRT0625]
FX This work was supported by the National Science Foundation of China
   (20333050, 20673044), PCSIRT (IRT0625). We would like to thank professor
   David A. Case et al. for giving us the Amber 10.0 software as a
   freeware.
CR AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Ambrus A, 2005, BIOCHEMISTRY-US, V44, P2048, DOI 10.1021/bi048242p
   BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061
   BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Berova N., 2000, CIRCULAR DICHROISM P
   Bugaut A, 2008, BIOCHEMISTRY-US, V47, P689, DOI 10.1021/bi701873c
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   Case DA, 2008, AMBER 10
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   Darden T, 1999, STRUCT FOLD DES, V7, pR55, DOI 10.1016/S0969-2126(99)80033-1
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   Fadrna E, 2009, J CHEM THEORY COMPUT, V5, P2514, DOI 10.1021/ct900200k
   Gabelica V, 1999, J MASS SPECTROM, V34, P1328, DOI 10.1002/(SICI)1096-9888(199912)34:12<1328::AID-JMS889>3.0.CO;2-F
   Gabelica V, 2002, INT J MASS SPECTROM, V219, P151, DOI 10.1016/S1387-3806(01)00580-2
   Gabelica V, 2001, J MASS SPECTROM, V36, P397, DOI 10.1002/jms.141                                                                 
   Gabelica V, 2000, RAPID COMMUN MASS SP, V14, P464, DOI 10.1002/(SICI)1097-0231(20000331)14:6<464::AID-RCM895>3.3.CO;2-D
   Gabelica V, 2007, J AM CHEM SOC, V129, P895, DOI 10.1021/ja065989p
   Gale DC, 1995, J AM SOC MASS SPECTR, V6, P1154, DOI 10.1016/1044-0305(95)00530-7
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658
   Haider S, 2008, BIOPHYS J, V95, P296, DOI 10.1529/biophysj.107.120501
   Hardin CC, 2001, BIOPOLYMERS, V56, P147
   Hauptman HA, 1997, METHOD ENZYMOL, V277, P3, DOI 10.1016/S0076-6879(97)77003-4
   Hazel P, 2004, J AM CHEM SOC, V126, P16405, DOI 10.1021/ja045154j
   HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0
   Hess B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031910
   Hess B, 2000, PHYS REV E, V62, P8438, DOI 10.1103/PhysRevE.62.8438
   Hofstadler SA, 2001, CHEM REV, V101, P377, DOI 10.1021/cr990105o
   HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5
   Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609
   Huppert JL, 2007, NUCLEIC ACIDS RES, V35, P406, DOI 10.1093/nar/gkl1057
   JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967                                                  
   Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y
   Kitao A, 1999, CURR OPIN STRUC BIOL, V9, P164, DOI 10.1016/S0959-440X(99)80023-2                                                   
   Li HH, 2008, J AM SOC MASS SPECTR, V19, P550, DOI 10.1016/j.jasms.2008.01.012
   Perez A, 2007, J AM CHEM SOC, V129, P14739, DOI 10.1021/ja0753546
   Perez A, 2007, BIOPHYS J, V92, P3817, DOI 10.1529/biophysj.106.097782
   Phillips K, 1997, J MOL BIOL, V273, P171, DOI 10.1006/jmbi.1997.1292
   Porumb H, 2002, ELECTROPHORESIS, V23, P1013, DOI 10.1002/1522-2683(200204)23:7/8<1013::AID-ELPS1013>3.0.CO;2-B
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Rachwal PA, 2007, BIOCHEMISTRY-US, V46, P3036, DOI 10.1021/bi062118j
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Ren JS, 2002, NUCLEIC ACIDS RES, V30, P2307, DOI 10.1093/nar/30.11.2307
   Rezler EM, 2005, J AM CHEM SOC, V127, P9439, DOI 10.1021/ja0505088
   Rosu F, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf081                                                              
   Rueda M, 2005, J AM CHEM SOC, V127, P11690, DOI 10.1021/ja0422110
   Rueda M, 2003, J AM CHEM SOC, V125, P8007, DOI 10.1021/ja0300564
   Rueda M, 2006, J AM CHEM SOC, V128, P3608, DOI 10.1021/ja055936s
   Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b
   SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0
   SHAMMELBAKER E, 2006, J AM CHEM SOC, V128, P2641
   Smargiasso N, 2008, J AM CHEM SOC, V130, P10208, DOI 10.1021/ja801535e
   Sponer J, 2007, METHODS, V43, P278, DOI 10.1016/j.ymeth.2007.02.004
   SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0                                                                
   Todd AK, 2005, NUCLEIC ACIDS RES, V33, P2901, DOI 10.1093/nar/gki553
   Wan KX, 2000, J AM CHEM SOC, V122, P300, DOI 10.1021/ja990684e                                                               
   WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415                                             
   WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
NR 63
TC 14
Z9 15
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1610-2940
J9 J MOL MODEL
JI J. Mol. Model.
PD APR
PY 2010
VL 16
IS 4
BP 645
EP 657
DI 10.1007/s00894-009-0592-0
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 563IM
UT WOS:000275122000004
PM 19802725
DA 2018-01-05
ER

PT J
AU Geckil, H
   Xu, F
   Zhang, XH
   Moon, S
   Demirci, U
AF Geckil, Hikmet
   Xu, Feng
   Zhang, Xiaohui
   Moon, SangJun
   Demirci, Utkan
TI Engineering hydrogels as extracellular matrix mimics
SO NANOMEDICINE
LA English
DT Review
DE biopatterning; cell-encapsulating microfluidic hydrogels; cell
   microenvironment; extracellular matrix; tissue engineering
ID PHOTOCROSSLINKABLE HYALURONIC-ACID; MESENCHYMAL STEM-CELLS; HIV-INFECTED
   SUBJECTS; DRUG-DELIVERY; IN-VITRO; MICROFLUIDIC CHANNELS; POLY(ETHYLENE
   GLYCOL); REGENERATIVE MEDICINE; MECHANICAL-PROPERTIES; FREEFORM
   FABRICATION
AB Extracellular matrix (ECM) is a complex cellular environment consisting of proteins, proteoglycans, and other soluble molecules. ECM provides structural support to mammalian cells and a regulatory milieu with a variety of important cell functions, including assembling cells into various tissues and organs, regulating growth and cell cell communication. Developing a tailored in vitro cell culture environment that mimics the intricate and organized nanoscale meshwork of native ECM is desirable. Recent studies have shown the potential of hydrogels to mimic native ECM. Such an engineered native-like ECM is more likely to provide cells with rational cues for diagnostic and therapeutic studies. The research for novel biomaterials has led to an extension of the scope and techniques used to fabricate biomimetic hydrogel scaffolds for tissue engineering and regenerative medicine applications. In this article, we detail the progress of the current state-of-the-art engineering methods to create cell-encapsulating hydrogel tissue constructs as well as their applications in in vitro models in biomedicine.
C1 [Geckil, Hikmet; Xu, Feng; Zhang, Xiaohui; Moon, SangJun; Demirci, Utkan] Harvard MIT Hlth Sci & Technol, Bioacoust MEMS Med Lab, Cambridge, MA 02139 USA.
   [Geckil, Hikmet] Inonu Univ, Dept Biol, Malatya, Turkey.
RP Demirci, U (reprint author), Harvard MIT Hlth Sci & Technol, Bioacoust MEMS Med Lab, 65 Landsdowne St,267, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu
RI Geckil, Hikmet/F-7647-2012; Xu, Feng/C-7430-2011; Zhang,
   Xiaohui/C-4569-2013; Xu, Feng/H-4468-2011; liu, fusheng/J-4815-2014
OI Geckil, Hikmet/0000-0003-0070-0691; Xu, Feng/0000-0003-4351-0222; 
FU J William Fulbright Foundation; Fulbright Scholar at the BAMM Labs;
   Center for Biomedical Engineering; Brigham and Women's Hospital (MA,
   USA); Harvard Medical School; NIH [R21-EB007707]; Randolph Hearst
   Foundation
FX Hikmet Geckil gratefully acknowledges the support of the J William
   Fulbright Foundation, as a Fulbright Scholar at the BAMM Labs, Center
   for Biomedical Engineering, Brigham and Women's Hospital (MA, USA),
   Harvard Medical School.; This work was partially supported by the
   NIH-R21-EB007707 and the Randolph Hearst Foundation, Brigham and Women's
   Hospital Department of Medicine Young Investigator in Medicine Award.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ahearne M, 2005, J R SOC INTERFACE, V2, P455, DOI 10.1098/rsif.2005.0065
   AHEARNE M, 2009, DUAL CAMERA SPHERICA, P2011
   Ahearne M, 2008, TOPICS TISSUE ENG, V4, P1
   Albrecht DR, 2005, LAB CHIP, V5, P111, DOI 10.1039/b406953f
   Albrecht DR, 2006, NAT METHODS, V3, P369, DOI 10.1038/NMETH873
   Ali M, 2007, J CONTROL RELEASE, V124, P154, DOI 10.1016/j.jconrel.2007.09.006
   Anderson DG, 2004, NAT BIOTECHNOL, V22, P863, DOI 10.1038/nbt981
   Anseth KS, 1996, BIOMATERIALS, V17, P1647, DOI 10.1016/0142-9612(96)87644-7                                                    
   Arumuganathar S, 2007, BIOMED MATER, V2, P158, DOI 10.1088/1748-6041/2/2/015
   Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9
   Atala A, 2005, EXPERT OPIN BIOL TH, V5, P879, DOI 10.1517/14712598.5.7.879                                                        
   Awad HA, 2004, BIOMATERIALS, V25, P3211, DOI 10.1016/j.biomaterials.2003.10.045
   Azab AK, 2006, J CONTROL RELEASE, V111, P281, DOI 10.1016/j.jconrel.2005.12.014
   Baker EL, 2009, BIOPHYS J, V97, P1013, DOI 10.1016/j.bpj.2009.05.054
   BANERJEE P, 2009, TRENDS BIOTECHNOL, V27, P177
   Banerjee P, 2008, LAB INVEST, V88, P196, DOI 10.1038/labinvest.3700703
   Baroli B, 2007, J PHARM SCI-US, V96, P2197, DOI 10.1002/jps.20873
   Barron JA, 2004, BIOMED MICRODEVICES, V6, P139, DOI 10.1023/B:BMMD.0000031751.67267.9f
   Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047
   Bettinger CJ, 2006, ADV MATER, V18, P165, DOI 10.1002/adma.200500438
   Bhatia SN, 2001, ABSTR PAP AM CHEM S, V221, pU127
   Black LD, 2008, BIOPHYS J, V94, P1916, DOI 10.1529/biophysj.107.107144
   Boland T, 2003, ANAT REC PART A, V272A, P497, DOI 10.1002/ar.a.10059
   Boland Thomas, 2006, Biotechnology Journal, V1, P910, DOI 10.1002/biot.200600081
   Bolland F, 2007, BIOMATERIALS, V28, P1061, DOI 10.1016/j.biomaterials.2006.10.005
   BORENSTEIN J, 2009, MICRONANOENGINEERING
   Boucard N, 2007, BIOMATERIALS, V28, P3478, DOI 10.1016/j.biomaterials.2007.04.021
   Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood-2006-12-063412
   Bryant SJ, 2007, BIOMATERIALS, V28, P2978, DOI 10.1016/j.biomaterials.2006.11.033
   Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131
   Burdick JA, 2009, NATURE, V460, P469, DOI 10.1038/460469a
   BURG T, 2007, SOUTHEASTCON 2007 P
   Cabodi M, 2005, J AM CHEM SOC, V127, P13788, DOI 10.1021/ja054820t
   Rodrikuez-Cabello JC, 2006, NANOMEDICINE-UK, V1, P267, DOI 10.2217/17435889.1.3.267
   Chai C, 2007, MOL THER, V15, P467, DOI 10.1038/sj.mt.6300084
   Chen CY, 2006, APPL SURF SCI, V252, P8641, DOI 10.1016/j.apsusc.2005.11.088
   Chen GP, 2004, TISSUE ENG, V10, P323, DOI 10.1089/107632704323061681                                                      
   Chen RN, 2004, BIOMATERIALS, V25, P2679, DOI 10.1016/j.biomaterials.2003.09.070
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Choi NW, 2007, NAT MATER, V6, P908, DOI 10.1038/nmat2022
   Chung BG, 2007, EXPERT OPIN DRUG DIS, V2, P1
   Cohen DL, 2006, TISSUE ENG, V12, P1325, DOI 10.1089/ten.2006.12.1325
   COLTON CK, 1995, CELL TRANSPLANT, V4, P415, DOI 10.1016/0963-6897(95)00025-S
   Cui XF, 2009, BIOMATERIALS, V30, P6221, DOI 10.1016/j.biomaterials.2009.07.056
   Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   Cushing MC, 2007, SCIENCE, V316, P1133, DOI 10.1126/science.1140171
   Dadsetan M, 2008, BIOMATERIALS, V29, P2193, DOI 10.1016/j.biomaterials.2008.01.006
   Dang TT, 2009, BIOMATERIALS, V30, P6896, DOI 10.1016/j.biomaterials.2009.09.012
   Dawson E, 2008, ADV DRUG DELIVER REV, V60, P215, DOI 10.1016/j.addr.2007.08.037
   DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]
   Dellatore SM, 2008, CURR OPIN BIOTECH, V19, P534, DOI 10.1016/j.copbio.2008.07.010
   Demirci U, 2005, IEEE T SEMICONDUCT M, V18, P709, DOI 10.1109/TSM.2005.858500
   Demirci U, 2004, IEEE T SEMICONDUCT M, V17, P517, DOI [10.1109/TSM.2004.835714, 10.1109/tsm.2004.835714]
   DEMIRCI U, 2007, J VIS EXP, V8, P314
   Demirci U, 2007, LAB CHIP, V7, P1428, DOI 10.1039/b705809h
   Demirci U, 2007, LAB CHIP, V7, P1139, DOI 10.1039/b704965j
   Demirci U, 2006, J MICROELECTROMECH S, V15, P957, DOI 10.1109/JMEMS.2006.878879
   Dendukuri D, 2006, NAT MATER, V5, P365, DOI 10.1038/nmat1617
   Doraiswamy A., 2006, J BIOMED MATER RES A, V80, P635
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5
   Du Y., 2008, MICROFLUIDICS BIOL A
   Du YA, 2008, P NATL ACAD SCI USA, V105, P9522, DOI 10.1073/pnas.0801866105
   Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004
   Eyrich D, 2007, BIOMATERIALS, V28, P55, DOI 10.1016/j.biomaterials.2006.08.027
   Fan HB, 2006, BIOMATERIALS, V27, P4573, DOI 10.1016/j.biomaterials.2006.04.013
   Federovich NE, 2007, TISSUE ENG, V13, P1905
   Fedorovich NE, 2007, TISSUE ENG, V13, P1905, DOI 10.1089/ten.2006.0175
   Fidkowski C, 2005, TISSUE ENG, V11, P302, DOI 10.1089/ten.2005.11.302
   Flaim CJ, 2005, NAT METHODS, V2, P119, DOI 10.1038/NMETH736
   Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102
   Franzesi GT, 2006, J AM CHEM SOC, V128, P15064, DOI 10.1021/ja065867x
   Fukuda J, 2006, BIOMATERIALS, V27, P1479, DOI 10.1016/j.biomaterials.2005.09.015
   Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044
   Gao D, 2008, NANO LETT, V8, P3320, DOI 10.1021/nl8017274
   Gelain F, 2008, INT J NANOMED, V3, P415
   Gillette BM, 2008, NAT MATER, V7, P636, DOI 10.1038/nmat2203
   Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2
   Godin J, 2008, J BIOPHOTONICS, V1, P355, DOI 10.1002/jbio.200810018
   Golden AP, 2007, LAB CHIP, V7, P720, DOI 10.1039/b618409j
   Gottwald E, 2007, LAB CHIP, V7, P777, DOI 10.1039/b618488j
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Hahn MS, 2006, ADV MATER, V18, P2679, DOI 10.1002/adma.200600647
   Han D, 2006, NANOMED-NANOTECHNOL, V2, P37, DOI 10.1016/j.nano.2006.01.002
   Hasirci V, 2006, NANOMEDICINE-UK, V1, P73, DOI 10.2217/17435889.1.1.73
   Hiraoka Y, 2003, TISSUE ENG, V9, P1101, DOI 10.1089/10763270360728017
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hong H, 2007, BIOMATERIALS, V28, P3824, DOI [10.1016/j.biomaterials.2007.05.007, 10.1016/j.biomaterials.2007.05-007]
   Hutmacher DW, 2004, TRENDS BIOTECHNOL, V22, P354, DOI 10.1016/j.tibtech.2004.05.006
   Jabbarzadeh E, 2008, P NATL ACAD SCI USA, V105, P11099, DOI 10.1073/pnas.0800069105
   Jagur-Grodzinski J, 2010, POLYM ADVAN TECHNOL, V21, P27, DOI 10.1002/pat.1504
   Jakab K, 2008, TISSUE ENG PT A, V14, P413, DOI 10.1089/tea.2007.0173
   Jakab K, 2006, BIORHEOLOGY, V43, P509
   Jay SM, 2009, NAT BIOTECHNOL, V27, P543, DOI 10.1038/nbt0609-543
   Jeong MK, 2006, KEY ENG MAT, V321-323, P1133, DOI 10.4028/www.scientific.net/KEM.321-323.1133                                     
   Khademhosseini A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/pnas.0507681102
   Khademhosseini A, 2007, BIOMATERIALS, V28, P5087, DOI 10.1016/j.biomaterials.2007.07.021
   Khademhosseini A, 2006, J BIOMED MATER RES A, V79A, P522, DOI 10.1002/jbm.a.30821
   Kidambi S, 2009, P NATL ACAD SCI USA, V106, P15714, DOI 10.1073/pnas.0906820106
   Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167-7799(98)01191-3
   Kim HJ, 2008, BONE, V42, P1226, DOI 10.1016/j.bone.2008.02.007
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kopecek J, 2007, BIOMATERIALS, V28, P5185, DOI 10.1016/j.biomaterials.2007.07.044
   Kretlow JD, 2007, ADV DRUG DELIVER REV, V59, P263, DOI 10.1016/j.addr.2007.03.013
   Lam CXF, 2002, MAT SCI ENG C-BIO S, V20, P49, DOI 10.1016/S0928-4931(02)00012-7                                                   
   Landers R, 2002, BIOMATERIALS, V23, P4437, DOI 10.1016/S0142-9612(02)00139-4
   LANGER R, 1993, SCIENCE, V920, P260
   Leach JB, 2005, BIOMATERIALS, V26, P125, DOI 10.1016/j.biomaterials.2004.02.018
   Lee CSD, 2007, BIOMATERIALS, V28, P2987, DOI 10.1016/j.biomaterials.2007.02.035
   Lee JN, 2003, ANAL CHEM, V75, P6544, DOI 10.1021/ac0346712
   Lee KH, 2009, SMALL, V5, P1264, DOI 10.1002/smll.200801667
   Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x
   Lee SA, 2009, LAB CHIP, V9, P1670, DOI 10.1039/b819999j
   Leong KF, 2003, BIOMATERIALS, V24, P2363, DOI 10.1016/S0142-9612(03)00030-9
   Levenberg S, 2003, P NATL ACAD SCI USA, V100, P12741, DOI 10.1073/pnas.1735463100
   Li Q, 2004, J BIOMED MATER RES A, V68A, P28, DOI 10.1002/jbm.a.20007
   Li ZY, 2008, MICROFLUID NANOFLUID, V4, P145, DOI 10.1007/s10404-007-0225-9
   Lin P, 2004, TISSUE ENG, V10, P1046
   Ling Y, 2007, LAB CHIP, V7, P756, DOI 10.1039/b615486g
   Liu JJ, 2009, LAB CHIP, V9, P1301, DOI 10.1039/b819219g
   Lutolf MP, 2009, INTEGR BIOL, V1, P235, DOI 10.1039/b902243k
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6
   Madurantakam PA, 2009, NANOMEDICINE-UK, V4, P193, DOI 10.2217/17435889.4.2.193
   Mahler GJ, 2009, BIOTECHNOL BIOENG, V104, P193, DOI 10.1002/bit.22366
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   Marenzana M, 2007, CELL TISSUE RES, V327, P293, DOI 10.1007/s00441-006-0316-z
   Mauney JR, 2004, CALCIFIED TISSUE INT, V74, P458, DOI 10.1007/s00223-003-0104-7
   Mazzoleni G, 2009, GENES NUTR, V4, P13, DOI 10.1007/s12263-008-0107-0
   McGuigan AP, 2007, J TISSUE ENG REGEN M, V1, P136, DOI 10.1002/term.14
   McGuigan AP, 2006, NAT PROTOC, V1, P2963, DOI 10.1038/nprot.2006.443
   Mcguigan AP, 2007, TISSUE ENG, V13, P1079, DOI 10.1089/ten.2006.0245
   Mcguigan AP, 2007, TISSUE ENG, V13, P1069, DOI 10.1089/ten.2006.0253
   McGuigan AP, 2006, P NATL ACAD SCI USA, V103, P11461, DOI 10.1073/pnas.0602740103
   McGuigan AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002258
   Mikos AG, 2006, TISSUE ENG, V12, P3307, DOI 10.1089/ten.2006.12.3307                                                        
   Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7
   Moon S, 2010, TISSUE ENG PART C-ME, V16, P157, DOI [10.1089/ten.tec.2009.0179, 10.1089/ten.TEC.2009.0179]
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   MOON SJ, 2007, J VIS EXP, V8, P315
   Nahmias Y, 2005, BIOTECHNOL BIOENG, V92, P129, DOI 10.1002/bit.20585
   Nahmias Y, 2007, ADV BIOCHEM ENG BIOT, V103, P309, DOI 10.1007/10_029
   Nahmias Y, 2006, FASEB J, V20, P2531, DOI 10.1096/fj.06-6192fje
   Nelson CM, 2006, CURR OPIN BIOTECH, V17, P518, DOI 10.1016/j.copbio.2006.08.011
   Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000
   Ni Y, 2009, BIOTECHNOL LETT, V31, P1661, DOI 10.1007/s10529-009-0077-3
   Nichol JW, 2009, SOFT MATTER, V5, P1312, DOI 10.1039/b814285h
   Nickerson CA, 2007, J NEUROIMMUNE PHARM, V2, P26, DOI 10.1007/s11481-006-9047-x
   Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332
   Nomi M, 2002, MOL ASPECTS MED, V23, P463, DOI 10.1016/S0098-2997(02)00008-0
   Norotte C, 2009, BIOMATERIALS, V30, P5910, DOI 10.1016/j.biomaterials.2009.06.034
   Nuttelman CR, 2005, MATRIX BIOL, V24, P208, DOI 10.1016/j.matbio.2005.03.004
   Ochsner M, 2007, LAB CHIP, V7, P1074, DOI 10.1039/b704449f
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Panda P, 2008, LAB CHIP, V8, P1056, DOI 10.1039/b804234a
   Park Y, 2004, TISSUE ENG, V10, P515, DOI 10.1089/107632704323061870
   Peppas N., 2006, ADV MATER, V18, P1
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Pfister A, 2004, J POLYM SCI POL CHEM, V42, P624, DOI 10.1002/pola.10807
   Pirlo Russell K., 2006, Biotechnology Journal, V1, P1007, DOI 10.1002/biot.200600127
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/NMAT2441, 10.1038/nmat2441]
   Placzek MR, 2009, J R SOC INTERFACE, V6, P209, DOI 10.1098/rsif.2008.0442
   Porro D, 2005, MOL BIOTECHNOL, V31, P245, DOI 10.1385/MB:31:3:245                                                             
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Regehr KJ, 2009, LAB CHIP, V9, P2132, DOI 10.1039/b903043c
   Rettig JR, 2005, ANAL CHEM, V77, P5628, DOI 10.1021/ac0505977
   Revzin A, 2004, LANGMUIR, V20, P2999, DOI 10.1021/la035827w
   Ringeisen Bradley R., 2006, Biotechnology Journal, V1, P930, DOI 10.1002/biot.200600058
   Rivest C, 2007, J MECH MATER STRUCT, V2, P1103, DOI 10.2140/jomms.2007.2.1103
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0                                                   
   Sachlos E., 2003, European Cells & Materials, V5, P29
   Saha K, 2007, CURR OPIN CHEM BIOL, V11, P381, DOI 10.1016/j.cbpa.2007.05.030
   Sahiner N, 2008, J BIOMAT SCI-POLYM E, V19, P223, DOI 10.1163/156856208783432462
   Sahoo S, 2008, BIOMACROMOLECULES, V9, P1088, DOI 10.1021/bm800051m
   Salvay DM, 2006, MOL BIOSYST, V2, P36, DOI 10.1039/b514174p
   Sanjana NE, 2004, J NEUROSCI METH, V136, P151, DOI 10.1016/j.jneumeth.2004.01.011
   Saunders BR, 2009, ADV COLLOID INTERFAC, V147-48, P251, DOI 10.1016/j.cis.2008.08.008
   Saunders RE, 2008, BIOMATERIALS, V29, P193, DOI 10.1016/j.biomatei-ials.2007.09.032
   Savina IN, 2009, J BIOMAT SCI-POLYM E, V20, P1781, DOI 10.1163/156856208X386390
   Schenke-Layland K, 2003, J STRUCT BIOL, V143, P201, DOI 10.1016/j.jsb.2003.08.002
   Schneider GB, 2004, BIOMATERIALS, V25, P3023, DOI 10.1016/j.biomaterials.2003.09.084
   Seidlits SK, 2008, NANOMEDICINE-UK, V3, P183, DOI 10.2217/17435889.3.2.183
   Seunarine K, 2006, NANOMEDICINE-UK, V1, P281, DOI 10.2217/17435889.1.3.281
   Singh M, 2008, TISSUE ENG PART B-RE, V14, P341, DOI 10.1089/ten.teb.2008.0304
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   SMIDSROD O, 1990, TRENDS BIOTECHNOL, V8, P71, DOI 10.1016/0167-7799(90)90139-O
   Song YS, 2010, P NATL ACAD SCI USA, V107, P4596, DOI 10.1073/pnas.0914059107
   Song YS, 2009, ANAL BIOANAL CHEM, V395, P185, DOI 10.1007/s00216-009-2935-1
   Soppimath KS, 2002, DRUG DEV IND PHARM, V28, P957, DOI 10.1081/DDC-120006428
   Stuhrmann B, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2214961
   Sun W, 2002, COMPUT METH PROG BIO, V67, P85, DOI 10.1016/S0169-2607(01)00116-X                                                   
   Sung JH, 2009, LAB CHIP, V9, P1385, DOI 10.1039/b901377f
   Tan WH, 2007, ADV MATER, V19, P2696, DOI 10.1002/adma.200700433
   Tang LP, 2005, EXPERT REV MED DEVIC, V2, P493, DOI 10.1586/17434440.2.4.493
   Teo Wee-Eong, 2006, Biotechnology Journal, V1, P918, DOI 10.1002/biot.200600044
   Therriault D, 2003, NAT MATER, V2, P265, DOI 10.1038/nmat863
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   Tsang VL, 2007, FASEB J, V21, P790, DOI 10.1096/fj.06-7117com
   Tu CF, 2003, POLYM ADVAN TECHNOL, V14, P565, DOI 10.1002/pat.370
   Tumarkin E, 2009, CHEM SOC REV, V38, P2161, DOI 10.1039/b809915b
   Uchimura E, 2003, J BIOMED MATER RES A, V67A, P834, DOI 10.1002/jbm.a.10097
   Uematsu K, 2005, BIOMATERIALS, V26, P4273, DOI 10.1016/j.biomaterials.2004.10.037
   Varghese D, 2005, J THORAC CARDIOV SUR, V129, P470, DOI 10.1016/j.jtcvs.2004.06.050
   Vasita R, 2006, INT J NANOMED, V1, P15, DOI 10.2147/nano.2006.1.1.15
   Weibel DB, 2007, NAT REV MICROBIOL, V5, P209, DOI 10.1038/nrmicro1616
   Wenger MPE, 2007, BIOPHYS J, V93, P1255, DOI 10.1529/biophysj.106.103192
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335                                                  
   Xu F, 2007, ANAL CHEM, V79, P9007, DOI 10.1021/ac7016597
   Xu F, 2010, PHILOS T R SOC A, V368, P561, DOI 10.1098/rsta.2009.0248
   Xu T, 2006, BIOMATERIALS, V27, P3580, DOI 10.1016/j.biomaterials.2006.01.048
   Xu T, 2005, BIOMATERIALS, V26, P93, DOI 10.1016/j.biomaterials.2004.04.011
   Yang SF, 2002, TISSUE ENG, V8, P1, DOI 10.1089/107632702753503009                                                      
   Yeh J, 2006, BIOMATERIALS, V27, P5391, DOI 10.1016/j.biomaterials.2006.06.005
   Zahir N, 2004, CURR OPIN GENET DEV, V14, P71, DOI 10.1016/j.gde.2003.12.005
   Zhang XH, 2009, ADV DRUG DELIVER REV, V61, P988, DOI 10.1016/j.addr.2009.07.005
   Zhang XH, 2009, BIOMATERIALS, V30, P3213, DOI 10.1016/j.biomaterials.2009.02.002
NR 220
TC 260
Z9 264
U1 18
U2 188
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD APR
PY 2010
VL 5
IS 3
BP 469
EP 484
DI 10.2217/NNM.10.12
PG 16
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 588MI
UT WOS:000277074000015
PM 20394538
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Park, EH
AF Park, Eun Hee
TI Small flow cytometry with a single optical system using fluorescence
   nanoparticles for HIV screening
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Park, Eun Hee] Dept Res Digital Bio Technol, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD MAR 21
PY 2010
VL 239
MA 147-ANYL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V21DW
UT WOS:000208189300273
DA 2018-01-05
ER

PT J
AU Swanson, MD
   Winter, HC
   Goldstein, IJ
   Markovitz, DM
AF Swanson, Michael D.
   Winter, Harry C.
   Goldstein, Irwin J.
   Markovitz, David M.
TI A Lectin Isolated from Bananas Is a Potent Inhibitor of HIV Replication
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; INFECTIOUS
   MOLECULAR CLONE; HEPATITIS-C VIRUS; CYANOVIRIN-N; PLANT-LECTINS;
   CARBOHYDRATE-BINDING; ANTIBODY 2G12; IN-VITRO; V3 LOOP
AB BanLec is a jacalin-related lectin isolated from the fruit of bananas, Musa acuminata. This lectin binds to high mannose carbohydrate structures, including those found on viruses containing glycosylated envelope proteins such as human immunodeficiency virus type-1 (HIV-1). Therefore, we hypothesized that BanLec might inhibit HIV-1 through binding of the glycosylated HIV-1 envelope protein, gp120. We determined that BanLec inhibits primary and laboratory-adapted HIV-1 isolates of different tropisms and subtypes. BanLec possesses potent anti-HIV activity, with IC(50) values in the low nanomolar to picomolar range. The mechanism for BanLec-mediated antiviral activity was investigated by determining if this lectin can directly bind the HIV-1 envelope protein and block entry of the virus into the cell. Anenzyme-linked immunosorbent assay confirmed direct binding of BanLec to gp120 and indicated that BanLec can recognize the high mannose structures that are recognized by the monoclonal antibody 2G12. Furthermore, BanLec is able to block HIV-1 cellular entry as indicated by temperature-sensitive viral entry studies and by the decreased levels of the strong-stop product of early reverse transcription seen in the presence of BanLec. Thus, our data indicate that BanLec inhibits HIV-1 infection by binding to the glycosylated viral envelope and blocking cellular entry. The relative anti-HIV activity of BanLec compared favorably to other anti-HIV lectins, such as snowdrop lectin and Griffithsin, and to T-20 and mara-viroc, two anti-HIV drugs currently in clinical use. Based on these results, BanLec is a potential component for an anti-viral microbicide that could be used to prevent the sexual transmission of HIV-1.
C1 [Markovitz, David M.] Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA.
   [Swanson, Michael D.; Markovitz, David M.] Univ Michigan, Med Ctr, Program Immunol, Ann Arbor, MI 48109 USA.
   [Markovitz, David M.] Univ Michigan, Med Ctr, Cellular & Mol Biol Program, Ann Arbor, MI 48109 USA.
   [Winter, Harry C.; Goldstein, Irwin J.] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA.
RP Markovitz, DM (reprint author), Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, 5220 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM dmarkov@umich.edu
FU National Institutes of Health [R01 AI062248]; Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01 AI062248 (of D. M. M.). This work was also supported by
   a Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research.
CR ADACHI A, 1986, J VIROL, V59, P284
   ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290                                                         
   Arhel NJ, 2007, EMBO J, V26, P3025, DOI 10.1038/sj.emboj.7601740
   BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141                                                          
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1                                                   
   Barrientos LG, 2004, J INFECT DIS, V189, P1440, DOI 10.1086/382658
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bertaux C, 2007, VIROLOGY, V366, P40, DOI 10.1016/j.virol.2007.04.008
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0
   Chackerian B, 1997, J VIROL, V71, P3932
   CHESEBRO B, 1991, J INFECT DIS, V163, P64, DOI 10.1093/infdis/163.1.64                                                         
   CHESEBRO B, 1991, J VIROL, V65, P5782
   CHESEBRO B, 1992, J VIROL, V66, P6547
   Clevestig P, 2006, J GEN VIROL, V87, P607, DOI 10.1099/vir.0.81510-0
   COLLMAN R, 1992, J VIROL, V66, P7517
   Crosby R, 2005, J AM COLL HEALTH, V54, P143, DOI 10.3200/JACH.54.3.143-148
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   FREED EO, 1995, J VIROL, V69, P3949
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Gavrovic-Jankulovic M, 2008, INT J BIOCHEM CELL B, V40, P929, DOI 10.1016/j.biocel.2007.10.033
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   Gray ES, 2007, J VIROL, V81, P10769, DOI 10.1128/JVI.01106-07
   Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183                                                        
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Huskens D, 2008, INT J BIOCHEM CELL B, V40, P2802, DOI 10.1016/j.biocel.2008.05.023
   Jeyaprakash AA, 2004, J MOL BIOL, V338, P757, DOI 10.1016/j.jmb.2004.03.040
   Keyaerts E, 2007, ANTIVIR RES, V75, P179, DOI 10.1016/j.antiviral.2007.03.003
   KOSHTE VL, 1990, BIOCHEM J, V272, P721, DOI 10.1042/bj2720721                                                               
   Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011
   Li BQ, 2000, BIOCHEM BIOPH RES CO, V276, P534, DOI 10.1006/bbrc.2000.3485
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   LI Y, 1993, J VIROL, V67, P584
   Lis H., 2003, LECTINS
   MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424                                                         
   Meagher JL, 2005, GLYCOBIOLOGY, V15, P1033, DOI 10.1093/glycob/cwi088
   Mkrtchyan SR, 2005, J VIROL, V79, P11161, DOI 10.1128/JVI.79.17.11161-11169.2005
   Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Nakamura-Tsuruta S, 2008, FEBS J, V275, P1227, DOI 10.1111/j.1742-4658.2008.06282.x
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106
   Peumans WJ, 2000, PLANTA, V211, P546, DOI 10.1007/s004250000307
   Platt EJ, 1998, J VIROL, V72, P2855
   Randolph ME, 2007, ARCH SEX BEHAV, V36, P844, DOI 10.1007/s10508-007-9213-0
   Saidi H, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-28
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Schmidtmayerova H, 1998, J VIROL, V72, P4633
   Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08
   Singh DD, 2005, GLYCOBIOLOGY, V15, P1025, DOI 10.1093/glycob/cwi087
   Smee DF, 2008, ANTIVIR RES, V80, P266, DOI 10.1016/j.antiviral.2008.06.003
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   TOOHEY K, 1995, VIROLOGY, V213, P70, DOI 10.1006/viro.1995.1547
   Trkola A, 1996, J VIROL, V70, P1100
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   UNAIDS, 2008, REP GLOB AIDS EP
   Underhill K, 2007, BMJ-BRIT MED J, V335, P248, DOI 10.1136/bmj.39245.446586.BE
   VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1                                                    
   Warrilow D, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-77
   Warrilow D, 2008, J VIROL, V82, P1425, DOI 10.1128/JVI.01808-07
   WATTS C, 2002, MICROBICIDES
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Zappe H, 2008, ADV DRUG DELIVER REV, V60, P79, DOI 10.1016/j.addr.2007.05.016
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 73
TC 70
Z9 73
U1 0
U2 20
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 19
PY 2010
VL 285
IS 12
BP 8646
EP 8655
DI 10.1074/jbc.M109.034926
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 568VZ
UT WOS:000275553700017
PM 20080975
OA gold
DA 2018-01-05
ER

PT J
AU Lee, WG
   Kim, YG
   Chung, BG
   Demirci, U
   Khademhosseini, A
AF Lee, Won Gu
   Kim, Yun-Gon
   Chung, Bong Geun
   Demirci, Utkan
   Khademhosseini, Ali
TI Nano/Microfluidics for diagnosis of infectious diseases in developing
   countries
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nano/Microfluidics; Infectious diseases; HIV/AIDS; Point-of-care;
   Diagnostics; Global health
ID OF-CARE DIAGNOSTICS; ON-A-CHIP; RESOURCE-POOR SETTINGS; ATOMIC-FORCE
   MICROSCOPY; TOTAL ANALYSIS SYSTEMS; CLINICAL DIAGNOSTICS; GLOBAL HEALTH;
   MICROFLUIDIC TECHNOLOGIES; FLOW CHROMATOGRAPHY; DEVELOPING-WORLD
AB Nano/Microfluidic technologies are emerging as powerful enabling tools for diagnosis and monitoring of infectious diseases in both developed and developing countries. Miniaturized nano/microfluidic platforms that precisely manipulate small fluid volumes can be used to enable medical diagnosis in a more rapid and accurate manner. In particular, these nano/microfluidic diagnostic technologies are potentially applicable to global health applications, since they are disposable, inexpensive, portable, and easy-to-use for detection of infectious diseases. In this paper, we review recent advances in nano/microfluidic technologies for clinical point-of-care applications at resource-limited settings in developing countries. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Lee, Won Gu; Kim, Yun-Gon; Chung, Bong Geun; Demirci, Utkan; Khademhosseini, Ali] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Biomed Engn,Dept Med, Cambridge, MA 02139 USA.
   [Lee, Won Gu; Kim, Yun-Gon; Chung, Bong Geun; Demirci, Utkan; Khademhosseini, Ali] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Kim, Yun-Gon; Demirci, Utkan] Harvard Univ, Sch Med, Brigham & Womens Hosp, BAMM Lab, Cambridge, MA 02139 USA.
RP Demirci, U (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Biomed Engn,Dept Med, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu; alik@rics.bwh.harvard.edu
RI Khademhosseini, Ali/A-9435-2010
OI Khademhosseini, Ali/0000-0002-2692-1524; Khademhosseini,
   Ali/0000-0001-6322-8852; Lee, Won Gu/0000-0003-1473-0672
FU National Institute of Health [EB007249, DE019024, HL092836, AI081534];
   Korean Government (MOEHRD) [KRF-2007-357-D00035]
FX This work was supported by the National Institute of Health by grants
   (EB007249, DE019024, HL092836, and AI081534). W. G. Lee was partially
   supported by the Korea Research Foundation Grant funded by the Korean
   Government (MOEHRD) (KRF-2007-357-D00035).
CR Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Antia M, 2007, PLOS PATHOG, V3, P939, DOI 10.1371/journal.ppat.0030099
   Bang HW, 2006, LAB CHIP, V6, P1381, DOI 10.1039/b604578b
   Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474
   Bhattacharyya A, 2007, BIOMED MICRODEVICES, V9, P245, DOI 10.1007/s10544-006-9026-2
   Breslauer DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006320
   Burg TP, 2007, NATURE, V446, P1066, DOI 10.1038/nature05741
   Hay Burgess D. C., 2006, NATURE S1, V444, P1, DOI DOI 10.1038/NATURE05440
   Butte MJ, 2005, CLIN IMMUNOL, V116, P282
   Carter DJ, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm269
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Cho JH, 2006, ANAL CHEM, V78, P793, DOI 10.1021/ac051453v
   Chung S, 2009, SMALL, V5, P609, DOI 10.1002/smll.200800748
   Cohen J, 2004, SCIENCE, V304, P1936, DOI 10.1126/science.304.5679.1936
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Dittrich PS, 2006, ANAL CHEM, V78, P3887, DOI 10.1021/ac0605602
   Dittrich PS, 2006, NAT REV DRUG DISCOV, V5, P210, DOI 10.1038/nrd1985
   Eijkel JCT, 2005, MICROFLUID NANOFLUID, V1, P249, DOI 10.1007/s10404-004-0012-9
   El-Ali J, 2006, NATURE, V442, P403, DOI 10.1038/nature05063
   Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hcho93
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Fu AY, 1999, NAT BIOTECHNOL, V17, P1109
   Fu E, 2007, ANN NY ACAD SCI, V1098, P335, DOI 10.1196/annals.1384.026
   Girosi Federico, 2006, Nature, V444 Suppl 1, P3, DOI 10.1038/nature05441
   Goddard GR, 2007, ANAL CHEM, V79, P8740, DOI 10.1021/ac071402t
   Granot Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002075
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Hatch A, 2001, NAT BIOTECHNOL, V19, P461, DOI 10.1038/88135
   Helton KL, 2007, LAB CHIP, V7, P1581, DOI 10.1039/b709585f
   Herr AE, 2007, P NATL ACAD SCI USA, V104, P5268, DOI 10.1073/pnas.0607254104
   Holtzel A, 2007, J SEP SCI, V30, P1398, DOI 10.1002/jssc.200600427
   Houpt ER, 2008, LANCET, V372, P873, DOI 10.1016/S0140-6736(08)61377-X
   Huckle D, 2006, EXPERT REV MED DEVIC, V3, P421, DOI 10.1586/17434440.3.4.421
   Huckle D, 2008, EXPERT REV MOL DIAGN, V8, P679, DOI 10.1586/14737159.8.6.679
   Jain KK, 2007, CLIN CHEM, V53, P2002, DOI 10.1373/clinchem.2007.090795
   Jorgensen P, 2006, AM J TROP MED HYG, V74, P750
   Kang LF, 2008, DRUG DISCOV TODAY, V13, P1, DOI 10.1016/j.drudis.2007.10.003
   Ke C, 2004, SENSOR ACTUAT B-CHEM, V102, P308, DOI 10.1016/j.snb.2004.04.083
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kokoris M, 2005, METHODS, V37, P114, DOI 10.1016/j.ymeth.2005.07.002
   Lagally ET, 2004, ANAL CHEM, V76, P3162, DOI 10.1021/ac035310p
   LAVERAN CLA, 1982, REV INFECT DIS, V4, P908
   Lee H, 2008, NAT MED, V14, P869, DOI 10.1038/nm.1711
   Lee SH, 2008, LAB CHIP, V8, P2121, DOI 10.1039/b811131f
   Lee WG, 2007, LAB CHIP, V7, P516, DOI 10.1039/b614912j
   Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x
   Ly N, 2007, ANAL CHEM, V79, P2546, DOI 10.1021/ac061932+
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Mandy FF, 2004, CYTOM PART A, V58A, P55, DOI 10.1002/cyto.a.10102
   Martinez AW, 2008, LAB CHIP, V8, P2146, DOI 10.1039/b811135a
   Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Morozov VN, 2007, J AM CHEM SOC, V129, P12628, DOI 10.1021/ja075069m
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Nelson KE, 2007, ANAL CHEM, V79, P3542, DOI 10.1021/ac062349w
   Nettikadan SR, 2004, NANOTECHNOLOGY, V15, P383, DOI 10.1088/0957-4484/15/3/027
   Nettikadan SR, 2003, BIOCHEM BIOPH RES CO, V311, P540, DOI 10.1016/j.bbrc.2003.10.022
   Ohashi T, 2009, LAB CHIP, V9, P991, DOI 10.1039/b815475a
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Padayatchi N, 2008, INT J TUBERC LUNG D, V12, P978
   Parsa H, 2008, LAB CHIP, V8, P2062, DOI 10.1039/b813350f
   PEELING RW, 2006, NAT REV MICROBIOL S, V4, pS2, DOI DOI 10.1038/NRMICO1522
   Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363
   Psaltis D, 2006, NATURE, V442, P381, DOI 10.1038/nature05060
   Rafael Maria E, 2006, Nature, V444 Suppl 1, P39, DOI 10.1038/nature05445
   Ridderhof JC, 2007, B WORLD HEALTH ORGAN, V85, P354, DOI 10.2471/BLT.06.039081
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Schulte TH, 2002, CLIN CHIM ACTA, V321, P1, DOI 10.1016/S0009-8981(02)00093-1
   Shelby JP, 2003, P NATL ACAD SCI USA, V100, P14618, DOI 10.1073/pnas.2433968100
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772
   Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050
   Song YS, 2009, LAB CHIP, V9, P1874, DOI 10.1039/b823062e
   Spacek LA, 2006, JAIDS-J ACQ IMM DEF, V41, P607, DOI 10.1097/01.qai.0000214807.98465.a2
   Star A, 2006, P NATL ACAD SCI USA, V103, P921, DOI 10.1073/pnas.0504146103
   Star A, 2004, ADV MATER, V16, P2049, DOI 10.1002/adma.200400322
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8                                                   
   Stevens DY, 2008, LAB CHIP, V8, P2038, DOI 10.1039/b811158h
   Tabak LA, 2007, ANN NY ACAD SCI, V1098, P7, DOI 10.1196/annals.1384.043
   Toner M, 2005, ANNU REV BIOMED ENG, V7, P77, DOI 10.1146/annurev.bioeng.7.011205.135108
   Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448
   van den Berg A, 2007, NATURE, V445, P726, DOI 10.1038/445726a
   VanDelinder V, 2007, ANAL CHEM, V79, P2023, DOI 10.1021/ac061659b
   Weigl B, 2008, LAB CHIP, V8, P1999, DOI 10.1039/b811314a
   West J, 2008, ANAL CHEM, V80, P4403, DOI 10.1021/ac800680j
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   *WHO, 2008, PAT MON GUID HIV CAR
   *WHO, REG IN VITR DIAGN GL
   *WHO, 2005, PAT MON GUID HIV CAR
   Willyard C, 2007, NAT MED, V13, P1131, DOI 10.1038/nm1007-1131
   Yacoub-George E, 2007, BIOSENS BIOELECTRON, V22, P1368, DOI 10.1016/j.bios.2006.06.003
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   YUN H, 2007, 11 INT C MIN SYST CH, P1258
   Zimmermann M, 2005, BIOMED MICRODEVICES, V7, P99, DOI 10.1007/s10544-005-1587-y
NR 97
TC 173
Z9 180
U1 9
U2 140
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 449
EP 457
DI 10.1016/j.addr.2009.11.016
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400007
PM 19954755
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU das Neves, J
   Amiji, MM
   Bahia, MF
   Sarmento, B
AF das Neves, Jose
   Amiji, Mansoor M.
   Bahia, Maria Fernanda
   Sarmento, Bruno
TI Nanotechnology-based systems for the treatment and prevention of
   HIV/AIDS
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Antiretroviral therapy; Drug carriers; Drug targeting; HIV reservoir
   sites; Macrophages; Lymphatic system; Central nervous system;
   Microbicides; Vaccines
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY SYSTEMS; ACTIVE
   ANTIRETROVIRAL THERAPY; SOLID LIPID NANOPARTICLES; AMNIOTIC-FLUID
   ACCUMULATION; MEDIATED IMMUNE-RESPONSES; MATERNAL-FETAL TRANSFER;
   CENTRAL-NERVOUS-SYSTEM; ANTI-HIV DRUGS; INACTIVATED HIV-1-CAPTURING
   NANOSPHERES
AB The HIV/AIDS pandemic is an increasing global burden with devastating health-related and socioeconomic effects. The widespread use of antiretroviral therapy has dramatically improved life quality and expectancy of infected individuals, but limitations of currently available drug regimens and dosage forms, alongside with the extraordinary adapting capacity of the virus, have impaired further success. Alongside, circumventing the escalating number of new infections can only be attained with effective and practical preventative strategies. Recent advances in the field of drug delivery are providing evidence that engineered nanosystems may contribute importantly for the enhancement of current antiretroviral therapy. Additionally, groundwork is also being carried out in the field nanotechnology-based systems for developing preventative solutions for HIV transmission. This manuscript reviews recent advances in the field of nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Particular attention is given to antiretroviral drug targeting to HIV reservoirs and the usefulness of nanosystems for developing topical microbicides and vaccines. (C) 2009 Elsevier B.V. All rights reserved.
C1 [das Neves, Jose; Bahia, Maria Fernanda; Sarmento, Bruno] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, P-4050047 Oporto, Portugal.
   [Amiji, Mansoor M.] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Sarmento, B (reprint author), Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Anibal Cunha 164, P-4050047 Oporto, Portugal.
EM bruno.sarmento@ff.up.pt
RI das Neves, Jose/J-8369-2013; Sarmento, Bruno/J-6265-2013; Amiji,
   Mansoor/A-4365-2014
OI das Neves, Jose/0000-0002-2317-2759; Sarmento,
   Bruno/0000-0001-5763-7553; Amiji, Mansoor/0000-0001-6170-881X
FU Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BD/43393/2008]
FX Jose das Neves is supported by Fundacao para a Ciencia e a Tecnologia,
   Portugal (grant SFRH/BD/43393/2008).
CR Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Anthonypillai Christy, 2006, Cerebrospinal Fluid Res, V3, P1, DOI 10.1186/1743-8454-3-1
   ARIAS MA, 2008, AIDS VACC 2008 C CAP
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Aweeka F, 1999, J ACQ IMMUN DEF SYND, V20, P39, DOI 10.1097/00042560-199901010-00006                                                
   Babiker A, 2000, LANCET, V355, P1131
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   Begley DJ, 2004, PHARMACOL THERAPEUT, V104, P29, DOI 10.1016/j.pharmthera.2004.08.001
   Bekkara-Aounallah F, 2008, ADV FUNCT MATER, V18, P3715, DOI 10.1002/adfm.200800705
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bennetto-Hood C, 2009, HIV CLIN TRIALS, V10, P41, DOI [10.1310/hct1001-041, 10.1310/hct1001-41]
   BEST B, 2009, 16 C RETR OPP INF MO
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   BLUM MR, 1988, AM J MED, V85, P189
   Boudad H, 2001, STP PHARMA SCI, V11, P369
   Boyle J, 2007, VACCINE, V25, P2541, DOI 10.1016/j.vaccine.2006.12.018
   Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1
   Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Chappuy H, 2004, ANTIMICROB AGENTS CH, V48, P4332, DOI 10.1128/AAC.48.11.4332-4336.2004
   Chappuy H, 2004, AM J OBSTET GYNECOL, V191, P558, DOI 10.1016/j.ajog.2004.01.034
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   CHOWDHURY DF, 2008, PHARM MANUFACTURING, P1289
   Cocohoba J, 2008, CLIN THER, V30, P1747, DOI 10.1016/j.clinthera.2008.10.012
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Collins KB, 2000, NAT MED, V6, P475
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621                                                           
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   Couvreur P, 2006, PHARM RES, V23, P1417, DOI 10.1007/s11095-006-0284-8
   Cristillo AD, 2007, VIROLOGY, V366, P197, DOI 10.1016/j.virol.2007.04.012
   Croom KF, 2005, DRUGS, V65, P1669, DOI 10.2165/00003495-200565120-00005
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Danel C, 2006, LANCET, V367, P1981, DOI 10.1016/S0140-6736(06)68887-9
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2008, AIDS, V22, P908, DOI 10.1097/QAD.0b013e3282f73870
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb                                              
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   Deeks ED, 2008, DRUGS, V68, P2357, DOI 10.2165/0003495-200868160-00007
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   *DEP EC SOC AFF PO, 2004, IMP AIDS
   DESORMEAUX A, 1994, AIDS, V8, P1545, DOI 10.1097/00002030-199411000-00005                                                
   Diebold SS, 1999, J BIOL CHEM, V274, P19087, DOI 10.1074/jbc.274.27.19087                                                        
   Dinauer N, 2004, J CONTROL RELEASE, V96, P497, DOI 10.1016/j.jconrel.02.020
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dumond JB, 2007, AIDS, V21, P1899, DOI 10.1097/QAD.0b013e328270385a
   Duzgunes N, 2001, NUCLEOS NUCLEOT NUCL, V20, P515, DOI 10.1081/NCN-100002327
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Fauci AS, 2007, CLIN INFECT DIS, V45, pS206, DOI 10.1086/522540
   FLASHER D, 1994, BBA-BIOMEMBRANES, V1194, P185, DOI 10.1016/0005-2736(94)90219-4                                                    
   Foster RH, 1998, DRUGS, V55, P729, DOI 10.2165/00003495-199855050-00018
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Gamsiz DE, 2008, BIOTECHNOL BIOENG, V101, P1072, DOI 10.1002/bit.21958
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Garg M, 2007, AAPS PHARMSCITECH, V8
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Gill CJ, 2002, J ACQ IMMUN DEF SYND, V30, P485, DOI 10.1097/01.QAI.0000024372.97844.B4
   Gingelmaier A, 2006, AIDS, V20, P1737, DOI 10.1097/01.aids.0000242820.67001.2c
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   HARTMAN NR, 1990, CLIN PHARMACOL THER, V47, P647, DOI 10.1038/clpt.1990.86                                                            
   HARVIE P, 1995, AIDS, V9, P701, DOI 10.1097/00002030-199507000-00006
   Haworth SJ, 1998, J ACQ IMMUN DEF SYND, V17, P235, DOI 10.1097/00042560-199803010-00008                                                
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Heiati H, 1998, J MICROENCAPSUL, V15, P173, DOI 10.3109/02652049809006847
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   Hillaireau H, 2007, INT J PHARM, V331, P148, DOI 10.1016/j.ijpharm.2006.10.031
   Hillaireau H, 2006, INT J PHARM, V324, P37, DOI 10.1016/j.ijpharm.2006.07.006
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Ishii N, 1997, AIDS RES HUM RETROV, V13, P1421, DOI 10.1089/aid.1997.13.1421
   Jain S, 2007, AAPS PHARMSCITECH, V8
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin YG, 2008, J COLLOID INTERF SCI, V326, P275, DOI 10.1016/j.jcis.2008.07.014
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   Johnson Victoria A, 2008, Top HIV Med, V16, P138
   KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288                                                       
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Khoo SH, 2002, ANTIMICROB AGENTS CH, V46, P3228, DOI 10.1128/AAC.46.10.3228.2002
   Kilmarx PH, 1998, AIDS, V12, P767, DOI 10.1097/00002030-199807000-00013                                                
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   KIM S, 1990, J INFECT DIS, V162, P750, DOI 10.1093/infdis/162.3.750                                                        
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kish-Catalone T, 2007, AIDS RES HUM RETROV, V23, P33, DOI 10.1089/aid.2006.0076
   Kish-Catalone TM, 2006, ANTIMICROB AGENTS CH, V50, P1497, DOI 10.1128/AAC.50.4.1497-1509.2006
   Klasse PJ, 2006, PLOS MED, V3, P1501, DOI 10.1371/journal.pmed.0030351
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Koopman G, 2007, J MED VIROL, V79, P474, DOI [10.1002/jmv.20860, 10.1002/jmw.20860]
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kukhanova M, 2000, CURR PHARM DESIGN, V6, P585, DOI 10.2174/1381612003400687                                                        
   Kumar GN, 2004, PHARM RES, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d                                              
   Kunisawa J, 2001, ADV DRUG DELIVER REV, V52, P177, DOI 10.1016/S0169-409X(01)00214-9
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Kwara A, 2008, CLIN INFECT DIS, V46, P719, DOI 10.1086/527387
   Lackner AA, 2007, ANNU REV MED, V58, P461, DOI 10.1146/annurev.med.58.082405.094316
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Langer R, 1998, NATURE, V392, P5
   Lea AP, 1996, DRUGS, V51, P846, DOI 10.2165/00003495-199651050-00009
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Leroux JC, 1996, PHARMACEUT RES, V13, P485, DOI 10.1023/A:1016073416332                                                         
   Levy JA, 2007, HIV AND THE PATHOGENESIS OF AIDS, 3RD EDITION, P1
   Levy JA, 2009, AIDS, V23, P147, DOI 10.1097/QAD.0b013e3283217f9f
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz Julianna, 2006, Current Drug Delivery, V3, P83, DOI 10.2174/156720106775197574
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   Locher CP, 2003, IMMUNOL LETT, V90, P67, DOI 10.1016/j.imlet.2003.02.001
   Lori F, 2007, CURR MED CHEM, V14, P1911
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Mandelbrot L, 2001, AM J OBSTET GYNECOL, V184, P153, DOI 10.1067/mob.2001.108344
   MARTINEZAVILA O, 2007, TNT2007 TRENDS NANOT
   McCoombe SG, 2006, AIDS, V20, P1491, DOI 10.1097/01.aids.0000237364.11123.98
   McCutchan FE, 2006, J MED VIROL, V78, pS7, DOI 10.1002/jmv.20599
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   MILLER CJ, 1992, J MED PRIMATOL, V21, P64
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moscicki Anna-Barbara, 2008, Journal of Infection and Chemotherapy, V14, P337, DOI 10.1007/s10156-008-0630-3
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ojikutu B, 2007, J INFECT DIS, V196, pS523, DOI 10.1086/521119
   Okada E, 1997, J IMMUNOL, V159, P3638
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   PEREIRA A, 2000, 7 C RETR OPP INF SAN
   *PHARM WORK GROUP, 2002, EC MICR DEV CAS INV
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI 10.1172/JCI200421540
   Poonia B, 2006, J REPROD IMMUNOL, V72, P74, DOI 10.1016/j.jri.2006.02.004
   Porter K, 2003, LANCET, V362, P1267
   Price RW, 2008, ANTIVIR THER, V13, P369
   PUTKONEN P, 1994, J ACQ IMMUN DEF SYND, V7, P551
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Sawchuk RJ, 1999, ADV DRUG DELIVER REV, V39, P5, DOI 10.1016/S0169-409X(99)00017-4                                                   
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140
   SHELTON MJ, 1992, ANN PHARMACOTHER, V26, P660, DOI 10.1177/106002809202600511                                                      
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   Smith PF, 2001, CLIN PHARMACOKINET, V40, P893, DOI 10.2165/00003088-200140120-00002                                                
   Snedecor SJ, 2006, PHARM RES, V23, P1750, DOI 10.1007/s11095-006-9026-1
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291
   STEFANIDOU M, 2006, MICR 2006 C CAP TOWN
   STOVER J, 2006, POLITICS EC AFRICA, V6, P1
   Taylor S, 2000, AIDS, V14, P1979, DOI 10.1097/00002030-200009080-00014
   Thomson MM, 2005, AIDS REV, V7, P210
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x
   Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6
   Torchilin V, 2008, MULTIFUNCTIONAL PHAR
   Torchilin VP, 2006, NANOPARTICULATES DRU
   Tymchuk CN, 2008, EXPERT OPIN DRUG SAF, V7, P1, DOI [10.1517/14740338.7.1.1, 10.1517/14740338.7.1.1 ]
   UNAIDS, 2008, REP GLOB AIDS EP
   Vajdy M, 2004, AIDS RES HUM RETROV, V20, P1269, DOI 10.1089/aid.2004.20.1269
   van de Wijgert JHHM, 2007, AIDS, V21, P2369, DOI 10.1097/QAD.0b013e3282ef83fd                                                    
   VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166                                                       
   Vella S, 1998, CLIN PHARMACOKINET, V34, P189, DOI 10.2165/00003088-199834030-00002                                                
   Venzke Stephanie, 2006, Expert Rev Clin Immunol, V2, P613, DOI 10.1586/1744666X.2.4.613
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   von Kleist M, 2009, EUR J PHARM SCI, V36, P532, DOI 10.1016/j.ejps.2008.12.010
   VONBRIESEN H, 2000, AIDS REV, V2, P31
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Walker DK, 2008, XENOBIOTICA, V38, P1330, DOI [10.1080/00498250802447409, 10.1080/00498250802447409 ]
   Wang X, 2007, MINI-REV ORG CHEM, V4, P51, DOI 10.2174/157019307779815857                                                      
   Wilkinson J, 2006, CURR DRUG TARGETS, V7, P1563, DOI 10.2174/138945006779025482
   Wilson DP, 2008, CURR OPIN HIV AIDS, V3, P587, DOI 10.1097/COH.0b013e328305b959
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Xin KQ, 1998, IMMUNOLOGY, V94, P438, DOI 10.1046/j.1365-2567.1998.00533.x
   YARCHOAN R, 1988, LANCET, V1, P76
   Yeh RF, 2009, ANTIMICROB AGENTS CH, V53, P2367, DOI 10.1128/AAC.01523-08
   Yilmaz A, 2009, AIDS RES HUM RETROV, V25, P457, DOI 10.1089/aid.2008.0216
   2004, SIZING NANOTECHNOLOG
   2009, TREAT GUIDE MED LETT, P11
NR 223
TC 83
Z9 84
U1 4
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 458
EP 477
DI 10.1016/j.addr.2009.11.017
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400008
PM 19914314
DA 2018-01-05
ER

PT J
AU Gupta, U
   Jain, NK
AF Gupta, Umesh
   Jain, Narendra K.
TI Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nanotechnology; AIDS; Nanocarrier in Anti HIV; Liposomes
ID SOLID LIPID NANOPARTICLES; HUMAN-IMMUNODEFICIENCY-VIRUS;
   BLOOD-BRAIN-BARRIER; PRODRUG 3'-AZIDO-3'-DEOXYTHYMIDINE PALMITATE;
   LOADED GALACTOSYLATED LIPOSOMES; MONOCYTES/MACROPHAGES IN-VITRO; POLY
   PROPYLENEIMINE DENDRIMER; AIDS-ASSOCIATED RETROVIRUS; ENHANCED CELLULAR
   UPTAKE; ANTI-HIV ACTIVITY
AB Development of an effective drug delivery approach for the treatment of HIV/AIDS is a global challenge. The conventional drug delivery approaches including Highly Active Anti Retroviral Therapy (HAART) have increased the life span of the HIV/AIDS patient. However, the eradication of HIV is still not possible with these approaches due to some limitations. Emergence of polymeric and non-polymeric nanotechnological approaches can be opportunistic in this direction. Polymeric carriers like, dendrimers and nanoparticles have been reported for the targeting of anti HIV drugs. The synthetic pathways as well polymeric framework create some hurdles in their successful formulation development as well as in the possible drug delivery approaches. In the present article, we have discussed the general physiological aspects of the infection along with the relevance of non-polymeric nanocarriers like liposomes, solid lipid nanoparticles (SLN), ethosomes, etc. in the treatment of this disastrous disease. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Gupta, Umesh; Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
EM jnarendr@yahoo.co.in
RI Gupta, Umesh/G-4107-2012
OI Gupta, Umesh/0000-0001-8947-2749
CR Agarwal A, 2009, BIOMATERIALS, V30, P3588, DOI 10.1016/j.biomaterials.2009.03.016
   Agrawal AK, 2000, ADV DRUG DELIVER REV, V41, P135, DOI 10.1016/S0169-409X(99)00061-7                                                   
   Agrawal P, 2007, BIOMATERIALS, V28, P3349, DOI 10.1016/j.biomaterials.2007.04.004
   Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   BETAGERI GV, 1993, INT J PHARM, V98, P149, DOI 10.1016/0378-5173(93)90051-G                                                    
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   Bummer PM, 2004, CRIT REV THER DRUG, V21, P1
   Bushman FD, 2002, CURR TOP MICROBIOL, V261, P165
   Castor Trevor P., 2005, Current Drug Delivery, V2, P329, DOI 10.2174/156720105774370195
   CDC Kaposi's sarcoma, 1982, MMWR-MORBID MORTAL W, V31, p[507, 513]
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chauhan AS, 2003, J CONTROL RELEASE, V90, P335, DOI 10.1016/S0168-3659(03)00200-1
   Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/vir.0.18313-0
   CLERCQ ED, 2001, FARMACO, V56, P3
   Clercq ED, 2002, MED RES REV, V22, P531
   Clercq E.D., 2004, INT J BIOCHEM CELL B, V36, P1800
   COFFIN J, 1986, SCIENCE, V232, P697, DOI 10.1126/science.3008335                                                         
   Constantinides PP, 2008, ADV DRUG DELIVER REV, V60, P757, DOI 10.1016/j.addr.2007.10.013
   Covreur PV. C., 2006, PHARM RES, V23, P1417
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   Dayan N, 2000, BIOMATERIALS, V21, P1879, DOI 10.1016/S0142-9612(00)00063-6
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   DESORMEAUX A, 1994, AIDS, V8, P1545, DOI 10.1097/00002030-199411000-00005                                                
   Dubey V, 2007, EXPERT OPIN DRUG DEL, V4, P579, DOI 10.1517/17425247.4.6.579
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3
   FARNET CM, 1991, J VIROL, V65, P1910
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274                                                         
   FAULDS D, 1992, DRUGS, V44, P94, DOI 10.2165/00003495-199244010-00008
   Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GALLO RC, 1982, J NATL CANCER I, V69, P1209
   GALLO RC, 1987, NATURE, V326, P435
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   GARG M, 2007, AAPS PHARMSCITECH, V8, pE1
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Gohla SH, 2001, PHARMAZIE, V56, P61
   GONDA MA, 1985, SCIENCE, V227, P173, DOI 10.1126/science.2981428
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta U, 2006, BIOMACROMOLECULES, V7, P649, DOI 10.1021/bm050802s
   Gupta U, 2007, J PHARM PHARM SCI, V10, P358
   Gupta U, 2006, NANOMED-NANOTECHNOL, V2, P66, DOI 10.1016/j.nano.2006.04.002
   HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0
   Haffar Omar, 2005, Expert Rev Anti Infect Ther, V3, P41, DOI 10.1586/14787210.3.1.41
   Harvie P, 1996, ANTIMICROB AGENTS CH, V40, P225
   HARVIE P, 1995, AIDS, V9, P701, DOI 10.1097/00002030-199507000-00006
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668                                                         
   HIGHLEYMAN L, 2003, HIV DRUGS HIV LIFECY
   INGRAHAM JL, 2000, INTRO MICROBIOLOGY, P336
   Jain S.K., 2007, AAPS PHARMSCITECH, V8, pE1
   Jain S., 2004, INDIAN J PHARM SCI, V66, P72
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin SX, 2005, PHARMAZIE, V60, P840
   Kapitza SB, 2007, EUR J PHARM BIOPHARM, V66, P146, DOI 10.1016/j.ejpb.2006.08.010
   KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654                                                          
   Katragadda A, 2000, CELL MOL BIOL LETT, V5, P483
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   KIM S, 1990, J INFECT DIS, V162, P750, DOI 10.1093/infdis/162.3.750                                                        
   King PJ, 1998, J VIROL, V72, P8420
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kompella UB, 1999, DRUG DELIV, V6, P9, DOI 10.1080/107175499267101                                                         
   Kozubek A, 2000, ACTA BIOCHIM POL, V47, P639
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481                                                           
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   MAKABIPANZU B, 1994, AIDS RES HUM RETROV, V10, P1463, DOI 10.1089/aid.1994.10.1463                                                        
   MAKABIPANZU B, 1995, J ACQ IMMUN DEF SYND, V8, P227, DOI 10.1097/00042560-199503010-00002                                                
   Manjunath K, 2005, METHOD FIND EXP CLIN, V27, P127, DOI 10.1358/mf.2005.27.2.876286
   Marengo E, 2000, INT J PHARM, V205, P3, DOI 10.1016/S0378-5173(00)00471-3
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Menne S, 2008, ANTIMICROB AGENTS CH, V52, P3617, DOI 10.1128/AAC.00654-08
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   Moore J.P., 1993, VIRAL FUSION MECH, P233
   Mueller R. H., 2002, Advanced Drug Delivery Reviews, V54, pS131
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller RH, 2000, HDB PHARM CONTROLLED, P359
   Nahar M, 2006, CRIT REV THER DRUG, V23, P259, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i4.10                                    
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Pereira de Oliveira M, 2005, PHARM RES-DORDR, V22, P1898, DOI 10.1007/s11095-005-7147-6
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   PIERIBONE D, 2002, HIV LIFE CYCLE
   Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909
   POPOVIC M, 1984, SCIENCE, V224, P500
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   RATNER L, 1985, NATURE, V313, P636, DOI 10.1038/313636c0                                                                
   RAY GF, 1990, DRUG METAB DISPOS, V18, P654
   Reinke RA, 2002, J MED CHEM, V45, P3669, DOI 10.1021/jm010359d
   ROSSI L, 1992, CHEM-BIOL INTERACT, V85, P255, DOI 10.1016/0009-2797(92)90066-T                                                    
   SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   SATIJA J, 2007, CRIT REV THER DRUG, V24, P261
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4
   Shahgaldian P, 2003, INT J PHARM, V253, P23, DOI 10.1016/S0378-5173(02)00639-7
   SHAHIWALA A, 2007, FUTURE HIV THER, V1
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004
   Singh P, 2008, BIOCONJUGATE CHEM, V19, P2239, DOI 10.1021/bc800125u
   STOWRING L, 1979, J VIROL, V29, P523
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Tekade RK, 2009, CHEM REV, V109, P49, DOI 10.1021/cr068212n
   TEMIN HM, 1989, J ACQ IMMUN DEF SYND, V2, P1
   TEMIN HM, 1988, REV INFECT DIS, V10, P399
   Touitou E, 2000, J CONTROL RELEASE, V65, P403, DOI 10.1016/S0168-3659(99)00222-9
   Touitou E, 2001, BIOMATERIALS, V22, P3053, DOI 10.1016/S0142-9612(01)00052-7
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Van Maele B, 2005, AIDS REV, V7, P26
   van Rensburg EJ, 2000, S AFR J SCI, V96, P267
   Vitas AI, 1996, ANTIMICROB AGENTS CH, V40, P146
   Voinea M, 2002, J CELL MOL MED, V6, P465, DOI 10.1111/j.1582-4934.2002.tb00450.x                                              
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
   Wan Li, 2006, AIDS Res Ther, V3, P12, DOI 10.1186/1742-6405-3-12
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Weiss R, 1993, RETROVIRIDAE, P1
   WOFSY CB, 1986, LANCET, V1, P527
   WU HB, 2007, ACTA PHARM SIN, V42, P538
   Xiang J, 2002, INT J PHARM, V231, P57, DOI 10.1016/S0378-5173(01)00865-1
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Touitou E, 1996, US patent, Patent No. [5 540 934, 5540934, US 5540934 A]
   Touitou E., 1998, US patent, Patent No. [5716638, 5 716 638]
NR 154
TC 65
Z9 68
U1 2
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 478
EP 490
DI 10.1016/j.addr.2009.11.018
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400009
PM 19913579
DA 2018-01-05
ER

PT J
AU Sharma, P
   Garg, S
AF Sharma, Puneet
   Garg, Sanjay
TI Pure drug and polymer based nanotechnologies for the improved
   solubility, stability, bioavailability and targeting of anti-HIV drugs
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE HIV; Polymer; Nanoparticle; Nanocrystal; Polymeric micelle; Dendrimer
ID CACO-2 CELL MONOLAYERS; PLURONIC BLOCK-COPOLYMERS; POLYAMIDOAMINE PAMAM
   DENDRIMERS; SMALL-INTERFERING RNA; BLOOD-BRAIN-BARRIER; IN-VIVO
   TOXICITY; P-GLYCOPROTEIN; PROTEASE INHIBITORS; DELIVERY-SYSTEMS;
   POLY(AMIDOAMINE) DENDRIMERS
AB The impact of human immunodeficiency virus (HIV) infection has been devastating with nearly 7400 new infections every day. Although, the advent of highly active antiretroviral therapy (HAART) has made a tremendous contribution in reducing the morbidity and mortality in developed countries, the situation in developing countries is still grim with millions of people being infected by this disease. The new advancements in the field of nanotechnology based drug delivery systems hold promise to improve the situation. These nanoscale systems have been successfully employed in other diseases such as cancer, and therefore, we now have a better understanding of the practicalities and technicalities associated with their clinical development. Nanotechnology based approaches offer some unique opportunities specifically for the improvement of water solubility, stability, bioavailability and targeting of antiretroviral drugs. This review presents discussion on the contribution of pure drug and polymer based nanotechnologies for the delivery anti-HIV drugs. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Sharma, Puneet; Garg, Sanjay] Univ Auckland, Sch Pharm, Auckland 1, New Zealand.
RP Garg, S (reprint author), Univ Auckland, Sch Pharm, Private Bag 92019, Auckland 1, New Zealand.
EM s.garg@auckland.ac.nz
RI Garg, Sanjay/B-2516-2012
OI Garg, Sanjay/0000-0001-7253-2629
CR Adams ML, 2005, J PHARM SCI-US, V94, P1160, DOI 10.1002/jps.20368                                                               
   Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Aillon KL, 2009, ADV DRUG DELIVER REV, V61, P457, DOI 10.1016/j.addr.2009.03.010
   Alakhov VY, 1996, BIOCONJUGATE CHEM, V7, P209, DOI 10.1021/bc950093n
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Aliabadi HM, 2008, CLIN PHARMACOKINET, V47, P619, DOI 10.2165/00003088-200847100-00001
   Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2                                                   
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Batrakova EV, 1998, PHARMACEUT RES, V15, P850, DOI 10.1023/A:1011964213024
   Batrakova EV, 2001, J PHARMACOL EXP THER, V296, P551
   BOTTOMLEY K, 2006, NANOTECHNOLOGY DRUG, P20
   Bromberg L, 2008, J CONTROL RELEASE, V128, P99, DOI 10.1016/j.jconrel.2008.01.018
   Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196                                                     
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Chen HT, 2004, J AM CHEM SOC, V126, P10044, DOI 10.1021/ja048548j
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2009, AAPS PHARMSCITECH, V10, P1, DOI 10.1208/s12249-008-9168-z
   Constantinides PP, 2008, ADV DRUG DELIVER REV, V60, P757, DOI 10.1016/j.addr.2007.10.013
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Cui ZR, 2003, DRUG DEV IND PHARM, V29, P689, DOI 10.1081/DDC-120021318
   D'Emanuele A, 2004, J CONTROL RELEASE, V95, P447, DOI 10.1016/j.jconrel.2003.12.006
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   El-Sayed M, 2003, INT J PHARM, V265, P151, DOI 10.1016/S0378-5173(03)00391-0
   El-Sayed M, 2003, J BIOACT COMPAT POL, V18, P7, DOI 10.1177/088391103032794
   El-Sayed M, 2002, J CONTROL RELEASE, V81, P355, DOI 10.1016/S0168-3659(02)00087-1
   Fakes MG, 2009, INT J PHARMACEUT, V370, P167, DOI 10.1016/j.ijpharm.2008.11.018
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Galli C, 2006, INT J PHARM, V313, P114, DOI 10.1016/j.ijpharm.2006.01.030
   Giri MS, 2009, J IMMUNOL, V182, P4459, DOI 10.4049/jimmunol.0801450
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hu WY, 2002, CURR BIOL, V12, P1301, DOI 10.1016/S0960-9822(02)00975-2
   Huisman MT, 2001, MOL PHARMACOL, V59, P806
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Jevprasesphant R, 2003, PHARMACEUT RES, V20, P1543, DOI 10.1023/A:1026166729873                                                         
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   Johnson M, 2005, AIDS, V19, P685, DOI 10.1097/01.aids.0000166091.39317.99
   Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h
   Keller M, 2009, INT J PHARMACEUT, V379, P210, DOI 10.1016/j.ijpharm.2009.03.038
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kitchens KM, 2007, PHARM RES, V24, P2138, DOI 10.1007/s11095-007-9415-0
   Kitchens KM, 2006, PHARM RES, V23, P2818, DOI 10.1007/s11095-006-9122-2
   Kitchens KM, 2005, ADV DRUG DELIVER REV, V57, P2163, DOI 10.1016/j.addr.2005.09.013
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Kolhatkar RB, 2007, BIOCONJUGATE CHEM, V18, P2054, DOI 10.1021/bc0603889
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   LEU D, 1984, J PHARM SCI, V73, P1433, DOI 10.1002/jps.2600731028
   Lledo-Garcia R, 2007, J PHARM SCI-US, V96, P633, DOI 10.1002/jps.20683
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387                                                             
   Martin A, 1993, INTERFACIAL PHENOMEN, P362
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Miller DW, 1999, PHARMACEUT RES, V16, P396, DOI 10.1023/A:1018873702411                                                         
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Nagasaki Y, 2001, BIOMACROMOLECULES, V2, P1067, DOI 10.1021/bm015574q
   Neerman MF, 2004, INT J PHARM, V281, P129, DOI 10.1016/j.ijpharm.2004.04.023
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Orenstein JM, 2001, IMMUNOBIOLOGY, V204, P598, DOI 10.1078/0171-2985-00098                                                         
   Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Perloff ES, 2005, DRUG METAB DISPOS, V33, P764, DOI 10.1124/dmd.104.002931
   Pierige F, 2008, ADV DRUG DELIVER REV, V60, P286, DOI 10.1016/j.addr.2007.08.029
   Pisal DS, 2008, INT J PHARM, V350, P113, DOI 10.1016/j.ijpharm.2007.08.033
   Polli JW, 1999, PHARMACEUT RES, V16, P1206, DOI 10.1023/A:1018941328702
   Ribera E, 2006, AIDS, V20, P1131, DOI 10.1097/01.aids.0000226953.56976.ad
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Richter M, 2004, PHARM RES, V21, P1862, DOI 10.1023/B:PHAM.0000045240.81664.be
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   STORM G, 1995, ADV DRUG DELIVER REV, V17, P31, DOI 10.1016/0169-409X(95)00039-A
   Tong L, 2007, ANTIMICROB AGENTS CH, V51, P3498, DOI 10.1128/AAC.00671-07
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2005, EXPERT OPIN THER PAT, V15, P63, DOI 10.1517/13543776.15.1.63                                                        
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   TORCHILIN VP, 2000, ACS SYM SER, V752, P297
   Usansky HH, 2008, DRUG METAB DISPOS, V36, P863, DOI 10.1124/dmd.107.017483
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Villalonga-Barber C, 2008, CURR TOP MED CHEM, V8, P1294, DOI 10.2174/156802608785849012
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Whelan JW, 2005, DRUG DISCOV TODAY, V10, P1014, DOI 10.1016/S1359-6446(05)03547-6
   Williams GC, 1999, ADV DRUG DELIVER REV, V39, P211, DOI 10.1016/S0169-409X(99)00027-7                                                   
   Wiwattanapatapee R, 2000, PHARMACEUT RES, V17, P991, DOI 10.1023/A:1007587523543
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
   Wu Y, 2004, INT J PHARM, V285, P135, DOI 10.1016/j.ijpharm.2004.08.001
   Young B, 2002, JAIDS, V31, P478, DOI 10.1097/00126334-200212150-00004                                                
   Yu LX, 2002, PHARMACEUT RES, V19, P921, DOI 10.1023/A:1016473601633                                                         
   Zastre JA, 2009, J NEUROSCI RES, V87, P1023, DOI 10.1002/jnr.21898
   Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002
   LIVERSIDGE GG, Patent No. 51456841992
NR 109
TC 82
Z9 84
U1 3
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 491
EP 502
DI 10.1016/j.addr.2009.11.019
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400010
PM 19931328
DA 2018-01-05
ER

PT J
AU Wong, HL
   Chattopadhyay, N
   Wu, XY
   Bendayan, R
AF Wong, Ho Lun
   Chattopadhyay, Niladri
   Wu, Xiao Yu
   Bendayan, Reina
TI Nanotechnology applications for improved delivery of antiretroviral
   drugs to the brain
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Human immunodeficiency virus; Brain delivery; Antiretroviral;
   Nanotechnology; Blood-brain barrier; ATP-binding cassette membrane
   transporters
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CENTRAL-NERVOUS-SYSTEM; SOLID LIPID
   NANOPARTICLES; RESISTANCE-ASSOCIATED PROTEINS; CELL-PENETRATING PEPTIDE;
   MICROVESSEL ENDOTHELIAL-CELLS; HIV-1 PROTEASE INHIBITORS; P-GLYCOPROTEIN
   INHIBITION; IN-VITRO MODEL; FUNCTIONAL EXPRESSION
AB Human immunodeficiency virus (HIV) can gain access to the central nervous system during the early course of primary infection. Once in the brain compartment the virus actively replicates to form an independent viral reservoir, resulting in debilitating neurological complications, latent infection and drug resistance. Current antiretroviral drugs (ARVs) often fail to effectively reduce the HIV viral load in the brain. This, in part, is due to the poor transport of many ARVs, in particular protease inhibitors, across the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSBF). Studies have shown that nanocarriers including polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLN) and micelles can increase the local drug concentration gradients, facilitate drug transport into the brain via endocytotic pathways and inhibit the ATP-binding cassette (ABC) transporters expressed at the barrier sites. By delivering ARVs with nanocarriers, significant increase in the drug bioavailability to the brain is expected to be achieved. Recent studies show that the specificity and efficiency of ARVs delivery can be further enhanced by using nanocarriers with specific brain targeting, cell penetrating ligands or ABC-transporters inhibitors. Future research should focus on achieving brain delivery of ARVs in a safe, efficient, and yet cost-effective manner. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Chattopadhyay, Niladri; Wu, Xiao Yu; Bendayan, Reina] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON MSS 2S2, Canada.
   [Wong, Ho Lun] Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA.
RP Bendayan, R (reprint author), Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON MSS 2S2, Canada.
EM r.bendayan@utoronto.ca
FU Canadian Institutes of Health Research; Ontario HIV Treatment Network;
   U.S Army [W81XWH-08-1-0519]; CIHR
FX This work is supported by grants from the Canadian Institutes of Health
   Research and the Ontario HIV Treatment Network (awarded to RB). NC is
   supported by a U.S Army DOD BCRP predoctoral fellowship
   (W81XWH-08-1-0519) and a CIHR Vanier Canada Graduate Scholarship.
CR Abulrob A, 2005, INT CONGR SER, V1277, P212, DOI 10.1016/j.ics.2005.02.024
   Abulrob A, 2005, J NEUROCHEM, V95, P1201, DOI 10.1111/j.1471-4159.2005.03463.x
   Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917
   Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Amyere M, 2002, INT J MED MICROBIOL, V291, P487
   Ances BM, 2007, SEMIN NEUROL, V27, P86, DOI 10.1055/s-2006-956759
   Anda T., 1995, DRUG DELIV SYST, V10, P425
   ANDERSON BD, 1995, PHARMACEUT RES, V12, P1126, DOI 10.1023/A:1016299507382
   Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8
   Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002
   Batrakova EV, 2003, J PHARMACOL EXP THER, V304, P845, DOI 10.1124/jpet.102.043307
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Bendayan R, 2002, MICROSC RES TECHNIQ, V57, P365, DOI 10.1002/jemt.10090
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Boado RJ, 2007, BIOTECHNOL BIOENG, V96, P381, DOI 10.1002/bit.21120
   Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chekhonin VP, 2005, DRUG DELIV, V12, P1, DOI 10.1080/10717540590889556
   Chen HX, 2000, J NEUROVIROL, V6, P498, DOI 10.3109/13550280009091950                                                       
   Choo EF, 2000, DRUG METAB DISPOS, V28, P655
   Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250
   Clifford David B, 2008, Top HIV Med, V16, P94
   DALGLEISH AG, 1984, NATURE, V312, P767
   Dallas S, 2004, NEUROREPORT, V15, P1183, DOI 10.1097/01.wnr.0000126754.02091.c3
   Dallas S, 2003, J PHARMACOL EXP THER, V307, P282, DOI 10.1124/jpet.103.054304
   Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3
   DAVSON H, 1987, PHYSL PATHOPHYSIOLOG, P375
   de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957
   Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R
   DEAN M, 2002, NCBI HUMAN ATP BINDI
   Dechy-Cabaret O, 2004, CHEM REV, V104, P6147, DOI 10.1021/cr040002s
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   DUSSERRE N, 1995, AIDS, V9, P833, DOI 10.1097/00002030-199508000-00002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Ellis RJ, 1997, ARCH NEUROL-CHICAGO, V54, P416, DOI 10.1001/archneur.1997.00550160054016                                            
   Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886
   Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017
   Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158
   Fortin D, 2007, CANCER-AM CANCER SOC, V109, P751, DOI 10.1002/cncr.22450
   Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287
   FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x                                              
   Ganguly S, 2008, OLIGONUCLEOTIDES, V18, P277, DOI 10.1089/oli.2008.0140
   Gao KP, 2006, INT J PHARM, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Gershkovich P, 2008, CRIT REV THER DRUG, V25, P545, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i6.20                                    
   Ghafouri M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-28
   Gimenez F, 2004, JAIDS-J ACQ IMM DEF, V36, P649, DOI 10.1097/00126334-200406010-00001                                                
   Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5
   Giri N, 2008, DRUG METAB DISPOS, V36, P1476, DOI 10.1124/dmd.108.020974
   Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Hartmann JT, 2006, DRUG SAFETY, V29, P209, DOI 10.2165/00002018-200629030-00005
   Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Huwyler J, 1997, J PHARMACOL EXP THER, V282, P1541
   Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718
   Janneh O, 2005, AIDS, V19, P2097, DOI 10.1097/01.aids.0000194793.36175.40
   Janneh O, 2007, J ANTIMICROB CHEMOTH, V60, P987, DOI 10.1093/jac/dkm353
   JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   *JOINT UN PROGR HI, WHO AIDS EP UPD DEC
   Jones K, 2001, AIDS, V15, P1353, DOI 10.1097/00002030-200107270-00004                                                
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
   Kabanov AV, 2003, J CONTROL RELEASE, V91, P75, DOI 10.1016/S0168-3659(03)00211-6
   Kanmogne GD, 2002, J NEUROPATH EXP NEUR, V61, P992, DOI 10.1093/jnen/61.11.992                                                          
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212
   Kaul M, 2005, CELL DEATH DIFFER, V12, P878, DOI 10.1038/sj.cdd.4401623
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kerwin BA, 2008, J PHARM SCI-US, V97, P2924, DOI 10.1002/jps.21190
   Kerza-Kwiatecki Al P., 1999, Journal of Neurovirology, V5, P113, DOI 10.3109/13550289909021992
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200
   Kolchinsky P, 2001, J VIROL, V75, P2041, DOI 10.1128/JVI.75.5.2041-2050.2001
   Koziara JM, 2004, J CONTROL RELEASE, V99, P259, DOI 10.1016/j.jconrel.2004.07.006
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7                                                   
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Kusuhara H, 2001, DRUG DISCOV TODAY, V6, P150, DOI 10.1016/S1359-6446(00)01632-9
   Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x                                                               
   Lee G, 2001, J PHARMACOL EXP THER, V299, P204
   Lee YJ, 2006, J PHARMACOL EXP THER, V316, P647, DOI 10.1124/jpet.105.088328
   Leonard DJ, 2009, J BIOMED MATER RES A, V89A, P567, DOI 10.1002/jbm.a.31998
   LEVY RM, 1997, PRACTICE NEUROSURGER, pCH228
   LIU F, 1995, PHARMACEUT RES, V12, P1060, DOI 10.1023/A:1016274801930                                                         
   Liu Y, 2004, J VIROL, V78, P4120, DOI 10.1128/JVI.78.8.4120-4133.2004
   Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936
   Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI [10.1586/erm.09.15, 10.1586/ERM.09.15]
   Lyketsos CG, 1997, J NEUROPSYCH CLIN N, V9, P277
   MacKay JA, 2005, BRAIN RES, V1035, P139, DOI 10.1016/j.brainres.2004.12.007
   Maher J, 1997, MOVEMENT DISORD, V12, P593, DOI 10.1002/mds.870120418
   Maliepaard M, 2001, CANCER RES, V61, P3458
   Martin J, 2001, J VIROL, V75, P3568, DOI 10.1128/JVI.75.8.3568-3580.2001
   MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137
   McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109
   McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010
   Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY                                                     
   Meairs S, 2007, PROG BIOPHYS MOL BIO, V93, P354, DOI 10.1016/j.pbiomolbio.2006.07.019
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Miller DS, 2000, MOL PHARMACOL, V58, P1357
   Mori N, 1995, BRAIN RES, V703, P184, DOI 10.1016/0006-8993(95)01095-5
   Muller RH, 1997, PHARMACEUT RES, V14, P458, DOI 10.1023/A:1012043315093
   Nermut MV, 2003, J VIROL, V77, P8196, DOI 10.1128/JVI.77.15.8196-8206.2003
   NEUWELT EA, 1984, NEUROSURGERY, V15, P362, DOI 10.1227/00006123-198409000-00011                                                
   New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806                                                       
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Oldfield V, 2006, DRUGS, V66, P1275, DOI 10.2165/00003495-200666090-00012
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Olivier Jean-Christophe, 2005, NeuroRx, V2, P108, DOI 10.1007/BF03206647
   Panel on Antiretroviral Guidelines for Adult and Adolescents, 2008, GUID US ANT AG HIV 1, P1
   PARDRIDGE WM, 1996, P W PHARMACOL SOC, V39, P93
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Perloff ES, 2005, DRUG METAB DISPOS, V33, P764, DOI 10.1124/dmd.104.002931
   Perloff MD, 2003, PHARMACEUT RES, V20, P1177, DOI 10.1023/A:1025092829696
   Perloff MD, 2002, J CLIN PHARMACOL, V42, P1269, DOI 10.1177/0091270002238770
   Perry CM, 2005, DRUGS, V65, P2209, DOI 10.2165/00003495-200565150-00015
   PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509
   Popovic N, 2006, INT J PHARM, V314, P120, DOI 10.1016/j.ijpharm.2005.09.040
   Poruchynsky MS, 2008, CELL CYCLE, V7, P940, DOI 10.4161/cc.7.7.5625                                                             
   Qin Li-Juan, 2009, Neurosci Lett, V450, P172, DOI 10.1016/j.neulet.2008.10.080
   Reid G, 2003, MOL PHARMACOL, V63, P1094, DOI 10.1124/mol.63.5.1094
   Ricardo-Dukelow M, 2007, J NEUROIMMUNOL, V185, P37, DOI 10.1016/j.jneuroim.2007.01.004
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Ronaldson PT, 2006, MOL PHARMACOL, V70, P1087, DOI 10.1124/mol.106.025973
   Ronaldson PT, 2004, PHARM RES, V21, P811, DOI 10.1023/B:PHAM.0000026433.27773.47
   Ronaldson PT, 2004, J NEUROCHEM, V89, P788, DOI 10.1111/j.1471-4159.2004.02417.x
   Ruff MR, 2001, ANTIVIR RES, V52, P63, DOI 10.1016/S0166-3542(01)00163-2
   Ryan SM, 2008, EXPERT OPIN DRUG DEL, V5, P371, DOI 10.1517/17425247.5.4.371 
   SABATIER JM, 1991, J VIROL, V65, P961
   Sacktor N, 2001, NEUROLOGY, V56, P257, DOI 10.1212/WNL.56.2.257                                                            
   SALAHUDDIN TS, 1988, NEUROPATH APPL NEURO, V14, P467, DOI 10.1111/j.1365-2990.1988.tb01338.x                                              
   Salama NN, 2005, J PHARM SCI-US, V94, P1216, DOI 10.1002/jps.20344
   Sawant Krutika K, 2008, Recent Pat Drug Deliv Formul, V2, P120, DOI 10.2174/187221108784534081
   Schnyder A, 2005, J DRUG TARGET, V13, P325, DOI 10.1080/10611860500206674
   Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487                                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sesti Settimio, 2005, BMC Physiol, V5, P2, DOI 10.1186/1472-6793-5-2
   Sharom FJ, 2006, BIOCHEM CELL BIOL, V84, P979, DOI 10.1139/O06-199
   Smith DE, 2004, ADV DRUG DELIVER REV, V56, P1765, DOI 10.1016/j.addr.2004.07.008
   Song L, 2003, J NEUROVIROL, V9, P399, DOI 10.1080/13550280390201704
   SONI S, 2005, AM J DRUG DELIV, V3, P205
   Soni V., 2005, AM J DRUG DELIV, V3, P155
   Sood RR, 2008, J CEREBR BLOOD F MET, V28, P431, DOI 10.1038/sj.jcbfm.9600534
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Storch CH, 2007, BIOCHEM PHARMACOL, V73, P1573, DOI 10.1016/j.bcp.2007.01.027
   Suzuki T, 2004, J NUCL MED, V45, P1766
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   SWAINSTON HT, 2005, DRUGS, V65, P2309
   Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x
   Tozzi V, 2007, JAIDS-J ACQ IMM DEF, V45, P174, DOI 10.1097/QAI.0b013e318042e1ee
   Trillo-Pazos G, 2003, BRAIN PATHOL, V13, P144
   Ulbrich K, 2009, EUR J PHARM BIOPHARM, V71, P251, DOI 10.1016/j.ejpb.2008.08.021
   van der Sandt ICJ, 2001, PHARMACEUT RES, V18, P587, DOI 10.1023/A:1011016923346
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004
   Washington CB, 2000, DRUG METAB DISPOS, V28, P1058
   Webb Murray S, 2007, Recent Pat Drug Deliv Formul, V1, P185, DOI 10.2174/187221107782331593
   WEI B, 2008, BIOMED PHARMACOTHER, V63, P313
   Weiss J, 2007, DRUG METAB DISPOS, V35, P340, DOI 10.1124/dmd.106.012765
   Wong HL, 2004, J PHARM SCI-US, V93, P1993, DOI 10.1002/jps.20100
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Wong HL, 2006, J CONTROL RELEASE, V116, P275, DOI 10.1016/j.jconrel.2006.09.007
   Wong JK, 1997, J VIROL, V71, P2059
   Wu DF, 1998, DRUG METAB DISPOS, V26, P937
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Wynn HE, 2002, CNS DRUGS, V16, P595, DOI 10.2165/00023210-200216090-00002
   YARCHOAN R, 1988, SCI AM, V259, P110, DOI 10.1038/scientificamerican1088-110                                              
   Yousif S, 2007, BRAIN RES, V1134, P1, DOI 10.1016/j.brainres.2006.11.089
   Zhang XB, 2003, J DRUG TARGET, V11, P117, DOI 10.1080/1061186031000115150
   Zhang XB, 2009, J NEUROIMMUNE PHARM, V4, P35, DOI 10.1007/s11481-008-9119-1
   Zheng Lin, 2005, J Zhejiang Univ Sci B, V6, P668, DOI 10.1631/jzus.2005.B0668
   Zhu WL, 2009, CHEM BIOL DRUG DES, V73, P209, DOI 10.1111/j.1747-0285.2008.00769.x
NR 193
TC 105
Z9 111
U1 6
U2 92
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 503
EP 517
DI 10.1016/j.addr.2009.11.020
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400011
PM 19914319
DA 2018-01-05
ER

PT J
AU Gunaseelan, S
   Gunaseelan, K
   Deshmukh, M
   Zhang, XP
   Sinko, PJ
AF Gunaseelan, Simi
   Gunaseelan, Krishnan
   Deshmukh, Manjeet
   Zhang, Xiaoping
   Sinko, Patrick J.
TI Surface modifications of nanocarriers for effective intracellular
   delivery of anti-HIV drugs
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE HIV/AIDS; Anti-HIV drugs; Nanocarriers; Surface modification;
   Macrophages; Intracellular delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BIODEGRADABLE POLYMERIC NANOPARTICLES;
   POLY PROPYLENEIMINE DENDRIMER; CELL-PENETRATING PEPTIDES; HUMAN PRIMARY
   MACROPHAGES; IN-VIVO EVALUATION; TARGETED DELIVERY; LYMPHOID-TISSUES;
   T-CELLS; LIPOSOMAL 2',3'-DIDEOXYCYTIDINE
AB A variety of nanocarriers such as bioconjugates, dendrimers, liposomes, and nanoparticles have been widely evaluated as potential targeted drug delivery systems. Passive targeting of nanoscale carriers is based on a size-flow-filtration phenomenon that is usually limited to tumors, the reticular endothelial system, and possibly lymph nodes (LNs). In fact, targeting the delivery of drugs to pivotal physiological sites such as the lymph nodes has emerged as a promising strategy in treating HIV disease. Ligands for specific cell surface receptors can be displayed on nanocarriers in order to achieve active targeting. The approach has been extensively used preclinically in cancer where certain receptors are over-expressed at various stages of the disease. Unfortunately, markers of HIV infection are lacking and latently infected cells do not show any signs of infection on their surface. However, the disease naturally targets only a few cell types. The HIV receptor CD4, coreceptors (CCR5 and CXCR4), and some receptors relatively specific for macrophages provide potentially valuable surface targets for drug delivery to all susceptible cells in patients infected by HIV. This review focuses on nanoscale targeting with an emphasis on surface modifications of drug delivery nanocarriers for active targeting. A number of related issues, including HIV biology, targets, pharmacokinetics, and intracellular fate as well as literature-cited examples of emerging surface-modified targeted carrier systems are discussed. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Gunaseelan, Simi; Gunaseelan, Krishnan; Deshmukh, Manjeet; Zhang, Xiaoping; Sinko, Patrick J.] Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Gunaseelan, Krishnan; Deshmukh, Manjeet; Sinko, Patrick J.] Rutgers State Univ, UMDNJ Rutgers CounterACT Res Ctr Excellence, Piscataway, NJ 08854 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA.
EM sinko@rutgers.edu
FU NIH [AI51214, U54AR055073]; Parke-Davis Endowed Chair in Pharmaceutics
   and Drug Delivery
FX Partial financial support from NIH AI51214, NIH CounterACT Program
   U54AR055073 and the Parke-Davis Endowed Chair in Pharmaceutics and Drug
   Delivery is gratefully acknowledged. We would like to thank Dr. Howard
   Gendelman and Dr. Robin Taylor for their help.
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Allen TM, 2002, J LIPOSOME RES, V12, P5, DOI 10.1081/LPR-120004771
   Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774
   Aquaro S, 2002, J MED VIROL, V68, P479, DOI 10.1002/jmv.10245
   Aquaro S, 2000, J LEUKOCYTE BIOL, V68, P429
   Aquaro S, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-76
   Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55
   BETAGERI CV, 1993, DRUG DEV IND PHARM, V19, P2109
   BETAGERI GV, 1993, J PHARM PHARMACOL, V45, P48, DOI 10.1111/j.2042-7158.1993.tb03678.x                                              
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   BUCHENOSMOND C, 2006, ICTVDB UN VIR DAT, V4
   BUCHENOSMOND C, 2006, ICTVDB UN VIR DAT
   Burton GF, 2002, SEMIN IMMUNOL, V14, P275, DOI 10.1016/S1044-5323(02)00060-X
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Cassol E, 2006, J LEUKOCYTE BIOL, V80, P1018, DOI 10.1189/jlb.0306150
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Collman Ronald G, 2003, Res Initiat Treat Action, V8, P6
   CROWE SM, 1990, AIDS RES HUM RETROV, V6, P1031
   D'Emanuele A, 2005, ADV DRUG DELIVER REV, V57, P2147, DOI 10.1016/j.addr.2005.09.012
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Ehrlich P., 1960, COLLECTED PAPERS P E
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Fahmy TM, 2007, AAPS J, V9, pE171, DOI 10.1208/aapsj0902019
   Fahmy TM, 2005, MATER TODAY, V8, P18, DOI 10.1016/S1369-7021(05)71033-6
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Gunaseelan S, 2004, BIOCONJUGATE CHEM, V15, P1322, DOI 10.1021/bc0498875
   Gunaseelan S, 2009, BIOMATERIALS, V30, P5649, DOI 10.1016/j.biomaterials.2009.05.068
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026
   Hong S, 2007, CHEM BIOL, V14, P107, DOI 10.1016/j.chembiol.2006.11.015
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang SY, 1998, BIOCONJUGATE CHEM, V9, P612, DOI 10.1021/bc980038p
   Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226                                                   
   *JOINT UN PROGR HI, 2005, AIDS EP UPD
   Katragadda A, 2000, CELL MOL BIOL LETT, V5, P483
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kazmierski WM, 2006, CHEM BIOL DRUG DES, V67, P13, DOI 10.1111/j.1747-0285.2005.00319.x
   Kedzierska K, 2003, REV MED VIROL, V13, P39, DOI 10.1002/rmv.369
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kolhe P, 2003, INT J PHARM, V259, P143, DOI 10.1016/S0378-5173(03)00225-4
   Kondo A, 2001, CLIN CHEM, V47, P893
   Kreuter J., 2004, ENCY NANOSCIENCE NAN, V7, P161
   Kuritzkes DR, 2009, CURR OPIN HIV AIDS, V4, P82, DOI 10.1097/COH.0b013e328322402e
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0
   Lawn SD, 2004, J INFECTION, V48, P1, DOI 10.1016/j.jinf.2003.09.001
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Mainardes RM, 2005, INT J PHARM, V290, P137, DOI 10.1016/j.ijpharm.2004.11.027
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   MAKABIPANZU B, 1995, J ACQ IMMUN DEF SYND, V8, P227, DOI 10.1097/00042560-199503010-00002                                                
   Mankertz J, 1996, BBA-MOL BASIS DIS, V1317, P233, DOI 10.1016/S0925-4439(96)00059-2
   Muthu MS, 2009, NANOMEDICINE-UK, V4, P105, DOI 10.2217/17435889.4.1.105
   Muthu MS, 2008, NANOMEDICINE-UK, V3, P305, DOI 10.2217/17435889.3.3.305
   Opanasopit P, 2002, CRIT REV THER DRUG, V19, P191
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Panyam Jayanth, 2004, Current Drug Delivery, V1, P235, DOI 10.2174/1567201043334768
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   Prokop A, 2008, J PHARM SCI-US, V97, P3518, DOI 10.1002/jps.21270
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Reiner SL, 2007, CELL, V129, P33, DOI 10.1016/j.cell.2007.03.019
   Rusconi S, 2007, CURR TOP MED CHEM, V7, P1273
   Sant S, 2008, J BIOMED MATER RES A, V87A, P885, DOI 10.1002/jbm.a.31800
   Sapra P, 2003, PROG LIPID RES, V42, P439, DOI 10.1016/S0163-7827(03)00032-8
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   SHIVE MS, 1997, ADV DRUG DELIV REV, V28, P5
   Singh S, 2007, NANOMEDICINE-UK, V2, P233, DOI 10.2217/17435889.2.2.233
   Singh Y, 2008, CURR MED CHEM, V15, P1802, DOI 10.2174/092986708785132997
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   UNAIDS and WHO, 2007, AIDS EP UPD
   VISSCHER GE, 1986, J BIOMED MATER RES, V20, P667, DOI 10.1002/jbm.820200510
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Wan Li, 2006, AIDS Res Ther, V3, P12, DOI 10.1186/1742-6405-3-12
   WARR GW, 1974, CELL TISSUE KINET, V7, P559, DOI 10.1111/j.1365-2184.1974.tb00439.x
   Waterhouse DN, 2005, METHOD ENZYMOL, V391, P40, DOI 10.1016/S0076-6879(05)91002-1                                                   
   WIENER EC, 1994, MAGNET RESON MED, V31, P1, DOI 10.1002/mrm.1910310102
   WU HB, 2007, ACTA PHARM SIN, V42, P538
   Zhang K, 2008, BIOCONJUGATE CHEM, V19, P1880, DOI 10.1021/bc800160b
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhang XP, 2009, MOL PHARMACEUT, V6, P836, DOI 10.1021/mp800121f
NR 102
TC 67
Z9 69
U1 1
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 518
EP 531
DI 10.1016/j.addr.2009.11.021
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400012
PM 19941919
OA green_accepted
DA 2018-01-05
ER

PT J
AU du Toit, LC
   Pillay, V
   Choonara, YE
AF du Toit, Lisa C.
   Pillay, Viness
   Choonara, Yahya E.
TI Nano-microbicides: Challenges in drug delivery, patient ethics and
   intellectual property in the war against HIV/AIDS
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Human immunodeficiency virus; Microbicide; Drug delivery systems;
   Dendrimer; Nanoparticle; Nano-enabled; Intellectual property; Patents
ID SURFACE CONFOCAL MICROSCOPY; ANTI-HIV PROPERTIES; FULLERENE DERIVATIVES;
   TOPICAL MICROBICIDES; SEXUAL TRANSMISSION; CARBON NANOTUBES; VAGINAL
   DELIVERY; VIRUS INFECTION; IN-VITRO; PREVENTION
AB As we continue to be embroiled in the global battle against the human immunodeficiency virus (HIV), there has been an ongoing evolution in the understanding of the molecular mode of sexual transmission of HIV. This has gone hand-in-hand with a paradigm shift and research focus on the development of microbicides - compounds designed for vaginal (and possibly rectal) administration that are envisaged to put safe, affordable and accessible protection into the hands of women. However, an effective microbicide is not yet available; innovative approaches for the design of topical vaginal microbicides are urgently needed. The potential of the advancing field of nanomedicine has been earmarked in the increasing efforts to address the major health problems of the developing world. In this review, advances in the design of innovative microbicide nanocarriers and nano-enabled microbicides, henceforth referred to as 'nano-microbicides', are presented; elaborating on nanotechnology's role in the antiviral arena. The role of nanotechnology in the antiviral arena and the unique issues facing the generation of intellectual property relating to nano-microbicides in the ongoing global 'tug-of-war' of 'patients versus patents' are also explicated. (C) 2009 Elsevier B.V. All rights reserved.
C1 [du Toit, Lisa C.; Pillay, Viness; Choonara, Yahya E.] Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, South Africa.
RP Pillay, V (reprint author), Univ Witwatersrand, Dept Pharm & Pharmacol, 7 York Rd,Parktown, ZA-2193 Johannesburg, South Africa.
EM viness.pillay@wits.ac.za
RI Pillay, Viness/C-1569-2010; Choonara, Yahya/B-2955-2013
OI Pillay, Viness/0000-0002-8119-3347; Choonara, Yahya/0000-0002-3889-1529
CR Ahuja A, 1997, DRUG DEV IND PHARM, V23, P489, DOI 10.3109/03639049709148498                                                       
   Aitken R.J., 2004, NANOPARTICLES OCCUPA, V2004
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   ANDERSON PW, 1972, SCIENCE, V177, P393, DOI 10.1126/science.177.4047.393
   ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916                                                         
   *AUSTR DEP EMPL WO, 2005, INQ WORKPL EXP UNPUB
   Bakry R, 2007, INT J NANOMED, V2, P639
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barker TF, 2008, NANOTECHNOLOGY & SOCIETY: CURRENT AND EMERGING ETHICAL ISSUES, P243
   Barnard D. L., 1997, Antiviral Research, V34, pA88
   Bawa R., 2004, NANOTECHNOLOGY PATEN
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Bosman AW, 1999, CHEM REV, V99, P1665, DOI 10.1021/cr970069y                                                               
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Burlaka AP, 2004, EXP ONCOL, V26, P326
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Chaudhry Q, 2006, SCOPING STUDY IDENTI
   Cho KH, 2005, ELECTROCHIM ACTA, V51, P956, DOI 10.1016/j.electacta.2005.04.071
   Coplan PM, 2004, SCIENCE, V304, P1911, DOI 10.1126/science.1100441                                                         
   CRISTOFARO P, 2005, PREV STRAT VACC MICR, P22
   Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130
   Elechiguerra J.L., 2005, NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-1
   Elias CJ, 1996, AIDS, V10, pS43
   Eng T. R., 1997, HIDDEN EPIDEMIC CONF
   *ETC GROUP, 2008, DEV DOSS INTRO NAN T, P1
   European Science Foundation, 2005, NAN ESF EUR MED RES
   Faunce TA, 2007, MED J AUSTRALIA, V186, P189
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544                                                          
   *FORB WOLF NAN, 2006, VIVAGEL COULD CUR ST, V5, P1
   Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   GARBER C, 2007, POTENTIAL PITFALLS N
   GHEZZO E, 1992, INT J PHARM, V87, P21, DOI 10.1016/0378-5173(92)90223-O
   Gorelik J, 2002, P NATL ACAD SCI USA, V99, P16018, DOI 10.1073/pnas.252458399
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Harris D, 2004, NANOTECHNOL LAW BUS, V1, P1
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74
   *JAIN PHARMABIOTEC, 2009, ROL NAN DEV ANT AG E
   Jang WD, 2009, PROG POLYM SCI, V34, P1, DOI 10.1016/j.progpolymsci.2008.08.003
   KISER PF, 2006, MOL CONDOM AIDS, P1
   Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Linkov I, 2008, NANOMED-NANOTECHNOL, V4, P167, DOI 10.1016/j.nano.2008.01.001
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   MACLURCAN DC, 2005, AZOJONO AZO OPEN A 1
   MACLURCAN DC, 2005, AZOJONO AZO OPEN A 2
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Marcorin GL, 2000, ORG LETT, V2, P3955, DOI 10.1021/ol000217y
   Marx V, 2008, NAT BIOTECHNOL, V26, P729, DOI 10.1038/nbt0708-729
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mathiowitz Edith, 1999, ENCY CONTROLLED DRUG, VI, P9
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910                                                          
   Milstien J, 2004, B WORLD HEALTH ORGAN, V82, P128
   Mirkin C., NANOTECHNOLOGY BASED
   MITCHELL S, 2006, HIV MICROBICIDES GAI
   Mnyusiwalla A., 2003, NANOTECHNOLOGY, V14, pR9
   MOULARD M, 2000, J VIROL, V74, P1048
   MULLALLY MV, 2004, N Y L J         0706
   *NAN, 2005, NAN DEL IMP NAN DRUG
   NDESENDO VMK, 2008, AAPS PHARMSCITECH, V9, P205
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   NORDAN MM, 2005, IND BIOTECHNOLOGY, V1, P146, DOI DOI 10.1089/IND.2005.1.146
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Patel J, 2007, DRUG DEL TECH, V7, P54
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Phillips DM, 2004, CONTRACEPTION, V70, P107, DOI 10.1016/j.contraception.2004.04.008
   Potts M, 2003, SCIENCE, V300, P431
   Richardson JL, 1999, DRUGS PHARM SCI, V98, P563
   Richardson JL, 1996, J CONTROL RELEASE, V42, P133, DOI 10.1016/0168-3659(96)01451-4
   Rosenthal SL, 1998, SEX TRANSM DIS, V25, P368, DOI 10.1097/00007435-199808000-00009                                                
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   SCHUON A, POSITIVE INITIAL RES
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shattock RJ, 2002, NAT MED, V8, P425, DOI 10.1038/nm0502-425
   Shevchuk AI, 2008, BIOPHYS J, V94, P4089, DOI 10.1529/biophysj.107.112524
   STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   Tang YJJ, 2007, NANO LETT, V7, P754, DOI 10.1021/nl063020t
   TAO Y, 2008, J ECOL RURAL ENVIRON, V24, P5
   Tegos GP, 2005, CHEM BIOL, V12, P1127, DOI 10.1016/j.chembiol.2005.08.014
   Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Trager RS, 2003, SCIENCE, V299, P39, DOI 10.1126/science.299.5603.39
   van de Wijgert JHHM, 2007, AIDS, V21, P2369, DOI 10.1097/QAD.0b013e3282ef83fd                                                    
   Vasir JK, 2003, INT J PHARM, V255, P13, DOI 10.1016/S0378-5173(03)00087-5
   Watts C, 2001, AIDS, V15, pS43, DOI 10.1097/00002030-200102001-00064
   Weber J, 2001, AIDS, V15, P1563, DOI 10.1097/00002030-200108170-00014
   World Health Organization, 2009, MICR
   WITROUW M, 1999, ANTIVIR RES, V41, pA25
   Wood S., 2007, NANOTECHNOLOGY SCI S
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   YACAMAN MJ, Patent No. 20060115495
   KISER PF, Patent No. 20070166382
   VIVAGEL MARKET UPDAT
   2005, MINTEK ANN REPORT
   Greiner A., 2008, PCT Int. Appl. WO, Patent No. [2008049250 A1, 2008049250]
   Ross M B, 2001, US Patent, Patent No. [6,190,650BI, 6190650]
   2005, HIV AIDS EPIDEMIOLOG
NR 105
TC 44
Z9 45
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 18
PY 2010
VL 62
IS 4-5
BP 532
EP 546
DI 10.1016/j.addr.2009.11.022
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 576DD
UT WOS:000276123400013
PM 19922751
DA 2018-01-05
ER

PT J
AU Lewis, MG
   Norelli, S
   Collins, M
   Barreca, ML
   Iraci, N
   Chirullo, B
   Yalley-Ogunro, J
   Greenhouse, J
   Titti, F
   Garaci, E
   Savarino, A
AF Lewis, Mark G.
   Norelli, Sandro
   Collins, Matt
   Barreca, Maria Letizia
   Iraci, Nunzio
   Chirullo, Barbara
   Yalley-Ogunro, Jake
   Greenhouse, Jack
   Titti, Fausto
   Garaci, Enrico
   Savarino, Andrea
TI Response of a simian immunodeficiency virus (SIVmac251) to raltegravir:
   a basis for a new treatment for simian AIDS and an animal model for
   studying lentiviral persistence during antiretroviral therapy
SO RETROVIROLOGY
LA English
DT Article
ID HIV-1 INTEGRASE INHIBITORS; STRAND TRANSFER INHIBITORS; IN-VITRO;
   1H-BENZYLINDOLE DERIVATIVES; PHYLOGENETIC ANALYSIS; VIRAL REPLICATION;
   RESISTANT HIV-1; INFECTION; BINDING; DNA
AB Background: In this study we successfully created a new approach to ART in SIVmac251 infected nonhuman primates. This drug regimen is entirely based on drugs affecting the pre-integration stages of replication and consists of only two nucleotidic/nucleosidic reverse transcriptase inhibitors (Nt/NRTIs) and raltegravir, a promising new drug belonging to the integrase strand transfer inhibitor (INSTI) class.
   Results: In acutely infected human lymphoid CD4(+) T-cell lines MT-4 and CEMx174, SIVmac251 replication was efficiently inhibited by raltegravir, which showed an EC(90) in the low nanomolar range. This result was confirmed in primary macaque PBMCs and enriched CD4(+) T cell fractions. In vivo monotherapy with raltegravir for only ten days resulted in reproducible decreases in viral load in two different groups of animals. When emtricitabine (FTC) and tenofovir (PMPA) were added to treatment, undetectable viral load was reached in two weeks, and a parallel increase in CD4 counts was observed. In contrast, the levels of proviral DNA did not change significantly during the treatment period, thus showing persistence of this lentiviral reservoir during therapy.
   Conclusions: In line with the high conservation of the three main amino acids Y143, Q148 and N155 (responsible for raltegravir binding) and molecular docking simulations showing similar binding modes of raltegravir at the SIVmac251 and HIV-1 IN active sites, raltegravir is capable of inhibiting SIVmac251 replication both in tissue culture and in vivo. This finding may help to develop effective ART regimens for the simian AIDS model entirely based on drugs adopted for treatment in humans. This ART-treated AIDS nonhuman primate model could be employed to find possible strategies for virus eradication from the body.
C1 [Norelli, Sandro; Chirullo, Barbara; Savarino, Andrea] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy.
   [Lewis, Mark G.; Collins, Matt; Yalley-Ogunro, Jake; Greenhouse, Jack] BIOQUAL Inc, Rockville, MD 20850 USA.
   [Barreca, Maria Letizia; Iraci, Nunzio] Univ Perugia, Fac Farm, Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy.
   [Titti, Fausto] Ist Super Sanita, CNAIDS, I-00161 Rome, Italy.
   [Garaci, Enrico] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy.
RP Savarino, A (reprint author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM andrea.savarino@iss.it
RI Iraci, Nunzio/B-4945-2015
OI Iraci, Nunzio/0000-0002-1359-8684; Barreca, Maria
   Letizia/0000-0003-3530-5042
FU Italian Ministry of Health; Fondazione Roma
FX This work was supported by grants from 1%-Italian Ministry of Health
   (AS), and Fondazione Roma (EG).
CR Alsina M. M. P., 2008, ENFERM INFECC MICR S, V26, P23
   Barreca ML, 2009, CHEMMEDCHEM, V4, P1446, DOI 10.1002/cmdc.200900166
   Bensi T, 2009, EXPERT OPIN THER TAR, V13, P141, DOI [10.1517/14728220802637147, 10.1517/14728220802637147 ]
   Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334                                           
   CECCHERINISILBE.F, 2009, AIDS REV, V29, P11
   Chen X, 2008, J MOL BIOL, V380, P504, DOI 10.1016/j.jmb.2008.04.054
   Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451
   Chevenet F, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-439
   Chirch LM, 2009, EXPERT OPIN PHARMACO, V10, P1203, DOI [10.1517/14656560902911488 , 10.1517/14656560902911488]
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Chun T. W., 2007, J INFECT DIS, V195, P1734
   COTELLE P, 2006, RECENT PAT ANTIINFEC, P11
   Cox Arthur G., 2006, Antiviral Chemistry & Chemotherapy, V17, P343
   DENTON PW, 2009, CURR HIV AIDS REP, V9, P6
   Dereeper A, 2008, NUCLEIC ACIDS RES, V36, pW465, DOI 10.1093/nar/gkn180
   Dicker IB, 2007, J BIOL CHEM, V282, P31186, DOI 10.1074/jbc.M704935200
   Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Ferro S, 2009, J MED CHEM, V52, P569, DOI 10.1021/jm8009266
   Gifford RJ, 2008, P NATL ACAD SCI USA, V105, P20362, DOI 10.1073/pnas.0807873105
   Grobler JA, 2008, ANTIVIR THER, V13, pA41
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hamer DH, 2004, CURR HIV RES, V2, P99, DOI 10.2174/1570162043484915
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Hombrouck A, 2008, ANTIMICROB AGENTS CH, V52, P2861, DOI 10.1128/AAC.00210-08
   Jiang Yonghou, 2009, AIDS Res Ther, V6, P23, DOI 10.1186/1742-6405-6-23
   Johnson AA, 2007, MOL PHARMACOL, V71, P893, DOI 10.1124/mol.106.030817
   Jones G, 2007, 14 C RETR OPP INF LO
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200
   Kulkosky J, 2006, CURR HIV RES, V4, P199, DOI 10.2174/157016206776055084
   Liao CZ, 2007, BIOORG MED CHEM LETT, V17, P5361, DOI 10.1016/j.bmcl.2007.08.011
   Loizidou EZ, 2009, BIOORGAN MED CHEM, V17, P4806, DOI 10.1016/j.bmc.2009.04.058
   Malet I, 2009, J ANTIMICROB CHEMOTH, V63, P795, DOI 10.1093/jac/dkp014
   Mannioui A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-106
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   Mouscadet JF, 2009, J MOL RECOGNIT, V22, P480, DOI 10.1002/jmr.970
   NAKASHIMA H, 1989, J VIROL METHODS, V26, P319, DOI 10.1016/0166-0934(89)90114-6
   Neamati N, 2002, EXPERT OPIN THER PAT, V12, P709, DOI 10.1517/13543776.12.5.709                                                       
   Norelli S, 2008, CURR HIV RES, V6, P306, DOI 10.2174/157016208785132527                                                      
   North T.W., 2009, J VIROL, V84, P2913
   NU H, 2006, J CHEM INF MODEL, V46, P243
   Owen SM, 1998, J VIROL, V72, P5425
   Pal R, 2009, VIROLOGY, V386, P102, DOI 10.1016/j.virol.2009.01.002
   Parkin NT, 2004, ANTIVIR THER, V9, P3
   PISTELLO M, 2008, FUTURE HIV THER, V2, P301
   Richardson MW, 2004, DNA CELL BIOL, V23, P1, DOI 10.1089/104454904322745880
   Roquebert B, 2008, J ANTIMICROB CHEMOTH, V62, P914, DOI 10.1093/jac/dkn335
   Roquebert B, 2008, AIDS, V22, P2045, DOI 10.1097/QAD.0b013e32830f4c7d
   Salemi M, 2003, J VIROL, V77, P7202, DOI 10.1128/JVI.77.13.7202-7213.2003
   Savarino A, 1997, CELL BIOCHEM FUNCT, V15, P171
   Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002                                                
   SAVARINO A, 2007, RETROVIROLOGY, V1, P4
   Savarino A, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-79
   Savarino A, 2006, EXPERT OPIN INV DRUG, V15, P1507, DOI 10.1517/13543784.15.12.1507
   Savarino A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-52
   Serrao E, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-25
   Shao W, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-101
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   SHIMURA K, 2008, FUTURE HIV THERAPY, V2, P411
   Sichtig N, 2009, J ANTIMICROB CHEMOTH, V64, P25, DOI 10.1093/jac/dkp153
   Steigbigel RT, 2008, NEW ENGL J MED, V359, P339, DOI 10.1056/NEJMoa0708975
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183                                                         
   ten Haaft P, 2001, J MED PRIMATOL, V30, P207, DOI 10.1034/j.1600-0684.2001.d01-54.x
   Vahey MT, 2007, J INFECT DIS, V196, P384, DOI 10.1086/519388
   Valkov E, 2009, NUCLEIC ACIDS RES, V37, P243, DOI 10.1093/nar/gkn938
   Williams KC, 2009, APMIS, V117, P400, DOI 10.1111/j.1600-0463.2009.02450.x
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   2009, PROJ INF PERSPECT, V48, P6
NR 71
TC 29
Z9 29
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAR 16
PY 2010
VL 7
AR 21
DI 10.1186/1742-4690-7-21
PG 19
WC Virology
SC Virology
GA 584HM
UT WOS:000276742100001
PM 20233398
OA gold
DA 2018-01-05
ER

PT J
AU Jokerst, JV
   Jacobson, JW
   Bhagwandin, BD
   Floriano, PN
   Christodoulides, N
   McDevitt, JT
AF Jokerst, Jesse V.
   Jacobson, James W.
   Bhagwandin, Bryon D.
   Floriano, Pierre N.
   Christodoulides, Nicolaos
   McDevitt, John T.
TI Programmable Nano-Bio-Chip Sensors: Analytical Meets Clinical
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID POINT-OF-CARE; LARGE-SCALE INTEGRATION; MULTIPLEXED DETECTION;
   MICROFLUIDIC DEVICES; PLASMA PROTEOME; DIAGNOSTICS; SYSTEMS; CANCER;
   ARRAYS; TECHNOLOGIES
AB There have been many recent advances in the nano-bio-chip analysis methodology with implications for a number of high-morbidity diseases including HIV, cancer, and heart disease. (To listen to a podcast about this article, please go to the Analytical Chemistry multimedia page at pubs.acs.org/page/ancham/audio/index.html.)
C1 [McDevitt, John T.] Rice Univ, Dept Chem, Houston, TX 77005 USA.
   [Jokerst, Jesse V.] Univ Texas Austin, Austin, TX 78712 USA.
RP McDevitt, JT (reprint author), Rice Univ, Dept Chem, 6100 Main St, Houston, TX 77005 USA.
EM mcdevitt@rice.edu
RI McDevitt, John/P-4108-2014
OI McDevitt, John/0000-0001-8789-9351
FU National Institutes of Health (NIH) through the National Institute of
   Dental and Craniofacial Research [U01 DE15017, U01 DE,017793]
FX Funding for this work was provided by the National Institutes of Health
   (NIH) through the National Institute of Dental and Craniofacial Research
   (U01 DE15017 and U01 DE,017793). The authors also thank Jorge Wong for
   graphic assistance with Figure L The content is solely the
   responsibility of the authors and does not necessarily represent or
   reflect views of the NIH of the U.S. government.
CR Ali MF, 2003, ANAL CHEM, V75, P4732, DOI 10.1021/ac034106z
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Christodoulides N, 2005, CLIN CHEM, V51, P2391, DOI 10.1373/clinchem.2005.054882
   Christodoulides Nicolaos, 2007, V385, P131, DOI 10.1007/978-1-59745-426-1_10
   Davis G, 1998, CHEM ANAL SERIES MON, V148, P47
   Floriano PN, 2009, CLIN CHEM, V55, P1530, DOI 10.1373/clinchem.2008.117713
   Floriano PN, 2005, BIOSENS BIOELECTRON, V20, P2079, DOI 10.1016/j.bios.2004.08.046
   Goluch ED, 2006, LAB CHIP, V6, P1293, DOI 10.1039/b606294f
   Goodey A, 2001, J AM CHEM SOC, V123, P2559, DOI 10.1021/ja003341l
   Goodey AP, 2003, J AM CHEM SOC, V125, P2870, DOI 10.1021/ja029696h
   Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916
   Herr AE, 2007, ANN NY ACAD SCI, V1098, P362, DOI 10.1196/annals.1384.004
   Herr AE, 2007, P NATL ACAD SCI USA, V104, P5268, DOI 10.1073/pnas.0607254104
   HOLMESFARLEY SR, 1988, LANGMUIR, V4, P921, DOI 10.1021/la00082a025                                                             
   Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162
   Jokerst JV, 2010, NANOMEDICINE-UK, V5, P143, DOI 10.2217/NNM.09.94
   Jokerst JV, 2009, BIOSENS BIOELECTRON, V24, P3622, DOI 10.1016/j.bios.2009.05.026
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Kim JS, 2009, ANAL CHEM, V81, P5426, DOI 10.1021/ac9005827
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Lavigne JJ, 1998, J AM CHEM SOC, V120, P6429, DOI 10.1021/ja9743405                                                               
   Lee HJ, 2008, ANALYST, V133, P975, DOI 10.1039/b717527b
   Li SF, 2006, J MICROELECTROMECH S, V15, P223, DOI 10.1109/JMEMS.2005.859083
   Ligler FS, 2009, ANAL CHEM, V81, P519, DOI 10.1021/ac8016289
   Madou M, 2006, ANNU REV BIOMED ENG, V8, P601, DOI 10.1146/annurev.bioeng.8.061505.095758
   MANDEL ID, 1993, J AM DENT ASSOC, V124, P85, DOI 10.14219/jada.archive.1993.0007                                                 
   Martinez AW, 2008, P NATL ACAD SCI USA, V105, P19606, DOI 10.1073/pnas.0810903105
   McCleskey SC, 2003, J AM CHEM SOC, V125, P1114, DOI 10.1021/ja021230b
   Melin J, 2007, ANNU REV BIOPH BIOM, V36, P213, DOI 10.1146/annurev.biophys.36.040306.132646
   Mukhopadhyay R, 2005, ANAL CHEM, V77, p429A, DOI 10.1021/ac053496h                                                               
   Mukhopadhyay Rajendrani, 2007, Anal Chem, V79, P3248, DOI 10.1021/ac071903e
   Mukhopadhyay R, 2009, ANAL CHEM, V81, P4169, DOI 10.1021/ac900638w
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Osterfeld SJ, 2008, P NATL ACAD SCI USA, V105, P20637, DOI 10.1073/pnas.0810822105
   Ouellette AL, 2009, ANAL CHEM, V81, P3216, DOI 10.1021/ac900475u
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   SIMONSEN M, 2005, BBI NEWSLETTER, P13117
   Stoeva SI, 2006, J AM CHEM SOC, V128, P8378, DOI 10.1021/ja0613106
   Thekkek N, 2008, NAT REV CANCER, V8, P725, DOI 10.1038/nrc2462
   Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996
   Vilkner T, 2004, ANAL CHEM, V76, P3373, DOI 10.1021/ac040063q
   Vitzthum F, 2005, J PROTEOME RES, V4, P1086, DOI 10.1021/pr050080b
   Walt DR, 2005, SCIENCE, V308, P217, DOI 10.1126/science.1108161
   Wang WU, 2005, P NATL ACAD SCI USA, V102, P3208, DOI 10.1073/pnas.0406368102
   WEIGUM SE, 2010, CAN PREV RE IN PRESS, P13117
   Weigum SE, 2007, LAB CHIP, V7, P995, DOI 10.1039/b703918b
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   WONG DT, 2008, SALIVARY DIAGNOSTICS, P301
   Wright AT, 2005, J AM CHEM SOC, V127, P17405, DOI 10.1021/ja055696g
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 51
TC 43
Z9 44
U1 0
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD MAR 1
PY 2010
VL 82
IS 5
BP 1571
EP 1579
DI 10.1021/ac901743u
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 559QN
UT WOS:000274841300003
PM 20128622
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhang, CY
   Hu, J
AF Zhang, Chun-yang
   Hu, Juan
TI Single Quantum Dot-Based Nanosensor for Multiple DNA Detection
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; RESONANCE ENERGY-TRANSFER; FLUORESCENCE
   SPECTROSCOPY; MOLECULE DETECTION; MESSENGER-RNA; BIOSENSORS; REDUCTION;
   SENSOR
AB Owing to their unique optical properties, quantum dots (QDs) with different colors have been applied for simultaneous detection of multiple analytes. However, the use of single QD for multiplex detection of analytes with single-molecule detection has not been explored. Here we report it single QD-based nanosensor for multiplex detection of HIV-1. and HIV-2 at single-molecule level in a homogeneous format. In this single QD-based nanosensor, the QD functions not only as a fluorescence pair for coincidence detection and as a fluorescence-resonance-energy-transfer (FRET) donor for FRET detection but also as it local nanoconcentrator which significantly amplifies the coincidence-related fluorescence signals and the FRET signals. This single-QD-based nanosensor takes advantage of it simple 'mix and detection' assay with extremely low sample consumption, high sensitivity, and short analysis time and has the potential to be applied for rapid point-of-care testing, gene expression studies, high-through put screening, and clinical diagnostics.
C1 [Zhang, Chun-yang; Hu, Juan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed Engn & Hlth Technol, Shenzhen 518055, Peoples R China.
RP Zhang, CY (reprint author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed Engn & Hlth Technol, Shenzhen 518055, Peoples R China.
EM cy.zhang@sub.siat.ac.cn
FU Chinese Academy of Science [KGCX2-YW-130]; National Basic Research
   Program 973 [2010CB732600]
FX This work was supported by the Knowledge Innovation Project of the
   Chinese Academy of Science (KGCX2-YW-130) and by the National Basic
   Research Program 973 (Grant No. 2010CB732600).
CR ALGAR WR, 2010, J ANAL CHEM+, V82, P400
   ALIVISATOS AP, 2004, NAT BIOTECHNOL, V22, P47, DOI DOI 10.1038/NBT927
   Camacho A, 2004, J BIOTECHNOL, V107, P107, DOI 10.1016/j.jbiotec.2003.10.003
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Castro A, 1997, ANAL CHEM, V69, P3915, DOI 10.1021/ac970389h
   Cederquist KB, 2008, LANGMUIR, V24, P9162, DOI 10.1021/la703854x
   Chan PM, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni162
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Ferguson JA, 2000, ANAL CHEM, V72, P5618, DOI 10.1021/ac0008284
   Gerion D, 2003, ANAL CHEM, V75, P4766, DOI 10.1021/ac034482j
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   Hsin TM, 2007, ANGEW CHEM INT EDIT, V46, P8032, DOI 10.1002/anie.200702348
   Kricka LJ, 2002, ANN CLIN BIOCHEM, V39, P114, DOI 10.1258/0004563021901865                                                        
   Li HT, 2003, ANAL CHEM, V75, P1664, DOI 10.1021/ac026367z
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Liu JW, 2007, ANAL CHEM, V79, P4120, DOI 10.1021/ac070055k
   Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753
   Medintz IL, 2004, P NATL ACAD SCI USA, V101, P9612, DOI 10.1073/pnas.0403343101
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   MEDINTZ IL, 2005, NAT MATER, V4, P437
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   Nolan RL, 2003, ANAL CHEM, V75, P6236, DOI 10.1021/ac034803r
   Orte A, 2006, ANAL CHEM, V78, P7707, DOI 10.1021/ac061122y
   Patolsky F, 2003, J AM CHEM SOC, V125, P13918, DOI 10.1021/ja035848c
   Pons T, 2009, ANN BIOMED ENG, V37, P1934, DOI 10.1007/s10439-009-9715-0
   POPOVIC M, 1984, SCIENCE, V224, P500
   Raz SR, 2009, ANAL CHEM, V81, P7743, DOI 10.1021/ac901230v
   Ren XJ, 2006, J AM CHEM SOC, V128, P4992, DOI 10.1021/ja056613z
   Rigler R, 1998, J BIOTECHNOL, V63, P97, DOI 10.1016/S0168-1656(98)00079-0
   Sambrook J, 2001, MOL CLONING LAB MANN
   Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639
   Vet JAM, 1999, P NATL ACAD SCI USA, V96, P6394, DOI 10.1073/pnas.96.11.6394
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Wang SX, 2008, IEEE T MAGN, V44, P1687, DOI 10.1109/TMAG.2008.920962
   Wei F, 2009, CLIN CANCER RES, V15, P4446, DOI 10.1158/1078-0432.CCR-09-0050
   Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676
   WILKE WW, 1995, DIAGN MICR INFEC DIS, V21, P181, DOI 10.1016/0732-8893(95)00041-8
   Wilson MS, 2006, ANAL CHEM, V78, P6476, DOI 10.1021/ac060843u
   Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106
   Zhang CY, 2007, ANGEW CHEM INT EDIT, V46, P3482, DOI 10.1002/anie.200604861
   Zhang CY, 2006, J AM CHEM SOC, V128, P5324, DOI 10.1021/ja060537y
   Zhang CY, 2006, ANALYST, V131, P484, DOI 10.1039/b514309h
NR 42
TC 107
Z9 109
U1 15
U2 147
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD MAR 1
PY 2010
VL 82
IS 5
BP 1921
EP 1927
DI 10.1021/ac9026675
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 559QN
UT WOS:000274841300051
PM 20121246
DA 2018-01-05
ER

PT J
AU Lu, D
   Sham, YY
   Vince, R
AF Lu, Ding
   Sham, Yuk Yin
   Vince, Robert
TI Design, asymmetric synthesis, and evaluation of pseudosymmetric
   sulfoximine inhibitors against HIV-1 protease
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV; HIV protease; Sulfoximine inhibitors; Transition state mimetic;
   Peptidomimetic; Asymmetric synthesis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING FREE-ENERGIES; ANTIVIRAL ACTIVITY;
   CRYSTAL-STRUCTURE; POTENT; COMPLEX; SIMULATIONS; ALKYLATION; RESOLUTION;
   MECHANISM
AB The HIV-1 protease is a validated drug target for the design of antiretroviral drugs to combat AIDS. We previously established the sulfoximine functionality as a valid transition state mimetic (TSM) in the HIV-1 protease inhibitors ( PI) design and have identified a lead pseudosymmetric compound with nano-molar enzymatic inhibitory activity. Here, we report the asymmetric synthesis of this compound and its application in the synthesis of sulfoximine-based peptidomimetic HIV-1 protease inhibitors. Molecular modeling revealed the potential mode of binding of the sulfoximine inhibitor as a TSM. The predicted absolute binding free energies suggested similar inhibitory effect as observed in our enzymatic inhibitory studies. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lu, Ding; Sham, Yuk Yin; Vince, Robert] Univ Minnesota, Ctr Drug Design, Acad Hlth Ctr, Minneapolis, MN 55455 USA.
RP Vince, R (reprint author), Univ Minnesota, Ctr Drug Design, Acad Hlth Ctr, 516 Delaware St SE, Minneapolis, MN 55455 USA.
EM vince001@umn.edu
RI Sham, Yuk/A-6472-2011
OI Sham, Yuk/0000-0003-2601-8930
FU Center for Drug Design at the University of Minnesota
FX This research work was supported by the Center for Drug Design at the
   University of Minnesota. We thank Ms. Christine Dreis for performing the
   HIV protease assay and Southern Research Institute for the antiviral
   testing data. We also thank Dr. William M. Shannon for his advice as a
   consultant for the antiviral work on this project. The authors thank Dr.
   Zhengqiang Wang for critical reading of the manuscript and helpful
   scientific discussions. The University of Minnesota Supercomputing
   Institute provided all the necessary computational resources.
CR Andersson HO, 2003, EUR J BIOCHEM, V270, P1746, DOI 10.1046/j.1432-1033.2003.03533.x
   ASKIN D, 1992, J ORG CHEM, V57, P2771, DOI 10.1021/jo00036a004
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   Campbell RF, 2003, TETRAHEDRON LETT, V44, P5477, DOI 10.1016/S0040-4039(03)01270-X
   Carr JA, 2004, ORG LETT, V6, P3297, DOI 10.1021/ol048802c
   DIEM MJ, 1977, J ORG CHEM, V42, P1801, DOI 10.1021/jo00430a029                                                             
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   FEHRENTZ JA, 1992, BIOCHEM BIOPH RES CO, V188, P865, DOI 10.1016/0006-291X(92)91136-E
   Hansson T, 1995, PROTEIN ENG, V8, P1137, DOI 10.1093/protein/8.11.1137
   Hou T, 2008, PROTEINS, V71, P1163, DOI 10.1002/prot.21808
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024
   ITOH T, 1993, J ORG CHEM, V58, P5717, DOI 10.1021/jo00073a034
   IVERSEN T, 1981, J CHEM SOC CHEM COMM, P1240, DOI 10.1039/c39810001240                                                            
   JOHNSON CR, 1973, J AM CHEM SOC, V95, P7424, DOI 10.1021/ja00803a035                                                             
   JOHNSON CR, 1970, J AM CHEM SOC, V92, P6594, DOI 10.1021/ja00725a035                                                             
   JOHNSON CR, 1993, J ORG CHEM, V58, P1922, DOI 10.1021/jo00059a052                                                             
   JonesHertzog DK, 1997, J MED CHEM, V40, P1539, DOI 10.1021/jm960684e
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   KEDZIERSKA K, 2004, MED CHEM REV, V1, P351
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
   LIU KKC, 1990, BIOCATALYSIS, V3, P169
   Lu D, 2007, BIOORG MED CHEM LETT, V17, P5614, DOI 10.1016/j.bmcl.2007.07.095
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   Muhlman A, 2001, J MED CHEM, V44, P3407, DOI 10.1021/jm0011171
   Raza A, 2008, BIOORG MED CHEM LETT, V18, P5406, DOI 10.1016/j.bmcl.2008.09.044
   SANTANIELLO E, 1992, CHEM REV, V92, P1071, DOI 10.1021/cr00013a016                                                             
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   Sham YY, 2000, PROTEINS, V39, P393, DOI 10.1002/(SICI)1097-0134(20000601)39:4<393::AID-PROT120>3.3.CO;2-8
   Spino C, 2004, ORG LETT, V6, P2801, DOI 10.1021/ol048936q
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   THAISRIVONGS S, 1993, J MED CHEM, V36, P941, DOI 10.1021/jm00060a001
   UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259                                                      
   *UNAIDS WHO, 2007, AIDS EP UPD
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   Yeni P, 2006, J HEPATOL, V44, pS100, DOI 10.1016/j.jhep.2005.11.021
   Zhu XM, 2004, CHEM-EUR J, V10, P875, DOI 10.1002/chem.200305163
NR 41
TC 18
Z9 18
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 1
PY 2010
VL 18
IS 5
BP 2037
EP 2048
DI 10.1016/j.bmc.2010.01.020
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 561DY
UT WOS:000274957100032
PM 20138769
DA 2018-01-05
ER

PT J
AU Luksch, T
   Blum, A
   Klee, N
   Diederich, WE
   Sotriffer, CA
   Klebe, G
AF Luksch, Torsten
   Blum, Andreas
   Klee, Nina
   Diederich, Wibke E.
   Sotriffer, Christoph A.
   Klebe, Gerhard
TI Pyrrolidine Derivatives as Plasmepsin Inhibitors: Binding Mode Analysis
   Assisted by Molecular Dynamics Simulations of a Highly Flexible Protein
SO CHEMMEDCHEM
LA English
DT Article
DE induced-fit adaptations; ligand design; molecular dynamics; plasmepsins;
   pyrrolidine derivatives
ID PARASITE PLASMODIUM-FALCIPARUM; DIGESTIVE VACUOLE PLASMEPSINS; HUMAN
   MALARIA PARASITE; HIV-1 PROTEASE; ASPARTIC PROTEASES; HEMOGLOBIN
   DEGRADATION; LIGAND EFFICIENCY; DESIGN; IV; IDENTIFICATION
AB Plasmepsins II (EC number: 3.4.23.39) and IV (EC number: 3.4.23.1314) are aspartic proteases present in the food vacuole of the malaria parasite Plasmodium falciparum and are involved in host hemoglobin degradation. A series of pyrrolidine derivatives, originally synthesized as HIV-1 protease inhibitors, were tested for activity against plasmepsin (Plm). Inhibitors in the nanomolar range were discovered for the Plm II and IV isoforms. Detailed studies were carried out to identify putative binding modes that help to explain the underlying structure-activity relationships. Reasonable binding modes were generated for pyrrolidine-3,4-diester derivatives and a substituted 3,4-diaminopyrrolidine inhibitor by using a crystal structure of inhibitor-bound Plm II (PDB ID: I LEE). Modeling studies indicated that the flap of available Plm crystal structures is not sufficiently opened to accommodate the 3,4-bis(aminomethylene)pyrrolidines. Molecular dynamics simulations were performed to analyze the flexibility of the protein in greater detail, leading to a binding mode hypothesis for the 3,4-bis(aminomethylene)pyrrolidines and providing further insight and general implications for the design of Plm II inhibitors.
C1 [Luksch, Torsten; Blum, Andreas; Klee, Nina; Diederich, Wibke E.; Sotriffer, Christoph A.; Klebe, Gerhard] Univ Marburg, Inst Pharmaceut Chem, D-35032 Marburg, Germany.
RP Klebe, G (reprint author), Univ Marburg, Inst Pharmaceut Chem, Marbacher Weg 6, D-35032 Marburg, Germany.
EM Klebe@staff.uni-marburg.de
FU DFG-Graduiertenkolleg [GRK541, KL120415-3, D182713-Z]; Studienstiftung
   des deutschen Volkes
FX We gratefully acknowledge financial support of our research by the
   DFG-Graduiertenkolleg GRK541 "Proteinfunktion auf atomarer Ebene" (TL.),
   the-joint DFG research project KL120415-3 and D182713-Z and the
   Studienstiftung des deutschen Volkes (N.K). The authors ore grateful to
   Serghei Glinco for technical help. The clone of the protease was kindly
   provided by Prof Dr. Daniel E. Goldberg, Department of Molecular
   Microbiology, Washington University School of Medicine, St. Louis, MO
   (USA).
CR Andrews KT, 2006, ANTIMICROB AGENTS CH, V50, P639, DOI 10.1128/AAC.50.2.639-648.2006
   Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6
   Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695
   Bjelic S, 2007, CELL MOL LIFE SCI, V64, P2285, DOI 10.1007/s00018-007-7102-2
   Blum A, 2008, J MED CHEM, V51, P2078, DOI 10.1021/jm701142s
   Bottcher J, 2008, CHEMMEDCHEM, V3, P1337, DOI 10.1002/cmdc.200800113
   Bonilla JA, 2007, MOL MICROBIOL, V65, P64, DOI 10.1111/j.1365-2958.2007.05768.x
   CABANI S, 1971, T FARADAY SOC, V67, P1933, DOI 10.1039/tf9716701933
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2
   Czodrowski P, 2007, J CHEM INF MODEL, V47, P1590, DOI 10.1021/ci600522c
   DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411
   Ersmark K, 2006, BIOORGAN MED CHEM, V14, P2197, DOI 10.1016/j.bmc.2005.11.003
   Ersmark K, 2005, J MED CHEM, V48, P6090, DOI 10.1021/jm0504631
   Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g
   Ersmark K, 2003, BIOORGAN MED CHEM, V11, P3723, DOI 10.1016/S0968-0896(03)00339-0
   Ersmark K, 2006, MED RES REV, V26, P626, DOI 10.1002/med.20082
   FRANCIS SE, 1994, EMBO J, V13, P306
   Friedman R, 2009, CHEMMEDCHEM, V4, P1317, DOI 10.1002/cmdc.200900078
   Friedman R, 2008, PROTEINS, V73, P814, DOI 10.1002/prot.22105
   GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456
   GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140
   GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961
   GUSTCHINA A, 1990, FEBS LETT, V269, P269, DOI 10.1016/0014-5793(90)81171-J
   Gutierrez-de-Teran H, 2006, BIOCHEMISTRY-US, V45, P10529, DOI 10.1021/bi0609669
   Gutierrez-de-Teran H, 2006, FEBS LETT, V580, P5910, DOI 10.1016/j.febslet.2006.09.057
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Humphreys MJ, 1999, FEBS LETT, V463, P43, DOI 10.1016/S0014-5793(99)01597-5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   KUMAR SKP, 2001, DRUG DES DISCOV, V17, P293
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Linares GEG, 2007, CURR MED CHEM, V14, P289
   Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200
   Luksch T, 2008, CHEMMEDCHEM, V3, P1323, DOI 10.1002/cmdc.200700270
   Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x
   Nezami A, 2002, BIOCHEMISTRY-US, V41, P2273, DOI 10.1021/bi0117549
   Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200
   Prade L, 2005, J BIOL CHEM, V280, P23837, DOI 10.1074/jbc.M501519200
   Reynolds CH, 2008, J MED CHEM, V51, P2432, DOI 10.1021/jm701255b
   Reynolds CH, 2007, BIOORG MED CHEM LETT, V17, P4258, DOI 10.1016/j.bmcl.2007.05.038
   ROSENTHAL PJ, 2001, ANTIMALARIAL CHEMOTH
   Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034
   Specker E, 2005, ANGEW CHEM INT EDIT, V44, P3140, DOI 10.1002/anie.200462643
   SPECKER E, 2005, ANGEW CHEM, V117, P3200
   Specker E, 2006, CHEMMEDCHEM, V1, P106, DOI 10.1002/cmdc.200500008
   Valiente PA, 2008, PROTEINS, V73, P440, DOI 10.1002/prot.22068
   World Health Organization, 2004, WORLD HLTH REP
   WIK S, 2006, CHEMMEDCHEM, V1, P445
NR 50
TC 9
Z9 9
U1 0
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1860-7179
J9 CHEMMEDCHEM
JI ChemMedChem
PD MAR
PY 2010
VL 5
IS 3
BP 443
EP 454
DI 10.1002/cmdc.200900452
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 568KM
UT WOS:000275521200014
PM 20112327
DA 2018-01-05
ER

PT J
AU Kadiu, I
   Gendelman, H
AF Kadiu, I.
   Gendelman, H.
TI HIV-1 Hijacks the Endocytic Trafficking Networks for Direct
   Intercellular Dissemination Through Tunneling Nanotubes in Human
   Macrophages
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Kadiu, I.; Gendelman, H.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2010
VL 5
SU 1
BP S27
EP S27
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 582AO
UT WOS:000276567600054
DA 2018-01-05
ER

PT J
AU Pagba, CV
   Lane, SM
   Wachsmann-Hogiu, S
AF Pagba, Cynthia V.
   Lane, Stephen M.
   Wachsmann-Hogiu, Sebastian
TI Raman and surface-enhanced Raman spectroscopic studies of the 15-mer DNA
   thrombin-binding aptamer
SO JOURNAL OF RAMAN SPECTROSCOPY
LA English
DT Article
DE Raman spectra; SERS spectra; aptamer; quadruplex; biosensors
ID IN-VITRO SELECTION; HIV-1 TAT PROTEIN; NUCLEIC-ACIDS; G-QUADRUPLEX;
   EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; TELOMERIC DNA; A-DNA;
   B-DNA; RECOGNITION
AB Aptamers are single-stranded oligonucleotides that selectively bind to their target molecules owing to their ability to form secondary structures and shapes. The 15-mer (5'-GGTTGGTGTGGTTGG-3') DNA thrombin-binding aptamer (TBA) binds to thrombin following the formation of a quadruplex structure via the Hoogsten-type G-G interactions. In the present study, Raman and SERS spectra of TBA and thiolated TBA (used to facilitate covalent bonding to metal nanoparticle) in different conditions are investigated. The spectra of the two analogs exhibit vibrations, such as the C8=N7-H2 deformation band at similar to 1480 cm(-1) of the guanine tetrad, that are characteristic of the quadruplex structure in the presence of K(+) ions or at low temperature. Interestingly, SERS spectra of the two analogs differ markedly from their respective normal Raman spectra, possibly due to changes in the conformation of the aptamer upon binding, as well as to the specific interaction of individual vibrational modes with the metal surface. In addition, the SERS spectra of the thiolated aptamer show significant changes with different concentrations, which may be due to different orientation of the molecule with respect to the metal surface. This study provides useful information for the development of label-free aptamer-based SERS sensors and assays. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Pagba, Cynthia V.; Lane, Stephen M.; Wachsmann-Hogiu, Sebastian] Univ Calif Davis, Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA.
   [Lane, Stephen M.] Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA.
   [Wachsmann-Hogiu, Sebastian] Univ Calif Davis, Dept Pathol & Lab Med, Sacramento, CA 95817 USA.
RP Pagba, CV (reprint author), Univ Calif Davis, Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA.
EM cvpagba@ucdavis.edu; swachsmann@ucdavis.edu
FU National Science Foundation (NSF); Lawrence Livermore National
   Laboratory
FX This work is supported by funding from the National Science Foundation
   (NSF) and the Laboratory Directed Research and Development Program of
   Lawrence Livermore National Laboratory. The Center for Biophotonics
   Science and Technology is a designated NSF Science and Technology
   Center, managed by the University of California, Davis, under
   Cooperative Agreement No. PHY 0120999.
CR Alberti P, 2003, P NATL ACAD SCI USA, V100, P1569, DOI 10.1073/pnas.0335459100
   Baldrich E, 2004, ANAL CHEM, V76, P7053, DOI 10.1021/ac049258o
   Barhoumi A, 2008, J AM CHEM SOC, V130, P14040, DOI 10.1021/ja804367c
   Barhoumi A, 2008, J AM CHEM SOC, V130, P5523, DOI 10.1021/ja800023j
   BENEVIDES JM, 1983, NUCLEIC ACIDS RES, V11, P5747, DOI 10.1093/nar/11.16.5747
   BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P5955, DOI 10.1021/bi00238a020
   BENEVIDES JM, 1988, BIOCHEMISTRY-US, V27, P931, DOI 10.1021/bi00403a014
   BENEVIDES JM, 1986, BIOCHEMISTRY-US, V25, P41, DOI 10.1021/bi00349a007
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Boozer C, 2004, ANAL CHEM, V76, P6967, DOI 10.1021/ac048908l
   Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7
   Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100
   Cho H, 2008, NANO LETT, V8, P4386, DOI 10.1021/nl802245w
   de-los-Santos-Alvarez N, 2008, TRAC-TREND ANAL CHEM, V27, P437, DOI 10.1016/j.trac.2008.03.003
   Driskell JD, 2005, ANAL CHEM, V77, P6147, DOI 10.1021/ac0504159
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Grubisha DS, 2003, ANAL CHEM, V75, P5936, DOI 10.1021/ac034356f
   Guthrie JW, 2006, METHODS, V38, P324, DOI 10.1016/j.ymeth.2006.01.001
   He F, 2005, J AM CHEM SOC, V127, P12343, DOI 10.1021/ja051507i
   Hering K, 2008, ANAL BIOANAL CHEM, V390, P113, DOI 10.1007/s00216-007-1667-3
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Kankia BI, 2001, J AM CHEM SOC, V123, P10799, DOI 10.1021/ja010008o
   KNEIPP K, 1986, J MOL STRUCT, V145, P173, DOI 10.1016/0022-2860(86)87041-7
   Krafft C, 2002, NUCLEIC ACIDS RES, V30, P3981, DOI 10.1093/nar/gkf517                                                              
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Li JWJ, 2002, BIOCHEM BIOPH RES CO, V292, P31, DOI 10.1006/bbrc.2002.6581
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4
   Marathias VM, 1999, BIOCHEMISTRY-US, V38, P4355, DOI 10.1021/bi982604+                                                               
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   MIURA T, 1994, BIOCHEMISTRY-US, V33, P7848, DOI 10.1021/bi00191a012                                                             
   MIURA T, 1995, BIOCHEMISTRY-US, V34, P9645, DOI 10.1021/bi00029a042
   Mondragon-Sanchez JA, 2004, J BIOMOL STRUCT DYN, V22, P365, DOI 10.1080/07391102.2004.10507008                                                  
   Nagatoishi S, 2007, BIOCHEM BIOPH RES CO, V352, P812, DOI 10.1016/j.bbrc.2006.11.088
   Narayanan R, 2008, ANAL CHEM, V80, P2265, DOI 10.1021/ac7026436
   NISHIMURA Y, 1986, J MOL STRUCT, V146, P123, DOI 10.1016/0022-2860(86)80288-5                                                    
   Ortiz C, 2006, ANAL BIOCHEM, V353, P157, DOI 10.1016/j.ab.2006.03.025
   OTTO C, 1986, J RAMAN SPECTROSC, V17, P289, DOI 10.1002/jrs.1250170311                                                          
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   PETICOLAS WL, 1992, METHOD ENZYMOL, V211, P335
   Porter MD, 2008, CHEM SOC REV, V37, P1001, DOI 10.1039/b708461g
   PRESCOTT B, 1984, BIOPOLYMERS, V23, P235, DOI 10.1002/bip.360230206
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   Smirnov I, 2000, J MOL BIOL, V296, P1, DOI 10.1006/jmbi.1999.3441
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Tang JJ, 2007, BIOSENS BIOELECTRON, V22, P2456, DOI 10.1016/j.bios.2006.09.015
   Tang JJ, 2006, ELECTROPHORESIS, V27, P1303, DOI 10.1002/elps.200500489
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vairamani M, 2003, J AM CHEM SOC, V125, P42, DOI 10.1021/ja0284299
   Wang CL, 2003, J BIOTECHNOL, V102, P15, DOI 10.1016/S0168-1656(02)00360-7
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P11285, DOI 10.1021/bi00093a004
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   Zhang DM, 2003, ANAL CHEM, V75, P5703, DOI 10.1021/ac0345087
NR 60
TC 26
Z9 26
U1 5
U2 62
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0377-0486
J9 J RAMAN SPECTROSC
JI J. Raman Spectrosc.
PD MAR
PY 2010
VL 41
IS 3
BP 241
EP 247
DI 10.1002/jrs.2428
PG 7
WC Spectroscopy
SC Spectroscopy
GA 583CI
UT WOS:000276649900001
DA 2018-01-05
ER

PT J
AU Adam, V
   Huska, D
   Hubalek, J
   Kizek, R
AF Adam, Vojtech
   Huska, Dalibor
   Hubalek, Jaromir
   Kizek, Rene
TI Easy to use and rapid isolation and detection of a viral nucleic acid by
   using paramagnetic microparticles and carbon nanotubes-based
   screen-printed electrodes
SO MICROFLUIDICS AND NANOFLUIDICS
LA English
DT Article
DE Paramagnetic microparticles; Viral nucleic acid; Electrochemical
   detection; Voltammetry; Screen-printed electrode
ID SQUARE-WAVE VOLTAMMETRY; ON-A-CHIP; DNA HYBRIDIZATION; ELECTROCHEMICAL
   DETECTION; MICROFLUIDIC CHANNEL; MAGNETIC BEADS; SENSORS; INFLUENZA;
   AVIDIN; PROTEIN
AB A method that is easy to use, rapid, with a low cost of detecting viral nucleic acid in a biological sample represents the essential tool in targeted therapy. In this study, we report the use of paramagnetic microparticles covered by streptavidin and modified by an oligonucleotide probe with a specific viral sequence labeled by biotin to detect human immunodeficiency virus (HIV) and influenza virus subtype H5N1. The viral nucleic acids were primarily detected by adsorptive transfer stripping technique coupled with square wave voltammetry using carbon paste, hanging mercury drop or carbon nanotubes-based screen-printed working electrodes. Detection limits were estimated for both sequences down to picograms per 3 mu l. To isolate the viral sequences, paramagnetic microparticles covered with biotin-labeled oligonucleotides were used. We calculated the yield of isolation for H5N1 and/or HIV sequences, which was defined as "isolated concentration of viral nucleic acid sequence"/"given viral nucleic acid sequence" x 100. We estimated the yield for both sequences as 59%. Moreover, we studied the influence of human serum, dsDNA and non-complementary sequence of nucleic acids on isolation of viral nucleic acids. We also used carbon nanotubes-based screen-printed electrodes coupled with micro-flow instrument to detect viral nucleic acids. We were able to isolate and detect nanogram amounts of nucleic acids.
C1 [Adam, Vojtech; Huska, Dalibor; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic.
   [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic.
   [Huska, Dalibor] Mendel Univ Agr & Forestry Brno, Dept Plant Biol, Fac Agron, CZ-61300 Brno, Czech Republic.
   [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-60200 Brno, Czech Republic.
RP Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.
EM kizek@sci.muni.cz
RI Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek,
   Rene/D-7748-2012
OI Adam, Vojtech/0000-0002-8527-286X; 
FU KAN [208130801]; GACR [102/08/1546]
FX The financial support from the grants KAN 208130801 and GACR 102/08/1546
   is highly acknowledged.
CR Adam V, 2008, SENSORS-BASEL, V8, P2293, DOI 10.3390/s8042293                                                                
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Estes MD, 2009, BIOMED MICRODEVICES, V11, P509, DOI 10.1007/s10544-008-9257-5
   Fojta M, 2008, CURR ANAL CHEM, V4, P250, DOI 10.2174/157341108784911415                                                      
   Gessain A, 2008, FUTURE VIROL, V3, P71, DOI 10.2217/17460794.3.1.71
   Gorodetsky AA, 2008, J AM CHEM SOC, V130, P2924, DOI 10.1021/ja7106756
   HUSKA D, 2009, TALANTA IN PRESS
   HUSKA D, 2008, J MAGN MAGN MATER, V321, P1474
   Huska D, 2008, ELECTROPHORESIS, V29, P4964, DOI 10.1002/elps.200800445
   Jelen F, 2004, BIOELECTROCHEMISTRY, V63, P249, DOI 10.1016/j.bioelechem.2003.10.021
   Kell AJ, 2008, ACS NANO, V2, P1777, DOI 10.1021/nn700183g
   Kizek R, 2005, ANAL BIOANAL CHEM, V381, P1167, DOI 10.1007/s00216-004-3027-x
   Kizek R, 2002, BIOELECTROCHEMISTRY, V55, P119, DOI 10.1016/S1567-5394(01)00139-6                                                   
   Kjeang E, 2007, MICROFLUID NANOFLUID, V3, P403, DOI 10.1007/s10404-006-0128-1
   Kourilova A, 2005, ANAL LETT, V38, P2493, DOI 10.1080/00032710500369679
   Kumar SA, 2008, SENSORS-BASEL, V8, P739, DOI 10.3390/s8020739                                                                
   Le Drogoff B, 2008, MICROFLUID NANOFLUID, V5, P373, DOI 10.1007/s10404-007-0249-1
   LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001                                                             
   Lund-Olesen T, 2007, J MAGN MAGN MATER, V311, P396, DOI 10.1016/j.jmmm.2006.10.1171
   Masarik M, 2003, ANAL CHEM, V75, P2663, DOI 10.1021/ac020788z
   Mcfee RB, 2007, DM-DIS MON, V53, P348, DOI 10.1016/j.disamonth.2007.05.005
   McGovern BH, 2007, ANTIVIR THER, V12, pH3
   Moscona A, 2008, ANNU REV MED, V59, P397, DOI 10.1146/annurev.med.59.061506.213121
   Neuzil P, 2006, NUCLEIC ACIDS RES, V34, P9
   Neuzil P, 2006, MOL BIOSYST, V2, P292, DOI 10.1039/b605957k
   Oliveira-Brett AM, 2004, ANAL BIOCHEM, V332, P321, DOI 10.1016/j.ab.2004.06.021
   Palecek E, 2004, TRENDS BIOTECHNOL, V22, P55, DOI 10.1016/j.tibtech.2003.11.009
   Palecek E, 2002, CRIT REV ANAL CHEM, V32, P261, DOI 10.1080/10408340290765560                                                       
   Palecek E, 2002, TALANTA, V56, P919, DOI 10.1016/S0039-9140(01)00666-X
   Palecek E, 2002, BIOELECTROCHEMISTRY, V56, P85, DOI 10.1016/S1567-5394(02)00025-7                                                   
   Palecek E, 2002, ANAL CHIM ACTA, V469, P73, DOI 10.1016/S0003-2670(01)01605-1                                                   
   Palecek E, 2002, TALANTA, V56, P809, DOI 10.1016/S0039-9140(01)00649-X
   PALECEK E, 2008, ELECTROANAL, V21, P239
   Palecek E, 2007, TALANTA, V74, P276, DOI 10.1016/j.talanta.2007.08.020
   Petrlova J, 2007, PLANT SOIL ENVIRON, V53, P345
   Petrlova J, 2007, ELECTROANAL, V19, P1177, DOI 10.1002/elan.200603837
   Prasek J, 2006, SENSORS-BASEL, V6, P1498, DOI 10.3390/s6111498                                                                
   Smistrup K, 2006, J MAGN MAGN MATER, V300, P418, DOI 10.1016/j.jmmm.2005.05.031
   Smistrup K, 2008, MICROFLUID NANOFLUID, V4, P565, DOI 10.1007/s10404-007-0213-0
   Smistrup K, 2007, J MAGN MAGN MATER, V311, P409, DOI 10.1016/j.jmmm.2006.10.1190
   Teles FRR, 2008, TALANTA, V77, P606, DOI 10.1016/j.talanta.2008.07.024
   Vernet G, 2007, EXPERT REV ANTI-INFE, V5, P89, DOI 10.1586/14787210.5.1.89
   Wang J, 2004, ANALYST, V129, P1, DOI 10.1039/b313431h
   XIE X, 2006, J MAGN MAGN MATER, V311, P416
NR 44
TC 34
Z9 34
U1 3
U2 63
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1613-4982
J9 MICROFLUID NANOFLUID
JI Microfluid. Nanofluid.
PD MAR
PY 2010
VL 8
IS 3
BP 329
EP 339
DI 10.1007/s10404-009-0464-z
PG 11
WC Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics,
   Fluids & Plasmas
SC Science & Technology - Other Topics; Instruments & Instrumentation;
   Physics
GA 551MC
UT WOS:000274212700004
DA 2018-01-05
ER

PT J
AU Zybin, A
   Kuritsyn, YA
   Gurevich, EL
   Temchura, VV
   Uberla, K
   Niemax, K
AF Zybin, Alexander
   Kuritsyn, Yurii A.
   Gurevich, Evgeny L.
   Temchura, Vladimir V.
   Ueberla, Klaus
   Niemax, Kay
TI Real-time Detection of Single Immobilized Nanoparticles by Surface
   Plasmon Resonance Imaging
SO PLASMONICS
LA English
DT Article
DE Surface plasmon resonance; Nanoparticles; Microscopy; HIV-1; Virus like
   particles
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIGH-THROUGHPUT; INDEX STEP; MICROSCOPY;
   PARTICLES; PROPAGATION; EXCITATION; SCATTERING; BINDING; ARRAYS
AB In this manuscript, a new approach in surface plasmon resonance microscopy is presented. The method provides optical real-time detection of single nanoparticles on surfaces. The potential of the method is demonstrated recording spherical dielectric particles as small as 40 nm in diameter and single HIV virus-like particles having diameters of similar to 100 nm both immobilized on functionalized surfaces. The surface plasmon resonance signal in the binding spots was found to be almost linearly proportional to the size of the particles and, therefore, surpasses the intensity of Mie scattering on spherical particle (dependence similar to r(-6)) by orders of magnitude for small objects. The physical reason leading to this strong effect is discussed.
C1 [Zybin, Alexander; Gurevich, Evgeny L.; Niemax, Kay] ISAS Inst Analyt Sci, D-44139 Dortmund, Germany.
   [Kuritsyn, Yurii A.] ISAN Inst Spect, Troitsk 142092, Moscow Reg, Russia.
   [Temchura, Vladimir V.; Ueberla, Klaus] Ruhr Univ Bochum, Dept Mol & Med Virol, D-44801 Bochum, Germany.
RP Gurevich, EL (reprint author), ISAS Inst Analyt Sci, Bunsen Kirchhoff Str 11, D-44139 Dortmund, Germany.
EM zybin@isas.de; gurevich@isas.de
RI Gurevich, Evgeny/C-6222-2008
OI Gurevich, Evgeny/0000-0001-9451-8983
FU Ministry of Innovation, Science, Research, and Technology of the state
   of North Rhine-Westphalia; Ministry of Education and Research of the
   Federal Republic of Germany; European Union (EU) [LSHP-CT-2006-037611]
FX Financial support by the Ministry of Innovation, Science, Research, and
   Technology of the state of North Rhine-Westphalia and the Ministry of
   Education and Research of the Federal Republic of Germany is gratefully
   acknowledged. We are also grateful for support by the European Union (EU
   projects: RaSP and EUROPRISE, LSHP-CT-2006-037611).
CR Berger CEH, 1999, OPT COMMUN, V167, P183, DOI 10.1016/S0030-4018(99)00309-0
   Brockman JM, 2000, ANNU REV PHYS CHEM, V51, P41, DOI 10.1146/annurev.physchem.51.1.41                                                
   Campbell CT, 2007, BIOMATERIALS, V28, P2380, DOI 10.1016/j.biomaterials.2007.01.047
   Erickson D, 2008, MICROFLUID NANOFLUID, V4, P33, DOI 10.1007/s10404-007-0198-8
   Fu E, 2003, REV SCI INSTRUM, V74, P3182, DOI 10.1063/1.1574603
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Hecht B, 1996, PHYS REV LETT, V77, P1889, DOI 10.1103/PhysRevLett.77.1889
   Kabashin AV, 1999, SENSOR ACTUAT B-CHEM, V54, P51, DOI 10.1016/S0925-4005(98)00326-8
   Lee HJ, 2006, ANAL CHEM, V78, P6504, DOI 10.1021/ac060881d
   Leskova TA, 2005, OPT COMMUN, V249, P23, DOI 10.1016/j.optcom.2005.01.014
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Piliarik M, 2008, SENSOR ACTUAT B-CHEM, V134, P353, DOI 10.1016/j.snb.2008.06.011
   ROTHENHAUSLER B, 1988, APPL PHYS LETT, V52, P1554, DOI 10.1063/1.99698                                                                 
   ROTHENHAUSLER B, 1988, NATURE, V332, P615, DOI 10.1038/332615a0
   SCHNORRENBERG HJ, 1995, OPT COMMUN, V117, P532, DOI 10.1016/0030-4018(95)00240-9
   Shumaker-Parry JS, 2004, ANAL CHEM, V76, P918, DOI 10.1021/ac034964v
   Suraniti E, 2007, LAB CHIP, V7, P1206, DOI 10.1039/b708292d
   Thariani R, 2008, SENSOR ACTUAT B-CHEM, V130, P765, DOI 10.1016/j.snb.2007.10.065
   Trkola A, 1996, J VIROL, V70, P1100
   Valle PJ, 1997, OPT COMMUN, V137, P334, DOI 10.1016/S0030-4018(96)00786-9
   Wagner R, 2000, HUM GENE THER, V11, P2403, DOI 10.1089/104303400750038507
   Wanekaya AK, 2006, ELECTROANAL, V18, P533, DOI 10.1002/elan.200503449
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
   Zybin A, 2007, ANAL CHEM, V79, P4233, DOI 10.1021/ac070074u
NR 25
TC 38
Z9 38
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1955
J9 PLASMONICS
JI Plasmonics
PD MAR
PY 2010
VL 5
IS 1
BP 31
EP 35
DI 10.1007/s11468-009-9111-5
PG 5
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 578AK
UT WOS:000276265400005
DA 2018-01-05
ER

PT J
AU Bonini, C
   Chiummiento, L
   De Bonis, M
   Di Blasio, N
   Funicello, M
   Lupattelli, P
   Pandolfo, R
   Tramutola, F
   Berti, F
AF Bonini, Carlo
   Chiummiento, Lucia
   De Bonis, Margherita
   Di Blasio, Nadia
   Funicello, Maria
   Lupattelli, Paolo
   Pandolfo, Rocco
   Tramutola, Francesco
   Berti, Federico
TI Synthesis of New Thienyl Ring Containing HIV-1 Protease Inhibitors:
   Promising Preliminary Pharmacological Evaluation against Recombinant
   HIV-1 Proteases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; CONTROLLED-TRIAL; THIOPHENE;
   ZIDOVUDINE; RESISTANCE; MUTATIONS; INDINAVIR; THERAPY; ANALOGS; AIDS
AB A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different Substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated. In general thienyl groups spaced from the core by a methylene group gave products showing IC(50) in the nanomolar range, Irrespective of the type and the substitution pattern of the heterocycle. The range of activity of the two most active compounds is substantially maintained or even Increased against two commonly selected mutants, under drug pressure, Such as V32I and V82A.
C1 [Bonini, Carlo; Chiummiento, Lucia; De Bonis, Margherita; Di Blasio, Nadia; Funicello, Maria; Lupattelli, Paolo; Pandolfo, Rocco; Tramutola, Francesco] Univ Basilicata, Dipartimento Chim, I-85100 Potenza, Italy.
   [Berti, Federico] Univ Trieste, Dipartimento Sci Chim, I-34127 Trieste, Italy.
RP Bonini, C (reprint author), Univ Basilicata, Dipartimento Chim, Via Nazario Sauro 85, I-85100 Potenza, Italy.
EM bonini@unibas.it
OI Funicello, Maria/0000-0003-1104-3439; , Lucia/0000-0001-8181-9138
FU University of Trieste; MIUR (Ministry of Instruction, University and
   Research-Rome) [FIRB: RBNE017178N]; University of Basilicata
FX The authors greatfully acknowledge Prof. Silvano Geremia (University of
   Trieste) for the generous gift of protease mutants, Dr. Adrian Ostric
   (University of Trieste) for inhibition tests oil mutants, MIUR (Ministry
   of Instruction, University and Research-Rome, Project FIRB:
   RBNE017178N), and University of Basilicata for financial support.
CR Bonini C, 2005, TETRAHEDRON, V61, P6580, DOI 10.1016/j.tet.2005.04.048
   Bonini C, 2004, TETRAHEDRON LETT, V45, P2797, DOI 10.1016/j.tetlet.2004.02.026
   Bonini C, 2006, TETRAHEDRON-ASYMMETR, V17, P2919, DOI 10.1016/j.tetasy.2006.10.035
   Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5                                                   
   Cihlar T, 2000, ANNU REP MED CHEM, V35, P177, DOI 10.1016/S0065-7743(00)35017-5
   Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602
   Corral C, 1999, BIOORGAN MED CHEM, V7, P1349, DOI 10.1016/S0968-0896(99)00070-X                                                   
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   FLEXNER CW, 2001, PROTEASE INHIBITORS, P139
   FREIRE E, 2006, DRUG DISCOV TODAY, V3, P281
   GANTE J, 1994, ANGEW CHEM INT EDIT, V33, P1720
   Ghosh AK, 2001, SYNTHESIS-STUTTGART, P2203
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Kovalevsky AY, 2008, J MED CHEM, V51, P6599, DOI 10.1021/jm800283k
   Mosebi S, 2008, J VIROL, V82, P11476, DOI 10.1128/JVI.00726-08
   Muhlman A, 2001, J MED CHEM, V44, P3402, DOI 10.1021/jm0011169
   NAPOLITANO E, 1986, SYNTHESIS-STUTTGART, P122
   RUSCONI S, 2006, THERAPY, V3, P79
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Svicher V, 2005, ANTIMICROB AGENTS CH, V49, P2015, DOI 10.1128/AAC..49.5.2015-2025.2005
   Tomasselli AG, 2000, BBA-PROTEIN STRUCT M, V1477, P189, DOI 10.1016/S0167-4838(99)00273-3
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8
   Zhang A, 2002, BIOORG MED CHEM LETT, V12, P993, DOI 10.1016/S0960-894X(02)00103-8                                                   
   BONINI C, 2008, Patent No. 2008000415
NR 27
TC 12
Z9 13
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 25
PY 2010
VL 53
IS 4
BP 1451
EP 1457
DI 10.1021/jm900846f
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 556HN
UT WOS:000274581200003
PM 20108932
DA 2018-01-05
ER

PT J
AU Monforte, AM
   Logoteta, P
   De Luca, L
   Iraci, N
   Ferro, S
   Maga, G
   De Clercq, E
   Pannecouque, C
   Chimirri, A
AF Monforte, Anna-Maria
   Logoteta, Patrizia
   De Luca, Laura
   Iraci, Nunzio
   Ferro, Stefania
   Maga, Giovanni
   De Clercq, Erik
   Pannecouque, Christophe
   Chimirri, Alba
TI Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent
   non-nucleoside HIV-1 reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE 1,3-Dihydro-benzimidazol-2-ones; HIV-1 reverse transcriptase; Molecular
   modeling; Synthesis
ID AMINO-ACID SUBSTITUTIONS; DRUG-RESISTANCE; LYS103ASN MUTATION; EFAVIRENZ
   DMP-266; STRUCTURAL BASIS; WILD-TYPE; RESILIENCE; DESIGN; MUTANT; RT
AB A series of novel benzimidazolones and their analogues, characterized by the presence of one or more methyl groups or other bioisosteric moieties at different positions of the phenyl ring at N-1, were synthesized and evaluated as inhibitors of human immunodeficiency virus type-1 (HIV-1). Most of the new compounds proved to be highly effective in inhibiting both HIV-1 replication in MT4 cells with minimal cytotoxicity and RT enzyme at nanomolar concentrations. Some derivatives were also tested against RTs containing single amino acid mutations responsible for resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs). The different potencies displayed by the new compounds were studied using molecular modeling. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Monforte, Anna-Maria; Logoteta, Patrizia; De Luca, Laura; Ferro, Stefania; Chimirri, Alba] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   [Iraci, Nunzio] Univ Perugia, Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy.
   [Maga, Giovanni] CNR, IGM, I-27100 Pavia, Italy.
   [De Clercq, Erik; Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Leuven, Belgium.
RP Monforte, AM (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
EM ammonforte@pharma.unime.it
RI Maga, Giovanni/C-5409-2009; Iraci, Nunzio/B-4945-2015; De Luca,
   Laura/D-8532-2011
OI Maga, Giovanni/0000-0001-8092-1552; Iraci, Nunzio/0000-0002-1359-8684; 
FU Fondo Ateneo di ricerca (2005, Messina, Italy)
FX Financial support for this research by the Fondo Ateneo di ricerca
   (2005, Messina, Italy).
CR BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barreca ML, 2007, BIOORG MED CHEM LETT, V17, P1956, DOI 10.1016/j.bmcl.2007.01.025
   Barreca ML, 2005, J MED CHEM, V48, P3433, DOI 10.1021/jm049279a
   Barreca ML, 2002, J MED CHEM, V45, P5410, DOI 10.1021/jm020977+
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c
   Michel F. S., 1999, J MOL GRAPH MODEL, V17, P57
   Minuto Joshua J, 2008, Futur HIV Ther, V2, P525, DOI 10.2217/17469600.2.6.525
   Monforte AM, 2008, BIOORGAN MED CHEM, V16, P7429, DOI 10.1016/j.bmc.2008.06.012
   Monforte AM, 2009, BIOORGAN MED CHEM, V17, P5962, DOI 10.1016/j.bmc.2009.06.068
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   Ren JS, 2007, J MED CHEM, V50, P2301, DOI 10.1021/jm061117m
   Rodriguez-Barrios F, 2005, J AM CHEM SOC, V127, P7570, DOI 10.1021/ja042289g
   *SCHROD LLC, 2007, MAESTRO0 VERS 8
   *SCHROD LLC, 2007, MACROMODEL VERS 9 5M
   Shen LL, 2003, BIOPHYS J, V84, P3547, DOI 10.1016/S0006-3495(03)75088-7                                                   
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   Williams IG, 2003, INT J CLIN PRACT, V57, P890
   Zhang H, 2004, CHINESE CHEM LETT, V15, P121
NR 29
TC 25
Z9 25
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD FEB 15
PY 2010
VL 18
IS 4
BP 1702
EP 1710
DI 10.1016/j.bmc.2009.12.059
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 554HG
UT WOS:000274425500035
PM 20097079
DA 2018-01-05
ER

PT J
AU Jin, YG
   Qi, NN
   Tong, L
   Chen, DW
AF Jin, Yiguang
   Qi, Ningning
   Tong, Li
   Chen, Dawei
TI Self-assembled drug delivery systems. Part 5: Self-assemblies of a
   bolaamphiphilic prodrug containing dual zidovudine
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Anti-HIV; Bolaamphiphilic; Macrophage; Nanotechnology; Prodrug;
   Molecular self-assembly; Zidovudine
ID CHOLESTERYL ACYL DIDANOSINE; NUCLEOTIDE BOLAAMPHIPHILES; ANTIRETROVIRAL
   THERAPY; AIR/WATER INTERFACE; VITRO/IN-VIVO; IN-VITRO; NANOPARTICLES;
   DERIVATIVES; STABILITY; NANOSTRUCTURES
AB A bolaamphiphilic prodrug containing dual zidovudine, pentadecanedioyl dizidovudine (PDDZ), was prepared. The vesicular self-assemblies were formed in aqueous media through injecting the methanol solution of PDDZ into water. Hydrophobic interaction between lipid chains should drive molecular self-assembly. The nonionic surfactant, Tween 20, was used to increase the physical stability of self-assemblies because the surfactant micelles could prevent the assemblies from aggregating. The doping hydroxylpropylmethylcellulose (HPMC) slowed down the degradation of prodrugs due to adsorption,The self-assemblies were nanoscale with the mean particle size of 156 nm. Degradation of PDDZ was very slow in buffered solutions, but very rapid in enzyme and plasma, and the parent drug zidovudine (AZT) was the unique product. PDDZ self-assemblies showed strong anti-HIV activity on MT4 cell model. The 50% effective concentration (EC(50)) of PDDZ was 5 nM, equal to that of AZT. PDDZ was rapidly eliminated from circulation and mainly distributed into liver, spleen and testis followed by the rapid production of AZT after intravenous administration of the self-assemblies to rabbits. Macrophages in liver, spleen and testis are the reservoir of HIV so that the macrophage targeting effect of PDDZ self-assemblies would benefit to anti-HIV therapy. The self-assemblies composed of bolaamphiphilic PDDZ are a promising self-assembled drug delivery system (SADDS). (C) 2009 Elsevier B.V. All rights reserved.
C1 [Jin, Yiguang; Qi, Ningning] Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
   [Qi, Ningning; Chen, Dawei] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China.
   [Tong, Li] Beijing Normal Univ, Coll Life Sci, Beijing 100875, Peoples R China.
RP Jin, YG (reprint author), Beijing Inst Radiat Med, Dept Pharmaceut Chem, 27 Taiping Rd, Beijing 100850, Peoples R China.
EM jin_yiguang@yahoo.com.cn
RI Jin, Yiguang/H-6742-2013; Jin, Yiguang/A-9306-2008
OI Jin, Yiguang/0000-0002-3528-1397
FU National Natural Science Foundation of China [30672542]; National Key
   Technologies R&D Program for New Drugs [2009ZX09301-002]
FX This work is supported by the National Natural Science Foundation of
   China (No. 30672542) and the National Key Technologies R&D Program for
   New Drugs (No. 2009ZX09301-002). We also thank Prof. Minghua Liu of
   Chinese Academy of Science for the suggestive communication.
CR [Anonymous], 2006, ACD CHEMSKETCH FREEW
   Ambrosi M, 2006, J AM CHEM SOC, V128, P7209, DOI 10.1021/ja057730x
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   CAPPELLACCI L, 2008, NUCLEOS NUCLEOT, P460
   Cook JL, 2007, ANGEW CHEM INT EDIT, V46, P3706, DOI 10.1002/anie..200604966
   Fabio K, 2003, BIOCONJUGATE CHEM, V14, P358, DOI 10.1021/bc025645y
   Fuhrhop AH, 2004, CHEM REV, V104, P2901, DOI 10.1021/cr030602b
   Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102
   Gao P, 2006, LANGMUIR, V22, P6727, DOI 10.1021/la0604836
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Guenther S, 2002, BIOORG MED CHEM LETT, V12, P2233, DOI 10.1016/S0960-894X(02)00353-0
   Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4
   Iwaura R, 2003, ANGEW CHEM INT EDIT, V42, P1009, DOI 10.1002/anie.200390257                                                          
   Iwaura R, 2002, CHEM MATER, V14, P3047, DOI 10.1021/cm020263n
   JIN Y, 2009, INT J PHARMACEUT, V345, P40
   Jin Y., 2008, PHARM MANUFACTURING, P1249
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Jin YG, 2005, COLLOID SURFACE B, V42, P45, DOI 10.1016/j.colsurfb.2005.02.001
   Jin YG, 2008, J COLLOID INTERF SCI, V326, P275, DOI 10.1016/j.jcis.2008.07.014
   Jin YG, 2008, COLLOID SURFACE B, V64, P229, DOI 10.1016/j.colsurfb.2008.01.023
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   KIM JM, 1992, LANGMUIR, V8, P631
   Krielgaard L., 1998, J PHARM SCI, V87, P1593
   LASCH J, 1995, BBA-REV BIOMEMBRANES, V1241, P269, DOI 10.1016/0304-4157(95)00010-O                                                    
   Lau WM, 2008, CURR PHARM DESIGN, V14, P794, DOI 10.2174/138161208784007653
   Lazrek HB, 2007, NUCLEOS NUCLEOT NUCL, V26, P1103, DOI 10.1080/15257770701519452
   Li SY, 2009, J PHYS CHEM B, V113, P1143, DOI 10.1021/jp808079h
   Meister A, 2007, CURR OPIN COLLOID IN, V12, P138, DOI 10.1016/j.cocis.2007.05.003
   Muzzalupo R, 2005, COLLOID SURFACE B, V46, P78, DOI 10.1016/j.colsurfb.2005.09.003
   Romeo S, 2008, CHEMMEDCHEM, V3, P418, DOI 10.1002/cmdc.200700166
   Roulet V, 2006, AM J PATHOL, V169, P2094, DOI 10.2353/ajpath.2006.060191
   RUBALCAVA CGD, 2000, INT J PHARMACEUT, V203, P99
   Savelli G, 2000, CURR OPIN COLLOID IN, V5, P111, DOI 10.1016/S1359-0294(00)00043-1                                                   
   Shimizu T, 2005, CHEM REV, V105, P1401, DOI 10.1021/cr030072j
   Sirieix J, 2000, LANGMUIR, V16, P9221, DOI 10.1021/la000577u
   Torchilin VP, 2006, NANOPARTICULATES DRU
   Wang L, 2006, ANAL CHEM, V78, P646, DOI 10.1021/ac0693619                                                               
   Weissig V, 2001, ADV DRUG DELIVER REV, V49, P127, DOI 10.1016/S0169-409X(01)00131-4
   Yan Y, 2007, J PHYS CHEM B, V111, P2225, DOI 10.1021/jp065235x
   Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502                                                     
NR 41
TC 16
Z9 18
U1 1
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD FEB 15
PY 2010
VL 386
IS 1-2
BP 268
EP 274
DI 10.1016/j.ijpharm.2009.11.018
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 560BI
UT WOS:000274876400035
PM 19941945
DA 2018-01-05
ER

PT J
AU Tozzini, V
AF Tozzini, Valentina
TI Multiscale Modeling of Proteins
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID GREEN FLUORESCENT PROTEIN; MOLECULAR-DYNAMICS SIMULATIONS;
   COARSE-GRAINED MODELS; ELASTIC NETWORK MODELS; HIV-1 PROTEASE;
   BIOMOLECULAR SYSTEMS; ENERGY LANDSCAPE; BINDING; CHROMOPHORE; ABSORPTION
AB The activity within a living cell is based on a complex network of interactions among biomolecules, exchanging information and energy through biochemical processes. These events occur on different scales, from the nano- to the macroscale, spanning about 10 orders of magnitude in the space domain and 15 orders of magnitude in the time domain. Consequently, many different modeling techniques, each proper for a particular time or space scale, are commonly used. In addition, a single process often spans more than a single time or space scale. Thus, the necessity arises for combining the modeling techniques in multiscale approaches.
   In this Account, I first review the different modeling methods for bio-systems, from quantum mechanics to the coarse-grained and continuum-like descriptions, passing through the atomistic force field simulations. Special attention is devoted to their combination in different possible multiscale approaches and to the questions and problems related to their coherent matching in the space and time domains. These aspects are often considered secondary, but in fact, they have primary relevance when the aim is the coherent and complete description of bioprocesses.
   Subsequently, applications are illustrated by means of two paradigmatic examples: (i) the green fluorescent protein (GFP) family and (ii) the proteins involved in the human immunodeficency virus (HIV) replication cycle. The GFPs are currently one of the most frequently used markers for monitoring protein trafficking within living cells; nanobiotechnology and cell biology strongly rely on their use in fluorescence microscopy techniques. A detailed knowledge of the actions of the virus-specific enzymes of HIV (specifically HIV protease and integrase) is necessary to study novel therapeutic strategies against this disease. Thus, the insight accumulated over years of intense study is an excellent framework for this Account.
   The foremost relevance of these two biomolecular systems was recently confirmed by the assignment of two of the Nobel prizes in 2008: in chemistry for the discovery of GFP and in medicine for the discovery of HIV. Accordingly, these proteins were studied with essentially all of the available modeling techniques, making them ideal examples for studying the details of multiscale approaches in protein modeling.
C1 NEST, CNR, INFM, I-56126 Pisa, Italy.
RP Tozzini, V (reprint author), NEST, CNR, INFM, Piazza Cavalieri 7, I-56126 Pisa, Italy.
EM tozzini@nest.sns.it
RI Tozzini, Valentina/E-8206-2011
OI Tozzini, Valentina/0000-0002-7586-5039
FU HT research unit Scuola Normale Superiore
FX I thank Riccardo Nifosi, Joanna Trylska, Chia-En Chang, David Minh, and
   Dylan Morris for providing data to produce part of the graphics and
   Riccardo Nifosi and Fabio Beltram for useful discussions. This work was
   partially supported by HT research unit Scuola Normale Superiore.
CR Ayton GS, 2007, CURR OPIN STRUC BIOL, V17, P192, DOI 10.1016/j.sbi.2007.03.004
   Ayton GS, 2009, CURR OPIN STRUC BIOL, V19, P138, DOI 10.1016/j.sbi.2009.03.001
   Camilloni C, 2007, J PHYS CHEM B, V111, P10807, DOI 10.1021/jp072511e
   Carnevale V, 2007, J PHYS CHEM A, V111, P12327, DOI 10.1021/jp0751716
   CASCELLA M, 2008, CURR OPIN STRUC BIOL, V18, P630
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Chang CE, 2006, BIOPHYS J, V90, P3880, DOI 10.1529/biophysj.105.074575
   Chang CEA, 2007, CHEM BIOL DRUG DES, V69, P5, DOI 10.1111/j.1747-0285.2007.00464.x
   Cheung MS, 2002, P NATL ACAD SCI USA, V99, P685, DOI 10.1073/pnas.022387699
   Chu JW, 2007, MOL PHYS, V105, P167, DOI 10.1080/00268970701256696
   Chu JW, 2007, BIOPHYS J, V93, P3860, DOI 10.1529/biophysj.107.112060
   Das P, 2005, P NATL ACAD SCI USA, V102, P10141, DOI 10.1073/pnas.0409471102
   Demachy I, 2005, J PHYS CHEM B, V109, P24121, DOI 10.1021/jp054656w
   Di Fenza A, 2009, PROTEINS, V76, P946, DOI 10.1002/prot.22399
   Dror RO, 2009, P NATL ACAD SCI USA, V106, P4689, DOI 10.1073/pnas.0811065106
   Grochowski P, 2008, BIOPOLYMERS, V89, P93, DOI 10.1002/bip.20877
   Hamacher K, 2006, J CHEM THEORY COMPUT, V2, P873, DOI 10.1021/ct050247s
   Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103
   HUEDA Y, 1987, BIOPOLYMERS, V17, P1531
   Izvekov S, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2360580
   Jeong JI, 2006, J MOL GRAPH MODEL, V24, P296, DOI 10.1016/j.jmgm.2005.09.006
   Jernigan RL, 1996, CURR OPIN STRUC BIOL, V6, P195, DOI 10.1016/S0959-440X(96)80075-3
   Klimov DK, 2000, P NATL ACAD SCI USA, V97, P2544, DOI 10.1073/pnas.97.6.2544                                                          
   KNOWLES P, 2000, AB INTIO METHODS ELE
   KOHL N, 1988, P NATL ACAD SCI USA, V84, P4686
   Koumoutsakos P, 2005, ANNU REV FLUID MECH, V37, P457, DOI 10.1146/annurev.fluid.37.061903.175753
   Kurup A, 2003, CURR MED CHEM, V10, P1679, DOI 10.2174/0929867033457070                                                        
   Laino T, 2004, CHEM PHYS, V298, P17, DOI 10.1016/j.chemphys.2003.10.040
   Lauria A, 2007, J MOL MODEL, V13, P1151, DOI 10.1007/s00894-007-0242-3
   Liwo A, 2005, P NATL ACAD SCI USA, V102, P2362, DOI 10.1073/pnas.0408885102
   Luin S, 2009, J AM CHEM SOC, V131, P96, DOI 10.1021/ja804504b
   Lyman E, 2008, BIOPHYS J, V95, P4183, DOI 10.1529/biophysj.108.139733
   Maragakis P, 2005, J MOL BIOL, V352, P807, DOI 10.1016/j.jmb.2005.07.031
   Marini U., 2000, J PHYS CONDENS MATT, V12, pA413
   Marques MAL, 2004, ANNU REV PHYS CHEM, V55, P427, DOI 10.1146/annurev.physchem.55.091602.094449
   Marx D, 2000, NIC SERIES, V1
   Minh DDL, 2006, J AM CHEM SOC, V128, P6006, DOI 10.1021/ja0604873s
   Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x
   Mukherjee A, 2003, J CHEM PHYS, V118, P4733, DOI 10.1063/1.1542599
   NERI, 2005, PHYS REV LETT, V95
   Nifosi R, 2006, CHEM PHYS, V323, P358, DOI 10.1016/j.chemphys.2005.09.032
   Nifosi R, 2003, PROTEINS, V51, P378, DOI 10.1002/prot.10335
   NIFOSI R, 2003, J PHYS CHEM B, V107, P1670
   Nifosi R, 2007, J PHYS CHEM B, V111, P14043, DOI 10.1021/jp075545v
   Nifosi R, 2007, J COMPUT CHEM, V28, P2366, DOI 10.1002/jcc.20764
   Noid WG, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2938857
   Noid WG, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2938860
   PATNAIK S, 2006, BIOPOLYMERS, V28, P253
   Perarol M. D., 2007, CURR OPIN STRUC BIOL, V17, P149
   Perryman AL, 2006, BIOPOLYMERS, V82, P272, DOI 10.1002/bip.20497
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Reithmann C, 2003, EUR HEART J, V24, P1264, DOI 10.1016/S0195-668X(03)00233-1
   RUSSEL DD, 2009, CURR OPIN CELL BIOL, V21, P1
   Sbalzarini IF, 2005, BIOPHYS J, V89, P1482, DOI 10.1529/biophysj.104.057885
   Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f                                                               
   Sherwood P, 2008, CURR OPIN STRUC BIOL, V18, P630, DOI 10.1016/j.sbi.2008.07.003
   SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302                                                          
   Tanizaki S, 2008, BIOPHYS J, V94, P747, DOI 10.1529/biophysj.107.116236
   TERRENI M, RETROVIROLOGY UNPUB
   Thorpe IF, 2008, J PHYS CHEM B, V112, P13079, DOI 10.1021/jp8015968
   Tozzini V, 2006, J CHEM THEORY COMPUT, V2, P667, DOI 10.1021/ct050294k
   Tozzini V, 2005, CHEM PHYS LETT, V413, P123, DOI 10.1016/j.cplett.2005.07.075
   Tozzini V, 2005, CURR OPIN STRUC BIOL, V15, P144, DOI 10.1016/j.sbi.2005.02.005
   Tozzini V, 2007, J STRUCT BIOL, V157, P606, DOI 10.1016/j.jsb.2006.08.005
   Trylska J, 2005, BIOPHYS J, V89, P1455, DOI 10.1529/biophysj.104.058495
   Trylska J, 2002, BIOPHYS J, V83, P794, DOI 10.1016/S0006-3495(02)75209-0                                                   
   Trylska J, 2007, BIOPHYS J, V92, P4179, DOI 10.1529/biophysj.106.100560
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509                                                
   Vakser IA, 2008, CURR PHARM BIOTECHNO, V9, P57, DOI 10.2174/138920108783955209
   Vendrell O, 2006, J AM CHEM SOC, V128, P3564, DOI 10.1021/ja0549998
   Voth GA, 2008, COARSE GRAINING COND
   Yang LW, 2008, BIOINFORM BIOL INSIG, V2, P25
   Yap EH, 2008, PROTEINS, V70, P626, DOI 10.1002/prot.21515
   1998, J PHYS CHEM B, V102, P3586
NR 74
TC 79
Z9 79
U1 3
U2 65
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD FEB
PY 2010
VL 43
IS 2
BP 220
EP 230
DI 10.1021/ar9001476
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 558SF
UT WOS:000274765400006
PM 19785400
DA 2018-01-05
ER

PT J
AU Hopkins, S
   Scorneaux, B
   Huang, ZH
   Murray, MG
   Wring, S
   Smitley, C
   Harris, R
   Erdmann, F
   Fischer, G
   Ribeill, Y
AF Hopkins, Sam
   Scorneaux, Bernard
   Huang, Zhuhui
   Murray, Michael G.
   Wring, Stephen
   Smitley, Craig
   Harris, Richard
   Erdmann, Frank
   Fischer, Gunter
   Ribeill, Yves
TI SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That
   Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MITOCHONDRIAL PERMEABILITY TRANSITION; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CYCLOPHILIN INHIBITOR; INFECTION; RIBAVIRIN; COMBINATION; INTERFERON;
   DEBIO-025; NIM811; MECHANISM
AB SCY-635 is a novel nonimmunosuppressive cyclosporine-based analog that exhibits potent suppression of hepatitis C virus (HCV) replication in vitro. SCY-635 inhibited the peptidyl prolyl isomerase activity of cyclophilin A at nanomolar concentrations but showed no detectable inhibition of calcineurin phosphatase activity at concentrations up to 2 mu M. Metabolic studies indicated that SCY-635 did not induce the major cytochrome P450 enzymes 1A2, 2B6, and 3A4. SCY-635 was a weak inhibitor and a poor substrate for P-glycoprotein. Functional assays with stimulated Jurkat cells and stimulated human peripheral blood mononuclear cells indicated that SCY-635 is a weaker inhibitor of interleukin-2 secretion than cyclosporine. A series of two-drug combination studies was performed in vitro. SCY-635 exhibited synergistic antiviral activity with alpha interferon 2b and additive antiviral activity with ribavirin. SCY-635 was shown to be orally bioavailable in multiple animal species and produced blood and liver concentrations of parent drug that exceeded the 50% effective dose determined in the bicistronic con1b-derived replicon assay. These results suggest that SCY-635 warrants further investigation as a novel therapeutic agent for the treatment of individuals who are chronically infected with HCV.
C1 [Hopkins, Sam; Scorneaux, Bernard; Wring, Stephen; Smitley, Craig; Harris, Richard; Ribeill, Yves] Scynexis Inc, Durham, NC 27713 USA.
   [Erdmann, Frank; Fischer, Gunter] Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany.
   [Huang, Zhuhui; Murray, Michael G.] So Res Inst, Frederick, MD 21701 USA.
RP Hopkins, S (reprint author), Scynexis Inc, 3501C Trictr Blvd, Durham, NC 27713 USA.
EM sam.Hopkins@scynexis.com
CR ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1016/0270-9139(94)90203-8
   Baumgrass R, 2004, J BIOL CHEM, V279, P2470, DOI 10.1074/jbc.M304754200
   BILLICH A, 1995, J VIROL, V69, P2451
   Chatterji U, 2009, J BIOL CHEM, V284, P16998, DOI 10.1074/jbc.M109.007625
   Edlich E, 2006, HANDB EXP PHARM, V172, P359
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0
   Flisiak R, 2008, J HEPATOL, V48, pS62, DOI 10.1016/S0168-8278(08)60145-2
   Flisiak R, 2008, HEPATOLOGY, V47, P817, DOI 10.1002/hep.22131
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Hinrichsen H, 2004, GASTROENTEROLOGY, V127, P1347, DOI 10.1053/j.gastro.2004.08.002
   Hopkins S, 2009, J HEPATOL, V50, pS36, DOI 10.1016/S0168-8278(09)60091-X                                                   
   KAUL A, 2009, PLOS PATHOG, V5
   Krippendorff BF, 2007, J BIOMOL SCREEN, V12, P92, DOI 10.1177/1087057106295897
   LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991
   Ma S, 2006, ANTIMICROB AGENTS CH, V50, P2976, DOI 10.1128/AAC.00310-06
   MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3
   Paeshuyse J, 2006, HEPATOLOGY, V43, P761, DOI 10.1002/hep.21102
   Pawlotsky JM, 2004, GASTROENTEROLOGY, V126, P703, DOI 10.1053/j.gastro.2003.12.002
   Payeli SK, 2008, ATHEROSCLEROSIS, V197, P564, DOI 10.1016/j.atherosclerosis.2007.08.025
   Peel M, 2008, HEPATOLOGY, V48, p1167A
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   REICHEL C, 1994, EUR J CLIN PHARMACOL, V46, P417, DOI 10.1007/BF00191903                                                              
   Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119
   Szabo E, 2003, PATHOL ONCOL RES, V9, P215, DOI 10.1007/BF02893380                                                              
   Taylor S, 2006, J PHARMACEUT BIOMED, V41, P299, DOI 10.1016/j.jpba.2005.10.031
   TERAOKA S, 1988, TRANSPLANT P, V20, P868
   Theruvath TP, 2008, HEPATOLOGY, V47, P236, DOI 10.1002/hep.21912
   Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22
   Wang Q, 2005, INT J PHARMACEUT, V288, P349, DOI 10.1016/j.ijpharm.2004.10.007
   Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449
   YANG D, 2004, BIOCHEM PHARMACOL, V68, P1889
   Yang F, 2008, J VIROL, V82, P5269, DOI 10.1128/JVI.02614-07
NR 34
TC 77
Z9 80
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2010
VL 54
IS 2
BP 660
EP 672
DI 10.1128/AAC.00660-09
PG 13
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 547BR
UT WOS:000273860600012
PM 19933795
OA gold
DA 2018-01-05
ER

PT J
AU Azijn, H
   Tirry, I
   Vingerhoets, J
   de Bethune, MP
   Kraus, G
   Boven, K
   Jochmans, D
   Van Craenenbroeck, E
   Picchio, G
   Rimsky, LT
AF Azijn, Hilde
   Tirry, Ilse
   Vingerhoets, Johan
   de Bethune, Marie-Pierre
   Kraus, Guenter
   Boven, Katia
   Jochmans, Dirk
   Van Craenenbroeck, Elke
   Picchio, Gaston
   Rimsky, Laurence T.
TI TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor
   (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; EXPERIENCED HIV-1-INFECTED PATIENTS;
   PLACEBO-CONTROLLED TRIAL; IN-VITRO; PHENOTYPIC RESISTANCE; ANTIVIRAL
   ACTIVITY; TMC125 ETRAVIRINE; CROSS-RESISTANCE; DOUBLE-BLIND; DRUG
AB Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral suppression, efavirenz and nevirapine select for resistant viruses. The diarylpyrimidine etravirine has demonstrated durable efficacy for patients infected with NNRTI-resistant HIV-1. A screening strategy used to test NNRTI candidates from the same series as etravirine identified TMC278 (rilpivirine). TMC278 is an NNRTI showing subnanomolar 50% effective concentrations (EC(50) values) against wild-type HIV-1 group M isolates (0.07 to 1.01 nM) and nanomolar EC(50) values against group O isolates (2.88 to 8.45 nM). Sensitivity to TMC278 was not affected by the presence of most single NNRTI resistance-associated mutations (RAMs), including those at positions 100, 103, 106, 138, 179, 188, 190, 221, 230, and 236. The HIV-1 site-directed mutant with Y181C was sensitive to TMC278, whereas that with K101P or Y181I/V was resistant. In vitro, considerable cross-resistance between TMC278 and etravirine was observed. Sensitivity to TMC278 was observed for 62% of efavirenz-and/or nevirapine-resistant HIV-1 recombinant clinical isolates. TMC278 inhibited viral replication at concentrations at which first-generation NNRTIs could not suppress replication. The rates of selection of TMC278-resistant strains were comparable among HIV-1 group M subtypes. NNRTI RAMs emerging in HIV-1 under selective pressure from TMC278 included combinations of V90I, L100I, K101E, V106A/I, V108I, E138G/K/Q/R, V179F/I, Y181C/I, V189I, G190E, H221Y, F227C, and M230I/L. E138R was identified as a new NNRTI RAM. These in vitro analyses demonstrate that TMC278 is a potent next-generation NNRTI, with a high genetic barrier to resistance development.
C1 [Azijn, Hilde; Tirry, Ilse; Vingerhoets, Johan; de Bethune, Marie-Pierre; Kraus, Guenter; Jochmans, Dirk; Van Craenenbroeck, Elke; Rimsky, Laurence T.] Tibotec BVBA, B-2800 Mechelen, Belgium.
   [Boven, Katia; Picchio, Gaston] Tibotec Inc, Yardley, PA USA.
RP Rimsky, LT (reprint author), Tibotec BVBA, Gen Wittelaan L11 B3, B-2800 Mechelen, Belgium.
EM lrimsky@its.jnj.com
OI JOCHMANS, DIRK/0000-0002-9265-6028
FU Tibotec Pharmaceuticals, Ltd
FX This study was supported by Tibotec Pharmaceuticals, Ltd. We were
   provided with editorial assistance by Ian Woolveridge of
   Gardiner-Caldwell Communications (GCC) Ltd., Macclesfield, United
   Kingdom, funding for which was also provided by Tibotec.
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4680.2004
   Antinori A, 2002, AIDS RES HUM RETROV, V18, P835, DOI 10.1089/08892220260190308                                                       
   Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001
   Balotta C, 2001, J ACQ IMMUN DEF SYND, V27, P499
   Basavapathruni A, 2006, BIOCHEMISTRY-US, V45, P7334, DOI 10.1021/bi052362v
   Benjahad A, 2005, J MED CHEM, V48, P1948, DOI 10.1021/jm0408621
   BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
   Bilello JA, 1996, ANTIMICROB AGENTS CH, V40, P1491
   BRENNAN TM, 1995, ANTIVIR RES, V26, P173, DOI 10.1016/0166-3542(94)00074-I
   BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497
   BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Cook ND, 1996, DRUG DISCOV TODAY, V1, P287, DOI 10.1016/1359-6446(96)10026-X                                                    
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   de Bethune M. P., 2005, 12 C RETR OPP INF CR
   DEBETHUNE MP, 1999, ANTIVIRAL THERAPY S1, V4, P33
   Delaugerre C, 2001, J MED VIROL, V65, P445, DOI 10.1002/jmv.2055.abs
   *EMEA, 2008, SUMM PROD CHAR INT E
   Fang C, 2008, P NATL ACAD SCI USA, V105, P1472, DOI 10.1073/pnas.0709320104
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269
   JAKUBIK JJ, 2008, 17 INT HIV DRUG RES
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   KALTENBACH JP, 1958, EXP CELL RES, V15, P112, DOI 10.1016/0014-4827(58)90067-3
   LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0
   Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4
   LEITNER T, 2005, HIV 1 SUBTYPE CIRCUL
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2                                                   
   Madruga J. V. R., 2008, 9 INT C DRUG THER HI
   OIE S, 1993, J ACQ IMMUN DEF SYND, V6, P531
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pelemans H, 2001, VIROLOGY, V280, P97, DOI 10.1006/viro.2000.0742
   Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5
   POZNIAK A, 2007, 14 C RETR OPP INF
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609
   RIMSKY LT, 2007, 16 INT HIV DRUG RES
   Rosenkilde MM, 2004, J BIOL CHEM, V279, P3033, DOI 10.1074/jbc.M309546200
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5                                                    
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   Tambuyzer Lotke, 2009, Antivir Ther, V14, P103
   *TIB PHARM LTD, 2008, INT PROD INF
   Vermeiren H, 2007, J VIROL METHODS, V145, P47, DOI 10.1016/j.jviromet.2007.05.009
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   *VIRC BVBA, 2009, VIRC TYPE HIV 1 REP
   *VIRC BVBA, 2009, ANT PHEN REP
   Zhang H, 2004, CHINESE CHEM LETT, V15, P121
   LARDER B, 2007, Patent No. 7292944
NR 52
TC 170
Z9 175
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2010
VL 54
IS 2
BP 718
EP 727
DI 10.1128/AAC.00986-09
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 547BR
UT WOS:000273860600019
PM 19933797
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Stelter, L
   Pinkernelle, JG
   Michel, R
   Schwartlander, R
   Raschzok, N
   Morgul, MH
   Koch, M
   Denecke, T
   Ruf, J
   Baumler, H
   Jordan, A
   Hamm, B
   Sauer, IM
   Teichgraber, U
AF Stelter, Lars
   Pinkernelle, Jens G.
   Michel, Roger
   Schwartlaender, Ruth
   Raschzok, Nathanael
   Morgul, Mehmet H.
   Koch, Martin
   Denecke, Timm
   Ruf, Juri
   Baeumler, Hans
   Jordan, Andreas
   Hamm, Bernd
   Sauer, Igor M.
   Teichgraeber, Ulf
TI Modification of Aminosilanized Superparamagnetic Nanoparticles:
   Feasibility of Multimodal Detection Using 3T MRI, Small Animal PET, and
   Fluorescence Imaging
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Aminosilane; Nanoparticle; Multimodal molecular imaging in vitro and in
   vivo; MRI; PET
ID CROSS-LINKED NANOPARTICLES; IN-VIVO; MAGNETIC NANOPARTICLES; STEM-CELLS;
   PEPTIDE; VITRO; TRANSPLANTATION; ENDOCYTOSIS; TRACKING; DELIVERY
AB The aim of our study was to modify an aminosilane-coated superparamagnetic nanoparticle for cell labeling and subsequent multimodal imaging using magnetic resonance imaging (MRI), positron emission tomography (PET), and fluorescent imaging in vivo.
   We covalently bound the transfection agent HIV-1 tat, the fluorescent dye fluorescein isothiocyanate, and the positron-emitting radionuclide gallium-68 to the particle and injected them intravenously into Wistar rats, followed by animal PET and MRI at 3.0 T. As a proof of principle hepatogenic HuH7 cells were labeled with the particles and observed for cell toxicity as well as detectability by MRI and biodistribution in vivo.
   PET imaging and MRI revealed increasing hepatic and splenic accumulation of the particles over 24 h. Adjacent in vitro studies in hepatogenic HuH7 cells showed a rapid intracellular accumulation of the particles with high labeling efficiency and without any signs of toxicity. In vivo dissemination of the labeled cells could be followed by dynamic biodistribution studies.
   We conclude that our modified superparamagnetic nanoparticles are stable under in vitro and in vivo conditions and are therefore applicable for efficient cell labeling and subsequent multimodal molecular imaging. Moreover, their multiple free amino groups suggest the possibility for further modifications and might provide interesting opportunities for various research fields.
C1 [Stelter, Lars; Pinkernelle, Jens G.; Michel, Roger; Ruf, Juri; Hamm, Bernd; Teichgraeber, Ulf] Univ Med Berlin, Charite Campus Virchow Klinikum, Klin Strahlenheilkunde, CC6, D-13353 Berlin, Germany.
   [Koch, Martin] Univ Med Berlin, Inst Pathol, CC5, D-10117 Berlin, Germany.
   [Schwartlaender, Ruth; Raschzok, Nathanael; Morgul, Mehmet H.; Sauer, Igor M.] Univ Med Berlin, Charite Campus Virchow Klinikum, Klin Allgemein Visceral & Transplantat Chirurg, CC8, D-13353 Berlin, Germany.
   [Baeumler, Hans] Univ Med Berlin, Inst Transfus Med, CC14, D-10117 Berlin, Germany.
   [Morgul, Mehmet H.] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey.
   [Jordan, Andreas] MagForce Nanotechnol AG, Berlin, Germany.
   [Denecke, Timm] Otto von Guericke Univ, Klin Radiol & Nukl Med, D-39120 Magdeburg, Germany.
RP Stelter, L (reprint author), Univ Med Berlin, Charite Campus Virchow Klinikum, Klin Strahlenheilkunde, CC6, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM lars.stelter@charite.de
OI Teichgraber, Ulf/0000-0002-4048-3938; Denecke, Timm/0000-0003-3313-3208
CR Amsalem Y., 2007, CIRCULATION, V116, P138
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P710, DOI 10.1021/bc049945m
   DeNardo SJ, 2007, J NUCL MED, V48, P437
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Gilad AA, 2008, MAGN RESON MED, V60, P1, DOI 10.1002/mrm.21622
   Hendrikx PJ, 1996, EXP HEMATOL, V24, P129
   Horslen SP, 2004, TRANSPLANTATION, V77, P1481, DOI 10.1097/01.TP.0000113809.53415.C2
   Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Kikkawa H, 2000, CANCER-AM CANCER SOC, V89, P1626, DOI 10.1002/1097-0142(20001001)89:7<1626::AID-CNCR28>3.0.CO;2-T                     
   Koch AM, 2003, BIOCONJUGATE CHEM, V14, P1115, DOI 10.1021/bc034123v
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Ma YJ, 2007, J MATER SCI-MATER M, V18, P2145, DOI 10.1007/s10856-007-3015-8
   MAKOWKA L, 1980, SCIENCE, V210, P901, DOI 10.1126/science.7001630
   MATAS AJ, 1976, SCIENCE, V192, P892, DOI 10.1126/science.818706
   MENGER MD, 1993, IMMUNOL TODAY, V14, P519, DOI 10.1016/0167-5699(93)90179-O
   Misgeld T, 2007, NAT PROTOC, V2, P263, DOI 10.1038/nprot.2007.24
   Moore A, 2004, DIABETES, V53, P1459, DOI 10.2337/diabetes.53.6.1459
   Nahrendorf M, 2008, CIRCULATION, V117, P379, DOI 10.1161/CIRCULATIONAHA.107.741181
   Perez JM, 2004, CHEMBIOCHEM, V5, P261, DOI 10.1002/cbic.200300730
   Pinkernelle J, 2005, MAGNET RESON MED, V53, P1187, DOI 10.1002/mrm.20455
   Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11
   Reynolds F, 2005, BIOCONJUGATE CHEM, V16, P1240, DOI 10.1021/bc0501451
   Rossin R, 2005, J NUCL MED, V46, P1210
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhernosekov KP, 2007, J NUCL MED, V48, P1741, DOI 10.2967/jnumed.107.040378
NR 29
TC 42
Z9 43
U1 1
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD FEB
PY 2010
VL 12
IS 1
BP 25
EP 34
DI 10.1007/s11307-009-0237-9
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 542FV
UT WOS:000273479300005
PM 19582510
DA 2018-01-05
ER

PT J
AU Kim, SS
   Peer, D
   Kumar, P
   Subramanya, S
   Wu, HQ
   Asthana, D
   Habiro, K
   Yang, YG
   Manjunath, N
   Shimaoka, M
   Shankar, P
AF Kim, Sang-Soo
   Peer, Dan
   Kumar, Priti
   Subramanya, Sandesh
   Wu, Huaquan
   Asthana, Deshratan
   Habiro, Katsuyoshi
   Yang, Yong-Guang
   Manjunath, N.
   Shimaoka, Motomu
   Shankar, Premlata
TI RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents
   HIV Infection in BLT Mice
SO MOLECULAR THERAPY
LA English
DT Article
ID SMALL INTERFERING RNA; T-CELLS; ENTRY INHIBITORS; IMMUNE-SYSTEM;
   TARGET-CELLS; MOUSE MODEL; DELIVERY; SIRNA; LIPOSOMES; LFA-1
AB RNA interference (RNAi)-mediated knockdown of gene expression offers a novel treatment strategy for human immunodeficiency virus (HIV) infection. However, the major hurdle for clinical use is a practical strategy for small interfering RNA (siRNA) delivery to the multiple immune cell types important in viral pathogenesis. We have developed a novel immunoliposome method targeting the lymphocyte function-associated antigen-1 (LFA-1) integrin expressed on all leukocytes and evaluated it for systemic delivery of siRNA in a humanized mouse model. We show that in vivo administration of the LFA-1 integrin-targeted and stabilized nanoparticles (LFA-1 I-tsNPs) results in selective uptake of siRNA by T cells and macrophages, the prime targets of HIV. Further, in vivo administration of anti-CCR5 siRNA/LFA-1 I-tsNPs resulted in leukocyte-specific gene silencing that was sustained for 10 days. Finally, humanized mice challenged with HIV after anti-CCR5 siRNA treatment showed enhanced resistance to infection as assessed by the reduction in plasma viral load and disease-associated CD4 T-cell loss. This study demonstrates the potential in vivo applicability of LFA-1-directed siRNA delivery as anti-HIV prophylaxis.
C1 [Kim, Sang-Soo; Subramanya, Sandesh; Wu, Huaquan; Manjunath, N.; Shankar, Premlata] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Biomed Sci,Ctr Excellence Infect Dis, El Paso, TX 79905 USA.
   [Kim, Sang-Soo; Peer, Dan; Subramanya, Sandesh; Wu, Huaquan; Manjunath, N.; Shimaoka, Motomu; Shankar, Premlata] Immune Dis Inst, Boston, MA USA.
   [Peer, Dan; Shimaoka, Motomu] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Peer, Dan; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
   [Peer, Dan] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, Lab Nanomed, IL-69978 Tel Aviv, Israel.
   [Kumar, Priti] Yale Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT USA.
   [Asthana, Deshratan] Univ Miami, Miller Sch Med, Lab Clin & Biol Studies, Miami, FL 33136 USA.
   [Habiro, Katsuyoshi; Yang, Yong-Guang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
RP Shankar, P (reprint author), Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Dept Biomed Sci,Ctr Excellence Infect Dis, 5001 El Paso Dr, El Paso, TX 79905 USA.
EM shimaoka@idi.harvard.edu; premlata.shankar@ttuhsc.edu
RI Peer, Dan/A-1785-2011; Kumar, Priti/C-5699-2009
OI Peer, Dan/0000-0001-8238-0673; 
FU NIH (National Institutes of Health) [AI071882, AI063421]; Leukemia &
   Lymphoma Society; KRF (Korea Research Foundation); MOEHRD (Ministry of
   Education and Human Resource Development) [KRF-2006-352-D00070]; CFAR
   (Center for AIDS Research) [P30 A060354]
FX This work was supported by grants from NIH (National Institutes of
   Health), AI071882 (P.S.) and AI063421 (M.S.); the Leukemia & Lymphoma
   Society (M.S.); the KRF (Korea Research Foundation) and MOEHRD (Ministry
   of Education and Human Resource Development), KRF-2006-352-D00070
   (S.-S.K.); and the CFAR (Center for AIDS Research) fellowship P30
   A060354 (P.K.). We thank Erica Nakajima from the Yale School of Medicine
   for technical assistance and critical reading of the manuscript.
CR An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76
   Fais S, 1999, J VIROL, V73, P6453
   Giguere JF, 2004, J VIROL, V78, P12062, DOI 10.1128/JVI.78.21.12062-12065.2004
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Hioe CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001                                                 
   Jacovina A, 2008, MT SINAI J MED, V75, P297, DOI 10.1002/msj.20050
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388
   Lee SK, 2005, BLOOD, V106, P818, DOI 10.1182/blood-2004-10-3959
   Lu CF, 2004, J IMMUNOL, V173, P3972, DOI 10.4049/jimmunol.173.6.3972                                                     
   Manjunath N, 2006, TRENDS IMMUNOL, V27, P328, DOI 10.1016/j.it.2006.05.006
   Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161
   Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Ostrowski MA, 1999, J VIROL, V73, P6430
   Peer D, 2000, ARCH BIOCHEM BIOPHYS, V383, P185, DOI 10.1006/abbi.2000.2046                                                          
   Peer D, 2004, INT J CANCER, V108, P780, DOI 10.1002/ijc.11615
   Peer D, 2003, BBA-BIOMEMBRANES, V1612, P76, DOI 10.1016/S0005-2736(03)00106-8
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   ROSSI JJ, 2006, BIOTECHNIQUES S, P25
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Sun XG, 2008, NAT BIOTECHNOL, V26, P1379, DOI 10.1038/nbt.1512
   Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020
NR 31
TC 113
Z9 123
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD FEB
PY 2010
VL 18
IS 2
BP 370
EP 376
DI 10.1038/mt.2009.271
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 554PQ
UT WOS:000274447300017
PM 19997090
OA gold
DA 2018-01-05
ER

PT J
AU Mamo, T
   Moseman, EA
   Kolishetti, N
   Morales, CS
   Shi, J
   Kuritzkes, DR
   Langer, R
   von Andrian, U
   Farokhzad, OC
AF Mamo, Tewodros
   Moseman, E. Ashley
   Kolishetti, Nagesh
   Morales, Carolina Salvador
   Shi, Jinjun
   Kuritzkes, Daniel R.
   Langer, Robert
   von Andrian, Ulrich
   Farokhzad, Omid C.
TI Emerging nanotechnology approaches for HIV/AIDS treatment and prevention
SO NANOMEDICINE
LA English
DT Review
DE AIDS; antiretroviral therapy; gene therapy; HIV; immunotherapy;
   microbicides; nanomedicine; nanoparticles; nanotechnology; vaccines
ID BIODEGRADABLE POLYMER NANOPARTICLES; LENTIVIRAL-MEDIATED DELIVERY;
   PRIMARY HEMATOPOIETIC-CELLS; VAGINAL SHIV TRANSMISSION;
   SMALL-INTERFERING RNA; ANTI-HIV PROPERTIES; DRUG-DELIVERY; DENDRITIC
   CELLS; IN-VITRO; PLA NANOPARTICLES
AB Currently, there is no cure and no preventive vaccine for HIV/AIDS. Combination antiretroviral therapy has dramatically improved treatment, but it has to be taken for a lifetime, has major side effects and is ineffective in patients in whom the virus develops resistance. Nanotechnology is an emerging multidisciplinary field that is revolutionizing medicine in the 21st century. It has a vast potential to radically advance the treatment and prevention of HIV/AIDS. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for HIV/AIDS by advancing antiretroviral therapy, gene therapy, immunotherapy, vaccinology and microbicides.
C1 [Mamo, Tewodros; Morales, Carolina Salvador; Shi, Jinjun; Farokhzad, Omid C.] Brigham & Womens Hosp, Lab Nanomed & Biomat, Boston, MA 02115 USA.
   [Mamo, Tewodros] Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
   [Moseman, E. Ashley; von Andrian, Ulrich] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA.
   [Kolishetti, Nagesh; Morales, Carolina Salvador; Shi, Jinjun; Langer, Robert; Farokhzad, Omid C.] MIT, Harvard MIT Ctr Canc Nanotechnol Excellence, Cambridge, MA 02139 USA.
   [Kuritzkes, Daniel R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Sect Retroviral Therapeut, Cambridge, MA 02138 USA.
   [Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
RP Farokhzad, OC (reprint author), Brigham & Womens Hosp, Lab Nanomed & Biomat, 75 Francis St, Boston, MA 02115 USA.
EM ofarokhzad@zeus.bwh.harvard.edu
RI Kolishetti, Nagesh/K-2810-2012; von Andrian, Ulrich/A-5775-2008
OI Kolishetti, Nagesh/0000-0001-5574-673X; Farokhzad,
   Omid/0000-0003-2009-270X
FU NIH [EB003647, U54-CA119349, 732 HL07623]; Cancer Nanotherapeutics
FX Daniel R Kuritzkes constelts for pharmaceutical companies involved in
   HIV/AIDS drug development. The authors are supported in-part with
   funding from NIH EB003647 (Omid C Farokhzad), NIH U54-CA119349 (Robert
   Langer, Omid C Farokhzad), and Kocb-PCF Program in Cancer
   Nanotherapeutics (Omid C Farokhzad, Robert Lange?). E Ashley Moseman is
   recipient of an NIH training grant (732 HL07623) in Hematology. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Barnor JS, 2005, NUCLEOS NUCLEOT NUCL, V24, P431, DOI 10.1081/NCN-200059981
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Bass Emily, 2009, BETA, V21, P24
   Berkhout B, 2009, EXPERT OPIN BIOL TH, V9, P161, DOI [10.1517/14712590802653619, 10.1517/14712590802653619 ]
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   BLATTNER W, 1988, SCIENCE, V241, P515, DOI 10.1126/science.3399881
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Bourinbaiar AS, 2006, CURR PHARM DESIGN, V12, P2017, DOI 10.2174/138161206777442119
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brave A, 2007, VACCINE, V25, P6882, DOI 10.1016/j.vaccine.2007.07.012
   Burke B, 2009, VIROLOGY, V387, P147, DOI 10.1016/j.virol.2009.02.005
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755                                                                   
   Cohen J, 2008, SCIENCE, V319, P1026, DOI 10.1126/science.319.5866.1026b
   Cohen J, 2007, SCIENCE, V317, P612, DOI 10.1126/science.317.5838.612
   Copland MJ, 2005, IMMUNOL CELL BIOL, V83, P97, DOI 10.1111/j.1440-1711.2005.01315.x
   Csaba N, 2009, ADV DRUG DELIVER REV, V61, P140, DOI 10.1016/j.addr.2008.09.005
   Damge C, 2008, EXPERT OPIN DRUG DEL, V5, P45, DOI 10.1517/17425247.5.1.45
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Dorrell L, 2007, VACCINE, V25, P3277, DOI 10.1016/j.vaccine.2007.01.005
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Durdagi S, 2009, J CHEM INF MODEL, V49, P1139, DOI 10.1021/ci900047s
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Fahmy TM, 2008, NANOMEDICINE-UK, V3, P343, DOI 10.2217/17435889.3.3.343
   FAIRMAN J, 2008, VACCIN, V5
   Farokhzad OC, 2008, EXPERT OPIN DRUG DEL, V5, P927, DOI [10.1517/17425240802370043, 10.1517/17425247.5.9.927 ]
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Furin JJ, 2008, ANN NY ACAD SCI, V1136, P12, DOI 10.1196/annals.1425.004
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Gallo RC, 2002, SCIENCE, V298, P1728, DOI 10.1126/science.1078050
   Gandhi RT, 2009, VACCINE, V27, P6088, DOI 10.1016/j.vaccine.2009.05.016
   Gandhi RT, 2002, ANNU REV MED, V53, P149, DOI 10.1146/annurev.med.53.082901.104011
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Gao X, 2007, AAPS J, V9, pE92, DOI 10.1208/aapsj0901009
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828                                        
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Haasnoot J, 2007, NAT BIOTECHNOL, V25, P1435, DOI 10.1038/nbt1369
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192                                                                  
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Hori Y, 2008, BIOMATERIALS, V29, P3671, DOI 10.1016/j.biomaterials.2008.05.033
   Jefferys R, 2008, NATURE, V453, P719, DOI 10.1038/453719d
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   [Anonymous], 2008, REP GLOB HIV AIDS EP
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Kotelnikova RA, 2003, J NANOPART RES, V5, P561, DOI 10.1023/B:NAN0.0000006070.61144.93
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lamers SL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005065
   Lang L, 2009, GASTROENTEROLOGY, V136, P7, DOI 10.1053/j.gastro.2008.11.047
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Ledford H, 2008, NAT BIOTECHNOL, V26, P591, DOI 10.1038/nbt0608-591
   Ledford H, 2008, NAT BIOTECHNOL, V26, P3, DOI 10.1038/nbt0108-3
   Lee ALZ, 2009, BIOMATERIALS, V30, P919, DOI 10.1016/j.biomaterials.2008.10.062
   Lee SK, 2005, BLOOD, V106, P818, DOI 10.1182/blood-2004-10-3959
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Leung L, 2004, AIDS, V18, P991, DOI 10.1097/01.aids.0000111468.61782.5b
   Li MJ, 2006, ANN NY ACAD SCI, V1082, P172, DOI 10.1196/annals.1348.006
   Li Mingjie, 2008, V433, P287, DOI 10.1007/978-1-59745-237-3_18
   Li MJ, 2005, MOL THER, V12, P900, DOI 10.1016/j.ymthe.2005.07.524
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lori F, 2007, CURR MED CHEM, V14, P1911
   Lundin KE, 2009, GENETICA, V137, P47, DOI 10.1007/s10709-009-9372-0
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Marsden MD, 2009, J ANTIMICROB CHEMOTH, V63, P7, DOI 10.1093/jac/dkn455
   Masse PJ, 2008, ANNU REV MED, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY                                                     
   McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732
   MCMICHAEL AJ, 2009, NAT REV IMMUNOL
   Merson MH, 2006, NEW ENGL J MED, V354, P2414, DOI 10.1056/NEJMp068074                                                             
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Mitsuyasu RT, 2009, NAT MED, V15, P285, DOI 10.1038/nm.1932
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Montagnier L, 2002, SCIENCE, V298, P1727, DOI 10.1126/science.1079027
   Morris KV, 2006, GENE THER, V13, P553, DOI 10.1038/sj.gt.3302688
   Nie SM, 2007, ANNU REV BIOMED ENG, V9, P257, DOI 10.1146/annurev.bioeng.9.060906.152025
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Ott G, 1995, Pharm Biotechnol, V6, P277
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pett SL, 2009, CURR OPIN HIV AIDS, V4, P188, DOI 10.1097/COH.0b013e328329d090
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Rodriguez-Saona Cesar R., 2007, Great Lakes Entomologist, V40, P1
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Rossi JJ, 2006, GENE THER, V13, P1483, DOI 10.1038/sj.gt.3302764
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Rupp R, 2007, INT J NANOMED, V2, P561
   Saidi H, 2009, REV MED VIROL, V19, P69, DOI 10.1002/rmv.601
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   SAX PE, 2007, HIV ESSENTIALS
   Shacklett BL, 2008, PLOS MED, V5, P16, DOI 10.1371/journal.pmed.0050013
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Singh SK, 2006, VACCINE, V24, P4161, DOI 10.1016/j.vaccine.2006.02.047
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tanimoto S, 2008, CHEM COMMUN, P5767, DOI 10.1039/b811726h
   Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084
   Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538
   Troshina OA, 2007, ORG BIOMOL CHEM, V5, P2783, DOI 10.1039/b705331b
   Uberla K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000114
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wagner A, 2007, J LIPOSOME RES, V17, P139, DOI 10.1080/08982100701530159
   Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Wang W, 2006, CHEM BIOL DRUG DES, V68, P314, DOI 10.1111/j.1747-0285.2006.00454.x
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Wang Y, 2006, NAT MATER, V5, P791, DOI 10.1038/nmat1737
   WATSON DS, 2009, IMMUNOL CELL BIOL
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Whiteside TL, 2009, CLIN VACCINE IMMUNOL, V16, P233, DOI 10.1128/CVI.00066-08
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Xing JF, 2009, INT J NANOMED, V4, P227
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhang LF, 2007, CHEMMEDCHEM, V2, P1268, DOI 10.1002/cmdc.200700121
NR 154
TC 77
Z9 77
U1 2
U2 35
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD FEB
PY 2010
VL 5
IS 2
BP 269
EP 285
DI 10.2217/NNM.10.1
PG 17
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 561UY
UT WOS:000275006300015
PM 20148638
OA green_accepted
DA 2018-01-05
ER

PT J
AU Toropov, AA
   Toropova, AP
   Benfenati, E
   Leszczynska, D
   Leszczynski, J
AF Toropov, Andrey A.
   Toropova, Alla P.
   Benfenati, Emilio
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI SMILES-Based Optimal Descriptors: QSAR Analysis of Fullerene-Based HIV-1
   PR Inhibitors by Means of Balance of Correlations
SO JOURNAL OF COMPUTATIONAL CHEMISTRY
LA English
DT Article
DE Fullrene; QSAR; HIV-1 PR; SMILES; optimal descriptor; correlation
   balance
ID MOLECULAR-DYNAMICS; ORGANIC-SOLVENTS; 3D QSAR; QSPR; SOLUBILITY;
   NANOMATERIALS; PREDICTION; TOXICITY; DOCKING; MODELS
AB Quantitative structure-activity relationships (QSAR) for prediction of binding affinities (pEC50. i.e., minus decimal logarithm of the 50% effective concentration) of 20 fullerene derivatives inhibitors of the HIV-1 PR (human immunodeficiency virus type 1 protease) have been developed by application of the optimal descriptors approach calculated with SMILES (simplified molecular input line entry system). The applied models were constructed by the balance of correlations. Three various splits of the experimental data into subtraining set, calibration set, and test set were examined. Comparison of classic scheme (training-test system) and the balance of correlations (subtraining-calibration-text system) show that the balance of correlations gives more robust predictions than the classic scheme for the pEC50 of the fullerene derivatives. (C) 2009 Wiley periodicals, Inc. J Comput Chem 31: 381-391, 2010
C1 [Toropov, Andrey A.; Toropova, Alla P.] Inst Geol & Geophys, Lab Physicochem Methods Anal, Tashkent 100041, Uzbekistan.
   [Toropov, Andrey A.; Toropova, Alla P.; Benfenati, Emilio] Ist Ric Farmacol Mario Negri, Lab Environm Chem & Toxicol, I-20156 Milan, Italy.
   [Leszczynska, Danuta; Leszczynski, Jerzy] Jackson State Univ, Dept Chem, Nanotox Ctr, Jackson, MS 39217 USA.
RP Toropov, AA (reprint author), Inst Geol & Geophys, Lab Physicochem Methods Anal, Khodzhibaev St 49, Tashkent 100041, Uzbekistan.
EM aatoropov@yahoo.com
OI Toropova, Alla/0000-0002-4194-9963; Toropov, Andrey/0000-0001-6864-6340
FU Marie Curie Fellowship (CHEMPREDICT) [39036]; NSF-CREST [HRD-0833178]
FX Contract/grant sponsor: NSF-CREST: contract/grant number: HRD-0833178
CR *ADV CHEM DEV INC, 2007, ACD CHEMSKETCH FREEW, P74506
   Afantitis A, 2006, QSAR COMB SCI, V25, P928, DOI 10.1002/qsar.200530208
   Afantitis A, 2006, POLYMER, V47, P3240, DOI 10.1016/j.polymer.2006.02.060
   Castillo-Garit JA, 2008, CHEM PHYS LETT, V464, P107, DOI 10.1016/j.cplett.2008.08.094
   Doweyko AM, 2008, J COMPUT AID MOL DES, V22, P81, DOI 10.1007/s10822-007-9162-7
   Duchowicz PR, 2008, BIOORGAN MED CHEM, V16, P7944, DOI 10.1016/j.bmc.2008.07.067
   Duchowicz PR, 2008, J MATH CHEM, V44, P541, DOI 10.1007/s10910-007-9327-6
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Johnson SR, 2008, J CHEM INF MODEL, V48, P25, DOI 10.1021/ci700332k
   Puzyn T, 2008, ATMOS ENVIRON, V42, P6627, DOI 10.1016/j.atmosenv.2008.04.048
   Ray S, 2008, CENT EUR J CHEM, V6, P267, DOI 10.2478/s11532-008-0014-7
   ROY K, 2009, CHEM BIOL DRUG DES, V72, P383
   Roy PP, 2008, QSAR COMB SCI, V27, P302, DOI 10.1002/qsar.200710043
   Toropov AA, 2005, CROAT CHEM ACTA, V78, P503
   Toropov AA, 2005, INDIAN J CHEM A, V44, P1545
   Toropov AA, 2008, BIOORGAN MED CHEM, V16, P5999, DOI 10.1016/j.bmc.2008.04.055
   Toropov AA, 2008, CHEM PHYS LETT, V457, P332, DOI 10.1016/j.cplett.2008.04.013
   Toropov AA, 2007, MATER LETT, V61, P4777, DOI 10.1016/j.matlet.2007.03.026
   Toropov AA, 2007, CHEM PHYS LETT, V441, P119, DOI 10.1016/j.cplett.2007.04.094
   Toropov AA, 2007, COMPUT BIOL CHEM, V31, P127, DOI 10.1016/j.compbiolchem.2007.02.002
   Toropov AA, 2006, CHEM PHYS LETT, V433, P125, DOI 10.1016/j.cplett.2006.11.010
   Vidal D, 2005, J CHEM INF MODEL, V45, P386, DOI 10.1021/ci0496797
   WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005
   WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005                                                             
NR 27
TC 40
Z9 40
U1 1
U2 19
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0192-8651
J9 J COMPUT CHEM
JI J. Comput. Chem.
PD JAN 30
PY 2010
VL 31
IS 2
BP 381
EP 392
DI 10.1002/jcc.21333
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA 541KE
UT WOS:000273412900013
PM 19479738
DA 2018-01-05
ER

PT J
AU Chen, GD
   Alberts, CJ
   Rodriguez, W
   Toner, M
AF Chen, Grace D.
   Alberts, Catharina J.
   Rodriguez, William
   Toner, Mehmet
TI Concentration and Purification of Human Immunodeficiency Virus Type 1
   Virions by Microfluidic Separation of Superparamagnetic Nanoparticles
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; HIV-1 VIRAL LOAD; MAGNETIC NANOPARTICLES;
   CELL-SEPARATION; ON-CHIP; SAMPLES; CAPTURE; SYSTEMS; MIXER;
   MICROCHANNELS
AB The low concentration and complex sample matrix of many clinical and environmental viral samples presents a significant challenge in the development of low cost, point-of-care viral assays. To address this problem, we investigated the use of a microfluidic passive magnetic separator combined with on-chip mixer to both purify and concentrate whole-particle human immunodeficiency virus type 1 (HIV-1) virions. Virus-containing plasma samples are first mixed to allow specific binding of the viral particles with antibody-conjugated superparamagnetic nanoparticles, and several passive mixer geometries were assessed for their mixing efficiencies. The virus-nanoparticle complexes are then separated from the plasma in a novel magnetic separation chamber, where packed micrometer-sized ferromagnetic particles serve as high magnetic gradient concentrators for an externally applied magnetic field. Thereafter, a viral lysis buffer was flowed through the chip and the released HIV proteins were assayed off-chip. Viral protein extraction efficiencies of 62% and 45% were achieved at 10 and 30 mu L/min throughputs, respectively. More importantly, an 80-fold concentration was observed for an initial sample volume of 1 mL and a 44-fold concentration for an initial sample volume of 0.5 mL. The system is broadly applicable to microscale sample preparation of any viral sample and can be used for nucleic acid extraction as well as 40-80-fold enrichment of target viruses.
C1 [Chen, Grace D.; Alberts, Catharina J.; Toner, Mehmet] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Charlestown, MA 02129 USA.
   [Rodriguez, William] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.
RP Rodriguez, W (reprint author), Daktari Diagnost Inc, Arlington, MA 02476 USA.
EM wrodriguez@daktaridx.com; mtoner@hms.harvard.edu
FU Center for Integration of Medicine and Innovative Technology [09-441];
   National Institute of Biomedical Imaging and Bioengineering [P41
   EB002503]
FX We thank Mr. Octavio Hurtado for technical support with microfabrication
   procedures and Ms. Alicja Trocha for assistance with the biosafety of
   HIV handling. We thank Partners AIDS Research Center for provision of
   HIV samples and use of tissue Culture facilities. This work was
   supported by the Center for Integration of Medicine and Innovative
   Technology under Grant 09-441 and the National Institute of Biomedical
   Imaging and Bioengineering under Grant P41 EB002503 (BioMEMS Resource
   Center).
CR Al-Raoush R, 2007, POWDER TECHNOL, V176, P47, DOI 10.1016/j.powtec.2007.02.007
   Auroux PA, 2004, LAB CHIP, V4, P534, DOI 10.1039/b408850f
   Bentzen E, 2006, FUTURE VIROL, V1, P769, DOI 10.2217/17460794.1.6.769
   Blumel J, 2005, TRANSFUS MED HEMOTH, V32, P196, DOI 10.1159/000087620
   Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073
   Cheng XH, 2009, ANAL BIOANAL CHEM, V393, P487, DOI 10.1007/s00216-008-2514-x
   Choi JW, 2000, SENSOR ACTUAT B-CHEM, V68, P34, DOI 10.1016/S0925-4005(00)00458-5
   Deng T, 2002, APPL PHYS LETT, V80, P461, DOI 10.1063/1.1436282
   Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Gijs MAM, 2004, MICROFLUID NANOFLUID, V1, P22, DOI 10.1007/s10404-004-0010-y
   HAUKANES BI, 1993, BIO-TECHNOL, V11, P60, DOI 10.1038/nbt0193-60                                                              
   Hong CC, 2004, LAB CHIP, V4, P109, DOI 10.1039/b305892a
   Inglis DW, 2004, APPL PHYS LETT, V85, P5093, DOI 10.1063/1.1823015
   Jen CP, 2003, LAB CHIP, V3, P77, DOI 10.1039/b211091a
   Jothikumar N, 1998, APPL ENVIRON MICROB, V64, P504
   Lien KY, 2007, LAB CHIP, V7, P868, DOI 10.1039/b700516d
   Liu YJ, 2002, ANAL CHEM, V74, P3063, DOI 10.1021/ac020094q
   Mansur EA, 2008, CHINESE J CHEM ENG, V16, P503, DOI 10.1016/S1004-9541(08)60114-7                                                   
   McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q
   MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203
   Munson MS, 2004, ANAL CHIM ACTA, V507, P63, DOI 10.1016/j.aca.2003.11.064
   Myrmel M, 2000, INT J FOOD MICROBIOL, V62, P17, DOI 10.1016/S0168-1605(00)00262-2
   Nguyen NT, 2005, J MICROMECH MICROENG, V15, pR1, DOI 10.1088/0960-1317/15/2/R01
   Pamme N, 2006, LAB CHIP, V6, P24, DOI 10.1039/b513005k
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Perez JM, 2003, J AM CHEM SOC, V125, P10192, DOI 10.1021/ja036409g
   Ramadan Q, 2006, BIOMED MICRODEVICES, V8, P151, DOI 10.1007/s10544-006-7710-x
   Rouet F, 2007, CLIN LAB, V53, P135
   Safarik I, 1999, J CHROMATOGR B, V722, P33, DOI 10.1016/S0378-4347(98)00338-7                                                   
   Smistrup K, 2005, J MAGN MAGN MATER, V293, P597, DOI 10.1016/j.jmmm.2005.01.079
   Smistrup K, 2005, LAB CHIP, V5, P1315, DOI 10.1039/b510995g
   Soelberg SD, 2009, ANAL CHEM, V81, P2357, DOI 10.1021/ac900007c
   Stroock AD, 2002, SCIENCE, V295, P647, DOI 10.1126/science.1066238                                                         
   Varshney M, 2007, BIOSENS BIOELECTRON, V22, P2408, DOI 10.1016/j.bios.2006.08.030
   Veyret R, 2005, ANAL BIOCHEM, V346, P59, DOI 10.1016/j.ab.2005.07.036
   *WHO, 2008, GLOB SUMM AIDS EP 20
   Xia HM, 2005, LAB CHIP, V5, P748, DOI 10.1039/b502031j
   Xia N, 2006, BIOMED MICRODEVICES, V8, P299, DOI 10.1007/s10544-006-0033-0
NR 39
TC 58
Z9 60
U1 4
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD JAN 15
PY 2010
VL 82
IS 2
BP 723
EP 728
DI 10.1021/ac9024522
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 542HR
UT WOS:000273484200039
PM 19954210
OA green_accepted
DA 2018-01-05
ER

PT J
AU Olsen, GL
   Bardaro, MF
   Echodu, DC
   Drobny, GP
   Varani, G
AF Olsen, Greg L.
   Bardaro, Michael F., Jr.
   Echodu, Dorothy C.
   Drobny, Gary P.
   Varani, Gabriele
TI Intermediate Rate Atomic Trajectories of RNA by Solid-State NMR
   Spectroscopy
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID NUCLEAR-MAGNETIC-RESONANCE; P-31-F-19 REDOR NMR; TAR RNA; LINE-SHAPES;
   DYNAMICS; RECOGNITION; PROTEIN; RELAXATION; BINDING; SITE
AB Many RNAs undergo large conformational changes in response to the binding of proteins and small molecules. However, when RNA functional dynamics occur in the nanosecond-microsecond time scale, they become invisible to traditional solution NMR relaxation methods. Residual dipolar coupling methods have revealed the presence of extensive nanosecond-microsecond domain motions in HIV-1 TAR RNA, but this technique lacks information on the rates of motions. We have used solid-state deuterium NMR to quantitatively describe trajectories of key residues in TAR by exploiting the sensitivity of this technique to motions that occur in the nanosecond-microsecond regime. Deuterium line shape and relaxation data were used to model motions of residues within the TAR binding interface. The resulting motional models indicate two functionally essential bases within the single-stranded bulge sample both the free and Tat-bound conformations on the microsecond time scale in the complete absence of the protein. Thus, our results strongly support a conformational capture mechanism for recognition: the protein does not induce a new RNA structure, but instead captures an already-populated conformation.
C1 [Olsen, Greg L.; Bardaro, Michael F., Jr.; Echodu, Dorothy C.; Drobny, Gary P.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Varani, Gabriele] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
RP Drobny, GP (reprint author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.
EM drobny@chem.washington.edu; varani@chem.washington.edu
RI Olsen, Greg/B-7525-2008
OI Olsen, Greg/0000-0001-6039-8434
FU NSF [MCB-0642253]; NIH [RO1-EB03152]
FX This work was supported by grants from the NSF (MCB-0642253) and NIH
   (RO1-EB03152) to G.P.D. and G.V. We arc grateful to Dr. Zahra Shajam for
   many stimulating discussions and to members of the Varani research group
   for reading the manuscript.
CR Aboul-ela F, 1998, THEOCHEM-J MOL STRUC, V423, P29, DOI 10.1016/S0166-1280(96)04995-0                                                   
   AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   ALAM TM, 1991, CHEM REV, V91, P1545, DOI 10.1021/cr00007a014                                                             
   Bardaro MF, 2009, NUCLEIC ACIDS RES, V37, P1529, DOI 10.1093/nar/gkn1074
   Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258
   CRUSE WBT, 1986, J MOL BIOL, V192, P891, DOI 10.1016/0022-2836(86)90035-5                                                    
   DAVIS JH, 1979, BIOPHYS J, V27, P339, DOI 10.1016/S0006-3495(79)85222-4                                                   
   FALK M, 1962, J AM CHEM SOC, V84, P3843, DOI 10.1021/ja00879a012                                                             
   GREENFIELD MS, 1987, J MAGN RESON, V72, P89, DOI 10.1016/0022-2364(87)90177-6                                                    
   HANSEN AL, 2007, J AM CHEM SOC, P1
   Henzler-Wildman KA, 2007, NATURE, V450, P913, DOI 10.1038/nature06407
   HOATSON GL, 1991, J MAGN RESON, V94, P152, DOI 10.1016/0022-2364(91)90302-A                                                    
   Huang XN, 1997, NUCLEIC ACIDS RES, V25, P4758, DOI 10.1093/nar/25.23.4758                                                          
   KAM J, 1999, J MOL BIOL, V293, P235
   Korzhnev DM, 2004, NATURE, V430, P586, DOI 10.1038/nature02655
   Lange OF, 2008, SCIENCE, V320, P1471, DOI 10.1126/science.1157092
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   Lorieau JL, 2006, J AM CHEM SOC, V128, P11505, DOI 10.1021/ja062443u
   Merritt ME, 1999, J AM CHEM SOC, V121, P6070, DOI 10.1021/ja984173o                                                               
   Olsen GL, 2005, NUCLEIC ACIDS RES, V33, P3447, DOI 10.1093/nar/gki626
   Olsen GL, 2008, J AM CHEM SOC, V130, P2896, DOI 10.1021/ja0778803
   Olsen GL, 2009, J BIOMOL NMR, V45, P133, DOI 10.1007/s10858-009-9355-6
   Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1                                                   
   Palmer AG, 1996, J PHYS CHEM-US, V100, P13293, DOI 10.1021/jp9606117                                                               
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Schurr JM, 1999, J MAGN RESON, V140, P404, DOI 10.1006/jmre.1999.1858
   SPIESS HW, 1978, NMR BASIC PRINCIPLES, V15, P59
   Sprangers R, 2007, NATURE, V445, P618, DOI 10.1038/nature05512
   TORCHIA DA, 1982, J MAGN RESON, V49, P107, DOI 10.1016/0022-2364(82)90301-8                                                    
   Vold RL, 2009, J MAGN RESON, V198, P57, DOI 10.1016/j.jmr.2009.01.008
   Vold R. L., 1991, ADV MAGN OPT RESON, P85
   WANG AC, 1994, J MAGN RESON SER B, V105, P1, DOI 10.1006/jmrb.1994.1092                                                          
   WEAST RC, 1979, CRC HDB CHEM PHYSICS, pE46
   WIMPERIS S, 1986, CHEM PHYS LETT, V132, P194, DOI 10.1016/0009-2614(86)80106-3
   WITTEBORT RJ, 1987, J CHEM PHYS, V86, P5411, DOI 10.1063/1.452565                                                                
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
NR 40
TC 26
Z9 26
U1 2
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JAN 13
PY 2010
VL 132
IS 1
BP 303
EP 308
DI 10.1021/ja907515s
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 562VW
UT WOS:000275084400065
PM 19994901
OA green_accepted
DA 2018-01-05
ER

PT J
AU Lehto, T
   Abes, R
   Oskolkov, N
   Suhorutsenko, J
   Copolovici, DM
   Mager, I
   Viola, JR
   Simonson, OE
   Ezzat, K
   Guterstam, P
   Eriste, E
   Smith, CIE
   Lebleu, B
   El Andaloussi, S
   Langel, U
AF Lehto, Taavi
   Abes, Rachida
   Oskolkov, Nikita
   Suhorutsenko, Julia
   Copolovici, Dana-Maria
   Mager, Imre
   Viola, Joana R.
   Simonson, Oscar E.
   Ezzat, Kariem
   Guterstam, Peter
   Eriste, Elo
   Smith, C. I. Edvard
   Lebleu, Bernard
   El Andaloussi, Samir
   Langel, Ulo
TI Delivery of nucleic acids with a stearylated (RxR)(4) peptide using a
   non-covalent co-incubation strategy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Cell-penetrating peptide; Gene delivery; Oligonucleotide delivery;
   Splice correction; Stearylation
ID CELL-PENETRATING PEPTIDES; HIV-1 TAT PROTEIN; ARGININE-RICH PEPTIDES;
   GENE DELIVERY; ANTISENSE OLIGONUCLEOTIDES; NANO DEVICE; INTERNALIZATION
   MECHANISMS; MORPHOLINO OLIGOMERS; TRANSDUCTION DOMAIN; DRUG-DELIVERY
AB In recent years, oligonucleotide-based molecules have been intensely used to modulate gene expression. All these molecules share the common feature of being essentially impermeable over cellular membranes and they therefore require efficient delivery vectors. Cell-penetrating peptides are a group of delivery peptides that has been readily used for nucleic acid delivery. In particular, polyarginine and derivates thereof, i.e. the (RxR)(4) peptide, have been applied with success both in vitro and in vivo. A major problem, however, with these arginine-rich peptides is that they frequently remain trapped in endosomal compartments following internalization. The activity of polyarginine has previously been improved by conjugation to a stearyl moiety. Therefore, we sought to investigate what impact such modification would have on the pre-clinically used (RxR)4 peptide for non-covalent delivery of plasmids and splice-correcting oligonucleotides (SCOs) and compare it with stearylated Arg9 and Lipofectamine (TM) 2000.
   We show that stearyl-(RxR)(4) mediates efficient plasmid transfections in several cell lines and the expression levels are significantly higher than when using unmodified (RxR)4 or stearylated Arg9. Although the transfection efficiency is lower than with Lipofectamine (TM) 2000, we show that stearyl-(RxR)4 is substantially less toxic. Furthermore, using a functional splice-correction assay, we show that stearyl-(RxR)4 complexed with 2'-OMe SCOs promotes significant splice correction whereas stearyl-Arg9 fails to do so. Moreover, stearyl(RxR)4 promotes dose-dependent splice correction in parity with (RxR)(4)-PMO covalent conjugates, but at least 10-times lower concentration. These features make this stearic acid modified analog of (RxR)4 an intriguing vector for future in vivo experiments. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Lehto, Taavi; Oskolkov, Nikita; Suhorutsenko, Julia; Copolovici, Dana-Maria; Mager, Imre; Eriste, Elo; El Andaloussi, Samir; Langel, Ulo] Univ Tartu, Inst Technol, Mol Biotechnol Lab, EE-50411 Tartu, Estonia.
   [Abes, Rachida; Lebleu, Bernard] Univ Montpellier 2, CNRS, UMR 5235, F-34095 Montpellier 5, France.
   [Lehto, Taavi; Mager, Imre; Ezzat, Kariem; Guterstam, Peter; El Andaloussi, Samir; Langel, Ulo] Stockholm Univ, Arrhenius Labs Nat Sci, Dept Neurochem, SE-10691 Stockholm, Sweden.
   [Viola, Joana R.; Simonson, Oscar E.; Smith, C. I. Edvard] Karolinska Univ, Huddinge Hosp, SE-14186 Huddinge, Sweden.
RP Lehto, T (reprint author), Univ Tartu, Inst Technol, Mol Biotechnol Lab, Nooruse 1, EE-50411 Tartu, Estonia.
EM tlehto@ut.ee
RI Copolovici, Dana/C-5207-2012; Ezzat, Kariem/D-1436-2015; Lehto,
   Taavi/B-7798-2010
OI Copolovici, Dana/0000-0002-1491-0473; Mager, Imre/0000-0003-2242-7227;
   Smith, C. I. Edvard/0000-0003-1907-3392; Ezzat Ahmed,
   Kariem/0000-0003-4186-0675
FU Swedish Research Council; Center for Biomembrane Research, Stockholm;
   Knut and Alice Wallenberg's Foundation; Estonian Government
   [SF0180027s08]; European Social Fund; Archimedes Foundation; Association
   Francaise contre les Myopathies; Ligue Regionale Fran aise contre le
   cancer; European Union [FP6-2005-037283]
FX The work presented in this article was supported by the Swedish Research
   Council (VR-NT); by the Center for Biomembrane Research, Stockholm; by
   the Knut and Alice Wallenberg's Foundation; by the EU through the
   European Regional Development Fund through the Center of Excellence in
   Chemical Biology, Estonia; by the targeted financing SF0180027s08 from
   the Estonian Government; by the DoRa Program of The European Social
   Fund; and by the Archimedes Foundation. Work in the group of B. Lebleu
   was supported by the Association Francaise contre les Myopathies and the
   Ligue Regionale Fran aise contre le cancer. Work in the group of CIE
   Smith was supported by the Swedish Research Council, KI Faculty funds
   for funding of postgraduate students, and the European Union FP6 grant
   EuroPharmacoGene (FP6-2005-037283).
CR Abes R, 2008, NUCLEIC ACIDS RES, V36, P6343, DOI 10.1093/nar/gkn541
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Fernandez-Carneado J, 2005, J PEPT RES, V65, P580, DOI 10.1111/j.1399-3011.2005.00253.x
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Fujita T, 2008, J CONTROL RELEASE, V129, P124, DOI 10.1016/j.jconrel.2008.04.010
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   GADI J, 2008, MOL BIOTECHNOL, V42, P41
   Guo XD, 2008, BIOMATERIALS, V29, P4838, DOI 10.1016/j.biomaterials.2008.07.053
   Guterstam P, 2008, BIOCHEM J, V412, P307, DOI 10.1042/BJ20080013
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Ivanova GD, 2008, NUCLEIC ACIDS RES, V36, P6418, DOI 10.1093/nar/gkn671
   Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kogure K, 2008, ADV DRUG DELIVER REV, V60, P559, DOI 10.1016/j.addr.2007.10.007
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5
   Moriguchi R, 2005, INT J PHARM, V301, P277, DOI 10.1016/j.ijpharm.2005.05.021
   Moulton HM, 2007, BIOCHEM SOC T, V35, P826, DOI 10.1042/BST0350826                                                              
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nelson AR, 2007, BIOCHEMISTRY-US, V46, P14771, DOI 10.1021/bi701295k
   Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Yin H, 2008, HUM MOL GENET, V17, P3909, DOI 10.1093/hmg/ddn293
NR 45
TC 87
Z9 88
U1 0
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 4
PY 2010
VL 141
IS 1
BP 42
EP 51
DI 10.1016/j.jconrel.2009.08.028
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 550CF
UT WOS:000274104200007
PM 19744531
DA 2018-01-05
ER

PT S
AU Fachin, F
   Wardle, BL
   Chen, GD
   Toner, M
AF Fachin, F.
   Wardle, B. L.
   Chen, G. D.
   Toner, M.
GP IEEE
TI Integration of Vertically-Aligned Carbon Nanotube Forests in
   Microfluidic Devices for Multiscale Isolation of Bioparticles
SO 2010 IEEE SENSORS
SE IEEE Sensors
LA English
DT Proceedings Paper
CT 2010 IEEE Sensors Conference
CY NOV 01-04, 2010
CL Kona, HI
SP IEEE
ID DRUG-DELIVERY; TRANSPORTERS
AB Presently, an estimated 35 million people are living with HIV, 300 million with Hepatitis C (HCV), with thousands of human fatalities registered ever day due to these and similar infectious diseases. Efficient, reliable, inexpensive medical solutions are therefore needed to tackle these issues. Identification of HIV and HCV is however not easy. Being significantly smaller than cells and bacteria, these viruses escape the isolation capabilities of both macroscopic and microscopic (MEMS) medical instrumentation. Allowing access to sub-micron species such as viruses and cancer cells, integration of nanotechnologies in medical devices has the potential to revolutionize the field of biomedicine. In this work, we explore the potential of nanoporous, patterned forests of vertically-aligned carbon nanotubes (VACNTs) for bioparticle isolation, demonstrating their ability to access particles over several orders of magnitude in size, from viruses (similar to 40nm) to cells (similar to 10 mu m). Modifying the flow field inside microfluidic channels, CNT-enhanced biodevices result in a seven-fold increase in capture efficiency compared to a nonporous design, as well as the ability to simultaneously isolate multiple distinct biospecies both inside and on the outer surface of the VACNT features. Our technology represents a versatile, highly efficient approach to biological isolation, with applications ranging from point-of-care diagnostics to subsequent therapeutic modalities in both infectious diseases as well as cancer applications.
C1 [Fachin, F.; Wardle, B. L.] MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA.
   [Chen, G. D.; Toner, M.] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Charlestown, MA 02129 USA.
RP Fachin, F (reprint author), MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA.
EM ffachin@mit.edu; wardle@mit.edu; gracec@mit.edu;
   mehmet_toner@hms.harvard.edu
CR Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Liu Z, 2008, CANCER RES, V68, P6652, DOI 10.1158/0008-5472.CAN-08-1468
   Liu Z, 2009, NANO RES, V2, P85, DOI 10.1007/s12274-009-9009-8
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Wang W., 2006, BIOMEMS TECHNOLOGIES
   Wardle BL, 2008, ADV MATER, V20, P2707, DOI 10.1002/adma.200800295
NR 8
TC 4
Z9 4
U1 1
U2 13
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1930-0395
BN 978-1-4244-8168-2
J9 IEEE SENSOR
PY 2010
BP 47
EP 51
DI 10.1109/ICSENS.2010.5690852
PG 5
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA BTS59
UT WOS:000287982100010
DA 2018-01-05
ER

PT J
AU Hu, J
   Zheng, PC
   Jiang, JH
   Shen, GL
   Yu, RQ
   Liu, GK
AF Hu, Juan
   Zheng, Peng-Cheng
   Jiang, Jian-Hui
   Shen, Guo-Li
   Yu, Ru-Qin
   Liu, Guo-Kun
TI Sub-attomolar HIV-1 DNA detection using surface-enhanced Raman
   spectroscopy
SO ANALYST
LA English
DT Article
ID COATED MAGNETIC NANOPARTICLES; SCATTERING SUBSTRATE; SEPARATION TOOLS;
   PROBES; SERS; IMMUNOASSAY; MOLECULES; FILMS; FLUORESCENCE; MONOLAYERS
AB A subattomolar HIV-1 DNA detection assay based on multilayer metal-molecule-metal nanojunctions (NJs) has been developed using surface-enhanced Raman spectroscopy (SERS). There is a two-step mechanism involved. First, label free target DNA facilitated the precipitation of Detection Unit I on the substrate through forming a sandwiched structure based on the capture probe, resulting in the first level amplification of target. Following that, the binding site on Detection probe I was further recognized by Detection Unit II. These two complementary probes acted as bricks to build up the multi-metal-molecule-metal NJs between Au nanoparticles (NPs) that not only created SERS "hot spots'' by the conjugated Au NPs, but also obviously decreased the distance between Au NPs and Raman labels. Therefore, the Raman signal of the tag molecules on these detection probes was significantly enhanced due to the distance dependent electromagnetic enhancement (EM) of SERS. With regards to a HIV-1 DNA sequence, the platform could detect a concentration as low as 10(-19) M (similar to 10(-23) mol) with the ability of single base mismatch discrimination.
C1 [Hu, Juan; Zheng, Peng-Cheng; Jiang, Jian-Hui; Shen, Guo-Li; Yu, Ru-Qin; Liu, Guo-Kun] Hunan Univ, State Key Lab Chem Biosensing & Chemometr, Coll Chem & Chem Engn, Changsha 410082, Hunan, Peoples R China.
   [Hu, Juan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed Engn & Hlth Technol, Shenzhen 518055, Peoples R China.
RP Yu, RQ (reprint author), Hunan Univ, State Key Lab Chem Biosensing & Chemometr, Coll Chem & Chem Engn, Changsha 410082, Hunan, Peoples R China.
EM rqyu@hnu.cn; guokunliu@163.com
RI Jiang, Jian-Hui/K-2054-2012
FU NSFC [20775023, 20675028]; 973 National Basic Research Program of China
   [2007CB310500]; National Science Foundation for Post-doctoral Scientists
   of China [20070410981]
FX Thanks for the financial supports from the NSFC (No. 20775023,
   20675028), 973 National Basic Research Program of China (2007CB310500),
   and the National Science Foundation for Post-doctoral Scientists of
   China (No. 20070410981).
CR ARAVIND PK, 1983, SURF SCI, V124, P506, DOI 10.1016/0039-6028(83)90806-3
   ARAVIND PK, 1982, J PHYS CHEM-US, V86, P5076, DOI 10.1021/j100223a007                                                             
   Baker GA, 2005, ANAL BIOANAL CHEM, V382, P1751, DOI 10.1007/s00216-005-3353-7
   Bell SEJ, 2006, J AM CHEM SOC, V128, P15580, DOI 10.1021/ja066263w
   BLOOMFIEDL VA, 2000, NUCL ACIDS STRUCTURE
   Bonham AJ, 2007, J AM CHEM SOC, V129, P14572, DOI 10.1021/ja0767837
   Braun G, 2007, J AM CHEM SOC, V129, P6378, DOI 10.1021/ja070514z
   Cao YC, 2003, J AM CHEM SOC, V125, P14676, DOI 10.1021/ja0366235
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chang R. K., 1982, SURFACE ENHANCED RAM
   Culha M, 2003, ANAL CHEM, V75, P6196, DOI 10.1021/ac0346003
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Devare SG, 2007, J MED VIROL, V79, pS11, DOI 10.1002/jmv.20967
   Doering WE, 2003, ANAL CHEM, V75, P6171, DOI 10.1021/ac034672u
   Driskell JD, 2005, ANAL CHEM, V77, P6147, DOI 10.1021/ac0504159
   Erts D, 2003, J PHYS CHEM B, V107, P3591, DOI 10.1021/jp0261657
   Fabris L, 2007, J AM CHEM SOC, V129, P6086, DOI 10.1021/ja0705184
   Faulds K, 2004, ANAL CHEM, V76, P412, DOI 10.1021/ac035060c
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Gong JL, 2007, BIOSENS BIOELECTRON, V22, P1501, DOI 10.1016/j.bios.2006.07.004
   Graham D, 2008, NAT NANOTECHNOL, V3, P548, DOI 10.1038/nnano.2008.189
   Grubisha DS, 2003, ANAL CHEM, V75, P5936, DOI 10.1021/ac034356f
   Hamatake M, 2007, J VIROL METHODS, V142, P113, DOI 10.1016/j.jviromet.2007.01.012
   Han XX, 2009, ANAL CHEM, V81, P3350, DOI 10.1021/ac802553a
   Hu J, 2009, ANAL CHEM, V81, P87, DOI 10.1021/ac801431m
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Kennedy BJ, 1999, J PHYS CHEM B, V103, P3640, DOI 10.1021/jp984454i                                                               
   Kim JH, 2006, ANAL CHEM, V78, P6967, DOI 10.1021/ac0607663
   Kneipp J, 2005, ANAL CHEM, V77, P2381, DOI 10.1021/ac050109v
   Lacy WB, 1996, ANAL CHEM, V68, P1003, DOI 10.1021/ac950860b                                                               
   Liang Y, 2007, TALANTA, V72, P443, DOI 10.1016/j.talanta.2006.11.002
   Lombardi JR, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2748386
   Lu Y, 2005, NANO LETT, V5, P5, DOI 10.1021/nl048965u
   Michaels AM, 1999, J AM CHEM SOC, V121, P9932, DOI 10.1021/ja992128q                                                               
   MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783
   Mulvaney P, 1996, LANGMUIR, V12, P788, DOI 10.1021/la9502711                                                               
   Mulvaney SP, 2003, LANGMUIR, V19, P4784, DOI 10.1021/la026706j
   NABIEV IR, 1991, EUR BIOPHYS J, V19, P311
   Ni J, 1999, ANAL CHEM, V71, P4903, DOI 10.1021/ac990616a                                                               
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   Otto A, 2005, J RAMAN SPECTROSC, V36, P497, DOI 10.1002/jrs.1355
   OTTO A, 1992, J PHYS-CONDENS MAT, V4, P1143, DOI 10.1088/0953-8984/4/5/001
   Pai NP, 2007, EXPERT REV MOL DIAGN, V7, P325, DOI 10.1586/14737159.7.4.325
   Ruan CM, 2006, ANAL CHEM, V78, P3379, DOI 10.1021/ac0522106
   Sabatte G, 2008, ANAL CHEM, V80, P2351, DOI 10.1021/ac071343j
   Shafer-Peltier KE, 2003, J AM CHEM SOC, V125, P588, DOI 10.1021/ja028255v
   Smith E, 2005, MODERN RAMAN SPECTROSCOPY: A PRACTICAL APPROACH, P1
   Spiro T. G., 1987, BIOL APPL RAMAN SPEC
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Stosch R, 2005, ANAL CHEM, V77, P7386, DOI 10.1021/ac0511647
   Sun L, 2008, ANAL CHEM, V80, P3342, DOI 10.1021/ac702542n
   Tian ZQ, 2002, J PHYS CHEM B, V106, P9463, DOI 10.1021/jp0257449
   Vo-Dinh T, 2002, J RAMAN SPECTROSC, V33, P511, DOI 10.1002/jrs.883
   Wabuyele MB, 2005, ANAL CHEM, V77, P7810, DOI 10.1021/ac0514671
   Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357                                                     
   Yang L, 2008, ANAL CHEM, V80, P6222, DOI 10.1021/ac800556f
   Zou SL, 2006, TOP APPL PHYS, V103, P67
NR 57
TC 51
Z9 52
U1 5
U2 53
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
J9 ANALYST
JI Analyst
PY 2010
VL 135
IS 5
BP 1084
EP 1089
DI 10.1039/b920358c
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 588AG
UT WOS:000277037500034
PM 20419260
DA 2018-01-05
ER

PT J
AU Mahmoud, KA
   Luong, JHT
AF Mahmoud, Khaled A.
   Luong, John H. T.
TI A SENSITIVE ELECTROCHEMICAL ASSAY FOR EARLY DETECTION OF HIV-1 PROTEASE
   USING FERROCENE-PEPTIDE CONJUGATE/AU NANOPARTICLE/SINGLE WALLED CARBON
   NANOTUBE MODIFIED ELECTRODE
SO ANALYTICAL LETTERS
LA English
DT Article
DE Electrochemistry; Ferrocene; Gold nanoparticle; HIV-1; Pepstatin;
   Protease; Single-walled carbon nanotube
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BIOSENSORS; VIROLOGY
AB A rapid and simple electrochemical detection method has been developed to detect the presence of protease (HIV-1 PR) in HIV patients' sera. In this assay format, disposable screen printed gold electrode (SPGE) surface was modified with gold nanoparticles (AuNPs) or thiolated single-walled carbon nanotubes/gold nanoparticles (SWCNT/AuNPs). Thiol-terminated ferrocene (Fc)-pepstatin was then self-assembled on such modified surfaces. The interaction between the Fc-pepstatin modified substrates and HIV-1 PR was confirmed by scanning electron (SEM) and atomic force microscopy (AFM) and probed by differential pulse voltammetry (DPV). A linear relationship was observed between the shift in peak potential and the increasing number of HIV-1 viral replications in the HIV-infected serum samples.
C1 [Mahmoud, Khaled A.; Luong, John H. T.] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
RP Luong, JHT (reprint author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.
EM john.luong@nrc.ca
OI Mahmoud, Khaled/0000-0003-1246-4067; Luong, John/0000-0002-1709-1223
CR Amano Y, 2005, ANAL BIOANAL CHEM, V381, P156, DOI 10.1007/s00216-004-2927-0
   BELAK S, 1993, VET RES COMMUN, V17, P55, DOI 10.1007/BF01839180
   DOMINGUEZ EA, 1993, J CLIN MICROBIOL, V31, P2286
   ELFATH AMA, 2000, CLIN MICROBIOLOGY RE, V13, P559
   HJELLE B, 1989, ARCH PATHOL LAB MED, V113, P975
   Iqbal SS, 2000, BIOSENS BIOELECTRON, V15, P549, DOI 10.1016/S0956-5663(00)00108-1                                                   
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Lennette EH, 1999, LAB DIAGNOSIS VIRAL
   LOUIE LLM, 2000, CMAJ, V63, P301
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   Niesters HGM, 2004, CLIN MICROBIOL INFEC, V10, P5, DOI 10.1111/j.1469-0691.2004.00699.x                                                
   PAREKH BS, 2001, AIDS REV, V3, P183
   Pejcic B, 2006, ANALYST, V131, P1079, DOI 10.1039/b603402k
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   *WHO, EARL DET HIV INF
   Xu YM, 2001, TETRAHEDRON LETT, V42, P2601, DOI 10.1016/S0040-4039(01)00251-9                                                   
NR 19
TC 12
Z9 12
U1 1
U2 36
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PY 2010
VL 43
IS 10-11
BP 1680
EP 1687
DI 10.1080/00032711003653924
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 629LQ
UT WOS:000280200400010
DA 2018-01-05
ER

PT J
AU Huet, T
   Kerbarh, O
   Schols, D
   Clayette, P
   Gauchet, C
   Dubreucq, G
   Vincent, L
   Bompais, H
   Mazinghien, R
   Querolle, O
   Salvador, A
   Lemoine, J
   Lucidi, B
   Balzarini, J
   Petitou, M
AF Huet, Thierry
   Kerbarh, Olivier
   Schols, Dominique
   Clayette, Pascal
   Gauchet, Cecile
   Dubreucq, Guy
   Vincent, Loic
   Bompais, Heidi
   Mazinghien, Romain
   Querolle, Olivier
   Salvador, Arnaud
   Lemoine, Jerome
   Lucidi, Bruno
   Balzarini, Jan
   Petitou, Maurice
TI Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent
   Anti-Human Immunodeficiency Virus Type 1 Activity
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID FUSION INHIBITOR ENFUVIRTIDE; INJECTION SITE REACTIONS; III-BINDING
   PENTASACCHARIDE; DEFICIENCY SYNDROME AIDS; HIV ENTRY INHIBITORS; PLASMA
   PHARMACOKINETICS; HIV-1-INFECTED PATIENTS; ANTIVIRAL ACTIVITY; PEPTIDE
   INHIBITOR; MEMBRANE-FUSION
AB Enfuvirtide (also known as Fuzeon, T-20, or DP-178) is an antiretroviral fusion inhibitor which prevents human immunodeficiency virus type 1 (HIV-1) from entering host cells. This linear 36-mer synthetic peptide is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1-infected individuals and AIDS patients with multidrug-resistant HIV infections. Although enfuvirtide is an efficient anti-HIV-1 drug, its clinical use is limited by a short plasma half-life, i.e., approximately 2 h, which requires twice-daily subcutaneous injections, often resulting in skin sensitivity reaction side effects at the injection sites. Ultimately, 80% of patients stop enfuvirtide treatment within 6 months because of these side effects. We report on the development of long-lasting enfuvirtide conjugates by the use of the site-specific conjugation of enfuvirtide to an antithrombin-binding carrier pentasaccharide (CP) through polyethylene glycol (PEG) linkers of various lengths. These conjugates showed consistent and broad anti-HIV-1 activity in the nanomolar range. The coupling of the CP to enfuvirtide only moderately affected the in vitro anti-HIV-1 activity in the presence of antithrombin. Most importantly, one of these conjugates, enfuvirtide-PEG12-CP (EP40111), exhibited a prolonged elimination half-life of more than 10 h in rat plasma compared to the half-life of native enfuvirtide, which was 2.8 h. On the basis of the pharmacokinetic properties of antithrombin-binding pentasaccharides, the anticipated half-life of EP40111 in humans would putatively be about 120 h, which would allow subcutaneous injection once a week instead of twice daily. In conclusion, EP40111 is a promising compound with strong potency as a novel long-lasting anti-HIV-1 drug.
C1 [Huet, Thierry; Kerbarh, Olivier; Gauchet, Cecile; Querolle, Olivier; Lucidi, Bruno; Petitou, Maurice] Endotis Pharma, F-93230 Romainville, France.
   [Schols, Dominique; Balzarini, Jan] Katholieke Univ Leuven, Lab Virol & Chemotherapy, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Clayette, Pascal] CEA, SPI Bio, Neurovirol Dept, F-92265 Fontenay Aux Roses, France.
   [Dubreucq, Guy; Vincent, Loic; Bompais, Heidi; Mazinghien, Romain] Endotis Pharma, F-59120 Loos, France.
   [Salvador, Arnaud; Lemoine, Jerome] Univ Lyon 1, CNRS, UMR 5180, F-69622 Villeurbanne, France.
RP Huet, T (reprint author), Endotis Pharma, Parc Biocitech,102 Ave Gaston Roussel, F-93230 Romainville, France.
EM thierryhuet@endotis.com
RI Schols, Dominique/S-9057-2017; lemoine, jerome/C-4272-2014
OI Schols, Dominique/0000-0003-3256-5850; lemoine,
   jerome/0000-0002-5497-6880; Salvador, Arnaud/0000-0002-5981-3028
FU European Commission EMPRO [503558]; Fonds voor Wetenschappelijk
   Onderzoek (FWO) Krediet [G-485-08]; Centers of Excellence of the K. U.
   Leuven [EF/05/015]; European Community (FEDER); region Nord-Pas de
   Calais (France); CNRS; Universite de Lille 1
FX We are grateful to the following for excellent technical assistance: F.
   Cantais and C. Villedieu from Endotis Pharma; S. Claes, R. Provinciael,
   L. Ingels, and E. Fonteyn from the Rega Institute for Medical Research;
   and N. Dereuddre-Bosquet and R. Yousfi from SPI-Bio.; D. S. and J.B.
   thank the European Commission EMPRO no. 503558 of the 6th Frame Work
   Program, the Fonds voor Wetenschappelijk Onderzoek (FWO) Krediet (no.
   G-485-08), and the Centers of Excellence of the K. U. Leuven (Krediet
   no. EF/05/015) for financial support. We also thank the MS facility of
   the Universite des Sciences et Technologies de Lille 1 used in this
   study, which is funded by the European Community (FEDER), the region
   Nord-Pas de Calais (France), the CNRS, and the Universite de Lille 1.
CR ADACHI A, 1986, J VIROL, V59, P284
   Bai Y, 2006, PHARM RES, V23, P2116, DOI 10.1007/s11095-006-9059-5
   Ball RA, 2003, J AM ACAD DERMATOL, V49, P826, DOI 10.1067/S0190-9622(03)02099-1
   Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Beals John M, 2006, Drug Discov Today Technol, V3, P87, DOI 10.1016/j.ddtec.2006.03.001
   Bjork I, 1997, ADV EXP MED BIOL, V425, P17
   Briz V, 2006, J ANTIMICROB CHEMOTH, V57, P619, DOI 10.1093/jac/dkl027
   Buijsman RC, 1999, BIOORG MED CHEM LETT, V9, P2013, DOI 10.1016/S0960-894X(99)00320-0
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chang D, 2005, J PHARMACEUT BIOMED, V38, P487, DOI 10.1016/j.jpba.2005.01.024
   Chuang VTG, 2002, PHARMACEUT RES, V19, P569
   de Kort M, 2008, CHEMMEDCHEM, V3, P1189, DOI 10.1002/cmdc.200800053
   Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300                                                              
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Eckert DM, 2008, PROTEIN SCI, V17, P2091, DOI 10.1110/ps.038273.108
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823                                                         
   Garber AJ, 2005, DIABETES OBES METAB, V7, P666, DOI 10.1111/j.1463-1326.2005.00457.x
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   Goffinet C, 2007, P NATL ACAD SCI USA, V104, P1015, DOI 10.1073/pnas.0607414104
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Harrison SC, 2005, ADV VIRUS RES, V64, P231, DOI 10.1016/S0065-3527(05)64007-9
   Herbert JM, 1998, BLOOD, V91, P4197
   Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294                                                      
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Krambovitis E, 2005, ACTA PHARMACOL SIN, V26, P1165, DOI 10.1111/j.1745-7254.2005.00193.x
   Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/01.aids.0000050825.06065.84
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Low SC, 2005, HUM REPROD, V20, P1805, DOI 10.1093/humrep/deh896
   Lu J, 2006, JAIDS-J ACQ IMM DEF, V43, P60, DOI 10.1097/01.qai.0000234083.34161.55
   Ma Q, 2004, IDRUGS, V7, P1028
   Maggi P, 2004, J ANTIMICROB CHEMOTH, V53, P678, DOI 10.1093/jac/dkh141
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Myers SA, 2006, ANTIVIR THER, V11, P935
   Naicker KP, 2004, ORG BIOMOL CHEM, V2, P660, DOI 10.1039/b313844e
   ORLOFF SL, 1993, J VIROL, V67, P1461
   Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640
   Reeves JD, 2005, J VIROL, V79, P4991, DOI 10.1128/JVI.79.8.4991-4999.2005
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Roisin A, 2004, J BIOL CHEM, V279, P9208, DOI 10.1074/jbc.M311594200
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Sinclair AM, 2005, J PHARM SCI-US, V94, P1626, DOI 10.1002/jps.20319
   Stocker H, 2006, ANTIMICROB AGENTS CH, V50, P667, DOI 10.1128/AAC.50.2.667-673.2006
   Stoddart CA, 2008, J BIOL CHEM, V283, P34045, DOI 10.1074/jbc.M805536200
   van den Broek I, 2007, J CHROMATOGR B, V854, P245, DOI 10.1016/j.jchromb.2007.04.026
   VANAMSTERDAM RGM, 1995, ARTERIOSCL THROM VAS, V15, P495, DOI 10.1161/01.ATV.15.4.495                                                         
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0                                                   
   Walenga JM, 2005, EXPERT OPIN INV DRUG, V14, P847, DOI 10.1517/13543784.14.7.847
   Weitz JI., 2004, CIRCULATION S1, V110, pI19
   Werle M, 2006, AMINO ACIDS, V30, P351, DOI 10.1007/s00726-005-0289-3
   Wheeler DA, 2004, J CLIN VIROL, V30, P183, DOI 10.1016/j.jvc.2003.10.006
   WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051
   Zhang XP, 2002, CLIN PHARMACOL THER, V72, P10, DOI 10.1067/mcp.2002.125945
   BAILON PS, 2006, Patent No. 7049415
NR 59
TC 23
Z9 23
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2010
VL 54
IS 1
BP 134
EP 142
DI 10.1128/AAC.00827-09
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 534XQ
UT WOS:000272931200016
PM 19805567
OA gold
DA 2018-01-05
ER

PT J
AU Gao, XL
   Chen, W
   Guo, CW
   Qian, CW
   Liu, G
   Ge, F
   Huang, YD
   Kitazato, K
   Wang, YF
   Xiong, S
AF Gao, Xianglei
   Chen, Wei
   Guo, Chaowan
   Qian, Chuiwen
   Liu, Ge
   Ge, Feng
   Huang, Yadong
   Kitazato, Kaio
   Wang, Yifei
   Xiong, Sheng
TI Soluble cytoplasmic expression, rapid purification, and characterization
   of cyanovirin-N as a His-SUMO fusion
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Cyanovirin-N; SUMO; Escherichia coli; Soluble expression; Anti HIV-1
ID VIRUS-INACTIVATING PROTEIN; ESCHERICHIA-COLI; MICROBICIDE DEVELOPMENT;
   HIV-1 INFECTION; MODIFIER FUSION; GP120; TRANSMISSION; GLYCOPROTEIN;
   TECHNOLOGY; DISULFIDE
AB Cyanovirin-N (CVN) is a promising antiviral candidate that has an extremely low sequence homology with any other known proteins. The efficient and soluble expression of biologically functional recombinant CVN (rCVN) is still an obstacle due to insufficient yield, aggregation, and abnormal modification. Here, we describe an improved approach to preparing native rCVN from Escherichia coli more efficiently. A fusion gene consisting of cvn and sumo (small ubiquitin-related modifier) and a hexahistidine tag was constructed according to the codon bias of the host cell. This small ubiquitin-related modifier (SUMO)-fused CVN is expressed in the cytoplasm of E. coli in a folded and soluble form (> 30% of the total soluble protein), yielding 3 to 4 mg of native rCVN from 1 g of wet cells to a purity up to 97.6%. Matrix-assisted laser desorption ionization coupled to time-of-flight mass spectrometry and reverse-phase high-performance liquid chromatographic analysis showed that the purified rCVN was an intact and homogeneous protein with a molecular weight of 11,016.68 Da. Potent antiviral activity of rCVN against herpes simplex virus type 1 and human immunodeficiency virus type 1/IIIB was confirmed in a dose-dependent manner at nanomolar concentrations. Thus, the His-SUMO double-fused CVN provides an efficient approach for the soluble expression of rCVN in the cytoplasm of E. coli, allowing an alternative system to develop bioprocess for the large-scale production of this antiviral candidate.
C1 [Gao, Xianglei; Chen, Wei; Qian, Chuiwen; Ge, Feng; Huang, Yadong; Wang, Yifei; Xiong, Sheng] Jinan Univ, Biomed R&D Ctr, Guangdong Prov Key Lab Bioengn Med, Natl Engn Res Ctr Genet Med, Guangzhou 510632, Guangdong, Peoples R China.
   [Guo, Chaowan; Liu, Ge; Kitazato, Kaio; Xiong, Sheng] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Div Mol Pharmacol Infect Agents, Nagasaki 8528521, Japan.
RP Xiong, S (reprint author), Jinan Univ, Biomed R&D Ctr, Guangdong Prov Key Lab Bioengn Med, Natl Engn Res Ctr Genet Med, 5-F Bldg Biol, Guangzhou 510632, Guangdong, Peoples R China.
EM xiongsheng@jnu.edu.cn
RI ge, feng/E-9158-2011
OI ge, feng/0000-0002-1032-280X
FU National Natural Science Foundation of China [30873082, U0632010];
   Ministry of Science and Technology of China [2008BAI63B05]; Program for
   New Century Excellent Talents in University [NCET-07-0376]; Jinan
   University; Tokyo Biochemistry Research Foundation of Japan
   [TBRF-RF-08-52]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30873082, U0632010), the Ministry of Science and
   Technology of China (2008BAI63B05), the Program for New Century
   Excellent Talents in University (NCET-07-0376), and the 211 Project of
   Jinan University. The anti-HIV bioactivity determination was supported
   by Tokyo Biochemistry Research Foundation of Japan (TBRF-RF-08-52). We
   are most grateful to Dr. Jun Fan of Kyoto University for helpful
   discussions and revision of the manuscript.
CR Assadi-Porter FM, 2008, PROTEIN EXPRES PURIF, V58, P263, DOI 10.1016/j.pep.2007.11.009
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0
   Butt TR, 2005, PROTEIN EXPRES PURIF, V43, P1, DOI 10.1016/j.pep.2005.03.016
   Colleluori DM, 2005, PROTEIN EXPRES PURIF, V39, P229, DOI 10.1016/j.pep.2004.10.009
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127                                                           
   Fischetti L, 2009, AIDS, V23, P319, DOI 10.1097/QAD.0b013e328321b778
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Henzel WJ, 2003, J AM SOC MASS SPECTR, V14, P931, DOI 10.1016/S1044-0305(03)00214-9
   HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4
   Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee CD, 2008, PROTEIN SCI, V17, P1241, DOI 10.1110/ps.035188.108
   Lee SY, 1996, TRENDS BIOTECHNOL, V14, P98, DOI 10.1016/0167-7799(96)80930-9
   Liu CC, 2006, NAT BIOTECHNOL, V24, P1436, DOI 10.1038/nbt1254
   Liu L, 2008, PROTEIN EXPRES PURIF, V62, P21, DOI 10.1016/j.pep.2008.07.010
   Malakhov Michael P., 2004, Journal of Structural and Functional Genomics, V5, P75, DOI 10.1023/B:JSFG.0000029237.70316.52
   Marblestone JG, 2006, PROTEIN SCI, V15, P182, DOI 10.1110/ps.051812706
   Mergulhao FJM, 2004, J BIOTECHNOL, V109, P31, DOI 10.1016/j.jbiotec.2003.10.024
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661
   Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252                                                          
   Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Smee DF, 2008, ANTIVIR RES, V80, P266, DOI 10.1016/j.antiviral.2008.06.003
   Sun ZY, 2008, APPL MICROBIOL BIOT, V78, P495, DOI 10.1007/s00253-007-1330-0
   TAKEUCHI H, 1991, J VIROL METHODS, V33, P61, DOI 10.1016/0166-0934(91)90008-N                                                    
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   UNAIDS, 2008, REP GLOB AIDS EP 200
   Xia XX, 2008, PROTEOMICS, V8, P2089, DOI 10.1002/pmic.200700826
   [熊盛 XIONG Sheng], 2007, [生物工程学报, Chinese Journal of Biotechnology], V23, P508
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Ye TM, 2008, APPL MICROBIOL BIOT, V81, P311, DOI 10.1007/s00253-008-1655-3
   Zuo Xun, 2005, Journal of Structural and Functional Genomics, V6, P103, DOI 10.1007/s10969-005-2664-4
NR 42
TC 16
Z9 17
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD JAN
PY 2010
VL 85
IS 4
BP 1051
EP 1060
DI 10.1007/s00253-009-2078-5
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 543EW
UT WOS:000273554900024
PM 19547966
DA 2018-01-05
ER

PT J
AU Yang, L
   Chen, LQ
   Zeng, R
   Li, C
   Qiao, RZ
   Hu, LM
   Li, ZL
AF Yang, Lin
   Chen, Liqiang
   Zeng, Rong
   Li, Chao
   Qiao, Renzhong
   Hu, Liming
   Li, Zelin
TI Synthesis, nanosizing and in vitro drug release of a novel anti-HIV
   polymeric prodrug: Chitosan-O-isopropyl-5 '-O-d4T monophosphate
   conjugate
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Drug delivery; Chitosan-nucleoside monophosphate conjugate; Anti-HIV
   activity; Polymeric prodrug
ID NUCLEOSIDE ANALOGS; PHOSPHORAMIDATE DERIVATIVES; DELIVERY;
   NANOPARTICLES; D4T; FORMULATIONS; METABOLISM; STAVUDINE; SYSTEMS
AB A novel approach to improve the antiviral efficacy of nucleoside reverse transcriptase inhibitors (NRTIs) and reduce their side effects was developed by constructing a nanosized NRTI monophosphate-polymer conjugate using d4T as a model NRTI. Firstly, a novel chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate with a phosphoramidate linkage was efficiently synthesized through Atherton-Todd reaction under mild conditions. The anti-HIV activity and cytotoxicity of the polymeric conjugate were evaluated in MT4 cell line. Then the conjugate nanoparticles were prepared by the process of ionotropic gelation between TPP and chitosan-d4T conjugate to improve their delivery to viral reservoirs, and their physicochemical properties were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS) techniques and X-ray diffraction (XRD). In vitro drug release studies in pH 1.1 and pH 7.4 suggested that both chitosan-d4T conjugate and its nanoparticles prefer to release d4T 5'-(O-isopropyl) monophosphate than free d4T for prolonged periods, which resulted in the enhancement of anti-HIV selectivity of the polymeric conjugate relative to free d4T due to bypassing the metabolic bottleneck of monophosphorylation. Additionally, the crosslinked conjugate nanoparticles can prevent the coupled drug from leaking out of the nanoparticles before entering the target viral reservoirs and provide a mild sustained release of d4T 5'-(O-isopropyl) monophosphate without the burst release. The results suggested that this kind of chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate nano-prodrugs may be used as a targeting and sustained polymeric prodrugs for improving therapy efficacy and reducing side effects in antiretroviral treatment. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zeng, Rong] Jinan Univ, Coll Sci & Engn, Dept Mat Sci & Engn, Guangzhou 510632, Guangdong, Peoples R China.
   [Yang, Lin; Chen, Liqiang; Li, Chao; Qiao, Renzhong] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
   [Hu, Liming; Li, Zelin] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.
RP Zeng, R (reprint author), Jinan Univ, Coll Sci & Engn, Dept Mat Sci & Engn, Guangzhou 510632, Guangdong, Peoples R China.
EM tzengronga@jnu.edu.cn; qiaorz@mail.buct.edu.cn
FU National Natural Science Foundation of China [20872010, 20732004,
   20972014]; National Basic Research Program of China [2009CB930203]
FX The authors would like to acknowledge financial support from the
   National Natural Science Foundation of China (Grant Nos. 20872010,
   20732004 and 20972014) and the National Basic Research Program of China
   (No. 2009CB930203).
CR Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4                 
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Chimalakonda KC, 2007, BIOCONJUGATE CHEM, V18, P2097, DOI 10.1021/bc700193d
   Clercq E. D., 1995, J MED CHEM, V38, P2491
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   Gan Q, 2005, COLLOID SURFACE B, V44, P65, DOI 10.1016/j.colsurfb.2005.06.001
   Giammona G, 1998, J CONTROL RELEASE, V54, P321, DOI 10.1016/S0168-3659(98)00020-0
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2                                                   
   KUMAR MNV, 2004, J CHEM REV, V104, P6017
   McGuigan C, 1996, J MED CHEM, V39, P1748, DOI 10.1021/jm950605j
   NISHIMURA SI, 1991, MACROMOLECULES, V24, P4745, DOI 10.1021/ma00017a003                                                             
   Pasut G, 2007, PROG POLYM SCI, V32, P933, DOI 10.1016/j.progpolymsci.2007.05.008
   Rando RF, 2000, DRUG DISCOV TODAY, V5, P465, DOI 10.1016/S1359-6446(00)01558-0                                                   
   RIDDLER SA, 1995, ANTIVIR RES, V27, P189, DOI 10.1016/0166-3542(95)00016-F
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sun XB, 2002, CHEM COMMUN, P2414, DOI 10.1039/b207657h
   Tan XL, 1999, ADV DRUG DELIVER REV, V39, P117, DOI 10.1016/S0169-409X(99)00023-X
   Venkatachalam TK, 2006, BIOORGAN MED CHEM, V14, P5161, DOI 10.1016/j.bmc.2006.04.006
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wiebe LI, 1999, ADV DRUG DELIVER REV, V39, P63, DOI 10.1016/S0169-409X(99)00020-4                                                   
   Yang L, 2009, BIOORG MED CHEM LETT, V19, P2566, DOI 10.1016/j.bmcl.2009.03.044
   Zeng R, 2006, MACROMOL RAPID COMM, V27, P548, DOI 10.1002/marc.200500876
NR 26
TC 42
Z9 43
U1 0
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JAN 1
PY 2010
VL 18
IS 1
BP 117
EP 123
DI 10.1016/j.bmc.2009.11.013
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 534JJ
UT WOS:000272892100013
PM 19959368
DA 2018-01-05
ER

PT J
AU Petri, L
   Ferreira, M
   Moraes, ML
AF Petri, Lais
   Ferreira, Marystela
   Moraes, Marli L.
TI Immobilization and Incorporation of Antigenic Peptide P17-1 from HIV-1
   P17 Protein in Nanostructured Films
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
C1 [Petri, Lais; Ferreira, Marystela; Moraes, Marli L.] Univ Fed Sao Carlos, Sorocaba, SP, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JAN
PY 2010
VL 98
IS 3
SU 1
BP 606A
EP 606A
DI 10.1016/j.bpj.2009.12.3302                                              
          
PG 1
WC Biophysics
SC Biophysics
GA V29QD
UT WOS:000208762006024
OA gold
DA 2018-01-05
ER

PT J
AU Ganguli, S
   Mazumder, M
   Basu, P
   Roy, P
   Mitra, S
   Datta, A
AF Ganguli, Sayak
   Mazumder, Manjita
   Basu, Protip
   Roy, Paushali
   Mitra, Sayani
   Datta, Abhijit
TI In silico screening of herbal and nanoparticle lead compounds for
   effectivity against H5N1, H1N1 neuraminidase and telomerase (Retracted
   article. See vol. 11, art. no. 258, 2010)
SO BMC BIOINFORMATICS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 8th Asia Pacific Bioinformatics Conference
CY JAN 18-21, 2010
CL Bangalore, INDIA
ID CELL-LINES; BAICALEIN; INHIBITION; SIMILARITY
AB Background: Traditionally, drugs were discovered by testing compounds synthesized in time consuming multi-step processes against a battery of in vivo biological screens. Promising compounds were then further studied in development, where their pharmacokinetic properties, metabolism and potential toxicity were investigated.
   Methods: Here we present a study on the most talked about herbal lead compounds and their potential binding affinity to the effector molecules of major disease causing agents, H5N1 and H1N1(Neuraminidase). The work also encompasses the screening of the nanoparticle compound fullerene which have been reported to have anti HIV activity. Further studies were also performed with telomerase which has been the target of numerous anti cancer experiments.
   Results: The results revealed that most herbal lead compounds were effective targets against H5N1 neuraminidase, namely baicalein was found to be an effective target for inhibiting the neuraminidase of H1N1 virus. Telomerase was found to be effectively bound by curcumin at the RNA binding interface. The study with nanoparticle fullerene also showed that it has the potential of serving as an effective ligand for inhibiting H1N1 neuraminidase and telomerase.
   Conclusion: Our data demonstrate that the new in silico screening method is highly efficient for identifying potential lead compounds against major infectious disease.
C1 [Ganguli, Sayak; Mazumder, Manjita; Basu, Protip; Roy, Paushali; Mitra, Sayani; Datta, Abhijit] Presidency Coll, DBT Ctr Bioinformat, Kolkata, India.
RP Ganguli, S (reprint author), Presidency Coll, DBT Ctr Bioinformat, Kolkata, India.
EM sayakbif@yahoo.com; manjita_bonny@gmail.com; basuprotip@gmail.com;
   paushali.06@gmail.com; sayanimitra@gmail.com; abhijit_datta21@yahoo.com
CR Aristotle L, 2004, ANTICANCER RES, V24, P987
   Bakry R, 2007, INT J NANOMED, V2, P639
   Chen X, 2002, J CHEM INF COMP SCI, V42, P1407, DOI 10.1021/ci025531g
   Cui SX, 2006, INT J MOL MED, V18, P227
   Gao DY, 1996, BIOCHEM MOL BIOL INT, V39, P215
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Matsuzaki Y, 1996, JPN J CANCER RES, V87, P170, DOI 10.1111/j.1349-7006.1996.tb03155.x                                              
   SEKIYA K, 1982, BIOCHEM BIOPH RES CO, V105, P1090, DOI 10.1016/0006-291X(82)91081-6
   Thimm M, 2004, J CHEM INF COMP SCI, V44, P1816, DOI 10.1021/ci049920h
   Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953
   Youssef KM, 2005, ARCH PHARM, V338, P181, DOI 10.1002/ardp.200400939
NR 11
TC 1
Z9 1
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PY 2010
VL 11
SU 1
AR S13
DI 10.1186/1471-2105-11-S1-S13
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 548NE
UT WOS:000273969500014
PM 20122184
OA gold
DA 2018-01-05
ER

PT B
AU Pedro, L
   Ferreira, GNM
AF Pedro, Luisa
   Ferreira, Guilherme N. M.
BE Noll, T
TI Purification of a Chimeric Simian - Human Immunodeficiency Virus-Like
   Nanoparticle from HEK293 Cell Culture
SO CELLS AND CULTURE
SE ESACT Proceedings
LA English
DT Proceedings Paper
CT 20th ESACT Meeting
CY JUN 17-OCT 05, 2007
CL Dresden, GERMANY
SP ESACT
DE Virus-like particles; Ion-exchange chromatography; Diafiltration
ID ROTAVIRUS-LIKE PARTICLES; GENE-THERAPY; EXPRESSION; PROTEIN;
   CONSTRUCTION
AB Virus-like nanoparticles (VNPs) have a promising future in vaccination, gene therapy and drug delivery. These artificial vectors consist only of the recombinantly produced virus shell without any viral genetic information packaged inside. Similarly to viruses, the structural proteins that comprise a VNP can spontaneously self-assemble to form the particle or can assemble through several intermediate steps. This work focus on the purification of complex self-assembled nanoparticles from cell cultures. A chimeric Simian - Human Immunodeficiency virus-like nanoparticle was constructed by fusion of Simian matrix protein (p17) and HIV-1 p6 protein. This fusion protein assembles as spherical nanoparticles of similar to 80 nm diameter which are released to the culture medium when expressed in HEK 293T cells. A simple two-step purification process was developed to purify these enveloped chimeric particles. Diafiltration using a 300 kDa cut-off PPV ( polyvinylpyrrolidone) membrane operating in tangential flow was initially performed to recover and concentrate enveloped nanoparticles released to the cell culture medium while simultaneously promoting buffer exchange and conditioning. Concentrated nanoparticles were further purified by ion exchange chromatography using strong anion exchangers being eluted from the column at similar to 34 mS/cm conductivity, pH of 8.
C1 [Pedro, Luisa; Ferreira, Guilherme N. M.] Univ Algarve, Ctr Mol & Struct Biomed, IBB Inst Biotechnol & Bioengn, Faro, Portugal.
RP Ferreira, GNM (reprint author), Univ Algarve, Ctr Mol & Struct Biomed, IBB Inst Biotechnol & Bioengn, Faro, Portugal.
EM gferrei@ualg.pt
FU Fundacao para a Ciencia e a Tecnologia [POCI/BIO/62476/2004]
FX Financial support from Fundacao para a Ciencia e a Tecnologia, project
   number POCI/BIO/62476/2004, is acknowledged.
CR Andreadis ST, 1999, BIOTECHNOL PROGR, V15, P1, DOI 10.1021/bp980106m
   Bachmann AS, 2004, J VIROL METHODS, V115, P159, DOI 10.1016/j.jviromet.2003.09.025
   Benavides J, 2006, J CHROMATOGR B, V842, P48, DOI 10.1016/j.jchromb.2006.05.006
   Camp JP, 2005, BIOPHYS CHEM, V113, P115, DOI 10.1016/j.bpc.2004.07.034
   Chen XJS, 2001, J MOL BIOL, V307, P173, DOI 10.1006/jmbi.2000.4464
   Costa MJL, 2007, BIOTECHNOL APPL BIOC, V48, P35, DOI 10.1042/BA20060208
   Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1                                                   
   Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X                                                   
   Peixoto C, 2007, J BIOTECHNOL, V127, P452, DOI 10.1016/j.jbiotec.2006.08.002
   Rolland D, 2001, J CHROMATOGR B, V753, P51, DOI 10.1016/S0378-4347(00)00538-7
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Stubenrauch K, 2000, J CHROMATOGR B, V737, P77, DOI 10.1016/S0378-4347(99)00392-8
   Wagner R, 1996, VIROLOGY, V220, P128, DOI 10.1006/viro.1996.0293
   YAMSHCHIKOV GV, 1995, VIROLOGY, V214, P50, DOI 10.1006/viro.1995.9955                                                          
   Zhou WB, 2005, J CHROMATOGR A, V1095, P119, DOI 10.1016/j.chroma.2005.08.006
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-90-481-3419-9; 978-90-481-3418-2
J9 ESACT PROCEED
PY 2010
VL 4
BP 521
EP 527
DI 10.1007/978-90-481-3419-9_92
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA BH3JS
UT WOS:000399748800092
DA 2018-01-05
ER

PT J
AU Song, MY
   Jiang, GB
   Yin, JF
   Wang, HL
AF Song Maoyong
   Jiang Guibin
   Yin Junfa
   Wang Hailin
TI Inhibition of polymerase activity by pristine fullerene nanoparticles
   can be mitigated by abundant proteins
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID HIV-1 PROTEASE; IN-VIVO; C-60; DERIVATIVES; TOXICITY; CORONA
AB Pristine fullerene nanoparticles are capable of adsorbing polymerase and significantly inhibiting its biologically important replication activity; however, the inhibition can be partially mitigated by abundant proteins through competitive binding.
C1 [Song Maoyong; Jiang Guibin; Yin Junfa; Wang Hailin] Chinese Acad Sci, Ecoenvironm Sci Res Ctr, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China.
RP Wang, HL (reprint author), Chinese Acad Sci, Ecoenvironm Sci Res Ctr, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China.
EM hlwang@rcees.ac.cn
OI yin, jun fa/0000-0001-8028-2375
FU National Natural Science Foundation of China [20707034, 20877091,
   20890112]; National Basic Research Program of China [09CB421605,
   2010CB933500]; National High Technology Research and Development Program
   of China [2007AA06A407]
FX This research was supported by grants from the National Natural Science
   Foundation of China (Nos. 20707034, 20877091 and 20890112), the National
   Basic Research Program of China (Nos. 09CB421605 and 2010CB933500), and
   the National High Technology Research and Development Program of China
   (No. 2007AA06A407) to Drs M. Song and H. Wang. We thank Ms Yuling Song
   for preparing the cover figure.
CR Ashcroft JM, 2006, CHEM COMMUN, P3004, DOI 10.1039/b601717g
   Bakry R, 2007, INT J NANOMED, V2, P639
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   Brant J, 2005, ENVIRON SCI TECHNOL, V39, P6343, DOI 10.1021/es050090d
   Brant JA, 2006, LANGMUIR, V22, P3878, DOI 10.1021/la053293o
   Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   OBERDORSTER E, 2004, ENVIRON SCI TECHNOL, V43, P948
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Porter AE, 2007, ENVIRON SCI TECHNOL, V41, P3012, DOI 10.1021/es062541f
   Satoh M, 2006, J PHARMACOL SCI, V100, P513, DOI 10.1254/jphs.CPJ06002X
   Tanimoto S, 2008, CHEM COMMUN, P5767, DOI 10.1039/b811726h
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zhao XC, 2005, BIOPHYS J, V89, P3856, DOI 10.1529/biophysj.105.064410
NR 18
TC 9
Z9 9
U1 2
U2 23
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2010
VL 46
IS 9
BP 1404
EP 1406
DI 10.1039/b922711c
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 556HI
UT WOS:000274580700003
DA 2018-01-05
ER

PT J
AU Yang, B
   Gu, K
   Sun, XR
   Huang, HA
   Ding, YB
   Wang, FQ
   Zhou, GH
   Huang, LL
AF Yang, Bing
   Gu, Kai
   Sun, Xiaoru
   Huang, Huan
   Ding, Yibing
   Wang, Fuqiang
   Zhou, Guohua
   Huang, Lequn Lee
TI Simultaneous detection of attomolar pathogen DNAs by Bio-MassCode mass
   spectrometry
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID NANOPARTICLE PROBES; LIFE-SCIENCE; PCR; CHEMISTRY; ASSAY
AB A general method is described to analyze pathogen DNAs in homogenous solution by a novel Bio-MassCode probe, using a small organic (namely disulfide) "reporter mass" that self-assembled in oligonucleotide-modified gold nanoparticles. With conventional MALDI TOF MS, the assay simultaneously detected DNAs for HIV, HBV, HCV, and TP with extraordinarily high sensitivity in the low attomolar (10(-18) M) range without any other amplification.
C1 [Yang, Bing; Sun, Xiaoru; Ding, Yibing; Zhou, Guohua; Huang, Lequn Lee] Nanjing Univ, Inst Mol Med, Nanjing 210093, Peoples R China.
   [Yang, Bing; Sun, Xiaoru; Ding, Yibing; Zhou, Guohua; Huang, Lequn Lee] Nanjing Univ, Sch Med, Nanjing 210093, Peoples R China.
   [Gu, Kai] Nanjing Univ, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
   [Huang, Huan; Zhou, Guohua] Huadong Res Inst Med & Biotech, Lab Mol Diagnost, Nanjing 210002, Peoples R China.
   [Wang, Fuqiang] Nanjing Med Univ, Lab Reprod Med, Dept Histol & Embryol, Nanjing, Peoples R China.
RP Zhou, GH (reprint author), Nanjing Univ, Inst Mol Med, Nanjing 210093, Peoples R China.
EM ghzhou@nju.edu.cn; huanglq@nju.edu.cn
OI Zhou, Guohua/0000-0001-6675-4452
FU Scientific Research Foundation for Returned Overseas Chinese Scholars
   from the Education Ministry of China [0214168001]; National Key Science
   & Technology Special Project of China [2008zxj09014-012]
FX This work was supported by the Scientific Research Foundation for
   Returned Overseas Chinese Scholars from the Education Ministry of China
   (No. 0214168001), and National Key Science & Technology Special Project
   of China (2008zxj09014-012)
CR Brenner S, 1996, NATURE, V381, P567, DOI 10.1038/381567a0                                                                
   Demeestere K, 2010, ANAL BIOANAL CHEM, V396, P825, DOI 10.1007/s00216-009-3270-2
   Ekegren T, 2008, J MASS SPECTROM, V43, P559, DOI 10.1002/jms.1409
   Fox S, 2003, GENET ENG NEWS, V23, P12
   Godin JP, 2007, MASS SPECTROM REV, V26, P751, DOI 10.1002/mas.20149
   Hall TA, 2009, ANAL CHEM, V81, P7515, DOI 10.1021/ac901222y
   Han MS, 2006, ANGEW CHEM INT EDIT, V45, P1807, DOI 10.1002/anie.200504277
   Hill HD, 2007, ANAL CHEM, V79, P9218, DOI 10.1021/ac701626y
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Jelic A, 2009, TALANTA, V80, P363, DOI 10.1016/j.talanta.2009.06.077
   KANEMAGUIRE LAP, 1995, J ORGANOMET CHEM, V486, P243, DOI 10.1016/0022-328X(94)05041-9                                                    
   Lee KO, 2009, CLIN CHEM, V55, pA140
   Lurie N, 2009, NEW ENGL J MED, V361, P843, DOI 10.1056/NEJMp0905330
   MCLAFFERTY FW, 1995, J AM SOC MASS SPECTR, V6, P993, DOI 10.1016/1044-0305(95)00586-2
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Patel DA, 2009, J VIROL METHODS, V160, P78, DOI 10.1016/j.jviromet.2009.04.024
   Qiu F, 2008, ANGEW CHEM INT EDIT, V47, P5009, DOI 10.1002/anie.200800435
   Richardson SD, 2008, ANAL CHEM, V80, P4373, DOI 10.1021/ac800660d
   Sandros MG, 2005, CHEM COMMUN, P2832, DOI 10.1039/b501315a
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Vessecchi R, 2008, QUIM NOVA, V31, P840, DOI 10.1590/S0100-40422008000400026
   Whelen CA, 2009, J MOL DIAGN, V11, P648
NR 22
TC 10
Z9 10
U1 1
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2010
VL 46
IS 43
BP 8288
EP 8290
DI 10.1039/c0cc03156a
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 671IU
UT WOS:000283495500052
PM 20886141
DA 2018-01-05
ER

PT J
AU Ezzat, K
   El Andaloussi, S
   Abdo, R
   Langel, U
AF Ezzat, Kariem
   El Andaloussi, Samir
   Abdo, Rania
   Langel, Ulo
TI Peptide-Based Matrices as Drug Delivery Vehicles
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell penetrating peptide; protein transduction domain; delivery; siRNA;
   splice correction; Poly-L-lysine; antimicrobial peptides
ID CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; ANTISENSE MORPHOLINO
   OLIGOMERS; ANTENNAPEDIA HOMEOBOX PEPTIDE; EFFICIENT SPLICING CORRECTION;
   HUMAN IMMUNODEFICIENCY VIRUS; VECTOR-MEDIATED STRATEGY; SINGLE-CHAIN
   ANTIBODIES; PLURIPOTENT STEM-CELLS; ISCHEMIC BRAIN-INJURY
AB Peptides, polypeptides, and proteins have been extensively studied for their various structural and functional roles in living organisms. However, breakthrough discoveries in the last decades identified some peptide-based matrices that posses the ability to traverse biological membranes, and many peptides, polypeptides and even complete proteins have been shown to have such properties. Hence, these matrices have been successfully used for the intracellular delivery of many therapeutic cargos including small molecules, proteins, peptides, oligonucleutides, plasmids and nanoparticles both in vitro and in vivo. Being neither toxic nor carcinogenic and meanwhile efficient in delivery, they are recognized as very promising vectors to overcome the shortcomings of the available technologies. The characteristics of these peptide-based matrices and their applications in drug delivery are here briefly illustrated together with current challenges and future prospects.
C1 [Ezzat, Kariem; El Andaloussi, Samir; Abdo, Rania; Langel, Ulo] Stockholm Univ, Dept Neurochem, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden.
RP Langel, U (reprint author), Stockholm Univ, Dept Neurochem, Arrhenius Labs Nat Sci, Svante Arrhenius V 21A, SE-10691 Stockholm, Sweden.
EM Ulo@neurochem.su.se
RI Ezzat, Kariem/D-1436-2015
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   Aroui S, 2009, PHARM RES-DORD, V26, P836, DOI 10.1007/s11095-008-9782-1
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Bendifallah N, 2006, BIOCONJUGATE CHEM, V17, P750, DOI 10.1021/bc050253q
   BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635
   Cavazzana-Calvo M, 2009, GENE THER, V16, P309, DOI 10.1038/gt.2009.15
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Clark AG, 2000, NATURE, V403, P261, DOI 10.1038/35002236                                                                
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Crombez L, 2008, CURR PHARM DESIGN, V14, P3656, DOI 10.2174/138161208786898842
   Dass CR, 2004, J MOL MED-JMM, V82, P579, DOI 10.1007/s00109-004-0558-8
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Edenhofer F, 2008, CURR PHARM DESIGN, V14, P3628, DOI 10.2174/138161208786898833                                                      
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Enback J, 2007, BIOCHEM SOC T, V35, P780, DOI 10.1042/BST0350780                                                              
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fisher L, 2004, GENE THER, V11, P1264, DOI 10.1038/sj.gt.3302291
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Glukhov E, 2005, J BIOL CHEM, V280, P33960, DOI 10.1074/jbc.M507042200
   Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224
   Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527
   Harada Hiroshi, 2006, Breast Cancer, V13, P16, DOI 10.2325/jbcs.13.16
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Inomata K, 2009, NATURE, V458, P106, DOI 10.1038/nature07839
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jain M, 2007, EUR J NUCL MED MOL I, V34, P973, DOI 10.1007/s00259-007-0395-4
   Jalota-Badhwar A, 2007, J BIOL CHEM, V282, P9902, DOI 10.1074/jbc.M608434200
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111
   Kaouass M, 2006, J CONTROL RELEASE, V113, P245, DOI 10.1016/j.jconrel.2006.04.013
   Kasim V, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh061
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Kersemans V, 2008, CURR PHARM DESIGN, V14, P2415, DOI 10.2174/138161208785777432                                                      
   Khafagy ES, 2009, J CONTROL RELEASE, V133, P103, DOI 10.1016/j.jconrel.2008.09.076
   Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100
   Kilic U, 2003, STROKE, V34, P1304, DOI 10.1161/01.STR.0000066869.45310.50
   Klink DT, 2001, MOL THER, V3, P831, DOI 10.1006/mthe.2001.0332
   Kobayashi N, 2006, ANTIMICROB AGENTS CH, V50, P1118, DOI 10.1128/AAC.50.3.1118-1119.2006
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Letoha T, 2005, J PEPT SCI, V11, P805, DOI 10.1002/psc.678
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lochmann D, 2004, EUR J PHARM BIOPHARM, V58, P237, DOI 10.1016/j.ejpb.2004.03.031
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Mae M, 2009, INT J PEPT RES THER, V15, P11, DOI 10.1007/s10989-008-9156-x
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Maier MA, 2006, J MED CHEM, V49, P2534, DOI 10.1021/jm051275y
   Marshall NB, 2007, J IMMUNOL METHODS, V325, P114, DOI 10.1016/j.jim.2007.06.009
   Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231
   Mason AJ, 2007, J CONTROL RELEASE, V118, P95, DOI 10.1016/j.jconrel.2006.12.004
   Mason AJ, 2006, FASEB J, V20, P320, DOI 10.1096/fj.05-4293fje
   Mazzanti M, 2001, PHYSIOL REV, V81, P1
   McClorey G, 2006, GENE THER, V13, P1373, DOI 10.1038/sj.gt.3302800
   McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556                                                     
   Melo MN, 2009, NAT REV MICROBIOL, V7, P245, DOI 10.1038/nrmicro2095
   Morishita R, 2004, CURR OPIN PHARMACOL, V4, P139, DOI 10.1016/j.coph.2003.10.008
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moss JA, 2005, J AM CHEM SOC, V127, P538, DOI 10.1021/ja0443171
   Moulton HM, 2004, BIOCONJUGATE CHEM, V15, P290, DOI 10.1021/bc034221g
   Moulton HM, 2003, ANTISENSE NUCLEIC A, V13, P31, DOI 10.1089/108729003764097322
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje
   Nelson MH, 2005, BIOCONJUGATE CHEM, V16, P959, DOI 10.1021/bc0501045
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Oren Z, 1998, BIOPOLYMERS, V47, P451
   Palm C, 2006, PEPTIDES, V27, P1710, DOI 10.1016/j.peptides.2006.01.006
   Parseghian MH, 2006, BIOCHEM CELL BIOL, V84, P589, DOI 10.1139/O06-082
   Patel EN, 2009, MOL PHARMACEUT, V6, P492, DOI 10.1021/mp800174g
   Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Reshetnyak YK, 2006, P NATL ACAD SCI USA, V103, P6460, DOI 10.1073/pnas.0601463103
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rousselle C, 2002, J DRUG TARGET, V10, P309, DOI 10.1080/10611860290031886
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547
   Senatus PB, 2006, MOL CANCER THER, V5, P20, DOI 10.1158/1535-7163.MCT-05-0181
   Shin I, 2005, CANCER RES, V65, P2815, DOI 10.1158/0008-5472.CAN-04-2898                                                   
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024                                                      
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Tonges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JC125052
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Vavere AL, 2009, CANCER RES, V69, P4510, DOI 10.1158/0008-5472.CAN-08-3781
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wolf Y, 2006, BIOCHEMISTRY-US, V45, P14944, DOI 10.1021/bi0606896
   Yang S, 2009, J CONTROL RELEASE, V135, P159, DOI 10.1016/j.jconrel.2008.12.015
   Yin W, 2006, NEUROBIOL DIS, V21, P358, DOI 10.1016/j.nbd.2005.07.015
   Yoshida T, 2003, APPL MICROBIOL BIOT, V62, P21, DOI 10.1007/s00253-003-1312-9
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
NR 141
TC 25
Z9 26
U1 3
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2010
VL 16
IS 9
BP 1167
EP 1178
DI 10.2174/138161210790963832                                              
          
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 563RE
UT WOS:000275150300014
PM 20030616
DA 2018-01-05
ER

PT J
AU Mallipeddi, R
   Rohan, LC
AF Mallipeddi, Rama
   Rohan, Lisa Cencia
TI Nanoparticle-based vaginal drug delivery systems for HIV prevention
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE HIV prevention; nanoparticles; topical microbicides; vaginal drug
   delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYSTIC-FIBROSIS SPUTUM; HUMAN
   CERVICAL-MUCUS; BIODEGRADABLE NANOPARTICLES; POLYMERIC NANOPARTICLES;
   IN-VITRO; CHITOSAN NANOPARTICLES; MUCOADHESIVE POLYMERS; MEDIATED
   ENDOCYTOSIS; SEXUAL TRANSMISSION
AB Importance of the Field. Several strategies are being investigated for the prevention of heterosexual transmission of HIV. Of these, topical vaginal drug delivery systems, microbicides, are being actively pursued. HIV prevention by means of a topical microbicide has several drug delivery challenges. These challenges include the vaginal mucosal barriers and potential degradation of the drugs in the vaginal lumen due to pH and enzymes present. Also, new drugs being evaluated as microbicides have specific mechanisms of action, which in some cases require drug targeting to a specific site of action. Nanoparticles provide a delivery strategy for targeted or controlled delivery to the vagina which can be applied in the field of HIV prevention.
   Areas covered in the review. This review summarizes nanoparticulate systems and their use in mucosal delivery to date. The sexual transmission of HIV along with the various targets to prevent transmission are discussed as well as the potential opportunities, challenges and advantages in using a nanoparticle-based approach for microbicidal drug delivery.
   What the reader will gain: This review provides a general understanding of vaginal drug delivery, its challenges, and nanoparticulate delivery systems. Additionally, insight will be gained as to the limited existing application of this technology to the field of HIV prevention.
   Take home message: To date, few studies have been published that exploit nanoparticle-based microbicidal delivery to the vagina. The use of nanoparticles for vaginal drug delivery provides an approach to overcome the existing barriers to success.
C1 [Mallipeddi, Rama; Rohan, Lisa Cencia] Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
   [Mallipeddi, Rama; Rohan, Lisa Cencia] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.
   [Rohan, Lisa Cencia] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
RP Rohan, LC (reprint author), Magee Womens Res Inst, 204 Craft Ave,B509, Pittsburgh, PA 15213 USA.
EM rohanlc@upmc.edu
CR Ballagh SA, 2002, CONTRACEPTION, V66, P369, DOI 10.1016/S0010-7824(02)00433-X                                                   
   Barnhart K, 1998, VAG MICR FORM WORKSH, P1
   Bernkop-Schnurch A, 2005, ADV DRUG DELIVER REV, V57, P1553, DOI 10.1016/j.addr.2005.07.007
   Boggiano C, 2007, IMMUNITY, V26, P145, DOI 10.1016/j.immuni.2007.02.001
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Calvo P, 1997, PHARMACEUT RES, V14, P1431, DOI 10.1023/A:1012128907225
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Csaba N, 2009, ADV DRUG DELIVER REV, V61, P140, DOI 10.1016/j.addr.2008.09.005
   Cui FY, 2006, INT J PHARM, V316, P154, DOI 10.1016/j.ijpharm.2006.02.031
   Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005
   Dawson M, 2004, BIOTECHNOL PROGR, V20, P851, DOI 10.1021/bp0342553
   Dawson M, 2003, J BIOL CHEM, V278, P50393, DOI 10.1074/jbc.M309026200
   Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676
   Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300                                                              
   Dyer AM, 2002, PHARMACEUT RES, V19, P998, DOI 10.1023/A:1016418523014                                                         
   Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446                                                         
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Fu K, 2003, J PHARM SCI, V92, P1582, DOI 10.1002/jps.10414
   Galindo-Rodriguez SA, 2005, CRIT REV THER DRUG, V22, P419, DOI 10.1615/CritRevTherDrugCarrierSyst.v22.i5.10                                    
   Garg S, 2003, AIDS PATIENT CARE ST, V17, P17, DOI 10.1089/108729103321042881                                                      
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   Henke MO, 2007, PAEDIATR RESPIR REV, V8, P24, DOI 10.1016/j.prrv.2007.02.009
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Huh KM, 2005, J CONTROL RELEASE, V101, P59, DOI 10.1016/j.jconrel.2004.07.003
   ILLUM L, 1987, BIOMATERIALS, V8, P113, DOI 10.1016/0142-9612(87)90099-8
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Kawamura T, 2000, J EXP MED, V192, P1491, DOI 10.1084/jem.192.10.1491
   Kawamura T, 2005, J DERMATOL SCI, V40, P147, DOI 10.1016/j.jdermsci.2005.08.009
   Kawashima Y, 2000, PHARM DEV TECHNOL, V5, P77, DOI 10.1081/PDT-100100522                                                           
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   KIM S, 2008, NANOTECHNOLOGY DRUG, P581
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   Krishnan S, 2008, ANN NY ACAD SCI, V1136, P101, DOI 10.1196/annals.1425.013
   Kurakhmaeva KB, 2009, J DRUG TARGET, V17, P564, DOI 10.1080/10611860903112842
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Langer R, 1998, NATURE, V392, P5
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   LEHR CM, 1992, PHARMACEUT RES, V9, P547, DOI 10.1023/A:1015804816582
   Liu XD, 2007, BIOMATERIALS, V28, P1280, DOI 10.1016/j.biomaterials.2006.11.004
   Liu YL, 2008, BIOCONJUGATE CHEM, V19, P1009, DOI 10.1021/bc700421u
   Liu ZB, 2009, DRUG DELIV, V16, P341, DOI 10.1080/10717540903047387
   Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001
   Mauck CK, 2008, JAIDS-J ACQ IMM DEF, V49, P243, DOI 10.1097/QAI.0b013e318186eae7
   Mayer KH, 2003, AIDS, V17, P321, DOI 10.1097/01.aids.0000050805.28043.11
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Montisci MJ, 2001, PHARMACEUT RES, V18, P829, DOI 10.1023/A:1011044730790
   Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287                                                             
   Mrsny RJ, 2009, ADV DRUG DELIVER REV, V61, P172, DOI 10.1016/j.addr.2008.09.009
   Narain R, 2007, LANGMUIR, V23, P12835, DOI 10.1021/la702378n
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pauwels R, 1996, J ACQ IMMUN DEF SYND, V11, P211, DOI 10.1097/00042560-199603010-00001                                                
   PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959
   Perera G, 2009, DRUG DELIV, V16, P254, DOI 10.1080/10717540902937471
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Pudney J, 2005, BIOL REPROD, V73, P1253, DOI 10.1095/biolreprod.105.043133
   Quintanar-Guerrero D, 1998, PHARMACEUT RES, V15, P1056, DOI 10.1023/A:1011934328471                                                         
   Quintanar-Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571                                                       
   Rekha MR, 2009, J CONTROL RELEASE, V135, P144, DOI 10.1016/j.jconrel.2009.01.011
   Rezayat SM, 2009, EUR J MED CHEM, V44, P1554, DOI 10.1016/j.ejmech.2008.07.030
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Rodriguez S.G., 2004, PHARM RES, V21, P1428
   Rohan LC, 2004, SEX TRANSM DIS, V31, P143, DOI 10.1097/01.OLQ.0000114655.79109.ED
   Rubin BK, 2006, CHEST, V130, P1433, DOI 10.1378/chest.130.5.1433
   Sanders NN, 2000, AM J RESP CRIT CARE, V162, P1905, DOI 10.1164/ajrccm.162.5.9909009                                                    
   Sapra P, 2003, PROG LIPID RES, V42, P439, DOI 10.1016/S0163-7827(03)00032-8
   Sarmento B, 2007, PHARM RES, V24, P2198, DOI 10.1007/s11095-007-9367-4
   Schmidt C, 2009, NANOTHERAPEUTICS: DRUG DELIVERY CONCEPTS IN NANOSCIENCE, P3
   SCHUMACH.GF, 1970, FERTIL STERIL, V21, P697
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468
   Smart JD, 2005, ADV DRUG DELIVER REV, V57, P1556, DOI 10.1016/j.addr.2005.07.001
   STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   Teijeiro-Osorio D, 2009, EUR J PHARM BIOPHARM, V71, P257, DOI 10.1016/j.ejpb.2008.09.020
   Teijeiro-Osorio D, 2009, BIOMACROMOLECULES, V10, P243, DOI 10.1021/bm800975j
   Thirawong N, 2008, J CONTROL RELEASE, V125, P236, DOI 10.1016/j.jconrel.2007.10.023
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   TREVES C, 1986, INT J FERTIL, V31, P59
   Utech M, 2006, METH MOL B, V341, P185
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Wang X, 2009, J BIOMED MATER RES B, V88B, P150, DOI 10.1002/jbm.b.31161
   Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685                                                               
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yoo HS, 1999, PHARMACEUT RES, V16, P1114, DOI 10.1023/A:1018908421434                                                         
   ZEKENG L, 1993, AIDS, V7, P725, DOI 10.1097/00002030-199305000-00018
   Zhang XL, 2009, PHARM RES-DORD, V26, P1516, DOI 10.1007/s11095-009-9864-8
   Zou WW, 2009, DRUG DELIV, V16, P15, DOI 10.1080/10717540802481307
NR 97
TC 46
Z9 46
U1 7
U2 31
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JAN
PY 2010
VL 7
IS 1
BP 37
EP 48
DI 10.1517/17425240903338055
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 546QM
UT WOS:000273825300004
PM 20017659
DA 2018-01-05
ER

PT J
AU Saiyed, ZM
   Gandhi, NH
   Nair, MPN
AF Saiyed, Zainulabedin M.
   Gandhi, Nimisha H.
   Nair, Madhavan P. N.
TI Magnetic nanoformulation of azidothymidine 5 '-triphosphate for targeted
   delivery across the blood-brain barrier
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE AZTTP; magnetic liposomes; HIV-1 infectivity; transendothelial
   migration; blood-brain barrier
ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POLYMERIC NANOGEL FORMULATIONS;
   NUCLEOSIDE ANALOGS; DRUG-DELIVERY; IN-VITRO; ANTIRETROVIRAL DRUG;
   LIPOSOMES; NANOPARTICLES; HIV-1; NEUROAIDS
AB Despite significant advances in highly active antiretroviral therapy (HAART), the prevalence of neuroAIDS remains high. This is mainly attributed to inability of antiretroviral therapy (ART) to cross the blood-brain barrier (BBB), thus resulting in insufficient drug concentration within the brain. Therefore, development of an active drug targeting system is an attractive strategy to increase the efficacy and delivery of ART to the brain. We report herein development of magnetic azidothymidine 5'-triphosphate (AZTTP) liposomal nanoformulation and its ability to transmigrate across an in vitro BBB model by application of an external magnetic field. We hypothesize that this magnetically guided nanoformulation can transverse the BBB by direct transport or via monocyte-mediated transport. Magnetic AZTTP liposomes were prepared using a mixture of phosphatidyl choline and cholesterol. The average size of prepared liposomes was about 150 nm with maximum drug and magnetite loading efficiency of 54.5% and 45.3%, respectively. Further, magnetic AZTTP liposomes were checked for transmigration across an in vitro BBB model using direct or monocyte-mediated transport by application of an external magnetic field. The results show that apparent permeability of magnetic AZTTP liposomes was 3-fold higher than free AZTTP. Also, the magnetic AZTTP liposomes were efficiently taken up by monocytes and these magnetic monocytes showed enhanced transendothelial migration compared to normal/non-magnetic monocytes in presence of an external magnetic field. Thus, we anticipate that the developed magnetic nanoformulation can be used for targeting active nucleotide analog reverse transcriptase inhibitors to the brain by application of an external magnetic force and thereby eliminate the brain HIV reservoir and help to treat neuroAIDS.
C1 [Saiyed, Zainulabedin M.; Gandhi, Nimisha H.; Nair, Madhavan P. N.] Florida Int Univ, Dept Immunol, Coll Med, Miami, FL 33199 USA.
RP Nair, MPN (reprint author), Florida Int Univ, Dept Immunol, Coll Med, 11200 SW 8th St,HLS I Lab 306-307-308-311, Miami, FL 33199 USA.
EM nairm@fiu.edu
FU National Institute on Drug Abuse [R37DA025576, RO1DA027049]
FX This work was supported in part by National Institute on Drug Abuse
   grant R37DA025576 and RO1DA027049. Also, we are sincerely grateful to
   Horacio Priestap, Department of Biological Sciences, Florida
   International University, for his assistance in HPLC analysis. The
   authors report no conflicts of interest.
CR Afergan E, 2008, J CONTROL RELEASE, V132, P84, DOI 10.1016/j.jconrel.2008.08.017
   Antonelli G, 1996, AIDS RES HUM RETROV, V12, P223, DOI 10.1089/aid.1996.12.223                                                         
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Doualla-Bell F, 2004, M S-MED SCI, V20, P882, DOI 10.1051/medsci/20042010882
   Gandhi N, 2009, AIDS RES HUM RETROV, V25, P691, DOI 10.1089/aid.2008.0299
   Haorah J, 2005, J LEUKOCYTE BIOL, V78, P1223, DOI 10.1189/jlb.0605340
   Hofmann H., 2001, EUR CELLS MATER, V2, P29
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Jain S, 2003, INT J PHARM, V261, P43, DOI 10.1016/S0378-5173(03)00269-2
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Kubo T, 2000, INT J ONCOL, V17, P309
   Lesniak MS, 2004, NAT REV DRUG DISCOV, V3, P499, DOI 10.1038/nrd1414
   LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407                                                     
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x
   MOLEMA G, 1992, J CHROMATOGR, V579, P104
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Muthana M, 2008, GENE THER, V15, P902, DOI 10.1038/gt.2008.57
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Perry VH, 1997, MOL MED TODAY, V3, P335, DOI 10.1016/S1357-4310(97)01077-0
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Potula R, 2008, AIDS, V22, P1539, DOI 10.1097/QAD.0b013e3283081e08
   Riviere C, 2007, RADIOLOGY, V244, P439, DOI 10.1148/radiol.2442060912
   Robertson KR, 2007, J NEUROIMMUNE PHARM, V2, P105, DOI 10.1007/s11481-006-9052-0
   Safarik I, 2002, MONATSH CHEM, V133, P737, DOI 10.1007/s007060200047
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Saiyed Z. M., 2003, BIOMAGN RES TECHNOL, V1, P1
   Sarin H, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-77
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
   Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745-6673-2-16
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
NR 41
TC 61
Z9 62
U1 0
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2010
VL 5
BP 157
EP 166
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 674DW
UT WOS:000283715300015
PM 20463931
DA 2018-01-05
ER

PT J
AU Mallipeddi, R
   Rohan, LC
AF Mallipeddi, Rama
   Rohan, Lisa Cencia
TI Progress in antiretroviral drug delivery using nanotechnology
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE drug delivery; HIV; antiretrovirals; nanoparticles; liposomes;
   dendrimers
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SOLID LIPID NANOPARTICLES;
   BLOOD-BRAIN-BARRIER; PRODRUG 3'-AZIDO-3'-DEOXYTHYMIDINE PALMITATE;
   ELASTIC LIPOSOMAL FORMULATION; IN-VITRO TOXICITY; ANTI-HIV ACTIVITY;
   SILVER NANOPARTICLES; TISSUE DISTRIBUTION; GOLD NANOPARTICLES
AB There are currently a number of antiretroviral drugs that have been approved by the Food and Drug Administration for use in the treatment of human immunodeficiency virus (HIV). More recently, antiretrovirals are being evaluated in the clinic for prevention of HIV infection. Due to the challenging nature of treatment and prevention of this disease, the use of nanocarriers to achieve more efficient delivery of antiretroviral drugs has been studied. Various forms of nanocarriers, such as nanoparticles (polymeric, inorganic, and solid lipid), liposomes, polymeric micelles, dendrimers, cyclodextrins, and cell-based nanoformulations have been studied for delivery of drugs intended for HIV prevention or therapy. The aim of this review is to provide a summary of the application of nanocarrier systems to the delivery of anti-HIV drugs, specifically antiretrovirals. For anti-HIV drugs to be effective, adequate distribution to specific sites in the body must be achieved, and effective drug concentrations must be maintained at those sites for the required period of time. Nanocarriers provide a means to overcome cellular and anatomical barriers to drug delivery. Their application in the area of HIV prevention and therapy may lead to the development of more effective drug products for combating this pandemic disease.
C1 [Mallipeddi, Rama; Rohan, Lisa Cencia] Univ Pittsburgh, Magee Womens Res Inst, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15213 USA.
RP Rohan, LC (reprint author), Univ Pittsburgh, Magee Womens Res Inst, Dept Pharmaceut Sci, Sch Pharm, 204 Craft Ave, Pittsburgh, PA 15213 USA.
EM rohanlc@upmc.edu
CR Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   BARNARD DL, 1997, ANTIVIR RES, V34, P88
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Bernkop-Schnurch A, 2005, ADV DRUG DELIVER REV, V57, P1553, DOI 10.1016/j.addr.2005.07.007
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Blanzat M, 2002, CHEM COMMUN, P1864, DOI 10.1039/b204287h
   Boggiano C, 2007, IMMUNITY, V26, P145, DOI 10.1016/j.immuni.2007.02.001
   Bosman AW, 1999, CHEM REV, V99, P1665, DOI 10.1021/cr970069y                                                               
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   BUCHANAN CM, 2007, BIOMACROMOLECULES, V9, P305
   Canizal G, 2001, J NANOPART RES, V3, P475, DOI 10.1023/A:1012578821566
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Choi Y, 1996, CARBOHYD RES, V282, P113, DOI 10.1016/0008-6215(95)00372-X
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300                                                              
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   DUBEY V, 2010, NANOMEDICINE    0120
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Duzgunes N, 1999, MOL MEMBR BIOL, V16, P111, DOI 10.1080/096876899294832                                                         
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   FLASHER D, 1994, BBA-BIOMEMBRANES, V1194, P185, DOI 10.1016/0005-2736(94)90219-4                                                    
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Fu K, 2003, J PHARM SCI, V92, P1582, DOI 10.1002/jps.10414
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   GUPTA U, 2004, INDIAN J PHARM SCI, V66, P72
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Han SQ, 2010, CARBOHYD POLYM, V80, P1111, DOI 10.1016/j.carbpol.2010.01.031
   HAROUSE JM, 1989, J VIROL, V63, P2527
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Holtgrave DR, 2005, INT J STD AIDS, V16, P777, DOI 10.1258/095646205774988109
   Hussain SM, 2005, TOXICOL IN VITRO, V19, P975, DOI 10.1016/j.tiv.2005.06.034
   Jain KK, 2003, EXPERT REV MOL DIAGN, V3, P153, DOI 10.1586/14737159.3.2.153                                                        
   JAIN SAK, 2007, AAPS PHARMSCITECH, V8, pNIL67
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Jin SX, 2005, PHARMAZIE, V60, P840
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   KIM S, 2009, NANOTECHNOLOGY DRUG
   Kim YS, 2008, INHAL TOXICOL, V20, P575, DOI 10.1080/08958370701874663 
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Langer R, 1998, NATURE, V392, P5
   LARA HH, 2010, J NANOBIOTECHNOL, V8, pNIL1, DOI DOI 10.1186/1477-3155-8-1
   Liu YL, 2008, BIOCONJUGATE CHEM, V19, P1009, DOI 10.1021/bc700421u
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936
   Lu L, 2008, ANTIVIR THER, V13, P253
   Macri RV, 2009, BIOORGAN MED CHEM, V17, P3162, DOI 10.1016/j.bmc.2009.02.055
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGowan I, 2008, SEX TRANSM INFECT, V84, P413, DOI 10.1136/sti.2008.031328
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Mrsny RJ, 2009, ADV DRUG DELIVER REV, V61, P172, DOI 10.1016/j.addr.2008.09.009
   Nagasaki Y, 2001, BIOMACROMOLECULES, V2, P1067, DOI 10.1021/bm015574q
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Oka H, 2009, BIOORGAN MED CHEM, V17, P5465, DOI 10.1016/j.bmc.2009.06.035
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pauwels R, 1996, J ACQ IMMUN DEF SYND, V11, P211, DOI 10.1097/00042560-199603010-00001                                                
   PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959
   Perera G, 2009, DRUG DELIV, V16, P254, DOI 10.1080/10717540902937471
   Perez-Anes A, 2010, BIOORGAN MED CHEM, V18, P242, DOI 10.1016/j.bmc.2009.10.058
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Porcel E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085103
   Pretzer E, 1997, ANTIVIR RES, V34, P1, DOI 10.1016/S0166-3542(96)01017-0
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Rekha MR, 2009, J CONTROL RELEASE, V135, P144, DOI 10.1016/j.jconrel.2009.01.011
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   ROY R, 1993, J CHEM SOC CHEM COMM, P1869, DOI 10.1039/c39930001869                                                            
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   Schmidt C, 2009, NANOTHERAPEUTICS: DRUG DELIVERY CONCEPTS IN NANOSCIENCE, P3
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   Thirawong N, 2008, J CONTROL RELEASE, V125, P236, DOI 10.1016/j.jconrel.2007.10.023
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang J, 2010, COLLOID SURFACE B, V75, P520, DOI 10.1016/j.colsurfb.2009.09.029
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wei DW, 2009, CARBOHYD RES, V344, P2375, DOI 10.1016/j.carres.2009.09.001
   WHO UNAIDS, 2009, AIDS EP UPD
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
   Yoo HS, 1999, PHARMACEUT RES, V16, P1114, DOI 10.1023/A:1018908421434                                                         
   Yu YY, 1997, J PHYS CHEM B, V101, P6661
   Zara GP, 2002, J DRUG TARGET, V10, P327, DOI 10.1080/10611860290031868
   Zara GP, 1999, PHARMACOL RES, V40, P281, DOI 10.1006/phrs.1999.0509
   Zhao JS, 2009, J TOXICOL ENV HEAL A, V72, P1141, DOI 10.1080/15287390903091764
   Zhou Y, 1999, CHEM MATER, V11, P545, DOI 10.1021/cm981122h                                                               
NR 139
TC 59
Z9 63
U1 0
U2 17
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2010
VL 5
BP 533
EP 547
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 674DW
UT WOS:000283715300055
PM 20957115
DA 2018-01-05
ER

PT J
AU Sakaue, Y
   Kim, J
   Miyamoto, Y
AF Sakaue, Yuri
   Kim, Juewon
   Miyamoto, Yusei
TI Effects of TAT-conjugated platinum nanoparticles on lifespan of
   mitochondrial electron transport complex I-deficient Caenorhabditis
   elegans, nuo-1
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE platinum nanoparticles; Caenorhabditis elegans; complex I-deficient
   mutant; LB25; lifespan
ID CELL-PENETRATING PEPTIDES; GOLD NANOPARTICLES; MUTATIONS; DELIVERY;
   STRESS
AB Platinum nanoparticle (Pt-np) species are superoxide dismutase/catalase mimetics and also have an activity similar to that of mitochondrial electron transport complex I. To examine if this complex I-like activity functions in vivo, we studied the effects of Pt-nps on the lifespan of a mitochondrial complex I-deficient Caenorhabditis elegans mutant, nuo-1 (LB25) compared with wild-type N2. We synthesized a fusion protein of a cell-penetrating peptide, human immunodeficiency virus-1 TAT (48-60), C-terminally linked to a peptide with a high affinity to platinum (GRKKRRQRRRPPQ-DRTSTWR). Pt-nps were functionalized by conjugation with this fusion protein at a 1:1 ratio of TAT-PtBP to Pt atoms. Adult worms were treated with conjugated Pt-nps for 10 days. The mean lifespan of untreated N2 and LB25 was 19.6 +/- 0.4 and 11.8 +/- 0.3 days, respectively. Using 5 mu M of conjugated Pt-nps, the lifespan of N2 and LB25 was maximally extended. This maximal lifespan extension of LB25 was 31.9 +/- 2.6%, which was significantly greater than that of N2 (21.1 +/- 1.7%, P < 0.05 by Student's t-test). Internalization of Pt into the whole body and mitochondria was similar between these two strains. Excessive accumulation of reactive oxygen species was not observed in the cytosol or mitochondria of untreated LB25. Treatment for five days with 5 mu M conjugated Pt-nps decreased cytosolic and mitochondrial reactive oxygen species in N2 and LB25 to a similar extent. The ratio of [NAD(+)]/[NADH] was very low in the whole body and mitochondria of control LB25. After five days of treatment with 5 mu M conjugated Pt-nps, the ratio of [NAD(+)]/[NADH] was increased in N2 and LB25. However, the degree of the increase was much higher in LB25 than in N2. Pt-nps function as NADH oxidase and recover the [NAD(+)]/[NADH] ratio in LB25, leading to effective extension of the lifespan of LB25.
C1 [Miyamoto, Yusei] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan.
RP Miyamoto, Y (reprint author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Biosci Bldg 402,5-1-5 Kashiwanoha, Chiba 2778562, Japan.
EM yusei74@k.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
FX This work was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science, and
   Technology, Japan.
CR Barone M, 2008, J MATER CHEM, V18, P5531, DOI 10.1039/b809121h
   Benit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   BRENNER S, 1974, GENETICS, V77, P71
   Cao ZX, 2007, ANAL LETT, V40, P2116, DOI 10.1080/00032710701566909
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Delom F, 2007, BIOCHEM BIOPH RES CO, V352, P587, DOI 10.1016/j.bbrc.2006.11.046
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Grad LI, 2004, HUM MOL GENET, V13, P303, DOI 10.1093/hmg/ddh027
   HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C
   Heidler T, 2010, BIOGERONTOLOGY, V11, P183, DOI 10.1007/s10522-009-9239-x
   Hikosaka K, 2008, COLLOID SURFACE B, V66, P195, DOI 10.1016/j.colsurfb.2008.06.008
   Hirst J, 2010, BIOCHEM J, V425, P327, DOI 10.1042/BJ20091382
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603
   Kajita M, 2007, FREE RADICAL RES, V41, P615, DOI 10.1080/10715760601169679
   Kim J, 2008, MECH AGEING DEV, V129, P322, DOI 10.1016/j.mad.2008.02.011
   Kim J, 2010, BIOMATERIALS, V31, P5849, DOI 10.1016/j.biomaterials.2010.03.077
   Korenaga M, 2005, J CLIN GASTROENTEROL, V39, pS162, DOI 10.1097/01.mcg.0000155517.02468.46                                              
   Pelka J, 2009, CHEM RES TOXICOL, V22, P649, DOI 10.1021/tx800354g
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Ross MF, 2004, BIOCHEM SOC T, V32, P1072, DOI 10.1042/BST0321072                                                              
   Sarikaya M, 2003, NAT MATER, V2, P577, DOI 10.1038/nmat964
   Schuelke M, 1999, NAT GENET, V21, P260
   SULSTON JE, 1974, GENETICS, V77, P95
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   VIVES E, 2002, CELL PENETRATING PEP
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Watanabe A, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/45/455105
   Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013
   Zhang LB, 2010, NANO LETT, V10, P219, DOI 10.1021/nl903313r
NR 34
TC 12
Z9 13
U1 1
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2010
VL 5
BP 687
EP 695
PG 9
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 674DW
UT WOS:000283715300072
PM 20957220
DA 2018-01-05
ER

PT J
AU Vo-Dinh, T
   Wang, HN
   Scaffidi, J
AF Vo-Dinh, Tuan
   Wang, Hsin-Neng
   Scaffidi, Jonathan
TI Plasmonic nanoprobes for SERS biosensing and bioimaging
SO JOURNAL OF BIOPHOTONICS
LA English
DT Review
DE Raman; SERS; plasmonics; hyperspectral surface-enhanced Raman imaging;
   gene diagnostics; metallic nanoprobes; molecular sentinel; pH nanosensor
ID SURFACE-ENHANCED-RAMAN; SCATTERING SERS; SINGLE-MOLECULE; METAL
   NANOSPHERES; SILVER; SPECTROSCOPY; DNA; SPECTROMETRY; NANOPARTICLES;
   COLLOIDS
AB This article provides an overview of the development and application of plasmonic nanoprobes developed in our laboratory for biosensing and bioimaging. We describe the use of plasmonics surface-enhanced Raman scattering (SERS) gene probes for the detection of diseases using DNA hybridization to target biospecies (HIV gene, breast cancer genes etc.). For molecular imaging, we describe a hyperspectral surface-enhanced Raman imaging (HSERI) system that combines imaging capabilities with SERS detection to identify cellular components using Raman dye-labeled silver nanoparticles in cellular systems The detection of specific target DNA sequences associated with breast cancer using "molecular sentinel" nanoprobes and the use of a plasmonic nanosensor to monitor pH in single cells are presented and discussed.
   [GRAPHICS]
   Plasmonic nanosensors and nanoprobes have been developed as sensitive and selective tolls for environmental monitoring, cellular biosensing, medical diagnostics and high throughput screnning (C) 2010 by WILEY-VCH Verlag GmbH & Co. KGaA. Weinheim
C1 [Vo-Dinh, Tuan] Duke Univ, Fitzpatrick Inst Photon, Dept Biomed Engn, Durham, NC 27708 USA.
   Duke Univ, Fitzpatrick Inst Photon, Dept Chem, Durham, NC 27708 USA.
RP Vo-Dinh, T (reprint author), Duke Univ, Fitzpatrick Inst Photon, Dept Biomed Engn, Durham, NC 27708 USA.
EM tuan.vodinh@duke.edu
RI Wang, Hsin-Neng/D-9631-2013
FU National Institutes of Health [R01 EB006201, R01 ES014774-01A1]
FX The authors acknowledge the contribution of D. L. Stokes, M. Wabuyele,
   G. D. Griffin, N. Isola, F. Yan, C. Khoury, and M. Gregas. This work was
   sponsored by the National Institutes of Health (Grants R01 EB006201 and
   R01 ES014774-01A1).
CR ALAK AM, 1987, ANAL CHEM, V59, P2149, DOI 10.1021/ac00144a030
   ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   Allain LR, 2002, ANAL CHIM ACTA, V469, P149, DOI 10.1016/S0003-2670(01)01537-9                                                   
   BELLO JM, 1989, ANAL CHEM, V61, P1779, DOI 10.1021/ac00190a600                                                             
   BELLO JM, 1989, APPL SPECTROSC, V43, P1325, DOI 10.1366/0003702894204326
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chang R. K., 1982, SURFACE ENHANCED RAM
   DHAWAN A, NANOBIOTECH IN PRESS, DOI DOI 10.1007/S12030-008-9017-X
   Doering WE, 2002, J PHYS CHEM B, V106, P311, DOI 10.1021/jp011730b
   ENLOW PD, 1986, ANAL CHEM, V58, P1119, DOI 10.1021/ac00297a031
   Faulds K, 2005, ANALYST, V130, P1125, DOI 10.1039/b500248f
   Faulds K, 2004, ANAL CHEM, V76, P412, DOI 10.1021/ac035060c
   Graham D, 1997, ANAL CHEM, V69, P4703, DOI 10.1021/ac970657b                                                               
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Jackson JB, 2003, APPL PHYS LETT, V82, P257, DOI 10.1063/1.1534916
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V1, P84
   KERKER M, 1984, ACCOUNTS CHEM RES, V17, P271, DOI 10.1021/ar00104a002                                                             
   Khoury CG, 2008, J PHYS CHEM C, V112, P18849, DOI 10.1021/jp8054747
   Kneipp J, 2007, NANO LETT, V7, P2819, DOI 10.1021/nl071418z
   Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667
   Kneipp K., 2006, SURFACE ENHANCED RAM
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Leopold N, 2003, J PHYS CHEM B, V107, P5723, DOI 10.1021/jp027460u
   Li KR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.227402
   LIU G, 2005, APPL PHYS LETT, V87
   Michaels AM, 2000, J PHYS CHEM B, V104, P11965, DOI 10.1021/jp0025476
   MOODY RL, 1987, APPL SPECTROSC, V41, P966, DOI 10.1366/0003702874447761
   Moskovits M, 2005, J RAMAN SPECTROSC, V36, P485, DOI 10.1002/jrs.1362
   MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   Norton SJ, 2007, IEEE T NANOTECHNOL, V6, P627, DOI 10.1109/TNANO.2007.909074
   Norton SJ, 2008, J OPT SOC AM A, V25, P2767, DOI 10.1364/JOSAA.25.002767
   Norton SJ, 2008, J NANOPHOTONICS, V2, DOI 10.1117/1.3001731
   OTTO A, 1992, J PHYS-CONDENS MAT, V4, P1143, DOI 10.1088/0953-8984/4/5/001
   POCKRAND I, 1984, SURFACE ENHANCED RAM
   Scaffidi JP, 2009, ANAL BIOANAL CHEM, V393, P1135, DOI 10.1007/s00216-008-2521-y
   SCHATZ GC, 1984, ACCOUNTS CHEM RES, V17, P370, DOI 10.1021/ar00106a005                                                             
   Stockman MI, 2004, PROC SPIE, V5512, P87, DOI 10.1117/12.555743
   Stokes DL, 2004, APPL SPECTROSC, V58, P292, DOI 10.1366/000370204322886636                                                      
   Talley CE, 2004, ANAL CHEM, V76, P7064, DOI 10.1021/ac049093j
   Vo-Dinh T, 1998, TRAC-TREND ANAL CHEM, V17, P557, DOI 10.1016/S0165-9936(98)00069-7                                                   
   Vo-Dinh T, 2005, J RAMAN SPECTROSC, V36, P640, DOI 10.1002/jrs.1348
   VO-DINH T, 1984, ANAL CHEM, V56, P1667, DOI 10.1021/ac00273a029                                                             
   Vo-Dinh T, 2002, J RAMAN SPECTROSC, V33, P511, DOI 10.1002/jrs.883
   VO-DINH T, 1987, APPL SPECTROSC, V41, P605, DOI 10.1366/0003702874448616                                                        
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   VODINH T, 1988, SPECTROCHIM ACTA B, V415, P605
   WABUYELE M, 2005, REV SCI INSTRUM, V76
   Wabuyele MB, 2005, ANAL CHEM, V77, P7810, DOI 10.1021/ac0514671
   Wang HN, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/6/065101
   WOKAUN A, 1982, PHYS REV LETT, V48, P957, DOI 10.1103/PhysRevLett.48.957
   Xu HX, 2000, PHYS REV E, V62, P4318, DOI 10.1103/PhysRevE.62.4318
   Zeisel D, 1998, CHEM PHYS LETT, V283, P381, DOI 10.1016/S0009-2614(97)01391-2
NR 53
TC 110
Z9 112
U1 6
U2 157
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD JAN
PY 2010
VL 3
IS 1-2
BP 89
EP 102
DI 10.1002/jbio.200910015
PG 14
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA 552BY
UT WOS:000274262900016
PM 19517422
OA gold
DA 2018-01-05
ER

PT J
AU Read, SP
   Cashman, SM
   Kumar-Singh, R
AF Read, Sarah Parker
   Cashman, Siobhan M.
   Kumar-Singh, Rajendra
TI A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA
   into nanoparticles for gene delivery to post-mitotic tissues in vivo
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE cell penetrating peptide; gene delivery; nonviral; POD
ID PHOTORECEPTOR CELL DEGENERATION; HIV-1 TAT PROTEIN; POLY-L-LYSINE;
   PLASMID DNA; TRANSFECTION; EXPRESSION; VECTORS; COMPLEXES; SERUM; LUNG
AB Background We have Previously shown that a novel synthetic peptide for ocular delivery (POD) can efficiently compact DNA and deliver it to cells in vitro. This observation prompted us to develop use of POD as a nonviral vector in vivo.
   Methods POD peptide was modified using poly(ethylene) glycol (PEG-POD) and used to compact DNA into nanoparticles that were then analysed using electron microscopy, dynamic light scattering, and fluorescent labeling. Transfection efficiency and localization were determined 48 h post-injection into the subretinal space of the mouse eye using luciferase and LacZ, respectively. Efficiency of ocular transfection was compared to two other PEGylated peptides: PEG-TAT and PEG-CK30.
   Results PEG-POD can compact DNA and form discrete nanoparticles of approximately 136 nm that can penetrate and transduce the retinal pigment epithelium (RPE) in vivo. PEG-POD significantly increased expression of plasmid DNA by 215-fold, PEG-TAT by 56.52-fold, and PEG-CK30 by 24.73-fold relative to DNA injected alone. In all cases beta-galactosidase was observed primarily in the RPE layer after subretinal injection. Electrophysiological analyses of PEG-POD transduced retina indicates an absence of PEG-POD-mediated toxicity. PEG-POD can protect plasmid DNA from DNaseI digestion, resulting in significant transfection of the lung after intravenous injection in mice.
   Conclusions PEG-POD was found to significantly increase gene delivery relative to both DNA alone and other pegylated peptides. These findings highlight the use of pegylated peptides, and specifically PEG-POD, as novel gene delivery vectors. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Read, Sarah Parker; Cashman, Siobhan M.; Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
RP Kumar-Singh, R (reprint author), Tufts Univ, Sch Med, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
FU National Institutes of Health/National Eye Institute [EY014991,
   EY013887]; The Foundation for Fighting Blindness; The Ellison
   Foundation; Virginia B Smith Trust; Lions Eye Foundation and Research to
   Prevent Blindness
FX This study was supported by grants to R.K-S. from the National
   Institutes of Health/National Eye Institute (EY014991 and EY013887), The
   Foundation for Fighting Blindness, The Ellison Foundation, the Virginia
   B Smith Trust, and grants to the Department of ophthalmology at Tufts
   University from the Lions Eye Foundation and Research to Prevent
   Blindness. We would also like to thank David Kaplan at Tufts University
   for his assistance in performing the dynamic light scattering
   experiments.
CR Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102
   Davis PB, 2007, AAPS J, V9, pE11, DOI 10.1208/aapsj0901002                                                            
   Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534
   Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   JOHNSON LN, 2009, VISION RES IN PRESS
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505
   Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255                                                        
   Kumar-Singh R, 2008, VISION RES, V48, P1671, DOI 10.1016/j.visres.2008.05.005
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   LOVE JD, 1979, J BIOL CHEM, V254, P2588
   Mishra S, 2004, EUR J CELL BIOL, V83, P97, DOI 10.1078/0171-9335-00363
   Moore D., 2008, PRACTICE BUSINESS ST
   Neuner-Jehle M, 2000, HUM GENE THER, V11, P1875, DOI 10.1089/10430340050129495
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Takeshita H, 2004, CLIN CHEM, V50, P446, DOI 10.1373/clinchem.2003.025304
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126                                                          
   Ward MS, 2007, J PHARM SCI-US, V96, P558, DOI 10.1002/jps.20629
   Zhu CN, 2002, INVEST OPHTH VIS SCI, V43, P3075
   Ziady AG, 2003, MOL THER, V8, P936, DOI 10.1016/j.ymthe.2003.07.007
   Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002
NR 30
TC 22
Z9 22
U1 0
U2 16
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1099-498X
J9 J GENE MED
JI J. Gene. Med.
PD JAN
PY 2010
VL 12
IS 1
BP 86
EP 96
DI 10.1002/jgm.1415
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 547NF
UT WOS:000273895600009
PM 19937991
OA gold
DA 2018-01-05
ER

PT J
AU Gao, J
   Wang, HL
   Iyer, R
AF Gao, Jun
   Wang, Hsing-Lin
   Iyer, Rashi
TI Suppression of Proinflammatory Cytokines in Functionalized
   Fullerene-Exposed Dermal Keratinocytes
SO JOURNAL OF NANOMATERIALS
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; EPIDERMAL-KERATINOCYTES; BIOLOGICAL
   APPLICATIONS; HIV-1 PROTEASE; EXPRESSION; FAMILY; CELLS; SKIN;
   INFLAMMATION; DERIVATIVES
AB Initial experiments using differentially functionalized fullerenes, CD-C-60, hexa-C-60, and tris-C-60, suggested a properties dependent effect on cytotoxic and proliferative responses in human skin keratinocytes. In the present study we investigated the cytokine secretion profile of dermal epithelial cells exposed to functionalized fullerenes. Keratinocyte-derived cytokines affect homing and trafficking of normal and malignant epidermal immune as well as nonimmune cells in vivo. These cytokines are critical for regulating activation, proliferation, and differentiation of epidermal cells. Our results indicate that tris-C-60 (size range < 100 nm) significantly reduces inflammatory cytokine release in a dose- and time-dependent manner. In contrast CD-C-60 demonstrated a relatively pro-inflammatory cytokine response, while hexa-C-60 did not significantly perturb cytokine responses. Physical and chemical characterizations of these engineered nanomaterials suggest that the disparate biological responses observed may potentially be a function of the aggregation properties of these fullerenes.
C1 [Gao, Jun; Iyer, Rashi] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA.
   [Wang, Hsing-Lin] Los Alamos Natl Lab, Div Chem, Los Alamos, NM 87545 USA.
RP Iyer, R (reprint author), Los Alamos Natl Lab, Biosci Div, M888,TA 43,HRL-2, Los Alamos, NM 87545 USA.
EM rashi@lanl.gov
FU Los Alamos National Laboratory, LDRD-DR program; Center for Integrated
   Nanotechnologies, a U. S. Department of Energy, Office of Basic Energy
   Sciences user facility, Los Alamos National Laboratory
   [DE-AC52-06NA25396]; Sandia National Laboratory [DE-AC04-94AL85000]
FX This work was supported by Los Alamos National Laboratory, LDRD-DR
   program. This work was performed, in part, at the Center for Integrated
   Nanotechnologies, a U. S. Department of Energy, Office of Basic Energy
   Sciences user facility, Los Alamos National Laboratory (Contract
   DE-AC52-06NA25396), and Sandia National Laboratory (Contract
   DE-AC04-94AL85000). The authors thank Gabriel A. Montano and Jennifer
   Martinez for their assistance with the physical characterization of the
   fullerenes.
CR ANDERSSON T, 1992, J CHEM SOC CHEM COMM, P604, DOI 10.1039/c39920000604
   ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783
   BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2
   Bisaglia M, 2000, J NEUROCHEM, V74, P1197
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   CHABOTFLETCHER M, 1994, J INVEST DERMATOL, V103, P509, DOI 10.1111/1523-1747.ep12395658
   Corsini Emanuela, 1998, Toxicology Letters (Shannon), V102-103, P277, DOI 10.1016/S0378-4274(98)00323-3
   Da Ros T, 2001, CROAT CHEM ACTA, V74, P743
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Fukuoka M, 1998, BRIT J DERMATOL, V138, P63
   Grone A, 2002, VET IMMUNOL IMMUNOP, V88, P1, DOI 10.1016/S0165-2427(02)00136-8
   Ibisch C, 2007, VET RES COMMUN, V31, P835, DOI 10.1007/s11259-007-0004-9
   JIANG YL, 1992, J IMMUNOL, V148, P2423
   Lisby S, 2002, EXP DERMATOL, V11, P592, DOI 10.1034/j.1600-0625.2002.110612.x                                               
   McKenzie R. C., 1990, J INVEST DERMATOL S, V95, P105
   NORRIS DA, 1990, J INVEST DERMATOL, V95, P111
   Nose K, 2000, BIOL PHARM BULL, V23, P897
   Paus R, 1993, Exp Dermatol, V2, P3, DOI 10.1111/j.1600-0625.1993.tb00192.x
   Rebecca M, 2009, TOXICOL APPL PHARM, V234, P58, DOI 10.1016/j.taap.2008.08.021
   RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209
   ROLLINS BJ, 1991, BLOOD, V78, P1112
   SAUDER DN, 1990, J INVEST DERMATOL, V95, pS27, DOI 10.1111/1523-1747.ep12505705
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4                                                    
   Schroder J M, 1992, Exp Dermatol, V1, P12, DOI 10.1111/j.1600-0625.1992.tb00066.x
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Uekawa N, 2004, FEBS LETT, V575, P30, DOI 10.1016/j.febslet.2004.08.033
   VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039                                                             
   WILLIAMS SR, 1992, AM J PHYSIOL, V263, pC194
   Ye J, 2002, EXP DERMATOL, V11, P209, DOI 10.1034/j.1600-0625.2002.110303.x                                               
   Yoshimura T, 1992, Cytokines, V4, P131
   Zhang LW, 2008, TOXICOL APPL PHARM, V228, P200, DOI 10.1016/j.taap.2007.12.022
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 34
TC 2
Z9 2
U1 3
U2 5
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1687-4110
EI 1687-4129
J9 J NANOMATER
JI J. Nanomater.
PY 2010
AR 416408
DI 10.1155/2010/416408
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 578OD
UT WOS:000276302200001
OA gold
DA 2018-01-05
ER

PT J
AU Yun, H
   Bang, H
   Min, J
   Chung, C
   Chang, JK
   Han, DC
AF Yun, Hoyoung
   Bang, Hyunwoo
   Min, Junggi
   Chung, Chanil
   Chang, Jun Keun
   Han, Dong-Chul
TI Simultaneous counting of two subsets of leukocytes using fluorescent
   silica nanoparticles in a sheathless microchip flow cytometer
SO LAB ON A CHIP
LA English
DT Article
ID ACTIVATED CELL SORTER; HYDRODYNAMIC FILTRATION; PARTICLE-CONCENTRATION;
   SEPARATION; BLOOD; MICROPARTICLES; MICROCHANNELS; ENUMERATION; CHANNEL;
   COST
AB A portable flow cytometer has been recognized as an important tool for many clinical applications such as HIV/AIDS screening in developing countries and regions with limited medical facilities and resources. Conventional flow cytometers typically require multiple detectors for simultaneous identification of multiple subsets of immune cell. To minimize the number of detectors toward portable flow cytometry or to analyze multi-parametric cellular information with minimum number of detectors in conventional flow cytometers, we propose a versatile multiplexed cell-counting method using functional silica nanoparticles (SiNPs). FITC-doped SiNPs, which are 100 times brighter than the FITC molecules itself, were used as new intensity-based fluorescent dye complexes to simultaneously measure two subsets of leukocytes using a single detector. CD45(+)CD4(+) cells tagged with these FITC-doped SiNPs were 50 times brighter than CD45(+)CD4(-) cells tagged only with FITC. To make the overall system compact, a disposable microchip flow cytometer that does not require sheath flow was developed. Combining these dye-doped SiNPs based detection schemes and the sheathless microchip flow cytometer scheme, we successfully identified and counted two subsets of leukocytes simultaneously (R(2) = 0.876). These approaches can be the building blocks for a truly portable and disposable flow cytometer for various clinical cytometry applications.
C1 [Yun, Hoyoung; Han, Dong-Chul] Seoul Natl Univ, Inst Adv Machinery & Design, Seoul 151742, South Korea.
   [Yun, Hoyoung; Bang, Hyunwoo; Min, Junggi] Seoul Natl Univ, Sch Mech & Aerosp Engn, Seoul 151742, South Korea.
   [Chung, Chanil; Chang, Jun Keun] NanoEnTek Inc, Seoul, South Korea.
   [Han, Dong-Chul] Seoul Natl Univ, AMED Inc, Seoul 151742, South Korea.
RP Han, DC (reprint author), Seoul Natl Univ, Inst Adv Machinery & Design, San 56-1 Shinlim Dong, Seoul 151742, South Korea.
EM ho02@snu.ac.kr
FU Korea Ministry of Knowledge Economy (MKE) [F0001017-2009-34]; MKE
FX The authors wish to thank W. G. Lee (Kyung Hee University) for helpful
   discussions; S. Chung (Korea University) for invaluable guidance; and D.
   S. Hur and E. H. Park (NanoEnTek, Inc) for providing silica
   nanoparticles and helpful information. This research has been supported
   by the Intelligent Microsystem Center, which carries out one of the 21st
   century's Frontier R&D Projects sponsored by the Korea Ministry of
   Knowledge Economy (MKE, F0001017-2009-34) and Advanced Microsystem
   Packing Program of MKE.
CR Aoki R, 2009, MICROFLUID NANOFLUID, V6, P571, DOI 10.1007/s10404-008-0334-0
   Ateya DA, 2008, ANAL BIOANAL CHEM, V391, P1485, DOI 10.1007/s00216-007-1827-5
   Bang HW, 2006, MICROSYST TECHNOL, V12, P746, DOI 10.1007/s00542-005-0076-9
   Bang HW, 2006, LAB CHIP, V6, P1381, DOI 10.1039/b604578b
   BHAGAT A, 2009, BIOMED MICRODEVICES, P1
   Bhagat AAS, 2008, LAB CHIP, V8, P1906, DOI 10.1039/b807107a
   Bikoue A, 1996, CYTOMETRY, V26, P137, DOI 10.1002/(SICI)1097-0320(19960615)26:2<137::AID-CYTO7>3.3.CO;2-E
   Bonetta L, 2005, NAT METHODS, V2, P785, DOI 10.1038/nmeth1005-785                                                           
   Bradford JA, 2004, CYTOM PART A, V61A, P142, DOI 10.1002/cyto.a.20037
   Brando B, 2000, CYTOMETRY, V42, P327, DOI 10.1002/1097-0320(20001215)42:6<327::AID-CYTO1000>3.0.CO;2-F                    
   Burns A, 2006, CHEM SOC REV, V35, P1028, DOI 10.1039/b600562b
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Choi S, 2008, SMALL, V4, P634, DOI 10.1002/smll.200700308
   Choi S, 2007, LAB CHIP, V7, P890, DOI 10.1039/b701227f
   Cohen J, 2004, SCIENCE, V304, P1936, DOI 10.1126/science.304.5679.1936
   Cottinghamm K., 2005, ANAL CHEM, V77, p73A
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477
   DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802
   Denny TN, 1996, CYTOMETRY, V26, P265, DOI 10.1002/(SICI)1097-0320(19961215)26:4<265::AID-CYTO5>3.0.CO;2-B                 
   Di Carlo D, 2008, ANAL CHEM, V80, P2204, DOI 10.1021/ac702283m
   Di Carlo D, 2007, P NATL ACAD SCI USA, V104, P18892, DOI 10.1073/pnas.0704958104
   Estevez MC, 2009, NANO RES, V2, P448, DOI [10.1007/S12274-009-9041-8, 10.1007/s12274-009-9041-8]
   Fiorini GS, 2005, BIOTECHNIQUES, V38, P429, DOI 10.2144/05383RV02
   Fu AY, 1999, NAT BIOTECHNOL, V17, P1109
   Glencross D, 2002, CYTOMETRY, V50, P69, DOI 10.1002/cyto.10068
   Goddard G, 2006, CYTOM PART A, V69A, P66, DOI 10.1002/cyto.a.20205
   Goddard GR, 2007, ANAL CHEM, V79, P8740, DOI 10.1021/ac071402t
   GOSSETT D, 2009, ANAL CHEM, P136
   Greve B, 2003, TRANSFUS MED HEMOTH, V30, P8, DOI 10.1159/000069339
   Harding CL, 2000, BIOTECHNOL PROGR, V16, P800, DOI 10.1021/bp0000813
   Holmes D, 2006, BIOSENS BIOELECTRON, V21, P1621, DOI 10.1016/j.bios.2005.10.017
   HONG DC, 1992, PHYSICA A, V187, P159, DOI 10.1016/0378-4371(92)90416-N                                                    
   HORAN PK, 1986, P NATL ACAD SCI USA, V83, P8361, DOI 10.1073/pnas.83.21.8361
   Houwen B, 2001, LAB HEMATOL, V7, P89
   Huh D, 2002, BIOMED MICRODEVICES, V4, P141, DOI 10.1023/A:1014691416614
   Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x
   Janossy G, 2003, CLIN APPL IMMUNOL RE, V4, P91
   Kapoor V, 2007, NAT METHODS, V4, P678, DOI 10.1038/nmeth0907-678
   Karcher H, 2006, CYTOM PART B-CLIN CY, V70B, P163, DOI 10.1002/cyto.b.20093
   Kassab GS, 2000, ANN BIOMED ENG, V28, P424, DOI 10.1114/1.280
   Kim JS, 2010, MICROFLOW CYTOMETER, P311
   Kim SB, 2008, ANAL CHEM, V80, P2628, DOI 10.1021/ac8000918
   LAERUM OD, 1981, CYTOMETRY, V2, P1, DOI 10.1002/cyto.990020102
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Mandy F, 2008, CYTOM PART B-CLIN CY, V74B, pS27, DOI 10.1002/cyto.b.20414
   Mandy FF, 1997, CYTOMETRY, V30, P157, DOI 10.1002/(SICI)1097-0320(19970815)30:4<157::AID-CYTO1>3.3.CO;2-I
   Mandy Francis F, 2003, MMWR Recomm Rep, V52, P1
   Marella SV, 2004, PHYS FLUIDS, V16, P244, DOI 10.1063/1.1629691
   Masur P. b. H., 2002, ANN INTERN MED, V137, P435
   Ow H, 2005, NANO LETT, V5, P113, DOI [10.1021/nl0482478, 10.1012/nl0482478]
   Park JS, 2009, ANAL CHEM, V81, P8280, DOI 10.1021/ac9005765
   Park JS, 2009, LAB CHIP, V9, P939, DOI 10.1039/b813952k
   Park J, 2006, CURR APPL PHYS, V6, P992, DOI 10.1016/j.cap.2005.07.004
   Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416
   Phillips CG, 1997, RESP PHYSIOL, V107, P85, DOI 10.1016/S0034-5687(96)02506-6
   Qhobosheane M, 2001, ANALYST, V126, P1274, DOI 10.1039/b101489g                                                                
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Santra S, 2006, J LUMIN, V117, P75, DOI 10.1016/j.jlumin.2005.04.008
   Schmid I, 2007, NAT PROTOC, V2, P187, DOI 10.1038/nprot.2006.458
   SHAPIRO HM, 1983, CYTOMETRY, V3, P227, DOI 10.1002/cyto.990030402
   Sharma P, 2006, ADV COLLOID INTERFAC, V123, P471, DOI 10.1016/j.cis.2006.05.026
   Sharp KV, 2005, MICROFLUID NANOFLUID, V1, P376, DOI 10.1007/s10404-005-0043-x
   Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1067/mai.2003.1778
   Shelby JP, 2003, NATURE, V425, P38, DOI 10.1038/425038a
   Shi JJ, 2008, LAB CHIP, V8, P221, DOI 10.1039/b716321e
   Smith AM, 2006, EXPERT REV MOL DIAGN, V6, P231, DOI 10.1586/14737159.6.2.231
   Srithanaviboonchai K, 2008, JAIDS-J ACQ IMM DEF, V47, P135, DOI 10.1097/QAI.0b013e3181624ab5                                                    
   To K, 2001, PHYS REV LETT, V86, P71, DOI 10.1103/PhysRevLett.86.71                                                       
   Tung JW, 2004, CLIN IMMUNOL, V110, P277, DOI 10.1016/j.clim.2003.11.016
   Verpoorte E, 2003, LAB CHIP, V3, p42N, DOI 10.1039/b307927a
   Wang L, 2007, LAB CHIP, V7, P1114, DOI 10.1039/b705386j
   Wang MM, 2005, NAT BIOTECHNOL, V23, P83, DOI 10.1038/nbt1050
   World Health Organization, 2006, HIV AIDS PROGR ANT T
   Wyss HM, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.061402
   Yamada M, 2005, LAB CHIP, V5, P1233, DOI 10.1039/b509386d
   Yan JL, 2007, NANO TODAY, V2, P44, DOI 10.1016/S1748-0132(07)70086-5                                                   
   Zhao XJ, 2004, ADV MATER, V16, P173, DOI 10.1002/adma.200305622
NR 80
TC 29
Z9 30
U1 0
U2 25
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2010
VL 10
IS 23
BP 3243
EP 3254
DI 10.1039/c0lc00041h
PG 12
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 678IV
UT WOS:000284068200009
PM 20941407
DA 2018-01-05
ER

PT S
AU Liu, J
   Wright, ER
   Winkler, H
AF Liu, Jun
   Wright, Elizabeth R.
   Winkler, Hanspeter
BE Jensen, GJ
TI 3D VISUALIZATION OF HIV VIRIONS BY CRYOELECTRON TOMOGRAPHY
SO METHODS IN ENZYMOLOGY, VOL 483: CRYO-EM, PART C: ANALYSES,
   INTERPRETATION, AND CASE STUDIES
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ELECTRON TOMOGRAPHY; 3-DIMENSIONAL
   STRUCTURE; ENVELOPE GLYCOPROTEIN; GAG PROTEIN; INTERSUBUNIT
   INTERACTIONS; FLAGELLAR MOTOR; MATRIX PROTEIN; TILT-SERIES; GP120 CORE
AB The structure of the human immunodeficiency virus (HIV) and some of its components have been difficult to study in three-dimensions (3D) primarily because of their intrinsic structural variability. Recent advances in cryoelectron tomography (cryo-ET) have provided a new approach for determining the 3D structures of the intact virus, the HIV capsid, and the envelope glycoproteins located on the viral surface. A number of cryo-ET procedures related to specimen preservation, data collection, and image processing are presented in this chapter. The techniques described herein are well suited for determining the ultrastructure of bacterial and viral pathogens and their associated molecular machines in situ at nanometer resolution.
C1 [Liu, Jun] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA.
   [Wright, Elizabeth R.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   [Winkler, Hanspeter] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.
RP Liu, J (reprint author), Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA.
FU NIGMS NIH HHS [R01 GM082948]; NIAID NIH HHS [R01 AI087946-01,
   1R01AI087946, R01 AI087946]
CR Accola MA, 1998, J VIROL, V72, P2072
   Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311
   Bartesaghi A, 2008, J STRUCT BIOL, V162, P436, DOI 10.1016/j.jsb.2008.02.008
   Baumeister W, 1999, TRENDS CELL BIOL, V9, P81, DOI 10.1016/S0962-8924(98)01423-8                                                   
   Beck M, 2007, NATURE, V449, P611, DOI 10.1038/nature06170
   Benjamin J, 2005, J MOL BIOL, V346, P577, DOI 10.1016/j.jmb.2004.11.064
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Briggs JAG, 2006, J MOL BIOL, V355, P157, DOI 10.1016/j.jmb.2005.10.025
   Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Byeon IJL, 2009, CELL, V139, P780, DOI 10.1016/j.cell.2009.10.010
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chen L, 2009, SCIENCE, V326, P1123, DOI 10.1126/science.1175868
   Dai W, 2008, J STRUCT BIOL, V161, P428, DOI 10.1016/j.jsb.2007.10.010
   DOUGLAS CC, 2004, BIOCHEMISTRY-US, V43, P10433
   DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297
   Forster F, 2008, J STRUCT BIOL, V161, P276, DOI 10.1016/j.jsb.2007.07.006
   Forster F, 2005, P NATL ACAD SCI USA, V102, P4729, DOI 10.1073/pnas.0409178102
   FRANGAKIS AS, 2006, ELECT TOMOGRAPHY MET
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9
   Ganser BK, 2003, EMBO J, V22, P2886, DOI 10.1093/emboj/cdg276                                                            
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Gay B, 1998, VIROLOGY, V247, P160, DOI 10.1006/viro.1998.9237
   GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   HARAUZ G, 1986, OPTIK, V73, P11
   Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933                                                          
   KOSTER AJ, 1992, ULTRAMICROSCOPY, V46, P207, DOI 10.1016/0304-3991(92)90016-D                                                    
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lanman J, 2003, J MOL BIOL, V325, P759, DOI 10.1016/S0022-2836(02)01245-7
   Lanman J, 2002, J VIROL, V76, P6900, DOI 10.1128/JVI.76.14.6900-6908.2002
   Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100
   Li S, 2000, NATURE, V407, P409
   Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002
   Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Liu J, 2009, J BACTERIOL, V191, P5026, DOI 10.1128/JB.00340-09
   Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112
   Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174
   Massiah MA, 1996, PROTEIN SCI, V5, P2391, DOI 10.1002/pro.5560051202                                                          
   MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   MCEWEN BF, 1995, ULTRAMICROSCOPY, V60, P357, DOI 10.1016/0304-3991(95)00082-8
   Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184                                                         
   Murphy GE, 2006, NATURE, V442, P1062, DOI 10.1038/nature05015
   Nermut MV, 1998, J STRUCT BIOL, V123, P143, DOI 10.1006/jsbi.1998.4024
   Nickell S, 2005, J STRUCT BIOL, V149, P227, DOI 10.1016/j.jsb.2004.10.006
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pornillos O., 2009, CELL, V137, P1282
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Subramaniam S, 2005, CURR OPIN MICROBIOL, V8, P316, DOI 10.1016/j.mib.2005.04.012
   Subramaniam S, 2007, CURR OPIN STRUC BIOL, V17, P596, DOI 10.1016/j.sbi.2007.09.009
   Suloway C, 2009, J STRUCT BIOL, V167, P11, DOI 10.1016/j.jsb.2009.03.019
   Walz J, 1997, J STRUCT BIOL, V120, P387, DOI 10.1006/jsbi.1997.3934                                                          
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   Winkler H, 2006, ULTRAMICROSCOPY, V106, P240, DOI 10.1016/j.ultramic.2005.07.007
   Winkler H, 2007, J STRUCT BIOL, V157, P126, DOI 10.1016/j.jsb.2006.07.014
   Winkler H, 2009, J STRUCT BIOL, V165, P64, DOI 10.1016/j.jsb.2008.10.004
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   Ye F, 2008, J MOL BIOL, V378, P976, DOI 10.1016/j.jmb.2008.03.014
   Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083
   Zheng QXS, 2004, J STRUCT BIOL, V147, P91, DOI 10.1016/j.jsb.2004.02.005
   Zhou J, 2005, J BIOL CHEM, V280, P42149, DOI 10.1074/jbc.M508951200
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.26334931100
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zhu P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000203
NR 78
TC 14
Z9 14
U1 0
U2 5
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-384993-9
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2010
VL 483
BP 267
EP 290
DI 10.1016/S0076-6879(10)83014-9
PN C
PG 24
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BRR12
UT WOS:000283461900013
PM 20888479
OA green_accepted
DA 2018-01-05
ER

PT S
AU Serbin, A
   Karaseva, E
   Tsvetkov, V
   Alikhanova, O
   Rodionov, I
AF Serbin, Alexander
   Karaseva, Ekaterina
   Tsvetkov, Vladimir
   Alikhanova, Olga
   Rodionov, Igor
BE Stelzer, F
   Wiesbrock, E
TI Hybrid Polymeric Systems for Nano-Selective Counter Intervention in
   Virus Life Cycle
SO MODERN TRENDS IN POLYMER SCIENCE-EPF 09
SE MACROMOLECULAR SYMPOSIA
LA English
DT Proceedings Paper
CT 12th European-Polymer-Federation Congress
CY JUL 12-17, 2009
CL Graz, AUSTRIA
SP European Polymer Federat
DE antiviral selective polymers; nanocomplexes; viruses
ID IN-VITRO; CYTOMEGALOVIRUS-INFECTION; HIV-1 REPLICATION; MATRIX PROTEIN;
   ANTIVIRALS; AGENTS; INHIBITION; POLYANIONS
AB Self assembly of viral biopolymers to nano-complexes forming virions during virus delivery from infected cell and reverse disintegration to virus entry into new cells play a crucial role in viral life cycle and in viral diseases. Therefore artificial instruments for selective counter intervention into these processes are dramatically required for the high effective antiviral protection. Hybrid macromolecular systems (HMS) rationally integrating heterogeneous structure-functional factors for selective recognition - inhibition of viruses (nano-objects) without detriment for cells (micro-objects) can become a molecular basis for cardinal progress in this area. Here we discuss approaches to design and current experimental results of synthesis, and antiviral selectivity evaluations of the HMS, based on combinations of polyelectrolyte-grafted components constructed on principles of mimicry and/or complementarity to viral targets or virus-sensitive cell receptors. Particularly, the HMS generations strongly inhibiting the human immunodeficiency virus (HIV) were created as platform to novel drug development against HIV/AIDS and other sexually transmitted infections.
C1 [Serbin, Alexander; Karaseva, Ekaterina; Tsvetkov, Vladimir; Alikhanova, Olga; Rodionov, Igor] Hlth Res & Dev Fdn, Biomodulators & Drugs Res Ctr, Moscow 117042, Russia.
RP Serbin, A (reprint author), Hlth Res & Dev Fdn, Biomodulators & Drugs Res Ctr, Blvd Adm Ushakova 14-209, Moscow 117042, Russia.
EM serbin@ips.ac.ru
RI Tsvetkov, Vladimir/L-9399-2013
OI Tsvetkov, Vladimir/0000-0003-0494-3332
CR Barinsky I.F., 1991, SOV MED REV E, P79
   Bourchteine M, 2000, ANTIVIR RES, V46, pA44
   Bukrinskaya A, 2006, ANTIVIR RES, V70, pA85
   Bukrinskaya AG, 2007, BIOL MEMBRANY, V24, P355
   BUKRINSKAYA AG, 2006, 2281297 RUS IV I VIR
   BUKRINSKAYA AG, 1993, ANTIVIR RES, V20, P183
   Burstein ME, 1999, ANTIVIR RES, V41, P135, DOI 10.1016/S0166-3542(99)00006-6
   Cowie JMG, 1985, ALTERNATING COPOLYME, P19
   Egorov Y, 2007, ANTIVIR RES, V74, pA49, DOI 10.1016/j.antiviral.2007.01.060
   Egorov Y, 2006, ANTIVIR RES, V70, pA42
   Karaseva E, 2009, ANTIVIR RES, V82, pA59, DOI 10.1016/j.antiviral.2009.02.140
   Kiseleva Ia Iu, 2005, Mol Gen Mikrobiol Virusol, P33
   Kozeletskaya K. N., 2003, Voprosy Virusologii, V48, P19
   OTTENBRITE RM, 1985, ANN NY ACAD SCI, V446, P160, DOI 10.1111/j.1749-6632.1985.tb18398.x
   Pavlova M, 2009, ANTIVIR RES, V82, pA50, DOI 10.1016/j.antiviral.2009.02.115
   Pavlova M. V., 2008, Antibiotiki i Khimioterapiya, V53, P3
   Pavlova M. V., 2008, Antibiotiki i Khimioterapiya, V53, P8
   Perminova N. G., 2003, Biotekhnologiya, P26
   Serbin A, 2007, ANTIVIR RES, V74, pA51, DOI 10.1016/j.antiviral.2007.01.066
   Serbin A, 2006, ANTIVIR RES, V70, pA86
   Serbin A, 2009, ANTIVIR RES, V82, pA66, DOI 10.1016/j.antiviral.2009.02.160
   SERBIN A, 2005, EPF C MOSC RUSS, P161
   SERBIN A, 2009, EPF 09 GRAZ AUSTR, P75
   Serbin A V, 2007, Antibiot Khimioter, V52, P8
   Serbin AV, 2004, ANTIVIR RES, V62, pA35
   Serbin AV, 2002, ANTIVIR RES, V53, pA50
   Serbin A.V., 1999, ANTIVIR RES, V41, P46
   SERBIN AV, 2005, THESIS HLTH RDF MOSC
   SERBIN AV, 2002, RUSSIAN J HIV AIDS R, V6, P167
   STOTSKAYA LL, 1995, PHARM CHEM J MOSCOW, V29, P171
   Timofeev D. I., 2003, Antibiotiki i Khimioterapiya, V48, P29
   TIMOFEEV DI, 2003, ANTIBIOT KHIMIOTERAP, V48, P7
   Timofeev I, 2008, INFECT GENET EVOL, V8, pS47
   TIMOFEEV IV, 2002, BIOTECHNOLOGY RUSSIA, P11
   Timofeyev I. V., 2003, Biotekhnologiya, P3
   [Воркунова Г.К. Vorkunova G.K.], 2009, [Вопросы вирусологии, Voprosy virusologii], V54, P27
   Boukrinskaia A.G., 1999, Polymeric adamantane analogues US, Patent No. [5880154 A, 5880154]
NR 37
TC 5
Z9 6
U1 1
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PAPPELALLEE 3, W-69469 WEINHEIM, GERMANY
SN 1022-1360
J9 MACROMOL SY
PY 2010
VL 296
BP 466
EP 477
DI 10.1002/masy.201051063
PG 12
WC Polymer Science
SC Polymer Science
GA BTT87
UT WOS:000288040600063
DA 2018-01-05
ER

PT J
AU Sawant, R
   Torchilin, V
AF Sawant, Rupa
   Torchilin, Vladimir
TI Intracellular transduction using cell-penetrating peptides
SO MOLECULAR BIOSYSTEMS
LA English
DT Review
ID HIV-1 TAT-PEPTIDE; HUMAN-IMMUNODEFICIENCY-VIRUS; BIOLOGICALLY-ACTIVE
   PROTEINS; CROSS-LINKED NANOPARTICLES; RED FLUORESCENT PEPTIDE;
   ARGININE-RICH PEPTIDES; DRUG-DELIVERY SYSTEMS; POORLY SOLUBLE DRUGS;
   ACIDIC SOLID TUMORS; BREAST-CANCER CELLS
AB Cell penetrating peptides (CPPs), TATp, in particular, has been used widely for intracellular delivery of various agents ranging from small molecules to proteins, peptides, range of pharmaceutical nanocarriers and imaging agents. This review highlights the mechanisms of CPP-mediated delivery and summarizes numerous examples illustrating the potential of CPPs in the fields of biology and medicine.
C1 [Torchilin, Vladimir] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA.
RP Torchilin, V (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Mugar Bldg,Room 312,360 Huntington Ave, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Allen MJ, 2004, CHEM BIOL, V11, P301, DOI 10.1016/j.chembiol.2004.03.003
   Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P710, DOI 10.1021/bc049945m
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Bullok KE, 2007, BIOCHEMISTRY-US, V46, P4055, DOI 10.1021/bi061959n
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Coles DJ, 2008, BIOPOLYMERS, V90, P651, DOI 10.1002/bip.21019
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Cornelissen B, 2007, NUCL MED BIOL, V34, P37, DOI 10.1016/j.nucmedbio.2006.10.008
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Doeppner TR, 2009, J CEREBR BLOOD F MET, V29, P1187, DOI 10.1038/jcbfm.2009.44
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   Fischer R, 2006, CHEMBIOCHEM, V7, P1428, DOI 10.1002/cbic.200600209
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta B, 2007, ONCOL RES, V16, P351
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471                                                     
   Hu MD, 2006, EUR J NUCL MED MOL I, V33, P301, DOI 10.1007/s00259-005-1908-7
   Hu MD, 2006, BIOCONJUGATE CHEM, V17, P1280, DOI 10.1021/bc060053r
   Huang ZH, 2005, MOL THER, V11, P409, DOI 10.1016/j.ymthe.2004.10.013
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jaracz S, 2005, BIOORGAN MED CHEM, V13, P5043, DOI 10.1016/j.bmc.2005.04.084
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Juliano RL, 2006, ANN NY ACAD SCI, V1082, P18, DOI 10.1196/annals.1348.011
   Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587                                                     
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Khafagy ES, 2009, J CONTROL RELEASE, V133, P103, DOI 10.1016/j.jconrel.2008.09.076
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Ko YT, 2009, GENE THER, V16, P52, DOI 10.1038/gt.2008.135
   Lasic D, 1995, STEALTH LIPOSOMES
   Lasic D. D., 1993, LIPOSOMES PHYS APPL
   Law M, 2008, BIOTECHNOL PROGR, V24, P957, DOI [10.1002/btpr.13, 10.1021/bp.13]
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Liu M, 2006, ACTA BIOCH BIOPH SIN, V38, P865, DOI 10.1111/j.1745-7270.2006.00239.x
   Lukyanov AN, 2004, J CONTROL RELEASE, V94, P187, DOI 10.1016/j.jconrel.2003.10.008
   Lukyanov AN, 2004, ADV DRUG DELIVER REV, V56, P1273, DOI 10.1016/j.addr.2003.12.004
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mortensen MW, 2006, BIOCONJUGATE CHEM, V17, P284, DOI 10.1021/bc050208v
   Moschos SA, 2007, BIOCHEM SOC T, V35, P807, DOI 10.1042/BST0350807                                                              
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767                                                              
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Nguyen J, 2008, J GENE MED, V10, P1236, DOI 10.1002/jgm.1255
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Pooga M, 1998, FASEB J, V12, P67
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rinne J, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-1
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rozenzhak SM, 2005, CHEM COMMUN, P2217, DOI 10.1039/b418454h
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawant RR, 2008, J DRUG TARGET, V16, P596, DOI 10.1080/10611860802230240
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Pappalardo JS, 2009, J CONTROL RELEASE, V134, P41, DOI 10.1016/j.jconrel.2008.11.006
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Shiraishi T, 2006, NAT PROTOC, V1, P633, DOI 10.1038/nprot.2006.92
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Silver J, 2005, NANO LETT, V5, P1445, DOI 10.1021/nl050808n
   Sirsi SR, 2008, HUM GENE THER, V19, P795, DOI 10.1089/hum.2007.129
   Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Su Y, 2008, J AM CHEM SOC, V130, P8856, DOI 10.1021/ja802383t
   Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2004, CELL MOL LIFE SCI, V61, P2549, DOI 10.1007/s00018-004-4153-5
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torchilin VP, 1996, BBA-BIOMEMBRANES, V1279, P75, DOI 10.1016/0005-2736(95)00248-0
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399
   Widera A, 2003, ADV DRUG DELIVER REV, V55, P1439, DOI 10.1016/j.addr.2003.07.004
   Yagi N, 2007, BIOORG MED CHEM LETT, V17, P2590, DOI 10.1016/j.bmcl.2007.02.001
   Yamada Y, 2008, BBA-BIOMEMBRANES, V1778, P423, DOI 10.1016/j.bbamem.2007.11.002
   Yang SR, 2008, J BIOMED MATER RES A, V86A, P137, DOI 10.1002/jbm.a.31331
   Youngblood DS, 2007, BIOCONJUGATE CHEM, V18, P50, DOI 10.1021/bc060138s
   Zaro JL, 2006, MOL PHARMACEUT, V3, P181, DOI 10.1021/mp0500869
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 171
TC 87
Z9 90
U1 1
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742-206X
J9 MOL BIOSYST
JI Mol. Biosyst.
PY 2010
VL 6
IS 4
BP 628
EP 640
DI 10.1039/b916297f
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 570YP
UT WOS:000275715000003
PM 20237640
DA 2018-01-05
ER

PT J
AU Jokerst, JV
   McDevitt, JT
AF Jokerst, Jesse V.
   McDevitt, John T.
TI Programmable nano-bio-chips: multifunctional clinical tools for use at
   the point-of-care
SO NANOMEDICINE
LA English
DT Article
DE integrated sensor; lab-on-a-chip; Moore's law; nano-bio-chip;
   point-of-care; programmable
ID LARGE-SCALE INTEGRATION; C-REACTIVE PROTEIN; ANALYSIS SYSTEMS; PLASMA
   PROTEOME; SENSOR ARRAYS; CARDIAC RISK; ASSAY SYSTEM; DIAGNOSTICS;
   MICROCHIP; CANCER
AB A new generation of programmable diagnostic devices is needed to take advantage of information generated from the study of genomics, proteomics, metabolomics and glycomics. This report describes the 'programmable nano-bio-chip' with potential to bridge the significant scientific, technology and clinical gaps through the creation of a diagnostic platform to measure the molecules of life. This approach, with results at the point-of-care, possesses capabilities for measuring such diverse analyte classes as cells, proteins, DNA and small molecules in the same compact device. Applications such as disease diagnosis and prognosis for areas including cancer, heart disease and HIV are described. New diagnostic panels are inserted as 'plug and play' elements into the modular platform with universal assay operating systems and standard read out sequences. The nano-bio-chip ensemble exhibits excellent analytical performance and cost-effectiveness with extensive validation versus standard reference methods (R(2) = 0.95-0.99). This report describes the construction and use of two major classes of nano-bio-chip designs that serve as cellular and chemical processing units, and provides perspective on future growth in this newly emerging field of programmable nano-bio-chip sensor systems,
C1 [Jokerst, Jesse V.; McDevitt, John T.] Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
   [Jokerst, Jesse V.; McDevitt, John T.] Rice Univ, Dept Chem, Houston, TX 77005 USA.
   [Jokerst, Jesse V.] Stanford Univ, Mol Imaging Program Stanford, Sch Med, Stanford, CA 94305 USA.
RP McDevitt, JT (reprint author), Rice Univ, Dept Bioengn, 6100 Main St, Houston, TX 77005 USA.
EM jokerst@stanford.edu; mcdevitt@rice.edu
RI McDevitt, John/P-4108-2014
OI McDevitt, John/0000-0001-8789-9351
FU NIH [U01 DE017793]
FX The authors acknowledge funding provided by the NIH through the National
   Institute of Dental and Cranio/acial Research (U01 DE017793). The
   content is solely the responsibility of the authors and does not
   necessarily represent or reflect views of the NIH or the Federal
   Government. John TMcDevitt serves as the scientific founder for LabNow.
   The authors have applied for patents in areas related to nano-bio-cbip
   sensor systems. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Agnew HD, 2009, ANGEW CHEM INT EDIT, V48, P4944, DOI 10.1002/anie.200900488
   Ali MF, 2003, ANAL CHEM, V75, P4732, DOI 10.1021/ac034106z
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1
   Cheng XH, 2009, LAB CHIP, V9, P1357, DOI 10.1039/b818813k
   Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Christodoulides N, 2005, LAB CHIP, V5, P261, DOI 10.1039/b414194f
   Christodoulides N, 2005, CLIN CHEM, V51, P2391, DOI 10.1373/clinchem.2005.054882
   Christodoulides N, 2002, ANAL CHEM, V74, P3030, DOI 10.1021/ac011150a
   Christodoulides N, 2007, ANN NY ACAD SCI, V1098, P411, DOI 10.1196/annals.1384.035
   Christodoulides Nicolaos, 2007, V385, P131, DOI 10.1007/978-1-59745-426-1_10
   Cohen J, 2004, SCIENCE, V304, P1936, DOI 10.1126/science.304.5679.1936
   Curey TE, 2001, ANAL BIOCHEM, V293, P178, DOI 10.1006/abio.2001.5114
   deMello AJ, 2009, NAT CHEM, V1, P28, DOI 10.1038/nchem.156
   ERICKSON KA, 1993, CLIN CHEM, V39, P283
   Floriano PN, 2009, CLIN CHEM, V55, P1530, DOI 10.1373/clinchem.2008.117713
   Floriano PN, 2005, BIOSENS BIOELECTRON, V20, P2079, DOI 10.1016/j.bios.2004.08.046
   Fulton RJ, 1997, CLIN CHEM, V43, P1749
   Ginsburg PB, 2006, HEALTH AFFAIR, V25, pW486, DOI 10.1377/hlthaff.25.w486
   Goluch ED, 2006, LAB CHIP, V6, P1293, DOI 10.1039/b606294f
   Goodey A, 2001, J AM CHEM SOC, V123, P2559, DOI 10.1021/ja003341l
   Goodey AP, 2003, J AM CHEM SOC, V125, P2870, DOI 10.1021/ja029696h
   Gustavsson PE, 1999, J CHROMATOGR A, V830, P275, DOI 10.1016/S0021-9673(98)00899-1
   Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916
   Herr AE, 2007, P NATL ACAD SCI USA, V104, P5268, DOI 10.1073/pnas.0607254104
   HOLMESFARLEY SR, 1988, LANGMUIR, V4, P921, DOI 10.1021/la00082a025                                                             
   Hunter DJ, 2008, NEW ENGL J MED, V358, P105, DOI 10.1056/NEJMp0708162
   Jackson DJ, 2003, ANAL CHEM, V75, P3643, DOI 10.1021/ac0206622
   Janasek D, 2006, NATURE, V442, P374, DOI 10.1038/nature05059
   Jokerst JV, 2009, BIOSENS BIOELECTRON, V24, P3622, DOI 10.1016/j.bios.2009.05.026
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Kilby J S, 2001, Chemphyschem, V2, P482, DOI 10.1002/1439-7641(20010917)2:8/9<482::AID-CPHC482>3.0.CO;2-Y
   Kim JS, 2009, ANAL CHEM, V81, P5426, DOI 10.1021/ac9005827
   KINEIKO RW, 1983, CLIN CHEM, V29, P688
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Lavigne JJ, 1998, J AM CHEM SOC, V120, P6429, DOI 10.1021/ja9743405                                                               
   Ligler FS, 2009, ANAL CHEM, V81, P519, DOI 10.1021/ac8016289
   Madou M, 2006, ANNU REV BIOMED ENG, V8, P601, DOI 10.1146/annurev.bioeng.8.061505.095758
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   McCarley RL, 2005, J AM CHEM SOC, V127, P842, DOI 10.1021/ja0454135
   McCleskey SC, 2003, J AM CHEM SOC, V125, P1114, DOI 10.1021/ja021230b
   Melin J, 2007, ANNU REV BIOPH BIOM, V36, P213, DOI 10.1146/annurev.biophys.36.040306.132646
   Mukhopadhyay R, 2005, ANAL CHEM, V77, p429A, DOI 10.1021/ac053496h                                                               
   Mukhopadhyay R, 2009, ANAL CHEM, V81, P4169, DOI 10.1021/ac900638w
   Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h
   Osterfeld SJ, 2008, P NATL ACAD SCI USA, V105, P20637, DOI 10.1073/pnas.0810822105
   Ouellette AL, 2009, ANAL CHEM, V81, P3216, DOI 10.1021/ac900475u
   Qin LD, 2009, LAB CHIP, V9, P2016, DOI 10.1039/b821247c
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Sanhai WR, 2008, NAT NANOTECHNOL, V3, P242, DOI 10.1038/nnano.2008.114
   Sia SK, 2008, LAB CHIP, V8, P1982, DOI 10.1039/b817915h
   Soper SA, 2006, BIOSENS BIOELECTRON, V21, P1932, DOI 10.1016/j.bios.2006.01.006
   Srivastava N, 2009, ANAL CHEM, V81, P3261, DOI 10.1021/ac8024224
   THORSEN T, SCIENCE, V298, P580
   Toriello NM, 2008, P NATL ACAD SCI USA, V105, P20173, DOI 10.1073/pnas.0806355106
   Vilkner T, 2004, ANAL CHEM, V76, P3373, DOI 10.1021/ac040063q
   Vitzthum F, 2005, J PROTEOME RES, V4, P1086, DOI 10.1021/pr050080b
   Waggoner PS, 2007, LAB CHIP, V7, P1238, DOI 10.1039/b707401h
   Walt DR, 2005, SCIENCE, V308, P217, DOI 10.1126/science.1108161
   Weigum SE, 2007, LAB CHIP, V7, P995, DOI 10.1039/b703918b
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Wong DT, 2006, J AM DENT ASSOC, V137, P313, DOI 10.14219/jada.archive.2006.0180                                                 
   Wright AT, 2005, J AM CHEM SOC, V127, P17405, DOI 10.1021/ja055696g
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 64
TC 23
Z9 23
U1 0
U2 28
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JAN
PY 2010
VL 5
IS 1
BP 143
EP 155
DI 10.2217/NNM.09.94
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 544QV
UT WOS:000273674900018
PM 20025471
OA green_accepted
DA 2018-01-05
ER

PT J
AU Sacha, JB
   Watkins, DI
AF Sacha, Jonah B.
   Watkins, David I.
TI Synchronous infection of SIV and HIV in vitro for virology, immunology
   and vaccine-related studies
SO NATURE PROTOCOLS
LA English
DT Article
ID CD8(+) T-CELLS; VIRAL PROTEIN; VIRUS; RECOGNIZE; MAGNETOFECTION;
   REPLICATION; LYMPHOCYTES; CULTURES; ESCAPE
AB the development of an HIV vaccine will require a more precise understanding of the immunological and virological underpinnings of HIV infection. Magnetofection, the process of magnetizing HIV by coupling it to ferrous nanoparticles and coordinating infection using a magnetic field, synchronizes the viral replication cycle at attachment while recapitulating the events of natural infection. although spinoculation also concentrates virus onto target cells to increase infection, it does not synchronize infection. the synchronization of HIV infection in vitro facilitates the study of events in the viral replication cycle and the antiviral immune response on timelines previously impossible. Furthermore, by infecting a high percentage of cells in a short time frame, magnetofection increases the throughput of in vitro assays. once a virus stock is generated, magnetofection of target cells is rapid, requiring only 1-2 h. Here we present a detailed protocol for this assay and review its applications for studying the immune response to HIV.
C1 [Sacha, Jonah B.; Watkins, David I.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
RP Sacha, JB (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
EM jbsacha@wisc.edu
FU NIH [RO1 AI076114, R01 AI049120]
FX This work was supported by NIH grants RO1 AI076114 and R01 AI049120 to
   D. I. W. We thank M. Buechler and L. Newman for technical assistance and
   A. Espinosa for administrative support.
CR Buerli T, 2007, NAT PROTOC, V2, P3090, DOI 10.1038/nprot.2007.445
   Haim H, 2005, J VIROL, V79, P622, DOI 10.1128/JVI.79.1.622-625.2005
   Haim H, 2007, J VIROL, V81, P3525, DOI 10.1128/JVI.02293-06
   Haim H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000360
   Loffredo JT, 2007, J VIROL, V81, P2624, DOI 10.1128/JVI.01912-06
   Maness NJ, 2007, J EXP MED, V204, P2505, DOI 10.1084/jem.20071261
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   Minang JT, 2008, VIROLOGY, V375, P307, DOI 10.1016/j.virol.2008.02.005
   Minang JT, 2008, VIROLOGY, V372, P430, DOI 10.1016/j.virol.2007.11.013
   Minang JT, 2009, VIROLOGY, V391, P130, DOI 10.1016/j.virol.2009.06.008
   Mykhaylyk O, 2007, NAT PROTOC, V2, P2391, DOI 10.1038/nprot.2007.352
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   Sacha JB, 2008, J VIROL, V82, P9293, DOI 10.1128/JVI.00749-08
   Sacha JB, 2007, J VIROL, V81, P11703, DOI 10.1128/JVI.00926-07
   Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746                                                     
   Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
   Thomas JA, 2007, J VIROL, V81, P4367, DOI 10.1128/JVI.02357-06
   van't Wout AB, 2008, NAT PROTOC, V3, P363, DOI 10.1038/nprot.2008.3
NR 18
TC 18
Z9 18
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PY 2010
VL 5
IS 2
BP 239
EP 246
DI 10.1038/nprot.2009.227
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 564HQ
UT WOS:000275204300006
PM 20134424
OA green_accepted
DA 2018-01-05
ER

PT J
AU Caminade, AM
   Turrin, CO
   Majoral, JP
AF Caminade, Anne-Marie
   Turrin, Cedric-Olivier
   Majoral, Jean-Pierre
TI Biological properties of phosphorus dendrimers
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Review
ID OCULAR DRUG-DELIVERY; DELTA T-CELLS; DENDRITIC ARCHITECTURES; TERMINATED
   DENDRIMERS; CAPPED DENDRIMERS; ORGANIC NANODOTS; DNA MICROARRAYS; HUMAN
   MONOCYTES; PRION DISEASES; QUANTUM DOTS
AB This review will display the special role played by phosphorus-containing dendrimers when interacting with biological systems. After some synthetic aspects, the usefulness of these dendrimers for elaboration of highly sensitive bio-sensors and for in vitro drug delivery (for instance as transfection agents, or against HIV-1 and the scrapie form of prions) will be demonstrated. Then, emphasis will be put on the favourable influence of these dendrimers on cells growth, in particular for neuronal cells, and for human immune blood cells such as monocytes and Natural Killer cells, the latter playing a key-role for fighting against viral infections and cancers. This review will finally describe in vivo biological properties of these phosphorus dendrimers as anti-prion agents, for ocular drug delivery, and for imaging rat brain blood vessels. Some of these properties can be found also with other types of dendrimers, but others, in particular the interaction with the human immune blood cells, occur only and specifically with phosphorus dendrimers.
C1 [Caminade, Anne-Marie; Turrin, Cedric-Olivier; Majoral, Jean-Pierre] CNRS, Chim Coordinat Lab, F-31077 Toulouse, France.
   [Caminade, Anne-Marie; Turrin, Cedric-Olivier; Majoral, Jean-Pierre] Univ Toulouse, UPS, INPT, LCC, F-31077 Toulouse, France.
RP Caminade, AM (reprint author), CNRS, Chim Coordinat Lab, 205 Route Narbonne, F-31077 Toulouse, France.
EM caminade@lcc-toulouse.fr; majoral@lcc-toulouse.fr
RI Caminade, Anne-Marie/E-2819-2015; Turrin, cedric-olivier/C-1746-2013
OI Caminade, Anne-Marie/0000-0001-8487-3578; Turrin,
   cedric-olivier/0000-0001-7187-8070
FU CNRS; COST [TD0802, CM0802]
FX We thank the CNRS for financial support, and the COST programs TD0802
   (Biodendrimers) and CM0802 (PhoSciNet).
CR Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Blanzat M, 2002, CHEM COMMUN, P1864, DOI 10.1039/b204287h
   Born WK, 2006, CURR OPIN IMMUNOL, V18, P31, DOI 10.1016/j.coi.2005.11.007
   Caminade AM, 2005, ADV DRUG DELIVER REV, V57, P2130, DOI 10.1016/j.addr.2005.09.011
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Caminade AM, 2008, CHEM-EUR J, V14, P7422, DOI 10.1002/chem.200800584
   Caminade AM, 2006, SENSORS-BASEL, V6, P901, DOI 10.3390/s6080901                                                                
   Caminade AM, 2006, POLYM INT, V55, P1155, DOI 10.1002/pi.1929
   Caminade AM, 2009, CHEM-EUR J, V15, P9270, DOI 10.1002/chem.200901597
   Chaize B, 2006, BIOCONJUGATE CHEM, V17, P245, DOI 10.1021/bc050273p
   Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3                                                   
   Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   Feng CL, 2007, ADV MATER, V19, P1933, DOI 10.1002/adma.200602311
   Fruchon S, 2009, J LEUKOCYTE BIOL, V85, P553, DOI 10.1189/jlb.0608371
   Galliot C, 1997, SCIENCE, V277, P1981, DOI 10.1126/science.277.5334.1981
   Goller R, 2001, TETRAHEDRON LETT, V42, P3587, DOI 10.1016/S0040-4039(01)00509-3
   Griffe L, 2007, ANGEW CHEM INT EDIT, V46, P2523, DOI 10.1002/anie.200604651
   Hadad C, 2009, TETRAHEDRON LETT, V50, P1902, DOI 10.1016/j.tetlet.2009.02.015
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Hernandez-Lopez JL, 2008, THIN SOLID FILMS, V516, P1256, DOI 10.1016/j.tsf.2007.05.049
   HUDSON RHE, 1993, J AM CHEM SOC, V115, P2119, DOI 10.1021/ja00059a004
   Kazmierczak-Baranska J, 2010, NUCLEOS NUCLEOT NUCL, V29, P155, DOI 10.1080/15257771003708462
   Kim BS, 2005, LANGMUIR, V21, P7200, DOI 10.1021/la0504208
   Kim DH, 2005, SMALL, V1, P99, DOI 10.1002/smll.200400024
   Klajnert B, 2007, BIOCHEM BIOPH RES CO, V364, P20, DOI 10.1016/j.bbrc.2007.09.083
   Klajnert B, 2007, MACROMOL BIOSCI, V7, P1065, DOI 10.1002/mabi.200700049
   Klajnert B, 2009, NEW J CHEM, V33, P1087, DOI 10.1039/b820632p
   Klingemann HG, 2005, CYTOTHERAPY, V7, P16, DOI 10.1080/14653240510018000
   Krishna TR, 2006, ANGEW CHEM INT EDIT, V45, P4645, DOI 10.1002/anie.200601246
   Kunzmann V, 2000, BLOOD, V96, P384
   Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780
   Lartigue ML, 1997, MACROMOLECULES, V30, P7335, DOI 10.1021/ma970570s                                                               
   LAUNAY N, 1994, ANGEW CHEM INT EDIT, V33, P1589, DOI 10.1002/anie.199415891                                                          
   LAUNAY N, 1995, J AM CHEM SOC, V117, P3282, DOI 10.1021/ja00116a037                                                             
   Launay N, 1997, J ORGANOMET CHEM, V529, P51, DOI 10.1016/S0022-328X(96)06293-6                                                   
   Le Berre V, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng088
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Majoral JP, 1998, TOP CURR CHEM, V197, P79
   Majoral JP, 1999, CHEM REV, V99, P845, DOI 10.1021/cr970414j                                                               
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Maraval V, 2006, NEW J CHEM, V30, P1731, DOI 10.1039/b610632n
   Marchand P, 2009, BIOORG MED CHEM LETT, V19, P3963, DOI 10.1016/j.bmcl.2009.03.003
   Marmillon C, 2001, ANGEW CHEM INT EDIT, V40, P2626, DOI 10.1002/1521-3773(20010716)40:14<2626::AID-ANIE2626>3.0.CO;2-F                  
   Martinez-Ferrero E, 2008, CHEM-EUR J, V14, P7658, DOI 10.1002/chem.200800606
   Maszewska M, 2003, OLIGONUCLEOTIDES, V13, P193, DOI 10.1089/154545703322460586                                                      
   Mongin O, 2006, CHEM COMMUN, P915, DOI 10.1039/b517270e
   Mongin O., 2008, SPIE NANOBIOSYSTEMS, V7040, P4006
   Mongin O, 2007, NEW J CHEM, V31, P1354, DOI 10.1039/b702452p
   Newkome GR, 2008, POLYMER, V49, P1, DOI 10.1016/j.polymer.2007.10.021
   Nicu L, 2005, SENSOR ACTUAT B-CHEM, V110, P125, DOI 10.1016/j.snb.2005.01.021
   Padie C, 2009, NEW J CHEM, V33, P318, DOI 10.1039/b815259d
   Perez-Anes A, 2010, BIOORGAN MED CHEM, V18, P242, DOI 10.1016/j.bmc.2009.10.058
   Picart C, 2005, ADV FUNCT MATER, V15, P83, DOI 10.1002/adfm.200400106
   Poniatowska E, 2003, TETRAHEDRON LETT, V44, P4315, DOI 10.1016/S0040-4039(03)00982-1
   Portevin D, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-82
   Poupot M, 2004, IMMUNOL LETT, V95, P129, DOI 10.1016/j.imlet.2004.06.013
   Poupot M, 2006, FASEB J, V20, P2339, DOI 10.1096/fj.06-5742com
   Prevote D, 1997, SYNTHESIS-STUTTGART, P1199
   Prevote D, 1997, J ORG CHEM, V62, P4834, DOI 10.1021/jo9701750                                                               
   PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762
   Reinert P, 2007, NEW J CHEM, V31, P1259, DOI 10.1039/b613788c
   RENGAN K, 1990, J CHEM SOC CHEM COMM, P1084, DOI 10.1039/c39900001084                                                            
   Rolland O, 2008, CHEM-EUR J, V14, P4836, DOI 10.1002/chem.200701063
   Rolland O, 2009, TETRAHEDRON LETT, V50, P2078, DOI 10.1016/j.tetlet.2009.02.127
   Roy R, 1997, TOP CURR CHEM, V187, P241
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Salamonczyk GM, 2003, TETRAHEDRON LETT, V44, P7449, DOI 10.1016/j.tetlet.2003.08.035
   Salamonczyk GM, 2002, TETRAHEDRON LETT, V43, P1747, DOI 10.1016/S0040-4039(02)00088-6                                                   
   Salamonczyk GM, 2001, CHEM COMMUN, P2202, DOI 10.1039/b106849k                                                                
   Salamonczyk GM, 2000, TETRAHEDRON LETT, V41, P1643
   Sebastian RM, 2000, TETRAHEDRON, V56, P6269, DOI 10.1016/S0040-4020(00)00576-7                                                   
   Slomkowski S, 1999, REACT FUNCT POLYM, V41, P45, DOI 10.1016/S1381-5148(99)00019-X                                                   
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   SOLERILLIA GJD, 2000, ANGEW CHEM INT EDIT, V39, P4249
   Spataro G, 2010, EUR J MED CHEM, V45, P326, DOI 10.1016/j.ejmech.2009.10.017
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Terenziani F, 2009, ANGEW CHEM INT EDIT, V48, P8691, DOI 10.1002/anie.200903519
   Trevisiol E, 2003, NEW J CHEM, V27, P1713, DOI 10.1039/b307928g
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Yu YM, 2009, LANGMUIR, V25, P13680, DOI 10.1021/la901988r
NR 84
TC 57
Z9 57
U1 0
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
J9 NEW J CHEM
JI New J. Chem.
PY 2010
VL 34
IS 8
BP 1512
EP 1524
DI 10.1039/c0nj00116c
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA 633PC
UT WOS:000280514300003
DA 2018-01-05
ER

PT J
AU Glisoni, RJ
   Chiappetta, DA
   Finkielsztein, LM
   Moglioni, AG
   Sosnik, A
AF Glisoni, Romina J.
   Chiappetta, Diego A.
   Finkielsztein, Liliana M.
   Moglioni, Albertina G.
   Sosnik, Alejandro
TI Self-aggregation behaviour of novel thiosemicarbazone drug candidates
   with potential antiviral activity
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID ISATIN-BETA-THIOSEMICARBAZONES; PHASE LIQUID-CHROMATOGRAPHY; ANTI-HIV
   ACTIVITY; 2-ACETYLPYRIDINE THIOSEMICARBAZONES; AMPHIPHILIC PENICILLINS;
   POLYMERIC MICELLES; ANTITUMOR-ACTIVITY; IRON CHELATORS; DERIVATIVES;
   COMPLEXES
AB The present work aimed to gain further insight into the mechanisms governing the aggregation process of 1-indanone thiosemicarbazone drug candidates. Regardless of the relatively low lipophilicity predicted by theoretical calculations, these compounds were very insoluble in water. This performance was especially notorious for methoxylated (and non-N-allylated) derivatives. Thermal analysis revealed that the introduction of one and two CH(3)O- moieties into the aromatic ring increases the T(m) pronouncedly from 185 degrees C to 229 degrees C and 258 degrees C, respectively. The formation of nano-aggregates in water was suggested by the appearance of a new strong absorption peak at 233-239 nm in the UV spectra. DLS analysis showed the early formation nanoscopic particles (120-300 nm) that undergo a gradual size growth to generate larger submicron structures; these particles remained invisible to the naked eye. The negatively-charged character of the surface was established by zeta potential measurements. These results suggest the generation of an inner hydrophobic "core'' due to the interaction of highly hydrophobic aromatic rings that is surface-decorated by C=S groups available in a thiolato anionic form. This aggregation mechanism is supported by the fact that methoxylation of the aromatic ring dramatically strengthens the solute-solute affinity, as expressed by the sharp increase in T(m) and makes these derivatives much more water-insoluble. Finally, overall findings indicate that for these compounds, solubility predictions based on lipophilicity calculations are not reliable and a more thorough characterization is required.
C1 [Glisoni, Romina J.; Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Dept Pharmaceut Technol, Fac Pharm & Biochem, Grp Biomat & Nanotechnol Improved Med BIONIMED, Buenos Aires, DF, Argentina.
   [Glisoni, Romina J.; Finkielsztein, Liliana M.; Moglioni, Albertina G.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, Buenos Aires, DF, Argentina.
   [Glisoni, Romina J.; Chiappetta, Diego A.; Moglioni, Albertina G.; Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Dept Pharmaceut Technol, Fac Pharm & Biochem, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Junin St,6th Floor,CP1113, Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
FU CONICET
FX RJG thanks a PhD scholarship of the CONICET. The authors thank Dr S.
   Lucangioli and Dr V. Tripodi (Department of Analytical Chemistry,
   Faculty of Pharmacy and Biochemistry, University of Buenos Aires) and
   Pharm. L. Fabian (Department of Organic Chemistry, Faculty of Pharmacy
   and Biochemistry, University of Buenos Aires) for assistance in HPLC
   analysis and FT-IR, respectively. AGM and AS are scientist members of
   the CONICET.
CR Attwood D, 2000, J COLLOID INTERF SCI, V227, P356, DOI 10.1006/jcis.2000.6908
   Bal TR, 2005, BIOORG MED CHEM LETT, V15, P4451, DOI 10.1016/j.bmcl.2005.07.046
   Beraldo H, 2004, QUIM NOVA, V27, P461, DOI 10.1590/S0100-40422004000300017
   Bermejo E, 2003, POLYHEDRON, V22, P1147, DOI 10.1016/S0277-5387(03)00100-1
   BHAMARIA RP, 1968, INDIAN J EXP BIOL, V6, P62
   Birch N, 2006, EXPERT OPIN THER PAT, V16, P1533, DOI 10.1517/13543776.16.11.1533
   Brousse BN, 2004, J CHIL CHEM SOC, V49, P45, DOI 10.4067/S0717-97072004000100009
   Brousse BN, 2002, ARKIVOC, P14
   Casoni D, 2009, J CHROMATOGR A, V1216, P2456, DOI 10.1016/j.chroma.2009.01.029
   Cheema MA, 2008, J CHEM ENG DATA, V53, P368, DOI 10.1021/je7003963
   Chen Y, 2008, BIOORGAN MED CHEM, V16, P5914, DOI 10.1016/j.bmc.2008.04.064
   Chiappetta D. A., 2010, POLYM AGING STABILIZ
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   CHRISTENSON B, 1985, ANTIMICROB AGENTS CH, V27, P570, DOI 10.1128/AAC.27.4.570                                                            
   Dilovic I, 2008, BIOORGAN MED CHEM, V16, P5189, DOI 10.1016/j.bmc.2008.03.006
   DOBEK AS, 1980, ANTIMICROB AGENTS CH, V18, P27, DOI 10.1128/AAC.18.1.27                                                             
   Domagk G., 1951, IRISH J MED SCI, V26, P474
   Du XH, 2002, J MED CHEM, V45, P2695, DOI 10.1021/jm010459j
   Durantel D, 2005, ADV EXP MED BIOL, V564, P5
   Espada R, 2008, INT J PHARMACEUT, V361, P64, DOI 10.1016/j.ijpharm.2008.05.013
   Fernandez DA, 1997, J PHOTOCH PHOTOBIO B, V41, P227, DOI 10.1016/S1011-1344(97)00106-1                                                   
   Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0
   Finkielsztein LM, 2008, EUR J MED CHEM, V43, P1767, DOI 10.1016/j.ejmech.2007.10.023
   Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i
   FUJITA T, 1964, J AM CHEM SOC, V86, P5175, DOI 10.1021/ja01077a028                                                             
   Garcia Cybele C., 2003, Antiviral Chemistry & Chemotherapy, V14, P99
   Hall MD, 2009, J MED CHEM, V52, P3191, DOI 10.1021/jm800861c
   Halve AK, 2008, J ENZYM INHIB MED CH, V23, P77, DOI 10.1080/14756360701408614 
   HANSCH C, 1979, SUBSTITUENT CONSTANT
   HSIEH MM, 1995, ANAL CHEM, V67, P48, DOI 10.1021/ac00097a009
   Iakovidou Z, 2001, ANTI-CANCER DRUG, V12, P65, DOI 10.1097/00001813-200101000-00009
   Konstantinovic SS, 2008, J SERB CHEM SOC, V73, P7, DOI 10.2298/JSC0801007K
   Latheef L, 2009, INORG CHIM ACTA, V362, P2515, DOI 10.1016/j.ica.2008.10.012
   Li MX, 2009, BIOORG MED CHEM LETT, V19, P2704, DOI 10.1016/j.bmcl.2009.03.135
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lopez-Nicolas JM, 2010, FOOD CHEM, V118, P648, DOI 10.1016/j.foodchem.2009.05.039
   Martinez F, 2003, J BRAZIL CHEM SOC, V14, P803, DOI 10.1590/S0103-50532003000500016
   Mendes IC, 2001, J MOL STRUCT, V559, P355, DOI 10.1016/S0022-2860(00)00729-8
   Mishra V, 2002, ARCH PHARM, V335, P183, DOI 10.1002/1521-4184(200205)335:5<183::AID-ARDP183>3.0.CO;2-U
   MOGLIONI AG, UNPUB
   MORTON I, 1999, CONCISE DICT PHARM A
   Mrkvickova Z, 2008, J PHARMACEUT BIOMED, V48, P310, DOI 10.1016/j.jpba.2007.12.040
   Pirrung MC, 2005, J MED CHEM, V48, P3045, DOI 10.1021/jm049147h
   QURESHI AS, 2009, EUR J CLIN MICROBIOL, V28, P1409
   Richardson DR, 2006, J MED CHEM, V49, P6510, DOI 10.1021/jm0606342
   Riddick T., 1968, ZETA METER MANUAL
   Rouge PD, 2005, ARKIVOC, P8
   SHAW D, MRK50501 MALV INSTR
   Shervani Z, 1996, COLLOID SURFACE B, V7, P31, DOI 10.1016/0927-7765(96)01283-0                                                    
   Sriram D, 2007, BIOORG MED CHEM LETT, V17, P1888, DOI 10.1016/j.bmcl.2007.01.037
   Taboada P, 1999, LANGMUIR, V15, P2022, DOI 10.1021/la981501p                                                               
   Taboada P, 2000, J COLLOID INTERF SCI, V221, P242, DOI 10.1006/jcis.1999.6586                                                          
   Tadros AB, 2004, ANTI-CORROS METHOD M, V51, P406, DOI 10.1108/00035590410560958
   Tanaka R, 2008, ANTIMICROB AGENTS CH, V52, P782, DOI 10.1128/AAC.01613-06
   VOLLHABER HH, 1983, THERAPIEWOCHE, V33, P5345
   YALKOWSKY SH, 1980, DRUG DESIGN, V9
   Yu Y, 2009, J MED CHEM, V52, P5271, DOI 10.1021/jm900552r
NR 58
TC 20
Z9 20
U1 2
U2 9
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
J9 NEW J CHEM
JI New J. Chem.
PY 2010
VL 34
IS 9
BP 2047
EP 2058
DI 10.1039/c0nj00061b
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA 644DP
UT WOS:000281352700034
DA 2018-01-05
ER

PT J
AU Ozoemena, KI
   Mathebula, NS
   Pillay, J
   Toschi, G
   Verschoor, JA
AF Ozoemena, Kenneth I.
   Mathebula, Nsovo S.
   Pillay, Jeseelan
   Toschi, Gianna
   Verschoor, Jan A.
TI Electron transfer dynamics across self-assembled N-(2-mercaptoethyl)
   octadecanamide/mycolic acid layers: impedimetric insights into the
   structural integrity and interaction with anti-mycolic acid antibodies
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID WALLED CARBON NANOTUBE-OCTA(HYDROXYETHYLTHIO)PHTHALOCYANINATOIRON(II);
   ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; LANGMUIR-BLODGETT TECHNIQUE;
   MODIFIED GOLD ELECTRODES; MYCOBACTERIUM-TUBERCULOSIS;
   SALMONELLA-TYPHIMURIUM; PULMONARY TUBERCULOSIS; CYCLIC VOLTAMMETRY;
   THIOL MONOLAYERS; CHARGE-TRANSFER
AB The integrity and properties of mycolic acid (MA) antigens integrated into a self-assembled monolayer (SAM) of N-(2-mercaptoethyl)octadecanamide, (MEODA), on a gold electrode have been interrogated using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). EIS data showed that Au-MEODA and Au-MEODA-MA behave as microelectrode arrays, with pinholes acting as the microelectrodes that permit electron transport between a redox-active probe in solution and the underlying gold surface. The average radii of the pinholes (r(a)) and half the distance between the centers of the neighbouring pinholes (r(b)), were estimated from EIS using the pore size model, and discussed. Anti-MA antibodies present in a tuberculosis (TB)-infected patient (co-infected with HIV) strongly interact with Au-MEODA-MA showing a rather compact and stable bio-complex structure that is virtually defect-free. The electrochemical impedimetric properties associated with the ability of the Au-MEODA-MA to discriminate between TB positive and negative human sera are also discussed. We prove that the Au-MEODA and Au-MEODA-MA electrodes, as well as the MA-anti-MA antibody interactions, are characterized with time-constant dispersion, typical of microstructures with grain/grain boundary phases. These crucial physico-electrochemical insights into the behaviour of surface-confined MA should provide a useful basis for the design and development of a potential impedimetric immunosensing platform for active tuberculosis.
C1 [Ozoemena, Kenneth I.] CSIR, ZA-0001 Pretoria, South Africa.
   [Ozoemena, Kenneth I.; Mathebula, Nsovo S.; Pillay, Jeseelan; Toschi, Gianna] Univ Pretoria, Dept Chem, ZA-0002 Pretoria, South Africa.
   [Verschoor, Jan A.] Univ Pretoria, Dept Biochem, ZA-0002 Pretoria, South Africa.
RP Ozoemena, KI (reprint author), CSIR, ZA-0001 Pretoria, South Africa.
EM kozoemena@csir.co.za
RI Verschoor, Jan/B-7971-2009
OI Verschoor, Jan/0000-0002-0128-8398
FU CSIR; NRF [2073666, 65305, 68338, 45489]; EDCTP [CT.2004.32040.001]
FX We thank CSIR, NRF (GUN # 2073666, 65305, 68338, 45489), EDCTP
   (CT.2004.32040.001) and Cape Biotech/Lifelab for their support. NSM
   thanks NRF for MSc bursary. JP thanks MinTEK and NRF for PhD
   bursaries/scholarships.
CR Agboola BO, 2008, PHYS CHEM CHEM PHYS, V10, P2399, DOI 10.1039/b800611c
   AMATORE C, 1983, J ELECTROANAL CHEM, V147, P39, DOI 10.1016/S0022-0728(83)80055-2
   Barsoukov E., 2005, IMPEDANCE SPECTROSCO
   Benadie Y, 2008, CHEM PHYS LIPIDS, V152, P95, DOI 10.1016/j.chemphyslip.2008.01.004
   Bonanos N., 2005, IMPEDANCE SPECTROSCO
   Campuzano S, 2006, J ELECTROANAL CHEM, V586, P112, DOI 10.1016/j.jelechem.2005.09.007
   Castner DG, 1996, LANGMUIR, V12, P5083, DOI 10.1021/la960465w                                                               
   Chattopadhyay J, 2006, CHEM MATER, V18, P5864, DOI 10.1021/cm0611082
   Compton RG, 2007, UNDERSTANDING VOLTAM
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Cui XL, 1999, BIOELECTROCH BIOENER, V48, P243, DOI 10.1016/S0302-4598(98)00202-5
   Davies TJ, 2005, J SOLID STATE ELECTR, V9, P797, DOI 10.1007/s10008-005-0699-x
   Davies TJ, 2005, J ELECTROANAL CHEM, V585, P63, DOI 10.1016/j.jelechem.2005.07.022
   Devi KRU, 2003, DIAGN MICR INFEC DIS, V46, P205, DOI 10.1016/S0732-8893(03)00047-6
   Diao P, 1999, J ELECTROANAL CHEM, V464, P61, DOI 10.1016/S0022-0728(98)00470-7                                                   
   Diao P, 2001, J ELECTROANAL CHEM, V495, P98, DOI 10.1016/S0022-0728(00)00424-1                                                   
   Doron-Mor H, 2000, NATURE, V406, P382, DOI 10.1038/35019025                                                                
   FINKLEA HO, 1987, LANGMUIR, V3, P409, DOI 10.1021/la00075a024                                                             
   FINKLEA HO, 1993, LANGMUIR, V9, P3660, DOI 10.1021/la00036a050                                                             
   Garcia-Raya D, 2008, ELECTROCHIM ACTA, V53, P8026, DOI 10.1016/j.electacta.2008.06.017
   Girija TC, 2006, J APPL ELECTROCHEM, V36, P531, DOI 10.1007/s10800-005-9075-x
   Gooding JJ, 2003, J AM CHEM SOC, V125, P9006, DOI 10.1021/ja035722f
   Goodrum MA, 2001, MICROBIOS, V106, P55
   Hasegawa T, 2003, LANGMUIR, V19, P105, DOI 10.1021/la026548w
   Hasegawa T, 2000, LANGMUIR, V16, P7325, DOI 10.1021/la0004606
   Hatzor A, 2000, LANGMUIR, V16, P4420, DOI 10.1021/la0001979                                                               
   Hobara D, 1999, LANGMUIR, V15, P5073, DOI 10.1021/la981631y                                                               
   Mantzila AG, 2008, ANAL CHEM, V80, P1169, DOI [10.1021/ac071570l, 10.1021/ac071570I]
   MARECEK V, 1978, J ELECTROANAL CHEM, V94, P169, DOI 10.1016/S0022-0728(78)80312-X
   Mathebula NS, 2009, CHEM COMMUN, P3345, DOI 10.1039/b905192a
   MINNIKIN DE, 1983, J GEN MICROBIOL, V129, P889
   Muilenberg G. E., 1979, HDB XRAY PHOTOELECTR
   Nkosi D, 2008, J ELECTROANAL CHEM, V621, P304, DOI 10.1016/j.jelechem.2008.02.014
   Nkosi D, 2008, ELECTROCHIM ACTA, V53, P2782, DOI 10.1016/j.electacta.2007.10.073
   NUZO RG, 1983, J AM CHEM SOC, V105, P4481
   Orazem M. E., 2008, ELECTROCHEMICAL IMPE
   Orazem M. E., 2008, ELECTROCHEMICAL IMPE
   Park JY, 2008, ANAL CHEM, V80, P4986, DOI 10.1021/ac8002374
   Pillay J, 2009, ELECTROCHEM COMMUN, V11, P1292, DOI 10.1016/j.elecom.2009.04.028
   Pillay J, 2009, ELECTROCHIM ACTA, V54, P5053, DOI 10.1016/j.electacta.2008.12.056
   Pournaras AV, 2008, ANAL CHIM ACTA, V624, P301, DOI 10.1016/j.aca.2008.06.043
   Protsailo LV, 2000, ELECTROCHIM ACTA, V45, P3497, DOI 10.1016/S0013-4686(00)00420-5                                                   
   SABATANI E, 1987, J PHYS CHEM-US, V91, P6663, DOI 10.1021/j100311a021
   Schleicher GK, 2002, CLIN CHEM LAB MED, V40, P882, DOI 10.1515/CCLM.2002.156
   Sekanka G, 2007, EXPERT OPIN THER PAT, V17, P315, DOI 10.1517/13543776.17.3.315
   Thanyani ST, 2008, J IMMUNOL METHODS, V332, P61, DOI 10.1016/j.jim.2007.12.009
   TOKUDA K, 1979, J ELECTROANAL CHEM, V102, P41, DOI 10.1016/S0022-0728(79)80027-3
   WHO, GLOB TUB CONTR EP ST
   Wilkop T, 2007, LANGMUIR, V23, P1403, DOI 10.1021/la0625502
   XU J, 1993, J PHYS CHEM-US, V97, P11497, DOI 10.1021/j100146a025                                                             
NR 50
TC 16
Z9 16
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2010
VL 12
IS 2
BP 345
EP 357
DI 10.1039/b915930d
PG 13
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 534DG
UT WOS:000272875100007
PM 20023812
DA 2018-01-05
ER

PT J
AU Baclayon, M
   Wuite, GJL
   Roos, WH
AF Baclayon, M.
   Wuite, G. J. L.
   Roos, W. H.
TI Imaging and manipulation of single viruses by atomic force microscopy
SO SOFT MATTER
LA English
DT Review
ID HERPES-SIMPLEX-VIRUS; TOBACCO-MOSAIC-VIRUS; CHLOROTIC MOTTLE VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL CAPSIDS; CRYOELECTRON MICROSCOPY;
   MECHANICAL-PROPERTIES; HUMAN RHINOVIRUS; HIGH-RESOLUTION; BIOLOGICAL
   APPLICATIONS
AB The recent developments in virus research and the application of functional viral particles in nanotechnology and medicine rely on sophisticated imaging and manipulation techniques at nanometre resolution in liquid, air and vacuum. Atomic force microscopy (AFM) is a tool that combines these requirements and imaging of viruses dates back to the early days of AFM. AFM has a comparable resolution to electron microscopy, but has the advantage that it can be used to image in fluid. This implies that dynamic processes in physiologically relevant environments can be studied and one of the first examples of AFM imaging of viruses was the real-time observation of viral infection of living cells. Improvement of the imaging techniques led the way to image fragile viruses in non-destructive ways, to visualise viral capsomeres in liquid and to image genome uncoating. In addition to imaging, AFM is also used as a tool to manipulate viral nanoparticles. Translation, rotation and nanodissection of viruses are possible and by performing nanoindentation experiments the viral material properties can be examined. Next to providing the Young's modulus and breaking force of viral shells, such experiments have also elucidated the impact of the genome on the overall viral mechanical properties and the effect of capsid structural modifications. The combination of modelling and AFM experiments finally, yields a deeper insight into their structure, function and behaviour. Here we review the early AFM experiments on viruses, the achievements made since then and the recent advances in imaging and manipulation.
C1 [Baclayon, M.; Wuite, G. J. L.; Roos, W. H.] Vrije Univ Amsterdam, Nat Sterrenkunde & Laserctr, NL-1081 HV Amsterdam, Netherlands.
RP Roos, WH (reprint author), Vrije Univ Amsterdam, Nat Sterrenkunde & Laserctr, De Boelelaan 1081, NL-1081 HV Amsterdam, Netherlands.
EM wroos@few.vu.nl
RI Roos, Wouter/L-8346-2014
OI Roos, Wouter/0000-0002-5104-0139
FU Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) through a
   CW-ECHO; STW administered NanoSci-E+
FX This work is supported by the Nederlandse Organisatie voor
   Wetenschappelijk Onderzoek (NWO) through a CW-ECHO grant and by a STW
   administered NanoSci-E+ grant, both to GJLW.
CR Amro NA, 2000, LANGMUIR, V16, P2789, DOI 10.1021/la991013x                                                               
   ANDERSON DL, 1966, J BACTERIOL, V91, P2081
   ANDERSON TF, 1953, ANN I PASTEUR PARIS, V84, P5
   Ando T, 2008, PFLUG ARCH EUR J PHY, V456, P211, DOI 10.1007/s00424-007-0406-0
   ANSELMETTI D, 1994, J VAC SCI TECHNOL B, V12, P1500, DOI 10.1116/1.587272
   ANSELMETTI D, 1994, NANOTECHNOLOGY, V5, P87, DOI 10.1088/0957-4484/5/2/004
   Arkhipov A, 2006, STRUCTURE, V14, P1767, DOI 10.1016/j.str.2006.10.003
   Arkhipov A, 2009, BIOPHYS J, V97, P2061, DOI 10.1016/j.bpj.2009.07.039
   Baines JD, 2005, VIRAL GENOME PACKAGI, P135
   Baker ML, 2005, J VIROL, V79, P14967, DOI 10.1128/JVI.79.23.14967-14970.2005
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   Boevink P, 2005, PLANT PHYSIOL, V138, P1815, DOI 10.1104/pp.105.066761
   Bowen WR, 2000, BIOTECHNOL LETT, V22, P893, DOI 10.1023/A:1005604028444
   Buenemann M, 2007, P NATL ACAD SCI USA, V104, P9925, DOI 10.1073/pnas.0611472104
   BUSHELL GR, 1995, J MICROSC-OXFORD, V180, P174, DOI 10.1111/j.1365-2818.1995.tb03673.x                                              
   Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6                                                   
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Carrasco C, 2009, P NATL ACAD SCI USA, V106, P5475, DOI 10.1073/pnas.0810095106
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   CASJENS SR, 1974, J MOL BIOL, V88, P535, DOI 10.1016/0022-2836(74)90500-2
   CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1
   Casuso I, 2009, BIOPHYS J, V97, P1354, DOI 10.1016/j.bpj.2009.06.019
   Chen YY, 2009, LANGMUIR, V25, P4607, DOI 10.1021/la8036346
   Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504
   Cheung CL, 2006, J AM CHEM SOC, V128, P10801, DOI 10.1021/ja0616884
   CRICK FHC, 1956, NATURE, V177, P473, DOI 10.1038/177473a0
   DEPABLO, 1998, APPL PHYS LETT, V73, P3300
   DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545
   Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211
   Douglas T, 2002, ADV MATER, V14, P415, DOI 10.1002/1521-4095(20020318)14:6<415::AID-ADMA415>3.0.CO;2-W                     
   DROZ E, 1993, BIOPHYS J, V65, P1180, DOI 10.1016/S0006-3495(93)81174-3                                                   
   Drygin YF, 1998, FEBS LETT, V425, P217, DOI 10.1016/S0014-5793(98)00232-4
   Dubrovin EV, 2008, LANGMUIR, V24, P13068, DOI 10.1021/la8022612
   ENGEL A, 1991, ANNU REV BIOPHYS BIO, V20, P79, DOI 10.1146/annurev.biophys.20.1.79
   Falvo MR, 1997, BIOPHYS J, V72, P1396, DOI 10.1016/S0006-3495(97)78786-1                                                   
   Fang JY, 1997, J PHYS CHEM B, V101, P8692, DOI 10.1021/jp971057j                                                               
   Fischlechner M, 2007, ANGEW CHEM INT EDIT, V46, P3184, DOI 10.1002/anie.200603445
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Fokine A, 2005, J MOL BIOL, V352, P117, DOI 10.1016/j.jmb.2005.07.018
   Fox JM, 1996, VIROLOGY, V222, P115, DOI 10.1006/viro.1996.0402
   Freddolino PL, 2006, STRUCTURE, V14, P437, DOI 10.1016/j.str.2005.11.014
   Gaczynska M, 2008, CURR OPIN COLLOID IN, V13, P351, DOI 10.1016/j.cocis.2008.01.004
   Gelbart WM, 2009, SCIENCE, V323, P1682, DOI 10.1126/science.1170645
   Gibbons MM, 2008, BIOPHYS J, V95, P3640, DOI 10.1529/biophysj.108.136176
   Gibbons MM, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.031901
   Gibbons MM, 2007, J MATER SCI, V42, P8995, DOI 10.1007/s10853-007-1741-4
   Gladnikoff M, 2008, BIOPHYS J, V94, P320, DOI 10.1529/biophysj.107.114579
   Gladnikoff M, 2009, BIOPHYS J, V97, P2419, DOI 10.1016/j.bpj.2009.08.016
   Guthold M, 2000, IEEE-ASME T MECH, V5, P189, DOI 10.1109/3516.847092
   Guthold M, 1999, SURF INTERFACE ANAL, V27, P437, DOI 10.1002/(SICI)1096-9918(199905/06)27:5/6<437::AID-SIA505>3.0.CO;2-N
   HABERLE W, 1992, ULTRAMICROSCOPY, V42, P1161, DOI 10.1016/0304-3991(92)90418-J
   Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0
   Han WH, 1996, APPL PHYS LETT, V69, P4111, DOI 10.1063/1.117835
   HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555                                             
   HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795                                                                
   Hewat EA, 2002, MOL CELL, V10, P317, DOI 10.1016/S1097-2765(02)00603-2
   Heymann JB, 2003, NAT STRUCT BIOL, V10, P334, DOI 10.1038/nsb922
   Homa FL, 1997, REV MED VIROL, V7, P107, DOI 10.1002/(SICI)1099-1654(199707)7:2<107::AID-RMV191>3.0.CO;2-M                   
   HORBER JKH, 1992, SCANNING MICROSCOPY, V6, P919
   IKAI A, 1993, FEBS LETT, V326, P39, DOI 10.1016/0014-5793(93)81756-P                                                    
   IMAI K, 1993, JPN J APPL PHYS 1, V32, P2962, DOI 10.1143/JJAP.32.2962
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   KARRASCH S, 1993, BIOPHYS J, V65, P2437, DOI 10.1016/S0006-3495(93)81327-4                                                   
   Kasas S, 1997, INT J IMAG SYST TECH, V8, P151, DOI 10.1002/(SICI)1098-1098(1997)8:2<151::AID-IMA2>3.0.CO;2-9                       
   Kienberger F, 2005, STRUCTURE, V13, P1247, DOI 10.1016/j.str.2005.06.012
   Kienberger F, 2004, J VIROL, V78, P3203, DOI 10.1128/JVI.78.7.3203-3209.2004
   Kienberger F, 2001, SINGLE MOL, V2, P99, DOI 10.1002/1438-5171(200107)2:2<99::AID-SIMO99>3.3.CO;2-8
   Kiselyova OI, 2003, J MOL BIOL, V332, P321, DOI 10.1016/S0022-2836(03)00835-0
   Klug WS, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.228101
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   KOLBE WF, 1992, ULTRAMICROSCOPY, V42, P1113, DOI 10.1016/0304-3991(92)90411-C
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Kuznetsov YG, 2002, BIOPHYS J, V83, P3665, DOI 10.1016/S0006-3495(02)75366-6                                                   
   Kuznetsov YG, 2001, J GEN VIROL, V82, P2025, DOI 10.1099/0022-1317-82-9-2025                                                     
   Kuznetsov YG, 2006, VIROLOGY, V352, P329, DOI 10.1016/j.virol.2006.04.008
   LASCOL, 2003, SCIENCE, V299, P2033
   Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054
   Liashkovich I, 2008, J CELL SCI, V121, P2287, DOI 10.1242/jcs.032284
   Lidmar J, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.051910
   LlamasSaiz AL, 1997, ACTA CRYSTALLOGR D, V53, P93, DOI 10.1107/S0907444996010566
   Low A, 2007, J VIROL, V81, P3685, DOI 10.1128/JVI.01538-06
   Lucas RW, 2001, VIROLOGY, V286, P290, DOI 10.1006/viro.2000.0897
   Lucas WJ, 2006, VIROLOGY, V344, P169, DOI 10.1016/j.virol.2005.09.026
   LYUBCHENKO YL, 1993, NUCLEIC ACIDS RES, V21, P1117, DOI 10.1093/nar/21.5.1117                                                           
   Malkin AJ, 1999, J STRUCT BIOL, V127, P35, DOI 10.1006/jsbi.1999.4128
   MALKIN AJ, 1995, NAT STRUCT BIOL, V2, P956, DOI 10.1038/nsb1195-956
   MALKIN AJ, 1995, PHYS REV LETT, V75, P2778, DOI 10.1103/PhysRevLett.75.2778                                                     
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Matsko N, 2001, J ELECTRON MICROSC, V50, P417, DOI 10.1093/jmicro/50.5.417
   McGeoch DJ, 2006, VIRUS RES, V117, P90, DOI 10.1016/j.virusres.2006.01.002
   Melcher J, 2009, P NATL ACAD SCI USA, V106, P13655, DOI 10.1073/pnas.0902240106
   MEYER E, 1992, PHYS REV LETT, V69, P1777, DOI 10.1103/PhysRevLett.69.1777                                                     
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Mitragotri S, 2009, NAT MATER, V8, P15, DOI [10.1038/NMAT2344, 10.1038/nmat2344]
   Moloney M, 2004, ULTRAMICROSCOPY, V100, P163, DOI 10.1016/j.ultramic.2003.12.011
   MORRIS VJ, 1994, PROG BIOPHYS MOL BIO, V61, P131, DOI 10.1016/0079-6107(94)90008-6
   NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490
   NEWCOMB WW, 1994, J VIROL, V68, P433
   NEWCOMB WW, 1993, J MOL BIOL, V232, P499, DOI 10.1006/jmbi.1993.1406
   NEWCOMB WW, 1991, J VIROL, V65, P613
   Newcomb WW, 1996, J MOL BIOL, V263, P432, DOI 10.1006/jmbi.1996.0587
   Nguyen TT, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.051923
   Nurmemmedov E, 2007, Q REV BIOPHYS, V40, P327, DOI 10.1017/S0033583508004666
   Ohnesorge FM, 1997, BIOPHYS J, V73, P2183, DOI 10.1016/S0006-3495(97)78250-X                                                   
   Parot P, 2007, J MOL RECOGNIT, V20, P418, DOI 10.1002/jmr.857
   Peremyslov VV, 2004, P NATL ACAD SCI USA, V101, P5030, DOI 10.1073/pnas.0400303101
   Plomp M, 2002, AM J PATHOL, V160, P1959, DOI 10.1016/S0002-9440(10)61145-5
   Ponchon L, 2005, BBA-GEN SUBJECTS, V1724, P255, DOI 10.1016/j.bbagen.2005.04.016
   PRCHLA E, 1994, J VIROL, V68, P3713
   Purohit PK, 2005, BIOPHYS J, V88, P851, DOI 10.1529/biophysj.104.047134
   Purohit PK, 2003, P NATL ACAD SCI USA, V100, P3173, DOI 10.1073/pnas.0737893100
   PUTMAN CAJ, 1994, APPL PHYS LETT, V64, P2454, DOI 10.1063/1.111597                                                                
   Roos WH, 2007, CELL MOL LIFE SCI, V64, P1484, DOI 10.1007/s00018-007-6451-1
   Roos WH, 2003, CHEMPHYSCHEM, V4, P872, DOI 10.1002/cphc.200300712
   Roos WH, 2009, ADV MATER, V21, P1187, DOI 10.1002/adma.200801709
   Roos WH, 2009, P NATL ACAD SCI USA, V106, P9673, DOI 10.1073/pnas.0901514106
   ROY A, 1970, J VIROL, V6, P333
   Schmatulla A, 2007, J MICROSC-OXFORD, V225, P264, DOI 10.1111/j.1365-2818.2007.01741.x
   Shahin V, 2006, J CELL SCI, V119, P23, DOI 10.1242/jcs.02705
   Sheehan PE, 1996, SCIENCE, V272, P1158, DOI 10.1126/science.272.5265.1158                                                   
   SHERMAN G, 1988, VIROLOGY, V163, P471, DOI 10.1016/0042-6822(88)90288-7
   Singh P, 2006, DRUG DEVELOP RES, V67, P23, DOI 10.1002/ddr.20064
   Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581
   SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6
   STEVEN AC, 1986, J VIROL, V57, P578
   Steven AC, 2005, CURR OPIN STRUC BIOL, V15, P227, DOI 10.1016/j.sbi.2005.03.008
   Stockley P. G., 2010, EMERGING TOPICS PHYS
   STOKES GV, 1976, J VIROL, V18, P636
   Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009
   Tama F, 2005, J MOL BIOL, V345, P299, DOI 10.1016/j.jmb.2004.10.054
   Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0
   THUNDAT T, 1992, SCANNING MICROSCOPY, V6, P903
   Trus BL, 2007, MOL CELL, V26, P479, DOI 10.1016/j.molcel.2007.04.010
   Uetrecht C, 2008, P NATL ACAD SCI USA, V105, P9216, DOI 10.1073/pnas.0800406105
   VESENKA J, 1993, BIOPHYS J, V65, P992, DOI 10.1016/S0006-3495(93)81171-8                                                   
   Vliegenthart GA, 2006, BIOPHYS J, V91, P834, DOI 10.1529/biophysj.106.081422
   Wang XN, 2008, J BIOMED MATER RES A, V87A, P8, DOI 10.1002/jbm.a.31617
   Xiao CA, 2005, J MOL BIOL, V353, P493, DOI 10.1016/j.jmb.2005.08.060
   Xiao C, 2009, PLOS BIOL, V7, P958, DOI 10.1371/journal.pbio.1000092
   Xu X, 2008, BIOPHYS J, V95, P2520, DOI 10.1529/biophysj.108.132829
   Yang Z, 2009, BIOPHYS J, V96, P4438, DOI 10.1016/j.bpj.2009.03.016
   Zandi R, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021917
   ZENHAUSERN F, 1992, ULTRAMICROSCOPY, V42, P1168, DOI 10.1016/0304-3991(92)90419-K
   Zhang DQ, 2004, BIOPOLYMERS, V75, P325, DOI 10.1002/bip.20120
   Zhao Y, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.031914
   Zink M, 2009, BIOPHYS J, V96, P1350, DOI 10.1016/j.bpj.2008.11.028
NR 148
TC 35
Z9 37
U1 0
U2 49
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1744-683X
J9 SOFT MATTER
JI Soft Matter
PY 2010
VL 6
IS 21
BP 5273
EP 5285
DI 10.1039/b923992h
PG 13
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Multidisciplinary; Polymer Science
SC Chemistry; Materials Science; Physics; Polymer Science
GA 666XF
UT WOS:000283155300003
DA 2018-01-05
ER

PT J
AU Dang, Z
   Lai, WH
   Qian, KD
   Ho, P
   Lee, KH
   Chen, CH
   Huang, L
AF Dang, Zhao
   Lai, Weihong
   Qian, Keduo
   Ho, Phong
   Lee, Kuo-Hsiung
   Chen, Chin-Ho
   Huang, Li
TI Betulinic Acid Derivatives as Human Immunodeficiency Virus Type 2
   (HIV-2) Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; ANTI-AIDS AGENTS; TRITERPENE
   DERIVATIVES; MATURATION INHIBITOR; SIV; GP120; ENTRY
AB We previously reported that [[N-[3 beta-hydroxyllup-20(29)-en-28-oyl]-7-aminoheptyl]carbamoyl]methane (A43D, 4) was a potent HIV-1 entry inhibitor. However, 4 was inactive against HIV-2 virus, suggesting the structural requirements for targeting these two retroviruses are different. In this study, a series of new betulinic acid derivatives were synthesized, and some of them displayed selective anti-HIV-2 activity at nanomolar concentrations. In comparison to compounds with anti-HIV-1 activity, a shorter C-28 side chain is required for optimal anti-HIV-2 activity.
C1 [Dang, Zhao; Lai, Weihong; Ho, Phong; Chen, Chin-Ho; Huang, Li] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [Qian, Keduo; Lee, Kuo-Hsiung] Univ N Carolina, Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA.
RP Chen, CH (reprint author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
EM chc@duke.edu; lihuang@duke.edu
OI Huang, Li/0000-0001-5659-4053
FU National Institute of Allergy and Infectious Diseases (NIAID)
   [AI-65310]; National Institutes of Drug Abuse (NIDA) [DA-024589]; MAID
   [AI-077417]
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID) Grant AI-65310 awarded to C.-H.C., National
   Institutes of Drug Abuse (NIDA) Grant DA-024589 awarded to L.H.,and in
   part by Grant AI-077417 from MAID awarded to K.-H.L. The authors are
   grateful to Dr. George Dubay of the Department of Chemistry and Dr.
   Anthony Ribeiro of the NMR Spectroscopy Center of Duke University for
   their assistance oil mass and NMR spectroscopy data collection. We also
   thank Dominique Soroka for her help on preparation of this manuscript.
CR DASILVA, 2008, AIDS, V19, P1195
   Davis KL, 2009, J VIROL, V83, P1240, DOI 10.1128/JVI.01743-08
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hashimoto F, 1997, BIOORGAN MED CHEM, V5, P2133, DOI 10.1016/S0968-0896(97)00158-2
   Huang L, 2006, BIOORGAN MED CHEM, V14, P2279, DOI 10.1016/j.bmc.2005.11.016
   Huang L, 2004, ANTIMICROB AGENTS CH, V48, P663, DOI 10.1128/AAC.48.2.663-665.2004
   Huang L, 2007, LETT DRUG DES DISCOV, V4, P471, DOI 10.2174/157018007781788561                                                      
   Huang L, 2007, AIDS RES HUM RETROV, V23, P28, DOI 10.1089/aid.2006.0137
   Huang Li, 2002, Current Drug Targets - Infectious Disorders, V2, P33, DOI 10.2174/1568005024605936
   Isaka Y, 2001, ARCH VIROL, V146, P743, DOI 10.1007/s007050170143                                                           
   Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462
   Kashiwada Y, 1996, J MED CHEM, V39, P1016, DOI 10.1021/jm950922q
   Lai WH, 2008, ANTIMICROB AGENTS CH, V52, P128, DOI 10.1128/AAC.00737-07
   Li F, 2006, VIROLOGY, V356, P217, DOI 10.1016/j.virol.2006.07.023
   Martin David E., 2008, Antiviral Chemistry & Chemotherapy, V19, P107
   Soler F, 1996, J MED CHEM, V39, P1069, DOI 10.1021/jm950669u
   Wainberg MA, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-31
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
   Yu DL, 2006, J MED CHEM, V49, P5462, DOI 10.1021/jm0601912
   Zhou Jing, 2004, Retrovirology, V1, P15, DOI 10.1186/1742-4690-1-15
NR 21
TC 26
Z9 27
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 10
PY 2009
VL 52
IS 23
BP 7887
EP 7891
DI 10.1021/jm9004253
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 527AK
UT WOS:000272338000053
PM 19526990
OA green_accepted
DA 2018-01-05
ER

PT J
AU Destache, CJ
   Belgum, T
   Christensen, K
   Shibata, A
   Sharma, A
   Dash, A
AF Destache, Christopher J.
   Belgum, Todd
   Christensen, Keith
   Shibata, Annemarie
   Sharma, Akhilesh
   Dash, Alekha
TI Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYBUTYLCYANOACRYLATE NANOPARTICLES;
   TARGETED DELIVERY; THERAPY; INFECTION; SYSTEM; REPLICATION; MACROPHAGES;
   MONOCYTES; EFFICIENCY
AB Background: Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and characterized the size, shape, and surface charge. Additionally, we investigated the in vitro release of the AR drugs from the NP using peripheral blood mononuclear cells (PBMCs).
   Methods: Poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing ritonavir (RTV), lopinavir (LPV), and efavirenz (EFV) were fabricated using multiple emulsion-solvent evaporation procedure. The nanoparticles were characterized by electron microscopy and zeta potential for size, shape, and charge. The intracellular concentration of AR drugs was determined over 28 days from NPs incubated with PBMCs. Macrophages were imaged by fluorescent microscopy and flow cytometry after incubation with fluorescent NPs. Finally, macrophage cytotoxicity was determined by MTT assay.
   Results: Nanoparticle size averaged 262 +/- 83.9 nm and zeta potential -11.4 +/- 2.4. AR loading averaged 4% (w/v). Antiretroviral drug levels were determined in PBMCs after 100 mu g of NP in 75 mu L PBS was added to media. Intracellular peak AR levels from NPs (day 4) were RTV 2.5 +/- 1.1; LPV 4.1 +/- 2.0; and EFV 10.6 +/- 2.7 mu g and continued until day 28 (all AR = 0.9 mu g). Free drugs (25 mu g of each drug in 25 mu L ethanol) added to PBMCs served as control were eliminated by 2 days. Fluorescence microscopy and flow cytometry demonstrated phagocytosis of NP into monocytes-derived macrophages (MDMs). Cellular MTT assay performed on MDMs demonstrated that NPs are not significantly cytotoxic.
   Conclusion: These results demonstrated AR NPs could be fabricated containing three antiretroviral drugs (RTV, LPV, EFV). Sustained release of AR from PLGA NP show high drug levels in PBMCs until day 28 without cytotoxicity.
C1 [Destache, Christopher J.; Belgum, Todd; Christensen, Keith] Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
   [Shibata, Annemarie] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Sharma, Akhilesh] Creighton Univ, Sch Med, Dept Internal Med, Omaha, NE USA.
   [Dash, Alekha] Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Sci, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
EM destache@creighton.edu; toddbelgum@creighton.edu;
   kchristensen@creighton.edu; annemarieshibata@creighton.edu;
   AkhileshSharma@creighton.edu; adash@creighton.edu
OI Destache, Christopher/0000-0001-7923-3939
FU National Institute of Health [1R15AI076039-01A1]
FX The authors would like to thank Greg Perry, Ph. D. of the FLOW cytometry
   and Karen Bovard, B. S., MT of the Electron Microscopy, Core
   Laboratories of Creighton University for their work and expertise. This
   work was supported in part by National Institute of Health grant
   1R15AI076039-01A1. We thank Carol Peters for her excellent secretarial
   assistance.
CR Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   BECK P, 1993, J MICROENCAPSUL, V10, P101, DOI 10.3109/02652049309015316                                                       
   BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   CHEN RY, 2002, AIDS TRD HUM RETROVI, V18, P900
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324
   Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755                                                                   
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   COUVREUR P, 1982, J PHARM SCI, V71, P790, DOI 10.1002/jps.2600710717
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P277
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kreuter J., 1994, COLLOIDAL DRUG DELIV, P219
   Kuhnel H., 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2382
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   MCGANN KA, 1994, J INFECT DIS, V169, P746, DOI 10.1093/infdis/169.4.746                                                        
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   Palepua A, 2006, DRUG ALCOHOL DEPEN, V84, P188, DOI 10.1016/j.drugalcdep.2006.02.003
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004
   ROCKSTRON J, 2008, AIDS RES HUM RETROV, V2, P141
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   Weller DR, 2007, J CHROMATOGR B, V848, P369, DOI 10.1016/j.jchromb.2006.10.022
   Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101                                                     
NR 39
TC 48
Z9 48
U1 1
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 9
PY 2009
VL 9
AR 198
DI 10.1186/1471-2334-9-198
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 549AJ
UT WOS:000274012800001
PM 20003214
OA gold
DA 2018-01-05
ER

PT J
AU Boulais, PE
   Dulude, D
   Cabana, J
   Heveker, N
   Escher, E
   Lavigne, P
   Leduc, R
AF Boulais, Philip E.
   Dulude, Dominic
   Cabana, Jerome
   Heveker, Nikolaus
   Escher, Emanuel
   Lavigne, Pierre
   Leduc, Richard
TI Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140
   binding site
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE CXCR4; T140; GPCR; Photoaffinity labeling; Molecular modeling;
   Ligand-binding pocket
ID IMMUNODEFICIENCY-VIRUS TYPE-1; WEAK PARTIAL AGONISTS; CHEMOKINE
   RECEPTOR; ANGIOTENSIN-II; RHEUMATOID-ARTHRITIS; BREAST-CANCER; HIV-1
   ENTRY; INHIBITOR; LIGAND; ANTAGONISTS
AB CXCR4, a G-protein-coupled receptor, which binds the chemokine stromal cell-derived factor I alpha (SDF-1 alpha, CXCL12), is one of two co-receptors most frequently used by HIV-1 to infect CD4+ lymphocytes. The SDF-1 alpha/CXCR4 axis is also involved in angiogenesis, in stem cell homing to bone marrow, in rheumatoid arthritis and in cancer. Here, we directly determined the binding site of the inverse agonist T140 on CXCR4 using photoaffinity labeling. Two T140 photoanalogs were synthesized containing the photoreactive amino acid p-benzoyl-L-phenylalanine (Bpa) in positions 5 or 10, yielding [Bpa(5)]T140 and [Bpa(10)]T140. Binding experiments on HEK293 cells stably expressing the wild-type CXCR4 receptor using (125)I-SDF-1 alpha demonstrated that T140 and both photoanalogs had affinities in the nanomolar range, similar to SDF-1 alpha. Photolabeling led to the formation of specific, covalent 42 kDa T140-CXCR4 complexes. V8 protease digestion of both CXCR4/(125)I-[Bpa(5)]T140 and CXCR4/(125)I-[Bpa(10)]T140 adducts generated a fragment of 6 kDa suggesting that the T140 photoanalogs labeled a fragment corresponding to Lys(154)-Glu(179) of the receptor's 4th transmembrane domain. Further digestion of this 6 kDa fragment with endo Asp-N led to the generation of a shorter fragment validating the photolabeled region. Our results demonstrate that T140 interacts with residues of the fourth transmembrane domain of the CXCR4 receptor and provide new structural constraints enabling us to model the complex between T140 and CXCR4. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Boulais, Philip E.; Cabana, Jerome; Escher, Emanuel; Lavigne, Pierre; Leduc, Richard] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.
   [Dulude, Dominic; Heveker, Nikolaus] Univ Montreal, Dept Biochem, Montreal, PQ H3T 1J4, Canada.
   [Dulude, Dominic; Heveker, Nikolaus] Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada.
RP Leduc, R (reprint author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.
EM Richard.Leduc@USherbrooke.ca
RI Heveker, Nikolaus/G-5306-2012
FU Canadian Institutes for Health Research (CIHR)
FX We thank Michel Bouvier (Department of Biochemistry, Institute for
   Research in Immunology and Cancer, Universite de Montreal, Montreal,
   Quebec, Canada) for the HEK293-CXCR4 stable cell line and Marie-Reine
   Lefebvre (Department of Pharmacology, Universite de Sherbrooke,
   Sherbrooke, Quebec, Canada) for the synthesis of T140 and T140
   photoanalogs. We also thank Brian J. Holleran for critical reading of
   the manuscript. This work was supported by a grant from the Canadian
   Institutes for Health Research (CIHR) Team in GPCR Allosteric Regulation
   (CTiGAR) and is part of the Ph.D. thesis of P.E.B. D.D. holds a CIHR
   postdoctoral fellowship. E.E. is the recipient of the J.C. Edwards Chair
   in cardiovascular research. P.L. is a Chercheur boursier senior of the
   Fonds de la Recherche en Sante du Quebec (FRSQ). N.H. is a CIHR New
   Investigator. R.L is a Chercheur National of the FRSQ.
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200
   Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002
   Benovic JL, 2004, CANCER CELL, V6, P429, DOI 10.1016/j.ccr.2004.10.017                                                       
   Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v
   Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200                                                          
   Broxmeyer HE, 2008, CURR OPIN HEMATOL, V15, P49, DOI 10.1097/MOH.0b013e3282f29012                                                    
   Chute JP, 2006, CURR OPIN HEMATOL, V13, P399, DOI 10.1097/01.moh.0000245698.62511.3d
   COLLMAN R, 1992, J VIROL, V66, P7517
   Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fillion D, 2006, J MED CHEM, V49, P2200, DOI 10.1021/jm050958a
   FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
   Fujii N, 2001, Curr Opin Investig Drugs, V2, P1198
   Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0
   Holleran BJ, 2007, BIOCHEM J, V402, P51, DOI 10.1042/BJ20060943
   Iwamoto T, 2008, FEBS J, V275, P4448, DOI 10.1111/j.1742-4658.2008.06580.x
   Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389
   Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578
   Lin G, 2007, J VIROL, V81, P9956, DOI 10.1128/JVI.00385-07
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   Munch J, 2002, ANTIMICROB AGENTS CH, V46, P982, DOI 10.1128/AAC.46.4.982-990.2002
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Price MR, 2005, MOL PHARMACOL, V68, P1484, DOI 10.1124/mol.105.016162
   Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013
   Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200
   Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330
   Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104
   Suratt BT, 2004, BLOOD, V104, P565, DOI 10.1182/blood-2003-10-3638
   Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P359, DOI 10.1016/S0960-894X(00)00664-8                                                   
   Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7
   Tamamura H, 2004, FEBS LETT, V569, P99, DOI 10.1016/j.febslet.2004.05.056
   Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Tamamura H, 2006, ORG BIOMOL CHEM, V4, P2354, DOI 10.1039/b603818b
   Trent JO, 2003, J BIOL CHEM, V278, P47136, DOI 10.1074/jbc.M307850200
   Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050
   Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200
   Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200
NR 43
TC 17
Z9 18
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC 1
PY 2009
VL 78
IS 11
BP 1382
EP 1390
DI 10.1016/j.bcp.2009.07.007
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 510EA
UT WOS:000271069600005
PM 19631193
DA 2018-01-05
ER

PT J
AU Tang, JF
   Zhou, L
   Gao, WJ
   Cao, X
   Wang, YF
AF Tang, Jingfeng
   Zhou, Li
   Gao, Wenjuan
   Cao, Xuan
   Wang, Yefu
TI Visual DNA microarrays for simultaneous detection of human
   immunodeficiency virus type-1 and Treponema pallidum coupled with
   multiplex asymmetric polymerase chain reaction
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE HIV-1; T. pallidum; DNA microarrays; Gold nanoparticles; Gold-conjugated
   streptavidins; Gold label silver stain; Multiplex asymmetric PCR
ID COLORIMETRIC SILVER DETECTION; PCR; GENE; EXPRESSION; HIV-1
AB Based on gold label silver stain and coupled with multiplex asymmetric polymerase chain reaction (PCR) analysis, we developed the visual DNA microarray for simultaneous, sensitive, and specific detection of human immunodeficiency virus type-1 (HIV-1) and Treponema pallidum. The 5'-end amino-modified oligonucleotides were immobilized on glass surface, which were used as the capturing probes to bind the complement biotinylated target DNA. The gold-conjugated streptavidins were introduced to the microarray for specific binding to biotin. The black image of microarray spots, which were the result from the precipitation of silver onto nanogold particles and bound to streptavidins, was visualized and accounted as the detection of biotinylated target DNA. Multiplex asymmetric PCR products of HIV-1 and T pallidum and Bacillus subtilis (used as positive control) were performed for preparing the abundant biotinylated single-stranded target DNA of which could affect detection efficiency and sensitivity of hybridization on microarray. One hundred sixty-nine clinical samples of HIV-1 and T pallidum from infected patients were tested using the homemade DNA microarrays. The results were identical to those shown in the assays of ELISA and fluorescence quantitative real-time PCR. Our results demonstrate that we have developed the visual gene detection technique, which is of high sensitivity and specificity; it may have potential in clinical applications. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Tang, Jingfeng; Zhou, Li; Gao, Wenjuan; Cao, Xuan; Wang, Yefu] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
RP Wang, YF (reprint author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
EM wangyefu9930@163.com
FU Foundation of Scientific and Technological Project of Hubei Province
   [2007AA302B05]
FX This work was supported by the Foundation of Scientific and
   Technological Project of Hubei Province (grant 2007AA302B05). The
   authors thank Zhongnan Hospital, Renmin Hospital of Wuhan University,
   and Hubei EntryExit Inspection and Quarantine Bureau (Wuhan, China) for
   offering clinical samples.
CR Alexandre I, 2001, ANAL BIOCHEM, V295, P1, DOI 10.1006/abio.2001.5176
   Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455                                                                    
   Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462
   Cao X, 2006, BIOSENS BIOELECTRON, V22, P393, DOI 10.1016/j.bios.2006.05.011
   Centres for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V52, P1117
   Centers for Disease Control and Prevention (CDC), 2002, MMWR-MORBID MORTAL W, V51, P971
   Corless CE, 2001, J CLIN MICROBIOL, V39, P1553, DOI 10.1128/JCM.39.4.1553-1558.2001
   Ding YP, 2002, PROG BIOCHEM BIOPHYS, V29, P640
   Hainfeld JF, 2000, J HISTOCHEM CYTOCHEM, V48, P459, DOI 10.1177/002215540004800402                                                      
   Heredia A, 1996, CLIN DIAGN VIROL, V7, P85, DOI 10.1016/S0928-0197(96)00255-3
   Ji MJ, 2004, CLIN CHIM ACTA, V342, P145, DOI 10.1016/j.cccn.2003.12.017
   Kwok PY, 2001, ANNU REV GENOM HUM G, V2, P235, DOI 10.1146/annurev.genom.2.1.235                                                   
   LIN WM, 1995, BOOK CONCERN DEMOS S, P25
   Liu H, 2001, J CLIN MICROBIOL, V39, P1941, DOI 10.1128/JCM.39.5.1941-1946.2001
   Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701
   Mary M, 2002, MOL BIOL LAB, V10, P16
   Sato Neuza Satomi, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P115, DOI 10.1590/S0036-46651999000200009
   Tao SC, 2002, ANAL LETT, V35, P1149, DOI 10.1081/AL-120005969
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   TERESA J, 2002, NATL NANOFABRICATION, P42
   Wang CW, 2005, J WUHAN UNIV TECHNOL, V20, P38
   Wang YF, 2003, J MED VIROL, V70, P205, DOI 10.1002/jmv.10379
   ZAMMATTEO N, 1995, J VIROL METHODS, V55, P185, DOI 10.1016/0166-0934(95)00050-5
NR 23
TC 14
Z9 16
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD DEC
PY 2009
VL 65
IS 4
BP 372
EP 378
DI 10.1016/j.diagmicrobio.2009.07.017
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 523YY
UT WOS:000272112200004
PM 19765935
DA 2018-01-05
ER

PT J
AU Xi, LF
   Hughes, JP
   Edelstein, ZR
   Kiviat, NB
   Koutsky, LA
   Mao, C
   Ho, J
   Schiffman, M
AF Xi, Long Fu
   Hughes, James P.
   Edelstein, Zoe R.
   Kiviat, Nancy B.
   Koutsky, Laura A.
   Mao, Constance
   Ho, Jesse
   Schiffman, Mark
TI Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and
   Persistence of Type-Specific Infection during a 2-Year Follow-Up
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK
   HUMAN-PAPILLOMAVIRUS; CARCINOMA IN-SITU; FORMER SOVIET-UNION; VIRAL
   LOAD; INDEPENDENT STATES; NATURAL-HISTORY; WOMEN; CLEARANCE
AB Background. Studies of viral load-associated persistence of human papillomavirus (HPV) infection are rare, with inconsistent results reported.
   Methods. The study subjects were 741 and 289 women who were positive for HPV type 16 (HPV-16) and HPV type 18 (HPV-18), respectively, at the time of enrollment into in the ASCUS-LSIL ( Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion) Triage Study and who returned 1 or more times for HPV testing during a biannual 2-year follow-up. The numbers of HPV-16 and HPV-18 copies per nanogram of cellular DNA at baseline were measured by use of real-time polymerase chain reaction.
   Results. Women with, compared with women without, persistent infection at month 6 of follow-up had a higher viral load at enrollment (P < .001, for HPV-16; P = .01, for HPV-18). The association of each 1-log(10) increase in viral load with persistence of HPV-16 or HPV-18 during the first 6 months of the study was statistically significant among women with multiple HPV types at enrollment ( for HPV-16: odds ratio [ OR], 1.53 [ 95% confidence interval {CI}, 1.29-1.82]; for HPV-18: OR, 1.35 [ 95% CI, 1.09-1.68]) but not among women with monotype infections ( in tests assessing the interaction between viral load and coinfection, P = .002 for HPV-16 and P = .34 for HPV-18). Among women who continued to have positive results at month 6, 12, or 18, persistence of infection for another 6 months was unassociated with the viral load at baseline.
   Conclusion. Prevalent infection with a higher viral load of HPV-16 or HPV-18 was associated with short-but not long-term persistence.
C1 [Xi, Long Fu; Kiviat, Nancy B.; Ho, Jesse] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98195 USA.
   [Mao, Constance] Univ Washington, Dept Obstet & Gynecol, Sch Med, Seattle, WA 98195 USA.
   [Xi, Long Fu; Edelstein, Zoe R.; Koutsky, Laura A.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
   [Hughes, James P.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA.
   [Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Xi, LF (reprint author), Northgate Execut Ctr 1,Bldg B,155 NE 100th St,Ste, Seattle, WA 98125 USA.
EM longfu@u.washington.edu
FU Public Health Service [CA 84396]
FX Financial support: Public Health Service ( grant CA 84396 to L. F. X.).
CR Ahdieh L, 2001, J INFECT DIS, V184, P682, DOI 10.1086/323081
   Combita AL, 2002, J VIROL, V76, P6480, DOI 10.1128/JVI.76.13.6480-6486.2002
   Dalstein W, 2003, INT J CANCER, V106, P396, DOI 10.1002/ijc.11222
   Fen J, 2004, ONCOL REP, V12, P375
   Fontaine J, 2008, J CLIN VIROL, V43, P307, DOI 10.1016/j.jcv.2008.07.013
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   HO GYF, 1995, J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703                                                     
   Josefsson AM, 2000, LANCET, V355, P2189, DOI 10.1016/S0140-6736(00)02401-6
   Kovacic MB, 2006, CANCER RES, V66, P10112, DOI 10.1158/0008-5472.CAN-06-1812
   Kulmala SMA, 2007, CANCER EPIDEM BIOMAR, V16, P17, DOI 10.1158/1055-9965.EPI-06-0649
   Lai CH, 2008, INT J CANCER, V123, P1685, DOI 10.1002/ijc.23679
   Liaw KL, 2001, J INFECT DIS, V183, P8, DOI 10.1086/317638
   MAUCORTBOULCH D, 2009, INT J CANC      0716
   McCarthy C, 2006, INT J CANCER, V118, P2514, DOI 10.1002/ijc.21643
   Moberg M, 2005, BRIT J CANCER, V92, P891, DOI 10.1038/sj.bjc.6602436
   Molano M, 2003, AM J EPIDEMIOL, V158, P486, DOI 10.1093/aje/kwg171
   Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641                                                            
   Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X                                                   
   Nobbenhuis MAE, 2001, LANCET, V358, P1782, DOI 10.1016/S0140-6736(01)06809-X                                                   
   Park JY, 2008, GYNECOL ONCOL, V108, P549, DOI 10.1016/j.ygyno.2007.11.009
   Pinto LA, 2006, VIROLOGY, V353, P451, DOI 10.1016/j.virol.2006.06.021
   REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305
   Rodriguez AC, 2008, J NATL CANCER I, V100, P513, DOI 10.1093/jnci/djn044
   Rowhani-Rahbar A, 2007, J INFECT DIS, V196, P887, DOI 10.1086/520883
   Sarian LO, 2005, TUMORI, V91, P188
   Schiffman M, 2000, ACTA CYTOL, V44, P726, DOI 10.1159/000328554                                                               
   Schlecht NF, 2001, JAMA-J AM MED ASSOC, V286, P3106, DOI 10.1001/jama.286.24.3106
   SLINKER BK, 1988, AM J PHYSIOL, V255, pR353
   Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457
   Song SH, 2006, GYNECOL ONCOL, V101, P418, DOI 10.1016/j.ygyno.2005.10.028
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903                                                     
   Syrjanen S, 2005, EUR J OBSTET GYN R B, V119, P219, DOI 10.1016/j.ejogrb.2004.07.036
   Trottier H, 2008, J INFECT DIS, V197, P1436, DOI 10.1086/587698
   van Duin M, 2002, INT J CANCER, V98, P590, DOI 10.1002/ijc.10232
   VERNON SD, 1994, J INFECT DIS, V169, P1108, DOI 10.1093/infdis/169.5.1108                                                       
   Xi LF, 2008, J INFECT DIS, V198, P324, DOI 10.1086/589715
   Xi LF, 2009, CANCER EPIDEM BIOMAR, V18, P2507, DOI 10.1158/1055-9965.EPI-09-0482
   Xi LF, 2009, JNCI-J NATL CANCER I, V101, P153, DOI 10.1093/jnci/djn461
   Ylitalo N, 2000, CANCER RES, V60, P6027
   Ylitalo N, 2000, LANCET, V355, P2194, DOI 10.1016/S0140-6736(00)02402-8
NR 44
TC 25
Z9 25
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2009
VL 200
IS 11
BP 1789
EP 1797
DI 10.1086/647993
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 518AP
UT WOS:000271662100024
PM 19848609
OA gold
DA 2018-01-05
ER

PT J
AU Partidos, CD
   Hoebeke, J
   Wieckowski, S
   Chaloin, O
   Bianco, A
   Moreau, E
   Briand, JP
   Desgranges, C
   Muller, S
AF Partidos, Charalambos D.
   Hoebeke, Johan
   Wieckowski, Sebastien
   Chaloin, Olivier
   Bianco, Alberto
   Moreau, Emmanuel
   Briand, Jean-Paul
   Desgranges, Claude
   Muller, Sylviane
TI Immunomodulatory consequences of ODN CpG-polycation complexes
SO METHODS
LA English
DT Review
DE Immunomodulation; CpG motifs; Carbon nanotubes; Tat protein; Adjuvants;
   Delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 TAT PROTEIN; FUNCTIONALIZED CARBON
   NANOTUBES; PLASMACYTOID DENDRITIC CELLS; CYTOTOXIC T-LYMPHOCYTES; B
   SURFACE-ANTIGEN; INNATE IMMUNITY; TYPE-1 TAT; NEUTRALIZING ANTIBODIES;
   INTRANASAL IMMUNIZATION
AB Immunostimulatory ODN CpGs have extensively been tested as adjuvants and immunotherapeutics and hold a lot of promise for human use. In our studies we took advantage of their negative charge to study their biological activities after being complexed with carbon nanotubes, a novel vector for vaccine delivery and Tat protein of HIV, a target protein for therapeutic or prophylactic intervention. In the case of carbon nanotubes, ODN CpGs were able to form stable complexes based on charge interaction and exert increased immunostimulatory activity in vitro. With regard to the Tat protein, ODN CpGs were shown to bind effectively through the basic domain of the protein representing residues 44-61. Moreover, using surface Plasmon Resonance Technology and an in vitro cellular system, ODN CpGs were shown to inhibit the interaction of Tat protein with the transactivation responsive element, a bulged RNA hairpin structure. However, when ODN CpGs were complexed with Tat they readily increased the apoptotic properties of this protein as studied in CD3-stimulated Jurkat cells. Overall, our findings together with published data support the view that for harnessing the beneficial effects of ODN CpGs a careful consideration has to be given depending on the target intervention. (c) 2009 Published by Elsevier Inc.
C1 [Partidos, Charalambos D.; Hoebeke, Johan; Wieckowski, Sebastien; Chaloin, Olivier; Bianco, Alberto; Briand, Jean-Paul; Muller, Sylviane] CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-67084 Strasbourg, France.
   [Partidos, Charalambos D.] Inviragen, Madison, WI 53719 USA.
   [Partidos, Charalambos D.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Moreau, Emmanuel; Desgranges, Claude] Univ Paris 05, Inst Cochin, CNRS, INSERM,UMR 8104,U567, Paris, France.
   [Moreau, Emmanuel] McGill Univ, Montreal, PQ, Canada.
RP Partidos, CD (reprint author), CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-67084 Strasbourg, France.
EM hpartidos@inviragen.com; J.Hoebeke@skynet.be; s.muller@ibmc.u-strasbg.fr
RI Muller, Sylviane/J-5319-2014
FU CNRS; French National AIDS Research Agency (ANRS); Association Ensembles
   Contre le SIDA (SIDACTION)
FX This study was supported by CNRS and grants from the French National
   AIDS Research Agency (ANRS) and the Association Ensembles Contre le SIDA
   (SIDACTION).
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781                                                          
   Becker Y, 2005, VIRUS GENES, V30, P251, DOI 10.1007/s11262-004-5632-2
   Beignon AS, 2002, IMMUNOLOGY, V105, P204, DOI 10.1046/j.0019-2805.2001.01357.x
   Belliard G, 2003, VACCINE, V21, P3186, DOI 10.1016/S0264-410X(03)00233-0
   BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4
   Bianco A, 2005, J AM CHEM SOC, V127, P58, DOI 10.1021/ja044293y
   Bianco A, 2008, EXPERT OPIN DRUG DEL, V5, P331, DOI [10.1517/17425247.5.3.331, 10.1517/17425247.5.3.331 ]
   Bianco Alberto, 2005, Current Drug Delivery, V2, P253, DOI 10.2174/1567201054367959
   Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791                                                         
   Butto S, 2003, J INFECT DIS, V188, P1171, DOI 10.1086/378412
   Capini CJ, 2001, BIOMED PHARMACOTHER, V55, P23, DOI 10.1016/S0753-3322(00)00018-4                                                   
   Chaloin O, 2005, CELL MOL LIFE SCI, V62, P355, DOI 10.1007/s00018-004-4477-1
   Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623
   Endo S, 1989, Virus Genes, V3, P99
   FROEBEL KS, 1994, AIDS RES HUM RETROV, V10, pS83
   Fulcher AJ, 2003, IUBMB LIFE, V55, P669, DOI 10.1080/15216540310001643440
   Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8
   Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987
   Hemmi H, 2000, NATURE, V408, P740
   Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313
   Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593                                                          
   KAM J, 1999, J MOL BIOL, V293, P235
   Kanellos TS, 1999, IMMUNOLOGY, V96, P507, DOI 10.1046/j.1365-2567.1999.00771.x
   Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831
   Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5
   Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
   Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116
   Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242
   Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320                                                     
   Marinaro M, 2003, VACCINE, V21, P3972, DOI 10.1016/S0264-410X(03)00295-0
   McCluskie MJ, 2002, FEMS IMMUNOL MED MIC, V32, P179, DOI 10.1016/S0928-8244(01)00305-4
   Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5                                                   
   Moreau E, 2004, J GEN VIROL, V85, P2893, DOI 10.1099/vir.0.80365-0
   Moreau E, 2004, J VIROL, V78, P3792, DOI 10.1128/JVI.78.7.3792-3796.2004
   Muller S, 2006, CELL DEATH DURING HIV INFECTION, P143
   Olszewska W, 2000, INFECT IMMUN, V68, P4923, DOI 10.1128/IAI.68.9.4923-4929.2000
   Pantarotto D, 2003, CHEM BIOL, V10, P961, DOI 10.1016/j.chembiol.2003.09.011
   Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r
   Partidos CD, 2005, EUR J IMMUNOL, V35, P1521, DOI 10.1002/eji.200425676
   Partidos CD, 2004, VACCINE, V22, P2385, DOI 10.1016/j.vaccine.2003.11.063
   Prato M, 2008, ACCOUNTS CHEM RES, V41, P60, DOI 10.1021/ar700089b
   Re MC, 1996, CLIN DIAGN LAB IMMUN, V3, P230
   Schlaepfer E, 2004, J VIROL, V78, P12344, DOI 10.1128/JVI.78.22.12344-12354.2004
   Tasis D, 2006, CHEM REV, V106, P1105, DOI 10.1021/cr050569o
   Teleshova N, 2004, J IMMUNOL, V173, P1647, DOI 10.4049/jimmunol.173.3.1647                                                     
   Tidd DM, 2000, NUCLEIC ACIDS RES, V28, P2242, DOI 10.1093/nar/28.11.2242
   Tikhonov I, 2003, J VIROL, V77, P3157, DOI 10.1128/JVI.77.5.3157-3166.2003
   Toossi Z, 2003, J INFECT DIS, V188, P1146, DOI 10.1086/378676                                                                  
   vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913                                                     
   VERTHELYI D, 2003, IMMUNOLOGY, V170, P4717
   Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6                                                   
   Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032
   Watson K, 1999, BIOCHEM PHARMACOL, V58, P1521, DOI 10.1016/S0006-2952(99)00209-9
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Yandara N, 2008, VACCINE, V26, P5864, DOI 10.1016/j.vaccine.2008.08.014
   Zagury J F, 1998, J Hum Virol, V1, P282
NR 59
TC 5
Z9 6
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD DEC
PY 2009
VL 49
IS 4
BP 328
EP 333
DI 10.1016/j.ymeth.2009.03.005
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 524FP
UT WOS:000272129500006
PM 19303048
DA 2018-01-05
ER

PT J
AU Nowacek, AS
   Miller, RL
   McMillan, J
   Kanmogne, G
   Kanmogne, M
   Mosley, RL
   Ma, ZY
   Graham, S
   Chaubal, M
   Werling, J
   Rabinow, B
   Dou, HY
   Gendelman, HE
AF Nowacek, Ari S.
   Miller, Reagan L.
   McMillan, JoEllyn
   Kanmogne, Georgette
   Kanmogne, Michel
   Mosley, R. Lee
   Ma, Zhiya
   Graham, Sabine
   Chaubal, Mahesh
   Werling, Jane
   Rabinow, Barrett
   Dou, Huanyu
   Gendelman, Howard E.
TI NanoART synthesis, characterization, uptake, release and toxicology for
   human monocyte-macrophage drug delivery
SO NANOMEDICINE
LA English
DT Article
DE antiretroviral therapy; antiviral response; HIV; monocyte-derived
   macrophage; nanoART; nanoparticle
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD-BRAIN-BARRIER; ANTIRETROVIRAL
   THERAPY; CLINICAL-PRACTICE; HIV-INFECTION; VIROLOGICAL RESPONSE;
   NANOPARTICLES; MECHANISMS; SYSTEM; TISSUE
AB Background: Factors limiting the efficacy of conventional antiretroviral therapy for HIV-1 infection include treatment adherence, pharmacokinetics and penetration into viral sanctuaries. These affect the rate of viral mutation and drug resistance. In attempts to bypass such limitations, nanoparticles containing ritonavir, indinavir and efavirenz (described as nanoART) were manufactured to assess macrophage-based drug delivery. Methods: NanoART were made by high-pressure homogenization of crystalline drug with various surfactants. Size, charge and shape of the nanoparticles were assessed. Monocyte-derived macrophage nanoART uptake, drug release, migration and cytotoxicity were determined. Drug levels were measured by reverse-phase high-performance liquid chromatography. Results: Efficient monocyte-derived macrophage cytoplasmic vesicle uptake in less than 30 min based on size, charge and coating was observed. Antiretroviral drugs were released over 14 days and showed dose-dependent reduction in progeny virion production and HIV-1 p24 antigen. Cytotoxicities resulting from nanoART carriage were limited. Conclusion: These results support the continued development of macrophage-mediated nanoART carriage for HIV-1 disease.
C1 [Nowacek, Ari S.; McMillan, JoEllyn; Kanmogne, Georgette; Kanmogne, Michel; Mosley, R. Lee; Ma, Zhiya; Dou, Huanyu; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Miller, Reagan L.; Graham, Sabine; Chaubal, Mahesh; Werling, Jane; Rabinow, Barrett] Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU NIH [2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635, P01MH64570,
   P01 NS43985]; Baxter Healthcare
FX The work was supported by grants 2R01 NS034239,2R37 NS36126, P01
   NS31492, P20RR 15635, P01MH64570, and P01 NS43985 (to HE Gendelman)from
   the NIH and a grant from Baxter Healthcare in nanomedicine. S Graham, M
   Chaubal, J Werling and B Rainbow are employees of Baxter Healthcare
   Corporation who developed the nanoART formulations used in this article.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR AHMED SA, 1994, J IMMUNOL METHODS, V170, P211
   Alos L, 2005, MODERN PATHOL, V18, P127, DOI 10.1038/modpathol.3800267
   Altamura AC, 2003, DRUGS, V63, P493, DOI 10.2165/00003495-200363050-00004
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bruce RD, 2006, CLIN INFECT DIS, V43, pS216, DOI 10.1086/508186                                                                  
   Bruce RD, 2006, JAIDS-J ACQ IMM DEF, V41, P563, DOI 10.1097/01.qai.0000219769.89679.ec
   Chaudhuri A, 2008, J CEREBR BLOOD F MET, V28, P697, DOI 10.1038/sj.jcbfm.9600567
   Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   De Cock K, 2006, B WORLD HEALTH ORGAN, V84, P506, DOI 10.2471/BLT.06.0339104                                                          
   Delaugerre C, 2005, J MED VIROL, V77, P345, DOI 10.1002/jmv.20462
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duval X, 2004, HIV MED, V5, P307, DOI 10.1111/j.1468-1293.2004.00226.x                                                
   EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Gaucher G, 2009, BIOMACROMOLECULES, V10, P408, DOI 10.1021/bm801178f
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gendelman HE, 2008, J NEUROIMMUNE PHARM, V3, P58, DOI 10.1007/s11481-008-9103-9
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   KALTER DC, 1991, J IMMUNOL, V146, P3396
   Kane JM, 2003, AM J PSYCHIAT, V160, P1125, DOI 10.1176/appi.ajp.160.6.1125                                                     
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   McKinnon JE, 2009, ANTIVIR THER, V14, P1
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rainer Michael K, 2008, Neuropsychiatr Dis Treat, V4, P919
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Sant S, 2008, J BIOMED MATER RES A, V87A, P885, DOI 10.1002/jbm.a.31800
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Swindells S, 2006, JAMA-J AM MED ASSOC, V296, P806, DOI 10.1001/jama.296.7.806                                                          
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   Taylor DM, 2009, J CLIN PSYCHIAT, V70, P196, DOI 10.4088/JCP.08m04427                                                            
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Vonarbourg A, 2006, J BIOMED MATER RES A, V78A, P620, DOI 10.1002/jbm.a.30711
NR 49
TC 61
Z9 63
U1 1
U2 13
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD DEC
PY 2009
VL 4
IS 8
BP 903
EP 917
DI 10.2217/NNM.09.71
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 532TO
UT WOS:000272773000013
PM 19958227
OA green_accepted
DA 2018-01-05
ER

PT J
AU Baoum, A
   Xie, SX
   Fakhari, A
   Berkland, C
AF Baoum, Abdulgader
   Xie, Sheng-Xue
   Fakhari, Amir
   Berkland, Cory
TI "Soft" Calcium Crosslinks Enable Highly Efficient Gene Transfection
   Using TAT Peptide
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE A549 cells; gene delivery; plasmid DNA; polyethylenimine; TAT
ID CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAINS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; POLYCATION-DNA COMPLEXES; ARGININE-RICH
   PEPTIDES; IN-VIVO; DELIVERY-SYSTEMS; INTRACELLULAR DELIVERY;
   MAMMALIAN-CELLS; CATIONIC LIPIDS
AB Typically, low molecular weight cationic peptides or polymers exhibit poor transfection efficiency due to an inability to condense plasmid DNA into small nanoparticles. Here, efficient gene delivery was attained using TAT/pDNA complexes containing calcium crosslinks.
   Electrostatic complexes of pDNA with TAT or PEI were studied with increasing calcium concentration. Gel electrophoresis was used to determine DNA condensation. The morphology of the complexes was probed by transmission electron microscopy. Transfection efficiency was assessed using a luciferase reporter plasmid. The accessibility of phosphate and amine groups within complexes was evaluated to determine the effect of calcium on structure.
   TAT/pDNA complexes were condensed into small, 50-100 nm particles by optimizing the concentration of calcium. Complexes optimized for small size also exhibited higher transfection efficiency than PEI polyplexes in A549 cells. TAT and TAT complexes displayed negligible cytotoxicity up to 5 mg/mL, while PEI exhibited high cytotoxicity, as expected. Probing the TAT-Ca/pDNA structure suggested that calcium interacted with both phosphate and amine groups to compact the complexes; however, these "soft" crosslinks could be competitively disrupted to facilitate DNA release.
   Small and stable TAT-Ca/pDNA complexes were obtained via "soft" calcium crosslinks leading to sustained gene expression levels higher than observed for control PEI gene vectors. TAT-Ca/pDNA complexes were stable, maintaining particle size and transfection efficiency even in the presence of 10% of FBS. TAT-Ca complexes offer an effective vehicle offering potential for translatable gene delivery.
C1 [Baoum, Abdulgader; Xie, Sheng-Xue; Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA.
   [Fakhari, Amir] Univ Kansas, Dept Bioengn, Lawrence, KS 66047 USA.
   [Berkland, Cory] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66047 USA.
RP Berkland, C (reprint author), Univ Kansas, Dept Pharmaceut Chem, 2030 Becker Dr, Lawrence, KS 66047 USA.
EM berkland@ku.edu
FU Coulter Foundation; Higuchi Biosciences Center; Cystic Fibrosis
   Foundation; American Heart Association; NIH [R03 AR054035, P20 RR016443,
   T32 GM08359-11]; Department of Defense; NSF [CHE 0719464]
FX We would like to acknowledge support for this work from the Coulter
   Foundation, the Higuchi Biosciences Center, and the Cystic Fibrosis
   Foundation as well as additional lab funding from the American Heart
   Association, the NIH (R03 AR054035, P20 RR016443 and T32 GM08359-11) and
   the Department of Defense. In addition, we acknowledge the support of
   the NSF (CHE 0719464). We also thank Prof. C. Russ Middaugh for the use
   of laboratory equipment and the Microscopy Lab for assistance with
   electron microscopy.
CR Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947                                                      
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a
   Choosakoonkriang S, 2003, J PHARM SCI, V92, P1710, DOI 10.1002/jps.10437
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Davis ME, 2002, CURR OPIN BIOTECH, V13, P128, DOI 10.1016/S0958-1669(02)00294-X
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102                                              
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   Gupta Bhawna, 2006, Expert Opin Drug Deliv, V3, P177, DOI 10.1517/17425247.3.2.177
   Haberland A, 2000, PHARMACEUT RES, V17, P229, DOI 10.1023/A:1007581700996
   HENRIQUES ST, 2005, BIOCHEMISTRY-US, V5, P9
   Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040
   Hope MJ, 1998, MOL MEMBR BIOL, V15, P1, DOI 10.3109/09687689809027512
   Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422                                                     
   Huang CY, 2002, J PHARM SCI, V91, P1371, DOI 10.1002/jps.10130
   Huang L, 1999, NONVIRAL VECTORS GEN
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Kwon DS, 1997, J BIOL CHEM, V272, P2429
   Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6                                                   
   Lobo BA, 2003, J PHARM SCI-US, V92, P1905, DOI 10.1002/jps.10450
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Mae M, 2005, BBA-BIOMEMBRANES, V1669, P101, DOI 10.1016/j.bbamem.2005.01.006
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244                                                   
   MED JG, 2005, J GENE MED, V7, P198
   Moret I, 2001, J CONTROL RELEASE, V76, P169, DOI 10.1016/S0168-3659(01)00415-1                                                   
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nchinda Godwin, 2002, BMC Biotechnol, V2, P12, DOI 10.1186/1472-6750-2-12
   Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Peeters MJTFDV, 1996, HUM GENE THER, V7, P1693, DOI 10.1089/hum.1996.7.14-1693
   Pouton CW, 1998, J CONTROL RELEASE, V53, P289, DOI 10.1016/S0168-3659(98)00015-7                                                   
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Ruponen M, 1999, BBA-BIOMEMBRANES, V1415, P331, DOI 10.1016/S0005-2736(98)00199-0
   SAMBROOK J, 2001, MOL CLONING LAB MANU, V16
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Simberg D, 2001, J BIOL CHEM, V276, P47453, DOI 10.1074/jbc.M105588200
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647
   Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Tiyaboonchai W, 2003, EUR J PHARM SCI, V19, P191, DOI 10.1016/S0928-0987(03)00102-7
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Tung CH, 2000, BIOCONJUGATE CHEM, V11, P605, DOI 10.1021/bc0000334
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Turek J, 2000, J GENE MED, V2, P32, DOI 10.1002/(SICI)1521-2254(200001/02)2:1<32::AID-JGM78>3.0.CO;2-U
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255                                                         
   Wiethoff CM, 2004, J PHARM SCI-US, V93, P108, DOI 10.1002/jps.10519
   YEI SP, 1994, GENE THER, V1, P192
   Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0
NR 74
TC 17
Z9 17
U1 2
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORD
JI Pharm. Res.
PD DEC
PY 2009
VL 26
IS 12
BP 2619
EP 2629
DI 10.1007/s11095-009-9976-1
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 515IT
UT WOS:000271464100009
PM 19789962
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wittrup, A
   Zhang, SH
   ten Dam, GB
   van Kuppevelt, TH
   Bengtson, P
   Johansson, M
   Welch, J
   Morgelin, M
   Belting, M
AF Wittrup, Anders
   Zhang, Si-He
   ten Dam, Gerdy B.
   van Kuppevelt, Toin H.
   Bengtson, Per
   Johansson, Maria
   Welch, Johanna
   Morgelin, Matthias
   Belting, Mattias
TI ScFv Antibody-induced Translocation of Cell-surface Heparan Sulfate
   Proteoglycan to Endocytic Vesicles EVIDENCE FOR HEPARAN SULFATE EPITOPE
   SPECIFICITY AND ROLE OF BOTH SYNDECAN AND GLYPICAN
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTRACELLULAR DEGRADATIVE PATHWAYS; PHAGE DISPLAY ANTIBODIES;
   ARGININE-RICH PEPTIDES; MEDIATED GENE-TRANSFER; MAMMALIAN-CELLS;
   MACROPINOCYTOSIS; INTERNALIZATION; 2-O-SULFATION; PROTEINS; DOMAINS
AB Cellular uptake of several viruses and polybasic macromolecules requires the expression of cell-surface heparan sulfate proteoglycan (HSPG) through as yet ill defined mechanisms. We unexpectedly found that among several cell-surface-binding single chain variable fragment (scFv) anti-HS antibody (alpha HS) clones, only one, AO4B08, efficiently translocated macromolecular cargo to intracellular vesicles through induction of HSPG endocytosis. Interestingly, AO4B08-induced PG internalization was strictly dependent on HS 2-O-sulfation and appeared independent of intact N-sulfation. AO4B08 and human immunodeficiency virus (HIV)-Tat, i.e. a well known cell-penetrating peptide, were shown to compete for the internalizing PG population. To obtain a more detailed characterization of this pathway, we have developed a procedure for the isolation of endocytic vesicles by conjugating AO4B08 with superparamagnetic nanoparticles. [(35)S] sulfate-labeled HSPG was found to accumulate in isolated, AO4B08-containing vesicles, providing the first biochemical evidence for intact HSPG co-internalization with its ligand. Further analysis revealed the existence of both syndecan, i.e. a transmembrane HSPG, and glycosyl-phosphatidyl-inositol-anchored glypican in purified vesicles. Importantly, internalized syndecan and glypican were found to colocalize in AO4B08-containing vesicles. Our data establish HSPGs as true internalizing receptors of macromolecular cargo and indicate that the sorting of cell-surface HSPG to endocytic vesicles is determined by a specific HS epitope that can be carried by both syndecan and glypican core protein.
C1 [Wittrup, Anders; Zhang, Si-He; Bengtson, Per; Johansson, Maria; Welch, Johanna; Belting, Mattias] Lund Univ, Sect Oncol, Dept Clin Sci, SE-22185 Lund, Sweden.
   [Morgelin, Matthias] Lund Univ, Sect Clin & Expt Infect Med, Dept Clin Sci, SE-22185 Lund, Sweden.
   [ten Dam, Gerdy B.; van Kuppevelt, Toin H.] Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands.
RP Wittrup, A (reprint author), Lund Univ, Sect Oncol, Dept Clin Sci, Barngatan 2-1, SE-22185 Lund, Sweden.
EM anders.wittrup@med.lu.se; mattias.belting@med.lu.se
RI Kuppevelt, A.H.M.S.M./L-4463-2015
OI Wittrup, Anders/0000-0003-4918-0500; Zhang, Si-he/0000-0002-8923-1993
FU Swedish Cancer Fund; Swedish Research Council; Swedish Foundation for
   Strategic Research (FLAK); Swedish Society of Medicine; Physiographic
   Society, Lund; Crafoordska, Gunnar Nilsson, and Kamprad Foundations;
   Lund University Hospital (ALF)
FX This work was supported by grants from the Swedish Cancer Fund; the
   Swedish Research Council; the Swedish Foundation for Strategic Research
   (FLAK); the Swedish Society of Medicine; the Physiographic Society,
   Lund; the Crafoordska, Gunnar Nilsson, and Kamprad Foundations; and the
   Lund University Hospital (ALF).
CR Bai X, 2001, Methods Mol Biol, V171, P309
   Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172
   Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711                                                        
   BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081                                                               
   Beauvais DeannaLee M, 2004, Reprod Biol Endocrinol, V2, P3, DOI 10.1186/1477-7827-2-3
   Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317
   Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391
   Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257
   Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200
   ENGEL J, 1987, METHOD ENZYMOL, V145, P3
   Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224
   Fransson LA, 2004, CELL MOL LIFE SCI, V61, P1016, DOI 10.1007/s00018-004-3445-0
   Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607
   Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685
   Gonzalez A D, 1998, J Cell Biol, V141, P1407, DOI 10.1083/jcb.141.6.1407
   Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035
   Kurup S, 2007, J BIOL CHEM, V282, P21032, DOI 10.1074/jbc.M702073200
   Landgraf P, 2008, J BIOL CHEM, V283, P25036, DOI 10.1074/jbc.M800963200
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x
   POWELL AK, 2004, GLYCOBIOLOGY, V14, P17
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200
   Smits NC, 2004, AM J RESP CELL MOL, V30, P166, DOI 10.1165/remb.2003-01980C
   Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1                                                   
   ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727
   Tkachenko E, 2004, J CELL SCI, V117, P3189, DOI 10.1242/jcs.01190
   Wittrup A, 2007, J BIOL CHEM, V282, P27897, DOI 10.1074/jbc.M701611200
   YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505
   YANAGISHITA M, 1984, J BIOL CHEM, V259, P270
NR 36
TC 36
Z9 36
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 20
PY 2009
VL 284
IS 47
BP 32959
EP 32967
DI 10.1074/jbc.M109.036129
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 522VR
UT WOS:000272028400079
PM 19783663
OA gold
DA 2018-01-05
ER

PT J
AU Gudmundsson, KS
   Boggs, SD
   Catalano, JG
   Svolto, A
   Spaltenstein, A
   Thomson, M
   Wheelan, P
   Jenkinson, S
AF Gudmundsson, Kristjan S.
   Boggs, Sharon D.
   Catalano, John G.
   Svolto, Angilique
   Spaltenstein, Andrew
   Thomson, Michael
   Wheelan, Pat
   Jenkinson, Stephen
TI Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with
   potent activity against HIV-1
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CXCR4; HIV; Antiviral; Imidazopyridine; Tetrahydroquinoline
ID CHEMOKINE RECEPTOR CXCR4; ANTAGONIST; INHIBITORS; ENTRY
AB Synthesis of several novel imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV are described. Synthetic approaches allowing for variation of the substitution pattern are outlined and resulting changes in antiviral activity and pharmacokinetics are highlighted. Several compounds with low nanomolar anti-HIV activity and oral bioavailability are described. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Gudmundsson, Kristjan S.; Boggs, Sharon D.; Catalano, John G.; Svolto, Angilique; Spaltenstein, Andrew] GlaxoSmithKline Res & Dev Ltd, Dept Med Chem, Metab & Virol Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Thomson, Michael] GlaxoSmithKline Res & Dev Ltd, Dept Virol, Metab & Virol Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Wheelan, Pat] GlaxoSmithKline Res & Dev Ltd, Dept DMPK, Metab & Virol Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Jenkinson, Stephen] GlaxoSmithKline Res & Dev Ltd, Dept Biochem & Analyt Pharmacol, Metab & Virol Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
RP Gudmundsson, KS (reprint author), GlaxoSmithKline Res & Dev Ltd, Dept Med Chem, Metab & Virol Ctr Excellence Drug Discovery, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM ksgudmundsson@gmail.com
CR Berson JF, 1996, J VIROL, V70, P6288
   Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423                                                     
   Crawford JB, 2008, ORG PROCESS RES DEV, V12, P823, DOI 10.1021/op8000993
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   DeMarco SJ, 2006, BIOORGAN MED CHEM, V14, P8396, DOI 10.1016/j.bmc.2006.09.003
   Fujii N, 2003, ANGEW CHEM INT EDIT, V42, P3251, DOI 10.1002/anie.200351024
   Gudmundsson KS, 2009, BIOORG MED CHEM LETT, V19, P5048, DOI 10.1016/j.bmcl.2009.07.037
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   Ichiyama K, 2003, P NATL ACAD SCI USA, V100, P4185, DOI 10.1073/pnas.0630420100
   Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686                                                     
   *NCI, 2005, NCI CANC B, V17, P4
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354
   Shaheen F, 2004, CURR OPIN INFECT DIS, V17, P7, DOI 10.1097/01.qco.0000113643.29255.5c
   Skupinska KA, 2003, J ORG CHEM, V68, P3546, DOI 10.1021/jo026701r
   SUMNERSMITH M, 1995, DRUG EXP CLIN RES, V21, P1
   Tamamura H, 2004, FEBS LETT, V569, P99, DOI 10.1016/j.febslet.2004.05.056
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
   BRIDGER GJ, 2003, Patent No. 2003055876
   CRAWFORD JB, 2006, Patent No. 2006039250
NR 20
TC 37
Z9 37
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 15
PY 2009
VL 19
IS 22
BP 6399
EP 6403
DI 10.1016/j.bmcl.2009.09.056
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 509PH
UT WOS:000271029600032
PM 19818609
DA 2018-01-05
ER

PT J
AU Massignani, M
   LoPresti, C
   Blanazs, A
   Madsen, J
   Armes, SP
   Lewis, AL
   Battaglia, G
AF Massignani, Marzia
   LoPresti, Caterina
   Blanazs, Adam
   Madsen, Jeppe
   Armes, Steven P.
   Lewis, Andrew L.
   Battaglia, Giuseppe
TI Controlling Cellular Uptake by Surface Chemistry, Size, and Surface
   Topology at the Nanoscale
SO SMALL
LA English
DT Article
DE biomimetics; cells; intracellular delivery; nanovectors; polymersomes
ID ZWITTERIONIC DIBLOCK COPOLYMER; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMER
   VESICLES; INTRACELLULAR DELIVERY; MAMMALIAN-CELLS; DENDRITIC CELLS;
   SYSTEMS; DRUG; DNA
AB Cell cytosol and the different subcellular organelles house the most important biochemical processes that control cell functions. Effective delivery of bioactive agents within cells is expected to have an enormous impact on both gene therapy and the future development of new therapeutic and/or diagnostic strategies based on single-cell-bioactive-agent interactions. Herein a biomimetic nanovector is reported that is able to enter cells, escape from the complex endocytic pathway, and efficiently deliver actives within clinically relevant cells without perturbing their metabolic activity. This nanovector is based on the pH-controlled self-assembly of amphiphilic copolymers into nanometer-sized vesicles (or polymersomes). The cellular-uptake kinetics can be regulated by controlling the surface chemistry, the polymersome size, and the polymersome surface topology. The latter is controlled by the extent of polymer-polymer phase separation within the external envelope of the polymersome.
C1 [Massignani, Marzia; LoPresti, Caterina; Battaglia, Giuseppe] Univ Sheffield, Kroto Res Inst, Dept Mat Engn, Sheffield S3 7HQ, S Yorkshire, England.
   [Blanazs, Adam; Madsen, Jeppe; Armes, Steven P.] Univ Sheffield, Dept Chem, Sheffield S3 7HQ, S Yorkshire, England.
   [Lewis, Andrew L.] Biocompatibles UK Ltd, Surrey, England.
RP Battaglia, G (reprint author), Univ Sheffield, Kroto Res Inst, Dept Mat Engn, Broad Lane, Sheffield S3 7HQ, S Yorkshire, England.
EM g.battaglia@sheffield.ac.uk
RI Battaglia, Giuseppe/I-2142-2013; Battaglia, Giuseppe/A-2253-2012;
   Madsen, Jeppe/A-3184-2015
OI Battaglia, Giuseppe/0000-0003-3349-6770; Madsen,
   Jeppe/0000-0001-7625-9498; Armes, Steven/0000-0002-8289-6351; Lewis,
   Andrew/0000-0001-5779-5631
FU Biocompatibles Ltd; EPSRC1White Rose LS1 -DTC; EPSRC [EP/E03103X/1];
   Royal Society
FX We thank Dr. Irene Canton for useful discussions and assistance with
   cell-culture studies and Prof Sheila MacNeil, Ms. Claudia Marques, Ms.
   Pollovi Deshpande, Ms. Vanessa Hearden, and Ms. Anna Tellechea Lopez for
   providing access to the dermal and oral fibroblasts, epidermal and oral
   keratinocytes, dermal endothelium, melanoma A816i, C8375, H357, Limbal
   epithelium cells. We thank Dr. John Haycock and Ms. Celia Morris-Smith
   for providing access to the Rat Schwonnoma NeMaP22 cells and Dr. Gwen
   Reilly for the Preosteocytes MLOA5 and the primary MSC Stem cells. We
   also acknowledge Dr. Jonathan Bury and Dr. Nicola Green for help in
   extracting the oesophogus cells and Prof Martin Thornhill and Dr. Craig
   Murdoch for assistance with all oral cancer cells and the blood cell
   types. This work was sponsored by Biocompatibles Ltd. MM is recipient of
   an EPSRC1White Rose LS1 -DTC 'studentship. CL is sponsored by EPSRC
   (EP/E03103X/1). SPA is the recipient of a five-year Royal
   Society-Wolfson Research Merit Award.
CR Ahmed F, 2006, J CONTROL RELEASE, V116, P150, DOI 10.1016/j.jconrel.2006.07.012
   ALBERTS B, 2002, MOL BIOL CELL
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Battaglia G, 2005, J AM CHEM SOC, V127, P8757, DOI 10.1021/ja050742y
   Comeau JWD, 2006, BIOPHYS J, V91, P4611, DOI 10.1529/biophysj.106.089441
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972
   Du JZ, 2005, J AM CHEM SOC, V127, P17982, DOI 10.1021/ja056514l                                                               
   Forster S, 2001, MACROMOLECULES, V34, P4610, DOI 10.1021/ma001923h
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259                                                         
   Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102
   Gedde U.W., 1995, POLYM PHYS
   Hashida M, 1996, J CONTROL RELEASE, V41, P91, DOI 10.1016/0168-3659(96)01360-0
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Hu Y, 2007, NANO LETT, V7, P3056, DOI 10.1021/nl071542i
   Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596                                                            
   Kheirolomoom A, 2007, BIOMATERIALS, V28, P4311, DOI 10.1016/j.biomaterials.2007.06.008
   Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339
   Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209
   LASIC DD, 1998, MED APPL LIPOSOMES, P794
   Lomas H, 2008, FARADAY DISCUSS, V139, P143, DOI 10.1039/b717431d
   LOPRESTI C, UNPUB
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   NEUMANN E, 1982, EMBO J, V1, P841
   OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Photos PJ, 2003, J CONTROL RELEASE, V90, P323, DOI 10.1016/S0168-3659(03)00201-3
   Ralston DR, 1999, BRIT J DERMATOL, V140, P605
   Robinson KL, 2002, J MATER CHEM, V12, P890, DOI 10.1039/b200348c
   Shen L, 2008, LANGMUIR, V24, P10019, DOI 10.1021/la801190z
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Zhang SL, 2009, ADV MATER, V21, P419, DOI 10.1002/adma.200801393
NR 35
TC 151
Z9 152
U1 1
U2 102
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1613-6810
J9 SMALL
JI Small
PD NOV 2
PY 2009
VL 5
IS 21
BP 2424
EP 2432
DI 10.1002/smll.200900578
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 519TK
UT WOS:000271791100012
PM 19634187
DA 2018-01-05
ER

PT J
AU Sexton, A
   Whitney, PG
   Chong, SF
   Zelikin, AN
   Johnston, APR
   De Rose, R
   Brooks, AG
   Caruso, F
   Kent, SJ
AF Sexton, Amy
   Whitney, Paul G.
   Chong, Siow-Feng
   Zelikin, Alexander N.
   Johnston, Angus P. R.
   De Rose, Robert
   Brooks, Andrew G.
   Caruso, Frank
   Kent, Stephen J.
TI A Protective Vaccine Delivery System for In Vivo T Cell Stimulation
   Using Nanoengineered Polymer Hydrogel Capsules
SO ACS NANO
LA English
DT Article
DE layer-by layer; hydrogel; nanoengineering; vaccine; delivery; in vivo; T
   cell stimulation
ID DENDRITIC CELLS; CROSS-PRESENTATION; SELF-ANTIGENS; ENCAPSULATION;
   RESPONSES; PEPTIDES; CARRIERS; SPHERES; HELP
AB Successful delivery of labile vaccine antigens, such as peptides and proteins, to stimulate CD4 and CD8 T cell immunity could improve vaccine strategies against chronic infections such as HIV and Hepatitis C. Layer-by-layer (LbL)-assembled nanoengineered hydrogel capsules represent a novel and promising technology for the protection and delivery of labile vaccine candidates to antigen-presenting cells (APCs). Here we report on the in vitro and in vivo immunostimulatory capabilities of LbL-assembled disulfide cross-linked poly(methacrylic acid) (PMA(SH)) hydrogel capsules as a delivery strategy for protein and peptide vaccines using robust transgenic mice models and ovalbumin (OVA) as a model vaccine. We demonstrate that OVA protein as well as multiple OVA peptides can be successfully encapsulated within nanoengineered PMASH hydrogel capsules. OVA-containing PMASH capsules are internalized by mouse APCs, resulting in presentation of OVA epitopes and subsequent activation of OVA-specific CD4 and CD8 T cells in vitro. OVA-specific CD4 and CD8 T cells are also activated to proliferate in vivo following intravenous vaccination of mice with OVA protein- and OVA peptide-loaded PMA(SH) hydrogel capsules. Furthermore, we show that OVA encapsulated within the PMAsH capsules resulted in at least 6-fold greater proliferation of OVA-specific CD8 T cells and 70-fold greater proliferation of OVA-specific CD4 T cells in vivo compared to the equivalent amount of OVA protein administered alone. These results highlight the potential of nanoengineered hydrogel capsules for vaccine delivery.
C1 [Sexton, Amy; Whitney, Paul G.; De Rose, Robert; Brooks, Andrew G.; Kent, Stephen J.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.
   [Chong, Siow-Feng; Zelikin, Alexander N.; Johnston, Angus P. R.; Caruso, Frank] Univ Melbourne, Dept Chem & Biomol Engn, Ctr Nanosci & Nanotechnol, Parkville, Vic 3010, Australia.
RP Kent, SJ (reprint author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.
EM fcaruso@unimelb.edu.au; skent@unimelb.edu.au
RI Johnston, Angus/A-9254-2011; Caruso, Frank/A-9587-2011; Zelikin,
   Alexander/J-3659-2012
OI Johnston, Angus/0000-0001-5611-4515; Caruso, Frank/0000-0002-0197-497X;
   Zelikin, Alexander/0000-0002-9864-321X; De Rose,
   Robert/0000-0003-4316-3910; Whitney, Paul/0000-0003-3836-7601; Kent,
   Stephen/0000-0002-8539-4891; Brooks, Andrew/0000-0002-4085-9683
FU National Health and Medical Research Council; Australian Research
   Council grants under the Federation Fellowship; Discovery Project;
   University of Melbourne Strategic Research Infrastructure Fund
FX We thank staff at the Microbiology and Immunology animal facility at The
   University of Melbourne. This work is supported by National Health and
   Medical Research Council grants (S.J.K), Australian Research Council
   grants under the Federation Fellowship (F.C.) and Discovery Project
   (F.C., A.P.R.J., A.N.Z.) schemes, and The University of Melbourne
   Strategic Research Infrastructure Fund (F.C., S.J.X).
CR Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017
   Altfeld M, 2000, CURR OPIN IMMUNOL, V12, P375, DOI 10.1016/S0952-7915(00)00103-5
   BAMDEN MJ, 1998, IMMUNOL CELL BIOL, V76, P34
   Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724
   Belz GT, 2007, NAT IMMUNOL, V8, P1060, DOI 10.1038/ni1505
   Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111                                                   
   Chong SF, 2009, BIOMATERIALS, V30, P5178, DOI 10.1016/j.biomaterials.2009.05.078
   Clarke SRM, 2000, IMMUNOL CELL BIOL, V78, P110, DOI 10.1046/j.1440-1711.2000.00889.x
   De Rose R, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000055
   De Rose R, 2008, ADV MATER, V20, P4698, DOI 10.1002/adma.200801826
   Discher DE, 2006, ANNU REV BIOMED ENG, V8, P323, DOI 10.1146/annurev.bioeng.8.061505.095838
   Donath E, 1998, ANGEW CHEM INT EDIT, V37, P2201
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774                                                         
   Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1                                                   
   KOUP RA, 1994, J VIROL, V68, P4650
   Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239                                                           
   Lensen D, 2008, MACROMOL BIOSCI, V8, P991, DOI 10.1002/mabi.200800112
   Nayak JV, 2006, J IMMUNOL, V177, P8493, DOI 10.4049/jimmunol.177.12.8493                                                    
   Neundorf I, 2008, BIOCONJUGATE CHEM, V19, P1596, DOI 10.1021/bc800149f
   Quinn JF, 2007, CHEM SOC REV, V36, P707, DOI 10.1039/b610778h
   Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200                                                          
   Sivakumar S, 2009, ADV MATER, V21, P1820, DOI 10.1002/adma.200802475
   Standley SM, 2007, BIOCONJUGATE CHEM, V18, P77, DOI 10.1021/bc060165i
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Wang YJ, 2005, CHEM MATER, V17, P953, DOI 10.1021/cm0483137
   Werle M, 2006, J CONTROL RELEASE, V111, P41, DOI 10.1016/j.cornel.2005.11.011
   Zelikin AN, 2008, CHEM MATER, V20, P2655, DOI 10.1021/cm703403p
   Zelikin AN, 2007, ACS NANO, V1, P63, DOI 10.1021/nn700063w
   Zelikin AN, 2006, BIOMACROMOLECULES, V7, P27, DOI 10.1021/bm050832v
   Zhang XQ, 2007, J PHARM SCI-US, V96, P3283, DOI 10.1002/jps.20978
NR 31
TC 115
Z9 115
U1 6
U2 73
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD NOV
PY 2009
VL 3
IS 11
BP 3391
EP 3400
DI 10.1021/nn900715g
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 521UY
UT WOS:000271951200010
PM 19824668
OA gold
DA 2018-01-05
ER

PT J
AU Alexander, L
   Zhang, SR
   McAuliffe, B
   Connors, D
   Zhou, NN
   Wang, T
   Agler, M
   Kadow, J
   Lin, PF
AF Alexander, Louis
   Zhang, Sharon
   McAuliffe, Brian
   Connors, David
   Zhou, Nannon
   Wang, Tao
   Agler, Michele
   Kadow, John
   Lin, Pin-Fang
TI Inhibition of Envelope-Mediated CD4(+)-T-Cell Depletion by Human
   Immunodeficiency Virus Attachment Inhibitors
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID T-CELL DEPLETION; CD4 RECEPTOR-BINDING; HIV-INFECTION; ANTIRETROVIRAL
   THERAPY; TYPE-1 GP120; CONFORMATIONAL-CHANGES; CORECEPTOR USE;
   APOPTOSIS; CXCR4; TROPISM
AB Human immunodeficiency virus type 1 (HIV-1) envelope (Env) binding induces proapoptotic signals in CD4(+) T cells without a requirement of infection. Defective virus particles, which represent the majority of HIV-1, usually contain a functional Env and therefore represent a potentially significant cause of such CD4(+)-T-cell loss. We reasoned that an HIV-1 inhibitor that prohibits Env-host cell interactions could block the destructive effects of defective particles. HIV-1 attachment inhibitors (AIs), which potently inhibit Env-CD4 binding and subsequent downstream effects of Env, display low-nanomolar antiapoptotic potency and prevent CD4(+)-T-cell depletion from mixed lymphocyte cultures, also with low-nanomolar potency. Specific Env amino acid changes that confer resistance to AI antientry activity eliminate AI antiapoptotic effects. We observed that CD4(+)-T-cell destruction is specific for CXCR4-utilizing HIV-1 strains and that the fusion blocker enfuvirtide inhibits Env-mediated CD4(+)-T-cell killing but is substantially less potent than AIs. These observations, in conjunction with observed antiapoptotic activities of soluble CD4 and the CXCR4 blocker AMD3100, suggest that this AI activity functions through a mechanism common to AI antientry activity, e. g., prevention of Env conformation changes necessary for specific interactions with cellular factors that facilitate viral entry. Our study suggests that AIs, in addition to having potent antientry activity, could contribute to immune system homeostasis in individuals infected with HIV-1 that can engage CXCR4, thereby mitigating the increased risk of adverse clinical events observed in such individuals on current antiretroviral regimens.
C1 [Alexander, Louis; Zhang, Sharon; McAuliffe, Brian; Zhou, Nannon; Lin, Pin-Fang] Bristol Myers Squibb Co, Dept Virol, Wallingford, CT 06492 USA.
   [Connors, David; Agler, Michele] Bristol Myers Squibb Co, Dept Lead Discovery, Wallingford, CT 06492 USA.
   [Wang, Tao; Kadow, John] Bristol Myers Squibb Co, Dept Virol Chem, Wallingford, CT 06492 USA.
RP Alexander, L (reprint author), Bristol Myers Squibb Co, Dept Virol, 5 Res Pkwy, Wallingford, CT 06492 USA.
EM louis.alexander@bms.com
CR Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   Barretina J, 2003, ANTIVIR THER, V8, P155
   Berkowitz RD, 1998, J VIROL, V72, P10108
   Blanco J, 2000, ANTIMICROB AGENTS CH, V44, P51, DOI 10.1128/AAC.44.1.51-56.2000                                                     
   Briggs JAG, 2006, J MOL BIOL, V355, P157, DOI 10.1016/j.jmb.2005.10.025
   Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519                                                                  
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Esser MT, 2001, J VIROL, V75, P1152, DOI 10.1128/JVI.75.3.1152-1164.2001                                                 
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678
   Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111
   Geng EH, 2009, CLIN INFECT DIS, V48, P362, DOI 10.1086/595889
   Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319
   Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1016/JVI.77.19.10528-10536.2003
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   Holm GH, 2005, J VIROL, V79, P6299, DOI 10.1128/JVI.79.10.6299-6311.2005
   Holm GH, 2004, J VIROL, V78, P4541, DOI 10.1128/JVI.78.9.4541-4551.2004
   Hung CS, 1999, VIROLOGY, V264, P278, DOI 10.1006/viro.1999.0013                                                          
   Hunt PW, 2006, J INFECT DIS, V194, P926, DOI 10.1086/507312
   Kuritzkes DR, 2009, CURR OPIN HIV AIDS, V4, P82, DOI 10.1097/COH.0b013e328322402e
   Lawson VA, 2004, VIROLOGY, V327, P70, DOI 10.1016/j.virol.2004.06.012
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549                                                         
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Lum JJ, 2005, AIDS, V19, P1125, DOI 10.1097/01.aids.0000176212.16205.23
   Makinson A, 2009, CURR OPIN HIV AIDS, V4, P150, DOI 10.1097/COH.0b013e32832498d8
   Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186                                                                
   McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648
   McKnight A, 1997, J VIROL, V71, P1692
   Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77
   Moyle GJ, 2005, J INFECT DIS, V191, P866, DOI 10.1086/428096                                                                  
   Penn ML, 1999, P NATL ACAD SCI USA, V96, P663, DOI 10.1073/pnas.96.2.663                                                           
   PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089
   Rogalinska M, 2002, CELL MOL BIOL LETT, V7, P995
   Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001                                                
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Silvestri G, 2008, J MED PRIMATOL, V37, P6, DOI 10.1111/j.1600-0684.2008.00328.x
   Smith CL, 2002, ANN PHARMACOTHER, V36, P280
   Smyth RJ, 1998, J VIROL, V72, P4478
   Soriano V, 2008, AIDS, V22, P2231, DOI 10.1097/QAD.0b013e3283136d95
   SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2
   Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000
   Sullivan N, 1998, J VIROL, V72, P4694
   Vlahakis SR, 2001, J CLIN INVEST, V107, P207, DOI 10.1172/JCI11109
   Wang BZ, 2007, J VIROL, V81, P10869, DOI 10.1128/JVI.00542-07
   Wang HGH, 2004, CURR PHARM DESIGN, V10, P1785, DOI 10.2174/1381612043384565                                                        
   Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o
   Waters L, 2008, CLIN INFECT DIS, V46, P1617, DOI 10.1086/587660
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0
   Wilkin TJ, 2007, CLIN INFECT DIS, V44, P591, DOI 10.1086/511035                                                                  
   Yao QZ, 2001, VIROLOGY, V285, P128, DOI 10.1006/viro.2001.0927
   Yi Y, 2008, JAIDS-J ACQ IMM DEF, V47, P285, DOI 10.1097/QAI.0b013e31816520f6
   Yuan W, 2004, J VIROL, V78, P5448, DOI 10.1128/JVI.78.10.5448-5457.2004
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 58
TC 14
Z9 14
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2009
VL 53
IS 11
BP 4726
EP 4732
DI 10.1128/AAC.00494-09
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 507US
UT WOS:000270881200020
PM 19721067
OA gold
DA 2018-01-05
ER

PT J
AU Tang, SX
   Hewlett, IK
AF Tang, Shixing
   Hewlett, Indira K.
TI Europium nanoparticle-based immunoassays for sensitive detection of
   pathogens
SO CHIMICA OGGI-CHEMISTRY TODAY
LA English
DT Article
DE Nanoparticle; europium; immunoassay; detection; infectious pathogen
ID TIME-RESOLVED FLUORESCENCE; PROSTATE-SPECIFIC ANTIGEN; SIGNAL
   AMPLIFICATION; ASSAYS; LABEL
AB We describe and review the application of europium (Eu(3+)) nanoparticle (NP)-based immunoassays (ENIA) for rapid, sensitive, and quantitative detection of pathogens through antibody-antigen recognition. The extremely intense luminescence of the NPs can be directly detected without the need for enzymatic signal amplification or sample preparation. Incorporation of biotinylated anti-streptavidin (SA) and SA-coated Eu(3+) molecules or tyramide molecules for signal amplification (TSA) results in enhanced signal intensity, and further improves detection sensitivity of ENIAs. Our studies demonstrate that ENIA provides a highly specific, ultrasensitive and relatively simple format for detection of HIV-1 p24 antigen, anthrax toxin, and F1 factor and LcrV antigen of Y. pestis., and has the potential for broad application in clinical diagnosis and laboratory research.
C1 [Tang, Shixing; Hewlett, Indira K.] US FDA, Ctr Biol Evaluat & Res, Mol Virol Lab, Bethesda, MD 20892 USA.
RP Tang, SX (reprint author), US FDA, Ctr Biol Evaluat & Res, Mol Virol Lab, Bldg 29B,Room 4NN16,8800 Rockville Pike, Bethesda, MD 20892 USA.
FU Biodefense Advanced Research and Development Agency (BARDA), DHHS;
   NHLBI; NIAID, NIH
FX We wish to acknowledge the Biodefense Advanced Research and Development
   Agency (BARDA), DHHS for funding and/or supporting. This work was also
   supported in part by NHLBI and NIAID, NIH. We wish to acknowledge Robert
   Purcell, Steve Leppla, Karen Meysick and Harri Harma for providing
   reagents. We thank Eric Y. Wong, Krishna Devadas and Hira Nakhasi for
   review of the manuscript. The findings and conclusions in this article
   have not been formally disseminated by the FDA and should not be
   construed to represent any Agency determination or policy.
CR BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X                                                    
   Fischer NO, 2007, ANALYST, V132, P187, DOI 10.1039/b615477h
   Harma H, 2000, LUMINESCENCE, V15, P351, DOI 10.1002/1522-7243(200011/12)15:6<351::AID-BIO624>3.0.CO;2-3
   Harma H, 2001, CLIN CHEM, V47, P561
   HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   Schupbach Jorg, 2002, AIDS Reviews, V4, P83
   TANG S, 2009, J INFECT DI IN PRESS, V200
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2009, CLIN VACCINE IMMUNOL, V16, P408, DOI 10.1128/CVI.00412-08
   Teramura Y, 2006, ANAL BIOCHEM, V357, P208, DOI 10.1016/j.ab.2006.07.032
   Valanne A, 2005, J CLIN VIROL, V33, P217, DOI 10.1016/j.jcv.2004.11.007
   Zhang HQ, 2007, ANALYST, V132, P724, DOI 10.1039/b704256f
   Zhao XJ, 2003, J AM CHEM SOC, V125, P11474, DOI 10.1021/ja0358854
NR 15
TC 2
Z9 3
U1 1
U2 8
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1973-8250
J9 CHIM OGGI
JI Chim. Oggi-Chem. Today
PD NOV-DEC
PY 2009
VL 27
IS 6
BP 50
EP 52
PG 3
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary
SC Biotechnology & Applied Microbiology; Chemistry
GA 648PQ
UT WOS:000281706800011
DA 2018-01-05
ER

PT J
AU Berry, CC
   Harianawalw, H
   Loebus, J
   Oreffo, ROC
   de la Fuente, J
AF Berry, C. C.
   Harianawalw, H.
   Loebus, J.
   Oreffo, R. O. C.
   de la Fuente, J.
TI Enhancement of Human Bone Marrow Cell Uptake of Quantum Dots using Tat
   Peptide
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Cell; nanoparticles; quantum dots; tat peptide
ID HUMAN IMMUNODEFICIENCY VIRUS; PENETRATING PEPTIDES; INTRACELLULAR
   DELIVERY; PROGENITOR CELLS; STEM-CELLS; IN-VIVO; NANOPARTICLES;
   NANOCRYSTALS; BIOLOGY; PROTEIN
AB Nanotechnology is proving to play a major role in the future of biomedical applications such as drug delivery, gene therapy and cell imaging/tracking, in particular the use of nanoparticles is regularly highlighted. However with regards to nanoparticles, direct intracellular and intranuclear delivery has, until recently, been difficult to achieve due to the impermeable nature of the plasma and nuclear membranes. The advent of cell penetrating peptides being employed as delivery vectors has opened up many avenues with respect to targeted delivery systems. In this paper, quantum dots were synthesised and functionalised with the HIV-1 tat peptide, and uptake into human bone marrow derived cell populations was assessed. Results demonstrated an increase in uptake for tat modified quantum dots, possibly via a different mechanism to non-modified dots.
C1 [Berry, C. C.; Harianawalw, H.; Loebus, J.; Oreffo, R. O. C.; de la Fuente, J.] Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
RP Berry, CC (reprint author), Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
EM catherine.berry@bio.gla.ac.uk
RI Oreffo, Richard/A-4615-2011
OI Oreffo, Richard/0000-0001-5995-6726; de la Fuente, Jesus
   M/0000-0003-1081-8482
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Baksh D, 2003, EXP HEMATOL, V31, P723, DOI 10.1016/S0301-472X(03)00106-1
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180                                                      
   BRUCHEZ M, 2005, CURR OPIN CHEM BIOL, V281, P2013
   BRUCHEZ M, 1998, SCIENCE, V281, P2016
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562                                                               
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   LANGEL U, 2006, BIOCH BIOPHY ACTA, V1758, P260
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Maitra A, 2005, EXPERT REV MOL DIAGN, V5, P893, DOI 10.1586/14737159.5.6.893
   MICHALET X, 2001, SINGLE MOL, V9, P533
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m                                                               
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rosenthal SJ, 2002, J AM CHEM SOC, V124, P4586, DOI 10.1021/ja003486s
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
NR 28
TC 5
Z9 5
U1 1
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
J9 CURR NANOSCI
JI Curr. Nanosci.
PD NOV
PY 2009
VL 5
IS 4
BP 390
EP 395
PG 6
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 514IB
UT WOS:000271386500001
DA 2018-01-05
ER

PT J
AU Plattner, VE
   Ratzinger, G
   Engleder, ET
   Gallauner, S
   Gabor, F
   Wirth, M
AF Plattner, V. E.
   Ratzinger, G.
   Engleder, E. T.
   Gallauner, S.
   Gabor, F.
   Wirth, M.
TI Alteration of the glycosylation pattern of monocytic THP-1 cells upon
   differentiation and its impact on lectin-mediated drug delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Monocytes/macrophages; Glycosylation pattern; Lectins; Bioadhesion; Drug
   targeting; Nanoparticles
ID PERITONEAL-MACROPHAGE; ADHESION; LINE
AB In the present study, human monocytic THP-1 cells were treated with phorbol-12-myristate-13-acetate (PMA) in order to obtain macrophage-like cells. Before and after treatment, plant lectins with distinct sugar specificities were applied in order to elucidate the glycosylation patterns of both monocytic and macrophage-like cell types and to follow changes during differentiation.
   As a result of flow-cytometric analyses, for untreated as well as for PMA-differentiated cells WGA yielded the highest binding rate without significant changes in the binding capacity. For the other lectins, divergent results were obtained which point to reorganization of sugar residues on the cell surface during differentiation.
   Additionally, cytoinvasion being beneficial for enhanced drug absorption was studied with WGA which had displayed a high binding capacity together with a high specificity. For both untreated and PMA-differentiated cells decreased fluorescence intensity at 37 degrees C as compared to 4 degrees C was observable pointing to internalization and accumulation within acidic compartments. Moreover, WGA-functionalized PLGA nanoparticles were prepared, and their uptake evaluated. Uptake rates of 55% in case of PMA-differentiated cells suggested that WGA-grafted drug delivery systems might be an interesting approach for treatment of infectious diseases provoked by parasites, facultative intracellular bacteria, or viruses such as HIV. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Plattner, V. E.; Ratzinger, G.; Engleder, E. T.; Gallauner, S.; Gabor, F.; Wirth, M.] Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, A-1090 Vienna, Austria.
RP Wirth, M (reprint author), Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, Waehringer Guertel 18, A-1090 Vienna, Austria.
EM michael.wirth@univie.ac.at
RI Ratzinger, Gerda/D-2210-2015
CR AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244
   BENNETT HS, 1963, J HISTOCHEM CYTOCHEM, V11, P14, DOI 10.1177/11.1.14                                                                 
   Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x
   Brandhonneur N, 2009, EUR J PHARM SCI, V36, P474, DOI 10.1016/j.ejps.2008.11.013
   CARR I, 1970, Z ZELLFORSCH MIK ANA, V105, P339, DOI 10.1007/BF00335461                                                              
   Chen QY, 2004, EXP CELL RES, V297, P68, DOI 10.1016/j.yexcr.2004.02.017
   GALLILY R, 1984, IMMUNOLOGY, V52, P679
   Gendelman H E, 1989, Curr Opin Immunol, V2, P414
   HOUNSELL EF, 2000, CARBOHYDRATES CHEM B, P1029
   KUBIN M, 1994, BLOOD, V83, P1847
   MALDONADO G, 1994, IMMUNOL INVEST, V23, P429, DOI 10.3109/08820139409066837
   Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011-007-6115-5
   Sabri S, 2000, J CELL SCI, V113, P1589
   Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555
   SIMMONS DL, 1989, BLOOD, V73, P284
   Soler M, 1997, J LEUKOCYTE BIOL, V61, P609
   Takashiba S, 1999, INFECT IMMUN, V67, P5573
   Thomas-Ecker S, 2007, P NATL ACAD SCI USA, V104, P5539, DOI 10.1073/pnas.0700732104
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Videira PA, 2008, GLYCOCONJUGATE J, V25, P259, DOI 10.1007/s10719-007-9092-6
   Weissenbock A, 2004, J CONTROL RELEASE, V99, P383, DOI 10.1016/j.jconrel.2004.07.025
   Wirth M, 2002, CELL CULTURE MODELS OF BIOLOGICAL BARRIERS, P62
NR 23
TC 9
Z9 9
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD NOV
PY 2009
VL 73
IS 3
BP 324
EP 330
DI 10.1016/j.ejpb.2009.07.004
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 526JX
UT WOS:000272285500002
PM 19602437
DA 2018-01-05
ER

PT J
AU Zhang, Q
   Al-Hashimi, HM
AF Zhang, Qi
   Al-Hashimi, Hashim M.
TI Domain-elongation NMR spectroscopy yields new insights into RNA dynamics
   and adaptive recognition
SO RNA-A PUBLICATION OF THE RNA SOCIETY
LA English
DT Review
DE adaptive recognition; induced fit; tertiary capture; functional
   dynamics; NMR
ID RESIDUAL DIPOLAR COUPLINGS; HIV-1 TAR RNA; PROTEIN RECOGNITION;
   STRUCTURAL PLASTICITY; MOLECULAR-DYNAMICS; ORIENTED MEDIA;
   RIBOSOMAL-RNA; MG2+ BINDING; INDUCED FIT; RELAXATION
AB By simplifying the interpretation of nuclear magnetic resonance spin relaxation and residual dipolar couplings data, recent developments involving the elongation of RNA helices are providing new atomic insights into the dynamical properties that allow RNA structures to change functionally and adaptively. Domain elongation, in concert with spin relaxation measurements, has allowed the detailed characterization of a hierarchical network of local and collective motional modes occurring at nanosecond timescale that mirror the structural rearrangements that take place following adaptive recognition. The combination of domain elongation with residual dipolar coupling measurements has allowed the experimental three-dimensional visualization of very large amplitude rigid-body helix motions in HIV-1 transactivation response element (TAR) that trace out a highly choreographed trajectory in which the helices twist and bend in a correlated manner. The dynamic trajectory allows unbound TAR to sample many of its ligand bound conformations, indicating that adaptive recognition occurs by "conformational selection'' rather than "induced fit.'' These studies suggest that intrinsic flexibility plays essential roles directing RNA conformational changes along specific pathways.
C1 [Al-Hashimi, Hashim M.] Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
   [Zhang, Qi] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
RI Zhang, Qi/B-5869-2014; Zhang, Qi/E-1722-2011; Zhang, Qi/F-3323-2010
OI Zhang, Qi/0000-0003-1754-4058; 
FU NIH; NSF [RO1 AI066975-01, MCB 0644278]; Life Sciences Research
   Foundation
FX This work was supported by NIH and NSF grants to H.M.A.-H. (RO1
   AI066975-01 and MCB 0644278). Q.Z. is a Baltimore Family Fellow of the
   Life Sciences Research Foundation. We thank present and past members of
   the Al-Hashimi laboratory for their contributions to various aspects of
   domain-elongation NMR spectroscopy reviewed here. The Al-Hashimi
   laboratory acknowledges collaborations with the laboratories of
   Professor Ioan Andricioaei (UC Irvine) and Professor Carol Fierke
   (University of Michigan).
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Al-Hashimi HM, 2008, CURR OPIN STRUC BIOL, V18, P321, DOI 10.1016/j.sbi.2008.04.004
   Al-Hashimi HM, 2005, CHEMBIOCHEM, V6, P1506, DOI 10.1002/cbic.200500002
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Bardaro MF, 2009, NUCLEIC ACIDS RES, V37, P1529, DOI 10.1093/nar/gkn1074
   Bruschweiler R, 2003, CURR OPIN STRUC BIOL, V13, P175, DOI 10.1016/S0959-440X(03)00036-8
   Chen SJ, 2008, ANNU REV BIOPHYS, V37, P197, DOI 10.1146/annurev.biophys.37.032807.125957
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   Dethoff EA, 2008, BIOPHYS J, V95, P3906, DOI 10.1529/biophysj.108.140285
   Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5
   EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   Fisher CK, 2009, J PHYS CHEM B, V113, P6173, DOI 10.1021/jp900411z
   Fisher CK, 2008, J PHYS CHEM B, V112, P16815, DOI 10.1021/jp806188j
   FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370
   Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367
   Frank AT, 2009, NUCLEIC ACIDS RES, V37, P3670, DOI 10.1093/nar/gkp156
   Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3                                                   
   Furtig B, 2007, BIOPOLYMERS, V86, P360, DOI 10.1002/bip.20761
   Getz M, 2007, BIOPOLYMERS, V86, P384, DOI 10.1002/bip.20765
   Getz MM, 2007, RNA, V13, P251, DOI 10.1261/rna.264207
   Hall KB, 2008, CURR OPIN CHEM BIOL, V12, P612, DOI 10.1016/j.cbpa.2008.09.033
   Hansen AL, 2007, J AM CHEM SOC, V129, P16072, DOI 10.1021/ja0757982
   Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522
   Hermann T, 2006, BIOCHIMIE, V88, P1021, DOI 10.1016/j.biochi.2006.04.020
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008
   KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98
   Latham MP, 2005, CHEMBIOCHEM, V6, P1492, DOI 10.1002/cbic.200500123
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Li PTX, 2008, ANNU REV BIOCHEM, V77, P77, DOI 10.1146/annurev.biochem.77.061206.174353
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Liu SX, 2007, P NATL ACAD SCI USA, V104, P12634, DOI 10.1073/pnas.0610597104
   MacKerell AD, 2008, CURR OPIN STRUC BIOL, V18, P194, DOI 10.1016/j.sbi.2007.12.012
   Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403
   Miller PA, 2006, J AM CHEM SOC, V128, P15970, DOI 10.1021/ja066329n
   Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964
   Montange RK, 2008, ANNU REV BIOPHYS, V37, P117, DOI 10.1146/annurev.biophys.37.032807.130000
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9                                                    
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   Musselman C, 2007, BIOPHYS J, V93, P411, DOI 10.1529/biophysj.107.104620
   Musselman C, 2006, J BIOMOL NMR, V36, P235, DOI 10.1007/s10858-006-9087-9
   Olsen GL, 2008, J AM CHEM SOC, V130, P2896, DOI 10.1021/ja0778803
   Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t
   Peti W, 2002, J AM CHEM SOC, V124, P5822, DOI 10.1021/ja011883c
   Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982
   Sclavi B, 1998, SCIENCE, V279, P1940, DOI 10.1126/science.279.5358.1940
   Serganov A, 2008, CURR OPIN STRUC BIOL, V18, P120, DOI 10.1016/j.sbi.2007.12.006
   Shajani Z, 2007, BIOPOLYMERS, V86, P348, DOI 10.1002/bip.20650
   Shajani Z, 2007, BIOCHEMISTRY-US, V46, P5875, DOI 10.1021/bi602658x
   Shcherbakova I, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl055
   SHOWALTER SA, 2005, METHOD ENZYMOL, V394, P465
   Stone MD, 2007, NATURE, V446, P458, DOI 10.1038/nature05600
   Sun XY, 2007, NUCLEIC ACIDS RES, V35, P1698, DOI 10.1093/nar/gkm020
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292                                                             
   Tolman JR, 2002, J AM CHEM SOC, V124, P12020, DOI 10.1021/ja0261123
   Vicens Q, 2003, BIOPOLYMERS, V70, P42, DOI 10.1002/bip.10414
   Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345
   WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7                                                    
   Williamson JR, 2008, CURR OPIN STRUC BIOL, V18, P299, DOI 10.1016/j.sbi.2008.05.001
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
   Woodson SA, 2008, CURR OPIN CHEM BIOL, V12, P667, DOI 10.1016/j.cbpa.2008.09.024
   Xia TB, 2008, CURR OPIN CHEM BIOL, V12, P604, DOI 10.1016/j.cbpa.2008.08.033
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2003, J AM CHEM SOC, V125, P10530, DOI 10.1021/ja0363056
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
NR 72
TC 24
Z9 24
U1 0
U2 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
J9 RNA
JI RNA-Publ. RNA Soc.
PD NOV
PY 2009
VL 15
IS 11
BP 1941
EP 1948
DI 10.1261/rna.1806909
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 507KC
UT WOS:000270851000001
PM 19776156
OA gold
DA 2018-01-05
ER

PT J
AU Mishra, SH
   Spring, AM
   Germann, MW
AF Mishra, Subrata H.
   Spring, Alexander M.
   Germann, Markus W.
TI Thermodynamic Profiling of HIV RREIIB RNA-Zinc Finger Interactions
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE zinc finger; thermodynamics; solvent; specific heat; RNA-protein
   interactions
ID VIRUS TYPE-1 AFFECTS; VIRAL MESSENGER-RNA; HEAT-CAPACITY; REV PROTEIN;
   LINKED PROTONATION; GENE-EXPRESSION; DNA-BINDING; BASE-PAIRS; IN-VITRO;
   RECOGNITION
AB The interactions between the HIV Rev-responsive element (RRE) RNA and the HTV regulatory protein Rev, are crucial for the HIV life-cycle. Earlier, we showed that single C(2)H(2) zinc fingers (znfs) have the same binding site as the Rev peptide and exhibit nanomolar affinity. In this study, the specific role of amino acid side chains and molecular processes involved with complex formation were investigated by perturbation of the binding energetics via changes in temperature, pH, buffers, and salt concentrations, as well as znf and RNA mutations, by isothermal titration calorimetry. Interestingly, despite the large cationic charge on the znfs, the number of interactions with the RNA phosphate backbone was lower than intuitively expected. The presence of binding induced protonation was established by ITC and localized by NMR to a histidine on the znf beta-sheet. The Delta C(p) of znf-RNA binding was observed to be substantially negative and could not be accounted for by conventional solvent-accessible surface area models. An alternative model, based on the extent of hydrogen bond changes as a result of differences in ligand-induced water displacement at the binding site, provided reasonable explanation of the trends in Delta C(p), as well as Delta H and Delta S. Our studies show that incorporation of favorable interactions at the solvent-excluded binding interface can be used to alleviate the unfavorable enthalpic penalties of displacing water molecules from the hydrated RNA surface. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Mishra, Subrata H.; Spring, Alexander M.; Germann, Markus W.] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
   [Mishra, Subrata H.] Georgia State Univ, Dept Biol, Brains & Behav Program, Ctr Behav Neurosci, Atlanta, GA 30303 USA.
RP Germann, MW (reprint author), Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
EM mwg@gsu.edu
RI German, Markus/L-1531-2013
FU NIH [AI/GM47459]; Georgia Cancer Coalition; Molecular Basis of Disease
   Program at GSU
FX This work was supported by grants from the NIH (AI/GM47459) and the
   Georgia Cancer Coalition. A.M.S. was supported by the Molecular Basis of
   Disease Program at GSU. We are indebted to Dr David Wilson for
   discussions and helpful suggestions in the preparation of this
   manuscript. We thank Dunay Busto, Xiaoguang Qu and Yoshiko Santoso for
   help with protein production and purification.
CR Bahadur RP, 2008, NUCLEIC ACIDS RES, V36, P2705, DOI 10.1093/nar/gkn102
   Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1                                                   
   BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6
   BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Berg JM, 2003, NAT STRUCT BIOL, V10, P986, DOI 10.1038/nsb1203-986
   Bergqvist S, 2004, J MOL BIOL, V336, P829, DOI 10.1016/j.jmb.2003.12.061
   Brice PC, 1999, NUCLEIC ACIDS RES, V27, P2080, DOI 10.1093/nar/27.10.2080
   Chapman RL, 2002, ANTIVIR RES, V54, P149, DOI 10.1016/S0166-3542(01)00222-4
   Clarke C, 2001, J AM CHEM SOC, V123, P12238, DOI 10.1021/ja004315q
   Cooper A, 2005, BIOPHYS CHEM, V115, P89, DOI 10.1016/j.bpc.2004.12.011
   DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375                                                           
   DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   Fischer U, 1999, NUCLEIC ACIDS RES, V27, P4128, DOI 10.1093/nar/27.21.4128
   Freire E, 1995, METHOD ENZYMOL, V259, P144
   FRIED MG, 1993, EUR J BIOCHEM, V218, P469, DOI 10.1111/j.1432-1033.1993.tb18398.x
   Friesen WJ, 2001, J BIOL CHEM, V276, P1968, DOI 10.1074/jbc.M008927200
   Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.0.CO;2-E
   GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410
   GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501                                                          
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265
   Hall TMT, 2005, CURR OPIN STRUC BIOL, V15, P367, DOI 10.1016/j.sbi.2005.04.004
   Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+
   Hope TJ, 1999, ARCH BIOCHEM BIOPHYS, V365, P186, DOI 10.1006/abbi.1999.1207
   HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5
   Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943                                                            
   KIM SY, 1989, J VIROL, V63, P3708
   KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R
   KJEMS J, 1992, EMBO J, V11, P1119
   Kozlov A G, 2000, Proteins, VSuppl 4, P8
   Kupce E, 2001, METHOD ENZYMOL, V338, P82
   LEE MS, 1992, FEBS LETT, V309, P29, DOI 10.1016/0014-5793(92)80732-V
   Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660
   Lohman TM, 1996, BIOCHEMISTRY-US, V35, P5272, DOI 10.1021/bi9527606
   Lu D, 2003, NATURE, V426, P96, DOI 10.1038/nature02088
   MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180                                                          
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   Mascotti DP, 1997, BIOCHEMISTRY-US, V36, P7272, DOI 10.1021/bi970272n
   McColl DJ, 1999, P NATL ACAD SCI USA, V96, P9521, DOI 10.1073/pnas.96.17.9521                                                         
   Mishra SH, 2006, BIOPOLYMERS, V83, P352, DOI 10.1002/bip.20565
   Nguyen B, 2006, BIOPHYS J, V90, P1319, DOI 10.1529/biophysj.105.071381
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010                                                          
   Peled-Zehavi H, 2003, RNA, V9, P252, DOI 10.1261/rna.2152303
   PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067                                                             
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   POMERANTZ RJ, 1992, J VIROL, V66, P1809
   Privalov PL, 1999, J MOL BIOL, V294, P997, DOI 10.1006/jmbi.1999.3285                                                          
   PURCELL DFJ, 1993, J VIROL, V67, P6365
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X                                                   
   Ren JS, 2000, BIOCHEMISTRY-US, V39, P8439, DOI 10.1021/bi000474a
   RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055
   SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294
   SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009                                                             
   Tang CL, 2007, J MOL BIOL, V366, P1475, DOI 10.1016/j.jmb.2006.12.001
   TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758
   Treger M, 2001, J MOL RECOGNIT, V14, P199, DOI 10.1002/jmr.534
   Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061
   Zapp ML, 1997, BIOORGAN MED CHEM, V5, P1149, DOI 10.1016/S0968-0896(97)00063-1
NR 61
TC 10
Z9 10
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD OCT 23
PY 2009
VL 393
IS 2
BP 369
EP 382
DI 10.1016/j.jmb.2009.07.066
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 513RU
UT WOS:000271341700009
PM 19646998
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jin, YG
   Xing, L
   Tian, Y
   Li, M
   Gao, CS
   Du, LN
   Dong, JX
   Chen, HX
AF Jin, Yiguang
   Xing, Lei
   Tian, Ying
   Li, Miao
   Gao, Chunsheng
   Du, Lina
   Dong, Junxing
   Chen, Hongxuan
TI Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies
   of the self-assemblies of cholesteryl-phosphonyl zidovudine
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Anti-HIV; Cholesterol; Phosphonate; Prodrugs; Self-assembly; Zidovudine
ID MONOCYTES/MACROPHAGES IN-VITRO; ANTIVIRAL AGENTS; NANOPARTICLES;
   MACROPHAGES; METABOLISM; AZT; PHARMACOKINETICS; DERIVATIVES; VESICLES;
   CELLS
AB An amphiphilic prodrug of anti-HIV nucleoside analogue, cholesteryl-phosphonyl zidovudine(CPNZ)was synthesized. An aqueous suspension containing CPNZ self-assemblies was obtained through injecting the ethanol solution of CPNZ and cholesteryl succinyl poly(ethylene glycol) 1500 (20: 1, mol/mol) into water under agitation. Hydrophobic interaction may be the driving force of molecular self-assembly. The self-assemblies were nanoscale with similar to 100 nm in size, and remained stable for a long time. Degradation of CPNZ self-assemblies was investigated in various environments including buffered solutions, plasma and rabbit tissue homogenates. CPNZ was degraded very slowly in neutral solutions but rapidly in various plasma with the half-lives (t(1/2)) of less than 20 h. Tissue homogenates degraded CPNZ with varied rates depending on enzyme activity. CPNZ self-assemblies showed potent anti-HIV activity on MT4 cell model, the anti-HIV 50% effective concentration (EC(50)) of which was 1 nM, only equal to 1/5 of AZT EC(50). CPNZ was rapidly eliminated from circulation and distributed into the mononuclear phagocyte system (MPS) including liver, spleen and lung after bolus intravenous administration of CPNZ self-assemblies followed slowly elimination. The possible products include AZT-5'-H-phosphonate, AZT and their derivatives. The MPS-targeted effect and high anti-HIV activity of CPNZ self-assemblies make them become a promising self-assembled drug delivery system (SADDS). (C) 2009 Elsevier B.V. All rights reserved.
C1 [Jin, Yiguang; Xing, Lei; Tian, Ying; Li, Miao; Du, Lina; Dong, Junxing] Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
   [Jin, Yiguang; Xing, Lei; Chen, Hongxuan] Henan Univ, Pharmaceut Coll, Kaifeng 475004, Peoples R China.
   [Gao, Chunsheng] Beijing Inst Toxicol & Pharmacol, Beijing 100850, Peoples R China.
RP Jin, YG (reprint author), Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
EM jin_yiguang@yahoo.com.cn; dongjx@vip.sina.com
RI Jin, Yiguang/A-9306-2008; Jin, Yiguang/H-6742-2013
OI Jin, Yiguang/0000-0002-3528-1397
FU National Natural Science Foundation of China [30672542]; National Key
   Technologies R&D Program for New Drugs [2009ZX09301-002]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30672542) and The National Key Technologies R&D Program for
   New Drugs (No. 2009ZX09301-002). We acknowledge Prof. Jingyun Li and Ms.
   Siyang Liu for the help of the in vitro anti-HIV experiment. We thank
   Helen Qing Zhang for the help of English writing.
CR Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Awasthi VD, 2003, INT J PHARM, V253, P121, DOI 10.1016/S0378-5173(02)00703-2
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Duzgunes N, 1999, MOL MEMBR BIOL, V16, P111, DOI 10.1080/096876899294832                                                         
   Fux CA, 2008, ANTIVIR THER, V13, P1077
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Garbuzenko O, 2005, CHEM PHYS LIPIDS, V135, P117, DOI 10.1016/j.chemphyslip.2005.02.003
   HAN GY, 1992, CLIN CHEM, V38, P377
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4
   HOFFMANN C, 2007, HIV MED 2007, P127
   Ishida T, 2002, BIOSCIENCE REP, V22, P197, DOI 10.1023/A:1020134521778
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   Joannic R, 1997, PHYS REV LETT, V78, P3402, DOI 10.1103/PhysRevLett.78.3402                                                     
   KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030                                                             
   Machado J, 1999, NUCLEOS NUCLEOT, V18, P901, DOI 10.1080/15257779908041597
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Pokrovsky AG, 2001, NUCLEOS NUCLEOT NUCL, V20, P767, DOI 10.1081/NCN-100002426
   Pretzer E, 1997, ANTIVIR RES, V34, P1, DOI 10.1016/S0166-3542(96)01017-0
   Sintov AC, 2002, J CONTROL RELEASE, V79, P113, DOI 10.1016/S0168-3659(01)00531-4                                                   
   Skoblov Y, 2004, ANTIVIR RES, V63, P107, DOI 10.1016/j.antiviral.2004.03.001
   Somogyi G, 2004, PHARMAZIE, V59, P378
   Somogyi G, 1998, INT J PHARM, V166, P27, DOI 10.1016/S0378-5173(98)00012-X
   Sou K, 2000, BIOCONJUGATE CHEM, V11, P372, DOI 10.1021/bc990135y
   Stella V., 2007, PRODRUGS CHALLENGES
   Taira MC, 2004, DRUG DELIV, V11, P123, DOI 10.1080/10717540490280769
   Testa B., 2003, HYDROLYSIS DRUG PROD
   Tobin P, 2006, BRIT J CLIN PHARMACO, V62, P122, DOI 10.1111/j.1365-2125.2005.02477.x
   Torchilin VP, 2006, NANOPARTICULATES DRU
   Veal GJ, 1995, GEN PHARMACOL, V26, P1469, DOI 10.1016/0306-3623(95)00047-X
   vonEckardstein A, 1996, CURR OPIN LIPIDOL, V7, P308, DOI 10.1097/00041433-199610000-00009                                                
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Wang L, 2006, ANAL CHEM, V78, P646, DOI 10.1021/ac0693619                                                               
   Xiao Q, 2003, RAPID COMMUN MASS SP, V17, P1405, DOI 10.1002/rcm.1069
   Yang DB, 2008, COLLOID SURFACE B, V63, P192, DOI 10.1016/j.colsurfb.2007.11.019
   Zhao B, 2008, J LIPID RES, V49, P2212, DOI 10.1194/jlr.M800277-JLR200
   Zhao B, 2007, AM J PHYSIOL-CELL PH, V292, pC405, DOI 10.1152/ajpcell.00306.2006
NR 44
TC 19
Z9 21
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 20
PY 2009
VL 381
IS 1
BP 40
EP 48
DI 10.1016/j.ijpharm.2009.07.024
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 513WX
UT WOS:000271355900005
PM 19646518
DA 2018-01-05
ER

PT J
AU Frenkel, YV
   Gallicchio, E
   Das, K
   Levy, RM
   Arnold, E
AF Frenkel, Yulia Volovik
   Gallicchio, Emilio
   Das, Kalyan
   Levy, Ronald M.
   Arnold, Eddy
TI Molecular Dynamics Study of Non-nucleoside Reverse Transcriptase
   Inhibitor
   4-[[4-[[4-[(E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]a
   mino]benzonitrile (TMC278/Rilpivirine) Aggregates: Correlation between
   Amphiphilic Properties of the Drug and Oral Bioavailability
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID WATER-SOLUBLE DRUGS; INITIO QUANTUM-CHEMISTRY; POLARIZABLE FORCE-FIELD;
   ANTI-HIV DRUG; PROMISCUOUS INHIBITORS; DELIVERY-SYSTEMS; PHASE-BEHAVIOR;
   POSITIONAL ADAPTABILITY; CATIONIC SURFACTANTS; FLUCTUATING CHARGE
AB The non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278/rilpivirine is an anti-AIDS therapeutic agent with high oral bioavailability despite its high hydrophobicity. Previous studies established a correlation between ability of the drug molecule to form stable, homogeneous populations of spherical nanoparticles (similar to 100-120 nm. in diameter) at low pH in surfactant-independent fashion and good oral bioavailability. Here, we hypothesize that the drug is able to assume surfactant-like properties under physiologically relevant conditions, thus facilitating formation of nanostructures in the absence of other surfactants. The results of all-atom molecular dynamics simulations indeed show that protonated drug molecules behave as surfactants at the water/aggregate interface while neutral drug molecules assist aggregate packing via conformational variability. Our simulation results suggest that amphiphilic behavior at low pH and intrinsic flexibility influence drug aggregation and are believed to play critical roles in the favorable oral bioavailability of hydrophobic drugs.
C1 [Gallicchio, Emilio; Levy, Ronald M.] Rutgers State Univ, BioMaPS Inst Quantitat Biol, Piscataway, NJ 08854 USA.
   [Frenkel, Yulia Volovik; Das, Kalyan; Arnold, Eddy] Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.
   [Frenkel, Yulia Volovik; Gallicchio, Emilio; Das, Kalyan; Levy, Ronald M.; Arnold, Eddy] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
RP Gallicchio, E (reprint author), Rutgers State Univ, BioMaPS Inst Quantitat Biol, Piscataway, NJ 08854 USA.
EM emilio@biomaps.rutgers.edu; arnold@cabm.rutgers.edu
RI Sanguansri, Luz/B-6630-2011
OI Sanguansri, Luz/0000-0003-1908-7604
FU NTH [R37 AT 27690, 5 T90 DK070135, 1 S 10 RR022375]
FX We are grateful to Paul Lewi, Larry Rornsted, Edward Castner, and other
   members of our research groups for helpful comments and discussion. E.A.
   is grateful to NTH MERIT award R37 AT 27690 for support of this work and
   Y.V.F. was supported by NTH Interdisciplinary Research Workforce
   fellowship 5 T90 DK070135, The computer simulations for this work have
   been performed at the BioMaPS High Performance Computing Center at
   Rutgers University, funded in part by the NTH shared instrumentation
   grant no. 1 S 10 RR022375.
CR Ambade AV, 2007, J ORG CHEM, V72, P8167, DOI 10.1021/jo070447r
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Banks JL, 1999, J CHEM PHYS, V110, P741, DOI 10.1063/1.478043
   Bhattacharya S, 2004, LANGMUIR, V20, P7940, DOI 10.1021/la0495433
   CHEN LJ, 1995, J CHEM PHYS, V103, P10214, DOI 10.1063/1.469924
   Chen ZX, 2007, COLLOID SURFACE A, V301, P437, DOI 10.1016/j.colsurfa.2007.01.022
   Coan KED, 2008, J AM CHEM SOC, V130, P9606, DOI 10.1021/ja802977h
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   DEGENNES PG, 1982, J PHYS CHEM-US, V86, P2294, DOI 10.1021/j100210a011                                                             
   Derecskei B, 1999, LANGMUIR, V15, P1981, DOI 10.1021/la980419r                                                               
   EICKE HF, 1987, SURF SCI, V21, P140
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Feng BY, 2005, NAT CHEM BIOL, V1, P146, DOI 10.1038/nchembio718
   Fraaije JGEM, 1997, J CHEM PHYS, V106, P4260, DOI 10.1063/1.473129
   Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i
   FRENKEL YV, SMALL MOL C IN PRESS
   Gershanik T, 2000, EUR J PHARM BIOPHARM, V50, P179, DOI 10.1016/S0939-6411(00)00089-8
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Haldar J, 2005, J COLLOID INTERF SCI, V282, P156, DOI 10.1016/j.cis.2004.08.145
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Kaminski GA, 2002, J COMPUT CHEM, V23, P1515, DOI 10.1002/jcc.10125
   Kaminski GA, 2004, J PHYS CHEM A, V108, P621, DOI 10.1021/jp0301103
   Kipp JE, 2004, INT J PHARM, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   Lewis PJ, 2003, J COMPUT AID MOL DES, V17, P129, DOI 10.1023/A:1025313705564
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2225, DOI 10.1016/S0960-894X(01)00410-3
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Maple JR, 2005, J CHEM THEORY COMPUT, V1, P694, DOI 10.1021/ct049855i
   McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   Narang AS, 2007, INT J PHARM, V345, P9, DOI 10.1016/j.ijpharm.2007.08.057
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   O'Driscoll CM, 2008, ADV DRUG DELIVER REV, V60, P617, DOI 10.1016/j.addr.2007.10.012
   Porter CJH, 2008, ADV DRUG DELIVER REV, V60, P673, DOI 10.1016/j.addr.2007.10.014
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Regev O, 1999, J COLLOID INTERF SCI, V210, P8, DOI 10.1006/jcis.1998.5776                                                          
   Rosen M.J., 1989, SURFACTANTS INTERFAC
   Ryjkina E, 2002, ANGEW CHEM INT EDIT, V41, P983, DOI 10.1002/1521-3773(20020315)41:6<983::AID-ANIE983>3.0.CO;2-Y                     
   Schlossman ML, 2008, ANNU REV PHYS CHEM, V59, P153, DOI 10.1146/annurev.physchem.59.032607.093822
   Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r
   Serajuddin ATM, 2007, ADV DRUG DELIVER REV, V59, P603, DOI 10.1016/j.addr.2007.05.010
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197
   Shoichet BK, 2006, DRUG DISCOV TODAY, V11, P607, DOI 10.1016/j.drudis.2006.05.014
   SRIDHARAN S, 1992, Biophysical Journal, V61, pA174
   Stegemann S, 2007, EUR J PHARM SCI, V31, P249, DOI 10.1016/j.ejps.2007.05.110
   Stern HA, 1999, J PHYS CHEM B, V103, P4730, DOI 10.1021/jp984498r                                                               
   Stern HA, 2001, J CHEM PHYS, V115, P2237, DOI 10.1063/1.1376165
   TSUJII K, 1997, SURFACE ACTIVITY PRI
   Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005
   Kiekens F. R. I., 2007, Process for preparing spray dried formulations of Etravirine, Patent No. [WO2007141308A1, 2007141308]
NR 57
TC 12
Z9 12
U1 3
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 8
PY 2009
VL 52
IS 19
BP 5896
EP 5905
DI 10.1021/jm900282z
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 501EF
UT WOS:000270361600013
PM 19739675
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kimura, A
   Kamo, Y
   Takashima, Y
   Kanazawa, T
   Okada, H
   Fukuda, T
AF Kimura, Aki
   Kamo, Yosuke
   Takashima, Yuuki
   Kanazawa, Takanori
   Okada, Hiroaki
   Fukuda, Tsunehiko
TI Synthesis and Transport Activities of HIV-Tat Peptide-modified
   Cholesterol Pullulan
SO CHEMISTRY LETTERS
LA English
DT Article
ID NANOPARTICLES; CHAPERONE; DNA
AB A complex in which the cell-penetrating peptide HIV-Tat and cholesterol pullulan were conjugated through a disulfide bond was synthesized. The complex showed marked cell penetrating activities as a vector.
C1 [Fukuda, Tsunehiko] Nagahama Inst Biosci & Technol, Nagahama 5260829, Japan.
   [Kimura, Aki; Kamo, Yosuke; Takashima, Yuuki; Kanazawa, Takanori; Okada, Hiroaki] Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan.
RP Fukuda, T (reprint author), Nagahama Inst Biosci & Technol, Nagahama 5260829, Japan.
EM t_fukuda@nagahama-i-bio.ac.jp
CR Akiyoshi K, 1999, BIOCONJUGATE CHEM, V10, P321, DOI 10.1021/bc9801272                                                               
   AKIYOSHI K, 1993, MACROMOLECULES, V26, P3062, DOI 10.1021/ma00064a011                                                             
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   BERNATOWICZ MS, 1989, TETRAHEDRON LETT, V30, P4645, DOI 10.1016/S0040-4039(01)80764-4
   Chen L, 1997, J MED CHEM, V40, P864, DOI 10.1021/jm9607156
   FUKUTA M, 1994, PHARMACEUT RES, V11, P1681, DOI 10.1023/A:1018942728317
   Morimoto N, 2009, CHEM LETT, V38, P496, DOI 10.1246/cl.2009.496
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wang L, 1999, INT J ONCOL, V14, P695
NR 10
TC 0
Z9 0
U1 0
U2 5
PU CHEMICAL SOC JAPAN
PI TOKYO
PA 1-5 KANDA-SURUGADAI CHIYODA-KU, TOKYO, 101-8307, JAPAN
SN 0366-7022
EI 1348-0715
J9 CHEM LETT
JI Chem. Lett.
PD OCT 5
PY 2009
VL 38
IS 10
BP 970
EP 971
DI 10.1246/cl.2009.970
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 520MT
UT WOS:000271849600015
DA 2018-01-05
ER

PT J
AU Caputo, A
   Gavioli, R
   Bellino, S
   Longo, O
   Tripiciano, A
   Francavilla, V
   Sgadari, C
   Paniccia, G
   Titti, F
   Cafaro, A
   Ferrantelli, F
   Monini, P
   Ensoli, F
   Ensoli, B
AF Caputo, Antonella
   Gavioli, Riccardo
   Bellino, Stefania
   Longo, Olimpia
   Tripiciano, Antonella
   Francavilla, Vittorio
   Sgadari, Cecilia
   Paniccia, Giovanni
   Titti, Fausto
   Cafaro, Aurelio
   Ferrantelli, Flavia
   Monini, Paolo
   Ensoli, Fabrizio
   Ensoli, Barbara
TI HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of
   HIV/AIDS Vaccine Development
SO INTERNATIONAL REVIEWS OF IMMUNOLOGY
LA English
DT Review
DE HIV/AIDS; vaccine; HIV-1 Tat; preclinical development; clinical trials
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; TYPE-1 SUBTYPE-C; 2ND
   CODING EXON; SYSTEMIC NEUTRALIZING ANTIBODIES; MULTIPROTEIN DNA/MVA
   VACCINE; INFECTED RHESUS MACAQUES; CORE-SHELL NANOPARTICLES; REGULATORY
   PROTEINS TAT; STRONG IMMUNE-RESPONSES
AB The HIV epidemic continues to represent one of the major problems worldwide, particularly in the Asia and Sub-Saharan regions of the world, with social and economical devastating effects. Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals that have access to treatment, it has had a negligible impact on the global epidemic. Hence, the inexorable spreading of the HIV pandemic and the increasing deaths from AIDS, especially in developing countries, underscore the urgency for an effective vaccine against HIV/AIDS. However the generation of such a vaccine has turned out to be extremely challenging. Here we provide an overview on the rationale for the use of non-structural HIV proteins, such as the Tat protein, alone or in combination with other HIV early and late structural HIV antigens, as novel, promising preventative and therapeutic HIV/AIDS vaccine strategies.
C1 [Bellino, Stefania; Longo, Olimpia; Sgadari, Cecilia; Titti, Fausto; Cafaro, Aurelio; Ferrantelli, Flavia; Monini, Paolo; Ensoli, Barbara] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
   [Caputo, Antonella] Univ Padua, Dept Histol Microbiol & Med Biotechnol, Padua, Italy.
   [Gavioli, Riccardo] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy.
   [Tripiciano, Antonella; Francavilla, Vittorio; Paniccia, Giovanni; Ensoli, Fabrizio] San Gallicano Hosp, Ist Fisioterapici Ospitalieri, Rome, Italy.
RP Ensoli, B (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM barbara.ensoli@iss.it
RI Ferrantelli, Flavia/J-7794-2016; Cafaro, Aurelio/K-5314-2016; Ensoli,
   Barbara/J-9169-2016; Tripiciano, Antonella/K-4635-2016; Monini,
   Paolo/K-1429-2016; Paniccia, Giovanni/M-7440-2017; Sgadari,
   Cecilia/H-4302-2016; Gavioli, Riccardo/K-7594-2016
OI Ferrantelli, Flavia/0000-0002-0768-1078; Ensoli,
   Barbara/0000-0002-0545-8737; Tripiciano, Antonella/0000-0001-7814-984X;
   Monini, Paolo/0000-0002-4941-6854; Paniccia,
   Giovanni/0000-0002-9850-5802; Sgadari, Cecilia/0000-0003-0364-4912;
   Gavioli, Riccardo/0000-0002-7805-4290
CR Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781                                                          
   Agwale SM, 2002, P NATL ACAD SCI USA, V99, P10037, DOI 10.1073/pnas.152313899
   Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002
   Allen TM, 2000, NATURE, V407, P386
   Allen TM, 2003, J ALLERGY CLIN IMMUN, V112, P829, DOI 10.1067/mai.2003.1821
   Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200
   Althaus CL, 2008, PLOS COMPUT BIOL, V4, P1
   Amara RR, 2002, VACCINE, V20, P1949, DOI 10.1016/S0264-410X(02)00076-2                                                   
   Amara RR, 2005, VIROLOGY, V334, P124
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002
   Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774
   Areste Cristina, 2006, Biochem J, V396, pe13
   ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040
   Asakura Y, 1997, SCAND J IMMUNOL, V46, P326, DOI 10.1046/j.1365-3083.1997.d01-146.x
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002
   Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001                                                
   Barnett SW, 2005, MICROBES INFECT, V7, P1386, DOI 10.1016/j.micinf.2005.07.018
   Barnetta SW, 2008, AIDS, V22, P339, DOI 10.1097/QAD.0b013e3282f3ca57
   Bartz SR, 1999, J VIROL, V73, P1956
   BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0
   Beattie Tara, 2002, J HIV Ther, V7, P35
   Belliard G, 2005, VACCINE, V23, P1399, DOI 10.1016/j.vaceine.2004.08.037
   Belliard G, 2003, VACCINE, V21, P3186, DOI 10.1016/S0264-410X(03)00233-0
   Benito JM, 2004, AIDS REV, V6, P79
   Bertley FMN, 2004, J IMMUNOL, V172, P3745, DOI 10.4049/jimmunol.172.6.3745                                                     
   Billich Andreas, 2004, Curr Opin Investig Drugs, V5, P214
   BLAZEVIC V, 1993, J ACQ IMMUN DEF SYND, V6, P881
   Blazquez MV, 1999, AIDS RES HUM RETROV, V15, P1209, DOI 10.1089/088922299310304
   Bogers WMJM, 2008, VIROLOGY, V382, P217, DOI 10.1016/j.virol.2008.09.016
   Borsetti A, 2009, VIRAL IMMUNOL, V22, P117, DOI 10.1089/vim.2008.0082
   Borsutzky S, 2003, EUR J IMMUNOL, V33, P1548, DOI 10.1002/eji.200323954
   Borsutzky S, 2006, VACCINE, V24, P2049, DOI 10.1016/j.vaccine.2005.11.025
   Bozac A, 2006, VACCINE, V24, P7148, DOI 10.1016/j.vaccine.2006.06.061
   BRAKE DA, 1990, J VIROL, V64, P962
   Brave A, 2008, VACCINE, V26, P5957, DOI 10.1016/j.vaccine.2008.08.060
   Brave A, 2007, VACCINE, V25, P6882, DOI 10.1016/j.vaccine.2007.07.012
   Brown Scott A., 2005, Current Drug Targets - Infectious Disorders, V5, P113, DOI 10.2174/1568005054201571
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Buckner C, 2004, VIROLOGY, V320, P167, DOI 10.1016/j.virol.2003.12.003
   Buge SL, 2003, AIDS RES HUM RETROV, V19, P891, DOI 10.1089/088922203322493067
   Burgers WA, 2006, J GEN VIROL, V87, P399, DOI 10.1099/vir.0.81379-0
   Burgers WA, 2009, J GEN VIROL, V90, P468, DOI 10.1099/vir.0.004614-0
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Butler IF, 2007, CURR HIV RES, V5, P23, DOI 10.2174/157016207779316297                                                      
   Butto S, 2003, J INFECT DIS, V188, P1171, DOI 10.1086/378412
   Cafaro A, 1999, NAT MED, V5, P643
   Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0
   Cafaro A, 2000, J MED PRIMATOL, V29, P193, DOI 10.1034/j.1600-0684.2000.290313.x                                               
   Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3
   Calarota SA, 1999, J IMMUNOL, V163, P2330
   Campbell GR, 2007, VACCINE, V25, P8441, DOI 10.1016/j.vaccine.2007.09.070
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   Caputo A, 2003, VACCINE, V21, P1103, DOI 10.1016/S0264-410X(02)00555-8                                                   
   Caputo A, 2002, VACCINE, V20, P2303, DOI 10.1016/S0264-410X(02)00099-3
   Caputo A, 2008, VACCINE, V26, P1214, DOI 10.1016/j.vaccine.2007.12.030
   Caputo Antonella, 2008, Current Drug Delivery, V5, P230, DOI 10.2174/156720108785914961
   Caselli E, 1999, J IMMUNOL, V162, P5631
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Castelli FA, 2008, EUR J IMMUNOL, V38, P2821, DOI 10.1002/eji.200738072
   Cellini S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-81
   Cherpelis S, 2001, J VIROL, V75, P1547, DOI 10.1128/JVI.75.3.1547-1550.2001                                                 
   Cho HI, 2007, CANCER LETT, V258, P189, DOI 10.1016/j.canlet.2007.08.023
   Cohen J, 2004, SCIENCE, V306, P1276
   Crotty S, 2001, J VIROL, V75, P7435, DOI 10.1128/JVI.75.16.7435-7452.2001
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Dale CJ, 2004, J VIROL, V78, P13819, DOI 10.1128/JVI.78.24.13819-13828.2004
   Dale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024
   De Rose R, 2005, VACCINE, V23, P1949, DOI 10.1016/j.vaccine.2004.10.012
   De Rose R, 2007, J VIROL, V81, P292, DOI 10.1128/JVI.01727-06
   Demberg T, 2007, J VIROL, V81, P3414, DOI 10.1128/JVI.02453-06
   Demirhan I, 2000, J HUMAN VIROL, V3, P137
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Devadas K, 2007, PEPTIDES, V28, P496, DOI 10.1016/j.peptides.2006.11.007
   Dominici S, 2003, VACCINE, V21, P2073, DOI 10.1016/S0264-410X(02)00746-6
   Doria-Rose NA, 2003, J VIROL, V77, P11563, DOI 10.1128/JVI.77.21.11563-11577.2003
   Douek Daniel C., 2003, AIDS Reviews, V5, P172
   Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.14053
   Egan MA, 2006, VACCINE, V24, P4510, DOI 10.1016/j.vaccine.2005.08.024
   ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0
   Ensoli B, 2005, MICROBES INFECT, V7, P1445, DOI 10.1016/j.micinf.2005.07.024
   Ensoli B, 2005, MICROBES INFECT, V7, P1433, DOI 10.1016/j.micinf.2005.07.019
   ENSOLI B, 1993, J VIROL, V67, P277
   Ensoli B, 2005, MICROBES INFECT, V7, P1392, DOI 10.1016/j.micinf.2005.07.016
   Ensoli B, 2008, AIDS, V22, P2207, DOI 10.1097/QAD.0b013e32831392d4
   Ensoli B, 2006, AIDS, V20, P2245, DOI 10.1097/QAD.0b013e3280112cd1
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Fanales-Belasio E, 2009, J IMMUNOL, V182, P2888, DOI 10.4049/jimmunol.0711406
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrantelli F, 2004, CURR OPIN BIOTECH, V15, P543, DOI 10.1016/j.copbio.2004.10.008
   Ferrantelli F, 2004, J INFECT DIS, V189, P2167, DOI 10.1086/420833
   Ferrantelli F, 2002, CURR OPIN IMMUNOL, V14, P495, DOI 10.1016/S0952-7915(02)00362-X                                                   
   Ferrantelli F, 2006, SPRINGER SEMIN IMMUN, V28, P289, DOI 10.1007/s00281-006-0026-3
   Florese RH, 2008, VACCINE, V26, P3312, DOI 10.1016/j.vaccine.2008.03.100
   Fuller DH, 2006, VIROLOGY, V348, P200, DOI 10.1016/j.virol.2005.12.008
   Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838                                                     
   Gavioli R, 2008, VACCINE, V26, P727, DOI 10.1016/j.vaccine.2007.11.040
   Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005
   Genesca M, 2009, J INTERN MED, V265, P67, DOI 10.1111/j.1365-2796.2008.02051.x
   Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68
   Giannouli C, 2003, ANTICANCER RES, V23, P3523
   Girard M, 2008, INT REV IMMUNOL, V27, P447, DOI 10.1080/08830180802432160
   Goepfert PA, 2007, VACCINE, V25, P510, DOI 10.1016/j.vaccine.2006.07.050
   Goldstein G, 2000, VACCINE, V18, P2789, DOI 10.1016/S0264-410X(00)00085-2
   Goldstein G, 2001, VACCINE, V19, P1738, DOI 10.1016/S0264-410X(00)00393-5                                                   
   Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000
   Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641                                                        
   Gruters RA, 2002, VACCINE, V20, P2011, DOI 10.1016/S0264-410X(02)00089-0
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Gupta S, 2008, J IMMUNOL, V180, P79, DOI 10.4049/jimmunol.180.1.79                                                       
   Halsey RJ, 2008, VIRUS RES, V133, P259, DOI 10.1016/j.virusres.2008.01.012
   Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85                                                       
   Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5
   Hinkula J, 1997, J VIROL, V71, P5528
   Hinkula J, 2007, EXPERT REV VACCINES, V6, P203, DOI 10.1586/14760584.6.2.203
   Horn Michael E, 2003, J Drug Target, V11, P539
   Huang TX, 2008, JAIDS-J ACQ IMM DEF, V47, P403
   HUET T, 1989, AIDS, V3, P707, DOI 10.1097/00002030-198911000-00004                                                
   Im EJ, 2006, EUR J IMMUNOL, V36, P2574, DOI 10.1002/eji.200636482
   Jia MM, 2008, BIOMED ENVIRON SCI, V21, P314, DOI 10.1016/S0895-3988(08)60048-3
   John GC, 1996, EPIDEMIOL REV, V18, P149, DOI 10.1093/oxfordjournals.epirev.a017922                                           
   Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511
   Kameoka M, 2001, J VIROL, V75, P2675, DOI 10.1128/JVI.75.6.2675-2683.2001
   Karasev AV, 2005, VACCINE, V23, P1875, DOI 10.1016/j.vaccine.2004.11.021
   Kawada M, 2008, J VIROL, V82, P10199, DOI 10.1128/JVI.01103-08
   Kelleher AD, 2006, AIDS, V20, P294, DOI 10.1097/01.aids.0000199819.40079.e9
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kim TG, 2004, PLANT CELL REP, V22, P382, DOI 10.1007/s00299-003-0697-3
   King JE, 2006, MICROBES INFECT, V8, P1347, DOI 10.1016/j.micinf.2005.11.014
   Kittiworakarn J, 2006, J BIOL CHEM, V281, P3105, DOI 10.1074/jbc.M509899200
   Kjerrstrom A, 2001, VIROLOGY, V284, P46, DOI 10.1006/viro.2001.0905
   KOLSON DL, 1993, AIDS RES HUM RETROV, V9, P677, DOI 10.1089/aid.1993.9.677
   Kourtis AP, 2003, LANCET INFECT DIS, V3, P786, DOI 10.1016/S1473-3099(03)00832-6
   Krohn K, 2005, MICROBES INFECT, V7, P1405, DOI 10.1016/j.micinf.2005.07.023
   KRONE WJA, 1988, J MED VIROL, V26, P261, DOI 10.1002/jmv.1890260306
   Kulkarni Prasad S., 2003, AIDS Reviews, V5, P87
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lecoq A, 2008, VACCINE, V26, P2615, DOI 10.1016/j.vaccine.2008.02.057
   Leifert JA, 2003, GENE THER, V10, P2067, DOI 10.1038/sj.gt.3302115
   Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Levy J A, 2006, Adv Dent Res, V19, P10
   Levy JA, 2003, TRENDS IMMUNOL, V24, P628, DOI 10.1016/j.it.2003.10.005
   Levy JA, 2003, CLIN IMMUNOL, V108, P167, DOI 10.1016/S1521-6616(03)00178-5
   Liang XP, 2005, J VIROL, V79, P12321, DOI 10.1128/JVI.79.19.12321-12331.2005
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Loh L, 2008, PLOS PATHOG, V4, P27, DOI 10.1371/journal.ppat.0040012
   Lubeck MD, 1997, NAT MED, V3, P651, DOI 10.1038/nm0697-651                                                              
   Lundholm P, 2002, VIRUS RES, V82, P141
   Ma MH, 1997, J VIROL, V71, P2495
   Maggiorella MT, 2007, J MED PRIMATOL, V36, P180, DOI 10.1111/j.1600-0684.2007.00236.x
   Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009
   Mahlknecht U, 2008, J LEUKOCYTE BIOL, V83, P718, DOI 10.1189/jlb.0607405
   Makitalo B, 2004, J GEN VIROL, V85, P2407, DOI 10.1099/vir.0.79869-0
   Malkevitch N, 2003, J IMMUNOL, V170, P4281, DOI 10.4049/jimmunol.170.8.4281                                                     
   Malm M, 2007, VACCINE, V25, P3293, DOI 10.1016/j.vaccine.2007.01.003
   Marinaro M, 2003, VACCINE, V21, P3972, DOI 10.1016/S0264-410X(03)00295-0
   Martinon F, 2008, VACCINE, V26, P532, DOI 10.1016/j.vaccine.2007.11.025
   Mascarell L, 2006, VACCINE, V24, P3490, DOI 10.1016/j.vaccine.2006.02.009
   Mascarell L, 2005, J VIROL, V79, P9872, DOI 10.1128/JVI.779.15.9872-9884.2005
   Mattner F, 2002, CANCER RES, V62, P1477
   Mayol K, 2007, VACCINE, V25, P6047, DOI 10.1016/j.vaccine.2007.05.048
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874
   Mooij P, 2004, J VIROL, V78, P3333, DOI 10.1128/JVI.78.7.3333-3342.2004
   Moreau E, 2004, J GEN VIROL, V85, P2893, DOI 10.1099/vir.0.80365-0
   Morris CB, 2001, VACCINE, V20, P12, DOI 10.1016/S0264-410X(01)00271-7                                                   
   Mossman SP, 2004, AIDS RES HUM RETROV, V20, P425, DOI 10.1089/088922204323048177
   Negri DRM, 2004, J IMMUNOL METHODS, V291, P153, DOI 10.1016/j.jim.2004.05.007
   Neuveut C, 2003, J BIOMED SCI, V10, P651, DOI 10.1159/000073531
   Novitsky V, 2001, J VIROL, V75, P9210, DOI 10.1128/JVI.75.19.9210-9228.2001                                                
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   NURMARI G, 2008, J EXP CLIN CANC RES, V27, P3
   O'Connor DH, 2002, DNA CELL BIOL, V21, P659, DOI 10.1089/104454902760330192                                                      
   Opi S, 2002, J BIOL CHEM, V277, P35915, DOI 10.1074/jbc.M204393200
   Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057
   Osterhaus ADME, 1999, VACCINE, V17, P2713, DOI 10.1016/S0264-410X(98)00498-8                                                   
   Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481
   Pal R, 2006, J VIROL, V80, P3732, DOI 10.1128/JVI.80.8.3732-3742.2006
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Partidos CD, 2004, EUR J IMMUNOL, V34, P3723, DOI 10.1002/eji.200425313
   Partidos CD, 2005, EUR J IMMUNOL, V35, P1521, DOI 10.1002/eji.200425676
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797
   Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473
   Ramirez YJP, 2007, CLIN VACCINE IMMUNOL, V14, P685, DOI 10.1128/CVI.00028-07
   Peng B, 2005, J VIROL, V79, P10200, DOI 10.1128/JVI.79.16.10200-10209.2005
   Piacentini L, 2008, VACCINE, V26, P3002, DOI 10.1016/j.vaccine.2007.11.062
   Pilkington GR, 1996, MOL IMMUNOL, V33, P439, DOI 10.1016/0161-5890(95)00153-0
   Polonis VR, 2008, VIROLOGY, V375, P315, DOI 10.1016/j.virol.2008.02.007
   Putkonen P, 1998, VIROLOGY, V250, P293, DOI 10.1006/viro.1998.9379
   Ramakrishna L, 2004, J VIROL, V78, P9174, DOI 10.1128/JVI.78.17.9174-9189.2004
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Ramsay AJ, 1999, IMMUNOL REV, V171, P27, DOI 10.1111/j.1600-065X.1999.tb01341.x                                              
   Re M. C., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P408, DOI 10.1097/00042560-199512000-00003
   Re MC, 2001, J CLIN VIROL, V21, P81, DOI 10.1016/S1386-6532(00)00189-X
   Re MC, 1996, CLIN DIAGN LAB IMMUN, V3, P230
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Remoli AL, 2006, BIOCHEM J, V396, P371, DOI 10.1042/BJ20051570
   Reynolds MR, 2008, J EXP MED, V205, P2537, DOI 10.1084/jem.20081524
   Rezza G, 2005, J INFECT DIS, V191, P1321, DOI 10.1086/428909                                                                  
   Richardson MW, 2003, BIOMED PHARMACOTHER, V57, P4, DOI 10.1016/S0753-3322(02)00327-X
   Richardson TM, 1996, J VIROL, V70, P753
   Robb ML, 2008, LANCET, V372, P1857, DOI 10.1016/S0140-6736(08)61593-7
   Robert-Guroff M, 1998, J VIROL, V72, P10275
   Robinson HL, 2007, CLIN PHARMACOL THER, V82, P686, DOI 10.1038/sj.clpt.6100408
   RODMAN TC, 1993, P NATL ACAD SCI USA, V90, P7719, DOI 10.1073/pnas.90.16.7719
   Rodman TC, 2001, EXP HEMATOL, V29, P1004, DOI 10.1016/S0301-472X(01)00678-6
   Rodriguez-Chavez Isaac R, 2006, Curr HIV/AIDS Rep, V3, P39, DOI 10.1007/s11904-006-0007-0
   Rolland M, 2007, J VIROL, V81, P8507, DOI 10.1128/JVI.02683-06
   Rollman E, 2005, MICROBES INFECT, V7, P1414, DOI 10.1016/j.micinf.2005.07.017
   Rollman E, 2007, VACCINE, V25, P2145, DOI 10.1016/j.vaccine.2006.10.057
   Ruprecht RM, 2003, VACCINE, V21, P3370, DOI 10.1016/S0264-410X(03)00335-9
   Saksena NK, 2008, CURR HIV RES, V6, P1, DOI 10.2174/157016208783572008
   Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507
   Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259                                                             
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Scriba TJ, 2005, VACCINE, V23, P1158, DOI 10.1016/j.vaccine.2004.08.026
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Sernicola L, 1999, VIROLOGY, V256, P291, DOI 10.1006/viro.1999.9652
   Shibagaki N, 2003, EUR J IMMUNOL, V33, P850, DOI 10.1002/eji.200323709
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a                                                                 
   Silvera P, 2002, J VIROL, V76, P3800, DOI 10.1128/JVI.76.8.3800-3809.2002
   Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200
   Sparnacci K, 2005, J BIOMAT SCI-POLYM E, V16, P1557, DOI 10.1163/156856205774576673
   Spearman P, 2003, CURR HIV RES, V1, P101, DOI 10.2174/1570162033352093
   Srivastava IK, 2003, J VIROL, V77, P11244, DOI 10.1128/JVI.77.20.11244-11259.2003
   Srivastava IK, 2003, J VIROL, V77, P2310, DOI 10.1128/JVI.77.4.2310-2320.2003
   Srivastava I, 2008, VACCINE, V26, P2796, DOI 10.1016/j.vaccine.2007.11.083
   Srivastava IK, 2008, VIROLOGY, V372, P273, DOI 10.1016/j.virol.2007.10.022
   STEINAA L, 1994, ARCH VIROL, V139, P263, DOI 10.1007/BF01310790                                                              
   Stiegler G, 2003, J ANTIMICROB CHEMOTH, V51, P757, DOI 10.1093/jac/dkg172
   Stittelaar KJ, 2002, VACCINE, V20, P2921, DOI 10.1016/S0264-410X(02)00219-0                                                   
   Tahtinen M, 2001, VACCINE, V19, P2039, DOI 10.1016/S0264-410X(00)00420-5
   Tanaka Yoshiyuki, 2003, Journal of Immunology, V170, P1291
   Tebit DM, 2007, AIDS REV, V9, P75
   Tikhonov I, 2003, J VIROL, V77, P3157, DOI 10.1128/JVI.77.5.3157-3166.2003
   Titti F, 2007, EXPERT OPIN EMERG DR, V12, P23, DOI 10.1517/14728214.12.1.23
   TONGSTARKSEN SE, 1993, VIROLOGY, V195, P826, DOI 10.1006/viro.1993.1438
   Tryniszewska E, 2002, J IMMUNOL, V169, P5347, DOI 10.4049/jimmunol.169.9.5347                                                     
   Uberla K, 2007, J MED PRIMATOL, V36, P2, DOI 10.1111/j.1600-0684.2006.00190
   Valentine LE, 2008, TRENDS MICROBIOL, V16, P605, DOI 10.1016/j.tim.2008.08.010
   Valvatne H, 1996, AIDS RES HUM RETROV, V12, P611, DOI 10.1089/aid.1996.12.611
   vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913                                                     
   Verhoef K, 1998, AIDS RES HUM RETROV, V14, P1553, DOI 10.1089/aid.1998.14.1553                                                        
   Verhoef K, 1996, VIROLOGY, V225, P316, DOI 10.1006/viro.1996.0606
   Verrier B, 2002, DNA CELL BIOL, V21, P653, DOI 10.1089/104454902760330183
   Vogel TU, 2003, J VIROL, V77, P13348, DOI 10.1128/JVI.77.24.13348-13360.2003
   Voltan R, 2007, PHARM RES-DORDR, V24, P1870, DOI 10.1007/s11095-007-9310-8
   Voss G, 2003, J VIROL, V77, P1049, DOI 10.1128/JVI.77.2.1049-1058.2003
   Wahren B, 2002, VACCINE, V20, P1988, DOI 10.1016/S0264-410X(02)00084-1
   Watkins DI, 2008, MEM I OSWALDO CRUZ, V103, P119, DOI 10.1590/S0074-02762008000200001
   Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
   Watkins JD, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-8
   Webster DE, 2005, IMMUNOL CELL BIOL, V83, P239, DOI 10.1111/j.1440-1711.2005.01341.x
   Wensing Annemarie M. J., 2003, AIDS Reviews, V5, P140
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Xu R, 2008, VACCINE, V26, P4819, DOI 10.1016/j.vaccine.2008.06.103
   Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001
   Zhao J, 2005, VIROLOGY, V342, P1, DOI 10.1016/j.virol.2005.07.016
   Zhao J, 2003, VACCINE, V21, P4022, DOI 10.1016/S0264-410X(03)00266-4
   Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307
   Zolla-Pazner S, 1998, J VIROL, V72, P1052
   Zolla-Pazner Susan, 2005, Human Antibodies, V14, P69
NR 269
TC 22
Z9 23
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0883-0185
J9 INT REV IMMUNOL
JI Int. Rev. Immunol.
PD OCT
PY 2009
VL 28
IS 5
BP 285
EP 334
DI 10.1080/08830180903013026
PG 50
WC Immunology
SC Immunology
GA 512GO
UT WOS:000271234500003
PM 19811313
DA 2018-01-05
ER

PT J
AU Lei, Y
   Tang, HY
   Feng, MF
   Zou, BS
AF Lei, Yun
   Tang, Haiyang
   Feng, Meifu
   Zou, Bingsuo
TI Applications of Fluorescent Quantum Dots to Stem Cell Tracing In Vivo
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE CdSe/ZnS Quantum Dots; Tat Peptide; Stem Cells; Transplantation;
   Tracking and Imaging
ID HIV-1 TAT PROTEIN; LIVING CELLS; LIVE CELLS; INTRACELLULAR DELIVERY;
   MOUSE-BODY; LONG-TERM; TRACKING; NANOCRYSTALS; BINDING; DOMAIN
AB Fluorescent quantum dots have great potential to act as labels in biological research, especially cellular tracking in vivo. Here, small thiol molecules-capped CdSe/ZnS quantum dots attached to Tat peptide were used for label agents, and introduced into living stem cells. The stem cells labeled with quantum dots were intravenously injected into the tail veins of NOD/SCID beta2M null mice, and whose tissue sections of major organs of null mice were examined with fluorescence microscope to assess the distribution of transplanted stem cells. Stem cells with internalized quantum dots offer a promising approach in stem cell transplantation, which will hold a significant impact on stem cell based therapy for several disorders.
C1 [Lei, Yun; Zou, Bingsuo] Wuhan Univ Technol, Sch Resource & Environm Engn, Wuhan 430070, Hubei, Peoples R China.
   [Lei, Yun; Zou, Bingsuo] Beijing Inst Technol, Sch Mat Sci & Engn, Beijing 100081, Peoples R China.
   [Lei, Yun; Zou, Bingsuo] Hunan Univ, State Key Lab CBSC, Changsha 410082, Hunan, Peoples R China.
   [Tang, Haiyang; Feng, Meifu] Chinese Acad Sci, Inst Zool, Beijing 100080, Peoples R China.
RP Zou, BS (reprint author), Wuhan Univ Technol, Sch Resource & Environm Engn, Wuhan 430070, Hubei, Peoples R China.
RI Tang, Haiyang/J-4006-2013
FU NSFC [20873039, 90606001, 30370383, 90406024]
FX The authors would like to thank the NSFC fund (Grant No. 20873039,
   90606001, 30370383 and 90406024) of China for financial supports.
CR Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Chakraborty SK, 2007, NANO LETT, V7, P2618, DOI 10.1021/nl0709930
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194
   Dudu V, 2008, J NANOSCI NANOTECHNO, V8, P2293, DOI 10.1166/jnn.2008.185
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hakansson S, 2001, PROTEIN SCI, V10, P2138, DOI 10.1110/ps.23401                                                                
   Hashizume K, 2002, J LUMIN, V98, P49, DOI 10.1016/S0022-2313(02)00251-X                                                   
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Hoshino A, 2004, BIOCHEM BIOPH RES CO, V314, P46, DOI 10.1016/j.bbrc.2003.11.185
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Li ZB, 2007, J NANOSCI NANOTECHNO, V7, P2567, DOI 10.1166/jnn.2007.628
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Pinaud F, 2004, J AM CHEM SOC, V126, P6115, DOI 10.1021/ja031691c
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Silver J, 2005, NANO LETT, V5, P1445, DOI 10.1021/nl050808n
   Smith AM, 2006, ANN BIOMED ENG, V34, P3, DOI 10.1007/s10439-005-9000-9
   Su JF, 2008, J NANOSCI NANOTECHNO, V8, P1174, DOI 10.1166/jnn.2008.317
   Tan WB, 2007, J NANOSCI NANOTECHNO, V7, P2389, DOI 10.1166/jnn.2007.415
   Toita S, 2008, J NANOSCI NANOTECHNO, V8, P2279, DOI 10.1166/jnn.2008.240
   VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461
   Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096
   WEEKS BS, 1993, J BIOL CHEM, V268, P5279
   Zhang J, 2008, J NANOSCI NANOTECHNO, V8, P1155, DOI 10.1166/jnn.2008.316
NR 31
TC 9
Z9 10
U1 0
U2 6
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2009
VL 9
IS 10
BP 5726
EP 5730
DI 10.1166/jnn.2009.1258
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 487XE
UT WOS:000269310700005
PM 19908444
DA 2018-01-05
ER

PT J
AU Bourgeois, J
   Pierson, LA
   Nicolas, J
   Lalanne, M
   Couvreur, P
   Andrieux, K
AF Bourgeois, Jennifer
   Pierson, Laure-Anne
   Nicolas, Julien
   Lalanne, Muriel
   Couvreur, Patrick
   Andrieux, Karine
TI Application of thermal analysis to the study of lipidic prodrug
   incorporation into nanocarriers
SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
LA English
DT Article
DE Didanosine; DSC; Glycerolipidic prodrug; HIV; Incorporation ratio;
   Nanocarriers; Polyethyleneglycol
ID RECEPTOR-MEDIATED ENDOCYTOSIS; BRAIN ENDOTHELIAL-CELLS; SODIUM
   TAUROCHOLATE; LYMPHATIC DELIVERY; NANOPARTICLES; TRANSLOCATION;
   DIDANOSINE; LIPOSOMES; DSC; HIV
AB Anti HIV molecules as numerous drugs cannot efficiently penetrate into the brain. Prodrug synthesis and encapsulation into pegylated nanocarriers have been proposed as an approach for brain delivery. Pegylated polymeric nanoparticles and liposomes were chosen to incorporate glycerolipidic prodrugs of didanosine. Differential scanning calorimetry experiments were performed on mixtures of prodrugs and lipids or polymer in order to study their interaction. The optimal incorporation ratios were determined for each prodrug and compared for both types of nanocarriers. All these results would be used to prepare optimised formulations of didanosine prodrugs loaded into pegylated nanocarriers for brain drug delivery.
C1 [Bourgeois, Jennifer; Pierson, Laure-Anne; Nicolas, Julien; Lalanne, Muriel; Couvreur, Patrick; Andrieux, Karine] Univ Paris 11, Fac Pharm, CNRS, Lab Physicochim Pharmacotech & Biopharm,UMR 8612, F-92296 Chatenay Malabry, France.
RP Andrieux, K (reprint author), Univ Paris 11, Fac Pharm, CNRS, Lab Physicochim Pharmacotech & Biopharm,UMR 8612, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
EM karine.andrieux@u-psud.fr
RI COUVREUR, Patrick/G-4844-2011; Andrieux, Karine/P-3010-2017; NICOLAS,
   Julien/A-4312-2010
OI COUVREUR, Patrick/0000-0001-7961-5443; Andrieux,
   Karine/0000-0002-2002-7556; NICOLAS, Julien/0000-0002-1597-0873
CR Andrieux K, 2004, PHARM RES, V21, P1505, DOI 10.1023/B:PHAM.0000036927.37888.93                                              
   Andrieux K, 2009, EUR J PHARM BIOPHARM, V71, P346, DOI 10.1016/j.ejpb.2008.09.004
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669
   Forte L, 1998, J THERM ANAL CALORIM, V51, P773, DOI 10.1007/BF03341454                                                              
   Garcia-Garcia E, 2005, INT J PHARM, V298, P274, DOI 10.1016/j.ijpharm.2005.03.031
   Kanaze FI, 2006, J THERM ANAL CALORIM, V83, P283, DOI 10.1007/s10973-005-6989-9
   Kim HR, 2007, CELL MOL LIFE SCI, V64, P356, DOI 10.1007/s00018-007-6390-x
   Kim HR, 2007, BIOMACROMOLECULES, V8, P793, DOI 10.1021/bm060711a
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   LALANNE M, 2009, INT J PHARM
   LALANNE M, J CONTROL REL UNPUB
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lawrence DM, 2002, MICROBES INFECT, V4, P301, DOI 10.1016/S1286-4579(02)01542-3
   Lira AAM, 2007, J THERM ANAL CALORIM, V87, P899, DOI 10.1007/s10973-006-7684-1
   Misra M, 2007, J THERM ANAL CALORIM, V89, P803, DOI 10.1007/s10973-007-8531-8
   Nicolas J, 2008, MACROMOLECULES, V41, P8418, DOI 10.1021/ma8013349
   Peracchia MT, 1997, MACROMOLECULES, V30, P846, DOI 10.1021/ma961453k                                                               
   Singh M, 1999, J CONTROL RELEASE, V59, P43, DOI 10.1016/S0168-3659(98)00174-6
   Wiebe LI, 1999, ADV DRUG DELIVER REV, V39, P63, DOI 10.1016/S0169-409X(99)00020-4                                                   
NR 20
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-6150
J9 J THERM ANAL CALORIM
JI J. Therm. Anal. Calorim.
PD OCT
PY 2009
VL 98
IS 1
BP 65
EP 71
DI 10.1007/s10973-009-0350-7
PG 7
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 512WI
UT WOS:000271282000009
DA 2018-01-05
ER

PT J
AU Rannard, S
   Owen, A
AF Rannard, Steve
   Owen, Andrew
TI Nanomedicine: Not a case of "One size fits all"
SO NANO TODAY
LA English
DT Editorial Material
DE Opinion; Nanomedicine; HIV/AIDS; Cancer; Toxicology
ID DRUG-DELIVERY; NANOTECHNOLOGY
AB Nanomedicine offers many benefits for the future treatment of disease conditions. The development of a nanomedicine may take different approaches but considerations of the disease, clinical practice, patient compliance and risk/benefit profiles are key to selecting the appropriate technologies. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Rannard, Steve] Univ Liverpool, Dept Chem, Liverpool L69 7ZD, Merseyside, England.
   [Owen, Andrew] Univ Liverpool, Sch Biomed Sci, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England.
RP Rannard, S (reprint author), Univ Liverpool, Dept Chem, Crown St, Liverpool L69 7ZD, Merseyside, England.
EM srannard@liv.ac.uk
RI Owen, Andrew/M-7509-2017
OI Owen, Andrew/0000-0002-9819-7651; Rannard, Steve/0000-0002-6946-1097
CR Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Jiang W, 2007, EXPERT OPIN DRUG DEL, V4, P621, DOI 10.1517/17425247.4.6.621
   Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003
   Mauludin R, 2009, EUR J PHARM SCI, V36, P502, DOI 10.1016/j.ejps.2008.12.002
   Mitropoulos AC, 2008, J COLLOID INTERF SCI, V317, P643, DOI 10.1016/j.jcis.2007.10.001
   Nazarov GV, 2009, PHARM CHEM J+, V43, P163, DOI 10.1007/s11094-009-0259-2
   Owen A, 2006, PHARMACOGENET GENOM, V16, P693, DOI 10.1097/01.fpc.0000236338.41799.57
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   Tevaarwerk AJ, 2009, CLIN CANCER RES, V15, P1460, DOI 10.1158/1078-0432.CCR-08-1599
   UNAIDS, 2008, REP GLOB AIDS EP
   Zhang HF, 2008, NAT NANOTECHNOL, V3, P506, DOI 10.1038/nnano.2008.188
NR 11
TC 10
Z9 10
U1 1
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1748-0132
J9 NANO TODAY
JI Nano Today
PD OCT
PY 2009
VL 4
IS 5
BP 382
EP 384
DI 10.1016/j.nantod.2009.07.002
PG 3
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 514AG
UT WOS:000271365100007
DA 2018-01-05
ER

PT J
AU Baleux, F
   Loureiro-Morais, L
   Hersant, Y
   Clayette, P
   Arenzana-Seisdedos, F
   Bonnaffe, D
   Lortat-Jacob, H
AF Baleux, Francoise
   Loureiro-Morais, Latino
   Hersant, Yael
   Clayette, Pascal
   Arenzana-Seisdedos, Fernando
   Bonnaffe, David
   Lortat-Jacob, Hugues
TI A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4
   HIV-1 attachment and entry
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CORECEPTOR BINDING-SITE; HEPARAN-SULFATE;
   IN-VITRO; GP120; RECEPTOR; PROTEOGLYCANS; ANTIBODIES; DRUG; V3
AB The HIV-1 envelope, gp120, which features the binding determinants for both CD4 and coreceptor recognition, is key for virus entry and represents an attractive pharmacological target. However, critical domains for entry (coreceptor and CD4 binding sites) are either cryptic or located in partially occluded cavities. Here we developed a chemical approach to synthesize a CD4-mimetic peptide linked to a heparan sulfate dodecasaccharide. This molecule binds to gp120, induces the exposure of the coreceptor binding domain and renders it available for interaction with the oligosaccharide. The linkage between the CD4 mimetic and the heparan sulfate derivative provides strong cooperative effects, resulting in low-nanomolar antiviral activity toward both CCR5- and CXCR4-tropic HIV-1 strains. This compound, which has the unique ability to simultaneously target two critical and highly conserved regions of gp120, establishes a new type of inhibitor and suggests a general concept for the inhibition of numerous other biological systems.
C1 [Lortat-Jacob, Hugues] Univ Grenoble 1, CNRS, Inst Biol Struct, UMR 5075,Commissariat Energie Atom, Grenoble, France.
   [Baleux, Francoise] Inst Pasteur, Unite Chim Biomol, Unite Rech Assoc 2128, CNRS, Paris, France.
   [Loureiro-Morais, Latino; Hersant, Yael; Bonnaffe, David] Univ Paris 11, CNRS, UMR 8182,Lab Chim Organ Multifonct, Inst Chim Mol & Mat Orsay,Equipe Glycochim Mol &, F-91405 Orsay, France.
   [Clayette, Pascal] Commissariat Energie Atom, SPI bio, Lab Neurovirol, Fontenay Aux Roses, France.
   [Arenzana-Seisdedos, Fernando] Inst Pasteur, INSERM, Lab Pathogenie Virale, U819, F-75724 Paris, France.
RP Lortat-Jacob, H (reprint author), Univ Grenoble 1, CNRS, Inst Biol Struct, UMR 5075,Commissariat Energie Atom, Grenoble, France.
EM hugues.lortat-jacob@ibs.fr
RI Arenzana-Seisdedos, Fernando/E-5835-2016
OI Baleux, Francoise/0000-0003-4926-1060
FU US National Institutes of Health
FX We thank L. Klemm, C. Rogez-Kreuz, R. Yousfi and V.I. Iuyot for
   technical assistance and R. R. Vives for stimulating discussions. This
   work was supported by the Agence Nationale de la Recherche sur le
   Syndrome d'Immunodeficience Acquise. Soluble CD4 and monoclonal
   antibodies 17b and E51 were obtained through the US National Institutes
   of Health AIDS Research and Reference Reagent Program from S. Iyer and
   J. Robinson. Infectious HIV-1 proviral clones pNL4-3 Luc were a gift
   from J. Alcami (Unidad de Inmunopatolog a del Sida, Instituto de Salud
   Carlos III).
CR Adibekian A, 2007, CHEM-EUR J, V13, P4510, DOI 10.1002/chem.200700141
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Chan W. C., 2000, FMOC SOLID PHASE PEP
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105
   Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7
   Crublet E, 2008, J BIOL CHEM, V283, P15193, DOI 10.1074/jbc.M800066200
   de Witte L, 2007, P NATL ACAD SCI USA, V104, P19464, DOI 10.1073/pnas.0703747104
   Endress T, 2008, EUR BIOPHYS J BIOPHY, V37, P1291, DOI 10.1007/s00249-008-0322-z
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171                                                         
   Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   KWONG PD, 1998, NATURE, V393, P659
   Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003
   Lubineau A, 2004, CHEM-EUR J, V10, P4265, DOI 10.1002/chem.200306063
   Moncunill G, 2008, AIDS, V22, P23, DOI 10.1097/QAD.0b013e3282f303e6                                                    
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640
   Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1
   RIDER CC, 1994, BIOCHEMISTRY-US, V33, P6974, DOI 10.1021/bi00188a029
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   RODERIQUEZ G, 1995, J VIROL, V69, P2233
   Roisin A, 2004, J BIOL CHEM, V279, P9208, DOI 10.1074/jbc.M311594200
   Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029
   Shafer RW, 2008, AIDS REV, V10, P67
   THALI M, 1993, J VIROL, V67, P3978
   Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200
   Xiang SH, 2002, AIDS RES HUM RETROV, V18, P1207, DOI 10.1089/08892220260387959                                                       
NR 37
TC 82
Z9 83
U1 1
U2 21
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD OCT
PY 2009
VL 5
IS 10
BP 743
EP 748
DI 10.1038/nchembio.207
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 497EV
UT WOS:000270039900012
PM 19734912
DA 2018-01-05
ER

PT J
AU Fonseca, SB
   Pereira, MP
   Kelley, SO
AF Fonseca, Sonali B.
   Pereira, Mark P.
   Kelley, Shana O.
TI Recent advances in the use of cell-penetrating peptides for medical and
   biological applications
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Drug delivery; Cell penetrating peptides
ID HUMAN IMMUNODEFICIENCY VIRUS; SMALL-MOLECULE INHIBITORS; BREAST-CANCER
   CELLS; IN-VIVO; DRUG-DELIVERY; MULTIDRUG-RESISTANCE; NUCLEIC-ACIDS;
   LIVING CELLS; TAT PROTEIN; PHOTOCHEMICAL INTERNALIZATION
AB The selective permeability of the plasma membrane prohibits most exogenous agents from gaining cellular access. Since many therapeutics and reporter molecules must be internalized for activity, crossing the plasma membrane is essential. A very effective class of transporters harnessed for this purpose are cell penetrating peptides (CPPs), a group of short cationic sequences with a remarkable capacity for membrane translocation. Since their discovery in 1988, CPPs have been employed for the delivery of a wide variety of cargo including small molecules, nucleic acids, antibodies and nanoparticles. This review describes recent advances in the use of CPPs for biological and therapeutic applications. In particular, an emphasis is placed on novel systems and insights acquired since 2006. Basic research on CPPs has recently yielded techniques that provide further information on the controversial mechanism of CPP uptake and has also resulted in the development of new model membrane systems to evaluate these mechanisms. In addition, recent use of CPPs for the development of new cellular imaging tools, biosensors, or biomolecular delivery systems have been highlighted. Lastly, novel peptide delivery vectors, designed to tackle some of the drawbacks of CPPs and enhance their versatility, will be described. This review will illustrate the diverse applications for which CPPs have been harnessed and also demonstrate the remarkable advancements these peptides have facilitated in cell biology. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Fonseca, Sonali B.; Pereira, Mark P.; Kelley, Shana O.] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 1A1, Canada.
   [Kelley, Shana O.] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A1, Canada.
RP Kelley, SO (reprint author), Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 1A1, Canada.
EM shana.kelley@utoronto.ca
OI Kelley, Shana/0000-0003-3360-5359
CR Abes R, 2008, NUCLEIC ACIDS RES, V36, P6343, DOI 10.1093/nar/gkn541
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Bais MV, 2008, BIOCHEM BIOPH RES CO, V370, P27, DOI 10.1016/j.bbrc.2008.03.023
   Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867                                                                   
   Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X
   Bennett RP, 2002, NAT BIOTECHNOL, V20, P20, DOI 10.1038/nbt0102-20                                                              
   Berclaz G, 2001, INT J ONCOL, V19, P1155
   Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081
   Berg K, 1999, CANCER RES, V59, P1180
   Berg K, 2007, CURR PHARM BIOTECHNO, V8, P362, DOI 10.2174/138920107783018354
   Berg Kristian, 2003, Oftalmologia, V56, P67
   Bian J, 2007, CIRC RES, V100, P1626, DOI 10.1161/01.RES.0000269778.75877.68
   Bleifuss E, 2006, CELL MOL LIFE SCI, V63, P627, DOI 10.1007/s00018-005-5548-7
   Bozym RA, 2006, ACS CHEM BIOL, V1, P103, DOI 10.1021/cb500043a
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5                                                   
   Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347                                                  
   Ciftci K, 2001, INT J PHARM, V218, P81, DOI 10.1016/S0378-5173(01)00623-8
   Cobb NJ, 2009, BIOCHEMISTRY-US, V48, P2574, DOI 10.1021/bi900108v
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Divgi C R, 1996, Oncology (Williston Park), V10, P939
   DIVGI CR, 1996, ONCOLOGY HUNTINGT, V10, P957
   DIVGI CR, 1996, ONCOLOGY HUNTINGT, V10, P954
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Endoh T, 2008, BIOCONJUGATE CHEM, V19, P1017, DOI 10.1021/bc800020n
   Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Filipits M, 2004, DRUG DISCOV TODAY, V1, P229, DOI DOI 10.1016/J.DDMEC.2004.10.001
   Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6
   Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608                                                        
   Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196
   Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JC126321
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Holm T, 2005, FEBS LETT, V579, P5217, DOI 10.1016/j.febslet.2005.07.099
   Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015
   Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471                                                     
   Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002                                                
   Hotchkiss RS, 1999, J IMMUNOL, V162, P4148
   Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541
   Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493                                                     
   Hu MD, 2007, EUR J NUCL MED MOL I, V34, P368, DOI 10.1007/s00259-006-0189-0
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   Johnson JR, 2008, BIOCONJUGATE CHEM, V19, P1033, DOI 10.1021/bc700466z
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Jorgensen P, 2002, GENETICS, V162, P1091
   Kamei N, 2008, J CONTROL RELEASE, V132, P21, DOI 10.1016/j.jconrel.2008.08.001
   Kamei N, 2008, J CONTROL RELEASE, V131, P94, DOI 10.1016/j.jconrel.2008.07.016
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Lee HL, 2008, J AM CHEM SOC, V130, P9364, DOI 10.1021/ja710798b
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lofgren K, 2008, FASEB J, V22, P2177, DOI 10.1096/fj.07-099549
   Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Mahon KP, 2007, CHEM BIOL, V14, P923, DOI 10.1016/j.chembiol.2007.07.011
   Maiolo JR, 2004, J AM CHEM SOC, V126, P15376, DOI 10.1021/ja044867z
   Malet G, 2006, CELL DEATH DIFFER, V13, P1523, DOI 10.1038/sj.cdd.4401828
   Manceur AP, 2009, MOL THER, V17, P500, DOI 10.1038/mt.2008.271
   McClorey G, 2006, GENE THER, V13, P1373, DOI 10.1038/sj.gt.3302800
   McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556                                                     
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593
   Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038                                                         
   Orzaez M, 2007, PEPTIDES, V28, P958, DOI 10.1016/j.peptides.2007.02.014
   Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651                                                                   
   Patil SD, 2005, AAPS J, V7, pE61, DOI 10.1208/aapsj070109
   Pauwels EKJ, 2007, DRUG NEWS PERSPECT, V20, P371, DOI 10.1358/dnp.2007.20.6.1141496
   Pavlinkova G, 1999, J NUCL MED, V40, P1536
   PEREZ F, 1992, J CELL SCI, V102, P717
   PERKINS DJ, 1953, BIOCHEM J, V55, P649, DOI 10.1042/bj0550649                                                               
   Pierce SE, 2007, NAT PROTOC, V2, P2958, DOI 10.1038/nprot.2007.427
   Ray A, 2000, FASEB J, V14, P1041
   Luque-Ortega JR, 2008, FASEB J, V22, P1817, DOI 10.1096/fj.07-096081
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rozenzhak SM, 2005, CHEM COMMUN, P2217, DOI 10.1039/b418454h
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Scott CW, 2003, J PHARMACOL EXP THER, V304, P433, DOI 10.1124/jpet.102.039651
   Sensi SL, 1997, J NEUROSCI, V17, P9554
   Shaw JD, 2001, EXP CELL RES, V271, P1, DOI 10.1006/excr.2001.5373
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Su Y, 2008, J AM CHEM SOC, V130, P8856, DOI 10.1021/ja802383t
   Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x                                                
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Tan M, 1997, CANCER RES, V57, P1199
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q                                                    
   Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200                                                          
   VALLEE BL, 1993, PHYSIOL REV, V73, P79
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Webster A, 2005, ANALYST, V130, P163, DOI 10.1039/b413725f
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Yeh HY, 2008, P NATL ACAD SCI USA, V105, P17522, DOI 10.1073/pnas.0807066105
   Yeh HY, 2008, APPL ENVIRON MICROB, V74, P2239, DOI 10.1128/AEM.00259-08
   YOKOYAMA M, 1986, NEUROSCI LETT, V71, P351, DOI 10.1016/0304-3940(86)90646-4
   Zheng TS, 2000, NAT MED, V6, P1241
NR 124
TC 324
Z9 338
U1 10
U2 209
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 30
PY 2009
VL 61
IS 11
BP 953
EP 964
DI 10.1016/j.addr.2009.06.001
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 511BC
UT WOS:000271137600007
PM 19538995
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Teesalu, T
   Sugahara, KN
   Kotamraju, VR
   Ruoslahti, E
AF Teesalu, Tambet
   Sugahara, Kazuki N.
   Kotamraju, Venkata Ramana
   Ruoslahti, Erkki
TI C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and
   tissue penetration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE homing peptides; vascular permeability; VEGF; cell penetrating peptides
ID ENDOTHELIAL GROWTH-FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; TUMOR-CELLS;
   PERMEABILITY FACTOR; HEPARIN-BINDING; PROTEIN; ANGIOGENESIS; RECEPTOR;
   SECRETE; DOMAINS
AB Screening of phage libraries expressing random peptides for binding to prostate cancer cells primarily yielded peptides that had a C-terminal arginine (or rarely lysine) residue, usually in a consensus context R/KXXR/K. Phage expressing these sequences and synthetic nanoparticles coated with them bound to and were internalized into cells. The C-terminal arginine (or lysine) was essential to the activity; adding another amino acid, or even blocking the free carboxyl group of this arginine residue by amidation, eliminated the binding and internalizing activity. An internal R/KXXR/K can be exposed and switched on by a cleavage by a protease. The strict requirement for C-terminal exposure of the motif prompted us to term the phenomenon the C-end rule (CendR). Affinity chromatography showed that the CendR peptides bind to neuropilin-1 (NRP-1) on the target cells. NRP-1 is a cell-surface receptor that plays an essential role in angiogenesis, regulation of vascular permeability, and the development of the nervous system. VEGF-A165 and other ligands of NRP-1 possess a C-terminal CendR sequence that interacts with the b1 domain of NRP-1 and causes cellular internalization and vascular leakage. Our CendR peptides have similar effects, particularly when made multivalent through coupling to a particle. We also noted a unique and important activity of these peptides: penetration and transportation through tissues. The peptides were able to take payloads up to the nanoparticle size scale deep into extravascular tissue. Our observations have implications in drug delivery and penetration of tissue barriers and tumors.
C1 [Teesalu, Tambet; Sugahara, Kazuki N.; Kotamraju, Venkata Ramana; Ruoslahti, Erkki] Univ Calif Santa Barbara, Burnham Inst Med Res, Vasc Mapping Ctr, Santa Barbara, CA 93106 USA.
   [Ruoslahti, Erkki] Burnham Inst Med Res, Canc Res Ctr, La Jolla, CA 92037 USA.
RP Teesalu, T (reprint author), Univ Calif Santa Barbara, Burnham Inst Med Res, Vasc Mapping Ctr, Santa Barbara, CA 93106 USA.
EM tteesalu@burnham.org; ruoslahti@burnham.org
RI Teesalu, Tambet/J-1802-2015
FU National Cancer Institute [CA104898, CA115410, CA119414, CA119335]; U.
   S. Department of Defense [W81XWH-08-1-0727]
FX We thank Drs. Eva Engvall, Elena Pasquale, and Douglas Hanahan for their
   critical reading of the manuscript; Dr. Michael Klagsbrun for the NRP- 1
   cDNA construct; Dr. David Cheresh for the M21 cell line; Roslind
   Varghese for editing; and Dr. Lianglin Zhang, Dr. Tero Jarvinen,
   Christopher B. Brunquell, and Olivia M. Yu for their help with the phage
   display experiments. This work was supported by National Cancer
   Institute Grants CA104898, CA115410, CA119414, and CA119335 and U. S.
   Department of Defense Grant W81XWH-08-1-0727.
CR Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205
   Baban DF, 1998, ADV DRUG DELIVER REV, V34, P109, DOI 10.1016/S0169-409X(98)00003-9                                                   
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49                                              
   CHERESH DA, 1987, J BIOL CHEM, V262, P17703
   Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401                                                      
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3                                                   
   HOFFMAN JA, 2004, PHAGE DISPLAY PRACTI, pCH10
   Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001
   Jarvinen TAH, 2007, AM J PATHOL, V171, P702, DOI 10.2353/ajpath.2007.061251
   Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200
   Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P469, DOI 10.1006/bbrc.2001.4790
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Langel U., 2007, HDB CELL PENETRATING
   Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0
   Mamluk Roni, 2005, Angiogenesis, V8, P217, DOI 10.1007/s10456-005-9009-6
   Michel CC, 1996, CARDIOVASC RES, V32, P644, DOI 10.1016/0008-6363(96)00064-8
   Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599
   Rabbani MLM, 2001, REPRODUCTION, V122, P85, DOI 10.1530/rep.0.1220085
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6                                                   
   Starzec A, 2007, PEPTIDES, V28, P2397, DOI 10.1016/j.peptides.2007.09.013
   Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005
   Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182
   Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899
   Vander Kooi CW, 2007, P NATL ACAD SCI USA, V104, P6152, DOI 10.1073/pnas.0700043104
   von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Weis SM, 2008, CURR OPIN HEMATOL, V15, P243, DOI 10.1097/MOH.0b013e3282f97d86
NR 37
TC 242
Z9 252
U1 4
U2 68
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 22
PY 2009
VL 106
IS 38
BP 16157
EP 16162
DI 10.1073/pnas.0908201106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 497PF
UT WOS:000270071600031
PM 19805273
OA gold
DA 2018-01-05
ER

PT J
AU Tian, XT
   Qin, BJ
   Lu, H
   Lai, WH
   Jiang, SB
   Lee, KH
   Chen, CH
   Xie, L
AF Tian, Xingtao
   Qin, Bingjie
   Lu, Hong
   Lai, Weihong
   Jiang, Shibo
   Lee, Kuo-Hsiung
   Chen, Chin Ho
   Xie, Lan
TI Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1
   reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Diarylpyridine derivatives; HIV-1 NNRTIs; Drug resistance
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG; FLEXIBILITY; RESISTANCE; MUTATIONS;
   ANALOGS; TMC125
AB Two series (4 and 5) of diarylpyridine derivatives were designed, synthesized, and evaluated for anti-HIV-1 activity. The most promising compound, 5e, inhibited HIV-1 IIIB, NL4-3, and RTMDR1 with low nanomolar EC(50) values and selectivity indexes of >10,000. The results of this study indicate that diarylpyridine can be used as a novel scaffold to derive a new class of potent NNRTIs, active against both wild-type and drug-resistant HIV-1 strains. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Tian, Xingtao; Qin, Bingjie; Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Lu, Hong; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [Lee, Kuo-Hsiung] Univ N Carolina, Nat Prod Res Labs, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Lai, Weihong; Chen, Chin Ho] Duke Univ, Med Ctr, Surg Oncol Res Facil, Durham, NC 27710 USA.
RP Xie, L (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM lanxieshi@yahoo.com
RI Xie, Lan /A-4533-2012; Jiang, Shibo/L-4500-2014
FU National Natural Science Foundation of China and Beijing government
   [20472114, 7052057]; NIH [AI46221, AI33066, AI65310]
FX This investigation was supported by Grants 20472114 and 7052057 from the
   National Natural Science Foundation of China and Beijing government,
   respectively, awarded to L. Xie, as well as NIH Grants AI46221 to S.
   Jiang, AI33066 to K. H. Lee, and AI65310 to C. H. Chen
CR Andries K, 2004, ANTIMICROB AGENTS CH, V48, P4680, DOI 10.1128/AAC.48.12.4680-4680.2004
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p
   GRUZDEV B, 2001, 8 C RETR OPP INF CHI
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   REDEMANN CT, 1949, ORG SYNTH, V29, P8
   Rodriguez JG, 2006, TETRAHEDRON, V62, P3355, DOI 10.1016/j.tet.2006.01.058
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Xie L, 2008, J MED CHEM, V51, P7689, DOI 10.1021/jm8003009
NR 16
TC 23
Z9 28
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 15
PY 2009
VL 19
IS 18
BP 5482
EP 5485
DI 10.1016/j.bmcl.2009.07.080
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 493TM
UT WOS:000269760900046
PM 19666220
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gudmundsson, KS
   Sebahar, PR
   Richardson, LD
   Miller, JF
   Turner, EM
   Catalano, JG
   Spaltenstein, A
   Lawrence, W
   Thomson, M
   Jenkinson, S
AF Gudmundsson, Kristjan S.
   Sebahar, Paul R.
   Richardson, Leah D'Aurora
   Miller, John F.
   Turner, Elizabeth M.
   Catalano, John G.
   Spaltenstein, Andrew
   Lawrence, Wendell
   Thomson, Michael
   Jenkinson, Stephen
TI Amine substituted
   N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as
   CXCR4 antagonists with potent activity against HIV-1
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; PHARMACOKINETICS; MICROENVIRONMENT;
   INHIBITORS; AMD070; SAFETY; CELLS; ENTRY
AB Several novel amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines were synthesized which had potent activity against HIV-1. The synthetic approaches adopted allowed for variation of the substitution pattern and resulting changes in antiviral activity are highlighted. This led to the identification of compounds with low and sub-nanomolar anti-HIV-1 activity. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Gudmundsson, Kristjan S.; Sebahar, Paul R.; Richardson, Leah D'Aurora; Miller, John F.; Turner, Elizabeth M.; Catalano, John G.; Spaltenstein, Andrew] GlaxoSmithKline Res & Dev Ltd, Metab & Virol Ctr Excellence Drug Discovery, Dept Med Chem, Res Triangle Pk, NC 27709 USA.
   [Lawrence, Wendell; Thomson, Michael] GlaxoSmithKline Res & Dev Ltd, Metab & Virol Ctr Excellence Drug Discovery, Dept Virol, Res Triangle Pk, NC 27709 USA.
   [Jenkinson, Stephen] GlaxoSmithKline Res & Dev Ltd, Metab & Virol Ctr Excellence Drug Discovery, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA.
RP Gudmundsson, KS (reprint author), GlaxoSmithKline Res & Dev Ltd, Metab & Virol Ctr Excellence Drug Discovery, Dept Med Chem, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM ksgudmundsson@gmail.com
CR Berson JF, 1996, J VIROL, V70, P6288
   Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423                                                     
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Crawford JB, 2008, ORG PROCESS RES DEV, V12, P823, DOI 10.1021/op8000993
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   DeMarco SJ, 2006, BIOORGAN MED CHEM, V14, P8396, DOI 10.1016/j.bmc.2006.09.003
   Fujii N, 2003, ANGEW CHEM INT EDIT, V42, P3251, DOI 10.1002/anie.200351024
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   Ichiyama K, 2003, P NATL ACAD SCI USA, V100, P4185, DOI 10.1073/pnas.0630420100
   Kelly TR, 2002, J ORG CHEM, V67, P2197, DOI 10.1021/jo016250v
   Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686                                                     
   *NCI, 2005, NCI CANC B, V17, P4
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354
   Shaheen F, 2004, CURR OPIN INFECT DIS, V17, P7, DOI 10.1097/01.qco.0000113643.29255.5c
   Stone ND, 2007, ANTIMICROB AGENTS CH, V51, P2351, DOI 10.1128/AAC.00013-07
   SUMNERSMITH M, 1995, DRUG EXP CLIN RES, V21, P1
   Tamamura H, 2004, FEBS LETT, V569, P99, DOI 10.1016/j.febslet.2004.05.056
   Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024
   MCEACHERN EJ, 2003, Patent No. 2003022785
   BRIDGER GJ, 2003, Patent No. 2003055876
   CRAWFORD JB, 2006, Patent No. 2006039250
NR 22
TC 34
Z9 35
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2009
VL 19
IS 17
BP 5048
EP 5052
DI 10.1016/j.bmcl.2009.07.037
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 482DH
UT WOS:000268863800034
PM 19640718
DA 2018-01-05
ER

PT J
AU Su, DS
   Lim, JJ
   Tinney, E
   Wan, BL
   Young, MB
   Anderson, KD
   Rudd, D
   Munshi, V
   Bahnck, C
   Felock, PJ
   Lu, MQ
   Lai, MT
   Touch, S
   Moyer, G
   DiStefano, DJ
   Flynn, JA
   Liang, YX
   Sanchez, R
   Prasad, S
   Yan, YW
   Perlow-Poehnelt, R
   Torrent, M
   Miller, M
   Vacca, JP
   Williams, TM
   Anthony, NJ
AF Su, Dai-Shi
   Lim, John J.
   Tinney, Elizabeth
   Wan, Bang-Lin
   Young, Mary Beth
   Anderson, Kenneth D.
   Rudd, Deanne
   Munshi, Vandna
   Bahnck, Carolyn
   Felock, Peter J.
   Lu, Meiqing
   Lai, Ming-Tain
   Touch, Sinoeun
   Moyer, Gregory
   DiStefano, Daniel J.
   Flynn, Jessica A.
   Liang, Yuexia
   Sanchez, Rosa
   Prasad, Sridhar
   Yan, Youwei
   Perlow-Poehnelt, Rebecca
   Torrent, Maricel
   Miller, Mike
   Vacca, Joe P.
   Williams, Theresa M.
   Anthony, Neville J.
TI Substituted tetrahydroquinolines as potent allosteric inhibitors of
   reverse transcriptase and its key mutants
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Non-nucleoside reverse transcriptase inhibitor (NNRTI); SAR; Molecular
   modeling; Crystal structure; Mutant virus; Tetrahydroquinoline
ID MOLECULAR-FORCE FIELD; NONNUCLEOSIDE INHIBITORS; DISTANCE GEOMETRY;
   MMFF94
AB Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key elements of multidrug regimens, called HAART (Highly Active Antiretroviral Therapy), that are used to treat HIV-1 infections. Elucidation of the structure-activity relationships of the thiocarbamate moiety of the previous published lead compound 2 provided a series of novel tetrahydroquinoline derivatives as potent inhibitors of HIV-1 RT with nanomolar intrinsic activity on the WT and key mutant enzymes and potent antiviral activity in infected cells. The SAR optimization, mutation profiles, preparation of compounds, and pharmacokinetic profile of compounds are described. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Su, Dai-Shi; Lim, John J.; Tinney, Elizabeth; Wan, Bang-Lin; Young, Mary Beth; Anderson, Kenneth D.; Rudd, Deanne; Prasad, Sridhar; Yan, Youwei; Perlow-Poehnelt, Rebecca; Torrent, Maricel; Vacca, Joe P.; Williams, Theresa M.; Anthony, Neville J.] Merck Res Lab, Dept Med Chem & Struct Biol, West Point, PA 19486 USA.
RP Su, DS (reprint author), GlaxoSmithKline Inc, 1250 S Collegeville Rd,UP1205, Collegeville, PA 19426 USA.
EM Dai-Shi.X.Su@gsk.com
CR Crippen C. M., 1988, DISTANCE GEOMETRY MO
   De La Rosa M, 2006, BIOORG MED CHEM LETT, V16, P4444, DOI 10.1016/j.bmcl.2006.06.048
   Feuston BP, 2001, J CHEM INF COMP SCI, V41, P754, DOI 10.1021/ci000464g
   Gagnon A, 2007, BIOORG MED CHEM LETT, V17, P4437, DOI 10.1016/j.bmcl.2007.06.012
   Halgren TA, 1996, J COMPUT CHEM, V17, P520, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<520::AID-JCC2>3.0.CO;2-W
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Halgren TA, 1996, J COMPUT CHEM, V17, P616, DOI 10.1002/(SICI)1096-987X(199604)17:6<616::AID-JCC5>3.3.CO;2-3
   Halgren TA, 1996, J COMPUT CHEM, V17, P553
   Halgren TA, 1996, J COMPUT CHEM, V17, P587, DOI 10.1002/(SICI)1096-987X(199604)17:6<587::AID-JCC4>3.0.CO;2-P
   KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799
   Muraglia E, 2006, BIOORG MED CHEM LETT, V16, P2748, DOI 10.1016/j.bmcl.2006.02.024
   O'Meara JA, 2007, BIOORG MED CHEM LETT, V17, P3362, DOI 10.1016/j.bmcl.2007.03.097
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Saggar S., 2007, U.S. Patent, Patent No. [2,007,021,442, 2007021442]
NR 15
TC 14
Z9 15
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2009
VL 19
IS 17
BP 5119
EP 5123
DI 10.1016/j.bmcl.2009.07.031
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 482DH
UT WOS:000268863800051
PM 19631528
DA 2018-01-05
ER

PT J
AU Gour, JK
   Srivastava, A
   Kumar, V
   Bajpai, S
   Kumar, H
   Mishra, M
   Singh, RK
AF Gour, Jalaj Kumar
   Srivastava, Ankita
   Kumar, Vinod
   Bajpai, Surabhi
   Kumar, Hemant
   Mishra, Manish
   Singh, Rakesh K.
TI NANOMEDICINE AND LEISHMANIASIS: FUTURE PROSPECTS
SO DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES
LA English
DT Article
DE Liposomes; Nanoparticles; Leishmanial drugs
ID VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; SILVER NANOPARTICLES;
   IMMUNE-RESPONSE; DIAGNOSIS; NANOTECHNOLOGY; INFECTION; DISEASE;
   NANOMATERIALS; MACROPHAGE
AB The increasing incidences of leishmaniasis due to toxicity and resistance of drug as a result of high drug dose and its spreading to newer areas needt to develop newer drugs for its effective control. Major problem in the treatment of leishmaniasis is failure of humoral response. Moreover, immunodepression and particularly HIV-VL co-infection also present a major cause of treatment failure. Chemotherapy using present antileishmanial drugs is difficult due to the location of parasites within lysosomal vacuoles of the macrophages, which restricts the bioavailability of many potential antileishmanial compounds. So the treatment strategies mainly rely on induction of cellular immune response that can be effectively achieved by targeted drug delivery and the vaccine. Lacuna in its treatment regimen provokes scientists to generate a therapy that is cheaper, requires low dose of drugs and specific to its target of action as well. The causative agent of the disease, an intracellular parasite harbors macrophage and specific tissue sites, which can be the target of drug. Thus targeted drug delivery system is the need of the day. Nowadays the advancement in technology rekindles the hope for the treatment of this disease. This new hope is nanotechnology that employs the use of nanoparticles as drug carriers for the targeted drug delivery. Nanoparticles have proved to be highly stable as well as good carrier capacity as well as reduced toxicity. There are several carriers or drug delivery systems available and for leishmaniasis successful therapy with liposomes have shown some good results. For the researchers to develop the nanomedicine (anti leishmanial drugs) for leishmaniasis is on the top priority in order to get the lesser cost and pain of the patients. This article is an attempt to demonstrate the use of nanomedicine for the benefit of patients suffering with deadly disease leishmaniasis all over the world.
C1 [Gour, Jalaj Kumar; Srivastava, Ankita; Kumar, Vinod; Bajpai, Surabhi; Singh, Rakesh K.] Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
   [Kumar, Hemant; Mishra, Manish] Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India.
RP Gour, JK (reprint author), Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
FU Council of Scientific and Industrial Research, New Delhi; Council of
   Science and Technology, Uttar Pradesh, India
FX The authors are thankful to Council of Scientific and Industrial
   Research, New Delhi and Council of Science and Technology, Uttar
   Pradesh, India for financial support.
CR Alrajhi AA, 2002, NEW ENGL J MED, V346, P891, DOI 10.1056/NEJMoa011882
   Arya A. K., 2008, DIG J NANOMATER BIOS, V3, p221 225
   Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186                                                        
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x                                              
   Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006
   Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                                   
   DAS N, 1990, BIOCHEM MED METAB B, V43, P133, DOI 10.1016/0885-4505(90)90018-V
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   Davies CR, 2003, BRIT MED J, V326, P377, DOI 10.1136/bmj.326.7385.377
   Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0                                                    
   Handman E, 2002, TRENDS PARASITOL, V18, P332, DOI 10.1016/S1471-4922(02)02352-8
   Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2
   Iqbal J, 2002, J CLIN MICROBIOL, V40, P475, DOI 10.1128/JCM.40.2.475-479.2002
   Kemp M, 1996, IMMUNOL TODAY, V17, P13, DOI 10.1016/0167-5699(96)80562-7
   LIEW FY, 1993, ADV PARASIT, V32, P161, DOI 10.1016/S0065-308X(08)60208-0
   Mathuria JP, 2009, DIG J NANOMATER BIOS, V4, P309
   McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002
   Mishra M, 2008, DIG J NANOMATER BIOS, V3, P109
   Mishra M, 2008, DIG J NANOMATER BIOS, V3, P49
   Mitra R, 2009, DIG J NANOMATER BIOS, V4, P109
   Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177
   Pandey A, 2008, DIG J NANOMATER BIOS, V3, P141
   SCHARTONKERSTEN T, 1995, J LEUKOCYTE BIOL, V57, P515
   SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y
   SCOTT P, 1991, J IMMUNOL, V147, P3149
   Singh AK, 2008, DIG J NANOMATER BIOS, V3, P135
   Singh M, 2008, DIG J NANOMATER BIOS, V3, P115
   Singh S, 2008, DIG J NANOMATER BIOS, V3, P75
   Solano-Gallego L, 2000, VET PARASITOL, V90, P37, DOI 10.1016/S0304-4017(00)00223-5
   Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100
   Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x
   Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121
   *WHO, 1999, WKLY EPIDEMIOL REC, V74, P365
   *WHO, 1998, TDR NEWS, V34, P1
   *WHO UN DEV PROGR, 1990, TDR NEWS, V34, P1
NR 36
TC 6
Z9 6
U1 0
U2 5
PU INST MATERIALS PHYSICS
PI BUCHAREST
PA NATL INST R&D MATERIALS PHYSICS, ATOMISTILOR STR, 105 BIS, BUCHAREST,
   077125, ROMANIA
SN 1842-3582
J9 DIG J NANOMATER BIOS
JI Dig. J. Nanomater. Biostruct.
PD SEP
PY 2009
VL 4
IS 3
BP 495
EP 499
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 520AJ
UT WOS:000271811800015
DA 2018-01-05
ER

PT J
AU Liu, YY
   Yang, DY
   Yu, T
   Jiang, XY
AF Liu, Yingyi
   Yang, Dayong
   Yu, Tao
   Jiang, Xingyu
TI Incorporation of electrospun nanofibrous PVDF membranes into a
   microfluidic chip assembled by PDMS and scotch tape for immunoassays
SO ELECTROPHORESIS
LA English
DT Article
DE Cross-array; Electrospinning; Immunoassay; Microfluidics; PVDF
ID HIV-INFECTION; POLY(DIMETHYLSILOXANE); TUBERCULOSIS; FABRICATION;
   SUBSTRATE; DIAGNOSIS; SETTINGS; CHANNELS; CELL
AB This paper demonstrates a microfluidic chip for multiple immunoassays on electrospun (ES) nanofibrous membranes made of PVDF. This microchip enables the detection of multiple pairs of protein-protein interactions in one experiment by crossing parallel arrays of microchannels. This chip uses ESPVDF membrane with high specific surface area as the substrate to adsorb protein for immobilized immunoassays so that increased levels of protein adsorption may lower the LOD in immunoassays. We employ a simple and effective method for chip assembly by scotch tape to incorporate the ESPVDF membrane into the microchip. We believe that the present work will facilitate the development of methods for the on-site diagnosis of diseases whose detection is based on antigen-antibody recognition, and improve the efficiencies of certain experiments that need to identify tens to hundreds of protein-protein interactions with relatively low cost in the future.
C1 [Liu, Yingyi; Yang, Dayong; Yu, Tao; Jiang, Xingyu] Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafe, Beijing 100190, Peoples R China.
   [Yang, Dayong] Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, Suzhou, Peoples R China.
RP Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafe, 11 Beiyitiao, Beijing 100190, Peoples R China.
EM xingyujiang@nanoctr.cn
RI Yang, Dayong/E-2966-2010
OI Yang, Dayong/0000-0002-2634-9281; Jiang, Xingyu/0000-0002-5008-4703
FU Ministry of Science and Technology [2007CB714502, 2006CB705600,
   2006AA03Z323, 2009CB930001]; Chinese Academy of Sciences; National
   Natural Science Foundation of China [20605006, 20890020, 90813032]
FX The authors thank the financial support provided by the Ministry of
   Science and Technology (2007CB714502, 2006CB705600, 2006AA03Z323,
   2009CB930001), the Chinese Academy of Sciences, and the National Natural
   Science Foundation of China (20605006, 20890020, 90813032).
CR Bernard A, 2001, ANAL CHEM, V73, P8, DOI 10.1021/ac0008845
   Dertinger SKW, 2002, P NATL ACAD SCI USA, V99, P12542, DOI 10.1073/pnas.192457199
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Gu W, 2004, P NATL ACAD SCI USA, V101, P15861, DOI 10.1073/pnas.0404353101
   Huang B, 2007, SCIENCE, V315, P81, DOI 10.1126/science.1133992
   Jiang L, 2004, ANGEW CHEM INT EDIT, V43, P4338, DOI 10.1002/anie.200460333
   Jiang XY, 2003, J AM CHEM SOC, V125, P5294, DOI 10.1021/ja034566
   Juncker D, 2005, NAT MATER, V4, P622, DOI 10.1038/nmat1435
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Li Y, 2007, ANGEW CHEM INT EDIT, V46, P1094, DOI 10.1002/anie.200603844
   Li ZY, 2008, J AM CHEM SOC, V130, P5036, DOI 10.1021/ja800176s
   McDonald JC, 2002, ACCOUNTS CHEM RES, V35, P491, DOI 10.1021/ar010110q
   McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.3.CO;2-3
   Nie HR, 2008, BIOMACROMOLECULES, V9, P1362, DOI 10.1021/bm701349j
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Sun K, 2008, LAB CHIP, V8, P1536, DOI 10.1039/b806140h
   Swaminathan S, 2008, J BIOSCIENCES, V33, P527, DOI 10.1007/s12038-008-0071-2
   UNAIDS, 2008, 2008 REP GLOB AIDS E
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   World Health Organization, 2009, GLOB TUB CONTR 2009
   Wolbers M, 2008, HIV MED, V9, P397, DOI 10.1111/j.1468-1293.2008.00566.x
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153                                                 
   Yang DY, 2007, ADV MATER, V19, P3702, DOI 10.1002/adma.200700171
   Yang DY, 2008, ADV MATER, V20, P4770, DOI 10.1002/adma.200801302
   YANG DY, 2009, CHINESE SCI BULL, V9, P1161
   Zhang CX, 2005, EUR POLYM J, V41, P423, DOI 10.1016/j.europolymj.2004.10.027
   Zheng JF, 2007, MACROMOL RAPID COMM, V28, P2159, DOI 10.1002/marc.200700544
   Zhou XC, 2008, MACROMOL RAPID COMM, V29, P1363, DOI 10.1002/marc.200800229
NR 29
TC 38
Z9 40
U1 8
U2 79
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0173-0835
J9 ELECTROPHORESIS
JI Electrophoresis
PD SEP
PY 2009
VL 30
IS 18
BP 3269
EP 3275
DI 10.1002/elps.200900128
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 502GZ
UT WOS:000270446200022
PM 19722208
DA 2018-01-05
ER

PT J
AU Peetla, C
   Rao, KS
   Labhasetwar, V
AF Peetla, Chiranjeevi
   Rao, Kavitha S.
   Labhasetwar, Vinod
TI Relevance of Biophysical Interactions of Nanoparticles with a Model
   Membrane in Predicting Cellular Uptake: Study with TAT
   Peptide-Conjugated Nanoparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
CT NanoMedicine Summit on Nanoparticles for Imaging, Diagnosis and
   Therapeutics
CY SEP 25-26, 2008-2009
CL Cleveland, OH
SP Case Western Reserve Univ, Cleveland Clinic
DE Drug delivery; nanocarriers; cell-penetrating peptides; polymers;
   nanotoxicity
ID PROTEIN-TRANSDUCTION-DOMAINS; HYDROPHOBIC INTERACTIONS; PENETRATING
   PEPTIDES; CARGO DELIVERY; LIPID-BILAYERS; DRUG-DELIVERY; NUCLEIC-ACIDS;
   HIV-1; MECHANISM; CELLS
AB The aim of the study was to test the hypothesis that the biophysical interactions of the transactivating transcriptor (TAT) peptide-conjugated nanoparticles (NIPS) with a model cell membrane could predict the cellular uptake of the encapsulated therapeutic agent. To test the above hypothesis, the biophysical interactions of ritonavir-loaded poly(L-lactide) nanoparticles (RNPs), conjugated to either a TAT peptide (TAT-RNPs) or a scrambled TAT peptide (sc-TAT-RNPs), were studied with an endothelial cell model membrane (EMM) using a Langmuir film balance, and the corresponding human vascular endothelial cells (HUVECs) were used to study the uptake of the encapsulated therapeutic. Biophysical interactions were determined from the changes in surface pressure (SIP) of the EMM as a function of time following interaction with NIPS, and the compression isotherm (pi-A) of the EMM lipid mixture in the presence of NIPS. In addition, the EMMs were transferred onto a silicon substrate following interactions with NPs using the Langmuir-Schaeffer (LS) technique. The transferred LS films were imaged by atomic force microscopy (AFM) to determine the changes in lipid morphology and to characterize the NP-membrane interactions, TAT-RNPs showed an increase in SP of the EMM, which was dependent upon the amount of the peptide bound to NPs and the concentration of NIPS, whereas sc-TAT-RNPs and RNPs did not show any significant change in SP. The isotherm experiment showed a shift toward higher mean molecular area (mmA) in the presence of TAT-RNPs, indicating their interactions with the lipids of the EMM, whereas sc-TAT-RNPs and RNPs did not show any significant change. The AFM images showed condensation of the lipids following interaction with TAT-RNPs, indicating their penetration into the EMM, whereas RNPs did not cause any change. Surface analysis and 3-D AFM images of the EMM further confirmed penetration of TAT-RNPs into the EMM, whereas RNPs were seen anchored loosely to the membrane, and were significantly less in number than TAT-RNPs. We speculate that hydrophobic tyrosine of the TAT that forms the NP-interface drives the initial interactions of TAT-RNPs with the EMM, followed by electrostatic interactions with the anionic phospholipids of the membrane. In the Case of sc-TAT-RNPs, hydrophilic arginine forms the NP-interface that does not interact with the EMM, despite having the similar cationic charge on these NPs as TAT-RNPs. TAT peptide alone did not show any change in SIP, suggesting that the interaction occurs when the peptide is conjugated to a carder system. HUVECs showed higher uptake of the drug with TAT-RNPs as compared to that with sc-TAT-RNPs or RNPs, suggesting that the biophysical interactions of NPs with cell membrane lipids play a role in cellular internalization of NIPS. In conclusion, TAT peptide sequence and the amount of TAT conjugated to NPs significantly affect the biophysical interactions of NIPS with the EMM, and these interactions correlate with the cellular delivery of the encapsulated drug. Biophysical interactions with a model membrane thus could be effectively used in developing efficient functionalized nanocarrier systems for drug delivery applications.
C1 [Peetla, Chiranjeevi; Rao, Kavitha S.; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA.
RP Labhasetwar, V (reprint author), Cleveland Clin, Dept Biomed Engn ND 20, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
RI Peetla, Chiranjeevi/E-4916-2010
OI Peetla, Chiranjeevi/0000-0002-9471-7322
FU NIMH NIH HHS [R21 MH067525, R21 MH067525-02, R21 MH06 7525]; NIBIB NIH
   HHS [R01 EB003975, 1R01 EB 003975, R01 EB003975-05]
CR Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Alsenz J, 1998, PHARMACEUT RES, V15, P423, DOI 10.1023/A:1011924314899
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   CHEN LL, 1995, ANAL BIOCHEM, V227, P168, DOI 10.1006/abio.1995.1267
   Christian NA, 2007, BIOCONJUGATE CHEM, V18, P31, DOI 10.1021/bc0601267
   Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f
   Dennison SR, 2007, BIOCHEM BIOPH RES CO, V363, P178, DOI 10.1016/j.bbrc.2007.08.162
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Deshayes Sebastien, 2007, V386, P299, DOI 10.1007/978-1-59745-430-8_11
   Eum Won Sik, 2005, Mol Cells, V19, P191
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Leray C, 1997, J CHROMATOGR B, V696, P33, DOI 10.1016/S0378-4347(97)00230-2
   MATHEW CJ, 1995, ANAL CHEM, V67, P1210
   Nagy IB, 2000, BIOCONJUGATE CHEM, V11, P30, DOI 10.1021/bc9900385
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Peetla C, 2008, MOL PHARM, V5, P418, DOI 10.1021/mp700140a
   Peetla C, 2009, LANGMUIR, V25, P2369, DOI 10.1021/la803361y
   Qaddoumi MG, 2004, PHARM RES, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76                                              
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Ren L, 2001, J SOL-GEL SCI TECHN, V21, P115, DOI 10.1023/A:1011226104173                                                         
   Ryu J, 2003, MOL CELLS, V16, P385
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Tiriveedhi V, 2007, BIOCHEMISTRY-US, V46, P3888, DOI 10.1021/bi602527t
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018
   Van Mau N, 1999, J MEMBRANE BIOL, V167, P241
   Vasir JK, 2008, BIOMATERIALS, V29, P4244, DOI 10.1016/j.biomaterials.2008.07.020
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5                                                   
   Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c
   Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842
   Yandek LE, 2007, BIOPHYS J, V92, P2434, DOI 10.1529/biophysj.106.100198
   Yezhelyev M, 2009, NANOMEDICINE-UK, V4, P83, DOI 10.2217/17435889.4.1.83
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 43
TC 31
Z9 31
U1 0
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP-OCT
PY 2009
VL 6
IS 5
BP 1311
EP 1320
DI 10.1021/mp900011h
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 501BR
UT WOS:000270354400007
PM 19243206
OA green_accepted
DA 2018-01-05
ER

PT J
AU Xu, WF
   Santini, PA
   Sullivan, JS
   He, B
   Shan, MM
   Ball, SC
   Dyer, WB
   Ketas, TJ
   Chadburn, A
   Cohen-Gould, L
   Knowles, DM
   Chiu, A
   Sanders, RW
   Chen, K
   Cerutti, A
AF Xu, Weifeng
   Santini, Paul A.
   Sullivan, John S.
   He, Bing
   Shan, Meimei
   Ball, Susan C.
   Dyer, Wayne B.
   Ketas, Thomas J.
   Chadburn, Amy
   Cohen-Gould, Leona
   Knowles, Daniel M.
   Chiu, April
   Sanders, Rogier W.
   Chen, Kang
   Cerutti, Andrea
TI HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic
   and intestinal B cells via long-range intercellular conduits
SO NATURE IMMUNOLOGY
LA English
DT Article
ID CLASS-SWITCH RECOMBINATION; IMMUNOLOGICAL SYNAPSE; TUNNELING
   NANOTUBULES; EFFECTOR FUNCTIONS; DILEUCINE MOTIF; CD4 ENDOCYTOSIS;
   DOWN-REGULATION; LYMPH-NODES; T-CELLS; NEF
AB Contact-dependent communication between immune cells generates protection but also facilitates viral spread. Here we found that macrophages formed long-range actin-propelled conduits in response to negative factor (Nef), a human immunodeficiency virus type 1 (HIV-1) protein with immunosuppressive functions. Conduits attenuated immunoglobulin G2 (IgG2) and IgA class switching in systemic and intestinal lymphoid follicles by shuttling Nef from infected macrophages to B cells through a guanine-exchange factor-dependent pathway involving the amino-terminal anchor, central core and carboxy-terminal flexible loop of Nef. By showing stronger virus-specific IgG2 and IgA responses in patients with Nef-deficient virions, our data suggest that HIV-1 exploits intercellular 'highways' as a 'Trojan horse' to deliver Nef to B cells and evade humoral immunity systemically and at mucosal sites of entry.
C1 [Xu, Weifeng; Santini, Paul A.; He, Bing; Knowles, Daniel M.; Chen, Kang; Cerutti, Andrea] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA.
   [Santini, Paul A.; Chen, Kang; Cerutti, Andrea] Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA.
   [Sullivan, John S.; Dyer, Wayne B.] Univ Sydney, Fac Med, Cent Clin Sch, Viral Immunol Lab,Australian Red Cross Blood Serv, Sydney, NSW 2006, Australia.
   [Shan, Meimei] Mt Sinai Sch Med, Dept Genet, New York, NY USA.
   [Ball, Susan C.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.
   [Ketas, Thomas J.] Cornell Univ, Weill Med Coll, Dept Immunol & Microbiol, New York, NY 10021 USA.
   [Chadburn, Amy; Chiu, April] Northwestern Univ, Feinberg Sch Med, Dept Pathol & Lab Med, Chicago, IL 60611 USA.
   [Cohen-Gould, Leona] Cornell Univ, Weill Med Coll, Electron Microscopy & Histol Core Facil, New York, NY 10021 USA.
   [Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.
RP Cerutti, A (reprint author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA.
EM acerutti@med.cornell.edu
FU US National Institutes of Health [AI07621, R01 AI057653, R01
   AI057653-S1, R01 AI074378]; Irma T. Hirschl Charitable Trust; Cornell
   Comprehensive Cancer Center; Ministerio de Ciencia e Innovacion;
   Desarollo e Innovacion Tecnologica [SAF 2008-02725]; Cancer Research
   Institute
FX We thank M. Stevenson (University of Massachusetts Medical School) for
   the Delta Nef-ADA plasmid; B. Berkhout (Academic Medical Center) for the
   Delta Nef-LAI plasmid; S. J. Burakoff (New York University) for the
   Nef-dsRED vector; M. G. Caron, (Duke University) for dominant negative
   dynamin-K44A and beta-arrestin-2-V54D; J. G. Donaldson (National
   Institutes of Health) for dominant negative ARF6-T27N; Y. Zheng
   (Cincinnati Children's Hospital Medical Center) for dominant negative
   RhoA-N19, Cdc42-N17 and Rac1-N17; P. Marignani (Dalhousie University)
   for dominant negative Vav2-R/S; J. P. Moore (Weill Medical College of
   Cornell University) for the Delta Nef-HIV-1-expressing NL4-3/9-7-dsRed
   plasmid; A. Pernis (Columbia University) for reagents; and all reagent
   donors for discussions. Supported by the US National Institutes of
   Health (AI07621 to W. X.; and R01 AI057653, R01 AI057653-S1 and R01
   AI074378 to A. Ce.), The Irma T. Hirschl Charitable Trust (to A. Ce.),
   the Cornell Comprehensive Cancer Center (Chronic Lymphocytic Leukemia
   Research Center Award; to A. Ce.), the Ministerio de Ciencia e
   Innovacion (Plan Nacional de Investigacion Cientifica, Desarollo e
   Innovacion Tecnologica SAF 2008-02725 to A. Ce.) and the Cancer Research
   Institute (to P. A. S.).
CR AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3
   Begum NA, 2007, J BIOL CHEM, V282, P731, DOI 10.1074/jbc.M607439200
   Binley JM, 1997, J VIROL, V71, P2799
   Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324                                                         
   Costa LJ, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-33
   Davis DM, 2007, NAT REV IMMUNOL, V7, P238, DOI 10.1038/nri2020
   De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375
   Dyer WB, 1999, J VIROL, V73, P436
   Fackler OT, 2007, NAT REV IMMUNOL, V7, P310, DOI 10.1038/nri2041
   Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8                                                   
   Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9                                                    
   Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0
   Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964                                                        
   Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777
   Hart M, 2007, J IMMUNOL, V178, P8212, DOI 10.4049/jimmunol.178.12.8212                                                    
   He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014
   He B, 2006, J IMMUNOL, V176, P3931, DOI 10.4049/jimmunol.176.7.3931                                                     
   Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357
   LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803
   Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1039/ni829
   Mann J, 2005, J IMMUNOL, V175, P6560, DOI 10.4049/jimmunol.175.10.6560                                                    
   Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320                                                                  
   Mestecky J, 2004, AIDS RES HUM RETROV, V20, P972, DOI 10.1089/0889222042222791
   Moir S, 2003, P NATL ACAD SCI USA, V100, P6057, DOI 10.1073/pnas.0730819100
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524
   Muratori C, 2007, J VIROL, V81, P9078, DOI 10.1128/JVI.00675-07
   Peng B, 2001, IMMUNOL LETT, V78, P195, DOI 10.1016/S0165-2478(01)00250-4
   Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998
   Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472
   Popovic M, 2005, P NATL ACAD SCI USA, V102, P14807, DOI 10.1073/pnas.0506857102
   Poudrier J, 2001, IMMUNITY, V15, P173, DOI 10.1016/S1074-7613(01)00177-7                                                   
   Prost S, 2008, J CLIN INVEST, V118, P1765, DOI 10.1172/JCI33037
   Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302
   Regulier EG, 2005, JAIDS-J ACQ IMM DEF, V40, P1
   Rodriguez B, 2003, AIDS, V17, P1983, DOI 10.1097/01.aids.0000076325.42412.a1
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Santa-Marta M, 2007, MOL IMMUNOL, V44, P583, DOI 10.1016/j.molimm.2006.02.005
   Schafer F, 2002, GUT, V50, P608, DOI 10.1136/gut.50.5.608
   Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005
   Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Swingler S, 2008, CELL HOST MICROBE, V4, P63, DOI 10.1016/j.chom.2008.05.015
   Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016
   Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Xu WF, 2007, NAT IMMUNOL, V8, P294, DOI 10.1038/ni1434
NR 56
TC 151
Z9 155
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD SEP
PY 2009
VL 10
IS 9
BP 1008
EP U106
DI 10.1038/ni.1753
PG 12
WC Immunology
SC Immunology
GA 485KV
UT WOS:000269120900015
PM 19648924
OA green_accepted
DA 2018-01-05
ER

PT J
AU Thiel, KW
   Giangrande, PH
AF Thiel, Kristina W.
   Giangrande, Paloma H.
TI Therapeutic Applications of DNA and RNA Aptamers
SO OLIGONUCLEOTIDES
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; TARGETED DRUG-DELIVERY; HIV-1
   REVERSE-TRANSCRIPTASE; PLGA-PEG NANOPARTICLES; PROSTATE-CANCER CELLS;
   VON-WILLEBRAND-FACTOR; FACTOR-IXA ACTIVITY; IN-VITRO SELECTION; VEIN
   GRAFT FAILURE
AB Structured single-stranded nucleic acids, or aptamers, bind target molecules with high affinity and specificity, which translates into unique therapeutic possibilities. Currently, aptamers can be identified to most proteins, including blood-clotting factors, cell-surface receptors, and transcription factors. Chemical modifications to the oligonucleotides enhance their pharmacokinetics and pharmacodynamics, thus extending their therapeutic potential. Several aptamers have entered the clinical pipeline for applications and diseases such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer. Furthermore, the functional repertoire of aptamers has expanded with the descriptions of multivalent agonistic aptamers and aptamers-siRNA chimeras. This review highlights those aptamers and aptamer-based approaches with particular likelihood of achieving therapeutic application.
C1 [Thiel, Kristina W.; Giangrande, Paloma H.] Univ Iowa, Dept Internal Med, Dept Radiat Oncol, Iowa City, IA 52242 USA.
   [Giangrande, Paloma H.] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA.
RP Giangrande, PH (reprint author), Univ Iowa, Dept Internal Med, Dept Radiat Oncol, 285 Newton Rd,5202 MERF, Iowa City, IA 52242 USA.
EM paloma-giangrande@uiowa.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
FU NCI NIH HHS [R01 CA138503]; NHLBI NIH HHS [T32 HL007344]
CR Adler A, 2008, COMB CHEM HIGH T SCR, V11, P16
   Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Alexander JH, 2005, AM HEART J, V150, P643, DOI 10.1016/j.ahj.2005.05.021
   Alexander JH, 2005, JAMA-J AM MED ASSOC, V294, P2446
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Bassett SE, 2004, BIOCHEMISTRY-US, V43, P9105, DOI 10.1021/bi036220h
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   Bock C, 2004, PROTEOMICS, V4, P609, DOI 10.1002/pmic.200300631
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Boomer RM, 2005, OLIGONUCLEOTIDES, V15, P183, DOI 10.1089/oli.2005.15.183
   Boucard D, 2006, BIOCHEMISTRY-US, V45, P1518, DOI 10.1021/bi051187f
   Browning CM, 1999, J VIROL, V73, P5191
   Bunka DHJ, 2007, J BIOL CHEM, V282, P34500, DOI 10.1074/jbc.M703679200
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Cassiday LA, 2003, P NATL ACAD SCI USA, V100, P3930, DOI 10.1073/pnas.0736013100
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Chan MY, 2008, J THROMB HAEMOST, V6, P789, DOI 10.1111/j.1538-7836.2008.02932.x
   Chan MY, 2008, CIRCULATION, V117, P2865, DOI 10.1161/CIRCULATIONAHA.107.745687
   Chelliserrykattil J, 2004, NAT BIOTECHNOL, V22, P1155, DOI 10.1038/nbt1001
   Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100
   Chen CHB, 2008, P NATL ACAD SCI USA, V105, P15908, DOI 10.1073/pnas.0808360105
   Chen F, 2007, BIOCHEM BIOPH RES CO, V357, P743, DOI 10.1016/j.bbrc.2007.04.007
   Cheng CS, 2008, BIOCHEM BIOPH RES CO, V366, P670, DOI 10.1016/j.bbrc.2007.11.183
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Collett JR, 2005, METHODS, V37, P4, DOI 10.1016/j.ymeth.2005.05.009
   Conte MS, 2006, J VASC SURG, V43, P742, DOI 10.1016/j.jvs.2005.12.058
   Conte MS, 2006, J VASC SURG, V43, P751
   Cox JC, 1998, BIOTECHNOL PROGR, V14, P845, DOI 10.1021/bp980097h
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Dapic V, 2002, BIOCHEMISTRY-US, V41, P3676, DOI 10.1021/bi0119520
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105
   Dollins CM, 2008, CHEM BIOL, V15, P675, DOI 10.1016/j.chembiol.2008.05.016
   Dyke CK, 2006, CIRCULATION, V114, P2490, DOI 10.1161/CIRUCLATIONAHA.106.668434
   Ehsan A, 2001, J THORAC CARDIOV SUR, V121, P714, DOI 10.1067/mtc.2001.111204
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Eulberg D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni044
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Giangrande PH, 2007, P NATL ACAD SCI USA, V104, P12988, DOI 10.1073/pnas.0704754104
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   Healy JM, 2004, PHARM RES, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006
   Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386
   Jason TLH, 2004, TOXICOL APPL PHARM, V201, P66, DOI 10.1016/j.taap.2004.04.017
   Keefe AD, 2008, CURR OPIN CHEM BIOL, V12, P448, DOI 10.1016/j.cbpa.2008.06.028
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kim Y, 2008, P NATL ACAD SCI USA, V105, P5664, DOI 10.1073/pnas.0711803105
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Kohn DB, 1999, BLOOD, V94, P368
   Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x                                                               
   LEE TC, 1992, NEW BIOL, V4, P66
   Li N, 2009, J PROTEOME RES, V8, P2438, DOI 10.1021/pr801048z
   Li N, 2008, NUCLEIC ACIDS RES, V36, P6739, DOI 10.1093/nar/gkn775
   Lou XH, 2009, P NATL ACAD SCI USA, V106, P2989, DOI 10.1073/pnas.0813135106
   Lupold SE, 2002, CANCER RES, V62, P4029
   Manoharan M, 2002, ANTISENSE NUCLEIC A, V12, P103, DOI 10.1089/108729002760070849                                                      
   Matteucci M, 1997, CIBA F SYMP, V209, P5
   Mayer G, 2009, CHEMBIOCHEM, V10, P654, DOI 10.1002/cbic.200800814
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365
   Mendonsa SD, 2004, J AM CHEM SOC, V126, P20, DOI 10.1021/ja037832s
   Michienzi A, 2002, P NATL ACAD SCI USA, V99, P14047, DOI 10.1073/pnas.212229599
   Muller J, 2007, CHEMBIOCHEM, V8, P2223, DOI 10.1002/cbic.200700535
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ohuchi SP, 2006, BIOCHIMIE, V88, P897, DOI 10.1016/j.biochi.2006.02.004
   Oney S, 2007, OLIGONUCLEOTIDES, V17, P265, DOI 10.1089/oli.2007.0089
   Pestourie C, 2006, OLIGONUCLEOTIDES, V16, P323, DOI 10.1089/oli.2006.16.323                                                         
   PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967
   Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C
   Rentmeister A, 2006, RNA, V12, P1650, DOI 10.1261/rna.126306
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   Rusconi CP, 2000, THROMB HAEMOSTASIS, V84, P841
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   Santulli-Marotto S, 2003, CANCER RES, V63, P7483
   Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0893
   Shamah SM, 2008, ACCOUNTS CHEM RES, V41, P130, DOI 10.1021/ar700142z
   Shangguan DH, 2007, CLIN CHEM, V53, P1153, DOI 10.1373/clinchem.2006.083246
   Shi H, 1999, P NATL ACAD SCI USA, V96, P10033, DOI 10.1073/pnas.96.18.10033
   Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723
   SULLENGER BA, 1991, J VIROL, V65, P6811
   SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N
   Tang ZW, 2007, ANAL CHEM, V79, P4900, DOI 10.1021/ac070189y
   Tian L, 2009, BIOCHEMISTRY-US, V48, P264, DOI 10.1021/bi801630b
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vento MT, 2008, MOL CANCER THER, V7, P3381, DOI 10.1158/1535-7163.MCT-08-0580
   Weiss S, 1997, J VIROL, V71, P8790
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Wurster SE, 2008, RNA, V14, P1037, DOI 10.1261/rna.878908
   Yamamoto R, 2000, GENES CELLS, V5, P371, DOI 10.1046/j.1365-2443.2000.00330.x                                                
   Ylera F, 2002, BIOCHEM BIOPH RES CO, V290, P1583, DOI 10.1006/bbrc.2002.6354
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
NR 116
TC 90
Z9 95
U1 1
U2 47
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1545-4576
J9 OLIGONUCLEOTIDES
JI Oligonucleotides
PD SEP
PY 2009
VL 19
IS 3
BP 209
EP 222
DI 10.1089/oli.2009.0199
PG 14
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 506OU
UT WOS:000270785700001
PM 19653880
DA 2018-01-05
ER

PT J
AU Bennett, AE
   Narayan, K
   Shi, D
   Hartnell, LM
   Gousset, K
   He, HF
   Lowekamp, BC
   Yoo, TS
   Bliss, D
   Freed, EO
   Subramaniam, S
AF Bennett, Adam E.
   Narayan, Kedar
   Shi, Dan
   Hartnell, Lisa M.
   Gousset, Karine
   He, Haifeng
   Lowekamp, Bradley C.
   Yoo, Terry S.
   Bliss, Donald
   Freed, Eric O.
   Subramaniam, Sriram
TI Ion-Abrasion Scanning Electron Microscopy Reveals Surface-Connected
   Tubular Conduits in HIV-Infected Macrophages
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA-MEMBRANE; IN-VITRO; CELL; TYPE-1;
   RESERVOIR; TOMOGRAPHY; GENERATION; ENDOSOMES; LYSOSOMES
AB HIV-1-containing internal compartments are readily detected in images of thin sections from infected cells using conventional transmission electron microscopy, but the origin, connectivity, and 3D distribution of these compartments has remained controversial. Here, we report the 3D distribution of viruses in HIV-1-infected primary human macrophages using cryo-electron tomography and ion-abrasion scanning electron microscopy (IA-SEM), a recently developed approach for nanoscale 3D imaging of whole cells. Using IA-SEM, we show the presence of an extensive network of HIV-1-containing tubular compartments in infected macrophages, with diameters of,150-200 nm, and lengths of up to,5 mm that extend to the cell surface from vesicular compartments that contain assembling HIV-1 virions. These types of surface-connected tubular compartments are not observed in T cells infected with the 29/31 KE Gag-matrix mutant where the virus is targeted to multi-vesicular bodies and released into the extracellular medium. IA-SEM imaging also allows visualization of large sheet-like structures that extend outward from the surfaces of macrophages, which may bend and fold back to allow continual creation of viral compartments and virion-lined channels. This potential mechanism for efficient virus trafficking between the cell surface and interior may represent a subversion of pre-existing vesicular machinery for antigen capture, processing, sequestration, and presentation.
C1 [Bennett, Adam E.; Narayan, Kedar; Shi, Dan; Hartnell, Lisa M.; Subramaniam, Sriram] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Gousset, Karine; Freed, Eric O.] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA.
   [He, Haifeng] FEI Co, Hillsboro, OR USA.
   [Lowekamp, Bradley C.; Yoo, Terry S.; Bliss, Donald] NIH, Natl Lib Med, Bethesda, MD 20892 USA.
RP Bennett, AE (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM ss1@nih.gov
OI Gousset, Karine/0000-0002-0988-2332
FU National Cancer Institute; NIH
FX This work was entirely supported by funds from the intramural program of
   the National Cancer Institute, NIH. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aquaro S, 2002, J MED VIROL, V68, P479, DOI 10.1002/jmv.10245
   Brown A, 2006, J LEUKOCYTE BIOL, V80, P1127, DOI 10.1189/jlb.0206126
   Carr JM, 1999, VIROLOGY, V265, P319, DOI 10.1006/viro.1999.0047                                                          
   Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075
   FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70
   Gousset K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000015
   Heymann JAW, 2006, J STRUCT BIOL, V155, P63, DOI 10.1016/j.jsb.2006.03.006
   Heymann JAW, 2009, J STRUCT BIOL, V166, P1, DOI 10.1016/j.jsb.2008.11.005
   Hildebrand M, 2009, J STRUCT BIOL, V166, P316, DOI 10.1016/j.jsb.2009.02.014
   Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798
   Joshi A, 2009, J VIROL, V83, P5375, DOI 10.1128/JVI.00109-09
   Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435
   Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998
   Mastronarde DN, 1997, J STRUCT BIOL, V120, P343, DOI 10.1006/jsbi.1997.3919
   MCKEEVER PE, 1977, J HISTOCHEM CYTOCHEM, V25, P1063, DOI 10.1177/25.9.333019                                                             
   Murk JLAN, 2003, J MICROSC-OXFORD, V212, P81, DOI 10.1046/j.1365-2818.2003.01238.x
   NARASIMHA R, 2008, PATTERN RECOGN, V42, P1067
   Ogata T, 1997, HISTOL HISTOPATHOL, V12, P739
   Orenstein JM, 2000, ULTRASTRUCT PATHOL, V24, P67, DOI 10.1080/01913120050118530                                                       
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Sharova N, 2005, EMBO J, V24, P2481, DOI 10.1038/sj.emboj.7600707
   Smith PD, 2003, J LEUKOCYTE BIOL, V74, P642, DOI 10.1189/jlb.0503219
   STRECK RJ, 1990, J LEUKOCYTE BIOL, V48, P237
   Voronov I, 1998, J BIOMED MATER RES, V39, P40, DOI 10.1002/(SICI)1097-4636(199801)39:1<40::AID-JBM6>3.3.CO;2-Y
   Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036
   YEE JK, 1994, METHOD CELL BIOL, V43, P99
NR 30
TC 93
Z9 94
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2009
VL 5
IS 9
AR e1000591
DI 10.1371/journal.ppat.1000591
PG 10
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 506VO
UT WOS:000270804900007
PM 19779568
OA gold
DA 2018-01-05
ER

PT J
AU Seale-Goldsmith, MM
   Leary, JF
AF Seale-Goldsmith, Mary-Margaret
   Leary, James F.
TI Nanobiosystems
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID WALLED CARBON NANOTUBES; SEMICONDUCTOR QUANTUM DOTS; IRON-OXIDE
   NANOPARTICLES; IN-VIVO; MAGNETIC NANOPARTICLES; GENE DELIVERY; MOLECULAR
   BIOSENSORS; GOLD NANOPARTICLES; OPTICAL-PROPERTIES; MAMMALIAN-CELLS
AB 'Nanobiosystems' is a relatively new term describing objects in the size range below 150 nm and having structures or functions that link to biological functions. Key features are that these nanosized objects typically self-assemble, are not capable of self-replication, and have functions that take advantage of its size. Nanobiosystems can be made entirely of biological or organic molecules that are organized into nanoparticles (e.g., liposomes, dendrimers) or be totally inorganic (with the exception of surface coatings used for biocompatibility) nanoparticles (e.g., gold, iron oxide, quantum dot nanocrystals). More complex nanobiosystems are inorganic/biologic hybrid composites that may include complex multilayered structures with targeting molecules (e.g., peptides, antibodies, aptamers), cell entry-promoting molecules (e.g., HIV-tat peptide sequence), drugs (small molecules), genes (therapeutic genes, reporter genes), and core nanomaterials (e.g., gold, quantum dot, iron oxide) that give the nanobiosystems sometimes unique detection capabilities by a variety of optical and non-optical modalities (fluorescence, surface plasmon resonance, magnetic resonance imaging). (C) 2009 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2009 1 553-567
C1 [Leary, James F.] Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Leary, James F.] Purdue Univ, Weldon Sch Biomed Engn, Bindley Biosci Ctr, W Lafayette, IN 47907 USA.
   [Leary, James F.] Purdue Univ, Birck Nanotechnol Ctr, W Lafayette, IN 47907 USA.
RP Leary, JF (reprint author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
EM jfleary@purdue.edu
RI Leary, James/H-8554-2014
OI Leary, James/0000-0002-0250-4427
CR Averitt RD, 1999, J OPT SOC AM B, V16, P1824, DOI 10.1364/JOSAB.16.001824
   Awasthi VD, 2003, INT J PHARM, V253, P121, DOI 10.1016/S0378-5173(02)00703-2
   Berry CC, 2004, BIOMATERIALS, V25, P5405, DOI 10.1016/j.biomaterials.2003.12.046
   Bianco A, 2003, ADV MATER, V15, P1765, DOI 10.1002/adma.200301646
   Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176                                                          
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chen QR, 1999, CANCER RES, V59, P3308
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   Du FY, 2008, BIOSENS BIOELECTRON, V24, P415, DOI 10.1016/j.bios.2008.04.020
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Esumi K, 2004, LANGMUIR, V20, P2536, DOI 10.1021/la036299r
   Falciani C, 2007, MOL CANCER THER, V6, P2441, DOI 10.1158/1535-7163.MCT-07-0164
   Fischer HC, 2007, CURR OPIN BIOTECH, V18, P565, DOI 10.1016/j.copbio.2007.11.008
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Guo SC, 2005, HUM GENE THER, V16, P1097, DOI 10.1089/hum.2005.16.1097
   HAGLUND E, 2008, P SOC PHOTO-OPT INS, V6866, pS1
   Hahm J, 2004, NANO LETT, V4, P51, DOI 10.1021/nl034853b
   Harrell CC, 2004, J AM CHEM SOC, V126, P15646, DOI 10.1021/ja044948v
   Hoeprich S, 2002, J BIOL CHEM, V277, P20794, DOI 10.1074/jbc.M112061200
   Inoue K, 2000, PROG POLYM SCI, V25, P453, DOI 10.1016/S0079-6700(00)00011-3                                                   
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   Jeng HA, 2006, J ENVIRON SCI HEAL A, V41, P2699, DOI 10.1080/10934520600966177
   JOHNSON SM, 1971, BIOCHIM BIOPHYS ACTA, V233, P820, DOI 10.1016/0005-2736(71)90184-2
   Jun KW, 2006, MATER CHEM PHYS, V96, P494, DOI 10.1016/j.matchemphys.2005.07.041
   Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m
   Kohler N, 2006, SMALL, V2, P785, DOI 10.1002/smll.200600009
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li J, 1999, APPL PHYS LETT, V75, P367, DOI 10.1063/1.124377
   Li JWJ, 2002, NANO LETT, V2, P315, DOI [10.1021/nl015713+, 10.1021/n1015713+]
   Liu Z, 2008, P NATL ACAD SCI USA, V105, P1410, DOI 10.1073/pnas.0707654105
   Loo C, 2005, OPT LETT, V30, P1012, DOI 10.1364/OL.30.001012
   Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s
   Lovric J, 2005, CHEM BIOL, V12, P1227, DOI 10.1016/j.chembiol.2005.09.008
   Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Morishita N, 2005, BIOCHEM BIOPH RES CO, V334, P1121, DOI 10.1016/j.bbrc.2005.06.204
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nigavekar SS, 2004, PHARM RES, V21, P476, DOI 10.1023/B:PHAM.0000019302.26097.cc
   Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017
   O'Neill P, 2006, NANO LETT, V6, P1379, DOI 10.1021/nl0603505
   Park JH, 2008, ADV MATER, V20, P1630, DOI 10.1002/adma.200800004
   Patri AK, 2005, ADV DRUG DELIVER REV, V57, P2203, DOI 10.1016/j.addr.2005.09.014
   Pisanic TR, 2007, BIOMATERIALS, V28, P2572, DOI 10.1016/j.biomaterials.2007.01.043
   Prow T, 2006, MOL VIS, V12, P616
   Prow T, 2006, MOL VIS, V12, P606
   Prow TW, 2005, P SOC PHOTO-OPT INS, V5692, P199, DOI 10.1117/12.589422
   Prow TW, 2004, J MOL HISTOL, V35, P555
   Prow TW, 2004, P SOC PHOTO-OPT INS, V5318, P1, DOI 10.1117/12.547922
   Rapoport N, 2007, J NATL CANCER I, V99, P1095, DOI 10.1093/jnci/dim043
   Russ V, 2008, J CONTROL RELEASE, V132, P131, DOI 10.1016/j.jconrel.2008.09.003
   Salem AK, 2005, NANOTECHNOLOGY, V16, P484, DOI 10.1088/0957-4484/16/4/025
   Santangelo P, 2006, ANN BIOMED ENG, V34, P39, DOI 10.1007/s10439-005-9003-6
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Scarberry KE, 2008, J AM CHEM SOC, V130, P10258, DOI 10.1021/ja801969b
   Schneider G, 2004, NANO LETT, V4, P1833, DOI 10.1021/nl0490826
   SEALE M, 2007, P SPIE INT SOC OPT E, V6430, P1
   SEALE MM, 2007, P SPIE INT SOC OPT E, V6447, P1
   Seo WS, 2006, NAT MATER, V5, P971, DOI 10.1038/nmat1775
   Shen HB, 2006, BIOPHYS CHEM, V122, P1, DOI 10.1016/j.bpc.2006.01.003
   Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j
   Tejada-Berges T, 2002, Expert Rev Anticancer Ther, V2, P143, DOI 10.1586/14737140.2.2.143
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Unfried K, 2008, AM J PHYSIOL-LUNG C, V294, pL358, DOI 10.1152/ajplung.00323.2007
   Williams D, 2008, BIOMATERIALS, V29, P1737, DOI 10.1016/j.biomaterials.2008.01.003
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Yu CX, 2007, ANAL CHEM, V79, P572, DOI 10.1021/ac061730d
   YU KY, 2008, ANGEW CHEM INT EDIT, V47, P5362
   Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2
NR 80
TC 17
Z9 17
U1 1
U2 18
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD SEP-OCT
PY 2009
VL 1
IS 5
BP 553
EP 567
DI 10.1002/wnan.49
PG 15
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 585PV
UT WOS:000276839800008
PM 20049817
DA 2018-01-05
ER

PT J
AU Aline, F
   Brand, D
   Pierre, J
   Roingeard, P
   Severine, M
   Verrier, B
   Dimier-Poisson, I
AF Aline, Fleur
   Brand, Denys
   Pierre, Josette
   Roingeard, Philippe
   Severine, Munier
   Verrier, Bernard
   Dimier-Poisson, Isabelle
TI Dendritic cells loaded with HIV-1 p24 proteins adsorbed on
   surfactant-free anionic PLA nanoparticles induce enhanced cellular
   immune responses against HIV-1 after vaccination
SO VACCINE
LA English
DT Article
DE Dendritic cells; HIV-1; p24; Immunization; PLA nanoparticle; Vaccine
   adjuvant; Th1/Th2 balance
ID STRUCTURED TREATMENT INTERRUPTION; THERAPEUTIC IMMUNIZATION;
   ANTIRETROVIRAL THERAPY; VIRAL SUPPRESSION; INFECTION; VIREMIA;
   IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTES; MECHANISMS
AB Biodegradable nanoparticles with surface adsorbed antigens represent a promising method for in vivo delivery of vaccines targeting a wide range of infectious diseases or cancers. We investigated the feasibility of loading dendritic cells with a vaccine antigen, HIV p24 protein, on the surface of surfactant-free anionic (D,L-lactic acid, PLA) nanoparticles. The p24 protein had a high affinity for the nanoparticles and the antigenicity and immunogenicity of the p24 protein on the nanoparticle was well preserved after immunization. p24-coated nanoparticles were efficiently taken up by mouse dendritic cells (DCs), inducing DC maturation by increasing MHC-I, MHC-II, CD40, CD80 and CD86 surface expression and secreting IL-12 (p70) and IL-4. We evaluated the ability of DCs pulsed with p24-coated nanoparticles to elicit an optimal humoral and cellular immune response in the blood and intestine. DCs pulsed with p24-nanoparticles induced high seric and mucosal antibody production and elicited strong systemic and local lymproliferative responses, correlated with a Th1/Th2-type response, and systemic CTL responses in mice. Thus, DCs pulsed with antigen-loaded PLA nanoparticles may provide a novel delivery tool for cell therapy vaccination against chronic infectious diseases. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Aline, Fleur; Pierre, Josette; Dimier-Poisson, Isabelle] Univ Tours, INRA, F-37200 Tours, France.
   [Aline, Fleur; Pierre, Josette; Dimier-Poisson, Isabelle] Univ INRA Immunol Parasitaire & Vaccinol Biothera, UMR 0483, F-37200 Tours, France.
   [Aline, Fleur; Pierre, Josette; Dimier-Poisson, Isabelle] UFR Sci Pharmaceut, IFR Agents Transmissibles Infectiol, F-37200 Tours, France.
   [Brand, Denys; Roingeard, Philippe] Univ Tours, INSERM, U966, Fac Med, F-37000 Tours, France.
   [Severine, Munier; Verrier, Bernard] CNRS UCBL, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France.
RP Dimier-Poisson, I (reprint author), Univ Tours, INRA, 31 Ave Monge, F-37200 Tours, France.
EM isabelle.poisson@univ-tours.fr
FU ANRS; ANR; FP6; Europrise and MuNanoVac
FX We thank D. Tabareau, T. Papin and J.-M. Rith for their excellent
   technical assistance. Part of this study was supported through the ANRS,
   ANR and two FP6 grants, Europrise and MuNanoVac, which funded B.
   Verrier. S. Munier was funded through the MuNanoVac strep programme.
CR ALINE F, 2007, MICROBES INFECT, V4, P536
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BORROW P, 1994, J VIROL, V68, P6103
   CHEYNET V, 1993, PROTEIN EXPRES PURIF, V4, P367, DOI 10.1006/prep.1993.1048                                                          
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109                                                        
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fajardo-Moser M, 2008, INT J MED MICROBIOL, V298, P11, DOI 10.1016/j.ijmm.2007.07.003
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Ide F, 2006, J MED VIROL, V78, P711, DOI 10.1002/jmv.20612
   Jeon HJ, 2000, INT J PHARM, V207, P99, DOI 10.1016/S0378-5173(00)00537-8
   KOUP RA, 1994, J VIROL, V68, P4650
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lou Q, 2006, CLIN IMMUNOL, V118, P66, DOI 10.1016/j.clin.2005.08.014
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199
   Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013
   Ruiz S, 2005, CELL MICROBIOL, V7, P1659, DOI 10.1111/j.1462-5822.2005.00583.x
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Sinkovics JG, 2000, INT J ONCOL, V16, P81
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Waeckerle-Men Y, 2005, ADV DRUG DELIVER REV, V57, P475, DOI 10.1016/j.addr.2004.09.007
   Wierecky J, 2006, CANCER IMMUNOL IMMUN, V55, P63, DOI 10.1007/s00262-005-0673-6
NR 29
TC 39
Z9 42
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 20
PY 2009
VL 27
IS 38
BP 5284
EP 5291
DI 10.1016/j.vaccine.2009.05.028
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 484UB
UT WOS:000269071900021
PM 19450633
DA 2018-01-05
ER

PT J
AU Sosnik, A
   Chiappetta, DA
   Carcaboso, AM
AF Sosnik, Alejandro
   Chiappetta, Diego A.
   Carcaboso, Angel M.
TI Drug delivery systems in HIV pharmacotherapy: What has been done and the
   challenges standing ahead
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE HIV infection; Drug delivery systems (DDS); Antiretroviral drug
   targeting
ID IMMUNODEFICIENCY-VIRUS-INFECTION; REVERSE-TRANSCRIPTASE INHIBITORS;
   LOADED GALACTOSYLATED LIPOSOMES; POLY PROPYLENEIMINE DENDRIMER;
   CELL-PENETRATING PEPTIDES; SOLID LIPID NANOPARTICLES;
   BLOOD-BRAIN-BARRIER; IN-VIVO EVALUATION; TRANSDERMAL DELIVERY;
   P-GLYCOPROTEIN
AB Worldwide, over 40 million people are infected with the Human immunodeficiency Virus (HIV). The High Activity Antiretroviral Therapy (HAART) combines at least three antiretroviral (ARV) drugs and, for over a decade, has been used to extend the lifespan of the HIV-infected patients. Chronic intake of HAART is mandatory to control HIV infection. The frequent administration of several drugs in relatively high doses is a main cause of patient incompliance and a hurdle toward the fulfillment of the pharmacotherapy. High adherence to HAART does not lead to complete HIV virus elimination from the host. Intracellular and anatomical viral reservoirs are responsible for the perpetuation of the infection. Active transport mechanisms involving proteins of the ATP-binding cassette superfamily prevent the penetration of ARV drugs into the brain and may account for the limited bioavailability after oral administration. A new research that addresses from simple organoleptic or technological problems to more complex issues involving the targeting of specific tissues and organs has emerged. With the aim to reduce dosing frequency, to improve the compliance of the existing pharmacotherapy and to target viral reservoirs, the design of drug delivery systems (DDS) is becoming complementary to new drug discovery. Based on the common molecular features that characterize the different families of ARV drugs, the present review describes state-of-the-art ARV DDS and thoroughly discusses the challenges in the development of medicines with enhanced biopharmaceutical properties. In addition, a number of specific issues such as pediatric HAART, preventive pharmacotherapy and specific HIV-associated ethical issues are addressed in an integrative manner. Finally, the impact of such novel drug development on the Pharmaceutical Technology field is discussed. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Sosnik, Alejandro; Chiappetta, Diego A.; Carcaboso, Angel M.] Univ Buenos Aires, Dept Pharmaceut Technol, Fac Pharm & Biochem, Natl Sci Res Council CONICET, RA-1113 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Dept Pharmaceut Technol, Fac Pharm & Biochem, Natl Sci Res Council CONICET, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
OI Carcaboso, Angel/0000-0002-8485-426X
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Abu-Izza Khawla A., 1996, Journal of Pharmaceutical Sciences, V85, P144
   Adamson CS, 2008, DRUG DISCOV TODAY, V13, P424, DOI 10.1016/j.drudis.2008.02.003
   Allaway GP, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-S1-S8
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Baert L, 2008, INT J PHARM, V355, P38, DOI 10.1016/j.ijpharm.2008.01.029
   Bahal SM, 2003, PHARM DEV TECHNOL, V8, P111, DOI 10.1081/PDT-120017518
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Barrueco N, 2005, Farm Hosp, V29, P367
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Betageri GV, 2001, DRUG DEV IND PHARM, V27, P129, DOI 10.1081/DDC-100000479
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Bonfanti P, 1999, BIOMED PHARMACOTHER, V53, P93, DOI 10.1016/S0753-3322(99)80066-3
   Boudad H, 2001, INT J PHARM, V218, P113, DOI 10.1016/S0378-5173(01)00622-6
   Boyd M, 2005, ANTIVIR THER, V10, P301
   Brown E., 2007, ANTIRETROVIRAL THERA, P419
   Buchanan CM, 2008, BIOMACROMOLECULES, V9, P305, DOI 10.1021/bm700827h
   Busse Kristin H, 2008, Expert Rev Clin Pharmacol, V1, P533, DOI 10.1586/17512433.1.4.533
   CADA DJ, 2008, HOSP PHARM, V43, P498
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2009, AAPS PHARMSCITECH, V10, P1, DOI 10.1208/s12249-008-9168-z
   Chimalakonda KC, 2007, BIOCONJUGATE CHEM, V18, P2097, DOI 10.1021/bc700193d
   Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001                                                
   Conroy S, 2003, ACTA PAEDIATR, V92, P408
   Correll T, 2008, PHARMACOTHERAPY, V28, P90, DOI 10.1592/phco.28.1.90
   Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Delaney M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-S1-S6                                                       
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Deshmukh D, 2003, DRUG DELIV, V10, P47, DOI 10.1080/10717540390169575
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   DEUTSCH G, 1993, INT C AIDS, V9
   Devi Kusum V., 2006, Indian Journal of Pharmaceutical Sciences, V68, P1
   Dionisio D, 2007, CURR HIV RES, V5, P155, DOI 10.2174/157016207780077075
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dufresne I, 1999, BBA-BIOMEMBRANES, V1421, P284, DOI 10.1016/S0005-2736(99)00137-6                                                   
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   *FOOD DRUG ADM, 2007, DRUGS US TREATM PED
   Fretz MM, 2005, INT J PHARM, V298, P305, DOI 10.1016/j.ijpharm.2005.02.040
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GAMZIZ DE, 2008, BIOENG BIOTECH, V101, P1072
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Gerber M, 2008, INT J PHARM, V351, P186, DOI 10.1016/j.ijpharm.2007.09.040
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Giaquinto C, 2007, CLIN DRUG INVEST, V27, P509, DOI 10.2165/00044011-200727080-00001
   Godin B, 2003, CRIT REV THER DRUG, V20, P63, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i1.20                                    
   Gopinath D, 2002, INT J PHARM, V246, P187, DOI 10.1016/S0378-5173(02)00397-6
   Greene WC, 2008, ANTIVIR RES, V80, P251, DOI 10.1016/j.antiviral.2008.08.003
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Havlir DV, 2008, NEW ENGL J MED, V359, P416, DOI 10.1056/NEJMe0804289
   Havlir DV, 2005, NEW ENGL J MED, V353, P749, DOI 10.1056/NEJMp058106                                                             
   Heald AE, 1998, AIDS, V12, P1667, DOI 10.1097/00002030-199813000-00015                                                
   Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906
   Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Jain S., 2004, INDIAN J PHARM SCI, V66, P72
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jain S, 2007, AAPS PHARMSCITECH, V8
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   Jin YG, 2008, J COLLOID INTERF SCI, V326, P275, DOI 10.1016/j.jcis.2008.07.014
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   KAIRUZ DT, 2007, CURR DRUG SAFETY, V2, P89
   Kapitza SB, 2007, EUR J PHARM BIOPHARM, V66, P146, DOI 10.1016/j.ejpb.2006.08.010
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kim DD, 1996, J PHARM SCI, V85, P214, DOI 10.1021/js950141c
   Kim DD, 1996, DRUG DEV IND PHARM, V22, P1047, DOI 10.3109/03639049609065940                                                       
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Knoll BM, 2008, DRUG TODAY, V44, P23, DOI 10.1358/dot.2008.44.1.1152213
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lalezari JP, 2008, AIDS RES HUM RETROV, V24, P805, DOI 10.1089/aid.2007.0251
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Lin JH, 1999, ADV DRUG DELIVER REV, V39, P33, DOI 10.1016/S0169-409X(99)00018-6                                                   
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Mueller BU, 1998, PEDIATRICS, V102, P101, DOI 10.1542/peds.102.1.101                                                          
   Narishetty STK, 2004, BIOPHARM DRUG DISPOS, V25, P9, DOI 10.1002/bdd.381
   Narishetty STK, 2004, J CONTROL RELEASE, V95, P367, DOI 10.1016/j.jconrel.2003.11.022
   Nath A, 2006, CURR OPIN NEUROL, V19, P358, DOI 10.1097/01.wco.0000236614.51592.ca                                              
   *NIAID, 2007, PHAS 1 STUD MAT SING
   Nunn T, 2005, BRIT J CLIN PHARMACO, V59, P674, DOI 10.1111/j.1365-2125.2005.02410.x
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Peralta G, 2008, ENFERM INFEC MICR CL, V26, P150, DOI 10.1157/13116752                                                                
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   Pozniak A, 2008, INT J CLIN PRACT, V62, P1285, DOI 10.1111/j.1742-1241.2008.01817.x
   Pretzer E, 1997, ANTIVIR RES, V34, P1, DOI 10.1016/S0166-3542(96)01017-0
   Rabel SR, 2001, AAPS PHARMSCI, V3
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Saksena Nitin K., 2003, Current Drug Targets - Infectious Disorders, V3, P179, DOI 10.2174/1568005033481187
   Sanchez-Lafuente C, 2002, INT J PHARM, V234, P213, DOI 10.1016/S0378-5173(01)00962-0
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   Schiffman SS, 1999, NUTRITION, V15, P767, DOI 10.1016/S0899-9007(99)00152-5
   SCHOLLERGYURE M, 2008, 17 INT AIDS C
   Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487                                                                   
   SEKI T, 1991, J CONTROL RELEASE, V17, P41, DOI 10.1016/0168-3659(91)90129-2
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   SHAIK N, 2007, DRUG METAB DISPOS, V35, P1165
   SHAIK N, J PHARM SCI IN PRESS
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Smith KA, 2001, CURR OPIN IMMUNOL, V13, P617, DOI 10.1016/S0952-7915(00)00270-3                                                   
   Spitzenberger TJ, 2006, J CEREB BLOOD FLOW M, V27, P1033
   Standing JF, 2005, INT J PHARM, V300, P56, DOI 10.1016/j.ijpharm.2005.05.006
   Starr SE, 2002, PEDIATR INFECT DIS J, V21, P659, DOI 10.1097/01.inf.0000020966.06388.92
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273
   Thomas NS, 2003, EUR J PHARM SCI, V18, P71, DOI 10.1016/S0928-0987(02)00242-7
   TOME S, 2007, J INCL PHENOM MACRO, V57, P689
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   True AL, 2006, PHARMACOTHERAPY, V26, P1679, DOI 10.1592/phco.26.12.1679
   Johnson GM, 2002, PEDIATRICS, V109, P61
   VONBRIESEN H, 2000, AIDS REV, V2, P31
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Warnke D, 2007, J CLIN PHARMACOL, V47, P1570, DOI 10.1177/0091270007308034
   Waters L, 2007, INT J CLIN PRACT, V61, P105, DOI 10.1111/j.1742-1241.2006.01146.x
   WHO, 2007, MAK MED CHILD SIZ
   *WHO, 2007, AIDS EP UPD 2007
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   Wu CY, 2005, PHARM RES, V22, P11, DOI 10.1007/s11095-004-9004-4
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yeung VW, 2005, PHARM WORLD SCI, V27, P399, DOI 10.1007/s11096-005-7911-z
   Youle M, 2007, J ANTIMICROB CHEMOTH, V60, P1195, DOI 10.1093/jac/dkm364
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   2007, CHILDREN HIV AIDS IN
   [Anonymous], 2006, GUIDELINES USE ANTIR
NR 157
TC 66
Z9 68
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 19
PY 2009
VL 138
IS 1
BP 2
EP 15
DI 10.1016/j.jconrel.2009.05.007
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 481QJ
UT WOS:000268826100002
PM 19445981
DA 2018-01-05
ER

PT J
AU Orrling, KM
   Marzahn, MR
   Gutierrez-de-Teran, H
   Aqvist, J
   Dunn, BM
   Larhed, M
AF Orrling, Kristina M.
   Marzahn, Melissa R.
   Gutierrez-de-Teran, Hugo
   Aqvist, Johan
   Dunn, Ben M.
   Larhed, Mats
TI alpha-Substituted norstatines as the transition-state mimic in
   inhibitors of multiple digestive vacuole malaria aspartic proteases
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Malaria; Plasmepsin; Inhibitors; Microwave-assisted synthesis; Molecular
   dynamics; Linear interaction energy mehtod
ID PARASITE PLASMODIUM-FALCIPARUM; ACTIVE-SITE SPECIFICITY; HIV-1 PROTEASE;
   PLASMEPSIN-II; TERTIARY-ALCOHOL; FOOD VACUOLE; BINDING-AFFINITY;
   INFECTING MAN; DESIGN; PROTEINASE
AB The impact of moving the P1 side-chain from the beta-position to the alpha-position in norstatine-containing plasmepsin inhibitors was investigated, generating two new classes of tertiary alcohol-comprising alpha-benzylnorstatines and alpha-phenylnorstatines. Twelve alpha-substituted norstatines were designed, synthesized and evaluated for their inhibitory potencies against plasmepsin II and the plasmepsin IV orthologues (PM4) present in the digestive vacuole of all four Plasmodium species causing malaria in man. New synthetic routes were developed for producing the desired alpha-substituted norstatines as pure stereoisomers. The best compounds provided K(i) values in the nanomolar range for all PM4, with a best value of 110 nM in PM4 from Plasmodium ovale. In addition, excellent selectivity over the closely related human aspartic protease Cathepsin D was achieved. The loss of affinity to Plasmodium falciparum PM4, which was experienced upon the move of the P1 substituent, was rationalized by the calculation of inhibitor-protein binding affinities using the linear interaction energy method (LIE). (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Orrling, Kristina M.; Larhed, Mats] Uppsala Univ, Div Organ Pharmaceut Chem, Dept Med Chem, BMC, S-75123 Uppsala, Sweden.
   [Marzahn, Melissa R.; Dunn, Ben M.] Univ Florida, Coll Med, Gainesville, FL USA.
   [Gutierrez-de-Teran, Hugo] Hosp Clin Santiago de Compostela, Fdn Publ Galega Med Xenom, Santiago De Compostela 15705, Spain.
   [Aqvist, Johan] Uppsala Univ, Dept Cell & Mol Biol, BMC, S-75123 Uppsala, Sweden.
RP Larhed, M (reprint author), Uppsala Univ, Div Organ Pharmaceut Chem, Dept Med Chem, BMC, Box 574, S-75123 Uppsala, Sweden.
EM Mats.Larhed@orgfarm.uu.se
RI Gutierrez de Teran, Hugo/E-1391-2011
OI Gutierrez de Teran, Hugo/0000-0003-0459-3491
CR AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385
   Back M, 2008, BIOORGAN MED CHEM, V16, P9471, DOI 10.1016/j.bmc.2008.09.041
   Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099
   Beyer BB, 2005, BIOCHEMISTRY-US, V44, P1768, DOI 10.1021/bi047886u
   Bjelic S, 2007, CELL MOL LIFE SCI, V64, P2285, DOI 10.1007/s00018-007-7102-2
   Bonilla JA, 2007, MOL MICROBIOL, V65, P64, DOI 10.1111/j.1365-2958.2007.05768.x
   Brynda J, 2004, J MED CHEM, V47, P2030, DOI 10.1021/jm031105q
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Clemente JC, 2006, ACTA CRYSTALLOGR D, V62, P246, DOI 10.1107/S0907444905041260
   Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2
   COPELAND RA, 1996, ENZYMES PRACTICAL IN, P300
   Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3
   DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8
   Danielson H, 1998, ADV EXP MED BIOL, V436, P99
   EISTETTER K, 1982, J MED CHEM, V25, P109, DOI 10.1021/jm00344a003
   Ekegren JK, 2006, ORG BIOMOL CHEM, V4, P3040, DOI 10.1039/b606859f
   Ekegren JK, 2005, J MED CHEM, V48, P8098, DOI 10.1021/jm050790t
   Ersmark K, 2006, MED RES REV, V26, P626, DOI 10.1002/med.20082
   FRAISSEJULLIEN R, 1970, B SOC CHIM FR, P219
   GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931
   Gutierrez-de-Teran H, 2006, BIOCHEMISTRY-US, V45, P10529, DOI 10.1021/bi0609669
   Hansson T, 1998, J COMPUT AID MOL DES, V12, P27, DOI 10.1023/A:1007930623000
   Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t
   Hidaka K, 2008, BIOORGAN MED CHEM, V16, P10049, DOI 10.1016/j.bmc.2008.10.011
   Hidaka K, 2007, BIOORG MED CHEM LETT, V17, P3048, DOI 10.1016/j.bmcl.2007.03.052
   HOWARDLOCK HE, 1986, CAN J CHEM, V64, P1215, DOI 10.1139/v86-201
   Janka L, 2008, PROTEIN PEPTIDE LETT, V15, P868, DOI 10.2174/092986608785849218
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kiso A, 2004, J PEPT SCI, V10, P641, DOI 10.1002/psc.609
   LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997
   Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010
   Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200
   Liu XW, 2002, J ORGANOMET CHEM, V646, P212, DOI 10.1016/S0022-328X(01)01388-2                                                   
   Luksch T, 2008, CHEMMEDCHEM, V3, P1323, DOI 10.1002/cmdc.200700270
   Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(98)80006-5
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z
   Nillroth U, 1997, ANTIMICROB AGENTS CH, V41, P2383
   Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200
   Tanimori S, 2004, SYNTHETIC COMMUN, V34, P4043, DOI 10.1081/SCC-20036576
   THOMPSON WJ, 1992, J MED CHEM, V35, P1685, DOI 10.1021/jm00088a003                                                             
   Westling J, 1997, EXP PARASITOL, V87, P185, DOI 10.1006/expr.1997.4225
   Westling J, 1999, PROTEIN SCI, V8, P2001, DOI 10.1110/ps.8.10.2001                                                            
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   World Health Organization, 2004, GLOB BURD DIS 2004 U, P146
   World Health Organization, 2008, WHO REP GLOB TOB EP, P1
   Wu XY, 2008, J MED CHEM, V51, P1053, DOI 10.1021/jm070680h
   Yamansarova ET, 2001, RUSS J ORG CHEM+, V37, P246, DOI 10.1023/A:1012387131029                                                         
NR 50
TC 18
Z9 18
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 15
PY 2009
VL 17
IS 16
BP 5933
EP 5949
DI 10.1016/j.bmc.2009.06.065
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 480UR
UT WOS:000268762900020
PM 19635672
DA 2018-01-05
ER

PT J
AU Wang, JB
   Zuo, XB
   Yu, P
   Byeon, IJL
   Jung, JW
   Wang, XX
   Dyba, M
   Seifert, S
   Schwieters, CD
   Qin, J
   Gronenborn, AM
   Wang, YX
AF Wang, Jinbu
   Zuo, Xiaobing
   Yu, Ping
   Byeon, In-Ja L.
   Jung, Jinwon
   Wang, Xiaoxia
   Dyba, Marzena
   Seifert, Soenke
   Schwieters, Charles D.
   Qin, Jun
   Gronenborn, Angela M.
   Wang, Yun-Xing
TI Determination of Multicomponent Protein Structures in Solution Using
   Global Orientation and Shape Restraints
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID INTEGRIN-LINKED KINASE; RESIDUAL DIPOLAR COUPLINGS;
   NUCLEAR-MAGNETIC-RESONANCE; X-RAY-SCATTERING; SMALL-ANGLE SCATTERING;
   BIOLOGICAL MACROMOLECULES; SECONDARY STRUCTURE; NMR; COMPLEXES;
   SPECTROSCOPY
AB Determining architectures of multicomponent proteins or protein complexes in solution is a challenging problem. Here we report a methodology that simultaneously uses residual dipolar couplings (RDC) and the small-angle X-ray scattering (SAXS) restraints to mutually orient subunits and define the global shape of multicomponent proteins and protein complexes. Our methodology is implemented in an efficient algorithm and demonstrated using five examples. First, we demonstrate the general approach with simulated data for the HIV-1 protease, a globular homodimeric protein. Second, we use experimental data to determine the structures of the two-domain proteins L11 and gamma D-Crystallin, in which the linkers between the domains are relatively rigid. Finally, complexes with K(d) values in the high micro- to millimolar range (weakly associating proteins), such as a homodimeric GB1 variant, and with K(d) values in the nanomolar range (tightly bound), such as the heterodimeric complex of the ILK ankyrin repeat domain (ARD) and PINCH LIM1 domain, respectively, are evaluated. Furthermore, the proteins or protein complexes that were determined using this method exhibit better solution structures than those obtained by either NMR or X-ray crystallography alone as judged based on the pair-distance distribution functions (PDDF) calculated from experimental SAXS data and back-calculated from the structures.
C1 [Wang, Jinbu; Zuo, Xiaobing; Yu, Ping; Wang, Yun-Xing] NCI, Prot Nucle Acid Interact Sect, NIH, Frederick, MD 21702 USA.
   [Yu, Ping; Dyba, Marzena] NCI, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA.
   [Byeon, In-Ja L.; Jung, Jinwon; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15261 USA.
   [Seifert, Soenke] Argonne Natl Lab, Adv Photon Source, Xray Sci Div, Argonne, IL 60439 USA.
   [Schwieters, Charles D.] NIH, Div Computat Biosci, Ctr Informat, Bethesda, MD 20892 USA.
   [Wang, Xiaoxia; Qin, Jun] Lerner Res Inst, Struct Biol Program, Dept Mol Cardiol, Cleveland, OH 44195 USA.
   [Dyba, Marzena] NCI, Struct Biophys Lab, NIH, Frederick, MD 21702 USA.
RP Wang, YX (reprint author), NCI, Prot Nucle Acid Interact Sect, NIH, Frederick, MD 21702 USA.
EM wangyu@ncifcrf.gov
RI Qin, Jun/D-5559-2009; Zuo, Xiaobing/F-1469-2010; Jung,
   Jinwon/F-6038-2010
OI Gronenborn, Angela M/0000-0001-9072-3525; Zuo,
   Xiaobing/0000-0002-0134-4804; Jung, Jinwon/0000-0002-7981-3316
FU NCI of NIH; CIT Intramural Research Program of the NIH; NIH [GM082251,
   HL58758, GM62823, N01-CO-12400]; National Cancer Institute
FX We thank Dr. Xinhua Ji for insightful discussions about the
   crystallography of weakly associated multisubunit proteins and Dr. David
   M. Tiede for useful discussion and allowing us using his software for
   X-ray scattering 2D image processing. This project has been funded in
   part with federal funds from an intramural grant from the NCI of NIH to
   Y.X.W., the CIT Intramural Research Program of the NIH to C.D.S., and
   NIH grants GM082251 and HL58758, GM62823 to A.M.G. and J.Q.,
   respectively. This research was also supported in whole or in part with
   federal funds from the National Cancer Institute, National Institues of
   health, under under contract N01-CO-12400. This Research was supported
   in part by the Intramural Research Program of the NIH, National Cancer
   Institute, Center for Cancer Research.
CR Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907
   Al-Hashimi HM, 2000, J MAGN RESON, V142, P153, DOI 10.1006/jmre.1999.1937
   ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002                                                             
   Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8                                                   
   BREG JN, 1989, BIOCHEMISTRY-US, V28, P9826, DOI 10.1021/bi00451a042
   BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012
   Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903
   Chiswell BP, 2008, P NATL ACAD SCI USA, V105, P20677, DOI 10.1073/pnas.0811415106
   CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004
   Clore GM, 2003, J AM CHEM SOC, V125, P2902, DOI 10.1021/ja028893d
   Dobrodumov A, 2003, PROTEINS, V53, P18, DOI 10.1002/prot.10439
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213
   Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200
   Gabel F, 2008, J BIOMOL NMR, V41, P199, DOI 10.1007/s10858-008-9258-y
   Gaponenko V, 2000, PROTEIN SCI, V9, P302
   GRIFFEY RH, 1987, Q REV BIOPHYS, V19, P51, DOI 10.1017/S0033583500004029                                                       
   Grishaev A, 2005, J AM CHEM SOC, V127, P16621, DOI 10.1021/ja054342m
   GUINIER A, 1955, ACTA METALL MATER, V3, P510, DOI 10.1016/0001-6160(55)90145-0                                                    
   Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524
   Huang HC, 2007, ONCOGENE, V26, P2781, DOI 10.1038/sj.onc.1210078
   Jee J, 2008, PROTEINS, V71, P1420, DOI 10.1002/prot.21831
   Jung J, 2009, BIOCHEMISTRY-US, V48, P2597, DOI 10.1021/bi802292q
   Koch MHJ, 2003, Q REV BIOPHYS, V36, P147, DOI 10.1017/S0033583503003871
   LATTMAN EE, 1989, PROTEINS, V5, P149, DOI 10.1002/prot.340050209                                                          
   Lee D, 2007, J MOL BIOL, V367, P1007, DOI 10.1016/j.jmb.2007.01.013
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h
   NINIO J, 1972, J MOL BIOL, V71, P217, DOI 10.1016/0022-2836(72)90347-6
   Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047
   SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663                                                       
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tu YZ, 1999, MOL CELL BIOL, V19, P2425
   VENTERS RA, 1995, J BIOMOL NMR, V5, P339
   Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048
   Walters KJ, 2001, METHOD ENZYMOL, V339, P238, DOI 10.1016/S0076-6879(01)39316-3                                                   
   Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X
   Yamazaki T, 1996, PROTEIN SCI, V5, P495
   Yang YW, 2009, J BIOL CHEM, V284, P5836, DOI 10.1074/jbc.M805319200
   Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166
   Zuo XB, 2008, J AM CHEM SOC, V130, P3292, DOI 10.1021/ja7114508
NR 41
TC 33
Z9 33
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD AUG 5
PY 2009
VL 131
IS 30
BP 10507
EP 10515
DI 10.1021/ja902528f
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 479FF
UT WOS:000268644400045
PM 19722627
OA green_accepted
DA 2018-01-05
ER

PT J
AU Roy, R
   Jerry, DJ
   Thayumanavan, S
AF Roy, Raghunath
   Jerry, D. Joseph
   Thayumanavan, S.
TI Virus-Inspired Approach to Nonviral Gene Delivery Vehicles
SO BIOMACROMOLECULES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING PEPTIDES; TAT PEPTIDE;
   CATIONIC POLYMERS; DNA COMPLEXES; IN-VITRO; THERAPY; NANOPARTICLES;
   TRANSFECTION; PROTEIN
AB The basic TAT peptide, responsible for translocation of the HIV-TAT protein, has been conjugated to a variety of artificial nanoscopic materials to transport them across the cellular membrane. However, attempts to translocate genes using the TAT-peptide had met with limited success. We hypothesized that the cationic nature of the peptide does not allow for displaying these peptides on the surface of the polyplex. To circumvent this potential issue, we have developed a new molecular design strategy where the TAT-peptide can be effectively displayed on the Surface of the polyplex, thus enhancing gene expression.
C1 [Roy, Raghunath; Thayumanavan, S.] Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
   [Jerry, D. Joseph] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.
RP Thayumanavan, S (reprint author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
EM thai@chem.umass.edu
OI Thayumanavan, S/0000-0002-6475-6726
FU NSF-MRSEC; University of Massachusetts President's Science and
   Technology Initiative program
FX This work was supported by NSF-MRSEC and the University of Massachusetts
   President's Science and Technology Initiative program. We thank Dr.
   Ellen Dickinson and Pardeep Thandi for their generous help.
CR Alexis F, 2006, ADV MATER, V18, P2174, DOI 10.1002/adma.200502173
   ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Douglas KL, 2008, BIOTECHNOL PROGR, V24, P871, DOI 10.1021/bp070319o
   Eldred SE, 2005, BIOCONJUGATE CHEM, V16, P694, DOI 10.1021/bc050017c
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fong TC, 2000, CRIT REV THER DRUG, V17, P1
   Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949                                                    
   Funhoff AM, 2004, BIOCONJUGATE CHEM, V15, P1212, DOI 10.1021/bc049864q
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002
   Kawakami S, 2008, J PHARM SCI-US, V97, P726, DOI 10.1002/jps.21024
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Liu XH, 2008, BIOMACROMOLECULES, V9, P2063, DOI 10.1021/bm800291v
   Liu YM, 2004, J AM CHEM SOC, V126, P7422, DOI 10.1021/ja049831l
   MANN DA, 1991, EMBO J, V10, P1733
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   PFEIFER AV, 2001, ANNU REV GENOM HUM G, V17, P7
   Piskin E, 2004, J BIOMAT SCI-POLYM E, V15, P1181, DOI 10.1163/1568562041753016                                                        
   Prata CAH, 2004, J AM CHEM SOC, V126, P12196, DOI 10.1021/ja0474906
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   SUDA T, 2008, CONCEPTS GENET MED, V10, P3
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 35
TC 9
Z9 10
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD AUG
PY 2009
VL 10
IS 8
BP 2189
EP 2193
DI 10.1021/bm900370p
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 479LR
UT WOS:000268661400021
PM 19722558
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gan, N
   Wang, LY
   Li, TH
   Zheng, L
   Wang, F
AF Gan Ning
   Wang Lu-Yan
   Li Tian-Hua
   Zheng Lei
   Wang Feng
TI Reagentless Amperometric Immunosensor Based on Human Immunodefficiency
   Virus Diagnosis Marker Glycoprotein 160 Antibody Coated Gold-magnetic
   Particles Modified Electrode
SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
LA Chinese
DT Article
DE Dimethyl fumarate bipyridine copper(II) complex; nano Au/Fe(3)O(4);
   magnetic particles; chitosan; human immunodefficiency virus; diagnosis
   marker glycoprotein; reagentless amperometric immunosensor
ID FILM; ELECTROCATALYSIS; NANOPARTICLES; COPPER(II); NANOWIRES; MATRIX
AB A novel amperometric immunosensor for human immunodefficiency virus (HIV) glycoprotein 160 (gp160) based on nanoAu/Fe(3)O(4)/Chitosan(chit) composite film as immobilization matrix was investigated. Firstly, the complex [Cu(bpy)(2) (H(2)O)](2) (C(6)H(8)O(4))(2) (ClO(4))(4), (CuL) was prepared and adsorbed on the surface of glassy carbon electrode(GCE), then nanoAu/Fe(3)O(4)/Chitosan composite film was modified on the surface of GCE|CuL and HIV gp160 antibody was furthermore immobilized on the surface to form one gp160 immunosensor(GCE|CuL/nanoAu/Fe(3)O(4)/Chit/anti gp160). CuL can be employed as an electron transfer mediator for catalytic activity detection of H(2)O(2). After the immunosensor was incubated with HIV gp160 solution at 37 degrees C for 30 min, the electron transfer access of CuL to H(2)O(2) Is partly inhibited, which led to a linear decrease of the catalytic efficiency to H(2)O(2) by the oxidation of immobilized CuL by H(2)O(2) at - 300 mV in pH 7.0 PBS. Under the optimal conditions, the linear range of gp160 by the immunosensor is 1-400 mu g/L and the detection limit is 0.5 mu g/L at 3 times noise. The immunosensor shows more sensitivity and accuracy than that only modified by gp160 antibody coated nano Au/chitosan film. This method simplifies the detection system without adding electron transfer media to solution and shortens the analytical time with one-step Immunoassay, thus would be valuable for clinical immunoassay for HIV gp160 in AIDs patients' serums
C1 [Gan Ning; Wang Lu-Yan; Li Tian-Hua; Wang Feng] Ninbo Univ, State Key Lab, Ningbo 315211, Zhejiang, Peoples R China.
   [Zheng Lei] Nanfang Med Univ, Dept Lab, Guangzhou 410003, Guangdong, Peoples R China.
RP Gan, N (reprint author), Ninbo Univ, State Key Lab, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn
RI Zhang, Yong/H-1774-2012
OI Zhang, Yong/0000-0002-5831-637X
CR Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265                                                     
   Cai CX, 1997, J APPL ELECTROCHEM, V27, P793, DOI 10.1023/A:1018416610935                                                         
   Cao C, 2006, BIOSENS BIOELECTRON, V21, P2106, DOI 10.1016/j.bios.2005.10.014
   Crumbliss A. L., 1993, Biosensors and Bioelectronics, V8, P331, DOI 10.1016/0956-5663(93)85014-F
   CUI YL, 2006, CHINA SCI B, V36, P159
   DAI Z, 2004, J IMMUNOL METHODS, V287, P3
   Du Y, 2007, BIOELECTROCHEMISTRY, V70, P342, DOI 10.1016/j.bioelechem.2006.05.002
   Gan N, 2007, CHINESE J ANAL CHEM, V35, P1553
   He XL, 2008, J BIOCHEM BIOPH METH, V70, P823, DOI 10.1016/j.jbbm.2007.06.002
   Li C, 2005, J AM CHEM SOC, V127, P12484, DOI 10.1021/ja053761g
   Li JP, 2006, CHINESE J ANAL CHEM, V34, P1141
   Liu GD, 2004, ANAL CHEM, V76, P7126, DOI 10.1021/ac0491071
   RAJU K, 2008, ELECTROCHEM COMMUN, V10, P492
   Ravanshad M, 2006, SAUDI MED J, V27, P31
   SANDRA KW, 2002, J IMMUNOL METHODS, V264, P69
   Wang J, 2004, ADV MATER, V16, P137, DOI 10.1002/adma.200306136
   Zhao G, 2006, ELECTROCHEM COMMUN, V8, P148, DOI 10.1016/j.elecom.2005.11.001
   Zheng YQ, 2008, EUR J INORG CHEM, P4453, DOI 10.1002/ejic.200800309
NR 18
TC 3
Z9 3
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0253-3820
J9 CHINESE J ANAL CHEM
JI Chin. J. Anal. Chem.
PD AUG
PY 2009
VL 37
IS 8
BP 1125
EP 1130
DI 10.1016/S1872-2040(08)60121-8                                           
          
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 491RH
UT WOS:000269596400006
DA 2018-01-05
ER

PT J
AU Baert, L
   van 't Klooster, G
   Dries, W
   Francois, M
   Wouters, A
   Basstanie, E
   Iterbeke, K
   Stappers, F
   Stevens, P
   Schueller, L
   Van Remoortere, P
   Kraus, G
   Wigerinck, P
   Rosier, J
AF Baert, Lieven
   van 't Klooster, Gerben
   Dries, Willy
   Francois, Marc
   Wouters, Alfons
   Basstanie, Esther
   Iterbeke, Koen
   Stappers, Fred
   Stevens, Paul
   Schueller, Laurent
   Van Remoortere, Pieter
   Kraus, Guenter
   Wigerinck, Piet
   Rosier, Jan
TI Development of a long-acting injectable formulation with nanoparticles
   of rilpivirine (TMC278) for HIV treatment
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Rilpivirine; Long-acting; Injectable; HIV; Pharmacokinetics
ID HIV-1-INFECTED PATIENTS; VIROLOGICAL RESPONSE; PROTEASE INHIBITORS;
   ANTIVIRAL ACTIVITY; INFECTED PATIENTS; DRUG-RESISTANCE; ADHERENCE;
   THERAPY; NANOSUSPENSIONS; REGIMENS
AB Long-acting parenteral formulations of anti retrovirals could facilitate maintenance and prophylactic treatment in HIV. Using the poorly water- and oil-soluble non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) as base or hydrochloride (HCl), nanosuspensions were prepared by wet milling (Elan NanoCrystal (R) technology) in an aqueous carrier. Laser diffraction showed that the average particles size were (I) close to the targeted size proportionality (200-400-800 nm), with increasing distributions the larger the average particle size, and (2) were stable over 6 months. Following single-dose administration, the plasma concentration profiles showed Sustained release of TMC278 over 3 months in dogs and 3 weeks in mice. On comparison of intramuscular and subcutaneous injection of 5 mg/kg (200 nm) in dogs, the subcutaneous route resulted in the most stable plasma levels (constant at 25 ng/mL for 20 days, after which levels declined slowly to 1-3 ng/mL at 3 months): 200 nm nanosuspensions achieved higher and less variable plasma concentration profiles than 400 and 800 nm nanosuspensions. in mice, the pharmacokinetic profiles after a single 20 mg/kg dose (200 nm) were similar with two different surfactants used (poloxamer 338, or D-alpha-tocopheryl polyethylene glycol 1000 succinate). In conclusion, this study provides proof-of-concept that 200-nm sized TMC278 nanosuspensions may act as long-acting injectable. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Baert, Lieven; van 't Klooster, Gerben; Schueller, Laurent; Van Remoortere, Pieter; Kraus, Guenter; Wigerinck, Piet; Rosier, Jan] Tibotec Bvba, B-2800 Mechelen, Belgium.
   [Dries, Willy; Francois, Marc; Wouters, Alfons; Basstanie, Esther; Iterbeke, Koen; Stappers, Fred; Stevens, Paul] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium.
RP Baert, L (reprint author), Tibotec Bvba, Gen Wittelaan L11B 3, B-2800 Mechelen, Belgium.
EM lbaert@its.jnj.com
CR Burger DM, 2004, J PEDIATR-US, V145, P403, DOI 10.1016/j.jpeds.2004.04.048
   Clotet B, 2004, AIDS REV, V6, P123
   Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205
   *DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1
   DRAPER BH, 2007, COCHRANE DATABASE SY
   Duong M, 2005, ANN PHARMACOTHER, V39, P603, DOI 10.1345/aph.1E563
   Elan Drug Technologies, 2008, NAN TECHN TECHN FOC
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   Gatti G, 2002, HIV Med, V3, P125, DOI 10.1046/j.1468-1293.2002.00108.x
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Harrison TS, 2004, CNS DRUGS, V18, P113
   Hirschel B, 2007, LANCET, V370, P3, DOI 10.1016/S0140-6736(07)61022-8                                                   
   HOETELMANS R, 2005, INT AIDS C IAS RIO D
   Kirschner DE, 1997, EMERG INFECT DIS, V3, P273, DOI 10.3201/eid0303.970303                                                          
   Langford Simone E, 2007, AIDS Res Ther, V4, P11, DOI 10.1186/1742-6405-4-11
   Mordant C, 2007, EUR J MED CHEM, V42, P567, DOI 10.1016/j.ejmech.2006.11.014
   Muller RH, 1998, INT J PHARMACEUT, V160, P229, DOI 10.1016/S0378-5173(97)00311-6
   Pauwels R, 2006, ANTIVIR RES, V71, P77, DOI 10.1016/j.antiviral.2006.05.007
   POZNIAC A, 2007, 4 INT AIDS SOC C HIV
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Ramirez Garcia Pilar, 2003, J Assoc Nurses AIDS Care, V14, P37
   Rathbun RC, 2005, CLIN THER, V27, P199, DOI 10.1016/j.clinthera.2005.02.010
   RUXRUNGTHAM K, 2007, 4 INT AIDS SOC C HIV
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   Thaisrivongs S, 1996, J MED CHEM, V39, P2400, DOI 10.1021/jm950888f
   Torti C, 2005, CLIN INFECT DIS, V40, P1828, DOI 10.1086/429917
   Van Gyseghem E, 2008, EUR J PHARM BIOPHARM, V70, P853, DOI 10.1016/j.ejpb.2008.06.030
   van't Klooster G., 2008, 15 C RETR OPP INF BO
   Wu HL, 2006, J PHARMACOKINET PHAR, V33, P399, DOI 10.1007/s10928-006-9006-4
NR 29
TC 111
Z9 114
U1 38
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD AUG
PY 2009
VL 72
IS 3
BP 502
EP 508
DI 10.1016/j.ejpb.2009.03.006
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 472GT
UT WOS:000268119300004
PM 19328850
DA 2018-01-05
ER

PT J
AU Rao, KS
   Ghorpade, A
   Labhasetwar, V
AF Rao, Kavitha S.
   Ghorpade, Anuja
   Labhasetwar, Vinod
TI Targeting anti-HIV drugs to the CNS
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE AIDS; anti-HIV drugs; BBB; CNS; macrophage; nanocarrier systems; viral
   reservoirs
ID BLOOD-BRAIN-BARRIER; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL
   THERAPY; CENTRAL-NERVOUS-SYSTEM; CELL-PENETRATING PEPTIDES;
   NEUROCOGNITIVE DISORDERS; PROTEASE INHIBITOR; TRANSPORT-SYSTEM;
   DELIVERY; INFECTION
AB The development of antiretroviral drugs over the past couple of decades has been commendable owing to the identification of several new targets within the overall HIV replication cycle. However, complete control over HIV/AIDS is yet to be achieved. This is because the current anti-HIV drugs, although effective in reducing plasma viral levels, cannot eradicate the virus completely from the body. This occurs because most anti-HIV drugs do not accumulate in certain cellular and anatomical reservoirs including the CNS. Insufficient delivery of anti-HIV drugs to the CNS is attributed to their low permeability across the BBB. Hence, low and sustained viral replication within the CNS continues even during prolonged antiretroviral drug therapy. Therefore, developing novel approaches that are targeted at enhancing the CNS delivery of anti-HIV drugs are required. In this review, we discuss the potential of nanocarriers and the role of cell-penetrating peptides in enhancing drug delivery to the CNS. Such drug delivery approaches could also lead to higher drug delivery to other cellular and anatomical reservoirs where the virus harbors than with conventional treatment, thus providing an effective therapy to eliminate the virus completely from the body.
C1 [Rao, Kavitha S.; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Ghorpade, Anuja] Univ N Texas, Dept Cell Biol & Genet, Ft Worth, TX 76107 USA.
RP Rao, KS (reprint author), Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, ND-20,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
FU National Institute of Mental Health [R21 MH067525]; National Institute
   of Stroke and Neurological Disorders [2R01 NS048837]; American Heart
   Association, Heartland Affiliate [0710119Z]
FX The study reported here is funded by grants R21 MH067525 from the
   National Institute of Mental Health (to V I-abhaserwar) and 2R01
   NS048837 from the National Institute of Stroke and Neurological
   Disorders (to A Ghorpade) of the National Institutes of Health. KS Rao
   is supported by a pre-doctoral fellowship from the American Heart
   Association, Heartland Affiliate (Grant # 0710119Z).
CR Alirezaei M, 2007, J NEUROSCI, V27, P11047, DOI 10.1523/JNEUROSCI.2733-07.2007
   Alyautdin RN, 1998, J MICROENCAPSUL, V15, P67, DOI 10.3109/02652049809006836
   An SF, 1999, ACTA NEUROPATHOL, V98, P481, DOI 10.1007/s004010051113                                                           
   Ances BM, 2007, SEMIN NEUROL, V27, P86, DOI 10.1055/s-2006-956759
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002
   Bocedi A, 2004, IUBMB LIFE, V56, P609, DOI 10.1080/15216540400016286
   Boisse L, 2008, NEUROL CLIN, V26, P799, DOI 10.1016/j.ncl.2008.04.002
   Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003
   BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648
   Canto-Noges C, 2005, J MOL NEUROSCI, V27, P79, DOI 10.1385/JMN:27:01:79
   *CDC, 2006, HIV AIDS STAT SURV
   Chaudhuri J D, 2000, Med Sci Monit, V6, P1213
   Clifford David B, 2008, Top HIV Med, V16, P94
   Coloma MJ, 2000, PHARMACEUT RES, V17, P266, DOI 10.1023/A:1007592720793
   Cook JE, 2005, ANN NEUROL, V57, P795, DOI 10.1002/ana.20479                                                               
   Corasaniti MT, 2000, BIOCHEM BIOPH RES CO, V274, P664, DOI 10.1006/bbrc.2000.3160
   CRONE C, 1981, J GEN PHYSIOL, V77, P349, DOI 10.1085/jgp.77.4.349
   CROWE SM, 1989, J MED VIROL, V29, P176, DOI 10.1002/jmv.1890290306                                                          
   Dechy-Cabaret O, 2004, CHEM REV, V104, P6147, DOI 10.1021/cr040002s
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Drugan C, 2002, BLOOD CELL MOL DIS, V28, P13, DOI 10.1006/bcmd.2001.0479
   DUSSERRE N, 1995, AIDS, V9, P833, DOI 10.1097/00002030-199508000-00002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dwibhashyam VSNM, 2008, INDIAN J PHARM SCI, V70, P145, DOI 10.4103/0250-474X.41446
   Fleury S, 1998, NAT MED, V4, P794, DOI 10.1038/nm0798-794                                                              
   FOLKS T, 1986, J IMMUNOL, V136, P4049
   Ghafouri M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-28
   Gorry PR, 2003, CURR HIV RES, V1, P463, DOI 10.2174/1570162033485122
   Grant I, 2008, INT REV PSYCHIATR, V20, P33, DOI 10.1080/09540260701877894
   Greene J N, 1999, Chest Surg Clin N Am, V9, P39
   GREENE JN, 1999, CHEST SURG CLIN N AM, V9, pR7
   Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5
   Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ
   Hinkin CH, 2001, J CLIN EPIDEMIOL, V54, pS44, DOI 10.1016/S0895-4356(01)00446-2
   HO D, 1998, 5 C RETR OPP INF CHI
   Ho DD, 1996, B NEW YORK ACAD MED, V73, P37
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Hynynen K, 2007, EXPERT OPIN DRUG DEL, V4, P27, DOI 10.1517/17425247.4.1.27
   Ikeda M, 2002, BIOCHEM BIOPH RES CO, V291, P669, DOI 10.1006/bbrc.2002.6495
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   Kaul M, 2008, FRONT BIOSCI-LANDMRK, V13, P2484, DOI 10.2741/2860
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   KWEI GY, 1995, PHARMACEUT RES, V12, P884, DOI 10.1023/A:1016269206048
   Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002
   Letendre Scott, 2008, Top HIV Med, V16, P15
   LIN JH, 1995, DRUG METAB DISPOS, V23, P730
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Markowitz M, 2005, LANCET, V365, P1031, DOI 10.1016/S0140-6736(05)71139-9
   Maschke M, 2000, J NEUROL NEUROSUR PS, V69, P376, DOI 10.1136/jnnp.69.3.376
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Nath A, 2002, J INFECT DIS, V186, pS193, DOI 10.1086/344528                                                                  
   NEUWELT EA, 1984, NEUROSURGERY, V15, P362, DOI 10.1227/00006123-198409000-00011                                                
   Nottet HSLM, 1996, J IMMUNOL, V156, P1284
   OJEWOLE E, 2008, EUR J PHARM BIOPHARM, P697
   OZTAS B, 1995, NEUROSCI LETT, V190, P203, DOI 10.1016/0304-3940(95)11542-5
   Paparizos VA, 2008, JAIDS-J ACQ IMM DEF, V49, P111, DOI 10.1097/QAI.0b013e31816d9d2b
   Pardridge WM, 2006, CURR OPIN PHARMACOL, V6, P494, DOI 10.1016/j.coph.2006.06.001
   PARDRIDGE WM, 2003, BRAIN DRUG TARGETING
   PEETLA C, 2009, MOL PHARM IN PRESS
   ProkaiTatrai K, 1996, J MED CHEM, V39, P4775, DOI 10.1021/jm960356e
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Robinson-Papp J, 2008, ARCH NEUROL-CHICAGO, V65, P1096, DOI 10.1001/archneur.65.8.1096
   Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11
   Rumbaugh JA, 2006, CURR PHARM DESIGN, V12, P1023, DOI 10.2174/138161206776055877
   SABATIER JM, 1991, J VIROL, V65, P961
   Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295
   SALAHUDDIN TS, 1988, NEUROPATH APPL NEURO, V14, P467, DOI 10.1111/j.1365-2990.1988.tb01338.x                                              
   Schinkel AH, 2001, ADV EXP MED BIOL, V500, P365
   Schnyder Anita, 2005, NeuroRx, V2, P99, DOI 10.1007/BF03206646
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sevigny JJ, 2004, NEUROLOGY, V63, P2084, DOI 10.1212/01.WNL.0000145763.68284.15                                              
   SPIGELMAN MK, 1984, J NEUROSURG, V61, P674, DOI 10.3171/jns.1984.61.4.0674
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000
   TADAYONI BM, 1993, BIOCONJUGATE CHEM, V4, P139, DOI 10.1021/bc00020a006
   Takasawa K, 1997, J PHARMACOL EXP THER, V281, P369
   Tan H, 2008, PROTEINS, V74, P881
   Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9
   Temsamani J, 2001, EXPERT OPIN BIOL TH, V1, P773, DOI 10.1517/14712598.1.5.773
   THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300                                                            
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022
   Tozzi V, 2007, JAIDS-J ACQ IMM DEF, V45, P174, DOI 10.1097/QAI.0b013e318042e1ee
   Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1007/BF03206642
   UNAIDS and WHO, 2007, AIDS EP UPD
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WANG YF, 1995, J PHARM SCI, V84, P871, DOI 10.1002/jps.2600840717
   Webb K, 2000, CRIT REV BIOMED ENG, V28, P203, DOI 10.1615/CritRevBiomedEng.v28.i12.350                                            
   Wiley CA, 1999, AIDS, V13, P2055, DOI 10.1097/00002030-199910220-00007
   WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089                                                         
   Wiseman MB, 1999, J NEUROPSYCH CLIN N, V11, P222
   Wolinsky JB, 2008, ADV DRUG DELIVER REV, V60, P1037, DOI 10.1016/j.addr.2008.02.012
   Yoo JY, 2005, BIO-MED MATER ENG, V15, P279
   Zhang Y, 2003, MOL THER, V7, P11, DOI 10.1016/S1525-0016(02)00018-7
   Zhang ZP, 2006, BIOMATERIALS, V27, P4025, DOI 10.1016/j.biomaterials.2006.03.006
   Zheng Lin, 2005, J Zhejiang Univ Sci B, V6, P668, DOI 10.1631/jzus.2005.B0668
NR 106
TC 39
Z9 41
U1 2
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD AUG
PY 2009
VL 6
IS 8
BP 771
EP 784
DI 10.1517/17425240903081705
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 483UB
UT WOS:000268992600001
PM 19566446
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bonoiu, A
   Mahajan, SD
   Ye, L
   Kumar, R
   Ding, H
   Yong, KT
   Roy, I
   Aalinkeel, R
   Nair, B
   Reynolds, JL
   Sykes, DE
   Imperiale, MA
   Bergey, EJ
   Schwartz, SA
   Prasad, PN
AF Bonoiu, Adela
   Mahajan, Supriya D.
   Ye, Ling
   Kumar, Rajiv
   Ding, Hong
   Yong, Ken-Tye
   Roy, Indrajit
   Aalinkeel, Ravikumar
   Nair, Bindukumar
   Reynolds, Jessica L.
   Sykes, Donald E.
   Imperiale, Marco A.
   Bergey, Earl J.
   Schwartz, Stanley A.
   Prasad, Paras N.
TI MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to
   maintain the integrity of the blood brain barrier
SO BRAIN RESEARCH
LA English
DT Article
DE Nanotechnology; siRNA; Nanoplex; Blood brain barrier; Matrix
   metalloproteinases; MMP-9; Quantum dot; CNS
ID FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; MATRIX METALLOPROTEINASES; HIV-1
   ENCEPHALITIS; TISSUE INHIBITORS; CELLS; TRANSCRIPTION; INFECTION;
   INVASION; MODEL
AB The matrix-degrading metalloproteinases (MMPs), particularly MMP-9, are involved in the neuroinflammation processes leading to disrupting of the blood brain barrier (BBB), thereby exacerbating neurological diseases such as HIV-1 AIDS dementia and cerebral ischemia. Nanoparticles have been proposed to act as non-viral gene delivery vectors and have great potential for therapeutic applications in several disease states. In this study, we evaluated the specificity and efficiency of quantum dot (QD) complexed with MMP-9-siRNA (nanoplex) in downregulating the expression of MMP-9 gene in brain microvascular endothelial cells (BMVEC) that constitute the BBB. We hypothesize that silencing MMP-9 gene expression in BMVECs and other cells such as leukocytes may help prevent breakdown of the BBB and inhibit subsequent invasion of the central nervous system (CNS) by infected and inflammatory cells. Our results show that silencing of MMP-9 gene expression resulted in the up-regulation of extracellular matrix (ECM) proteins like collagen I, IV, V and a decrease in endothelial permeability, as reflected by reduction of transendothelial resistance across the BBB in a well validated in-vitro BBB model. MMP-9 gene silencing also resulted in an increase in expression of the gene tissue inhibitor of metalloproteinase-1 (TIMP-1). This indicates the importance of a balance between the levels of MMP-9 and its natural inhibitor TIMP-1 in maintaining the basement membrane integrity. These studies promise the application of a novel nanoparticle based siRNA delivery system in modulating the MMP-9 activity in BMVECs and other MMP-9 producing cells. This will prevent neuroinflammation and maintain the integrity of the BBB. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Bonoiu, Adela; Ye, Ling; Kumar, Rajiv; Ding, Hong; Yong, Ken-Tye; Roy, Indrajit; Bergey, Earl J.; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Nair, Bindukumar; Reynolds, Jessica L.; Sykes, Donald E.; Imperiale, Marco A.; Schwartz, Stanley A.] SUNY Buffalo, Dept Med, Div Rheumatol Allergy & Immunol, Buffalo, NY 14203 USA.
   [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Nair, Bindukumar; Reynolds, Jessica L.; Sykes, Donald E.; Imperiale, Marco A.; Schwartz, Stanley A.] Kaleida Hlth, Buffalo, NY 14203 USA.
RP Prasad, PN (reprint author), SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
EM pnprasad@buffalo.edu
RI Ding, Hong/C-2322-2011; Kumar, Rajiv/A-1457-2011
OI Ding, Hong/0000-0003-0376-0008; Kumar, Rajiv/0000-0003-2926-9866; Kumar,
   Rajiv/0000-0002-2363-3930
FU National Institute of Health [R01CA119397, R01CA104492]; Kaleida Health
   Foundation; John R. Oishei Foundation
FX This study was supported by grants from the National Institute of Health
   (R01CA119397 and R01CA104492), the Kaleida Health Foundation, and the
   John R. Oishei Foundation. Support from the Center of Excellence in
   Bioinformatics and Life Sciences at the University at Buffalo is also
   acknowledged. The authors are also indebted to Dr. Kenneth M. Tramposch
   for providing his expert comments on this manuscript.
CR Abbott N Joan, 2004, Drug Discov Today Technol, V1, P407, DOI 10.1016/j.ddtec.2004.11.014
   Abbott NJ, 2005, CELL MOL NEUROBIOL, V25, P5, DOI 10.1007/s10571-004-1374-y
   Annunziata P, 2003, J NEUROL, V250, P901, DOI 10.1007/s00415-003-1159-0
   Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050
   Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707
   Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Burggraf D, 2005, EUR J NEUROSCI, V22, P273, DOI 10.1111/j.1460-9568.2005.04187.x
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209                                                      
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4
   Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004
   GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583
   Langford TD, 2003, BRAIN PATHOL, V13, P195
   Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1
   MAQUART FX, 1988, FEBS LETT, V238, P343, DOI 10.1016/0014-5793(88)80509-X
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Paul R, 1998, ANN NEUROL, V44, P592, DOI 10.1002/ana.410440404
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Prasad P. N., 2004, NANOPHOTONICS
   Prasad P. N., 2003, INTRO BIOPHOTONICS
   Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
   Qian J, 2007, J PHYS CHEM B, V111, P6969, DOI 10.1021/jp070620n
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066
   Schmidt R, 2008, CIRC RES, V102, P302, DOI 10.1161/CIRCRESAHA.107.157990
   Schmidtmayerova H, 1997, VIROLOGY, V232, P379, DOI 10.1006/viro.1997.8584
   Sundstrom JB, 2001, AIDS RES HUM RETROV, V17, P1605, DOI 10.1089/088922201753342013                                                      
   Teichberg VI, 2007, P NATL ACAD SCI USA, V104, P7315, DOI 10.1073/pnas.0702450104
   TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x
   Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   WOESSNER FJ, 1991, FASEB J, V5, P2145
   Wu DT, 2000, J NEUROVIROL, V6, pS82
   Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m
   2007, CURRENT PROTOCOLS IM
NR 39
TC 61
Z9 64
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JUL 28
PY 2009
VL 1282
BP 142
EP 155
DI 10.1016/j.brainres.2009.05.047
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 477PG
UT WOS:000268530400016
PM 19477169
OA green_accepted
DA 2018-01-05
ER

PT J
AU Torres-Chavolla, E
   Alocilja, EC
AF Torres-Chavolla, Edith
   Alocilja, Evangelyn C.
TI Aptasensors for detection of microbial and viral pathogens
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Review
DE Aptamers; Aptasensor; Pathogen detection; Complex targets;
   Nanoparticle-based platforms
ID IN-VITRO SELECTION; HEPATITIS-C VIRUS; APTAMER-BASED BIOSENSORS;
   MOLECULAR RECOGNITION ELEMENTS; NUCLEIC-ACID APTAMERS; HIGH-AFFINITY
   LIGANDS; DNA CAPTURE ELEMENTS; HIV-1 TAT PROTEIN; BIO-BAR CODES; RNA
   APTAMERS
AB Aptamers are specific nucleic acid sequences that can bind to a wide range of non-nucleic acid targets with high affinity and specificity. These molecules are identified and selected through an in vitro process called SELEX (systematic evolution of ligands by exponential enrichment). Proteins are the most common targets in aptamer selection. In diagnostic and detection assays, aptamers; represent an alternative to antibodies as recognition agents. Cellular detection is a promising area in aptamer research. one of its principal advantages is the ability to target and specifically differentiate microbial strains without having previous knowledge of the membrane molecules or structural changes present in that particular microorganism. The present review focuses on aptamers, SELEX procedures, and aptamer-based biosensors (aptasensors) for the detection of pathogenic microorganisms and viruses. Special emphasis is placed on nanoparticle-based platforms. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Torres-Chavolla, Edith; Alocilja, Evangelyn C.] Michigan State Univ, E Lansing, MI 48824 USA.
RP Alocilja, EC (reprint author), Michigan State Univ, E Lansing, MI 48824 USA.
EM alocilja@msu.edu
CR Adler A, 2008, COMB CHEM HIGH T SCR, V11, P16
   Alocilja EC, 2003, BIOSENS BIOELECTRON, V18, P841, DOI 10.1016/S0956-5663(03)00009-5
   Bagalkot V, 2007, NANO LETT, V7, P3065, DOI 10.1021/nl071546n
   Baker BR, 2006, J AM CHEM SOC, V128, P3138, DOI 10.1021/ja056957p
   Balamurugan S, 2008, ANAL BIOANAL CHEM, V390, P1009, DOI 10.1007/s00216-007-1587-2
   Bang GS, 2005, BIOSENS BIOELECTRON, V21, P863, DOI 10.1016/j.bios.2005.02.002
   Bannantine JP, 2007, CLIN VACCINE IMMUNOL, V14, P518, DOI 10.1128/CVI.00022-07
   Biroccio A, 2002, J VIROL, V76, P3688, DOI 10.1128/JVI.76.8.3688-3696.2002
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7
   Bruno JG, 2002, BIOTECHNIQUES, V32, P178
   Cai H, 2006, SENSOR ACTUAT B-CHEM, V114, P433, DOI 10.1016/j.snb.2005.06.017
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Cerchia L, 2002, FEBS LETT, V528, P12, DOI 10.1016/S0014-5793(02)03275-1                                                   
   Cerchia Laura, 2007, Methods Mol Biol, V361, P187
   Chen F, 2007, BIOCHEM BIOPH RES CO, V357, P743, DOI 10.1016/j.bbrc.2007.04.007
   Cheng CS, 2008, BIOCHEM BIOPH RES CO, V366, P670, DOI 10.1016/j.bbrc.2007.11.183
   Choi JH, 2006, J AM CHEM SOC, V128, P15584, DOI 10.1021/ja066506k
   Chu T, 2007, CURR OPIN MOL THER, V9, P137
   Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E                     
   Collett JR, 2005, METHODS, V37, P4, DOI 10.1016/j.ymeth.2005.05.009
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Deisingh AK, 2006, HANDB EXP PHARM, V173, P341
   DeStefano JJ, 2006, NUCLEIC ACIDS RES, V34, P130, DOI 10.1093/nar/gkj426
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Fischer N, 2007, CURR OPIN CHEM BIOL, V11, P316, DOI 10.1016/j.cbpa.2007.05.017
   Fitter S, 2005, J BIOL CHEM, V280, P34193, DOI 10.1074/jbc.M504772200
   Fukuda K, 2000, EUR J BIOCHEM, V267, P3685, DOI 10.1046/j.1432-1327.2000.01400.x                                                
   Gopinath SCB, 2006, J GEN VIROL, V87, P479, DOI 10.1099/vir.0.81508-0
   Guo KT, 2006, STEM CELLS, V24, P2220, DOI 10.1634/stemcells.2006-0015
   Hamula CLA, 2006, TRAC-TREND ANAL CHEM, V25, P681, DOI 10.1016/j.trac.2006.05.007
   Hansen JA, 2006, J AM CHEM SOC, V128, P2228, DOI 10.1021/ja060005h
   He PL, 2007, ANAL CHEM, V79, P8024, DOI 10.1021/ac070772e
   Herr JK, 2006, ANAL CHEM, V78, P2918, DOI 10.1021/ac052015r
   Heyduk E, 2005, ANAL CHEM, V77, P1147, DOI 10.1021/ac0487449
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006
   Homann M, 2001, BIOORGAN MED CHEM, V9, P2571, DOI 10.1016/S0968-0896(01)00032-3                                                   
   Huang CC, 2005, ANAL CHEM, V77, P5735, DOI 10.1021/ac050957q
   Hwang B, 2004, RNA, V10, P1277, DOI 10.1261/rna.7100904
   Ikanovic M, 2007, J FLUORESC, V17, P193, DOI 10.1007/s10895-007-0158-4
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   James W, 2007, J GEN VIROL, V88, P351, DOI 10.1099/vir.0.82442-0
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jhaveri SD, 2000, J AM CHEM SOC, V122, P2469, DOI 10.1021/ja992393b                                                               
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kiel JL, 2004, P SOC PHOTO-OPT INS, V5617, P382, DOI 10.1117/12.566640
   Kiel JL, 2004, P SOC PHOTO-OPT INS, V5416, P105, DOI 10.1117/12.532043
   Kouassi GK, 2007, BIOTECHNOL PROGR, V23, P1239, DOI 10.1021/bp0602101
   Kusser W., 2000, REV MOL BIOTECHNOL, V74, P27
   Lazcka O, 2007, BIOSENS BIOELECTRON, V22, P1205, DOI 10.1016/j.bios.2006.06.036
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Lee JO, 2008, ANAL BIOANAL CHEM, V390, P1023, DOI 10.1007/s00216-007-1643-y
   Lee M, 2000, ANAL BIOCHEM, V282, P142, DOI 10.1006/abio.2000.4595                                                          
   Lee S, 2007, BIOCHEM BIOPH RES CO, V358, P47, DOI 10.1016/j.bbrc.2007.04.057
   Levy M, 2005, CHEMBIOCHEM, V6, P2163, DOI 10.1002/cbic.200500218
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Mir M, 2006, ELECTROCHEM COMMUN, V8, P505, DOI 10.1016/j.elecom.2005.12.022
   Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902                                                          
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nitsche A., 2007, BMC BIOTECHNOL, P7
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   Ohuchi SP, 2006, BIOCHIMIE, V88, P897, DOI 10.1016/j.biochi.2006.02.004
   Pagratis NC, 1997, NAT BIOTECHNOL, V15, P68, DOI 10.1038/nbt0197-68
   Pan Q, 2005, ANTIMICROB AGENTS CH, V49, P4052, DOI 10.1128/AAC.49.10.4052-4060.2005
   PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Proske D, 2005, APPL MICROBIOL BIOT, V69, P367, DOI 10.1007/s00253-005-0193-5
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Rodriguez MC, 2005, CHEM COMMUN, P4267, DOI 10.1039/b506571b
   Sando S, 2007, BIOORG MED CHEM LETT, V17, P1216, DOI 10.1016/j.bmcl.2006.12.013
   Shamah SM, 2008, ACCOUNTS CHEM RES, V41, P130, DOI 10.1021/ar700142z
   Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Smith JE, 2007, ANAL CHEM, V79, P3075, DOI 10.1021/ac062151b
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   So HM, 2008, SMALL, V4, P197, DOI 10.1002/smll.200700664
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Spiridonova VA, 2002, BIOCHEMISTRY-MOSCOW+, V67, P706, DOI 10.1023/A:1016110724564                                                         
   STRATISCULLUM DN, 2007, P SPIE C, V6554
   STRATISCULLUM DN, 2005, P SPIE C, V5994
   Tang ZW, 2007, ANAL CHEM, V79, P4900, DOI 10.1021/ac070189y
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200
   Vivekananda J, 2006, LAB INVEST, V86, P610, DOI 10.1038/labinvest.3700417
   Wang WJ, 2008, ANAL BIOCHEM, V373, P213, DOI 10.1016/j.ab.2007.11.013
   Willner I, 2007, ANGEW CHEM INT EDIT, V46, P6408, DOI 10.1002/anie.200604524
   Xiao ZY, 2008, CHEM-EUR J, V14, P1769, DOI 10.1002/chem.200701330
   Yamamoto R, 2000, GENES CELLS, V5, P371, DOI 10.1046/j.1365-2443.2000.00330.x                                                
   Zayats M, 2006, J AM CHEM SOC, V128, P13666, DOI 10.1021/ja0651456
   Zhang ZR, 2004, ARCH IMMUNOL THER EX, V52, P307
   Zhen B, 2002, ACTA BIOCH BIOPH SIN, V34, P635
NR 104
TC 134
Z9 143
U1 3
U2 118
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JUL 15
PY 2009
VL 24
IS 11
BP 3175
EP 3182
DI 10.1016/j.bios.2008.11.010
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 465IY
UT WOS:000267577900001
PM 19117748
DA 2018-01-05
ER

PT J
AU Matejicek, P
   Zednik, J
   Uselova, K
   Plestil, J
   Fanfrlik, J
   Nykanen, A
   Ruokolainen, J
   Hobza, P
   Prochazka, K
AF Matejicek, Pavel
   Zednik, Jiri
   Uselova, Katerina
   Plestil, Josef
   Fanfrlik, Jindrich
   Nykanen, Antti
   Ruokolainen, Janne
   Hobza, Pavel
   Prochazka, Karel
TI Stimuli-Responsive Nanoparticles Based on Interaction of
   Metallacarborane with Poly(ethylene oxide)
SO MACROMOLECULES
LA English
DT Article
ID NEUTRON-CAPTURE THERAPY; BLOCK-COPOLYMER MICELLES;
   POLYSTYRENE-BLOCK-POLY(METHACRYLIC ACID) MICELLES; LIGHT-SCATTERING;
   AQUEOUS-MEDIA; HIV PROTEASE; POLYMER ELECTROLYTES; DICARBOLLIDE ANIONS;
   MOLECULAR-DYNAMICS; BORON CLUSTERS
AB We report the first evidence that the antiviral active (inhibitor of HIV protease) boron cluster [3-cobalt bis(1,2-dicarbollide)](-) anion. CoD-, interacts and forms a stable complex with one of the most widely used polymeric components of drug delivery systems: poly(ethylene oxide), PEO. The metallacarborane/polymer complex is insoluble in aqueous solutions. The amount of the precipitate depends oil concentration of alkaline or earth-alkaline cations. The formation of insoluble complex is the result of a combination of several Factors. One of the decisive contributions is the formation of dihydrogen bonds between negatively charged hydrogen atoms attached to boron atoms and slightly positively charged H atoms in repealing -CH2-CH2-O- units. It is also important that alkaline cations interact with oxygen atoms of PEO. The formation of the insoluble NaCoD/PEO complex can be exploited ill design of water-soluble [3-cobalt bis(1,2-dicarbollide)]-containing nanoparticles which could offer applications ill medicine. We studied the boron cluster interaction with well-defined double hydrophilic block copolymer: poly(ethylene oxide)-block-poly(methacrylic acid), PEO-PMA. The interaction leads to it spontaneous formation of core-shell nanoparticles. The insoluble core contains the PEO/CoD- complex, while the polyanionic PMA blocks, which do not interact with the cobaltacarborane, form the pH-responsive micellar shell and stabilize the particles in aqueous media. The nanoparticles were studied by light and X-ray scattering, NMR spectroscopy, electrophoresis, and microscopy techniques like AFM and cryo-TEM. It was found that the cores are not completely frozen in aqueous media. Their composition depends oil salt concentration, and the metallacarborane call diffuse from/into the nanoparticle after the salinity change.
C1 [Matejicek, Pavel; Zednik, Jiri; Uselova, Katerina; Prochazka, Karel] Charles Univ Prague, Dept Phys & Macromol Chem, Fac Sci, Prague 12840 2, Czech Republic.
   [Plestil, Josef] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic.
   [Fanfrlik, Jindrich; Hobza, Pavel] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Ctr Biomol & Complex Mol Syst, Gilead Sci & IOCB Res Ctr, CR-16610 Prague 6, Czech Republic.
   [Nykanen, Antti; Ruokolainen, Janne] Aalto Univ, Dept Engn Phys, FI-02150 Espoo, Finland.
RP Matejicek, P (reprint author), Charles Univ Prague, Dept Phys & Macromol Chem, Fac Sci, Hlavova 2030, Prague 12840 2, Czech Republic.
EM matej@vivien.natur.cuni.cz
RI Plestil, Josef/H-6807-2014; Hobza, Pavel/G-8060-2014; Ruokolainen,
   Janne/F-6369-2010; Prochazka, Karel/C-3012-2014; Zednik,
   Jiri/F-2637-2014; Uselova, Katerina/L-1759-2017; Matejicek,
   Pavel/M-6582-2017; Nykanen, Antti/F-6941-2010
OI Prochazka, Karel/0000-0003-2144-5378; Zednik, Jiri/0000-0001-7325-8684;
   Uselova, Katerina/0000-0001-6830-1705; Matejicek,
   Pavel/0000-0001-5482-3465; Nykanen, Antti/0000-0003-4989-2911; Fanfrlik,
   Jindrich/0000-0002-1257-1201
FU Agency of the Czech Republic [203/06/13138, 203/06/P261, 203/05/1-1001];
   Agency of the Academy of Sciences of the Czech Republic [IAAX00320901];
   Ministry of Education of the Czech Republic [0021620857]; Academy of
   Sciences of the Czech Republic [T400500402, Z40550506]
FX Authors acknowledge the financial support of the Grant Agency of the
   Czech Republic (Grants 203/06/13138, 203/06/P261, and 203/05/1-1001) and
   the Grant Agency of the Academy of Sciences of the Czech Republic
   (IAAX00320901). The authors were supported by long-term Research Plan of
   the Ministry of Education of the Czech Republic No. MSM 0021620857. J.P.
   gratefully acknowledges the financial support of the Academy of Sciences
   of the Czech Republic (Project T400500402 in the prograrn "Information
   Society"), and P.H. and J.F. acknowledge the research Project No.
   Z40550506. The authors thank Drmtrij V. Bondarev for help with FTIR
   measurements, Petr Kadlec for the dn/dc measurenients, Zdenek Tuzar for
   a fruitful discussion concerning light scattering, and Blanka Vlckkova
   for valuable advice concerning interpretation off R spectra.
CR Adam MJ, 2005, CHEM SOC REV, V34, P153, DOI 10.1039/b313872k
   AHLRICHS R, 1989, CHEM PHYS LETT, V162, P165, DOI 10.1016/0009-2614(89)85118-8
   Armstrong AF, 2007, DALTON T, P4240, DOI 10.1039/b709843j
   Barth RF, 1999, NEUROSURGERY, V44, P433, DOI 10.1097/00006123-199903000-00001
   Benhabbour SR, 2007, MACROMOLECULES, V40, P5678, DOI 10.1021/ma0702039
   Bregadze V. I., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P75, DOI 10.2174/187152006776119180
   BREGADZE VI, 2007, RUSS CHEM B, V56, P620
   Bronich TK, 2005, J AM CHEM SOC, V127, P8236, DOI 10.1021/ja043042m
   Chevrot G, 2007, PHYS CHEM CHEM PHYS, V9, P1991, DOI 10.1039/b616753e
   Chevrot G, 2007, PHYS CHEM CHEM PHYS, V9, P5928, DOI 10.1039/b711284j
   Chevrot G, 2006, J PHYS CHEM B, V110, P9488, DOI 10.1021/jp060930q
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   Cigler P, 2008, COLLOID SURFACE B, V64, P145, DOI 10.1016/j.colsurfb.2008.01.011
   COSGROVE T, 1992, ADV COLLOID INTERFAC, V42, P175, DOI 10.1016/0001-8686(92)80023-Q                                                    
   COSSI M, 1996, J CHEM PHYS LETT, V255, P327, DOI DOI 10.1016/0009-2614(96)00349-1
   Crespo E, 2007, J PHYS CHEM C, V111, P18381, DOI 10.1021/jp0755443
   Debnath AK, 1999, MED CHEM RES, V9, P267
   DiNoto V, 1996, MACROMOL CHEM PHYSIC, V197, P375, DOI 10.1002/macp.1996.021970129                                                     
   Fanfrlik J, 2006, CHEMPHYSCHEM, V7, P1100, DOI 10.1002/cphc.200500648
   Fanfrlik J, 2007, PHYS CHEM CHEM PHYS, V9, P2085, DOI 10.1039/b617776j
   Fanfrlik J, 2008, J PHYS CHEM B, V112, P15094, DOI 10.1021/jp803528w
   Farras P, 2008, INORG CHEM, V47, P9497, DOI 10.1021/ic801139x
   FEYEREISEN M, 1993, CHEM PHYS LETT, V208, P359, DOI 10.1016/0009-2614(93)87156-W                                                    
   Fox MA, 2002, J MATER CHEM, V12, P1301, DOI 10.1039/b108721e
   Frisch M. J., 2003, GAUSSIAN03
   Fujii S, 2005, J MED CHEM, V48, P4654, DOI 10.1021/jm050115j
   Gatsouli KA, 2007, J PHYS CHEM C, V111, P15201, DOI 10.1021/jp071681o
   Gil ES, 2004, PROG POLYM SCI, V29, P1173, DOI 10.1016/j.progpolymsci.2004.08.003
   GREEN J, 1964, J POLYM SCI POL LETT, V2, P109, DOI 10.1002/pol.1964.110020126                                                      
   Grimes RN, 2004, J CHEM EDUC, V81, P658
   Hao E, 2007, CHEM-EUR J, V13, P9035, DOI 10.1002/chem.200700752
   Harada A, 2006, PROG POLYM SCI, V31, P949, DOI 10.1016/j.progpolymsci.2006.09.004
   HAWTHORNE MF, 1965, J AM CHEM SOC, V87, P1818, DOI 10.1021/ja01086a053                                                             
   Hawthorne MF, 2003, J NEURO-ONCOL, V62, P33, DOI 10.1007/BF02699932
   Hawthorne MF, 1998, MOL MED TODAY, V4, P174, DOI 10.1016/S1357-4310(98)01226-X
   HAWTHORNE MF, 1993, ANGEW CHEM INT EDIT, V32, P950, DOI 10.1002/anie.199309501                                                          
   Henderson WA, 2003, J AM CHEM SOC, V125, P12098, DOI 10.1021/ja036535k
   Jakle F, 2005, J INORG ORGANOMET P, V15, P293, DOI 10.1007/s10904-005-7870-9
   Julius RL, 2007, P NATL ACAD SCI USA, V104, P4808, DOI 10.1073/pnas.0700316104
   Jurecka P, 2007, J COMPUT CHEM, V28, P555, DOI 10.1002/jcc.20570
   Kawaguchi S, 1996, MACROMOLECULES, V29, P4465, DOI 10.1021/ma950726t                                                               
   Konak C, 2007, MACROMOL CHEM PHYSIC, V208, P1893, DOI 10.1002/macp.200700214
   Kozisek M, 2008, J MED CHEM, V51, P4839, DOI 10.1021/jm8002334
   Krylov SN, 2007, ELECTROPHORESIS, V28, P69, DOI 10.1002/elps.200600577
   Kubat P, 2007, J PHYS CHEM B, V111, P4539, DOI 10.1021/jp066494p
   Kumar JS, 2007, J MATER SCI, V42, P5752, DOI 10.1007/s10853-006-0743-y
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   LEITES LA, 1992, CHEM REV, V92, P279, DOI 10.1021/cr00010a006                                                             
   Lesnikowski ZJ, 2007, CURR ORG CHEM, V11, P355, DOI 10.2174/138527207780059358                                                      
   Lesnikowski ZJ, 2007, COLLECT CZECH CHEM C, V72, P1646, DOI 10.1135/cccc20071646
   Lesnikowski ZJ, 1999, J ORGANOMET CHEM, V581, P156, DOI 10.1016/S0022-328X(99)00129-1                                                   
   LIGHTFOOT P, 1992, J MATER CHEM, V2, P379, DOI 10.1039/jm9920200379
   Matejicek P, 2006, LANGMUIR, V22, P575, DOI 10.1021/la052201s
   Matejicek P, 2004, MACROMOLECULES, V37, P10141, DOI 10.1021/ma049258q
   Matejicek P, 2002, MACROMOLECULES, V35, P9487, DOI 10.1021/ma012074g
   Matejicek P, 2008, LANGMUIR, V24, P2625, DOI 10.1021/la702852e
   Matejicek P, 2007, J PHYS CHEM B, V111, P8394, DOI 10.1021/jp0685075
   Newman CID, 2008, ELECTROPHORESIS, V29, P44, DOI 10.1002/elps.200700086
   PAPKE BL, 1981, J PHYS CHEM SOLIDS, V42, P493, DOI 10.1016/0022-3697(81)90030-5                                                    
   Pedersen JS, 1996, MACROMOLECULES, V29, P1363, DOI 10.1021/ma9512115                                                               
   Planas JG, 2005, J AM CHEM SOC, V127, P15976, DOI 10.1021/ja055210w
   PLESEK J, 1992, CHEM REV, V92, P269, DOI 10.1021/cr00010a005                                                             
   PLESEK J, 1984, COLLECT CZECH CHEM C, V49, P2776, DOI 10.1135/cccc19842776                                                            
   PLESTIL J, 1988, MAKROMOL CHEM-M SYMP, V15, P185, DOI 10.1002/masy.19880150113                                                        
   Plestil J, 2000, J APPL CRYSTALLOGR, V33, P600, DOI 10.1107/S0021889899012224                                                       
   POLIK WF, 1983, MACROMOLECULES, V16, P978, DOI 10.1021/ma00240a030                                                             
   PROCHAZKA K, 1990, J LIQ CHROMATOGR, V13, P1765, DOI 10.1080/01483919008048991                                                       
   RAIS J, 2005, SOLVENT EXTRACTION, P243
   Rodriguez-Hernandez J, 2005, PROG POLYM SCI, V30, P691, DOI 10.1016/j.progpolymsci.2005.04.002
   Rozenberg M, 1998, SPECTROCHIM ACTA A, V54, P1819, DOI 10.1016/S1386-1425(98)00062-6                                                   
   SEIDLER J, 2003, J MED CHEM, V46, P4486
   SEMIOSHKIN AA, 2008, DALTION T, V8, P977
   Sibrian-Vazquez M, 2006, BIOCONJUGATE CHEM, V17, P928, DOI 10.1021/bc060047v
   Simon YC, 2007, MACROMOLECULES, V40, P5628, DOI 10.1021/ma0709093
   Sivaev IB, 1999, COLLECT CZECH CHEM C, V64, P783, DOI 10.1135/cccc19990783                                                            
   SMITH IC, 1967, PRODUCTION BORANES R
   Soloway AH, 1997, J NEURO-ONCOL, V33, P9, DOI 10.1023/A:1005753610355
   Soloway AH, 1998, CHEM REV, V98, P1515, DOI 10.1021/cr941195u                                                               
   Sommer C, 2004, J PHYS CHEM B, V108, P6242, DOI 10.1021/jp036963c
   Sreekanth T, 1999, J POWER SOURCES, V79, P105, DOI 10.1016/S0378-7753(99)00051-8
   Stepanek M, 2001, LANGMUIR, V17, P4240, DOI 10.1021/la010246x
   Stepanek M, 1999, LANGMUIR, V15, P4185, DOI 10.1021/la981129d
   Stuart MAC, 2005, CURR OPIN COLLOID IN, V10, P30, DOI 10.1016/j.cocis.2005.04.004
   Teixidor F, 2003, PURE APPL CHEM, V75, P1305, DOI 10.1351/pac200375091305                                                         
   Trapp O, 2006, ELECTROPHORESIS, V27, P534, DOI 10.1002/elps.200500708
   Tsuji M, 2000, BIOL PHARM BULL, V23, P513
   TUZAR Z, 1967, COLLECT CZECH CHEM C, V32, P3358, DOI 10.1135/cccc19673358                                                            
   Uhlik F, 2003, J CHEM PHYS, V118, P11258, DOI 10.1063/1.1575732
   Valliant JF, 2002, COORDIN CHEM REV, V232, P173, DOI 10.1016/S0010-8545(02)00087-5                                                   
   Vicente M. G. H., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P73, DOI 10.2174/187152006776119162
   VINCENT CA, 1987, PROG SOLID STATE CH, V17, P145, DOI 10.1016/0079-6786(87)90003-3                                                    
   Vitale A. A., 2005, MOL MED CHEM, V8, P1
   Warren L. F., 1970, J AM CHEM SOC, V92, P1157, DOI DOI 10.1021/JA00708A009
   Wei XL, 2006, CHEM MATER, V18, P1113, DOI 10.1021/cm0524603
   Yamamoto K, 2001, BIOORG MED CHEM LETT, V11, P2389, DOI 10.1016/S0960-894X(01)00438-3                                                   
   Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s                                                               
   Zhao Q, 2006, PROG CHEM, V18, P768
NR 97
TC 27
Z9 27
U1 4
U2 40
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD JUL 14
PY 2009
VL 42
IS 13
BP 4829
EP 4837
DI 10.1021/ma900484y
PG 9
WC Polymer Science
SC Polymer Science
GA 472NJ
UT WOS:000268138500068
DA 2018-01-05
ER

PT J
AU Sloot, PMA
   Coveney, PV
   Ertaylan, G
   Muller, V
   Boucher, CA
   Bubak, M
AF Sloot, P. M. A.
   Coveney, Peter V.
   Ertaylan, G.
   Mueller, V.
   Boucher, C. A.
   Bubak, M.
TI HIV decision support: from molecule to man
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL
   AND ENGINEERING SCIENCES
LA English
DT Article; Proceedings Paper
CT UK e-Science All Hands Meeting
CY SEP 08-11, 2008
CL Edinburgh, SCOTLAND
DE human immunodeficiency virus; multilevel modelling; drug resistance;
   systems biology; decision support
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; IN-VIVO;
   PHYSICIAN EXPERIENCE; MUTATION-RATE; RESISTANCE; PROTEASE; SIMULATION;
   PREDICTION; INFECTION
AB Human immunodeficiency virus (HIV) is recognized to be one of the most destructive pandemics in recorded history. Effective highly active antiretroviral therapy and the availability of genetic screening of patient virus data have led to sustained viral suppression and higher life expectancy in patients who have been infected with HIV. The sheer complexity of the disease stems from the multiscale and highly dynamic nature of the system under study. The complete cascade from genome, proteome, metabolome and physiome to health forms a multidimensional system that crosses many orders of magnitude in temporal and spatial scales. Understanding, quantifying and handling this complexity is one of the biggest challenges of our time, which requires a highly multidisciplinary approach. In order to supply researchers with an interactive framework and to provide the medical professional with appropriate tools and information for making a balanced and reliable clinical decision, we have developed 'ViroLab', a collaborative decision-support system (http://www.virolab.org/). ViroLab contains computational models that cover various spatial and temporal scales from atomic-level interactions in nanoseconds up to sociological interactions on the epidemiological level, spanning years of disease progression. ViroLab allows for personalized drug ranking. It is on trial in six hospitals and various virology and epidemiology laboratories across Europe.
C1 [Sloot, P. M. A.; Ertaylan, G.; Bubak, M.] Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands.
   [Bubak, M.] AGH Univ Sci & Technol, Inst Comp Sci, PL-30056 Krakow, Poland.
   [Coveney, Peter V.] UCL, CCS, London WC1H 0AJ, England.
   [Mueller, V.] Eotvos Lorand Univ, Inst Biol, H-1117 Budapest, Hungary.
   [Boucher, C. A.] Erasmus MC, Dept Virol, NL-3000 CA Rotterdam, Netherlands.
RP Sloot, PMA (reprint author), Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands.
EM p.m.a.sloot@uva.nl
RI Sloot, Peter/B-3078-2014; Muller, Viktor/B-3493-2009; Ertaylan,
   Gokhan/A-3061-2009
OI Sloot, Peter/0000-0002-3848-5395; Muller, Viktor/0000-0001-8212-4880;
   Ertaylan, Gokhan/0000-0001-5602-6435
CR Bubak M, 2008, COMP MED SY, P373, DOI 10.1109/CBMS.2008.47
   Coveney PV, 2007, COMPUT PHYS COMMUN, V176, P406, DOI 10.1016/j.cpc.2006.11.011
   Deforche K, 2008, BIOINFORMATICS, V24, P34, DOI 10.1093/bioinformatics/btm540
   Deforche K, 2007, INFECT GENET EVOL, V7, P382, DOI 10.1016/j.meegid.2006.09.004
   Delgado J, 2003, ANTIVIR THER, V8, P471
   *DEP HLTH HUM SERV, 2008, AIDSINFO
   Ermolieff J, 1997, BIOCHEMISTRY-US, V36, P12364, DOI 10.1021/bi971072e
   ERTAYLAN G, 2008, P 3 INT WORKSH TARG, V2, P25
   Fang CT, 2007, QJM-INT J MED, V100, P97, DOI 10.1093/qjmed/hcl141
   GUBALA T, 2007, CRAC GRID WORKSH 200, P35
   HAUB C, 2007, POPULATION B POPULAT
   Hoffman NG, 2003, VIROLOGY, V314, P536, DOI 10.1016/S0042-6822(03)00484-7
   Huang KJ, 2005, J VIROL METHODS, V124, P95, DOI 10.1016/j.jviromet.2004.11.010
   Kitahata MM, 2000, J ACQ IMMUN DEF SYND, V24, P106
   MANSKY LM, 1995, J VIROL, V69, P5087
   Maschera B, 1996, J BIOL CHEM, V271, P33231, DOI 10.1074/jbc.271.52.33231                                                        
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Sadiq SK, 2008, J CHEM INF MODEL, V48, P1909, DOI 10.1021/ci8000937
   Sadiq S Kashif, 2007, Biochemistry, V46, P14865, DOI 10.1021/bi700864p
   Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P8396, DOI 10.1073/pnas.0400146101
   Sloot P, 2002, LECT NOTES COMPUT SC, V2493, P282
   Sloot PMA, 2008, INT J COMPUT MATH, V85, P1175, DOI 10.1080/00207160701750583
   Sloot PMA, 2006, COMPUTER, V39, P40, DOI 10.1109/MC.2006.380
   Sloot P.M.A., 2008, REV ANTIVIRAL THER, V3, P4
   Stoica I, 2008, J AM CHEM SOC, V130, P2639, DOI 10.1021/ja0779250
   UNAIDS, 2008, REP GLOB AIDS EP
NR 26
TC 19
Z9 19
U1 0
U2 7
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1364-503X
J9 PHILOS T R SOC A
JI Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.
PD JUL 13
PY 2009
VL 367
IS 1898
BP 2691
EP 2703
DI 10.1098/rsta.2009.0043
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 461PW
UT WOS:000267281800008
PM 19487205
OA gold
DA 2018-01-05
ER

PT J
AU Yesylevskyy, S
   Marrink, SJ
   Mark, AE
AF Yesylevskyy, Semen
   Marrink, Siewert-Jan
   Mark, Alan E.
TI Alternative Mechanisms for the Interaction of the Cell-Penetrating
   Peptides Penetratin and the TAT Peptide with Lipid Bilayers
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; ANTENNAPEDIA HOMEODOMAIN; ANTIMICROBIAL
   PEPTIDES; 3RD HELIX; PHOSPHOLIPID-VESICLES; PROTEIN TRANSDUCTION;
   MEDIATED DELIVERY; HIV-1; MEMBRANES; BINDING
AB Cell-penetrating peptides (CPPs) have recently attracted much interest due to their apparent ability to penetrate cell membranes in an energy-independent manner. Here molecular-dynamics simulation techniques were used to study the interaction of two CPPs: penetratin and the TAT peptide with 1,2-Dipaimitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) phospolipid bilayers shed light on alternative mechanisms by which these peptides might cross biological membranes. In contrast to previous simulation studies of charged peptides interacting with lipid bilayers, no spontaneous formation of transmembrane pores was observed. Instead, the simulations suggest that the peptides may enter the cell by micro-pinocytosis, whereby the peptides induce curvature in the membrane, ultimately leading to the formation of small vesicles within the cell that encapsulate the peptides. Specifically, multiple peptides were observed to induce large deformations in the lipid bilayer that persisted throughout the timescale of the simulations (hundreds of nanoseconds). Pore formation could be induced in simulations in which an external potential was used to pull a single penetratin or TAT peptide into the membrane. With the use of umbrella-sampling techniques, the free energy of inserting a single penetratin peptide into a DPPC bilayer was estimated to be similar to 75 kJmol(-1), which suggests that the spontaneous penetration of single peptides would require a timescale of at least seconds to minutes. This work also illustrates the extent to which the results of such simulations can depend on the initial conditions, the extent of equilibration, the size of the system, and the conditions under which the simulations are performed. The implications of this with respect to the current systems and to simulations of membrane-peptide interactions in general are discussed.
C1 [Yesylevskyy, Semen; Marrink, Siewert-Jan; Mark, Alan E.] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biophys Chem, Groningen, Netherlands.
   [Mark, Alan E.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
   [Mark, Alan E.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Yesylevskyy, Semen] Natl Acad Sci Ukraine, Dept Phys Biol Syst, Inst Phys, Kiev, Ukraine.
RP Mark, AE (reprint author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biophys Chem, Groningen, Netherlands.
EM a.e.mark@uq.edu.au
RI Mark, Alan/A-8799-2011; Marrink, Siewert/G-3706-2014; Yesylevskyy,
   Semen/G-2704-2014
OI Mark, Alan/0000-0001-5880-4798; Yesylevskyy, Semen/0000-0002-6748-8931
FU Marie Curie International Incoming Fellowship [MIF1-CT-2006-039150];
   SARA [MP-143]; Australian Research Council
FX This work was supported by a Marie Curie International Incoming
   Fellowship to S.Y. (MIF1-CT-2006-039150). S.Y. acknowledges the
   Netherlands Organisation for Scientific Research for allowing access to
   the Netherlands national computer facility SARA (grant MP-143). A.E.M.
   is all Australian Research Council Federation Fellow.
CR Anezo C, 2003, J PHYS CHEM B, V107, P9424, DOI 10.1021/jp0348981
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Babakhani A., 2009, J PHYS CHEM B, V112, P10528
   Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2                                                   
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3                                                   
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Herce HD, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2714527
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hristova K, 2001, BIOPHYS J, V80, P801, DOI 10.1016/S0006-3495(01)76059-6                                                   
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Kastner J, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2052648
   Lensink MF, 2005, BIOPHYS J, V88, P939, DOI 10.1529/biophysj.104.052787
   Leontiadou H, 2006, J AM CHEM SOC, V128, P12156, DOI 10.1021/ja062927q
   Lin JH, 2000, BIOPHYS J, V78, P1714, DOI 10.1016/S0006-3495(00)76723-3                                                   
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5                                                   
   Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583503004014
   Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2
   Marrink SJ, 2009, BBA-BIOMEMBRANES, V1788, P149, DOI 10.1016/j.bbamem.2008.10.006
   Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g
   Matyus E, 2007, CURR MED CHEM, V14, P2789, DOI 10.2174/092986707782360105                                                      
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805                                                           
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Salamon Z, 2003, BIOPHYS J, V84, P1796, DOI 10.1016/S0006-3495(03)74987-X                                                   
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Sengupta D, 2008, BBA-BIOMEMBRANES, V1778, P2308, DOI 10.1016/j.bbamem.2008.06.007
   Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797
   Tieleman DP, 2006, J AM CHEM SOC, V128, P12462, DOI 10.1021/ja0624321
   TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273                                                                
   Tom D., 1993, J CHEM PHYS, V98, P10089, DOI DOI 10.1063/1.464397
   Tristram-Nagle S, 1998, BIOPHYS J, V75, P917, DOI 10.1016/S0006-3495(98)77580-0                                                   
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   van Gunsteren W. F., 1996, BIOMOLECULAR SIMULAT
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0                                                   
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 49
TC 99
Z9 100
U1 2
U2 34
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD JUL 8
PY 2009
VL 97
IS 1
BP 40
EP 49
DI 10.1016/j.bpj.2009.03.059
PG 10
WC Biophysics
SC Biophysics
GA 469BV
UT WOS:000267871000004
PM 19580742
OA gold
DA 2018-01-05
ER

PT J
AU Zensi, A
   Begley, D
   Pontikis, C
   Legros, C
   Mihoreanu, L
   Wagner, S
   Buchel, C
   von Briesen, H
   Kreuter, J
AF Zensi, Anja
   Begley, David
   Pontikis, Charles
   Legros, Celine
   Mihoreanu, Larisa
   Wagner, Sylvia
   Buechel, Claudia
   von Briesen, Hagen
   Kreuter, Joerg
TI Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis
   and are delivered to neurones
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Apolipoprotein E; Blood-brain barrier; Brain targeting; Nanoparticles;
   Transcytosis
ID BLOOD-BRAIN-BARRIER; POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; ELECTRON
   MICROSCOPY; DRUG TRANSPORT; HEALTHY RATS; DOXORUBICIN; CHEMOTHERAPY;
   SURFACTANTS; FORMULATION; TOLERANCE
AB The blood-brain barrier (BBB) represents a considerable obstacle to brain entry of the majority of drugs and thus severely restricts the therapy of many serious CNS diseases including brain tumours, brain HIV, Alzheimer and other neurodegenerative diseases. The use of nanoparticles coated with polysorbate 80 or with attached apolipoprotein E has enabled the delivery of drugs across the BBB. However, the mechanism of this enhanced transport is still not fully understood. In this present study, human serum albumin nanoparticles, with covalently bound apolipoprotein E (Apo E) as a targetor as well as without apolipoprotein E, were manufactured and injected intravenously into SV 129 mice. The animals were sacrificed after 15 and 30 min, and their brains were examined by transmission electron microscopy. Only the nanoparticles with covalently bound apolipoprotein E were detected in brain capillary endothelial cells and neurones, whereas no uptake into the brain was detectable with nanoparticles without apolipoprotein E. We have also demonstrated uptake of the albumin/ApoE nanoparticles into mouse endothelial (b.End3) cells in vitro and their intracellular localisation. These findings indicate that nanoparticles with covalently bound apolipoprotein E are taken up into the cerebral endothelium by an endocytic mechanism followed by transcytosis into brain parenchyma. (c) 2009 Elsevier B.V. All rights reserved.
C1 [Zensi, Anja; Kreuter, Joerg] Univ Frankfurt, Inst Pharmaceut Technol, Biozentrum, D-60438 Frankfurt, Germany.
   [Begley, David; Pontikis, Charles; Legros, Celine; Mihoreanu, Larisa] Kings Coll London, Pharmaceut Sci Res Div, Barrier Grp, London, England.
   [Wagner, Sylvia; von Briesen, Hagen] Fraunhofer Inst Biomed Engn, St Ingbert, Germany.
   [Buechel, Claudia] Univ Frankfurt, Inst Mol Biosci, D-60438 Frankfurt, Germany.
RP Kreuter, J (reprint author), Univ Frankfurt, Inst Pharmaceut Technol, Biozentrum, Max von Laue Str 9, D-60438 Frankfurt, Germany.
EM Kreuter@em.uni-frankfurt.de
RI Fachbereich14, Dekanat/C-8553-2015
OI Buchel, Claudia/0000-0001-6640-7610
CR Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
   Ambruosi A, 2006, J MICROENCAPSUL, V23, P582, DOI 10.1080/02652040600788080
   Begley DJ, 2008, CURR PHARM DESIGN, V14, P1566, DOI 10.2174/138161208784705504
   Begley DJ, 1996, J PHARM PHARMACOL, V48, P136, DOI 10.1111/j.2042-7158.1996.tb07112.x                                              
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Davson H., 1996, PHYSL CSF BLOOD BRAI
   Gaillard Pieter J, 2005, Expert Opin Drug Deliv, V2, P299, DOI 10.1517/17425247.2.2.299
   GLAUERT AM, 1958, J BIOPHYS BIOCHEM CY, V4, P191, DOI 10.1083/jcb.4.2.191
   Hasadsri L, 2009, J BIOL CHEM, V284, P6972, DOI 10.1074/jbc.M805956200
   HERTZ J, 2003, CELL, V112, P289
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   Kreuter J, 2006, NANOPARTICLES DRUG C, P527
   Kreuter J, 2006, MICROENCAPSULATION M, P689
   Kreuter J, 2007, J CONTROL RELEASE, V118, P54, DOI 10.1016/j.jconrel.2006.12.012
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Neuwel E. A., 1989, IMPLICATIONS BLOOD B, V2, P195
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   PARDRIDGE WM, 1985, AM J PHYSIOL, V249, pE264
   Pereverzeva E, 2008, TOXICOL LETT, V178, P9, DOI 10.1016/j.toxlet.2008.01.020
   Pereverzeva E, 2007, INT J PHARM, V337, P346, DOI 10.1016/j.ijpharm.2007.01.031
   PETERS A, 1991, FINE STRUCTURES NERV
   Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j,jconrel.2006.10.015
   Reimold I, 2008, EUR J PHARM BIOPHARM, V70, P627, DOI 10.1016/j.ejpb.2008.05.007
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208                                                            
   Rhaese S, 2003, J CONTROL RELEASE, V92, P199, DOI 10.1016/S0168-3659(03)00302-X
   Rosen GD, 2000, INT MOUS GEN C
   Steiniger SCJ, 2004, INT J CANCER, V109, P759, DOI 10.1002/ijc.20048
   Weber C, 2000, INT J PHARM, V196, P197, DOI 10.1016/S0378-5173(99)00420-2                                                   
   Wolburg H, 2008, HISTOCHEM CELL BIOL, V130, P127, DOI 10.1007/s00418-008-0410-2
NR 32
TC 201
Z9 207
U1 4
U2 63
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUL 1
PY 2009
VL 137
IS 1
BP 78
EP 86
DI 10.1016/j.jconrel.2009.03.002
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 465XY
UT WOS:000267624900013
PM 19285109
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Dou, HY
   Grotepas, CB
   McMillan, JM
   Destache, CJ
   Chaubal, M
   Werling, J
   Kipp, J
   Rabinow, B
   Gendelman, HE
AF Dou, Huanyu
   Grotepas, Cassi B.
   McMillan, JoEllyn M.
   Destache, Christopher J.
   Chaubal, Mahesh
   Werling, Jane
   Kipp, James
   Rabinow, Barrett
   Gendelman, Howard E.
TI Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain
   in a Murine Model of NeuroAIDS
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA
   COMPLEX; MULTINUCLEATED GIANT-CELLS; HIV-1 ASSOCIATED DEMENTIA;
   CEREBROSPINAL-FLUID; IN-VIVO; NEUROCOGNITIVE DISORDERS; HIV-1-INFECTED
   PATIENTS; PHENOTYPIC RESISTANCE
AB Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease. The Journal of Immunology, 2009, 183: 661-669.
C1 [Dou, Huanyu; Grotepas, Cassi B.; McMillan, JoEllyn M.; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   [Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Chaubal, Mahesh; Werling, Jane; Kipp, James; Rabinow, Barrett] Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Destache, Christopher/0000-0001-7923-3939
FU National Institutes of Health [2R01 NS034239, 2107 NS36126, P01 NS31492,
   P20RR 15635, P20RR 21937, P01 MH64570, P01 NS43995]
FX This work was supported by Grants 2R01 NS034239, 2107 NS36126, P01
   NS31492, P20RR 15635, P20RR 21937, P01 MH64570, and P01 NS43995 (to
   H.E.G.) from the National Institutes of Health.
CR Anderson E, 2002, JAIDS, V31, pS43, DOI 10.1097/01.QAI.0000027931.48986.D8
   Anthony IC, 2006, ACTA NEUROPATHOL, V111, P529, DOI 10.1007/s00401-006-0037-0
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Antinori A, 2005, CLIN INFECT DIS, V41, P1787, DOI 10.1086/498310                                                                  
   Antinori A, 2001, AIDS, V15, P1483, DOI 10.1097/00002030-200108170-00005                                                
   Aweeka F, 1999, J ACQ IMMUN DEF SYND, V20, P39, DOI 10.1097/00042560-199901010-00006                                                
   Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186                                                        
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006
   Berger JR, 2004, FRONT BIOSCI, V9, P2680, DOI 10.2741/1427
   BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301                                                              
   Burke W. J., 2003, Current Drug Targets - CNS and Neurological Disorders, V2, P143, DOI 10.2174/1568007033482913
   Cao YZ, 2005, CELL RES, V15, P883, DOI 10.1038/sj.cr.7290363
   Chan WCW, 2006, BIOL BLOOD MARROW TR, V12, P87, DOI 10.1016/j.bbmt.2005.10.004
   Cherner M, 2007, J NEUROVIROL, V13, P23, DOI 10.1080/13550280601089175
   D'Amico R, 2007, SCAND J INFECT DIS, V39, P347, DOI 10.1080/00365540600951341
   De Luca A, 2002, NEUROLOGY, V59, P342, DOI 10.1212/WNL.59.3.342                                                            
   DELCO JA, 2004, NEUROSCIENTIST, V10, P40
   DICKSON DW, 1986, ARCH PATHOL LAB MED, V110, P967
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Doualla-Bell F, 2004, M S-MED SCI, V20, P882, DOI 10.1051/medsci/20042010882
   Eggers C, 2003, AIDS, V17, P1897, DOI 10.1097/01.aids.0000076273.54156.8f
   Enzensberger W, 1999, Eur J Med Res, V4, P456
   Epstein LG, 1999, J LEUKOCYTE BIOL, V65, P453
   Epstein LG, 1998, ACTA PAEDIATR JAPON, V40, P107
   Flandre P, 2007, J INFECT DIS, V195, P392, DOI 10.1086/510754
   Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69
   Garcia F, 2000, J ACQ IMMUN DEF SYND, V25, P26, DOI 10.1097/00126334-200009010-00004
   Garzino-Demo A, 1998, J CLIN IMMUNOL, V18, P243, DOI 10.1023/A:1027329721892                                                         
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gibbs JE, 2003, J PHARMACOL EXP THER, V306, P1035, DOI 10.1124/jpet.103.053827
   GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510                                                           
   Goodkin K, 2006, J NEUROVIROL, V12, P178, DOI 10.1080/13550280600827344
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Gray F, 1996, BRAIN PATHOL, V6, P1, DOI 10.1111/j.1750-3639.1996.tb00775.x                                              
   Gray F, 1997, REV NEUROL, V153, P629
   Griffin DE, 1997, J CLIN INVEST, V100, P2948, DOI 10.1172/JCI119847                                                               
   HOFFMANN C, 2001, AIDS, V15, P1119
   Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x
   Jacobsen H, 1996, J INFECT DIS, V173, P1379, DOI 10.1093/infdis/173.6.1379                                                       
   Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7                                                   
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P407, DOI 10.1177/153303460500400408                                                      
   Kaul M, 2006, J NEUROIMMUNE PHARM, V1, P138, DOI 10.1007/s11481-006-9011-9
   Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Lambotte O, 2003, BRAIN PATHOL, V13, P95
   Liu YT, 2008, J NEUROIMMUNOL, V200, P41, DOI 10.1016/j.jneuroim.2008.06.009
   Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728
   Michaelis M, 2000, ANTI-CANCER DRUG, V11, P369, DOI 10.1097/00001813-200006000-00007
   Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1                                                   
   NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603
   Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186                                                       
   Peterson KE, 2009, IMMUNOL RES, V43, P149, DOI 10.1007/s12026-008-8060-y
   POWER C, 1995, CAN J NEUROL SCI, V22, P92, DOI 10.1017/S0317167100040154                                                       
   Ramirez SH, 2008, J IMMUNOL, V180, P1854, DOI 10.4049/jimmunol.180.3.1854                                                     
   Resch W, 2005, J VIROL, V79, P10638, DOI 10.1128/JVI.79.16.10638-10649.2005
   ROSCI MA, 1992, AIDS, V6, P1309, DOI 10.1097/00002030-199211000-00011
   ROYAL W, 1994, ANN NEUROL, V36, P32, DOI 10.1002/ana.410360109
   Saez-Llorens X, 2001, Rev Med Panama, V26, P13
   Skiest DJ, 2003, AIDS, V17, P1787, DOI 10.1097/01.aids.0000072662.21517.2a
   Smit TK, 2004, J VIROL, V78, P10133, DOI 10.1128/JVI.78.18.10133-10148.2004
   Speth C, 2005, MOL IMMUNOL, V42, P213, DOI 10.1016/j.molimm.2004.06.018
   Spudich SS, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-98
   Stingl G, 1989, Curr Probl Dermatol, V18, P250
   Stockmann M, 2000, ANN NY ACAD SCI, V915, P293, DOI 10.1111/j.1749-6632.2000.tb05257.x                                              
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Tong N, 2000, J IMMUNOL, V164, P1333, DOI 10.4049/jimmunol.164.3.1333                                                     
   Trujillo JR, 2005, CELL RES, V15, P962, DOI 10.1038/sj.cr.7290374                                                           
   Van Rie A, 2007, EUR J PAEDIATR NEURO, V11, P1, DOI 10.1016/j.ejpn.2006.10.006
   Varela MC, 2001, EUR J PHARM SCI, V12, P471
   Vitiello B, 2007, AIDS, V21, P1415, DOI 10.1097/QAD.0b013e328220e71a                                                    
   Wegner SA, 2000, AIDS, V14, P1009, DOI 10.1097/00002030-200005260-00013
   Wiley CA, 2006, J NEUROVIROL, V12, P262, DOI 10.1080/13550280600873868
   Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105
   Wingertsmann Laure, 1997, Archives d'Anatomie et de Cytologie Pathologiques, V45, P106
   Xing XL, 2005, J NANOSCI NANOTECHNO, V5, P1688, DOI 10.1166/jnn.2005.199
   Zhang H, 1996, J VIROL, V70, P628
NR 79
TC 117
Z9 118
U1 0
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 1
PY 2009
VL 183
IS 1
BP 661
EP 669
DI 10.4049/jimmunol.0900274
PG 9
WC Immunology
SC Immunology
GA 563HS
UT WOS:000275119400072
PM 19535632
OA gold
DA 2018-01-05
ER

PT J
AU Zhan, P
   Li, ZY
   Liu, XY
   De Clercq, E
AF Zhan, Peng
   Li, Zhenyu
   Liu, Xinyong
   De Clercq, Erik
TI Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE AIDS; HIV-1; reverse transcriptase (RT); sulfanyltriazole/tetrazoles;
   NNRTIs; SAR; scaffold hopping
ID REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS TYPE-1; POTENT
   NONNUCLEOSIDE INHIBITORS; PRIMER GRIP REGION; DE-NOVO DESIGN; POSITIONAL
   ADAPTABILITY; ANTIVIRAL ACTIVITY; RATIONAL DESIGN; WILD-TYPE; RESISTANT
AB There is an urgent need for the design and development of new and safer drugs for the treatment of human immunodeficiency virus (HIV) infection, specifically active against drug-resistant viral strains. Recently, sulfanyltriazole/tetrazole derivatives were reported as potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), with low nanomolar intrinsic activity against RT and submicromolar antiviral activity in HIV infected cells. In this review, the structural modifications, SAR analysis and docking studies of sulfanyltriazole/tetrazoles HIV-1 NNRTIs are discussed, and other interesting NNRTIs with the same or similar pharmacophore as the sulfanyltriazole/tetrazole derivatives are also presented and analyzed for their in SAR.
C1 [Zhan, Peng; Li, Zhenyu; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China.
   [De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China [30873133, 30772629,
   30371686]; Key Project of The International Cooperation; Ministry of
   Science and Technology of China [2003DF000033]; Research Fund for the
   Doctoral Program of Higher Education of China [070422083]
FX The financial support from the National Natural Science Foundation of
   China (NSFC No. 30873133, No. 30772629, No. 30371686), Key Project of
   The International Cooperation, Ministry of Science and Technology of
   China (2003DF000033) and Research Fund for the Doctoral Program of
   Higher Education of China (070422083) is gratefully acknowledged.
CR Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   BUTINI S, 2009, J MED CHEM      0126
   Chan JH, 2004, J MED CHEM, V47, P1175, DOI 10.1021/jm030255y
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   De La Rosa M, 2006, BIOORG MED CHEM LETT, V16, P4444, DOI 10.1016/j.bmcl.2006.06.048
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Fattorusso C, 2005, J MED CHEM, V48, P7153, DOI 10.1021/jm050257d
   Ferris RG, 2005, ANTIMICROB AGENTS CH, V49, P4046, DOI 10.1128/AAC.49.10.4046-4051.2005
   Gagnon A, 2007, BIOORG MED CHEM LETT, V17, P4437, DOI 10.1016/j.bmcl.2007.06.012
   Gagnon A, 2009, BIOORG MED CHEM LETT, V19, P1199, DOI 10.1016/j.bmcl.2008.12.074
   Hazen RJ, 2005, ANTIMICROB AGENTS CH, V49, P4465, DOI 10.1128/AAC.49.11.4465-4473.2005
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Ilina T, 2008, ADV PHARMACOL, V56, P121, DOI 10.1016/S1054-3589(07)56005-9
   Jochmans D, 2008, VIRUS RES, V134, P171, DOI 10.1016/j.virusres.2008.01.003
   *JOINT UN PROGR HI, 2007, AIDS EP UPD DEC 2007
   Lloyd DG, 2004, J MED CHEM, V47, P493, DOI 10.1021/jm034222u
   Mauser H, 2008, CURR OPIN DRUG DISC, V11, P365
   Muraglia E, 2006, BIOORG MED CHEM LETT, V16, P2748, DOI 10.1016/j.bmcl.2006.02.024
   O'Meara JA, 2007, BIOORG MED CHEM LETT, V17, P3362, DOI 10.1016/j.bmcl.2007.03.097
   Pelemans H, 2000, MOL PHARMACOL, V57, P954
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Ren JS, 2000, J BIOL CHEM, V275, P14316, DOI 10.1074/jbc.275.19.14316
   Romines KR, 2006, J MED CHEM, V49, P727, DOI 10.1021/jm0506701
   Sax Paul E, 2008, AIDS Clin Care, V20, P17
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Sweeney ZK, 2008, BIOORG MED CHEM LETT, V18, P4352, DOI 10.1016/j.bmcl.2008.06.072
   Sweeney ZK, 2008, BIOORG MED CHEM LETT, V18, P4348, DOI 10.1016/j.bmcl.2008.06.080
   Sweeney ZK, 2008, J MED CHEM, V51, P7449, DOI 10.1021/jm800527x
   SWEENEY ZK, 2008, CHEMMEDCHEM, V4, P88
   Tucker TJ, 2008, J MED CHEM, V51, P6503, DOI 10.1021/jm800856c
   Tucker TJ, 2008, BIOORG MED CHEM LETT, V18, P2959, DOI 10.1016/j.bmcl.2008.03.064
   Wang ZW, 2006, BIOORG MED CHEM LETT, V16, P4174, DOI 10.1016/j.bmcl.2006.05.096
   Wu BG, 2006, BIOORG MED CHEM LETT, V16, P3430, DOI 10.1016/j.bmcl.2006.04.012
   Zanoli S, 2008, BIOCHEM PHARMACOL, V76, P156, DOI 10.1016/j.bcp.2008.04.009
   ZHAN P, 2008, THESIS SHANDONG U
   ZHAN P, 2008, 6 INT S MED CHEM SHA
   Zhan P, 2008, BIOORG MED CHEM LETT, V18, P5368, DOI 10.1016/j.bmcl.2008.09.055
   Zhang ZJ, 2007, ANTIMICROB AGENTS CH, V51, P429, DOI 10.1128/AAC.01032-06
   Simoneau B, 2004, Non-nucleoside reverse transcriptase inhibitors, Patent No. [WO 2004050643, 2004050643, WO2004050643]
   Shaw-Reid CA, 2005, HIV reverse transcriptase inhibitors, Patent No. [WO 2005115147, 2005115147]
   Girardet JL, 2004, Non-nucleoside reverse transcriptase inhibitors, Patent No. [WO2,004,030,611, 2004030611, WO 2004030611]
   Koch U, 2006, Patent, Patent No. [WO 2006037468, 2006037468]
   Girardet JL, 2006, S-Triazolyl-mercaptoacetanildes as inhibitors of HIV reverse transcriptase, Patent No. [WO 2006026356, 2006026356]
   Simoneau B, 2005, Non nucleoside reverse transcriptase inhibitors, Patent No. [WO 2005118575, 2005118575]
NR 48
TC 38
Z9 41
U1 1
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD JUL
PY 2009
VL 9
IS 8
BP 1014
EP 1023
DI 10.2174/138955709788681618                                              
          
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 473PG
UT WOS:000268219100013
PM 19601897
DA 2018-01-05
ER

PT J
AU Mangipudi, SS
   Canine, BF
   Wang, YH
   Hatefi, A
AF Mangipudi, Sriramchandra S.
   Canine, Brenda F.
   Wang, Yuhua
   Hatefi, Arash
TI Development of a Genetically Engineered Biomimetic Vector for Targeted
   Gene Transfer to Breast Cancer Cells
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Biomimetic vector; nonviral vector; cancer gene therapy
ID TRANSFER EFFICIENCY; DNA CONDENSATION; FUSION PROTEIN; DELIVERY;
   NANOCARRIERS; ADENOVIRUS; APOPTOSIS; TRANSPORT; POLYMERS; RECEPTOR
AB A biomimetic vector was genetically engineered to contain at precise locations (a) an adenovirus mu peptide to condense pDNA into nanosize particles, (b) a synthetic cyclic peptide to target breast cancer cells and enhance internalization of nanoparticles, (c) a pH-responsive synthetic fusogenic peptide to disrupt endosome membranes and facilitate escape of the nanoparticles into the cytosol, and (d) a nuclear localization signal from human immunodeficiency virus for microtubule mediated transfer of genetic material to the nucleus. The vector was characterized using physicochemical and biological assays to demonstrate the functionality of each motif in the vector backbone. The results demonstrated that the vector is able to condense plasmid DNA into nanosize particles (<100 nm), protect pDNA from serum endonucleases, target ZR-75-1 breast cancer cells and internalize, efficiently disrupt endosome membranes, exploit microtubules to reach nucleus and mediate gene expression. The therapeutic potential of the vector was evaluated by complexing with plasmid DNA encoding TRAIL (pTRAIL) and transfecting ZR-75-1 cells The results demonstrated that up to 62% of the ZR-75-1 breast cancer cells can be killed after administration of pTRAIL in complex with the vector.
C1 [Mangipudi, Sriramchandra S.; Canine, Brenda F.; Wang, Yuhua; Hatefi, Arash] Washington State Univ, Dept Pharmaceut Sci, Ctr Integrated Biotechnol, Pullman, WA 99164 USA.
RP Hatefi, A (reprint author), Washington State Univ, Dept Pharmaceut Sci, Ctr Integrated Biotechnol, POB 646534, Pullman, WA 99164 USA.
EM ahatefi@wsu.edu
FU NIGMS NIH HHS [T32 GM008336-20, T32 GM008336-19, T32 GM008336-18]
CR Behr JP, 1997, CHIMIA, V51, P34
   Boeckle S, 2006, J CONTROL RELEASE, V112, P240, DOI 10.1016/j.jconrel.2006.02.002
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Canine BF, 2008, J CONTROL RELEASE, V129, P117, DOI 10.1016/j.jconret.2008.04.012
   COCHRANE AW, 1990, J VIROL, V64, P881
   Collins L, 2006, METH MOL B, V333, P201
   Dane KY, 2006, J IMMUNOL METHODS, V309, P120, DOI 10.1016/j.jim.2005.11.021
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   Fominaya J, 1998, GENE THER, V5, P521, DOI 10.1038/sj.gt.3300614
   Haberland A, 2005, BIOTECHNOL APPL BIOC, V42, P107, DOI 10.1042/BA20040155
   Hatefi A, 2006, J GENE MED, V8, P468, DOI 10.1002/jgm.872
   Kagawa S, 2001, CANCER RES, V61, P3330
   Keller M, 2002, BIOCHEMISTRY-US, V41, P652, DOI 10.1021/bi0156299
   Li DQ, 1999, CLIN CANCER RES, V5, P4175
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Murzin AG, 2008, SCIENCE, V320, P1725, DOI 10.1126/science.1158868
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Paul RW, 1997, HUM GENE THER, V8, P1253, DOI 10.1089/hum.1997.8.10-1253
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Shen Y, 2006, CANCER GENE THER, V13, P975, DOI 10.1038/sj.cgt.7700946
   Shigeta K, 2007, J CONTROL RELEASE, V118, P262, DOI 10.1016/j.jconrel.2006.12.019
   Singh TR, 2003, CANCER RES, V63, P5390
   Subramanian A, 2002, J GENE MED, V4, P75, DOI 10.1002/jgm.235
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Suh JH, 2004, BIOTECHNOL PROGR, V20, P598, DOI 10.1021/bp034251y
   Tecle M, 2003, BIOCHEMISTRY-US, V42, P10343, DOI 10.1021/bi034325e
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Uherek C, 1998, J BIOL CHEM, V273, P8835, DOI 10.1074/jbc.273.15.8835
NR 30
TC 23
Z9 25
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL-AUG
PY 2009
VL 6
IS 4
BP 1100
EP 1109
DI 10.1021/mp800251x
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 476QC
UT WOS:000268456300007
PM 19419197
DA 2018-01-05
ER

PT J
AU Nowacek, A
   Kosloski, LM
   Gendelman, HE
AF Nowacek, Ari
   Kosloski, Lisa M.
   Gendelman, Howard E.
TI Neurodegenerative disorders and nanoformulated drug development
SO NANOMEDICINE
LA English
DT Review
DE Alzheimer's disease; amyotrophic lateral sclerosis; fullerene;
   nanomedicine; nanoparticles; neurodegeneration; neuroregeneration;
   Parkinson's disease; stroke
ID AMYOTROPHIC-LATERAL-SCLEROSIS; LIPOSOME-ENCAPSULATED HEMOGLOBIN; SOLID
   LIPID NANOPARTICLES; CONVENTIONAL MULTIPLE-SCLEROSIS; AMYLOID-INDUCED
   TOXICITY; MIDDLE CEREBRAL-ARTERY; ANTI-HIV DRUGS; ALZHEIMERS-DISEASE;
   PARKINSONS-DISEASE; OXIDATIVE STRESS
AB Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.
C1 [Nowacek, Ari; Kosloski, Lisa M.; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorders, 600 S 42nd St, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU Frances and Louie Blumkin Foundation; Community Neuroscience Pride of
   Nebraska Research Initiative; Alan Baer Charitable Trust; NIH
   [5P01NS31492, 2R37 NS36126, 2R01 NS034239, P20RR15635, U54NS43011,
   P01MH64570, P01 NS43985]
FX This work was supported by the Frances and Louie Blumkin Foundation, the
   Community Neuroscience Pride of Nebraska Research Initiative, the Alan
   Baer Charitable Trust and NIH grants 5P01NS31492, 2R37 NS36126, 2R01
   NS034239, P20RR15635, U54NS43011, P01MH64570 and P01 NS43985. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003
   Aliev G, 2008, MINI-REV MED CHEM, V8, P1395, DOI 10.2174/138955708786369582
   Bakry R, 2007, INT J NANOMED, V2, P639
   Basso AS, 2008, J CLIN INVEST, V118, P1532, DOI 10.1172/JCI33464
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100
   Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200
   Block ML, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S8
   Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067
   Boster A, 2008, LANCET NEUROL, V7, P173, DOI 10.1016/S1474-4422(08)70020-6
   Braak Heiko, 2009, Adv Anat Embryol Cell Biol, V201, P1
   BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404
   Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001
   Bruijn Lucie I, 2006, Expert Rev Neurother, V6, P417, DOI 10.1586/14737175.6.3.417
   BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293
   Cabaleiro-Lago C, 2008, J AM CHEM SOC, V130, P15437, DOI 10.1021/ja8041806
   Cai XQ, 2008, J NEUROSCI RES, V86, P3622, DOI 10.1002/jnr.21805
   Castellani RJ, 2009, INT J MOL SCI, V10, P1386, DOI 10.3390/ijms10031386
   Chan A, 2008, J NEUROL, V255, P22, DOI 10.1007/s00415-008-6005-y
   Chari DM, 2007, INT REV NEUROBIOL, V79, P589, DOI 10.1016/S0074-7742(07)79026-8
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chauvire V, 2007, ENCEPHALE, V33, P933, DOI 10.1016/j.encep.2006.12.001
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Cho Y, 2008, NANOMEDICINE-UK, V3, P507, DOI 10.2217/17435889.3.4.507
   Chu DF, 2007, CHEM PHARM BULL, V55, P625, DOI 10.1248/cpb.55.625
   CLERICO M, 2008, COCHRANE DATABASE SY, V2
   Collister KA, 2005, DRUG NEWS PERSPECT, V18, P623, DOI 10.1358/dnp.2005.18.10.959576
   COOK C, 2009, BIOCH BIOPHYS ACTA
   Corti O, 2005, CR BIOL, V328, P131, DOI 10.1016/j.crvi.2004.10.009
   Crotty S, 2008, EUR J NEUROSCI, V27, P294, DOI 10.1111/j.1460-9568.2007.06018.x
   CROWE A, 1994, NEUROCHEM RES, V19, P71, DOI 10.1007/BF00966731
   Cui ZR, 2005, EUR J PHARM BIOPHARM, V59, P263, DOI 10.1016/j.ejpb.2004.07.009
   Das M, 2007, BIOMATERIALS, V28, P1918, DOI 10.1016/j.biomaterials.2006.11.036
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Dubow Jordan S, 2007, Dis Mon, V53, P265, DOI 10.1016/j.disamonth.2007.02.004
   Eisen A, 2009, J CLIN NEUROSCI, V16, P505, DOI 10.1016/j.jocn.2008.07.072
   Elman LB, 2007, J PALLIAT MED, V10, P433, DOI 10.1089/jpm.2006.9978
   Esposito E, 2008, PHARM RES-DORDR, V25, P1521, DOI 10.1007/s11095-007-9514-y
   Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0
   Filomeni G, 2007, J BIOL CHEM, V282, P12010, DOI 10.1074/jbc.M610927200
   Fitzgerald P, 2008, BEHAV BRAIN RES, V195, P271, DOI 10.1016/j.bbr.2008.08.041
   Flachenecker P, 2006, J NEUROL, V253, P2, DOI 10.1007/500415-006-5001-3
   Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480
   Fukumoto D, 2009, ARTIF ORGANS, V33, P159, DOI 10.1111/j.1525-1594.2008.00701.x
   Galariotis Vasilis, 2005, Ideggyogy Sz, V58, P220
   Gardiner J, 2009, NEUROSCIENTIST, V15, P47, DOI 10.1177/1073858408325269
   Genova HM, 2009, FRONT BIOSCI-LANDMRK, V14, P1730, DOI 10.2741/3336
   Giannakopoulos P, 2007, ACTA NEUROPATHOL, V113, P1, DOI 10.1007/s00401-006-0144-y
   Giannakopoulos Panteleimon, 2009, V24, P20, DOI 10.1159/000197881
   Golde TE, 2006, J NEUROCHEM, V99, P689, DOI 10.1111/j.1471-4159.2006.04211.x
   Hasadsri L, 2009, J BIOL CHEM, V284, P6972, DOI 10.1074/jbc.M805956200
   Hashimoto M, 2003, J BIOL CHEM, V278, P44205, DOI 10.1074/jbc.M306735200
   HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X
   HIDER RC, 1994, ADV EXP MED BIOL, V356, P343
   Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6
   Hong S, 2009, ANAL CHEM, V81, P1378, DOI 10.1021/ac802099c
   HUANG X, 2009, J NEUROIMMUNOL
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818                                                              
   Kang DY, 2009, BIOSENS BIOELECTRON, V24, P1431, DOI 10.1016/j.bios.2008.08.018
   Kantarci O, 2006, CURR OPIN NEUROL, V19, P248, DOI 10.1097/01.wco.0000227033.47458.82
   Kaul M, 2005, CELL DEATH DIFFER, V12, P878, DOI 10.1038/sj.cdd.4401623
   Kawaguchi AT, 2007, STROKE, V38, P1626, DOI 10.1161/STROKEAHA.106.467290
   Kawaguchi AT, 2009, ARTIF ORGANS, V33, P153, DOI 10.1111/j.1525-1594.2008.00700.x
   Kessler H, 2008, J NEURAL TRANSM, V115, P1181, DOI 10.1007/s00702-008-0080-1
   Klajnert B, 2007, MACROMOL BIOSCI, V7, P1065, DOI 10.1002/mabi.200700049
   Kogan MJ, 2006, NANO LETT, V6, P110, DOI 10.1021/nl0516862
   Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P168
   Korn T, 2008, J NEUROL, V255, P2, DOI 10.1007/s00415-008-6001-2
   Krokosz Anita, 2007, Postepy Biochem, V53, P91
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X
   Lassmann H, 2005, BRAIN PATHOL, V15, P217
   LEE JH, 2009, ULTRAMICROSCOPY
   Lee JY, 2004, NEUROBIOL AGING, V25, P1315, DOI 10.1016/j.neurobiolaging.2004.01.005
   Lesage S, 2009, HUM MOL GENET, V18, pR48, DOI 10.1093/hmg/ddp012
   Li W, 2007, J NEUROIMMUNOL, V184, P227, DOI 10.1016/j.jneuroim.2006.12.010
   Listerud J, 2009, J INT NEUROPSYCH SOC, V15, P459, DOI 10.1017/S1355617709090742
   Liu G, 2006, NEUROSCI LETT, V406, P189, DOI 10.1016/j.neulet.2006.07.020
   Liu G, 2009, NEUROSCI LETT, V455, P187, DOI 10.1016/j.neulet.2009.03.064
   Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6
   Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
   Magerkurth C, 2005, CLIN AUTON RES, V15, P76, DOI 10.1007/s10286-005-0253-z
   Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005
   Marsh JN, 2007, NANOMEDICINE-UK, V2, P533, DOI 10.2217/17435889.2.4.533
   Mateo-Alonso A, 2007, ANGEW CHEM INT EDIT, V46, P8120, DOI 10.1002/anie.200702725
   Mayeux R, 2003, ANNU REV NEUROSCI, V26, P81, DOI 10.1146/annurev.neuro.26.043002.094919
   McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042
   McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631
   Minati L, 2009, AM J ALZHEIMERS DIS, V24, P95, DOI 10.1177/1533317508328602
   Mitchell JD, 2007, LANCET, V369, P2031, DOI 10.1016/S0140-6736(07)60944-1
   Mosley RL, 2006, CLIN NEUROSCI RES, V6, P261, DOI 10.1016/j.cnr.2006.09.006
   Murray J, 2004, Int MS J, V11, P79
   Nazem A, 2008, J ALZHEIMERS DIS, V13, P199
   Nerelius C, 2009, FRONT BIOSCI, V14, P1716, DOI 10.2741/3335
   Neuhaus O, 2007, NEUROTHERAPEUTICS, V4, P654, DOI 10.1016/j.nurt.2007.08.003
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Ohira T, 2006, STROKE, V37, P2493, DOI 10.1161/01.STR.0000239694.19359.88
   Olmedo I, 2008, BIOCONJUGATE CHEM, V19, P1154, DOI 10.1021/bc800016y
   Pai AS, 2006, PEPTIDES, V27, P2858, DOI 10.1016/j.peptides.2006.04.022
   Patel D, 2006, BBA-GEN SUBJECTS, V1760, P1802, DOI 10.1016/j.bbagen.2006.08.008
   Patel DA, 2007, BRAIN RES, V1161, P95, DOI 10.1016/j.brainres.2007.05.055
   Petry KG, 2007, NEUROTHERAPEUTICS, V4, P434, DOI 10.1016/j.nurt.2007.05.005                                                      
   Pezeshki MZ, 2008, MED HYPOTHESES, V70, P1223, DOI 10.1016/j.mehy.2007.12.008
   Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100
   Pihlajamaki M, 2009, CURR ALZHEIMER RES, V6, P179, DOI 10.2174/156720509787602898                                                      
   Podolski IY, 2007, J NANOSCI NANOTECHNO, V7, P1479, DOI 10.1166/jnn.2007.330
   QUERBES O, 2009, BRAIN
   Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596
   RABINOVICI R, 1990, CIRC SHOCK, V32, P1
   Rafii MS, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-7
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   REDDY BM, 2001, INT J HUM GENET, V1, P1
   Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1
   REYNOLDS AD, 2009, J PROTEOME RES
   Reynolds AD, 2007, J LEUKOCYTE BIOL, V82, P1083, DOI 10.1189/jlb.0507296
   Reynolds AD, 2009, J IMMUNOL, V182, P4137, DOI 10.4049/jimmunol.0803982
   Robichaud AJ, 2006, CURR TOP MED CHEM, V6, P553, DOI 10.2174/156802606776743039                                                      
   Rojas JI, 2009, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD006643.PUB2
   Rojo LE, 2008, ARCH MED RES, V39, P1, DOI 10.1016/j.arcmed.2007.10.001
   Roodveldt C, 2008, J CELL MOL MED, V12, P1820, DOI 10.1111/j.1582-4934.2008.00450.x
   Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665                                                      
   Salloway S, 2008, ALZHEIMERS DEMENT, V4, P65, DOI [10.1016/j.jalz.2007.10.001, 10.1016/j.,jalz.2007.10.001]
   Santos SG, 2008, J PHYS CHEM B, V112, P14267, DOI 10.1021/jp8048263
   Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0
   Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x                                              
   Schrag A, 2006, J NEUROL NEUROSUR PS, V77, P275
   Schubert D, 2006, BIOCHEM BIOPH RES CO, V342, P86, DOI 10.1016/j.bbrc.2006.01.129
   Shaw PJ, 2005, J NEUROL NEUROSUR PS, V76, P1046, DOI 10.1136/jnnp.2004.048652
   Shibata N, 2000, ACTA NEUROPATHOL, V100, P275, DOI 10.1007/s004019900173                                                           
   Shinohara N, 2009, ENVIRON SCI TECHNOL, V43, P948, DOI 10.1021/es802182f
   Sigurdsson EM, 2008, J ALZHEIMERS DIS, V15, P157
   Singh S, 2008, DIG J NANOMATER BIOS, V3, P75
   SKAAT H, 2008, J BIOMED MAT RES A
   STAUGEL M, 2008, J NEUROL S6, V255, P77
   Gendelman HE, 2009, ANTIOXID REDOX SIGNA
   STROZYK D, 2007, NEUROBIOL AGING, V30, P1069
   Talmard C, 2007, BIOCHEMISTRY-US, V46, P13658, DOI 10.1021/bi701355j
   Treiber C, 2009, BIOCHEMISTRY-US, V48, P4273, DOI 10.1021/bi900290c
   Triulzi RC, 2008, COLLOID SURFACE B, V63, P200, DOI 10.1016/j.colsurfb.2007.12.006
   Tyler CM, 2006, CELL TRANSPLANT, V15, P267, DOI 10.3727/000000006783982007
   Urakami T, 2009, ARTIF ORGANS, V33, P164, DOI 10.1111/j.1525-1594.2008.00702.x
   van Kasteren SI, 2009, P NATL ACAD SCI USA, V106, P18, DOI 10.1073/pnas.0806787106
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Ventruti A, 2007, CURR NEUROL NEUROSCI, V7, P443, DOI 10.1007/s11910-007-0068-5
   Vestergaard M, 2008, TALANTA, V74, P1038, DOI 10.1016/j.talanta.2007.06.009
   Wallin MT, 2006, J REHABIL RES DEV, V43, P63, DOI 10.1682/JRRD.2004.09.0120
   Wang CY, 2007, BASIC CLIN PHARMACOL, V100, P190, DOI 10.1111/j.1742-7843.2007.00041.x
   Watson D, 2005, NEUROL RES, V27, P869, DOI 10.1179/016164105X49436
   Weimer DL, 2009, ALZHEIMERS DEMENT, V5, P215, DOI 10.1016/j.jalz.2009.01.028
   Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3
   Wilson B, 2009, J NEUROSCI METH, V177, P427, DOI 10.1016/j.jneumeth.2008.10.036
   Yokoyama H, 2008, NEUROL SCI, V29, P293, DOI 10.1007/s10072-008-0986-2
   Yokoyama H, 2008, J NEURAL TRANSM, V115, P831, DOI 10.1007/s00702-008-0019-6
   Zhang LH, 2008, BRAIN RES BULL, V77, P55, DOI 10.1016/j.brainresbull.2008.03.014
   Zhou C, 2008, ANN NY ACAD SCI, V1147, P93, DOI 10.1196/annals.1427.023
   Zoccolella S, 2006, EUR J NEUROL, V13, P789, DOI 10.1111/j.1468-1331.2006.01384.x
NR 161
TC 27
Z9 28
U1 1
U2 18
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUL
PY 2009
VL 4
IS 5
BP 541
EP 555
DI 10.2217/NNM.09.37
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 472TN
UT WOS:000268155200013
PM 19572820
OA green_accepted
DA 2018-01-05
ER

PT J
AU Nowacek, A
   Gendelman, HE
AF Nowacek, Ari
   Gendelman, Howard E.
TI NanoART, neuroAIDS and CNS drug delivery
SO NANOMEDICINE
LA English
DT Review
DE BBB; CNS; drug delivery; HIV; nanoparticles; nanotechnology
ID BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; SOLID LIPID NANOPARTICLES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE HIV-1 ENCEPHALITIS; IN-VITRO;
   P-GLYCOPROTEIN; ANTIRETROVIRAL THERAPY;
   METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE; NEURODEGENERATIVE DISORDERS
AB A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and lipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.
C1 [Nowacek, Ari; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorders, 600 S 42nd St, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU Frances and Louie Blumkin Foundation; Community Neuroscience Pride of
   Nebraska Research Initiative; Alan Baer Charitable Trust; NIH
   [5P01NS31492, 2R37 NS36126, 2R01 NS034239, P20RR15635, U54NS43011,
   P01MH64570, P01 NS43985]
FX This work was supported by the Frances and Louie Blumkin Foundation, the
   Community Neuroscience Pride of Nebraska Research Initiative, the Alan
   Baer Charitable Trust and NIH grants 5P01NS31492, 2R37 NS36126, 2R01
   NS034239, P20RR15635, U54NS43011, P01MH64570 and P01 NS43985. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342                                                            
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Alos L, 2005, MODERN PATHOL, V18, P127, DOI 10.1038/modpathol.3800267
   ANDERSON E, 2002, DEFIC SYNDR S2, V31, pS43
   BAERT L, 2009, EUR J PHARM BIOPHARM
   Bagasra O, 2006, EXPERT OPIN BIOL TH, V6, P1135, DOI 10.1517/14712598.6.11.1135
   Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Banks WA, 2008, BIOPOLYMERS, V90, P589, DOI 10.1002/bip.20980
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Bauer B, 2005, EXP BIOL MED, V230, P118
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013
   Boffito M, 2003, AIDS RES HUM RETROV, V19, P825, DOI 10.1089/088922203769232629
   Borgmann Kathleen, 2005, Methods Mol Biol, V304, P49
   Bousquet L, 2008, AIDS RES HUM RETROV, V24, P1147, DOI 10.1089/aid.2007.0022
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707
   Buescher James L, 2007, Handb Clin Neurol, V85, P45, DOI 10.1016/S0072-9752(07)85004-4
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Champion JA, 2008, PHARM RES-DORDR, V25, P1815, DOI 10.1007/s11095-008-9562-y
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chen Y., 2004, Current Drug Delivery, V1, P361, DOI 10.2174/1567201043334542
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416
   Denora N, 2009, CURR TOP MED CHEM, V9, P182, DOI 10.2174/156802609787521571                                                      
   DOU H, 2009, J IMMUNOL
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002
   Gamsiz DE, 2008, BIOTECHNOL BIOENG, V101, P1072, DOI 10.1002/bit.21958
   Gasparyan VK, 2009, CURR CLIN PHARMACOL, V4, P159, DOI 10.2174/157488409788184954
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   GENDELMAN HE, 2007, AIDS SA, V11, pS35
   Gendelman HE, 2009, J NEUROIMMUNE PHARM, V4, P47, DOI 10.1007/s11481-008-9135-1
   Ghorpade A, 2005, J NEUROIMMUNOL, V163, P145, DOI 10.1016/j.jneuroim.2005.01.022
   Ghorpade A, 2001, J VIROL, V75, P6572, DOI 10.1128/JVI.75.14.6572-6583.2001
   Gibbs Winter J, 2005, Expert Rev Anti Infect Ther, V3, P167, DOI 10.1586/14787210.3.2.167
   Gilmore JL, 2008, J NEUROIMMUNE PHARM, V3, P83, DOI 10.1007/s11481-007-9099-6
   Girardin Francois, 2006, Dialogues Clin Neurosci, V8, P311
   Gorantla S, 2008, GLIA, V56, P223, DOI 10.1002/glia.20607
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5
   Haughey NJ, 2002, JAIDS, V31, pS55, DOI 10.1097/01.QAI.0000028065.79472.50
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Hill HD, 2006, NAT PROTOC, V1, P324, DOI 10.1038/nprot.2006.51
   Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6
   Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545                                                         
   HUANG X, 2009, J NEUROIMMUNOL
   Inafuku H, 2004, J DERMATOL, V31, P671, DOI 10.1111/j.1346-8138.2004.tb00575.x                                              
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jennings T, 2007, ADV EXP MED BIOL, V620, P34
   Jiang ZG, 2001, J NEUROIMMUNOL, V117, P97, DOI 10.1016/S0165-5728(01)00315-0
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818                                                              
   Kanmogne Georgette D, 2007, J Cereb Blood Flow Metab, V27, P123, DOI 10.1038/sj.jcbfm.9600330
   Kastin AJ, 2008, CURR PHARM DESIGN, V14, P1615, DOI 10.2174/138161208784705423
   Kaul M, 2005, CELL DEATH DIFFER, V12, P878, DOI 10.1038/sj.cdd.4401623
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   KEHLESH JP, 2009, J NEUROIMMUNE PHARM
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kostrzewa RM, 2009, CURRENT PROTOCOLS NE
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Li W, 2005, NEUROTOX RES, V8, P119, DOI 10.1007/BF03033824                                                              
   Liang XJ, 2006, CURR DRUG TARGETS, V7, P911, DOI 10.2174/138945006778019264
   LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407                                                     
   Liu JU, 2009, J IMMUNOL, V182, P3855, DOI 10.4049/jimmunol.0803330
   Liu XR, 2008, J PHARMACOL EXP THER, V325, P349, DOI 10.1124/jpet.107.130294
   Liu XR, 2005, CURR OPIN DRUG DISC, V8, P505
   Liu YT, 2008, J NEUROIMMUNOL, V200, P41, DOI 10.1016/j.jneuroim.2008.06.009
   Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006
   Luo X, 2003, NEUROLOGY, V60, P1931, DOI 10.1212/01.WNL.0000064396.54554.26                                              
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241
   McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042
   Mcgee B, 2006, HIV CLIN TRIALS, V7, P142, DOI 10.1310/AW2H-TP5C-NP43-K6BY                                                     
   Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239
   Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Newton Herbert B, 2006, Expert Rev Neurother, V6, P1495, DOI 10.1586/14737175.6.10.1495
   Nottet HSLM, 1996, J IMMUNOL, V156, P1284
   Ohtsuki S, 2007, PHARM RES, V24, P1745, DOI 10.1007/s11095-007-9374-5
   Owen A, 2005, FUND CLIN PHARMACOL, V19, P283, DOI 10.1111/j.1472-8206.2005.00324.x
   Pan WH, 2008, PROG NEUROBIOL, V84, P148, DOI 10.1016/j.pneurobio.2007.10.008
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pastor-Anglada M, 2005, VIRUS RES, V107, P151, DOI 10.1016/j.virusres.2004.11.005
   Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Poluektova L, 2005, GLIA, V52, P344, DOI 10.1002/glia.20253
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2
   Ricardo-Dukelow M, 2007, J NEUROIMMUNOL, V185, P37, DOI 10.1016/j.jneuroim.2007.01.004
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Rozek W, 2007, J PROTEOME RES, V6, P4189, DOI 10.1021/pr070220c
   Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001                                                
   SALFORD LG, 1994, MICROSC RES TECHNIQ, V27, P535, DOI 10.1002/jemt.1070270608
   Schifitto G, 2009, J NEUROVIROL, V15, P176, DOI 10.1080/13550280902758973
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Shiota Masaki, 2007, J Nippon Med Sch, V74, P306, DOI 10.1272/jnms.74.306
   Silva GA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S4
   Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521
   SMITH BJ, 2006, HERITAGE WEATHERING, V1, P191
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Valcour V, 2006, CLIN INFECT DIS, V42, P1449, DOI 10.1086/503565
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vestweber D, 2007, Ernst Schering Found Symp Proc, P151
   WANG CX, 2009, BRAIN RES
   Wang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002507
   Wang T, 2008, J NEUROIMMUNE PHARM, V3, P173, DOI 10.1007/s11481-008-9110-x
   WEISS N, 2009, REV NEUROL PARIS
   Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x
   Wilson B, 2008, EUR J PHARM BIOPHARM, V70, P75, DOI 10.1016/j.ejpb.2008.03.009
   Zahr AS, 2006, LANGMUIR, V22, P8178, DOI 10.1021/la060951b
   Ziylan YZ, 2009, CELL BIOCHEM FUNCT, V27, P63, DOI 10.1002/cbf.1538
NR 135
TC 61
Z9 62
U1 0
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUL
PY 2009
VL 4
IS 5
BP 557
EP 574
DI 10.2217/NMM.09.38
PG 18
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 472TN
UT WOS:000268155200014
PM 19572821
DA 2018-01-05
ER

PT J
AU Veldkamp, CT
   Ziarek, JJ
   Su, JD
   Basnet, H
   Lennertz, R
   Weiner, JJ
   Peterson, FC
   Baker, JE
   Volkman, BF
AF Veldkamp, Christopher T.
   Ziarek, Joshua J.
   Su, Jidong
   Basnet, Harihar
   Lennertz, Richard
   Weiner, Joshua J.
   Peterson, Francis C.
   Baker, John E.
   Volkman, Brian F.
TI Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12
SO PROTEIN SCIENCE
LA English
DT Article
DE NMR; bicelle; dipolar coupling; chemokine; monomer-dimer equilibrium;
   myocardial infarction
ID CELL-DERIVED FACTOR-1-ALPHA; IN-VIVO ACTIVITY; MYOCARDIAL-INFARCTION;
   CRYSTAL-STRUCTURE; DIMER EQUILIBRIUM; DIPOLAR COUPLINGS; RECEPTOR CXCR4;
   FACTOR 1-ALPHA; HIV-1 ENTRY; NMR
AB The chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) directs leukocyte migration, stem cell homing, and cancer metastasis through activation of CXCR4, which is also a coreceptor for T-tropic HIV-1. Recently, SDF-1 was shown to play a protective role after myocardial infarction, and the protein is a candidate for development of new anti-ischemic compounds. SDF-1 is monomeric at nanomolar concentrations but binding partners promote self-association at higher concentrations to form a typical CXC chemokine homodimer. Two NMR structures have been reported for the SDF-1 monomer, but only one matches the conformation observed in a series of dimeric crystal structures. In the other model, the C-terminal helix is tilted at an angle incompatible with SDF-1 dimerization. Using a rat heart explant model for ischemia/reperfusion injury, we found that dimeric SDF-1 exerts no cardioprotective effect, suggesting that the active species is monomeric. To resolve the discrepancy between existing models, we solved the NMR structure of the SDF-1 monomer in different solution conditions. Irrespective of pH and buffer composition, the C-terminal helix remains tilted at an angle with no evidence for the perpendicular arrangement. Furthermore, we find that phospholipid bicelles promote dimerization that necessarily shifts the helix to the perpendicular orientation, yielding dipolar couplings that are incompatible with the NOE distance constraints. We conclude that interactions with the alignment medium biased the previous structure, masking flexibility in the helix position that may be essential for the distinct functional properties of the SDF-1 monomer.
C1 [Veldkamp, Christopher T.; Ziarek, Joshua J.; Su, Jidong; Basnet, Harihar; Lennertz, Richard; Weiner, Joshua J.; Peterson, Francis C.; Baker, John E.; Volkman, Brian F.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
RP Volkman, BF (reprint author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM bvolkman@mcw.edu
OI Ziarek, Joshua/0000-0002-3740-9999
FU NIAID NIH HHS [R01 AI058072]
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529
   ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039                                                             
   Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x
   Baker JE, 1997, CIRCULATION, V95, P1278
   Baker JE, 2000, AM J PHYSIOL-HEART C, V278, pH1395
   Baryshnikova OK, 2006, PROTEIN SCI, V15, P2568, DOI 10.1110/ps.062255806
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Campanella GSV, 2006, J IMMUNOL, V177, P6991, DOI 10.4049/jimmunol.177.10.6991                                                    
   Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740                                                         
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215
   Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838                                       
   Fleming Kieran, 2004, Methods Mol Biol, V278, P79
   Gozansky EK, 2005, J MOL BIOL, V345, P651, DOI 10.1016/j.jmb.2004.11.003
   Handel TM, 2008, J LEUKOCYTE BIOL, V84, P1101, DOI 10.1189/jlb.0108061
   Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7
   Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   Hu XF, 2007, CIRCULATION, V116, P654, DOI 10.1161/CIRCULATIONAHA.106.672451
   Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776                                                     
   Koch KC, 2006, BASIC RES CARDIOL, V101, P69, DOI 10.1007/s00395-005-0570-3
   Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299
   Markley John L, 2003, Methods Biochem Anal, V44, P89
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390
   Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361
   Ottiger M, 1998, J BIOMOL NMR, V12, P361, DOI 10.1023/A:1008366116644
   Penn MS, 2004, INT J CARDIOL, V95, pS23, DOI 10.1016/j.ijcard.2004.04.000
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420                                                         
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Ryu EK, 2007, PROTEINS, V67, P1193, DOI 10.1002/prot.21350
   Sasaki T, 2007, PEDIATR INT, V49, P966, DOI 10.1111/j.1442-200X.2007.02491.x
   Saxena A, 2008, CIRCULATION, V117, P2224, DOI 10.1161/CIRCULATIONAHA.107.694992
   Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718
   Sudmeier JL, 1996, J MAGN RESON SER B, V113, P236, DOI 10.1006/jmrb.1996.0182
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732
   UEDAIRA H, 1970, J PHYS CHEM-US, V74, P2211, DOI 10.1021/j100909a030                                                             
   Veldkamp CT, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160755
   Veldkamp CT, 2007, PROTEIN EXPRES PURIF, V52, P202, DOI 10.1016/j.pep.2006.09.009
   Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052
   Veldkamp CT, 2005, PROTEIN SCI, V14, P1071, DOI 10.1110/ps.041219505
   Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22
   Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 54
TC 50
Z9 53
U1 0
U2 11
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD JUL
PY 2009
VL 18
IS 7
BP 1359
EP 1369
DI 10.1002/pro.167
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 469FV
UT WOS:000267882200003
PM 19551879
OA gold
DA 2018-01-05
ER

PT J
AU Le Van, K
   Cauvin, C
   de Walque, S
   Georges, B
   Boland, S
   Martinelli, V
   Demonte, D
   Durant, F
   Hevesi, L
   Van Lint, C
AF Le Van, Kiet
   Cauvin, Christine
   de Walque, Stephane
   Georges, Benoit
   Boland, Sandro
   Martinelli, Valerie
   Demonte, Dominique
   Durant, Francois
   Hevesi, Laszlo
   Van Lint, Carine
TI New Pyridinone Derivatives as Potent HIV-1 Nonnucleoside Reverse
   Transcriptase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-RESISTANT STRAINS; SOCIETY-USA PANEL;
   ANTIVIRAL ACTIVITY; TYPE-1; RECOMMENDATIONS; COMPLEXES; 4-BENZYL;
   MUTATION; ANALOGS
AB Several 5-ethyl-6-methyl-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized and evaluated for their anti HIV-1 activities against wild-type virus and clinically relevant mutant strains. A racemic mixture (10) with methyl substituents at positions 3 and 5 of the cyclohexyloxy moiety had potent antiviral activity against wild-type HIV-1. Subsequent stereoselective synthesis of a stereoisomer displaying both methyl groups in equatorial position was found to have the best EC(50). Further modulations focused on position 3 of the pyridinone ring improved the antiviral activity against mutant viral strains. Compounds bearing a 3-ethyl (22) or 3-isopropyl group (23) had the highest activity against wild-type HIV-1 and displayed low-nanomolar potency against several clinically relevant mutant strains.
C1 [Cauvin, Christine; Boland, Sandro; Durant, Francois] Fac Univ Notre Dame Paix, Lab Chim Mol Struct, B-5000 Namur, Belgium.
   [Le Van, Kiet; Georges, Benoit; Hevesi, Laszlo] Fac Univ Notre Dame Paix, Lab Chim Mat Organ, B-5000 Namur, Belgium.
   [Durant, Francois; Hevesi, Laszlo; Van Lint, Carine] Univ Libre Bruxelles, Mol Virol Lab, Inst Biol & Med Mol, B-6041 Gosselies, Belgium.
RP Cauvin, C (reprint author), Fac Univ Notre Dame Paix, Lab Chim Mol Struct, B-5000 Namur, Belgium.
EM christine.cauvin@fundp.ac.be
OI Boland, Sandro/0000-0001-5819-8273
FU DGTRE
FX This work was supported by grants from the DGTRE (Direction Generale des
   Technologies, de la Recherche et de I'Energie, Region Wallonne)
   (Programs WA-LEO). S.B. thanks F.R.I.A. for financial support. The
   authors thank Pr. Dr. Christophe Pannecouque (Rega Institute for Medical
   Research, Katholieke Universiteit Leuven, Leuven, Belgium) for
   performing the HIV-1 mutant strain selection experiments and the RT
   sequence determination of drug-resistant virus strains.
CR [Anonymous], DISC 3
   [Anonymous], INS 2
   Arnold E, 1996, Drug Des Discov, V13, P29
   Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001
   Balzarini J, 1998, AIDS RES HUM RETROV, V14, P255, DOI 10.1089/aid.1998.14.255                                                         
   Benjahad A, 2005, J MED CHEM, V48, P1948, DOI 10.1021/jm0408621
   CLAVEL F, 1994, J VIROL, V68, P179
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Dolle V, 2000, J MED CHEM, V43, P3949, DOI 10.1021/jm0009437
   DOLLE V, 1995, J MED CHEM, V38, P4679, DOI 10.1021/jm00023a007
   Fujiwara T, 1998, ANTIMICROB AGENTS CH, V42, P1340
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Himmel DM, 2005, J MED CHEM, V48, P7582, DOI 10.1021/jm0500323
   Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597                                                                  
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Minuto Joshua J, 2008, Futur HIV Ther, V2, P525, DOI 10.2217/17469600.2.6.525
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Spek A. L., 2001, PLATON
   Stevens M, 2003, ANTIMICROB AGENTS CH, V47, P2951, DOI 10.1128/AAC.47.9.2951-2957.2003
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   CURVEEXPERT1 3 COMPR
NR 30
TC 11
Z9 11
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 25
PY 2009
VL 52
IS 12
BP 3636
EP 3643
DI 10.1021/jm801438e
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 460IE
UT WOS:000267180600004
PM 19469474
OA gold
DA 2018-01-05
ER

PT J
AU Rudnicka, D
   Feldmann, J
   Porrot, F
   Wietgrefe, S
   Guadagnini, S
   Prevost, MC
   Estaquier, J
   Haase, AT
   Sol-Foulon, N
   Schwartz, O
AF Rudnicka, Dominika
   Feldmann, Jerome
   Porrot, Francoise
   Wietgrefe, Steve
   Guadagnini, Stephanie
   Prevost, Marie-Christine
   Estaquier, Jerome
   Haase, Ashley T.
   Sol-Foulon, Nathalie
   Schwartz, Olivier
TI Simultaneous Cell-to-Cell Transmission of Human Immunodeficiency Virus
   to Multiple Targets through Polysynapses
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIROLOGICAL SYNAPSE FORMATION; PLASMA-MEMBRANE; HIV-INFECTION;
   IMMUNOLOGICAL SYNAPSE; LIPID RAFTS; TYPE-1; CYTOSKELETON; SPREAD;
   LYMPHOCYTES; POLARIZATION
AB Human immunodeficiency virus type 1 (HIV-1) efficiently propagates through cell-to-cell contacts, which include virological synapses (VS), filopodia, and nanotubes. Here, we quantified and characterized further these diverse modes of contact in lymphocytes. We report that viral transmission mainly occurs across VS and through "polysynapses," a rosette-like structure formed between one infected cell and multiple adjacent recipients. Polysynapses are characterized by simultaneous HIV clustering and transfer at multiple membrane regions. HIV Gag proteins often adopt a ring-like supramolecular organization at sites of intercellular contacts and colocalize with CD63 tetraspanin and raft components GM1, Thy-1, and CD59. In donor cells engaged in polysynapses, there is no preferential accumulation of Gag proteins at contact sites facing the microtubule organizing center. The LFA-1 adhesion molecule, known to facilitate viral replication, enhances formation of polysynapses. Altogether, our results reveal an underestimated mode of viral transfer through polysynapses. In HIV-infected individuals, these structures, by promoting concomitant infection of multiple targets in the vicinity of infected cells, may facilitate exponential viral growth and escape from immune responses.
C1 [Rudnicka, Dominika; Feldmann, Jerome; Porrot, Francoise; Sol-Foulon, Nathalie; Schwartz, Olivier] Inst Pasteur, CNRS, URA 3015, Virus & Immun Unit,Dept Virol, F-75724 Paris 15, France.
   [Wietgrefe, Steve; Haase, Ashley T.] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.
   [Guadagnini, Stephanie; Prevost, Marie-Christine] Inst Pasteur, Electron Microscopy Core Facil, F-75724 Paris 15, France.
   [Estaquier, Jerome] Fac Med Henri Mondor, INSERM, U841, F-94010 Creteil, France.
RP Sol-Foulon, N (reprint author), Inst Pasteur, CNRS, URA 3015, Virus & Immun Unit,Dept Virol, 28 Rue Dr Roux, F-75724 Paris 15, France.
EM natsol@pasteur.fr; schwartz@pasteur.fr
OI SCHWARTZ, OLIVIER/0000-0002-0729-1475; Estaquier,
   Jerome/0000-0002-9432-8044
FU Agence Nationale de Recherche sur le SIDA (ANRS); Sidaction; CNRS;
   Fondation de France; European Community [201412]; Institut Pasteur;
   Marie Curie fellowship
FX This work was supported by grants from Agence Nationale de Recherche sur
   le SIDA (ANRS), Sidaction, CNRS, Fondation de France, European Community
   (FP7 contract no. 201412), and Institut Pasteur. D. R. is supported by a
   Marie Curie fellowship (FP6 contract, INTRAPATH program).
CR Alfsen A, 2005, MOL BIOL CELL, V16, P4267, DOI 10.1091/mbc.E05-03-0192
   Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Depoil D, 2005, IMMUNITY, V22, P185, DOI 10.1016/j.immuni.2004.12.010
   Dixit R, 2008, NEUROSCI LETT, V440, P113, DOI 10.1016/j.neulet.2008.05.031
   Dustin ML, 2007, CURR OPIN CELL BIOL, V19, P529, DOI 10.1016/j.ceb.2007.08.003
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Fackler OT, 2006, CURR OPIN MICROBIOL, V9, P409, DOI 10.1016/j.mib.2006.06.010
   Fortin JF, 1999, VIROLOGY, V257, P228, DOI 10.1006/viro.1999.9687
   Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x
   Gousset K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000015
   Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566
   Groot F, 2008, BLOOD, V111, P4660, DOI 10.1182/blood-2007-12-130070
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Hioe CE, 2001, J VIROL, V75, P1077, DOI 10.1128/JVI.75.2.1077-1082.2001                                                 
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hope TJ, 2007, NAT CELL BIOL, V9, P243, DOI 10.1039/ncb0307-243
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2007, J VIROL, V81, P13916, DOI 10.1128/JVI.01585-07
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jolly C, 2007, J VIROL, V81, P5547, DOI 10.1128/JVI.01469-06
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2006, CELL MICROBIOL, V8, P1803, DOI 10.1111/j.1462-5822.2006.00750.x
   Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5
   Leung K, 2008, CELL HOST MICROBE, V3, P285, DOI 10.1016/j.chom.2008.04.004
   Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001
   Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Naghavi MH, 2007, CURR OPIN IMMUNOL, V19, P402, DOI 10.1016/j.coi.2007.07.003
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   PANTALEO G, 1991, J EXP MED, V173, P511, DOI 10.1084/jem.173.2.511
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   Puigdomenech I, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-32
   Ruggiero E, 2008, J VIROL, V82, P7773, DOI 10.1128/JVI.00695-08
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Schelhaas M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000148
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.embroj.7601509
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Tardif MR, 2005, J IMMUNOL, V175, P926, DOI 10.4049/jimmunol.175.2.926                                                      
   Vasiliver-Shamis G, 2008, J VIROL, V82, P9445, DOI 10.1128/JVI.00835-08
   Wiedemann A, 2006, P NATL ACAD SCI USA, V103, P10985, DOI 10.1073/pnas.0600651103
   Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101
NR 54
TC 139
Z9 140
U1 1
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN 15
PY 2009
VL 83
IS 12
BP 6234
EP 6246
DI 10.1128/JVI.00282-09
PG 13
WC Virology
SC Virology
GA 448BV
UT WOS:000266237900027
PM 19369333
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, HX
   Wang, JX
   Zhang, ZB
   Le, Y
   Shen, ZG
   Chen, JF
AF Zhang, Hai-Xia
   Wang, Jie-Xin
   Zhang, Zhi-Bing
   Le, Yuan
   Shen, Zhi-Gang
   Chen, Jian-Feng
TI Micronization of atorvastatin calcium by antisolvent precipitation
   process
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Atorvastatin calcium; Ultrafine particle; Antisolvent precipitation;
   Poorly water-soluble drug
ID ANTI-SOLVENT PRECIPITATION; HIV DRUG UC-781; REACTIVE PRECIPITATION;
   HYDROCORTISONE ACETATE; SOLID DISPERSIONS; VIVO EVALUATION; SOLUBLE
   DRUGS; SAS PROCESS; CRYSTALLIZATION; NANOSUSPENSIONS
AB Amorphous atorvastatin calcium (AC) ultrafine powder has been successfully prepared by antisolvent precipitation and spray drying process, in which hydroxypropyl methylcellulose (HPMC) was employed to control the particle size and morphology. The effects of experimental parameters, such as stirring time, drug concentration and drying methods, on particle size and morphology were investigated. The average particle size of AC obviously increased from 410 nm to 1200 nm as the stirring time changed from 30 s to 60 min. The enhancement of drug concentration favored to decrease the particle size from 410 nm to 240 nm. After spray drying process, ultrafine AC powder was obtained, which had good dispersibility and narrow particle size distribution of 1-3 mu m. The as-prepared ultrafine AC was characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared (IFT-IR) spectroscopy, thermal gravimetric analysis (TG), differential scanning calorimetry (DSC), specific surface area and dissolution test. The XRD analyses indicated that the ultrafine AC was amorphous. In the dissolution tests, the amorphous AC ultrafine powder exhibited enhanced dissolution property when compared to the raw material. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zhang, Hai-Xia; Wang, Jie-Xin; Zhang, Zhi-Bing; Le, Yuan] Beijing Inst Chem Technol, Minist Educ, Key Lab Nanomat, Beijing 100029, Peoples R China.
   [Zhang, Hai-Xia; Shen, Zhi-Gang; Chen, Jian-Feng] Beijing Inst Chem Technol, Minist Educ High Grav Engn & Technol, Res Ctr, Beijing 100029, Peoples R China.
RP Wang, JX (reprint author), Beijing Inst Chem Technol, Minist Educ, Key Lab Nanomat, Beijing 100029, Peoples R China.
EM wangjx@mail.buct.edu.cn; chenjf@mail.buct.edu.cn
FU National Natural Science Foundation of China [20806004, 20821004];
   Talent Training Program of Beijing City [200713022]
FX This work was financially supported by National Natural Science
   Foundation of China (Nos. 20806004 and 20821004) and The Talent Training
   Program of Beijing City (No. 200713022).
CR Chen JF, 2004, INT J PHARM, V269, P267, DOI 10.1016/j.ijpharm.2003.09.044
   Chiou H, 2007, INT J PHARM, V331, P93, DOI 10.1016/j.ijpharm.2006.09.022
   DIRKSEN JA, 1991, CHEM ENG SCI, V46, P2389, DOI 10.1016/0009-2509(91)80035-W                                                    
   Douroumis D, 2006, EUR J PHARM BIOPHARM, V63, P173, DOI 10.1016/j.ejpb.2006.02.004
   Goddeeris C, 2007, EUR J PHARM BIOPHARM, V66, P173, DOI 10.1016/j.ejpb.2006.10.005
   Goddeeris C, 2008, EUR J PHARM SCI, V34, P293, DOI 10.1016/j.ejps.2008.05.005
   Hecq J, 2006, EUR J PHARM BIOPHARM, V64, P360, DOI 10.1016/j.ejpb.2006.05.008
   Kim JS, 2008, INT J PHARM, V359, P211, DOI 10.1016/j.ijpharm.2008.04.006
   Kim MS, 2008, EUR J PHARM BIOPHARM, V69, P454, DOI 10.1016/j.ejpb.2008.01.007
   Krause KP, 2001, INT J PHARM, V214, P21, DOI 10.1016/S0378-5173(00)00626-8
   Larsson A, 2008, POWDER TECHNOL, V188, P139, DOI 10.1016/j.powtec.2008.04.039
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Li XS, 2007, INT J PHARM, V342, P26, DOI 10.1016/j.ijpharm.2007.04.025
   Lindfors L, 2006, LANGMUIR, V22, P906, DOI 10.1021/la0523661
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Muller RH, 1998, INT J PHARMACEUT, V160, P229, DOI 10.1016/S0378-5173(97)00311-6
   Pathak P, 2004, J AM CHEM SOC, V126, P10842, DOI 10.1021/ja046914t
   Perrut M, 2005, INT J PHARMACEUT, V288, P3, DOI 10.1016/j.ijpharm.2004.09.007
   Radl S, 2002, TETRAHEDRON LETT, V43, P2087, DOI 10.1016/S0040-4039(02)00175-2
   Raghavan SL, 2003, INT J PHARM, V261, P153, DOI 10.1016/S0378-5173(03)00299-0
   Raghavan SL, 2001, INT J PHARM, V221, P95, DOI 10.1016/S0378-5173(01)00673-1
   Raghavan SL, 2001, INT J PHARM, V212, P213, DOI 10.1016/S0378-5173(00)00610-4
   Rasenack N, 2004, POWDER TECHNOL, V143, P291, DOI 10.1016/j.powtec.2004.04.021
   Rasenack N, 2003, J PHARM SCI, V92, P35, DOI 10.1002/jps.10274
   Reinhard V, 2008, PHARM RES, V25, P999
   Reverchon E, 2008, J SUPERCRIT FLUID, V46, P185, DOI 10.1016/j.supflu.2008.04.010
   Tenorio A, 2007, J SUPERCRIT FLUID, V40, P308, DOI 10.1016/j.supflu.2006.07.003
   Wade RA, 1997, ORG PROCESS RES DEV, V1, P320, DOI 10.1021/op9701088                                                               
   Wang Z, 2007, IND ENG CHEM RES, V46, P4839, DOI 10.1021/ie0615537
   WEERD J, 2004, VIB SPECTROSC, V35, P9
   Won DH, 2005, INT J PHARM, V301, P199, DOI 10.1016/j.ijpharm.2005.05.017
   Zhang JY, 2006, INT J PHARM, V323, P153, DOI 10.1016/j.ijpharm.2006.05.048
   Zhao H, 2007, IND ENG CHEM RES, V46, P8229, DOI 10.1021/ie070498e
   Zhong J, 2005, INT J PHARM, V301, P286, DOI 10.1016/j.ijpharm.2005.06.005
NR 34
TC 75
Z9 86
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUN 5
PY 2009
VL 374
IS 1-2
BP 106
EP 113
DI 10.1016/j.ijpharm.2009.02.015
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 456JO
UT WOS:000266841800016
PM 19446766
DA 2018-01-05
ER

PT J
AU Higashi, T
   Khalil, IA
   Maiti, KK
   Lee, WS
   Akita, H
   Harashima, H
   Chung, SK
AF Higashi, Tomoko
   Khalil, Ikramy A.
   Maiti, Kaustabh K.
   Lee, Woo Sirl
   Akita, Hidetaka
   Harashima, Hideyoshi
   Chung, Sung-Kee
TI Novel lipidated sorbitol-based molecular transporters for non-viral gene
   delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Sorbitol; Octaarginine; Guanidine; Condensation; Non-viral gene
   delivery; MEND
ID ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; CELLULAR UPTAKE; NANO DEVICE;
   INTRACELLULAR TRAFFICKING; OCTAARGININE; DESIGN; MACROPINOCYTOSIS;
   NANOPARTICLES; COMPLEXES
AB In this study, we investigated the possible use of novel lipiclated sorbitol-based transporters as functional devices for the improvement of non-viral gene delivery. These transporters are composed of a sorbitol scaffold bearing 8 guanidine moieties that mimic the arginine residues of well-known cell-penetrating peptides. In addition, the transporters carry different lipid groups to aid DNA condensation and facilitate lipid vesicle-binding. We found that the transporters described in this study have the potential to function as plasmid DNA/siRNA-condensers and surface ligands for the enhancement of cellular uptake of lipid vesicles. Shorter lipid chains were found to be better for condensation, whereas longer chains were superior surface ligands. The differential activity of different cores might be explained by facilitated decondensation of cores prepared with transporters comprised of shorter lipid chains. However, we suggest that there is an optimum value of decondensation to achieve higher transfection activities. The proper use of the transporters presented in this study enabled us to prepare a highly efficient non-viral gene delivery system based on a core-shell structure, in which a condensed DNA core is encapsulated by a lipid envelope. A multifunctional envelope-type nano-device prepared with an optimal surface ligand favorably competes with commonly used transfection systems. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Sapporo, Hokkaido 0600812, Japan.
   [Higashi, Tomoko; Khalil, Ikramy A.; Akita, Hidetaka; Harashima, Hideyoshi] Japan Sci & Technol Agcy, Core Res Educ Sci & Technol, Kawaguchi, Saitama, Japan.
   [Maiti, Kaustabh K.; Lee, Woo Sirl; Chung, Sung-Kee] Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea.
RP Harashima, H (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.
EM harasima@pharm.hokudai.ac.jp; skchung@postech.ac.kr
RI Harashima, Hideyoshi/D-8390-2012
FU Korean MOEHR [BK-21]; MOST; National Frontier Research Program
   administered through KRICT/CBM; Ministry of Education, Culture, Sports,
   Science and Technology of Japan; Japan Society for the Promotion of
   Science
FX This work was financially supported by Korean MOEHR (BK-21) and MOST
   (National Frontier Research Program administered through KRICT/CBM), by
   Grants-in-Aid for Scientific Research (A) from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan, and by
   Grants-in-Aid for Scientific Research on Priority Areas from the Japan
   Society for the Promotion of Science.
CR Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Gius DR, 1999, CANCER RES, V59, P2577
   Hama S, 2006, MOL THER, V13, P786, DOI 10.1016/j.ymthe.2005.10.007
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Kaiser J, 2005, SCIENCE, V310, P1894, DOI 10.1126/science.310.5756.1894                                                   
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Khalil Ikramy A, 2008, Int J Pharm, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Kostarelos K, 2005, CHEM SOC REV, V34, P970, DOI 10.1039/b307062j
   Maiti KK, 2007, ANGEW CHEM INT EDIT, V46, P5880, DOI 10.1002/anie.200701346
   Maiti KK, 2007, CHEM-EUR J, V13, P762, DOI 10.1002/chem.200600898
   Maiti KK, 2006, ANGEW CHEM INT EDIT, V45, P2907, DOI 10.1002/anie.200600312
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Moriguchi R, 2005, INT J PHARM, V301, P277, DOI 10.1016/j.ijpharm.2005.05.021
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Williams DA, 2003, SCIENCE, V302, P400, DOI 10.1126/science.1091258                                                         
   Yuan JP, 2002, CANCER RES, V62, P4186
   Zhou P, 2003, J AM CHEM SOC, V125, P6878, DOI 10.1021/ja029665m
NR 26
TC 16
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 5
PY 2009
VL 136
IS 2
BP 140
EP 147
DI 10.1016/j.jconrel.2009.01.024
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 455EB
UT WOS:000266739200008
PM 19331845
DA 2018-01-05
ER

PT J
AU Caputo, A
   Castaldello, A
   Brocca-Cofano, E
   Voltan, R
   Bortolazzi, F
   Altavilla, G
   Sparnacci, K
   Laus, M
   Tondelli, L
   Gavioli, R
   Ensoli, B
AF Caputo, Antonella
   Castaldello, Arianna
   Brocca-Cofano, Egidio
   Voltan, Rebecca
   Bortolazzi, Francesca
   Altavilla, Giuseppe
   Sparnacci, Katia
   Laus, Michele
   Tondelli, Luisa
   Gavioli, Riccardo
   Ensoli, Barbara
TI Induction of humoral and enhanced cellular immune responses by novel
   core-shell nanosphere- and microsphere-based vaccine formulations
   following systemic and mucosal administration
SO VACCINE
LA English
DT Article
DE Functional core-shell nano- and microspheres; Antigen surface
   adsorption; HIV-1 Tat vaccine; Mice
ID HIV-1 TAT PROTEIN; CYTOTOXIC T-LYMPHOCYTES; POTENT DELIVERY-SYSTEM; DNA
   VACCINES; CATIONIC MICROPARTICLES; NEUTRALIZING ANTIBODIES; POLYMERIC
   MICROSPHERES; COATED NANOPARTICLES; LIPOPEPTIDE MALP-2; CYNOMOLGUS
   MONKEYS
AB Anionic surfactant-free polymeric core-shell nanospheres and microspheres were previously described with an inner core constituted by poly(methylmethacrylate) (PMMA) and a highly hydrophilic outer shell composed of a hydiosoluble co-polymer (Eudragit L100-55). The outer shell is tightly linked to the core and bears carboxylic groups capable of adsorbing high amounts (antigen loading ability of up to 20%, w/w) of native basic proteins, mainly by electrostatic interactions, while preserving their activity. In the present study we have evaluated in mice the safety and immunogenicity of new vaccine formulations composed of these nano- and microspheres and the HIV-1 Tat protein. Vaccines were administered by different routes, including intramuscular, subcutaneous or intranasal and the results were compared to immunization with Tat alone or with Tat delivered with the alum adjuvant. The data demonstrate that the nano- and microspheres/Tat formulations are safe and induce robust and long-lasting cellular and humoral responses in mice after systemic and/or mucosal immunization. These delivery systems may have great potential for novel Tat protein-based vaccines against HIV-1 and hold promise for other protein-based vaccines. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Caputo, Antonella] Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, I-35122 Padua, Italy.
   [Altavilla, Giuseppe] Univ Padua, Dept Med Diagnost Sci & Special Therapies, I-35122 Padua, Italy.
   [Sparnacci, Katia; Laus, Michele] Univ Piemonte Orientale, Dept Life & Ambient Sci, I-15100 Alessandria, Italy.
   [Sparnacci, Katia; Laus, Michele] UdR Piemonte Orientale, INSTM, I-15100 Alessandria, Italy.
   [Tondelli, Luisa] CNR, ISOF, I-40129 Bologna, Italy.
   [Gavioli, Riccardo] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy.
   [Ensoli, Barbara] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
RP Caputo, A (reprint author), Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, Via A Gabelli 63, I-35122 Padua, Italy.
EM antonella.caputo@unipd.it
RI Gavioli, Riccardo/K-7594-2016; Sparnacci, Katia/C-1138-2009; Ensoli,
   Barbara/J-9169-2016; tondelli, luisa/C-1414-2012
OI Gavioli, Riccardo/0000-0002-7805-4290; Sparnacci,
   Katia/0000-0003-2102-9649; Ensoli, Barbara/0000-0002-0545-8737;
   tondelli, luisa/0000-0002-3971-3361; Laus, Michele/0000-0002-4296-3732
FU Istituto Superiore di Sanita; Ministero dell'Istruzione, dell'Universita
   e della Ricerca (MIUR)
FX This work was supported by grants from the Istituto Superiore di Sanita
   [Italian Concerted Action on HIV-AIDS Vaccine Development(ICAV)], and
   from the Ministero dell'Istruzione, dell'Universita e della Ricerca
   (MIUR). We are grateful to Mauro Magnani (Diatheva, Fano, Italy) for
   providing GLP batches of HIV-1 Tat protein.
CR Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Borsutzky S, 2003, EUR J IMMUNOL, V33, P1548, DOI 10.1002/eji.200323954
   Borsutzky S, 2006, VACCINE, V24, P2049, DOI 10.1016/j.vaccine.2005.11.025
   Bramwell VW, 2006, J PHARM PHARMACOL, V58, P717, DOI 10.1211/jpp.56.6.0002
   Brave A, 2007, VACCINE, V25, P6882, DOI 10.1016/j.vaccine.2007.07.012
   Cafaro A, 1999, NAT MED, V5, P643
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   Caputo A, 2003, VACCINE, V21, P1103, DOI 10.1016/S0264-410X(02)00555-8                                                   
   Caputo A, 2008, VACCINE, V26, P1214, DOI 10.1016/j.vaccine.2007.12.030
   Caputo Antonella, 2008, Current Drug Delivery, V5, P230, DOI 10.2174/156720108785914961
   Caselli E, 1999, J IMMUNOL, V162, P5631
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   DAVIS SS, 2006, VACCINE S2, V24
   ENSOLI B, 1993, J VIROL, V67, P277
   Ensoli B, 2008, AIDS, V22, P2207, DOI 10.1097/QAD.0b013e32831392d4
   Ensoli B, 2006, AIDS, V20, P2245, DOI 10.1097/QAD.0b013e3280112cd1
   Espuelas S, 2005, MOL IMMUNOL, V42, P721, DOI 10.1016/j.molimm.2004.09.022
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Ferrantelli F, 2004, CURR OPIN BIOTECH, V15, P543, DOI 10.1016/j.copbio.2004.10.008
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838                                                     
   Gavioli R, 2008, VACCINE, V26, P727, DOI 10.1016/j.vaccine.2007.11.040
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Jabbal-Gill I, 1999, VACCINE, V18, P238, DOI 10.1016/S0264-410X(99)00195-4
   Kasturi SP, 2005, BIOMATERIALS, V26, P6375, DOI 10.1016/j.biomaterials.2005.03.043
   Kasturi SP, 2006, J CONTROL RELEASE, V113, P261, DOI 10.1016/j.jcornel.2006.04.006
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Langer R., 1997, ADV DRUG DELIV REV, V28, P97
   Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009
   Marinaro M, 2003, VACCINE, V21, P3972, DOI 10.1016/S0264-410X(03)00295-0
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269
   O'Hagan DT, 2004, VACCINE, V23, P672, DOI 10.1016/j.vaccine.2004.06.037
   Oster CG, 2005, J CONTROL RELEASE, V104, P359, DOI 10.1016/j.jconrel.2005.02.004
   Ott G, 1995, Pharm Biotechnol, V6, P277
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Podda Audino, 2003, Expert Rev Vaccines, V2, P197, DOI 10.1586/14760584.2.2.197
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Rydell Niclas, 2005, Expert Opin Drug Deliv, V2, P807, DOI 10.1517/17425247.2.5.807
   Sah H, 1999, J CONTROL RELEASE, V58, P143, DOI 10.1016/S0168-3659(98)00148-5
   Sesardic D, 2004, VACCINE, V22, P2452, DOI 10.1016/j.vaccine.2003.11.071
   Singh M, 2006, VACCINE, V24, P1680, DOI 10.1016/j.vaccine.2005.09.046
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   Sparnacci K, 2005, J BIOMAT SCI-POLYM E, V16, P1557, DOI 10.1163/156856205774576673
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   Titti F, 2007, EXPERT OPIN EMERG DR, V12, P23, DOI 10.1517/14728214.12.1.23
   Vajdy M, 2006, J GEN VIROL, V87, P2253, DOI 10.1099/vir.0.81849-0
   Voltan R, 2007, PHARM RES-DORDR, V24, P1870, DOI 10.1007/s11095-007-9310-8
   ENSOLI B, 2003, Patent No. 03256245
   ENSOLI B, 2005, Patent No. 2005048997
   ENSOLI B, 2005, Patent No. 2005049093
NR 58
TC 26
Z9 26
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 2
PY 2009
VL 27
IS 27
BP 3605
EP 3615
DI 10.1016/j.vaccine.2009.03.047
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 463VG
UT WOS:000267459900015
PM 19464541
DA 2018-01-05
ER

PT J
AU Jorgensen, WL
AF Jorgensen, William L.
TI Efficient Drug Lead Discovery and Optimization
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID HIV-1 REVERSE-TRANSCRIPTASE; FREE-ENERGY CALCULATIONS; MONTE-CARLO
   SIMULATIONS; P38 MAP KINASE; NONNUCLEOSIDE INHIBITORS; BIOMOLECULAR
   SYSTEMS; SCORING FUNCTIONS; DOCKING; BINDING; PREDICTION
AB During the 1980s, advances in the abilities to perform computer simulations of chemical and biomolecular systems and to calculate free energy changes led to the expectation that such methodology would soon show great utility for guiding molecular design. Important potential applications included design of selective receptors, catalysts, and regulators of biological function including enzyme inhibitors. This time also saw the rise of high-throughput screening and combinatorial chemistry along with complementary computational methods for de novo design and virtual screening including docking. These technologies appeared poised to deliver diverse lead compounds for any biological target. As with many technological advances, realization of the expectations required significant additional effort and time. However, as summarized here, striking success has now been achieved for computer-aided drug lead generation and optimization.
   De novo design using both molecular growing and docking are illustrated for lead generation, and lead optimization features free energy perturbation calculations in conjunction with Monte Carlo statistical mechanics simulations for protein-inhibitor complexes in aqueous solution. The specific applications are to the discovery of non-nucleoside inhibitors of HIV reverse transcriptase (HIV-RT) and inhibitors of the binding of the proinflammatory cytokine MIF to its receptor CD74. A standard protocol is presented that includes scans for possible additions of small substituents to a molecular core, interchange of heterocycles, and focused optimization of substituents at one site. Initial leads with activities at low-micromolar concentrations have been advanced rapidly to low-nanomolar inhibitors.
C1 Yale Univ, Dept Chem, New Haven, CT 06520 USA.
RP Jorgensen, WL (reprint author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.
FU National Institute of General Medical Sciences [GM32136]; National
   Institute of Allergy and Infectious Diseases [A144676]; National
   Foundation for Cancer Research; Alliance for Lupus Research
FX Gratitude is expressed to the National Institute of General Medical
   Sciences (Grant GM32136), National Institute of Allergy and Infectious
   Diseases (Grant A144676), National Foundation for Cancer Research, and
   Alliance for Lupus Research for support of this research and to the many
   stalwart co-workers at Yale.
CR Barreiro G, 2007, J MED CHEM, V50, P5324, DOI 10.1021/jm070683u
   Barreiro G, 2007, J CHEM INF MODEL, V47, P2416, DOI 10.1021/ci700271z
   Blagovic M. U., 2004, J MED CHEM, V47, P2389
   Chipot C., 2007, SPRINGER SERIES CHEM, V86, P33
   Congreve M, 2008, J MED CHEM, V51, P3661, DOI 10.1021/jm8000373
   Cournia Z, 2009, J MED CHEM, V52, P416, DOI 10.1021/jm801100v
   Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e
   Erion MD, 2007, J AM CHEM SOC, V129, P15480, DOI 10.1021/ja074869u
   Essex JW, 1997, J PHYS CHEM B, V101, P9663, DOI 10.1021/jp971990m                                                               
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gohlke Holger, 2002, Angew Chem Int Ed Engl, V41, P2644, DOI 10.1002/1521-3773(20020802)41:15<2644::AID-ANIE2644>3.0.CO;2-O
   Guimaraes CRW, 2005, J AM CHEM SOC, V127, P17377, DOI 10.1021/ja055438j
   Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Jorgensen WL, 2008, J CHEM THEORY COMPUT, V4, P869, DOI 10.1021/ct800011m
   Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297
   JORGENSEN WL, 1985, J CHEM PHYS, V83, P3050, DOI 10.1063/1.449208                                                                
   Jorgensen WL, 2006, BIOORG MED CHEM LETT, V16, P663, DOI 10.1016/j.bmcl.2005.10.038
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361                                                         
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Jorgensen WL, 2005, P NATL ACAD SCI USA, V102, P6665, DOI 10.1073/pnas.0408037102
   Jorgensen W.L., 2006, QIKPROP V 3 0
   Kim JT, 2006, J AM CHEM SOC, V128, P15372, DOI 10.1021/ja066472g
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004                                                             
   Leach AR, 2006, J MED CHEM, V49, P5851, DOI 10.1021/jm060999m
   Leach AR, 2006, MOL BIOSYST, V2, P429
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   MCCAMMON JA, 1987, SCIENCE, V238, P486, DOI 10.1126/science.3310236                                                         
   MERZ KM, 1989, J AM CHEM SOC, V111, P5649, DOI 10.1021/ja00197a022
   Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029
   Norinder U, 2006, CHEMMEDCHEM, V1, P920, DOI 10.1002/cmdc.200600155
   Pearlman DA, 2005, J MED CHEM, V48, P7796, DOI 10.1021/jm050306m
   Pearlman DA, 2001, J MED CHEM, V44, P3417, DOI 10.1021/jm0100279
   Pierce AC, 1997, ANGEW CHEM INT EDIT, V36, P1466, DOI 10.1002/anie.199714661                                                          
   Plount-Price M. L., 2000, J AM CHEM SOC, V122, P9455
   PLOUNTPRICE ML, 2001, BIOORG MED CHEM LETT, V11, P1541
   Proudfoot JR, 2005, BIOORG MED CHEM LETT, V15, P1087, DOI 10.1016/j.bmcl.2004.12.024
   Reddy MR, 2001, J AM CHEM SOC, V123, P6246, DOI 10.1021/ja0103288
   Rizzo RC, 2000, J AM CHEM SOC, V122, P12898, DOI 10.1021/ja003113r
   Ruiz-Caro J, 2006, BIOORG MED CHEM LETT, V16, P668, DOI 10.1016/j.bmcl.2005.10.037
   Thakur VV, 2006, BIOORG MED CHEM LETT, V16, P5664, DOI 10.1016/j.bmcl.2006.08.037
   Tirado-Rives J, 2006, J MED CHEM, V49, P5880, DOI 10.1021/jm060763i
   Udier-Blagovic M, 2003, J AM CHEM SOC, V125, P6016, DOI 10.1021/ja034308c
   Wang DP, 2001, BIOORG MED CHEM LETT, V11, P2799, DOI 10.1016/S0960-894X(01)00510-8
   WONG CF, 1986, J AM CHEM SOC, V108, P3830, DOI 10.1021/ja00273a048
   Zeevaart JG, 2008, J AM CHEM SOC, V130, P9492, DOI 10.1021/ja8019214
   Zhou ZY, 2007, J CHEM INF MODEL, V47, P1599, DOI 10.1021/ci7000346
NR 49
TC 274
Z9 277
U1 12
U2 118
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD JUN
PY 2009
VL 42
IS 6
BP 724
EP 733
DI 10.1021/ar800236t
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 458UC
UT WOS:000267049000005
PM 19317443
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Woodrow, KA
   Cu, Y
   Booth, CJ
   Saucier-Sawyer, JK
   Wood, MJ
   Saltzman, WM
AF Woodrow, Kim A.
   Cu, Yen
   Booth, Carmen J.
   Saucier-Sawyer, Jennifer K.
   Wood, Monica J.
   Saltzman, W. Mark
TI Intravaginal gene silencing using biodegradable polymer nanoparticles
   densely loaded with small-interfering RNA
SO NATURE MATERIALS
LA English
DT Article
ID IN-VIVO; SIRNA DELIVERY; HIV-1 INFECTION; CATIONIC LIPIDS;
   DRUG-DELIVERY; CELL-GROWTH; MICE; MICROBICIDES; TOXICITY; RELEASE
AB Vaginal instillation of small-interfering RNA (siRNA) using liposomes has led to silencing of endogenous genes in the genital tract and protection against challenge from infectious disease. Although siRNA lipoplexes are easily formulated, several of the most effective transfection agents available commercially may be toxic to the mucosal epithelia and none are able to provide controlled or sustained release. Here, we demonstrate an alternative approach using nanoparticles composed entirely of FDA-approved materials. To render these materials effective for gene silencing, we developed novel approaches to load them with high amounts of siRNA. A single dose of siRNA-loaded nanoparticles to the mouse female reproductive tract caused efficient and sustained gene silencing. Knockdown of gene expression was observed proximal (in the vaginal lumen) and distal (in the uterine horns) to the site of topical delivery. In addition, nanoparticles penetrated deep into the epithelial tissue. This is the first report demonstrating that biodegradable polymer nanoparticles are effective delivery vehicles for siRNA to the vaginal mucosa.
C1 [Woodrow, Kim A.; Cu, Yen; Saucier-Sawyer, Jennifer K.; Wood, Monica J.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA.
   [Booth, Carmen J.] Yale Univ, Comparat Med Sect, New Haven, CT 06511 USA.
RP Saltzman, WM (reprint author), Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA.
EM mark.saltzman@yale.edu
FU NIBIB NIH HHS [R01 EB000487, R01 EB000487-14, R01 EB000487-17, R01
   EB000487-16, R01-EB0000487-18, R01 EB000487-15]; NHLBI NIH HHS [T32
   HL007950, T32-HL007950-08]
CR Bachrach U, 2005, CURR PROTEIN PEPT SC, V6, P559, DOI 10.2174/138920305774933240
   Braden A, 2007, J BIOMED NANOTECHNOL, V3, P148, DOI 10.1166/jbn.2007.010
   Breunig M, 2007, P NATL ACAD SCI USA, V104, P14454, DOI 10.1073/pnas.0703882104
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Conwell CC, 2008, MOL THER, V16, P370, DOI 10.1038/sj.mt.6300356
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   FLYNN MA, 2004, J INFLAMM, V1, P1
   Freiberg S, 2004, INT J PHARM, V282, P1, DOI 10.1016/j.ijpharm.2004.04.013
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Grayson ACR, 2006, PHARM RES, V23, P1868, DOI 10.1007/s11095-006-9009-2
   Gu W, 2006, CANCER GENE THER, V13, P1023, DOI 10.1038/sj.cgt.7700971
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Khan A, 2004, J DRUG TARGET, V12, P393, DOI 10.1080/10611860400003858
   Khazanov E, 2006, J GENE MED, V8, P998, DOI 10.1002/jgm.933
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Murata N, 2008, J CONTROL RELEASE, V126, P246, DOI 10.1016/j.jconrel.2007.11.017
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153                                                             
   RICHARDSON JL, 1992, ADV DRUG DELIVER REV, V8, P341, DOI 10.1016/0169-409X(92)90008-E
   Robbins M, 2008, HUM GENE THER, V19, P991, DOI 10.1089/hum.2008.131
   Sato Y, 2008, NAT BIOTECHNOL, V26, P431, DOI 10.1038/nbt1396
   Shen H, 2003, J CONTROL RELEASE, V86, P339, DOI 10.1016/S0168-3659(02)00354-1
   Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilson DP, 2008, P NATL ACAD SCI USA, V105, P9835, DOI 10.1073/pnas.0711813105
   Yuan XD, 2006, J NANOSCI NANOTECHNO, V6, P2821, DOI 10.1166/jnn.2006.436
   Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100                                                         
   Zhang JS, 2005, ADV DRUG DELIVER REV, V57, P689, DOI 10.1016/j.addr.2004.12.004
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 47
TC 250
Z9 252
U1 10
U2 104
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
J9 NAT MATER
JI Nat. Mater.
PD JUN
PY 2009
VL 8
IS 6
BP 526
EP 533
DI 10.1038/NMAT2444
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 447RE
UT WOS:000266208700026
PM 19404239
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI HIV needs point-of-care nano-sensors
SO TRAC-TRENDS IN ANALYTICAL CHEMISTRY
LA English
DT News Item
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0165-9936
J9 TRAC-TREND ANAL CHEM
JI Trac-Trends Anal. Chem.
PD JUN
PY 2009
VL 28
IS 6
SI SI
BP VII
EP VIII
PG 2
WC Chemistry, Analytical
SC Chemistry
GA 463RR
UT WOS:000267450100004
DA 2018-01-05
ER

PT J
AU Boros, EE
   Edwards, CE
   Foster, SA
   Fuji, M
   Fujiwara, T
   Garvey, EP
   Golden, PL
   Hazen, RJ
   Jeffrey, JL
   Johns, BA
   Kawsuji, T
   Kiyama, R
   Koble, CS
   Kurose, N
   Miller, WH
   Mote, AL
   Murai, H
   Sato, A
   Thompson, JB
   Woodward, MC
   Yoshinaga, T
AF Boros, Eric E.
   Edwards, Cynthia E.
   Foster, Scott A.
   Fuji, Masahiro
   Fujiwara, Tamio
   Garvey, Edward P.
   Golden, Pamela L.
   Hazen, Richard J.
   Jeffrey, Jerry L.
   Johns, Brian A.
   Kawsuji, Takashi
   Kiyama, Ryuichi
   Koble, Cecilia S.
   Kurose, Noriyuki
   Miller, Wayne H.
   Mote, Angela L.
   Murai, Hitoshi
   Sato, Akihiko
   Thompson, James B.
   Woodward, Mark C.
   Yoshinaga, Tomokazu
TI Synthesis and Antiviral Activity of
   7-Benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV Integrase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID INFECTION; MODEL
AB The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naphthyridinone ring system. Low nanomolar IC(50) values were achieved in an HIV-integrase strand transfer assay with both carboxylic ester and carboxamide groups at C-3. More importantly, several carboxamide congeners showed potent antiviral activity in cellular assays. A 7-benzyl substituent was found to be critical for potent enzyme inhibition, and an N-(2-methoxyethyl)-carboxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro. Pharmacokinetic data in rats for one carboxamide analogue demonstrated oral bioavailability and reasonable in vivo clearance.
C1 [Boros, Eric E.; Edwards, Cynthia E.; Foster, Scott A.; Garvey, Edward P.; Golden, Pamela L.; Hazen, Richard J.; Jeffrey, Jerry L.; Johns, Brian A.; Koble, Cecilia S.; Miller, Wayne H.; Mote, Angela L.; Thompson, James B.; Woodward, Mark C.] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA.
   [Fuji, Masahiro; Fujiwara, Tamio; Kawsuji, Takashi; Kiyama, Ryuichi; Kurose, Noriyuki; Murai, Hitoshi; Sato, Akihiko; Yoshinaga, Tomokazu] Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5330002, Japan.
RP Boros, EE (reprint author), GlaxoSmithKline Res & Dev Ltd, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM eric.e.boros@gsk.com
FU Shionogi Co. Ltd; GlaxoSmithKline
FX This work was conducted as part of a research collaboration between
   Shionogi & Co. Ltd. and GlaxoSmithKline.
CR ASHCROFT WR, 1981, J CHEM SOC PERK T 1, P3012, DOI 10.1039/p19810003012                                                            
   Bajgrowicz JA, 2003, BIOORGAN MED CHEM, V11, P2931, DOI 10.1016/S0968-0896(03)00189-5
   Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
   Bonnefous C, 2005, BIOORG MED CHEM LETT, V15, P1197, DOI 10.1016/j.bmcl.2004.11.078
   Boros EE, 2007, ORG PROCESS RES DEV, V11, P899, DOI 10.1021/op7001326
   Cabrera C, 2008, CURR OPIN INVEST DR, V9, P885
   Chen X, 2008, J MOL BIOL, V380, P504, DOI 10.1016/j.jmb.2008.04.054
   DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122
   Ferro S, 2009, J MED CHEM, V52, P569, DOI 10.1021/jm8009266
   Garvey EP, 2008, ANTIMICROB AGENTS CH, V52, P901, DOI 10.1128/AAC.01218-07
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   ISOBE K, 1989, CHEM PHARM BULL, V37, P3236
   JEFFERY T, 1984, J CHEM SOC CHEM COMM, P1287, DOI 10.1039/c39840001287
   Johns BA, 2008, EXPERT OPIN THER PAT, V18, P1225, DOI 10.1517/13543770802500450
   Kawasuji T, 2006, BIOORGAN MED CHEM, V14, P8420, DOI 10.1016/j.bmc.2006.08.043
   MacArthur RD, 2008, CLIN INFECT DIS, V47, P236, DOI 10.1086/589289
   Manfredi R, 2006, CURR MED CHEM, V13, P2369, DOI 10.2174/092986706777935069
   Pace P, 2008, CURR OPIN DRUG DISC, V11, P471
   Sorbera LA, 2006, DRUG FUTURE, V31, P310, DOI 10.1358/dof.2006.031.04.982081
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   von Hentig N, 2008, DRUG TODAY, V44, P103, DOI 10.1358/dot.2008.44.2.1137107
   Anthony N. J., 2002, Patent, Patent No. [2002030930, WO 2002/030930 A2]
   SHIONOGI CO LTD, 2005, Patent No. 2005075475
   EGBERTSON M, 2003, Patent No. 03062204
   SHIONOGI CO LTD, 2004, Patent No. 2004024693
   SHIONOGI CO LTD, 2002, Patent No. 2002070486
NR 26
TC 30
Z9 31
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 14
PY 2009
VL 52
IS 9
BP 2754
EP 2761
DI 10.1021/jm801404b
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 443LP
UT WOS:000265911800013
PM 19374386
DA 2018-01-05
ER

PT J
AU Wiederhold, K
   Fasshauer, D
AF Wiederhold, Katrin
   Fasshauer, Dirk
TI Is Assembly of the SNARE Complex Enough to Fuel Membrane Fusion?
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SYNAPTIC VESICLE FUSION; T-SNARE; NEURONAL SNARES; 4-HELIX BUNDLE; HIV-1
   GP120; PROTEINS; SYNTAXIN; HEMIFUSION; MECHANISMS; EXOCYTOSIS
AB The three key players in the exocytotic release of neurotransmitters from synaptic vesicles are the SNARE (soluble N-ethylmaleimidesensitive factor attachment protein receptor) proteins synaptobrevin 2, syntaxin 1a, and SNAP-25. Their assembly into a tight four-helix bundle complex is thought to pull the two membranes into close proximity. It is debated, however, whether the energy generated suffices for membrane fusion. Here, we have determined the thermodynamic properties of the individual SNARE assembly steps by isothermal titration calorimetry. We found extremely large favorable enthalpy changes counterbalanced by positive entropy changes, reflecting the major conformational changes upon assembly. To circumvent the fact that ternary complex formation is essentially irreversible, we used a stabilized syntaxin-SNAP-25 heterodimer to study synaptobrevin binding. This strategy revealed that the N-terminal synaptobrevin coil binds reversibly with nanomolar affinity. This suggests that individual, membrane-bridging SNARE complexes can provide much less pulling force than previously claimed.
C1 [Wiederhold, Katrin; Fasshauer, Dirk] Max Planck Inst Biophys Chem, Dept Neurobiol, Res Grp Struct Biochem, D-37077 Gottingen, Germany.
RP Fasshauer, D (reprint author), Max Planck Inst Biophys Chem, Dept Neurobiol, Res Grp Struct Biochem, Fassberg 11, D-37077 Gottingen, Germany.
EM dfassha@gwdg.de
RI Fasshauer, Dirk/B-1563-2013
OI Fasshauer, Dirk/0000-0002-1040-4282
FU Deutsche Forschungsgemeinschaft [SFB523]
FX Supported by Deutsche Forschungsgemeinschaft Grant the SFB523.
CR Burkhardt P, 2008, EMBO J, V27, P923, DOI 10.1038/emboj.2008.37
   Chen XC, 2006, BIOPHYS J, V90, P2062, DOI 10.1529/biophysj.105.071415
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Dennison SM, 2006, BIOPHYS J, V90, P1661, DOI 10.1529/biophysj.105.069617
   Durrieu MP, 2008, BIOPHYS J, V94, P3436, DOI 10.1529/biophysj.107.123117
   Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Engelman DM, 2005, NATURE, V438, P578, DOI 10.1038/nature04394
   Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200
   Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750                                                                  
   Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440
   Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036
   Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582                                                          
   Li F, 2007, NAT STRUCT MOL BIOL, V14, P890, DOI 10.1038/nsmb1310
   Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002
   Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103
   Giraudo CG, 2008, J BIOL CHEM, V283, P21211, DOI 10.1074/jbc.M803478200
   Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3
   Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002
   Kim CS, 2002, BIOCHEMISTRY-US, V41, P10928, DOI 10.1021/bi026266v
   KWONG PD, 1998, NATURE, V393, P659
   Leavitt SA, 2004, CURR PROTEIN PEPT SC, V5, P1
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Liu W, 2008, BIOPHYS J, V95, P419, DOI 10.1529/biophysj.107.127886
   Liu W, 2006, BIOPHYS J, V91, P744, DOI 10.1529/biophysj.105.073312
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Lu XB, 2005, J BIOL CHEM, V280, P30538, DOI 10.1074/jbc.M506862200
   Malsam J, 2008, CELL MOL LIFE SCI, V65, P2814, DOI 10.1007/s00018-008-8352-3
   Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200
   Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417
   Martens S, 2007, SCIENCE, V316, P1205, DOI 10.1126/science.1142614
   Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565                                                        
   Parpura V, 2008, TRENDS NEUROSCI, V31, P435, DOI 10.1016/j.tins.2008.06.003
   Pobbati AV, 2006, SCIENCE, V313, P673, DOI 10.1126/science.1129486
   Rizo J, 2008, NAT STRUCT MOL BIOL, V15, P665, DOI 10.1038/nsmb.1450
   Rizo J, 2008, STRUCTURE, V16, P163, DOI 10.1016/j.str.2008.01.001
   Rizo J, 2007, NAT STRUCT MOL BIOL, V14, P880, DOI 10.1038/nsmb1007-880
   Sutton RB, 1998, NATURE, V395, P347
   Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030
   Verhage M, 2007, CURR OPIN CELL BIOL, V19, P402, DOI 10.1016/j.ceb.2007.05.002
   Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X
   Weiss Carol D, 2003, AIDS Rev, V5, P214
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 2007, FEBS LETT, V581, P2150, DOI 10.1016/j.febslet.2007.01.093
   Wojcik SM, 2007, NEURON, V55, P11, DOI 10.1016/j.neuron.2007.06.013
   Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174
   Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921
   Yersin A, 2003, P NATL ACAD SCI USA, V100, P8736, DOI 10.1073/pnas.1533137100
   Yoon TY, 2008, NAT STRUCT MOL BIOL, V15, P707, DOI 10.1038/nsmb.1446
   Yoon TY, 2006, P NATL ACAD SCI USA, V103, P19731, DOI 10.1073/pnas.0606032103
   YOON TY, 2008, CELL MOL LIFE SCI, V3, P460
   Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200
NR 57
TC 48
Z9 49
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 8
PY 2009
VL 284
IS 19
BP 13143
EP 13152
DI 10.1074/jbc.M900703200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 440GH
UT WOS:000265688300061
PM 19258315
OA gold
DA 2018-01-05
ER

PT J
AU Subramanyam, R
   Goud, M
   Sudhamalla, B
   Reddeem, E
   Gollapudi, A
   Nellaepalli, S
   Yadavalli, V
   Chinnaboina, M
   Amooru, DG
AF Subramanyam, Rajagopal
   Goud, Mahesh
   Sudhamalla, Babu
   Reddeem, Eswarreddy
   Gollapudi, Anilkishor
   Nellaepalli, Sreedhar
   Yadavalli, Venkateswarlu
   Chinnaboina, Madhurarekha
   Amooru, Damu G.
TI Novel binding studies of human serum albumin with trans-feruloyl
   maslinic acid
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Binding constant; Feruloyl maslinic acid; Fluorescence emission; Human
   serum albumin; Ligand binding; MicroTOF-Q mass spectrometry
ID PENTACYCLIC TRITERPENES; CRYSTALLOGRAPHIC ANALYSIS;
   GLYCOGEN-PHOSPHORYLASE; BIOLOGICAL EVALUATION; CRYSTAL-STRUCTURE;
   LIGAND-BINDING; RETINOIC ACID; FATTY-ACIDS; INHIBITORS; CONSTITUENTS
AB Human serum albumin (HSA) is a predominant protein in the blood. Most drugs can bind to HSA and be transported to target locations of the body. For this study, we have extracted 3-trans-feruloyl maslinic acid (FMA) from the medicinal plant Tetracera asiatica, its a non-fluorescent derivative have potent anti-cancer, anti-HIV, anti-diabetic, and anti-inflammatory activities. The binding constant of the compound with HSA, calculated from fluorescence data, was found as K(FMA) = 1.42 +/- 0.01 x 10(8) M(-1), which corresponds to 10.9 kcal M(-1) of free energy. Furthermore, microTOF-Q mass spectrometry data showed binding of FMA at nanomolar concentrations of FMA to free HSA. The study detected a mass increase from 66,560 Da (free HSA) to 67,919 Da (HSA + drug). This indicated a strong binding of FMA to HSA, resulting in an increase of the protein's absorbance and fluorescence. The secondary structure of HSA + FMA (0.1 mM) complexes showed the protein secondary structure became partially unfolded upon interaction of FMA with HSA, as well as indicating that HSA-FMA complexes were formed. Docking experiments uncovered the binding mode of FMA in HSA molecule. It was found that FMA binds strongly in different places with hydrogen bonding at 113 domain of Arg 114, Leu 115 and Asp 173. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Subramanyam, Rajagopal; Goud, Mahesh; Sudhamalla, Babu; Reddeem, Eswarreddy; Gollapudi, Anilkishor; Nellaepalli, Sreedhar; Yadavalli, Venkateswarlu; Chinnaboina, Madhurarekha] Univ Hyderabad, Dept Biochem, Sch Life Sci, Hyderabad 500046, Andhra Pradesh, India.
   [Amooru, Damu G.] Yogi Vemana Univ, Dept Chem, Kadapa 516003, Andhra Pradesh, India.
RP Subramanyam, R (reprint author), Univ Hyderabad, Dept Biochem, Sch Life Sci, Hyderabad 500046, Andhra Pradesh, India.
EM psrajagopal@yahoo.com
CR Ahmad B, 2006, BIOMACROMOLECULES, V7, P1350, DOI 10.1021/bm050996b
   Beauchemin R, 2007, BIOMACROMOLECULES, V8, P3177, DOI 10.1021/bm700697a
   Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158
   BHATTACHARYYA J, 1994, BIOCHEM PHARMACOL, V47, P2049, DOI 10.1016/0006-2952(94)90080-9
   Chen J, 2006, BIOORG MED CHEM LETT, V16, P2915, DOI 10.1016/j.bmcl.2006.03.009
   Chuang VTG, 2001, BBA-PROTEIN STRUCT M, V1546, P337, DOI 10.1016/S0167-4838(01)00151-0
   Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   Dufour C, 2005, BBA-GEN SUBJECTS, V1721, P164, DOI 10.1016/j.bbagen.2004.10.013
   DZUBAK P, 2006, J NAT PROD REP, V23, P394
   Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075
   Grelamo E.L., 2002, BIOCHIM BIOPHYS ACTA, V1594, P84
   HABERLEIN H, 1994, PHYTOCHEMISTRY, V35, P765, DOI 10.1016/S0031-9422(00)90601-0
   He H. M., 1992, NATURE, V358, P209
   He WY, 2006, J PHOTOCH PHOTOBIO A, V182, P158, DOI 10.1016/j.jphotochem.2006.02.004
   He Y, 2008, J FLUORESC, V18, P433, DOI 10.1007/s10895-007-0283-0
   Jiang YL, 2008, BIOORGAN MED CHEM, V16, P6406, DOI 10.1016/j.bmc.2008.05.002
   Kanakis CD, 2006, J MOL STRUCT, V798, P69, DOI 10.1016/j.nolstruc.2006.03.051
   Karnaukhova E, 2007, BIOCHEM PHARMACOL, V73, P901, DOI 10.1016/j.bcp.2006.11.023
   KARUSH F, 1964, ANAL BIOCHEM, V9, P100, DOI 10.1016/0003-2697(64)90088-0
   KOJIMA H, 1989, PHYTOCHEMISTRY, V28, P1703, DOI 10.1016/S0031-9422(00)97829-4
   KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57
   Liang L, 2008, BIOMACROMOLECULES, V9, P50, DOI 10.1021/bm700728k
   Maiti TK, 2008, J PHOTOCH PHOTOBIO A, V194, P297, DOI 10.1016/j.jphotochem.2007.08.028
   Martin R, 2007, CANCER RES, V67, P3741, DOI 10.1158/0008-5472.CAN-06-4759
   Min J., 2004, J MOL STRUCT, V692, P71, DOI DOI 10.1016/J.MOLSTRUC.2004.01.003
   Montilla MP, 2003, PLANTA MED, V69, P472, DOI 10.1055/s-2003-39698
   N'soukpoe-Kossi CN, 2007, INT J BIOL MACROMOL, V40, P484, DOI 10.1016/j.ijbiomac.2006.11.005
   NOWAK I, 1995, CLIN CHEM, V41, P1011
   NUMATA A, 1989, CHEM PHARM BULL, V37, P648
   PETERS T, 1996, ALL ALBUMIN BIOCH GE
   Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2001.5208
   Sen P, 2008, EUR BIOPHYS J BIOPHY, V37, P1303, DOI 10.1007/s00249-008-0335-7
   Sinha SS, 2008, J PHYS CHEM B, V112, P4884, DOI 10.1021/jp709809b
   Subramanyam R., 2008, J PHOTOCH PHOTOBIO B, V94, P8
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439
   TANGENYI OH, 1996, THESIS U PATRICE EME
   Taniguchi S, 2002, PHYTOCHEMISTRY, V59, P315, DOI 10.1016/S0031-9422(01)00455-1
   Wen XA, 2006, BIOORG MED CHEM LETT, V16, P722, DOI 10.1016/j.bmcl.2005.10.014
   Wen XA, 2005, BIOORG MED CHEM LETT, V15, P4944, DOI 10.1016/j.bmcl.2005.08.026
   Xu HX, 1996, J NAT PROD, V59, P643, DOI 10.1021/np960165e
   YAGI A, 1978, CHEM PHARM BULL, V26, P3075
   Zunszain PA, 2008, J MOL BIOL, V381, P394, DOI 10.1016/j.jmb.2008.06.016
NR 43
TC 34
Z9 34
U1 0
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD MAY 4
PY 2009
VL 95
IS 2
BP 81
EP 88
DI 10.1016/j.jphotobiol.2009.01.002
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 440MT
UT WOS:000265705100002
PM 19230701
DA 2018-01-05
ER

PT J
AU Li, JW
   Xie, WJ
   Fang, N
   Yeung, ES
AF Li, Jiangwei
   Xie, Wenjun
   Fang, Ning
   Yeung, Edward S.
TI Single-molecule immunosorbent assay as a tool for human immunodeficiency
   virus-1 antigen detection
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Single-molecule immunosorbent assay (SMISA); Early diagnosis; HIV-1;
   Fluorescence detection
ID HEALTH-CARE WORKERS; ANTIBODY-AFFINITY; DNA; HIV; IMMUNOASSAY;
   DIAGNOSTICS; MICROARRAYS; NANOPORES
AB Ultrasensitive detection and quantification of viral antigen with a novel single-molecule immunosorbent assay (SMISA) was achieved. Antigen from human immunodeficiency virus type 1 (HIV-1), the major etiological agent of acquired immune deficiency syndrome, served as the screening target in this study. The target molecule was sandwiched between a polyclonal capture antibody and a monoclonal detector antibody. The capture antibody was covalently immobilized on (3-glycidoxypropyl) trimethoxy silane-modified glass slides. The detector antibody was conjugated with fluorescent Alexa Fluor 532 labeled secondary antibody prior to being used as a probe for the antigen. Imaging was performed with a total internal reflection fluorescence single-molecule detection system. This technique is demonstrated for detecting HIV-1 p24 antigen down to 0.1 pg/mL with a dynamic range of over four orders of magnitude. A Langmuir isotherm fits the molecule count dependence on the target concentration. The target antigen was further tested in 20% human serum, and the results showed that neither sensitivity nor dynamic range was affected by the biological matrix. SMISA is therefore a promising approach for the early diagnosis of viral induced diseases.
C1 [Li, Jiangwei; Xie, Wenjun; Fang, Ning; Yeung, Edward S.] Iowa State Univ, Ames Lab, USDOE, Ames, IA 50011 USA.
   [Li, Jiangwei; Xie, Wenjun; Fang, Ning; Yeung, Edward S.] Iowa State Univ, Dept Chem, Ames, IA 50011 USA.
RP Yeung, ES (reprint author), Iowa State Univ, Ames Lab, USDOE, Ames, IA 50011 USA.
EM yeung@ameslab.gov
RI Fang, Ning/A-8456-2011
FU Director of Science, Office of Basic Energy Science, Division of
   Chemical Sciences
FX We thank Dr. Mary Jo Schmerr and Dr. Gufeng Wang for valuable
   discussions. E.S.Y. thanks the Robert Allen Wright Endowment for
   Excellence for support. The Ames Laboratory is operated for the U. S.
   Department of Energy by Iowa State University under contract no.
   DE-AC02-07CH11358. This work was supported by the Director of Science,
   Office of Basic Energy Science, Division of Chemical Sciences.
CR BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3
   Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468
   Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR RECOMM REP, V47, P1
   Centers for Disease Control and Prevention, 2001, MMWR RECOMM REP, V50, P1
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001
   Fang N, 2007, ANAL CHEM, V79, P6047, DOI 10.1021/ac071009n
   Han A, 2008, ANAL CHEM, V80, P4651, DOI 10.1021/ac7025207
   He Y, 2005, J PHYS CHEM B, V109, P8820, DOI 10.1021/jp0447284
   Howorka S, 2001, NAT BIOTECHNOL, V19, P636, DOI 10.1038/90236
   Jain KK, 2007, CLIN CHEM, V53, P2002, DOI 10.1373/clinchem.2007.090795
   Kusnezow W, 2003, PROTEOMICS, V3, P254, DOI 10.1002/pmic.200390038
   Lee JY, 2007, ANAL CHEM, V79, P8083, DOI 10.1021/ac071159y
   Li JW, 2006, ANAL CHEM, V78, P6490, DOI 10.1021/ac060864o
   Ma YF, 2001, ELECTROPHORESIS, V22, P421, DOI 10.1002/1522-2683(200102)22:3<421::AID-ELPS421>3.0.CO;2-W
   Nalefski EA, 2006, CLIN CHEM, V52, P2172, DOI 10.1373/clinchem.2006.072850
   Panlilio Adelisa L., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Qiu H, 2007, CLIN CHEM, V53, P2010, DOI 10.1373/clinchem.2007.091306
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Saville RD, 2001, J CLIN MICROBIOL, V39, P2518, DOI 10.1128/JCM.39.7.2518-2524.2001
   Seidel M, 2008, ANAL BIOANAL CHEM, V391, P1521, DOI 10.1007/s00216-008-2039-3
   Storhoff JJ, 2004, NAT BIOTECHNOL, V22, P883, DOI 10.1038/nbt977
   Temirov JP, 2008, ANAL CHEM, V80, P8642, DOI 10.1021/ac8015592
   Tetin SY, 2004, CURR PHARM BIOTECHNO, V5, P9, DOI 10.2174/1389201043489602                                                        
   Tetin SY, 2002, ANAL BIOCHEM, V307, P84, DOI 10.1016/S0003-2697(02)00011-8
   Wabuyele MB, 2003, J AM CHEM SOC, V125, P6937, DOI 10.1021/ja034716g
   Wang SA, 2000, INFECT CONT HOSP EP, V21, P780, DOI 10.1086/501736
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   1996, MMWR MORB MORTAL WKL, V45, P468
NR 30
TC 9
Z9 9
U1 0
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD MAY
PY 2009
VL 394
IS 2
BP 489
EP 497
DI 10.1007/s00216-009-2712-1
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 436BU
UT WOS:000265388400012
PM 19267241
DA 2018-01-05
ER

PT J
AU Rahimi, R
   Jeddi, M
   Mohammad, S
   Ravanfar, R
AF Rahimi, Rahmatollah
   Jeddi, Maryam
   Mohammad, Sayyed
   Ravanfar, Reza
TI Characterization of Nano Tetrakis(4-sulfonatophenyl)porphyrin
   Aggregation Through Atomic Force Microscopy and UV-Vis Spectroscopy
   Methods
SO ASIAN JOURNAL OF CHEMISTRY
LA English
DT Article
DE Tetrakis(4-sulfonatophenyl)porphyrin; Aggregation; Nanotube; Porphyrin;
   Atomic force microscopy
ID CONTRAST AGENTS; PORPHYRINS; WATER; CHEMISTRY; KINETICS;
   METALLOPORPHYRINS; REDUCTION; DYE
AB The biological roles of porphyrins and metalloporphyrins as biological model compounds arc known since the significant biological macromolecules like hemoglobin and chlorophyll were discovered. The,known biological roles for these compounds are in photosynthesis and respiration processes. In addition, the porphyrins have been applied at different fields such as photoconverter, photocatalysts, photosensitizes in diagnosis and photodynamic therapy and also, as an anti Aids (HIV) drugs. In this work the tetrakis(4-sulfonatophenyl)-porphyfin (TPPS(4)) was synthesized and metallated according to the reference method, for this compound is very active model of biological porphyrins. The aggregations of TPPS(4) in acidic solution were investigated by two methods, atomic force microscopy (AFM) and ultra violet -visible spectroscopy (UV-Vis). The synthesized compound of TPPS,, was deposited on the surface of glass and the spatial structure was imaged by scanning on atomic force microscopy. The size of nanotubes calculated by section analysis was about (20 nm x 100 nm x 200 nm). Atomic force microscopy confirmed the J-aggregations of TPPS(4). The UV-Vis spectroscopy method was also used for investigation of TPPS(4) aggregation. The measured UV-Vis spectrum of the aggregated form of the compound in acidic solutions has shown maximum absorption at 433, 490 and 705 run, which has to be attributed to the formation of J-aggregates (490 nm). The synthesized TPPS(4) nanotubes can be used in future as electronic devices.
C1 [Rahimi, Rahmatollah; Jeddi, Maryam; Mohammad, Sayyed; Ravanfar, Reza] Iran Univ Sci & Technol, Coll Chem, Tehran, Iran.
RP Rahimi, R (reprint author), Iran Univ Sci & Technol, Coll Chem, Tehran, Iran.
EM rahimi.rah2008@gmail.com
CR BOHDIEWICZ PJ, 1990, INVEST RADIOL, V25, P765, DOI 10.1097/00004424-199007000-00003                                                
   Bulak FE, 1999, TURK J CHEM, V23, P407
   FLEISCHER EB, 1971, J AM CHEM SOC, V93, P3162, DOI 10.1021/ja00742a012
   Harrison WJ, 1996, J PHYS CHEM-US, V100, P2310, DOI 10.1021/jp952532l                                                               
   Herzog B, 2003, LANGMUIR, V19, P5223, DOI 10.1021/la020980w
   Hofkens J, 1997, J PHYS CHEM B, V101, P10588, DOI 10.1021/jp972305e                                                               
   HUANG X, 2000, PORPHYRINS METALLOPO, V2, P237
   Kano H, 2001, J PHYS CHEM B, V105, P413, DOI 10.1021/jp0026134
   Kano K, 2000, J AM CHEM SOC, V122, P7494, DOI 10.1021/ja000738g
   Kobayashi T., 1996, J AGGREGATES
   KRISHNAMURTHY M, 1978, INORG CHEM, V17, P2242, DOI 10.1021/ic50186a045                                                             
   KRISHNAMURTHY M, 1977, INORG CHIM ACTA, V25, P215, DOI 10.1016/S0020-1693(00)95715-3                                                   
   LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041
   LONGO FR, 1967, J ORG CHEM, V32, P476
   LYON RC, 1987, MAGNET RESON MED, V4, P24, DOI 10.1002/mrm.1910040104
   NETS GP, 1992, INORG CHEM, V31, P4849
   OHNO O, 1993, J CHEM PHYS, V99, P4128, DOI 10.1063/1.466109
   Okada S, 2003, J AM CHEM SOC, V125, P2792, DOI 10.1021/ja017768j
   PASTERNA.RF, 1972, J AM CHEM SOC, V94, P4511, DOI 10.1021/ja00768a016
   Pasternack RF, 2000, BIOPHYS J, V79, P550, DOI 10.1016/S0006-3495(00)76316-8                                                   
   PATRONAS NJ, 1986, CANCER TREAT REP, V70, P391
   Pawlik A, 1997, J PHYS CHEM B, V101, P5646, DOI 10.1021/jp9708308                                                               
   Rahimi R, 1998, J PORPHYR PHTHALOCYA, V2, P493, DOI 10.1002/(SICI)1099-1409(199811/12)2:6<493::AID-JPP88>3.0.CO;2-Y
   Rubires R, 1999, NEW J CHEM, V23, P189, DOI 10.1039/a808943d                                                                
   SUTTER TPG, 1993, J CHEM SOC FARADAY T, V89, P495, DOI 10.1039/ft9938900495                                                            
   Valanciunaite J, 2007, J PHYS CONF SER, V61, P1207, DOI 10.1088/1742-6596/61/1/238
   WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191
   WHITESIDES GM, 1995, ACCOUNTS CHEM RES, V28, P37, DOI 10.1021/ar00049a006                                                             
   Yao H, 1998, J PHYS CHEM B, V102, P7691, DOI 10.1021/jp982830t                                                               
NR 29
TC 4
Z9 4
U1 1
U2 6
PU ASIAN JOURNAL OF CHEMISTRY
PI SAHIBABAD
PA 11/100 RAJENDRA NAGAR, SECTOR 3,, SAHIBABAD 201 005, GHAZIABAD, INDIA
SN 0970-7077
J9 ASIAN J CHEM
JI Asian J. Chem.
PD MAY
PY 2009
VL 21
IS 5
BP 3988
EP 3994
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 427DE
UT WOS:000264759200084
DA 2018-01-05
ER

PT J
AU Heitz, F
   Morris, MC
   Divita, G
AF Heitz, Frederic
   Morris, May Catherine
   Divita, Gilles
TI Twenty years of cell-penetrating peptides: from molecular mechanisms to
   therapeutics
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE cell-penetrating peptide; non-covalent delivery system; siRNA;
   nanoparticle; drug delivery; molecular mechanisms; therapeutics
ID SMALL INTERFERING RNA; ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN;
   EFFICIENT SPLICING CORRECTION; IN-VIVO DELIVERY; MAMMALIAN-CELLS; GENE
   DELIVERY; FUSION PROTEIN; NUCLEIC-ACIDS; INTRACELLULAR DELIVERY
AB The recent discovery of new potent therapeutic molecules that do not reach the clinic due to poor delivery and low bioavailability have made of delivery a key stone in therapeutic development. Several technologies have been designed to improve cellular uptake of therapeutic molecules, including cell-penetrating peptides (CPPs). CPPs were first discovered based on the potency of several proteins to enter cells. Numerous CPPs have been described so far, which can be grouped into two major classes, the first requiring chemical linkage with the drug for cellular internalization and the second involving formation of stable, non-covalent complexes with drugs. Nowadays, CPPs constitute very promising tools for non-invasive cellular import of cargo and have been successfully applied for in vitro and in vivo delivery of therapeutic molecules varying from small chemical molecule, nucleic acids, proteins, peptides, liposomes and particles. This review will focus on the structure/function and cellular uptake mechanism of CPPs in the general context of drug delivery. We will also highlight the application of peptide carriers for the delivery of therapeutic molecules and provide an update of their clinical evaluation.
C1 [Heitz, Frederic; Morris, May Catherine; Divita, Gilles] CRBM, Dept Mol Biophys & Therapeut, CNRS, UMR 5237,UM 1,UM 2, F-34293 Montpellier, France.
RP Divita, G (reprint author), CRBM, Dept Mol Biophys & Therapeut, CNRS, UMR 5237,UM 1,UM 2, 1919 Route Mende, F-34293 Montpellier, France.
EM gilles.divita@crbm.cnrs.fr
RI MORRIS, May/J-5940-2016
OI MORRIS, May/0000-0001-8106-9728
FU Agence Nationale de Recherche [ANR-06-BLAN-0071]; EU
   [QLK2-CT-2001-01451, LSHB-CT-2003-503480/TRIoH]
FX This work was supported in part by the Centre National de la Recherche
   Scientifique (CNRS), Active Motif (Carlsbad, CA), Panomics Inc.
   (Fremont, CA) and by grants from the Agence Nationale de Recherche (ANR:
   Grant ANR-06-BLAN-0071) and the EU (Grant QLK2-CT-2001-01451 & Grant
   LSHB-CT-2003-503480/TRIoH). We thank members of the laboratory and our
   collaborators for fruitful discussions.
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002.0090OC
   Asai A, 2003, CANCER RES, V63, P3931
   Beauvais DeannaLee M, 2004, Reprod Biol Endocrinol, V2, P3, DOI 10.1186/1477-7827-2-3
   Bowne Wilbur B, 2007, Cancer Ther, V5B, P331
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004
   Burrer R, 2007, J VIROL, V81, P5637, DOI 10.1128/JVI.02360-06
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635
   Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821                                                              
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   ESBJORNER EK, 2007, CELL PENETRATING PEP, P109
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P1656, DOI 10.1016/j.freeradbiomed.2004.07.028
   Kurreck J., 2008, THERAPEUTIC OLIGONUC, P80
   Farrera-Sinfreu Josep, 2007, V386, P241, DOI 10.1007/978-1-59745-430-8_9
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Fisher L, 2004, GENE THER, V11, P1264, DOI 10.1038/sj.gt.3302291
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gait MJ, 2003, CELL MOL LIFE SCI, V60, P844, DOI 10.1007/s00018-003-3044-5
   Gallo G, 2003, METHOD CELL BIOL, V71, P325, DOI 10.1016/S0091-679X(03)01015-X
   Gallo G, 2002, J CELL BIOL, V158, P1219, DOI 10.1083/jcb.200204140
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577
   Gondeau C, 2005, J BIOL CHEM, V280, P13793, DOI 10.1074/jbc.M413690200
   Gottschalk S, 1996, GENE THER, V3, P448
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gryaznov S, 2003, NUCLEOS NUCLEOT NUCL, V22, P577, DOI 10.1081/NCN-120021958
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Hosotani R, 2002, CLIN CANCER RES, V8, P1271
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Knight JS, 2006, VIROLOGY, V354, P207, DOI 10.1016/j.virol.2006.06.034
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Kong HJ, 2007, NAT REV DRUG DISCOV, V6, P455, DOI 10.1038/nrd2309
   Koppelhus U, 2003, ADV DRUG DELIVER REV, V55, P267, DOI 10.1016/S0169-409X(02)00182-5                                                   
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Krauss U, 2004, BIOORG MED CHEM LETT, V14, P51, DOI 10.1016/j.bmcl.2003.10.014
   Krautwald S, 2004, J BIOL CHEM, V279, P44005, DOI 10.1074/jbc.M401327200
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   LEAR JD, 1987, J BIOL CHEM, V262, P6500
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Lee HL, 2008, J AM CHEM SOC, V130, P9364, DOI 10.1021/ja710798b
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   MacKay JA, 2008, MOL THER, V16, P893, DOI 10.1038/mt.2008.36
   Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583503004014
   Maron M. B., 2005, AM J PHYSIOL-LUNG C, V289, P349
   Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Melnick A, 2007, BIOCHEM SOC T, V35, P802, DOI 10.1042/BST0350802                                                              
   Michl J, 2006, INT J CANCER, V119, P1577, DOI 10.1002/ijc.22029
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Morris MC, 2004, GENE THER, V11, P757, DOI 10.1038/sj.gt.3302235
   Morris M. C., 2007, CELL PENETRATING PEP, P387
   MOSCHOS S, 2007, CELL PENETRATING PEP, P423
   Moulton HM, 2004, DRUG DISCOV TODAY, V9, P870, DOI 10.1016/S1359-6446(04)03226-X                                                   
   Moulton H. M., 2008, THERAPEUTIC OLIGONUC, P43
   Munoz-Morris MA, 2007, BIOCHEM BIOPH RES CO, V355, P877, DOI 10.1016/j.bbrc.2007.02.046
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739
   Myou S, 2003, J IMMUNOL, V171, P4399, DOI 10.4049/jimmunol.171.8.4399                                                     
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nan L, 2005, EXP MOL PATHOL, V78, P1, DOI 10.1016/j.yexmp.2004.08.006
   Nguyen QN, 2006, BBA-BIOMEMBRANES, V1758, P394, DOI 10.1016/j.bbamem.2006.01.003
   Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923
   Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8713, DOI 10.1021/bi00489a030
   Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097
   Park IY, 1998, FEBS LETT, V437, P258, DOI 10.1016/S0014-5793(98)01238-1                                                   
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Rhyner C, 2007, BIOCHEM SOC T, V35, P833, DOI 10.1042/BST0350833                                                              
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Sugioka R, 2003, ONCOGENE, V22, P8432, DOI 10.1038/sj.onc.1207180
   Tang XR, 2007, CANCER RES, V67, P1308, DOI 10.1158/0008-5472.CAN-06-1600                                                   
   Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   THYNER C, 2007, BIOCHEM SOC T, V35, P833
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2007, P NATL ACAD SCI USA, V104, P10340, DOI 10.1073/pnas.0703919104
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
NR 151
TC 467
Z9 480
U1 16
U2 249
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2009
VL 157
IS 2
BP 195
EP 206
DI 10.1111/j.1476-5381.2009.00057.x
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 440NP
UT WOS:000265707300005
PM 19309362
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Franceschin, M
AF Franceschin, Marco
TI G-Quadruplex DNA Structures and Organic Chemistry: More Than One
   Connection
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Review
DE DNA structures; G-Quadruplex ligands; G-Quadruplexes; Telomerase
   inhibitors
ID ELECTROSPRAY MASS-SPECTROMETRY; TELOMERE TARGETING AGENTS;
   3,4,9,10-PERYLENETETRACARBOXYLIC ACID DIIMIDES; CRYSTALLINE CORONENE
   DERIVATIVES; TETRAD-FORMING OLIGONUCLEOTIDES; INTRAMOLECULAR
   G-QUADRUPLEX; STRUCTURE-BASED DESIGN; DIFFERENT SIDE-CHAINS; HIV DRUG
   DESIGN; IN-VITRO
AB G-Quadruplexes represent a group of unusual DNA secondary structures, based on Hoogsteen G-G paired hydrophobic planar rings consisting of four guanine units. Many studies have shown that G-quadruplex structures appear to be involved in several important biological processes, such as DNA replication, gene expression and recombination, as well as cell transformation. For these reasons, in the last few years G-quadruplexes have become the main research interest of many eminent scientists in different fields: from molecular to cellular biologists, from physicians to chemists. In this respect, organic chemists can play fundamental roles in many different areas. First of all, research into specific G-quadruplex ligands as potential drugs, in particular as telomerase inhibitors and thus potential anticancer drugs, has attracted strong attention. The rational design of and the various synthetic approaches toward these kinds of ligands represent two specific fields of interest for organic chemists. The molecules capable of stabilizing G-quadruplexes covered in this review are each characterized by an aromatic core that favours stacking interactions with the G-tetrads and, in most cases, by basic side chains that interact with DNA grooves. First generations and new classes of synthetic G-quadruplex ligands, as well as natural compounds, are presented. Moreover, because the specificities of the interactions between the studied ligands and different DNA structures (both duplex and quadruplex) are without doubt a main concern, determining the different biological effects of these compounds, several chemists are involved in developing approaches to explore this important subject. The last part of this review is devoted to a brief introduction of new fields of application of G-quadruplex structures with open synthetic challenges: quadruplex-forming modified oligonucleotides and nanostructures based on the G-quadruplex. ((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
C1 Univ Roma La Sapienza, Dipartimento Chim, I-00185 Rome, Italy.
RP Franceschin, M (reprint author), Univ Roma La Sapienza, Dipartimento Chim, Piazzale A Moro 5, I-00185 Rome, Italy.
EM marco.franceschin@uniroma1.it
FU Department of Chemistry; Ministero dell'Universit e delta Ricerca
   (MIUR); Sapienza Universit di Roma
FX Financial support for the work at the Department of Chemistry, including
   the author's postdoctoral fellowship, came from the Ministero
   dell'Universit e delta Ricerca (MIUR) and Sapienza Universit di Roma.
   The author would like to thank all the people working on this project,
   in particular Professors A. Bianco, M. Savino and G. Ortaggi, and PhD
   students Antonello Alvino, Valentina Casagrande and Luca Ginnari, for
   their fundamental support, and Professors S. Neidle (London, UK) and E.
   De Pauw (Liege, Belgium) for fruitful collaborations. Thanks are due to
   Christoph Schultes for help in the final revision of the manuscript and
   to Lorenzo Velluti and Giorgio Franceschin for graphical aid.
CR Ahrens MJ, 2006, J ORG CHEM, V71, P2107, DOI 10.1021/jo052394o
   Alvino A, 2007, TETRAHEDRON, V63, P7858, DOI 10.1016/j.tet.2007.05.096
   Arola A, 2008, CURR TOP MED CHEM, V8, P1405, DOI 10.2174/156802608786141106
   Bates P, 2007, EMBO REP, V8, P1003, DOI 10.1038/sj.embor.7401073
   Bertrand H, 2007, J BIOL INORG CHEM, V12, P1003, DOI 10.1007/s00775-007-0273-3
   Binz N, 2005, EUR J CANCER, V41, P2873, DOI 10.1016/j.ecja.2005.08.025
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Bourdoncle A, 2006, J AM CHEM SOC, V128, P11094, DOI 10.1021/ja0608040
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910
   Campbell NH, 2008, J AM CHEM SOC, V130, P6722, DOI 10.1021/ja8016973
   Campbell NH, 2007, METHODS, V43, P252, DOI 10.1016/j.ymeth.2007.08.005
   Casagrande V, 2009, J MASS SPECTROM, V44, P530, DOI 10.1002/jms.1529
   Chou SH, 2005, TRENDS BIOCHEM SCI, V30, P231, DOI 10.1016/j.tibs.2005.03.004
   Coppola T, 2008, BIOORGAN MED CHEM, V16, P8244, DOI 10.1016/j.bmc.2008.07.040
   D'Onofrio J, 2007, BIOCONJUGATE CHEM, V18, P1194, DOI 10.1021/bc070062f
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   Davis JT, 2007, CHEM SOC REV, V36, P296, DOI 10.1039/b600282j
   Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589                                                          
   De Cian A, 2007, METHODS, V42, P183, DOI 10.1016/j.ymeth.2006.10.004
   Dixon IM, 2005, CHEMBIOCHEM, V6, P123, DOI 10.1002/cbic.200400113
   Dixon IM, 2007, J AM CHEM SOC, V129, P1502, DOI 10.1021/ja065591t
   Doi T, 2006, ORG LETT, V8, P4165, DOI 10.1021/ol061793i
   Erra E, 2005, NUCLEOS NUCLEOT NUCL, V24, P753, DOI 10.1081/NCN-200060070
   Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n                                                               
   Franceschin M, 2006, BIOORG MED CHEM LETT, V16, P1707, DOI 10.1016/j.bmcl.2005.12.001
   Franceschin M, 2004, TETRAHEDRON LETT, V45, P9015, DOI 10.1016/j.tetlet.2004.10.040
   Franceschin M, 2008, BIOORGAN MED CHEM, V16, P2292, DOI 10.1016/j.bmc.2007.11.065
   Franceschin M, 2007, BIOORG MED CHEM LETT, V17, P2515, DOI 10.1016/j.bmcl.2007.02.021
   Franceschin M, 2007, BIOORGAN MED CHEM, V15, P1848, DOI 10.1016/j.bmc.2006.11.032
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   GHOSH AK, 1985, EXP PARASITOL, V60, P404, DOI 10.1016/0014-4894(85)90047-5
   Gomez D, 2003, CANCER RES, V63, P6149
   Gomez D, 2002, CANCER RES, V62, P3365
   Gornall KC, 2007, RAPID COMMUN MASS SP, V21, P1759, DOI 10.1002/rcm.3019
   Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154                                                           
   Granotier C, 2005, NUCLEIC ACIDS RES, V33, P4182, DOI 10.1093/nar/gki722
   Guittat L, 2005, BBA-GEN SUBJECTS, V1724, P375, DOI 10.1016/j.bbagen.2005.04.023
   Haider SM, 2003, J MOL BIOL, V326, P117, DOI 10.1016/S0022-2836(02)01354-2
   Han HY, 1999, BIOCHEMISTRY-US, V38, P6981, DOI 10.1021/bi9905922                                                               
   Harrison RJ, 1999, BIOORG MED CHEM LETT, V9, P2463, DOI 10.1016/S0960-894X(99)00394-7
   Harrison RJ, 2003, J MED CHEM, V46, P4463, DOI 10.1021/jm0308693
   Held DM, 2006, FRONT BIOSCI, V11, P89, DOI 10.2741/1782
   Hounsou C, 2007, CHEMMEDCHEM, V2, P655, DOI 10.1002/cmdc.200600286
   Huang HS, 2005, BIOORGAN MED CHEM, V13, P1435, DOI 10.1016/j.bmc.2004.12.036
   Huppert JL, 2008, CHEM SOC REV, V37, P1375, DOI 10.1039/b702491f
   Incles Christopher M, 2003, Curr Opin Investig Drugs, V4, P675
   Incles CM, 2004, MOL CANCER THER, V3, P1201
   Jantos K, 2006, J AM CHEM SOC, V128, P13662, DOI 10.1021/ja064713e
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jing NJ, 2000, EXPERT OPIN INV DRUG, V9, P1777, DOI 10.1517/13543784.9.8.1777                                                       
   Karimata H., 2007, NUCL ACIDS S SER, V51, P251
   Kaucher MS, 2006, J AM CHEM SOC, V128, P38, DOI 10.1021/ja056888e
   Keating LR, 2004, BIOCHEMISTRY-US, V43, P15891, DOI 10.1021/bi0483209
   Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024
   Kern JT, 2002, BIOORG MED CHEM LETT, V12, P3395, DOI 10.1016/S0960-894X(02)00763-1
   Kern JT, 2002, BIOCHEMISTRY-US, V41, P11379, DOI 10.1021/bi0263107
   Kerwin SM, 2002, BIOORG MED CHEM LETT, V12, P447, DOI 10.1016/S0960-894X(01)00775-2                                                   
   Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q
   Luu KN, 2006, J AM CHEM SOC, V128, P9963, DOI 10.1021/ja062791w
   MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696                                                            
   Martins C, 2007, BIOORG MED CHEM LETT, V17, P2293, DOI 10.1016/j.bmcl.2007.01.056
   Mazzitelli CL, 2006, J AM SOC MASS SPECTR, V17, P593, DOI 10.1016/j.jasms.2005.12.011
   Mergny JL, 2001, CHEMBIOCHEM, V2, P124, DOI 10.1002/1439-7633(20010202)2:2<124::AID-CBIC124>3.3.CO;2-C
   Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839
   Miyoshi D, 2007, J AM CHEM SOC, V129, P5919, DOI 10.1021/ja068707u
   Miyoshi D, 2006, ANGEW CHEM INT EDIT, V45, P7716, DOI 10.1002/anie.200602404
   Monchaud D, 2008, ANGEW CHEM INT EDIT, V47, P4858, DOI 10.1002/anie.200800468
   Moore MJB, 2006, ORG BIOMOL CHEM, V4, P3479, DOI 10.1039/b607707b
   Moore MJB, 2006, J MED CHEM, V49, P582, DOI 10.1021/jm050555a
   Muller S, 2009, CHEM COMMUN, P80, DOI 10.1039/b816861j
   Murat P, 2008, CHEMBIOCHEM, V9, P2588, DOI 10.1002/cbic.200800457
   Naasani I, 1999, CANCER RES, V59, P4004
   Nagatoishi S, 2007, ANAL CHIM ACTA, V581, P125, DOI 10.1016/j.aca.2006.08.010
   Neidle S, 2000, PHARMACOL THERAPEUT, V85, P133, DOI 10.1016/S0163-7258(99)00065-0
   Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1
   Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793
   Neidle S, 2008, BIOCHIMIE, V90, P1184, DOI 10.1016/j.biochi.2008.03.003
   Neidle Stephen, 2000, Biopolymers, V56, P195, DOI 10.1002/1097-0282(2000)56:3<195::AID-BIP10009>3.0.CO;2-5
   Nikan M, 2008, ANGEW CHEM INT EDIT, V47, P4900, DOI 10.1002/anie.200704199
   Oliviero G, 2004, TETRAHEDRON LETT, V45, P4869, DOI 10.1016/j.tetlet.2004.04.149
   Oliviero G, 2006, BIOCONJUGATE CHEM, V17, P889, DOI 10.1021/bc060009b
   Paeschke K, 2005, NAT STRUCT MOL BIOL, V12, P847, DOI 10.1038/nsmb982
   Pagano B, 2008, BIOPHYS J, V94, P562, DOI 10.1529/biophysj.107.117382
   Pagano B, 2007, CURR CANCER DRUG TAR, V7, P520, DOI 10.2174/156800907781662257
   Paramasivan S, 2007, METHODS, V43, P324, DOI 10.1016/j.ymeth.2007.02.009
   Parkinson GN, 2007, BIOCHEMISTRY-US, V46, P2390, DOI 10.1021/bi062244n
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Pisano S, 2008, BIOPHYS CHEM, V136, P159, DOI 10.1016/j.bpc.2008.04.009
   Ragazzon P, 2007, METHODS, V43, P313, DOI 10.1016/j.ymeth.2007.08.003
   Randazzo A, 2002, NUCLEOS NUCLEOT NUCL, V21, P535, DOI 10.1081/NCN-120015067
   Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598
   Redman JE, 2007, METHODS, V43, P302, DOI 10.1016/j.ymeth.2007.05.008
   Redman JE, 2009, ORG BIOMOL CHEM, V7, P76, DOI 10.1039/b814682a
   Reed JE, 2007, CHEM COMMUN, P4366, DOI 10.1039/b709898g
   Reed JE, 2006, J AM CHEM SOC, V128, P5992, DOI 10.1021/ja058509n
   Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s
   Rezler EM, 2005, J AM CHEM SOC, V127, P9439, DOI 10.1021/ja0505088
   RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1
   Riou Jean-Francois, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P439, DOI 10.2174/1568011043352740
   Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099
   Rohr U, 2001, J MATER CHEM, V11, P1789, DOI 10.1039/b009708j                                                                
   Rohr U, 1998, ANGEW CHEM INT EDIT, V37, P1434
   Rossetti L, 2002, BIOORG MED CHEM LETT, V12, P2527, DOI 10.1016/S0960-894X(02)00504-8
   Rossetti L, 2005, BIOORG MED CHEM LETT, V15, P413, DOI 10.1016/j.bmcl.2004.10.061
   Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h
   Rosu F, 2003, BIOCHEMISTRY-US, V42, P10361, DOI 10.1021/bi034531m
   Rosu F, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf081                                                              
   Rosu F, 2002, RAPID COMMUN MASS SP, V16, P1729, DOI 10.1002/rcm.778
   Rosu F, 2008, BIOCHIMIE, V90, P1074, DOI 10.1016/j.biochi.2008.01.005
   Rusconi S, 2007, CURR TOP MED CHEM, V7, P1273
   Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461
   Schouten JA, 2003, J AM CHEM SOC, V125, P5594, DOI 10.1021/ja029356w
   Seenisamy J, 2005, J AM CHEM SOC, V127, P2944, DOI 10.1021/ja0444482
   Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03
   Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q
   Shirude PS, 2007, J AM CHEM SOC, V129, P11890, DOI 10.1021/ja073775h
   Sissi C, 2007, BIOORGAN MED CHEM, V15, P555, DOI 10.1016/j.bmc.2006.09.029
   Sonogashira K., 1975, TETRAHEDRON LETT, V16, P4467, DOI DOI 10.1016/S0040-4039(00)91094-3
   Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z
   Sun HX, 2006, BIOORG MED CHEM LETT, V16, P3586, DOI 10.1016/j.bmcl.2006.03.087
   Tauchi T, 2006, ONCOGENE, V25, P5719, DOI 10.1038/sj.onc.1209577
   Teng Y, 2007, CANCER RES, V67, P10491, DOI 10.1158/0008-5472.CAN-06-4206
   Tera M, 2008, ANGEW CHEM INT EDIT, V47, P5557, DOI 10.1002/anie.200801235
   Teulade-Fichou MP, 2003, J AM CHEM SOC, V125, P4732, DOI 10.1021/ja021299j
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Wei CY, 2006, BIOCHEMISTRY-US, V45, P6681, DOI 10.1021/bi052356z
   White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9                                                   
   Wu HL, 1999, INT J CANCER, V81, P923, DOI 10.1002/(SICI)1097-0215(19990611)81:6<923::AID-IJC14>3.0.CO;2-D
   Yamashita T, 2005, BIOORGAN MED CHEM, V13, P2423, DOI 10.1016/j.bmc.2005.01.041
   ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0
   ZHANG RX, 1990, CHINESE MED J-PEKING, V103, P658
   Zhang WJ, 2007, BIOORGAN MED CHEM, V15, P5493, DOI 10.1016/j.bmc.2007.05.050
   Zhao YY, 1999, TETRAHEDRON LETT, V40, P7047, DOI 10.1016/S0040-4039(99)01468-9                                                   
   Zhou JA, 2007, CHEM-EUR J, V13, P5018, DOI 10.1002/chem.200601605
NR 137
TC 71
Z9 71
U1 3
U2 42
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1434-193X
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD MAY
PY 2009
IS 14
BP 2225
EP 2238
DI 10.1002/ejoc.200801196
PG 14
WC Chemistry, Organic
SC Chemistry
GA 449EB
UT WOS:000266312500001
DA 2018-01-05
ER

PT J
AU Rapoport, M
   Lorberboum-Galski, H
AF Rapoport, Matan
   Lorberboum-Galski, Haya
TI TAT-based drug delivery system - new directions in protein delivery for
   new hopes?
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE cell-penetrating peptides; drug delivery; enzyme replacement therapy;
   fusion proteins; protein transduction domains; TAT
ID MEDIATED INTRACELLULAR DELIVERY; ENZYME-REPLACEMENT THERAPY; HUMAN
   IMMUNODEFICIENCY VIRUS; CELL-PENETRATING PEPTIDES; CONJUGATED QUANTUM
   DOTS; PHARMACEUTICAL NANOCARRIERS; TRANSDUCTION DOMAIN; FUSION PROTEINS;
   MAMMALIAN-CELLS; NUCLEIC-ACIDS
AB There has been great progress in the use of TAT-based drug delivery systems for the delivery of different macromolecules into cells in vitro and in vivo, thus circumventing the bioavailability barrier that is a problem for so many drugs. There are many advantages to using this system, such as the ability to deliver these cargoes into all types of cells in culture and into all organs in vivo. This system can even deliver cargoes into the brain across the blood-brain barrier. in addition, the ability to target specific intracellular sub-localizations such as the nuclei, the mitochondria and lysosomes further expands the possibilities of this drug delivery system to the development of sub-cellular organelle-targeted therapy. The therapeutic applications seem almost unlimited, and the use of the TAT-based delivery system has extended from proteins to a large variety of cargoes such as oligonucleotides, imaging agents, low molecular mass drugs, nanoparticles, micelles and liposomes. In this review the most recent advances in the use of the TAT-based drug delivery system will be described, mainly discussing TAT-mediated protein delivery and the use of the TAT system for enzyme replacement therapy.
C1 [Rapoport, Matan; Lorberboum-Galski, Haya] Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.
RP Lorberboum-Galski, H (reprint author), Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.
EM hayag@ekmd.huji.ac.il
CR Abes R, 2007, BIOCHEM SOC T, V35, P775, DOI 10.1042/BST0350775                                                              
   Amand HL, 2008, BIOCHEM BIOPH RES CO, V371, P621, DOI 10.1016/j.bbrc.2008.04.039
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Brady RO, 2004, LANCET NEUROL, V3, P752, DOI 10.1016/S1474-4422(04)00938-X                                                   
   Brady RO, 2006, ANNU REV MED, V57, P283, DOI 10.1146/annurev.med.57.110104.115650
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   Del Gaizo V, 2003, MOL GENET METAB, V80, P170, DOI 10.1016/j.ymgme.2003.08.017
   Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8
   Eavri R, 2007, J BIOL CHEM, V282, P23402, DOI 10.1074/jbc.M703367200
   Folini M, 2007, CELL PROLIFERAT, V40, P905, DOI 10.1111/j.1365-2184.2007.00470.x
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gupta Bhawna, 2006, Expert Opin Drug Deliv, V3, P177, DOI 10.1517/17425247.3.2.177
   Harada Hiroshi, 2006, Breast Cancer, V13, P16, DOI 10.2325/jbcs.13.16
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767                                                              
   Jeong MS, 2008, BMB REP, V41, P537, DOI 10.5483/BMBRep.2008.41.7.537                                                    
   Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kim K, 2008, BIOTECHNOL LETT, V30, P1331, DOI 10.1007/s10529-008-9695-4
   Kubo E, 2008, AM J PHYSIOL-CELL PH, V294, pC842, DOI 10.1152/ajpcell.00540.2007
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   Liu Lihong, 2008, Biomaterials, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Luft FC, 2003, J MOL MED-JMM, V81, P521, DOI 10.1007/s00109-003-0475-2
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767                                                              
   Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rapoport M, 2008, MOL THER, V16, P691, DOI 10.1038/mt.2008.4
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JC125052
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wang DN, 2005, MOL GENET METAB, V85, P181, DOI 10.1016/j.ymgme.2005.03.007
   Wang Q, 2008, ANESTHESIOLOGY, V108, P1071, DOI 10.1097/ALN.0b013e318173f66b
   Wang Q, 2009, CELL MOL NEUROBIOL, V29, P97, DOI 10.1007/s10571-008-9301-2
   Xavier J, 2009, J CONTROL RELEASE, V133, P154, DOI 10.1016/j.jconrel.2008.09.090
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   Yoshikawa T, 2008, J MOL BIOL, V380, P777, DOI 10.1016/j.jmb.2008.05.047
   Zhang XY, 2008, J NEUROCHEM, V104, P1055, DOI 10.1111/j.1471-4159.2007.05030.x
   Zhou Y, 2008, BLOOD, V112, P2474, DOI 10.1182/blood-2007-12-130211
NR 58
TC 55
Z9 61
U1 1
U2 21
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD MAY
PY 2009
VL 6
IS 5
BP 453
EP 463
DI 10.1517/17425240902887029
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 448RX
UT WOS:000266280800001
PM 19413454
DA 2018-01-05
ER

PT J
AU Ferraz, RM
   Rodriguez-Carmona, E
   Ferrer-Miralles, N
   Meyerhans, A
   Villaverde, A
AF Maria Ferraz, Rosa
   Rodriguez-Carmona, Escarlata
   Ferrer-Miralles, Neus
   Meyerhans, Andreas
   Villaverde, Antonio
TI Screening HIV-1 antigenic peptides as receptors for antibodies and CD4
   in allosteric nanosensors
SO JOURNAL OF MOLECULAR RECOGNITION
LA English
DT Article
DE biosensor; antibody; virus receptor; CD4; cell binding
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENGINEERED BETA-GALACTOSIDASE;
   MOUTH-DISEASE VIRUS; NEUTRALIZATION RESISTANCE; ENVELOPE GLYCOPROTEIN;
   DISTINCT MECHANISMS; BINDING; GP120; GP41; FUSION
AB We have analyzed the suitability of six antigenic peptides from several HIV-1 structural proteins (namely gp41, gp120, p17, and p24), as anti-HIV-1 antibody receptors in an allosteric enzymatic biosensor. These peptides were inserted in a solvent-exposed surface of Escherichia coli (E. coli) beta-galactosidase by means of conventional recombinant DNA technology. The resulting enzymes were tested to allosterically respond to sera from HIV-1-infected individuals. Only stretches from gp41 and gp120 envelope proteins were able to transduce the molecular contact signal in the presence of immunoreactive sera. Intriguingly, the enzyme displaying the CD4 binding site segment KQFINMWQEVGKAMYAPP was activated by soluble CD4, suggesting that it produces conformational modifications on the allosteric enzyme as those occurring during antibody-promoted induced fit. This fact is discussed in the context of the design of smart protein drugs and markers targeted to CD4(+) cells. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Maria Ferraz, Rosa; Rodriguez-Carmona, Escarlata; Ferrer-Miralles, Neus; Villaverde, Antonio] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
   [Maria Ferraz, Rosa; Rodriguez-Carmona, Escarlata; Ferrer-Miralles, Neus; Villaverde, Antonio] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
   [Maria Ferraz, Rosa] Univ Politecn Cataluna, Dept Matemat Aplicada 4, ES-08034 Barcelona, Spain.
   [Maria Ferraz, Rosa; Rodriguez-Carmona, Escarlata; Ferrer-Miralles, Neus; Villaverde, Antonio] CIBER BBN Bioingn Biomat & Nanomed, Barcelona 08193, Spain.
   [Meyerhans, Andreas] Univ Saarland, Dept Virol, D-6650 Homburg, Germany.
RP Villaverde, A (reprint author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
EM avilloverde@servet.uab.es
RI Ferrer-Miralles, Neus/G-7934-2016; Meyerhans, Andreas/D-3382-2014
OI Ferrer-Miralles, Neus/0000-0003-2981-3913; Meyerhans,
   Andreas/0000-0003-0620-5317; Villaverde, Antonio/0000-0002-2615-4521
FU MEC [BIO2007-61194]; AGAUR [2005SGR-00956]; CIBER de Bioingenieria,
   Biomateriales y Nanomedicina (CIBER-BBN), Spain
FX We are indebted to M. A. Martinez for generously providing same sera
   samples. This work has been supported by grants BIO2007-61194 (MEC) and
   2005SGR-00956 (AGAUR) to AV. We also acknowledge the support of the
   CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
   During the development of this work, RF was recipient of a doctoral
   fellowship from AGAUR with the support of the European Social Funds.
CR Alcala P, 2001, BIOCHEM BIOPH RES CO, V285, P201, DOI 10.1006/bbrc.2001.5157
   Benito A, 1996, J BIOL CHEM, V271, P21251, DOI 10.1074/jbc.271.35.21251                                                        
   Berkower I, 2008, VIROLOGY, V377, P330, DOI [10.1016/j.virol.2008.03.040, 10.1016/j.virol.2008.0:3.040]
   BROLIDEN PA, 1992, P NATL ACAD SCI USA, V89, P461, DOI 10.1073/pnas.89.2.461
   CAZORLA D, 2002, BIOTECHNOL LETT, V24, P467
   CHARGELEGUE D, 1995, CLIN EXP IMMUNOL, V99, P175
   de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Feliu JX, 1998, BIOTECHNOL BIOENG, V58, P536, DOI 10.1002/(SICI)1097-0290(19980605)58:5<536::AID-BIT10>3.0.CO;2-9
   Feliu JX, 1998, J MOL BIOL, V283, P331, DOI 10.1006/jmbi.1998.2104
   Feliu JX, 1998, FEBS LETT, V438, P267, DOI 10.1016/S0014-5793(98)01315-5                                                   
   Feliu JX, 1998, FEBS LETT, V434, P23, DOI 10.1016/S0014-5793(98)00943-0                                                   
   Ferrao YA, 2006, J AFFECT DISORDERS, V94, P199, DOI 10.1016/j.jad.2006.04.019
   Ferraz RM, 2007, ENZYME MICROB TECH, V41, P492, DOI 10.1016/j.enzmictec.2007.04.001
   Ferraz RM, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-15
   Ferraz RM, 2006, MOL IMMUNOL, V43, P2119, DOI 10.1016/j.molimm.2005.12.012
   Ferraz RM, 2004, BIOCHEM BIOPH RES CO, V314, P854, DOI 10.1016/j.bbrc.2003.12.169
   Ferrer-Miralles N, 2000, BIOCHEM BIOPH RES CO, V275, P360, DOI 10.1006/bbrc.2000.3309
   Ferrer-Miralles N, 2001, J BIOL CHEM, V276, P40087, DOI 10.1074/jbc.M104704200
   Ferrer-Miralles N, 2008, TRENDS BIOTECHNOL, V26, P267, DOI 10.1016/j.tibtech.2008.02.003
   Fiorentini S, 2004, BIOPOLYMERS, V76, P334, DOI 10.1002/bip.20130
   Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002
   HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   JANVIER B, 1991, J CLIN MICROBIOL, V29, P488
   Ferraz RM, 2008, J BIOMOL SCREEN, V13, P817, DOI 10.1177/1087057108323126
   Miller JH, 1972, EXPT MOL GENETICS
   MORROW WJW, 1992, IMMUNOLOGY, V75, P557
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Park EJ, 1998, J VIROL, V72, P7099
   Park EJ, 2000, J VIROL, V74, P4183, DOI 10.1128/JVI.74.9.4183-4191.2000
   Robey FA, 1996, J BIOL CHEM, V271, P17990, DOI 10.1074/jbc.271.30.17990                                                        
   Sambrook J, 1989, MOL CLONING LAB MANU
   THALI M, 1994, J VIROL, V68, P674
   ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8
   Villaverde A, 2003, FEBS LETT, V554, P169, DOI 10.1016/S0014-5793(03)01160-8
   Watkins BA, 1996, J VIROL, V70, P8431
   Yingliang Wu, 2007, J Biomol Struct Dyn, V25, P1
   Zhang PF, 2002, J VIROL, V76, P644, DOI 10.1128/JVI.76.2.644-655.2002
NR 39
TC 2
Z9 2
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0952-3499
J9 J MOL RECOGNIT
JI J. Mol. Recognit.
PD MAY-JUN
PY 2009
VL 22
IS 3
BP 255
EP 260
DI 10.1002/jmr.940
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 434VX
UT WOS:000265303300010
PM 19177495
DA 2018-01-05
ER

PT J
AU Huang, WL
   Chen, YH
   Gao, SJ
   Zhang, C
AF Huang, Wenlin
   Chen, Yuhai
   Gao, Shijuan
   Zhang, Chao
TI Minicircle Carrying HIV-1 Candidate Gene Encapsulated within
   Biodegradable Nanoparticles as Novel HIV-1 Vaccine
SO MOLECULAR THERAPY
LA English
DT Meeting Abstract
CT 12th Annual Meeting of the American Society of Gene Therapy
CY MAY 27-30, 2009
CL San Diego, CA
SP Amer Soc Gene Therapy
C1 Chinese Acad Sci, Inst Microbiol, Beijing, Peoples R China.
   Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
   Yangzhou Univ, Coll Biosci & Biotechnol, Yangzhou, Jiangsu, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD MAY
PY 2009
VL 17
SU 1
MA 220
BP S86
EP S87
PG 2
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 600WO
UT WOS:000278019800221
DA 2018-01-05
ER

PT J
AU Zhou, JH
   Swiderski, P
   Li, HT
   Zhang, J
   Neff, CP
   Akkina, R
   Rossi, JJ
AF Zhou, Jiehua
   Swiderski, Piotr
   Li, Haitang
   Zhang, Jane
   Neff, C. Preston
   Akkina, Ramesh
   Rossi, John J.
TI Selection, characterization and application of new RNA HIV gp 120
   aptamers for facile delivery of Dicer substrate siRNAs into HIV infected
   cells
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT SOLUBLE CD4; NEUTRALIZES R5
   STRAINS; PROSTATE-CANCER CELLS; IN-VIVO; ENVELOPE GLYCOPROTEIN; ENTRY
   INHIBITORS; RATIONAL DESIGN; RECEPTOR; THERAPY
AB The envelope glycoprotein of human immunodeficiency virus (HIV) consists of an exterior glycoprotein (gp120) and a trans-membrane domain (gp41) and has an important role in viral entry into cells. HIV-1 entry has been validated as a clinically relevant anti-viral strategy for drug discovery. In the present work, several 2-F substituted RNA aptamers that bind to the HIV-1(BaL) gp120 protein with nanomole affinity were isolated from a RNA library by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) procedure. From two of these aptamers we created a series of new dual inhibitory function anti-gp120 aptamersiRNA chimeras. The aptamers and aptamersiRNA chimeras specifically bind to and are internalized into cells expressing HIV gp160. The Dicer-substrate siRNA delivered by the aptamers is functionally processed by Dicer, resulting in specific inhibition of HIV-1 replication and infectivity in cultured CEM T-cells and primary blood mononuclear cells (PBMCs). Moreover, we have introduced a sticky sequence onto a chemically synthesized aptamer which facilitates attachment of the Dicer substrate siRNAs for potential multiplexing. Our results provide a set of novel inhibitory agents for blocking HIV replication and further validate the use of aptamers for delivery of Dicer substrate siRNAs.
C1 [Zhou, Jiehua; Li, Haitang; Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA.
   [Zhang, Jane; Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA.
   [Neff, C. Preston; Akkina, Ramesh] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Rossi, JJ (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA.
EM jrossi@coh.org
RI zhou, Jiehua/B-4045-2010
FU National Institutes of Health [AI29329, HL07470]
FX National Institutes of Health (AI29329, HL07470 to J. J. R). Funding for
   open access charge: National Institutes of Health (AI29329).
CR ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   Amarzguioui M, 2006, NAT PROTOC, V1, P508, DOI 10.1038/nprot.2006.72
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Blair WS, 2000, DRUG DISCOV TODAY, V5, P183, DOI 10.1016/S1359-6446(00)01484-7
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHU TC, 2006, NUCLEIC ACIDS RES, V34, pC73
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Collingwood MA, 2008, OLIGONUCLEOTIDES, V18, P187, DOI 10.1089/oli.2008.0123
   Cooley LA, 2003, J CLIN VIROL, V26, P121, DOI 10.1016/S1386-6532(02)00111-7                                                   
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Dey AK, 2005, RNA, V11, P873, DOI 10.1261/rna.7205405
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Engels FK, 2007, ANTI-CANCER DRUG, V18, P95, DOI 10.1097/CAD.0b013e3280113338
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550                                                   
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Farokhzad OC, 2006, EXPERT OPIN DRUG DEL, V3, P311, DOI 10.1517/17425247.3.3.311
   Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
   Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324
   HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0
   Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698                                                                  
   Jiang SB, 2002, CURR PHARM DESIGN, V8, P563
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Lupold SE, 2002, CANCER RES, V62, P4029
   Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meanwell NA, 2003, CURR OPIN DRUG DI DE, V6, P451
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Pestourie C, 2005, BIOCHIMIE, V87, P921, DOI 10.1016/j.biochi.2005.04.013
   Pierson TC, 2003, IMMUNOL LETT, V85, P113, DOI 10.1016/S0165-2478(02)00235-3
   Pomerantz RJ, 2003, NAT MED, V9, P867, DOI 10.1038/nm0703-867
   Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732
   Ryser HJP, 2005, DRUG DISCOV TODAY, V10, P1085, DOI 10.1016/S1359-6446(05)03550-6                                                   
   SATTENTAU QJ, 1993, PHILOS T ROY SOC B, V342, P59, DOI 10.1098/rstb.1993.0136
   SCHACKER T, 1994, J INFECT DIS, V169, P37, DOI 10.1093/infdis/169.1.37                                                         
   Shearer WT, 2000, J INFECT DIS, V182, P1774, DOI 10.1086/317622
   SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514
   TRKOLA A, 1995, J VIROL, V69, P6609
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   WEISS CD, 1993, J VIROL, V67, P7060
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
NR 53
TC 156
Z9 160
U1 7
U2 32
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAY
PY 2009
VL 37
IS 9
BP 3094
EP 3109
DI 10.1093/nar/gkp185
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 449UB
UT WOS:000266354600028
PM 19304999
OA gold
DA 2018-01-05
ER

PT J
AU Blajchman, MA
AF Blajchman, M. A.
TI Protecting the blood supply from emerging pathogens: The role of
   pathogen inactivation
SO TRANSFUSION CLINIQUE ET BIOLOGIQUE
LA English
DT Article; Proceedings Paper
CT 24th Congress of the Societe-Francaise-de-Transfusion-Sanguine
CY JUN 22-25, 2009
CL Strasbourg, FRANCE
SP Soc Francaise Transfus Sanguine
DE Blood products; Plasma; Blood cellular products; Pathogen inactivation;
   Solvent-detergent; Nanofiltration; Photosensitive chemicals
ID CONSENSUS CONFERENCE; TRANSFUSION; PLATELETS; REDUCTION; SAFETY; PLASMA;
   TECHNOLOGIES; DECISIONS; HAZARDS; RISK
AB As a consequence of the many blood-safety interventions introduced since the mid-1980s, the major causes of transfusion-associated mortality have shifted from being mainly due to transfusion-transmitted infections (TTIs) to being mainly due to non-infectious serious events such as TRALI, hemolytic reactions, transfusion overload, and graft versus host disease. Thus, TTIs now account for only 10 to 15% a of all transfusion associated mortalities! Relevantly, manufacturers of purified plasma protein fractions have, over the same time period, shown that pathogen inactivation technologies can be successfully implemented resulting in little or no transmission of HIV, HCV or HBV since the late 1980s. These technologies, however, cannot be applied to cellular blood components. Thus, new technologies have evolved over the past decade to treat cellular blood components as well as plasma. These technologies, particularly those involving plasma and platelets, have begun to be used in Europe and this proactive paradigm has evolved to become a potential pre-emptive approach for ridding the blood supply of most TTIs (virus, bacteria, and protozoa). However, in order for pathogen inactivation technologies to become widely accepted, they must be shown to be both cost effective and not associated with new risks to recipients! (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
RP Blajchman, MA (reprint author), McMaster Univ, Dept Pathol & Mol Med, HSC 4N67,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM blajchma@mcmaster.ca
CR Allain JP, 2005, TRANSFUS MED REV, V19, P110, DOI 10.1016/j.tmrv.2004.11.005
   Alter HJ, 2008, BLOOD, V112, P2617, DOI 10.1182/blood-2008-07-077370
   Alter HJ, 2008, TRANSFUS MED REV, V22, P97, DOI 10.1016/j.tmrv.2008.01.001
   Blajchman MA, 2004, TRANSFUS MED REV, V18, P11, DOI 10.1016/j.tmrv.2003.10.002
   Blajchman MA, 2006, NEW ENGL J MED, V355, P1303, DOI 10.1056/NEJMp068178                                                             
   Bryant BJ, 2007, ARCH PATHOL LAB MED, V131, P719
   Burnouf T, 2007, TRANSFUS MED REV, V21, P101, DOI 10.1016/j.tmrv.2006.11.001
   GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6
   Goodrich RP, 2006, TRANSFUS APHER SCI, V35, P5, DOI 10.1016/j.transci.2006.01.007
   Goodrich RP, 2009, TRANSFUSION, V49, P64, DOI 10.1111/j.1537-2995.2008.01940.x
   Hendrickson JE, 2009, ANESTH ANALG, V108, P759, DOI 10.1213/ane.0b013e3181930a6e
   Klein HG, 2007, TRANSFUSION, V47, P2338, DOI 10.1111/j.1537-2995.2007.01512.x
   KLEIN HG, TRANSFUSION IN PRESS
   Kleinman S, 2009, TRANSFUSION, V49, P903, DOI 10.1111/j.1537-2995.2008.02048.x
   McCullough J, 2004, BLOOD, V104, P1534, DOI 10.1182/blood-2003-12-4443
   Prowse C, 2009, TRANSFUS MED REV, V23, P124, DOI 10.1016/j.tmrv.2008.12.004
   Reddy HL, 2008, TRANSFUS MED REV, V22, P133, DOI 10.1016/j.tmrv.2007.12.003
   Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643
   Webert KE, 2008, TRANSFUS MED REV, V22, P1, DOI 10.1016/j.tmrv.2007.09.001
   Yomtovian RA, 2006, TRANSFUSION, V46, P719, DOI 10.1111/j.1537-2995.2006.00790.x
NR 20
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 1246-7820
J9 TRANSFUS CLIN BIOL
JI Transfu. Clin. Biol.
PD MAY
PY 2009
VL 16
IS 2
BP 70
EP 74
DI 10.1016/j.tracli.2009.04.004
PG 5
WC Hematology; Immunology
SC Hematology; Immunology
GA 466UY
UT WOS:000267689800002
PM 19427252
DA 2018-01-05
ER

PT J
AU DeGoey, DA
   Grampovnik, DJ
   Flentge, CA
   Flosi, WJ
   Chen, HJ
   Yeung, CM
   Randolph, JT
   Klein, LL
   Dekhtyar, T
   Colletti, L
   Marsh, KC
   Stoll, V
   Mamo, M
   Morfitt, DC
   Nguyen, B
   Schmidt, JM
   Swanson, SJ
   Mo, H
   Kati, WM
   Molla, A
   Kempf, DJ
AF DeGoey, David A.
   Grampovnik, David J.
   Flentge, Charles A.
   Flosi, William J.
   Chen, Hui-ju
   Yeung, Clinton M.
   Randolph, John T.
   Klein, Larry L.
   Dekhtyar, Tatyana
   Colletti, Lynn
   Marsh, Kennan C.
   Stoll, Vincent
   Mamo, Mulugeta
   Morfitt, David C.
   Nguyen, Bach
   Schmidt, James M.
   Swanson, Sue J.
   Mo, Hongmei
   Kati, Warren M.
   Molla, Akhteruzzaman
   Kempf, Dale J.
TI 2-Pyridyl P1 '-Substituted Symmetry-Based Human Immunodeficiency Virus
   Protease Inhibitors (A-792611 and A-790742) with Potential for
   Convenient Dosing and Reduced Side Effects
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIV PROTEASE; PHARMACOKINETIC ENHANCEMENT; RITONAVIR;
   HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; RESISTANCE; DISCOVERY; EFFICACY;
   ABT-378; CORE
AB A series of symmetry-based HIV protease inhibitors was designed and synthesized. Modification of the core regiochemistry and stereochemistry significantly affected the potency, metabolic stability, and oral bioavailability of the inhibitors, as did the variation of a pendent arylmethyl P3 group. Optimization led to the selection of two compounds, 10c (A-790742) and 9d (A-792611), for advancement to preclinical studies. Both compounds displayed low nanomolar potency against wild type HIV in the presence of human serum, low rates of metabolism in human liver microsomes, and high oral bioavailability in animal models. The compounds were examined in a preclinical model for the hyperbilirubinemia observed with some HIV PIs, and both exhibited less bilirubin elevation than comparator compounds. X-ray crystallographic analyses of the new cores were used to examine differences in their binding modes. The antiviral activity of the compounds against protease inhibitor resistant strains of HIV was also determined.
C1 [DeGoey, David A.; Grampovnik, David J.; Flentge, Charles A.; Flosi, William J.; Chen, Hui-ju; Yeung, Clinton M.; Randolph, John T.; Klein, Larry L.; Dekhtyar, Tatyana; Colletti, Lynn; Marsh, Kennan C.; Stoll, Vincent; Mamo, Mulugeta; Morfitt, David C.; Nguyen, Bach; Schmidt, James M.; Swanson, Sue J.; Mo, Hongmei; Kati, Warren M.; Molla, Akhteruzzaman; Kempf, Dale J.] Abbott Labs, Global Pharmaceut Res & Dev, Antiviral Res, Abbott Pk, IL 60064 USA.
RP DeGoey, DA (reprint author), Abbott Labs, Global Pharmaceut Res & Dev, Antiviral Res, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM David.DeGoey@abbott.com
FU companies of the Industrial Macromolecular Crystallography Association
   through a contract with Illinois Institute of Technology (IIT); U.S.
   Department of Energy, Basic Energy Sciences, Office of Science
   [W-31-109-Eng-38]
FX X-ray data were collected at beamline 17-ID in the facilities of the
   Industrial Macromolecular Crystallography Association Collaborative
   Access Team (IMCA-CAT) at the Advanced Photon Source. These facilities
   are supported by the companies of the Industrial Macromolecular
   Crystallography Association through a contract with Illinois Institute
   of Technology (IIT), executed through IIT's Center for Synchrotron
   Radiation Research and Instrumentation. Use of the Advanced Photon
   Source was supported by the U.S. Department of Energy, Basic Energy
   Sciences, Office of Science, under Contract No. W-31-109-Eng-38.
CR BADGER J, 1999, CNX SOFTWARE MANUAL
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Carrillo A, 1998, J VIROL, V72, P7532
   Dekhtyar T, 2008, ANTIMICROB AGENTS CH, V52, P1337, DOI 10.1128/AAC.01132-07
   Engstrom K, 2006, J ORG CHEM, V71, P5369, DOI 10.1021/jo060737s
   Flosi WJ, 2006, BIOORGAN MED CHEM, V14, P6695, DOI 10.1016/j.bmc.2006.05.063
   Ghosh AK, 2007, BIOORGAN MED CHEM, V15, P7576, DOI 10.1016/j.bmc.2007.09.010
   Hagen SE, 2001, J MED CHEM, V44, P2319, DOI 10.1021/jm0003844
   Haight AR, 1999, ORG PROCESS RES DEV, V3, P94, DOI 10.1021/op9802071                                                               
   HOSUR MV, 1994, J AM CHEM SOC, V116, P847, DOI 10.1021/ja00082a004
   Jew S, 2003, BIOORG MED CHEM LETT, V13, P609, DOI 10.1016/S0960-894X(02)01041-7
   Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+
   Kempf DJ, 2006, ANTIMICROB AGENTS CH, V50, P762, DOI 10.1128/AAC.50.2.762-764.2006
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654
   King JR, 2004, CLIN PHARMACOKINET, V43, P291, DOI 10.2165/00003088-200443050-00003
   Lum PY, 2007, GENOMICS, V90, P464, DOI 10.1016/j.ygeno.2007.06.004
   Martinez-Cajas JL, 2007, ANTIVIR RES, V76, P203, DOI 10.1016/j.antiviral.2007.06.010
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   Murphy RL, 2008, HIV CLIN TRIALS, V9, P1, DOI 10.1310/hct0901-1
   Nolan David, 2005, Expert Opin Drug Saf, V4, P201, DOI 10.1517/14740338.4.2.201
   Parker RA, 2005, MOL PHARMACOL, V67, P1909, DOI 10.1124/mol.104.010165
   Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330                                                        
   Randolph JT, 2006, BIOORGAN MED CHEM, V14, P4035, DOI 10.1016/j.bmc.2006.02.013
   RANDOLPH JT, 2004, 44 INT C ANT AG CHEM
   Shafran SD, 2005, HIV MED, V6, P421, DOI 10.1111/j.1468-1293.2005.00328.x                                                
   Sherer R, 2003, JAIDS-J ACQ IMM DEF, V34, pS123, DOI 10.1097/00126334-200310012-00005
   Stoll V, 2002, BIOORGAN MED CHEM, V10, P2803, DOI 10.1016/S0968-0896(02)00051-2
   Turner SR, 1998, J MED CHEM, V41, P3467, DOI 10.1021/jm9802158
   WARING J, 2005, 12 C RETR OPP INF BO
   WARING JF, IDENTIFICATION UNPUB
   Yeung CM, 2005, BIOORG MED CHEM LETT, V15, P2275, DOI 10.1016/j.bmcl.2005.03.008
   Zhang DL, 2005, DRUG METAB DISPOS, V33, P1729, DOI 10.1124/dmd.105.005447
   Zucker SD, 2001, P NATL ACAD SCI USA, V98, P12671, DOI 10.1073/pnas.231140698
   DEGOEY DA, 2005, Patent No. 2005058841
NR 34
TC 20
Z9 21
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 23
PY 2009
VL 52
IS 8
BP 2571
EP 2586
DI 10.1021/jm900044w
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 434RV
UT WOS:000265292700040
PM 19323562
DA 2018-01-05
ER

PT J
AU Tam, JM
   Song, L
   Walt, DR
AF Tam, Jenny M.
   Song, Linan
   Walt, David R.
TI DNA detection on ultrahigh-density optical fiber-based nanoarrays
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE DNA; Nanoarray; Genomics; Ultrahigh density; Fiber-optic
ID UNIVERSAL ARRAY; MICROARRAYS; FABRICATION; SUBSTRATE; GENOME; ASSAY
AB Nanoarrays for DNA detection were fabricated on etched nanofiber bundles based on recently developed techniques for microscale arrays. Two different-sized nanoarrays were created: one with 700 nm feature sizes and a 1 mu m center-to-center pitch (similar to 1 x 10(6) array elements/mm(2)) and one with 300 nm feature sizes and a 500 nm center-to-center pitch (4.6 x 10(6) array elements/mm(2)). A random, multiplexed array composed of oligonucleotide-functionalized nanospheres was constructed and used for parallel detection and analysis of fluorescently labeled DNA targets. We have used these arrays to detect a variety of target sequences including Bacillus thuringiensis kurstaki and vaccina virus sequences, two potential biowarfare agents, as well as interleukin-2 sequences, an immune system modulator that has been used for the diagnosis of HIV. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Tam, Jenny M.; Song, Linan; Walt, David R.] Tufts Univ, Dept Chem, Medford, MA 02155 USA.
RP Walt, DR (reprint author), Tufts Univ, Dept Chem, 62 Talbot Ave, Medford, MA 02155 USA.
EM david.walt@tufts.edu
FU Center for Nanoscale Systems (CNS); DARPA [2763-TU-ONR-0659]
FX We thank Schott Fiber Optics for providing the nanofiber material, the
   Center for Nanoscale Systems (CNS) at Harvard University for the use of
   their scanning electron microscope, and DARPA (2763-TU-ONR-0659) for
   support of this work.
CR ABRAMOWITZ M, 1994, OPTICS PRIMER
   Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564
   Epstein JR, 2003, J AM CHEM SOC, V125, P13753, DOI 10.1021/ja0365577
   Epstein JR, 2003, BIOSENS BIOELECTRON, V18, P541, DOI 10.1016/S0956-5663(03)00021-6
   Epstein JR, 2002, ANAL CHIM ACTA, V469, P3, DOI 10.1016/S0003-2670(02)00030-2                                                   
   Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504
   Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901
   Ferguson JA, 2000, ANAL CHEM, V72, P5618, DOI 10.1021/ac0008284
   Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393                                                    
   Hessner MJ, 2006, PEDIATR CLIN N AM, V53, P579, DOI 10.1016/j.pcl.2006.05.013
   Hozumi A, 2004, J VAC SCI TECHNOL A, V22, P1836, DOI [10.1116/1.1738662, 10.1116/1738662]
   Huang SX, 2007, NANO LETT, V7, P3116, DOI 10.1021/nl071643g
   Hyun J, 2004, J AM CHEM SOC, V126, P7330, DOI 10.1021/ja049721e
   Kreil DP, 2006, METHOD ENZYMOL, V410, P73, DOI 10.1016/S0076-6879(06)10004-X
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Lee M, 2000, ANAL BIOCHEM, V282, P142, DOI 10.1006/abio.2000.4595                                                          
   Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773
   Lynch M, 2004, PROTEOMICS, V4, P1695, DOI 10.1002/pmic.200300701
   Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r                                                               
   Pantano P, 1996, CHEM MATER, V8, P2832, DOI 10.1021/cm9603314                                                               
   Parman C, 2004, GENET ENG NEWS, V24, P36
   Sinensky AK, 2007, NAT NANOTECHNOL, V2, P653, DOI 10.1038/nnano.2007.293
   Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91
   Tam JM, 2005, TALANTA, V67, P498, DOI 10.1016/j.talanta.2005.06.021
   Warrington JA, 2002, HUM MUTAT, V19, P402, DOI 10.1002/humu.10075
   Yan MD, 2002, NANO LETT, V2, P275, DOI 10.1021/nl0156742
   Zhang K, 2006, NAT GENET, V38, P382, DOI 10.1038/ng1741
NR 27
TC 15
Z9 15
U1 2
U2 14
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2009
VL 24
IS 8
BP 2488
EP 2493
DI 10.1016/j.bios.2008.12.034
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 442AC
UT WOS:000265811000029
PM 19195871
DA 2018-01-05
ER

PT J
AU McNaughton, BR
   Cronican, JJ
   Thompson, DB
   Liu, DR
AF McNaughton, Brian R.
   Cronican, James J.
   Thompson, David B.
   Liu, David R.
TI Mammalian cell penetration, siRNA transfection, and DNA transfection by
   supercharged proteins
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cell-penetrating protein; nucleic acid delivery
ID SMALL INTERFERING RNA; PERMEABLE MINIATURE PROTEINS; HUMAN
   IMMUNODEFICIENCY VIRUS; IN-VIVO DELIVERY; NUCLEIC-ACIDS; GENE; PEPTIDES;
   INTERNALIZATION; NANOPARTICLES; THERAPEUTICS
AB Nucleic acid reagents, including small interfering RNA (siRNA) and plasmid DNA, are important tools for the study of mammalian cells and are promising starting points for the development of new therapeutic agents. Realizing their full potential, however, requires nucleic acid delivery reagents that are simple to prepare, effective across many mammalian cell lines, and nontoxic. We recently described the extensive surface mutagenesis of proteins in a manner that dramatically increases their net charge. Here, we report that superpositively charged green fluorescent proteins, including a variant with a theoretical net charge of +36 (+36 GFP), can penetrate a variety of mammalian cell lines. Internalization of +36 GFP depends on nonspecific electrostatic interactions with sulfated proteoglycans present on the surface of most mammalian cells. When +36 GFP is mixed with siRNA, protein-siRNA complexes approximate to 1.7 mu m in diameter are formed. Addition of these complexes to five mammalian cell lines, including four that are resistant to cationic lipid-mediated siRNA transfection, results in potent siRNA delivery. In four of these five cell lines, siRNA transfected by +36 GFP suppresses target gene expression. We show that +36 GFP is resistant to proteolysis, is stable in the presence of serum, and extends the serum half-life of siRNA and plasmid DNA with which it is complexed. A variant of +36 GFP can mediate DNA transfection, enabling plasmid-based gene expression. These findings indicate that superpositively charged proteins can overcome some of the key limitations of currently used transfection agents.
C1 [McNaughton, Brian R.; Cronican, James J.; Thompson, David B.; Liu, David R.] Harvard Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
RP Liu, DR (reprint author), Harvard Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.
EM drliu@fas.harvard.edu
FU National Institute of General Medical Sciences/National Institutes of
   Health [R01 GM 065400]; Howard Hughes Medical Institute; National
   Science Foundation
FX We thank Sara Jones and Professor Xiaowei Zhuang (Harvard University,
   Cambridge, MA) for assistance with live cell imaging and for providing
   CHO and PGD-CHO cell lines. Alan Saghatelian, Gregory Verdine, Matthew
   Shair, and Paula Nunes (Harvard University) kindly provided 3T3-L,
   Jurkat, HeLa, and IMCD cells, respectively. This work was supported by
   the National Institute of General Medical Sciences/National Institutes
   of Health Grant R01 GM 065400 and by the Howard Hughes Medical
   Institute. J. J. C. is supported by a National Science Foundation
   Graduate Student Fellowship.
CR Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8                                                   
   Cardoso ALC, 2007, J GENE MED, V9, P170, DOI 10.1002/jgm.1006
   Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021
   Daniels DS, 2007, J AM CHEM SOC, V129, P14578, DOI 10.1021/ja0772445
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Deshayes Sebastien, 2007, V386, P299, DOI 10.1007/978-1-59745-430-8_11
   Fisher AA, 2002, J BIOL CHEM, V277, P22980, DOI 10.1074/jbc.M203347200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Fuchs SM, 2007, PROTEIN ENG DES SEL, V20, P505, DOI 10.1093/protein/gzm051
   Fuchs SM, 2007, ACS CHEM BIOL, V2, P167, DOI 10.1021/cb600429k
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508                                                            
   Jantsch J, 2008, J IMMUNOL METHODS, V337, P71, DOI 10.1016/j.jim.2008.04.004
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lawrence MS, 2007, J AM CHEM SOC, V129, P10110, DOI 10.1021/ja071641y
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Ma H, 2002, NEUROSCIENCE, V112, P1
   McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754                                                    
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x
   Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Segura T, 2007, BIOCONJUGATE CHEM, V18, P736, DOI 10.1021/bc060284y
   Smith BA, 2008, J AM CHEM SOC, V130, P2948, DOI 10.1021/ja800074v
   Sokolova V, 2008, ANGEW CHEM INT EDIT, V47, P1382, DOI 10.1002/anie.200703039
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Strait KA, 2007, AM J PHYSIOL-RENAL, V293, pF601, DOI 10.1152/ajprenal.00085.2007
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
NR 38
TC 122
Z9 128
U1 3
U2 51
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 14
PY 2009
VL 106
IS 15
BP 6111
EP 6116
DI 10.1073/pnas.0807883106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 433AB
UT WOS:000265174600017
PM 19307578
OA gold
DA 2018-01-05
ER

PT J
AU Bonoiu, AC
   Mahajan, SD
   Ding, H
   Roy, I
   Yong, KT
   Kumar, R
   Hu, R
   Bergey, EJ
   Schwartz, SA
   Prasad, PN
AF Bonoiu, Adela C.
   Mahajan, Supriya D.
   Ding, Hong
   Roy, Indrajit
   Yong, Ken-Tye
   Kumar, Rajiv
   Hu, Rui
   Bergey, Earl J.
   Schwartz, Stanley A.
   Prasad, Paras N.
TI Nanotechnology approach for drug addiction therapy: Gene silencing using
   delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE DARPP-32; dark field imaging; surface plasmon resonance; nanoplexes;
   blood-brain barrier
ID BLOOD-BRAIN-BARRIER; PHOSPHATASE-1 CASCADE; HIV-1 ENCEPHALITIS;
   NANOPARTICLES; DARPP-32; PERMEABILITY; MODELS; ABUSE; THERAPEUTICS;
   PLASTICITY
AB Drug abuse is a worldwide health concern in which addiction involves activation of the dopaminergic signaling pathway in the brain. Here, we introduce a nanotechnology approach that utilizes gold nanorod-DARPP-32 siRNA complexes (nanoplexes) that target this dopaminergic signaling pathway in the brain. The shift in the localized longitudinal plasmon resonance peak of gold nanorods (GNRs) was used to show their interaction with siRNA. Plasmonic enhanced dark field imaging was used to visualize the uptake of these nanoplexes in dopaminergic neurons in vitro. Gene silencing of the nanoplexes in these cells was evidenced by the reduction in the expression of key proteins (DARPP-32, ERK, and PP-1) belonging to this pathway, with no observed cytotoxicity. Moreover, these nanoplexes were shown to transmigrate across an in vitro model of the blood-brain barrier (BBB). Therefore, these nanoplexes appear to be suited for brain-specific delivery of appropriate siRNA for therapy of drug addiction and other brain diseases.
C1 [Bonoiu, Adela C.; Ding, Hong; Roy, Indrajit; Yong, Ken-Tye; Kumar, Rajiv; Hu, Rui; Bergey, Earl J.; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Mahajan, Supriya D.; Schwartz, Stanley A.] SUNY Buffalo, Dept Med, Div Rheumatol Allergy & Immunol, Buffalo Gen Hosp, Buffalo, NY 14203 USA.
RP Prasad, PN (reprint author), SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
EM pnprasad@buffalo.edu
RI HU, Rui/A-1874-2011; Kumar, Rajiv/A-1457-2011; Ding, Hong/C-2322-2011
OI HU, Rui/0000-0001-7412-8451; Kumar, Rajiv/0000-0003-2926-9866; Ding,
   Hong/0000-0003-0376-0008; Kumar, Rajiv/0000-0002-2363-3930
FU National Cancer Institute [CA119397, CA104492]; Kaleida Health Cameron
   Troup Foundation; Oishei Foundation; Chemistry and Life Sciences
   Division of the Air Force Office of Scientific Research; Center of
   Excellence in Bioinformatics and Life Sciences
FX This study was supported by grants from the National Cancer Institute
   Grants CA119397, and CA104492, the Kaleida Health Cameron Troup
   Foundation, the John R. Oishei Foundation, and the Chemistry and Life
   Sciences Division of the Air Force Office of Scientific Research.
   Support from the Center of Excellence in Bioinformatics and Life
   Sciences at the University at Buffalo is also acknowledged.
CR Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Calabresi P, 2000, J NEUROSCI, V20, P8443
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Davidovitz M, 1997, MICROW OPT TECHN LET, V15, P224
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Deli MA, 2005, CELL MOL NEUROBIOL, V25, P59, DOI 10.1007/s10571-004-1377-8
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gould TD, 2005, P NATL ACAD SCI USA, V102, P253, DOI 10.1073/pnas.0408700102
   Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X                                                   
   Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   KUHN R, 2007, HDB EXP PHARM, V178
   Mahajan SD, 2008, J CLIN IMMUNOL, V28, P528, DOI 10.1007/s10875-008-9208-1
   Mahajan SD, 2008, BRAIN RES, V1203, P133, DOI 10.1016/j.brainres.2008.01.093
   Nairn AC, 2004, NEUROPHARMACOLOGY, V47, P14, DOI 10.1016/j.neuropharm.2004.05.010
   Pardridge WM, 2008, BIOCONJUGATE CHEM, V19, P1327, DOI 10.1021/bc800148t
   Pardridge WM, 2007, ADV DRUG DELIVER REV, V59, P141, DOI 10.1016/j.addr.2007.03.008
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Prasad P. N., 2004, INTRO BIOPHOTONICS
   Sokolov K, 2003, CANCER RES, V63, P1999
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Stone JW, 2007, NANO LETT, V7, P116, DOI 10.1021/nl062248d
   Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415                                       
   Tahti H, 2003, ATLA-ALTERN LAB ANIM, V31, P273
   Terasaki T, 2003, DRUG DISCOV TODAY, V8, P944, DOI 10.1016/S1359-6446(03)02858-7
   Valjent E, 2005, M S-MED SCI, V21, P453, DOI 10.1051/medsci/2005215453
   Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102
   Valjent E, 2001, MOL NEUROBIOL, V23, P83
   Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u
NR 35
TC 142
Z9 144
U1 5
U2 71
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 7
PY 2009
VL 106
IS 14
BP 5546
EP 5550
DI 10.1073/pnas.0901715106
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 430CX
UT WOS:000264967500019
PM 19307583
OA gold
DA 2018-01-05
ER

PT J
AU Woods, MN
   Wanke, CA
   Ling, PR
   Hendricks, KM
   Tang, AM
   Andersson, CE
   Dong, KR
   Sheehan, HMB
   Bistrian, BR
AF Woods, Margo N.
   Wanke, Christine A.
   Ling, Pei-Ra
   Hendricks, Kristy M.
   Tang, Alice M.
   Andersson, Charlotte E.
   Dong, Kimberly R.
   Sheehan, Heidi M. B.
   Bistrian, Bruce R.
TI Metabolic syndrome and serum fatty acid patterns in serum phospholipids
   in hypertriglyceridemic persons with human immunodeficiency virus
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID INSULIN SENSITIVITY; DIETARY-FAT; PROTEASE INHIBITORS;
   GLUCOSE-TOLERANCE; PLASMA; RESISTANCE; INFECTION; CHOLESTEROL; MEN;
   HYPERLIPIDEMIA
AB Background: HIV infection and its treatment are associated with abnormal lipid profiles. High triglyceride concentrations and low HDL-cholesterol concentrations are the most common health abnormalities and raise concerns about an increased risk of cardiovascular disease.
   Objective: We compared the fatty acid patterns of serum phospholipids between persons with HIV and non-HIV controls to determine whether there are differences that explain the elevated triglyceride concentrations, insulin resistance, and inflammation that are part of the metabolic syndrome in patients with HIV.
   Design: Thirty-nine persons with HIV and elevated serum triglycerides (> 150 mg/dL) and/or indicators of insulin resistance were recruited to examine fatty acid profiles in serum phospholipid fractions relative to those of 2 control groups without HIV (n = 31).
   Results: Higher concentrations of 16: 1 and 18: 0 fatty acids in the phospholipid fraction indicated increased lipogenesis in the HIV patients and in the non-HIV controls at risk of the metabolic syndrome. However, the subjects with HIV had higher concentrations of both n-6 (omega-6) and n-3 fatty acids of higher elongation and desaturation levels, which indicated a greater promotion of these pathways in this population. The nanomolar percentage (% nmol) arachidonic acid was the same in all 3 groups.
   Conclusions: Persons with and without HIV, at risk of the metabolic syndrome, show indications of increased lipogenesis, more so in subjects with HIV taking medication. Higher proportions of distal elongation and desaturation fatty acid products were seen only in the phospholipids fatty acid fraction of the subjects with HIV. Am J Clin Nutr 2009; 89: 1180-7.
C1 [Woods, Margo N.; Wanke, Christine A.; Tang, Alice M.; Dong, Kimberly R.; Sheehan, Heidi M. B.] Tufts Univ, Sch Med, Dept Publ Hlth & Family Med, Nutr Infect Unit, Boston, MA 02111 USA.
   [Ling, Pei-Ra; Bistrian, Bruce R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Clin Nutr, Boston, MA 02215 USA.
   [Andersson, Charlotte E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA.
   [Hendricks, Kristy M.] Dartmouth Med Sch, Dept Pediat, Lebanon, NH USA.
RP Woods, MN (reprint author), Tufts Univ, Sch Med, Dept Publ Hlth & Family Med, Nutr Infect Unit, 150 Harrison Ave,Jaharis 265, Boston, MA 02111 USA.
EM margo.woods@tufts.edu
FU National Institute of Diabetes and Digestive; Kidney Diseases, National
   Institutes of Health [R01 DK63619, P01-D45734, P30 DA013868]; General
   Clinical Research Center; Tufts-New England Medical Center, Boston, MA;
   Division of Research Resources, National Institutes of Health
   [M01-RR00054]
FX Supported by the National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institutes of Health (grants R01 DK63619, P01-D45734,
   and P30 DA013868); by the General Clinical Research Center, Tufts-New
   England Medical Center, Boston, MA; and by the Division of Research
   Resources, National Institutes of Health (grant M01-RR00054).
CR Aldamiz-Echevarria L, 2005, ACTA PAEDIATR, V94, P672, DOI 10.1080/08035250510028362
   ALVAREZ JG, 1995, MOL REPROD DEV, V42, P334, DOI 10.1002/mrd.1080420311
   ALVAREZ JG, 1992, J CHROMATOGR-BIOMED, V577, P142, DOI 10.1016/0378-4347(92)80609-T
   BEGIN ME, 1989, PROSTAG LEUKOTR ESS, V37, P135, DOI 10.1016/0952-3278(89)90110-5
   Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001                                                
   Berry EM, 1997, AM J CLIN NUTR, V66, P991
   Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y
   Calder P. C., 2006, AM J CLIN NUTR, V83, p1505S
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   CHRISTEFF N, 1988, EUR J CANCER CLIN ON, V24, P1179, DOI 10.1016/0277-5379(88)90125-3
   CONSTANS J, 1995, CLIN BIOCHEM, V28, P421, DOI 10.1016/0009-9120(95)00017-4
   Fernandez-Real JM, 2003, DIABETES CARE, V26, P1362, DOI 10.2337/diacare.26.5.1362
   Ferrucci L, 2006, J CLIN ENDOCR METAB, V91, P439, DOI 10.1210/jc.2005-1303
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045
   HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559
   HOMMES MJT, 1991, CLIN SCI, V80, P359, DOI 10.1042/cs0800359                                                               
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Laaksonen DE, 2002, DIABETIC MED, V19, P456, DOI 10.1046/j.1464-5491.2002.00707.x
   Lovejoy JC, 2001, METABOLISM, V50, P86, DOI 10.1053/meta.2001.19440
   McCowen KC, 2005, CURR OPIN GASTROEN, V21, P207, DOI 10.1097/01.mog.0000153361.90653.cb                                              
   Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005                                                
   Pelikanova T, 2001, METABOLISM, V50, P1472, DOI 10.1053/meta.2001.27195
   Perez-Jimenez F, 2001, DIABETOLOGIA, V44, P2038, DOI 10.1007/s001250100009
   Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006
   Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3                                                       
   Vessby B, 2000, BRIT J NUTR, V83, pS91
   Vessby B, 2002, ANN NY ACAD SCI, V967, P183
   Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620
   VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353
   Vessby B, 2003, CURR OPIN LIPIDOL, V14, P15, DOI 10.1097/01.mol.0000052859.26236.5f
   Vigouroux C, 1999, DIABETES METAB, V25, P225
   Whelan J, 1996, J NUTR, V126, pS1086
NR 34
TC 9
Z9 9
U1 0
U2 0
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD APR 1
PY 2009
VL 89
IS 4
BP 1180
EP 1187
DI 10.3945/ajcn.2009.27444
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 420WF
UT WOS:000264319200026
PM 19244367
OA gold
DA 2018-01-05
ER

PT J
AU Lalanne, M
   Andrieux, K
   Couvreur, P
AF Lalanne, Muriel
   Andrieux, Karine
   Couvreur, Patrick
TI Strategies to Increase the Oral Bioavailability of Nucleoside Analogs
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Nucleoside analogs; oral absorption; prodrug
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; DNA
   METHYLTRANSFERASE INHIBITOR; PEPTIDE CARRIER SYSTEM; ANTI-HIV
   NUCLEOSIDES; PHASE-I TRIALS; INTESTINAL-ABSORPTION;
   CYTOSINE-ARABINOSIDE; CYTIDINE DEAMINASE; CYANOACRYLATE NANOPARTICLES
AB Nucleoside analogs are first line chemotherapy in various severe diseases: AIDS (acquired immunodeficiency disease syndrome), cytomegalovirus infections, cancer etc. However, most of these compounds suffer from poor bioavailability via oral route. In order to get around this drawback, researchers have imagined many strategies including drug metabolism inhibitors, bio adhesive nanoparticles, amino ester prodrugs, as well as enhancing absorption by increasing drug lipophilicity. This paper illustrated these approaches by developing their application to some nucleoside analogs. Moreover, some of these strategies were very successful and some resulting compounds are now approved by FDA (Food and Drug Administration).
C1 [Andrieux, Karine] Univ Paris Sud, UMR 8612, IFR 141, F-92296 Chatenay Malabry, France.
   CNRS, UMR 8612, IFR 141, F-92296 Chatenay Malabry, France.
RP Andrieux, K (reprint author), Univ Paris Sud, UMR 8612, IFR 141, F-92296 Chatenay Malabry, France.
EM karine.andrieux@u-psud.fr
RI Andrieux, Karine/P-3010-2017
OI Andrieux, Karine/0000-0002-2002-7556; Patrick,
   COUVREUR/0000-0001-7961-5443
CR AGGARWAL SK, 1990, J MED CHEM, V33, P1505, DOI 10.1021/jm00167a034
   Antman MD, 2007, PRODRUGS CHALLENGE 1, P1369
   Asif G, 2005, ANTIMICROB AGENTS CH, V49, P560, DOI 10.1128/AAC.49.2.560-564.2005
   BAI JPF, 1992, J PHARM SCI, V81, P113, DOI 10.1002/jps.2600810202
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   BEAUCHAMP LM, 1992, ANTIVIR CHEM CHEMOTH, V3, P157, DOI 10.1177/095632029200300305                                                      
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X
   Beumer JH, 2008, CLIN CANCER RES, V14, P3529, DOI 10.1158/1078-0432.CCR-07-4885
   Beumer JH, 2006, CLIN CANCER RES, V12, P7483, DOI 10.1158/1078-0432.CCR-06-1250
   BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546                                                           
   Biron KK, 2006, ANTIVIR RES, V71, P154, DOI 10.1016/j.antiviral.2006.05.022
   BOOTHMAN DA, 1987, CANCER RES, V47, P2354
   CAMIENER GW, 1965, BIOCHEM PHARMACOL, V14, P1405, DOI 10.1016/0006-2952(65)90175-9                                                    
   CAMIENER GW, 1968, BIOCHEM PHARMACOL, V17, P1981, DOI 10.1016/0006-2952(68)90114-7                                                    
   Charman WN, 1996, ADV DRUG DELIVER REV, V19, P149, DOI 10.1016/0169-409X(95)00105-G
   COHEN RM, 1971, J BIOL CHEM, V246, P7561
   COLLINS JM, 1988, J PHARMACOL EXP THER, V245, P466
   COUVREUR P, 1977, FEBS LETT, V84, P323, DOI 10.1016/0014-5793(77)80717-5                                                    
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   CREASEY WA, 1966, BIOCHEM PHARMACOL, V15, P1417, DOI 10.1016/0006-2952(66)90186-9
   CROOG SH, 1995, J PSYCHOSOM RES, V39, P39, DOI 10.1016/0022-3999(94)00089-N
   Cundy KC, 1999, CLIN PHARMACOKINET, V36, P127, DOI 10.2165/00003088-199936020-00004
   Cvetkovic RS, 2005, DRUGS, V65, P859, DOI 10.2165/00003495-200565060-00012                                                
   Daluge SM, 1997, ANTIMICROB AGENTS CH, V41, P1082
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   De Clercq E, 2005, BRIT J PHARMACOL, V147, P1
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   DRUSANO GL, 1992, ANTIMICROB AGENTS CH, V36, P1280, DOI 10.1128/AAC.36.6.1280                                                           
   DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480                                                        
   ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716
   FERNANDEZURRUSUNO R, 1995, TOXICOL APPL PHARM, V130, P272, DOI 10.1006/taap.1995.1032
   Guo AL, 1999, J PHARMACOL EXP THER, V289, P448
   GUSTAVSON LE, 1990, J ACQ IMMUN DEF SYND, V3, P28
   Hagens WI, 2007, REGUL TOXICOL PHARM, V49, P217, DOI 10.1016/j.yrtph.2007.07.006
   Hale JT, 2002, BIOCHEM PHARMACOL, V64, P1493, DOI 10.1016/S0006-2952(02)01413-2                                                   
   Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810
   HANZE AR, 1967, J AM CHEM SOC, V89, P6720, DOI 10.1021/ja01001a057
   HARTMAN NR, 1990, CLIN PHARMACOL THER, V47, P647, DOI 10.1038/clpt.1990.86                                                            
   HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5                                                    
   HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003
   Hernandez-Santiago BI, 2005, ANTIMICROB AGENTS CH, V49, P2589, DOI 10.1128/AAC.49.7.2589-2597.2005
   Holleran JL, 2005, CLIN CANCER RES, V11, P3862, DOI 10.1158/1078-0432.CCR-04-2406
   HOSTETLER KY, 1994, ANTIMICROB AGENTS CH, V38, P2792, DOI 10.1128/AAC.38.12.2792                                                          
   HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112
   HU M, 1989, PHARMACEUT RES, V6, P66, DOI 10.1023/A:1015855820488
   Inui K, 1999, Pharm Biotechnol, V12, P269
   KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49                                                            
   KLECKER RW, 1988, J CLIN PHARMACOL, V28, P837, DOI 10.1002/j.1552-4604.1988.tb03225.x                                              
   KNUPP CA, 1991, CLIN PHARMACOL THER, V49, P523, DOI 10.1038/clpt.1991.63                                                            
   KREIS W, 1977, CANCER TREAT REP, V61, P1347
   Lalezari JP, 2002, J CLIN VIROL, V24, P67, DOI 10.1016/S1386-6532(01)00229-3                                                   
   Lalezari JP, 1997, ANN PATHOL LAB MED, V124, P362
   LALIBERTE J, 1992, CANCER CHEMOTH PHARM, V30, P7, DOI 10.1007/BF00686478
   LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804                                                         
   LENAERTS V, 1984, BIOMATERIALS, V5, P65, DOI 10.1016/0142-9612(84)90002-4
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   MANOUILOV KK, 1995, ANTIVIR CHEM CHEMOTH, V6, P230, DOI 10.1177/095632029500600405                                                      
   Manouilov KK, 1997, ANTIVIR RES, V34, P91, DOI 10.1016/S0166-3542(96)01023-6
   MCDONALD GB, 1987, Q J EXP PHYSIOL CMS, V72, P153, DOI 10.1113/expphysiol.1987.sp003059                                                
   MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   MORSE GD, 1993, CLIN PHARMACOKINET, V24, P101, DOI 10.2165/00003088-199324020-00002                                                
   NEIL GL, 1970, CANCER RES, V30, P2166
   NELSON JA, 1988, LANCET, V1, P259
   Neutra MR, 1999, J INFECT DIS, V179, pS441, DOI 10.1086/314800                                                                  
   Painter GR, 2004, TRENDS BIOTECHNOL, V22, P423, DOI 10.1016/j.tibtech.2004.06.008
   Parker S, 2008, ANTIVIR RES, V77, P39, DOI 10.1016/j.antiviral.2007.08.003
   PERRY CM, 1995, DRUGS, V50, P396, DOI 10.2165/00003495-199550020-00011
   Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009                                                
   Peyriere H, 2001, REV MED INTERNE, V22, P297, DOI 10.1016/S0248-8663(00)00332-5                                                   
   Ponchel G, 1997, EUR J PHARM BIOPHARM, V44, P25, DOI 10.1016/S0939-6411(97)00098-2
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   ROLAN P, 1995, CLIN PHARMACOKINET, V29, P333, DOI 10.2165/00003088-199529050-00003                                                
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   ROZENCWEIG M, 1990, REV INFECT DIS, V12, pS570
   SINKO PJ, 1995, J PHARM SCI, V84, P959, DOI 10.1002/jps.2600840811
   SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759                                                          
   STOLLER RG, 1978, BIOCHEM PHARMACOL, V27, P53, DOI 10.1016/0006-2952(78)90256-3                                                    
   Sugawara M, 2000, J PHARM SCI, V89, P781, DOI 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7                   
   Tamai I, 1998, J PHARM SCI, V87, P1542, DOI 10.1021/js980186o
   Toschi L, 2005, Future Oncol, V1, P7, DOI 10.1517/14796694.1.1.7
   Tsuji A, 1996, PHARM RES-DORDR, V13, P963, DOI 10.1023/A:1016086003070
   VANGROENINGEN CJ, 1991, J NATL CANCER I, V83, P437
   VANLEEUWEN R, 1992, AIDS, V6, P1471, DOI 10.1097/00002030-199212000-00008                                                
   Wachsman M, 1996, ANTIVIR RES, V29, P153, DOI 10.1016/0166-3542(95)00829-2
   XIE H, 1995, ANTIVIR RES, V228, P761
   YARCHOAN R, 1990, REV INFECT DIS, V12, pS522
   MYHREN F, 2000, Patent No. 0986570
NR 89
TC 6
Z9 6
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD APR
PY 2009
VL 16
IS 11
BP 1391
EP 1399
DI 10.2174/092986709787846550                                              
          
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 440HV
UT WOS:000265692300007
PM 19355894
DA 2018-01-05
ER

PT J
AU Spallarossa, A
   Cesarini, S
   Ranise, A
   Bruno, O
   Schenone, S
   La Colla, P
   Collu, G
   Sanna, G
   Secci, B
   Loddo, R
AF Spallarossa, Andrea
   Cesarini, Sara
   Ranise, Angelo
   Bruno, Olga
   Schenone, Silvia
   La Colla, Paolo
   Collu, Gabriella
   Sanna, Giuseppina
   Secci, Barbara
   Loddo, Roberta
TI Novel modifications in the series of
   O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their
   ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase
   inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE O-(2-Phthalimidoethyl)-N-arylthiocarbamates; HIV-1; Non-nucleoside
   reverse transcriptase inhibitors; Parallel synthesis; Molecular docking
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRUCTURE-BASED DESIGN; PETT ANALOGS;
   PARALLEL SYNTHESIS; THIOUREA COMPOUNDS; PHENETHYLTHIAZOLYLTHIOUREA
   DERIVATIVES; CRYSTAL-STRUCTURES; RATIONAL DESIGN; POTENT; BINDING
AB The structure-activity relationships (SARs) of N-aryl-O-(2-phthalimidoethyl)thiocarbamates (C-TCs) and their imide ring-opened congeners (O-TCs) as non-nucleoside HIV-1 reverse transcriptase inhibitors were further investigated. The SAR strategy involved modifications of the N-phenyl ring followed by the hybridization of the most promising N-aryl and O-(2-phthalimidoethyl)substructures. The role of stereochemistry and tert-butyl substitution of the phthalimidoethyl moiety on activity was also investigated. Seventy-six analogues were prepared by parallel solution-phase synthesis. Twenty-two C-TCs displayed nanomolar activity against wild-type HIV-1 and a number of analogues were effective against the Y181C mutant. Compound 56 combined the highest activity so far identified against Y181C (EC(50)=1.3 mu M) with good potency against the K103R mutant (EC(50)=4.8 mu M). Docking simulations helped to rationalize the SARs. (c) 2008 Elsevier Masson SAS. All rights reserved.
C1 [Spallarossa, Andrea; Cesarini, Sara; Ranise, Angelo; Bruno, Olga; Schenone, Silvia] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   [La Colla, Paolo; Collu, Gabriella; Sanna, Giuseppina; Secci, Barbara; Loddo, Roberta] Univ Cagliari, Dipartimento Sci & Tecnol Biomed, I-09042 Cagliari, Italy.
RP Spallarossa, A (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto 15 3, I-16132 Genoa, Italy.
EM andrea.spallarossa@unige.it; placolla@unica.it
RI Loddo, Roberta/B-9038-2011; La Colla , Paolo /B-8587-2011
OI Sanna, Giuseppina/0000-0002-3999-4263
FU MURST (Cofinanziamento Nazionale); CNR (Rome); Ministero Italiano della
   Salute - Istituto Superiore di Sanita [40D.46]; Fondazione Banca Carige
FX This work was supported by MURST (Cofinanziamento Nazionale), CNR (Rome)
   and Ministero Italiano della Salute - Istituto Superiore di Sanita
   (grant no 40D.46). Fondazione Banca Carige is gratefully acknowledged
   for financially supporting SC. The authors thank Mr. O. Gagliardo for
   the microanalyses, Mr. F. Tuberoni, Dr. C. Rossi and Dr. R. Raggio for
   the IR and NMR spectra.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Campanelli AR, 2000, STRUCT CHEM, V11, P155, DOI 10.1023/A:1009213726034                                                         
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Carocci A, 2000, TETRAHEDRON-ASYMMETR, V11, P3619, DOI 10.1016/S0957-4166(00)00332-3                                                   
   Castro HC, 2006, CURR MED CHEM, V13, P313, DOI 10.2174/092986706775476089                                                      
   Cesarini S, 2008, BIOORGAN MED CHEM, V16, P4160, DOI 10.1016/j.bmc.2007.12.050
   Cesarini S, 2008, BIOORGAN MED CHEM, V16, P4173, DOI 10.1016/j.bmc.2007.12.046
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464
   D'Cruz OJ, 2006, J ENZYM INHIB MED CH, V21, P329, DOI 10.1080/14756360600774413
   D'Cruz OJ, 2006, CURR HIV RES, V4, P329, DOI 10.2174/157016206777709519
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106
   Dong YH, 2000, BIOORG MED CHEM LETT, V10, P87, DOI 10.1016/S0960-894X(99)00581-8                                                   
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1                                                   
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Hogberg M, 1999, J MED CHEM, V42, P4150, DOI 10.1021/jm990095j
   Hogberg M, 2000, BIOORG MED CHEM LETT, V10, P265, DOI 10.1016/S0960-894X(99)00675-7
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   La Regina G, 2007, J MED CHEM, V50, P5034, DOI 10.1021/jm070488f
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Ranise A, 2005, J MED CHEM, V48, P3858, DOI 10.1021/jm049252r
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   Rao A, 2002, FARMACO, V57, P747, DOI 10.1016/S0014-827X(02)01268-5
   Rao Angela, 2004, Farmaco (Lausanne), V59, P33, DOI 10.1016/j.farmac.2003.09.001
   Ravichandran V, 2007, BIOORG MED CHEM LETT, V17, P2197, DOI 10.1016/j.bmcl.2007.01.103
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   Ren JS, 2000, J BIOL CHEM, V275, P14316, DOI 10.1074/jbc.275.19.14316
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   Shaw-Reid CA, 2005, BIOCHEMISTRY-US, V44, P1595, DOI 10.1021/bi0486740
   Sluis-Cremer N, 2004, CURR HIV RES, V2, P323, DOI 10.2174/1570162043351093
   Spallarossa A, 2008, BIOCHEM BIOPH RES CO, V365, P764, DOI 10.1016/j.bbrc.2007.11.036
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Uckun FM, 2007, ARZNEIMITTEL-FORSCH, V57, P164
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Venkatachalam TK, 2004, BIOORGAN MED CHEM, V12, P4275, DOI 10.1016/j.bmc.2004.04.050
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
NR 48
TC 17
Z9 18
U1 0
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD APR
PY 2009
VL 44
IS 4
BP 1650
EP 1663
DI 10.1016/j.ejmech.2008.09.024
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 429KT
UT WOS:000264920000031
PM 18954921
DA 2018-01-05
ER

PT J
AU Fakes, MG
   Vakkalagadda, BJ
   Qian, F
   Desikan, S
   Gandhi, RB
   Lai, CJ
   Hsieh, A
   Franchini, MK
   Toale, H
   Brown, J
AF Fakes, Michael G.
   Vakkalagadda, Blisse J.
   Qian, Feng
   Desikan, Sridhar
   Gandhi, Rajesh B.
   Lai, Chiajen
   Hsieh, Alice
   Franchini, Miriam K.
   Toale, Helen
   Brown, Jonathan
TI Enhancement of oral bioavailability of an HIV-attachment inhibitor by
   nanosizing and amorphous formulation approaches
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE BCS Class-II; HIV-attachment inhibitor; Spray drying; Amorphous;
   Nanosuspension; Spray-dried intermediate (SDI); BMS-488043
ID PARTICLE-SIZE REDUCTION; WATER-SOLUBLE DRUGS; SOLID DISPERSIONS; STATE;
   CRYSTALLIZATION; INDOMETHACIN; DISSOLUTION; DELIVERY; DANAZOL; SYSTEMS
AB BMS-488043 is an HIV-attachment inhibitor that exhibited suboptimal oral bioavailability upon using conventional dosage forms prepared utilizing micronized crystalline drug substance. BMS-488043 is classified as a Biopharmaceutics Classification System (BCS) Class-II compound with a poor aqueous solubility of 0.04 mg/mL and an acceptable permeability of 178 nm/s in the Caco2 cell-line model. Two strategies were evaluated to potentially enhance the oral bioavailability of BMS-488043. The first strategy targeted particle size reduction through nanosizing the crystalline drug substance. The second strategy aimed at altering the drug's physical form by producing an amorphous drug. Both strategies provided an enhancement in oral bioavailability in dogs as compared to a conventional formulation containing the micronized crystalline drug substance. BMS-488043 oral bioavailability enhancement was similar to 5- and 9-folds for nanosizing and amorphous formulation approaches, respectively. The stability of the amorphous coprecipitated drug prepared at different compositions of BMS-488043/polyvinylpyrrolidone (PVP) was evaluated upon exposure to stressed stability conditions of temperature and humidity. The drastic effect of exposure to humidity on conversion of the amorphous drug to crystalline form was observed. Additionally, the dissolution behavior of coprecipitated drug was evaluated under discriminatory conditions of different pH values to optimize the BMS-488043/PVP composition and produce a stabilized, amorphous BMS-488043/PVP (40/60, w/w) spray-dried intermediate (SDI), which was formulated into an oral dosage form for further development and evaluation. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Fakes, Michael G.; Qian, Feng; Desikan, Sridhar; Gandhi, Rajesh B.; Hsieh, Alice] Bristol Myers Squibb, Biopharmaceut R&D, New Brunswick, NJ 08903 USA.
   [Vakkalagadda, Blisse J.] Bristol Myers Squibb, Discovery Med & Clin Pharmacol, Princeton, NJ 08543 USA.
   [Lai, Chiajen] Bristol Myers Squibb, PR&D Engn Technol, New Brunswick, NJ 08903 USA.
   [Toale, Helen; Brown, Jonathan] Bristol Myers Squibb, Biopharmaceut R&D, Moreton CH46 1QW, England.
RP Fakes, MG (reprint author), Bristol Myers Squibb, Biopharmaceut R&D, 1 Squibb Dr,POB 191, New Brunswick, NJ 08903 USA.
EM michael.fakes@bms.com
RI Sanguansri, Luz/B-6630-2011
OI Sanguansri, Luz/0000-0003-1908-7604
CR Castagna A, 2005, DRUGS, V65, P879, DOI 10.2165/00003495-200565070-00001
   Chen XX, 2004, J PHARM SCI-US, V93, P1867, DOI 10.1002/jps.20001                                                               
   COLONNO R, 2004, 13 INT S HIV ENG INF
   Crowley KJ, 2001, THERMOCHIM ACTA, V380, P79, DOI 10.1016/S0040-6031(01)00662-1                                                   
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   FUKUOKA E, 1989, CHEM PHARM BULL, V37, P1047
   Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896                                                               
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   Hu JH, 2004, DRUG DEV IND PHARM, V30, P233, DOI 10.1081/DDC-120030422
   Kaushal Aditya Mohan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P133, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
   Keck CM, 2006, EUR J PHARM BIOPHARM, V62, P3, DOI 10.1016/j.ejpb.2005.05.009
   Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003
   Law D, 2004, J PHARM SCI-US, V93, P563, DOI 10.1002/jps.10566
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   LIVERSIDGE GG, 1995, INT J PHARM, V125, P91, DOI 10.1016/0378-5173(95)00122-Y
   LIVERSIDGE GG, 1995, INT J PHARM, V125, P309, DOI 10.1016/0378-5173(95)00148-C
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Sarsfield B.A., 2006, POWDER XRAY DIFFRACT, P322
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   Sethia S, 2003, CRIT REV THER DRUG, V20, P215, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.40                                   
   YOSHIOKA M, 1995, J PHARM SCI, V84, P983, DOI 10.1002/jps.2600840814
   YOSHIOKA M, 1994, J PHARM SCI, V83, P1700, DOI 10.1002/jps.2600831211
NR 23
TC 61
Z9 63
U1 3
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAR 31
PY 2009
VL 370
IS 1-2
BP 167
EP 174
DI 10.1016/j.ijpharm.2008.11.018
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 425WX
UT WOS:000264669600023
PM 19100319
DA 2018-01-05
ER

PT J
AU Avilov, SV
   Godet, J
   Piemont, E
   Mely, Y
AF Avilov, Sergiy V.
   Godet, Julien
   Piemont, Etienne
   Mely, Yves
TI Site-Specific Characterization of HIV-1 Nucleocapsid Protein Binding to
   Oligonucleotides with Two Binding Sites
SO BIOCHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACID-CHAPERONE ACTIVITY; ZINC-FINGER;
   REVERSE TRANSCRIPTION; STRUCTURAL DETERMINANTS; RECOGNITION ELEMENT;
   INFECTION PROCESSES; DNA-SYNTHESIS; CTAR DNA; IN-VITRO
AB The nucleocapsid protein (NC) of HIV-1 is a highly conserved protein essential for the virus life cycle that constitutes an attractive target for new antiviral agents. Most NC functions rely on its binding to the HIV-1 genomic RNA and its DNA copies that contain multiple and possibly interdependent binding sites. Therefore, a detailed understanding of NC binding requires a site-specific experimental approach. We have recently shown that 2-aminopurine (2Ap), a fluorescent adenine analogue, can site-selectively probe the binding of NC. Here, we introduced 2Ap at various positions of model single-stranded dodecanucleotides containing two TG motifs which constitute putative specific binding sites. Steady-state and time-resolved fluorescence experiments indicated that NC binding strongly increased the fluorescence quantum yield of 2AP by reducing the dynamic quenching of 2Ap by its close neighbors and slowing the picosecond to nanosecond conformational fluctuations of the oligonucleotides. The dodecanucleotides were found to bind two NC molecules at physiological salt concentrations, confirming the preferential binding of NC to TG motifs and an occluded binding site size for NC of five to six bases. Using the NC-induced changes in 2Ap fluorescence, we determined the microscopic affinity constants of the individual binding sites and showed that affinities can significantly differ from one site to another within the same dodecanucleotide, depending on the position of the TG dinucleotide and the nature of its close neighbors. Moreover, our data suggest that binding of NC even to close binding sites shows no strong cooperativity.
C1 [Avilov, Sergiy V.; Godet, Julien; Piemont, Etienne; Mely, Yves] Univ Strasbourg, Lab Biophoton & Pharmacol, CNRS, UMR 7213,Fac Pharm, F-67401 Illkirch Graffenstaden, France.
   [Avilov, Sergiy V.] AV Palladin Biochem Inst, UA-01030 Kiev, Ukraine.
RP Mely, Y (reprint author), Univ Strasbourg, Lab Biophoton & Pharmacol, CNRS, UMR 7213,Fac Pharm, 74 Route Rhin, F-67401 Illkirch Graffenstaden, France.
EM mely@pharma.u-strasbg.fr
RI Godet, Julien/A-7250-2015; Avilov, Sergiy/A-2904-2012
OI Godet, Julien/0000-0002-8470-0092; 
FU Agence Nationale de Recherches sur le SIDA (ANRS); European consortium
   'Targeting Replication and integration of HIV'; Fondation pour la
   Recherche Medicale, France
FX The study was supported by Agence Nationale de Recherches sur le SIDA
   (ANRS) and the European consortium 'Targeting Replication and
   integration of HIV'. S.V.A. was a fellow of Fondation pour la Recherche
   Medicale, France.
CR ALDOVINI A, 1990, J VIROL, V64, P1920
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Avilov SV, 2008, NUCLEIC ACIDS RES, V36, P885, DOI 10.1093/nar/gkm1109
   Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024
   Beltz H, 2005, J MOL BIOL, V348, P1113, DOI 10.1016/j.jmb.2005.02.042
   Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019
   Ben G. N., 2005, NUCLEIC ACIDS RES, V33, P1031
   Bourbigot S, 2008, J MOL BIOL, V383, P1112, DOI 10.1016/j.jmb.2008.08.046
   Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003
   CLEVER J, 1995, J VIROL, V69, P2101
   Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070
   D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210
   Darlix J L, 2000, Adv Pharmacol, V48, P345
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   de Rocquigny H, 2008, MINI-REV MED CHEM, V8, P24
   DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006
   DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0
   DORFMAN T, 1993, J VIROL, V67, P6159
   Egele C, 2004, J MOL BIOL, V342, P453, DOI 10.1016/j.jmb.2004.07.059
   Egele C, 2007, BIOCHEMISTRY-US, V46, P14650, DOI 10.1021/bi7012239
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Fisher RJ, 1998, J VIROL, V72, P1902
   Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003
   Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629
   GORELICK RJ, 1990, J VIROL, V64, P3207
   GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015
   Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000                                                
   Hagan N, 2003, BIOCHEMISTRY-US, V42, P10736, DOI 10.1021/bi0348922
   Jean JM, 2004, BIOCHEMISTRY-US, V43, P10277, DOI 10.1021/bi049701p
   KARPEL RL, 1987, J BIOL CHEM, V262, P4961
   KHAN R, 1994, J BIOL CHEM, V269, P22538
   Krishnamoorthy G, 2003, NUCLEIC ACIDS RES, V31, P5425, DOI 10.1093/nar/gkg738
   Lakowicz J. R., 1999, PRINCIPLES FLUORESCE
   Larsen OFA, 2001, BIOPHYS J, V81, P1115, DOI 10.1016/S0006-3495(01)75768-2                                                   
   Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6
   MELY, 1995, J BIOL CHEM, V270, P1650
   MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011
   Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d
   MORELLET N, 1992, EMBO J, V11, P3059
   Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098
   Nag N., 2006, REV FLUORESCENCE, P311
   OTTMANN M, 1995, J VIROL, V69, P1778
   Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n
   Ramboarina S, 1999, BIOCHEMISTRY-US, V38, P9600, DOI 10.1021/bi9905258
   Ramreddy T, 2007, J PHYS CHEM B, V111, P5757, DOI 10.1021/jp068818f
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Spriggs S, 2008, BIOCHEMISTRY-US, V47, P13064, DOI 10.1021/bi8014373
   Stote RH, 2004, BIOCHEMISTRY-US, V43, P7687, DOI 10.1021/bi036137u
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520
   Thomas JA, 2008, VIRUS RES, V134, P39, DOI 10.1016/j.virusres.2007.12.006
   Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521                                                          
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   WARD DC, 1969, J BIOL CHEM, V244, P1228
   XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027
   YOU JC, 1993, J BIOL CHEM, V268, P16519
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 59
TC 23
Z9 23
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 24
PY 2009
VL 48
IS 11
BP 2422
EP 2430
DI 10.1021/bi8022366
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 420EW
UT WOS:000264272700016
PM 19186983
DA 2018-01-05
ER

PT J
AU Kim, BC
   Ju, MK
   Dan-Chin-Yu, A
   Sommer, P
AF Kim, Byoung Chan
   Ju, Moon Kyeong
   Dan-Chin-Yu, Alexey
   Sommer, Peter
TI Quantitative Detection of HIV-1 Particles Using HIV-1 Neutralizing Anti
   body-Conjugated Beads
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; P24 ANTIGEN; RT-PCR; ANTIBODIES;
   INFECTION; RNA; DIAGNOSIS; PLASMA; SERUM; PROTEINS
AB The human immunodeficiency virus (HIV) pandemic mainly affects developing countries, where the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates suggest that less than 1 in 10 people are aware of their HIV sero-status. In order to enhance epidemiological surveys, prevention programs, and therapeutic interventions, development of specific, rapid, and convenient diagnostic detection systems is still warranted. Here we report the direct detection of HIV particles using broadly HIV-1 neutralizing gp120 monoclonal antibody (gp120MAbs)-conjugated magnetic beads (MBs) and fluorescent nanosized polymeric beads (FNBs). The HIV-1 envelope glycoprotein gp120 is anchored to the viral surface through gp41 and mediates entry into target cells by interaction with the main cellular receptor (CD4) and coreceptors (e.g., CCR5 and CXCR4). FNBs conjugated to gp120MAbs (gp120MAbs-FNBs) were used to generate fluorescent signals, whereas MBs conjugated to gp120MAbs (gp120MAbs-MBs) were employed to isolate HIV-1 particles. In presence of HIV-1 particles, addition of gp120MAbs-FNBs and gp120MAbs-MBs leads to the formation of a MBs/HIV-1 particles/FNB complex, which can be easily isolated and concentrated by common magnet separation. We demonstrate the ability of detecting HIV-1 particles specifically and directly using MBs and FNBs with low sample volume (less than 100 mu L) and rapidity (less than 1.5 h) without any pretreatment of test samples. The specific binding of FNBs with HIV-1 particles on the surface of MBs was confirmed by fluorescence microscopy and fluorescence-activated cell sorting (FACS). Imaging and FACS analysis revealed the specific and quantitative detection of HIV-1 particles. These results provide proof-of-principle that broadly HIV-1 neutralizing gp120 antibodies coupled to nano-beads can be employed for the direct detection of HIV-1 particles with potential implication for the development of specific, rapid, and convenient diagnostic systems.
C1 [Kim, Byoung Chan; Dan-Chin-Yu, Alexey] Inst Pasteur Korea, Diagnost Grp, Seoul 136791, South Korea.
   [Ju, Moon Kyeong; Sommer, Peter] Inst Pasteur Korea, Cell Biol Retroviruses Grp, Seoul 136791, South Korea.
RP Kim, BC (reprint author), Inst Pasteur Korea, Diagnost Grp, 39-1 Hawolgok Dong, Seoul 136791, South Korea.
EM bckim@ip-korea.org
CR Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Chang WS, 2008, ANALYST, V133, P233, DOI 10.1039/b710997k
   Contreras-Galindo R, 2006, J VIROL METHODS, V136, P51, DOI 10.1016/j.jviromet.2006.03.029
   de Mendoza C, 2005, J VIROL METHODS, V127, P54, DOI 10.1016/j.jviromet.2005.03.013
   Deback C, 2008, J VIROL METHODS, V149, P285, DOI 10.1016/j.jviromet.2008.01.026
   Eggink D, 2007, TRENDS MICROBIOL, V15, P291, DOI 10.1016/j.tim.2007.05.006                                                       
   Fabris P, 2008, CURR HIV RES, V6, P173, DOI 10.2174/157016208783885029
   Hamatake M, 2007, J VIROL METHODS, V142, P113, DOI 10.1016/j.jviromet.2007.01.012
   Hashida S, 1997, J CLIN LAB ANAL, V11, P267, DOI 10.1002/(SICI)1098-2825(1997)11:5<267::AID-JCLA5>3.3.CO;2-T
   KOST TA, 1991, J VIROL, V65, P3276
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605
   Ott DE, 1997, REV MED VIROL, V7, P167, DOI 10.1002/(SICI)1099-1654(199709)7:3<167::AID-RMV199>3.3.CO;2-B
   Pai NP, 2007, EXPERT REV MOL DIAGN, V7, P325, DOI 10.1586/14737159.7.4.325
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Perletti G, 2004, J Cell Mol Med, V8, P142, DOI 10.1111/j.1582-4934.2004.tb00269.x
   Reynolds SJ, 2004, EXPERT REV MOL DIAGN, V4, P587, DOI 10.1586/14737159.4.5.587
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Schupbach J, 2003, INT ARCH ALLERGY IMM, V132, P196, DOI 10.1159/000074552
   STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4
   Triques K, 1999, J CLIN MICROBIOL, V37, P110
   Xiao L, 2008, BIOTECHNOL ADV, V26, P389, DOI 10.1016/j.biotechadv.2008.04.007
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
NR 25
TC 22
Z9 22
U1 1
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD MAR 15
PY 2009
VL 81
IS 6
BP 2388
EP 2393
DI 10.1021/ac802267u
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 418IN
UT WOS:000264142000047
PM 19222190
DA 2018-01-05
ER

PT J
AU Bedoya, LM
   Marquez, N
   Martinez, N
   Gutierrez-Eisman, S
   Alvarez, A
   Calzado, MA
   Rojas, JM
   Appendino, G
   Munoz, E
   Alcami, J
AF Bedoya, Luis M.
   Marquez, Nieves
   Martinez, Natalia
   Gutierrez-Eisman, Silvia
   Alvarez, Amparo
   Calzado, Marco A.
   Rojas, Jose M.
   Appendino, Giovanni
   Munoz, Eduardo
   Alcami, Jose
TI SJ23B, a jatrophane diterpene activates classical PKCs and displays
   strong activity against HIV in vitro
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE HIV-1 and latency reactivation; SJ23B; Prostratin and phorbol esters;
   Receptors down-regulation; NF-kappa B and PKC pathways
ID PROTEIN-KINASE-C; IMMUNODEFICIENCY-VIRUS REACTIVATION; BLOOD
   T-LYMPHOCYTES; NF-KAPPA-B; PHORBOL ESTERS; CELLULAR RESERVOIRS; VIRAL
   RESERVOIRS; INFECTION; PROSTRATIN; EXPRESSION
AB Existence of virus reservoirs makes the eradication of HIV infection extremely difficult. Current drug therapies neither eliminate these viral reservoirs nor prevent their formation. Consequently, new strategies are needed to target these reservoirs with the aim of decreasing their size. We analysed a series of jatrophane diterpenes isolated from Euphorbia hyberna and we found that one of them, SJ23B, induces the internalization of the HIV-1 receptors CD4, CXCR4 and CCR5 and prevents R5 and X4 viral infection in human primary T cells at the nanomolar range. Moreover, SJ23B is a potent antagonist of HIV-1 latency. Using Jurkat-LAT-GFP cells, a model for HIV-1 latency, we found that prostratin and SJ23B activate HIV-1 gene expression, with SJ23B being at least 10-fold more potent than prostratin. SJ23B did not elicit transforming foci activity in NIH 3T3 cells but is a potent activator of PKC alpha and delta as measured by in vitro kinase assays and by cellular translocation experiments. By using isoform-specific PKC inhibitors we found that cPKCs are critical for SJ23B-induced HIV-1 reactivation. We also showed that both SJ23B-induced I kappa B alpha degradation and NF-kappa B activation were inhibited by the classical PKC inhibitor, Go6976. Accordingly, SJ23B synergizes with ionomycin to translocate PKC alpha to the plasma membrane and to activate the NF-kappa B pathway. Moreover, SJ23B activates both NF-kappa B and Sp1-dependent transcriptional activities in primary T cells. We have shown that diterpene jatrophanes represent a new member of anti-AIDS agents that could be developed for mitigating HIV reactivation. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Bedoya, Luis M.; Alvarez, Amparo; Alcami, Jose] Inst Salud Carlos III, Ctra Majadahonda Pozuelo, Ctr Nacl Microbiol, Unidad Immunopatol SIDA, Madrid 28220, Spain.
   [Marquez, Nieves; Calzado, Marco A.; Munoz, Eduardo] Univ Cordoba, Fac Med, Dept Biol Celular Fisiol & Immunol, E-14004 Cordoba, Spain.
   [Martinez, Natalia; Gutierrez-Eisman, Silvia; Rojas, Jose M.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Madrid 28220, Spain.
   [Appendino, Giovanni] Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, I-28100 Novara, Italy.
RP Alcami, J (reprint author), Inst Salud Carlos III, Ctra Majadahonda Pozuelo, Ctr Nacl Microbiol, Unidad Immunopatol SIDA, Km 2, Madrid 28220, Spain.
EM ppalcami@isciii.es
RI Munoz, Eduardo/I-5225-2012; Calzado, Marco/E-9046-2016; Appendino,
   Giovanni/O-4832-2015; BEDOYA DEL OLMO, LUIS MIGUEL/I-5500-2016
OI Munoz, Eduardo/0000-0001-8478-5842; Calzado, Marco/0000-0002-5338-535X;
   Appendino, Giovanni/0000-0002-4170-9919; BEDOYA DEL OLMO, LUIS
   MIGUEL/0000-0001-6249-6847
FU Ministerio de Ciencia y Tecnologia [SAF2006-04247, SAF2004-04258,
   SAF0037-C04-01]; Ministerio de Sanidad y Consurno [ISCIII-INTRAMURAL
   03/ESP27, P10500017, ISCIII-RETIC RD06/0020]; Fondo de Investigacion
   Sanitaria [FIS-040614, PI040526]; Fundacion para la Investigacion y la
   Prevencion del Sida [FIPSE-36584]; junta de Andalucia [P06-CTS-01353];
   Spanish RIS Network; Red de Investigacion en SIDA [RD06-0006]
FX This work was supported by Ministerio de Ciencia y Tecnologia
   (SAF2006-04247, SAF2004-04258 and SAF0037-C04-01), Ministerio de Sanidad
   y Consurno (ISCIII-INTRAMURAL 03/ESP27, P10500017 and ISCIII-RETIC
   RD06/0020), Fondo de Investigacion Sanitaria (FIS-040614 and PI040526),
   Fundacion para la Investigacion y la Prevencion del Sida (FIPSE-36584),
   the junta de Andalucia (P06-CTS-01353) and by the Spanish RIS Network
   "Red de Investigacion en SIDA" (RD06-0006). We thank Centro de
   Transfusion de la Comunidad de Madrid for the supply of Buffy-coats.
   Prostratin was a generous gift from the AIDS Research Alliance (ARA).
   Finally, we thank Ms. Carmen CabreroDoncel for her assistance with the
   manuscript.
CR ADACHI A, 1986, J VIROL, V59, P284
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Appendino G, 2002, FITOTERAPIA, V73, P576, DOI 10.1016/S0367-326X(02)00213-7
   ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596
   Baryza JL, 2004, CHEM BIOL, V11, P1261, DOI 10.1016/j.chembiol.2004.06.014
   Bermejo M, 1998, EUR J IMMUNOL, V28, P3192
   Bocklandt S, 2003, ANTIVIR RES, V59, P89, DOI 10.1016/S0166-3542(03)00034-2
   Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001
   Corea G, 2003, J MED CHEM, V46, P3395, DOI 10.1021/jm030787e
   de Lera TL, 1999, ONCOGENE, V18, P1581
   Fraser C, 2000, AIDS, V14, P659, DOI 10.1097/00002030-200004140-00005
   Garcia-Perez J, 2007, J MED VIROL, V79, P127, DOI 10.1002/jmv.20770
   GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006
   Hamer DH, 2003, J VIROL, V77, P10227, DOI 10.1128/JVI.77.19.10227-10236.2003
   HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003
   Hezareh M, 2005, DRUG NEWS PERSPECT, V18, P496, DOI 10.1358/dnp.2005.18.8.944543
   HORNUNG RL, 1992, CANCER RES, V52, P101
   Jorge B, 2002, J BIOL CHEM, V277, P44171, DOI 10.1074/jbc.M204423200
   Kulkosky J, 2006, CURR HIV RES, V4, P199, DOI 10.2174/157016206776055084
   Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006
   Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5
   Marquez N, 2008, BIOCHEM PHARMACOL, V75, P1370, DOI 10.1016/j.bcp.2007.12.004
   Miglietta A, 2003, CANCER CHEMOTH PHARM, V51, P67, DOI 10.1007/s00280-002-0541-4
   Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200
   PHILIP PA, 1995, CONCEPTS MECH NEW TA, V3, P28
   Rullas J, 2004, ANTIVIR THER, V9, P545
   Shen L, 2008, J ALLERGY CLIN IMMUN, V122, P22, DOI 10.1016/j.jaci.2008.05.033
   Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511
   Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160
   Slater SJ, 1996, J BIOL CHEM, V271, P4627
   Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777
   SZALLASI Z, 1993, CANCER RES, V53, P2507
   Trushin SA, 2005, J VIROL, V79, P9821, DOI 10.1128/JVI.79.15.9821-9830.2005
   Tuthill MC, 2006, MOL CANCER THER, V5, P602, DOI 10.1158/1535-7163.MCT-05-0317
   Wang Qiming J., 2000, Journal of Biological Chemistry, V275, P12136, DOI 10.1074/jbc.275.16.12136
   Warrilow D, 2006, AIDS RES HUM RETROV, V22, P854, DOI 10.1089/aid.2006.22.854
   Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
NR 40
TC 40
Z9 42
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 15
PY 2009
VL 77
IS 6
BP 965
EP 978
DI 10.1016/j.bcp.2008.11.025
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 418PM
UT WOS:000264160500004
PM 19100719
DA 2018-01-05
ER

PT J
AU Dreesen, IAJ
   Luchinger, NA
   Stark, WJ
   Fussenegger, M
AF Dreesen, Imke A. J.
   Luechinger, Norman A.
   Stark, Wendelin J.
   Fussenegger, Martin
TI Tricalcium Phosphate Nanoparticles Enable Rapid Purification, Increase
   Transduction Kinetics, and Modify the Tropism of Mammalian Viruses
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE adeno-associated virus type 2 (AAV); adenovirus type 5; amorphous
   tricalcium phosphate nanoparticles (ATCP); gene therapy; human
   immunodeficiency virus type 1 (HIV-1); murine leukemia virus (MLV)
ID OF-THE-ART; GENE-THERAPY; VIRAL VECTORS; RETROVIRAL VECTORS;
   CALCIUM-PHOSPHATE; OVARIAN-CANCER; DRUG-DELIVERY; CELLS; EXPRESSION;
   COMPLEXATION
AB Adenoviral, adeno-associated viral, and retroviral particles are chosen as gene delivery shuttles in more than 50% of all gene therapy clinical trials. Bulk availability of clinical-grade viral particles and their efficiency to transduce the therapeutic cargo into specific target cells remain the most critical bottlenecks in gene therapy applications to date. Capitalizing on the flame-spray technology for the reproducible economic large-scale production of amorphous tricalcium phosphate nanoparticulate powders (ATCP), we designed a scalable ready-to-use gravity-flow column set-up for the straightforward concentration and purification of transgenic adenoviral, adeno-associated viral, and lentiviral particles. Specific elution buffers enabled rapid release of viral particles from the ATCP matrix of the column and provided high-titer virus preparations in an unsurpassed period of time. The interaction of ATCP with adenoviral, adeno-associated viral, and lentiviral particles in solution increased the transduction kinetics of several mammalian cell lines in culture. The nanoparticles were also able to modify the tropism of murine leukemia virus (MLV) towards transduction of human cells. Based on these findings, we believe that the use of flame-spray tricalcium phosphate nanoparticles will lead to important progress in the development Of future gene therapy initiatives.
C1 [Dreesen, Imke A. J.; Luechinger, Norman A.; Stark, Wendelin J.; Fussenegger, Martin] ETH, Inst Chem & Bioengn, HCI F115, CH-8093 Zurich, Switzerland.
RP Fussenegger, M (reprint author), ETH, Inst Chem & Bioengn, HCI F115, Wolfang Pauli Str 10, CH-8093 Zurich, Switzerland.
EM fussenegger@chen.ethz.ch
RI Stark, Wendelin/A-8680-2008
FU EC Framework 7 (Persist); Swiss National Science Foundation SNF
   [200021-116123/1]; Gerbert Ruf Foundation [GRS-48/04]
FX The authors thank David Fluri for providing AAV, Tobias Brunner for the
   preparation of tricalcium phosphate nanoparticles, Frank Krumeich for
   performing transmission electron microscopy and Marcia Schoenberg as
   well as Domenick Grasso and David Fluri for critical comments on the
   manuscript. This work was supported by the EC Framework 7 (Persist), the
   Swiss National Science Foundation SNF 200021-116123/1 and the Gerbert
   Ruf Foundation GRS-48/04.
CR Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037
   Andreas B, 1999, J HIGH ENERGY PHYS
   Billinge SJL, 2007, SCIENCE, V316, P1698
   Bonifazi D, 2007, ADV FUNCT MATER, V17, P1051, DOI 10.1002/adfm.200600586
   BRUNNER TJ, 2006, ENVIRON SCI TECHNOL, V40, P4373
   Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8
   Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Fischer A, 2004, M S-MED SCI, V20, P115, DOI 10.1051/medsci/2004201115
   Fluri DA, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-75
   Gonzalez-Nicolini V, 2005, J GENE MED, V7, P1573, DOI 10.1002/jgm.787
   Green AP, 2002, HUM GENE THER, V13, P1921, DOI 10.1089/10430340260355338
   Grimm D, 2003, MOL THER, V7, P839, DOI 10.1016/S1525-0016(03)00095-9
   Hou DZ, 2003, BIOMATERIALS, V24, P1781, DOI 10.1016/S0142-9612(02)00578-1
   Kamen A, 2004, J GENE MED, V6, pS184, DOI 10.1002/jgm.503
   Kohane DS, 2007, BIOTECHNOL BIOENG, V96, P203, DOI 10.1002/bit.21301
   Landazuri N, 2004, J GENE MED, V6, P1304, DOI 10.1002/jgm.618
   Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110
   Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o
   Link N, 2007, BIOTECHNOL BIOENG, V98, P1083, DOI 10.1002/bit.21525
   Loher S, 2005, CHEM MATER, V17, P36, DOI 10.1021/cm048776c
   McTaggart S, 2002, BIOTECHNOL ADV, V20, P1, DOI 10.1016/S0734-9750(01)00087-8
   Merten OW, 2004, J GENE MED, V6, pS105, DOI 10.1002/jgm.499
   Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Murthy SK, 2007, INT J NANOMED, V2, P129
   Patwardhan SV, 2002, J INORG ORGANOMET P, V12, P49, DOI 10.1023/A:1021250131231                                                         
   Pham L, 2001, J GENE MED, V3, P188, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM159>3.0.CO;2-9
   Reiser J, 2000, GENE THER, V7, P910, DOI 10.1038/sj.gt.3301188
   Rice E, 1998, J PERINAT NEONAT NUR, V12, P16, DOI 10.1097/00005237-199812000-00004                                                
   Rocconi RP, 2005, CURR GENE THER, V5, P643, DOI 10.2174/156652305774964668
   Segura MD, 2006, BIOTECHNOL ADV, V24, P321, DOI 10.1016/j.biotechadv.2005.12.001
   Stark WJ, 2002, POWDER TECHNOL, V126, P103, DOI 10.1016/S0032-5910(02)00077-3                                                   
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Wickramasinghe SR, 2005, BIOTECHNOL BIOENG, V92, P199, DOI 10.1002/bit.20599
   Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zufferey R, 2002, CURR TOP MICROBIOL, V261, P107
NR 38
TC 7
Z9 7
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD MAR 1
PY 2009
VL 102
IS 4
BP 1197
EP 1208
DI 10.1002/bit.22157
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 404EZ
UT WOS:000263135000023
PM 18979539
DA 2018-01-05
ER

PT J
AU Couvreur, P
AF Couvreur, Patrick
TI "Squalenoylation" : a new approach to the design of anticancer and
   antiviral nanomedicines
SO BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE
LA French
DT Article
DE SQUALENE; NANOPARTICLES; NANOMEDICINE; NUCLEOSIDES; DISEASE
   TRANSMISSION; GEMCITABINE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS
ID GEMCITABINE; BIOSYNTHESIS
AB Some nucleoside analogs display significant activity against malignancies (gemcitabine, cytarabine) or viruses (ddI, ddC, AZT) by interfering with DNA synthesis. However, their use is limited by their relatively poor intracellular diffusion, rapid metabolism and induction of resistance. We have discovered that linking nucleoside analogs to squalene produces amphiphilic molecules that self-organize in water as nanoassemblies of 100-300 nm, irrespective of the nucleoside analog used. Gemcitabine nanoassemblies exhibited far greater activity than free gemcitabine against both subcutaneously grafted solid tumors (L1210 and P388) and aggressive metastatic leukemia (leukemia L1210 wt, P388 and RNK-16 LGL). Likewise, squalenated ddI and ddC nanoassemblies were more efficient than free ddI and ddC against HIV-infected lymphocytes. It is of prime importance to unravel the supramolecular organization of these nanoassemblies. For example, it has been shown that squalenated gemcitabine nanoassemblies form inverted hexagonal phases.
C1 Univ Paris Sud, F-92296 Chatenay Malabry, France.
RP Couvreur, P (reprint author), Univ Paris Sud, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
RI COUVREUR, Patrick/G-4844-2011
OI COUVREUR, Patrick/0000-0001-7961-5443
CR ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491                                                        
   BEKKARAAOUNALLA.F, 2008, ADV FUNCT M IN PRESS
   BLONGIN GA, 1966, COMP BIOCHEM PHYSIOL, V17, P391, DOI 10.1016/0010-406X(66)90576-7
   Couvreur P, 2008, SMALL, V4, P247, DOI 10.1002/smll.200700731
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   OURISSON G, 1994, J PLANT PHYSIOL, V143, P434, DOI 10.1016/S0176-1617(11)81803-1                                                   
   Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002
   Reddy LH, 2008, DRUG METAB DISPOS, V36, P1570, DOI 10.1124/dmd.108.020735
   Reddy LH, 2008, J NANOPART RES, V10, P887, DOI 10.1007/s11051-007-9322-7
   Reddy LH, 2008, J PHARMACOL EXP THER, V325, P484, DOI 10.1124/jpet.107.133751
   Reddy LH, 2007, J CONTROL RELEASE, V124, P20, DOI 10.1016/j.jeonrel.2007.08.018
   COUVREUR P, Patent No. 2005050488
NR 12
TC 4
Z9 4
U1 0
U2 5
PU ACAD NATL MEDECINE
PI PARIS 06
PA 16 RUE BONAPARTE, 75272 PARIS 06, FRANCE
SN 0001-4079
J9 B ACAD NAT MED PARIS
JI Bull. Acad. Natl. Med.
PD MAR
PY 2009
VL 193
IS 3
BP 663
EP 673
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 501XZ
UT WOS:000270419100018
PM 19883017
DA 2018-01-05
ER

PT J
AU Li, X
   Breukers, C
   Ymeti, A
   Lunter, B
   Terstappen, LWMM
   Greve, J
AF Li, Xiao
   Breukers, Christian
   Ymeti, Aurel
   Lunter, Bjorn
   Terstappen, Leon W. M. M.
   Greve, Jan
TI CD4 and CD8 Enumeration for HIV Monitoring in Resource-Constrained
   Settings
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article
DE single platform; image cytometer; CD4 and CD8 enumeration; HIV
   monitoring; immunomagnetic separation; immunofluorescent labeling;
   point-of-care
ID PLATFORM IMAGE CYTOMETER; T-LYMPHOCYTE; ANTIRETROVIRAL THERAPY; POOR
   SETTINGS; CELL COUNTS; SINGLE; INFECTION; AIDS
AB Background: We developed a volumetric single platform image cytometer (SP ICM) that is dedicated to count CD4(+) and CD8(+) T lymphocytes for HIV monitoring in resource-constrained settings. The instrument was designed to be low-cost, yet reliable, easy-to-use, and robust.
   Methods: Whole blood is incubated with CD3-magnetic nanoparticles, CD4-phycoerythrin (PE), and CD8-peridinin-chlorophyll-protein complex (PerCP). The CD3 cells are immunomagnetically attracted to an analysis surface, where fluorescence images of CD4(+) and CD8(+) T lymphocytes are recorded and analyzed, respectively. We compared CD4, CD8 counts, and CD4/CD8 ratio obtained by the SP ICM with those from a SP flow cytometer (FCM) tetraCXP method on blood samples from 145 patients.
   Results: Good correlations were obtained (R: 0.96-0.99) between the SP ICM and the SP FCM. There was similar to 10% CD8 undercount in the SP ICM, which could be partly caused by CD8(+dim) T lymphocytes that were not detected by the instrument or not counted by the image analysis due to the cross-talk from the CD4-PE signal in the CD8-PerCP image.
   Conclusions: The SP ICM is a good candidate for HIV monitoring in point-of-care settings of resource-constrained countries. (C) 2008 Clinical Cytometry Society
C1 [Li, Xiao; Breukers, Christian; Ymeti, Aurel; Lunter, Bjorn; Terstappen, Leon W. M. M.; Greve, Jan] Univ Twente, Fac Sci & Technol, Med Cell Biophys Grp, NL-7500 AE Enschede, Netherlands.
RP Terstappen, LWMM (reprint author), Univ Twente, Fac Sci & Technol, Med Cell Biophys Grp, Bldg Zuidhorst,Drienerlolaan 5, NL-7500 AE Enschede, Netherlands.
EM l.w.m.m.terstappen@utwente.nl
FU STW, The Dutch Technology Foundation [TGT.6146]
FX Grant sponsor: STW, The Dutch Technology Foundation; Grant number:
   TGT.6146.
CR Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0
   Barnett D, 1999, BRIT J HAEMATOL, V106, P1059
   BLAND JM, 1986, LANCET, V1, P307
   CDC, 1981, MMWR-MORBID MORTAL W, V30, P3
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Department of Health and Human Services (DHHS), 2005, GUID US ANT AG HIV 1
   GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8
   Gulzar N, 2004, CURR HIV RES, V2, P23, DOI 10.2174/1570162043485077
   Janeway C. A., 2005, IMMUNOBIOLOGY
   Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x
   Janossy G, 2003, CLIN APPL IMMUNOL RE, V4, P91
   Li X, 2007, CYTOM PART B-CLIN CY, V72B, P397, DOI 10.1002/cyto.b.20165
   Li X, 2007, CLIN VACCINE IMMUNOL, V14, P412, DOI 10.1128/CVI.00372-06
   Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003
   O'Gorman MRG, 2008, CYTOM PART B-CLIN CY, V74B, pS19, DOI 10.1002/cyto.b.20398
   OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002
   Pattanapanyasat K, 2007, CYTOM PART B-CLIN CY, V72B, P387, DOI 10.1002/cyto.b.20167
   POLLOCK MA, 1992, ANN CLIN BIOCHEM, V29, P556, DOI 10.1177/000456329202900512                                                      
   Rasband W. S, 1997, IMAGEJ
   Reimann KA, 2000, CLIN DIAGN LAB IMMUN, V7, P344, DOI 10.1128/CDLI.7.3.344-351.2000
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Tibbe AGJ, 2002, CYTOMETRY, V47, P163, DOI 10.1002/cyto.10060
   *UNAIDS WHO, 2006, UNAIDS0629E WHO
   Whitby L, 2002, CYTOMETRY, V50, P102, DOI 10.1002/cyto.10094
   Ymeti A, 2007, CYTOM PART A, V71A, P132, DOI 10.1002/cyto.a.20375
   ZIJENAH LS, 2005, J TRANSL MED, V3, P6, DOI DOI 10.1186/1479-5876-3-6
   2001, CI CIDSE POL WORKSH
   DROOG EJ, 2003, Patent No. 03069421
NR 28
TC 9
Z9 9
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4949
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD MAR
PY 2009
VL 76B
IS 2
BP 118
EP 126
DI 10.1002/cyto.b.20445
PG 9
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 412WP
UT WOS:000263755200007
PM 18825776
OA gold
DA 2018-01-05
ER

PT J
AU Gopi, H
   Cocklin, S
   Pirrone, V
   McFadden, K
   Tuzer, F
   Zentner, I
   Ajith, S
   Baxter, S
   Jawanda, N
   Krebs, FC
   Chaiken, IM
AF Gopi, Hosahudya
   Cocklin, Simon
   Pirrone, Vanessa
   McFadden, Karyn
   Tuzer, Ferit
   Zentner, Isaac
   Ajith, Sandya
   Baxter, Sabine
   Jawanda, Navneet
   Krebs, Fred C.
   Chaiken, Irwin M.
TI Introducing metallocene into a triazole peptide conjugate reduces its
   off-rate and enhances its affinity and antiviral potency for HIV-1 gp120
SO JOURNAL OF MOLECULAR RECOGNITION
LA English
DT Article; Proceedings Paper
CT 17th Biennial Meeting of the
   International-Society-for-Molecular-Recognition
CY JUL 08-12, 2007
CL New York, NY
SP Int Soc Mole Recognit
DE HIV-1 gp120; entry inhibitors; peptide triazoles; surface plasmon
   resonance; cell infection
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; ENTRY INHIBITORS;
   CD4 RECEPTOR; BINDING-SITE; ANTIBODY; FUSION; MINIPROTEIN; MOTIF; GP41
AB In this work, we identified a high affinity and potency metallocene-containing triazole peptide conjugate that suppresses the interactions of HIV-1 envelope gp120 at both its CD4 and co-receptor binding sites. The ferrocene-peptide conjugate, HNG-156, was formed by an on-resin copper-catalysed [2 + 3] cycloaddition reaction. Surface plasmon resonance interaction analysis revealed that, compared to a previously reported phenyl-containing triazole conjugate HNG-105 (105), peptide 156 had a higher direct binding affinity for several subtypes of HIV-1 gp120 due mainly to the decreased dissociation rate of the conjugate-gp120 complex. The ferrocene triazole conjugate bound to gp 120 of both clade A (92UG037-08) and clade B (YU-2 and SF162) virus subtypes with nanomolar K-D in direct binding and inhibited the binding of gp120 to soluble CD4 and to antibodies that bind to HIV-1(YU-2) gp120 at both the CD4 binding site and CD4-induced binding sites. HNG-156 showed a close-to nanomolar IC50 for inhibiting cell infection by HIV-1(BaL) whole virus. The dual receptor site antagonist activity and potency of HNG-156 make it a promising viral envelope inhibitor lead for developing anti-HIV-1 treatments. Copyright (c) 2008 John Wiley & Sons, Ltd.
C1 [Gopi, Hosahudya; Cocklin, Simon; McFadden, Karyn; Tuzer, Ferit; Zentner, Isaac; Ajith, Sandya; Baxter, Sabine; Jawanda, Navneet; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Pirrone, Vanessa; Krebs, Fred C.] Drexel Univ, Coll Med, Inst Mol Med & Infect Dis, Dept Microbiol & Immunol, Philadelphia, PA 19102 USA.
   [Pirrone, Vanessa; Krebs, Fred C.] Drexel Univ, Coll Med, Inst Mol Med & Infect Dis, Ctr Mol Therapeut, Philadelphia, PA 19102 USA.
RP Chaiken, IM (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
EM ichaiken@drexelmed.edu
FU PHS HHS [P0156550]; NIAID NIH HHS [R21 AI071965, R21 AI 071965, U01
   AI067854, U01 AI067854-02]
CR Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542
   Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06
   DeMarco SJ, 2006, BIOORGAN MED CHEM, V14, P8396, DOI 10.1016/j.bmc.2006.09.003
   Dowd CS, 2002, BIOCHEMISTRY-US, V41, P7038, DOI 10.1021/bi012168i
   Ferrer M, 1999, J VIROL, V73, P5795
   Gallo SA, 2006, J BIOL CHEM, V281, P18787, DOI 10.1074/jbc.M602422200
   GOPI H, 2008, J MED CHEM
   Gopi HN, 2006, CHEMMEDCHEM, V1, P54, DOI 10.1002/cmdc.200500037
   ISHINO P, 2006, BIOCHEMISTRY-US, V45, P1106
   Ketas TJ, 2007, VIROLOGY, V364, P431, DOI 10.1016/j.virol.2007.03.001
   Krebs FC, 1999, ANTIVIR RES, V43, P157, DOI 10.1016/S0166-3542(99)00044-3
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   McFadden K, 2007, PROTEINS, V67, P617, DOI 10.1002/prot.21295
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Munk C, 2003, AIDS RES HUM RETROV, V19, P875, DOI 10.1089/088922203322493049
   Pancera M, 2005, J VIROL, V79, P9954, DOI 10.1128/JVI.79.15.9954-9969.2005
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Steckbeck JD, 2005, J VIROL, V79, P12311, DOI 10.1128/JVI.79.19.12311-12320.200
   Trkola A, 1996, J VIROL, V70, P1100
   Tsibris AMN, 2007, ANNU REV MED, V58, P445, DOI 10.1146/annurev.med.58.080105.102908
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Vita C, 1999, P NATL ACAD SCI USA, V96, P13091, DOI 10.1073/pnas.96.23.13091
   WHO/UNAIDS, 2006, AIDS EP UPD
   Yuan W, 2006, J VIROL, V80, P6725, DOI 10.1128/JVI.00118-06
   Zhang MY, 2007, CURR PHARM DESIGN, V13, P203, DOI 10.2174/138161207779313669                                                      
   Zhang MY, 2003, J IMMUNOL METHODS, V283, P17, DOI 10.1016/j.jim.2003.07.003
   Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
NR 31
TC 26
Z9 27
U1 1
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0952-3499
J9 J MOL RECOGNIT
JI J. Mol. Recognit.
PD MAR-APR
PY 2009
VL 22
IS 2
SI SI
BP 169
EP 174
DI 10.1002/jmr.892
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 410GV
UT WOS:000263566400016
PM 18498083
OA green_accepted
DA 2018-01-05
ER

PT J
AU Buch, I
   Brooks, BR
   Wolfson, HJ
   Nussinov, R
AF Buch, Idit
   Brooks, Bernard R.
   Wolfson, Haim J.
   Nussinov, Ruth
TI Computational Validation of Protein Nanotubes
SO NANO LETTERS
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; SURFACTANT-LIKE PEPTIDES; SELF-ASSEMBLY
   PATHWAYS; HIV-1 CAPSID PROTEIN; NANOSTRUCTURE DESIGN; BUILDING-BLOCKS;
   CYCLIC-PEPTIDES; MONTE-CARLO; NANOSCALE; DOMAIN
AB We present a novel generic computational method to assess protein nanotubes with variable diameter sizes at the atomic level given their low resolution protomeric structures. The method is based on the symmetrical assembly of a repeating protein subunit into a nanotube. Given the protein unit-cell, and the tube diameter and helicity, we carry out all-atom molecular dynamics simulations, combined with a unique mathematical transformation. This allows us to mimic nanotubes of even huge sizes without end or edge effects. All our simulation setups attempt to explicitly adhere to the conditions under which the experiments were conducted. Thus, we are able to obtain high resolution atomic-scale structures at reasonable computational costs. We expect that our approach would prove useful in assessing protein nanotubes, as well as in silico constructions of novel nanobiomaterials.
C1 [Buch, Idit; Nussinov, Ruth] Tel Aviv Univ, Sackler Fac Med, Sch Comp Sci,Sackler Inst Mol Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.
   [Brooks, Bernard R.] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA.
   [Nussinov, Ruth] NCI, SAIC Frederick Inc, Ctr Canc Res Nanobiol Program, Frederick, MD 21702 USA.
   [Wolfson, Haim J.] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), Tel Aviv Univ, Sackler Fac Med, Sch Comp Sci,Sackler Inst Mol Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.
EM ruthn@ncifcrf.gov
RI Wolfson, Haim/A-1837-2011
FU National Cancer Institute; NIH [NO1-CO-12400]; National Heart, Lung and
   Blood Institute
FX We thank Barbie K. Ganser-Pornillos for providing the atomic model of
   the HIV-1 CA hexamer. We also thank Chung-Jung Tsai, Dan Fishelovitch,
   Nurit Haspel, Tim Miller, Richard Venable, Ehud Gazit, and Ruth Arav for
   fruitful discussions and support. This project has been funded in part
   with Federal funds from the National Cancer Institute, NIH, under
   contract number NO1-CO-12400. This research was supported in part by the
   Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer Research, and the National Heart, Lung and Heart
   Institute. The content of this publication does not necessarily reflect
   the views or policies of the Department of Health and Human Services,
   nor does mention of trade names, commercial products, or organizations
   imply endorsement by the U.S. government.
CR Adams DJ, 2007, LANGMUIR, V23, P12729, DOI 10.1021/la7011183
   Andre I, 2007, P NATL ACAD SCI USA, V104, P17656, DOI 10.1073/pnas.0702626104
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Catte A, 2008, BIOPHYS J, V94, P2306, DOI 10.1529/biophysj.107.115857
   Chirikjian GS, 2005, J MECH DESIGN, V127, P695, DOI 10.1115/1.1901706                                                               
   Colombo G, 2007, TRENDS BIOTECHNOL, V25, P211, DOI 10.1016/j.tibtech.2007.03.004
   Ehrlich LS, 2001, BIOPHYS J, V81, P586, DOI 10.1016/S0006-3495(01)75725-6                                                   
   Favrin G, 2004, BIOPHYS J, V87, P3657, DOI 10.1529/biophysj.104.046839
   Ferrari M, 2005, CURR OPIN CHEM BIOL, V9, P343, DOI 10.1016/j.cbpa.2005.06.001
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1                                                   
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004
   GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0
   Ghosh S, 2007, ANGEW CHEM INT EDIT, V46, P2002, DOI 10.1002/anie.200604383
   Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231
   Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999
   Haspel N, 2006, STRUCTURE, V14, P1137, DOI 10.1016/j.str.2006.05.016
   Horne WS, 2003, J AM CHEM SOC, V125, P9372, DOI 10.1021/ja034358h
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Irback A, 2008, PROTEINS, V71, P207, DOI 10.1002/prot.21682
   Jagannathan K, 2002, BIOPHYS J, V83, P1902, DOI 10.1016/S0006-3495(02)73954-4                                                   
   Jang H, 2007, BIOPHYS J, V93, P1938, DOI 10.1529/biophysj.107.110148
   Khurana E, 2006, J PHYS CHEM B, V110, P18965, DOI 10.1021/jp057471y
   Klein ML, 2008, SCIENCE, V321, P798, DOI 10.1126/science.1157834
   Li S, 2000, NATURE, V407, P409
   Ma BY, 2002, P NATL ACAD SCI USA, V99, P14126, DOI 10.1073/pnas.212206899                                                          
   Pidaparti RM, 2007, J NANOSCI NANOTECHNO, V7, P4248, DOI 10.1166/jnn.2007.863
   Rosenthal-Aizman K, 2004, J AM CHEM SOC, V126, P3372, DOI 10.1021/ja0372659
   Schatz GC, 2007, P NATL ACAD SCI USA, V104, P6885, DOI 10.1073/pnas.0702187104
   Schwartz R, 1998, BIOPHYS J, V75, P2626, DOI 10.1016/S0006-3495(98)77708-2                                                   
   Shih AY, 2007, J STRUCT BIOL, V157, P579, DOI 10.1016/j.jsb.2006.08.006
   Sitharam M, 2006, J COMPUT BIOL, V13, P1232, DOI 10.1089/cmb.2006.13.1232
   Speelman B, 2001, BIOPHYS J, V80, P121, DOI 10.1016/S0006-3495(01)75999-1                                                   
   Tarek M, 2003, BIOPHYS J, V85, P2287, DOI 10.1016/S0006-3495(03)74653-0
   Tsai CJ, 2006, PLOS COMPUT BIOL, V2, P311, DOI 10.1371/journal.pcbi.0020042
   Tsai CJ, 2007, PROTEINS, V68, P1, DOI 10.1002/prot.21413
   Tsonchev S, 2004, NANO LETT, V4, P427, DOI 10.1021/nl0351439
   Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599
   Wei GH, 2004, BIOPHYS J, V87, P3648, DOI 10.1529/biophysj.104.047688
   Wong HC, 2008, BIOCHEMISTRY-US, V47, P2289, DOI 10.1021/bi7022128
   Zanuy D, 2003, BIOPHYS J, V84, P1884, DOI 10.1016/S0006-3495(03)74996-0                                                   
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
NR 43
TC 3
Z9 3
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD MAR
PY 2009
VL 9
IS 3
BP 1096
EP 1102
DI 10.1021/nl803521j
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 418IO
UT WOS:000264142100032
PM 19199488
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ham, AS
   Cost, MR
   Sassi, AB
   Dezzutti, CS
   Rohan, LC
AF Ham, Anthony S.
   Cost, Marilyn R.
   Sassi, Alexandra B.
   Dezzutti, Charlene S.
   Rohan, Lisa Cencia
TI Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable
   Nanoparticles
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE drug delivery; HIV-1 prevention; microbicide; nanoparticles; PSC-RANTES
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY; LANGERHANS CELLS;
   CONTROLLED-RELEASE; IN-VIVO; PLGA NANOPARTICLES; ENTRY INHIBITORS;
   MOLECULAR-WEIGHT; MICROSPHERES; TRANSMISSION
AB Nanoparticles formulated from the biodegradable co-polymer poly(lactic-co-glycolic acid) (PLGA), were investigated as a drug delivery system to enhance tissue uptake, permeation, and targeting for PSC-RANTES anti-HIV-1 activity.
   PSC-RANTES nanoparticles formulated via a double emulsion process and characterized in both in vitro and ex vivo systems to determine PSC-RANTES release rate, nanoparticle tissue permeation, and anti-HIV bioactivity.
   Spherical, monodisperse (PDI = 0.098 +/- 0.054) PSC-RANTES nanoparticles (d = 256.58 +/- 19.57 nm) with an encapsulation efficiency of 82.23 +/- 8.35% were manufactured. In vitro release studies demonstrated a controlled release profile of PSC-RANTES (71.48 +/- 5.25% release). PSC-RANTES nanoparticle maintained comparable anti-HIV activity with unformulated PSC-RANTES in a HeLa cell-based system with an IC(50) of approximately 1pM. In an ex vivo cervical tissue model, PSC-RANTES nanoparticles displayed a fivefold increase in tissue uptake, enhanced tissue permeation, and significant localization at the basal layers of the epithelium over unformulated PSC-RANTES.
   These results indicate that PSC-RANTES can readily be encapsulated into a PLGA nanoparticle drug delivery system, retain its anti-HIV-1 activity, and deliver PSC-RANTES to the target tissue. This is crucial for the success of this drug candidate as a topical microbicide product.
C1 [Ham, Anthony S.; Cost, Marilyn R.; Dezzutti, Charlene S.; Rohan, Lisa Cencia] Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
   [Ham, Anthony S.; Sassi, Alexandra B.; Rohan, Lisa Cencia] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [Dezzutti, Charlene S.; Rohan, Lisa Cencia] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA.
RP Rohan, LC (reprint author), Magee Womens Res Inst, 204 Craft Ave B509, Pittsburgh, PA 15213 USA.
EM rsilcr@mwri.magee.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
FU National Institute of Allergy and Infectious Diseases (NIAID) at the
   National Institute of Health [AI-51649]; Pendleton Charitable Trust;
   Irene McLenahan Young Investigator Research Fellowship
FX The work presented was supported through grants from the National
   Institute of Allergy and Infectious Diseases (NIAID) at the National
   Institute of Health (AI-51649, Principle Investigator: Michael Lederman,
   Case Western Reserve University), the Pendleton Charitable Trust Fund,
   and the Irene McLenahan Young Investigator Research Fellowship. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIAID. We would like to
   thank the Department of Material Sciences and Engineering of the
   University of Pittsburgh for the provision of access to the electron
   microscopy instrumentation and for assistance with the execution of this
   part of the study.
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Bilati U, 2003, PHARM DEV TECHNOL, V8, P1, DOI 10.1081/PDT-120017517
   BODMEIER R, 1989, INT J PHARM, V51, P1, DOI 10.1016/0378-5173(89)90068-9
   Castellanos IJ, 2005, J PHARM PHARMACOL, V57, P1261, DOI 10.1211/jpp.57.10.0004
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Coester C, 2006, EUR J PHARM BIOPHARM, V62, P306, DOI 10.1016/j.ejpb.2005.09.009
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Cummins JE, 2003, J CLIN MICROBIOL, V41, P4081, DOI 10.1128/JCM.41.9.4081-4088.2003
   Dailey LA, 2006, TOXICOL APPL PHARM, V215, P100, DOI 10.1016/j.tapp2.006.01.016
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Fahrbach KM, 2007, J VIROL, V81, P6858, DOI 10.1128/JVI.02472-06
   Feng SS, 2004, EXPERT REV MED DEVIC, V1, P115, DOI 10.1586/17434440.1.1.115                                                        
   Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1079/pnas.0402874101
   Gaertner H, 2008, BIOCONJUGATE CHEM, V19, P480, DOI 10.1021/bc7900304
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   Harrison PF, 2003, CLIN INFECT DIS, V36, P1290, DOI 10.1086/374834
   Hartley O, 2004, P NATL ACAD SCI USA, V101, P16460, DOI 10.1073/pnas.0404802101
   Heffernan MJ, 2005, BIOCONJUGATE CHEM, V16, P1340, DOI 10.1021/bc050176w
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Kawamura T, 2000, J EXP MED, V192, P1491, DOI 10.1084/jem.192.10.1491
   Kawamura T, 2005, J DERMATOL SCI, V40, P147, DOI 10.1016/j.jdermsci.2005.08.009
   Kawamura T, 2004, J VIROL, V78, P7602, DOI 10.1128/JVI.78.14.7602-7609.2004                                                
   Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052                                                    
   Lamprecht A, 1999, INT J PHARM, V184, P97, DOI 10.1016/S0378-5173(99)00107-6                                                   
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   Moench TR, 2001, AIDS, V15, P1595, DOI 10.1097/00002030-200109070-00001
   Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060                                                                
   Mosier DE, 1999, J VIROL, V73, P3544
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168-3659(02)00320-6
   Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785
   NORVELL MK, 1984, J REPROD MED, V29, P269
   Oh JE, 1999, J CONTROL RELEASE, V57, P269, DOI 10.1016/S0168-3659(98)00123-0
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Panyam J, 2003, INT J PHARM, V262, P1, DOI 10.1016/S0378-5173(03)00295-3
   PARK TG, 1995, BIOMATERIALS, V16, P1123, DOI 10.1016/0142-9612(95)93575-X
   Penco M, 1996, BIOMATERIALS, V17, P1583, DOI 10.1016/0142-9612(95)00323-1
   Peng T, 2006, J BIOMED MATER RES A, V76A, P163, DOI 10.1002/jbm.a.30550
   Pettit DK, 1997, PHARMACEUT RES, V14, P1422, DOI 10.1023/A:1012176823155                                                         
   Pool R, 2000, Cult Health Sex, V2, P197, DOI 10.1080/136910500300804
   Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478
   Roney C, 2005, J CONTROL RELEASE, V108, P193, DOI 10.1016/j.jconrel.2005.07.024
   Sassi AB, 2004, J PHARM SCI-US, V93, P2009, DOI 10.1002/jps.20107
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   SUONPAA M, 1992, J IMMUNOL METHODS, V149, P247, DOI 10.1016/0022-1759(92)90256-S
   Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000                                                
   TURPIN J, 2002, EXPERT OPIN INV DRUG, V11, P1007, DOI DOI 10.1517/13543784.11.8.1077
   UNAIDS and WHO, 2007, AIDS EP UPD
   Vangelista L, 2008, VACCINE, V26, P3008, DOI 10.1016/j.vaccine.2007.12.023
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9                                                   
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wells TNC, 1999, IMMUNOL LETT, V65, P35, DOI 10.1016/S0165-2478(98)00121-7                                                   
   Westedt U, 2007, J CONTROL RELEASE, V119, P41, DOI 10.1016/j.jconrel.2007.01.009
NR 59
TC 80
Z9 83
U1 1
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORD
JI Pharm. Res.
PD MAR
PY 2009
VL 26
IS 3
BP 502
EP 511
DI 10.1007/s11095-008-9765-2
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 403XZ
UT WOS:000263116600003
PM 19002569
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jin, YG
   Ai, P
   Xin, R
   Tian, Y
   Dong, JX
   Chen, DW
   Wang, W
AF Jin, Yiguang
   Ai, Ping
   Xin, Rui
   Tian, Ying
   Dong, Junxing
   Chen, Dawei
   Wang, Wei
TI Self-assembled drug delivery systems Part 3. In vitro/in vivo studies of
   the self-assembled nanoparticulates of cholesteryl acyl didanosine
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Degradation; Derivative; Didanosine; Nanoparticulates; Prodrugs;
   Self-assembly
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LIPOSOMAL FORMULATION; LYMPHATIC DELIVERY;
   RAT PLASMA; PRODRUGS; 2',3'-DIDEOXYINOSINE; PHARMACOKINETICS;
   HYDROLYSIS; TISSUE; HIV
AB Self-assembled drug delivery systems (SADDS) are defined as the self-assemblies of amphiphilic prodrugs, integrating prodrugs, molecular self-assembly and nanotechnology for drug targeting and controlled release. Cholesteryl-succinyl didanosine (CSD) and cholesteryl-adipoyl didanosine (CAD) nanoparticulate systems in water were previously prepared and optimized. In this paper, the in vitro and in vivo behavior of them was investigated. Precipitation occurred when they were mixed with acid solutions due to rapid production of hypoxanthine and subsequent disruption of supramolecular structures. They showed pH-dependent degradation and kept relatively stable in the neutral pH range. CSD is more stable than CAD due to the shorter spacer and poloxamer protection. CSD showed different degradation rates in various plasma with the descending order of rat, mouse, rabbit, dog and human. The half-life (t(1/2)) of CSD is 9 days in rat plasma, and 5.9 days in rat liver homogenates. CAD has a faster degradation than CSD though the t(1/2) in rat liver homogenates is long to 23 h. CSD nanoparticulates showed no significant anti-HIV effect in MT4 cell model because of very slow degradation. CSD nanoparticulates showed the distribution t(1/2) Of 7.6 min after bolus intravenous (i.v.) administration to rats, and the site-specific distribution in liver, lung and spleen with the high t(1/2) of 10 days in liver. The factors affecting achievement of successful SADDS are discussed. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Jin, Yiguang; Ai, Ping; Xin, Rui; Tian, Ying; Dong, Junxing] Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
   [Jin, Yiguang; Xin, Rui; Wang, Wei] Henan Univ, Pharmaceut Coll, Kaifeng 475000, Peoples R China.
   [Ai, Ping; Chen, Dawei] Shenyang Pharmaceut Univ, Shenyang 110016, Peoples R China.
RP Jin, YG (reprint author), Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
EM jin_yiguang@yahoo.com.cn
RI Jin, Yiguang/A-9306-2008; Jin, Yiguang/H-6742-2013
OI Jin, Yiguang/0000-0002-3528-1397
FU National Natural Science Foundation of China [30371700]; Beijing Natural
   Science Foundation [7053074]
FX This work was supported by the National Natural Science Foundation of
   China (30371700) and partly by Beijing Natural Science Foundation
   (7053074).
CR Aquaro S, 2000, ANTIMICROB AGENTS CH, V44, P173, DOI 10.1128/AAC.44.1.173-177.2000                                                   
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   BEKERS O, 1993, J PHARMACEUT BIOMED, V11, P489, DOI 10.1016/0731-7085(93)80162-T                                                    
   Bodor N, 2000, MED RES REV, V20, P58, DOI 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.3.CO;2-O
   Dipali SR, 1997, INT J PHARM, V152, P89, DOI 10.1016/S0378-5173(97)00070-7
   FAULDS D, 1992, DRUGS, V44, P94, DOI 10.2165/00003495-199244010-00008
   Goppert TM, 2005, EUR J PHARM BIOPHARM, V60, P361, DOI 10.1016/j.ejpb.2005.02.006
   Harvie P, 1996, ANTIMICROB AGENTS CH, V40, P225
   HASEGAWA T, 1994, CLIN PHARMACOKINET, V27, P331, DOI 10.2165/00003088-199427050-00001
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   IONESCU C, 2006, DRUG METABOLISM CURR
   Ishida T, 2002, BIOSCIENCE REP, V22, P197, DOI 10.1023/A:1020134521778
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jemal M, 1997, J CHROMATOGR B, V698, P123, DOI 10.1016/S0378-4347(97)00292-2                                                   
   Jin Y., 2008, PHARM MANUFACTURING, P1249
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Jin YG, 2005, COLLOID SURFACE B, V42, P45, DOI 10.1016/j.colsurfb.2005.02.001
   Jin YG, 2008, J COLLOID INTERF SCI, V326, P275, DOI 10.1016/j.jcis.2008.07.014
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   KANG HJK, 1994, BIOCHEM PHARMACOL, V48, P2109
   KAWAGUCHI T, 1992, CHEM PHARM BULL, V40, P1338
   KAWAGUCHI T, 1985, CHEM PHARM BULL, V33, P2956
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Manouilov KK, 1997, ANTIVIR RES, V34, P91, DOI 10.1016/S0166-3542(96)01023-6
   MINAGAWA T, 1995, BIOCHEM PHARMACOL, V49, P1361, DOI 10.1016/0006-2952(95)00071-7
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Morris-Natschke SL, 2003, CURR PHARM DESIGN, V9, P1441, DOI 10.2174/1381612033454702
   Natarajan R, 1996, BIOCHEM BIOPH RES CO, V225, P413, DOI 10.1006/bbrc.1996.1188
   Periti P, 2002, CLIN PHARMACOKINET, V41, P485, DOI 10.2165/00003088-200241070-00003
   Redhead HM, 2001, J CONTROL RELEASE, V70, P353, DOI 10.1016/S0168-3659(00)00367-9                                                   
   Ren S, 2008, INT J PHARMACEUT, V350, P197, DOI 10.1016/j.ijpharm.2007.08.035
   SHAO ZZ, 1994, PHARMACEUT RES, V11, P237, DOI 10.1023/A:1018903407592
   Stolnik S, 2001, BBA-BIOMEMBRANES, V1514, P261, DOI 10.1016/S0005-2736(01)00376-5                                                   
   Torchilin VP, 2006, NANOPARTICULATES DRU
NR 36
TC 17
Z9 19
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD FEB 23
PY 2009
VL 368
IS 1-2
BP 207
EP 214
DI 10.1016/j.ijpharm.2008.10.009
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 414ET
UT WOS:000263847400030
PM 19007871
DA 2018-01-05
ER

PT J
AU Radi, M
   Maga, G
   Alongi, M
   Angeli, L
   Samuele, A
   Zanoli, S
   Bellucci, L
   Tafi, A
   Casaluce, G
   Giorgi, G
   Armand-Ugon, M
   Gonzalez, E
   Este, JA
   Baltzinger, M
   Bec, G
   Dumas, P
   Ennifar, E
   Botta, M
AF Radi, Marco
   Maga, Giovanni
   Alongi, Maddalena
   Angeli, Lucilla
   Samuele, Alberta
   Zanoli, Samantha
   Bellucci, Luca
   Tafi, Andrea
   Casaluce, Gianni
   Giorgi, Gianluca
   Armand-Ugon, Mercedes
   Gonzalez, Emmanuel
   Este, Jose A.
   Baltzinger, Mireille
   Bec, Guillaume
   Dumas, Philippe
   Ennifar, Eric
   Botta, Maurizio
TI Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine
   (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors
   with High Activity Against Clinically Relevant Mutants
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID STRUCTURE-BASED DESIGN; NONNUCLEOSIDE INHIBITORS; MOLECULAR-DYNAMICS;
   STRUCTURAL BASIS; WILD-TYPE; ENANTIOSELECTIVE CYCLOPROPANATION; KINETIC
   CHARACTERIZATION; DRUG-RESISTANCE; DOCKING; SERIES
AB The role played by stereochemistry in the C2-substituent (left part) on the S-DABO scaffold for anti-HIV-1 activity has been investigated for the first time. A series of S-DABO analogues, where the double bond in the C2-substituent is replaced by an enantiopure isosteric cyclopropyl moiety, has been synthesized, leading to the identification of a potent lead compound endowed with picomolar activity against RT (wt) and nanomolar activity against selected drug-resistant mutants. Molecular modeling calculation, enzymatic studies, and surface plasmon resonance experiments allowed us to rationalize the biological behavior of the synthesized compounds, which act as mixed-type inhibitors of HIV-1 RT K103N, with a preferential association to the enzyme-substrate complex. Taken together, our data show that the right combination of stereochemistry on the left and right parts (C6-substituent) of the S-DABO scaffold plays a key role in the inhibition of both wild-type and drug-resistant enzymes, especially the K103N mutant.
C1 [Radi, Marco; Alongi, Maddalena; Angeli, Lucilla; Bellucci, Luca; Tafi, Andrea; Casaluce, Gianni; Botta, Maurizio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   [Maga, Giovanni; Samuele, Alberta; Zanoli, Samantha; Este, Jose A.] IGM CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Giorgi, Gianluca] Univ Siena, Dipartimento Chim, I-53100 Siena, Italy.
   [Armand-Ugon, Mercedes; Gonzalez, Emmanuel] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab irsiCaixa, E-08916 Badalona, Spain.
   [Bec, Guillaume; Dumas, Philippe; Ennifar, Eric] Univ Strasbourg, CNRS, UPR 9002, Architecture & Reactivite ARN, F-67084 Strasbourg, France.
   [Baltzinger, Mireille] Univ Strasbourg 1, CNRS, UMR 7175, Ecole Super Biotechnol Strasbourg, F-67400 Illkirch Graffenstaden, France.
RP Botta, M (reprint author), Univ Siena, Dipartimento Farmaco Chim Tecnol, Via Alcide Gasperi 2, I-53100 Siena, Italy.
EM botta@unisi.it
RI Maga, Giovanni/C-5409-2009; Este, Jose/B-5509-2008
OI Maga, Giovanni/0000-0001-8092-1552; Este, Jose/0000-0002-1436-5823;
   Armand-Ugon, Mercedes/0000-0002-4069-9915; Radi,
   Marco/0000-0002-0874-6697
FU European THiNC and ExCeIlENT-HIT Consortiums; The University of Siena
   and the Spanish [BFU2006-00966, FIS P1060624]; French National Agency
   for AIDS Research (ANRS); NIH [TMC-125]
FX This study was supported by grants from the European THiNC and
   ExCeIlENT-HIT Consortiums. The University of Siena and the Spanish
   BFU2006-00966 and FIS P1060624 are also acknowledged for financial
   support. S.Z. is the recipient of a Buzzati-Traverso Fellowship. This
   work was also supported by grants from the French National Agency for
   AIDS Research (ANRS) (to E.E.). The following reagent was obtained
   through the NIH AIDS Research and Reference Reagent Program, Division
   AIDS, MAID, NIH: TMC-125 (Etravifine), catalogue no. 11609, from Tibotec
   Pharmaceuticals, Inc. Prof. Gabfiele Cruciani (University of Perugia,
   Italy) is also acknowledged for kindly providing us with the GRID
   program.
CR Armand-Ugon M, 2003, ANTIVIR RES, V59, P137, DOI 10.1016/S0166-3542(03)00071-8
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barreiro G, 2007, J CHEM INF MODEL, V47, P2416, DOI 10.1021/ci700271z
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   Beroza P, 2000, DRUG DISCOV TODAY, V5, P364, DOI 10.1016/S1359-6446(00)01515-4                                                   
   Boone LR, 2006, CURR OPIN INVESTIG D, V7, P128
   Brito MA, 2008, J CHEM INF MODEL, V48, P1706
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Lano De, 2002, PYMOL MOL GRAPHICS S
   Denmark SE, 1997, J ORG CHEM, V62, P584, DOI 10.1021/jo961859v                                                               
   Denmark SE, 1997, J ORG CHEM, V62, P3390, DOI 10.1021/jo9702397                                                               
   DENMARK SE, 1991, J ORG CHEM, V56, P6974, DOI 10.1021/jo00025a007                                                             
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319
   FRISCH MJ, 2001, GUASSIAN 98 EVISION
   Geitmann M, 2006, J MED CHEM, V49, P2375, DOI 10.1021/jm0504050
   Geitmann M, 2006, J MED CHEM, V49, P2367, DOI 10.1021/jm0504048
   GREENEA WC, 2008, ANTIVIR RES IN PRESS
   Himmel DM, 2005, J MED CHEM, V48, P7582, DOI 10.1021/jm0500323
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034
   Kroeger Smith M B, 1995, Protein Sci, V4, P2203
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Mai A, 2007, J MED CHEM, V50, P5412, DOI 10.1021/jm070811e
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c
   *MOL DISC LTD, 2004, GRID VERS 22
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Nawrozkij MB, 2008, J MED CHEM, V51, P4641, DOI 10.1021/jm800340w
   Pata JD, 2004, P NATL ACAD SCI USA, V101, P10548, DOI 10.1073/pnas.0404151101                                                         
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Quaglia MG, 2001, CHIRALITY, V13, P75, DOI 10.1002/1520-636X(2001)13:2<75::AID-CHIR1001>3.0.CO;2-W                         
   Ragno R, 2005, J MED CHEM, V48, P200, DOI 10.1021/jm0493921
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   Saag M, 2007, 4 INT AIDS SOC C HIV
   Sheldrick G. M., 1997, SHELXL 97 RELEASE 97
   Sheldrick G. M, 1997, SHELXS 97 RELEASE 97
   Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739                                                        
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137                                                                
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   Botta M., 2007, [No title captured], Patent No. [WO/2007/043094, 2007043094]
NR 49
TC 37
Z9 39
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 12
PY 2009
VL 52
IS 3
BP 840
EP 851
DI 10.1021/jm801330n
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 404HN
UT WOS:000263142400027
PM 19140683
DA 2018-01-05
ER

PT J
AU Champagne, K
   Shishido, A
   Root, MJ
AF Champagne, Kelly
   Shishido, Akira
   Root, Michael J.
TI Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled
   Coil
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID VIRUS TYPE-1 FUSION; MEMBRANE-FUSION; POTENT INHIBITORS; TRANSMEMBRANE
   GLYCOPROTEIN; ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; ENTRY INHIBITOR;
   HELICAL DOMAIN; 6-HELIX BUNDLE; BINDING-SITE
AB Cellular entry of human immunodeficiency virus type 1 (HIV-1) involves fusion of viral and cellular membranes and is mediated by structural transitions in viral glycoprotein gp41. The antiviral C-peptide T20 targets the gp41 N-terminal heptad repeat region (N-HR), blocking gp41 conformational changes essential for the entry process. To probe the T20 structure-activity relationship, we engineered a molecular mimic of the entire gp41 N-HR coiled coil using the 5-Helix design strategy. T20 bound this artificial protein (denoted 5H-ex) with nanomolar affinity (K(D) = 30 nM), close to its IC(50) concentration (similar to 3 nM) but much weaker than the affinity of a related inhibitory C-peptide C37 (K(D) = 0.0007 nM). T20/C37 competitive binding assays confirmed that T20 interacts with the hydrophobic groove on the surface of the N-HR coiled coil outside of a deep pocket region crucial for C37 binding. We used 5H-ex to investigate how the T20 N and C termini contributed to the inhibitor binding activity. Mutating three aromatic residues at the T20 C terminus (WNWF -> ANAA) had no effect on affinity, suggesting that these amino acids do not participate in T20 binding to the gp41 N-HR. The results support recent evidence pointing to a different role for these residues in T20 inhibition (Peisajovich, S. G., Gallo, S. A., Blumenthal, R., and Shai, Y. (2003) J. Biol. Chem. 278, 21012-21017; Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., and Jiang, S. (2007) J. Biol. Chem. 282, 9612-9620). By contrast, mutations near the T20 N terminus substantially influenced inhibitor binding strength. When Ile was substituted for Thr in the second T20 position, a 40-fold increase in binding affinity was measured (K(D) = 0.75 nM). The effect of this affinity enhancement on T20 inhibitory potency varied among different viral strains. The original T20 and the higher affinity T20 variant had similar potency against wild type HIV-1. However, the higher affinity T20 variant was significantly more potent against T20-resistant virus. The findings suggest that other factors in addition to binding affinity play a role in limiting T20 potency. As a mimetic of the complete gp41 N-HR coiled coil region, 5H-ex will be a useful tool to further elucidate mechanistic profiles of C-peptide inhibitors.
C1 [Champagne, Kelly; Shishido, Akira; Root, Michael J.] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.
RP Root, MJ (reprint author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, 233 S 10th St,Rm 802, Philadelphia, PA 19107 USA.
EM mroot@mail.jci.tju.edu
FU National Institutes of Health [5-T32-DK0775, R01 GM66682]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants 5-T32-DK0775 (to K. C.) and R01 GM66682 (to M. J. R.). The
   costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be hereby marked
   "advertisement" in accordance with 18 U. S. C. Section 1734 solely to
   indicate this fact.
CR Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005
   Bellamy-Mclntyre AK, 2007, J BIOL CHEM, V282, P23104, DOI 10.1074/jbc.M703485200
   BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699                                                               
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   FENOUILLET E, 1995, J GEN VIROL, V76, P1509, DOI 10.1099/0022-1317-76-6-1509                                                     
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Hamburger AE, 2005, J BIOL CHEM, V280, P12567, DOI 10.1074/jbc.M412770200
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Liu SW, 2007, CURR PHARM DESIGN, V13, P143, DOI 10.2174/138161207779313722
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Lorizate M, 2006, BIOCHEMISTRY-US, V45, P14337, DOI 10.1021/bi0612521
   Lorizate M, 2006, J MOL BIOL, V360, P45, DOI 10.1016/j.jmb.2006.04.056
   Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Luftig MA, 2006, NAT STRUCT MOL BIOL, V13, P740, DOI 10.1038/nsmb1127
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Nameki D, 2005, J VIROL, V79, P764, DOI 10.1128/JVI.79.2.764-770.2005
   Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200
   Reeves JD, 2004, J VIROL, V78, P5476, DOI 10.1128/JVI.78.10.5476-5485.2004
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Rimsky LT, 1998, J VIROL, V72, P986
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Root MJ, 2003, P NATL ACAD SCI USA, V100, P5016, DOI 10.1073/pnas.0936926100
   Steger HK, 2006, J BIOL CHEM, V281, P25813, DOI 10.1074/jbc.M601457200
   Tallarida RJ., 2000, DRUG SYNERGISM DOSE, P1
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   WANG ZX, 1995, FEBS LETT, V360, P111, DOI 10.1016/0014-5793(95)00062-E
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wexler-Cohen Y, 2006, J BIOL CHEM, V281, P9005, DOI 10.1074/jbc.M512475200
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
NR 46
TC 36
Z9 39
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 6
PY 2009
VL 284
IS 6
BP 3619
EP 3627
DI 10.1074/jbc.M809269200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 400MO
UT WOS:000262872500030
PM 19073602
OA gold
DA 2018-01-05
ER

PT J
AU Zhu, RR
   Qin, LL
   Wang, M
   Wu, SM
   Wang, SL
   Zhang, R
   Liu, ZX
   Sun, XY
   Yao, SD
AF Zhu, R. R.
   Qin, L. L.
   Wang, M.
   Wu, S. M.
   Wang, S. L.
   Zhang, R.
   Liu, Z. X.
   Sun, X. Y.
   Yao, S. D.
TI Preparation, characterization, and anti-tumor property of
   podophyllotoxin-loaded solid lipid nanoparticles
SO NANOTECHNOLOGY
LA English
DT Article
ID ANTI-HIV ACTIVITY; DRUG-DELIVERY; AIDS AGENTS; IN-VITRO; DERIVATIVES;
   CYTOTOXICITY; SLN; PACLITAXEL; THERAPY; CELLS
AB In an effort to develop an alternative formulation of podophyllotoxin suitable for drug release and delivery, podophyllotoxin-loaded solid lipid nanoparticles (PPT-SLNs) were constructed, characterized and examined for in vitro cytotoxicity and tumor inhibition. The SLNs were prepared by using a solvent emulsification-evaporation method, and their size was around 50 nm. TEM detection showed that the SLNs were homogeneous and spherical in shape, and differential scanning calorimetry (DSC) measurement revealed a new conformation of PPT-SLNs. An in vitro drug release study showed that PPT was released from the SLNs in a slow but time-dependent manner. Furthermore, the treatment of 293T and HeLa cells with PPT-SLNs demonstrated that PPT-SLNs were less toxic to normal cells and more effective in anti-tumor potency compared with unconjugated PPT. A colony forming efficiency assay showed an effective long-term cancer growth suppression of PPT-SLNs; in addition, they can also enhance the apoptotic and cellular uptake processes on tumor cells compared with PPT. These results collectively demonstrated that this SLN formulation has a potential application as an alternative delivery system for anti-tumor drugs.
C1 [Zhu, R. R.; Qin, L. L.; Wang, M.; Wu, S. M.; Wang, S. L.; Zhang, R.; Liu, Z. X.; Sun, X. Y.; Yao, S. D.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
RP Wang, SL (reprint author), Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
EM wsl@mail.tongji.edu.cn
FU National Natural Science Foundation of China [50673078]; Shanghai
   Special Foundation [07DZ19603]; Shanghai Educational Development
   Foundation [2008CG26]; Program for Young Excellent Talents in Tongji
   University [2007KJ062]
FX The work was financially supported by the National Natural Science
   Foundation of China ( Grant no. 50673078), Shanghai Special Foundation (
   Grant no. 07DZ19603), Shanghai Educational Development Foundation (
   Grant no. 2008CG26), and Program for Young Excellent Talents in Tongji
   University (2007KJ062).
CR ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71
   Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011
   Canel C, 2000, PHYTOCHEMISTRY, V54, P115, DOI 10.1016/S0031-9422(00)00094-7
   Chen HB, 2006, J CONTROL RELEASE, V110, P296, DOI 10.1016/jjconrel.2005.09.052
   Chen SW, 2007, BIOORG MED CHEM LETT, V17, P2091, DOI 10.1016/j.bmcl.2006.11.070
   Choy JH, 2004, BIOMATERIALS, V25, P3059, DOI 10.1016/j.biomaterials.2003.09.083
   Gordaliza M, 2000, CURR PHARM DESIGN, V6, P1811, DOI 10.2174/1381612003398582                                                        
   GREENSPAN EM, 1950, J NATL CANCER I, V10, P1295
   Imbert TF, 1998, BIOCHIMIE, V80, P207, DOI 10.1016/S0300-9084(98)80004-7
   Kim JH, 2008, BIOMATERIALS, V29, P1920, DOI 10.1016/j.biomaterials.2007.12.038
   Lee CTL, 1997, BIOORG MED CHEM LETT, V7, P2897, DOI 10.1016/S0960-894X(97)10108-1                                                   
   Lee MK, 2007, BIOMATERIALS, V28, P2137, DOI 10.1016/j.biomaterials.2007.01.014
   Liu J, 2007, INT J PHARM, V340, P153, DOI 10.1016/j.ijpharm.2007.03.009
   Longstaff E, 2001, REGUL TOXICOL PHARM, V33, P117, DOI 10.1006/rtph.2000.1446
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller RH, 2002, ADV DRUG DELIV REV, V54, P131, DOI 10.1016/S0169-409X(02)00118-7
   Roberts JE, 2008, TOXICOL APPL PHARM, V228, P49, DOI 10.1016/j.taap.2007.12.010
   Suresh G, 2007, AAPS PHARMSCITECH, V8
   Uner M, 2006, PHARMAZIE, V61, P375
   Wissing SA, 2003, INT J PHARM, V254, P65, DOI 10.1016/S0378-5173(02)00684-1
   Yuan H, 2008, INT J PHARM, V348, P137, DOI 10.1016/j.ijpharm.2007.07.012
   Zhu XK, 2004, BIOORGAN MED CHEM, V12, P4267, DOI 10.1016/j.bmc.2004.04.048
NR 23
TC 31
Z9 32
U1 2
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD FEB 4
PY 2009
VL 20
IS 5
AR 055702
DI 10.1088/0957-4484/20/5/055702
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 393LV
UT WOS:000262375700030
PM 19417361
DA 2018-01-05
ER

PT J
AU Yu, X
   Wang, QM
   Yang, JC
   Buch, I
   Tsai, CJ
   Ma, BY
   Cheng, SZD
   Nussinov, R
   Zheng, J
AF Yu, Xiang
   Wang, Qiuming
   Yang, Jui-Chen
   Buch, Idit
   Tsai, Chung-Jung
   Ma, Buyong
   Cheng, Stephen Z. D.
   Nussinov, Ruth
   Zheng, Jie
TI Mutational Analysis and Allosteric Effects in the HIV-1 Capsid Protein
   Carboxyl-Terminal Dimerization Domain
SO BIOMACROMOLECULES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MOLECULAR-DYNAMICS; BUILDING-BLOCKS;
   ALZHEIMER A-BETA(17-42); NANOSTRUCTURE DESIGN; VIRION MORPHOGENESIS;
   CYCLOPHILIN-A; ASSOCIATION; SIMULATIONS; INHIBITOR
AB The carboxyl-terminal domain (CTD, residues 146-231) of the HIV-1 capsid (CA) protein plays an important role in the CA-CA dimerization and viral assembly of the human immunodeficiency virus type 1. Disrupting the native conformation of the CA is essential for blocking viral capsid formation and viral replication. Thus, it is important to identify the exact nature of the structural changes and driving forces of the CTD dimerization that take place in mutant forms. Here, we compare the structural stability, conformational dynamics, and association force of the CTD dimers for both wild-type and mutated sequences using all-atom explicit-solvent molecular dynamics (MD). The simulations show that Q155N and E159D at the major homology region (MHR) and W184A and M185A at the helix 2 region are energetically less favorable than the wild-type, imposing profound negative effects on intermolecular CA-CA dimerization. Detailed structural analysis shows that three mutants Q155N, E159D, and W184A) display much more flexible local structures and weaker CA-CA association than the wildtype, primarily due to the loss of interactions (hydrogen bonds, side chain hydrophobic contacts, and pi-stacking) with their neighboring residues. Most interestingly, the MHR that is far from the interacting dimeric interface is more sensitive to the mutations than the helix 2 region that is located at the CA-CA dimeric interface, indicating that structural changes in the distinct motif of the CA could similarly allosterically prevent the CA capsid formation. In addition, the structural and free energy comparison of the five residues shorter CA (151-231) dimer with the CA (146-231) dimer further indicates that hydrophobic interactions, side chain packing, and hydrogen bonds are the major, dominant driving forces in stabilizing the CA interface.
C1 [Tsai, Chung-Jung; Ma, Buyong; Nussinov, Ruth] NCI, Nanobiol Program, Ctr Canc Res, SAIC Frederick Inc,Basic Res Program, Frederick, MD 21702 USA.
   [Yu, Xiang; Wang, Qiuming; Yang, Jui-Chen] Univ Akron, Dept Chem & Biomol Engn, Akron, OH 44325 USA.
   [Cheng, Stephen Z. D.] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Buch, Idit; Nussinov, Ruth] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), NCI, Nanobiol Program, Ctr Canc Res, SAIC Frederick Inc,Basic Res Program, Frederick, MD 21702 USA.
EM ruthn@ncifcrf.gov; zhengj@uakron.edu
RI Ma, Buyong/F-9491-2011; Yu, Xiang/A-9765-2012; Wang,
   Qiuming/E-6254-2014; Zheng, Jie/B-5057-2013
OI Ma, Buyong/0000-0002-7383-719X; Yu, Xiang/0000-0002-0486-1110; Zheng,
   Jie/0000-0003-1547-3612
FU American Chemical Society Petroleum Research Fund [48188-G5]; Faculty
   Research Summer Fellowship; University of Akron; National Cancer
   Institute, National Institutes of Health [N01-CO-12400]; National Cancer
   Institute; Center for Cancer Research
FX This work is supported by American Chemical Society Petroleum Research
   Fund (48188-G5), Faculty Research Summer Fellowship, and Firestone
   Research Program at the University of Akron. This project has been
   funded in whole or in part with federal funds from the National Cancer
   Institute, National Institutes of Health, under Contract N01-CO-12400.
   This research was supported (in part) by the Intramural Research Program
   of the NIH, National Cancer Institute, Center for Cancer Research. The
   content of this publication does not necessarily reflect the views or
   policies of the Department of Health and Human Services, nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the U.S. Government.
CR Alcaraz LA, 2008, FEBS J, V275, P3299, DOI 10.1111/j.1742-4658.2008.06478.x
   Alcaraz LA, 2007, BIOPHYS J, V93, P1264, DOI 10.1529/biophysj.106.101089
   Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   BROOKS BR, 1983, J COMPUT CHEM, V4, P217
   Carlsson J, 2008, J MED CHEM, V51, P2648, DOI 10.1021/jm7012198
   Damm KL, 2008, BIOPOLYMERS, V89, P643, DOI 10.1002/bip.20993
   del Alamo M, 2003, J BIOL CHEM, V278, P27923, DOI 10.1074/jbc.M304466200
   Ding F, 2008, J AM CHEM SOC, V130, P7184, DOI 10.1021/ja800893d
   Douglas CC, 2004, BIOCHEMISTRY-US, V43, P10435, DOI 10.1021/bi049359g
   FRANKE EK, 1994, J VIROL, V68, P5300
   Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1                                                   
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004
   Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp                                                           
   Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231
   Haspel N, 2007, BIOPHYS J, V93, P245, DOI 10.1529/biophysj.106.100644
   Hornak V, 2006, J AM CHEM SOC, V128, P2812, DOI 10.1021/ja058211x
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Im W, 2003, BIOPHYS J, V85, P2900, DOI 10.1016/S0006-3495(03)74712-2                                                   
   Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Li S, 2000, NATURE, V407, P409
   Lidon-Moya MC, 2005, PROTEIN SCI, V14, P2387, DOI 10.1110/ps.041324305
   LIU J, 2007, P NATL ACAD SCI USA, V105, P901
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   MacKerell Alexander D. Jr., 2000, Biopolymers, V56, P257, DOI 10.1002/1097-0282(2000)56:4<257::AID-BIP10029>3.0.CO;2-W
   MAMMANO F, 1994, J VIROL, V68, P4927
   Reicin AS, 1996, J VIROL, V70, P8645
   Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964
   Sundquist WI, 2007, CELL, V131, P17, DOI 10.1016/j.cell.2007.09.028
   Tama F, 2005, J MOL BIOL, V345, P299, DOI 10.1016/j.jmb.2004.10.054
   Ternois F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967
   THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0
   TSAI, 2006, PLOS COMPUT BIOL, V2, pE42
   Tsai CJ, 2007, PROTEINS, V68, P1, DOI 10.1002/prot.21413
   Tsai CJ, 2006, TRENDS BIOTECHNOL, V24, P449, DOI 10.1016/j.tibtech.2006.08.004
   Verkhivker G, 2008, BIOPHYS J, V95, P550, DOI 10.1529/biophysj.107.127621
   William L.J., 1983, J CHEM PHYS, V79, P926, DOI DOI 10.1063/1.445869
   Zheng J, 2008, J PHYS CHEM B, V112, P6856, DOI 10.1021/jp711335b
   Zheng J, 2008, FRONT BIOSCI, V13, P3919, DOI 10.2741/2980
   Zheng J, 2008, BIOCHEMISTRY-US, V47, P2497, DOI 10.1021/bi7019194
   Zheng J, 2007, BIOPHYS J, V93, P3046, DOI 10.1529/biophysj.107.110700
   Zheng J, 2007, BIOCHEMISTRY-US, V46, P1205, DOI 10.1021/bi061674a
   Zheng J, 2006, BIOPHYS J, V91, P824, DOI 10.1529/biophysj.106.083246
NR 47
TC 13
Z9 13
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD FEB
PY 2009
VL 10
IS 2
BP 390
EP 399
DI 10.1021/bm801151r
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 405LM
UT WOS:000263226300025
PM 19199580
OA gold
DA 2018-01-05
ER

PT J
AU Mintzer, MA
   Simanek, EE
AF Mintzer, Meredith A.
   Simanek, Eric E.
TI Nonviral Vectors for Gene Delivery
SO CHEMICAL REVIEWS
LA English
DT Review
ID SOLID-LIPID NANOPARTICLES; IN-VITRO TRANSFECTION; LOW-MOLECULAR-WEIGHT;
   POLY-L-LYSINE; MODIFIED SILICA-NANOPARTICLES; HIV-1 TAT PROTEIN;
   CARBOHYDRATE-CONTAINING POLYCATIONS; POLY(PROPYLENE IMINE) DENDRIMERS;
   FUNCTIONALIZED CARBON NANOTUBES; SOLUBLE CARBOSILANE DENDRIMERS
C1 [Mintzer, Meredith A.; Simanek, Eric E.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
RP Simanek, EE (reprint author), Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
EM simanek@mail.chem.tamu.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
FU NSF [GK-12]; Robert A. Welch Foundation [A 1439]; N.I.H. [R01 GM 64560]
FX The authors wish to acknowledge the NSF GK-12 program for a pre-doctoral
   fellowship to M.A.M. and research support from the Robert A. Welch
   Foundation (A 1439) and N.I.H. (R01 GM 64560).
CR Aa M. A. E. M., 2007, PHARM RES, V24, P1590
   Aberle AM, 1998, BIOCHEMISTRY-US, V37, P6533, DOI 10.1021/bi9801154                                                               
   Ahn CH, 2002, J CONTROL RELEASE, V80, P273, DOI 10.1016/S0168-3659(01)00547-8                                                   
   Ahn CH, 2004, J CONTROL RELEASE, V97, P567, DOI 10.1016/j.jconrel.2004.04.002
   Aissaoui A, 2004, J MED CHEM, V47, P5210, DOI 10.1021/jm0408159
   Aissaoui A, 2002, CURR DRUG TARGETS, V3, P1, DOI 10.2174/1389450023348082                                                        
   Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Akinc A, 2002, BIOTECHNOL BIOENG, V78, P503, DOI 10.1002/bit.20215
   Akinc A, 2003, BIOCONJUGATE CHEM, V14, P979, DOI 10.1021/bc034067y
   Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Allcock HR, 1998, MACROMOLECULES, V31, P5255, DOI 10.1021/ma980211c                                                               
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Anderson WF, 1998, NATURE, V392, P25
   Aoyama Y, 2003, J AM CHEM SOC, V125, P3455, DOI 10.1021/ja029608t
   Arima H, 2001, BIOCONJUGATE CHEM, V12, P476, DOI 10.1021/bc000111n
   Arote R, 2007, BIOMATERIALS, V28, P735, DOI 10.1016/j.biomaterials.2006.09.028
   Asasutjarit R, 2007, PHARM RES, V24, P1098, DOI 10.1007/s11095-007-9234-3
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Azzam T, 2002, J MED CHEM, V45, P1817, DOI 10.1021/jm0105528
   Azzam T, 2002, MACROMOLECULES, V35, P9947, DOI 10.1021/ma0209592
   Bae YM, 2007, BIOCONJUGATE CHEM, V18, P2029, DOI 10.1021/bc070012a
   Balasubramaniam RP, 1996, GENE THER, V3, P163
   Banerjee R, 2001, J MED CHEM, V44, P4176, DOI 10.1021/jm000466a
   Barany-Wallje E, 2007, FEBS LETT, V581, P2389, DOI 10.1016/j.febslet.2007.04.046
   BARBUCCI R, 1981, MACROMOLECULES, V14, P1203, DOI 10.1021/ma50006a013                                                             
   Bayele HK, 2005, J PHARM SCI-US, V94, P446, DOI 10.1002/jps.20230
   Behr JP, 1997, CHIMIA, V51, P34
   BEHR JP, 1993, ACCOUNTS CHEM RES, V26, P274, DOI 10.1021/ar00029a008                                                             
   BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982
   Bell PC, 2003, J AM CHEM SOC, V125, P1551, DOI 10.1021/ja020707g
   Bellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
   Belmont P, 2002, J GENE MED, V4, P517, DOI 10.1002/jgm.297
   BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
   Bennett MJ, 1997, J MED CHEM, V40, P4069, DOI 10.1021/jm970155q
   Benns JM, 2000, BIOCONJUGATE CHEM, V11, P637, DOI 10.1021/bc0000177
   BENTZ J, 1985, P NATL ACAD SCI USA, V82, P5742, DOI 10.1073/pnas.82.17.5742                                                         
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102
   Bielinska AU, 1999, BIOCONJUGATE CHEM, V10, P843, DOI 10.1021/bc990036k
   Bielinska AU, 1997, BBA-GENE STRUCT EXPR, V1353, P180, DOI 10.1016/S0167-4781(97)00069-9
   Bikram M, 2005, J CONTROL RELEASE, V103, P221, DOI 10.1016/j.conrel.2004.11.011
   Bikram M, 2004, MACROMOLECULES, V37, P1903, DOI 10.1021/ma035650c
   Blessing T, 1998, J AM CHEM SOC, V120, P8519, DOI 10.1021/ja980620o                                                               
   BONNER WM, 1975, J CELL BIOL, V64, P421, DOI 10.1083/jcb.64.2.421
   Boomer JA, 2002, PHARMACEUT RES, V19, P1292, DOI 10.1023/A:1020342523694
   Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3                                                   
   Boulanger C, 2004, BIOCONJUGATE CHEM, V15, P901, DOI 10.1021/bc049942+
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638                                                              
   BRAUNLIN WH, 1982, BIOPOLYMERS, V21, P1301, DOI 10.1002/bip.360210704
   Brissault B, 2003, BIOCONJUGATE CHEM, V14, P581, DOI 10.1021/bc0200529
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Brus C, 2004, BIOCONJUGATE CHEM, V15, P677, DOI 10.1021/bc034160m
   BUHLEIER E, 1978, SYNTHESIS-STUTTGART, V155, P8
   BUIJNSTERS PJJ, 2002, B EUR J ORG CHEM, V139, P7
   Byk G, 2000, J MED CHEM, V43, P4377, DOI 10.1021/jm000284y
   Byk G, 1998, J MED CHEM, V41, P224, DOI 10.1021/jm9704964                                                               
   Cai D, 2005, NAT METHODS, V2, P449, DOI 10.1038/NMETH761
   CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39
   Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   Chabaud P, 2006, BIOCONJUGATE CHEM, V17, P466, DOI 10.1021/bc050162q
   Chan P, 2007, BIOMATERIALS, V28, P540, DOI 10.1016/j.biomaterials.2006.08.046
   CHEN AA, 2005, NUCL ACIDS RES, V33
   Chen HG, 2007, J MED CHEM, V50, P4269, DOI 10.1021/jm060128c
   Chen HH, 2008, MOL THER, V16, P324, DOI 10.1038/sj.mt.6300392
   Chen W, 2000, LANGMUIR, V16, P15, DOI 10.1021/la981429v                                                               
   Chen Yuxiang, 2003, Current Gene Therapy, V3, P273, DOI 10.2174/1566523034578339
   Cherng JY, 1996, PHARMACEUT RES, V13, P1038, DOI 10.1023/A:1016054623543
   Chittimalla C, 2005, J AM CHEM SOC, V127, P11436, DOI 10.1021/ja0522332
   Cho KC, 2005, MACROMOL BIOSCI, V5, P512, DOI 10.1002/mabi.200500018
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Choi JS, 2003, BIOCONJUGATE CHEM, V14, P420, DOI 10.1021/bc025625w
   Choi JS, 2001, BIOCONJUGATE CHEM, V12, P108, DOI 10.1021/bc000081o
   Choi SH, 2008, EUR J PHARM BIOPHARM, V68, P545, DOI 10.1016/j.ejpb.2007.07.011
   Choi YH, 1998, J CONTROL RELEASE, V54, P39, DOI 10.1016/S0168-3659(97)00174-0
   Choi YH, 1998, BIOCONJUGATE CHEM, V9, P708, DOI 10.1021/bc980017v
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   CHRISTOU P, 1988, PLANT PHYSIOL, V87, P671, DOI 10.1104/pp.87.3.671
   CHRISTOU P, 1990, TRENDS BIOTECHNOL, V8, P145, DOI 10.1016/0167-7799(90)90160-Y
   CHRISTOU P, 1989, P NATL ACAD SCI USA, V86, P7500, DOI 10.1073/pnas.86.19.7500
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Colin M, 2001, GENE THER, V8, P1643, DOI 10.1038/sj.gt.3301572
   Collins L, 2004, J GENE MED, V6, P185, DOI 10.1002/jgm.482
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142-9612(02)00507-0                                                   
   CROMWELL WC, 1985, J PHYS CHEM-US, V89, P326, DOI 10.1021/j100248a029                                                             
   CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850
   Dash PR, 1999, GENE THER, V6, P643, DOI 10.1038/sj.gt.3300843                                                           
   Dauty E, 2001, J AM CHEM SOC, V123, P9227, DOI 10.1021/ja015867r
   de Brabander-van den Berg E. M. M., 1993, ANGEW CHEM INT EDIT, V105, P1370
   DEBRABANDERVANDENBERG EMM, 1993, ANGEW CHEM INT EDIT, V32, P1308, DOI 10.1002/anie.199313081                                                          
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9                                                    
   Densmore CL, 1999, J GENE MED, V1, P251
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Desigaux L, 2007, P NATL ACAD SCI USA, V104, P16534, DOI 10.1073/pnas.0707431104
   DIMITRIADIS GJ, 1978, NUCLEIC ACIDS RES, V5, P1381, DOI 10.1093/nar/5.4.1381
   DIMITRIADIS GJ, 1978, NATURE, V274, P923, DOI 10.1038/274923a0                                                                
   Dom G, 2003, NUCLEIC ACIDS RES, V31, P556, DOI 10.1093/nar/gkg160
   DOMARD A, 1983, INT J BIOL MACROMOL, V5, P49, DOI 10.1016/0141-8130(83)90078-8
   DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572
   Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k
   Dubruel P, 2003, EUR J PHARM SCI, V18, P211, DOI 10.1016/S0928-0987(02)00280-4
   Dufes C, 2005, CANCER RES, V65, P8079, DOI 10.1158/0008-5472.CAN-04-4402
   Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095                                                          
   Edelstein ML, 2007, J GENE MED, V9, P833, DOI 10.1002/jgm.1100
   Edelstein ML, 2004, J GENE MED, V6, P597, DOI 10.1002/jgm.619
   Eom KD, 2007, PHARM RES, V24, P1581, DOI 10.1007/s11095-006-9231-y
   Erbacher P, 1998, PHARMACEUT RES, V15, P1332, DOI 10.1023/A:1011981000671
   ERITJA R, 1991, TETRAHEDRON, V47, P4113, DOI 10.1016/S0040-4020(01)86448-6
   Ewert K, 2002, J MED CHEM, V45, P5023, DOI 10.1021/jm020233w
   Ewert KK, 2006, BIOCONJUGATE CHEM, V17, P877, DOI 10.1021/bc050310c
   Ewert KK, 2006, J AM CHEM SOC, V128, P3998, DOI 10.1021/ja055907h
   Fabio K, 2005, BBA-GEN SUBJECTS, V1724, P203, DOI 10.1016/j.bbagen.2005.03.007
   FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0
   Ferrari S, 1997, GENE THER, V4, P1100, DOI 10.1038/sj.gt.3300503
   Ferruti P, 2000, MACROMOLECULES, V33, P7793, DOI 10.1021/ma000378h
   FERRUTI P, 1985, POLYMER, V26, P1336, DOI 10.1016/0032-3861(85)90309-X
   Ferruti P, 2007, BIOMACROMOLECULES, V8, P1498, DOI 10.1021/bm061126c
   Fielden ML, 2001, EUR J BIOCHEM, V268, P1269, DOI 10.1046/j.1432-1327.2001.01995.x                                                
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Floch V, 2000, J MED CHEM, V43, P4617, DOI 10.1021/jm000006z
   Floch V, 1998, BIOCHEM BIOPH RES CO, V251, P360, DOI 10.1006/bbrc.1998.9471
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRALEY R, 1980, J BIOL CHEM, V255, P431
   FRALEY RT, 1979, P NATL ACAD SCI USA, V76, P3348, DOI 10.1073/pnas.76.7.3348
   Franchini J, 2006, BIOMACROMOLECULES, V7, P1215, DOI 10.1021/bm060054m
   Fujiwara T, 2000, BBA-BIOMEMBRANES, V1468, P396, DOI 10.1016/S0005-2736(00)00278-9
   Fukushima S, 2005, J AM CHEM SOC, V127, P2810, DOI 10.1021/ja0440506
   FULLER WD, 1976, BIOPOLYMERS, V15, P1869, DOI 10.1002/bip.1976.360150922                                                      
   Funhoff AM, 2004, BIOCONJUGATE CHEM, V15, P1212, DOI 10.1021/bc049864q
   Funhoff AM, 2004, BIOMACROMOLECULES, V5, P32, DOI 10.1021/bm034041+
   Funhoff AM, 2004, PHARM RES, V21, P170, DOI 10.1023/B:PHAM.0000012165.68765.e6
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   GALLIOT C, 1995, J AM CHEM SOC, V117, P5470, DOI 10.1021/ja00125a006                                                             
   Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102
   Gao SY, 2003, INT J PHARM, V255, P57, DOI 10.1016/S0378-5173(03)00082-6
   Gao X, 1995, GENE THER, V2, P710
   GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K
   Gaucheron J, 2002, BIOCONJUGATE CHEM, V13, P671, DOI 10.1021/bc0101259
   Gaucheron J, 2001, BIOCONJUGATE CHEM, V12, P114, DOI 10.1021/bc000089y
   Gaucheron J, 2001, BIOCONJUGATE CHEM, V12, P949, DOI 10.1021/bc010033j
   Geall AJ, 1999, FEBS LETT, V459, P337, DOI 10.1016/S0014-5793(99)01262-4
   Gemeinhart RA, 2005, BIOTECHNOL PROGR, V21, P532, DOI 10.1021/bp049648w
   Germershaus O, 2008, J CONTROL RELEASE, V125, P145, DOI 10.1016/j.jconrel.2007.10.013
   Ghosh YK, 2002, BIOCONJUGATE CHEM, V13, P378, DOI 10.1021/bc010048h
   Ghosh YK, 2000, FEBS LETT, V473, P341, DOI 10.1016/S0014-5793(00)01558-1
   Gill DR, 1997, GENE THER, V4, P199, DOI 10.1038/sj.gt.3300391
   Godbey WT, 2000, J BIOMED MATER RES, V51, P321, DOI 10.1002/1097-4636(20000905)51:3<321::AID-JBM5>3.3.CO;2-I
   Godbey WT, 2001, BIOMATERIALS, V22, P471, DOI 10.1016/S0142-9612(00)00203-9
   Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q                 
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Goh SL, 2004, BIOCONJUGATE CHEM, V15, P467, DOI 10.1021/bc034159n
   Goncalves C, 2004, MOL THER, V10, P373, DOI 10.1016/j.ymthe.2004.05.023
   Gonzalez H, 1999, BIOCONJUGATE CHEM, V10, P1068, DOI 10.1021/bc990072j
   Gosselin MA, 2001, BIOCONJUGATE CHEM, V12, P989, DOI 10.1021/bc0100455
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Green JJ, 2006, BIOCONJUGATE CHEM, V17, P1162, DOI 10.1021/bc0600968
   GREGORIADIS G, 1977, NATURE, V265, P407, DOI 10.1038/265407a0
   Guenin E, 2000, ANGEW CHEM INT EDIT, V39, P629
   Guo X, 2003, ACCOUNTS CHEM RES, V36, P335, DOI 10.1021/ar9703241
   Guoi C, 2004, MOL PHARMACEUT, V1, P309, DOI 10.1021/mp049969a
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   GUYCAFFEY JK, 1995, N J BIOL CHEM, V270, P31391
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Han G, 2005, BIOCONJUGATE CHEM, V16, P1356, DOI 10.1021/bc050173j
   Han J, 2000, INT J PHARM, V202, P151, DOI 10.1016/S0378-5173(00)00441-5
   Han SO, 2001, BIOCONJUGATE CHEM, V12, P337, DOI 10.1021/bc000120w
   Harada A, 2006, BIOCONJUGATE CHEM, V17, P3, DOI 10.1021/bc0502863
   Harada A, 2001, EUR J PHARM SCI, V13, P35, DOI 10.1016/S0928-0987(00)00205-0
   HARALAMBIDIS J, 1987, TETRAHEDRON LETT, V28, P5199, DOI 10.1016/S0040-4039(00)95628-4
   Hasegawa S, 2002, BIOORG MED CHEM LETT, V12, P1299, DOI 10.1016/S0960-894X(02)00119-1
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   Hashimoto M, 2006, BIOCONJUGATE CHEM, V17, P309, DOI 10.1021/bc050228h
   Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104
   Hendrix M, 1997, ANGEW CHEM INT EDIT, V36, P95, DOI 10.1002/anie.199700951                                                          
   Heyes JA, 2002, J MED CHEM, V45, P99, DOI 10.1021/jm010918g
   HIRANO S, 1990, PROG BIOMED POLYM, V283, P90
   Ho YP, 2006, J CONTROL RELEASE, V116, P83, DOI 10.1016/j.jconrel.2006.09.005
   Hollins AJ, 2004, PHARM RES, V21, P458, DOI 10.1023/B:PHAM.0000019300.04836.51
   Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422                                                     
   Hosseinkhani H, 2004, GENE THER, V11, P194, DOI 10.1038/sj.gt.3302159
   Hosseinkhani H, 2006, BIOMATERIALS, V27, P4269, DOI 10.1016/j.biomaterials.2006.02.033
   Hu FQ, 2006, INT J PHARM, V315, P158, DOI 10.1016/j.ijpharm.2006.02.026
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Huang M, 2005, J CONTROL RELEASE, V106, P391, DOI 10.1016/j.cornel.2005.05.004
   Huang RQ, 2006, CHEM PHARM BULL, V54, P1254, DOI 10.1248/cpb.54.1254                                                             
   Hwang SJ, 2001, BIOCONJUGATE CHEM, V12, P280, DOI 10.1021/bc0001084
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Inoue Y, 2008, J CONTROL RELEASE, V126, P59, DOI 10.1016/j.jconrel.2007.10.022
   Ishii T, 2001, BBA-BIOMEMBRANES, V1514, P51, DOI 10.1016/S0005-2736(01)00362-5
   Issa MM, 2006, J CONTROL RELEASE, V115, P103, DOI 10.1016/j.jconrel.2006.06.029
   Jiang X, 2007, BIOCONJUGATE CHEM, V18, P2077, DOI 10.1021/bc0701186
   Joester D, 2003, ANGEW CHEM INT EDIT, V42, P1486, DOI 10.1002/anie.200250284
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones GD, 1944, J ORG CHEM, V9, P125, DOI 10.1021/jo01184a002                                                             
   Kabanov VA, 1999, MACROMOLECULES, V32, P1904, DOI 10.1021/ma9716443                                                               
   Kabanov VA, 2000, MACROMOLECULES, V33, P9587, DOI 10.1021/ma000674u
   Kakizawa Y, 2001, BIOMACROMOLECULES, V2, P491, DOI 10.1021/bm000142I
   Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k
   Kaneshiro TL, 2007, MOL PHARM, V4, P759, DOI 10.1021/mp070036z
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Kastrup L, 2006, J CELL PHYSIOL, V206, P428, DOI 10.1002/jcp.20479
   Katagiri K, 1999, CHEM LETT, P661, DOI 10.1246/cl.1999.661                                                             
   Katagiri K, 2002, J AM CHEM SOC, V124, P7892, DOI 10.1021/ja0259281
   Katayose S, 1997, BIOCONJUGATE CHEM, V8, P702, DOI 10.1021/bc9701306
   Kawano T, 2004, J CONTROL RELEASE, V99, P329, DOI 10.1016/j.jconrel.2004.07.012
   Kean T, 2005, J CONTROL RELEASE, V103, P643, DOI 10.1016/j.jconrel.2004.01.001
   Straughn JM, 2008, J CLIN ONCOL, V26
   Kiang T, 2004, BIOMATERIALS, V25, P5293, DOI 10.1016/j.biomaterials.2003.12.036
   Kichler A, 2005, J CONTROL RELEASE, V107, P174, DOI 10.1016/j.jconrel.2005.08.002
   KIELIAN MC, 1986, EMBO J, V5, P3103
   KIELY DE, 1994, J AM CHEM SOC, V116, P571, DOI 10.1021/ja00081a018
   Kihara F, 2003, BIOCONJUGATE CHEM, V14, P342, DOI 10.1021/bc025613a
   Kihara F, 2002, BIOCONJUGATE CHEM, V13, P1211, DOI 10.1021/bc025557d
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim HJ, 2006, BIOMATERIALS, V27, P2292, DOI 10.1016/j.biomaterials.2005.10.023
   Kim HJ, 2007, BIOORGAN MED CHEM, V15, P1708, DOI 10.1016/j.bmc.2006.12.004
   Kim JS, 1997, J CONTROL RELEASE, V47, P51, DOI 10.1016/S0168-3659(96)01615-X
   Kim JS, 1998, J CONTROL RELEASE, V53, P175, DOI 10.1016/S0168-3659(97)00251-4
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   Kim TH, 2007, PROG POLYM SCI, V32, P726, DOI 10.1016/j.progpolymsci.2007.05.001
   Kim TI, 2007, BIOMATERIALS, V28, P2061, DOI 10.1016/j.biomaterials.2006.12.013
   Kim TI, 2007, BIOCONJUGATE CHEM, V18, P309, DOI 10.1021/bc0601525
   Kim TG, 2004, BIOCONJUGATE CHEM, V15, P326, DOI 10.1021/bc0340262
   Kim TH, 2003, J CONTROL RELEASE, V93, P389, DOI 10.1016/j.jconrel.2003.08.016
   Kim TI, 2005, BIOCONJUGATE CHEM, V16, P1140, DOI 10.1021/bc0497012
   Kim YH, 2005, J CONTROL RELEASE, V103, P209, DOI 10.1016/j.jconrel.2004.11.008
   Kim YH, 2001, BIOCONJUGATE CHEM, V12, P932, DOI 10.1021/bc015510c
   KISH PE, 2007, J MOL PHARMACOL, V4, P95
   KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0
   Kloeckner J, 2006, BIOCONJUGATE CHEM, V17, P1339, DOI 10.1021/bc060133v
   KLOTZ IM, 1968, BIOCHEM BIOPH RES CO, V31, P421, DOI 10.1016/0006-291X(68)90493-2
   Klumpp C, 2006, BBA-BIOMEMBRANES, V1758, P404, DOI 10.1016/j.bbamem.2005.10.008
   Kneuer C, 2000, BIOCONJUGATE CHEM, V11, P926, DOI 10.1021/bc0000637
   Kneuer C, 2000, INT J PHARM, V196, P257, DOI 10.1016/S0378-5173(99)00435-4
   Knorr V, 2007, BIOCONJUGATE CHEM, V18, P1218, DOI 10.1021/bc060327a
   Ko KS, 2001, MOL THER, V4, P313, DOI 10.1006/mthe.2001.0459                                                          
   Koh JJ, 2000, GENE THER, V7, P2099, DOI 10.1038/sj.gt.3301334
   Kono K, 2005, BIOCONJUGATE CHEM, V16, P208, DOI 10.1021/bc049785e
   Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255                                                        
   Kopatz I, 2004, J GENE MED, V6, P769, DOI 10.1002/jgm.558
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Krajcik R, 2008, BIOCHEM BIOPH RES CO, V369, P595, DOI 10.1016/j.bbrc.2008.02.072
   Krska SW, 1998, J AM CHEM SOC, V120, P3604, DOI 10.1021/ja971865o                                                               
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Kulkarni RP, 2005, BIOCONJUGATE CHEM, V16, P986, DOI 10.1021/bc050081u
   Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   Kuriyama S, 2000, GENE THER, V7, P1132, DOI 10.1038/sj.gt.3301192                                                           
   Kwoh DY, 1999, BBA-GENE STRUCT EXPR, V1444, P171, DOI 10.1016/S0167-4781(98)00274-7
   KWON HY, 1989, MACROMOLECULES, V22, P3250, DOI 10.1021/ma00198a010                                                             
   Laczko I, 2004, BIOCHEM BIOPH RES CO, V313, P356, DOI 10.1016/j.bbrc.2003.11.129
   LAEMMLI UK, 1975, P NATL ACAD SCI USA, V72, P4288, DOI 10.1073/pnas.72.11.4288                                                         
   Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X
   Larregina AT, 2001, GENE THER, V8, P608, DOI 10.1038/sj.gt.3301404                                                           
   LAUNAY N, 1995, J AM CHEM SOC, V117, P3282, DOI 10.1021/ja00116a037                                                             
   Laxmi AA, 2001, BIOCHEM BIOPH RES CO, V289, P1057, DOI 10.1006/bbrc.2001.6065
   Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867
   Lee CC, 2008, BIOCONJUGATE CHEM, V19, P428, DOI 10.1021/bc7001659
   Lee D, 2007, PHARM RES, V24, P157, DOI 10.1007/s11095-006-9136-9
   Lee JH, 2003, BIOCONJUGATE CHEM, V14, P1214, DOI 10.1021/bc034095g
   Lee JW, 2001, ANGEW CHEM INT EDIT, V40, P746, DOI 10.1002/1521-3773(20010216)40:4<746::AID-ANIE7460>3.0.CO;2-P
   Lee M, 2003, J CONTROL RELEASE, V88, P333, DOI 10.1016/S0168-3659(03)00031-2
   Lee M, 2001, MOL THER, V4, P339, DOI 10.1006/mthe.2001.0458
   Lee Y, 2007, BIOCONJUGATE CHEM, V18, P13, DOI 10.1021/bc060113t
   LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670
   Leopold PL, 2000, HUM GENE THER, V11, P151, DOI 10.1089/10430340050016238
   Li WJ, 2007, PHARM RES, V24, P438, DOI 10.1007/s11095-006-9180-5
   Li XR, 2005, BIOMACROMOLECULES, V6, P3181, DOI 10.1021/bm050531l
   Li ZH, 2004, J CONTROL RELEASE, V98, P437, DOI 10.1016/j.jconrel.2004.05.013
   Lim DW, 2000, BIOCONJUGATE CHEM, V11, P688, DOI 10.1021/bc000014u
   Lim YB, 2000, PHARMACEUT RES, V17, P811, DOI 10.1023/A:1007552007765
   Lim YB, 2002, BIOCONJUGATE CHEM, V13, P952, DOI 10.1021/bc025541n
   Lim YB, 2002, BIOCONJUGATE CHEM, V13, P1181, DOI 10.1021/bc025581r
   Lim YB, 1999, J AM CHEM SOC, V121, P5633, DOI 10.1021/ja984012k                                                               
   Lim YB, 2000, J AM CHEM SOC, V122, P6524, DOI 10.1021/ja001033h
   Lim YB, 2001, J AM CHEM SOC, V123, P2460, DOI 10.1021/ja005715g
   Lin C, 2007, J CONTROL RELEASE, V123, P67, DOI 10.1016/j.jconrel.2007.07.006
   Lin C, 2006, J CONTROL RELEASE, V116, P130, DOI 10.1016/j.jconrel.2006.09.009
   Lin C, 2007, BIOCONJUGATE CHEM, V18, P138, DOI 10.1021/bc060200l
   Liu DL, 2005, BIOORG MED CHEM LETT, V15, P3147, DOI 10.1016/j.bmcl.2005.04.010
   Liu G, 2001, J BIOL CHEM, V276, P34379, DOI 10.1074/jbc.M105250200
   Liu WG, 2003, BIOCONJUGATE CHEM, V14, P782, DOI 10.1021/bc020051g
   Liu YM, 2007, BIOCONJUGATE CHEM, V18, P19, DOI 10.1021/bc060029d
   Liu YM, 2006, BIOCONJUGATE CHEM, V17, P101, DOI 10.1021/bc050275+
   Liu YM, 2005, J AM CHEM SOC, V127, P3004, DOI 10.1021/ja0436446                                                               
   Liu YM, 2004, J AM CHEM SOC, V126, P7422, DOI 10.1021/ja049831l
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Loretz B, 2007, BIOCONJUGATE CHEM, V18, P1028, DOI 10.1021/bc0603079
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910
   Luo D, 2000, NAT BIOTECHNOL, V18, P893, DOI 10.1038/78523                                                                   
   Luo D, 2004, J CONTROL RELEASE, V95, P333, DOI 10.1016/j.jconrel.2003.11.019
   Luo D, 2002, MACROMOLECULES, V35, P3456, DOI 10.1021/ma0106346
   Luten J, 2003, J CONTROL RELEASE, V89, P483, DOI 10.1016/S0168-3659(03)00127-5
   Luten J, 2006, BIOCONJUGATE CHEM, V17, P1077, DOI 10.1021/bc060068p
   Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Mackensen A, 1997, J MOL MED-JMM, V75, P290, DOI 10.1007/s001090050114
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   Maheshwari A, 2002, GENE THER, V9, P1075, DOI 10.1038/sj.gt.3301766
   Maheshwari A, 2000, MOL THER, V2, P121, DOI 10.1006/mthe.2000.0105
   Majeti BK, 2005, BIOCONJUGATE CHEM, V16, P676, DOI 10.1021/bc049687t
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   Maruyama A, 1998, BIOCONJUGATE CHEM, V9, P292, DOI 10.1021/bc9701510                                                               
   Mastrobattista E, 2001, CANCER GENE THER, V8, P405, DOI 10.1038/sj.cgt.7700311
   Maszewska M, 2003, OLIGONUCLEOTIDES, V13, P193, DOI 10.1089/154545703322460586                                                      
   Matsui K, 2006, J AM CHEM SOC, V128, P3114, DOI 10.1021/ja058016i
   Matsui K, 2007, BIOORG MED CHEM LETT, V17, P3935, DOI 10.1016/j.bmcl.2007.04.097
   McAllister K, 2002, J AM CHEM SOC, V124, P15198, DOI 10.1021/ja027759q
   McGregor C, 2001, J AM CHEM SOC, V123, P6215, DOI 10.1021/ja005681c
   MCKEE TD, 1994, BIOCONJUGATE CHEM, V5, P306, DOI 10.1021/bc00028a004
   McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i
   Meijer SL, 2002, J IMMUNOTHER, V25, P359, DOI 10.1097/01.CJI.0000018062.31201.75
   Merdan T, 2005, BIOCONJUGATE CHEM, V16, P785, DOI 10.1021/bc049743q
   Mesnil M, 2000, CANCER RES, V60, P3989
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262                                                          
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   MISLICK KA, 1995, BIOCONJUGATE CHEM, V6, P512, DOI 10.1021/bc00035a002
   Miyata K, 2004, J AM CHEM SOC, V126, P2355, DOI 10.1021/ja0379666
   Mizu M, 2004, J AM CHEM SOC, V126, P8372, DOI 10.1021/ja031978+
   Mok H, 2006, BIOCONJUGATE CHEM, V17, P1369, DOI 10.1021/bc060119i
   Molas M., 2003, Current Gene Therapy, V3, P468, DOI 10.2174/1566523034578195
   Montana G, 2007, BIOCONJUGATE CHEM, V18, P302, DOI 10.1021/bc0601166
   Moradpour D, 1996, BIOCHEM BIOPH RES CO, V221, P82, DOI 10.1006/bbrc.1996.0549
   Moreau L, 2005, MOL BIOSYST, V1, P260, DOI 10.1039/b503302k
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164
   Mousazadeh M, 2007, J DRUG TARGET, V15, P226, DOI 10.1080/10611860601148908
   MUJUMDAR AN, 1990, MACROMOLECULES, V23, P14, DOI 10.1021/ma00203a004                                                             
   MUKHERJEE AB, 1978, P NATL ACAD SCI USA, V75, P1361, DOI 10.1073/pnas.75.3.1361
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper R., 1995, P INT S CONTR REL BI, P178
   Murata J, 1997, CARBOHYD POLYM, V32, P105, DOI 10.1016/S0144-8617(96)00154-3
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Muzzarelli R. A. A., 1977, CHITIN
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   NAGAI T, 1996, COMPREHENSIVE SUPRAM, V3, P441
   Nagasaki T, 2004, BIOCONJUGATE CHEM, V15, P249, DOI 10.1021/bc034178x
   Nagasaki T, 2003, BIOCONJUGATE CHEM, V14, P513, DOI 10.1021/bc0256603
   Nakai T, 2003, J AM CHEM SOC, V125, P8465, DOI 10.1021/ja035636f
   Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773
   Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a
   Noh SM, 2007, BBA-GEN SUBJECTS, V1770, P747, DOI 10.1016/j.bbagen.2007.01.012
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Ohana P., 2004, GENE THER MOL BIOL, V8, P181
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Ohsaki M, 2002, BIOCONJUGATE CHEM, V13, P510, DOI 10.1021/bc015525a
   Oishi M, 2006, BIOCONJUGATE CHEM, V17, P677, DOI 10.1021/bc050364m
   Oishi M, 2006, CHEM LETT, V35, P1046, DOI 10.1246/cl.2006.1046                                                            
   Oja CD, 1996, BBA-BIOMEMBRANES, V1281, P31, DOI 10.1016/0005-2736(96)00003-X
   Okuda T, 2003, ORG BIOMOL CHEM, V1, P1270, DOI 10.1039/b212086k
   Okuda T, 2004, BIOMATERIALS, V25, P537, DOI 10.1016/S0142-9612(03)00542-8
   Olbrich C, 2001, J CONTROL RELEASE, V77, P345, DOI 10.1016/S0168-3659(01)00506-5
   Omidi Y, 2005, J DRUG TARGET, V13, P431, DOI 10.1080/10611860500418881
   ORTEGA P, 2006, EUR J INORG CHEM, V138, P8
   OSTRO MJ, 1978, NATURE, V274, P921, DOI 10.1038/274921a0
   Ottaviani MF, 2000, MACROMOLECULES, V33, P7842, DOI 10.1021/ma000877i
   Ou JS, 2003, BIOCHEM BIOPH RES CO, V305, P605, DOI 10.1016/S0006-291X(03)00803-9
   Oupicky D, 2000, BIOCONJUGATE CHEM, V11, P492, DOI 10.1021/bc990143e
   Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z
   Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437
   Park IK, 2001, J CONTROL RELEASE, V76, P349, DOI 10.1016/S0168-3659(01)00448-5                                                   
   Park MR, 2005, J CONTROL RELEASE, V105, P367, DOI 10.1016/j.jconrel.2005.04.008
   Park S, 2004, J CONTROL RELEASE, V95, P639, DOI 10.1016/j.jconrel.2003.12.002
   Park S, 2003, BIOCONJUGATE CHEM, V14, P311, DOI 10.1021/bc025623b
   Park YK, 2000, J CONTROL RELEASE, V69, P97, DOI 10.1016/S0168-3659(00)00298-4                                                   
   Parker AL, 2005, J GENE MED, V7, P1545, DOI 10.1002/jgm.809
   Parker AL, 2007, BBA-GEN SUBJECTS, V1770, P1331, DOI 10.1016/j.bbagen.2007.06.009
   Patel M, 2001, BIOCHEM BIOPH RES CO, V281, P536, DOI 10.1006/bbrc.2001.4401
   PENCZEK S, 1993, MACROMOLECULES, V26, P2228, DOI 10.1021/ma00061a014                                                             
   Peng JF, 2006, NANOMED-NANOTECHNOL, V2, P113, DOI 10.1016/j.nano.2006.04.003
   PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P812, DOI 10.1021/bc0255135
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P845, DOI 10.1021/bc025529v
   Picquet E, 2005, BIOCONJUGATE CHEM, V16, P1051, DOI 10.1021/bc050097k
   PIJPER D, 2003, EUR J ORG CHEM, V440, P6
   PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012
   Pooga M, 1998, FASEB J, V12, P67
   Popielarski SR, 2003, BIOCONJUGATE CHEM, V14, P672, DOI 10.1021/bc034010b
   Porteous DJ, 1997, GENE THER, V4, P210, DOI 10.1038/sj.gt.3300390
   Poste G, 1976, Methods Cell Biol, V14, P33, DOI 10.1016/S0091-679X(08)60468-9
   POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8
   Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169-409X(00)00133-2                                                   
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Prata CAH, 2004, J AM CHEM SOC, V126, P12196, DOI 10.1021/ja0474906
   Prata CAH, 2008, BIOCONJUGATE CHEM, V19, P418, DOI 10.1021/bc700451b
   Pun SH, 2004, BIOCONJUGATE CHEM, V15, P831, DOI 10.1021/bc049891g
   Pun SH, 2002, BIOCONJUGATE CHEM, V13, P630, DOI 10.1021/bc0155768
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   Putnam D, 1999, MACROMOLECULES, V32, P3658, DOI 10.1021/ma982004i                                                               
   Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Rajesh M, 2007, J AM CHEM SOC, V129, P11408, DOI 10.1021/ja0704683
   Reineke TM, 2003, BIOCONJUGATE CHEM, V14, P247, DOI 10.1021/bc025592k
   Reineke TM, 2003, BIOCONJUGATE CHEM, V14, P255, DOI 10.1021/bc025593c
   REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021                                                             
   Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o
   Rensen PCN, 2001, J BIOL CHEM, V276, P37577, DOI 10.1074/jbc.M101786200
   Reschel T, 2002, J CONTROL RELEASE, V81, P201, DOI 10.1016/S0168-3659(02)00045-7
   Ribeiro S, 2005, INT J PHARM, V298, P354, DOI 10.1016/j.ijpharm.2005.03.036
   Ribeiro S, 2007, INT J PHARM, V331, P228, DOI 10.1016/j.ijpharm.2006.11.063
   Richards JM, 2005, J CLIN ONCOL, V23, p720S
   Richardson S, 1999, J DRUG TARGET, V6, P391, DOI 10.3109/10611869908996846                                                       
   Richardson SCW, 2001, BIOMACROMOLECULES, V2, P1023, DOI 10.1021/bm010079f
   RIGBY PG, 1969, NATURE, V221, P968, DOI 10.1038/221968a0
   Romoren K, 2003, INT J PHARM, V261, P115, DOI 10.1016/S0378-5173(03)00301-6
   ROOSJEN A, 2002, EUR J ORG CHEM, V127, P1
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Roy I, 2005, P NATL ACAD SCI USA, V102, P279, DOI 10.1073/pnas.0408039101
   RUBEN S, 1989, J VIROL, V63, P1
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Rudolph C, 2002, BBA-GEN SUBJECTS, V1573, P75, DOI 10.1016/S0304-4165(02)00334-3
   Ruponen M, 2004, J GENE MED, V6, P405, DOI 10.1002/jgm.522
   Sagara K, 2002, J CONTROL RELEASE, V79, P271, DOI 10.1016/S0168-3659(01)00555-7
   Sainlos M, 2005, CHEMBIOCHEM, V6, P1023, DOI 10.1002/cbic.200400344
   Sainlos M, 2003, EUR J ORG CHEM, P2764, DOI 10.1002/ejoc.200300164
   Sakurai K, 2000, J AM CHEM SOC, V122, P4520, DOI 10.1021/ja0000145                                                               
   Sameti M, 2003, INT J PHARM, V266, P51, DOI 10.1016/S0378-5173(03)00380-6
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Sato T, 2001, BIOMATERIALS, V22, P2075, DOI 10.1016/S0142-9612(00)00385-9                                                   
   SCHAEFERRIDDER M, 1982, SCIENCE, V215, P166, DOI 10.1126/science.7053567                                                         
   Schatzlein AG, 2005, J CONTROL RELEASE, V101, P247, DOI 10.1016/j.jconrel.2004.08.024
   Shah DS, 2000, INT J PHARM, V208, P41, DOI 10.1016/S0378-5173(00)00534-2                                                   
   Shimada N, 2007, BIOCONJUGATE CHEM, V18, P1280, DOI 10.1021/bc0700178
   Shimada N, 2006, BIOCONJUGATE CHEM, V17, P1136, DOI 10.1021/bc060070g
   Shuai XT, 2005, BIOCONJUGATE CHEM, V16, P322, DOI 10.1021/bc0498471
   Shuai XT, 2003, MACROMOLECULES, V36, P5751, DOI 10.1021/ma034390w
   SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6                                                   
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Singh R, 2005, J AM CHEM SOC, V127, P4388, DOI 10.1021/ja0441561
   Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Srinivasachari S, 2006, J AM CHEM SOC, V128, P8176, DOI 10.1021/ja0585580
   Srinivasan C, 2006, MOL THER, V14, P192, DOI 10.1016/j.ymthe.2006.03.010
   STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005                                                             
   STEKAR J, 1995, ANGEW CHEM INT EDIT, V34, P238, DOI 10.1002/anie.199502381                                                          
   Stopeck AT, 1997, J CLIN ONCOL, V15, P341, DOI 10.1200/JCO.1997.15.1.341                                                       
   Stopeck AT, 2001, CLIN CANCER RES, V7, P2285
   SUDHOLTER EJR, 1980, J AM CHEM SOC, V102, P2467, DOI 10.1021/ja00527a061
   SUH J, 1994, BIOORG CHEM, V22, P318, DOI 10.1006/bioo.1994.1025
   Suh WH, 2001, J CONTROL RELEASE, V72, P171, DOI 10.1016/S0168-3659(01)00273-5
   Sun SJ, 2005, BIOCONJUGATE CHEM, V16, P972, DOI 10.1021/bc0500701
   Sung SJ, 2003, BIOL PHARM BULL, V26, P492
   Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c                                                               
   Szejtli J, 1996, COMPREHENSIVE SUPRAM, V3, P5
   TABATA K, 1981, CARBOHYD RES, V89, P121, DOI 10.1016/S0008-6215(00)85234-9
   Tabatt K, 2004, J CONTROL RELEASE, V97, P321, DOI 10.1016/j.jconrel.2004.02.029
   Takahashi T, 2005, BIOCONJUGATE CHEM, V16, P1160, DOI 10.1021/bc050012f
   Takahashi T, 2003, BIOCONJUGATE CHEM, V14, P764, DOI 10.1021/bc025663f
   Takahashi T, 2007, BIOCONJUGATE CHEM, V18, P1349, DOI 10.1021/bc060311k
   Takahashi T, 2007, BIOCONJUGATE CHEM, V18, P1163, DOI 10.1021/bc070014v
   Takeda Y, 2007, BIOMACROMOLECULES, V8, P1178, DOI 10.1021/bm0611937
   Tan JF, 2006, LANGMUIR, V22, P3744, DOI 10.1021/la052591i
   Tang FX, 1999, BIOCONJUGATE CHEM, V10, P791, DOI 10.1021/bc990016i                                                               
   Tang FX, 1998, BIOCHEM BIOPH RES CO, V242, P141, DOI 10.1006/bbrc.1997.7923
   Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   Tanimoto M, 2003, BIOCONJUGATE CHEM, V14, P1197, DOI 10.1021/bc034075e
   Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876                                                     
   Thanou M, 2002, BIOMATERIALS, V23, P153, DOI 10.1016/S0142-9612(01)00090-4
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Thomas M, 2002, P NATL ACAD SCI USA, V99, P14640, DOI 10.1073/pnas.192581499
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Toth I, 1999, STP PHARMA SCI, V9, P93
   TRUBETSKOY VS, 1992, BIOCONJUGATE CHEM, V3, P323, DOI 10.1021/bc00016a011
   Trubetskoy VS, 1999, BIOCONJUGATE CHEM, V10, P624, DOI 10.1021/bc9801530                                                               
   TRUFFERT JC, 1994, TETRAHEDRON LETT, V35, P2353, DOI 10.1016/0040-4039(94)85218-9
   Truffert JC, 1996, TETRAHEDRON, V52, P3005, DOI 10.1016/0040-4020(96)00018-X
   Uekama K., 1996, COMPREHENSIVE SUPRAM, V3, P451
   UYECHIOBRIEN LS, 2003, DRUGS PHARM SCI, V131, P79
   van de Wetering P, 1998, J CONTROL RELEASE, V53, P145, DOI 10.1016/S0168-3659(97)00248-4
   van de Wetering P, 2000, J CONTROL RELEASE, V64, P193, DOI 10.1016/S0168-3659(99)00130-3                                                   
   van de Wetering P, 1999, J GENE MED, V1, P156, DOI 10.1002/(SICI)1521-2254(199905/06)1:3<156::AID-JGM29>3.0.CO;2-O
   van de Wetering P, 1999, BIOCONJUGATE CHEM, V10, P589, DOI 10.1021/bc980148w                                                               
   van Duijvenbode RC, 1998, POLYMER, V39, P2657, DOI 10.1016/S0032-3861(97)00573-9                                                   
   van Steenis JH, 2003, J CONTROL RELEASE, V87, P167, DOI 10.1016/S0168-3659(02)00361-9
   VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160
   vandeWetering P, 1997, J CONTROL RELEASE, V49, P59, DOI 10.1016/S0168-3659(97)00059-X
   GONZALEZ H, 2000, Patent No. 0001734
   Gebeyehu G, 1994, U.S. Patent, Patent No. [5 (334): 761, 5334761, 5,334,761]
   Denkewalter R.G., 1981, U.S. Patent, Patent No. [4,289,872, 4289872]
   Veelken H, 1997, INT J CANCER, V70, P269, DOI 10.1002/(SICI)1097-0215(19970127)70:3<269::AID-IJC4>3.0.CO;2-V
   Verbaan F, 2003, EUR J PHARM SCI, V20, P419, DOI 10.1016/j.ejps.2003.09.005
   Verbaan FJ, 2001, INT J PHARM, V214, P99, DOI 10.1016/S0378-5173(00)00642-6
   Verbaan FJ, 2004, J GENE MED, V6, P64, DOI 10.1002/jbm.475
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Veron L, 2006, MACROMOL BIOSCI, V6, P540, DOI 10.1002/mabi.200600071
   Vigneron JP, 1996, P NATL ACAD SCI USA, V93, P9682, DOI 10.1073/pnas.93.18.9682
   Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107
   Vinogradov S, 1999, COLLOID SURFACE B, V16, P291, DOI 10.1016/S0927-7765(99)00080-6                                                   
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9                                                   
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Voges J, 2003, ANN NEUROL, V54, P479, DOI 10.1002/ana.10688
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wada K, 2005, BIOL PHARM BULL, V28, P500, DOI 10.1248/bpb.28.500
   Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2                                                   
   WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255                                                         
   WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006
   WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410
   Wakebayashi D, 2004, J CONTROL RELEASE, V95, P653, DOI 10.1016/j.jconrel.2004.01.003
   Walker GF, 2005, MOL THER, V11, P418, DOI 10.1016/j.ymthe.2004.11.006
   Walker S, 1996, P NATL ACAD SCI USA, V93, P1585, DOI 10.1073/pnas.93.4.1585                                                          
   WANG CY, 1989, BIOCHEMISTRY-US, V28, P9508, DOI 10.1021/bi00450a039
   Wang DA, 2002, BIOMACROMOLECULES, V3, P1197, DOI 10.1021/bm025563c
   Wang J, 2001, J AM CHEM SOC, V123, P9480, DOI 10.1021/ja016062m
   Wang J, 2003, INT J PHARM, V265, P75, DOI 10.1016/j.ijpharm.2003.07.006
   Wang J, 2002, J CONTROL RELEASE, V83, P157, DOI 10.1016/S0168-3659(02)00180-3
   Wang JK, 1998, J MED CHEM, V41, P2207, DOI 10.1021/jm950802i
   Wang Shixia, 2004, V245, P185
   Wetzer B, 2001, BIOCHEM J, V356, P747, DOI 10.1042/0264-6021:3560747                                                       
   Wheeler CJ, 1996, BBA-BIOMEMBRANES, V1280, P1, DOI 10.1016/0005-2736(95)00256-1                                                    
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187                                                                 
   Wilke M, 1996, GENE THER, V3, P1133
   WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726
   Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123
   Wolfert MA, 1996, GENE THER, V3, P269
   Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606                                                           
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wong K, 2006, BIOCONJUGATE CHEM, V17, P152, DOI 10.1021/bc0501597
   WONG TK, 1980, GENE, V10, P87
   Wood KC, 2008, BIOCONJUGATE CHEM, V19, P403, DOI 10.1021/bc700408r
   WORNER C, 1993, ANGEW CHEM INT EDIT, V32, P1306, DOI 10.1002/anie.199313061
   Wu DC, 2006, BIOMACROMOLECULES, V7, P1879, DOI 10.1021/bm0601878
   Wu DC, 2005, BIOMACROMOLECULES, V6, P3166, DOI 10.1021/bm0504983
   WU GY, 1987, J BIOL CHEM, V262, P4429
   WU GY, 1988, J BIOL CHEM, V263, P14621
   WU J, 2005, CHEM COMMUN, V313, P315
   Xiong MP, 2007, BIOCONJUGATE CHEM, V18, P746, DOI 10.1021/bc0602883
   Xu DM, 2007, INT J PHARM, V338, P291, DOI 10.1016/j.ijpharm.2007.01.050
   Xu DM, 2007, RADIAT PHYS CHEM, V76, P1606, DOI 10.1016/j.radphyschem.2007.02.007
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   Yamagata M, 2007, BIOORGAN MED CHEM, V15, P526, DOI 10.1016/j.bmc.2006.09.033
   YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568
   Yang R, 2006, GENE THER, V13, P1714, DOI 10.1038/sj.gt.3302808
   Yang ZR, 2007, CANCER GENE THER, V14, P599, DOI 10.1038/sj.cgt.7701054
   Yoo GH, 2001, CLIN CANCER RES, V7, P1237
   Yoo H, 2000, NUCLEIC ACIDS RES, V28, P4225, DOI 10.1093/nar/28.21.4225                                                          
   Yu HJ, 2007, BIOMACROMOLECULES, V8, P1425, DOI 10.1021/bm060910u
   Yudovin-Farber I, 2005, BIOCONJUGATE CHEM, V16, P1196, DOI 10.1021/bc050066p
   Zabner J, 1997, J CLIN INVEST, V100, P1529, DOI 10.1172/JCI119676
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
   Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071
   Zhang XQ, 2005, BIOMACROMOLECULES, V6, P341, DOI 10.1021/bm040060n
   Zhang ZH, 2006, CLIN CANCER RES, V12, P4933, DOI 10.1158/1078-0432.CCR-05-2831
   Zhang ZY, 2000, BIOCONJUGATE CHEM, V11, P805, DOI 10.1021/bc000018z
   Zhong ZY, 2005, J CONTROL RELEASE, V109, P317, DOI 10.1016/j.jconrel.2005.06.022
   ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3                                                    
   Zhu J, 2000, J AM CHEM SOC, V122, P2645, DOI 10.1021/ja994149q                                                               
   Zhu MZ, 2002, B CHEM SOC JPN, V75, P2207, DOI 10.1246/bcsj.75.2207                                                            
   Zinselmeyer BH, 2002, PHARMACEUT RES, V19, P960, DOI 10.1023/A:1016458104359
   Zou SM, 2000, J GENE MED, V2, P128, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W                 
   Zugates GT, 2007, BIOCONJUGATE CHEM, V18, P1887, DOI 10.1021/bc7002082
   Zugates GT, 2006, J AM CHEM SOC, V128, P12726, DOI 10.1021/ja061570n
   Zuo A, 2008, INT J PHARMACEUT, V352, P302, DOI 10.1016/j.ijpharm.2007.10.042
NR 574
TC 1289
Z9 1310
U1 22
U2 473
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2665
EI 1520-6890
J9 CHEM REV
JI Chem. Rev.
PD FEB
PY 2009
VL 109
IS 2
BP 259
EP 302
DI 10.1021/cr800409e
PG 44
WC Chemistry, Multidisciplinary
SC Chemistry
GA 410FM
UT WOS:000263562900002
PM 19053809
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Crabbe, R
   Vuagniaux, G
   Dumont, JM
   Nicolas-Metral, V
   Marfurt, J
   Novaroli, L
AF Crabbe, Raf
   Vuagniaux, Gregoire
   Dumont, Jean-Maurice
   Nicolas-Metral, Valerie
   Marfurt, Judith
   Novaroli, Laura
TI An evaluation of the cyclophilin inhibitor Debio 025 and its potential
   as a treatment for chronic hepatitis C
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE antiviral; cyclophilin inhibitor; Debio 025; HCV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MUSCULAR-DYSTROPHY; IN-VITRO;
   CYCLOSPORINE-A; INFECTION; REPLICATION; RESISTANCE; THERAPY;
   EPIDEMIOLOGY; INTERFERON
AB Debio 025 is a cyclophilin (Cyp) inhibitor without calcineurin-binding properties. The drug inhibits viral replication of genotype 1b and 2a replicons in nanomolar concentrations and shows an additive to synergistic antiviral effect with interferon, ribavirin, and specifically targeted antiviral therapy for hepatitis C (STAT-C) drugs. There is no cross-resistance with protease and polymerase inhibitors. In humans, Debio 025 has shown activity against genotypes 1, 2, 3, and 4, and displays an additive antiviral effect with pegylated interferon (peg-IFN)alpha 2a in genotype 1 and 4 patients. The most prominent side effect is reversible hyperbilirubinaemia caused by inhibition of biliary transporters. Debio 025 is a potent anti-HCV drug, with a novel mechanism of action and an efficacy profile that makes it an attractive candidate for combination with current and future HCV treatments.
C1 [Crabbe, Raf; Vuagniaux, Gregoire; Dumont, Jean-Maurice; Nicolas-Metral, Valerie; Marfurt, Judith; Novaroli, Laura] Debiopharm SA, CH-1002 Lausanne, Switzerland.
RP Crabbe, R (reprint author), Debiopharm SA, Chemin Messidor 5-7,POB 5911, CH-1002 Lausanne, Switzerland.
EM rcrabbe@debiopharm.com
CR Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436                                                        
   Angelin A, 2007, P NATL ACAD SCI USA, V104, P991, DOI 10.1073/pnas.0610270104
   BOBARDT M, 2008, 15 INT S HEP C VIR R
   BOOTH JCL, 2001, GUT               S1, V49, P1
   COELMONT I, 2007, 14 INT S HEP C VIR R
   COELMONT L, 2008, ANTIMICROB IN PRESS
   Cross TJS, 2008, POSTGRAD MED J, V84, DOI 10.1136/pgmj.2008.068205
   Dienstag JL, 2006, GASTROENTEROLOGY, V130, P231, DOI 10.1053/j.gastro.2005.11.010
   Fernandes F, 2007, HEPATOLOGY, V46, P1026, DOI 10.1002/hep.21809
   Fernandez I, 1997, SCAND J GASTROENTERO, V32, P70, DOI 10.3109/00365529709025066                                                       
   Flisiak R, 2008, HEPATOLOGY, V47, P817, DOI 10.1002/hep.22131
   GALLAY P, 2007, J HEPATOL S, V46, pS296
   GOMEZ L, 2006, WORLD C CARD BARC SP
   GOTO K, 2007, 14 INT S HEP C REL V
   Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45
   HOPKINS S, 2008, 59 ANN M AM ASS STUD
   Houck DR, 2006, HEPATOLOGY, V44, p534A
   Inoue K, 2007, HEPATOLOGY, V45, P921, DOI 10.1002/hep.21587
   Kamisako T, 1999, HEPATOLOGY, V30, P485, DOI 10.1002/hep.510300220                                                           
   KAUL A, 2008, 15 INT S HEP C VIR R
   Kowdley KV, 2005, J CLIN GASTROENTEROL, V39, pS3, DOI 10.1097/01.mcg.0000145494.76305.11                                              
   KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214
   Millay DP, 2008, NAT MED, V14, P442, DOI 10.1038/nm1736
   Nakagawa M, 2005, GASTROENTEROLOGY, V129, P1031, DOI 10.1053/j.gastro.2005.06.031
   NIH. Natonal Institute of Health, 2002, HEPATOLOGY, V36, pS3, DOI DOI 10.1053/JHEP.2002.37117
   Paeshuyse J, 2006, HEPATOLOGY, V43, P761, DOI 10.1002/hep.21102
   Pauli-Magnus C, 2005, J HEPATOL, V43, P342, DOI 10.1016/j.jhep.2005.03.017
   Ptak RG, 2008, ANTIMICROB AGENTS CH, V52, P1302, DOI 10.1128/AAC.01324-07
   Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013
   Reutenauer J, 2008, BRIT J PHARMACOL, V155, P574, DOI 10.1038/bjp.2008.285
   Robida JM, 2007, J VIROL, V81, P5829, DOI 10.1128/JVI.02524-06
   Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1270, DOI 10.1053/j.gastro.2007.01.041
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Soriano V, 2008, EXPERT OPIN EMERG DR, V13, P1, DOI [10.1517/14728214.13.1.1, 10.1517/14728214.13.1.1 ]
   Steyn D., 2006, 13 C RETR OPP INF CR
   Watashi K, 2007, REV MED VIROL, V17, P245, DOI 10.1002/rmv.534
   WIEDERMANN B, 2008, 15 INT S HEP C REL V
   Yang F, 2008, J VIROL, V82, P5269, DOI 10.1128/JVI.02614-07
NR 39
TC 38
Z9 42
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3784
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD FEB
PY 2009
VL 18
IS 2
BP 211
EP 220
DI 10.1517/13543780802651583
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 405FZ
UT WOS:000263209700009
PM 19236267
DA 2018-01-05
ER

PT J
AU Shiohara, T
   Saito, H
   Inoue, T
AF Shiohara, Tomoaki
   Saito, Hirohide
   Inoue, Tan
TI A designed RNA selection: establishment of a stable complex between a
   target and selectant RNA via two coordinated interactions
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IN-VITRO SELECTION; DIMERIZATION INITIATION SITE; LOOP-LOOP
   INTERACTIONS; SELF-FOLDING RNA; LIGASE RIBOZYME; APTAMERS; HIV-1;
   DETERMINANTS; DOMAIN; CONSTRUCTION
AB In this paper, we describe a new method for selecting RNA aptamers that cooperatively bind to two specific sites within a target RNA. We designed a selection system in which two RNAs, a target RNA and a RNA pool, were assembled by employing a pre-organized GAAA tetraloop-11-nt receptor interaction. This allows us to select the binding sequence against a targeted internal loop as well as a linker region optimized for binding of the two binding sites. After the selection, the aptamers bound with dissociation constants in the nanomolar range, thereby forming a stable complex with the target RNA. Thus this method enables identification of aptamers for a specific binding site together with a linker for cooperative binding of the two RNAs. It appears that our new method can be applied generally to select RNAs that adhere tightly to a target RNA via two specific sites. The method can also be applicable for further engineering of both natural and artificial RNAs.
C1 [Shiohara, Tomoaki; Saito, Hirohide; Inoue, Tan] Kyoto Univ, Grad Sch Biostudies, Lab Gene Biodynam, Sakyo Ku, Kyoto 6068502, Japan.
   [Saito, Hirohide; Inoue, Tan] Japan Sci & Technol Agcy, ICORP, Chiyoda Ku, Tokyo 1020075, Japan.
RP Saito, H (reprint author), Kyoto Univ, Grad Sch Biostudies, Lab Gene Biodynam, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.
EM h-saito@kuchem.kyoto-u.ac.jp; tan@kuchem.kyoto-u.ac.jp
FU Scientific Research of Priority Areas; ICORP; JST; Japan Science and
   Technology Agency
FX The work is supported by Grants-in-Aid for Scientific Research of
   Priority Areas and ICORP, JST (H.S., T.I.). Funding for open access
   charge: Japan Science and Technology Agency.
CR Afonin KA, 2006, J AM CHEM SOC, V128, P16131, DOI 10.1021/ja064289h
   Aldaz-Carroll L, 2002, BIOCHEMISTRY-US, V41, P5883, DOI 10.1021/bi0121508
   BATEY RT, 1999, ANGEW CHEM INT EDIT, V38, P2326
   Boucard D, 2006, BIOCHEMISTRY-US, V45, P1518, DOI 10.1021/bi051187f
   Cho BR, 1997, BIOORGAN MED CHEM, V5, P1107, DOI 10.1016/S0968-0896(97)00046-1                                                   
   Costa M, 1997, EMBO J, V16, P3289, DOI 10.1093/emboj/16.11.3289
   Darfeuille F, 2006, BIOCHEMISTRY-US, V45, P12076, DOI 10.1021/bi0606344
   Du ZH, 2004, BIOCHEMISTRY-US, V43, P5757, DOI 10.1021/bi0363228
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Geary C, 2008, NUCLEIC ACIDS RES, V36, P1138, DOI 10.1093/nar/gkm1048
   Gomes SD, 2004, BIOCHEM BIOPH RES CO, V322, P820, DOI 10.1016/j.bbrc.2004.07.185
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   Horie S, 2006, BIOCHEM BIOPH RES CO, V339, P115, DOI 10.1016/j.bbrc.2005.11.007
   Ikawa Y, 2004, P NATL ACAD SCI USA, V101, P13750, DOI 10.1073/pnas.0405886101
   Ikawa Y, 2002, STRUCTURE, V10, P527, DOI 10.1016/S0969-2126(02)00739-6
   Ikawa Yoshiya, 2005, RNA Biol, V2, P137, DOI 10.4161/rna.2.4.2302
   Jaeger L, 2000, ANGEW CHEM INT EDIT, V39, P2521, DOI 10.1002/1521-3773(20000717)39:14<2521::AID-ANIE2521>3.0.CO;2-P                  
   Jaeger L, 2001, NUCLEIC ACIDS RES, V29, P455, DOI 10.1093/nar/29.2.455
   Jaeger L, 1999, P NATL ACAD SCI USA, V96, P14712, DOI 10.1073/pnas.96.26.14712
   Jaeger L, 2006, CURR OPIN STRUC BIOL, V16, P531, DOI 10.1016/j.sbi.2006.07.001
   Kikuchi K, 2003, J BIOCHEM, V133, P263, DOI 10.1093/jb/mvg036
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Lescoute A, 2006, NUCLEIC ACIDS RES, V34, P6587, DOI 10.1093/nar/gkl963
   Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698
   Martick M, 2006, CELL, V126, P309, DOI 10.1016/j.cell.2006.06.036
   Muller J, 2007, CHEMBIOCHEM, V8, P2223, DOI 10.1002/cbic.200700535
   Ohuchi SP, 2008, NUCLEIC ACIDS RES, V36, P3600, DOI 10.1093/nar/gkn206
   Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096                                                          
   Qin PZ, 2001, BIOCHEMISTRY-US, V40, P6929, DOI 10.1021/bi010294g
   Saito H, 2007, J BIOTECHNOL, V132, P1, DOI 10.1016/j.jbiotec.2007.07.952
   Scarabino D, 1999, EMBO J, V18, P4571, DOI 10.1093/emboj/18.16.4571
   Tok JBH, 2000, NUCLEIC ACIDS RES, V28, P2902, DOI 10.1093/nar/28.15.2902
   Umehara T, 2005, J BIOCHEM, V137, P339, DOI 10.1093/jb/mvi042
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Yoshioka W, 2004, RNA, V10, P1900, DOI 10.1261/rna.7170304
NR 36
TC 7
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB
PY 2009
VL 37
IS 3
AR e23
DI 10.1093/nar/gkn1012
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 413YP
UT WOS:000263831400006
PM 19136470
OA gold
DA 2018-01-05
ER

PT J
AU Matoba, N
   Kajiura, H
   Cherni, I
   Doran, JD
   Bomsel, M
   Fujiyama, K
   Mor, TS
AF Matoba, Nobuyuki
   Kajiura, Hiroyuki
   Cherni, Irene
   Doran, Jeffrey D.
   Bomsel, Morgane
   Fujiyama, Kazuhito
   Mor, Tsafrir S.
TI Biochemical and immunological characterization of the plant-derived
   candidate human immunodeficiency virus type 1 mucosal vaccine
   CTB-MPR649-684
SO PLANT BIOTECHNOLOGY JOURNAL
LA English
DT Article
DE gp41 membrane proximal region; HIV vaccine; N-glycosylation;
   post-translational modification; transgenic plants
ID TOXIN-B-SUBUNIT; RECOMBINANT HUMAN ACETYLCHOLINESTERASE;
   TRANSCYTOSIS-BLOCKING ABS; TRANSGENIC TOMATO PLANTS; AUXIN-BINDING
   PROTEIN; CHOLERA-TOXIN; MONOCLONAL-ANTIBODY; ENDOPLASMIC-RETICULUM;
   FUSION PROTEIN; GALACTOSYL CERAMIDE
AB Plants are potentially the most economical platforms for the large-scale production of recombinant proteins. Thus, plant-based expression of subunit human immunodeficiency virus type 1 (HIV-1) vaccines provides an opportunity for their global use against the acquired immunodeficiency syndrome pandemic. CTB-MPR649-684 [CTB, cholera toxin B subunit; MPR, membrane proximal (ectodomain) region of gp41] is an HIV-1 vaccine candidate that has been shown previously to induce antibodies that block a pathway of HIV-1 mucosal transmission. In this article, the molecular characterization of CTB-MPR649-684 expressed in transgenic Nicotiana benthamiana plants is reported. Virtually all of the CTB-MPR649-684 proteins expressed in the selected line were shown to have assembled into pentameric, GM1 ganglioside-binding complexes. Detailed biochemical analyses on the purified protein revealed that it was N-glycosylated, predominantly with high-mannose-type glycans (more than 75%), as predicted from a consensus asparagine-X-serine/threonine (Asn-X-Ser/Thr) N-glycosylation sequon on the CTB domain and an endoplasmic reticulum retention signal attached at the C-terminus of the fusion protein. Despite this modification, the plant-expressed protein retained the nanomolar affinity to GM1 ganglioside and the critical antigenicity of the MPR649-684 moiety. Furthermore, the protein induced mucosal and serum anti-MPR649-684 antibodies in mice after mucosal prime-systemic boost immunization. Our data indicate that plant-based expression can be a viable alternative for the production of this subunit HIV-1 vaccine candidate.
C1 [Matoba, Nobuyuki; Cherni, Irene; Doran, Jeffrey D.; Mor, Tsafrir S.] Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, Tempe, AZ 85287 USA.
   [Matoba, Nobuyuki; Cherni, Irene; Doran, Jeffrey D.; Mor, Tsafrir S.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
   [Kajiura, Hiroyuki; Fujiyama, Kazuhito] Osaka Univ, Int Ctr Biotechnol, Suita, Osaka 5650871, Japan.
   [Bomsel, Morgane] Inst Cochin Genet Mol, Dept Biol Cellulaire, F-75014 Paris, France.
RP Mor, TS (reprint author), Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, POB 874501, Tempe, AZ 85287 USA.
EM tsafrir.mor@asu.edu
RI mor, tsafrir/E-9422-2013
FU National Institutes of Health (NIH) [IR21AI052761-01A2, U19AI62150]
FX The authors gratefully acknowledge Dan Brune (ASU Protein Chemistry
   Laboratory) for performing N-terminal sequencing and MALDI-TOF analysis
   on plant- and bacteria-derived CTB-MPR<INF>649-684</INF>. We thank
   Jacquelyn Kilbourne for her excellent support in animal immunization,
   and Michele Mittman for her help in protein purification. The work
   presented here was supported in part by National Institutes of Health
   (NIH) grants to TSM (IR21AI052761-01A2 and U19AI62150).
CR ALFSEN A, 2002, J BIOL CHEM, V8, P8
   Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810
   Arakawa T, 1998, NAT BIOTECHNOL, V16, P934, DOI 10.1038/nbt1098-934                                                             
   Bardor M, 2003, PLANT BIOTECHNOL J, V1, P451, DOI 10.1046/j.1467-7652.2003.00041.x
   Bauly JM, 2000, PLANT PHYSIOL, V124, P1229, DOI 10.1104/pp.124.3.1229
   Belec L, 2001, J INFECT DIS, V184, P1412, DOI 10.1086/324375                                                                  
   Belyakov IM, 2004, IMMUNITY, V20, P247, DOI 10.1016/S1074-7613(04)00053-6                                                   
   Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028
   Bomsel M, 2003, NAT REV MOL CELL BIO, V4, P57, DOI 10.1038/nrm1005
   Broliden K, 2001, IMMUNOL LETT, V79, P29, DOI 10.1016/S0165-2478(01)00263-2                                                   
   *COORD COMM GLOB H, 2005, PLOS MED, V2, pE25, DOI DOI 10.1371/JOURNAL.PMED.0020025
   Cox KM, 2006, NAT BIOTECHNOL, V24, P1591, DOI 10.1038/nbt1260
   Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921
   Daniell Henry, 2006, Biotechnology Journal, V1, P1071, DOI 10.1002/biot.200600145
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   Devito C, 2000, AIDS, V14, P1917, DOI 10.1097/00002030-200009080-00006                                                
   Devito C, 2002, J ACQ IMMUN DEF SYND, V30, P413, DOI 10.1097/01.QAI.0000021664.20213.5A
   East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7
   Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000
   FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024
   FITCHETTELAINE AC, 1994, PLANT J, V5, P673, DOI 10.1111/j.1365-313X.1994.00673.x
   Francis DP, 2003, AIDS, V17, P147, DOI 10.1097/01.aids.0000050786.28043.62
   Fujiyama K, 2006, J BIOSCI BIOENG, V101, P212, DOI 10.1263/jbb.101.212
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, V10, P571, DOI DOI 10.1385/1-59259-890-0:571
   Geyer BC, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-27
   Hanke T, 2008, EXPERT REV VACCINES, V7, P303, DOI 10.1586/14760584.7.3.303
   HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379                                                         
   Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752
   Henderson J, 1997, PLANTA, V202, P313, DOI 10.1007/s004250050133
   HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520
   Jani D, 2002, TRANSGENIC RES, V11, P447, DOI 10.1023/A:1020336332392
   Jefferis R, 2005, BIOTECHNOL PROGR, V21, P11, DOI 10.1021/bp040016j
   Kaul R, 2001, AIDS, V15, P431, DOI 10.1097/00002030-200102160-00026
   Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953
   Kim TG, 2003, PLANT CELL REP, V21, P884, DOI 10.1007/s00299-003-0599-4
   Ko KS, 2003, P NATL ACAD SCI USA, V100, P8013, DOI 10.1073/pnas.0832472100
   KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232                                                  
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215
   KUROSKY A, 1977, SCIENCE, V195, P299, DOI 10.1126/science.831277                                                          
   LAI CY, 1977, J BIOL CHEM, V252, P7249
   Lam JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001009
   Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654                                                         
   Lesieur C, 2002, J BIOL CHEM, V277, P16697, DOI 10.1074/jbc.M110561200
   Liljeqvist S, 1997, J IMMUNOL METHODS, V210, P125, DOI 10.1016/S0022-1759(97)00170-1
   LOCKMAN H, 1983, J BIOL CHEM, V258, P3722
   Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035
   MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2                                                    
   Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2
   Matoba N, 2006, VACCINE, V24, P5047, DOI 10.1016/j.vaccine.2006.03.045
   Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101
   MATOBA N, 2006, METABOLIC ENG MOL PH, P143
   Matoba N, 2008, CURR HIV RES, V6, P218, DOI 10.2174/157016208784324994                                                      
   Molinari M, 2007, NAT CHEM BIOL, V3, P313, DOI 10.1038/nchembio880
   Mor TS, 2001, BIOTECHNOL BIOENG, V75, P259, DOI 10.1002/bit.10012
   MOR TS, 2004, HDB PLANT BIOTECHNOL, P768
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Nochi T, 2007, P NATL ACAD SCI USA, V104, P10986, DOI 10.1073/pnas.0703766104
   Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001                                              
   Petruccelli S, 2006, PLANT BIOTECHNOL J, V4, P511, DOI 10.1111/j.1467-7652.2006.00200.x
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Saint-Jore-Dupas C, 2007, TRENDS BIOTECHNOL, V25, P317, DOI 10.1016/j.tibtech.2007.04.008
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Stambach NS, 2003, GLYCOBIOLOGY, V13, P401, DOI 10.1093/glycob/cwg045
   Steinbrook R, 2007, NEW ENGL J MED, V357, P2653, DOI 10.1056/NEJMp0708117
   Tacket CO, 2005, VACCINE, V23, P1866, DOI 10.1016/j.vaccine.2004.11.019
   Tekoah Y, 2004, ARCH BIOCHEM BIOPHYS, V426, P266, DOI 10.1016/j.abb.2004.02.034
   Thanavala Y, 2006, EXPERT REV VACCINES, V5, P249, DOI 10.1586/14760584.5.2.249
   Triguero A, 2005, PLANT BIOTECHNOL J, V3, P449, DOI 10.1111/j.1467-7652.2005.00137.x
   Van Droogenbroeck B, 2007, P NATL ACAD SCI USA, V104, P1430, DOI 10.1073/pnas.0609997104
   Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622
   Walmsley AM, 2003, PLANT CELL REP, V21, P1020, DOI 10.1007/s00299-003-0619-4
   Whaley KJ, 2005, VACCINE, V23, P1819, DOI 10.1016/j.vaccine.2004.11.012
   Wilkinson J, 2006, CURR DRUG TARGETS, V7, P1563, DOI 10.2174/138945006779025482
   Yu HF, 2008, CELL CALCIUM, V43, P73, DOI 10.1016/j.ceca.2007.04.011
   Yu J, 2001, NAT BIOTECHNOL, V19, P548, DOI 10.1038/89297
   Yuki Yoshikazu, 2007, Tuberculosis (Edinb), V87 Suppl 1, pS35, DOI 10.1016/j.tube.2007.05.005
   Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2
   Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171
NR 78
TC 36
Z9 38
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1467-7644
J9 PLANT BIOTECHNOL J
JI Plant Biotechnol. J.
PD FEB
PY 2009
VL 7
IS 2
BP 129
EP 145
DI 10.1111/j.1467-7652.2008.00381.x
PG 17
WC Biotechnology & Applied Microbiology; Plant Sciences
SC Biotechnology & Applied Microbiology; Plant Sciences
GA 393CR
UT WOS:000262349000002
PM 19037902
DA 2018-01-05
ER

PT J
AU Ferro, S
   De Luca, L
   Barreca, ML
   Iraci, N
   De Grazia, S
   Christ, F
   Witvrouw, M
   Debyser, Z
   Chimirri, A
AF Ferro, Stefania
   De Luca, Laura
   Barreca, Maria Letizia
   Iraci, Nunzio
   De Grazia, Sara
   Christ, Frauke
   Witvrouw, Myriam
   Debyser, Zeger
   Chimirri, Alba
TI Docking Studies on a New Human Immodeficiency Virus Integrase-Mg-DNA
   Complex: Phenyl Ring Exploration and Synthesis of 1H-Benzylindole
   Derivatives through Fluorine Substitutions
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID FULL-LENGTH INTEGRASE; HIV-1 INTEGRASE; STRAND-TRANSFER; ACTIVE-SITE;
   TN5 TRANSPOSASE; BINDING MODE; INHIBITORS; RESISTANCE; TYPE-1; MUTATIONS
AB A new model of HIV-1 integrase-Mg-DNA complex that is useful for docking experiments has been built. It was used to study the binding mode of integrase strand transfer inhibitor 1 (CHI-1043) and other fluorine analogues. Molecular modeling results prompted us to synthesize the designed derivatives which showed potent enzymatic inhibition at nanomolar concentration, high antiviral activity, and low toxicity. Microwave assisted organic synthesis (MAOS) was employed in several steps of the synthetic pathway, thus reducing reaction times and improving yields.
C1 [Chimirri, Alba] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy.
   Katholieke Univ Leuven, B-3000 Leuven, Belgium.
   KULAK, IRC, B-3000 Louvain, Flanders, Belgium.
RP Chimirri, A (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
EM chimirri@pharma.unime.it
RI De Luca, Laura/D-8532-2011; Iraci, Nunzio/B-4945-2015
OI Iraci, Nunzio/0000-0002-1359-8684; Barreca, Maria
   Letizia/0000-0003-3530-5042; De Luca, Laura/0000-0003-0614-5713;
   debyser, zeger/0000-0002-3982-1565
FU THINC project (European Commission) [HEALTH-F3-2008-201032]
FX We acknowledge technical assistance at the Katholieke Universiteit
   Leuven of Martine Michiels (integrase assays), Linda Desender (protein
   purification), and Barbara Van Remoortel (HIV assays). This work was
   Supported by THINC project (European Commission
   GrantHEALTH-F3-2008-201032).
CR ALVES CN, BIOPHYS J, DOI DOI 10.1529/BI0-PHYSJ.107.107623
   Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633                                                        
   Ason B, 2005, ANTIMICROB AGENTS CH, V49, P2035, DOI 10.1128/AAC.49.5.2035-2043.2005
   Barreca ML, 2007, BIOCHEM BIOPH RES CO, V363, P554, DOI 10.1016/j.bbrc.2007.08.199
   Barreca ML, 2006, J MED CHEM, V49, P3994, DOI 10.1021/jm060323r
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   BEESE LS, 1991, EMBO J, V10, P25
   Bohm HJ, 2004, CHEMBIOCHEM, V5, P637, DOI 10.1002/cbic.200301023
   Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161
   Busschots K, 2007, J MOL BIOL, V365, P1480, DOI 10.1016/j.jmb.2006.10.094
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   d'Angelo J, 2001, PATHOL BIOL, V49, P237, DOI 10.1016/S0369-8114(01)00135-3                                                   
   De Luca L, 2005, BIOCHEM BIOPH RES CO, V336, P1010, DOI 10.1016/j.bbrc.2005.08.211
   De Luca L, 2003, BIOCHEM BIOPH RES CO, V310, P1083, DOI 10.1016/j.bbrc.2003.09.120
   De Luca L, 2008, BIOORG MED CHEM LETT, V18, P2891, DOI 10.1016/j.bmcl.2008.03.089
   DeLano Warren, PYMOL MOL GRAPHICS S
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Fikkert V, 2003, J VIROL, V77, P11459, DOI 10.1128/JVI.77.21.11459-11470.2003
   Gerton JL, 1998, J VIROL, V72, P5046
   GOLDBECK J, 2003, J WEB SEMANT, V1, P1
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849
   Johnson AA, 2004, CURR TOP MED CHEM, V4, P1059, DOI 10.2174/1568026043388394                                                        
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600
   Maurin C, 2004, J MED CHEM, V47, P5583, DOI 10.1021/jm0408464
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   *SCHROD LLC, 2007, MAESTRO0 VERS 8
   *SCHROD LLC, 2007, MACROMODEL VERS 9 5M
   Steiniger-White M, 2004, CURR OPIN STRUC BIOL, V14, P50, DOI 10.1016/j.sbi.2004.01.008
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   Wielens J, 2005, J COMPUT AID MOL DES, V19, P301, DOI 10.1007/s10822-005-5256-2
   YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3
NR 38
TC 31
Z9 32
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 22
PY 2009
VL 52
IS 2
BP 569
EP 573
DI 10.1021/jm8009266
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 395KD
UT WOS:000262522100038
PM 19105658
DA 2018-01-05
ER

PT J
AU Subramanyam, R
   Gollapudi, A
   Bonigala, P
   Chinnaboina, M
   Amooru, DG
AF Subramanyam, Rajagopal
   Gollapudi, Anilkishor
   Bonigala, Persis
   Chinnaboina, Madhurarekha
   Amooru, Damu G.
TI Betulinic acid binding to human serum albumin: A study of protein
   conformation and binding affinity
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Betulinic acid; Binding constants; Circuar dichroisin; Human serum
   albumin; Micro TOF-Q mass spectrometry; Tephrosia calophylla
ID MICROBIAL TRANSFORMATIONS; CRYSTAL-STRUCTURE; LIGAND-BINDING;
   DRUG-BINDING; FATTY-ACIDS; INHIBITOR; CANCER; SPECIFICITY; STABILITY;
   REVEALS
AB Betulinic acid (BA) has anti cancer and anti-HIV activity and has been proved to be therapeutically effective against cancerous and HIV-infected cells. Human serum albumin (HSA) is the predominant protein in the blood. Most drugs that bind to HSA will be transported to other parts of the body. Using micro TOF-Q mass spectrometry, we have shown, for the first time that BA isolated from a plant (Tephrosio calophylla) binds to HSA. The binding constant of BA to HSA was calculated from fluorescence data and found to be I(BA = 1.685 +/- 0.01 x 10(6) M(-1), indicating a strong binding affinity. The secondary structure of the HSA-BA complex was determined by circular dichroism. The results indicate that the HSA in this complex is partially unfolded. Further, binding of BA at nanomolar concentrations of BA to free HSA was detected using micro TOF-Q mass spectrometry. The study revealed a mass increase from 65199 Da (free HSA) to 65643 Da (HSA + drug), where the additional mass of 444 Da was due to bound BA. Based on the results of this study, it is suggested that micro TOF-Q mass spectrometry is useful technique for drug binding studies. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Subramanyam, Rajagopal; Gollapudi, Anilkishor; Bonigala, Persis; Chinnaboina, Madhurarekha] Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India.
   [Amooru, Damu G.] Yogi Vemana Univ, Dept Chem, Kadapa 516003, Andhra Pradesh, India.
RP Subramanyam, R (reprint author), Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India.
EM psrajagopal@yahoo.com
CR Ahmad B, 2006, BIOMACROMOLECULES, V7, P1350, DOI 10.1021/bm050996b
   Akihisa T, 2002, J NAT PROD, V65, P278, DOI 10.1021/np010424m
   ARONSON JK, 1980, CLIN PHARMACOKINET, V5, P137, DOI 10.2165/00003088-198005020-00002                                                
   Beauchemin R, 2007, BIOMACROMOLECULES, V8, P3177, DOI 10.1021/bm700697a
   Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158
   BHATTACHARYYA J, 1994, BIOCHEM PHARMACOL, V47, P2049, DOI 10.1016/0006-2952(94)90080-9
   Chatterjee P, 2000, APPL ENVIRON MICROB, V66, P3850, DOI 10.1128/AEM.66.9.3850-3855.2000                                                 
   Chowdhury AR, 2002, MED SCI MONITOR, V8
   Cichewicz RH, 2004, MED RES REV, V24, P90, DOI 10.1002/med.10053
   Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   Dufour C, 2005, BBA-GEN SUBJECTS, V1721, P164, DOI 10.1016/j.bbagen.2004.10.013
   Ganguly A, 2007, CANCER RES, V67, P11848, DOI 10.1158/0008-5472.CAN-07-1615
   Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075
   He H. M., 1992, NATURE, V358, P209
   He WY, 2006, J PHOTOCH PHOTOBIO A, V182, P158, DOI 10.1016/j.jphotochem.2006.02.004
   JACKSON PR, 1982, CLIN PHARMACOL THER, V32, P295, DOI 10.1038/clpt.1982.163                                                           
   Jiang YL, 2008, BIOORGAN MED CHEM, V16, P6406, DOI 10.1016/j.bmc.2008.05.002
   Kanakis CD, 2007, J AGR FOOD CHEM, V55, P970, DOI 10.1021/jf062638l
   Kouzi SA, 2000, J NAT PROD, V63, P1653, DOI 10.1021/np000343a
   KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57
   Lewis DFV, 1998, XENOBIOTICA, V28, P235, DOI 10.1080/004982598239542                                                         
   Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100
   MCKICHAN JJ, 1990, APPL PHARMACOKINETIC, P5
   N'soukpoe-Kossi CN, 2007, INT J BIOL MACROMOL, V40, P484, DOI 10.1016/j.ijbiomac.2006.11.005
   Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2001.5208
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046                                                             
   Rajendran P, 2008, INVEST NEW DRUG, V26, P25, DOI 10.1007/s10637-007-9081-4
   SEGRE EJ, 1974, CLIN PHARMACOL THER, V15, P374
   Sen P, 2008, EUR BIOPHYS J BIOPHY, V37, P1303, DOI 10.1007/s00249-008-0335-7
   Sinha SS, 2008, J PHYS CHEM B, V112, P4884, DOI 10.1021/jp709809b
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439
   VANPEER AP, 1981, PHARMACOLOGY, V22, P146, DOI 10.1159/000137483
   Zhou J, 2004, J VIROL, V78, P922, DOI 10.1128/JVI.78.2.922-929.2004
NR 34
TC 74
Z9 75
U1 0
U2 3
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD JAN 9
PY 2009
VL 94
IS 1
BP 8
EP 12
DI 10.1016/j.jphotobiol.2008.09.002
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 395XK
UT WOS:000262556600002
PM 18945624
DA 2018-01-05
ER

PT J
AU van Kasteren, SI
   Campbell, SJ
   Serres, S
   Anthony, DC
   Sibson, NR
   Davis, BG
AF van Kasteren, Sander I.
   Campbell, Sandra J.
   Serres, Sebastien
   Anthony, Daniel C.
   Sibson, Nicola R.
   Davis, Benjamin G.
TI Glyconanoparticles allow pre-symptomatic in vivo imaging of brain
   disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE carbohydrates; MRI; multiple sclerosis; selectins
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CARBOHYDRATE-PROTEIN
   INTERACTION; EARLY ENDOTHELIAL ACTIVATION; MEDIATED SELF-RECOGNITION;
   CEREBRAL BLOOD-VOLUME; MARINE SPONGE CELLS; GOLD GLYCONANOPARTICLES;
   MAGNETIC-RESONANCE; E-SELECTIN; 2-IMINO-2-METHOXYETHYL 1-THIOGLYCOSIDES
AB Initial recruitment of leukocytes in inflammation associated with diseases such as multiple sclerosis (MS), ischemic stroke, and HIV-related dementia, takes place across intact, but activated brain endothelium. It is therefore undetectable to symptom-based diagnoses and cannot be observed by conventional imaging techniques, which rely on increased permeability of the blood-brain barrier (BBB) in later stages of disease. Specific visualization of the early-activated cerebral endothelium would provide a powerful tool for the presymptomatic diagnosis of brain disease and evaluation of new therapies. Here, we present the design, construction and in vivo application of carbohydrate-functionalized nanoparticles that allow direct detection of endothelial markers E-/P-selectin (CD62E/CD62P) in acute inflammation. These first examples of MRI-visible glyconanoparticles display multiple copies of the natural complex glycan ligand of selectins. Their resulting sensitivity and binding selectivity has allowed acute detection of disease in mammals with beneficial implications for treatment of an expanding patient population suffering from neurological disease.
C1 [Campbell, Sandra J.; Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England.
   [van Kasteren, Sander I.; Davis, Benjamin G.] Univ Oxford, Chem Res Lab, Dept Chem, Oxford OX1 3TA, England.
   [Serres, Sebastien; Sibson, Nicola R.] Univ Oxford, Radiobiol Res Inst, Gray Inst Radiat Oncol & Biol, Oxford OX3 7LJ, England.
   [Serres, Sebastien; Sibson, Nicola R.] Univ Oxford, MRC, Oxford OX3 7LJ, England.
RP Anthony, DC (reprint author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.
EM daniel.anthony@pharm.ox.ac.uk; nicola.sibson@rob.ox.ac.uk;
   ben.davis@chem.ox.ac.uk
RI Anthony, Daniel/F-7765-2010; Davis, Benjamin/C-5281-2011
OI Anthony, Daniel/0000-0003-1380-6655; Davis, Benjamin/0000-0002-5056-407X
FU Glycoform Ltd [G0400131]; Cancer Research United Kingdom [C28462/A10158]
FX We thank Andrew Lowe for technical assistance. This work was supported
   by a studentship from Glycoform Ltd. ( to S. I. v. K. and B. G. D.),
   Medical Research Council Grant G0400131 ( to N. R. S. and S. S.), and
   Cancer Research United Kingdom Grant C28462/A10158 ( to N. R. S.).
CR Andre JP, 2004, CHEM-EUR J, V10, P5804, DOI 10.1002/chem.200400187
   Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435
   Baia P, 2005, EUR J INORG CHEM, P2110, DOI 10.1002/ejic.200400766
   Barber PA, 2004, ANN NEUROL, V56, P116, DOI 10.1002/ana.20162
   Bernardes-Silva M, 2001, J CEREBR BLOOD F MET, V21, P1115, DOI 10.1097/00004647-200109000-00009                                                
   Blamire AM, 2000, J NEUROSCI, V20, P8153
   Boutry S, 2005, MAGNET RESON MED, V53, P800, DOI 10.1002/mrm.20403
   Boutry S, 2006, CONTRAST MEDIA MOL I, V1, P15, DOI 10.1002/cmmi.87
   Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256
   Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924
   Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551
   Chan W. C., 2000, FMOC SOLID PHASE PEP
   de la Fuente JDM, 2005, TETRAHEDRON-ASYMMETR, V16, P387, DOI 10.1016/j.tetasy.2004.12.002
   de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb                                              
   de la Fuente JM, 2001, ANGEW CHEM INT EDIT, V40, P2258
   de Souza AC, 2004, EUR J ORG CHEM, P4323, DOI 10.1002/ejoc.200400255
   de Souza AC, 2005, CHEMBIOCHEM, V6, P828, DOI 10.1002/cbic.200400380
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433                                             
   Flynn NT, 2003, LANGMUIR, V19, P10909, DOI 10.1021/la035331e
   Fulton DA, 2006, CHEM COMMUN, P1064, DOI 10.1039/b517997a
   GASSER DL, 1973, SCIENCE, V181, P872, DOI 10.1126/science.181.4102.872
   Halkes KM, 2005, EUR J ORG CHEM, P3650, DOI 10.1002/ejoc.200500256
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   LaConte L, 2005, MATER TODAY, V8, P32, DOI DOI 10.1016/S1369-7021(05)00893-X
   Lee BPL, 2008, NAT IMMUNOL, V9, P117, DOI 10.1038/ni0208-117
   LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008
   LEE YC, 1992, FASEB J, V6, P3193
   LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001                                                             
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101                                             
   McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631
   NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275                                                               
   Pearce OMT, 2005, ANGEW CHEM INT EDIT, V44, P1057, DOI 10.1002/anie.200461832
   Perez JM, 2002, J AM CHEM SOC, V124, P2856, DOI 10.1021/ja017773n
   Reynolds PR, 2006, RADIOLOGY, V241, P469, DOI 10.1148/radiol.2412050490
   Robinson MA, 2004, P NATL ACAD SCI USA, V101, P14527, DOI 10.1073/pnas.0303574101
   Schlenoff JB, 1995, J AM CHEM SOC, V117, P12528, DOI 10.1021/ja00155a016                                                             
   SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D
   SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108                                                          
   Sibson NR, 2008, J CEREBR BLOOD F MET, V28, P621, DOI 10.1038/sj.jcbfm.9600549
   Sibson NR, 2004, MAGNET RESON MED, V51, P248, DOI 10.1002/mrm.10723
   Sibson NR, 2002, BRAIN, V125, P2446, DOI 10.1093/brain/awf256                                                            
   SIBSON NR, 2007, J CEREB BLOOD FLOW M
   Sobenin IA, 1998, J LIPID RES, V39, P2293
   STOWELL CP, 1982, METHOD ENZYMOL, V83, P278
   Takahashi M, 2000, TETRAHEDRON LETT, V41, P8485, DOI 10.1016/S0040-4039(00)01488-X
   Tanaka H, 2005, ORG BIOMOL CHEM, V3, P3311, DOI 10.1039/b507824e                                                                
   Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e
   UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871                                                    
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407                                                     
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   WILLIAMS RM, 1973, J EXP MED, V138, P775, DOI 10.1084/jem.138.4.775
   Zhao Y, 2005, J AM CHEM SOC, V127, P7328, DOI 10.1021/ja050432f                                                               
   PALMACCI S, 1995, Patent No. 76829505669
NR 56
TC 151
Z9 151
U1 5
U2 40
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 6
PY 2009
VL 106
IS 1
BP 18
EP 23
DI 10.1073/pnas.0806787106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 391WC
UT WOS:000262263900007
PM 19106304
OA gold
DA 2018-01-05
ER

PT J
AU Hofmann, A
   Wenzel, D
   Becher, UM
   Freitag, DF
   Klein, AM
   Eberbeck, D
   Schulte, M
   Zimmermann, K
   Bergemann, C
   Gleich, B
   Roell, W
   Weyh, T
   Trahms, L
   Nickenig, G
   Fleischmann, BK
   Pfeifer, A
AF Hofmann, Andreas
   Wenzel, Daniela
   Becher, Ulrich M.
   Freitag, Daniel F.
   Klein, Alexandra M.
   Eberbeck, Dietmar
   Schulte, Maike
   Zimmermann, Katrin
   Bergemann, Christian
   Gleich, Bernhard
   Roell, Wilhelm
   Weyh, Thomas
   Trahms, Lutz
   Nickenig, Georg
   Fleischmann, Bernd K.
   Pfeifer, Alexander
TI Combined targeting of lentiviral vectors and positioning of transduced
   cells by magnetic nanoparticles
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cell positioning; gene transfer; vector targeting
ID IN-VIVO; VIRUS ENTRY; MAGNETOFECTION; INFECTION; THERAPY; VESSELS;
   FORCE; MICE; HIV
AB Targeting of viral vectors is a major challenge for in vivo gene delivery, especially after intravascular application. In addition, targeting of the endothelium itself would be of importance for gene-based therapies of vascular disease. Here, we used magnetic nanoparticles (MNPs) to combine cell transduction and positioning in the vascular system under clinically relevant, nonpermissive conditions, including hydrodynamic forces and hypothermia. The use of MNPs enhanced transduction efficiency of endothelial cells and enabled direct endothelial targeting of lentiviral vectors (LVs) by magnetic force, even in perfused vessels. In addition, application of external magnetic fields to mice significantly changed LV/MNP biodistribution in vivo. LV/MNP-transduced cells exhibited superparamagnetic behavior as measured by magnetorelaxometry, and they were efficiently retained by magnetic fields. The magnetic interactions were strong enough to position MNP-containing endothelial cells at the intima of vessels under physiological flow conditions. Importantly, magnetic positioning of MNP-labeled cells was also achieved in vivo in an injury model of the mouse carotid artery. Intravascular gene targeting can be combined with positioning of the transduced cells via nanomagnetic particles, thereby combining gene- and cell-based therapies.
C1 [Hofmann, Andreas; Schulte, Maike; Zimmermann, Katrin; Pfeifer, Alexander] Univ Bonn, Inst Pharmacol & Toxicol, D-53115 Bonn, Germany.
   [Wenzel, Daniela; Freitag, Daniel F.; Klein, Alexandra M.; Fleischmann, Bernd K.] Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany.
   [Becher, Ulrich M.; Nickenig, Georg] Univ Bonn, Dept Internal Med 2, D-53115 Bonn, Germany.
   [Roell, Wilhelm] Univ Bonn, Dept Cardiac Surg, D-53115 Bonn, Germany.
   [Fleischmann, Bernd K.; Pfeifer, Alexander] Univ Bonn, PharmaCtr Bonn, D-53115 Bonn, Germany.
   [Eberbeck, Dietmar; Trahms, Lutz] Phys Tech Bundesanstalt, D-10587 Berlin, Germany.
   [Bergemann, Christian] Chemicell GmbH, D-12103 Berlin, Germany.
   [Gleich, Bernhard; Weyh, Thomas] Tech Univ Munich, Zentralinst Med Tech, D-80333 Munich, Germany.
RP Pfeifer, A (reprint author), Univ Bonn, Inst Pharmacol & Toxicol, D-53115 Bonn, Germany.
EM alexander.pfeifer@uni-bonn.de
RI Wenzel, Daniela/B-7613-2014
OI Wenzel, Daniela/0000-0003-1100-6363
FU Deutsche Forschungsgemeinschaft Transregio Research Unit 535, the
   Germany Federal Ministry of Education and Research [FKZ 13N9150]; NRW
   International Graduate Research School
FX We thank Barbara Muller ( Department of Virology, Universitatsklinikum
   Heidelberg, Heidelberg, Germany) for providing the plasmids pCHIV(Env-)
   and pCHIV. eGFP(Env-). We are very grateful to Christina Stichnote,
   Jutta Mulich, Frank Holst, and Monika Czechowski for expert technical
   assistance. This work was supported by the Deutsche
   Forschungsgemeinschaft Transregio Research Unit 535, the Germany Federal
   Ministry of Education and Research (FKZ 13N9150), and the NRW
   International Graduate Research School.
CR Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979                                                                   
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Eberbeck D, 2006, J PHYS-CONDENS MAT, V18, pS2829, DOI 10.1088/0953-8984/18/38/S20
   Haim H, 2005, J VIROL, V79, P622, DOI 10.1128/JVI.79.1.622-625.2005
   Kadota S, 2005, J VIROL METHODS, V128, P61, DOI 10.1016/j.jviromet.2005.04.003
   Lampe M, 2007, VIROLOGY, V360, P92, DOI 10.1016/j.virol.2006.10.005
   LINDNER V, 1993, CIRC RES, V73, P792
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Pan D, 2002, MOL THER, V6, P19, DOI 10.1006/mthe.2002.0630
   Perea H, 2007, J TISSUE ENG REGEN M, V1, P318, DOI 10.1002/term.32
   Pfeifer A, 2006, J CLIN INVEST, V116, P3204, DOI 10.1172/JCI29236
   Pislaru SV, 2006, J AM COLL CARDIOL, V48, P1839, DOI 10.1016/j.jacc.2006.06.069
   Pislaru S.V., 2006, CIRCULATION, V114, P1314
   Roell W, 2007, NATURE, V450, P819, DOI 10.1038/nature06321
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   Shimizu K, 2007, J BIOSCI BIOENG, V103, P472, DOI 10.1263/jbb.103.472
   Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Wiznerowicz M, 2005, TRENDS BIOTECHNOL, V23, P42, DOI 10.1016/j.tibtech.2004.11.001
NR 19
TC 67
Z9 68
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 6
PY 2009
VL 106
IS 1
BP 44
EP 49
DI 10.1073/pnas.0803746106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 391WC
UT WOS:000262263900012
PM 19118196
OA gold
DA 2018-01-05
ER

PT J
AU del Pozo-Rodriguez, A
   Pujals, S
   Delgado, D
   Solinis, MA
   Gascon, AR
   Giralt, E
   Pedraz, JL
AF del Pozo-Rodriguez, A.
   Pujals, S.
   Delgado, D.
   Solinis, M. A.
   Gascon, A. R.
   Giralt, E.
   Pedraz, J. L.
TI A proline-rich peptide improves cell transfection of solid lipid
   nanoparticle-based non-viral vectors
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Solid lipid nanoparticles; Cell penetrating peptide; Transfection;
   Intracellular trafficking; Endocytic pathway
ID HIV-1 TAT PROTEIN; MEDIATED GENE-TRANSFER; LEBER CONGENITAL AMAUROSIS;
   PIGMENT EPITHELIAL-CELLS; PLASMID DNA; TRANSDUCTION DOMAIN; CATIONIC
   LIPOSOMES; MOUSE MODEL; DELIVERY; ENDOCYTOSIS
AB The aim of this work was to improve the transfection efficacy of solid lipid nanoparticle (SLN)-based non-viral vectors into ARPE-19 cells through the addition of Sweet Arrow Peptide (SAP). First, we prepared SAP-DNA complexes at ratios of at least 50:1, and then incorporated them into the SLNs. All formulations were able to protect DNA, and the peptide favoured the most bioactive form (supercoiled) of open circular DNA turns. In vitro transfection studies of the vectors containing the pCMS-EGFP plasmid in HEK293 and ARPE-19 cell lines revealed that incorporation of SAP led to greater transfection in both cell lines, although via different mechanisms. The presence of SAP in the formulations did not affect the viability of HEK293 or ARPE-19 cells. In HEK293 cells, SAP enabled greater uptake of the vectors, and an SAP to DNA ratio of 50:1 was sufficient for enhancing transfection. In contrast, in ARPE-19 cells, SAP induced a change in the dominant entrance mechanism, from clathrin endocytosis to caveolae/raft-dependent endocytosis, thereby decreasing use of the lysosomal pathway and consequently, reducing vector degradation. The extent to which SAP uses one mechanism or the other largely depends on its concentration in the formulation. (C) 2008 Elsevier B.V. All rights reserved.
C1 [del Pozo-Rodriguez, A.; Delgado, D.; Solinis, M. A.; Gascon, A. R.; Pedraz, J. L.] Univ Basque Country, Fac Pharm, Pharm & Pharmaceut Technol Lab, Vitoria 01006, Spain.
   [Pujals, S.; Giralt, E.] Inst REs Biomed, Barcelona 08028, Spain.
   [Giralt, E.] Univ Barcelona, Dept Organ Chem, E-08028 Barcelona, Spain.
RP Pedraz, JL (reprint author), Univ Basque Country, Fac Pharm, Pharm & Pharmaceut Technol Lab, Paseo Univ 7, Vitoria 01006, Spain.
EM joseluis.pedraz@ehu.es
RI giralt, ernest/N-1669-2014; SGIKER, Cienciometria/A-5759-2012; Pujals,
   Silvia/G-3193-2016
OI giralt, ernest/0000-0001-8381-1797; Pujals, Silvia/0000-0003-1776-4296;
   PEDRAZ MUNOZ, JOSE LUIS/0000-0002-3938-2267
FU Spanish Ministry for Science and Innovation [AP2003-4780, AP2004-2343];
   Departamento de Educacion, Universidades e lnvestigacion del Gobierno
   Vasco; MCYT-FEDER [Bio2005-00295, NAN2004-09159-CO4-02]; Generalitat de
   Catalunya (CERBA) [2005SGR-00663]
FX We would like to thank the Spanish Ministry for Science and Innovation
   for research grants awarded to Ana del Pozo-Rodriguez (AP2003-4780) and
   Silvia Pujals (AP2004-2343). The authors also acknowledge the General
   Service of Analytical Microscopy and High Resolution in Biomedicine of
   the University of the Basque Country (UPV-EHU) for technical advice on
   confocal microscopy. This work was supported by the Departamento de
   Educacion, Universidades e lnvestigacion del Gobierno Vasco (IT-407-07),
   MCYT-FEDER (Bio2005-00295 and NAN2004-09159-CO4-02) and the Generalitat
   de Catalunya (CERBA and 2005SGR-00663).
CR Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Bejjani R, 2005, MOL VIS, V11, P124
   Belting M, 2005, ADV DRUG DELIVER REV, V57, P505, DOI 10.1016/j.addr.2004.10.004
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Borgia SL, 2005, J CONTROL RELEASE, V110, P151, DOI 10.1016/j.jconrel.2005.09.045
   Boulanger C, 2005, EUR J MED CHEM, V40, P1295, DOI 10.1016/j.ejmech.2005.07.015
   Chaum E, 2000, J CELL BIOCHEM, V76, P153, DOI 10.1002/(SICI)1097-4644(20000101)76:1<153::AID-JCB15>3.0.CO;2-#                 
   Christiaens B, 2005, EUR J PHARM SCI, V24, P525, DOI 10.1016/j.ejps.2005.01.004
   del Pozo-Rodriguez A, 2008, INT J PHARM, V360, P177, DOI 10.1016/j.ijpharm.2008.04.023
   del Pozo-Rodriguez A, 2007, INT J PHARM, V339, P261, DOI 10.1016/j.ijpharm.2007.02.015
   Doi K, 2002, VISION RES, V42, P551, DOI 10.1016/S0042-6989(01)00237-1
   Fernandez-Carneado J, 2004, BIOPOLYMERS, V76, P196, DOI 10.1002/bip.10585
   Fernandez-Carneado J, 2004, ANGEW CHEM INT EDIT, V43, P1811, DOI 10.1002/anie.200352540
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Harush-Frenkel O, 2007, BIOCHEM BIOPH RES CO, V353, P26, DOI 10.1016/j.bbrc.2006.11.135
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   Huth US, 2006, J CONTROL RELEASE, V110, P490, DOI 10.1016/j.jconrel.2005.10.018
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Khalil Ikramy A, 2008, Int J Pharm, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Kim TW, 2002, J CONTROL RELEASE, V82, P455, DOI 10.1016/S0168-3659(02)00138-4
   Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1                                                   
   Liu F, 1996, PHARMACEUT RES, V13, P1856, DOI 10.1023/A:1016041326636
   Mannisto M, 2005, J GENE MED, V7, P466, DOI 10.1002/jgm.693
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Middaugh CR, 1998, J PHARM SCI, V87, P130, DOI 10.1021/js970367a
   Min SH, 2005, MOL THER, V12, P644, DOI 10.1016/j.ymthe.2005.06.002
   Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028
   Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529
   Olbrich C, 2001, J CONTROL RELEASE, V77, P345, DOI 10.1016/S0168-3659(01)00506-5
   Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905
   PITKANEN L, 2004, AAPS J, V6, P1
   PUJALS S, 2007, CHEMMEDCHEM, V3, P296
   Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084
   Rea JC, 2008, J PHARM SCI-US, V97, P4794, DOI 10.1002/jps.21338
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Remaut K, 2006, J CONTROL RELEASE, V115, P335, DOI 10.1016/j.jconrel.2006.08.009
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Salvati A, 2006, BIOPHYS CHEM, V121, P21, DOI 10.1016/j.bpc.2005.12.009
   SANDERS NN, 2006, THERAPEUTIC ENZYMES, P97
   Suzuki K, 2004, J MOL CELL CARDIOL, V36, P603, DOI 10.1016/j.yjmcc.2004.01.007
   Tabatt K, 2004, J CONTROL RELEASE, V97, P321, DOI 10.1016/j.jconrel.2004.02.029
   Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756
NR 45
TC 57
Z9 58
U1 1
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 5
PY 2009
VL 133
IS 1
BP 52
EP 59
DI 10.1016/j.jconrel.2008.09.004
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 400NG
UT WOS:000262874400010
PM 18854203
DA 2018-01-05
ER

PT B
AU Bolopion, A
   Cagneau, B
   Redon, S
   Regnier, S
AF Bolopion, Aude
   Cagneau, Barthelemy
   Redon, Stephane
   Regnier, Stephane
GP IEEE
TI Haptic feedback for molecular simulation
SO 2009 IEEE-RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS
LA English
DT Proceedings Paper
CT IEEE RSJ International Conference on Intelligent Robots and Systems
CY OCT 10-15, 2009
CL St Louis, MO
SP IEEE Robot & Automat Soc (RA), Robot Soc Japan (RSJ), Soc Instruments & Control Engn, IEEE Ind Elect Soc, Inst Control, Robot & Syst Korea, ABB, Barrett Technol, Inc, Willow Garage, ROBOTIS, Aldebaran Robot
ID DOCKING
AB In this paper, a new tool dedicated to the analysis and the conception of molecules is presented. It is composed of an adaptive simulation software and a haptic device used to interact with molecules while feeling either the forces applied by the environment or the internal forces. The adaptive articulated body algorithm allows fast simulations of complex flexible molecules. To handle the coupling with the force feedback device, two different control schemes designed for nanoscale applications and providing high transparency rendering are proposed and compared.
   The system we propose is highly flexible since either a single rigid body or the entire molecule can be manipulated via the haptic device. The user can choose between setting a desired position/orientation of the molecule, or apply forces/torques to manipulate it. It allows the operator to control each stage of the design process of new molecular structures.
   The validity of this tool is demonstrated through examples of haptic interaction between the HIV protease and its inhibitors, and unfolding one of these drugs.
C1 [Bolopion, Aude; Cagneau, Barthelemy; Regnier, Stephane] Univ Paris 06, CNRS, Inst Syst Intelligents & Robot, UMR 7222, 4 Pl Jussieu, F-75005 Paris, France.
   [Redon, Stephane] INRIA, NANO D, Saint Ismier, France.
RP Bolopion, A (reprint author), Univ Paris 06, CNRS, Inst Syst Intelligents & Robot, UMR 7222, 4 Pl Jussieu, F-75005 Paris, France.
EM bolopion@isir.fr; cagneau@isir.fr; stephane.redon@inria.fr;
   regnier@isir.fr
FU French National Agency of Research, through the PACMAN project
FX This work was supported by the French National Agency of Research,
   through the PACMAN project.
CR Atakan B., 2007, BIOINSPIRED MODELS N, P33
   Bolopion A., 2009, P IEEE INT C ROB AUT, P4320
   Daunay B., 2007, P IEEE INT C ROB SYS, P2704
   Daunay B, 2007, IEEE INT CONF ROBOT, P840, DOI 10.1109/ROBOT.2007.363090
   Diolaiti N, 2006, IEEE T ROBOT, V22, P256, DOI 10.1109/TRO.2005.862487
   Grove TJ, 2005, IEEE T ADV PACKAGING, V28, P556, DOI 10.1109/TADVP.2005.858341
   Lai-Yuen S. K., 2006, P IEEE S HAPT INT VI, P233
   Moore M., 2007, IEEE INT C SYST MAN, P18
   Morin S, 2007, IEEE INT CONF ROBOT, P3245, DOI 10.1109/ROBOT.2007.363973
   Ouh-young M., 1988, Proceedings of the 1988 IEEE International Conference on Robotics and Automation (Cat. No.88CH2555-1), P1824, DOI 10.1109/ROBOT.1988.12330
   Rossi D. D., 1994, IEEE ENG MED BIOL, V13, P103
   Rossi R, 2007, BIOINFORMATICS, V23, pI408, DOI 10.1093/bioinformatics/btm191
   Teodoro ML, 2001, IEEE INT CONF ROBOT, P960, DOI 10.1109/ROBOT.2001.932674
NR 13
TC 4
Z9 4
U1 1
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4244-3803-7
PY 2009
BP 237
EP 242
DI 10.1109/IROS.2009.5354256
PG 6
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Robotics
SC Computer Science; Engineering; Robotics
GA BSQ11
UT WOS:000285372900038
DA 2018-01-05
ER

PT J
AU Kerman, K
   Kraatz, HB
AF Kerman, Kagan
   Kraatz, Heinz-Bernhard
TI Electrochemical probing of HIV enzymes using ferrocene-conjugated
   peptides on surfaces
SO ANALYST
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE;
   INTEGRASE INHIBITORS; MODIFIED ELECTRODE; ENTRY INHIBITORS; PROTEASE;
   MECHANISMS; THERAPY; MUTATIONS
AB One of the current pathways to develop inhibitors that target different steps in the life cycle of the human immunodeficiency virus (HIV) is blocking the function of the HIV-related proteins such as HIV-1 integrase (HIV-1 IN), HIV-1 reverse transcriptase (HIV-1 RT)and HIV-1 protease (HIV-1 PR), which are essential proteins that control the ability of HIV to infect cells, produce new copies of the virus, or cause disease. We have demonstrated for the first time the detection of these enzymes at nanomolar levels using ferrocene (Fc)-conjugated peptides on gold microelectrodes. The interaction between the Fc-conjugated peptides and the enzymes was studied by cyclic voltammetry. As the protein concentration increased, the electrochemical behaviour of the surface-bound Fc-bioconjugate changed, indicating that HIV protein was binding to the peptide film and encapsulating the Fc redox center on the surface. The electrochemical responses shifted to higher potentials and decreased in the current intensity, as the concentrations of the HIV-1 enzymes increased. The optimization studies were performed by changing the pH and NaCl concentration. Control experiments involved the exposure of the Fc-conjugated peptides with all the enzymes. This general procedure can be readily applied in the future to the multiplexed detection of several HIV-related proteins, as well as the high-throughput screening of candidate inhibitors for AIDS therapy.
C1 [Kerman, Kagan; Kraatz, Heinz-Bernhard] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada.
RP Kraatz, HB (reprint author), Univ Western Ontario, Dept Chem, 1265 Richmond St, London, ON N6A 5B7, Canada.
EM hkraatz@uwo.ca
RI Kraatz, Heinz-Bernhard/D-2246-2014
OI Kraatz, Heinz-Bernhard/0000-0002-7149-0110
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   University of Western Ontario (UWO); Ontario Ministry of Research and
   Innovation
FX This work was funded by Natural Sciences and Engineering Research
   Council of Canada (NSERC). We also appreciate the financial support from
   the University of Western Ontario (UWO). K. K. gratefully acknowledges
   funding from the Ontario Ministry of Research and Innovation in the form
   of a post-doctoral fellowship.
CR Anderson N, 2009, FOREST CHRON, V85, P110, DOI 10.5558/tfc85110-1                                                              
   BOZZI A, 2008, CURR CLIN PHARM, V3, P20
   Correll T, 2008, PHARMACOTHERAPY, V28, P90, DOI 10.1592/phco.28.1.90
   de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Finklea H. O., 1996, ELECTROANALYTICAL CH, V19, P110
   Ghosh AK, 2008, ACCOUNTS CHEM RES, V41, P78, DOI 10.1021/ar7001232
   Gleenberg IO, 2007, J MOL BIOL, V369, P1230, DOI 10.1016/j.jmb.2007.03.073
   Gupta R, 2008, CLIN INFECT DIS, V47, P712, DOI 10.1086/590943
   Kaushik-Basu N, 2008, BIODRUGS, V22, P161, DOI 10.2165/00063030-200822030-00003
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mahmoud KA, 2007, CHEM-EUR J, V13, P5885, DOI 10.1002/chem.200601878
   MILLER JC, 1993, ADV ANAL CHEM, P119
   Pace P, 2008, CURR OPIN DRUG DISC, V11, P471
   Piana S, 2001, J AM CHEM SOC, V123, P8730, DOI 10.1021/ja003145e
   Plumb K, 2003, BIOCONJUGATE CHEM, V14, P601, DOI 10.1021/bc0256446
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Shafer RW, 2008, AIDS REV, V10, P67
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Tsygankov AY, 2009, CURR OPIN INVEST DR, V10, P137
   Wilson LE, 2009, CLIN INFECT DIS, V48, P214, DOI 10.1086/595701
   Xu YM, 2001, TETRAHEDRON LETT, V42, P2601, DOI 10.1016/S0040-4039(01)00251-9                                                   
NR 27
TC 30
Z9 30
U1 0
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
J9 ANALYST
JI Analyst
PY 2009
VL 134
IS 12
BP 2400
EP 2404
DI 10.1039/b912083a
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 520RW
UT WOS:000271864900004
PM 19918608
DA 2018-01-05
ER

PT J
AU Liu, ZM
   Li, ZJ
   Shen, GL
   Yu, RQ
AF Liu, Zhi-Min
   Li, Zhe-Jian
   Shen, Guo-Li
   Yu, Ru-Qin
TI Label-Free Detection of DNA Hybridization Based on MnO2 Nanoparticles
SO ANALYTICAL LETTERS
LA English
DT Article
DE DNA; electrochemical impedance spectroscopy; HIV gene; nano-MnO2
ID GENE SEQUENCE DETECTION; IMPEDANCE SPECTROSCOPY; MODIFIED ELECTRODE;
   HYDROGEN-PEROXIDE; CARBON NANOTUBES; MANGANESE OXIDES; BIOSENSOR; FILM;
   SENSOR
AB Nano-MnO2/chitosan composite film modified glassy carbon electrode (MnO2/CHIT/GCE) was fabricated and a DNA probe was immobilized on the electrode surface. The immobilization and hybridization events of DNA were characterized by cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). The EIS was applied to the label-free detection of the target DNA. The human immunodeficiency virus (HIV) gene fragment was successfully detected by this DNA electrochemical sensor. The dynamic detection range was from 2.0x10-11 to 2.0x10-6mol/L, with a detection limit of 1.0x10-12mol/L.
C1 [Liu, Zhi-Min; Li, Zhe-Jian] Henan Univ Technol, Coll Chem & Chem Engn, Zhengzhou 450052, Peoples R China.
   [Shen, Guo-Li; Yu, Ru-Qin] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
RP Liu, ZM (reprint author), Henan Univ Technol, Coll Chem & Chem Engn, Zhengzhou 450052, Peoples R China.
EM zhimin@haut.edu.cn
FU National Natural Science Foundation [20675028]; Foundation of the
   Ministry of Education of Henan [2008B150006]; Ministry of Education of
   Henan Province [001135]
FX The financial support from the National Natural Science Foundation (No.
   20675028), Foundation of the Ministry of Education of Henan
   (2008B150006) and 2008 Youth Foundation of the Ministry of Education of
   Henan Province (001135) are gratefully acknowledged.
CR Ammundsen B, 2001, ADV MATER, V13, P943, DOI 10.1002/1521-4095(200107)13:12/13<943::AID-ADMA943>3.0.CO;2-J                   
   Berggren C, 1999, ELECTROANAL, V11, P156, DOI 10.1002/(SICI)1521-4109(199903)11:3<156::AID-ELAN156>3.0.CO;2-O                 
   Cai H, 2003, ELECTROANAL, V15, P1864, DOI 10.1002/elan.200302755
   Ceres DM, 2007, J PHYS CHEM B, V111, P663, DOI 10.1021/jp066324c
   Gooding JJ, 2002, ELECTROANAL, V14, P1149, DOI 10.1002/1521-4109(200209)14:17<1149::AID-ELAN1149>3.0.CO;2-8                    
   Guo CX, 2007, BIOSENS BIOELECTRON, V22, P1830, DOI 10.1016/j.bios.2006.09.006
   HASHIMOTO K, 1994, ANAL CHEM, V66, P3830, DOI 10.1021/ac00093a045
   Hocevar SB, 2004, ELECTROANAL, V16, P1711, DOI 10.1002/elan.200303019
   Lin YH, 2005, ELECTROCHEM COMMUN, V7, P166, DOI 10.1016/j.elecom.2004.12.005
   Luo XL, 2004, BIOSENS BIOELECTRON, V19, P1295, DOI 10.1016/j.bios.2003.11.019
   Luo XL, 2004, SENSOR ACTUAT B-CHEM, V97, P249, DOI 10.1016/j.snb.2003.08.024
   Ma KS, 2006, SENSOR ACTUAT B-CHEM, V114, P58, DOI 10.1016/j.snb.2005.04.038
   Ma Y, 2008, SENSOR ACTUAT B-CHEM, V131, P565, DOI 10.1016/j.sub.2007.12.046
   Ma YF, 2006, J PHYS CHEM B, V110, P16359, DOI 10.1021/jp0614897
   Ozkan D, 2002, ELECTROCHEM COMMUN, V4, P796, DOI 10.1016/S1388-2481(02)00448-4                                                   
   Palecek E, 2002, ANAL CHIM ACTA, V469, P73, DOI 10.1016/S0003-2670(01)01605-1                                                   
   Pan SL, 2005, LANGMUIR, V21, P1022, DOI 10.1021/la048083a
   Panke O, 2008, Adv Biochem Eng Biotechnol, V109, P195
   Peng H, 2007, BIOSENS BIOELECTRON, V22, P1868, DOI 10.1016/j.bios.2006.07.010
   Wang J, 2006, ANALYST, V131, P477, DOI 10.1039/b516038c
   Wang J, 2002, ANALYST, V127, P383, DOI 10.1039/b110821m
   Yao SJ, 2006, ANAL CHIM ACTA, V557, P78, DOI 10.1016/j.aca.2005.10.052
   Zhang W, 2008, APPL SURF SCI, V254, P4750, DOI 10.1016/j.apsusc.2008.01.102
NR 23
TC 13
Z9 13
U1 2
U2 25
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PY 2009
VL 42
IS 18
BP 3046
EP 3057
AR PII 916769490
DI 10.1080/00032710903276638
PG 12
WC Chemistry, Analytical
SC Chemistry
GA 520AL
UT WOS:000271812000009
DA 2018-01-05
ER

PT J
AU Liu, YA
   Carroll, JR
   Holt, LA
   McMahon, J
   Giomarelli, B
   Ghirlanda, G
AF Liu, Yinan
   Carroll, Jacob R.
   Holt, Lindsey A.
   McMahon, James
   Giomarelli, Barbara
   Ghirlanda, Giovanna
TI Multivalent Interactions with gp120 Are Required for the Anti-HIV
   Activity of Cyanovirin
SO BIOPOLYMERS
LA English
DT Article
DE Cyanovirin; lectin; antiviral protein; HIV; multivalency
ID VIRUS-INACTIVATING PROTEIN; DOMAIN-SWAPPED STRUCTURE;
   CARBOHYDRATE-BINDING; ANTIVIRAL ACTIVITY; CRYSTAL-STRUCTURE; STRUCTURAL
   BASIS; VIRAL ENTRY; CV-N; INHIBITION; FUSION
AB Cyanovirin-N (CV-N) is a cyanobacterial lectin that binds to specific oligomannoses on the surface of gp120, resulting in nanomolar antiviral activity against HIV fit its monomeric form, CV-N contains two functional carbohydrate-binding domains, A and B. When refolded at high concentration, the protein can form a domain-swapped dimer. To clarify the role of multiple-binding sites in CV-N, we previously designed a monomeric mutant, P51G-m4-CVN, in which the binding site on domain A was rendered ineffective by four mutations (m4); in addition, a hinge region mutation (P51G) hinders the formation of a domain swapped dimer. The protein bound gp120 with diminished affinity and was completely inactive against HIV Here, we present two mutants, Delta Q50-m4-CVN and S52P-m4-CVN, which fold exclusively as domain-swapped dimers while containing the four mutations that abolish domain A. The dimers contain two intact B domains, thus restoring multivalency. Delta Q50-m4-CVN and S52P-m4-CVN bind gp120 at low-nanomolar concentrations and recover in part the antiviral activity of wt CV-N. These results indicate that the number of carbohydrate binding domains, rather than their identity, is crucial to CV-N functionality. (C) 2009 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 92: 194-200, 2009.
C1 [Liu, Yinan; Carroll, Jacob R.; Holt, Lindsey A.; Ghirlanda, Giovanna] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.
   [McMahon, James; Giomarelli, Barbara] NCI, Ctr Canc Res, Frederick, MD 21702 USA.
RP Ghirlanda, G (reprint author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.
EM gghirlanda@asu.edu
FU ASU-Mayo; Intramural Research Program, NIH, National Cancer Institute,
   Center for Cancer Research
FX Contract grant sponsors: ASU-Mayo; Intramural Research Program, NIH,
   National Cancer Institute, Center for Cancer Research
CR Balzarini J, 2006, ANTIVIR RES, V71, P237, DOI 10.1016/j.antiviral.2006.02.004
   Balzarini Jan, 2007, Antiviral Chemistry & Chemotherapy, V18, P1
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Barrientos LG, 2006, PROTEIN ENG DES SEL, V19, P525, DOI 10.1093/protein/gzl040
   Barrientos LG, 2004, STRUCTURE, V12, P1799, DOI 10.1016/j.str.2004.07.019
   Barrientos LG, 2002, PROTEINS, V46, P153, DOI 10.1002/prot.10024
   Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Botos I, 2002, BIOCHEM BIOPH RES CO, V294, P184, DOI 10.1016/S0006-291X(02)00455-2
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   Chiba H, 2004, BIOCHEM BIOPH RES CO, V316, P203, DOI 10.1016/j.bbrc.2004.02.036
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   Esser MT, 1999, J VIROL, V73, P4360
   Fromme R, 2008, PROTEIN SCI, V17, P939, DOI 10.1110/ps.083472808
   Fromme R, 2007, BIOCHEMISTRY-US, V46, P9199, DOI 10.1021/bi700666m
   GULAKOWSKI RJ, 1991, J VIROL METHODS, V33, P87, DOI 10.1016/0166-0934(91)90010-W
   Han ZZ, 2002, BIOCHEM BIOPH RES CO, V292, P1036, DOI 10.1006/bbrc.2002.6741
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Manimala JC, 2006, ANGEW CHEM INT EDIT, V45, P3607, DOI 10.1002/anie.200600591
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   Mori T, 2001, ANTIMICROB AGENTS CH, V45, P664, DOI 10.1128/AAC.45.3.664-672.2001
   NUSSBAUM O, 1994, J VIROL, V68, P5411
   Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Ziolkowska NE, 2006, ACTA BIOCHIM POL, V53, P617
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 36
TC 16
Z9 16
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 2009
VL 92
IS 3
BP 194
EP 200
DI 10.1002/bip.21173
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 438PX
UT WOS:000265568900007
PM 19235857
DA 2018-01-05
ER

PT J
AU Eugenin, EA
   Gaskill, PJ
   Berman, JW
AF Eugenin, E. A.
   Gaskill, P. J.
   Berman, J. W.
TI Tunneling nanotubes (TNT) are induced by HIV-infection of macrophages: A
   potential mechanism for intercellular HIV trafficking
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Filopodia; Communication; AIDS; Inflammation; Infectivity; HIV
ID FUNCTIONAL GAP-JUNCTIONS; MEMBRANE NANOTUBES; IMMUNE CELLS;
   TRANSMISSION; CYTOSKELETON; ASTROCYTES; EXPRESSION; MICROGLIA;
   TRANSPORT; PROTEINS
AB Cell to cell communication is essential for the organization/coordination of multicellular systems and cellular development. Cellular communication is mediated by soluble factors, including growth factors, neurotransmitters, cytokines/chemokines, gap junctions, and the recently described tunneling nanotubes (TNT). TNT are long cytoplasmatic bridges that enable long range directed communication between cells. The proposed function for TNT is the cell-to-cell transfer of large cellular structures such as vesicles and organelles. We demonstrate that HIV-infection of human macrophages results in an increased number of TNT, and show HIV particles within these structures. We propose that HIV "highjacks" TNT communication to spread HIV through an intercellular route between communicated cells, contributing to the pathogenesis of AIDS. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Eugenin, E. A.; Gaskill, P. J.; Berman, J. W.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA.
   [Berman, J. W.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
RP Eugenin, EA (reprint author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM eeugenin@aecom.yu.edu
FU NIAID NIH HHS [AI-051519, P30 AI051519]; NIDA NIH HHS [F32DA024965, F32
   DA024965]; NIMH NIH HHS [MH076679, K01 MH076679, K01 MH076679-01A1, R01
   MH075679, K01 MH076679-04, K01 MH076679-03, MH075679, R01 MH070297,
   MH070297, K01 MH076679-02]; NINDS NIH HHS [NS07098, T32 NS007098]
CR Buckner CM, 2006, J NEUROIMMUNE PHARM, V1, P160, DOI 10.1007/s11481-006-9017-3
   Davis DM, 2006, SCI AM, V294, P48, DOI 10.1038/scientificamerican0206-48                                               
   Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137                                                
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Eugenin EA, 2003, J IMMUNOL, V170, P1320, DOI 10.4049/jimmunol.170.3.1320                                                     
   Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298
   Eugenin EA, 2007, J NEUROSCI, V27, P12844, DOI 10.1523/JNEUROSCI.4154-07.2007
   Favoreel HW, 2005, P NATL ACAD SCI USA, V102, P8990, DOI 10.1073/pnas.0409099102
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   GURKE S, 2008, HISTOCHEM CELL BIOL
   Hope TJ, 2007, NAT CELL BIOL, V9, P243, DOI 10.1039/ncb0307-243
   Hsiung F, 2005, NATURE, V437, P560, DOI 10.1038/nature03951
   Kalvelyte A, 2003, BIOCHEM PHARMACOL, V66, P1661, DOI 10.1016/S0006-2952(03)00540-9
   King JE, 2006, MICROBES INFECT, V8, P1347, DOI 10.1016/j.micinf.2005.11.014
   Kornberg T, 1999, Trends Cell Biol, V9, P434, DOI 10.1016/S0962-8924(99)01653-0
   La Boissiere S, 2004, J VIROL, V78, P8002, DOI 10.1128/JVI.78.15.8002-8014.2004
   Magalhaes AC, 2005, J NEUROSCI, V25, P5207, DOI 10.1523/JNEUROSCI.0653-05.2005
   Martinez AD, 2002, BRAIN RES, V943, P191, DOI 10.1016/S0006-8993(02)02621-5                                                   
   Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B., 2005, SCI STKE, V2005, ppe55
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Tabiasco J, 2003, J IMMUNOL, V170, P5993, DOI 10.4049/jimmunol.170.12.5993                                                    
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Wehland J, 1998, Int Microbiol, V1, P11
   Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507
NR 30
TC 100
Z9 104
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2009
VL 254
IS 2
BP 142
EP 148
DI 10.1016/j.cellimm.2008.08.005
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 392VN
UT WOS:000262330400010
PM 18835599
OA green_accepted
DA 2018-01-05
ER

PT J
AU Loakes, D
   Holliger, P
AF Loakes, David
   Holliger, Philipp
TI Polymerase engineering: towards the encoded synthesis of unnatural
   biopolymers
SO CHEMICAL COMMUNICATIONS
LA English
DT Review
ID HIV-1 REVERSE-TRANSCRIPTASE; TRANSLESION DNA-SYNTHESIS; SITE-SPECIFIC
   INCORPORATION; CRICK HYDROGEN-BONDS; I KLENOW FRAGMENT; SELECTIVE
   INCORPORATION OPPOSITE; MOLECULE-LABELED NUCLEOTIDES; THIOREDOXIN
   BINDING DOMAIN; MINOR-GROOVE INTERACTIONS; CROSS-COUPLING REACTIONS
AB DNA is not only a repository of genetic information for life, it is also a unique polymer with remarkable properties: it associates according to well-defined rules, it can be assembled into diverse nanostructures of defined geometry, it can be evolved to bind ligands and catalyse chemical reactions and it can serve as a supramolecular scaffold to arrange chemical groups in space. However, its chemical makeup is rather uniform and the physicochemical properties of the four canonical bases only span a narrow range. Much wider chemical diversity is accessible through solid-phase synthesis but oligomers are limited to <100 nucleotides and variations in chemistry can usually not be replicated and thus are not amenable to evolution. Recent advances in nucleic acid chemistry and polymerase engineering promise to bring the synthesis, replication and ultimately evolution of nucleic acid polymers with greatly expanded chemical diversity within our reach.
C1 [Loakes, David; Holliger, Philipp] MRC, Mol Biol Lab, Cambridge CB2 0QH, England.
RP Holliger, P (reprint author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.
EM ph1@mrc-lmb.cam.ac.uk
FU Medical Research Council [MC_U105178804]
CR Abraham ML, 2007, BIOTECHNIQUES, V43, P617, DOI 10.2144/000112602
   Ahle JD, 2005, NUCLEIC ACIDS RES, V33, P3176, DOI 10.1093/nar/gki628
   Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672
   Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402                                                          
   Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479
   Benner SA, 2004, ACCOUNTS CHEM RES, V37, P784, DOI 10.1021/ar040004z
   Berger M, 2000, NUCLEIC ACIDS RES, V28, P2911, DOI 10.1093/nar/28.15.2911                                                          
   Brakmann S, 2001, CHEMBIOCHEM, V2, P773, DOI 10.1002/1439-7633(20011001)2:10<773::AID-CBIC773>3.0.CO;2-S                     
   Brudno Y, 2009, CHEM BIOL, V16, P265, DOI 10.1016/j.chembiol.2009.02.004
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Cahova H, 2008, ORG BIOMOL CHEM, V6, P3657, DOI 10.1039/b811935j
   Cahova H, 2008, ANGEW CHEM INT EDIT, V47, P2059, DOI 10.1002/anie.200705088
   Capek P, 2007, CHEM-EUR J, V13, P6196, DOI 10.1002/chem.200700220
   Chaput JC, 2003, J AM CHEM SOC, V125, P9274, DOI 10.1021/ja035917n
   Chaput JC, 2003, J AM CHEM SOC, V125, P856, DOI 10.1021/ja028589k
   Chelliserrykattil J, 2008, CHEMBIOCHEM, V9, P2976, DOI 10.1002/cbic.200800339
   Chiaramonte M, 2003, BIOCHEMISTRY-US, V42, P10472, DOI 10.1021/bi0347631
   Crey-Desbiolles C, 2005, NUCLEIC ACIDS RES, V33, P1532, DOI 10.1093/nar/gki293
   d'Abbadie M, 2007, NAT BIOTECHNOL, V25, P939, DOI 10.1038/nbt1321
   Davidson JF, 2003, NUCLEIC ACIDS RES, V31, P4702, DOI 10.1093/nar/gkg667
   Declercq R, 2002, J AM CHEM SOC, V124, P928, DOI 10.1021/ja016570w
   Delaney JC, 2003, P NATL ACAD SCI USA, V100, P4469, DOI 10.1073/pnas.0837277100
   Di Pasquale F, 2008, J AM CHEM SOC, V130, P10748, DOI 10.1021/ja8028284
   Dzantiev L, 2001, BIOCHEMISTRY-US, V40, P3215, DOI 10.1021/bi002569i
   Endo M, 2004, BIOORG MED CHEM LETT, V14, P2593, DOI 10.1016/j.bmcl.2004.02.072
   Fa M, 2004, J AM CHEM SOC, V126, P1748, DOI 10.1021/ja038525p
   Foldes-Papp Z, 2001, J BIOTECHNOL, V86, P237, DOI 10.1016/S0168-1656(00)00416-8
   Foldes-Papp Z, 2001, J BIOTECHNOL, V86, P203, DOI 10.1016/S0168-1656(00)00414-4
   Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545                                                          
   Gardner AF, 2002, NUCLEIC ACIDS RES, V30, P605, DOI 10.1093/nar/30.2.605
   Geyer CR, 2003, STRUCTURE, V11, P1485, DOI 10.1016/j.str.2003.11.008
   Ghadessy FJ, 2004, NAT BIOTECHNOL, V22, P755, DOI 10.1038/nbt974
   Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198                                                          
   Giller G, 2003, NUCLEIC ACIDS RES, V31, P2630, DOI 10.1093/nar/gkg370
   Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303
   Gloeckner C, 2007, ANGEW CHEM INT EDIT, V46, P3115, DOI 10.1002/anie.200603987
   GOMMERSAMPT JH, 1995, FASEB J, V9, P1034
   Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100
   Hari Y, 2008, CHEMBIOCHEM, V9, P2796, DOI 10.1002/cbic.200800577
   Harki DA, 2002, BIOCHEMISTRY-US, V41, P9026, DOI 10.1021/bi026120w
   Heuberger BD, 2008, J AM CHEM SOC, V130, P412, DOI 10.1021/ja0770680
   Heuberger BD, 2006, ORG LETT, V8, P5809, DOI 10.1021/ol062368s
   Hirao I, 2002, NAT BIOTECHNOL, V20, P177, DOI 10.1038/nbt0202-177                                                             
   Hirao I, 2004, J AM CHEM SOC, V126, P13298, DOI 10.1021/ja047201d
   Hirao I, 2004, BIOORG MED CHEM LETT, V14, P4887, DOI 10.1016/j.bmcl.2004.07.038
   Hirao I, 2007, J AM CHEM SOC, V129, P15549, DOI 10.1021/ja073830m
   Hirao I, 2006, NAT METHODS, V3, P729, DOI 10.1038/nmeth915
   Hocek M, 2008, ORG BIOMOL CHEM, V6, P2233, DOI 10.1039/b803664k
   Hollenstein M, 2009, NUCLEIC ACIDS RES, V37, P1638, DOI 10.1093/nar/gkn1070
   Horhota A, 2005, J AM CHEM SOC, V127, P7427, DOI 10.1021/ja0428255
   Horhota AT, 2006, ORG LETT, V8, P5345, DOI 10.1021/ol062232u
   HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567                                                          
   Hwang GT, 2006, NUCLEIC ACIDS RES, V34, P2037, DOI 10.1093/nar/gkl049
   Hwang HS, 2004, BIOCHEMISTRY-US, V43, P14612, DOI 10.1021/bi0489558
   Ichida JK, 2005, NUCLEIC ACIDS RES, V33, P5219, DOI 10.1093/nar/gki840
   Ichida JK, 2005, J AM CHEM SOC, V127, P2802, DOI 10.1021/ja045364w
   Ignatov KB, 1999, FEBS LETT, V448, P145, DOI 10.1016/S0014-5793(99)00353-1
   Jager S, 2005, J AM CHEM SOC, V127, P15071, DOI 10.1021/ja051725b
   Jager S, 2004, ANGEW CHEM INT EDIT, V43, P3337, DOI 10.1002/anie.200453926
   Jestin JL, 1999, ANGEW CHEM INT EDIT, V38, P1124, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1124::AID-ANIE1124>3.0.CO;2-W
   Jestin JL, 2001, RES MICROBIOL, V152, P187, DOI 10.1016/S0923-2508(01)01191-3
   Kang HM, 2004, NUCLEIC ACIDS RES, V32, P4411, DOI 10.1093/nar/gkh775
   Kawai R, 2005, J AM CHEM SOC, V127, P17286, DOI 10.1021/ja0542946
   Keefe AD, 2008, CURR OPIN CHEM BIOL, V12, P448, DOI 10.1016/j.cbpa.2008.06.028
   Kempeneers V, 2003, NUCLEIC ACIDS RES, V31, P6221, DOI 10.1093/nar/gkg833
   Kerremans L, 2001, ORG LETT, V3, P4129, DOI 10.1021/ol016183r
   Kim B, 1996, J BIOL CHEM, V271, P4872
   Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102
   Kim TW, 2005, J ORG CHEM, V70, P2048, DOI 10.1021/jo048061t
   Kim Y, 2006, ANGEW CHEM INT EDIT, V45, P7809, DOI 10.1002/anie.200602579
   Kimoto M, 2004, CHEM BIOL, V11, P47, DOI 10.1016/j.chembiol.2003.12.016
   Kimoto M, 2007, NUCLEIC ACIDS RES, V35, P5360, DOI 10.1093/nar/gkm508
   Kimoto M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn956
   Kirby TW, 2005, BIOCHEMISTRY-US, V44, P15230, DOI 10.1021/bi0511742
   Kolb G, 2005, BIOCHEMISTRY-US, V44, P2926, DOI 10.1021/bi048393s
   Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1                                                  
   Kornberg A., 1992, DNA REPLICATION
   Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497
   Kuwahara M, 2008, NUCLEIC ACIDS RES, V36, P4257, DOI 10.1093/nar/gkn404
   Lam C, 2008, EUR J ORG CHEM, P4915, DOI 10.1002/ejoc.200800381
   Lato SM, 2002, NUCLEIC ACIDS RES, V30, P1401, DOI 10.1093/nar/30.6.1401                                                           
   Lavrik IN, 2001, BIOCHEMISTRY-US, V40, P11777, DOI 10.1021/bi010836u
   Leconte AM, 2008, J AM CHEM SOC, V130, P2336, DOI 10.1021/ja078223d
   Leconte AM, 2005, J AM CHEM SOC, V127, P12470, DOI 10.1021/ja053322h
   Leconte AM, 2006, J AM CHEM SOC, V128, P6780, DOI 10.1021/ja060853c
   Leconte AM, 2006, ANGEW CHEM INT EDIT, V45, P4326, DOI 10.1002/anie.20061272
   Lee AHF, 2005, J AM CHEM SOC, V127, P3332, DOI 10.1021/ja0430604
   Lee I, 2006, CHEMBIOCHEM, V7, P1990, DOI 10.1002/cbic.200600128
   Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491
   Liu HB, 2005, J ORG CHEM, V70, P639, DOI 10.1021/jo048357z
   Liu HB, 2004, J AM CHEM SOC, V126, P1102, DOI 10.1021/ja038384r
   LOAKES D, 1994, NUCLEIC ACIDS RES, V22, P4039, DOI 10.1093/nar/22.20.4039
   Loakes D, 2001, NUCLEIC ACIDS RES, V29, P2437, DOI 10.1093/nar/29.12.2437
   Loh E, 2005, DNA REPAIR, V4, P1390, DOI 10.1016/j.dnarep.2005.09.006
   Loh E, 2007, J BIOL CHEM, V282, P12201, DOI 10.1074/jbc.M611294200
   Maier T, 2005, J AM CHEM SOC, V127, P2937, DOI 10.1021/ja045843v
   Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453                                                                   
   Matsuda S, 2006, J AM CHEM SOC, V128, P6369, DOI 10.1021/ja057575m
   Matsuda S, 2004, J AM CHEM SOC, V126, P14419, DOI 10.1021/ja047291m
   Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n
   Mitsui T, 2005, J AM CHEM SOC, V127, P8652, DOI 10.1021/ja0425280
   Mitsui T, 2003, BIOORG MED CHEM LETT, V13, P4515, DOI 10.1016/j.bmcl.2003.09.059
   Mitsui T, 2003, J AM CHEM SOC, V125, P5298, DOI 10.1021/ja028806h
   Mizukami S, 2006, BIOCHEMISTRY-US, V45, P2772, DOI 10.1021/bi051961z
   Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o
   Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+
   Morales JC, 2000, J AM CHEM SOC, V122, P1001, DOI 10.1021/ja993464+                                                               
   Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a
   Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506
   Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g
   Moriyama K, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni128
   NICHOLS R, 1994, NATURE, V369, P492, DOI 10.1038/369492a0
   NIELSEN PE, 1995, ANNU REV BIOPH BIOM, V24, P167, DOI 10.1146/annurev.bb.24.060195.001123
   Obika S, 1997, CHEM COMMUN, P1643, DOI 10.1039/a704376g                                                                
   ONG J, 2004, THESIS CAMBRIDGE U
   Ong JL, 2006, J MOL BIOL, V361, P537, DOI 10.1016/j.jmb.2006.06.050
   Pallan PS, 2003, ANGEW CHEM INT EDIT, V42, P5893, DOI 10.1002/anie.200352553
   Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200
   Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i
   Rackham O, 2005, NAT CHEM BIOL, V1, P159, DOI 10.1038/nchembio719
   Rappaport HP, 2004, BIOCHEM J, V381, P709, DOI 10.1042/BJ20031776
   Reineks EZ, 2004, BIOCHEMISTRY-US, V43, P393, DOI 10.1021/bi034948s
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Sauter KBM, 2006, ANGEW CHEM INT EDIT, V45, P7633, DOI 10.1002/anie.200602772
   Schlegel MK, 2007, CHEMBIOCHEM, V8, P927, DOI 10.1002/cbic.200600435
   Schmidt JG, 1997, NUCLEIC ACIDS RES, V25, P4792, DOI 10.1093/nar/25.23.4792
   Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347                                                   
   Seela F, 1999, HELV CHIM ACTA, V82, P726, DOI 10.1002/(SICI)1522-2675(19990505)82:5<726::AID-HLCA726>3.3.CO;2-B
   Seo YJ, 2009, J AM CHEM SOC, V131, P3246, DOI 10.1021/ja807853m
   Sheriff A, 2008, BIOCHEMISTRY-US, V47, P8527, DOI 10.1021/bi800324r
   Silverman AP, 2008, BIOCHEMISTRY-US, V47, P4800, DOI 10.1021/bi702427y
   Silverman AP, 2007, BIOCHEMISTRY-US, V46, P13874, DOI 10.1021/bi700851z
   Silverman AP, 2007, J AM CHEM SOC, V129, P10626, DOI 10.1021/ja072791b
   Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c                                                                
   Sismour AM, 2005, NUCLEIC ACIDS RES, V33, P5640, DOI 10.1093/nar/gki873
   Smirnov S, 2002, NUCLEIC ACIDS RES, V30, P5561, DOI 10.1093/nar/gkf688                                                              
   Smith CL, 1998, NUCLEOS NUCLEOT, V17, P541, DOI 10.1080/07328319808005197
   SMITH TH, 1995, CLIN CHEM, V41, P10
   Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074
   Strerath M, 2002, J AM CHEM SOC, V124, P11230, DOI 10.1021/ja027060k
   Summerer D, 2001, ANGEW CHEM INT EDIT, V40, P3693, DOI 10.1002/1521-3773(20011001)40:19<3693::AID-ANIE3693>3.0.CO;2-O                  
   Summerer D, 2002, J AM CHEM SOC, V124, P910, DOI 10.1021/ja017224j
   Summerer D, 2005, ANGEW CHEM INT EDIT, V44, P4712, DOI 10.1002/anie.200500047
   Summerer D, 2002, ANGEW CHEM INT EDIT, V41, P3620, DOI 10.1002/1521-3773(20021004)41:19<3620::AID-ANIE3620>3.0.CO;2-C
   SUMMERER D, 2002, ANGEW CHEM INT EDIT, V41, P3516
   Sun LP, 2000, BIOCHEMISTRY-US, V39, P14603, DOI 10.1021/bi001446v
   Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670                                                         
   SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626
   Tae EJL, 2001, J AM CHEM SOC, V123, P7439, DOI 10.1021/ja010731e
   Tasara T, 2003, NUCLEIC ACIDS RES, V31, P2636, DOI 10.1093/nar/gkg371
   Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652
   TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027
   Tsai CH, 2007, P NATL ACAD SCI USA, V104, P14598, DOI 10.1073/pnas.0704211104
   Vastmans K, 2000, BIOCHEMISTRY-US, V39, P12757, DOI 10.1021/bi001297g
   Vastmans K, 2001, NUCLEIC ACIDS RES, V29, P3154, DOI 10.1093/nar/29.15.3154
   Veedu RN, 2008, J AM CHEM SOC, V130, P8124, DOI 10.1021/ja801389n
   Veedu RN, 2007, NUCLEOS NUCLEOT NUCL, V26, P1207, DOI 10.1080/15257770701527844
   Veedu RN, 2007, CHEMBIOCHEM, V8, P490, DOI 10.1002/cbic.200600501
   Verbeure B, 2001, NUCLEIC ACIDS RES, V29, P4941, DOI 10.1093/nar/29.24.4941
   Vichier-Guerre S, 2006, ANGEW CHEM INT EDIT, V45, P6133, DOI 10.1002/anie.200601217
   Vineyard D, 2007, ORG BIOMOL CHEM, V5, P3623, DOI 10.1039/b712480e
   Vrabel M, 2009, CHEM-EUR J, V15, P1144, DOI 10.1002/chem.200801538
   Wang J, 2001, NUCLEOS NUCLEOT NUCL, V20, P785, DOI 10.1081/NCN-100002430                                                           
   Wang LR, 2007, NAT CHEM BIOL, V3, P709, DOI 10.1038/nchembio.2007.39
   Wang Y, 2004, NUCLEIC ACIDS RES, V32, P1197, DOI 10.1093/nar/gkh271
   Weisbrod SH, 2008, CHEM COMMUN, P5675, DOI 10.1039/b809528k
   Wilds CJ, 2002, J AM CHEM SOC, V124, P13716, DOI 10.1021/ja0207807
   Williams JGK, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn531
   Wilson C, 2006, CURR OPIN CHEM BIOL, V10, P607, DOI 10.1016/j.cbpa.2006.10.001
   Xia G, 2002, P NATL ACAD SCI USA, V99, P6597, DOI 10.1073/pnas.102577799
   Yang ZY, 2007, NUCLEIC ACIDS RES, V35, P4238, DOI 10.1093/nar/gkm395
   Zhang LL, 2005, J AM CHEM SOC, V127, P74, DOI 10.1021/ja043904j
   Zhang XM, 2005, BIOCHEMISTRY-US, V44, P13101, DOI 10.1021/bi050585f
   Zhang XM, 2004, ORG BIOMOL CHEM, V2, P1703, DOI 10.1039/b401732c
   Zhang XM, 2006, J AM CHEM SOC, V128, P143, DOI 10.1021/ja0546830
   Zhang XM, 2005, BIOCHEMISTRY-US, V44, P13111, DOI 10.1021/bi050584n
   Zhang XM, 2006, BIOCHEMISTRY-US, V45, P13293, DOI 10.1021/bi060418v
   ZHU ZR, 1994, NUCLEIC ACIDS RES, V22, P3418, DOI 10.1093/nar/22.16.3418
NR 178
TC 36
Z9 36
U1 1
U2 41
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2009
IS 31
BP 4619
EP 4631
DI 10.1039/b903307f
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA 477RX
UT WOS:000268537500001
PM 19641798
DA 2018-01-05
ER

PT J
AU Amadasi, A
   Mozzarelli, A
   Meda, C
   Maggi, A
   Cozzini, P
AF Amadasi, Alessio
   Mozzarelli, Andrea
   Meda, Clara
   Maggi, Adriana
   Cozzini, Pietro
TI Identification of Xenoestrogens in Food Additives by an Integrated in
   Silico and in Vitro Approach
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Review
ID ESTROGEN-RECEPTOR-BETA; PROTEIN-LIGAND DOCKING; EFFICIENT MOLECULAR
   DOCKING; SUBTYPE-SELECTIVE LIGANDS; FREE-ENERGY; HIV-1 PROTEASE;
   BINDING-AFFINITY; DRUG DESIGN; ER-ALPHA; INTUITIVE CALCULATIONS
AB In the search for xenoestrogens within food additives, we have analyzed the Joint FAO-WHO expert committee database, containing 1500 compounds, using an integrated in silico and in vitro approach. This analysis identified 31 potential estrogen receptor a ligands that were reduced to 13 upon applying a stringent filter based on ligand volume and binding mode. Among the 13 potential xenoestrogens, four were already known to exhibit an estrogenic activity, and the other nine were assayed in vitro, determining the binding affinity to the receptor and biological effects. Propyl gallate was found to act as an antagonist, and 4-hexylresorcinol was found to act as a potent transactivator; both ligands were active at nanomolar concentrations, as predicted by the in silico analysis. Some caution should be issued for the use of propyl gallate and 4-hexylresorcinol as food additives.
C1 [Mozzarelli, Andrea; Cozzini, Pietro] Natl Inst Biostruct & Biosyst, I-00136 Rome, Italy.
   [Amadasi, Alessio; Mozzarelli, Andrea] Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy.
   [Cozzini, Pietro] Univ Parma, Dept Gen & Inorgan Chem, I-43100 Parma, Italy.
   [Meda, Clara; Maggi, Adriana] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy.
RP Cozzini, P (reprint author), Natl Inst Biostruct & Biosyst, Viale Medaglie doro 305, I-00136 Rome, Italy.
EM pietro.cozzini@unipr.it
RI Mozzarelli, Andrea/C-3615-2014; Meda, Clara/G-8680-2013
OI Mozzarelli, Andrea/0000-0003-3762-0062; Meda, Clara/0000-0003-3524-2010;
   Maggi, Adriana/0000-0001-5700-5273
FU SIQUAL; European Union [LSHM-CT-2005-518245]; NIH [ROIAG027713-02]
FX This work was carried out with the support of Regione-Emilia Romagna in
   the frame of the SIQUAL project (A.M. and P.C.) and by the European
   Union within the projects (Strep EWA, LSHM-CT-2005-518245) and NIH
   (ROIAG027713-02) (to A.M.). We thank Prof. Glen E. Kellogg and Donald J.
   Abraham for the HINT software and Prof. Simone Ottonello and Dr. Roberta
   Ruotolo for helpful discussions.
CR Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   Amadasi A, 2006, J MOL BIOL, V358, P289, DOI 10.1016/j.jmb.2006.01.053
   Amadasi A, 2007, BIOORGAN MED CHEM, V15, P1420, DOI 10.1016/j.bmc.2006.11.001
   Amari G, 2004, BIOORGAN MED CHEM, V12, P3763, DOI 10.1016/j.bmc.2004.05.015
   Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Birch L, 2002, J COMPUT AID MOL DES, V16, P855, DOI 10.1023/A:1023844626572                                                         
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138                                                         
   Blizzard TA, 2005, BIOORG MED CHEM LETT, V15, P107, DOI 10.1016/j.bmcl.2004.10.036
   Blizzard TA, 2003, BIOORG MED CHEM LETT, V13, P479, DOI 10.1016/S0960-894X(02)00985-X
   Broughton HB, 2000, J MOL GRAPH MODEL, V18, P247, DOI 10.1016/S1093-3263(00)00036-X
   BROUGHTON HB, 2000, J MOL GRAPH MODEL, V18, P302
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Burnett JC, 2001, PROTEINS, V42, P355, DOI 10.1002/1097-0134(20010215)42:3<355::AID-PROT60>3.0.CO;2-F                      
   Capra V, 2004, MOL PHARMACOL, V66, P880, DOI 10.1124/mol.104.001487
   Carlson HA, 2000, J MED CHEM, V43, P2100, DOI 10.1021/jm990322h                                                               
   Carlson HA, 2002, CURR OPIN CHEM BIOL, V6, P447, DOI 10.1016/S1367-5931(02)00341-1                                                   
   Carlson HA, 2000, MOL PHARMACOL, V57, P213
   Cavasotto CN, 2005, J AM CHEM SOC, V127, P9632, DOI 10.1021/ja042260c
   Charifson PS, 1999, J MED CHEM, V42, P5100, DOI 10.1021/jm990352k
   Chen HY, 2004, BIOORG MED CHEM LETT, V14, P1417, DOI 10.1016/j.bmcl.2004.01.031
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104
   Claussen H, 2001, J MOL BIOL, V308, P377, DOI 10.1006/jmbi.2001.4551
   Cozzini P, 2004, CURR MED CHEM, V11, P3093, DOI 10.2174/0929867043363929                                                        
   Cozzini P, 2004, EUR J MED CHEM, V39, P601, DOI 10.1016/j.ejmech.2004.02.014
   Cozzini P, 2002, J MED CHEM, V45, P2469, DOI 10.1021/jm0200299
   Cummings MD, 2005, J MED CHEM, V48, P962, DOI 10.1021/jm049798d
   Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8.
   DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492
   Dykstra KD, 2007, BIOORG MED CHEM LETT, V17, P2322, DOI 10.1016/j.bmcl.2007.01.054
   Erickson JA, 2004, J MED CHEM, V47, P45, DOI 10.1021/jm030209y                                                               
   Evers A, 2004, J MED CHEM, V47, P5381, DOI 10.1021/jm0311487
   Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Fornabaio M, 2004, J MED CHEM, V47, P4507, DOI 10.1021/jm030596b
   Fujimoto N, 2004, LIFE SCI, V74, P1417, DOI 10.1016/j.lfs.2003.08.012
   GANTCHEV TG, 1994, J MED CHEM, V37, P4164, DOI 10.1021/jm00050a013
   Gauthier S, 1997, J MED CHEM, V40, P2117, DOI 10.1021/jm970095o
   Graves AP, 2005, J MED CHEM, V48, P3714, DOI 10.1021/jm0491187
   Gruneberg S, 2002, J MED CHEM, V45, P3588, DOI 10.1021/jm011112j
   Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379
   HANSCH C, 1979, SUBSTITUENT CONSTANT
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Hoffmann D, 1999, J MED CHEM, V42, P4422, DOI 10.1021/jm991090p                                                               
   Hsieh RW, 2006, J BIOL CHEM, V281, P17909, DOI 10.1074/jbc.M513684200
   Huang SY, 2007, PROTEINS, V66, P399, DOI 10.1002/prot.21214
   Huang SY, 2007, PROTEIN SCI, V16, P43, DOI 10.1110/ps.062501507
   Hummel CW, 2005, J MED CHEM, V48, P6772, DOI 10.1021/jm050723z
   JIANG F, 1991, J MOL BIOL, V219, P79, DOI 10.1016/0022-2836(91)90859-5
   JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kellenberger E, 2007, J MED CHEM, V50, P1294, DOI 10.1021/jm061389p
   Kellogg GE, 2000, EUR J MED CHEM, V35, P651
   Kellogg GE, 2001, J COMPUT AID MOL DES, V15, P381, DOI 10.1023/A:1011136228678
   Kim S, 2004, J MED CHEM, V47, P2171, DOI 10.1021/jm034243o
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   Knegtel RMA, 1997, J MOL BIOL, V266, P424, DOI 10.1006/jmbi.1996.0776
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/endo.138.3.4979
   LEACH AR, 1994, J MOL BIOL, V235, P345, DOI 10.1016/S0022-2836(05)80038-5
   Lyne PD, 2004, J MED CHEM, V47, P1962, DOI 10.1021/jm030504i
   Lyne PD, 2002, DRUG DISCOV TODAY, V7, P1047, DOI 10.1016/S1359-6446(02)02483-2                                                   
   Manas ES, 2004, STRUCTURE, V12, P2197, DOI 10.1016/j.str.2004.09.015
   Manas ES, 2004, J AM CHEM SOC, V126, P15106, DOI 10.1021/ja047633o
   Meyers MJ, 1999, J MED CHEM, V42, P2456, DOI 10.1021/jm990101b
   Miller CP, 2001, J MED CHEM, V44, P1654, DOI 10.1021/jm010086m
   Moitessier N, 2006, J MED CHEM, V49, P5885, DOI 10.1021/jm050138y
   Mueller SO, 2004, ANAL BIOANAL CHEM, V378, P582, DOI 10.1007/s00216-003-2238-x
   Murray CW, 1999, J COMPUT AID MOL DES, V13, P547, DOI 10.1023/A:1008015827877
   Nettles KW, 2007, EMBO REP, V8, P563, DOI 10.1038/sj.embor.7400963
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Norman BH, 2007, BIOORG MED CHEM LETT, V17, P5082, DOI 10.1016/j.bmcl.2007.07.009
   Norman BH, 2006, J MED CHEM, V49, P6155, DOI 10.1021/jm060491j
   Oostenbrink BC, 2000, J MED CHEM, V43, P4594, DOI 10.1021/jm001045d
   Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172                                                     
   Osterberg F, 2002, PROTEINS, V46, P34, DOI 10.1002/prot.10028
   Perola E, 2004, PROTEINS, V56, P235, DOI 10.1002/prot.20088
   Porotto M, 2006, J VIROL, V80, P1204, DOI 10.1128/JVI.80.3.1204-1213.2006
   Pozzi S, 2006, ANN NY ACAD SCI, V1089, P302, DOI 10.1196/annals.1386.035
   Renaud J, 2005, J MED CHEM, V48, P364, DOI 10.1021/jm040858p
   Richardson TI, 2007, BIOORG MED CHEM LETT, V17, P4824, DOI 10.1016/j.bmcl.2007.06.052
   Rosati RL, 1998, J MED CHEM, V41, P2928, DOI 10.1021/jm980048b
   Schaffer L, 1998, PROTEINS, V33, P295, DOI 10.1002/(SICI)1097-0134(19981101)33:2<295::AID-PROT12>3.0.CO;2-F
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787
   Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1                                                   
   Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197
   Sivanesan D, 2005, J COMPUT AID MOL DES, V19, P213, DOI 10.1007/s10822-005-4788-9
   Spyrakis F, 2004, J AM CHEM SOC, V126, P11764, DOI 10.1021/ja0465754
   Spyrakis F, 2007, EUR J MED CHEM, V42, P921, DOI 10.1016/j.ejmech.2006.12.037
   Spyrakis F, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-4
   Stahl M, 1998, J MOL GRAPH MODEL, V16, P121, DOI 10.1016/S1093-3263(98)00018-7                                                   
   Stahl M, 2001, J MED CHEM, V44, P1035, DOI 10.1021/jm0003992
   Suh N, 2001, CANCER RES, V61, P8412
   Tan Q, 2005, BIOORG MED CHEM LETT, V15, P1675, DOI 10.1016/j.bmcl.2005.01.046
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   ter Veld MGR, 2006, J AGR FOOD CHEM, V54, P4407, DOI 10.1021/jf052864f
   Tong WD, 1997, ENDOCRINOLOGY, V138, P4022, DOI 10.1210/endo.138.9.5487
   van Lipzig MMH, 2004, J MED CHEM, V47, P1018, DOI 10.1021/jm0309607
   Vargas R, 2000, J AM CHEM SOC, V122, P4750, DOI 10.1021/ja993600a                                                               
   Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n
   Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014
   Zavodszky MI, 2004, PROTEINS, V57, P243, DOI 10.1002/prot.20179
NR 103
TC 34
Z9 38
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD JAN
PY 2009
VL 22
IS 1
BP 52
EP 63
DI 10.1021/tx800048m
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA 396PF
UT WOS:000262602900010
PM 19063592
OA green_accepted
DA 2018-01-05
ER

PT J
AU Boisselier, E
   Astruc, D
AF Boisselier, Elodie
   Astruc, Didier
TI Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics,
   therapies and toxicity
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID SURFACE-ENHANCED RAMAN; FUNCTIONALIZED AU NANOPARTICLES; HUMAN
   CHORIONIC-GONADOTROPIN; GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR;
   BIO-BAR CODES; COLLOIDAL GOLD; DRUG-DELIVERY; CANCER-CELLS; PHOTOTHERMAL
   THERAPY
AB This critical review provides an overall survey of the basic concepts and up-to-date literature results concerning the very promising use of gold nanoparticles (AuNPs) for medicinal applications. It includes AuNP synthesis, assembly and conjugation with biological and biocompatible ligands, plasmon-based labeling and imaging, optical and electrochemical sensing, diagnostics, therapy (drug vectorization and DNA/gene delivery) for various diseases, in particular cancer (also Alzheimer, HIV, hepatitis, tuberculosis, arthritis, diabetes) and the essential in vitro and in vivo toxicity. It will interest the medicine, chemistry, spectroscopy, biochemistry, biophysics and nanoscience communities (211 references).
C1 [Boisselier, Elodie; Astruc, Didier] Univ Bordeaux 1, CNRS, Inst Mol Sci, UMR 5255, F-33405 Talence, France.
RP Boisselier, E (reprint author), Univ Bordeaux 1, CNRS, Inst Mol Sci, UMR 5255, F-33405 Talence, France.
EM d.astruc@ism.u-bordeaux1.fr
FU Universite Bordeaux I; Centre National de la Recherche Scientifique
   (CNRS); Institut Universitaire de France (IUF, DA); Agence Nationale de
   la Recherche (ANR)
FX We are grateful to the Universite Bordeaux I, the Centre National de la
   Recherche Scientifique (CNRS), the Institut Universitaire de France
   (IUF, DA) and the Agence Nationale de la Recherche (ANR) for financial
   support.
CR Aaron J, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2737351
   Astruc D, 1996, CR ACAD SCI II B, V322, P757
   ASTRUC D, 1995, ELECT TRANSFER RADIC, pCH4
   Astruc D, 2008, ACCOUNTS CHEM RES, V41, P841, DOI 10.1021/ar8000074
   Authier L, 2001, ANAL CHEM, V73, P4450, DOI 10.1021/ac0103221
   Azzam EMS, 2008, J SURFACTANTS DETERG, V11, P195, DOI 10.1007/s11743-008-1072-8
   Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391
   BATISTA P, 2008, ANAL BIOANAL CHEM, V391, P943
   Becue A, 2007, FORENSIC SCI INT, V168, P169, DOI 10.1016/j.forsciint.2006.07.014
   Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013
   Bishnoi SW, 2006, NANO LETT, V6, P1687, DOI 10.1021/nl060865w
   Boisselier E, 2008, CHEM COMMUN, P5788, DOI 10.1039/b812249k
   Boisselier E, 2008, CHEM COMMUN, P4819, DOI 10.1039/b808987f
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   CARASCOSA LG, 2006, TRENDS ANAL CHEM, V25, P196
   Cardinal J, 2008, SURGERY, V144, P125, DOI 10.1016/j.surg.2008.03.036
   Castaneda MT, 2007, ELECTROANAL, V19, P743, DOI 10.1002/elan.200603784
   Chamberland DL, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/9/095101
   CHAN CP, 2007, ADV BIOCH ENG BIOTEC
   Chang JY, 2005, CHEM COMMUN, P1092, DOI 10.1039/b414059a
   Chen SH, 2008, J MICROBIOL METH, V73, P7, DOI 10.1016/j.mimet.2008.01.004
   Cheng Y, 2008, J AM CHEM SOC, V130, P10643, DOI 10.1021/ja801631c
   Choi JS, 2008, CHEM COMMUN, P2197, DOI 10.1039/b803294g
   CONNOR E, 2005, SMALL, V21, P325
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Daniel MC, 2003, J AM CHEM SOC, V125, P2617, DOI 10.1021/ja021325d
   Daniel MC, 2003, J AM CHEM SOC, V125, P1150, DOI 10.1021/ja020833k                                                               
   De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037
   Debouttiere PJ, 2006, ADV FUNCT MATER, V16, P2330, DOI 10.1002/adfm.200600242
   Dequaire M, 2000, ANAL CHEM, V72, P5521, DOI 10.1021/ac000781m
   Dhar S, 2008, CHEM-EUR J, V14, P10244, DOI 10.1002/chem.200801093
   Diagaradjane P, 2008, NANO LETT, V8, P1492, DOI 10.1021/nl080496z
   Dixit V, 2006, BIOCONJUGATE CHEM, V17, P603, DOI 10.1021/bc050335b
   Doering WE, 2007, ADV MATER, V19, P3100, DOI 10.1002/adma.200701984
   Doria G, 2007, IET NANOBIOTECHNOL, V1, P53, DOI 10.1049/iet-nbt:20070001
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   Dreshler U., 2004, CHEM-EUR J, V10, P5570
   Dujardin E, 2001, CHEM COMMUN, P1264, DOI 10.1039/b102319p                                                                
   Eck W, 2008, ACS NANO, V2, P2263, DOI 10.1021/nn800429d
   Eghtedari M, 2009, NANO LETT, V9, P287, DOI 10.1021/nl802915q
   El-Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Faraday M., 1857, PHILOS T ROY SOC LON, V147, P145, DOI DOI 10.1098/RSTL.1857.0011
   Farma JM, 2007, INT J CANCER, V120, P2474, DOI 10.1002/ijc.22270
   FAULK WP, 1971, IMMUNOCHEMISTRY, V8, P1081
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Florence AT, 1997, PHARMACEUT RES, V14, P259, DOI 10.1023/A:1012029517394
   Ganesh T, 2007, BIOORGAN MED CHEM, V15, P3597, DOI 10.1016/j.bmc.2007.03.041
   Gannon Christopher J., 2008, Journal of Nanobiotechnology, V6, P2, DOI 10.1186/1477-3155-6-2
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   GIERSIG M, 1993, LANGMUIR, V9, P3408, DOI 10.1021/la00036a014                                                             
   GOEL R, 2008, P SPIE
   Goel R, 2007, MOL CANCER THER, V6, P2039, DOI 10.1158/1535-7163.MCT-06-0676
   GOLDMAN CM, 2004, BIOCONJUGATE CHEM, V15, P897
   Gole A, 2005, LANGMUIR, V21, P10756, DOI 10.1021/la0512704
   Gratton SEA, 2007, J CONTROL RELEASE, V121, P10, DOI 10.1016/j.jconrel.2007.05.027
   Gref R, 2003, BIOMATERIALS, V24, P4529, DOI 10.1016/S0142-9612(03)00348-X
   Guo SJ, 2007, ANAL CHIM ACTA, V598, P181, DOI 10.1016/j.aca.2007.07.054
   Haes AJ, 2004, NANO LETT, V4, P1029, DOI 10.1021/nl049670j
   Haes AJ, 2005, J AM CHEM SOC, V127, P2264, DOI 10.1021/ja044087q
   Han G, 2006, ANGEW CHEM INT EDIT, V45, P3165, DOI 10.1002/anie.200600214
   Han G, 2006, CHEM BIOL DRUG DES, V67, P78, DOI 10.1111/j.1747-0285.2005.00324.x
   Han G, 2005, BIOCONJUGATE CHEM, V16, P1356, DOI 10.1021/bc050173j
   Han G, 2007, ADV EXP MED BIOL, V620, P48
   Han G, 2007, NANOMEDICINE-UK, V2, P113, DOI 10.2217/17435889.2.1.113
   Hauck TS, 2008, SMALL, V4, P153, DOI 10.1002/smll.200700217
   HAWLEY AE, 1995, ADV DRUG DELIVER REV, V17, P129, DOI 10.1016/0169-409X(95)00045-9
   He H, 2008, ANAL CHEM, V80, P5951, DOI 10.1021/ac8005796
   Hillyer JF, 2001, J PHARM SCI, V90, P1927, DOI 10.1002/jps.1143
   Hirsch LR, 2006, ANN BIOMED ENG, V34, P15, DOI 10.1007/s10439-005-9001-8
   Hirsch LR, 2003, ANAL CHEM, V75, P2377, DOI 10.1021/ac0262210
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Hsieh BY, 2007, ANAL CHEM, V79, P3487, DOI 10.1021/ac0624389
   HU CH, 2007, J AM CHEM SOC, V129, P2139
   Hu KC, 2008, ANAL CHEM, V80, P9124, DOI 10.1021/ac8017197
   Hu KW, 2008, CHEM-EUR J, V14, P2956, DOI 10.1002/chem.200800114
   Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h                                                                
   Hu QY, 2007, J AM CHEM SOC, V129, P14, DOI 10.1021/ja0670005
   Huang XH, 2006, PHOTOCHEM PHOTOBIOL, V82, P412, DOI 10.1562/2005-12-14-RA-754
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c
   Huff TB, 2007, NANOMEDICINE-UK, V2, P125, DOI 10.2217/17435889.2.1.125
   Idegami K, 2008, ELECTROANAL, V20, P14, DOI 10.1002/elan.200704011
   Jain PK, 2007, PLASMONICS, V2, P107, DOI 10.1007/s11468-007-9031-1
   Jain PK, 2007, NANO TODAY, V2, P18, DOI 10.1016/S1748-0132(07)70016-6                                                   
   Ji XJ, 2007, J PHYS CHEM C, V111, P6245, DOI 10.1021/jp0702245
   KATZE, 2004, ANGEW CHEM INT EDIT, V43, P6042
   Kim YP, 2008, APPL SURF SCI, V255, P1064, DOI 10.1016/j.apsusc.2008.05.101
   Kimling J, 2006, J PHYS CHEM B, V110, P15700, DOI 10.1021/jp061667w
   Kneipp J, 2007, NANO LETT, V7, P2819, DOI 10.1021/nl071418z
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Labande A, 2002, J AM CHEM SOC, V124, P1782, DOI 10.1021/ja017015x
   Lai NS, 2007, ANAL BIOANAL CHEM, V388, P901, DOI 10.1007/s00216-007-1276-1
   Lal S, 2008, ACCOUNTS CHEM RES, V41, P1842, DOI 10.1021/ar800150g
   Lange SA, 2006, ANGEW CHEM INT EDIT, V45, P270, DOI 10.1002/anie.200501243
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   Larson TA, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/32/325101
   LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H                                                    
   Lee S, 2007, ANAL CHEM, V79, P916, DOI 10.1021/ac061246a
   Lee S, 2008, ANGEW CHEM INT EDIT, V47, P2804, DOI 10.1002/anie.200705240
   LEUVERING JHW, 1980, FRESEN Z ANAL CHEM, V301, P132, DOI 10.1007/BF00467777                                                              
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li JH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gnil163
   Li JL, 2009, CANCER LETT, V274, P319, DOI 10.1016/j.canlet.2008.09.024
   Li X, 2009, COLLOID SURFACE A, V332, P172, DOI 10.1016/j.colsurfa.2008.09.009
   Lim YT, 2007, CHEMBIOCHEM, V8, P2204, DOI 10.1002/cbic.200700416
   Lim YT, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/37/375105
   Lin JH, 2007, ANAL SCI, V23, P1059, DOI 10.2116/analsci.23.1059
   Lin JH, 2009, ANAL BIOCHEM, V384, P130, DOI 10.1016/j.ab.2008.09.033
   Liu JW, 2006, ORG BIOMOL CHEM, V4, P3435, DOI 10.1039/b605799c
   Liu MZ, 2005, J PHYS CHEM B, V109, P22192, DOI 10.1021/jp054808n
   Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s
   Maeda H., 2001, ADV ENZYME REGUL, V41, P187
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   MAINCENT P, 1992, PHARMACEUT RES, V9, P1534, DOI 10.1023/A:1015895804597
   Manso J, 2008, ANAL BIOCHEM, V375, P345, DOI 10.1016/j.ab.2007.12.020
   Martins R, 2008, J NON-CRYST SOLIDS, V354, P2580, DOI [10.1016/j.jnoncrysol.2007.09.074, 10.1016/j.jnoncryso1.2007.09.074]
   Marzan L. M., 2006, LANGMUIR, V22, P32
   Mbindyo JKN, 2001, ADV MATER, V13, P249, DOI 10.1002/1521-4095(200102)13:4<249::AID-ADMA249>3.0.CO;2-9                       
   Medley CD, 2008, ANAL CHEM, V80, P1067, DOI 10.1021/ac702037y
   Mie G, 1908, ANN PHYS-BERLIN, V25, P377
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Murphy CJ, 2008, CHEM COMMUN, P544, DOI 10.1039/b711069c
   Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u
   Murphy D, 2005, ANAL BIOANAL CHEM, V381, P1122, DOI 10.1007/s00216-004-3030-2
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017
   Nusz GJ, 2008, ANAL CHEM, V80, P984, DOI 10.1021/ac7017348
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Ou CF, 2007, ANAL CHIM ACTA, V603, P205, DOI 10.1016/j.aca.2007.08.052
   Paciotti GF, 2006, DRUG DEVELOP RES, V67, P47, DOI 10.1002/ddr.20066
   Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895
   Paciotti G. F., 2006, DRUG DEVELOP RES, V5, P2255
   Pal A, 2009, MATER CHEM PHYS, V113, P276, DOI 10.1016/j.matchemphys.2008.07.072
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pernodet N, 2006, SMALL, V2, P766, DOI 10.1002/smll.200500492
   Pissuwan D, 2008, BIOTECHNOL GENET ENG, V25, P93, DOI 10.5661/bger-25-93                                                              
   Podsiadlo P, 2008, LANGMUIR, V24, P568, DOI 10.1021/la702782k
   Pons T, 2007, NANO LETT, V7, P3157, DOI 10.1021/nI071729+
   Pumera M, 2007, SENSOR ACTUAT B-CHEM, V123, P1195, DOI 10.1016/j.snb.2006.11.016
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Ray PC, 2007, PLASMONICS, V2, P173, DOI 10.1007/s11468-007-9036-9
   Reinhard BM, 2005, NANO LETT, V5, P2246, DOI 10.1021/nl051592s
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   SANHU KK, 2002, BIOCONJUGATE CHEM, V13, P3
   Scodeller P, 2008, J AM CHEM SOC, V130, P12690, DOI 10.1021/ja802318f
   Scott RWJ, 2005, J PHYS CHEM B, V109, P692, DOI 10.1021/jp0469665
   SEMMLERBEHNKE M, 2008, SMALL, V12, P2108
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Sisco PN, 2008, NANO LETT, V8, P3409, DOI 10.1021/nl802142h
   Skala MC, 2008, NANO LETT, V8, P3461, DOI 10.1021/nl802351p
   Sokolov K, 2003, CANCER RES, V63, P1999
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Sonavane G, 2008, COLLOID SURFACE B, V65, P1, DOI 10.1016/j.colsurfb.2008.02.013
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Stehr J, 2008, NANO LETT, V8, P619, DOI 10.1021/nl073028i
   Stern JM, 2008, UROL ONCOL-SEMIN ORI, V26, P93, DOI 10.1016/j.urolonc.2007.03.019
   Stern JM, 2008, J UROLOGY, V179, P748, DOI 10.1016/j.juro.2007.09.018
   Stiti M, 2008, J AM CHEM SOC, V130, P16130, DOI 10.1021/ja805558k
   STOLNIK S, 1995, ADV DRUG DELIVER REV, V16, P195, DOI 10.1016/0169-409X(95)00025-3                                                    
   Takahashi H, 2006, LANGMUIR, V22, P2, DOI 10.1021/la0520029
   Takahashi H, 2006, CHEM LETT, V35, P500, DOI 10.1246/cl.2006.500                                                             
   Tanaka R, 2006, ANAL BIOANAL CHEM, V385, P1414, DOI 10.1007/s00216-006-0549-4
   Tang DP, 2005, BIOSENS BIOELECTRON, V21, P539, DOI 10.1016/j.bios.2004.11.024
   TATON TA, 2000, SCIENCE, V289, P1157
   Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Tkatchenko A., 2004, BIOCONJUGATE CHEM, V15, P482
   Treguer-Delapierre M, 2008, GOLD BULL, V41, P195, DOI 10.1007/BF03216597                                                              
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   Valerio C, 1997, J AM CHEM SOC, V119, P2588, DOI 10.1021/ja964127t                                                               
   Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381
   Wang H, 2006, ANAL CHIM ACTA, V575, P205, DOI 10.1016/j.aca.2006.05.080
   Wang J, 2002, J AM CHEM SOC, V124, P4208, DOI 10.1021/ja0255709
   Wang Y, 2009, MAT SCI ENG C-BIO S, V29, P50, DOI 10.1016/j.msec.2008.05.005
   Wang ZP, 2006, CLIN CHEM, V52, P1958, DOI 10.1373/clinchem.2006.071399
   Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872
   Wilson R, 2003, CHEM COMMUN, P108, DOI 10.1039/b208170a
   Wilson R, 2008, CHEM SOC REV, V37, P2028, DOI 10.1039/b712179m
   Wilson R, 2006, ANGEW CHEM INT EDIT, V45, P6104, DOI 10.1002/anie.200600288
   Wu H, 2008, ANGEW CHEM INT EDIT, V47, P3730, DOI 10.1002/anie.200800434
   Xi D., 2007, J NANJING MED U, V21, P207
   Xiao Y, 2003, SCIENCE, V299, P1877, DOI 10.1126/science.1080664
   Xu XY, 2007, ANGEW CHEM INT EDIT, V46, P3468, DOI 10.1002/anie.200605249
   Yamada M, 2003, CR CHIM, V6, P919, DOI 10.1016/j.crci.2003.07.005
   Yang PH, 2005, BIOCONJUGATE CHEM, V16, P494, DOI 10.1021/bc049775d
   Yelin D, 2003, OPT EXPRESS, V11, P1385, DOI 10.1364/OE.11.001385
   You CC, 2007, NAT NANOTECHNOL, V2, P318, DOI 10.1038/nnano.2007.99
   Yu CX, 2007, ANAL CHEM, V79, P572, DOI 10.1021/ac061730d
   Zhang CX, 2003, ANAL BIOCHEM, V320, P136, DOI 10.1016/S0003-2697(03)00353-1
   Zhang GD, 2009, BIOMATERIALS, V30, P1928, DOI 10.1016/j.biomaterials.2008.12.038
   Zharov VP, 2006, BIOPHYS J, V90, P619, DOI 10.1529/biophysj.105.061895
   Zharov VP, 2005, LASER SURG MED, V37, P219, DOI 10.1002/lsm.20223
   Zhu ZJ, 2008, J AM CHEM SOC, V130, P14139, DOI 10.1021/ja805392f
NR 205
TC 1298
Z9 1320
U1 191
U2 1766
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
EI 1460-4744
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2009
VL 38
IS 6
BP 1759
EP 1782
DI 10.1039/b806051g
PG 24
WC Chemistry, Multidisciplinary
SC Chemistry
GA 450OU
UT WOS:000266411500020
PM 19587967
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Martinez-Avila, O
   Hijazi, K
   Marradi, M
   Clavel, C
   Campion, C
   Kelly, C
   Penades, S
AF Martinez-Avila, Olga
   Hijazi, Karolin
   Marradi, Marco
   Clavel, Caroline
   Campion, Colin
   Kelly, Charles
   Penades, Soledad
TI Gold Manno-Glyconanoparticies: Multivalent Systems to Block HIV-1 gp120
   Binding to the Lectin DC-SIGN
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE glycoconjugates; glyconanoparticles; high-mannose oligosaccharides;
   multivalency; surface-plasmon resonance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE GLYCANS; SELF-ASSEMBLED
   MONOLAYERS; ENVELOPE GLYCOPROTEIN GP120; NEUTRALIZING ANTIBODY 2G12;
   N-PENTENYL GLYCOSIDES; C-TYPE LECTINS; OLIGOSACCHARIDE CLUSTERS;
   CARBOHYDRATE STRUCTURES; SELECTIVE RECOGNITION
AB The HIV envelope glycoprotein gp120 takes advantage of the high-mannose clusters on its surface to target the C-type lectin dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) on dendritic cells. Mimicking the cluster presentation of oligomannosides on the virus surface is a strategy for designing carbohydrate-based antiviral agents. Bio-inspired by the cluster presentation of gp120, we have designed and prepared it small library of multivalent water-soluble gold glyconanoparticles (manno-GNPs) presenting truncated (oligo)mannosides of the high-mannose undecasaccharide Man,GlcNAc, and have tested them as inhibitors of DC-SIGN binding to gp120. These glyconanoparticles are ligands for DC-SIGN, which also interacts in the early steps of infection with a large number of pathogens through specific recognition of associated glycans. (Oligo)mannosides endowed with different spacers ending in thiol groups, which enable attachment of the glycoconjugates to the gold surface, have been prepared. manno-GNPs with different spacers and variable density of mannose (oligo)saccharides have been obtained and characterized. Surface plasmon resonance (SPR) experiments with selected manno-GNPs have been performed to study their inhibition potency towards DC-SIGN binding to gp120. The tested manno-GNPs completely inhibit the binding from the micro- to the nanomolar range, while the corresponding monovalent mannosides require millimolar concentrations. manno-GNPs containing the disaccharide Man alpha 1-2Man alpha are the best inhibitors, showing more than 20000-fold increased activity (100% inhibition at 115 nm) compared to the corresponding monomeric disaccharide (100% inhibition at 2.2 mm). Furthermore, increasing the density of dimannoside on the gold platform from 50 to 100% does not improve the level of inhibition.
C1 [Martinez-Avila, Olga; Marradi, Marco; Clavel, Caroline; Penades, Soledad] CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, San Sebastian 20009, Spain.
   [Hijazi, Karolin; Kelly, Charles] Guys Hosp, Inst Dent, Kings Coll London, London SE1 9RT, England.
   [Campion, Colin] Carbohydrate Synth Ltd, Abingdon, Oxon, England.
RP Penades, S (reprint author), CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, Parque Tecnol,P Miramon 182, San Sebastian 20009, Spain.
EM spenades@cicbiomagune.es
RI biomaGUNE, CIC/J-9136-2014; Marradi, Marco/H-7247-2012
OI biomaGUNE, CIC/0000-0001-7690-0660; 
FU EU [EMPRO LSHP-CT2003-503558, MRTN-CT2004-005645]; Spanish Ministry of
   Education and Science [C702008-04638]; Fondation Dormeur; CSIC; MEC
FX The work was supported by the EU (grants EMPRO LSHP-CT2003-503558 and
   Glycogold MRTN-CT2004-005645), the Spanish Ministry of Education and
   Science (MEC, grant C702008-04638), and the Fondation Dormeur. O.M.A.
   thanks the CSIC (I3P program) and MEC for financial support.
CR Adams EW, 2008, CHEMBIOCHEM, V9, P294, DOI 10.1002/cbic.200700310
   Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200
   Arce E, 2003, BIOCONJUGATE CHEM, V14, P817, DOI 10.1021/bc034008k
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Bedouet L, 2001, BIOSCIENCE REP, V21, P839, DOI 10.1023/A:1015592926051
   [Anonymous], 1998, BIATECHNOLOGY HDB
   Buskas T, 2000, J ORG CHEM, V65, P958, DOI 10.1021/jo9909554
   CALARESE DA, 2005, P NATL ACAD SCI USA, V102, P13371
   Calarese D, 2006, ACS SYM SER, V932, P161
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   Cambi A, 2005, CURR OPIN IMMUNOL, V17, P345, DOI 10.1016/j.coi.2005.05.011
   CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356                                                         
   de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb                                              
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   de la Fuente J.M., 2001, ANGEW CHEM INT EDIT, V40, P2257, DOI DOI 10.1002/1521-3773(20010618)40:12
   de la Fuente J. M., 2001, ANGEW CHEM, V113, P2317
   Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g                                                               
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Feinberg H, 2007, J BIOL CHEM, V282, P4202, DOI 10.1074/jbc.M609689200
   FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17
   FENOUILLET E, 1994, TRENDS BIOCHEM SCI, V19, P65, DOI 10.1016/0968-0004(94)90034-5                                                    
   FRASERREID B, 1992, SYNLETT, P927
   Frisch B, 1996, BIOCONJUGATE CHEM, V7, P180, DOI 10.1021/bc950092v
   Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200
   Frison N, 2002, BIOCHEM J, V368, P111, DOI 10.1042/BJ20020673
   Garcia-Barrientos A, 2001, SYNTHESIS-STUTTGART, P1057
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   Grice P, 1996, ANGEW CHEM INT EDIT, V35, P197, DOI 10.1002/anie.199601971                                                          
   Grice P, 1997, CHEM-EUR J, V3, P431
   Grice P., 1996, ANGEW CHEM, V108, P206
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   HANSEN JES, 1991, J VIROL, V65, P6461
   HANSEN JES, 1990, J VIROL, V64, P2833
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Jayaraman N, 1997, TETRAHEDRON LETT, V38, P6767, DOI 10.1016/S0040-4039(97)01548-7
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   KARTHA KPR, 1990, J CARBOHYD CHEM, V9, P777, DOI 10.1080/07328309008543873                                                       
   KIESSLING LL, 2003, CARBOHYDRATE BASED D, V2, P575
   KOZIARA A, 1989, J CHEM RES-S, P296
   Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105
   Lee H. K., 2004, ANGEW CHEM, V116, P1018
   LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001                                                             
   Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Lin CC, 2002, J AM CHEM SOC, V124, P3508, DOI 10.1021/ja0200903
   Lindhorst TK, 2001, J CHEM SOC PERK T 1, P823, DOI 10.1039/b009786l
   Loiseau FA, 2004, J ORG CHEM, V69, P639, DOI 10.1021/jo035042v
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200
   MARNMEN M, 1998, ANGEW CHEM INT EDIT, V37, P2754
   McReynolds KD, 2007, CHEM REV, V107, P1533, DOI 10.1021/cr0502652
   MERRITT JR, 1994, J ORG CHEM, V59, P4443, DOI 10.1021/jo00095a020
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Mizuochi T, 1988, Biomed Chromatogr, V2, P260
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Mrksich M, 1996, ANNU REV BIOPH BIOM, V25, P55, DOI 10.1146/annurev.bb.25.060196.000415                                             
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-27
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   OGAWA T, 1981, TETRAHEDRON, V37, P2779, DOI 10.1016/S0040-4020(01)92345-2                                                   
   OGAWA T, 1985, CARBOHYD RES, V136, P135, DOI 10.1016/0008-6215(85)85192-2
   OGAWA T, 1981, TETRAHEDRON, V37, P2787, DOI 10.1016/S0040-4020(01)92346-4                                                   
   OGAWA T, 1981, CARBOHYD RES, V93, P53, DOI 10.1016/S0008-6215(00)80752-1
   OGAWA T, 1983, CARBOHYD RES, V114, P225, DOI 10.1016/0008-6215(83)88189-0
   Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018
   PALEGROSDEMANGE C, 1991, J AM CHEM SOC, V113, P12, DOI 10.1021/ja00001a002
   Pashov A, 2007, CURR PHARM DESIGN, V13, P185, DOI 10.2174/138161207779313678
   Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6
   Reddy GVS, 2000, SYNTHETIC COMMUN, V30, P2233, DOI 10.1080/00397910008087402
   Revell DJ, 1998, LANGMUIR, V14, P4517, DOI 10.1021/la9802466                                                               
   Rojo J, 2004, CHEMBIOCHEM, V5, P291, DOI 10.1002/cbic.200300726
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Strong LE, 1999, J AM CHEM SOC, V121, P6193, DOI 10.1021/ja990223t                                                               
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2006, ACS SYM SER, V932, P133
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Zemplen G, 1927, BER DTSCH CHEM GES, V60, P1555, DOI 10.1002/cber.19270600717                                                        
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
NR 87
TC 107
Z9 108
U1 2
U2 44
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0947-6539
J9 CHEM-EUR J
JI Chem.-Eur. J.
PY 2009
VL 15
IS 38
BP 9874
EP 9888
DI 10.1002/chem.200900923
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA 502DR
UT WOS:000270435600031
PM 19681073
DA 2018-01-05
ER

PT J
AU Kim, SS
   Peer, D
   Kumar, P
   Shimaoka, M
   Shankar, P
AF Kim, Sang-Soo
   Peer, Dan
   Kumar, Priti
   Shimaoka, Motomu
   Shankar, Premlata
TI siRNA Delivery with Integrin LFA-1-targeted Nanoparticles Prevents HIV
   Infection in Humanized Mice
SO CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies
CY JUN 11-14, 2009
CL San Francisco, CA
SP Federat Clin Immunol Soc
C1 [Kim, Sang-Soo; Shankar, Premlata] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, El Paso, TX USA.
   [Peer, Dan; Shimaoka, Motomu] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
   [Kumar, Priti] Yale Univ, Sch Med, New Haven, CT USA.
RI Peer, Dan/A-1785-2011
OI Peer, Dan/0000-0001-8238-0673
NR 0
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PY 2009
VL 131
BP S75
EP S76
DI 10.1016/j.clim.2009.03.221
PG 2
WC Immunology
SC Immunology
GA 449PK
UT WOS:000266342300214
DA 2018-01-05
ER

PT S
AU Berry, CC
   de la Fuente, JM
AF Berry, Catherine C.
   de la Fuente, Jesus M.
BE Osinski, M
   Jovin, TM
TI Functionalization of Gold Nanoparticles and CdS Quantum Dots with Cell
   Penetrating Peptides
SO COLLOIDAL QUANTUM DOTS FOR BIOMEDICAL APPLICATIONS IV
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Colloidal Quantum Dots for Biomedical Applications IV
CY JAN 24-26, 2009
CL San Jose, CA
SP SPIE, Ocean Opt Inc
DE Cell penetrating peptides; HIV-1 tat; nanoparticles; chemical
   functionalization; quantum dots; nuclear targeting
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNALS;
   SEMICONDUCTOR NANOCRYSTALS; MAGNETIC NANOPARTICLES; PLASMA-MEMBRANE;
   PORE COMPLEX; TAT PEPTIDE; TIOPRONIN; DELIVERY; DOMAINS
AB During the last decade, there has been great deal of interest in the self-assembly fabrication of hybrid materials from inorganic nanoparticles and biomolecules. Nanoparticles are similar in size range to many common biomolecules, thus, nanoparticles appear to be natural companions in hybrid systems. At present, it is straightforward to control and modify properties of nanostructures to better suit their integration with biological systems; for example, controlling their size, modifying their surface layer for enhanced aqueous solubility, biocompatibility, or biorecognition. A particularly desirable target for therapeutic uses is the cell nucleus, because the genetic information is there. We review in this article the synthesis developed by our research group of water-soluble gold nanoparticles and CdS nanocrystals functionalized with a Tat protein-derived peptide sequence by straightforward and economical methodologies. The particles were subsequently tested in vitro with a human fibroblast cell line using optical and transmission electron microscopy to determine the biocompatibility of these nanoparticles and whether the functionalization with the cell penetrating peptide allowed particles to transfer across the cell membrane and locate into the nucleus.
C1 [Berry, Catherine C.] Univ Glasgow, Ctr Cell Engn, Inst Biomed & Life Sci, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
   [de la Fuente, Jesus M.] Univ Zaragoza, ARAID Inst Nanociencia Aragon, Edif Interfacultat 2, Zaragoza 50009, Spain.
RP Berry, CC (reprint author), Univ Glasgow, Ctr Cell Engn, Inst Biomed & Life Sci, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
FU ARAID; MEC; Royal Society; Dorothy Hodgkin
FX J.M.F. thanks to ARAID and MEC for financial support. C.C.B. thanks to
   The Royal Society for financial support via the Dorothy Hodgkin
   Fellowship funds. We also thank the general assistance of staff in the
   Centre for Cell Engineering.
CR Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Castillo PM, 2008, NANOMEDICINE-UK, V3, P627, DOI 10.2217/17435889.3.5.627
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   de la Fuente JM, 2006, LANGMUIR, V22, P3286, DOI 10.1021/la053029v
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   DENNEBERG T, 1983, P EUR DIAL TRANS, V20, P427
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELDHERR CM, 1992, P NATL ACAD SCI USA, V89, P11002, DOI 10.1073/pnas.89.22.11002
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fukati S., 2002, INT J PHARMACEUT, V245, P1
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hogemann D, 2002, BIOCONJUGATE CHEM, V13, P116, DOI 10.1021/bc015549h
   Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kole R, 2001, CURR OPIN MOL THER, V3, P229
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Marinakos SM, 2001, J PHYS CHEM B, V105, P8872, DOI 10.1021/jp010820d
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Michalet X, 2001, SINGLE MOL, V2, P261, DOI 10.1002/1438-5171(200112)2:4<261::AID-SIMO261>3.0.CO;2-P                        
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   Namdeo M, 2008, J NANOSCI NANOTECHNO, V8, P3247, DOI 10.1166/jnn.2008.399
   Noguchi H, 2006, ACTA MED OKAYAMA, V60, P1
   Prunuske AJ, 2006, CURR OPIN CELL BIOL, V18, P108, DOI 10.1016/j.ceb.2005.12.004
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198
   Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6
   Templeton AC, 1999, LANGMUIR, V15, P66, DOI 10.1021/la9808420                                                               
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   West JL, 2000, CURR OPIN BIOTECH, V11, P215, DOI 10.1016/S0958-1669(00)00082-3                                                   
   Wilson R, 2008, CHEM SOC REV, V37, P2028, DOI 10.1039/b712179m
   Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
NR 44
TC 0
Z9 0
U1 6
U2 12
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-7435-3
J9 PROC SPIE
PY 2009
VL 7189
AR UNSP 71890U
DI 10.1117/12.816237
PG 11
WC Crystallography; Engineering, Biomedical; Nanoscience & Nanotechnology;
   Optics
SC Crystallography; Engineering; Science & Technology - Other Topics;
   Optics
GA BSS52
UT WOS:000285710600015
DA 2018-01-05
ER

PT J
AU Farrer, NJ
   Salassa, L
   Sadler, PJ
AF Farrer, Nicola J.
   Salassa, Luca
   Sadler, Peter J.
TI Photoactivated chemotherapy (PACT): the potential of excited-state
   d-block metals in medicine
SO DALTON TRANSACTIONS
LA English
DT Review
ID CONJUGATED GOLD NANOPARTICLES; PHOTODYNAMIC THERAPY WINDOW; ANTI-HIV
   AGENTS; NITRIC-OXIDE; DNA-BINDING; PHOTOCHEMICAL PROPERTIES; QUANTUM
   DOTS; CANCER-CELLS; DIPYRIDOPHENAZINE COMPLEXES; SUPRAMOLECULAR
   COMPLEXES
AB The fields of phototherapy and of inorganic chemotherapy both have long histories. Inorganic photoactivated chemotherapy (PACT) offers both temporal and spatial control over drug activation and has remarkable potential for the treatment of cancer. Following photoexcitation, a number of different decay pathways (both photophysical and photochemical) are available to a metal complex. These pathways can result in radiative energy release, loss of ligands or transfer of energy to another species, such as triplet oxygen. We discuss the features which need to be considered when developing a metal-based anticancer drug, and the common mechanisms by which the current complexes are believed to operate. We then provide a comprehensive overview of PACT developments for complexes of the different d-block metals for the treatment of cancer, detailing the more established areas concerning Ti, V, Cr, Mn, Re, Fe, Ru, Os, Co, Rh, Pt, and Cu and also highlighting areas where there is potential for greater exploration. Nanoparticles (Ag, Au) and quantum dots (Cd) are also discussed for their photothermal destructive potential. We also discuss the potential held in particular by mixed-metal systems and Ru complexes.
C1 [Farrer, Nicola J.; Salassa, Luca; Sadler, Peter J.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
RP Sadler, PJ (reprint author), Univ Warwick, Dept Chem, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.
EM P.J.Sadler@warwick.ac.uk
RI Salassa, Luca/M-7300-2014
OI Salassa, Luca/0000-0002-2112-9095
FU MRC [G070162]; EPSRC [EP/G006792/1]; MarieCurie Intra European
   Fellowship [220281]
FX We thank the MRC (G070162) and EPSRC (EP/G006792/1) for support and
   members of COST Action D39 for stimulating discussions. L. S. was
   supported by the MarieCurie Intra European Fellowship 220281 PHOTORUACD
   within the 7th European Community Framework Programme. We also thank the
   EDRF for support for Science City/AWM.
CR Adams CJ, 2008, INORG CHEM, V47, P8242, DOI 10.1021/ic800850h
   Anas A, 2008, J PHYS CHEM B, V112, P10005, DOI 10.1021/jp8018606
   Arounaguiri S, 1996, INORG CHEM, V35, P4267, DOI 10.1021/ic9508684                                                               
   Bae E, 2008, CHEMOSPHERE, V72, P174, DOI 10.1016/j.chemosphere.2008.01.071
   Balzani V, 2007, TOP CURR CHEM, V281, pIX
   Banfi S, 2003, BIOORGAN MED CHEM, V11, P3595, DOI 10.1016/S0968-0896(03)00368-7
   BARTON JK, 1985, P NATL ACAD SCI USA, V82, P6460, DOI 10.1073/pnas.82.19.6460
   Bednarski PJ, 2007, ANTI-CANCER AGENT ME, V7, P75, DOI 10.2174/187152007779314053
   Billadeau MA, 1996, MET IONS BIOL SYST, V33, P269
   BILLADEAU MA, 1995, J INORG BIOCHEM, V57, P249, DOI 10.1016/0162-0134(94)00029-A                                                    
   Blower PJ, 2001, J INORG BIOCHEM, V85, P15, DOI 10.1016/S0162-0134(00)00228-2
   BONNETT R, 2004, METAL COMPLEXES PHOT, V9, P945
   Boyd S, 2008, AUST J CHEM, V61, P585, DOI 10.1071/CH08189
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   Bucking M, 2000, J PHOTOCH PHOTOBIO B, V58, P87, DOI 10.1016/S1011-1344(00)00108-1
   Buda M, 2002, J AM CHEM SOC, V124, P6090, DOI 10.1021/ja017834h
   Balzani V, 2007, TOP CURR CHEM, V280, P1, DOI 10.1007/978-3-540-73347-8
   Che CM, 2003, CHEM COMMUN, P1718, DOI 10.1039/b303294a
   Chifotides HT, 2005, ACCOUNTS CHEM RES, V38, P146, DOI 10.1021/ar0302078
   Coleman A, 2008, COORDIN CHEM REV, V252, P2585, DOI 10.1016/j.ccr.2008.07.001
   Conrado CL, 2004, INORG CHEM, V43, P5543, DOI 10.1021/ic049459a
   DeLeo MA, 2000, COORDIN CHEM REV, V208, P47, DOI 10.1016/S0010-8545(00)00271-X                                                   
   DEMESMAEKER A, 1995, ACCOUNTS CHEM RES, V28, P366, DOI 10.1021/ar00057a002                                                             
   Denny WA, 2001, EUR J MED CHEM, V36, P577, DOI 10.1016/S0223-5234(01)01253-3                                                   
   DeRosa F, 2005, INORG CHEM, V44, P4157, DOI 10.1021/ic048311o
   Desoize B, 2004, ANTICANCER RES, V24, P1529
   Dixon IM, 2000, CHEM SOC REV, V29, P385, DOI 10.1039/b000704h                                                                
   Dorcier A, 2006, ORGANOMETALLICS, V25, P4090, DOI 10.1021/om060394o
   Elias B, 2006, COORDIN CHEM REV, V250, P1627, DOI 10.1016/j.ccr.2005.11.011
   Failes TW, 2007, CHEM-EUR J, V13, P2974, DOI 10.1002/chem.200601137
   Farrer NJ, 2008, AUST J CHEM, V61, P669, DOI 10.1071/CH08088
   Fortner A, 2007, CHEM PHYS LETT, V434, P127, DOI 10.1016/j.cplett.2006.11.106
   Foxon SP, 2007, ANGEW CHEM INT EDIT, V46, P3686, DOI 10.1002/anie.200604837
   Fricker SP, 2007, DALTON T, P4903, DOI 10.1039/b705551j
   Fujishima A., 2000, J PHOTOCH PHOTOBIO C, V1, P1, DOI DOI 10.1016/S1389-5567(00)00002-2
   Funston AM, 2005, AUST J CHEM, V58, P206, DOI 10.1071/CH04206
   Goswami TK, 2009, ORGANOMETALLICS, V28, P1992, DOI 10.1021/om900012b
   Hambley TW, 2008, AUST J CHEM, V61, P647, DOI 10.1071/CH08180
   He GS, 2008, CHEM REV, V108, P1245, DOI 10.1021/cr050054x
   Herman L, 2008, J PHYS ORG CHEM, V21, P670, DOI 10.1002/poc.1355
   Hiort C, 1996, BIOCHEMISTRY-US, V35, P12354, DOI 10.1021/bi9606253                                                               
   Holder AA, 2004, INORG CHEM, V43, P303, DOI 10.1021/ic035029t
   Holder AA, 2007, INORG CHEM, V46, P4760, DOI 10.1021/ic0619916
   Hsu MH, 2007, BIOCONJUGATE CHEM, V18, P1709, DOI 10.1021/bc700222n
   Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308                                                      
   Hwu JR, 2009, J AM CHEM SOC, V131, P66, DOI 10.1021/ja804947u
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Jakupec MA, 2004, MET IONS BIOL SYST, V42, P425
   Johnson TR, 2003, ANGEW CHEM INT EDIT, V42, P3722, DOI 10.1002/anie.200301634
   Juban EA, 2006, COORDIN CHEM REV, V250, P1783, DOI 10.1016/j.ccr.2006.02.010
   Junicke H, 2003, P NATL ACAD SCI USA, V100, P3737, DOI 10.1073/pnas.0537194100
   Juzenas P, 2008, ADV DRUG DELIVER REV, V60, P1600, DOI 10.1016/j.addr.2008.08.004
   Kalbacova M, 2008, PHYS STATUS SOLIDI-R, V2, P194, DOI 10.1002/pssr.200802080
   KIM GS, 1994, J MED CHEM, V37, P816, DOI 10.1021/jm00032a016
   Kostova Irena, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P591, DOI 10.2174/156801105774574694
   Kratochwil NA, 1999, ANGEW CHEM INT EDIT, V38, P1460, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1460::AID-ANIE1460>3.0.CO;2-Z            
   Lahiri D, 2009, INORG CHEM, V48, P339, DOI 10.1021/ic800806j
   LEGAC S, 2009, ANGEW CHEM, V121, P1142
   Li JL, 2009, CANCER LETT, V274, P319, DOI 10.1016/j.canlet.2008.09.024
   Loganathan D, 2006, PHOTOCHEM PHOTOBIOL, V82, P237, DOI 10.1562/2005-01-19-RA-420
   Loganathan D, 2005, CURR OPIN DRUG DISC, V8, P478
   Lottner C, 2004, CANCER LETT, V215, P167, DOI 10.1016/j.canlet.2004.06.035
   Lutterman DA, 2006, J AM CHEM SOC, V128, P738, DOI 10.1021/ja057620q
   Mackay FS, 2007, P NATL ACAD SCI USA, V104, P20743, DOI 10.1073/pnas.0707742105
   Mackay FS, 2009, DALTON T, P2315, DOI 10.1039/b820550g
   Mackay FS, 2009, INORG CHIM ACTA, V362, P811, DOI 10.1016/j.ica.2008.02.039
   Maeda D, 2009, DALTON T, P140, DOI 10.1039/b809262a
   Magennis SW, 2007, INORG CHEM, V46, P5059, DOI 10.1021/ic062111q
   Maheswari PU, 2008, INORG CHEM, V47, P3719, DOI 10.1021/ic702306f
   MATSUDA Y, 1986, B CHEM SOC JPN, V59, P1839, DOI 10.1246/bcsj.59.1839                                                            
   Maurer TD, 2000, CHEM COMMUN, P69, DOI 10.1039/a908005h                                                                
   Mesmaeker A. Kirsch- De, 1996, TOP CURR CHEM, V177, P25
   MEYER TJ, 1989, ACCOUNTS CHEM RES, V22, P163, DOI 10.1021/ar00161a001                                                             
   MITCHELL JB, 1993, CANCER RES, V53, P5845
   Mody TD, 2001, J PORPHYR PHTHALOCYA, V5, P134, DOI 10.1002/jpp.326                                                                 
   MOLNAR SM, 1994, J PHOTOCH PHOTOBIO A, V80, P315, DOI 10.1016/1010-6030(93)01024-V                                                    
   MOODY LM, 2008, ANNU REP PROG CHEM A, V104, P477
   Moore CM, 2009, NAT CLIN PRACT UROL, V6, P18, DOI 10.1038/ncpuro1274
   Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530                                                           
   Nazeeruddin MK, 2004, COORDIN CHEM REV, V248, P1317, DOI 10.1016/j.ccr.2004.03.012
   NEUMANNSPALLART M, 1980, HELV CHIM ACTA, V63, P1111, DOI 10.1002/hlca.19800630502                                                        
   NGUEWA P, 2005, METAL COMPOUNDS CANC, P1
   Niesel J, 2008, CHEM COMMUN, P1798, DOI 10.1039/b719075a
   Ortmans I, 2004, DALTON T, P668, DOI 10.1039/b313213g
   Ott I, 2009, COORDIN CHEM REV, V253, P1670, DOI 10.1016/j.ccr.2009.02.019
   Paradies J, 2006, J INORG BIOCHEM, V100, P1260, DOI 10.1016/j.jinorgbio.2006.02.011
   Patmore N. J., 2008, ANNU REP PROG CHEM A, V104, P498, DOI DOI 10.1039/B716592G
   Patra AK, 2009, INORG CHEM, V48, P2932, DOI 10.1021/ic8017425
   Pfennig BW, 2009, INORG CHIM ACTA, V362, P1701, DOI 10.1016/j.ica.2008.07.023
   Phillips HIA, 2009, CHEM-EUR J, V15, P1588, DOI 10.1002/chem.200802206
   Prabhakara MC, 2008, MAIN GROUP CHEM, V7, P97, DOI 10.1080/10241220802200347
   Radu A, 2003, GASTROINTEST ENDOSC, V57, P897, DOI 10.1067/mge.2003.275
   Ronconi L, 2008, CHEM COMMUN, P235, DOI 10.1039/b714216a
   Roy M, 2007, INORG CHEM, V46, P4368, DOI 10.1021/ic0620561
   Roy M, 2009, DALTON T, P4671, DOI 10.1039/b901337g
   Rzigalinski BA, 2009, TOXICOL APPL PHARM, V238, P280, DOI 10.1016/j.taap.2009.04.010
   Salassa L, 2008, J AM CHEM SOC, V130, P9590, DOI 10.1021/ja8025906
   Salassa L, 2009, PHYS CHEM CHEM PHYS, V11, P10311, DOI 10.1039/b912496a
   Salassa L, 2009, INORG CHEM, V48, P1469, DOI 10.1021/ic8015436
   Sam M, 2004, INORG CHEM, V43, P8447, DOI 10.1021/ic0486419
   Sasmal PK, 2007, INORG CHEM, V46, P11112, DOI 10.1021/ic7011793
   Sasmal PK, 2009, CHEM COMMUN, P1703, DOI 10.1039/b822229k
   Schuitmaker JJ, 1996, J PHOTOCH PHOTOBIO B, V34, P3, DOI 10.1016/1011-1344(96)07342-3                                                    
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9                                                   
   Sun RWY, 2007, DALTON T, P4884, DOI 10.1039/b705079h
   Szacilowski K, 2005, CHEM REV, V105, P2647, DOI 10.1021/cr030707e
   Talib J, 2009, DALTON T, P504, DOI 10.1039/b814156h
   Trushina OI, 2008, PHOTODIAGN PHOTODYN, V5, P256, DOI 10.1016/j.pdpdt.2008.09.005
   Tshuva EY, 2009, EUR J INORG CHEM, P2203, DOI 10.1002/ejic.200900198
   Vakrat-Haglili Y, 2005, J AM CHEM SOC, V127, P6487, DOI 10.1021/ja046210j
   Valicsek Z, 2008, J PHYS CHEM B, V112, P14509, DOI 10.1021/jp804039s
   Vlcek A, 2002, COORDIN CHEM REV, V230, P225, DOI 10.1016/S0010-8545(02)00047-4
   Wang CG, 2009, ANGEW CHEM INT EDIT, V48, P2759, DOI 10.1002/anie.200805282
   Wecksler SR, 2006, J AM CHEM SOC, V128, P3831, DOI 10.1021/ja057977u
   Wecksler SR, 2007, INORG CHEM, V46, P395, DOI 10.1021/ic0607336
   Weeden SH, 2007, J ARTHROPLASTY, V22, P151, DOI 10.1016/j.arth.2007.04.024
   Weersink RA, 2005, J PHOTOCH PHOTOBIO B, V79, P211, DOI 10.1016/j.jphotobiol.2005.01.008
   Xu J, 2007, INT J PHOTOENERGY, DOI 10.1155/2007/97308
   Zeglis BM, 2007, NAT PROTOC, V2, P357, DOI 10.1038/nprot.2007.22
   Zhang KY, 2009, INORG CHEM, V48, P6011, DOI 10.1021/ic900412n
   Zhao S, 2008, INORG CHEM, V47, P6144, DOI 10.1021/ic7023296
   Zheng QD, 2008, MOL PHARM, V5, P389, DOI 10.1021/mp700117s
   Zigler DF, 2007, INORG CHEM COMMUN, V10, P295, DOI 10.1016/j.inoche.2006.10.024
   Zinchenko AA, 2008, CHEM LETT, V37, P1096, DOI 10.1246/cl.2008.1096
NR 124
TC 196
Z9 197
U1 14
U2 125
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-9226
EI 1477-9234
J9 DALTON T
JI Dalton Trans.
PY 2009
IS 48
BP 10690
EP 10701
DI 10.1039/b917753a
PG 12
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 527IE
UT WOS:000272359900032
PM 20023896
OA green_accepted
DA 2018-01-05
ER

PT B
AU Hubalek, J
   Adam, V
   Kizek, R
AF Hubalek, Jaromir
   Adam, Vojtech
   Kizek, Rene
BE Conley, EC
   Doarn, C
   HajjamElHassani, A
TI New Approach in Rapid Viruses Detection and its Implementation on a Chip
SO INTERNATIONAL CONFERENCE ON EHEALTH, TELEMEDICINE, AND SOCIAL MEDICINE:
   ETELEMED 2009, PROCEEDINGS
LA English
DT Proceedings Paper
CT International Conference on eHealth, Telemedicine and Social Medicine
CY FEB 01-07, 2009
CL Cancun, MEXICO
SP IEEE
DE lab on a chip; viral DNA; nanobeads; microelectrode; nanostructures;
   HIV; H5N1; electrochemical detection
ID DNA HYBRIDIZATION; NUCLEIC-ACIDS; CAPILLARY-ELECTROPHORESIS;
   ELECTROCHEMICAL DNA; SENSORS; MICROCHANNELS; VOLTAMMETRY; ELECTRODES;
   SURFACES; PROTEIN
AB Mortal viruses attack mankind last years and others can arrive early. The rapid detection of the viruses is very important to prevent against pandemic spread. The method of rapid detection is presented in this work. Techniques using micro- and nanotechnology are used for implementation of the method to lab on a chip. The paramagnetic particles are modified using biotechnology to make easy separation and electrochemical detection of viral nucleic acids. The method was approved for detection of viruses HIV and H5N1. Finally the device is designed with aim to prepare low-cost miniature system for mass screening in a case of pandemic.
C1 [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, Brno, Czech Republic.
   [Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic.
RP Hubalek, J (reprint author), Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, Brno, Czech Republic.
EM hubalek@feec.vutbr.cz; ilabo@seznam.cz; kizek@sci.muni.cz
RI Hubalek, Jaromir/D-7753-2012; Kizek, Rene/D-7748-2012; Adam,
   Vojtech/D-7686-2012
OI Adam, Vojtech/0000-0002-8527-286X
FU Czech Ministry of Education in the frame of Research Plan MSM
   [0021630503]; Grant Agency of the Academy of Sciencies of the Czech
   Republic [GAAV KAN208130801]
FX This research has been supported by the Czech Ministry of Education in
   the frame of Research Plan MSM 0021630503 and Grant Agency of the
   Academy of Sciencies of the Czech Republic under the contract GAAV
   KAN208130801.
CR Arnold AK, 2008, P I MECH ENG C-J MEC, V222, P753, DOI 10.1243/09544062JMES784
   Becker H., 2000, MST News, P20
   Cahill BP, 2005, SENSOR ACTUAT B-CHEM, V110, P157, DOI 10.1016/j.snb.2005.01.006
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   FUCHS A, DNA CHIPS BREAKTHROU
   Gajovic-Eichelmann N, 2003, BIOSENS BIOELECTRON, V19, P417, DOI 10.1016/S0956-5663(03)00224-0
   Garcia-Canas V, 2008, ELECTROPHORESIS, V29, P294, DOI 10.1002/elps.200700438
   Gardeniers H., 2000, MST News, P10
   Gessain A, 2008, FUTURE VIROL, V3, P71, DOI 10.2217/17460794.3.1.71
   Goral VN, 2006, LAB CHIP, V6, P414, DOI 10.1039/b513239h
   Gorodetsky AA, 2008, J AM CHEM SOC, V130, P2924, DOI 10.1021/ja7106756
   Hartinger CG, 2007, ELECTROPHORESIS, V28, P3436, DOI 10.1002/elps.200700114
   Heller MJ, 2000, ELECTROPHORESIS, V21, P157, DOI 10.1002/(SICI)1522-2683(20000101)21:1<157::AID-ELPS157>3.3.CO;2-5
   Huang YF, 2006, ELECTROPHORESIS, V27, P3503, DOI 10.1002/elps.200600100
   Hubalek J, 2007, SENSORS-BASEL, V7, P1238, DOI 10.3390/s7071238                                                                
   Jelen F, 2004, BIOELECTROCHEMISTRY, V63, P249, DOI 10.1016/j.bioelechem.2003.10.021
   Kizek R, 2002, BIOELECTROCHEMISTRY, V55, P119, DOI 10.1016/S1567-5394(01)00139-6                                                   
   Kleparnik K, 2007, CHEM REV, V107, P5279, DOI 10.1021/cr0101860
   Klosova K, 2008, PHYS STATUS SOLIDI A, V205, P1435, DOI 10.1002/pssa.200778169
   KOURILOVA A, 2005, ANAL LEFT, P2493
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee KB, 2004, SENSOR ACTUAT A-PHYS, V111, P44, DOI 10.1016/j.sna.2003.10.027
   LEGGE C, 2000, MSTNEWS          SEP, P8
   Lu AH, 2007, ANGEW CHEM INT EDIT, V46, P1222, DOI 10.1002/anie.200602866
   Mcfee RB, 2007, DM-DIS MON, V53, P348, DOI 10.1016/j.disamonth.2007.05.005
   MCGOVERN BH, 2007, ANTIVIR THER, pH3
   Moscona A, 2008, ANNU REV MED, V59, P397, DOI 10.1146/annurev.med.59.061506.213121
   Nguyen NT, 2000, SENSOR ACTUAT A-PHYS, V79, P115, DOI 10.1016/S0924-4247(99)00279-4
   Palecek E, 2004, TRENDS BIOTECHNOL, V22, P55, DOI 10.1016/j.tibtech.2003.11.009
   Palecek E, 2002, CRIT REV ANAL CHEM, V32, P261, DOI 10.1080/10408340290765560                                                       
   Palecek E, 2002, TALANTA, V56, P919, DOI 10.1016/S0039-9140(01)00666-X
   Palecek E, 2002, BIOELECTROCHEMISTRY, V56, P85, DOI 10.1016/S1567-5394(02)00025-7                                                   
   Palecek E, 2002, ANAL CHIM ACTA, V469, P73, DOI 10.1016/S0003-2670(01)01605-1                                                   
   Palecek E, 2002, TALANTA, V56, P809, DOI 10.1016/S0039-9140(01)00649-X
   Palecek E, 2007, TALANTA, V74, P276, DOI 10.1016/j.talanta.2007.08.020
   Pottek M., 2006, MST News, P38
   PRASEK J, 2008, P EUR 22 VDI VDE DRE
   Ramanathan V, 2008, APPL LINGUIST, V29, P1, DOI 10.1093/applin/amm013
   Sabate N, 2006, SENSOR ACTUAT A-PHYS, V125, P260, DOI 10.1016/j.sna.2005.07.024
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Shah RK, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369-7021(08)70053-1
   Urbanski JP, 2007, J COLLOID INTERF SCI, V309, P332, DOI 10.1016/j.jcis.2007.01.095
   Vernet G, 2007, EXPERT REV ANTI-INFE, V5, P89, DOI 10.1586/14787210.5.1.89
   Yao P, 2005, J MICROELECTROMECH S, V14, P799, DOI 10.1109/JMEMS.2005.845403
NR 44
TC 3
Z9 3
U1 0
U2 2
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 978-1-4244-3360-5
PY 2009
BP 108
EP +
PG 3
WC Computer Science, Information Systems; Public, Environmental &
   Occupational Health; Telecommunications
SC Computer Science; Public, Environmental & Occupational Health;
   Telecommunications
GA BJQ81
UT WOS:000267007800019
DA 2018-01-05
ER

PT J
AU Jha, RK
   Jha, PK
   Rana, SVS
   Guha, SK
AF Jha, Rakhi K.
   Jha, Pradeep K.
   Rana, Suresh V. S.
   Guha, Sujoy K.
TI Spermicidal Action of Styrene Maleic Anhydride Polyelectrolyte in
   Combination with Magnetic and Electrically Conductive Particles
SO INTERNATIONAL JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE SMA-Fe(3)O(4)-Cu-DMSO; Smart RISUG; treated sperm cells; AFM; FESEM;
   sperm inactivation; contraception
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VAS-DEFERENS; ANTIFERTILITY AGENT;
   CONTRACEPTIVE RISUG; HUMAN SPERMATOZOA; CLINICAL-TRIAL; IRON-OXIDE;
   PHASE-I; SPERM; SEMEN
AB The aim of this study is to evaluate impact of a new polymeric contraceptive SMA-Fe(3)O(4)-Cu-DMSO called Smart RISUG (acronym for Smart Reversible Inhibition of Sperm under Guidance), a colloidal suspension of styrene maleic anhydride co-polymer (SMA), nano-micro iron oxide (Fe(3)O(4)) and copper powder (Cu) (one milligram) dissolved in dimethylsulphoxide (DMSO) (1:30); on Albino rat's sperm solution (one milliliter). Experiments to assess the morphology and viability of control as well as treated sperm cells were performed by using microscopic techniques like High Resolution Transmission Electron Microscopy (HRTEM), Field Emission Scanning Electron Microscopy (FESEM), Atomic Force Microscopy (AFM), Scanning Electron Microscopy (SEM)-X ray microanalysis, phase contrast microscopy and Fluorescent Activated Cell Sorting (FACS). Treated cells indicate uniform adhesion of Smart RISUG particles to the sperm cell membrane, topological alteration, decrease in the cell count, reduced cell motility and viability, increased sperm abnormality and complete cell inactivation in about 72 h. This study suggests use of smart RISUG as a potential non-invasively reversible male/female contraceptive in future.
C1 [Jha, Rakhi K.; Jha, Pradeep K.; Guha, Sujoy K.] Indian Inst Technol, Dept Biomed Engn, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
   [Jha, Rakhi K.; Rana, Suresh V. S.] Ch Charan Singh Univ, Dept Zool, Toxicol Lab, Meerut, Uttar Pradesh, India.
   [Jha, Pradeep K.] Uttar Pradesh Tech Univ, Dept Management Sci, Visweshereya Inst Engn & Technol, Lucknow, Uttar Pradesh, India.
RP Guha, SK (reprint author), Indian Inst Technol, Dept Biomed Engn, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
FU Ministry of Health and Family Welfare (MOHFW), Government of India
FX This study has been supported by Ministry of Health and Family Welfare
   (MOHFW), Government of India. The authors thank the chairman and members
   of Institutional Animal Ethics Committee for their understanding and
   permission given for carrying out the experiments. We also thank Central
   research facility, Indian Institute of Technology Kharagpur for
   providing instrumentation facility.
CR Chaki SP, 2003, CONTRACEPTION, V67, P73, DOI 10.1016/S0010-7824(02)00442-0
   Chaudhury K, 2004, HUM REPROD, V19, P1826, DOI 10.1093/humrep/deh332
   Chen JY, 2005, J PHARMACOL EXP THER, V312, P546, DOI 10.1124/jpet.104.075424
   Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002
   D'Cruz OJ, 2002, BIOL REPROD, V67, P1959, DOI 10.1095/biolreprod.102.006478
   D'Cruz OJ, 1998, BIOL REPROD, V59, P503, DOI 10.1095/biolreprod59.3.503                                                      
   D'Souza Urban J A, 2003, Malays J Med Sci, V10, P43
   Franken Daniel R., 1998, Frontiers in Bioscience, V3, pE247
   Guha SK, 2005, MED HYPOTHESES, V65, P61, DOI 10.1016/j.mehy.2004.12.030
   Guha SK, 1997, CONTRACEPTION, V56, P245, DOI 10.1016/S0010-7824(97)00142-X
   GUHA SK, 1993, CONTRACEPTION, V48, P367, DOI 10.1016/0010-7824(93)90082-I
   Gupta AK, 2004, IEEE T NANOBIOSCI, V3, P66, DOI 10.1109/TNB.2003.820277
   Lee SW, 2005, IEEE T MAGN, V41, P4114, DOI 10.1109/TMAG.2005.855337
   Lohiya NK, 2000, INT J ANDROL, V23, P36, DOI 10.1046/j.1365-2605.2000.00203.x
   Lubbe AS, 1996, CANCER RES, V56, P4686
   Maeda Y, 2002, CELL DEATH DIFFER, V9, P742, DOI 10.1038/sj.cdd.4401046
   MANN T, 1982, CRC CR REV TOXICOL, V11, P1, DOI 10.3109/10408448209089846
   MARCHAL G, 1989, AM J ROENTGENOL, V152, P771, DOI 10.2214/ajr.152.4.771                                                           
   MAYNARD PV, 1975, J REPROD FERTIL, V43, P41
   MISRO M, 1979, CONTRACEPTION, V20, P467, DOI 10.1016/0010-7824(79)90052-0                                                    
   Narayana K, 2005, MUTAT RES-GEN TOX EN, V588, P28, DOI 10.1016/j.mrgentox.2005.08.012
   Paumgartten FJR, 1998, BRAZ J MED BIOL RES, V31, P955, DOI 10.1590/S0100-879X1998000700012                                                 
   Raji Y., 2005, African Journal of Biomedical Research, V8, P105
   Roblero L, 1996, REPROD FERT DEVELOP, V8, P871, DOI 10.1071/RD9960871
   Sandhyakumary K, 2003, PHYTOTHER RES, V17, P508, DOI 10.1002/ptr.1308
   SETHI N, 1992, INT J FERTIL, V37, P183
   SETHI N, 1989, CONTRACEPTION, V39, P217, DOI 10.1016/S0010-7824(89)80010-1
   Sharma S, 2003, COLLOID SURFACE B, V32, P43, DOI 10.1016/S0927-7765(03)00131-0
   Sharma U, 2001, REPRODUCTION, V122, P431
   Skandhan KP, 2005, UROLOGIA, V72, P461
   VERMA K, 1981, J REPROD FERTIL, V63, P539
   Vijayalaxmi K. K., 2004, International Journal of Human Genetics, V4, P249
   Williams D. N., 2006, J NANOBIOTECHNOL, V4, P1
   WYROBEK AJ, 1975, P NATL ACAD SCI USA, V72, P4425, DOI 10.1073/pnas.72.11.4425
   Zairi A, 2005, CONTRACEPTION, V72, P447, DOI 10.1016/j.contraception.2005.06.055
   Guha SK, 1996, US Patent, Patent No. [5488075, 5,488,075]
   GUHA SK, 2006, Patent No. 2367414
NR 37
TC 9
Z9 9
U1 0
U2 3
PU ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET
PI FAISALABAD
PA 307-LASANI TOWN, SARGODHA RD, FAISALABAD, 38090, PAKISTAN
SN 1811-7775
J9 INT J PHARMACOL
JI Int. J. Pharmacol.
PD JAN
PY 2009
VL 5
IS 1
BP 1
EP 12
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 456BD
UT WOS:000266812100001
DA 2018-01-05
ER

PT J
AU Palombo, MS
   Singh, Y
   Sinko, PJ
AF Palombo, M. S.
   Singh, Y.
   Sinko, P. J.
TI Prodrug and conjugate drug delivery strategies for improving HIV/AIDS
   therapy
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Review
DE Anti-viral; Conjugate; Fosamprenavir; HIV; Nanocarrier; Prodrug;
   Targeted drug delivery; Tenofovir disoproxil fumarate
ID TENOFOVIR DISOPROXIL FUMARATE; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1
   REVERSE-TRANSCRIPTASE; P-GLYCOPROTEIN; ANTIRETROVIRAL ACTIVITY;
   EXPERIENCED PATIENTS; PROTEASE INHIBITOR; PLASMA-MEMBRANE; ORAL
   ABSORPTION; TAT NONAPEPTIDE
AB Despite the wide variety of highly potent anti-HIV drugs that have been developed and made available in clinical practice over the years, eradication of HIV infection has not been achieved. Currently, HIV infection and AIDS are thought to be chronically treatable. HIV attacks host immune cells namely macrophages and CD4(+) T-cells and sequesters itself into sanctuary and reservoir sites such as the lymphoid tissues, testes, and brain. Initial drug delivery efforts with prodrugs and drug conjugates focused on improving the physiochemical (i.e. solubility), biopharmaceutic (i.e. absorption, metabolism), and pharmacokinetic (i.e. blood concentrations) properties of the parent drugs. Eradicating HIV, however, will require advanced drug delivery approaches in order to access and maintain effective drug concentrations for prolonged periods of time in sanctuary sites. The current review discusses prodrug/conjugate efforts, clinical successes and describes drug delivery challenges and approaches for eradicating HIV infection.
C1 [Palombo, M. S.; Singh, Y.; Sinko, P. J.] Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM sinko@rutgers.edu
FU NIH MERIT Award [AI51214]
FX This work was supported by grants from NIH MERIT Award (AI51214). We
   also wish to acknowledge our graduate students, postdoctoral fellows,
   and colleagues who have contributed to this work over the years. Their
   names appear in the references.
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Anthonypillai Christy, 2006, Cerebrospinal Fluid Res, V3, P1, DOI 10.1186/1743-8454-3-1
   Antoniou T, 2003, PHARMACOTHERAPY, V23, P29, DOI 10.1592/phco.23.1.29.31915
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Arimilli MN, 1997, ANTIVIR CHEM CHEMOTH, V8, P557, DOI 10.1177/095632029700800610                                                      
   Auge M., 1992, NATURAL IMMUNE SYSTE, P2
   Barditch-Crovo P, 2001, ANTIMICROB AGENTS CH, V45, P2733, DOI 10.1128/AAC.45.10.2733-2739.2001
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002
   Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P1610, DOI 10.1128/AAC.46.5.1610-1613.2002
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Burton GF, 2002, SEMIN IMMUNOL, V14, P275, DOI 10.1016/S1044-5323(02)00060-X
   Chapman TM, 2004, DRUGS, V64, P2101, DOI 10.2165/00003495-200464180-00014                                                
   Chapman TM, 2003, DRUGS, V63, P1597, DOI 10.2165/00003495-200363150-00006                                                
   Chaudry NI, 2002, CLIN INFECT DIS, V35, P760, DOI 10.1086/342389
   Chen L, 2004, CURR PHARM DESIGN, V10, P1045, DOI 10.2174/1381612043452749                                                        
   CHERRINGTON JM, 1995, ANTIVIR CHEM CHEMOTH, V6, P217, DOI 10.1177/095632029500600403                                                      
   CIHLAR T, 1995, ANTIMICROB AGENTS CH, V39, P117, DOI 10.1128/AAC.39.1.117                                                            
   CLERCQ E, 2003, EXPERT REV ANTI-INFE, V1, P21
   CLERCQ E, 2003, CLIN MICROBIOL REV, V16
   CLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963
   Clercq E.D., 2002, NAT REV DRUG DISCOV, V1, P13
   Cohen J, 2008, SCIENCE, V319, P888, DOI 10.1126/science.319.5865.888
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Deeks SG, 1998, ANTIMICROB AGENTS CH, V42, P2380
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Farese-Di Giorgio A, 2000, ANTIVIR CHEM CHEMOTH, V11, P97
   Finzi D, 1999, NAT MED, V5, P512
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   Fung HB, 2002, CLIN THER, V24, P1515, DOI 10.1016/S0149-2918(02)80058-3
   Furfine ES, 2004, ANTIMICROB AGENTS CH, V48, P791, DOI 10.1128/AAC.48.3.791-798.2004
   GARRAFFO R, 2005, 6 INT WORKSH CLIN PH
   *GIL SCI INC, VIR TEN DIS FUM TABL
   *GLAX, LEXV FOS CALC TABL O
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gunaseelan S, 2004, BIOCONJUGATE CHEM, V15, P1322, DOI 10.1021/bc0498875
   HAASE A, 1999, ANN REV IMMUNOL, V17
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Holy A, 2006, ANTIVIR RES, V71, P248, DOI 10.1016/j.antiviral.2006.06.002
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Kazmierski WM, 2006, CHEM BIOL DRUG DES, V67, P13, DOI 10.1111/j.1747-0285.2005.00319.x
   Kearney BP, 2004, CLIN PHARMACOKINET, V43, P595, DOI 10.2165/00003088-200443090-00003
   Kedzierska K, 2003, REV MED VIROL, V13, P39, DOI 10.1002/rmv.369
   Kim RB, 2002, DRUG METAB REV, V34, P47, DOI 10.1081/DMR-120001389                                                           
   Kratz F, 2008, CHEMMEDCHEM, V3, P20, DOI 10.1002/cmdc.200700159
   Louis JM, 1999, NAT STRUCT BIOL, V6, P868
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   McColl DJ, 2004, JAIDS-J ACQ IMM DEF, V37, P1340, DOI 10.1097/00126334-200411010-00002
   MEARES CF, 1993, PERSPECTIVES BIOCONJ, P1
   Merson MH, 2006, NEW ENGL J MED, V354, P2414, DOI 10.1056/NEJMp068074                                                             
   Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471
   Naesens L, 1998, ANTIMICROB AGENTS CH, V42, P1568
   Nakai T, 2003, J AM CHEM SOC, V125, P8465, DOI 10.1021/ja035636f
   Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   POLLI J, 1999, PHARM RES, V16
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3                                                   
   Ramanathan S, 2001, J CONTROL RELEASE, V77, P199, DOI 10.1016/S0168-3659(01)00474-6
   Ramanathan S, 2001, PHARMACEUT RES, V18, P950, DOI 10.1023/A:1010932126662
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   REINER S, 2000, CELL, V129, P33
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612
   Robbins BL, 2003, PHARMACOTHERAPY, V23, P695, DOI 10.1592/phco.23.6.695.32189
   ROBBINS BL, 1996, INT ANTIVIR NEWS, V4, P57
   Rouquayrol M, 2001, CARBOHYD RES, V336, P161, DOI 10.1016/S0008-6215(01)00260-9
   Sadler BM, 2001, J CLIN PHARMACOL, V41, P386, DOI 10.1177/00912700122010249                                                       
   Schols D, 2004, CURR TOP MED CHEM, V4, P883, DOI 10.2174/1568026043388501
   SCHUITEMAKER H, 1991, J VIROL, V65, P356
   Shaw JP, 1997, PHARMACEUT RES, V14, P1824, DOI 10.1023/A:1012108719462                                                         
   Shehu-Xhilaga M, 2005, CURR HIV RES, V3, P345, DOI 10.2174/157016205774370375
   Singh Y, 2008, CURR MED CHEM, V15, P1802, DOI 10.2174/092986708785132997
   SINKO R, 2004, J PHARMACOL EXP THER, V46, P359
   Struble K, 2005, AIDS, V19, P747, DOI 10.1097/01.aids.0000168968.34810.ca
   STUDENBERG S, 2004, MECH ABSORPTION GW43
   Su YM, 2006, EXPERT OPIN DRUG DEL, V3, P419, DOI 10.1517/17425247.3.3.419
   Su YM, 2004, MOL PHARMACEUT, V1, P49, DOI 10.1021/mp0340136
   Suo ZC, 1998, J BIOL CHEM, V273, P27250, DOI 10.1074/jbc.273.42.27250                                                        
   Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9
   *THOMS HEALTHC INC, MAY CLIN COM FOS OR
   Tuske S, 2004, NAT STRUCT MOL BIOL, V11, P469, DOI 10.1038/nsmb760
   TUSKE S, 2002, 9 C RETR OPP INF SEA
   Usansky HH, 2008, DRUG METAB DISPOS, V36, P863, DOI 10.1124/dmd.107.017483
   van Gelder J, 2002, DRUG METAB DISPOS, V30, P924, DOI 10.1124/dmd.30.8.924
   vanRompay KKA, 1996, ANTIMICROB AGENTS CH, V40, P2586
   Wainberg MA, 1999, ANTIVIR THER, V4, P87
   WAN L, 2007, PHARM RES, V24, P2100
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wan Li, 2006, AIDS Res Ther, V3, P12, DOI 10.1186/1742-6405-3-12
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   *WHO JOINT UN PROG, 2007, 2007 AIDS EP UPD
   *WHO JOINT UN PROG, 2006, 2006 REP GLOB AIDS E
   Williams GC, 2002, ANTIMICROB AGENTS CH, V46, P3456, DOI 10.1128/AAC.46.11.3456-3462.2002
   Wire MB, 2006, CLIN PHARMACOKINET, V45, P137, DOI 10.2165/00003088-200645020-00002
   Wire MB, 2004, 44 INT C ANT AG CHEM
   WOOD R, 2004, ANTIMICROB AGENTS CH, V48, P124
   Wu DA, 1998, BRAIN RES, V791, P313, DOI 10.1016/S0006-8993(98)00139-5
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
NR 103
TC 13
Z9 13
U1 2
U2 11
PU EDITIONS SANTE
PI PARIS
PA 47 RUE GALILEE, 75116 PARIS, FRANCE
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD JAN-FEB
PY 2009
VL 19
IS 1
BP 3
EP 14
DI 10.1016/S1773-2247(09)50001-9                                           
          
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 413QL
UT WOS:000263807500001
PM 20717488
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bourgeois, J
   Lalanne, M
   Pierson, LA
   Marsaud, V
   Nicolas, V
   Tsapis, N
   Ball, R
   Stanimirovic, D
   Couvreur, P
   Andrieux, K
AF Bourgeois, J.
   Lalanne, M.
   Pierson, L. -A.
   Marsaud, V.
   Nicolas, V.
   Tsapis, N.
   Ball, R.
   Stanimirovic, D.
   Couvreur, P.
   Andrieux, K.
TI Formulation of glycerolipidic prodrugs into PEGylated liposomes for
   brain delivery
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Glycerolipidic prodrug; PEGylated liposome; Brain delivery; Didanosine;
   HIV; Formulation optimization; BBB in vitro model
ID LYMPHATIC DELIVERY; BARRIER; NANOPARTICLES; HIV; TRANSLOCATION;
   DIDANOSINE; CARRIERS; CANCER; MODEL
AB Although numerous drugs are used to treat HIV infection with increasing efficacy, the patient's brain is often infected by the virus and acts as a sanctuary where drugs cannot penetrate due to their low passage through the blood brain barrier. Therefore, the design of new medicine able to reach the brain is extemely challenging. An approach based on prodrug synthesis and encapsulation into PEGylated nanocarriers was proposed and applied to didanosine, a nucleosidic analogue used to treat HIV-1 associated dementia. In this study, appropriate formulations of PEGylated liposomes were designed to incorporate two glycerolipidic prodrugs of didanosine. Preparation methods based on Bangham's or emulsion/evaporation techniques formulations exhibited particle size under 300 nm with high incorporation of prodrugs as shown by light scattering, optical microscopy experiments and differential scanning calorimetry. Finally the uptake of fluorescently labeled PEGylated formulations by rat brain immortalized endothelial cells modeling the BBB was evidence by confocal laser scanning microscopy. All the results suggest that the encapsulation of didanosine prodrugs into PEGylated liposomes is a promising approach in the goal increasing didanosine concentration in the brain and treating HIV-1-associated dementia.
C1 [Bourgeois, J.; Lalanne, M.; Pierson, L. -A.; Marsaud, V.; Tsapis, N.; Couvreur, P.; Andrieux, K.] Univ Paris Sud, CNRS, UMR 8612, Fac Pharm, F-92296 Chatenay Malabry, France.
   [Ball, R.; Stanimirovic, D.] Natl Res Council Canada, Cerebrovasc Res Grp, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
   [Nicolas, V.] Univ Paris Sud, Imager Cellulaire IFR 141, F-92296 Chatenay Malabry, France.
RP Andrieux, K (reprint author), Univ Paris Sud, CNRS, UMR 8612, Fac Pharm, Ave J-B Clement, F-92296 Chatenay Malabry, France.
EM karine.andrieux@u-psud.fr
RI Andrieux, Karine/P-3010-2017; COUVREUR, Patrick/G-4844-2011; Tsapis,
   Nicolas/D-5606-2009
OI Andrieux, Karine/0000-0002-2002-7556; COUVREUR,
   Patrick/0000-0001-7961-5443; Tsapis, Nicolas/0000-0003-2095-2626
CR Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Bangham AD, 1974, METHODS MEMBRANE BIO, V1, P1
   Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669
   Garberg P, 2005, TOXICOL IN VITRO, V19, P299, DOI 10.1016/j.tiv.2004.06.011
   Garcia-Garcia E, 2005, INT J PHARM, V298, P274, DOI 10.1016/j.ijpharm.2005.03.031
   Garcia-Garcia E, 2005, CELL MOL LIFE SCI, V62, P1400, DOI 10.1007/s00018-005-5094-3
   Kim HR, 2007, CELL MOL LIFE SCI, V64, P356, DOI 10.1007/s00018-007-6390-x
   KIM HR, 2007, BIOMACROMOL, V12, P793
   Kreuter J, 2008, TUMORI, V94, P271
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lambert DM, 2000, EUR J PHARM SCI, V11, pS15, DOI 10.1016/S0928-0987(00)00161-5
   Lawrence DM, 2002, MICROBES INFECT, V4, P301, DOI 10.1016/S1286-4579(02)01542-3
   Muruganandam A, 1997, FASEB J, V11, P1187
   Shashoua VE, 1996, LIFE SCI, V58, P1347, DOI 10.1016/0024-3205(96)00101-4
   Singh M, 1999, J CONTROL RELEASE, V59, P43, DOI 10.1016/S0168-3659(98)00174-6
   UNEZAKI S, 1994, PHARMACEUT RES, V11, P1180, DOI 10.1023/A:1018949218380
   Wiebe LI, 1999, ADV DRUG DELIVER REV, V39, P63, DOI 10.1016/S0169-409X(99)00020-4                                                   
   Yatvin MB, 1999, ADV DRUG DELIVER REV, V39, P165, DOI 10.1016/S0169-409X(99)00025-3                                                   
NR 19
TC 3
Z9 3
U1 0
U2 6
PU EDITIONS SANTE
PI PARIS
PA 47 RUE GALILEE, 75116 PARIS, FRANCE
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD JAN-FEB
PY 2009
VL 19
IS 1
BP 61
EP 66
DI 10.1016/S1773-2247(09)50008-1                                           
          
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 413QL
UT WOS:000263807500008
DA 2018-01-05
ER

PT J
AU Snasel, J
   Rosenberg, I
   Paces, O
   Pichova, I
AF Snasel, Jan
   Rosenberg, Ivan
   Paces, Ondrej
   Pichova, Iva
TI The strand transfer oligonucleotide inhibitors of HIV-integrase
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1 integrase; inhibition; phosphonate oligonucleotides
ID TETRAD-FORMING OLIGONUCLEOTIDES; RETROVIRAL DNA INTEGRATION; PROTEIN
   IN-VITRO; VIRAL-DNA; BINDING DOMAIN; CRYSTAL-STRUCTURE; ZINC-BINDING;
   CORE; SITE; IDENTIFICATION
AB Retroviral integrase participates in two catalytic reactions, which require interactions with the two ends of the viral DNA in the 3'processing reaction, and with a targeted host DNA in the strand transfer reaction. The 3'-hydroxyl group of 2'-deoxyadenosine resulting from the specific removing of GT dinucleotide from the viral DNA in the processing reaction provides the attachment site for the host DNA in a transesterification reaction. We synthesized oligonucleotides (ONs) of various lengths that mimic the processed HIV-1 U5 terminus of the proviral long terminal repeat (LTR) and are ended by 2'-deoxyadenosine containing a 3'-O-phosphonomethyl group. The duplex stability of phosphonomethyl ONs was increased by covalent linkage of the modified strand with its complementary strand by a triethylene glycol loop (TEG). Modified ONs containing up to 10 bases inhibited in vitro the strand transfer reaction catalyzed by HIV-1 integrase at nanomolar concentrations.
C1 [Snasel, Jan; Rosenberg, Ivan; Paces, Ondrej; Pichova, Iva] Acad Sci Czech Republic, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
RP Pichova, I (reprint author), Acad Sci Czech Republic, Inst Organ Chem & Biochem, Flemingovo Namesti 2, CR-16610 Prague 6, Czech Republic.
EM iva.pichova@uochb.cas.cz
RI Rosenberg, Ivan/G-5602-2014; Pichova, Iva/G-7917-2014
FU Centre for New Antivirals and Antineoplastics [1M6138896301]; Czech
   Ministry of Education; Czech Science Foundation [IAA 4055304]; Academy
   of Sciences of the Czech Republic;  [Z40550506]
FX This work was supported by the "Centre for New Antivirals and
   Antineoplastics" 1M6138896301 of the programme of Czech Ministry of
   Education, by research projects Z 40550506, by grant No.
   203/05/P557,203/05/0827of the Czech Science Foundation, and by a grant
   No. IAA 4055304 of the Grant agency of the Academy of Sciences of the
   Czech Republic.
CR BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525
   BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144
   BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451
   CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y                                                    
   Dayam R, 2006, MED RES REV, V26, P271, DOI 10.1002/med.20054
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807                                                             
   ENGELMAN A, 1992, J VIROL, V66, P6361
   FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2
   Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150                                                         
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jing NJ, 2002, BIOCHEMISTRY-US, V41, P5397, DOI 10.1021/bi0120401
   KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U                                                    
   KATZMAN M, 1989, J VIROL, V63, P5319
   LEAVITT AD, 1993, J BIOL CHEM, V268, P2113
   LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Rejman D, 2004, NUCLEOS NUCLEOT NUCL, V23, P1683, DOI 10.1081/NCN-200033912
   Rejman D, 2001, NUCLEOS NUCLEOT NUCL, V20, P819, DOI 10.1081/NCN-100002437                                                           
   Ren G, 2007, J MOL BIOL, V366, P286, DOI 10.1016/j.jmb.2006.11.029
   Snasel J, 2001, EUR J BIOCHEM, V268, P980, DOI 10.1046/j.1432-1327.2001.01956.x
   SZABO T, 1995, NUCLEIC ACIDS RES, V23, P893, DOI 10.1093/nar/23.6.893
   TAMURA Y, 2000, NUCL ACIDS S SER, V44, P181
   Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o                                                               
   Van Maele B, 2005, AIDS REV, V7, P26
   VANGENT DC, 1993, EMBO J, V12, P3261
   VINCENT KA, 1993, J VIROL, V67, P425
   VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   Williams KL, 2005, J BIOL CHEM, V280, P7949, DOI 10.1074/jbc.M413579200
   Witvrouw M, 2004, CURR DRUG METAB, V5, P291, DOI 10.2174/1389200043335487
NR 40
TC 1
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1475-6366
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PY 2009
VL 24
IS 1
BP 241
EP 246
AR PII 791856647
DI 10.1080/14756360802051578
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 398FT
UT WOS:000262718700034
PM 18608742
OA gold
DA 2018-01-05
ER

PT J
AU Buffa, V
   Stieh, D
   Mamhood, N
   Hu, QX
   Fletcher, P
   Shattock, RJ
AF Buffa, Viviana
   Stieh, Daniel
   Mamhood, Naheed
   Hu, Qinxue
   Fletcher, Patricia
   Shattock, Robin J.
TI Cyanovirin-N potently inhibits human immunodeficiency virus type 1
   infection in cellular and cervical explant models
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID HIV-1 INFECTION; SEMINAL PLASMA; INACTIVATING PROTEIN; IN-VITRO;
   TRANSMISSION; BINDING; MICROBICIDES; GP120; RESISTANCE; FUSION
AB In the absence of a protective vaccine against human immunodeficiency virus (HIV), there is an urgent need for the development of effective topical microbicides to prevent HIV infection. Candidate vaginal microbicides should provide protection against circulating strains, be cheap, stable on storage, safe and easy to use. Here we describe a detailed study of the safety and efficacy of Cyanovirin-N (CV-N) in vitro, and in an ex vivo model of female genital tissue explants. CV-N demonstrated potent activity in the low nanomolar range against laboratory and primary isolates. Activity was related to the affinity of CV-N for binding to whole virions as determined by acoustic resonance. Potent activity was also observed against cell-associated HIV-1, although slightly reduced. CV-N activity in the presence of whole semen was reduced by 7-10-fold, although it remained in the low nanomolar range and was minimally modified by the presence of Candida albicans. Furthermore, CV-N potently inhibited infection of ectocervical explants and virus dissemination by tissue-emigrating cells. In peripheral blood mononuclear cell (PBMC) assays, CV-N was shown to have some mitogenic activity following 3 days exposure to compound, and this was associated with a modest increase in expression of gamma interferon, stromal cell-derived factor 1[3 and interleukin 4. However, 2 h exposure to CV-N had no effect on cytokine expression in PBMC or tissue explant culture over a 24 h period, suggesting that the potential for inflammation is low. Data presented here indicate that targeting HIV envelope glycoproteins may provide an effective strategy to prevent HIV-1 infection mediated by either cell-free virus or infected cells.
C1 [Buffa, Viviana; Stieh, Daniel; Mamhood, Naheed; Hu, Qinxue; Fletcher, Patricia; Shattock, Robin J.] Univ London, St Georges Hosp, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England.
RP Shattock, RJ (reprint author), Univ London, St Georges Hosp, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England.
EM shattock@sgul.ac.uk
FU National Institutes of Health [A1051650]
FX This work was supported by grant A1051650 frorn the National Institutes
   of Health. The following reagents were obtained through the NIH AIDS
   Research and Reference Reagent Program, Division of AIDS, NIAID, NIH:
   TZM-bl from Dr lohn C. Kappes, Dr Xiaoyun Wu and Tranzyme and PM1 cells
   from Dr Marvin Reitz. We would like to think Biosyn Inc. (Huntingdon
   Valley, PA, USA) for providing us with CV-N, Professor C. Kelly for C.
   albicans lysates and the Dormeur Foundation for providing funding to
   purchase the Luminex 100 reader. We are grateful to Dr C. Herrera and Dr
   B. Van Maele for helpful discussion on experimental design and data
   interpretation, Miss N. Armanasco for co-ordinition and collection of
   tissue samples, and the departments of Obstetrics and Gynaecology and
   Histopathology of St George's, Kingston and
CR Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155
   Balzarini J, 2006, J VIROL, V80, P8411, DOI 10.1128/JVI.00369-06
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Bouhlal H, 2002, J IMMUNOL, V169, P3301, DOI 10.4049/jimmunol.169.6.3301                                                     
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   DEVINCENZI I, 1992, BRIT MED J, V304, P809
   Dhawan Darpun, 2006, AIDS Read, V16, P144
   DUPONT B, 1992, J MED VET MYCOL, V30, P19
   Esser MT, 1999, J VIROL, V73, P4360
   Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001
   Fichtenbaum CJ, 1998, CLIN INFECT DIS, V26, P556, DOI 10.1086/514571                                                                  
   Fletcher P, 2005, J VIROL, V79, P11179, DOI 10.1128/JVI.79.17.11179-11186.2005
   Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46
   Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Honey K, 2007, J CLIN INVEST, V117, P1116, DOI 10.1172/JCI32291
   Hu QX, 2007, VIROLOGY, V368, P145, DOI 10.1016/j.virol.2007.06.029
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   Ketas TJ, 2007, VIROLOGY, V364, P431, DOI 10.1016/j.virol.2007.03.001
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li X, 2006, ASSAY DRUG DEV TECHN, V4, P565, DOI 10.1089/adt.2006.4.565
   Lillegard JB, 2006, J INFECT DIS, V193, P1589, DOI 10.1086/503804
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Neurath AR, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-150
   Patel S, 2007, J INFECT DIS, V196, P1394, DOI 10.1086/522606
   Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489
   Sabatte J, 2007, J VIROL, V81, P13723, DOI 10.1128/JVI.01079-07
   Segura MDM, 2006, J VIROL METHODS, V133, P82, DOI 10.1016/j.jviromet.2005.10.030
   Shattock R, 2004, LANCET, V363, P1002, DOI 10.1016/S0140-6736(04)15876-5                                                   
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Turville SG, 2005, J VIROL, V79, P13519, DOI 10.1128/JVI.79.21.13519-13527.2005
   UNAIDS/WHO, 2007, UNAIDS0727EJC1322E W
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453
NR 42
TC 59
Z9 61
U1 0
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JAN
PY 2009
VL 90
BP 234
EP 243
DI 10.1099/vir.0.004358-0
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 391VT
UT WOS:000262263000027
PM 19088294
OA gold
DA 2018-01-05
ER

PT J
AU Saiyed, ZM
   Gandhi, NH
   Nair, MPN
AF Saiyed, Zainulabedin M.
   Gandhi, Nimisha H.
   Nair, Madhavan P. N.
TI AZT 5 '-triphosphate nanoformulation suppresses human immunodeficiency
   virus type 1 replication in peripheral blood mononuclear cells
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE NRTIs; AZTTP; HIV-1 infectivity; magnetic nanoparticles
ID POLYMERIC NANOGEL FORMULATIONS; NUCLEOSIDE ANALOGS; IN-VIVO; MAGNETIC
   NANOPARTICLES; PHOSPHORYLATION; INHIBITION; DELIVERY; HIV-1; ACTIVATION;
   LIPOSOMES
AB Inefficient cellular phosphorylation of nucleoside and nucleotide analog reverse transcriptase inhibitors (NRTIs) to their active nucleoside 5'-triphosphate (NTPs) form is one of the limitations for human immunodeficiency virus (HIV) therapy. We report herein direct binding of 3'-azido-3'-deoxythymidine-5'-triphosphate (AZTTP) onto magnetic nanoparticles (Fe(3)O(4); magnetite) due to ionic interaction. This magnetic nanoparticle bound AZTTP (MP-AZTTP) completely retained its biological activity as assessed by suppression of HIV-1 replication in peripheral blood mononuclear cells. The developed MP-AZTTP nanoformulation can be used for targeting active NRTIs to the brain by application of an external magnetic force and thereby eliminate the brain HIV reservoir and help to treat NeuroAIDS. Journal of NeuroVirology (2009) 15, 343-347.
C1 [Saiyed, Zainulabedin M.; Gandhi, Nimisha H.; Nair, Madhavan P. N.] Florida Int Univ, Dept Immunol, Coll Med, Miami, FL 33199 USA.
RP Nair, MPN (reprint author), Florida Int Univ, Dept Immunol, Coll Med, 11200 SW 8th St,HLS I Lab 307-308-311, Miami, FL 33199 USA.
EM nairm@fiu.edu
FU National Institute on Drug Abuse [R01-DA012366, R01-DA014218,
   R01-DA015628, R01-DA021537, R37-DA025576, R01-DA027049]
FX This work was supported in part by National Institute on Drug Abuse
   grants R01-DA012366, R01-DA014218, R01-DA015628, R01-DA021537,
   R37-DA025576, and R01-DA027049.
CR Antonelli G, 1996, AIDS RES HUM RETROV, V12, P223, DOI 10.1089/aid.1996.12.223                                                         
   BACRI JC, 1990, J MAGN MAGN MATER, V85, P27, DOI 10.1016/0304-8853(90)90010-N
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Koneracka M., 2006, IMMOBILIZATION ENZYM, P217
   Kreller DI, 2003, COLLOID SURFACE A, V212, P249, DOI 10.1016/S0927-7757(02)00325-4                                                   
   Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Nair MPN, 2009, J NEUROIMMUNE PHARM, V4, P129, DOI 10.1007/s11481-008-9128-0
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Potula R, 2008, AIDS, V22, P1539, DOI 10.1097/QAD.0b013e3283081e08
   Riviere C, 2007, RADIOLOGY, V244, P439, DOI 10.1148/radiol.2442060912
   Saiyed ZM, 2007, J BIOTECHNOL, V131, P240, DOI 10.1016/j.jbiotec.2007.06.017
   Saiyed Z. M., 2003, BIOMAGN RES TECHNOL, V1, P1
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z                          
   Wohrl BM, 2005, J GEN VIROL, V86, P757, DOI 10.1099/vir.0.80529-0
NR 21
TC 21
Z9 23
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PY 2009
VL 15
IS 4
BP 343
EP 347
DI 10.1080/13550280903062813
PG 5
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 500DU
UT WOS:000270278800006
PM 19575326
DA 2018-01-05
ER

PT J
AU Dimitrov, DS
AF Dimitrov, Dimiter S.
TI Engineered CH2 domains (nanoantibodies)
SO MABS
LA English
DT Review
DE CH2; nanoantibodies; scaffold; Fabs; antibodies
ID BINDING-PROTEINS; ANTIBODY DOMAIN; SCAFFOLDS; MECHANISM
AB Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size antibodies mostly in IgG1 format of about 150 kDa size. A fundamental problem for such large molecules is their poor penetration into tissues (e.g., solid tumors) and poor or absent binding to regions on the surface of some molecules (e.g., on the HIV envelope glycoprotein) which are fully accessible only by molecules of smaller size. Therefore, much work especially during the last decade has been aimed at developing novel scaffolds of much smaller size and high stability. Here I briefly describe a proposition to use the immunoglobulin (Ig) constant CH2 domain (CH3 for IgE and IgM) as a scaffold. CH2 is critical for the Ig effector functions. Isolated CH2 is stable monomer in contrast to all other constant domains and most of the variable domains. CH2 and engineered CH2 domains with improved stability can be used as scaffolds for construction of libraries containing diverse binders to various antigens. Such binders based on a CH2 scaffold could also confer some effector functions. Because the CH2 domains are the smallest independently folded antibody domains that can be engineered to contain simultaneously antigen-binding sites and binding sites mediating effector and stability functions, and to distinguish them from domain antibodies which are used to denote engineered VH or VL domains or nanobodies which are used to denote camelid VHH, I termed them nanoantibodies (nAbs).
C1 NCI, Prot Interact Grp, Ctr Canc Res Nanobiol Program, NIH, Frederick, MD 21702 USA.
RP Dimitrov, DS (reprint author), NCI, Prot Interact Grp, Ctr Canc Res Nanobiol Program, NIH, Bldg 469,Rm 150B, Frederick, MD 21702 USA.
EM dimitrov@ncifcrf.gov
FU NIH
FX This work was supported by the NIH NO CCR intramural program, the NIH
   intramural AIDS program (IATAP) and the NIH intramural biodefense
   program. I would like to thank to Dr. Prabakaran Ponraj for helpful
   discussions and help with the figures.
CR Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127
   Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105
   Chen WZ, 2008, J MOL BIOL, V382, P779, DOI 10.1016/j.jmb.2008.07.054
   Feige MJ, 2004, J MOL BIOL, V344, P107, DOI 10.1016/j.jmb.2004.09.033
   Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Holt LJ, 2003, TRENDS BIOTECHNOL, V21, P484, DOI 10.1016/j.tibtech.2003.08.007
   Kolmar H, 2008, FEBS J, V275, P2667, DOI 10.1111/j.1742-4658.2008.06437.x
   Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1
   Nygren PA, 2004, J IMMUNOL METHODS, V290, P3, DOI 10.1016/j.jim.2004.04.006
   Prabakaran P, 2008, ACTA CRYSTALLOGR D, V64, P1062, DOI 10.1107/S0907444908025274
   Saerens D, 2008, CURR OPIN PHARMACOL, V8, P600, DOI 10.1016/j.coph.2008.07.006
   Skerra A, 2007, CURR OPIN BIOTECH, V18, P295, DOI 10.1016/j.copbio.2007.04.010
   VU BK, 2008, METH MOL BI IN PRESS
NR 14
TC 30
Z9 31
U1 0
U2 7
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1942-0862
J9 MABS
JI mAbs
PD JAN-FEB
PY 2009
VL 1
IS 1
BP 26
EP 28
DI 10.4161/mabs.1.1.7480                                                   
          
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 519ZJ
UT WOS:000271809200004
PM 20046570
OA gold
DA 2018-01-05
ER

PT J
AU DiPilato, LM
   Zhang, J
AF DiPilato, Lisa M.
   Zhang, Jin
TI The role of membrane microdomains in shaping beta(2)-adrenergic
   receptor-mediated cAMP dynamics
SO MOLECULAR BIOSYSTEMS
LA English
DT Article
ID LIPID RAFTS; FLUORESCENT INDICATORS; NANOSCALE ORGANIZATION;
   SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CYCLIC-AMP; KINASE; COMPARTMENTS;
   ACTIVATION; PROTEINS
AB Recently, membrane rafts and caveolae have received much attention for their role as signaling platforms, particularly due to their involvement in the pathogenesis of a number of diseases, including HIV as well as neurological and cardiovascular conditions. Signaling mediated by the beta-adrenergic receptor (beta-AR), a member of the large family of G-protein coupled receptors (GPCRs) that transduce extracellular messages via the ubiquitous second messenger, cAMP, has been a focus of raft studies since multiple components of the pathway are compartmentalized by these membrane microdomains. However, how these membrane rafts behave and regulate signaling dynamics in a cellular context is poorly understood. Here, we describe a live-cell assay based on single-cell, real-time fluorescence imaging, via an improved FRET-based cAMP biosensor, to monitor raft regulation of second messenger dynamics. Upon cholesterol depletion with methyl-beta-cyclodextrin (M beta CD), beta(2)-AR-mediated cAMP accumulation was enhanced and prolonged in HEK-293 cells, demonstrating that membrane raft integrity helps shape beta-AR signaling. Single-cell imaging in parallel with fractionation studies reveal that the enhancement and change of dynamics are mediated by the receptor and correlated with its redistribution. Finally, the effect of cholesterol depletion is receptor-type specific as M beta CD treatment did not show the same effect when the raft-excluded prostaglandin E receptor was stimulated. This study highlights the potential of a live-cell, real-time imaging assay for studying membrane rafts, including high sensitivity and spatiotemporal resolution, to achieve a better understanding of the nuances of membrane microdomains in both healthy and diseased states.
C1 [DiPilato, Lisa M.; Zhang, Jin] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
   [Zhang, Jin] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA.
   [Zhang, Jin] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21218 USA.
RP Zhang, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
FU NIH [R01 DK073368]; Young Clinical Scientist Award; American Heart
   Association [3M, F31 DK074381]
FX We would like to thank Drs David Zukerman and Carolyn Machamer for help
   with sucrose density gradient fractionation, Dr Robert J. Lefkowitz for
   providing us with the b- arrestin recruitment FRET probe and Qiang Ni
   and Dr Xinxin Gao for critical reading of the manuscript. This work is
   funded by NIH R01 DK073368, the Young Clinical Scientist Award Program
   of the Flight Attendant Medical Research Institute, a Scientist
   Development Award from the American Heart Association, and 3M (to J. Z.)
   and F31 DK074381 (L. M. D).
CR Allen MD, 2006, ACS CHEM BIOL, V1, P371, DOI 10.1021/cb600202f
   Brady JD, 2004, MOL PHARMACOL, V65, P503, DOI 10.1124/mol.65.3.503
   BUXTON ILO, 1983, J BIOL CHEM, V258, P233
   Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325
   DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101
   Gao XX, 2008, MOL BIOL CELL, V19, P4366, DOI 10.1091/mbc.E08-05-0449
   Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5
   Michel V, 2007, BIOL CELL, V99, P129, DOI 10.1042/BC20060051
   Miura Y, 2001, BIOCHEMISTRY-US, V40, P15418, DOI 10.1021/bi015574a
   Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101
   Nikolaev VO, 2006, CIRC RES, V99, P1084, DOI 10.1161/01.RES.0000250046.69918.d5
   Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200
   Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672
   Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200
   Pontier SM, 2008, J BIOL CHEM, V283, P24659, DOI 10.1074/jbc.M800778200
   Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200
   Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9                                                   
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Violin JD, 2008, J BIOL CHEM, V283, P2949, DOI 10.1074/jbc.M707009200
   Violin JD, 2006, J BIOL CHEM, V281, P20577, DOI 10.1074/jbc.M513605200
   Willoughby D, 2008, NAT METHODS, V5, P29, DOI [10.1038/nmeth1135, 10.1038/NMETH1135]
   Willoughby D, 2007, PHYSIOL REV, V87, P965, DOI 10.1152/physrev.00049.2006
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
NR 24
TC 47
Z9 49
U1 0
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742-206X
J9 MOL BIOSYST
JI Mol. Biosyst.
PY 2009
VL 5
IS 8
BP 832
EP 837
DI 10.1039/b823243a
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 471DA
UT WOS:000268033800009
PM 19603118
DA 2018-01-05
ER

PT S
AU Destache, CJ
AF Destache, Christopher J.
BE Sharma, HS
TI Brain as an HIV sequestered site: use of nanoparticles as a therapeutic
   option
SO NANONEUROSCIENCE AND NANONEUROPHARMACOLOGY
SE Progress in Brain Research
LA English
DT Review; Book Chapter
DE HIV-1; antiretroviral nanoparticles; P-glycoprotein; multidrug resistant
   protein; drug penetration; blood-brain barrier
ID CENTRAL-NERVOUS-SYSTEM; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES;
   P-GLYCOPROTEIN EXPRESSION; PROTEASE INHIBITOR CONCENTRATIONS;
   REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS-INFECTION;
   RESISTANCE-ASSOCIATED PROTEINS; ACTIVE ANTIRETROVIRAL THERAPY; DRUG
   EFFLUX TRANSPORTERS; ENDOTHELIAL-CELLS
AB Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.
C1 Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Destache, Christopher/0000-0001-7923-3939
FU NIAID NIH HHS [R15 AI076039]
CR Alakhov V, 1999, COLLOID SURFACE B, V16, P113, DOI 10.1016/S0927-7765(99)00064-8                                                   
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Bachmeier CJ, 2005, PHARM RES, V22, P1259, DOI 10.1007/s11095-005-5271-y
   Banks WA, 2001, J VIROL, V75, P4681, DOI 10.1128/JVI.75.10.4681-4691.2001
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Bobardt MD, 2004, J VIROL, V78, P6567, DOI 10.1128/JVI.78.12.6567-6584.2004
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Calvo P, 2001, J NEUROSCI METH, V111, P151, DOI 10.1016/S0165-0270(01)00450-2
   Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869
   Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3
   Davidovitz M, 1997, MICROW OPT TECHN LET, V15, P224
   DESTACHE CJ, 2009, BMC INFECT DIS UNPUB
   Eggers C, 2003, AIDS, V17, P1897, DOI 10.1097/01.aids.0000076273.54156.8f
   Eilers M, 2008, EXP BIOL MED, V233, P1149, DOI 10.3181/0802-RM-59
   Ellis RJ, 2002, ARCH NEUROL-CHICAGO, V59, P923, DOI 10.1001/archneur.59.6.923
   Fiala M, 1997, MOL MED, V3, P553
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   Fiorillo A, 2004, J NEURO-ONCOL, V66, P179, DOI 10.1023/B:NEON.0000013471.53015.52
   Ghosn J, 2004, AIDS, V18, P1958, DOI 10.1097/00002030-200409240-00014
   Giri N, 2008, DRUG METAB DISPOS, V36, P1476, DOI 10.1124/dmd.108.020974
   GOLLAPUDI S, 1990, BIOCHEM BIOPH RES CO, V171, P1002, DOI 10.1016/0006-291X(90)90783-J
   Haas DW, 2000, AIDS RES HUM RETROV, V16, P1491, DOI 10.1089/088922200750006010                                                      
   Haas DW, 2003, NEUROLOGY, V61, P1391, DOI 10.1212/WNL.61.10.1391                                                          
   Hau P, 2004, CANCER, V100, P1199, DOI 10.1002/cncr.20073
   Hayashi K, 2005, J NEUROCHEM, V93, P1231, DOI 10.1111/j.1471-4159.2005.03114.x
   Jung N, 2008, DRUG METAB DISPOS, V36, P1616, DOI 10.1124/dmd.108.020826
   KABANOV AV, 1989, FEBS LETT, V258, P343, DOI 10.1016/0014-5793(89)81689-8                                                    
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Koukourakis MI, 2000, ACTA ONCOL, V39, P207
   Langford D, 2006, J NEUROVIROL, V12, P100, DOI 10.1080/13550280600713932
   Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31
   Letendre Scott L, 2009, Top HIV Med, V17, P46
   Letendre SL, 2004, ANN NEUROL, V56, P416, DOI 10.1002/ana.20198
   LIU Y, 2000, J NEUROVIROL, V6, P70
   Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006
   MCARTHUR JC, 2004, J NEUROIMMUNOL, V157, P2
   Monforte AD, 2004, ANN NEUROL, V55, P320, DOI 10.1002/ana.10827
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Peracchia MT, 1998, PHARMACEUT RES, V15, P550, DOI 10.1023/A:1011973625803                                                         
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Perloff MD, 2007, J PHARM PHARMACOL, V59, P947, DOI 10.1211/jpp.59.7.0006
   Persidsky Y, 1999, AM J PATHOL, V155, P1599, DOI 10.1016/S0002-9440(10)65476-4
   Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4
   Polli JW, 1999, PHARMACEUT RES, V16, P1206, DOI 10.1023/A:1018941328702
   ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4
   Ronaldson PT, 2006, MOL PHARMACOL, V70, P1087, DOI 10.1124/mol.106.025973
   Saito R, 2004, CANCER RES, V64, P2572, DOI 10.1158/0008-5472.CAN-03-3631
   SIEGAL T, 1995, J NEUROSURG, V83, P1237
   Smit TK, 2004, J VIROL, V78, P10133, DOI 10.1128/JVI.78.18.10133-10148.2004
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Soontornmalai A, 2006, NEUROSCIENCE, V138, P159, DOI 10.1016/j.neuroscience.2005.11.011
   Stormer E, 2002, PHARMACEUT RES, V19, P1038, DOI 10.1023/A:1016430825740
   Valcour V, 2006, CLIN INFECT DIS, V42, P1449, DOI 10.1086/503565
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   VINOGRADOV SV, 2002, COLLOID SURFACE B, V16, P291
   Weiss J, 2007, DRUG METAB DISPOS, V35, P340, DOI 10.1124/dmd.106.012765
   Weller DR, 2007, J CHROMATOGR B, V848, P369, DOI 10.1016/j.jchromb.2006.10.022
   Wolka AM, 2003, ADV DRUG DELIVER REV, V55, P987, DOI 10.1016/S0169-409X9(03)00100-5
   Zhang L, 2000, DRUG METAB DISPOS, V28, P329
NR 62
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0079-6123
BN 978-0-444-53431-6
J9 PROG BRAIN RES
JI Prog. Brain Res.
PY 2009
VL 180
BP 225
EP 233
DI 10.1016/S0079-6123(08)80012-X
PG 9
WC Nanoscience & Nanotechnology; Neurosciences
SC Science & Technology - Other Topics; Neurosciences & Neurology
GA BQC14
UT WOS:000280620600013
PM 20302837
DA 2018-01-05
ER

PT B
AU Goel, N
   Sharma, R
AF Goel, N.
   Sharma, R.
BE Laudon, M
   Romanowicz, B
TI Infant HIV and Nanotechnology
SO NANOTECH CONFERENCE & EXPO 2009, VOL 2, TECHNICAL PROCEEDINGS:
   NANOTECHNOLOGY 2009: LIFE SCIENCES, MEDICINE, DIAGNOSTICS, BIO MATERIALS
   AND COMPOSITES
LA English
DT Proceedings Paper
CT Nanotech 2009 Conference
CY MAY 03-07, 2009
CL Houston, TX
SP Acctron AG, Adv Energy Consortium, Alliance NanoHealth, Appl Mat, Bayer Material Science, Buchanan Ingersoll & Rooney PC, Buhler PARTEC GmbH, Ctr Appl Nanotechnol GmbH, Ctr Biol & Environm Nanotechnol, Clean Technol & Sustainable Ind Org, CMP, CTC Nanotechnol GmbH, DREEBIT GmbH, ETH Zurich, ETH Transfer, ETH Zurich, MNSP, Foley & Lardner LLP, FDA, Goodwin Procter LLC, HiNanoAnalytics, Houston Technol Ctr, Inno X GmbH, Innovat Alliance Carbon Nanotubes, Italian Trade Commiss, Jackson Walker LLP, JENOPTIK, Lockheed Martin, Nano Sci & Technol Inst, nano tech 2009 Japan, NanoEurope Fair & Conf, Nanograde Llc, NanoInk, NANOSENSORS, NanoSPRINT, NanoWorld AG, NCI, NIH, Opportun Houston, OSEC, Pearland Econ Dev Corp, Res Germany Land Ideas, Richard Smalley Inst Nanoscale Sci & Technol, Taylor & Francis Grp LLC, CRC Press, TechConnect, Texas Nanotechnol Initiat, IEEE Stand Assoc, Russian Corp Nanotechnologies, TurboBeads Llc, Weidmann Plast Technol AG
DE infant HIV; DNA; RNA; CD4/CD8 counting; nanobarcode
AB Background: New methods have emerged in detection and monitoring HIV using nanotechnology techniques but HIV in infants got less attention. Purpose: We report here the Human Immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) of under 5 years old children, especially in developing countries. Study Design: Different from adult HIV, in infants it is a challenge of accuracy in diagnosing HIV infection. The success depends on accuracy and sensitivity of HIV infection diagnostics. Materials and Methods: Different HIV-1 DNA and RNA Assays, 1124 antigen assay, CD4 counting and DBS methods were compared for adult and infant HIV diagnosis and feasibility in tertiary care hospital set up. Results: The HIV DNA and RNA assays were qualitative and semiquantitative methods. Other methods p24 antigen biobarcode amplification, nanoarray and FITC (Fluorescein-5-isothiocyanate) doped silica nanoparticle for CD4/CD8 counting were upcoming possible nanotechnology based methods but these are in infancy. Conclusion: HIV DNA and RNA techniques offer good HIV detection in infants. P24 antigen and CD4/CD8 counting offer better quantitative results and further precision by nanoparticle based miniature bar code analysis.
C1 [Goel, N.] Pt BDS Post Grad Inst Med Sci, Dept Microbiol, Rohtak 124001, Haryana, India.
   [Sharma, R.] TCC, Ctr Nanomagnet Biotechnol, Tallahassee, FL 32304 USA.
   [Sharma, R.] Florida State Univ, Tallahassee, FL 32304 USA.
RP Goel, N (reprint author), Pt BDS Post Grad Inst Med Sci, Dept Microbiol, Rohtak 124001, Haryana, India.
EM ngoel_2003@yahoo.com
CR Darbha GK, 2008, CHEM-EUR J, V14, P3896, DOI 10.1002/chem.200701850
   JENNIFER S, 2007, PEDIATRICS, V120, P1547
   Li Y, 2005, Adv Dent Res, V18, P3
   Salaita K, 2007, NAT NANOTECHNOL, V2, P145, DOI 10.1038/nnano.2007.39
   SHIXING T, 2007, AIDS, V46, P231
   SNINSKY JJ, 1990, ARCH PATHOL LAB MED, V114, P259
   SUSAN A, 2007, J CLIN MICROBIOL, V45, P2274
   YUN H, 2006, PROGR BIOMED OPT IMA, V7
   2006 REPORT AIDS
NR 9
TC 0
Z9 0
U1 0
U2 3
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-1783-4
PY 2009
BP 229
EP +
PG 2
WC Biotechnology & Applied Microbiology; Engineering, Biomedical;
   Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Engineering; Science & Technology
   - Other Topics
GA BMQ02
UT WOS:000273330500063
DA 2018-01-05
ER

PT S
AU Ymeti, A
   Nederkoorn, PHJ
   Dudia, A
   Subramaniam, V
   Kanger, JS
AF Ymeti, Aurel
   Nederkoorn, Paul H. J.
   Dudia, Alma
   Subramaniam, Vinod
   Kanger, Johannes S.
BE Halvorson, CS
   Southern, SO
   Kumar, BVKV
   Prabhakar, S
   Ross, AA
TI Rapid, ultrasensitive detection of microorganisms based on
   interferometry and lab-on-a-chip nanotechnology
SO OPTICS AND PHOTONICS IN GLOBAL HOMELAND SECURITY V AND BIOMETRIC
   TECHNOLOGY FOR HUMAN IDENTIFICATION VI
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Optics and Photonics in Global Homeland Security
   V/Biometric Technology for Human Identification VI
CY APR 13-16, 2009
CL Orlando, FL
SP SPIE
DE microorganisms; rapid detection; integrated optics; biosensors;
   interferometry; microfluidics; nanotechnology; lab-on-a-chip;
   point-of-care diagnostics; portable device
ID SENSITIVE DETECTION; VIRUS DETECTION; INFECTION; PLASMA; SENSOR; HIV-1
AB Future viral outbreaks are a major threat to societal and economic development throughout the world. A rapid, sensitive, and easy-to-use test for viral infections is essential to prevent and to control such viral pandemics. Furthermore, a compact, portable device is potentially very useful in remote or developing regions without easy access to sophisticated laboratory facilities. We have developed a rapid, ultrasensitive sensor that could be used in a handheld device to detect various viruses and measure their concentration. The essential innovation in this technique is the combination of an integrated optical interferometric sensor with antibody-antigen recognition approaches to yield a very sensitive, very rapid test for virus detection. The sensor is able to spot the herpes virus at concentrations of just 850 particles per milliliter under physiological conditions. The sensitivity of the sensor approaches detection of a single virus particle, yielding a sensor of unprecedented sensitivity with wide applications for viral diagnostics. The sensor's detection principle can be extended to any biological target such as bacteria, cells and proteins and for which there are specific antibodies. The nature of the sensor enables multiplexed detection of several analytes at the same time.
C1 [Ymeti, Aurel; Nederkoorn, Paul H. J.; Dudia, Alma] Ostendum R&D BV, POB 217, NL-7500 AE Enschede, Netherlands.
   [Ymeti, Aurel; Dudia, Alma; Subramaniam, Vinod; Kanger, Johannes S.] Univ Twente, MESA Inst Nanotechnol, Biophys Engn, NL-7500 AE Enschede, Netherlands.
   [Ymeti, Aurel; Dudia, Alma; Subramaniam, Vinod; Kanger, Johannes S.] Univ Twente, BMTI Inst Biomed, NL-7500 AE Enschede, Netherlands.
RP Ymeti, A (reprint author), Ostendum R&D BV, POB 217, NL-7500 AE Enschede, Netherlands.
EM A.Ymeti@ostendum.com
CR Berger CEH, 1998, ANAL CHEM, V70, P703, DOI 10.1021/ac970929a                                                               
   [Anonymous], 2009, BIACORE SER
   Cooper MA, 2001, NAT BIOTECHNOL, V19, P833, DOI 10.1038/nbt0901-833
   Gupta A, 2004, APPL PHYS LETT, V84, P1976, DOI 10.1063/1.1667011
   Heideman RG, 1999, SENSOR ACTUAT B-CHEM, V61, P100, DOI 10.1016/S0925-4005(99)00283-X
   Kanger J. S., ADV PHOTONI IN PRESS
   Kumarasamy V, 2007, J VIROL METHODS, V140, P75, DOI 10.1016/j.jviromet.2006.11.001
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Pachl C., 1995, J ACQ IMMUN DEF SYND, V8, P446
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Piatak M., 1993, SCIENCE, V259, P1749
   Shanmukh S, 2006, NANO LETT, V6, P2630, DOI 10.1021/nl061666f
   Ymeti A, 2005, BIOSENS BIOELECTRON, V20, P1417, DOI 10.1016/j.bios.2004.04.015
   Ymeti A, 2003, APPL OPTICS, V42, P5649, DOI 10.1364/AO.42.005649
   Ymeti A., 2008, BIODETECTION TECHNOL, P533
   Ymeti A, 2007, EXPERT REV MED DEVIC, V4, P447, DOI 10.1586/17434440.4.4.447
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
NR 17
TC 2
Z9 2
U1 0
U2 6
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-7572-5
J9 PROC SPIE
PY 2009
VL 7306
AR 73060J
DI 10.1117/12.818466
PG 7
WC Mathematical & Computational Biology; Optics
SC Mathematical & Computational Biology; Optics
GA BVR68
UT WOS:000292555700013
DA 2018-01-05
ER

PT S
AU Gan, N
   Wang, F
   Wang, LY
AF Gan Ning
   Wang Feng
   Wang Lu-yan
BE Shi, R
   Fu, WJ
   Wang, YQ
   Wang, HB
TI One Novel Nano Fe3O4-Au Modified Amperometric Immunosensor for Human
   Immunodeficiency Virus p24 Antigen
SO PROCEEDINGS OF THE 2009 2ND INTERNATIONAL CONFERENCE ON BIOMEDICAL
   ENGINEERING AND INFORMATICS, VOLS 1-4
SE International Conference on Biomedical Engineering and Informatics
LA English
DT Proceedings Paper
CT 2nd International Conference on Biomedical Engineering and Informatics
   (BMEI)
CY OCT 17-19, 2009
CL Tianjin Univ Technol, Tianjin, PEOPLES R CHINA
SP IEEE Engn Med & Biol Soc
HO Tianjin Univ Technol
DE Sebacato-bridged Cu(II) phen complex; amperometric immunosensor; HIV p24
   antigen; Fe3O4-Au colloid
AB A novel nano Fe3O4-Au modified amperometric immunosensor for rapid separation-free determination of human immunodeficiency virus (HIV) p24 antigen in acquired immunodeficiency syndrome (AIDS) patients' serum is proposed. Firstly, one novel sebacato-bridged Cu(II) phen complex Cu(phen)L-2 (referred to as CuL, H2L=sebacic acid; phen=1, 10-phenanthroline) was absorbed on the surface of glassy carbon electrode (GCE), then gold magnetic nanoparticles Fe3O4-Au/Chit composite was immobilized onto the surface of CuL modified GCE by its excellent membrane-forming ability, and finally the anti-p24 was adsorbed onto the surface of Fe3O4-Au colloid to construct an GCE vertical bar CuL/Fe3O4-Au/Ab-p24 immunosensor. The modified electrode were characterized by cyclic voltammetry (CV), scanning electron microscope (SEM), and Xray photo electron spectrum (XPS). Based on a competition immunoreaction, CV method for p24 antigen was established. The decrease of current results from the competition of HRP labeled p24 antigen (HRP-p24) and p24 in serum samples to antip-24 immobilized on the working electrode (WE), which leads to a linear decrease of the catalytic efficiency of H2O2 in p24 concentration ranges from 0.5 similar to 90 ng/mL with the detection limit of 0.2 ng/mL (3 sigma). The proposed method needs neither separation nor washing up step, which simplifies the immunoassay procedure, shortens the analytical time, and provides a new promising platform to diagnosing the AIDS disease.
C1 [Gan Ning; Wang Feng; Wang Lu-yan] Ningbo Univ, Fac Chem Engn & Mat Sci, Ningbo, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, Fac Chem Engn & Mat Sci, Ningbo, Peoples R China.
EM ganning@nbu.edu.cn
CR Chen J, 2005, BIOSENS BIOELECTRON, V21, P330, DOI 10.1016/j.bios.2004.10.023
   Gan N, 2006, CHINESE J ANAL CHEM, V34, P479
   He XL, 2008, J BIOCHEM BIOPH METH, V70, P823, DOI 10.1016/j.jbbm.2007.06.002
   He Y, 2003, J VIROL, V77, P1666, DOI 10.1128/JVI.77.3.1666-1671.2003
   LUKACS Z, 2005, SIMULTANEOUS DETERMI, P141
   Perez-Filgueira DM, 2004, J VIROL METHODS, V121, P201, DOI 10.1016/j.viromet.2004.06.022
   Statistics Canada, 2003, TREAT CAR CHIN CHIN, P11
   SUSANNE P, METHODS MOL BIOL, V304, P229
   Yu H, 2005, NANO LETT, V5, P379, DOI 10.1021/nl047955q
   Zheng YQ, 2008, EUR J INORG CHEM, P4453, DOI 10.1002/ejic.200800309
NR 10
TC 0
Z9 0
U1 0
U2 5
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1948-2914
BN 978-1-4244-4133-4
J9 INT CONF BIOMED
PY 2009
BP 1038
EP 1040
PG 3
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Computer Science, Theory & Methods;
   Engineering, Biomedical; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BNP62
UT WOS:000275179900231
DA 2018-01-05
ER

PT J
AU Halim, VA
   Muck, A
   Hartl, M
   Ibanez, AJ
   Giri, A
   Erfurth, F
   Baldwin, IT
   Svatos, A
AF Halim, Vincentius A.
   Muck, Alexander
   Hartl, Markus
   Ibanez, Alfredo J.
   Giri, Ashok
   Erfurth, Florian
   Baldwin, Ian T.
   Svatos, Ales
TI A dual fluorescent/MALDI chip platform for analyzing enzymatic activity
   and for protein profiling
SO PROTEOMICS
LA English
DT Article
DE Enzyme activity assay; Fluorescamine; Fluorescence screening; pMALDI
   chip; Protease inhibitor
ID FLIGHT-MASS-SPECTROMETRY; LASER DESORPTION/IONIZATION-TIME; DENSITY
   NANOVIAL ARRAYS; FLUOROMETRIC ASSAY; INHIBITOR ACTIVITY; PRECURSOR
   PROTEIN; RADIAL DIFFUSION; SOLANUM-NIGRUM; PRIMARY AMINES; FLUORESCAMINE
AB Being able to rapidly and sensitively detect specific enzymatic products is important when screening biological samples for enzymatic activity. We present a simple method for assaying protease activity in the presence of protease inhibitors (Pis) by measuring tryptic peptide accumulation on copolymer pMALDl target chips using a dual fluorescence/MALDI-TOF-MS readout. The small platform of the chip accommodates microliter amounts of sample and allows for rapid protein digestion. Fluorescamine labeling of tryptic peptides is used to indicate the proteolytic activity and is shown to be an affordable, simple process, yielding a strong fluorescence signal with a low background. Subsequent MALDI-TOF-MS analysis, performed in the same sample well, or in a parallel well without adding fluorescamine, detects the specific tryptic peptides and provides confidence in the assay. The dual read-out method was applied to screen the inhibition activity of plant Pis, components of plant defense against herbivores and pathogens. Extracts of Pis from Solanum nigrum and trypsin were applied together to a pMALDI chip on which a suitable substrate was adsorbed. The fluorescence and MALDI-TOF-MS signal decrease were associated with the inhibitory effect of the Pis on trypsin. The developed platform can be modified to screen novel protease inhibitors, namely, those potentially useful for treating or preventing infection by viruses, including HIV and hepatitis C.
C1 [Halim, Vincentius A.; Muck, Alexander; Ibanez, Alfredo J.; Svatos, Ales] Max Planck Inst Chem Ecol, Mass Spectrometry Res Grp, D-07745 Jena, Germany.
   [Hartl, Markus; Giri, Ashok; Baldwin, Ian T.] Max Planck Inst Chem Ecol, Dept Mol Ecol, D-07745 Jena, Germany.
   [Erfurth, Florian] Assoc Med Biol & Environm Technol, Dept Photon & Sensors, Jena, Germany.
RP Svatos, A (reprint author), Max Planck Inst Chem Ecol, Mass Spectrometry Res Grp, Hans Knoll Str 8, D-07745 Jena, Germany.
EM svatos@ice.mpg.de
RI Ibanez, Alfredo/D-4021-2014; Hartl, Markus/F-2866-2010; Svatos,
   Ales/A-3305-2014; Baldwin, Ian/K-1809-2013
OI Ibanez, Alfredo/0000-0001-9206-1537; Hartl, Markus/0000-0002-4970-7336;
   Svatos, Ales/0000-0003-1032-7288; Baldwin, Ian/0000-0001-5371-2974
FU Max Planck Society; Alexander von Humboldt foundation
FX We gratefully acknowledge the financial support by the Max Planck
   Society and thank Emily Wheeler for her editorial help. AG acknowledges
   support of the Alexander von Humboldt foundation for research
   fellowship.
CR Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511
   ATKINSON AH, 1993, PLANT CELL, V5, P203
   Babiak P, 2005, ANAL CHEM, V77, P373, DOI 10.1021/ac048611n
   BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Bungert D, 2004, ANAL BIOCHEM, V326, P167, DOI 10.1016/j.ab.2003.11.013
   Ekstrom S, 2001, ELECTROPHORESIS, V22, P3984, DOI 10.1002/1522-2683(200110)22:18<3984::AID-ELPS3984>3.0.CO;2-T
   Finnskog D, 2004, J PROTEOME RES, V3, P988, DOI 10.1021/pr0499287
   Horn M, 2005, PLANT PHYSIOL, V139, P375, DOI 10.1104/pp.105.064006
   Ibanez AJ, 2007, J PROTEOME RES, V6, P1183, DOI 10.1021/pr060554m
   JONGSMA MA, 1993, ANAL BIOCHEM, V212, P79, DOI 10.1006/abio.1993.1294
   JONGSMA MA, 1994, PLANTA, V195, P29
   KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028
   KRUGER NJ, 1995, PHYTOCHEMISTRY, V38, P1065, DOI 10.1016/0031-9422(94)00787-T                                                    
   Lee MCS, 1999, NAT STRUCT BIOL, V6, P526, DOI 10.1038/9293
   Marko-Varga G, 2001, ELECTROPHORESIS, V22, P3978, DOI 10.1002/1522-2683(200110)22:18<3978::AID-ELPS3978>3.0.CO;2-7
   Min DH, 2004, ANAL CHEM, V76, P3923, DOI 10.1021/ac049816z
   Muck A, 2005, ELECTROPHORESIS, V26, P2835, DOI 10.1002/elps.200400014
   Muck A, 2006, ELECTROPHORESIS, V27, P4952, DOI 10.1002/elps.200600391
   PEARCE G, 1993, PLANT PHYSIOL, V102, P639, DOI 10.1104/pp.102.2.639
   Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkh071
   Richardson M., 1991, METHODS PLANT BIOCH, V5, P259
   Robinson S, 2008, PROTEOMICS, V8, P435, DOI 10.1002/pmic.200700680
   RYAN CA, 1967, ANAL BIOCHEM, V19, P434, DOI 10.1016/0003-2697(67)90233-3                                                    
   RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233
   Saghatelian A, 2005, NAT CHEM BIOL, V1, P130, DOI 10.1038/nchembio0805-130
   Schluter H, 2003, ANAL BIOANAL CHEM, V377, P1102, DOI 10.1007/s00216-003-2211-8
   Schmidt DD, 2004, MOL ECOL, V13, P981, DOI 10.1111/j.1365-294X.2004.02111.x
   Schmidt S, 2006, PLANT PHYSIOL, V142, P1751, DOI 10.1104/pp.106.089755
   Shevchenko A, 2001, ANAL CHEM, V73, P1917, DOI 10.1021/ac0013709
   Sieber SA, 2006, NAT CHEM BIOL, V2, P274, DOI 10.1038/nchembio781
   STEIN S, 1973, ARCH BIOCHEM BIOPHYS, V155, P202
   UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871                                                    
   WEIGELE M, 1972, J AM CHEM SOC, V94, P5927, DOI 10.1021/ja00771a084                                                             
   Weinberger SR, 2002, CURR OPIN CHEM BIOL, V6, P86, DOI 10.1016/S1367-5931(01)00282-4                                                   
   Xu ZF, 2001, PLANT MOL BIOL, V47, P727, DOI 10.1023/A:1013623628857
   Zhu YC, 2005, INSECT BIOCHEM MOLEC, V35, P23, DOI 10.1016/j.ibmb.2004.09.006
   SCHURENBERG M, 2002, Patent No. 0045270
   HUTCHENS T, 2002, Patent No. 0123043
NR 39
TC 7
Z9 7
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD JAN
PY 2009
VL 9
IS 1
BP 171
EP 181
DI 10.1002/pmic.200800390
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 396BZ
UT WOS:000262568500016
PM 19053144
DA 2018-01-05
ER

PT J
AU Kadiu, I
   Orenstein, JM
   Gendelman, HE
AF Kadiu, Irena
   Orenstein, Jan M.
   Gendelman, Howard E.
TI HIV-1 hijacks tunneling nanotubes and secretory microvesicles for
   intercellular spread in monocyte-derived macrophages
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Kadiu, Irena; Gendelman, Howard E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Orenstein, Jan M.] George Washington Univ, Dept Anat Pathol, Washington, DC 20037 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR O22
DI 10.1186/1742-4690-6-S2-O22                                              
          
PG 2
WC Virology
SC Virology
GA 498MX
UT WOS:000270146200047
DA 2018-01-05
ER

PT J
AU Primard, C
   Weber, C
   Martinon, F
   Munier, S
   Calamel, A
   Luciani, E
   Delair, T
   Le Grand, R
   Verrier, B
AF Primard, C.
   Weber, C.
   Martinon, F.
   Munier, S.
   Calamel, A.
   Luciani, E.
   Delair, T.
   Le Grand, R.
   Verrier, B.
TI Induction of a mucosal immune response to HIV after systemic
   immunization with poly (lactic acid) nanoparticles formulated with gag
   antigen and polyI:C
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Primard, C.; Weber, C.; Munier, S.; Calamel, A.; Luciani, E.; Verrier, B.] CNRS, IBCP, Lyon, France.
   [Martinon, F.; Le Grand, R.] CEA, Paris, France.
   [Delair, T.] Univ Lyon 1, F-69365 Lyon, France.
RI Delair, Thierry/E-7896-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P160
DI 10.1186/1742-4690-6-S3-P160                                             
          
PG 1
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300211
DA 2018-01-05
ER

PT J
AU Sexton, A
   Whitney, PG
   De Rose, R
   Zelikin, AN
   Chong, S
   Johnston, AP
   Caruso, F
   Kent, SJ
AF Sexton, A.
   Whitney, P. G.
   De Rose, R.
   Zelikin, A. N.
   Chong, S.
   Johnston, A. P.
   Caruso, F.
   Kent, S. J.
TI Nanoengineered layer-by-layer capsules as a novel delivery system for
   HIV vaccines
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Sexton, A.; Whitney, P. G.; De Rose, R.; Zelikin, A. N.; Chong, S.; Johnston, A. P.; Caruso, F.; Kent, S. J.] Univ Melbourne, Melbourne, Vic, Australia.
RI Zelikin, Alexander/J-3659-2012
OI Zelikin, Alexander/0000-0002-9864-321X; Whitney,
   Paul/0000-0003-3836-7601; Johnston, Angus/0000-0001-5611-4515; Kent,
   Stephen/0000-0002-8539-4891
NR 0
TC 0
Z9 0
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
AR P285
DI 10.1186/1742-4690-6-S3-P285                                             
          
PG 2
WC Virology
SC Virology
GA 509KL
UT WOS:000271015300336
DA 2018-01-05
ER

PT S
AU Ilyinskii, P
AF Ilyinskii, P.
BE Magarshak, Y
   Kozyrev, S
   Vaseashta, AK
TI ASPECTS OF MICROPARTICLE UTILIZATION FOR POTENTIATION OF NOVEL VACCINES:
   PROMISES AND RISKS
SO SILICON VERSUS CARBON
SE NATO Science for Peace and Security Series B - Physics and Biophysics
LA English
DT Proceedings Paper
CT NATO Advanced Research Workshop on Environmental and Biological Risks of
   Hybrid Organic-Silicon Nanodevices
CY JUN 18-20, 2008
CL St Petersburg, RUSSIA
SP NATO
DE vaccine; adjuvant; targeted delivery; nanoparticle; microparticle
ID VIRUS-LIKE PARTICLES; YOUNG-WOMEN; ADJUVANT; DELIVERY; NANOPARTICLES;
   EFFICACY; TYPE-18; TRIAL
AB Many recombinant vaccines against novel (HIV, HCV) or ever-changing (influenza) infectious agents require the presence of adjuvants/delivery vehicles to induce strong immune responses. The necessity of their improvement led to the major effort towards development of vaccine delivery systems that are generally particulate (e.g., nano- and microparticles) and have comparable dimensions to the pathogens (viruses or bacteria). The mode of action of these adjuvants is not fully understood but implies the stimulation of the innate or antigen-specific immune responses, and/or the increase of antigen uptake or processing by antigen-presenting cells (APC). Moreover, enhancement of adjuvant activity through the use of micro- and nanoparticulate delivery systems often resulted from the synergistic effects producing immune responses stronger than those elicited by the adjuvant or delivery system alone. Among particulate adjuvants, biodegradable micro- and nanoparticles of poly(D,L-lactide-co-glycoside) (PLGA) or poly(D,L-lactide) (PLA) have been reported to enhance both humoral and cellular immune responses against an encapsulated protein antigen. Cationic and anionic polylactide co-glycolide (PLG) microparticles have been successfully used to adsorb a variety of agents, which include plasmid DNA, recombinant proteins and adjuvant active oligonucleotides and are also currently tested in several vaccine applications. Another approach envisions specific targeting of APC, especially peripheral DC and exploitation of particulate systems that are small enough for lymphatic uptake (polystyrene nanobeads). Micro- and nanoparticles offer the possibility of enhancement of their uptake by appropriate cells through manipulation of their surface properties. Still, questions regarding toxicity and molecular interaction between micro- and nanoparticles and immune cells, tissues and whole organisms remain to be addressed. These risks and other possible side effects should be assessed in detail especially if mass-production and massive administration of such preparations is to be considered.
C1 Cure Lab Inc, Canton, MA 02021 USA.
RP Ilyinskii, P (reprint author), Cure Lab Inc, Bolivar Str 216, Canton, MA 02021 USA.
EM p.ilyinskii@verizon.net
CR Aguilar JC, 2007, VACCINE, V25, P3752, DOI 10.1016/j.vaccine.2007.01.111
   Babensee Julia E, 2008, Semin Immunol, V20, P101, DOI 10.1016/j.smim.2007.10.013
   Conner M.E., 2004, NEW GENERATION VACCI, P283
   De Filette M, 2006, VACCINE, V24, P6597, DOI 10.1016/j.vaccine.2006.05.082
   Fischer HC, 2007, CURR OPIN BIOTECH, V18, P565, DOI 10.1016/j.copbio.2007.11.008
   GLUECK R, 2004, NEW GENERATION VACCI, P295
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4
   HARPER DM, 2006, LANCET, V24, P5571
   HARRUB B, 2006, GUARD GARDASIL
   He XZ, 2000, J COLLOID INTERF SCI, V225, P128, DOI 10.1006/jcis.1999.6699                                                          
   HOUPPERT K, 2007, NATION
   Ilyinskii PO, 2008, VACCINE, V26, P3223, DOI 10.1016/j.vaccine.2008.03.078
   Jones T, 2004, VACCINE, V22, P3691, DOI 10.1016/j.vaccine.2004.03.035
   Ledford H, 2007, NATURE, V450, P325, DOI 10.1038/450325a
   LEVINE MM, 2004, NEW GENERATION VACCI, P1
   LOWELL GH, 2004, NEW GENERATION VACCI, P271
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Mast E, 2004, VACCINES, P299
   MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875
   Mottram PL, 2007, MOL PHARMACEUT, V4, P73, DOI 10.1021/mp060096p
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI [10.1128/IAI.72.11.6519-6527.2004, 10.1128/IAI.72.11.6519-6529.2004]
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   O'Hagan D.T., 2004, NEW GENERATION VACCI, P259
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Plotkin S.L., 2004, VACCINES, V5, P1
   PODDA A, 2004, NEW GENERATION VACCI, P213
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Rimmelzwaan GF, 2000, VACCINE, V19, P1180, DOI 10.1016/S0264-410X(00)00310-8                                                   
   Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010
   Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
   [Anonymous], 2007, NATURE, V449, P390
NR 35
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 1871-465X
BN 978-90-481-2521-0
J9 NATO SCIENCE PEACE S
PY 2009
BP 397
EP 411
DI 10.1007/978-90-481-2523-4_26
PG 15
WC Biotechnology & Applied Microbiology; Geochemistry & Geophysics;
   Environmental Sciences; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Geochemistry & Geophysics;
   Environmental Sciences & Ecology; Science & Technology - Other Topics
GA BLJ84
UT WOS:000270327700026
DA 2018-01-05
ER

PT J
AU De Rose, R
   Zelikin, AN
   Johnston, APR
   Sexton, A
   Chong, SF
   Cortez, C
   Mulholland, W
   Caruso, F
   Kent, SJ
AF De Rose, Robert
   Zelikin, Alexander N.
   Johnston, Angus P. R.
   Sexton, Amy
   Chong, Siow-Feng
   Cortez, Christina
   Mulholland, William
   Caruso, Frank
   Kent, Stephen J.
TI Binding, Internalization, and Antigen Presentation of Vaccine-Loaded
   Nanoengineered Capsules in Blood
SO ADVANCED MATERIALS
LA English
DT Article
ID DNA MULTILAYER FILMS; DENDRITIC CELLS; HIV VACCINE; IMMUNE ESCAPE;
   T-CELLS; VIRUS; IMMUNOGENICITY; MICROCAPSULES; INFECTION; RESPONSES
AB Nanoengineered microcapsules (shown in green) can be used to encapsulate vaccine antigens conferring protection of the cargo until the capsules are taken up by specialized antigen presenting cells in human blood such as dendritic cells (cell membrane in red, nucleus in blue). This technique offers potential applications for in vivo vaccine delivery.
C1 [Zelikin, Alexander N.; Johnston, Angus P. R.; Chong, Siow-Feng; Cortez, Christina; Mulholland, William; Caruso, Frank] Univ Melbourne, Dept Chem & Biomol Engn, Ctr Nanosci & Nanotechnol, Melbourne, Vic 3010, Australia.
   [De Rose, Robert; Sexton, Amy; Kent, Stephen J.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.
RP Caruso, F (reprint author), Univ Melbourne, Dept Chem & Biomol Engn, Ctr Nanosci & Nanotechnol, Melbourne, Vic 3010, Australia.
EM fcaruso@unimelb.edu.au; skent@unimelb.edu.au
RI Johnston, Angus/A-9254-2011; Zelikin, Alexander/J-3659-2012; Caruso,
   Frank/A-9587-2011
OI Johnston, Angus/0000-0001-5611-4515; Zelikin,
   Alexander/0000-0002-9864-321X; Caruso, Frank/0000-0002-0197-497X; Kent,
   Stephen/0000-0002-8539-4891
CR Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111                                                   
   Chea S, 2005, J VIROL, V79, P3748, DOI 10.1128/JVI.79.6.3748-3757.2005
   Cohen J, 2007, SCIENCE, V318, P1048, DOI 10.1126/science.318.5853.1048                                                   
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   De Geest BG, 2007, CHEM SOC REV, V36, P636, DOI 10.1039/b600460c
   De Rose R, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000055
   Donath E, 1998, ANGEW CHEM INT EDIT, V37, P2201
   Fernandez CS, 2007, J VIROL, V81, P4137, DOI 10.1128/JVI.02193-06
   Johnston APR, 2008, SMALL, V4, P612, DOI 10.1002/smll.200700813
   Johnston APR, 2007, ANGEW CHEM INT EDIT, V46, P2677, DOI 10.1002/anie.200605135
   Johnston APR, 2006, ANAL CHEM, V78, P5913, DOI 10.1021/ac060765a
   Johnston APR, 2006, CURR OPIN COLLOID IN, V11, P203, DOI 10.1016/j.cocis.2006.05.001
   Johnston APR, 2005, NANO LETT, V5, P953, DOI 10.1021/nl050608b
   Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267                                                            
   KOUP RA, 1994, J VIROL, V68, P4650
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Ma YJ, 2006, NAT MATER, V5, P724, DOI 10.1038/nmat1716
   Murthy N, 2003, P NATL ACAD SCI USA, V100, P4995, DOI 10.1073/pnas.0930644100
   NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609
   Nchinda G, 2008, J CLIN INVEST, V118, P1427, DOI 10.1172/JCI34224
   Pantaleo G, 2008, LANCET INFECT DIS, V8, P82, DOI 10.1016/S1473
   Peyratout CS, 2004, ANGEW CHEM INT EDIT, V43, P3762, DOI 10.1002/anie.200300568
   Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993
   Quinn JF, 2007, CHEM SOC REV, V36, P707, DOI 10.1039/b610778h
   Rollman E, 2007, J IMMUNOL, V179, P4571, DOI 10.4049/jimmunol.179.7.4571                                                     
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
   Smith MZ, 2005, J VIROL, V79, P684, DOI 10.1128/JVI.79.2.684-695.2005
   Smith MZ, 2005, J MED PRIMATOL, V34, P282, DOI 10.1111/j.1600-0684.2005.00126.x                                                
   Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105
   Zelikin AN, 2007, ACS NANO, V1, P63, DOI 10.1021/nn700063w
   Zelikin AN, 2006, BIOMACROMOLECULES, V7, P27, DOI 10.1021/bm050832v
NR 32
TC 102
Z9 103
U1 4
U2 51
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD DEC 17
PY 2008
VL 20
IS 24
BP 4698
EP +
DI 10.1002/adma.200801826
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 392GW
UT WOS:000262292200010
DA 2018-01-05
ER

PT J
AU Yang, DY
   Niu, X
   Liu, YY
   Wang, Y
   Gu, X
   Song, LS
   Zhao, R
   Ma, LY
   Shao, YM
   Jiang, XY
AF Yang, Dayong
   Niu, Xin
   Liu, Yingyi
   Wang, Yang
   Gu, Xuan
   Song, Lusheng
   Zhao, Rui
   Ma, Liying
   Shao, Yiming
   Jiang, Xingyu
TI Electrospun Nanofibrous Membranes: A Novel Solid Substrate for
   Microfluidic Immunoassays for HIV
SO ADVANCED MATERIALS
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; POROUS POLYMER MONOLITHS; ELECTROCHEMICAL
   DESORPTION; CHANNELS; FIBERS; ARRAYS; FABRICATION; MICROBEADS;
   SCAFFOLDS; CELLS
AB The combination of electrospun nanofibrous membranes and microfluidic channels dramatically improves the sensitivities of HIV immunoassays in microfluidic channels. Simplicity and effectiveness of the new system can potentially pave the way for inexpensive, portable and highly sensitive diagnostic devices.
C1 [Yang, Dayong; Niu, Xin; Liu, Yingyi; Wang, Yang; Gu, Xuan; Song, Lusheng; Zhao, Rui; Jiang, Xingyu] Natl Ctr NanoSci & Technol, Beijing 100190, Peoples R China.
   [Yang, Dayong; Song, Lusheng] Chinese Acad Sci, Grad Sch, Beijing 100864, Peoples R China.
   [Ma, Liying; Shao, Yiming] Chinese Ctr Dis Control & Prevent, Beijing 100050, Peoples R China.
RP Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, 11 Beiyitiao, Beijing 100190, Peoples R China.
EM xingyujiang@nanoctr.cn
RI Yang, Dayong/E-2966-2010
OI Yang, Dayong/0000-0002-2634-9281; Jiang, Xingyu/0000-0002-5008-4703
FU National Science Foundation of China [20605006, 20890020]; Ministry of
   Science and Technology [2006CB705600, 2006AA03Z323, 2009CB930001]
FX We thank Prof. Lei Jiang and Prof. Meng He for the help with the
   equipment for ES. This work was supported by the CAS Innovation Program,
   the National Science Foundation of China (20605006 and 20890020) and the
   Ministry of Science and Technology (2006CB705600, 2006AA03Z323 and
   2009CB930001).
CR Bange A, 2005, BIOSENS BIOELECTRON, V20, P2488, DOI 10.1016/j.bios.2004.10.016
   Bernard A, 2001, ANAL CHEM, V73, P8, DOI 10.1021/ac0008845
   de Jong J, 2006, LAB CHIP, V6, P1125, DOI 10.1039/b603275c
   DOSHI J, 1995, J ELECTROSTAT, V35, P151, DOI 10.1016/0304-3886(95)00041-8
   Formo E, 2008, NANO LETT, V8, P668, DOI 10.1021/nl073163v
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Henares TG, 2008, ANAL CHIM ACTA, V611, P17, DOI 10.1016/j.aca.2008.01.064
   Huang ZM, 2003, COMPOS SCI TECHNOL, V63, P2223, DOI 10.1016/S0266-3538(03)00178-7
   Ismagilov RF, 2001, ANAL CHEM, V73, P5207, DOI 10.1021/ac010502a
   Jiang XY, 2003, J AM CHEM SOC, V125, P5294, DOI 10.1021/ja034566
   Jiang XY, 2003, J AM CHEM SOC, V125, P2366, DOI 10.1021/ja029485c
   Katta P, 2004, NANO LETT, V4, P2215, DOI 10.1021/nl0486158
   Krishnappa RVN, 2003, J MATER SCI, V38, P2357, DOI 10.1023/A:1023984514389
   Li D, 2004, ADV MATER, V16, P361, DOI 10.1002/adma.200306226
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Li D, 2005, NANO LETT, V5, P913, DOI 10.1021/nl0504235
   Li Y, 2007, ANGEW CHEM INT EDIT, V46, P1094, DOI 10.1002/anie.200603844
   Li ZY, 2008, J AM CHEM SOC, V130, P5036, DOI 10.1021/ja800176s
   Lilliehorn T, 2005, SENSOR ACTUAT B-CHEM, V106, P851, DOI 10.1016/j.snb.2004.07.003
   Murugan R, 2006, TISSUE ENG, V12, P435, DOI 10.1089/ten.2006.12.435
   Norman J, 2006, ANN BIOMED ENG, V34, P89, DOI 10.1007/s10439-005-9005-4
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   Rohr T, 2001, ELECTROPHORESIS, V22, P3959, DOI 10.1002/1522-2683(200110)22:18<3959::AID-ELPS3959>3.0.CO;2-5
   Theron A, 2001, NANOTECHNOLOGY, V12, P384, DOI 10.1088/0957-4484/12/3/329
   Wang XY, 2004, NANO LETT, V4, P331, DOI 10.1021/nl034885z
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Xia Y.N., 1998, ANGEW CHEM INT EDIT, V37, P551, DOI DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yang DY, 2007, ADV MATER, V19, P3702, DOI 10.1002/adma.200700171
   Yoon J, 2007, J AM CHEM SOC, V129, P3038, DOI 10.1021/ja067856+
   Yu C, 2002, J POLYM SCI POL CHEM, V40, P755, DOI 10.1002/pola.10155
   Yu C, 2000, ELECTROPHORESIS, V21, P120, DOI 10.1002/(SICI)1522-2683(20000101)21:1<120::AID-ELPS120>3.0.CO;2-H               
   Zhang Q, 2006, ELECTROPHORESIS, V27, P4943, DOI 10.1002/elps.200600024
NR 33
TC 104
Z9 109
U1 8
U2 96
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD DEC 17
PY 2008
VL 20
IS 24
BP 4770
EP +
DI 10.1002/adma.200801302
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 392GW
UT WOS:000262292200024
DA 2018-01-05
ER

PT J
AU Martin, AL
   Bernas, LM
   Rutt, BK
   Foster, PJ
   Gillies, ER
AF Martin, Amanda L.
   Bernas, Lisa M.
   Rutt, Brian K.
   Foster, Paula J.
   Gillies, Elizabeth R.
TI Enhanced Cell Uptake of Superparamagnetic Iron Oxide Nanoparticles
   Functionalized with Dendritic Guanidines
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID IN-VIVO TRACKING; CLICK CHEMISTRY; TAT PEPTIDE; MOLECULAR TRANSPORTERS;
   CONTRAST AGENTS; STEM-CELLS; MULTIVALENT; DELIVERY; CONJUGATION;
   DENDRIMERS
AB Magnetic resonance imaging (MRI) is a powerful tool for the diagnosis of disease and the study of biological processes such as cancer metastasis and inflammation. Superparamagnetic iron oxide (SPIO) nanoparticles have been shown to be effective contrast agents for labeling cells to provide high sensitivity in MRI, but this sensitivity depends on the ability to label cells with sufficient quantities of SPIO, which can be challenging for nonphagocytic cells such as cancer cells. To address this issue, a novel cell-penetrating polyester dendron with peripheral guanidines was developed and conjugated to the surface of SPIO. The functionalized nanoparticles were characterized by transmission electron microscopy, infrared spectroscopy, and dynamic light scattering, and it was found that the surface functionalization reaction proceeded to completion and did not have any adverse effects on the SPIO. In GL261 mouse glioma cells, the dendritic guanidine exhibited remarkably similar cell-penetrating capabilities to the HIV-Tat(47-57) peptide for the transport of fluorescein, and when conjugated to SPIO, it provided significantly enhanced uptake in comparison with nanoparticles having no dendron or dendrons with hydroxyl or amine peripheries. This uptake led to substantial decreases in the transverse relaxation time (T(2)) of labeled cells relative to control cells. While the nanoparticles functionalized with dendritic guanidines exhibited somewhat greater toxicity than those functionalized with dendrons having hydroxyl or amine peripheries, they were still relatively nontoxic at the low concentrations required for labeling.
C1 [Martin, Amanda L.; Gillies, Elizabeth R.] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada.
   [Gillies, Elizabeth R.] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B7, Canada.
   [Bernas, Lisa M.; Rutt, Brian K.; Foster, Paula J.] Univ Western Ontario, Dept Med Biophys, London, ON N6A 5B7, Canada.
   [Bernas, Lisa M.; Rutt, Brian K.; Foster, Paula J.] Univ Western Ontario, Robarts Res Inst, Imaging Res Labs, London, ON N6A 5B7, Canada.
RP Gillies, ER (reprint author), Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 5B7, Canada.
EM egillie@uwo.ca
RI Gillies, Elizabeth/E-4333-2015; Foster, Paula/M-2201-2013
OI Foster, Paula/0000-0002-4868-3395
FU NSERC; Canada Research Chairs Program; Ontario Institute for Cancer
   Research One Millimetre Cancer Challenge Program; Ontario Graduate
   Scholarship; Barnett-Ivey Heart and Stroke Foundation of Ontario Endowed
   Chair award; CIHR [MGC-14973]
FX We thank NSERC, the Canada Research Chairs Program, and the Ontario
   Institute for Cancer Research One Millimetre Cancer Challenge Program
   for funding this work. A.L.M. is supported by an Ontario Graduate
   Scholarship in Science and Technology. B.K.R. receives salary support
   from the Barnett-Ivey Heart and Stroke Foundation of Ontario Endowed
   Chair award. L.M.B. is supported by CIHR Grant MGC-14973. Jessica Watson
   is acknowledged for assistance in the preparation of compound 4 and
   Michael Maris for compound 8.
CR ANDEE JH, 2007, NAT MED, V13, P95
   Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x                                                               
   Choi SH, 2006, RADIOLOGY, V241, P753, DOI 10.1148/radiol.2413051979
   Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597
   Corot C, 2006, ADV DRUG DELIVER REV, V58, P1471, DOI 10.1016/j.addr.2006.09.013
   De Jesus OLP, 2002, BIOCONJUGATE CHEM, V13, P453, DOI 10.1021/bc010103m
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   DUBOIS M, 1956, ANAL CHEM, V28, P356, DOI DOI 10.1021/AC60111A017
   Foster P, 2008, NEOPLASIA, V10, P207, DOI 10.1593/neo.07937
   Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638
   Frechet J., 2001, DENDRIMERS OTHER DEN
   Gillies ER, 2005, MOL PHARMACEUT, V2, P129, DOI 10.1021/mp049886u
   Gong Y, 2006, J AM CHEM SOC, V128, P14430, DOI 10.1021/ja0644576
   Hatzakis NS, 2006, CHEM COMMUN, P2012, DOI 10.1039/b516551b
   Helms B, 2004, J AM CHEM SOC, V126, P15020, DOI 10.1021/ja044744e
   Heyn C, 2006, MAGNET RESON MED, V55, P23, DOI 10.1002/mrm.20747
   Huang K, 2007, BIOCONJUGATE CHEM, V18, P403, DOI 10.1021/bc060287a
   IHRE H, 2002, BIOCONJUGATE CHEM, V13, P433
   Jeong U, 2007, ADV MATER, V19, P33, DOI 10.1002/adma.200600674
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kohler N, 2004, J AM CHEM SOC, V126, P7206, DOI 10.1021/ja049195r
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Leroueil PR, 2008, NANO LETT, V8, P420, DOI 10.1021/nl0722929
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li B, 2007, CHEM COMMUN, P5217, DOI 10.1039/b713569f
   Li Z, 2005, ADV MATER, V17, P1001, DOI 10.1002/adma.200401545
   MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2
   Montet X, 2006, J MED CHEM, V49, P6087, DOI 10.1021/jm060515m
   Newkome G. R., 2001, DENDRIMERS DENDRONS
   Nguyen T, 2003, ORG LETT, V5, P3245, DOI 10.1021/o1035135z
   Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11
   Potocky TB, 2005, J AM CHEM SOC, V127, P3686, DOI 10.1021/ja042566j
   Reynolds F, 2005, BIOCONJUGATE CHEM, V16, P1240, DOI 10.1021/bc0501451
   Schellenberger EA, 2002, MOL IMAGING, V1, P102, DOI 10.1162/153535002320162769
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Semelka RC, 2001, RADIOLOGY, V218, P27, DOI 10.1148/radiology.218.1.r01ja2427                                               
   SHEN T, 1993, MAGNET RESON MED, V29, P599, DOI 10.1002/mrm.1910290504
   Shi XY, 2007, PHYS CHEM CHEM PHYS, V9, P5712, DOI 10.1039/b709147h
   Strable E, 2001, CHEM MATER, V13, P2201, DOI 10.1021/cm010125i
   Sun EY, 2006, MOL IMAGING, V5, P122, DOI 10.2310/7290.2006.00013
   Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e
   WEISSLEDER R, 1995, ADV DRUG DELIVER REV, V16, P321, DOI 10.1016/0169-409X(95)00033-4
   Wender PA, 2005, ORG LETT, V7, P4815, DOI 10.1021/ol051496y
   White MA, 2006, J AM CHEM SOC, V128, P11356, DOI 10.1021/ja064041s
   Wu P, 2005, CHEM COMMUN, P5775, DOI 10.1039/b512021g
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 47
TC 87
Z9 88
U1 1
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD DEC
PY 2008
VL 19
IS 12
BP 2375
EP 2384
DI 10.1021/bc800209u
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 384TT
UT WOS:000261767800012
PM 19053308
DA 2018-01-05
ER

PT J
AU Zhang, ZW
   Xi, XM
   Scholes, CP
   Karim, CB
AF Zhang, Zhiwen
   Xi, Xiangmei
   Scholes, Charles P.
   Karim, Christine B.
TI Rotational Dynamics of HIV-1 Nucleocapsid Protein NCp7 as Probed by a
   Spin Label Attached by Peptide Synthesis
SO BIOPOLYMERS
LA English
DT Article
DE CD; EPR; NCp7; spin label; TFE; TOAC; Psi RNA
ID NUCLEIC-ACID-CHAPERONE; ELECTRON-PARAMAGNETIC-RESONANCE; RNA PACKAGING
   SIGNAL; SIDE-CHAINS; REVERSE TRANSCRIPTION; BIOLOGICAL-ACTIVITY;
   CIRCULAR-DICHROISM; GENOME RECOGNITION; SELF-ASSOCIATION; STRAND
   TRANSFER
AB 2,2,6,6-Tetramethylpiperidine-1-oxyl-4-amino-4carboxylic acid (TOAC) spin label was attached at the N-terminal position to interrogate the dynamics of the HIV-1 nucleocapsid Zn-finger protein, NCp7. NCp7 is a 6.4-kDa 55-mer critical to the recognition, packaging, and efficient reverse transcription of viral RNA that has stein-loop structures, such as the RNA stem-loop 3 used in this work. The NCp7, made by solid-phase peptide synthesis with TOAC incorporated into the alpha-carbon backbone at the N-terininal "0" position, showed analytical purity and biological activity. Electron Paramagnetic Resonance (EPR) spectra of the N-terminal TOAC indicated rapid temperature-sensitive motion of the probe (<= 0.33 ns correlation time) on the flexible N-terminal segment. This N-terminal TOAC-NCp7 reported a RNA-NCp7 interaction at a 1:1 ratio of NCp7 to RNA, which caused the tumbling time to be slowed from about 0.3 ns to about 0.5 ns. NCp7 is a largely disordered protein that adapts to its RNA targets. However, as shown by circular dichroism, >= 90% trifluoroethanol [(TFE), an alpha-helix enhancer] caused the TOAC-NCp7 without zinc in its fingers to change to a fully helical conformation, while the TOAC spin label was concurrently reporting a tumbling time of well over a nanosecond, as the N-terminal TOAC became inflexibly enfolded. Even with TFE present, the existence of intact Zn-finger regions in NCp7 prevented complete formation of helical structure, as shown by circular dichroism, and decreased the N-terminal TOAC tumbling time, as shown by EPR. This study demonstrated TOAC at the N-terminal of NCp7 to be a reporter for the considerable conformational lability of NCp7. (C) 2008 Wiley Periodicals, Inc. Biopolymers 89:1125-1135, 2008.
C1 [Zhang, Zhiwen; Karim, Christine B.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Xi, Xiangmei; Scholes, Charles P.] SUNY Albany, Dept Chem, Albany, NY 12222 USA.
RP Karim, CB (reprint author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
EM cps14@albany.edu; cbk@ddt.biochem.umn.edu
FU NIGMS NIH HHS [GM066253-01A1, R01 GM066253-01A1, R01 GM066253]
CR Adler A J, 1973, Methods Enzymol, V27, P675
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2001.5182
   Barnes JP, 1999, BIOPHYS J, V76, P3298, DOI 10.1016/S0006-3495(99)77482-5                                                   
   Barnham KJ, 1999, BBA-PROTEIN STRUCT M, V1435, P127, DOI 10.1016/S0167-4838(99)00214-9
   BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409
   Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113
   Carteau S, 1999, J VIROL, V73, P6670
   CHEN M, 2007, J BIOL CHEM, V34, P24790
   Columbus L, 2001, BIOCHEMISTRY-US, V40, P3828, DOI 10.1021/bi002645h
   Cosa G, 2006, J PHYS CHEM B, V110, P2419, DOI 10.1021/jp054189i
   Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0
   Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   DIBHAJJ F, 1993, PROTEIN SCI, V2, P231
   Earle K. A., 2006, ADV ESR METHODS POLY
   GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403
   GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031
   Gregoire CJ, 1997, J BIOL CHEM, V272, P25143, DOI 10.1074/jbc.272.40.25143                                                        
   GRIFFITH OH, 1965, J CHEM PHYS, V43, P2909, DOI 10.1063/1.1697233
   Grigoryants VM, 2000, BIOPHYS J, V78, P2702, DOI 10.1016/S0006-3495(00)76814-7                                                   
   Grigoryants VM, 2004, J PHYS CHEM B, V108, P9463, DOI 10.1021/jp030925b
   Hargittai MRS, 2004, J MOL BIOL, V337, P951, DOI 10.1016/j.jmb.2004.01.054
   Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200
   Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956                                                                   
   Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8
   Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i
   Kankia BI, 2005, NUCLEIC ACIDS RES, V33, P4395, DOI 10.1093/nar/gki741
   Karim CB, 2004, P NATL ACAD SCI USA, V101, P14437, DOI 10.1073/pnas.0402801101
   Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   Lee BM, 1998, J MOL BIOL, V279, P633, DOI 10.1006/jmbi.1998.1766
   Lockwood NA, 2003, BIOPOLYMERS, V69, P283, DOI 10.1002/bip.10365
   MARCHETTO R, 1993, J AM CHEM SOC, V115, P11042, DOI 10.1021/ja00076a093
   Margittai M, 2006, METHOD ENZYMOL, V413, P122, DOI 10.1016/S0076-6879(06)13007-4
   Marsh D., 1989, BIOL MAGN RESON, V8, P255
   Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k
   MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016                                                             
   Nesmelov YE, 2007, BIOPHYS J, V93, P2805, DOI 10.1529/biophysj.107.108910
   Qin PZ, 2003, BIOCHEMISTRY-US, V42, P6772, DOI 10.1021/bi027222p
   Qin PZ, 2001, BIOCHEMISTRY-US, V40, P6929, DOI 10.1021/bi010294g
   Qu KB, 1997, BIOCHEMISTRY-US, V36, P2884, DOI 10.1021/bi962155i
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Schreier S, 2004, BIOPOLYMERS, V74, P389, DOI 10.1002/bip.20092
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3<301::AID-BIP5>3.3.CO;2-#
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011                                                          
   Tisne C, 2001, J MOL BIOL, V306, P443, DOI 10.1006/jmbi.2000.4391
   Tompa P, 2004, FASEB J, V18, P1169, DOI 10.1096/fj.04-1584rev
   Toniolo C, 1995, J Pept Sci, V1, P45, DOI 10.1002/psc.310010107
   TSUCHIHASHI Z, 1994, J VIROL, V68, P5863
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999
   Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198
   XI X, 2008, BIOCHEMISTR IN PRESS
   Yao SG, 2000, J BIOMOL NMR, V16, P109, DOI 10.1023/A:1008382624724                                                         
   YOU JC, 1994, J BIOL CHEM, V269, P31491
NR 62
TC 10
Z9 10
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PD DEC
PY 2008
VL 89
IS 12
BP 1125
EP 1135
DI 10.1002/bip.21064
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 365JZ
UT WOS:000260403600008
PM 18690667
OA green_accepted
DA 2018-01-05
ER

PT J
AU He, JH
AF He, Ji-Huan
TI Fatalness of virus depends upon its cell fractal geometry
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
ID ALLOMETRIC SCALING LAWS; E-INFINITY THEORY; ELECTROSPUN NANOFIBERS;
   BODY-SIZE; BIOLOGY; FIBERS; BRAIN; MODEL
AB Why do more complex viruses (e.g., HIV, AIDS-virus and SARS coronavirus) tend to be more fatal? The paper concludes that the cell fractal geometry of viruses is the key. This paper also suggests two possible new approaches using nanotechnology and temperature to cure or prevent virus infection. (c) 2008 Elsevier Ltd. All rights reserved.
C1 Donghua Univ, Modern Text Inst, Shanghai 200051, Peoples R China.
RP He, JH (reprint author), Donghua Univ, Modern Text Inst, 1882 Yanan Xilu Rd, Shanghai 200051, Peoples R China.
EM jhhe@dhu.edu.cn
RI He, Ji-Huan /K-8504-2013
FU National Natural Science Foundation of China [10772054];  [NCET-05-0417]
FX The project is supported by National Natural Science Foundation of China
   under Grand No. 10772054 and the Program for New Century Excellent
   Talents in University under Grand No. NCET-05-0417.
CR Al-Suwaiyel MI, 2006, INT J NONLINEAR SCI, V7, P133
   Banavar JR, 2002, P NATL ACAD SCI USA, V99, P10506, DOI 10.1073/pnas.162216899
   El Naschie MS, 2007, INT J NONLINEAR SCI, V8, P11
   El Naschie MS, 2006, INT J NONLINEAR SCI, V7, P129
   Fan J, 2008, INT J NONLIN SCI NUM, V9, P293
   He JH, 2006, CHAOS SOLITON FRACT, V28, P1026, DOI 10.1016/j.chaos.2005.08.143
   He JH, 2006, CHAOS SOLITON FRACT, V27, P864, DOI 10.1016/j.chaos.2005.04.081
   He JH, 2004, CELL BIOL INT, V28, P809, DOI 10.1016/j.cellbi.2004.07.011
   He JH, 2006, CHAOS SOLITON FRACT, V27, P1108, DOI 10.1016/j.chaos.2005.04.082
   He JH, 2006, CHAOS SOLITON FRACT, V28, P285, DOI 10.1016/j.chaos.2005.08.001
   He JH, 2007, ACTA TROP, V104, P140, DOI 10.1016/j.actatropica.2007.07.012
   He JH, 2007, POLYM INT, V56, P1323, DOI 10.1002/pi.2370
   He JH, 2007, POLYM INT, V56, P1321, DOI 10.1002/pi.2388
   He JH, 2007, CHAOS SOLITON FRACT, V34, P727, DOI 10.1016/j.chaos.2006.04.052
   He JH, 2007, CHAOS SOLITON FRACT, V33, P26, DOI 10.1016/j.chaos.2006.09.023
   He JH, 2007, CHAOS SOLITON FRACT, V32, P1096, DOI 10.1016/j.chaos.2006.07.045
   Kuikka JT, 2006, INT J NONLIN SCI NUM, V7, P239
   Liu Y, 2007, INT J NONLINEAR SCI, V8, P393
   Wang ZM, 2001, J NUTR, V131, P2967
   West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122                                                    
   Xu L, 2007, INT J NONLINEAR SCI, V8, P199
NR 21
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD DEC
PY 2008
VL 38
IS 5
BP 1390
EP 1393
DI 10.1016/j.chaos.2008.04.018
PG 4
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA 357NB
UT WOS:000259851400024
DA 2018-01-05
ER

PT J
AU Laufer, SD
   Restle, T
AF Laufer, S. D.
   Restle, T.
TI Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics
   In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to
   Handle Reporter Systems
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell-Penetrating Peptides (CPPs); nucleic acid delivery; endocytosis;
   fluorescence microscopy; RNAi; siRNA; steric block; splice correction
ID DUCHENNE MUSCULAR-DYSTROPHY; SMALL INTERFERING RNA; TOF
   MASS-SPECTROMETRY; SHORT HAIRPIN RNAS; HIV-1 TAT PROTEIN; EFFICIENT
   SPLICING CORRECTION; HUMAN IMMUNODEFICIENCY VIRUS; ARGININE-RICH
   PEPTIDES; PENETRATING PEPTIDES; NUCLEIC-ACIDS
AB Cellular uptake of therapeutic oligonucleotides and subsequent intracellular trafficking to their target sites represents the major technical hurdle for the biological effectiveness of these potential drugs. Accordingly, laboratories worldwide focus on the development of suitable delivery systems. Among the different available non-viral systems like cationic polymers, cationic liposomes and polymeric nanoparticles, cell-penetrating peptides (CPPs) represent an attractive concept to bypass the problem of poor membrane permeability of these charged macromolecules. While uptake per se in most cases does not represent the main obstacle of nucleic acid delivery in vitro, it becomes increasingly apparent that intracellular trafficking is the bottleneck. As a consequence, in order to optimize a given delivery system, a side-by-side analysis of nucleic acid cargo internalized and the corresponding biological effect is required to determine the overall efficacy. In this review, we will concentrate on peptide-mediated delivery of siRNAs and steric block oligonucleotides and discuss different methods for quantitative assessment of the amount of cargo taken up and how to correlate those numbers with biological effects by applying easy to handle reporter systems. To illustrate current limitations of non-viral nucleic acid delivery systems, we present own data as an example and discuss options of how to enhance trafficking of molecules entrapped in cellular compartments.
C1 [Laufer, S. D.; Restle, T.] Med Univ Lubeck, Inst Mol Med, D-23538 Lubeck, Germany.
RP Restle, T (reprint author), Med Univ Lubeck, Inst Mol Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM restle@imm.uni-luebeck.de
FU EC [QLK2-2001-01451, LSHG-CT-2003-503480]
FX We apologize to those authors whose work was not cited directly owing to
   space limitations. We thank Alexander Trampe for microscopic images,
   Anna Lena Recke, Sandra Veldhoen, Georg Sczakiel and members of his
   group for fruitful discussions, Silke Degen for critically reading the
   manuscript and our co-workers in the EC project 'Peptides in Drug
   Delivery', Annette G. Beck-Sickinger, Ernest Giralt, Frederic Heitz,
   Christian LeGrimellec and Hans-Peter Merkle for constructive
   collaborations. T. R. acknowledges funding by EC-grants QLK2-2001-01451
   and LSHG-CT-2003-503480.
CR Aartsma-Rus A, 2007, RNA, V13, P1609, DOI 10.1261/rna.653607
   Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026
   Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   AIGNER A, CURR PHARM IN PRESS
   Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Aussedat B, 2006, BBA-BIOMEMBRANES, V1758, P375, DOI 10.1016/j.bbamem.2006.01.012
   Bayele HK, 2006, J PHARM SCI-US, V95, P1227, DOI 10.1002/jps.20606
   Benchaouir R, 2007, CELL STEM CELL, V1, P646, DOI 10.1016/j.stem.2007.09.016
   Berg K, 2007, CURR PHARM BIOTECHNO, V8, P362, DOI 10.2174/138920107783018354
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110                                                                
   Bertoni C, 2008, FRONT BIOSCI-LANDMRK, V13, P517, DOI 10.2741/2697
   Boe S, 2007, OLIGONUCLEOTIDES, V17, P166, DOI 10.1089/oli.2007.0076
   Bonsted Anette, 2008, V434, P171, DOI 10.1007/978-1-60327-248-3_11
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3                                                   
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Burlina F, 2005, ANGEW CHEM INT EDIT, V44, P4244, DOI 10.1002/anie.200500477
   Burlina F, 2006, NAT PROTOC, V1, P200, DOI 10.1038/nprot.2006.30
   Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9                                                   
   Chan JHP, 2006, CLIN EXP PHARMACOL P, V33, P533, DOI 10.1111/j.1440-1681.2006.04403.x
   Check E, 2005, NATURE, V433, P561, DOI 10.1038/433561a
   Chen QR, 2001, NUCLEIC ACIDS RES, V29, P1334, DOI 10.1093/nar/29.6.1334
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   CROMBEZ L, CURR PHARM IN PRESS
   Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2006, BBA-BIOMEMBRANES, V1758, P328, DOI 10.1016/j.bbamem.2005.10.004
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   DETZER A, CURR PHARM IN PRESS
   Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x
   Eckstein F, 2007, EXPERT OPIN BIOL TH, V7, P1021, DOI 10.1517/14712598.7.7.1021                                                       
   EDENHOFER F, CURR PHARM IN PRESS
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301                                                              
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   ENDOH T, 2007, NUCL ACIDS S SER OXF, V127
   Endoh T, 2008, BIOCONJUGATE CHEM, V19, P1017, DOI 10.1021/bc800020n
   Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X
   Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105
   Folini M, 2007, CELL PROLIFERAT, V40, P905, DOI 10.1111/j.1365-2184.2007.00470.x
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2005, J GENE MED, V7, P1450, DOI 10.1002/jgm.796
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964
   Goyenvalle A, 2004, SCIENCE, V306, P1796, DOI 10.1126/science.1104297
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Hama S, 2006, MOL THER, V13, P786, DOI 10.1016/j.ymthe.2005.10.007
   Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023                                                         
   Haque ME, 2005, BIOPHYS J, V89, P3183, DOI 10.1529/biophysj.105.063032
   HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4
   Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   JEARAWIRIYAPAIS.N, 2008, MOL THER
   Jiang M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni144
   Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kameyama S, 2007, BIOPOLYMERS, V88, P98, DOI 10.1002/bip.20689
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kootstra NA, 2003, ANNU REV PHARMACOL, V43, P413, DOI 10.1146/annurev.pharmtox.43.100901.140257
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h
   Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591
   Langel U, 2006, HDB CELL PENETRATING
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Leng QX, 2005, J GENE MED, V7, P977, DOI 10.1002/jgm.748
   Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004
   Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lopez-Bigas N, 2005, FEBS LETT, V579, P1900, DOI 10.1016/j.febslet.2005.02.047
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Manickam DS, 2006, BIOCONJUGATE CHEM, V17, P1395, DOI 10.1021/bc060104k
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645
   MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676
   McClorey G, 2006, GENE THER, V13, P1373, DOI 10.1038/sj.gt.3302800
   MEADE BR, 2007, ADV DRUG DELIV REV
   Mescalchin A, 2007, EXPERT OPIN BIOL TH, V7, P1531, DOI 10.1517/14712598.7.10.1531                                                      
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moschos SA, 2007, BIOCHEM SOC T, V35, P807, DOI 10.1042/BST0350807                                                              
   MOSCHOS SA, CURR PHARM IN PRESS
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moulton HM, 2007, BIOCHEM SOC T, V35, P826, DOI 10.1042/BST0350826                                                              
   Moulton HM, 2004, BIOCONJUGATE CHEM, V15, P290, DOI 10.1021/bc034221g
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Mustard D, 2005, PROTEINS, V60, P269, DOI 10.1002/prot.20569
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nielsen PE, 2004, MOL BIOTECHNOL, V26, P233, DOI 10.1385/MB:26:3:233
   Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   OLIVEIRA S, CURR PHARM IN PRESS
   Oliveira S, 2007, INT J PHARM, V331, P211, DOI 10.1016/j.ijpharm.2006.11.050
   Oliveira S, 2007, BBA-BIOMEMBRANES, V1768, P1211, DOI 10.1016/j.bbamem.2007.01.013
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Orengo JP, 2007, ADV EXP MED BIOL, V623, P212, DOI 10.1007/978-0-387-77374-2_13
   Overhoff M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh168
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002                                                              
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pichon C, 1999, ANTISENSE NUCLEIC A, V9, P89, DOI 10.1089/oli.1.1999.9.89
   Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2                                                   
   Pooga M, 1998, FASEB J, V12, P67
   Preuss M, 2003, ORG BIOMOL CHEM, V1, P2430, DOI 10.1039/b302361c
   Rahbek UL, 2008, J GENE MED, V10, P81, DOI 10.1002/jgm.1120
   Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085
   Raper SE, 2002, HUM GENE THER, V13, P163, DOI 10.1089/10430340152712719
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Rasmussen FW, 2006, OLIGONUCLEOTIDES, V16, P43, DOI 10.1089/oli.2006.16.43
   Read ML, 2003, J GENE MED, V5, P232, DOI 10.1002/jgm.331
   Read ML, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni085
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Ritter W, 2003, J MOL MED-JMM, V81, P708, DOI 10.1007/s00109-003-0483-2
   Roberts J, 2006, MOL THER, V14, P471, DOI 10.1016/j.ymthe.2006.05.017
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Sakai N, 2005, CHEMBIOCHEM, V6, P114, DOI 10.1002/cbic.200400256
   Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9
   Shiraishi T, 2006, BIOCONJUGATE CHEM, V17, P189, DOI 10.1021/bc050246z
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Shiraishi T, 2006, NAT PROTOC, V1, P633, DOI 10.1038/nprot.2006.92
   Silva JN, 2006, BIO-MED MATER ENG, V16, pS147
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snove O, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-231
   Snove O, 2006, NAT METHODS, V3, P689, DOI 10.1038/NMETH927
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Soughayer JS, 2004, BIOCHEMISTRY-US, V43, P8528, DOI 10.1021/bi036296d
   STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285
   Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Thierry AR, 2006, BBA-BIOMEMBRANES, V1758, P364, DOI 10.1016/j.bbamem.2005.10.010
   Tonges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tu Y, 2008, J GENE MED, V10, P646, DOI 10.1002/jgm.1184
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P6837, DOI 10.1093/nar/gki991
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vacek M, 2003, CELL MOL LIFE SCI, V60, P825, DOI 10.1007/s00018-003-3042-7
   van Ommen GJ, 2008, CURR OPIN MOL THER, V10, P140
   Varga CM, 2005, GENE THER, V12, P1023, DOI 10.1038/sj.gt.3302495
   Varga CM, 2001, MOL THER, V4, P438, DOI 10.1006/mthe.2001.0475
   Veldhoen S, 2008, INT J MOL SCI, V9, P1276, DOI 10.3390/ijms9071276
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164
   Wilton SD, 2006, CURR OPIN MOL THER, V8, P130
   Wolf Y, 2006, BIOCHEMISTRY-US, V45, P14944, DOI 10.1021/bi0606896
   Yin HF, 2008, MOL THER, V16, P38, DOI 10.1038/sj.mt.6300329
   Yokota T, 2007, EXPERT OPIN BIOL TH, V7, P831, DOI 10.1517/14712598.7.6.831
   Youngblood DS, 2007, BIOCONJUGATE CHEM, V18, P50, DOI 10.1021/bc060138s
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
   ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
   Zhou JY, 2007, PHARM RES, V24, P1079, DOI 10.1007/s11095-006-9229-5
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 205
TC 33
Z9 33
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD DEC
PY 2008
VL 14
IS 34
BP 3637
EP 3655
DI 10.2174/138161208786898806                                              
          
PG 19
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 386XU
UT WOS:000261916700005
PM 19075740
OA green_published
DA 2018-01-05
ER

PT J
AU Crombez, L
   Morris, MC
   Deshayes, S
   Heitz, F
   Divita, G
AF Crombez, Laurence
   Morris, May Catherine
   Deshayes, Sebastien
   Heitz, Frederic
   Divita, Gilles
TI Peptide-Based Nanoparticle for Ex Vivo and In Vivo Dug Delivery
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell-penetrating peptide; non-covalent delivery system; nanoparticle;
   drug carrier; siRNA; cellular targeting
ID CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; SMALL INTERFERING
   RNA; HIV-1 TAT PROTEIN; EFFICIENT GENE-TRANSFER; MAMMALIAN-CELLS;
   NUCLEIC-ACIDS; INTRACELLULAR DELIVERY; ENHANCED DELIVERY; FUSION
   PROTEINS
AB One of the major challenges for new therapeutics molecules to enter the clinic remains improving their bioavailability and cellular uptake. Therefore, delivery has become a key stone in therapeutic development and several technologies have been designed to improve cellular uptake of therapeutic molecules, including cell-penetrating peptides (CPPs) or protein transduction domain (PTD). PTDs or CPPs were discovered twenty years ago, based on the potency of several proteins to enter cells and nowadays, numerous peptide carriers have been described and successfully applied for ex vivo and in vivo delivery of varying therapeutic molecules. Two CPP-strategies have been reported; the first one requires chemical linkage between the drug and the carrier for cellular drug internalization and the second is based on the formation of stable complexes with drugs depending on their chemical nature. Peptide-Based-Nanoparticle Devices (PBND), correspond to short amphipathic peptides able to form stable nanoparticles with proteins and/or nucleic acids. Three PBND-families, PEP, MPG and CADY have been described, these carriers mainly enter cells independently of the endosomal pathway and efficiently deliver cargoes in a large variety of challenging cell lines as well as in animal models. This review will focus on the structure/function relationship of the PBND: CADY, PEP and MPG, in the general context of drug delivery. It will also highlight the requirement of primary or secondary amphipathic carriers for in vitro and in vivo delivery of therapeutic molecules and provide an update of their pre-clinical evaluation.
C1 [Crombez, Laurence; Morris, May Catherine; Deshayes, Sebastien; Heitz, Frederic; Divita, Gilles] CRBM, Ctr Rech Biochim Macromol, UMR 5237,CNRS,UM 1,UM 2, Dept Mol Biophys & Therapeut, F-34293 Montpellier, France.
RP Divita, G (reprint author), CRBM, Ctr Rech Biochim Macromol, UMR 5237,CNRS,UM 1,UM 2, Dept Mol Biophys & Therapeut, 1919 Route Mcndc, F-34293 Montpellier, France.
EM gilles.divita@crbm.cnrs.fr
RI MORRIS, May/J-5940-2016
OI MORRIS, May/0000-0001-8106-9728
FU Centre National de la Recherche Scientifique (CNRS), Active Motif
   (Carlsbad, CA); Panomics Inc. (Fremont, CA); Agence Nationale de
   Recherche (ANR) [ANR-06-BLAN-0071]; EU [QLK2-CT-2001-01451,
   LSHB-CT-2003-503480/TRIoH]
FX This work was supported in part by the Centre National de la Recherche
   Scientifique (CNRS), Active Motif (Carlsbad, CA), Panomics Inc.
   (Fremont, CA) and by grants from the Agence Nationale de Recherche (ANR:
   Grant ANR-06-BLAN-0071) and the EU (Grant QLK2-CT-2001-01451 & Grant
   LSHB-CT-2003-503480/TRIoH). We thank members of the laboratory and our
   collaborators for fruitful discussions.
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002.0090OC
   Asai A, 2003, CANCER RES, V63, P3931
   BADAGGORCE F, 2003, EXP MOL PATHOL, V74, P160
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Chan SA, 2005, J NEUROPHYSIOL, V94, P1037, DOI 10.1152/jn.01213.2004
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   CROMBEZ L, COMMUNICATION
   CROMBEZ L, 2008, MOL THER IN PRESS
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Efimov V, 2001, NUCLEOS NUCLEOT NUCL, V20, P419, DOI 10.1081/NCN-100002316
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   ESBJORNER EK, 2007, HDB CELL PENETRATING, P109
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P1656, DOI 10.1016/j.freeradbiomed.2004.07.028
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gait MJ, 2003, CELL MOL LIFE SCI, V60, P844, DOI 10.1007/s00018-003-3044-5
   Gallo G, 2003, METHOD CELL BIOL, V71, P325, DOI 10.1016/S0091-679X(03)01015-X
   Gallo G, 2002, J CELL BIOL, V158, P1219, DOI 10.1083/jcb.200204140
   Garnon J, 2005, J BIOL CHEM, V280, P5750, DOI 10.1074/jbc.M401988200
   Gehler S, 2004, J NEUROSCI, V24, P10741, DOI 10.1523/JNEUROSCI.2836-04.2004
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577
   Gottschalk S, 1996, GENE THER, V3, P448
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gryaznov S, 2003, NUCLEOS NUCLEOT NUCL, V22, P577, DOI 10.1081/NCN-120021958
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Jevsek M, 2006, P NATL ACAD SCI USA, V103, P6374, DOI 10.1073/pnas.0601468103
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   KONATE K, COMMUNICATION
   Kong HJ, 2007, NAT REV DRUG DISCOV, V6, P455, DOI 10.1038/nrd2309
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Kowolik CM, 2003, MOL THER, V8, P324, DOI 10.1016/S1525-0016(03)00166-7
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   MacKay JA, 2008, MOL THER, V16, P893, DOI 10.1038/mt.2008.36
   Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583503004014
   Maron MB, 2005, AM J PHYSIOL-LUNG C, V289, pL349, DOI 10.1152/ajplung.00134.2004
   Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231
   Mattheakis LC, 2004, ANAL BIOCHEM, V327, P200, DOI 10.1016/j.ab.2004.01.031
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Morris MC, 2004, GENE THER, V11, P757, DOI 10.1038/sj.gt.3302235
   MOSCHOS S, 2007, HDB CELL PENETRATING, P423
   Munoz-Morris MA, 2007, BIOCHEM BIOPH RES CO, V355, P877, DOI 10.1016/j.bbrc.2007.02.046
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nan L, 2005, EXP MOL PATHOL, V78, P1, DOI 10.1016/j.yexmp.2004.08.006
   Nguyen QN, 2006, BBA-BIOMEMBRANES, V1758, P394, DOI 10.1016/j.bbamem.2006.01.003
   Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8713, DOI 10.1021/bi00489a030
   Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097
   Payne C, 2003, J CELL SCI, V116, P4727, DOI 10.1242/jcs.00784
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Rawe VY, 2004, DEV BIOL, V276, P253, DOI 10.1016/j.ydbio.2004.07.043
   Rennert R, 2008, ADV DRUG DELIVER REV, V60, P485, DOI 10.1016/j.addr.2007.09.008
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Szoka F, 2008, SCIENCE, V319, P578, DOI 10.1126/science.1154253
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   VIVES E, 2008, BIOCH BIOPHYS ACTA
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
NR 110
TC 64
Z9 69
U1 2
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD DEC
PY 2008
VL 14
IS 34
BP 3656
EP 3665
DI 10.2174/138161208786898842
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 386XU
UT WOS:000261916700006
PM 19075741
DA 2018-01-05
ER

PT J
AU Coutant, J
   Yu, HF
   Clement, MJ
   Alfsen, A
   Toma, F
   Curmi, PA
   Bomsel, M
AF Coutant, Jerome
   Yu, Huifeng
   Clement, Marie-Jeanne
   Alfsen, Annette
   Toma, Flavio
   Curmi, Patrick A.
   Bomsel, Morgane
TI Both lipid environment and pH are critical for determining physiological
   solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER
   peptide P1
SO FASEB JOURNAL
LA English
DT Article
DE 2F5 IgG; 4E10 IgG; glycosphingolipid; mucosa; HIV envelope glycoprotein;
   NMR
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTI-GP41 2F5; PROXIMAL
   EXTERNAL REGION; MEMBRANE-FUSION; DENDRITIC CELLS; BIOLOGICAL
   MACROMOLECULES; MONOCLONAL-ANTIBODIES; GALACTOSYL CERAMIDE; VACCINE
   CANDIDATE; GLYCOPROTEIN GP41
AB In terms of background, the solution structure of monomeric peptide P1 (residues 649-683), located in the conserved membrane proximal region (MPER) of HIV-1 envelope glycoprotein gp41, is first reported here in dodecylphosphocholine (DPC) micelles. P1 is the minimal MPER region that permits interaction with the mucosal galactosyl ceramide HIV-receptor; it also contains epitopes recognized by major gp41-specific, broadly neutralizing immunoglobulin Gs (IgGs), 2F5 and 4E10, determinant in HIV fusion/infection. Our principal findings were as follows: the structural stability of P1 is pH dependent, as the alpha-helix comprising Q653 I682, present at pH 3.3, is destabilized at higher pH values. At pH 6, the E-rich N-terminal half of P1 (residues 650 666), partially overlapping the 2F5-specific epitope, becomes fully disordered, while the W-rich C-terminal half conserves two shorter helices (W666-W670 and W672 W680), separated by a well-defined bend overlapped by the 4E10-specific epitope. The two IgGs bind to P1 on DPC micelles with binding parameters (K(d)) in the nanomolar range. Next, P1 was derivatized with phosphatidylethanolamine at its C terminal and inserted into liposomes of varied lipid composition, thereby enabling P1 to move laterally. Alternatively, an infectious virus-binding assay was established. The Kd of both 2F5 and 4E10 IgGs measured on viral liposome and virus are similar and much lower than for the binding of the free peptide. In conclusion, P1, in a lipid environment, is an optimized MPER-derived peptide suitable for designing an immunogen inducing broadly neutralizing antibodies to HIV. Coutant, J., Yu, H., Clement, M.- J., Alfsen, A., Toma, F., Curmi, P. A., Bomsel, M. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 22, 4338-4351 (2008)
C1 [Yu, Huifeng; Alfsen, Annette; Bomsel, Morgane] Univ Paris 05, CNRS,UMR 8104, Dept Biol Cellulaire,Inst Cochin, Entre Muqueuse VIH & Immun Muqueuse, F-75014 Paris, France.
   [Coutant, Jerome; Clement, Marie-Jeanne; Toma, Flavio; Curmi, Patrick A.] Univ Evry, INSERM, U829, UEVE, Evry, France.
   [Yu, Huifeng; Alfsen, Annette; Bomsel, Morgane] INSERM, U567, Paris, France.
RP Bomsel, M (reprint author), Univ Paris 05, CNRS,UMR 8104, Dept Biol Cellulaire,Inst Cochin, Entre Muqueuse VIH & Immun Muqueuse, 22 Rue Mechain, F-75014 Paris, France.
EM flavio.toma@univ-evry.fr; pcurmi@univ-evry.fr; morgane.bomsel@inserm.fr
RI CURMI, Patrick/G-4036-2013
OI Bomsel, Morgane/0000-0002-9577-7474
FU ANRS; Sidaction-Ensemble contre le SIDA
FX We thank B. Weksler for English editing. H.Y. benefited from financial
   support by Sidaction and Agence Nationale de Recherche sur le SIDA
   (ANRS), M. B. and P. C. were supported by grants from ANRS, and M. B.
   was supported by a grant from Sidaction-Ensemble contre le SIDA. We are
   grateful to S. Fleury (Mymetics, Nyon, Switzerland) for providing P1-PE.
   We gratefully thank the Conseil Regional d'Ile de France, the Conseil
   General de l'Essonne, the Genopole, the Commissariat a l'Ennergie
   Atomique, and the Association Francaise contre les Myopathies for the
   NMR equipment of INSERM/UEVE U829.
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   Baba TW, 2000, NAT MED, V6, P200
   Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9
   Berjanskii MV, 2006, NUCLEIC ACIDS RES, V34, pW63, DOI 10.1093/nar/gkl341
   Beswick V, 1996, BIOCHEMISTRY-US, V35, P14717, DOI 10.1021/bi961710d                                                               
   Biron Z, 2005, BIOCHEMISTRY-US, V44, P13602, DOI 10.1021/bi0509254
   Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   BOMSEL M, 2006, PCT IB 2006 000466 I
   BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3                                                    
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Cardoso RMF, 2007, J MOL BIOL, V365, P1533, DOI 10.1016/j.jmb.2006.10.088
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Fantini J, 2000, GLYCOCONJUGATE J, V17, P173, DOI 10.1023/A:1026580905156
   GODDARD TD, 1982, SPARKY 3
   Killian JA, 2006, CURR OPIN STRUC BIOL, V16, P473, DOI 10.1016/j.sbi.2006.06.007
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X                                                    
   KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6                                                    
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Le Lan C, 2006, FEBS LETT, V580, P5301, DOI 10.1016/j.febslet.2006.08.075
   Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200
   Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matoba N, 2006, VACCINE, V24, P5047, DOI 10.1016/j.vaccine.2006.03.045
   Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101
   Maurin T, 2007, J MOL BIOL, V367, P702, DOI 10.1016/j.jmb.2007.01.031
   McLaughlin S, 2005, J GEN PHYSIOL, V126, P41, DOI 10.1085/jgp.200509274
   Munoz-Barroso I, 1999, J VIROL, V73, P6089
   Nyholm TKM, 2007, BIOCHEMISTRY-US, V46, P1457, DOI 10.1021/bi061941c
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7                                                   
   Sabado RL, 2007, EUR J IMMUNOL, V37, P1752, DOI 10.1002/eji.200636981
   Salzwedel K, 1999, J VIROL, V73, P2469
   Sanchez-Martinez S, 2006, FEBS LETT, V580, P2395, DOI 10.1016/j.febslet.2006.03.067
   Sanchez-Martinez S, 2006, AIDS RES HUM RETROV, V22, P998, DOI 10.1089/aid.2006.22.998
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3
   STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3
   Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027                                                          
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6
   TAMM LK, 2007, BIOCHIM BIOPHYS ACTA, V12, P3052
   Vidricaire G, 2007, J MOL BIOL, V368, P1267, DOI 10.1016/j.jmb.2007.03.003
   Wang JH, 2007, J VIROL, V81, P8933, DOI 10.1128/JVI.00878-07
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706                                                         
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   YU H, 2008, CELL CALCIUM, V48, P73
   Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 63
TC 24
Z9 24
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD DEC
PY 2008
VL 22
IS 12
BP 4338
EP 4351
DI 10.1096/fj.08-113142
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 377MH
UT WOS:000261254800032
PM 18776068
DA 2018-01-05
ER

PT J
AU Weber, N
   Ortega, P
   Clemente, MI
   Shcharbin, D
   Bryszewska, M
   de la Mata, FJ
   Gomez, R
   Munoz-Fernandez, MA
AF Weber, Nick
   Ortega, Paula
   Clemente, Maria Isabel
   Shcharbin, Dzmitry
   Bryszewska, Maria
   de la Mata, F. Javier
   Gomez, Rafael
   Munoz-Fernandez, M. Angeles
TI Characterization of carbosilane dendrimers as effective carriers of
   siRNA to HIV-infected lymphocytes
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Dendrimer; siRNA; HIV; Nanoparticle; Transfection
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL INTERFERING RNA; GENE DELIVERY;
   IN-VITRO; PRIMARY MACROPHAGES; T-CELLS; INHIBITION; THERAPY;
   BIOCOMPATIBILITY; OLIGONUCLEOTIDES
AB One of the primary limitations of RNA interference as a technique for gene regulation is effective delivery of siRNA into the target cells. Dendrimers are nanoparticles that are increasingly being used as oligonucleotide and drug delivery vehicles. We have developed amino-terminated carbosilane dendrimers (CBS) as a means to protect and transport siRNA. Initially, stability studies showed that CBS bind siRNA via electrostatic interactions. Dendrimer-bound siRNA was found to be resistant to degradation by RNase. Cytotoxicity assays of CBS/siRNA dendriplexes with peripheral blood mononuclear cells (PBMC) and the lymphocytic cell line SupT1 revealed a maximum safe dendrimer concentration of 25 mu g/ml. Next, utilizing flow cytometry and confocal microscopy, lymphocytes were seen to be successfully transfected by fluorochrome-labeled siRNA either naked or complexed with CBS. Dendriplexes with +/- charge ratio of 2 were determined to have the highest transfection efficiency while maintaining a low level of toxicity in these systems including hard-to-transfect HIV-infected PBMC, Finally, CBS/siRNA dendriplexes were shown to silence GAPDH expression and reduce HIV replication in SupT1 and PBMC. These results point to the possibility of utilizing dendrimers such as CBS to deliver and transfect siRNA into lymphocytes thus allowing the use of RNA interference as a potential alternative therapy for HIV infection. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Weber, Nick; Clemente, Maria Isabel; Munoz-Fernandez, M. Angeles] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Ortega, Paula; de la Mata, F. Javier; Gomez, Rafael] Univ Alcala de Henares, Dept Quim Inorgan, Madrid, Spain.
   [Shcharbin, Dzmitry; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, PL-90131 Lodz, Poland.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@salud.madrid.org
RI Shcharbin, Dzmitry/G-2046-2011; ortega lopez, paula/K-3910-2014; De la
   Mata, F. Javier/K-1649-2014; Gomez Ramirez, Rafael/K-1216-2014
OI Shcharbin, Dzmitry/0000-0002-1414-4465; ortega lopez,
   paula/0000-0003-0377-5429; De la Mata, F. Javier/0000-0003-0418-3935;
   Gomez Ramirez, Rafael/0000-0001-6448-2414;
   Munoz-Fernandez/0000-0002-0813-4500; Bryszewska,
   Maria/0000-0003-4676-3743
FU Fondos de Investigacion Sanitaria (FIS) del Ministerio de Sanidad y
   Consumo [PI052476, PI061479]; Red RIS [RD06-0006-0035]; FIPSE [36514/05,
   24534/05, 24632/07]; ERA-NET [NAN2007-31198-E]; Fundacion Caja Navarra
   and Comunidad de Madrid [S-SAL-0159-2006]
FX Potential conflicts of interest: The authors do not have commercial or
   other associations that might pose a conflict of interest. Sources of
   financial support: This work has been supported by grants from Fondos de
   Investigacion Sanitaria (FIS) del Ministerio de Sanidad y Consumo
   (PI052476, PI061479); Red RIS RD06-0006-0035; FIPSE (36514/05, 24534/05,
   24632/07), ERA-NET NAN2007-31198-E; Fundacion Caja Navarra and Comunidad
   de Madrid (S-SAL-0159-2006).; We would like to thank Rafael Samaniego
   for assistance with confocal microscopy imaging.
CR Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Bermejo J. F., 2006, EUR J SCI RES, V15, P113
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196                                                     
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Coburn GA, 2003, J ANTIMICROB CHEMOTH, V51, P753, DOI 10.1093/jac/dkg166
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   De Clercq E, 2007, Verh K Acad Geneeskd Belg, V69, P65
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Finzi D, 1999, NAT MED, V5, P512
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Germershaus O, 2008, J CONTROL RELEASE, V125, P145, DOI 10.1016/j.jconrel.2007.10.013
   Han WL, 2004, VIROLOGY, V330, P221, DOI 10.1016/j.virol.2004.09.027
   Hirko A, 2003, CURR MED CHEM, V10, P1185, DOI 10.2174/0929867033457412                                                        
   Imai E, 2001, NEPHROL DIAL TRANSPL, V16, P26, DOI 10.1093/ndt/16.suppl_5.26                                                       
   Kolber MA, 2007, AIDS REV, V9, P68
   Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003
   Liu YP, 2008, NUCLEIC ACIDS RES, V36, P2811, DOI 10.1093/nar/gkn109
   Ma BC, 2007, J CONTROL RELEASE, V123, P184, DOI 10.1016/j.jconrel.2007.08.022
   Mahato RI, 2005, ADV DRUG DELIVER REV, V57, P699, DOI 10.1016/j.addr.2004.12.005
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   Niculescu-Duvaz D, 2003, CURR MED CHEM, V10, P1233, DOI 10.2174/0929867033457476
   Nishitsuji H, 2006, J VIROL, V80, P7658, DOI 10.1128/JVI.00078-06
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Paleos CM, 2007, MOL PHARM, V4, P169, DOI 10.1021/mp060076n
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003
   Pomerantz RJ, 2002, NAT MED, V8, P659, DOI 10.1038/nm0702-659
   Samaniego R, 2007, J CELL SCI, V120, P3534, DOI 10.1242/jcs.006296
   Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001                                                              
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   Singh SK, 2008, EXPERT OPIN BIOL TH, V8, P449, DOI 10.1517/14712598.8.4.449 
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Turner JJ, 2006, BBA-BIOMEMBRANES, V1758, P290, DOI 10.1016/j.bbamem.2005.10.013
   Tziveleka LA, 2007, J CONTROL RELEASE, V117, P137, DOI 10.1016/j.jconrel.2006.10.019
   YANG YP, 1995, J VIROL, V69, P2004
   Yin JY, 2006, J IMMUNOL METHODS, V312, P1, DOI 10.1016/j.jim.2006.01.023
   Zuhorn IS, 2007, MOL THER, V15, P946, DOI 10.1038/mt.sj.6300139
NR 44
TC 119
Z9 121
U1 4
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 24
PY 2008
VL 132
IS 1
BP 55
EP 64
DI 10.1016/j.jconrel.2008.07.035
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 378WD
UT WOS:000261354400009
PM 18727943
DA 2018-01-05
ER

PT J
AU He, W
   Huang, CZ
   Li, YF
   Xie, JP
   Yang, RG
   Zhou, PF
   Wang, J
AF He, Wei
   Huang, Cheng Zhi
   Li, Yuan Fang
   Xie, Jian Ping
   Yang, Rong Ge
   Zhou, Pei Fu
   Wang, Jian
TI One-Step Label-Free Optical Genosensing System for Sequence-Specific DNA
   Related to the Human Immunodeficiency Virus Based on the Measurements of
   Light Scattering Signals of Gold Nanorods
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SINGLE-STRANDED-DNA; ENHANCED RAMAN-SCATTERING; COLORIMETRIC DETECTION;
   SILVER NANOPARTICLES; CATIONIC SURFACTANTS; METAL NANOPARTICLES;
   LATEX-PARTICLES; ABSORPTION; ADSORPTION; SHAPE
AB A one-step label-free optical genosensing method has been developed in this contribution by taking short DNA target with its sequence related to the human immunodeficiency virus type 1 (HIV-1) as an example. By employing anisotropic nonspherical and positively charged gold nanorods (Au-NRs) as the recognition platform, which show high stability against aggregation under high ionic strength conditions without any additional stable reagent, we found that the addition of target DNA to the mixture of nonmodified Au-NRs suspension and label-free probe DNA in high ionic strength buffer leads to a color change from red to fight purple in less than 5 min, displaying strong plasmon resonance light scattering (PRLS) signals. Mechanism investigations showed that the strong PRLS signals should be ascribed to the aggregation ofAu-NRs induced by the formed double-stranded oligonucleotides (dsDNA) from the hybridization of target DNA with probe DNA. With the PRLS signals, we monitored the hybridization process of a 2 1-mer single-stranded oligonucleotide (ssDNA) from the fHV-1 U5 long terminal repeat (LTR) sequence with its complementary oligonucleotide and detected the effect of single-base-pair mismatches. Two polymerase chain reaction (PCR) amplicon artificial samples derived from Mycobacterium tuberculosis glmS and genes encoding for Bacillus glucanase and an HIV-1 LTR sample isolated from HIV-1-positive blood were detected with satisfactory results, showing that the present method has simplicity, sensitivity, specificity, and reliability for sequence-specific DNA detection related to the HIV gene.
C1 [Huang, Cheng Zhi; Li, Yuan Fang] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400715, Peoples R China.
   [Xie, Jian Ping; Zhou, Pei Fu] Southwest Univ, Educ Minist, Key Lab Luminescence & Real Time Anal, Coll Life Sci,Inst Modern Biopharmaceut, Chongqing 400715, Peoples R China.
   [Yang, Rong Ge] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, AIDS & HIV Res Grp, Wuhan 430071, Peoples R China.
   [He, Wei; Wang, Jian] Southwest Univ, Coll Chem & Chem Engn, Chongqing 400715, Peoples R China.
RP Huang, CZ (reprint author), Southwest Univ, Coll Pharmaceut Sci, Chongqing 400715, Peoples R China.
EM chengzhi@swu.edu.cn
FU Ministry of Science and Technology of the People's Republic of China
   [2006CB 933100]; National Natural Science Foundation of China (NSFC)
   [20425517, 20675065]
FX This research was supported by the Ministry of Science and Technology of
   the People's Republic of China (2006CB 933100) and the National Natural
   Science Foundation of China (NSFC, No: 20425517, 20675065).
CR Aslan K, 2005, J AM CHEM SOC, V127, P12115, DOI 10.1021/ja052739k
   Brioude A, 2005, J PHYS CHEM B, V109, P13138, DOI 10.1021/jp0507288
   DU BA, 2006, ANGEW CHEM INT EDIT, V45, P1
   Dujardin E, 2001, CHEM COMMUN, P1264, DOI 10.1039/b102319p                                                                
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Ganachaud F, 1997, LANGMUIR, V13, P7021, DOI 10.1021/la9704819                                                               
   Ganachaud F, 1997, LANGMUIR, V13, P701, DOI 10.1021/la960896e                                                               
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jain PK, 2006, J PHYS CHEM B, V110, P18243, DOI 10.1021/jp063879z
   Jana NR, 2001, LANGMUIR, V17, P6782, DOI [10.1021/la0104323, 10.1021/1a0104323]
   Jiang XC, 2006, COLLOID SURFACE A, V277, P201, DOI 10.1016/j.colsurfa.2005.11.062
   Leal C, 2007, J PHYS CHEM B, V111, P5999, DOI 10.1021/jp065358h
   Li CZ, 2005, CHEM COMMUN, P3924, DOI 10.1039/b504186d
   Li HX, 2005, ANAL CHEM, V77, P6229, DOI 10.1021/ac050921y
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li HX, 2004, J AM CHEM SOC, V126, P10958, DOI 10.1021/ja048749n
   Liang Y, 2007, TALANTA, V72, P443, DOI 10.1016/j.talanta.2006.11.002
   Link S, 1999, J PHYS CHEM B, V103, P3073, DOI 10.1021/jp990183f
   LIVACHE T, 1994, ANAL BIOCHEM, V217, P248, DOI 10.1006/abio.1994.1116                                                          
   Liz-Marzan LM, 2006, LANGMUIR, V22, P32, DOI 10.1021/la0513353
   MULDER J, 1994, J CLIN MICROBIOL, V32, P292
   Murphy CJ, 2005, J PHYS CHEM B, V109, P13857, DOI 10.1021/jp0516846
   Nakashima H, 2007, CHEM COMMUN, P1080, DOI 10.1039/b609162h
   Nappa J, 2004, FARADAY DISCUSS, V125, P145, DOI 10.1039/b3O3308b
   Nikoobakht B, 2001, LANGMUIR, V17, P6368, DOI 10.1021/la010530o
   Orendorff CJ, 2006, J PHYS CHEM B, V110, P3990, DOI 10.1021/jp0570972
   Pan BF, 2007, J PHYS CHEM C, V111, P12572, DOI 10.1021/jp072335+
   PASTERNACK RF, 1995, SCIENCE, V269, P935, DOI 10.1126/science.7638615
   PROFFITT M, 1993, ANAL CHEM, V65, P396
   RAY PC, 2006, ANGEW CHEM, V118, P1169
   Rex M, 2006, ANAL CHEM, V78, P445, DOI 10.1021/ac051166r
   Roll D, 2003, ANAL CHEM, V75, P3440, DOI 10.1021/ac020799s
   Rosa M, 2005, BIOMACROMOLECULES, V6, P2164, DOI 10.1021/bm050137n
   Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z
   Sudeep PK, 2005, J AM CHEM SOC, V127, P6516, DOI 10.1021/ja051145e
   Thelwell N, 2000, NUCLEIC ACIDS RES, V28, P3752, DOI 10.1093/nar/28.19.3752
   Wabuyele MB, 2005, ANAL CHEM, V77, P7810, DOI 10.1021/ac0514671
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang YL, 2001, LANGMUIR, V17, P1670, DOI 10.1021/la0010673
   Wei G, 2005, J PHYS CHEM B, V109, P23941, DOI 10.1021/jp054752x
   Wu LP, 2006, ANAL CHEM, V78, P5570, DOI 10.1021/ac0603577
   Yu CX, 2007, ANAL CHEM, V79, P572, DOI 10.1021/ac061730d
   Yu YY, 1997, J PHYS CHEM B, V101, P6661
   Zhu DM, 2006, LANGMUIR, V22, P3735, DOI 10.1021/la052161s
   Zhu J, 2005, MAT SCI ENG B-SOLID, V121, P199, DOI 10.1016/j.mseb.2005.03.022
NR 47
TC 96
Z9 102
U1 8
U2 63
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD NOV 15
PY 2008
VL 80
IS 22
BP 8424
EP 8430
DI 10.1021/ac801005d
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 372OM
UT WOS:000260910900009
PM 18937420
DA 2018-01-05
ER

PT J
AU Wang, ZY
   Zhao, Y
   Ren, L
   Jin, LH
   Sun, LP
   Yin, P
   Zhang, YF
   Zhang, QQ
AF Wang, Zu-yong
   Zhao, Yang
   Ren, Lei
   Jin, Li-hua
   Sun, Li-ping
   Yin, Pei
   Zhang, Ya-fei
   Zhang, Qi-qing
TI Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors
   for gene therapy
SO NANOTECHNOLOGY
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; CELLULAR UPTAKE; IN-VITRO; TRANSFECTION
   EFFICIENCY; SILICA NANOPARTICLES; CATIONIC POLYMERS; DELIVERY-SYSTEMS;
   DNA; PROTEIN; CELLS
AB In principle, the technique of gene delivery involves taking complete or parts of genes that can code specific messages and delivering them to selected cells in the body. Such a transfer of plasmid DNA into mammalian cells has posed major challenges for gene therapy. A series of gelatin-siloxane nanoparticles (GS NPs) with controlled size and surface charge were synthesized through a two-step sol-gel process. In order to increase the efficiency of cellular uptake, HIV-derived Tat peptide was further grafted to GS NPs. In vitro co-location and endocytosis inhibition experiments suggested that the as-synthesized TG NPs may enter HeLa cells via a combined pathway of lipid-raft- and receptor-dependent endocytosis, and only cause little cell damage. Moreover, this study shows the encapsulation of a plasmid DNA in TG NPs to be obtained as a non-viral gene vector. This kind of encapsulation provides complete protection to the plasmid DNA from the external DNase and serum environment, and generates the hope that the resulting formulation can be developed into a potential vector for effective gene delivery. In order to check this potential, the reporter gene pSV beta-gal was encapsulated, and in vitro transfection efficiency of this system was found to be nearly 130% compared to the commercially available transfection reagent Lipofectamine T.
C1 [Wang, Zu-yong; Zhao, Yang; Ren, Lei; Jin, Li-hua; Sun, Li-ping; Yin, Pei; Zhang, Ya-fei; Zhang, Qi-qing] Xiamen Univ, Dept Biomat, Coll Mat, Biomed Engn Res Ctr, Xiamen 361005, Peoples R China.
   [Ren, Lei] Xiamen Univ, State Key Lab Phys Chem Solid Surfaces, Xiamen 361005, Peoples R China.
RP Ren, L (reprint author), Xiamen Univ, Dept Biomat, Coll Mat, Biomed Engn Res Ctr, Xiamen 361005, Peoples R China.
EM renlei@xmu.edu.cn
RI Sun, LP/G-3476-2010; Zhao, Yang/J-2690-2014; ren, lei/G-3459-2010; Wang,
   Zuyong/A-9511-2013; Zhang, QQ/G-3361-2010
OI ren, lei/0000-0003-2131-1601; 
FU National Natural Science Foundation of China [30670559]; National Basic
   Research Program of China (973 Program) [2007CB935603]; Nature Science
   Foundation of Fujian Province of China [2006J0121]; Program for New
   Century Excellent Talents in Fujian Province University
FX This work was financially supported by the National Natural Science
   Foundation of China (grant no. 30670559), the National Basic Research
   Program of China (973 Program) (2007CB935603), the Nature Science
   Foundation of Fujian Province of China (2006J0121) and the Program for
   New Century Excellent Talents in Fujian Province University. We thank Ms
   Huang XH for assistance in CLSM and Professor Li DH for helpful advice
   and discussions.
CR Balthasar S, 2005, BIOMATERIALS, V26, P2723, DOI 10.1016/j.biomaterials.2004.07.047
   Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102
   Choi HS, 2006, BBA-GEN SUBJECTS, V1760, P1604, DOI 10.1016/j.bbagen.2006.09.011
   Dang JM, 2006, ADV DRUG DELIVER REV, V58, P487, DOI 10.1016/j.addr.2006.03.001
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   Dincer S, 2005, GENE THER, V12, pS139, DOI 10.1038/sj.gt.3302628
   Eyles JE, 2003, J CONTROL RELEASE, V86, P25, DOI 10.1016/S0168-3659(02)00296-1                                                   
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gillan L, 2005, THERIOGENOLOGY, V63, P445, DOI 10.1016/j.theriogenology.2004.09.024
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Heyde M, 2007, J PHARM PHARMACOL, V59, P329, DOI 10.1211/jpp.59.3.0002
   Hussain N, 2003, INT J PHARM, V254, P27, DOI 10.1016/S0378-5173(02)00672-5
   Jen CP, 2004, LANGMUIR, V20, P1369, DOI 10.1021/la036154k
   Jiang L, 2007, J GENE MED, V9, P253, DOI 10.1002/jgm.1017
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kawakami S, 2000, GENE THER, V7, P292, DOI 10.1038/sj.gt.3301089
   Kuriyama S, 2000, GENE THER, V7, P1132, DOI 10.1038/sj.gt.3301192                                                           
   Kusumanto YH, 2007, DRUG DELIV, V14, P273, DOI 10.1080/10717540601098807
   Lai E, 2002, J PHARM SCI, V91, P1225, DOI 10.1002/jps.10108
   Lee H, 2002, J CONTROL RELEASE, V79, P283, DOI 10.1016/S0168-3659(02)00002-0
   Liu F, 2007, J GENE MED, V9, P613, DOI 10.1002/jgm.1054
   Luo D, 2004, J CONTROL RELEASE, V95, P333, DOI 10.1016/j.jconrel.2003.11.019
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   MEYER H, 1957, BIOCHEM J, V67, P333, DOI 10.1042/bj0670333                                                               
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Ren L, 2001, J SOL-GEL SCI TECHN, V21, P115, DOI 10.1023/A:1011226104173                                                         
   Ren L, 2002, BIOMATERIALS, V23, P4765, DOI 10.1016/S0142-9612(02)00226-0                                                   
   Ren L, 2008, J BIOMED MATER RES A, V85A, P787, DOI 10.1002/jbm.a.31608
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rudge SR, 2000, BIOMATERIALS, V21, P1411, DOI 10.1016/S0142-9612(00)00006-5
   SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307                                                          
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   von Gersdorff K, 2006, MOL THER, V14, P745, DOI 10.1016/j.ymthe.2006.07.006
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang Y, 2006, J BIOL CHEM, V281, P24803, DOI 10.1074/jbc.M600183200
   Xu ZP, 2006, CHEM ENG SCI, V61, P1027, DOI 10.1016/j.ces.2005.06.019
   Yao GH, 2007, INT IMMUNOPHARMACOL, V7, P444, DOI 10.1016/j.intimp.2006.11.013
NR 44
TC 26
Z9 28
U1 0
U2 19
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD NOV 5
PY 2008
VL 19
IS 44
AR 445103
DI 10.1088/0957-4484/19/44/445103
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 355IE
UT WOS:000259701800003
PM 21832720
DA 2018-01-05
ER

PT J
AU Rao, KS
   Reddy, MK
   Horning, JL
   Labhasetwar, V
AF Rao, Kavitha S.
   Reddy, Mararn K.
   Horning, Jayrne L.
   Labhasetwar, Vinod
TI TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs
SO BIOMATERIALS
LA English
DT Article
DE Trans-activating transcriptor; Nanoparticles; Blood-brain-barrier;
   P-glycoprotein; Transport; Anti-HIV drugs
ID BLOOD-BRAIN-BARRIER; CELL PENETRATING PEPTIDE; PACLITAXEL-LOADED
   NANOPARTICLES; MICROVESSEL ENDOTHELIAL-CELLS; P-GLYCOPROTEIN EXPRESSION;
   PROTEASE INHIBITORS; CEREBROSPINAL-FLUID; IN-VIVO; TRANSPORT; MEMBRANE
AB We have shown that nanoparticles (NPs) conjugated to trans-activating transcriptor (TAT) peptide bypass the efflux action of P-glycoprotein and increase the transport of the encapsulated ritonavir, a protease inhibitor (PI), across the blood-brain-barrier (BBB) to the central nervous system (CNS). A steady increase in the drug parenchyma/capillary ratio over time without disrupting the BBB integrity suggests that TAT-conjugated NPs are first immobilized in the brain vasculature prior to their transport into parenchyma. Localization of NPs in the brain parenchyma was further confirmed with histological analysis of the brain sections. The brain drug level with conjugated NPs was 800-fold higher than that with drug in solution at two weeks. Drug clearance was seen within four weeks. in conclusion, TAT-conjugated NPs enhanced the CNS bioavailability of the encapsulated PI and maintained therapeutic drug levels in the brain for a sustained period that could be effective in reducing the viral load in the CNS, which acts as a reservoir for the replicating HIV-1 virus. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Rao, Kavitha S.; Reddy, Mararn K.; Labhasetwar, Vinod] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
   [Rao, Kavitha S.; Horning, Jayrne L.; Labhasetwar, Vinod] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
RP Labhasetwar, V (reprint author), Cleveland Clin, Lerner Res Inst, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
FU National Institutes of Health, Mental Health [R21 MH06 7525]; Cleveland
   Clinic; American Heart Association, Heartland Affiliate [0710119Z]
FX Grant support was provided by the National Institutes of Health, Mental
   Health (R21 MH06 7525) and Cleveland Clinic (to VL). KSR is supported by
   a Pre-doctoral Fellowship from the American Heart Association, Heartland
   Affiliate (Grant # 0710119Z). We are appreciative of Dr. Donald Miller
   for the kind gift of MDCK cell lines. We would like to thank Drs.
   Sivakumar Vijayaraghvalu and jasmine P. Davda for their assistance with
   the in vivo studies and Dr. Sanjeeb Sahoo for conjugation chemistry. We
   are grateful to Drs. Judy Drazba and John Peterson of the imaging core
   facility at Cleveland Clinic for their assistance with microscopic
   techniques. We thank Ms. Melissa Jedlicka for proof-reading the
   manuscript.
CR Banks WA, 2001, J VIROL, V75, P4681, DOI 10.1128/JVI.75.10.4681-4691.2001
   BAZILE DV, 1992, BIOMATERIALS, V13, P1093, DOI 10.1016/0142-9612(92)90142-B
   Begley DJ, 2003, ACTA PAEDIATR, V92, P83, DOI 10.1080/08035320310020904
   Brewster ME, 1997, ANTIMICROB AGENTS CH, V41, P122
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Choo EF, 2000, DRUG METAB DISPOS, V28, P655
   Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1
   Dennison SR, 2007, BIOCHEM BIOPH RES CO, V363, P178, DOI 10.1016/j.bbrc.2007.08.162
   Dizhe EB, 2006, BIOCHEMISTRY-MOSCOW+, V71, P1350, DOI 10.1134/S0006297906120108
   Finzi D, 2000, NAT MED, V6, P735, DOI 10.1038/77444                                                                   
   Franke H, 2000, BRAIN RES PROTOC, V5, P248, DOI 10.1016/S1385-299X(00)00020-9
   Hayashi K, 2005, J NEUROCHEM, V93, P1231, DOI 10.1111/j.1471-4159.2005.03114.x
   Kaddoumi A, 2007, DRUG METAB DISPOS, V35, P1459, DOI 10.1124/dmd.107.016220
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Kravcik S, 1999, J ACQ IMMUN DEF SYND, V21, P371
   Lavie Y, 1999, LIPIDS, V34, pS57, DOI 10.1007/BF02562229
   Lee CGL, 1998, J CLIN INVEST, V101, P287, DOI 10.1172/JCI2575                                                                 
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Letendre Scott, 2007, Top HIV Med, V15, P32
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Notermans DW, 1998, AIDS, V12, P1483, DOI 10.1097/00002030-199812000-00010
   Panyam J, 2004, J PHARM SCI-US, V93, P1804, DOI 10.1002/jps.20094                                                               
   Patsalides AD, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.4.1790999                                                       
   Perloff MD, 2007, J PHARM PHARMACOL, V59, P947, DOI 10.1211/jpp.59.7.0006
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Rao KS, 2006, J BIOMED NANOTECHNOL, V2, P173, DOI 10.1166/jbn.2006.036
   Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z
   Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405
   SAMII A, 1994, AM J PHYSIOL, V267, pE124
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sheha MM, 2003, ARCH PHARM, V336, P47, DOI 10.1002/ardp.200390003
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   TORCHILIN VP, 2008, BIOPOLYMERS
   TORRENCE PF, 1993, J MED CHEM, V36, P529, DOI 10.1021/jm00057a002                                                             
   Tripathi S, 2005, NUCLEIC ACIDS RES, V33, P4345, DOI 10.1093/nar/gki743
   Wang Q, 2005, INT J PHARMACEUT, V288, P349, DOI 10.1016/j.ijpharm.2004.10.007
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Xin HW, 2006, EUR J CLIN PHARMACOL, V62, P871, DOI 10.1007/s00228-006-0182-3
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
   ANDRE P, 2003, Patent No. 6506555
NR 47
TC 150
Z9 154
U1 1
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2008
VL 29
IS 33
BP 4429
EP 4438
DI 10.1016/j.biomaterials.2008.08.004
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 361WL
UT WOS:000260158100008
PM 18760470
OA green_accepted
DA 2018-01-05
ER

PT J
AU Back, M
   Nyhlen, J
   Kvarnstrom, I
   Appelgren, S
   Borkakoti, N
   Jansson, K
   Lindberg, J
   Nystrom, S
   Hallberg, A
   Rosenquist, A
   Samuelsson, B
AF Back, Marcus
   Nyhlen, Jonas
   Kvarnstrom, Ingemar
   Appelgren, Sara
   Borkakoti, Neera
   Jansson, Katarina
   Lindberg, Jimmy
   Nystrom, Susanne
   Hallberg, Anders
   Rosenquist, Asa
   Samuelsson, Bertil
TI Design, synthesis and SAR of potent statine-based BACE-1 inhibitors:
   Exploration of P1 phenoxy and benzyloxy residues
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Alzheimer's disease; BACE-1 inhibitors; P1 modifications;
   Peptidomimetics
ID HIV-1 PROTEASE INHIBITORS; HUMAN BETA-SECRETASE; ALZHEIMERS-DISEASE;
   PLASMEPSIN-II; PROGRESS; THERAPEUTICS; DISCOVERY; LACTONES; SUGARS;
   BRAIN
AB Several BACE-1 inhibitors with low nanomolar level activities, encompassing a statine-based core structure with phenyloxymethyl- and benzyloxymethyl residues in the P1 position, are presented. The novel P1 modi. cation introduced to allow the facile exploration of the S1 binding pocket of BACE-1, delivered highly promising inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Back, Marcus; Nyhlen, Jonas; Kvarnstrom, Ingemar; Rosenquist, Asa] Linkoping Univ, Dept Chem, S-58183 Linkoping, Sweden.
   [Appelgren, Sara; Borkakoti, Neera; Jansson, Katarina; Lindberg, Jimmy; Nystrom, Susanne; Rosenquist, Asa; Samuelsson, Bertil] Medivir AB, S-14144 Huddinge, Sweden.
   [Hallberg, Anders] Uppsala Univ, Dept Organ Pharmaceut Chem, S-75123 Uppsala, Sweden.
   [Samuelsson, Bertil] Stockholm Univ, Dept Organ Chem, Arrhenius Lab, S-10691 Stockholm, Sweden.
RP Rosenquist, A (reprint author), Linkoping Univ, Dept Chem, S-58183 Linkoping, Sweden.
EM asa.rosenquist@medivir.se; bertil.samuelsson@medivir.se
FU Medivir AB
FX We gratefully thank the following personnel at Medivir AB: Mr. Kurt
   Benkestock for conducting HRMS data, Elizabeth Hamelink and Ian
   Henderson for BACE-I and CathD enzyme data, Alexandra Johansson, and
   Elisabet Lilja for excellent technical assistance in the production of
   BACE-1, Dr. Anders Blomqvist for the original cloning of the human gene
   for BACE-1. We also thank Prof. Torsten Unge at Uppsala University for
   helpful discussions during development of the expression of soluble
   BACE-1. Finally, we acknowledge Medivir AB for financial support.
CR Alterman M, 1998, J MED CHEM, V41, P3782, DOI 10.1021/jm970777b                                                               
   Arslan T, 1998, NUCLEOS NUCLEOT, V17, P515, DOI 10.1080/07328319808005195
   BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796
   Baxter EW, 2005, ANNU REP MED CHEM, V40, P35, DOI 10.1016/S0065-7743(05)40003-2
   Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940
   Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004
   Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495
   Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803
   Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994                                                         
   Hills ID, 2007, CURR OPIN DRUG DISC, V10, P383
   Hom RK, 2003, J MED CHEM, V46, P1799, DOI 10.1021/jm025619l
   Hu BH, 2004, BIOORG MED CHEM LETT, V14, P3457, DOI 10.1016/j.bmcl.2004.04.068
   Johansson PO, 2005, J MED CHEM, V48, P4400, DOI 10.1021/jm040884n
   Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i
   John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h
   Kimura T, 2005, BIOORG MED CHEM LETT, V15, P211, DOI 10.1016/j.bmcl.2004.09.090
   Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059
   Muller M, 1999, J ORG CHEM, V64, P6190, DOI 10.1021/jo990132e
   Pyring D, 2001, J MED CHEM, V44, P3083, DOI 10.1021/jm001134q
   RASMUSSEN JR, 1981, J ORG CHEM, V46, P4843, DOI 10.1021/jo00337a004                                                             
   Rauter AP, 2001, TETRAHEDRON-ASYMMETR, V12, P1131, DOI 10.1016/S0957-4166(01)00197-5                                                   
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317
   RONDOT B, 1993, TETRAHEDRON LETT, V34, P8245, DOI 10.1016/S0040-4039(00)61401-6
   Senior K, 2001, LANCET, V357, P692, DOI 10.1016/S0140-6736(05)71453-7                                                   
   Silvestri R, 2009, MED RES REV, V29, P295, DOI 10.1002/med.20132
   Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785
   Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g
   Thompson LA, 2005, CURR PHARM DESIGN, V11, P3383, DOI 10.2174/138161205774370825
   Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341
   Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897
   YANAGISAWA H, 1989, CHEM LETT, P687, DOI 10.1246/cl.1989.687                                                             
   Ziora Z, 2007, BIOORG MED CHEM LETT, V17, P1629, DOI 10.1016/j.bmcl.2006.12.097
   Zuccarello G, 1998, J ORG CHEM, V63, P4898, DOI 10.1021/jo971562c                                                               
NR 35
TC 24
Z9 25
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD NOV 1
PY 2008
VL 16
IS 21
BP 9471
EP 9486
DI 10.1016/j.bmc.2008.09.041
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 361NM
UT WOS:000260134400010
PM 18842420
DA 2018-01-05
ER

PT J
AU Ojewole, E
   Mackraj, I
   Naidoo, P
   Govender, T
AF Ojewole, Elizabeth
   Mackraj, Irene
   Naidoo, Panjasaram
   Govender, Thirumala
TI Exploring the use of novel drug delivery systems for antiretroviral
   drugs
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Review
DE HIV/AIDS; Antiretroviral drugs; Novel drug delivery systems; Sustained
   release; Targeting
ID ANTI-HIV DRUGS; SOLID LIPID NANOPARTICLES; BLOOD-BRAIN-BARRIER; PRODRUG
   3'-AZIDO-3'-DEOXYTHYMIDINE PALMITATE; STERICALLY STABILIZED LIPOSOMES;
   MONOCYTES/MACROPHAGES IN-VITRO; RELEASE MATRIX TABLETS; RAT SKIN
   PERMEATION; TRANSDERMAL DELIVERY; TARGETED DELIVERY
AB Novel drug delivery systems present an opportunity for formulation scientists to overcome the many challenges associated with antiretroviral (ARV) drug therapy, thereby improving the management of patients with HIV/AIDS. This paper provides a comprehensive review of the various ARV delivery systems that have been developed for achieving sustained drug release kinetics, specifically targeting drugs to the macrophages, brain and gastric mucosa, and for addressing formulation difficulties such as poor solubility, stability and drug entrapment. Studies on the potential of systems for alternative routes of ARV drug administration, i.e., transdermal, buccal and rectal, are also highlighted. The physico-chemical properties and the in vitro/in vivo performances of various systems such as Sustained release tablets, ceramic implants, nanoparticles, nanocontainers, liposomes, emulsomes, aspasomes, microemulsions, nanopowders and Pheroid (TM) are summarised. Further studies that remain to be undertaken for formulation optimisation are also identified. This review highlights the significant potential that novel drug delivery systems have for the future effective treatment of HIV/AIDS patients on ARV drug therapy. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Ojewole, Elizabeth; Naidoo, Panjasaram; Govender, Thirumala] Univ KwaZulu Natal, Sch Pharm & Pharmacol, ZA-4000 Durban, South Africa.
   [Mackraj, Irene] Univ KwaZulu Natal, Sch Med Sci, ZA-4000 Durban, South Africa.
RP Govender, T (reprint author), Univ KwaZulu Natal, Sch Pharm & Pharmacol, Private Bag X54001, ZA-4000 Durban, South Africa.
EM govenderth@ukzn.ac.za
FU Aspen Pharmacare (South Africa) and University of KwaZulu Natal
FX The authors are grateful to Aspen Pharmacare (South Africa) and
   University of KwaZulu Natal for financial support. Ms. A. Sevakram is
   also acknowledged for her technical assistance.
CR ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   ANDERSON BD, 1988, INT J PHARM, V45, P27, DOI 10.1016/0378-5173(88)90031-2
   Arendt CW, 2001, GENOME BIOL, V2
   BANAKEF UV, 1987, AM PHARM, V2, P39
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Benghuzzi H, 2000, Biomed Sci Instrum, V36, P343
   Benghuzzi H A, 1989, Biomed Sci Instrum, V25, P169
   BENGHUZZI HA, 1990, BIOMED SCI INSTRUM, V26, P151
   BETAGERI GV, 1993, DRUG DEV IND PHARM, V19, P531, DOI 10.3109/03639049309062965                                                       
   Betageri GV, 2001, DRUG DEV IND PHARM, V27, P129, DOI 10.1081/DDC-100000479
   BETAGERI GV, 1993, INT J PHARM, V98, P149, DOI 10.1016/0378-5173(93)90051-G                                                    
   Boudad H, 2001, STP PHARMA SCI, V11, P369
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Cannon M R, 1995, Biomed Sci Instrum, V31, P159
   CHATTOPADHYAY N, 2008, PHARM RES IN PRESS, DOI DOI 10.1007/S11095-008-96150-2
   CHINEN J, 2008, J ALLERGY CLIN IMMUN, V121, pS417
   Chinen J, 2008, J ALLERGY CLIN IMMUN, V121, pS388, DOI 10.1016/j.jaci.2007.06.003
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Deshmukh D, 2003, DRUG DELIV, V10, P47, DOI 10.1080/10717540390169575
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   ELION RA, NUCLEOSIDE NUCLEOTID
   FAUCI AS, 1991, HARRISONS PRINCIPLES, P1402
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   GATES KA, 1994, PHARMACEUT RES, V11, P1605, DOI 10.1023/A:1018913921956
   Gerber M, 2008, INT J PHARM, V351, P186, DOI 10.1016/j.ijpharm.2007.09.040
   Girard MP, 2006, VACCINE, V24, P4062, DOI 10.1016/j.vaccine.2006.02.031
   Gopinath D, 2004, INT J PHARM, V271, P95, DOI 10.1016/j.ijpharm.2003.10.032
   Govender S, 2005, INT J PHARM, V306, P24, DOI 10.1016/j.ijpharm.2005.07.026
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   Griffin BT, 2006, J PHARM PHARMACOL, V58, P917, DOI 10.1211/jpp.58.7.0006
   GROBLER AF, 2004, POTCHEFSTROOM 20 CON
   HAIVIE P, 1995, AIDS, V9, P701
   Harvie P, 1996, ANTIMICROB AGENTS CH, V40, P225
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   HIGHLEYMAN L, 2003, HIV DRUGS HIV LIFECY
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   JASTI BR, 2005, THEORY PRACTICE CONT, P423
   Jeong SY, 1996, POLYM-KOREA, V20, P347
   Jin SX, 2005, PHARMAZIE, V60, P840
   KAMATH KR, 1994, ENCY PHARM TECHNOLOG, V10, P133
   KARARLI TT, 1995, J CONTROL RELEASE, V34, P43, DOI 10.1016/0168-3659(94)00128-H
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   KAWAGUCHI T, 1991, INT J PHARMACEUT, V77, P71, DOI 10.1016/0378-5173(91)90303-6
   KIM DD, 1995, AIDS, V9, P1331, DOI 10.1097/00002030-199512000-00005
   Kim DD, 1996, J PHARM SCI, V85, P214, DOI 10.1021/js950141c
   Kim DD, 1996, J CONTROL RELEASE, V40, P67, DOI 10.1016/0168-3659(95)00172-7
   Kim DD, 1996, J PHARM SCI, V85, P1191, DOI 10.1021/js9601041
   KIM DD, 1995, J PHARM SCI, V84, P1061, DOI 10.1002/jps.2600840906
   Kim DD, 1996, DRUG DEV IND PHARM, V22, P1047, DOI 10.3109/03639049609065940                                                       
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kompella UB, 1999, DRUG DELIV, V6, P9, DOI 10.1080/107175499267101                                                         
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203
   Li Jiebo, 2007, Infectious Disorders - Drug Targets, V7, P238, DOI 10.2174/187152607782110013
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4
   Liu MJ, 1999, PHARM SCI TECHNOL TO, V2, P393, DOI 10.1016/S1461-5347(99)00203-5                                                   
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lucas S, 2001, Intensive Crit Care Nurs, V17, P155, DOI 10.1054/iccn.2000.1541
   MAINARDES RM, 2008, J PHARM SCI IN PRESS, DOI DOI 10.1002/JPS
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   MAKABIPANZU B, 1995, J ACQ IMMUN DEF SYND, V8, P227, DOI 10.1097/00042560-199503010-00002                                                
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4                                                   
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   MUKHERJI E, 1994, PHARMACEUT RES, V11, P809, DOI 10.1023/A:1018965305234
   Munasur AP, 2006, INT J PHARM, V323, P43, DOI 10.1016/j.ijpharm.2006.05.051
   Nagy E A, 1994, Biomed Sci Instrum, V30, P181
   Naidoo P, 2006, S AFR FAM PRACT, V48, P55, DOI 10.1080/20786204.2006.10873343
   Narishetty STK, 2005, J CONTROL RELEASE, V102, P59, DOI 10.1016/j.jconrel.2004.09.016
   Narishetty STK, 2004, J CONTROL RELEASE, V95, P367, DOI 10.1016/j.jconrel.2003.11.022
   Oh SY, 1998, J CONTROL RELEASE, V51, P161, DOI 10.1016/S0168-3659(97)00162-4                                                   
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Perugini P, 2003, INT J PHARM, V252, P1, DOI 10.1016/S0378-5173(02)00602-6
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   PIERIBONE D, HIV LIFE CYCLE 2002
   RANADE VV, 2004, DRUG DELIVERY SYSTEM, P207
   RATHBONE MJ, 1994, ADV DRUG DELIVER REV, V13, P1, DOI 10.1016/0169-409X(94)90024-8                                                    
   Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840
   Reed D, 1997, Biomed Sci Instrum, V34, P59
   ROSSI L, 1992, CHEM-BIOL INTERACT, V85, P255, DOI 10.1016/0009-2797(92)90066-T                                                    
   Rossi Silvia, 2005, Drug Discov Today Technol, V2, P59, DOI 10.1016/j.ddtec.2005.05.018
   *RXLIST INC, RXLIST INT DRUG IND
   Sanchez-Lafuente C, 2002, INT J PHARM, V234, P213, DOI 10.1016/S0378-5173(01)00962-0
   Sanchez-Lafuente C, 2002, INT J PHARM, V237, P107, DOI 10.1016/S0378-5173(02)00028-5
   SANDE MA, 2003, SANFORD GUIDE HIV AI
   Saunders J, 1999, J PHARM PHARM SCI, V2, P99
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SEKI T, 1991, J CONTROL RELEASE, V17, P41, DOI 10.1016/0168-3659(91)90129-2
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   Shojaei AH, 1998, PHARMACEUT RES, V15, P1182, DOI 10.1023/A:1011927521627
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   SQUIER CA, 1985, J INVEST DERMATOL, V84, P176, DOI 10.1111/1523-1747.ep12264711
   Stoddart C, 2006, DRUG DISCOV TODAY, V3, P113
   STOLNIK S, 1995, ADV DRUG DELIVER REV, V16, P195, DOI 10.1016/0169-409X(95)00025-3                                                    
   SUBHEET J, 2006, CURR DRUG DELIV, V3, P157
   Suwanpidokkul N, 2004, AAPS PHARMSCITECH, V5
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Thomas NS, 2003, PHARMAZIE, V58, P895
   Tomalia DA, 2004, ALDRICHIM ACTA, V37, P39
   TORCHILIN VP, 1992, FASEB J, V6, P2716
   TOUITOU E, 1994, J PHARM SCI, V83, P1189, DOI 10.1002/jps.2600830902
   UNAIDS and WHO, 2007, AIDS EP UPD
   *US DEP HHS, HIV AIDS DRUG INF
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Vauthier C, 2003, J CONTROL RELEASE, V93, P151, DOI 10.1016/j.jconrel.2003.08.005
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Wintergerst U, 1997, ANTIMICROB AGENTS CH, V41, P1143
   WU HB, 2007, ACTA PHARM SIN, V42, P538
   Xiang J, 2002, INT J PHARM, V231, P57, DOI 10.1016/S0378-5173(01)00865-1
   ANTIRETROVIRAL TREAT
NR 131
TC 78
Z9 80
U1 2
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD NOV
PY 2008
VL 70
IS 3
BP 697
EP 710
DI 10.1016/j.ejpb.2008.06.020
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 380SA
UT WOS:000261484300001
PM 18655830
DA 2018-01-05
ER

PT J
AU Chen, JN
   Wu, YZ
   Wang, CX
   Cai, JY
AF Chen, Jianan
   Wu, Yangzhe
   Wang, Chenxi
   Cai, Jiye
TI Nanoscale Organization of CD4 Molecules of Human T Helper Cell Mapped by
   NSOM and Quantum Dots
SO SCANNING
LA English
DT Article
DE near-field scanning optical microscopy (NSOM); quantum dots (QDs); CD4
   molecule
ID SCANNING OPTICAL MICROSCOPY; CHEMOKINE RECEPTORS; LIPID RAFTS; RESPONSES
AB CD4 molecule, the surface marker of T helper cell, has been comfirmed to be the main cellular receptor for the human immunodeficiency Viruses HIV-1, HIV-2 and SIV. Recent research demonstrated the importance of the spatial arrangement of CD4 on the cell membrane to its binding efficiency to virus. In this article, the combined near-field scanning optical microscopy (NSOM) and quantum dots (QDs) fluorescent labeling technology were performed to investigate the nanoscale organization of CD4 molecules with a spatial resolution about 100 nm. Simultaneous topographic image of the T helper cell and fluorescent Image of QDs have been directly gained by NSOM/QDs-based system. Intensity- and size-distribution histograms of the QDs fluorescent spots verify that approximately 80% of the CD4 molecules are organized in nanosized domains randomly distributed on the cell surface. Intensity-size correlation analysis revealed heterogeneity in the molecular packing density of the domains. Our results also Illustrated the combination of NSOM imaging and QDs labeling is an ultrasensitive. high-resolution technique to probe nanoscale organization of molecules on the cell Surface. SCANNING 30: 448-451, 2008. (C) 2008 Wiley Periodicals, Inc.
C1 [Chen, Jianan; Wu, Yangzhe; Cai, Jiye] Jinan Univ, Coll Life Sci & Technol, Guangzhou, Guangdong, Peoples R China.
   [Wang, Chenxi] Jinan Univ, Coll Sci & Engn, Guangzhou, Guangdong, Peoples R China.
RP Cai, JY (reprint author), Jinan Univ, Dept Chem, Guangzhou, Guangdong, Peoples R China.
EM tjycai@jnu.edu.cn
RI Wu, Yangzhe/C-4435-2012
FU National Natural Science Foundation China [30230350, 60578025]
FX Contract grant sponsor: National Natural Science Foundation China:
   contract grant number: 30230350, 60578025.
CR Chen Y, 2008, BLOOD, V111, P4220, DOI 10.1182/blood-2007-07-101691
   Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297
   de Bakker BI, 2007, CHEMPHYSCHEM, V8, P1473, DOI 10.1002/cphc.200700169
   de Bakker BI, 2008, J CELL SCI, V121, P627, DOI 10.1242/jcs.019513
   de Lange F, 2001, J CELL SCI, V114, P4153
   Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194
   Gao XH, 2007, ADV EXP MED BIOL, V620, P57
   Koopman M, 2004, FEBS LETT, V573, P6, DOI 10.1016/j.febslet.2004.07.035
   KWONG PD, 1998, NATURE, V393, P659
   Landry A, 2006, METH MOL B, V341, P251
   Nguyen DH, 2005, EXP CELL RES, V304, P559, DOI 10.1016/j.yexcr.2004.11.022
   Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002
   SINGER H, 2001, J VIROL, V75, P3779
NR 13
TC 7
Z9 8
U1 0
U2 9
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0161-0457
J9 SCANNING
JI Scanning
PD NOV-DEC
PY 2008
VL 30
IS 6
BP 448
EP 451
DI 10.1002/sca.20128
PG 4
WC Instruments & Instrumentation; Microscopy
SC Instruments & Instrumentation; Microscopy
GA 401SQ
UT WOS:000262962800003
PM 18828144
DA 2018-01-05
ER

PT J
AU Trovato, F
   Tozzini, V
AF Trovato, Fabio
   Tozzini, Valentina
TI Supercoiling and Local Denaturation of Plasmids with a Minimalist DNA
   Model
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; COARSE-GRAINED MODELS; HIV-1 PROTEASE;
   HISTONE TAILS; NUCLEOSOME; KINKING
AB We report molecular dynamics simulations of DNA nanocircles and submicrometer-sized plasmids with torsional stress. The multiple microseconds time scale is reached thanks to a new one-bead-per-nucleotide coarse-grained model that combines structural accuracy and predictive power, achieved by means of the accurate choice of the force field terms and their unbiased statistically based parametrization. The model is validated with experimental structural data and available all-atom simulations of DNA nanocircles. Besides reproducing the nanocircles' structures and behavior on the short time scale, our model is capable of exploring three orders of magnitude further in time and to sample more efficiently the configuration space, unraveling novel behaviors. We explored the microsecond dynamics of entire small plasmids and observed supercoiling and compaction in the overtwisted case. The stability of overtwisted nanocircles and plasmids is predicted LIP to macroscopic time scales. Conversely, in the undertwisted case, at physiological values of the superhelical density, after a metastable phase of supercoiling-compaction, we observe the formation and the complex dynamics of denaturation bubbles over a multiple microseconds time scale. Our results indicate that the torsional stress is involved in a delicate balance with the temperature to determine the denaturation equilibrium and regulate the transcription process.
C1 [Trovato, Fabio; Tozzini, Valentina] Scuola Normale Super Pisa, NEST CNR INFM, I-56126 Pisa, Italy.
RP Tozzini, V (reprint author), Scuola Normale Super Pisa, NEST CNR INFM, Piazza Cavalieri 7, I-56126 Pisa, Italy.
EM tozzini@nest.sns.it
RI Tozzini, Valentina/E-8206-2011
OI Tozzini, Valentina/0000-0002-7586-5039; Trovato,
   Fabio/0000-0002-1324-0930
CR Arya G, 2006, P NATL ACAD SCI USA, V103, P16236, DOI 10.1073/pnas.0604817103
   Bates A. D., 2005, DNA TOPOLOGY
   Benham CJ, 2004, J COMPUT BIOL, V11, P519
   Drukker K, 2001, J CHEM PHYS, V114, P579, DOI 10.1063/1.1329137
   Du Q, 2008, NUCLEIC ACIDS RES, V36, P1120, DOI 10.1093/nar/gkm1125
   Forrey C, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2746246
   Guipaud O, 1997, P NATL ACAD SCI USA, V94, P10606, DOI 10.1073/pnas.94.20.10606
   Harris SA, 2008, NUCLEIC ACIDS RES, V36, P21, DOI 10.1093/nar/gkm891
   HATFIELD GW, 2002, J ANN REV GENET, V36, P175
   Huertas ML, 1997, BIOPHYS J, V73, P3142, DOI 10.1016/S0006-3495(97)78340-1                                                   
   Knotts TA, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2431804
   Korolev N, 2006, BIOPHYS J, V90, P4305, DOI 10.1529/biophysj.105.080226
   Lankas F, 2006, STRUCTURE, V14, P1527, DOI 10.1016/j.str.2006.08.004
   Li W, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051915
   Mielke SP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2038767
   Reith D, 2003, J COMPUT CHEM, V24, P1624, DOI 10.1002/jcc.10307
   Smith W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4                                                   
   Stevens MJ, 2001, BIOPHYS J, V80, P130, DOI 10.1016/S0006-3495(01)76000-6                                                   
   Tepper HL, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1869417
   Tozzini V, 2005, CHEM PHYS LETT, V413, P123, DOI 10.1016/j.cplett.2005.07.075
   Tozzini V, 2005, CURR OPIN STRUC BIOL, V15, P144, DOI 10.1016/j.sbi.2005.02.005
   TOZZINI V, 2008, COARSE GRAINING COND, pCH19
   Tozzini V, 2007, J STRUCT BIOL, V157, P606, DOI 10.1016/j.jsb.2006.08.005
   Trylska J, 2005, BIOPHYS J, V89, P1455, DOI 10.1529/biophysj.104.058495
   Voltz K, 2008, J COMPUT CHEM, V29, P1429, DOI 10.1002/jcc.20902
   Voltz K, 2007, BIOPHYS J, p540A
   WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6
   WHITE GJ, 1988, P NATL ACAD SCI USA, V85, P772
   ZHANG F, 1995, PHYS REV E, V52, P4217, DOI 10.1103/PhysRevE.52.4217                                                        
   Zhou J, 2007, BIOPHYS J, V92, P4289, DOI 10.1529/biophysj.106.094425
NR 30
TC 30
Z9 31
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD OCT 23
PY 2008
VL 112
IS 42
BP 13197
EP 13200
DI 10.1021/jp807085d
PG 4
WC Chemistry, Physical
SC Chemistry
GA 361AW
UT WOS:000260100900008
PM 18826184
DA 2018-01-05
ER

PT J
AU Chen, B
   Liu, QL
   Zhang, YL
   Xu, L
   Fang, XH
AF Chen, Bo
   Liu, Qiaoling
   Zhang, Yuliang
   Xu, Li
   Fang, Xiaohong
TI Transmembrane Delivery of the Cell-Penetrating Peptide Conjugated
   Semiconductor Quantum Dots
SO LANGMUIR
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; TAT-FUSION PROTEINS; IN-VIVO; LIVING CELLS;
   INTRACELLULAR DELIVERY; DEPENDENT ENDOCYTOSIS; CARBON NANOTUBES;
   INTERNALIZATION; MECHANISM; DNA
AB Conjugation of the cell-penetrating peptide derived from the human immunodeficiency virus-1 transactivator protein (TAT) to semiconductor quantum dots (QDs) is an effective way to enhance transmembrane delivery of QDs for intracellular and molecular imaging. In this work, the internalization pathway of TAT-QDs was studied systematically in living cells. Cellular uptake of TAT-QDs, under different endocytosis-inhibiting conditions, was compared by fluorescence imaging and flow cytometry. The results suggest TAT-QDs internalize through lipid-raft-dependent macropinocytosis, which is different from that of FITC-labeled TAT. They also provide new information for better understanding of the TAT-mediated cell uptake mechanism.
C1 [Chen, Bo; Liu, Qiaoling; Zhang, Yuliang; Xu, Li; Fang, Xiaohong] Chinese Acad Sci, Inst Chem, BNLMS, Key Lab Mol Nanostruct & Nanotechnol, Beijing 100080, Peoples R China.
   [Chen, Bo; Liu, Qiaoling] Chinese Acad Sci, Grad Sch, Beijing 100080, Peoples R China.
RP Fang, XH (reprint author), Chinese Acad Sci, Inst Chem, BNLMS, Key Lab Mol Nanostruct & Nanotechnol, Beijing 100080, Peoples R China.
EM xfang@iccas.ac.cn
RI chen, bo/G-4459-2013
OI chen, bo/0000-0003-3935-305X
FU National Natural Science Foundation of China [90713024]; National Basic
   Research Program of China [2007CB935601]; Chinese Academy of Sciences
FX This work was supported by the National Natural Science Foundation of
   China (No 90713024), the National Basic Research Program of China
   (2007CB935601), and the Chinese Academy of Sciences.
CR Chen X, 2007, P NATL ACAD SCI USA, V104, P8218, DOI 10.1073/pnas.0700567104
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Ebenstein Y, 2002, NANO LETT, V2, P945, DOI 10.1021/nl025673p
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   Jamieson T, 2007, BIOMATERIALS, V28, P4717, DOI 10.1016/j.biomaterials.2007.07.014
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Le Gac S, 2006, NANO LETT, V6, P1863, DOI 10.1021/nl060694v
   Letoha T, 2003, J MOL RECOGNIT, V16, P272, DOI 10.1002/jmr.637
   Ma XY, 2007, BIOCHEM BIOPH RES CO, V356, P67, DOI 10.1016/j.bbrc.2007.02.080
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028
   Nan XL, 2005, J PHYS CHEM B, V109, P24220, DOI 10.1021/jp056360w
   Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rinne J, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-1
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Shi HQG, 2003, PHARMACEUT RES, V20, P479, DOI 10.1023/A:1022676709565                                                         
   Shinohara H, 2000, CANCER RES, V60, P1766
   Silver J, 2005, NANO LETT, V5, P1445, DOI 10.1021/nl050808n
   SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302                                                            
   SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1
   Tekle C, 2008, NANO LETT, V8, P1858, DOI 10.1021/nl0803848
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Vu TQ, 2005, NANO LETT, V5, P603, DOI 10.1021/nl047977c
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HD, 2002, BIOPHYS J, V83, P3619, DOI 10.1016/S0006-3495(02)75362-9                                                   
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
NR 40
TC 76
Z9 80
U1 2
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD OCT 21
PY 2008
VL 24
IS 20
BP 11866
EP 11871
DI 10.1021/la802048s
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 360HT
UT WOS:000260049300074
PM 18823093
DA 2018-01-05
ER

PT J
AU Zhan, P
   Liu, XY
   Cao, Y
   Wang, Y
   Pannecouque, C
   De Clercq, E
AF Zhan, Peng
   Liu, Xinyong
   Cao, Yuan
   Wang, Yan
   Pannecouque, Christophe
   De Clercq, Erik
TI 1,2,3-thiadiazole thioacetanilides as a novel class of potent HIV-1
   non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; NNRTIs; thiadiazole thioacetanilides; 1,2,3-thiadiazole; synthesis;
   SAR
ID COLORIMETRIC ASSAY; DRUG DESIGN; BIOISOSTERISM; MUTANT
AB A novel series of 1,2,3-thiadiazole thioacetanilide (TTA) derivatives have been designed, synthesized and evaluated for its anti-HIV activities in MT-4 cells. Some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations. Among them, 2-[4-(2,4-dichlorophenyl)-1,2,3-thiadiazol-5- ylthio]-N-(2-nitrophenyl)acetamide 7d2 was identified as the most promising compound (EC(50) = 0.059 +/- 0.02 mu M, CC(50) > 283.25 mu M, SI > 4883). The structure-activity relationship (SAR) of these novel structural congeners is discussed. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
C1 [Zhan, Peng; Liu, Xinyong; Cao, Yuan; Wang, Yan] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China.
   [Pannecouque, Christophe; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn; erik.declercq@rega.kuleuven.ac.be
FU National Natural Science Foundation of China (NSFC) [30371686,
   30772629]; The International Cooperation; Ministry of Science and
   Technology of China [2003DF000033]; Research Fund for the Doctoral
   Program of Higher Education of China [070422083]
FX Financial support of this work by the National Natural Science
   Foundation of China (NSFC No. 30371686, No. 30772629), Key Project of
   The International Cooperation, Ministry of Science and Technology of
   China (2003DF000033) and Research Fund for the Doctoral Program of
   Higher Education of China (070422083), is gratefully acknowledged.
CR De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   De La Rosa M, 2006, BIOORG MED CHEM LETT, V16, P4444, DOI 10.1016/j.bmcl.2006.06.048
   Gagnon A, 2007, BIOORG MED CHEM LETT, V17, P4437, DOI 10.1016/j.bmcl.2007.06.012
   HURD CD, 1955, J AM CHEM SOC, V77, P5359, DOI 10.1021/ja01625a047                                                             
   Ilina T, 2008, ADV PHARMACOL, V56, P121, DOI 10.1016/S1054-3589(07)56005-9
   Jochmans D, 2008, VIRUS RES, V134, P171, DOI 10.1016/j.virusres.2008.01.003
   Lima LMA, 2005, CURR MED CHEM, V12, P23, DOI 10.2174/0929867053363540                                                        
   Muraglia E, 2006, BIOORG MED CHEM LETT, V16, P2748, DOI 10.1016/j.bmcl.2006.02.024
   O'Meara JA, 2007, BIOORG MED CHEM LETT, V17, P3362, DOI 10.1016/j.bmcl.2007.03.097
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q                                                               
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Stanetty P, 1998, HETEROCYCLES, V48, P259, DOI 10.3987/COM-97-8015                                                             
   THOMAS EW, 1985, J MED CHEM, V28, P442, DOI 10.1021/jm00382a009
   *UNAIDS WHO, 2007, AIDS EP UPD
   Veerapen N, 2006, J AM CHEM SOC, V128, P227, DOI 10.1021/ja0557029
   Wang ZW, 2006, BIOORG MED CHEM LETT, V16, P4174, DOI 10.1016/j.bmcl.2006.05.096
   Zhang ZJ, 2007, ANTIMICROB AGENTS CH, V51, P429, DOI 10.1128/AAC.01032-06
   CURRAN WV, 1984, Patent No. 104403
NR 19
TC 61
Z9 63
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 15
PY 2008
VL 18
IS 20
BP 5368
EP 5371
DI 10.1016/j.bmcl.2008.09.055
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 359FW
UT WOS:000259972800006
PM 18824350
DA 2018-01-05
ER

PT J
AU Dethoff, EA
   Hansen, AL
   Musselman, C
   Watt, ED
   Andricioaei, I
   Al-Hashimi, HM
AF Dethoff, Elizabeth A.
   Hansen, Alexandar L.
   Musselman, Catherine
   Watt, Eric D.
   Andricioaei, Ioan
   Al-Hashimi, Hashim M.
TI Characterizing complex dynamics in the transactivation response element
   apical loop and motional correlations with the bulge by NMR, molecular
   dynamics, and mutagenesis
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HIV-1 TAR RNA; RESIDUAL DIPOLAR COUPLINGS; ELECTROSTATIC INTERACTIONS;
   NUCLEOCAPSID PROTEIN; FUNCTIONAL-GROUPS; MESSENGER-RNA; STEM-LOOP;
   RECOGNITION; VIRUS; RELAXATION
AB The HIV-1 transactivation response element (TAR) RNA binds a variety of proteins and is a target for developing anti-HIV therapies. TAR has two primary binding sites: a UCU bulge and a CUGGGA apical loop. We used NMR residual dipolar couplings, carbon spin relaxation (R(1) and R(2)), and relaxation dispersion (R(1p)) in conjunction with molecular dynamics and mutagenesis to characterize the dynamics of the TAR apical loop and investigate previously proposed long-range interactions with the distant bulge. Replacement of the wild-type apical loop with a UUCG loop did not significantly affect the structural dynamics at the bulge, indicating that the apical loop and the bulge act largely as independent dynamical recognition centers. The apical loop undergoes complex dynamics at multiple timescales that are likely important for adaptive recognition: U31 and G33 undergo limited motions, G32 is highly flexible at picosecond-nanosecond timescales, and G34 and C30 form a dynamic Watson-Crick basepair in which G34 and A35 undergo a slow (similar to 30 mu s) likely concerted looping in and out motion, with A35 also undergoing large amplitude motions at picosecond-nanosecond timescales. Our study highlights the power of combining NMR, molecular dynamics, and mutagenesis in characterizing RNA dynamics.
C1 [Dethoff, Elizabeth A.; Hansen, Alexandar L.; Musselman, Catherine; Watt, Eric D.; Al-Hashimi, Hashim M.] Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
   [Andricioaei, Ioan] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
RI Hansen, Alexandar/B-6794-2011; Watt, Eric/K-9819-2015
OI Hansen, Alexandar/0000-0003-4474-7141; Watt, Eric/0000-0002-1211-0229;
   Musselman, Catherine/0000-0002-8356-7971
FU National Institutes of Health (NIH) [RO1 AI066975-01]; National Science
   Foundation (NSF) [CHE-0548047]; Michigan Economic Development
   Cooperation; Michigan Technology Tri-Corridor; NSF CAREER Award
   [CHE-0548047]; NIH-sponsored Molecular Biophysics Training Grant
FX This work was supported by funding from the National Institutes of
   Health (NIH) (RO1 AI066975-01) to H. M. A. and the National Science
   Foundation (NSF) (CHE-0548047). The Michigan Economic Development
   Cooperation and the Michigan Technology Tri-Corridor supported and
   purchased the 600 MHz spectrometer. I. A. is grateful for the support of
   the NSF CAREER Award program, grant CHE-0548047. C. M. was supported by
   funding from the NIH-sponsored Molecular Biophysics Training Grant.
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Al-Hashimi HM, 2002, J MOL BIOL, V318, P637, DOI 10.1016/S0022-2836(02)00160-2
   Andersen ES, 2004, J BIOL CHEM, V279, P22243, DOI 10.1074/jbc.M314326200
   Bailor MH, 2007, NAT PROTOC, V2, P1536, DOI 10.1038/nprot.2007.221
   Bannwarth S, 2005, CURR HIV RES, V3, P61, DOI 10.2174/1570162052772924                                                        
   Ben-Asouli Y, 2000, NUCLEIC ACIDS RES, V28, P1011, DOI 10.1093/nar/28.4.1011                                                           
   Brodsky AS, 1997, J MOL BIOL, V267, P624, DOI 10.1006/jmbi.1996.0879
   BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724
   Casiano-Negroni A, 2007, BIOCHEMISTRY-US, V46, P6525, DOI 10.1021/bi700335n
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   CHANG YN, 1994, J VIROL, V68, P7008
   Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f                                                               
   CRITCHLEY AD, 1993, J MOL GRAPHICS, V11, P92, DOI 10.1016/0263-7855(93)87002-M                                                    
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   Dayie KT, 2002, J MOL BIOL, V317, P263, DOI 10.1006/jmbi.2001.5424
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5
   Edwards TE, 2003, BIOCHEM BIOPH RES CO, V303, P721, DOI 10.1016/S0006-291X(03)00411-X
   Edwards TE, 2002, BIOCHEMISTRY-US, V41, P14843, DOI 10.1021/bi026299a
   Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   Furtig B, 2003, CHEMBIOCHEM, V4, P936, DOI 10.1002/cbic.200300700
   Fushman D, 1999, J AM CHEM SOC, V121, P8577, DOI 10.1021/ja9904991                                                               
   Getz M, 2007, BIOPOLYMERS, V86, P384, DOI 10.1002/bip.20765
   GETZ MM, 2006, RNA, V13, P251
   Goddard T., 2004, SPARKY 3
   Hansen AL, 2006, J MAGN RESON, V179, P299, DOI 10.1016/j.jmr.2005.12.012
   Hansen AL, 2007, J AM CHEM SOC, V129, P16072, DOI 10.1021/ja0757982
   Hansen MR, 2000, METHOD ENZYMOL, V317, P220
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695                                                        
   Huthoff H, 2004, RNA, V10, P412, DOI 10.1261/rna.5161304
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593                                                          
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kanevsky I, 2005, J MOL BIOL, V348, P1059, DOI 10.1016/j.jmb.2005.03.046
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Kim I, 2006, J MOL BIOL, V358, P430, DOI 10.1016/j.jmb.2006.01.099
   Kulinski T, 2003, J BIOL CHEM, V278, P38892, DOI 10.1074/jbc.M301939200
   Lebars I, 2007, NUCLEIC ACIDS RES, V35, P6103, DOI 10.1093/nar/gkm655
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Litovchick A, 2000, BIOCHEMISTRY-US, V39, P2838, DOI 10.1021/bi9917885
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   MacKerell Alexander D. Jr., 2000, Biopolymers, V56, P257, DOI 10.1002/1097-0282(2000)56:4<257::AID-BIP10029>3.0.CO;2-W
   Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822
   Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u                                                               
   Meissner A, 1999, J MAGN RESON, V139, P439, DOI 10.1006/jmre.1999.1788
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9                                                    
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   Musselman C, 2007, BIOPHYS J, V93, P411, DOI 10.1529/biophysj.107.104620
   Musselman C, 2006, J BIOMOL NMR, V36, P235, DOI 10.1007/s10858-006-9087-9
   NEIDLE S, 1999, OXFORD HDB NUCL ACID
   Nifosi R, 2000, NUCLEIC ACIDS RES, V28, P4944, DOI 10.1093/nar/28.24.4944
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334                                                                
   Olsen GL, 2008, J AM CHEM SOC, V130, P2896, DOI 10.1021/ja0778803
   Palmer AG, 2006, CHEM REV, V106, P1700, DOI 10.1021/cr0404287
   Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0
   Pitt SW, 2005, ANGEW CHEM INT EDIT, V44, P3412, DOI 10.1002/anie.200500075
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Raghunathan D, 2006, NUCLEIC ACIDS RES, V34, P3599, DOI 10.1093/nar/gkl494
   Richter S, 2002, P NATL ACAD SCI USA, V99, P7928, DOI 10.1073/pnas.122119999
   Richter S, 2002, BIOCHEMISTRY-US, V41, P6391, DOI 10.1021/bi0159579
   Rueda D, 2004, P NATL ACAD SCI USA, V101, P10066, DOI 10.1073/pnas.0403575101
   SKLENAR V, 1993, J BIOMOL NMR, V3, P721, DOI 10.1007/BF00198375
   Song R, 2008, BIOCHEMISTRY-US, V47, P3283, DOI 10.1021/bi7023173
   Tinsley RA, 2007, BIOL CHEM, V388, P705, DOI 10.1515/BC.2007.088
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
   Wohnert J, 2003, J BIOMOL NMR, V26, P79, DOI 10.1023/A:1023040520291
   ZACHARIAS M, 1995, J MOL BIOL, V247, P486, DOI 10.1006/jmbi.1995.0155
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
NR 79
TC 41
Z9 41
U1 2
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD OCT 15
PY 2008
VL 95
IS 8
BP 3906
EP 3915
DI 10.1529/biophysj.108.140285
PG 10
WC Biophysics
SC Biophysics
GA 352NM
UT WOS:000259503900033
PM 18621815
OA gold
DA 2018-01-05
ER

PT J
AU Landovitz, RJ
   Angel, JB
   Hoffmann, C
   Horst, H
   Opravil, M
   Long, J
   Greaves, W
   Fatkenheuer, G
AF Landovitz, Raphael J.
   Angel, Jonathan B.
   Hoffmann, Christian
   Horst, Heinz
   Opravil, Milos
   Long, Jianmin
   Greaves, Wayne
   Faetkenheuer, Gerd
TI Phase II study of vicriviroc versus efavirenz (both with
   zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 13th Conference on Retroviruses and Opportunistic Infections
CY FEB 05-09, 2006
CL Denver, CO
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE;
   ANTIRETROVIRAL-DRUG-RESISTANCE; MYOCARDIAL-INFARCTION; DISEASE
   PROGRESSION; PROGNOSTIC VALUE; CCR5 ANTAGONIST; AIDS; EPIDEMIOLOGY;
   INDIVIDUALS
AB Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We report the results of a phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatment-naive HIV-1-infected subjects.
   Methods. This study was a randomized, double-blind, placebo-controlled trial that began with a 14-day comparison of 3 dosages of VCV with placebo in treatment-naive subjects infected with CCR5-using HIV-1. After 14 days of monotherapy, lamivudine/zidovudine was added to the VCV arms; subjects receiving placebo were treated with efavirenz and lamivudine/zidovudine; the planned treatment duration was 48 weeks.
   Results. Ninety-two subjects enrolled. After 14 days of once-daily monotherapy, the mean viral loads decreased from baseline values by 0.07 log(10) copies/mL in the placebo arm, 0.93 log(10) copies/mL in the VCV 25 mg arm, 1.18 log(10) copies/mL in the VCV 50 mg arm, and 1.34 log(10) copies/mL in the VCV 75 mg arm (P <.001 for each VCV arm vs. the placebo arm). The combination-therapy portion of the study was stopped because of increased rates of virologic failure in the VCV 25 mg/day arm (relative hazard [RH], 21.6; 95% confidence interval [CI], 2.8-168.9) and the VCV 50 mg/day arm (RH, 11.7; 95% CI, 1.5-92.9), compared with that in the control arm.
   Conclusions. VCV administered with dual NRTIs in treatment-naive subjects with HIV-1 infection had increased rates of virologic failure, compared with efavirenz plus dual NRTIs. No treatment-limiting toxicity was observed. Study of higher doses of VCV as part of combination therapy is warranted.
C1 [Landovitz, Raphael J.; Long, Jianmin; Greaves, Wayne] Schering Plough Res Inst, Kenilworth, NJ USA.
   [Angel, Jonathan B.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [Hoffmann, Christian; Horst, Heinz] Univ Schleswig Holstein, Dept Med 2, Kiel, Germany.
   [Faetkenheuer, Gerd] Univ Cologne, Dept Internal Med 1, Cologne, Germany.
   [Opravil, Milos] Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland.
RP Landovitz, RJ (reprint author), 9911 W Pico Blvd Ste 980, Los Angeles, CA 90035 USA.
EM rlandovitz@mednet.ucla.edu
RI Infektiologie, USZ/A-6921-2011
OI Landovitz, Raphael/0000-0002-1442-714X
CR Autar RS, 2007, ANTIVIR THER, V12, P1265
   Azevedo-Pereira JM, 2003, VIROLOGY, V313, P136, DOI 10.1016/S0042-6822(03)00343-X
   Broder CC, 1999, HUMAN RETROVIRUSES A, P517
   Brumme ZL, 2005, J INFECT DIS, V192, P466, DOI 10.1086/431519                                                                  
   Calza L, 2004, METAB SYNDR RELAT D, V2, P241, DOI 10.1089/met.2004.2.241
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   DEMAREST J, 2004, 44 INT C ANT AG CHEM
   Dunkle L, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-S1-S12
   Gulick RM, 2007, J INFECT DIS, V196, P304, DOI 10.1086/518797
   Hansen BR, 2004, SCAND J INFECT DIS, V36, P244, DOI 10.1080/00365540410019381
   HOLUIGUE S, 2007, 14 C RETR OPP INF LO
   HUANG Y, 1997, NAT MED, V3, P252
   Ketas TJ, 2007, VIROLOGY, V364, P281, DOI 10.1016/j.virol.2007.02.022
   KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004
   Koot M, 1999, J INFECT DIS, V179, P254, DOI 10.1086/314539
   KOZAL MJ, 1994, ANN INTERN MED, V120, P811, DOI 10.7326/0003-4819-120-9-199405010-00019
   Little SJ, 2006, ANTIVIR THER, V11, pS110
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   MAYER H, 2006, 16 INT AIDS C TOR CA
   Mosley M, 2006, 13 C RETR OPP INF DE
   Moyle GJ, 2005, J INFECT DIS, V191, P866, DOI 10.1086/428096                                                                  
   Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786
   Polesel J, 2008, AIDS, V22, P301, DOI 10.1097/QAD.0b013e3282f2705d                                                    
   Pugach P, 2007, VIROLOGY, V361, P212, DOI 10.1016/j.virol.2006.11.004
   RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968                                                        
   Sabin CA, 2008, LANCET, V371, P1417
   SAMSON M, 1996, NATURE, V382, P668
   Schurmann D, 2007, AIDS, V21, P1293
   Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x                                                
   Stein JH, 2008, LANCET, V371, P1391, DOI 10.1016/S0140-6736(08)60491-2
   Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005
   TSIBRIS A, 2007, 14 C RETR OPP INF LO
   Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789
   Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916
   Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06
   Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06
   Yi YJ, 2001, VIROLOGY, V284, P142, DOI 10.1006/viro.2001.0904
   ZINGMAN B, 2008, 15 C RETR OPP INF BO
NR 39
TC 52
Z9 53
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 15
PY 2008
VL 198
IS 8
BP 1113
EP 1122
DI 10.1086/592052
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 358BQ
UT WOS:000259891800005
PM 18783318
OA gold
DA 2018-01-05
ER

PT J
AU Munier, S
   Xu, W
   Durand, PY
   Lamalle-Bernard, D
   Delair, T
   Verrier, B
AF Munier, S.
   Xu, W.
   Durand, P. Y.
   Lamalle-Bernard, D.
   Delair, T.
   Verrier, B.
TI Combination of rMVA and Poly (D, L-lactide) Acid (PLA) Nanoparticles
   Immunization Induces High Levels of Both Systemic and Mucosal HIV Immune
   Responses
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Munier, S.; Xu, W.; Durand, P. Y.; Lamalle-Bernard, D.; Delair, T.; Verrier, B.] CNRS, Lyon, Rhone, France.
RI Delair, Thierry/E-7896-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 86
EP 86
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800215
DA 2018-01-05
ER

PT J
AU Arias, MA
   Loxley, A
   Fairhurst, D
   Eatmon, C
   Kim, Y
   Wegmann, F
   Mitchnick, M
   Shattock, R
AF Arias, M. A.
   Loxley, A.
   Fairhurst, D.
   Eatmon, C.
   Kim, Y.
   Wegmann, F.
   Mitchnick, M.
   Shattock, R.
TI HIV-gp140 Antigen-Adsorbed Wax Nanoparticles Induce Strong In Vivo
   Systemic and Mucosal Humoral Immune Responses
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT AIDS Vaccine 2008 Conference
CY OCT 13-16, 2008
CL Cape Town, SOUTH AFRICA
SP NIAID, Div AIDS, NIH, Div AIDS
C1 [Arias, M. A.; Shattock, R.] St Georges Univ London, London, England.
   [Loxley, A.; Fairhurst, D.; Eatmon, C.; Kim, Y.; Mitchnick, M.] Particle Sci Inc, Bethesda, PA USA.
   [Wegmann, F.] Univ Oxford, Oxford, Oxon, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2008
VL 24
BP 91
EP 91
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 367CT
UT WOS:000260530800228
DA 2018-01-05
ER

PT J
AU Haller, C
   Fackler, OT
AF Haller, Claudia
   Fackler, Oliver T.
TI HIV-1 at the immunological and T-lymphocytic virological synapse
SO BIOLOGICAL CHEMISTRY
LA English
DT Article
DE human immunodeficiency virus type 1 (HIV-1); human T-cell leukemia virus
   type 1 (HTLV-1); immunological synapse; Nef; T-cell receptor (TCR);
   virological synapse
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ALDRICH-SYNDROME PROTEIN; RECEPTOR
   SIGNAL-TRANSDUCTION; DENDRITIC CELLS; MEMBRANE NANOTUBES; ACTIN
   CYTOSKELETON; SECRETORY GRANULES; LYMPHOTROPIC-VIRUS; ANTIGEN RECEPTOR;
   ACTIVATION
AB Cell-cell transmission of human immunodeficiency virus type 1 (HIV-1) is considered the most effective mode of viral spread in T-lymphocyte cultures. Evidence has accumulated that HIV-1 assembles polarized synapticlike structures, referred to as virological synapses, as specialized sites of viral transfer. Interestingly, it was recently also discovered that HIV-1 impairs the formation of the structurally similar immunological synapse, thereby modulating exogenous T-lymphocyte stimulation to yield an optimal activation state for productive HIV-1 infection. The careful dissection of these opposing effects will contribute to our understanding of retroviral spread and cellular signal transduction machineries.
C1 [Haller, Claudia; Fackler, Oliver T.] Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany.
RP Fackler, OT (reprint author), Univ Heidelberg, Dept Virol, INF 324, D-69120 Heidelberg, Germany.
EM oliver.fackler@med.uni-heidelberg.de
FU Deutsche Forschungs-gemeinschaft [SPP1150, SFB638]
FX We are grateful to Maik Lehman for critical reading of the manuscript.
   Our research is supported by the Deutsche Forschungs-gemeinschaft
   (grants to O.T.F. within SPP1 150 and SFB638).
CR Alfsen A, 2005, MOL BIOL CELL, V16, P4267, DOI 10.1091/mbc.E05-03-0192
   Badour K, 2004, SEMIN IMMUNOL, V16, P395, DOI 10.1016/j.smim.2004.08.019
   Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2                                                   
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143
   Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850
   Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021
   Blanchard N, 2002, IMMUNITY, V17, P389, DOI 10.1016/S1074-7613(02)00421-1
   Blanco J, 2004, J BIOL CHEM, V279, P51305, DOI 10.1074/jbc.M408547200
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913
   Carr JM, 1999, VIROLOGY, V265, P319, DOI 10.1006/viro.1999.0047                                                          
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Cho NH, 2004, J EXP MED, V200, P681, DOI 10.1084/jem.20040924
   Choi J, 2005, J VIROL, V79, P264, DOI 10.1128/JVI.79.1.264-276.2004
   Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2                                                   
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Dustin ML, 2002, SCIENCE, V298, P785, DOI 10.1126/science.1076386
   Fackler OT, 2007, NAT REV IMMUNOL, V7, P310, DOI 10.1038/nri2041
   Fackler OT, 2006, VIROLOGY, V351, P322, DOI 10.1016/j.virol.2006.03.044
   Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2                                                   
   Fackler OT, 2001, CURR BIOL, V11, P1294, DOI 10.1016/S0960-9822(01)00373-6
   Fenard D, 2005, J IMMUNOL, V175, P6050, DOI 10.4049/jimmunol.175.9.6050                                                     
   Friedl P, 2005, NAT REV IMMUNOL, V5, P532, DOI 10.1038/nri1647
   Fukumoto R, 2007, J VIROL, V81, P9088, DOI 10.1128/JVI.02703-06
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Glushakova S, 1999, J VIROL, V73, P3968
   Gordon-Alonso M, 2006, J IMMUNOL, V177, P5129, DOI 10.4049/jimmunol.177.8.5129                                                     
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Haller C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001212
   Haller C, 2006, J BIOL CHEM, V281, P19618, DOI 10.1074/jbc.M513802200
   Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X
   Jolly C, 2007, TRENDS IMMUNOL, V28, P474, DOI 10.1016/j.it.2007.08.008
   Jolly C, 2007, J VIROL, V81, P13916, DOI 10.1128/JVI.01585-07
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jolly C, 2007, J VIROL, V81, P5547, DOI 10.1128/JVI.01469-06
   Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Lekkerkerker AN, 2006, CURR HIV RES, V4, P169, DOI 10.2174/157016206776055020
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Messmer D, 2000, J VIROL, V74, P2406, DOI 10.1128/JVI.74.5.2406-2413.2000                                                 
   Miranda LR, 2002, P NATL ACAD SCI USA, V99, P8031, DOI 10.1073/pnas.122696599
   Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200
   Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036
   NORCROSS MA, 1984, ANN INST PASTEUR IMM, VD135, P113, DOI 10.1016/S0769-2625(84)81105-8
   Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984
   Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812
   POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045
   POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9
   Roeth JF, 2006, MICROBIOL MOL BIOL R, V70, P548, DOI 10.1128/MMBR.00042-05
   Saito T, 2006, CURR OPIN IMMUNOL, V18, P305, DOI 10.1016/j.coi.2006.03.014
   Sancho D, 2002, IMMUNOL REV, V189, P84, DOI 10.1034/j.1600-065X.2002.18908.x
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Sechi AS, 2004, TRENDS IMMUNOL, V25, P257, DOI 10.1016/j.it.2004.03.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.embroj.7601509
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071
   Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5                                                   
   Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016
   Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010
   von Essen M, 2004, J IMMUNOL, V173, P384, DOI 10.4049/jimmunol.173.1.384                                                      
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272
   Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329                                                          
   Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353
   Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024
NR 76
TC 35
Z9 35
U1 0
U2 2
PU WALTER DE GRUYTER & CO
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
J9 BIOL CHEM
JI Biol. Chem.
PD OCT
PY 2008
VL 389
IS 10
BP 1253
EP 1260
DI 10.1515/BC.2008.143
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 359EL
UT WOS:000259969100002
PM 18713012
DA 2018-01-05
ER

PT J
AU Gaczynska, M
   Osmulski, PA
AF Gaczynska, Maria
   Osmulski, Pawel A.
TI AFM of biological complexes: What can we learn?
SO CURRENT OPINION IN COLLOID & INTERFACE SCIENCE
LA English
DT Review
DE atomic force microscopy; protein complexes; protein structure;
   allostery; proteasome; GroEL; amyloid; nanomedicine
ID ATOMIC-FORCE MICROSCOPY; VON-WILLEBRAND-FACTOR; MURINE LEUKEMIA-VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; TOBACCO-MOSAIC-VIRUS; SUPPORTED
   LIPID-BILAYERS; 20 S PROTEASOME; AMYLOID FIBRILS; HIGH-RESOLUTION;
   AQUEOUS CONDITIONS
AB The term "biological complexes" broadly encompasses particles as diverse as multisubunit enzymes, viral capsids, transport cages, molecular nets, ribosomes, nucleosomes, biological membrane components and amyloids. The complexes represent a broad range of stability and composition. Atomic force microscopy offers a wealth of structural and functional data about such assemblies. For this review, we choose to comment on the significance of AFM to study various aspects of biology of selected non-membrane protein assemblies. Such particles are large enough to reveal many structural details under the AFM probe. Importantly, the specific advantages of the method allow for gathering dynamic information about their formation, stability or allosteric structural changes critical for their function. Some of them have already found their way to nanomedical or nanotechnological applications. Here we present examples of studies where the AFM provided pioneering information about the biology of complexes, and examples of studies where the simplicity of the method is used toward the development of potential diagnostic applications. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Gaczynska, Maria; Osmulski, Pawel A.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.
RP Gaczynska, M (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM Gaczynska@uthscsa.edu
OI Osmulski, Pawel/0000-0002-5359-9200
FU NIGMS NIH HHS [R01 GM069819-05, R01 GM069819]
CR Abdelhady HG, 2005, NANOTECHNOLOGY, V16, P966, DOI 10.1088/0957-4484/16/6/058
   Agnihotri A, 2004, LANGMUIR, V20, P8846, DOI 10.1021/la049239
   Aso Y, 2007, BIOSCI BIOTECH BIOCH, V71, P1313, DOI 10.1271/bbb.60718
   AXFORD DN, 2007, NANOTECHNOLOGY, P18
   BAI Z, 2004, T 7 WORLD BIOM C, P1740
   Barg A, 2007, THROMB HAEMOSTASIS, V97, P514, DOI 10.1160/TH06-05-0274
   Barkhordarian H, 2006, PROTEIN ENG DES SEL, V19, P497, DOI 10.1093/protein/gzl036
   Berglin M, 2004, BIOMATERIALS, V25, P4581, DOI 10.1016/j.biomaterials.2003.11.050
   Blinc A, 2000, FIBRINOLYSIS PROTEOL, V14, P288, DOI 10.1054/fipr.2000.0085
   BLINC A, 1998, FIBRINOLYSIS PROTEOL, V12, P26
   BonHomme M, 2003, BIOPHYS CHEM, V105, P67, DOI 10.1016/S0301-4622(03)00063-2
   Boukari A, 2006, J BIOMED MATER RES A, V78A, P466, DOI 10.1002/jbm.a.30778
   Bremmell KE, 2006, LANGMUIR, V22, P313, DOI 10.1021/la052143a
   Cacciafesta P, 2001, SURF SCI, V491, P405, DOI 10.1016/S0039-6028(01)01303-6                                                   
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Caruso F, 1997, J COLLOID INTERF SCI, V186, P129, DOI 10.1006/jcis.1996.4625                                                          
   Chamberlain AK, 2000, BIOPHYS J, V79, P3282, DOI 10.1016/S0006-3495(00)76560-X                                                   
   Chen X, 1997, LANGMUIR, V13, P4106, DOI 10.1021/la970172i                                                               
   CHOI SH, 2005, P SPIE INT SOC OPT E, P213
   Chu SH, 2004, P SOC PHOTO-OPT INS, V5389, P443, DOI 10.1117/12.539239
   Conti M, 2002, J BIOMED MATER RES, V61, P370, DOI 10.1002/jbm.10168
   Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571
   Dahlgren PR, 2005, NANOMED-NANOTECHNOL, V1, P52, DOI 10.1016/j.nano.2004.11.004
   Dickert FL, 2004, ANAL BIOANAL CHEM, V378, P1929, DOI 10.1007/s00216-004-2521-5
   Dorn IT, 1999, J MOL BIOL, V288, P1027, DOI 10.1006/jmbi.1999.2714
   DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794                                                         
   Driskell JD, 2005, ANAL CHEM, V77, P6147, DOI 10.1021/ac0504159
   Du XZ, 2005, BIOSENS BIOELECTRON, V20, P2053, DOI 10.1016/j.bios.2004.08.044
   Dubrovin EV, 2004, COLLOID J+, V66, P673, DOI 10.1007/s10595-005-0048-x                                                       
   Dubrovin EV, 2007, NANOMED-NANOTECHNOL, V3, P128, DOI 10.1016/j.nano.2007.01.005
   Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105
   Emadi S, 2007, J MOL BIOL, V368, P1132, DOI 10.1016/j.jmb.2007.02.089
   Epand RF, 2001, BBA-BIOMEMBRANES, V1513, P167, DOI 10.1016/S0005-2736(01)00350-9
   Evans-Nguyen KM, 2006, LANGMUIR, V22, P5115, DOI 10.1021/la053070y
   Fotiadis D, 2002, MICRON, V33, P385, DOI 10.1016/S0968-4328(01)00026-9
   Francois P, 1996, BIOMATERIALS, V17, P667, DOI 10.1016/0142-9612(96)86736-6
   Fritzsche W, 1998, J MICROSC-OXFORD, V189, P50
   FRITZSCHE W, 1997, PROBE MICROSC, V1, P81
   Furuike S, 2003, BBA-BIOMEMBRANES, V1615, P1, DOI 10.1016/S0005-2736(03)00227-X
   Gaczynska M, 2004, P NATL ACAD SCI USA, V101, P17952, DOI 10.1073/pnas.0408369102
   Gaczynska M, 2003, BIOCHEMISTRY-US, V42, P8663, DOI 10.1021/bi034784f
   Gaczynska M, 2006, EXPERT REV PROTEOMIC, V3, P115, DOI 10.1586/14789450.3.1.115
   Gaczynska Maria, 2005, V301, P3
   Gergely C, 2000, P NATL ACAD SCI USA, V97, P10802, DOI 10.1073/pnas.180293097
   Gibbons MM, 2007, J MATER SCI, V42, P8995, DOI 10.1007/s10853-007-1741-4
   Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299
   Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040
   Green J, 2003, J MOL BIOL, V326, P1147, DOI 10.1016/S0022-2836(02)01377-3
   Green JD, 2004, J MOL BIOL, V342, P877, DOI 10.1016/j.jmb.2004.07.052
   Green JD, 2004, J BIOL CHEM, V279, P12206, DOI 10.1074/jbc.M312452200
   Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992                                                                   
   Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0                                                                
   Grudzielanek S, 2005, J MOL BIOL, V351, P879, DOI 10.1016/j.jmb.2005.06.046
   Grudzielanek S, 2007, J MOL BIOL, V370, P372, DOI 10.1016/j.jmb.2007.04.053
   Gunasekaran K, 2004, PROTEINS, V57, P433, DOI 10.1002/prot.20232
   HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795                                                                
   Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149
   Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3
   Hayama M, 2004, BIOMATERIALS, V25, P1019, DOI 10.1016/S0142-9612(03)00629-X
   Hemmerle J, 1999, P NATL ACAD SCI USA, V96, P6705, DOI 10.1073/pnas.96.12.6705
   Henderson Eric, 2007, Nanomedicine (Lond), V2, P391, DOI 10.2217/17435889.2.3.391
   Horwich AL, 2006, CHEM REV, V106, P1917, DOI 10.1021/cr040435v
   Huff JL, 2004, J BIOMOL SCREEN, V9, P491, DOI 10.1177/1087057104268803
   Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   James A, 2003, LANCET, V361, P8, DOI 10.1016/S0140-6736(03)12184-8                                                   
   Jansen R, 2005, BIOPHYS J, V88, P1344, DOI 10.1529/biophysj.104.048843
   Jansen R, 2004, J MOL BIOL, V338, P203, DOI 10.1016/j.jmb.2004.02.056
   Jin AJ, 2006, BIOPHYS J, V90, P3333, DOI 10.1529/biophysj.105.068742
   Jo E, 2004, EUR J BIOCHEM, V271, P3180, DOI 10.1111/j.1432-1033.2004.04250.x
   Johnson JC, 2004, J BIOCHEM BIOPH METH, V59, P167, DOI 10.1016/j.jbbm.2003.12.007
   Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7
   Kajava AV, 2002, J BIOL CHEM, V277, P49791, DOI 10.1074/jbc.M204982200
   Kang I, 2007, THROMB RES, V119, P731, DOI 10.1016/j.thromres.2006.06.010
   Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0
   Kim HS, 2006, PROTEOMICS, V6, P6426, DOI 10.1002/pmic.200600432
   KIM YH, 2004, T 7 WORLD BIOM C, P1665
   Knez M, 2004, LANGMUIR, V20, P441, DOI 10.1021/la035425o
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091
   Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688
   Kuznetsov YG, 2005, J STRUCT BIOL, V149, P256, DOI 10.1016/j.jsb.2004.10.007
   Kuznetsov YG, 2005, J VIROL, V79, P1970, DOI 10.1128/JVI.79.3.1970-1974.2005
   Kuznetsov YG, 2004, SCANNING, V26, P209
   Kuznetsov YG, 2004, VIROLOGY, V323, P189, DOI 10.1016/j.virol.2004.02.023
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Kuznetsov YG, 2002, BIOPHYS J, V83, P3665, DOI 10.1016/S0006-3495(02)75366-6                                                   
   Kuznetsov YG, 2001, J GEN VIROL, V82, P2025, DOI 10.1099/0022-1317-82-9-2025                                                     
   Kuznetsov YG, 2007, VIROLOGY, V360, P434, DOI 10.1016/j.virol.2006.10.015
   Kuznetsov YG, 2006, VIROLOGY, V352, P329, DOI 10.1016/j.virol.2006.04.008
   Lord ST, 2007, CURR OPIN HEMATOL, V14, P236, DOI 10.1097/MOH.0b013e3280dce58c                                                    
   Low A, 2007, J VIROL, V81, P3685, DOI 10.1128/JVI.01538-06
   LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097
   Maeda H, 1997, LANGMUIR, V13, P4150, DOI 10.1021/la962105e                                                               
   Makino DL, 2005, ACTA CRYSTALLOGR D, V61, P173, DOI 10.1107/S090744490403077X
   MALKIN AJ, 1995, NAT STRUCT BIOL, V2, P956, DOI 10.1038/nsb1195-956
   Malyuchenko N. V., 2006, Biophysics, V51, P385, DOI 10.1134/S0006350906030080
   Marchant RE, 2002, CURR PROTEIN PEPT SC, V3, P249, DOI 10.2174/1389203023380611
   Marchant RE, 1997, THROMB HAEMOSTASIS, V77, P1048
   Marchin KL, 2003, LANGMUIR, V19, P9883, DOI 10.1021/la035127r
   Matsuura T, 2006, BIOSCI BIOTECH BIOCH, V70, P300, DOI 10.1271/bbb.70.300                                                              
   Mauro M, 2007, J MOL BIOL, V366, P258, DOI 10.1016/j.jmb.2006.11.008
   McAllister C, 2005, J MOL BIOL, V354, P1028, DOI 10.1016/j.jmb.2005.10.012
   McPherson A, 2004, J SYNCHROTRON RADIAT, V11, P21, DOI 10.1107/S0909049503023914
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Mikamo E, 2005, J STRUCT BIOL, V151, P106, DOI 10.1016/j.jsb.2005.05.002
   Mitsakakis K, 2007, BIOMOL ENG, V24, P119, DOI 10.1016/j.bioeng.2006.05.013
   Mollica V, 2001, EUR BIOPHYS J BIOPHY, V30, P313, DOI 10.1007/s002490100165
   Moloney M, 2002, ULTRAMICROSCOPY, V91, P275, DOI 10.1016/S0304-3991(02)00109-2
   MORENOHERRERO F, 2004, PHYS REV E, P69
   Mou JX, 1996, BIOPHYS J, V71, P2213, DOI 10.1016/S0006-3495(96)79422-5                                                   
   Mou JX, 1996, FEBS LETT, V381, P161, DOI 10.1016/0014-5793(96)00112-3                                                    
   Muller DJ, 1997, EMBO J, V16, P2547, DOI 10.1093/emboj/16.10.2547
   Negishi A, 2004, GLYCOBIOLOGY, V14, P969, DOI 10.1093/glycob/cwh118
   Nettikadan SR, 2004, NANOTECHNOLOGY, V15, P383, DOI 10.1088/0957-4484/15/3/027
   Nettikadan SR, 2003, BIOCHEM BIOPH RES CO, V311, P540, DOI 10.1016/j.bbrc.2003.10.022
   Novak L, 2002, BLOOD, V99, P2070, DOI 10.1182/blood.V99.6.2070
   OHNISHI S, 1992, BIOPHYS J, V63, P1425, DOI 10.1016/S0006-3495(92)81719-8                                                   
   OHNISHI S, 1993, BIOPHYS J, V65, P573, DOI 10.1016/S0006-3495(93)81125-1                                                   
   Osmulski PA, 2005, METHOD ENZYMOL, V398, P414, DOI 10.1016/S0076-6879(05)98034-8
   Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130
   Osmulski PK, 2000, J BIOL CHEM, V275, P13171, DOI 10.1074/jbc.C901035199
   Peremyslov VV, 2004, P NATL ACAD SCI USA, V101, P5030, DOI 10.1073/pnas.0400303101
   Perrin A, 1998, COLLOID SURFACE B, V11, P103, DOI 10.1016/S0927-7765(98)00020-4
   Plomp M, 2002, AM J PATHOL, V160, P1959, DOI 10.1016/S0002-9440(10)61145-5
   Podesta A, 2006, BIOPHYS J, V90, P589, DOI 10.1529/biophysj.105.068833
   Radke KM, 2004, ANAL BIOCHEM, V330, P350, DOI 10.1016/j.ab.2004.03.037
   RADMACHER M, 1994, BIOPHYS J, V66, P2159, DOI 10.1016/S0006-3495(94)81011-2                                                   
   Raghavachari M, 2000, COLLOID SURFACE B, V19, P315, DOI 10.1016/S0927-7765(00)00140-5                                                   
   Rauscher S, 2006, STRUCTURE, V14, P1667, DOI 10.1016/j.str.2006.09.008
   Relini A, 2006, J BIOL CHEM, V281, P16521, DOI 10.1074/jbc.M51387200
   Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687
   Savage B, 2002, P NATL ACAD SCI USA, V99, P425, DOI 10.1073/pnas.012459599
   Schmatulla A, 2007, J MICROSC-OXFORD, V225, P264, DOI 10.1111/j.1365-2818.2007.01741.x
   Sedman VL, 2005, PROTEIN PEPTIDE LETT, V12, P79, DOI 10.2174/0929866053406129
   SHEPHERD CM, 2006, NUCLEIC ACIDS RES, P34
   Siedlecki CA, 1996, BLOOD, V88, P2939
   SIEDLECKI CA, 2006, MICROSC MICROANAL, V12, P34
   Sit PS, 1999, THROMB HAEMOSTASIS, V82, P1053
   Sit PS, 2001, SURF SCI, V491, P421, DOI 10.1016/S0039-6028(01)01308-5
   Smith JF, 2006, P NATL ACAD SCI USA, V103, P15806, DOI 10.1073/pnas.0604035103
   Soldi G, 2005, BIOPHYS J, V89, P4234, DOI 10.1529/biophysj.105.067538
   Sprangers R, 2007, NATURE, V445, P618, DOI 10.1038/nature05512
   Stroh C, 2004, P NATL ACAD SCI USA, V101, P12503, DOI 10.1073/pnas.0403538101
   Suci PA, 2005, LANGMUIR, V21, P8686, DOI 10.1021/la050217c
   Taatjes DJ, 1997, CELL BIOL INT, V21, P715, DOI 10.1006/cbir.1997.0216                                                          
   Tan XL, 2006, CURR MED CHEM, V13, P155, DOI 10.2174/092986706775197926                                                      
   Thess A, 2002, J BIOL CHEM, V277, P36321, DOI 10.1074/jbc.M202145200
   Tinazli A, 2007, NAT NANOTECHNOL, V2, P220, DOI 10.1038/nnano.2007.63
   Tominaga M, 2005, J ELECTROANAL CHEM, V579, P51, DOI 10.1016/j.jelechem.2005.01.024
   Torrance L, 2006, J MOL BIOL, V357, P1, DOI 10.1016/j.jmb.2005.12.021
   Trindade GS, 2007, J VIROL METHODS, V141, P198, DOI 10.1016/j.jviromet.2006.12.006
   Tsapikouni TS, 2007, COLLOID SURFACE B, V57, P89, DOI 10.1016/j.colsurfb.2007.01.011
   Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7
   Valle F, 2002, ULTRAMICROSCOPY, V93, P83, DOI 10.1016/S0304-3991(02)00149-3
   Valle F, 2001, J MICROSC-OXFORD, V203, P195, DOI 10.1046/j.1365-2818.2001.00891.x
   Vega RA, 2006, CHEMBIOCHEM, V7, P1653, DOI 10.1002/cbic.200600271
   Venkataraman S, 2006, ULTRAMICROSCOPY, V106, P829, DOI 10.1016/j.ultramic.2006.01.014
   Viani MB, 2000, NAT STRUCT BIOL, V7, P644, DOI 10.1038/77936
   Vinckier A, 1998, BIOPHYS J, V74, P3256, DOI 10.1016/S0006-3495(98)78032-4                                                   
   Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015                                               
   WAGNER P, 1994, FEBS LETT, V356, P267, DOI 10.1016/0014-5793(94)01296-2
   Wang H, 2007, ANAL BIOCHEM, V361, P273, DOI 10.1016/j.ab.2006.11.039
   WIGREN R, 1991, FEBS LETT, V280, P225, DOI 10.1016/0014-5793(91)80298-H
   WU X, 1997, PROG BIOCHEM BIOPHYS, V24, P434
   Wu XH, 1997, BIOL CHEM, V378, P363, DOI 10.1515/bchm.1997.378.5.363                                                     
   Xu DG, 2005, NANO LETT, V5, P571, DOI 10.1021/nl048218x
   Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061
   Yamashita I, 2001, THIN SOLID FILMS, V393, P12, DOI 10.1016/S0040-6090(01)01083-5                                                   
   Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0
   Yokota H, 1999, ANAL CHEM, V71, P4418, DOI 10.1021/ac9902695
   Yoshida T, 1997, J ELECTRON MICROSC, V46, P503, DOI 10.1093/oxfordjournals.jmicro.a023550                                           
   Young A, 2007, SEMIN CELL DEV BIOL, V18, P448, DOI 10.1016/j.semcdb.2007.07.006
   Zhou C, 2005, LANGMUIR, V21, P5988, DOI 10.1021/la0471590
   Zuber G, 2000, BIOPHYS J, V78, P373, DOI 10.1016/S0006-3495(00)76600-8                                                   
NR 176
TC 28
Z9 29
U1 1
U2 30
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1359-0294
J9 CURR OPIN COLLOID IN
JI Curr. Opin. Colloid Interface Sci.
PD OCT
PY 2008
VL 13
IS 5
BP 351
EP 367
DI 10.1016/j.cocis.2008.01.004
PG 17
WC Chemistry, Physical
SC Chemistry
GA 356AC
UT WOS:000259750100005
PM 19802337
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jin, YG
   Ai, P
   Xin, R
   Chen, DW
AF Jin, Yiguang
   Ai, Ping
   Xin, Rui
   Chen, Dawei
TI Morphological transformation of self-assembled nanostructures prepared
   from cholesteryl acyl didanosine and the optimal formulation of
   nanoparticulate systems: Effects of solvents, acyl chain length and
   poloxamer 188
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE bilayers; cholesteryl derivatives; didanosine; drug delivery;
   nanoribbons; nanotubes; poloxamer; tetrahydrofuran; self-assembly;
   vesicles
ID LIPID MONOLAYERS; LANGMUIR MONOLAYERS; TRIBLOCK COPOLYMERS;
   SURFACE-PROPERTIES; INTERFACE; LIPOSOMES; BEHAVIOR; STABILITY;
   MEMBRANES; INSERTION
AB Self-assembled nanostructures were obtained through injecting cholesteryl-succinyl didanosine (CSD) solutions in tetrahydrofuran (THF) into water. The incorporation of THF leads to CSD flexible bilayers. Spherical vesicles of CSD initially formed based on hydrophobic interaction and transformed to short nanotubes with THF leaving. A large proportion of THF led to formation of long flexible nanoribbons, also transforming to short nanotubes after removing THF because of rigid bilayers recovering. Cholesteryl-adipoyl didanosine (CAD) only formed spherical vesicles due to its long and flexible tails. A triblock copolymer, poloxamer 188 (P188) could insert into CSD monolayers at the air/water interface. P188 stabilized CSD nanoparticulate systems by incorporation and adsorption. The optimal formulation of nanoparticulate systems was identified and the appropriate ratio of CSD/P188 and CSD concentration in injected solutions were the keys. A highly concentrated system had a narrow size distribution, allowing heat sterilization at 100 degrees C, and resisting aggregation under high gravity accelerations in spite of the low zeta potential of -18.5 mV. A gel-liquid crystalline phase transition at 47 degrees C occurred. The system may become promising self-assembled drug delivery systems (SADDS) for anti-HIV therapy. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Jin, Yiguang; Ai, Ping; Xin, Rui] Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
   [Ai, Ping; Chen, Dawei] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China.
RP Jin, YG (reprint author), Beijing Inst Radiat Med, Dept Pharmaceut Chem, Beijing 100850, Peoples R China.
EM jin_yiguang@yahoo.com.cn
RI Jin, Yiguang/A-9306-2008; Jin, Yiguang/H-6742-2013
OI Jin, Yiguang/0000-0002-3528-1397
CR BARRY JA, 1994, BIOCHEMISTRY-US, V33, P8082, DOI 10.1021/bi00192a013
   BENITA S, 1993, J PHARM SCI, V82, P1069, DOI 10.1002/jps.2600821102
   Bergstrand N, 2004, J COLLOID INTERF SCI, V276, P400, DOI 10.1016/j.jcis.2004.03.013
   Castile JD, 1999, INT J PHARM, V188, P87, DOI 10.1016/S0378-5173(99)00207-0                                                   
   Cevc G, 1999, ADV DRUG DELIVER REV, V38, P207, DOI 10.1016/S0169-409X(99)00030-7
   Chen WJ, 2004, J COLLOID INTERF SCI, V278, P447, DOI 10.1016/j.jcis.2004.05.036
   Du N, 2008, COLLOID SURFACE A, V312, P104, DOI 10.1016/j.colsurfa.2007.06.030
   Firestone MA, 2005, BIOMACROMOLECULES, V6, P2678, DOI 10.1021/bm0500998
   Frey SL, 2007, LANGMUIR, V23, P2631, DOI 10.1021/la0626398
   Giulieri F, 2003, J COLLOID INTERF SCI, V258, P335, DOI 10.1016/S0021-9797(03)00016-X
   Goppert TM, 2005, EUR J PHARM BIOPHARM, V60, P361, DOI 10.1016/j.ejpb.2005.02.006
   Gordeliy VI, 1998, BIOPHYS J, V75, P2343, DOI 10.1016/S0006-3495(98)77678-7                                                   
   Gregoriadis G., 2007, LIPOSOME TECHNOLOGY
   Grindel JM, 2002, J PHARM SCI, V91, P1936, DOI 10.1002/jps.10190
   ITOJIMA Y, 1992, BIOCHEMISTRY-US, V31, P4757, DOI 10.1021/bi00135a003                                                             
   JIN Y, 2008, INT J PHARM, V305, P330
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Jin YG, 2005, COLLOID SURFACE B, V42, P45, DOI 10.1016/j.colsurfb.2005.02.001
   Jin YG, 2008, COLLOID SURFACE B, V64, P229, DOI 10.1016/j.colsurfb.2008.01.023
   Korchowiec B, 2006, CHEM PHYS LIPIDS, V144, P127, DOI 10.1016/j.chemphyslip.2006.08.005
   Kostarelos K, 1999, LANGMUIR, V15, P369, DOI 10.1021/la971052d                                                               
   LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018                                                             
   Lee KY, 1998, J CONTROL RELEASE, V51, P213, DOI 10.1016/S0168-3659(97)00173-9
   LI JT, 1994, LANGMUIR, V10, P4475, DOI 10.1021/la00024a016                                                             
   Li XX, 2004, LANGMUIR, V20, P8437, DOI 10.1021/la048886y
   Lourenco C, 1996, INT J PHARM, V138, P1, DOI 10.1016/0378-5173(96)04486-9
   Maskarinec SA, 2003, LANGMUIR, V19, P1809, DOI 10.1021/la026175z
   Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4                                                   
   Menger FM, 2002, P NATL ACAD SCI USA, V99, P4818, DOI 10.1073/pnas.062524299
   Mohanty A, 2007, LANGMUIR, V23, P1033, DOI 10.1021/la0625143
   Mozafari M. R., 2006, NANOCARRIER TECHNOLO
   New R. R. C., 1990, LIPOSOMES PRACTICAL
   PENCER J, 2001, BIOPHYS J, V81, P271
   Percec V, 2006, SCIENCE, V313, P55, DOI 10.1126/science.1129512
   Polidori A, 2005, CHEM PHYS LIPIDS, V136, P23, DOI 10.1016/j.chemphyslip.2005.03.006
   Sedev R, 2002, PHYSICA B, V315, P267, DOI 10.1016/S0921-4526(02)00513-6                                                   
   Sedev R, 1999, COLLOID SURFACE A, V156, P65, DOI 10.1016/S0927-7757(99)00014-X                                                   
   Singh M, 2004, LANGMUIR, V20, P9931, DOI 10.1021/la048967u
   Smeijers AF, 2006, J PHYS CHEM B, V110, P13212, DOI 10.1021/jp060824o
   Studart AR, 2007, LANGMUIR, V23, P1081, DOI 10.1021/la062042s
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   VIERL U, 1994, BIOPHYS J, V67, P1067, DOI 10.1016/S0006-3495(94)80572-7                                                   
   Weis M, 2006, APPL SURF SCI, V253, P2425, DOI 10.1016/j.apsusc.2006.04.053
   Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821
   Wu GH, 2005, BIOPHYS J, V89, P3159, DOI 10.1529/biophysj.104.052290
   Wydro P, 2007, J PHYS CHEM B, V111, P2495, DOI 10.1021/jp066950+
   Yan Y, 2007, J PHYS CHEM B, V111, P2225, DOI 10.1021/jp065235x
   Yang DB, 2006, DRUG DEV IND PHARM, V32, P219, DOI 10.1080/03639040500466270
   Zhang J. Z., 2004, SELF ASSEMBLED NANOS
NR 50
TC 12
Z9 13
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 1
PY 2008
VL 326
IS 1
BP 275
EP 282
DI 10.1016/j.jcis.2008.07.014
PG 8
WC Chemistry, Physical
SC Chemistry
GA 346EQ
UT WOS:000259051800038
PM 18672249
DA 2018-01-05
ER

PT J
AU Chattopadhyay, N
   Zastre, J
   Wong, HL
   Wu, XY
   Bendayan, R
AF Chattopadhyay, Niladri
   Zastre, Jason
   Wong, Ho-Lun
   Wu, Xiao Yu
   Bendayan, Reina
TI Solid lipid nanoparticles enhance the delivery of the HIV protease
   inhibitor, atazanavir, by a human brain endothelial cell line
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE atazanavir; drug delivery; hCMEC/D3 human brain microvessel endothelial
   cells; HIV-protease inhibitor; solid lipid nanoparticles
ID BREAST-CANCER CELLS; P-GLYCOPROTEIN; IN-VITRO; BODY DISTRIBUTION;
   NON-STEALTH; RAT-BRAIN; DOXORUBICIN; DRUG; SYSTEM; LOCALIZATION
AB Purpose. Protease inhibitors (PIs) exhibit low brain permeability. As a result, unchallenged HIV viral replication can lead to HIV-encephalitis and antiretroviral drug resistance. The objective of this study was to develop and evaluate a lipid nanoparticle system for enhanced brain delivery of the potent and frequently used HIV PI, atazanavir, using a well characterized human brain microvessel endothelial cell line (hCMEC/D3) representative of the blood-brain barrier.
   Methods. Solid lipid nanoparticles (SLNs) were prepared by a thin film hydration technique and analyzed for atazanavir encapsulation efficiency, particle size, morphology, zeta potential and drug release. Cell viability experiments demonstrate that SLNs exhibit no toxicity in hCMEC/D3 cells up to a concentration corresponding to 200 nM of atazanavir.
   Results. Spherical SLNs with an average particle size of similar to 167 nm were formulated. Delivery of [(3)H]-atazanavir by SLNs led to a significantly higher accumulation by the endothelial cell monolayer as compared to the drug aqueous solution. Furthermore, release of Rhodamine-123 (a fluorescent probe) by SLNs also resulted in a higher cellular accumulation.
   Conclusions. These data suggest that SLNs could be a promising drug delivery system to enhance brain uptake of atazanavir and potentially other PIs.
C1 [Chattopadhyay, Niladri; Zastre, Jason; Wong, Ho-Lun; Wu, Xiao Yu; Bendayan, Reina] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada.
RP Bendayan, R (reprint author), Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada.
EM r.bendayan@utoronto.ca
FU Ontario HIV Treatment Network
FX This research is supported by a grant from the Ontario HIV Treatment
   Network awarded to Dr. R. Bendayan. The authors thank Mr. K.
   Babakhanian, Mr. B. Calvieri and Mr. S. Doyle for technical assistance
   with fluorescence and electron microscopy imaging.
CR Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   AQUILANO D, 1993, THERMOCHIM ACTA, V230, P29, DOI 10.1016/0040-6031(93)80344-A                                                    
   Aweeka F, 1999, J ACQ IMMUN DEF SYND, V20, P39, DOI 10.1097/00042560-199901010-00006                                                
   Bargoni A, 1998, PHARMACEUT RES, V15, P745, DOI 10.1023/A:1011975120776
   BARKER AJ, 2005, J APPL PHYS, V98, P1
   Bendayan R, 2006, J HISTOCHEM CYTOCHEM, V54, P1159, DOI 10.1369/jhc.5A6870.2006
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Budavari S, 2001, MERCK INDEX ENCY CHE
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   DEISORMEAUX A, 2005, METHOD ENZYMOL, V391, P330
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GONG Y, 1998, 38 INT C ANT AG CHEM
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Hamdani J, 2002, INT J PHARM, V245, P167, DOI 10.1016/S0378-5173(02)00348-4                                                   
   Harivardhan R.L., 2005, J CONTROL RELEASE, V105, P185, DOI DOI 10.1016/J.JCONREL.2005.02.028
   HONG M, 2001, THESIS U TORONTO
   JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990
   Kim HR, 2007, CELL MOL LIFE SCI, V64, P356, DOI 10.1007/s00018-007-6390-x
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   KOMATSU H, 1995, CHEM PHARM BULL, V43, P1412
   Koziara JM, 2005, PHARM RES, V22, P1821, DOI 10.1007/s11095-005-7547-7
   Koziara JM, 2004, J CONTROL RELEASE, V99, P259, DOI 10.1016/j.jconrel.2004.07.006
   Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   LEE JS, 1994, MOL PHARMACOL, V46, P627
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Lockman PR, 2003, PHARMACEUT RES, V20, P705, DOI 10.1023/A:1023492015851
   Lucia MB, 2005, JAIDS-J ACQ IMM DEF, V39, P635
   MICHAEL D, 2004, TRIPLETT, V2
   Muller RH, 1997, PHARMACEUT RES, V14, P458, DOI 10.1023/A:1012043315093
   OLBRICH C, 2005, LIPOSPHERES DRUG TAR
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   Rabasseda X., 1999, Drugs of the Future, V24, P375, DOI 10.1358/dof.1999.024.04.489140
   Ronaldson PT, 2006, MOL PHARMACOL, V70, P1087, DOI 10.1124/mol.106.025973
   Schnyder Anita, 2005, NeuroRx, V2, P99, DOI 10.1007/BF03206646
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sparidans RW, 2006, BIOMED CHROMATOGR, V20, P72, DOI 10.1002/bmc.530
   Steiniger S., 1999, P INT S CONTR REL BI, V26, P789
   SUTANANTA W, 1995, J PHARM PHARMACOL, V47, P355, DOI 10.1111/j.2042-7158.1995.tb05810.x                                              
   SWINDELLS S, 2005, NEUROLOGY AIDS
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang JX, 2002, EUR J PHARM BIOPHARM, V54, P285, DOI 10.1016/S0939-6411(02)00083-8                                                   
   Wei M, 1999, J BIOMED MATER RES, V45, P11, DOI 10.1002/(SICI)1097-4636(199904)45:1<11::AID-JBM2>3.0.CO;2-7
   Wong HL, 2004, J PHARM SCI-US, V93, P1993, DOI 10.1002/jps.20100
   Wong HL, 2006, PHARM RES, V23, P1574, DOI 10.1007/s11095-006-0282-x
   Wong HL, 2006, J PHARMACOL EXP THER, V317, P1372, DOI 10.1124/jpet.106.101154
   Zara GP, 2002, J DRUG TARGET, V10, P327, DOI 10.1080/10611860290031868
   Gasco M. R., 1993, US Patent, Patent No. [005250236A, 005250236, 5,250,236, 5250236]
NR 56
TC 85
Z9 88
U1 0
U2 20
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2008
VL 25
IS 10
BP 2262
EP 2271
DI 10.1007/s11095-008-9615-2
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 348CE
UT WOS:000259187800007
PM 18516666
DA 2018-01-05
ER

PT J
AU Cantin, R
   Diou, J
   Belanger, D
   Tremblay, AM
   Gilbert, C
AF Cantin, Rejean
   Diou, Juliette
   Belanger, Dave
   Tremblay, Alexandre M.
   Gilbert, Caroline
TI Discrimination between exosomes and HIV-1: Purification of both vesicles
   from cell-free supernatants
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE exosomes; purification; HIV-1; acetylcholinesterase; primary cells
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; HUMAN T-CELLS;
   RECOMBINANT ADENOASSOCIATED VIRUS; INTESTINAL EPITHELIAL EXOSOMES;
   DIACYLGLYCEROL-KINASE-ALPHA; MATURE DENDRITIC CELLS; BEARING FAS LIGAND;
   HOST HLA-DR; RETICULOCYTE MATURATION
AB Although enveloped retroviruses bud from the cell surface of T lymphocytes, they use the endocytic pathway and the internal membrane of multivesicular bodies for their assembly and release from macrophages and dendritic cells (DCs). Exosomes, physiological nanoparticles produced by hematopoietic cells, egress from this same pathway and are similar to retroviruses in terms of size, density, the molecules they incorporate and their ability to activate immune cells. Retroviruses are therefore likely to contaminate in vitro preparations of exosomes and vice versa and sucrose gradients are inefficient at separating them. However, we have found that their sedimentation velocities in an iodixanol (Optiprep (TM)) velocity gradient are sufficiently different to allow separation and purification of both vesicles. Using acetylcholinesterase as an exosome marker, we demonstrate that Optiprep (TM) velocity gradients are very efficient in separating exosomes from HIV-1 particles produced on 293T cells, primary CD4(+) T cells, macrophages or DCs, with exosomes collecting at 8.4-12% iodixanol and HIV-1 at 15.6%. We also show that immunodepletion with an anti-acetylcholinesterase antibody rapidly produces highly purified preparations of HIV-1 or exosomes. These findings have applications in fundamental research on exosomes and/or AIDS, as well as in clinical applications where exosomes are involved, more specifically in tumour therapy or in gene therapy using exosomes generated from DCs genetically modified by transfection with virus. Crown Copyright (C) 2008 Published by Elsevier B.V. All rights reserved.
C1 [Gilbert, Caroline] Univ Laval, Fac Med, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada.
   [Cantin, Rejean; Diou, Juliette; Belanger, Dave; Tremblay, Alexandre M.] Univ Laval, Fac Med, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada.
RP Gilbert, C (reprint author), Univ Laval, Fac Med, Ctr Rech Rhumatol & Immunol, T 1-49,2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.
EM caroline.gilbert@crchul.ulaval.ca
FU Centre Hospitalier Universitaire de Quebec
FX This work was funded by start-up funds to C.G. from the Centre
   Hospitalier Universitaire de Quebec and the centre de recherche en
   rhumatologie et immunologie (CRRI).
CR Abusamra AJ, 2005, BLOOD CELL MOL DIS, V35, P169, DOI 10.1016/j.bcmd.2005.07.001
   Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615
   AHN JH, 1993, BLOOD, V81, P2442
   ALAIN R, 1987, J VIROL METHODS, V16, P209, DOI 10.1016/0166-0934(87)90005-X
   ALLAN D, 1980, BIOCHEM J, V188, P881, DOI 10.1042/bj1880881                                                               
   Alonso R, 2005, J BIOL CHEM, V280, P28439, DOI 10.1074/jbc.M501112200
   Alonso R, 2007, BIOCHIMIE, V89, P213, DOI 10.1016/j.biochi.2006.07.018
   Altieri SL, 2004, J IMMUNOTHER, V27, P282, DOI 10.1097/00002371-200407000-00004                                                
   Amigorena S, 2000, MEDICINA-BUENOS AIRE, V60, P51
   Andre F, 2001, ADV EXP MED BIOL, V495, P349
   Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126                                                     
   Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968
   BAYNES RD, 1991, P SOC EXP BIOL MED, V197, P416
   Berube P, 1996, J VIROL, V70, P4009
   Bess JW, 1997, VIROLOGY, V230, P134, DOI 10.1006/viro.1997.8499
   Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235                                                     
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002
   Cantin R, 2005, J VIROL, V79, P6577, DOI 10.1128/JVI.79.11.6577-6587.2005
   Cantin R, 1997, J VIROL, V71, P1922
   Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206                                                          
   Cantin R, 2001, J GEN VIROL, V82, P2979, DOI 10.1099/0022-1317-82-12-2979                                                    
   Chaput N, 2004, CANCER IMMUNOL IMMUN, V53, P234, DOI 10.1007/s00262-003-0472-x
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Clayton A, 2003, EUR J IMMUNOL, V33, P522, DOI 10.1002/immu.200310028
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   DERSE D, 1987, J VIROL, V61, P743
   Dettenhofer M, 1999, J VIROL, V73, P1460
   Dornadula G, 1999, VIROLOGY, V253, P10, DOI 10.1006/viro.1998.9465
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9                                                    
   Fomina AF, 2003, EXP CELL RES, V291, P150, DOI 10.1016/S0014-4827(03)00372-0
   FORD T, 1994, ANAL BIOCHEM, V220, P360, DOI 10.1006/abio.1994.1350
   Fortin JF, 2000, VIROLOGY, V268, P493, DOI 10.1006/viro.2000.0190                                                          
   Fortin JF, 1997, J VIROL, V71, P3588
   Frangsmyr L, 2005, MOL HUM REPROD, V11, P35, DOI 10.1093/molehr/gah129
   Gansuvd B, 2003, HUM IMMUNOL, V64, P427, DOI 10.1016/S0198-8859(03)00016-8
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Gilbert C, 2005, VIRAL IMMUNOL, V18, P474, DOI 10.1089/vim.2005.18.474                                                         
   Gilbert C, 2002, J IMMUNOL METHODS, V261, P85, DOI 10.1016/S0022-1759(01)00553-1
   Gilbert C, 2007, J VIROL, V81, P7672, DOI 10.1128/JVI.02810-06
   Gilbert C, 2007, J IMMUNOL, V178, P2862, DOI 10.4049/jimmunol.178.5.2862                                                     
   Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453
   Gould SJ, 2004, Q REV BIOL, V79, P359, DOI 10.1086/426088
   HAMMOND GW, 1981, J CLIN MICROBIOL, V14, P210
   Hao SG, 2007, CANCER BIOTHER RADIO, V22, P692, DOI 10.1089/cbr.2007.368-R
   Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100
   Hermens WTJMC, 1999, HUM GENE THER, V10, P1885, DOI 10.1089/10430349950017563                                                       
   Horstman LL, 2007, INT REV NEUROBIOL, V79, P227, DOI 10.1016/S0074-7742(07)79010-4
   Ikeda M, 2003, J SURG RES, V115, P174, DOI 10.1016/S0022-4804(03)00370-6
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Kapsogeorgou EK, 2005, ARTHRITIS RHEUM, V52, P1517, DOI 10.1002/art.21005
   Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I                   
   Kim HP, 2006, EXPERT OPIN THER TAR, V10, P759, DOI 10.1517/14728222.10.5.759
   Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015
   Kleijmeer MJ, 2001, TRAFFIC, V2, P124, DOI 10.1034/j.1600-0854.2001.020207.x
   Kramer B, 2005, BLOOD CELL MOL DIS, V35, P136, DOI 10.1016/j.bcmd.2005.06.006
   Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200
   Larregina AT, 2004, BLOOD, V103, P811, DOI 10.1182/blood-2003-02-0524
   Lebedeva T, 2005, CURR OPIN IMMUNOL, V17, P251, DOI 10.1016/j.coi.2005.04.008
   Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343                                                     
   Mackman N, 2006, BLOOD CELL MOL DIS, V36, P104, DOI 10.1016/j.bcmd.2005.12.008
   Mallegol J, 2005, BLOOD CELL MOL DIS, V35, P11, DOI 10.1016/j.bcmd.2005.04.001
   Mignot G, 2006, J CELL MOL MED, V10, P376, DOI 10.1111/j.1582-4934.2006.tb00406.x
   Moller-Larsen A, 1998, J VIROL METHODS, V73, P151, DOI 10.1016/S0166-0934(98)00052-4
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Ostman S, 2005, IMMUNOLOGY, V116, P464, DOI 10.1111/j.1365-2567.2005.02245.x
   Peche H, 2006, AM J TRANSPLANT, V6, P1541, DOI 10.1111/j.1600-6143.2006.01344.x
   Peche H, 2003, TRANSPLANTATION, V76, P1503, DOI 10.1097/01.TP.0000092494.75313.38
   Quah B, 2000, CANCER BIOTHER RADIO, V15, P185, DOI 10.1089/cbr.2000.15.185
   Quah BJC, 2005, BLOOD CELL MOL DIS, V35, P94, DOI 10.1016/j.bcmd.2005.05.002
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161                                                          
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x                                                
   Segura E, 2005, BLOOD, V106, P216, DOI 10.1182/blood-2005-01-0220
   Segura E, 2005, BLOOD CELL MOL DIS, V35, P89, DOI 10.1016/j.bcmd.2005.05.003
   Skokos D, 2001, INT ARCH ALLERGY IMM, V124, P133, DOI 10.1159/000053691
   Sprent J, 2005, BLOOD CELL MOL DIS, V35, P17, DOI 10.1016/j.bcmd.2005.04.004
   Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x
   Tardif MR, 2003, J VIROL, V77, P12299, DOI 10.1128/JVI.77.22.12299-12309.2003
   Taylor DD, 2006, J IMMUNOL, V176, P1534, DOI 10.4049/jimmunol.176.3.1534                                                     
   Tesselaar MET, 2007, J THROMB HAEMOST, V5, P520, DOI 10.1111/j.1538-7836.2007.02369.x                                                
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309                                                    
   Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854
   Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599
   Thibault S, 2007, J IMMUNOL, V179, P4357, DOI 10.4049/jimmunol.179.7.4357                                                     
   Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003
   Van Niel G, 2003, GUT, V52, P1690, DOI 10.1136/gut.52.12.1690
   van Niel G, 2002, AM J PHYSIOL-GASTR L, V283, pG251, DOI 10.1152/ajpgi.00102.2002
   VanVeldhoven PP, 1996, ANAL BIOCHEM, V237, P17, DOI 10.1006/abio.1996.0194
   Vidal M, 1997, J CELL SCI, V110, P1867
   Vincent-Schneider H, 2002, INT IMMUNOL, V14, P713, DOI 10.1093/intimm/dxf048                                                           
   Wang JJ, 1999, AIDS, V13, P281, DOI 10.1097/00002030-199902040-00018
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Zhao CQ, 2005, J INFECT DIS, V191, P1665, DOI 10.1086/429673
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 98
TC 111
Z9 111
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD SEP 30
PY 2008
VL 338
IS 1-2
BP 21
EP 30
DI 10.1016/j.jim.2008.07.007
PG 10
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 357ER
UT WOS:000259829600004
PM 18675270
DA 2018-01-05
ER

PT J
AU Hassen, WM
   Chaix, C
   Abdelghani, A
   Bessueille, F
   Leonard, D
   Jaffrezic-Renault, N
AF Hassen, Walid Mohamed
   Chaix, Carole
   Abdelghani, Adnane
   Bessueille, Francois
   Leonard, Didier
   Jaffrezic-Renault, Nicole
TI An impedimetric DNA sensor based on functionalized magnetic
   nanoparticles for HIV and HBV detection
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE HIV; HBV; Magnetic nanoparticles; Impedance spectroscopy; Cyclic
   voltammetry; Atomic force microscopy
ID SELF-ASSEMBLED MONOLAYERS; HEPATITIS-B-VIRUS; IMPEDANCE SPECTROSCOPY;
   POLYPYRROLE; PERFORMANCE; ELECTRODES; AU(111); POLYMER; CHARGE; ASSAYS
AB We report a new approach based on DNA hybridization for detecting HBV virus using non-faradic electro-chemical impedance spectroscopy. DNA probes modified with biotin in 5' position were immobilized on streptavidin modified magnetic nanoparticles by biotin-streptavidin interaction. A layer of functionalized nanoparticles was directly immobilized on bare gold electrode using a magnet. Before detection atomic force microscopy was used to visualize the layer of magnetic nanoparticles and cyclic voltammetry permitted to characterize DNA probe immobilization. The hybridization reactions with specific complementary DNA target and no complementary target were investigated by non-faradic impedance spectroscopy. Results show the good immobilization of the DNA probes and the hybridization with different concentrations of complementary DNA. Non-faradic impedance spectroscopy allows to detect 50 pmol of HBV DNA and 160 pmol of HIV DNA on sample of 20 mu L Saturations were reached for the same concentration 12.65 nmol/mL for a same quantity of immobilized DNA probes. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Hassen, Walid Mohamed; Chaix, Carole; Bessueille, Francois; Leonard, Didier; Jaffrezic-Renault, Nicole] Univ Lyon 1, CNRS, Sci Analyt Lab, UMR 5180, F-69622 Villeurbanne, France.
   [Abdelghani, Adnane] IPEST, Unite Rech Phys Semicond & Capteurs, Tunis 2070, Tunisia.
RP Hassen, WM (reprint author), Univ Lyon 1, CNRS, Sci Analyt Lab, UMR 5180, Batiment Raulin, F-69622 Villeurbanne, France.
EM hassen_walid@yahoo.fr; nicole.jaffrezic@univ-lyon1.fr
FU NATO [CBP.MD.CLG 982802]
FX This work was supported by NATO Grant No. CBP.MD.CLG 982802.
CR Bouchet A, 2007, BIOSENS BIOELECTRON, V23, P735, DOI 10.1016/j.bios.2007.06.018
   Candotti D, 2004, J VIROL METHODS, V118, P39, DOI [10.1016/S0166-0934(04)00019-9, 10.1016/j.jviromet.2004.01.017]
   Hleli S, 2006, SENSOR ACTUAT B-CHEM, V113, P711, DOI 10.1016/j.snb.2005.07.023
   Hou YX, 2006, BIOSENS BIOELECTRON, V21, P1393, DOI 10.1016/j.bios.2005.06.002
   Jaffrezic-Renault N, 2007, SENSORS-BASEL, V7, P589, DOI 10.3390/s7040589                                                                
   Janek RP, 1997, J PHYS CHEM B, V101, P8550, DOI 10.1021/jp971698e                                                               
   Janek RP, 1998, LANGMUIR, V14, P3011, DOI 10.1021/la970980+                                                               
   Katz BA, 1997, J MOL BIOL, V274, P776, DOI 10.1006/jmbi.1997.1444
   Kularatne BY, 2002, CYTOMETRY, V50, P160, DOI 10.1002/cyto.10071
   KUOSHENG M, 2006, SENSOR ACTUAT B-CHEM, V114, P58
   Kwon JA, 2006, J VIROL METHODS, V133, P20, DOI 10.1016/j.jviromet.2005.10.013
   LEE SY, 2007, SENS ACTUAT B
   LI ZX, 2007, PROTEIN EXPRESSION P
   Minard-Basquin C, 2000, BIOCONJUGATE CHEM, V11, P795, DOI 10.1021/bc000010p
   OUA CY, 2007, J VIROL METHODS, V144, P109
   Tlili C, 2005, TALANTA, V68, P131, DOI 10.1016/j.talanta.2005.04.069
   Uchida E, 2007, J VIROL METHODS, V143, P95, DOI 10.1016/j.jviromet.2007.02.014
   Ye YK, 2003, BIOSENS BIOELECTRON, V18, P1501, DOI 10.1016/S0956-5663(03)00121-0
   Zou ZW, 2007, SENSOR ACTUAT A-PHYS, V136, P518, DOI 10.1016/j.sna.2006.12.006
NR 19
TC 58
Z9 60
U1 2
U2 34
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD SEP 25
PY 2008
VL 134
IS 2
BP 755
EP 760
DI 10.1016/j.snb.2008.06.020
PG 6
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 361SJ
UT WOS:000260147100064
DA 2018-01-05
ER

PT J
AU Xi, XM
   Sun, Y
   Karim, CB
   Grigoryants, VM
   Scholes, CP
AF Xi, Xiangmei
   Sun, Yan
   Karim, Christine B.
   Grigoryants, Vladimir M.
   Scholes, Charles P.
TI HIV-1 nucleocapsid protein NCp7 and its RNA stem loop 3 partner:
   Rotational dynamics of spin-labeled RNA stem loop 3
SO BIOCHEMISTRY
LA English
DT Article
ID ELECTRON-PARAMAGNETIC-RESONANCE; STRAND TRANSFER; IN-VITRO; TAR RNA;
   CONFORMATIONAL-CHANGES; RECOGNITION ELEMENT; SECONDARY STRUCTURE; GENOME
   RECOGNITION; PACKAGING SIGNAL; DNA CONDENSATION
AB The tumbling dynamics of a 20-mer HIV-1 RNA stem loop 3 spin-labeled at the 5 ' position were probed in the nanosecond time range. This RNA interacted with the HIV-1 nucleocapsid Zn-finger protein, 1-55 NCp7, and specialized stopped-flow EPR revealed concomitant kinetics of probe immobilization from milliseconds to seconds. RNA stem loop 3 is highly conserved in HIV, while NCp7 is critical to HIV-RNA packaging and annealing. The 5 ' probe did not perturb RNA melting or the NCp7/ RNA interaction monitored by gel shift and fluorescence. The 5 '-labeled RNA tumbled with a subnanosecond isotropic correlation time (similar to 0.60 ns at room temperature) reflecting both local viscosity-independent bond rotation of the probe and viscosity-dependent diffusion of 40-60% of the RNA. The binding of NCp7 to spin-labeled RNA stem loop 3 in a 1:1 ratio increased the spin-labeled tumbling time by about 40%. At low ionic strength with a ratio of NCp7 to RNA >= 3 (i.e., an NCp7 to nucleotide ratio <= 7, which is the threshold ratio for chaperone effects), the probe tumbling time markedly increased to several nanoseconds, signifying a NCP7/RNA complex with restricted motion even at the initially mobile 5 ' position. Increasing the ionic strength to shield the electrostatic attraction between polyanionic RNA and polycationic NCp7 eliminated this immobilization. Forming the immobilized >= 3:1 complex also required intact Zn fingers. Stopped-flow EPR kinetics with NCP7/RNA mixed at a 4:1 ratio showed the major phase of NCp7 interaction with RNA stem loop 3 occurred within 4 ms, a second phase occurred with a time constant of similar to 30 ms, and a slower immobilization, possibly concomitant with large complex formation, proceeded over seconds. This work points the way for spin-labeling to investigate oligonucleotide-protein complexes, notably those lacking precise stoichiometry, that are requisite for viral packaging and genome fabrication.
C1 [Xi, Xiangmei; Sun, Yan; Grigoryants, Vladimir M.; Scholes, Charles P.] SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   [Karim, Christine B.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
RP Scholes, CP (reprint author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.
EM cps14@albany.edu
FU NIH [GM066253-01A1]; Minnesota Medical Foundation (MMF)
FX This work supported by the NIH (Grant GM066253-01A1 to C.P.S.) and the
   Minnesota Medical Foundation (MMF Grant to C.B.K.).
CR Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2001.5182
   Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2001.5429
   Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T
   Bloomfield VA, 2000, BIOPOLYMERS, V54, P168, DOI 10.1002/1097-0282(200009)54:3<168::AID-BIP20>3.0.CO;2-9
   Borbat PP, 2002, J AM CHEM SOC, V124, P5304, DOI 10.1021/ja020040y
   Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113
   CAI Q, 2007, BIOPHYS J
   CHEN M, 2007, J BIOL CHEM, V34, P24790
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Deweerd K, 2001, BIOCHEMISTRY-US, V40, P15846, DOI 10.1021/bi011414n
   Earle K. A., 2006, ADV ESR METHODS POLY
   Edwards TE, 2005, CHEM BIOL, V12, P329, DOI 10.1016/j.chembiol.2005.01.012
   Edwards TE, 2002, BIOCHEMISTRY-US, V41, P14843, DOI 10.1021/bi026299a
   Edwards TE, 2001, J AM CHEM SOC, V123, P1527, DOI 10.1021/ja005649i
   Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Fisher RJ, 1998, J VIROL, V72, P1902
   Grigoryants VM, 2000, BIOPHYS J, V78, P2702, DOI 10.1016/S0006-3495(00)76814-7                                                   
   Grigoryants VM, 2004, J PHYS CHEM B, V108, P9463, DOI 10.1021/jp030925b
   Guo JH, 1997, J VIROL, V71, P5178
   Hagan N, 2003, BIOCHEMISTRY-US, V42, P10736, DOI 10.1021/bi0348922
   Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200
   Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4
   Karim CB, 2006, J MOL BIOL, V358, P1032, DOI 10.1016/j.jmb.2006.02.051
   Karim CB, 2007, NAT PROTOC, V2, P42, DOI 10.1038/nprot.2007.2
   KHAN R, 1992, J BIOL CHEM, V267, P6689
   Kim NK, 2004, CHEM BIOL, V11, P939, DOI 10.1016/j.chembiol.2004.04.013
   Krishnamoorthy G, 2003, NUCLEIC ACIDS RES, V31, P5425, DOI 10.1093/nar/gkg738
   Macosko JC, 1999, RNA, V5, P1158, DOI 10.1017/S1355838299990830                                                       
   Margittai M, 2006, METHOD ENZYMOL, V413, P122, DOI 10.1016/S0076-6879(06)13007-4
   Marsh D., 1989, BIOL MAGN RESON, V8, P255
   Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k
   MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016                                                             
   Pappalardo L, 1998, J MOL BIOL, V282, P801, DOI 10.1006/jmbi.1998.2046
   PRICE EA, 2007, COMPUTATION NITROXID
   Qin PZ, 2005, J MOL BIOL, V351, P1, DOI 10.1016/j.jmb.2005.06.007
   Qin PZ, 2004, CURR OPIN STRUC BIOL, V14, P350, DOI 10.1016/j.sbi.2004.04.002
   Qin PZ, 2003, BIOCHEMISTRY-US, V42, P6772, DOI 10.1021/bi027222p
   Qin PZ, 2001, BIOCHEMISTRY-US, V40, P6929, DOI 10.1021/bi010294g
   Qu KB, 1997, BIOCHEMISTRY-US, V36, P2884, DOI 10.1021/bi962155i
   Ramboarina S, 2002, J MOL BIOL, V316, P611, DOI 10.1006/jmbi.2001.5379
   Ramos A, 1998, J AM CHEM SOC, V120, P10992, DOI 10.1021/ja982496e                                                               
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240
   Schiemann O, 2003, J AM CHEM SOC, V125, P3434, DOI 10.1021/ja0274610
   SCHOLES CP, 2005, BIOL MAGNETIC RESO B, P53
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3<301::AID-BIP5>3.3.CO;2-#
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520
   Theimer CA, 1998, J MOL BIOL, V279, P545, DOI 10.1006/jmbi.1998.1812                                                          
   TIRADO MM, 1980, J CHEM PHYS, V73, P1986, DOI 10.1063/1.440288
   TSUCHIHASHI Z, 1994, J VIROL, V68, P5863
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521                                                          
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   Wu WX, 1996, J VIROL, V70, P7132
   XIAO WS, 2000, BIOL MAGN RESON, P249
   YOU JC, 1994, J BIOL CHEM, V269, P31491
NR 63
TC 15
Z9 15
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD SEP 23
PY 2008
VL 47
IS 38
BP 10099
EP 10110
DI 10.1021/bi800602e
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 349GA
UT WOS:000259268100019
PM 18729386
DA 2018-01-05
ER

PT J
AU Mahmoud, KA
   Luong, JHT
AF Mahmoud, Khaled A.
   Luong, John H. T.
TI Impedance method for detecting HIV-1 protease and screening for its
   inhibitors using ferrocene-peptide conjugate/Au
   nanoparticle/single-walled carbon nanotube modified electrode
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY-ANTIGEN REACTIONS; IMMUNOSENSOR;
   SPECTROSCOPY; PROTEINASE; PEPSTATIN; ASSAY; IMMOBILIZATION; THERAPY
AB A highly sensitive screening assay based on electrochemical impedance spectroscopy (EIS) has been developed for detecting HIV-1 protease (PR) and subsequent evaluation of its corresponding inhibitors at picomolar levels. The assay format was based on the immobilization of the thiol terminated ferrocene(Fc)-pepstatin conjugate on a single-walled carbon nanotube/gold nanoparticle (SWCNT/ AuNP) modified gold electrode. The alteration of the interfacial properties of electrodes upon HIV-1 PR and Fc-pepstatin conjugate interaction was traced by EIS. On the basis of the charge transfer resistance data obtained and using a mixed kinetic and diffusion model, this procedure was capable of detecting picomolar HIV-1 PR owing to the specific binding of this enzyme to Fc modified pepstatin. A competitive inhibition assay format was then performed using four potent HIV-1 PR inhibitors. The estimated inhibition constant (K-i) attested that lopinavir/ ritonavir (K-i = 20 +/- 3 pM) and saquinavir (K-i = 57 +/- 8 pM) even at 10 pM competed strongly with pepstatin for effective binding to HIV-1 PR. Indinavir (K-i = 630 +/- 22 pM) only competed well with pepstatin at a much higher concentration (1 nM). No significant inhibitory effect was observed for the fosamprenavir (K-i = 11 +/- 0.5 nM) as expected from this pro-drug. Such results agreed well with the values reported in the literature. This assay format is a definite asset for the expedited development of effective HIV-1 PR inhibitors,with low molecular weights.
C1 [Mahmoud, Khaled A.; Luong, John H. T.] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
   [Luong, John H. T.] Univ Coll Cork, Dept Chem, Cork, Ireland.
RP Luong, JHT (reprint author), Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
EM john.luong@cnrc-nrc.gc.ca
OI Mahmoud, Khaled/0000-0003-1246-4067; Luong, John/0000-0002-1709-1223
CR Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
   Aruksakunwong O, 2007, CURR COMPUT-AID DRUG, V3, P201, DOI 10.2174/157340907781695431                                                      
   Cai H, 2006, SENSOR ACTUAT B-CHEM, V114, P433, DOI 10.1016/j.snb.2005.06.017
   Cai W, 2004, BIOSENS BIOELECTRON, V19, P1013, DOI 10.1016/j.bios.2003.09.009
   Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151
   Chen H, 2006, SENSOR ACTUAT B-CHEM, V117, P211, DOI 10.1016/j.snb.2005.11.026
   Chen XJ, 2008, ANAL CHEM, V80, P2133, DOI 10.1021/ac7021376
   Cheng TJ, 2004, ANTIMICROB AGENTS CH, V48, P2437, DOI 10.1128/AAC.48.7.2437-2447.2004
   Cihlar T, 2006, J MOL BIOL, V363, P635, DOI 10.1016/j.jmb.2006.07.073
   Darain F, 2004, BIOSENS BIOELECTRON, V19, P1245, DOI 10.1016/j.bios.2003.11.014
   Dijksma M, 2001, ANAL CHEM, V73, P901, DOI 10.1021/ac001051h
   Fuse T, 2006, MICROBES INFECT, V8, P1783, DOI 10.1016/j.micinf.2006.02.016
   Gillim L, 2001, CLIN DIAGN LAB IMMUN, V8, P437, DOI 10.1128/CDLI.8.2.437-440.2001                                                   
   Hu K, 2005, J VIROL METHODS, V128, P93, DOI 10.1016/j.jviromet.2005.04.012
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   Li CZ, 2003, J PHYS CHEM B, V107, P2291, DOI 10.1021/jp026792w
   Lindsten K, 2001, ANTIMICROB AGENTS CH, V45, P2616, DOI 10.1128/AAC.45.9.2616-2622.2001
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Nolan D, 2003, DRUGS, V63, P2555, DOI 10.2165/00003495-200363230-00001                                                
   Patolsky F, 1999, ANAL CHEM, V71, P3171, DOI 10.1021/ac9901541                                                               
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7
   Sadik OA, 2002, ANAL CHEM, V74, P3142, DOI 10.1021/ac0156722
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259                                                      
   Wang MJ, 2004, BIOSENS BIOELECTRON, V19, P575, DOI 10.1016/S0956-5663(03)00252-5
   Xu DK, 2005, ANAL CHEM, V77, P5107, DOI 10.1021/ac050192m
NR 34
TC 61
Z9 63
U1 2
U2 46
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD SEP 15
PY 2008
VL 80
IS 18
BP 7056
EP 7062
DI 10.1021/ac801174r
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 348GQ
UT WOS:000259199400027
PM 18707132
DA 2018-01-05
ER

PT J
AU Turville, SG
   Aravantinou, M
   Miller, T
   Kenney, J
   Teitelbaum, A
   Hu, LY
   Chudolij, A
   Zydowsky, TM
   Piatak, M
   Bess, JW
   Lifson, JD
   Blanchard, J
   Gettie, A
   Robbiani, M
AF Turville, Stuart G.
   Aravantinou, Meropi
   Miller, Todd
   Kenney, Jessica
   Teitelbaum, Aaron
   Hu, Lieyu
   Chudolij, Anne
   Zydowsky, Tom M.
   Piatak, Michael, Jr.
   Bess, Julian W., Jr.
   Lifson, Jeffrey D.
   Blanchard, James
   Gettie, Agegnehu
   Robbiani, Melissa
TI Efficacy of Carraguard (R)-Based Microbicides In Vivo Despite Variable
   In Vitro Activity
SO PLOS ONE
LA English
DT Article
AB Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident with demonstrating efficacy in vivo, is central to advancing new generation microbicides. We evaluated Carraguard (R) and a new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (PC-817). Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV reverse transcriptase). Carraguard showed limited activity against cell-free and mature DC-driven RT-SHIV infections and, surprisingly, low doses of Carraguard enhanced infection. However, nanomolar amounts of MIV-150 overcame enhancement and blocked DC-transmitted infection. In contrast, Carraguard impeded infection of immature DCs coincident with DC maturation. Despite this variable activity in vitro, Carraguard and PC-817 prevented vaginal transmission of RT-SHIV when applied 30 min prior to challenge. PC-817 appeared no more effective than Carraguard in vivo, due to the limited activity of a single dose of MIV-150 and the dominant barrier effect of Carraguard. However, 3 doses of MIV-150 in placebo gel at and around challenge limited vaginal infection, demonstrating the potential activity of a topically applied NNRTI. These data demonstrate discordant observations when comparing in vitro and in vivo efficacy of Carraguard-based microbicides, highlighting the difficulties in testing putative anti-viral strategies in vitro to predict in vivo activity. This work also underscores the potential of Carraguard-based formulations for the delivery of anti-viral drugs to prevent vaginal HIV infection.
C1 [Turville, Stuart G.; Aravantinou, Meropi; Miller, Todd; Kenney, Jessica; Teitelbaum, Aaron; Hu, Lieyu; Chudolij, Anne; Zydowsky, Tom M.; Robbiani, Melissa] Ctr Biomed Res, Populat Council, HIV & AIDS Program, New York, NY USA.
   [Piatak, Michael, Jr.; Bess, Julian W., Jr.; Lifson, Jeffrey D.] NCI, SAIC Frederick, AIDS & Canc Virus Program, Frederick, MD USA.
   [Blanchard, James] Tulane Univ Hlth Sci Ctr, Tulane Natl Primate Res Ctr, Covington, LA USA.
   [Gettie, Agegnehu] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY USA.
RP Turville, SG (reprint author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Ctr Virus Res, Sydney, NSW, Australia.
EM mrobbiani@popcouncil.org
FU USAID [GPO-A-00-04-00019-00]; NIH [R37 AI040877, AI065412, RR00164];
   2002 Elizabeth Glaser Scientist; NH&MRC of Australia [CJ Martin
   Fellowship]
FX Supported by the USAID Cooperative Agreement GPO-A-00-04-00019-00, NIH
   grants R37 AI040877 and AI065412, and the NIH base grant RR00164. MR is
   a 2002 Elizabeth Glaser Scientist. SGT is supported by a CJ Martin
   Fellowship of the NH&MRC of Australia. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript
CR Alan A, 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   Bakri Y, 2001, J IMMUNOL, V166, P3780, DOI 10.4049/jimmunol.166.6.3780                                                     
   Balzarini J, 1998, AIDS, V12, P1129, DOI 10.1097/00002030-199810000-00004
   Bartolini B, 2003, ANTIVIR RES, V58, P139, DOI 10.1016/S0166-3542(02)00209-7                                                   
   Bollen LJM, 2008, JAIDS-J ACQ IMM DEF, V47, P253, DOI 10.1097/QAI.0b013e31815d2f12                                                    
   Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069
   Canque B, 1999, BLOOD, V93, P3866
   Cavrois M, 2006, J VIROL, V80, P1992, DOI 10.1128/JVI.80.4.1992-1999.2006
   *CDCP, 2000, JAMA-J AM MED ASSOC, V284, P1376
   CHOU TC, 1977, J BIOL CHEM, V252, P6438
   Cline AN, 2005, J MED PRIMATOL, V34, P303
   CRUBLET E, 2008, J BIOL CHEM
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   DiClemente RJ, 2004, JAMA-J AM MED ASSOC, V292, P171, DOI 10.1001/jama.292.2.171
   Dong CS, 2007, J VIROL, V81, P11352, DOI 10.1128/JVI.01081-07
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Fahrbach KM, 2007, J VIROL, V81, P6858, DOI 10.1128/JVI.02472-06
   Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b
   Frank I, 2008, J VIROL, V82, P5329, DOI 10.1128/JVI.01987-07
   Frank I, 2003, JAIDS-J ACQ IMM DEF, V34, P7, DOI 10.1097/00126334-200309010-00002
   Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002
   Granelli-Piperno A, 1998, J VIROL, V72, P2733
   Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   *I LAB AN RES COMM, 1985, GUID CAR US LAB AN, P1
   Izquierdo-Useros N, 2007, J VIROL, V81, P7559, DOI 10.1128/JVI.02572-06
   Jagodzinski PP, 1999, VIRAL IMMUNOL, V12, P23, DOI 10.1089/vim.1999.12.23
   Kaiser J, 2008, SCIENCE, V320, P30, DOI 10.1126/science.320.5872.30
   Kawamura T, 2000, J EXP MED, V192, P1491, DOI 10.1084/jem.192.10.1491
   Ketas TJ, 2003, AIDS RES HUM RETROV, V19, P177, DOI 10.1089/088922203763315678
   Ketas TJ, 2003, J VIROL, V77, P2762, DOI 10.1128/JVI.77.4.2762-2767.2003
   Kilmarx PH, 2008, SEX TRANSM DIS, V35, P226, DOI 10.1097/OLQ.0b013e31815d6e0d
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001
   Lifson JD, 2004, AIDS RES HUM RETROV, V20, P772, DOI 10.1089/0889222041524661
   Lore K, 2005, J EXP MED, V201, P2023, DOI 10.1084/jem.20042413
   Maguire RA, 2001, SEX TRANSM DIS, V28, P259, DOI 10.1097/00007435-200105000-00003
   Maguire RA, 1998, SEX TRANSM DIS, V25, P494, DOI 10.1097/00007435-199810000-00010
   McDermott AB, 2004, J VIROL, V78, P3140, DOI 10.1128/JVI.78.6.3140-3144.2004
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   MCDONALD D, 2003, ENHANCEMENT HIV INFE
   MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910                                                          
   MILLER CJ, 1994, J VIROL, V68, P6391
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623
   Richardson BA, 2002, JAMA-J AM MED ASSOC, V287, P1171, DOI 10.1001/jama.287.9.1171
   Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Schmitz JE, 1999, AM J PATHOL, V154, P1923, DOI 10.1016/S0002-9440(10)65450-8                                                   
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   SKOLER S, 2008, EFFICACY CARRA UNPUB
   Smith SM, 1999, AIDS RES HUM RETROV, V15, P1691, DOI 10.1089/088922299309739
   Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166
   TRAPP S, 2008, DOUBLE STRANDE UNPUB
   Trapp S, 2006, J LEUKOCYTE BIOL, V80, P1076, DOI 10.1189/jlb.0206121
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129
   Turville SG, 2005, J VIROL, V79, P13519, DOI 10.1128/JVI.79.21.13519-13527.2005
   Turville SG, 2008, NAT METHODS, V5, P75, DOI 10.1038/NMETH1137
   UBERLA K, 1995, P NATL ACAD SCI USA, V92, P8210, DOI 10.1073/pnas.92.18.8210                                                         
   Vachot L, 2008, JAIDS-J ACQ IMM DEF, V48, P398, DOI 10.1097/QAI.0b013e3181776bc7
   van de Wiigert JHHM, 2007, JAIDS-J ACQ IMM DEF, V46, P538, DOI 10.1097/QAI.0b013e318159d5a8                                                    
   van de Wijgert JHHM, 2007, AIDS, V21, P2369, DOI 10.1097/QAD.0b013e3282ef83fd                                                    
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200
   Wang JH, 2007, J VIROL, V81, P8933, DOI 10.1128/JVI.00878-07
   West JT, 2002, J VIROL, V76, P3338, DOI 10.1128/JVI.76.7.3338-3349.2002
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zacharopoulos VR, 1997, CLIN DIAGN LAB IMMUN, V4, P465
   ZARETZKY FR, 1995, INFECT IMMUN, V63, P3520
   Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353
   Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101
NR 81
TC 63
Z9 64
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2008
VL 3
IS 9
AR e3162
DI 10.1371/journal.pone.0003162
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 422JQ
UT WOS:000264424300007
PM 18776937
OA gold
DA 2018-01-05
ER

PT J
AU Zahm, JA
   Bera, S
   Pandey, KK
   Vora, A
   Stillmock, K
   Hazuda, D
   Grandgenett, DP
AF Zahm, Jacob A.
   Bera, Sibes
   Pandey, Krishan K.
   Vora, Ajaykumar
   Stillmock, Kara
   Hazuda, Daria
   Grandgenett, Duane P.
TI Mechanisms of human immunodeficiency virus type 1 concerted integration
   related to strand transfer inhibition and drug resistance
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID VIRAL-DNA ENDS; HIV-1 INTEGRASE; IN-VITRO; REPLICATION; LEUKEMIA;
   PATHWAY; TARGET; CELLS; VIVO
AB The "strand transfer inhibitors" of human immunodeficiency virus type-1 (HIV-1) integrase (IN), so named because of their pronounced selectivity for inhibiting strand transfer over 3' OH processing, block virus replication in vivo and ex vivo and prevent concerted integration in vitro. We explored the kinetics of product formation and strand transfer inhibition within reconstituted synaptic complexes capable of concerted integration. Synaptic complexes were formed with viral DNA donors containing either two blunt ends, two 3'-OH-processed ends, or one of each. We determined that one blunt end within a synaptic complex is a sufficient condition for low-nanomolar-range strand transfer inhibition with naphthyridine carboxamide inhibitors L-870,810 and L-870,812. We further explored the catalytic properties and drug resistance profiles of a set of clinically relevant strand transfer inhibitor-resistant HIV-1 IN mutants. The diketo acids and naphthyridine carboxamides, mechanistically similar but structurally distinct strand transfer inhibitors, each select for a distinct set of drug resistance mutations ex vivo. The S153Y and N155S IN resistance mutants were selected with the diketo acid L-841,411, and the N155H mutant was selected with L-810,812. Each mutant exhibited some degree of catalytic impairment relative to the activity of wild type IN, although the N155H mutant displayed near-wild-type IN activities. The resistance profiles indicated that the S153Y mutation potentiates susceptibility to L-870,810 and L-870,812, while the N155S mutation confers resistance to L-870,810 and L-870,812. The N155H mutation confers resistance to L- 870,810 and potentiates susceptibility to L-841,411. This study illuminates the interrelated mechanisms of concerted integration, strand transfer inhibition, and resistance to strand transfer inhibitors.
C1 [Zahm, Jacob A.; Bera, Sibes; Pandey, Krishan K.; Vora, Ajaykumar; Grandgenett, Duane P.] St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO USA.
   [Stillmock, Kara; Hazuda, Daria] Merck Res Labs, Dept Antiviral Res, West Point, PA USA.
RP Grandgenett, DP (reprint author), Doisy Res Ctr, Inst Mol Virol, 1100 S Grand Blvd, St Louis, MO 63104 USA.
EM Grandgdp@slu.edu
RI Pandey, Krishan/A-3503-2008
OI Pandey, Krishan/0000-0002-3973-9844
FU National Institute of Allergy and Infectious Diseases [AI31334];
   National Cancer Institute [CA16312]
FX We thank David Wirth, a rotating graduate student in our laboratory, for
   carrying out the first combined blunt- and recessed-ended experiments.
   We also thank Patrick P. Hecker for the design of Fig. 1.; This work was
   supported by National Institute of Allergy and Infectious Diseases grant
   AI31334 and National Cancer Institute grant CA16312.
CR Anthony NJ, 2004, CURR TOP MED CHEM, V4, P979, DOI 10.2174/1568026043388448
   Brown P. O., 1997, P161
   Chen HM, 2001, MOL CELL BIOL, V21, P6758, DOI 10.1128/MCB.21.20.6758-6767.2001
   Craigie R, 2002, MOBILE DNA, VII, P613
   Daniel R, 2004, J VIROL, V78, P8573, DOI 10.1128/JVI.78.16.8573-8581.2004
   DeJesus E, 2006, JAIDS-J ACQ IMM DEF, V43, P1, DOI 10.1097/01.qai.0000233308.82860.2f
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Evering TH, 2007, DRUG TODAY, V43, P865, DOI 10.1358/dot.2007.43.12.1146063
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Hindmarsh P, 1999, J VIROL, V73, P2994
   Lataillade M, 2007, ANTIVIR THER, V12, P563
   Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005
   Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200
   Moreau K, 2002, ARCH VIROL, V147, P1761, DOI 10.1007/s00705-002-0831-5
   MURPHY JE, 1992, J VIROL, V66, P5092
   Pandey KK, 2007, J VIROL, V81, P12189, DOI 10.1128/JVI.02863-06
   Pandey KK, 2007, J VIROL, V81, P3969, DOI 10.1128/JVI.02322-06
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002
   Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005
   Vora A, 2001, J VIROL, V75, P3556, DOI 10.1128/JVI.75.8.3556-3567.2001
   VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454
NR 24
TC 13
Z9 13
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2008
VL 52
IS 9
BP 3358
EP 3368
DI 10.1128/AAC.00271-08
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 340TG
UT WOS:000258667300048
PM 18591263
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, K
   Fang, HF
   Chen, ZY
   Taylor, JSA
   Wooley, KL
AF Zhang, Ke
   Fang, Huafeng
   Chen, Zhiyun
   Taylor, John-Stephen A.
   Wooley, Karen L.
TI Shape effects of nanoparticles conjugated with cell-penetrating peptides
   (HIV Tat PTD) on CHO cell uptake
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID CROSS-LINKED NANOPARTICLES; TRIBLOCK COPOLYMER ASSEMBLIES;
   BLOCK-COPOLYMERS; ENDOCYTOSIS; NANOTUBES; MICELLES; DELIVERY; LINKING;
   SIZE
AB In order to probe the nanoparticle shape/size effect on cellular uptake, a spherical and two cylindrical nanoparticles, whose lengths were distinctively varied, were constructed by the selective cross-linking of amphiphilic block copolymer micelles. Herein, we demonstrate that, when the nanoparticles were functionalized with the protein transduction domain of human immunodeficiency virus type 1 Tat protein (HIV Tat PTD), the smaller, spherical nanoparticles had a higher rate of cell entry into Chinese hamster ovary (CHO) cells than did the larger, cylindrical nanoparticles. It was also found that nanoparticles were released after internalization and that the rate of cell exit was dependent on both the nanoparticle shape and the amount of surface-bound PTD.
C1 [Zhang, Ke; Fang, Huafeng; Chen, Zhiyun; Taylor, John-Stephen A.; Wooley, Karen L.] Washington Univ, Sch Arts & Sci, Dept Chem, St Louis, MO 63130 USA.
   [Zhang, Ke; Wooley, Karen L.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
RP Zhang, K (reprint author), Washington Univ, Sch Arts & Sci, Dept Chem, 1 Brookings Dr, St Louis, MO 63130 USA.
EM klwooley@artsci.wustl.edu
RI Zhang, Ke/F-4197-2010; Wooley, Karen/D-4399-2015
OI Wooley, Karen/0000-0003-4086-384X; Taylor,
   John-Stephen/0000-0002-8615-7257
FU National Heart Lung and Blood Institute [NHLBIPEN HL080729]
FX The authors gratefully acknowledge support from the National Heart Lung
   and Blood Institute of the National Institutes of Health as a Program of
   Excellence in Nanotechnology (NHLBIPEN HL080729). The authors also thank
   senior microscopist G. Michael Veith of the Washington University
   Department of Biology Microscopy Facility for providing technical
   support with TEM and fluorescence confocal microscopy.
CR Bao G, 2005, P NATL ACAD SCI USA, V102, P9997, DOI 10.1073/pnas.050455102
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P710, DOI 10.1021/bc049945m
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cui HG, 2007, SCIENCE, V317, P647, DOI 10.1126/science.1141768
   Cui HG, 2006, MACROMOLECULES, V39, P6599, DOI 10.1021/ma0609026
   Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   FOERG C, 2007, J PHARM SCI, V97, P144
   Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102
   Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70
   Hamley IW, 2005, SOFT MATTER, V1, P36, DOI 10.1039/b418226j
   Hirano K, 2004, FEBS LETT, V570, P149, DOI 10.1016/j.febslet.2004.05.084
   Huang HY, 1998, CHEM COMMUN, P1415, DOI 10.1039/a708686e                                                                
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Krikorian V, 2007, MACROMOLECULAR ENG, P1387
   Lazzari M, 2006, BLOCK COPOLYMERS NAN
   Ma QG, 2002, P NATL ACAD SCI USA, V99, P5058, DOI 10.1073/pnas.052653099
   Ma QG, 2000, J POLYM SCI POL CHEM, V38, P4805, DOI 10.1002/1099-0518(200012)38:1+<4805::AID-POLA180>3.0.CO;2-O
   MATTHAEUS C, 2008, MOL PHARM
   Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a
   Pan DJ, 2004, MACROMOLECULES, V37, P7109, DOI 10.1021/ma048824e
   Pochan DJ, 2004, SCIENCE, V306, P94, DOI 10.1126/science.1102866
   Pressly ED, 2007, BIOMACROMOLECULES, V8, P3126, DOI 10.1021/bm700541e
   Read ES, 2007, CHEM COMMUN, P3021, DOI 10.1039/b701217a
   Remsen EE, 1999, MACROMOLECULES, V32, P3685, DOI 10.1021/ma981951o                                                               
   Rossin R, 2005, J NUCL MED, V46, P1210
   SUN G, 2007, ADV MAT
   Turner JL, 2005, ADV FUNCT MATER, V15, P1248, DOI 10.1002/adfm.200500005
   YANG TF, 2006, BIOMATERIALS, V28, P725
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
   Ziegler A, 2007, BIOCHEMISTRY-US, V46, P8138, DOI 10.1021/bi700416h
NR 35
TC 120
Z9 124
U1 1
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD SEP
PY 2008
VL 19
IS 9
BP 1880
EP 1887
DI 10.1021/bc800160b
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 350MZ
UT WOS:000259358000018
PM 18690739
OA green_accepted
DA 2018-01-05
ER

PT J
AU Li, HH
   Yuan, G
AF Li, Hui Hui
   Yuan, Gu
TI Investigation of formation of dimeric G-quadruplex of HIV-1 integrase
   inhibitor by nuclear magnetic resonance
SO CHINESE CHEMICAL LETTERS
LA English
DT Article
DE G-quadruplex; HIV-1 integrase inhibitor; Nuclear magnetic resonance
ID SEQUENCE; DNA
AB In this research, an unusually dimeric G-quadruplex of d(GGGTGGGTGGGTGGGT) (S1), the potent nanomolar HIV-1 integrase inhibitor, was detected by nuclear magnetic resonance (NMR). This result has been confirmed by electrospray ionization mass spectrometry (ESI-MS) and circular dichroism (CD). (c) 2008 Gu Yuan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
C1 [Li, Hui Hui; Yuan, Gu] Peking Univ, Beijing Natl Lab Mol Sci, Key Lab Bioorgan Chem & Mol Engn, Dept Chem Biol,Coll Chem & Mol Engn,Minist Educ, Beijing 100871, Peoples R China.
RP Yuan, G (reprint author), Peking Univ, Beijing Natl Lab Mol Sci, Key Lab Bioorgan Chem & Mol Engn, Dept Chem Biol,Coll Chem & Mol Engn,Minist Educ, Beijing 100871, Peoples R China.
EM guyuan@pku.edu.cn
FU National Natural Science Foundation of China [20472009]; Research Fund
   for the Doctoral Program of Higher Education
FX Project was supported by the National Natural Science Foundation of
   China (No. 20472009) and the Research Fund for the Doctoral Program of
   Higher Education.
CR Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Crnugelj M, 2003, J AM CHEM SOC, V125, P7866, DOI 10.1021/ja0348694
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Kypr J, 2001, EUR BIOPHYS J BIOPHY, V30, P555, DOI 10.1007/s002490100174
   Li HH, 2008, J AM SOC MASS SPECTR, V19, P550, DOI 10.1016/j.jasms.2008.01.012
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
NR 6
TC 8
Z9 8
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1001-8417
J9 CHINESE CHEM LETT
JI Chin. Chem. Lett.
PD SEP
PY 2008
VL 19
IS 9
BP 1108
EP 1110
DI 10.1016/j.cclet.2008.06.010
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 411RW
UT WOS:000263669100026
DA 2018-01-05
ER

PT J
AU Khanna, VK
AF Khanna, V. K.
TI Nanoparticle-based sensors
SO DEFENCE SCIENCE JOURNAL
LA English
DT Review
DE nanoparticles; nanomaterials; chemical warfare; biological warfare;
   toxins; sensors; biosensors; quantum dots; chemiresistors
ID SURFACE-PLASMON RESONANCE; BIOLOGICAL WARFARE AGENTS; GOLD
   NANOPARTICLES; TIN OXIDE; BIOTERRORISM; METAL; FILMS; SENSITIVITY;
   PESTICIDES; BIOSENSORS
AB Nanoparticles exhibit several unique properties that call be applied to develop chemical and biosensors possessing desirable features like enhanced sensitivity and lower detection limits. Gold nanoparticles are coated With Sugars tailored to recognise different biological substances. When mixed with a weak Solution of the sugar-coated nanoparticle, the target substance, e.g., ricin or E.coli, attaches to the sugar, thereby altering its properties and changing the colour. Spores of bacterium labeled with carbon dots have beer) found to glow upon illumination when viewed with a confocal microscope. Enzyme/nanoparticle-based optical sensors Cor the detection of organophosphate (OP) compounds employ nanoparticle-modified fluorescence of an inhibitor of the enzyme to generate the signal Cor the OP compound detection, Nanoparticles shaped as nanoprisms, built Of silver atoms, appear red oil exposure to light. These nanoparticles are used as diagnostic labels that glow when target DNA, e.g., those of anthrax or HIV, are present. Of great importance are tools like gold nanoparticle-enhanced surface-plasmon resonance sensor and silver nanoparticle surface-enhanced portable Raman integrated tunable sensor. Nanoparticle metal oxide chemiresistors using micro electro mechanical system hotplate are very promising devices Cor toxic gas sensing. Chemiresistors comprising thin films of nanogold particles, encapsulated, in monomolecular layers of functionalised alkamethiols, deposited oil interdigitated microelectrodes, show resistance changes through reversible absorption of vapours of harmful oases. This, paper reviews the state-of-the-art sensors for chemical and biological (error agents, indicates their capabilities and applications, and presents the future scope of these devices.
C1 Cent Elect Engn Res Inst, Pilani 333031, Rajasthan, India.
RP Khanna, VK (reprint author), Cent Elect Engn Res Inst, Pilani 333031, Rajasthan, India.
CR Arakaki A, 2004, BIOTECHNOL BIOENG, V88, P543, DOI 10.1002/bit.20262
   Binder P, 2003, COMP IMMUNOL MICROB, V26, P401, DOI 10.1016/S0147-9571(03)00023-7
   Bray M, 2003, ANTIVIR RES, V57, P53, DOI 10.1016/S0166-3542(02)00200-0
   Brook I, 2002, INT J ANTIMICROB AG, V20, P320, DOI 10.1016/S0924-8579(02)00200-5
   Casadevall A, 2004, TRENDS MICROBIOL, V12, P259, DOI 10.1016/j.tim.2004.04.007
   Cavicchi RE, 2001, SENSOR ACTUAT B-CHEM, V77, P145, DOI 10.1016/S0925-4005(01)00686-4
   CAVICCHI RE, 1995, APPL PHYS LETT, V66, P812, DOI 10.1063/1.113429
   Chinowsky TM, 2007, BIOSENS BIOELECTRON, V22, P2268, DOI 10.1016/j.bios.2006.11.026
   Chinowsky TM, 2003, SENSOR ACTUAT B-CHEM, V91, P266, DOI 10.1016/S0925-4005(03)00113-8
   Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Ellison D., 2000, HDB CHEM BIOL WARFAR
   EVANS SD, 2000, J MATER CHEM, V10, P83
   Franke ME, 2006, SMALL, V2, P36, DOI 10.1002/smll.200500261
   FRANZ DR, 2002, DIS A MONTH, V48, P489
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   GOLDMAN ER, 2005, J AM CHEM SOC, V127, P684
   Gooding JJ, 2006, ANAL CHIM ACTA, V559, P137, DOI 10.1016/j.aca.2005.12.020
   Hamburg MA, 2002, TRENDS BIOTECHNOL, V20, P296, DOI 10.1016/S0167-7799(02)01989-3
   He L, 2000, J AM CHEM SOC, V122, P9071, DOI 10.1021/ja001215b
   Hillman MR, 2002, VACCINE, V20, P3055, DOI 10.1016/S0264-410X(02)00300-6
   Hone DC, 2003, LANGMUIR, V19, P7141, DOI 10.1021/la034358v
   Ivanov P, 2005, IEEE SENS J, V5, P798, DOI [10.1109/JSEN.2005.844340, 10.1109/JSEN2005.844340]
   Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541
   Joo BS, 2007, SENSOR ACTUAT B-CHEM, V121, P47, DOI 10.1016/j.snb.2006.09.013
   Joseph Y, 2004, SENSOR ACTUAT B-CHEM, V98, P188, DOI 10.1016/j.snb.2003.10.006
   Khardori N., 2005, CLIN MICROBIOL NEWSL, V27, P1
   Kim IB, 2005, CHEM COMMUN, P1273, DOI 10.1039/b416587j
   KUMAR A, 2004, ADA433585 NTIS
   Lee JH, 2005, B KOR CHEM SOC, V26, P36
   Ler SG, 2006, J CHROMATOGR A, V1133, P1, DOI 10.1016/j.chroma.2006.08.078
   Liu GD, 2005, ANAL CHEM, V77, P5894, DOI 10.1021/ac0507911
   Mauroni Albert J., 2007, CHEM BIOL WARFARE RE
   Mawhinney DB, 2007, J CHROMATOGR B, V852, P235, DOI 10.1016/j.jchromb.2007.01.023
   Meier DC, 2007, SENSOR ACTUAT B-CHEM, V121, P282, DOI 10.1016/j.snb.2006.09.050
   Meier DC, 2005, IEEE SENS J, V5, P712, DOI 10.1109/JSEN.2005.848139
   Meyer MHF, 2007, J MICROBIOL METH, V68, P218, DOI 10.1016/j.mimet.2006.08.004
   NIKITIN P, 2006, SCAMC C KREMS AUSTR, P74
   Panchapakesan B, 2001, NANOTECHNOLOGY, V12, P336, DOI 10.1088/0957-4484/12/3/323
   Peruski AH, 2002, J IMMUNOL METHODS, V263, P35, DOI 10.1016/S0022-1759(02)00030-3
   Salata O.V., 2004, J NANOBIOTECHNOL, V2, P3, DOI DOI 10.1186/1477-3155-2-3
   Sapsford KE, 2006, SENSORS-BASEL, V6, P925, DOI 10.3390/s6080925                                                                
   SEMANCIK S, 2003, KNOWL FDN 4 INT S DE
   Simonian AL, 2005, ANAL CHIM ACTA, V534, P69, DOI 10.1016/j.aca.2004.06.056
   Soelberg SD, 2005, J IND MICROBIOL BIOT, V32, P669, DOI 10.1007/s10295-005-0044-5
   Sun YP, 2006, J AM CHEM SOC, V128, P7756, DOI 10.1021/ja062677d
   Szeto A L, 2004, Homeopathy, V93, P173, DOI 10.1016/j.homp.2004.07.001
   Szinicz L, 2005, TOXICOLOGY, V214, P167, DOI 10.1016/j.tox.2005.06.011
   TUCKER JB, 2002, TOXIC TERROR ASSESSI
   Vreugdenhil AJ, 2006, J NON-CRYST SOLIDS, V352, P3879, DOI 10.1016/j.jnoncrysol.2006.06.032
   Wang J, 2005, ANALYST, V130, P421, DOI 10.1039/b414248a
   Whitley RJ, 2003, ANTIVIR RES, V57, P7, DOI 10.1016/S0166-3542(02)00195-X
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   Wohltjen H, 1998, ANAL CHEM, V70, P2856, DOI 10.1021/ac9713464                                                               
   XU CN, 1991, SENSOR ACTUAT B-CHEM, V3, P147, DOI 10.1016/0925-4005(91)80207-Z                                                    
   Xu XHN, 2004, J PHYS CHEM B, V108, P15543, DOI 10.1021/jp048124b
   Yan F, 2007, SENSOR ACTUAT B-CHEM, V121, P61, DOI 10.1016/j.snb.2006.09.032
   Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138
NR 58
TC 28
Z9 29
U1 2
U2 71
PU DEFENCE SCIENTIFIC INFORMATION DOCUMENTATION CENTRE
PI DELHI
PA METCALFE HOUSE, DELHI 110054, INDIA
SN 0011-748X
J9 DEFENCE SCI J
JI Def. Sci. J.
PD SEP
PY 2008
VL 58
IS 5
BP 608
EP 616
DI 10.14429/dsj.58.1683                                                    
          
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 353VT
UT WOS:000259597500003
OA gold
DA 2018-01-05
ER

PT J
AU Pandey, A
   Singh, AK
   Maurya, SK
   Rai, R
   Shukla, HS
AF Pandey, Anjita
   Singh, Alok Kumar
   Maurya, Sanjeev K.
   Rai, Rajani
   Shukla, H. S.
TI Nanoscience and their biological importance: Human health and disease
SO DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES
LA English
DT Article
DE nano-biosensors; DNA nano-chips; drug delivery; gene therapy;
   nano-carriers
ID CANCER-CELLS; NANOTECHNOLOGY; SCAFFOLDS; NANOPARTICLES; NANOMEDICINE;
   TECHNOLOGY; DIAGNOSIS; MEDICINE; THERAPY; INSULIN
AB Nano-science is at the leading edge of the rapidly developing field of nanotechnology. Several areas of medical care are already benefiting from the advantages that nanotechnology can offer. Applications of nano-science in biotechnology, medicine, pharmaceuticals, physics, material science and electronics are also covered in this review. Mankind is still fighting against a high number of serious and complex illnesses like cancer, cardiovascular diseases, multiple sclerosis, Alzheimer's and Parkinson's disease, and diabetes as well as different kinds of serious inflammatory or infectious diseases (e. g. HIV). Most of theses diseases have a tremendous negative impact not only on the patient himself but also on the whole society and linked social and insurance systems. It is of utmost importance to face these plagues with appropriate means. This brief review tries to recapitulate the most recent developments in the field of applied nano-science, particularly in their relevance in treatment of various diseases and their biological importance in human health and to discuss their future prospects.
C1 [Pandey, Anjita; Maurya, Sanjeev K.; Rai, Rajani; Shukla, H. S.] Banaras Hindu Univ, Inst Med Sci, Dept Surg Oncol, Varanasi 221005, Uttar Pradesh, India.
   [Singh, Alok Kumar] Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
RP Shukla, HS (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Surg Oncol, Varanasi 221005, Uttar Pradesh, India.
EM harishukla@usa.net
CR Angeli E, 2008, TUMORI, V94, P206
   Banerjee HN, 2008, TECHNOL CANCER RES T, V7, P149, DOI 10.1177/153303460800700208                                                      
   Bar H, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-37
   Barnes CP, 2007, ADV DRUG DELIVER REV, V59, P1413, DOI 10.1016/j.addr.2007.04.022
   Byrne James D, 2008, Mcgill J Med, V11, P43
   Campbell GR, 2008, J TISSUE ENG REGEN M, V2, P50, DOI 10.1002/term.66
   Chaikof EL, 2002, ANN NY ACAD SCI, V961, P96, DOI 10.1111/j.1749-6632.2002.tb03057.x                                              
   Chang Wesley C, 2007, Clin Neurosurg, V54, P137
   Chatterjee DK, 2008, NANOMEDICINE-UK, V3, P73, DOI 10.2217/17435889.3.1.73
   Di Paolo J., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P79, DOI 10.1080/10255840500523139
   Diehl KA, 2005, J BIOMED MATER RES A, V75A, P603, DOI 10.1002/jbm.a.30467
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Fong J, 2006, INT J NANOMED, V1, P441, DOI 10.2147/nano.2006.1.4.441
   Hertz A, 2007, NANOMEDICINE-UK, V2, P899, DOI 10.2217/17435889.2.6.899
   JABRMILANE LS, 2008, CANC TREAT REV
   Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014
   Koch M, 2006, NANOMEDICINE-UK, V1, P373, DOI 10.2217/17435889.1.3.373
   LEVYNISSENBAUM E, 2008, TRENDS BIOT IN PRESS
   Mah C, 2000, MOL THERAPY, V1, P239
   Mahony O, 2008, NANOMEDICINE-UK, V3, P233, DOI 10.2217/17435889.3.2.233
   Murosaki Takayuki, 2006, Nihon Rinsho, V64, P206
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   Nohynek GJ, 2008, SKIN PHARMACOL PHYS, V21, P136, DOI 10.1159/000131078
   Panatarotto D., 2003, CHEM BIOL, V10, P961
   Pathak A, 2008, INT J NANOMED, V3, P31
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Plotkin S.L., 2004, VACCINES, V5, P1
   Radwan MA, 2002, J MICROENCAPSUL, V19, P225, DOI 10.1080/02652040110081406
   Retel VP, 2008, TUMORI, V94, P284
   Rotomskis R, 2008, TUMORI, V94, P200
   SANVICENS N, 2008, TRENDS BIOTECHNOL
   Schoenhagen Paul, 2008, Recent Pat Cardiovasc Drug Discov, V3, P98, DOI 10.2174/157489008784705377
   SUN C, 2008, ADV DRUG DE IN PRESS
   SUN C, 2008, ADV DRUG DELIV REV
   Yacoby I, 2008, NANOMEDICINE-UK, V3, P329, DOI 10.2217/17435889.3.3.329
   Yezhelyev MV, 2006, LANCET ONCOL, V7, P657, DOI 10.1016/S1470-2045(06)70793-8
   Zhang H, 2008, NANOMEDICINE-UK, V3, P83, DOI 10.2217/17435889.3.1.83
   ZOU X, 2008, CANC TREAT REV
NR 39
TC 7
Z9 7
U1 1
U2 18
PU INST MATERIALS PHYSICS
PI BUCHAREST
PA NATL INST R&D MATERIALS PHYSICS, ATOMISTILOR STR, 105 BIS, BUCHAREST,
   077125, ROMANIA
SN 1842-3582
J9 DIG J NANOMATER BIOS
JI Dig. J. Nanomater. Biostruct.
PD SEP
PY 2008
VL 3
IS 3
BP 141
EP 146
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 348EZ
UT WOS:000259195100006
DA 2018-01-05
ER

PT J
AU Schneider, B
   Fryer, JF
   Oldenburg, J
   Brackmann, HH
   Baylis, SA
   Eis-Hubinger, AM
AF Schneider, B.
   Fryer, J. F.
   Oldenburg, J.
   Brackmann, H. -H.
   Baylis, S. A.
   Eis-Huebinger, A. M.
TI Frequency of contamination of coagulation factor concentrates with novel
   human parvovirus PARV4
SO HAEMOPHILIA
LA English
DT Article
DE coagulation factor concentrates; genotypes 1 and 2; human parvovirus 4;
   viral contamination
ID B19 DNA; BLOOD-DONORS; LIVER-TISSUE; HUMAN PLASMA; BONE-MARROW;
   PERSISTENCE; NANOFILTRATION; HEPATITIS; REMOVAL; VIRUSES
AB Human parvovirus, PARV4 was identified in a plasma sample from a patient presenting with symptoms resembling acute HIV infection. Further strains of PARV4 and those of a closely related variant virus, were identified in plasma pools used in the manufacture of blood derivatives. DNA sequence analysis of these strains demonstrated two distinct PARV4 genotypes. It has subsequently been proposed that transmission of PARV4 occurs by parenteral routes. To investigate the risk of contamination of plasma-derived coagulation factor concentrates, we analysed 169 lots for PARV4 DNA by polymerase chain reaction. Positive samples were confirmed by nucleotide sequence analysis and quantification of the viral load. Twenty-one lots, representing eight different products were administered until the beginning of the 1980s and were not vitally inactivated. Two lots examined were used in 1997, and 146 lots representing 13 products had been administered between October 2000 and February 2003. PARV4 DNA was detected in 7(33%) of the formerly administered lots, in one lot used in 1997, and in 13(9%) recently used lots. PARV4 genotype 2 DNA was predominantly present in the older concentrates, whilst genotype 1 was found more frequently in recently used lots. In three lots, both PARV4 genotypes were detected. Viral loads ranged between <100 and 10(5.8) copies mL(-1) of product, with higher viral loads in the older concentrates. The results show that PARV4 contamination can be detected ill an appreciable proportion of clotting factor concentrates. Further studies are needed to determine whether or not PARV4 contamination of coagulation factors causes harm to the product recipients.
C1 [Schneider, B.; Eis-Huebinger, A. M.] Univ Bonn, Med Ctr, Inst Virol, D-53105 Bonn, Germany.
   [Fryer, J. F.; Baylis, S. A.] Natl Inst Biol Stand & Controls, Div Virol, Potters Bar EN6 3QG, Herts, England.
   [Oldenburg, J.; Brackmann, H. -H.] Univ Bonn, Med Ctr, Inst Expt Haematol & Transfus Med, D-53105 Bonn, Germany.
RP Eis-Hubinger, AM (reprint author), Univ Bonn, Med Ctr, Inst Virol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM anna-maria.cis-huebinger@ukb.uni-bonn.de
FU BONFOR [0-151.0021]
FX The authors greatly appreciate the excellent technical assistance of Mrs
   Ulrike Reber. This work was funded by BONFOR (Grant 0-151.0021).
CR Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x                                                
   Brown KE, 2007, TRANSFUSION, V47, P1745, DOI 10.1111/j.1537-2995.2007.01459.x                                                
   Cassinotti P, 1997, J MED VIROL, V53, P229, DOI 10.1002/(SICI)1096-9071(199711)53:3<229::AID-JMV8>3.0.CO;2-A
   Eis-Hubinger AM, 2001, J MED VIROL, V65, P395, DOI 10.1002/jmv.2047                                                                
   Fryer JF, 2007, VOX SANG, V93, P341, DOI 10.1111/j.1423-0410.2007.00979.x
   Fryer JF, 2007, J GEN VIROL, V88, P2162, DOI 10.1099/vir.0.82620-0
   Fryer JF, 2007, TRANSFUSION, V47, P1054, DOI 10.1111/j.1537-2995.2007.01235.x
   Fryer JF, 2007, EMERG INFECT DIS, V13, P175
   Fryer JF, 2006, EMERG INFECT DIS, V12, P151, DOI 10.3201/eid1201.050916                                                          
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   KERR JR, 1995, BRIT J RHEUMATOL, V34, P809
   Kreil TR, 2006, TRANSFUSION, V46, P1143, DOI 10.1111/j.1537-2995.2006.00864.x
   Longhi E, 2007, AIDS, V21, P1481, DOI 10.1097/QAD.0b013e3281e38558                                                    
   Manning A, 2007, J INFECT DIS, V195, P1345, DOI 10.1086/513280
   Norja P, 2006, P NATL ACAD SCI USA, V103, P7450, DOI 10.1073/pnas.0602259103
   Omar A, 2002, TRANSFUSION, V42, P1005, DOI 10.1046/j.1537-2995.2002.00145.x
   Schneider B, 2004, THROMB HAEMOSTASIS, V92, P838, DOI 10.1106/TH04-04-0229
   Schneider B, 2008, J MED VIROL, V80, P345, DOI 10.1002/jmv.21069
   Simmonds P, 2007, EMERG INFECT DIS, V13, P1386, DOI 10.3201/eid1309.070428
   Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vallerini D, 2008, EMERG INFECT DIS, V14, P185, DOI 10.3201/eid1401.070610
   Wong S, 2003, J INFECT DIS, V187, P1581, DOI 10.1086/374781
   Yunoki M, 2003, VOX SANG, V85, P67, DOI 10.1046/j.1423-0410.2003.00301.x-i1                                             
NR 25
TC 28
Z9 30
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1351-8216
J9 HAEMOPHILIA
JI Haemophilia
PD SEP
PY 2008
VL 14
IS 5
BP 978
EP 986
DI 10.1111/j.1365-2516.2008.01800.x
PG 9
WC Hematology
SC Hematology
GA 353OL
UT WOS:000259577200015
PM 18565125
DA 2018-01-05
ER

PT J
AU Hai, NH
   Chau, N
   Luong, NH
   Van Anh, NT
   Nghia, PT
AF Hai, Nguyen Hoang
   Chau, Nguyen
   Luong, Nguyen Hoang
   Van Anh, Nguyen Thi
   Nghia, Phan Tuan
TI Applications of magnetite nanoparticles for water treatment and for DNA
   and cell separation
SO JOURNAL OF THE KOREAN PHYSICAL SOCIETY
LA English
DT Article; Proceedings Paper
CT 5th International Conference on Advanced Materials
CY DEC 12-14, 2007
CL Cheju Isl, SOUTH KOREA
DE CD4(+) T cell; magnetic nanoparticles; arsenic removal; cell separation;
   DNA separation
ID SIZE
AB Magnetic nanoparticles with a diameter of 15 nm prepared by using the coprecipitation method have been applied to enforce the sedimentation of the solid waste, to adsorb the arsenic ions in water, to increase the DNA concentration by using a magnetic field for the electrochemical DNA sensor and to separate the helper CD4(+) T cells to determine the number of the cells in blood. A combination of magnetic nanoparticles and alum makes the solid waste in water under a magnetic field aggregate a dozen times faster than under the gravity alone. A concentration of 0.1 mg/l of arsenic in water was reduced to a value lower than the permissible concentration of 0.01 mg/l after few minutes of stirring. The particles functionalized with 3-aminopropyl triethoxysilane were used to enrich the DNA of the Herpes virus, which extended the sensitivity of all electrochemical sensor down to a concentration lower than nM/l. The particles coated with fluorescent-labeled autiCD4 antibody were used to count the helper CD4+ T cells. The fluorescence signals of the particle/cell system were two times stronger than those of the fluorescence antiCD4 cell system. This call be used for the treatment of an HIV-infected patient with a simple fluorescent microscope.
C1 [Hai, Nguyen Hoang; Chau, Nguyen; Luong, Nguyen Hoang] Vietnam Natl Univ, Hanoi Univ Sci, Fac Phys, Ctr Mat Sci, Hanoi, Vietnam.
   [Van Anh, Nguyen Thi; Nghia, Phan Tuan] Vietnam Natl Univ, Hanoi Univ Sci, Fac Biol, Ctr Life Sci Res, Hanoi, Vietnam.
RP Hai, NH (reprint author), Vietnam Natl Univ, Hanoi Univ Sci, Fac Phys, Ctr Mat Sci, 334 Nguyen Trai, Hanoi, Vietnam.
EM nhhai@vnu.edu.vn
CR Bruce IJ, 2005, LANGMUIR, V21, P7029, DOI 10.1021/la050553t
   Hai NH, 2008, J KOREAN PHYS SOC, V52, P1327, DOI 10.3938/jkps.52.1327
   Khuat NT, 2008, J KOREAN PHYS SOC, V52, P1323, DOI 10.3938/jkps.52.1323
   LESLIEPELECKY DL, 2005, NANOBIOMAGNETICS ADV, P6065
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Ryan K.J., 2004, SHERRIS MED MICROBIO
   Thach CV, 2008, J KOREAN PHYS SOC, V52, P1332, DOI 10.3938/jkps.52.1332
   TUAN A, 2005, COMM PBYS, V15, P218
   Yean S, 2005, J MATER RES, V20, P3255, DOI 10.1557/JMR.2005.0403
NR 9
TC 5
Z9 5
U1 0
U2 0
PU KOREAN PHYSICAL SOC
PI SEOUL
PA 635-4, YUKSAM-DONG, KANGNAM-KU, SEOUL 135-703, SOUTH KOREA
SN 0374-4884
J9 J KOREAN PHYS SOC
JI J. Korean Phys. Soc.
PD SEP
PY 2008
VL 53
IS 3
SI SI
BP 1601
EP 1606
DI 10.3938/jkps.53.1601                                                    
          
PN 1
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 348EW
UT WOS:000259194800063
DA 2018-01-05
ER

PT J
AU Faridani, OR
   McInerney, GM
   Gradin, K
   Good, L
AF Faridani, Omid R.
   McInerney, Gerald M.
   Gradin, Katarina
   Good, Liam
TI Specific ligation to double-stranded RNA for analysis of cellular RNA ::
   RNA interactions
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CELLS; DNA; TRANSCRIPTION; HIF-1-ALPHA; HYPOXIA; CLONING; LIGASE;
   CANCER; AHIF; TAT
AB Double-stranded RNA (dsRNA) is formed in cells as intra- and intermolecular RNA interactions and is involved in a range of biological processes including RNA metabolism, RNA interference and translation control mediated by natural antisense RNA and microRNA. Despite this breadth of activities, few molecular tools are available to analyse dsRNA as native hybrids. We describe a two-step ligation method for enzymatic joining of dsRNA adaptors to any dsRNA molecule in its duplex form without a need for prior sequence or termini information. The method is specific for dsRNA and can ligate various adaptors to label, map or amplify dsRNA sequences. When combined with reverse transcriptionpolymerase chain reaction, the method is sensitive and can detect low nanomolar concentrations of dsRNA in total RNA. As examples, we mapped dsRNA/single-stranded RNA junctions within Escherichia coli hok mRNA and the human immunodeficiency virus TAR element using RNA from bacteria and mammalian cells.
C1 [Faridani, Omid R.; McInerney, Gerald M.; Gradin, Katarina; Good, Liam] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.
   [McInerney, Gerald M.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden.
   [Good, Liam] Univ London, Royal Vet Coll, Dept Pathol & Infect Dis, N Mymms AL9 7TA, Herts, England.
RP Faridani, OR (reprint author), Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden.
EM omid.faridani@ki.se
RI McInerney, Gerald/G-5344-2012
OI McInerney, Gerald/0000-0003-2257-7241; Faridani,
   Omid/0000-0001-9330-887X
FU Ministry of Science, Research and Technology; Swedish Research Council
FX O.R.F. is supported by a scholarship from the Ministry of Science,
   Research and Technology I. R. Iran. This work was supported by a grant
   from the Swedish Research Council. Funding to pay the Open Access
   publication charges for this article was provided by the Swedish
   Research Council.
CR Cayre A, 2003, BREAST CANCER RES, V5, pR223, DOI 10.1186/bcr652
   Dekker NH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh138
   Gullerova M, 2008, CELL, V132, P983, DOI 10.1016/j.cell.2008.02.040
   HIGGINS NP, 1979, NUCLEIC ACIDS RES, V6, P1013, DOI 10.1093/nar/6.3.1013                                                            
   IMAI M, 1983, P NATL ACAD SCI-BIOL, V80, P373, DOI 10.1073/pnas.80.2.373
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415
   LAMBDEN PR, 1992, J VIROL, V66, P1817
   Lehmann R.I., 1981, ENZYMES, V4, P193
   Munroe SH, 2006, CELL MOL LIFE SCI, V63, P2102, DOI 10.1007/s00018-006-6070-2
   Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0
   Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481
   SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0
   SHISHIDO K, 1981, BIOCHIM BIOPHYS ACTA, V656, P123, DOI 10.1016/0005-2787(81)90035-6
   Tariq M, 2004, TRENDS GENET, V20, P244, DOI 10.1016/j.tig.2004.04.005
   Thrash-Bingham CA, 1999, J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143
   Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200
   VOGT VM, 1973, EUR J BIOCHEM, V33, P192, DOI 10.1111/j.1432-1033.1973.tb02669.x                                              
NR 18
TC 4
Z9 4
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD SEP
PY 2008
VL 36
IS 16
AR e99
DI 10.1093/nar/gkn445
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 348JA
UT WOS:000259205600001
PM 18628292
OA gold
DA 2018-01-05
ER

PT J
AU Lewerenz, HJ
AF Lewerenz, H. J.
TI Enzyme-semiconductor interactions: Routes from fundamental aspects to
   photoactive devices
SO PHYSICA STATUS SOLIDI B-BASIC SOLID STATE PHYSICS
LA English
DT Article
ID SCANNING-TUNNELING-MICROSCOPY; ENERGY-TRANSFER; REVERSE-TRANSCRIPTASE;
   ELECTRICAL DETECTION; CHARGE-TRANSFER; SURFACE-STATES; WATER; TITANIA;
   LEVEL; PHOTOSYNTHESIS
AB Scanning tunnelling microscopy (STK) experiments at protein-semiconductor systems are analyzed using concepts from applied semiconductor physics such as Fermi level pinning and MIS (metal - insulator- semiconductor) junction electronics. Routes for immobilization of enzymes (proteins) on nanostructured surfaces of MoTe2 and Si are outlined using so-called DLVO and non-DLVO interactin forces. An overview of the catalytic activity of the imaged enzymes, reverse transcriptases of the retroviruses HIV 1 and AMV (avian myeloblastosis virus), is given including their tertiary structural properties which is revealed also in the STM and tapping mode AFM images. For the interpretation of STM images, a resonant charge transfer mechanism is invoked, based on the potential dependence of the image contrast and the energy band structure of MoTe, near the valence band maximum. First analyses of the charge transport from the semiconductor to the STM tip at negative bias of MoTe2 suggest that the observed uninhibited conductivity in the constant current experiments results from solvation-assisted release of electrons from traps that exist along the polypeptide chains and that charge transport occurs at the circumference of the enzymes where biological water is present. Therefore, charge injection into catalytically active enzymes such as hydrogenase or water oxidase of Photosystem I and II with subsequent charge transport to the active sites appears difficult to realize. Possibilities of radiation-less long-distance energy transfer based on the Forster mechanism, its multichromic extension and on Dexter exciton hopping are considered for catalytically active hybrid inorganic/organic absorber-enzyme structures. (c) 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
C1 Hahn Meitner Inst Berlin GmbH, Div Solar Energy, D-14109 Berlin, Germany.
RP Lewerenz, HJ (reprint author), Hahn Meitner Inst Berlin GmbH, Div Solar Energy, Glienicker Str 100, D-14109 Berlin, Germany.
EM lewerenz@hmi.de
CR Allison FJ, 2004, J MATER RES, V19, P1808, DOI 10.1557/JMR.2004.0250
   ALTARELLI M, 1973, PHYS REV B, V7, P5335, DOI 10.1103/PhysRevB.7.5335
   Becker K, 2006, NAT MATER, V5, P777, DOI 10.1038/nmat1738
   Callister W. D., 2003, MAT SCI ENG INTRO
   Campbell SA, 2007, J ELECTROANAL CHEM, V599, P313, DOI 10.1016/j.jelechem.2006.05.035
   Chan S, 2000, PROG BIOM O, V1, P23, DOI 10.1117/12.379577
   Coe JV, 1997, J CHEM PHYS, V107, P6023, DOI 10.1063/1.474271
   Cukier E, 2005, CHEM PHYS LETT, V402, P186, DOI 10.1016/j.cplett.2004.11.127
   DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0
   Derjaguin B.V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L
   DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044
   FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55
   Frenkel J, 1938, PHYS REV, V54, P647, DOI 10.1103/PhysRev.54.647                                                          
   Garcia SP, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166102
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   GERISCHER H, 1960, Z PHYS CHEM, V26, P325
   Gerischer H., 1961, Z PHYS CHEM, V27, P48
   Gerischer H., 1960, Z PHYSIK CHEM FRANKF, V6, P223
   Grossman AR, 1995, ANNU REV GENET, V29, P231, DOI 10.1146/annurev.ge.29.120195.001311                                             
   GUCKENBERGER R, 1994, SCIENCE, V266, P1538, DOI 10.1126/science.7985024
   Haas E, 2005, PROTEIN FOLDING HANDBOOK, P573, DOI 10.1002/9783527619498.ch17
   Hackstein JHP, 2005, BIOCHEM SOC T, V33, P47, DOI 10.1042/BST0330047                                                              
   Huang P, 2004, J INORG BIOCHEM, V98, P733, DOI 10.1016/j.jinorgbio.2003.12.009
   JANG S, 2004, PHYS REV LETT, V92
   Jang S, 2007, J PHYS CHEM B, V111, P6807, DOI 10.1021/jp070111l
   Jochims HW, 2004, CHEM PHYS, V298, P279, DOI 10.1016/j.chemphys.2003.11.035
   JUNGBLUT H, 1992, FARADAY DISCUSS, V94, P183, DOI 10.1039/fd9929400183
   Jungblut H, 2002, J ELECTROANAL CHEM, V527, P41, DOI 10.1016/S0022-0728(02)00707-6                                                   
   Jungblut H, 2001, APPL PHYS LETT, V78, P168, DOI 10.1063/1.1338501
   JUNGBLUT H, 1992, APPL PHYS COMMUN, V11, P1
   KASOWSKI RV, 1973, PHYS REV LETT, V30, P1175, DOI 10.1103/PhysRevLett.30.1175                                                     
   KHAMBAMPATI P, 2002, J PHYS CHEM A, V106, P2374
   Kloepfer JA, 1998, CHEM PHYS LETT, V298, P120, DOI 10.1016/S0009-2614(98)01210-X
   KOHISTAEDT LA, 1992, SCIENCE, V256, P1783
   KOLB DM, 1981, PHYS REV LETT, V47, P1921, DOI 10.1103/PhysRevLett.47.1921                                                     
   KORNBERS A, 1992, RNA REPLICATION S
   Koslowski T, 1999, J CHEM PHYS, V110, P12233, DOI 10.1063/1.479161
   Kupiec JJ, 1996, J GEN VIROL, V77, P1987, DOI 10.1099/0022-1317-77-9-1987
   LEWERENZ HJ, 1988, J APPL PHYS, V63, P2420, DOI 10.1063/1.341036
   LEWERENZ HJ, 1984, J ELECTROCHEM SOC, V131, P100, DOI 10.1149/1.2115467
   LEWERENZ HJ, 1993, J ELECTROANAL CHEM, V356, P121, DOI 10.1016/0022-0728(93)80515-J                                                    
   LEWERENZ HJ, 2008, J SOLID STAT IN PRES
   Manso M, 2002, BIOMATERIALS, V23, P349, DOI 10.1016/S0142-9612(01)00112-0
   Neumann B, 2005, J PHYS CHEM B, V109, P16579, DOI 10.1021/jp051339g
   Nevo R, 2005, EMBO REP, V6, P482, DOI 10.1038/sj.embor.7400403
   Pal SK, 2002, P NATL ACAD SCI USA, V99, P1763, DOI 10.1073/pnas.042697899
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568
   Ratner MA, 2001, P NATL ACAD SCI USA, V98, P387, DOI 10.1073/pnas.98.2.387
   Schafer H., 1962, CHEM TRANSPORTREAKTI
   Schlag EW, 2000, P NATL ACAD SCI USA, V97, P1068, DOI 10.1073/pnas.97.3.1068
   Schnyder B, 2002, SURF INTERFACE ANAL, V34, P40, DOI 10.1002/sia.1248
   SEN RK, 1975, ANNU REV PHYS CHEM, V26, P287, DOI 10.1146/annurev.pc.26.100175.001443
   Skorupska K, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2150267
   SKORUPSKA K, IN PRESS
   SKORUPSKA K, 2007, ECS T, V2, P63, DOI DOI 10.1149/1.2409009
   SKORUPSKA K, UNPUB
   STUBNER R, 1995, THESIS TU BERLIN
   SZE SM, 1980, SEMICONDUCTOR DEVICE
   Takeda K, 1996, J PHYS SOC JPN, V65, P421, DOI 10.1143/JPSJ.65.421                                                             
   Teschner D, 2005, J CATAL, V230, P195, DOI 10.1016/j.jcat.2004.11.035                                                      
   TRIBUTSCH H, 1977, Z NATURFORSCH A, V32, P972
   Verwey E. J. W., 1948, THEORY STABILITY LYO
   Helmholtz H. von, 1879, ANN PHYS, V7, P337
   Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282                                                   
   West JL, 2003, ANNU REV BIOMED ENG, V5, P285, DOI 10.1146/annurev.bioeng.5.011303.120723
   Wilson KR, 2006, INT J MASS SPECTROM, V249, P155, DOI 10.1016/j.ijms.2005.12.044
   WONG TW, 2004, BIOPHOTONICS, V14, P70
   Wydrzynski T, 2007, PHOTOSYNTH RES, V94, P225, DOI 10.1007/s11120-007-9271-0
   Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138
   Zhou SA, 2003, INT J ENG SCI, V41, P313, DOI 10.1016/S0020-7225(02)00207-0
   ZIELINSKI M, 1977, J PHYS D APPL PHYS, V10, pL105, DOI 10.1088/0022-3727/10/8/004
   Zigah D, 2007, ELECTROCHEM COMMUN, V9, P2387, DOI 10.1016/j.elecom.2007.07.016
   Collings AF, 2005, ARTIFICIAL PHOTOSYNTHESIS: FROM BASIC BIOLOGY TO INDUSTRIAL APPLICATION, P1, DOI 10.1002/3527606742
NR 74
TC 9
Z9 9
U1 0
U2 13
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0370-1972
EI 1521-3951
J9 PHYS STATUS SOLIDI B
JI Phys. Status Solidi B-Basic Solid State Phys.
PD SEP
PY 2008
VL 245
IS 9
BP 1884
EP 1898
DI 10.1002/pssb.200879541
PG 15
WC Physics, Condensed Matter
SC Physics
GA 350IJ
UT WOS:000259345700021
DA 2018-01-05
ER

PT J
AU El-Sayed, A
   Khalil, IA
   Kogure, K
   Futaki, S
   Harashima, H
AF El-Sayed, Ayman
   Khalil, Ikramy A.
   Kogure, Kentaro
   Futaki, Shiroh
   Harashima, Hideyoshi
TI Octaarginine- and octalysine-modified nanoparticles have different modes
   of endosomal escape
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS;
   HUMAN IMMUNODEFICIENCY VIRUS; INTRACELLULAR TRAFFICKING; NUCLEAR
   DELIVERY; MEMBRANE-FUSION; ENTERS CELLS; NANO DEVICE; TRANSDUCTION
AB The present study examines the role of surface modification with an octaarginine peptide (R8) in liposomal escape from endocytic vesicles, using octalysine (K8) as a control cationic peptide; the mechanism of endosomal escape of liposomes was also investigated. Gene expression of condensed plasmid DNA encapsulated in R8-modified nanoparticles was more than 1 order of magnitude higher than that of K8-modified nanoparticles, and 2 orders of magnitude higher than gene expression using unmodified nanoparticles. The difference in gene expression could not be attributed to differences in uptake, as R8- and K8-modified liposomes were taken up primarily via macropinocytosis with comparable efficiency. The extent of R8-nanoparticle escape to the cytosol was double that of K8-nanoparticles. Suppression of endosome acidification inhibited R8-nanoparticle endosomal escape, but enhanced that of K8-nanoparticles. Using spectral imaging in live cells, we showed that R8- and K8-liposomes escaped from endocytic vesicles via fusion between the liposomes and the endosomal membrane. R8- liposomes fused efficiently at both acidic and neutral pH, whereas K8- liposomes fused only at neutral pH. Similar behavior was observed during in vitro lipid mixing and calcein-release experiments. Co-incubation of cells with distinctly labeled K8- and R8-modified nanoparticles confirmed a common uptake pathway and different rates of endosomal escape particularly at longer time intervals. Therefore, it was concluded that R8 on the liposome surface stimulates efficient escape from endocytic vesicles via a fusion mechanism that works at both neutral and acidic pH; in contrast, K8 mediates escape mainly at neutral pH.
C1 [El-Sayed, Ayman; Khalil, Ikramy A.; Kogure, Kentaro; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0608012, Japan.
   [Kogure, Kentaro] Kyoto Pharmaceut Univ, Yamashina Ku, Kyoto 6078414, Japan.
   [Futaki, Shiroh] Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.
   [El-Sayed, Ayman; Khalil, Ikramy A.; Harashima, Hideyoshi] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan.
   [Futaki, Shiroh] Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan.
RP Harashima, H (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0608012, Japan.
EM harasima@pharm.hokudai.ac.jp
RI Harashima, Hideyoshi/D-8390-2012
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan Society for the Promotion of Science
FX This work was supported, in part, by grants-in-aid for Scientific
   Research (A) from the Ministry of Education, Culture, Sports, Science
   and Technology of Japan, and by grants-in-aid for Scientific Research on
   Priority Areas from the Japan Society for the Promotion of Science.
CR Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026
   Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005
   Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Brabec M, 2005, J VIROL, V79, P1008, DOI 10.1128/JVI.79.2.1008-1016.2005
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   DEKRUIJFF B, 1985, BIOCHIM BIOPHYS ACTA, V820, P295, DOI 10.1016/0005-2736(85)90124-5                                                    
   DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V601, P235, DOI 10.1016/0005-2736(80)90528-3                                                    
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Iwasa A, 2006, BBA-BIOMEMBRANES, V1758, P713, DOI 10.1016/j.bbamem.2006.04.015
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472
   MEERS P, 1988, BIOCHEMISTRY-US, V27, P4430, DOI 10.1021/bi00412a033
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Peitz M, 2002, P NATL ACAD SCI USA, V99, P4489, DOI 10.1073/pnas.032068699
   Potocky TB, 2005, J AM CHEM SOC, V127, P3686, DOI 10.1021/ja042566j
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Potocky TB, 2007, CHEMBIOCHEM, V8, P917, DOI 10.1002/cbic.200600563
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267
   Sakai N, 2003, J AM CHEM SOC, V125, P14348, DOI 10.1021/ja0376011
   STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023
   SUBTIL A, 1994, J CELL SCI, V107, P3461
   Tachibana R, 2003, METHOD ENZYMOL, V372, P349
   Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016
   Tilstra J, 2007, BIOCHEM SOC T, V35, P811, DOI 10.1042/BST0350811                                                              
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731
   Yamada Y, 2008, BBA-BIOMEMBRANES, V1778, P423, DOI 10.1016/j.bbamem.2007.11.002
   YANAGISHITA M, 1984, J BIOL CHEM, V259, P270
   Yang LL, 2003, CANCER RES, V63, P831
NR 53
TC 106
Z9 108
U1 1
U2 29
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 22
PY 2008
VL 283
IS 34
BP 23450
EP 23461
DI 10.1074/jbc.M709387200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 337SI
UT WOS:000258455400054
PM 18550548
OA gold
DA 2018-01-05
ER

PT J
AU Ray, P
AF Ray, Paresh
TI INOR 670-Sensing of sequence specific HIV-1 virus DNA using hyper
   Rayleigh scattering spectroscopy of gold nanorod
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 236th National Meeting of the American-Chemical-Society
CY AUG 17-21, 2008
CL Philadelphia, PA
SP Amer Chem Soc
C1 [Ray, Paresh] Jackson State Univ, Dept Chem, Jackson, MS 39217 USA.
EM paresh.c.ray@jsums.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 17
PY 2008
VL 236
MA 670-INOR
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 499WD
UT WOS:000270256306745
DA 2018-01-05
ER

PT J
AU Nawrozkij, MB
   Rotili, D
   Tarantino, D
   Botta, G
   Eremiychuk, AS
   Musmuca, I
   Ragno, R
   Samuele, A
   Zanoli, S
   Armand-Ugon, M
   Clotet-Codina, I
   Novakov, IA
   Orlinson, BS
   Maga, G
   Este, JA
   Artico, M
   Mai, A
AF Nawrozkij, Maxim B.
   Rotili, Dante
   Tarantino, Domenico
   Botta, Giorgia
   Eremiychuk, Alexandre S.
   Musmuca, Ira
   Ragno, Rino
   Samuele, Alberta
   Zanoli, Samantha
   Armand-Ugon, Mercedes
   Clotet-Codina, Imma
   Novakov, Ivan A.
   Orlinson, Boris S.
   Maga, Giovanni
   Este, Jose A.
   Artico, Marino
   Mai, Antonello
TI 5-alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a
   series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine
   family with peculiar structure-activity relationship profile
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN
   DATA-BANK; DEVELOPMENT KIT CDK; SOURCE JAVA LIBRARY; S-DABO DERIVATIVES;
   NONNUCLEOSIDE INHIBITORS; ANTIVIRAL ACTIVITY; IN-VITRO;
   3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES DABOS
AB A series of dihydro-alkylthio-benzyl-oxopyrimidines (S-DABOs) bearing a 2-aryl-2-oxoethylsulfanyl chain at pyrimidine C2, an alkyl group at C5, and a 2,6-dichloro-, 2-chloro-6-fluoro-, and 2,6-difluoro-benzyl substitution at C6 (oxophenethyl-S-DABOs, 6-8) is here described. The new compounds showed low micromolar to low nanomolar (in one case subnanomolar) inhibitory activity against wt HIV-1. Against clinically relevant HIV-1 mutants (K103N, Y181C, and Y188L) as well as in enzyme (wt and K103N, Y181I, and L1001 mutated RTs) assays, compounds carrying an ethylliso-propyl group at C5 and a 2,6-dichloro-/2-chloro-6-fluoro-benzyl moiety at C6 were the most potent derivatives, also characterized by low fold resistance ratio. Interestingly, the structure-activity relationship (SAR) data drawn from this DABO series are more related to HEPT than to DABO derivatives. These findings were at least in part rationalized by the description of a fair superimposition between the 6-8 and TNK-651 (a HEPT analogue) binding modes in both WT and Y181C RTs.
C1 [Rotili, Dante; Tarantino, Domenico; Botta, Giorgia; Musmuca, Ira; Ragno, Rino; Artico, Marino; Mai, Antonello] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, I-00185 Rome, Italy.
   [Nawrozkij, Maxim B.; Eremiychuk, Alexandre S.; Novakov, Ivan A.; Orlinson, Boris S.] Volgograd State Tech Univ, Volgograd 400131, Russia.
   [Samuele, Alberta; Zanoli, Samantha; Maga, Giovanni] IGM CNR, I-27100 Pavia, Italy.
   [Armand-Ugon, Mercedes; Clotet-Codina, Imma; Este, Jose A.] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab IrsiCaixa, Badalona 08916, Spain.
RP Mai, A (reprint author), Univ Roma La Sapienza, Dipartimento Studi Farmaceut, PA Moro 5, I-00185 Rome, Italy.
EM antonello.mai@uniroma1.it
RI Novakov, Ivan/I-4668-2015; Nawrozkij, Maxim/N-6646-2015; Este,
   Jose/B-5509-2008; Maga, Giovanni/C-5409-2009; Rotili, Dante/J-9157-2016
OI Nawrozkij, Maxim/0000-0001-5432-1326; Este, Jose/0000-0002-1436-5823;
   Maga, Giovanni/0000-0001-8092-1552; Mai, Antonello/0000-0001-9176-2382;
   Ragno, Rino/0000-0001-5399-975X; Rotili, Dante/0000-0002-8428-8763;
   Armand-Ugon, Mercedes/0000-0002-4069-9915; Novakov,
   Ivan/0000-0002-0980-6591
CR Armand-Ugon M, 2003, ANTIVIR RES, V59, P137, DOI 10.1016/S0166-3542(03)00071-8
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BOTTA M, 1992, EUR J MED CHEM, V27, P251, DOI 10.1016/0223-5234(92)90009-P
   BROWN HC, 1968, J AM CHEM SOC, V90, P1911, DOI 10.1021/ja01009a048                                                             
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   Cancio R, 2007, CHEMMEDCHEM, V2, P445, DOI 10.1002/cmdc.200600310
   Case D. A., 2004, AMBER, V8
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   Deshpande N, 2005, NUCLEIC ACIDS RES, V33, pD233
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Ettorre A, 1996, ACTA CRYSTALLOGR C, V52, P2115, DOI 10.1107/S0108270196006117                                                       
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   He YP, 2004, BIOORG CHEM, V32, P536, DOI 10.1016/j.bioorg.2004.05.007
   He YP, 2004, BIOORG MED CHEM LETT, V14, P3173, DOI 10.1016/j.bmcl.2004.04.008
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Krause S, 2000, MOLECULES, V5, P93, DOI 10.3390/50100093                                                                
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MAI A, 1995, J MED CHEM, V38, P3258, DOI 10.1021/jm00017a010
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Mai A, 2007, J MED CHEM, V50, P5412, DOI 10.1021/jm070811e
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   MARONGIU ME, 2001, RRD MED CHE, V1, P65
   MARTIN ACR, PROFIT 2 2
   MASSA S, 1995, ANTIVIR CHEM CHEMOTH, V6, P1
   MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   Moncunill G, 2008, AIDS, V22, P23, DOI 10.1097/QAD.0b013e3282f303e6                                                    
   Moncunill G, 2008, MOL PHARMACOL, V73, P1264, DOI 10.1124/mol.107.042911
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mugnaini C, 2006, BIOORG MED CHEM LETT, V16, P3541, DOI 10.1016/j.bmcl.2006.03.080
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Pani Alessandra, 2001, Antiviral Chemistry and Chemotherapy, V12, P51
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Quaglia MG, 2001, CHIRALITY, V13, P75, DOI 10.1002/1520-636X(2001)13:2<75::AID-CHIR1001>3.0.CO;2-W                         
   Ragno R, 2005, J MED CHEM, V48, P200, DOI 10.1021/jm0493921
   Ragno R, 2004, J MED CHEM, V47, P928, DOI 10.1021/jm0309856
   Ren J, 2004, J MOL BIOL, V336, P569, DOI 10.1016/j.jmb.2003.12.055
   Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988
   Sbardella G, 2001, ANTIVIR CHEM CHEMOTH, V12, P37, DOI 10.1177/095632020101200102                                                      
   Sbardella G, 2000, MED CHEM RES, V10, P30
   Sousa SF, 2006, PROTEINS, V65, P15, DOI 10.1002/prot.21082
   Steinbeck C, 2006, CURR PHARM DESIGN, V12, P2111, DOI 10.2174/138161206777585274
   Steinbeck C, 2003, J CHEM INF COMP SCI, V43, P493, DOI 10.1021/ci025584y
   TANAKA H, 1995, J MED CHEM, V38, P2860, DOI 10.1021/jm00015a008
   TRAMONTANO E, 1994, MICROBIOLOGICA, V17, P269
   Westbrook J, 2003, NUCLEIC ACIDS RES, V31, P489, DOI 10.1093/nar/gkg068
   YUASA S, 1993, MOL PHARMACOL, V44, P895
NR 58
TC 46
Z9 47
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 14
PY 2008
VL 51
IS 15
BP 4641
EP 4652
DI 10.1021/jm800340w
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 335KP
UT WOS:000258289800033
PM 18630898
DA 2018-01-05
ER

PT J
AU Lee, ES
   Gao, ZG
   Kim, D
   Park, K
   Kwon, IC
   Bae, YH
AF Lee, Eun Seong
   Gao, Zhonggao
   Kim, Dongin
   Park, Kyeongsoon
   Kwon, Ick Chan
   Bae, You Han
TI Super pH-sensitive multifunctional polymeric micelle for tumor pH(e)
   specific TAT exposure and multidrug resistance
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE pop-up pH-sensitive polymeric micelle; tumor pH; triggering drug
   release; multidrug resistance
ID EXTRACELLULAR PH; TRANSDUCTION DOMAIN; BREAST-CANCER; SOLID TUMORS;
   MCF-7 CELLS; HIV-1 TAT; PEPTIDE; EXPRESSION; NANOPARTICLES; ACCUMULATION
AB As an alternative to cell specific cancer targeting strategies (which are often afflicted with the heterogeneity of cancer cells as with most biological systems), a novel polymeric micelle constitute of two block copolymers of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)-TAT (transactivator of transcription) and poly(L-histidine)-b-poly(ethylene glycol) was developed. The micelle formed via the dialysis method was approximately 95 nm in diameter and contained 15 wt.% of doxorubicin (DOX) by weight. The micelle surface hides TAT during circulation, which has the strong capability to translocate the micelle into cells. and exposes TAT at a slightly acidic tumor extracellular pH to facilitate the internalization process. The micelle core was engineered for disintegration in early endosomal pH of tumor cells, quickly releasing DOX. The ionization process of the block copolymers and ionized polymers assisted in disrupting the endosomal membrane. This processes permitted high DOX concentrations in the cytosol and its target site of the nucleus, thus increasing DOX potency in various wild and multidrug resistant (MDR) cell lines (3.8-8.8 times lower IC50 than free DOX, depending on cell line). When tested with the xenografted tumors of human ovarian tumor drug-resistant A2780/AD, human breast tumor drug-sensitive MCF-7, human lung tumor A549 and human epidermoid tumor KB in a nude mice model, all tumors significantly regressed in size by three bolus injections at a dose of DOX 10 mg equivalent/kg body per injection of DOX-loaded micelle at three day interval, while minimum weight loss was observed. This approach may replace the need for cell-specific antibodies or targeting ligands, thereby providing a general strategy for solid tumor targeting. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Lee, Eun Seong; Gao, Zhonggao; Kim, Dongin; Bae, You Han] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84108 USA.
   [Park, Kyeongsoon; Kwon, Ick Chan] Korea Adv Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea.
RP Bae, YH (reprint author), Univ Utah, Dept Pharmaceut & Pharmaceut Chem, 421 Wakara Way,Suite 315, Salt Lake City, UT 84108 USA.
EM you.bae@utah.edu
RI Kim, Dongin /G-3237-2012
OI Kim, Dongin/0000-0003-2078-6138
FU NIH [CA 122356, 101850]
FX The authors thank Profs. D. W. Grainger, C. Lim (Dept of Pharmaceutics,
   University of Utah), and I E. Cheatham (Dept of Bioengineering,
   University of Utah) for their kind discussion/suggestion and
   proof-reading. This work was supported by NIH CA 122356 and 101850.
CR CHAIDARUN SS, 1994, ENDOCRINOLOGY, V135, P2012, DOI 10.1210/en.135.5.2012
   Chaudhry A, 1999, CLIN CANCER RES, V5, P3385
   Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311
   Desoize B, 2000, CRIT REV ONCOL HEMAT, V36, P193, DOI 10.1016/S1040-8428(00)00086-X
   Dreher MR, 2007, CANCER RES, V67, P4418, DOI 10.1158/0008-5472.CAN-06-4444
   Dreher MR, 2006, J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kim GM, 2005, MACROMOL BIOSCI, V5, P1118, DOI 10.1002/mabi.200500121                                                          
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2005, J CONTROL RELEASE, V103, P405, DOI 10.1016/j.jconrel.2004.12.018
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   Lee ES, 2007, J CONTROL RELEASE, V123, P19, DOI 10.1016/j.jconrel.2007.08.006
   LEEPER DB, 1994, INT J RADIAT ONCOL, V28, P935, DOI 10.1016/0360-3016(94)90114-7                                                    
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Mahadevan D, 2004, BLOOD, V104, P1940, DOI 10.1182/blood-2004-07-2490
   Mehta K, 2002, J NATL CANCER I, V94, P1652
   Mohajer G, 2007, PHARM RES-DORDR, V24, P1618, DOI 10.1007/s11095-007-9277-5
   MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802                                                     
   Oh IK, 2006, BIOCONJUGATE CHEM, V17, P721, DOI 10.1021/bc060030c
   Park K, 2007, J CONTROL RELEASE, V122, P305, DOI 10.1016/j.jconrel.2007.04.009
   Parker N, 2005, ANAL BIOCHEM, V338, P284, DOI 10.1016/j.ab.2004.12.026
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Scholler N, 1999, P NATL ACAD SCI USA, V96, P11531, DOI 10.1073/pnas.96.20.11531                                                        
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shan SQ, 2003, MICROVASC RES, V65, P109, DOI 10.1016/S0026-2862(02)00017-1
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044                                                             
   van Sluis R, 1999, MAGN RESON MED, V41, P743
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Yang SR, 2006, J CONTROL RELEASE, V114, P60, DOI 10.1016/j.jconrel.2006.05.016
   Yin HQ, 2008, J CONTROL RELEASE, V126, P130, DOI 10.1016/j.jconrel.2007.11.014
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 35
TC 250
Z9 268
U1 9
U2 156
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 7
PY 2008
VL 129
IS 3
BP 228
EP 236
DI 10.1016/j.jconrel.2008.04.024
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 345HH
UT WOS:000258986500012
PM 18539355
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Wayengera, M
   Kajumbula, H
   Byarugaba, W
AF Wayengera, Misaki
   Kajumbula, Henry
   Byarugaba, Wilson
TI Identification of restriction endonuclease with potential ability to
   cleave the HSV-2 genome: inherent potential for biosynthetic versus live
   recombinant microbicides
SO THEORETICAL BIOLOGY AND MEDICAL MODELLING
LA English
DT Article
ID HERPES-SIMPLEX-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-RELATED
   PROTEIN-1; LOADED PLGA NANOPARTICLES; POLIOVIRUS RECEPTOR; SEXUAL
   TRANSMISSION; ECORII RESTRICTION; GLYCOPROTEIN-D; HIV-INFECTION; SURFACE
AB Background: Herpes Simplex virus types 1 and 2 are enveloped viruses with a linear dsDNA genome of similar to 120-200 kb. Genital infection with HSV-2 has been denoted as a major risk factor for acquisition and transmission of HIV-1. Developing biomedical strategies for HSV-2 prevention is thus a central strategy in reducing global HIV-1 prevalence. This paper details the protocol for the isolation of restriction endunucleases (REases) with potent activity against the HSV-2 genome and models two biomedical interventions for preventing HSV-2.
   Methods and results: Using the whole genome of HSV-2, 289 REases and the bioinformatics software Webcutter2; we searched for potential recognition sites by way of genome wide palindromics. REase application in HSV-2 biomedical therapy was modeled concomitantly. Of the 289 enzymes analyzed; 77(26.6%) had potential to cleave the HSV-2 genome in > 100 but < 400 sites; 69(23.9%) in > 400 but < 700 sites; and the 9(3.1%) enzymes: BmyI, Bsp1286I, Bst2UI, BstNI, BstOI, EcoRII, HgaI, MvaI, and SduI cleaved in more than 700 sites. But for the 4: PacI, PmeI, SmiI, SwaI that had no sign of activity on HSV-2 genomic DNA, all 130(45%) other enzymes cleaved < 100 times. In silico palindromics has a PPV of 99.5% for in situ REase activity (2) Two models detailing how the REase EcoRII may be applied in developing interventions against HSV-2 are presented: a nanoparticle for microbicide development and a "recombinant lactobacillus" expressing cell wall anchored receptor (truncated nectin-1) for HSV-2 plus EcoRII.
   Conclusion: Viral genome slicing by way of these bacterially-derived R-M enzymatic peptides may have therapeutic potential in HSV-2 infection; a cofactor for HIV-1 acquisition and transmission.
C1 [Wayengera, Misaki; Kajumbula, Henry; Byarugaba, Wilson] Restrizymes Biotherapeut Uganda Ltd, Kampala, Uganda.
   [Wayengera, Misaki] Restrizymes Corp, Toronto, ON, Canada.
   [Wayengera, Misaki; Kajumbula, Henry] Makerere Univ, Coll Hlth Sci, Dept Microbiol, Div Mol Biol, Kampala, Uganda.
   [Wayengera, Misaki; Byarugaba, Wilson] Makerere Univ, Coll Hlth Sci, Dept Pathol, Div Human & Mol Genet, Kampala, Uganda.
RP Wayengera, M (reprint author), Restrizymes Biotherapeut Uganda Ltd, Kampala, Uganda.
EM wmisaki@yahoo.com; jumbic@hotmail.com; wbyarugaba@yahoo.co.uk
OI Wayengera, Misaki/0000-0001-7239-8079; Kajumbula,
   Henry/0000-0002-2075-0007
FU Virology Educ.; global AIDS vaccine Initiative; Microbicide2008; Bill
   and Melinda Gates AIDS foundation through Keystone
FX The authors received no specific funding for this work. W.M. has in the
   past, however, received scholarly grant support in this line of study
   from Virology Educ., the global AIDS vaccine Initiative,
   Microbicide2008, and the Bill and Melinda Gates AIDS foundation through
   Keystone.
CR ALBRECHT MA, 1989, J VIROL, V63, P1861
   Anderson R.M., 1999, SEXUALLY TRANSMITTED, P25
   Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Beninati C, 2000, NAT BIOTECHNOL, V18, P1060, DOI 10.1038/80250
   Betancourt T, 2007, NANOMEDICINE-UK, V2, P219, DOI 10.2217/17435889.2.2.219
   BHAGWAT AS, 1990, J BIOL CHEM, V265, P767
   BUTKUS V, 1985, NUCLEIC ACIDS RES, V13, P5727, DOI 10.1093/nar/13.16.5727                                                          
   Calistri A, 1999, J ACQ IMMUN DEF SYND, V21, P90
   CUNNINGHAM AL, 1985, J CLIN INVEST, V75, P226, DOI 10.1172/JCI111678
   DiJoseph JF, 2007, CANCER IMMUNOL IMMUN, V56, P1107, DOI 10.1007/s00262-006-0260-5
   EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274                                                         
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3                                                              
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, V10, P571, DOI DOI 10.1385/1-59259-890-0:571
   Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618
   Giomarelli B, 2002, AIDS, V16, P1351, DOI 10.1097/00002030-200207050-00006
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2                                                   
   Hillier SL, 1998, AIDS RES HUM RETROV, V14, pS17
   HUANG LH, 1982, NUCLEIC ACIDS RES, V10, P1579, DOI 10.1093/nar/10.5.1579
   JANULAITIS A, 1981, FEBS LETT, V134, P172, DOI 10.1016/0014-5793(81)80594-7
   KOSSYKH V, 1989, BIOCHIM BIOPHYS ACTA, V1009, P290, DOI 10.1016/0167-4781(89)90117-6
   KOSSYKH VG, 1989, DOKL AKAD NAUK SSSR, V308, P1497
   KOSYKH VG, 1978, DOKL AKAD NAUK SSSR+, V238, P1227
   Kruger C, 2002, NAT BIOTECHNOL, V20, P702, DOI 10.1038/nbt0702-702
   Krummenacher C, 1998, J VIROL, V72, P7064
   LeGoff J, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-2
   LEPIKHOV K, 2001, NUCLEIC ACIDS RES, V15, P4691
   Liu XM, 2008, APPL ENVIRON MICROB, V74, P4626, DOI 10.1128/AEM.00104-08
   LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G                                                    
   MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T
   MURRAY N, 2002, MICROBIAL MOL BIOL R, V64, P412
   Nam SH, 2007, B KOR CHEM SOC, V28, P397
   Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174
   NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045                                                       
   Pant N, 2006, J INFECT DIS, V194, P1580, DOI 10.1086/508747
   Patton DL, 2006, SEX TRANSM DIS, V33, P691, DOI 10.1097/01.olq.0000216022.18321.d3
   Rodriguez MDM, 2002, AIDS, V16, P451
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   SHIBATA T, 1976, J BACTERIOL, V128, P473
   Subramanian RP, 2007, P NATL ACAD SCI USA, V104, P2903, DOI 10.1073/pnas.0608374104
   SUGISAKI H, 1993, B I CHEM RES KYOTO U, V71, P338
   UNAIDS, 2006, REP GLOB HIV AIDS EP
   WAGNER E, 1990, NUCLEIC ACIDS RES, V18, P3088, DOI 10.1093/nar/18.10.3088
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218
   WAYENGERA M, 2007, AFR J BIOTECHNOL, V6, P1750
   Wayengera M., 2008, J APPL BIOL SCI, V1, P56
   WAYENGERA M, 2007, AFR J BIOTECHNOL, V6, P1225
   WAYENGERA M, AIDS VACCINE
   WAYENGERA M, 2008, MICROBICIDE NEW DELH
   *WHO UNAIDS, 2001, HERP SIMPL VIR TYP 2
   Wilkinson D, 2002, LANCET INFECT DIS, V2, P613, DOI 10.1016/S1473-3099(02)00396-1
   Zhou XYE, 2004, J MOL BIOL, V335, P307, DOI 10.1016/j.jmb.2003.10.030
   ZHU ZH, 1990, J ACQ IMMUN DEF SYND, V3, P215
NR 56
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1742-4682
J9 THEOR BIOL MED MODEL
JI Theor. Biol. Med. Model.
PD AUG 7
PY 2008
VL 5
AR 18
DI 10.1186/1742-4682-5-18
PG 12
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 439RG
UT WOS:000265644100001
PM 18687114
OA gold
DA 2018-01-05
ER

PT J
AU Matei, E
   Furey, W
   Gronenborn, AM
AF Matei, Elena
   Furey, William
   Gronenborn, Angela M.
TI Solution and crystal structures of a sugar binding site mutant of
   cyanovirin-N: No evidence of domain swapping
SO STRUCTURE
LA English
DT Article
ID HIV-INACTIVATING PROTEIN; STRONGLY INHIBIT AGGLUTINATION; HIGH-MANNOSE
   OLIGOSACCHARIDES; ANTIVIRAL ACTIVITY; NMR-SPECTRA; NOESY-HSQC; CONTAINS
   2; X-RAY; GP120; VIRUS
AB The cyanobacterial lectin Cyanovirin-N (CV-N) exhibits antiviral activity against H IV at a low nanomolar concentration by interacting with high-mannose oligosaccharides on the virus surface envelope glycoprotein gpl 20. Atomic structures of wild-type CV-N revealed a monomer in solution and a domain-swapped dimer in the crystal, with the monomer comprising two independent carbohydrate binding sites that individually bind with micromolar affinity to di- and mutDB trimannoses. In the mutant CVN, the binding site on domain B was abolished and the protein was found to be completely inactive against HIV. We determined the solution NIVIR and crystal structures of this variant and characterized its sugar binding properties. In solution and the crystal, CVN,tDE3 is a monomer and no domain-swapping was observed. The protein binds to Man-3 and Man-9 with similar dissociation constants (-4 IuM). This confirms that the nanomolar activity of wild-type CV-N is related to the multisite nature of the protein carbohydrate interaction.
C1 [Matei, Elena; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [Furey, William] Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA.
   [Furey, William] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.
RP Gronenborn, AM (reprint author), Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
EM amgl00@pitt.edu
OI Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health [R01 GM080642]
FX We thank Laura Barrientos for kindly providing the CVN<SUP>mutDB</SUP>
   clone and guidance in protein expression and purification, JunGoo Jee
   for assistance and useful discussions regarding CYANA, In-Ja Beyon for
   continuous help setting up NMR experiments, and John Louis for generous
   advice, expertise and discussions. We are grateful to Corine Sandstrom
   for kindly supplying the trimannoside sample. This work was in part
   funded by a National Institutes of Health grant to A.M.G. (R01
   GM080642).
CR ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164                                                         
   Barrientos LG, 2006, PROTEIN ENG DES SEL, V19, P525, DOI 10.1093/protein/gzl040
   Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Barrientos LG, 2002, BIOCHEM BIOPH RES CO, V298, P598, DOI 10.1016/S0006-291X(02)02489-0                                                   
   BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001                                                             
   Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Botos I, 2002, BIOCHEM BIOPH RES CO, V294, P184, DOI 10.1016/S0006-291X(02)00455-2
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Bundle D. R, 1992, CURR OPIN STRUC BIOL, V2, P666
   CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740                                                         
   Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610
   DeFrees SA, 1996, J AM CHEM SOC, V118, P6101, DOI 10.1021/ja954122g                                                               
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   FESIK SW, 1990, Q REV BIOPHYS, V23, P97, DOI 10.1017/S0033583500005515                                                       
   Fromme R, 2007, BIOCHEMISTRY-US, V46, P9199, DOI 10.1021/bi700666m
   GRZESIEK S, 1993, J BIOMOL NMR, V3, P487
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3
   Johnson Bruce A, 2004, Methods Mol Biol, V278, P313
   Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   LEE YC, 1992, FASEB J, V6, P3193
   LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027
   Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g                                                               
   Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402
   LOGAN TM, 1993, J BIOMOL NMR, V3, P225
   Meunier SJ, 1996, TETRAHEDRON LETT, V37, P5469, DOI 10.1016/0040-4039(96)01167-7
   MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109
   Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q                                                               
   MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102
   Nagi AD, 1997, FOLD DES, V2, P67, DOI 10.1016/S1359-0278(97)00007-2                                                   
   Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9                                                   
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361
   PATTERSON GML, 1993, J PHYCOL, V29, P125, DOI 10.1111/j.1529-8817.1993.tb00290.x
   Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X                                                       
   Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7
   SABESAN S, 1991, CARBOHYD RES, V218, P27, DOI 10.1016/0008-6215(91)84084-R
   Sandstrom C, 2004, BIOCHEMISTRY-US, V43, P13926, DOI 10.1021/bi048676k
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u                                                               
   SPENGARD U, 1996, ANGEW CHEM INT EDIT, V35, P321
   Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 55
TC 31
Z9 32
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
J9 STRUCTURE
JI Structure
PD AUG 6
PY 2008
VL 16
IS 8
BP 1183
EP 1194
DI 10.1016/j.str.2008.05.011
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 337JA
UT WOS:000258431200007
PM 18682220
OA gold
DA 2018-01-05
ER

PT J
AU Joo, KI
   Lei, YN
   Lee, CL
   Lo, J
   Xie, JS
   Hamm-Alvarez, SF
   Wang, P
AF Joo, Kye-Il
   Lei, Yuning
   Lee, Chi-Lin
   Lo, Jonathon
   Xie, Jiansong
   Hamm-Alvarez, Sarah F.
   Wang, Pin
TI Site-specific labeling of enveloped viruses with quantum dots for single
   virus tracking
SO ACS NANO
LA English
DT Article
DE quantum dot; virus tracking; nanobiotechnology; retrovirus; human
   immunodeficiency virus
ID CLATHRIN-MEDIATED ENDOCYTOSIS; INDIVIDUAL INFLUENZA-VIRUSES; LIVING
   CELLS; DENDRITIC CELLS; EARLY ENDOSOMES; LENTIVIRAL VECTORS;
   SURFACE-PROTEINS; BIOTIN LIGASE; DC-SIGN; ENTRY
AB This study reports a general method of labeling enveloped viruses with semiconductor quantum dots (QDs) for use in single virus trafficking studies. Retroviruses, including human immunodeficiency virus (HIV), could be successfully tagged with QDs through the membrane incorporation of a short acceptor peptide (AP) that is susceptible to site-specific biotinylation and attachment of streptavidin-conjugated QDs. It was found that this AP tag-based QD labeling had little effect on the viral infectivity and allowed for the study of the kinetics of the internalization of the recombinant lentivirus enveloped with vesicular stomatitis virus glycoprotein (VSVG) into the early endosomes. It also allows for the live cell imaging of the trafficking of labeled virus to the Rab(5+) endosomal compartments. This study further demonstrated by direct visualization of QD-labeled virus that VSVG-pseudotyped lentivirus enters cells independent of clatherin- and caveolin-pathways, while the entry of VSVG-pseudotyped retrovirus occurs via the clathrin pathway. The studies monitoring HIV particles using QD-labeling showed that we could detect single virions on the surface of target cells expressing either CD4/CCR5 or DC-SIGN. Further internalization studies of QD-HIV evidently showed that the clathrin pathway is the major route for DC-SIGN-mediated uptake of viruses. Taken together, our data demonstrate the potential of this QD-labeling for visualizing the dynamic interactions between viruses and target cell structures.
C1 [Joo, Kye-Il; Lei, Yuning; Lee, Chi-Lin; Lo, Jonathon; Wang, Pin] Univ So Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA.
   [Xie, Jiansong; Hamm-Alvarez, Sarah F.] Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA.
RP Wang, P (reprint author), Univ So Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA.
EM pinwang@usc.edu
OI Hamm-Alvarez, Sarah/0000-0001-8195-5703
FU National Institute of Health [A1068978]
FX We thank April Tai and Lili Yang for critical reading of the manuscript,
   and the USC Norris Center Cell and Tissue Imaging Core. This work was
   supported by a National Institute of Health Grant A1068978. The
   following reagents were obtained through the AIDS Research and Reference
   Reagent Program, Division of AIDS, MAID, NIH: Monoclonal Antibody to
   HIV-1 p24 (AG3.0) from Dr. Jonathan Allan; HeLa/CD4/CCR5 (TZM-bl) cell
   line from Drs. John C. Kappes, Xiaoyun Wu, and Tranzyme Inc.
CR Agrawal A, 2005, J VIROL, V79, P8625, DOI 10.1128/JVI.79.13.8625-8628.2005                                                
   Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921                                                              
   Bentzen EL, 2005, NANO LETT, V5, P591, DOI 10.1021/nl048073u
   Blanchard E, 2006, J VIROL, V80, P6964, DOI 10.1128/JVI.00024-06
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Cambi A, 2007, NANO LETT, V7, P970, DOI 10.1021/nl0700503
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735
   Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005
   DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915                                                           
   Dixit SK, 2006, NANO LETT, V6, P1993, DOI 10.1021/nl061165u
   Gaidarov I, 1999, NAT CELL BIOL, V1, P1
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7
   Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102
   Kohn DB, 2007, NAT BIOTECHNOL, V25, P65, DOI 10.1038/nbt0107-65
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038
   Lee SY, 1999, J VIROL, V73, P5994
   Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Medina-Kauwe LK, 2005, GENE THER, V12, P1734, DOI 10.1038/sj.gt.3302592
   Medintz IL, 2005, LANGMUIR, V21, P5501, DOI 10.1021/la0468287
   Meertens L, 2006, J VIROL, V80, P11571, DOI 10.1128/JVI.01717-06
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367
   Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   PIRAN U, 1990, J IMMUNOL METHODS, V133, P141, DOI 10.1016/0022-1759(90)90328-S
   PORTNEY NG, 2007, APPL PHYS LETT, V90
   Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043
   Romer W, 2007, NATURE, V450, P670, DOI 10.1038/nature05996
   Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x                                                
   Somia N, 2000, NAT REV GENET, V1, P91, DOI 10.1038/35038533
   Sun XJ, 2005, VIROLOGY, V338, P53, DOI 10.1016/j.virol.2005.05.006
   Tagawa A, 2005, J CELL BIOL, V170, P769, DOI 10.1083/jcb.200506103
   Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129
   Vonderheit A, 2005, PLOS BIOL, V3, P1225, DOI 10.1371/journal.pbio.0030233
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Yang L, 2005, P NATL ACAD SCI USA, V102, P4518, DOI 10.1073/pnas.0500600102
   Yang L, 2008, NAT BIOTECHNOL, V26, P326, DOI 10.1038/nbt1390
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055                                                                
NR 50
TC 75
Z9 78
U1 4
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD AUG
PY 2008
VL 2
IS 8
BP 1553
EP 1562
DI 10.1021/nn8002136
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 342HK
UT WOS:000258775000008
PM 19079775
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hou, Y
   Gochin, M
AF Hou, Yanxia
   Gochin, Miriam
TI Artificial ion channel biosensor in human immunodeficiency virus gp41
   drug sensing
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID 6-HELIX BUNDLE FORMATION; CELL-FUSION ASSAY; COIL-LIKE MOTIFS; HIV-1
   GP41; MEMBRANE-FUSION; TYPE-1 GP41; ANTI-HIV-1 ACTIVITY; SCREENING
   ASSAY; HELICAL DOMAIN; CORE STRUCTURE
AB An ion channel biosensor is described for label-free detection of inhibitors which bind to the coiled coil domain of human immunodeficiency virus type 1 gp41. gp41 is the viral transmembrane glycoprotein responsible for fusion between HIV-1 and host cells. The N-terminal coiled coil domain binds three antiparallel C-heptad repeat peptides in the six helix bundle structure of trimeric gp41 that forms during fusion. Compounds able to prevent six-helix bundle formation by binding to the gp41 coiled coil could inhibit fusion and have important therapeutic potential. We have immobilized on gold a positively charged metallopeptide mimic of a section of the gp41 coiled coil containing a hydrophobic pocket suitable for small molecule binding. We demonstrate that the resulting sensor is able to transmit a current in the presence of negatively charged redox marker ions, therefore acting as an artificial ion channel. The electrochemical signal, measured by cyclic voltammetry, was modulated by specific analyte binding to the coiled coil. Nanomolar quantities of peptides and small molecules that bind in the hydrophobic pocket could be selectively detected, providing a method for label-free detection of binding to gp41.
C1 [Hou, Yanxia; Gochin, Miriam] Touro Univ Calif, Dept Basic Sci, Vallejo, CA 94592 USA.
   [Hou, Yanxia; Gochin, Miriam] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
RP Gochin, M (reprint author), Touro Univ Calif, Dept Basic Sci, Vallejo, CA 94592 USA.
EM mgochin@touro.edu
RI HOU, yanxia/B-2576-2009
CR Ayela C, 2007, BIOSENS BIOELECTRON, V22, P3113, DOI 10.1016/j.bios.2007.01.020
   Bonanni A, 2006, ANAL BIOANAL CHEM, V385, P1195, DOI 10.1007/s00216-006-0558-3
   Bradley J, 2004, J BIOMOL SCREEN, V9, P516, DOI 10.1177/1087057104264577
   Cai LF, 2007, ANTIMICROB AGENTS CH, V51, P2388, DOI 10.1128/AAC.00150-07
   Case MA, 2003, NANO LETT, V3, P425, DOI 10.1021/nl025795h
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w
   Cooper MA, 2006, DRUG DISCOV TODAY, V11, P1068, DOI 10.1016/j.drudis.2006.10.001
   Cretich M, 2006, BIOMOL ENG, V23, P77, DOI 10.1016/j.bioeng.2006.02.001
   Debnath AK, 2006, CURR OPIN INVEST DR, V7, P118
   Engel KH, 1930, J AM CHEM SOC, V52, P211, DOI 10.1021/ja01364a030                                                             
   Ernst JT, 2001, ANGEW CHEM INT EDIT, V41, P278, DOI 10.1002/1521-3773(20020118)41:2<278::AID-ANIE278>3.0.CO;2-A
   EVERETT WR, 1995, ANAL CHIM ACTA, V307, P253, DOI 10.1016/0003-2670(95)00004-J                                                    
   Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, V10, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gochin M, 2006, BIOL CHEM, V387, P477, DOI 10.1515/BC.2006.063
   Han SB, 2001, CHEM COMMUN, P609, DOI 10.1039/b100371m                                                                
   Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405
   Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9
   HUANG TLJ, 1981, CAN J CHEM, V59, P1689, DOI 10.1139/v81-252                                                                 
   Ji CH, 2006, J BIOMOL SCREEN, V11, P65, DOI 10.1177/1087057105282959
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5
   Jiang SB, 2000, BIOCHEM BIOPH RES CO, V270, P153, DOI 10.1006/bbrc.2000.2411                                                          
   Katayama Y, 2000, ANAL CHEM, V72, P4671, DOI 10.1021/ac990847h
   Keusgen M, 2002, NATURWISSENSCHAFTEN, V89, P433, DOI 10.1007/s00114-002-0358-3
   Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003
   Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319
   Kuramitz H, 2003, ANALYST, V128, P182, DOI 10.1039/b209590b
   Manfredi R, 2006, CURR MED CHEM, V13, P2369, DOI 10.2174/092986706777935069
   Meadows D, 1996, ADV DRUG DELIVER REV, V21, P179, DOI 10.1016/S0169-409X(96)00406-1                                                   
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Mo HM, 2004, VIROLOGY, V329, P319, DOI 10.1016/j.virol.2004.08.025
   Murata M, 2004, BIOORG MED CHEM LETT, V14, P137, DOI 10.1016/j.bmcl.2003.10.002
   Murata M, 2001, ANAL SCI, V17, P387, DOI 10.2116/analsci.17.387                                                          
   Naicker KP, 2004, BIOORGAN MED CHEM, V12, P1215, DOI 10.1016/j.bmc.2003.11.006
   Park HE, 2003, NAT STRUCT BIOL, V10, P1048, DOI 10.1038/nsb1012
   Root MJ, 2004, CURR PHARM DESIGN, V10, P1805, DOI 10.2174/1381612043384448
   Schon P, 2005, J AM CHEM SOC, V127, P11486, DOI 10.1021/ja051574c
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796
   Singh M, 1998, P NATL ACAD SCI USA, V95, P2738, DOI 10.1073/pnas.95.6.2738
   Strockbine B, 2007, PROTEINS, V67, P630, DOI 10.1002/prot.21301
   Umezawa Y, 2004, ANAL CHEM, V76, p320A, DOI 10.1021/ac0416259                                                               
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
NR 48
TC 8
Z9 8
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 1
PY 2008
VL 80
IS 15
BP 5924
EP 5929
DI 10.1021/ac800511n
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 332PX
UT WOS:000258096700039
PM 18590277
DA 2018-01-05
ER

PT J
AU Monforte, AM
   Rao, A
   Logoteta, P
   Ferro, S
   De Luca, L
   Barreca, ML
   Iraci, N
   Maga, G
   De Clercq, E
   Pannecouque, C
   Chimirri, A
AF Monforte, Anna-Maria
   Rao, Angela
   Logoteta, Patrizia
   Ferro, Stefania
   De Luca, Laura
   Barreca, Maria Letizia
   Iraci, Nunzio
   Maga, Giovanni
   De Clercq, Erik
   Pannecouque, Christophe
   Chimirri, Alba
TI Novel N(1)-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent
   non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE RT inhibitors; benzimidazolones; molecular modeling; microwave-assisted
   synthesis
ID AMINO-ACID SUBSTITUTIONS; DESIGN; DRUGS; STRATEGIES; RESISTANCE;
   MUTANTS; STRAINS
AB Several N(1)-substituted 1,3-dihydro-2H-benzimidazol-2-ones were synthesized and evaluated as anti-HIV agents. Some of them proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentration as potent non-nucleoside HIV-1 RT inhibitors (NNRTIs) with low cytotoxicity. SAR studies highlighted that the nature of the substituents at N(1) and on the benzene ring of benzimidazolone moiety significantly influenced the anti-HIV activity of this class of potent antiretroviral agents. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Monforte, Anna-Maria; Rao, Angela; Logoteta, Patrizia; Ferro, Stefania; De Luca, Laura; Iraci, Nunzio; Chimirri, Alba] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   [Barreca, Maria Letizia] Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy.
   [Maga, Giovanni] CNR, Inst Genet Mol, I-27100 Pavia, Italy.
   [De Clercq, Erik; Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Monforte, AM (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
EM ammonforte@pharma.unime.it
RI Iraci, Nunzio/B-4945-2015; De Luca, Laura/D-8532-2011; Maga,
   Giovanni/C-5409-2009
OI Iraci, Nunzio/0000-0002-1359-8684; Maga, Giovanni/0000-0001-8092-1552;
   Barreca, Maria Letizia/0000-0003-3530-5042; De Luca,
   Laura/0000-0003-0614-5713
FU Fondo Ateneo di ricerca (Messina, Italy); European TRIoH Consortium
   [LSHB-CT-2003-503480]
FX Financial support for this research by Fondo Ateneo di ricerca (2004,
   Messina, Italy), European TRIoH Consortium (LSHB-CT-2003-503480) is
   gratefully acknowledged.
CR BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   Barreca ML, 2007, BIOORG MED CHEM LETT, V17, P1956, DOI 10.1016/j.bmcl.2007.01.025
   Barreca ML, 2005, J MED CHEM, V48, P3433, DOI 10.1021/jm049279a
   Barreca ML, 2002, J MED CHEM, V45, P5410, DOI 10.1021/jm020977+
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jvc.2004.02.009
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Imamichi T, 2004, CURR PHARM DESIGN, V10, P4039, DOI 10.2174/1381612043382440                                                        
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
NR 10
TC 30
Z9 32
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 1
PY 2008
VL 16
IS 15
BP 7429
EP 7435
DI 10.1016/j.bmc.2008.06.012
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 341XR
UT WOS:000258749500038
PM 18585918
DA 2018-01-05
ER

PT J
AU Kersemans, V
   Kersemans, K
   Cornelissen, B
AF Kersemans, Veerle
   Kersemans, Ken
   Cornelissen, Bart
TI Cell penetrating peptides for in vivo molecular imaging applications
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE CPP; cell penetrating peptides; molecular imaging; applications
ID ARGININE-RICH PEPTIDES; NUCLEAR-LOCALIZATION SEQUENCE; BREAST-CANCER
   CELLS; EFFICIENT INTRACELLULAR DELIVERY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   PROTEIN TRANSDUCTION DOMAIN; DEPENDENT KINASE INHIBITOR; RED FLUORESCENT
   PEPTIDE; TAT-FUSION PROTEINS; MAGNETIC NANOPARTICLES
AB Cell penetrating peptides (CPPs) are a relatively new class of peptides that have the promising capability to cross cell membranes. While details remain to be resolved, various non-receptor-mediated endocytic pathways likely contribute most to the cell penetrating properties of these peptides. CPPs have been used to deliver many different cargos - ranging from radionuclides and other peptides to antibodies and nanoparticles - into cells. Besides many different drug delivery applications, CPPs have also seen a limited use in molecular imaging. Molecular imaging of intracellular and intranuclear targets, by techniques such as SPECT, PET, optical imaging, and MRI, relies heavily on the delivery of contrast agents to the cytoplasm and/or nuclei of the target tissue. Therefore, the number of applications in molecular imaging of intracellular targets has remained relatively low, because of the effective barrier presented by the cell membrane. One of the key strategies to overcome this challenge is the introduction of membrane-transducing peptides in the design of new contrast agents. This review presents an overview of the literature on CPPs, focusing on their use for molecular imaging. Applications using proteins and peptides, DNA/RNA, and CPP-loaded cells as the imaging agents will be looked at. Moreover, the difficulties and pitfalls regarding the use of CPPs in molecular imaging will be discussed.
C1 [Kersemans, Ken] Free Univ Brussels, Dept Cyclotron BEFY, Brussels, Belgium.
RP Kersemans, V (reprint author), Univ Oxford, Churchill Hosp, Dept Radiat Oncol & Biol, Radiobiol Res Inst, Oxford OX3 7LJ, England.
EM Veerle.Kersemans@rob.ox.ac.uk
OI Cornelissen, Bart/0000-0001-7581-3303
CR Aints A, 1999, J GENE MED, V1, P275
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Barnett EM, 2006, INVEST OPHTH VIS SCI, V47, P2589, DOI 10.1167/iovs.05-1470
   Bauer C, 2005, J NUCL MED, V46, P1066
   Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
   Beven L, 1997, BBA-BIOMEMBRANES, V1329, P357, DOI 10.1016/S0005-2736(97)00130-2                                                   
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Blankenberg FG, 2007, Q J NUCL MED MOL IM, V51, P99
   Bonfanti M, 1997, CANCER RES, V57, P1442
   Borsello T, 2007, CURR PHARM DESIGN, V13, P1875
   BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340                                                          
   Brunelle A, 2007, CURR PHARM DESIGN, V13, P3335, DOI 10.2174/138161207782360618
   Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Bullok KE, 2007, BIOCHEMISTRY-US, V46, P4055, DOI 10.1021/bi061959n
   Bullok KE, 2006, MOL IMAGING, V5, P1, DOI 10.2310/7290.2006.00001
   Chaloin L, 1998, BIOCHEM BIOPH RES CO, V243, P601, DOI 10.1006/bbrc.1997.8050
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   Chico DE, 2003, PEPTIDES, V24, P3, DOI 10.1016/S0196-9781(02)00270-X                                                   
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Cornelissen B, 2007, NUCL MED BIOL, V34, P37, DOI 10.1016/j.nucmedbio.2006.10.008
   Costantini DL, 2007, J NUCL MED, V48, P1357, DOI 10.2967/jnumed.106.037937
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Elliott G, 1998, J VIROL, V72, P6448
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Fang B, 1998, GENE THER, V5, P1420, DOI 10.1038/sj.gt.3300741                                                           
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fernandez-Carneado J, 2004, ANGEW CHEM INT EDIT, V43, P1811, DOI 10.1002/anie.200352540
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fonovic M, 2007, CURR PHARM DESIGN, V13, P253, DOI 10.2174/138161207779313623                                                      
   Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gallazzi F, 2003, BIOCONJUGATE CHEM, V14, P1083, DOI 10.1021/bc034084n
   Gil-Parrado S, 2003, BIOL CHEM, V384, P395, DOI 10.1515/BC.2003.045
   Gius DR, 1999, CANCER RES, V59, P2577
   Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Guo YM, 2007, CHINESE MED J-PEKING, V120, P50
   Gupta Bhawna, 2006, Expert Opin Drug Deliv, V3, P177, DOI 10.1517/17425247.3.2.177
   Haberkorn U, 2001, NUCL MED BIOL, V28, P793, DOI 10.1016/S0969-8051(01)00247-5                                                   
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   HARVEY L, 1995, MOL CELL BIOL
   Heckl S, 2003, CANCER RES, V63, P4766
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Ho A, 2001, CANCER RES, V61, P474
   Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767                                                              
   Hu MD, 2006, EUR J NUCL MED MOL I, V33, P301, DOI 10.1007/s00259-005-1908-7
   Hu MD, 2007, EUR J NUCL MED MOL I, V34, P368, DOI 10.1007/s00259-006-0189-0
   Hu MD, 2006, BIOCONJUGATE CHEM, V17, P1280, DOI 10.1021/bc060053r
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   James S, 2006, BIOCONJUGATE CHEM, V17, P579, DOI 10.1021/bc050297w
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kabouridis PS, 2003, TRENDS BIOTECHNOL, V21, P498, DOI 10.1016/j.tibtech.2003.09.008
   Kamada H, 2007, BIOL PHARM BULL, V30, P218, DOI 10.1248/bpb.30.218
   Kerkis A, 2004, FASEB J, V18, P1407, DOI 10.1096/fj.03-1459fje
   Kilk K, 2001, BIOCONJUGATE CHEM, V12, P911, DOI 10.1021/bc0100298
   Kim D, 2006, EXP CELL RES, V312, P1277, DOI 10.1016/j.yexcr.2005.12.029
   Klibanov AL, 2005, E SCHERING RES FDN W, V49, P171
   Koch AM, 2003, BIOCONJUGATE CHEM, V14, P1115, DOI 10.1021/bc034123v
   Lang S, 1998, PEPTIDES, V19, P599, DOI 10.1016/S0196-9781(97)00470-1
   Langedijk JPM, 2004, MOL DIVERS, V8, P101, DOI 10.1023/B:MODI.0000025653.26130.ce
   Langedijk JPM, 2002, J BIOL CHEM, V277, P5308, DOI 10.1074/jbc.M104147200
   Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327
   Letoha T, 2003, J MOL RECOGNIT, V16, P272, DOI 10.1002/jmr.637
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lewis MR, 2002, BIOCONJUGATE CHEM, V13, P1176, DOI 10.1021/bc025591s
   Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305                                                         
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Lundberg P, 2002, BIOCHEM BIOPH RES CO, V299, P85, DOI 10.1016/S0006-291X(02)02595-0
   Machova Z, 2002, CHEMBIOCHEM, V3, P672, DOI 10.1002/1439-7633(20020703)3:7<672::AID-CBIC672>3.0.CO;2-D
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Maiolo JR, 2004, J AM CHEM SOC, V126, P15376, DOI 10.1021/ja044867z
   MANN DA, 1991, EMBO J, V10, P1733
   Massoud TF, 2007, TRENDS MOL MED, V13, P183, DOI 10.1016/j.molmed.2007.03.003
   Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403
   Mazel M, 2001, ANTI-CANCER DRUG, V12, P107, DOI 10.1097/00001813-200102000-00003                                                
   McCarthy JR, 2007, NANOMEDICINE-UK, V2, P153, DOI 10.2217/17435889.2.2.153
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Montet X, 2007, RADIOLOGY, V242, P751, DOI 10.1148/radiol.2423052065
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mukai Y, 2006, BIOL PHARM BULL, V29, P1570, DOI 10.1248/bpb.29.1570
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Noguchi H, 2003, DIABETES, V52, P1732, DOI 10.2337/diabetes.52.7.1732
   Nomura T, 2007, PHARMAZIE, V62, P569, DOI 10.1691/ph.2007.8.6278
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 1997, FEBS LETT, V415, P196, DOI 10.1016/S0014-5793(97)01123-X
   Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154                                                           
   Ohmori N, 1997, BIOCHEM BIOPH RES CO, V235, P726, DOI 10.1006/bbrc.1997.6880
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Ragin AD, 2002, CHEM BIOL, V9, P943, DOI 10.1016/S1074-5521(02)00189-8
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Robertson MP, 2004, RNA, V10, P114, DOI 10.1261/rna.5900204
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Schaffer P, 2005, J LABELLED COMPD RAD, V48, pS44
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Schorderet DF, 2005, CLIN EXP OPHTHALMOL, V33, P628, DOI 10.1111/j.1442-9071.2005.01108.x                                                
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056
   Singh D, 1998, BIOCHEMISTRY-US, V37, P5798, DOI 10.1021/bi972762l
   SOUKCHAREUN S, 1995, BIOCONJUGATE CHEM, V6, P43, DOI 10.1021/bc00031a004
   Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198
   Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114
   Su W, 2007, CONTRAST MEDIA MOL I, V2, P42, DOI 10.1002/cmmi.126
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Taguchi T, 2004, BIOCHEM BIOPH RES CO, V320, P18, DOI 10.1016/j.bbrc.2004.05.126
   Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018
   Troy CM, 1996, J NEUROSCI, V16, P253
   Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200
   Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang Y, 2007, BIOCONJUGATE CHEM, V18, P1338, DOI 10.1021/bc070032c
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184                                                         
   Zhang YM, 2006, NUCL MED BIOL, V33, P263, DOI 10.1016/j.nucmedbio.2005.10.009
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 152
TC 48
Z9 49
U1 1
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD AUG
PY 2008
VL 14
IS 24
BP 2415
EP 2427
DI 10.2174/138161208785777432                                              
          
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 351TG
UT WOS:000259448200004
PM 18781991
DA 2018-01-05
ER

PT J
AU Pang, W
   Wang, RR
   Yang, LM
   Liu, CM
   Tien, P
   Zheng, YT
AF Pang, Wei
   Wang, Rui-Rui
   Yang, Liu-Meng
   Liu, Chang-Mei
   Tien, Po
   Zheng, Yong-Tang
TI Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor
   with potent anti-HIV action in vitro
SO VIROLOGY
LA English
DT Article
DE HR212; enfuvirtide; fusion inhibitor; HIV-1; HIV-2; Anti-HIV agents;
   proteinase K; T20-resistant strains
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENFUVIRTIDE; ENTRY; GP41;
   PHARMACOKINETICS
AB HR212, a recombinant protein expressed in Escherichia coli, has been previously reported to inhibit HIV-1 membrane fusion at low nanomolar level. Here we report that HR212 is effective in blocking laboratory strain HIV-1,B entry and replication with EC50 values of 3.92 +/- 0.62 and 6.59 +/- 1.74 nM, respectively, and inhibiting infection by clinic isolate HIV-1(KM018)with EC50 values of 44.44 +/- 10.20 nM, as well as suppressing HIV-1-induced cytopathic effect with an EC50 value of 3.04 +/- 1.20 nM. It also inhibited HIV-2(ROD) and HIV-2(CBL-20) entry and replication in the mu M range. Notably, HR212 was highly effective against T20-resistant strains with EC50 values ranging from 5.09 to 7.75 nM. Unlike T20, HR212 showed stability sufficient to inhibit syncytia formation in a time-of-addition assay, and was insensitive to proteinase K digestion These results suggest that HR212 has great potential to be further developed as novel HIV-1 fusion inhibitor for treatment of HIV/AIDS patients, particularly for those infected by T20-resistant variants. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Pang, Wei; Liu, Chang-Mei; Tien, Po] Chinese Acad Sci, Inst Microbiol, Ctr Mol Virol, Beijing 100101, Peoples R China.
   [Pang, Wei; Wang, Rui-Rui; Yang, Liu-Meng; Zheng, Yong-Tang] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Lab Mol Immunopharmacol, Kunming 650223, Peoples R China.
   [Pang, Wei] Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China.
RP Tien, P (reprint author), Chinese Acad Sci, Inst Microbiol, Ctr Mol Virol, Beijing 100101, Peoples R China.
EM tienpo@sun.im.ac.cn; zhengyt@mail.kiz.ac.cn
RI Liu, Changmei/H-9600-2012
CR Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428.12437.2004
   Baldwin CE, 2003, CURR MED CHEM, V10, P1633, DOI 10.2174/0929867033457124                                                        
   Boyd MA, 2003, J CLIN PHARMACOL, V43, P1382, DOI 10.1188/009120003259220
   Center RJ, 1997, J VIROL, V71, P5706
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368
   Liu GJ, 2007, CELL MOL IMMUNOL, V4, P203
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Ni L, 2005, BIOCHEM BIOPH RES CO, V332, P831, DOI 10.1016/j.bbrc.2005.05.037
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Rusconi S, 2007, CURR TOP MED CHEM, V7, P1273
   Ruxrungtham K, 2004, J CLIN PHARMACOL, V44, P793, DOI 10.1177/0091270004266489
   Snoeck R, 2002, ANTIVIR RES, V55, P413, DOI 10.1016/S0166-3542(02)00074-8
   Stocker H, 2006, ANTIMICROB AGENTS CH, V50, P667, DOI 10.1128/AAC.50.2.667-673.2006
   Tashima KT, 2003, NEW ENGL J MED, V348, P2249, DOI 10.1056/NEJMe030042
   Wang JH, 2002, FEBS LETT, V531, P295, DOI 10.1016/S0014-5793(02)03539-1
   Wang Q, 2004, BIOCHEM BIOPH RES CO, V324, P605, DOI 10.1016/j.bbrc.2004.09.093
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Zhang GH, 2005, BIOCHEM BIOPH RES CO, V334, P812, DOI 10.1016/j.bbrc.2005.06.166
   Zhang XP, 2004, CLIN PHARMACOL THER, V75, P558, DOI 10.1016/j.clpt.2004.02.003
NR 20
TC 17
Z9 20
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUL 20
PY 2008
VL 377
IS 1
BP 80
EP 87
DI 10.1016/j.virol.2008.04.013
PG 8
WC Virology
SC Virology
GA 317SR
UT WOS:000257040700010
PM 18499209
OA gold
DA 2018-01-05
ER

PT J
AU Liashkovich, I
   Hafezi, W
   Kuhn, JE
   Oberleithner, H
   Kramer, A
   Shahin, V
AF Liashkovich, Ivan
   Hafezi, Wali
   Kuehn, Joachim E.
   Oberleithner, Hans
   Kramer, Armin
   Shahin, Victor
TI Exceptional mechanical and structural stability of HSV-1 unveiled with
   fluid atomic force microscopy
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE atomic force microscopy; herpes simplex virus type-1; nano-indentation
ID HERPES-SIMPLEX-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL CAPSIDS; DNA;
   SURFACE; TYPE-1; ELASTICITY; PARTICLES; MOLECULE; RELEASE
AB Evidence is emerging that changes in the structural and mechanical properties of viral particles are closely linked and that such changes are essential to infectivity. Here, applying the nanostructural and nanomechanical approach of atomic force microscopy, we visualised capsids of the ubiquitous human pathogen herpes simplex virus type 1 (HSV-1) at nano-scale resolution in physiologically relevant conditions. Simultaneously performed nano-indentation measurements on genome-containing and genome-free capsids revealed that genome-containing HSV-1 capsids withstand an exceptionally large mechanical force of similar to 6 nN, which is three times larger than the highest values previously reported for other viruses. Greater mechanical forces, however, led to a release of the viral genome. The resulting genome-free capsids, which largely retained their overall structure, were found to be utterly elastic. HSV-1 capsids thus exhibit an exceptional structural and mechanical stability, which is largely provided by the densely packaged genome. This stability might be the key determinant for capsid survival over long distances in the axonal cytoplasm where it is exposed to mechanical forces by molecular motors before it reaches the nuclear pore for crucial genome uncoating.
C1 [Liashkovich, Ivan; Oberleithner, Hans; Kramer, Armin; Shahin, Victor] Univ Munster, Inst Physiol 2, D-48149 Munster, Germany.
   [Hafezi, Wali; Kuehn, Joachim E.] Univ Munster, Inst Med Microbiol, D-48149 Munster, Germany.
   [Hafezi, Wali; Kuehn, Joachim E.] Univ Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany.
RP Shahin, V (reprint author), Univ Munster, Inst Physiol 2, Robert Koch Str 27B, D-48149 Munster, Germany.
EM shahin@uni-muenster.de
RI Liashkovich, Ivan/B-3946-2008; Kramer, Armin/C-1382-2010
CR BATTERSON W, 1983, J VIROL, V45, P397
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R
   Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Del Sol R, 2007, J BACTERIOL, V189, P2219, DOI 10.1128/JB.01470-06
   Engel A, 2000, NAT STRUCT BIOL, V7, P715, DOI 10.1038/78929
   Greenleaf WJ, 2007, ANNU REV BIOPH BIOM, V36, P171, DOI 10.1146/annurev.biophys.36.101106.101451
   Heinz WF, 1999, TRENDS BIOTECHNOL, V17, P143, DOI 10.1016/S0167-7799(99)01304-9                                                   
   Hillebrand U, 2006, CARDIOVASC RES, V69, P916, DOI 10.1016/j.cardiores.2005.11.025
   HOH JH, 1994, J CELL SCI, V107, P1105
   HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   Jovasevic V, 2008, J VIROL, V82, P3311, DOI 10.1128/JVI.01919-07
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   NEWCOMB WW, 1994, J VIROL, V68, P433
   Oberleithner H, 2005, KIDNEY INT, V67, P1680, DOI 10.1111/j.1523-1755.2005.00263.x                                                
   Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000                                                
   Roos WH, 2007, CELL MOL LIFE SCI, V64, P1484, DOI 10.1007/s00018-007-6451-1
   Saad A, 1999, J VIROL, V73, P6821
   Schafer C, 2007, PFLUG ARCH EUR J PHY, V453, P809, DOI 10.1007/s00424-006-0165-3
   Shahin V, 2001, FASEB J, V15, P1895, DOI 10.1096/fj.00-0838com
   Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581
   Tan SS, 2004, LANGMUIR, V20, P7015, DOI 10.1021/la049597c
   Zhou ZH, 2000, SCIENCE, V288, P877, DOI 10.1126/science.288.5467.877
NR 29
TC 28
Z9 29
U1 0
U2 7
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD JUL 15
PY 2008
VL 121
IS 14
BP 2287
EP 2292
DI 10.1242/jcs.032284
PG 6
WC Cell Biology
SC Cell Biology
GA 321XL
UT WOS:000257339700002
PM 18559888
OA gold
DA 2018-01-05
ER

PT J
AU Law, M
   Jafari, M
   Chen, P
AF Law, Maggie
   Jafari, Mousa
   Chen, P.
TI Physicochemical characterization of siRNA-peptide complexes
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article; Proceedings Paper
CT 57th Annual Meeting of the Canadian-Society-for-Chemical-Engineering
CY OCT 28-31, 2007
CL Edmonton, CANADA
SP Canadian Soc Chem Engn
DE peptide; siRNA silencing; complexation; equilibrium; spectroscopy;
   noncovalent interaction
ID DRUG-DELIVERY; POLYMERIC PRODRUGS; STRAND; NANOPARTICLES; THERAPEUTICS;
   TRANSFECTION; BINDING; CANCER; RNA
AB Short interfering RNAs (siRNAs) trigger RNA interference (RNAi), where the complementary mRNA is degraded, resulting in silencing of the encoded protein. A delivery carrier is desired to increase the solution stability of siRNA and improve its cellular uptake to overcome its rapid enzymatic degradation and low transfection efficiency. In this study, Arginine-9 (R9), a cell-penetrating peptide derived from the HIV 1 Tat protein, was investigated as a potential carrier for siRNAs. A connective tissue growth factor (CTGF) encoding siRNA was used because of its therapeutic potential of treating breast cancer. The interaction between R9 and siRNA was studied by UV/vis spectroscopy and circular dichroism (CD). The hydrodynamic diameter of the siRNA-R9 complexes was determined by dynamic light scattering (DLS), and the Zeta potential of the complexes was obtained by measuring the electrophoretic mobility. The effect of salt addition is also quantified using UV-vis spectroscopy. The siRNA and R9 readily formed complexes/aggregates through molecular association, accompanying a change in surface charge with increasing peptide concentration, reaching a maximum hydrodynamic diameter of similar to 1 mu m at siRNA saturation. The highest binding ratio of R9 to siRNA determined from the UV/vis spectra and CD is 103:1 and 39.1:1 from DLS (corresponds to charge ratios of 2.2:1 (+/-) and 84:1, respectively). The difference in binding ratio is possibly because of the difference in signal contribution between absorption and light scattering. The physicochemical characterization of CTGF siRNA-R9 complexes presented here have shown that various methods call be used to control the properties of the siRNA-peptide complexes, which provide a basis for the formulation of siRNA therapeutics with peptide carriers.
C1 [Law, Maggie; Jafari, Mousa; Chen, P.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
RP Chen, P (reprint author), Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
EM p4chen@uwaterloo.ca
CR Agrawal S, 1997, PHARMACOL THERAPEUT, V76, P151, DOI 10.1016/S0163-7258(97)00108-3
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE
   BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023                                                             
   D'Souza AJM, 2004, J PHARM SCI-US, V93, P1962, DOI 10.1002/jps.20096
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   Eliyahu H, 2006, BIOMATERIALS, V27, P1646, DOI 10.1016/j.biomaterials.2005.09.005
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Hashida M, 1999, J CONTROL RELEASE, V62, P253, DOI 10.1016/S0168-3659(99)00045-0
   Hunter R. J., 1981, ZETA POTENTIAL COLLO
   Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943                                                            
   Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8                                                   
   Lejeune D, 2005, PROTEINS, V61, P258, DOI 10.1002/prot.20607
   Liang HF, 2006, BIOMATERIALS, V27, P2051, DOI 10.1016/j.biomaterials.2005.10.027
   LODISH H, 1999, MOL CELL BIOL
   Mahato R. I., 2005, BIOMATERIALS DELIVER
   Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a
   Oberdorster Gunter, 2005, Part Fibre Toxicol, V2, P8, DOI 10.1186/1743-8977-2-8
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002                                                              
   Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   WAGNER KG, 1969, EUR J BIOCHEM, V10, P261, DOI 10.1111/j.1432-1033.1969.tb00683.x                                              
   Wang M, 2007, BIOPHYS J, V93, P2477, DOI 10.1529/biophysj.106.102624
NR 26
TC 30
Z9 31
U1 1
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 8756-7938
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD JUL-AUG
PY 2008
VL 24
IS 4
BP 957
EP 963
DI 10.1002/btpr.13
PG 7
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 348KA
UT WOS:000259208200020
PM 19194904
OA gold
DA 2018-01-05
ER

PT J
AU Kim, IS
   Choi, YW
   Kang, Y
   Sung, HM
   Sohn, KW
   Kim, YS
AF Kim, In Seop
   Choi, Yong Woon
   Kang, Yong
   Sung, Hark Mo
   Sohn, Ki Whan
   Kim, Yong-Sung
TI Improvement of virus safety of an antihemophilc factor IX by virus
   filtration process
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE antihemophilic factor IX; virus filter; virus removal; log reduction
   factor
ID MICROPOROUS MEMBRANE-FILTER; DRY-HEAT-TREATMENT; HEPATITIS-C VIRUS;
   B-VIRUS; PLASMA; PRODUCTS; BLOOD; NANOFILTRATION; COMPLICATIONS;
   INACTIVATION
AB Viral safety is an important prerequisite for clinical preparations of plasma-derived pharmaceuticals. One potential way to increase the safety of therapeutic biological products is the use of a virus-retentive filter. In order to increase the viral safety of human antihemophilic factor IX, particularly in regard to non-enveloped viruses, a virus removal process using a polyvinylidene fluoride membrane filter (Viresolve NFP) has been optimized. The most critical factor affecting the filtration efficiency was operating pH and the optimum pH was 6 or 7. Flow rate increased with increasing operating pressure and temperature. Recovery yield in the optimized production-scale process was 96%. No substantial changes were observed in the physical and biochemical characteristics of the filtered factor IX in comparison with those before filtration. A 47-mm disk membrane filter was used to simulate the process performance of the production-scale cartridges and to test if it could remove several experimental model viruses for human pathogenic viruses, including human hepatitis A virus (HAV), porcine parvovirus (PPV), murine encephalomyocarditis virus (EMCV), human immunodeficiency virus type 1 (HIV), bovine viral diarrhea virus (BVDV), and bovine herpes virus (BHV). Non-enveloped viruses (HAV, PPV, and EMCV) as well as enveloped viruses (HIV, BVDV, and BHV) were completely removed during filtration. The log reduction factors achieved were >= 6.12 for HAV, >= 4.28 for PPV, >= 5.33 for EMCV, >= 5.51 for HIV >= 5.17 for BVDV, and >= 5.75 for BHV. These results indicate that the virus filtration process successfully improved the viral safety of factor IX.
C1 [Kim, In Seop] Hannam Univ, Coll Life Sci & Nanotechnol, Dept Biol Sci, Taejon 305811, South Korea.
   [Kim, In Seop; Sung, Hark Mo] Hannam Univ, Grad Program BT NT Fus Sci & Technol, Taejon 305811, South Korea.
   [Choi, Yong Woon; Kang, Yong; Sung, Hark Mo; Sohn, Ki Whan] Green Cross Co, Yongin 449900, South Korea.
   [Choi, Yong Woon; Kim, Yong-Sung] Ajou Univ, Coll Engn, Dept Mol Sci & Technol, Suwon 443749, South Korea.
RP Kim, IS (reprint author), Hannam Univ, Coll Life Sci & Nanotechnol, Dept Biol Sci, Taejon 305811, South Korea.
EM inskim@hannam.ac.kr
OI Kim, In Seop/0000-0002-6066-1930
CR ANDREWES C, 1989, ANDREWES VIRUSES VER, P120
   ARAHANA H, 2001, BIOL PHARM 2     FEB, P32
   Aranha-Creado H, 1998, BIOLOGICALS, V26, P167, DOI 10.1006/biol.1998.0130                                                          
   AranhaCreado H, 1997, PDA J PHARM SCI TECH, V51, P119
   BERKMAN SA, 1988, BLOOD REV, V2, P206, DOI 10.1016/0268-960X(88)90026-4
   Bolton GR, 2006, BIOTECHNOL APPL BIOC, V43, P55, DOI 10.1042/BA20050108
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129                                                          
   Carter J, 2002, EUR J PARENTER SCI, V7, P72
   Chandra S, 2002, THROMB RES, V105, P391, DOI 10.1016/S0049-3848(02)00044-0
   Chudy M, 1999, J MED VIROL, V57, P91, DOI 10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
   Eibl J, 1996, BIOLOGICALS, V24, P285, DOI 10.1006/biol.1996.0036
   Furuya K, 2006, VOX SANG, V91, P119, DOI 10.1111/j.1423-0410.2006.00792.x
   Guertler LG, 2002, THROMB RES, V107, pS39, DOI 10.1016/S0049-3848(02)00151-2                                                   
   ICH, 1998, FED REGISTER, V63, P51074
   KARBER J, 1931, ARCH EXP PATHOL PH, V162, P480
   Kim H, 2007, J MICROBIOL BIOTECHN, V17, P701
   Kim IS, 2004, J MICROBIOL BIOTECHN, V14, P140
   Kim I.S., 2001, BIOTECHNOL BIOPROC E, V6, P25
   KIM IS, 2004, BIOTECHNOL BIOPROC E, V9, P57
   Klein HG, 2005, J INTERN MED, V257, P224, DOI 10.1111/j.1365-2796.2005.01451.x
   Kohler M, 1998, THROMB HAEMOSTASIS, V80, P399
   Laub R, 2002, PATHOL BIOL, V50, P339, DOI 10.1016/S0369-8114(02)00303-6
   LAWLOR E, 1996, VOX SANG, V73, P189
   LEVY JA, 1994, VIROLOGY, P153
   LIMENTANI SA, 1995, ACTA HAEMATOL-BASEL, V94, P12, DOI 10.1159/000204023                                                               
   Morgenthaler JJ, 2000, VOX SANG, V78, P217
   Mosley JW, 1999, TRANSFUSION, V39, P1041, DOI 10.1046/j.1537-2995.1999.39101041.x                                             
   O'Connell NM, 2003, BLOOD COAGUL FIBRIN, V14, P59
   Oshima KH, 1998, VOX SANG, V75, P181, DOI 10.1159/000030984
   Powell JS, 2000, HAEMOPHILIA, V6, P140, DOI 10.1046/j.1365-2516.2000.00407.x                                                
   Robertson B H, 2000, Dev Biol (Basel), V102, P29
   ROBINSON SM, 1992, LANCET, V340, P1465, DOI 10.1016/0140-6736(92)92652-V
   Shin JS, 2006, BIOTECHNOL BIOPROC E, V11, P19, DOI 10.1007/BF02931863
   Shin KS, 2006, J MICROBIOL BIOTECHN, V16, P1634
   Song MS, 2006, J MICROBIOL BIOTECHN, V16, P1570
   SUOMELA H, 1976, EUR J BIOCHEM, V71, P145, DOI 10.1111/j.1432-1033.1976.tb11100.x                                              
   Tabor E, 1999, TRANSFUSION, V39, P1160, DOI 10.1046/j.1537-2995.1999.39111160.x                                             
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
NR 38
TC 6
Z9 10
U1 0
U2 3
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD JUL
PY 2008
VL 18
IS 7
BP 1317
EP 1325
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 331DV
UT WOS:000257993800017
PM 18667862
DA 2018-01-05
ER

PT J
AU Schweizer, A
   Rusert, P
   Berlinger, L
   Ruprecht, CR
   Mann, A
   Corthesy, S
   Turville, SG
   Aravantinou, M
   Fischer, M
   Robbiani, M
   Amstutz, P
   Trkola, A
AF Schweizer, Andreas
   Rusert, Peter
   Berlinger, Livia
   Ruprecht, Claudia R.
   Mann, Axel
   Corthesy, Stephanie
   Turville, Stuart G.
   Aravantinou, Meropi
   Fischer, Marek
   Robbiani, Melissa
   Amstutz, Patrick
   Trkola, Alexandra
TI CD4-specific Designed Ankyrin Repeat Proteins are novel potent HIV entry
   inhibitors with unique characteristics
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; IN-VITRO
   SELECTION; NEUTRALIZING ANTIBODIES; PICOMOLAR AFFINITY; RIBOSOME
   DISPLAY; GP120 BINDING; CELL-FUSION; CD4+ CELLS; ENV CLONES
AB Here, we describe the generation of a novel type of HIV entry inhibitor using the recently developed Designed Ankyrin Repeat Protein (DARPin) technology. DARPin proteins specific for human CD4 were selected from a DARPin DNA library using ribosome display. Selected pool members interacted specifically with CD4 and competed with gp120 for binding to CD4. DARPin proteins derived in the initial selection series inhibited HIV in a dose-dependent manner, but showed a relatively high variability in their capacity to block replication of patient isolates on primary CD4 T cells. In consequence, a second series of CD4-specific DARPins with improved affinity for CD4 was generated. These 2nd series DARPins potently inhibit infection of genetically divergent (subtype B and C) HIV isolates in the low nanomolar range, independent of coreceptor usage. Importantly, the actions of the CD4 binding DARPins were highly specific: no effect on cell viability or activation, CD4 memory cell function, or interference with CD4-independent virus entry was observed. These novel CD4 targeting molecules described here combine the unique characteristics of DARPins-high physical stability, specificity and low production costs-with the capacity to potently block HIV entry, rendering them promising candidates for microbicide development.
C1 [Schweizer, Andreas; Rusert, Peter; Berlinger, Livia; Ruprecht, Claudia R.; Mann, Axel; Corthesy, Stephanie; Fischer, Marek; Trkola, Alexandra] Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland.
   [Turville, Stuart G.; Aravantinou, Meropi; Robbiani, Melissa] Populat Council, Ctr Biomed Res, New York, NY 10021 USA.
   [Amstutz, Patrick] Mol Partners AG, Zurich, Switzerland.
RP Trkola, A (reprint author), Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland.
EM alexandra.trkola@usz.ch
RI Infektiologie, USZ/A-6921-2011
OI Trkola, Alexandra/0000-0003-1013-876X
FU Swiss National Science Foundation [PP00B-102647]; Kanton Zurich; Velux,
   Vontobel, Novartis, and Hartmann Muller; Elizabeth Glaser Pediatric AIDS
   Foundation; NIH [AI040877]; CJ Martin Fellowship of the NH&MRC of
   Australia
FX Support was provided by the Swiss National Science Foundation
   (PP00B-102647 to AT), by a research grant of the Kanton Zurich, and by
   research grants from the following foundations: Velux, Vontobel,
   Novartis, and Hartmann Muller. AT is an Elizabeth Glaser Scientist
   supported by the Elizabeth Glaser Pediatric AIDS Foundation. Additional
   support was provided by NIH grant AI040877. MR was a 2002 Elizabeth
   Glaser Scientist. SGT was supported by a CJ Martin Fellowship of the
   NH&MRC of Australia.
CR ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   Amstutz P, 2006, PROTEIN ENG DES SEL, V19, P219, DOI 10.1093/protein/gzl004
   AMSTUTZ P, 2005, J BIOL CHEM
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Belyakov IM, 2004, IMMUNITY, V20, P247, DOI 10.1016/S1074-7613(04)00053-6                                                   
   BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122                                                        
   Berkley SF, 2007, LANCET, V370, P94, DOI 10.1016/S0140-6736(07)61054-X                                                   
   Binley JM, 2000, J INFECT DIS, V182, P945, DOI 10.1086/315774
   Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Boon L, 2002, TOXICOLOGY, V172, P191, DOI 10.1016/S0300-483X(02)00002-1
   BURKLY LC, 1992, J IMMUNOL, V149, P1779
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   CHECK E, 2007, NATURE, V446, P12
   CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0
   D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464
   DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0
   Doncel GF, 2006, HUM REPROD UPDATE, V12, P103, DOI 10.1093/humupd/dmi040
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Fletcher P, 2005, J VIROL, V79, P11179, DOI 10.1128/JVI.79.17.11179-11186.2005
   FRANK I, 2008, J VIROL IN PRESS
   Furuta RA, 2006, MICROBES INFECT, V8, P520, DOI 10.1016/j.micinf.2005.08.004
   Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633                                                          
   Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937                                                         
   HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233
   HEALEY DG, 1991, EUR J IMMUNOL, V21, P1491, DOI 10.1002/eji.1830210624
   Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74
   Huber T, 2007, J STRUCT BIOL, V159, P206, DOI 10.1016/j.jsb.2007.01.013
   Hughes LM, 2007, CURR MED CHEM, V14, P775, DOI 10.2174/092986707780090972
   *JOINT UN PROGR HI, 2007, AIDS EP UPD DEC 2007
   Kawe M, 2006, J BIOL CHEM, V281, P40252, DOI 10.1074/jbc.M602506200
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100
   Kuritzkes DR, 2004, J INFECT DIS, V189, P286, DOI 10.1086/380802                                                                  
   LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Loewe S, 1928, ERGEBN PHYSL, V27, P47, DOI DOI 10.1007/BF02322290
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4
   Manrique A, 2007, J VIROL, V81, P8793, DOI 10.1128/JVI.00598-07
   Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815
   Montefiori DC, 2004, EVALUATING NEUTRALIZ
   Montefiori D.C., 2004, CURRENT PROTOCOLS IM
   MOORE JP, 1992, J VIROL, V66, P4784
   MOORE JP, 1992, J VIROL, V66, P235
   Olson WC, 1999, J VIROL, V73, P4145
   Pugach P, 2007, VIROLOGY, V361, P212, DOI 10.1016/j.virol.2006.11.004
   Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003
   Ramjee G, 2007, PLOS MED, V4, P1167, DOI 10.1371/journal.pmed.0040235
   Reichelt P, 2006, PROTEIN EXPRES PURIF, V46, P483, DOI 10.1016/j.pep.2005.09.027
   Reimann KA, 1997, AIDS RES HUM RETROV, V13, P933, DOI 10.1089/aid.1997.13.933                                                         
   Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598
   Rusert P, 2005, J VIROL, V79, P8454, DOI 10.1128/JVI.79.13.8454-8469.2005
   Rusert P, 2004, VIROLOGY, V326, P113, DOI 10.1016/j.virol.2004.05.022
   SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444
   Schweizer A, 2007, STRUCTURE, V15, P625, DOI 10.1016/j.str.2007.03.014
   Sennhauser G, 2007, PLOS BIOL, V5, P106, DOI 10.1371/journal.pbio.0050007
   Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   Stumpp MT, 2007, CURR OPIN DRUG DISC, V10, P153
   Trkola A, 2004, BLOOD, V104, P1784, DOI 10.1182/blood-2004-01-0251
   Trkola A, 1996, J VIROL, V70, P1100
   TRUNEH A, 1991, J BIOL CHEM, V266, P5942
   van de Wiigert JHHM, 2007, JAIDS-J ACQ IMM DEF, V46, P538, DOI 10.1097/QAI.0b013e318159d5a8                                                    
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200
   Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200
   Zahnd C, 2007, J MOL BIOL, V369, P1015, DOI 10.1016/j.jmb.2007.03.028
   Zahnd C, 2007, NAT METHODS, V4, P269, DOI 10.1038/NMETH1003
   Zahnd C, 2006, J BIOL CHEM, V281, P35167, DOI 10.1074/jbc.M602547200
NR 78
TC 34
Z9 34
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUL
PY 2008
VL 4
IS 7
AR e1000109
DI 10.1371/journal.ppat.1000109
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 356MT
UT WOS:000259783000015
PM 18654624
OA gold
DA 2018-01-05
ER

PT J
AU Daminelli, EN
   Spada, C
   Treitinger, A
   Oliveira, TV
   Latrilha, MD
   Maranhao, RC
AF Daminelli, Elaine Nunes
   Spada, Celso
   Treitinger, Aricio
   Oliveira, Tatiane Vanessa
   Latrilha, Maria da Conceicao
   Maranhao, Raul Cavalcante
TI Alterations in lipid transfer to high-density lipoprotein (HDL) and
   activity of paraoxonase-1 in HIV(+) patients
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE high-density lipoproteins; lipid transfer protein; paraoxonase-1;
   lipids; HIV; AIDS
ID REVERSE CHOLESTEROL TRANSPORT; IMMUNODEFICIENCY-VIRUS-INFECTION;
   ANTIRETROVIRAL THERAPY; CARDIOVASCULAR-DISEASE; A-I; ATHEROSCLEROSIS;
   DYSLIPIDEMIA; METABOLISM; INFLAMMATION; DISORDERS
AB HIV patients often develop alterations of the plasma lipids that may implicate in development of premature coronary artery disease. High-density lipoprotein (HDL) has all important role ill preventing atherogenesis and the aim of this study was to investigate aspects of HDL function in HIV(+) patients. HIV(+) patients (n = 48) and healthy control Subjects (it = 45) of both sexes with similar age were Studied. Twenty-five were not being treated with antiretroviral agents. 13 were under reverse transcriptase inhibitor nucleosidic and non-nucleosidic (NRTI+NNRTI) and 10 were under NRTI + protease inhibitors (NRTI+PI) treatment. Paraoxonase 1 (PON1) activity and the transfer of free and esterified cholesterol, tryglicerides and phospholipids from a lipidic nanoemulsion to HDL were analyzed. In comparison with healthy controls, HIV(+) patients presented low PON-1 activity and diminished transfer of free cholesterol and tryglicerides. In contrast. phospholipid transfer was increased ill those patients, whereas the transfer of cholesteryl esters was Unchanged. NRTI+NNRTI increases the transfer of cholesteryl esters and triglycerides but in NRTI+PI there was no difference in respect to non-treated HIV(+) patients. HDL from HIV(+) patients has smallerantioxidant properties. as shown by lower PON-1 activity, and the transfer of lipids to this lipoprotein fraction is also altered, suggesting that HDL function is defective in those patients.
C1 [Oliveira, Tatiane Vanessa; Latrilha, Maria da Conceicao; Maranhao, Raul Cavalcante] Univ Sao Paulo, INCOR, Lipid Metab Lab, BR-05403000 Sao Paulo, Brazil.
   [Daminelli, Elaine Nunes; Spada, Celso; Treitinger, Aricio] Univ Fed Santa Catarina, Fac Pharmaceut Sci, Florianopolis, SC, Brazil.
   [Maranhao, Raul Cavalcante] Univ Sao Paulo, Fac Pharmaceut Sci, BR-05403000 Sao Paulo, Brazil.
RP Maranhao, RC (reprint author), Univ Sao Paulo, INCOR, Lipid Metab Lab, Av Dr Eneas de Carvalho Aguiar 44,Bloco 2,Subsolo, BR-05403000 Sao Paulo, Brazil.
EM ramarans@usp.br
RI Maranhao, Raul/I-5996-2012
OI Maranhao, Raul/0000-0003-1520-4914
CR Andrade Ana Cristina O, 2006, Braz J Infect Dis, V10, P139, DOI 10.1590/S1413-86702006000200012
   Barter P, 2003, ATHEROSCLEROSIS, V168, P195, DOI 10.1016/S0021-9150(03)00006-6
   Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13
   Bergersen BM, 2006, DRUGS, V66, P1971, DOI 10.2165/00003495-200666150-00006                                                
   BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028
   Calza L, 2004, J ANTIMICROB CHEMOTH, V53, P10, DOI 10.1093/jac/dkh013
   Caramelli B, 2001, Braz J Infect Dis, V5, P332
   Carr A, 2006, PLOS MED, V3, P1986, DOI 10.1371/journal.pmed.0030496
   Chanu B, 2005, PRESSE MED, V34, P1087, DOI 10.1016/S0755-4982(05)84124-7                                                   
   Crook MA, 1999, INT J STD AIDS, V10, P353, DOI 10.1258/0956462991914212                                                        
   Esteve E, 2005, CLIN NUTR, V24, P16, DOI 10.1016/j.clnu.2004.08.004
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541
   HUI DY, 2003, PROGR LIPIDI RES, V42, pS1
   Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1
   Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c                                              
   Mackness M, 2004, FREE RADICAL BIO MED, V37, P1317, DOI 10.1016/j.freeradbiomed.2004.07.034
   MACKNESS MI, 1991, ATHEROSCLEROSIS, V86, P193, DOI 10.1016/0021-9150(91)90215-O
   Mackness MI, 2002, ATHEROSCLEROSIS SUPP, V3, P49, DOI 10.1016/S1567-5688(02)00046-6
   Manfredi R, 2001, J INFECTION, V42, P181, DOI 10.1053/jinf.2001.0829
   MARANHAO RC, 1993, LIPIDS, V28, P691, DOI 10.1007/BF02535988
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   Ohashi R, 2005, QJM-INT J MED, V98, P845, DOI 10.1093/qjmed/hci136
   Parra S, 2007, ATHEROSCLEROSIS, V194, P175, DOI 10.1016/j.atherosclerosis.2006.07.024
   Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978
   Rose H, 2006, METABOLISM, V55, P90, DOI 10.1016/j.metabol.2005.07.012
   Santos R D, 2001, Arq Bras Cardiol, V77 Suppl 3, P1
   Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3
   Thaveeratitham P, 2007, J ENDOTOXIN RES, V13, P58, DOI 10.1177/0968051907078611
   Wang MH, 2004, CHEM REV, V104, P119, DOI 10.1021/cr020466v
   Young J, 2005, ANTIVIR THER, V10, P585
   ZANGERLE R, 1994, J ACQ IMMUN DEF SYND, V7, P1149
NR 32
TC 9
Z9 9
U1 0
U2 1
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD JUL-AUG
PY 2008
VL 50
IS 4
BP 223
EP 227
DI 10.1590/S0036-46652008000400007                                         
          
PG 5
WC Tropical Medicine
SC Tropical Medicine
GA 347PQ
UT WOS:000259153900007
PM 18813762
OA gold
DA 2018-01-05
ER

PT J
AU Cesarini, S
   Spallarossa, A
   Ranise, A
   Schenone, S
   Bruno, O
   La Colla, P
   Casula, L
   Collu, G
   Sanna, G
   Loddo, R
AF Cesarini, Sara
   Spallarossa, Andrea
   Ranise, Angelo
   Schenone, Silvia
   Bruno, Olga
   La Colla, Paolo
   Casula, Laura
   Collu, Gabriella
   Sanna, Giuseppina
   Loddo, Roberta
TI Parallel one-pot synthesis and structure-activity relationship study of
   symmetric formimidoester disulfides as a novel class of potent
   non-nucleoside HIV-1 reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE symmetric formimidoester disulfides; HIV-1; non-nucleoside reverse
   transcriptase inhibitors; parallel one-pot synthesis
ID IMMUNODEFICIENCY-VIRUS TYPE-1; OXYDATIONSPRODUKTE VON
   THIOCARBONSAUREAMIDEN; ANTI-HIV; PHENETHYLTHIAZOLYLTHIOUREA DERIVATIVES;
   NUCLEOCAPSID PROTEIN; PETT COMPOUNDS; RT INHIBITORS; ANALOGS; DESIGN;
   METHODOLOGIES
AB The molecular duplication of non-nucleoside reverse transcriptase inhibitor (NNRTI) O-(2-phthalimidoethyl)-N-arylthiocarbamates (C-TCs) led to the identification of symmetric formimidoester disulfides (DSs) as a novel class of potent NNRTIs. The lead compound 1 [dimer of the isothiocarbamic form of TC O-(2-phthalimidoethyl) -N-phenylthiocarbamate] turned out to prevent the wild-type HIV-1 multiplication in MT-4 cell culture with an EC(50) value of 0.35 mu M. In order to perform a structure-activity relationship (SAR) study, we prepared 40 analogues of 1 by an unprecedented one-pot method of solutionphase parallel synthesis. The SAR strategy was focused on the variation of the N-aryl portion (mono-, diand trisubstitution of the phenyl ring and its replacement with a 1-naphthyl, cyclopropyl or benzyl group) and of the 2-phthalimidoethyl moiety (introduction of a methyl on the phthalimide substructure, replacement of the phthalimide moiety with a phenyl ring and elongation of the ethyl linker). Most DSs proved to inhibit the wild-type HIV-1 replication in cell-based assays and 15 of them were active at nano-molar concentrations. The most potent congeners (11, 15, 16, 17, 18, 19, 20 and 32, EC(50): 10 -70 nM) shared the N-para-substituted phenyl moiety. Compound 17 tested in enzyme assay against recombinant wild-type reverse transcriptase displayed an IC(50) value of 0.74 mu M. Compounds 19 and 33 were active at micromolar concentrations against the clinically relevant Y181C and/ or K103R resistant mutants. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Cesarini, Sara; Spallarossa, Andrea; Ranise, Angelo; Schenone, Silvia; Bruno, Olga] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   [La Colla, Paolo; Casula, Laura; Collu, Gabriella; Sanna, Giuseppina; Loddo, Roberta] Univ Cagliari, Dipartimento Sci & Tecnol Biomed, I-09042 Cagliari, Italy.
RP Cesarini, S (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto XV 3, I-16132 Genoa, Italy.
EM sara.cesarini@unige.it; placolla@unica.it
RI La Colla , Paolo /B-8587-2011; Loddo, Roberta/B-9038-2011
OI Sanna, Giuseppina/0000-0002-3999-4263
CR An HY, 2000, CHEM REV, V100, P3311, DOI 10.1021/cr990014r
   Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420                                                        
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   BARRETT AGM, 1980, J CHEM SOC P1, V3, P665
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Cesarini S, 2008, BIOORGAN MED CHEM, V16, P4160, DOI 10.1016/j.bmc.2007.12.050
   Cesarini S, 2008, BIOORGAN MED CHEM, V16, P4173, DOI 10.1016/j.bmc.2007.12.046
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2001, FARMACO, V56, P3, DOI 10.1016/S0014-827X(01)01007-2                                                   
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   DECLERCQ E, 2004, BIODIVERSITY, V1, P44
   Gupta SP, 2005, COMB CHEM HIGH T SCR, V8, P375, DOI 10.2174/1386207054546478                                                        
   HIROOKA S, 1970, NIPPON KAGAKU ZASSHI, V91, P270, DOI 10.1246/nikkashi1948.91.3_270                                                   
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   LEIGHBROWN AJ, 2003, J INFECT DIS, V187, P683
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   MITSCHER L, 2003, BURGERS MED CHEM DRU, V2, P14
   Motakis D, 2002, ANTIMICROB AGENTS CH, V46, P1851, DOI 10.1128/AAC.46.6.1851-1856.2002
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   Pedersen OS, 1999, ANTIVIR CHEM CHEMOTH, V10, P285, DOI 10.1177/095632029901000601                                                      
   Pedersen OS, 2000, SYNTHESIS-STUTTGART, P479
   Ranise A, 2005, J MED CHEM, V48, P3858, DOI 10.1021/jm049252r
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   RICHMAN DD, 2004, AIDS, V18
   Sanchez-Martin RM, 2004, CURR TOP MED CHEM, V4, P653, DOI 10.2174/1568026043451113                                                        
   Spallarossa A, 2008, BIOCHEM BIOPH RES CO, V365, P764, DOI 10.1016/j.bbrc.2007.11.036
   STRICKLEY RG, 1993, PHARMACEUT RES, V10, P1076, DOI 10.1023/A:1018935311304                                                         
   TAN GT, 1992, J MED CHEM, V35, P4846, DOI 10.1021/jm00104a010
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Tummino PJ, 1997, ANTIMICROB AGENTS CH, V41, P394
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   WALTER W, 1966, LIEBIGS ANN CHEM, V698, P122
   WALTER W, 1963, ANGEW CHEM INT EDIT, V75, P208, DOI 10.1002/ange.19630750411                                                        
   WALTER W, 1965, LIEBIGS ANN CHEM, V681, P64
   WALTER W, 1963, ANGEW CHEM INT EDIT, V2, P154
NR 38
TC 9
Z9 10
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 15
PY 2008
VL 16
IS 12
BP 6353
EP 6363
DI 10.1016/j.bmc.2008.05.010
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 311AY
UT WOS:000256573600006
PM 18502646
DA 2018-01-05
ER

PT J
AU Bowman, MC
   Ballard, TE
   Ackerson, CJ
   Feldheim, DL
   Margolis, DM
   Melander, C
AF Bowman, Mary-Catherine
   Ballard, T. Eric
   Ackerson, Christopher J.
   Feldheim, Daniel L.
   Margolis, David M.
   Melander, Christian
TI Inhibition of HIV fusion with multivalent gold nanoparticles
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONPEPTIDE CCR5 ANTAGONIST;
   SMALL-MOLECULE; ANTIBODY; ENTRY
AB The design and synthesis of a multivalent gold nanoparticle therapeutic is presented. eSDC-1721, a fragment of the potent HIV inhibitor TAK-779, was synthesized and conjugated to 2.0 nm diameter gold nanoparticles. Free SDC-1721 had no inhibitory effect on HIV infection; however, the (SDC-1721) -gold nanoparticle conjugates displayed activity comparable to that of TAK-779. This result suggests that multivalent presentation of small molecules on gold nanoparticle surfaces can convert inactive drugs into potent therapeutics.
C1 [Ackerson, Christopher J.; Feldheim, Daniel L.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
   [Bowman, Mary-Catherine; Margolis, David M.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Dept Immunol, Chapel Hill, NC 27599 USA.
   [Ballard, T. Eric; Melander, Christian] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
RP Feldheim, DL (reprint author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.
EM daniel.feldheim@colorado.edu; dmargo@med.unc.edu;
   christian_melander@ncsu.edu
OI Margolis, David/0000-0001-5714-0002
FU NIAID NIH HHS [R01 AI045297, P30 AI050410, P30 AI050410-08, R56
   AI045297, AI50410, AI045297, R01 AI045297-10]; NEI NIH HHS [R21
   EY017568, EY017568]
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Ikemoto T, 2000, ORG PROCESS RES DEV, V4, P520, DOI 10.1021/op000074v
   Jadzinsky PD, 2007, SCIENCE, V318, P430, DOI 10.1126/science.1148624
   Lytton-Jean AKR, 2005, J AM CHEM SOC, V127, P12754, DOI 10.1021/ja052255o
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567
   Nicewarner Pena Sheila R., 2002, Journal of the American Chemical Society, V124, P7314, DOI 10.1021/ja0177915
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Safarian D, 2006, VIROLOGY, V352, P477, DOI 10.1016/j.virol.2006.05.016
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
NR 13
TC 192
Z9 195
U1 7
U2 62
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUN 4
PY 2008
VL 130
IS 22
BP 6896
EP +
DI 10.1021/ja710321g
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 307EQ
UT WOS:000256301200002
PM 18473457
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ndesendo, VMK
   Pillay, V
   Choonara, YE
   Buchmann, E
   Bayever, DN
   Meyer, LCR
AF Ndesendo, Valence M. K.
   Pillay, Viness
   Choonara, Yahya E.
   Buchmann, Eckhart
   Bayever, David N.
   Meyer, Leith C. R.
TI A review of current intravaginal drug delivery approaches employed for
   the prophylaxis of HIV/AIDS and prevention of sexually transmitted
   infections
SO AAPS PHARMSCITECH
LA English
DT Review
DE HIV; STIs; intravaginal drug delivery systems; microbicides;
   nanostructures; polymers; prophylaxis
ID IMMUNODEFICIENCY-VIRUS MICROBICIDE; CONTRACEPTIVE VAGINAL RING; GENITAL
   HERPES INFECTION; SODIUM DODECYL-SULFATE; IN-VITRO; TOPICAL MICROBICIDE;
   CELLULOSE SULFATE; HIV-INFECTION; PHASE-I; MONOCLONAL-ANTIBODIES
AB The objective of this review is to describe the current status of several intravaginal anti-HIV microbicidal delivery systems these delivery systems and microbicidal compounds in the context of their stage within clinical trials and their potential cervicovaginal defence successes. The global Human Immuno-Deficiency Virus (HIV) pandemic continues to spread at a rate of more than 15,000 new infections daily and sexually transmitted infections (STIs) can predispose people to acquiring HIV infection. Male-to-female transmission is eight times more likely to occur than female-to-male transmission due to the anatomical structure of the vagina as well as socio-economic factors and the disempowerment of women that renders them unable to refuse unsafe sexual practices in some communities. The increased incidence of HIV in women has identified the urgent need for efficacious and safe intravaginal delivery of anti-HIV agents that can be used and controlled by women. To meet this challenge, several intravaginal anti-HIV microbicidal delivery systems are in the process of been developed. The outcomes of three main categories are discussed in this review: namely, dual-function polymeric systems, non-polymeric systems and nanotechnology-based systems. These delivery systems include formulations that modify the genital environment (e.g. polyacrylic acid gels and lactobacillus gels), surfactants (e.g. sodium lauryl sulfate), polyanionic therapeutic polymers (e.g. carageenan and carbomer/lactic acid gels), proteins (e.g. cyanovirin-N, monoclonal antibodies and thromspondin-1 peptides), protease inhibitors and other molecules (e.g. dendrimer based-gels and the molecular condom). Intravaginal microbicide delivery systems are providing a new option for preventing the transmission of STIs and HIV.
C1 [Ndesendo, Valence M. K.; Pillay, Viness; Choonara, Yahya E.; Bayever, David N.] Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, South Africa.
   [Buchmann, Eckhart] Chris Hani Baragwanath Hosp, Dept Gynecol & Obstet, ZA-2013 Johannesburg, South Africa.
   [Meyer, Leith C. R.] Univ Witwatersrand, Sch Physiol, Brain Funct Res Grp, ZA-2193 Johannesburg, South Africa.
RP Pillay, V (reprint author), Univ Witwatersrand, Dept Pharm & Pharmacol, 7 York Rd, ZA-2193 Johannesburg, South Africa.
EM viness.pillay@witz.ac.za
RI Pillay, Viness/C-1569-2010; Choonara, Yahya/B-2955-2013
OI Pillay, Viness/0000-0002-8119-3347; Choonara, Yahya/0000-0002-3889-1529
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Al-Tahami Khaled, 2007, Recent Pat Drug Deliv Formul, V1, P65, DOI 10.2174/187221107779814113
   *ALL MICR DEV, 2005, MICR RES DEV DAT
   Amaral E, 2004, CONTRACEPTION, V70, P492, DOI 10.1016/j.contraception.2004.06.007
   Anderson RA, 2000, J ANDROL, V21, P862
   Anderson RA, 2002, J ANDROL, V23, P426
   BABA M, 1990, ANTIMICROB AGENTS CH, V34, P134, DOI 10.1128/AAC.34.1.134                                                            
   Ballagh SA, 2001, CLIN OBSTET GYNECOL, V44, P106, DOI 10.1097/00003081-200103000-00014                                                
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1                                                   
   BARBARA E, 2006, AIDS, V20, P2245
   BENKOPSCHNURCH A, 2003, AM J DRUG DELIVERY, V1, P241
   Berger J., 2004, DEV UPDATE, V5, P45
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Best CJM, 2000, ANAL CELL PATHOL, V20, P1
   Bilensoy E, 2006, AAPS PHARMSCITECH, V7
   BOB R, 2000, INT ASS PHYS AIDS CA, V6, P157
   Bonferoni MC, 2006, AAPS PHARMSCITECH, V7
   BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503
   BOSKEY EA, 2000, BUFFERGEL FAVORS VIT
   Boskey ER, 2001, HUM REPROD, V16, P1809, DOI 10.1093/humrep/16.9.1809
   Bourinbaiar AS, 2006, CURR PHARM DESIGN, V12, P2017, DOI 10.2174/138161206777442119
   Bourne N, 1999, J INFECT DIS, V180, P203, DOI 10.1086/314853                                                                  
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRANNONPEPPAS L, 1993, ADV DRUG DELIVER REV, V11, P169, DOI 10.1016/0169-409X(93)90031-X
   BRIGGS K, 2000, MICROBICIDES, P13
   Brown TJ, 1999, J AM ACAD DERMATOL, V41, P511, DOI 10.1016/S0190-9622(99)80045-0
   Buck CB, 2006, PLOS PATHOG, V2, P671, DOI 10.1371/journal.ppat.0020069
   CAIRNS G, MICROBICIDES TRIALS
   CARMEN A, 2003, AM J DRUG DELIV, V1, P77
   Castle PE, 1997, BIOL REPROD, V56, P153, DOI 10.1095/biolreprod56.1.153                                                      
   Ceschel GC, 2001, DRUG DEV IND PHARM, V27, P541, DOI 10.1081/DDC-100105179                                                           
   Cheshenko N, 2004, ANTIMICROB AGENTS CH, V48, P2025, DOI 10.1128/AAC.48.6.2025-2036.2004
   Cho KH, 2005, ELECTROCHIM ACTA, V51, P956, DOI 10.1016/j.electacta.2005.04.071
   Christensen ND, 2001, ANTIMICROB AGENTS CH, V45, P3427, DOI 10.1128/AAC.45.12.3427-3432.2001                                                
   COETZEE N, 2006, SAFETY LAMBDA CARAGE
   CONE RA, 1994, AM J REPROD IMMUNOL, V32, P114, DOI 10.1111/j.1600-0897.1994.tb01102.x                                              
   CONE RA, 1999, HDB MUCOSAL IMMUNOLO
   CRISTOFARO P, 2005, 12 C RETR OPP INF BO, P22
   Crombie R, 2000, AIDS PATIENT CARE ST, V14, P211, DOI 10.1089/108729100317821                                                         
   Crombie R, 1998, J BIOL CHEM, V273, P4855, DOI 10.1074/jbc.273.9.4855
   Crombie R, 2001, J ACQ IMMUN DEF SYND, V27, P91
   D'Cruz OJ, 2004, BIOL REPROD, V71, P2037, DOI 10.1095/biolreprod.104.032870
   D'Cruz OJ, 2004, FERTIL STERIL, V81, P831, DOI 10.1016/j.fertnstert.2003.08.037
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   D'CRUZ O.J., 2003, AM J DRUG DELIV, V1, P275
   De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A                          
   De Clereq E, 2006, AIDS, V20, P1990, DOI 10.1097/01.aids.0000247128.27505.28
   DECLERCQ E, 2004, FRONT MED CHEM, V1, P543
   DELISE AM, 2000, DEV BIOL PROTOCOLS, V3, P359
   Dezarnaulds G, 2003, EXPERT OPIN PHARMACO, V4, P201, DOI 10.1517/eoph.4.2.201.21090
   Dhawan D, 2006, J INFECT DIS, V193, P36, DOI 10.1086/499163
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   *DIV HIV AIDS PREV, HIV ITS TRANSM
   *DRUG DIG, 2004, SEX TRANSM INF STIS
   duBouchet L, 1998, SEX TRANSM DIS, V25, P176, DOI 10.1097/00007435-199803000-00012
   ELKAMEL A, 2002, AAPS PHARMSCI, V4, P1
   Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b
   Fichorova RN, 2005, ANTIMICROB AGENTS CH, V49, P323, DOI 10.1128/ACC.49.1.323-335.2005
   FINLEY BM, 2006, AIDS C TOR CAN AUG
   FORBES A, 2000, MICROBICIDES AIDS CO
   GADI B, 2001, AID SCI, V1, P12
   GARG S, 2004, INT C AIDS
   Gavini E, 2002, AAPS PHARMSCITECH, V3, P1, DOI [10.1208/pt030320, DOI 10.1208/PT030320]
   Harrison PF, 2003, CLIN INFECT DIS, V36, P1290, DOI 10.1086/374834
   Harwood B, 2001, SEMIN REPROD MED, V19, P381, DOI 10.1055/s-2001-18646                                                            
   Hatcher RA, 2004, CONTRACEPTIVE TECHNO
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Herold BC, 2000, J INFECT DIS, V181, P770, DOI 10.1086/315228
   Herrewege Y.V., 2004, ANTIMICROB AGENTS CH, V48, P337
   HIGHLEYMAN L, 2007, 4 INT C HIV TREATM P
   HOLMES V, 2007, ALLIANCE MICROBICIDE, V8, P1
   Howett MK, 1999, ANTIMICROB AGENTS CH, V43, P314
   HWANG S, 1976, J PHARM SCI, V65, P1574, DOI 10.1002/jps.2600651105
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   JOHNSON VE, 1962, WESTERN J SURG OB GY, V70, P202
   Joshi SN, 2005, T ROY SOC TROP MED H, V99, P769, DOI 10.1016/j.trstmh.2005.01.007
   JOSHI SN, 2006, AIDS RES THER, V3, P2
   Justin-Temu M, 2004, J WOMENS HEALTH, V13, P834, DOI 10.1089/jwh.2004.13.834                                                         
   Kast CE, 2002, J CONTROL RELEASE, V81, P347, DOI 10.1016/S0168-3659(02)00077-9
   KATZ DF, 1993, ADV DRUG DELIVER REV, V11, P385, DOI 10.1016/0169-409X(93)90017-X                                                    
   KATZ DF, 1997, ENG MED BIOL SOC, V6, P2656
   KATZ DF, 1997, ENG MED BIOL SOC, V30, P2656
   Keller MJ, 2005, J ANTIMICROB CHEMOTH, V55, P420, DOI 10.1093/jac/dki056
   Kerr M, 2007, ANTIMICROB AGENTS CH, V51, P1608
   KISER P, MOL CONDOM AIDS
   Klavinskis LS, 1999, J IMMUNOL, V162, P254
   KNUTH K, 1993, ADV DRUG DELIVER REV, V11, P137, DOI 10.1016/0169-409X(93)90030-8                                                    
   Krebs FC, 2000, ANTIMICROB AGENTS CH, V44, P1954, DOI 10.1128/AAC.44.7.1954-1960.2000
   Kristmundsdottir T, 1999, J PHARM SCI-US, V88, P1011, DOI 10.1021/js9900396
   Lamont Ronald F, 2003, Infect Dis Obstet Gynecol, V11, P181, DOI 10.1080/10647440300025519
   Lee CH, 1996, J PHARM SCI, V85, P91, DOI 10.1021/js9501876                                                               
   Lee JW, 2000, J PHARM SCI, V89, P850, DOI 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G
   Maggi L, 2000, EUR J PHARM BIOPHARM, V50, P389, DOI 10.1016/S0939-6411(00)00121-1
   MALCOLM K, 2004, BIOTECHNOL GENET ENG, P81
   MALCOLM KR, 2006, J CONTROL RELEASE, P52
   Manson KH, 2000, ANTIMICROB AGENTS CH, V44, P3199, DOI 10.1128/AAC.44.11.3199-3202.2000
   MARIAELISA P, 2003, BIOL REPROD, V69, P933
   Mayer KH, 2003, AIDS, V17, P321, DOI 10.1097/01.aids.0000050805.28043.11
   MITCHEL D, 2006, INT HLTH C CAN
   MOM A, HIV VAGINAL GEL OVER
   Moore JP, 2003, J ANTIMICROB CHEMOTH, V52, P890, DOI 10.1093/jac/dkh011
   Morrow K, 2003, J WOMENS HEALTH, V12, P655, DOI 10.1089/154099903322404302                                                      
   MOSHER DF, 1990, ANNU REV MED, V41, P85
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Neyts J, 2000, J MED VIROL, V61, P107, DOI 10.1002/(SICI)1096-9071(200005)61:1<107::AID-JMV17>3.0.CO;2-W
   Nikolic DS, 2007, EXPERT REV ANTI-INFE, V5, P77, DOI 10.1586/14787210.5.1.77
   Novak A, 2003, CONTRACEPTION, V67, P187, DOI 10.1016/S0010-7824(02)00514-0
   Nuttall J, 2007, INFECT DIS CLIN N AM, V21, P219, DOI 10.1016/j.idc.2007.01.009
   O'Keefe BR, 2001, J NAT PROD, V64, P1373, DOI 10.1021/np0103362
   OKADA H, 1991, PEPTIDE PROTEIN DRUG, P633
   Owen DH, 1999, J CONTROL RELEASE, V60, P23, DOI 10.1016/S0168-3659(99)00017-6
   PAAVONEN J, 1983, SCAND J INFECT DIS, P31
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   PENTTINEN P, 2005, MICROBICIDES OPTION
   Perotti ME, 2003, BIOL REPROD, V69, P933, DOI 10.1095/biolreprod.102.014555
   PETTIFOR AE, HIV SEXUAL BEHAV YOU
   Piret J, 2000, J CLIN MICROBIOL, V38, P110
   Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384                                                       
   POTTS M, 2004, INT C AIDS U CAL BER
   PSCHERA H, 1989, GYNECOL OBSTET INVES, V27, P204, DOI 10.1159/000293657                                                               
   Pusch O, 2005, JAIDS-J ACQ IMM DEF, V40, P512, DOI 10.1097/01.qai.0000187446.76579.d3
   Reddy S.P., 2003, UMTHENTHE UHLABA USA
   RICHARDSON JL, 1992, ADV DRUG DELIVER REV, V8, P341, DOI 10.1016/0169-409X(92)90008-E
   Richardson JL, 1999, BIOADHESIVE DRUG DEL, P563
   ROUMELIOTIS G, 2006, ALLIANCE MICROBICIDE, V73, P542
   Roumen FJME, 1999, CONTRACEPTION, V59, P59, DOI 10.1016/S0010-7824(98)00145-0
   ROY S, 1999, NAT HIV PREV C NAT H
   Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234
   *SAN FRANC AIDS FD, HIV IS SPREAD
   SANDERS JM, 1990, HUM EXP TOXICOL, V9, P71, DOI 10.1177/096032719000900202                                                      
   SAPPEY C, 1995, ARCH BIOCHEM BIOPHYS, V321, P263, DOI 10.1006/abbi.1995.1394
   Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468
   Simoes JA, 2002, ANTIMICROB AGENTS CH, V46, P2692, DOI 10.1128/AAC.46.8.2692-2695.2002
   SJOBERG I, 1988, GYNECOL OBSTET INVES, V26, P136, DOI 10.1159/000293685                                                               
   Smit AJ, 2004, J APPL PHYCOL, V16, P245, DOI 10.1023/B:JAPH.0000047783.36600.ef
   Smita Joshi, 2006, AIDS Res Ther, V3, P4, DOI 10.1186/1742-6405-3-4
   SMITH M, 2006, 16 INT C TOR CAN
   STONE A, 2002, NATURE REV
   Tang C, 2005, EUR POLYM J, V41, P557, DOI 10.1016/j.eurpolymj.2004.10.017
   THOM A, S AFRICA MICROBICIDE
   Thormar H, 1999, SEX TRANSM INFECT, V75, P181, DOI 10.1136/sti.75.3.181                                                            
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   TURPIN J, 2006, NEW SCI MAGAZINE, V17, P2572
   *UNAIDS WHO, OV GLOB AIDS EP REP
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Van Damme L, 2000, SEX TRANSM INFECT, V76, P126, DOI 10.1136/sti.76.2.126                                                            
   Van Damme L, 2002, CONTRACEPTION, V66, P133, DOI 10.1016/S0010-7824(02)00328-1
   van de Wijgert J, 2001, J ACQ IMMUN DEF SYND, V26, P21
   van Laarhoven JAH, 2002, INT J PHARM, V232, P163, DOI 10.1016/S0378-5173(01)00900-0
   VANDAMME L, 2002, HLTH SEXUALITY MICRO, P1
   VERHELST A, 2005, BMC MICROBIOL, DOI DOI 10.1186/1471-2180-5-61
   Voravuthikunchai SP, 2006, ANAEROBE, V12, P221, DOI 10.1016/j.anerobe.2006.06.003
   Wang YC, 2004, INT J PHARM, V282, P173, DOI 10.1016/j.ijpharm.2004.06.016
   WARD RL, 1979, APPL ENVIRON MICROB, V38, P314
   WASHINGTON N, 2001, PHYSL PHARM BARRIERS, P271
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   *WHO, 2004, SEX TRANSM INF STIS
   Woodley J, 2001, CLIN PHARMACOKINET, V40, P77, DOI 10.2165/00003088-200140020-00001
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
   Woolfson AD, 2000, CRIT REV THER DRUG, V17, P509
   XIAOWEN L, 2006, ANTIMICROB AGENTS CH, V50, P3250
   Zacharopoulos VR, 1997, CLIN DIAGN LAB IMMUN, V4, P465
   Zaneveld LJD, 2002, BIOL REPROD, V66, P886, DOI 10.1095/biolreprod66.4.886                                                      
   Zeitlin L, 1999, EMERG INFECT DIS, V5, P54, DOI 10.3201/eid0501.990107                                                          
   DURRANI MJ, 2000, Patent No. 6159491
   MOL TREES BEAR FRUIT
   YIV S, 2006, Patent No. 064114
   BLAKEMORE WR, 2005, Patent No. 0171053
   ROBINSON JR, 2002, Patent No. 6017521
   BOGENTOFT C, 1996, Patent No. 5492937
   YACAMAN MJ, Patent No. 0115495
   LEW CW, 1994, Patent No. 5364634
NR 175
TC 54
Z9 55
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD JUN
PY 2008
VL 9
IS 2
BP 505
EP 520
DI 10.1208/s12249-008-9073-5
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 327DO
UT WOS:000257710000024
PM 18431651
OA gold
DA 2018-01-05
ER

PT J
AU Xiong, YZ
   Chen, FE
   Balzarini, J
   De Clercq, E
   Pannecouque, C
AF Xiong, Yuan-Zhen
   Chen, Fen-Er
   Balzarini, Jan
   De Clercq, Erik
   Pannecouque, Christophe
TI Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11:
   Structural modulations of diaryltriazines with potent anti-HIV activity
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE non-nucleoside HIV-1 reverse transcriptase inhibitors; diaryltriazine;
   anti-HIV activity
ID DRUG CANDIDATES; DATA ANALOGS; EVOLUTION
AB A series of novel 6-naphthyloxy substituted DATA analogues bearing different substituents on the C-6 position of triazine ring were synthesized and evaluated for their in vitro anti-HIV activity in MT-4 cells. The results demonstrated that most of the compounds in this series are potent activity against HIV-1 with moderate to high selectivity. Among these analogues, two compounds exhibited excellent effect in inhibiting HIV-1 replication at nanomolar concentration (for compound 9h: IC(50) = 9.3 nM, SI = 15,385; for compound 9i: IC(50) = 9.4 nM, SI = 14,094), which are about 15-fold more active than nevirapine. In addition, several compounds are active against both HIV-1 and HIV-2, whose mechanism may be different from typical NNRTIs. (c) 2007 Elsevier Masson SAS. All rights reserved.
C1 [Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200031, Peoples R China.
   [Xiong, Yuan-Zhen; Chen, Fen-Er] Fudan Univ, Sch Pharm, Shanghai 200031, Peoples R China.
   [Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Balzarini, Jan; De Clercq, Erik; Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Chen, FE (reprint author), Fudan Univ, Inst Biomed Sci, Shanghai 200031, Peoples R China.
EM rfchen@fudan.edu.cn
CR ANU A, 2005, BIOORG MED CHEM LETT, V15, P531
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2225, DOI 10.1016/S0960-894X(01)00410-3
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   WANG YP, CHEM BIODIV IN PRESS
   Xiong YZ, 2006, ACTA CHIM SINICA, V64, P1627
NR 7
TC 60
Z9 63
U1 1
U2 3
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN
PY 2008
VL 43
IS 6
BP 1230
EP 1236
DI 10.1016/j.ejmech.2007.08.001
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 320UW
UT WOS:000257261500011
PM 17869386
DA 2018-01-05
ER

PT J
AU Lavigne, MD
   Yates, L
   Coxhead, P
   Gorecki, DC
AF Lavigne, Matthieu D.
   Yates, Laura
   Coxhead, Peter
   Gorecki, Dariusz C.
TI Nuclear-targeted chimeric vector enhancing nonviral gene transfer into
   skeletal muscle of Fabry mice in vivo
SO FASEB JOURNAL
LA English
DT Article
DE cell penetration peptides; gene therapy; TAT; pluronic
ID ALPHA-GALACTOSIDASE-A; PROTEIN TRANSDUCTION DOMAIN; ENZYME REPLACEMENT
   THERAPY; INTRACELLULAR DELIVERY; MAMMALIAN-CELLS; DEFICIENT MICE; HIV
   TAT; DNA; EXPRESSION; PEPTIDE
AB Poor nuclear entry, especially into nondividing cells, is a limiting factor in nonviral gene delivery. We have engineered a novel chimeric vector relying on the controlled assembly of a TAT-tagged multisubunit DNA binding protein (EcoR124I) with expression plasmids containing the EcoR124I recognition site. Molecular interactions of this molecular assembly were studied by electrophoretic mobility shift assay and atomic force microscopy. Maintenance of nanocomplexes in an appropriate stoichiometric ratio was both necessary and sufficient to produce a significant (> 8-fold) increase in the activity of the therapeutic alpha-galactosidase A enzyme after intramuscular administration in the mouse model of Fabry disease. To our knowledge, this is the first molecular targeting system significantly enhancing plasmid-based expression in skeletal muscle. Coinjection with pluronic SP1017 produced further enhancement of gene expression, demonstrating cumulative effects of the increased nuclear delivery by TAT chimeras and transcription activation by the pluronic. Cell penetration peptides (CPP), such as TAT, have been shown to improve delivery of macromolecules, when linked directly. However, in our system TAT-enhanced targeting took place even though it was linked to the plasmid DNA molecule indirectly via two noncovalent bonds. Therefore, this proof-of principle result indicates that TAT (and potentially other CPP) can be used for targeting modular chimeric vectors and therapeutic nanodevices.
C1 [Lavigne, Matthieu D.; Yates, Laura; Gorecki, Dariusz C.] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England.
   [Coxhead, Peter] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Biol Sci, Portsmouth PO1 2DT, Hants, England.
RP Gorecki, DC (reprint author), Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.
EM darek.gorecki@port.ac.uk
OI Lavigne, Matthieu/0000-0003-1543-8745; Yates, Laura/0000-0002-1620-1603;
   Coxhead, Peter/0000-0001-7550-0235
FU Wellcome Trust [067484]
CR Beck M, 2007, HUM GENET, V121, P1, DOI 10.1007/s00439-006-0280-4
   Benenson Y, 2004, NATURE, V429, P423, DOI 10.1038/nature02551
   Cardarelli F, 2007, MOL THER, V15, P1313, DOI 10.1038/sj.mt.6300172
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635
   Chan CK, 1999, HUM GENE THER, V10, P1695, DOI 10.1089/10430349950017699
   Chang CW, 2007, J CONTROL RELEASE, V118, P245, DOI 10.1016/j.jconrel.2006.11.025
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821                                                              
   Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534
   Desnick RJ, 2003, ANN INTERN MED, V138, P338, DOI 10.7326/0003-4819-138-4-200302180-00014
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102
   Gorecki Dariusz C, 2006, Discov Med, V6, P191
   Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721                                                        
   Ioannou YA, 2001, AM J HUM GENET, V68, P14, DOI 10.1086/316953
   Janscak P, 1996, J MOL BIOL, V257, P977, DOI 10.1006/jmbi.1996.0217
   Lavigne MD, 2005, MOL THER, V12, P985, DOI 10.1016/j.ymthe.2005.02.032
   LAVIGNE MD, 2006, J GENE MED, V9, P44
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Mernagh DR, 1998, BIOL CHEM, V379, P497, DOI 10.1515/bchm.1998.379.4-5.497
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Novo FJ, 1997, GENE THER, V4, P488, DOI 10.1038/sj.gt.3300410
   Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540
   PATEL J, 1992, GENE, V112, P21, DOI 10.1016/0378-1119(92)90298-4
   Pennadam SS, 2007, LANGMUIR, V23, P41, DOI 10.1021/la061991a
   Pennadam SS, 2004, J AM CHEM SOC, V126, P13208, DOI 10.1021/ja045275j
   Pennadam S, 2004, J NANOBIOTECHNOL, V2, P8, DOI DOI 10.1186/1477-3155-2-8
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Ramaswami U, 2007, ACTA PAEDIATR, V96, P122, DOI 10.1111/j.1651-2227.2007.00029.x
   Ratanamart J, 2006, CURR GENE THER, V6, P93, DOI 10.2174/156652306775515583                                                      
   Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Seelig G, 2006, SCIENCE, V314, P1585, DOI 10.1126/science.1132493
   Seidel R, 2004, NAT STRUCT MOL BIOL, V11, P838, DOI 10.1038/nsmb816
   Seidel R, 2007, CURR OPIN STRUC BIOL, V17, P80, DOI 10.1016/j.sbi.2006.12.003
   Sloots A, 2005, FEBS J, V272, P4221, DOI 10.1111/j.1742-4658.2005.04834.x
   SRIADIBHATLA S, 2005, MOL THER, V13, P804
   SUK JS, 2006, BIOMATERIALS, V29, P5143
   TAYLOR I, 1992, NUCLEIC ACIDS RES, V20, P179, DOI 10.1093/nar/20.2.179
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchinsky A, 2006, AM J REPROD IMMUNOL, V55, P36, DOI 10.1111/j.1600-0897.2005.00321x
   Torchinsky Arkady, 2002, BMC Dev Biol, V2, P2, DOI 10.1186/1471-213X-2-2
   Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JC125052
   Trollet C, 2006, CURR GENE THER, V6, P561, DOI 10.2174/156652306778520656
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Twaites BR, 2005, J CONTROL RELEASE, V108, P472, DOI 10.1016/j.jconrel.2005.08.009
   Twaites BR, 2004, J CONTROL RELEASE, V97, P551, DOI 10.1016/j.jconrel.2004.03.032
   Utvik JK, 1999, HUM GENE THER, V10, P291, DOI 10.1089/10430349950019075
   Vaysse L, 2006, J GENE MED, V8, P754, DOI 10.1002/jgm.883
   Volcke C, 2006, J BIOTECHNOL, V125, P11, DOI 10.1016/j.jbiotec.2006.02.010
   Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/mt.sj.6300093
   Yoshimitsu M, 2006, CIRC J, V70, P1503, DOI 10.1253/circj.70.1503
   Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91                                                            
   Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015
   Zinkevich V, 1997, NUCLEIC ACIDS RES, V25, P503, DOI 10.1093/nar/25.3.503                                                            
NR 60
TC 14
Z9 16
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JUN
PY 2008
VL 22
IS 6
BP 2097
EP 2107
DI 10.1096/fj.07-093765
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 307XK
UT WOS:000256352700049
PM 18202142
DA 2018-01-05
ER

PT J
AU Kerman, K
   Tamiya, E
AF Kerman, Kagan
   Tamiya, Eiichi
TI Aptamer-functionalized Au nanoparticles for the electrochemical
   detection of thrombin
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE aptamer; Au nanoparticles; thrombin; biosensor; electrochemical
ID SINGLE-STRANDED-DNA; MODIFIED GOLD NANOPARTICLES; HIV-1 TAT PROTEIN;
   CATALYTIC LABELS; SELECTION; RECOGNITION; BIOSENSORS; MOLECULES; BIND;
   HYBRIDIZATION
AB An aptamer-based sandwich assay with electrochemical detection for thrombin analysis is reported using Au nanoparticles. The primary aptamer was immobilized on the surface of a screen-printed carbon electrode (SPCE) and the secondary aptamer was immobilized on Au nanoparticles. The electrochemical reduction current response of Au nanoparticles was monitored for the quantitative detection of thrombin. The limit of detection was determined as 1 nM. The proposed work demonstrates the high specificity of aptamers; together with the use of Au nanoparticles. The effect of interfering proteins such as bovine serum albumin (BSA) was investigated. Control experiments also involved the use of an aptamer that has a binding affinity to immunoglobulin E (IgE). Aptamer-based analysis using Au nanoparticles opens the possibility of applications in complex biological fluids and a step closer towards diagnostics or medical investigation.
C1 [Kerman, Kagan; Tamiya, Eiichi] Japan Adv Inst Sci & Technol, Sch Mat Sci, Nomi City, Ishikawa 9231292, Japan.
RP Kerman, K (reprint author), Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 5B7, Canada.
CR Berezovski M, 2003, J AM CHEM SOC, V125, P13451, DOI 10.1021/ja037186x
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brainina K, 2003, ANAL BIOANAL CHEM, V376, P481, DOI 10.1007/s00216-003-1912-3
   Buchanan DD, 2003, ELECTROPHORESIS, V24, P1375, DOI 10.1002/elps.200390176
   Burmeister J, 2004, ANAL BIOANAL CHEM, V379, P391, DOI 10.1007/s00216-004-2601-6
   Cai H, 2004, ANAL CHIM ACTA, V523, P61, DOI 10.1016/j.aca.2004.06.072
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Chikae M, 2006, ELECTROCHEM COMMUN, V8, P1375, DOI 10.1016/j.elecom.2006.06.019
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Farokhzad O. C., 2006, P NATL ACAD SCI USA, V103, P6315, DOI DOI 10.1073/PNAS.0601755103
   Farokhzad OC, 2006, EXPERT OPIN DRUG DEL, V3, P311, DOI 10.1517/17425247.3.3.311
   Gill R, 2006, SMALL, V2, P1037, DOI 10.1002/smll.200600133
   Huang CC, 2005, ANAL CHEM, V77, P5735, DOI 10.1021/ac050957q
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jiang YX, 2003, ANAL CHEM, V75, P2112, DOI 10.1021/ac026182s
   Kerman K, 2004, ANAL CHEM, V76, P1877, DOI 10.1021/ac0351872
   KERMAN K, 2005, ENCY MED GENOMICS PR, P346
   Li C, 2005, J AM CHEM SOC, V127, P12484, DOI 10.1021/ja053761g
   Liu GD, 2005, J NANOSCI NANOTECHNO, V5, P1060, DOI 10.1166/jnn.2005.178
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   Lu F, 2005, ANALYST, V130, P1513, DOI 10.1039/b507682j
   Luzi E, 2003, TRAC-TREND ANAL CHEM, V22, P810, DOI 10.1016/S0165-9936(03)01208-1
   Maehashi K, 2007, ANAL CHEM, V79, P782, DOI 10.1021/ac060830g
   MAO XA, 2005, BIOPHYS CHEM, V113, P15
   Michaud M, 2004, ANAL CHEM, V76, P1015, DOI 10.1021/ac035090f
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Pumera M, 2005, LANGMUIR, V21, P9625, DOI 10.1021/la051917k
   Pumera M, 2005, ELECTROCHIM ACTA, V50, P3702, DOI 10.1016/j.electacta.2005.01.035
   Rajendran M, 2003, NUCLEIC ACIDS RES, V31, P5700, DOI 10.1093/nar/gkg764
   Rehder-Silinski MA, 2003, J CHROMATOGR A, V1008, P233, DOI 10.1016/S0021-9673(03)00973-7
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275                                                          
   Teply B.A., 2006, AM J DRUG DELIV, V4, P123
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wang J, 2007, ELECTROANAL, V19, P769, DOI 10.1002/elan.200603789
   Wang LH, 2006, CHEM COMMUN, P3780, DOI 10.1039/b607448k
NR 45
TC 10
Z9 10
U1 3
U2 24
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1550-7033
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD JUN
PY 2008
VL 4
IS 2
BP 159
EP 164
DI 10.1166/jbn.2008.013
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA 328JH
UT WOS:000257794200004
DA 2018-01-05
ER

PT J
AU Kim, EY
   Stanton, J
   Korber, BTM
   Krebs, K
   Bogdan, D
   Kunstman, K
   Wu, S
   Phair, JP
   Mirkin, C
   Wolinsky, SM
AF Kim, Eun-Young
   Stanton, Jennifer
   Korber, Bette T. M.
   Krebs, Kendall
   Bogdan, Derek
   Kunstman, Kevin
   Wu, Samuel
   Phair, John P.
   Mirkin, Chad A.
   Wolinsky, Steven M.
TI Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based
   bio-barcode-amplification method
SO NANOMEDICINE
LA English
DT Article
DE bio-barcode-amplification method; HIV-1; major core protein of HIV-1;
   (p24 Gag)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RESOURCE-LIMITED SETTINGS; BLOOD
   MONONUCLEAR-CELLS; REAL-TIME PCR; ANTIRETROVIRAL THERAPY; SIGNAL
   AMPLIFICATION; TYPE-1 INFECTION; BOOSTED ELISA; ANTIGEN-ASSAY; VIRAL
   LOAD
AB Background: Detection of HIV-1 in patients is limited by the sensitivity and selectivity of available tests. The nanotechnology-based bio-barcode-amplification method offers an innovative approach to detect specific HIV-1 antigens from diverse HIV-1 subtypes. We evaluated the efficacy of this protein-detection method in detecting HIV-1 in men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS). Methods: The method relies on magnetic microparticles with antibodies that specifically bind the HIV-1 p24 Gag protein and nanoparticles that are encoded with DNA and antibodies that can sandwich the target protein captured by the microparticle-bound antibodies. The aggregate sandwich structures are magnetically separated from solution, and treated to remove the conjugated barcode DNA. The DNA barcodes (hundreds per target) were identified by a nanoparticle-based detection method that does not rely on PCR.
   Results: Of 112 plasma samples from HIV-1 -infected subjects, 111 were positive for HIV-1 p24 Gag protein (range: 0.11-71.5 ng/ml of plasma) by the bio-barcode-amplification method. HIV-1 p24 Gag protein was detected in only 23 out of 112 men by the conventional ELISA. A total of 34 uninfected subjects were negative by both tests. Thus, the specificity of the bio-barcode-amplification method was 100% and the sensitivity 99%. The bio-barcode-amplification method detected HIV-1 p24 Gag protein in plasma from all study subjects with less than 200 CD4(+) Tcells/mu l of plasma (100%) and 19 out of 20 (95%) HIV-1 -infected men who had less than 50 copies/ml of plasma of HIV-1 RNA. In a separate group of 60 diverse international isolates, representative of clades A, B, C and D and circulating recombinant forms CRF01_AE and CRF02_AG, the bio-barcode-amplification method identified the presence of virus correctly.
   Conclusions: The bio-barcode-amplification method was superior to the conventional ELISA assay for the detection of HIV-1 p24 Gag protein in plasma with a breadth of coverage for diverse HIV-1 subtypes. Because the bio-barcocle-amplification method does not require enzymatic amplification, this method could be translated into a robust point-of-care test.
C1 [Kim, Eun-Young; Stanton, Jennifer; Krebs, Kendall; Bogdan, Derek; Kunstman, Kevin; Wu, Samuel; Phair, John P.; Wolinsky, Steven M.] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA.
   [Kim, Eun-Young; Mirkin, Chad A.; Wolinsky, Steven M.] NW Univ, Int Inst Nanotechnol, Evanston, IL 60208 USA.
   [Korber, Bette T. M.] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA.
RP Wolinsky, SM (reprint author), Northwestern Univ, Feinberg Sch Med, Div Infect Dis, 676 N St Clair, Chicago, IL 60611 USA.
EM s-wolinsky@northwestern.edu
RI Mirkin, Chad/E-3911-2010; Wolinsky, Steven/B-2893-2012
OI Wolinsky, Steven/0000-0002-9625-6697; Korber, Bette/0000-0002-2026-5757
FU NIAID NIH HHS [R01 AI052764, R01 AI052764-03, U01 AI061297-01, U01
   AI061297]
CR Bao YP, 2006, ANAL CHEM, V78, P2055, DOI 10.1021/ac051798d
   BIANCO C, 1996, MMWR-MORBID MORTAL W, V45, P1
   BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X                                                    
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Brown BK, 2005, J VIROL, V79, P6089, DOI 10.1128/JVI.79.10.6089-6101.2005
   Burgisser P, 2000, J ACQ IMMUN DEF SYND, V23, P138
   CHADWICK EG, 1989, J INFECT DIS, V160, P954, DOI 10.1093/infdis/160.6.954                                                        
   Cunningham CK, 1999, PEDIATR INFECT DIS J, V18, P30, DOI 10.1097/00006454-199901000-00009                                                
   de Baar MP, 2001, J CLIN MICROBIOL, V39, P1895, DOI 10.1128/JCM.39.5.1895-1902.2001
   FERNS RB, 1987, J GEN VIROL, V68, P1543, DOI 10.1099/0022-1317-68-6-1543
   Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005
   KAPLAN AH, 1993, J VIROL, V67, P4050
   Kim EY, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl147
   Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601
   Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366
   Lewin SR, 1999, J VIROL, V73, P6099
   MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501                                                     
   Mylonakis E, 2000, AM J MED, V109, P568, DOI 10.1016/S0002-9343(00)00583-0
   Nadal D, 1999, J INFECT DIS, V180, P1089, DOI 10.1086/315012
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825
   Pascual A, 2002, J CLIN MICROBIOL, V40, P2472, DOI 10.1128/JCM.40.7.2472-2475.2002
   Prado JG, 2004, J CLIN MICROBIOL, V42, P1620, DOI 10.1128/JCM.42.4.1620-1625.2004
   Respess RA, 2005, J CLIN MICROBIOL, V43, P506, DOI 10.1128/JCM.43.1.506-508.2005
   Ribas SG, 2003, J VIROL METHODS, V113, P29, DOI 10.1016/S0166-0934(03)00219-2
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   Schupbach J, 2005, JAIDS-J ACQ IMM DEF, V40, P250
   Schupbach J, 2001, J MED VIROL, V65, P225, DOI 10.1002/jmv.2024
   Shaikh KA, 2005, P NATL ACAD SCI USA, V102, P9745, DOI 10.1073/pnas.0504082102
   Sivapalasingam S, 2005, J CLIN MICROBIOL, V43, P3793, DOI 10.1128/JCM.43.8.3793-3796.2005
   Sterling TR, 2002, J INFECT DIS, V186, P1181, DOI 10.1086/343807                                                                  
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Wang SW, 2002, J VIROL, V76, P11853, DOI 10.1128/JVI.76.23.11853-11865.2002
NR 37
TC 39
Z9 42
U1 4
U2 35
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUN
PY 2008
VL 3
IS 3
BP 293
EP 303
DI 10.2217/17435889.3.3.293
PG 11
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 314DN
UT WOS:000256789400007
PM 18510425
OA green_accepted
DA 2018-01-05
ER

PT J
AU Berry, CC
AF Berry, C. C.
TI Intracellular delivery of nanopartides via the HIV-1 tat pepticle
SO NANOMEDICINE
LA English
DT Review
DE cell uptake; gold nanoparticles; liposomes; magnetic nanoparticles;
   nanoparticles; nuclear targeting; quantum dots; tat
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING PEPTIDES; QUANTUM DOTS;
   IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; MAGNETIC NANOPARTICLES; TRANSDUCTION
   DOMAINS; PROTEIN DELIVERY; MAMMALIAN-CELLS; PLASMA-MEMBRANE
AB Functionalized nanoparticles are heralded as part of the future with regards to targeted cell and nuclear delivery. However, direct intracellular and intranuclear delivery has, until recently, been difficult to achieve owing to the impermeable nature of the plasma and nuclear membranes. During the past 15 years, a range of peptides, termed cell-penetrating peptides (CPPs), which have the ability to translocate into living cells, have been discovered. Thus, in more recent years, the combination of CPPs with nanoparticles, enabling CPP-mediated cell delivery, has opened up many avenues of research. This review discusses the use of various CPPs, focusing on tat peptide, to functionalize nanoparticles and the possible move from the laboratory to the clinic.
C1 Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
RP Berry, CC (reprint author), Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
EM ccb9y@udcf.ga.ac.uk
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Ballou B, 2004, BIOCONJUGATE CHEM, V15, P79, DOI 10.1021/bc034153y
   BRUCHEZ M, 1998, SCIENCE, V281, P2016
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   de la Fuente JM, 2006, LANGMUIR, V22, P3286, DOI 10.1021/la053029v
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELDHERR CM, 1992, P NATL ACAD SCI USA, V89, P11002, DOI 10.1073/pnas.89.22.11002
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2005, INT J PHARM, V298, P305, DOI 10.1016/j.ijpharm.2005.02.040
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gupta Bhawna, 2006, Expert Opin Drug Deliv, V3, P177, DOI 10.1517/17425247.3.2.177
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Ho A, 2001, CANCER RES, V61, P474
   Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   King JE, 2006, MICROBES INFECT, V8, P1347, DOI 10.1016/j.micinf.2005.11.014
   Kogan MJ, 2007, NANOMEDICINE-UK, V2, P287, DOI 10.2217/17435889.2.3.287
   LANGEL U, 2006, BIOCH BIOPHY ACTA, V1758, P260
   Lanzkron SM, 1999, BLOOD, V93, P1916
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Michalet X, 2001, SINGLE MOL, V2, P261, DOI 10.1002/1438-5171(200112)2:4<261::AID-SIMO261>3.0.CO;2-P                        
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nath A, 1996, J VIROL, V70, P1475
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pooga M, 1998, FASEB J, V12, P67
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Prakash O, 1997, ARCH BIOCHEM BIOPHYS, V343, P173, DOI 10.1006/abbi.1997.0168
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T
   Rosenthal SJ, 2002, J AM CHEM SOC, V124, P4586, DOI 10.1021/ja003486s
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   SUK JS, 2006, BIOMATERIALS, V29, P5143
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
   ZEIGLER A, 2005, BIOCHEMISTRY-US, V44, P138
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 67
TC 67
Z9 67
U1 0
U2 19
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JUN
PY 2008
VL 3
IS 3
BP 357
EP 365
DI 10.2217/17435889.3.3.357
PG 9
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 314DN
UT WOS:000256789400012
PM 18510430
DA 2018-01-05
ER

PT J
AU Wurster, SE
   Maher, LJ
AF Wurster, Susan E.
   Maher, L. James, III
TI Selection and characterization of anti-NF-kappa B p65 RNA aptamers
SO RNA
LA English
DT Article
DE NF-kappa B; aptamer; in vitro selection; p65
ID TRANSCRIPTION FACTOR TARGET; CANCER DEVELOPMENT; INVITRO SELECTION;
   DNA-BINDING; DUPLEX DNA; RECOGNITION; INFLAMMATION; PROGRESSION;
   INHIBITION; POLYMERASE
AB NF-kappa B transcription factors include a group of five mammalian proteins that form hetero- or homodimers and regulate hundreds of target genes involved in acute inflammation, HIV-1 transcription activation, and resistance to cancer therapy. We previously used in vitro selection to develop a small RNA aptamer (anti-p50) that binds the DNA-binding domain of NF-kappa B p50(2) with low nanomolar affinity but does not bind NF-kappa B p65(2). Here, we report the in vitro selection of anti-NF-kappa B p65 RNA aptamers using parallel in vitro selections with either a fully randomized RNA library or a degenerate RNA library based on the primary sequence of the 31-nucleotide anti-p50 RNA aptamer. We report the characterization of these aptamers with respect to NF-kappa B target specificity, affinity, minimal sequence requirements, secondary structure, and competition with DNA kappa B sites. These results expand opportunities for artificial inhibition of NF-kappa B transcription factor dimers containing p65 subunits.
C1 [Wurster, Susan E.; Maher, L. James, III] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MI USA.
RP Maher, LJ (reprint author), Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.
EM maher@mayo.edu
FU NIGMS NIH HHS [GM68128, R01 GM068128]
CR Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649                                                
   BEG AA, 1996, SCIENCE, V274, P784
   Brown TS, 2005, BIOTECHNIQUES, V38, P368, DOI 10.2144/05383BM04                                                               
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   BURKE JM, 1993, FASEB J, V7, P106
   Carmody RJ, 2007, SCIENCE, V317, P675, DOI 10.1126/science.1142953
   Cassiday LA, 2003, P NATL ACAD SCI USA, V100, P3930, DOI 10.1073/pnas.0736013100
   Cassiday LA, 2002, ANAL BIOCHEM, V306, P290, DOI 10.1006/abio.2002.5710
   Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512
   Cassiday LA, 2001, BIOCHEMISTRY-US, V40, P2433, DOI 10.1021/bi002376v
   Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224
   Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67
   Choi KH, 2006, MOL CANCER THER, V5, P2428, DOI 10.1158/1535-7163.MCT-05-0204
   Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645                                                        
   Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Escarcega RO, 2007, CLIN ONCOL-UK, V19, P154, DOI 10.1016/j.clon.2006.11.013
   FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775                                                             
   Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj/leu/2402482
   GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0
   Guo J, 2004, CLIN CANCER RES, V10, P3333, DOI 10.1158/1078-0432.CCR-03-0366                                                   
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Huang DB, 2003, P NATL ACAD SCI USA, V100, P9268, DOI 10.1073/pnas.1632011100
   Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173
   JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706
   JAEGER JA, 1990, METHOD ENZYMOL, V183, P281
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224                                                         
   Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x                                                               
   Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1                                                   
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   MCDONALD CD, 1995, NUCLEIC ACIDS RES, V23, P500, DOI 10.1093/nar/23.3.500
   Mi J, 2006, NUCLEIC ACIDS RES, V34, P3577, DOI 10.1093/nar/gkl482
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Reiter NJ, 2008, NUCLEIC ACIDS RES, V36, P1227, DOI 10.1093/nar/gkm1141
   Soukup GA, 1996, J MOL BIOL, V259, P216, DOI 10.1006/jmbi.1996.0314
   SUZAN M, 1991, J IMMUNOL, V146, P377
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Zhao XC, 2006, NUCLEIC ACIDS RES, V34, P3755, DOI 10.1093/nar/gkl470
   ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181
NR 46
TC 24
Z9 25
U1 0
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
EI 1469-9001
J9 RNA
JI RNA
PD JUN
PY 2008
VL 14
IS 6
BP 1037
EP 1047
DI 10.1261/rna.878908
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 303TW
UT WOS:000256064800006
PM 18426920
OA gold
DA 2018-01-05
ER

PT J
AU Peek, LJ
   Middaugh, CR
   Berkland, C
AF Peek, Laura J.
   Middaugh, C. Russell
   Berkland, Cory
TI Nanotechnology in vaccine delivery
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE adjuvant; immunopotentiator; humoral immunity; cellular immunity;
   immunization; nanoparticle; antigen
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HEPATITIS-B-VACCINE; PHASE-I TRIAL;
   HUMORAL IMMUNE-RESPONSES; T-CELL RESPONSES; MF59-ADJUVANTED INFLUENZA
   VACCINE; ASSEMBLED HYDROGEL NANOPARTICLE; PLASMODIUM-FALCIPARUM MALARIA;
   HUMAN-PAPILLOMAVIRUS TYPE-16; ADJUVANT MONTANIDE ISA-720
AB With very few adjuvants currently being used in marketed human vaccines, a critical need exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral, cellular and mucosal immunity. Such crucial vaccine components could facilitate the development of novel vaccines for viral and parasitic infections, such as hepatitis, HIV, malaria, cancer, etc. In this review, we discuss clinical trial results for various vaccine adjuvants and delivery vehicles being developed that are approximately nanoscale (< 1000 nm) in size. Humoral immune responses have been observed for most adjuvants and delivery platforms while only viral vectors, ISCOMs and Montanide(TM) ISA 51 and 720 have shown cytotoxic T cell responses in the clinic. MF59 and MPL(R) have elicited Th 1 responses, and virus-like particles, non-degradable nanoparticles and liposomes have also generated cellular immunity. Such vaccine components have also been evaluated for alternative routes of administration with clinical successes reported for intranasal delivery of viral vectors and proteosomes and oral delivery of a VLP vaccine. Published by Elsevier B.V.
C1 [Peek, Laura J.; Middaugh, C. Russell; Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA.
   [Peek, Laura J.; Berkland, Cory] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66047 USA.
RP Berkland, C (reprint author), 2030 Becker Dr, Lawrence, KS 66047 USA.
EM berkland@ku.edu
CR Akiyoshi K, 1998, J CONTROL RELEASE, V54, P313, DOI 10.1016/S0168-3659(98)00017-0
   Alving C R, 1980, Prog Clin Biol Res, V47, P339
   ALVING CR, 1995, ANN NY ACAD SCI, V754, P143, DOI 10.1111/j.1749-6632.1995.tb44447.x
   ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5                                                    
   Amara RR, 2002, VACCINE, V20, P1949, DOI 10.1016/S0264-410X(02)00076-2                                                   
   Atmar RL, 2006, CLIN INFECT DIS, V43, P1135, DOI 10.1086/508174
   Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111
   Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2                                                   
   Auger F, 2006, TOXICOL APPL PHARM, V215, P285, DOI 10.1016/j.taap.2006.03.002
   Baldridge JR, 1999, METHODS, V19, P103, DOI 10.1006/meth.1999.0834                                                          
   Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149
   Barr IG, 1998, ADV DRUG DELIVER REV, V32, P247, DOI 10.1016/S0169-409X(98)00013-1
   Berencsi K, 2001, J INFECT DIS, V183, P1171, DOI 10.1086/319680
   *BIOSANTE PHARM, 2007, VACC ADJ
   *BIOSANTE PHARM, 2007, CALC PHOSPH NAN CAP
   Borges O, 2005, INT J PHARM, V299, P155, DOI 10.1016/j.ijpharm.2005.04.037
   Borm PJA, 2004, J NANOSCI NANOTECHNO, V4, P521, DOI 10.1166/jnn.2004.081
   Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
   Boyce TG, 2000, VACCINE, V19, P217, DOI 10.1016/S0264-410X(00)00171-7                                                   
   Bricks Lucia Ferro, 2006, J Pediatr (Rio J), V82, pS67, DOI 10.1590/S0021-75572006000400008
   Burgers WA, 2006, J GEN VIROL, V87, P399, DOI 10.1099/vir.0.81379-0
   Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258                                                                  
   Chianese-Bullock KA, 2005, J IMMUNOL, V174, P3080, DOI 10.4049/jimmunol.174.5.3080                                                     
   CHOI C, 2006, VACCINE DEADLIEST AL
   Copland MJ, 2005, IMMUNOL CELL BIOL, V83, P97, DOI 10.1111/j.1440-1711.2005.01315.x
   Coulter A, 2003, VACCINE, V21, P946, DOI 10.1016/S0264-410X(02)00545-5
   *CSL, 2007, BIOTH HCV VACC
   Cyr SL, 2007, VACCINE, V25, P3228, DOI 10.1016/j.vaccine.2007.01.037
   Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101
   de Bruijn IA, 2005, VACCINE, V23, pS39, DOI 10.1016/j.vaccine.2005.04.020
   DORRELL L, 2007, VACCINE, V11, P11
   Drane Debbie, 2006, P191, DOI 10.1016/B978-012088403-2/50013-7
   Duncan G, 2005, J CONTROL RELEASE, V110, P34, DOI 10.1016/j.jconrel.2005.09.007
   Dupuis M, 1998, CELL IMMUNOL, V186, P18, DOI 10.1006/cimm.1998.1283
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978
   Ennis FA, 1999, VIROLOGY, V259, P256, DOI 10.1006/viro.1999.9765
   Excler JL, 1997, AIDS, V11, pS127
   Fenner F., 1988, SMALLPOX ITS ERADICA
   Frazer IH, 2004, VACCINE, V23, P172, DOI 10.1016/j.vaccine.2004.05.013
   Frey S, 2003, VACCINE, V21, P4234, DOI 10.1016/S0264-410X(03)00456-0
   Fries LF, 2001, INFECT IMMUN, V69, P4545, DOI 10.1128/IAI.69.7.4545-4553.2001
   FROST L, 1985, ALLERGY, V40, P368, DOI 10.1111/j.1398-9995.1985.tb00249.x
   Fuller DH, 2006, METHODS, V40, P86, DOI 10.1016/j.ymeth.2006.05.022
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Gallichan WS, 1996, J EXP MED, V184, P1879, DOI 10.1084/jem.184.5.1879
   Garcon Nathalie, 2006, P161, DOI 10.1016/B978-012088403-2/50011-3
   Gasparini R, 2001, EUR J EPIDEMIOL, V17, P135, DOI 10.1023/A:1017919305501                                                         
   Genton B, 2000, VACCINE, V18, P2504, DOI 10.1016/S0264-410X(00)00036-0
   Gherardi RK, 2001, BRAIN, V124, P1821, DOI 10.1093/brain/124.9.1821
   Glenny AT, 1931, J PATHOL BACTERIOL, V34, P267, DOI 10.1002/path.1700340214
   Gluck R, 2004, EXPERT OPIN BIOL TH, V4, P1139, DOI 10.1517/14712598.4.7.1139
   GLUCK R, 1992, VACCINE, V10, P915, DOI 10.1016/0264-410X(92)90325-E
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   GOTO N, 1993, VACCINE, V11, P914, DOI 10.1016/0264-410X(93)90377-A
   Goto N, 1997, VACCINE, V15, P1364, DOI 10.1016/S0264-410X(97)00054-6
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Gu XG, 1998, CANCER RES, V58, P3385
   Guan HH, 1998, BIOCONJUGATE CHEM, V9, P451, DOI 10.1021/bc970183n
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Gupta RK, 1995, VACCINE DESIGN SUBUN, P229
   Hanke T, 1999, J VIROL, V73, P7524
   Hanke T, 2007, J GEN VIROL, V88, P1, DOI 10.1099/vir.0.82493-0
   Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4
   Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S01406736(06)68439-0
   Harrop R, 2006, ADV DRUG DELIVER REV, V58, P931, DOI 10.1016/j.addr.2006.05.005
   Hasegawa K, 2006, CLIN CANCER RES, V12, P1921, DOI 10.1158/1078-0432.CCR-05-1900
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000                                                   
   Heath PT, 1998, PEDIATR INFECT DIS J, V17, pS117, DOI 10.1097/00006454-199809001-00005
   Heineman TC, 1999, VACCINE, V17, P2769, DOI 10.1016/S0264-410X(99)00088-2
   Hersey P, 2005, CANCER IMMUNOL IMMUN, V54, P208, DOI 10.1007/s00262-004-0587-8
   Hirunpetcharat C, 2003, VACCINE, V21, P2923, DOI 10.1016/S0264-410X(03)00132-4
   HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X
   Hu KF, 2001, ADV DRUG DELIVER REV, V51, P149, DOI 10.1016/S0169-409X(01)00165-X
   Huckriede A, 2005, VACCINE, V23, pS26, DOI 10.1016/j.vaccine.2005.04.026
   Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013
   Hutcheon CJ, 2006, VACCINE, V24, P7214, DOI 10.1016/j.vaccine.2006.06.043
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893
   Ikuta Y, 2002, BLOOD, V99, P3717, DOI 10.1182/blood.V99.10.3717                                                       
   Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718
   Jiang DP, 2004, VACCINE, V23, P693, DOI 10.1016/j.vaccine.2004.06.029
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Jin HL, 2005, BIOCHEM BIOPH RES CO, V328, P979, DOI 10.1016/j.bbrc.2005.01.048
   Johansen P, 2003, IMMUNOL LETT, V90, P81, DOI 10.1016/S0165-2478(03)00176-7
   JOHNSON AG, 1956, J EXP MED, V103, P225, DOI 10.1084/jem.103.2.225                                                           
   Jones LS, 2005, J BIOL CHEM, V280, P13406, DOI 10.1074/jbc.M500687200
   Jones T, 2006, VACCINE, V24, P1625, DOI 10.1016/j.vaccine.2005.09.052
   Jones T, 2004, VACCINE, V22, P3691, DOI 10.1016/j.vaccine.2004.03.035
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288                                                       
   Kamath AT, 1999, INFECT IMMUN, V67, P1702
   KANG EC, 1994, INT J BIOL MACROMOL, V16, P348, DOI 10.1016/0141-8130(94)90068-X
   Katre N. V., 2004, AM J DRUG DELIV, V2, P213
   Kawabata R, 2007, INT J CANCER, V120, P2178, DOI 10.1002/ijc.22583
   Kim HD, 2007, J GENE MED, V9, P88, DOI 10.1002/jgm.993
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040
   LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001
   Langley JM, 2006, VACCINE, V24, P1601, DOI 10.1016/j.vaccine.2005.09.056
   Lawrence G, 2000, VACCINE, V18, P1925, DOI 10.1016/S0264-410X(99)00444-2
   Lawrence GW, 1997, VACCINE, V15, P176, DOI 10.1016/S0264-410X(96)00150-8
   LI S, 2006, VACCINE
   Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.1440-1711.2004.01286.x
   Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.3.CO;2-D
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004
   MACLEAN GD, 1993, CANCER IMMUNOL IMMUN, V36, P215, DOI 10.1007/BF01740902
   MACLEAN GD, 1992, J IMMUNOTHER, V11, P292, DOI 10.1097/00002371-199205000-00008
   Madalinski K, 2001, VACCINE, V20, P92, DOI 10.1016/S0264-410X(01)00312-7                                                   
   Mahvi DM, 2002, HUM GENE THER, V13, P1711, DOI 10.1089/104303402760293556                                                      
   MARTIN SJ, 1993, AIDS, V7, P1315, DOI 10.1097/00002030-199310000-00003
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McCormack S, 2000, VACCINE, V18, P1166, DOI 10.1016/S0264-410X(99)00388-6
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Meidenbauer N, 2000, PROSTATE, V43, P88, DOI 10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G
   Men Y, 1997, VACCINE, V15, P1405, DOI 10.1016/S0264-410X(97)00047-9
   Metcalfe Ian C., 2006, P179, DOI 10.1016/B978-012088403-2/50012-5
   Miles AP, 2005, VACCINE, V23, P2530, DOI 10.1016/j.vaccine.2004.08.049
   Miller E, 1996, J CLIN PATHOL, V49, P620, DOI 10.1136/jcp.49.8.620                                                            
   Mischler R, 2002, VACCINE, V20, pB17, DOI 10.1016/S0264-410X(02)00512-1
   Mitchell DK, 2002, PEDIATR INFECT DIS J, V21, P133, DOI 10.1097/00006454-200202000-00009
   MITCHELL MS, 1988, CANCER RES, V48, P5883
   Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   Nakanishi T, 1999, J CONTROL RELEASE, V61, P233, DOI 10.1016/S0168-3659(99)00097-8                                                   
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI [10.1128/IAI.72.11.6519-6527.2004, 10.1128/IAI.72.11.6519-6529.2004]
   *NAT CTR INF DIS, 2005, DIS LIST MEN DIS GEN
   *NAT I ALL INF DIS, UND VACC WHAT THE AR
   Nishikawa T, 1996, J AM CHEM SOC, V118, P6110, DOI 10.1021/ja953843c                                                               
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   O'Hagan Derek T., 2006, P123, DOI 10.1016/B978-012088403-2/50009-5
   O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269
   OHAGAN DT, 1991, IMMUNOLOGY, V73, P239
   OHAGAN DT, 1991, VACCINE, V9, P768, DOI 10.1016/0264-410X(91)90295-H
   Oka Y, 2004, P NATL ACAD SCI USA, V101, P13885, DOI 10.1073/pnas.0405884101
   Okada M, 2005, VACCINE, V23, P2269, DOI 10.1016/j.vaccine.2005.01.036
   Oliveira GA, 2005, INFECT IMMUN, V73, P3587, DOI 10.1128/IAI.73.6.3587-3597.2005
   Ott G, 1995, Pharm Biotechnol, V6, P277
   Palmer M, 2001, CLIN LUNG CANCER, V3, P49, DOI 10.3816/CLC.2001.n.018
   Panlilio Adelisa L., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001                                                
   Patil SD, 2005, AAPS J, V7, pE61, DOI 10.1208/aapsj070109
   Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006
   Perlaza BL, 1998, INFECT IMMUN, V66, P3423
   Persing David H., 2006, P93, DOI 10.1016/B978-012088403-2/50007-1
   PIALOUX G, 1995, AIDS RES HUM RETROV, V11, P373, DOI 10.1089/aid.1995.11.373                                                         
   Plante M, 2001, VACCINE, V20, P218, DOI 10.1016/S0264-410X(01)00268-7                                                   
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   PLOTKIN SL, 2004, VACCINES, P15
   Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0
   Podda Audino, 2006, P149, DOI 10.1016/B978-012088403-2/50010-1
   RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064
   Raghuvanshi RJ, 2001, J MICROENCAPSUL, V18, P723
   Redwood AJ, 2007, VACCINE, V25, P698, DOI 10.1016/j.vaccine.2006.08.021
   RIETSCHEL ET, 1987, REV INFECT DIS, V9, pS527
   Rimmelzwaan GF, 2001, VACCINE, V20, P158, DOI 10.1016/S0264-410X(01)00262-6                                                   
   Rimmelzwaan GF, 2000, VACCINE, V19, P1180, DOI 10.1016/S0264-410X(00)00310-8                                                   
   RIMMELZWAAN GF, 1994, VACCINE DESIGN SUBUN
   RONNBERG B, 1995, VACCINE, V13, P1375, DOI 10.1016/0264-410X(95)00105-A
   ROUSE BT, 1988, REV INFECT DIS, V10, P16
   *ROYAL AC ENG ROYA, 2004, NAN NAN OPP UNC, pCH5
   Santosuosso M, 2005, VIRAL IMMUNOL, V18, P283, DOI 10.1089/vim.2005.18.283
   Saul A, 1999, VACCINE, V17, P3145, DOI 10.1016/S0264-410X(99)00175-9
   Saupe A, 2006, EXPERT OPIN DRUG DEL, V3, P345, DOI 10.1517/17425247.3.3.345
   SCALZO AA, 1995, J VIROL, V69, P1306
   Shi ZK, 2001, J VIROL, V75, P11474, DOI 10.1128/JVI.75.23.11474-11482.2001
   Shinoda K, 2004, VACCINE, V22, P3676, DOI 10.1016/j.vaccine.2004.03.015
   SHOUVAL D, 1994, VACCINE, V12, P1453, DOI 10.1016/0264-410X(94)90155-4
   Simon Jakub K., 2006, P319, DOI 10.1016/B978-012088403-2/50019-8
   Sjolander A, 1998, ADV DRUG DELIVER REV, V34, P321, DOI 10.1016/S0169-409X(98)00046-5
   Sjolander S, 2001, VACCINE, V19, P4072, DOI 10.1016/S0264-410X(01)00110-4
   Smith J, 2004, B WORLD HEALTH ORGAN, V82, P24
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   Tacket CO, 2003, CLIN IMMUNOL, V108, P241, DOI 10.1016/S1521-6616(03)00120-7
   THAPAR MA, 1991, VACCINE, V9, P129, DOI 10.1016/0264-410X(91)90269-C
   Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6
   Treanor J, 2006, VACCINE, V24, P254, DOI 10.1016/j.vaccine.2005.07.088
   Ulrich J T, 1995, Pharm Biotechnol, V6, P495
   ULRICH JT, 1994, VACCINE DESIGN SUBUN
   Van Kampen KR, 2005, VACCINE, V23, P1029, DOI 10.1016/j.vaccine.2004.07.043
   Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
   VOGEL FR, 1995, VACCINE DESIGN SUBUN
   WALSH G, 1998, BIOPHARMACEUTICALS B
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
   *WHO, 2006, TEMP SENS VACC
   YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568
   YAP I, 1992, VACCINE, V10, P439, DOI 10.1016/0264-410X(92)90391-V
   Zhang L, 2004, BIOELECTROCHEMISTRY, V63, P369, DOI 10.1016/j.bioelechem.2003.11.011
   Zhang L, 2003, DNA CELL BIOL, V22, P815, DOI 10.1089/104454903322625028
   2006, 10Q WYETH Q REPORT
NR 195
TC 272
Z9 287
U1 12
U2 174
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAY 22
PY 2008
VL 60
IS 8
BP 915
EP 928
DI 10.1016/j.addr.2007.05.017
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 305VI
UT WOS:000256205500006
PM 18325628
HC Y
HP N
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Fighting HIV with multivalent gold nanoparticles
SO CHEMICAL & ENGINEERING NEWS
LA English
DT News Item
AB CCR5 is a receptor where HIV gains entry to a cell. SDC-1721 is a compound that binds only weakly to CCR5 and when attached to a gold nanoparticle, this is able to keep HIV from infecting cells. This also inhibits HIV replication at a concentration of just 10 nm.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2347
J9 CHEM ENG NEWS
JI Chem. Eng. News
PD MAY 19
PY 2008
VL 86
IS 20
BP 39
EP 39
PG 1
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA 302XW
UT WOS:000256004400039
DA 2018-01-05
ER

PT J
AU Mahmoud, KA
   Hrapovic, S
   Luong, JHT
AF Mahmoud, Khaled A.
   Hrapovic, Sabahudin
   Luong, John H. T.
TI Picomolar detection of protease using peptide/single walled carbon
   nanotube/gold nanoparticle-modified electrode
SO ACS NANO
LA English
DT Article
DE protease; ferrocene-pepstatin inhibitor; carbon nanotubes; gold
   nanoparticles; biosensor
ID VIRUS TYPE-1 PROTEASE; HIV-1 PROTEASE; GOLD NANOPARTICLES; INHIBITOR;
   PROTEINASE; BINDING; PEPSTATIN; ASSAY
AB Picomolar electrochemical detection of human immunodeficiency virus type-1 protease (HIV-1 PR) using ferrocene (Fc)-pepstatin-modified surfaces has been presented. Gold electrode surface was modified with gold nanoparticles (AuNP) or thiolated single walled carbon nanotubes/gold nanciparticles (SWCNT/AuNP). Thiol-terminated Fc-pepstatin was then self-assembled on such surfaces as confirmed by Raman spectroscopy and scanning electron microscope. The interaction between the Fc-pepstatin-modified substrates and HIV-1 PR was studied by cyclic voltammetry and electrochemical impedance spectroscopy. Both electrode materials showed enhanced electrochemical responses to increasing concentrations of HIV-1 PR with shifting to higher potentials as well as decrease in the overall signal intensity. However, the sensing electrode modified with thiolated SWCNTs/AuNPs showed remarkable detection sensitivity with an estimated detection limit of 0.8 pM.
C1 [Mahmoud, Khaled A.; Hrapovic, Sabahudin; Luong, John H. T.] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
   [Luong, John H. T.] Natl Univ Ireland Univ Coll Cork, Dept Chem, Cork, Ireland.
RP Luong, JHT (reprint author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.
EM John.Luong@cnrc-nrc.gc.ca
OI Luong, John/0000-0002-1709-1223; Mahmoud, Khaled/0000-0003-1246-4067
CR Azamian BR, 2002, CHEM COMMUN, P366, DOI 10.1039/b110690b                                                                
   BIEBUYCK HA, 1994, LANGMUIR, V10, P1825, DOI 10.1021/la00018a034                                                             
   BLAIR IS, 1995, CURR MICROBIOL, V31, P180, DOI 10.1007/BF00293551
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Castaneda MT, 2007, BIOSENS BIOELECTRON, V22, P1961, DOI 10.1016/j.bios.2006.08.031
   Cheng YSE, 2006, J VIROL METHODS, V137, P82, DOI 10.1016/j.jviromet.2006.06.003
   DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201
   Eggeling C, 2005, CURR PHARM BIOTECHNO, V6, P351, DOI 10.2174/138920105774370571
   Eggeling C, 2005, BIOPHYS J, V89, P605, DOI 10.1529/biophysj.104.052753
   Ellis AV, 2003, NANO LETT, V3, P279, DOI 10.1021/nl025824o
   Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004
   Fuse T, 2006, MICROBES INFECT, V8, P1783, DOI 10.1016/j.micinf.2006.02.016
   Gosalina DN, 2006, BIOTECHNOL BIOENG, V94, P1099, DOI 10.1002/bit.20927
   Grant SA, 2007, SENSOR ACTUAT B-CHEM, V121, P482, DOI 10.1016/j.snb.2006.04.096
   Hook VYH, 1996, PEPTIDE RES, V9, P183
   Hrapovic S, 2004, ANAL CHEM, V76, P1083, DOI 10.1021/ac035143t
   Ionescu RE, 2006, ANAL CHEM, V78, P6327, DOI 10.1021/ac060253w
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   Jayatilleke PRN, 2000, J MED CHEM, V43, P4446, DOI 10.1021/jm9905357
   Kaufmann S. H., 1999, APOPTOSIS NEUROBIOLO, P205
   KERMAN K, 2007, CHEM COMMUN, V3829, P3831
   Kilian KA, 2007, ACS NANO, V1, P355, DOI 10.1021/nn700141n
   Kohl T, 2002, P NATL ACAD SCI USA, V99, P12161, DOI 10.1073/pnas.192433499
   Li CZ, 2005, ANAL CHEM, V77, P478, DOI 10.1021/ac048672l
   Lim JK, 2003, SYNTHETIC MET, V139, P521, DOI 10.1016/S0379-6779(03)00337-0
   Mahmoud KA, 2007, CHEM-EUR J, V13, P5885, DOI 10.1002/chem.200601878
   MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088
   Miller J. C., 1993, E HORWOOD SERIES, P119
   Nalam MNL, 2007, ANTIVIR THER, V12, pS138
   Nalam MNL, 2007, J VIROL, V81, P9512, DOI 10.1128/JVI.00799-07
   Orosco MM, 2006, ADV MATER, V18, P1393, DOI 10.1002/adma.200502420
   PETERS T, 1996, ALL ALBUMIN BIOCH GE
   Pinto MR, 2004, P NATL ACAD SCI USA, V101, P7505, DOI 10.1073/pnas.0402280101
   Pumera M, 2007, SENSOR ACTUAT B-CHEM, V123, P1195, DOI 10.1016/j.snb.2006.11.016
   Sham YY, 2000, PROTEINS, V39, P393, DOI 10.1002/(SICI)1097-0134(20000601)39:4<393::AID-PROT120>3.3.CO;2-8
   UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259                                                      
   Valentini F, 2003, ANAL CHEM, V75, P5413, DOI 10.1021/ac0300237
   Wainberg MA, 2007, AIDS PATIENT CARE ST, V21, P609, DOI 10.1089/apc.2006.0176
   Wang J, 2005, ELECTROANAL, V17, P7, DOI 10.1002/elan.200403113
   Wegner GJ, 2004, ANAL CHEM, V76, P5677, DOI 10.1021/ac0494275
   Willey TM, 2004, LANGMUIR, V20, P4939, DOI 10.1021/la049868j
   WILLIAMS BA, 1993, J ORG CHEM, V58, P3507, DOI 10.1021/jo00065a010
   Wu BY, 2007, BIOSENS BIOELECTRON, V22, P2854, DOI 10.1016/j.bios.2006.11.028
   Zhu J, 2001, J COMPUT AID MOL DES, V15, P979, DOI 10.1023/A:1014817911249
NR 44
TC 84
Z9 85
U1 1
U2 66
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2008
VL 2
IS 5
BP 1051
EP 1057
DI 10.1021/nn8000774
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 306FP
UT WOS:000256234000032
PM 19206503
DA 2018-01-05
ER

PT J
AU De Luca, L
   Barreca, ML
   Ferro, S
   Iraci, N
   Michiels, M
   Christ, F
   Debyser, Z
   Witvrouw, M
   Chimirri, A
AF De Luca, Laura
   Barreca, Maria Letizia
   Ferro, Stefania
   Iraci, Nunzio
   Michiels, Martine
   Christ, Frauke
   Debyser, Zeger
   Witvrouw, Myriam
   Chimirri, Alba
TI A refined pharmacophore model for HIV-1 integrase inhibitors:
   Optimization of potency in the 1H-benzylindole series
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE integrase; HIV; DKAs; pharmacophore model; synthesis of indole
   derivatives
ID STRAND-TRANSFER
AB We report herein the development of a new three-dimensional pharmacophore model for HIV-1 integrase inhibitors which led to the discovery of some 4-[1-(4-fluorobenzyl)-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acids that are able to specifically inhibit the strand transfer step of integration at nanomolar concentration. The synthesis of the new designed molecules is also described. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [De Luca, Laura; Ferro, Stefania; Iraci, Nunzio; Chimirri, Alba] Univ Messina, Dipartimento Farmaco Chim, I-98168 Messina, Italy.
   [Barreca, Maria Letizia] Dipartiment Chim & Technol Farmaco, I-06123 Perugia, Italy.
   [Michiels, Martine; Christ, Frauke; Debyser, Zeger; Witvrouw, Myriam] Katholieke Univ Leuven, B-3000 Louvain, Belgium.
   [Michiels, Martine; Christ, Frauke; Debyser, Zeger; Witvrouw, Myriam] IRC KULAK, B-3000 Louvain, Belgium.
RP Chimirri, A (reprint author), Univ Messina, Dipartimento Farmaco Chim, Viale Anmunziata, I-98168 Messina, Italy.
EM chimirri@pharma.unime.it
RI De Luca, Laura/D-8532-2011; Iraci, Nunzio/B-4945-2015
OI Iraci, Nunzio/0000-0002-1359-8684; De Luca, Laura/0000-0003-0614-5713;
   Barreca, Maria Letizia/0000-0003-3530-5042; debyser,
   zeger/0000-0002-3982-1565
CR Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
   Ferro S, 2007, ARCH PHARM, V340, P292, DOI 10.1002/ardp.200700066
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Johnson AA, 2004, CURR TOP MED CHEM, V4, P1059, DOI 10.2174/1568026043388394                                                        
   Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   RAMACHARAN J, 2006, FUTURE MED, V1, P717
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   *VAISD, 2006, CATALYST
NR 12
TC 33
Z9 34
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2008
VL 18
IS 9
BP 2891
EP 2895
DI 10.1016/j.bmcl.2008.03.089
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 294ZH
UT WOS:000255444300025
PM 18417342
DA 2018-01-05
ER

PT J
AU Matoba, N
   Griffin, TA
   Mittman, M
   Doran, JD
   Alfsen, A
   Montefiori, DC
   Hanson, CV
   Bomsel, M
   Mor, TS
AF Matoba, Nobuyuki
   Griffin, Tagan A.
   Mittman, Michele
   Doran, Jeffrey D.
   Alfsen, Annette
   Montefiori, David C.
   Hanson, Carl V.
   Bomsel, Morgane
   Mor, Tsafrir S.
TI Transcytosis-blocking Abs elicited by an oligomeric immunogen based on
   the membrane proximal region of HIV-1 gp41 target non-neutralizing
   epitopes
SO CURRENT HIV RESEARCH
LA English
DT Article
DE HIV vaccine; mucosal transmission; functional non-neutralizing
   antibodies; prime/boost; transcytosis
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TOXIN B-SUBUNIT; TIGHT EPITHELIAL
   BARRIERS; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; EXTERNAL REGION;
   TRANSMEMBRANE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; VACCINE CANDIDATE;
   ATOMIC-STRUCTURE
AB CTB-MPR649-684, a translational fusion protein consisting of cholera toxin B subunit (CTB) and residues 649-684 of gp41 membrane proximal region (MPR), is a candidate vaccine aimed at blocking early steps of HIV-1 mucosal transmission. Bacterially produced CTB-MPR649-684 was purified to homogeneity by two affinity chromatography steps. Similar to gp41 and derivatives thereof, the MPR domain can specifically and reversibly self-associate. The affinities of the broadly-neutralizing monoclonal Abs 4E10 and 2F5 to CTB-MPR649-684 were equivalent to their nanomolar affinities toward an MPR peptide. The fusion protein's affinity to GM1 ganglioside was comparable to that of native CTB. Rabbits immunized with CTB-MPR649-684 raised only a modest level of anti-MPR649-684 Abs. However, a prime-boost immunization with CTB-MPR649-684 and a second MPR649-684-based immunogen elicited a more productive anti-MPR649-684 antibody response. These Abs strongly blocked the epithelial transcytosis of a primary subtype B HIV-1 isolate in a human tight epithelial model, expanding our previously reported results using a clade D virus. The Abs recognized epitopes at the N-terminal portion of the MPR peptide, away from the 2F5 and 4E10 epitopes and were not effective in neutralizing infection of CD4+ cells. These results indicate distinct vulnerabilities of two separate interactions of HIV-1 with human cells - Abs against the C-terminal portion of the MPR can neutralize CD4+-dependent infection, while Abs targeting the MPR's N-terminal portion can effectively block galactosyl ceramide dependent transcytosis. We propose that Abs induced by MPR649-684-based immunogens may provide broad protective value independent of infection neutralization.
C1 [Matoba, Nobuyuki; Griffin, Tagan A.; Mittman, Michele; Doran, Jeffrey D.; Mor, Tsafrir S.] Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, Tempe, AZ 85287 USA.
   [Matoba, Nobuyuki; Griffin, Tagan A.; Mittman, Michele; Doran, Jeffrey D.; Mor, Tsafrir S.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
   [Alfsen, Annette; Bomsel, Morgane] Inst Cochin Genet Mol, Dept Biol Cellulaire, F-75014 Paris, France.
   [Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC 27710 USA.
   [Bomsel, Morgane] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA.
RP Mor, TS (reprint author), Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, POB 874501, Tempe, AZ 85287 USA.
EM tsafrir.mor@asu.edu
RI mor, tsafrir/E-9422-2013
FU NIAID NIH HHS [U19AI62150, U19 AI062150, U19 AI062150-05, N01AI30034,
   R21 AI052761-02, IR21AI052761-01A2, R21 AI052761]
CR Alfsen A, 2005, MOL BIOL CELL, V16, P4267, DOI 10.1091/mbc.E05-03-0192
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   ALFSEN A, 2002, J BIOL CHEM, V8, P8
   Belec L, 2001, J INFECT DIS, V184, P1412, DOI 10.1086/324375                                                                  
   Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Binley JM, 1996, AIDS RES HUM RETROV, V12, P911, DOI 10.1089/aid.1996.12.911
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   Broliden K, 2001, IMMUNOL LETT, V79, P29, DOI 10.1016/S0165-2478(01)00263-2                                                   
   Brunel FM, 2006, J VIROL, V80, P1680, DOI 10.1128/JVI.80.4.1680-1687.2006
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Choi JH, 2004, APPL MICROBIOL BIOT, V64, P625, DOI 10.1007/s00253-004-1559-9
   Dakappagari NK, 2003, J IMMUNOL, V170, P4242, DOI 10.4049/jimmunol.170.8.4242                                                     
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   Devito C, 2000, AIDS, V14, P1917, DOI 10.1097/00002030-200009080-00006                                                
   Devito C, 2002, J ACQ IMMUN DEF SYND, V30, P413, DOI 10.1097/01.QAI.0000021664.20213.5A
   DSOUZA MP, 1995, AIDS, V9, P867, DOI 10.1097/00002030-199508000-00006
   Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002
   George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001
   Gray ES, 2006, PLOS MED, V3, P1023, DOI 10.1371/journal.pmed.0030255
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   Kaul R, 2001, AIDS, V15, P431, DOI 10.1097/00002030-200102160-00026
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200
   Li B, 2006, J VIROL, V80, P5211, DOI 10.1128/JVI.00201-06
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Liljeqvist S, 1997, J IMMUNOL METHODS, V210, P125, DOI 10.1016/S0022-1759(97)00170-1
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Mantis NJ, 2001, VACCINE, V19, P3990, DOI 10.1016/S0264-410X(01)00115-3
   Matoba N, 2006, VACCINE, V24, P5047, DOI 10.1016/j.vaccine.2006.03.045
   Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101
   MUSTER T, 1993, J VIROL, V67, P6642
   Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001                                              
   Qiao ZS, 2005, J BIOL CHEM, V280, P23138, DOI 10.1074/jbc.M414515200
   ROBINSON WE, 1991, J VIROL, V65, P4169
   Saez-Cirion A, 2003, BIOPHYS J, V85, P3769, DOI 10.1016/S0006-3495(03)74792-4                                                   
   Santona A, 2002, INFECT IMMUN, V70, P171, DOI 10.1128/IAI.70.1.171-176.2002
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Trivedi VD, 2003, PROTEIN ENG, V16, P311, DOI 10.1093/proeng/gzg036
   TYLER DS, 1990, J IMMUNOL, V145, P3276
   UESAKA Y, 1994, MICROB PATHOGENESIS, V16, P71, DOI 10.1006/mpat.1994.1007                                                          
   Vanniasinkam T, 2001, J CLIN MICROBIOL, V39, P1633, DOI 10.1128/JCM.39.4.1633-1637.2001
   Viard M, 2002, ELECTROPHORESIS, V23, P1659, DOI 10.1002/1522-2683(200206)23:11<1659::AID-ELPS1659>3.0.CO;2-R
   Wang CY, 1999, P NATL ACAD SCI USA, V96, P10367, DOI 10.1073/pnas.96.18.10367                                                        
   Wang CY, 2002, VACCINE, V21, P89, DOI 10.1016/S0264-410X(02)00432-2
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 1996, EMBO J, V15, P1507
   Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065
   Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806                                                          
   Yasuda Y, 1998, FEMS IMMUNOL MED MIC, V20, P311, DOI 10.1111/j.1574-695X.1998.tb01141.x
   Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41
NR 56
TC 17
Z9 17
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD MAY
PY 2008
VL 6
IS 3
BP 218
EP 229
DI 10.2174/157016208784324994                                              
          
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 311RA
UT WOS:000256616100005
PM 18473785
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tsurumoto, T
   Zhu, D
   Sommer, AP
AF Tsurumoto, Toshiyuki
   Zhu, Dan
   Sommer, Andrei P.
TI Identification of nanobacteria in human arthritic synovial fluid by
   method validated in human blood and urine using 200 nm model
   nanoparticles
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID PRIMORDIAL PROTEINS; RHEUMATOID-ARTHRITIS; POSSIBLE PROVENANCE;
   EVAPORATING DROPS; PART II; HIV; CALCIFICATION; PARTICLES; MECHANISM;
   CRYSTALS
AB Earlier we introduced a biosensor for the identification of nanobacteria in water drops. Here, we generalize its principle and apply it to identify nanobacteria in synovial fluid from a patient with osteoarthritis. Results indicate the prevalence of nanobacteria in the synovial fluid. The identification method is applicable to body fluids such as unfiltered human blood and urine, is independent of culturing procedures, and permits for a rapid detection of nanoparticles in liquid drops. In view of increasing clinical evidence on a contribution of nanobacteria in disease, their reported detection in HIV-infected people in South Africa, laboratory experiments indicating the excretion of viable (i.e., propagating) nanobacteria from humans via urine, the use of human excreta in agricultural irrigation, models predicting an injection of nanoaerosols contained in irrigation water enriched with human excreta into the atmosphere, and the identification of nanobacteria in the terrestrial atmosphere, promote the identification method described in this work to an important tool to monitor nanobacteria in body fluids and environmental samples.
C1 [Zhu, Dan; Sommer, Andrei P.] Univ Ulm, Inst Micro & Nanomat, D-89081 Ulm, Germany.
   [Tsurumoto, Toshiyuki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Orthopaed, Nagasaki 8528501, Japan.
RP Sommer, AP (reprint author), Univ Ulm, Inst Micro & Nanomat, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Benzerara K, 2006, J INVEST MED, V54, P367, DOI 10.2310/6650.2006.06016
   Berckmans RJ, 2002, ARTHRITIS RHEUM, V46, P2857, DOI 10.1002/art.10587
   Berckmans RJ, 2005, ARTHRITIS RES THER, V7, pR536, DOI 10.1186/ar1706
   BRATOSPEREZ MA, 2008, IN PRESS EUR HEART J
   Ciftcioglu N, 2007, LANCET, V369, P2078, DOI 10.1016/S0140-6736(07)60977-5                                                   
   Cisar JO, 2000, P NATL ACAD SCI USA, V97, P11511, DOI 10.1073/pnas.97.21.11511
   GUR H, 1994, CLIN RHEUMATOL, V13, P537, DOI 10.1007/BF02242960
   Jansen TL, 2006, NEW ENGL J MED, V355, P421, DOI 10.1056/NEJMc066303                                                             
   Jelic TM, 2007, J HEART VALVE DIS, V16, P101
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KALIMO H, 1981, MUSCLE NERVE, V4, P228, DOI 10.1002/mus.880040310
   King RHM, 2001, J CLIN PATHOL-MOL PA, V54, P400
   Li FI, 2006, J PHYS CHEM B, V110, P25838, DOI 10.1021/jp0653398
   Li QW, 2006, J PHYS CHEM B, V110, P13926, DOI 10.1021/jp061554c
   Major ML, 2007, BIOCHEM BIOPH RES CO, V355, P654, DOI 10.1016/j.bbrc.2007.01.177
   MARKHAM JG, 1976, ANN RHEUM DIS, V35, P1, DOI 10.1136/ard.35.1.1                                                              
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   MYERS DB, 1980, NEW ZEAL MED J, V92, P9
   Nalbant S, 2003, OSTEOARTHR CARTILAGE, V11, P50, DOI 10.1053/joca.2002.0861
   PAETAU A, 1976, ACTA NEUROPATHOL, V36, P185, DOI 10.1007/BF00685280                                                              
   Pascual E, 2005, BEST PRACT RES CL RH, V19, P371, DOI 10.1016/j.berh.2005.01.004
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Sanchis AM, 2005, ANN RHEUM DIS, V64, P1769
   Shiekh FA, 2006, UROL RES, V34, P53, DOI 10.1007/s00240-005-0034-0
   Socol Y, 2006, J PHYS CHEM B, V110, P18347, DOI 10.1021/jp0637577
   Sommer AP, 2007, CORROS ENG SCI TECHN, V42, P344, DOI 10.1179/174327807X238954
   Sommer AP, 2007, CRYST GROWTH DES, V7, P1031, DOI 10.1021/cg070182+
   Sommer AP, 2004, J PHYS CHEM B, V108, P8, DOI 10.1021/jp0363747
   Sommer AP, 2006, CRYST GROWTH DES, V6, P749, DOI 10.1021/eg050427n
   Sommer AP, 2006, J ENVIRON MONITOR, V8, P341, DOI 10.1039/b512496d
   Sommer AP, 2006, CRYST GROWTH DES, V6, P492, DOI 10.1021/cg050418e
   Sommer AP, 2005, J PROTEOME RES, V4, P1022, DOI 10.1021/pr050064e
   Sommer AP, 2005, CRYST GROWTH DES, V5, P551, DOI 10.1021/cg0496989
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2005, J PROTEOME RES, V4, P180, DOI 10.1021/pr0498382
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   SOMMER AP, 2008, IN PRESS LEXIKON INF
   STRANSKY G, 1993, BRIT J RHEUMATOL, V32, P1044
   Suzuki H, 2007, ENVIRON SCI TECHNOL, V41, P3018, DOI 10.1021/es0625632
   SWAN A, 1994, ANN RHEUM DIS, V53, P467, DOI 10.1136/ard.53.7.467
   Tsurumoto T, 2006, J PROTEOME RES, V5, P1276, DOI 10.1021/pr050450w
   Urbano P, 2007, PLOS PATHOG, V3, P567, DOI 10.1371/journal.ppat.0030055
NR 43
TC 7
Z9 8
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAY 1
PY 2008
VL 42
IS 9
BP 3324
EP 3328
DI 10.1021/es702857s
PG 5
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 294ZF
UT WOS:000255444100038
PM 18522113
DA 2018-01-05
ER

PT J
AU Chugh, A
   Eudes, F
AF Chugh, Archana
   Eudes, Francois
TI Study of uptake of cell penetrating peptides and their cargoes in
   permeabilized wheat immature embryos
SO FEBS JOURNAL
LA English
DT Article
DE cell membrane permeabilization; cell-penetrating peptide; endocytosis;
   macropinocytosis; nanocarrier
ID HIV-1 TAT PROTEIN; INTRACELLULAR DELIVERY PEPTIDE; BASIC DOMAIN; PLASMID
   DNA; PLANT-CELLS; MAMMALIAN-CELLS; GENE DELIVERY; MEDIATED DELIVERY;
   FUSION PROTEINS; HELA-CELLS
AB The uptake of five fluorescein labeled cell-penetrating peptides (Tat, Tat(2), mutated-Tat, peptide vascular endothelial-cadherin and transportan) was studied in wheat immature embryos. Interestingly, permeabilization treatment of the embryos with toluene/ethanol (1 : 20, v/v with permeabilization buffer) resulted in a remarkably higher uptake of cell-penetrating peptides, whereas nonpermeabilized embryos failed to show significant cell-penetrating peptide uptake, as observed under fluorescence microscope and by fluorimetric analysis. Among the cell-penetrating peptides investigated, Tat monomer (Tat) showed highest fluorescence uptake (4.2-fold greater) in permeabilized embryos than the nonpermeabilized embryos. On the other hand, mutated-Tat serving as negative control did not show comparable fluorescence levels even in permeabilized embryos. A glucuronidase histochemical assay revealed that Tat peptides can efficiently deliver functionally active beta-glucuronidase (GUS) enzyme in permeabilized immature embryos. Tat(2)-mediated GUS enzyme delivery showed the highest number of embryos with GUS uptake (92.2%) upon permeabilization treatment with toluene/ethanol (1 : 40, v/v with permeabilization buffer) whereas only 51.8% of nonpermeabilized embryos showed Tat(2)-mediated GUS uptake. Low temperature, endocytosis and macropinocytosis inhibitors reduced delivery of the Tat(2)-GUS enzyme cargo complex. The results suggest that more than one mechanism of cell entry is involved simultaneously in cell-penetrating peptide-cargo uptake in wheat immature embryos. We also studied Tat(2)-plasmid DNA (carrying Act-1GUS) complex formation by gel retardation assay, DNaseI protection assay and confocal laser microscopy. Permeabilized embryos transfected with Tat(2)-plasmid DNA complex showed 3.3-fold higher transient GUS gene expression than the nonpermeabilized embryos. Furthermore, addition of cationic transfecting agent Lipofectamine (TM) 2000 to the Tat(2)-plasmid DNA complex resulted in 1.5-fold higher transient GUS gene expression in the embryos. This is the first report demonstrating translocation of various cell-penetrating peptides and their potential to deliver macromolecules in wheat immature embryos in the presence of a cell membrane permeabilizing agent.
C1 [Chugh, Archana; Eudes, Francois] Agr & Agri Food Canada, Lethbridge Res Ctr, Lethbridge, AB T1J 4B1, Canada.
RP Eudes, F (reprint author), Agr & Agri Food Canada, Lethbridge Res Ctr, POB 3000,5403 1st Ave S, Lethbridge, AB T1J 4B1, Canada.
EM eudesf@agr.gc.ca
CR Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Choi HS, 2006, BBA-GEN SUBJECTS, V1760, P1604, DOI 10.1016/j.bbagen.2006.09.011
   Chugh A, 2008, J PEPT SCI, V14, P477, DOI 10.1002/psc.937
   Chugh A, 2007, BBA-BIOMEMBRANES, V1768, P419, DOI 10.1016/j.bbamem.2006.11.012
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   DESHAYES S, 2004, EUR J BIOCHEM, V269, P494
   Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044                                                             
   Emi N, 1997, BIOCHEM BIOPH RES CO, V231, P421, DOI 10.1006/bbrc.1997.6125
   Eudes F, 2003, PLANT CELL TISS ORG, V73, P147, DOI 10.1023/A:1022800512708
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   Fang B, 1998, GENE THER, V5, P1420, DOI 10.1038/sj.gt.3300741                                                           
   Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Gait MJ, 2003, CELL MOL LIFE SCI, V60, P844, DOI 10.1007/s00018-003-3044-5
   Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123
   Hellgren I, 2004, J DRUG TARGET, V12, P39, DOI 10.1080/106118604200041403
   Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   KOSUGI S, 1990, PLANT SCI, V70, P133, DOI 10.1016/0168-9452(90)90042-M
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   Langel U., 2002, CELL PENETRATING PEP
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Mae M, 2005, BBA-BIOMEMBRANES, V1669, P101, DOI 10.1016/j.bbamem.2005.01.006
   MAHALAKSHMI A, 2000, PLANT BIOTECHNOL, V17, P235
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rolland Alain, 2006, Expert Opin Drug Deliv, V3, P1, DOI 10.1517/17425247.3.1.1
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Simeoni F, 2005, METH MOL B, V309, P251
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Unnamalai N, 2004, FEBS LETT, V566, P307, DOI 10.1016/j.febslet.2004.04.018
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wu Y, 2003, PLANT J, V33, P131, DOI 10.1046/j.0960-7412.2002.001614.x
NR 54
TC 19
Z9 20
U1 0
U2 22
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1742-464X
J9 FEBS J
JI FEBS J.
PD MAY
PY 2008
VL 275
IS 10
BP 2403
EP 2414
DI 10.1111/j.1742-4658.2008.06384.x
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292SF
UT WOS:000255285700006
PM 18397318
OA gold
DA 2018-01-05
ER

PT J
AU Driskell, JD
   Shanmukh, S
   Liu, YJ
   Hennigan, S
   Jones, L
   Zhao, YP
   Dluhy, RA
   Krause, DC
   Tripp, RA
AF Driskell, Jeremy D.
   Shanmukh, Saratchandra
   Liu, Yong-Jun
   Hennigan, Sue
   Jones, Les
   Zhao, Yi-Ping
   Dluhy, Richard A.
   Krause, Duncan C.
   Tripp, Ralph A.
TI Infectious agent detection with SERS-active silver nanorod arrays
   prepared by oblique angle deposition
SO IEEE SENSORS JOURNAL
LA English
DT Article
DE chemometrics; oblique angle deposition; pathogen classification;
   surface-enhanced Raman spectroscopy (SERS)
ID SURFACE-ENHANCED RAMAN; RESPIRATORY SYNCYTIAL VIRUS;
   MYCOPLASMA-PNEUMONIAE; ENZYME-IMMUNOASSAY; SCATTERING; SPECTROSCOPY;
   BACTERIA; PCR; DISCRIMINATION; SPECTRA
AB The aligned silver nanorod array substrates prepared by the oblique angle deposition method are capable of providing extremely high enhancement factors (similar to 5 x 10(8)) at near-infrared wavelengths (785 nn) for a standard reporter molecule 1,2 trans-(bis)pyridyl-ethene (BPE). The enhancement factor depends strongly on the length of the Ag nanorods, the substrate coating, the polarization of the excitation light, as well as the incident angle. With the current optimum structure, we demonstrate that the detection limit for BPE can be lower than 0.1 fM. We also show that this surface-enhanced Raman spectroscopy (SERS)-active substrate can serve as a sensor to detect and differentiate the molecular fingerprints of several important human pathogens, particularly, respiratory syncytial virus, human immunodeficiency virus, rotavirus, and the bacterium Mycoplasma pneumoniae. Utilizing chemometric methods, SERS nanorod array data can be used to sensitively detect and to classify viruses at the strain level. These results suggest that the SERS Ag nanorod array is a powerful technique for direct, rapid, and sensitive detection of infectious agents.
C1 [Driskell, Jeremy D.; Shanmukh, Saratchandra; Dluhy, Richard A.] Univ Georgia, Dept Chem, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA.
   [Driskell, Jeremy D.; Shanmukh, Saratchandra; Liu, Yong-Jun; Hennigan, Sue; Jones, Les; Zhao, Yi-Ping; Dluhy, Richard A.; Krause, Duncan C.; Tripp, Ralph A.] Univ Georgia, Fac Infect Dis, Athens, GA 30602 USA.
   [Liu, Yong-Jun; Zhao, Yi-Ping] Univ Georgia, Dept Phys & Astron, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA.
   [Hennigan, Sue; Krause, Duncan C.] Univ Georgia, Dept Microbiol, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA.
   [Jones, Les; Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA.
RP Driskell, JD (reprint author), Univ Georgia, Dept Chem, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA.
EM jdriskel@uga.edu
RI Zhao, Yiping/A-4968-2008
OI Driskell, Jeremy/0000-0001-5082-898X; Tripp, Ralph/0000-0002-2924-9956
FU NIH [EB001956-RAD, SS]; National Science Foundation [ECS-0304340-YPZ,
   YJL, SBC, ECS-070178-YPZ, RAD]; U.S. Army Research Laboratory [RAD,
   W911NF-07-2-0065-YPZ]
FX Manuscript received July 27, 2007; revised October 29, 2007; accepted
   January 15, 2008. This work was supported in part by NIH under Grant
   EB001956-RAD and SS, in part by the National Science Foundation under
   Grant ECS-0304340-YPZ, YJL, and SBC, in part by the National Science
   Foundation under Grant ECS-070178-YPZ, and RAD, and in part by the the
   U.S. Army Research Laboratory under W911NF-07-2-0065-YPZ, RAD, and JDD.
   The associate editor coordinating the review of this paper and approving
   it for publication was Dr. James Jensen.
CR Bao PD, 2001, J RAMAN SPECTROSC, V32, P227, DOI 10.1002/jrs.665.abs
   BEEBE K, 1998, CHEMOMETRICS PRACTIC
   Brereton RG, 2003, CHEMOMETRICS DATA AN
   Carey P. R., 1982, BIOCH APPL RAMAN RES
   Chaney SB, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.1988980
   CHAO RK, 1979, J INFECT DIS, V139, P483, DOI 10.1093/infdis/139.4.483                                                        
   Cousin-Allery A, 2000, EPIDEMIOL INFECT, V124, P103, DOI 10.1017/S0950268899003313
   Driskell JD, 2005, ANAL CHEM, V77, P6147, DOI 10.1021/ac0504159
   DRISKELL JD, 2007, J PHYS CHEM C UNPUB
   Everitt B, 1980, CLUSTER ANAL
   Felidj N, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.075419
   FREYMUTH F, 1995, J CLIN MICROBIOL, V33, P3352
   Grow AE, 2003, J MICROBIOL METH, V53, P221, DOI 10.1016/S0167-7012(03)00026-5
   Gupta R, 2003, CHEM PHYS LETT, V374, P302, DOI 10.1016/S0009-2614(03)00737-1
   Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m
   Henkel JH, 1997, J MED VIROL, V53, P366
   Jarvis RM, 2006, FARADAY DISCUSS, V132, P281, DOI 10.1039/b506413a
   Jarvis RM, 2004, ANAL CHEM, V76, P5198, DOI 10.1021/ac049663f
   Jarvis RM, 2004, ANAL CHEM, V76, P40, DOI 10.1021/ac034689c
   Kahl M, 2000, PHYS REV B, V61, P14078, DOI 10.1103/PhysRevB.61.14078
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   KERKER M, 1984, J PHYS CHEM-US, V88, P3168, DOI 10.1021/j150659a003                                                             
   Laucks ML, 2005, APPL SPECTROSC, V59, P1222, DOI 10.1366/000370205774430891
   LAVINE BK, 2006, PRACTICAL GUIDE CHEM
   LIAO PF, 1982, OPT LETT, V7, P483, DOI 10.1364/OL.7.000483
   Long D.A., 1977, RAMAN SPECTROSCOPY
   Moskovits M, 2005, J RAMAN SPECTROSC, V36, P485, DOI 10.1002/jrs.1362
   Norrod KL, 1997, APPL SPECTROSC, V51, P994, DOI 10.1366/0003702971941377                                                        
   Pearman WF, 2006, APPL SPECTROSC, V60, P356, DOI 10.1366/000370206776593744
   PEDNEAULT L, 1994, J CLIN MICROBIOL, V32, P2861
   Petitjean-Lecherbonnier J, 2006, PATHOL BIOL, V54, P603, DOI 10.1016/j.patbio.2006.07.038
   Pitcher D, 2006, J MED MICROBIOL, V55, P149, DOI 10.1099/jmm.0.46281-0
   Premasiri WR, 2005, J PHYS CHEM B, V109, P312, DOI 10.1021/jp040442n
   Sengupta A, 2005, APPL SPECTROSC, V59, P1016, DOI 10.1366/0003702054615124
   Shah K, 2006, J MED VIROL, V78, P1124, DOI 10.1002/jmv.20672
   Shanmukh S, 2006, NANO LETT, V6, P2630, DOI 10.1021/nl061666f
   Tripp RA, 1999, J VIROL, V73, P7099
   Trully J. G., 1997, SCIENCE, V233, P241
   WEITZ DA, 1982, OPT LETT, V7, P168, DOI 10.1364/OL.7.000168
   Yang WH, 1996, J CHEM PHYS, V104, P4313, DOI 10.1063/1.471241                                                                
   Zeiri L, 2002, COLLOID SURFACE A, V208, P357, DOI 10.1016/S0927-7757(02)00162-0                                                   
   Zhao YP, 2006, J PHYS CHEM B, V110, P3153, DOI 10.1021/jp057406o
NR 42
TC 35
Z9 35
U1 0
U2 30
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1530-437X
EI 1558-1748
J9 IEEE SENS J
JI IEEE Sens. J.
PD MAY-JUN
PY 2008
VL 8
IS 5-6
BP 863
EP 870
DI 10.1109/JSEN.2008.922682
PG 8
WC Engineering, Electrical & Electronic; Instruments & Instrumentation;
   Physics, Applied
SC Engineering; Instruments & Instrumentation; Physics
GA 342CW
UT WOS:000258763200064
DA 2018-01-05
ER

PT J
AU MacKay, JA
   Li, W
   Huang, Z
   Dy, EE
   Huynh, G
   Tihan, T
   Collins, R
   Deen, DF
   Szoka, FC
AF MacKay, J. Andrew
   Li, Weijun
   Huang, Zhaohua
   Dy, Edward E.
   Huynh, Grace
   Tihan, Tarik
   Collins, Rodney
   Deen, Dennis F.
   Szoka, Francis C., Jr.
TI HIV TAT peptide modifies the distribution of DNA nanolipoparticles
   following convection-enhanced delivery
SO MOLECULAR THERAPY
LA English
DT Article
ID PLASMID-LIPID PARTICLES; GENE DELIVERY; MODIFIED LIPOSOMES;
   BRAIN-TUMORS; RAT-BRAIN; INFUSION; CELLS; DRUG; NANOPARTICLES;
   ENDOCYTOSIS
AB We evaluated gene transfer using PEGylated bioresponsive nanolipid particles (NLPs) containing plasmid DNA administered by convection-enhanced delivery (CED) into orthotopically implanted U87-MG tumors in rat brain. We hypothesized that attachment of the human immunodeficiency virus trans-acting transcriptional activator peptide (TATp) to pH-sensitive, reduction-sensitive NLPs would increase gene transfer. TATp was attached either directly to a phospholipid (TATp-lipid) or via a 2-kd polyethylene glycol ( PEG) to a lipid (TATp-PEG-lipid). Incorporation of 0.3 mol% TATp-PEG into pH-sensitive NLPs improved transfection 100,000-fold compared to NLPs in culture. In the brain or implanted tumors, the TATpPEG restricted NLP convection to regions adjacent to the infusion catheter. Gene transfer in the brain from TATp-PEG NLPs, measured by green fluorescent protein (GFP) expression, was substantially greater than from NLPs adjacent to the catheter. Gene transfer using TATp-PEG NLPs, measured by luciferase expression, was 8-12-fold greater than from a 1,2-dioleoyl-3-trimethylammoniumpropane/cholesterol cationic lipoplex but 13-27-fold less than from the NLPs. Brain luciferase expression was localized in perivascular macrophages. Thus a cationic ligand, such as the TATp-PEG-lipid, can dramatically increase gene expression in culture, in the normal brain, and in implanted tumors; however, restriction of NLP distribution to the vicinity of the infusion catheter reduces the absolute level of gene transfer.
C1 [MacKay, J. Andrew; Li, Weijun; Huang, Zhaohua; Dy, Edward E.; Huynh, Grace; Szoka, Francis C., Jr.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.
   [MacKay, J. Andrew; Huynh, Grace; Szoka, Francis C., Jr.] Univ Calif San Francisco, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA.
   [MacKay, J. Andrew; Huynh, Grace; Szoka, Francis C., Jr.] Univ Calif Berkeley, Joint Grad Grp Bioengn, San Francisco, CA USA.
   [Li, Weijun; Huang, Zhaohua; Dy, Edward E.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
   [Tihan, Tarik; Collins, Rodney] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA.
   [Deen, Dennis F.] Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA USA.
RP Szoka, FC (reprint author), Univ Calif San Francisco, Dept Biopharmaceut Sci, HSE 1145,513 Parnassus Ave, San Francisco, CA 94143 USA.
EM szoka@cgl.ucsf.edu
RI Huang, Zhaohua/C-3607-2009
OI Huang, Zhaohua/0000-0002-5963-0088
FU NINDS NIH HHS [NS42927]; Howard Hughes Medical Institute; NCI NIH HHS
   [R01CA107268, CA-85356]; NIBIB NIH HHS [8R01EB002047]
CR *ACS, 2007, 500807 ACS
   Bankiewicz KS, 2000, EXP NEUROL, V164, P2, DOI 10.1006/exnr.2000.7408
   BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076
   Chen MY, 1999, J NEUROSURG, V90, P315, DOI 10.3171/jns.1999.90.2.0315
   Choi JS, 2003, BIOCONJUGATE CHEM, V14, P420, DOI 10.1021/bc025625w
   Eliaz RE, 2001, CANCER RES, V61, P2592
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Groothuis DR, 1999, J NEUROSURG, V90, P321, DOI 10.3171/jns.1999.90.2.0321
   Gupta B, 2007, ONCOL RES, V16, P351
   Hamilton JF, 2001, EXP NEUROL, V168, P155, DOI 10.1006/exnr.2000.7571
   Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200                                                         
   Huang ZH, 2005, MOL THER, V11, P409, DOI 10.1016/j.ymthe.2004.10.013
   Huynh GH, 2006, J CONTROL RELEASE, V110, P236, DOI 10.1016/j.jconrel.2005.09.053
   Jorgensen K, 2001, CELL MOL BIOL LETT, V6, P255
   Krauze MT, 2005, J NEUROSURG, V103, P923, DOI 10.3171/jns.2005.103.5.0923                                                     
   Lampson LA, 2003, J NEURO-ONCOL, V64, P3, DOI 10.1007/BF02700015
   Li WJ, 2007, PHARM RES, V24, P438, DOI 10.1007/s11095-006-9180-5
   Li WJ, 2005, J GENE MED, V7, P67, DOI 10.1002/jgm.634
   LIEBERMAN DM, 1995, J NEUROSURG, V82, P1021, DOI 10.3171/jns.1995.82.6.1021                                                      
   Lonser RR, 1999, J NEUROSURG, V91, P294, DOI 10.3171/jns.1999.91.2.0294
   Lonser RR, 2002, J NEUROSURG, V97, P905, DOI 10.3171/jns.2002.97.4.0905                                                      
   MacKay JA, 2005, BRAIN RES, V1035, P139, DOI 10.1016/j.brainres.2004.12.007
   Mamot C, 2004, J NEURO-ONCOL, V68, P1, DOI 10.1023/B:NEON.0000024743.56415.4b
   MANN DA, 1991, EMBO J, V10, P1733
   Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9
   Mok KWC, 1999, BBA-BIOMEMBRANES, V1419, P137, DOI 10.1016/S0005-2736(99)00059-0
   Nguyen JB, 2001, NEUROREPORT, V12, P1961, DOI 10.1097/00001756-200107030-00037
   Noble CO, 2006, CANCER RES, V66, P2801, DOI 10.1158/0008-5472.CAN-05-3535
   Polfliet MMJ, 2001, J NEUROIMMUNOL, V116, P188, DOI 10.1016/S0165-5728(01)00282-X                                                   
   Saito R, 2004, CANCER RES, V64, P2572, DOI 10.1158/0008-5472.CAN-03-3631
   Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497
   Tam P, 2000, GENE THER, V7, P1867, DOI 10.1038/sj.gt.3301308
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Voges J, 2002, HUM GENE THER, V13, P675
   Weyerbrock Astrid, 1999, Current Opinion in Oncology, V11, P168, DOI 10.1097/00001622-199905000-00005
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
NR 37
TC 32
Z9 32
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD MAY
PY 2008
VL 16
IS 5
BP 893
EP 900
DI 10.1038/mt.2008.36
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 296AT
UT WOS:000255516600017
PM 18388927
OA gold
DA 2018-01-05
ER

PT J
AU Fromme, R
   Katiliene, Z
   Fromme, P
   Ghirlanda, G
AF Fromme, Raimund
   Katiliene, Zivile
   Fromme, Petra
   Ghirlanda, Giovanna
TI Conformational gating of dimannose binding to the antiviral protein
   cyanovirin revealed from the crystal structure at 1.35 angstrom
   resolution
SO PROTEIN SCIENCE
LA English
DT Article
DE cyanovirin; lectins; sugar binding; antiviral protein; X-ray structure
   analysis
ID DOMAIN-SWAPPED DIMER; ANTI-HIV PROTEIN; N CONTAINS 2;
   CARBOHYDRATE-BINDING; INACTIVATING PROTEIN; RELATIVE ORIENTATION;
   DIPOLAR COUPLINGS; X-RAY; POTENT; ENVELOPE
AB Cyanovirin (CV-N) is a small lectin with potent HIV neutralization activity, which could be exploited for a mucosal defense against HIV infection. The wild-type (wt) protein binds with high affinity to mannose-rich oligosaccharides on the surface of gp120 through two quasi-symmetric sites, located in domains A and B. We recently reported on a mutant of CV-N that contained a single functional mannose-binding site, domain B, showing that multivalent binding to oligomannosides is necessary for antiviral activity. The structure of the complex with dimannose determined at 1.8 A resolution revealed a different conformation of the binding site than previously observed in the NMR structure of wt CV-N. Here, we present the 1.35 A resolution structure of the complex, which traps three different binding conformations of the site and provides experimental support for a locking and gating mechanism in the nanoscale time regime observed by molecular dynamics simulations.
C1 [Fromme, Raimund; Katiliene, Zivile; Fromme, Petra; Ghirlanda, Giovanna] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.
RP Ghirlanda, G (reprint author), Arizona State Univ, Dept Chem & Biochem, 1711 S Rural Rd, Tempe, AZ 85287 USA.
EM Pfromme@asu.edu; gghirlanda@asu.edu
RI Fromme, Raimund/C-8885-2012
OI Fromme, Raimund/0000-0003-4835-1080
CR Balzarini Jan, 2007, Antiviral Chemistry & Chemotherapy, V18, P1
   Barrientos LG, 2006, PROTEIN ENG DES SEL, V19, P525, DOI 10.1093/protein/gzl040
   Barrientos LG, 2004, STRUCTURE, V12, P1799, DOI 10.1016/j.str.2004.07.019
   Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Barrientos LG, 2002, BIOCHEM BIOPH RES CO, V298, P598, DOI 10.1016/S0006-291X(02)02489-0                                                   
   BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127
   Bewley CA, 2000, J AM CHEM SOC, V122, P6009, DOI 10.1021/ja000858o
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489
   Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fromme R, 2007, BIOCHEMISTRY-US, V46, P9199, DOI 10.1021/bi700666m
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402
   Margulis CJ, 2005, J PHYS CHEM B, V109, P3639, DOI 10.1021/jp0406971
   McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007
   Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263
   Reeves JD, 2005, DRUGS, V65, P1747, DOI 10.2165/00003495-200565130-00002
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684                                                       
   Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Ziolkowska NE, 2006, ACTA BIOCHIM POL, V53, P617
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
   Zwart PH, 2004, ACTA CRYSTALLOGR D, V60, P2230, DOI 10.1107/S0907444904012995
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 44
TC 19
Z9 19
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD MAY
PY 2008
VL 17
IS 5
BP 939
EP 944
DI 10.1110/ps.083472808
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292UC
UT WOS:000255290600015
PM 18436959
OA gold
DA 2018-01-05
ER

PT J
AU Kwon, EJ
   Bergen, JM
   Pun, SH
AF Kwon, Ester J.
   Bergen, Jamie M.
   Pun, Suzie H.
TI Application of an HIV gp41-derived peptide for enhanced intracellular
   trafficking of synthetic gene and siRNA delivery vehicles
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID POLYLYSINE DNA COMPLEXES; ENVELOPE GLYCOPROTEIN; PLASMID DNA; TRANSGENE
   EXPRESSION; PENETRATING PEPTIDES; AMPHIPATHIC PEPTIDE; MAMMALIAN-CELLS;
   TAT PEPTIDE; PROTEIN; POLYETHYLENIMINE
AB Endosomal release is an efficiency-limiting step for many nonviral gene delivery vehicles. In this work, nonviral gene delivery vehicles were modified with a membrane-lytic peptide taken from the endodomain of HIV gp41. Peptide was covalently linked to polyethylenimine (PEI) and the peptide-modified polymer was complexed with DNA. The resulting nanoparticles were shown to have similar physicochemical properties as complexes formed with unmodified PEI. The gp41-derived peptide demonstrated significant lytic activity both as free peptide and when conjugated to PEI. Significant increases in transgene expression were achieved in HeLa cells when compared to unmodified polyplexes at low polymer to DNA ratios. Additionally, peptide-modified polyplexes mediated significantly enhanced siRNA delivery compared to unmodified polyplexes. Despite increases in transgene expression and siRNA knockdown, there was no increase in internalization or binding of modified carriers as determined by flow cytometry. The hypothesis that the gp41-derived peptide increases the endosomal escape of vehicles is supported by confocal microscopy imaging of DNA distributions in transfected cells. This work demonstrates the use of a lytic peptide for improved trafficking, of nonviral gene delivery vehicles.
C1 [Kwon, Ester J.; Bergen, Jamie M.; Pun, Suzie H.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Pun, SH (reprint author), Univ Washington, Dept Bioengn, 1705 NE Pacific St, Seattle, WA 98195 USA.
EM spun@u.washington.edu
OI Kwon, Ester/0000-0002-6335-9681
FU NINDS NIH HHS [5R21NS052030]
CR Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005
   Bergen JM, 2008, BIOCONJUGATE CHEM, V19, P377, DOI 10.1021/bc700315v
   Bergen JM, 2005, MRS BULL, V30, P663, DOI 10.1557/mrs2005.194                                                             
   Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598
   Boeckle S, 2006, J CONTROL RELEASE, V112, P240, DOI 10.1016/j.jconrel.2006.02.002
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Chen CP, 2006, BIOCONJUGATE CHEM, V17, P1057, DOI 10.1021/bc060028l
   Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001
   Cheng JJ, 2006, J MED CHEM, V49, P6522, DOI 10.1021/jm060736s
   CHERNOMORDIK L, 1994, J VIROL, V68, P7115
   Cho YW, 2003, J PHARM PHARMACOL, V55, P721, DOI 10.1211/0022357021206
   Costin JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-123
   Demeneix B, 2004, CURR GENE THER, V4, P445
   Densmore Charles L., 2006, Current Drug Delivery, V3, P55, DOI 10.2174/156720106775197547
   Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Florea Bogdan I, 2002, AAPS PharmSci, V4, pE12
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557                                                
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nishiyama N, 2006, J DRUG TARGET, V14, P413, DOI 10.1080/10611860600834508
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   Oishi M, 2006, BIOCONJUGATE CHEM, V17, P677, DOI 10.1021/bc050364m
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Park IK, 2007, J GENE MED, V9, P691, DOI 10.1002/jgm.1062
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Saul JM, 2008, ADV MATER, V20, P19, DOI 10.1002/adma.200700633
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099
   Wiethoff CM, 2005, J VIROL, V79, P1992, DOI 10.1128/JVI.79.4.1992-2000.2005
   Yessine MA, 2007, BIOCONJUGATE CHEM, V18, P1010, DOI 10.1021/bc060159m
   Zhang XH, 2001, J GENE MED, V3, P560, DOI 10.1002/jgm.224                                                                 
NR 44
TC 62
Z9 65
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2008
VL 19
IS 4
BP 920
EP 927
DI 10.1021/bc700448h
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 289QC
UT WOS:000255068000015
PM 18376855
DA 2018-01-05
ER

PT J
AU Cesarini, S
   Spallarossa, A
   Ranise, A
   Bruno, O
   La Colla, P
   Secci, B
   Collu, G
   Loddo, R
AF Cesarini, Sara
   Spallarossa, Andrea
   Ranise, Angelo
   Bruno, Olga
   La Colla, Paolo
   Secci, Barbara
   Collu, Gabriella
   Loddo, Roberta
TI Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors.
   Part 2: Parallel synthesis, molecular modelling and structure-activity
   relationship studies on analogues of
   O-(2-phenylethyl)-N-phenylthiocarbamate
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE thiocarbamates; HIV-1; non-nucleoside reverse transcriptase inhibitors;
   parallel synthesis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRUCTURE-BASED DESIGN; PETT ANALOGS;
   PHENETHYLTHIAZOLYLTHIOUREA DERIVATIVES; BIOLOGICAL EVALUATION; THIOUREA
   COMPOUNDS; RATIONAL DESIGN; RESISTANT; MOLSCRIPT; SERIES
AB To acquire further insight into the structure-activity relationship (SAR) of the thiocarbamates (TCs) described in the preceding work, 57 analogues of the lead compound O-(2-phenylethyl)-N-phenylthiocarbamate I were prepared by parallel solution-phase synthesis. We varied the 2-phenylethyl moiety (mono-substitution on the phenyl ring and modi. cation of the ethyl linker), keeping constant the N-phenyl ring substitutions which have given the best results in the previous series. Most of the new TCs inhibited wild-type HIV-1 at micro-and nanomolar concentrations in MT-4 cell-based assays. Some TCs were also active at micromolar concentrations against the Y181C and/or K103N/Y181C resistant mutants. The SARs were rationalized by docking simulations. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Cesarini, Sara; Spallarossa, Andrea; Ranise, Angelo; Bruno, Olga] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   [La Colla, Paolo; Secci, Barbara; Collu, Gabriella; Loddo, Roberta] Univ Cagliari, Dipartimento Sci & Technol Biomed, I-09042 Cagliari, Italy.
RP Cesarini, S (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto XV 3, I-16132 Genoa, Italy.
EM sara.cesarini@unige.it; placolla@unica.it
RI Loddo, Roberta/B-9038-2011; La Colla , Paolo /B-8587-2011
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Campiani G, 2000, ANTIVIR CHEM CHEMOTH, V11, P141, DOI 10.1177/095632020001100206                                                      
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Cesarini S, 2008, BIOORGAN MED CHEM, V16, P4160, DOI 10.1016/j.bmc.2007.12.050
   D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464
   D'Cruz OJ, 2006, CURR HIV RES, V4, P329, DOI 10.2174/157016206777709519
   DCRUZ OJ, 2006, J ENZYM INHIB MED CH, P329
   Dong YH, 2000, BIOORG MED CHEM LETT, V10, P87, DOI 10.1016/S0960-894X(99)00581-8                                                   
   Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1                                                   
   Hogberg M, 2000, BIOORG MED CHEM LETT, V10, P265, DOI 10.1016/S0960-894X(99)00675-7
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Ranise A, 2005, J MED CHEM, V48, P3858, DOI 10.1021/jm049252r
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   Ravichandran V, 2007, BIOORG MED CHEM LETT, V17, P2197, DOI 10.1016/j.bmcl.2007.01.103
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Uckun FM, 2007, ARZNEIMITTEL-FORSCH, V57, P164
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
NR 26
TC 10
Z9 12
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD APR 1
PY 2008
VL 16
IS 7
BP 4173
EP 4185
DI 10.1016/j.bmc.2007.12.046
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 292DE
UT WOS:000255245900070
PM 18226533
DA 2018-01-05
ER

PT J
AU Xu, WF
   Santini, PA
   Shan, MM
   Chen, K
   Ball, SC
   Chiu, A
   Kingsley, LA
   Rinaldo, CR
   Chadburn, A
   Knowles, DM
   He, B
   Cerutti, A
AF Xu, Weifeng
   Santini, Paul A.
   Shan, Meimei
   Chen, Kang
   Ball, Susan C.
   Chiu, April
   Kingsley, Lawrence A.
   Rinaldo, Charles R.
   Chadburn, Amy
   Knowles, Daniel M.
   He, Bing
   Cerutti, Andrea
TI Long-Distance Tunneling Nanotubules Shuttle Immunoglobulin Class
   Switch-Suppressing Factors from HIV-Infected Macrophages to B Cells
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Xu, Weifeng; Santini, Paul A.; Chen, Kang; Chiu, April; Chadburn, Amy; Knowles, Daniel M.; He, Bing; Cerutti, Andrea] Cornell Univ, Dept Pathol & Lab Med, Weill Med Coll, New York, NY 10021 USA.
   [Santini, Paul A.; Chen, Kang; Cerutti, Andrea] Cornell Univ, Weill Med Coll, Weill Grad Sch Med Sci, New York, NY 10021 USA.
   [Shan, Meimei] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.
   [Ball, Susan C.] Cornell Univ, Dept Med, Weill Med Coll, New York, NY 10021 USA.
   [Kingsley, Lawrence A.; Rinaldo, Charles R.] Univ Pittsburgh, Dept Pathol & Lab Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2008
VL 22
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V25GZ
UT WOS:000208467801165
DA 2018-01-05
ER

PT J
AU Wiwanitkit, V
AF Wiwanitkit, V.
TI An Explanation in Nanostructure Level Based on the View of Energy Change
   for G333d Mutation Relating to Drug Resistance in HIV-1 Reverse
   Transcriptase
SO INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Letter
C1 Wiwanitkit House, Dept Lab Med, Bangkok 10160, Thailand.
RP Wiwanitkit, V (reprint author), Wiwanitkit House, Dept Lab Med, Bangkok 10160, Thailand.
EM wviroj@yahoo.com
CR Bennett DE, 2006, CURR OPIN INFECT DIS, V19, P607, DOI 10.1097/QCO.0b013e3280109ff1
   Gallego O, 2002, AIDS RES HUM RETROV, V18, P857, DOI 10.1089/08892220260190335
   Klumpp K, 2006, CURR PHARM DESIGN, V12, P1909, DOI 10.2174/138161206776873653
   Zelina S, 2008, ANTIMICROB AGENTS CH, V52, P157, DOI 10.1128/AAC.00904-07
NR 4
TC 1
Z9 3
U1 0
U2 0
PU MEDKNOW PUBLICATIONS
PI MUMBAI
PA A-108-109 KANARA BUSINESS CENTRE, GHAKTOPAR, MUMBAI, 400075, INDIA
SN 0255-0857
J9 INDIAN J MED MICROBI
JI Indian J. Med. Microbiol.
PD APR-JUN
PY 2008
VL 26
IS 2
BP 202
EP U108
DI 10.4103/0255-0857.40549                                                 
          
PG 2
WC Immunology
SC Immunology
GA 361DA
UT WOS:000260106500029
PM 18445971
DA 2018-01-05
ER

PT J
AU Li, HH
   Yuan, G
   Du, DM
AF Li, Huihui
   Yuan, Gu
   Du, Daming
TI Investigation of formation, recognition, stabilization, and conversion
   of dimeric G-quadruplexes of HIV-1 integrase inhibitors by Electrospray
   ionization mass Spectrometry
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
ID STRUCTURAL-CHARACTERIZATION; DNA; OLIGONUCLEOTIDE; BINDING; SEQUENCE;
   STRANDS; DRUGS
AB The dimeric G-quadruplex structures of d(GGGTGGGTGGGTGGGT) (SI) and d(GTGGTGGGTGGGTGGGT) (S2), the potent nanomolar HIV-1 integrase inhibitors, were detected by electrospray ionization mass spectrometry (ESI-MS) for the first time. The formation and conversion of the dimers were induced by NH4+, DNA concentration, pH, and the binding molecules. We directly observed the specific binding of a perylene derivative (TeL03) and hnhnIm beta Dp in one system consisting of the intramolecular and the dimeric G-quadruplexes of the HIV-1 integrase inhibitor, which suggested that Tel03 could shift the equilibrium to the dimeric G-quadruplex formation, while hnImIm beta Dp induces preferentially a structural change from the dimer to the intramolecular G-quadruplex. The results of this study indicated that TeL03 and ImImIm beta Dp favor the stabilizationof the dimeric G-quadruplex structures.
C1 [Li, Huihui; Yuan, Gu; Du, Daming] Peking Univ, Beijing Natl Lab Mol Sci, Key Lab Bioorgan Chem & Mol Engn, Minist Educ,Dept Chem Biol,Coll Chem & Mol Engn, Beijing 100871, Peoples R China.
RP Yuan, G (reprint author), Peking Univ, Beijing Natl Lab Mol Sci, Key Lab Bioorgan Chem & Mol Engn, Minist Educ,Dept Chem Biol,Coll Chem & Mol Engn, Beijing 100871, Peoples R China.
EM guyuan@pku.edu.cn
RI Du, Da-Ming/B-1475-2009
OI Du, Da-Ming/0000-0002-9924-5117
CR Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   Anantha NV, 1998, BIOCHEMISTRY-US, V37, P2709, DOI 10.1021/bi973009v
   Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1
   Baker ES, 2006, INT J MASS SPECTROM, V253, P225, DOI 10.1016/j.ijms.2006.03.016
   Baker ES, 2005, J AM SOC MASS SPECTR, V16, P989, DOI 10.1016/j.jasms.2005.03.012
   Chen H, 2003, J MASS SPECTROM, V38, P839, DOI 10.1002/jms.496
   CRAIGIE R, 2001, J BIOL CHEM, V276, P213
   Crnugelj M, 2003, J AM CHEM SOC, V125, P7866, DOI 10.1021/ja0348694
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   David WM, 2002, ANAL CHEM, V74, P2029, DOI 10.1021/ac011283w
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   Gabelica V, 1999, J MASS SPECTROM, V34, P1328, DOI 10.1002/(SICI)1096-9888(199912)34:12<1328::AID-JMS889>3.0.CO;2-F
   Guo XH, 2005, NUCLEIC ACIDS RES, V33, P3659, DOI 10.1093/nar/gki671
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   JING N, 1997, BIOCHEMISTRY-US, V36, P498
   JING N, 1998, J BIOL CHEM, V273, P992
   JING N, 2000, J BIOL CHEM, V275, P460
   Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967                                                  
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3
   Kypr J, 2001, EUR BIOPHYS J BIOPHY, V30, P555, DOI 10.1007/s002490100174
   MAZUMDER A, 1996, BIOCHEMISTRY-US, V35, P762
   Mazzitelli CL, 2006, J AM SOC MASS SPECTR, V17, P593, DOI 10.1016/j.jasms.2005.12.011
   Neamati N, 2000, Adv Pharmacol, V49, P147
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Rosu F, 2002, RAPID COMMUN MASS SP, V16, P1729, DOI 10.1002/rcm.778
   Rueda M, 2006, J AM CHEM SOC, V128, P3608, DOI 10.1021/ja055936s
   Tarrago-Litvak L, 2002, CURR PHARM DESIGN, V8, P595, DOI 10.2174/1381612024607162
   Vairamani M, 2003, J AM CHEM SOC, V125, P42, DOI 10.1021/ja0284299
   VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S
   Wan KX, 2000, J AM CHEM SOC, V122, P300, DOI 10.1021/ja990684e                                                               
   Zhou JA, 2007, CHEM-EUR J, V13, P5018, DOI 10.1002/chem.200601605
NR 34
TC 37
Z9 39
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1044-0305
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD APR
PY 2008
VL 19
IS 4
BP 550
EP 559
DI 10.1016/j.jasms.2008.01.012
PG 10
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 289ZD
UT WOS:000255091500010
PM 18313939
OA gold
DA 2018-01-05
ER

PT J
AU Phogat, S
   Svehla, K
   Tang, M
   Spadaccini, A
   Muller, J
   Mascola, J
   Berkower, I
   Wyatt, R
AF Phogat, S.
   Svehla, K.
   Tang, M.
   Spadaccini, A.
   Muller, J.
   Mascola, J.
   Berkower, I.
   Wyatt, R.
TI Analysis of the human immunodeficiency virus type 1 gp41 membrane
   proximal external region arrayed on hepatitis B surface antigen
   particles
SO VIROLOGY
LA English
DT Article
DE HIV-1; neutralizing antibodies; envelope glycoproteins; gp41; particles
ID ENVELOPE GLYCOPROTEINS; HIV-1 ENTRY; NEUTRALIZING EPITOPE;
   FALCIPARUM-MALARIA; ANTIBODY-RESPONSES; CELL RESPONSES; VACCINE;
   PROTEIN; FUSION; IMMUNOGENICITY
AB Vaccine immunogens derived from the envelope glycoproteins of the human immunodeficiency virus type 1 (HIV-1) that elicit broad neutralizing antibodies remain an elusive goal. The highly conserved 30 amino-acid membrane proximal external region (MPER) of HIV gp41 contains the hydrophobic epitopes for two rare HIV-1 broad cross-reactive neutralizing antibodies, 2F5 and 4E10. Both these antibodies possess relatively hydrophobic HCDR3 loops and demonstrate enhanced binding to their epitopes in the context of the native gp160 precursor envelope glycoprotein by the intimate juxtaposition of a lipid membrane. The hepatitis B surface antigen (HBsAg) S1 protein forms nanoparticles that can be utilized both as an immunogenic array of the MPER and to provide the lipid environment needed for enhanced 2175 and 4E10 binding. We show that recombinant HBsAg particles with MPER (HBsAg-MPER) appended at the C-terminus of the S1 protein are recognized by 2F5 and 4E10 with high affinity compared to positioning the MPER at the N-terminus or the extracellular loop (ECL) of S1. Addition of C-terminal hydrophobic residues derived from the HIV-1 Env transmembrane region further enhances recognition of the MPER by both 2F5 and 4E10. Delipidation of the HBsAg-MPER particles decreases 2F5 and 4E10 binding and subsequent reconstitution with synthetic lipids restores optimal binding. Inoculation of the particles into small animals raised cross-reactive antibodies that recognize both the MPER and HIV-1 gp160 envelope glycoproteins expressed on the cell surface; however, no neutralizing activity could be detected. Prime:Boost immunization of the HBsAg-MPER particles in sequence with HIV envelope glycoprotein proteoliposomes (Env-PLs) did not raise neutralizing antibodies that could be mapped to the MPER region. However, the Env-PLs did raise anti-Env antibodies that had the ability to neutralize selected HIV-1 isolates. The first generation HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system. Published by Elsevier Inc.
C1 [Phogat, S.; Svehla, K.; Tang, M.; Mascola, J.; Wyatt, R.] NIAID, Struct Virol Sect, NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA.
   [Spadaccini, A.; Muller, J.; Berkower, I.] US FDA, Ctr Biol, Bethesda, MD USA.
RP Wyatt, R (reprint author), NIAID, Struct Virol Sect, NIH, Vaccine Res Ctr, 40 Covent Dr,Bldg 40,Room 4512, Bethesda, MD 20892 USA.
EM richardwyatt@nih.gov
FU Intramural NIH HHS [Z99 AI999999]
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024
   Berkower I, 2004, VIROLOGY, V321, P75, DOI 10.1016/j.virol.2003.12.017
   Berson JF, 1996, J VIROL, V70, P6288
   Brown DR, 2004, VACCINE, V22, P2936, DOI 10.1016/j.vaccine.2003.11.059
   Brunel FM, 2006, J VIROL, V80, P1680, DOI 10.1128/JVI.80.4.1680-1687.2006
   CABRAL GA, 1978, J GEN VIROL, V38, P339, DOI 10.1099/0022-1317-38-2-339
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dey B, 2007, J VIROL, V81, P5579, DOI 10.1128/JVI.02500-06
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001
   Ernst W, 1998, NUCLEIC ACIDS RES, V26, P1718, DOI 10.1093/nar/26.7.1718
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fife KH, 2004, VACCINE, V22, P2943, DOI 10.1016/j.vaccine.2003.11.058
   Frazer IH, 2004, NAT REV IMMUNOL, V4, P46, DOI 10.1038/nri1260
   Grundner C, 2002, J VIROL, V76, P3511, DOI 10.1128/JVI.76.7.3511-3521.2002
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042
   Ho J, 2002, VACCINE, V20, P1169, DOI 10.1016/S0264-410X(01)00441-8
   KIMBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180
   Koch M, 2003, VIROLOGY, V313, P387, DOI 10.1016/S0042-6822(03)00294-0
   Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586                                                            
   Li Y, 2006, J VIROL, V80, P1414, DOI 10.1128/JVI.80.3.1414-1426.2006
   LI Y, UNPUB STRATEGIES MAP
   Liang XP, 1999, VACCINE, V17, P2862, DOI 10.1016/S0264-410X(99)00125-5
   Lowe RS, 1997, J INFECT DIS, V176, P1141, DOI 10.1086/514105                                                                  
   Mahoney F, 1999, VACCINES
   Mangold CMT, 1997, ARCH VIROL, V142, P2257, DOI 10.1007/s007050050240                                                           
   Mascola JR, 2002, J VIROL, V76, P4810, DOI 10.1128/JVI.76.10.4810-4821.2002
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   MUSTER T, 1994, J VIROL, V68, P4031
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Pancera M, 2005, VIROLOGY, V332, P145, DOI 10.1016/j.virol.2004.10.042
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Phogat S, 2007, J INTERN MED, V262, P26, DOI 10.1111/j.1365-2796.2007.01820.x
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Piza AT, 2002, MEM I OSWALDO CRUZ, V97, P265, DOI 10.1590/S0074-02762002000200022
   Plotkin SA, 2003, J INFECT DIS, V187, P1349, DOI 10.1086/374419
   Salzwedel K, 1999, J VIROL, V73, P2469
   Schirmbeck R, 1996, INTERVIROLOGY, V39, P111, DOI 10.1159/000150482                                                               
   Shu Y, 2007, VACCINE, V25, P1398, DOI 10.1016/j.vaccine.2006.10.046
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Xiao Y, 2000, IMMUNOL INVEST, V29, P41, DOI 10.3109/08820130009105143
   Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333
   Zinkernagel RM, 2001, ADV IMMUNOL, V79, P1, DOI 10.1016/S0065-2776(01)79001-3
NR 52
TC 48
Z9 48
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 30
PY 2008
VL 373
IS 1
BP 72
EP 84
DI 10.1016/j.virol.2007.11.005
PG 13
WC Virology
SC Virology
GA 279JA
UT WOS:000254350300008
PM 18155743
OA gold
DA 2018-01-05
ER

PT J
AU Setny, P
AF Setny, Piotr
TI Hydrophobic interactions between methane and a nanoscopic pocket: Three
   dimensional distribution of potential of mean force revealed by computer
   simulations
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID MOLECULAR-DYNAMICS; LIQUID WATER; FREE-ENERGY; THERMODYNAMIC PROPERTIES;
   PRESSURE-DEPENDENCE; AQUEOUS-SOLUTION; HIV-1 PROTEASE; MONTE-CARLO;
   COLLAPSE; TEMPERATURE
AB We consider a model system of methane molecule and a hemispherical, hydrophobic pocket of an 8 angstrom radius, remaining together in aqueous environment. A spatial map of potential of mean force acting on methane molecule due to presence of pocket is constructed, based on a series of explicit solvent molecular dynamics simulations. A relation between free energy variations associated with methane translocations and accompanying changes in solvent density distribution is analyzed. A funnel-like area where free energy is diminished with respect to bulk is present over the pocket entrance and extends up to 9 angstrom toward the bulk solvent. In order to get into the pocket, however, methane has to cross a free energy barrier, which is more prominent around the circumferential part of pocket entrance, while achieving bulklike free energy values at the very center. As a methane molecule crosses this barrier, the pocket gets completely dehydrated, which leads to "hydrophobic collapse," manifested by a sharp decrease in free energy. We find that the observed free energy changes are closely related to interactions between the methane hydration shell and the surrounding solvent. Results presented here are a continuation of our previous studies of methane-pocket systems. (C) 2008 American Institute of Physics.
C1 [Setny, Piotr] Univ Warsaw, Dept Biophys, Inst Expt Phys, PL-02089 Warsaw, Poland.
   [Setny, Piotr] Univ Warsaw, Interdisciplinary Ctr Math & Comp Modelling, PL-02106 Warsaw, Poland.
RP Setny, P (reprint author), Univ Warsaw, Dept Biophys, Inst Expt Phys, PL-02089 Warsaw, Poland.
EM piosto@icm.edu.pl
CR Allen M.P., 1987, COMPUTER SIMULATION
   Ashbaugh HS, 2006, REV MOD PHYS, V78, P159, DOI 10.1103/RevModPhys.78.159
   Beckstein O, 2003, P NATL ACAD SCI USA, V100, P7063, DOI 10.1073/pnas.1136844100
   BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451                                                          
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Chandler D, 2005, NATURE, V437, P640, DOI 10.1038/nature04162
   Choudhury N, 2005, J AM CHEM SOC, V127, P3556, DOI 10.1021/ja0441817
   Czaplewski C, 2005, J PHYS CHEM B, V109, P8108, DOI 10.1021/jp040691b
   DANG LX, 1994, J CHEM PHYS, V100, P9032, DOI 10.1063/1.466708
   Durell SR, 1996, BIOPHYS J, V71, P1695, DOI 10.1016/S0006-3495(96)79371-2                                                   
   Feller SE, 1996, J PHYS CHEM-US, V100, P17011, DOI 10.1021/jp9614658
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Ghosh T, 2002, J CHEM PHYS, V116, P2480, DOI 10.1063/1.1431582
   Griffith JH, 2004, J MOL STRUC-THEOCHEM, V682, P97, DOI 10.1016/j.theochem.2004.06.003
   Han BG, 2006, J MOL BIOL, V360, P285, DOI 10.1016/j.jmb.2006.04.039
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695                                                        
   Huang DM, 2000, P NATL ACAD SCI USA, V97, P8324, DOI 10.1073/pnas.120176397
   Huang DM, 2002, J PHYS CHEM B, V106, P2047, DOI 10.1021/jp013289v
   Huang DM, 2001, J PHYS CHEM B, V105, P6704, DOI 10.1021/jp0104029
   Huang X, 2003, P NATL ACAD SCI USA, V100, P11953, DOI 10.1073/pnas.1934837100
   Huang XH, 2005, J PHYS CHEM B, V109, P3546, DOI 10.1021/jp0455201
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   JORGENSEN WL, 1984, J AM CHEM SOC, V106, P6638, DOI 10.1021/ja00334a030
   KAUTZMANN W, 1959, ADV PROTEIN CHEM, V14, P1
   KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812                                                           
   LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226                                                                
   LEE SH, 1994, J CHEM PHYS, V100, P3334, DOI 10.1063/1.466425                                                                
   Liu P, 2005, NATURE, V437, P159, DOI 10.1038/nature03926
   Ludemann S, 1996, J CHEM PHYS, V104, P286, DOI 10.1063/1.470899
   Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m                                                               
   LyndenBell RM, 1997, J CHEM PHYS, V107, P1981, DOI 10.1063/1.474550
   NEMETHY G, 1962, J PHYS CHEM-US, V66, P1773, DOI 10.1021/j100816a004                                                             
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334                                                                
   PANGALI C, 1979, J CHEM PHYS, V71, P2975, DOI 10.1063/1.438701
   Payne VA, 1997, J PHYS CHEM B, V101, P2054, DOI 10.1021/jp962977p                                                               
   PRATT LR, 1980, J CHEM PHYS, V73, P3434, DOI 10.1063/1.440541
   Pratt LR, 2002, CHEM REV, V102, P2671, DOI 10.1021/cr000692+
   Pratt LR, 2002, ANNU REV PHYS CHEM, V53, P409, DOI 10.1146/annurev.physchem.53.090401.093500
   PREUSSER A, 1989, ACM T MATH SOFTWARE, V15, P79, DOI 10.1145/62038.69651
   PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417
   Raschke TM, 2001, P NATL ACAD SCI USA, V98, P5965, DOI 10.1073/pnas.111158498
   Rick SW, 1997, J PHYS CHEM B, V101, P10488, DOI 10.1021/jp971579z                                                               
   Roux B, 2004, STRUCTURE, V12, P1343, DOI 10.1016/j.str.2004.06.013
   ROUX B, 1995, COMPUT PHYS COMMUN, V91, P275, DOI 10.1016/0010-4655(95)00053-I
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SETNV P, 2006, J CHEM PHYS, V124
   Setny P, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2749250
   Shimizu S, 2000, J CHEM PHYS, V113, P4683, DOI 10.1063/1.1288922
   SMITH DE, 1993, J CHEM PHYS, V98, P6445, DOI 10.1063/1.464809                                                                
   Southall NT, 2002, J PHYS CHEM B, V106, P521, DOI 10.1021/jp015514e
   Stillinger FH, 1973, J SOLUTION CHEM, V2, P141, DOI 10.1007/BF00651970                                                              
   Tanford C, 1973, HYDROPHOBIC EFFECT F
   ten Wolde P R, 2001, PHYS REV E, V65, DOI DOI 10.1103/PHYSREVE.65.011201
   Tsai J, 1997, PROTEIN SCI, V6, P2606
   WALLQVIST A, 1991, J PHYS CHEM-US, V95, P8921, DOI 10.1021/j100175a090                                                             
   WALLQVIST A, 1995, J PHYS CHEM-US, V99, P2893, DOI 10.1021/j100009a053                                                             
   WALLQVIST A, 1988, CHEM PHYS LETT, V145, P26, DOI 10.1016/0009-2614(88)85127-3                                                    
   Wallqvist A, 2001, J PHYS CHEM B, V105, P6745, DOI 10.1021/jp010945i
   Wells DB, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2770738
   Wernet P, 2004, SCIENCE, V304, P995, DOI 10.1126/science.1096205
   Yaminsky VV, 2001, CURR OPIN COLLOID IN, V6, P342, DOI 10.1016/S1359-0294(01)00104-2                                                   
   Young T, 2007, P NATL ACAD SCI USA, V104, P808, DOI 10.1073/pnas.0610202104
   Young WS, 1997, J CHEM PHYS, V106, P9265, DOI 10.1063/1.474027
   Zhang DX, 2001, APPL MATH MECH-ENGL, V22, P597, DOI 10.1023/A:1016352608299                                                         
   Zhou RH, 2004, SCIENCE, V305, P1605, DOI 10.1126/science.1101176
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   ZICHI DA, 1985, J CHEM PHYS, V83, P797, DOI 10.1063/1.449495                                                                
NR 69
TC 16
Z9 16
U1 0
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD MAR 28
PY 2008
VL 128
IS 12
AR 125105
DI 10.1063/1.2839885
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 281ZK
UT WOS:000254537200081
PM 18376980
DA 2018-01-05
ER

PT J
AU Matejicek, P
   Cigler, P
   Olejniczak, AB
   Andrysiak, A
   Wojtczak, B
   Prochazka, K
   Lesnikowski, ZJ
AF Matejicek, Pavel
   Cigler, Petr
   Olejniczak, Agnieszka B.
   Andrysiak, Agnieszka
   Wojtczak, Blazej
   Prochazka, Karel
   Lesnikowski, Zbigniew J.
TI Aggregation behavior of nucleoside-boron cluster conjugates in aqueous
   solutions
SO LANGMUIR
LA English
DT Article
ID NEUTRON-CAPTURE THERAPY; ELECTRON-SPIN-RESONANCE; DICARBOLLIDE ANIONS;
   DNA-OLIGONUCLEOTIDE; MOLECULAR-DYNAMICS; LIGHT-SCATTERING;
   NUCLEIC-ACIDS; HIV PROTEASE; CARBORANE; INHIBITORS
AB We report the first evidence that boron-containing nucleoside conjugates have a tendency to associate in water solutions. The size, charge, and exoskeletal pattern of the boron cluster can strongly influence the aggregation. The aggregation of nucleosides with attached boron clusters was observed using light scattering and atomic force microscopy techniques. Although the species containing either the bulky amphiphilic [3-cobalt(III) bis(1,2-dicarbollide)](-) anion or the electroneutral dicarba-closo-dodecaboranyl moiety tend to form stable nanoparticles in aqueous solutions, the compounds bearing the smaller, negatively charged dicarba-nido-undecaboranyl moiety as well as the unmodified nucleosides do not aggregate. The light scattering measurements also showed that the aggregated species can interact with nonionic surfactant Triton X-100 in solution. The partition coefficients P in the water-octanol system correlate fairly well with the aggregation tendency observed by light scattering measurements. This finding allows us to predict the association behavior of boron-cluster-containing nucleosides on a qualitative level. The observed phenomenon can contribute to a better understanding of biological properties of boronated nucleosides and the design of boronated nucleoside-based drugs such as boron carriers for boron neutron capture therapy of tumors (BNCT) and antiviral agents.
C1 [Olejniczak, Agnieszka B.; Andrysiak, Agnieszka; Wojtczak, Blazej; Lesnikowski, Zbigniew J.] Polish Acad Sci, Ctr Med Biol, Lab Mol Virol & Biol Chem, PL-93232 Lodz, Poland.
   [Matejicek, Pavel; Prochazka, Karel] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843 2, Czech Republic.
   [Cigler, Petr] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Gilead Sci & IOCB Res Ctr, AS CR, CR-16610 Prague, Czech Republic.
   [Cigler, Petr] Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague, Czech Republic.
RP Lesnikowski, ZJ (reprint author), Polish Acad Sci, Ctr Med Biol, Lab Mol Virol & Biol Chem, 106 Lodowa St, PL-93232 Lodz, Poland.
EM zlesnikowski@cbm.pan.pl
RI Wojtczak, Blazej/H-4913-2017; Prochazka, Karel/C-3012-2014; Matejicek,
   Pavel/M-6582-2017; Cigler, Petr/B-1142-2012; Olejniczak,
   Agnieszka/K-3325-2013
OI Wojtczak, Blazej/0000-0002-7448-7216; Prochazka,
   Karel/0000-0003-2144-5378; Matejicek, Pavel/0000-0001-5482-3465;
   Olejniczak, Agnieszka/0000-0003-4628-9017
CR Barth RF, 2004, CANCER RES, V64, P6287, DOI 10.1158/0008-5472.CAN-04-0437
   Bonechi C, 2007, BIOPHYS CHEM, V125, P320, DOI 10.1016/j.bpc.2006.09.004
   Chevrot G, 2007, PHYS CHEM CHEM PHYS, V9, P1991, DOI 10.1039/b616753e
   Chevrot G, 2006, J PHYS CHEM B, V110, P9488, DOI 10.1021/jp060930q
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   DAGLE JM, 1991, NUCLEIC ACIDS RES, V19, P1805, DOI 10.1093/nar/19.8.1805
   Endo Y, 2001, CHEM BIOL, V8, P341, DOI 10.1016/S1074-5521(01)00016-3
   Endo Y, 2001, BIOORG MED CHEM LETT, V11, P1307, DOI 10.1016/S0960-894X(01)00204-9
   Fanfrlik J, 2006, CHEMPHYSCHEM, V7, P1100, DOI 10.1002/cphc.200500648
   Feng BY, 2007, J MED CHEM, V50, P2385, DOI 10.1021/jm061317y
   Forster S, 1996, J CHEM PHYS, V104, P9956
   Hall IH, 2000, ANTICANCER RES, V20, P2345
   Hao E, 2005, CHEM COMMUN, P1306, DOI 10.1039/b415649h
   Hao EH, 2005, BIOCONJUGATE CHEM, V16, P1495, DOI 10.1021/bc0502098
   Julius RL, 2007, P NATL ACAD SCI USA, V104, P4808, DOI 10.1073/pnas.0700316104
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kubat P, 2007, J PHYS CHEM B, V111, P4539, DOI 10.1021/jp066494p
   Lesnikowski ZJ, 2007, CURR ORG CHEM, V11, P355, DOI 10.2174/138527207780059358                                                      
   Lesnikowski ZJ, 2005, BIOORGAN MED CHEM, V13, P4168, DOI 10.1016/j.bmc.2005.04.042
   Lesnikowski ZJ, 2003, EUR J ORG CHEM, P4489, DOI 10.1002/ejoc.200300259
   Lesnikowski ZJ, 1999, J ORGANOMET CHEM, V581, P156, DOI 10.1016/S0022-328X(99)00129-1                                                   
   Ma L, 2005, INORG CHEM, V44, P7249, DOI 10.1021/ic050895m
   Maderna A, 2001, J AM CHEM SOC, V123, P10423, DOI 10.1021/ja016768g
   Matejicek P, 2006, LANGMUIR, V22, P575, DOI 10.1021/la052201s
   McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   MISHRA NC, 1991, J CHEM SOC CHEM COMM, P1276, DOI 10.1039/c39910001276
   Morandi S, 2004, BBA-BIOMEMBRANES, V1664, P53, DOI 10.1016/j.bbamem.2004.04.002
   Olejniczak AB, 2003, ANGEW CHEM INT EDIT, V42, P5740, DOI 10.1002/anie.200352505
   Olejniczak AB, 2002, ANTISENSE NUCLEIC A, V12, P79, DOI 10.1089/108729002760070821
   OLEJNICZAK AB, 2007, CHEM-EUR J, V13, P311
   PLESEK J, 1992, CHEM REV, V92, P269, DOI 10.1021/cr00010a005                                                             
   PLESEK J, 1984, COLLECT CZECH CHEM C, V49, P2776, DOI 10.1135/cccc19842776                                                            
   Rossi S, 2003, LANGMUIR, V19, P5608, DOI 10.1021/la0209841
   SCHINAZI RF, 1994, INT J RADIAT ONCOL, V28, P1113, DOI 10.1016/0360-3016(94)90485-5                                                    
   Schreier S, 2000, BBA-BIOMEMBRANES, V1508, P210, DOI 10.1016/S0304-4157(00)00012-5                                                   
   Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r
   Sibrian-Vazquez M, 2006, BIOCONJUGATE CHEM, V17, P928, DOI 10.1021/bc060047v
   Sjoberg S, 1997, J NEURO-ONCOL, V33, P41, DOI 10.1023/A:1005756929011
   Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y
   Thirumamagal BTS, 2006, BIOCONJUGATE CHEM, V17, P1141, DOI 10.1021/bc060075d
   Tjarks W, 2000, J ORGANOMET CHEM, V614, P37, DOI 10.1016/S0022-328X(00)00574-X                                                   
   VALLIANT JF, 2000, CHEM REV, V232, P173
   Yamamoto K, 2001, BIOORG MED CHEM LETT, V11, P2389, DOI 10.1016/S0960-894X(01)00438-3                                                   
NR 44
TC 32
Z9 32
U1 2
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 18
PY 2008
VL 24
IS 6
BP 2625
EP 2630
DI 10.1021/la702852e
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 273OM
UT WOS:000253941000052
PM 18257589
DA 2018-01-05
ER

PT J
AU Wang, SK
   Liang, PH
   Astronomo, RD
   Hsu, TL
   Hsieh, SL
   Burton, DR
   Wong, CH
AF Wang, Sheng-Kai
   Liang, Pi-Hui
   Astronomo, Rena D.
   Hsu, Tsui-Ling
   Hsieh, Shie-Liang
   Burton, Dennis R.
   Wong, Chi-Huey
TI Targeting the carbohydrates on HIV-1: Interaction of oligomannose
   dendrons with human monoclonal antibody 2G12 and DC-SIGN
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE glycodendron; high mannose; multivalency; HIV vaccine; antiviral agent
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN INTERACTIONS; VACCINE DESIGN;
   BINDING; OLIGOSACCHARIDES; RECOGNITION; ANTIGEN; CLUSTER; GP120;
   GLYCODENDRIMERS
AB It is widely accepted that the heavily glycosylated glycoprotein gp120 on the surface of HIV-1 shields peptide epitopes from recognition by the immune system and may promote infection in vivo by interaction with dendritic cells and transport to tissue rich in CD4(+) T cells such as lymph nodes. A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. We report an efficient synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay. The solution and the surface binding analysis of 2G12 to a prototype oligomannose dendron clearly demonstrated the efficacy of dendrimeric display. We further showed that these glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGNI with IC50 in the nanomolar range. A second-generation Man(9) dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
C1 [Wang, Sheng-Kai; Liang, Pi-Hui; Wong, Chi-Huey] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Astronomo, Rena D.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.
   [Wang, Sheng-Kai; Wong, Chi-Huey] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Liang, Pi-Hui; Hsu, Tsui-Ling; Hsieh, Shie-Liang; Wong, Chi-Huey] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Hsieh, Shie-Liang] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan.
RP Wong, CH (reprint author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM wong@scripps.edu
RI Hsu, Tsui-Ling/H-6704-2015; Liang, Pi-hui/D-4166-2012
OI Liang, Pi-hui/0000-0001-6668-4642; Wang, Sheng-Kai/0000-0002-3827-7983
CR BALZARINIJ T, 2007, NAT REV MICROBIOL, V5, P583
   BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291
   Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101
   Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597
   Cohen J, 2007, SCIENCE, V318, P1360, DOI 10.1126/science.318.5855.1360                                                   
   Crespo L, 2005, CHEM REV, V105, P1663, DOI 10.1021/cr030449l
   de Paz JL, 2007, CHEM BIOL, V14, P879, DOI 10.1016/j.chembiol.2007.07.007
   Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g                                                               
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a
   KIESSLING ILL, 2006, ANGEW CHEM INT EDIT, V45, P2348
   Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095                                                                
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Krist P, 2004, CHEMBIOCHEM, V5, P445, DOI 10.1002/cbic.200300669
   Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105
   LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001                                                             
   LEEYC S, 1978, CARBOHYD RES, V67, P509
   Liang PH, 2007, J AM CHEM SOC, V129, P11177, DOI 10.1021/ja072931h
   LINCHORST T, 2002, TOP CURR CHEM, V218, P201
   Lue J, 2002, J VIROL, V76, P10299, DOI 10.1128/JVI.76.20.10299-10306.2002
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   MARNMEN M, 1998, ANGEW CHEM INT EDIT, V37, P2754
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Pukin AV, 2007, CHEMBIOCHEM, V8, P1500, DOI 10.1002/cbic.200700266
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Roy R, 2001, J AM CHEM SOC, V123, P1809, DOI 10.1021/ja002596w
   ROYR A, 2003, TRENDS GLYCOSCI GLYC, V15, P291
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Suda Y, 2006, BIOCONJUGATE CHEM, V17, P1125, DOI 10.1021/bc0600620
   TRENDS F, 2006, MACROMOLECULES, V39, P2113
   Trkola A, 1996, J VIROL, V70, P1100
   TURNBULL WB, 2002, REV MOL BIOTECHNOL, V90, P231
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zhou Z, 2004, J AM CHEM SOC, V126, P8862, DOI 10.1021/ja049684r
NR 44
TC 199
Z9 200
U1 1
U2 45
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 11
PY 2008
VL 105
IS 10
BP 3690
EP 3695
DI 10.1073/pnas.0712326105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273KZ
UT WOS:000253930600007
PM 18310320
OA gold
DA 2018-01-05
ER

PT J
AU Kaur, A
   Jain, S
   Tiwary, AK
AF Kaur, Amandeep
   Jain, Subheet
   Tiwary, Ashok K.
TI Mannan-coated gelatin nanoparticles for sustained and targeted delivery
   of didanosine: In vitro and in vivo evaluation
SO ACTA PHARMACEUTICA
LA English
DT Article
DE macrophage; targeting; didanosine; anti-HIV; mannan; receptor mediated
   endocytosis
ID ALVEOLAR MACROPHAGES; CELL UPTAKE; 2',3'-DIDEOXYINOSINE; LIPOSOMES;
   MICROSPHERES; PHAGOCYTOSIS; ABSORPTION; INFECTION; CARRIERS; SYSTEM
AB Macrophages of the reticuloendothelial system and brain act as major reservoir for HIV because of their long term survival after HIV infection and ability to spread virus particles to bystander CD4 positive lymphocyte cells. The objective of the present study was to investigate mannan-coated nanoparticles for macrophage targeting of didanosine. Different didanosine loaded nanoparticles were prepared using the double desolvation technique and were characterized in vitro, ex vivo and in vivo. Results of the ex vivo cellular uptake study indicated 5-fold higher uptake of didanosine from the mannan-coated nanoparticles formulation (62.5 +/- 5.4%) by the macrophages in comparison with didanosine solution in phosphate buffer saline (PBS, pH 7.4) (12.1 +/- 2.3%). The better cellular uptake from the nanoparticles formulation was further confirmed by fluorescence microscopy using hydrophilic 6-carboxyfluorescein as a marker. Results of the quantitative biodistribution study showed 1.7, 12.6 and 12.4 times higher localization of didanosine in the spleen, lymph nodes and brain, respectively, after administration of mannan-coated nanoparticles compared to that after injection of didanosine solution in PBS (pH 7.4). Results of the present study showed that the mannan-coated nanoparticles targeted didanosine to the macrophage by mannosyl receptor mediated endocytosis.
C1 [Kaur, Amandeep; Jain, Subheet; Tiwary, Ashok K.] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India.
RP Jain, S (reprint author), Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India.
EM subheetjain@rediffmail.com
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Apostolopoulos V., 2001, Current Molecular Medicine (Hilversum), V1, P469, DOI 10.2174/1566524013363645
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   BEKERS O, 1993, J PHARMACEUT BIOMED, V11, P489, DOI 10.1016/0731-7085(93)80162-T                                                    
   Coester CJ, 2000, J MICROENCAPSUL, V17, P187
   COOLEY TP, 1990, REV INFECT DIS, V12, pS552
   COURTNEY VF, 2000, ANTIMICROB AGENTS CH, V44, P1029
   Cui ZR, 2003, DRUG DEV IND PHARM, V29, P689, DOI 10.1081/DDC-120021318
   Gabr YA, 1996, ARZNEIMITTEL-FORSCH, V46, P763
   HOPPE CA, 1983, J BIOL CHEM, V258, P4193
   Jain Subheet, 2005, AAPS PharmSciTech, V6, pE513, DOI 10.1208/pt060364
   KAUL S, 1993, DRUG METAB DISPOS, V21, P447
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125
   MUKHERJI E, 1994, PHARMACEUT RES, V11, P809, DOI 10.1023/A:1018965305234
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   REBASAMEN E, 1987, ADV ANIMAL CELL TECH, V66, P557
   Sanchez-Lafuente C, 2002, FARMACO, V57, P649, DOI 10.1016/S0014-827X(02)01240-5                                                   
   SCHAFER V, 1994, J MICROENCAPSUL, V11, P261, DOI 10.3109/02652049409040455
   Shao J, 1997, DRUG DELIV, V4, P43, DOI 10.3109/10717549709033187                                                       
   TAYADE PT, 2004, AAPS PHARM SCI, V6
   Vandervoort J, 2004, EUR J PHARM BIOPHARM, V57, P251, DOI 10.1016/s0939-6411(03)00187-5
   Velinova M, 1996, BBA-LIPID LIPID MET, V1299, P207, DOI 10.1016/0005-2760(95)00208-1
   Wadhwa MS, 2003, J DRUG TARGET, V11, P255, DOI 10.1080/10611860310001636557
   YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840                                                         
NR 25
TC 58
Z9 58
U1 3
U2 15
PU HRVATSKO FARMACEUTSKO DRUSTOV (HFD)-CROATION PHARMACEUTICAL SOC
PI ZAGREB
PA MASARYKOVA 2, 10000 ZAGREB, CROATIA
SN 1330-0075
J9 ACTA PHARMACEUT
JI Acta Pharm.
PD MAR
PY 2008
VL 58
IS 1
BP 61
EP 74
DI 10.2478/v10007-007-0045-1
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 300JX
UT WOS:000255821200005
PM 18337208
OA gold
DA 2018-01-05
ER

PT J
AU Meade, BR
   Dowdy, SF
AF Meade, Bryan R.
   Dowdy, Steven F.
TI Enhancing the cellular uptake of siRNA duplexes following noncovalent
   packaging with protein transduction domain peptides
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE RNA interference; peptide transduction domain; cell penetrating peptide;
   siRNA delivery; macromolecular delivery; HIV-1 TAT peptide
ID ARGININE-RICH PEPTIDES; SMALL INTERFERING RNA; TAT-FUSION PROTEINS;
   PENETRATING PEPTIDES; MAMMALIAN-CELLS; EFFICIENT DELIVERY; IN-VIVO;
   GENE; MEMBRANE; MACROPINOCYTOSIS
AB The major limitation in utilizing information rich macromolecules for basic science and therapeutic applications is the inability of these large molecules to readily diffuse across the cellular membrane. While this restriction represents an efficient defense system against cellular penetration of unwanted foreign molecules and thus a crucial component of cell survival, overcoming this cellular characteristic for the intracellular delivery of macromolecules has been the focus of a large number of research groups worldwide. Recently, with the discovery of RNA interference, many of these groups have redirected their attention and have applied previously characterized cell delivery methodologies to synthetic short interfering RNA duplexes (siRNA). Protein transduction domain and cell penetrating peptides have been shown to enhance the delivery of multiple types of macromolecular cargo including peptides, proteins and antisense oligonucleotides and are now being utilized to enhance the cellular uptake of siRNA molecules. The dense cationic charge of these peptides that is critical for interaction with cell membrane components prior to internalization has also been shown to readily package siRNA molecules into stable nanoparticles that are capable of traversing the cell membrane. This review discusses the recent advances in noncovalent packaging of siRNA molecules with cationic peptides and the potential for the resulting complexes to successfully induce RNA interference within both in vitro and in vivo settings. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Meade, Bryan R.; Dowdy, Steven F.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
RP Dowdy, SF (reprint author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM sdowdy@ucsd.edu
FU Howard Hughes Medical Institute
CR Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007                                                    
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   TURNER JJ, 2007, MOL DIS, V38, P1
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WOLFRAM C, 2007, NAT BIOTECH     0916, P16
NR 41
TC 115
Z9 120
U1 3
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 1
PY 2008
VL 60
IS 4-5
BP 530
EP 536
DI 10.1016/j.addr.2007.10.004
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 275JP
UT WOS:000254068000008
PM 18155315
OA green_accepted
DA 2018-01-05
ER

PT J
AU Torchilin, VP
AF Torchilin, Vladimir P.
TI Tat peptide-mediated intracellular delivery of pharmaceutical
   nanocarriers
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE cell-penetrating peptides; TAT peptide; pharmaceutical nanocarriers;
   liposomes; DNA; intracellular delivery
ID CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAINS; HUMAN
   IMMUNODEFICIENCY VIRUS; CROSS-LINKED NANOPARTICLES; IN-VIVO;
   GENE-TRANSFER; DRUG-DELIVERY; MODIFIED LIPOSOMES; FUSION PROTEINS;
   MAGNETIC NANOPARTICLES
AB Cell-penetrating peptides (CPPs) including TAT peptide (TATp) have been successfully used for intracellular delivery of a broad variety of cargoes including various nanoparticulate pharmaceutical carriers (liposomes, micelles, nanoparticles). Here, we will consider the main results in this area, with a special emphasis on TATp-mediated delivery of liposomes and DNA. We will also address the development of "smart" stimuli-sensitive nanocarriers, where cell-penetrating function can be activated by the decreased pH only inside the biological target minimizing thus the interaction of drug-loaded nanocarriers with non-target cells. (C) 2007 Elsevier B.V. All rights reserved.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   [Torchilin, Vladimir P.] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR ALLEN TM, 1995, INT J CANCER, V62, P199, DOI 10.1002/ijc.2910620215
   AMHEITER H, 1988, EMBO J, V7, P1315
   Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P710, DOI 10.1021/bc049945m
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Cortese R, 1995, COMBINATORIAL LIBRAR
   CRYAN SA, 2006, NAT PROTOC, V1, P73
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969                                                   
   GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta B, 2007, ONCOL RES, V16, P351
   Huang ZH, 2005, MOL THER, V11, P409, DOI 10.1016/j.ymthe.2004.10.013
   Hussain SP, 2001, LUNG CANCER, V34, pS7, DOI 10.1016/S0169-5002(01)00339-7
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Jaracz S, 2005, BIOORGAN MED CHEM, V13, P5043, DOI 10.1016/j.bmc.2005.04.084
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Juliano RL, 2006, ANN NY ACAD SCI, V1082, P18, DOI 10.1196/annals.1348.011
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   KAMATA H, 1994, NUCLEIC ACIDS RES, V22, P536, DOI 10.1093/nar/22.3.536
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Katz BA, 1997, ANNU REV BIOPH BIOM, V26, P27, DOI 10.1146/annurev.biophys.26.1.27                                                 
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Lackey CA, 2002, BIOCONJUGATE CHEM, V13, P996, DOI 10.1021/bc010053l
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lasic D, 1995, STEALTH LIPOSOMES
   Lasic D. D., 1993, LIPOSOMES PHYS APPL
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   LISZIEWICZ J, 1995, GENE THER, V2, P218
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lochmann D, 2004, EUR J PHARM BIOPHARM, V58, P237, DOI 10.1016/j.ejpb.2004.03.031
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mortensen MW, 2006, BIOCONJUGATE CHEM, V17, P284, DOI 10.1021/bc050208v
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   PALMER TN, 1984, BIOCHIM BIOPHYS ACTA, V797, P363, DOI 10.1016/0304-4165(84)90258-7
   Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7
   Pooga M, 1998, FASEB J, V12, P67
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Roth JA, 1998, SEMIN ONCOL, V25, P33
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P                      
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689                                                        
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Tang FX, 1999, BIOCONJUGATE CHEM, V10, P791, DOI 10.1021/bc990016i                                                               
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2004, CELL MOL LIFE SCI, V61, P2549, DOI 10.1007/s00018-004-4153-5
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin VP, 1996, BBA-BIOMEMBRANES, V1279, P75, DOI 10.1016/0005-2736(95)00248-0
   TORCHILIN VP, 2000, CONTROLLED DRUG DELI, P297
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Widera A, 2003, ADV DRUG DELIVER REV, V55, P1439, DOI 10.1016/j.addr.2003.07.004
   Workman P, 2001, CURR CANCER DRUG TAR, V1, P33, DOI 10.2174/1568009013334269                                                        
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Yagi N, 2007, BIOORG MED CHEM LETT, V17, P2590, DOI 10.1016/j.bmcl.2007.02.001
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 109
TC 266
Z9 284
U1 10
U2 74
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR 1
PY 2008
VL 60
IS 4-5
BP 548
EP 558
DI 10.1016/j.addr.2007.10.008
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 275JP
UT WOS:000254068000010
PM 18053612
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Garvey, EP
   Johns, BA
   Gartland, MJ
   Foster, SA
   Miller, WH
   Ferris, RG
   Hazen, RJ
   Underwood, MR
   Boros, EE
   Thompson, JB
   Weatherhead, JG
   Koble, CS
   Allen, SH
   Schaller, LT
   Sherrill, RG
   Yoshinaga, T
   Kobayashi, M
   Wakasa-Morimoto, C
   Miki, S
   Nakahara, K
   Noshi, T
   Sato, A
   Fujiwara, T
AF Garvey, Edward P.
   Johns, Brian A.
   Gartland, Margaret J.
   Foster, Scott A.
   Miller, Wayne H.
   Ferris, Robert G.
   Hazen, Richard J.
   Underwood, Mark R.
   Boros, Eric E.
   Thompson, James B.
   Weatherhead, Jason G.
   Koble, Cecilia S.
   Allen, Scott H.
   Schaller, Lee T.
   Sherrill, Ronald G. .
   Yoshinaga, Tomokazu
   Kobayashi, Masanori
   Wakasa-Morimoto, Chiaki
   Miki, Shigeru
   Nakahara, Koichiro
   Noshi, Takeshi
   Sato, Akihiko
   Fujiwara, Tamio
TI The naphthyridinone GSK364735 is a novel, potent human immunodeficiency
   virus type 1 integrase inhibitor and antiretroviral
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 INTEGRASE; STRAND-TRANSFER; ANTIVIRAL ACTIVITY; TREATMENT-NAIVE;
   PHASE-II; IN-VITRO; CELLS; ASSAY; PHARMACOKINETICS; REPLICATION
AB The naphthyridinone GSK364735 potently inhibited recombinant human immunodeficiency virus type 1 (HIV-1) integrase in a strand transfer assay (mean 50% inhibitory concentration standard deviation, 8 2 nM). As expected based on the structure of the drug, it bound competitively with another two-metal binding inhibitor (K(d) [binding constant], 6 4 nM). In a number of different cellular assays, GSK364735 inhibited HIV replication with potency at nanomolar concentrations (e.g., in peripheral blood mononuclear cells and MT-4 cells, 50% effective concentrations were 1.2 +/- 0.4 and 5 +/- 1 nM, respectively), with selectivity indexes of antiviral activity versus in-assay cytotoxicity of at least 2,200. When human serum was added, the antiviral potency decreased (e.g., a 35-fold decrease in the presence of 100% human serum was calculated by extrapolation from the results of the MT-4 cell assay). In cellular assays, GSK364735 blocked viral DNA integration, with a concomitant increase in two-long-terminal-repeat circles. As expected, this integrase inhibitor was equally active against wild-type viruses and mutant viruses resistant to approved drugs targeting either reverse transcriptase or protease. In contrast, some but not all viruses resistant to other integrase inhibitors were resistant to GSK364735. When virus was passaged in the presence of the inhibitor, we identified resistance mutations within the integrase active site that were the same as or similar to mutations arising in response to other two-metal binding inhibitors. Finally, either additive or synergistic effects were observed when GSK364735 was tested in combination with approved antiretrovirals (i.e., no antagonistic effects were seen). Thus, based on all the data, GSK364735 exerted potent antiviral activity through the inhibition of viral DNA integration by interacting at the two-metal binding site within the catalytic center of HIV integrase.
C1 [Garvey, Edward P.; Foster, Scott A.; Miller, Wayne H.; Ferris, Robert G.; Hazen, Richard J.; Underwood, Mark R.] GlaxoSmithKline Inc, Dept Virol, Res Triangle Pk, NC 27709 USA.
   [Johns, Brian A.; Boros, Eric E.; Thompson, James B.; Weatherhead, Jason G.; Koble, Cecilia S.; Allen, Scott H.; Schaller, Lee T.; Sherrill, Ronald G. .] GlaxoSmithKline Inc, Dept Med Chem, Res Triangle Pk, NC 27709 USA.
   [Gartland, Margaret J.] GlaxoSmithKline Inc, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA.
   [Gartland, Margaret J.] GlaxoSmithKline Inc, Dept Discovery Technol Grp, Res Triangle Pk, NC 27709 USA.
   [Yoshinaga, Tomokazu; Kobayashi, Masanori; Wakasa-Morimoto, Chiaki; Miki, Shigeru; Nakahara, Koichiro; Noshi, Takeshi; Sato, Akihiko; Fujiwara, Tamio] Shionogi & Co Ltd, Shionogi Res Lab, Mishima Ku, Osaka 5560022, Japan.
RP Garvey, EP (reprint author), GlaxoSmithKline Inc, Dept Virol, RC2-3938,5 Moore Dr,Res Triangle Pk, Res Triangle Pk, NC 27709 USA.
EM edward.p.garvey@gsk.com
CR ADACHI A, 1986, J VIROL, V59, P284
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
   Boros EE, 2006, BIOORG MED CHEM LETT, V16, P5668, DOI 10.1016/j.bmcl.2006.08.007
   Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124-2003
   Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979                                                                   
   DAHN P, 2007, LANCET, V369, P1235
   DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590                                                           
   Cohen C, 2007, 4 INT AIDS SOC C HIV
   DeJesus E, 2006, JAIDS-J ACQ IMM DEF, V43, P1, DOI 10.1097/01.qai.0000233308.82860.2f
   Deng JX, 2007, CURR PHARM DESIGN, V13, P129, DOI 10.2174/138161207779313687                                                      
   EGBERTSON MS, 2006, BIOORG MED CHEM LETT, V17, P1392
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Hazen R, 2007, ANTIMICROB AGENTS CH, V51, P3147, DOI 10.1128/AAC.00401-07
   Hazuda DJ, 2007, ANTIVIR THER, V12, pS10
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   HILL AV, 1910, J PHYSIOL-LONDON, V40, P4
   Hoggard PG, 1997, ANTIMICROB AGENTS CH, V41, P1231
   Isaka Y, 1999, VIROLOGY, V264, P237, DOI 10.1006/viro.1999.0006
   Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040
   Kawasuji T, 2006, BIOORGAN MED CHEM, V14, P8430, DOI 10.1016/j.bmc.2006.08.044
   Kawasuji T, 2006, BIOORGAN MED CHEM, V14, P8420, DOI 10.1016/j.bmc.2006.08.043
   Ledford RM, 2007, 4 INT AIDS SOC C HIV
   MAGER ME, 1972, DATA ANAL BIOCH BIOP
   MARKOWITZ M, 2007, 4 INT AIDS SOC C HIV
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   McColl DJ, 2007, ANTIVIR THER, V12, pS11
   Selleseth DW, 2003, ANTIMICROB AGENTS CH, V47, P1468, DOI 10.1128/AAC.47.4.1468-1471.2003
   Miller M., 2007, 14 C RETR OPP INF LO
   ZOLOPA A, 2007, 14 C RETR OPP INF LO
   Johns BA, 2004, Patent, Patent No. [WO 2005/077050 A2, 2005077050]
NR 32
TC 55
Z9 56
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2008
VL 52
IS 3
BP 901
EP 908
DI 10.1128/AAC.01218-07
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 268BS
UT WOS:000253553500012
PM 18160521
OA gold
DA 2018-01-05
ER

PT J
AU Neumann, AK
   Thompson, NL
   Jacobson, K
AF Neumann, Aaron K.
   Thompson, Nancy L.
   Jacobson, Ken
TI Distribution and lateral mobility of DC-SIGN on immature dendritic cells
   - implications for pathogen uptake
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE CD209; DC-SIGN; endocytosis; microdomain; plasma membrane; protein
   cluster
ID IMMUNODEFICIENCY-VIRUS TYPE-1; C-TYPE LECTIN; MOTILE FIBROBLASTS;
   T-CELLS; MICROTUBULE TRANSLOCATION; TRANS-ENHANCEMENT; INFECTION;
   PROTEIN; CYTOSKELETON; ENTRY
AB The receptor C-type lectin DC-SIGN (CD209) is expressed by immature dendritic cells, functioning as an antigen capture receptor and cell adhesion molecule. Various microbes, including HIV-1, can exploit binding to DC-SIGN to gain entry to dendritic cells. DC-SIGN forms discrete nanoscale clusters on immature dendritic cells that are thought to be important for viral binding. We confirmed that these DC-SIGN clusters also exist both in live dendritic cells and in cell lines that ectopically express DC-SIGN. Moreover, DC-SIGN has an unusual polarized lateral distribution in the plasma membrane of dendritic cells and other cells: the receptor is preferentially localized to the leading edge of the dendritic cell lamellipod and largely excluded from the ventral plasma membrane. Colocalization of DC-SIGN clusters with endocytic activity demonstrated that surface DC-SIGN clusters are enriched near the leading edge, whereas endocytosis of these clusters occurred preferentially at lamellar sites posterior to the leading edge. Therefore, we predicted that DC-SIGN clusters move from the leading edge to zones of internalization. Two modes of lateral mobility were evident from the trajectories of DC-SIGN clusters at the leading edge, directed and non-directed mobility. Clusters with directed mobility moved in a highly linear fashion from the leading edge to rearward locations in the lamella at remarkably high velocity (1420 +/- 260 nm/second). Based on these data, we propose that DC-SIGN clusters move from the leading edge - where the dendritic cell is likely to encounter pathogens in tissue - to a medial lamellar site where clusters enter the cell via endocytosis. Immature dendritic cells may acquire and internalize HIV and other pathogens by this process.
C1 [Neumann, Aaron K.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.
   [Neumann, Aaron K.; Jacobson, Ken] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Thompson, Nancy L.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.
RP Jacobson, K (reprint author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.
EM frap@med.unc.edu
OI Neumann, Aaron/0000-0002-1689-8324
FU NIAID NIH HHS [F32AI71900]; NCI NIH HHS [T32 CA09156]; NIGMS NIH HHS
   [R01GM041402]
CR Andersen CAS, 2006, INT IMMUNOL, V18, P1295, DOI 10.1093/intimm/dxl062
   Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762
   Boggiano C, 2007, J VIROL, V81, P2519, DOI 10.1128/JVI.01661-06
   Burns S, 2004, CELL MOTIL CYTOSKEL, V57, P118, DOI 10.1002/cm.10163
   Cambi A, 2004, J CELL BIOL, V164, P145, DOI 10.1083/jcb.200306112                                                           
   Cambi A, 2005, CELL MICROBIOL, V7, P481, DOI 10.1111/j.1462-5822.2005.00506.x
   Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252
   Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118                                                     
   Falk J, 2004, MOL BIOL CELL, V15, P4695, DOI 10.1091/mbc.E04-03-0171
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Granelli-Piperno A, 2005, J IMMUNOL, V175, P4265, DOI 10.4049/jimmunol.175.7.4265                                                     
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1                                                   
   HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Hodges A, 2007, NAT IMMUNOL, V8, P569, DOI 10.1038/ni1470
   HOLIFIELD BF, 1990, J CELL BIOL, V111, P2499, DOI 10.1083/jcb.111.6.2499
   HOLIFIELD BF, 1991, J CELL SCI, V98, P191
   Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002
   Koopman M, 2004, FEBS LETT, V573, P6, DOI 10.1016/j.febslet.2004.07.035
   KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097
   Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812
   Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x                                                
   Ray N, 2006, CURR TOP MICROBIOL, V303, P97, DOI 10.1007/978-3-540-33397-5_5
   SAXTON MJ, 1994, BIOPHYS J, V67, P2110, DOI 10.1016/S0006-3495(94)80694-0                                                   
   Steinberg G, 1996, J BIOL CHEM, V271, P7516, DOI 10.1074/jbc.271.13.7516                                                         
   Tardif MR, 2005, J IMMUNOL, V175, P926, DOI 10.4049/jimmunol.175.2.926                                                      
   Tardif MR, 2005, J VIROL, V79, P13714, DOI 10.1128/JVI.79.21.13714-13724.2005
   THERIOT JA, 1992, J CELL BIOL, V119, P367, DOI 10.1083/jcb.119.2.367
   VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4
   VALE RD, 1989, J CELL BIOL, V108, P2327, DOI 10.1083/jcb.108.6.2327
   VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589
   van Helden SFG, 2006, J IMMUNOL, V177, P1567, DOI 10.4049/jimmunol.177.3.1567                                                     
   Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x                                              
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
NR 43
TC 32
Z9 32
U1 0
U2 4
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD MAR 1
PY 2008
VL 121
IS 5
BP 634
EP 643
DI 10.1242/jcs.022418
PG 10
WC Cell Biology
SC Cell Biology
GA 266HU
UT WOS:000253425900011
PM 18270264
OA gold
DA 2018-01-05
ER

PT J
AU Jain, SK
   Gupta, Y
   Jain, A
   Saxena, AR
   Khare, P
   Jain, A
AF Jain, Sanjay K.
   Gupta, Yashwant
   Jain, Anekant
   Saxena, Asheesh R.
   Khare, Piush
   Jain, Aviral
TI Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine
   for site-specific delivery
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Gelatin nanoparticles; Mannose; Didanosine; Anti-HIV; Mannosylated
   nanoparticles
ID BIODEGRADABLE NANOPARTICLES; ALVEOLAR MACROPHAGES; ENHANCED DELIVERY;
   IN-VITRO; CELLS; MICROSPHERES; LOCALIZATION; CARRIERS; TISSUE
AB The present investigation was aimed at developing and exploring the use of mannosylated gelatin nanoparticles for the selective delivery of an anti-HIV drug, didanosine, to the target organs. The mannosylated gelatin nanoparticles (MN-G-NPs) were prepared using a two-step desolvation technique and coupled with mannose using the amino group of gelatin present on the surface of nanoparticles. The mannosylation was confirmed using infrared and nuclear magnetic resonance spectroscopy. MN-G-NPs were characterized for shape, particle size, zeta potential, and percentage drug entrapment. The size of nanoparticles was found to be in range of 248-325 nm, and maximum drug payload was found to be 40.2% to 48.5%. Average size was found to be more, but drug payload was less in the case of MN-G-NPs as compared with unconjugated nanoparticles (G-NPs). The results of the in vitro release profile demonstrated that G-NPs release a comparatively higher percentage of drug than MN-G-NPs. Cellular uptake by MN-G-NPs was 2.7 times more as compared with G-NPs. Fluorescence studies revealed the enhanced uptake of MN-G-NPs in the macrophage tissues when compared with unmodified G-NPs. Intravenous administration of free-drug solution resulted in a high concentration of drug in serum, whereas it was much less in the case of G-NPs. Coupling of the nanoparticles with mannose significantly enhanced the lung, liver, and lymph nodes uptake of drug, which is reflected in the recovery of a higher percentage of the dose from these organs following administration of MN-G-NPs in comparison to noncoupled G-NPs or free drug. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Jain, Sanjay K.; Gupta, Yashwant; Jain, Anekant; Saxena, Asheesh R.; Khare, Piush; Jain, Aviral] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar, MP, India.
RP Jain, SK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar, MP, India.
EM drskjainsagar@rediffmail.com
OI Jain, Aviral/0000-0001-7808-6180
FU All India Council for Technical Education (AICTE), New Delhi
FX Financial assistance provided by All India Council for Technical
   Education (AICTE), New Delhi to one of the authors is duly acknowledged.
CR AMMOURY N, 1991, PHARMACEUT RES, V8, P101, DOI 10.1023/A:1015846810474
   Andrianov AK, 1998, ADV DRUG DELIVER REV, V34, P155, DOI 10.1016/S0169-409X(98)00038-6                                                   
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Coester C, 2006, EUR J PHARM BIOPHARM, V62, P306, DOI 10.1016/j.ejpb.2005.09.009
   Coester CJ, 2000, J MICROENCAPSUL, V17, P187
   GRANGIER JL, 1991, J CONTROL RELEASE, V15, P3, DOI 10.1016/0168-3659(91)90098-X                                                    
   GUPTA Y, 2005, DRUG DELIV TECH, V5, P66
   Gupta Y, 2007, J PHARM PHARMACOL, V59, P935, DOI 10.1211/jpp.59.7.0004
   Gupta Y, 2007, J DRUG TARGET, V15, P231, DOI 10.1080/10611860701289719
   HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696
   Hamdi G, 1998, J CONTROL RELEASE, V55, P193, DOI 10.1016/S0168-3659(98)00055-8
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   HOLLAND SJ, 1992, ADV PHARM SCI, V6, P101
   LARGENT BL, 1984, J BIOL CHEM, V259, P1764
   Leo E, 1997, INT J PHARM, V155, P75, DOI 10.1016/S0378-5173(97)00149-X
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Liang WW, 1996, BBA-BIOMEMBRANES, V1279, P227, DOI 10.1016/0005-2736(95)00237-5                                                    
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   Mitchell JP, 1999, BIOORG MED CHEM LETT, V9, P2785, DOI 10.1016/S0960-894X(99)00480-1
   Mladenovska K, 2002, INT J PHARM, V242, P247, DOI 10.1016/S0378-5173(02)00167-9
   NAKADA Y, 1996, PHARM RES, V13, P37
   OLIVEIRA AMC, 2005, J PHARM BIOMED ANAL, V38, P751
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   SAKUMA S, 1990, J COLLOID INTERF SCI, V135, P455, DOI 10.1016/0021-9797(90)90016-H                                                    
   Schwick H G, 1969, Bibl Haematol, V33, P111
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   WARD AG, 1977, CIENCE TECHNOLOGY GE
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
NR 29
TC 79
Z9 80
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD MAR
PY 2008
VL 4
IS 1
BP 41
EP 48
DI 10.1016/j.nano.2007.11.004
PG 8
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 397NA
UT WOS:000262668200005
PM 18207463
DA 2018-01-05
ER

PT J
AU Lee, AM
   Rojek, JM
   Gundersen, A
   Stroher, U
   Juteau, JM
   Vaillant, A
   Kunz, S
AF Lee, Andrew M.
   Rojek, Jillian M.
   Gundersen, Anette
   Stroher, Ute
   Juteau, Jean-Marc
   Vaillant, Andrew
   Kunz, Stefan
TI Inhibition of cellular entry of lymphocytic choriomeningitis virus by
   amphipathic DNA polymers
SO VIROLOGY
LA English
DT Article
DE arenavirus; anti-virals; DNA polymer; entry inhibitor
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR ALPHA-DYSTROGLYCAN; LASSA FEVER
   VIRUS; CYNOMOLGUS MONKEYS; VIRAL PERSISTENCE; IMMUNE PLASMA;
   ARENAVIRUSES; BINDING; GLYCOPROTEIN; INFECTION
AB The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) represents a powerful experimental model for the study of the basic virology and pathogenesis of arenaviruses. In the present study, we used the LCMV model to evaluate the anti-viral potential of phosphorothioate oligonucleotides against arenaviruses. Our findings indicate that amphipathic DNA polymers (APs) are potent inhibitors of infection with a series of LCMV isolates with IC50 in the low nanomolar range. APs target the surface glycoprotein (GP) of LCMV and block viral entry and cell-cell propagation of the virus, without affecting later steps in replication or release of progeny virus from infected cells. The anti-viral action of APs is sequence-in dependent but is critically dependent on their size and hydrophobicity. Mechanistically, we provide evidence that APs disrupt the interaction between LCMVGP and its cellular receptor, alpha-dystroglycan. Exposure of LCMV to APs does not affect the stability of the GP virion spike and has no effect on the conformation of a neutralizing antibody epitope, suggesting rather subtle changes in the conformation and/or conformational dynamics of the viral GP. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Juteau, Jean-Marc; Vaillant, Andrew] REPLICor Inc, Laval, PQ H7V 5B7, Canada.
   [Lee, Andrew M.; Rojek, Jillian M.; Gundersen, Anette; Kunz, Stefan] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA.
   [Stroher, Ute] Canadian Sci Ctr Human & Anim Hlth, Publ Hlth Agency Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada.
   [Stroher, Ute] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.
RP Vaillant, A (reprint author), REPLICor Inc, 500 Blvd Cartier W,Suite 135, Laval, PQ H7V 5B7, Canada.
EM availlant@replicor.com; stefanku@scripps.edu
RI Lee, Andrew/G-5470-2011
OI Kunz, Stefan/0000-0001-6030-9550
FU NIAID NIH HHS [1 U54 AI 065359, U54 AI065359, R21 AI055540, R21
   AI055540-01, R01 AI055540, U54 AI065359-03, AI 55540]
CR AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521
   BORROW P, 1992, J VIROL, V66, P7270
   BORROW P, 1994, VIROLOGY, V198, P1, DOI 10.1006/viro.1994.1001
   BUCHMEIER MJ, 1981, VIROLOGY, V113, P73, DOI 10.1016/0042-6822(81)90137-9
   BURNS JW, 1991, VIROLOGY, V183, P620, DOI 10.1016/0042-6822(91)90991-J                                                    
   Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079                                                   
   DUTKO FJ, 1983, J GEN VIROL, V64, P1689, DOI 10.1099/0022-1317-64-8-1689
   ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809
   Eschli B, 2006, J VIROL, V80, P5897, DOI 10.1128/JVI.00008-06
   Este JA, 1998, MOL PHARMACOL, V53, P340
   Fischer SA, 2006, NEW ENGL J MED, V354, P2235, DOI 10.1056/NEJMoa053240
   FRAME JD, 1984, T ROY SOC TROP MED H, V78, P319, DOI 10.1016/0035-9203(84)90107-X                                                    
   Gallaher William R., 2001, BMC Microbiology, V1, P1, DOI 10.1186/1471-2180-1-1
   Geisbert TW, 2004, NAT MED S, V10, P110
   Imperiali M, 2005, J VIROL, V79, P14297, DOI 10.1128/JVI.79.22.14297-14308.2005
   JAHRLING PB, 1984, J INFECT DIS, V149, P420, DOI 10.1093/infdis/149.3.420                                                        
   JAHRLING PB, 1985, T ROY SOC TROP MED H, V79, P380, DOI 10.1016/0035-9203(85)90388-8
   JAHRLING PB, 1984, INFECT IMMUN, V44, P528
   JAHRLING PB, 1983, J MED VIROL, V12, P93, DOI 10.1002/jmv.1890120203
   Jamieson DJ, 2006, AM J OBSTET GYNECOL, V194, P1532, DOI 10.1016/j.ajog.2005.11.040
   KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0
   Kunz S, 2005, J VIROL, V79, P14282, DOI 10.1128/JVI.79.22.14282-14296.2005
   Kunz S, 2005, J VIROL, V79, P5979, DOI 10.1128/JVI.79.10.5979-5987.2005                                                
   Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103
   LEIFER E, 1970, AM J TROP MED HYG, V19, P677, DOI 10.4269/ajtmh.1970.19.677                                                       
   MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706
   MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104
   McCormick JB, 2002, CURR TOP MICROBIOL, V262, P75
   Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837
   MONATH TP, 1974, AM J TROP MED HYG, V23, P1140, DOI 10.4269/ajtmh.1974.23.1140                                                      
   Oldstone MBA, 2002, CURR TOP MICROBIOL, V263, P83
   PAREKH BS, 1986, VIROLOGY, V153, P168, DOI 10.1016/0042-6822(86)90020-6
   Parker WB, 2005, VIRUS RES, V107, P165, DOI 10.1016/j.virusres.2004.11.006
   Perez M, 2001, J VIROL, V75, P7078, DOI 10.1128/JVI.75.15.7078-7085.2001
   Rojek JA, 2007, J VIROL, V81, P5685, DOI 10.1128/JVI.02574-06
   Rojek JM, 2006, VIROLOGY, V349, P476, DOI 10.1016/j.virol.2006.02.033
   Rose JK, 2001, FIELDS VIROLOGY, P1221
   SALVATO M, 1988, VIROLOGY, V164, P517, DOI 10.1016/0042-6822(88)90566-1
   Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249
   Smelt SC, 2001, J VIROL, V75, P448, DOI 10.1128/JVI.75.1.448-457.2001                                                   
   Stein CA, 2005, SEMIN ONCOL, V32, P563, DOI 10.1053/j.seminoncol.2005.09.003
   STEIN CA, 1989, AIDS RES HUM RETROV, V5, P639, DOI 10.1089/aid.1989.5.639
   STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686
   Teng MN, 1996, J VIROL, V70, P8438
   Vaillant A, 2006, ANTIMICROB AGENTS CH, V50, P1393, DOI 10.1128/AAC.50.4.1393-1401.2006
   WEBER EL, 1988, VIROLOGY, V164, P30, DOI 10.1016/0042-6822(88)90616-2                                                    
   WRIGHT KE, 1989, VIROLOGY, V171, P417, DOI 10.1016/0042-6822(89)90610-7
   YAMAMOTO KR, 1997, HARVEY LECT, V91, P1
   Zhang Chuanbo, 2007, Methods Mol Biol, V361, P163
NR 49
TC 25
Z9 26
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 1
PY 2008
VL 372
IS 1
BP 107
EP 117
DI 10.1016/j.virol.2007.10.016
PG 11
WC Virology
SC Virology
GA 264YC
UT WOS:000253325300011
PM 18022208
OA gold
DA 2018-01-05
ER

PT J
AU Muraglia, E
   Kinzel, O
   Gardelli, C
   Crescenzi, B
   Donghi, M
   Ferrara, M
   Nizi, E
   Orvieto, F
   Pescatore, G
   Laufer, R
   Gonzalez-Paz, O
   Di Marco, A
   Fiore, F
   Monteagudo, E
   Fonsi, M
   Felock, PJ
   Rowley, M
   Summa, V
AF Muraglia, Ester
   Kinzel, Olaf
   Gardelli, Cristina
   Crescenzi, Benedetta
   Donghi, Monica
   Ferrara, Marco
   Nizi, Emanuela
   Orvieto, Federica
   Pescatore, Giovanna
   Laufer, Ralph
   Gonzalez-Paz, Odalys
   Di Marco, Annalise
   Fiore, Fabrizio
   Monteagudo, Edith
   Fonsi, Massimiliano
   Felock, Peter J.
   Rowley, Michael
   Summa, Vincenzo
TI Design and synthesis of bicyclic pyrimidinones as potent and orally
   bioavailable HIV-1 integrase inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; PROTEASE INHIBITORS; MORTALITY;
   INFECTION; DISCOVERY
AB HIV integrase is one of the three enzymes encoded by HIV genome and is essential for viral replication, but integrase inhibitors as marketed drugs have just very recently started to emerge. In this study, we show the evolution from the N-methylpyrimidinone structure to bicyclic pyrimidinones. Introduction of a suitably substituted amino moiety modulated the physical-chemical properties of the molecules and conferred nanomolar activity in the inhibition of spread of HIV-1 infection in cell culture. An extensive SAR study led to sulfamide (R)-22b, which inhibited the strand transfer with an IC50 of 7 nM and HIV infection in MT4 cells with a CIC95 of 44 nM, and ketoamide (S)-28c that inhibited strand transfer with an IC50 of 12 nM and the HIV infection in MT4 cells with a CIC95 of 13 nM and exhibited a good pharmacokinetic profile when dosed orally to preclinical species.
C1 [Muraglia, Ester; Kinzel, Olaf; Gardelli, Cristina; Crescenzi, Benedetta; Donghi, Monica; Ferrara, Marco; Nizi, Emanuela; Orvieto, Federica; Pescatore, Giovanna; Laufer, Ralph; Gonzalez-Paz, Odalys; Di Marco, Annalise; Fiore, Fabrizio; Monteagudo, Edith; Fonsi, Massimiliano; Rowley, Michael; Summa, Vincenzo] IRBM, Merck Res Labs, I-00040 Pomezia, Italy.
   [Felock, Peter J.] Merck Res Labs, Dept Antiviral Res, West Point, PA USA.
RP Muraglia, E (reprint author), IRBM, Merck Res Labs, Via Pontina Km 30600, I-00040 Pomezia, Italy.
EM ester_muraglia@merck.com
RI Laufer, Ralph/H-9336-2013
CR Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8
   Ferrara M, 2007, TETRAHEDRON LETT, V48, P8379, DOI 10.1016/j.tetlet.2007.09.072
   Gardelli C, 2007, J MED CHEM, V50, P4953, DOI 10.1021/jm0704705
   Guare JP, 2006, BIOORG MED CHEM LETT, V16, P2900, DOI 10.1016/j.bmcl.2006.03.003
   Hazuda DJ, 1997, J VIROL, V71, P7005
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Hogberg M, 2000, EXPERT OPIN THER PAT, V10, P1189, DOI 10.1517/13543776.10.8.1189
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   KATRITZKY AR, 1992, ORG PREP PROCED INT, V24, P463, DOI 10.1080/00304949209356228                                                       
   Kinzel OD, 2007, TETRAHEDRON LETT, V48, P6552, DOI 10.1016/j.tetlet.2007.07.043
   Lebon F, 2000, CURR MED CHEM, V7, P455, DOI 10.2174/0929867003375146                                                        
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2
   MONTEAGUDO E, UNPUB
   Pace P, 2007, J MED CHEM, V50, P2225, DOI 10.1021/jm070027u
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Petrocchi A, 2007, BIOORG MED CHEM LETT, V17, P350, DOI 10.1016/j.bmcl.2006.10.054
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Sheppard GS, 2006, J MED CHEM, V49, P3832, DOI 10.1021/jm0601001
   SUMMA V, 2006, 232 NAT M AM CHEM SO
   Summa V, 2006, J MED CHEM, V49, P6646, DOI 10.1021/jm060854f
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Vacca JP, 1997, DRUG DISCOV TODAY, V2, P261, DOI 10.1016/S1359-6446(97)01053-2                                                   
   Williams IG, 2003, INT J CLIN PRACT, V57, P890
   Young S D, 2001, Curr Opin Drug Discov Devel, V4, P402
   Zhuang LC, 2003, J MED CHEM, V46, P453, DOI 10.1021/jm025553u
NR 30
TC 48
Z9 52
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 28
PY 2008
VL 51
IS 4
BP 861
EP 874
DI 10.1021/jm701164t
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 265JB
UT WOS:000253353800018
PM 18217703
DA 2018-01-05
ER

PT J
AU Yadegari, H
   Jabbari, A
   Heli, H
   Moosavi-Movahedi, AA
   Karimian, K
   Khodadadi, A
AF Yadegari, H.
   Jabbari, A.
   Heli, H.
   Moosavi-Movahedi, A. A.
   Karimian, K.
   Khodadadi, A.
TI Electrocatalytic oxidation of deferiprone and its determination on a
   carbon nanotube-modified glassy carbon electrode
SO ELECTROCHIMICA ACTA
LA English
DT Article
DE carbon nanotube; modified electrode; deferiprone; anti-thalassaemia
   drug; electrocatalysis; HIV-1 replication inhibitor
ID IRON CHELATORS; BIOLOGICAL-FLUIDS; PASTE ELECTRODES; CLINICAL-USE;
   DEHYDROGENASE; ACTIVATION; BIOSENSORS; ALUMINUM; COMPLEX; CELLS
AB The electrochemical behavior of the anti-thalassemia and anti-HIV replication drug,deferiprone, was investigated on a carbon nanotube-modified glassy carbon (GC-CNT) electrode in phosphate buffer solution, pH 7.40 (PBS). During oxidation of deferiprone, two irreversible anodic peaks, with E-1(0)=452 and E-2(0) = 906 mV, appeared, using GC-CNT Cyclic voltammetric study indicated that the oxidation process is irreversible and diffusion controlled. The number of exchanged electrons in the electro-oxidation process was obtained, and the data indicated that deferiprone is oxidized via two two-electron steps. The results revealed that carbon nanotube (CNT) promotes the rate of oxidation by increasing the peak current, so that deferiprone is oxidized at lower potentials, which thermodynamically is more favorable. This result was confirmed by impedance measurements. The diffusion coefficient, electron-transfer coefficient and heterogeneous electron-transfer rate constant of deferiprone were found to be 1.49 x 10(-6) cm(2) s(-1), 0.44, and 3.83 x 10(-3) cm s(-1) , respectively. A sensitive, simple and time-saving differential-pulse voltammetric procedure was developed for the analysis of deferiprone. Using the proposed method, deferiprone can be determined with a detection limit of 5.25 x 10(-7) M. The applicability of the method to direct assays of spiked human serum and urine fluids is described. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Yadegari, H.; Jabbari, A.] KN Toosi Univ Technol, Dept Chem, Fac Sci, Tehran, Iran.
   [Heli, H.; Moosavi-Movahedi, A. A.] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran.
   [Karimian, K.] Arasto Pharmaceut Chem Inc, Tehran, Iran.
   [Khodadadi, A.] Univ Tehran, Fac Engn, Dept Chem Engn, Tehran, Iran.
RP Jabbari, A (reprint author), KN Toosi Univ Technol, Dept Chem, Fac Sci, POB 16315-1618, Tehran, Iran.
EM jabbat-i@kntu.ac.ir
RI Heli, Hossein/T-8014-2017; Heli, Hossein/T-7318-2017; Moosavi-Movahedi,
   Ali A./K-7453-2013
OI Heli, Hossein/0000-0003-1753-1193; Khodadadi, Abbas
   Ali/0000-0002-1431-5340
CR Ajayan PM, 1999, CHEM REV, V99, P1787, DOI 10.1021/cr970102g                                                               
   Antiochia R, 2006, ANAL LETT, V39, P1643, DOI 10.1080/00032710600713537
   Antiochia R, 2004, ELECTROANAL, V16, P1451, DOI 10.1002/elan.200302971
   Banks CE, 2006, ANALYST, V131, P15, DOI 10.1039/b512688f
   Bard A. J., 2001, ELECTROCHEMICAL METH, P231
   Bard A. J., 2001, ELECTROCHEMICAL METH, P595
   Bard A.J., 2001, ELECTROCHEMICAL METH, P236
   Barsoukov E, 2005, IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, 2ND EDITION, pXII
   Britto PJ, 1999, ADV MATER, V11, P154, DOI 10.1002/(SICI)1521-4095(199902)11:2<154::AID-ADMA154>3.0.CO;2-B
   Dai X, 2006, ANALYST, V131, P901, DOI 10.1039/b606197d
   Di JW, 2004, ELECTROANAL, V16, P644, DOI 10.1002/elan.200302855
   DRESOW B, 1995, FRESEN J ANAL CHEM, V352, P562, DOI 10.1007/BF00323074
   Edgeworth JP, 2007, SMALL, V3, P860, DOI 10.1002/smll.200700029
   EPEMOLU RO, 1990, J CHROMATOGR, V519, P171, DOI 10.1016/0021-9673(90)85145-L
   Fukuda S, 2005, CURR MED CHEM, V12, P2765, DOI 10.2174/092986705774463012                                                      
   Georgiou NA, 2000, J INFECT DIS, V181, P484, DOI 10.1086/315223
   GODDARD JG, 1990, CLIN CHEM, V36, P5
   Gooding JJ, 2005, ELECTROCHIM ACTA, V50, P3049, DOI 10.1016/j.electacta.2004.08.052
   Heli H, 2007, J SOLID STATE ELECTR, V11, P593, DOI 10.1007/s10008-006-0204-1
   HESAMZADEH H, 2005, P INT C CARB KOR
   HOFFBRAND AV, 1976, BRIT J HAEMATOL, V33, P517, DOI 10.1111/j.1365-2141.1976.tb03570.x
   Hu CG, 2006, J ELECTROANAL CHEM, V586, P77, DOI 10.1016/j.jelechem.2005.09.008
   Huang H, 2005, J COLLOID INTERF SCI, V284, P593, DOI 10.1016/j.jcis.2004.10.067
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Jafarian M, 2003, ELECTROCHIM ACTA, V48, P3423, DOI 10.1016/S0013-4686(03)00399-2
   Jang JW, 2002, SOLID STATE COMMUN, V122, P619, DOI 10.1016/S0038-1098(02)00153-9                                                   
   Kissenger P. T., 1996, LAB TECHNIQUES ELECT
   KLINE MA, 1992, CLIN CHEM, V38, P562
   Kontoghiorghes GJ, 2004, CURR MED CHEM, V11, P2161, DOI 10.2174/0929867043364685                                                        
   Kontoghiorghes GJ, 2001, DRUGS TODAY, V37, P23, DOI 10.1358/dot.2001.37.1.608779
   Lund H., 1991, ORGANIC ELECTROCHEMI
   Majdi S, 2007, J SOLID STATE ELECTR, V11, P601, DOI 10.1007/s10008-006-0205-0
   Majdi S, 2007, ELECTROCHIM ACTA, V52, P4622, DOI 10.1016/j.electacta.2007.01.022
   MARITAN A, 1990, ELECTROCHIM ACTA, V35, P141, DOI 10.1016/0013-4686(90)85051-N                                                    
   Miller J. C., 1994, STAT ANAL CHEM, P115
   MOTEKAITIS RJ, 1991, INORG CHIM ACTA, V183, P71, DOI 10.1016/S0020-1693(00)82997-7                                                   
   Musameh M, 2005, ELECTROCHEM COMMUN, V7, P14, DOI 10.1016/j.elecom.2004.10.007
   Nugent JM, 2001, NANO LETT, V1, P87, DOI 10.1021/nl005521z
   Odom TW, 1998, NATURE, V391, P62
   Ozkan SA, 2003, CRIT REV ANAL CHEM, V33, P155, DOI 10.1080/713609162                                                               
   PARIENTE F, 1995, ANAL CHEM, V67, P3936, DOI 10.1021/ac00117a019                                                             
   Paschalidis I, 1999, J RADIOANAL NUCL CHE, V242, P181
   Poh WC, 2004, LANGMUIR, V20, P5484, DOI 10.1021/la0490947
   Ricci F, 2003, ANAL LETT, V36, P1921, DOI 10.1081/AL-120023622
   SAPPEY C, 1995, AIDS RES HUM RETROV, V11, P1049, DOI 10.1089/aid.1995.11.1049
   SMYTH MR, 1992, ANAL VOLTAMMERTY
   Tekleab D, 2000, APPL PHYS LETT, V76, P3594, DOI 10.1063/1.126717
   Valentini F, 2004, SENSOR ACTUAT B-CHEM, V100, P117, DOI 10.1016/j.snb.2003.12.036
   Wang J, 2003, ANAL CHEM, V75, P2075, DOI 10.1021/ac030007+
   Wang J, 2004, ANAL CHEM, V76, P298, DOI 10.1021/ac035130f
   Wang J., 1996, ELECTROANALYTICAL TE
   Wang S. F., 2006, BIOELECTROCHEMISTRY, V71, P1
   Zhang FP, 2002, ANAL LETT, V35, P135, DOI 10.1081/AL-120002367
NR 53
TC 51
Z9 51
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0013-4686
EI 1873-3859
J9 ELECTROCHIM ACTA
JI Electrochim. Acta
PD FEB 15
PY 2008
VL 53
IS 6
BP 2907
EP 2916
DI 10.1016/j.electacta.2007.11.003
PG 10
WC Electrochemistry
SC Electrochemistry
GA 263JO
UT WOS:000253213600032
DA 2018-01-05
ER

PT J
AU Yan, MC
   Sha, Y
   Wang, J
   Xiong, XQ
   Ren, JH
   Cheng, MS
AF Yan, Mao-Cai
   Sha, Yu
   Wang, Jian
   Xiong, Xu-Qiong
   Ren, Jin-Hong
   Cheng, Mao-Sheng
TI Molecular dynamics simulations of HIV-1 protease monomer: Assembly of
   N-terminus and C-terminus into beta-sheet in water solution
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE HIV-1 protease; termini conformation; molecular dynamics simulations;
   dynamics behavior; dimerization inhibitor
ID LINKED INTERFACIAL PEPTIDES; DIMERIZATION INTERFACE; INHIBITION;
   STABILITY
AB HIV-1 protease (HIV-PR) consists of two identical subunits that are united together through a four-stranded antiparallel beta-sheet formed of the peptide termini of each monomer. Since the active site exists only in the dimer, a strategy that is attracting more and more attention in inhibitor design and which may overcome the serious drug resistance caused by competitive inhibitors is to block the peptide termini of the monomer, thereby interfering with formation of the active dimer. In the present work, we performed several extensive molecular dynamics (MD) simulations of the HIV-PR monomer in water to illustrate its solvated conformation and dynamics behavior. We found that the peptide termini usually assembled into beta-sheet after several nanoseconds' simulation, and became much less flexible. This beta-sheet is stabilized by intramolecular interactions and is not easily disaggregated under the present MD simulation conditions. This transformation may be an important transition during the relaxing and equilibrating of the HIV-PR monomer in aqueous solution, and the terminal beta-sheet may be one of the major conformations of the solvated HIV-PR monomer termini in water. This work may provide new insights into the dynamics behavior and dimerization mechanism of HIV-PR, and more significantly, offer a more rational receptor model for the design and discovery of novel dimerization inhibitors than crystalline structures.
C1 [Yan, Mao-Cai; Sha, Yu; Wang, Jian; Xiong, Xu-Qiong; Ren, Jin-Hong; Cheng, Mao-Sheng] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Key Lab New Drugs Design & Discovery Liaoning Pro, Shenyang 110016, Peoples R China.
RP Cheng, MS (reprint author), Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Key Lab New Drugs Design & Discovery Liaoning Pro, 103 Wenhua Rd, Shenyang 110016, Peoples R China.
EM mscheng@syphu.edu.cn
RI Yan, Maocai/Q-1435-2015
OI Yan, Maocai/0000-0002-1117-9398
CR BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Bowman MJ, 2002, BIOPOLYMERS, V66, P126, DOI 10.1002/bip.10232
   Broglia RA, 2005, PROTEIN SCI, V14, P2668, DOI 10.1110/ps.051670905
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Levy Y, 2004, J MOL BIOL, V340, P67, DOI 10.1016/j.jmb.2004.04.028
   Levy Y, 2003, J PHYS CHEM B, V107, P3068, DOI 10.1021/jp0219956
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Louis JM, 1999, NAT STRUCT BIOL, V6, P868
   Quere L, 1996, BIOCHEM BIOPH RES CO, V227, P484, DOI 10.1006/bbrc.1996.1533
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090                                                          
   *TRIP INC, SYB 6 9
   vanderSpoel D, 1996, J BIOMOL NMR, V8, P229, DOI 10.1007/BF00410322                                                              
   VANGUNSTEREN WF, 1987, GROMOS 87 MANUAL
   VENABLE RM, 1993, PROTEINS, V15, P374, DOI 10.1002/prot.340150405
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
NR 25
TC 7
Z9 7
U1 0
U2 6
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD FEB 15
PY 2008
VL 70
IS 3
BP 731
EP 738
DI 10.1002/prot.21539
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 257YT
UT WOS:000252836300011
PM 17729281
DA 2018-01-05
ER

PT J
AU Briones, E
   Colino, CI
   Lanao, JM
AF Briones, Elsa
   Colino, Clara Isabel
   Lanao, Jose M.
TI Delivery systems to increase the selectivity of antibiotics in
   phagocytic cells
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE delivery systems; antibiotics; phagocytic cells; intracellular
   infections; selectivity
ID LIPOSOMAL AMPHOTERICIN-B; HUMAN-IMMUNODEFICIENCY-VIRUS; TUFTSIN-BEARING
   LIPOSOMES; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MYCOBACTERIUM-AVIUM
   COMPLEX; SOLID LIPID NANOPARTICLES; HERPES-SIMPLEX-VIRUS; INTRACELLULAR
   CANDIDA-ALBICANS; ERYTHROCYTE-MEDIATED DELIVERY; RESPIRABLE PLGA
   MICROSPHERES
AB Many infectious diseases are caused by facultative organisms that are able to survive in phagocytic cells. The intracellular location of these microorganisms protects them from the host defence systems and from some antibiotics with poor penetration into phagocytic cells. One strategy used to improve the penetration of antibiotics into phagocytic cells is the use of carrier systems that deliver these drugs directly to the target cell. Delivery systems such as liposomes, micro/nanoparticles, lipid systems, conjugates, and biological carriers such as erythrocyte ghosts may contribute to increasing the therapeutic efficacy of antibiotics and antifungal agents in the treatment of infections caused by intracellular microorganisms. The main objective of this review is to analyze recent advances and current perspectives in the use of antibiotic delivery systems in the treatment of intracellular infections such as mycobacterial infections, brucellosis, salmonellosis, lysteriosis, fungal infections, visceral leishmaniasis, and HIV (C) 2007 Elsevier B.V. All rights reserved.
C1 [Briones, Elsa; Colino, Clara Isabel; Lanao, Jose M.] Univ Salamanca, Fac Pharm, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain.
RP Lanao, JM (reprint author), Univ Salamanca, Fac Pharm, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain.
EM jmlanao@usal.es
RI 2008, Ibsal/A-1268-2012
CR ADAMS DH, 1977, J NEUROL SCI, V31, P173, DOI 10.1016/0022-510X(77)90104-6
   Adams LB, 1999, ANTIMICROB AGENTS CH, V43, P1638
   Adler-Moore J, 2002, J ANTIMICROB CHEMOTH, V49, P21, DOI 10.1093/jac/49.suppl_1.21                                                       
   AGATHAT W, 2003, J PHARM PHARM SCI, V6, P67
   Agrawal AK, 2000, ADV DRUG DELIVER REV, V41, P135, DOI 10.1016/S0169-409X(99)00061-7                                                   
   Agrawal AK, 2002, J DRUG TARGET, V10, P41, DOI 10.1080/10611860290007513
   Ahren IL, 2002, J ANTIMICROB CHEMOTH, V50, P903, DOI 10.1093/jac/dkf221
   Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Alonso-Vargas Rocio, 2000, Revista Iberoamericana de Micologia, V17, P90
   ALVAREZ FE, 1995, ANN CLIN LAB SCI, V25, P283
   ANDERSON R, 1986, J INFECT DIS, V153, P593, DOI 10.1093/infdis/153.3.593                                                        
   BAKKERWOUDENBERG IAJM, 1988, ANTIMICROB AGENTS CH, V32, P1560, DOI 10.1128/AAC.32.10.1560                                                          
   Balland O, 1996, J ANTIMICROB CHEMOTH, V37, P105, DOI 10.1093/jac/37.1.105
   Banerjee G, 1996, J ANTIMICROB CHEMOTH, V38, P145, DOI 10.1093/jac/38.1.145                                                            
   Banerjee G, 1998, ANTIMICROB AGENTS CH, V42, P348
   Barcia-Macay M, 2006, ANTIMICROB AGENTS CH, V50, P841, DOI 10.1128/AAC.50.3.841-851.2006
   Barratt G, 2005, CURR OPIN INFECT DIS, V18, P527, DOI 10.1097/01.qco.0000191508.48481.f4
   Barratt G, 2003, CELL MOL LIFE SCI, V60, P21, DOI 10.1007/s000180300002                                                           
   Barrow ELW, 1998, ANTIMICROB AGENTS CH, V42, P2682
   BASU MK, 2006, NANOPARTICULATES DRU, P463
   Bax BE, 1999, CLIN SCI, V96, P171, DOI 10.1042/CS19980229                                                              
   Benatti U, 1996, BIOCHEM BIOPH RES CO, V220, P20, DOI 10.1006/bbrc.1996.0349
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BERMUDEZ LE, 1994, IMMUNOBIOLOGY, V191, P578, DOI 10.1016/S0171-2985(11)80465-1                                                   
   Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
   Berrocal MC, 2000, DRUG DELIV, V7, P37, DOI 10.1080/107175400266777                                                         
   Bhadra D, 2006, PHARM RES, V23, P623, DOI 10.1007/s11095-005-9396-9
   CARLIER MB, 1990, J ANTIMICROB CHEMOTH, V26, P27, DOI 10.1093/jac/26.suppl_B.27                                                       
   Carryn S, 2003, INFECT DIS CLIN N AM, V17, P615, DOI 10.1016/S0891-5520(03)00066-7
   Carter KC, 2001, ANTIMICROB AGENTS CH, V45, P3555, DOI 10.1128/AAC.45.12.3555-3559.2001
   Chakraborty KK, 2003, J PHARM PHARM SCI, V6, P231
   Chiarantini L, 1992, Adv Exp Med Biol, V326, P269
   Clemons KV, 1998, ANTIMICROB AGENTS CH, V42, P899
   Cordeiro C, 2000, ANTIMICROB AGENTS CH, V44, P533, DOI 10.1128/AAC.44.3.533-539.2000                                                   
   Coukell AJ, 1998, DRUGS, V55, P585, DOI 10.2165/00003495-199855040-00008
   Deol P, 1997, ANTIMICROB AGENTS CH, V41, P1211
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Duzgunes N, 1996, ANTIMICROB AGENTS CH, V40, P2618
   EASMON CSF, 1984, BRIT J EXP PATHOL, V65, P725
   Echevarria I, 2000, ANTIMICROB AGENTS CH, V44, P898, DOI 10.1128/AAC.44.4.898-904.2000
   EICHLER HG, 1986, CLIN PHARMACOL THER, V40, P300, DOI 10.1038/clpt.1986.180                                                           
   Eldem T, 2001, INT J PHARM, V213, P153, DOI 10.1016/S0378-5173(00)00663-3
   Erni C, 2002, BIOMATERIALS, V23, P4667, DOI 10.1016/S0142-9612(02)00216-8
   Ernst JD, 2006, ADV M C M, P246, DOI 10.1017/CBO9780511541513.008
   Espuelas MS, 2003, J ANTIMICROB CHEMOTH, V52, P419, DOI 10.1093/jac/dkg351
   Falk R, 1999, ANTIMICROB AGENTS CH, V43, P1975
   FIERER J, 1990, ANTIMICROB AGENTS CH, V34, P343, DOI 10.1128/AAC.34.2.343                                                            
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   Franchetti P, 2000, ANTIVIR RES, V47, P149, DOI 10.1016/S0166-3542(00)00101-7
   Fraternale A, 2003, J ANTIMICROB CHEMOTH, V52, P551, DOI 10.1093/jac/dkg428
   Fraternale A, 2002, ANTIVIR RES, V56, P263, DOI 10.1016/S0166-3542(02)00128-6
   Fraternale A, 2001, EUR J CLIN INVEST, V31, P248, DOI 10.1046/j.1365-2362.2001.00806.x
   Freitas C, 1998, EUR J PHARM BIOPHARM, V46, P145, DOI 10.1016/S0939-6411(97)00172-0                                                   
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   Fukui H, 2003, INT J PHARM, V267, P101, DOI 10.1016/j.ijpharm.2003.08.002
   Fukui H, 2003, INT J PHARM, V265, P37, DOI 10.1016/S0378-5173(03)00404-6
   Gangneux JP, 1996, ANTIMICROB AGENTS CH, V40, P1214
   Garcia I, 2003, J ANTIMICROB CHEMOTH, V52, P24, DOI 10.1093/jac/dkg290
   Gardai SJ, 2006, J LEUKOCYTE BIOL, V79, P896, DOI 10.1189/jlb.1005550
   Gasparini A, 1992, Adv Exp Med Biol, V326, P291
   Gibbs Winter J, 2005, Expert Rev Anti Infect Ther, V3, P167, DOI 10.1586/14787210.3.2.167
   GLADUE RP, 1990, ANTIMICROB AGENTS CH, V34, P1056, DOI 10.1128/AAC.34.6.1056                                                           
   GLADUE RP, 1989, ANTIMICROB AGENTS CH, V33, P277, DOI 10.1128/AAC.33.3.277                                                            
   Golenser J, 1999, ANTIMICROB AGENTS CH, V43, P2209
   GomezFlores R, 1996, ANTIMICROB AGENTS CH, V40, P2545
   GONDAL JA, 1989, ANTIMICROB AGENTS CH, V33, P1544, DOI 10.1128/AAC.33.9.1544                                                           
   GRAYBILL JR, 1982, J INFECT DIS, V145, P748, DOI 10.1093/infdis/145.2.748                                                        
   GREF R, 2006, NANOPARTICULATES DRU, P255
   Grimaldi S, 1997, RES VIROLOGY, V148, P177, DOI 10.1016/S0923-2516(97)89906-2
   Groll AH, 2000, J INFECT DIS, V182, P274, DOI 10.1086/315643
   Gupta CM, 2005, METHOD ENZYMOL, V391, P291, DOI 10.1016/S0076-6879(05)91016-1                                                   
   Hamidi M, 2003, DRUG DELIV, V10, P9, DOI 10.1080/10717540390169520
   Hammel M, 2003, CHEM PHYS LIPIDS, V123, P193, DOI 10.1016/S0009-3084(02)00002-1
   Hand W. Lee, 2003, Current Medicinal Chemistry - Anti-Infective Agents, V2, P73, DOI 10.2174/1568012033354612
   Hand WL, 2001, INT J ANTIMICROB AG, V18, P419, DOI 10.1016/S0924-8579(01)00430-7                                                   
   HAND WL, 1987, ANTIMICROB AGENTS CH, V31, P1553, DOI 10.1128/AAC.31.10.1553                                                          
   HAND WL, 1993, ANTIMICROB AGENTS CH, V37, P2557, DOI 10.1128/AAC.37.12.2557                                                          
   Hazenbos WLW, 2006, ADV M C M, P4, DOI 10.1017/CBO9780511541513.002
   Hillery AM, 1997, ADV DRUG DELIVER REV, V24, P345, DOI 10.1016/S0169-409X(96)00496-6
   Hoarau D, 2004, PHARM RES, V21, P1783, DOI 10.1023/B:PHAM.0000045229.87844.21
   HOLMES B, 1966, NATURE, V210, P1131, DOI 10.1038/2101131a0                                                               
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Huter V, 1999, J CONTROL RELEASE, V61, P51, DOI 10.1016/S0168-3659(99)00099-1
   Jahn B, 1998, ANTIMICROB AGENTS CH, V42, P2569
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Jain Sanjay, 1997, Indian Journal of Pharmaceutical Sciences, V59, P275
   Johnson EM, 1998, ANTIMICROB AGENTS CH, V42, P1412
   Kader A, 2002, J CONTROL RELEASE, V80, P29, DOI 10.1016/S0168-3659(01)00536-3                                                   
   Kader A, 1998, J CONTROL RELEASE, V55, P231, DOI 10.1016/S0168-3659(98)00052-2
   Kansal RG, 1997, ANTIMICROB AGENTS CH, V41, P17
   KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654                                                          
   Katragadda A, 2000, CELL MOL BIOL LETT, V5, P483
   Kayser O, 2003, PARASITOL RES, V90, pS63, DOI 10.1007/s00436-002-0769-2
   Kayser O, 2000, INT J PHARM, V196, P253, DOI 10.1016/S0378-5173(99)00434-2
   Khan MA, 2005, J ANTIMICROB CHEMOTH, V56, P726, DOI 10.1093/jac/dki307
   Khan MA, 2005, J ANTIMICROB CHEMOTH, V55, P223, DOI 10.1093/jac/dkh522
   Khuller GK, 2004, CURR PHARM DESIGN, V10, P3263, DOI 10.2174/1381612043383250
   KLEMENS SP, 1990, ANTIMICROB AGENTS CH, V34, P967, DOI 10.1128/AAC.34.6.967                                                            
   KLEMPNER MS, 1981, J INFECT DIS, V144, P472, DOI 10.1093/infdis/144.5.472                                                        
   KLEMPNER MS, 1984, ANTIMICROBIAL THERAP, P513
   Kozubek A, 2000, ACTA BIOCHIM POL, V47, P639
   Kshirsagar N A, 2005, J Postgrad Med, V51 Suppl 1, pS5
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Kuo JHS, 2005, J PHARM PHARMACOL, V57, P489, DOI 10.1211/0022357055803
   Kutlin A, 1999, ANTIMICROB AGENTS CH, V43, P2268
   Laguna F, 2003, ANN TROP MED PARASIT, V97, P135, DOI 10.1179/000349803225002606
   Lamprecht A, 2002, J CONTROL RELEASE, V84, P59, DOI 10.1016/S0168-3659(02)00258-4                                                   
   LANAO JM, 2006, NANOPARTICULATES DRU, P329
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Lecaroz C, 2006, J NANOSCI NANOTECHNO, V6, P3296, DOI 10.1166/jnn.2006.478
   Lecaroz C, 2006, J ANTIMICROB CHEMOTH, V58, P549, DOI 10.1093/jac/dkl257
   Leitzke S, 1998, ANTIMICROB AGENTS CH, V42, P459
   Liu S, 2006, NANOPARTICULATES DRU, P173
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lutwyche P, 1998, ANTIMICROB AGENTS CH, V42, P2511
   LYNCH WE, 1980, AM J HEMATOL, V9, P249, DOI 10.1002/ajh.2830090303                                                          
   Mader K, 2006, NANOPARTICULATES DRU, P187
   Maesaki S, 2002, CURR PHARM DESIGN, V8, P433, DOI 10.2174/1381612023395916
   MAGNANI M, 1992, P NATL ACAD SCI USA, V89, P6477, DOI 10.1073/pnas.89.14.6477                                                         
   Magnani M, 2002, GENE THER, V9, P749, DOI 10.1038/sj.gt.3301758
   MAGNANI M, 1995, VET IMMUNOL IMMUNOP, V46, P151, DOI 10.1016/0165-2427(94)07014-X
   Mankertz J, 1996, BBA-MOL BASIS DIS, V1317, P233, DOI 10.1016/S0925-4439(96)00059-2
   Mankertz J, 1997, BIOCHEM BIOPH RES CO, V240, P112, DOI 10.1006/bbrc.1997.7625
   MAURIN M, 1994, J INFECT DIS, V169, P330, DOI 10.1093/infdis/169.2.330                                                        
   Maurin M, 2001, ANTIMICROB AGENTS CH, V45, P2977, DOI 10.1128/AAC.45.11.2977-2986.2001
   MAYHEW E, 1987, EXP CELL RES, V171, P195, DOI 10.1016/0014-4827(87)90262-X
   Medda S, 1999, J ANTIMICROB CHEMOTH, V44, P791, DOI 10.1093/jac/44.6.791
   MEHTA RT, 1993, ANTIMICROB AGENTS CH, V37, P2584, DOI 10.1128/AAC.37.12.2584                                                          
   MEHTA RT, 1987, ANTIMICROB AGENTS CH, V31, P1901, DOI 10.1128/AAC.31.12.1901                                                          
   MEHTA RT, 1987, ANTIMICROB AGENTS CH, V31, P1897, DOI 10.1128/AAC.31.12.1897                                                          
   Mehta RT, 1996, ANTIMICROB AGENTS CH, V40, P1893
   Millan CG, 2004, J CONTROL RELEASE, V95, P27, DOI 10.1016/j.jconrel.2003.11.018
   Minodier P, 2003, FUND CLIN PHARMACOL, V17, P183, DOI 10.1046/j.1472-8206.2003.00168.x
   Moghimi SM, 2006, NANOPARTICULATES DRU, P29
   Moss HA, 2000, EUR J ANAESTH, V17, P680, DOI 10.1046/j.1365-2346.2000.00741.x
   Mukherjee S, 2004, J INFECT DIS, V189, P1024, DOI 10.1086/382048
   Mukhopadhyay A, 2003, ADV BIOCHEM ENG BIOT, V84, P183
   Mullen AB, 1997, ANTIMICROB AGENTS CH, V41, P2089
   Mullen AB, 1998, ANTIMICROB AGENTS CH, V42, P2722
   Muller RH, 1996, INT J PHARM, V138, P85, DOI 10.1016/0378-5173(96)04539-5
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Nan A, 2004, J CONTROL RELEASE, V94, P115, DOI 10.1016/j.jconrel.2003.09.012
   Nasti TH, 2006, J ANTIMICROB CHEMOTH, V57, P349, DOI 10.1093/jac/dki454
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Noel-Hocquet S, 1992, Adv Exp Med Biol, V326, P215
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887                                                         
   Oakley KL, 1999, ANTIMICROB AGENTS CH, V43, P1264
   OH YK, 1995, ANTIMICROB AGENTS CH, V39, P2104, DOI 10.1128/AAC.39.9.2104                                                           
   ONYEJI CO, 1994, ANTIMICROB AGENTS CH, V38, P523, DOI 10.1128/AAC.38.3.523                                                            
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   OWAIS M, 1993, FEBS LETT, V326, P56, DOI 10.1016/0014-5793(93)81760-W
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Paukner S, 2003, J DRUG TARGET, V11, P151, DOI 10.1080/10611860310001593366
   Paul M, 1997, ANTIMICROB AGENTS CH, V41, P1731
   Perno CF, 1997, ANTIVIR RES, V33, P153, DOI 10.1016/S0166-3542(96)01011-X
   PERRETT S, 1991, J PHARM PHARMACOL, V43, P154, DOI 10.1111/j.2042-7158.1991.tb06657.x                                              
   Pinto-Alphandary H, 2000, INT J ANTIMICROB AG, V13, P155, DOI 10.1016/S0924-8579(99)00121-1
   Prior S, 2000, INT J PHARM, V196, P115, DOI 10.1016/S0378-5173(99)00448-2                                                   
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   PROKESCH RC, 1982, ANTIMICROB AGENTS CH, V21, P373, DOI 10.1128/AAC.21.3.373                                                            
   Raulin J, 2002, PROG LIPID RES, V41, P27, DOI 10.1016/S0163-7827(01)00019-4                                                   
   Rawat M, 2006, BIOL PHARM BULL, V29, P1790, DOI 10.1248/bpb.29.1790
   REINOSO RJ, 1995, REV ESP QUIM, V8, P100
   Roseeuw E, 2003, ANTIMICROB AGENTS CH, V47, P3435, DOI 10.1128/AAC.47.11.3435-3441.2003
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Rossi L, 2001, J ANTIMICROB CHEMOTH, V47, P819, DOI 10.1093/jac/47.6.819
   Salem II, 2005, METHOD ENZYMOL, V391, P261, DOI 10.1016/S0076-6879(05)91015-X                                                   
   Salem II, 2003, INT J PHARM, V250, P403, DOI 10.1016/S0378-5173(02)00552-5                                                   
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Schiffelers R, 2001, J ANTIMICROB CHEMOTH, V48, P333, DOI 10.1093/jac/48.3.333
   Schiffelers R.M., 2006, NANOPARTICULATES DRU, P697
   Sinha J, 2000, DRUG DELIV, V7, P209
   Smistad G, 2007, INT J PHARM, V330, P14, DOI 10.1016/j.ijpharm.2006.08.044
   SMITH A, 1986, INT J PHARM, V30, P215, DOI 10.1016/0378-5173(86)90081-5
   Suarez S, 2001, PHARMACEUT RES, V18, P1315, DOI 10.1023/A:1013094112861
   Sugai Y, 2001, TRANSFUS APHER SCI, V24, P255, DOI 10.1016/S1473-0502(01)00067-2
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   SZOKA FC, 1990, BIOTECHNOL APPL BIOC, V12, P496
   TALWAR N, 1992, J MICROENCAPSUL, V9, P357, DOI 10.3109/02652049209021250
   TAYLOR RL, 1982, AM REV RESPIR DIS, V125, P610
   Tempone AG, 2004, J ANTIMICROB CHEMOTH, V54, P60, DOI 10.1093/jac/dkh281
   Tomii Y, 2002, CURR PHARM DESIGN, V8, P467, DOI 10.2174/1381612023395871
   Torchilin VP, 2006, NANOPARTICULATES DRU
   TORRECISNEROS J, 1993, CLIN INFECT DIS, V17, P625, DOI 10.1093/clinids/17.4.625                                                        
   TREMBLAY C, 1984, ANTIMICROB AGENTS CH, V26, P170, DOI 10.1128/AAC.26.2.170                                                            
   Valbonesi M, 2001, TRANSFUS APHER SCI, V24, P91, DOI 10.1016/S0955-3886(00)00128-4
   Van Bambeke F, 2006, CURR OPIN DRUG DISC, V9, P218
   Van Etten EWM, 2000, ANTIMICROB AGENTS CH, V44, P540, DOI 10.1128/AAC.44.3.540-545.2000
   Van Etten EWM, 1998, ANTIMICROB AGENTS CH, V42, P2437
   van Lent PLEM, 2001, J LEUKOCYTE BIOL, V70, P708
   vanEtten EWM, 1995, J ANTIMICROB CHEMOTH, V36, P961, DOI 10.1093/jac/36.6.961
   Vasir JK, 2005, CURR NANOSCI, V1, P47, DOI 10.2174/1573413052953110                                                        
   Vitas AI, 1996, ANTIMICROB AGENTS CH, V40, P146
   VONBRIESEN H, 2000, AIDS REV, V2, P31
   VOSBECK K, 1984, ANTIMICROB AGENTS CH, V25, P735, DOI 10.1128/AAC.25.6.735                                                            
   Vyas SP, 2004, INT J PHARM, V269, P37, DOI 10.1016/j.ijpharm.2003.08.017
   Vyas SP, 2000, INT J PHARM, V210, P1, DOI 10.1016/S0378-5173(00)00522-6
   Wallace TL, 1997, ANTIMICROB AGENTS CH, V41, P2238
   Webb MS, 1998, ANTIMICROB AGENTS CH, V42, P45
   Whitehead TC, 1998, EUR J CLIN MICROBIOL, V17, P794, DOI 10.1007/s100960050189
   Yamamoto T, 1996, ANTIMICROB AGENTS CH, V40, P2756
   Yanagihara K, 2002, CURR PHARM DESIGN, V8, P475, DOI 10.2174/1381612023395808
   YANEZ AM, 1995, ANESTHESIOLOGY, V82, P1189, DOI 10.1097/00000542-199505000-00014
   Yang H, 2006, J BIOMAT SCI-POLYM E, V17, P3, DOI 10.1163/156856206774879171
   Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8
   Yardley V, 1997, ANTIMICROB AGENTS CH, V41, P752
   ZOCCHI E, 1989, P NATL ACAD SCI USA, V86, P2040, DOI 10.1073/pnas.86.6.2040
NR 210
TC 90
Z9 91
U1 4
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 11
PY 2008
VL 125
IS 3
BP 210
EP 227
DI 10.1016/j.jconrel.2007.10.027
PG 18
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 270UG
UT WOS:000253745100003
PM 18077047
DA 2018-01-05
ER

PT J
AU Bielinska, AU
   Janczak, KW
   Landers, JJ
   Markovitz, DM
   Montefiori, DC
   Baker, JR
AF Bielinska, Anna U.
   Janczak, Katarzyna W.
   Landers, Jeffrey J.
   Markovitz, David M.
   Montefiori, David C.
   Baker, James R., Jr.
TI Nasal immunization with a recombinant HIV gp120 and nanoemulsion
   adjuvant produces th1 polarized responses and neutralizing antibodies to
   primary HIV type 1 isolates
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TOXIN-B-SUBUNIT; HUMORAL IMMUNE-RESPONSES;
   CYTOTOXIC T-LYMPHOCYTES; INFLUENZA-A VIRUS; MUCOSAL IMMUNIZATION;
   CHOLERA-TOXIN; GENITAL-TRACT; INTRANASAL IMMUNIZATION; AIDS VACCINE
AB Epidemiological and experimental data suggest that both robust neutralizing antibodies and potent cellular responses play important roles in controlling primary HIV-1 infection. In this study we have investigated the induction of systemic and mucosal immune responses to HIV gp120 monomer immunogen administered intranasally in a novel, oil-in-water nanoemulsion (NE) adjuvant. Mice and guinea pigs intranasally immunized by the application of recombinant HIV gp120 antigen mixed in NE demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA in mice. The serum of these animals demonstrated antibodies that cross-reacted with heterologous serotypes of gp120 and had significant neutralizing activity against two clade-B laboratory strains of HIV (HIVBaL and HIVSF162) and five primary HIV-1 isolates. The analysis of gp120-specific CTL proliferation, INF-gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses. This study suggests that NE should be evaluated as a mucosal adjuvant for multivalent HIV vaccines.
C1 [Bielinska, Anna U.; Janczak, Katarzyna W.; Landers, Jeffrey J.; Markovitz, David M.; Baker, James R., Jr.] Univ Michigan, MNIMBS, Ann Arbor, MI 48109 USA.
   [Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC 27706 USA.
RP Baker, JR (reprint author), Univ Michigan, MNIMBS, 1150 W Med Ctr Dr,9220 MSRB 3, Ann Arbor, MI 48109 USA.
EM jbakerjr@umich.edu
FU Wellcome Trust; NCI NIH HHS [R01 CA119409, R33 CA112141]
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Albu Diana I., 2003, Journal of Virology, V77, P5589, DOI 10.1128/JVI.77.10.5589-5597.2003
   Amara RR, 2002, VACCINE, V20, P1949, DOI 10.1016/S0264-410X(02)00076-2                                                   
   Andrianov AM, 2006, BIOCHEMISTRY-MOSCOW+, V71, P906, DOI 10.1134/S000629790608013X
   Baba TW, 2000, NAT MED, V6, P200
   Balmelli C, 2002, J VIROL, V76, P12596, DOI 10.1128/JVI.76.24.12596-12602.2002
   Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001                                                
   Belyakov Igor M, 2004, Expert Rev Vaccines, V3, pS65, DOI 10.1586/14760584.3.4.S65
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07
   Bradley LM, 1996, J IMMUNOL, V157, P1350
   Bradney CP, 2002, J VIROL, V76, P517, DOI 10.1128/JVI.76.2.517-524.2002
   Buonaguro L, 2006, J VIROL, V80, P9134, DOI 10.1128/JVI.00050-06
   Buonaguro L, 2002, ANTIVIR RES, V54, P189, DOI 10.1016/S0166-3542(02)00004-9
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018
   Carmichael A, 1996, J VIROL, V70, P8468
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258                                                                  
   Cohen J, 2003, SCIENCE, V302, P1309
   Donnelly S, 2001, INFECT IMMUN, V69, P4217, DOI 10.1128/IAI.69.7.4217-4223.2001
   Dumais N, 2002, J INFECT DIS, V186, P1098, DOI 10.1086/344232
   Eriksson K, 2002, CURR OPIN IMMUNOL, V14, P666, DOI 10.1016/S0952-7915(02)00384-9
   Gallichan WS, 2001, J IMMUNOL, V166, P3451, DOI 10.4049/jimmunol.166.5.3451                                                     
   Gherardi MM, 2005, J GEN VIROL, V86, P2925, DOI 10.1099/vir.0.81181-0
   Goepfert PA, 2005, J INFECT DIS, V192, P1249, DOI 10.1086/432915                                                                  
   Golding B, 2002, VACCINE, V20, P1445, DOI 10.1016/S0264-410X(01)00477-7
   Goodenow MM, 2006, J LEUKOCYTE BIOL, V80, P965, DOI 10.1189/jlb.0306148
   Gorse GJ, 1999, AIDS RES HUM RETROV, V15, P115, DOI 10.1089/088922299311547
   Graham BS, 2006, J INFECT DIS, V194, P1650, DOI 10.1086/509259
   Green S, 1995, ADV EXP MED BIOL, V383, P83
   Grundner C, 2005, VIROLOGY, V331, P33, DOI 10.1016/j.virol.2004.09.022
   Hamouda T, 2001, MICROBIOL RES, V156, P1, DOI 10.1078/0944-5013-00069
   Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617                                                     
   Holmgren J, 2005, IMMUNOL LETT, V97, P181, DOI 10.1016/j.imlet.2004.11.009
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Johansson EL, 1998, INFECT IMMUN, V66, P514
   Johansson EL, 2001, INFECT IMMUN, V69, P7481, DOI 10.1128/IAI.69.12.7481-7486.2001
   Joseph J, 2006, EXPERT REV VACCINES, V5, P827, DOI 10.1586/14760584.5.6.827
   Klinman DM, 2006, ANN NY ACAD SCI, V1082, P137, DOI 10.1196/annals.1348.030
   Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4
   Kornbluth RS, 2006, J LEUKOCYTE BIOL, V80, P1084, DOI 10.1189/jlb.0306147
   KOUP RA, 1994, J VIROL, V68, P4650
   Kozlowski PA, 1997, INFECT IMMUN, V65, P1387
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li Y, 2006, J VIROL, V80, P1414, DOI 10.1128/JVI.80.3.1414-1426.2006
   Lu XQ, 2007, IMMUNOLOGY, V120, P207, DOI 10.1111/j.1365-2567.2006.02492.x
   Lundholm P, 2002, VIRUS RES, V82, P141
   Mascola JR, 2005, J VIROL, V79, P10103, DOI 10.1128/JVI.79.16.10103-10107.2005
   Mascola JR, 2005, J VIROL, V79, P771, DOI 10.1128/JVI.79.2.771-779.2005
   Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799                                                        
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605
   Mestecky J, 2006, J REPROD IMMUNOL, V72, P1, DOI 10.1016/j.jri.2006.05.006
   Moldoveanu Z, 1998, VACCINE, V16, P1216, DOI 10.1016/S0264-410X(98)80122-9                                                   
   Montefiori D.C., 2004, CURRENT PROTOCOLS IM
   MOSMANN TR, 1992, ANN NY ACAD SCI, V664, P89, DOI 10.1111/j.1749-6632.1992.tb39751.x
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5
   Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   O'Hagan DT, 2000, VACCINE, V18, P1793, DOI 10.1016/S0264-410X(99)00522-8
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Russell MW, 2002, MICROBES INFECT, V4, P667, DOI 10.1016/S1286-4579(02)01585-X
   Shu Y, 2007, VACCINE, V25, P1398, DOI 10.1016/j.vaccine.2006.10.046
   Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8                                                   
   Spearman P, 2006, CURR PHARM DESIGN, V12, P1147, DOI 10.2174/138161206776055859
   Srivastava IK, 2002, J VIROL, V76, P2835, DOI 10.1128/JVI.76.6.2835-2847.2002
   Takada A, 2003, VACCINE, V21, P3212, DOI 10.1016/S0264-410X(03)00234-2
   TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448
   Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x
   Vajdy M, 2004, AIDS RES HUM RETROV, V20, P1269, DOI 10.1089/aid.2004.20.1269
   Vajdy Michael, 2006, Expert Opin Drug Deliv, V3, P247, DOI 10.1517/17425247.3.2.247
   van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778                                                     
   VanCott TC, 1998, J IMMUNOL, V160, P2000
   Varona-Santos JT, 2006, VIRAL IMMUNOL, V19, P237, DOI 10.1089/vim.2006.19.237
   WRIN T, 1995, J VIROL, V69, P39
   WU HY, 1993, INFECT IMMUN, V61, P314
   Wu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005
   Yasuda Y, 2003, VACCINE, V21, P2954, DOI 10.1016/S0264-410X(03)00114-2
   Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398
NR 84
TC 55
Z9 55
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 2008
VL 24
IS 2
BP 271
EP 281
DI 10.1089/aid.2007.0148
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 268PI
UT WOS:000253591300019
PM 18260780
DA 2018-01-05
ER

PT J
AU Drogoz, A
   Munier, S
   Verrier, B
   David, L
   Dornard, A
   Delair, T
AF Drogoz, Alexandre
   Munier, Severine
   Verrier, Bernard
   David, Laurent
   Dornard, Alain
   Delair, Thierry
TI Towards biocompatible vaccine delivery systems: Interactions of
   colloidal PECs based on polysaccharides with HIV-1 p24 antigen
SO BIOMACROMOLECULES
LA English
DT Article
ID SPHERICAL POLYELECTROLYTE BRUSHES; CHITOSAN NANOPARTICLES; COMPLEX
   NANOPARTICLES; AQUEOUS-SOLUTION; GENE DELIVERY; IN-VIVO; PROTEINS;
   ADSORPTION; MICROSPHERES; IMMOBILIZATION
AB This work reports on the interactions of a model protein (p24, the capside protein of HIV-1 virus) with colloids obtained from polyelectrolyte complexes (PECs) involving two polysaccharides: chitosan and dextran sulfate (DS). The PECs were elaborated by a one-shot addition of default amounts of one counterpart to the polymer in excess. Depending on the nature of the excess poly electrolyte, the submicrometric colloid was either positively or negatively charged. HIV-1 capsid p24 protein was chosen as antigen, the ultrapure form, lipopolysaccharide-free (endotoxin-, vaccine grade) was used in most experiments, as the level of purity of the protein had a great impact on the immobilization process. p24 sorption kinetics, isotherms, and loading capacities were investigated for positively and negatively charged particles of chitosans and dextran sulfates differing in degrees of polymerization (DP) or acetylation (DA). Compared with the positive particles, negatively charged colloids had higher binding capacities, faster kinetics, and a better stability of the adsorbed p24. Capacities up to 600 mg.g(-1) (protein-colloid) were obtained, suggesting that the protein interacted within the shell of the particles. Small-angle X-rays scattering experiments confirmed this hypothesis. Finally, the immunogenicity of the p24-covered particles was assessed for vaccine purposes in mice. The antibody titers obtained with immobilized p24 was dose dependent and in the same range as for Freund's adjuvant, a gold standard for humoral responses.
C1 [Drogoz, Alexandre; Delair, Thierry] Ecole Normale Super Lyon, UMR 2714, BioMerieux, CNRS,Unite Mixte, F-69364 Lyon 07, France.
   [Drogoz, Alexandre; Delair, Thierry] CNRS, UMR 5086, F-69967 Lyon, France.
   [Drogoz, Alexandre; David, Laurent; Dornard, Alain] Univ Lyon 1, CNRS, UMR 5223, Ingn Mat Polymeres,Lab Mat Polymeres & Biomat, F-69622 Villeurbanne, France.
   [Munier, Severine; Verrier, Bernard] CNRS, UMR 5086, Inst Biol Chim Prot, F-75700 Paris, France.
RP Delair, T (reprint author), Ecole Normale Super Lyon, UMR 2714, BioMerieux, CNRS,Unite Mixte, 46 Allee Italie, F-69364 Lyon 07, France.
EM Thierry.Delair@ens-lyon.fr
RI d2am, beamline/I-6445-2015; Delair, Thierry/E-7896-2012
CR Allard L, 2002, BIOTECHNOL BIOENG, V80, P341, DOI 10.1002/bit.10390
   Buchhammer HM, 2003, COLLOID SURFACE A, V218, P151, DOI 10.1016/S0927-7757(02)00582-4
   CALIS S, 1995, PHARM RES-DORDR, V12, P1072, DOI 10.1023/A:1016278902839
   Caruso F, 2000, LANGMUIR, V16, P9595, DOI 10.1021/la000942h
   Chen Y, 2003, LETT PEPT SCI, V10, P621, DOI 10.1007/BF02442596                                                              
   CHEYNET V, 1993, PROTEIN EXPRES PURIF, V4, P367, DOI 10.1006/prep.1993.1048                                                          
   COOMBES AGA, 1994, BIOMATERIALS, V15, P673, DOI 10.1016/0142-9612(94)90165-1
   CZESLIK C, 2004, PHYS REV E, V15
   Dautzenberg H, 1997, MACROMOLECULES, V30, P7810, DOI 10.1021/ma970803f                                                               
   Davidova VN, 1999, BIOL MEMBRANY, V16, P42
   Davidova VN, 2006, BIOCHEMISTRY-MOSCOW+, V71, P332, DOI 10.1134/S0006297906030151
   Douglas KL, 2005, J BIOMAT SCI-POLYM E, V16, P43, DOI 10.1163/1568562052843339
   Dragan ES, 2004, J POLYM SCI POL CHEM, V42, P2495, DOI 10.1002/pola.20110
   Drogoz A, 2007, LANGMUIR, V23, P10950, DOI 10.1021/la7008545
   Dumitriu S, 1997, BIOTECHNOL PROGR, V13, P539, DOI 10.1021/bp970059i
   Etrych T, 2005, EUR J PHARM SCI, V25, P281, DOI 10.1016/j.ejps.2005.03.005
   FAIR BD, 1980, J COLLOID INTERF SCI, V77, P525, DOI 10.1016/0021-9797(80)90325-2                                                    
   Gu HW, 2003, CHEM COMMUN, P1966, DOI 10.1039/b305421g
   Guo X, 1999, MACROMOLECULES, V32, P6043, DOI 10.1021/ma990609o                                                               
   HIRAI A, 1991, POLYM BULL, V26, P87, DOI 10.1007/BF00299352                                                              
   Ichikawa S, 2005, BIOSCI BIOTECH BIOCH, V69, P1637, DOI 10.1271/bbb.69.1637
   JENNISSEN HP, 1976, H-S Z PHYSIOL CHEM, V357, P1201
   Kabanov VA, 2004, J PHYS CHEM B, V108, P1485, DOI 10.1021/jp035821f
   Kim MH, 2004, J APPL CRYSTALLOGR, V37, P643, DOI 10.1107/S0021889804013196
   KISSEL T, 2006, J PHARM SCI, P1035
   Koping-Hoggard M, 2005, EXPERT REV VACCINES, V4, P185, DOI 10.1586/14760584.4.2.185
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Lin YH, 2005, BIOMACROMOLECULES, V6, P1104, DOI 10.1021/bm049312a
   Luo QL, 1998, J COLLOID INTERF SCI, V200, P104, DOI 10.1006/jcis.1997.5364                                                          
   Nagamoto T, 2004, PHARM RES, V21, P671, DOI 10.1023/B:PHAM.0000022414.17183.58
   Ouyang W, 2006, MACROMOL BIOSCI, V6, P929, DOI 10.1002/mabi.200600143
   Ozbas-Turan S, 2002, J PHARM SCI, V91, P1245, DOI 10.1002/jps.10122
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Petsch D, 2000, J BIOTECHNOL, V76, P97, DOI 10.1016/S0168-1656(99)00185-6                                                   
   Rosenfeldt S., 2004, PHYS REV E, P70
   Sarmento B, 2006, COLLOID SURFACE B, V53, P193, DOI 10.1016/j.colsurfb.2006.09.012
   Schatz C, 2004, LANGMUIR, V20, P7766, DOI 10.1021/la049460m
   Schatz C, 2004, BIOMACROMOLECULES, V5, P1882, DOI 10.1021/bm049786
   Schatz C, 2003, BIOMACROMOLECULES, V4, P641, DOI 10.1021/bm025724c
   Seferian PG, 2000, VACCINE, V19, P661, DOI 10.1016/S0264-410X(00)00248-6
   Shi XW, 2006, J APPL POLYM SCI, V100, P4614, DOI 10.1002/app.23021
   Vachoud L, 1997, CARBOHYD RES, V302, P169, DOI 10.1016/S0008-6215(97)00126-2
   van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3
   Vila A, 2004, EUR J PHARM BIOPHARM, V57, P123, DOI 10.1016/j.ejpb.2003.09.006
   Wittemann A, 2005, J AM CHEM SOC, V127, P9688, DOI 10.1021/ja0513234
   Wittemann A, 2003, PHYS CHEM CHEM PHYS, V5, P1671, DOI 10.1039/b300607g
   Xu YM, 2003, INT J PHARM, V250, P215, DOI 10.1016/S0378-5173(02)00548-3
   Yu SY, 2006, LANGMUIR, V22, P2754, DOI 10.1021/la053158b
NR 48
TC 19
Z9 19
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD FEB
PY 2008
VL 9
IS 2
BP 583
EP 591
DI 10.1021/bm701154h
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 261TE
UT WOS:000253102100024
PM 18208314
DA 2018-01-05
ER

PT J
AU Costantini, DL
   Hu, MD
   Reilly, RM
AF Costantini, Danny L.
   Hu, Meiduo
   Reilly, Raymond M.
TI Peptide motifs for insertion of radiolabeled biomolecules into cells and
   routing to the nucleus for cancer imaging or radiotherapeutic
   applications
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Review
DE cell-penetrating peptides; tat; nuclear-localizing sequences; monoclonal
   antibodies; intracellular epitopes; gene therapy; imaging; Auger
   electrons
ID HUMAN-BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; RECEPTOR RADIONUCLIDE
   THERAPY; LOCALIZATION SIGNAL PEPTIDE; DEPENDENT KINASE INHIBITOR; HIV-1
   TAT PEPTIDES; CARBON NANOTUBES; MAMMALIAN-CELLS; INTRACELLULAR DELIVERY;
   MONOCLONAL-ANTIBODIES
AB Intracellular compartments, in particular the cytoplasm or nucleus, have generally been poorly accessible or inaccessible to radiolabeled biomolecules (e.g., monoclonal antibodies [mAbs], peptides, or oligonucleotides [ODNs]). However, recently cell-penetrating peptides (CPPs) and nuclear localizing peptide sequences (NLSs) have been shown to have the capability of inserting biomolecules into cells and transporting them to the cell nucleus. This discovery now presents intriguing new opportunities to design radiopharmaceuticals that could potentially probe, through imaging, the expression of key intracellular or intranuclear, regulatory proteins that define the tumor phenotype, predict outcome, or act as sensitive reporters of response or resistance to treatment. CPPs could also more efficiently internalize radiolabeled antisense ODNs or peptide nucleid acids (PNAs) into tumor cells to enhance the sensitivity of imaging gene expression at the mRNA level. Perhaps one of the most exciting new developments to emerge is the use of NLS to route mAbs and peptides conjugated to nanometer-micrometer range Auger-electron-emitting radionuclides (e.g., In-111) to the nucleus of cancer cells following their receptor-mediated internalization. In the nucleus, these electrons are highly potent in causing lethal DNA strand breaks. In some cases, NLSs are present naturally in peptide growth factors or their receptors, where they function to deliver internalized ligands to the nucleus, or alternatively, they can be introduced synthetically. This update reviews the properties of CPPs and NLS and focuses on their use for inserting radiolabeled biomolecules into cancer cells for imaging or targeted Auger electron radiotherapy of malignancies.
C1 [Reilly, Raymond M.] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada.
RP Reilly, RM (reprint author), Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, 144 Coll St, Toronto, ON M5S 3M2, Canada.
EM raymond.reilly@utoronto.ca
CR AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002                                                
   Andersson ML, 1997, FEBS LETT, V416, P291, DOI 10.1016/S0014-5793(97)01223-4
   Andersson P, 1996, J NUCL MED, V37, P2002
   Anthony LB, 2002, SEMIN NUCL MED, V32, P123, DOI 10.1053/snuc.2002.31769
   Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475
   Areberg J, 2001, INT J RADIAT ONCOL, V49, P827, DOI 10.1016/S0360-3016(00)01419-X                                                   
   ARNHEITER H, 1988, EMBO J, V7, P1315
   Aronov O, 2004, BIOCONJUGATE CHEM, V15, P814, DOI 10.1021/bc0499331
   ARTUSO M, 1995, ONCOGENE, V11, P1427
   Baselga J, 2001, ANN ONCOL, V12, P35, DOI 10.1023/A:1011163824080                                                         
   BERGSTEIN M, 2000, BREAST CANC MOL GENE, P143
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   BLOOMER WD, 1980, INT J RADIAT BIOL, V38, P197, DOI 10.1080/09553008014551101
   Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1
   Branden LJ, 2001, GENE THER, V8, P84, DOI 10.1038/sj.gt.3301345
   Buchegger F, 2006, EUR J NUCL MED MOL I, V33, P1352, DOI 10.1007/s00259-006-0187-2
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Chen P, 2006, J NUCL MED, V47, P827
   Chen P, 2003, J NUCL MED, V44, P1469
   Chen P, 2002, NUCL MED BIOL, V29, P693, DOI 10.1016/S0969-8051(02)00325-6
   Chen QQ, 2005, CELL RES, V15, P504, DOI 10.1038/sj.cr.7290320
   Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190
   COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136                                                           
   COMELISSEN N, 2007, NUCL MED BIOL, V34, P37
   Costantini DL, 2007, J NUCL MED, V48, P1357, DOI 10.2967/jnumed.106.037937
   Cutrona G, 2000, NAT BIOTECHNOL, V18, P300
   DAIDONE MG, 1999, PRIMARY MED THERAPY
   de Jong M, 2004, J NUCL MED, V45, P1168
   DeNardo SJ, 2005, SEMIN NUCL MED, V35, P143, DOI 10.1053/j.semnuclmed.2004.12.001
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   DESANTES K, 1992, CANCER RES, V52, P1916
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   DEWANJEE MK, 1994, J NUCL MED, V35, P1054
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   FARAGGI M, 1994, J NUCL MED, V35, P113
   Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790
   FRANANO FN, 1994, NUCL MED BIOL, V21, P1023, DOI 10.1016/0969-8051(94)90174-0
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Gallazzi F, 2003, BIOCONJUGATE CHEM, V14, P1083, DOI 10.1021/bc034084n
   GINJ M, 2005, J NUCL MED, V209, P7
   Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005
   GODDU SM, 1994, J NUCL MED, V35, P303
   Goldenberg DM, 2002, J NUCL MED, V43, P693
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Haefliger P, 2005, BIOCONJUGATE CHEM, V16, P582, DOI 10.1021/bc0500084
   Hafliger P, 2005, CHEMBIOCHEM, V6, P414, DOI 10.1002/cbic.200400210
   He YJ, 2004, EUR J NUCL MED MOL I, V31, P837, DOI 10.1007/s00259-003-1446-0
   HOWELL RW, 1992, MED PHYS, V19, P1371, DOI 10.1118/1.596927
   HOWELL RW, 1994, RADIAT RES, V140, P55, DOI 10.2307/3578568
   HOWELL RW, 1986, P 4 INT RAD DOS S CO
   Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200
   Hu MD, 2006, EUR J NUCL MED MOL I, V33, P301, DOI 10.1007/s00259-005-1908-7
   Hu MD, 2007, EUR J NUCL MED MOL I, V34, P368, DOI 10.1007/s00259-006-0189-0
   Hu MD, 2006, BIOCONJUGATE CHEM, V17, P1280, DOI 10.1021/bc060053r
   Hua M, 2007, NUCL MED BIOL, V34, P887, DOI 10.1016/j.nucmedbio.2007.06.010
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jain M, 2007, EUR J NUCL MED MOL I, V34, P973, DOI 10.1007/s00259-007-0395-4
   Jans DA, 1996, PHYSIOL REV, V76, P651
   JANS DA, 1994, FASEB J, V8, P841
   Janson ET, 2000, J NUCL MED, V41, P1514
   JOHNSON HM, 2005, ENCY LIFE SCI
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Jong M, 2003, EUR J NUCL MED MOL I, V30, P463, DOI 10.1007/s00259-002-1107-8
   KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Karamychev VN, 2000, ACTA ONCOL, V39, P687
   Karamychev VN, 2000, J NUCL MED, V41, P1093
   Kassis AI, 2003, J NUCL MED, V44, P1479
   KHAW BA, 1979, CIRCULATION, V60, P1527
   KIEFER P, 1994, EMBO J, V13, P4126
   KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765                                                              
   Kwekkeboom DJ, 2005, J NUCL MED, V46, p62S
   Lane HA, 2001, ANN ONCOL, V12, P21, DOI 10.1023/A:1011155606333                                                         
   LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527                                                           
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lewis MR, 2002, BIOCONJUGATE CHEM, V13, P1176, DOI 10.1021/bc025591s
   Li GP, 2005, NUCL MED BIOL, V32, P59, DOI 10.1016/j.nucmedbio.2004.09.003
   Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Liu WM, 1998, INT J ONCOL, V12, P793
   LO HW, 2006, CELL BIOCH, V98, P1570
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251                                                            
   McClelland RA, 1999, J PATHOL, V188, P126
   McDevitt MR, 2007, J NUCL MED, V48, P1180, DOI 10.2967/jnumed.106.039131
   MCLAUGHLIN WH, 1989, J NATL CANCER I, V81, P437, DOI 10.1093/jnci/81.6.437                                                           
   Michel RB, 2005, MOL CANCER THER, V4, P927, DOI 10.1158/1535-7163.MCT-04-0340                                                   
   Miederer M, 2004, J NUCL MED, V45, P129
   Misek DE, 2004, PHARMACOGENOMICS, V5, P1129, DOI 10.1517/14622416.5.8.1
   Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476
   Nakamura K, 2005, J NUCL MED, V46, P509
   Nakamura K, 2004, BIOCONJUGATE CHEM, V15, P1475, DOI 10.1021/bc0499073
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Park JW, 2002, CLIN CANCER RES, V8, P1172
   Piche A, 1998, CANCER RES, V58, P2134
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   Pouton CW, 1998, ADV DRUG DELIVER REV, V34, P51, DOI 10.1016/S0169-409X(98)00050-7
   Press OW, 1996, CANCER RES, V56, P2123
   RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728
   Reilly R, 2004, CANCER BIOTHER RADIO, V19, P669, DOI 10.1089/cbr.2004.19.669
   Reilly RM, 2007, J NUCL MED, V48, P1039, DOI 10.2967/jnumed.107.041723
   REILLY RM, 1995, CLIN PHARMACOKINET, V28, P126, DOI 10.2165/00003088-199528020-00004                                                
   Reilly RM, 2000, J NUCL MED, V41, P429
   REILLY RM, 2007, HDB BIOPHARMACEUTICA, P987
   REILLY RM, 2005, MODERN BIOPHARMACEUT, P497
   REUBI JC, 2005, NUCL MED S1, V46, pS67
   Sedelnikova OA, 2002, ANTISENSE NUCLEIC A, V12, P43, DOI 10.1089/108729002753670256
   Sedelnikova OA, 2001, INT J RADIAT ONCOL, V49, P391, DOI 10.1016/S0360-3016(00)01486-3
   Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5
   Shen CX, 2003, CANCER BIOTHER RADIO, V18, P17, DOI 10.1089/108497803321269296
   Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200
   Slooter GD, 2002, J NUCL MED, V43, P1681
   Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011
   Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114
   Tang Y, 2005, NUCL MED BIOL, V32, P51, DOI 10.1016/j.nucmedbio.204.08.003
   Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tsai SW, 2000, BIOCONJUGATE CHEM, V11, P327, DOI 10.1021/bc9901292                                                               
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Valkema R, 2002, SEMIN NUCL MED, V32, P110, DOI 10.1053/snuc.2002.31025
   Van de Wiele C, 2004, Q J NUCL MED MOL IM, V48, P317
   Wang J, 2003, EUR J NUCL MED MOL I, V30, P1273, DOI 10.1007/s00259-003-1134-0
   Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3
   WELT S, 1987, P NATL ACAD SCI USA, V84, P4200, DOI 10.1073/pnas.84.12.4200
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wesche J, 2005, BIOCHEMISTRY-US, V44, P6071, DOI 10.1021/bi047403m
   Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155
   Yasui LS, 2001, RADIAT RES, V155, P328, DOI 10.1667/0033-7587(2001)155[0328:RBEOAI]2.0.CO;2
   YLIKOMI T, 1992, EMBO J, V11, P3681
   YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3
   YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H
   Zammit C, 2001, J PATHOL, V194, P27, DOI 10.1002/path.846                                                                
   Zeng FQ, 2006, BIOCONJUGATE CHEM, V17, P399, DOI 10.1021/bc050350g
   Zhang YM, 2006, NUCL MED BIOL, V33, P263, DOI 10.1016/j.nucmedbio.2005.10.009
   Zhang Yu-Min, 2003, Mol Imaging Biol, V5, P240, DOI 10.1016/S1536-1632(03)00106-9
   ZUTTER M, 1991, BLOOD, V78, P1062
NR 141
TC 44
Z9 44
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084-9785
EI 1557-8852
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD FEB
PY 2008
VL 23
IS 1
BP 3
EP 24
DI 10.1089/cbr.2007.0430
PG 22
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA 274TT
UT WOS:000254025100002
PM 18298325
DA 2018-01-05
ER

PT J
AU Grande, F
   Garofalo, A
   Neamati, N
AF Grande, Fedora
   Garofalo, Antonio
   Neamati, Nouri
TI Small molecules anti-HIV therapeutics targeting CXCR4
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE HIV infection; chemokine receptors; CXCR4 antagonists
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4; MEDIATED
   ANTI-S(N)2' REACTIONS; CYCLIC TETRAPEPTIDE-SCAFFOLDS; BIOAVAILABLE CCR5
   ANTAGONIST; CELL-DERIVED FACTOR-1-ALPHA; BREAST-CANCER METASTASIS;
   BIOLOGICAL EVALUATION; RHEUMATOID-ARTHRITIS; ENTRY INHIBITORS
AB HIV cellular entry is a multistep process that requires the interaction of a viral envelope glycoprotein (gp120) and a host receptor (CD4) followed by binding to a co-receptor. The CC-chemokine receptor 5 (CCR5) and CXC-chemokine receptor 4 (CXCR4) have been identified as the major HIV co-receptors and therefore are promising targets for the development of new anti-HIV drugs. CXCR4 is also involved in several diseases such as angiogenesis, metabolic and neurological disorders, rheumatoid arthritis and in different forms of metastatic cancer. Herein, we present a review focusing on small molecule CXCR4 antagonists. These compounds are divided into 11 classes that include cyclic penta- and tetrapeptides, diketopiperazine mimetics, bicyclams, non-bicyclams, tetrahydroquinolines, thiazolylisothiourea derivatives, benzodiazepines, alkyl amine analogs and non-peptides derivatives, dipicolylamine-zinc(II) complexes, ampelopsin and distamycin analogs. The most advanced CXCR4 antagonists documented are bicyclam derivatives, which are specific CXCR4 antagonists and exhibit potency in the nanomolar range. Further development of selective CXCR4 antagonists continues to be crucial for the design of second generation of anti-HIV drugs. We aim to provide a comprehensive summary of diverse structural templates that could be useful for optimization and discovery of novel CXCR4 antagonists.
C1 [Grande, Fedora; Neamati, Nouri] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.
   [Garofalo, Antonio] Univ Calabria, Dipartimento Sci Farmaceut, I-87036 Arcavacata Di Rende, Italy.
RP Neamati, N (reprint author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.
EM neamati@usc.edu
RI Liu, Deyu/G-5665-2012; garofalo, antonio/E-9964-2011
OI garofalo, antonio/0000-0003-1337-5509; Grande,
   Fedora/0000-0002-6154-4330
CR Agrawal L, 2006, CURR PHARM DESIGN, V12, P2031, DOI 10.2174/138161206777442100
   Arakaki R, 1999, J VIROL, V73, P1719
   Bajetto A, 1999, ANN NY ACAD SCI, V876, P201, DOI 10.1111/j.1749-6632.1999.tb07640.x                                              
   Balzarini J, 2001, ANTIVIR CHEM CHEMOTH, V12, P301, DOI 10.1177/095632020101200505                                                      
   Berson JF, 1996, J VIROL, V70, P6288
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925
   Borthwick AD, 2005, J MED CHEM, V48, P6956, DOI 10.1021/jm050557v
   Bourgeois R, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-31
   Breslin HJ, 1999, BIOORGAN MED CHEM, V7, P2427, DOI 10.1016/S0968-0896(99)00198-4                                                   
   Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423                                                     
   Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097
   CBR institute for biomedical research Inc, 2006, [No title captured], Patent No. [2006116185, WO2006116185]
   Cervia JS, 2003, CLIN INFECT DIS, V37, P1102, DOI 10.1086/378302
   Choi WT, 2005, J VIROL, V79, P15398, DOI 10.1128/JVI.79.24.15398-15404.2005
   Citterio P, 2007, EXPERT OPIN INV DRUG, V16, P11, DOI 10.1517/13543784.16.1.11
   CLANTON DJ, 1995, ANTIVIR RES, V27, P335, DOI 10.1016/0166-3542(95)00017-G
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Daelemans D, 2000, MOL PHARMACOL, V57, P116
   Davies SL, 2007, DRUG FUTURE, V32, P123, DOI 10.1358/dof.2007.032.02.1071897
   DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668                                                            
   Decaudin D, 2004, ANTI-CANCER DRUG, V15, P737, DOI 10.1097/00001813-200409000-00001
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286                                                         
   Delcroix-Genete D, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-16
   Delobel P, 2005, JAIDS-J ACQ IMM DEF, V38, P382, DOI 10.1097/01.qai.0000152835.17747.47
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Deng JX, 2006, EXPERT OPIN THER PAT, V16, P165, DOI 10.1517/13543776.16.2.165
   Doms RW, 2000, VIROLOGY, V276, P229, DOI 10.1006/viro.2000.0612
   Donkor IO, 2001, BIOORG MED CHEM LETT, V11, P2647, DOI 10.1016/S0960-894X(01)00524-8
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395
   Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.14053
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fujii N, 2003, ANGEW CHEM INT EDIT, V42, P3251, DOI 10.1002/anie.200351024
   Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/eoid.12.2.185.21405
   Garred P, 1997, LANCET, V349, P1884, DOI 10.1016/S0140-6736(05)63874-3
   Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200                                                          
   Gregson SJ, 2001, J MED CHEM, V44, P737, DOI 10.1021/jm001064n
   Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171                                                         
   Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621                                                          
   Harvey JR, 2007, CLIN CANCER RES, V13, P1562, DOI 10.1158/1078-0432.CCR-06-1987
   Hatse S, 2005, BIOCHEM PHARMACOL, V70, P752, DOI 10.1016/j.bcp.2005.05.035
   Hatse S, 2001, MOL PHARMACOL, V60, P164
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   Howard OMZ, 1998, J MED CHEM, V41, P2184, DOI 10.1021/jm9801253                                                               
   Howard OMZ, 1998, J LEUKOCYTE BIOL, V64, P6
   Ichiyama K, 2003, P NATL ACAD SCI USA, V100, P4185, DOI 10.1073/pnas.0630420100
   Jenkins CL, 2005, ORG LETT, V7, P2619, DOI 10.1021/ol050780m
   Jensen MA, 2003, J VIROL, V77, P13376, DOI 10.1128/JVI.77.24.13376-13388.2003
   JOAO HC, 1995, J MED CHEM, V38, P3865, DOI 10.1021/jm00019a017
   Juarez J, 2004, CURR PHARM DESIGN, V10, P1245, DOI 10.2174/1381612043452640
   Kamal A, 2002, J MED CHEM, V45, P4679, DOI 10.1021/jm020124h
   Kamal Ahmed, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P215, DOI 10.2174/1568011023354119
   Kazmierski WM, 2006, CHEM BIOL DRUG DES, V67, P13, DOI 10.1111/j.1747-0285.2005.00319.x
   Labrosse B, 1998, J VIROL, V72, P6381
   Lack NA, 2005, CLIN PHARMACOL THER, V77, P427, DOI 10.1016/j.clpt.2004.12.268
   Lehmann C, 2006, J CLIN VIROL, V37, P300, DOI 10.1016/j.jcv.2006.08.008
   Leonard JT, 2006, CURR MED CHEM, V13, P911, DOI 10.2174/092986706776361030
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027                                                       
   Liang XY, 2002, J AM CHEM SOC, V124, P9105, DOI 10.1021/ja0260723
   Liu De-yu, 2003, Zhongguo Zhongyao Zazhi, V28, P957
   Liu DY, 2004, BIOMED ENVIRON SCI, V17, P153
   Lo TCM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-S1-P58
   Louie M, 2002, ANTIVIR RES, V55, P15, DOI 10.1016/S0166-3542(02)00022-0
   Luo Gao-qin, 2006, Zhong Yao Cai, V29, P146
   Maas JJJ, 2000, AIDS, V14, P1155, DOI 10.1097/00002030-200006160-00012                                                
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   Markovic I, 2006, CURR PHARM DESIGN, V12, P1105, DOI 10.2174/138161206776055822
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686                                                     
   Meanwell NA, 2003, CURR OPIN DRUG DI DE, V6, P451
   Meanwell NA, 2007, CURR OPIN INVEST DR, V8, P669
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Mild M, 2007, J VIROL, V81, P3369, DOI 10.1128/JVI.01295-06
   Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060                                                                
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   MURAKAMI T, 2004, TOPICS HIV MED, P541
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   Niida A, 2006, J ORG CHEM, V71, P3942, DOI 10.1021/jo060390t
   Niida A, 2005, TETRAHEDRON LETT, V46, P4183, DOI 10.1016/j.tetlet.2005.04.057
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Ojida A, 2002, J AM CHEM SOC, V124, P6256, DOI 10.1021/ja025761b
   Palani A, 2003, BIOORG MED CHEM LETT, V13, P705, DOI 10.1016/S0960-894X(02)01062-4
   Pohlmann S, 2006, CURR PHARM DESIGN, V12, P1963, DOI 10.2174/138161206777442155
   Princen K, 2005, CYTOKINE GROWTH F R, V16, P659, DOI 10.1016/j.cytogfr.2005.05.009
   Princen K, 2003, CYTOM PART A, V51A, P35, DOI 10.1002/cyto.a.10008
   Raboisson P, 2005, BIOORG MED CHEM LETT, V15, P1857, DOI 10.1016/j.bmcl.2005.02.018
   Regoes RR, 2005, TRENDS MICROBIOL, V13, P269, DOI 10.1016/j.tim.2005.04.005
   Rosen O, 2006, P NATL ACAD SCI USA, V103, P13950, DOI 10.1073/pnas.0606312103
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8
   Schols D, 2004, CURR TOP MED CHEM, V4, P883, DOI 10.2174/1568026043388501
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Schols D, 2006, CURR OPIN HIV AIDS, V1, P361, DOI 10.1097/01.COH.0000239847.13205.ce
   Schols D, 2006, ANTIVIR RES, V71, P216, DOI 10.1016/j.antiviral.2006.04.009
   Schwarz M, 2001, RECEPTOR CHANNEL, V7, P417
   Scotton CJ, 2001, CANCER RES, V61, P4961
   Scotton CJ, 2002, CANCER RES, V62, P5930
   Scozzafava A, 2002, J ENZYM INHIB MED CH, V17, P69, DOI 10.1080/14756360290024227
   Seibert C, 2004, CURR PHARM DESIGN, V10, P2041, DOI 10.2174/1381612043384312
   Shaheen F, 2004, CURR OPIN INFECT DIS, V17, P7, DOI 10.1097/01.qco.0000113643.29255.5c
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Spoo AC, 2007, BLOOD, V109, P786, DOI 10.1182/blood-2006-05-024844
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   SUMNERSMITH M, 1995, DRUG EXP CLIN RES, V21, P1
   Tagat JR, 2004, J MED CHEM, V47, P2405, DOI 10.1021/jm0304515
   Tamamura H, 2003, J MED CHEM, V46, P1764, DOI 10.1021/jm020537i
   Tamamura H, 2005, CURR HIV RES, V3, P289, DOI 10.2174/157016205774370429
   Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7
   Tamamura H, 2004, FEBS LETT, V569, P99, DOI 10.1016/j.febslet.2004.05.056
   Tamamura H, 2002, BIOORG MED CHEM LETT, V12, P923, DOI 10.1016/S0960-894X(02)00041-0
   Tamamura H, 2005, EXPERT OPIN THER TAR, V9, P1267, DOI 10.1517/14728222.9.6.1267
   Tamamura H, 2005, J MED CHEM, V48, P380, DOI 10.1021/jm0494239h
   Tamamura H, 2005, J MED CHEM, V48, P3280, DOI 10.1021/jm050009h
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Tamamura H, 2007, CURR MED CHEM, V14, P93, DOI 10.2174/092986707779313499                                                      
   Tamamura H, 2006, J MED CHEM, V49, P3412, DOI 10.1021/jm060025u
   Tamamura Hirokazu, 2004, Current Drug Targets - Infectious Disorders, V4, P103, DOI 10.2174/1568005043340957
   Tian SM, 2005, J VIROL, V79, P12667, DOI 10.1128/JVI.79.20.12667-12673.2005
   Tsibris AMN, 2007, ANNU REV MED, V58, P445, DOI 10.1146/annurev.med.58.080105.102908
   Ueda S, 2007, J MED CHEM, V50, P192, DOI 10.1021/jm0607350
   UNAIDS: Joint United Nations Programme on HIV/AIDS, 2006, REP GLOB AIDS EP 200
   Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200
   Valks GC, 2006, J MED CHEM, V49, P6162, DOI 10.1021/jm0607810
   Verani Alessia, 2002, Current Molecular Medicine (Hilversum), V2, P691, DOI 10.2174/1566524023361862
   Westby M, 2006, J VIROL, V80, P4909, DOI 10.1128/JVI.80.10.4909-4920.2006
   Wipf P, 2005, ORG LETT, V7, P103, DOI 10.1021/ol0477529
   Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6
   Yang LH, 2007, CANCER RES, V67, P651, DOI 10.1158/0008-5472.CAN-06-2762
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6                                                   
   Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406                                                   
   Zeng Sa, 2006, Zhong Yao Cai, V29, P260
   Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200
   BRIDGER GJ, 2000, Patent No. 2000002870
   LUENGO J, 2000, Patent No. 2000066112
   KOKUBO M, 2007, Patent No. 2007058322
   SHIM H, 2006, Patent No. 2006074426
   BRIDGER GJ, 2002, Patent No. 2002034745
   GUDMUNDSSON K, 2006, Patent No. 2006076131
   MAKINO T, 1999, Patent No. 199923069
   WU CH, 2006, Patent No. 2006160860
   LAPIDOT T, 2007, Patent No. 2007074456
   BRIDGER GJ, 2002, Patent No. 2002022599
   DUAN M, 2004, Patent No. 2004054581
   GUDMUNDSSON K, 2006, Patent No. 2006020415
   GLICKMAN F, 2005, Patent No. 2005085219
   YEN CF, 2006, Patent No. 2006160860
   GUDMUNDSSON K, 2007, Patent No. 2007008539
   KOKUBO M, 2007, Patent No. 2007049771
   BRIDGER GJ, 2000, Patent No. 2000056729
   YOUNGMAN M, 2004, Patent No. 2004055012
   AQUINO CJ, 2004, Patent No. 2004055011
   GUDMUNDSSON K, 2006, Patent No. 2006023400
   Kazmierski W. M., 2004, Application, Patent No. [PCT 2004054974, 2004054974, WO 2004054974]
   YAMAZAKI T, 2003, Patent No. 2003029218
   SHIM H, 2004, Patent No. 2004087068
   YAMAZAKI T, 2004, Patent No. 2004024697
   BRIDGER GJ, 2001, Patent No. 2001044229
   CRAWFORD JB, 2006, Patent No. 20060069122
   2006, CANC WEEKLY
   FUJII N, 2007, Patent No. 2007074871
   BRIDGER GJ, 2004, Patent No. 20040171638
   ZUMBRUNN J, 2004, Patent No. 2004096839
   Gudmundsson K., 2006, PCT Int. Appl., Patent No. [WO2006026703, 2006026703]
   GUDMUNDSSON K, 2006, Patent No. 2006096444
   OPLINGER JA, 1995, Patent No. 1995009619
   BACHMAN M, 2006, Patent No. 2006138304
   GSK, 2004, Patent No. 2004055016
   CRAWFORD JB, 2005, Patent No. 20050209277
   PECKHAM JP, 2004, Patent No. 2004055010
   GUDMUNDSSON K, 2006, Patent No. 2006036816
   MARSHALL G, 2005, Patent No. 20050192272
NR 173
TC 29
Z9 31
U1 1
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2008
VL 14
IS 4
BP 385
EP 404
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 274XW
UT WOS:000254037100009
PM 18289065
DA 2018-01-05
ER

PT J
AU Hermann, GE
   Van Meter, MJ
   Rogers, RC
AF Hermann, Gerlinda E.
   Van Meter, Montina J.
   Rogers, Richard C.
TI CXCR4 receptors in the dorsal medulla: implications for autonomic
   dysfunction
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE chemokines; gastric; hindbrain; vagus
ID CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA;
   NUCLEUS-TRACTUS-SOLITARIUS; GASTRIC RELAXATION REFLEX; ADULT-RAT BRAIN;
   VAGAL COMPLEX; MOTOR NUCLEUS; CHEMOKINE RECEPTORS; DENTATE GYRUS
AB The chemokine receptor, CXCR4, plays an essential role in guiding neural development of the CNS. Its natural agonist, CXCL12 [or stromal cell-derived factor-1 (SDF-1)], normally is derived from stromal cells, but is also produced by damaged and virus-infected neurons and glia. Pathologically, this receptor is critical to the proliferation of the HIV virus and initiation of metastatic cell growth in the brain. Anorexia, nausea and failed autonomic regulation of gastrointestinal (GI) function cause morbidity and contribute to the mortality associated with these disease states. Our previous work on the peripheral cytokine, tumor necrosis factor-alpha, demonstrated that similar morbidity factors involving GI dysfunction are attributable to agonist action on neural circuit elements of the dorsal vagal complex (DVC) of the hindbrain. The DVC includes vagal afferent terminations in the solitary nucleus, neurons in the solitary nucleus (NST) and area postrema, and visceral efferent motor neurons in the dorsal motor nucleus (DMN) that are responsible for the neural regulation of digestive functions from the oral cavity to the transverse colon. Immunohistochemical techniques demonstrate a dense concentration of CXCR4 receptors on neurons throughout the DVC and the hypoglossal nucleus. CXCR4-immunoreactivity is also intense on microglia within the DVC, though not on the astrocytes. Physiological studies show that nanoinjection of SDF-1 into the DVC produces a significant reduction in gastric motility in parallel with an elevation in the numbers of cFOS-activated neurons in the NST and DMN. These results suggest that this chemokine receptor may contribute to autonomically mediated pathophysiological events associated with CNS metastasis and infection.
C1 [Hermann, Gerlinda E.; Van Meter, Montina J.; Rogers, Richard C.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
RP Rogers, RC (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
EM Richard.Rogers@pbrc.edu
RI Hermann, Gerlinda/N-1967-2017
OI Hermann, Gerlinda/0000-0003-0405-2820
FU NIDDK NIH HHS [R01 DK052142, R01 DK056373, DK52142, DK56373]; NICHD NIH
   HHS [HD047643, R21 HD047643]
CR Andrews PLR, 2006, AUTON NEUROSCI-BASIC, V125, P100, DOI 10.1016/j.autneu.2006.01.008
   ANDREWS PLR, 1990, CAN J PHYSIOL PHARM, V68, P325, DOI 10.1139/y90-047                                                                 
   ARMSTRONG DM, 1990, J CHEM NEUROANAT, V3, P133
   Banisadr G, 2003, EUR J NEUROSCI, V18, P1593, DOI 10.1046/j.1460-9568.2003.02893.x
   Banisadr G, 2002, EUR J NEUROSCI, V16, P1661, DOI 10.1046/j.1460-9568.2002.02237.x
   Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3
   Blessing WW, 1997, LOWER BRAINSTEM BODI, P323
   BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059                                                          
   BUELKESAM J, 1978, LAB ANIM SCI, V28, P157
   Chalasani SH, 2003, J NEUROSCI, V23, P1360
   CUELLO AC, 1983, Q J EXP PHYSIOL CMS, V68, P545, DOI 10.1113/expphysiol.1983.sp002748                                                
   DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x                                              
   Elenkov IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104
   Fong AY, 2005, J COMP NEUROL, V493, P274, DOI 10.1002/cne.20758
   Gabuzda D, 2000, J NEUROVIROL, V6, pS24
   Glabinski AR, 2000, ANN NY ACAD SCI, V917, P135
   Grill HJ, 2002, FRONT NEUROENDOCRIN, V23, P2, DOI 10.1006/frne.2001.0224
   GROSS PM, 1990, AM J PHYSIOL, V259, pR1131
   Guo JFJ, 2001, AM J PHYSIOL-GASTR L, V280, pG361
   HERMANN G, 1995, NEUROIMMUNOMODULAT, V2, P74, DOI 10.1159/000096874
   Hermann GE, 1999, AM J PHYSIOL-REG I, V276, pR59
   Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414
   Hermann GE, 2006, AM J PHYSIOL-REG I, V290, pR1570, DOI 10.1152/ajpregu.00717.2005
   Hermann GE, 2005, J PHYSIOL-LONDON, V562, P553, DOI 10.1113/jphysiol.2004.076919
   Hermann GE, 2005, CURR PHARM DESIGN, V11, P1391, DOI 10.2174/1381612053507828
   Hermann GE, 2001, AM J PHYSIOL-REG I, V280, pR289
   Hornbuckle K, 2000, J CLIN GASTROENTEROL, V30, P117, DOI 10.1097/00004836-200003000-00004                                                
   KALIA M, 1984, NEUROSCI LETT, V50, P57, DOI 10.1016/0304-3940(84)90462-2
   Kanmogne Georgette D, 2007, J Cereb Blood Flow Metab, V27, P123, DOI 10.1038/sj.jcbfm.9600330
   Knaut H, 2005, NEURON, V47, P653, DOI 10.1016/j.neuron.2005.07.014
   Krowicki ZK, 1999, J AUTONOM NERV SYST, V77, P83, DOI 10.1016/S0165-1838(99)00033-8
   Krowicki ZK, 1997, J COMP NEUROL, V377, P49, DOI 10.1002/(SICI)1096-9861(19970106)377:1<49::AID-CNE6>3.0.CO;2-J
   Lagman RL, 2005, SURG CLIN N AM, V85, P237, DOI 10.1016/j.suc.2004.11.004
   LANG IM, 1990, CAN J PHYSIOL PHARM, V68, P242, DOI 10.1139/y90-038                                                                 
   Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139
   Li GN, 2005, DEV NEUROSCI-BASEL, V27, P93, DOI 10.1159/000085980
   Lieberam I, 2005, NEURON, V47, P667, DOI 10.1016/j.neuron.2005.08.011
   Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799
   MANIER M, 1987, NEUROSCI LETT, V80, P141, DOI 10.1016/0304-3940(87)90643-4
   MCCANN MJ, 1988, J AUTONOM NERV SYST, V25, P35, DOI 10.1016/0165-1838(88)90005-7
   Miller AD, 1999, DIGEST DIS SCI, V44, p39S
   Morrow GR, 2002, SUPPORT CARE CANCER, V10, P96, DOI 10.1007/s005200100294
   NORRIS PJ, 1995, HISTOCHEM J, V27, P745
   ORMSBEE HS, 1976, AM J PHYSIOL, V230, P389
   Plata-Salaman CR, 2000, NUTRITION, V16, P1009, DOI 10.1016/S0899-9007(00)00413-5
   Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2
   RINAMAN L, 1993, J COMP NEUROL, V338, P475, DOI 10.1002/cne.903380402
   Rogers RC, 2003, AM J PHYSIOL-REG I, V285, pR479, DOI 10.1152/ajpregu.00155.2003
   ROGERS RC, 1985, PEPTIDES, V6, P1143, DOI 10.1016/0196-9781(85)90441-3
   ROGERS RC, 2005, PHYSL GASTROINTESTIN, P851
   Rogers RC, 2006, J NEUROSCI, V26, P12642, DOI 10.1523/JNEUROSCI.3530-06.2006
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   TAKAYAMA K, 1994, NEUROSCI LETT, V176, P59, DOI 10.1016/0304-3940(94)90871-0
   Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082                                                           
   Wu DT, 2000, J NEUROVIROL, V6, pS82
   Zheng ZL, 1999, NEUROSCIENCE, V90, P685, DOI 10.1016/S0306-4522(98)00586-7
NR 56
TC 6
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD FEB
PY 2008
VL 27
IS 4
BP 855
EP 864
DI 10.1111/j.1460-9568.2008.06058.x
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 272UP
UT WOS:000253886100006
PM 18333961
OA green_accepted
DA 2018-01-05
ER

PT J
AU Choi, SU
   Bui, T
   Ho, RJY
AF Choi, Sung-Up
   Bui, Tot
   Ho, Rodney J. Y.
TI pH-dependent interactions of indinavir and lipids in nanoparticlies and
   their ability to entrap a solute
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE indinavir; PMPA; lipid-indinavir interaction; pH-dependent release; drug
   delivery; drug incorporation
ID TARGET-SENSITIVE IMMUNOLIPOSOMES; IMMUNODEFICIENCY-VIRUS-INFECTION;
   HIV-1 PROTEASE INHIBITORS; X-RAY-DIFFRACTION; ANTIRETROVIRAL THERAPY;
   LYMPHOID-TISSUES; NUCLEOSIDE ANALOGS; VIRAL LOAD; REPLICATION;
   METABOLISM
AB We have investigated the ability of lipid-indinavir particles composed of 3-to- 1 lipid-drug molar ratio to encapsulate an aqueous marker calcein and anti-HIV drug H-3-phosphonylmethoxypropyl-adenine (PMPA). Even at a high density of indinavir associated to lipid-indinavir nanoparticles, they form an enclosed lipid membrane that allows encapsulation of calcein and PMPA in an aqueous compartment. At neutral pH, practically all indinavir was incorporated into lipid bilayer and lipid associated indinavir can be dissociated with half-maximum pH recorded between 5.2 and 5.5. pH-Dependent release of indinavir did not influence calcein release significantly. However, pH-dependent release of indinavir affected PMPA release. By lowering pH, PMPA release was enhanced in the presence of indinavir in the lipid bilayer. Collectively, these data indicate that indinavir incorporated in lipid particles provides (1) stable bilayers capable of encapsulating other hydrophilic drugs, (2) ability to dissociate indinavir (which is acid stable) from lipid membranes, by lowering the pH, and (3) enabling enhancement in pH-dependent release of aqueous contents. However, the degree of pH-dependent release could be related to the charge and size of an aqueous molecule. (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
C1 [Choi, Sung-Up; Bui, Tot; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
FU NHLBI NIH HHS [HL 56548]; NINDS NIH HHS [NS 39178]; NCRR NIH HHS [RR
   00166]; NIGMS NIH HHS [GM 62883]; NIEHS NIH HHS [ES 07033]; NIAID NIH
   HHS [AI 52663]
CR BABBITT B, 1984, BIOCHEMISTRY-US, V23, P3920, DOI 10.1021/bi00312a020
   BALASUBRAMANIAN SV, 1994, BIOCHEMISTRY-US, V33, P8941, DOI 10.1021/bi00196a011
   Brodie SJ, 2000, J LEUKOCYTE BIOL, V68, P351
   Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Choo EF, 2000, DRUG METAB DISPOS, V28, P655
   Eisenberg EJ, 2001, NUCLEOS NUCLEOT NUCL, V20, P1091, DOI 10.1081/NCN-100002496                                                           
   GRUNER SM, 1988, BIOCHEMISTRY-US, V27, P2853, DOI 10.1021/bi00408a029                                                             
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   HO RJY, 1986, BIOCHEMISTRY-US, V25, P5500, DOI 10.1021/bi00367a023
   HO RJY, 1987, J BIOL CHEM, V262, P13979
   HO RJY, 2003, ADV DRUG DELIVERY BI, pP17
   Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545                                                         
   Kevin NJ, 2003, BIOORG MED CHEM LETT, V13, P4027, DOI 10.1016/j.bmcl.2003.08.049
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   KOYAMA TM, 1999, CHEM ED, V4, P12
   LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030                                                             
   LIN JH, 1995, DRUG METAB DISPOS, V23, P730
   Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
   Lindner LH, 2004, CLIN CANCER RES, V10, P2168, DOI 10.1158/1078-0432.CCR-03-0035
   ONCEL M, 1990, INT OPHTHALMOL, V14, P245, DOI 10.1007/BF00159859
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   POTTEL H, 1983, BIOCHIM BIOPHYS ACTA, V730, P181, DOI 10.1016/0005-2736(83)90331-0
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612
   Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001                                                
   SHINITZKY M, 1971, BIOCHEMISTRY-US, V10, P2106
   Slepushkin VA, 1997, J BIOL CHEM, V272, P2382
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   TURNER DC, 1992, BIOCHEMISTRY-US, V31, P1340, DOI 10.1021/bi00120a009                                                             
   van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472
   Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   WRIGHT KM, 1994, J EXP BOT, V45, P35, DOI 10.1093/jxb/45.1.35                                                             
NR 35
TC 31
Z9 31
U1 2
U2 7
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0022-3549
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD FEB
PY 2008
VL 97
IS 2
BP 931
EP 943
DI 10.1002/jps.21020
PG 13
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 257SC
UT WOS:000252817800023
PM 17546665
DA 2018-01-05
ER

PT J
AU Murakami, T
   Tsuchida, K
AF Murakami, Tatsuya
   Tsuchida, Kunihiro
TI Recent advances in inorganic nanoparticle-based drug delivery systems
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE nanomedicine; drug delivery; gene delivery; drug carrier; iron oxide
   nanoparticle; gold nanoparticle; fullerene; carbon nanohorn
ID SUPERPARAMAGNETIC IRON-OXIDE; WALL CARBON NANOHORNS; CATIONIC FULLERENE
   DERIVATIVES; BREAST-CANCER CELLS; MRI CONTRAST AGENTS; ANTI-HIV
   PROPERTIES; GOLD NANOPARTICLES; IN-VIVO; MAGNETITE NANOPARTICLES; GENE
   DELIVERY
AB Drug delivery systems, designed to enhance drug efficacy and reduce their adverse effects, have evolved accompanied by the development of novel materials. Nanotechnology is an emerging scientific area that has created a variety of intriguing inorganic nanoparticles. In this review, we focus on the feasibility of inorganic nanoparticles, including iron oxide nanoparticles, gold nanoparticles, fullerenes and carbon nanohorns, as drug carriers, and summarize recent advances in this field.
C1 [Murakami, Tatsuya; Tsuchida, Kunihiro] Fujita Hlth Univ, Div Therapies Interactable Dis, Inst Comprehens Med Sci, Aichi 4701192, Japan.
RP Tsuchida, K (reprint author), Fujita Hlth Univ, Div Therapies Interactable Dis, Inst Comprehens Med Sci, 1-98 Dengakugakubo, Aichi 4701192, Japan.
EM tsuchida@fujita-hu.ac.jp
CR ADLERMOORE J, 1994, BONE MARROW TRANSPL, V14, pS3
   Ajima K, 2006, J PHYS CHEM B, V110, P5773, DOI 10.1021/jp056813x
   Ajima K, 2004, ADV MATER, V16, P397, DOI 10.1002/adma.200306142
   Ajima K, 2005, MOL PHARMACEUT, V2, P475, DOI 10.1021/mp0500566
   Alexiou C, 2000, CANCER RES, V60, P6641
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Barratt G, 2003, CELL MOL LIFE SCI, V60, P21, DOI 10.1007/s000180300002                                                           
   Bergen JM, 2006, MACROMOL BIOSCI, V6, P506, DOI 10.1002/mabi.200600075
   Bolskar RD, 2003, J AM CHEM SOC, V125, P5471, DOI 10.1021/ja03400984
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chen J, 2005, NANO LETT, V5, P473, DOI 10.1021/nl047950t
   CHEN LT, 1973, BLOOD, V41, P529
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Cuenca AG, 2006, CANCER, V107, P459, DOI 10.1002/cncr.22035
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   FARADAY M, 1957, PHILOS T R SOC LONDO, V14, P137
   FINKELSTEIN AE, 1976, ANN RHEUM DIS, V35, P251, DOI 10.1136/ard.35.3.251
   Fiorito S, 2006, J NANOSCI NANOTECHNO, V6, P591, DOI 10.1166/jnn.2006.125
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Gonzalez KA, 2002, BIOORGAN MED CHEM, V10, P1991, DOI 10.1016/S0968-0896(02)00049-4                                                   
   Gu HW, 2003, NANO LETT, V3, P1261, DOI 10.1021/nl034396z
   GUPTA AK, 1993, MICROSPHERES REDIONA, P1
   Hashimoto A, 2004, P NATL ACAD SCI USA, V101, P8527, DOI 10.1073/pnas.0400596101
   Hillyer JF, 1998, MICROSC MICROANAL, V4, P481, DOI 10.1017/S143192769898045X
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Iijima S, 1999, CHEM PHYS LETT, V309, P165, DOI 10.1016/S0009-2614(99)00642-9
   Ikuta Y, 2002, BLOOD, V99, P3717, DOI 10.1182/blood.V99.10.3717                                                       
   Isobe H, 2006, CHEM-ASIAN J, V1, P167, DOI 10.1002/asia.200600051
   Isobe H, 2006, ANGEW CHEM INT EDIT, V45, P6676, DOI 10.1002/anie.200601718
   Isobe H, 2006, MOL PHARMACEUT, V3, P124, DOI 10.1021/mp050068r
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Ito A, 2004, CANCER LETT, V212, P167, DOI 10.1016/j.canlet.2004.03.038
   Jain TK, 2005, MOL PHARMACEUT, V2, P194, DOI 10.1021/mp0500014
   Joshi HM, 2006, LANGMUIR, V22, P300, DOI 10.1021/la051982u
   Kawano T, 2006, J CONTROL RELEASE, V111, P382, DOI 10.1016/j.jconrel.2005.12.022
   Kerr JB, 1999, ATLAS FUNCTIONAL HIS
   KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0
   Kumar CSSR, 2004, J NANOSCI NANOTECHNO, V4, P245, DOI 10.1166/jnn.2004.085
   Larregina AT, 2001, GENE THER, V8, P608, DOI 10.1038/sj.gt.3301404                                                           
   Lubbe AS, 1996, CANCER RES, V56, P4694
   Lubbe AS, 1996, CANCER RES, V56, P4686
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mashino T, 2003, BIOORG MED CHEM LETT, V13, P4395, DOI 10.1016/j.bmcl.2003.09.040
   Mastrobattista E, 1999, ADV DRUG DELIVER REV, V40, P103, DOI 10.1016/S0169-409X(99)00043-5                                                   
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Michel SCA, 2002, RADIOLOGY, V225, P527, DOI 10.1148/radiol.2252011605
   Mirakyan AL, 2002, J CHEM SOC PERK T 2, P1173, DOI 10.1039/b200145d
   Miyawaki J, 2006, ADV MATER, V18, P1010, DOI 10.1002/adma.200502174
   Miyawaki J, 2006, J PHYS CHEM B, V110, P5179, DOI 10.1021/jp0607622
   Mizushima Y, 1993, J DRUG TARGET, V1, P93, DOI 10.3109/10611869308996065
   MOGHIMI SM, 1991, BIOCHEM BIOPH RES CO, V177, P861, DOI 10.1016/0006-291X(91)91869-E
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Mottram PL, 2003, IMMUNOL CELL BIOL, V81, P350, DOI 10.1046/j.1440-1711.2003.01184.x
   Muangmoonchai R, 2002, MOL BIOTECHNOL, V20, P145, DOI 10.1385/MB:20:2:145
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482                                                   
   Muralkami T, 2006, MOL PHARMACEUT, V3, P407, DOI 10.1021/mp060027a
   Muralkami T, 2004, MOL PHARMACEUT, V1, P399, DOI 10.1021/mp049928e
   Murata K, 2004, ADV MATER, V16, P1520, DOI 10.1002/adma.200400240
   Murata K, 2002, J PHYS CHEM B, V106, P11132, DOI 10.1021/jp020583u
   Murata K, 2001, J PHYS CHEM B, V105, P10210, DOI 10.1021/jp010754f
   Nguyen BC, 1999, JMRI-J MAGN RESON IM, V10, P468, DOI 10.1002/(SICI)1522-2586(199909)10:3<468::AID-JMRI31>3.3.CO;2-9
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Noble CO, 2004, EXPERT OPIN THER TAR, V8, P335, DOI 10.1517/14728222.8.4.335                                                        
   Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x                                              
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Okumura M, 2002, ACAD RADIOL, V9, pS495, DOI 10.1016/S1076-6332(03)80274-X                                                   
   Oldenburg SJ, 1998, CHEM PHYS LETT, V288, P243, DOI 10.1016/S0009-2614(98)00277-2
   Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895
   Petersen J, 1983, Scand J Rheumatol Suppl, V51, P28
   Pitsillides CM, 2003, BIOPHYS J, V84, P4023, DOI 10.1016/S0006-3495(03)75128-5                                                   
   Rajagopalan P, 1996, ANTIMICROB AGENTS CH, V40, P2262
   Rancan F, 2005, J PHOTOCH PHOTOBIO B, V80, P1, DOI 10.1016/j.jphotobiol.2005.01.007
   Ren L, 2003, MAT SCI ENG C-BIO S, V23, P113, DOI 10.1016/S0928-4931(02)00247-3                                                   
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Sayes CM, 2005, BIOMATERIALS, V26, P7587, DOI 10.1016/j.biomaterials.2005.05.027
   Sershen SR, 2000, J BIOMED MATER RES, V51, P293, DOI 10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
   Shinkai M, 2002, J BIOSCI BIOENG, V94, P606, DOI 10.1016/S1389-1723(02)80202-X
   Shinkai M, 1996, JPN J CANCER RES, V87, P1179, DOI 10.1111/j.1349-7006.1996.tb03129.x                                              
   Shinkai M, 2001, JPN J CANCER RES, V92, P1138, DOI 10.1111/j.1349-7006.2001.tb01070.x                                              
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/15287390390231566
   Sonvico F, 2005, BIOCONJUGATE CHEM, V16, P1181, DOI 10.1021/bc050050z
   STARK DD, 1988, RADIOLOGY, V168, P297, DOI 10.1148/radiology.168.2.3393649                                                 
   Tabata Y, 1997, JPN J CANCER RES, V88, P1108, DOI 10.1111/j.1349-7006.1997.tb00336.x                                              
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Tong XD, 2001, BIOTECHNOL PROGR, V17, P134, DOI 10.1021/bp000134g
   Toth E, 2005, J AM CHEM SOC, V127, P799, DOI 10.1021/ja044688h
   Tsao N, 1999, ANTIMICROB AGENTS CH, V43, P2273
   Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474                                                 
   WIDDER KJ, 1981, P NATL ACAD SCI-BIOL, V78, P579, DOI 10.1073/pnas.78.1.579
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209
   YANG NS, 1995, NAT MED, V1, P481, DOI 10.1038/nm0595-481
   Yudasaka M, 2003, CHEM PHYS LETT, V380, P42, DOI 10.1016/j.cplett.2003.08.095
   Yuge R, 2004, ADV MATER, V16, P1420, DOI 10.1002/adma.200400130                                                          
   Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525
   Zhang Y, 2005, J COLLOID INTERF SCI, V283, P352, DOI 10.1016/j.jcis.2004.09.042
NR 104
TC 49
Z9 52
U1 8
U2 51
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD FEB
PY 2008
VL 8
IS 2
BP 175
EP 183
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 276FD
UT WOS:000254125800010
PM 18289101
DA 2018-01-05
ER

PT J
AU Sowinski, S
   Jolly, C
   Berninghausen, O
   Purbhoo, MA
   Chauveau, A
   Kohler, K
   Oddos, S
   Eissmann, P
   Brodsky, FM
   Hopkins, C
   Onfelt, B
   Sattentau, Q
   Davis, DM
AF Sowinski, Stefanie
   Jolly, Clare
   Berninghausen, Otto
   Purbhoo, Marco A.
   Chauveau, Anne
   Koehler, Karsten
   Oddos, Stephane
   Eissmann, Philipp
   Brodsky, Frances M.
   Hopkins, Colin
   Oenfelt, Bjoern
   Sattentau, Quentin
   Davis, Daniel M.
TI Membrane nanotubes physically connect T cells over long distances
   presenting a novel route for HIV-1 transmission
SO NATURE CELL BIOLOGY
LA English
DT Article
ID DENDRITIC CELLS; IMMUNE CELLS; PROTEINS; SYNAPSE; REPLICATION;
   RETRACTION; FILOPODIA; INFECTION; FISSION; KINASE
AB Transmission of HIV-1 via intercellular connections has been estimated as 100-1000 times more efficient than a cell-free process, perhaps in part explaining persistent viral spread in the presence of neutralizing antibodies(1,2). Such effective intercellular transfer of HIV-1 could occur through virological synapses(3-5) or target-cell filopodia connected to infected cells(6). Here we report that membrane nanotubes, formed when T cells make contact and subsequently part, provide a new route for HIV-1 transmission. Membrane nanotubes are known to connect various cell types, including neuronal and immune cells(7-13), and allow calcium-mediated signals to spread between connected myeloid cells(9). However, T-cell nanotubes are distinct from open-ended membranous tethers between other cell types(7,12), as a dynamic junction persists within T-cell nanotubes or at their contact with cell bodies. We also report that an extracellular matrix scaffold allows T-cell nanotubes to adopt variably shaped contours. HIV-1 transfers to uninfected T cells through nanotubes in a receptor-dependent manner. These data lead us to propose that HIV-1 can spread using nanotubular connections formed by short-term intercellular unions in which T cells specialize.
C1 [Sowinski, Stefanie; Berninghausen, Otto; Purbhoo, Marco A.; Chauveau, Anne; Koehler, Karsten; Oddos, Stephane; Eissmann, Philipp; Hopkins, Colin; Davis, Daniel M.] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England.
   [Jolly, Clare; Sattentau, Quentin] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   [Brodsky, Frances M.] Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA.
   [Oenfelt, Bjoern] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.
RP Davis, DM (reprint author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.
EM d.davis@imperial.ac.uk
RI Jolly, Clare/A-4501-2013
OI Jolly, Clare/0000-0002-4603-2281; Brodsky, Frances/0000-0002-1334-9258;
   Davis, Daniel/0000-0002-9182-291X
FU Medical Research Council [G0500563, G0400453]; Biotechnology and
   Biological Sciences Research Council [BB/D011663/1]; Wellcome Trust;
   NIAID NIH HHS [P01-AI064520]
CR Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736
   Cramer LP, 1997, MOL BIOL CELL, V8, P109
   Daniels DR, 2007, LANGMUIR, V23, P6667, DOI 10.1021/la0635000
   Davis DM, 2007, NAT REV IMMUNOL, V7, P238, DOI 10.1038/nri2020
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002
   Favoreel HW, 2005, P NATL ACAD SCI USA, V102, P8990, DOI 10.1073/pnas.0409099102
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673
   Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7                                                   
   Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   La Boissiere S, 2004, J VIROL, V78, P8002, DOI 10.1128/JVI.78.15.8002-8014.2004
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236
   MITCHISON TJ, 1992, CELL MOTIL CYTOSKEL, V22, P135, DOI 10.1002/cm.970220207
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Roux A, 2006, NATURE, V441, P528, DOI 10.1038/nature04718
   Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.embroj.7601509
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5                                                   
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
NR 31
TC 382
Z9 391
U1 0
U2 40
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD FEB
PY 2008
VL 10
IS 2
BP 211
EP 219
DI 10.1038/ncb1682
PG 9
WC Cell Biology
SC Cell Biology
GA 258VO
UT WOS:000252897800017
PM 18193035
DA 2018-01-05
ER

PT J
AU Schaffer, P
   Gleave, JA
   Lemon, JA
   Reid, LC
   Pacey, LKK
   Farncombe, TH
   Boreham, DR
   Zubieta, J
   Babich, JW
   Doering, LC
   Valliant, JF
AF Schaffer, Paul
   Gleave, Jacqueline A.
   Lemon, Jennifer A.
   Reid, Leslie C.
   Pacey, Laura K. K.
   Farncombe, Troy H.
   Boreham, Douglas R.
   Zubieta, Jon
   Babich, John W.
   Doering, Laurie C.
   Valliant, John F.
TI Isostructural fluorescent and radioactive probes for monitoring neural
   stem and progenitor cell transplants
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Review
DE neurospheres; imaging; technetium; transplants; peptide
ID IN-VIVO TRACKING; TAT-PEPTIDE; MAGNETIC NANOPARTICLES;
   MYOCARDIAL-INFARCTION; COMET ASSAY; BIOMOLECULES; COMPLEXES; APOPTOSIS;
   THERAPY; TC-99M
AB A construct for tagging neurospheres and monitoring cell transplantations was developed using a new technology for producing luminescent and radiolabeled probes that have identical structures. The HIV I -Tat basic domain derivatives NAcGRKKRRQRRR(SAACQ)G (SAACQ-1) and [NAeGRKKRRQRRR(Re(CO)(3)SAACQ)G](+) (ReSAACQ-1) were prepared in excellent yields using the single amino acid chelate-quinoline (SAACQ) ligand and its Re(I) complex and conventional automated peptide synthesis methods. The distribution of the luminescent Re probe, using epifluorescence microscopy, showed that it localized primarily in the cell nucleus with a significant degree of association on the nuclear envelope. A smaller amount was found to be dispersed in the cytoplasm. The Tc-99m analogue was then prepared in 43 +/- 7% (n=12) yield and very high effective specific activity. Following incubation, average uptake of the probe in neurospheres ranged between 10 and 20 Bq/cell. As determined by colorimetric assays, viability for cells labeled with high effective specific activity (99m)TcSAACQ-1 was 97 +/- 4% at 2 h postlabeling and 85 +/- 25% at 24 h postlabeling for incubation activities ranging from 245 to 8900 Bq/cell. DNA analysis showed that at these levels, there was no significant difference between the extent of DNA damage in the treated cells versus control cells. A series of preliminary SPECT/CT studies of transplants in mice were performed, which showed that the strategy is convenient and feasible and that it is possible to routinely assess procedures noninvasively and determine the number of cells transplanted. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Reid, Leslie C.; Valliant, John F.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada.
   [Schaffer, Paul] McMaster Univ, McMaster Nucl Reactor, Hamilton, ON L8S 4K1, Canada.
   [Gleave, Jacqueline A.; Pacey, Laura K. K.; Doering, Laurie C.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada.
   [Lemon, Jennifer A.; Boreham, Douglas R.; Valliant, John F.] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8S 4K1, Canada.
   [Farncombe, Troy H.] Hamilton Hlth Sci, Dept Nucl Med, Hamilton, ON L8N 3Z5, Canada.
   [Zubieta, Jon] Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.
   [Babich, John W.] Mol Insight Pharmaceut Inc, Cambridge, MA 02142 USA.
RP Valliant, JF (reprint author), McMaster Univ, Dept Chem, 1280 Main St, Hamilton, ON L8S 4M1, Canada.
EM valliant@mcmaster.ca
OI Lemon, Jennifer/0000-0002-3910-5438; Pacey, Laura/0000-0003-4787-7136
CR Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9
   Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t                                                               
   ATHERTON E, 1985, J CHEM SOC PERK T 1, P2065, DOI 10.1039/p19850002065
   Bai JZ, 2004, NEUROREPORT, V15, P1117, DOI 10.1097/01.wnr.0000126505.97607.1b
   Banerjee SR, 2002, INORG CHEM, V41, P5795, DOI 10.1021/ic020391d
   Banerjee SR, 2002, INORG CHEM, V41, P6417, DOI 10.1021/ic020476e
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Brenner W, 2004, J NUCL MED, V45, P512
   Chin BB, 2003, NUCL MED COMMUN, V24, P1149, DOI 10.1097/01.mnm.0000101606.64255.03
   de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154
   Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7
   Ford JW, 1996, J SURG RES, V62, P23, DOI 10.1006/jsre.1996.0167
   Frangioni JV, 2004, CIRCULATION, V110, P3378, DOI 10.1161/01.CIR.0000149840.46523.FC
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119
   Jin Y, 2005, PHYS MED BIOL, V50, P4445, DOI 10.1088/0031-9155/50/19/001
   KISO Y, 1980, CHEM COMMUN, P1063
   Kizilian N, 1999, BIOTECHNIQUES, V27, P926
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004                                                          
   Ma B, 2005, NUCL MED BIOL, V32, P701, DOI 10.1016/j.nucmelbio.2005.04.018
   McNamee JP, 2000, MUTAT RES-GEN TOX EN, V466, P63, DOI 10.1016/S1383-5718(00)00004-8
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Ryan LA, 2006, HEALTH PHYS, V91, P68, DOI 10.1097/01.HP.0000200339.91550.6b                                               
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Stephenson KA, 2004, J AM CHEM SOC, V126, P8598, DOI 10.1021/ja047751b
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zhou R, 2005, J NUCL MED, V46, P816
NR 30
TC 41
Z9 41
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0969-8051
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD FEB
PY 2008
VL 35
IS 2
BP 159
EP 169
DI 10.1016/j.nucmedbio.2007.11.001
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 265BC
UT WOS:000253333100002
PM 18312825
DA 2018-01-05
ER

PT J
AU Avilov, SV
   Piemont, E
   Shvadchak, V
   de Rocquigny, H
   Mely, Y
AF Avilov, S. V.
   Piemont, E.
   Shvadchak, V.
   de Rocquigny, H.
   Mely, Y.
TI Probing dynamics of HIV-1 nucleocapsid protein/target hexanucleotide
   complexes by 2-aminopurine
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TIME-RESOLVED FLUORESCENCE; MINUS-STRAND
   TRANSFER; SECONDARY STRUCTURE; CHARGE-TRANSFER; CTAR DNA; STRUCTURAL
   DETERMINANTS; COMPLEMENTARY SEQUENCE; DESTABILIZING ACTIVITY;
   CONFORMATIONAL-CHANGES
AB The nucleocapsid protein (NC) plays an important role in HIV-1, mainly through interactions with the genomic RNA and its DNA copies. Though the structures of several complexes of NC with oligonucleotides (ODNs) are known, detailed information on the ODN dynamics in the complexes is missing. To address this, we investigated the steady state and time-resolved fluorescence properties of 2-aminopurine (2Ap), a fluorescent adenine analog introduced at positions 2 and 5 of AACGCC and AATGCC sequences. In the absence of NC, 2Ap fluorescence was strongly quenched in the flexible ODNs, mainly through picosecond to nanosecond dynamic quenching by its neighboring bases. NC strongly restricted the ODN flexibility and 2Ap local mobility, impeding the collisions of 2Ap with its neighbors and thus, reducing its dynamic quenching. Phe(16)-> Ala and Trp(37)-> Leu mutations largely decreased the ability of NC to affect the local dynamics of 2Ap at positions 2 and 5, respectively, while a fingerless NC was totally ineffective. The restriction of 2Ap local mobility was thus associated with the NC hydrophobic platform at the top of the folded fingers. Since this platform supports the NC chaperone properties, the restriction of the local mobility of the bases is likely a mechanistic component of these properties.
C1 [Avilov, S. V.; Piemont, E.; Shvadchak, V.; de Rocquigny, H.; Mely, Y.] Univ Louis Pasteur Strasbourg 1, UMR CNRS 7175, Inst Gilbert Laustriat, Dept Pharmacol & Physiochim,Fac Pharm, F-67401 Illkirch Graffenstaden, France.
   [Avilov, S. V.] AV Palladin Biochem Inst, UA-01030 Kiev, Ukraine.
RP Mely, Y (reprint author), Univ Louis Pasteur Strasbourg 1, UMR CNRS 7175, Inst Gilbert Laustriat, Dept Pharmacol & Physiochim,Fac Pharm, 74 Route Rhin, F-67401 Illkirch Graffenstaden, France.
EM mely@pharma.u-strasbg.fr
RI Avilov, Sergiy/A-2904-2012; Shvadchak, Volodymyr/E-1475-2017
OI Shvadchak, Volodymyr/0000-0001-8302-8073
CR Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710
   Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2001.5182
   Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4
   Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024
   Beltz H, 2005, J MOL BIOL, V348, P1113, DOI 10.1016/j.jmb.2005.02.042
   Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019
   Beltz H, 2003, J MOL BIOL, V328, P95, DOI 10.1016/S0022-2836(03)00244-4
   Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2001.5429
   Bombarda E, 1999, BIOPHYS J, V76, P1561, DOI 10.1016/S0006-3495(99)77315-7                                                   
   Bradrick TD, 2004, RNA, V10, P1459, DOI 10.1261/rna.7620304
   CLEVER J, 1995, J VIROL, V69, P2101
   Cosa G, 2006, J PHYS CHEM B, V110, P2419, DOI 10.1021/jp054189i
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070
   D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210
   Darlix J L, 2000, Adv Pharmacol, V48, P345
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0
   DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472                                                         
   DORFMAN T, 1993, J VIROL, V67, P6159
   Egele C, 2005, CR BIOL, V328, P1041, DOI 10.1016/j.crvi.2005.06.005
   Egele C, 2004, J MOL BIOL, V342, P453, DOI 10.1016/j.jmb.2004.07.059
   Fiebig T, 2002, CHEMPHYSCHEM, V3, P781, DOI 10.1002/1439-7641(20020916)3:9<781::AID-CPHC781>3.0.CO;2-U                      
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Fisher RJ, 1998, J VIROL, V72, P1902
   Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629
   GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015
   Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000                                                
   Hariharan C, 2005, BIOCHEMISTRY-US, V44, P15674, DOI 10.1021/bi051462y
   Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4
   Jean JM, 2004, BIOCHEMISTRY-US, V43, P10277, DOI 10.1021/bi049701p
   Jean JM, 2002, BIOCHEMISTRY-US, V41, P13152, DOI 10.1021/bi020308y
   Jean JM, 2001, P NATL ACAD SCI USA, V98, P37, DOI 10.1073/pnas.011442198
   Kaul M, 2004, J AM CHEM SOC, V126, P3447, DOI 10.1021/ja030568i
   Krishnamoorthy G, 2003, NUCLEIC ACIDS RES, V31, P5425, DOI 10.1093/nar/gkg738
   LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P304
   Larsen OFA, 2001, BIOPHYS J, V81, P1115, DOI 10.1016/S0006-3495(01)75768-2                                                   
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5                                                   
   Liu HW, 2007, P NATL ACAD SCI USA, V104, P5261, DOI 10.1073/pnas.0700166104
   Liu HW, 2005, BIOPHYS J, V89, P3470, DOI 10.1529/biophysj.105.065326
   Maki AH, 2001, BIOCHEMISTRY-US, V40, P1403, DOI 10.1021/bi002010i
   Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148                                                         
   Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d
   Mollova ET, 2002, CURR OPIN CHEM BIOL, V6, P823, DOI 10.1016/S1367-5931(02)00394-0                                                   
   Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098
   Nag N, 2006, REV FLUORESCENCE, V3, P311
   O'Neill MA, 2002, J AM CHEM SOC, V124, P13053, DOI 10.1021/ja0208198
   OTTMANN M, 1995, J VIROL, V69, P1778
   Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o
   Rai P, 2003, NUCLEIC ACIDS RES, V31, P2323, DOI 10.1093/nar/gkg339
   RAMALANJAONA N, 2007, J MOL BIOL, V374, P1074
   Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2
   Ramreddy T, 2007, J PHYS CHEM B, V111, P5757, DOI 10.1021/jp068818f
   Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819                                                          
   Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240
   Somsen OJG, 2005, CHEMPHYSCHEM, V6, P1622, DOI 10.1002/cphc.200400648
   Stote RH, 2004, BIOCHEMISTRY-US, V43, P7687, DOI 10.1021/bi036137u
   Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521                                                          
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000
   Wan CZ, 2000, P NATL ACAD SCI USA, V97, P14052, DOI 10.1073/pnas.250483297
   WARD DC, 1969, J BIOL CHEM, V244, P1228
   Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198
   XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
NR 67
TC 39
Z9 40
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB
PY 2008
VL 36
IS 3
BP 885
EP 896
DI 10.1093/nar/gkm1109
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 267EC
UT WOS:000253491300023
PM 18086707
OA gold
DA 2018-01-05
ER

PT J
AU Song, SP
   Wang, LH
   Li, J
   Zhao, JL
   Fan, CH
AF Song, Shiping
   Wang, Lihua
   Li, Jiang
   Zhao, Jianlong
   Fan, Chunhai
TI Aptamer-based biosensors
SO TRAC-TRENDS IN ANALYTICAL CHEMISTRY
LA English
DT Article
DE aptamer; biosensor; nanomaterial; nanotechnology
ID LABEL-FREE DETECTION; HIV-1 TAT PROTEIN; ELECTROCHEMICAL DETECTION; RNA
   APTAMER; DNA APTAMER; QUANTUM-DOT; MOLECULAR RECOGNITION; RECEPTOR
   MOLECULES; COLORIMETRIC PROBE; BIOLOGICAL-FLUIDS
AB Nucleic-acid aptamers have attracted intense interest and found wide applications in a range of areas. in this review, we summarize recent advances in the development of aptamer-based biosensors and bioassay methods, most of which have employed electrochemical, optical and mass-sensitive analytical techniques. Aptamers exhibit many advantages as recognition elements in biosensing when compared to traditional antibodies. They are small in size, chemically stable and cost effective. More importantly, aptamers offer remarkable flexibility and convenience in the design of their structures, which has led to novel biosensors that have exhibited high sensitivity and selectivity. Recently, the combination of aptamers with novel nanomaterials has significantly improved the performance of aptamer-based sensors, which we also review in this article. In view of the unprecedented advantages brought by aptamers, we expect aptamer-based biosensors to find broad applications in biomedical diagnostics, environmental monitoring and homeland security. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Zhao, Jianlong] Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, Shanghai 200050, Peoples R China.
   [Song, Shiping; Wang, Lihua; Li, Jiang; Fan, Chunhai] Chinese Acad Sci, Inst Appl Phys, Shanghai 201800, Peoples R China.
RP Zhao, JL (reprint author), Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, Shanghai 200050, Peoples R China.
EM jlzhao@mail.sim.ac.cn
RI Li, Jiang/B-9351-2009; Fan, Chunhai/A-7569-2011
OI Li, Jiang/0000-0003-2372-6624; Fan, Chunhai/0000-0002-7171-7338
CR Bagalkot V, 2007, NANO LETT, V7, P3065, DOI 10.1021/nl071546n
   Baker BR, 2006, J AM CHEM SOC, V128, P3138, DOI 10.1021/ja056957p
   Bang GS, 2005, BIOSENS BIOELECTRON, V21, P863, DOI 10.1016/j.bios.2005.02.002
   Bini A, 2007, ANAL CHEM, V79, P3016, DOI 10.1021/ac070096g
   Cheng AKH, 2007, ANAL CHEM, V79, P5158, DOI 10.1021/ac062214q
   Choi JH, 2006, J AM CHEM SOC, V128, P15584, DOI 10.1021/ja066506k
   Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E                     
   de-los-Santos-Alvarez N, 2007, J AM CHEM SOC, V129, P3808, DOI 10.1021/ja0689482
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0                                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Famulok M, 2006, NATURE, V439, P666, DOI 10.1038/439666a
   Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029
   Gronewold TMA, 2005, BIOSENS BIOELECTRON, V20, P2044, DOI 10.1016/j.bios.2004.09.007
   Guthrie JW, 2006, METHODS, V38, P324, DOI 10.1016/j.ymeth.2006.01.001
   He PL, 2007, ANAL CHEM, V79, P8024, DOI 10.1021/ac070772e
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Hwang KS, 2007, BIOSENS BIOELECTRON, V23, P459, DOI 10.1016/j.bios.2007.05.006
   Ikanovic M, 2007, J FLUORESC, V17, P193, DOI 10.1007/s10895-007-0158-4
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Lai RY, 2007, ANAL CHEM, V79, P229, DOI 10.1021/ac061592s
   Le Floch F, 2006, ANAL CHEM, V78, P4727, DOI 10.1021/ac0521955
   Lee S, 2007, BIOCHEM BIOPH RES CO, V358, P47, DOI 10.1016/j.bbrc.2007.04.057
   Levy M, 2005, CHEMBIOCHEM, V6, P2163, DOI 10.1002/cbic.200500218
   Li Y, 2007, ANAL CHEM, V79, P1082, DOI 10.1021/ac061849m
   Li YY, 2007, CLIN CHEM, V53, P1061, DOI 10.1373/clinchem.2006.082271
   Liu J., 2005, ANGEW CHEM INT EDIT, V45, P90
   Liu JW, 2007, J AM CHEM SOC, V129, P8634, DOI 10.1021/ja072075+
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P7955, DOI 10.1002/anie.200603106
   Luzi E, 2003, TRAC-TREND ANAL CHEM, V22, P810, DOI 10.1016/S0165-9936(03)01208-1
   Maehashi K, 2007, ANAL CHEM, V79, P782, DOI 10.1021/ac060830g
   MAIRAL T, 2007, ANAL BIOANAL CHEM
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Mir M, 2007, MOL BIOSYST, V3, P620, DOI 10.1039/b708858b
   Niu WZ, 2007, ANAL BIOCHEM, V362, P126, DOI 10.1016/j.ab.2006.12.011
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   Nutiu R, 2004, CHEM-EUR J, V10, P1868, DOI 10.1002/cheem.200305470
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Radi AE, 2006, CHEM COMMUN, P3432, DOI 10.1039/b606804a
   Radi AE, 2006, J AM CHEM SOC, V128, P117, DOI 10.1021/ja053121d
   Ramos E, 2007, LAB INVEST, V87, P409, DOI 10.1038/labinvest.3700535
   Rankin CJ, 2006, NUCLEOS NUCLEOT NUCL, V25, P1407, DOI 10.1080/15257770600919084
   Rupcich N, 2006, ANGEW CHEM INT EDIT, V45, P3295, DOI 10.1002/anie.200504576
   Savran CA, 2004, ANAL CHEM, V76, P3194, DOI 10.1021/ac049859f
   Schlensog MD, 2004, SENSOR ACTUAT B-CHEM, V101, P308, DOI 10.1016/j.snb.2004.03.015
   Senior K, 2006, LANCET ONCOL, V7, P712, DOI 10.1016/S1470-2045(06)70850-6
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   Stojanovic MN, 2002, J AM CHEM SOC, V124, P9678, DOI 10.1021/ja0259483
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wang LH, 2006, CHEM COMMUN, P3780, DOI 10.1039/b607448k
   Wei H, 2007, CHEM COMMUN, P3735, DOI 10.1039/b707642h
   Willner I, 2007, ANGEW CHEM INT EDIT, V46, P6408, DOI 10.1002/anie.200604524
   Xiao Y, 2005, J AM CHEM SOC, V127, P17990, DOI 10.1021/ja056555h
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   Yamamoto R, 2000, GENES CELLS, V5, P389, DOI 10.1046/j.1365-2443.2000.00331.x
   Yang CJ, 2005, P NATL ACAD SCI USA, V102, P17278, DOI 10.1073/pnas.0508821102
   Zhao WA, 2007, CHEMBIOCHEM, V8, P727, DOI 10.1002/cbic.200700014
   Zhou L, 2007, ANAL CHEM, V79, P7492, DOI 10.1021/ac071059s                                                               
   Zuo XL, 2007, J AM CHEM SOC, V129, P1042, DOI 10.1021/ja067024b
NR 67
TC 503
Z9 526
U1 41
U2 375
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-9936
J9 TRAC-TREND ANAL CHEM
JI Trac-Trends Anal. Chem.
PD FEB
PY 2008
VL 27
IS 2
BP 108
EP 117
DI 10.1016/j.trac.2007.12.004
PG 10
WC Chemistry, Analytical
SC Chemistry
GA 290KJ
UT WOS:000255121400016
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Vyas, TK
   Shahiwala, A
   Amiji, MM
AF Vyas, Tushar K.
   Shahiwala, Aliasgar
   Amiji, Mansoor M.
TI Improved oral bioavailability and brain transport of Saquinavir upon
   administration in novel nanoemulsion formulations
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE oil-in-water nanoemulsions; biodistribution; HIV/AIDS; protease
   inhibitor; reservoir sites; oral administration; CNS delivery
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTION; RESERVOIRS; HIV/AIDS;
   DELIVERY; BARRIER; DRUGS; RATS
AB The aim of this investigation was to develop novel oil-in-water (o/w) nanoemulsions containing Saquinavir (SQV), an anti-HIV protease inhibitor, for enhanced oral bioavailability and brain disposition. SQV was dissolved in different types of edible oils rich in essential polyunsaturated fatty acids (PUFA) to constitute the internal oil phase of the nanoemulsions. The external phase consisted of surfactants Lipoid (R)-80 and deoxycholic acid dissolved in water. The nanoemulsions with an average oil droplet size of 100-200 nm, containing tritiated [H-3]-SQV, were administered orally and intravenously to male Balb/c mice. The SQV bioavailability as well as distribution in different organ systems was examined. SQV concentrations in the systemic circulation administered in flax-seed oil nanoemulsions were threefold higher as compared to the control aqueous suspension. The oral bioavailability and distribution to the brain, a potential sanctuary site for HIV, were significantly enhanced with SQV delivered in nanoemulsion formulations. In comparing SQV in flax-seed oil nanoemulsion with aqueous suspension, the maximum concentration (C-max) and the area-under-the-curve (AUC) values were found to be five- and threefold higher in the brain, respectively, suggesting enhanced rate and extent of SQV absorption following oral administration of nanoemulsions. The results of this study show that oil-in-water nanoemulsions made with PUFA-rich oils may be very promising for HIV/AIDS therapy, in particular, for reducing the viral load in important anatomical reservoir sites. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Vyas, Tushar K.; Shahiwala, Aliasgar; Amiji, Mansoor M.] NE Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Amiji, MM (reprint author), NE Univ, Sch Pharm, Dept Pharmaceut Sci, 110 Mugar Life Sci Bldg, Boston, MA 02115 USA.
EM m.amiji@neu.edu
RI Amiji, Mansoor/A-4365-2014
OI Amiji, Mansoor/0000-0001-6170-881X
FU NCI NIH HHS [R01 CA119617-01, R01 CA119617-03, R01 CA119617, R01
   CA119617-02]
CR BOLES JA, 2005, J ANIM SCI, V83, P217
   Chearskul Pimpanada, 2006, Indian Journal of Pediatrics, V73, P335, DOI 10.1007/BF02825828
   Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481
   Clarke J.R., 2000, AIDS REV, V2, P15
   Edmond J, 2001, J MOL NEUROSCI, V16, P181, DOI 10.1385/JMN:16:2-3:181
   Figgitt DP, 2000, DRUGS, V60, P481, DOI 10.2165/00003495-200060020-00016
   Frezzini C, 2005, J ORAL PATHOL MED, V34, P513, DOI 10.1111/j.1600-0714.2005.00337.x
   Gallo RC, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-72
   HIRUNPANICH V, 2005, DRUG METAB DISPOS, V34, P305
   Holtgrave DR, 2005, INT J STD AIDS, V16, P777, DOI 10.1258/095646205774988109
   Huisman MT, 2001, MOL PHARMACOL, V59, P806
   Jafari SM, 2006, INT J FOOD PROP, V9, P475, DOI 10.1080/10942910600596464
   Kandanearatchi A, 2003, BRAIN PATHOL, V13, P104
   KEMIN Q, 2002, CURR OPIN CLIN NUTR, V5, P133
   King JR, 2004, CLIN PHARMACOKINET, V43, P291, DOI 10.2165/00003088-200443050-00003
   Kulkosky J, 2006, CURR HIV RES, V4, P199, DOI 10.2174/157016206776055084
   Lo YL, 2000, BIOCHEM PHARMACOL, V59, P665, DOI 10.1016/S0006-2952(99)00377-9
   Meyer S, 2006, MEAS SCI TECHNOL, V17, P289, DOI 10.1088/0957-0233/17/2/009
   O'Driscoll C, 2003, STP PHARMA SCI, V13, P17
   Obaru K, 1998, Nihon Rinsho, V56, P769
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sonza S, 2001, AIDS PATIENT CARE ST, V15, P511, DOI 10.1089/108729101753205676                                                      
   Taogoshi T, 2005, J PHARM PHARMACOL, V57, P61, DOI 10.1211/0022357055173
   Tiwari SB, 2006, J NANOSCI NANOTECHNO, V6, P3215, DOI 10.1166/jnn.2006.440
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   ZHAO DL, 1990, DIGESTION, V47, P200, DOI 10.1159/000200498                                                               
NR 27
TC 124
Z9 126
U1 2
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD JAN 22
PY 2008
VL 347
IS 1-2
BP 93
EP 101
DI 10.1016/j.ijpharm.2007.06.016
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 253LM
UT WOS:000252519700013
PM 17651927
OA green_accepted
DA 2018-01-05
ER

PT J
AU Pollielta, M
   Schols, D
   Aquaro, S
   Peumans, WJ
   Van Damme, EJM
   Perno, CF
   Balzarini, J
AF Pollielta, M.
   Schols, D.
   Aquaro, S.
   Peumans, W. J.
   Van Damme, E. J. M.
   Perno, C. F.
   Balzarini, J.
TI Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human
   primary monocyte-derived macrophages (MDMs) and efficiently prevent
   MDM-directed viral capture and subsequent transmission to CD4(+) T
   lymphocytes
SO VIROLOGY
LA English
DT Article
DE monocyte-derived macrophages (MDMs); carbohydrate-binding agents (CBAs);
   glycans; HIV-1; envelope glycoprotein gp120; HIV-1 capture; HIV-1
   transmission; DC-SIGN; macrophage mannose-binding receptor (MMR)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MANNOSE RECEPTOR; DENDRITIC CELLS; ANTIGEN
   PRESENTATION; GP120; RECOGNITION; INVOLVEMENT; APOPTOSIS; GLYCANS;
   PATTERN
AB Carbohydrate-binding agents (CBAs) have been proposed as innovative anti-HIV compounds selectively targeting the glycans of the HIV-1 envelope glycoprotein gp 120 and preventing DC-SIGN-directed HIV capture by dendritic cells (DCs) and transmission to CD4(+) T-lymphocytes. We now show that CBAs efficiently prevent R5 HIV-1 infection of human primary monocyte-derived macrophage (MDM) cell cultures in the nanomolar range. Both R5 and X4 HIV-1 strains were efficiently captured by the macrophage mannose-binding receptor (MMR) present on MDM. HIV-1 capture by MMR-expressing MDM was inhibited by soluble mannose-binding lectin and MMR antibody. Short pre-exposure of these HIV-1 strains to CBAs is able to prevent virus capture by MDM and subsequent syncytia formation in cocultures of the CBA-exposed HIV-1-captured MDM and uninfected CD4(+) T-lymphocytes. The potential of CBAs to impair MDM in their capacity to capture and to transmit HIV to T-lymphocytes might be an important property to be taken into consideration in the eventual choice to select microbicide candidate drugs for clinical investigation. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Schols, D.; Balzarini, J.] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.
   [Pollielta, M.; Aquaro, S.; Perno, C. F.] Univ Rome, Tor Vergata, Italy.
   [Aquaro, S.] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy.
   [Peumans, W. J.; Van Damme, E. J. M.] Univ Ghent VIB, Dept Mol Biol, B-9052 Ghent, Belgium.
RP Balzarini, J (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.be
RI perno, carlo federico/O-1544-2016; Van Damme, Els/B-4410-2015; Schols,
   Dominique/S-9057-2017
OI Schols, Dominique/0000-0003-3256-5850; Van Damme,
   Els/0000-0001-9848-766X
CR Aquaro S, 2000, J LEUKOCYTE BIOL, V68, P429
   AQUARO S., 2005, HUMAN RETROVIRUS PRO, P445
   Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55
   Balzarini Jan, 2007, Antiviral Chemistry & Chemotherapy, V18, P1
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155
   Balzarini J, 2007, J VIROL, V81, P362, DOI 10.1128/JVI.01404-06
   Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1                                                   
   Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2                                                   
   Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158
   Chougnet C, 2003, J LEUKOCYTE BIOL, V74, P702, DOI 10.1189/jlb.0403171
   Chougnet Claire, 2002, Curr Infect Dis Rep, V4, P266, DOI 10.1007/s11908-002-0090-3
   DEWHITE L, 2007, NAT MED, V13, P367
   Donaghy H, 2004, CURR OPIN INFECT DIS, V17, P1, DOI 10.1097/01.qco.0000113642.29255.15
   Engering AJ, 1997, ADV EXP MED BIOL, V417, P183
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Greenhead P, 2000, J VIROL, V74, P5577, DOI 10.1128/JVI.74.12.5577-5586.2000
   Herbein G., 2002, Current Molecular Medicine (Hilversum), V2, P723, DOI 10.2174/1566524023361844
   Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000
   Linehan SA, 1999, J EXP MED, V189, P1961, DOI 10.1084/jem.189.12.1961
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024                                                          
   Reading PC, 2000, J VIROL, V74, P5190, DOI 10.1128/JVI.74.11.5190-5197.2000                                                
   Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9                                                   
   Tan MCAA, 1997, ADV EXP MED BIOL, V417, P171
   Tomkowicz B, 2006, BLOOD, V108, P1145, DOI 10.1182/blood-2005-12-012815
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1987, PLANT PHYSIOL, V85, P566, DOI 10.1104/pp.85.2.566                                                             
   VANDAMME EJM, 1992, EUR J BIOCHEM, V209, P751
   Vermeire K, 2003, MOL PHARMACOL, V63, P203, DOI 10.1124/mol.63.1.203
   Williams KC, 2002, ANNU REV NEUROSCI, V25, P537, DOI 10.1146/annurev.neuro.25.112701.142822                                          
   Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200
   Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m
NR 34
TC 19
Z9 21
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 20
PY 2008
VL 370
IS 2
BP 382
EP 391
DI 10.1016/j.virol.2007.08.033
PG 10
WC Virology
SC Virology
GA 242BF
UT WOS:000251698800017
PM 17928023
OA gold
DA 2018-01-05
ER

PT B
AU Yang, DY
   Song, LS
   Liu, YY
   Zhao, R
   Ma, LY
   Shao, YM
   Jiang, XY
AF Yang, Dayong
   Song, Lusheng
   Liu, Yingyi
   Zhao, Rui
   Ma, Liying
   Shao, Yiming
   Jiang, Xingyu
GP IEEE
TI A fast, high throughput, and low-cost microfluidic bioassays for
   detecting HIV
SO 2008 INTERNATIONAL SPECIAL TOPIC CONFERENCE ON INFORMATION TECHNOLOGY
   AND APPLICATIONS IN BIOMEDICINE, VOLS 1 AND 2
LA English
DT Proceedings Paper
CT 5th Int Conference on Information Technol and Applications in
   Biomedicine in Conjunction with the 2nd Int Symposium and Summer School
   on Biomedical and Health Engineering
CY MAY 30-31, 2008
CL Shenzhen, PEOPLES R CHINA
SP Inst Biomed & Hlth Engn, Chinese Acad Sci, Key Lab Biomed Informat, Shenzhen Inst Adv Technol, CAS Shenzhen Academician Consultat Ctr, Chinese Univ Hong Kong, Chinese Soc Biomed Engn, IEEE EMBS, IEEE EMBS, Hong Kong Chapter, Int Federat Automat, Int Union Phys & Engn Sci Med
ID PUBLIC-HEALTH; ARRAYS
AB This paper demonstrates a fast, high throughput, and low-cost bioassay version based on microfluidics and nanostructured polymer membranes fabricated via electrospinning. This assay outperforms conventional assays for the detection of HIV-specific antibodies.
C1 [Yang, Dayong; Song, Lusheng; Liu, Yingyi; Zhao, Rui; Jiang, Xingyu] Natl Ctr NanoSci & Technol, 11 Beiyitiao, Beijing 100190, Peoples R China.
   [Ma, Liying; Shao, Yiming] Chinese Ctr Disease Control & Prevent, Beijing 100050, Peoples R China.
RP Yang, DY (reprint author), Natl Ctr NanoSci & Technol, 11 Beiyitiao, Beijing 100190, Peoples R China.
EM xingyujiang@nanoctr.cn
FU CAS Innovation Program; National Science Foundation of China; Ministry
   of Science and Technology
FX This work was supported by CAS Innovation Program, National Science
   Foundation of China and the Ministry of Science and Technology.
CR Ismagilov RF, 2001, ANAL CHEM, V73, P5207, DOI 10.1021/ac010502a
   Jiang XY, 2003, J AM CHEM SOC, V125, P5294, DOI 10.1021/ja034566
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Li Y, 2007, ANGEW CHEM INT EDIT, V46, P1094, DOI 10.1002/anie.200603844
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Wu ZY, 2006, SCIENCE, V312, P1475, DOI 10.1126/science.1120682
   Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.3.CO;2-7
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yang DY, 2007, ADV MATER, V19, P3702, DOI 10.1002/adma.200700171
NR 10
TC 0
Z9 0
U1 0
U2 2
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4244-2254-8
PY 2008
BP 90
EP +
PG 2
WC Engineering, Biomedical
SC Engineering
GA BID74
UT WOS:000258746900024
DA 2018-01-05
ER

PT J
AU Ghosh, AK
   Chapsal, BD
   Weber, IT
   Mitsuya, H
AF Ghosh, Arun K.
   Chapsal, Bruno D.
   Weber, Irene T.
   Mitsuya, Hiroaki
TI Design of HIV protease inhibitors targeting protein backbone: An
   effective strategy for combating drug resistance
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID VIRUS TYPE-1 PROTEASE; ORALLY BIOAVAILABLE INHIBITOR; HIGH-AFFINITY
   P-2-LIGANDS; CRYSTAL-STRUCTURE; ACTIVE-SITE; IN-VITRO; POTENT;
   GENERATION; RESOLUTION; TMC114
AB The discovery of human immunodeficiency virus (HIV) protease inhibitors (Pls) and their utilization in highly active antiretroviral therapy (HAART) have been a major turning point in the management of HIV/acquired immune-deficiency syndrome (AIDS). However, despite the successes in disease management and the decrease of HIV/AIDS-related mortality, several drawbacks continue to hamper first-generation protease inhibitor therapies. The rapid emergence of drug resistance has become the most urgent concern because it renders current treatments ineffective and therefore compels the scientific community to continue efforts in the design of inhibitors that can efficiently combat drug resistance.
   The present line of research focuses on the presumption that an inhibitor that can maximize interactions in the HIV-1 protease active site, particularly with the enzyme backbone atoms, will likely retain these interactions with mutant enzymes. Our structure-based design of HIV Pls specifically targeting the protein backbone has led to exceedingly potent inhibitors with superb resistance profiles.
   We initially introduced new structural templates, particulary non-peptidic conformationally constrained P-2 ligands that would efficiently mimic peptide binding in the S-2 subsite of the protease and provide enhanced bioavailability to the inhibitor. Cyclic ether derived ligands appeared as privileged structural features and allowed us to obtain a series of potent Pls. Following our structure-based design approach, we developed a high-affinity 3(R),3a(R),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) ligand that maximizes hydrogen bonding and hyrophobic interactions in the protease S2 subsite. Combination of this ligand with a range of different isosteres led to a series of exceedingly potent inhibitors.
   Darunavir, initially TMC-114, which combines the bis-THF ligand with a sulfonamide isostere, directly resulted from this line of research. This inhibitor displayed unprecedented enzyme inhibitory potency (K-i = 16 pM) and antiviral activity (IC90 = 4.1 nM) Most importantly, it consistently retained is potency against highly drug-resistant HIV strains. Darunavir's IC50 remained in the low nanomolar range against highly mutated HIV strains that displayed resistance to most available Pls.
   Our detailed crystal structure analyses of darunavir-bound protease complexes clearly demonstrated extensive hydrogen bonding between the inhibitor and the protease backbone. Most strikingly, these analyses provided ample evidence of the unique contribution of the bis-THF as a P-2-ligand. With numerous hydrogen bonds, bis-THF was shown to closely and tightly bind to the backbone atoms of the S-2 subsite of the protease. Such tight interactions were consistently observed with mutant proteases and might therefore account for the unusually high resistance profile of darunavir. Optimization attempts of the backbone binding in other subsites of the enzyme, through rational modifications of the isostere or tailor made P-2 ligands, led to equally impressive inhibitors with excellent resistance profiles.
   The concept of targeting the protein backbone in current structure-based drug design may offer a reliable strategy for combating drug resistance.
C1 [Ghosh, Arun K.] Purdue Univ, Dept Chem, Indiana, PA USA.
   [Ghosh, Arun K.; Chapsal, Bruno D.] Purdue Univ, Dept Med Chem, Indiana, PA USA.
   [Weber, Irene T.] Georgia State Univ, Dept Biol, Mol Basis Dis Program, Atlanta, GA 30303 USA.
   [Mitsuya, Hiroaki] Kumamoto Univ, Dept Hematol, Sch Med, Kumamoto 8608556, Japan.
   [Mitsuya, Hiroaki] Kumamoto Univ, Dept Infect Dis, Sch Med, Kumamoto 8608556, Japan.
   [Mitsuya, Hiroaki] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA.
RP Ghosh, AK (reprint author), Purdue Univ, Dept Chem, W Lafayette, Indiana, PA USA.
EM akghosh@purdue.edu
FU Intramural NIH HHS; NIGMS NIH HHS [R01 GM062920-09, GM 53386, R01
   GM062920-10, R01 GM062920]
CR Amano M, 2007, ANTIMICROB AGENTS CH, V51, P2143, DOI 10.1128/AAC.01413-06
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   CHEN ZG, 1994, J BIOL CHEM, V269, P26344
   Clemente JC, 2004, BIOCHEMISTRY-US, V43, P12141, DOI 10.1021/bi049459m
   Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S01406736(07)60497-8
   COREY EJ, 1988, J AM CHEM SOC, V110, P649, DOI 10.1021/ja00210a083
   COREY EJ, 1988, TETRAHEDRON LETT, V29, P3205, DOI 10.1016/0040-4039(88)85122-0
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   De Meyer S., 2004, 11 C RETR OPP INF CR
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y
   Ghosh AK, 2002, ANTIVIR RES, V54, P29, DOI 10.1016/S0166-3542(01)00209-1
   GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002                                                             
   Ghosh AK, 1996, J MED CHEM, V39, P3278, DOI 10.1021/jm960128k
   GHOSH AK, 1993, J MED CHEM, V36, P292, DOI 10.1021/jm00054a015                                                             
   GHOSH AK, 1995, TETRAHEDRON LETT, V36, P505, DOI 10.1016/0040-4039(94)02296-N                                                    
   Ghosh AK, 2006, SYNTHESIS-STUTTGART, P3015, DOI 10.1055/s-2006-942547
   Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m
   Glesby M. J., 2001, PROTEASE INHIBITORS, P237
   Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009
   GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449
   van der Geest M., 2003, 10 C RETR OPP INF CR
   Hong L, 2000, PROTEIN SCI, V9, P1898, DOI 10.1110/ps.9.10.1898                                                            
   KATLAMA C, 2005, 3 IAS C HIV PATH TRE
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007
   Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c
   KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028
   Laco GS, 1997, BIOCHEMISTRY-US, V36, P10696, DOI 10.1021/bi9707436
   Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035
   NAKANISHI KOJI, 1967, PURE APPL CHEM, V14, P89, DOI 10.1351/pac196714010089
   Spaltenstein A, 2005, CURR TOP MED CHEM, V5, P1589, DOI 10.2174/156802605775009694
   SPEKOWITZ KA, 2001, NEW ENGL J MED, V344, P1764
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
   1995, ANTIVIRAL AGENTS B, V8, P353
NR 42
TC 141
Z9 144
U1 0
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD JAN
PY 2008
VL 41
IS 1
BP 78
EP 86
DI 10.1021/ar7001232
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 252BJ
UT WOS:000252419500010
PM 17722874
DA 2018-01-05
ER

PT J
AU Mayer, G
   Ackermann, D
   Kuhn, N
   Famulok, M
AF Mayer, Guenter
   Ackermann, Damian
   Kuhn, Nicole
   Famulok, Michael
TI Construction of DNA architectures with RNA hairpins
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE DNA structures; hairpins; nanostructures; RNA structures; self-assembly
ID DIMERIZATION INITIATION SITE; LOOP-LOOP INTERACTIONS; HIGH-DENSITY;
   FUNCTIONALIZED DNA; BUILDING-BLOCKS; G-QUARTETS; HIV-1; NANOSTRUCTURES;
   NANOTECHNOLOGY; NANOPARTICLES
C1 [Mayer, Guenter; Ackermann, Damian; Kuhn, Nicole; Famulok, Michael] Univ Bonn, LIMES Life & Med Sci Inst, Programmeinheit Chem Biol & Med Chem, D-53121 Bonn, Germany.
RP Mayer, G (reprint author), Univ Bonn, LIMES Life & Med Sci Inst, Programmeinheit Chem Biol & Med Chem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.
EM m.famulok@uni-bonn.de
RI Mayer, Gunter/F-2937-2010
CR Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589                                                          
   Davis J. T., 2004, ANGEW CHEM, V116, P684
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Ennifar E, 1999, STRUCT FOLD DES, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7
   Erben CM, 2007, J AM CHEM SOC, V129, P6992, DOI 10.1021/ja071493b
   Feldkamp U, 2006, ANGEW CHEM INT EDIT, V45, P1856, DOI 10.1002/anie.200502358
   Feldkamp U., 2006, ANGEW CHEM, V118, P1888
   Gierlich J, 2006, ORG LETT, V8, P3639, DOI 10.1021/ol0610946
   Gugliotti LA, 2004, SCIENCE, V304, P850, DOI 10.1126/science.1095678
   Jaeger L, 2006, CURR OPIN STRUC BIOL, V16, P531, DOI 10.1016/j.sbi.2006.07.001
   Jager S, 2005, J AM CHEM SOC, V127, P15071, DOI 10.1021/ja051725b
   Jager S, 2004, ANGEW CHEM INT EDIT, V43, P3337, DOI 10.1002/anie.200453926
   Jager S., 2004, ANGEW CHEM, V116, P3399
   Leontis NB, 2006, CURR OPIN STRUC BIOL, V16, P279, DOI 10.1016/j.sbi.2006.05.009
   Mao CD, 1997, NATURE, V386, P137, DOI 10.1038/386137b0                                                                
   Mayer G., 2007, ANGEW CHEM, V119, P563
   Mayer G, 2007, ANGEW CHEM INT EDIT, V46, P557, DOI 10.1002/anie.200603166
   Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r
   Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S
   Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096                                                          
   RASCHED G, 2008, ANGEW CHEM, V120, P981
   Rasched G, 2008, ANGEW CHEM INT EDIT, V47, P967, DOI 10.1002/anie.200704004
   Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586
   Rothemund PWK, 2004, J AM CHEM SOC, V126, P16344, DOI 10.1021/ja0443191
   Scheffler M., 1999, ANGEW CHEM INT EDIT, V38, P3311
   Wustefeld M., 1999, ANGEW CHEM, V111, P3513
   Schmidt TL, 2007, ANGEW CHEM INT EDIT, V46, P4382, DOI 10.1002/anie.200700469
   Schmidt T. L., 2007, ANGEW CHEM, V119, P4460
   Seeman NC, 2005, Q REV BIOPHYS, V38, P363, DOI 10.1017/S0033583505004087
   Seeman NC, 1999, TRENDS BIOTECHNOL, V17, P437, DOI 10.1016/S0167-7799(99)01360-8
   Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406
   Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3220::AID-ANIE3220>3.0.CO;2-C            
   Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073                                                             
   Thum O, 2001, ANGEW CHEM INT EDIT, V40, P3990, DOI 10.1002/1521-3773(20011105)40:21<3990::AID-ANIE3990>3.0.CO;2-O                  
   Thum O., 2001, ANGEW CHEM, V113, P4112
   Wengel J, 2004, ORG BIOMOL CHEM, V2, P277, DOI 10.1039/b313986g
   WILLIAMSON JR, 1993, P NATL ACAD SCI USA, V90, P3124, DOI 10.1073/pnas.90.8.3124                                                          
NR 39
TC 22
Z9 22
U1 1
U2 14
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1433-7851
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2008
VL 47
IS 5
BP 971
EP 973
DI 10.1002/anie.200704709
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 255IH
UT WOS:000252651200033
PM 18176928
DA 2018-01-05
ER

PT J
AU Lu, L
   Sun, RWY
   Chen, R
   Hui, CK
   Ho, CM
   Luk, JM
   Lau, GKK
   Che, CM
AF Lu, Lei
   Sun, Raymond Wai-Yin
   Chen, Rong
   Hui, Chee-Kin
   Ho, Chi-Ming
   Luk, John M.
   Lau, George K. K.
   Che, Chi-Ming
TI Silver nanoparticles inhibit hepatitis B virus replication
SO ANTIVIRAL THERAPY
LA English
DT Article
ID CLOSED CIRCULAR DNA; NATURAL-HISTORY; INFECTION; HBV; INTERFERON; CELLS;
   QUANTIFICATION; MECHANISMS; EXPRESSION; THERAPY
AB Background: Silver nanoparticles have been shown to exhibit promising cytoprotective activities towards HIV-infected T-cells; however, the effects of these nanoparticles towards other kinds of viruses remain largely unexplored. The aim of the present study was to investigate the effects of silver nanoparticles on hepatitis B virus (HBV).
   Methods: Monodisperse silver nanoparticles with mean particle diameters of similar to 10 nm (Ag10Ns) and similar to 50 nm (Ag50Ns) were prepared from AgNO3 in HEPES buffer. The in vitro anti-HBV activities of these particles were determined using the HepAD38 cell line as infection model.
   Results: Ag10Ns and Ag50Ns were able to reduce the extracellular HBV DNA formation of HepAD38 cells by >50% compared with the vehicle control (that is, HepAD38 cells in the absence of silver nanoparticles). Silver nanoparticles had little effect on the amount of HBV covalently closed circular DNA (cccDNA), but could inhibit the formation of intracellular HBV RNA. Gel mobility shift assays indicated that Ag10Ns bound HBV double-stranded DNA at a DNA:silver molar ratio of 1:50; an absorption titration assay showed that the nanoparticles have good binding affinity for HBV DNA with a binding constant (K.) of (8.8 +/- 1.0)x10(5) dm(3)mol(-1). As both the viral and Ag10Ns systems are in the nanometer size range, we found that Ag10Ns could directly interact with the HBV viral particles as revealed by transmission electronic microscopy.
   Conclusions: Silver nanoparticles could inhibit the in vitro production of HBV RNA and extracellular virions. We hypothesize that the direct interaction between these nanoparticles and HBV double-stranded DNA or viral particles is responsible for their antiviral mechanism.
C1 [Sun, Raymond Wai-Yin; Chen, Rong; Ho, Chi-Ming; Che, Chi-Ming] Univ Hong Kong, Dept Chem, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China.
   [Lu, Lei; Lau, George K. K.] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   [Sun, Raymond Wai-Yin; Chen, Rong; Ho, Chi-Ming; Che, Chi-Ming] Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China.
   [Hui, Chee-Kin] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Luk, John M.] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
RP Che, CM (reprint author), Univ Hong Kong, Dept Chem, Inst Mol Technol Drug Discovery & Synth, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM cmche@hku.hk
RI Sun, Raymond/D-3165-2009; Luk, John/A-4085-2008; Chen, Rong/E-9474-2011
OI Luk, John/0000-0002-6323-7940; Chen, Rong/0000-0003-1455-5093
CR Alt V, 2004, BIOMATERIALS, V25, P4383, DOI 10.1016/j.biomaterials.2003.10.078
   Bowden S, 2004, METH MOLEC MED, V95, P41
   Cacciola I, 2000, HEPATOLOGY, V31, P507, DOI 10.1002/hep.510310235                                                           
   DAVIS GL, 1986, HEPATOLOGY, V6, P1038, DOI 10.1002/hep.1840060537
   El-Sayed MA, 2004, ACCOUNTS CHEM RES, V37, P326, DOI 10.1021/ar020204f
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2                                                   
   GUNTHER S, 1995, J VIROL, V69, P5437
   Hui CK, 2006, GASTROENTEROLOGY, V131, P59, DOI 10.1053/j.gastro.2006.04.015
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715
   Lau GKK, 2007, J HEPATOL, V46, P6, DOI 10.1016/j.jhep.2006.10.008
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Li CKL, 2006, CHEM-EUR J, V12, P5253, DOI 10.1002/chem.200600117
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lok CN, 2006, J PROTEOME RES, V5, P916, DOI 10.1021/pr0504079
   Mandal S, 2005, CURR APPL PHYS, V5, P118, DOI 10.1016/j.cap.2004.06.006
   Merga G, 2007, J PHYS CHEM C, V111, P12220, DOI 10.1021/jp074257w
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503
   Radloff C, 2005, NANO LETT, V5, P1187, DOI 10.1021/nl050658g
   Roduner E, 2006, CHEM SOC REV, V35, P583, DOI 10.1039/b502142c
   Shaw T, 2006, J HEPATOL, V44, P593, DOI 10.1016/j.jhep.2006.01.001
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Sung JJY, 2005, GASTROENTEROLOGY, V128, P1890, DOI 10.1053/j.gastro.2005.03.009
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   Vinogradov SV, 2006, CURR PHARM DESIGN, V12, P4703, DOI 10.2174/138161206779026254
   WILL H, 1987, J VIROL, V61, P904
   WOLFE A, 1987, BIOCHEMISTRY-US, V26, P6392, DOI 10.1021/bi00394a013
   Wright JB, 1999, AM J INFECT CONTROL, V27, P344, DOI 10.1016/S0196-6553(99)70055-6
NR 31
TC 169
Z9 185
U1 2
U2 36
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2008
VL 13
IS 2
BP 253
EP 262
PG 10
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 288EO
UT WOS:000254969200010
PM 18505176
DA 2018-01-05
ER

PT J
AU Wan, L
   Zhang, XP
   Pooyan, S
   Palombo, MS
   Leibowitz, MJ
   Stein, S
   Sinko, PJ
AF Wan, Li
   Zhang, Xiaoping
   Pooyan, Shahriar
   Palombo, Matthew S.
   Leibowitz, Michael J.
   Stein, Stanley
   Sinko, Patrick J.
TI Optimizing size and copy number for PEG-fMLF
   (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by
   macrophages
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCYTE CELL-LINE; PEGYLATED
   INTERFERONS; PROTEIN PEGYLATION; HIV-1 INFECTION; DELIVERY; PEPTIDES;
   INDIVIDUALS; RESISTANCE; RECEPTORS
AB Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-formyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20-60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide-backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier-approach are discussed.
C1 [Wan, Li; Zhang, Xiaoping; Pooyan, Shahriar; Palombo, Matthew S.; Stein, Stanley; Sinko, Patrick J.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.
   [Leibowitz, Michael J.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA.
   [Leibowitz, Michael J.; Sinko, Patrick J.] Canc Inst New Jersy, New Brunswick, NJ 08903 USA.
   [Sinko, Patrick J.] Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM sinko@rci.rutgers.edu
FU NIAID NIH HHS [R37 AI051214-07, R01 AI051214, R37 AI051214-05, R37
   AI051214-06, R37 AI051214-08, AI 51214, AI 33789, R37 AI051214]
CR Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   ARENDSHORST WJ, 1988, RENAL CIRCULATION
   Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008                                                
   Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X
   Connor RI, 1996, J VIROL, V70, P8758
   Conover CD, 1998, CANCER CHEMOTH PHARM, V42, P407, DOI 10.1007/s002800050837
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   FISCHER DG, 1980, J IMMUNOL, V125, P463
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1                                                   
   Greenwald RB, 2001, J CONTROL RELEASE, V74, P159, DOI 10.1016/S0168-3659(01)00331-5                                                   
   Gunaseelan S, 2004, BIOCONJUGATE CHEM, V15, P1322, DOI 10.1021/bc0498875
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
   HARRIS JM, 1991, POLY ETHYLENE GLYCOL
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Kozlowski A, 2001, BIODRUGS, V15, P419, DOI 10.2165/00063030-200115070-00001                                                
   Kozlowski A, 2001, J CONTROL RELEASE, V72, P217, DOI 10.1016/S0168-3659(01)00277-2
   Le YY, 2002, INT IMMUNOPHARMACOL, V2, P1, DOI 10.1016/S1567-5769(01)00150-3
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Nakai T, 2003, J AM CHEM SOC, V125, P8465, DOI 10.1021/ja035636f
   NIEDEL JE, 1979, SCIENCE, V205, P1412, DOI 10.1126/science.472759
   Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a
   PIKE MC, 1980, J EXP MED, V152, P31, DOI 10.1084/jem.152.1.31
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3                                                   
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427                                                        
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   SCHUITEMAKER H, 1991, J VIROL, V65, P356
   SHERMAN MR, 1997, CONJAGATION HIGH MOL
   Van Eerd JEM, 2003, Q J NUCL MED, V47, P246
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   Wan Li, 2006, AIDS Res Ther, V3, P12, DOI 10.1186/1742-6405-3-12
NR 35
TC 18
Z9 19
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JAN
PY 2008
VL 19
IS 1
BP 28
EP 38
DI 10.1021/bc070066k
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 253LS
UT WOS:000252520300007
PM 18092743
OA green_accepted
DA 2018-01-05
ER

PT J
AU Darbha, GK
   Rai, US
   Singh, AK
   Ray, PC
AF Darbha, Gopala Krishna
   Rai, Uma Shanker
   Singh, Anant Kumar
   Ray, Paresh Chandra
TI Gold-nanorod-based sensing of sequence specific HIV-1 virus DNA by using
   hyper-Rayleigh scattering spectroscopy
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE DNA; gold; human immunodeficiency virus; nanostructures; sensors
ID NONLINEAR-OPTICAL PROPERTIES; ULTRASENSITIVE DETECTION; NEAR-FIELD;
   NANOPARTICLES; CHROMOPHORES; ORIENTATION; COLLOIDS; SILVER; PNA
AB Infectious diseases caused by the human immunodeficiency virus (HIV) remain the leading killers of human beings worldwide, and function to destabilize societies in Africa, Asia, and the Middle East. Driven by the need to detect the presence of HIV viral sequence, here we demonstrate that the second-order nonlinear optical (NLO) properties of gold nanorods can be used for screening HIV-1 viral DNA sequence without any modification, with good sensitivity (100 picomolar) and selectivity (single base-pair mismatch). The hyper-Rayleigh scattering (HRS) intensity increases 45 times when a label-free 145-mer, ss-gag gene DNA, was hybridized with 100 pM target DNA. The mechanism of HRS intensity change has been discussed with experimental evidence for higher multipolar contribution to the NLO response of gold nanorods.
C1 [Darbha, Gopala Krishna; Rai, Uma Shanker; Singh, Anant Kumar; Ray, Paresh Chandra] Jackson State Univ, Dept Chem, Jackson, MS 39217 USA.
RP Ray, PC (reprint author), Jackson State Univ, Dept Chem, Jackson, MS 39217 USA.
EM paresh.c.ray@jsums.edu
RI Darbha, Gopala /F-8827-2011
FU NIGMS NIH HHS [S06GM 008047]
CR ALIVISATOS AP, 2004, NAT BIOTECHNOL, V22, P47, DOI DOI 10.1038/NBT927
   Chan GH, 2007, NANO LETT, V7, P1947, DOI 10.1021/nl070648a
   Chu LQ, 2007, ANGEW CHEM INT EDIT, V46, P4944, DOI 10.1002/anie.200605247
   Chu L.-Q., 2007, ANGEW CHEM, V119, P5032
   CLAYS K, 1991, PHYS REV LETT, V66, P2980, DOI 10.1103/PhysRevLett.66.2980                                                     
   Coe BJ, 2005, J AM CHEM SOC, V127, P4845, DOI 10.1021/ja0424124
   Darbha GK, 2007, ACS NANO, V1, P208, DOI 10.1021/nn7001954
   Durr NJ, 2007, NANO LETT, V7, P941, DOI 10.1021/nl062962v
   Fabris L, 2007, J AM CHEM SOC, V129, P6086, DOI 10.1021/ja0705184
   Galletto P, 1999, J PHYS CHEM B, V103, P8706, DOI 10.1021/jp991937t                                                               
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Grossmann T. N., 2007, ANGEW CHEM, V119, P5315
   Grossmann TN, 2007, ANGEW CHEM INT EDIT, V46, P5223, DOI 10.1002/anie.200700289
   Hennrich G, 2007, CHEM-EUR J, V13, P7753, DOI 10.1002/chem.200700615
   Huang CC, 2007, ANGEW CHEM, V119, P6948, DOI DOI 10.1002/ANGE.200700803
   Huang CC, 2007, ANGEW CHEM INT EDIT, V46, P6824, DOI 10.1002/anie.200700803
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c
   Hubert C, 2005, NANO LETT, V5, P615, DOI 10.1021/nl047956i
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jennings TL, 2006, J AM CHEM SOC, V128, P5462, DOI 10.1021/ja0583665
   Kang H, 2006, J AM CHEM SOC, V128, P6194, DOI 10.1021/ja060185v
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Katz E., 2004, ANGEW CHEM, V116, P6166
   Khanal BP, 2007, ANGEW CHEM INT EDIT, V46, P2195, DOI 10.1002/anie.200604889
   KHANAL BP, 2007, ANGEW CHEM, V119, P2245
   Kujala S, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.167403
   Lal S, 2006, NANO LETT, V6, P2338, DOI 10.1021/nl061892p
   Mie G, 1908, ANN PHYS-BERLIN, V25, P377
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Murphy CJ, 2005, J PHYS CHEM B, V109, P13857, DOI 10.1021/jp0516846
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Novak JP, 2000, J AM CHEM SOC, V122, P12029, DOI 10.1021/ja003129h
   OUDAR JL, 1977, J CHEM PHYS, V67, P446, DOI 10.1063/1.434888                                                                
   Ray PC, 2006, J PHYS CHEM B, V110, P20745, DOI 10.1021/jp0651211
   Ray PC, 2006, ANGEW CHEM INT EDIT, V45, P1151, DOI 10.1002/anie.200503114
   Ray P. C., 2007, NANOTECHNOLOGY, V18
   Russier-Antoine I, 2007, J PHYS CHEM C, V111, P9044, DOI 10.1021/jp0675025
   Satyabrata S., 2007, CHEM-EUR J, V13, P3160
   Sonnichsen C, 2005, NANO LETT, V5, P301, DOI 10.1021/nl048089k
   Strzalka J, 2006, NANO LETT, V6, P2395, DOI 10.1021/nl062092h
   Tiwari VS, 2007, CHEM PHYS LETT, V446, P77, DOI 10.1016/j.cplett.2007.07.106
   Viau L, 2004, J AM CHEM SOC, V126, P8386, DOI 10.1021/ja048143z
   Wang HF, 2005, P NATL ACAD SCI USA, V102, P15752, DOI 10.1073/pnas.0504892102
   XING J, 2006, NATURE, V441, P489
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
NR 46
TC 82
Z9 83
U1 2
U2 37
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0947-6539
J9 CHEM-EUR J
JI Chem.-Eur. J.
PY 2008
VL 14
IS 13
BP 3896
EP 3903
DI 10.1002/chem.200701850
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 298QU
UT WOS:000255703000010
PM 18348156
DA 2018-01-05
ER

PT J
AU Govender, T
   Ojewole, E
   Naidoo, P
   Mackraj, I
AF Govender, T.
   Ojewole, E.
   Naidoo, P.
   Mackraj, I.
TI Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy
SO DRUG DELIVERY
LA English
DT Article
DE AIDS; Antiretroviral; HIV; Nanoparticles; Novel Drug Delivery
ID SOLID LIPID NANOPARTICLES; PRODRUG 3'-AZIDO-3'-DEOXYTHYMIDINE PALMITATE;
   MONOCYTES/MACROPHAGES IN-VITRO; BLOOD-BRAIN-BARRIER;
   METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE; ORAL BIOAVAILABILITY;
   CEREBROSPINAL-FLUID; TARGETED DELIVERY; BODY DISTRIBUTION; HIV
AB There is a surge of interest internationally in the study of nanoparticles for enhancing antiretroviral (ARV) drug therapy. This paper presents a comprehensive review on polymeric nanoparticles for ARV drug therapy. Their main applications for targeting to macrophages and the brain, as well as other studies on modifications to enhance drug loading, decrease toxicity, and also to increase drug absorption are reviewed. The physicochemical characterization properties and their in vitro/in vivo performances are summarized. Further studies that need to be undertaken for formulation optimization are also identified. This review highlights the significant potential that nanoparticles have for the future effective treatment of HIV/AIDS patients on ARV drug therapy.
C1 [Govender, T.; Ojewole, E.; Naidoo, P.] Univ KwaZulu Natal, Sch Pharm & Pharmacol, ZA-4000 Durban, Kwazulu Natal, South Africa.
   [Mackraj, I.] Univ KwaZulu Natal, Sch Med Sci, ZA-4000 Durban, Kwazulu Natal, South Africa.
RP Govender, T (reprint author), Univ KwaZulu Natal, Sch Pharm & Pharmacol, Private Bag X54001, ZA-4000 Durban, Kwazulu Natal, South Africa.
EM govenderth@ukzn.ac.za
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Benghuzzi H, 2000, Biomed Sci Instrum, V36, P343
   Boudad H, 2001, STP PHARMA SCI, V11, P369
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Dipali SR, 1997, INT J PHARM, V152, P89, DOI 10.1016/S0378-5173(97)00070-7
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   FAUCI AS, 1991, HARRISONS PRINCIPLES, P1402
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Girard MP, 2006, VACCINE, V24, P4062, DOI 10.1016/j.vaccine.2006.02.031
   Gopinath D, 2004, INT J PHARM, V271, P95, DOI 10.1016/j.ijpharm.2003.10.032
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   HIGHLEYMAN L, 2003, HIV DRUGS HIV LIFECY
   KAWAGUCHI T, 1991, INT J PHARMACEUT, V77, P71, DOI 10.1016/0378-5173(91)90303-6
   KAWAGUCHI T, 1992, CHEM PHARM BULL, V40, P1338
   KUO YC, 2007, INT J PHARM, V351, P271
   KUO YC, 2007, INT J PHARM
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lucas S, 2001, Intensive Crit Care Nurs, V17, P155, DOI 10.1054/iccn.2000.1541
   MAMALIS AG, 2006, J MAT PROTEC, V181, P52
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   NAIDOO P, SA FAM PRAC IN PRESS, V48
   Narishetty STK, 2005, J CONTROL RELEASE, V102, P59, DOI 10.1016/j.jconrel.2004.09.016
   PAMYAM J, 2003, ADV DRUG DELIV REV, V55, P329
   PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   PIERIBONE D, 2002, HIV LIFE CYCLE
   Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840
   SACHEZLAFUENTE C, 2002, INT J PHARM, V234, P213
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SEKI T, 1994, BIOL PHARM BULL, V17, P1135
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   Stoddart C, 2006, DRUG DISCOV TODAY, V3, P113
   STOLNIK S, 1995, ADV DRUG DELIVER REV, V16, P195, DOI 10.1016/0169-409X(95)00025-3                                                    
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   *UNAIDS, 2007, UNAIDS AIDS EP UPD 2
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Vauthier C, 2003, J CONTROL RELEASE, V93, P151, DOI 10.1016/j.jconrel.2003.08.005
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Xiang J, 2002, INT J PHARM, V231, P57, DOI 10.1016/S0378-5173(01)00865-1
   Yajima T, 1998, BIOL PHARM BULL, V21, P272
NR 56
TC 22
Z9 24
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-7544
J9 DRUG DELIV
JI Drug Deliv.
PY 2008
VL 15
IS 8
BP 493
EP 501
DI 10.1080/10717540802321776
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 360QS
UT WOS:000260073100003
PM 18720133
OA gold
DA 2018-01-05
ER

PT J
AU Foged, C
   Nielsen, HM
AF Foged, Camilla
   Nielsen, Hanne Moerck
TI Cell-penetrating peptides for drug delivery across membrane barriers
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE biomacromolecule; cell-penetrating peptides; colloidal carriers; drug
   delivery; endocytosis; intracellular delivery; nucleic acid; peptide;
   protein; transduction; translocation
ID ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS;
   SMALL INTERFERING RNA; MAMMALIAN-CELLS; INTRACELLULAR DELIVERY; IN-VIVO;
   PHARMACEUTICAL NANOCARRIERS; EFFICIENT DELIVERY; CARGO DELIVERY
AB During the last decade, cell-penetrating peptides have been investigated for their ability to overcome the plasma membrane barrier of mammalian cells for the intracellular or transcellular delivery of cargoes as diverse as low molecular weight drugs, imaging agents, oligonucleotides, peptides, proteins and colloidal carriers such as liposomes and polymeric nanoparticles. Their ability to cross biological membranes in a non-disruptive way without apparent toxicity is highly desired for increasing drug bioavailability. This review provides an overview of the application of cell-penetrating peptides as transmembrane drug delivery agents, according to the recent literature, and discusses critical issues and future challenges in relation to fully understanding the fundamental principles of the cell-penetrating peptide-mediated membrane translocation of cargoes and the exploitation of their therapeutic potential.
C1 [Nielsen, Hanne Moerck] Univ Copenhagen, Dept Pharmaceut & Analyt Chem, DK-2100 Copenhagen O, Denmark.
EM cfo@farma.ku.dk
RI Nielsen, Hanne/L-9481-2015
OI Nielsen, Hanne/0000-0002-7285-9100
FU Danish Research Council for Technology and Production Sciences
FX C Foged is supported financially by a grant from the Danish Research
   Council for Technology and Production Sciences.
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Aussedat B, 2006, BBA-BIOMEMBRANES, V1758, P375, DOI 10.1016/j.bbamem.2006.01.012
   Barany-Wallje E, 2007, FEBS LETT, V581, P2389, DOI 10.1016/j.febslet.2007.04.046
   Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
   Bendifallah N, 2006, BIOCONJUGATE CHEM, V17, P750, DOI 10.1021/bc050253q
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Chen YP, 2006, NAT BIOTECHNOL, V24, P455, DOI 10.1038/nbt1193
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044                                                             
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Foerg C, 2007, PHARM RES, V24, P628, DOI 10.1007/s11095-006-9212-1
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Henriques ST, 2004, BIOCHEMISTRY-US, V43, P9716, DOI 10.1021/bi036325k
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   Lagerholm B Christoffer, 2007, Methods Mol Biol, V374, P105
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Mano M, 2007, J PEPT SCI, V13, P301, DOI 10.1002/psc.842
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Mazel M, 2001, ANTI-CANCER DRUG, V12, P107, DOI 10.1097/00001813-200102000-00003                                                
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Myrberg H, 2007, BIOCONJUGATE CHEM, V18, P170, DOI 10.1021/bc060266g
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nishihara M, 2005, ORG BIOMOL CHEM, V3, P1659, DOI 10.1093/b501472g
   Orzaez M, 2007, PEPTIDES, V28, P958, DOI 10.1016/j.peptides.2007.02.014
   Palm C, 2007, BBA-BIOMEMBRANES, V1768, P1769, DOI 10.1016/j.bbamem.2007.03.029
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Rennert R, 2006, BBA-BIOMEMBRANES, V1758, P347, DOI 10.1016/j.bbamem.2005.10.006
   Resina S, 2007, INT J PHARM, V344, P96, DOI 10.1016/j.ijpharm.2007.04.039
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rousselle C, 2000, FASEB J, V14, pA1480
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sakai N, 2005, CHEMBIOCHEM, V6, P114, DOI 10.1002/cbic.200400256
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trehin R, 2004, BIOCHEM J, V382, P945, DOI 10.1042/BJ20040238                                                              
   Trehin R, 2004, PHARM RES, V21, P33, DOI 10.1023/B:PHAM.0000012149.83119.bf
   Trehin R, 2004, PHARM RES, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P6837, DOI 10.1093/nar/gki991
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Weller K, 2005, BIOCHEMISTRY-US, V44, P15799, DOI 10.1021/bi051535d
   Wolf Y, 2006, BIOCHEMISTRY-US, V45, P14944, DOI 10.1021/bi0606896
   Youngblood DS, 2007, BIOCONJUGATE CHEM, V18, P50, DOI 10.1021/bc060138s
   Zaro JL, 2005, EXP CELL RES, V307, P164, DOI 10.1016/j.yexcr.2005.02.024
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 103
TC 116
Z9 115
U1 3
U2 45
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JAN
PY 2008
VL 5
IS 1
BP 105
EP 117
DI 10.1517/17425247.5.1.105
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 357WK
UT WOS:000259877700007
PM 18095931
DA 2018-01-05
ER

PT J
AU Wendorf, J
   Chesko, J
   Kazzaz, J
   Ugozzoli, M
   Vajdy, M
   O'Hagan, D
   Singh, M
AF Wendorf, Janet
   Chesko, James
   Kazzaz, Jina
   Ugozzoli, Mildred
   Vajdy, Michael
   O'Hagan, Derek
   Singh, Manmohan
TI A comparison of anionic nanoparticles and microparticles as vaccine
   delivery systems
SO HUMAN VACCINES
LA English
DT Article
DE nanoparticles; microparticles; vaccine delivery; vaccine adjuvants
ID IMMUNE-RESPONSE; BIODEGRADABLE MICROPARTICLES; NEISSERIA-MENINGITIDIS;
   PARTICLE-SIZE; CPG DNA; ANTIGEN; IMMUNOGENICITY; MICROSPHERES;
   INTRANASAL; ADJUVANTS
AB The objective of this work was to conduct an in vivo comparison of nanoparticles and microparticles as vaccine delivery systems. Poly (lactide-co-glycolide) (PLG) polymers were used to create nanoparticles size 110 nm and microparticles of size 800-900 nm. Protein antigens were then adsorbed to these particles. The efficacy of these delivery systems was tested with two protein antigens. A recombinant antigen from Neisseria meningitides type B ( MenB) was administered intramuscularly (i.m.) or intraperitonealy (i.p.). An antigen from HIV-1, env glycoprotein gp140 was administered intranasally (i.n.) followed by an i.m. boost. From three studies, there were no differences between the nanoparticles and micro particles formulations. Both particles led to comparable immune responses in mice. The immune responses for MenB ( serum bactericidal activity and antibody titers) were equivalent to the control of aluminum hydroxide. For the gp140, the LTK63 was necessary for high titers. Both nanoparticles and microparticles are promising delivery systems.
C1 [Wendorf, Janet; Chesko, James; Kazzaz, Jina; Ugozzoli, Mildred; Vajdy, Michael; O'Hagan, Derek; Singh, Manmohan] Novartis Vaccines & Diagnost Inc, Emeryville, CA 94608 USA.
RP Singh, M (reprint author), Novartis Vaccines & Diagnost Inc, 4560 Horton St, Emeryville, CA 94608 USA.
EM manmohan.singh@novartis.com
CR Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   Davis HL, 1998, J IMMUNOL, V160, P870
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148                                                     
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Holmgren J, 2005, IMMUNOL LETT, V97, P181, DOI 10.1016/j.imlet.2004.11.009
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Katare YK, 2006, VACCINE, V24, P3599, DOI 10.1016/j.vaccine.2006.01.066
   Katare YK, 2005, INT J PHARM, V301, P149, DOI 10.1016/j.ijpharm.2005.05.028
   Katare YK, 2003, DRUG DELIV, V10, P231, DOI 10.1080/10717540390235454
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   Nagamoto T, 2004, PHARM RES, V21, P671, DOI 10.1023/B:PHAM.0000022414.17183.58
   Nakaoka R, 1996, VACCINE, V14, P1251, DOI 10.1016/S0264-410X(96)00016-3
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   OHAGAN DT, 1993, VACCINE, V11, P965, DOI 10.1016/0264-410X(93)90387-D
   O'Hagan DT, 1994, NOVEL DELIVERY SYSTE, P175
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   PIZZA M, 1994, MOL MICROBIOL, V14, P51, DOI 10.1111/j.1365-2958.1994.tb01266.x
   Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816                                                   
   Quintanar-Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571                                                       
   Singh M, 2006, VACCINE, V24, P1680, DOI 10.1016/j.vaccine.2005.09.046
   Singh M, 2004, J PHARM SCI-US, V93, P273, DOI 10.1002/jps.10538
   Srivastava IK, 2003, J VIROL, V77, P11244, DOI 10.1128/JVI.77.20.11244-11259.2003
   Tabata Y, 1996, VACCINE, V14, P1677, DOI 10.1016/S0264-410X(96)00149-1
   Vajdy M, 2004, AIDS RES HUM RETROV, V20, P1269, DOI 10.1089/aid.2004.20.1269
   Vila A, 2004, J AEROSOL MED, V17, P174, DOI 10.1089/0894268041457183
   Wall RA, 2002, ANN MED, V34, P624, DOI 10.1080/078538902321117850
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
NR 32
TC 32
Z9 33
U1 0
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1554-8619
J9 HUM VACCINES
JI Hum. Vaccines
PD JAN-FEB
PY 2008
VL 4
IS 1
BP 44
EP 49
DI 10.4161/hv.4.1.4886                                                     
          
PG 6
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA 317DX
UT WOS:000257001000006
PM 18438105
OA gold
DA 2018-01-05
ER

PT J
AU Prasad, KK
   Verma, S
AF Prasad, K. Krishna
   Verma, Sandeep
TI Facilitation of peptide fibre formation by
   arginine-phosphate/carboxylate interactions
SO JOURNAL OF CHEMICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT 10th National Symposium in Chemistry
CY FEB 01-03, 2008
CL Indian Inst Sci, Bangalore, INDIA
SP Chem Res Soc India
HO Indian Inst Sci
DE peptide; self-assembly; arginine; microscopy
ID AMPHIPHILE NANOFIBERS; AGGREGATION; CONJUGATE; BINDING; PROTEIN; HIV-1;
   SITE; GUANIDINIUM; RECOGNITION; ATTRACTION
AB This study describes peptide fibre formation in a hexapeptide, derived from the V3 loop of HIV-1, mediated by the interactions between arginine residues and phosphate/carboxylate anions. This charge neutralization approach was further confirmed when the deletion of arginine residue from the hexapeptide sequence resulted in fibre formation, which was studied by a combination of microscopic techniques.
C1 [Prasad, K. Krishna; Verma, Sandeep] Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
RP Verma, S (reprint author), Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
EM sverma@iitk.ac.in
CR Aggeli A, 2003, J AM CHEM SOC, V125, P9619, DOI 10.1021/ja021047i
   Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298                                                          
   ANTICLIFF JF, 2005, EMBO J, V24, P229
   BATEMAN RC, 1989, J BIOL CHEM, V264, P6151
   Behanna HA, 2005, J AM CHEM SOC, V127, P1193, DOI 10.1021/ja044863u
   BRANLANT G, 1982, EUR J BIOCHEM, V121, P407, DOI 10.1111/j.1432-1033.1982.tb05802.x
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   Caplan MR, 2000, BIOMACROMOLECULES, V1, P627, DOI 10.1021/bm005586w
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Colombo G, 2007, TRENDS BIOTECHNOL, V25, P211, DOI 10.1016/j.tibtech.2007.03.004
   de Parseval A, 2005, J BIOL CHEM, V280, P39493, DOI 10.1074/jbc.M504233200
   Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829                                                        
   Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp                                                           
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   Ghosh S, 2007, ANGEW CHEM INT EDIT, V46, P2002, DOI 10.1002/anie.200604383
   Ghosh S, 2007, J PHYS CHEM B, V111, P3750, DOI 10.1021/jp066546a
   Haack T, 1999, J AM CHEM SOC, V121, P11813, DOI 10.1021/ja9910154                                                               
   JOSHI KB, 2007, J PEP SCI, P955
   Koga T, 2006, CHEM-EUR J, V12, P1360, DOI 10.1002/chem.200500611
   Konno T, 2001, BIOCHEMISTRY-US, V40, P2148, DOI 10.1021/bi002156h
   Lougheed T, 2004, BIOORGAN MED CHEM, V12, P1337, DOI 10.1016/j.bmc.2003.06.005
   Madhavaiah C, 2005, TETRAHEDRON LETT, V46, P3745, DOI 10.1016/j.tetlet.2005.03.145
   Madhavaiah C, 2004, CHEM COMMUN, P638, DOI 10.1039/b316793c
   Mesquida P, 2005, ADV MATER, V17, P893, DOI 10.1002/adma.200401229                                                          
   Niece KL, 2003, J AM CHEM SOC, V125, P7146, DOI 10.1021/ja028215r
   Ozbas B, 2004, MACROMOLECULES, V37, P7331, DOI 10.1021/ma0491762
   Pantos A, 2005, LANGMUIR, V21, P7483, DOI 10.1021/la0510331
   Paramonov SE, 2006, J AM CHEM SOC, V128, P7291, DOI 10.1021/ja060573x
   Perez-Salas UA, 2004, BIOCHEMISTRY-US, V43, P1746, DOI 10.1021/bi035642o
   Prasad KK, 2006, BIOPOLYMERS, V83, P289, DOI 10.1002/bip.20562
   Prasad KK, 2005, CHEM COMMUN, P2564, DOI 10.1039/b500654f
   Ribalet B, 2003, BIOPHYS J, V84, P266, DOI 10.1016/S0006-3495(03)74847-4                                                   
   Ryadnov MG, 2003, ANGEW CHEM INT EDIT, V42, P3021, DOI 10.1002/anie.200351418
   Sano KI, 2003, J AM CHEM SOC, V125, P14234, DOI 10.1021/ja038414q
   Schug KA, 2005, CHEM REV, V105, P67, DOI 10.1021/cr040603j
   Stendahl JC, 2006, ADV FUNCT MATER, V16, P499, DOI 10.1002/adfm.200500161
   Takahashi Y, 2002, MACROMOL RAPID COMM, V23, P540, DOI 10.1002/1521-3927(20020601)23:9<540::AID-MARC540>3.0.CO;2-7                     
   TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051                                                             
   TSIKARIS V, 1992, PEPTIDE RES, V5, P110
   Tsonchev S, 2004, J PHYS CHEM B, V108, P8817, DOI 10.1021/jp037731g
   Tsonchev S, 2003, NANO LETT, V3, P623, DOI 10.1021/nl0340531
NR 41
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0253-4134
J9 J CHEM SCI
JI J. Chem. Sci.
PD JAN
PY 2008
VL 120
IS 1
BP 155
EP 162
DI 10.1007/s12039-008-0018-z
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 272AL
UT WOS:000253829700018
DA 2018-01-05
ER

PT J
AU Kaur, CD
   Nahar, M
   Jain, NK
AF Kaur, Chanchal Deep
   Nahar, Manoj
   Jain, Narendra K.
TI Lymphatic targeting of zidovudine using surface-engineered liposomes
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE HIV; lymphatic targeting; surface-engineered liposomes; zidovudine
ID HEMATOPOIETIC TOXICITY; ENHANCED ACTIVITY; DRUG-DELIVERY; MACROPHAGES;
   AIDS; PHOSPHOLIPIDS; ENCAPSULATION; LOCALIZATION; NODES
AB The present investigation was aimed at lymphatic targeting of zidovudine (ZDV)-loaded surface-engineered liposomes (SE liposomes). Surface of liposomes was engineered by incorporation of charges (positive or negative) and site-specific ligand (mannose) in order to enhance localization to lymphatics, specifically to lymph node and spleen. Positively and negatively charged nanosized SE liposomes (12010nm) were prepared using stearylamine (SA) and dicetyl phosphate (DCP), respectively, while ligand-coated SE liposomes were prepared using mannose-terminated SA (mannose conjugate). The SE liposomes were characterized for shape and surface morphology, size, entrapment efficiency, and in vitro drug release. All the SE liposomes formulations showed biphasic ZDV release, whereas mannose-coated liposomes (MAN-Lip) significantly reduced (p0.05) drug release compared with conventional liposome (Lip). The organ distribution pattern of the SE liposomes exhibited significant reduction in free ZDV concentration in serum, whereas significantly increased quantity was detected in the spleen and lymph nodes (p0.05). Fluorescent microscopy suggested enhanced uptake and localization of the SE liposomes in the lymph nodes and spleen, which were in the order: mannose coatednegatively chargedpositively chargedLip. Thus, the SE liposomes appeared to be promising novel vesicular system for enhanced targeting of ZDV to lymphatics, in AIDS chemotherapy.
C1 [Kaur, Chanchal Deep; Nahar, Manoj; Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, India.
EM mnjnahar@yahoo.co.in; jnarendr@yahoo.co.in
OI Kaur, Chanchal Deep/0000-0002-0890-2397
FU University Grants Commission, New Delhi, India
FX One of the authors Mrs Chanchal acknowledges the University Grants
   Commission, New Delhi, India, for providing financial assistance to
   carry out this work. The authors are also thankful to Dr N. Ganesh,
   Research Scientist, Jawaharlal Nehru Cancer Hospital, Bhopal, India, for
   undertaking fluorescence microscopic studies, and All Indian Institute
   of Medical Sciences, New Delhi, India, for providing electron microscope
   facility.
CR Allen TM, 1996, ADV DRUG DELIVER REV, V21, P117, DOI 10.1016/S0169-409X(96)00402-4
   AMIJI MM, 2006, EXPERT OPIN DRUG DEL, V3, P613
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   BARRATT G, 1986, BIOCHIM BIOPHYS ACTA, V862, P153, DOI 10.1016/0005-2736(86)90479-7
   BERGQVIST L, 1984, CHARACTERIZATION RAD, P263
   CHIEN Y W, 1989, Drugs of Today, V25, P19
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   GARCON N, 1988, IMMUNOLOGY, V64, P743
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   HIRANO K, 1985, J PHARM SCI, V74, P915, DOI 10.1002/jps.2600740902                                                          
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   MANGAT S, 1985, LIFE SCI, V36, P1917, DOI 10.1016/0024-3205(85)90440-0
   Mitchell JP, 1999, BIOORG MED CHEM LETT, V9, P2785, DOI 10.1016/S0960-894X(99)00480-1
   MOHAN P, 1992, PHARM RES-DORDR, V9, P703, DOI 10.1023/A:1015882901078                                                         
   Mukhopadhyay A, 2003, ADV BIOCHEM ENG BIOT, V84, P183
   MULLER CD, 1989, BIOCHIM BIOPHYS ACTA, V986, P97, DOI 10.1016/0005-2736(89)90277-0
   Oussoren C, 1998, INT J PHARM, V162, P39, DOI 10.1016/S0378-5173(97)00410-9
   Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5
   PATEL HM, 1984, BIOCHIM BIOPHYS ACTA, V801, P76, DOI 10.1016/0304-4165(84)90214-9
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   SINGH M, 1999, UNDERSTANDING AIDS, P51
   TUMER A, 1983, BIOCHIM BIOPHYS ACTA, V760, P119, DOI 10.1016/0304-4165(83)90132-0
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   YAMASHITA C, 1991, JPN J CANCER RES, V82, P569, DOI 10.1111/j.1349-7006.1991.tb01888.x                                              
NR 26
TC 44
Z9 45
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 2008
VL 16
IS 10
BP 798
EP 805
AR PII 905457495
DI 10.1080/10611860802475688
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 371SP
UT WOS:000260851900008
PM 19005941
DA 2018-01-05
ER

PT J
AU Wang, X
   Uto, T
   Akagi, T
   Akashi, M
   Baba, M
AF Wang, Xin
   Uto, Tomofumi
   Akagi, Takami
   Akashi, Mitsuru
   Baba, Masanori
TI Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery
   and adjuvant system: Potential for an AIDS vaccine
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE nanoparticle; antigen delivery; adjuvant; dendritic cell; HIV-1
ID HUMAN DENDRITIC CELLS; INACTIVATED HIV-1-CAPTURING NANOSPHERES;
   BIODEGRADABLE MICROPARTICLES; CAPTURING NANOSPHERES; ANTIBODY-RESPONSE;
   IMMUNE-RESPONSES; IN-VITRO; T-CELLS; IMMUNIZATION; INDUCTION
AB Antigen delivery systems using polymeric nanoparticles are of special interest as stable protein-based antigen carriers. In the present study, novel biodegradable poly(,gamma-glutamic acid) (gamma-PGA) nanoparticles were examined for their antigen delivery and immunostimulatory activities in vitro and in vivo. The uptake of ovalbumin by dendritic cells was markedly enhanced by gamma-PGA nanoparticles, and the ovalbumin was gradually released from gamma-PGA nanoparticles into the cells. In addition, gamma-PGA nanoparticles appeared to have great potential as an adjuvant, because they could induce the maturation of dendritic cells. Although not only ovalbumin-encapsulating nanoparticles (OVA-NPs) but also a simple mixture of ovalbumin and nanoparticles induced dendritic cell maturation, the only dendritic cells exposed to OVA-NPs could strongly activate antigen-specific interferon (IFN)-gamma-producing T cells. Subcutaneous immunization of mice with human immunodeficiency virus type 1 (HIV-1) p24-encapsulating nanoparticles activated antigen-specific IFN-gamma-producing T cells in spleen cells and induced p24-specific serum antibodies, as compared to immunization with p24 alone. Like ovalbumin, a mixture of p24 and nanoparticles also induced antigen-specific serum antibodies but did not activate IFN-gamma-producing T cells in spleen cells, suggesting that nanoparticles play a critical role in inducing cellular immune responses. Furthermore, gamma-PGA nanoparticles had a capacity comparable to that of the complete Freund's adjuvant (CFA) in inducing p24-specific serum antibody. However, unlike CFA, they predominantly activated p24-specific IFN-gamma-producing T cells. Thus, gamma-PGA nanoparticles encapsulating various antigens may have great potential as novel and efficient protein-based vaccines against infectious diseases, including HIV-1 infection.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, 8-35-1,Sakuragaoka, Kagoshima 8908544, Japan.
EM m-baba@vanilla.ocn.ne.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fonteneau JF, 2003, BLOOD, V102, P4448, DOI 10.1182/bloo-2003-06-1801
   Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911
   Jilek S, 2005, ADV DRUG DELIVER REV, V57, P377, DOI 10.1016/j.addr.2004.09.010
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Kerkmann M, 2006, OLIGONUCLEOTIDES, V16, P313, DOI 10.1089/oli.2006.16.313
   Labeur MS, 1999, J IMMUNOL, V162, P168
   Levine MM, 2004, NAT IMMUNOL, V5, P460, DOI 10.1038/ni0504-465
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Mascola JR, 1999, J VIROL, V73, P4009
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   OHagan DT, 1996, J ANAT, V189, P477
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4
   Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Singh M, 1997, VACCINE, V15, P1773, DOI 10.1016/S0264-410X(97)00109-6
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   Waeckerle-Men Y, 2006, VACCINE, V24, P1847, DOI 10.1016/j.vaccine.2005.10.032
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Wang X, 2007, MINI-REV ORG CHEM, V4, P51, DOI 10.2174/157019307779815857                                                      
   WOODARD LF, 1985, VACCINE, V3, P137, DOI 10.1016/0264-410X(85)90063-5
NR 33
TC 61
Z9 63
U1 0
U2 16
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD JAN
PY 2008
VL 80
IS 1
BP 11
EP 19
DI 10.1002/jmv.21029
PG 9
WC Virology
SC Virology
GA 236XE
UT WOS:000251335900003
PM 18041033
OA gold
DA 2018-01-05
ER

PT J
AU Shimura, K
   Kodama, E
   Sakagami, Y
   Matsuzaki, Y
   Watanabe, W
   Yamataka, K
   Watanabe, Y
   Ohata, Y
   Doi, S
   Sato, M
   Kano, M
   Ikeda, S
   Matsuoka, M
AF Shimura, Kazuya
   Kodama, Eiichi
   Sakagami, Yasuko
   Matsuzaki, Yuji
   Watanabe, Wataru
   Yamataka, Kazunobu
   Watanabe, Yasuo
   Ohata, Yoshitsugu
   Doi, Satoki
   Sato, Motohide
   Kano, Mitsuki
   Ikeda, Satoru
   Matsuoka, Masao
TI Broad Antiretroviral activity and resistance profile of the novel human
   immunodeficiency virus integrase inhibitor elvitegravir
   (JTK-303/GS-9137)
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HIV-1 INTEGRASE; REVERSE-TRANSCRIPTASE; PROTEASE INHIBITORS; DNA
   INTEGRATION; IN-VITRO; MOLECULAR-MECHANISMS; EXPERIENCED PATIENTS;
   POTENT INHIBITORS; VIRAL REPLICATION; MONONUCLEAR-CELLS
AB Integrase (IN), an essential enzyme of human immunodeficiency virus (HIV), is an attractive antiretroviral drug target. The antiviral activity and resistance profile in vitro of a novel IN inhibitor, elvitegravir (EVG) (also known as JTK-303/GS-9137), currently being developed for the treatment of HIV-1 infection are described. EVG blocked the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. EVG inhibited the replication of HIV-1, including various subtypes and multiple-drug-resistant clinical isolates, and HIV-2 strains with a 50% effective concentration in the subnanomolar to nanomolar range. EVG-resistant variants were selected in two independent inductions, and a total of 8 amino acid substitutions in the catalytic core domain of IN were observed. Among the observed IN mutations, T661 and E92Q substitutions mainly contributed to EVG resistance. These two primary resistance mutations are located in the active site, and other secondary mutations identified are proximal to these primary mutations. The EVG-selected IN mutations, some of which represent novel IN inhibitor resistance mutations, conferred reduced susceptibility to other IN inhibitors, suggesting that a common mechanism is involved in resistance and potential cross-resistance. The replication capacity of EVG-resistant variants was significantly reduced relative to both wild-type virus and other IN inhibitor-resistant variants selected by L-870,810. EVG and L-870,810 both inhibited the replication of murine leukemia virus and simian immunodeficiency virus, suggesting that IN inhibitors bind to a conformationally conserved region of various retroviral IN enzymes and are an ideal drug for a range of retroviral infections.
C1 [Shimura, Kazuya; Kodama, Eiichi; Sakagami, Yasuko; Matsuoka, Masao] Kyoto Univ, Inst Virus Res, Lab Virus Immunol, Sakyo Ku, Kyoto 6068507, Japan.
   [Sakagami, Yasuko; Matsuzaki, Yuji; Watanabe, Wataru; Yamataka, Kazunobu; Watanabe, Yasuo; Ohata, Yoshitsugu; Sato, Motohide; Kano, Mitsuki; Ikeda, Satoru] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Osaka 5691125, Japan.
   [Doi, Satoki] Japan Tabacco Inc, Cent Pharmaceut Res Inst, Pharmaceut Frontier Res Lab, Kanazawa Ku, Kanagawa 2360004, Japan.
RP Kodama, E (reprint author), Kyoto Univ, Inst Virus Res, Lab Virus Immunol, Sakyo Ku, 53 Kawara Machi, Kyoto 6068507, Japan.
EM ekodama@virus.kyoto-u.ac.jp
RI Kodama, Eiichi/C-4032-2009
OI Kodama, Eiichi/0000-0002-6622-2752; Matsuoka, Masao/0000-0002-0473-754X;
   SHIMURA, Kazuya/0000-0001-7819-5184
CR Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6
   BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X                                                    
   BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125
   Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979                                                                   
   Chackerian B, 1997, J VIROL, V71, P3932
   Chakrabarti LA, 2003, J VIROL, V77, P1245, DOI 10.1128/JVI.77.2.1245-1256.2003
   Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200
   Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   Cooper DA, 2007, 14 C RETR OPP INF
   De Luca L, 2005, BIOCHEM BIOPH RES CO, V336, P1010, DOI 10.1016/j.bbrc.2005.08.211
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C
   Fan J, 2005, CANCER RES, V65, P6927, DOI 10.1158/0008-5472.CAN-04-3495                                                   
   Fikkert V, 2004, AIDS, V18, P2019, DOI 10.1097/00002030-200410210-00006
   Fikkert V, 2003, J VIROL, V77, P11459, DOI 10.1128/JVI.77.21.11459-11470.2003
   Gatanaga H, 2002, J BIOL CHEM, V277, P5952, DOI 10.1074/jbc.M108005200
   Gleenberg IO, 2005, J BIOL CHEM, V280, P21987, DOI 10.1074/jbc.M414679200
   Goldberg D, 1998, Commun Dis Public Health, V1, P95
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004
   JONES GR, 2007, 14 C RETR OPP INF
   KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128
   Kaufmann GR, 2000, CURR OPIN MICROBIOL, V3, P508, DOI 10.1016/S1369-5274(00)00131-4
   Kehlenbeck S, 2006, J VIROL, V80, P6883, DOI 10.1128/JVI.00306-06
   Kodama EI, 2001, ANTIMICROB AGENTS CH, V45, P1539, DOI 10.1128/AAC.45.5.1539-1546.2001
   LAFEMINA RL, 1992, J VIROL, V66, P7414
   Lee MC, 2005, BIOPHYS J, V88, P3133, DOI 10.1529/biophysj.104.058446
   LITTLE S, 2005, 12 C RETR OPP INF
   *LOS AL NAT LAB TH, 2001, HIV SEQ COMP 2001
   Matsuoka-Aizawa S, 2003, J VIROL, V77, P318, DOI 10.1128/JVI.77.1.318-327.2003
   Myint L, 2004, ANTIMICROB AGENTS CH, V48, P444, DOI 10.1128/AAC.48.2.444-452.2004
   Nameki D, 2005, J VIROL, V79, P764, DOI 10.1128/JVI.79.2.764-770.2005
   Neuveut C, 1996, J VIROL, V70, P5572
   PATELLA F, 1998, NEW ENGL J MED, V338, P853
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Reinke R, 2002, ANTIMICROB AGENTS CH, V46, P3301, DOI 10.1128/AAC.46.10.3301-3303.2002
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Savarino A, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-21
   Sharma PL, 1997, J VIROL, V71, P8846
   SHIBATA R, 1991, J VIROL, V65, P3514
   SHIN CG, 1994, J VIROL, V68, P1633
   STEIGBIGEL R, 2007, 14 C RETR OPP INF
   Sugiura W, 2002, ANTIMICROB AGENTS CH, V46, P708, DOI 10.1128/AAC.46.3.708-715.2002
   TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704                                                           
   Toossi Z, 2005, CLIN EXP IMMUNOL, V142, P327, DOI 10.1111/j.1365-2249.2005.02913.x
   Verheyen J, 2006, ANTIVIR THER, V11, P879
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6                                                    
   White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002
   Zolopa A.R., 2007, 14 C RETR OPP INF
NR 56
TC 212
Z9 224
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 2008
VL 82
IS 2
BP 764
EP 774
DI 10.1128/JVI.01534-07
PG 11
WC Virology
SC Virology
GA 249LF
UT WOS:000252229100018
PM 17977962
OA gold
DA 2018-01-05
ER

PT J
AU Jokerst, JV
   Floriano, PN
   Christodoulides, N
   Simmons, GW
   McDevitt, JT
AF Jokerst, Jesse V.
   Floriano, Pierre N.
   Christodoulides, Nicolaos
   Simmons, Glennon W.
   McDevitt, John T.
TI Integration of semiconductor quantum dots into nano-bio-chip systems for
   enumeration of CD4+T cell counts at the point-of-need
SO LAB ON A CHIP
LA English
DT Article
ID C-REACTIVE PROTEIN; HUMAN CD4(+) CELLS; FLOW-CYTOMETRY; HIGH-THROUGHPUT;
   CARDIAC RISK; ASSAY SYSTEM; ON-CHIP; NANOCRYSTALS; SENSOR; CONJUGATION
AB Recent humanitarian efforts have led to the widespread release of antiretroviral drugs for the treatment of the more than 33 million HIV afflicted people living in resource-scarce settings. Here, the enumeration of CD4+ T lymphocytes is required to establish the level at which the immune system has been compromised. The gold standard method used in developed countries, based on flow cytometry, though widely accepted and accurate, is precluded from widespread use in resource-scarce settings due to its high expense, high technical requirements, difficulty in operation-maintenance and the lack of portability for these sophisticated laboratory-confined systems. As part of continuing efforts to develop practical diagnostic instrumentation, the integration of semiconductor nanocrystals (quantum dots, QDs) into a portable microfluidic-based lymphocyte capture and detection device is completed. This integrated system is capable of isolating and counting selected lymphocyte sub-populations (CD3+CD4+) from whole blood samples. By combining the unique optical properties of the QDs with the sample handling capabilities and cost effectiveness of novel microfluidic systems, a practical, portable lymphocyte measurement modality that correlates nicely with flow cytometry (R(2) = 0.97) has been developed. This QD-based system reduces the optical requirements significantly relative to molecular fluorophores and the mini-CD4 counting device is projected to be suitable for use in both point-of-need and resource-scarce settings.
C1 [Jokerst, Jesse V.; Floriano, Pierre N.; Christodoulides, Nicolaos; Simmons, Glennon W.; McDevitt, John T.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA.
   [McDevitt, John T.] Univ Texas Austin, Ctr Nano & Mol Sci & Technol, Austin, TX 78712 USA.
   [McDevitt, John T.] Univ Texas Austin, Texas Mat Inst, Austin, TX 78712 USA.
RP McDevitt, JT (reprint author), Univ Texas Austin, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.
EM mcdevitt@mail.utexas.edu
RI McDevitt, John/P-4108-2014
OI McDevitt, John/0000-0001-8789-9351
FU National Institutes of Health [1 U01 DE017793-01]; Bill and Melinda
   Gates Foundation; Welch Foundation [F-1193]
FX This work was supported by grants from the National Institutes of Health
   (1 U01 DE017793-01), the Bill and Melinda Gates Foundation, and the
   Welch Foundation (F-1193).
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   BOCSI J, 2006, P SPIE, V6096
   BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243
   CDC, 1997, MMWR, V46
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Chattopadhyay PK, 2006, NAT MED, V12, P972, DOI 10.1038/nm1371
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Christodoulides N, 2005, LAB CHIP, V5, P261, DOI 10.1039/b414194f
   Christodoulides N, 2005, CLIN CHEM, V51, P2391, DOI 10.1373/clinchem.2005.054882
   Christodoulides N, 2002, ANAL CHEM, V74, P3030, DOI 10.1021/ac011150a
   Clapp AR, 2006, NAT PROTOC, V1, P1258, DOI 10.1038/nprot.2006.184
   Cohen J, 2004, SCIENCE, V304, P1936, DOI 10.1126/science.304.5679.1936
   Cottingham K, 2005, ANAL CHEM, V77, p354A, DOI 10.1021/ac053454t                                                               
   Dainiak MB, 2007, ADV BIOCHEM ENG BIOT, V106, P1, DOI 10.1007/10_2007_069
   Davis KA, 1998, CYTOMETRY, V33, P197, DOI 10.1002/(SICI)1097-0320(19981001)33:2<197::AID-CYTO14>3.0.CO;2-P                
   Empedocles SA, 1996, PHYS REV LETT, V77, P3873, DOI 10.1103/PhysRevLett.77.3873
   Gao XH, 2004, ANAL CHEM, V76, P2406, DOI 10.1021/ac0354600
   Goldman Ellen R, 2007, Methods Mol Biol, V374, P207
   Goldman ER, 2002, J AM CHEM SOC, V124, P6378, DOI 10.1021/ja0125570
   Goodey A, 2001, J AM CHEM SOC, V123, P2559, DOI 10.1021/ja003341l
   Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562                                                               
   Hua XF, 2006, ANAL BIOANAL CHEM, V386, P1665, DOI 10.1007/s00216-006-0807-5
   Jovin TM, 2003, NAT BIOTECHNOL, V21, P32, DOI 10.1038/nbt0103-32
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   Kyewski B, 2008, SCIENCE, V321, P776, DOI 10.1126/science.1162966
   Lavigne JJ, 1998, J AM CHEM SOC, V120, P6429, DOI 10.1021/ja9743405                                                               
   Liu W, 2008, J AM CHEM SOC, V130, P1274, DOI 10.1021/ja076069p
   Liu WH, 2007, J AM CHEM SOC, V129, P14530, DOI 10.1021/ja073790m
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   MEDINTZ IL, 2005, PMSE PREPRINTS, V93, P5
   MEDINTZ IL, 2003, PMSE PREPRINTS, V89, P205
   Mishra NN, 2005, BIOSENS BIOELECTRON, V21, P696, DOI 10.1016/j.bios..2005.01.011
   MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025                                                             
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Parak WJ, 2003, NANOTECHNOLOGY, V14, pR15, DOI 10.1088/0957-4484/14/7/201
   Pathak S, 2007, NANO LETT, V7, P1839, DOI 10.1021/nl062706i
   Potapova I, 2003, J AM CHEM SOC, V125, P320, DOI 10.1021/ja028641c
   Resch-Genger U, 2008, NAT METHODS, V5, P763, DOI 10.1038/NMETH.1248
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Simonnet C, 2006, ANAL CHEM, V78, P5653, DOI 10.1021/ac060340o
   Skaff H, 2004, J AM CHEM SOC, V126, P11322, DOI 10.1021/ja047260r
   Song EQ, 2007, CLIN CHEM, V53, P2177, DOI 10.1373/clinchem.2007.092023
   Sukhanova A, 2004, ANAL BIOCHEM, V324, P60, DOI 10.1016/j.ab.2003.09.031
   Tanabe R, 2006, MICROELECTRON ENG, V83, P1646, DOI 10.1016/j.mee.2006.01.233
   Thorslund S, 2007, SENSOR ACTUAT B-CHEM, V123, P847, DOI 10.1016/j.snb.2006.10.034
   Truett AA, 2006, JAIDS-J ACQ IMM DEF, V41, P168, DOI 10.1097/01.qai.0000191282.77954.fc
   Tudos AJ, 2001, LAB CHIP, V1, P83, DOI 10.1039/b106958f
   *UN PROG HIV AIDS, 2007, AIDS EP UPD
   Vilkner T, 2004, ANAL CHEM, V76, P3373, DOI 10.1021/ac040063q
   Weigum SE, 2007, LAB CHIP, V7, P995, DOI 10.1039/b703918b
   Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872
   *WHO UNAIDS, 2005, CD 4 T CELL EN TECHN
   Xiao Y, 2008, INT J CANCER, V122, P2178, DOI 10.1002/ijc.23320
   Xing Y, 2007, NAT PROTOC, V2, P1152, DOI 10.1038/nprot.2007.107
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yarchoan R, 2005, NAT CLIN PRACT ONCOL, V2, P406, DOI 10.1038/ncponc0253
   Zajac A, 2007, COLLOID SURFACE B, V58, P309, DOI 10.1016/j.colsurfb.2007.02.019
   Zheng SY, 2008, SENSOR ACTUAT B-CHEM, V132, P558, DOI 10.1016/j.snb.2007.11.031
   ZIJENAH LS, 2006, J T MED, V4
NR 62
TC 42
Z9 42
U1 0
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2008
VL 8
IS 12
BP 2079
EP 2090
DI 10.1039/b817116e
PG 12
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 383PT
UT WOS:000261686200013
PM 19023471
OA green_accepted
DA 2018-01-05
ER

PT J
AU Lee, SH
   Kim, SW
   Kang, JY
   Ahn, CH
AF Lee, Soo Hyun
   Kim, Sung-Woo
   Kang, Ji Yoon
   Ahn, Chong H.
TI A polymer lab-on-a-chip for reverse transcription (RT)-PCR based
   point-of-care clinical diagnostics
SO LAB ON A CHIP
LA English
DT Article
ID CHAIN-REACTION AMPLIFICATION; DNA AMPLIFICATION; NANOLITER VOLUMES; PCR;
   SYSTEM; DEVICE; BIOCHIP; VALVES
AB An innovative polymer lab-on-a-chip (LOC) for reverse transcription (RT)-polymerase chain reaction (PCR) has been designed, fabricated, and characterized for point-of-care testing (POCT) clinical diagnostics. In addition, a portable analyzer that consists of a non-contact infrared (IR) based temperature control system for RT-PCR process and an optical detection system for on-chip detection, has also been developed and used to monitor the RT-PCR LOC. The newly developed LOC and analyzer have been interfaced and optimized for performing RT-PCR procedures and chemiluminescence assays in sequence. As a clinical diagnostic application, human immunodeficiency virus (HIV) for the early diagnosis of acquired immune deficiency syndrome (AIDS) has been successfully detected and analyzed using the newly developed LOC and analyzer, where the primer sets for p24 and gp120 were used as the makers for HIV. The developed polymer LOC and analyzer for RTPCR can be used for POCT for the analysis of HIV with the on-chip RT-PCR and chemiluminescence assays in shorter than one hour with minimized cross-contamination.
C1 [Lee, Soo Hyun; Ahn, Chong H.] Univ Cincinnati, Dept Elect & Comp Engn, Microsyst & BioMEMS Lab, Cincinnati, OH 45221 USA.
   [Lee, Soo Hyun; Kang, Ji Yoon] Korea Inst Sci & Technol, NanoBio Res Ctr, Seoul 130650, South Korea.
   [Kim, Sung-Woo] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA.
RP Lee, SH (reprint author), Univ Cincinnati, Dept Elect & Comp Engn, Microsyst & BioMEMS Lab, Cincinnati, OH 45221 USA.
EM dream.ideal@gmail.com; chong.ahn@uc.edu
CR Belgrader P, 2003, ANAL CHEM, V75, P3446, DOI 10.1021/ac034062u
   CREWS N, 2007, P SPIE, V6465
   Curcio M, 2003, ANAL CHEM, V75, P1, DOI 10.1021/ac0204146
   Gulliksen A, 2004, ANAL CHEM, V76, P9, DOI 10.1021/ac034779h
   HAN J, 2005, 9 INT C MIN SYST CHE, P43
   Huang WJ, 2000, POLYMER, V41, P6095, DOI 10.1016/S0032-3861(99)00842-3                                                   
   Huhmer AFR, 2000, ANAL CHEM, V72, P5507, DOI 10.1021/ac000423j
   Koh CG, 2003, ANAL CHEM, V75, P4591, DOI 10.1021/ac0343836
   Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046
   Lee TMH, 2003, LAB CHIP, V3, P100, DOI 10.1039/b300799e
   Liao CS, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni157
   Lin YC, 2000, SENSOR ACTUAT B-CHEM, V71, P2, DOI 10.1016/S0925-4005(00)00558-X                                                   
   Liu J, 2002, ELECTROPHORESIS, V23, P1531, DOI 10.1002/1522-2683(200205)23:10<1531::AID-ELPS1531>3.0.CO;2-D                    
   Liu RH, 2004, ANAL CHEM, V76, P1824, DOI 10.1021/ac0353029
   Liu YJ, 2002, ANAL CHEM, V74, P3063, DOI 10.1021/ac020094q
   Mullis K.B., 1994, POLYM CHAIN REACTION
   Northrup M. A., 1995, 8th International Conference on Solid-State Sensors and Actuators and Eurosensors IX. Digest of Technical Papers (IEEE Cat. No.95TH8173), P764
   Obeid PJ, 2003, ANAL CHIM ACTA, V494, P1, DOI 10.1016/S0003-2670(03)00898-5
   Oda RP, 1998, ANAL CHEM, V70, P4361, DOI 10.1021/ac980452i                                                               
   Oh KW, 2005, J MICROMECH MICROENG, V15, P2449, DOI 10.1088/0960-1317/15/12/029
   Schneegass I, 2001, LAB CHIP, V1, P42, DOI 10.1039/b103846j
   TIMOTHY CG, 2004, J CLIN VIROL, V30, P229
   WANG C, 2006, 19 IEEE INT C MEMS, P374
   Wang J, 2005, BIOMED MICRODEVICES, V7, P313, DOI 10.1007/s10544-005-6073-z
   Weast RC, 1983, CRC HDB CHEM PHYS
   West J, 2002, LAB CHIP, V2, P224, DOI 10.1039/b206756k
   Yoon DS, 2002, J MICROMECH MICROENG, V12, P813, DOI 10.1088/0960-1317/12/6/312
   Zhao Z, 2003, SENSOR ACTUAT A-PHYS, V108, P162, DOI 10.1016/S0924-4247(03)00258-9
   Zhou ZM, 2004, ELECTROPHORESIS, V25, P3032, DOI [10.1002/elps.200305965, 10.1002/elps.200305966]
NR 29
TC 66
Z9 66
U1 3
U2 33
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2008
VL 8
IS 12
BP 2121
EP 2127
DI 10.1039/b811131f
PG 7
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 383PT
UT WOS:000261686200017
PM 19023475
DA 2018-01-05
ER

PT S
AU Ray, PC
   Darbha, GK
   Nittala, MR
   Yu, HT
   Griffin, J
AF Ray, Paresh Chandra
   Darbha, Gopala Krishna
   Nittala, Marry R.
   Yu, Hongtao
   Griffin, Jelani
BE Collery, P
   Maymard, I
   Theophanides, T
   Khassanova, L
   Collery, T
TI Gold nanoparticle based NSET probe for HIV-1 DNA and breast cancer cell
   detection
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 10
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 10th International Symposium on Metal Ions in Biology and Medicine
CY MAY 19-22, 2008
CL Bastia, FRANCE
SP Polyclin Maymard
DE HIV-1 DNA detection; cancer cell detection; gold nanoparticle; NSET
ID NANORODS; HYBRIDIZATION; THERAPY; SENSORS; MERCURY
AB AIDS and Cancer have claimed the lives of more than 100 million people worldwide, making it one of the largest epidemics in history. Here we discuss our recent progress on gold nanoparticle based surface resonance energy transfer (NSET) probe for screening HIV DNA and Cancer Cell Selectively. The NSET intensity increases linearly with the increased target DNA concentration, thus providing a quantitative measurement tool for the HIV-1 gag gene DNA. The sensitivity of our assay is about 1-2 orders of magnitude higher than the current technology.
C1 [Ray, Paresh Chandra; Darbha, Gopala Krishna; Nittala, Marry R.; Yu, Hongtao; Griffin, Jelani] Jackson State Univ, Dept Chem, Jackson, MS 39217 USA.
RP Ray, PC (reprint author), Jackson State Univ, Dept Chem, Jackson, MS 39217 USA.
EM paresh.c.ray@jsums.edu
RI Darbha, Gopala /F-8827-2011
CR Darbha GK, 2007, ACS NANO, V1, P208, DOI 10.1021/nn7001954
   Huang CC, 2006, ANAL CHEM, V78, P8332, DOI 10.1021/ac061487i
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c
   Kim CK, 2006, NANOTECHNOLOGY, V17, P3085, DOI 10.1088/0957-4484/17/13/001
   Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s
   Ray PC, 2006, J PHYS CHEM B, V110, P20745, DOI 10.1021/jp0651211
   Ray PC, 2006, ANGEW CHEM INT EDIT, V45, P1151, DOI 10.1002/anie.200503114
   RAY PC, 2007, NANOTECHNOLOGY, V18
   Rex M, 2006, ANAL CHEM, V78, P445, DOI 10.1021/ac051166r
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Thaxton CS, 2005, NAT BIOTECHNOL, V23, P681, DOI 10.1038/nbt0605-681
   *UNAIDS WHO, 2005, AIDS EP UPD 2005
   Wang CG, 2007, CHEM MATER, V19, P5809, DOI 10.1021/cm0700899
   Yu CX, 2007, NANO LETT, V7, P2300, DOI 10.1021/nl070894m
NR 15
TC 0
Z9 0
U1 0
U2 4
PU JOHN LIBBEY EUROTEXT
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1257-2535
BN 978-2-7420-0714-1
J9 METAL IONS BIOL MED
JI Met. Ions Biol. Med.
PY 2008
VL 10
BP 749
EP 753
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
SC Biochemistry & Molecular Biology; Chemistry
GA BIC67
UT WOS:000258426900125
DA 2018-01-05
ER

PT S
AU Penades, S
   de la Fuente, JM
   Barrientos, AG
   Clavel, C
   Martinez-Avila, O
   Alcantara, D
AF Penades, Soledad
   de la Fuente, Jesus M.
   Barrientos, Africa G.
   Clavel, Caroline
   Martinez-Avila, Olga
   Alcantara, David
BE Giersig, M
   Khomutov, GB
TI Multifunctional glyconanoparticles: Applications in biology and
   biomedicine
SO NANOMATERIALS FOR APPLICATIONS IN MEDICINE AND BIOLOGY
SE NATO Science for Peace and Security Series B-Physics and Biophysics
LA English
DT Proceedings Paper
CT NATO Advanced Research Workshop on Nanomaterials for Applications in
   Medicine and Biology
CY OCT 04-06, 2006
CL Dept Nanoparticle Technol, Bonn, GERMANY
SP NATO Sci Programme
HO Dept Nanoparticle Technol
DE glyconanotechnology; multifunctional glyconanoparticles; quantum dots;
   magnetic glyconanoparticles; carbohydrate interactions; multivalence;
   glycobiology
ID GOLD GLYCONANOPARTICLES; MAGNETIC NANOPARTICLES; DC-SIGN; RECOGNITION;
   GLYCOCALYX; RECEPTORS; SCIENCE; SYSTEM; TOOLS; CELLS
AB The design and preparation of complex bio-functional glyconanoparticles (GNPs) and their application as polyvalent tools to study and intervene in carbohydrate mediated biological interactions are highlighted. As examples, the preparation and study of GNPs as anti-adhesion agents in inhibition of metastasis, as potential microbicides for blocking HIV-1 infection, or as anti-cancer vaccines are also discussed. In addition, magnetic glyconanoparticles for application in cellular labelling and magnetic resonance imaging (MRI) are also reviewed.
C1 [Penades, Soledad; de la Fuente, Jesus M.; Barrientos, Africa G.; Clavel, Caroline; Martinez-Avila, Olga; Alcantara, David] Parque Tecnol San Sebastian, CIC BiomaGUNE, Lab Glyconanotechnol, San Sebastian 20009, Spain.
RP Penades, S (reprint author), Parque Tecnol San Sebastian, CIC BiomaGUNE, Lab Glyconanotechnol, Paseo Miramon 182, San Sebastian 20009, Spain.
EM spenades@cicbiomagune.es
RI Alcantara, David /A-3357-2014; biomaGUNE, CIC/J-9136-2014
OI biomaGUNE, CIC/0000-0001-7690-0660; de la Fuente, Jesus
   M/0000-0003-1081-8482
CR Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022-3727/36/13/203
   BRUST M, 1995, J CHEM SOC CHEM COMM, P1655, DOI 10.1039/c39950001655                                                            
   Crespo P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.177203
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   de la Fuente JDM, 2005, TETRAHEDRON-ASYMMETR, V16, P387, DOI 10.1016/j.tetasy.2004.12.002
   de la Fuente JM, 2006, J PHYS CHEM B, V110, P13021, DOI 10.1021/jp062522s
   de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb                                              
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   de la Fuente JM, 2005, J AM CHEM SOC, V127, P6192, DOI 10.1021/ja0431354
   de la Fuente J.M., 2001, ANGEW CHEM INT EDIT, V40, P2257, DOI DOI 10.1002/1521-3773(20010618)40:12
   Drechsler U, 2004, CHEM-EUR J, V10, P5570, DOI 10.1002/chem.200306076
   Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b                                                               
   *ESF, EUR SCI FDN ESF NAN
   Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   HAKOMORI SI, 1989, ADV CANCER RES, V52, P257, DOI 10.1016/S0065-230X(08)60215-8
   Hernaiz MJ, 2002, ANGEW CHEM INT EDIT, V41, P1554, DOI 10.1002/1521-3773(20020503)41:9<1554::AID-ANIE1554>3.0.CO;2-3
   Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S
   Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Perez JM, 2004, CHEMBIOCHEM, V5, P261, DOI 10.1002/cbic.200300730
   POLAK JM, 1984, IMMUNOLABELING ELECT
   Rojas TC, 2002, ADV MATER, V14, P585, DOI 10.1002/1521-4095(20020418)14:8<585::AID-ADMA585>3.0.CO;2-W                     
   Rojo J, 2004, CHEMBIOCHEM, V5, P291, DOI 10.1002/cbic.200300726
   Tartaj P, 2003, J PHYS D APPL PHYS, V36, pR182, DOI 10.1088/0022-3727/36/13/202
   VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97                                                           
   Verma A, 2005, CHEM COMMUN, P303, DOI 10.1039/b410889b
   Wang J, 2005, SMALL, V1, P1036, DOI 10.1002/smll.200500214
NR 33
TC 1
Z9 1
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 1871-465X
BN 978-1-4020-6827-0
J9 NATO SCI PEACE SEC B
PY 2008
BP 93
EP 101
DI 10.1007/978-1-4020-6829-4_8
PG 9
WC Biophysics; Nanoscience & Nanotechnology; Physics, Applied
SC Biophysics; Science & Technology - Other Topics; Physics
GA BHG35
UT WOS:000252924900008
DA 2018-01-05
ER

PT B
AU Denver, H
   de Noronha, C
   Borca-Tasciuc, DA
AF Denver, Heather
   de Noronha, Carlos
   Borca-Tasciuc, Diana-Andra
BE Laudon, M
   Romanowicz, B
TI Cell mediated, heat-based therapy for treating HIV infection
SO NSTI NANOTECH 2008, VOL 2, TECHNICAL PROCEEDINGS: LIFE SCIENCES,
   MEDICINE, AND BIO MATERIALS
LA English
DT Proceedings Paper
CT Nanotechnology Conference and Trade Show (Nanotech 2008)
CY JUN 01-05, 2008
CL Boston, MA
SP Accelrys Software, Ace Glass, Advance Reprod Corp, Adv Mat Technolog Pte Ltd, Agilent Technol, AIXTRON AG, AJA Int, ALM, Amuneal Mfg Corp, ANSYS, Anton Paar, Appl MicroStruct, Appl Surface Technol, Arkalon Chem Technolog, LLC, Arkema Grp, Artech House Publishers, Asemblon, ASML, Asylum Res, AZoNano, Banner & Witcoff, Beckman Coulter, Bio Nano Counsulting, BioForce Nanosci, Boneer Corp, Birck Nanotechnol Ctr, Purdue Univ, Discovery Pk, Brookhaven Instruments Corp, Buchanan Ingersoll & Rooney PC, Buhler AG, Business Week, Calif NanoSyst Inst, Capovani Brothers, Los Alamos, Ctr Integrated Nanotechnologies, Sandia Natl Labs, Ctr Integrated Nanotechnologies, Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Argonne Natl Lab, Ctr Nanoscale Mat, Cheap tubes, Clean Technol & Sustainable Ind Org, COMSOL, Cooley Godward Kronish LLP, Core Technol Grp, CRESTEC Corp, CSEM, CVI Melles Griot, Dept Innovat, Ind, Sci & Res, Digital Matrix, Draiswerke, ETH Zurich, Eulitha AG, Marks & Clerk, Marubent Techno Syst Corp, Massachusetts Technol Transfer Ctr, Mat Res Soc, Merck & Co, Microfluidics, Micromerit Instrument Corp, Microtrac, MINAT 2008, Messe Stuttgart, Minus K Technol, Misonix, Lawrence Berkeley Natl Lab, Mol Foundry, Motorola, Nano Korea 2008, Nano Sci & Technol Inst, nano tech 2009 Japan, Nano Technol Res Assoc Korea, NanoAndMore USA, NanoDynamics, NanoEurope 2008, NanoInk, Nanomotion, Nanon Imaging Ltd, NANOSENSORS, Nanosyst Initiat Munich, Nanotech No Europe 2008, nano Tox, Nano World AG, NCI, Natl Inst Stand & Technol, NIH, Natl Nanomfg Network, Natl Nanotechnol Infrastruct, GATech, Microelect Res Ctr, Nat Nano, Nat Publishing Grp, NETZSCH Fine Particle Technol LLC, NIL Technol ApS, Novomer, NTT Adv Technol Corp, Olympus Ind Amer, OSEC, Business Network Switzerland, Oxford Instruments, Particle Technol Labs, Penn State Univ, Photon Spectra, Physik Instrumente LP, picoDrill SA, Piezo Inst, PVD Prod, Q Sense, Quantum Analyt, Raith USA, European Patent Off, Evans Analyt Grp, EXAKT Technologies, First Nano, Flow Sci, FDA, Goodwin Procter LLP, Greater Houston Partnership, Greenberg Traurig LLP, Halcyonics, Headwaters Technol Innovat LLC, Heidelberg Instruments, Hielscher USA, HighNano Analyti, Hiscock & Barclay LLP, Hitachi High Technologies Amer, Hochschule Offenburg Univ Appl Sci, HOCKMEYER Equipment Corp, HORIBA Jobin Yvon, IBU-tec adv mat GmbH, IDA Ireland, ImageXpert, Inspec, Inc, IEEE, Inst Nanoscale & Quantum Sci & Technol Adv Res, IntelliSense Software Corp, Invest Germany, IOP Publishing, Italian Trade Commiss, JENOPTIK, Justus Liebig Univ, KAUST, Keithley Instruments, Kelvin Nanotechnol Ltd, Kodak, Kotobuki Ind Co, Ltd, Lake Shore Cryotron, MACRO M, NanoClay, Res Germany Land Ideas, RKS Legal Solut LLC, Dandia Natl Labs, Scottish Enterprise, SEMTech Solut, Serendip, Silvix Corp, SNS Nano Fiber Technol LLC, SoftMEMS LLC, Son & Mat, SW Nano Technologies, Specialty Coating Syst, Spectrum Labs, SPEX SamplePrep LLC, Springer, Sterne, Kessler, Goldstein & Fox PLLC, Strem Chem, Sukgyung A T Co, Lts, Surrey NanoSyst, SUSS MicroTec, Swissnanotech Pavilion, Taylor & Francis Grp LLC, CRC Press, TechConnect, Technovel Corp, Tekna Plasma Syst, Thinky Corp, Thomas Swan & Co Ltd, UGL Unicco, UK Trade & Investment, UniJet, Univ Munster, Univ Appl Sci, Univ Duisburg, Ctr Nanointegrat Duisburg, Vecco Instruments, Wasatch Mol Inc, Weidmann Plast Technol, Whiteman Osterman & Hanna LLP, Willy A Bachofen AG, WITec GmbH, World Gold Council
ID MACROPHAGES; TYPE-1
AB Although several treatment strategies have developed to control HIV infections, most of them have major drawbacks. Hence, HIV infection control still remains a major medical challenge and unconventional therapies to combat the disease have started to emerge. This work investigates remote heating of internalized nanoparticle as a potential method for targeted killing of HIV infected macrophages, one of the host cells for virus multiplication. First, radio frequency heating (RF) of 1.4 nm gold nanoparticle in solutions is evaluated employing fluorescence thermometry and quantum dots as temperature sensors. It is found that the particles are capable of generating sufficient temperature increase to cause cell apoptosis. Then THP-1 cells are exposed to gold nanoparticle solutions of different concentration, left to incubate for 24 hours and after which were subjected to RF electromagnetic field. Significant cell death was observed in specimen exposed to higher particle concentration and higher power of electromagnetic field.
C1 [Denver, Heather; Borca-Tasciuc, Diana-Andra] Rensselaer Polytech Inst, Troy, NY 12181 USA.
   [de Noronha, Carlos] Albany Med Coll, Albany, NY USA.
RP Denver, H (reprint author), Rensselaer Polytech Inst, Troy, NY 12181 USA.
EM denveh@rpi.edu; borcad@rpi.edu
CR BENEFRAIM S, 1994, MED ONCOL, V11, P7, DOI 10.1007/BF02990085
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   DADACHOVA K, 2006, PLOS MED, V3, pE427, DOI DOI 10.1371/JOURNAL.PMED.0030427
   DADACHOVA K, 2006, PLOS MED, V3, P1
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Fidler I J, 1994, Adv Pharmacol, V30, P271, DOI 10.1016/S1054-3589(08)60177-5
   Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x
   Hamad-Schifferli K, 2002, NATURE, V415, P152, DOI 10.1038/415152a                                                                 
   Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798
   Jorge PAS, 2006, MEAS SCI TECHNOL, V17, P1032, DOI 10.1088/0957-0233/17/5/S16
   Keblinski P, 2006, J APPL PHYS, V100, DOI 10.1063/1.2335783
   Salemi M, 2005, J VIROL, V79, P11343, DOI 10.1128/JVI.79.17.11343-11352.2005
   SPAGNUOLO AM, 2004, P 26 ANN INT C IEEE, P722
   Tullis R H, 2001, Am Clin Lab, V20, P22
NR 14
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4200-8504-4
PY 2008
BP 361
EP +
PG 2
WC Nanoscience & Nanotechnology; Medicine, General & Internal; Medicine,
   Research & Experimental; Materials Science, Biomaterials
SC Science & Technology - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine; Materials Science
GA BMF49
UT WOS:000272169900098
DA 2018-01-05
ER

PT S
AU Kuo, YC
   Chen, HH
AF Kuo, Yung-Chih
   Chen, Hung-Hao
BE Long, CA
   Anninos, P
   Pham, T
   Anastassopoulos, G
   Mastorakis, NE
TI Effect of Electromagnetic Field on Vesicular Endocytosis and Blood-Brain
   Barrier Permeability of Saquinavir-Entrapping Cationic Colid Lipid
   Nanoparticles
SO PROCEEDINGS OF THE 1ST WSEAS INTERNATIONAL CONFERENCE ON BIOMEDICAL
   ELECTRONICS AND BIOMEDICAL INFORMATICS
SE Recent Advances in Biology and Biomedicine
LA English
DT Proceedings Paper
CT 1st WSEAS International Conference on Biomedical Electronics and
   Biomedical Informatics
CY AUG 20-22, 2008
CL Rhodes, GREECE
DE Cationic solid lipid nanoparticle; Electromagnetic field; Vesicular
   endocytosis; Blood-brain barrier; Permeability; Saquinavir
ID METHYLMETHACRYLATE-SULFOPROPYLMETHACRYLATE; POLYBUTYLCYANOACRYLATE;
   ZIDOVUDINE; TRANSPORT; CELLS
AB In the present study, cationic solid lipid nanoparticles (CSLNs) were fabricated as carriers for the transport of saquinavir (SQV), an anti-human immunodeficiency virus agent, across the blood-brain barrier (BBB) exposed to electromagnetic field (EMF). The immunocytochemical staining revealed that uptake of SQV-entrapping CSLNs by human brain-microvascular endothelial cells (HBMECs) was via vesicular endocytosis. Amount of vesicular clathrin in HBMECs during CSLN uptake was enhanced by EMF exposure. However, apparent variation in the expression of P-glycoprotein was not observed by treatment of CSLNs and/or EMF. As compared with molecular SQV, the BBB permeability of SQV-entrapping CSLNs became 17fold. The permeability of molecular SQV across HBMEC monolayer was slightly increased by exposure to amplitude modulation (AM) and frequency modulation (FM) EMF. It was worth to note that synergistic effect on improvement in the BBB permeability of SQV was obtained by combination of the present CSLNs and the appropriate EMF exposure.
C1 [Kuo, Yung-Chih; Chen, Hung-Hao] Natl Chung Cheng Univ, Dept Chem Engn, 168 Univ Rd, Chiayi 62102, Taiwan.
RP Kuo, YC (reprint author), Natl Chung Cheng Univ, Dept Chem Engn, 168 Univ Rd, Chiayi 62102, Taiwan.
EM chmyck@ccu.edu.tw
FU National Science Council of the Republic of China
FX This work is supported by the National Science Council of the Republic
   of China.
CR Kuo YC, 2005, J CHIN INST CHEM ENG, V36, P627
   KUO YC, 2008, INT J PHARM IN PRESS
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2007, J PHYS CHEM B, V111, P11228, DOI 10.1021/jp072876z
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Markkanen A, 2004, BIOELECTROMAGNETICS, V25, P127, DOI 10.1002/bem.10167
   Varani K, 2003, BIOCHEM PHARMACOL, V66, P1897, DOI 10.1016/S0006-2952(03)00454-4
NR 7
TC 0
Z9 0
U1 0
U2 2
PU WORLD SCIENTIFIC AND ENGINEERING ACAD AND SOC
PI ATHENS
PA AG LOANNOU THEOLOGOU 17-23, 15773 ZOGRAPHOU, ATHENS, GREECE
SN 1790-5125
BN 978-960-6766-93-0
J9 REC ADV BIOL BIOMED
PY 2008
BP 29
EP +
PG 2
WC Engineering, Biomedical; Mathematical & Computational Biology
SC Engineering; Mathematical & Computational Biology
GA BIK87
UT WOS:000260437900002
DA 2018-01-05
ER

PT S
AU Numata, M
   Shinkai, S
AF Numata, Munenori
   Shinkai, Seiji
BE Shimizu, T
TI Self-Assembled Polysaccharide Nanotubes Generated from beta-1,3-Glucan
   Polysaccharides
SO SELF-ASSEMBLED NANOMATERIALS II: NANOTUBES
SE Advances in Polymer Science
LA English
DT Review; Book Chapter
DE Helical structure; Inclusion complex; Nanomaterials; Polysaccharide;
   Self-assemble
ID WALLED CARBON NANOTUBES; ONE-DIMENSIONAL HOST; SCHIZOPHYLLUM-COMMUNE
   POLYSACCHARIDE; INSULATED MOLECULAR WIRE; X-RAY-DIFFRACTION; INCLUSION
   COMPLEX-FORMATION; TARGETED ANTISENSE CARRIER; ATOMIC-FORCE MICROSCOPY;
   SINGLE-STRANDED RNA; ANTI-HIV ACTIVITY
AB beta-1,3-Glucans act as unique natural nanotubes, the features of which are greatly different from other natural or synthetic helical polymers. The origin mostly stems from their strong helix-forming nature and reversible interconversion between single-strand random coil and triple-strand helix. During this interconversion process, they can accept functional polymers, molecular assemblies and nanoparticles in an induced-fit manner to create water-soluble one-dimensional nanocomposites, where individual conjugated polymers or molecular assemblies can be incorporated into the one-dimensional hollow constructed by the helical superstructure of beta-1,3-glucans. The advantageous point of the beta-1,3-glucan hosting system is that the selective modification of beta-1,3-glucans leads to the creation of various functional one-dimensional nanocomposites in a supramolecular manner, being applicable toward fundamental nanomaterials such as sensors or circuits. Furthermore, the composites with functional surfaces can act as one-dimensional building blocks toward further hierarchical self-assemblies, leading to the creation of two- or three-dimensional nanoarchitectures.
C1 [Numata, Munenori] Ritsumeikan Univ, Dept Biosci & Biotechnol, Fac Sci & Engn, Shiga 5258577, Japan.
   [Shinkai, Seiji] Kyushu Univ, Dept Chem & Biochem, Grad Sch Engn, Fukuoka 8190395, Japan.
RP Numata, M (reprint author), Ritsumeikan Univ, Dept Biosci & Biotechnol, Fac Sci & Engn, Shiga 5258577, Japan.
EM numata@fc.ritsumei.ac.jp
RI U-ID, Kyushu/C-5291-2016
CR Akai T, 2001, JPN J APPL PHYS 2, V40, pL1327, DOI 10.1143/JJAP.40.L1327                                                           
   Antonietti M, 1998, CHEM-EUR J, V4, P2493, DOI 10.1002/(SICI)1521-3765(19981204)4:12<2493::AID-CHEM2493>3.0.CO;2-V             
   Aoki K, 2000, J AM CHEM SOC, V122, P10997, DOI 10.1021/ja001790f
   ATKINS EDT, 1968, NATURE, V220, P784, DOI 10.1038/220784a0
   Atwood J. L., 1996, COMPREHENSIVE SUPRAM, V3
   Bae AH, 2005, ANGEW CHEM INT EDIT, V44, P2030, DOI 10.1002/anie.200462810
   Bae AH, 2007, NEW J CHEM, V31, P618, DOI 10.1039/b615757b
   Belosludov RV, 2003, JPN J APPL PHYS 1, V42, P2492, DOI 10.1143/JJAP.42.2492
   BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0
   BLUHM TL, 1982, CARBOHYD RES, V100, P117, DOI 10.1016/S0008-6215(00)81030-7                                                   
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3
   Buey J, 2000, ANGEW CHEM INT EDIT, V39, P608, DOI 10.1002/(SICI)1521-3773(20000204)39:3<608::AID-ANIE608>3.0.CO;2-W               
   Choi LS, 1998, MACROMOLECULES, V31, P9406, DOI 10.1021/ma981151d                                                               
   CHUAH CT, 1983, MACROMOLECULES, V16, P1375, DOI 10.1021/ma00242a020                                                             
   Clays K, 1998, CHEM PHYS LETT, V293, P337, DOI 10.1016/S0009-2614(98)00795-7
   Coleman JN, 2004, APPL PHYS LETT, V84, P798, DOI 10.1063/1.1643538
   Davis SA, 2001, CHEM MATER, V13, P3218, DOI 10.1021/cm011068w
   DEMLEITNER S, 1992, CARBOHYD RES, V226, P239, DOI 10.1016/0008-6215(92)84071-Y
   DESLANDES Y, 1980, MACROMOLECULES, V13, P1466, DOI 10.1021/ma60078a020                                                             
   DeVries GA, 2007, SCIENCE, V315, P358, DOI 10.1126/science.1133162
   DiCesare N, 2002, LANGMUIR, V18, P7785, DOI 10.1021/la0264926
   Dieckmann GR, 2003, J AM CHEM SOC, V125, P1770, DOI 10.1021/ja029084x
   Do Nascimento GM, 2002, MOL CRYST LIQ CRYST, V374, P53, DOI 10.1080/10587250210439
   Endo M, 2006, CHEM-EUR J, V12, P3735, DOI 10.1002/chem.200501309
   Ewert KK, 2006, J AM CHEM SOC, V128, P3998, DOI 10.1021/ja055907h
   Fan CH, 2002, J AM CHEM SOC, V124, P5642, DOI 10.1021/ja025899u
   Frampton MJ, 2007, ANGEW CHEM INT EDIT, V46, P1028, DOI 10.1002/anie.200601780
   Frank J., 1996, 3 DIMENSIONAL ELECT
   Frecer V, 2000, BIOMACROMOLECULES, V1, P91, DOI 10.1021/bm990002f
   FRENCH AD, 1967, BIOPOLYMERS, V5, P457, DOI 10.1002/bip.1967.360050506
   FUJIKI M, 1994, J AM CHEM SOC, V116, P6017, DOI 10.1021/ja00092a082                                                             
   Gao Y, 1999, MACROMOLECULES, V32, P8319, DOI 10.1021/ma990782k                                                               
   Garoff RA, 2002, LANGMUIR, V18, P6330, DOI 10.1021/la025742f
   Gattuso G, 1997, ANGEW CHEM INT EDIT, V36, P1451, DOI 10.1002/anie.199714511                                                          
   Goto H, 2004, MACROMOL RAPID COMM, V25, P1482, DOI 10.1002/marc.200400184
   Goto H, 2002, CHEM-EUR J, V8, P4027, DOI 10.1002/1521-3765(20020902)8:17<4027::AID-CHEM4027>3.0.CO;2-Q
   Groenendaal L., 2000, ADV MATER, P481, DOI DOI 10.1002/(SICI)1521-4095(200004)12:7<LESS
   Han MG, 2004, ADV MATER, V16, P231, DOI 10.1002/adma.200305642
   Han MG, 2003, LANGMUIR, V19, P4523, DOI 10.1021/la020753u
   Hannah KC, 2004, ACCOUNTS CHEM RES, V37, P845, DOI 10.1021/ar030257c
   Hapiot P, 2002, J PHYS CHEM B, V106, P3622, DOI 10.1021/jp015575c
   HARADA A, 1993, NATURE, V364, P516, DOI 10.1038/364516a0                                                                
   Harada A, 2001, ACCOUNTS CHEM RES, V34, P456, DOI 10.1021/ar000174l
   HARADA A, 1992, NATURE, V356, P325, DOI 10.1038/356325a0                                                                
   HARADA A, 1994, NATURE, V370, P126, DOI 10.1038/370126a0
   Harada A, 1997, ADV POLYM SCI, V133, P141
   HARADA T, 1968, ARCH BIOCHEM BIOPHYS, V124, P292, DOI 10.1016/0003-9861(68)90330-5                                                    
   Haraguchi S, 2005, ORG LETT, V7, P5605, DOI 10.1021/ol052170s
   HASAGAWA T, 2004, CHEM COMMUN, P382
   Hasegawa T, 2006, CHEM LETT, V35, P82, DOI 10.1246/cl.2006.82
   Hasegawa T, 2006, CARBOHYD RES, V341, P35, DOI 10.1016/j.carres.2005.10.009
   Hasegawa T, 2005, ORG BIOMOL CHEM, V3, P4321, DOI 10.1039/b510646j
   Hasegawa T, 2005, CHEM LETT, V34, P1118, DOI 10.1246/cl.2005.1118
   Hasegawa T, 2005, CHEM LETT, V34, P40, DOI 10.1246/cl.2005.40
   Hasegawa T, 2005, BIOORG MED CHEM LETT, V15, P327, DOI 10.1016/j.bmcl.2004.10.071
   Hasegawa T, 2004, ORG BIOMOL CHEM, V2, P3091, DOI 10.1039/b412124b
   Hasegawa T, 2004, CHEM COMMUN, P2150, DOI 10.1039/b407409b
   Hecht S, 2001, ANGEW CHEM INT EDIT, V40, P74, DOI 10.1002/1521-3773(20010105)40:1<74::AID-ANIE74>3.0.CO;2-C
   HELLERT W, 1994, J BIOL MACROMOL, V16, P207
   Heuer WB, 1998, CHEM COMMUN, P2649, DOI 10.1039/a808359b                                                                
   HINRICHS W, 1987, SCIENCE, V238, P205, DOI 10.1126/science.238.4824.205                                                    
   Huang JG, 2003, J AM CHEM SOC, V125, P11834, DOI 10.1021/ja037419k
   Hulvat JF, 2004, ADV MATER, V16, P589, DOI 10.1002/adma.200306263
   ICHINO Y, 2000, J PHYS CHEM-US, V105, P4111
   Ichinose I, 2004, CHEM LETT, V33, P656, DOI 10.1246/cl.2004.656
   IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0                                                                
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Ikeda M, 2007, CHEM-ASIAN J, V2, P1290, DOI 10.1002/asia.200700150
   Ikeda M, 2007, ORG BIOMOL CHEM, V5, P2219, DOI 10.1039/b705997c
   Ikeda M, 2007, J AM CHEM SOC, V129, P3979, DOI 10.1021/ja0684343
   Ikeda M, 2006, ANGEW CHEM INT EDIT, V45, P6491, DOI 10.1002/anie.200602134
   Immel S, 2000, STARCH-STARKE, V52, P1
   Jinnai H, 2000, PHYS REV LETT, V84, P518, DOI 10.1103/PhysRevLett.84.518                                                      
   Jones RM, 2001, P NATL ACAD SCI USA, V98, P14769, DOI 10.1073/pnas.251555298
   KADOKAWA J, 2001, CHEM COMMUN, P459
   Kashida H, 2004, ANGEW CHEM INT EDIT, V43, P6522, DOI 10.1002/anie.200460870
   Kashida H, 2006, CHEM COMMUN, P2768, DOI 10.1039/b604776a
   KASHIWAGI Y, 1981, MACROMOLECULES, V14, P1220, DOI 10.1021/ma50006a016                                                             
   Katsuraya K, 1999, CARBOHYD RES, V315, P234, DOI 10.1016/S0008-6215(98)00315-2
   KATSURAYA K, 1994, CARBOHYD RES, V260, P51, DOI 10.1016/0008-6215(94)80021-9                                                    
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   KERMER JR, 1996, J STRUCT BIOL, V116, P71
   Kida T, 2007, CHEM COMMUN, P1559, DOI 10.1039/b616231b
   Kim BH, 2003, APPL PHYS LETT, V83, P539, DOI 10.1063/1.1592004
   Kim J, 2000, ANGEW CHEM INT EDIT, V39, P3868, DOI 10.1002/1521-3773(20001103)39:21<3868::AID-ANIE3868>3.0.CO;2-2                  
   Kim OK, 2006, J AM CHEM SOC, V128, P510, DOI 10.1021/ja0533141
   Kim OK, 2003, J AM CHEM SOC, V125, P4426, DOI 10.1021/ja029233b
   KIM OK, 1994, LANGMUIR, V10, P2842, DOI 10.1021/la00020a055                                                             
   Kimura T, 2000, CHEM LETT, P1242, DOI 10.1246/cl.2000.1242
   Kool ET, 2002, ACCOUNTS CHEM RES, V35, P936, DOI 10.1021/ar000183u                                                               
   Koti ASR, 2003, CHEM MATER, V15, P369, DOI 10.1021/cm025664h
   Koumoto K, 2004, CARBOHYD RES, V339, P161, DOI 10.1016/j.carres.2003.09.022
   Kubo Y, 2006, ANGEW CHEM INT EDIT, V45, P1548, DOI 10.1002/anie.200503128
   Kumaraswamy S, 2004, P NATL ACAD SCI USA, V101, P7511, DOI 10.1073/pnas.0402367101
   Lagrost C, 1999, J MATER CHEM, V9, P2351, DOI 10.1039/a903277k                                                                
   Lagrost C, 1999, J ELECTROANAL CHEM, V476, P1, DOI 10.1016/S0022-0728(99)00353-8                                                   
   LangeveldVoss BMW, 1996, J AM CHEM SOC, V118, P4908, DOI 10.1021/ja9600643                                                               
   LEHN JM, 1995, SUPRAMOLECULER CHEM
   Li C, 2005, ANGEW CHEM INT EDIT, V44, P6371, DOI 10.1002/anie.200501823
   Li C, 2005, CHEM LETT, V34, P1532, DOI 10.1246/cl.2005.1532
   Li C, 2005, J AM CHEM SOC, V127, P4548, DOI 10.1021/ja050168q
   Li C, 2004, TETRAHEDRON, V60, P8037, DOI 10.1016/j.tet.2004.06.110
   Li C, 2004, MACROMOLECULES, V37, P2411, DOI 10.1021/ma035188w
   LI G, 1994, SCIENCE, V264, P249, DOI 10.1126/science.264.5156.249
   Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253                                                   
   LU FL, 1986, J AM CHEM SOC, V108, P8311, DOI 10.1021/ja00286a057                                                             
   MACDIARMID AG, 1987, SYNTHETIC MET, V18, P285, DOI 10.1016/0379-6779(87)90893-9
   MACDIARMID AG, 1985, MOL CRYST LIQ CRYST, V121, P173, DOI 10.1080/00268948508074857                                                       
   MADALIA O, 2002, SCIENCE, V298, P1209
   MARCHESSAULT RH, 1977, CAN J CHEM, V55, P300, DOI 10.1139/v77-045                                                                 
   Martin RE, 1999, ANGEW CHEM INT EDIT, V38, P1350, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1350::AID-ANIE1350>3.0.CO;2-6            
   McIntire TM, 1998, J AM CHEM SOC, V120, P6909, DOI 10.1021/ja981203e                                                               
   McQuade DT, 2000, CHEM REV, V100, P2537, DOI 10.1021/cr9801014
   Menzel H, 1999, ADV MATER, V11, P131, DOI 10.1002/(SICI)1521-4095(199902)11:2<131::AID-ADMA131>3.0.CO;2-V
   Michels JJ, 2003, CHEM-EUR J, V9, P6167, DOI 10.1002/chem.200305245                                                          
   Midgley PA, 2001, CHEM COMMUN, P907, DOI 10.1039/b101819c                                                                
   Morigaki K, 2002, LANGMUIR, V18, P4082, DOI 10.1021/la0157420
   Morikawa M, 2005, J AM CHEM SOC, V127, P1358, DOI 10.1021/ja043844h
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Nakagawa M, 2005, ADV MATER, V17, P200, DOI 10.1002/adma.200400520
   Nakashima H, 2001, J AM CHEM SOC, V123, P1963, DOI 10.1021/ja000869h
   Nakashima N, 2003, CHEM LETT, V32, P456, DOI 10.1246/cl.2003.456
   Nepogodiev SA, 1998, CHEM REV, V98, P1959, DOI 10.1021/cr970049w                                                               
   Niwa M, 2000, J MATER CHEM, V10, P2647, DOI 10.1039/b004371k                                                                
   NORISUYE T, 1980, J POLYM SCI POL PHYS, V18, P547, DOI 10.1002/pol.1980.180180314                                                      
   Numata M, 2005, CHEM COMMUN, P4655, DOI 10.1039/b509285j
   Numata M, 2005, J AM CHEM SOC, V127, P5875, DOI 10.1021/ja044168m
   Numata M, 2004, ORG LETT, V6, P4447, DOI 10.1021/ol0483448
   Numata M, 2004, CHEM LETT, V33, P232, DOI 10.1246/cl.2004.232                                                             
   NUMATA M, 2003, BIOORG CHEM, V163, P171
   Numata M, 2008, CHEM-EUR J, V14, P2398, DOI 10.1002/chem.200701205
   Numata M, 2007, SUPRAMOL CHEM, V19, P107, DOI 10.1080/10610270600982508
   Numata M, 2006, ORG LETT, V8, P5533, DOI 10.1021/ol062229a
   Okumura H, 2001, MACROMOLECULES, V34, P6338, DOI 10.1021/ma010516i
   Okumura H, 2003, MACROMOLECULES, V36, P6422, DOI 10.1021/ma030164a
   Okumura H, 2002, MACROMOL RAPID COMM, V23, P781, DOI 10.1002/1521-3927(20020901)23:13<781::AID-MARC781>3.0.CO;2-C                    
   Onouchi H, 2006, ANGEW CHEM INT EDIT, V45, P2381, DOI 10.1002/anie.200504162
   Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r
   PARINS LJ, 2001, P NATL ACAD SCI USA, V98, P10042
   Peng WQ, 2004, J AM CHEM SOC, V126, P13822, DOI 10.1021/ja046235i
   Pinto MR, 2004, P NATL ACAD SCI USA, V101, P7505, DOI 10.1073/pnas.0402280101
   Pistolis G, 1996, J PHYS CHEM-US, V100, P15562, DOI 10.1021/jp9613403                                                               
   Pringsheim E, 1999, ADV MATER, V11, P865, DOI 10.1002/(SICI)1521-4095(199907)11:10<865::AID-ADMA865>3.0.CO;2-B
   Qi LM, 2001, CHEM-EUR J, V7, P3526, DOI 10.1002/1521-3765(20010817)7:16<3526::AID-CHEM3526>3.0.CO;2-Z
   Rao V. S. R., 1998, CONFORMATION CARBOHY
   RAPPENECKER G, 1981, CARBOHYD RES, V89, P11, DOI 10.1016/S0008-6215(00)85225-8                                                   
   Raymo FM, 1999, CHEM REV, V99, P1643, DOI 10.1021/cr970081q                                                               
   REKBARSKY MV, 1998, CHEM REV, V98, P1875
   Renikuntla BR, 2005, LANGMUIR, V21, P5362, DOI 10.1021/la0500651
   Roncali J, 1997, CHEM REV, V97, P173, DOI 10.1021/cr950257t                                                               
   Rundle RE, 1943, J AM CHEM SOC, V65, P2200, DOI 10.1021/ja01251a055                                                             
   Sakurai K, 2005, CHEM COMMUN, P4383, DOI 10.1039/b506673p
   Sakurai K, 2000, J AM CHEM SOC, V122, P4520, DOI 10.1021/ja0000145                                                               
   Sanji T, 2006, ORG LETT, V8, P235, DOI 10.1021/ol052494g
   Sanji T, 2005, ANGEW CHEM INT EDIT, V44, P7301, DOI 10.1002/anie.200502073
   Sanji T, 2005, CHEM LETT, V34, P1144, DOI 10.1246/cl.2005.1144
   Sano M, 2001, SCIENCE, V293, P1299, DOI 10.1126/science.1061050                                                         
   SATO T, 1981, CARBOHYD RES, V95, P195, DOI 10.1016/S0008-6215(00)85576-7                                                   
   SATO T, 1983, MACROMOLECULES, V16, P185, DOI 10.1021/ma00236a006                                                             
   Sato T, 1999, J AM CHEM SOC, V121, P10658, DOI 10.1021/ja9922983                                                               
   Sauvage JP, 2002, NEW J CHEM, V26, P1287, DOI 10.1039/b201853p
   Shen XH, 1998, CHEM PHYS LETT, V298, P201, DOI 10.1016/S0009-2614(98)01181-6
   Shimomura T, 2000, POLYM ADVAN TECHNOL, V11, P837, DOI 10.1002/1099-1581(200008/12)11:8/12<837::AID-PAT61>3.0.CO;2-B                   
   Shimomura T, 2002, J CHEM PHYS, V116, P1753, DOI 10.1063/1.1446423
   Shirai E, 1998, J PHYS CHEM B, V102, P3765, DOI 10.1021/jp980150k                                                               
   Soler-illia GJD, 2002, CHEM REV, V102, P4093, DOI 10.1021/cr0200062
   Star A, 2002, ANGEW CHEM INT EDIT, V41, P2508, DOI 10.1002/1521-3773(20020715)41:14<2508::AID-ANIE2508>3.0.CO;2-A                  
   STOKKE BT, 1991, MACROMOLECULES, V24, P6349, DOI 10.1021/ma00023a046                                                             
   Tajima K, 2000, CHEM COMMUN, P2399, DOI 10.1039/b007618j                                                                
   Takahashi T, 2002, CHEM LETT, P690, DOI 10.1246/cl.2002.690                                                             
   Takahashi Y, 2004, MACROMOLECULES, V37, P6827, DOI 10.1021/ma0490956
   Takashima Y, 2004, MACROMOLECULES, V37, P3962, DOI 10.1021/ma049763n
   Tan CY, 2004, J AM CHEM SOC, V126, P13685, DOI 10.1021/ja046856b
   Thomas JM, 2004, CHEM COMMUN, P1253, DOI 10.1039/b315513g
   Tour JM, 1996, CHEM REV, V96, P537, DOI 10.1021/cr9500287                                                               
   Uemura T, 2006, CHEM-ASIAN J, V1, P36, DOI 10.1002/asia.200600074
   van Bommel KJC, 2003, ANGEW CHEM INT EDIT, V42, P980, DOI 10.1002/anie.200390284
   van den Boogaard M, 2004, CHEM MATER, V16, P4383, DOI 10.1021/cm049665g
   VANDERVALK P, 1977, EXP MYCOL, V1, P69, DOI 10.1016/S0147-5975(77)80032-7                                                   
   Wang MM, 2000, J AM CHEM SOC, V122, P9977, DOI 10.1021/ja002184n
   WENZ G, 1984, MACROMOLECULES, V17, P837, DOI 10.1021/ma00134a052                                                             
   WENZ G, 1992, ANGEW CHEM INT EDIT, V31, P197, DOI 10.1002/anie.199201971                                                          
   Wenz G, 2006, CHEM REV, V106, P782, DOI 10.1021/cr970027+
   Wosnick JH, 2005, J AM CHEM SOC, V127, P3400, DOI 10.1021/ja043134b
   WU HCH, 1978, CARBOHYD RES, V61, P7
   Wurthner F, 2003, ANGEW CHEM INT EDIT, V42, P3247, DOI 10.1002/anie.200351414
   Yamaguchi I, 2004, MACROMOL RAPID COMM, V25, P1163, DOI 10.1002/marc.200400024
   YANAKI T, 1980, MACROMOLECULES, V13, P1462, DOI 10.1021/ma60078a019                                                             
   YANAKI T, 1983, BIOPHYS CHEM, V17, P337, DOI 10.1016/0301-4622(83)80018-0
   Yao S, 2004, J AM CHEM SOC, V126, P8336, DOI 10.1021/ja0496367
   Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E
   Yoshida K, 1999, LANGMUIR, V15, P910, DOI 10.1021/la9812471                                                               
   YOSHIDA T, 1995, CARBOHYD RES, V276, P425, DOI 10.1016/0008-6215(95)00186-W
   ZAHN S, 2002, ANGEW CHEM INT EDIT, V41, P4226
   Zhang J, 2003, J PHYS CHEM B, V107, P3712, DOI 10.1021/jp027500u
   Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911
   Ziegler KJ, 2005, J AM CHEM SOC, V127, P1541, DOI 10.1021/ja044537e
   Zorbas V, 2004, J AM CHEM SOC, V126, P7222, DOI 10.1021/ja049202b
NR 198
TC 26
Z9 27
U1 2
U2 26
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-3195
BN 978-3-540-85104-2
J9 ADV POLYM SCI
JI Adv. Polym. Sci.
PY 2008
VL 220
BP 65
EP 121
DI 10.1007/12_2008_145
PG 57
WC Polymer Science
SC Polymer Science
GA BIZ23
UT WOS:000263901800003
DA 2018-01-05
ER

PT J
AU Poelsler, G
   Berting, A
   Kindermann, J
   Spruth, M
   Hammerle, T
   Teschner, W
   Schwarz, HP
   Kreil, TR
AF Poelsler, G.
   Berting, A.
   Kindermann, J.
   Spruth, M.
   Haemmerle, T.
   Teschner, W.
   Schwarz, H. P.
   Kreil, T. R.
TI A new liquid intravenous immunoglobulin with three dedicated virus
   reduction steps: virus and prion reduction capacity
SO VOX SANGUINIS
LA English
DT Review
DE blood-borne; immunoglobulin; pathogen; prion; TSE; viral safety
ID CREUTZFELDT-JAKOB-DISEASE; PLASMA DERIVATIVES; IMMUNE GLOBULIN;
   BLOOD-PRODUCTS; IGG SOLUTIONS; INACTIVATION; REMOVAL; SAFETY;
   NANOFILTRATION; PROTEIN
AB Background and Objectives A new 10% liquid human intravenous immunoglobulin (US trade name: Gammagard Liquid; European trade name: KIOVIG) manufactured by a process with three dedicated pathogen inactivation/removal steps (solvent/detergent treatment, 35-nm nanofiltration and low pH/elevated temperature incubation) was developed. The ability of the manufacturing process to inactivate/remove viruses and prions was investigated.
   Materials and Methods Virus and prion removal capacities were assessed with down-scale spiking experiments, validated for equivalence to the large-scale process.
   Results Lipid-enveloped viruses were completely inactivated/removed by each of the three dedicated virus clearance steps, and for human immunodeficiency virus 1 (HIV-1) and pseudorabies virus (PRV), also by the upstream cold ethanol fractionation step. Relevant non-enveloped viruses [i.e. hepatitis A virus (HAV) and parvovirus B19 (B19V)] were effectively removed by nanofiltration and the cold ethanol fractionation step, and partial inactivation of non-enveloped viruses was achieved by low pH incubation. Overall log reduction factors were > 20.0 for HIV-1, > 18.1 for bovine viral diarrhoea virus, > 16.3 for West Nile virus, > 10.0 for influenza A virus subtype H5N1, > 21.8 for PRV, 12.0 for HAV, > 12.1 for encephalomyocarditis virus, 10.6 for B19V and 10.3 for mice minute virus. Prions (Western blot assay) were completely removed (>= 3.2 mean log reduction) by a step of the cold ethanol fractionation process.
   Conclusions Introducing three dedicated virus-clearance steps in the manufacturing process of immunoglobulins from human plasma provides high margins of safety.
C1 [Poelsler, G.; Berting, A.; Kindermann, J.; Spruth, M.; Kreil, T. R.] Baxter Biosci, Global Pathogen Safety, Vienna, Austria.
   [Haemmerle, T.] Baxter Biosci, Operat Cent Europe, Vienna, Austria.
   [Teschner, W.; Schwarz, H. P.] Baxter Biosci, Preclin R&D, Vienna, Austria.
RP Kreil, TR (reprint author), Baxter Biosci, Global Pathogen Safety, Vienna, Austria.
EM thomas_kreil@baxter.com
CR BOULAY F, 1987, EMBO J, V6, P2643
   Burnouf T, 2006, TRANSFUS CLIN BIOL, V13, P320, DOI 10.1016/j.tracli.2006.11.001
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129                                                          
   BURNOUF T, 1993, DEV BIOL STAND, V81, P199
   Cai K, 2002, BBA-PROTEIN STRUCT M, V1597, P28, DOI 10.1016/S0167-4838(02)00282-0
   Collins SJ, 2004, LANCET, V363, P51, DOI 10.1016/S0140-6736(03)15171-9                                                   
   *EMEA, 1996, CPMP NOT GUID VIR VA
   *EMEA, 1996, CPMP NOT GUID PLASM
   *EMEA, 2003, NOT GUID WARN TRANSM
   Farrugia A, 2004, VOX SANG, V86, P1, DOI 10.1111/j.0042-9007.2004.00386.x
   Farshid M, 2005, CURR OPIN BIOTECH, V16, P561, DOI 10.1016/j.copbio.2005.07.006
   *FDA, 1998, NAT I ALL INF DIS NI
   Gregori L, 2004, BIOLOGICALS, V32, P1, DOI 10.1016/j.biologicals.2003.08.004
   HAMALAINEN E, 1992, VOX SANG, V63, P6
   Hewitt PE, 2006, VOX SANG, V91, P221, DOI 10.1111/j.1423-0410.2006.00833.x
   HOROWITZ B, 1993, DEV BIOL STAND, V81, P147
   Kreil TR, 2007, TRANSFUSION, V47, P452, DOI 10.1111/j.1537-2995.2007.01135.x
   Kreil TR, 2006, TRANSFUSION, V46, P1143, DOI 10.1111/j.1537-2995.2006.00864.x
   Kreil TR, 2003, TRANSFUSION, V43, P1023, DOI 10.1046/j.1537-2995.2003.00496.x
   Lee DC, 2001, TRANSFUSION, V41, P449, DOI 10.1046/j.1537-2995.2001.41040449.x
   Mitra G, 1989, Curr Stud Hematol Blood Transfus, P34
   Omar A, 2002, TRANSFUSION, V42, P1005, DOI 10.1046/j.1537-2995.2002.00145.x
   Omar A, 1996, TRANSFUSION, V36, P866, DOI 10.1046/j.1537-2995.1996.361097017171.x
   Roberts P, 2000, BIOLOGICALS, V28, P29, DOI 10.1006/biol.1999.0236                                                          
   Roberts PL, 2003, VOX SANG, V84, P170, DOI 10.1046/j.1423-0410.2003.00275.x
   Teschner W, 2007, VOX SANG, V92, P42, DOI 10.1111/j.1423-0410.2006.00846.x
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   Van Holten RW, 2003, VOX SANG, V85, P20, DOI 10.1046/j.1423-0410.2003.00312.x
   Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4
NR 29
TC 25
Z9 26
U1 8
U2 10
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PY 2008
VL 94
IS 3
BP 184
EP 192
DI 10.1111/j.1423-0410.2007.01016.x
PG 9
WC Hematology
SC Hematology
GA 274DH
UT WOS:000253981500004
PM 18167162
DA 2018-01-05
ER

PT J
AU Hansen, AL
   Al-Hashimi, HM
AF Hansen, Alexandar L.
   Al-Hashimi, Hashim M.
TI Dynamics of large elongated RNA by NMR carbon relaxation
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID RESIDUAL DIPOLAR COUPLINGS; CHEMICAL-SHIFT TENSORS; OPTIMAL SAMPLING
   STRATEGIES; ROTATING-FRAME RELAXATION; LIQUID-CRYSTALLINE MEDIUM;
   MODEL-FREE APPROACH; HIV-1 TAR RNA; SHIELDING TENSORS; PROTEIN DYNAMICS;
   BIOLOGICAL MACROMOLECULES
AB We present an NMR strategy for characterizing picosecond-to-nanosecond internal motions in uniformly C-13/N-15-labeled RNAs that combines measurements of R-1, R-i rho, and heteronuclear C-13{H-1} NOEs for protonated base (C2, C5, C6, and C8) and sugar (C1') carbons with a domain elongation strategy for decoupling internal from overall motions and residual dipolar coupling (RDC) measurements for determining the average RNA global conformation and orientation of the principal axis of the axially symmetric rotational diffusion. TROSY-detected pulse sequences are presented for the accurate measurement of nucleobase carbon R-1 and R-1 rho rates in large RNAs. The relaxation data is analyzed using a model free formalism which takes into account the very high anisotropy of overall rotational diffusion (D-ratio approximate to 4.7), asymmetry of the nucleobase CSAs and noncollinearity of C - C, C - H dipolar and CSA interactions under the assumption that all interaction tensors for a given carbon experience identical isotropic internal motions. The approach is demonstrated and validated on an elongated HIV-1 TAR RNA (tau(m)approximate to 18 ns) both in free form and bound to the ligand argininamide (ARG). Results show that, while ARG binding reduces the amplitude of collective. helix motions and local mobility at the binding pocket, it leads to a drastic increase in the local mobility of '' spacer '' bulge residues linking the two helices which undergo virtually unrestricted internal motions (S-2 approximate to 0.2) in the ARG bound state. Our results establish the ability to quantitatively study the dynamics of RNAs which are significantly larger and more anisotropic than customarily studied by NMR carbon relaxation.
C1 [Hansen, Alexandar L.; Al-Hashimi, Hashim M.] Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem & Biophys, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
RI Hansen, Alexandar/B-6794-2011
OI Hansen, Alexandar/0000-0003-4474-7141
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Al-Hashimi HM, 2005, CHEMBIOCHEM, V6, P1506, DOI 10.1002/cbic.200500002
   Bannwarth S, 2005, CURR HIV RES, V3, P61, DOI 10.2174/1570162052772924                                                        
   Bax A, 1997, J BIOMOL NMR, V10, P289, DOI 10.1023/A:1018308717741
   BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4                                                    
   Boisbouvier J, 2003, J BIOMOL NMR, V27, P133, DOI 10.1023/A:1024931619957
   Boisbouvier J, 1999, J BIOMOL NMR, V14, P241, DOI 10.1023/A:1008365712799
   Brodsky AS, 1997, J MOL BIOL, V267, P624, DOI 10.1006/jmbi.1996.0879
   Brutscher B, 1998, J AM CHEM SOC, V120, P11845, DOI 10.1021/ja982853l                                                               
   Bryce DL, 2005, J AM CHEM SOC, V127, P7387, DOI 10.1021/ja051039c
   Case DA, 1999, J BIOMOL NMR, V15, P95, DOI 10.1023/A:1008349812613
   Chang SL, 2005, J MAGN RESON, V174, P43, DOI 10.1016/j.jmr.2005.01.008
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f                                                               
   Czernek J, 2000, J MAGN RESON, V145, P142, DOI 10.1006/jmre.2000.2091
   Czerneky J, 2001, J PHYS CHEM A, V105, P1357, DOI 10.1021/jp003471g
   d'Auvergne EJ, 2006, J BIOMOL NMR, V35, P117, DOI 10.1007/s10858-006-9007-z
   d'Auvergne EJ, 2003, J BIOMOL NMR, V25, P25, DOI 10.1023/A:1021902006114
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Duchardt E, 2005, J BIOMOL NMR, V32, P295, DOI 10.1007/s10858-005-0659-x
   Furtig B, 2007, BIOPOLYMERS, V86, P360, DOI 10.1002/bip.20761
   Getz M, 2007, BIOPOLYMERS, V86, P384, DOI 10.1002/bip.20765
   GETZ MM, 2006, RNA, P251
   Hall JB, 2006, J AM CHEM SOC, V128, P7855, DOI 10.1021/ja060406x
   Hall KB, 1998, BIOCHEMISTRY-US, V37, P9323, DOI 10.1021/bi9805285
   Hallock KJ, 2000, J CHEM PHYS, V113, P11187, DOI 10.1063/1.1326475
   Hansen AL, 2006, J MAGN RESON, V179, P299, DOI 10.1016/j.jmr.2005.12.012
   Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176                                                                    
   Igumenova TI, 2006, J AM CHEM SOC, V128, P8110, DOI 10.1021/ja061692f
   JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272
   Johnson JE, 2006, J BIOMOL NMR, V35, P261, DOI 10.1007/s10858-006-9041-x
   Jones JA, 1996, J MAGN RESON SER B, V113, P25, DOI 10.1006/jmrb.1996.0151                                                          
   Jones JA, 1997, J MAGN RESON, V126, P283, DOI 10.1006/jmre.1997.1167
   Korzhnev DM, 2002, J AM CHEM SOC, V124, P10743, DOI 10.1021/ja0204776
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Lilley David M J, 2004, Methods Mol Biol, V252, P77
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Loria JP, 1999, J BIOMOL NMR, V15, P151, DOI 10.1023/A:1008355631073                                                         
   Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403
   MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073                                                          
   Massi F, 2004, J AM CHEM SOC, V126, P2247, DOI 10.1021/ja038721w
   Micura R, 2003, CHEMBIOCHEM, V4, P984, DOI 10.1002/cbic.200300664
   Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964
   Mulder FAA, 1998, J MAGN RESON, V131, P351, DOI 10.1006/jmre.1998.1380                                                          
   Musselman C, 2006, J BIOMOL NMR, V36, P235, DOI 10.1007/s10858-006-9087-9
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308                                                          
   Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1                                                   
   Palmer AG, 2006, CHEM REV, V106, P1700, DOI 10.1021/cr0404287
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   Poon A, 2004, J PHYS CHEM B, V108, P16577, DOI 10.1021/jp0471913
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Ravindranathan S, 2005, J BIOMOL NMR, V33, P163, DOI 10.1007/s10858-005-3472-7
   SAUPE A, 1968, ANGEW CHEM INT EDIT, V7, P97, DOI 10.1002/anie.196800971                                                          
   Schwalbe H, 2007, ANGEW CHEM INT EDIT, V46, P1212, DOI 10.1002/anie.200604163
   Shajani Z, 2005, J MOL BIOL, V349, P699, DOI 10.1016/j.jmb.2005.04.012
   Shajani Z, 2007, BIOPOLYMERS, V86, P348, DOI 10.1002/bip.20650
   Shajani Z, 2007, BIOCHEMISTRY-US, V46, P5875, DOI 10.1021/bi602658x
   SHOWALTER SA, 2005, METHOD ENZYMOL, V394, P465
   SHOWALTER SA, 2005, J BIOMOL NMR, V32, P173
   SPIESS HW, 1977, NMR-BASIC PRINC PROG, V15, P55
   Stueber D, 2002, J AM CHEM SOC, V124, P10539, DOI 10.1021/ja012485c
   Sun XY, 2007, NUCLEIC ACIDS RES, V35, P1698, DOI 10.1093/nar/gkm020
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020                                                             
   Vallurupalli P, 2005, J AM CHEM SOC, V127, P6893, DOI 10.1021/ja0427799
   van Dijk ADJ, 2005, PROTEINS, V60, P367, DOI 10.1002/prot.20476
   Walter Nils G, 2002, Biologist (London), V49, P199
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
   WILLIAMSON JR, 1988, NUCLEIC ACIDS RES, V16, P1529, DOI 10.1093/nar/16.4.1529
   YAMAZAKI T, 1994, J AM CHEM SOC, V116, P8266, DOI 10.1021/ja00097a037
   Ying JF, 2006, J AM CHEM SOC, V128, P11443, DOI 10.1021/ja061984g
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2003, J AM CHEM SOC, V125, P10530, DOI 10.1021/ja0363056
   ZHANG Q, 2007, UNPUB NATURE
   Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022
   Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908                                                               
NR 79
TC 60
Z9 61
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 26
PY 2007
VL 129
IS 51
BP 16072
EP 16082
DI 10.1021/ja0757982
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 245YF
UT WOS:000251974000059
PM 18047338
DA 2018-01-05
ER

PT J
AU Al-Mawsawi, LQ
   Dayam, R
   Taheri, L
   Witvrouw, M
   Debyser, Z
   Neamati, N
AF Al-Mawsawi, Laith Q.
   Dayam, Raveendra
   Taheri, Laleh
   Witvrouw, Myriam
   Debyser, Zeger
   Neamati, Nouri
TI Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1
   integrase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE substructure; SAR; HIV-1 integrase; cytotoxicity
ID TREATMENT-EXPERIENCED PATIENTS; TREATMENT-NAIVE; PHARMACOKINETICS;
   MK-0518; VIRUS
AB The previously discovered salicylhydrazide class of compounds displayed potent HIV-1 integrase ( IN) inhibitory activity. The development of this class of compounds as antiretroviral agents was halted due to cytotoxicity in the nanomolar to sub-micromolar range. We identified a novel class of non-cytotoxic hydrazide IN inhibitors utilizing the minimally required salicylhydrazide substructure as a template in a small-molecule database search. The novel hydrazides displayed low micromolar IN inhibitory activity and are several hundred-fold less cytotoxic than previously disclosed salicylhydrazide IN inhibitors. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Al-Mawsawi, Laith Q.; Dayam, Raveendra; Taheri, Laleh; Neamati, Nouri] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.
   [Witvrouw, Myriam; Debyser, Zeger] Katholieke Univ Leuven, B-30006 Louvain, Belgium.
   [Witvrouw, Myriam; Debyser, Zeger] IRC KULAK, B-30006 Louvain, Belgium.
RP Neamati, N (reprint author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.
EM neamati@usc.edu
OI debyser, zeger/0000-0002-3982-1565
CR Al-Mawsawi LQ, 2007, FEBS LETT, V581, P1151, DOI 10.1016/j.febslet.2007.02.023
   Brown P. O., 1997, P161
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   Dayam Raveendra, 2007, Drugs R D, V8, P155, DOI 10.2165/00126839-200708030-00003
   DeJesus E, 2006, JAIDS-J ACQ IMM DEF, V43, P1, DOI 10.1097/01.qai.0000233308.82860.2f
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Hong HX, 1997, J MED CHEM, V40, P930, DOI 10.1021/jm960754h
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   Nair V, 2007, REV MED VIROL, V17, P277, DOI 10.1002/rmv.539
   Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760                                                               
   Neamati N, 2002, J MED CHEM, V45, P5661, DOI 10.1021/jm0201417
   Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Plasencia C, 2005, MOL CANCER THER, V4, P1105, DOI 10.1158/1535-7163.MCT-04-0288
   Stanwell C, 1996, BIOCHEM PHARMACOL, V52, P475, DOI 10.1016/0006-2952(96)00250-X
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Zhao H, 1997, J MED CHEM, V40, P937, DOI 10.1021/jm960755+                                                               
NR 17
TC 33
Z9 33
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 1
PY 2007
VL 17
IS 23
BP 6472
EP 6475
DI 10.1016/j.bmcl.2007.09.102
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 267DF
UT WOS:000253489000014
PM 17950601
DA 2018-01-05
ER

PT J
AU Link, N
   Brunner, TJ
   Dreesen, IAJ
   Stark, WJ
   Fussenegger, M
AF Link, Nils
   Brunner, Tobias J.
   Dreesen, Imke A. J.
   Stark, Wendelin J.
   Fussenegger, Martin
TI Inorganic nanoparticles for Transfection of mammalian cells and removal
   of viruses from aqueous solutions
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE adeno-associated virus; adenovirus; biopharmaceutical manufacturing;
   human immunodeficiency virus (HIV); inorganic nanoparticles; murine
   leukemia virus (MLV); virus removal
ID ADJUSTABLE TRANSGENE EXPRESSION; IN-VIVO TRANSDUCTION; TRANSIENT
   TRANSFECTION; CALCIUM-PHOSPHATE; DRINKING-WATER; RECOMBINANT PROTEIN;
   CARBON NANOTUBES; FLAME SYNTHESIS; NANO-PARTICLES; SILICA
AB Owing to their small size, synthetic nanoparticles show unprecedented biophysical and biochemical properties which may foster novel advances in life-science I research. Using flame-spray synthesis technology we have produced non-coated aluminum-, calcium-, cerium-, and zirconium-derived inorganic metal oxide nano articles I which not only exhibit high affinity for nucleic acids, but can sequester such compounds from aqueous solution. This non-covalent DNA-binding capacity was successfully used to transiently transfect a variety of mammalian cells including human, reaching transfection efficiencies which compared favorably with classic calcium phosphate precipitation (CaP) procedures and lipofection. In this straightforward protocol, transfection was enabled by simply mixing nanoparticles with DNA in solution prior to addition to the target cell population. Transiently transfected cells showed higher 1 production levels of the human secreted glycoprotein SEAP compared to isogenic populations transfected with established technologies. Inorganic metal oxide nanoparticles also showed a high binding capacity to human-pathogenic viruses including adenovirus, adeno -associated virus and human immunodeficiency virus type I and were able to clear these Pathogens from aqueous solutions. The DNA transfection and viral clearance capacities of inorganic metal oxide nanoparticles may provide cost-effective biopharmaceutical manufacturing and water treatment in developing countries.
C1 ETH, ICB, CH-8093 Zurich, Switzerland.
RP Fussenegger, M (reprint author), ETH, ICB, HCI F115,Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.
EM fussenegger@cheiii.ethz.ch
RI Stark, Wendelin/A-8680-2008
CR Ashbolt NJ, 2004, TOXICOLOGY, V198, P229, DOI 10.1016/j.tox.2004.01.030                                                       
   Azzam Tony, 2004, Current Drug Delivery, V1, P165, DOI 10.2174/1567201043479902
   Barry Peter A., 2004, V245, P207
   Brunner TJ, 2006, ENVIRON SCI TECHNOL, V40, P4374, DOI 10.1021/es052069i
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Chowdhury EH, 2005, CURR GENE THER, V5, P669, DOI 10.2174/156652305774964613                                                      
   Clasen T, 2004, WATER SCI TECHNOL, V50, P111
   Cui YL, 2005, BIOMED MICRODEVICES, V7, P153, DOI 10.1007/s10544-005-1596-x
   Dalba C, 2005, CURR GENE THER, V5, P655, DOI 10.2174/156652305774964659                                                      
   Dass CR, 2004, J MOL MED-JMM, V82, P579, DOI 10.1007/s00109-004-0558-8
   Derouazi M, 2006, BIOTECHNOL LETT, V28, P373, DOI 10.1007/s10529-005-6062-6
   Derouazi M, 2004, BIOTECHNOL BIOENG, V87, P537, DOI 10.1002/bit.20161
   Fluri DA, 2007, BIOTECHNOL BIOENG, V98, P655, DOI 10.1002/bit.21461
   GAMBLE DR, 1979, LANCET, V1, P425
   Geisse Sabine, 2005, Journal of Structural and Functional Genomics, V6, P165, DOI 10.1007/s10969-005-2826-4
   Godfree A, 2005, J ENVIRON QUAL, V34, P105, DOI 10.2134/jeq2005.0105                                                            
   Gonzalez-Nicolini V, 2005, J GENE MED, V7, P1573, DOI 10.1002/jgm.787
   Grass RN, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/3/035703
   Grass RN, 2005, CHEM COMMUN, P1767, DOI 10.1039/b419099h
   Grimm D, 2003, MOL THER, V7, P839, DOI 10.1016/S1525-0016(03)00095-9
   Hou DZ, 2003, BIOMATERIALS, V24, P1781, DOI 10.1016/S0142-9612(02)00578-1
   Jacangelo JG, 2003, WATER SCI TECHNOL, V47, P193
   Jordan M, 2004, METHODS, V33, P136, DOI 10.1016/j.ymeth.2003.11.011
   Kaupert N., 1999, Revista Argentina de Microbiologia, V31, P49
   Khandurina J, 2002, CURR OPIN CHEM BIOL, V6, P359, DOI 10.1016/S1367-5931(02)00323-X                                                   
   KLEIN CPAT, 1983, J BIOMED MATER RES, V17, P769, DOI 10.1002/jbm.820170505
   KRUIS FE, 1993, AEROSOL SCI TECH, V19, P514, DOI 10.1080/02786829308959656                                                       
   Kursawe M, 2005, J SOL-GEL SCI TECHN, V33, P71, DOI 10.1007/s10971-005-6702-2                                                       
   LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3
   Le CT, 2001, J MED MICROBIOL, V50, P571, DOI 10.1099/0022-1317-50-6-571                                                      
   Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o
   Link N, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj014
   Liu RM, 2002, THIN SOLID FILMS, V420, P145, DOI 10.1016/S0040-6090(02)00752-6
   Loher S, 2005, CHEM MATER, V17, P36, DOI 10.1021/cm048776c
   Maedler L., 2002, J AEROSOL SCI, V33, P369
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Meunier L, 2006, WATER RES, V40, P1864, DOI 10.1016/j.watres.2006.02.030
   Mitta B, 2005, J GENE MED, V7, P1400, DOI 10.1002/jgm.798
   Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112
   O'Brien J, 2002, BRAIN RES PROTOC, V10, P12
   Osterwalder N, 2006, J NANOPART RES, V8, P1, DOI 10.1007/s11051-005-8384-7
   Park JH, 2006, JPN J APPL PHYS 1, V45, P7512, DOI 10.1143/JJAP.45.7512
   Patnaik S, 2006, J CONTROL RELEASE, V114, P398, DOI 10.1016/j.jconrel.2006.06.025
   Patwardhan SV, 2002, J INORG ORGANOMET P, V12, P49, DOI 10.1023/A:1021250131231                                                         
   Persidis A, 1998, NAT BIOTECHNOL, V16, P488, DOI 10.1038/nbt0598-488                                                             
   Peters K, 2004, J MATER SCI-MATER M, V15, P321, DOI 10.1023/B:JMSM.0000021095.36878.1b
   Pham PL, 2006, MOL BIOTECHNOL, V34, P225, DOI 10.1385/MB:34:2:225
   Pomogailo AD, 2003, SOL ST PHEN, V94, P313, DOI 10.4028/www.scientific.net/SSP.94.313                                           
   RAMIA S, 1985, REV INFECT DIS, V7, P180
   Roberts PL, 2006, TRANSFUSION, V46, P1648, DOI 10.1111/j.1537-2995.2006.00948.x                                                
   ROBERTS PL, 2006, TRANSFUSION, V46, P1650
   Rosser MP, 2005, PROTEIN EXPRES PURIF, V40, P237, DOI 10.1016/j.pep.2004.07.015
   Scanlon KJ, 2004, ANTICANCER RES, V24, P501
   Schlatter S, 2002, GENE, V282, P19, DOI 10.1016/S0378-1119(01)00824-1
   Schulz H, 2003, J MATER CHEM, V13, P2979, DOI 10.1039/b307754c
   Staiger M, 2002, J DISPER SCI TECHNOL, V23, P619, DOI 10.1081/DIS-120015367
   Stark WJ, 2002, IND ENG CHEM RES, V41, P4921, DOI 10.1021/ie020200e
   Stark WJ, 2002, POWDER TECHNOL, V126, P103, DOI 10.1016/S0032-5910(02)00077-3                                                   
   Su CH, 2006, SURF COAT TECH, V200, P3211, DOI 10.1016/j.surfcoat.2005.07.013
   Suarez M, 2003, BIOTECHNOL BIOENG, V81, P13, DOI 10.1002/bit.10550
   Sun Y, 2006, J PHYS CHEM B, V110, P23022, DOI 10.1021/jp060432h
   Tan WH, 2004, MED RES REV, V24, P621, DOI 10.1002/med.20003
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Thompson CD, 1999, BIOTECHNIQUES, V27, P824
   THOMPSON CD, 1999, ADV DRUG DELIV, V27, P828
   Thompson CD, 1999, BIOTECHNIQUES, V27, P832
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   van Drunen Littel-van den Hurk Sylvia, 2006, Current Drug Delivery, V3, P3
   Weber W, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng071
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
NR 70
TC 20
Z9 20
U1 0
U2 13
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD DEC 1
PY 2007
VL 98
IS 5
BP 1083
EP 1093
DI 10.1002/bit.21525
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 228PG
UT WOS:000250741300014
PM 17546691
DA 2018-01-05
ER

PT J
AU Ludwig, C
   Wagner, R
AF Ludwig, Christine
   Wagner, Ralf
TI Virus-like particles - universal molecular toolboxes
SO CURRENT OPINION IN BIOTECHNOLOGY
LA English
DT Review
ID HUMAN-PAPILLOMAVIRUS TYPE-16; RANDOMIZED CONTROLLED-TRIAL; VESICULAR
   STOMATITIS-VIRUS; ACTIVATE DENDRITIC CELLS; INFLUENZA VIROSOMES;
   IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; HIV-1 ENVELOPE; INSECT CELLS;
   HEPATITIS-B
AB Virus-like particles (VLPs) are highly organised spheres that self-assemble from virus-derived structural antigens. These stable and versatile subviral particles possess excellent adjuvant properties capable of inducing innate and cognate immune responses. Commercialised VLP-based vaccines have been successful in protecting humans from hepatitis B virus (HBV) and human papillomavirus (HPV) infection and are currently explored for their potential to combat other infectious diseases and cancer. Much insight into VLP-mediated immune stimulation and optimised VLP design has been gained from human immunodeficiency virus (HIV)-derived VLPs presenting promising components of current AIDS vaccine approaches. Owing to their unique features, VLPs and virosomes, the in vitro-reconstituted VLP counterparts, have recently gained ground in the field of nanobiotechnology as organic templates for the development of new biomaterials.
C1 [Ludwig, Christine; Wagner, Ralf] Univ Regensburg, Mol Microbiol & Gene Therapy Unit, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany.
   [Wagner, Ralf] GENEART AG, D-93053 Regensburg, Germany.
RP Ludwig, C (reprint author), Univ Regensburg, Mol Microbiol & Gene Therapy Unit, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany.
EM christine.ludwig@klinik.uni-regensburg.de;
   ralf.wagner@klinik.uni-regensburg.de
CR Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005
   Abe T, 2003, J IMMUNOL, V171, P1133, DOI 10.4049/jimmunol.171.3.1133                                                     
   Adamina M, 2006, EXPERT OPIN BIOL TH, V6, P1113, DOI 10.1517/14712598.6.11.1113
   Aires KA, 2006, APPL ENVIRON MICROB, V72, P745, DOI [10.1128/AEM.72.1.745-752.2006, 10.1128/AFM.72.1.745-752.2006]
   Angel J, 2007, VACCINE, V25, P3913, DOI 10.1016/j.vaccine.2007.01.101
   BAYER ME, 1968, NATURE, V218, P1057, DOI 10.1038/2181057a0
   Bellier B, 2006, VACCINE, V24, P2643, DOI 10.1016/j.vaccine.2005.11.034
   BLUMBERG BS, 1985, NEW ENGL J MED, V312, P189
   Buonaguro L, 2006, J VIROL, V80, P9134, DOI 10.1128/JVI.00050-06
   Buonaguro L, 2005, J VIROL, V79, P7059, DOI 10.1128/JVI.79.11.7059-7067.2005
   Cusi MG, 2006, HUM VACCINES, V2, P1
   Cusi MG, 2000, VIROLOGY, V277, P111, DOI 10.1006/viro.2000.0605
   Cusi MG, 2005, J IMMUNOL, V174, P7210, DOI 10.4049/jimmunol.174.11.7210                                                    
   de Jonge J, 2007, BIOCHEM J, V405, P41, DOI 10.1042/BJ20061756
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   Doan LX, 2005, REV MED VIROL, V15, P75, DOI 10.1002/rmv.449
   Gomez CE, 2007, VACCINE, V25, P1969, DOI 10.1016/j.vaccine.2006.11.051
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Gleba Y, 2007, CURR OPIN BIOTECH, V18, P134, DOI 10.1016/j.copbio.2007.03.002
   Gluck R, 2004, EXPERT OPIN BIOL TH, V4, P1139, DOI 10.1517/14712598.4.7.1139
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Hervas-Stubbs S, 2007, J IMMUNOL, V178, P6653, DOI 10.4049/jimmunol.178.10.6653                                                    
   Hervas-Stubbs S, 2007, J IMMUNOL, V178, P2361, DOI 10.4049/jimmunol.178.4.2361                                                     
   Holzer BR, 1996, VACCINE, V14, P982, DOI 10.1016/0264-410X(96)00042-4                                                    
   HOLZER BR, 1997, VACCINE, V15, P245
   Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017
   Huckriede A, 2007, J LIPOSOME RES, V17, P39, DOI 10.1080/08982100601186516
   Karpenko LI, 2004, VACCINE, V22, P1692, DOI 10.1016/j.vaccine.2003.09.050
   Kuate S, 2006, VIROLOGY, V351, P133, DOI 10.1016/j.virol.2006.03.009
   LIU X, 2006, ACS CHEM BIOL, V25, P161
   LU X, 2007, IMMUNOLOGY
   Mao CB, 2004, SCIENCE, V303, P213, DOI 10.1126/science.1092740
   Marsac D, 2002, J VIROL, V76, P7544, DOI 10.1128/JVI.76.15.7544-7553.2002
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   McBurney SP, 2007, VIROLOGY, V358, P334, DOI 10.1016/j.virol.2006.08.032
   Nam KT, 2006, SCIENCE, V312, P885, DOI 10.1126/science.1122716
   Okitsu SL, 2007, CHEM BIOL, V14, P577, DOI 10.1016/j.chembiol.2007.04.008
   OSTERRIEDER N, 1995, VIROLOGY, V208, P500, DOI 10.1006/viro.1995.1181                                                          
   Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5
   Paliard X, 2000, AIDS RES HUM RETROV, V16, P273, DOI 10.1089/088922200309368                                                         
   PEACEY M, 2007, BIOTECHNOL BIOENG
   Peretti S, 2006, VIROLOGY, V345, P115, DOI 10.1016/j.virol.2005.09.054
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Russell JT, 2005, ANGEW CHEM INT EDIT, V44, P2420, DOI 10.1002/anie.200462653
   Sailaja G, 2007, VIROLOGY, V362, P331, DOI 10.1016/j.virol.2006.12.014
   Santi L, 2006, METHODS, V40, P66, DOI 10.1016/j.ymeth.2006.05.020
   Schauber CA, 2004, GENE THER, V11, P266, DOI 10.1038/sj.gt.3302170
   Skountzou I, 2007, J VIROL, V81, P1083, DOI 10.1128/JVI.01692-06
   Swenson DL, 2005, VACCINE, V23, P3033, DOI 10.1016/j.vaccine.2004.11.070
   Tan PH, 2007, MOL MED, V13, P216, DOI 10.2119/2006-00052.Tan
   Tsunetsugu-Yokota Y, 2003, J VIROL, V77, P10250, DOI 10.1128/JVL.77.19.10250-10259.2003
   Waelti E, 2002, CANCER RES, V62, P437
   WAGNER R, 1992, ARCH VIROL, V127, P117, DOI 10.1007/BF01309579
   Wagner R, 1994, BEHRING I MITT, V95, P23
   Wang Q, 2002, ANGEW CHEM INT EDIT, V41, P459
   Westerfeld N, 2006, WIEN KLIN WOCHENSCHR, V118, P50, DOI 10.1007/s00508-006-0684-0
   Ye L, 2006, VIROLOGY, V351, P260, DOI 10.1016/j.virol.2006.03.021
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
NR 61
TC 140
Z9 145
U1 4
U2 53
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0958-1669
J9 CURR OPIN BIOTECH
JI Curr. Opin. Biotechnol.
PD DEC
PY 2007
VL 18
IS 6
BP 537
EP 545
DI 10.1016/j.copbio.2007.10.013
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 257MG
UT WOS:000252802600010
PM 18083549
DA 2018-01-05
ER

PT J
AU Jorquera, JI
AF Jorquera, J. I.
TI Safety procedures of coagulation factors
SO HAEMOPHILIA
LA English
DT Article
DE coagulation factor concentrates; safety
ID CREUTZFELDT-JAKOB-DISEASE; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY;
   PATHOGENIC PRION PROTEIN; BLOOD-TRANSFUSION; PARVOVIRUS B19; PLASMA
   DERIVATIVES; HEAT SENSITIVITY; INACTIVATION; INFECTIVITY; PRODUCTS
AB Two main types of safety procedures must be applied to biological products, including plasma derivatives: (i) preventive procedures and (ii) elimination procedures. Prevention includes epidemiological control of donor populations; checks on each donor's health condition; analysis of each donation for the main pathogens using serological methods; additional analysis of all plasma for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A virus (HAV) and the 131.9 virus, using nucleic acid amplification techniques (NAT). A 60 days or longer inventory hold of all plasma donations is applied, to allow additional time to discard previous donations from potential seroconverting or otherwise rejectable donors. Elimination procedures minimize the low residual risk of transmitting pathogens, including unknown or previously undetected ones. Since the introduction 20 years ago of solvent-detergent treatment, very effective against enveloped viruses (HIV, HBV, HCV, West Nile virus, SARS, avian influenza virus etc), there have been no known cases of transmission of this type of pathogens by products manufactured according to this procedure. Other inactivation procedures such as pasteurization, dry-heat or nanofiltration may prove equally effective. In addition, dry-heat treatment and nanofiltration are capable of effectively eliminating non-enveloped viruses (HAV, B19 virus). Recent studies show that the B19 virus is much more sensitive to heat (in lyophilized state or by pasteurization) and acid pH than previously thought. Although there is no evidence for the transmission of classic transmissible spongiform encephalopathies (TSEs) through blood or blood-products transfusion, four possible cases have been reported in the United Kingdom involving transmission by non-leukoreduced blood components of the agent that causes variant Creutzfeldt-Jakob Disease (vCJD), a disease linked to the outbreak of bovine spongiform encephalopathy (BSE) which took place in that country. However, there are no cases of human TSE (classic or variant) transmission by plasma-derived products. Analytical methods capable of detecting the vCJD agent in patients' brains (where high titres are found) and other tissues (such as the spleen, appendix and lymph nodes, where much lower concentrations are found) are unable to detect the agent in blood or plasma from patients with vCJD, even in the clinical phase of the disease. Experiments by Grifols and other groups show that the capacity of the production processes to eliminate vCJD agent models is many orders of magnitude greater than the maximum expected load of the agent. In this regard, the efficacy of precipitation, affinity chromatography, depth filtration and nanofiltration are particularly notable.
C1 Inst Grifols, Res & Dev Area, Barcelona 08150, Spain.
RP Jorquera, JI (reprint author), Inst Grifols, Res & Dev Area, SA Can Guasch 2,Poligono Levante, Barcelona 08150, Spain.
EM juanignacio.jorquera@grifols.coin
CR *AG FRANC SEC SAN, 2004, AN RISK TRANSM VAR C
   BARON H, 2000, BIOL SAFETY PRINCIPL, P187
   BIESCAS H, 1999, HAEMATOLOGICA, V84, P218
   BIESCAS H, 2006, HAEMOPHILIA S2, V12, P5
   Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x                                                
   Bradley R, 2006, FOLIA NEUROPATHOL, V44, P93
   Brown P, 2001, EMERG INFECT DIS, V7, P6, DOI 10.3201/eid0701.010102                                                          
   Brown P, 2005, VOX SANG, V89, P63, DOI 10.1111/j.1423-0410.2005.00683.x
   Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x
   Burnouf T, 2006, TRANSFUS CLIN BIOL, V13, P320, DOI 10.1016/j.tracli.2006.11.001
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   Chamberland ME, 2001, EMERG INFECT DIS, V7, P552, DOI 10.3201/eid0703.010331                                                          
   Evatt B, 1998, TRANSFUSION, V38, P817, DOI 10.1046/j.1537-2995.1998.38998409000.x                                          
   Foster PR, 2004, VOX SANG, V87, P7, DOI 10.1111/j.1741-6892.2004.00444.x
   Hewitt PE, 2006, VOX SANG, V91, P221, DOI 10.1111/j.1423-0410.2006.00833.x
   *HLTH PROT AG, 4 CAS VAR CJD INF AS
   HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x
   Kreil TR, 2007, TRANSFUSION, V47, P452, DOI 10.1111/j.1537-2995.2007.01135.x
   Kreil TR, 2004, DEV BIOLOGICALS, V118, P101
   Lee CA, 1998, THROMB HAEMOSTASIS, V80, P909
   Lee DC, 2001, TRANSFUSION, V41, P449, DOI 10.1046/j.1537-2995.2001.41040449.x
   Lee DC, 2000, J VIROL METHODS, V84, P77, DOI 10.1016/S0166-0934(99)00135-4
   Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X
   *NAT CREUTZF JAK D, VAR CREUTZF JAK DIS
   OIE (World Organization for Animal Health), 2015, NUMB CAS BOV SPONG E
   Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6
   Prikhod'ko GG, 2005, TRANSFUSION, V45, P1692, DOI 10.1111/j.1537-2995.2005.00589.x
   Smith PG, 2003, BRIT MED BULL, V66, P185, DOI 10.1093/bmb/66.1.185
   Stenland CJ, 2002, TRANSFUSION, V42, P1497, DOI 10.1046/j.1537-2995.2002.00216.x                                                
   Yunoki M, 2005, BRIT J HAEMATOL, V128, P401, DOI 10.1111/j.1365-2141.2004.05309.x
   Yunoki M, 2003, VOX SANG, V84, P164, DOI 10.1046/j.1423-0410.2003.00280.x                                                
   Zou S, 2005, TRANSFUSION, V45, p32A
NR 32
TC 9
Z9 10
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1351-8216
J9 HAEMOPHILIA
JI Haemophilia
PD DEC
PY 2007
VL 13
SU 5
BP 41
EP 46
DI 10.1111/j.1365-2516.2007.01578.x                                        
          
PG 6
WC Hematology
SC Hematology
GA 250PD
UT WOS:000252311600006
PM 18078396
DA 2018-01-05
ER

PT J
AU Berry, CC
   de la Fuente, JM
   Mullin, M
   Chu, SWL
   Curtis, ASG
AF Berry, C. C.
   de la Fuente, J. M.
   Mullin, M.
   Chu, S. Wai Ling
   Curtis, A. S. G.
TI Nuclear localization of HIV-1 tat functionalized gold nanoparticles
SO IEEE TRANSACTIONS ON NANOBIOSCIENCE
LA English
DT Article
DE cell; cell penetrating peptides; HIV-1 tat; nanoparticles; nuclear
   targeting; TEM
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING PEPTIDES; FUSION
   PROTEINS; IN-VIVO; MAGNETIC NANOPARTICLES; INTRACELLULAR DELIVERY;
   CAVEOLAR ENDOCYTOSIS; MEDIATED DELIVERY; PLASMA-MEMBRANE; PORE COMPLEX
AB The impermeable nature of the cell plasma membrane limits the therapeutic uses of many macromolecules and there is therefore a growing effort to circumvent this problem by designing strategies for targeted intracellular delivery. During the last decade several cell penetrating peptides, such as the HIV-1 tat peptide, have been shown to traverse the cell membrane, where integral protein transduction domains (PTDs) are responsible for their cellular uptake, and to reach the nucleus while retaining biological activity. It has since been discovered that PTDs can enable the cellular delivery of conjugated biomolecules and even nanoparticles, but nuclear delivery has remained problematic. This present study focuses on the development of water soluble, biocompatible gold nanoparticles of differing size functionalized with the HIV-1 tat PTD with the aim of producing nuclear targeting agents. The particles were subsequently tested in vitro with a human fibroblast cell line, with results demonstrating successful nanoparticle transfer across the plasma membrane, with 5 nm particles achieving nuclear entry while larger 30 ran particles are retained in the cytoplasm, suggesting entry is blocked via nuclear pores dimensions.
C1 [Berry, C. C.; Mullin, M.; Chu, S. Wai Ling] Univ Glasgow, Inst Biomed & Life Sci, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
   [de la Fuente, J. M.] Univ Zaragoza, INA, E-50009 Zaragoza, Spain.
RP Berry, CC (reprint author), Univ Glasgow, Inst Biomed & Life Sci, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
EM Catherine.berry@bio.gla.ac.uk
RI Delehanty, James/F-7454-2012
OI de la Fuente, Jesus M/0000-0003-1081-8482
CR Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Cashman SM, 2003, MOL THER, V8, P130, DOI 10.1016/S1525-0016(03)00131-X
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Faucheux N, 2004, BIOMATERIALS, V25, P2721, DOI 10.1016/j.biomaterials.2003.09.069
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Massia SP, 2001, J BIOMED MATER RES, V56, P390, DOI 10.1002/1097-4636(20010905)56:3<390::AID-JBM1108>3.0.CO;2-L
   Mazzanti M, 2001, PHYSIOL REV, V81, P1
   Moroianu J, 1999, J Cell Biochem, VSuppl 32-33, P76
   Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013                                                          
   NOGUCHI N, 2006, ACTA MED OKAYAMA, V60, P1
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Prunuske AJ, 2006, CURR OPIN CELL BIOL, V18, P108, DOI 10.1016/j.ceb.2005.12.004
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198
   Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6
   Templeton AC, 1999, LANGMUIR, V15, P66, DOI 10.1021/la9808420                                                               
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
NR 38
TC 77
Z9 78
U1 4
U2 31
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 1536-1241
J9 IEEE T NANOBIOSCI
JI IEEE Trans. Nanobiosci.
PD DEC
PY 2007
VL 6
IS 4
BP 262
EP 269
DI 10.1109/TNB.2007.908973
PG 8
WC Biochemical Research Methods; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA 240LW
UT WOS:000251590100002
PM 18217618
DA 2018-01-05
ER

PT J
AU Xu, WF
   Santini, PA
   Shan, MM
   Chen, K
   Ball, SC
   Chiu, A
   Kingsley, LA
   Rinaldo, CR
   Chadburn, A
   Knowles, DM
   He, B
   Cerutti, A
AF Xu, Weifeng
   Santini, Paul A.
   Shan, Meimei
   Chen, Kang
   Ball, Susan C.
   Chiu, April
   Kingsley, Lawrence A.
   Rinaldo, Charles R.
   Chadburn, Amy
   Knowles, Daniel M.
   He, Bing
   Cerutti, Andrea
TI Long-distance tunneling nanotubules shuttle viral immunoglobulin class
   switch-suppressing factors from HIV-infected macrophages to B cells
SO BLOOD
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the American-Society-of-Hematology
CY DEC 08-11, 2007
CL Atlanta, GA
SP Amer Soc Hematol
C1 [Xu, Weifeng; Santini, Paul A.; Shan, Meimei; Chen, Kang; Ball, Susan C.; Chiu, April; Chadburn, Amy; Knowles, Daniel M.; He, Bing; Cerutti, Andrea] Cornell Univ, Weill Med Coll, Pathol & Lab Med, New York, NY USA.
   [Kingsley, Lawrence A.; Rinaldo, Charles R.] Univ Pittsburgh, Pathol & Lab Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2007
VL 110
IS 11
MA 2278
BP 676A
EP 676A
PN 1
PG 1
WC Hematology
SC Hematology
GA 233OS
UT WOS:000251100803060
DA 2018-01-05
ER

PT J
AU Lev, N
   Shai, Y
AF Lev, Naama
   Shai, Yechiel
TI Fatty acids can substitute the HIV fusion peptide in lipid merging and
   fusion: An analogy between viral and palmitoylated eukaryotic fusion
   proteins
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE membrane fusion; peptide-lipid interaction; HIV-1 gp41; AFM; fusion
   peptide
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TERMINAL HEPTAD REPEAT; MEDIATED
   MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; LEUCINE-ZIPPER; TRANSMEMBRANE
   GLYCOPROTEIN; CONFORMATIONAL-CHANGES; ACTIVE CONFORMATION; MUTATIONAL
   ANALYSIS; GP41 ECTODOMAIN
AB Various fusion proteins from eukaryotes and viruses share structural similarities such as a coiled coil motif. However, compared with eukaryotic proteins, a viral fusion protein contains a fusion pepticle (FP), which is an N-terminal hydrophobic fragment that is primarily involved in directing fusion via anchoring the protein to the target cell membrane. In various eukaryotic fusion proteins the membrane targeting domain is cysteine-rich and must undergo palmitoylation prior to the fusion process. Here we examined whether fatty acids can replace the FP of human immunodeficiency virus type 1 (HIV-1), thereby discerning between the contributions of the sequence versus hydrophobicity of the FP in the lipid-merging process. For that purpose, we structurally and functionally characterized peptides derived from the N terminus of HIV fusion protein - gp41 in which the FP is lacking or replaced by fatty acids. We found that fatty acid conjugation dramatically enhanced the capability of the peptides to induce lipid mixing and aggregation of zwitterionic phospholipids composing the outer leaflet of eukaryotic cell membranes. The enhanced effect of the acylated peptides on membranes was further supported by real-time atomic force microscopy (AFM) showing nanoscale holes in zwitterionic membranes. Membrane-binding experiments revealed that fatty acid conjugation did not increase the affinity of the peptides to the membrane significantly. Furthermore, all free and acylated peptides exhibited similar alpha-helical structures in solution and in zwitterionic membranes. Interestingly, the fusogenic active conformation of N36 in negatively charged membranes composing the inner leaflet of eukaryotic cells is beta-sheet. Apparently, N-terminal heptad repeat (NHR) can change its conformation as a response to a change in the charge of the membrane head group. Overall, the data suggest an analogy between the eukaryotic cysteine-rich domains and the viral fusion peptide, and mark the hydrophobic nature of FP as an important characteristic for its role in lipid merging. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
RP Shai, Y (reprint author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
EM Yechiel.Shai@weizmann.ac.il
CR BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0                                                                
   Bloch I, 2007, FASEB J, V21, P393, DOI 10.1096/fj.06-7061com
   Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   CHEN SSL, 1994, J VIROL, V68, P2002
   CHEN SSL, 1993, J VIROL, V67, P3615
   Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169
   Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d
   Dimitrov AS, 2003, BIOCHEMISTRY-US, V42, P14150, DOI 10.1021/bi035154g
   Driesen RB, 2005, CARDIOVASC RES, V68, P37, DOI 10.1016/j.cardiores.2005.05.020
   DUBAY JW, 1992, J VIROL, V66, P4748
   Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170                                                       
   Epand RF, 1999, J MOL BIOL, V286, P489, DOI 10.1006/jmbi.1998.2500
   FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Gautier I, 2003, EXP CELL RES, V289, P174, DOI 10.1016/S0014-4827(03)00258-1
   Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097
   GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0
   JAMESON DM, 1995, METHOD ENZYMOL, V246, P283
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404                                                           
   Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004
   Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091
   KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244
   Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573
   Martin I, 1996, J VIROL, V70, P298
   Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JV.80.7.3249-3258.2006
   Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Munoz-Barroso I, 1999, J VIROL, V73, P6089
   Pallavi B, 2003, J BIOL CHEM, V278, P12737, DOI 10.1074/jbc.M208598200
   Pascual R, 2005, BIOCHEMISTRY-US, V44, P14275, DOI 10.1021/bi050928
   Pascual R, 2005, J VIROL, V79, P5142, DOI 10.1128/JVI.79.8.5142-5152.2005
   Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i
   PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955
   Poumbourios P, 1997, J VIROL, V71, P2041
   Pritsker M, 1999, BIOCHEMISTRY-US, V38, P11359, DOI 10.1021/bi990232e
   Quintana FJ, 2005, J CLIN INVEST, V115, P2149, DOI 10.1172/JCI23956
   RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016
   Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322
   Sackett K, 2003, J MOL BIOL, V333, P47, DOI 10.1016/j.jmb.2003.07.008
   Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030
   Sakai T, 2002, J VIROL, V76, P4603, DOI 10.1128/JVI.76.9.4603-4611.2002
   Salzwedel K, 1999, J VIROL, V73, P2469
   SCHAAL H, 1995, J VIROL, V69, P3308
   STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023
   Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000
   SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001                                                             
   Tamm LK, 2000, BIOSCIENCE REP, V20, P501, DOI 10.1023/A:1010406920417
   van den Eijnde SM, 2001, J CELL SCI, V114, P3631
   Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145
   VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223
   Vigano C, 2003, CHEM PHYS LIPIDS, V122, P121, DOI 10.1016/S0009-3084(02)00183-4                                                   
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wexler-Cohen Y, 2005, BIOCHEMISTRY-US, V44, P5853, DOI 10.1021/bi047666g
   WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331                                             
   WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676                                                        
   WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019
   Yang TL, 2000, ANAL CHEM, V72, P2587, DOI 10.1021/ac000131i                                                               
NR 59
TC 13
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD NOV 16
PY 2007
VL 374
IS 1
BP 220
EP 230
DI 10.1016/j.jmb.2007.09.008
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 230PA
UT WOS:000250887200018
PM 17919659
DA 2018-01-05
ER

PT J
AU Akagi, T
   Baba, M
   Akashi, M
AF Akagi, Takami
   Baba, Masanori
   Akashi, Mitsuru
TI Preparation of nanoparticles by the self-organization of polymers
   consisting of hydrophobic and hydrophilic segments: Potential
   applications
SO POLYMER
LA English
DT Review
DE nanoparticles; drug delivery system; protein carrier
ID POLY(ETHYLENE GLYCOL) MACROMONOMER; DRUG-DELIVERY SYSTEM;
   POLY(GAMMA-GLUTAMIC ACID)-POLY(LACTIDE) NANOPARTICLES; INACTIVATED
   HIV-1-CAPTURING NANOSPHERES; IMMOBILIZED POLYSTYRENE NANOSPHERES;
   CROSS-SECTIONAL MORPHOLOGIES; FREE-RADICAL POLYMERIZATION; ORAL PEPTIDE
   DELIVERY; IN-SITU FORMATION; GRAFT-COPOLYMERS
AB This review describes the preparation of core-corona type polymeric nanoparticles and their applications in various technological and biomedical fields. Over the past two decades, we have studied the synthesis and clinical applications of core-corona polymeric nanoparticles composed of hydrophobic polystyrene and hydrophilic macromonomers. These nanoparticles were utilized as catalyst carriers, carriers for oral peptide delivery, virus capture agents, and vaccine carriers, and so on. Moreover, based on this research, we attempted to develop novel biodegradable nanoparticles composed of hydrophobic poly(gamma-glutamic acid) (gamma-PGA) derivatives (gamma-hPGA). Various model proteins were efficiently entrapped on/into the nanoparticles under different conditions: encapsulation, covalent immobilization, and physical adsorption. The encapsulation method showed the most promising results for protein loading. It is expected that biodegradable gamma-hPGA nanoparticles can encapsulate and immobilize various biomacromolecules. Nanoparticles consisting of hydrophobic and hydrophilic segments have great potential as multifunctional carriers for pharmaceutical and biomedical applications, such as drug, protein, peptide or DNA delivery systems. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Kagoshima Univ, Ctr Chronic Viral Dis, Grad Sch Med & Dent Sci, Div Antiviral Chemotherap, Kagoshima 8908544, Japan.
   Japan Sci & Technol Agency, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Abe K, 1997, BIOSCI BIOTECH BIOCH, V61, P1621, DOI 10.1271/bbb.61.1621                                                             
   Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2006, BIOMACROMOLECULES, V7, P297, DOI 10.1021/bm050657i
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   AKASHI M, 1985, ANGEW MAKROMOL CHEM, V132, P81, DOI 10.1002/apmc.1985.051320107                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   AKASHI M, 1990, J APPL POLYM SCI, V39, P2027, DOI 10.1002/app.1990.070390917                                                      
   Akiyoshi K, 2000, MACROMOLECULES, V33, P6752, DOI 10.1021/ma991949c
   Akiyoshi K, 1998, J CONTROL RELEASE, V54, P313, DOI 10.1016/S0168-3659(98)00017-0
   AKIYOSHI K, 1993, MACROMOLECULES, V26, P3062, DOI 10.1021/ma00064a011                                                             
   Allemann E, 1998, ADV DRUG DELIVER REV, V34, P171, DOI 10.1016/S0169-409X(98)00039-8
   Allen C, 2000, J CONTROL RELEASE, V63, P275, DOI 10.1016/S0168-3659(99)00200-X
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Arimura H, 2005, BIOMACROMOLECULES, V6, P720, DOI 10.1021/bm0494491
   Barbosa MEM, 2004, BIOMACROMOLECULES, V5, P137, DOI 10.1021/bm0300608
   Behan N, 2001, BIOMATERIALS, V22, P1335, DOI 10.1016/S0142-9612(00)00286-6                                                   
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   CAPEK I, 1995, EUR POLYM J, V31, P895, DOI 10.1016/0014-3057(95)00043-7                                                    
   CAPEK I, 1992, POLYM J, V24, P959, DOI 10.1295/polymj.24.959                                                           
   CAPEK I, 1992, MAKROMOL CHEM, V193, P2843
   CAPEK I, 1993, J MACROMOL SCI R M C, VC33, P369, DOI 10.1080/15321799308021565                                                       
   Cetinus SA, 2003, ENZYME MICROB TECH, V32, P889, DOI 10.1016/S0141-0229(03)00065-6
   Chen CW, 1999, LANGMUIR, V15, P7998, DOI 10.1021/la9817462                                                               
   Chen CW, 1998, CHEM COMMUN, P831, DOI 10.1039/a800203g                                                                
   Chen CW, 1998, ADV MATER, V10, P1122, DOI 10.1002/(SICI)1521-4095(199810)10:14<1122::AID-ADMA1122>3.3.CO;2-E
   Chen CW, 2002, CHEM MATER, V14, P2232, DOI 10.1021/cm011634n
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   Chen CW, 2000, MACROMOL CHEM PHYSIC, V201, P2811, DOI 10.1002/1521-3935(20001201)201:18<2811::AID-MACP2811>3.0.CO;2-0
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Chen MQ, 1999, POLYM ADVAN TECHNOL, V10, P120, DOI 10.1002/(SICI)1099-1581(199901/02)10:1/2<120::AID-PAT781>3.3.CO;2-7
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   Chen MQ, 2000, J POLYM SCI POL CHEM, V38, P1811, DOI 10.1002/(SICI)1099-0518(20000515)38:10<1811::AID-POLA660>3.0.CO;2-V             
   Chiu HC, 1997, J BIOMED MATER RES, V34, P381, DOI 10.1002/(SICI)1097-4636(19970305)34:3<381::AID-JBM13>3.0.CO;2-J
   Duval-Terrie C, 2003, COLLOID SURFACE A, V220, P105, DOI 10.1016/S0927-7757(03)00062-1
   Fan KS, 1996, J ENVIRON POLYM DEGR, V4, P253, DOI 10.1007/BF02070694
   GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27
   GOTO A, 1992, BIOSCI BIOTECH BIOCH, V56, P1031, DOI 10.1271/bbb.56.1031
   Gref R, 2002, MACROMOLECULES, V35, P9861, DOI 10.1021/ma021132a
   Guan HL, 2005, BIOMACROMOLECULES, V6, P1954, DOI 10.1021/bm0492069
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   HAYASHI T, 1995, EUR POLYM J, V31, P453, DOI 10.1016/0014-3057(94)00189-8                                                    
   Hiwatari K, 2001, POLYM J, V33, P424, DOI 10.1295/polymj.33.424                                                           
   Holowka EP, 2005, J AM CHEM SOC, V127, P12423, DOI 10.1021/ja053557t
   Holowka EP, 2007, NAT MATER, V6, P52, DOI 10.1038/nmat1794
   Hu Y, 2004, BIOMACROMOLECULES, V5, P1756, DOI 10.1021/bm049845j
   Iijima M, 1999, MACROMOLECULES, V32, P1140, DOI 10.1021/ma9815962                                                               
   Ishizu K, 1996, POLYMER, V37, P1729, DOI 10.1016/0032-3861(96)83726-8                                                    
   Jaturanpinyo M, 2004, BIOCONJUGATE CHEM, V15, P344, DOI 10.1021/bc034149m
   Jeong JH, 2003, POLYMER, V44, P583, DOI 10.1016/S0032-3861(02)00816-9                                                   
   Jung SW, 2003, INT J PHARM, V254, P109, DOI 10.1016/S0378-5173(03)00006-1
   Kaneko T, 2005, CHEM MATER, V17, P2484, DOI 10.1021/cm048196f
   Kang K, 2005, MACROMOL BIOSCI, V5, P344, DOI 10.1002/mabi.200400178
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9                                                   
   KAWAGUCHI H, 1995, MACROMOLECULES, V28, P1159
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Kishida A, 1998, J BIOACT COMPAT POL, V13, P270, DOI 10.1177/088391159801300403                                                      
   Koping-Hoggard M, 2005, EXPERT REV VACCINES, V4, P185, DOI 10.1586/14760584.4.2.185
   Kubitschko S, 1997, ANAL BIOCHEM, V253, P112, DOI 10.1006/abio.1997.2337                                                          
   Kubota H, 1996, J POLYM SCI POL CHEM, V34, P1347, DOI 10.1002/(SICI)1099-0518(199605)34:7<1347::AID-POLA24>3.3.CO;2-B
   KUBOTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1212, DOI 10.1271/bbb.57.1212
   Lavelle EC, 1999, VACCINE, V17, P512, DOI 10.1016/S0264-410X(98)00229-1                                                   
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   LEE VHL, 1990, ADV DRUG DELIV REV, V4, P171
   Lemoine D, 1996, BIOMATERIALS, V17, P2191, DOI 10.1016/0142-9612(96)00049-X
   Leonard M, 2004, J CONTROL RELEASE, V98, P395, DOI 10.1016/j.jconrel.2004.05.009
   Li C, 2002, ADV DRUG DELIVER REV, V54, P695, DOI 10.1016/S0169-409X(02)00045-5
   Li XH, 2000, J APPL POLYM SCI, V78, P140, DOI 10.1002/1097-4628(20001003)78:1<140::AID-APP180>3.0.CO;2-P                      
   Liang HF, 2005, J CONTROL RELEASE, V105, P213, DOI 10.1016/j.jconrel.2005.03.021
   Liang HF, 2006, BIOCONJUGATE CHEM, V17, P291, DOI 10.1021/bc0502107
   Liang HF, 2006, BIOMATERIALS, V27, P2051, DOI 10.1016/j.biomaterials.2005.10.027
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Liggins RT, 2001, INT J PHARM, V222, P19, DOI 10.1016/S0378-5173(01)00690-1                                                   
   Lin JP, 2007, INT J PHARM, V336, P49, DOI 10.1016/j.ijpharm.2006.11.026
   Liu JC, 2004, WOMAN ART J, V25, P26, DOI 10.2307/3566495                                                                 
   Matsusaki M, 2005, NANO LETT, V5, P2168, DOI 10.1021/nl050541s
   Matsusaki M, 2005, BIOMACROMOLECULES, V6, P2374, DOI 10.1021/bm050204d
   Matsusaki M, 2002, BIOCONJUGATE CHEM, V13, P23, DOI 10.1021/bc010008d
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Na K, 2003, EUR J PHARM SCI, V18, P165, DOI 10.1016/S0928-0987(02)00257-9
   Nie T, 2003, MACROMOLECULES, V36, P8825, DOI 10.1021/ma035131+
   Obst M, 2004, BIOMACROMOLECULES, V5, P1166, DOI 10.1021/bm049949u
   OHAGAN DT, 1994, INT J PHARM, V103, P37, DOI 10.1016/0378-5173(94)90201-1
   OHAGAN DT, 2002, AIDS, V16, P115
   Oppermann FB, 1998, POLYM DEGRAD STABIL, V59, P337, DOI 10.1016/S0141-3910(97)00175-4                                                   
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park JH, 2004, J CONTROL RELEASE, V95, P579, DOI 10.1016/j.jconrel.2003.12.020
   PARK TG, 1995, J CONTROL RELEASE, V33, P211, DOI 10.1016/0168-3659(94)00084-8
   Prego C, 2005, J CONTROL RELEASE, V101, P151, DOI 10.1016/j.jconrel.2004.07.030
   Quellec P, 1998, J BIOMED MATER RES, V42, P45, DOI 10.1002/(SICI)1097-4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O
   REGINE A, 1998, PHARM RES, V15, P1111
   Reis CP, 2006, J MICROENCAPSUL, V23, P245, DOI 10.1080/02652040500286086
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   RIZA M, 1993, ANGEW MAKROMOL CHEM, V206, P69, DOI 10.1002/apmc.1993.052060107                                                     
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   RIZA M, 1994, NEW POLYM MAT, V4, P189
   Rypacek F, 1998, POLYM DEGRAD STABIL, V59, P345, DOI 10.1016/S0141-3910(97)00182-1                                                   
   Sah H, 1999, J CONTROL RELEASE, V58, P143, DOI 10.1016/S0168-3659(98)00148-5
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   Sakuma S, 1997, INT J PHARM, V159, P181, DOI 10.1016/S0378-5173(97)00284-6                                                   
   Sakuma S, 2002, J CONTROL RELEASE, V81, P281, DOI 10.1016/S0168-3659(02)00072-X                                                   
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378-5173(02)00113-8
   Sakuma S, 2001, ADV DRUG DELIVER REV, V47, P21, DOI 10.1016/S0169-409X(00)00119-8
   Sakuma S, 1997, INT J PHARM, V158, P69, DOI 10.1016/S0378-5173(97)00247-0
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Serizawa T, 2005, POLYM J, V37, P39, DOI 10.1295/polymj.37.39
   Serizawa T, 1999, J BIOMAT SCI-POLYM E, V10, P391, DOI 10.1163/156856299X00441                                                         
   Serizawa T, 2000, MACROMOLECULES, V33, P1759, DOI 10.1021/ma9907486                                                               
   Serizawa T, 2001, BIOMACROMOLECULES, V2, P469, DOI 10.1021/bm000131s
   Serizawa T, 1998, LANGMUIR, V14, P1278, DOI 10.1021/la970992v                                                               
   Serizawa T, 1998, J POLYM SCI POL CHEM, V36, P2581, DOI 10.1002/(SICI)1099-0518(199810)36:14<2581::AID-POLA17>3.0.CO;2-E
   Shen SY, 1999, BIOTECHNOL APPL BIOC, V29, P185
   Shimokuri T, 2004, MACROMOL BIOSCI, V4, P407, DOI 10.1002/mabi.200300073
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 2002, PHARMACEUT RES, V19, P715, DOI 10.1023/A:1016104910582
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   Takeuchi H, 1996, PHARMACEUT RES, V13, P896, DOI 10.1023/A:1016009313548
   TAKEUCHI S, 1993, MAKROMOL CHEM, V194, P551
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   Wang W, 2001, LANGMUIR, V17, P631, DOI 10.1021/la001078w
   Wang W, 2004, MACROMOLECULES, V37, P9114, DOI 10.1021/ma049042o
   Wang W, 2000, LANGMUIR, V16, P7859, DOI 10.1021/la000633r
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   WEBER J, 1990, J BIOL CHEM, V265, P9664
   Wu C, 1997, MACROMOLECULES, V30, P2187, DOI 10.1021/ma9608333                                                               
   Xiong XY, 2004, MACROMOLECULES, V37, P3425, DOI 10.1021/ma049662p
   Yih TC, 2006, J CELL BIOCHEM, V97, P1184, DOI 10.1002/jcb.20796
   ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728
   Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s                                                               
   Zhang WQ, 2003, LANGMUIR, V19, P6026, DOI 10.1021/la034300g
   Zhang Y, 2005, BIOMATERIALS, V26, P6736, DOI 10.1016/j.biomaterials.2005.03.045
   ZHAO Z, 1996, J PHARM SCI, V85, P261
NR 142
TC 70
Z9 71
U1 3
U2 47
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD NOV 2
PY 2007
VL 48
IS 23
BP 6729
EP 6747
DI 10.1016/j.polymer.2007.08.038
PG 19
WC Polymer Science
SC Polymer Science
GA 232TA
UT WOS:000251041200001
OA gold
DA 2018-01-05
ER

EF